FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Montoure, A
   Janich, K
   Cusick, JF
   Kurpad, SN
   Wang, MC
AF Montoure, Andrew
   Janich, Karl
   Cusick, Joseph F.
   Kurpad, Shekar N.
   Wang, Marjorie C.
TI Great Hospitals in North America: The Medical College of Wisconsin
   Neurological Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Medical College of Wisconsin; Neurosurgery history; Spine fellowship
AB The Medical College of Wisconsin Department of Neurosurgery delivers subspecialty adult and pediatric neurosurgical care that is patient-centered, evidence-informed, and value-based. Medical College of Wisconsin research advances the science of neurological disease with the goal of a positive translational effect on clinical care. The department supports an environment of education and scholarship for trainees, faculty, and staff alike. The journey to become a neurosurgical center of excellence was accomplished with the leadership and foresight of the men and women who turned their dreams into reality. The establishment and rise of the department as a national force for neurosurgery and spine is an elegant example of the combination of individual leadership and foresight with synergistic institutional support.
C1 [Montoure, Andrew; Janich, Karl; Cusick, Joseph F.; Kurpad, Shekar N.; Wang, Marjorie C.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
RP Montoure, A (reprint author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
EM amontoure@mcw.edu
RI Kurpad, Shekar/V-2188-2019
CR Cerletty JM, 2004, WIS MED J, V103, P29
   Duffy Thomas P., 2011, Yale Journal of Biology and Medicine, V84, P269
   Edwin H, 2017, ELLISON MEMORIAL LEC
   Engbring NH, 1991, ANCHOR FUTURE HIST M
   Fauber J, 2012, MILWAUKEE J SENTINEL
   Fowler G, 1982, NY TIMES
   Gennarelli D, 2005, TXB TRAUMATIC BRAIN, P34
   LARSON S J, 1964, Surg Forum, V15, P397
   Maiman D, 1986, THESIS
   Marshall T, 1993, LOS ANGELES TIMES
   Medical College of Wisconsin, 2018, HIST OF MCW
   Survey Committee Congress of Neurological Surgeons, 1960, HIST C NEUR SURG
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 55
EP 66
DI 10.1016/j.wneu.2018.12.210
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700167
PM 30660875
DA 2020-05-12
ER

PT J
AU Chung, KC
   Lin, CH
   Tsai, CL
   Li, YH
   Liao, CH
AF Chung, Kai-Chen
   Lin, Chih-Hung
   Tsai, Chung-Lin
   Li, Yu-Hsuan
   Liao, Chih-Hsiang
TI Tracheomalacia as Complication of Stenting for Esophageal Injury After
   Transsternal Approach to High Thoracic Vertebral Metastasis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Esophageal injury; Esophageal stenting; Tracheomalacia; Transsternal
   approach; Vertebral metastasis
AB BACKGROUND: Esophageal injury is a severe surgical complication of a transsternal approach to high thoracic vertebral metastasis, which can result in mediastinitis and life-threatening consequences. A covered stent can be placed in the esophagus to prevent mediastinal leakage. However, tracheomalacia is a rare complication following esophageal stenting.
   CASE DESCRIPTION: A 56-year-old man had a pathologic fracture of the T3 vertebral body with spinal cord compression, myelopathy, and neurogenic bladder. An esophageal injury was noticed during the transsternal approach. Immediate suture repair, drainage tube placement, and subsequent esophageal stenting were carried out. One month after discharge, the endoscopic examination revealed nonhealing of the esophagus, and a new covered stent was replaced. Episodes of severe stridor and dyspnea led to the patient being sent to the emergency department. Computed tomography scan of the chest revealed a focal collapse of the trachea at the thoracic inlet, and tracheomalacia was suspected. The covered stent was removed, despite nonhealing of the esophagus. His stridor, dyspnea, and constant coughing subsided afterwards. The endoscopic examination at 3 months after stent removal showed complete healing of the esophagus.
   CONCLUSIONS: Esophageal stenting can be used to prevent mediastinal leakage due to esophageal injury in the transsternal approach for high thoracic vertebral metastasis, but the stent might be a cause of tracheomalacia. Stent removal should be considered if upper airway obstruction occurs. Awareness of the radial force of the stent, esophageal composition (e.g., status post suture repair), and esophageal diameter must be considered for optimal stent tolerance to avoid complications.
C1 [Chung, Kai-Chen; Liao, Chih-Hsiang] Taichung Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taichung, Taiwan.
   [Lin, Chih-Hung] Taichung Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taichung, Taiwan.
   [Tsai, Chung-Lin] Taichung Vet Gen Hosp, Cardiovasc Ctr, Dept Cardiovasc Surg, Taichung, Taiwan.
   [Li, Yu-Hsuan] Taichung Vet Gen Hosp, Dept Internal Med, Div Endocrinol & Metab, Taichung, Taiwan.
   [Lin, Chih-Hung; Liao, Chih-Hsiang] Chung Shan Med Univ, Inst Med, Taichung, Taiwan.
RP Liao, CH (reprint author), Taichung Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taichung, Taiwan.; Liao, CH (reprint author), Chung Shan Med Univ, Inst Med, Taichung, Taiwan.
EM seb.ch.liao@gmail.com
OI Liao, Chih-Hsiang/0000-0003-3459-1913
CR Repici A, 2014, DIGEST LIVER DIS, V46, P1093, DOI 10.1016/j.dld.2014.08.037
   Vermeulen Bram D, 2018, Curr Treat Options Gastroenterol, V16, P260, DOI 10.1007/s11938-018-0181-3
   Xiao ZM, 2010, J NEUROSURG-SPINE, V13, P461, DOI 10.3171/2010.4.SPINE09808
   2015, WORLD J GASTROINTEST, V7, P135, DOI DOI 10.4253/WJGE.V7.I2.135
   2017, SURG ENDOSC, V31, P5076, DOI DOI 10.1007/S00464-017-5571-4
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 67
EP 71
DI 10.1016/j.wneu.2019.01.149
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700168
PM 30721772
DA 2020-05-12
ER

PT J
AU Xin, WQ
   Li, MQ
   Li, K
   Li, QF
   Zhao, Y
   Wang, WH
   Gao, YK
   Wang, HY
   Yang, XY
AF Xin, Wen-qiang
   Li, Meng-qi
   Li, Ke
   Li, Qi-feng
   Zhao, Yan
   Wang, Wei-han
   Gao, Yi-kuan
   Wang, Hong-yu
   Yang, Xin-yu
TI Systematic and Comprehensive Comparison of Incidence of Restenosis
   Between Carotid Endarterectomy and Carotid Artery Stenting in Patients
   with Atherosclerotic Carotid Stenosis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carotid artery stenting; Carotid endarterectomy; Carotid stenosis; CAS;
   CEA; Meta-analysis; Restenosis
ID TERM-FOLLOW-UP; TRANSLUMINAL ANGIOPLASTY; TRIAL; OUTCOMES; PREDICTORS;
   STROKE
AB OBJECTIVE: The purpose of the present study was to conduct a meta-analysis to systematically compare the incidence rates of in-stent restenosis after carotid artery stenting (CAS) and restenosis after carotid endarterectomy (CEA) for patients with atherosclerotic carotid stenosis.
   METHODS: We retrieved potential academic reports comparing restenosis between CEA and CAS from the MEDLINE, PubMed, and EMBASE databases and the Cochrane Library from the date of the first CEA (January 1951) to July 20, 2018. The references of the identified studies were carefully reviewed to ensure that all available reports were included in the present study.
   RESULTS: Our meta-analysis included 27 studies (15 randomized controlled trials, 12 nonrandomized controlled trials) and 20,479 participants with atherosclerotic carotid stenosis. A statistically significant difference was found in the cumulative incidence of restenosis >70% between CEA and CAS (risk difference, -0.033, 95% confidence interval [CI] -0.054 to -0.013; P = 0.002). For the restenosis >70% outcomes, although CEA was relevant with a lower rate of restenosis than CAS within 6 months (odds ratio [OR], 0.495; 95% CI, 0.285-0.861; P = 0.013) and 1 year (OR, 0.626; 95% CI, 0.483-0.811; P < 0.001), no statistically significant differences were found at 1.5 years (P = 0.210), 2 years (P = 0.123), 4 years (P = 0.124), 5 years (P = 0.327), or 10 years (P = 0.839). For the restenosis >50% outcomes, a significant difference was found in the rate of restenosis between the CEA and CAS groups within 1 year (OR, 0.317; 95% CI, 0.228-0.441; P < 0.001) but not at 1.5 years (P = 0.301), 2 years (P = 0.686), or 5 years (P = 0.920). No nominally significant effects were demonstrated with respect to the cumulative incidence of occlusion (P = 0.195) or the cumulative incidence of restenosis for symptomatic patients (P = 0.170) between CEA and CAS.
   CONCLUSIONS: Although CAS was preferred over CEA, regardless of restenosis >50% or >70% after revascularization within 1 year, no significant difference was observed with extension of the follow-up period to >1 year. CAS was not associated with a greater cumulative incidence of occlusion or the cumulative incidence of restenosis for symptomatic patients.
C1 [Xin, Wen-qiang; Li, Meng-qi; Li, Qi-feng; Zhao, Yan; Wang, Wei-han; Gao, Yi-kuan; Wang, Hong-yu; Yang, Xin-yu] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.
   [Li, Ke] Tianjin Med Univ, Gen Hosp, Dept Obstet & Gynecol, Tianjin, Peoples R China.
RP Yang, XY (reprint author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.
EM tumeduxinyu@yeah.net
OI Li, Mengqi/0000-0003-3894-5651
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81570507]; Natural Science Foundation of Tianjin
   CityNatural Science Foundation of Tianjin [16JCZDJC35700]; Tianjin
   Science and Technology Projects in Key Areas of Traditional Chinese
   Medicine [2018001]
FX Our work was supported by funding from the National Natural Science
   Foundation of China (grant 81570507 to X.Y.Y.), the Project of the
   Natural Science Foundation of Tianjin City (grant 16JCZDJC35700), and
   Tianjin Science and Technology Projects in Key Areas of Traditional
   Chinese Medicine (grant 2018001).
CR AbuRahma AF, 2002, J VASC SURG, V35, P125, DOI 10.1067/mva.2002.119034
   AbuRahma AF, 2010, J VASC SURG, V52, P1180, DOI 10.1016/j.jvs.2010.06.074
   Akhigbe T, 2017, J CLIN NEUROSCI, V39, P45, DOI 10.1016/j.jocn.2017.02.016
   Akinci T, 2016, NEUROSCIENCES, V21, P319, DOI 10.17712/nsj.2016.4.20160079
   Arquizan C, 2011, STROKE, V42, P1015, DOI 10.1161/STROKEAHA.110.589309
   Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002
   Barros P, 2014, J STROKE CEREBROVASC, V23, P1416, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.002
   Becquemin JP, 2003, J ENDOVASC THER, V10, P687, DOI 10.1583/1545-1550(2003)010<0687:CSVCSA>2.0.CO;2
   Bonati LH, 2009, LANCET NEUROL, V8, P908, DOI 10.1016/S1474-4422(09)70227-3
   Brooks WH, 2014, JACC-CARDIOVASC INTE, V7, P163, DOI 10.1016/j.jcin.2013.09.010
   Brott TG, 2016, NEW ENGL J MED, V374, P1021, DOI 10.1056/NEJMoa1505215
   Brown MM, 2001, LANCET, V357, P1729
   Cao P, 2006, STROKE, V37, P1221, DOI 10.1161/01.STR.0000217435.21051.60
   Cosottini M, 2010, STROKE RES TREAT, V2010, DOI 10.4061/2010/864724
   Cui LK, 2018, EUR J VASC ENDOVASC, V55, P614, DOI 10.1016/j.ejvs.2018.02.020
   Dai ZZ, 2017, VASCULAR, V25, P576, DOI 10.1177/1708538117706273
   Daou B, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011783
   De Borst GJ, 2012, J CARDIOVASC SURG, V53, P27
   de Borst GJ, 2007, J VASC SURG, V45, P118, DOI 10.1016/j.jvs.2006.09.013
   De Borst GJ, 2006, J CARDIOVASC SURG, V47, P49
   De Rango P, 2010, J VASC SURG, V51, P337, DOI 10.1016/j.jvs.2009.08.095
   Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0
   Ederle J, 2009, LANCET NEUROL, V8, P898, DOI 10.1016/S1474-4422(09)70228-5
   Featherstone RL, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20200
   Flaherty ML, 2013, NEUROEPIDEMIOLOGY, V40, P36, DOI 10.1159/000341410
   Giannopoulos S, 2018, CARDIOVASC REVASCULA, V19, P638, DOI 10.1016/j.carrev.2018.01.014
   Gray WA, 2002, STROKE, V33, P1063, DOI 10.1161/hs0402.105304
   Heo SH, 2017, EUR J VASC ENDOVASC, V54, P573, DOI 10.1016/j.ejvs.2017.08.006
   Hirschberg K, 2009, J CARDIOVASC SURG, V50, P655
   Hoffmann A, 2006, SCHWEIZ ARCH NEUROL, V157, P191
   Horst HM, 2002, AM SURGEON, V68, P279
   Hunter GC, 1997, AM J SURG, V174, P583, DOI 10.1016/S0002-9610(97)80927-0
   Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302
   Jung JM, 2017, J NEUROINTERV SURG, V9, P750, DOI 10.1136/neurintsurg-2016-012293
   Kang DH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133845
   Khan MA, 2003, AM J CARDIOL, V92, P895, DOI 10.1016/S0002-9149(03)00912-3
   Lal BK, 2012, LANCET NEUROL, V11, P755, DOI 10.1016/S1474-4422(12)70159-X
   Lattimer CR, 1997, BRIT J SURG, V84, P1206
   Li Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180804
   LING F, 2006, CHIN J CEREBROVASC D, V3, P4
   Liu B, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.03.067
   Liu Chang-Wei, 2009, Zhonghua Wai Ke Za Zhi, V47, P267
   Manheim D, 2017, J CARDIOVASC SURG, V58, P814, DOI 10.23736/S0021-9509.16.09513-6
   Mas JL, 2014, STROKE, V45, P2750, DOI 10.1161/STROKEAHA.114.005671
   Mazighi M, 2010, AM J NEURORADIOL, V31, P496, DOI 10.3174/ajnr.A1778
   McCabe DJH, 2005, STROKE, V36, P281, DOI 10.1161/01.STR.0000152333.75932.fe
   Moon K, 2016, J NEUROINTERV SURG, V8, P1006, DOI 10.1136/neurintsurg-2015-011938
   Petty GW, 2000, STROKE, V31, P1062, DOI 10.1161/01.STR.31.5.1062
   Pourier VEC, 2016, J VASC SURG, V64, P1486, DOI 10.1016/j.jvs.2016.07.106
   Rajagopal Vivek, 2007, Curr Cardiol Rep, V9, P20, DOI 10.1007/s11886-007-0005-x
   Sadideen H, 2006, INT J CLIN PRACT, V60, P1625, DOI 10.1111/j.1742-1241.2005.00775.x
   Setacci F, 2013, ANN VASC SURG, V27, P888, DOI 10.1016/j.avsg.2013.02.013
   Shao AW, 2014, J CRANIOFAC SURG, V25, P1441, DOI 10.1097/SCS.0000000000000791
   Steinbauer MGM, 2008, J VASC SURG, V48, P93, DOI 10.1016/j.jvs.2008.02.049
   Stilo F, 2017, INT J CARDIOL, V249, P392, DOI 10.1016/j.ijcard.2017.09.166
   Takigawa T, 2009, NEUROL MED-CHIR, V49, P413, DOI 10.2176/nmc.49.413
   Van Laanen J, 2008, J CARDIOVASC SURG, V49, P743
   Vos JA, 2009, J VASC SURG, V50, P755, DOI 10.1016/j.jvs.2009.04.060
   White RA, 2005, J VASC SURG, V42, P213, DOI 10.1016/j.jvs.2005.04.023
   Willfort-Ehringer A, 2004, J VASC SURG, V39, P728, DOI 10.1016/j.jvs.2003.12.029
   Xu BF, 2017, BIOMED REP, V7, P128, DOI 10.3892/br.2017.933
   Yang L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23061-7
   Younis GA, 2007, CATHETER CARDIO INTE, V69, P673, DOI 10.1002/ccd.20809
   Zarins CK, 2009, J ENDOVASC THER, V16, P397, DOI 10.1583/08-2685.1
   Zhang L, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001060
   Zheng J, 2014, EUR J VASC ENDOVASC, V47, P8, DOI 10.1016/j.ejvs.2013.10.011
   2002, AM SURG, V68, P275
NR 67
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 74
EP 86
DI 10.1016/j.wneu.2019.01.118
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700170
PM 30710719
DA 2020-05-12
ER

PT J
AU Kim, JH
   Lee, SK
   Hong, JH
   Moon, BJ
   Lee, JK
AF Kim, Ju-Hwi
   Lee, Seul-Kee
   Hong, Jong-Hwan
   Moon, Bong Ju
   Lee, Jung-Kil
TI Retropharyngeal Granulation: Delayed Complication of Anterior Cervical
   Diskectomy and Fusion in C2-3
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior surgery; Cervical; Dysphagia; Granulation tissue; Plate
ID SPINE SURGERY; ZERO-PROFILE; RISK-FACTORS; POSTOPERATIVE DYSPHAGIA;
   PLATE FIXATION; REDUCES RATE; ACDF; CAGE; DECOMPRESSION; SINGLE
AB BACKGROUND: A 26-year-old man presented with acute quadriparesis owing to a traffic accident. A computed tomography scan revealed a hangman fracture and locking of the left facet joint at C2-3. Magnetic resonance imaging showed a high signal change of the spinal cord on T2-weighted image and hemorrhage in the C2-3 level.
   CASE DESCRIPTION: An emergency closed reduction after anterior cervical diskectomy and fusion were performed for spinal stability and decompression of the dural sac. Five months postoperatively, C1-2-3 posterior wiring using an iliac bone graft with the Brook method was performed due to nonunion of C2-3. After using the posterior cervical approach, the patient began complaining about the difficulty in swallowing. A 5 x 2 x 1-cm-sized posterior pharyngeal wall mass was detected on an endoscopic examination. Despite conservative management, the retropharyngeal mass progressed and dysphagia worsened, so the retropharyngeal wall granulation mass was resected by a laryngologist. Despite removal of the granulation mass, dysphagia and throat discomfort persisted for about 2 years. The plate and screws were removed considering their possible correlation with the granulation tissue. One month after plate removal, the retropharyngeal granulation tissue resolved almost spontaneously. At the last follow-up, the radiologic examination showed well-fused C1-2-3 with good alignment. The patient had no residual neurologic deficits or dysphagia.
   CONCLUSIONS: Retropharyngeal granulation can occur as a late complication associated with plate fixation after anterior cervical diskectomy and fusion. Recurrent retropharyngeal wall granulation caused by plate irritation might only be resolved after plate and screw removal.
C1 [Lee, Jung-Kil] Chonnam Natl Univ Hosp, Dept Neurosurg, Gwangju, South Korea.
   Med Sch, Gwangju, South Korea.
RP Lee, JK (reprint author), Chonnam Natl Univ Hosp, Dept Neurosurg, Gwangju, South Korea.
EM leejk0261@hanmail.net
CR Barbagallo GMV, 2013, EUR SPINE J, V22, pS868, DOI 10.1007/s00586-013-3005-0
   Bazaz R, 2002, SPINE, V27, P2453, DOI 10.1097/00007632-200211150-00007
   Campbell P, 2010, CLIN ORTHOP RELAT R, V468, P2321, DOI 10.1007/s11999-010-1372-y
   Chin KR, 2007, SPINE, V32, P2585, DOI 10.1097/BRS.0b013e318158dec8
   Finn MA, 2016, CLIN SPINE SURG, V29, pE536
   Fisahn C, 2018, WORLD NEUROSURG, V109, pE382, DOI 10.1016/j.wneu.2017.09.188
   Fogel Guy R, 2005, Spine J, V5, P140
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   Fraser JF, 2007, J NEUROSURG-SPINE, V6, P298, DOI 10.3171/spi.2007.6.4.298
   Hofstetter CP, 2015, J SPINAL DISORD TECH, V28, pE284, DOI 10.1097/BSD.0b013e31828873ed
   Jung A, 2005, J NEUROSURG-SPINE, V2, P123, DOI 10.3171/spi.2005.2.2.0123
   Kaiser MG, 2002, NEUROSURGERY, V50, P229, DOI 10.1097/00006123-200202000-00001
   Kriskovich MD, 2000, LARYNGOSCOPE, V110, P1467, DOI 10.1097/00005537-200009000-00011
   Lee MJ, 2007, SPINE J, V7, P141, DOI 10.1016/j.spinee.2006.02.024
   Lee SE, 2016, J CLIN NEUROSCI, V29, P121, DOI 10.1016/j.jocn.2015.10.039
   Li ZH, 2017, EUR SPINE J, V26, P1129, DOI 10.1007/s00586-016-4739-2
   McAfee PC, 2010, J SPINAL DISORD TECH, V23, P1, DOI 10.1097/BSD.0b013e31819e2ab8
   Min Y, 2016, CLIN SPINE SURG, V29, pE177, DOI 10.1097/BSD.0000000000000060
   Oliver JD, 2018, SPINE, V43, pE413, DOI 10.1097/BRS.0000000000002441
   Riley LH, 2005, SPINE, V30, P2564, DOI 10.1097/01.brs.0000186317.86379.02
   Schindler JS, 2002, LARYNGOSCOPE, V112, P589, DOI 10.1097/00005537-200204000-00001
   Schleicher P, 2018, GLOB SPINE J, V8, p25S, DOI 10.1177/2192568217745062
   Smith-Hammond CA, 2004, SPINE, V29, P1441, DOI 10.1097/01.BRS.0000129100.59913.EA
   Song KJ, 2014, ASIAN SPINE J, V8, P531, DOI 10.4184/asj.2014.8.4.531
   Veeravagu A, 2014, SPINE J, V14, P1125, DOI 10.1016/j.spinee.2013.07.474
   Wang T, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007916
   Winslow CP, 2001, ARCH OTOLARYNGOL, V127, P51, DOI 10.1001/archotol.127.1.51
   Wu B, 2017, CLIN SPINE SURG, V30, pE554, DOI 10.1097/BSD.0000000000000180
   Xiao SW, 2017, EUR SPINE J, V26, P975, DOI 10.1007/s00586-016-4914-5
   Yang HS, 2015, ARCH ORTHOP TRAUM SU, V135, P781, DOI 10.1007/s00402-015-2212-z
   Yang Y, 2016, CLIN NEUROL NEUROSUR, V148, P72, DOI 10.1016/j.clineuro.2016.07.020
NR 31
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 87
EP 92
DI 10.1016/j.wneu.2019.01.156
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700171
PM 30735876
DA 2020-05-12
ER

PT J
AU Jain, S
   Chan, HM
   Yeo, TT
   Teo, K
AF Jain, Swati
   Chan, Hui-Minn
   Yeo, Tseng Tsai
   Teo, Kejia
TI Language Mapping of Hindi and English in a Bilingual Patient During
   Resection of a Right Frontal Glioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Awake surgeries; Gliomas; Language mapping; Neuronal plasticity
ID SURGERY; MIND
AB BACKGROUND: Recent advancements in understanding the molecular basis of gliomas and new concepts of neuronal plasticity have shown the importance of maximal resection in gliomas to improve progression-free overall survival. Awake craniotomies with intraoperative cortical and subcortical mapping have helped to achieve this aim while allowing us to preserve executive function including language. Language mapping becomes a daunting task in individuals who are bilingual because of the complexity of varied cortical representation of different languages.
   CASE DESCRIPTION: We present a case of a bilingual patient who underwent re-resection of right frontal astrocytoma using principles of awake surgery and language mapping. Our patient was fluent in English and Hindi. She underwent a complete neurophysiologic cognitive assessment in both languages preoperatively. She was tested for speech arrest, nominal aphasia, and semantic paraphasia intraoperatively for both English and Hindi. She underwent a gross total resection with postoperative preservation of both English and Hindi. Intraoperative language mapping revealed that while certain cortical areas overlapped between 2 languages, other aspects were represented by distinct areas. Postoperative assessment at 2 months revealed most major aspects of language remained preserved or had improved relative to the preoperative baseline.
   CONCLUSIONS: Advancements in anesthesia and neuromonitoring have further allowed for long awake periods, permitting complex language tasks to be tested intraoperatively. The results obtained from this case study have allowed us to further plan for awake surgeries for patients with bilingualism. With understanding bilingual representation of languages, we hope to achieve maximal resection with minimal postoperative deficits.
C1 [Jain, Swati; Yeo, Tseng Tsai; Teo, Kejia] Univ Surg Cluster, Div Neurosurg, Singapore, Singapore.
   [Chan, Hui-Minn] Natl Univ Hlth Syst, Dept Psychol Med, Singapore, Singapore.
RP Jain, S (reprint author), Univ Surg Cluster, Div Neurosurg, Singapore, Singapore.
EM swati_jain@nuhs.edu.sg
RI Teo, Kejia/U-5524-2017
OI Teo, Kejia/0000-0003-4586-1683
CR BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x
   Bourdillon P, 2017, EPILEPSIA, V58, P2038, DOI 10.1111/epi.13935
   Dubey N, 2018, Q J EXP PSYCHOL, V71, P2421, DOI 10.1177/1747021817743241
   Duffau H, 2015, J NEUROSURG SCI, V59, P361
   Duffau H, 2013, NEUROCHIRURGIE, V59, P2, DOI 10.1016/j.neuchi.2012.11.001
   Duffau H, 2018, J CHEM NEUROANAT, V89, P73, DOI 10.1016/j.jchemneu.2017.04.003
   Duffau H, 2016, ACTA NEUROCHIR, V158, P51, DOI 10.1007/s00701-015-2621-3
   Friederici AD, 2017, NAT HUM BEHAV, V1, P713, DOI 10.1038/s41562-017-0184-4
   GOMEZTORTOSA E, 1995, BRAIN LANG, V48, P320, DOI 10.1006/brln.1995.1014
   Goyal L, 2011, INF SYST IND LANG MA
   Kumar U, 2014, NEUROSCI LETT, V580, P94, DOI 10.1016/j.neulet.2014.07.053
   Kumar U, 2013, BRAIN IMAGING BEHAV, V7, P91, DOI 10.1007/s11682-012-9198-8
   Kumar U, 2010, READ WRIT, V23, P239, DOI 10.1007/s11145-009-9176-8
   Libben MPG, 1987, ASSESSMENT BILINGUAL
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   OJEMANN GA, 1978, ARCH NEUROL-CHICAGO, V35, P409, DOI 10.1001/archneur.1978.00500310011002
   PARADIS J, 2001, INT J BILINGUAL, V5, P19, DOI DOI 10.1177/13670069010050010201
   Paradis M, 2011, CLIN LINGUIST PHONET, V25, P427, DOI 10.3109/02699206.2011.560326
   Price CJ, 2000, J ANAT, V197, P335, DOI 10.1046/j.1469-7580.2000.19730335.x
   Roux FE, 2004, BRAIN, V127, P1796, DOI 10.1093/brain/awh204
   Samson K, 2013, NEUROL TODAY, V13, P8
   Singapore DoS, 2018, POPULATION TRENDS
   Singh Nandini Chatterjee, 2014, Indian J Radiol Imaging, V24, P44, DOI 10.4103/0971-3026.130691
   Walker JA, 2004, NEUROSURGERY, V54, P113, DOI 10.1227/01.NEU.0000097270.95721.3B
   Xia L, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3909-x
   Yordanova YN, 2017, NEUROCHIRURGIE, V63, P243, DOI 10.1016/j.neuchi.2016.09.006
NR 26
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 106
EP 110
DI 10.1016/j.wneu.2019.01.153
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700175
PM 30735861
DA 2020-05-12
ER

PT J
AU Arsanious, D
   Sribnick, E
AF Arsanious, David
   Sribnick, Eric
TI Intrahepatic Cerebrospinal Fluid Pseudocyst: A Case Report and
   Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Complication; Hepatic pseudocyst; Intrahepatic pseudocyst;
   Ventriculoperitoneal shunt; VP shunt
ID VENTRICULOPERITONEAL SHUNT; LIVER-ABSCESS; ABDOMINAL COMPLICATIONS; RARE
   COMPLICATION; HEPATIC-ABSCESS; INFECTION; CATHETER
AB BACKGROUND: Perforation of a solid visceral organ and subsequent development of a cerebrospinal fluid pseudocyst is a rare complication of ventriculoperitoneal shunts.
   CASE DESCRIPTION: A patient with a history of global developmental delay presented with shunt failure secondary to an intrahepatic cerebrospinal fluid pseudocyst. The diagnosis had not been initially apparent owing to the absence of ventriculomegaly or a palpable abdominal mass and/or tenderness. Following diagnosis on abdominal imaging, the pseudocyst was aspirated, and the ventriculoperitoneal shunt was successfully revised.
   CONCLUSIONS: A series of 22 cases of previously reported intrahepatic pseudocysts and abscesses is presented, and the putative mechanisms that have been put forward to explain the development of these collections are discussed. Review of the literature demonstrates that several techniques have been successfully employed in the management of this complication.
C1 [Arsanious, David] West Virginia Univ, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA.
   [Sribnick, Eric] Nationwide Childrens Hosp, Dept Neurosurg, Columbus, OH USA.
RP Arsanious, D (reprint author), West Virginia Univ, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA.
EM david.arsanious@hsc.wvu.edu
RI Sribnick, Eric/AAH-6693-2020
CR Acharya R, 2001, J LAPAROENDOSC ADV A, V11, P167, DOI 10.1089/10926420152389323
   AGHA FP, 1983, SURG GYNECOL OBSTET, V156, P473
   Anderson CM, 2003, J AM COLL SURGEONS, V196, P297, DOI 10.1016/S1072-7515(02)01751-9
   Banka S, 2007, PEDIATR NEUROSURG, V43, P444, DOI 10.1159/000106402
   Berkmann S, 2011, MINIM INVAS NEUROSUR, V54, P83, DOI 10.1055/s-0031-1277174
   BRYANT MS, 1988, AM SURGEON, V54, P50
   Chitkara N, 2004, NEUROL INDIA, V52, P405
   Dabdoub Carlos B, 2013, Surg Neurol Int, V4, P162, DOI 10.4103/2152-7806.123783
   de Aquino HB, 2006, CHILD NERV SYST, V22, P1225, DOI 10.1007/s00381-005-0025-z
   FARRELL RJ, 1994, AM J GASTROENTEROL, V89, P140
   FISHER RA, 1984, NEUROSURGERY, V14, P480, DOI 10.1227/00006123-198404000-00015
   Hsieh CT, 2006, NEUROL INDIA, V54, P86
   Huang LT, 1998, PEDIATR SURG INT, V13, P6
   Kaplan M, 2007, PEDIATR NEUROSURG, V43, P501, DOI 10.1159/000108795
   Kolic Z, 2010, WIEN KLIN WOCHENSCHR, V122, P641, DOI 10.1007/s00508-010-1474-2
   Kumar M M, 1995, J Indian Med Assoc, V93, P403
   Limbrick DD, 2014, J NEUROSURG-PEDIATR, V14, P30, DOI 10.3171/2014.7.PEDS14324
   MATA J, 1986, J COMPUT ASSIST TOMO, V10, P341, DOI 10.1097/00004728-198603000-00037
   Mechaber AJ, 1997, CLIN INFECT DIS, V25, P1244, DOI 10.1086/516957
   PAONE RF, 1991, PEDIATR INFECT DIS J, V10, P338, DOI 10.1097/00006454-199104000-00017
   Peltier J, 2011, NEUROCHIRURGIE, V57, P31, DOI 10.1016/j.neuchi.2009.11.004
   PETERFY CG, 1990, AM J ROENTGENOL, V155, P894, DOI 10.2214/ajr.155.4.2119130
   RANA SR, 1985, CHILD NERV SYST, V1, P349, DOI 10.1007/BF00270822
   REDDY SC, 1987, SOUTH MED J, V80, P1309, DOI 10.1097/00007611-198710000-00026
   Shen MC, 2003, J FORMOS MED ASSOC, V102, P113
   TOUHO H, 1987, NEUROSURGERY, V21, P258, DOI 10.1227/00006123-198708000-00027
   Verma A, 2012, CLIN NEUROL NEUROSUR, V114, P389, DOI 10.1016/j.clineuro.2011.10.028
   WANG F, 1989, PEDIATR RADIOL, V19, P326, DOI 10.1007/BF02467305
   Yang TK, 2013, J KOREAN NEUROSURG S, V54, P441, DOI 10.3340/jkns.2013.54.5.441
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 111
EP 116
DI 10.1016/j.wneu.2019.01.150
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700176
PM 30721775
DA 2020-05-12
ER

PT J
AU Wang, XK
   Chen, Y
   Wu, XJ
   Zhang, HL
AF Wang, Xiaoke
   Chen, Yang
   Wu, Xiujuan
   Zhang, Hongliang
TI Intracranial Inflammatory Myofibroblastic Tumor with Negative Expression
   of Anaplastic Lymphoma Kinase: A Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anaplastic lymphoma kinase; Central nervous system; Inflammatory
   myofibroblastic tumor
ID CENTRAL-NERVOUS-SYSTEM
AB BACKGROUND: Inflammatory myofibroblastic tumor (IMT) is an indolent tumor mainly affecting children and young adults. As a rare mesenchymal tumor with unknown etiology and pathogenesis, IMT has a predilection for the lung and abdominopelvic region. Previous literature featuring IMT in the central nervous system (IMT-CNS) is rare. The clinical symptoms and radiologic features of IMT-CNS are not specific; therefore, the diagnosis is predominately based on the histopathologic and immunohistochemical analysis of the specimen.
   CASE DESCRIPTION: We herein present a case of a 21-year-old woman who complained of bilateral blurred vision for 15 days. Head magnetic resonance imaging demonstrated a round-shaped and irregular lesion located in the right frontal lobe. The boundary of the lesion was clear, and the lesion was homogeneously enhanced. Peripheral edema of the lesion was observed, and the mass effect was obvious. Supratentorial craniotomy tumor resection was performed. Histopathologic and immunohistochemical analysis revealed IMT, which had negative expression of anaplastic lymphoma kinase.
   CONCLUSIONS: Remission of her symptoms was observed, and no recurrence was recorded during a 6-month follow-up.
C1 [Wang, Xiaoke] Jilin Univ, Hosp 2, Dept Neurosurg, Changchun, Jilin, Peoples R China.
   [Chen, Yang; Wu, Xiujuan; Zhang, Hongliang] Jilin Univ, Hosp 1, Dept Neurol, Changchun, Jilin, Peoples R China.
RP Zhang, HL (reprint author), Jilin Univ, Hosp 1, Dept Neurol, Changchun, Jilin, Peoples R China.
EM drzhl@hotmail.com
RI Zhang, Hongliang/AAN-3077-2020
OI Zhang, Hongliang/0000-0001-9205-5559
CR Butrynski JE, 2010, NEW ENGL J MED, V363, P1727, DOI 10.1056/NEJMoa1007056
   Carswell C, 2012, CLIN NEUROL NEUROSUR, V114, P77, DOI 10.1016/j.clineuro.2011.07.026
   Chuah YY, 2016, WORLD NEUROSURG, V93, DOI 10.1016/j.wneu.2016.07.060
   Coffin CM, 2007, AM J SURG PATHOL, V31, P509, DOI 10.1097/01.pas.0000213393.57322.c7
   Denis Daniel J, 2013, Surg Neurol Int, V4, P70, DOI 10.4103/2152-7806.112614
   Dulskas A, 2016, ONCOL LETT, V11, P1586, DOI 10.3892/ol.2015.4060
   Fan Ming-chao, 2012, Chinese Medical Sciences Journal, V27, P185
   Fletcher CD, 2002, PATHOLOGY GENETICS T
   Fletcher CDM, 2006, HISTOPATHOLOGY, V48, P3, DOI 10.1111/j.1365-2559.2005.02284.x
   Gleason BC, 2008, J CLIN PATHOL, V61, P428, DOI 10.1136/jcp.2007.049387
   Hausler M, 2003, HUM PATHOL, V34, P253, DOI 10.1053/hupa.2003.35
   Jeon YK, 2005, J NEUROPATH EXP NEUR, V64, P254, DOI 10.1093/jnen/64.3.254
   Kato K, 2011, NEUROL MED-CHIR, V51, P79, DOI 10.2176/nmc.51.79
   Park Jong-Heok, 2015, Brain Tumor Res Treat, V3, P138, DOI 10.14791/btrt.2015.3.2.138
   Pascual-Gallego M, 2013, NEUROL INDIA, V61, P644, DOI 10.4103/0028-3886.125273
   Puntambekar P, 2012, J NEURO-ONCOL, V106, P327, DOI 10.1007/s11060-011-0667-5
   Schweisfurth MA, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/5/056010
   Surabhi VR, 2016, RADIOL CLIN N AM, V54, P553, DOI 10.1016/j.rcl.2015.12.005
   Swain RS, 2008, HUM PATHOL, V39, P410, DOI 10.1016/j.humpath.2007.07.012
   Tao J, 2015, INT J CLIN EXP MED, V8, P1604
   Welsh CT, 2016, SEMIN DIAGN PATHOL, V33, P13, DOI 10.1053/j.semdp.2015.09.003
   Zhang T, 2015, ONCOL LETT, V10, P675, DOI 10.3892/ol.2015.3297
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 117
EP 122
DI 10.1016/j.wneu.2019.01.155
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700177
PM 30735872
DA 2020-05-12
ER

PT J
AU Ben Elhend, S
   Belfquih, H
   Hammoune, N
   Athmane, E
   Mouhsine, A
AF Ben Elhend, Salah
   Belfquih, Hatim
   Hammoune, Nabil
   Athmane, El Mehdi
   Mouhsine, Abdelilah
TI Lipoma with Agenesis of Corpus Callosum: 2 Case Reports and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Dysgenesis of the corpus callosum; Epilepsy; Lipoma of the corpus
   callosum; Magnetic resonance imaging
ID MR
AB BACKGROUND: Intracranial lipomas are extremely rare fat-containing lesions, comprising 0.1-0.5% of all primary brain tumors. Lipoma of corpus callosum, the commonest variety of all intracranial lipomas (40%-50%), is associated with varying degrees of dysgenesis of corpus callosum and generally remains asymptomatic.
   CASE DESCRIPTION: In this study, we report 2 cases of pericallosal lipomas admitted with seizures and discuss the clinical and radiologic findings in light of the literature.
   CONCLUSIONS: Lipomas of the corpus callosum are rare, fat-containing asymptomatic lesions, mostly associated with dysgenesis of the corpus callosum. Diagnosis accidentally occurs during diagnostic procedures in case of an encephalic disorder. Magnetic resonance imaging is the most useful modality for a differential diagnosis. Prognosis and symptoms depend on associated malformations. Surgical treatment is mostly not indicated and should be avoided.
C1 [Ben Elhend, Salah; Hammoune, Nabil; Athmane, El Mehdi; Mouhsine, Abdelilah] Avicenne Mil Hosp, Dept Radiol, Marrakech, Morocco.
   [Belfquih, Hatim] Avicenne Mil Hosp, Dept Neurosurg, Marrakech, Morocco.
RP Ben Elhend, S (reprint author), Avicenne Mil Hosp, Dept Radiol, Marrakech, Morocco.
EM salahbenel4000@gmail.com
CR Alam A, 2006, Med J Armed Forces India, V62, P299, DOI 10.1016/S0377-1237(06)80032-8
   Kamoun B, 2018, J I M SFAX, V28, P61
   Park YS, 2010, J KOREAN NEUROSURG S, V47, P148, DOI 10.3340/jkns.2010.47.2.148
   Taglialatela G., 2009, NEUROANATOMY, V8, P39
   TART RP, 1991, J COMPUT ASSIST TOMO, V15, P805, DOI 10.1097/00004728-199109000-00015
   TRUWIT CL, 1990, AM J NEURORADIOL, V11, P665
   WICKREMESEKERA AC, 1993, BRIT J NEUROSURG, V7, P323, DOI 10.3109/02688699309023819
   Yilmaz MB, 2016, TURK NEUROSURG, V26, P364, DOI 10.5137/1019-5149.JTN.13008-14.0
   2014, J NEUROSCI RURAL PRA, V5, P91, DOI DOI 10.4103/0976-3147.127932
NR 9
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 123
EP 125
DI 10.1016/j.wneu.2019.01.088
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700178
PM 30703587
DA 2020-05-12
ER

PT J
AU Guo, XY
   Zhu, N
   Hao, DJ
AF Guo Xinyu
   Zhu Na
   Hao Dingjun
TI Rare Hereditary Klippel-Feil Syndrome and Arnold-Chiari Malformation
   Caused by Cervical Spondylotic Myelopathy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spondylotic myelopathy; Hereditary; Klippel-Feil syndrome;
   Numbness; Weakness
AB BACKGROUND: A rare case of familial genetic disorder Klippel-Feil syndrome and Arnold-Chiari malformation caused by cervical spondylotic myelopathy was reported here.
   CASE DESCRIPTION: The reconstruction of stability and spinal cord decompression was achieved by anterior cervical discectomy, fusion, and internal fixation.
   CONCLUSIONS: Although the disease genetic characteristics have been studied, operation is necessary when it leads to abnormal neurologic symptoms and the surgery of surgery can have a beneficial outcome.
C1 [Guo Xinyu; Hao Dingjun] Xi An Jiao Tong Univ, Dept Spinal Surg, Coll Med, Honghui Hosp, Xian, Shaanxi, Peoples R China.
   [Guo Xinyu; Hao Dingjun] Xian Med Univ, Dept Spinal Surg, Honghui Hosp, Xian, Shaanxi, Peoples R China.
   [Zhu Na] Xiangyang Ctr Hosp, Dept Imaging, Xiang Yang, Peoples R China.
RP Hao, DJ (reprint author), Xi An Jiao Tong Univ, Dept Spinal Surg, Coll Med, Honghui Hosp, Xian, Shaanxi, Peoples R China.; Hao, DJ (reprint author), Xian Med Univ, Dept Spinal Surg, Honghui Hosp, Xian, Shaanxi, Peoples R China.
EM haodingjun@126.com
OI Hao, Dingjun/0000-0002-0946-6080
NR 0
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 126
EP 128
DI 10.1016/j.wneu.2018.12.101
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700179
PM 30610988
DA 2020-05-12
ER

PT J
AU Luo, RJ
   Song, Y
   Liao, ZW
   Yin, HP
   Zhan, SF
   Yang, C
AF Luo, Rongjin
   Song, Yu
   Liao, Zhiwei
   Yin, Huipeng
   Zhan, Shengfeng
   Yang, Cao
TI Severe Kyphoscoliosis Associated with Multiple Giant Intraspinal
   Epidural Cysts: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Neurologic deficit; Posterior vertebral column resection; Severe
   kyphoscoliosis; Spinal epidural arachnoid cyst
ID EXTRADURAL ARACHNOID CYSTS
AB BACKGROUND: Severe kyphoscoliosis associated with multiple giant spinal epidural arachnoid cysts (SEACs) is an extremely rare condition and remains a challenge in clinical practice. This study aimed to present a case of severe spinal deformity associated with multiple giant SEACs and to discuss strategies for the preoperative diagnosis and treatment.
   CASE DESCRIPTION: A 22-year-old man with severe thoracolumbar kyphoscoliosis associated with multiple giant SEACs presented with progressive scoliosis, spastic paralysis, numbness, and abnormal gait. X-ray and magnetic resonance imaging revealed severe rigid kyphoscoliosis, extensive diffuse cystic space-occupying lesions, and diffuse spinal cord compression. After multidisciplinary consultation and discussion, the patient underwent a cystperitoneal shunting surgery followed by posterior vertebral column resection (PVCR) correction. The postoperative course was uneventful. Both kyphosis and scoliosis were significantly corrected, and muscle weakness of the lower extremities and sensory disturbance partially improved. At the 2-year follow-up visit, the patient could freely walk without the aid of crutches, but there were some residual neurologic deficits in both legs. A plain radiograph showed that bony fusion was achieved, and the correction was well maintained.
   CONCLUSIONS: Cyst-peritoneal shunting surgery followed by PVCR, as in our case, could be an alternative surgical strategy for multiple giant SEACs associated with severe rigid kyphoscoliosis.
C1 [Luo, Rongjin; Song, Yu; Liao, Zhiwei; Yin, Huipeng; Zhan, Shengfeng; Yang, Cao] Huazhong Univ Sci & Technol, Union Hosp, Dept Orthopaed, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
RP Yang, C (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Dept Orthopaed, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
EM caoyangunion@hust.edu.cn
OI Yang, Cao/0000-0002-0058-614X
CR Araujo SD, 2009, J CLIN NEUROSCI, V16, P1369, DOI 10.1016/j.jocn.2008.10.021
   Cho Ho-Yeon, 2015, Korean J Spine, V12, P217, DOI 10.14245/kjs.2015.12.3.217
   Choi JY, 2006, ACTA NEUROCHIR, V148, P579, DOI 10.1007/s00701-006-0744-2
   Ergun T, 2009, NEUROLOGIST, V15, P347, DOI 10.1097/NRL.0b013e318194022e
   Funao H, 2012, NEUROSURGERY, V71, P278, DOI 10.1227/NEU.0b013e318257bf74
   Garg K, 2017, BRIT J NEUROSURG, V31, P172, DOI 10.1080/02688697.2016.1229747
   Kanetaka M, 2011, J CLIN NEUROSCI, V18, P863, DOI 10.1016/j.jocn.2010.10.013
   Kizilay Zahir, 2015, Open Access Maced J Med Sci, V3, P135, DOI 10.3889/oamjms.2015.026
   Krings T, 2001, ACTA NEUROCHIR, V143, P227, DOI 10.1007/s007010170102
   Kulkarni AG, 2009, BRIT J NEUROSURG, V18, P484
   Lee CH, 2012, ACTA NEUROCHIR, V154, P1219, DOI 10.1007/s00701-012-1356-7
   Lee SH, 2014, EUR SPINE J, V23, P1755, DOI 10.1007/s00586-014-3393-9
   Liu James K, 2007, Neurosurg Focus, V22, pE6
   Miyakoshi Naohisa, 2010, Spine J, V10, pe14, DOI 10.1016/j.spinee.2010.08.029
   Nayak Raghavendra, 2017, Asian J Neurosurg, V12, P321, DOI 10.4103/1793-5482.150004
   Neal MT, 2018, J NEUROSURG-SPINE, V28, P181, DOI 10.3171/2017.6.SPINE17155
   Neo M, 2004, SPINE, V29, pE426, DOI 10.1097/01.brs.0000141189.41705.70
   Netra R, 2011, J SPINAL DISORD TECH, V24, P132, DOI 10.1097/BSD.0b013e3181e47b47
   Park HY, 2012, CHILD NERV SYST, V28, P1807, DOI 10.1007/s00381-012-1774-0
   Qi W, 2015, ACTA NEUROCHIR, V157, P539, DOI 10.1007/s00701-014-2278-3
   Saifi C, 2017, GLOB SPINE J, V7, P280, DOI 10.1177/2192568217699203
   Tureyen Kudret, 2009, Spine J, V9, pe10, DOI 10.1016/j.spinee.2009.03.006
   Wenger M, 2007, J CLIN NEUROSCI, V14, P693, DOI 10.1016/j.jocn.2006.02.011
   Woo Joon Bum, 2016, Korean J Neurotrauma, V12, P185, DOI 10.13004/kjnt.2016.12.2.185
   Yu J, 2012, TURK NEUROSURG, V22, P465, DOI 10.5137/1019-5149.JTN.3597-10.1
   Zhang Y, 2019, EUR SPINE J, V28, P421, DOI 10.1007/s00586-018-5522-3
   2001, ACTA NEUROCHIR WIEN, V143, P227
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 129
EP 135
DI 10.1016/j.wneu.2019.01.178
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700180
PM 30738941
DA 2020-05-12
ER

PT J
AU Sun, SW
   Li, YP
   Wang, XD
   Lu, GY
   She, L
   Yan, ZC
   Zhang, HZ
AF Sun, Shuwen
   Li, Yuping
   Wang, Xiaodong
   Lu, Guangyu
   She, Lei
   Yan, Zhengcun
   Zhang, Hengzhu
TI Safety and Efficacy of Laminoplasty Versus Laminectomy in the Treatment
   of Spinal Cord Tumors: A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Laminectomy; Laminoplasty; Meta-analysis; Spinal cord tumor
ID DEFORMITY; CHILDREN; RESECTION; FUSION; INSTABILITY; SURGERY
AB BACKGROUND: Laminectomy (LAMT) and laminoplasty (LAMP) have been widely applied on patients with spinal cord tumors (SCTs). However, the clinical efficacy of LAMP versus LAMT remains controversial. The purpose of this study is to assess the safety and efficacy of LAMP compared to LAMT in the treatment of SCTs.
   METHODS: We searched several English and Chinese databases (PubMed, EMBASE, the Cochrane Library, CBM, CNKI and Wan Fang) to identify relevant randomized controlled trials or observational studies. The quality of included studies was assessed by the Cochrane Collaboration's tool and the Newcastle-Ottawa Scale. The outcome measures included the primary and secondary outcomes. Subgroups analysis was performed to explore the impact of study type, age, type of tumor, tumor size, surgical levels, follow-up time, surgical methods (whether with fusion) on the outcome measures.
   RESULTS: Sixteen studies of 1096 patients with SCTs were included in this meta-analysis. The results showed statistically significant differences between the LAMP and LAMT groups in terms of effective recovery rate (P = 0.003), blood loss (P < 0.00001), hospital stays (P = 0.006), spinal deformity (P = 0.01), and cerebrospinal fluid leak (P < 0.00001). However, there was no significant differences in total resection rate of tumor (P = 0.21) and operation time (P = 0.14). In the subgroup analysis, the results indicated that age, type of tumor, follow-up time, surgical levels, and methods were the influence factors for the incidence of spinal deformity.
   CONCLUSIONS: LAMP might be a safer and more effective surgical method in the treatment of SCTs. In addition, the advantage of fusion in preventing the occurrence of spinal deformity should not to be ignored. However, because of the lack of high quality randomized controlled trials and adequate data, the safety and validity of LAMP was undermined.
C1 [Sun, Shuwen; Li, Yuping; Wang, Xiaodong; She, Lei; Yan, Zhengcun; Zhang, Hengzhu] Yangzhou Univ, Clin Med Coll, Dept Neurosurg, Yangzhou, Jiangsu, Peoples R China.
   [Lu, Guangyu] Yangzhou Univ, Med Coll, Dept Prevent Med, Yangzhou, Jiangsu, Peoples R China.
RP Zhang, HZ (reprint author), Yangzhou Univ, Clin Med Coll, Dept Neurosurg, Yangzhou, Jiangsu, Peoples R China.
EM zhanghengzhu@sina.com
OI Sun, Shuwen/0000-0002-2492-1483
FU "Six One Project" Top Talent Research Plan of Jiangsu High Level Health
   Talents [LGY2017026]; Society and Development Plan of Yangzhou Science
   and Technology Bureau [YZ2017068]; Practice and Innovation Plan of Yang
   Zhou University [XSJCX17_042]; Clinical Medical College of Yangzhou
   University [yzucms201602]
FX This research was supported by the "Six One Project" Top Talent Research
   Plan of Jiangsu High Level Health Talents (LGY2017026) from Hengzhu
   Zhang; Society and Development Plan of Yangzhou Science and Technology
   Bureau (YZ2017068) from Xiaodong Wang; Practice and Innovation Plan of
   Yang Zhou University (XSJCX17_042) from Shuwen Sun; and funding from the
   Clinical Medical College of Yangzhou University (yzucms201602) from
   Yuping Li.
CR Albert TJ, 1998, SPINE, V23, P2738, DOI 10.1097/00007632-199812150-00014
   Anakwenze OA, 2011, J PEDIATR ORTHOPED, V31, P475, DOI 10.1097/BPO.0b013e318220bb46
   Anderson PA, 2009, J NEUROSURG-SPINE, V11, P150, DOI 10.3171/2009.2.SPINE08727
   Cai DH, 2016, MOD DIAGN TREAT, V27, P2185
   Chen ZW, 2017, J CLIN ORTHOP, V20, P276
   de Jonge T, 2005, EUR SPINE J, V14, P765, DOI 10.1007/s00586-004-0778-1
   Du XY, 2010, J CLIN NEUROSURG, V7, P195
   Duan F, 2016, J HUNAN NORM U SCI, V13, P111
   EVANS AE, 1991, CANCER, V67, P331, DOI 10.1002/1097-0142(19910115)67:2<331::AID-CNCR2820670202>3.0.CO;2-7
   Fassett Daniel R, 2006, Neurosurg Focus, V20, pE2
   Guang-Hui XU, 2013, J QIQIHAR U MED, V34, P1095
   Hersh DS, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.7.FOCUS17329
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hong GL, 2000, CHINESE J NEUROSURG, V16, P162
   Huang C, 2013, CHINESE J MINIM INVA, V18, P18
   Inoue A, 1996, SPINAL CORD, V34, P536, DOI 10.1038/sc.1996.97
   KATSUMI Y, 1989, SPINE, V14, P1171, DOI 10.1097/00007632-198911000-00007
   Kawahara N, 1999, SPINE, V24, P1363, DOI 10.1097/00007632-199907010-00015
   Kushel' Iu V, 2007, Zh Vopr Neirokhir Im N N Burdenko, P20
   [李德志 Li Dezhi], 2014, [中华神经外科杂志, Chinese Journal of Neurosurgery], V30, P653
   McGirt MJ, 2008, J NEUROS-PEDIATR, V1, P57, DOI 10.3171/PED-08/01/057
   McGirt MJ, 2010, NEUROSURGERY, V66, P1005, DOI 10.1227/01.NEU.0000367721.73220.C9
   Mearini Massimo, 2012, Surg Neurol Int, V3, P164, DOI 10.4103/2152-7806.105275
   MIKAWA Y, 1987, SPINE, V12, P6, DOI 10.1097/00007632-198701000-00002
   Miyakoshi N, 2015, BMC SURG, V15, DOI 10.1186/s12893-015-0066-5
   Montano N, 2014, CLIN NEUROL NEUROSUR, V125, P69, DOI 10.1016/j.clineuro.2014.07.024
   Nath PC, 2016, WORLD NEUROSURG, V85, DOI 10.1016/j.wneu.2015.09.058
   Park SB, 2009, J NEUROSURG-SPINE, V10, P603, DOI 10.3171/2009.2.SPINE08257
   Sciubba DM, 2008, J NEUROSURG-SPINE, V8, P413, DOI 10.3171/SPI/2008/8/5/413
   Simon SL, 2008, J PEDIATR ORTHOPED, V28, P244, DOI 10.1097/BPO.0b013e3181623819
   Tobias ME, 2008, CHILD NERV SYST, V24, P219, DOI 10.1007/s00381-007-0405-7
   Vijayakumar V, 2004, INTERNET J NUCL MED, V2, P4
   Wells GA, 2014, APPL ENG AGRIC, V18, P727
   Wen JP, 2006, CHINESE J CLIN NEURO, V12, P720
   Woods BI, 2011, CLIN ORTHOP RELAT R, V469, P688, DOI 10.1007/s11999-010-1653-5
   Wu Xuanxuan, 2014, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V28, P733
   Yang LL, 2017, ANHUI MED J, V38, P898
   Yao KC, 2007, J NEUROSURG, V107, P463, DOI 10.3171/PED-07/12/463
   YASUOKA S, 1982, J NEUROSURG, V57, P441, DOI 10.3171/jns.1982.57.4.0441
   Yeh JS, 2001, PEDIATR NEUROSURG, V35, P318, DOI 10.1159/000050444
   Zadegan Shayan Abdollah, 2017, Asian J Neurosurg, V12, P347, DOI 10.4103/1793-5482.175640
   Zhang JS, 2008, J CLIN RES, V25, P2048
   [张显峰 ZHANG Xianfeng], 2007, [中华神经外科杂志, Chinese Journal of Neurosurgery], V23, P768
   Zhou Q, 2015, J CLIN MED PRACT, V19, P5
   2003, J NEUROSURG S, V98, P230
NR 45
TC 1
Z9 1
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 136
EP 145
DI 10.1016/j.wneu.2018.12.033
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700181
PM 30579011
DA 2020-05-12
ER

PT J
AU Senturk, S
   Unsal, UU
AF Senturk, Salim
   Unsal, Ulkun Unlu
TI Percutaneous Full-Endoscopic Removal of Lumbar Intradural Extramedullary
   Tumor via Translaminar Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscope; Meningioma; Translaminar approach
ID DECOMPRESSION; SURGERY
AB BACKGROUND: Despite the fact that technologic advances and surgical experience expand the use of endoscope in spinal surgery, there are few reports on its application in the management of spinal tumors. We present a case report of intradural extramedullary tumor excision with the percutaneous full endoscopic translaminar approach.
   CASE DESCRIPTION: A 67-year-old male presented to our clinic with lumbar, left thigh pain and paresthesia in both thighs. Preoperative magnetic resonance imaging revealed a contrast-enhanced intradural extramedullary mass with benign characteristics on L1 with the preliminary diagnosis of meningioma. The percutaneous translaminar endoscopic approach was planned to remove the intradural extramedullary tumor from a 7-mm skin incision. Surgery was planned in 4 stages: 1) exposure of the dura by opening a window on the lamina, 2) opening and expanding of the dura, 3) exposure of all sides of the tumor, and 4) excision of the tumor and hemostasis. Closing the dura and ending the surgery.
   CONCLUSIONS: This report supports that full endoscopic spinal intradural extramedullary mass excision may give good results in selected cases and in experienced hands.
C1 [Senturk, Salim; Unsal, Ulkun Unlu] Koc Univ Hosp, Dept Neurosurg, Istanbul, Turkey.
RP Unsal, UU (reprint author), Koc Univ Hosp, Dept Neurosurg, Istanbul, Turkey.
EM ulkununlu@hotmail.com
OI unsal, ulkun unlu/0000-0001-5194-3138
CR Ahn Y, 2011, EUR SPINE J, V20, P58, DOI 10.1007/s00586-010-1493-8
   DeAntoni DJ, 1996, ARTHROSCOPY, V12, P330, DOI 10.1016/S0749-8063(96)90069-9
   FORST R, 1983, ARCH ORTHOP TRAUM SU, V101, P219, DOI 10.1007/BF00436774
   Frank E, 1998, SURG NEUROL, V50, P333, DOI 10.1016/S0090-3019(98)00016-0
   HIJIKATA S, 1989, CLIN ORTHOP RELAT R, P9
   Minamide A, 2013, J NEUROSURG-SPINE, V19, P664, DOI 10.3171/2013.8.SPINE13125
   Muller SJ, 2018, WORLD NEUROSURG, V119, P494, DOI 10.1016/j.wneu.2018.05.251
   Nzokou A, 2013, J NEUROSURG-SPINE, V19, P708, DOI 10.3171/2013.9.SPINE121061
   Palmer Sylvain, 2012, Surg Neurol Int, V3, P41, DOI 10.4103/2152-7806.94294
   Parihar VS, 2017, J NEUROL SURG PART A, V78, P219, DOI 10.1055/s-0036-1594014
   Telfeian AE, 2015, CLIN NEUROL NEUROSUR, V134, P1, DOI 10.1016/j.clineuro.2015.03.022
   Teli M, 2010, EUR SPINE J, V19, P443, DOI 10.1007/s00586-010-1290-4
   Tsutsumimoto T, 2014, BONE JOINT J, V96B, P641, DOI 10.1302/0301-620X.96B5.32957
   Wong AP, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15129
   Ying GY, 2017, WORLD NEUROSURG, V99, P59, DOI 10.1016/j.wneu.2016.11.088
NR 15
TC 0
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 146
EP 149
DI 10.1016/j.wneu.2019.01.206
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700182
PM 30763742
DA 2020-05-12
ER

PT J
AU Takeda, R
   Kurita, H
AF Takeda, Ririko
   Kurita, Hiroki
TI "Mass Reduction" Clipping Technique for Large and Complex Intracranial
   Middle Cerebral Artery Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Clipping; Middle cerebral artery; Multiple clipping;
   Surgical technique; Tandem clipping
ID BYPASS-SURGERY; GIANT
AB BACKGROUND: Treatment of complex unruptured middle cerebral artery (MCA) aneurysms that are untreatable with conventional surgical techniques are rare, and direct aneurysmal clipping usually remains the first-line treatment for large and giant saccular MCA aneurysms. Tandem clipping and multiple clipping techniques represent neck reconstruction in direct clipping surgeries that address these aneurysms.
   CASE DESCRIPTION: The authors describe a simple variation of neck reconstructive clipping techniques for the large MCA unruptured aneurysm in a patient with an unruptured 20-mm MCA bifurcation aneurysm. The key of this technique is the application of an appropriate initial clip, the "mass reduction clip"; this clip is inserted not into the aneurysmal neck but on the center of the aneurysmal dome so as to compress the dome at first, which yields a change in the aneurysm's shape and reduces the size of the whole aneurysmal mass. This technique facilitates the ensuing neck reconstruction according to the concept of the ideal closure line using few clips.
   CONCLUSIONS: "Mass reduction" clipping, which changes the shape of the aneurysm and reduces the size of the whole aneurysmal mass, is a useful variation for the treatment of large aneurysms when conventional clipping across the neck is feasible.
C1 [Takeda, Ririko] Teikyo Univ, Sch Med, Mizonokuchi Hosp, Dept Neurosurg, Kawasaki, Kanagawa, Japan.
   [Takeda, Ririko; Kurita, Hiroki] Saitama Med Univ, Dept Cerebrovasc Surg, Int Med Ctr, Hidaka, Japan.
RP Takeda, R (reprint author), Teikyo Univ, Sch Med, Mizonokuchi Hosp, Dept Neurosurg, Kawasaki, Kanagawa, Japan.; Takeda, R (reprint author), Saitama Med Univ, Dept Cerebrovasc Surg, Int Med Ctr, Hidaka, Japan.
EM rtakeda@med.teikyo-u.ac.jp
CR Davies JM, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FocusVid.14632
   Horiuchi T, 2013, NEUROSURG REV, V36, P133, DOI 10.1007/s10143-012-0398-x
   Ishikawa T, 2009, NEUROL MED-CHIR, V49, P273, DOI 10.2176/nmc.49.273
   Kalani MYS, 2013, NEUROSURGERY, V72, P428, DOI 10.1227/NEU.0b013e3182804381
   Kato Y, 2003, MINIM INVAS NEUROSUR, V46, P339, DOI 10.1055/s-2003-812499
   Kivipelto L, 2014, J NEUROSURG, V120, P398, DOI 10.3171/2013.10.JNS13738
   Meybodi AT, 2017, J NEUROSURG, V127, P463, DOI 10.3171/2016.7.JNS16772
   Rayan T, 2015, J NEUROSURG, V123, P472, DOI 10.3171/2014.9.JNS141547
   Sano H, 2010, ACTA NEUROCHIR SUPPL, V107, P27, DOI 10.1007/978-3-211-99373-6_4
   Yang I, 2008, NEUROSURGERY, V62, P371, DOI 10.1227/01.NEU.0000312719.93685.9A
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 150
EP 155
DI 10.1016/j.wneu.2019.01.191
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700183
PM 30743028
OA Bronze
DA 2020-05-12
ER

PT J
AU Chidambaram, S
   Pannullo, SC
   Schwartz, TH
   Wernicke, AG
AF Chidambaram, Swathi
   Pannullo, Susan C.
   Schwartz, Theodore H.
   Wernicke, A. Gabriella
TI Reirradiation of Recurrent Brain Metastases: Where Do We Stand?
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brachytherapy; Brain metastases; Fractionated SRS; FSRT; Recurrent;
   Salvage; WBRT
ID SALVAGE STEREOTACTIC RADIOSURGERY; PROGNOSTIC-FACTORS;
   CLINICAL-OUTCOMES; BRACHYTHERAPY; RADIOTHERAPY; MANAGEMENT; PATIENT
AB Brain metastases occur in a large portion of patients with cancer. Although advances in radiotherapy have helped to improve survival, they have also raised questions regarding the best modality for retreatment in the context of recurrent disease. The spectrum of treatment options for recurrent intracranial metastatic disease after previous radiotherapy includes salvage stereotactic radiosurgery, whole brain radiotherapy, and brachytherapy. We have comprehensively reviewed the existing data on the efficacy and toxicity of the various reirradiation treatment modalities. We examined the key clinical considerations that guide patient selection, such as dose, tumor size, interval to retreatment, and local control and survival rates.
C1 [Chidambaram, Swathi; Pannullo, Susan C.; Schwartz, Theodore H.; Wernicke, A. Gabriella] Cornell Univ, Dept Neurosurg, Weill Med Coll, New York, NY 10021 USA.
   [Wernicke, A. Gabriella] Cornell Univ, Dept Radiat Oncol, Weill Med Coll, New York, NY 10021 USA.
RP Wernicke, AG (reprint author), Cornell Univ, Dept Neurosurg, Weill Med Coll, New York, NY 10021 USA.; Wernicke, AG (reprint author), Cornell Univ, Dept Radiat Oncol, Weill Med Coll, New York, NY 10021 USA.
EM gaw9008@med.cornell.edu
RI Schwartz, Theodore/AAK-3320-2020
CR Akiba T, 2012, JPN J CLIN ONCOL, V42, P264, DOI 10.1093/jjco/hys007
   Aktan M, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.12.21
   Ammirati M, 2010, J NEURO-ONCOL, V96, P85, DOI 10.1007/s11060-009-0055-6
   Bahl A, 2009, J CANC RES THER, V5, P161, DOI 10.4103/0973-1482.57120
   Balermpas P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198692
   Bilger A, 2018, CANCER MED-US, V7, P2350, DOI 10.1002/cam4.1486
   Caballero JA, 2012, INT J RADIAT ONCOL, V83, P303, DOI 10.1016/j.ijrobp.2011.06.1987
   Chao ST, 2008, CANCER, V113, P2198, DOI 10.1002/cncr.23821
   COOPER JS, 1990, RADIOLOGY, V174, P883, DOI 10.1148/radiology.174.3.2305074
   Frakes JM, 2015, J NEUROSURG, V123, P1261, DOI 10.3171/2014.12.JNS141919
   Guo S, 2016, AM J CLIN ONCOL-CANC, V39, P288, DOI 10.1097/COC.0000000000000051
   HAZUKA MB, 1988, INT J RADIAT ONCOL, V15, P433, DOI 10.1016/S0360-3016(98)90026-8
   HEROS DO, 1988, NEUROSURGERY, V23, P733, DOI 10.1227/00006123-198812000-00008
   Hocht S, 1999, FRONT RADIAT THER ON, V33, P327
   Holt DE, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00084
   Huang Z, 2017, J RADIAT RES, V58, P142, DOI 10.1093/jrr/rrw087
   Karam I, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-181
   Kim DH, 2013, J NEURO-ONCOL, V115, P37, DOI 10.1007/s11060-013-1191-6
   Kurtz G, 2014, INT J RADIAT ONCOL, V88, P137, DOI 10.1016/j.ijrobp.2013.10.003
   KURUP P, 1980, CANCER, V46, P2587, DOI 10.1002/1097-0142(19801215)46:12<2587::AID-CNCR2820461209>3.0.CO;2-4
   Li GH, 2012, JPN J CLIN ONCOL, V42, P856, DOI 10.1093/jjco/hys091
   Logie Natalie, 2017, Adv Radiat Oncol, V2, P381, DOI 10.1016/j.adro.2017.05.010
   Maranzano E, 2012, RADIOTHER ONCOL, V102, P192, DOI 10.1016/j.radonc.2011.07.018
   Marvaso G, 2013, ONCOL LETT, V6, P897, DOI 10.3892/ol.2013.1509
   Minniti G, 2016, J NEURO-ONCOL, V126, P91, DOI 10.1007/s11060-015-1937-4
   Moreau J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195608
   Noel G, 2001, RADIOTHER ONCOL, V60, P61, DOI 10.1016/S0167-8140(01)00359-0
   Olson AC, 2012, J CANCER RES THER, V8, P411, DOI 10.4103/0973-1482.103522
   PRADOS M, 1989, CANCER, V63, P657, DOI 10.1002/1097-0142(19890215)63:4<657::AID-CNCR2820630410>3.0.CO;2-Q
   Rana N, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00279
   Sadikov E, 2007, CLIN ONCOL-UK, V19, P532, DOI 10.1016/j.clon.2007.06.001
   Scharp M, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-4
   Schulder M, 1997, J NEURO-ONCOL, V33, P213, DOI 10.1023/A:1005798027813
   Son CH, 2012, INT J RADIAT ONCOL, V82, P167, DOI DOI 10.1016/J.IJR0BP.2011.03.020
   Sterzing F, 2009, STRAHLENTHER ONKOL, V185, P89, DOI 10.1007/s00066-009-1971-2
   Stockham AL, 2012, PROG NEUROL SURG, V25, P273, DOI 10.1159/000331200
   Terakedis BE, 2014, J RADIOSURGERY SBRT, V3, P21
   Wernicke AG, 2017, J NEUROSURG, V126, P1212, DOI 10.3171/2016.3.JNS152836
   Wong WW, 1996, INT J RADIAT ONCOL, V34, P585, DOI 10.1016/0360-3016(95)02156-6
   Xia YX, 2018, CUREUS, V10, DOI 10.7759/cureus.3075
   Yomo S, 2016, J NEURO-ONCOL, V127, P119, DOI 10.1007/s11060-015-2019-3
   Yomo S, 2013, J NEURO-ONCOL, V113, P459, DOI 10.1007/s11060-013-1138-y
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 156
EP 163
DI 10.1016/j.wneu.2019.01.182
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700184
PM 30738931
DA 2020-05-12
ER

PT J
AU Rustagi, T
   Yener, U
   Blakaj, D
   Kenda, K
   Mendel, E
AF Rustagi, Tarush
   Yener, Ulas
   Blakaj, Dukagjin
   Kenda, Kari
   Mendel, Ehud
TI Long-Term Survival After Brain and Spine Metastasis in Malignant
   Melanoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cancer; Melanoma; Metastasis; Survival
ID IPILIMUMAB; SURGERY
AB BACKGROUND: Metastasis from melanoma carries poor prognosis and survival. Average life expectancy is estimated 4 to 6 months after diagnosis of skeletal metastasis. Comprehensive treatment, along with newer immunotherapies, has shown promising results.
   CASE DESCRIPTION: We report a case of long-term survival after metastasis to the brain and spine and discuss associated factors.
   CONCLUSIONS: Our report emphasizes the importance of regular and critical surveillance of the disease and aggressive surgical and medical management in melanoma.
C1 [Rustagi, Tarush; Yener, Ulas; Blakaj, Dukagjin; Kenda, Kari; Mendel, Ehud] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Rustagi, Tarush; Yener, Ulas; Blakaj, Dukagjin; Kenda, Kari; Mendel, Ehud] Arthur G James Canc Hosp, Columbus, OH 43210 USA.
   [Rustagi, Tarush] Indian Spinal Injuries Ctr, New Delhi, India.
RP Rustagi, T (reprint author), Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA.; Rustagi, T (reprint author), Arthur G James Canc Hosp, Columbus, OH 43210 USA.; Rustagi, T (reprint author), Indian Spinal Injuries Ctr, New Delhi, India.
EM tarush.rustagi@gmail.com
OI Rustagi, Tarush/0000-0001-9950-3780
CR Atallah Ehab, 2005, Curr Treat Options Oncol, V6, P185
   BARTH A, 1995, J AM COLL SURGEONS, V181, pA193
   Cadili A, 2009, ANZ J SURG, V79, P509, DOI 10.1111/j.1445-2197.2009.04976.x
   Chapman PB, 2017, ANN ONCOL, V28, P2581, DOI 10.1093/annonc/mdx339
   Colman MW, 2014, MELANOMA RES, V24, P354, DOI 10.1097/CMR.0000000000000076
   DONALDSON WF, 1993, J SPINAL DISORD, V6, P360, DOI 10.1097/00002517-199306040-00010
   Eggermont AMM, 2014, LANCET, V383, P816, DOI 10.1016/S0140-6736(13)60802-8
   Goodwin CR, 2016, J NEUROSURG-SPINE, V24, P837, DOI 10.3171/2015.4.SPINE15239
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Huang KY, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-70
   Jennings L, 2009, BRIT J DERMATOL, V161, P496, DOI 10.1111/j.1365-2133.2009.09324.x
   Lee ML, 2000, MELANOMA RES, V10, P81
   Ollila DW, 2011, J SURG ONCOL, V104, P420, DOI 10.1002/jso.21961
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428
   Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621
   SAKATSUME M, 1991, INT IMMUNOL, V3, P377, DOI 10.1093/intimm/3.4.377
   Schadendorf D, 2016, EUR J CANCER, V67, P46, DOI 10.1016/j.ejca.2016.07.018
   Sellin JN, 2015, NEUROSURGERY, V77, P386, DOI 10.1227/NEU.0000000000000790
   Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302
   Strom T, 2014, CANCER-AM CANCER SOC, V120, P1369, DOI 10.1002/cncr.28412
NR 21
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 164
EP 169
DI 10.1016/j.wneu.2019.01.215
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700185
PM 30763741
DA 2020-05-12
ER

PT J
AU Yuan, CW
   Duan, HZ
   Yi, ZQ
   Zhang, Y
   Zhang, JY
AF Yuan, Changwei
   Duan, Hongzhou
   Yi, Zhiqiang
   Zhang, Yang
   Zhang, Jiayong
TI Stenting for Middle Cerebral Artery Stenosis Associated with a
   Nonbifurcating Cervical Carotid Artery: Case Report and Naming
   Consideration
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anomaly; Middle cerebral artery stenosis; Nonbifurcating cervical
   carotid artery; Stenting
ID ANASTOMOSIS
AB BACKGROUND: A nonbifurcating cervical carotid artery (NBCCA) is a rare anatomic variation of the carotid artery which directly arises from the common carotid artery without forming a bifurcation. A rare case of an NBCCA associated with middle cerebral artery (MCA) stenosis is reported herein.
   CASE DESCRIPTION: A 70-year-old man was admitted to the hospital for fresh infarctions in the left frontoparietal lobe. The angiographic imaging showed severe atherosclerotic stenosis in the left MCA associated with an ipsilateral NBCCA. The origin of the left internal carotid artery (ICA) was occluded leaving a stump. A tortuous anastomotic vessel arose from the external carotid artery and continued as the cervical ICA. A stent was placed in the left MCA, and the patient recovered uneventfully and without further ischemia during follow-up. Embryogenesis and naming considerations are briefly discussed.
   CONCLUSIONS: This is the first report of an NBCCA accompanied by ipsilateral MCA stenosis. The name hypogenesis/agenesis of the proximal ICA might describe the congenital anatomic variation of an NBCCA more accurately than NBCCA.
C1 [Yuan, Changwei; Duan, Hongzhou; Yi, Zhiqiang; Zhang, Yang; Zhang, Jiayong] Peking Univ, Hosp 1, Dept Neurosurg, Beijing, Peoples R China.
RP Duan, HZ (reprint author), Peking Univ, Hosp 1, Dept Neurosurg, Beijing, Peoples R China.
EM duanhongzhou@126.com
FU Chinese National Nature Science FoundationNational Natural Science
   Foundation of China [81541119]; Peking University First Hospital Cross
   Clinical Study Foundation
FX This work was supported by the Chinese National Nature Science
   Foundation (81541119) and Peking University First Hospital Cross
   Clinical Study Foundation.
CR He YK, 2014, ANN VASC SURG, V28, P386, DOI 10.1016/j.avsg.2013.03.014
   Kansara A, 2012, J NEUROINTERV SURG, V4, P274, DOI 10.1136/neurintsurg-2011-010024
   Kim CH, 2015, KOREAN J RADIOL, V16, P914, DOI 10.3348/kjr.2015.16.4.914
   Kiyosue H, 2009, NEURORADIOLOGY, V51, P697, DOI 10.1007/s00234-009-0542-7
   Krischek O, 2011, MINIM INVAS NEUROSUR, V54, P21, DOI 10.1055/s-0031-1271681
   Lourenco P, 2014, NEURORADIOL J, V27, P393, DOI 10.15274/NRJ-2014-10062
   Ma N, 2018, STROKE VASC NEUROL, V3, P1
   MORIMOTO T, 1990, J NEUROSURG, V72, P130, DOI 10.3171/jns.1990.72.1.0130
   Murono S, 2009, BRIT J RADIOL, V82, P197, DOI DOI 10.1259/BJR/78301422
   Nakai K, 2012, NEURORADIOLOGY, V54, P521, DOI 10.1007/s00234-011-0956-x
   Nas OF, 2016, NEURORADIOL J, V29, P213, DOI 10.1177/1971400916638355
   Natori T, 2019, INTERNAL MED, V58, P123, DOI 10.2169/internalmedicine.1526-18
   Ooigawa H, 2006, J CLIN NEUROSCI, V13, P944, DOI 10.1016/j.jocn.2005.10.015
   Rodriguez HE, 2002, J VASC SURG, V35, P573, DOI 10.1067/mva.2002.118812
   Sasaki T, 2013, NEUROL MED-CHIR, V53, P228, DOI 10.2176/nmc.53.228
   Turan TN, 2018, J STROKE CEREBROVASC, V27, P801, DOI 10.1016/j.jstrokecerebrovasdis.2017.10.017
   Uchino A, 2011, AM J NEURORADIOL, V32, P1119, DOI 10.3174/ajnr.A2462
   Yoshida Shinsuke, 2016, NMC Case Rep J, V3, P59, DOI 10.2176/nmccrj.cr.2015-0232
NR 18
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 170
EP 174
DI 10.1016/j.wneu.2019.01.208
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700186
PM 30763749
DA 2020-05-12
ER

PT J
AU de Laurentis, C
   Del Bene, M
   Fociani, P
   Tonello, C
   Pollo, B
   DiMeco, F
AF de Laurentis, Camilla
   Del Bene, Massimiliano
   Fociani, Paolo
   Tonello, Cristina
   Pollo, Bianca
   DiMeco, Francesco
TI 5-ALA Fluorescence in Case of Brain Abscess by Aggregatibacter Mimicking
   Glioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE 5-aminolevulenic acid; Aggregatibacter; Brain abscess; Glioblastoma;
   Intraoperative fluorescence; PCR; Protoporphyrin IX
ID 5-AMINOLEVULINIC ACID
AB BACKGROUND: At present, the differential diagnosis of magnetic resonance imaging enhancing lesions can still be challenging. Preoperative imaging is a valuable tool characterized by high informative value, even if false-positive and false-negative results are possible. In this context, 5-aminolevulenic acid (5-ALA) represents a significant adjunct in glioblastoma (GBM) surgery displaying an assumed specific accumulation only in tumor cells. However, it was anecdotally reported that in some cases it can also be detected in nonneoplastic lesions mimicking GBM, thus potentially leading to misdiagnosis. Moreover, precise identification of involved pathogens from intraoperative brain samples may remain difficult. We report the case of an abscess from Aggregatibacter mimicking a GBM both during preoperative imaging and intraoperatively, since showing 5-ALA fluorescence.
   CASE DESCRIPTION: A 54-year-old man presented with intense cephalalgia, vomiting, and scotomas in his left eye. Brain magnetic resonance imaging demonstrated a right temporo-occipital rim-enhancing mass, highly suggestive of a GBM, and for this reason the patient underwent 5-ALALguided complete removal. Histopathologic analysis proved the lesion to be a bacterial abscess from Aggregatibacter as confirmed by polymerase chain reaction on bacterial deoxyribonucleic acid.
   CONCLUSIONS: 5-ALA fluorescence may not be specifically involved only in malignant tumor cells, thus raising the suspect for alternative diagnoses to GBM and inviting caution into fluorescence-guided surgery.
C1 [de Laurentis, Camilla; Del Bene, Massimiliano; DiMeco, Francesco] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Milan, Italy.
   [Pollo, Bianca] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neuropathol, Milan, Italy.
   [Del Bene, Massimiliano] European Insitute Oncol IRCCS, Dept Expt Oncol, IEO, Milan, Italy.
   [Fociani, Paolo; Tonello, Cristina] Luigi Sacco Hosp, Pathol Unit, ASST Fatebenefratelli Sacco, Milan, Italy.
   [DiMeco, Francesco] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
   [DiMeco, Francesco] Johns Hopkins Sch Med, Dept Neurol Surg, Baltimore, MD USA.
RP de Laurentis, C (reprint author), Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Milan, Italy.
EM camilla.delaur@gmail.com
RI DiMeco, Francesco/Z-5431-2019
OI de Laurentis, Camilla/0000-0003-1867-7899; Pollo,
   Bianca/0000-0002-5523-4256
CR Evers G, 2017, WORLD NEUROSURG, V98, P375, DOI 10.1016/j.wneu.2016.11.011
   Franken ACW, 2011, APPL MICROBIOL BIOT, V91, P447, DOI 10.1007/s00253-011-3391-3
   Jenkinson MD, 2018, COCHRANE DATABASE SY, V2018
   Kiesel B, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.3.FOCUS1859
   Miyatake SI, 2007, NEUROSURGERY, V61, P82, DOI 10.1227/01.NEU.0000255434.47044.41
   Nestler U, 2012, ACTA NEUROCHIR, V154, P899, DOI 10.1007/s00701-012-1319-z
   Norskov-Lauritsen N, 2014, CLIN MICROBIOL REV, V27, P214, DOI 10.1128/CMR.00103-13
   RITTENHOUSEDIAKUN K, 1995, PHOTOCHEM PHOTOBIOL, V61, P523, DOI 10.1111/j.1751-1097.1995.tb02356.x
   Solis WG, 2017, BMJ CASE REP, P1
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Tonn Jorg-Christian, 2008, Clin Neurosurg, V55, P20
   Voellger B, 2014, ACTA NEUROCHIR, V156, P1977, DOI 10.1007/s00701-014-2169-7
   Yamamoto J, 2015, TURK NEUROSURG, V25, P796, DOI 10.5137/1019-5149.JTN.10594-14.1
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 175
EP 178
DI 10.1016/j.wneu.2019.01.190
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700187
PM 30743027
DA 2020-05-12
ER

PT J
AU Voldrich, R
   Majovsky, M
   Chovanec, M
   Netuka, D
AF Voldrich, Richard
   Majovsky, Martin
   Chovanec, Martin
   Netuka, David
TI First Case Report of Bilateral Spontaneous Otogenic Pneumocephalus
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Politzer maneuever; Spontaneous pneumocephalus; Superior
   semicircular canal dehiscence; Tegmen defects; Temporal encephalocele
ID TENSION PNEUMOCEPHALUS; CANAL DEHISCENCE; PNEUMATIZATION
AB BACKGROUND: Pneumocephalus is commonly associated with cranial trauma including surgical interventions. Spontaneous pneumocephalus on the other hand is a rare diagnosis. Reported cases were predominantly unilateral. We report a unique case of a bilateral spontaneous pneumocephalus probably related to a bilateral tegmen defect related to repeated Politzer maneuvers.
   CASE DESCRIPTION: A 78-year-old man suffered from vertigo, tinnitus, instability, and mild expressive aphasia. In the past 12 weeks before clinical deterioration he underwent series of Politzer maneuvers performed for repetitive inflammation of upper respiratory tract with otitis media. Brain computed tomography revealed a large bilateral collection of intracranial air with associated tegmen defects. Primarily, surgical revision of the middle fossa and multilayer reconstruction of the dura and skull base defect on the left side was performed. After 5 days, the other side was reconstructed in a similar way. Postoperative course was uneventful with brisk improvement of symptomatology. Both computed tomography scans undertaken after the first and second surgery showed satisfying regression of intracranial air.
   CONCLUSIONS: Spontaneous pneumocephalus represents a rare condition often associated with increased middle ear pressure, which can be caused by autoinflation (e.g., Valsalva or Politzer maneuver), sneezing, or coughing. The described case represents a unique presentation of the bilateral spontaneous pneumocephalus associated with bilateral tegmen and dura mater defects managed surgically. Despite its rarity, spontaneous pneumocephalus originating from the temporal bone should be considered as a possible diagnosis in patients with suggestive otologic presentation (e.g., tinnitus, instability, hearing loss) and associated nonspecific neurologic symptomatology.
C1 [Voldrich, Richard; Majovsky, Martin; Netuka, David] Charles Univ Prague, Dept Neurosurg & Neurooncol, Med Fac 1, Cent Mil Hosp, Stresovice, Czech Republic.
   [Chovanec, Martin] Charles Univ Prague, Univ Hosp Kralovske, Med Fac 3, Dept Otorhinolaryngol, Vinohrady, Czech Republic.
RP Netuka, D (reprint author), Charles Univ Prague, Dept Neurosurg & Neurooncol, Med Fac 1, Cent Mil Hosp, Stresovice, Czech Republic.
EM Netuka.david@gmail.com
RI Majovsky, Martin/AAC-6748-2020
OI Majovsky, Martin/0000-0001-7725-5181
FU Czech Health Research Council [15-327 91A, MO 1012]
FX The article was supported by grant project Czech Health Research Council
   15-327 91A and MO 1012, Q 25. The authors declare no actual or potential
   conflicts of interest.
CR Abbati Santiago G, 2012, Surg Neurol Int, V3, P32, DOI 10.4103/2152-7806.93861
   Ahren C, 1965, ACTA OTO-LARYNGOL, V60, P407
   ANDREWS JC, 1986, LARYNGOSCOPE, V96, P521, DOI 10.1288/00005537-198605000-00010
   Arick D S, 2000, Ear Nose Throat J, V79, P290
   Bahloul K, 2003, NEUROCHIRURGIE, V49, P110
   BRUNORI A, 1995, NEUROSURGERY, V36, P1237, DOI 10.1227/00006123-199506000-00042
   Casale M, 2007, LARYNGOSCOPE, V117, P2002, DOI 10.1097/MLG.0b013e31812eeded
   Chiari H., 1884, Z HEILK, V5, P383
   Clevens RA, 1999, OTOLARYNG HEAD NECK, V120, P579, DOI 10.1053/hn.1999.v120.a83901
   Dandy WE, 1926, ARCH SURG-CHICAGO, V12, P949, DOI 10.1001/archsurg.1926.01130050003001
   Davey S, 2015, LARYNGOSCOPE, V125, P1940, DOI 10.1002/lary.25243
   DIETZEL K, 1989, HNO, V37, P39
   DILORENZO N, 1986, ACTA NEUROCHIR, V83, P112, DOI 10.1007/BF01402388
   Dowd GC, 1998, J NEUROSURG, V89, P1036, DOI 10.3171/jns.1998.89.6.1036
   FRANKEL M, 1980, ARCH OTOLARYNGOL, V106, P437
   Hage P, 2015, CLIN NEUROL NEUROSUR, V138, P162, DOI 10.1016/j.clineuro.2015.08.025
   Horowitz M., 1964, J LARYNGOL OTOL, V78
   Hyam JA, 2008, CLIN NEUROL NEUROSUR, V110, P62, DOI 10.1016/j.clineuro.2007.08.008
   Krayenbuhl N, 2005, EUR ARCH OTO-RHINO-L, V262, P135, DOI 10.1007/s00405-004-0754-8
   Lookabaugh S, 2016, OTOL NEUROTOL, V37, P1393, DOI 10.1097/MAO.0000000000001182
   Luckett WH, 1913, SURG GYNECOL OBSTET, V17, P237
   Maier W, 1996, ANN OTO RHINOL LARYN, V105, P300, DOI 10.1177/000348949610500411
   Mohammed E, 2011, ACTA OTO-LARYNGOL, V131, P670, DOI 10.3109/00016489.2010.541941
   Nagai H, 2007, J NEUROSURG, V106, P1098, DOI 10.3171/jns.2007.106.6.1098
   Nyrop M, 1999, J LARYNGOL OTOL, V113, P480, DOI 10.1017/S0022215100144287
   PERERA R, 2006, COCHRANE DB SYST REV, V18
   Rabello FA, 2013, BRAZ J OTORHINOLAR, V79, P643, DOI 10.5935/1808-8694.20130115
   RAPPAPORT JM, 1994, J OTOLARYNGOL, V23, P430
   Schutt CA, 2015, OTOL NEUROTOL, V36, P551, DOI 10.1097/MAO.0000000000000555
   Scuotto A, 2016, RADIOGRAPHY, V22, P1
   Singh A, 2010, WEST J EMERG MED, V11, P107
   Soenen O, 2012, JBR-BTR, V95, P363, DOI 10.5334/jbr-btr.724
   Vallejo LA, 1999, OTOLARYNG HEAD NECK, V121, P662, DOI 10.1016/S0194-5998(99)70080-X
   Villa RA, 2008, NEW ENGL J MED, V358, pE13, DOI 10.1056/NEJMicm063225
   Wanna G, 2010, OTOLARYNG HEAD NECK, V143, P593, DOI 10.1016/j.otohns.2010.05.003
   Wilkinson EP, 2007, ACTA OTO-LARYNGOL, V127, P892, DOI 10.1080/00016480601053081
   Zhao NH, 2011, J NEUROSURG, V115, P679, DOI 10.3171/2011.6.JNS11104
NR 37
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 179
EP 182
DI 10.1016/j.wneu.2019.01.232
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700188
PM 30771540
DA 2020-05-12
ER

PT J
AU Metwali, H
   Raemaekers, M
   Kniese, K
   Kardavani, B
   Fahlbusch, R
   Samii, A
AF Metwali, Hussam
   Raemaekers, Mathijs
   Kniese, Katja
   Kardavani, Babak
   Fahlbusch, Rudolf
   Samii, Amir
TI Reliability of Functional Magnetic Resonance Imaging in Patients with
   Brain Tumors: A Critical Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Direct cortical stimulation; fMRI; Validation
ID PRESURGICAL IDENTIFICATION; FMRI ACTIVATION; MOTOR; LANGUAGE; MRI;
   STIMULATION; VALIDATION; CORTEX; LOCATION; 3-TESLA
AB BACKGROUND: Formal studies that validated functional magnetic resonance imaging (fMRI) against direct cortical stimulation (DCS) have shown inconsistencies.
   METHODS: We reviewed the reported data and performed a meta-analysis of studies that had validated fMRI using DCS and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We performed the meta-analysis of the studies that had met our inclusion criteria. The positive predictive values (PPVs), negative predictive values (NPVs), false omission rates (FORs), false discovery rates (FDRs), sensitivity, and specificity were calculated. We also identified the factors that could influence the fMRI findings.
   RESULTS: Six studies of language activation and two of motor activation were eligible for the present meta-analysis. The PPV of fMRI for the detection of eloquent motor cortex was 59.5%, and the FDR was 40.5%. The NPV was 96% and the FOR was 3.9%. The sensitivity and specificity of fMRI for the detection of the eloquent motor cortex was 91% and 76%, respectively. For language activation, the PPV was 71.7%, the NPV was 80%, the FDR was 28.2%, and the FOR was 19.5%. The sensitivity and specificity was 80% and 71.5%, respectively. The factors that could have caused a mismatch or affected the reliability were analyzed.
   CONCLUSION: The results from the present analysis of the available reported evidence suggest that fMRI itself (due to neurovascular uncoupling) or analysis of the findings have limitations regarding reliability when validated against DCS. From the existing studies, our results indicate that using fMRI alone for surgical planning could lead to undesirable outcomes.
C1 [Metwali, Hussam; Kniese, Katja; Kardavani, Babak; Fahlbusch, Rudolf; Samii, Amir] Int Neurosci Inst, Hannover, Germany.
   [Metwali, Hussam; Samii, Amir] Leibniz Inst Neurobiol, Magdeburg, Germany.
   [Metwali, Hussam; Raemaekers, Mathijs] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.
RP Metwali, H (reprint author), Int Neurosci Inst, Hannover, Germany.; Metwali, H (reprint author), Leibniz Inst Neurobiol, Magdeburg, Germany.; Metwali, H (reprint author), Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.
EM drhussamm@yahoo.com
CR Agarwal S, 2017, BRAIN CONNECT, V7, P228, DOI [10.1089/brain.2016.0480, 10.1089/brain.2016.0482]
   Agarwal S, 2016, BRAIN CONNECT, V6, P267, DOI 10.1089/brain.2015.0402
   Amaro E, 2006, BRAIN COGNITION, V60, P220, DOI 10.1016/j.bandc.2005.11.009
   Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613
   Bizzi A, 2008, RADIOLOGY, V248, P579, DOI 10.1148/radiol.2482071214
   Fandino J, 1999, J NEUROSURG, V91, P238, DOI 10.3171/jns.1999.91.2.0238
   FitzGerald DB, 1997, AM J NEURORADIOL, V18, P1529
   Grodd W, 2001, HUM BRAIN MAPP, V13, P55, DOI 10.1002/hbm.1025
   Gutbrod K, 2012, J NEUROIMAGING, V22, P266, DOI 10.1111/j.1552-6569.2011.00646.x
   Harrington GS, 2006, AM J NEURORADIOL, V27, P938
   Hou BL, 2006, NEUROIMAGE, V32, P489, DOI 10.1016/j.neuroimage.2006.04.188
   Ille S, 2015, J NEUROSURG, V123, P314, DOI 10.3171/2014.10.JNS141582
   Jiang Z, 2010, NEUROIMAGE, V52, P538, DOI 10.1016/j.neuroimage.2010.04.194
   Kapsalakis IZ, 2012, RADIOL RES PRACT, V2012, DOI 10.1155/2012/727810
   Kekhia H, 2011, NEUROSURG CLIN N AM, V22, P111, DOI 10.1016/j.nec.2011.01.004
   Kuchcinski G, 2015, NEUROLOGY, V84, P560, DOI 10.1212/WNL.0000000000001226
   Lehericy S, 2000, J NEUROSURG, V92, P589, DOI 10.3171/jns.2000.92.4.0589
   Meier MP, 2013, ACTA NEUROCHIR, V155, P675, DOI 10.1007/s00701-013-1624-1
   Morrison MA, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00461
   Ojemann JG, 1998, J CEREBR BLOOD F MET, V18, P148, DOI 10.1097/00004647-199802000-00004
   Ottenhausen M, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.10.FOCUS14611
   Pernet CR, 2016, INT J MED INFORM, V86, P37, DOI 10.1016/j.ijmedinf.2015.11.014
   Pillai JJ, 2012, TECHNOL CANCER RES T, V11, P361, DOI 10.7785/tcrt.2012.500284
   Poldrack R. A., 2012, HDB FUNCTIONAL MRI D
   PUCE A, 1995, J NEUROSURG, V83, P262, DOI 10.3171/jns.1995.83.2.0262
   Pujol J, 1996, J NEUROSURG, V84, P7, DOI 10.3171/jns.1996.84.1.0007
   Pujol J, 1998, J NEUROSURG, V88, P863, DOI 10.3171/jns.1998.88.5.0863
   Roessler K, 2005, J NEUROL NEUROSUR PS, V76, P1152, DOI 10.1136/jnnp.2004.050286
   Rosazza C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098860
   Roux FE, 2003, NEUROSURGERY, V53, P1342, DOI 10.1227/01.NEU.0000093424.71086.8F
   Schreiber A, 2000, AM J NEURORADIOL, V21, P1055
   Schulder M, 1998, J NEUROSURG, V89, P412, DOI 10.3171/jns.1998.89.3.0412
   Seto E, 2001, NEUROIMAGE, V14, P284, DOI 10.1006/nimg.2001.0829
   Shinoura N, 2005, STEREOT FUNCT NEUROS, V83, P135, DOI 10.1159/000088160
   Trinh VT, 2014, STEREOT FUNCT NEUROS, V92, P315, DOI 10.1159/000365224
   Xia HC, 2012, NEURAL REGEN RES, V7, P1563, DOI 10.3969/j.issn.1673-5374.2012.20.006
   Yetkin FZ, 1997, AM J NEURORADIOL, V18, P1311
   YOUSRY TA, 1995, RADIOLOGY, V195, P23, DOI 10.1148/radiology.195.1.7892475
   Zaca D, 2014, J MAGN RESON IMAGING, V40, P383, DOI 10.1002/jmri.24406
   Zaca D, 2011, WORLD J CLIN ONCOL, V2, P289, DOI 10.5306/wjco.v2.i7.289
   2003, NEUROSURGERY, V52, P1335, DOI DOI 10.1227/01.NEU.0000064803.05077.40
NR 41
TC 4
Z9 4
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 183
EP 190
DI 10.1016/j.wneu.2019.01.194
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700189
PM 30743033
DA 2020-05-12
ER

PT J
AU Bagatti, D
   D'Ammando, A
   Franzini, A
   Messina, G
AF Bagatti, Davide
   D'Ammando, Antonio
   Franzini, Angelo
   Messina, Giuseppe
TI Deep Brain Stimulation of the Caudal Zona Incerta and Motor Thalamus for
   Postischemic Dystonic Tremor of the Left Upper Limb: Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE DBS; Dystonic tremor; Motor thalamus; Single electrode; Zona incerta
ID SUBTHALAMIC AREA; RATING-SCALES; QUALITY; CORTEX; PROJECTIONS;
   RETROGRADE; NUCLEUS; STROKE; LIFE
AB BACKGROUND: Dystonic tremor is defined as a tremor occurring in a body region affected by dystonia. The pathophysiologic mechanisms behind dystonic tremor supposedly involve anomalies affecting the pallidothalamic-receiving area (for the dystonic component) and the ventralis intermedius-cortical loop (for the tremor component). Interest in posterior subthalamic area stimulation for various types of involuntary abnormal movements has arisen owing to positive results in patients affected by tremor refractory to ventralis intermedius deep brain stimulation.
   CASE DESCRIPTION: A 23-year-old man, with a 15-year history of left upper limb dystonic tremor due to a stroke in the right thalamus, underwent deep brain stimulation with a single electrode passing through the right ventralis oralis anterior/ventralis oralis posterior nuclei and caudal zona incerta. Objective movement outcomes were assessed through the Unified Dystonia Rating Scale and Fahn-Tolosa-Marin Clinical Rating Scale for Tremor. The impact of tremor on activities of daily living was assessed with the ADL-T24 questionnaire, and quality of life was assessed with the Quality of Life Scale. All questionnaires were administered before deep brain stimulation and at 5-year follow-up. Unified Dystonia Rating Scale and Fahn-Tolosa-Marin Clinical Rating Scale for Tremor scores decreased from 14.5 to 4.5 and from 46 to 7, respectively. ADL-T24 score decreased from 19 to 3, whereas Quality of Life Scale score increased from 49 to 82.
   CONCLUSIONS: Stimulation of motor thalamus and caudal zona incerta could be a viable treatment for patients affected by tremor of various origins, including dystonic tremor, refractory to medical therapy.
C1 [Bagatti, Davide] Univ Milan, Fac Med, Milan, Italy.
   [D'Ammando, Antonio; Franzini, Angelo; Messina, Giuseppe] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Milan, Italy.
RP Bagatti, D (reprint author), Univ Milan, Fac Med, Milan, Italy.
EM davide.bagatti@libero.it
OI Messina, Giuseppe/0000-0003-1060-1486; D'Ammando,
   Antonio/0000-0003-3209-4796; , Davide/0000-0002-5114-4245
CR Artusi CA, 2018, J NEUROL, V265, P2473, DOI 10.1007/s00415-018-8823-x
   Bansil S, 2012, TREMOR OTHER HYPERK, V2
   Blomstedt P, 2012, PARKINSONISM RELAT D, V18, P1062, DOI 10.1016/j.parkreldis.2012.05.024
   Blomstedt P, 2010, MOVEMENT DISORD, V25, P1350, DOI 10.1002/mds.22758
   Botzel K, 2014, DTSCH ARZTEBL INT, V111, P225, DOI 10.3238/arztebl.2014.0225
   BRIN MF, 2004, DYSTONIA ETIOLOGY CL
   Broggi G, 2006, ACTA NEUROCHIR SUPPL, V99, P13, DOI 10.1007/978-3-211-35205-2_2
   Budman E, 2018, EUR J NEUROL, V25, P434, DOI 10.1111/ene.13548
   BURCKHARDT CS, 1989, RES NURS HEALTH, V12, P347, DOI 10.1002/nur.4770120604
   BURCKHARDT CS, 1993, J RHEUMATOL, V20, P475
   Cho C, 2000, ARCH NEUROL-CHICAGO, V57, P1353, DOI 10.1001/archneur.57.9.1353
   Comella CL, 2003, MOVEMENT DISORD, V18, P303, DOI 10.1002/mds.10377
   Diederich NJ, 2008, STEREOT FUNCT NEUROS, V86, P167, DOI 10.1159/000120429
   Elble R, 2013, MOVEMENT DISORD, V28, P1793, DOI 10.1002/mds.25648
   Elble RJ, 2013, CURR NEUROPHARMACOL, V11, P48, DOI 10.2174/157015913804999478
   Elias GJB, 2018, BRAIN STIMUL, V11, P3, DOI 10.1016/j.brs.2017.10.005
   Fasano A, 2014, J NEUROL NEUROSUR PS, V85, P759, DOI 10.1136/jnnp-2013-305532
   FICALORA AS, 1989, NEUROSCIENCE, V29, P567, DOI 10.1016/0306-4522(89)90131-0
   FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138
   Foote KD, 2006, NEUROSURGERY, V58, P280, DOI 10.1227/01.NEU.0000192692.95455.FD
   Franzini A, 2012, NEUROL SCI, V33, P1285, DOI 10.1007/s10072-012-0937-9
   Grimaldi G, 2010, SENSORS-BASEL, V10, P1399, DOI 10.3390/s100201399
   Hess CW, 2012, TREMOR OTHER HYPERK, V2
   Hollingworth M, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7010009
   Holslag JAH, 2018, WORLD NEUROSURG, V110, pE580, DOI 10.1016/j.wneu.2017.11.064
   Jankovic J, 2015, PARKINSONS DIS MOVEM
   Jost WH, 2013, J NEURAL TRANSM, V120, P487, DOI 10.1007/s00702-012-0887-7
   Kobayashi K, 2014, J NEUROSURG, V120, P1025, DOI 10.3171/2014.1.JNS12392
   Krystkowiak P, 1998, J NEUROL NEUROSUR PS, V65, P703, DOI 10.1136/jnnp.65.5.703
   Manto M., 2008, TREMOR PATHOGENESIS
   Messina G, 2012, NEUROSURGERY, V70, P1169, DOI 10.1227/NEU.0b013e3182400a75
   Micheli F, 1998, Parkinsonism Relat Disord, V4, P119, DOI 10.1016/S1353-8020(98)00029-7
   Mitrofanis J, 2005, NEUROSCIENCE, V130, P1, DOI 10.1016/j.neuroscience.2004.08.017
   MOK D, 1986, AM J PHYSIOL, V251, pR823
   Montgomery Jr EB, 2017, DEEP BRAIN STIMULATI
   NICOLELIS MAL, 1995, NEUROSCIENCE, V65, P609, DOI 10.1016/0306-4522(94)00493-O
   Plaha P, 2008, J NEUROL NEUROSUR PS, V79, P504, DOI 10.1136/jnnp.2006.112334
   Ramirez-Zamora A, 2016, EXPERT REV NEUROTHER, V16, P389, DOI 10.1586/14737175.2016.1158103
   Rizzi M, 2015, BRAIN STIMUL, V8, P348
   ROGER M, 1985, J COMP NEUROL, V241, P480, DOI 10.1002/cne.902410407
   ROMANOWSKI CAJ, 1985, J ANAT, V143, P75
   SHAMMAHLAGNADO SJ, 1985, NEUROSCIENCE, V15, P109, DOI 10.1016/0306-4522(85)90127-7
   Sitsapesan HA, 2014, J NEUROL NEUROSUR PS, V85, P811, DOI 10.1136/jnnp-2013-305340
   VIVES F, 1985, BRAIN RES, V344, P329, DOI 10.1016/0006-8993(85)90811-X
   Wichmann T, 2011, BASAL GANGLIA, V1, P65, DOI 10.1016/j.baga.2011.05.001
   Xie T, 2012, TRANSL NEURODEGENER, V1, DOI 10.1186/2047-9158-1-20
   2015, NEUROLOGY, V84, P1904, DOI DOI 10.1212/WNL.0000000000001553
   2018, NEUROLOGY, V90, P476, DOI DOI 10.1212/WNL.0000000000005076
NR 48
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 191
EP 197
DI 10.1016/j.wneu.2019.01.183
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700190
PM 30738935
DA 2020-05-12
ER

PT J
AU Bertolini, G
   La Corte, E
   Aquino, D
   Greco, E
   Rossini, Z
   Cardia, A
   Nicolosi, F
   Bauer, D
   Bruzzone, MG
   Ferroli, P
   Serrao, G
AF Bertolini, Giacomo
   La Corte, Emanuele
   Aquino, Domenico
   Greco, Elena
   Rossini, Zefferino
   Cardia, Andrea
   Nicolosi, Federico
   Bauer, Dario
   Bruzzone, Maria Grazia
   Ferroli, Paolo
   Serrao, Graziano
TI Real-Time Ex-Vivo Magnetic Resonance Image-Guided Dissection of Human
   Brain White Matter: A Proof-of-Principle Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hodology; Human brain anatomy; Magnetic resonance imaging;
   Neuronavigation; White matter
ID POSTMORTEM HUMAN BRAINS; FIBER DISSECTION; HUMAN CONNECTOME; NETWORKS;
   LOCALIZATION; TRACTOGRAPHY; TRACT
AB OBJECTIVE: Modern neuroanatomic education should be based on interdisciplinary methods that allow an understanding of the cerebral circuitry, which is at the base of the structural connectivity. Ex-vivo MRI-guided dissection is an essential method for developing and refining the knowledge of complex 3-dimensional brain anatomy and the mutual relationships between structures and architecture of the white matter bundles. The aim of this technical note is to present a new and innovative method of studying human brain white matter.
   METHODS: Four adult human cerebral hemispheres were prepared according to the Klinger's method. T1-weighted and T2-weighted and fluid attenuated inversion recovery images were obtained with a 3T magnetic resonance machine. The dissection was performed in a dedicated neurosurgical laboratory equipped with a microscope and an electromagnetic neuronavigation system that guided the whole white matter dissection.
   RESULTS: Gyri and sulci morphology were studied in detail. The relations between superficial and inner structures were observed before and after the dissection. Gray matter was carefully removed with blunt dissectors, and the U-fibers were exposed. Afterwards, deeper association and projection fibers, such as the arcuate fasciculus, superior and inferior longitudinal fasciculus, corona radiata, extreme and external capsule, claustrum, anterior commissure, and internal capsule were visualized under high magnification. The neuronavigation system was crucial for continuously checking the whole dissection procedure to avoid any accidental excision of fibers.
   CONCLUSION: Image-guided neuronavigated dissection can significantly improve the quality of white matter dissection and represents a valid tool for learning the 3-dimensional anatomy of the human brain tracts.
C1 [Bertolini, Giacomo; La Corte, Emanuele; Greco, Elena; Bauer, Dario; Serrao, Graziano] Univ Milan, Dept Hlth Sci, Milan, Italy.
   [Bertolini, Giacomo; La Corte, Emanuele; Ferroli, Paolo] Fdn IRCCS Neurol Inst Carlo Besta, Dept Neurosurg, Milan, Italy.
   [Aquino, Domenico; Bruzzone, Maria Grazia] Fdn IRCCS Neurol Inst Carlo Besta, Dept Neuroradiol, Milan, Italy.
   [Rossini, Zefferino; Cardia, Andrea; Nicolosi, Federico] Humanitas Clin & Res Ctr, Dept Neurosurg, Rozzano, Italy.
RP Bertolini, G (reprint author), Univ Milan, Dept Hlth Sci, Milan, Italy.; Bertolini, G (reprint author), Fdn IRCCS Neurol Inst Carlo Besta, Dept Neurosurg, Milan, Italy.
EM giacomo.bertolini1@studenti.unimi.it
RI Bertolini, Giacomo/R-9028-2019; La Corte, Emanuele/F-1194-2016; Greco,
   Elena/AAF-3248-2019
OI Bertolini, Giacomo/0000-0002-0840-9535; La Corte,
   Emanuele/0000-0003-3752-8629; bruzzone, maria
   grazia/0000-0002-2786-1471; CARDIA, Andrea/0000-0002-7349-3753
CR Alarcon C, 2014, OPER NEUROSURG, V10, P294, DOI 10.1227/NEU.0000000000000271
   Ameis SH, 2015, CORTEX, V62, P158, DOI 10.1016/j.cortex.2014.10.014
   Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575
   Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004
   Catani M, 2012, CORTEX, V48, P1262, DOI 10.1016/j.cortex.2012.07.001
   Coras R, 2014, EPILEPSIA, V55, P2003, DOI 10.1111/epi.12828
   CRICK F, 1993, NATURE, V361, P109, DOI 10.1038/361109a0
   Crossley NA, 2016, PSYCHOL MED, V46, P897, DOI 10.1017/S0033291715002895
   D'Arceuil H, 2007, NEUROIMAGE, V36, P64, DOI 10.1016/j.neuroimage.2007.02.039
   De Benedictis A, 2011, NEUROSURGERY, V68, P1709, DOI 10.1227/NEU.0b013e3182124690
   Ghinda CD, 2017, FRONT SURG, V4, DOI 10.3389/fsurg.2017.00003
   Glasser MF, 2016, NAT NEUROSCI, V19, P1175, DOI 10.1038/nn.4361
   Goodkind M, 2015, JAMA PSYCHIAT, V72, P305, DOI 10.1001/jamapsychiatry.2014.2206
   Klingler J, 1935, SCHWEIZ ARCH NEUROL, V36, P247
   Ludwig E., 1956, ATLAS CEREBRI HUMANI
   Maier-Hein KH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01285-x
   Mandonnet E, 2017, WORLD NEUROSURG, V98, P239, DOI 10.1016/j.wneu.2016.10.020
   Mcnab JA, 2009, NEUROIMAGE, V46, P775, DOI 10.1016/j.neuroimage.2009.01.008
   Meola A, 2016, NEUROSURGICAL REV, P1
   Meola A, 2016, J NEUROSURG, V124, P1406, DOI 10.3171/2015.4.JNS142741
   Miller KL, 2012, NEUROIMAGE, V59, P2284, DOI 10.1016/j.neuroimage.2011.09.054
   Miller KL, 2011, NEUROIMAGE, V57, P167, DOI 10.1016/j.neuroimage.2011.03.070
   Park HJ, 2013, SCIENCE, V342, P579, DOI 10.1126/science.1238411
   Passingham RE, 2002, NAT REV NEUROSCI, V3, P606, DOI 10.1038/nrn893
   Peltier J, 2011, NEUROSURGERY, V69, P241, DOI 10.1227/NEU.0b013e31821bc822
   Petersen SE, 2015, NEURON, V88, P207, DOI 10.1016/j.neuron.2015.09.027
   Rhoton AL, 2003, RHOTON CRANIAL ANATO
   Roebroeck A, 2019, NMR BIOMED, V32, DOI 10.1002/nbm.3941
   Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042
   Sun SW, 2003, MAGN RESON MED, V50, P743, DOI 10.1002/mrm.10605
   Ture U, 2000, NEUROSURGERY, V47, P417, DOI 10.1097/00006123-200008000-00028
   Vesalius A, 1543, HUMANI CORPORIFABR
   Vieussens R., 1684, NEUROGRAPHIA UNIVERS
   Zemmoura I, 2014, NEUROIMAGE, V103, P106, DOI 10.1016/j.neuroimage.2014.09.016
   Zucca I, 2016, ANN NEUROL, V79, P42, DOI 10.1002/ana.24541
   2016, CURR OPIN NEUROBIOL, V40, P1, DOI DOI 10.1016/J.CONB.2016.05.003
NR 36
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 198
EP 206
DI 10.1016/j.wneu.2019.01.196
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700191
PM 30743041
DA 2020-05-12
ER

PT J
AU Gandhoke, GS
   Smith, KJ
   Niranjan, A
   Sekula, RF
   Lunsford, LD
AF Gandhoke, Gurpreet S.
   Smith, Kenneth J.
   Niranjan, Ajay
   Sekula, Raymond F.
   Lunsford, L. Dade
TI Comparing Microvascular Decompression with Gamma Knife Radiosurgery for
   Trigeminal Neuralgia. A Cost-Effectiveness Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cost-effectiveness; Gamma Knife radiosurgery; Microvascular
   decompression; Trigeminal neuralgia
ID STEREOTACTIC RADIOSURGERY; SURGICAL-MANAGEMENT; ELDERLY-PATIENTS;
   SURGERY
AB BACKGROUND AND OBJECTIVE: Both microvascular decompression (MVD) and Gamma Knife radiosurgery (GKRS) are time-tested treatment modalities for trigeminal neuralgia (TN). There is little evidence in the literature studying these modalities head to head in a cost-effectiveness comparison.
   OBJECTIVE: To evaluate the cost-effectiveness of MVD compared with GKRS for treating patients with TN.
   METHODS: We developed a Markov cost-effectiveness model for the U.S. health care system to account for all costs related to MVD and GKRS as treatment modalities for TN, from the health care system perspective, over a patient lifetime horizon. A base case was estimated using data from previous studies, from our own GKRS experience, and from a current data analysis of patients undergoing MVD. We derived model inputs, including health care costs, survival, and utility estimates, from the literature. We used age-specific, sex-specific, and race-specific mortality from national registries. Costs studied included those for MVD, for GKRS, for treating complications from either procedure, and for medications throughout patient lifetimes. We performed multiple 1-way, 2-way, and probabilistic sensitivity analyses to confirm the robustness of model assumptions and results. The incremental cost-effectiveness ratio (ICER), with a threshold of $50,000 per quality-adjusted life-year (QALY) gained, defined cost-effectiveness.
   RESULTS: The base case had an ICER of $12,154 per QALY for MVD compared with GKRS. Probabilistic sensitivity (Monte Carlo) analysis showed that MVD was cost-effective in 70% of model iterations. GKRS was favored when the willingness to pay threshold was <$12,000 per QALY gained.
   CONCLUSIONS: In patients medically eligible for either procedure, we found MVD to be the most cost-effective modality to treat TN, primarily because of its reported greater durability. MVD remained the most cost-effective strategy across a broad range of model input values in sensitivity analyses.
C1 [Gandhoke, Gurpreet S.] St Lukes Hosp, Marion Bloch Neurosci Inst, Kansas City, MO 64111 USA.
   [Smith, Kenneth J.] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA.
   [Niranjan, Ajay; Sekula, Raymond F.; Lunsford, L. Dade] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA.
RP Gandhoke, GS (reprint author), St Lukes Hosp, Marion Bloch Neurosci Inst, Kansas City, MO 64111 USA.
EM Gurpreet.gandhoke@gmail.com
CR American Association of Neurological Surgeons, 2000, NAT NEUR STAT 1999 P
   Asplund P, 2016, NEUROSURGERY, V78, P421, DOI 10.1227/NEU.0000000000001059
   Barker FG, 1996, NEW ENGL J MED, V334, P1077, DOI 10.1056/NEJM199604253341701
   Berger I, 2017, CUREUS, V9, DOI 10.7759/cureus.1000
   Braithwaite RS, 2008, MED CARE, V46, P349, DOI 10.1097/MLR.0b013e31815c31a7
   Cheng J, 2017, CLIN NEUROL NEUROSUR, V161, P88, DOI 10.1016/j.clineuro.2017.08.017
   Cohen J, 2017, STEREOT FUNCT NEUROS, V95, P158, DOI 10.1159/000468526
   Holland M, 2015, CLIN NEUROL NEUROSUR, V137, P34, DOI 10.1016/j.clineuro.2015.06.011
   HUNINK M, 2001, DECISION MAKING HLTH
   Kang IH, 2016, J KOREAN NEUROSURG S, V59, P637, DOI 10.3340/jkns.2016.59.6.637
   Kondziolka D, 2010, J NEUROSURG, V112, P758, DOI 10.3171/2009.7.JNS09694
   Maarbjerg S, 2015, BRAIN, V138, P311, DOI 10.1093/brain/awu349
   Perez C, 2009, Cephalalgia, V29, P781
   Pollock BE, 2005, CLIN J PAIN, V21, P317, DOI 10.1097/01.ajp.0000125267.40304.57
   Sekula RF, 2011, J NEUROSURG, V114, P172, DOI 10.3171/2010.6.JNS10142
   Sivakanthan S, 2014, NEUROSURGERY, V75, P220, DOI 10.1227/NEU.0000000000000430
   Tarricone Rosanna, 2008, Neuropsychiatr Dis Treat, V4, P647
   Wang DD, 2018, J NEUROSURG, V128, P68, DOI 10.3171/2016.9.JNS16149
   Wang Y, 2018, WORLD NEUROSURG, V110, pE593, DOI 10.1016/j.wneu.2017.11.062
   2014, NEUROSURGERY, V75, P220, DOI DOI 10.1227/NEU.0000000000000430
   2014, NEW ENGL J MED, V371, P796, DOI DOI 10.1056/NEJMP1405158
NR 21
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 207
EP 216
DI 10.1016/j.wneu.2018.12.204
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700192
PM 30660885
DA 2020-05-12
ER

PT J
AU Monteiro, A
   Agnoletto, GJ
   Granja, MF
   Bit-Ivan, EN
   Sauvageau, E
AF Monteiro, Andre
   Agnoletto, Guilherme Jose
   Granja, Manuel F.
   Bit-Ivan, Ester N.
   Sauvageau, Eric
TI Basilar Occlusion and Rupture Secondary to Rare Fungal Sinusitis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioinvasion; Basilar occlusion; Endovascular; Granulomatous fungal
   sinusitis; Invasive sinusitis; Stroke; Thrombectomy
ID CENTRAL-NERVOUS-SYSTEM; MYCOTIC-ANEURYSM; RHINOSINUSITIS; ASPERGILLOSIS
AB BACKGROUND: Intracranial vascular infections of fungal etiology are extremely rare. Most cases occur in immunocompromised patients with invasive fungal disease, most commonly originating in the paranasal sinuses or the lungs. Granulomatous invasive rhinosinusitis, which is extremely rare in North America, has been reported to affect immunocompetent patients in most cases, and its causative strain has potential to invade the intracranial arteries. We present a rare case of basilar artery rupture and infarction secondary to granulomatous invasive rhinosinusitis.
   CASE DESCRIPTION: A 50-year-old man in Florida presented with ischemic symptoms and a 6-month history of headache, dizziness, and falls. After biopsy, the patient developed subarachnoid hemorrhage and thrombosis. Several thrombectomy attempts were performed, resulting in persistent occlusion of the basilar artery and subsequent comatous state. After discussion with the patient's family, compassionate weaning and autopsy were authorized.
   CONCLUSIONS: Invasive fungal rhinosinusitis is more frequent nowadays owing to increased use of immunosuppressive therapies. However, it is still a disease that mostly affects immunocompromised patients. The development of new microbiologic investigation techniques has enabled the discovery of fungal diseases that can also affect immunocompetent hosts, such as granulomatous invasive rhinosinusitis. This is an extremely rare condition in North America, with very few cases documented in the last few decades.
C1 [Monteiro, Andre; Agnoletto, Guilherme Jose; Granja, Manuel F.; Bit-Ivan, Ester N.; Sauvageau, Eric] Baptist Hlth, Baptist Neurol Inst, Lyerly Neurosurg, Jacksonville, FL 32207 USA.
RP Monteiro, A (reprint author), Baptist Hlth, Baptist Neurol Inst, Lyerly Neurosurg, Jacksonville, FL 32207 USA.
EM andre.monteiro.md@gmail.com
OI Monteiro, Andre/0000-0001-6827-6650
CR AHUJA GK, 1978, J NEUROSURG, V49, P107, DOI 10.3171/jns.1978.49.1.0107
   Boissonneau S, 2018, WORLD NEUROSURG, V119, P353, DOI 10.1016/j.wneu.2018.08.086
   Chakrabarti A, 2007, NEUROL INDIA, V55, P191, DOI 10.4103/0028-3886.35679
   Chakrabarti A, 2009, LARYNGOSCOPE, V119, P1809, DOI 10.1002/lary.20520
   DeShazo RD, 1997, NEW ENGL J MED, V337, P254, DOI 10.1056/NEJM199707243370407
   Gorovoy IR, 2012, SAUDI J OPHTHALMOL, V26, P419, DOI 10.1016/j.sjopt.2012.08.009
   GREEN WR, 1969, ARCH OPHTHALMOL-CHIC, V82, P302, DOI 10.1001/archopht.1969.00990020304002
   Hurst RW, 2001, AM J NEURORADIOL, V22, P858
   MILOSEV B, 1969, BRIT J SURG, V56, P132, DOI 10.1002/bjs.1800560213
   Murthy JMK, 2001, MYCOSES, V44, P141, DOI 10.1046/j.1439-0507.2001.00643.x
   Sundaram C, 2007, J CLIN NEUROSCI, V14, P882, DOI 10.1016/j.jocn.2006.05.014
   Sundaram C, 2006, HISTOPATHOLOGY, V49, P396, DOI 10.1111/j.1365-2559.2006.02515.x
   Sundaram C, 2011, PATHOLOG RES INT, V2011
   WASHBURN RG, 1988, MEDICINE, V67, P231, DOI 10.1097/00005792-198807000-00004
   Winterholler M, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00113
NR 15
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 217
EP 221
DI 10.1016/j.wneu.2019.01.179
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700193
PM 30772526
DA 2020-05-12
ER

PT J
AU Mattei, TA
   Goulart, CR
   Rai, SS
   Rehman, AA
   Williams, M
   Mendel, E
AF Mattei, Tobias A.
   Goulart, Carlos R.
   Rai, Shawn S.
   Rehman, Azeem A.
   Williams, Michelle
   Mendel, Ehud
TI Rapid Development of Spinal Epidural Lipomatosis after Treatment of
   Metastatic Castration-Resistant Prostate Cancer with Second-Generation
   Androgen Receptor Antagonists
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anti-androgen therapy; Cauda equina syndrome; Epidural lipomatosis;
   Prostate cancer
ID THERAPIES; SECONDARY; MECHANISMS; PATIENT
AB BACKGROUND: Previous studies have described the association of spinal epidural lipomatosis with several conditions including chronic steroid therapy, Cushing's syndrome, obesity, Paget disease, and hypothyroidism. We present a report of rapid development of spinal epidural lipomatosis after treatment with second-generation anti-androgen therapy, a new strategy for treatment of metastatic castration-resistant prostate cancer that has been increasingly employed in the past few years. A comprehensive discussion of the underlying molecular networks involving androgen receptor blockage and adipocyte differentiation, as well as the clinical implications of such a phenomenon, are provided.
   CASE DESCRIPTION: We describe the clinical and radiological evolution of a 58-year-old male patient with metastatic prostate cancer, who developed new onset of rapidly progressing lumbosacral epidural lipomatosis with significant compression of the nerve roots of the cauda equina a few months after initiation of treatment with second-generation androgen receptor antagonists.
   CONCLUSIONS: The underlying pathophysiology of adipose tissue growth following the administration of anti-androgen therapy is discussed, with emphasis on both the canonical Wnt/beta-catenin pathway as well as in the Wnt-independent pathway involving direct activation of downstream transcription factors from the T-cell factor family by the androgen receptor. As second-generation androgen receptor antagonists have been increasingly used for treatment of castration-resistant stage metastatic prostate cancer, new onset of symptomatic epidural lipomatosis should be considered as a possible differential diagnosis, especially because the urinary symptoms of cauda equina compression may be improperly attributed to the primary prostate neoplasm.
C1 [Mattei, Tobias A.] St Louis Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63103 USA.
   [Goulart, Carlos R.; Rai, Shawn S.] SUNY Upstate Med Univ, Dept Neurosurg, Syracuse, NY 13210 USA.
   [Rehman, Azeem A.] West Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA.
   [Williams, Michelle] Wake Forest Sch Med, Dept Neurosurg, Winston Salem, NC USA.
   [Mendel, Ehud] Ohio State Univ, Wexner Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA.
RP Mattei, TA (reprint author), St Louis Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63103 USA.
EM tobias.mattei@health.slu.edu
RI Goulart, Carlos/AAB-3827-2019
CR Awwad Amir, 2018, Spinal Cord Ser Cases, V4, P75, DOI 10.1038/s41394-018-0107-2
   Baek SH, 2006, P NATL ACAD SCI USA, V103, P3100, DOI 10.1073/pnas.0510842103
   Borre DG, 2003, EUR RADIOL, V13, P1709, DOI 10.1007/s00330-002-1716-4
   Borstlap ACW, 1995, NEURORADIOLOGY, V37, P670, DOI 10.1007/BF00593392
   Boudadi K, 2016, CLIN MED INSIGHTS-ON, V10, P1, DOI 10.4137/CMO.S34534
   Chazenbalk G, 2013, STEROIDS, V78, P920, DOI 10.1016/j.steroids.2013.05.001
   Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972
   Choi Kyung-Chul, 2012, Eur Spine J, V21 Suppl 4, pS408, DOI 10.1007/s00586-011-1855-x
   Efstathiou E, 2015, EUR UROL, V67, P53, DOI 10.1016/j.eururo.2014.05.005
   Ferlic PW, 2016, SPINE J, V16, P1333, DOI 10.1016/j.spinee.2016.06.022
   Grayling M, 2000, AUST NZ J SURG, V70, P233, DOI 10.1046/j.1440-1622.2000.01793.x
   Gupta R, 2007, J SPINAL CORD MED, V30, P67, DOI 10.1080/10790268.2007.11753916
   Hierholzer J, 1998, CRIT REV NEUROSURG, V8, P279, DOI 10.1007/s003290050089
   Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200
   Ishikawa Y, 2006, J NEUROSURG-SPINE, V4, P24, DOI 10.3171/spi.2006.4.1.24
   Karantanos T, 2015, EUR UROL, V67, P470, DOI 10.1016/j.eururo.2014.09.049
   Koch CA, 2000, TRENDS ENDOCRIN MET, V11, P86, DOI 10.1016/S1043-2760(00)00236-8
   Kumar K, 1996, J NEUROSURG, V85, P348, DOI 10.3171/jns.1996.85.2.0348
   KURT E, 1995, CLIN NEUROL NEUROSUR, V97, P354, DOI 10.1016/0303-8467(95)00071-Q
   Lisai P, 2001, SPINE, V26, P307, DOI 10.1097/00007632-200102010-00017
   Longo DL, 2010, NEW ENGL J MED, V363, P479, DOI 10.1056/NEJMe1006300
   Mattei TA, 2013, SPINE J, V13, P1163, DOI 10.1016/j.spinee.2013.05.033
   Mitsuzuka K, 2018, INT J UROL, V25, P45, DOI 10.1111/iju.13473
   Moller JC, 2011, PEDIATR RHEUMATOL, V9, DOI 10.1186/1546-0096-9-5
   Munoz A, 2002, PEDIATR RADIOL, V32, P865, DOI 10.1007/s00247-002-0811-7
   Oikonomou A, 2007, SPINE, V32, pE789, DOI 10.1097/BRS.0b013e31815b7eb8
   Patel AJ, 2013, J CLIN NEUROSCI, V20, P1595, DOI 10.1016/j.jocn.2012.09.049
   Pinkhardt EH, 2008, ACTA NEUROL SCAND, V117, P409, DOI 10.1111/j.1600-0404.2007.00964.x
   QUINT DJ, 1988, RADIOLOGY, V169, P485, DOI 10.1148/radiology.169.2.3174998
   Ruiz Picazo D, 2016, CASE REP ORTHOP, V2016
   Saylor PJ, 2009, J UROLOGY, V181, P1998, DOI 10.1016/j.juro.2009.01.047
   Singh R, 2006, ENDOCRINOLOGY, V147, P141, DOI 10.1210/en.2004-1649
   Theyskens NC, 2017, SPINE J, V17, P969, DOI 10.1016/j.spinee.2017.02.010
   TOSHNIWAL PK, 1987, J NEUROL, V234, P172, DOI 10.1007/BF00314138
   Yildirim B, 2016, WORLD NEUROSURG, V96, P209, DOI 10.1016/j.wneu.2016.08.125
   Yin LN, 2013, INT J MOL SCI, V14, P13958, DOI 10.3390/ijms140713958
   Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235
   1995, NEUROLOGY, V45, P2281
NR 38
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 222
EP 227
DI 10.1016/j.wneu.2019.01.222
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700194
PM 30763756
DA 2020-05-12
ER

PT J
AU Guan, JY
   Lin, J
   Guan, XQ
   Jin, Q
AF Guan, Jingyu
   Lin, Jun
   Guan, Xueqing
   Jin, Qiang
TI Treatment of Central Paralysis of Upper Extremity Using Contralateral C7
   Nerve Transfer via Posterior Spinal Route
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central paralysis; C7 nerve; Nerve root transfer; Posterior spinal route
ID PLEXUS AVULSION INJURY; ROOT TRANSFER; PRESPINAL ROUTE; REPAIR; TRUNK
AB BACKGROUND: Contralateral C7 nerve transfer is widely applied for the treatment of brachial plexus injuries or central paralysis of the upper extremities. The surgical approach has evolved from the precervical subcutaneous route to the prespinal route, which is currently the most commonly used one. We report a patient with central paralysis of the right upper extremity treated with contralateral C7 nerve transfer via the posterior spinal route.
   CASE DESCRIPTION: A 59-year-old female patient was admitted on 3 July, 2018 with right hemiplegia. The muscle strength of the right lower and upper extremities was grade 4 and 0, respectively. On the basis of magnetic resonance imaging, she was diagnosed with central paralysis of the right upper extremity. Considering the short length of the patient's healthy C7 nerve, contralateral C7 nerve transfer via the posterior spinal route was performed. No intraoperative complication was encountered. The patient reported slight numbness of the volar side of the left thumb, middle finger, and index finger after surgery. The patient showed a right shrug movement 1.5 months after surgery.
   CONCLUSION: We propose carrying out contralateral C7 nerve transfer via the posterior spinal route because of the shorter distance, no need for nerve transplantation, and low occurrence of the complications encountered with the prespinal route (such as vertebral artery injuries, esophageal fistula, and upper extremity pain when swallowing).
C1 [Guan, Jingyu; Lin, Jun] PLA Shenyang Gen Hosp, Dept Neurosurg, Shenyang, Liaoning, Peoples R China.
   [Jin, Qiang] PLA Shenyang Gen Hosp, Dept Anesthesiol, Shenyang, Liaoning, Peoples R China.
   [Guan, Xueqing] China Med Univ, Coll Med, Shenyang, Liaoning, Peoples R China.
RP Guan, JY (reprint author), PLA Shenyang Gen Hosp, Dept Neurosurg, Shenyang, Liaoning, Peoples R China.
EM gjy777@126.com
CR Gao KM, 2013, MICROSURG, V33, P605, DOI 10.1002/micr.22137
   GU YD, 1992, J HAND SURG-BRIT EUR, V17B, P518, DOI 10.1016/S0266-7681(05)80235-9
   Hua XY, 2012, CLIN NEUROL NEUROSUR, V114, P1035, DOI 10.1016/j.clineuro.2012.01.047
   Leblebicioglu G, 2016, J HAND SURG-EUR VOL, V41, P863, DOI 10.1177/1753193416638999
   Li WJ, 2003, INT J SYST EVOL MICR, V53, P1421, DOI 10.1099/ijs.0.02543-0
   McGuiness CN, 2002, J HAND SURG-BRIT EUR, V27B, P159, DOI 10.1054/jhsb.2001.0665
   Wang GB, 2018, J NEUROSURG-SPINE, V29, P491, DOI 10.3171/2018.3.SPINE171251
   Wang L, 2011, MICROSURG, V31, P323, DOI 10.1002/micr.20836
   Wang SF, 2013, J BONE JOINT SURG AM, V95A, P821, DOI 10.2106/JBJS.L.00039
   Wang SF, 2012, MICROSURG, V32, P183, DOI 10.1002/micr.20963
   [夏长丽 Xia Changli], 2010, [吉林大学学报. 医学版, Journal of Jilin Univeristy. Medicine edition], V36, P727
   Xiang Qiansheng, 2012, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V26, P235
   Xu WD, 2011, MICROSURG, V31, P404, DOI 10.1002/micr.20877
   Yu AH, 2017, NEURORADIOLOGY, V59, P247, DOI 10.1007/s00234-017-1796-0
   Zhang CG, 2011, J BRACHIAL PLEX PERI, V6, DOI 10.1186/1749-7221-6-10
   Zheng MX, 2018, NEW ENGL J MED, V378, P22, DOI 10.1056/NEJMoa1615208
   2013, J BONE JOINT SURG AM, V95, P821, DOI DOI 10.2106/JBJS.L.00039
NR 17
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 228
EP 233
DI 10.1016/j.wneu.2019.01.181
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700195
PM 30738934
DA 2020-05-12
ER

PT J
AU Wang, XD
   Tang, GH
   Li, MC
AF Wang, Xiangdong
   Tang, Guohui
   Li, Mingchu
TI Bilateral Extradural Posterior Inferior Cerebellar Artery Origins Where
   Vertebral Artery Ascends Between Transverse Foramina of C-2 and C-1,
   with Simultaneous Right Double Origin PICA: Rare Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bilateral extradural PICA origins; C1/2 origin; Double-origin PICA
ID ENDOVASCULAR TREATMENT; DISSECTING ANEURYSM; RUPTURED ANEURYSM;
   MICROSURGICAL ANATOMY; ANGIOGRAPHY; COILING
AB BACKGROUND: The location of the origin of the posterior inferior cerebellar artery (PICA) is highly variable. An extracranial origin PICA from the vertebral artery (VA) is not rare. But the PICA originated extradurally where the VA ascends between the transverse foramina of C-2 and C-1, a rare anatomic variant. Double-origin PICA is another rare anatomic variant observed in 1%-4% of patients in whom 2 PICA branches converge distally.
   CASE DESCRIPTION: We present a rare cadaveric anatomy case in which both PICAs originated extradurally between the vertebrae C1 and C2, a simultaneously existing right double-origin PICA. For this case, the right PICA was a double-origin PICA, including 1 extradural origin in which the VA ascends between the transverse foramina of C-2 and C-1 and another being intradural and intracranial.
   CONCLUSIONS: To our knowledge, this is the first report of a cadaveric anatomy case of bilateral PICA that originated extradurally between the vertebrae C-1 and C-2, and simultaneously there existed a right double-origin PICA. Such a case is rare, but understanding of the anatomic variation is important. To avoid complications during surgery at the craniovertebral junction, these potential variations should be correctly identified preoperatively.
C1 [Wang, Xiangdong] Changzhi Med Coll, Heji Hosp, Dept Neurosurg, Changzhi City, Shanxi, Peoples R China.
   [Tang, Guohui] Songyuan Cent Hosp, Dept Neurosurg, Songyuan City, Jilin, Peoples R China.
   [Wang, Xiangdong; Tang, Guohui; Li, Mingchu] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Wang, XD (reprint author), Changzhi Med Coll, Heji Hosp, Dept Neurosurg, Changzhi City, Shanxi, Peoples R China.; Wang, XD (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM wxd770913@163.com
OI Wang, XiangDong/0000-0002-0280-5334
CR BAN M, 1986, SURG NEUROL, V26, P501, DOI 10.1016/0090-3019(86)90264-8
   Bhat DI, 2009, SURG NEUROL, V72, P406, DOI 10.1016/j.surneu.2008.09.021
   Chen CJ, 1997, NEURORADIOLOGY, V39, P344, DOI 10.1007/s002340050420
   Fan F, 2011, CATHETER CARDIO INTE, V77, P150, DOI 10.1002/ccd.22685
   Fine AD, 1999, J NEUROSURG, V91, P645, DOI 10.3171/jns.1999.91.4.0645
   Hongo K, 2003, NEUROSURGERY, V52, P597, DOI 10.1227/01.NEU.0000047892.12003.58
   ICARDO JM, 1982, ACTA ANAT, V113, P108
   Kawabata Y, 2016, INTERV NEURORADIOL, V22, P62, DOI 10.1177/1591019915618168
   Kim MS, 2016, SURG RADIOL ANAT, V38, P997, DOI 10.1007/s00276-016-1654-5
   Kwon BJ, 2007, NEUROSURGERY, V61, P242, DOI [10.1227/01.neu.0000303976.22054.9d, 10.1227/01.NEU.0000280120.36270.37]
   LASJAUNIAS P, 1985, J NEUROSURG, V63, P235, DOI 10.3171/jns.1985.63.2.0235
   Lee SH, 2011, INTERV NEURORADIOL, V17, P183, DOI 10.1177/159101991101700207
   Lee SH, 2009, CEREBELLUM, V8, P382, DOI 10.1007/s12311-009-0108-6
   Lesley WS, 2007, AM J ROENTGENOL, V189, P893, DOI 10.2214/AJR.07.2453
   Lesley WS, 2004, AM J NEURORADIOL, V25, P425
   LISTER JR, 1982, NEUROSURGERY, V10, P170
   Margolis MT, 1974, RADIOLOGY SKULL BRAI, P1719
   Nakamura H, 2010, NEUROL MED-CHIR, V50, P41, DOI 10.2176/nmc.50.41
   Omoto K, 2016, WORLD NEUROSURG, V90, DOI 10.1016/j.wneu.2016.03.048
   Osborn AG, 1980, INTRO CEREBRAL ANGIO
   Pasco A, 2002, J NEUROSURG, V96, P127, DOI 10.3171/jns.2002.96.1.0127
   Plumb AA, 2009, SURG RADIOL ANAT, V31, P393, DOI 10.1007/s00276-008-0448-9
   Razak A, 2011, NEUROL SCI, V32, P711, DOI 10.1007/s10072-011-0609-1
   Rhoton AL, 2000, NEUROSURGERY, V47, pS5, DOI 10.1097/00006123-200009001-00005
   Salas E, 1998, NEUROSURGERY, V42, P1326, DOI 10.1097/00006123-199806000-00079
   Salunke P, 2013, ACTA NEUROCHIR, V155, P1953, DOI 10.1007/s00701-013-1783-0
   Sedat J, 2002, J MANIP PHYSIOL THER, V25, P588, DOI 10.1067/mmt.2002.128955
   Sharifi M, 2010, SURG RADIOL ANAT, V32, P87, DOI 10.1007/s00276-009-0512-0
   Siclari F, 2007, AM J NEURORADIOL, V28, P1185, DOI 10.3174/ajnr.A0498
   Silva MA, 2017, OPER NEUROSURG, V13, pE8, DOI 10.1093/ons/opx002
   Stoodley MA, 2000, J NEUROSURG, V93, P899, DOI 10.3171/jns.2000.93.5.0899
   TANAKA A, 1993, NEUROSURGERY, V33, P742, DOI 10.1227/00006123-199310000-00028
   TOKUDA K, 1985, NEURORADIOLOGY, V27, P410, DOI 10.1007/BF00327604
   Uchino A, 2015, NEURORADIOL J, V28, P187, DOI 10.1177/1971400915576659
   Uchino A, 2012, NEURORADIOLOGY, V54, P19, DOI 10.1007/s00234-011-0849-z
   Uchiyama T, 2015, INTERV NEURORADIOL, V21, P451, DOI 10.1177/1591019915590363
   Vora N, 2009, J NEUROIMAGING, V19, P65, DOI 10.1111/j.1552-6569.2008.00243.x
   Wakao N, 2014, NEURORADIOLOGY, V56, P843, DOI 10.1007/s00234-014-1399-y
   Xu S, 2017, EUR SPINE J, V29
   Zhu SW, 2018, CLIN NEURORADIOL, V28, P75, DOI 10.1007/s00062-016-0520-5
   2003, NEUROSURGERY, V53, P589, DOI DOI 10.1227/01.NEU.0000079493.50657.1D
   2011, INTERV NEURORADIOL, V17, P351
NR 42
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 234
EP 239
DI 10.1016/j.wneu.2019.01.233
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700196
PM 30771546
DA 2020-05-12
ER

PT J
AU Dogan, I
   Sahin, OS
   Ozaydin, B
   Baskaya, MK
AF Dogan, Ihsan
   Sahin, Omer Selcuk
   Ozaydin, Burak
   Baskaya, Mustafa K.
TI Low-Cost Stereoscopic Recordings of Neurologic Surgery Operative
   Microscopy for Anatomic Laboratory Training
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D video; Neurologic surgery; Neurosurgery; Operative microscopy;
   Smartphone; Stereoscopic recording; Surgical training
ID TELEVISION SYSTEM
AB OBJECTIVE: Stereoscopic video recordings of operative microscopy during neuroanatomic dissections are an important component of surgical training and research in well-financed medical schools and teaching hospitals. However, the high cost of the latest operative microscopes with integrated video recording equipment can be a limiting factor in their worldwide use. The aim of the present work is to provide a simple low-cost 3-dimensional (3D) stereoscopic operative microscope recording system that can be used even in economically and resource-limited locations. This is achieved by using readily available smartphones, smartphone accessories, and computer software.
   METHODS: Stereoscopic recording is accomplished by attaching and aligning matched or similar smartphones to the eyepieces of an operative microscope using readily available smartphone mounting connectors. Video recordings from the smartphones are then transferred to a personal computer and processed with a video-editing software to generate stereoscopic movies that are viewed on a smartphone using virtual-reality glasses.
   RESULTS: The setup time to mount and align the smartphone cameras typically requires 15-30 minutes. Video image quality and 3D depth presentation is more than sufficient for surgical training and research purposes. The implementation cost ranges from $1,315-$7,066, or much less if smartphones and a computer are already available.
   CONCLUSIONS: The 3D video system demonstrated herein can be implemented on any type of operative microscope, including older units for which commercial stereo recording systems are not available. The system and method presented herein can be readily and affordably implemented in low-budget environments for clinical training and research.
C1 [Dogan, Ihsan; Sahin, Omer Selcuk; Ozaydin, Burak; Baskaya, Mustafa K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53706 USA.
RP Baskaya, MK (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53706 USA.
EM baskaya@neurosurgery.wisc.edu
RI Ozaydin, Burak/AAF-8608-2019
OI dogan, ihsan/0000-0002-1985-719X
CR Apfelbaum R I, 1981, Clin Neurosurg, V28, P246
   Rubino PA, 2014, WORLD NEUROSURG, V82, pE467, DOI 10.1016/j.wneu.2013.02.065
   Benet A, 2016, WORLD NEUROSURG, V91, P317, DOI 10.1016/j.wneu.2016.04.023
   Brock M., 1977, Electromedica, P165
   Christopher LA, 2013, NEUROSURGERY, V72, pA131, DOI 10.1227/NEU.0b013e318270d9c0
   Gilsbach J, 1989, ADV NEUROSURG, P198
   Okudera Hiroshi, 1992, Neurological Research, V14, P386
   SUGITA K, 1985, J NEUROSURG, V62, P610, DOI 10.3171/jns.1985.62.4.0610
NR 8
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 240
EP 244
DI 10.1016/j.wneu.2019.01.237
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700197
PM 30776517
DA 2020-05-12
ER

PT J
AU Torres, MJO
   Jahngir, M
   Qualls, K
   Litofsky, NS
   Nattanmai, P
   Qureshi, AI
AF Torres, Michael J. Ortiz
   Jahngir, Muhammad
   Qualls, Kathryn
   Litofsky, N. Scott
   Nattanmai, Premkumar
   Qureshi, Adnan I.
TI Intra-Arterial Dantrolene for Refractory Cerebral Vasospasm in Patients
   with Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Cerebral vasospasm; Dantrolene; Endovascular; Subarachnoid
   hemorrhage
ID CA2+ RELEASE; INHIBITION; VASOCONSTRICTION; DEATH
AB BACKGROUND: Dantrolene has a safe side-effect profile and a mechanism of action that makes it attractive as an option for treatment of cerebral vasospasm. The authors report 2 cases of refractory cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage that were successfully treated with intra-arterial (IA) dantrolene.
   CASE DESCRIPTION: Two patients, a 63-year-old woman and 36-year-old woman, developed severe vasospasm refractory to IA vasodilators after rupture of anterior communicating artery aneurysms. IA dantrolene was injected in doses of 15-30 mg in the affected distributions and mean arterial pressure, intracranial pressure, and heart rate were monitored. There was immediate improvement in lumen diameter of the affected vessels following dantrolene injection. No significant differences in mean arterial pressure or intracranial pressure before and after IA dantrolene were observed. Both patients demonstrated clinical improvement within 24 hours without any further deterioration during the rest of their admission. Follow-up angiography 48 hours after IA dantrolene treatment demonstrated continued resolution of cerebral vasospasm.
   CONCLUSIONS: This evidence suggests IA dantrolene as a safe and effective novel alternative for the treatment of cerebral vasospasm.
C1 [Torres, Michael J. Ortiz; Litofsky, N. Scott] Univ Missouri, Hosp & Clin, Div Neurosurg, Dept Surg, Columbia, MO 65211 USA.
   [Jahngir, Muhammad; Nattanmai, Premkumar; Qureshi, Adnan I.] Univ Missouri, Hosp & Clin, Dept Neurol, Columbia, MO USA.
   [Qualls, Kathryn] Univ Missouri, Hosp & Clin, Clin Pharm, Neurosci, Columbia, MO USA.
RP Torres, MJO (reprint author), Univ Missouri, Hosp & Clin, Div Neurosurg, Dept Surg, Columbia, MO 65211 USA.
EM ortiztorresm@health.missouri.edu
OI Qureshi, Adnan/0000-0003-4962-540X
CR Adamczyk P, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/462491
   ALAFACI C, 1990, ACTA PHYSIOL SCAND, V138, P317, DOI 10.1111/j.1748-1716.1990.tb08852.x
   Beg SS, 2007, J CEREBR BLOOD F MET, V27, P21, DOI 10.1038/sj.jcbfm.9600313
   Endo M, 2006, J PHARMACOL SCI, V100, P519, DOI 10.1254/jphs.CPJ06004X
   FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x
   Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965
   KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562
   Kato K, 2003, NEURORADIOLOGY, V45, P39, DOI 10.1007/s00234-002-0889-5
   Majidi S, 2012, NEUROCRIT CARE, V17, P245, DOI 10.1007/s12028-012-9737-6
   Muehlschlegel S, 2015, J NEUROL NEUROSUR PS, V86, P1029, DOI 10.1136/jnnp-2014-308778
   Muehlschlegel S, 2011, STROKE, V42, P1301, DOI 10.1161/STROKEAHA.110.603159
   Muehlschlegel S, 2009, NEUROCRIT CARE, V10, P116, DOI 10.1007/s12028-008-9132-5
   Sabouri M, 2017, ADV BIOMED RES, V6, P8
   Salomone S, 2009, NEUROCRIT CARE, V10, P93, DOI 10.1007/s12028-008-9153-0
   Tani Eiichi, 2004, Current Vascular Pharmacology, V2, P13, DOI 10.2174/1570161043476492
   YAMAURA I, 1993, J NEUROSURG, V79, P537, DOI 10.3171/jns.1993.79.4.0537
   Yano T, 2001, RESUSCITATION, V50, P117, DOI 10.1016/S0300-9572(00)00369-5
   ZHANG L, 1993, NEUROSCI LETT, V158, P105, DOI 10.1016/0304-3940(93)90623-S
NR 18
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 247
EP 252
DI 10.1016/j.wneu.2019.01.239
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700199
PM 30776519
DA 2020-05-12
ER

PT J
AU Sekar, A
   Rudrappa, S
   Gopal, S
   Ghosal, N
   Rai, A
AF Sekar, Arunkumar
   Rudrappa, Satish
   Gopal, Swaroop
   Ghosal, Nandita
   Rai, Abhishek
TI Rosette-Forming Glioneuronal Tumor in Opticochiasmatic Region-Novel
   Entity in New Location
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diagnosis; Management; Opticochiasmatic region; Rosette-forming
   glioneuronal tumor
ID NOONAN SYNDROME; 4TH-VENTRICLE; PATIENT
AB BACKGROUND: Rosette-forming glioneuronal tumour [RGNT] is a relatively rare entity first identified as a separate entity in 2002. We are reporting the second case of RGNT in the opticochiasmatic region.
   CASE DESCRIPTION: We report a case report and literature review of RGNT with syndromic association.
   CONCLUSIONS: Although initial reports were predominantly in the fourth ventricle, many recent reports have identified the possibility of its occurrence outside fourth ventricle in pineal gland, spinal cord, septum pellucidum, lateral ventricle, and suprasellar region. To date, only 1 case of RGNT involving the opticochiasmatic region has been reported in a patient with neurofibromatosis type 1. Genetic analysis of this rare tumor identified 3 hotspots involving somatic mutations of FGFR-1 and PIK3CA and a germline mutation involving PTPN11, which can be targets for therapeutic intervention in cases where complete resection is not possible. To the best of our knowledge, we report the first case of RGNT involving the opticochiasmatic region without any syndromic association. Other cases of RGNT with syndromic associations provide us with insight into possible therapeutic interventions.
C1 [Sekar, Arunkumar; Rudrappa, Satish; Gopal, Swaroop; Rai, Abhishek] Sakra World Hosp, Dept Neurosci, Bangalore, Karnataka, India.
   [Ghosal, Nandita] Sakra World Hosp, Dept Neuropathol, Bangalore, Karnataka, India.
RP Rudrappa, S (reprint author), Sakra World Hosp, Dept Neurosci, Bangalore, Karnataka, India.
EM drsatishr@gmail.com
OI Sekar, Arunkumar/0000-0001-9664-6620
CR Alturkustani M, 2012, CAN J NEUROL SCI, V39, P95, DOI 10.1017/S0317167100012786
   Anan M, 2009, HUM PATHOL, V40, P898, DOI 10.1016/j.humpath.2008.11.010
   Bidinotto LT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137690
   Chakraborti S, 2012, VIRCHOWS ARCH, V461, P581, DOI 10.1007/s00428-012-1313-0
   Gessi M, 2014, J NEUROPATH EXP NEUR, V73, P580, DOI 10.1097/NEN.0000000000000080
   Karafin M, 2011, CLIN NEUROPATHOL, V30, P297, DOI 10.5414/NP300374
   Kemp S, 2012, J CLIN NEUROSCI, V19, P1180, DOI 10.1016/j.jocn.2011.12.013
   Komori T, 2002, AM J SURG PATHOL, V26, P582, DOI 10.1097/00000478-200205000-00004
   Lin FY, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a001057
   Louis DN, 2007, WHO CLASSIFICATION T
   Marhold F, 2008, J NEURO-ONCOL, V90, P301, DOI 10.1007/s11060-008-9661-y
   Rauen KA, 2013, ANNU REV GENOM HUM G, V14, P355, DOI 10.1146/annurev-genom-091212-153523
   Scheithauer BW, 2009, NEUROSURGERY, V64, P771, DOI 10.1227/01.NEU.0000340979.81362.F3
   Sherman CB, 2009, J PEDIAT HEMATOL ONC, V31, P61, DOI 10.1097/MPH.0b013e31818ab2cf
   Yang C, 2017, ONCOTARGET, V8
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 253
EP 256
DI 10.1016/j.wneu.2019.02.003
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700200
PM 30790744
DA 2020-05-12
ER

PT J
AU Menendez, RH
   D'Osvaldo, DH
   Vilarino, A
   Amante, MF
   Dillon, HS
AF Menendez, Ricardo H.
   D'Osvaldo, Daniel H.
   Vilarino, Augusto
   Amante, Marcelo F.
   Dillon, Horacio S.
TI Neurenteric Cyst of the Ventral Craniocervical Junction: Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Neurenteric cyst; Posterior approach; Ventral cervicomedullary junction
ID CRANIOVERTEBRAL JUNCTION
AB BACKGROUND: Neurenteric cysts (NCs) are rare, non-neoplastic lesions arising from a failure of dissolution of the transient neurenteric canal between the foregut and the notochord. They are most frequently seen in the intradural extramedullary space in the lower cervical and upper thoracic spine. The authors describe a rare case of NC arising from the ventral cervicomedullary junction that was totally resected via a posterior approach.
   CASE DESCRIPTION: A 24-year-old woman presented with a 4-week history of neck pain and progressive left hemiparesis. Admission magnetic resonance imaging scans demonstrated an intradural extramedullary cystic mass lesion ventral to the upper spinal cord from medulla to C2. We performed a posterior approach and the lesion was totally removed. Surgical treatment resulted in resolution of the neurologic impairments. The histological results were consistent with NC. Postoperative course was uneventful. At the 6-month follow-up, the patient is asymptomatic and magnetic resonance imaging scan shows no residual lesion.
   CONCLUSIONS: NC is a rare lesion of the craniospinal junction and should be considered among differential diagnoses. Complete excision is the treatment of choice. In most instances a dorsal surgical approach will be satisfactory.
C1 [Menendez, Ricardo H.; D'Osvaldo, Daniel H.; Vilarino, Augusto; Dillon, Horacio S.] Hosp Aleman, Dept Neurosci, Buenos Aires, DF, Argentina.
   [Amante, Marcelo F.] Hosp Aleman, Dept Pathol, Buenos Aires, DF, Argentina.
RP Menendez, RH (reprint author), Hosp Aleman, Dept Neurosci, Buenos Aires, DF, Argentina.
EM rhmenendez@hotmail.com
CR Abe K, 1999, NEUROL MED-CHIR, V39, P875, DOI 10.2176/nmc.39.875
   BREEZE RE, 1990, J NEUROSURG, V73, P788, DOI 10.3171/jns.1990.73.5.0788
   De Oliveira RS, 2005, J NEUROSURG, V103, P512
   Ergun R, 2000, PEDIATR NEUROSURG, V32, P95, DOI 10.1159/000028907
   Fuse T, 1998, SURG NEUROL, V50, P431, DOI 10.1016/S0090-3019(97)00280-2
   KOKSEL T, 1990, British Journal of Neurosurgery, V4, P425, DOI 10.3109/02688699008992766
   Leitao F, 2001, J NEUROSURG, V94, P129, DOI 10.3171/spi.2001.94.1.0129
   Liu James K, 2005, Neurosurg Focus, V19, pE9
   MENEZES AH, 1995, PEDIATR NEUROSURG, V22, P88, DOI 10.1159/000120882
   Perry A, 1999, NEUROSURGERY, V44, P401, DOI 10.1097/00006123-199902000-00098
   Puussepp M, 1934, REV NEUROL-FRANCE, V61, P879
   Sakata H, 2008, NEUROL MED-CHIR, V48, P86, DOI 10.2176/nmc.48.86
   Shi W, 2010, SKULL BASE-INTERD AP, V20, P435, DOI 10.1055/s-0030-1265823
   2006, NEUROSURGERY, V58, P97, DOI DOI 10.1227/01.NEU.0000192160.79897.25
   1999, NEUROSURGERY, V44, P401
NR 15
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 257
EP 260
DI 10.1016/j.wneu.2019.01.090
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700201
PM 30703605
DA 2020-05-12
ER

PT J
AU Meola, A
   Rao, JH
   Chaudhary, N
   Song, GS
   Zheng, XC
   Chang, SD
AF Meola, Antonio
   Rao, Jianghong
   Chaudhary, Navjot
   Song, Guosheng
   Zheng, Xianchuang
   Chang, Steven D.
TI Magnetic Particle Imaging in Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Brain ischemia; Brain tumor; Head trauma; Magnetic particle
   imaging; Nanoparticle
ID SUPERPARAMAGNETIC IRON-OXIDE; NEURAL STEM-CELLS; LOADED MICROBUBBLES;
   FOCUSED-ULTRASOUND; NANOPARTICLES; MRI; SAFETY; MPI; TRANSPLANTATION;
   DIFFERENTIATE
AB BACKGROUND: Magnetic particle imaging (MPI) is a novel radiation-free tomographic imaging method that provides a background-free, signal attenuation-free, direct quantification of the spatial distribution of superparamagnetic iron-oxide nanoparticles (SPIONs) with high temporal resolution (milliseconds), high spatial resolution (<1 mm), and extreme sensitivity (mu mol). The technique is based on nonlinear magnetization of the SPIONs when exposed to an oscillating magnetic field. MPI was first described in 2001. Since then, the technique has been applied to experimental imaging of diseases affecting different organs in the human body. The aim of this paper is to review the potential applications of MPI in the field of neurosurgery.
   METHODS: A nonsystematic review of the existing literature on the use of MPI in neurosurgical diseases was performed.
   RESULTS: MPI has been used for the detection of locoregional invasion of brain tumors, tracking, and monitoring the viability of neural stem cells implanted for neuroregenerative purposes, diagnosis of cerebral ischemia, and diagnosis and morphofunctional assessment of brain aneurysms.
   CONCLUSIONS: MPI is at a preclinical stage. In the future, human-sized MPI scanners, along with the optimal toxicity profile of SPIONs will allow diagnostic applications in neurosurgical diseases..
C1 [Meola, Antonio; Chaudhary, Navjot; Chang, Steven D.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
   [Rao, Jianghong] Stanford Univ, Sch Med, Dept Radiol & Chem, Mol Imaging Program,Canc Biol,Biophys Programs, Stanford, CA USA.
   [Zheng, Xianchuang] Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program, Stanford, CA USA.
   [Song, Guosheng] Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemometr, Changsha, Hunan, Peoples R China.
RP Meola, A (reprint author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
EM ameola@stanford.edu
OI Meola, Antonio/0000-0003-2426-2884; Song, Guosheng/0000-0001-5628-6245
CR Anzai Y, 2003, RADIOLOGY, V228, P777, DOI 10.1148/radiol.2283020872
   Arami H, 2017, NANOSCALE, V9, P18723, DOI 10.1039/c7nr05502a
   Borgert J, 2013, BIOMED ENG-BIOMED TE, V58, P551, DOI 10.1515/bmt-2012-0064
   Bourrinet P, 2006, INVEST RADIOL, V41, P313, DOI 10.1097/01.rli.0000197669.80475.dd
   Brindle KM, 2017, J CLIN ONCOL, V35, P2432, DOI 10.1200/JCO.2017.72.7636
   Buckner JC, 2003, SEMIN ONCOL, V30, P10, DOI 10.1053/j.seminoncol.2003.11.031
   Bulte JWM, 2015, TOMOGRAPHY, V1, P91, DOI 10.18383/j.tom.2015.00172
   Cha S, 2006, AM J NEURORADIOL, V27, P475
   Chouly C, 1996, J MICROENCAPSUL, V13, P245, DOI 10.3109/02652049609026013
   Chu K, 2003, NEUROSCI LETT, V343, P129, DOI 10.1016/S0304-3940(03)00174-5
   Coccini T, 2017, J APPL TOXICOL, V37, P361, DOI 10.1002/jat.3367
   Costa C, 2016, J APPL TOXICOL, V36, P361, DOI 10.1002/jat.3213
   De Feo D, 2012, CURR OPIN NEUROL, V25, P322, DOI 10.1097/WCO.0b013e328352ec45
   Dossel O, 2013, BIOMED ENG-BIOMED TE, V58, P611, DOI 10.1515/bmt-2013-0065
   Duffau H., 2011, BRAIN MAPPING NEURAL
   Duffau H, 2009, CURR OPIN ONCOL, V21, P543, DOI 10.1097/CCO.0b013e3283305996
   Ewelt C, 2011, CLIN NEUROL NEUROSUR, V113, P541, DOI 10.1016/j.clineuro.2011.03.008
   Fan CH, 2013, BIOMATERIALS, V34, P3706, DOI 10.1016/j.biomaterials.2013.01.099
   Fan CH, 2013, BIOMATERIALS, V34, P2142, DOI 10.1016/j.biomaterials.2012.11.048
   Forkert ND, 2013, AM J NEURORADIOL, V34, P1697, DOI 10.3174/ajnr.A3460
   Geppert M, 2012, ACTA BIOMATER, V8, P3832, DOI 10.1016/j.actbio.2012.06.029
   Geppert M, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/14/145101
   Gleich B, 2005, NATURE, V435, P1214, DOI 10.1038/nature03808
   Goodwill PW, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3694534
   Goodwill PW, 2012, ADV MATER, V24, P3870, DOI 10.1002/adma.201200221
   Grabowski MM, 2014, J NEUROSURG, V121, P1115, DOI 10.3171/2014.7.JNS132449
   Grafe K, 2016, IEEE T MED IMAGING, V35, P1056, DOI 10.1109/TMI.2015.2507187
   Greish K, 2007, J DRUG TARGET, V15, P457, DOI 10.1080/10611860701539584
   Hong SC, 2011, INT J NANOMED, V6, P3219, DOI 10.2147/IJN.S26355
   Huang XY, 2017, J NEUROIMAGING, V27, P602, DOI 10.1111/jon.12442
   Ittrich H, 2013, ROFO-FORTSCHR RONTG, V185, P1149, DOI 10.1055/s-0033-1335438
   Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101
   Khan MI, 2012, BIOMATERIALS, V33, P1477, DOI 10.1016/j.biomaterials.2011.10.080
   Khandhar AP, 2013, BIOMATERIALS, V34, P3837, DOI 10.1016/j.biomaterials.2013.01.087
   Knopp T., 2012, MAGNETIC PARTICLE IM
   Knopp T, 2011, IEEE T MED IMAGING, V30, P1284, DOI 10.1109/TMI.2011.2113188
   Knopp T, 2010, IEEE T MED IMAGING, V29, P12, DOI 10.1109/TMI.2009.2021612
   Laffon B, 2018, ADV EXP MED BIOL, V1048, P199, DOI 10.1007/978-3-319-72041-8_12
   Latchaw RE, 2003, STROKE, V34, P1084, DOI 10.1161/01.STR.0000064840.99271.9E
   Laurent S, 2010, FUTURE MED CHEM, V2, P427, DOI 10.4155/FMC.09.164
   Lee Bruce, 2005, NeuroRx, V2, P372
   Ludewig P, 2017, ACS NANO, V11, P10480, DOI 10.1021/acsnano.7b05784
   Lunov O, 2010, BIOMATERIALS, V31, P9015, DOI 10.1016/j.biomaterials.2010.08.003
   Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403
   McRobbie D. W., 2007, MRI PICTURE PROTON
   Meola A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00328
   Mohanty S, 2017, MOL CANCER THER, V16, P1909, DOI 10.1158/1535-7163.MCT-17-0022
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Nguyen PK, 2014, CELL STEM CELL, V14, P431, DOI 10.1016/j.stem.2014.03.009
   Nune SK, 2009, EXPERT OPIN DRUG DEL, V6, P1175, DOI 10.1517/17425240903229031
   Orendorff R, 2017, PHYS MED BIOL, V62, P3501, DOI 10.1088/1361-6560/aa52ad
   Pablico-Lansigan MH, 2013, NANOSCALE, V5, P4040, DOI 10.1039/c3nr00544e
   Panagiotopoulos N, 2015, INT J NANOMED, V10, DOI 10.2147/IJN.S70488
   Rahmer Jurgen, 2009, BMC Med Imaging, V9, P4, DOI 10.1186/1471-2342-9-4
   Rear R, 2016, HEART, V102, P638, DOI 10.1136/heartjnl-2014-306962
   REILLY JP, 1991, MED BIOL ENG COMPUT, V29, P571, DOI 10.1007/BF02446087
   Saritas EU, 2013, IEEE T MED IMAGING, V32, P1600, DOI 10.1109/TMI.2013.2260764
   Saritas EU, 2013, J MAGN RESON, V229, P116, DOI 10.1016/j.jmr.2012.11.029
   Sedlacik J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160097
   Shellock FG, 2011, AM J ROENTGENOL, V196, P142, DOI 10.2214/AJR.10.5004
   Shubayev VI, 2009, ADV DRUG DELIVER REV, V61, P467, DOI 10.1016/j.addr.2009.03.007
   Tomitaka A, 2015, NANOSCALE, V7, P16890, DOI 10.1039/c5nr02831k
   Vogel P, 2014, IEEE T MED IMAGING, V33, P1954, DOI 10.1109/TMI.2014.2327515
   Wang YXJ, 2013, CURR PHARM DESIGN, V19, P6575
   WEISSLEDER R, 1989, AM J ROENTGENOL, V152, P167, DOI 10.2214/ajr.152.1.167
   Weizenecker J, 2007, PHYS MED BIOL, V52, P6363, DOI 10.1088/0031-9155/52/21/001
   Youns M, 2011, CURR DRUG TARGETS, V12, P357, DOI 10.2174/138945011794815257
   Zhang DY, 2019, NEUROSURGERY, V85, P312, DOI 10.1093/neuros/nyy315
   Zheng B, 2015, SCI REP-UK, V5, DOI 10.1038/srep14055
NR 69
TC 2
Z9 2
U1 7
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 261
EP 270
DI 10.1016/j.wneu.2019.01.180
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700202
PM 30738942
DA 2020-05-12
ER

PT J
AU Grandhi, R
   Brasiliense, LBC
   Williamson, R
   Zwagerman, NT
   Sauvageau, E
   Hanel, RA
AF Grandhi, Ramesh
   Brasiliense, Leonardo B. C.
   Williamson, Richard
   Zwagerman, Nathan T.
   Sauvageau, Eric
   Hanel, Ricardo A.
TI Delayed Pipeline Embolization of a Ruptured True Internal Carotid Artery
   Aneurysm Presenting with Epistaxis: Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Epistaxis; Flow-diverting stent; Internal carotid artery
ID FLOW-DIVERTOR DEVICES; INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT;
   PSEUDOANEURYSM; COMPLICATIONS
AB BACKGROUND: Massive epistaxis from rupture of an intracavernous internal carotid artery aneurysm is a potentially fatal event. Although rare, this presentation is seen most often in patients after trauma or iatrogenic injury secondary to transsphenoidal surgery or radiation therapy.
   CASE DESCRIPTION: We present our unusual case of a patient with no significant risk factors who had recurrent epistaxis owing to a ruptured true cavernous internal carotid artery aneurysm. The patient was treated initially with coil embolization followed by placement of a Pipeline embolization device. The patient had complete resolution of her bleeding events. A follow-up arteriogram performed 14 months later confirmed aneurysm obliteration, with parent artery preservation and no evidence of in-stent stenosis.
   CONCLUSIONS: Our case highlights the importance of evaluating for intracranial pathological conditions in patients who present with refractory epistaxis. In selected patients, the use of flow-diversion technology as an adjunct or alternative to primary coil embolization for treatment should be considered.
C1 [Grandhi, Ramesh] Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT 84132 USA.
   [Brasiliense, Leonardo B. C.] Univ Arizona, Div Neurosurg, Tucson, AZ USA.
   [Williamson, Richard] Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA.
   [Zwagerman, Nathan T.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
   [Sauvageau, Eric; Hanel, Ricardo A.] Baptist Med Ctr, Lyerly Neurosurg, Jacksonville, FL USA.
RP Grandhi, R (reprint author), Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT 84132 USA.
EM neuropub@hsc.utah.edu
OI Zwagerman, Nathan/0000-0001-9795-9303; Grandhi,
   Ramesh/0000-0001-9000-6083
CR Amenta Peter S, 2012, Surg Neurol Int, V3, P160, DOI 10.4103/2152-7806.105099
   Anderson E, 2014, THESCIENTIFICWORLDJO, V2014
   Arrese I, 2013, NEUROSURGERY, V73, P193, DOI 10.1227/01.neu.0000430297.17961.f1
   Beadles CF, 1907, BRAIN, V30, P285, DOI 10.1093/brain/30.3.285
   Briganti F, 2012, NEURORADIOLOGY, V54, P1145, DOI 10.1007/s00234-012-1047-3
   Brinjikji W, 2013, STROKE, V44, P442, DOI 10.1161/STROKEAHA.112.678151
   Chan T. T., 2011, Hong Kong Medical Journal, V17, P398
   Cinar C, 2013, INTERV NEURORADIOL, V19, P102, DOI 10.1177/159101991301900116
   Cirillo L, 2010, NEURORADIOL J, V23, P220, DOI 10.1177/197140091002300212
   Fontela PS, 2006, PEDIATR CRIT CARE ME, V7, P260, DOI 10.1097/01.PCC.0000216418.01278.5E
   Germanwala AV, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e318207b684
   Hue YH, 2008, J KOREAN NEUROSURG S, V44, P178, DOI 10.3340/jkns.2008.44.3.178
   Kassam AB, 2007, J NEUROSURG, V107, P1047, DOI 10.3171/JNS-07/11/1047
   Lehmann P, 2009, EUR ARCH OTO-RHINO-L, V266, P767, DOI 10.1007/s00405-008-0743-4
   Patel AS, 2015, J NEUROIMAGING, V25, P656, DOI 10.1111/jon.12221
   Ruiz-Juretschke F, 2009, ACTA NEUROCHIR, V151, P1681, DOI 10.1007/s00701-009-0294-5
   Siddiqui AH, 2012, NEUROSURGERY, V71, pE509, DOI 10.1227/NEU.0b013e318258e1f8
   Tsang ACO, 2015, J NEUROINTERV SURG, V7, P603, DOI 10.1136/neurintsurg-2014-011154
   Wang Jun, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P836
   Yu SCH, 2012, RADIOLOGY, V265, P893, DOI 10.1148/radiol.12120422
   2013, NEUROSURGERY, V73, P193, DOI DOI 10.1227/01.NEU.0000430297.17961.F1
NR 21
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 273
EP 276
DI 10.1016/j.wneu.2019.01.126
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700204
PM 30716493
DA 2020-05-12
ER

PT J
AU Acerbi, F
   Prada, F
   Vetrano, IG
   Falco, J
   Farago, G
   Ferroli, P
   DiMeco, F
AF Acerbi, Francesco
   Prada, Francesco
   Vetrano, Ignazio G.
   Falco, Jacopo
   Farago, Giuseppe
   Ferroli, Paolo
   DiMeco, Francesco
TI Indocyanine Green and Contrast-Enhanced Ultrasound Videoangiography: A
   Synergistic Approach for Real-Time Verification of Distal
   Revascularization and Aneurysm Occlusion in a Complex Distal Middle
   Cerebral Artery Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE CEUS; Distal clipping; EC-IC bypass; ICG; ICG videoangiography;
   Intracranial aneurysm; Middle cerebral artery
ID INTRAOPERATIVE ASSESSMENT; MANAGEMENT; BYPASS; SURGERY; ANGIOSONOGRAPHY
AB BACKGROUND: Distal outflow occlusion and extracranial-intracranial bypass represent a possible option for the surgical management of complex middle cerebral artery (MCA) aneurysm. A limitation of the distal clipping strategy combined to bypass is related to the difficulties in predicting intraoperatively the good blood flow supply to the brain territory distal to the aneurysm and the extent and speed of aneurysmal thrombosis.
   METHODS: We present an innovative approach in which contrast-enhanced ultrasound (CEUS) and indocyanine green videoangiography (ICG-VA) have been synergistically used to study the effect of distal clipping on the aneurysm flow and the parenchymal blood flow after the bypass. We used this approach in a patient harboring a fusiform, partially thrombosed distal left MCA aneurysm.
   RESULTS: The patient was treated by a superficial temporal artery-MCA bypass, followed by MCA clipping immediately distally to the aneurysm. ICG-VA was used to evaluate bypass patency and brain perfusion in the area supplied by the bypass. CEUS was used to confirm the characteristics of the aneurysm and to explore the proximal MCA compartment immediately after dural opening, and to verify in real time the effect on aneurysm flow determined by distal outflow occlusion. Postoperative imaging confirmed aneurysm occlusion and patency of the bypass. The patient did not experience any neurologic sequelae.
   CONCLUSIONS: We present the first report of a synergistic intraoperative utilization of ICG-VA and CEUS in studying parenchymal perfusion and aneurysm flow in complex neurovascular procedures.
C1 [Acerbi, Francesco; Vetrano, Ignazio G.; Falco, Jacopo; Ferroli, Paolo] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Vasc Neurosurg Unit, Milan, Italy.
   [Prada, Francesco; DiMeco, Francesco] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Oncol Neurosurg Unit, Milan, Italy.
   [Farago, Giuseppe] Fdn IRCCS Ist Neurol Carlo Besta, Diagnost Radiol & Intervent Neuroradiol Unit, Milan, Italy.
   [Prada, Francesco] Univ Virginia, Hlth Sci Ctr, Dept Neurol Surg, Charlottesville, VA 22908 USA.
   [DiMeco, Francesco] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
RP Acerbi, F (reprint author), Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Vasc Neurosurg Unit, Milan, Italy.
EM francesco.acerbi@istituto-besta.it
RI DiMeco, Francesco/Z-5431-2019; vetrano, ignazio/J-1573-2017
OI vetrano, ignazio/0000-0003-0664-9700; Farago,
   Giuseppe/0000-0002-7516-3512
CR Acerbi F, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.4.FOCUS18120
   Acerbi F, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.3.FOCUS1862
   Acerbi F, 2016, NEUROSURGERY, V78, pE310, DOI 10.1227/NEU.0000000000001053
   Bain MD, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f8889e
   Dashti R, 2007, SURG NEUROL, V67, P553, DOI 10.1016/j.surneu.2007.03.023
   Dengler J, 2013, J NEUROSURG, V118, P444, DOI 10.3171/2012.11.JNS121061
   Esposito G, 2016, ACTA NEUROCHIR, V158, P1523, DOI 10.1007/s00701-016-2868-3
   Esposito G, 2012, NEUROSURGERY, V71, P274, DOI 10.1227/NEU.0b013e3182684c45
   Ferroli P, 2007, J Neurosurg Sci, V51, P71
   Ferroli P, 2013, ACTA NEUROCHIR, V155, P1035, DOI 10.1007/s00701-013-1722-0
   Goyal A, 2018, CHILD NERV SYST, V34, P1627, DOI 10.1007/s00381-018-3852-4
   Gruber A, 2012, AJNR Am J Neuroradiol, V33, pE36, DOI 10.3174/ajnr.A2424
   Heros RC, 2009, J NEUROSURG, V111, P75, DOI 10.3171/2009.2.JNS09112
   Horie N, 2003, J NEUROSURG, V99, P391, DOI 10.3171/jns.2003.99.2.0391
   HOROWITZ MB, 1994, SURG NEUROL, V41, P221, DOI 10.1016/0090-3019(94)90126-0
   Joo SP, 2007, ACTA NEUROCHIR, V149, P661, DOI 10.1007/s00701-007-1061-5
   Kalani MYS, 2013, NEUROSURGERY, V72, P428, DOI 10.1227/NEU.0b013e3182804381
   Karnchanapandh K, 2002, MINIM INVAS NEUROSUR, V45, P245, DOI 10.1055/s-2002-36198
   Lane B, 2015, J NEUROSURG, V122, P618, DOI 10.3171/2014.10.JNS132766
   Lawton MT, 2008, NEUROSURGERY, V62, P1503, DOI [10.1227/01.NEU.0000043642.46308.D1, 10.1227/01.neu.0000333814.02649.a0]
   Lawton MT, 1996, NEUROSURGERY, V38, P83, DOI 10.1097/00006123-199601000-00020
   Mehta KS, 2017, J VASC SURG, V66, P266, DOI 10.1016/j.jvs.2016.12.133
   Peerless S J, 1982, Neurosurg Rev, V5, P149, DOI 10.1007/BF01742677
   Prada F, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15573
   Prada F, 2015, WORLD NEUROSURG, V84, P1699, DOI 10.1016/j.wneu.2015.07.025
   Prada F, 2015, ACTA NEUROCHIR, V157, P1025, DOI 10.1007/s00701-015-2412-x
   Raabe A, 2003, NEUROSURGERY, V52, P132, DOI 10.1097/00006123-200301000-00017
   Rodriguez-Hernandez A, 2013, WORLD NEUROSURG, V80, P103, DOI 10.1016/j.wneu.2012.09.010
   Rodriguez-Hernandez A, 2012, NEUROSURGERY, V70, P209, DOI 10.1227/NEU.0b013e31823158f3
   Sanai N, 2009, NEUROSURGERY, V65, P670, DOI 10.1227/01.NEU.0000348557.11968.F1
   Sidhu PS, 2018, ULTRASCHALL MED, V39, pE2, DOI 10.1055/a-0586-1107
   Ture U, 1999, J NEUROSURG, V90, P720, DOI 10.3171/jns.1999.90.4.0720
   Vetrano IG, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15162
   1996, NEUROSURGERY, V38, P83
   2009, J NEUROSURG, V111, P75, DOI DOI 10.3171/2009.2.JNS09112
NR 35
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 277
EP 284
DI 10.1016/j.wneu.2019.01.241
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700205
PM 30776513
DA 2020-05-12
ER

PT J
AU Wang, L
   Cai, L
   Qian, H
   Song, JP
   Tanikawa, R
   Lawton, M
   Shi, XE
AF Wang, Long
   Cai, Li
   Qian, Hai
   Song, Jianping
   Tanikawa, Rokuya
   Lawton, Michael
   Shi, Xiang'en
TI Intracranial-Intracranial Bypass with a Graft Vessel: A Comprehensive
   Review of Technical Characteristics and Surgical Experience
SO WORLD NEUROSURGERY
LA English
DT Review
DE Complex intracranial aneurysm; In situ interposition graft bypass;
   Intracranial-intracranial bypass; Jump graft bypass; Radial artery graft
   bypass; Saphenous vein graft bypass; Superficial temporal artery graft
   bypass
ID CEREBRAL-ARTERY ANEURYSMS; SUPERFICIAL TEMPORAL ARTERY; INFERIOR
   CEREBELLAR ARTERY; BILATERAL VERTEBRAL ARTERIES; SURGERY;
   REVASCULARIZATION; GIANT; COMPLICATIONS; MANAGEMENT; OUTCOMES
AB OBJECTIVE: Intracranial-intracranial (IC-IC) bypass with a graft vessel (IBGV) is a straightforward arterial reconstruction technique used for the treatment of complex aneurysms and skull base tumors. We have described the technical characteristics and summarized the clinical results of IBGV in complex cerebrovascular disorders.
   METHODS: We performed a search of the PubMed and Google Scholar online databases. The terms "intracranial-intracranial bypass," "jump graft bypass," "interposition graft bypass," "radial artery graft bypass," "saphenous vein graft bypass," and "superficial temporal artery graft bypass" were searched. Studies involving IBGV combined with other bypass methods were excluded. Illustrations of the technique have been provided to enhance comprehension.
   RESULTS: We identified 59 cases involving 6 types of graft vessels were identified from 1978 to July 2018. The IBGV technique was divided into the following 4 subtypes: type IA, in situ interposition graft bypass; type IB, Y-shaped double-barrel interposition graft bypass; type IIA, long jump graft bypass; and type IIB, Y-shaped double-barrel jump graft bypass. Grafts from the radial (44.1%; 26 of 59) and superficial temporal (39.3%; 22 of 59) arteries were used most frequently, and the middle cerebral artery territory was the most commonly involved region for IBGV. Of the cases with the specified postoperative characteristics, the graft patency and overall uneventful rates were 96.3% (52 of 54) and 82.2% (37 of 45), respectively. A higher patency rate (100% vs. 90.5%) and a lower complication rate (<20% vs. 60%) were observed with the type II group with an arterial graft.
   CONCLUSIONS: The IBGV method is a technically feasible option for vascular disease or complex cerebral tumors and should be considered by neurosurgeons. Long jump bypass with arterial grafts should be preferred when IC-IC bypass has been considered owing to the high rates of graft patency and favorable clinical outcomes.
C1 [Wang, Long; Qian, Hai; Shi, Xiang'en] Capital Med Univ, SanBo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Wang, Long; Tanikawa, Rokuya] Teishinkai Hosp, Stroke Ctr, Dept Neurosurg, Sapporo, Hokkaido, Japan.
   [Wang, Long; Lawton, Michael] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ USA.
   [Cai, Li] Univ South China, Affiliated Hosp 1, Dept Neurosurg, Hengyang, Peoples R China.
   [Cai, Li] St Vincent Hosp, Arkansas Neurosci Inst, Little Rock, AR USA.
   [Song, Jianping] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Shi, Xiang'en] Capital Med Univ, Fuxing Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Wang, L (reprint author), Capital Med Univ, SanBo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.; Wang, L (reprint author), Teishinkai Hosp, Stroke Ctr, Dept Neurosurg, Sapporo, Hokkaido, Japan.; Wang, L (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ USA.
EM wanglong@mail.ccmu.edu.cn
RI WANG, LONG/AAI-5029-2020
FU Beijing Municipal Natural Science FoundationBeijing Natural Science
   Foundation [7161005]; Science and Technology Commission Foundation of
   Beijing [Z161100000516019]
FX The present study was funded by the Beijing Municipal Natural Science
   Foundation (grant 7161005 to X.S.) and the Science and Technology
   Commission Foundation of Beijing (grant Z161100000516019 to X.S.).
CR Abe Takatsugu, 2016, Surg Neurol Int, V7, P5, DOI 10.4103/2152-7806.173319
   Abla AA, 2014, J NEUROSURG, V120, P1364, DOI 10.3171/2014.3.JNS132219
   Amenta PS, 2015, WORLD NEUROSURG, V83, P142, DOI 10.1016/j.wneu.2014.06.051
   Baaj AA, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.1.FOCUS08303
   Budillon AM, 2003, SURGERY, V133, P283, DOI 10.1067/msy.2003.43
   Burkhardt JK, 2017, WORLD NEUROSURG, V107, P554, DOI 10.1016/j.wneu.2017.08.032
   Davies JM, 2014, NEUROSURGERY, V74, pS7, DOI 10.1227/NEU.0000000000000193
   Dengler J, 2013, J NEUROSURG, V118, P444, DOI 10.3171/2012.11.JNS121061
   DOLENC V, 1978, J NEUROSURG, V49, P272, DOI 10.3171/jns.1978.49.2.0272
   Endo H, 2017, J NEUROSURG, V129, P1
   Gelfenbeyn M, 2009, NEUROSURGERY, V64, P1008, DOI 10.1227/01.NEU.0000339119.92564.29
   Hamada J, 2002, J NEUROSURG, V96, P867, DOI 10.3171/jns.2002.96.5.0867
   Hara Takayuki, 2016, Acta Neurochir Suppl, V123, P57, DOI 10.1007/978-3-319-29887-0_8
   Hasegawa Y, 2012, NEUROL MED-CHIR, V52, P443, DOI 10.2176/nmc.52.443
   Hauck EF, 2009, SURG NEUROL, V71, P600, DOI 10.1016/j.surneu.2008.01.058
   Jung JM, 2012, J KOREAN NEUROSURG S, V51, P292, DOI 10.3340/jkns.2012.51.5.292
   Kalani MYS, 2016, J CLIN NEUROSCI, V24, P151, DOI 10.1016/j.jocn.2015.08.007
   Kalani MYS, 2014, J NEUROSURG-PEDIATR, V13, P641, DOI 10.3171/2014.3.PEDS13444
   Kim LJ, 2013, J NEUROSURG-PEDIATR, V11, P533, DOI 10.3171/2013.1.PEDS12444
   Lawton MT, 2016, OPER NEUROSURG, V12, P91, DOI 10.1227/NEU.0000000000001054
   Lawton MT, 2018, 7 BYPASSES TENETS TE
   Lewis SB, 2002, J NEUROSURG, V97, P756, DOI 10.3171/jns.2002.97.4.0756
   Liu FJ, 2018, WORLD NEUROSURG, V109, P500, DOI 10.1016/j.wneu.2017.08.068
   Mascitelli JR, 2019, J NEUROSURG, V130, P1435, DOI 10.3171/2018.2.JNS173141
   Meybodi AT, 2017, J NEUROSURG, V127, P463, DOI 10.3171/2016.7.JNS16772
   Mrak G, 2014, OPER NEUROSURG, V10, pE172, DOI 10.1227/NEU.0000000000000168
   Mura J, 2013, NEUROSURGERY, V72, P235, DOI 10.1227/NEU.0b013e31827bc7c1
   Nossek E, 2018, WORLD NEUROSURG, V115, P44, DOI 10.1016/j.wneu.2018.03.214
   Nussbaum Leslie, 2011, Surg Neurol Int, V2, P98, DOI 10.4103/2152-7806.82991
   Ota N, 2016, WORLD NEUROSURG, V87, P328, DOI 10.1016/j.wneu.2015.10.079
   Otawara Y, 2002, NEUROSURGERY, V50, P1372
   Ramanathan D, 2013, WORLD NEUROSURG, V80, P322, DOI 10.1016/j.wneu.2012.01.035
   Raso JL, 2005, NEUROSURGERY, V57, P67
   Rodriguez-Hernandez A, 2013, WORLD NEUROSURG, V80, P103, DOI 10.1016/j.wneu.2012.09.010
   Rodriguez-Hernandez A, 2011, WORLD NEUROSURG, V76, pS72, DOI 10.1016/j.wneu.2011.06.032
   Sabik JF, 2011, CIRCULATION, V124, P273, DOI 10.1161/CIRCULATIONAHA.111.039842
   Sanai N, 2009, NEUROSURGERY, V65, P670, DOI 10.1227/01.NEU.0000348557.11968.F1
   Sekhar LN, 2008, NEUROSURGERY, V62, P1373, DOI [10.1227/01.NEU.0000315873.41953.74, 10.1227/01.neu.0000333803.97703.c6]
   Sekhar LN, 2007, NEUROSURGERY, V61, P273, DOI 10.1227/01.neu.0000303980.96504.d9
   Sekhar LN, 2001, NEUROSURGERY, V49, P646, DOI 10.1097/00006123-200109000-00023
   Shapira OM, 1999, CIRCULATION, V100, P322
   Shi XG, 2015, NEUROSURG REV, V38, P109, DOI 10.1007/s10143-014-0571-5
   Strickland BA, 2018, OPER NEUROSURG, V15, P285, DOI 10.1093/ons/opx241
   Terasaka S, 1997, SURG NEUROL, V48, P164, DOI 10.1016/S0090-3019(96)00476-4
   Wang L, 2019, NEUROSURG REV, V42, P619, DOI 10.1007/s10143-018-1036-z
   Wang L, 2018, WORLD NEUROSURG, V115, P357, DOI 10.1016/j.wneu.2018.04.173
   Wang L, 2018, WORLD NEUROSURG, V113, P320, DOI 10.1016/j.wneu.2018.02.158
   Wang L, 2017, WORLD NEUROSURG, V105, P568, DOI 10.1016/j.wneu.2017.06.014
   Wang L, 2017, WORLD NEUROSURG, V103, P395, DOI 10.1016/j.wneu.2017.04.055
   Wang L, 2017, NEUROSURG REV, V40, P319, DOI 10.1007/s10143-016-0778-8
   Wang L, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16252
   YOSHIMOTO T, 1991, SURG NEUROL, V36, P476, DOI 10.1016/0090-3019(91)90164-5
   2018, OPER NEUROSURG, V15, P601
NR 53
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 285
EP 298
DI 10.1016/j.wneu.2019.01.259
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700206
PM 30790733
DA 2020-05-12
ER

PT J
AU Prasad, GL
   Divya, S
AF Prasad, Govindaraju Lakshmi
   Divya, Siddalingappa
TI Eosinophilic Granuloma of the Cervical Spine in Adults: A Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adults; Cervical spine; Eosinophilic granuloma; Langerhans cell
   histiocytosis
ID LANGERHANS-CELL HISTIOCYTOSIS; TERM-FOLLOW-UP; PERCUTANEOUS
   VERTEBROPLASTY; CORD COMPRESSION; MANAGEMENT; DIAGNOSIS; CHILDREN
AB OBJECTIVE: Spinal eosinophilic granulomas (EGs) are uncommon tumors, constituting <1% of all bone tumors. They are mostly seen in the pediatric age group, whereas adult onset is rare. The cervical spine is an infrequent location for EG. The literature is sparse regarding the clinical and management aspects of these lesions, especially in adults.
   METHODS: A literature review was performed by searching online databases to analyze all the reported cases of adult-onset cervical EG.
   RESULTS: Sixty-two cases were identified and analyzed. The male/female ratio was 3.1:1. The mean age at presentation was 32.8 years (range, 18-71 years). Neck pain, limb weakness, and restriction of movement were the most frequent symptoms. The C2 vertebra was the most frequently involved. The vertebral body was involved in >80% of patients and only 2 had vertebra plana morphology. The cervical lesions involved single vertebra in 42 patients (82%), whereas 9 patients (18%) had multiple vertebral involvement. Fifteen patients were managed conservatively, of whom 7 failed and required surgery later; 40 patients underwent definitive surgery and 17 received adjuvant treatment. Posterior-only surgeries were performed in 5 patients, anterior-only in 20, and circumferential in 14. The mean follow-up duration was 68 months (range, 12-268 months). The outcome was good to excellent in all, except 1, irrespective of type of treatment received.
   CONCLUSIONS: Cervical spine EG is rare in adults and usually presents as an osteolytic lesion involving the vertebral body; vertebra plana is very rare. Surgery is typically reserved for patients with severe neurologic deficits and bony instability. The outcome seems good in most cases.
C1 [Prasad, Govindaraju Lakshmi] Kasturba Med Coll & Hosp, Dept Neurosurg, Manipal, India.
   [Divya, Siddalingappa] Manipal Acad Higher Educ, Manipal Coll Dent Sci, Dept Orthodont, Manipal, India.
RP Prasad, GL (reprint author), Kasturba Med Coll & Hosp, Dept Neurosurg, Manipal, India.
EM lakshmi.prasad@manipal.edu
CR BABER WW, 1987, CT-J COMPUT TOMOGR, V11, P346, DOI 10.1016/0149-936X(87)90070-1
   Bang WS, 2013, J KOREAN NEUROSURG S, V54, P54, DOI 10.3340/jkns.2013.54.1.54
   BASSET F, 1972, CANCER, V29, P1380, DOI 10.1002/1097-0142(197205)29:5<1380::AID-CNCR2820290540>3.0.CO;2-7
   Bavbek M, 2004, ACTA NEUROCHIR, V146, P165, DOI 10.1007/s00701-003-0182-3
   BELTRAN J, 1993, SKELETAL RADIOL, V22, P157
   Bertram C, 2002, SPINE, V27, P1408, DOI 10.1097/00007632-200207010-00007
   Brown CW, 2005, CAN J SURG, V48, P230
   Buchman J, 1927, J BONE JOINT SURG, V9, P55
   CARDON T, 1994, CLIN RHEUMATOL, V13, P518, DOI 10.1007/BF02242955
   CASSON IR, 1981, NEW YORK STATE J MED, V81, P1102
   COMPERE EL, 1954, J BONE JOINT SURG AM, V36-A, P969, DOI 10.2106/00004623-195436050-00006
   Denaro L, 2008, SPINE, V33, pE936, DOI 10.1097/BRS.0b013e3181859aab
   DESCHEPPER AMA, 1993, SKELETAL RADIOL, V22, P163, DOI 10.1007/BF00206146
   DICKINSON LD, 1991, SURG NEUROL, V35, P57, DOI 10.1016/0090-3019(91)90204-M
   Duarte-Silva EB, 1999, ARQ NEURO-PSIQUIAT, V57, P498, DOI 10.1590/S0004-282X1999000300025
   FAVARA BE, 1994, BRIT J CANCER, V70, pS17
   GREEN NE, 1980, J BONE JOINT SURG AM, V62, P1198, DOI 10.2106/00004623-198062070-00024
   HERRING JA, 1987, J PEDIATR ORTHOPED, V7, P481, DOI 10.1097/01241398-198707000-00020
   Howarth DM, 1999, CANCER-AM CANCER SOC, V85, P2278, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2278::AID-CNCR25>3.0.CO;2-U
   Huang WD, 2010, ACTA NEUROCHIR, V152, P1129, DOI 10.1007/s00701-010-0644-3
   Huang WDD, 2013, SPINE J, V13, P1108, DOI 10.1016/j.spinee.2013.03.013
   Islinger RB, 2000, CLIN ORTHOP RELAT R, P231
   Jiang L, 2011, EUR SPINE J, V20, P1961, DOI 10.1007/s00586-010-1390-1
   Jiang L, 2010, SPINE, V35, pE8, DOI 10.1097/BRS.0b013e3181b8aa2d
   JOHNSON S, 1993, SKELETAL RADIOL, V22, P63
   KUMAR A, 1990, ORTHOPEDICS, V13, P1310
   LAUFFENBURGER MD, 1995, J SPINAL DISORD, V8, P243, DOI 10.1097/00002517-199506000-00013
   Levy EI, 1999, PEDIATR NEUROSURG, V31, P159, DOI 10.1159/000028853
   LICHTENSTEIN L, 1964, J BONE JOINT SURG AM, V46, P76, DOI 10.2106/00004623-196446010-00007
   MACKENZIE WG, 1988, CAN J SURG, V31, P264
   MACNAB GH, 1955, P ROY SOC MED, V48, P303, DOI 10.1177/003591575504800410
   MARTIN N, 1985, ANN RADIOL, V28, P391
   Plasschaert F, 2002, J BONE JOINT SURG BR, V84B, P870, DOI 10.1302/0301-620X.84B6.12585
   Raab P, 1998, SPINE, V23, P1351, DOI 10.1097/00007632-199806150-00011
   Rai S, 2017, INDIAN J MED PAEDIAT, V38, P555, DOI 10.4103/ijmpo.ijmpo_130_16
   Reddy PK, 2000, SPINAL CORD, V38, P766, DOI 10.1038/sj.sc.3101061
   RICHTER MP, 1981, AM J PEDIAT HEMATOL, V3, P161
   Rimondi E, 2011, SKELETAL RADIOL, V40, P757, DOI 10.1007/s00256-010-1045-7
   SANCHEZ RL, 1984, ORTHOPEDICS, V7, P1721, DOI 10.3928/0147-7447-19841101-11
   Sayhan S, 2010, TURK NEUROSURG, V20, P409, DOI 10.5137/1019-5149.JTN.1625-08.2
   SCARFI G, 1974, MINERVA ORTOPED, V25, P298
   SCARPINATI M, 1995, NEUROSURG REV, V18, P209, DOI 10.1007/BF00383729
   Schar RT, 2019, J NEUROL SURG PART A, V80, P49, DOI 10.1055/s-0038-1655769
   SEIMON LP, 1981, J PEDIATR ORTHOPED, V1, P371, DOI 10.1097/01241398-198112000-00003
   Simanski C, 2004, MAGN RESON IMAGING, V22, P589, DOI 10.1016/j.mri.2004.01.006
   Song Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007197
   Stephens BH, 2017, J NEUROSURG-SPINE, V26, P252, DOI 10.3171/2016.8.SPINE15523
   SWEASEY TA, 1989, J NEUROSURG, V71, P942, DOI 10.3171/jns.1989.71.6.0942
   Tan HQ, 2007, PEDIATR RADIOL, V37, P1053, DOI 10.1007/s00247-007-0575-1
   Vielgut I, 2017, J ORTHOP, V14, P264, DOI 10.1016/j.jor.2017.03.010
   VILLAS C, 1993, J SPINAL DISORD, V6, P260, DOI 10.1097/00002517-199306030-00014
   Yeom JS, 1999, SPINE, V24, P1740, DOI 10.1097/00007632-199908150-00016
   Zheng W, 2014, SPINE J, V14, P2701, DOI 10.1016/j.spinee.2014.03.013
   Zhiyu L, 2018, CONT ONCOL POZN, V18, P290
   Zhong WQ, 2010, EUR SPINE J, V19, P19, DOI 10.1007/s00586-009-1172-9
   Zhu C, 2013, JBJS CASE CONNECT, V3, pe63
NR 56
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 301
EP 311
DI 10.1016/j.wneu.2019.01.230
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700208
PM 30771538
DA 2020-05-12
ER

PT J
AU Chaudhry, NS
   Bi, WL
   Gupta, S
   Keraliya, A
   Shimizu, N
   Chiocca, EA
AF Chaudhry, Nauman S.
   Bi, Wenya Linda
   Gupta, Saksham
   Keraliya, Abhishek
   Shimizu, Naomi
   Chiocca, E. Antonio
TI Pneumatosis Intestinalis After Molecular-Targeted Therapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bevacizumab; Bowel perforation; Free air; Molecular targeted therapy;
   Pneumatosis intestinalis; Ventriculoperitoneal shunt
ID BOWEL PERFORATION; CT FINDINGS; BEVACIZUMAB; COMPLICATIONS
AB BACKGROUND: Pneumoperitoneum after surgical manipulation of the abdomen implies a perforation. Rare cases of nonoperated cancer patients, largely with gastrointestinal or genitourinary cancers, have been noted to have radiologic findings of pneumatosis intestinalis and/or pneumoperitoneum as a complication of molecular-targeted therapy (MTT) without confounding factors for perforation. We present a patient with a cranial malignancy treated with bevacizumab who subsequently manifested with pneumatosis intestinalis.
   CASE DESCRIPTION: A 67-year-old man with metastatic melanoma, non-small cell lung cancer, and recurrent cerebellar subependymoma was initiated on bevacizumab treatment for subependymoma recurrence. He subsequently underwent an uncomplicated ventriculoperitoneal shunt for progressive obstructive hydrocephalus, confirmed by a normal postoperative abdominal radiograph. One week later, he returned with worsening lethargy and a computed tomography consistent with pneumomediastinum and pneumoperitoneum. Due to concern for bowel perforation, the patient underwent diagnostic laparoscopy and removal of ventriculoperitoneal shunt. Focal sigmoid pneumatosis was identified without any signs of bowel perforation or ischemia. Bevacizumab was discontinued, and the patient's radiologic and clinical findings improved.
   CONCLUSIONS: With increasing utilization of MTTs in brain tumor management, we raise MTT as a potential cause for pneumoperitoneum in neurosurgical patients. Pneumoperitoneum after extracranial procedures still requires workup and management for potential bowel perforation, but alternative causes such as bevacizumab should also be considered. Pneumatosis intestinalis patients on MTT can have benign physical examinations and will resolve, in the majority of cases, on discontinuation of the drug.
C1 [Chaudhry, Nauman S.] Univ Illinois, Coll Med, Dept Neurosurg, Chicago, IL USA.
   [Bi, Wenya Linda; Gupta, Saksham; Chiocca, E. Antonio] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
   [Keraliya, Abhishek] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
   [Shimizu, Naomi] Harvard Med Sch, Brigham & Womens Hosp, Dept Trauma Burns & Crit Care, Boston, MA 02115 USA.
RP Chiocca, EA (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
EM eachiocca@partners.org
CR ABUDALU K, 1983, NEUROSURGERY, V13, P167, DOI 10.1227/00006123-198308000-00011
   Akun E, 2012, J BUON, V17, P669
   Asmis TR, 2008, INVEST NEW DRUG, V26, P95, DOI 10.1007/s10637-007-9094-z
   Badgwell BD, 2008, ANN ONCOL, V19, P577, DOI 10.1093/annonc/mdm508
   Chung JJ, 2009, AM J ROENTGENOL, V193, P1311, DOI 10.2214/AJR.09.2463
   Diaz JP, 2010, GYNECOL ONCOL, V116, P335, DOI 10.1016/j.ygyno.2009.11.017
   DuBose JJ, 2013, J TRAUMA ACUTE CARE, V75, P15, DOI 10.1097/TA.0b013e318298486e
   Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573
   Hapani S, 2009, LANCET ONCOL, V10, P559, DOI 10.1016/S1470-2045(09)70112-3
   Hawn MT, 2004, AM SURGEON, V70, P19
   Ho LM, 2007, AM J ROENTGENOL, V188, P1604, DOI 10.2214/AJR.06.1309
   Miller JA, 2015, CASE REP ONCOL MED, DOI 10.1155/2015/214236
   Saif M Wasif, 2009, J Support Oncol, V7, P245
   Scappaticci FA, 2005, J SURG ONCOL, V91, P173, DOI 10.1002/jso.20301
   Shinagare AB, 2012, AM J ROENTGENOL, V199, P1259, DOI 10.2214/AJR.12.8782
   Thornton E, 2012, BRIT J RADIOL, V85, P1420, DOI 10.1259/bjr/19815818
   Uruga H, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4743-5
   Wayne E, 2010, J GASTROINTEST SURG, V14, P437, DOI 10.1007/s11605-009-1143-9
   Wiesner W, 2001, AM J ROENTGENOL, V177, P1319, DOI 10.2214/ajr.177.6.1771319
   2004, AM SURG, V70, P19
NR 20
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 312
EP 315
DI 10.1016/j.wneu.2019.01.225
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700209
PM 30763745
DA 2020-05-12
ER

PT J
AU Chen, XJ
   Xu, GK
   Bi, Q
   Huang, YZ
   Shao, HY
   Jin, MR
   Mesfin, A
   Zhang, J
AF Chen, Xinji
   Xu, Guokang
   Bi, Qing
   Huang, Yazeng
   Shao, Haiyu
   Jin, Mengran
   Mesfin, Addisu
   Zhang, Jun
TI Cauda Equina Syndrome as First Manifestation of von Hippel-Lindau
   Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cauda equina syndrome; Hemangioblastomas; Surgical treatment; VHL
   disease
ID LONG-TERM PROGNOSIS; SPINAL HEMANGIOBLASTOMAS; IMPACT; CNS
AB BACKGROUND: Von-Hippel Lindau (VHL) disease is rare neurocutaneous disorder arising from an inactivating mutation of the VHL gene on chromosome 3p35. The disease is inherited in an autosomal dominant fashion and predominantly involves tissues originating from the ectodermal germ layer. Although hemangioblastomas of retina and cerebellum are the most common clinical features, multiple-organ involvement in the form of renal cell carcinomas, spinal hemangioblastomas, renal cysts, and pancreatic cysts have also been reported. Hemangioblastomas of the spinal canal could present as cauda equina syndrome.
   CASE DESCRIPTION: We describe the case of a 55-year-old man with cauda equina syndrome as his first manifestation. An initial magnetic resonance imaging scan uncovered hemangiomas in the spinal canal. A thorough family history strongly suggested an autosomal dominant pattern of disease inheritance. Further physical examination and imaging revealed additional organ involvement consistent with VHL. We performed laminectomy and partial resection of hemangioblastoma for decompression. He recovered satisfactorily with his cauda equina syndrome resolving quickly post operation. No deterioration was apparent by the 12-month follow-up visit.
   CONCLUSIONS: To the best of our knowledge, this is the first case with cauda equina syndrome as the first manifestation of VHL disease. Laminectomy and partial resection of hemangioblastoma are safe and effective treatments to resolve impingement of the spinal cord. VHL disease resulting in hemangioblastoma in the spinal canal is rarely seen but should be included in the differential diagnosis of cauda equina syndrome to facilitate genetic counseling for the proband and offspring.
C1 [Chen, Xinji; Bi, Qing; Huang, Yazeng; Shao, Haiyu; Jin, Mengran; Zhang, Jun] Zhejiang Prov Peoples Hosp, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China.
   [Chen, Xinji; Bi, Qing; Huang, Yazeng; Shao, Haiyu; Jin, Mengran; Zhang, Jun] Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Chen, Xinji] Wenzhou Med Coll, Sch Clin Med, Wenzhou, Peoples R China.
   [Xu, Guokang] Fuyang First Peoples Hosp, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China.
   [Mesfin, Addisu] Univ Rochester, Med Ctr, Dept Spine Surg, Rochester, NY 14642 USA.
RP Zhang, J (reprint author), Zhejiang Prov Peoples Hosp, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China.; Zhang, J (reprint author), Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
EM spinezhangjun@aliyun.com
OI Mesfin, Addisu/0000-0003-0076-4185
FU Zhejiang Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Zhejiang Province [LY15H060006, LY16H060007]; Zhejiang
   Provincial Health Bureau Science Foundation of China [2018KY017];
   Hangzhou Bureau of Science Technology Foundation [20171226Y167]
FX This study was supported by grants from Zhejiang Provincial Natural
   Science Foundation of China (LY15H060006) and (LY16H060007), Zhejiang
   Provincial Health Bureau Science Foundation of China (2018KY017), and
   Hangzhou Bureau of Science Technology Foundation (20171226Y167).
CR Conway JE, 2001, NEUROSURGERY, V48, P55, DOI 10.1097/00006123-200101000-00009
   DELAMONTE SM, 1989, NEUROSURGERY, V25, P695, DOI 10.1227/00006123-198911000-00002
   Escott EJ, 2004, SURG NEUROL, V61, P262, DOI 10.1016/S0090-3019(03)00399-9
   Glasker S, 2005, NEUROSURGERY, V56, P503, DOI 10.1227/01.NEU.0000153909.70381.C8
   HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769
   Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885
   Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061
   MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443
   Moss JM, 2009, NEUROSURGERY, V65, P79, DOI 10.1227/01.NEU.0000348015.51685.D2
   Niemela M, 1999, ACTA NEUROCHIR, V141, P1147, DOI 10.1007/s007010050412
   Ohh M, 2000, NAT CELL BIOL, V2, P423
   Ortega-Martinez M, 2007, J NEUROSURG-SPINE, V7, P254, DOI 10.3171/SPI-07/08/254
   Park CH, 2012, J KOREAN NEUROSURG S, V52, P221, DOI 10.3340/jkns.2012.52.3.221
   Samil M, 1999, ACTA NEUROCHIR, V141, P1156
   Selch Michael T, 2012, Surg Neurol Int, V3, P73, DOI 10.4103/2152-7806.98386
   Sergides IG, 2009, ACTA NEUROL BELG, V109, P55
   Takai K, 2010, NEUROL MED-CHIR, V50, P560, DOI 10.2176/nmc.50.560
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 316
EP 319
DI 10.1016/j.wneu.2019.01.269
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700210
PM 30780037
DA 2020-05-12
ER

PT J
AU Venturini, S
   Still, MEH
   Vycheth, I
   Nang, S
   Vuthy, D
   Park, KB
AF Venturini, Sara
   Still, Megan E. H.
   Vycheth, Iv
   Nang, Sam
   Vuthy, Din
   Park, Kee B.
TI The National Motorcycle Helmet Law at 2 Years: Review of Its Impact on
   the Epidemiology of Traumatic Brain Injury in a Major Government
   Hospital in Cambodia
SO WORLD NEUROSURGERY
LA English
DT Review
DE Epidemiology; Global neurosurgery; Helmet law; Helmets; Motorcycle; TBI
   prevention; Traumatic brain injury
ID GLOBAL BURDEN; DISEASE
AB BACKGROUND: Traumatic brain injury (TBI) is major contributor to the global burden of disease, especially in low- and middle- income countries, where most TBIs are traffic-related. Evidence shows that helmets protect against severe TBI. Cambodia continues to have the greatest motorcycle fatality rate in Southeast Asia. We investigated whether the National Motorcycle Helmet Law introduced in January 2016 had an impact on the epidemiology of motorcycle-related TBI in a neurosurgical referral center in Phnom Penh.
   METHODS: This is a cross-sectional study of all patients admitted to the Department of Neurosurgery at Preah Kossamak Hospital with TBI following motorcycle accidents between January 2014 and December 2017.
   RESULTS: TBI admissions increased (from 234 in 2014 to 768 in 2017). The median age was 26 years, and most patients were male. The percentage of helmeted patients was 9% in 2014 and 13% in 2015; this increased to 18% in 2016, but dropped to 9% in 2017. Most TBIs occurred during the evening rush hour. Since 2016, more patients wore helmets in the daytime (up to 23%) than at night (5% between 1:00 and 5: 00 AM). Skull fracture, the most common pathology pre-law, decreased by 25% post-law (P < 0.001).
   CONCLUSIONS: With growing urbanization and motorization, TBI is a significant cause of morbidity and mortality in Cambodia. Two years after helmets became compulsory, most patients with TBI are still unhelmeted. Likely contributing factors are low penalty for noncompliance and inconsistent law enforcement. TBI is a major public health problem warranting further efforts to understand how to improve prevention strategies and advocate for change.
C1 [Venturini, Sara] Aberdeen Royal Infirm, Aberdeen, Scotland.
   [Venturini, Sara; Still, Megan E. H.; Vycheth, Iv; Nang, Sam; Vuthy, Din] Preah Kossamak Hosp, Dept Neurosurg, Phnom Penh, Cambodia.
   [Still, Megan E. H.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
   [Park, Kee B.] Harvard Med Sch, Program Global Surg & Social Change, Boston, MA 02115 USA.
RP Venturini, S (reprint author), Aberdeen Royal Infirm, Aberdeen, Scotland.; Venturini, S (reprint author), Preah Kossamak Hosp, Dept Neurosurg, Phnom Penh, Cambodia.
EM sara.venturini@nhs.net
OI Still, Megan/0000-0002-7665-2692
CR [Anonymous], PHNOM PENH POST
   [Anonymous], 2015, GLOB STAT REP ROAD S
   Bryan-Hancock C, 2010, INJURY PREV, V16, pA17, DOI 10.1136/ip.2010.029215.61
   Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5
   Gupta S, 2018, TRAFFIC INJ PREV, V19, P66, DOI 10.1080/15389588.2017.1342821
   Gupta S, 2017, WORLD NEUROSURG, V100, P267, DOI 10.1016/j.wneu.2016.12.104
   Hyder AA, 2007, NEUROREHABILITATION, V22, P341
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X
   National Institute of Neurological Disorders and Stroke, TRAUM BRAIN INJ INF
   Newman J. A., 1993, ACCIDENTAL INJURY BI, P292
   Peeters S, 2017, WORLD NEUROSURG, V97, P580, DOI 10.1016/j.wneu.2016.09.127
   Roehler DR, 2013, INT J INJ CONTROL SA, V20, P179, DOI 10.1080/17457300.2012.759594
   Rose J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089693
   WHO, 2016, HELM ROAD SAF MAN DE
   Willinger R, 2000, J SOUND VIB, V235, P611, DOI 10.1006/jsvi.1999.2931
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 320
EP 326
DI 10.1016/j.wneu.2019.01.255
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700211
PM 30790736
DA 2020-05-12
ER

PT J
AU Traylor, JI
   Johnson, GS
   Ashour, R
   Ghafoori, P
   Buchanan, RJ
AF Traylor, Jeffrey I.
   Johnson, Garrett S.
   Ashour, Ramsey
   Ghafoori, Paiman
   Buchanan, Robert J.
TI Volume-Staged CyberKnife Stereotactic Radiosurgery for Treatment of
   Drug-Resistant Epilepsy for a Spetzler-Martin Grade V Arteriovenous
   Malformation: A Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arteriovenous malformation; Drug-resistant epilepsy; Spetzler-Martin
   grade; Volume-staged stereotactic radiosurgery
ID TEMPORAL-LOBE EPILEPSY; SEIZURE OUTCOMES; BRAIN; MANAGEMENT
AB BACKGROUND: Evidence to support the use of stereotactic radiosurgery (SRS) in the treatment of epilepsy secondary to cerebral arteriovenous malformations (AVMs) is emerging. However, these studies have not clearly demonstrated the use of SRS in the treatment of drug-resistant epilepsy (DRE) in high Spetzler-Martin grade (IV-V) AVMs.
   CASE DESCRIPTION: We present a 48-year-old woman with DRE secondary to a Spetzler-Martin grade V cerebral AVM. She was treated with volume-staged SRS (VS-SRS) and achieved near-complete resolution of her seizures with incomplete obliteration of the AVM. Six years after treatment, she has experienced no serious complications.
   CONCLUSIONS: VS-SRS successfully controlled seizures (Engel Outcome Measure of 1A) in a patient with intractable, DRE secondary to a high-grade cerebral AVM.
C1 [Traylor, Jeffrey I.; Johnson, Garrett S.; Ashour, Ramsey; Buchanan, Robert J.] Univ Texas Austin, Dell Med Sch, Dept Neurosurg, Austin, TX 78712 USA.
   [Ghafoori, Paiman] Univ Texas Austin, Dell Med Sch, Dept Womens Hlth, Austin, TX 78712 USA.
RP Traylor, JI (reprint author), Univ Texas Austin, Dell Med Sch, Dept Neurosurg, Austin, TX 78712 USA.
EM jeff.traylor@utexas.edu
RI Traylor, Jeffrey I./AAC-4274-2020
OI Traylor, Jeffrey I./0000-0003-1749-8143; Ashour,
   Ramsey/0000-0002-3079-7052
CR Abecassis IJ, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.6.FOCUS14250
   Abla AA, 2015, J NEUROSURG, V122, P419, DOI 10.3171/2014.10.JNS1424
   Chen CJ, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.6.FOCUS1454
   Davidson AS, 2010, NEUROSURGERY, V66, P498, DOI 10.1227/01.NEU.0000365518.47684.98
   Ditty BJ, 2017, J NEUROSURG, V126, P845, DOI 10.3171/2015.12.JNS152461
   Duong DH, 1999, NEW ENGL J MED, V340, P1812
   Engel Jr J., 1993, SURG TREATMENT EPILE, P609
   Englot DJ, 2012, NEUROSURGERY, V71, P572, DOI 10.1227/NEU.0b013e31825ea3ba
   Han PP, 2003, J NEUROSURG, V98, P3, DOI 10.3171/jns.2003.98.1.0003
   Kano H, 2012, J NEUROSURG, V116, P54, DOI 10.3171/2011.9.JNS11177
   LEBLANC F, 1974, HDB CLIN NEUROLOGY, V15, P295
   Lim YJ, 2006, ACTA NEUROCHIR SUPPL, V99, P97, DOI 10.1007/978-3-211-35205-2_19
   Marciscano AE, 2017, NEUROSURGERY, V81, P136, DOI 10.1093/neuros/nyw041
   Mohr JP, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-012-0324-1
   Ogilvy CS, 2001, CIRCULATION, V103, P2644
   Patibandla MR, 2018, J NEUROSURG, V129, P498, DOI 10.3171/2017.3.JNS162635
   Przybylowski CJ, 2015, J NEUROSURG, V122, P1299, DOI 10.3171/2014.11.JNS141388
   Schramm J, 2017, HAND CLINIC, V143, P31, DOI 10.1016/B978-0-444-63640-9.00004-7
   Sirin S, 2008, NEUROSURGERY, V62, P744, DOI [10.1227/01.NEU.0000190653.42970.6B, 10.1227/01.neu.0000316278.14748.87]
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Spetzler RF, 2011, J NEUROSURG, V114, P842, DOI 10.3171/2010.8.JNS10663
   STEFAN H, 1987, J NEUROL, V234, P377, DOI 10.1007/BF00314081
   von der Brelie C, 2015, NEUROSURGERY, V77, P762, DOI 10.1227/NEU.0000000000000919
   WOLF HK, 1993, J NEUROPATH EXP NEUR, V52, P499, DOI 10.1097/00005072-199309000-00008
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 329
EP 332
DI 10.1016/j.wneu.2019.01.296
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700213
PM 30797935
DA 2020-05-12
ER

PT J
AU Mattei, TA
   Perret, CM
   Nunes, JC
AF Mattei, Tobias A.
   Perret, Caio M.
   Nunes, Julio C.
TI Development of a New Coupled Cobb-Suction Instrument for Posterior
   Spinal Approaches: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Paraspinal muscles; Posterior spinal approaches; Surgical
   instrumentation; Surgical smoke
ID SCOLIOSIS; SURGEONS; SINGLE; FUSION
AB BACKGROUND: During dissection of paraspinal muscles in posterior surgical approaches, the spine surgeon usually holds a subperiosteal (Cobb) elevator in 1 hand and a monopolar cautery in the other hand. In such a scenario, both the surgical smoke generated by the monopolar and eventual bleeding constitute a significant hindrance to simultaneous bilateral dissection of the paraspinal muscles by 2 surgeons.
   METHODS: To address the identified shortcomings in the currently available instrumentation, we initially analyzed the most common surgical techniques employed by residents and fellows at our institution for paraspinal muscle dissection during posterior spinal approaches. Additionally, we collected trainees' feedback regarding the efficacy of available strategies for dealing with surgical smoke.
   RESULTS: A new coupled Cobb elevator-suction instrument was designed, manufactured, and tested by residents, fellows, and experienced spine surgeons, and small additional design modifications were performed.
   CONCLUSIONS: We present what we believe is the first description of a new coupled Cobb-suction instrument that has been developed to enable simultaneous retraction and suction with 1 hand, while allowing the spine surgeon to use the monopolar cautery with the other hand. In our preliminary institutional experience, this new tool has been proven to be especially useful in long posterior spinal approaches in the thoracolumbar region.
C1 [Mattei, Tobias A.] St Louis Univ, Dept Neurol Surg, St Louis, MO 63103 USA.
   [Perret, Caio M.] Fed Univ Rio De Janeiro UFRJ, Fundacao Osvaldo Cruz FioCruz, Lab Neuroprotect & Regenerat Strategies, Rio De Janeiro, Brazil.
   [Nunes, Julio C.] Fed Univ State Rio De Janeiro UNIRIO, Rio De Janeiro, Brazil.
RP Mattei, TA (reprint author), St Louis Univ, Dept Neurol Surg, St Louis, MO 63103 USA.
EM tobias.mattei@health.slu.edu
OI Mattei, Tobias/0000-0001-8024-7094
CR Ames Christopher P, 2013, Spine Deform, V1, P51, DOI 10.1016/j.jspd.2012.10.004
   Atar Y, 2017, J VOICE, V31, DOI 10.1016/j.jvoice.2016.05.012
   Ball K, 2001, AANA J, V69, P125
   Bauer JM, 2019, J AM ACAD ORTHOP SUR, V27, pE408, DOI 10.5435/JAAOS-D-17-00717
   Buraimoh M Ayodele, 2017, Iowa Orthop J, V37, P211
   Calder J S, 1992, Ann R Coll Surg Engl, V74, P370
   Chan CYW, 2016, SPINE, V41, pE694, DOI 10.1097/BRS.0000000000001349
   Dobbie MK, 2017, AORN J, V106, P503, DOI 10.1016/j.aorn.2017.09.011
   Fencl JL, 2017, ASSOC OPER ROOM NURS, V105, P489, DOI 10.1016/j.aorn.2017.03.006
   Foster Mark R, 2005, Spine J, V5, P682, DOI 10.1016/j.spinee.2004.11.017
   Golish SR, 2017, SPINE J, V17, P150, DOI 10.1016/j.spinee.2016.09.015
   Halanski MA, 2013, J ORTHOP, V10, P54, DOI 10.1016/j.jor.2013.03.001
   Kumar K, 2002, SPINE, V27, P1000, DOI 10.1097/00007632-200205010-00029
   Neill BC, 2017, J AM ACAD DERMATOL, V77, pE137, DOI 10.1016/j.jaad.2017.05.046
   Scheer JK, 2017, SPINE, V42, P932, DOI 10.1097/BRS.0000000000002070
   Sethi Rajiv K, 2014, Spine Deform, V2, P95, DOI 10.1016/j.jspd.2013.12.002
   Sheehan JP, 1996, NEUROSURGERY, V39, P548, DOI 10.1097/00006123-199609000-00023
   Spetzler RF, 2011, WORLD NEUROSURG, V75, P20, DOI 10.1016/j.wneu.2010.12.029
   Tahal D, 2017, WORLD NEUROSURG, V100, P619, DOI 10.1016/j.wneu.2016.12.105
   Tramontini CC, 2016, REV ESC ENFERM USP, V50, P144, DOI 10.1590/S0080-623420160000100019
   Yashar Parham, 2013, World Neurosurg, V80, P240, DOI 10.1016/j.wneu.2011.11.009
   2011, WORLD NEUROSURG, V75, P1, DOI DOI 10.1016/J.WNEU.2011.02.007
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 333
EP 337
DI 10.1016/j.wneu.2019.01.240
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700214
PM 30776516
DA 2020-05-12
ER

PT J
AU Comes, PC
   Andre, A
   Nguyen-Khac, F
   Carpentier, A
   Bielle, F
   Amelot, A
AF Comes, Pierre-Cyril
   Andre, Arthur
   Nguyen-Khac, Florence
   Carpentier, Alexandre
   Bielle, Franck
   Amelot, Aymeric
TI Intracranial Cell Lymphomas That Mimic Meningiomas: Case Report To
   Understand Complex Genetic, Radiologic, and Histopathologic Entities
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Meningiomas; Primary central nervous system T-cell
   lymphomas; Surgery
ID NERVOUS-SYSTEM LYMPHOMA; NON-HODGKINS-LYMPHOMA; PRIMARY CNS LYMPHOMA;
   ABERRANT EXPRESSION; SURGERY; CD79A; CD20
AB BACKGROUND: We describe a patient affected by a T-cell primary central nervous system lymphoma (PCNSL) with highly aberrant specific B-cell markers (CD79a and CD20). An unusual imaging presentation leads us to misdiagnose this lesion for a meningioma and perform surgical resection.
   CASE DESCRIPTION: We think that this infrequent anatomic presentation might be due to the aberrant specific B-cell markers (CD79a and CD20) genotype expression. We believe this case to be relevant in order to appreciate the diagnosis of cerebral lymphomas according to various presentations. We wonder whether it was not the aberrant genotype that contributed to this quirky presentation and ultimately if surgery in PCNSL should not be discussed?
   CONCLUSIONS: Furthermore, this case calls attention to the complexity of lineage assignment, imaging diagnosis, and treatment strategy in PCNSL.
C1 [Comes, Pierre-Cyril; Andre, Arthur; Carpentier, Alexandre; Amelot, Aymeric] Sorbonne Univ, AP HP, Dept Neurosurg, Paris, France.
   [Bielle, Franck] Sorbonne Univ, La Pitie Salpetriere Hosp, AP HP, Dept Neuropathol, Paris, France.
   [Nguyen-Khac, Florence] Sorbonne Univ, La Pitie Salpetriere Hosp, AP HP, Haematol, Paris, France.
RP Amelot, A (reprint author), Sorbonne Univ, AP HP, Dept Neurosurg, Paris, France.
EM aymmed@hotmail.fr
OI Nguyen-Khac, Florence/0000-0003-3107-6668
CR Akiyama Y, 2000, J NUCL MED, V41, P1777
   Bierman PJ, 2014, ONCOLOGY-NY, V28, P632
   Chan WC, 1997, BLOOD, V89, P3909
   Gerstner ER, 2010, ARCH NEUROL-CHICAGO, V67, P291, DOI 10.1001/archneurol.2010.3
   Gupta N, 2017, INT J SURG PATHOL, V25, P599, DOI 10.1177/1066896917714325
   Iwamoto Fabio M, 2006, Neurosurg Focus, V21, pE5
   Iwamoto FM, 2006, NEUROLOGY, V66, P1763, DOI 10.1212/01.wnl.0000218284.23872.eb
   Kerbauy MN, 2017, RADIOTHER ONCOL, V122, P352, DOI 10.1016/j.radonc.2016.12.033
   Koubska E, 2016, NEUROENDOCRINOL LETT, V37, P318
   Li JH, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.196.13996
   MILLER DC, 1994, CANCER-AM CANCER SOC, V74, P1383, DOI 10.1002/1097-0142(19940815)74:4<1383::AID-CNCR2820740432>3.0.CO;2-1
   Raguz M, 2018, J SURG CASE REP, DOI 10.1093/jscr/rjy189
   Siasios Ioannis, 2015, J Clin Med Res, V7, P1007, DOI 10.14740/jocmr2376w
   Tu PH, 2005, J CLIN ONCOL, V23, P5718, DOI 10.1200/JCO.2005.17.624
   Wang L, 2015, J CRANIOFAC SURG, V26, pE492, DOI 10.1097/SCS.0000000000002007
   Weller M, 2012, NEURO-ONCOLOGY, V14, P1481, DOI 10.1093/neuonc/nos159
   Yao X, 2001, MODERN PATHOL, V14, P105, DOI 10.1038/modpathol.3880265
   Zeynalova PA, 2016, CANCER BIOL MED, V13, P514, DOI 10.20892/j.issn.2095-3941.2016.0070
   Zou YR, 2017, ONCOTARGET, V8, P41518, DOI 10.18632/oncotarget.17456
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 339
EP 342
DI 10.1016/j.wneu.2019.01.298
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700215
PM 30797915
DA 2020-05-12
ER

PT J
AU Abunimer, AM
   Abou-Al-Shaar, H
   White, TG
   Li, JY
   Chalif, DJ
AF Abunimer, Abdullah M.
   Abou-Al-Shaar, Hussam
   White, Timothy G.
   Li, Jian Y.
   Chalif, David J.
TI Metastatic Subdural Hematoma with Dural Metastasis Secondary to Poorly
   Differentiated Adenocarcinoma of Unknown Origin
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural membrane; Metastasis; Subdural hematoma; Trauma; Tumor of unknown
   origin
ID NEOPLASM
AB BACKGROUND: Metastatic subdural hematoma with dural metastasis in the setting of an underlying malignancy is a rare condition that is difficult to diagnose and associated with a poor prognosis. Knowledge of this rare entity is of a paramount importance to neurosurgeons, as its diagnosis may affect the management plan and overall survival. Here, we report a rare case of atraumatic subdural hematoma with dural metastasis in a patient with poorly differentiated adenocarcinoma of unknown origin.
   CASE DESCRIPTION: A 34-year-old man presented with an insidious onset of headaches, severe light headedness, progressive low back pain, and generalized weakness for 2 weeks. On imaging, he was found to have left-sided acute on chronic subdural hematoma with midline shift. The patient underwent surgical evacuation of the hematoma and the subdural membrane was biopsied. Histopathologic examination revealed metastatic poorly differentiated adenocarcinoma of unclear origin. A full metastatic workup was unremarkable.
   CONCLUSIONS: Metastatic subdural hematoma with dural metastasis should be included in differential diagnosis of subdural hematoma, especially in patients with atypical presentation and in the presence of an underlying malignancy, as it may affect the management plan and overall survival.
C1 [Abunimer, Abdullah M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
   [Abou-Al-Shaar, Hussam; White, Timothy G.; Chalif, David J.] Hofstra Northwell Sch Med, Dept Neurosurg, Manhasset, NY 11030 USA.
   [Li, Jian Y.] Hofstra Northwell Sch Med, Dept Pathol & Lab Med, Manhasset, NY USA.
RP Chalif, DJ (reprint author), Hofstra Northwell Sch Med, Dept Neurosurg, Manhasset, NY 11030 USA.
EM DChalif@northwell.edu
CR AMBIAVAGAR PC, 1978, CANCER, V42, P2015, DOI 10.1002/1097-0142(197810)42:4<2015::AID-CNCR2820420450>3.0.CO;2-Q
   Caputi F, 1999, REV NEUROL, V155, P383
   CHENG CLY, 1988, J NEUROSURG, V68, P642, DOI 10.3171/jns.1988.68.4.0642
   George Kuriakose J, 2012, Surg Neurol Int, V3, P60, DOI 10.4103/2152-7806.97004
   Hashiguchi K, 2003, JPN J NEUROSURG, V12, P564
   Laigle-Donadey F, 2005, J NEURO-ONCOL, V75, P57, DOI 10.1007/s11060-004-8098-1
   LEECH RW, 1974, J NEUROSURG, V41, P610, DOI 10.3171/jns.1974.41.5.0610
   MEYER PC, 1953, BRIT J CANCER, V7, P438, DOI 10.1038/bjc.1953.44
   Posner JB, 1995, NEUROLOGIC COMPLICAT, P77
   Raizer JJ, 2000, NEUROLOGY, V54, P1222, DOI 10.1212/WNL.54.6.1222
   Sato Mitsuo, 1995, Neurological Surgery, V23, P49
   SGOUROS S, 1994, BRIT J NEUROSURG, V8, P617, DOI 10.3109/02688699409002958
   Tseng SH, 2003, ACTA NEUROL SCAND, V108, P43, DOI 10.1034/j.1600-0404.2003.00080.x
NR 13
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 343
EP 346
DI 10.1016/j.wneu.2019.01.271
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700216
PM 30780034
DA 2020-05-12
ER

PT J
AU Sahinoglu, M
   Arun, O
   Orhan, A
   Nayman, A
   Calisir, A
   Bocu, Y
   Cebeci, Y
   Duman, A
   Yilmaz, H
   Koktekir, E
   Karabagli, H
AF Sahinoglu, Mert
   Arun, Oguzhan
   Orhan, Atilla
   Nayman, Alaaddin
   Calisir, Akin
   Bocu, Yasin
   Cebeci, Yasemin
   Duman, Ates
   Yilmaz, Huseyin
   Koktekir, Ender
   Karabagli, Hakan
TI Iliac Artery Injury During Lumbar Disc Hernia Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Discectomy; Iliac artery; Lumbar disc
ID VASCULAR INJURY; ENDOVASCULAR TREATMENT; DISKECTOMY
AB BACKGROUND: Vascular injury complications during lumbar discectomy are rare but potentially life-threatening. Therefore, an early diagnosis and effective treatment management is required for these complications.
   CASE DESCRIPTION: A 50-year-old female patient was admitted to our outpatient clinic with severe back and right leg pain. She underwent surgery for right L4-5 extruded disc herniation with general anesthesia. Sudden arterial hemorrhage occurred during discectomy performed with straight disc forceps and was controlled using hemostatic materials, with no significant decrease in blood pressure. However, the patient became hypotensive near the end of the operation. The incision was quickly closed, and she was turned to supine position. Emergency abdominal ultrasound, computed tomography, and computed tomography angiography revealed an injury of the left main iliac artery, which was repaired by endovascular stenting. Laparotomy and Bogota bag were applied because of increased intrabdominal pressure at 3 hours postoperative. In addition, a retroperitoneal catheter was placed into the area of the right retroperitoneal hematoma on the first postoperative day. Tissue plasminogen activator was administered through the catheter. On postoperative day 3, the Bogota bag was removed, and the abdomen was closed. The patient was discharged without neurodeficit on day 27. Her abdominal fascial defect was closed with a synthetic graft after 5 months.
   CONCLUSIONS: Although lumbar discectomy is one of the most commonly performed neurosurgical procedures, the routine rules of discectomy should not be neglected. Early detection and a multidisciplinary approach can help prevent mortality in the event of vascular injury.
C1 [Sahinoglu, Mert; Bocu, Yasin; Koktekir, Ender; Karabagli, Hakan] Selcuk Univ, Tip Fak, Beyin Sinir Cerrahisi Anabilim Dali, Konya, Turkey.
   [Arun, Oguzhan; Cebeci, Yasemin; Duman, Ates] Selcuk Univ, Tip Fak, Anesteziyol & Reanimasyon Anabilim Dali, Konya, Turkey.
   [Orhan, Atilla] Selcuk Univ, Tip Fak, Kalp & Damar Cerrahisi Anabilim Dali, Konya, Turkey.
   [Nayman, Alaaddin] Selcuk Univ, Tip Fak, Radyol Anabilim Dali, Konya, Turkey.
   [Calisir, Akin; Yilmaz, Huseyin] Selcuk Univ, Tip Fak, Gen Cerrahi Anabilim Dali, Konya, Turkey.
RP Sahinoglu, M (reprint author), Selcuk Univ, Tip Fak, Beyin Sinir Cerrahisi Anabilim Dali, Konya, Turkey.
EM msahinoglu09@gmail.com
RI SAHINOGLU, MERT/AAI-1100-2019
OI Sahinoglu, Mert/0000-0003-0633-8304
CR Bierdrager E, 2004, NEURORADIOLOGY, V46, P404, DOI 10.1007/s00234-004-1198-y
   Cakmakci M., 1998, DERGISI, V3, P51
   Chang CP, 2006, MINIM INVASIV THER, V15, P155, DOI 10.1080/13645700600771686
   Dosoglu M, 2006, CLIN NEUROL NEUROSUR, V108, P174, DOI 10.1016/j.clineuro.2004.11.019
   Henry M, 2000, J CARDIOVASC SURG, V41, P871
   Inamasu J, 2006, ACTA NEUROCHIR, V148, P375, DOI 10.1007/s00701-005-0669-1
   Jin SC, 2012, J KOREAN NEUROSURG S, V51, P227, DOI 10.3340/jkns.2012.51.4.227
   Keskin M, 2013, TURK NEUROSURG, V23, P385, DOI 10.5137/1019-5149.JTN.4930-11.1
   Leech M, 2014, CASE REP ANESTHESIOL, V2014, P895973
   Nam TK, 2009, J KOREAN NEUROSURG S, V46, P261, DOI 10.3340/jkns.2009.46.3.261
   NCEPOD, 2005, AC PROBL 2005 REP NA
   Papadoulas S, 2002, EUR J VASC ENDOVASC, V24, P189, DOI 10.1053/ejvs.2002.1682
   Prabhakar H, 2005, ACTA NEUROCHIR, V147, P327, DOI 10.1007/s00701-004-0405-2
   Schein M, 1996, COMPLICATIONS SURG, V15, P1
   Skippage P, 2008, EUR SPINE J, V17, pS228, DOI 10.1007/s00586-007-0470-3
   Szolar DH, 1996, NEURORADIOLOGY, V38, P521, DOI 10.1007/BF00626086
   Uguz E, 2018, DAMAR CER DERG, V27, P42
   Unlu Y, 1999, TURK J VASC SURG, V3, P127
   Yildiz R, 2013, TURK J SURG, V29, P192, DOI 10.5152/UCD.2013.33
   2011, EUR J VASC ENDOVASC, V42, P167, DOI DOI 10.1016/J.EJVS.2011.04.011
NR 20
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 347
EP 351
DI 10.1016/j.wneu.2019.02.025
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700217
PM 30797924
DA 2020-05-12
ER

PT J
AU Entezami, P
   Raval, MP
   Sanders, LN
   Adepoju, A
   Yamamoto, J
AF Entezami, Pouya
   Raval, Mihir Pradipkumar
   Sanders, Laura Nicole
   Adepoju, Adedamola
   Yamamoto, Junichi
TI Spontaneous Subdural Hematoma in Patient with Polycythemia Vera
SO WORLD NEUROSURGERY
LA English
DT Article
DE Myeloproliferative disorders; Polycythemia vera; Subdural hematoma
ID INITIAL PRESENTATION
AB BACKGROUND: Polycythemia vera (PV) is a myeloproliferative disorder usually characterized by an increase tendency toward thromboembolic events. Spontaneous hemorrhage/bleeding in PV patients is seldom reported in neurosurgical literature.
   CASE DESCRIPTION: We report the case of a 76-year-old male with PV who developed a spontaneous subdural hematoma requiring surgical evacuation. He improved significantly after the resolution of brain compression and mass effect caused by the hematoma.
   CONCLUSIONS: Sporadic reports of hemorrhage within the central nervous system in the setting of PV exist and are attributed to microvascular thrombotic events with hemorrhagic conversion. Though rare, spontaneous central nervous system hemorrhage in the absence of vascular malformation or an inciting event such as trauma can occur in the setting of myeloproliferative disorders like PV.
C1 [Entezami, Pouya; Sanders, Laura Nicole; Adepoju, Adedamola; Yamamoto, Junichi] Albany Med Ctr, Dept Neurosurg, Albany, NY 12208 USA.
   [Raval, Mihir Pradipkumar] Albany Med Ctr, Dept Med, Albany, NY USA.
   [Raval, Mihir Pradipkumar] New York Oncol & Hematol, Albany, NY USA.
RP Entezami, P (reprint author), Albany Med Ctr, Dept Neurosurg, Albany, NY 12208 USA.
EM entezap@amc.edu
CR Arboix A, 1997, EUR NEUROL, V37, P207, DOI 10.1159/000117444
   Buyukasik Y, 2018, TURK J MED SCI, V48, P698, DOI 10.3906/sag-1806-43
   Choi KS, 2015, J KOREAN NEUROSURG S, V58, P137, DOI 10.3340/jkns.2015.58.2.137
   KALINA P, 1995, POSTGRAD MED J, V71, P378, DOI 10.1136/pgmj.71.836.378
   Kivity S, 2010, ACTA HAEMATOL-BASEL, V123, P34, DOI 10.1159/000260068
   Opherk C, 2005, CEREBROVASC DIS, V19, P279, DOI 10.1159/000084372
   Pillai AA, 2018, POLYCYTHEMIASTATPEAR
   Sirin NG, 2010, CASE REP NEUROL, V2, P37, DOI 10.1159/000313953
NR 8
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 354
EP 356
DI 10.1016/j.wneu.2019.01.258
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700218
PM 30780039
DA 2020-05-12
ER

PT J
AU Maiuri, F
   Donzelli, R
   Pagano, S
   Mariniello, G
AF Maiuri, Francesco
   Donzelli, Renato
   Pagano, Serena
   Mariniello, Giuseppe
TI The Management of the Venous Sinuses During Surgery for Posterior Fossa
   Meningiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Posterior fossa meningioma; Transverse sinus; Venous sinus
ID LONG-TERM OUTCOMES; TENTORIAL MENINGIOMAS; SURGICAL EXPERIENCE;
   PETROCLIVAL; RADIOSURGERY
AB OBJECTIVE: To define, from a series of surgically treated meningiomas of the posterior fossa with dural attachment above the dural sinuses, the best management of the sinus invasion according to the pattern of venous circulation.
   METHODS: Seventy-five patients with posterior fossa meningioma whose dural attachment involved the major venous sinuses were included in the study. We considered tumor location and dural attachment, pattern of venous sinus circulation, degree of sinus involvement and its management, entity of surgical resection, complications, and recurrences.
   RESULTS: The resection of the involved sinus segment (Simpson I) was performed in 15 patients (20%) (10 with complete occlusion and pattern of circulation of types A and B and 5 with narrowed sinus and type B circulation); 42 cases (56%, all of type 1) were treated by coagulation and/or removal of the outer dural layer (Simpson II). In 14 (19%) the intrasinusal fragment was left (Simpson III), and in 4 (5%) the resection was partial, with residual intradural tumor (Simpson IV). No postoperative complications secondary to venous obstruction occurred. Eleven patients (15%) experienced tumor recurrence and were reoperated on. Only 4 of them with extensive dural invasion had further recurrence.
   CONCLUSIONS: In patients with posterior fossa meningiomas, we suggest to safety resect the involved sinus segment only when completely occluded. If the sinus lumen is not invaded or the tumor lies on the side of the unique or dominant transverse sinus, it should be preserved. This results in no or negligible risk of venous infarction and rather low recurrence rate.
C1 [Maiuri, Francesco; Donzelli, Renato; Pagano, Serena; Mariniello, Giuseppe] Univ Naples Federico II, Sch Med, Neurosurg Clin, Dept Neurosci & Reprod & Odontostomatol Sci, Naples, Italy.
RP Mariniello, G (reprint author), Univ Naples Federico II, Sch Med, Neurosurg Clin, Dept Neurosci & Reprod & Odontostomatol Sci, Naples, Italy.
EM giumarin@unina.it
RI Mariniello, Giuseppe/AAH-1589-2019
OI MARINIELLO, Giuseppe/0000-0001-7755-0105
CR Bassiouni H, 2004, NEUROSURGERY, V55, P108, DOI 10.1227/01.NEU.0000126886.48372.49
   Bret P, 2000, ACTA NEUROCHIR, V142, P513, DOI 10.1007/s007010050464
   CIRIC I, 1993, SURG NEUROL, V39, P530, DOI 10.1016/0090-3019(93)90040-8
   Colombo F, 2009, NEUROSURGERY, V14, P21
   Cudlip SA, 1998, ACTA NEUROCHIR, V140, P1007, DOI 10.1007/s007010050208
   Eskey CJ, 1998, J COMPUT ASSIST TOMO, V22, P530, DOI 10.1097/00004728-199807000-00006
   Flickinger JC, 2003, INT J RADIAT ONCOL, V56, P801, DOI 10.1016/S0360-3016(03)00126-3
   GOKALP HZ, 1995, NEUROSURGERY, V36, P46
   GUIDETTI B, 1988, J NEUROSURG, V69, P183, DOI 10.3171/jns.1988.69.2.0183
   Harrison M J, 1997, Clin Neurosurg, V44, P451
   Helie O, 1995, J NEURORADIOLOGY, V22, P252
   Hwang SK, 2004, SKULL BASE-INTERD AP, V14, P21, DOI 10.1055/s-2004-821356
   Kondziolka D, 1999, J NEUROSURG, V91, P44, DOI 10.3171/jns.1999.91.1.0044
   Lee JH, 2008, MENINGIOMAS DIAGNOSI
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Maiuri F, 2011, BRIT J NEUROSURG, V25, P492, DOI 10.3109/02688697.2010.550657
   Megerian CA, 1996, AM J OTOL, V17, P773
   Miabi Z, 2004, AM J NEURORADIOL, V25, P1181
   Raza SM, 2010, NEUROSURGERY, V67, P885, DOI 10.1227/NEU.0b013e3181ef2a18
   Roberti F, 2001, SURG NEUROL, V56, P8, DOI 10.1016/S0090-3019(01)00479-7
   Samii M, 1996, J NEUROSURG, V84, P375, DOI 10.3171/jns.1996.84.3.0375
   SAMII M, 1992, ACTA NEUROCHIR, V118, P27, DOI 10.1007/BF01400723
   Sekhar LN, 1996, J NEURO-ONCOL, V29, P249, DOI 10.1007/BF00165655
   SEKHAR LN, 1984, NEUROSURGERY, V14, P268, DOI 10.1227/00006123-198403000-00002
   Sen C., 1996, NEUROSURGERY, V1, P917
   Shukla D, 2009, ACTA NEUROCHIR, V151, P1037, DOI 10.1007/s00701-009-0421-3
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Sindou M, 2005, ACT NEUR S, V94, P167
   Sindou M, 1998, SKULL BASE SURG, V8, P57, DOI 10.1055/s-2008-1058576
   Sindou MP, 2006, J NEUROSURG, V105, P514, DOI 10.3171/jns.2006.105.4.514
   SPETZLER RF, 1992, J NEUROSURG, V76, P588, DOI 10.3171/jns.1992.76.4.0588
   Sughrue ME, 2011, J NEUROSURG, V114, P731, DOI 10.3171/2010.9.JNS10646
   Sughrue ME, 2010, J NEUROSURG, V113, P1029, DOI 10.3171/2010.3.JNS091971
   Ueba T, 2013, J NEUROSURG, V118, P632, DOI 10.3171/2012.11.JNS121113
   Woodhall B, 1936, ARCH SURG-CHICAGO, V33, P297, DOI 10.1001/archsurg.1936.01190020113010
   Wu ZB, 2005, J NEUROSURG, V102, P284, DOI 10.3171/jns.2005.102.2.0284
   1994, SURG NEUROL, V42, P105
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 357
EP 363
DI 10.1016/j.wneu.2019.02.032
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700219
PM 30797929
DA 2020-05-12
ER

PT J
AU Darbari, S
   Meena, RK
   Sawarkar, D
   Doddamani, RS
   Singh, M
   Chandra, PS
AF Darbari, Shaurya
   Meena, Rajesh Kumar
   Sawarkar, Dattaraj
   Doddamani, Ramesh Sharanappa
   Singh, Manmohan
   Chandra, P. Sarat
TI Intraventricular Meningioma Presenting as Lateral Posterior Choroidal
   Artery Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraventricular meningioma; Lacunar stroke; Lateral posterior choroidal
   artery; Transient ischemic attack; Transient tumor attack
AB BACKGROUND: Transient tumor attack is a rare but well-known phenomenon. Described by Ross in 1983, it demonstrated a transient ischemic attack-like picture in patients with intracranial mass lesions. Usually these attacks were recognized at sites anatomically away from the primary lesion that were not explained by primary mass effect of the lesion. The exact pathophysiology of such transient tumor attacks is postulated to be due to either a vascular steal phenomenon or compression of a vessel or localized prothrombotic state.
   CASE DESCRIPTION: Here we describe a case who was being evaluated for a lacunar stroke involving the lateral geniculate body, and a surprising finding of left intraventricular meningioma was detected.
   CONCLUSIONS: We try to shed some light on the pathophysiology of this unusual phenomenon.
C1 [Darbari, Shaurya; Meena, Rajesh Kumar; Sawarkar, Dattaraj; Doddamani, Ramesh Sharanappa; Singh, Manmohan; Chandra, P. Sarat] All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
RP Doddamani, RS (reprint author), All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
EM drsdramesh@gmail.com
OI Meena, Rajesh/0000-0003-2977-4977
CR [Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316
   DALY DD, 1961, ARCH NEUROL-CHICAGO, V5, P287, DOI 10.1001/archneur.1961.00450150053007
   HACHINSKI V, 1977, ARCH NEUROL-CHICAGO, V34, P149, DOI 10.1001/archneur.1977.00500150035006
   Jaiswal J, 2016, NEUROL INDIA, V64, P494, DOI 10.4103/0028-3886.181535
   Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024
   Ko JK, 2014, J KOREAN NEUROSURG S, V55, P99, DOI 10.3340/jkns.2014.55.2.99
   Masuoka J, 2010, NEUROL MED-CHIR, V50, P585, DOI 10.2176/nmc.50.585
   ROSS RT, 1983, ARCH NEUROL-CHICAGO, V40, P633, DOI 10.1001/archneur.1983.04050090069011
   Siddique K, 2003, INT J ONCOL, V22, P289
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 364
EP 367
DI 10.1016/j.wneu.2019.02.055
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700220
PM 30822588
DA 2020-05-12
ER

PT J
AU Anania, P
   Pavone, P
   Pacetti, M
   Truffelli, M
   Pavanello, M
   Ravegnani, M
   Consales, A
   Cama, A
   Piatelli, G
AF Anania, Pasquale
   Pavone, Piero
   Pacetti, Mattia
   Truffelli, Monica
   Pavanello, Marco
   Ravegnani, Marcello
   Consales, Alessandro
   Cama, Armando
   Piatelli, Gianluca
TI Grisel Syndrome in Pediatric Age: A Single-Center Italian Experience and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Atlantoaxial subluxation; Grisel; Torticollis
ID NONTRAUMATIC ATLANTOAXIAL SUBLUXATION; ROTATORY SUBLUXATION; ACQUIRED
   TORTICOLLIS; AXIAL SUBLUXATION; COMPLICATION; OTOLARYNGOLOGY;
   TONSILLECTOMY; FIXATION; CHILDREN; PATIENT
AB BACKGROUND: Nontraumatic atlantoaxial subluxation, also known as Grisel syndrome, is a rare disease that usually affects children. The typical presentation is torticollis in patients with a history of surgical operations or airway infections.
   METHODS: We describe 5 patients with Grisel syndrome, referring to medical care for a torticollis, a few weeks after an airway infection, with no trauma associated. Radiologic confirmation of the diagnosis, with computed tomography and magnetic resonance imaging studies, was carried out.
   RESULTS: The patients were treated with external immobilization for 3 months, followed by surgical fixation in the case of recurrence after collar removal or inveterate subluxation. We performed a review of the literature to define the best management of this disease.
   CONCLUSIONS: Management of Grisel syndrome depends on the degree of subluxation basing on the Fielding and Hawkins classification. The initial nonsurgical management consists of close reduction and immobilization. Surgical fixation is indicated in cases of conservative treatment failure.
C1 [Anania, Pasquale; Pacetti, Mattia; Truffelli, Monica; Pavanello, Marco; Ravegnani, Marcello; Consales, Alessandro; Cama, Armando; Piatelli, Gianluca] Univ Genoa, Pediat Hosp Giannina Gaslini, Neurosurg, Genoa, Italy.
   [Anania, Pasquale; Truffelli, Monica] Univ Genoa, Policlin San Martino, Dept Neurosci DINOGMI, Neurosurg, Genoa, Italy.
   [Pavone, Piero] Univ Hosp B Policlin Vittorio Emanuele, Dept Pediat, Catania, Italy.
   [Pavone, Piero] Univ Catania, AOU Policlin Vittorio Emanuele, Dept Pediat, Catania, Italy.
RP Anania, P (reprint author), Univ Genoa, Pediat Hosp Giannina Gaslini, Neurosurg, Genoa, Italy.; Anania, P (reprint author), Univ Genoa, Policlin San Martino, Dept Neurosci DINOGMI, Neurosurg, Genoa, Italy.
EM pas.anania@gmail.com
RI Marco, Pavanello/K-2859-2019; Pavone, Piero/H-5097-2019; Pacetti,
   Mattia/AAC-3306-2020; Anania, Pasquale/AAF-7424-2019
OI Marco, Pavanello/0000-0001-7312-0204; Pavone, Piero/0000-0002-5600-9560;
   Pacetti, Mattia/0000-0001-6426-6164; Anania,
   Pasquale/0000-0001-8477-9629
CR Ahn AR, 2017, ANN REHABIL MED-ARM, V41, P511, DOI 10.5535/arm.2017.41.3.511
   Al-Jishi A, 2000, CLIN NEUROL NEUROSUR, V102, P233, DOI 10.1016/S0303-8467(00)00087-1
   Baker LL, 1996, ANN OTO RHINOL LARYN, V105, P295, DOI 10.1177/000348949610500410
   Barcelos ACES, 2014, GLOB SPINE J, V4, P179, DOI 10.1055/s-0033-1363936
   Battiata Andrew P, 2004, Ear Nose Throat J, V83, P553
   Bedi HS, 1999, AUST NZ J SURG, V69, P163, DOI 10.1046/j.1440-1622.1999.01473.x
   Bocciolini C, 2005, Acta Otorhinolaryngol Ital, V25, P245
   BOITEN J, 1986, CLIN NEUROL NEUROSUR, V88, P95, DOI 10.1016/S0303-8467(86)80003-8
   Brisson P, 2000, PEDIATR SURG INT, V16, P421, DOI 10.1007/s003839900318
   Cornejo VJF, 2003, CHILD NERV SYST, V19, P342, DOI 10.1007/s00381-003-0749-6
   Cunnington P, 2000, ANAESTHESIA, V55, P927, DOI 10.1046/j.1365-2044.2000.01664-23.x
   Dasen KR, 1999, ANESTH ANALG, V89, P917, DOI 10.1097/00000539-199910000-00018
   Deichmueller CMC, 2010, EUR ARCH OTO-RHINO-L, V267, P1467, DOI 10.1007/s00405-010-1241-z
   Doshi J, 2007, J LARYNGOL OTOL, V121, P800, DOI 10.1017/S0022215107006263
   EADIE PA, 1989, BRIT J PLAST SURG, V42, P722, DOI 10.1016/0007-1226(89)90089-1
   Falsaperla R, 2019, CHILD NERV SYST, V35, P523, DOI 10.1007/s00381-018-3970-z
   Feldman J, 2003, LARYNGO RHINO OTOL, V82, P799
   FIELDING JW, 1977, J BONE JOINT SURG AM, V59, P37, DOI 10.2106/00004623-197759010-00005
   Galer C, 2005, INT J PEDIATR OTORHI, V69, P1689, DOI 10.1016/j.ijporl.2005.03.046
   Gourin CG, 2002, AM J OTOLARYNG, V23, P60, DOI 10.1053/ajot.2002.28781
   Grisel P., 1930, PRESSE MED, V38, P4
   Guleryuz A, 2002, J CLIN NEUROSCI, V9, P81, DOI 10.1054/jocn.2001.0944
   Harma A, 2008, J CRANIOFAC SURG, V19, P1119, DOI 10.1097/SCS.0b013e31817ac55
   Herzka A, 2000, SPINE, V25, P524, DOI 10.1097/00007632-200002150-00022
   Holcomb JD, 2001, ANN OTO RHINOL LARYN, V110, P1137, DOI 10.1177/000348940111001210
   HOPLA DM, 1983, LARYNGOSCOPE, V93, P1155
   Isern AE, 2004, SCAND J PLAST RECONS, V38, P53, DOI 10.1080/02844310310013028
   Karkos PD, 2007, INT J PEDIATR OTORHI, V71, P1823, DOI 10.1016/j.ijporl.2007.07.002
   Kasten P, 2002, UNFALLCHIRURG, V105, P565, DOI 10.1007/s00113-001-0393-0
   Kelly EJ, 1998, PLAST RECONSTR SURG, V102, P543, DOI 10.1097/00006534-199808000-00040
   Lehtinen P, 2003, ARCH DIS CHILD, V88, P349, DOI 10.1136/adc.88.4.349
   Martinez-Lage JF, 2001, ACTA NEUROCHIR, V143, P1223, DOI 10.1007/s007010100018
   MATHERN GW, 1989, CLIN ORTHOP RELAT R, P131
   Mezue WC, 2002, J LARYNGOL OTOL, V116, P280, DOI 10.1258/0022215021910753
   Nozaki F, 2013, EUR J PEDIATR, V172, P119, DOI 10.1007/s00431-012-1858-6
   Nucci P, 1996, AM J OPHTHALMOL, V122, P908, DOI 10.1016/S0002-9394(14)70400-3
   Okada Y, 2002, PEDIATR INT, V44, P192, DOI 10.1046/j.1328-8067.2001.01513.x
   Onerci M, 1997, OTOLARYNG HEAD NECK, V116, P271, DOI 10.1016/S0194-5998(97)70341-3
   Ortega-Evangelio G, 2011, EUR J PEDIATR, V170, P965, DOI 10.1007/s00431-011-1493-7
   Panopalis P, 2005, J RHEUMATOL, V32, P1619
   Park SH, 2013, ANN REHABIL MED-ARM, V37, P713, DOI 10.5535/arm.2013.37.5.713
   Park SW, 2005, SPINE, V30, pE444, DOI 10.1097/01.brs.0000172226.35474.fe
   PARKE WW, 1984, J BONE JOINT SURG AM, V66A, P568, DOI 10.2106/00004623-198466040-00012
   Patterson RM, 1943, J NERV MENT DIS, V98, P571, DOI 10.1097/00005053-194312000-00001
   Prado VM, 1955, ENT-EAR NOSE THROAT, V74, P54
   Reichman EF, 2015, PEDIATR EMERG CARE, V31, P577, DOI 10.1097/PEC.0000000000000278
   ROBERTSON S, 1987, ORTHOPEDICS, V10, P1545
   ROBINSON PH, 1981, BRIT J PLAST SURG, V34, P319, DOI 10.1016/0007-1226(81)90020-5
   SAMUEL D, 1995, J LARYNGOL OTOL, V109, P1005, DOI 10.1017/S0022215100131883
   Sangermani R, 1986, Pediatr Med Chir, V8, P735
   SIPILA P, 1981, ARCH OTOLARYNGOL, V107, P181
   Spennato P, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.060
   Spiegel D, 2017, WORLD J ORTHOP, V8, P836, DOI 10.5312/wjo.v8.i11.836
   Subach BR, 1998, SPINE, V23, P2174, DOI 10.1097/00007632-199810150-00006
   Ugur HC, 2003, ACTA NEUROCHIR, V145, P69, DOI 10.1007/s00701-002-0979-5
   Welinder NR, 1997, EUR ARCH OTO-RHINO-L, V254, P251, DOI 10.1007/BF00874099
   WETZEL FT, 1989, CLIN ORTHOP RELAT R, P141
   Wurm G, 2004, NEUROPEDIATRICS, V35, P134, DOI 10.1055/s-2004-815836
   Youssef K, 2009, CAN J NEUROL SCI, V36, P109, DOI 10.1017/S0317167100006430
   Yu KK, 2003, LARYNGOSCOPE, V113, P1047, DOI 10.1097/00005537-200306000-00024
   1994, OTOLARYNGOL HEAD NEC, V110, P584
   2018, J TROP PEDIATRICS, V64, P245, DOI DOI 10.1093/TROPEJ/FMX050
NR 62
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 374
EP 382
DI 10.1016/j.wneu.2019.02.035
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700223
PM 30797917
DA 2020-05-12
ER

PT J
AU Hamilton, RA
   Hathidara, M
   Shujaat, SD
   Strickland, AE
   Bohnstedt, BN
   Ray, B
AF Hamilton, Robert A.
   Hathidara, Mausaminben
   Shujaat, Syeda Dania
   Strickland, Allison E.
   Bohnstedt, Bradley N.
   Ray, Bappaditya
TI Dasatinib Reinitiation After Poststroke Thrombolysis Associated with
   Symptomatic Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Dasatinib; Symptomatic intracranial hemorrhage;
   Thrombolytic therapy; Tissue plasminogen activator
ID TYROSINE-KINASE INHIBITOR; ACTIVATION; IMATINIB
AB BACKGROUND: Dasatinib, a tyrosine kinase inhibitor commonly used in treatment of acute lymphoblastic leukemia and chronic myelogenous leukemia, is often associated with hemorrhagic complications. Safety of dasatinib after thrombolytic therapy in acute ischemic stroke is unknown.
   CASE DESCRIPTION: A 63-year-old man with multiple vascular risk factors and chronic myelogenous leukemia (in molecular remission) on dasatinib presented with signs and symptoms of right hemispheric stroke owing to acute intracranial internal carotid artery occlusion that was treated with intravenous thrombolysis and mechanical thrombectomy resulting in near-complete resolution of stroke symptoms. The patient developed clinical worsening (>24 hours of thrombolytic therapy) after receiving a second dose of dasatinib that was due to symptomatic intracerebral hemorrhage and necessitated decompressive hemi-craniectomy. Routine coagulation profile was normal. The etiology of this hemorrhagic complication was likely secondary to primary platelet dysfunction due to dasatinib as reported in some recent in vitro and ex vivo studies.
   CONCLUSIONS: It is advisable to withhold dasatinib during the poststroke period owing to its associated risk of symptomatic intracerebral hemorrhage.
C1 [Hamilton, Robert A.; Hathidara, Mausaminben; Shujaat, Syeda Dania; Ray, Bappaditya] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Neurol, Oklahoma City, OK 73190 USA.
   [Strickland, Allison E.; Bohnstedt, Bradley N.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Neurosurg, Oklahoma City, OK 73190 USA.
RP Ray, B (reprint author), Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Neurol, Oklahoma City, OK 73190 USA.
EM Bappaditya-Ray@ouhsc.edu
RI Ray, Bappaditya/AAB-4130-2020; Ray, Bappaditya/O-2556-2014
OI Ray, Bappaditya/0000-0001-8623-0920; Bohnstedt,
   Bradley/0000-0001-6254-2313
CR Acheampong P, 2012, EXPERT OPIN DRUG MET, V8, P271, DOI 10.1517/17425255.2012.652615
   Avraham HK, 2003, J BIOL CHEM, V278, P36661, DOI 10.1074/jbc.M301253200
   Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947
   Gratacap MP, 2009, BLOOD, V114, P1884, DOI 10.1182/blood-2009-02-205328
   Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315
   Kast RE, 2010, TRANSL ONCOL, V3, P13, DOI 10.1593/tlo.09280
   Keating GM, 2017, DRUGS, V77, P85, DOI 10.1007/s40265-016-0677-x
   Levade M, 2016, CURR PHARM DESIGN, V22, P2315, DOI 10.2174/1381612822666160226132630
   Mezei G, 2019, PLATELETS, V30, P836, DOI 10.1080/09537104.2018.1501470
   Naqvi K, 2018, CANCER-AM CANCER SOC, V124, P2740, DOI 10.1002/cncr.31357
   Quintas-Cardama A, 2009, BLOOD, V114, P261, DOI 10.1182/blood-2008-09-180604
   Talpaz M, 2018, CANCER-AM CANCER SOC, V124, P1660, DOI 10.1002/cncr.31232
NR 12
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 383
EP 386
DI 10.1016/j.wneu.2019.02.026
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700224
PM 30797908
DA 2020-05-12
ER

PT J
AU Doshi, PK
   Hegde, A
   Desai, A
AF Doshi, Paresh K.
   Hegde, Anaita
   Desai, Amit
TI Nucleus Accumbens Deep Brain Stimulation for Obsessive-Compulsive
   Disorder and Aggression in an Autistic Patient: A Case Report and
   Hypothesis of the Role of Nucleus Accumbens in Autism and Comorbid
   Symptoms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aggression; Autism; Nucleus accumbens deep brain stimulation;
   Obsessive-compulsive disorder
ID SELF-INJURIOUS-BEHAVIOR; SPECTRUM DISORDERS; OSCILLATIONS; INDIVIDUALS;
   RESPONSES
AB BACKGROUND: Autism spectrum disorder represents a set of developmental disorders characterized by lack of social interaction and verbal and nonverbal communication in the first 3 years of life. It is also associated with several comorbidities, including epilepsy, aggression, self-mutilating behavior, and obsessive-compulsive behavior. In some cases, obsessive-compulsive disorder (OCD) develops. The nucleus accumbens (NAc) plays a key role in reward circuitry and is involved in the control of OCD and aggression.
   CASE DESCRIPTION: A 42-year-old woman with autism was offered NAc deep brain stimulation for her comorbidities of OCD and aggression. The NAc was targeted using standard stereotactic methods, and postoperative scans confirmed the position of the active electrode to be within the NAc. The patient experienced significant symptom relief. At 1-year follow-up, the Yale-Brown Obsessive Compulsive Scale score for OCD, excluding items 1-5 of the scale, improved from 19 to 5. Hamilton Depression Scale and Hamilton Anxiety Scale scores similarly improved from 20 to 15 and from 30 to 18, respectively. Social Communication Questionnaire Current version for autism score improved from 26 to 16. Subscores for reciprocal social interactionimproved from 13 to 8; for communication improved from 5 to 4; and for restricted, repetitive, and stereotyped patterns of behavior improved from 6 to 3.
   CONCLUSIONS: This case report illustrated the role of the NAc in OCD and aggression in an autistic patient. We discussed the role of the NAc as a target to explain the outcome of this case.
C1 [Doshi, Paresh K.] Jaslok Hosp & Res Ctr, Dept Neurosurg, Mumbai, Maharashtra, India.
   [Hegde, Anaita] Jaslok Hosp & Res Ctr, Dept Pediat, Mumbai, Maharashtra, India.
   [Desai, Amit] Jaslok Hosp & Res Ctr, Dept Psychiat, Mumbai, Maharashtra, India.
RP Doshi, PK (reprint author), Jaslok Hosp & Res Ctr, Dept Neurosurg, Mumbai, Maharashtra, India.
EM pareshkd@gmail.com
FU Jaslok Hospital and Research Centre
FX The authors thank Jaslok Hospital and Research Centre for supporting
   this work and Ms. Bharati Karkera for helping in the collection of data
   for the article.
CR Adler BA, 2015, AUTISM, V19, P102, DOI 10.1177/1362361314524641
   Berney TP, 2000, BRIT J PSYCHIAT, V176, P20, DOI 10.1192/bjp.176.1.20
   DASILVA FHL, 1984, EXP BRAIN RES, V55, P205, DOI 10.1007/BF00237271
   Dawson G, 2001, J AUTISM DEV DISORD, V31, P337, DOI 10.1023/A:1010751404865
   Denys D, 2010, ARCH GEN PSYCHIAT, V67, P1061, DOI 10.1001/archgenpsychiatry.2010.122
   Dichter GS, 2012, J AUTISM DEV DISORD, V42, P147, DOI 10.1007/s10803-011-1221-1
   First MB, 2013, J NERV MENT DIS, V201, P727, DOI 10.1097/NMD.0b013e3182a2168a
   Gasic GP, 2009, AM J MED GENET B, V150B, P762, DOI 10.1002/ajmg.b.30944
   Grabenhorst F, 2011, TRENDS COGN SCI, V15, P56, DOI 10.1016/j.tics.2010.12.004
   Harat M, 2015, STEREOT FUNCT NEUROS, V93, P310, DOI 10.1159/000431373
   Just MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113879
   Klin A, 2007, J AUTISM DEV DISORD, V37, P748, DOI 10.1007/s10803-006-0229-4
   Knutson B, 2005, J NEUROSCI, V25, P4806, DOI 10.1523/JNEUROSCI.0642-05.2005
   Kohls G, 2012, J NEURODEV DISORD, V4, DOI 10.1186/1866-1955-4-10
   Mattila ML, 2011, J AM ACAD CHILD PSY, V50, P583, DOI 10.1016/j.jaac.2011.04.001
   McCracken CB, 2009, J NEUROSCI, V29, P5354, DOI 10.1523/JNEUROSCI.0131-09.2009
   MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0
   NARABAYASHI H, 1966, CONFIN NEUROL, V27, P168
   Neto LL, 2008, NEUROMODULATION, V11, P13, DOI 10.1111/j.1525-1403.2007.00138.x
   Nuttin B, 1999, LANCET, V354, P1526, DOI 10.1016/S0140-6736(99)02376-4
   Nuttin B, 2014, J NEUROL NEUROSUR PS, V85, P1003, DOI 10.1136/jnnp-2013-306580
   Nuttin BJ, 2003, NEUROSURGERY, V52, P1263, DOI 10.1227/01.NEU.0000064565.49299.9A
   Park HR, 2017, ACTA NEUROCHIR, V159, P137, DOI 10.1007/s00701-016-3002-2
   Paula-Perez I, 2013, REV PSIQUIATR SALUD, V6, P178, DOI 10.1016/j.rpsm.2012.07.005
   Richards C, 2012, J INTELL DISABIL RES, V56, P476, DOI 10.1111/j.1365-2788.2012.01537.x
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1
   Schultz W, 2007, ANNU REV NEUROSCI, V30, P259, DOI 10.1146/annurev.neuro.28.061604.135722
   Scott-Van Zeeland AA, 2010, AUTISM RES, V3, P53, DOI 10.1002/aur.122
   Sesia T, 2010, EXP NEUROL, V225, P302, DOI 10.1016/j.expneurol.2010.06.022
   Stocco A, 2014, PARKINSONISM RELAT D, V20, P1035, DOI 10.1016/j.parkreldis.2014.06.019
   Sturm V, 2013, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00341
   Tomycz ND, 2012, NEUROSURG REV, V35, P37, DOI 10.1007/s10143-011-0359-9
   Traub RD, 2004, ANNU REV NEUROSCI, V27, P247, DOI 10.1146/annurev.neuro.27.070203.144303
   van den Munckhof Pepijn, 2013, Acta Neurochir Suppl, V117, P53, DOI 10.1007/978-3-7091-1482-7_9
   van Steensel FJA, 2011, CLIN CHILD FAM PSYCH, V14, P302, DOI 10.1007/s10567-011-0097-0
   Virues-Ortega J, 2010, CLIN PSYCHOL REV, V30, P387, DOI 10.1016/j.cpr.2010.01.008
   2012, NEUROSURG REV, V35, P37, DOI DOI 10.1007/S10143-011-0359-9
NR 37
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 387
EP 391
DI 10.1016/j.wneu.2019.02.021
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700225
PM 30797934
DA 2020-05-12
ER

PT J
AU Rallo, MS
   Nosko, M
   Agag, RL
   Xiong, ZG
   Al-Mufti, F
   Roychowdhury, S
   Nanda, A
   Gupta, G
AF Rallo, Michael S.
   Nosko, Michael
   Agag, Richard L.
   Xiong, Zhenggang
   Al-Mufti, Fawaz
   Roychowdhury, Sudipta
   Nanda, Anil
   Gupta, Gaurav
TI Neurosurgical and Scalp Reconstructive Challenges During Craniotomy in
   the Setting of Cutis Verticis Gyrata
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniotomy; Cutis verticis gyrata; Neurosurgical challenges
ID REDUCTION
AB BACKGROUND: Cutis verticis gyrata (CVG) is a rare condition of the scalp in which thickening of the dermis induces rigid folds and furrows resembling the cerebral cortex. Two forms of primary CVG exist: essential, in which CVG is the only presenting problem, and nonessential, in which the scalp condition occurs along with neuropsychiatric ailments. CVG can also occur secondary to a variety of causes including inflammatory, neoplastic, and metabolic conditions or drug use. A review of the available literature, including description of the epidemiology, pathophysiology, histology, and typical management of CVG, is provided. However, we identified no literature describing the complications of CVG in the setting of a craniotomy.
   CASE REPORT: The patient presented here is a 54-year-old man with CVG who presented with occlusion of the M2/M2 branches of the middle cerebral artery, resulting in malignant cerebral edema, requiring emergent management via decompressive craniectomy. Because of the thickening of the scalp, skin incision was complicated by bleeding and difficulty in achieving hemostasis using Raney clips. Plastic surgery was consulted intraoperatively for assistance with complex closure of the wound in a multilayered fashion. Despite this, the patient's postoperative course was complicated by cerebrospinal fluid leakage due to difficulty in approximating the incision during closure. Subsequent cranioplasty was performed jointly between neurosurgery and plastic surgery.
   CONCLUSIONS: Despite its rarity, CVG is an important issue for neurosurgeons to understand as it can present complications in performing craniotomy, most notably during the scalp exposure and closure. CVG may also complicate the postoperative course if adequate approximation of the tissues cannot be achieved, resulting in wound infection and/or cerebrospinal fluid leak. The presented patient benefited from a combined neurosurgical and plastic surgical approach that was implemented intraoperatively and continued through the postoperative stages and the subsequent cranioplasty.
C1 [Rallo, Michael S.; Nosko, Michael; Nanda, Anil; Gupta, Gaurav] Rutgers Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ 08903 USA.
   [Agag, Richard L.] Rutgers Robert Wood Johnson Med Sch, Dept Plast Surg, New Brunswick, NJ USA.
   [Xiong, Zhenggang] Rutgers Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, New Brunswick, NJ USA.
   [Roychowdhury, Sudipta] Rutgers Robert Wood Johnson Med Sch, Dept Radiol, New Brunswick, NJ USA.
   [Al-Mufti, Fawaz] New York Med Coll, Westchester Med Ctr, Dept Neurol, New York, NY USA.
RP Gupta, G (reprint author), Rutgers Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ 08903 USA.
EM guptaga@rwjms.rutgers.edu
RI Gupta, Gaurav/AAL-3349-2020
OI Gupta, Gaurav/0000-0002-9442-6007; Al-Mufti, Fawaz/0000-0003-4461-7005
CR DIVEN DG, 1991, INT J DERMATOL, V30, P710, DOI 10.1111/j.1365-4362.1991.tb02615.x
   Ennouhi MA, 2018, CUREUS, V10, DOI 10.7759/cureus.2105
   GARDEN JM, 1984, ARCH DERMATOL, V120, P1480, DOI 10.1001/archderm.120.11.1480
   Golas AR, 2014, J NEURO-ONCOL, V119, P327, DOI 10.1007/s11060-014-1482-6
   Goodrich JT, 2004, PLASTIC TECHNIQUES N
   Yang JJH, 2014, AN BRAS DERMATOL, V89, P326, DOI 10.1590/abd1806-4841.20142949
   Hsu YJ, 2009, INT J DERMATOL, V48, P307, DOI 10.1111/j.1365-4632.2009.03927.x
   Khanijow K, 2013, DERMAT RES PRACT, DOI 10.1155/2013/941740
   Kolawole T M, 1999, West Afr J Med, V18, P130
   Lamelas Andreas M, 2016, Eplasty, V16, pic13
   Larsen F, 2007, AUSTRALAS J DERMATOL, V48, P91, DOI 10.1111/j.1440-0960.2007.00343.x
   Ma WB, 2017, EUR J MED GENET, V60, P433, DOI 10.1016/j.ejmg.2017.06.001
   Mishra A, 2010, J PLAST RECONSTR AES, V63, P1060, DOI 10.1016/j.bjps.2009.11.048
   MUSUMECI SA, 1991, AM J MED GENET, V38, P249, DOI 10.1002/ajmg.1320380217
   Nguyen Nathalie Q, 2003, Dermatol Online J, V9, P32
   PALAZZO R, 1993, ACTA DERM-VENEREOL, V73, P348
   Pinggera D, 2016, INDIAN J NEUROSURG, V5, P84, DOI 10.1055/s-0036-1584591
   Polan S, 1953, AM J MENT DEF, V57, P613
   Snyder MC, 2002, PLAST RECONSTR SURG, V110, P818, DOI 10.1097/01.PRS.0000019720.50128.7F
   Tan O, 2006, J DERMATOL, V33, P492, DOI 10.1111/j.1346-8138.2006.00116.x
   Tanese K, 2015, J DERMATOL, V42, P710, DOI 10.1111/1346-8138.12869
   Topper JN, 1998, CIRCULATION, V98, P2396, DOI 10.1161/01.CIR.98.22.2396
   Tucci A, 2017, AM J MED GENET A, V173, P638, DOI 10.1002/ajmg.a.38054
   Zeljko-Penavic J, 2016, ACTA DERMATOVENER CR, V24, P140
   1996, EPILEPSIA, V37, P284
   2004, CUTIS, V73, P254
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 392
EP 397
DI 10.1016/j.wneu.2019.01.217
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700226
PM 30763753
DA 2020-05-12
ER

PT J
AU Kim, S
   Dillon, WP
   Hope, TA
   El-Sayed, IH
   van Zante, A
   Wu, K
   Masharani, U
AF Kim, Stephanie
   Dillon, William P.
   Hope, Thomas A.
   El-Sayed, Ivan H.
   van Zante, Annemieke
   Wu, Karin
   Masharani, Umesh
TI Ectopic Thyroid-Stimulating Hormonee-Secreting Pituitary Adenoma of the
   Nasopharynx Diagnosed by Gallium 68 DOTATATE Positron Emission
   Tomography/Computed Tomography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ectopic pituitary adenoma; Ga-68-Dotatate; Hyperthyroidism; PET/CT; TSH
AB BACKGROUND: Ectopic thyroid-secreting hormone (TSH) esecreting pituitary adenomas are rare, with only 9 cases reported in the literature.
   CASE DESCRIPTION: We describe a case of an ectopic TSH-secreting pituitary adenoma located in the nasopharynx in a patient initially presenting with signs and symptoms of hyperthyroidism that persisted despite treatment with antithyroid medications. Magnetic resonance imaging of the pituitary gland was normal, although subsequent review by a neuroradiologist revealed a nodule attached to the posterior septum in the nasopharynx that was, in retrospect, seen on several other magnetic resonance imaging scans. Gallium 68 (Ga-68) DOTATATE positron emission tomography/computed tomography showed increased uptake in the nasopharyngeal nodule. The patient underwent resection of the nasopharyngeal mass with remission of hyperthyroidism. On pathology, the resected mass stained positive for TSH and prolactin.
   CONCLUSIONS: This is the first report of use of Ga-68-DOTATATE positron emission tomography/computed tomography to aid in localizing an ectopic TSH-secreting tumor. Prior studies have shown that Ga-68-DOTATATE positron emission tomography/computed tomography improves detection of small lesions with shorter imaging times and lower radiation doses compared with other modalities. Our case emphasizes the importance of using Ga-68-DOTATATE PET/CT in the diagnosis of ectopic pituitary adenomas, as these tumors can be challenging to diagnose radiographically.
C1 [Kim, Stephanie; Wu, Karin; Masharani, Umesh] Univ Calif San Francisco, Dept Med, Div Diabet Endocrinol & Metab, San Francisco, CA 94143 USA.
   [Dillon, William P.; Hope, Thomas A.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
   [El-Sayed, Ivan H.] Univ Calif San Francisco, Div Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
   [van Zante, Annemieke] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.
RP Kim, S (reprint author), Univ Calif San Francisco, Dept Med, Div Diabet Endocrinol & Metab, San Francisco, CA 94143 USA.
EM stephanie.kim@ucsf.edu
CR Collie RB, 2005, OTOLARYNG HEAD NECK, V133, P453, DOI 10.1016/j.otohns.2004.10.015
   Cooper DS, 1996, THYROID, V6, P337, DOI 10.1089/thy.1996.6.337
   Fukuhara N, 2015, ENDOCR J, V62, P21, DOI 10.1507/endocrj.EJ14-0118
   Hanaoka Y, 2018, ACTA NEUROCHIR, V160, P2001, DOI 10.1007/s00701-018-3638-1
   MINDERMANN T, 1993, J NEUROSURG, V79, P521, DOI 10.3171/jns.1993.79.4.0521
   Mojtahedi A, 2014, AM J NUCL MED MOLEC, V4, P426
   Nishiike S, 2014, AURIS NASUS LARYNX, V41, P586, DOI 10.1016/j.anl.2014.07.004
   Pasquini E, 2003, EUR J ENDOCRINOL, V148, P253, DOI 10.1530/eje.0.1480253
   Seltzer J, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.10.FOCUS14685
   Song MQ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-544
   Takata K, 2010, CLIN ENDOCRINOL, V72, P845, DOI 10.1111/j.1365-2265.2009.03745.x
   Tong AL, 2013, THYROID, V23, P1172, DOI 10.1089/thy.2012.0574
   Uchida T, 2014, ENDOCRINE, V47, P506, DOI 10.1007/s12020-014-0171-8
   Wang Q, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.062
   Yang J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008912
   Yu BX, 2017, MED SCI MONITOR, V23, P1947, DOI 10.12659/MSM.903377
NR 16
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 400
EP 404
DI 10.1016/j.wneu.2019.02.022
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700228
PM 30797906
DA 2020-05-12
ER

PT J
AU Titov, O
   Maryashev, S
   Bykanov, A
AF Titov, Oleg
   Maryashev, Sergey
   Bykanov, Andrey
TI Brain Mesh: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain; Brain mesh; Cortex; Electrostimulation mapping; Functional brain
   mapping; Surgical technique
AB BACKGROUND: Standard electrostimulation cortical mapping includes application of electrical current to the explored areas through an electrode and marking of functional zones by means of paper tags with different symbols. This approach has several disadvantages. First, the electrode is moved randomly. It leads to overlooking of some zones, which causes mapping deficiency, and restimulation of others, which can trigger epileptic seizures. Second, the tags easily shift and close the marked structures. We describe a new simple device that provides precise cortical mapping without indicated problems and the technique to apply it.
   METHODS: The device is a flexible polymer mesh with square pores of a certain size. The neurosurgeon applies the mesh onto the brain cortex and sequentially stimulates it through the pores. The functional areas are labeled. Pores corresponding to the lesion are cut out, and the lesion is removed through the cutout without removing the mesh. After operation, the mesh is removed.
   RESULTS: Using this technique, we operated on a patient with a glioma located near the primary motor cortex. The accessible cortical area was accurately mapped, and the tumor was resected without any complications. The mesh allowed us to significantly streamline the mapping process.
   CONCLUSIONS: Our case illustrates that the proposed invention can be successfully used in neurosurgical operations for precise electrostimulation mapping of the brain cortex.
C1 [Titov, Oleg] Sechenov Univ, Moscow, Russia.
   [Maryashev, Sergey; Bykanov, Andrey] Burdenko Neurosurg Ctr, Dept Neurooncol, Moscow, Russia.
RP Titov, O (reprint author), Sechenov Univ, Moscow, Russia.
EM neurolegtitov@gmail.com
RI Bykanov, Andrey/R-1370-2017
CR Girvin JP, 2015, OPERATIVE TECHNIQUES, P73
   Hamer PCD, 2012, J CLIN ONCOL, V30, P2559, DOI 10.1200/JCO.2011.38.4818
   Olivier A, 2012, TECHNIQUES IN EPILEPSY SURGERY: THE MNI APPROACH, P79
   Pamias-Portalatin Eva, 2018, Neurosurg Focus, V45, pV3, DOI 10.3171/2018.10.FocusVid.18201
   Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389
   Sani S, 2016, FUNCTIONAL MAPPING C, P159
   Selner AN, 2016, FUNCTIONAL MAPPING C, P115
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 405
EP 408
DI 10.1016/j.wneu.2019.02.040
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700229
PM 30797923
DA 2020-05-12
ER

PT J
AU Agyei, JO
   Smolar, DE
   Hartke, J
   Fanous, AA
   Gibbons, KJ
AF Agyei, Justice O.
   Smolar, David E.
   Hartke, Joelle
   Fanous, Andrew A.
   Gibbons, Kevin J.
TI Cervical Kyphotic Deformity Worsening After Extensor Cervical Muscle
   Paralysis from Botulinum Toxin Injection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Botox injection; Botulinum toxin injection; Kyphotic deformity; Neck
   extensor muscle weakness
ID DYSTONIA; WEAKNESS; EFFICACY; SAFETY; PAIN
AB BACKGROUND: Botulinum toxin (Botox) has long been used therapeutically to treat a variety of diseases, including migraine headaches, cervical spine dystonia, and chronic cervical spine pain, among many others. Although quite useful, Botox has been reported to cause adverse events, some of which may lead to devastating morbidity.
   CASE DESCRIPTION: An elderly woman presented with severe neck pain after a motor vehicle collision. She underwent Botox administration to the neck extensor muscles, after which she developed severe cervical kyphotic deformity, a complication previously reported only in patients with a history of cervical fusion. In addition, the patient had a pre-existing cervical spine degenerative disc disease with listhesis resulting in cervical kyphotic deformity and loss of cervical lordosis.
   CONCLUSIONS: This case illustrates a potential danger of using Botox in the neck of an elderly patient who may have pre-existing cervical spine instability, underlying cervical musculature weakness, and pre-existing cervical kyphosis. It demonstrates the need to evaluate patients who are predisposed to developing cervical kyphotic deformities before offering them Botox treatment.
C1 [Agyei, Justice O.; Smolar, David E.; Fanous, Andrew A.; Gibbons, Kevin J.] SUNY Buffalo, Dept Neurosurg, Buffalo, NY 14260 USA.
   [Hartke, Joelle] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA.
   [Agyei, Justice O.; Smolar, David E.; Fanous, Andrew A.; Gibbons, Kevin J.] Kaleida Hlth, Buffalo Gen Med Ctr, Dept Neurosurg, Buffalo, NY USA.
RP Gibbons, KJ (reprint author), SUNY Buffalo, Dept Neurosurg, Buffalo, NY 14260 USA.; Gibbons, KJ (reprint author), Kaleida Hlth, Buffalo Gen Med Ctr, Dept Neurosurg, Buffalo, NY USA.
EM kgibbons@ubns.com
CR Bhatia KP, 1999, J NEUROL NEUROSUR PS, V67, P90, DOI 10.1136/jnnp.67.1.90
   Caruso L, 2014, EUR SPINE J, V23, pS634, DOI 10.1007/s00586-014-3544-z
   Colosimo C, 2012, NEUROTOX RES, V22, P265, DOI 10.1007/s12640-012-9314-y
   Crowner BE, 2010, CLIN NEUROPHARMACOL, V33, P243, DOI 10.1097/WNF.0b013e3181f5329e
   Hogan KA, 2006, SOUTH MED J, V99, P888, DOI 10.1097/01.smj.0000221627.12416.e1
   Iyer RR, 2018, OPER NEUROSURG, V15, P278, DOI 10.1093/ons/opx221
   Jeynes Louise C, 2008, Pain Pract, V8, P269, DOI 10.1111/j.1533-2500.2008.00202.x
   Juan FJ, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-5
   Katz JS, 1996, NEUROLOGY, V46, P917, DOI 10.1212/WNL.46.4.917
   Konomi Tsunehiko, 2018, Spinal Cord Ser Cases, V4, P18, DOI 10.1038/s41394-018-0051-1
   Mills RR, 2015, PATIENT PREFER ADHER, V9, P725, DOI 10.2147/PPA.S75459
   Padberg M, 2007, J NEUROL, V254, P290, DOI 10.1007/s00415-006-0317-6
   Ramirez-Castaneda J, 2013, TOXINS, V5, P249, DOI 10.3390/toxins5020249
   Shen XL, 2011, MED HYPOTHESES, V77, P456, DOI 10.1016/j.mehy.2011.06.009
   Smith JS, 2016, WORLD NEUROSURG, V91, P228, DOI 10.1016/j.wneu.2016.04.020
   Yiannakopoulou E, 2015, PHARMACOLOGY, V95, P65, DOI 10.1159/000370245
NR 16
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 409
EP 413
DI 10.1016/j.wneu.2019.02.057
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700230
PM 30822591
DA 2020-05-12
ER

PT J
AU Texakalidis, P
   Tzoumas, A
   Giannopoulos, S
   Jonnalagadda, AK
   Jabbour, P
   Rangel-Castilla, L
   Machinis, T
   Rivet, DJ
   Reavey-Cantwell, J
AF Texakalidis, Pavlos
   Tzoumas, Andreas
   Giannopoulos, Stefanos
   Jonnalagadda, Anil K.
   Jabbour, Pascal
   Rangel-Castilla, Leonardo
   Machinis, Theofilos
   Rivet, Dennis J.
   Reavey-Cantwell, John
TI Risk Factors for Restenosis After Carotid Revascularization: A
   Meta-Analysis of Hazard Ratios
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carotid artery stenting; Carotid endarterectomy; Carotid restenosis;
   Risk factors
ID IN-STENT RESTENOSIS; ARTERY STENOSIS; PRIMARY CLOSURE; ENDARTERECTOMY;
   STATINS; ATHEROSCLEROSIS; ANGIOPLASTY; PROGRESSION; PREDICTORS; OUTCOMES
AB BACKGROUND: Carotid artery restenosis after carotid endarterectomy (CEA) or carotid artery stenting (CAS) will occur in 3%-30% of cases. Restenosis can lead to more frequent clinical and imaging monitoring and the potential for reoperation. We sought to define the demographic, clinical, and radiographic characteristics that influence the restenosis risk after carotid revascularization.
   METHODS: The present study was performed in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. A random effects model meta-analysis of hazard ratios (HRs) was conducted.
   RESULTS: Eighteen studies with 17,106 patients were included. Diabetes (HR, 1.68; 95% confidence interval [CI], 1.00-2.83; I-2, 76.7%), dyslipidemia (HR, 1.77; 95% CI, 1.08-2.91; I-2, 22.5%), female gender (HR, 1.50; 95% CI, 1.14-1.98, I-2, 0%), chronic kidney disease (HR, 4.15; 95% CI, 1.69-10.19; I-2, 44.5%), hypertension (HR, 1.99; 95% CI, 1.07-3.72; I-2, 68%), smoking (HR, 1.65; 95% CI, 1.15-2.37; I-2, 54.3%), and pretreatment stenosis >70% (HR, 1.04; 95% CI, 1.0-1.08; I-2, 0%) showed a statistically significant increase in restenosis risk after carotid revascularization. Subgroup analyses of CEA and CAS showed that female gender and smoking status were significantly associated with recurrent stenosis after CEA but not after CAS. In contrast, hypertension was associated with restenosis after CAS but not after CEA. Patch endarterectomy (HR, 0.33; 95% CI, 0.22-0.50; I-2, 0%) and symptomatic status at presentation in the CAS group (HR, 0.61; 95% CI, 0.41-0.90; I-2, 0%) were associated with a decreased risk of restenosis. Antiplatelet use and coronary artery disease were not associated with restenosis risk.
   CONCLUSIONS: Diabetes, dyslipidemia, female gender, renal failure, hypertension, and smoking were associated with an increased risk of restenosis, and patch endarterectomy and symptomatic status at presentation were associated with a decreased risk of carotid restenosis. Both female gender and current smoking status were only associated with recurrent stenosis after CEA, and hypertension was only associated with restenosis after CAS.
C1 [Texakalidis, Pavlos] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.
   [Tzoumas, Andreas] Aristotle Univ Thessaloniki, Sch Med, Thessaloniki, Greece.
   [Giannopoulos, Stefanos] 251 HAF & VA Hosp, Athens, Greece.
   [Jonnalagadda, Anil K.] Medstar Washington Hosp Ctr, Dept Cardiol, Washington, DC USA.
   [Jabbour, Pascal] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
   [Rangel-Castilla, Leonardo] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Machinis, Theofilos; Rivet, Dennis J.; Reavey-Cantwell, John] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA.
RP Texakalidis, P (reprint author), Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.
EM pavlostex.med@gmail.com
RI JONNALAGADDA, ANIL KUMAR/X-5875-2019; Giannopoulos, Stefanos/W-9294-2019
OI JONNALAGADDA, ANIL KUMAR/0000-0001-9817-6140; Giannopoulos,
   Stefanos/0000-0002-1942-911X
CR AbuRahma AF, 2010, J VASC SURG, V52, P1180, DOI 10.1016/j.jvs.2010.06.074
   Amann K, 2006, J AM SOC NEPHROL, V17, P2112, DOI 10.1681/ASN.2006030204
   Amarenco P, 2004, STROKE, V35, P2902, DOI 10.1161/01.STR.0000147965.52712.fa
   Avgerinos ED, 2016, J VASC SURG, V64, P678, DOI 10.1016/j.jvs.2016.03.415
   Bekelis K, 2013, BRIT J SURG, V100, P440, DOI 10.1002/bjs.9027
   Bonati LH, 2018, LANCET NEUROL, V17, P587, DOI 10.1016/S1474-4422(18)30195-9
   Bonati LH, 2014, INT J STROKE, V9, P297, DOI 10.1111/ijs.12084
   Bonati LH, 2009, LANCET NEUROL, V8, P908, DOI 10.1016/S1474-4422(09)70227-3
   Bond R, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000160.PUB2
   CALLOW AD, 1982, ARCH SURG-CHICAGO, V117, P1082
   Cao P, 2000, J VASC SURG, V31, P19, DOI 10.1016/S0741-5214(00)70064-4
   Dai ZZ, 2019, ANGIOLOGY, V70, P160, DOI 10.1177/0003319718784805
   Dai ZZ, 2018, STROKE, V49, P872, DOI 10.1161/STROKEAHA.117.019748
   Daou B, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011783
   de Donato G, 2008, J VASC SURG, V48, P1431, DOI 10.1016/j.jvs.2008.07.012
   De Letter J A, 1994, Ann Vasc Surg, V8, P54, DOI 10.1007/BF02133406
   Edwards JM, 2002, J VASC SURG, V35, P176, DOI 10.1067/mva.2002.119035
   Fluri F, 2010, EUR J NEUROL, V17, P493, DOI 10.1111/j.1468-1331.2009.02858.x
   Goldberg IJ, 2004, J CLIN INVEST, V114, P613, DOI 10.1172/JCI200422826
   Goodney P. P., 2010, J VASC SURG, V52, P904
   Goodney PP, 2010, J VASC SURG, V52, P897, DOI 10.1016/j.jvs.2010.05.005
   Hegland O, 2010, ACTA NEUROL SCAND, V121, P11, DOI 10.1111/j.1600-0404.2009.01280.x
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hung CS, 2016, ACTA CARDIOL SIN, V32, P205, DOI 10.6515/ACS20150119H
   Hunter GC, 1997, AM J SURG, V174, P583, DOI 10.1016/S0002-9610(97)80927-0
   Kon V, 2011, NAT REV NEPHROL, V7, P45, DOI 10.1038/nrneph.2010.157
   Krejza J, 2006, STROKE, V37, P1103, DOI 10.1161/01.STR.0000206440.48756.f7
   Lal BK, 2012, LANCET NEUROL, V11, P755, DOI 10.1016/S1474-4422(12)70159-X
   LaMuraglia GM, 2005, J VASC SURG, V41, P762, DOI 10.1016/j.jvs.2005.01.035
   Malas M, 2015, STROKE, V46, P757, DOI 10.1161/STROKEAHA.114.007634
   Mannheim D, 2005, J VASC SURG, V41, P403, DOI 10.1016/j.jvs.2004.11.036
   Misaki K, 2016, J NEURORADIOLOGY, V43, P18, DOI 10.1016/j.neurad.2015.09.002
   Mousa AY, 2015, J ENDOVASC THER, V22, P449, DOI 10.1177/1526602815581597
   Mughal MM, 2011, EXPERT REV CARDIOVAS, V9, P1315, DOI [10.1586/erc.11.120, 10.1586/ERC.11.120]
   Olechnowicz-Tietz S, 2013, INT UROL NEPHROL, V45, P1605, DOI 10.1007/s11255-013-0407-1
   OURIEL K, 1987, J VASC SURG, V5, P702, DOI 10.1067/mva.1987.avs0050702
   Paraskevas KI, 2016, INT J CARDIOL, V220, P680, DOI 10.1016/j.ijcard.2016.06.294
   Reina-Gutierrez T, 2005, EUR J VASC ENDOVASC, V29, P334, DOI 10.1016/j.ejvs.2004.10.007
   Sadideen H, 2006, INT J CLIN PRACT, V60, P1625, DOI 10.1111/j.1742-1241.2005.00775.x
   Skelly CL, 2006, J VASC SURG, V44, P1010, DOI 10.1016/j.jvs.2006.07.039
   Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002
   Texakalidis P, 2018, J ENDOVASC THER, V25, P624, DOI 10.1177/1526602818794030
   Texakalidis P, 2018, J ENDOVASC THER, V25, P523, DOI 10.1177/1526602818783505
   Texakalidis P, 2018, WORLD NEUROSURG, V116, P444, DOI 10.1016/j.wneu.2018.05.160
   Texakalidis P, 2018, WORLD NEUROSURG, V115, P421, DOI 10.1016/j.wneu.2018.02.196
   Trisal V, 2002, AM SURGEON, V68, P275
   van Haaften AC, 2010, J VASC INTERV RADIOL, V21, P1471, DOI 10.1016/j.jvir.2010.06.010
   Verzini F, 2011, J VASC SURG, V53, P71, DOI 10.1016/j.jvs.2010.08.024
   VOLTEAS N, 1994, INT ANGIOL, V13, P143
   Wagenknecht LE, 2003, ARTERIOSCL THROM VAS, V23, P1035, DOI 10.1161/01.ATV.0000072273.67342.6D
   Wasser K, 2012, PERSPECT MED, V1, P122, DOI [10.1016/j.permed.2012.02.051, DOI 10.1016/J.PERMED.2012.02.051]
   Wasser K, 2012, J NEUROL, V259, P1896, DOI 10.1007/s00415-012-6436-3
   Yamagami H, 2012, J STROKE CEREBROVASC, V21, P193, DOI 10.1016/j.jstrokecerebrovasdis.2010.06.007
   Zapata-Arriaza E, 2016, STROKE, V47, P2144, DOI 10.1161/STROKEAHA.116.012650
   ZIERLER RE, 1982, ARCH SURG-CHICAGO, V117, P1408
NR 56
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 414
EP 424
DI 10.1016/j.wneu.2019.02.065
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700231
PM 30822589
DA 2020-05-12
ER

PT J
AU Lin, GX
   Huang, P
   Kotheeranurak, V
   Park, CW
   Heo, DH
   Park, CK
   Park, JY
   Kim, JS
AF Lin, Guang-Xun
   Huang, Peng
   Kotheeranurak, Vit
   Park, Cheul-Woong
   Heo, Dong-Hwa
   Park, Choon-Keun
   Park, Jeong-Yoon
   Kim, Jin-Sung
TI A Systematic Review of Unilateral Biportal Endoscopic Spinal Surgery:
   Preliminary Clinical Results and Complications
SO WORLD NEUROSURGERY
LA English
DT Review
DE Biportal; Endoscopic spine decompression; Endoscopic spine discectomy;
   Endoscopic spine laminectomy; Spinal endoscopy
ID LUMBAR DISKECTOMY; DISC HERNIATION; INTERBODY FUSION; LEARNING-CURVE;
   DECOMPRESSION; STENOSIS; L5-S1
AB OBJECTIVE: Unilateral biportal endoscopic spine surgery (UBE) for the treatment of lumbar spinal diseases has achieved favorable results. In this systematic review, the technical nuances, surgical outcomes, and complications of UBE are summarized.
   METHODS: A systematic review of the literature published to June 2018 was performed. Reported studies related to UBE were identified through searching the PubMed database. The outcomes measured included operative time, hospital stay, complications, visual analog scale (VAS), Oswestry Disability Index, and the Macnab criteria.
   RESULTS: A total of 556 patients and 679 levels were collected from the selected 11 studies. The mean follow-up was 15.2 months, the mean operative time was 81.3 minutes, and the mean length of hospital stay was 4.4 days. The mean overall complication rate was 6.7% (range, 0%-13.8%). The mean VAS score for leg pain decreased from preoperative 7.9 to 1.9 at final follow-up visit and the mean VAS score for back pain decreased from 5.7 to 1.8. The mean Oswestry Disability Index significantly improved from preoperative 63.7 to 18.6 at the final follow-up. The average satisfied outcome (excellent/good; based on the Macnab criteria) was 84.3% (range, 75.35%-95%). There were similar results between UBE for the treatment of lumbar disc herniation and stenosis, including operative time, length of hospital stay, complications, and satisfaction rate.
   CONCLUSIONS: Although the existing studies are limited to small cohorts and short-term follow-up, based on the given preliminary results and experiences of current studies, UBE may be a feasible option for lumbar spinal surgery.
C1 [Lin, Guang-Xun; Kim, Jin-Sung] Catholic Univ Korea, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
   [Huang, Peng] Chinese Peoples Liberat Army, Hosp 301, Gen Hosp, Dept Orthopaed Surg, Beijing, Peoples R China.
   [Kotheeranurak, Vit] Queen Savang Vadhana Mem Hosp, Dept Orthopaed, Spine Unit, Sriracha, Chonburi, Thailand.
   [Park, Cheul-Woong] Daejeon Woori Spine Hosp, Dept Neurosurg, Daejeon, South Korea.
   [Heo, Dong-Hwa; Park, Choon-Keun] Leon Wiltse Mem Hosp, Spine Ctr, Dept Neurosurg, Suwon, South Korea.
   [Park, Jeong-Yoon] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Neurosurg, Seoul, South Korea.
RP Kim, JS (reprint author), Catholic Univ Korea, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
EM mdlukekim@gmail.com
RI Heo, Dong Hwa/AAE-2785-2019; Kim, Jin-Sung/Y-2904-2019
OI Heo, Dong Hwa/0000-0003-1203-4550; Kim, Jin-Sung/0000-0001-5086-0875
CR Ahn JS, 2018, J NEUROSURG-SPINE, V28, P492, DOI 10.3171/2017.8.SPINE17771
   Ahn Y, 2004, SPINE, V29, pE326, DOI 10.1097/01.BRS.0000134591.32462.98
   Ahn Y, 2012, EXPERT REV MED DEVIC, V9, P361, DOI [10.1586/erd.12.23, 10.1586/ERD.12.23]
   Akbary K, 2018, WORLD NEUROSURG, V117, P153, DOI 10.1016/j.wneu.2018.05.111
   Birkenmaier C, 2013, PAIN PHYSICIAN, V16, P335
   Choi CM, 2016, ACTA NEUROCHIR, V158, P459, DOI 10.1007/s00701-015-2670-7
   Choi DJ, 2016, CLIN ORTHOP SURG, V8, P325, DOI 10.4055/cios.2016.8.3.325
   Choi DJ, 2016, ASIAN SPINE J, V10, P624, DOI 10.4184/asj.2016.10.4.624
   Choi G, 2010, MINIM INVAS NEUROSUR, V53, P147, DOI 10.1055/s-0030-1254145
   Choi I, 2013, EUR SPINE J, V22, P2481, DOI 10.1007/s00586-013-2849-7
   Choi KC, 2018, WORLD NEUROSURG, V116, pE750, DOI 10.1016/j.wneu.2018.05.085
   Choi KC, 2013, PAIN PHYSICIAN, V16, P547
   DeAntoni DJ, 1996, ARTHROSCOPY, V12, P330, DOI 10.1016/S0749-8063(96)90069-9
   Eun SS, 2017, J NEUROL SURG PART A, V78, P390, DOI 10.1055/s-0036-1592157
   Gibson JNA, 2007, SPINE, V32, P1735, DOI 10.1097/BRS.0b013e3180bc2431
   Heo DH, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17146
   Ikuta K, 2007, MINIM INVAS NEUROSUR, V50, P145, DOI 10.1055/s-2007-985152
   Kim JE, 2018, J ORTHOP, V15, P354, DOI 10.1016/j.jor.2018.01.034
   Kim JE, 2018, J ORTHOP, V15, P366, DOI 10.1016/j.jor.2018.01.039
   Kim JE, 2018, CLIN ORTHOP SURG, V10, P248, DOI 10.4055/cios.2018.10.2.248
   Kim SK, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0725-1
   Lee SH, 2006, SPINE, V31, pE285, DOI 10.1097/01. brs.0000216446.13205.7a
   Lew SM, 2001, J NEUROSURG, V94, P216, DOI 10.3171/spi.2001.94.2.0216
   Liao Z, 2014, ORTHOPEDICS, V37, DOI 10.3928/01477447-20140728-58
   MAYER HM, 1993, NEUROSURG REV, V16, P115, DOI 10.1007/BF00258242
   Mobbs RJ, 2014, J NEUROSURG-SPINE, V21, P179, DOI 10.3171/2014.4.SPINE13420
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Nakagawa H, 2003, J CLIN NEUROSCI, V10, P231, DOI 10.1016/S0967-5868(02)00337-5
   Nowitzke AM, 2005, NEUROSURGERY, V56, P755, DOI 10.1227/01.NEU.0000156470.79032.7B
   Osman SG, 2012, INT J SPINE SURG, V6, P103, DOI 10.1016/j.ijsp.2012.02.004
   Park JH, 2017, ORTHOPEDICS, V40, pE779, DOI 10.3928/01477447-20170531-02
   Ruetten S, 2008, SPINE, V33, P931, DOI 10.1097/BRS.0b013e31816c8af7
   Soliman HM, 2015, SPINE J, V15, P2282, DOI 10.1016/j.spinee.2015.07.009
   Soliman HM, 2013, EUR SPINE J, V22, P1037, DOI 10.1007/s00586-013-2701-0
   Torudom Y, 2016, ASIAN SPINE J, V10, P335, DOI 10.4184/asj.2016.10.2.335
   Yorimitsu E, 2001, SPINE, V26, P652, DOI 10.1097/00007632-200103150-00019
   2016, J NEUROSURG-SPINE, V24, P602, DOI DOI 10.3171/2015.7.SPINE15304
NR 37
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 425
EP 432
DI 10.1016/j.wneu.2019.02.038
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700232
PM 30797907
DA 2020-05-12
ER

PT J
AU Bedi, MS
   Bhavthankar, TD
   Girijala, MR
   Babu, JK
   Ambati, V
   Jonalgadda, V
   Ogando-Rivas, E
   Konchada, K
   Juluru, CS
   Jvnk, A
AF Bedi, Manbachan Singh
   Bhavthankar, Tanmay D.
   Girijala, Malleswara R.
   Babu, Jagadeesh K.
   Ambati, Vimala
   Jonalgadda, Varun
   Ogando-Rivas, Elizabeth
   Konchada, Kamesh
   Juluru, Chaitanya S.
   Jvnk, Aravind
TI Lazy Glass Microsurgical Trainer: A Frugal Solution for Microsurgical
   Training
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dexterity; Hand-eye coordination; Lazy glasses; Learning curve in
   microsurgery; Microsurgery simulator; Microsurgery skill training;
   Operating microscope
ID SKILLS
AB BACKGROUND: The art of surgery is becoming increasingly complex and dependent on scopes, screens, and technology, inviting a complex learning curve and development of hand-eye coordination and dexterity among other skills. We introduce an affordable, do-it-yourself microsurgical simulator that can be set up using a smartphone and a pair of reflective prism glasses. The glasses employ periscopic prisms on either side that reflect light perpendicularly. When the visual input is combined with the magnification of a smartphone camera, a real-time microsurgical experience can be simulated.
   METHODS: We analyzed the performance of 2 trainee residents in performing their first 5 successful sutures with 5-0 polypropylene thread on the cut ends of a glove over the course of 3 months. The module was also assessed in a survey at an international conference of neurosurgeons.
   RESULTS: A significant improvement was observed in both residents at the end of each month versus baseline (P < 0.05). Of 27 survey participants, 3 (11%) reported access to a training laboratory in their institute. The module was rated 4/5 in terms of hand-eye coordination, 3.5/5 in management of microsurgical field, and 3.5/5 in depth perception.
   CONCLUSIONS: The microsurgical simulation technique proved to be useful in performing complex microsurgical tasks. A significant improvement in microsurgical skills was observed among our trainees. The cost of building the module can be as low as U.S. $5. We endorse the use of this technique for resident training and skill development, especially in resource-challenged environments.
C1 [Bedi, Manbachan Singh; Bhavthankar, Tanmay D.; Girijala, Malleswara R.; Babu, Jagadeesh K.; Ambati, Vimala; Jonalgadda, Varun; Konchada, Kamesh; Juluru, Chaitanya S.; Jvnk, Aravind] Mamata Med Coll & Superspecial Hosp, Dept Neurosurg, Khammam, Telangana, India.
   [Ogando-Rivas, Elizabeth] Univ Florida, McKnight Brain Inst, Dept Neurosurg, Gainesville, FL 32611 USA.
RP Bedi, MS (reprint author), Mamata Med Coll & Superspecial Hosp, Dept Neurosurg, Khammam, Telangana, India.
EM mbachan24@gmail.com
OI Ogando-Rivas, Elizabeth/0000-0001-7192-6714; Bedi, Manbachan
   Singh/0000-0001-6195-8843
CR Chan WY, 2007, MICROSURG, V27, P494, DOI 10.1002/micr.20393
   Choque-Velasquez J, 2018, WORLD NEUROSURG, V112, P126, DOI 10.1016/j.wneu.2018.01.067
   Hu YY, 2012, J AM COLL SURGEONS, V214, P115, DOI 10.1016/j.jamcollsurg.2011.10.009
   Huotarinen A, 2017, WORLD NEUROSURG, V107, P358, DOI 10.1016/j.wneu.2017.08.024
   Ilie VG, 2008, MICROSURG, V28, P571, DOI 10.1002/micr.20541
   Karakawa R, 2018, MICROSURG, V38, P124, DOI 10.1002/micr.30241
   Kim DM, 2015, MICROSURG, V35, P500, DOI 10.1002/micr.22369
   Leung CCM, 2013, ARCH PLAST SURG-APS, V40, P304, DOI 10.5999/aps.2013.40.4.304
   Malik MM, 2017, J PLAST RECONSTR AES, V70, P478, DOI 10.1016/j.bjps.2016.12.011
   Sugden C, 2012, ANN SURG, V255, P222, DOI 10.1097/SLA.0b013e3182306c99
   Taylor NW, 2014, PLAST RECONSTR SURG, V133, p78E, DOI 10.1097/01.prs.0000436803.50541.6b
NR 11
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 433
EP 442
DI 10.1016/j.wneu.2019.01.141
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700233
PM 30716484
DA 2020-05-12
ER

PT J
AU Zhang, WH
   Chen, MJ
   Yang, C
   Zhang, WJ
   Chai, Y
   Wei, WB
AF Zhang, Wenhao
   Chen, Minjie
   Yang, Chi
   Zhang, Weijie
   Chai, Ying
   Wei, Wenbin
TI Endoscope-Assisted Avulsion of the Masseter Nerve Attached to the
   Temporomandibular Joint Disc for the Treatment of Hemimasticatory Spasm:
   A Report of Two Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Avulsion; Coblation; Endoscopy; Hemimasticatory spasm; Masseter nerve
ID HEMIFACIAL SPASM; BOTULINUM-TOXIN; SYNOVIAL CHONDROMATOSIS; MRI
AB OBJECTIVE: Hemimasticatory spasm (HMS) is a rare masticatory muscle disorder. Drug therapy, microvascular decompression, and botulinum toxin have had varying efficacy and adverse effects. We have reported the cases of 2 patients who had undergone a novel therapy for HMS, based on endoscope-assisted nerve avulsion of the masseter nerve attached to the temporomandibular joint (TMJ) disc.
   METHODS: We performed a retrospective study of 2 patients with HMS who had undergone surgery from June 2014 to June 2017 at the oral surgery department of Shanghai Ninth People's Hospital affiliated to Shanghai JiaoTong University School of Medicine. Both patients had undergone endoscope-assisted avulsion of the masseter nerve attached to the TMJ disc. Both patients were evaluated by electromyography postoperatively and were followed up for 36 months after surgery.
   RESULTS: Both patients had had all the signs and symptoms of HMS. The HMS had resolved immediately after surgery. At 1 week after surgery, electromyography revealed that the high-frequency group discharge potential in the motor unit accompanying the spasm was no longer present, and the effect was maintained for the 36-month follow-up period. These results indicated a good curative effect. Electromyography also showed strength weakness and mild shape atrophy of the masseter muscle on the affected side.
   CONCLUSIONS: Endoscope-assisted avulsion of the masseter nerve attached to the TMJ disc showed a good curative effect, little trauma, few complications, and a quick postoperative recovery. It could be used as an alternative treatment of HMS for selected patients.
C1 [Zhang, Wenhao; Chen, Minjie; Yang, Chi; Zhang, Weijie; Chai, Ying; Wei, Wenbin] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Oral & Craniofacial Surg, Shanghai, Peoples R China.
RP Chen, MJ (reprint author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Oral & Craniofacial Surg, Shanghai, Peoples R China.
EM chenminjietougao@126.com
CR AUGER RG, 1992, NEUROLOGY, V42, P2263, DOI 10.1212/WNL.42.12.2263
   AUGER RG, 1990, ARCH NEUROL-CHICAGO, V47, P1233, DOI 10.1001/archneur.1990.00530110095023
   Chen M, 2004, CHIN J ORAL MAXILLOF, V2, P56
   Chen MJ, 2010, J ORAL MAXIL SURG, V68, P2085, DOI 10.1016/j.joms.2009.04.130
   Chen MJ, 2015, J CRANIO MAXILL SURG, V43, P349, DOI 10.1016/j.jcms.2015.01.011
   Chen MJ, 2012, J ORAL MAXIL SURG, V70, pE32, DOI 10.1016/j.joms.2011.07.014
   Chen MJ, 2005, CHINA J ORAL MAXILLO, V3, P189
   CRUCCU G, 1994, J NEUROL NEUROSUR PS, V57, P43, DOI 10.1136/jnnp.57.1.43
   Dai J, 2011, CHIN J AESTH MED, V20, P108
   Girard N, 1997, NEURORADIOLOGY, V39, P46, DOI 10.1007/s002340050366
   Gowers WR., 1897, MANUAL DIS CENTRAL N
   Hughes RAC, 1993, PERIPHERAL NEUROPATH
   Hwang K, 2005, J CRANIOFAC SURG, V16, P197, DOI 10.1097/00001665-200503000-00003
   JANNETTA PJ, 1977, NEUROCHIRURGIA, V20, P145
   Jimenez-Jimenez FJ, 2008, EUR NEUROL, V59, P276, DOI 10.1159/000115644
   KAUFMAN MD, 1980, ANN NEUROL, V7, P585, DOI 10.1002/ana.410070614
   Kaya B, 2014, J PLAST RECONSTR AES, V67, P1663, DOI 10.1016/j.bjps.2014.07.043
   Kim DH, 2010, J CRANIOFAC SURG, V21, P588, DOI 10.1097/SCS.0b013e3181d08bb3
   Kim HJ, 2000, ARCH NEUROL-CHICAGO, V57, P576, DOI 10.1001/archneur.57.4.576
   Liu Z, 2010, CHIN J AESTH MED, V19, P1550
   Nilsen B, 2004, NEUROLOGY, V63, P1532
   Pan D, 2013, CHIN J AESTH PLAST S, V24, P297
   Rosenstengel C, 2012, DTSCH ARZTEBL INT, V109, P667, DOI 10.3238/arztebl.2012.0667
   SHORR N, 1985, AM J OPHTHALMOL, V99, P542, DOI 10.1016/S0002-9394(14)77954-1
   Sun HT, 2016, WORLD NEUROSURG, V90, DOI 10.1016/j.wneu.2016.02.088
   THOMPSON PD, 1986, J NEUROL NEUROSUR PS, V49, P651, DOI 10.1136/jnnp.49.6.651
   Wang K, 2004, J CRANIOFAC SURG, V15, P780
   Yin T, 2003, J STOMATOL, V23, P246
   Zhang J, 2015, CHIN J AESTH PLAST S, V26, P750
NR 29
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 443
EP 448
DI 10.1016/j.wneu.2019.01.264
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700234
PM 30790727
DA 2020-05-12
ER

PT J
AU Vaishya, S
   Chauhan, A
   Patir, R
   Gupta, RK
AF Vaishya, Sandeep
   Chauhan, Abhishek
   Patir, Rana
   Gupta, Rakesh K.
TI Intramedullary Capillary Hemangioma Presenting with Hydrocephalus and
   Spastic Paraparesis in 2-Month-Old Infant
SO WORLD NEUROSURGERY
LA English
DT Article
DE Capillary; Hemangiomas; Intramedullary; Spinal; Tumor; Vascular
ID SPINAL-CORD; HEMANGIOBLASTOMAS; TUMORS
AB BACKGROUND: Intramedullary capillary hemangiomas are rare lesions with only 14 cases reported so far and are found in middle-aged persons. Until now only a single case has been reported in the pediatric population. Ours was the second pediatric case and the youngest of all to be diagnosed with an intramedullary capillary hemangioma.
   CASE DESCRIPTION: We are reporting the case of a 2-month male child who presented with features of hydrocephalus and spastic paraparesis. On magnetic resonance imaging he had features suggestive of a D10-11 intradural extramedullary lesion and hydrocephalus. We did a ventriculoperitoneal shunt followed by excision of the lesion in the same sitting. Intraoperatively it was found to be an intramedullary lesion, and histopathologic examination showed features suggestive of capillary hemangioma. Postoperatively he recovered well and there is no recurrence 18 months after surgery.
   CONCLUSIONS: Intramedullary capillary hemangiomas are extremely rare lesions in infants but should be kept in mind while treating any patient with the spinal lesion. Further reporting of similar cases will help in understanding the natural history, pathogenesis, and management.
C1 [Vaishya, Sandeep; Chauhan, Abhishek; Patir, Rana] Fortis Mem Res Inst, Dept Neurosurg, Gurugram, Haryana, India.
   [Gupta, Rakesh K.] Fortis Mem Res Inst, Dept Radiol, Gurugram, Haryana, India.
RP Vaishya, S (reprint author), Fortis Mem Res Inst, Dept Neurosurg, Gurugram, Haryana, India.
EM svaishya@hotmail.com
OI Chauhan, Abhishek/0000-0002-1138-4551
CR Abe M, 2004, J NEUROSURG, V101, P73, DOI 10.3171/jns.2004.101.1.0073
   Andaluz N, 2002, J NEURO-ONCOL, V56, P261, DOI 10.1023/A:1015058419026
   BECKER I, 1989, AM J PATHOL, V134, P271
   CINALLI G, 1995, J NEUROSURG, V83, P480, DOI 10.3171/jns.1995.83.3.0480
   HIDA K, 1993, NEUROSURGERY, V33, P1099
   Iannelli A, 2005, J NEUROSURG, V103, P272, DOI 10.3171/ped.2005.103.3.0272
   Kasukurthi R, 2000, RARE TUMORS, V1, P26
   Kelleher T, 2005, BRIT J NEUROSURG, V19, P345, DOI 10.1080/02688690500305464
   MAURICEWILLIAMS RS, 1975, BRIT J SURG, V62, P92, DOI 10.1002/bjs.1800620203
   MAWK JR, 1987, J NEUROSURG, V67, P456, DOI 10.3171/jns.1987.67.3.0456
   Miller DJ, 2000, J NEURO-ONCOL, V47, P253, DOI 10.1023/A:1006403500801
   Nowak DA, 2001, EUR SPINE J, V10, P464, DOI 10.1007/s005860100296
   RIDSDALE L, 1978, J NEUROL NEUROSUR PS, V41, P737, DOI 10.1136/jnnp.41.8.737
   RIFKINSONMANN S, 1990, NEUROSURGERY, V27, P749, DOI 10.1227/00006123-199011000-00012
   Roncaroli F, 2000, J NEUROSURG, V93, P148, DOI 10.3171/spi.2000.93.1.0148
   Roncaroli F, 2000, J NEUROSURG, V92, P229, DOI 10.3171/spi.2000.92.2.0229
   Russel DS, 1989, PATHOL TUMOURS NER, P727
   Tihan T, 2006, NEUROSURG CLIN N AM, V17, P7, DOI 10.1016/j.nec.2005.11.002
   Tunthanathip Thara, 2017, Asian J Neurosurg, V12, P556, DOI 10.4103/1793-5482.148793
   Wu L, 2013, J NEUROSURG-SPINE, V19, P477, DOI 10.3171/2013.7.SPINE1369
   AJNR AM J NEURORADIO, V21, P954
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 451
EP 455
DI 10.1016/j.wneu.2019.01.067
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700236
PM 30685376
DA 2020-05-12
ER

PT J
AU D'Angelo, L
   Paglia, F
   Caporlingua, A
   Sampirisi, L
   Guidetti, G
   Santoro, A
AF D'Angelo, Luca
   Paglia, Francesco
   Caporlingua, Alessandro
   Sampirisi, Luigi
   Guidetti, Giulio
   Santoro, Antonio
TI Atypical Manifestation of Direct Low-Flow Carotid-Cavernous Fistula:
   Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carotid-cavernous fistula; Cavernous segment of internal carotid artery;
   Cavernous sinus; External carotid artery
ID CLINICAL PRESENTATION; SINUS FISTULA
AB BACKGROUND: Carotid cavernous fistula (CCF) is a rare type of arteriovenous shunt that develops within the cavernous sinus (CS). Direct CCFs entail a direct communication between the cavernous internal carotid artery and the CS and are typically high-flow lesions. Most CCFs drain into the ophthalmic veins (typical venous drainage pattern), leading to the pathognomic ocular clinical triad associated with a CCF. When an obstruction of the typical venous outflow is present, the arterial pressure generated by the fistula is transmitted into the cerebral venous system via the sphenoparietal sinus, which might lead to intracerebral hemorrhage. We present a rare case of posttraumatic, direct, low-flow CCF associated with cerebral hemorrhage, a typical venous drainage pattern, and without ocular symptoms at presentation.
   CASE DESCRIPTION: A 76-year-old woman was hospitalized for a posttraumatic frontotemporopolar hemorrhage associated with multiple fractures of the maxillofacial and cranial base skeleton and midline shift >10 mm. On neurologic examination the Glasgow Coma Scale was 8 and right anisocoria was present. Immediate surgical evacuation of the hematoma was performed. Severe arterial bleeding from the anterior third of the middle cranial fossa floor was controlled intraoperatively. Postoperative brain angio - magnetic resonance imaging and digital subtraction angiography showed a direct CCF without theft phenomenon. Ocular symptoms, and ultimately loss of function of the right eye, appeared 2 weeks from surgery. Endovascular treatment of the CCF was attempted attaining partial closure of the shunt using coils.
   CONCLUSIONS: Direct low-flow CCFs are exceedingly rare lesions. Five cases have been described in the literature, 4 of which were associated with spontaneous rupture of a cavernous carotid aneurysm while only 1 case was associated with posttraumatic rupture of a cavernous internal carotid artery pseudoaneurysm. In addition, despite our patient having developed an intraparenchymal hemorrhage most probably correlated to the CCF, the latter was associated with a typical venous drainage via the superior ophthalmic vein, which is uncommonly correlated to intraparenchymal bleeding.
C1 [D'Angelo, Luca; Paglia, Francesco; Caporlingua, Alessandro; Sampirisi, Luigi; Guidetti, Giulio; Santoro, Antonio] Sapienza Univ Rome, Dept Neurol & Psychiat, Neurosurg, Rome, Italy.
RP Paglia, F (reprint author), Sapienza Univ Rome, Dept Neurol & Psychiat, Neurosurg, Rome, Italy.
EM francesco.paglia@hotmail.it
OI Caporlingua, Alessandro/0000-0003-2776-5399; guidetti,
   giulio/0000-0002-6092-4198
CR Aralasmak A, 2014, ISRN RADIOL, V2014
   BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248
   HIRAMATSU K, 1991, NEURORADIOLOGY, V33, P67, DOI 10.1007/BF00593339
   Korkmazer B, 2013, WORLD J RADIOL, V5, P143, DOI 10.4329/wjr.v5.i4.143
   Marin-Fernandez Ana-Belen, 2016, J Clin Exp Dent, V8, pe226, DOI 10.4317/jced.52913
   Miller NR, 2012, NEUROSURG CLIN N AM, V23, P179, DOI 10.1016/j.nec.2011.09.008
   Spinnato S, 1997, ACTA NEUROCHIR, V139, P1181, DOI 10.1007/BF01410980
   Su IC, 2014, INTERV NEURORADIOL, V20, P476, DOI 10.15274/NRJ-2014-10057
   TURNER DM, 1983, J NEUROSURG, V59, P680, DOI 10.3171/jns.1983.59.4.0680
   van Rooij WJ, 2006, AM J NEURORADIOL, V27, P185
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 456
EP 460
DI 10.1016/j.wneu.2019.02.027
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700237
PM 30818073
DA 2020-05-12
ER

PT J
AU Engele, T
   Brettschneider, C
   Emami, P
   Konig, HH
AF Engele, Tobias
   Brettschneider, Christian
   Emami, Pedram
   Koenig, Hans-Helmut
TI Cost Comparison of Surgical Clipping and Endovascular Coiling of
   Unruptured Intracranial Aneurysms: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Clipping; Coiling; Health care costs; Health economics; Hospital costs;
   Intracranial aneurysm; Subarachnoid hemorrhage; Treatment costs
ID LENGTH-OF-STAY; CEREBRAL ANEURYSMS; UNITED-STATES; EMBOLIZATION
AB OBJECTIVES: Rupture of unruptured intracranial aneurysms (UIA) is the main cause for subarachnoid hemorrhage. UIA are widespread among the population. Advanced technology enables us to diagnose UIAs with increasing reliability and subsequently treat them. There are 2 main treatment options: surgical clipping and endovascular treatment of the aneurysm. This article aims to analyze costs of neurosurgical clipping and the endovascular approach to treat UIA, and to give an overview over the existing literature.
   METHODS: A systematic literature search was conducted using the databases Ovid MEDLINE, PubMed, and NHS EED. Articles were divided into 2 groups based on the perspective from which costs were evaluated (health care provider or payer). Costs were inflated to the year 2015 and converted to international dollars.
   RESULTS: The literature search yielded 137 different articles out of which 15 have been considered relevant and have been included in this review. Not only absolute numbers but also the cost ratio of both treatment modalities showed substantial variations. The coiling procedure tends to be more expensive for health care providers but cheaper for cost bearers. Without any exception, the authors determined shorter lengths of stay for patients who underwent the coiling procedure.
   CONCLUSIONS: Due to different definitions of hospital costs and hardly reproducible calculations, comparability of the stated numbers is limited. Besides the economic impact, outcomes must be considered when making a treatment decision. The 2 treatment modalities are not equally suitable in every patient nor for every aneurysm location.
C1 [Engele, Tobias; Brettschneider, Christian; Koenig, Hans-Helmut] Univ Med Ctr Hamburg Eppendorf, Dept Hlth Econ & Hlth Serv Res, Hamburg, Germany.
   [Emami, Pedram] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Hamburg, Germany.
RP Engele, T (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Hlth Econ & Hlth Serv Res, Hamburg, Germany.
RI Konig, Hans-Helmut/P-1211-2018; Brettschneider, Christian/H-5920-2019
OI Konig, Hans-Helmut/0000-0001-5711-6862; Brettschneider,
   Christian/0000-0002-5280-1075
CR Barker FG, 2003, NEUROSURGERY, V52, P995, DOI 10.1227/01.NEU.0000057743.56678.5F
   Brandt T, 2012, THERAPY COURSE NEURO
   Brinjikji W, 2012, AM J NEURORADIOL, V33, P49, DOI 10.3174/ajnr.A2739
   Bureau of Labor Statistics, CPI ALL URB CONS CUR
   Cowan JA, 2007, J NEUROSURG, V107, P530, DOI 10.3171/JNS-07/09/0530
   Drazin D, 2010, J NEUROINTERV SURG, V2, P168, DOI 10.1136/jnis.2009.001065
   Duan YF, 2015, J NEUROINTERV SURG, V7, P614, DOI 10.1136/neurintsurg-2014-011249
   El-Chalouhi N, 2014, WORLD NEUROSURG, V82, P696, DOI 10.1016/j.wneu.2013.02.089
   Familiari P, 2015, NEUROSURGERY, V77, P733, DOI 10.1227/NEU.0000000000000917
   Frontera JA, 2014, J NEUROINTERV SURG, V6, P65, DOI 10.1136/neurintsurg-2012-010544
   Halkes PHA, 2006, CEREBROVASC DIS, V22, P40, DOI 10.1159/000092336
   Higashida RT, 2007, AM J NEURORADIOL, V28, P146
   Hoh BL, 2010, STROKE, V41, P337, DOI 10.1161/STROKEAHA.109.569269
   Hoh BL, 2009, NEUROSURGERY, V64, P614, DOI 10.1227/01.NEU.0000340784.75352.A4
   Johnston SC, 1999, NEUROLOGY, V52, P1799, DOI 10.1212/WNL.52.9.1799
   Johnston SC, 2001, STROKE, V32, P597, DOI 10.1161/01.STR.32.3.597
   Juvela S, 2013, STROKE, V44, P2414, DOI 10.1161/STROKEAHA.113.001838
   Kim M, 2015, J KOREAN NEUROSURG S, V57, P455, DOI 10.3340/jkns.2015.57.6.455
   Korja M, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2015.228
   Lad SP, 2013, NEUROSURGERY, V72, P1000, DOI 10.1227/01.neu.0000429284.91142.56
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Organisation for Economic Co-Operation and Development (OECD), HOSP AV LENGTH STAY
   Smith GA, 2011, J NEUROSURG, V114, P1768, DOI 10.3171/2011.1.JNS101528
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   2002, LANCET LOND ENGL, V360, P1267
NR 25
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 461
EP 468
DI 10.1016/j.wneu.2019.01.195
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700238
PM 30743038
DA 2020-05-12
ER

PT J
AU Hall, A
   O'Kane, R
AF Hall, Allan
   O'Kane, Roddy
TI The Management of Hypertension in Pre-Aneurysmal Treatment Subarachnoid
   Hemorrhage Patients
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysmal; Hypertension; Subarachnoid hemorrhage
ID DELAYED CEREBRAL-ISCHEMIA; BLOOD-PRESSURE; PULSE PRESSURE; MORTALITY;
   THERAPY; IMPACT
AB BACKGROUND: Management of hypertension in subarachnoid hemorrhage patients within the preaneurysmal treatment period remains ambiguous, in part due to the lack of high-level, evidence-based guidelines. Despite this, current recommendations offer guidance regarding certain parameters (e.g., mean arterial pressure, systolic blood pressure). However, managing hypertension within this critical period is difficult because a fine balance must be achieved between lowering blood pressure enough to minimize the risk of rebleeding and preventing reduced cerebral perfusion and subsequent ischemic damage. Furthermore, the different causes of hypertension within the preaneurysmal treatment period are polyfactorial and include pathophysiologic responses, sympathetic nervous system activation, and iatrogenic from hyperdynamic therapy and vasopressors, which requires consideration for these patients to receive optimal management. Other factors including loss of autoregulation and concomitant conditions must also be considered when deciding whether to start antihypertensive therapy.
   METHODS: We review the literature and provide a comprehensive update on management of hypertension within the preaneurysmal treatment period, which we hope stresses the need for better evidence-based guidelines that will in turn help manage this cohort.
   RESULTS: Thorough review revealed no high-grade, evidence-based guidelines to manage these patients, which results in variation in clinical practice among different clinicians and institutions. Despite this, current recommendations seem reasonable until such guidelines are established.
   CONCLUSIONS: It is clear that further, larger studies are warranted in order to clarify the effect of antihypertensive therapy on patient outcome and what the BP thresholds are, along with establishing the best treatment, for commencing antihypertensive therapy.
C1 [Hall, Allan; O'Kane, Roddy] Queen Elizabeth Univ Hosp, Dept Neurosurg, Inst Neurol Sci, Glasgow, Lanark, Scotland.
RP Hall, A (reprint author), Queen Elizabeth Univ Hosp, Dept Neurosurg, Inst Neurol Sci, Glasgow, Lanark, Scotland.
EM allanhall@nhs.net
CR Brown RJ, 2017, INT J NEUROSCI, V127, P51, DOI 10.3109/00207454.2016.1138952
   Chalouhi N, 2016, J NEUROSURG, V125, P730, DOI 10.3171/2015.7.JNS15956
   Chang JJ, 2017, AM J HYPERTENS, V30, P719, DOI 10.1093/ajh/hpx025
   Chang Melody M, 2016, Open Neurol J, V10, P155, DOI 10.2174/1874205X01610010155
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9
   Engquist H, 2018, NEUROCRIT CARE, V28, P143, DOI 10.1007/s12028-017-0439-y
   Gathier CS, 2018, STROKE, V49, P76, DOI 10.1161/STROKEAHA.117.017956
   Hillman J, 2002, J NEUROSURG, V97, P771, DOI 10.3171/jns.2002.97.4.0771
   HOUSTON MC, 1988, AM HEART J, V116, P515, DOI 10.1016/0002-8703(88)90627-8
   Inamasu J, 2015, BLOOD PRESS MONIT, V20, P132, DOI 10.1097/MBP.0000000000000106
   Isaksen J, 2002, J NEUROL NEUROSUR PS, V73, P185, DOI 10.1136/jnnp.73.2.185
   Ju Z, 2009, ACTA NEUROL BELG, V109, P18
   KASSELL NF, 1983, NEUROSURGERY, V13, P479, DOI 10.1227/00006123-198311000-00001
   Lakhani S, 2016, EUR J ANAESTH, V23, P902
   Lin QS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003028
   Loan JJM, 2018, BRIT J NEUROSURG, V32, P157, DOI 10.1080/02688697.2018.1426720
   Moussouttas M, 2012, NEUROCRIT CARE, V16, P381, DOI 10.1007/s12028-012-9673-5
   Naidech AM, 2005, ARCH NEUROL-CHICAGO, V62, P410, DOI 10.1001/archneur.62.3.410
   Naredi S, 2006, INTENS CARE MED, V32, P1955, DOI 10.1007/s00134-006-0408-y
   Oheda M, 2015, J CLIN NEUROSCI, V22, P1338, DOI 10.1016/j.jocn.2015.02.024
   Ohkuma H, 2001, STROKE, V32, P1176, DOI 10.1161/01.STR.32.5.1176
   Reynolds MR, 2015, J NEUROSURG, V123, P862, DOI 10.3171/2014.12.JNS141201
   Roy B, 2017, CEREBROVASC DIS, V43, P266, DOI 10.1159/000458536
   Sundboll J, 2015, J NEUROL NEUROSUR PS, V86, P748, DOI 10.1136/jnnp-2014-308948
   Tang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099536
   Tanno Y, 2007, J NEUROL SCI, V258, P11, DOI 10.1016/j.jns.2007.01.074
   van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249
   Vaur L, 1998, AM J HYPERTENS, V11, P165, DOI 10.1016/S0895-7061(97)00420-2
   WIJDICKS EFM, 1990, CLIN NEUROL NEUROSUR, V92, P111, DOI 10.1016/0303-8467(90)90085-J
   Zeiler FA, 2014, CASE REP CRIT CARE
   Zhang H, 2011, NEUROL RES, V33, P285, DOI 10.1179/016164110X12759951866911
NR 32
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 469
EP 474
DI 10.1016/j.wneu.2019.02.041
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700239
PM 30825622
DA 2020-05-12
ER

PT J
AU Thomas, AM
   Fahim, DK
AF Thomas, Alison M.
   Fahim, Daniel K.
TI Stand-Alone Balloon Kyphoplasty for Treatment of Traumatic Burst
   Fracture in Pediatric Patient
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cement; Kyphoplasty; Pediatric; Traumatic fracture
ID CALCIUM-PHOSPHATE CEMENT
AB BACKGROUND: Kyphoplasty is commonly employed in the treatment of compression fractures in the elderly and is increasingly used in the treatment of adult trauma along with concomitant instrumentation. Although kyphoplasty with instrumentation has been reported in pediatric patients, concerns regarding retardation of spinal growth and iatrogenic spinal deformity have been raised. The utilization of kyphoplasty without instrumentation has yet to be reported in the case of pediatric patients.
   CASE DESCRIPTION: A 13-year-old male presented to the emergency department with a traumatic L2 burst fracture with 50% loss of height, which continued to cause severe pain after a trial of bracing. He was subsequently treated with a kyphoplasty without instrumentation. He experienced a rapid and excellent recovery and resumed all previous activity.
   CONCLUSIONS: Kyphoplasty alone without instrumentation is a less invasive means to treat these patients and also prevents iatrogenic deformity or retardation of growth in the pediatric spine.
C1 [Thomas, Alison M.; Fahim, Daniel K.] Oakland Univ, William Beaumont Sch Med, Dept Neurosurg, Rochester, MI 48063 USA.
RP Fahim, DK (reprint author), Oakland Univ, William Beaumont Sch Med, Dept Neurosurg, Rochester, MI 48063 USA.
EM Daniel.fahim@beaumont.edu
CR Butler JS, 2005, INT ORTHOP, V29, P51, DOI 10.1007/s00264-004-0602-x
   Gioia G, 2012, EUR SPINE J, V21, pS108, DOI 10.1007/s00586-012-2225-z
   Hazzard MA, 2014, ASIAN SPINE J, V8, P605, DOI 10.4184/asj.2014.8.5.605
   LeGeros RZ, 2002, CLIN ORTHOP RELAT R, P81
   Lieberman IH, 2001, SPINE, V26, P1631, DOI 10.1097/00007632-200107150-00026
   Maestretti G, 2007, EUR SPINE J, V16, P601, DOI 10.1007/s00586-006-0258-x
   Rajasekaran S, 2010, EUR SPINE J, V19, P40, DOI 10.1007/s00586-009-1122-6
   Singer G, 2016, EUR SPINE J, V25, P651, DOI 10.1007/s00586-014-3686-z
   With the NC for HS in collaboration, 2000, PROM NC CDP H 2 20 Y
   Xu HHK, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.56
   Yu CW, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-3
NR 11
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 475
EP 480
DI 10.1016/j.wneu.2019.01.184
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700240
PM 30738932
DA 2020-05-12
ER

PT J
AU Ghali, GZ
   Ghali, MGZ
   Ghali, EZ
AF Ghali, George Zaki
   Ghali, Michael George Zaki
   Ghali, Emil Zaki
TI Endovascular Therapy for Brainstem Arteriovenous Malformations
SO WORLD NEUROSURGERY
LA English
DT Review
DE AVM; Brainstem; Curative; Embolization; Endovascular; Multimodal;
   Treatment
ID GAMMA-KNIFE RADIOSURGERY; STEREOTACTIC RADIOSURGERY; NATURAL-HISTORY;
   POSTERIOR-FOSSA; VASCULAR MALFORMATIONS; CURATIVE EMBOLIZATION;
   TRIGEMINAL NEURALGIA; GRADING SCALE; FOLLOW-UP; MULTIMODALITY TREATMENT
AB Brainstem arteriovenous malformations (AVMs) represent similar to 5% of all intracranial AVMs and carry a higher risk of hemorrhage than their supratentorial counterparts. There is a high and near-uniform mortality with initial and recurrent episodes of hemorrhage. Brainstem AVMs may also present symptomatically with focal neurologic deficits or hydrocephalus. Treatment is indicated for ruptured and symptomatic brainstem AVMs, as well as those possessing high-risk angioarchitectural features. Microsurgical resection and stereotactic radiosurgery are ideal therapeutic options when feasible. Embolization is most commonly used as adjunctive treatment before surgery or stereotactic radiosurgical irradiation. Preoperative embolization facilitates microsurgical resection and reduces intraoperative and postoperative hemorrhage rates. Use of embolization preradiosurgically helps to reduce nidal size, transforming a large lesion to a size amenable to radiosurgical intervention, increasing the probability of obliteration, decreasing procedural hemorrhage risk, stabilizing the lesion until radiotherapeutic effect achieves obliteration, and providing interval symptomatic resolution. Embolization may also be used effectively as stand-alone monotherapy for small lesions with 1 or 2 arterial feeders not supplying eloquent parenchyma. Although an extensive evidence base exists for clinical usefulness of stereotactic radiosurgery as monotherapy or in combination with other therapeutic modalities, only a few studies have reported specifically on obliteration and complication rates with monotherapeutic embolization in the treatment of brainstem AVMs. The potential role of embolization as monotherapy for brainstem AVMs is reviewed and discussed.
C1 [Ghali, George Zaki] US EPA, Arlington, VA USA.
   [Ghali, George Zaki] Purdue Univ, Dept Toxicol, W Lafayette, IN 47907 USA.
   [Ghali, Michael George Zaki] Houston Methodist Hosp, Dept Neurol Surg, Houston, TX 77030 USA.
   [Ghali, Michael George Zaki] Baylor Coll Med, Dept Neurol Surg, Houston, TX 77030 USA.
   [Ghali, Emil Zaki] Inova Alexandria Hosp, Dept Med, Alexandria, VA USA.
   [Ghali, Emil Zaki] EI Gomhoureya Gen Hosp, Dept Urol Surg, Alexandria, Egypt.
RP Ghali, MGZ (reprint author), Houston Methodist Hosp, Dept Neurol Surg, Houston, TX 77030 USA.; Ghali, MGZ (reprint author), Baylor Coll Med, Dept Neurol Surg, Houston, TX 77030 USA.
EM mgzghali@gmail.com
CR Akakin A, 2010, NEUROSURGERY, V66, P121, DOI 10.1227/01.NEU.0000363154.88768.34
   Alexander E 3rd, 1992, Clin Neurosurg, V39, P273
   Altschul D, 2014, CHILD NERV SYST, V30, P1099, DOI 10.1007/s00381-014-2404-9
   Andrade-Souza YM, 2008, ACTA NEUROCHIR, V150, P161, DOI 10.1007/s00701-007-1482-9
   Andrade-Souza YM, 2005, NEUROSURGERY, V56, P56, DOI 10.1227/01.NEU.0000145797.35968.ED
   ApSimon HT, 2002, STROKE, V33, P2794, DOI 10.1161/01.STR.0000043674.99741.9B
   Arnaout OM, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0914
   Baharvahdat H, 2014, AM J NEURORADIOL, V35, P978, DOI 10.3174/ajnr.A3906
   BATJER H, 1986, NEUROSURG REV, V9, P287, DOI 10.1007/BF01743635
   Bell DL, 2015, AM J NEURORADIOL, V36, P1303, DOI 10.3174/ajnr.A4286
   Bing F, 2012, AM J NEURORADIOL, V33, P320, DOI 10.3174/ajnr.A2943
   Buell TJ, 2014, J CLIN NEUROSCI, V21, P1866, DOI 10.1016/j.jocn.2014.04.010
   Choi HJ, 2012, J KOREAN NEUROSURG S, V52, P534, DOI 10.3340/jkns.2012.52.6.534
   Cohen-Inbar O, 2016, J CLIN NEUROSCI, V24, P30, DOI 10.1016/j.jocn.2015.11.007
   de Castro-Afonso LH, 2016, NEURORADIOLOGY, V58, P585, DOI 10.1007/s00234-016-1666-1
   Deruty R, 1996, ACTA NEUROCHIR, V138, P119, DOI 10.1007/BF01411350
   Deshaies Eric M, 2015, Neurodiagn J, V55, P12
   Ding D, 2013, J NEUROSURG, V118, P958, DOI 10.3171/2013.2.JNS121239
   Dion J E, 1994, Neurosurg Clin N Am, V5, P459
   DRAKE CG, 1986, J NEUROSURG, V64, P1, DOI 10.3171/jns.1986.64.1.0001
   DUMA CM, 1993, ACTA NEUROCHIR, P92
   Dumont TM, 2015, COMPREHENSIVE MANAGE
   Feliciano CE, 2010, P R HEALTH SCI J, V29, P117
   Flickinger JC, 1998, INT J RADIAT ONCOL, V40, P273, DOI 10.1016/S0360-3016(97)00718-9
   FLICKINGER JC, 1992, INT J RADIAT ONCOL, V23, P19, DOI 10.1016/0360-3016(92)90539-T
   Friedman WA, 2011, NEUROL RES, V33, P803, DOI 10.1179/1743132811Y.0000000043
   FULTS D, 1984, NEUROSURGERY, V15, P658, DOI 10.1227/00006123-198411000-00003
   GEORGE B, 1992, ACTA NEUROCHIR, V116, P119, DOI 10.1007/BF01540864
   Gobin YP, 1996, J NEUROSURG, V85, P19, DOI 10.3171/jns.1996.85.1.0019
   Han PP, 2003, J NEUROSURG, V98, P3, DOI 10.3171/jns.2003.98.1.0003
   Han SJ, 2015, J NEUROSURG, V122, P107, DOI 10.3171/2014.8.JNS1483
   Hernesniemi JA, 2008, NEUROSURGERY, V63, P823, DOI 10.1227/01.NEU.0000330401.82582.5E
   HEROS RC, 1990, NEUROSURGERY, V26, P570, DOI 10.1227/00006123-199004000-00003
   HUANG ZS, 1995, CHINESE MED J-PEKING, V108, P413
   Huo XC, 2015, INTERV NEURORADIOL, V21, P80, DOI 10.15274/INR-2014-10090
   Jin HW, 2017, INTERV NEURORADIOL, V23, DOI 10.1177/1591019917711679
   Kano H, 2012, J NEUROSURG, V116, P44, DOI 10.3171/2011.9.JNS11176
   Katsaridis V, 2008, NEURORADIOLOGY, V50, P589, DOI 10.1007/s00234-008-0382-x
   Kelly ME, 2008, J NEUROSURG, V108, P1152, DOI 10.3171/JNS/2008/108/6/1152
   Khaw AV, 2004, STROKE, V35, P660, DOI 10.1161/01.STR.0000117093.59726.F9
   Koga T, 2011, NEUROSURGERY, V69, P45, DOI 10.1227/NEU.0b013e31821421d1
   Kondziolka D, 1993, Neurosurg Clin N Am, V4, P469
   Kurita H, 2000, J NEUROL NEUROSUR PS, V68, P563, DOI 10.1136/jnnp.68.5.563
   Kwon OK, 2000, J CLIN NEUROSCI, V7, P69, DOI 10.1054/jocn.2000.0715
   LAWTON MT, 1995, NEUROSURGERY, V37, P29, DOI 10.1227/00006123-199507000-00004
   Lee CC, 2015, J NEUROSURG, V123, P126, DOI 10.3171/2014.12.JNS141437
   Lesley WS, 2009, CEPHALALGIA, V29, P980, DOI 10.1111/j.1468-2982.2008.01828.x
   Liu HM, 2003, NEURORADIOLOGY, V45, P644, DOI 10.1007/s00234-003-1055-4
   Liu J, 2014, INTERV NEURORADIOL, V20, P722, DOI 10.15274/INR-2014-10063
   Lv XL, 2012, NEURORADIOLOGY, V54, P349, DOI 10.1007/s00234-011-0880-0
   Lv XL, 2011, WORLD NEUROSURG, V76, P95, DOI 10.1016/j.wneu.2011.01.044
   Mamalui-Hunter M, 2011, J NEUROSURG, V115, P364, DOI 10.3171/2011.3.JNS10717
   Maruyama K, 2004, J NEUROSURG, V100, P407, DOI 10.3171/jns.2004.100.3.0407
   Massager N, 2000, J NEUROSURG, V93, P102, DOI 10.3171/jns.2000.93.supplement_3.0102
   Mast H, 1997, LANCET, V350, P1065, DOI 10.1016/S0140-6736(97)05390-7
   MATSUMURA H, 1977, J NEUROSURG, V47, P50, DOI 10.3171/jns.1977.47.1.0050
   MCCORMIC.WF, 1968, J NEUROSURG, V28, P241, DOI 10.3171/jns.1968.28.3.0241
   Meisel HJ, 2002, ACTA NEUROCHIR, V144, P879, DOI 10.1007/s00701-002-0978-6
   Miyamoto S, 2000, NEUROSURGERY, V46, P589, DOI 10.1097/00006123-200003000-00013
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   MONACO RG, 1990, NEURORADIOLOGY, V31, P471, DOI 10.1007/BF00340124
   Nozaki K, 2006, NEUROSURGERY, V58, P270
   O'Shaughnessy Brian A, 2005, Neurosurg Focus, V19, pE5
   Oermann EK, 2015, NEUROSURGERY, V77, P406, DOI 10.1227/NEU.0000000000000772
   Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458
   ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387
   Ovalle F, 2012, NEUROSURGERY, V70, P313, DOI 10.1227/NEU.0b013e3182357df3
   Pollock BE, 1998, NEUROSURGERY, V42, P1239, DOI 10.1097/00006123-199806000-00020
   Pollock BE, 2004, J NEUROSURG, V101, P390, DOI 10.3171/jns.2004.101.3.0390
   Pollock BE, 2004, J NEUROSURG, V100, P210, DOI 10.3171/jns.2004.100.2.0210
   Pollock BE, 2002, J NEUROSURG, V96, P79, DOI 10.3171/jns.2002.96.1.0079
   Pollock BE, 2013, PROG NEUROL SURG, V27, P58, DOI 10.1159/000341620
   PRIBIL S, 1983, SURG NEUROL, V20, P487, DOI 10.1016/0090-3019(83)90032-0
   Saatci I, 2011, J NEUROSURG, V115, P78, DOI 10.3171/2011.2.JNS09830
   Sackey FNA, 2017, CUREUS, V9, DOI 10.7759/cureus.1266
   SANG H, 1983, NEUROSURGERY, V12, P572, DOI 10.1227/00006123-198305000-00018
   Schmidt NO, 2011, ACTA NEUROCHIR SUPPL, V112, P131, DOI 10.1007/978-3-7091-0661-7_23
   Simon SD, 2009, CENT EUR NEUROSURG, V70, P161, DOI 10.1055/s-0029-1215567
   SOLOMON RA, 1986, J NEUROSURG, V64, P857, DOI 10.3171/jns.1986.64.6.0857
   SPETZLER RF, 1992, J NEUROSURG, V76, P918, DOI 10.3171/jns.1992.76.6.0918
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Spetzler RF, 2011, J NEUROSURG, V114, P842, DOI 10.3171/2010.8.JNS10663
   STAHL SM, 1980, ARCH NEUROL-CHICAGO, V37, P25, DOI 10.1001/archneur.1980.00500500055007
   Stapf C, 2006, NEUROLOGY, V66, P1350, DOI 10.1212/01.wnl.0000210524.68507.87
   Starke RM, 2013, J NEUROSURG, V119, P981, DOI 10.3171/2013.5.JNS1311
   Stefani MA, 2002, STROKE, V33, P920, DOI 10.1161/01.STR.0000014582.03429.F7
   Stefani MA, 2002, STROKE, V33, P1220, DOI 10.1161/01.STR.0000013738.53113.33
   Tawk RG, 2011, WORLD NEUROSURG, V76, P276, DOI 10.1016/j.wneu.2011.02.037
   Thines L, 2012, NEUROSURGERY, V70, P155, DOI 10.1227/NEU.0b013e31822670ac
   Valavanis A, 1998, ADV TECH STAND NEUR, V24, P131
   van Rooij WJ, 2012, AM J NEURORADIOL, V33, P1299, DOI 10.3174/ajnr.A2947
   Wankel I, 2005, ZBL NEUROCHIR, V66, P213, DOI 10.1055/s-2005-836601
   Westphal M, 2000, J NEUROSURG, V92, P995, DOI 10.3171/jns.2000.92.6.0995
   Wikholm G, 1996, NEUROSURGERY, V39, P448, DOI 10.1097/00006123-199609000-00004
   YAMAMOTO Y, 1995, J NEUROSURG, V83, P832, DOI 10.3171/jns.1995.83.5.0832
   Yang WY, 2016, WORLD NEUROSURG, V94, P64, DOI 10.1016/j.wneu.2016.06.082
   Yen CP, 2011, WORLD NEUROSURG, V76, P87, DOI 10.1016/j.wneu.2011.02.003
   Zacharia BE, 2012, CURR ATHEROSCLER REP, V14, P335, DOI 10.1007/s11883-012-0257-9
   2006, NEUROSURGERY, V58, P17, DOI DOI 10.1227/01.NEU.0000190653.42970.6B
   2006, NEUROSURGERY, V58, P270
   2011, NEUROSURGERY, V69, P45, DOI DOI 10.1227/NEU.0B013E31821421D1
   2011, WORLD NEUROSURG, V76, P87, DOI DOI 10.1016/J.WNEU.2011.02.003
   2005, NEUROSURGERY, V56, P56, DOI DOI 10.1227/01.NEU.0000145797.35968.ED
NR 103
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 481
EP 488
DI 10.1016/j.wneu.2018.08.099
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700241
PM 30149173
DA 2020-05-12
ER

PT J
AU Chen, CW
   Li, X
   Huang, LF
   Zhang, JR
   Chen, SH
   Ye, H
   Ye, Q
   Zhang, TH
   Zhang, X
   Chen, ZP
   Yang, C
   Liang, XL
AF Chen, Chengwei
   Li, Xu
   Huang, Lifa
   Zhang, Jingru
   Chen, Suihong
   Ye, Hui
   Ye, Qiang
   Zhang, Tiehui
   Zhang, Xin
   Chen, Zupeng
   Yang, Chao
   Liang, Xiaolong
TI Mechanical Thrombectomy with Intraoperative Local Thrombolysis Versus
   Mechanical Thrombectomy with Continuous Thrombolysis for Treatment of
   Cerebral Venous Sinus Thrombosis: A Systematic Review of 82 Cases
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebral venous sinus thrombosis; Continuous thrombolysis; Local
   thrombolysis; Mechanical thrombectomy; Systematic review
ID TISSUE-PLASMINOGEN-ACTIVATOR; SUPERIOR SAGITTAL SINUS; ENDOVASCULAR
   TREATMENT; RHEOLYTIC THROMBECTOMY; PENUMBRA SYSTEM; CATHETER; INFUSION;
   UROKINASE; OCCLUSION; HEPARIN
AB OBJECTIVE: The first-line treatment of cerebral venous sinus thrombosis (CVST) is systemic anticoagulation. However, patients with severe or a clinically worsening condition might benefit from mechanical thrombectomy (MT) combined with intraoperative thrombolysis (IOT) or MT with continuous thrombolytic infusion (CTI). The present study compared the efficacy and safety of these 2 endovascular therapeutic methods by performing a systematic review of the literature.
   METHODS: The present systematic review was conducted to identify all cases of CVST treated with MT+IOT or MT+CTI/MT+IOT+CTI reported in PubMed and Ovid. The recanalization rates, outcomes, operation-related complications, sequelae, and postoperative hemorrhage rates were evaluated.
   RESULTS: A total of 28 studies, including 82 patients, met the inclusion criteria. Alone, MT+IOT was performed in 42 patients (51%), and MT+CTI/MT+IOT+CTI was performed in 40 patients (49%). Overall, outcomes data were available for 69 patients, of whom 57 (82%) had had a good outcome and 12 (18%) had had a poor outcome or had died. Recanalization data were available for 68 patients. Of these patients, 28 (41%) had had complete recanalization, 40 (59%) had had partial, and no patient had had no recanalization. Operation-related complications occurred in 5 patients (6%), and 3 patients (4%) developed postoperative intracerebral hemorrhage. However, no significant differences were found in the recanalization rate or prognosis between the MT+IOT and MT+CTI/MT+IOTDCTI groups.
   CONCLUSIONS: The results from our review suggest that MT with local thrombolysis is relatively safe, with no significant differences in efficacy and safety between MT+IOT alone and MT+CTI/MT+IOT+CTI. However, randomized controlled studies are required to provide a definitive answer on its use for CVST.
C1 [Chen, Chengwei; Li, Xu; Huang, Lifa; Ye, Hui; Ye, Qiang; Zhang, Tiehui; Zhang, Xin; Chen, Zupeng; Yang, Chao; Liang, Xiaolong] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Chinese Med Hosp Zhejiang Prov, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Jingru] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Chinese Med Hosp Zhejiang Prov, Dept Rheumatol, Hangzhou, Zhejiang, Peoples R China.
   [Chen, Suihong] Longgang Dist Peoples Hosp Shenzhen, Shenzhen, Guangdong, Peoples R China.
RP Chen, CW (reprint author), Zhejiang Chinese Med Univ, Affiliated Hosp 1, Chinese Med Hosp Zhejiang Prov, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
EM edison99x@163.com
CR Adachi H, 2015, INTERV NEURORADIOL, V21, P719, DOI 10.1177/1591019915609120
   Akins Paul T, 2013, Surg Neurol Int, V4, P85, DOI 10.4103/2152-7806.113651
   Baker MD, 2001, NEUROSURGERY, V48, P487, DOI 10.1097/00006123-200103000-00005
   Blackham KA, 2011, J NEUROSURG, V114, P133, DOI 10.3171/2010.2.JNS091186
   Canhao P, 2003, CEREBROVASC DIS, V15, P159, DOI 10.1159/000068833
   CHOI EJ, 2014, BMJ CASE REP, V14, pNIL_
   Chow K, 2000, STROKE, V31, P1420, DOI 10.1161/01.STR.31.6.1420
   Coutinho JM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0299-0
   Coutinho JM, 2011, CEREBROVASC DIS, V32, P298, DOI 10.1159/000330646
   Curtin KR, 2004, AM J NEURORADIOL, V25, P1807
   Dowd CF, 1999, AM J NEURORADIOL, V20, P568
   Ekseth K, 1998, NEUROSURGERY, V43, P960, DOI 10.1097/00006123-199810000-00144
   El Tecle NE, 2015, J CLIN NEUROSCI, V22, P1018, DOI 10.1016/j.jocn.2014.12.023
   FRERICHS KU, 1994, J CEREBR BLOOD F MET, V14, P289, DOI 10.1038/jcbfm.1994.36
   FRIES G, 1992, J NEUROSURG, V77, P127, DOI 10.3171/jns.1992.77.1.0127
   Froehler MT, 2012, BMJ CASE REP, V2012
   Ilyas A, 2017, J NEUROINTERV SURG, V9, P1086, DOI 10.1136/neurintsurg-2016-012938
   Jankowitz BT, 2013, J NEUROINTERV SURG, V5, P534, DOI 10.1136/neurintsurg-2012-010476
   Khan SNH, 2009, CLIN MED RES, V7, P157, DOI 10.3121/cmr.2009.847
   Kulcsar Z, 2010, ACTA NEUROCHIR, V152, P911, DOI 10.1007/s00701-009-0570-4
   Kulkarni GB, 2017, J THROMB THROMBOLYS, V44, P247, DOI 10.1007/s11239-017-1518-9
   La Barge DV, 2009, AM J NEURORADIOL, V30, P1672, DOI 10.3174/ajnr.A1677
   Li GW, 2013, NEUROSURGERY, V72, P730, DOI 10.1227/NEU.0b013e318285c1d3
   Liao WH, 2015, NEURORADIOL J, V28, P177, DOI 10.1177/1971400915576633
   Lindvall P, 2013, CASE REP NEUROL, V5, P168, DOI 10.1159/000355394
   Mortimer AM, 2013, PEDIATR NEUROL, V49, P305, DOI 10.1016/j.pediatrneurol.2013.07.008
   Nakase H, 1996, J CEREBR BLOOD F MET, V16, P720, DOI 10.1097/00004647-199607000-00024
   Nimjee SM, 2011, J NEUROINTERV SURG, V3, P30, DOI 10.1136/jnis.2010.002469
   Pan SY, 2015, CLIN NEURORADIOL, V25, P305, DOI 10.1007/s00062-014-0338-y
   Poulsen FR, 2013, DAN MED J, V60
   Qiu ZM, 2015, J THROMB THROMBOLYS, V40, P353, DOI 10.1007/s11239-015-1205-7
   Qureshi AI, 2018, NEUROCRIT CARE, V29, P54, DOI 10.1007/s12028-018-0502-3
   Rahman M, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.7.FOCUS09146
   Rammos SK, 2013, J NEUROSURG-PEDIATR, V11, P140, DOI 10.3171/2012.11.PEDS12176
   Raychev R, 2013, BMJ CASE REP, V2013, P1
   Saadatnia M, 2009, INT J STROKE, V4, P111, DOI 10.1111/j.1747-4949.2009.00260.x
   Siddiqui FM, 2012, INTERV NEURORADIOL, V18, P314, DOI 10.1177/159101991201800311
   Sidhu M, 2013, BMJ CASE REP, V2013
   Stam J, 2008, STROKE, V39, P1487, DOI 10.1161/STROKEAHA.107.502658
   Summers Shane M, 2011, J Emerg Med, V41, pe95, DOI 10.1016/j.jemermed.2008.11.023
   Tsai FY, 2007, CARDIOVASC INTER RAD, V30, P675, DOI 10.1007/s00270-007-9046-1
   Wasay M, 2001, STROKE, V32, P2310, DOI 10.1161/hs1001.096192
   Yue XY, 2010, J THROMB THROMBOLYS, V29, P361, DOI 10.1007/s11239-009-0386-3
   ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977
   Zhang A, 2008, NEUROCRIT CARE, V9, P17, DOI 10.1007/s12028-008-9058-y
   2017, INTERV NEURORADIOL, V23, P84, DOI DOI 10.1177/1591019916674917
   2001, NEUROSURGERY, V48, P487
NR 47
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 489
EP +
DI 10.1016/j.wneu.2018.12.193
PG 23
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700242
PM 30659973
DA 2020-05-12
ER

PT J
AU Rijs, K
   Klimek, M
   Scheltens-de Boer, M
   Biesheuvel, K
   Harhangi, BS
AF Rijs, Koen
   Klimek, Markus
   Scheltens-de Boer, Marjan
   Biesheuvel, Karla
   Harhangi, Biswadjiet S.
TI Intraoperative Neuromonitoring in Patients with Intramedullary Spinal
   Cord Tumor: A Systematic Review, Meta-Analysis, and Case Series
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intramedullary tumor; Neurologic function; Neuromonitoring;
   Neurosurgery; Spinal cord
ID MOTOR-EVOKED-POTENTIALS; MUSCLE MOTOR; SURGERY; RESECTION; OUTCOMES
AB BACKGROUND: Intramedullary spinal cord tumors (IMSCT) comprise the least common types of spinal neoplasms; surgery is mostly conducted with intraoperative neuromonitoring (IONM). However, although IONM is widely used to prevent neurologic damage and many single-center studies have been reported, the added value, in terms of overall sensitivity and specificity, of different monitoring techniques used in IMSCT surgery remains to be clearly defined.
   OBJECTIVE: To summarize and review the reported evidence on the use of IONM in IMSCT surgery, including our own case series (n = 75 patients).
   METHODS: We systematically searched the literature published from January 2000 to February 2018. Articles included patients with IMSCT who underwent surgery with neuromonitoring. We estimated the sensitivity, specificity, 95% confidence interval (CI), positive likelihood ratio, and negative likelihood ratio.
   RESULTS: Of 1385 eligible articles, 31 were included in the systematic review. Fifteen of these articles were used for a meta-analysis, complemented with our own case series. All neuromonitoring modalities showed acceptable but not optimal test characteristics. For the indications used in the different studies, the motor evoked potentials approach showed the highest sensitivity (0.838; 95% CI, 0.703-0.919) and the best specificity (0.829; 95% CI, 0.668-0.921) for detecting neuronal injury. In our own case series, the extent of resection was significantly smaller in the false-positive group than in the true-negative group (P = 0.045).
   CONCLUSIONS: IONM showed high but not perfect sensitivity and specificity. IONM prevents neurologic damage but can also limit the extent of tumor resection. Prospective studies will have to define the definitive value of IONM.
C1 [Rijs, Koen; Klimek, Markus] Erasmus Univ, Med Ctr, Dept Anesthesiol, Rotterdam, Netherlands.
   [Scheltens-de Boer, Marjan; Biesheuvel, Karla] Erasmus Univ, Med Ctr, Dept Clin Neurophysiol, Rotterdam, Netherlands.
   [Harhangi, Biswadjiet S.] Erasmus Univ, Med Ctr, Dept Neurosurg, Rotterdam, Netherlands.
RP Harhangi, BS (reprint author), Erasmus Univ, Med Ctr, Dept Neurosurg, Rotterdam, Netherlands.
EM b.s.harhangi@erasmusmc.nl
OI Klimek, Markus/0000-0002-0122-9929
CR Ahn H, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E15
   Alkhani A, 2008, ANN SAUDI MED, V28, P109
   Ando M, 2015, CLIN NEUROL NEUROSUR, V133, P18, DOI 10.1016/j.clineuro.2015.03.004
   Azad TD, 2018, CLIN SPINE SURG, V31, P112, DOI [10.1097/BSD.0000000000000628, 10.1097/BSD.0000000000000558]
   Bakhshi Saqib K, 2016, Surg Neurol Int, V7, pS617, DOI 10.4103/2152-7806.189733
   Bostrom Azize, 2014, BMC Res Notes, V7, P908, DOI 10.1186/1756-0500-7-908
   Chang SH, 2016, ANN REHABIL MED-ARM, V40, P470, DOI 10.5535/arm.2016.40.3.470
   Cheng JS, 2014, J NEUROSURG-PEDIATR, V13, P591, DOI 10.3171/2014.2.PEDS1392
   Choi I, 2014, YONSEI MED J, V55, P1063, DOI 10.3349/ymj.2014.55.4.1063
   Costa P, 2013, EUR SPINE J, V22, P840, DOI 10.1007/s00586-012-2576-5
   Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016
   Duong LM, 2012, CANCER-AM CANCER SOC, V118, P4220, DOI 10.1002/cncr.27390
   Eiselsberg AS, 1910, WIEN MED WOCHENSCHR, V11, P648
   Forster MT, 2012, SPINE, V37, pE1001, DOI 10.1097/BRS.0b013e31824c76a8
   Garces-Ambrossi GL, 2009, J NEUROSURG-SPINE, V11, P591, DOI 10.3171/2009.4.SPINE08159
   Grimm S, 2009, EXPERT REV NEUROTHER, V9, P1487, DOI 10.1586/ERN.09.101
   Hsu W, 2010, CHILD NERV SYST, V26, P241, DOI 10.1007/s00381-009-1022-4
   Hyun SJ, 2009, BRIT J NEUROSURG, V23, P393, DOI 10.1080/02688690902964744
   Imagama S, 2017, GLOB SPINE J, V7, P6, DOI 10.1055/s-0036-1580612
   Jin SH, 2015, ACTA NEUROCHIR, V157, P2149, DOI 10.1007/s00701-015-2598-y
   Kim DG, 2016, J CLIN NEUROPHYSIOL, V33, P120, DOI 10.1097/WNP.0000000000000247
   Kobayashi S, 2014, J NEUROSURG-SPINE, V20, P102, DOI 10.3171/2013.10.SPINE12944
   Kothbauer KF, 2007, NEUROPHYSIOL CLIN, V37, P407, DOI 10.1016/j.neucli.2007.10.003
   Krassioukov AV, 2004, J NEUROSURG-SPINE, V1, P243, DOI 10.3171/spi.2004.1.3.0243
   Lakomkin N, 2018, SPINE, V43, P287, DOI 10.1097/BRS.0000000000002300
   Li TY, 2014, J NEUROSURG-SPINE, V21, P249, DOI 10.3171/2014.3.SPINE13481
   Matsuyama Y, 2009, J NEUROSURG-SPINE, V10, P404, DOI 10.3171/2009.2.SPINE08698
   Mehta AI, 2012, J SPINAL DISORD TECH, V25, P205, DOI 10.1097/BSD.0b013e318215953f
   Miller DC, 2000, J NEURO-ONCOL, V47, P189, DOI 10.1023/A:1006496204396
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Morota N, 1997, NEUROSURGERY, V41, P1327, DOI 10.1097/00006123-199712000-00017
   Muramoto A, 2014, SPINE, V39, pE1086, DOI 10.1097/BRS.0000000000000421
   Quinones-Hinojosa A, 2005, NEUROSURGERY, V56, P982, DOI 10.1277/01.NEU.0000158203.29369.37
   Rajshekhar V, 2011, J NEUROSURG-SPINE, V14, P748, DOI 10.3171/2011.1.SPINE10310
   Reitsma JB, 2005, J CLIN EPIDEMIOL, V58, P982, DOI 10.1016/j.jclinepi.2005.02.022
   Sandalcioglu IE, 2005, SPINAL CORD, V43, P34, DOI 10.1038/sj.sc.3101668
   Skinner Stanley A, 2005, Neurosurgery, V56, P299
   Sutter M, 2007, EUR SPINE J, V16, pS197
   TAMAKI T, 1975, ELECTROEN CLIN NEURO, V39, P539
   Tiruchelvarayan R, 2013, PROC SINGAP HEALTHC, V22, P183, DOI 10.1177/201010581302200305
   Velayutham P, 2016, WORLD NEUROSURG, V92, P264, DOI 10.1016/j.wneu.2016.04.117
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Wiedemayer H, 2002, J NEUROSURG, V96, P255, DOI 10.3171/jns.2002.96.2.0255
   Zielinski P, 2013, NEUROL NEUROCHIR POL, V47, P27, DOI 10.5114/ninp.2013.32937
   2006, NEUROSURGERY, V58, P1129, DOI DOI 10.1227/01.NEU.0000215948.97195.58
NR 45
TC 2
Z9 2
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 498
EP +
DI 10.1016/j.wneu.2019.01.007
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700243
PM 30659972
OA Other Gold
DA 2020-05-12
ER

PT J
AU Dodson, V
   Majmundar, N
   El-Ghanem, M
   Amuluru, K
   Gupta, G
   Nuoman, R
   Wainwright, J
   Kaur, G
   Cole, C
   Santarelli, J
   Chandy, D
   Bowers, C
   Gandhi, C
   Al-Mufti, F
AF Dodson, Vincent
   Majmundar, Neil
   El-Ghanem, Mohammad
   Amuluru, Krishna
   Gupta, Gaurav
   Nuoman, Rolla
   Wainwright, John
   Kaur, Gurmeen
   Cole, Chad
   Santarelli, Justin
   Chandy, Dipak
   Bowers, Christian
   Gandhi, Chirag
   Al-Mufti, Fawaz
TI Intracranial Administration of Nicardipine After Aneurysmal Subarachnoid
   Hemorrhage: A Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Intrathecal; Intraventricular; Nicardipine; Prolonged-release
   implant; Subarachnoid hemorrhage; Vasospasm
ID PROLONGED-RELEASE IMPLANTS; CEREBRAL VASOSPASM; INTRAVENTRICULAR
   NICARDIPINE; NIMODIPINE; ISCHEMIA
AB BACKGROUND: Intrathecal (IT), intraventricular (IVt), and intracisternal administration of nicardipine deliver treatment directly into the central nervous system. This route of drug delivery is being investigated as a potential treatment of vasospasm following aneurysmal subarachnoid hemorrhage (aSAH).
   OBJECTIVE: The authors reviewed the existing literature regarding the direct administration of nicardipine into the intracranial space for the treatment of vasospasm following aSAH.
   METHODS: An electronic search of literature published between 1994 and 2018 was performed using PubMed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. A variety of combinations of the search terms "intrathecal nicardipine," "intraventricular nicardipine," and "nicardipine prolonged-release" were used.
   RESULTS: A total of 17 studies were included in this systematic review, 3 of which were studies in animals. The studies consistently demonstrated that IT nicardipine successfully reverses vasospasm, but the effect, as shown in some studies, was limited to the immediate vicinity of drug release. The data regarding long-term clinical outcomes are variable, with some studies demonstrating marked improvement whereas others fail to demonstrate improved outcomes when compared with patients who receive standard of care. Although adverse sequalae were uncommon, IT and IVt administration and therapy were associated with adverse effects including headache, meningitis, and hydrocephalus.
   CONCLUSIONS: Given the findings presented in these studies, IT, IVt, and intracisternal (pellet) nicardipine administration can be useful treatment adjuncts for vasospasm following aSAH, especially in cases refractory to conventional forms of treatment. However, larger, controlled clinical trials are warranted.
C1 [Dodson, Vincent; Majmundar, Neil] Rutgers State Univ, New Jersey Med Sch, Dept Neurosurg, Newark, NJ USA.
   [Nuoman, Rolla] Rutgers State Univ, New Jersey Med Sch, Dept Neurol, Newark, NJ USA.
   [El-Ghanem, Mohammad] Univ Arizona, Coll Med, Dept Neurol & Med Imaging, Tucson, AZ USA.
   [Amuluru, Krishna] Univ Pittsburgh, Dept Neurointervent Radiol, Erie, PA USA.
   [Gupta, Gaurav; Al-Mufti, Fawaz] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Neurol Neurosurg & Radiol, New Brunswick, NJ 08901 USA.
   [Wainwright, John; Kaur, Gurmeen; Cole, Chad; Santarelli, Justin; Chandy, Dipak; Bowers, Christian; Gandhi, Chirag; Al-Mufti, Fawaz] New York Med Coll, Dept Neurol & Neurosurg, Westchester Med Ctr, Valhalla, NY 10595 USA.
RP Al-Mufti, F (reprint author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Neurol Neurosurg & Radiol, New Brunswick, NJ 08901 USA.; Al-Mufti, F (reprint author), New York Med Coll, Dept Neurol & Neurosurg, Westchester Med Ctr, Valhalla, NY 10595 USA.
EM fawaz.al-mufti@wmchealth.org
RI Gupta, Gaurav/AAL-3349-2020; Majmundar, Neil/AAH-9695-2020
OI Gupta, Gaurav/0000-0002-9442-6007; Majmundar, Neil/0000-0001-5910-6094;
   Wainwright, John/0000-0001-8269-8569
CR Al-Tamimi YZ, 2010, WORLD NEUROSURG, V73, P654, DOI 10.1016/j.wneu.2010.02.005
   Asano T, 1999, CRIT REV NEUROSURG, V9, P303, DOI 10.1007/s003290050147
   Barth M, 2007, STROKE, V38, P330, DOI 10.1161/01.STR.0000254601.74596.0f
   Barth M, 2011, BRIT J NEUROSURG, V25, P677, DOI 10.3109/02688697.2010.548878
   Barth M, 2009, J NEUROSURG, V110, P955, DOI 10.3171/2008.2.17670
   Dorhout Mees SM, 2007, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000277.PUB3
   Dorsch N, 2011, ACTA NEUROCHIR SUPPL, V110, P5, DOI 10.1007/978-3-7091-0353-1_1
   Dorsch Nicholas W C, 2002, Curr Opin Crit Care, V8, P128
   Ehtisham A, 2009, SOUTH MED J, V102, P150, DOI 10.1097/SMJ.0b013e31818f8ba4
   Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700
   Fujiwara K, 2001, NEUROL SURG TOKYO, V29, P23
   Goodson K, 2008, NEUROCRIT CARE, V8, P247, DOI 10.1007/s12028-007-9017-z
   Hanggi D, 2019, NEUROCRIT CARE, V30, P88, DOI 10.1007/s12028-018-0575-z
   JUVELA S, 1990, STROKE, V21, P1283, DOI 10.1161/01.STR.21.9.1283
   KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562
   Kawashima A, 1998, NEUROL SURG TOKYO, V26, P37
   Kawashima A, 2000, NEUROL RES, V22, P634
   Ko SB, 2016, CLIN NEUROL NEUROSUR, V144, P48, DOI 10.1016/j.clineuro.2016.02.037
   Krischek B, 2007, NEUROL MED-CHIR, V47, P389, DOI 10.2176/nmc.47.389
   Liu-DeRyke X, 2006, PHARMACOTHERAPY, V26, P182, DOI 10.1592/phco.26.2.182
   Lu N, 2012, NEUROCRIT CARE, V16, P368, DOI 10.1007/s12028-011-9659-8
   Mayberg MR, 1998, NEUROSURG CLIN N AM, V9, P615
   PETRUK KC, 1988, J NEUROSURG, V68, P505, DOI 10.3171/jns.1988.68.4.0505
   Schneider UC, 2011, ACTA NEUROCHIR, V153, P2119, DOI 10.1007/s00701-011-1129-8
   SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055
   SHIBUYA M, 1994, ACTA NEUROCHIR, V131, P19, DOI 10.1007/BF01401450
   Shibuya M, 1994, J Clin Neurosci, V1, P58, DOI 10.1016/0967-5868(94)90012-4
   Suzuki M, 2001, NEUROSURG REV, V24, P180, DOI 10.1007/s101430100152
   Washington CW, 2011, NEUROCRIT CARE, V15, P312, DOI 10.1007/s12028-011-9594-8
   Webb A, 2010, NEUROCRIT CARE, V12, P159, DOI 10.1007/s12028-009-9307-8
   WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173
   2005, NEUROSURGERY, V56, P895
   2007, NEUROL MED CHIR TOKY, V47, P389
   2015, TRANSL STROKE RES, V6, P167, DOI DOI 10.1007/S12975-015-0398-6
NR 34
TC 2
Z9 2
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 511
EP +
DI 10.1016/j.wneu.2019.01.103
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700244
PM 30708083
DA 2020-05-12
ER

PT J
AU Priola, SM
   Moghaddamjou, A
   Ku, JC
   Taslimi, S
   Yang, VXD
AF Priola, Stefano Maria
   Moghaddamjou, Ali
   Ku, Jerry C.
   Taslimi, Shervin
   Yang, Victor X. D.
TI Acupuncture-Induced Cranial Epidural Abscess: Case Report and Review of
   the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Acupuncture; Brain abscess; Immunosuppression; Streptococcus anginosus;
   Surgical evacuation
ID SPINAL INFECTION; SUBDURAL EMPYEMA; ADVERSE EVENTS; CHRONIC PAIN;
   SPONDYLODISCITIS; BONE
AB BACKGROUND: Acupuncture is a common form of alternative medicine that is used for pain control among other modalities of treatment. It is a relatively safe procedure, but complications, including those of infectious etiology, may still occur.
   CASE DESCRIPTION: A 47-year-old immunosuppressed woman presented with fever, altered level of consciousness, dysphasia, and a left occipital subgaleal fluctuant mass after acupuncture for headaches in the same area. Imaging demonstrated subgaleal and epidural collection localized in the left occipital region. She underwent urgent surgical evacuation of both collections. Cultures from intraoperative specimens grew Streptococcus anginosus. The patient started targeted antibiotic treatment leading to complete recovery.
   CONCLUSIONS: To our knowledge, this is the first report of intracranial abscess after acupuncture. Given the worldwide application of this alternative treatment, physicians, acupuncturists, and the general public should be aware of the possibility of this rare but serious complication.
C1 [Priola, Stefano Maria; Moghaddamjou, Ali; Ku, Jerry C.; Taslimi, Shervin; Yang, Victor X. D.] Univ Toronto, Div Neurosurg, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
RP Priola, SM (reprint author), Univ Toronto, Div Neurosurg, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
EM stefanopriola@gmail.com
RI Priola, Stefano Maria/O-3077-2019
OI Priola, Stefano Maria/0000-0002-5153-6230
CR Agrawal A, 2007, INFECT DIS CLIN PRAC, V15, P149, DOI 10.1097/01.idc.0000269905.67284.c7
   Bang MS, 2006, SPINAL CORD, V44, P258, DOI 10.1038/sj.sc.3101819
   Bartt Russell E, 2010, Handb Clin Neurol, V96, P75, DOI 10.1016/S0072-9752(09)96006-7
   Baxter GD, 2008, J ACUPUNCT MERIDIAN, V1, P65, DOI 10.1016/S2005-2901(09)60026-1
   Brett J., 2015, CLEAN NEEDLE TECHNIQ
   Bruce JN, 2003, J NEUROSURG, V98, P1203, DOI 10.3171/jns.2003.98.6.1203
   Callan A. K, 2016, SPINE DEFORM, V4, P156, DOI 10.1016/j.jspd.2015.09.045
   Chan JJ, 2016, INT J EMERG MED, V9, DOI 10.1186/s12245-016-0116-5
   Chen MH, 2004, J CLIN NEUROSCI, V11, P909, DOI 10.1016/j.jocn.2004.02.011
   Chen YSG, 1995, PEOPLES MIL SURG, P4
   Cheng Chaun-Yun, 1997, Kaohsiung Journal of Medical Sciences, V13, P328
   Cupler ZA, 2017, J CHIROPR MED, V16, P246, DOI 10.1016/j.jcm.2017.03.002
   Dlaska CE, 2015, MED J AUSTRALIA, V203, P408, DOI 10.5694/mja15.00727
   Ernst E, 2011, PAIN, V152, P755, DOI 10.1016/j.pain.2010.11.004
   Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8
   Fan GX, 2016, INT J CLIN EXP MED, V9, P16867
   Fierro E, 2018, AM J RESP CRIT CARE, V197
   French H, 2014, OCHSNER J, V14, P188
   Godhania V, 2016, J SURG CASE REP, DOI 10.1093/jscr/rjw035
   HADDEN WA, 1982, J BONE JOINT SURG AM, V64, P624, DOI 10.2106/00004623-198264040-00023
   He CJ, 2015, ACUPUNCT MED, V33, P154, DOI 10.1136/acupmed-2014-010717
   Hoffman P, 2001, Acupunct Med, V19, P112
   Huang Y, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-75
   Jiang F, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00596
   Kim Dong Min, 2017, Korean J Spine, V14, P20, DOI 10.14245/kjs.2017.14.1.20
   Kim YJ, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e164
   Lee JH, 2012, COMPLEMENT THER MED, V20, P228, DOI 10.1016/j.ctim.2012.02.009
   Lee JC, 2013, PLAST RECONSTR SURG, V132, P967, DOI 10.1097/PRS.0b013e31829f4b59
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Liu HL, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-216
   Lubana SS, 2015, CASE REP MED, DOI 10.1155/2015/524241
   Mayrink WC, 2018, J ACUPUNCT MERIDIAN, V11, P296, DOI [10.1016/j.jams.2018.07.003, 10.1016/j.jams.2018.01.004]
   McCarney RW, 2004, RESP MED, V98, P687, DOI 10.1016/j.rmed.2004.05.005
   Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F
   Mukaino Yoshito, 2005, Acupunct Med, V23, P70
   Robinson A, 2016, ACUPUNCT MED, V34, P149, DOI 10.1136/acupmed-2015-212110rep
   Simmons Roger, 2006, Acupunct Med, V24, P37
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wang HY, 2018, AM J CHINESE MED, V46, P1387, DOI 10.1142/S0192415X18500738
   White Adrian, 2006, Acupunct Med, V24, P149
   White Adrian, 2004, Acupunct Med, V22, P122
   WorldHealthOrganization (WHO), 1999, GUID BAS TRAIN SAF A
   Wu CT, 2009, EUR J PEDIATR, V168, P1147, DOI 10.1007/s00431-008-0892-x
   Xu C., 1990, NEI MONG J TRAD CHIN, P1
   Xu L, 2018, MEDICINE, V97
   Xu S, 2013, EVID-BASED COMPL ALT, V2013
   Yamashita H, 2001, COMPLEMENT THER MED, V9, P98, DOI 10.1054/ctim.2001.0446
   Yang CW, 2014, INTERNAL MED, V53, P1665, DOI 10.2169/internalmedicine.53.1620
   Yao YD, 2016, COMPLEMENT THER MED, V24, P108, DOI 10.1016/j.ctim.2015.12.002
   Yazawa S, 1998, INTERNAL MED, V37, P161, DOI 10.2169/internalmedicine.37.161
   Yu HJ, 2013, NEUROLOGY, V80, pE169, DOI 10.1212/WNL.0b013e31828c2f1d
   Zhang JH, 2010, B WORLD HEALTH ORGAN, V88, P915, DOI 10.2471/BLT.10.076737
   Zhang YP, 2018, CURR MED SCI, V38, P491, DOI 10.1007/s11596-018-1905-2
NR 53
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 519
EP +
DI 10.1016/j.wneu.2019.01.189
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700245
PM 30743042
DA 2020-05-12
ER

PT J
AU Ahn, Y
   Keum, HJ
   Lee, SG
   Lee, SW
AF Ahn, Yong
   Keum, Han Joong
   Lee, Sang-Gu
   Lee, Sheen-Woo
TI Transforaminal Endoscopic Decompression for Lumbar Lateral Recess
   Stenosis: An Advanced Surgical Technique and Clinical Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopy; Lateral recess stenosis; Lumbar; Percutaneous; Transforaminal
   endoscopic decompression
ID SPINAL-CANAL STENOSIS; DISC HERNIATION; CLASSIFICATION; DISKECTOMY
AB OBJECTIVE: The clinical application of endoscopic techniques for lumbar lateral recess stenosis (LRS) is still challenging. This study aimed to describe a transforaminal endoscopic decompression (TED) technique for LRS and to demonstrate its clinical results.
   METHODS: Two-year follow-up data were collected from 45 consecutive patients who underwent TED for LRS. Full-scale endoscopic decompression was performed in the dorsal and ventral aspects of the lateral recess with combined partial pediculectomy using an articulating bone burr and endoscopic instruments. Surgical outcomes were evaluated using the Visual Analog Pain Score (VAS), Oswestry Disability Index (ODI), and modified Macnab criteria.
   RESULTS: The mean age of the 27 female and 18 male patients was 64.9 years. The mean VAS for leg pain and mean ODI improved from 7.93 and 75.87 at baseline to 1.71 and 17.87, respectively, at 2 years after surgery (P < 0.001 and P < 0.001, respectively). Based on the modified Macnab criteria, excellent or good results were obtained in 86.7% of the patients, and symptomatic improvements were obtained in 97.8%. One patient underwent revision surgery because of incomplete decompression, and 2 experienced transient dysesthesia.
   CONCLUSION: TED with the patient under local anesthesia can be effective for the treatment of LRS, especially for the elderly or patients at a high risk for general anesthesia.
C1 [Ahn, Yong; Lee, Sang-Gu] Gachon Univ, Coll Med, Gil Med Ctr, Dept Neurosurg, Incheon, South Korea.
   [Lee, Sheen-Woo] Gachon Univ, Coll Med, Gil Med Ctr, Dept Radiol, Incheon, South Korea.
   [Keum, Han Joong] Wooridul Spine Hosp, Dept Neurosurg, Seoul, South Korea.
RP Ahn, Y (reprint author), Gachon Univ, Coll Med, Gil Med Ctr, Dept Neurosurg, Incheon, South Korea.
EM ns-ay@hanmail.net
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI16C2319]
FX This research was supported by a grant of the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   (grant number: HI16C2319).
CR Ahn Y, 2004, SPINE, V29, pE326, DOI 10.1097/01.BRS.0000134591.32462.98
   Ahn Y, 2014, EXPERT REV MED DEVIC, V11, P605, DOI 10.1586/17434440.2014.940314
   Ahn Y, 2012, EXPERT REV MED DEVIC, V9, P361, DOI [10.1586/erd.12.23, 10.1586/ERD.12.23]
   Bartynski WS, 2003, AM J NEURORADIOL, V24, P348
   CIRIC I, 1985, NEUROL CLIN, V3, P417, DOI 10.1016/S0733-8619(18)31046-6
   Demirayak M, 2015, ASIAN SPINE J, V9, P713, DOI 10.4184/asj.2015.9.5.713
   Kambin P, 1996, J NEUROSURG, V84, P462, DOI 10.3171/jns.1996.84.3.0462
   Kim DY, 2005, SPINE, V30, pE123, DOI 10.1097/01.brs.0000157172.00635.3a
   Kitahama Y, 2013, ASIAN J ENDOSC SURG, V6, P130, DOI 10.1111/ases.12004
   LEE CK, 1988, SPINE, V13, P313, DOI 10.1097/00007632-198803000-00015
   Lee S, 2010, AM J ROENTGENOL, V194, P1095, DOI 10.2214/AJR.09.2772
   Li ZZ, 2016, CLIN NEUROL NEUROSUR, V143, P90, DOI 10.1016/j.clineuro.2016.02.008
   MACNAB I, 1971, J BONE JOINT SURG AM, VA 53, P891, DOI 10.2106/00004623-197153050-00004
   MIKHAEL MA, 1981, RADIOLOGY, V140, P97, DOI 10.1148/radiology.140.1.7244248
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Ruetten S, 2013, OPER ORTHOP TRAUMATO, V25, P31, DOI 10.1007/s00064-012-0195-2
   Ruetten S, 2009, J NEUROSURG-SPINE, V10, P476, DOI 10.3171/2008.7.17634
   Schizas C, 2010, SPINE, V35, P1919, DOI 10.1097/BRS.0b013e3181d359bd
   Schubert Michael, 2005, Oper Orthop Traumatol, V17, P641, DOI 10.1007/s00064-005-1156-9
   Splettstosser A, 2017, WORLD J RADIOL, V9, P223, DOI 10.4329/wjr.v9.i5.223
   Tsou Paul Moody, 2002, Spine J, V2, P41, DOI 10.1016/S1529-9430(01)00153-X
   Wang YP, 2016, MED SCI MONITOR, V22, P4604, DOI 10.12659/MSM.901686
   Weinstein JN, 2008, NEW ENGL J MED, V358, P794, DOI 10.1056/NEJMoa0707136
   Yeung AT, 2002, SPINE, V27, P722, DOI 10.1097/00007632-200204010-00009
   2013, PAIN PHYS, V16, P547
NR 25
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E916
EP E924
DI 10.1016/j.wneu.2019.01.209
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700113
PM 30763754
DA 2020-05-12
ER

PT J
AU Aihara, M
   Shimizu, T
   Naito, I
   Miyamoto, N
   Yoshimoto, Y
AF Aihara, Masanori
   Shimizu, Tatsuya
   Naito, Isao
   Miyamoto, Naoko
   Yoshimoto, Yuhei
TI Surgical Strategies and Clinical Results of Site-Specific Treatment
   Using High-Flow Bypass for Ruptured Blood Blister-Like Anterior Wall
   Aneurysms of the Internal Carotid Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blister aneurysm; High-flow bypass; Subarachnoid hemorrhage
ID SUBARACHNOID HEMORRHAGE; DISSECTING ANEURYSM; NONBRANCHING SITES; GRAFT
AB OBJECTIVE: Surgical treatment of ruptured blood blister-like aneurysms (BBAs) arising from the internal carotid artery (ICA) is challenging. We retrospectively reviewed the results of our surgical strategies tailored for each aneurysm site.
   METHODS: All ruptured ICA BBAs treated between 2003 and 2015 were reviewed. Aneurysms on the lateral side of the ICA were classified as type A, on the medial side of C2 as type B, and on the medial side of C1 as type C. The principal strategy was high-flow bypass (HFB) by use of a radial artery graft, with clipping, trapping, or proximal occlusion selected on the basis of aneurysm type. The results of each treatment were examined.
   RESULTS: This study included 20 patients. There were 11 type A aneurysms (55%), 2 type B (10%), and 7 type C (35%). HFB was used in 13 patients (65%) and low-flow bypass in 4 (20%). Except for 1 case, no other cases of rerupture or recurrence occurred. Severe ischemia due to cerebral vasospasm was confirmed in 4 of 20 patients (20%), 3 of whom had not received HFB. Modified Rankin Scale score was 0e2 in 16 of 20 patients (80%).
   CONCLUSION: Inadequate cerebral blood flow is a distinct possibility even with HFB, so parent artery flow should be preserved to protect against ischemia whenever possible. However, if preservation of the anterior choroidal artery or posterior communicating artery during clipping or trapping is difficult, HFB combined with occlusion of the proximal portion of the ICA in the neck is a feasible option.
C1 [Aihara, Masanori; Shimizu, Tatsuya; Yoshimoto, Yuhei] Gunma Univ, Sch Med, Dept Neurosurg, Maebashi, Gunma, Japan.
   [Naito, Isao; Miyamoto, Naoko] Geriatr Res Inst & Hosp, Dept Neurosurg, Maebashi, Gunma, Japan.
RP Aihara, M (reprint author), Gunma Univ, Sch Med, Dept Neurosurg, Maebashi, Gunma, Japan.
EM masa.a6221@gmail.com
CR Baskaya MK, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E13
   Endo H, 2015, J STROKE CEREBROVASC, V24, P2358, DOI 10.1016/j.jstrokecerebrovasdis.2015.06.028
   Fang YB, 2014, CLIN NEUROL NEUROSUR, V123, P34, DOI 10.1016/j.clineuro.2014.04.023
   Fischer E, 1938, ZENTRALBL NEUROCHIR, V3, P300
   Fujimura M, 2013, SURG CEREBRAL STROKE, V41, P201
   Hunt W E, 1974, Clin Neurosurg, V21, P79
   Ishikawa T, 2009, NEUROL MED-CHIR, V49, P553, DOI 10.2176/nmc.49.553
   Kamijo K, 2010, J NEUROSURG, V113, P781, DOI 10.3171/2009.10.JNS09970
   Kamiyama Hiroyasu, 1994, Neurological Surgery, V22, P911
   Kawashima A, 2008, J CLIN NEUROSCI, V15, P797, DOI 10.1016/j.jocn.2007.03.012
   Kazumata K, 2014, OPER NEUROSURG, V10, P66, DOI 10.1227/NEU.0000000000000076
   Kubo Y, 2006, J NEUROSURG, V105, P785, DOI 10.3171/jns.2006.105.5.785
   Lee JW, 2009, ACTA NEUROCHIR, V151, P125, DOI 10.1007/s00701-008-0165-5
   Meckel S, 2011, AM J NEURORADIOL, V32, P764, DOI 10.3174/ajnr.A2392
   Morton RP, 2014, NEUROSURGERY, V74, P62, DOI 10.1227/NEU.0000000000000198
   Murai Y, 2013, SURG CEREB STROKE, V41, P33
   Nakatomi H, 1997, STROKE, V28, P1278, DOI 10.1161/01.STR.28.6.1278
   Ogawa A, 2000, NEUROSURGERY, V47, P578, DOI 10.1097/00006123-200009000-00008
   Ohkuma H, 2002, J NEUROSURG, V97, P576, DOI 10.3171/jns.2002.97.3.0576
   Park JH, 2007, J NEUROSURG, V106, P812, DOI 10.3171/jns.2007.106.5.812
   Peitz GW, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1751
   Ryan RW, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1757
   Satoh A, 2008, ACTA NEUROCHIR SUPPL, V103, P51
   Sim SY, 2006, J NEUROSURG, V105, P400, DOI 10.3171/jns.2006.105.3.400
   Yanaka K, 2002, NEUROSURGERY, V50, P218, DOI 10.1097/00006123-200201000-00037
   Zhu DY, 2017, WORLD NEUROSURG, V104, P729, DOI 10.1016/j.wneu.2017.03.092
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1247
EP E1255
DI 10.1016/j.wneu.2019.02.018
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700154
PM 30797930
DA 2020-05-12
ER

PT J
AU Alshareef, M
   Klapthor, G
   Alshareef, A
   Almadidy, Z
   Wright, Z
   Infinger, L
   Eskandari, R
AF Alshareef, Mohammed
   Klapthor, Gibson
   Alshareef, Ahmed
   Almadidy, Zayed
   Wright, Zachary
   Infinger, Libby
   Eskandari, Ramin
TI Pediatric Cranial Fasciitis: Discussion of Cases and Systematic Review
   of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cranial fasciitis; Craniectomy; Cranioplasty; Nodular fasciitis;
   Pediatric trauma; Scalp mass; Skull mass
ID NODULAR FASCIITIS; INTRACRANIAL MASS; CHILDHOOD; ADULT; CT
AB OBJECTIVE: Cranial fasciitis is a rare benign mass that typically presents in pediatric patients from 3 weeks to 6 years of age. It is classified as a subset of nodular fasciitis and was first reported in 1980. This study evaluates the literature for common characteristics that may affect diagnosis and treamtent.
   METHODS: We describe the case of a 13-month-old girl with a history of accidental head trauma 7 months before presentation and the case of a 5-month-old girl with an expansile skull lesion. We also performed a systematic review of the reported data on cranial fasciitis, including a total of 57 reported studies with 80 unique cases.
   RESULTS: There were 80 total cases reviewed in the literature. There was a male predominence, 1.75:1. The average age at presentation was 5.2 years. The most common causes for this lesion were idiopathic (65%), blunt trauma (14%) and radiation therapy (7%). Overall, there was a 9% recurrence rate following treatment.
   CONCLUSION: We report the characteristics at presentation, including, to the best of our knowledge, the first account of gender differences, and the treatment modalities used in the included studies and the implications in relation to the recurrence rates.
C1 [Alshareef, Mohammed; Infinger, Libby; Eskandari, Ramin] Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
   [Klapthor, Gibson] Med Univ South Carolina, Coll Med, Charleston, SC 29425 USA.
   [Alshareef, Ahmed] Univ Virginia, Dept Biomed Engn, Charlottesville, VA USA.
   [Almadidy, Zayed] Univ Illinois, Dept Neurosurg, Chicago, IL USA.
   [Wright, Zachary] Valley Childrens Hosp, Div Neurosurg, Madera, CA USA.
RP Eskandari, R (reprint author), Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
EM eskandar@musc.edu
OI Alshareef, Ahmed/0000-0003-4512-1618
CR ADLER R, 1986, J PEDIATR-US, V109, P85, DOI 10.1016/S0022-3476(86)80581-9
   Agozzino M, 2006, ACTA NEUROPATHOL, V111, P286, DOI 10.1007/s00401-005-0020-1
   BAROHN RJ, 1980, SURG NEUROL, V13, P283
   Boddie DE, 1997, BRIT J NEUROSURG, V11, P445
   Clapp CG, 1997, ARCH OTOLARYNGOL, V123, P223
   COATES DB, 1990, PLAST RECONSTR SURG, V85, P602, DOI 10.1097/00006534-199004000-00018
   Curtin E, 2014, CHILD NERV SYST, V30, P2163, DOI 10.1007/s00381-014-2488-2
   Dai R, 2017, J CRANIOFAC SURG, V28, P1821, DOI 10.1097/SCS.0000000000003860
   du Toit LE, 2009, J CRANIOFAC SURG, V20, P1197, DOI 10.1097/SCS.0b013e3181acdc98
   Fissenden TM, 2014, INT J PEDIATR OTORHI, V78, P1430, DOI 10.1016/j.ijporl.2014.05.014
   Flouty OE, 2017, CHILD NERV SYST, V33, P899, DOI 10.1007/s00381-017-3417-y
   Foureur N, 2002, ANN DERMATOL VENER, V129, P732
   Garza Lorena, 2012, J La State Med Soc, V164, P347
   Ginsberg B, 2014, DERMATOL ONLINE J, V20
   Govender PV, 2001, J NEUROSURG, V94, P681, DOI 10.3171/jns.2001.94.4.0681
   Halder A, 2012, PEDIATR DEVEL PATHOL, V15, P146, DOI 10.2350/11-02-0990-CR.1
   Hattab EM, 2014, NEUROPATHOLOGY, V34, P291, DOI 10.1111/neup.12082
   HOEFFEL JC, 1993, EUR J PEDIATR SURG, V3, P376
   Hoya K, 1996, CHILD NERV SYST, V12, P556
   Hussein MR, 2008, J CUTAN PATHOL, V35, P212, DOI 10.1111/j.1600-0560.2007.00775.x
   Imafuku S, 2011, J DERMATOL, V38, P1006, DOI 10.1111/j.1346-8138.2010.01161.x
   INAMURA T, 1991, NEUROSURGERY, V28, P888, DOI 10.1227/00006123-199106000-00019
   IQBAL K, 1995, J LARYNGOL OTOL, V109, P255, DOI 10.1017/S0022215100129858
   Johnson KK, 2008, J NEUROS-PEDIATR, V2, P370, DOI 10.3171/PED.2008.2.11.370
   Keyserling HF, 2003, AM J NEURORADIOL, V24, P1465
   KUMON Y, 1992, SURG NEUROL, V38, P68, DOI 10.1016/0090-3019(92)90215-9
   Lang DA, 1996, CHILD NERV SYST, V12, P218, DOI 10.1007/BF00301254
   Larralde M, 2003, INT J DERMATOL, V42, P137, DOI 10.1046/j.1365-4362.2003.01674_1.x
   LAUER DH, 1980, CANCER-AM CANCER SOC, V45, P401, DOI 10.1002/1097-0142(19800115)45:2<401::AID-CNCR2820450236>3.0.CO;2-C
   Lecavalier M, 2014, AM J OTOLARYNG, V35, P647, DOI 10.1016/j.amjoto.2014.06.004
   Lee JY, 2004, INT J DERMATOL, V43, P453, DOI 10.1111/j.1365-4632.2004.02113.x
   Liu CC, 2011, FORMOS J SURG, V44, P228, DOI 10.1016/j.fjs.2011.08.018
   Longatti P, 2004, NEUROSURGERY, V54, P1263, DOI 10.1227/01.NEU.0000119604.10923.63
   Marciano S, 1999, EUR RADIOL, V9, P1650, DOI 10.1007/s003300050903
   Marshall LR, 2009, J LARYNGOL OTOL, V123, P245, DOI 10.1017/S0022215108002946
   Martinez-Lage JF, 1997, CHILD NERV SYST, V13, P626, DOI 10.1007/s003810050156
   MOLLEJO M, 1990, SURG NEUROL, V33, P146, DOI 10.1016/0090-3019(90)90025-K
   Nabavizadeh SA, 2014, AM J NEURORADIOL, V35, P604, DOI 10.3174/ajnr.A3712
   Noguchi O, 1999, NEUROL SURG TOKYO, V27, P163
   Oh CK, 2007, PEDIATR DERMATOL, V24, P263, DOI 10.1111/j.1525-1470.2007.00399.x
   Okuyama Sumito, 2003, No To Shinkei, V55, P361
   PAGENSTECHER A, 1995, J NEUROSURG, V83, P744, DOI 10.3171/jns.1995.83.4.0744
   PASQUIER B, 1984, ANN PATHOL, V4, P371
   PATTERSON JW, 1989, ARCH DERMATOL, V125, P674, DOI 10.1001/archderm.125.5.674
   Piekarz Ewa, 2004, Pol Arch Med Wewn, V112, P1341
   Pollack IF, 2001, NEUROSURGERY, V48, P430, DOI 10.1097/00006123-200102000-00041
   Rakheja D, 2008, MODERN PATHOL, V21, P1330, DOI 10.1038/modpathol.2008.112
   Rapana A, 2002, CLIN NEUROL NEUROSUR, V105, P35, DOI 10.1016/S0303-8467(02)00095-1
   Riml S, 2011, J PLAST RECONSTR AES, V64, P949, DOI 10.1016/j.bjps.2010.11.021
   RINGSTED J, 1985, ACTA NEUROPATHOL, V66, P337, DOI 10.1007/BF00690967
   Sajben FP, 1999, PEDIATR DERMATOL, V16, P232, DOI 10.1046/j.1525-1470.1999.00068.x
   SantaCruz Karen, 2007, Neurosurgery, V61, pE1338
   Sarangarajan R, 1999, HUM PATHOL, V30, P87, DOI 10.1016/S0046-8177(99)90306-4
   SATO Y, 1993, EUR J PEDIATR SURG, V3, P107, DOI 10.1055/s-2008-1063522
   SAYAMA T, 1995, CHILD NERV SYST, V11, P242, DOI 10.1007/BF00277660
   Souza AA, 2016, CASE REP DENT, DOI 10.1155/2016/4231683
   Summers LE, 2007, J NEUROSURG, V106, P1080, DOI 10.3171/jns.2007.106.6.1080
   Takeda N, 2008, PEDIATR NEUROSURG, V44, P148, DOI 10.1159/000113119
   Velagaleti GVN, 2003, CANCER GENET CYTOGEN, V141, P160, DOI 10.1016/S0165-4608(02)00725-2
   Wagner RD, 2016, J CRANIOFAC SURG, V27, pE65, DOI 10.1097/SCS.0000000000002230
   Wu B, 2013, J NEUROSURG-PEDIATR, V12, P637, DOI 10.3171/2013.8.PEDS13171
   Yebenes Mireia, 2007, Pediatr Dermatol, V24, pE26, DOI 10.1111/j.1525-1470.2007.00434.x
   Zavras N, 2017, BMJ CASE REP, V2017
   2004, NEUROSURGERY, V54, P1263, DOI DOI 10.1227/01.NEU.0000119604.10923.63
NR 64
TC 1
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E829
EP E842
DI 10.1016/j.wneu.2019.01.193
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700103
PM 30743035
DA 2020-05-12
ER

PT J
AU Altafulla, J
   Iwanaga, J
   Lachkar, S
   Prickett, J
   Dupont, G
   Yilmaz, E
   Ishak, B
   Litvack, Z
   Tubbs, RS
AF Altafulla, Juan
   Iwanaga, Joe
   Lachkar, Stefan
   Prickett, Joshua
   Dupont, Graham
   Yilmaz, Emre
   Ishak, Basem
   Litvack, Zachary
   Tubbs, R. Shane
TI The Great Auricular Nerve: Anatomical Study with Application to Nerve
   Grafting Procedures
SO WORLD NEUROSURGERY
LA English
DT Article
DE External jugular vein; Great auricular nerve; Nerve graft;
   Sternocleidomastoid
ID SURFACE ANATOMY; ACCESSORY NERVE; RECONSTRUCTION; LANDMARKS;
   NEUROMODULATION; NEURORRHAPHY; ANASTOMOSIS; RESECTION; REMOVAL; INJURY
AB BACKGROUND: When it comes to autogenous nerve grafting, the sural and great auricular nerve (GAN) are the 2 nerves predominately used for trigeminal and facial nerve repair. Arising from the second and third cervical ventral rami, the GAN emerges from the posterior border of the sternocleidomastoid coursing superiorly and anteriorly toward the ear.
   METHODS: Eleven sides from 5 Caucasian and 1 Asian cadaveric heads (all fresh-frozen) were used. One man and 5 women were used with an age at death ranging from 57 to 91 years, with a mean of 80.3 years. Measurements were made from the inferior border of the ear to the GAN, the GAN to the external jugular vein, and the inferior border of the mastoid process to the GAN; the proximal, medial, and distal diameters of the GAN and the length of the GAN that was obtained from this exposure were also measured.
   RESULTS: The mean distance from the inferior border of the mastoid process to the GAN, inferior border of the ear to the GAN, and GAN to the external jugular vein was 27.71, 31.03, and 13.28 mm, respectively. The mean length of the GAN was 74.86 mm. The mean diameter of its distal, middle, and proximal portions was 1.51, 1.38, and 1.58 mm, respectively.
   CONCLUSIONS: The GAN is an excellent option for use in nerve grafting for repair of, for example, facial dysfunction. In this study, we review our measurements, techniques for identification, and dissecting techniques for the GAN. The proximity to the operative area and minimal complications associated with GAN grafting might contribute to improved patient satisfaction and better outcomes regarding functional restoration.
C1 [Altafulla, Juan; Iwanaga, Joe; Lachkar, Stefan; Dupont, Graham; Yilmaz, Emre; Ishak, Basem; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Altafulla, Juan; Prickett, Joshua; Yilmaz, Emre; Ishak, Basem; Litvack, Zachary] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA USA.
   [Altafulla, Juan] Hosp Santo Tomas, Neurosurg Dept, Panama City, Panama.
   [Iwanaga, Joe] Kurume Univ, Sch Med, Dent & Oral Med Ctr, Kurume, Fukuoka, Japan.
   [Iwanaga, Joe] Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
   [Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.; Iwanaga, J (reprint author), Kurume Univ, Sch Med, Dent & Oral Med Ctr, Kurume, Fukuoka, Japan.; Iwanaga, J (reprint author), Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
EM joei@seattlesciencefoundation.org
OI Altafulla, Juan/0000-0002-2110-8665
CR Badshah M, 2017, CLIN ANAT, V30, P781, DOI 10.1002/ca.22907
   Bagheri SC, 2009, J ORAL MAXIL SURG, V67, P1791, DOI 10.1016/j.joms.2009.04.115
   Bahadir O, 2008, INDIAN J PLAST SURG, V41, P201, DOI 10.4103/0970-0358.44948
   Benkhatar H, 2018, CORNEA, V37, P647, DOI 10.1097/ICO.0000000000001549
   Biglioli F, 2017, J NEUROSURG, V126, P312, DOI 10.3171/2015.12.JNS14601
   Biglioli F, 2012, J CRANIO MAXILL SURG, V40, P149, DOI 10.1016/j.jcms.2011.03.005
   Candido DNC, 2019, OPER NEUROSURG, V16, pE1, DOI 10.1093/ons/opy100
   Izquierdo JC, 2014, OTOL NEUROTOL, V35, pE64, DOI 10.1097/MAO.0b013e31829e1680
   Dalip D, 2018, CUREUS, V10, DOI 10.7759/cureus.2826
   De Bonnecaze G, 2019, CLIN ANAT, V32, P169, DOI 10.1002/ca.23081
   DELLON ES, 1993, J HAND SURG-AM, V18A, P369, DOI 10.1016/0363-5023(93)90378-G
   Elahi F, 2014, NEUROMODULATION, V17, P784, DOI 10.1111/ner.12114
   Elahi F, 2014, PAIN PHYSICIAN, V17, pE531
   Ginsberg LE, 2000, AM J NEURORADIOL, V21, P568
   Guo CB, 2005, BRIT J PLAST SURG, V58, P233, DOI 10.1016/j.bjps.2004.02.009
   Han Si-yuan, 2004, Zhonghua Zheng Xing Wai Ke Za Zhi, V20, P425
   Iwanaga J, 2017, CLIN ANAT, V30, P958, DOI 10.1002/ca.22964
   Jeon Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006325
   Jiang Li-xin, 2004, Zhonghua Er Bi Yan Hou Ke Za Zhi, V39, P219
   Katoh M, 1998, J CLIN NEUROSCI, V5, P342, DOI 10.1016/S0967-5868(98)90075-3
   Koshima I, 2004, J RECONSTR MICROSURG, V20, P357, DOI 10.1055/s-2004-829998
   Kunert P, 2011, NEUROL NEUROCHIR POL, V45, P505
   LABANC JP, 1987, J ORAL MAXIL SURG, V45, P621, DOI 10.1016/0278-2391(87)90275-8
   Lefkowitz T, 2013, AESTHET SURG J, V33, P19, DOI 10.1177/1090820X12469625
   Magliulo G, 2001, EUR ARCH OTO-RHINO-L, V258, P45, DOI 10.1007/s004059900211
   MCKINNEY P, 1985, ANN PLAS SURG, V14, P310, DOI 10.1097/00000637-198504000-00003
   MCKINNEY P, 1980, PLAST RECONSTR SURG, V66, P675, DOI 10.1097/00006534-198011000-00001
   Meyer R A, 2001, Atlas Oral Maxillofac Surg Clin North Am, V9, P77
   Miloro M, 2015, J ORAL MAXIL SURG, V73, P1844, DOI 10.1016/j.joms.2015.03.018
   MORI M, 1964, Okajimas Folia Anat Jpn, V40, P195
   Peuker ET, 2002, CLIN ANAT, V15, P35, DOI 10.1002/ca.1089
   Sharma VS, 2017, PLAST RECONSTR SURG, V139, p371E, DOI 10.1097/PRS.0000000000002980
   Shen XH, 2017, CLIN ANAT, V30, P330, DOI 10.1002/ca.22847
   SOO KC, 1986, HEAD NECK-J SCI SPEC, V9, P111, DOI 10.1002/hed.2890090207
   Sun Y, 2015, INT J CLIN EXP MED, V8, P12970
   Tomaszewski KA, 2017, CLIN ANAT, V30, P14, DOI 10.1002/ca.22800
   Tubbs RS, 2007, CLIN ANAT, V20, P235, DOI 10.1002/ca.20297
   Yamaki T, 1998, SURG NEUROL, V49, P538, DOI 10.1016/S0090-3019(97)00025-6
   Yoshimura H, 2013, J ORAL MAXIL SURG, V71, P2176, DOI 10.1016/j.joms.2013.04.034
   2016, CLIN ANAT, V29, P237, DOI DOI 10.1002/CA.22673
NR 40
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E403
EP E407
DI 10.1016/j.wneu.2019.01.087
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700053
PM 30703599
DA 2020-05-12
ER

PT J
AU Alwadei, A
   Almubarak, AO
   Bafaquh, M
   Qoqandi, O
   Alobaid, A
   Alsubaie, F
   Alzahrani, AS
   Alyahya, NM
   Almalki, S
   Alyamani, M
   Orz, Y
AF Alwadei, Ali
   Almubarak, Abdulaziz Oqalaa
   Bafaquh, Mohammed
   Qoqandi, Omar
   Alobaid, Abdullah
   Alsubaie, Fahd
   Alzahrani, Abdullah Saad
   Alyahya, Nawaf Mohammed
   Almalki, Sami
   Alyamani, Mahmoud
   Orz, Yasser
TI Supratentorial Craniotomies with or without Dural Closure-A Comparison
SO WORLD NEUROSURGERY
LA English
DT Article
DE CSF leak; Dural closure; Postcraniotomy headache; Postoperative
   infection; Surgical technique
ID HEADACHE; PAIN; COMPLICATIONS; SUBSTITUTE; EFFICACY; MATER
AB BACKGROUND: Dural closure is a routine surgical step in neurosurgery. The benefit of suturing the dura to achieve watertight closure-with or without the use of dural substitutes-has been questioned in supratentorial craniotomy. We performed a retrospective study to examine the possible benefits and harms of suturing the dura compared with no dural closure and the occurrence of postoperative infection, cerebrospinal fluid (CSF) leak, and postcraniotomy headaches.
   METHODS: We performed a retrospective study to compare the incidence of CSF leak, infection, surgical site swelling, and postcraniotomy headaches between patients with watertight dural closure (closed group) and patients without watertight dural closure (open group). Any method used to close the dura and to achieve watertight closure was included, whether primary or secondary closure (with or without using suturable dural substitute).
   RESULTS: Overall, 216 patients were included in the present study, with 112 patients in the open group and 114 in the closed group. The open group experienced a greater incidence of infection and CSF leak (6 in the open group vs. 2 in the closed group), but without statistical significance (P = 0.15). We found no difference in surgical site swelling (P = 0.29). However, the closed group showed a greater association with the development of postcraniotomy headaches (P = 0.001).
   CONCLUSION: We found no difference in the occurrence of CSF leak, infection, or surgical site swelling between the closed and open groups. The incidence of postcraniotomy headaches was greater in the closed group, and the difference was statistically significant.
C1 [Alwadei, Ali; Almubarak, Abdulaziz Oqalaa; Bafaquh, Mohammed; Qoqandi, Omar; Alobaid, Abdullah; Alsubaie, Fahd; Almalki, Sami; Alyamani, Mahmoud; Orz, Yasser] King Fahed Med City, Natl Neurosci Inst, Riyadh, Saudi Arabia.
   [Almubarak, Abdulaziz Oqalaa] Prince Mohammed Med City, Aljouf, Saudi Arabia.
   [Alzahrani, Abdullah Saad] King Fahad Hosp, Albaha, Saudi Arabia.
   [Alyahya, Nawaf Mohammed] King Abdul Aziz Med City, Riyadh, Saudi Arabia.
RP Bafaquh, M (reprint author), King Fahed Med City, Natl Neurosci Inst, Riyadh, Saudi Arabia.
EM bafaquh@gmail.com
OI Qoqandi, Omar/0000-0003-4945-5543
CR Abuzayed B, 2009, J CRANIOFAC SURG, V20, P435, DOI 10.1097/SCS.0b013e31819b968f
   ADEGBITE AB, 1983, J NEUROSURG, V58, P295, DOI 10.3171/jns.1983.58.2.0295
   Aoki N, 1988, Neurol Med Chir (Tokyo), V28, P994, DOI 10.2176/nmc.28.994
   Arieli A, 2002, J NEUROSCI METH, V114, P119, DOI 10.1016/S0165-0270(01)00507-6
   Artico M, 2001, MICROSC RES TECHNIQ, V53, P212, DOI 10.1002/jemt.1085
   Barth M, 2008, NEUROSURGERY, V63, P352, DOI 10.1227/01.NEU.0000310696.52302.99
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   CABANTOG AM, 1994, CAN J NEUROL SCI, V21, P213, DOI 10.1017/S0317167100041184
   Cavallotti D, 1998, HEADACHE, V38, P352, DOI 10.1046/j.1526-4610.1998.3805352.x
   Dandy W., 1933, PRACTICE OF SURG, V12
   de Gray LC, 2005, ANAESTHESIA, V60, P693, DOI 10.1111/j.1365-2044.2005.03997.x
   DeBenedittis G, 1996, NEUROSURGERY, V38, P466, DOI 10.1097/00006123-199603000-00008
   Di Vitantonio Hambra, 2016, Surg Neurol Int, V7, pS463, DOI 10.4103/2152-7806.185777
   Fontaine D, 2018, BRAIN, V141, P1040, DOI 10.1093/brain/awy005
   FUKAMACHI A, 1986, NEUROSURGERY, V19, P589, DOI 10.1227/00006123-198610000-00013
   Gonzalez-Lopez P, 2015, WORLD NEUROSURG, V83, P93, DOI 10.1016/j.wneu.2014.02.032
   GUDMUNDSSON G, 1995, ACTA NEUROCHIR, V132, P145, DOI 10.1007/BF01404863
   Hack GD, 2004, HEADACHE, V44, P84, DOI 10.1111/j.1526-4610.2004.04015.x
   Haldar R, 2015, BIOMED RES INT, DOI 10.1155/2015/509164
   Kaur A, 2000, NEUROSURGERY, V47, P633
   Kumar A, 2003, J CLIN NEUROSCI, V10, P661, DOI 10.1016/S0967-5868(03)00163-2
   Matula C, 2014, J NEUROL SURG PART A, V75, P241, DOI 10.1055/s-0033-1342928
   Palm SJ, 1999, NEUROSURGERY, V45, P875, DOI 10.1097/00006123-199910000-00029
   Roth J, 2018, WORLD NEUROSURG, V114, pE743, DOI 10.1016/j.wneu.2018.03.070
   Rocha PAS, 2015, HEADACHE, V55, P733, DOI 10.1111/head.12563
   Schaller B, 2003, OTOLARYNG HEAD NECK, V128, P387, DOI 10.1067/mhn.2003.104
   Schulte F, 2010, ARCH MED SCI, V6, P827, DOI 10.5114/aoms.2010.19286
   Sekhar LN, 2013, WORLD NEUROSURG, V79, P440, DOI 10.1016/j.wneu.2011.12.062
   THOMPSON D, 1994, J NEUROL NEUROSUR PS, V57, P646, DOI 10.1136/jnnp.57.5.646
   VALLFORS B, 1981, NEUROSURGERY, V9, P407, DOI 10.1227/00006123-198110000-00011
   Winston KR, 1998, PEDIATR NEUROSURG, V28, P230, DOI 10.1159/000028656
   Winston KR, 1999, J NEUROSURG, V91, P180, DOI 10.3171/jns.1999.91.2.0180
   WOLFF H, 1963, HEADACHE OTHER HEAD
   Zhao J Z, 1984, Zhonghua Shen Jing Jing Shen Ke Za Zhi, V17, P83
   2013, WORLD NEUROSURG, V79, P551, DOI DOI 10.1016/J.WNEU.2011.09.022
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1132
EP E1137
DI 10.1016/j.wneu.2019.01.262
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700141
PM 30780042
DA 2020-05-12
ER

PT J
AU Azab, WA
   Abdelnabi, EA
   Mostafa, KH
AF Azab, Waleed A.
   Abdelnabi, Ehab A.
   Mostafa, Kamal H.
TI Efficacy and Safety of the Rotational Technique for Endoscopic
   Transforaminal Excision of Colloid Cysts of the Third Ventricle
SO WORLD NEUROSURGERY
LA English
DT Article
DE Colloid cyst; Endoscope; Endoscopic; Rotational; Third ventricle;
   Transforaminal
ID 3RD VENTRICLE; MICROSURGICAL TREATMENT; RESECTION; MANAGEMENT;
   EXPERIENCE; SERIES
AB BACKGROUND: The main criticism of endoscopic excision of colloid cysts of the third ventricle is the decreased ability to completely resect the cyst wall, therefore increasing the risk of recurrence. The extent of resection varies widely across the endoscopic series and is largely influenced by the surgical technique. We report the results of the rotational technique for endoscopic transforaminal excision of colloid cysts in a series of consecutive patients. Our objective is to contribute to the current literature and to shed more light on an effective and safe yet less commonly used technique.
   METHODS: Retrospective analysis was performed on 19 patients. Preoperative magnetic resonance imaging (MRI) was evaluated for cyst characteristics. Postoperative MRI was evaluated for residual cyst membranes. Operative records were reviewed for residual cyst components. Excision grade was determined based on the Barrow Neurological Institute grading scale. Symptom resolution was documented clinically.
   RESULTS: The study included 13 men and 6 women, with a mean age of 35 years (range, 19-56 years) and mean follow-up of 27.74 months (range, 4-55 months). Total excision was achieved in 17 of 19 cysts (89.5%). A small residual was seen intraoperatively but not radiographically in 1 patient. In another patient, residual cyst membrane seen intraoperatively and radiologically led to recurrence 18 months postoperatively. No mortalities or permanent morbidities occurred.
   CONCLUSIONS: Our high total excision rate and low complication profile are in concordance with the recent reports of endoscopic resection of colloid cysts. The rotational technique for the endoscopic transforaminal approach is highly effective and a safe alternative to the bimanual dissection technique.
C1 [Azab, Waleed A.; Mostafa, Kamal H.] Ibn Sina Hosp, Dept Neurosurg, Kuwait, Kuwait.
   [Abdelnabi, Ehab A.] Ibn Sina Hosp, Dept Radiol, Kuwait, Kuwait.
RP Azab, WA (reprint author), Ibn Sina Hosp, Dept Neurosurg, Kuwait, Kuwait.
EM waleedazab@hotmail.com
CR Abdou MS, 1998, J NEUROSURG, V89, P1062, DOI 10.3171/jns.1998.89.6.1062
   ANTUNES JL, 1980, NEUROSURGERY, V7, P450, DOI 10.1227/00006123-198011000-00004
   Azab Waleed A, 2014, Surg Neurol Int, V5, P124, DOI 10.4103/2152-7806.138364
   Azab WA, 2017, ACTA NEUROCHIR, V159, P1053, DOI 10.1007/s00701-017-3176-2
   Boogaarts HD, 2011, NEUROSURGERY, V68, P179, DOI 10.1227/NEU.0b013e3181ffae71
   Brunori A, 2018, WORLD NEUROSURG, V117, pE457, DOI 10.1016/j.wneu.2018.06.051
   Caemaert J, 1996, TECH NEUROSURG, V1, P185
   Chibbaro S, 2014, NEUROSURG REV, V37, P235, DOI 10.1007/s10143-013-0508-4
   Dandy WE, 1922, B JOHNS HOPKINS HOSP, V33, P188
   Decq P, 1998, NEUROSURGERY, V42, P1288, DOI 10.1097/00006123-199806000-00051
   Decq P, 2013, WORLD NEUROSURG, V80, P498, DOI 10.1016/j.wneu.2012.10.034
   Delitala A, 2011, NEUROSURGERY, V69, P176, DOI 10.1227/NEU.0b013e318219563c
   Dorsch AB, 2017, J NEUROL SURG PART A, V78, P78, DOI 10.1055/s-0036-1584828
   El-Ghandour NMF, 2009, NEUROSURG REV, V32, P395, DOI 10.1007/s10143-009-0208-2
   Engh JA, 2010, NEUROSURGERY, V67, P198, DOI 10.1227/01.NEU.0000382974.81828.F9
   Gokalp HZ, 1996, ACTA NEUROCHIR, V138, P45, DOI 10.1007/BF01411723
   Greenlee JDW, 2008, NEUROSURGERY, V63, P51, DOI [10.1227/01.NEU.0000297004.20222.ED, 10.1227/01.neu.0000317373.00018.6f]
   Grondin RT, 2007, CAN J NEUROL SCI, V34, P197, DOI 10.1017/S0317167100006041
   Hellwig D, 2003, NEUROSURGERY, V52, P525, DOI 10.1227/01.NEU.0000047671.27057.55
   Hernesniemi J, 1996, SURG NEUROL, V45, P2, DOI 10.1016/0090-3019(95)00379-7
   Hernesniemi J, 2008, SURG NEUROL, V69, P447, DOI 10.1016/j.surneu.2007.11.005
   Hoffman CE, 2013, NEUROSURGERY, V73, P233, DOI 10.1227/01.neu.0000430300.10338.71
   Horn EM, 2007, NEUROSURGERY, V60, P613, DOI 10.1227/01.NEU.0000255409.61398.EA
   Hwang D H, 1996, J Am Optom Assoc, V67, P227
   Iacoangeli M, 2014, J NEUROSURG, V120, P1471, DOI 10.3171/2014.1.JNS131102
   Ibanez-Botella G, 2014, NEUROSURG REV, V37, P227, DOI 10.1007/s10143-014-0529-7
   Jeffree RL, 2001, J CLIN NEUROSCI, V8, P328, DOI 10.1054/jocn.2000.0800
   Kehler U, 2001, MINIM INVAS NEUROSUR, V44, P121, DOI 10.1055/s-2001-18122
   Konovalov AN, 2017, WORLD NEUROSURG, V105, P678, DOI 10.1016/j.wneu.2017.06.012
   Levine NB, 2007, MINIM INVAS NEUROSUR, V50, P313, DOI 10.1055/s-2007-993215
   LEWIS AI, 1994, J NEUROSURG, V81, P174, DOI 10.3171/jns.1994.81.2.0174
   Longatti P, 2006, CHILD NERV SYST, V22, P1263, DOI 10.1007/s00381-006-0105-8
   Margetis K, 2013, NEUROSURG FOCUS S, V34
   Margetis K, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.021
   POWELL MP, 1983, NEUROSURGERY, V13, P234, DOI 10.1227/00006123-198309000-00003
   Rodziewicz GS, 2000, NEUROSURGERY, V46, P655, DOI 10.1097/00006123-200003000-00025
   Samadian M, 2018, WORLD NEUROSURG, V111, pE440, DOI 10.1016/j.wneu.2017.12.093
   Sampath R, 2010, NEUROSURGERY, V66, P368, DOI 10.1227/01.NEU.0000363858.17782.82
   Shapiro S, 2009, J NEUROSURG, V110, P112, DOI 10.3171/2008.4.17495
   Sheikh AB, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.06.024
   Solaroglu I, 2004, NEUROSURG REV, V27, P89, DOI 10.1007/s10143-003-0309-2
   Sribnick EA, 2014, WORLD NEUROSURG, V81, P584, DOI 10.1016/j.wneu.2013.12.006
   Symss Nigel P, 2014, Asian J Neurosurg, V9, P51, DOI 10.4103/1793-5482.136708
   Vorbau C, 2019, WORLD NEUROSURG, V122, pE176, DOI 10.1016/j.wneu.2018.09.190
   Wilson DA, 2013, WORLD NEUROSURG, V80, P576, DOI 10.1016/j.wneu.2012.07.014
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E602
EP E611
DI 10.1016/j.wneu.2019.01.137
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700077
PM 30716482
DA 2020-05-12
ER

PT J
AU Ba, DC
   Zhu, ZP
   Yue, XJ
   Xu, P
   Yan, PF
   Xiao, DD
AF Ba, Dechun
   Zhu, Zhipeng
   Yue, Xiangji
   Xu, Ping
   Yan, Pengfei
   Xiao, Dongdong
TI Computational Fluid Dynamics Analysis of Carotid-Ophthalmic Aneurysms
   with Concomitant Ophthalmic Artery Infundibulum in a Patient-Specific
   Model
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid-ophthalmic aneurysm; Computational fluid dynamics; Infundibular
   dilatation; Infundibulum; Non-Newtonian fluid; Patient-specific model
ID WALL SHEAR-STRESS; FLOW; HEMODYNAMICS; SEGMENT
AB BACKGROUND: Although previous studies have reported cases of coexistence of carotid-ophthalmic aneurysm and ophthalmic artery (OA) infundibulum, the hemodynamic characteristics of this complicated structure and its damaging effects on vision remain to be elucidated. The aim of the present study was to analyze this artery structure using computational fluid dynamics (CFD) techniques.
   METHODS: We have presented the case of a patient with a diagnosis of carotid-ophthalmic aneurysm, who had been experiencing blurred vision. A transient analysis was performed to investigate the blood flowing in the parent artery. Hemodynamic parameters such as streamline, wall shear stress (WSS), oscillatory shear index (OSI), and relative residence time were obtained.
   RESULTS: When the inlet velocity of the parent artery was at the second peak, the flow rate and intensity of the vortex reached their maximum. In the aneurysm neck, a region of high time-averaged WSS (TAWSS) and a region of low TAWSS with a high OSI coexisted. In addition, a relaxation area was found. In the aneurysm dome, the minimum TAWSS was 2.5 Pa, the maximum OSI was 0.48, and the 2 regions did not overlap. In the OA infundibulum, the maximum OSI and relative residence time were 0.47 and 39.2, respectively; the minimum TAWSS was 0.59 Pa.
   CONCLUSIONS: We detected aneurysm regions that were susceptible to further expansion and assessed the rupture risk of each region. The relaxation area could promote aneurysm progression. In addition, the location of the vortex shear force center varied with time. Finally, double vortex streamlines influenced the blood supply through the OA, impairing the vision. Infundibulum might promote thrombus formation and, hence, retard OA blood flow.
C1 [Ba, Dechun; Zhu, Zhipeng; Yue, Xiangji] Northeastern Univ, Sch Mech Engn & Automat, Shenyang 110819, Liaoning, Peoples R China.
   [Xu, Ping] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430022, Hubei, Peoples R China.
   [Yan, Pengfei; Xiao, Dongdong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan 430022, Hubei, Peoples R China.
RP Xiao, DD (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan 430022, Hubei, Peoples R China.
EM xiaoddong@hust.edu.cn
CR Andaluz N, 2005, NEUROSURG QUART, V15, P91, DOI 10.1097/01.wnq.0000162817.04741.bf
   Baek H, 2009, ANN BIOMED ENG, V37, P2469, DOI 10.1007/s10439-009-9794-y
   Boersen JT, 2017, J VASC SURG, V66, P1844, DOI 10.1016/j.jvs.2016.10.077
   Box FMA, 2005, INVEST RADIOL, V40, P277, DOI 10.1097/01.rli.0000160550.95547.22
   Boyd J, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2772250
   CARMODY RF, 1994, AM J NEURORADIOL, V15, P775
   Chiu JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/physrev.00047.2009
   Choi YK, 2015, J MECH SCI TECHNOL, V29, P2565, DOI 10.1007/s12206-015-0551-x
   Chung B, 2015, ANN BIOMED ENG, V43, P122, DOI 10.1007/s10439-014-1093-6
   GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619
   Grinberg L, 2013, J COMPUT PHYS, V244, P131, DOI 10.1016/j.jcp.2012.08.023
   Johnston BM, 2004, J BIOMECH, V37, P709, DOI 10.1016/j.jbiomech.2003.09.016
   Kawaguchi T, 2012, J NEUROSURG, V117, P774, DOI 10.3171/2012.7.JNS111991
   Kolega J, 2011, J VASC RES, V48, P429, DOI 10.1159/000324840
   김현수, 2014, [Journal of The Korean Radiological Society, 대한영상의학회지], V71, P164, DOI 10.3348/jksr.2014.71.4.164
   Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035
   McKinney AM, 2017, ATLAS NORMAL IMAGING
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Nucci C, 2016, INT OPHTHALMOL, V36, P907, DOI 10.1007/s10792-016-0206-7
   Paliwal N, 2017, J BIOMECH ENG-T ASME, V139, DOI 10.1115/1.4037792
   Russin J, 2015, WORLD NEUROSURG, V83, P1057, DOI 10.1016/j.wneu.2014.12.038
   Sakamoto S, 2006, AM J NEURORADIOL, V27, P1332
   Sherif C, 2009, J NEUROL NEUROSUR PS, V80, P1261, DOI 10.1136/jnnp.2008.170860
   Singh PK, 2010, CLIN NEUROL NEUROSUR, V112, P306, DOI 10.1016/j.clineuro.2009.12.018
   Tang A.Y.S., 2012, J BIOMED SCI ENG, V5, P422, DOI [10.4236/jbise.2012.58054, DOI 10.4236/JBISE.2012.58054]
   Taylor CA, 1998, ANN BIOMED ENG, V26, P975, DOI 10.1114/1.140
   Tso MK, 2015, WORLD NEUROSURG, V84, P12, DOI 10.1016/j.wneu.2015.02.040
   Xiang J, 2014, J BIOMECH, V47, P3882, DOI 10.1016/j.jbiomech.2014.09.034
   Xiang JP, 2011, STROKE, V42, P144, DOI 10.1161/STROKEAHA.110.592923
   Zhao XM, 2017, ACTA MECH SINICA-PRC, V33, P472, DOI 10.1007/s10409-017-0636-0
   2013, ANN BIOMED ENG, V41, P2157, DOI DOI 10.1007/S10439-013-0811-9
   2012, MEDIAT INFLAMM
NR 32
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1023
EP E1033
DI 10.1016/j.wneu.2019.02.002
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700127
PM 30771545
DA 2020-05-12
ER

PT J
AU Balasundaram, P
   Sebastian, LJD
   Jain, N
   Prabhakar, A
   Garg, A
   Gaikwad, S
AF Balasundaram, Parthiban
   Sebastian, Leve Joseph Devarajan
   Jain, Nishchint
   Prabhakar, Anuj
   Garg, Ajay
   Gaikwad, Shailesh
TI Management of Arterial Pseudoaneurysms of the Neck in a Pediatric
   Population: An Endovascular Case Series and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arterial pseudoaneurysms; Neck aneurysms; Parent vessel sacrifice;
   Pediatric vascular; Stent graft
ID INTERNAL CAROTID-ARTERY; OCCLUSION; ANEURYSM; PATIENT; TONSILLECTOMY;
   COMPLICATION; SECONDARY; STROKE
AB BACKGROUND: Arterial pseudoaneurysms of the neck are rarely reported in the pediatric population and no dedicated large series are available. Trauma and infection are the most common causes for these aneurysms, with congenital and collagen vascular disorders being the less common causes. These lesions can be life threatening, especially when they present with bleeding or airway compromise.
   METHODS: We searched our radiology information system for all cases of pediatric neck aneurysm presented between June 2015 and May 2018. These cases were analyzed for clinicoepidemiologic variables, clinical presentation, imaging findings, management, and follow-up.
   RESULTS: Six children were included in the study (male/female ratio, 5:1), with a mean age of 7.8 years (range, 2.5-15 years). Four presented acutely with either bleeding or rapidly enlarging neck swelling, whereas 2 presented with slowly increasing pulsatile swelling. One had a traumatic cause, 2 had infections, and 1 had infective cervical lymphadenitis complicated by iatrogenic injury whereas no definite causative mechanisms could be accounted for in 2 patients. Two of the children were managed by trapping of the aneurysm and 2 only by proximal parent vessel occlusion. The other 2 children were treated with stent graft deployment across the aneurysm neck to reconstruct the parent vessel. All the patients were doing well during the follow-up period (mean, 14.8 months).
   CONCLUSIONS: Endovascular means of treatment for pediatric neck aneurysms is relatively simple and safe. Although parent vessel sacrifice is the gold-standard management, vessel-preserving strategies can be tried in select cases with favorable anatomy.
C1 [Balasundaram, Parthiban; Sebastian, Leve Joseph Devarajan; Jain, Nishchint; Prabhakar, Anuj; Garg, Ajay; Gaikwad, Shailesh] All India Inst Med Sci, Dept Neuroimaging & Intervent Neuroradiol, New Delhi, India.
RP Sebastian, LJD (reprint author), All India Inst Med Sci, Dept Neuroimaging & Intervent Neuroradiol, New Delhi, India.
EM leve_s@yahoo.com
RI Garg, Ajay/AAM-2603-2020
OI Garg, Ajay/0000-0002-9385-291X; Balasundaram,
   Parthiban/0000-0003-3848-2140; Sebastian, Leve Joseph
   Devarajan/0000-0002-4777-2804
CR Chen RQ, 2018, WORLD NEUROSURG, V116, pE951, DOI 10.1016/j.wneu.2018.05.140
   De Luccia N, 2010, ANN VASC SURG, V24, DOI 10.1016/j.avsg.2009.05.021
   Debette S, 2015, LANCET NEUROL, V14, P640, DOI 10.1016/S1474-4422(15)00009-5
   Garcia-Monaco RD, 2012, CARDIOVASC INTER RAD, V35, P704, DOI 10.1007/s00270-011-0246-3
   Gralla J, 2004, J ENDOVASC THER, V11, P734, DOI 10.1583/1308R.1
   John N, 2009, CLIN NEUROL NEUROSUR, V111, P105, DOI 10.1016/j.clineuro.2008.08.006
   Kikuchi K, 2014, WORLD J RADIOL, V6, P619, DOI 10.4329/wjr.v6.i8.619
   Lago DM, 2015, INT J PEDIATR OTORHI, V79, P2428, DOI 10.1016/j.ijporl.2015.08.035
   Liu AY, 2003, AM J NEURORADIOL, V24, P1520
   da Silva PSL, 2011, PEDIATR EMERG CARE, V27, P422, DOI 10.1097/PEC.0b013e3182187539
   Meyers PM, 1999, AM J NEURORADIOL, V20, P559
   Mitchell R, 2014, ROBBINS COTRAN PATHO, P501
   Nadarajah J, 2018, PEDIATR NEUROSURG, V53, P346, DOI 10.1159/000490063
   Raffin CN, 2002, INTERV NEURORADIOL, V8, P71, DOI 10.1177/159101990200800113
   Reddy Subash C, 2003, Interact Cardiovasc Thorac Surg, V2, P514, DOI 10.1016/S1569-9293(03)00080-X
   Requejo F, 2016, CHILD NERV SYST, V32, P505, DOI 10.1007/s00381-015-2992-z
   Ruff MW, 2017, J CHILD NEUROL, V32, P230, DOI 10.1177/0883073816678556
   Sankararaman S, 2012, PEDIATR NEUROL, V47, P312, DOI 10.1016/j.pediatrneurol.2012.06.008
   Sattur MG, 2019, OPER NEUROSURG, V16, pE60, DOI 10.1093/ons/opy087
   Steinberg J, 2017, J NEUROSURG-PEDIATR, V19, P8, DOI 10.3171/2016.7.PEDS14457
   Tan MA, 2009, J CHILD NEUROL, V24, P354, DOI 10.1177/0883073808324775
   Tannuri L, 2003, J PEDIATR SURG, V38, P1393, DOI 10.1016/S0022-3468(03)00403-2
   Wang A, 2016, CHILD NERV SYST, V32, P2459, DOI 10.1007/s00381-016-3171-6
   Welleweerd JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117915
   Windfuhr JP, 2001, INT J PEDIATR OTORHI, V61, P155, DOI 10.1016/S0165-5876(01)00557-2
   Wolfe SQ, 2008, J NEUROSURG-PEDIATR, V1, P240, DOI 10.3171/PED/2008/1/3/240
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E273
EP E281
DI 10.1016/j.wneu.2019.01.061
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700035
PM 30684708
DA 2020-05-12
ER

PT J
AU Baracchini, C
   Farina, F
   Pieroni, A
   Palmieri, A
   Kulyk, C
   Viaro, F
   Gabrieli, JD
   Cester, G
   Causin, F
   Manara, R
AF Baracchini, Claudio
   Farina, Filippo
   Pieroni, Alessio
   Palmieri, Anna
   Kulyk, Caterina
   Viaro, Federica
   Gabrieli, Joseph-Domenico
   Cester, Giacomo
   Causin, Francesco
   Manara, Renzo
TI Ultrasound Identification of Patients at Increased Risk of Intracranial
   Hemorrhage After Successful Endovascular Recanalization for Acute
   Ischemic Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular treatment; Intracranial hemorrhage; Transcranial ultrasound
ID BRAIN-BARRIER DISRUPTION; HEALTH-CARE PROFESSIONALS; MECHANICAL
   THROMBECTOMY; EARLY MANAGEMENT; TRANSFORMATION; REPERFUSION;
   CLASSIFICATION; GUIDELINES; THERAPY; THROMBOLYSIS
AB BACKGROUND: Intracranial hemorrhage (ICH) is the most feared complication of endovascular treatment (EVT) for acute ischemic stroke because of anterior circulation large vessel occlusion (LVO). The purpose of this study was to identify cerebral hemodynamic predictors of ICH and poor outcome in patients with successful recanalization.
   METHODS: Serial transcranial color-coded sonography (TCCS) examinations assessed vessel status and cerebral hemodynamics of 226 (mean age, 69.8 +/- 12.5 years; 130 men [57.5%]) consecutive patients with acute anterior circulation LVO at 48 hours and 1 week after EVT. Middle cerebral artery peak systolic velocity (PSVMCA) and PSVMCA ratio (recanalized PSVMCA/contralateral PSVMCA) were recorded.
   RESULTS: Out of 180 successfully recanalized patients (79.6%), 28 patients (15.5%) had ICH. They more often had arterial hypertension (25/28 [89.3%] vs. 106/152 [69.7%], P = 0.04), a more severe stroke syndrome (18 [range, 10-23] vs. 16 [range, 5-26], P = 0.01), a worse clinical outcome (90-day modified Rankin Scale [mRS] score 3-5: 16/28 [57.1%] vs. 42/152 [27.6%], P = 0.004), and soon after EVT showed a significantly higher mean PSVMCA ratio (3.4 +/- 0.1 vs. 2.4 +/- 0.1, P < 0.0001) than patients without ICH, respectively. In multivariate analysis, early PSVMCA ratio was independently associated with postinterventional ICH (odds ratio, 13.379; 95% confidence interval, 2.466-50.372; P < 0.01). The patients with ICH (19/28 [67.9%]) who resumed normal PSVMCA values at 1 week after EVT had a better outcome (90-day mRS score 0-2: 8/19 [42.1%] vs. 0/9 [0%], respectively).
   CONCLUSIONS: Early TCCS detection of a high PSVMCA ratio in successfully recanalized stroke patients indicates an increased risk of ICH, whereas cerebral hemodynamics normalization at 1 week in patients with postinterventional ICH predicts a relatively better 3-month outcome.
C1 [Baracchini, Claudio; Farina, Filippo; Pieroni, Alessio; Palmieri, Anna; Kulyk, Caterina; Viaro, Federica] Univ Padua, Sch Med, Dept Neurosci, Stroke Unit, Padua, Italy.
   [Baracchini, Claudio; Farina, Filippo; Pieroni, Alessio; Palmieri, Anna; Kulyk, Caterina; Viaro, Federica] Univ Padua, Sch Med, Dept Neurosci, Neurosonol Lab, Padua, Italy.
   [Gabrieli, Joseph-Domenico; Cester, Giacomo; Causin, Francesco; Manara, Renzo] Univ Padua, Sch Med, Neuroradiol Unit, Padua, Italy.
RP Baracchini, C (reprint author), Univ Padua, Sch Med, Dept Neurosci, Stroke Unit, Padua, Italy.; Baracchini, C (reprint author), Univ Padua, Sch Med, Dept Neurosci, Neurosonol Lab, Padua, Italy.
EM claudiobaracchini@gmail.com
RI Gabrieli, John/AAJ-2869-2020; Pieroni, Alessio/Q-9779-2016
OI Pieroni, Alessio/0000-0002-7094-2445
CR Arimura K, 2017, J ENDOVASC THER, V11, P391, DOI 10.5797/jnet.oa.2016-0089
   Bai J, 2015, INT J STROKE, V10, P143, DOI 10.1111/ijs.12434
   BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O
   Baracchini C, 2017, J NEUROIMAGING, V27, P409, DOI 10.1111/jon.12416
   Bartels E., 2016, MANUAL NEUROSONOLOGY, P118
   Baumgartner RW, 1999, STROKE, V30, P87, DOI 10.1161/01.STR.30.1.87
   Bracard S, 2016, LANCET NEUROL, V15, P1138, DOI 10.1016/S1474-4422(16)30177-6
   Chernyshev OY, 2005, STROKE, V36, P32, DOI 10.1161/01.STR.0000150496.27584.e3
   Desilles JP, 2013, NEUROLOGY, V80, P844, DOI 10.1212/WNL.0b013e31828406de
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Goyal N, 2017, NEUROLOGY, V89, P540, DOI 10.1212/WNL.0000000000004184
   Grant EG, 2003, RADIOLOGY, V229, P340, DOI 10.1148/radiol.2292030516
   Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083
   Hao YG, 2017, STROKE, V48, P1203, DOI 10.1161/STROKEAHA.116.016368
   Higashida RT, 2003, STROKE, V34, pE109, DOI 10.1161/01.STR.0000082721.62796.09
   Jiang SW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144452
   Kidwell CS, 2008, CEREBROVASC DIS, V25, P338, DOI 10.1159/000118379
   Kneihsl M, 2018, J NEUROINTERV SURG, V10, P882, DOI 10.1136/neurintsurg-2017-013617
   Krueger M, 2015, J CEREBR BLOOD F MET, V35, P292, DOI 10.1038/jcbfm.2014.199
   Marks MP, 2014, J NEUROINTERV SURG, V6, P724, DOI 10.1136/neurintsurg-2013-010973
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Nogueira RG, 2015, J NEUROINTERV SURG, V7, P16, DOI 10.1136/neurintsurg-2013-010743
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074
   Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647
   Shi ZS, 2018, J NEUROIMAGING, V28, P283, DOI 10.1111/jon.12504
   Thanvi BR, 2008, POSTGRAD MED J, V84, P361, DOI 10.1136/pgmj.2007.067058
   Tsivgoulis G, 2016, MANUAL NEUROSONOLOGY, P169
   van Mook WNKA, 2005, LANCET NEUROL, V4, P877, DOI 10.1016/S1474-4422(05)70251-9
   von Kummer R, 2015, STROKE, V46, P2981, DOI 10.1161/STROKEAHA.115.010049
   Wahlgren N, 2016, INT J STROKE, V11, P134, DOI 10.1177/1747493015609778
   Wang DT, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0442-x
   Wang W, 2015, MOL NEUROBIOL, V52, P1572, DOI 10.1007/s12035-014-8952-x
   Wang XY, 2003, MOL NEUROBIOL, V28, P229, DOI 10.1385/MN:28:3:229
   Yoo AJ, 2013, STROKE, V44, P2509, DOI 10.1161/STROKEAHA.113.001990
NR 35
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E849
EP E855
DI 10.1016/j.wneu.2019.01.198
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700105
PM 30743030
DA 2020-05-12
ER

PT J
AU Breshears, JD
   Haddad, AF
   Viner, J
   Rau, J
   Sankaran, S
   McDermott, MW
AF Breshears, Jonathan D.
   Haddad, Alexander F.
   Viner, Jennifer
   Rau, Johnny
   Sankaran, Sujatha
   McDermott, Michael W.
TI A Reduced Exogenous Steroid Taper for Postoperative Brain Tumor
   Patients-A Case-Control Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Dexamethasone; Postoperative cerebral edema; Steroid taper
ID CEREBRAL EDEMA; DEXAMETHASONE; MANAGEMENT; TOXICITY
AB BACKGROUND: Dexamethasone is a standard treatment for cerebral edema after brain tumor surgery. However, its side effects can negatively impact the quality and safety of care provided to patients. Sparse evidence exists in the literature regarding postoperative steroid dosing to guide clinicians. The objective of this study was to determine if a new reduced exogenous steroid taper (REST) protocol would effectively treat postoperative cerebral edema while reducing the incidence of steroid-related side effects including diabetes, hypertension, and insomnia.
   METHODS: A REST protocol (dexamethasone 38.5 mg tapered over 10 days) was instituted for patients with postoperative brain tumor of a single surgeon. Historical controls treated with a high-dose taper (dexamethasone 117 mg taper over 17 days) were selected to match for baseline characteristics. Outcomes of new or worsened diabetes, hypertension, and insomnia, as well as length of stay (LOS) and 30-day readmission rates, were compared.
   RESULTS: Twenty-five patients were included in each group. There were no significant differences in baseline characteristics. The REST group received a median of 34.5 mg (interquartile range, 32-41 mg) of dexamethasone, whereas controls received 43 mg (interquartile range, 16-91 mg) (P = 0.04). There was a significant reduction in the incidence of new or worsened hypertension in the REST group (0%) compared with controls (20%, P = 0.02). No difference was seen in the rates of diabetes mellitus, insomnia, LOS, or 30-day readmission rates.
   CONCLUSIONS: A reduced steroid taper after brain tumor surgery significantly reduced the incidence of hypertension without increasing LOS or 30-day readmissions compared with controls treated with a high-dose taper.
C1 [Breshears, Jonathan D.] Univ Texas MD Anderson Canc Ctr, Dept Neurol Surg, Houston, TX 77030 USA.
   [Haddad, Alexander F.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
   [Viner, Jennifer; Sankaran, Sujatha; McDermott, Michael W.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Rau, Johnny] Univ Calif San Francisco, Dept Pharmaceut Serv, San Francisco, CA 94143 USA.
   [Sankaran, Sujatha] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
RP Haddad, AF (reprint author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
EM alexander.haddad@ucsf.edu
CR Dietrich Jorg, 2011, Expert Rev Clin Pharmacol, V4, P233, DOI 10.1586/ecp.11.1
   Fan Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093264
   GALICICH JH, 1961, AM PRACT DIG TREAT, V12, P169
   GALICICH JH, 1961, J LANCET, V81, P46
   Gomes JA, 2005, CRIT CARE MED, V33, P1214, DOI 10.1097/01.CCM.0000166389.85273.38
   Kaal ECA, 2004, CURR OPIN ONCOL, V16, P593, DOI 10.1097/01.cco.0000142076.52721.b3
   Kim H, 2008, BIOCHEM BIOPH RES CO, V372, P243, DOI 10.1016/j.bbrc.2008.05.025
   LONG DM, 1966, J NEUROSURG, V24, P843, DOI 10.3171/jns.1966.24.5.0843
   Luedi MM, 2018, J NEUROSURG, V129, P1446, DOI 10.3171/2017.7.JNS17668
   Manson SC, 2009, RESP MED, V103, P975, DOI 10.1016/j.rmed.2009.01.003
   McClelland S, 2008, NEUROSURGERY, V62, P965, DOI 10.1227/01.neu.0000318183.25783.77
   RUDERMAN NB, 1965, CANCER, V18, P298, DOI 10.1002/1097-0142(196503)18:3<298::AID-CNCR2820180306>3.0.CO;2-H
   Ryan R, 2012, J NEURO-ONCOL, V106, P449, DOI 10.1007/s11060-011-0713-3
   Sturdza A, 2008, SUPPORT CARE CANCER, V16, P1041, DOI 10.1007/s00520-007-0395-8
   Tommasino C, 1992, Minerva Anestesiol, V58, P35
   WEISSMAN DE, 1987, J NEURO-ONCOL, V5, P125, DOI 10.1007/BF02571300
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E44
EP E47
DI 10.1016/j.wneu.2018.12.173
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700008
PM 30639502
DA 2020-05-12
ER

PT J
AU Buchanan, IA
   Lin, M
   Donoho, DA
   Ding, L
   Giannotta, SL
   Attenello, F
   Mack, WJ
   Liu, JC
AF Buchanan, Ian A.
   Lin, Michelle
   Donoho, Daniel A.
   Ding, Li
   Giannotta, Steven L.
   Attenello, Frank
   Mack, William J.
   Liu, John C.
TI Venous Thromboembolism After Degenerative Spine Surgery: A Nationwide
   Readmissions Database Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult cohort; Deep vein thrombosis (DVT); Nationwide database; Pulmonary
   embolism (PE); Readmission; Spine surgery; Venous thromboembolism (VTE)
ID RISK-FACTORS; CONSECUTIVE PATIENTS; AMERICAN-COLLEGE; PREVALENCE;
   THROMBOSIS; COMPLICATIONS; DISEASE; PATIENT; NEUROSURGERY; PROPHYLAXIS
AB BACKGROUND: Venous thromboembolism (VTE) is an appreciable burden on health care. The protracted recumbency experienced by many spinal patients juxtaposed with concerns for postoperative hemorrhage from early anticoagulation results in conflicting stances regarding chemoprophylaxis. Identifying risk factors associated with VTE is therefore instrumental in guiding management.
   OBJECTIVE: To identify VTE risk factors in patients undergoing degenerative spine surgery.
   METHODS: The Nationwide Readmissions Database was searched for adults undergoing spine surgery for degenerative diseases between 2010 and 2014. The 30-day and 90-day VTE incidence was estimated from readmissions with new VTE diagnoses. A multivariate survey-adjusted logistic regression model was used to identify variables associated with VTE diagnoses on readmission.
   RESULTS: Of 838,507 degenerative spine cases queried, 3499 patients (0.42%) were readmitted with a VTE diagnosis within 30 days and 4321 patients (0.62%) were readmitted within 90 days. In multivariate analysis, steroids were independently associated with a higher likelihood of readmission with VTE at both 30 days (odds ratio, 1.58; P < 0.001) and 90 days (odds ratio, 1.97; P < 0.001). Significant associations were also identified with thoracolumbar surgery, length of stay, and discharge to institutional care.
   CONCLUSIONS: The incidence of readmission with VTE diagnoses in spine surgery is low. However, their devastating consequences underscore the need to identify those patients deemed high risk. These patients include those having thoracolumbar surgery, of advanced age, with prolonged length of stay, using corticosteroids, and with a disposition to institutional care (e.g., skilled nursing facility or long-term acute care). Given the association between steroids and VTE, clinicians should be judicious about perioperative administration despite their obvious antiinflammatory benefits.
C1 [Buchanan, Ian A.; Lin, Michelle; Donoho, Daniel A.; Giannotta, Steven L.; Attenello, Frank; Mack, William J.; Liu, John C.] Univ Southern Calif, Dept Neurol Surg, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Ding, Li] Univ Southern Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA USA.
RP Buchanan, IA (reprint author), Univ Southern Calif, Dept Neurol Surg, Keck Sch Med, Los Angeles, CA 90033 USA.
EM ianbuchanan07@gmail.com
RI ding, li/AAN-2113-2020; Ding, Li/G-4031-2019
OI Ding, Li/0000-0001-8565-430X
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR001854]
CR Akeda K, 2014, SPINE, V39, P791, DOI 10.1097/BRS.0000000000000295
   Algattas H, 2015, WORLD NEUROSURG, V84, P1372, DOI 10.1016/j.wneu.2015.06.033
   ANDERSON FA, 1992, ARCH INTERN MED, V152, P1660, DOI 10.1001/archinte.152.8.1660
   Chew HK, 2006, ARCH INTERN MED, V166, P458
   Chibbaro S, 2018, WORLD NEUROSURG, V109, pE510, DOI 10.1016/j.wneu.2017.10.012
   Chitale R, 2015, J SPINAL DISORD TECH, V28, P126, DOI 10.1097/BSD.0b013e318270dad7
   Cox JB, 2014, J NEUROSURG-SPINE, V21, P677, DOI 10.3171/2014.6.SPINE13447
   Danish Shabbar F, 2004, Neurosurg Focus, V17, pE2
   Dhillon ES, 2017, J NEUROSURG-SPINE, V27, P681, DOI 10.3171/2017.3.SPINE161076
   Eskander RN, 2014, J CLIN ONCOL, V32, P4113, DOI 10.1200/JCO.2014.56.7743
   Glotzbecker MP, 2009, SPINE, V34, P291, DOI 10.1097/BRS.0b013e318195601d
   Goldhaber SZ, 2010, J AM COLL CARDIOL, V56, P1, DOI 10.1016/j.jacc.2010.01.057
   Hoefnagel D, 2014, CLIN NEUROL NEUROSUR, V123, P150, DOI 10.1016/j.clineuro.2014.06.001
   Jain A, 2017, J NEUROSURG-SPINE, V27, P534, DOI 10.3171/2017.3.SPINE161011
   Johannesdottir SA, 2013, JAMA INTERN MED, V173, P743, DOI 10.1001/jamainternmed.2013.122
   Khan NR, 2018, J NEUROSURG, V129, P906, DOI 10.3171/2017.2.JNS162040
   Khorana AA, 2007, CANCER-AM CANCER SOC, V110, P2339, DOI 10.1002/cncr.23062
   Kim DY, 2015, SPINE, V40, P299, DOI 10.1097/BRS.0000000000000754
   Kshettry VR, 2014, J CLIN NEUROSCI, V21, P282, DOI 10.1016/j.jocn.2013.07.003
   Leibson CL, 2008, MAYO CLIN PROC, V83, P151
   Marras LC, 2000, CANCER, V89, P640, DOI 10.1002/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E
   McClendon J, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.03.068
   Moayer AlirezaFarid, 2016, Bull Emerg Trauma, V4, P38
   Oda T, 2000, SPINE, V25, P2962, DOI 10.1097/00007632-200011150-00019
   Piper K, 2017, J NEUROSURG-SPINE, V26, P90, DOI 10.3171/2016.6.SPINE1656
   Ramos RD, 2016, J NEUROSURG-PEDIATR, V18, P730, DOI 10.3171/2016.6.PEDS16200
   Rolston JD, 2014, J NEUROSURG, V121, P908, DOI 10.3171/2014.6.JNS131419
   Sansone JM, 2010, J BONE JOINT SURG AM, V92A, P304, DOI 10.2106/JBJS.H.01815
   Schairer WW, 2014, SPINE, V39, P911, DOI 10.1097/BRS.0000000000000315
   Sebastian AS, 2016, GLOB SPINE J, V6, P738, DOI 10.1055/s-0036-1579553
   Sebastian AS, 2016, GLOB SPINE J, V6, P465, DOI 10.1055/s-0035-1569056
   Senders JT, 2018, J NEURO-ONCOL, V136, P135, DOI 10.1007/s11060-017-2631-5
   Sherrod BA, 2016, J NEUROSURG-PEDIATR, V18, P350, DOI 10.3171/2016.2.PEDS15604
   Simanek R, 2007, NEURO-ONCOLOGY, V9, P89, DOI 10.1215/15228517-2006-035
   Squizzato A, 2007, INTERN EMERG MED, V2, P76, DOI 10.1007/s11739-007-0026-x
   van Zaane B, 2010, J THROMB HAEMOST, V8, P2483, DOI 10.1111/j.1538-7836.2010.04034.x
   van Zaane B, 2013, SEMIN THROMB HEMOST, V39, P489, DOI 10.1055/s-0033-1343889
   Van Zaane B, 2009, J CLIN ENDOCR METAB, V94, P2743, DOI 10.1210/jc.2009-0290
   Wang TY, 2015, WORLD NEUROSURG, V84, P1605, DOI 10.1016/j.wneu.2015.07.008
   Wang X, 2017, CLIN NEUROL NEUROSUR, V155, P58, DOI 10.1016/j.clineuro.2017.02.018
   Wei JC, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0403-0
   Yoshioka K, 2015, SPINE, V40, pE301, DOI 10.1097/BRS.0000000000000727
   Yoshioka K, 2013, ORTHOPEDICS, V36, pE223, DOI 10.3928/01477447-20130122-26
   Zacharia BE, 2017, J NEUROSURG-SPINE, V27, P189, DOI 10.3171/2017.2.SPINE16861
   Zuckerman RB, 2016, NEW ENGL J MED, V375, P494, DOI 10.1056/NEJMc1606658
   2018, J NEUROSURG-SPINE, V28, P88, DOI DOI 10.3171/2017.5.SPINE161399
NR 46
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E165
EP E174
DI 10.1016/j.wneu.2019.01.029
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700022
PM 30684695
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Burkhardt, JK
   Lawton, MT
AF Burkhardt, Jan-Karl
   Lawton, Michael T.
TI Practice Trends in Intracranial Bypass Surgery in a 21-Year Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral revascularization; Extracranial-intracranial bypass;
   Intracranial bypass; Intracranial-intracranial bypass; Microsurgical
   treatment
ID CEREBRAL-ARTERY BYPASS; HIGH-FLOW BYPASS; ANEURYSMS; OCCLUSION; OPTIONS
AB OBJECTIVE: The aim of this study was to analyze practice trends in specific intracranial bypass types in a large, consecutive bypass experience.
   METHODS: This retrospective review of a prospectively maintained database included all intracranial bypasses performed by a single surgeon over 21 years. Bypass types were grouped into 7 categories and analyzed in seven 3-year time intervals: type 1 = extracranial-to-intracranial (EC-IC) bypass with scalp arteries as donors; type 2 = EC-IC bypass with interposition graft to cervical carotid arteries; type 3 = arterial reimplantation; type 4 = in situ bypass; type 5 = reanastomosis; type 6 = intracranial-to-intracranial bypass with interposition graft; and type 7 = combination bypass.
   RESULTS: In total, 598 intracranial bypasses were performed including 359 type 1, 59 type 2, 24 type 3, 30 type 4, 37 type 5, 36 type 6, and 53 type 7. Although type 1 and type 3-7 bypasses increased, type 2 bypasses decrease in frequency. Aneurysms were the most common bypass indication (41.8%), followed by moyamoya disease (31.8%), and intracranial arterial stenosis or occlusion (24.9%). Endovascular treatment failure was observed in 10.8% of the aneurysm patients treated with a bypass procedure.
   CONCLUSIONS: Intracranial bypass remains an essential technique for open vascular neurosurgeons. The classic low-flow EC-IC bypasses, intracranial-to-intracranial, and combination bypasses increased over time, whereas the high-flow EC-IC interpositional bypasses decreased over time. These trends reflect the increasing use of flow diverters as well as the need for surgical revascularization for complex aneurysms, and those that failed previous endovascular therapy.
C1 [Lawton, Michael T.] Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.
   [Burkhardt, Jan-Karl; Lawton, Michael T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Burkhardt, Jan-Karl] Baylor Coll Med, Dept Neurosurg, Med Ctr, Houston, TX 77030 USA.
RP Lawton, MT (reprint author), Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.; Lawton, MT (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
EM Michael.Lawton@barrowbrainandspine.com
CR Abe H, 2017, NEUROL MED-CHIR, V57, P284, DOI 10.2176/nmc.oa.2016-0319
   Abla AA, 2016, J NEUROSURG, V124, P1275, DOI 10.3171/2015.5.JNS15368
   Abla AA, 2014, J NEUROSURG, V120, P1364, DOI 10.3171/2014.3.JNS132219
   Arias EJ, 2014, NEUROSURGERY, V74, pS116, DOI 10.1227/NEU.0000000000000229
   Becske T, 2017, J NEUROSURG, V127, P81, DOI 10.3171/2015.6.JNS15311
   Bender MT, 2019, J NEUROSURG, V130, P259, DOI 10.3171/2017.11.JNS171738
   Cerejo R, 2017, NEURORADIOLOGY, V59, P1285, DOI 10.1007/s00234-017-1936-6
   Dumont TM, 2014, NEUROSURGERY, V74, pS17, DOI 10.1227/NEU.0000000000000217
   Esposito G, 2016, ACTA NEUROCHIR, V158, P1523, DOI 10.1007/s00701-016-2868-3
   Fujimura M, 2015, NEUROL MED-CHIR, V55, P189, DOI 10.2176/nmc.ra.2014-0307
   Griessenauer CJ, 2019, J NEUROSURG, V130, P923, DOI 10.3171/2017.9.JNS171376
   Ishishita Y, 2014, WORLD NEUROSURG, V82, P130, DOI 10.1016/j.wneu.2013.02.063
   Kawashima A, 2017, OPER NEUROSURG, V13, P309, DOI 10.1093/ons/opw033
   Langer DJ, 2005, SKULL BASE-INTERD AP, V15, P191, DOI 10.1055/s-2005-872048
   Lawton MT, 2018, 7 BYPASSES TENETS TE
   Matsukawa H, 2018, J NEUROSURG, V128, P1753, DOI 10.3171/2016.11.JNS161986
   Matsukawa H, 2016, WORLD NEUROSURG, V87, P35, DOI 10.1016/j.wneu.2015.12.009
   Mokin M, 2018, J NEUROINTERV SURG, V10, P1074, DOI 10.1136/neurintsurg-2017-013701
   Natarajan SK, 2016, J NEUROSURG, V125, P111, DOI 10.3171/2015.6.JNS1565
   Powers WJ, 2011, JAMA-J AM MED ASSOC, V306, P1983, DOI 10.1001/jama.2011.1610
   Sanai N, 2009, NEUROSURGERY, V65, P670, DOI 10.1227/01.NEU.0000348557.11968.F1
   Wessels L, 2019, NEUROSURG REV, V42, P389, DOI 10.1007/s10143-018-0966-9
   Yasargil M G, 1977, Neurosurgery, V1, P22
   Zhu W, 2011, WORLD NEUROSURG, V75, P476, DOI 10.1016/j.wneu.2010.07.043
   2018, OPER NEUROSURG, V15, P601
   2017, J NEUROSURG, V127, P463, DOI DOI 10.3171/2016.7.JNS16772
NR 26
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E717
EP E722
DI 10.1016/j.wneu.2019.01.161
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700089
PM 30735866
DA 2020-05-12
ER

PT J
AU Burkhardt, JK
   Winkler, EA
   Gandhi, S
   Lawton, MT
AF Burkhardt, Jan-Karl
   Winkler, Ethan A.
   Gandhi, Sirin
   Lawton, Michael T.
TI Single-Barrel Versus Double-Barrel Superficial Temporal Artery to Middle
   Cerebral Artery Bypass: A Comparative Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Double barrel; Extracranial-intracranial bypass; Microsurgical
   treatment; Single barrel; Superficial temporal artery to middle cerebral
   artery (STA-MCA)
AB OBJECTIVE: The superficial temporal artery to middle cerebral artery (STA-MCA) bypass is the most common bypass for augmenting or restoring cerebral blood flow. Although the single-barrel (SB) STA-MCA bypass is sufficient in most cases, the double-barrel (DB) STA-MCA bypass can supply the demands of different vascular territories or multiple efferent arteries. We present a comparative analysis of SB and DB STA-MCA bypass in a large, consecutive series to examine indications, surgical results, and patient outcomes.
   METHODS: A retrospective review of a prospectively maintained database identified all STA-MCA bypasses performed by a single surgeon over 21 years.
   RESULTS: In total, 261 patients received 378 STA-MCA bypasses in 351 surgeries. SB STA-MCA bypasses were performed in 234 patients (90%), whereas DB STA-MCA bypasses were performed in 27 patients (10%). Patients with DB STA-MCA bypasses were more likely to undergo bilateral bypass procedures than those receiving SB STAMCA bypass (P < 0.0001). In patients with bilateral STAMCA bypasses (n = 91, 35%), 69 patients received bilateral SB STA-MCA bypasses (76%), whereas 22 patients received a DB STA-MCA bypass on 1 hemisphere (24%). There was no difference in bypass patency or clinical outcome in patients with SB and DB STA-MCA bypasses.
   CONCLUSIONS: DB STA-MCA bypasses are reserved for patients requiring revascularization of multiple vascular territories or efferent arteries. DB STA-MCA bypasses have patency rates and patient outcomes comparable to SB STAMCA, with the advantages of a single incision and reduced operative complexity compared to high-flow bypasses. DB STA-MCA bypass is an important element in the vascular neurosurgeon's bypass armamentarium.
C1 [Burkhardt, Jan-Karl; Gandhi, Sirin; Lawton, Michael T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Burkhardt, Jan-Karl] Baylor Coll Med, Med Ctr, Dept Neurosurg, Houston, TX 77030 USA.
   [Winkler, Ethan A.; Lawton, Michael T.] Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.
RP Lawton, MT (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Lawton, MT (reprint author), Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.
EM Michael.Lawton@barrowbrainandspine.com
CR Cherian J, 2018, OPER NEUROSURG, V14, P288, DOI 10.1093/ons/opx119
   Choi HH, 2019, J INVEST SURG, V32, P731, DOI 10.1080/08941939.2018.1489566
   Choi Joon-Ho, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P258, DOI 10.7461/jcen.2016.18.3.258
   Duckworth EAM, 2013, NEUROSURGERY, V73, P30, DOI 10.1227/NEU.0b013e318285b587
   Esposito G, 2018, ACTA NEUROCHIR SUPPL, V129, P73, DOI 10.1007/978-3-319-73739-3_10
   Hanggi D, 2012, ACTA NEUROCHIR, V154, P1943, DOI 10.1007/s00701-012-1480-4
   Hu P, 2018, ACTA NEUROCHIR, V160, P1939, DOI 10.1007/s00701-018-3652-3
   Lawton MT, 2018, 7 BYPASSES TENETS TE
   Lee CH, 2018, TZU CHI MED J, V30, P110, DOI 10.4103/tcmj.tcmj_193_17
   Rodriguez-Hernandez A, 2012, NEUROCIRUGIA, V23, P5, DOI 10.1016/j.neucir.2011.11.001
   Rodriguez-Hernandez A, 2011, WORLD NEUROSURG, V76, pS72, DOI 10.1016/j.wneu.2011.06.032
   Wanebo JE, 2004, NEUROSURGERY, V55, P395, DOI 10.1227/01.NEU.0000129549.99061.94
   Wessels L, 2019, NEUROSURG REV, V42, P389, DOI 10.1007/s10143-018-0966-9
   YASARGIL MG, 1970, SURGERY, V67, P221
   Yoshimura S, 2010, NEUROL MED-CHIR, V50, P956, DOI 10.2176/nmc.50.956
   2017, J NEUROSURG, V127, P463, DOI DOI 10.3171/2016.7.JNS16772
   2004, NEUROSURGERY, V55, P395, DOI DOI 10.1227/01.NEU.0000129549.99061.94
NR 17
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E408
EP E415
DI 10.1016/j.wneu.2019.01.089
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700054
PM 30703593
DA 2020-05-12
ER

PT J
AU Cakir, T
   Kayaci, S
   Aydin, MD
   Ozoner, B
   Calik, I
   Altinkaynak, K
AF Cakir, Tayfun
   Kayaci, Selim
   Aydin, Mehmet Dumlu
   Ozoner, Baris
   Calik, Ilknur
   Altinkaynak, Konca
TI A New Neuropathologic Mechanism of Blood pH Irregularities After Neck
   Trauma: Importance of Carotid Body-Glossopharyngeal Nerve Network
   Degeneration
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood pH; Carotid body; Glossopharyngeal nerve; Neck trauma
ID SUBARACHNOID HEMORRHAGE; INJURIES; CHEMORECEPTORS; EPIDEMIOLOGY;
   PREDICTORS; MANAGEMENT; HYPOXIA; DISEASE
AB OBJECTIVE: We created a neck trauma model by injecting blood into the sheath of rabbits' carotid bodies (CBs). Then we determined the relationship between neuronal degeneration of the CB due to hemorrhage of this organ and its clinical effects such as blood pH and heart rhythm.
   METHODS: The present study included 24 adult male New Zealand rabbits. The animals were divided into 3 groups: control (n = 5); sham (0.5 mL saline injected into CBs; n = 5); and study (CB trauma model; n = 14). pH values and heart rhythms were recorded before the experiment to determine the values under normal conditions, and measurements were repeated thrice in the days following the experiment. The number of normal and degenerated neuron density of CBs was counted. The relationship between the blood pH values, heart rhythms, and degenerated neuron densities was analyzed.
   RESULTS: Heart rhythms were 218 +/- 20 in the control group, 197 +/- 16 in the sham group (P = 0.09), and 167 +/- 13 in the study group (P < 0.0005). pH values were 7.40 +/- 0.041 in the control group, 7.321 +/- 0.062 in the sham group (P = 0.203), and 7.23 +/- 0.02 in study group (P < 0.0005). Degenerated neuron densities were 12 +/- 4/mm(3) in the control group, 430 +/- 74/mm(3) in the sham group (P < 0.005), and 7434 +/- 810/mm(3) in the study group (P < 0.0001).
   CONCLUSIONS: A high degenerate neuron density in the CB can decrease blood pH and hearth rhythm after neck trauma, and there might be a close relationship between the number of degenerated neurons and clinical findings (such as heart rhythm and blood pH). This relationship suggests that injury to the glossopharyngeal nerve-CB network can cause acidosis by disturbing the breathing-circulating reflex and results in respiratory acidosis.
C1 [Cakir, Tayfun; Kayaci, Selim; Ozoner, Baris] Erzincan Binali Yildirim Univ, Fac Med, Dept Neurosurg, Erzincan, Turkey.
   [Aydin, Mehmet Dumlu] Ataturk Univ, Fac Med, Erzurum, Turkey.
   [Altinkaynak, Konca] Erzurum Research Training Hosp, Dept Biochem, Erzurum, Turkey.
   [Calik, Ilknur] Firat Univ, Fac Med, Dept Pathol, Elazig, Turkey.
RP Aydin, MD (reprint author), Ataturk Univ, Fac Med, Erzurum, Turkey.
EM nmda11@hotmail.com
RI Cakir, Tayfun/AAD-6595-2019
OI Ozoner, Baris/0000-0003-0534-2766; CAKIR, TAYFUN/0000-0002-9979-9291
CR Aydin MD, 2004, ACTA NEUROCHIR, V146, P1125, DOI 10.1007/s00701-004-0300-x
   Aydin MD, 2002, ACTA NEUROCHIR, V144, P369, DOI 10.1007/s007010200051
   Aydin MD, 2006, INT J DEV NEUROSCI, V24, P455, DOI 10.1016/j.ijdevneu.2006.07.001
   Chandran A, 2010, EPIDEMIOL REV, V32, P110, DOI 10.1093/epirev/mxq009
   Chang AJ, 2017, J APPL PHYSIOL, V123, P1335, DOI 10.1152/japplphysiol.00398.2017
   Conde SV, 2006, J NEUROCHEM, V99, P711, DOI 10.1111/j.1471-4159.2006.04094.x
   De Castro F, 2009, ADV EXP MED BIOL, V648, P1, DOI 10.1007/978-90-481-2259-2_1
   Doux JD, 2006, MED HYPOTHESES, V66, P176, DOI 10.1016/j.mehy.2005.03.016
   DRAGON R, 1981, AM J SURG, V141, P497, DOI 10.1016/0002-9610(81)90147-1
   Erickson JT, 1998, J PHYSIOL-LONDON, V509, P519, DOI 10.1111/j.1469-7793.1998.519bn.x
   Fassett DR, 2008, J SPINAL DISORD TECH, V21, P252, DOI 10.1097/BSD.0b013e3180cab162
   Fitzgerald RS, 2009, ADV EXP MED BIOL, V648, P19, DOI 10.1007/978-90-481-2259-2_2
   Fung ML, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/354279
   George E, 2019, EMERG RADIOL, V26, P75, DOI 10.1007/s10140-018-1630-y
   GONZALEZ E, 1987, J AUTONOM NERV SYST, V18, P249, DOI 10.1016/0165-1838(87)90123-8
   GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x
   Hasler RM, 2012, J TRAUMA ACUTE CARE, V72, P975, DOI 10.1097/TA.0b013e31823f5e8e
   Hasler RM, 2011, EUR SPINE J, V20, P2174, DOI 10.1007/s00586-011-1866-7
   HEATH D, 1970, THORAX, V25, P129, DOI 10.1136/thx.25.2.129
   Jubert P, 2013, ORTHOP TRAUMATOL-SUR, V99, pS301, DOI 10.1016/j.otsr.2013.07.007
   Kanat A, 2017, WORLD NEUROSURG, V104, P330, DOI 10.1016/j.wneu.2017.04.105
   Kumar P, 2012, COMPR PHYSIOL, V2, P141, DOI 10.1002/cphy.c100069
   Kummer C, 2007, INJURY, V38, P27, DOI 10.1016/j.injury.2006.09.002
   Lenehan B, 2009, EUR SPINE J, V18, P938, DOI 10.1007/s00586-009-0923-y
   Lu YJ, 2013, J PHYSIOL-LONDON, V591, P919, DOI 10.1113/jphysiol.2012.247189
   Makhani M, 2014, DIS ESOPHAGUS, V27, P630, DOI 10.1111/dote.12132
   MIR AK, 1982, BRAIN RES, V252, P335, DOI 10.1016/0006-8993(82)90401-2
   Ortiz F, 2009, ADV EXP MED BIOL, V648, P83, DOI 10.1007/978-90-481-2259-2_9
   Polistena A, 2016, OPEN MED-WARSAW, V11, P298, DOI 10.1515/med-2016-0058
   Sandstrom CK, 2018, NEUROIMAG CLIN N AM, V28, P471, DOI 10.1016/j.nic.2018.03.008
   Sawhney C, 2018, J ANAESTH CLIN PHARM, V34, P275, DOI 10.4103/0970-9185.168264
   Schultz H D, 2000, Heart Fail Rev, V5, P45
   STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x
   Strudwick K, 2018, EMERG MED AUSTRALAS, V30, P18, DOI 10.1111/1742-6723.12907
   Telischak N, 2014, J CLIN NEUROSCI, V21, P1176, DOI 10.1016/j.jocn.2013.11.012
   Trofa DP, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117741647
   Yolas C, 2014, J NEUROL SCI, V336, P220, DOI 10.1016/j.jns.2013.10.047
NR 37
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E972
EP E977
DI 10.1016/j.wneu.2019.01.218
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700120
PM 30763747
DA 2020-05-12
ER

PT J
AU Carl, B
   Bopp, M
   Voellger, B
   Sass, B
   Nimsky, C
AF Carl, Barbara
   Bopp, Miriam
   Voellger, Benjamin
   Sass, Benjamin
   Nimsky, Christopher
TI Augmented Reality in Transsphenoidal Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Augmented reality; Intraoperative computed tomography imaging;
   Registration; Transsphenoidal surgery
ID PITUITARY-TUMORS; SYSTEM; NAVIGATION; MICROSCOPE; NEURONAVIGATION;
   REGISTRATION; INTEGRATION
AB OBJECTIVE: We investigated how augmented reality (AR) can be applied to support transsphenoidal surgery.
   METHODS: AR was established using the head-up displays integrated into operating microscopes. Navigation registration was performed with either fiducial-based or automatic registration using intraoperative computed tomography (iCT). Correct microscope calibration was ensured by checking the geometric overlap between the AR representation of the reference array and the 3-dimensional reality while focusing on the reference array.
   RESULTS: From a consecutive single-surgeon series of 288 transsphenoidal procedures, 47 patients (16.3%) had undergone microscope-based AR to visualize the target and risk structures. AR was smoothly integrated into the surgical workflow. AR accuracy depended on navigation accuracy and microscope calibration. The target registration error in patients with fiducial-based registration was 2.33 +/- 1.30 mm. Automatic, user-independent iCT-based registration significantly (P < 0.001) increased AR accuracy (target registration error, 0.83 +/- 0.44 mm). Applying low-dose iCT protocols reduced the effective dose caused by iCT registration scanning to within the range of a single chest radiograph (0.041 mSv). No vascular injuries and no aggravation of neurological deficits occurred in the present series. AR greatly facilitated orientation in the reoperations and the patients with anatomical variants, thereby increasing surgeon comfort. Enhanced AR visualizations improved the 3-dimensional perception compared with the standard display of dashed lines by the head-up display of the operating microscope.
   CONCLUSIONS: Microscope-based AR is a reliable tool to increase patient safety in complicated transsphenoidal procedures. Intraoperative imaging-based automatic patient registration is recommended.
C1 [Carl, Barbara; Bopp, Miriam; Voellger, Benjamin; Sass, Benjamin; Nimsky, Christopher] Univ Marburg, Dept Neurosurg, Marburg, Germany.
   [Bopp, Miriam; Nimsky, Christopher] Marburg Ctr Mind Brain & Behav, Marburg, Germany.
RP Carl, B (reprint author), Univ Marburg, Dept Neurosurg, Marburg, Germany.
EM carlb@med.uni-marburg.de
RI Voellger, Benjamin/J-4803-2019; Nimsky, Christopher/E-3702-2014
OI Voellger, Benjamin/0000-0001-8615-5393; Nimsky,
   Christopher/0000-0002-8216-9410; Bopp, Miriam H. A./0000-0003-1574-7572;
   Sass, Benjamin/0000-0003-2855-3443; Carl, Barbara/0000-0003-3661-9908
CR Agten CA, 2018, INVEST RADIOL, V53, P495, DOI 10.1097/RLI.0000000000000478
   Ahmadipour Y, 2016, EUR ARCH OTO-RHINO-L, V273, P3929, DOI 10.1007/s00405-016-4052-z
   Amr AN, 2017, WORLD NEUROSURG, V105, P386, DOI 10.1016/j.wneu.2017.05.164
   Barnett G H, 1995, J Image Guid Surg, V1, P109, DOI 10.1002/(SICI)1522-712X(1995)1:2<109::AID-IGS6>3.0.CO;2-E
   Birkfellner W, 2000, LECT NOTES COMPUT SC, V1935, P869
   Bong JH, 2018, INT J MED ROBOT COMP, V14, DOI 10.1002/rcs.1886
   Brinker T, 1998, ACTA NEUROCHIR, V140, P883, DOI 10.1007/s007010050189
   Bumm K, 2005, MINIM INVAS NEUROSUR, V48, P159, DOI 10.1055/s-2005-870903
   Cabrilo I, 2014, NEUROCHIRURGIE, V60, P304, DOI 10.1016/j.neuchi.2014.07.001
   Cabrilo I, 2015, WORLD NEUROSURG, V83, P596, DOI 10.1016/j.wneu.2014.12.020
   Cabrilo I, 2014, ACTA NEUROCHIR, V156, P1769, DOI 10.1007/s00701-014-2183-9
   Cabrilo I, 2014, OPER NEUROSURG, V10, P252, DOI 10.1227/NEU.0000000000000328
   Carl B, 2018, ACTA NEUROCHIR, V160, P1681, DOI 10.1007/s00701-018-3641-6
   Carl B, 2018, WORLD NEUROSURG, V113, pE414, DOI 10.1016/j.wneu.2018.02.045
   Charalampaki P, 2006, MINIM INVAS NEUROSUR, V49, P93, DOI 10.1055/s-2006-932170
   Chu YK, 2017, MED IMAGE ANAL, V42, P241, DOI 10.1016/j.media.2017.08.003
   Cutolo F, 2017, COMPUT ASSIST SURG, V22, P39, DOI 10.1080/24699322.2017.1358400
   Carmen A, 2017, OPER NEUROSURG, V13, P138, DOI 10.1227/NEU.0000000000001180
   Dolati P, 2016, WORLD NEUROSURG, V95, P406, DOI 10.1016/j.wneu.2016.06.008
   Doyle WK, 1996, STUD HEALTH TECHNOL, V29, P1
   Fahlbusch R, 1998, INT CONGR SER, V1165, P583
   Gardner PA, 2013, NEUROSURGERY, V73, P261, DOI 10.1227/01.neu.0000430821.71267.f2
   Greenfield JP, 2008, MINIM INVAS NEUROSUR, V51, P244, DOI 10.1055/s-2008-1073131
   Kajiwara K, 2003, MINIM INVAS NEUROSUR, V46, P78, DOI 10.1055/s-2003-39340
   Kawamata T, 2002, NEUROSURGERY, V50, P1393, DOI 10.1097/00006123-200206000-00038
   KELLY PJ, 1982, NEUROSURGERY, V10, P324, DOI 10.1227/00006123-198203000-00005
   KIM H, 2017, INT J MED ROBOT, P19, DOI DOI 10.1145/3132847.3132982
   King AP, 1999, STEREOT FUNCT NEUROS, V72, P107, DOI 10.1159/000029708
   Kiya N, 1997, MINIM INVAS NEUROSUR, V40, P110, DOI 10.1055/s-2008-1053429
   Laws E R Jr, 1999, Pituitary, V2, P163
   Mascitelli JR, 2018, OPER NEUROSURG, V15, P184, DOI 10.1093/ons/opx205
   Meola A, 2018, OPER NEUROSURG, V14, pE71, DOI 10.1093/ons/opy048
   Mert A, 2014, WORLD NEUROSURG, V82, pS95, DOI 10.1016/j.wneu.2014.07.032
   Mirota DJ, 2013, IEEE T MED IMAGING, V32, P1215, DOI 10.1109/TMI.2013.2243464
   Nakajima S, 1997, NEUROSURGERY, V40, P1201, DOI 10.1097/00006123-199706000-00018
   Nakamura M, 2000, J CLIN NEUROSCI, V7, P10
   Nimsky C, 2004, MINIM INVAS NEUROSUR, V47, P41, DOI 10.1055/s-2003-812465
   Nimsky C, 1999, NEUROSURGERY, V44, P1249, DOI 10.1097/00006123-199906000-00044
   Onizuka M, 2001, NEUROL MED-CHIR, V41, P565, DOI 10.2176/nmc.41.565
   ROBERTS DW, 1986, J NEUROSURG, V65, P545, DOI 10.3171/jns.1986.65.4.0545
   Sack J, 2018, OPER NEUROSURG, V14, P395, DOI 10.1093/ons/opx145
   Sasagawa Y, 2016, PITUITARY, V19, P482, DOI 10.1007/s11102-016-0728-z
   Schulze F, 2010, INT J COMPUT ASS RAD, V5, P143, DOI 10.1007/s11548-009-0397-8
   Scraton R, 2018, J NEUROL SURG B S1, V79, pS1
   Sekhar L, 1998, NEUROSURGERY, V42, P251, DOI 10.1097/00006123-199802000-00021
   Shinomiya A, 2018, INTERDISCIP NEUROSUR, V13, P13, DOI 10.1016/j.inat.2018.02.002
   Sutherland I.E., 1968, P FALL JOINT COMP C, P757, DOI DOI 10.1145/1476589.1476686
   Thomale UW, 2005, ZBL NEUROCHIR, V66, P126, DOI 10.1055/s-2005-836602
   Wolfsberger S, 2006, NEUROSURGERY, V59, P1001, DOI 10.1227/01.NEU.0000245594.61828.41
   2014, NEUROSURGERY S2, V10, P252, DOI DOI 10.1227/NEU.0000000000000328
   2006, NEUROSURGERY, V59, P1001, DOI DOI 10.1227/01.NEU.0000245594.61828.41
NR 51
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E873
EP E883
DI 10.1016/j.wneu.2019.01.202
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700108
PM 30763743
DA 2020-05-12
ER

PT J
AU Chakravorty, A
   White, SJ
   Ye, IB
   Cheung, ZB
   Cho, SKW
AF Chakravorty, Ananya
   White, Samuel J.
   Ye, Ivan B.
   Cheung, Zoe B.
   Cho, Samuel Kang-Wook
TI Effects of Underlying Liver Disease on 30-Day Outcomes After Posterior
   Lumbar Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACS-NSQIP; Complications; Liver disease; MELD-Na; Posterior lumbar
   fusion
ID SURGICAL QUALITY IMPROVEMENT; CIRRHOTIC-PATIENTS; PROGRAM; MORTALITY;
   SURGERY; RISK; MORBIDITY; HEAD
AB OBJECTIVE: To examine the effects of underlying liver disease on 30-day postoperative complications after elective posterior lumbar fusion (PLF).
   METHODS: We performed a retrospective American College of Surgeons National Surgical Quality Improvement Program study of patients who had undergone elective PLF from 2011 to 2014. The patients were divided into 2 groups stratified by the presence of liver disease, assessed using the Model for End-stage Liver Disease plus sodium score (liver disease, >= 10; no liver disease, <10). The baseline patient and operative characteristics were compared between the 2 groups using univariate analysis. Subsequent multivariate regression analysis adjusted for differences in baseline characteristics was performed to identify 30-day postoperative complications independently associated with liver disease.
   RESULTS: Of 2965 patients, 55.9% had underlying liver disease. Those with liver disease were more frequently aged >65 years, male, and underweight or overweight and had had American Society of Anesthesiologists class >= 3, diabetes, pulmonary comorbidity, cardiac comorbidity, renal comorbidity, bleeding disorder, preoperative dyspnea at rest, and a prolonged operative time. On univariate analysis, patients with liver disease had a greater incidence of cardiac complications, pulmonary complications, renal complications, blood transfusion, sepsis, urinary tract infection, and prolonged hospitalization. On adjusted multivariate regression analysis, liver disease was independently associated with renal complications, pulmonary complications, sepsis, urinary tract infection, prolonged hospitalization, and blood transfusion.
   CONCLUSIONS: As the long-term survival of patients with liver disease continues to increase, a better understanding of the relationship between liver dysfunction and surgical outcomes is needed. The identification of modifiable risk factors would allow them to be addressed and optimized preoperatively to decrease the incidence and severity of complications and improve patient outcomes after PLF.
C1 [Chakravorty, Ananya] Prince Wales Hosp, Sydney, NSW, Australia.
   [White, Samuel J.; Ye, Ivan B.; Cheung, Zoe B.; Cho, Samuel Kang-Wook] Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
RP Cho, SKW (reprint author), Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
EM samuel.cho@mountsinai.org
RI Cheung, Zoe/AAG-4511-2020
OI Cheung, Zoe/0000-0002-0189-5390
CR Abbas N, 2017, HEALTH SERV INSIGHTS, V10, DOI 10.1177/1178632917691270
   Alberino F, 2001, NUTRITION, V17, P445, DOI 10.1016/S0899-9007(01)00521-4
   [Anonymous], 2015, ACS NSQIP PARTICIPAN
   Bell Christopher L, 2005, Curr Treat Options Gastroenterol, V8, P473, DOI 10.1007/s11938-005-0034-8
   Bernardi M, 2011, J HEPATOL, V54, P1297, DOI 10.1016/j.jhep.2010.11.008
   Biggins SW, 2006, GASTROENTEROLOGY, V130, P1652, DOI 10.1053/j.gastro.2006.02.010
   Causey MW, 2012, AM J SURG, V203, P589, DOI 10.1016/j.amjsurg.2012.01.009
   Centers for Disease Control and Prevention, 2016, CHRON LIV DIS CIRRH
   Corey KE, 2014, CLIN LIVER DIS, V18, P1, DOI 10.1016/j.cld.2013.09.019
   Cramer JD, 2017, LARYNGOSCOPE, V127, P102, DOI 10.1002/lary.26044
   Fink AS, 2002, ANN SURG, V236, P344, DOI 10.1097/00000658-200209000-00011
   Fotbolcu H, 2016, WORLD J GASTROENTERO, V22, P4079, DOI 10.3748/wjg.v22.i16.4079
   Friedman Lawrence S, 2010, Trans Am Clin Climatol Assoc, V121, P192
   Gines P, 2008, HEPATOLOGY, V48, P1002, DOI 10.1002/hep.22418
   Gines P, 2009, NEW ENGL J MED, V361, P1279, DOI 10.1056/NEJMra0809139
   Hsu CY, 2010, DIGEST LIVER DIS, V42, P137, DOI 10.1016/j.dld.2009.06.004
   Jie B, 2012, NUTRITION, V28, P1022, DOI 10.1016/j.nut.2012.01.017
   Kao HK, 2010, ANN SURG ONCOL, V17, P536, DOI 10.1245/s10434-009-0805-x
   Karavitis J, 2011, J LEUKOCYTE BIOL, V90, P1065, DOI 10.1189/jlb.0311114
   Keegan MT, 2005, AM J GASTROENTEROL, V100, P2116, DOI 10.1111/j.1572-0241.2005.41453.x
   Khuri SF, 1998, ANN SURG, V228, P491, DOI 10.1097/00000658-199810000-00006
   Kim SH, 2011, J GASTROINTEST SURG, V15, P2029, DOI 10.1007/s11605-011-1669-5
   Lin Tung-Yi, 2014, Biomed J, V37, P18, DOI 10.4103/2319-4170.113376
   Mansour A, 1997, SURGERY, V122, P730, DOI 10.1016/S0039-6060(97)90080-5
   Martini A, 2017, UNITED EUR GASTROENT, V5, P982, DOI 10.1177/2050640617696402
   Maze M., 1994, ANESTHESIA, P1969
   Millwala F, 2007, WORLD J GASTROENTERO, V13, P4056, DOI 10.3748/wjg.v13.i30.4056
   Molina CS, 2015, CLIN ORTHOP RELAT R, V473, P1574, DOI 10.1007/s11999-014-3597-7
   Rowell KS, 2007, J AM COLL SURGEONS, V204, P1293, DOI 10.1016/j.jamcollsurg.2007.03.024
   Shaikh AR, 2009, JSLS-J SOC LAPAROEND, V13, P592, DOI 10.4293/108680809X12589999537959
   Tsiaousi ET, 2008, J GASTROEN HEPATOL, V23, P527, DOI 10.1111/j.1440-1746.2008.05369.x
   Ziser A, 1999, ANESTHESIOLOGY, V90, P42, DOI 10.1097/00000542-199901000-00008
   2012, INT J HEPATOL
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E711
EP E716
DI 10.1016/j.wneu.2019.01.160
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700088
PM 30735863
DA 2020-05-12
ER

PT J
AU Chan, DYC
   Tsang, ACO
   Li, LF
   Cheng, KKF
   Tsang, FCP
   Taw, BBT
   Pu, JKS
   Ho, WWS
   Lui, WM
   Leung, GKK
AF Chan, David Yuen Chung
   Tsang, Anderson Chun On
   Li, Lai Fung
   Cheng, Kevin King Fai
   Tsang, Frederick Chun Pong
   Taw, Benedict Beng Teck
   Pu, Jenny Kan Suen
   Ho, Wilson Wai Shing
   Lui, Wai Man
   Leung, Gilberto Ka Kit
TI Improving Survival with Tranexamic Acid in Cerebral Contusions or
   Traumatic Subarachnoid Hemorrhage: Univariate and Multivariate Analysis
   of Independent Factors Associated with Lower Mortality
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral contusion; Subarachnoid hemorrhage; Tranexamic acid; Traumatic
   brain injury; Traumatic subarachnoid hemorrhage
ID BRAIN-INJURY; PROGRESSION
AB BACKGROUND: Fall with head injury is a pervasive challenge, especially in the aging population. Contributing factors for mortality include the development of cerebral contusions and delayed traumatic intracerebral hematoma. Currently, there is no established specific treatment for these conditions.
   OBJECT: This study aimed to investigate the impact of independent factors on the mortality rate of traumatic brain injury with contusions or traumatic subarachnoid hemorrhage.
   METHODS: Data were collected from consecutive patients admitted for cerebral contusions or traumatic subarachnoid hemorrhage at an academic trauma center from 2010 to 2016. The primary outcome was the 30-day mortality rate. Independent factors for analysis included patient factors and treatment modalities. Univariate and multivariate analyses were conducted to identify independent factors related to mortality. Secondary outcomes included thromboembolic complication rates associated with the use of tranexamic acid.
   RESULTS: In total, 651 consecutive patients were identified. For the patient factors, low Glasgow Coma Scale on admission, history of renal impairment, and use of warfarin were identified as independent factors associated with higher mortality from univariate and multivariate analyses. For the treatment modalities, univariate analysis identified tranexamic acid as an independent factor associated with lower mortality (P = 0.021). Thromboembolic events were comparable in patients with or without tranexamic acid.
   CONCLUSION: Tranexamic acid was identified by univariate analysis as an independent factor associated with lower mortality in cerebral contusions or traumatic subarachnoid hemorrhage. Further prospective studies are needed to validate this finding.
C1 [Chan, David Yuen Chung; Tsang, Anderson Chun On; Li, Lai Fung; Cheng, Kevin King Fai; Tsang, Frederick Chun Pong; Taw, Benedict Beng Teck; Pu, Jenny Kan Suen; Ho, Wilson Wai Shing; Lui, Wai Man; Leung, Gilberto Ka Kit] Univ Hong Kong, Li Ka Shing Fac Med, Queen Mary Hosp, Div Neurosurg,Dept Surg,Pokfulam, Hong Kong, Peoples R China.
RP Leung, GKK (reprint author), Univ Hong Kong, Li Ka Shing Fac Med, Queen Mary Hosp, Div Neurosurg,Dept Surg,Pokfulam, Hong Kong, Peoples R China.
EM gilberto@hku.hk
RI ; Leung, Gilberto Ka Kit/C-4337-2009; /E-1487-2011
OI CHAN, David Yuen Chung/0000-0002-9622-3799; Leung, Gilberto Ka
   Kit/0000-0003-3147-3057; /0000-0003-2758-3253
CR Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369
   [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795
   Cesarman-Maus G, 2005, BRIT J HAEMATOL, V129, P307, DOI 10.1111/j.1365-2141.2005.05444.x
   Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6
   Choudhry OJ, 2013, NEUROSURGERY, V73, P753, DOI 10.1227/NEU.0000000000000105
   Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87
   Folkerson LE, 2015, SURGERY, V158, P655, DOI 10.1016/j.surg.2015.02.029
   FUKAMACHI A, 1985, ACTA NEUROCHIR, V74, P35, DOI 10.1007/BF01413274
   Herou E, 2015, WORLD NEUROSURG, V83, P996, DOI 10.1016/j.wneu.2015.02.023
   Iorio-Morin C, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1358-5
   Jokar A, 2017, CHIN J TRAUMATOL, V20, P49, DOI 10.1016/j.cjtee.2016.02.005
   Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241
   Kageyama H, 2013, J NEUROSURG, V119, P332, DOI 10.3171/2013.3.JNS122162
   Kim B, 2018, AM J EMERG MED, V36, P271, DOI 10.1016/j.ajem.2017.08.009
   Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122
   Mahmood A, 2016, BMJ-BRIT MED J, V354, P4814
   Meretoja A, 2014, INT J STROKE, V9, P519, DOI 10.1111/ijs.12132
   Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385
   Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109
   Peitzman A, 2000, J TRAUMA, V48, P374
   Roberts I, 2011, LANCET, V377
   Servadei F, 2000, NEUROSURGERY, V46, P70
   Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5
   Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87
   Sprigg N, 2018, LANCET, V391, P2107, DOI 10.1016/S0140-6736(18)31033-X
   Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20
   Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023
   J TRAUMA, V48, P367
   2005, NEUROSURGERY, V56, P671, DOI DOI 10.1227/01.NEU.0000156200.76331.7A
NR 29
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E665
EP E670
DI 10.1016/j.wneu.2019.01.145
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700083
PM 30721773
DA 2020-05-12
ER

PT J
AU Chen, CC
   Yeap, MC
   Liu, ZH
   Hsieh, PC
   Chen, CT
   Liu, YT
   Lee, CY
   Lai, HY
   Wu, CT
   Tu, PH
AF Chen, Ching-Chang
   Yeap, Mun-Chun
   Liu, Zhuo-Hao
   Hsieh, Po-Chuan
   Chen, Chun-Ting
   Liu, Yu-Tse
   Lee, Ching-Yi
   Lai, Hong-Yi
   Wu, Chieh-Tsai
   Tu, Po-Hsun
TI A Novel Protocol to Reduce Early Seizures After Cranioplasty: A
   Single-Center Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Cranioplasty; Seizure; Seizure prophylaxis; Seizure
   recurrence
ID RECURRENT SEIZURES; COMPLICATIONS; PREDICTORS; PHENYTOIN; SURGERY;
   INJURY; TRIAL; RISK
AB BACKGROUND: Cranioplasty is a relatively simple and straightforward intervention; however, it is associated with a high incidence of postoperative seizures. Postcranioplasty seizures, especially early seizures, are common and associated with poor outcomes and longer hospital stays. Protocols for preventing and managing early seizures have not been well established.
   METHODS: The medical records of 595 patients who underwent cranioplasty were retrospectively reviewed. Of these patients, 259 had preexisting seizures and 336 had no seizures before cranioplasty. Prophylactic antiepileptic drugs (AEDs) were administered to patients who had no seizures before cranioplasty for 1 week, whereas an advanced AED regimen was administered to patients with preexisting seizures. Subsequently, clinical characteristics, occurrence of recurrent seizures, early seizures, and postoperative complications were analyzed.
   RESULTS: Our previous study showed positive results for prophylaxis in new-onset early seizures. In the patients with preexisting seizures, 46.7% of the patients (121/259) experienced recurrent seizures after cranioplasty and 17.4% of the patients (45/259) experienced early recurrent seizures within 1 week of their operation. In the group who received the advanced AEDs, early recurrent seizures were significantly reduced to 8.7% compared with the regular group (20.5%; P = 0.027). Younger age and preoperative hydrocephalus engendered a higher risk of recurrent seizures. The number of previous craniotomies was observed to have a trend of increasing early recurrent seizures.
   CONCLUSIONS: Cranioplasty is associated with a high incidence of postoperative seizures. Our management protocol for postcranioplasty seizures includes seizure prophylaxis and advanced use of AEDs, which can reduce the occurrence of early seizures.
C1 [Chen, Ching-Chang; Yeap, Mun-Chun; Liu, Zhuo-Hao; Hsieh, Po-Chuan; Chen, Chun-Ting; Liu, Yu-Tse; Lee, Ching-Yi; Lai, Hong-Yi; Wu, Chieh-Tsai; Tu, Po-Hsun] Chang Gung Med Coll & Univ, Dept Neurosurg, Chang Gung Mem Hosp, Linkou Med Ctr, Taoyuan, Taiwan.
RP Tu, PH (reprint author), Chang Gung Med Coll & Univ, Dept Neurosurg, Chang Gung Mem Hosp, Linkou Med Ctr, Taoyuan, Taiwan.
EM d12096@cloud.cgmh.org.tw
CR Alvarez PS, 2014, INT J DEV NEUROSCI, V33, P81, DOI 10.1016/j.ijdevneu.2013.12.004
   Beenen LFM, 1999, J NEUROL NEUROSUR PS, V67, P474, DOI 10.1136/jnnp.67.4.474
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Chen CC, 2012, J NEUROSURG, V117, P348, DOI 10.3171/2012.4.JNS111338
   Chen F, 2017, INT J SURG, V40, P113, DOI 10.1016/j.ijsu.2017.02.017
   Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818
   Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x
   Heo J, 2014, J NEUROSURG, V121, P313, DOI 10.3171/2014.2.JNS131480
   Honeybul S, 2017, J NEUROSURG, V126, P81, DOI 10.3171/2015.12.JNS152004
   Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532
   Hwang SL, 2001, J CLIN NEUROSCI, V8, P426, DOI 10.1054/jocn.2000.0825
   Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005
   Lee L, 2013, BRIT J NEUROSURG, V27, P629, DOI 10.3109/02688697.2013.815313
   Liang SL, 2017, WORLD NEUROSURG, V102, P284, DOI 10.1016/j.wneu.2017.03.020
   Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116
   Majidi S, 2017, NEUROCRIT CARE, V27, P90, DOI 10.1007/s12028-016-0363-6
   Manji RA, 2015, J CARDIOTHOR VASC AN, V29, P1206, DOI 10.1053/j.jvca.2015.03.020
   Morton RP, 2018, J NEUROSURG, V128, P1648, DOI 10.3171/2016.11.JNS161917
   SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024
   TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801
   Vespa P, 2016, ANN NEUROL, V79, P579, DOI 10.1002/ana.24606
   Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626
   Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37
   Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9
   Yao Z, 2018, BRIT J NEUROSURG, V32, P489, DOI 10.1080/02688697.2018.1481197
   Yeap MC, 2019, J NEUROSURG, V131, P936, DOI 10.3171/2018.4.JNS172519
   Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166
   Zanaty M, 2015, J NEUROSURG, V123, P182, DOI 10.3171/2014.9.JNS14405
   2007, NEUROSURGERY, V61, P489, DOI DOI 10.1227/01.NEU.0000280022.61888.13
NR 29
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E282
EP E288
DI 10.1016/j.wneu.2019.01.062
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700036
PM 30685374
DA 2020-05-12
ER

PT J
AU Chen, M
   Yang, M
   Zhou, WP
   Li, ST
AF Chen, Ming
   Yang, Min
   Zhou, Wei-ping
   Li, Shi-ting
TI Preliminary Study on the Relationship Between Inflammation and
   Hemifacial Spasm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemifacial spasm; Inflammation; Interleukin-6; Interleukin-2 receptor;
   White blood cell
ID MICROVASCULAR DECOMPRESSION; ARACHNOID CYST; SUBARACHNOID HEMORRHAGE;
   INTERLEUKIN-6; PURIFICATION; COMPRESSION; PEPTIDE; NERVE; PAIN
AB BACKGROUND: Complete pathogenesis of hemifacial spasm (HFS) is unknown. In some patients with HFS, thickened, opaque, and sticky arachnoid membranes have been found during microvascular decompression procedures. This phenomenon indicates a possible relationship between inflammation and HFS. The aim of this study was to explore the role of inflammation in pathogenesis of HFS.
   METHODS: Levels of interferon-gamma, interleukin-2 receptor, interleukin-6 (IL-6), interleukin-8, interleukin-10, and tumor necrosis factor alpha and white blood cell (WBC), neutrophil, and lymphocyte counts were compared between patients with HFS, patients with lumbar disc herniation, and healthy control subjects. A receiver operating characteristic curve analysis was performed to evaluate the diagnostic significance of peripheral blood inflammatory markers for HFS. All the inflammatory markers were further analyzed by single and multiple logistic regression analysis.
   RESULTS: Patients with HFS had greater IL-6, interleukin-8, white blood cell count, and neutrophil count than patients with lumbar disc herniation and healthy control subjects. Area under curve values of IL-6, white blood cell count, and neutrophil count were >0.8. Multiple logistic regression analysis indicated that only interleukin-2 receptor and IL-6 were relevant to HFS.
   CONCLUSIONS: Inflammation is relative to HFS. IL-6 may be 1 of many factors involved in pathogenesis of HFS.
C1 [Chen, Ming; Yang, Min; Zhou, Wei-ping; Li, Shi-ting] Shanghai Jiao Tong Univ, XinHua Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China.
RP Li, ST (reprint author), Shanghai Jiao Tong Univ, XinHua Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China.
EM lishiting@xinhuamed.com.cn
CR ADAMS CBT, 1989, J NEUROSURG, V70, P1, DOI 10.3171/jns.1989.70.1.0001
   Ataie-Kachoie P, 2014, J CLIN PATHOL, V67, P932, DOI 10.1136/jclinpath-2014-202493
   BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201
   Basaran R, 2015, BRIT J NEUROSURG, V29, P285, DOI 10.3109/02688697.2014.976175
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Chung SS, 2000, ACTA NEUROCHIR, V142, P901, DOI 10.1007/s007010070076
   Coelho SC, 2014, EUR J PAIN, V18, P957, DOI 10.1002/j.1532-2149.2013.00441.x
   Colosimo C, 2006, ARCH NEUROL-CHICAGO, V63, P441, DOI 10.1001/archneur.63.3.441
   De Ridder D, 2002, NEUROSURGERY, V51, P427, DOI 10.1097/00006123-200208000-00023
   Di Ieva A, 2010, CENT EUR NEUROSURG, V71, P207, DOI 10.1055/s-0029-1243201
   DOLAN RA, 1993, SURG NEUROL, V39, P479, DOI 10.1016/0090-3019(93)90035-Y
   Fielding CA, 2008, J IMMUNOL, V181, P2189, DOI 10.4049/jimmunol.181.3.2189
   Filipovic B, 2014, J NEURAL TRANSM, V121, P555, DOI 10.1007/s00702-013-1144-4
   HIGASHI S, 1992, SURG NEUROL, V37, P289, DOI 10.1016/0090-3019(92)90155-G
   Hirahara K, 2010, CYTOKINE GROWTH F R, V21, P425, DOI 10.1016/j.cytogfr.2010.10.006
   Hirai T, 2012, SPINE, V37, pE195, DOI 10.1097/BRS.0b013e31822ba817
   JANNETTA PJ, 1980, ANN SURG, V192, P518, DOI 10.1097/00000658-198010000-00010
   JHO HD, 1987, NEUROSURGERY, V20, P767, DOI 10.1227/00006123-198705000-00015
   Jordan SC, 2017, TRANSPLANTATION, V101, P32, DOI 10.1097/TP.0000000000001452
   KOBATA H, 1995, NEUROSURGERY, V36, P710, DOI 10.1227/00006123-199504000-00011
   Kok AJM, 2000, ACTA NEUROCHIR, V142, P795, DOI 10.1007/s007010070094
   Kondo A, 1997, NEUROSURGERY, V40, P46, DOI 10.1097/00006123-199701000-00009
   Launay PS, 2016, NEUROBIOL DIS, V88, P16, DOI 10.1016/j.nbd.2015.12.017
   Merida S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090216
   Park JS, 2008, ACTA NEUROCHIR, V150, P235, DOI 10.1007/s00701-007-1457-x
   Rodriguez-Cerdeira C, 2018, ACTA DERMATOVEN ALP, V27, P91, DOI 10.15570/actaapa.2018.20
   Rohleder N, 2012, ANN NY ACAD SCI, V1261, P88, DOI 10.1111/j.1749-6632.2012.06634.x
   SCHRODER JM, 1987, J IMMUNOL, V139, P3474
   Singh JK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3436
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tvedt TH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111823
   WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3
   YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233
   Zhao H, 2018, ONCOL LETT, V16, P849, DOI 10.3892/ol.2018.8760
   1997, NEUROSURGERY, V40, P46
   ACTA NEUROCHIR WIEN, V142, P795
   2002, NEUROSURGERY, V51, P427, DOI DOI 10.1227/01.NEU.0000020080.8116.9D
NR 37
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E214
EP E220
DI 10.1016/j.wneu.2019.01.044
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700028
PM 30684712
DA 2020-05-12
ER

PT J
AU Chen, QX
   Qin, MY
   Chen, F
   Ni, B
   Guo, QF
   Han, Z
AF Chen, Qunxiang
   Qin, Mingyue
   Chen, Fei
   Ni, Bin
   Guo, Qunfeng
   Han, Zhao
TI Comparison of Outcomes Between Anterior Cervical Decompression and
   Fusion and Posterior Laminoplasty in the Treatment of 4-Level Cervical
   Spondylotic Myelopathy
SO WORLD NEUROSURGERY
LA English
DT Article
DE 4-Level; Anterior; Cervical decompression; Cervical spondylotic
   myelopathy; Fusion; Laminoplasty; Posterior
ID OPEN-DOOR LAMINOPLASTY; POSTOPERATIVE C5 PALSY; SPINE SURGERY;
   DYSPHAGIA; DISKECTOMY; PRESERVATION; FORAMINOTOMY; RISK
AB OBJECTIVE: To compare the outcome of anterior cervical decompression and fusion (ACDF) and posterior laminoplasty (LAMP) for treating 4-level cervical spondylotic myelopathy (CSM).
   METHODS: Data of 80 patients with 4-level CSM treated using ACDF and another 56 cases treated using LAMP were retrospectively analyzed. Radiologic outcomes evaluated by C2-7 Cobb angle and cervical range of motion (ROM) and functional outcomes evaluated by Japanese Orthopaedic Association (JOA) scale score and visual analog scale score for axial pain were compared between the 2 groups.
   RESULTS: JOA scale score in both groups improved significantly after operation (P < 0.05). There was no significant difference in the JOA scale score improvement rate between the 2 groups (P > 0.05). The C2-7 Cobb angle increased significantly in the ACDF group (P < 0.05) and decreased in the LAMP group (P > 0.05). There was a significant difference in C2-7 Cobb angle improvement between the 2 groups (P < 0.05). Cervical ROM decreased in both groups after operation (P < 0.05), but there was no significant difference in ROM loss ratio between the 2 groups (P > 0.05). Blood loss in the LAMP group was significantly more than in the ACDF group (P < 0.05); however, there was no significant difference in operation time between the 2 groups (P > 0.05). There was no significant difference in the complication rate between the 2 groups (P > 0.05).
   CONCLUSIONS: Both ACDF and LAMP were effective in the treatment of multilevel CSM. Compared with LAMP, ACDF is less invasive and may be more suitable for elderly patients with poor tolerance of surgery.
C1 [Chen, Qunxiang; Qin, Mingyue; Chen, Fei; Ni, Bin; Guo, Qunfeng; Han, Zhao] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped, Shanghai, Peoples R China.
RP Ni, B (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthoped, Shanghai, Peoples R China.
EM 94438728@qq.com
FU Shanghai Natural Science FoundationNatural Science Foundation of
   Shanghai [16ZR1436600]
FX This study was supported by the Shanghai Natural Science Foundation
   (16ZR1436600).
CR Abdullah KG, 2012, GLOB SPINE J, V2, P15, DOI 10.1055/s-0032-1307258
   Anderson KK, 2013, GLOB SPINE J, V3, P273, DOI 10.1055/s-0033-1354253
   Bazaz R, 2002, SPINE, V27, P2453, DOI 10.1097/00007632-200211150-00007
   Bernstein DN, 2017, WORLD NEUROSURG, V103, P859, DOI 10.1016/j.wneu.2017.04.109
   Cao JM, 2017, SCI REP-UK, V7, DOI 10.1038/srep43443
   Chen Z, 2012, SPINE, V37, P1292, DOI 10.1097/BRS.0b013e3182477f26
   Chiba K, 2006, SPINE, V31, P2998, DOI 10.1097/01.brs.0000250307.78987.6b
   Danto J, 2012, J NEUROSURG ANESTH, V24, P350, DOI 10.1097/ANA.0b013e3182622843
   De la Garza-Ramos R, 2016, J NEUROSURG-SPINE, V24, P885, DOI 10.3171/2015.10.SPINE15795
   Denaro V, 2015, EUR SPINE J, V24, pS832, DOI 10.1007/s00586-015-4299-x
   Duetzmann S, 2015, J NEUROSURG-SPINE, V23, P24, DOI 10.3171/2014.11.SPINE14427
   Fang Z, 2016, CLIN SPINE SURG, V29, pE21, DOI 10.1097/BSD.0000000000000074
   Fehlings MG, 2013, J BONE JOINT SURG AM, V95A, P1651, DOI 10.2106/JBJS.L.00589
   Fehlings MG, 2012, J NEUROSURG-SPINE, V16, P425, DOI 10.3171/2012.1.SPINE11467
   Guo QF, 2011, EUR SPINE J, V20, P1539, DOI 10.1007/s00586-011-1735-4
   Healy AT, 2016, J NEUROSURG-SPINE, V24, P746, DOI 10.3171/2015.7.SPINE15229
   HIRABAYASHI K, 1981, SPINE, V6, P354, DOI 10.1097/00007632-198107000-00005
   Hosono N, 1996, SPINE, V21, P1969, DOI 10.1097/00007632-199609010-00005
   Hyun SJ, 2013, SPINE J, V13, P384, DOI 10.1016/j.spinee.2012.10.037
   Katsumi K, 2012, SPINE, V37, P748, DOI 10.1097/BRS.0b013e3182326957
   Kawakami M, 2000, CLIN ORTHOP RELAT R, P129
   Liu XZ, 2014, ORTHOPEDICS, V37, pE117, DOI 10.3928/01477447-20140124-12
   Nouri A, 2015, SPINE, V40, P171, DOI 10.1097/BRS.0000000000000678
   Papadopoulos EC, 2006, SPINE, V31, P897, DOI 10.1097/01.brs.0000209348.17377.be
   Radcliff KE, 2014, J SPINAL DISORD TECH, V27, P86, DOI 10.1097/BSD.0b013e31824e53af
   Riew K Daniel, 2013, Evid Based Spine Care J, V4, P42, DOI 10.1055/s-0033-1341606
   Seng CS, 2013, SPINE J, V13, P723, DOI 10.1016/j.spinee.2013.02.038
   Shigematsu H, 2010, EUR SPINE J, V19, P720, DOI 10.1007/s00586-010-1338-5
   Shorter C, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.03.029
   Shou FY, 2015, EUR SPINE J, V24, P2724, DOI 10.1007/s00586-015-4186-5
   Swank M L, 1997, Eur Spine J, V6, P138, DOI 10.1007/BF01358747
   Taniyama T, 2013, SPINE, V38, P496, DOI 10.1097/BRS.0b013e318273a4f7
   Tetreault L, 2015, NEUROSURGERY, V77, pS51, DOI 10.1227/NEU.0000000000000951
   Tsuji T, 2017, EUR SPINE J, V26, P2410, DOI 10.1007/s00586-017-5223-3
   Wang HY, 2015, INT J CLIN EXP MED, V8, P3983
   Wu XD, 2012, EUR SPINE J, V21, P1368, DOI 10.1007/s00586-012-2157-7
   Xu LP, 2017, INT J SURG, V48, P247, DOI 10.1016/j.ijsu.2017.06.030
   2004, J NEUROSURG SUPPL SP, V100, P13
NR 38
TC 1
Z9 1
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E341
EP E347
DI 10.1016/j.wneu.2019.01.075
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700044
PM 30703598
DA 2020-05-12
ER

PT J
AU Cheng, Y
   Yeung, WL
   Zhang, PD
   Li, N
   Kiang, MY
   Leung, GKK
AF Cheng, Yin
   Yeung, Wan Lung
   Zhang, Ping De
   Li, Ning
   Kiang, Mei Yee
   Leung, Gilberto K. K.
TI Progesterone Is More Effective Than Dexamethasone in Prolonging Overall
   Survival and Preserving Neurologic Function in Experimental Animals with
   Orthotopic Glioblastoma Allografts
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dexamethasone; Functional outcome; Glioblastoma; Peritumoral edema;
   Progesterone; Survival
ID TRAUMATIC BRAIN-INJURY; CLINICAL-TRIAL; MOUSE MODEL; PHASE-III; GLIOMA;
   EDEMA; GROWTH; EXPRESSION; STROKE; NEUROPROTECTION
AB OBJECTIVE: Dexamethasone (DEXA) has been widely used in the management of peritumoral brain edema. DEXA, however, has many systemic side effects and can interact negatively with glioma therapy. Progesterone (PROG), however, is a well-tolerated and readily accessible anti-inflammatory and antiedema agent, with potent neuroprotective properties. We investigated whether PROG could serve as a viable alternative to DEXA in the management of peritumoral brain edema.
   METHODS: We used an orthotopic C6 glioblastoma model with male Sprague-Dawley rats. Tumor grafts were allowed to grow for 14 days before drug treatment with DEXA 1 mg/kg, PROG 10 mg/kg, or PROG 20 mg/kg for 5 consecutive days. The overall animal survival and neurologic function were evaluated. Mechanistic studies on blood-brain barrier permeability and angiogenic responses were performed on the ex vivo tumor grafts.
   RESULTS: We found that all drug treatments prolonged overall survival to different extents. PROG 10 mg led to significantly longer survival and better preservation of neurologic function and body weight. The blood-brain barrier permeability was better preserved with PROG 10 mg than with DEXA, possibly through downregulation of matrix metalloproteinase-9 and aquaporin-4 expression. Antiangiogenic responses were also observed in the PROG group.
   CONCLUSIONS: The present proof-of-concept pilot study has provided novel information on the use of PROG as a corticosteroid-sparing agent in brain tumor management. Further translational and clinical studies are warranted.
C1 [Cheng, Yin; Yeung, Wan Lung; Zhang, Ping De; Li, Ning; Kiang, Mei Yee; Leung, Gilberto K. K.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Div Neurosurg,Pok Fu Lam, Hong Kong, Peoples R China.
RP Leung, GKK (reprint author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Div Neurosurg,Pok Fu Lam, Hong Kong, Peoples R China.
EM gilberto@hku.hk
RI Leung, Gilberto Ka Kit/C-4337-2009
OI Leung, Gilberto Ka Kit/0000-0003-3147-3057
CR Atif F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131441
   Atif F, 2015, J STEROID BIOCHEM, V146, P62, DOI 10.1016/j.jsbmb.2014.04.007
   Atif F, 2011, MOL MED, V17, P1084, DOI 10.2119/molmed.2010.00255
   Barnes PJ, 2005, IMMUNOL ALLERGY CLIN, V25, P451, DOI 10.1016/j.iac.2005.05.003
   Bebawy JF, 2012, J NEUROSURG ANESTH, V24, P173, DOI 10.1097/ANA.0b013e3182578bb5
   Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022
   Carlson MRJ, 2007, CLIN CANCER RES, V13, P2592, DOI 10.1158/1078-0432.CCR-06-2772
   Cheng SY, 2015, NEURAL REGEN RES, V10, P1379, DOI 10.4103/1673-5374.165221
   Dang M, 2013, COMPUT METH PROG BIO, V111, P480, DOI 10.1016/j.cmpb.2013.04.011
   De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001
   Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451
   Fan Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093264
   Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040
   Genazzani AR, 2000, HUM REPROD, V15, P14, DOI 10.1093/humrep/15.suppl_1.14
   German-Castelan L, 2014, BIOMED RES INT, DOI 10.1155/2014/393174
   Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183
   Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003
   Griesdale DEG, 2004, SURG NEUROL, V61, P418, DOI 10.1016/j.surneu.2003.10.047
   Jiang C, 2016, MOL NEUROBIOL
   Jiang C, 2009, INFLAMM RES, V58, P619, DOI 10.1007/s00011-009-0032-8
   Kilts JD, 2010, PAIN MED, V11, P1469, DOI 10.1111/j.1526-4637.2010.00927.x
   Kostaras X, 2014, CURR ONCOL, V21, pE493, DOI 10.3747/co.21.1769
   Kural C, 2018, NEUROL NEUROCHIR POL, V52, P495, DOI 10.1016/j.pjnns.2018.03.002
   Leasure JL, 2004, BEHAV BRAIN RES, V150, P83, DOI 10.1016/S0166-4328(03)00254-7
   Li XJ, 2015, INT J CLIN EXP MED, V8, P18831
   Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3
   Liu Y, 2013, BEHAV BRAIN RES, V257, P166, DOI 10.1016/j.bbr.2013.10.007
   MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255
   Mayer A, 2014, STRAHLENTHER ONKOL, V190, P933, DOI 10.1007/s00066-014-0696-z
   MILLER JD, 1975, J NEUROSURG, V42, P274, DOI 10.3171/jns.1975.42.3.0274
   Olson JJ, 2009, J NEURO-ONCOL, V93, P1, DOI 10.1007/s11060-009-9838-z
   Pitter KL, 2016, BRAIN, V139, P1458, DOI 10.1093/brain/aww046
   Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5
   Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001
   Schiff D, 2009, NAT REV CLIN ONCOL, V6, P596, DOI 10.1038/nrclinonc.2009.128
   Schumacher M, 2016, J STEROID BIOCHEM, V160, P53, DOI 10.1016/j.jsbmb.2015.11.010
   Shields LBE, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0527-0
   Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090
   Smith Sheryl S, 2004, Cleve Clin J Med, V71 Suppl 2, pS4
   Soltani Z, 2016, J PHYSIOL BIOCHEM, V72, P33, DOI 10.1007/s13105-015-0453-5
   Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013
   Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Villeneuve J, 2008, BRAIN PATHOL, V18, P401, DOI 10.1111/j.1750-3639.2008.00139.x
   Wali B, 2016, BEHAV BRAIN RES, V305, P46, DOI 10.1016/j.bbr.2016.02.024
   Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704
   Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131
   WHISHAW IQ, 2005, BEHAV LAB RAT HDB TE
   Won S, 2014, J CEREBR BLOOD F MET, V34, P72, DOI 10.1038/jcbfm.2013.163
   Wong R, 2014, BMC NEUROSCI, V15, DOI 10.1186/s12868-014-0131-5
   Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304
   Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289
   Yang LJ, 2012, ONCOL REP, V28, P1633, DOI 10.3892/or.2012.1973
   Zamora-Sanchez CJ, 2017, STEROIDS, V119, P36, DOI 10.1016/j.steroids.2017.01.004
   Zhao WJ, 2012, FOLIA NEUROPATHOL, V50, P176
NR 55
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E497
EP E507
DI 10.1016/j.wneu.2019.01.113
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700066
PM 30710720
DA 2020-05-12
ER

PT J
AU Croci, DM
   Dalolio, M
   Guzman, R
   Mariani, L
   Schaeren, S
   Kamenova, M
   Soleman, J
AF Croci, Davide Marco
   Dalolio, Martina
   Guzman, Raphael
   Mariani, Luigi
   Schaeren, Stefan
   Kamenova, Maria
   Soleman, Jehuda
TI Direct Oral Anticoagulants in Patients Undergoing Spine Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bleeding rate; Direct oral anticoagulants; Spine surgery; Thromboembolic
   events
ID ATRIAL-FIBRILLATION; VENOUS THROMBOEMBOLISM; SAFETY; RISK; PREVENTION;
   MANAGEMENT; HEMORRHAGE; EFFICACY; WARFARIN; STROKE
AB OBJECTIVE: Despite increasing use of direct oral anticoagulants (DOACs), guidelines for their perioperative use in spine surgery are still lacking. The main goal of our study was to analyze the occurrence of postoperative bleeding events and possible confounders in patients treated with DOACs who undergo spine surgery.
   METHODS: Of 2777 patients undergoing spine surgery at our institution, 82 (2.9%) were treated with DOACs. The primary endpoint was postoperative bleeding events. Secondary outcome measures were postoperative thromboembolic events and anemia, hematologic findings, perioperative packed red blood cell substitution, operative time, hospital length of stay, morbidity, and mortality. Subanalysis of possible confounders affecting the rates of bleeding was also performed. Additionally, correlation of bleeding event rates and preoperative and postoperative discontinuation of DOACs was analyzed.
   RESULTS: Overall postoperative bleeding events rate was 4.9% (n = 4). Preoperative DOAC discontinuation time of <24 hours increased significantly the rate of perioperative packed red blood cell substitution (P = 0.007). Treatment with concomitant blood thinners showed a trend toward higher incidence of bleeding events (P = 0.066), whereas pre-existing kidney failure increased significantly rates of postoperative anemia (P = 0.014). The rate of postoperative thromboembolic events was 4.9% (n = 4); all events occurred with DOAC resumption >72 hours postoperatively.
   CONCLUSIONS: Short preoperative discontinuation time of DOACs, even <24 hours, may be justified, considering an increased risk of perioperative packed red blood cell substitution. Care should be taken with patients treated with concomitant blood thinners and patients with pre-existing kidney disease. Postoperative DOAC resumption >72 hours may increase risk of thromboembolic events.
C1 [Croci, Davide Marco; Dalolio, Martina; Guzman, Raphael; Mariani, Luigi; Kamenova, Maria; Soleman, Jehuda] Univ Hosp Basel, Dept Neurosurg, Basel, Switzerland.
   [Croci, Davide Marco; Dalolio, Martina; Schaeren, Stefan; Kamenova, Maria] Univ Hosp Basel, Dept Spine Surg, Basel, Switzerland.
RP Croci, DM (reprint author), Univ Hosp Basel, Dept Neurosurg, Basel, Switzerland.; Croci, DM (reprint author), Univ Hosp Basel, Dept Spine Surg, Basel, Switzerland.
EM davidemarco.croci@usb.ch
RI Mariani, Luigi/AAB-9464-2019
OI Guzman, Raphael/0000-0001-9620-0581
CR Akin Muharrem, 2015, Cardiovascular & Hematological Disorders - Drug Targets, V15, P92, DOI 10.2174/1871529X1502151209110620
   Alturki A, 2016, WORLD NEUROSURG, V90, P262, DOI 10.1016/j.wneu.2016.02.070
   Bansilal S, 2015, AM HEART J, V170, P675, DOI 10.1016/j.ahj.2015.07.006
   Beyer-Westendorf J, 2014, EUR HEART J, V35, P1888, DOI 10.1093/eurheartj/eht557
   Connolly SJ, 2016, NEW ENGL J MED, V375, P1131, DOI 10.1056/NEJMoa1607887
   Croci DM, 2017, WORLD NEUROSURG, V105, P841, DOI 10.1016/j.wneu.2017.06.105
   Deekonda P, 2019, EUR SPINE J, V28, P688, DOI 10.1007/s00586-016-4822-8
   Eriksson BI, 2007, J THROMB HAEMOST, V5, P2178, DOI 10.1111/j.1538-7836.2007.02748.x
   Eriksson BI, 2015, THROMB J, V13, DOI 10.1186/s12959-015-0067-8
   Healey JS, 2012, CIRCULATION, V126, P343, DOI 10.1161/CIRCULATIONAHA.111.090464
   Kimmell KT, 2015, SPINE, V40, P1836, DOI 10.1097/BRS.0000000000001051
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Majeed A, 2013, BEST PRACT RES CL HA, V26, P191, DOI 10.1016/j.beha.2013.07.001
   Pink J, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6333
   Rostagno Carlo, 2015, Cardiovascular & Hematological Disorders - Drug Targets, V15, P204, DOI 10.2174/1871529X16666160101122632
   Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0
   Truumees E, 2012, SPINE, V37, pE863, DOI 10.1097/BRS.0b013e31824ee320
   Vakharia VN, 2015, BRIT J NEUROSURG, V29, P182, DOI 10.3109/02688697.2014.997667
   van der Hulle T, 2014, J THROMB HAEMOST, V12, P320, DOI 10.1111/jth.12485
   Verma A, 2018, JAMA SURG, V153, P577, DOI 10.1001/jamasurg.2018.0374
   Yarmohammadi H, 2012, AM J CARDIOL, V110, P222, DOI 10.1016/j.amjcard.2012.03.017
NR 21
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1034
EP E1041
DI 10.1016/j.wneu.2019.01.236
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700128
PM 30776515
DA 2020-05-12
ER

PT J
AU Depreitere, B
   Turner, I
   Vandoren, C
   Choi, D
AF Depreitere, Bart
   Turner, Isobel
   Vandoren, Cindy
   Choi, David
TI Cost-Utility Analysis of Surgery and Radiotherapy for Symptomatic Spinal
   Metastases in a Belgian Specialist Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cost; Cost-utility; ICER; Metastasis; QALY; Spine; Surgery
ID QUALITY-OF-LIFE; SURGICAL-TREATMENT; CORD COMPRESSION; RESECTION;
   SURVIVAL; TUMORS
AB OBJECTIVE: Spinal metastases represent the most common site of bony metastases and frequently reduce quality of life. A beneficial effect of surgery and radiotherapy versus radiotherapy alone has been demonstrated in symptomatic patients. The goal of our study was to perform a cost-utility analysis of surgery for spinal metastases based on patient-level costs and health status data in a specialist spine center in Belgium.
   METHODS: A cost-utility analysis was performed in a prospective cohort of patients undergoing surgery for symptomatic spinal metastases in 2011-2015. EQ-5D-3L measure of health-related quality of life data were collected preoperatively and at 3, 6, 12, and 24 months. Hospital costs relating to surgical management including postoperative radiotherapy were analyzed. A retrospective cohort of patients treated with radiotherapy alone between 2011 and 2015, which matched the surgical patients for disease load and presentation, also was assessed. Quality-adjusted life years (QALYs) for nonsurgical patients were modelled against the surgical group.
   RESULTS: In total, 38 consecutive surgical patients had information for cost-utility analysis and 8 nonsurgical patients were matched. Mean total cost in the surgical group was (sic)16,989 (SD (sic)8148), largely comprising nonmedical staffing cost (mean (sic)7721, 45.9%), followed by daily operational costs ((sic)2963, 17.6%) and medical staffing costs ((sic)2621, 15.6%). Median initial health status was 0.33 (interquartile range 0.15-0.55), and median postoperative QALYs were 0.70 (interquartile range 0.18-1.70). Mean total cost in the nonsurgical cohort was (sic)9354. The incremental cost-effectiveness ratio for surgical management was (sic)13,635 (range (sic)12,726-(sic)14,407) per QALY.
   CONCLUSIONS: Surgery for symptomatic spinal metastases in a specialist hospital in Belgium is cost-effective.
C1 [Depreitere, Bart] Univ Hosp Leuven, Div Neurosurg, Leuven, Belgium.
   [Vandoren, Cindy] Univ Hosp Leuven, Management Informat & Reporting, Leuven, Belgium.
   [Turner, Isobel; Choi, David] Natl Hosp Neurol & Neurosurg, Neurosurg Dept, Queen Sq, London, England.
RP Depreitere, B (reprint author), Univ Hosp Leuven, Div Neurosurg, Leuven, Belgium.
EM bart.depreitere@uzleuven.be
RI Depreitere, Bart/AAA-9846-2020
OI Depreitere, Bart/0000-0002-7458-0648
CR Annemans L., 2018, GEZONDHEIDSECONOMIE
   Barber Julie, 2004, J Health Serv Res Policy, V9, P197, DOI 10.1258/1355819042250249
   Bartels RHMA, 2007, CANCER-AM CANCER SOC, V110, P2042, DOI 10.1002/cncr.23002
   BAUER HCF, 1995, ACTA ORTHOP SCAND, V66, P143, DOI 10.3109/17453679508995508
   Body Jean-Jacques, 2013, J Med Econ, V16, P539, DOI 10.3111/13696998.2013.774279
   Choi D, 2016, BRIT J NEUROSURG, V30, P337, DOI 10.3109/02688697.2015.1133802
   Choi D, 2015, NEUROSURGERY, V77, P698, DOI 10.1227/NEU.0000000000000907
   Choi D, 2010, EUR SPINE J, V19, P215, DOI 10.1007/s00586-009-1252-x
   Furlan JC, 2012, NEURO-ONCOLOGY, V14, P631, DOI 10.1093/neuonc/nos062
   GOMEZ JAO, 1995, INT ORTHOP, V19, P309
   Ibrahim A, 2008, J NEUROSURG-SPINE, V8, P271, DOI 10.3171/SPI/2008/8/3/271
   Lau D, 2016, J NEUROSURG-SPINE, V25, P366, DOI 10.3171/2016.2.SPINE15954
   Laufer I, 2013, ONCOLOGIST, V18, P744, DOI 10.1634/theoncologist.2012-0293
   Miyazaki S, 2017, INT ORTHOP, V41, P1265, DOI 10.1007/s00264-017-3463-9
   National Institute for Health and Care Excellence, 2013, GUID METH TECHN APPR
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Rades D, 2011, INT J RADIAT ONCOL, V81, pE861, DOI 10.1016/j.ijrobp.2010.11.056
   Sarkiss CA, 2018, WORLD NEUROSURG, V114, pE1101, DOI 10.1016/j.wneu.2018.03.155
   Szende A, 2007, EQ 5D VALUE SETS INV
   Tipsmark LS, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1357-z
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632-200102010-00016
   Turner I, 2018, WORLD NEUROSURG, V109, pE389, DOI 10.1016/j.wneu.2017.09.189
   Turner I, 2015, WORLD NEUROSURG, V84, P1235, DOI 10.1016/j.wneu.2015.06.008
   Yoshihara H, 2014, SPINE J, V14, P1844, DOI 10.1016/j.spinee.2013.11.029
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E537
EP E543
DI 10.1016/j.wneu.2019.01.130
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700070
PM 30716490
DA 2020-05-12
ER

PT J
AU Dillmann, J
   Hafez, A
   Niemela, M
   Braun, V
AF Dillmann, Johannes
   Hafez, Ahmad
   Niemela, Mika
   Braun, Veit
TI Hybrid Capability to Integrate Multiple Treatment Modalities for
   Managing High-Grade Intracranial Dural Arteriovenous Fistulas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural arteriovenous fistulas; Hybrid capability; Multimodality treatment
ID SURGICAL-TREATMENT; ONYX EMBOLIZATION; STEREOTACTIC RADIOSURGERY;
   ENDOVASCULAR TREATMENT; CLINICAL-COURSE; SURGERY; RISK; MANAGEMENT; ERA
AB BACKGROUND: An integrated multimodality approach can be effective in treatment of high-grade dural arteriovenous fistulas. Nevertheless, this requires a high level of efficient cooperation between different departments, underlying a degree of bias in the decisional process. In comparison, hybrid capability, integrating these modalities in one hand, may allow aggregating multimodality treatment strategies by pooling their individual benefits, leading to a more holistic view of the consequences of each modality.
   METHODS: We retrospectively reviewed 18 cases of dural arteriovenous fistulas subjected to a hybrid treatment approach at the Diakonieklinikum Jung-Stilling, Siegen, Germany, between March 2008 and January 2017. Nine cases were excluded. We selected 4 cases that highlight different aspects of hybrid capability for illustrative purposes.
   RESULTS: Hybrid capability allows treatment of a dural arteriovenous fistula based on the individual clinical situation of the patient and features of the lesion, free of interdepartmental bias. The surgeon maintains a level of flexibility that enables him or her to move from a minimally invasive endovascular approach to a maximally invasive surgical access according to the specific situation. Hybrid capability can lead to a highly efficient treatment regimen with palliation of symptoms and complete obliteration of the fistula, improving performance in these complex pathologies.
   CONCLUSIONS: Hybrid capability has great potential in the treatment of complex neurovascular lesions. It remains to be seen if a single surgeon with hybrid capability can supersede the current multidepartmental practice and achieve better outcomes.
C1 [Dillmann, Johannes; Braun, Veit] Diakonieklinikum Jung Stilling, Dept Neurosurg, Siegen, Germany.
   [Hafez, Ahmad; Niemela, Mika] Helsinki Univ Cent Hosp, Dept Neurosurg, Toolo Hosp, Helsinki, Finland.
RP Dillmann, J (reprint author), Diakonieklinikum Jung Stilling, Dept Neurosurg, Siegen, Germany.
EM dillmann.johannes@gmail.com
CR Al-Mahfoudh R, 2015, WORLD NEUROSURG, V83, P652, DOI 10.1016/j.wneu.2014.12.025
   Bashir M, 2019, GEN THORAC CARDIOVAS, V67, P132, DOI 10.1007/s11748-018-0940-z
   BORDEN JA, 1995, J NEUROSURG, V82, P166, DOI 10.3171/jns.1995.82.2.0166
   Chandra RV, 2014, AM J NEURORADIOL, V35, P1793, DOI 10.3174/ajnr.A3938
   Chen CJ, 2015, J NEUROSURG, V122, P353, DOI 10.3171/2014.10.JNS14871
   Chew J, 2009, CAN J NEUROL SCI, V36, P168, DOI 10.1017/S0317167100006521
   Cognard C, 2008, AM J NEURORADIOL, V29, P235, DOI 10.3174/ajnr.A0817
   Duffau H, 1999, J NEUROSURG, V90, P78, DOI 10.3171/jns.1999.90.1.0078
   Finn Michael, 2007, Neurosurg Focus, V22, pEditorial
   Goto K, 1999, J NEUROSURG, V90, P289, DOI 10.3171/jns.1999.90.2.0289
   Gross BA, 2013, J CLIN NEUROSCI, V20, P1527, DOI 10.1016/j.jocn.2012.12.015
   Hu YC, 2011, J NEUROINTERV SURG, V3, P5, DOI 10.1136/jnis.2010.003707
   Kakarla UK, 2007, NEUROSURGERY, V61, P447, DOI 10.1227/01.NEU.0000290889.62201.7F
   Kawaguchi Shoichiro, 2008, Brain and Nerve (Tokyo), V60, P897
   Liao CH, 2019, ACTA NEUROCHIR, V161, P611, DOI 10.1007/s00701-018-3769-4
   Liu JK, 2009, J NEUROSURG, V110, P913, DOI 10.3171/2008.9.JNS08733
   Lv XL, 2008, J NEUROSURG, V109, P1083, DOI 10.3171/JNS.2008.109.12.1083
   Mao GH, 2013, BRIT J NEUROSURG, V27, P532, DOI 10.3109/02688697.2012.757290
   Natarajan SK, 2010, WORLD NEUROSURG, V73, P365, DOI 10.1016/j.wneu.2010.01.009
   Nogueira RG, 2008, AM J NEURORADIOL, V29, P91, DOI 10.3174/ajnr.A0768
   Oh JS, 2016, J KOREAN NEUROSURG S, V59, P17, DOI 10.3340/jkns.2016.59.1.17
   Pan DHC, 2013, PROG NEUROL SURG, V27, P176, DOI 10.1159/000341793
   Piippo A, 2013, J NEUROSURG, V118, P923, DOI 10.3171/2012.11.JNS111604
   Reynolds MR, 2017, STROKE, V48, P1424, DOI 10.1161/STROKEAHA.116.012784
   Serruys PW, 2015, EUROINTERVENTION, V11, P489, DOI 10.4244/EIJV11I5A98
   Shah MN, 2012, J NEUROSURG, V117, P539, DOI 10.3171/2012.5.JNS111257
   Shen SC, 2015, J NEUROINTERV SURG, V7, pE6, DOI [10.1136/neurintsurg-2013-011060.rep, 10.1136/bcr-2013-011060]
   Signorelli F, 2015, CLIN NEUROL NEUROSUR, V128, P123, DOI 10.1016/j.clineuro.2014.11.011
   Soderman M, 2006, J NEUROSURG, V104, P867, DOI 10.3171/jns.2006.104.6.867
   Stapleton CJ, 2018, INTERV NEURORADIOL, V24, P331, DOI 10.1177/1591019917754038
   van Dijk JMC, 2002, STROKE, V33, P1233, DOI 10.1161/01.STR.0000014772.02908.44
   Wachter D, 2011, NEUROSURG REV, V34, P337, DOI 10.1007/s10143-011-0318-5
   Yang HC, 2010, NEUROSURGERY, V67, P1276, DOI 10.1227/NEU.0b013e3181ef3f22
   Youssef PP, 2014, NEUROSURGERY, V74, pS32, DOI 10.1227/NEU.0000000000000228
   2010, NEUROSURGERY, V67, P1276, DOI DOI 10.1227/NEU.0B013E3181EF3F22
   2007, NEUROSURGERY, V61, P447, DOI DOI 10.1227/01.NEU.0000280007.72190.F1
NR 36
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E774
EP E783
DI 10.1016/j.wneu.2019.01.168
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700095
PM 30735869
DA 2020-05-12
ER

PT J
AU Doglietto, F
   Belotti, F
   Nucci, CG
   Roca, E
   Mattogno, PP
   Zappa, F
   Migliorati, K
   Panciani, PP
   Spena, G
   Cereda, C
   Cornali, C
   Fontanella, MM
AF Doglietto, Francesco
   Belotti, Francesco
   Nucci, Carlotta Ginevra
   Roca, Elena
   Mattogno, Pier Paolo
   Zappa, Francesca
   Migliorati, Karol
   Panciani, Pier Paolo
   Spena, Giannantonio
   Cereda, Claudio
   Cornali, Claudio
   Fontanella, Marco Maria
TI Three-Dimensional High-Definition Ventriculoscope: Single-Center Case
   Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopy; Technology assessment; Three-dimensional; Ventricular
   surgery; Ventriculoscope
ID ENDOSCOPY
AB OBJECTIVE: Three-dimensional (3D), high-definition (HD) endoscopy has been recently introduced in neurosurgery, and its value has been discussed extensively in endonasal skull base surgery. Because there has been no reported clinical series on the use of a recent 3D-HD ventriculoscope, the aim of this study was to describe our initial experience with this novel device.
   METHODS: Patients consecutively operated on from June 2016 to June 2018 with a 3D-HD ventriculoscope were prospectively collected. The system is a 6-mm, 0-degree optic with a 105-degree field of view, with a central working channel of 2.2-mm diameter and 2 side channels of 1.3-mm diameter. Patients' demographic data, preoperative symptoms, and neurologic status; neuroradiologic data; type of surgery; operative time; intraoperative and postoperative complications, and follow-up data were prospectively recorded and retrospectively reviewed.
   RESULTS: Twenty-four patients (age range: 3-84 years) underwent 25 procedures including endoscopic third ventriculocisternostomy, biopsy, and cyst fenestration. The technical goal of surgery was obtained in all patients. There were no intraoperative complications, expect for 1 intraoperative epileptic seizure. Postoperative complications included asymptomatic subdural collections in 2 patients, infection, and delayed endoscopic third ventriculocisternostomy closure in 1 patient each.
   Relative limits of the system are its size and the availability of only a 0-degree optic. Image quality appeared satisfactory in all procedures. The lack of a dedicated introducer was resolved, exploiting a vascular "peelaway" system.
   CONCLUSIONS: 3D-HD technology seems to provide potential advantages in ventricular surgery. This initial experience is promising but must be confirmed by larger series.
C1 [Doglietto, Francesco; Belotti, Francesco; Nucci, Carlotta Ginevra; Roca, Elena; Mattogno, Pier Paolo; Zappa, Francesca; Migliorati, Karol; Panciani, Pier Paolo; Spena, Giannantonio; Cereda, Claudio; Cornali, Claudio; Fontanella, Marco Maria] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Neurosurg, Brescia, Italy.
RP Doglietto, F (reprint author), Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Neurosurg, Brescia, Italy.
EM francesco.doglietto@unibs.it
RI Nucci, Carlotta Ginevra/AAE-4748-2019; CEREDA, CRISTINA/G-8208-2011;
   Mattogno, Pier Paolo/Y-1518-2019
OI CEREDA, CRISTINA/0000-0001-9571-0862; Mattogno, Pier
   Paolo/0000-0003-2857-9096; Doglietto, Francesco/0000-0002-7438-0734
CR Barkhoudarian G, 2013, NEUROSURGERY, V73, P74, DOI 10.1227/NEU.0b013e31828ba962
   D'Ammando A, 2018, OPER NEUROSURG, V14, P706, DOI 10.1093/ons/opx207
   Fraser JF, 2009, MINIM INVAS NEUROSUR, V52, P25, DOI 10.1055/s-0028-1104567
   Gaab MR., 2016, NEUROENDOSCOPIC SURG, P11
   Levy ML, 1998, NEUROSURGERY, V43, P392, DOI 10.1097/00006123-199808000-00141
   Manes RP, 2011, INT FORUM ALLERGY RH, V1, P191, DOI 10.1002/alr.20012
   Raheja A, 2016, WORLD NEUROSURG, V92, P378, DOI 10.1016/j.wneu.2016.05.031
   Rampinelli V, 2017, WORLD NEUROSURG, V105, P223, DOI 10.1016/j.wneu.2017.05.130
   Rangel-Castilla L, 2016, NEUROENDOSCOPIC SURG, P386
   Tabaee A, 2009, NEUROSURGERY, V64, P288, DOI 10.1227/01.NEU.0000338069.51023.3C
   Wasserzug O, 2010, SKULL BASE-INTERD AP, V20, P223, DOI 10.1055/s-0030-1247630
   Zaidi HA, 2016, WORLD NEUROSURG, V86, P419, DOI 10.1016/j.wneu.2015.10.004
   2009, NEUROSURGERY S2, V64, P288, DOI DOI 10.1227/01.NEU.0000338069.51023.3C
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E978
EP E983
DI 10.1016/j.wneu.2019.01.219
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700121
PM 30763750
DA 2020-05-12
ER

PT J
AU Enriquez-Marulanda, A
   Ravindran, K
   Salem, MM
   Ascanio, LC
   Kan, P
   Srinivasan, VM
   Griessenauer, CJ
   Schirmer, CM
   Jain, A
   Moore, JM
   Ogilvy, CS
   Thomas, AJ
   Alturki, AY
AF Enriquez-Marulanda, Alejandro
   Ravindran, Krishnan
   Salem, Mohamed M.
   Ascanio, Luis C.
   Kan, Peter
   Srinivasan, Visish M.
   Griessenauer, Christoph J.
   Schirmer, Clemens M.
   Jain, Abhi
   Moore, Justin M.
   Ogilvy, Christopher S.
   Thomas, Ajith J.
   Alturki, Abdulrahman Y.
TI Evaluation of Radiological Features of the Posterior Communicating
   Artery and Their Impact on Efficacy of Saccular Aneurysm Treatment with
   the Pipeline Embolization Device: A Case Series Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Flow diversion; Patency; Pipeline embolization device;
   Posterior communicating artery
ID PATENCY
AB BACKGROUND: Posterior communicating artery segment aneurysms are one of the most frequent intracranial aneurysms. Currently, limited data have described the use of the pipeline embolization device (PED) in these aneurysms.
   METHODS: We conducted a multicenter retrospective review of 3 prospectively collected databases of patients treated with the PED from January 2013 to December 2017. The primary objective was to assess the efficacy and safety of the PED in the treatment of saccular posterior communicating artery (PComA) aneurysms. We also assessed the effect of anatomical variations on the angiographic and clinical outcomes, including the presence of fetal PComA, vessel origin relationship to the aneurysm, and patency after PED placement.
   RESULTS: We identified 57 patients with 60 saccular aneurysms; Their mean age was 60.5 years, and 49 were female (86.0%). A total of 55 aneurysms (91.7%) were unruptured. The median imaging follow-up duration was 8.5 months. Complete occlusion at the last imaging follow-up study was 84.0%. At the last follow-up examination, 94.5% of patients had a modified Rankin scale score of <= 2. The presence of fetal PComA, origin type, and patency during follow-up did have a significant effect on aneurysm occlusion (P = 0.61, P = 0.40, and P = 0.14, respectively).
   CONCLUSIONS: PED use for treatment of PComA aneurysms resulted in acceptable occlusion rates. The present study did not find that fetal PComA, its origin, or its patency during follow-up had an effect on aneurysm occlusion.
C1 [Enriquez-Marulanda, Alejandro; Ravindran, Krishnan; Salem, Mohamed M.; Ascanio, Luis C.; Moore, Justin M.; Ogilvy, Christopher S.; Thomas, Ajith J.; Alturki, Abdulrahman Y.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02115 USA.
   [Kan, Peter; Srinivasan, Visish M.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Griessenauer, Christoph J.; Schirmer, Clemens M.; Jain, Abhi] Geisinger, Dept Neurosurg, Danville, PA USA.
   [Griessenauer, Christoph J.] Paracelsus Med Univ, Res Inst Neurointervent, Salzburg, Austria.
   [Alturki, Abdulrahman Y.] King Fahad Med City, Natl Neurosci Inst, Dept Neurosurg, Riyadh, Saudi Arabia.
RP Alturki, AY (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02115 USA.
EM dr.alturki.neurosurgery@gmail.com
OI Griessenauer, Christoph/0000-0002-2952-3812; Enriquez-Marulanda,
   Alejandro/0000-0001-6091-390X; Ascanio, Luis/0000-0001-9914-1599; Jain,
   Abhi/0000-0001-7398-1039
CR Becske T, 2017, NEUROSURGERY, V80, P40, DOI 10.1093/neuros/nyw014
   Bhogal P, 2017, WORLD NEUROSURG, V103, P789, DOI 10.1016/j.wneu.2017.04.092
   BISARIA KK, 1984, J NEUROSURG, V60, P572, DOI 10.3171/jns.1984.60.3.0572
   Brinjikji W, 2014, CLIN NEUROL NEUROSUR, V120, P84, DOI 10.1016/j.clineuro.2014.02.018
   Crobeddu E, 2013, J NEUROINTERV SURG, V5, P351, DOI 10.1136/neurintsurg-2012-010320
   Daou B, 2017, J NEUROSURG, V126, P564, DOI 10.3171/2016.2.JNS152544
   Golshani Kiarash, 2010, Surg Neurol Int, V1, P88, DOI 10.4103/2152-7806.74147
   Griessenauer CJ, 2016, J NEUROSURG, V125, P1352, DOI 10.3171/2015.12.JNS152499
   Hu YC, 2014, J NEUROSURG, V120, P365, DOI 10.3171/2013.11.JNS131599
   Kallmes DF, 2007, STROKE, V38, P2346, DOI 10.1161/STROKEAHA.106.479576
   Kan P, 2016, J NEUROINTERV SURG, V8, P945, DOI 10.1136/neurintsurg-2015-011959
   Kuhn AL, 2018, INTERV NEURORADIOL, V24, DOI 10.1177/1591019918759735
   Lambert SL, 2016, J INVEST MED HIGH IM, V4, DOI 10.1177/2324709616665409
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Neki H, 2015, J NEUROSURG, V123, P1540, DOI 10.3171/2014.11.JNS141603
   Patel PD, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1742
   Puffer RC, 2012, J NEUROSURG, V116, P892, DOI 10.3171/2011.11.JNS111612
   Roy AK, 2018, NEUROSURGERY, V82, P695, DOI 10.1093/neuros/nyx293
   Sadasivan C, 2009, STROKE, V40, P952, DOI 10.1161/STROKEAHA.108.533760
   Sanai N, 2012, NEUROSURGERY, V71, P285, DOI 10.1227/NEU.0b013e318256c3eb
   Tsang Anderson Chun On, 2015, Neurointervention, V10, P60, DOI 10.5469/neuroint.2015.10.2.60
   van Raamt AF, 2006, CEREBROVASC DIS, V22, P217, DOI 10.1159/000094007
   Wallace AN, 2017, CLIN NEUROL NEUROSUR, V160, P83, DOI 10.1016/j.clineuro.2017.06.014
   Zhou G, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS16450
   2012, NEUROSURGERY, V71, P285, DOI DOI 10.1227/NEU.0B013E318256C3EB
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E998
EP E1007
DI 10.1016/j.wneu.2019.01.228
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700124
PM 30771544
DA 2020-05-12
ER

PT J
AU Erdogan, U
   Tanik, C
   Tanriverdi, O
   Gunaldi, O
   Yilmaz, I
   Arslanhan, A
   Ofluoglu, AE
AF Erdogan, Uzay
   Tanik, Canan
   Tanriverdi, Osman
   Gunaldi, Omur
   Yilmaz, Ilhan
   Arslanhan, Ayca
   Ofluoglu, Ali Ender
TI Immunohistochemical Grading of Epidural Fibrosis with CD105 Antibody
SO WORLD NEUROSURGERY
LA English
DT Article
DE CD105; Epidural fibrosis; Immunohistochemistry; Spine; Tranexamic acid
ID PERIOPERATIVE BLOOD-LOSS; TRANEXAMIC ACID; MICROVESSEL DENSITY; ENDOGLIN
   EXPRESSION; LUMBAR LAMINECTOMY; SPINAL SURGERY; TRANSFUSION; THERAPY;
   DRUGS
AB OBJECTIVE: Grading of epidural fibrosis (EF) is usually performed by histopathologic staining in experimental studies. Immunohistochemical methods for grading are not available in routine practice yet. In our study, the effect of tranexamic acid (TXA), a commonly used hemostatic agent in surgical interventions, was evaluated for use against the development of EF with classical histopathologic methods and immunohistochemistry using the CD105 antibody, a marker of angiogenesis.
   METHODS: Sixteen rats were used. The rats were assigned to 2 groups, control and TXA. Laminectomy was performed on the control group. In the treatment group, laminectomy + topical TXA was applied. After sacrificing the rats in the sixth week, histopathologic and immunohistochemical examinations and grading of the EF tissue were performed.
   RESULTS: Conventional histopathologic parameters of fibroblast count, intensity of fibrosis density, and inflammatory cell density, as well as immunohistochemical evaluation with CD105, showed that the grading of EF was comparable between groups I and II (P < 0.001).
   DISCUSSION: The results of our study have demonstrated that CD105 is compatible with the conventional histopathologic grading methods and can be used as a marker to determine the grades of angiogenesis and fibrosis in experimental studies. The results of our study have also shown that TXA, administered locally for hemostasis, reduces the grade of EF in rats following laminectomy. TXA has been observed to cause no toxic effects on neural tissue as it is already commonly used in clinical practice.
C1 [Erdogan, Uzay; Tanriverdi, Osman; Gunaldi, Omur; Ofluoglu, Ali Ender] Univ Hlth Sci, Bakirkoy Prof Dr Mazhar Osman Training & Res Hosp, Istanbul, Turkey.
   [Tanik, Canan] Univ Hlth Sci, Sisli Hamidiye Etfal Training & Res Hosp, Dept Pathol, Istanbul, Turkey.
   [Yilmaz, Ilhan] Univ Hlth Sci, Sisli Hamidiye Etfal Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Arslanhan, Ayca] Marmara Univ, Inst Neurol Sci, Istanbul, Turkey.
RP Erdogan, U (reprint author), Univ Hlth Sci, Bakirkoy Prof Dr Mazhar Osman Training & Res Hosp, Istanbul, Turkey.
EM uzayerdogan@gmail.com
RI Gunaldi, Omur/AAH-9115-2019
CR Altun I, 2016, WORLD NEUROSURG, V90, P147, DOI 10.1016/j.wneu.2016.02.052
   Aydincak O, 2012, TURK NEUROSURG, V22, P706, DOI 10.5137/1019-5149.JTN.5966-12.1
   Badeaux J, 2014, J PERIANESTH NURS, V29, P459, DOI 10.1016/j.jopan.2014.06.003
   Brewer CA, 2000, OBSTET GYNECOL, V96, P224, DOI 10.1016/S0029-7844(00)00864-4
   Cheriyan T, 2015, SPINE J, V15, P752, DOI 10.1016/j.spinee.2015.01.013
   de Tribolet N, 1996, EUR SPINE J, V1, P18
   Faraoni D, 2014, ANESTH ANALG, V118, P628, DOI 10.1213/ANE.0000000000000080
   Gunaldi O, 2014, TURK NEUROSURG, V24, P849, DOI 10.5137/1019-5149.JTN.8783-13.0
   HE Y, 1995, SPINE, V20, P557, DOI 10.1097/00007632-199503010-00010
   Henry DA, 2007, COCHRANE DB SYST REV, V17
   HINTON JL, 1995, SPINE, V20, P564, DOI 10.1097/00007632-199503010-00011
   Ipema HJ, 2012, ANN PHARMACOTHER, V46, P97, DOI 10.1345/aph.1Q383
   Kagoma YK, 2009, THROMB RES, V123, P687, DOI 10.1016/j.thromres.2008.09.015
   Koukourakis MI, 2000, CANCER RES, V60, P3088
   Laupacis A, 1997, ANESTH ANALG, V85, P1258, DOI 10.1097/00000539-199712000-00014
   Lethaby A, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000249
   Li ZJ, 2013, EUR SPINE J, V22, P1950, DOI 10.1007/s00586-013-2774-9
   Lumsden MA, 2011, EXPERT OPIN PHARMACO, V12, P2089, DOI 10.1517/14656566.2011.598857
   Neilipovitz DT, 2001, ANESTH ANALG, V93, P82
   Ng W, 2015, ANAESTH INTENSIVE TH, V47, P339, DOI 10.5603/AIT.a2015.0011
   Perel P, 2013, COCHRANE DB SYST REV, V31
   Prieto M, 2005, KIDNEY BLOOD PRESS R, V28, P32, DOI 10.1159/000081439
   Segal H, 1997, HEPATOLOGY, V25, P683, DOI 10.1002/hep.510250332
   Sethna NF, 2005, ANESTHESIOLOGY, V102, P727, DOI 10.1097/00000542-200504000-00006
   Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5
   STEIB A, 1994, BRIT J ANAESTH, V73, P645, DOI 10.1093/bja/73.5.645
   Weidner N, 2004, AM J CLIN PATHOL, V122, P675, DOI 10.1309/KY6EHOLGY6D6PGP5
   Winter SF, 2016, GLOB SPINE J, V6, P284, DOI 10.1055/s-0035-1563609
   Xu CS, 2012, ARCH ORTHOP TRAUM SU, V132, P25, DOI 10.1007/s00402-011-1390-6
   Yang BH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055436
   Yao YX, 2005, NEUROPATHOLOGY, V25, P201, DOI 10.1111/j.1440-1789.2005.00632.x
   Yilmaz I, 2018, TURK NEUROSURG, V28, P954, DOI 10.5137/1019-5149.JTN.22633-18.2
   Zhang F, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-448
   2013, EVID-BASED COMPL ALT
NR 34
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E297
EP E303
DI 10.1016/j.wneu.2019.01.068
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700038
PM 30685375
DA 2020-05-12
ER

PT J
AU Feng, S
   Tian, W
   Sun, YQ
   Liu, YJ
   Wei, Y
AF Feng, Shuo
   Tian, Wei
   Sun, Yuqing
   Liu, Yajun
   Wei, Yi
TI Effect of Robot-Assisted Surgery on Lumbar Pedicle Screw Internal
   Fixation in Patients with Osteoporosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Orthopedic; Osteoporosis; Pedicle screw; Robot
ID SPINAL SURGERY; PLACEMENT; ACCURACY; COMPLICATIONS; FLUOROSCOPY;
   NAVIGATION
AB OBJECTIVE: We sought to compare clinical outcomes of robot-assisted versus conventional freehand fluoroscopy-assisted lumbar pedicle screw insertion in patients with osteoporosis.
   METHODS: This study included 80 patients with osteoporosis and lumbar disease treated with pedicle screw internal fixation in the Department of Spine Surgery, Beijing Jishuitan Hospital between June 2016 and July 2018. Patients were randomly assigned to receive either robot-assisted pedicle screw insertion (experimental group) or freehand fluoroscopy-assisted pedicle screw insertion (control group). The accuracy of screw placement was assessed with postoperative computed tomography. Operative time, pedicle screw placement time, radiation exposure to the medical team, and intraoperative blood loss were recorded.
   RESULTS: A total of 427 pedicle screws were inserted in 80 patients; 202 pedicle screws were placed in the experimental group, and 225 pedicle screws were placed in the control group. The accuracy of screw placement was significantly higher with robot-assisted pedicle screw insertion (98.5% [199/202]) compared with that achieved with the freehand technique (91.6% [206/225]) (P < 0.05). Robot-assisted pedicle screw insertion was associated with reductions in the mean total pedicle screw placement time (27.60 +/- 8.58 vs. 32.26 +/- 10.48 minutes), radiation exposure to the medical team (2.23 +/- 0.62 vs. 3.35 +/- 0.80 fluoroscopic images), and intraoperative blood loss (254.75 +/- 115.34 vs. 356.25 +/- 141.00 mL; P < 0.05). The mean operative time did not differ significantly between the groups.
   CONCLUSIONS: Robot-assisted pedicle screw insertion is a more effective surgical option for patients with osteoporosis who present with various spine diseases compared with fluoroscopy-assisted freehand screw placement techniques.
C1 [Feng, Shuo; Tian, Wei; Sun, Yuqing; Liu, Yajun; Wei, Yi] Beijing Jishuitan Hosp, Dept Spine Surg, Beijing, Peoples R China.
RP Tian, W (reprint author), Beijing Jishuitan Hosp, Dept Spine Surg, Beijing, Peoples R China.
EM jizhutongxun1997@163.com
FU National Key R&D Program of China [2016YFC0105800]; National High
   Technology Research and Development Program of ChinaNational High
   Technology Research and Development Program of China [2015AA043201]
FX This work was supported by the National Key R&D Program of China
   [2016YFC0105800] and the National High Technology Research and
   Development Program of China [2015AA043201].
CR Aoude AA, 2015, EUR SPINE J, V24, P990, DOI 10.1007/s00586-015-3853-x
   Armbrecht G, 2017, RHEUMATOLOGY, V56, P1189, DOI 10.1093/rheumatology/kex040
   Assaker R, 2001, SPINE, V26, P2160, DOI 10.1097/00007632-200110010-00024
   Borcek AO, 2014, TURK NEUROSURG, V24, P398, DOI 10.5137/1019-5149.JTN.10445-14.1
   Carbone JJ, 2003, SPINE, V28, P91, DOI 10.1097/00007632-200301010-00021
   Carmouche JJ, 2005, J NEUROSURG-SPINE, V3, P364, DOI 10.3171/spi.2005.3.5.0364
   Chan A, 2017, SPINE J, V17, P1215, DOI 10.1016/j.spinee.2017.04.001
   Chiang HW, 2015, BIO-MED MATER ENG, V26, pS1641, DOI 10.3233/BME-151463
   FAN Y, 2018, MEDICINE, V97
   GERTZBEIN SD, 1990, SPINE, V15, P11, DOI 10.1097/00007632-199001000-00004
   Goost H, 2014, TECHNOL HEALTH CARE, V22, P607, DOI 10.3233/THC-140815
   Hayashi D, 2012, AM J ROENTGENOL, V199, pW123, DOI 10.2214/AJR.11.6497
   Hu XB, 2014, CLIN ORTHOP RELAT R, V472, P1839, DOI 10.1007/s11999-013-3291-1
   Kaneyama S, 2015, SPINE, V40, pE341, DOI 10.1097/BRS.0000000000000772
   Kim HJ, 2017, INT J MED ROBOT COMP, V13, DOI 10.1002/rcs.1779
   Kim HJ, 2015, SPINE, V40, P87, DOI 10.1097/BRS.0000000000000680
   Larson AN, 2012, J PEDIATR ORTHOPED, V32, pE23, DOI 10.1097/BPO.0b013e318263a39e
   Tian W, 2017, CHINESE MED J-PEKING, V130, P1617, DOI 10.4103/0366-6999.208251
   Tome-Bermejo F, 2017, ARCH BONE JT SURG-AB, V5, P363
   Van de Kelft E, 2012, SPINE, V37, pE1580, DOI 10.1097/BRS.0b013e318271b1fa
   van Dijk JD, 2015, SPINE, V40, pE986, DOI 10.1097/BRS.0000000000000960
   Verma R, 2010, EUR SPINE J, V19, P370, DOI 10.1007/s00586-009-1258-4
   Yoshida G, 2012, ASIAN SPINE J, V6, P194, DOI 10.4184/asj.2012.6.3.194
NR 23
TC 3
Z9 3
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1057
EP E1062
DI 10.1016/j.wneu.2019.01.243
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700131
PM 30790729
DA 2020-05-12
ER

PT J
AU Foreman, PM
   Mooney, J
   Ilyas, A
   Agee, B
   Vivekanandan, S
   Fong, RP
   Okor, MO
   Riley, KO
   Griessenauer, CJ
AF Foreman, Paul M.
   Mooney, James
   Ilyas, Adeel
   Agee, Bonita
   Vivekanandan, Sheela
   Fong, Reginald P.
   Okor, Mamerhi O.
   Riley, Kristen O.
   Griessenauer, Christoph J.
TI Antiplatelet Medication and Operative Subdural Hematomas: A
   Retrospective Cohort Study Evaluating Reoperation Rates
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antiplatelet; Intracranial hemorrhage; Platelet transfusion;
   Reoperation; Subdural hematoma
ID PLATELET TRANSFUSION; HEMORRHAGE; THERAPY; PREDICTORS; MORTALITY;
   ASPIRIN
AB BACKGROUND: Antiplatelet therapy is common and complicates the operative management of subdural hematomas (SDH). The risk of reoperation inferred by antiplatelet medication and the ability of platelet transfusion to reduce hemorrhagic complications in patients presenting with antiplatelet associated SDHs are poorly defined.
   METHODS: We performed a retrospective review of consecutive patients treated with craniotomy or craniectomy for evacuation of an acute or mixed-density SDH between 2012 and 2017 at 2 academic institutions. Exclusion criteria included anticoagulant therapy, thrombocytopenia, and/or international normalized ratio >1.3. Clinical and radiographic data were collected; primary endpoint was reoperation within 30 days. Logistic regression models were used to identify predictors of reoperation.
   RESULTS: A total of 195 patients were included: 86 patients on antiplatelet medication and 109 with no antithrombotic history. Overall, 24 (12.3%) of patients required a reoperation. Reoperation rate in patients on antiplatelet medication was not significantly different than those not on antithrombotics (14.0% vs. 11.0%, P = 0.53). Patients taking antiplatelet medication were significantly older, more likely to have medical comorbidities, and more likely to receive preoperative platelet transfusion (36.0% vs. 3.7%, P < 0.001). Of patients taking antiplatelet medications, there was no difference in reoperation rate between those patients receiving preoperative platelet transfusion and those not receiving transfusion (16.1% vs. 12.7%, P = 0.75).
   CONCLUSIONS: Antiplatelet medication was not a significant predictor of reoperation following evacuation of an acute or mixed-density SDH. In patients on antiplatelet medication, preoperative platelet transfusion did not reduce reoperation rates.
C1 [Foreman, Paul M.; Mooney, James; Ilyas, Adeel; Agee, Bonita; Okor, Mamerhi O.; Riley, Kristen O.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
   [Foreman, Paul M.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Neurosurg, Boston, MA 02115 USA.
   [Vivekanandan, Sheela; Fong, Reginald P.; Griessenauer, Christoph J.] Geisinger, Dept Neurosurg, Danville, PA USA.
   [Griessenauer, Christoph J.] Paracelsus Med Univ, Res Inst Neurointervent, Salzburg, Austria.
RP Foreman, PM (reprint author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.; Foreman, PM (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Neurosurg, Boston, MA 02115 USA.
EM Pforeman03@gmail.com
CR Ajani UA, 2006, AM J PREV MED, V30, P74, DOI 10.1016/j.amepre.2005.08.042
   Baharoglu MI, 2016, LANCET, V387, P2605, DOI 10.1016/S0140-6736(16)30392-0
   Foreman PM, 2018, WORLD NEUROSURG, V116, pE649, DOI 10.1016/j.wneu.2018.05.064
   Forster MT, 2010, J CLIN NEUROSCI, V17, P975, DOI 10.1016/j.jocn.2009.11.023
   Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009
   Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x
   Gaist D, 2017, JAMA-J AM MED ASSOC, V317, P836, DOI 10.1001/jama.2017.0639
   Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa
   Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P990, DOI 10.1097/TA.0b013e3182a96591
   Li XW, 2013, J NEUROSURG, V118, P94, DOI 10.3171/2012.9.JNS112286
   Lukasiewicz AM, 2016, J NEUROSURG, V124, P760, DOI 10.3171/2015.2.JNS142721
   Motiei-Langroudi R, 2018, J NEUROSURG, V129, P1143, DOI 10.3171/2017.6.JNS17130
   Wada M, 2014, CLIN NEUROL NEUROSUR, V120, P49, DOI 10.1016/j.clineuro.2014.02.007
   Weimer JM, 2017, NEUROCRIT CARE, V26, P70, DOI 10.1007/s12028-016-0279-1
   Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E671
EP E677
DI 10.1016/j.wneu.2019.01.151
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700084
PM 30735874
DA 2020-05-12
ER

PT J
AU Funakoshi, Y
   Hanakita, J
   Takahashi, T
   Minami, M
   Kawaoka, T
   Ohtake, Y
   Oichi, Y
AF Funakoshi, Yusuke
   Hanakita, Junya
   Takahashi, Toshiyuki
   Minami, Manabu
   Kawaoka, Taigo
   Ohtake, Yasufumi
   Oichi, Yuki
TI Investigation of Radiologic Landmarks Used to Decide the Appropriate
   Surgical Approach for Upper Thoracic Ventral Degenerative Disorders
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervicothoracic junction; Intervertebral disc herniation; Ossification
   of posterior longitudinal ligament; Upper thoracic degenerative disease
ID POSTERIOR LONGITUDINAL LIGAMENT; CERVICOTHORACIC-JUNCTION; ANTERIOR
   APPROACH; DISC HERNIATION; OSSIFICATION; DECOMPRESSION; MYELOPATHY;
   STERNOTOMY; SPINE; FUSION
AB BACKGROUND: Ventral lesions of upper thoracic spinal cord due to degenerative diseases are rare and often have poor operative outcomes. Anterior decompression of the lesion is difficult because of the local anatomy. This retrospective study aimed to evaluate reproducible anatomic measurements for selecting the best surgical approach for anterior decompression of ventral lesions of upper thoracic spinal cord.
   METHODS: Cases of anterior decompression of ventral lesions of upper thoracic spinal cord due to degenerative diseases at our institution from 2004 to 2015 were assessed. Several lines were drawn on magnetic resonance imaging and computed tomography scans of midsagittal sections of the upper thoracic spine to evaluate the most optimal approach for treating upper thoracic lesions. A line from the suprasternal notch to the vertebral body (suprasternal notch to vertebral body [SV] line) was accepted as baseline.
   RESULTS: The caudal edge of the lesion was above the SV line in 10 cases, each of which was treated via an anterior approach without sternotomy. The caudal edge was below the SV line in 7 cases, 5 of which underwent surgery with the sternum-splitting or transthoracic approach. The other 2 lesions were approached via an obliquely deviated route without sternotomy. The SV line sometimes changed with patients' posture alterations.
   CONCLUSIONS: The SV line, a useful landmark for upper thoracic lesions, is not sufficiently reliable because it changes according to the patient's posture. By leaning in the direction of the surgical microscope, more caudal upper thoracic lesions can be reached than when using the SV line as a surgical landmark.
C1 [Funakoshi, Yusuke; Hanakita, Junya; Takahashi, Toshiyuki; Minami, Manabu; Kawaoka, Taigo; Ohtake, Yasufumi; Oichi, Yuki] Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Kobe, Hyogo, Japan.
RP Funakoshi, Y (reprint author), Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Kobe, Hyogo, Japan.
EM sf1wan0610@gmail.com
CR Aizawa T, 2007, J NEUROSURG-SPINE, V7, P13, DOI 10.3171/SPI-07/07/013
   AN HS, 1994, SPINE, V19, P2557, DOI 10.1097/00007632-199411001-00011
   Cauchoix J, 1957, Ann R Coll Surg Engl, V21, P237
   Comey CH, 1997, ACTA NEUROCHIR, V139, P712, DOI 10.1007/BF01420043
   Falavigna A, 2011, J NEUROSURG-SPINE, V15, P38, DOI 10.3171/2011.3.SPINE10342
   Fraser JF, 2002, SPINE, V27, P675, DOI 10.1097/00007632-200204010-00002
   Fujimura Y, 1996, SPINAL CORD, V34, P387, DOI 10.1038/sc.1996.70
   GIEGER M, 1995, NEUROSURGERY, V37, P704, DOI 10.1227/00006123-199510000-00014
   Hanai K, 2002, SPINE, V27, P1070, DOI 10.1097/00007632-200205150-00012
   Hanakita J, 1999, NEUROL MED-CHIR, V39, P428, DOI 10.2176/nmc.39.428
   HANAKITA J, 1988, Neurological Surgery, V16, P837
   Hanakita J, 2011, J SPINE RES, V2, P244
   Hanakita J, 1995, JPN J NEUROSURG, V4, P92
   Hanakita J, 2013, SPINAL SURG, V27, P106
   Huang YX, 2013, EUR SPINE J, V22, P1533, DOI 10.1007/s00586-013-2766-9
   Huang YX, 2010, EUR SPINE J, V19, P1936, DOI 10.1007/s00586-010-1478-7
   Karikari IO, 2009, NEUROSURGERY, V65, P165, DOI 10.1227/01.NEU.0000347472.07670.EB
   Kawahara N, 2008, SPINE, V33, P39, DOI 10.1097/BRS.0b013e31815e3911
   Kitahara T, 2014, JPN J NEUROSURG, V23, P897
   Kong WJ, 2018, WORLD NEUROSURG, V112, P287, DOI 10.1016/j.wneu.2018.01.099
   Lam FC, 2011, J NEUROSURG-SPINE, V15, P467, DOI 10.3171/2011.6.SPINE11189
   Matsumoto M, 2008, SPINE, V33, P1034, DOI 10.1097/BRS.0b013e31816c913b
   Morgan H, 1998, J NEUROSURG, V88, P148, DOI 10.3171/jns.1998.88.1.0148
   OHTANI K, 1982, CLIN ORTHOP RELAT R, P82
   Ozer AF, 2009, SPINE, V34, P1879, DOI 10.1097/BRS.0b013e3181aa7c62
   Park JH, 2015, J KOREAN NEUROSURG S, V58, P236, DOI 10.3340/jkns.2015.58.3.236
   Pointillart V, 2007, SPINE, V32, P2875, DOI 10.1097/BRS.0b013e31815b7632
   Seol HJ, 2002, J NEUROSURG, V97, P337, DOI 10.3171/spi.2002.97.3.0337
   Sharan AD, 2000, SPINE, V25, P910, DOI 10.1097/00007632-200004150-00003
   SUNDARESAN N, 1984, J NEUROSURG, V61, P686, DOI 10.3171/jns.1984.61.4.0686
   Tarantino R, 2013, SPINE J, V13, P1064, DOI 10.1016/j.spinee.2013.02.049
   Teng HL, 2009, J NEUROSURG-SPINE, V10, P531, DOI 10.3171/2009.2.SPINE08372
   YASUI T, 1984, Neurological Surgery, V12, P1021
NR 33
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E856
EP E862
DI 10.1016/j.wneu.2019.01.200
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700106
PM 30743040
DA 2020-05-12
ER

PT J
AU Gao, FL
   Li, M
   Wang, Z
   Shi, LF
   Lou, L
   Zhou, J
AF Gao, Faliang
   Li, Min
   Wang, Zheng
   Shi, Lingfei
   Lou, Lin
   Zhou, Jia
TI Efficacy and Safety of Gamma Knife Radiosurgery for Meningiomas in
   Patients with Neurofibromatosis Type 2: A Long-Term Follow-Up
   Single-Center Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gamma knife; Meningioma; Neurofibromatosis type 2; Stereotactic
   radiosurgery; Tumor control
ID NF2
AB OBJECTIVE: To explore the efficacy and safety of Gamma Knife radiosurgery (GKRS) for meningiomas in patients with neurofibromatosis type 2 (NF2).
   METHODS: A series of 35 consecutive patients with 99 meningiomas in our department were retrospectively included from January 2000 to December 2015. Clinical records, magnetic resonance images, and follow-up data were reviewed.
   RESULTS: A total of 35 patients (25 women and 10 men) with 99 NF2-associated meningiomas were identified. All patients initially received GKRS. The patients' median age at the time of GKRS was 40 years (range, 16-61 years). The median prescription dose at the tumor margin was 13 Gy (range, 12-15 Gy). The median follow-up time was 96 months (range, 25-224 months). Twenty-nine patients received GKRS only once, and 6 patients received it multiple times. Six patients (17.1%) had radiation-related complications 7.5 +/- 2.4 months after GKRS. Local control rates at 1, 3, and 5 years were 100%, 97.1%, and 90.6%, respectively. Distant control rates at 1, 3, and 5 years were 88.5%, 55.9%, and 45.5%, respectively. Five patients died of concomitant neurologic symptoms. No malignant transformation was observed during the follow-up periods in all 35 patients.
   CONCLUSIONS: GKRS represents an effective and safe management strategy with minimal invasion for patients with NF2-associated meningiomas. Our data showed a high local control rate of NF2-associated meningiomas by GKRS; however, the distant control rate is low, especially in young patients. For these patients, retreatment with GKRS may still be the advisable method.
C1 [Gao, Faliang; Li, Min; Wang, Zheng; Lou, Lin; Zhou, Jia] Zhejiang Prov Peoples Hosp, Peoples Hosp, Hangzhou Med Coll, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
   [Gao, Faliang; Li, Min; Wang, Zheng; Lou, Lin; Zhou, Jia] Zhejiang Prov Peoples Hosp, Peoples Hosp, Hangzhou Med Coll, Gamma Knife Ctr, Hangzhou, Zhejiang, Peoples R China.
   [Shi, Lingfei] Zhejiang Prov Peoples Hosp, Peoples Hosp, Hangzhou Med Coll, Ctr Diag & Treatment Osteoporosis, Hangzhou, Zhejiang, Peoples R China.
RP Zhou, J (reprint author), Zhejiang Prov Peoples Hosp, Peoples Hosp, Hangzhou Med Coll, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.; Zhou, J (reprint author), Zhejiang Prov Peoples Hosp, Peoples Hosp, Hangzhou Med Coll, Gamma Knife Ctr, Hangzhou, Zhejiang, Peoples R China.
EM cneagles@sina.com
CR Aichholzer M, 2000, ACTA NEUROCHIR, V142, P647, DOI 10.1007/s007010070108
   Alanin MC, 2016, INT J NEUROSCI, V126, P1002, DOI 10.3109/00207454.2015.1092443
   Baser ME, 2000, BRIT J CANCER, V82, P998
   Biezynski B, 2012, J NEUROSURG, V117, P109
   Birckhead B, 2016, J NEURO-ONCOL, V130, P553, DOI 10.1007/s11060-016-2257-z
   Evans DGR, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-16
   EVANS DGR, 1992, Q J MED, V84, P603
   Ferner RE, 2007, LANCET NEUROL, V6, P340, DOI 10.1016/S1474-4422(07)70075-3
   Goutagny S, 2010, J NEURO-ONCOL, V99, P341, DOI 10.1007/s11060-010-0339-x
   Gutmann DH, 2013, EXPERT OPIN INV DRUG, V22, P443, DOI 10.1517/13543784.2013.772979
   Hasegawa T, 2011, J NEUROSURG, V114, P1392, DOI 10.3171/2010.11.JNS10112
   Hoffman CE, 2007, NEUROSURG QUART, V17, P128, DOI 10.1097/WNQ.0b013e318036ae74
   Kollova A, 2007, J NEUROSURG, V107, P325, DOI 10.3171/JNS-07/08/0325
   KONDZIOLKA D, 1991, STEREOT FUNCT NEUROS, V57, P11, DOI 10.1159/000099552
   Kresak JL, 2016, J PEDIATR GENET, V5, P98, DOI 10.1055/s-0036-1579766
   Liscak R, 1999, ACTA NEUROCHIR, V141, P473, DOI 10.1007/s007010050327
   Liu A, 2015, J NEUROSURG, V122, P536, DOI 10.3171/2014.10.JNS132593
   Nunes FP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059941
   Patil CG, 2008, NEUROSURGERY, V63, P435, DOI 10.1227/01.NEU.0000325257.58684.92
   Paulsson AK, 2014, AM J CLIN ONCOL-CANC, V37, P177, DOI 10.1097/COC.0b013e318271ae03
   Pollock BE, 2012, NEUROSURGERY, V71, P604, DOI 10.1227/NEU.0b013e31825ea557
   Roche PH, 2003, ACTA NEUROCHIR, V145, P883, DOI 10.1007/s00701-003-0123-1
   Santacroce A, 2012, NEUROSURGERY, V70, P32, DOI 10.1227/NEU.0b013e31822d408a
   Stafford SL, 2001, NEUROSURGERY, V49, P1029, DOI 10.1097/00006123-200111000-00001
   2012, J NEUROSURG, V117, P109, DOI DOI 10.3171/2012.3.JNS111649
NR 25
TC 2
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E929
EP E936
DI 10.1016/j.wneu.2019.01.211
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700115
PM 30763746
DA 2020-05-12
ER

PT J
AU Giordano, M
   Samii, A
   Samii, M
   Nabavi, A
AF Giordano, Mario
   Samii, Amir
   Samii, Madjid
   Nabavi, Arya
TI Magnetic Resonance Imaging-Apparent Diffusion Coefficient Assessment of
   Vestibular Schwannomas: Systematic Approach, Methodology, and Pitfalls
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apparent diffusion coefficient; Diffusion tensor imaging; Magnetic
   resonance imaging; Vestibular schwannoma
ID FACIAL-NERVE; TUMORS; TRACT; DIFFERENTIATION; PREDICTION; GLIOMAS
AB OBJECTIVE: To investigate the validity of various approaches to extract quantitative measurements of diffusion imaging (i.e., apparent diffusion coefficient [ADC]) to investigate tumors of the central nervous system. In current studies, the region of interest (ROI) for the quantitative measurements are placed arbitrarily according to morphology. Our aim is to investigate how placement patterns influence the ADC estimation in intracranial tumors.
   METHODS: Twenty consecutive patients affected by vestibular schwannoma were studied using diffusion imaging. ADC values were obtained using different ROI placement methods: segmentation ADC values of the entire volume (vADC), random ADC values were obtained in 10 different ROI points, and a single ROI in the ADC of the internal auditory canal portion of the tumor.
   RESULTS: ADC of the internal auditory canal portion of the tumor and vADC differed significantly (P < 0.01). vADC was different between cystic and microcystic schwannomas (P = 0.009) and between cystic and solid schwannomas (P = 0.006).
   CONCLUSIONS: The positioning of ROI in these measurements is pivotal. Although "whole tumor volume" measurements represent the largest amount of information, multiple seed points can be used as well. However, there must be multiple seeds and their placement must be reported. ADC can be used as a versatile tool for tumor assessment but must be used judiciously and structured to yield comparable results.
C1 [Giordano, Mario; Samii, Amir; Samii, Madjid; Nabavi, Arya] Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
   [Samii, Amir] Leibniz Inst Neurobiol, Magdeburg, Germany.
RP Giordano, M (reprint author), Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
EM giordano.nch@gmail.com
CR Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782
   Bull JG, 2012, EUR RADIOL, V22, P447, DOI 10.1007/s00330-011-2255-7
   Chen X, 2009, NEUROIMAGE, V45, P286, DOI 10.1016/j.neuroimage.2008.11.038
   Choudhri AF, 2015, NEURORADIOL J, V28, P209, DOI 10.1177/1971400915581741
   Dumrongpisutikul N, 2012, AM J NEURORADIOL, V33, P550, DOI 10.3174/ajnr.A2806
   Engelter ST, 2008, SWISS MED WKLY, V138, P729, DOI 2008/49/smw-12249
   Gauvain KM, 2001, AM J ROENTGENOL, V177, P449, DOI 10.2214/ajr.177.2.1770449
   Gerganov VM, 2011, J NEUROSURG, V115, P1087, DOI 10.3171/2011.7.JNS11495
   Giordano M, 2015, CLIN NEUROL NEUROSUR, V136, P1, DOI 10.1016/j.clineuro.2015.05.004
   Hoque R, 2007, INT REV NEUROBIOL, V79, P491, DOI 10.1016/S0074-7742(07)79022-0
   Hori M, 2014, MAGN RESON IMAGING, V32, P625, DOI 10.1016/j.mri.2014.02.024
   Mehrotra N, 2008, BRIT J NEUROSURG, V22, P550, DOI 10.1080/02688690802159031
   Nimsky C, 2007, NEUROSURGERY, V61, P306, DOI [10.1227/01.NEU.0000204726.00088.6D, 10.1227/01.neu.0000279224.83998.7d]
   Nimsky C, 2006, NEUROIMAGE, V30, P1219, DOI 10.1016/j.neuroimage.2005.11.001
   Pavlisa G, 2008, CLIN IMAG, V32, P22, DOI 10.1016/j.clinimag.2007.07.007
   Prager AJ, 2015, AM J NEURORADIOL, V36, P877, DOI 10.3174/ajnr.A4218
   Rumboldt Z, 2006, AM J NEURORADIOL, V27, P1362
   Samii M, 1997, NEUROSURGERY, V40
   Samii M, 2006, J NEUROSURG, V105, P527, DOI 10.3171/jns.2006.105.4.527
   Stieglitz LH, 2011, NEUROSURGERY, V68, P1239, DOI 10.1227/NEU.0b013e31820b52e1
   Straka M, 2010, J MAGN RESON IMAGING, V32, P1024, DOI 10.1002/jmri.22338
   2010, J NEUROSURG S, V113, P97, DOI DOI 10.3171/2010.7.GKS10864
   2012, J NEUROSURG S, V117, P63, DOI DOI 10.3171/2012.7.GKS121003
   1997, NEUROSURGERY, V40, P684
   1997, NEUROSURGERY, V40, P248
NR 25
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E820
EP E823
DI 10.1016/j.wneu.2019.01.176
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700101
PM 30738940
DA 2020-05-12
ER

PT J
AU Goel, A
   Vutha, R
   Shah, A
   Dharurkar, P
   Jadhav, N
   Jadhav, D
AF Goel, Atul
   Vutha, Ravikiran
   Shah, Abhidha
   Dharurkar, Pralhad
   Jadhav, Neha
   Jadhav, Dikpal
TI Spinal Kyphoscoliosis Associated with Chiari Formation and Syringomyelia
   'Recovery' Following Atlantoaxial Fixation: A Preliminary Report and
   Early Results Based on Experience with 11 Surgically Treated Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial dislocation; Chiari formation; Kyphoscoliosis;
   Syringomyelia
ID MALFORMATION TYPE-I; BASILAR INVAGINATION; OUTCOME ANALYSIS;
   INSTABILITY; SCOLIOSIS
AB OBJECTIVE: Immediate postoperative and early clinical outcome of treatment of spinal kyphoscoliosis (SKS) associated with Chiari formation (CF) and syringomyelia (SM) and treated by atlantoaxial fixation is described.
   METHODS: During the period April 2016 to March 2018, 11 patients with SKS as a major presenting symptom in association with CF and SM were surgically treated and are analyzed retrospectively. The patients were 6 boys and 5 girls, and their ages ranged from 11-17 years (average 14 years). Six patients (54.5%) had associated neurologic symptoms and 9 patients had neck pain. All patients were treated by atlantoaxial fixation. No manipulation of foramen magnum bone or dura was performed. No surgery was performed on the subaxial cervical or dorsal spine. Patient Satisfaction Score was based on a specially designed questionnaire. Other outcome measures included clinical and radiologic assessment data, clinical photographs and video observation, and a Scoliosis Research Society Questionnaire.
   RESULTS: Apart from improvement in neurologic condition, more particularly in breathing capability and voice volume restoration, all patients and their relatives noticed recovery in SKS in the immediate postoperative phase. During the average follow-up of 14 months, all patients continued to have progressive symptomatic recovery and recovery from SKS. Patient Satisfaction Score suggested that all patients were 'highly' satisfied with the surgical outcome.
   CONCLUSIONS: Atlantoaxial fixation in patients with CF and SM associated with SKS results in reversal of several musculoskeletal and neural abnormalities that includes recovery from spinal deformity.
C1 [Goel, Atul; Vutha, Ravikiran; Shah, Abhidha; Dharurkar, Pralhad; Jadhav, Neha; Jadhav, Dikpal] King Edward Mem Hosp, Dept Neurosurg, Mumbai, Maharashtra, India.
   [Goel, Atul; Vutha, Ravikiran; Shah, Abhidha; Dharurkar, Pralhad; Jadhav, Neha; Jadhav, Dikpal] Seth Gordhandas Sunderdas Med Coll, Mumbai, Maharashtra, India.
   [Goel, Atul] Lilavati Hosp & Res Ctr, Mumbai, Maharashtra, India.
RP Goel, A (reprint author), King Edward Mem Hosp, Dept Neurosurg, Mumbai, Maharashtra, India.; Goel, A (reprint author), Seth Gordhandas Sunderdas Med Coll, Mumbai, Maharashtra, India.
EM atulgoel62@hotmail.com
CR Beauchamp EC, 2019, NEUROSURGERY, V84, P291, DOI 10.1093/neuros/nyy267
   Brockmeyer D, 2003, SPINE, V28, P2505, DOI 10.1097/01.BRS.0000092381.05229.87
   Brockmeyer DL, 2011, J NEUROSURG-PEDIATR, V7, P22, DOI 10.3171/2010.9.PEDS10383
   Eule JM, 2002, SPINE, V27, P1451, DOI 10.1097/00007632-200207010-00015
   Goal A, 2002, NEUROSURGERY, V51, P1356
   Godzik J, 2015, SPINE J, V15, P2002, DOI 10.1016/j.spinee.2015.04.048
   GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Goel A, 2019, WORLD NEUROSURG, V121, pE296, DOI 10.1016/j.wneu.2018.09.099
   Goel A, 2018, WORLD NEUROSURG, V111, pE668, DOI 10.1016/j.wneu.2017.12.137
   Goel A, 2018, WORLD NEUROSURG, V110, P533, DOI 10.1016/j.wneu.2017.07.007
   Goel A, 2017, WORLD NEUROSURG, V101, P702, DOI 10.1016/j.wneu.2017.02.063
   Goel A, 2017, WORLD NEUROSURG, V99, P186, DOI 10.1016/j.wneu.2016.11.143
   Goel A, 2017, WORLD NEUROSURG, V99, P164, DOI 10.1016/j.wneu.2016.11.093
   Goel A, 2017, J CRANIOVERTEBRAL JU, V8, P1, DOI 10.4103/0974-8237.199881
   Goel A, 2016, WORLD NEUROSURG, V95, P375, DOI 10.1016/j.wneu.2016.08.026
   Goel A, 2016, J CRANIOVERTEBRAL JU, V7, P20, DOI 10.4103/0974-8237.176613
   Goel A, 2015, J CRANIOVERTEBRAL JU, V6, P141, DOI 10.4103/0974-8237.167850
   Goel A, 2015, J NEUROSURG-SPINE, V22, P116, DOI 10.3171/2014.10.SPINE14176
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P107, DOI 10.4103/0974-8237.142302
   Goel A, 2011, J NEUROSURG-SPINE, V14, P3, DOI 10.3171/2010.9.SPINE1010
   Goel A, 2009, J NEUROSURG-SPINE, V10, P220, DOI 10.3171/2008.12.SPINE08499
   Haroun RI, 2000, PEDIATR NEUROSURG, V33, P311, DOI 10.1159/000055977
   Kelly MP, 2015, NEUROSURG CLIN N AM, V26, P579, DOI 10.1016/j.nec.2015.06.005
   Krieger MD, 2011, J NEUROSURG-PEDIATR, V7, P25, DOI 10.3171/2010.10.PEDS10154
   Lenke LG, 2001, J BONE JOINT SURG AM, V83A, P1169, DOI 10.2106/00004623-200108000-00006
   Li ZY, 2019, SPINE J, V19, P87, DOI 10.1016/j.spinee.2018.05.027
   Rustagi T, 2019, SPINE J, V19, P314, DOI 10.1016/j.spinee.2018.05.033
   Strahle J, 2015, J NEUROSURG-PEDIATR, V15, P607, DOI 10.3171/2014.11.PEDS14135
   Tambe AD, 2018, BONE JOINT J, V100B, P415, DOI 10.1302/0301-620X.100B4.BJJ-2017-0846.R2
   2011, J NEUROSURG PEDIAT, V7, P22, DOI DOI 10.3171/2010.9.PEDS10383
   2002, NEUROSURGERY, V51, P1351, DOI DOI 10.1227/01.NEU.0000035852.23082.C6
NR 31
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E937
EP E946
DI 10.1016/j.wneu.2019.01.212
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700116
PM 30763740
DA 2020-05-12
ER

PT J
AU Goertz, L
   Brinker, G
   Hamisch, C
   Kabbasch, C
   Borggrefe, J
   Hof, M
   Timmer, M
   Stavrinou, P
   Goldbrunner, R
   Krischek, B
AF Goertz, Lukas
   Brinker, Gerrit
   Hamisch, Christina
   Kabbasch, Christoph
   Borggrefe, Jan
   Hof, Marion
   Timmer, Marco
   Stavrinou, Pantelis
   Goldbrunner, Roland
   Krischek, Boris
TI Elective Treatment of Additional and Recurrent Aneurysms in Patients
   with a Previous Subarachnoid Hemorrhage: A Single-Center Analysis of
   Complications and Clinical Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clipping; Endovascular treatment; Ruptured aneurysm; Subarachnoid
   hemorrhage; Unruptured aneurysm
ID UNRUPTURED INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; COILING;
   SAFETY; METAANALYSIS; RATES; ISAT
AB OBJECTIVE: Subarachnoid hemorrhage (SAH) can be associated with a degree of resulting brain damage and subsequent reorganization of the central nervous system. The aim of this study was to evaluate complication rates and clinical outcome in patients with a previous SAH who were treated for a recurrent or an additional, initially unruptured aneurysm.
   METHODS: A retrospective single-center study was conducted for patients who underwent elective treatment by surgical or endovascular means between 2010 and 2018. We compared patients with a previous SAH and without history of SAH in terms of complication rates and functional outcomes (modified Rankin Scale [mRS]).
   RESULTS: The study population consisted of 337 patients (non-SAH, 270; SAH, 67) who underwent 390 elective procedures for treatment of 443 aneurysms. Procedure-related complications occurred in 13.5% of patients with a previous SAH and in 13.3% of patients without SAH (P = 1.0). At the 6-month follow-up, the morbidity (defined as any increase on the mRS) was comparable between the SAH group (6.7%) and the non-SAH group (7.6%; P = 0.5). Overall favorable outcome (mRS score <= 2) was achieved by 96.6% in the SAH group and 97.3% in the non-SAH group (P = 1.0). Also, in patients with a previous SAH, the choice of clipping or endovascular treatment did not have a significant impact on clinical outcome at the 6-month follow-up.
   CONCLUSIONS: Treatment of recurrent or additional aneurysms in patients with a previous SAH can be performed with acceptable complication rates and morbidity by either surgical or endovascular means.
C1 [Goertz, Lukas; Brinker, Gerrit; Hamisch, Christina; Hof, Marion; Timmer, Marco; Stavrinou, Pantelis; Goldbrunner, Roland; Krischek, Boris] Univ Cologne, Ctr Neurosurg, Dept Gen Neurosurg, Cologne, Germany.
   [Kabbasch, Christoph; Borggrefe, Jan] Univ Hosp Cologne, Dept Neuroradiol, Kerpener Str, Cologne, Germany.
RP Goertz, L (reprint author), Univ Cologne, Ctr Neurosurg, Dept Gen Neurosurg, Cologne, Germany.
EM lukas.goertz@uk-koeln.de
RI Borggrefe, Jan/N-6549-2018
OI Borggrefe, Jan/0000-0003-2908-7560; Kabbasch,
   Christoph/0000-0003-3712-2258
CR ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052
   Brinjikji W, 2011, AM J NEURORADIOL, V32, P1071, DOI 10.3174/ajnr.A2453
   BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342
   Darsaut TE, 2012, NEUROCHIRURGIE, V58, P61, DOI 10.1016/j.neuchi.2012.02.023
   Darsaut TE, 2017, J NEUROL NEUROSUR PS, V88, P663, DOI 10.1136/jnnp-2016-315433
   Dorfer C, 2012, NEUROSURGERY, V70, P537, DOI 10.1227/NEU.0b013e3182350da5
   Gerlach R, 2007, J NEUROL NEUROSUR PS, V78, P864, DOI 10.1136/jnnp.2006.106823
   Johnston SC, 2008, STROKE, V39, P120, DOI 10.1161/STROKEAHA.107.495747
   Johnston SC, 2006, STROKE, V37, P1437, DOI 10.1161/01.STR.0000221331.01830.ce
   Korja M, 2015, LANCET, V385, P2250, DOI 10.1016/S0140-6736(15)61059-5
   Kotowski M, 2013, J NEUROL NEUROSUR PS, V84, P42, DOI 10.1136/jnnp-2011-302068
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Naggara ON, 2012, RADIOLOGY, V263, P828, DOI 10.1148/radiol.12112114
   Naggara ON, 2010, RADIOLOGY, V256, P887, DOI 10.1148/radiol.10091982
   Ostrowski RP, 2006, NEUROL RES, V28, P399, DOI 10.1179/016164106X115008
   Schaafsma JD, 2009, STROKE, V40, P1758, DOI 10.1161/STROKEAHA.108.524751
   Seifert V, 2008, DTSCH ARZTEBL INT, V105, P449, DOI 10.3238/arztebl.2008.0449
   Sharma M, 2013, NEUROL INDIA, V61, P270, DOI 10.4103/0028-3886.115067
   Smith TR, 2015, WORLD NEUROSURG, V84, P942, DOI 10.1016/j.wneu.2015.05.073
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   Waldron JS, 2009, NEUROSURGERY, V64, P301, DOI 10.1227/01.NEU.0000335178.15274.B4
   Wermer MJH, 2005, STROKE, V36, P2394, DOI 10.1161/01.STR.0000185686.28035.d2
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   2009, NEUROSURGERY S2, V64, P301, DOI DOI 10.1227/01.NEU.0000335178.15274.B4
   1993, NEUROSURGERY, V33, P1052
NR 27
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1196
EP E1202
DI 10.1016/j.wneu.2019.01.279
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700149
PM 30794974
DA 2020-05-12
ER

PT J
AU Gorecka-Mazur, A
   Furgala, A
   Krygowska-Wajs, A
   Pietraszko, W
   Kwinta, B
   Gil, K
AF Gorecka-Mazur, Agnieszka
   Furgala, Agata
   Krygowska-Wajs, Anna
   Pietraszko, Wojciech
   Kwinta, Borys
   Gil, Krzysztof
TI Activities of Daily Living and Their Relationship to Health-Related
   Quality of Life in Patients with Parkinson Disease After Subthalamic
   Nucleus Deep Brain Stimulation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Activity of daily living; Health-related quality of life; Parkinson
   disease; Subthalamic nucleus deep brain stimulation
ID PHYSICAL-ACTIVITY; ASSOCIATION; COGNITION; PROGRAM; DECLINE; SURGERY;
   PEOPLE; IMPACT; INDEX
AB BACKGROUND: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) can reduce motor symptoms in patients with Parkinson disease (PD) and improve their health-related quality of life (HRQoL). The effect of STN DBS on activities of daily living (ADL), an important component of quality of life, is poorly understood. We aimed to investigate effects of STN DBS on HRQoL and ADL in patients with PD.
   METHODS: HRQoL and ADL were assessed using the following disease-specific and generic questionnaires at baseline and 3, 6, and 12 months after surgery: the Parkinson's Disease Questionnaire 39 (PDQ-39), the Short-Form 36 health survey questionnaire, the World Health Organization Quality of Life Scale-Brief version, the Unified Parkinson's Disease Rating Scale part II, the ADL scale, and the Instrumental Activities of Daily Living scale.
   RESULTS: We reported significant early improvements (3 months) in the HRQoL and ADL, and these benefits increased over time (6 months); however, further improvement between 6 and 12 months was nonsignificant. Two PDQ-39 subdomains (social support and communications) and a Short-Form 36 health survey questionnaire subdomain (social functioning) showed declines after surgery. Changes in the Instrumental Activities of Daily Living scale were significantly correlated with changes in the PDQ-39 summary index and other PDQ-39 subdomains, including mobility, emotional well-being, social support, and cognition, at all follow-up points.
   CONCLUSIONS: STN DBS caused a marked improvement in HRQoL at 3 and 6 months; however, HRQoL remained stable at the 12-month postoperative follow-up. Moreover, we have shown a significant correlation between ADL performance and HRQoL after STN DBS.
C1 [Gorecka-Mazur, Agnieszka; Furgala, Agata; Gil, Krzysztof] Jagiellonian Univ, Med Coll, Dept Pathophysiol, Krakow, Poland.
   [Gorecka-Mazur, Agnieszka; Pietraszko, Wojciech; Kwinta, Borys] Jagiellonian Univ, Med Coll, Dept Neurosurg, Krakow, Poland.
   [Krygowska-Wajs, Anna] Jagiellonian Univ, Med Coll, Dept Neurol, Krakow, Poland.
RP Gorecka-Mazur, A (reprint author), Jagiellonian Univ, Med Coll, Dept Pathophysiol, Krakow, Poland.; Gorecka-Mazur, A (reprint author), Jagiellonian Univ, Med Coll, Dept Neurosurg, Krakow, Poland.
EM a.gorecka-mazur@uj.edu.pl
FU Ministry of Science and Higher Education in Warsaw, Poland
   [K/ZDS/003969]
FX This study was supported by grant number K/ZDS/003969 (specific subsidy
   for holding the research capacity of the Ministry of Science and Higher
   Education in Warsaw, Poland).
CR Abboud H, 2017, PARKINSONS DIS-US, V2017, DOI 10.1155/2017/5609163
   Abboud H, 2015, PARKINSONISM RELAT D, V21, P249, DOI 10.1016/j.parkreldis.2014.12.018
   Bargiotas P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190027
   Cavanaugh JT, 2015, PHYS THER, V95, P1142, DOI 10.2522/ptj.20140498
   Daneault JF, 2015, J PARKINSON DIS, V5, P85, DOI 10.3233/JPD-140426
   Daneault JF, 2014, MOVEMENT DISORD, V29, P1816, DOI 10.1002/mds.25911
   Daniels C, 2011, MOVEMENT DISORD, V26, P2516, DOI 10.1002/mds.23907
   Defer GL, 1999, MOVEMENT DISORD, V14, P572, DOI 10.1002/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C
   Den Oudsten BL, 2007, MOVEMENT DISORD, V22, P1390, DOI 10.1002/mds.21539
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Dos Santos JFA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174512
   Duncan Ryan P, 2018, Pilot Feasibility Stud, V4, P54, DOI 10.1186/s40814-018-0243-2
   Ellis T, 2005, ARCH PHYS MED REHAB, V86, P626, DOI 10.1016/j.apmr.2004.08.008
   Erickson KI, 2014, NEUROBIOL AGING, V35, pS20, DOI 10.1016/j.neurobiolaging.2014.03.034
   Fahn S, 1987, RECENT DEV PARKINSON, V2, P153
   Floden D, 2014, NEUROLOGY, V83, P1627, DOI 10.1212/WNL.0000000000000943
   Hariz GM, 2011, ACTA NEUROL SCAND, V123, P20, DOI 10.1111/j.1600-0404.2010.01344.x
   Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667
   HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181
   Izumi H, 2017, BMC NEUROSCI, V18, DOI 10.1186/s12868-017-0335-6
   Janvin C, 2003, DEMENT GERIATR COGN, V15, P126, DOI 10.1159/000068483
   Jenkinson C, 1997, AGE AGEING, V26, P353, DOI 10.1093/ageing/26.5.353
   Jiang JL, 2015, J FORMOS MED ASSOC, V114, P835, DOI 10.1016/j.jfma.2013.09.006
   Just H, 2002, MOVEMENT DISORD, V17, P539, DOI 10.1002/mds.10111
   Kadastik-Eerme L, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0281-x
   KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20
   King LA, 2014, ARCH PHYS MED REHAB, V95, P2152, DOI 10.1016/j.apmr.2014.07.396
   Kleiner-Fisman G, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-91
   Krygowska-Wajs A, 2016, PARKINSONISM RELAT D, V26, P35, DOI 10.1016/j.parkreldis.2016.02.010
   KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k
   Lai YR, 2018, NEUROPSYCHIATRY, V8, P119
   Lawrence BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102294
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   Le Jeune F, 2009, NEUROLOGY, V73, P1746, DOI 10.1212/WNL.0b013e3181c34b34
   Lee JY, 2008, J KOREAN NEUROSURG S, V44, P26, DOI 10.3340/jkns.2008.44.1.26
   Lewis CJ, 2014, PARKINSONISM RELAT D, V20, P514, DOI 10.1016/j.parkreldis.2014.02.009
   Lezcano E, 2016, J NEUROL, V263, P895, DOI 10.1007/s00415-016-8077-4
   Martinez-Martin P, 2011, MOVEMENT DISORD, V26, P2371, DOI 10.1002/mds.23834
   Mehanna R, 2017, PARKINSONS DIS-US, V2017, DOI 10.1155/2017/3085140
   Nguyen H, 2017, J NEUROENG REHABIL, V14, DOI 10.1186/s12984-017-0241-2
   Nicoletti A, 2017, PLOS ONE, V5
   Nimura T, 2017, J CLIN NEUROSCI, V44, P164, DOI 10.1016/j.jocn.2017.06.018
   Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571
   Rosenthal E, 2010, MOVEMENT DISORD, V25, P1170, DOI 10.1002/mds.23073
   Shulman LM, 2006, MOVEMENT DISORD, V21, P794, DOI 10.1002/mds.20803
   Soh SE, 2013, QUAL LIFE RES, V22, P1543, DOI 10.1007/s11136-012-0289-1
   Thobois S, 2010, BRAIN, V133, P1111, DOI 10.1093/brain/awq032
   van Uem JMT, 2018, PARKINSONISM RELAT D, V48, P74, DOI 10.1016/j.parkreldis.2017.12.023
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   2013, LANCET NEUROL, V12, P37, DOI DOI 10.1016/S1474-4422(12)70264-8
NR 50
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E552
EP E562
DI 10.1016/j.wneu.2019.01.132
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700072
PM 30716489
DA 2020-05-12
ER

PT J
AU Grasso, G
   Leone, L
   Torregrossa, F
AF Grasso, Giovanni
   Leone, Ludovica
   Torregrossa, Fabio
TI Dysphagia Prevention in Anterior Cervical Discectomy Surgery: Results
   from a Prospective Clinical Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical discectomy surgery; Dysphagia; Preventive measures
ID TUBE CUFF PRESSURE; SPINE SURGERY; RISK-FACTORS; RETRACTION; OUTCOMES;
   DECOMPRESSION; RELIABILITY; IMPLANT; FUSION; PLATE
AB BACKGROUND: Dysphagia is a common complication after anterior cervical discectomy surgery (ACDS). Recent studies have shown that reducing the endotracheal tube cuff pressure, local irrigation with methylprednisolone, and minimizing the pharynx/esophagus retraction can decrease the incidence of postoperative dysphagia after ACDS. This is the first study assessing the efficacy of all these 3 measures simultaneously.
   METHODS: This prospective study included 35 patients (group 1) who underwent ACDS with the adoption of all the 3 preventive measures. Group 1 was compared with a homogenous group of 35 patients who underwent regular ACDS (group 2). Postoperative dysphagia and odynophagia were evaluated after 2, 7, and 14 days and 3, 6, and 12 months. Age, gender, body mass index (BMI), operating time, blood loss, and preoperative Japanese Orthopaedic Association score were collected.
   RESULTS: Postoperative dysphagia was observed in 3 cases (8.6%) in group 1 and 15 cases (42.9%) in group 2 (P < 0.05). Three patients in group 1 had transient dysphagia with complete resolution at the last follow-up whereas 6 patients in group 2 (17.1%) had permanent dysphagia (P < 0.05). Nine patients (25.7%) in group 2 presented with transient dysphagia with complete resolution at the last follow-up. The mean visual analog scale for odynophagia was significantly lower in group 1 compared with group 2 (P < 0.05).
   CONCLUSIONS: Postoperative dysphagia occurs frequently after ACDS. We show that the adoption of preventive measures during surgery can reduce the rate of dysphagia. Future evaluations in a large clinical trial are mandatory.
C1 [Grasso, Giovanni; Leone, Ludovica; Torregrossa, Fabio] Univ Palermo, Sch Med, Neurosurg Clin, Dept Biomed Neurosci & Adv Diagnost, Palermo, Italy.
RP Grasso, G (reprint author), Univ Palermo, Sch Med, Neurosurg Clin, Dept Biomed Neurosci & Adv Diagnost, Palermo, Italy.
EM giovanni.grasso@unipa.it
OI Torregrossa, Fabio/0000-0002-6835-8776
CR Arts MP, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-280
   Bazaz R, 2002, SPINE, V27, P2453, DOI 10.1097/00007632-200211150-00007
   Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x
   Edwards CC, 2004, J BONE JOINT SURG AM, V86A, P251, DOI 10.2106/00004623-200402000-00006
   Fountas Kostas N, 2005, Neurosurgery, V56, pE1166
   Grasso G, 2018, SPINE J, V18, P2164, DOI 10.1016/j.spinee.2018.06.351
   Grasso G, 2018, WORLD NEUROSURG, V116, P486, DOI 10.1016/j.wneu.2018.04.210
   Grasso G, 2018, J CRANIOVERTEBRAL JU, V9, P87, DOI 10.4103/jcvjs.JCVJS_36_18
   Grasso G, 2015, EUR SPINE J, V24, pS842, DOI 10.1007/s00586-015-4281-7
   Grasso G, 2014, EUR SPINE J, V23, pS650, DOI 10.1007/s00586-014-3553-y
   Heese O, 2006, EUR SPINE J, V15, P1833, DOI 10.1007/s00586-006-0069-0
   Kowalczyk I, 2015, J SPINAL DISORD TECH, V28, pE552, DOI 10.1097/BSD.0000000000000033
   Lee MJ, 2007, SPINE J, V7, P141, DOI 10.1016/j.spinee.2006.02.024
   Lee MJ, 2005, J SPINAL DISORD TECH, V18, P406, DOI 10.1097/01.bsd.0000177211.44960.71
   Lee SH, 2011, SPINE, V36, P2286, DOI 10.1097/BRS.0b013e318237e5d0
   Liu JH, 2010, ANESTH ANALG, V111, P1133, DOI 10.1213/ANE.0b013e3181f2ecc7
   Liu JW, 2018, EUR SPINE J, V27, P1209, DOI 10.1007/s00586-017-5311-4
   Mendoza-Lattes S, 2008, J BONE JOINT SURG AM, V90A, P256, DOI 10.2106/JBJS.G.00258
   Miao JH, 2013, J SPINAL DISORD TECH, V26, pE193, DOI 10.1097/BSD.0b013e31827a2812
   Olsson EC, 2015, ORTHOPEDICS, V38, pE319, DOI 10.3928/01477447-20150402-61
   Papavero L, 2007, SPINE, V32, P1089, DOI 10.1097/01.brs.0000261627.04944.cf
   Pattavilakom A, 2011, NEUROSURGERY, V69, P156, DOI 10.1227/NEU.0b013e318219565f
   Pedram M, 2003, EUR SPINE J, V12, P84, DOI 10.1007/s00586-002-0495-6
   Ratnaraj J, 2002, J NEUROSURG, V97, P176, DOI 10.3171/spi.2002.97.2.0176
   Rihn JA, 2011, CLIN ORTHOP RELAT R, V469, P658, DOI 10.1007/s11999-010-1731-8
   Shen Y, 2018, WORLD NEUROSURG, V115, pE226, DOI 10.1016/j.wneu.2018.04.019
   Sole ML, 2009, AM J CRIT CARE, V18, P133, DOI 10.4037/ajcc2009441
   Wu B, 2017, CLIN SPINE SURG, V30, pE554, DOI 10.1097/BSD.0000000000000180
   Yonenobu K, 2001, SPINE, V26, P1890, DOI 10.1097/00007632-200109010-00014
   Zaveri GR, 2001, J SPINAL DISORD, V14, P10, DOI 10.1097/00002517-200102000-00003
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1176
EP E1182
DI 10.1016/j.wneu.2019.01.273
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700146
PM 30794969
DA 2020-05-12
ER

PT J
AU Guduk, M
   Ozduman, K
   Pamir, MN
AF Guduk, Mustafa
   Ozduman, Koray
   Pamir, Mustafa Necmettin
TI Sphenoid Wing Meningiomas: Surgical Outcomes in a Series of 141 Cases
   and Proposal of a Scoring System Predicting Extent of Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Meningiomas; Skull base tumors; Sphenoid ridge meningiomas; Sphenoid
   wing meningiomas
ID CAVERNOUS SINUS; EN-PLAQUE; ORBITAL MENINGIOMAS; INTRACRANIAL
   MENINGIOMAS; MICROSURGICAL TREATMENT; MANAGEMENT; RECURRENCE;
   STRATEGIES; INVASION; SURGERY
AB OBJECTIVE: Sphenoid wing meningiomas are the third most common group of intracranial meningiomas. Their management is a challenge because of their bone invasion potential and their proximity to neurovascular structures and the cavernous sinus.
   METHODS: A cohort of 141 patients with sphenoid wing meningioma who were operated on and followed up between 1986 and 2018 were retrospectively analyzed. Demographic data, clinical and radiologic features, surgical results, and follow-up data are presented. The effects of adjuvant treatments (radiosurgery, radiotherapy, and chemotherapy) are reviewed. The invasion pattern of tumors and other factors were noted to analyze the extent of resection. Recurrence/regrowth rates were also analyzed.
   RESULTS: There were 96 female and 45 male patients with a median age of 51 years (range, 17-87 years). The median follow-up was 62 months (range, 1-303 months). Tumors were grouped as spheno-orbital (31 patients), lateral (34 patients), middle (35 patients), and medial (41 patients). Gross total resection was achieved in 98 patients, and 43 tumors were resected subtotally. One hundred and twenty of these cases had World Health Organization grade I pathology, whereas the remainder had grade II. In the follow-up, there were 14 recurrences of totally resected tumors, and 24 regrowths were observed in the subtotally resected group. No invasion pattern was strongly predictive of extent of resection alone, and a scoring system was built up and proposed.
   CONCLUSIONS: Sphenoid wing meningioma is a large group with characteristics associated with skull base meningiomas and convexity meningiomas. The results of surgery and other adjuvant treatments are heterogeneous.
C1 [Guduk, Mustafa; Ozduman, Koray; Pamir, Mustafa Necmettin] Acibadem Mehmet Ali Aydinlar Univ, Dept Neurosurg, Sch Med, Istanbul, Turkey.
RP Guduk, M (reprint author), Acibadem Mehmet Ali Aydinlar Univ, Dept Neurosurg, Sch Med, Istanbul, Turkey.
EM mustafaguduk@gmail.com
RI Ozduman, Koray/D-7007-2015
OI Ozduman, Koray/0000-0002-3543-0401
CR Abdel-Aziz KM, 2004, NEUROSURGERY, V54, P1383
   ALMEFTY O, 1990, J NEUROSURG, V73, P840, DOI 10.3171/jns.1990.73.6.0840
   Amirjamshidi Abbas, 2015, Surg Neurol Int, V6, P79, DOI 10.4103/2152-7806.157074
   Aziz KMA, 2004, NEUROSURGERY, V54, P1375, DOI 10.1227/01.NEU.0000125542.00834.6D
   BASSO A, 1978, NEUROCHIRURGIE, V24, P71
   Behari S, 2008, ACTA NEUROCHIR, V150, P865, DOI 10.1007/s00701-008-0006-6
   Bikmaz K, 2007, J NEUROSURG, V107, P905, DOI 10.3171/JNS-07/11/0905
   Bloss HG, 2010, ACTA NEUROCHIR, V152, P99, DOI 10.1007/s00701-009-0556-2
   BONNAL J, 1980, J NEUROSURG, V53, P587, DOI 10.3171/jns.1980.53.5.0587
   CASTELLANO F, 1952, J NEUROSURG, V9, P188, DOI 10.3171/jns.1952.9.2.0188
   Cushing H, 1938, MENINGIOMAS THEIR CL
   De Jesus O, 2001, SURG NEUROL, V55, P265, DOI 10.1016/S0090-3019(01)00440-2
   DEMONTE F, 1994, J NEUROSURG, V81, P245, DOI 10.3171/jns.1994.81.2.0245
   Floyd JR, 2012, SAUNDERS, P444, DOI DOI 10.1016/B978-1-4160-6839-6.10037-1
   Fohanno D, 1986, Adv Tech Stand Neurosurg, V14, P137
   Freeman JL, 2017, WORLD NEUROSURG, V99, P369, DOI 10.1016/j.wneu.2016.12.063
   Goel A, 2000, NEUROL MED-CHIR, V40, P610, DOI 10.2176/nmc.40.610
   Gonen L, 2018, NEUROSURG REV, V41, P291, DOI 10.1007/s10143-017-0855-7
   Guinto G., 2012, SCHMIDEK SWEET OPERA, P435
   HIRSCH WL, 1993, AM J ROENTGENOL, V160, P1083, DOI 10.2214/ajr.160.5.8470581
   HIRSCH WL, 1988, AM J ROENTGENOL, V151, P1015, DOI 10.2214/ajr.151.5.1015
   Honeybul S, 2001, ACTA NEUROCHIR, V143, P749, DOI 10.1007/s007010170028
   Honig S, 2010, CENT EUR NEUROSURG, V71, P189, DOI 10.1055/s-0030-1261945
   Honig S, 2010, NEUROL RES, V32, P314, DOI 10.1179/016164109X12464612122614
   Huang AP, 2011, AL MEFTYS MENINGIOMA, P413
   Kattner KA, 2001, SKULL BASE-INTERD AP, V11, P99, DOI 10.1055/s-2001-14430
   KLEINPETER G, 1990, ACTA NEUROCHIR, V103, P87, DOI 10.1007/BF01407511
   Lee JH, 2001, NEUROSURGERY, V48, P1012, DOI 10.1097/00006123-200105000-00009
   Li Y, 2009, CHINESE MED J-PEKING, V122, P2423, DOI 10.3760/cma.j.issn.0366-6999.2009.20.005
   Mariniello G, 2013, CLIN NEUROL NEUROSUR, V115, P1615, DOI 10.1016/j.clineuro.2013.02.012
   McCracken DJ, 2017, NEUROSURGERY, V80, P957, DOI 10.1093/neuros/nyw134
   MIRIMANOFF RO, 1985, J NEUROSURG, V62, P18, DOI 10.3171/jns.1985.62.1.0018
   Mirone G, 2009, NEUROSURGERY, V65, P100, DOI 10.1227/01.NEU.0000345652.19200.D5
   Nakamura M, 2006, NEUROSURGERY, V58, P626, DOI 10.1227/01.NEU.0000197104.78684.5D
   Ouyang TH, 2015, CLIN NEUROL NEUROSUR, V134, P85, DOI 10.1016/j.clineuro.2015.04.016
   Oya S, 2011, J NEUROSURG, V114, P1241, DOI 10.3171/2010.10.JNS101128
   Pamir MN, 2005, SURG NEUROL, V64, P58, DOI 10.1016/j.surneu.2005.07.053
   PAMIR MN, 2010, MENINGIOMAS, P399
   Ringel F, 2007, NEUROSURGERY, V60, P214, DOI 10.1227/01.NEU.0000255415.4793/.IA
   RISI P, 1994, BRIT J NEUROSURG, V8, P295, DOI 10.3109/02688699409029617
   Roser F, 2005, SURG NEUROL, V64, P37, DOI 10.1016/j.surneu.2004.08.092
   Russell SM, 2008, NEUROSURGERY, V63, P38, DOI [10.1227/01.neu.0000317372.92393.e8, 10.1227/01.NEU.0000297019.60125.71]
   Saeed P, 2011, BRIT J OPHTHALMOL, V95, P996, DOI 10.1136/bjo.2010.189050
   Saeed P, 2011, ACTA NEUROCHIR, V153, P395, DOI 10.1007/s00701-010-0878-0
   Sandalcioglu IE, 2005, J CRANIO MAXILL SURG, V33, P260, DOI 10.1016/j.jcms.2005.01.013
   Schick U, 2006, J NEUROSURG, V104, P208, DOI 10.3171/jns.2006.104.2.208
   Shrivastava RK, 2005, J NEUROSURG, V103, P491, DOI 10.3171/jns.2005.103.3.0491
   Simon M, 2010, MENINGIOMAS, P427
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Sindou MP, 1998, NEUROSURGERY, V42, P476, DOI 10.1097/00006123-199803000-00007
   Sughrue ME, 2013, J NEUROSURG, V119, P86, DOI 10.3171/2012.12.JNS11539
   Terrier LM, 2018, WORLD NEUROSURG, V112, pE145, DOI 10.1016/j.wneu.2017.12.182
   Yasargil MG, 1996, MICRONEUROSURGERY B, VIV-B, P134
   2001, NEUROSURGERY, V48, P1012
   2007, NEUROSURGERY S2, V60, P214, DOI DOI 10.1227/01.NEU.0000255415.4793/.IA
   NEUROL MED CHIR, V40, P610
NR 56
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E48
EP E59
DI 10.1016/j.wneu.2018.12.175
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700009
PM 30639480
DA 2020-05-12
ER

PT J
AU Guha, D
   Jakubovic, R
   Alotaibi, NM
   Klostranec, JM
   Saini, S
   Deorajh, R
   Gupta, S
   Fehlings, MG
   Mainprize, TG
   Yee, A
   Yang, VXD
AF Guha, Daipayan
   Jakubovic, Raphael
   Alotaibi, Naif M.
   Klostranec, Jesse M.
   Saini, Sidharth
   Deorajh, Ryan
   Gupta, Shaurya
   Fehlings, Michael G.
   Mainprize, Todd G.
   Yee, Albert
   Yang, Victor X. D.
TI Optical Topographic Imaging for Spinal Intraoperative Three-Dimensional
   Navigation in Mini-Open Approaches: A Prospective Cohort Study of
   Initial Preclinical and Clinical Feasibility
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computer-assisted surgery; Image guidance; Minimally invasive surgery;
   Navigation
ID PEDICLE SCREW PLACEMENT; POSTERIOR SCOLIOSIS SURGERY; LUMBAR FUSION;
   ACCURACY; PERFORATION; INSTRUMENTATION; METAANALYSIS; INSERTION;
   OUTCOMES; SYSTEM
AB OBJECTIVE: Computer-assisted three-dimensional navigation often guides spinal instrumentation. Optical topographic imaging (OTI) offers comparable accuracy and significantly faster registration relative to current navigation systems in open posterior thoracolumbar exposures. We validate the usefulness and accuracy of OTI in minimally invasive spinal approaches.
   METHODS: Mini-open midline posterior exposures were performed in 4 human cadavers. Square exposures of 25, 30, 35, and 40 mm were registered to preoperative computed tomography imaging. Screw tracts were fashioned using a tracked awl and probe with instrumentation placed. Navigation data were compared with screw positions on postoperative computed tomography imaging, and absolute translational and angular deviations were computed.
   In vivo validation was performed in 8 patients, with mini-open thoracolumbar exposures and percutaneous placement of navigated instrumentation. Navigated instrumentation was performed in the previously described manner.
   RESULTS: For 37 cadaveric screws, absolute translational errors were (1.79 +/- 1.43 mm) and (1.81 +/- 1.51 mm) in the axial and sagittal planes, respectively. Absolute angular deviations were (3.81 +/- 2.91 degrees) and (3.45 +/- 2.82 degrees), respectively (mean +/- standard deviation). The number of surface points registered by the navigation system, but not exposure size, correlated positively with the likelihood of successful registration (odds ratio, 1.02; 95% confidence interval, 1.009-1.024; P < 0.001).
   Fifty-five in vivo thoracolumbar pedicle screws were analyzed. Overall (mean +/- standard deviation) axial and sagittal translational errors were (1.79 +/- 1.41 mm) and (2.68 +/- 2.26 mm), respectively. Axial and sagittal angular errors were (3.63 degrees +/- 2.92 degrees) and (4.65 degrees +/- 3.36 degrees), respectively. There were no radiographic breaches >2 mm or any neurovascular complications.
   CONCLUSIONS: OTI is a novel navigation technique previously validated for open posterior exposures and in this study has comparable accuracy for mini-open minimally invasive surgery exposures. The likelihood of successful registration is affected more by the geometry of the exposure than by its size.
C1 [Guha, Daipayan; Alotaibi, Naif M.; Fehlings, Michael G.; Mainprize, Todd G.; Yang, Victor X. D.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.
   [Guha, Daipayan; Alotaibi, Naif M.; Fehlings, Michael G.; Yang, Victor X. D.] Univ Toronto, Sch Grad Studies, Inst Med Sci, Toronto, ON, Canada.
   [Guha, Daipayan; Jakubovic, Raphael; Deorajh, Ryan; Gupta, Shaurya; Yang, Victor X. D.] Sunnybrook Hlth Sci Ctr, Biophoton & Bioengn Lab, Toronto, ON, Canada.
   [Jakubovic, Raphael] Ryerson Univ, Dept Biomed Phys, Toronto, ON, Canada.
   [Klostranec, Jesse M.; Saini, Sidharth] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada.
   [Gupta, Shaurya] Univ Toronto, Fac Appl Sci & Engn, Toronto, ON, Canada.
   [Yee, Albert] Univ Toronto, Dept Surg, Div Orthoped Surg, Toronto, ON, Canada.
   [Yang, Victor X. D.] Ryerson Univ, Dept Elect & Comp Engn, Toronto, ON, Canada.
RP Guha, D (reprint author), Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.; Guha, D (reprint author), Univ Toronto, Sch Grad Studies, Inst Med Sci, Toronto, ON, Canada.; Guha, D (reprint author), Sunnybrook Hlth Sci Ctr, Biophoton & Bioengn Lab, Toronto, ON, Canada.
EM deep.guha@mail.utoronto.ca
OI Alotaibi, Naif/0000-0002-8227-347X
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada;
   Canada Foundation for Innovation (CFI)Canada Foundation for Innovation;
   Canadian Institutes of Health Research (CIHR) postdoctoral
   fellowshipCanadian Institutes of Health Research (CIHR) [FRN 142931]
FX This research is supported by the Natural Sciences and Engineering
   Research Council of Canada (NSERC) and the Canada Foundation for
   Innovation (CFI). Salary support for D.G. was provided in part by a
   Canadian Institutes of Health Research (CIHR) postdoctoral fellowship
   (FRN 142931).
CR Al-Khouja Lutfi, 2015, Surg Neurol Int, V6, pS323, DOI 10.4103/2152-7806.159381
   Amiot LP, 2000, SPINE, V25, P606, DOI 10.1097/00007632-200003010-00012
   Banczerowski P, 2015, NEUROSURG REV, V38, P11, DOI 10.1007/s10143-014-0565-3
   Bandiera S, 2013, EUR SPINE J, V22, pS919, DOI 10.1007/s00586-013-3032-x
   Barsa P, 2016, EUR SPINE J, V25, P1643, DOI 10.1007/s00586-016-4476-6
   Bourgeois AC, 2015, J SPINAL DISORD TECH, V28, P324, DOI 10.1097/BSD.0000000000000152
   Bydon M, 2014, CLIN NEUROL NEUROSUR, V125, P24, DOI 10.1016/j.clineuro.2014.07.017
   Castro WHM, 1996, SPINE, V21, P1320, DOI 10.1097/00007632-199606010-00008
   Choo Alexander D, 2008, SAS J, V2, P189, DOI 10.1016/SASJ-2008-0007-RR
   Costa F, 2016, J NEUROSURG-SPINE, V25, P654, DOI 10.3171/2016.3.SPINE151139
   Dea N, 2016, SPINE J, V16, P23, DOI 10.1016/j.spinee.2015.09.062
   Goldstein CL, 2016, J NEUROSURG-SPINE, V24, P416, DOI 10.3171/2015.2.SPINE14973
   Guha D, 2019, GLOB SPINE J, V9, P512, DOI 10.1177/2192568218804556
   Guha D, 2017, SPINE J, V17, P489, DOI 10.1016/j.spinee.2016.10.020
   Hartl R, 2013, WORLD NEUROSURG, V79, P162, DOI 10.1016/j.wneu.2012.03.011
   Heary RF, 2004, J NEUROSURG, V100, P325, DOI 10.3171/spi.2004.100.4.0325
   Hecht N, 2010, J NEUROSURG-SPINE, V36, pE1, DOI [10.3171/SPI.2008.9.11.450, DOI 10.3171/SPI.2008.9.11.450]
   Hecht N, 2016, EUR SPINE J, V25, P716, DOI 10.1007/s00586-015-3814-4
   Hu W, 2016, INT ORTHOP, V40, P1883, DOI 10.1007/s00264-016-3153-z
   Jakubovic R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32424-z
   Kotani Y, 2007, SPINE, V32, P1543, DOI 10.1097/BRS.0b013e318068661e
   Mason A, 2014, J NEUROSURG-SPINE, V20, P196, DOI 10.3171/2013.11.SPINE13413
   Mathew JE, 2013, INT J SPINE SURG, V7, DOI 10.1016/j.ijsp.2013.06.002
   McAnany SJ, 2015, GLOB SPINE J, V5, P148, DOI 10.1055/s-0035-1544176
   Nottmeier EW, 2009, J NEUROSURG-SPINE, V10, P33, DOI 10.3171/2008.10.SPI08383
   Papadopoulos Elias C, 2005, Spine J, V5, P263, DOI 10.1016/j.spinee.2004.10.048
   Phan K, 2016, SPINE, V41, pE91, DOI 10.1097/BRS.0000000000001161
   Phan K, 2015, ORTHOP SURG, V7, P213, DOI 10.1111/os.12185
   Rivkin MA, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13499
   Ryang YM, 2015, SPINE J, V15, P467, DOI 10.1016/j.spinee.2014.10.003
   Sakai Y, 2008, J SPINAL DISORD TECH, V21, P181, DOI 10.1097/BSD.0b013e318074d388
   Scheufler KM, 2011, NEUROSURGERY, V69, P1307, DOI 10.1227/NEU.0b013e31822ba190
   Shimizu M, 2014, EUR SPINE J, V23, P2211, DOI 10.1007/s00586-014-3512-7
   Shin BJ, 2012, J NEUROSURG-SPINE, V17, P113, DOI 10.3171/2012.5.SPINE11399
   Smith ZA, 2012, NAT REV NEUROL, V8, P443, DOI 10.1038/nrneurol.2012.110
   Tian NF, 2011, EUR SPINE J, V20, P846, DOI 10.1007/s00586-010-1577-5
   Wang YS, 2013, ARCH ORTHOP TRAUM SU, V133, P901, DOI 10.1007/s00402-013-1752-3
   Wong AP, 2014, NEUROSURG CLIN N AM, V25, P279, DOI 10.1016/j.nec.2013.12.007
   Wood MJ, 2014, INT J SPINE SURG, V8, DOI 10.14444/1027
   Wray S, 2015, J NEUROSURG-SPINE, V22, P503, DOI 10.3171/2014.10.SPINE14205
   Zhang W, 2017, EUR SPINE J, V26, P1756, DOI 10.1007/s00586-016-4930-5
NR 41
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E863
EP E872
DI 10.1016/j.wneu.2019.01.201
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700107
PM 30743024
DA 2020-05-12
ER

PT J
AU Ha, KY
   Kim, YH
   Oh, IS
   Seo, JY
   Chang, DG
   Park, HY
   Min, HK
   Kim, SI
AF Ha, Kee-Yong
   Kim, Young-Hoon
   Oh, In-Soo
   Seo, Jun-Yeong
   Chang, Dong-Gune
   Park, Hyung-Youl
   Min, Hyung-Ki
   Kim, Sang-Il
TI Clinical and Radiographic Features of Subtypes of Acute Proximal
   Junctional Failures Following Correction Surgery for Degenerative
   Sagittal Imbalance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute proximal junctional failure; Correction surgery; Degenerative;
   Risk factor; Sagittal imbalance; Subtype
ID SPINAL DEFORMITY SURGERY; PEDICLE SCREW CONSTRUCTS; SURGICAL-TREATMENT;
   RISK-FACTORS; KYPHOSIS; OUTCOMES; FUSION; INSTRUMENTATION; SACRUM
AB OBJECTIVE: To identify clinical and radiographic features of subtypes of acute proximal junctional failures (PJFs) following correction surgery for degenerative sagittal imbalance.
   METHODS: The study included 157 patients with mean age 68.0 +/- 6.3 years who underwent correction surgery for degenerative sagittal imbalance. Acute PJFs were categorized into 4 subtypes: fracture at uppermost instrumented vertebra (UIV), fracture at vertebra just proximal to UIV (UIV+1), fixation failure at UIV, and junctional subluxation. Demographic, clinical, and radiographic data were analyzed retrospectively.
   RESULTS: There were 18 patients with acute PJFs. PJF group had significantly lower T-score (-3.3 +/- 1.1 vs. -1.9 +/- 1.5) on bone densitometry and lower body mass index (BMI) (23.0 +/- 3.9 kg/m(2) vs. 25.6 +/- 3.7 kg/m(2)) than non-PJF group. Radiographic parameters exhibited no significant differences. UIV fracture, UIV+1 fracture, UIV fixation failure, and junctional subluxation were observed in 5, 6, 4, and 3 patients. Fixation failure developed the earliest (median 1.3 months), followed by UIV fracture (1.5 months). UIV fracture occurred earlier than UIV+1 fracture (36 months). Patients with UIV or UIV+1 fracture had significantly lower T-scores than others. Although BMI and T-score were significant risk factors for all PJFs (P = 0.043 and P = 0.021, respectively), different risk factors for each subtype of PJFs were identified on separate risk factor analysis.
   CONCLUSIONS: Patients with acute PJFs had lower T-score and BMI. Each subtype of PJFs had different clinical and radiographic features. Although BMI and T-score were associated with all PJFs, each subtype may have different risk factors. Identifying risk factors for each subtype of acute PJFs may help avoid it.
C1 [Ha, Kee-Yong; Kim, Young-Hoon; Park, Hyung-Youl; Min, Hyung-Ki; Kim, Sang-Il] Catholic Univ Korea, Coll Med, Dept Orthopaed Surg, Seoul St Marys Hosp, Seoul, South Korea.
   [Oh, In-Soo] Catholic Univ Korea, Coll Med, Dept Orthopaed Surg, Incheon St Marys Hosp, Seoul, South Korea.
   [Seo, Jun-Yeong] Jeju Natl Univ, Jeju Natl Univ Hosp, Dept Orthopaed Surg, Coll Med, Jeju, South Korea.
   [Chang, Dong-Gune] Inje Univ, Sanggye Paik Hosp, Dept Orthopaed Surg, Coll Med, Seoul, South Korea.
RP Kim, SI (reprint author), Catholic Univ Korea, Coll Med, Dept Orthopaed Surg, Seoul St Marys Hosp, Seoul, South Korea.
EM sang1kim81@gmail.com
OI Kim, Young-Hoon/0000-0003-1237-4600; Park,
   Hyung-Youl/0000-0002-0084-8867
CR Ailon T, 2015, NEUROSURGERY, V77, pS75, DOI 10.1227/NEU.0000000000000938
   Fradet L, 2016, CLIN BIOMECH, V39, P122, DOI 10.1016/j.clinbiomech.2016.10.008
   Glassman SD, 2005, SPINE, V30, P682, DOI 10.1097/01.brs.0000155425.04536.f7
   Glattes RC, 2005, SPINE, V30, P1643, DOI 10.1097/01.brs.0000169451.76359.49
   Ha Y, 2013, J NEUROSURG-SPINE, V19, P360, DOI 10.3171/2013.5.SPINE12737
   Hart RA, 2013, NEUROSURG CLIN N AM, V24, P213, DOI 10.1016/j.nec.2013.01.001
   Hostin R, 2013, SPINE, V38, P1008, DOI 10.1097/BRS.0b013e318271319c
   Kim HJ, 2016, J AM ACAD ORTHOP SUR, V24, P318, DOI 10.5435/JAAOS-D-14-00393
   Kim HJ, 2014, SPINE, V39, pE576, DOI 10.1097/BRS.0000000000000246
   Kim YJ, 2006, SPINE, V31, P2359, DOI 10.1097/01.brs.0000238969.59928.73
   Lee J, 2016, ASIAN SPINE J, V10, P593, DOI 10.4184/asj.2016.10.3.593
   Lee JH, 2014, BRIT J NEUROSURG, V28, P252, DOI 10.3109/02688697.2013.835369
   Lewis SJ, 2012, SPINE, V37, P1407, DOI 10.1097/BRS.0b013e31824fffb9
   Mac-Thiong JM, 2016, BIOMED RES INT, DOI 10.1155/2016/8058796
   Maruo K, 2013, SPINE, V38, pE1469, DOI 10.1097/BRS.0b013e3182a51d43
   O'Leary PT, 2009, SPINE, V34, P2134, DOI 10.1097/BRS.0b013e3181b2e17e
   Smith MW, 2015, SPINE J, V15, P2142, DOI 10.1016/j.spinee.2015.05.028
   Watanabe K, 2010, SPINE, V35, P138, DOI 10.1097/BRS.0b013e3181c8f35d
   Yagi M, 2016, OSTEOPOROSIS INT, V27, P3495, DOI 10.1007/s00198-016-3676-6
   Yagi M, 2014, SPINE, V39, pE607, DOI 10.1097/BRS.0000000000000266
   2017, NEUROSURGERY, V80, P279, DOI DOI 10.1227/NEU.0000000000001240
NR 21
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E304
EP E312
DI 10.1016/j.wneu.2019.01.069
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700039
PM 30685377
DA 2020-05-12
ER

PT J
AU Helmi, A
   Chan, A
   Towfighi, S
   Kapadia, A
   Perry, J
   Ironside, S
   Machnowska, M
   Symons, SP
   Fox, AJ
   Sahgal, A
   Maralani, PJ
AF Helmi, Ali
   Chan, Aimee
   Towfighi, Sohrab
   Kapadia, Anish
   Perry, James
   Ironside, Sarah
   Machnowska, Matylda
   Symons, Sean P.
   Fox, Allan J.
   Sahgal, Arjun
   Maralani, Pejman Jabehdar
TI Incidence of Dural Venous Sinus Thrombosis in Patients with Glioblastoma
   and Its Implications
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural venous sinus thrombosis; Glioblastoma; Magnetic resonance imaging;
   VASARI
ID MALIGNANT GLIOMA; CEREBRAL VEIN; THROMBOEMBOLISM; GRADE; CANCER; RISK;
   SURVIVAL; EPIDEMIOLOGY; COAGULATION; EXPRESSION
AB OBJECTIVE: Glioblastoma (GBM) is associated with increased risk of developing dural venous sinus thrombosis (DVST), which often goes undiagnosed as symptoms are readily attributed to tumor. The purpose of this study was to investigate the incidence of DVST, potential predictive features on imaging, complications, its effect on survival, and time of greatest risk for developing DVST.
   METHODS: A retrospective search of patients with GBM who had surgery followed by chemotherapy and/or radiation therapy between 2009 and 2015 at our institution was performed. Magnetic resonance imaging studies of the brain were reviewed on volumetric postgadolinium T1-weighted sequences for DVST. Tumors were characterized using the Visually Accessible REMBRANDT (Repository for Molecular Brain Neoplasia Data) Images classification, and identified thromboses were tracked for propagation, regression, or resolution. Statistical analyses were directed at identifying clinical predictors and survival differences between the DVST and no-DVST groups.
   RESULTS: In total, 163 cases totaling 1637 scans, were reviewed; 12 patients (7.4%) developed DVST, of whom 11 presented with thrombus before any treatment. Tumor invasion of dural sinuses and greater T1/fluid-attenuated inversion recovery ratios were significantly associated with thrombus development (P = 0.02 and P = 0.02, respectively). In patients who developed DVST, thrombosis was more likely to develop ipsilateral to tumor side (P = 0.01) and was associated with a greater likelihood of developing extracranial venous thromboembolism (P = 0.012). There were no venous infarcts and no significant difference in survival between groups (P = 0.83).
   CONCLUSIONS: Patients with GBM have increased risk of developing DVST, independent of surgical treatment or chemoradiation. DVST presence does not affect survival. Tumor invasion of dural sinuses and greater T1/fluid-attenuated inversion recovery ratio on preoperative imaging were the most significant predictors of DVST development.
C1 [Helmi, Ali; Towfighi, Sohrab; Maralani, Pejman Jabehdar] Univ Toronto, Fac Med, Toronto, ON, Canada.
   [Chan, Aimee; Kapadia, Anish; Machnowska, Matylda; Symons, Sean P.; Fox, Allan J.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada.
   [Perry, James; Ironside, Sarah] Univ Toronto, Dept Neurol, Toronto, ON, Canada.
   [Sahgal, Arjun] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada.
RP Maralani, PJ (reprint author), Univ Toronto, Fac Med, Toronto, ON, Canada.
EM pejman.maralani@sunnybrook.ca
OI Towfighi, Sohrab/0000-0002-3050-8943
CR Agnelli Giancarlo, 2008, Front Neurol Neurosci, V23, P16
   Bauersachs RM, 2012, BEST PRACT RES CL HA, V25, P243, DOI 10.1016/j.beha.2012.07.004
   Bleeker FE, 2012, J NEURO-ONCOL, V108, P11, DOI 10.1007/s11060-011-0793-0
   Brandes AA, 1997, EUR J CANCER, V33, P1592, DOI 10.1016/S0959-8049(97)00167-6
   CHERUKU R, 1991, CANCER, V68, P2621, DOI 10.1002/1097-0142(19911215)68:12<2621::AID-CNCR2820681218>3.0.CO;2-7
   Deitcher SR, 2003, J THROMB THROMBOLYS, V16, P21, DOI 10.1023/B:THRO.0000014589.17314.24
   DHAMI MS, 1993, THROMB HAEMOSTASIS, V70, P393
   Ferro JM, 2004, STROKE, V35, P664, DOI 10.1161/01.STR.0000117571.76197.26
   Ferro JM, 2001, CEREBROVASC DIS, V11, P177, DOI 10.1159/000047635
   Gutman DA, 2013, RADIOLOGY, V267, P560, DOI 10.1148/radiol.13120118
   Hamada K, 1996, CANCER, V77, P1877, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X
   Hanse MCJ, 2006, J NEURO-ONCOL, V78, P197, DOI 10.1007/s11060-005-9088-7
   KAYSERGATCHALIAN MC, 1975, J NEUROL, V209, P217, DOI 10.1007/BF00312543
   Knovich Mary Ann, 2004, Curr Treat Options Oncol, V5, P511, DOI 10.1007/s11864-004-0039-x
   Maralani PJ, 2012, CLIN RADIOL, V67, P656, DOI 10.1016/j.crad.2011.12.002
   Marras LC, 2000, CANCER, V89, P640, DOI 10.1002/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E
   Mazurowski MA, 2013, NEURO-ONCOLOGY, V15, P1389, DOI 10.1093/neuonc/nos335
   Morgan ER, 2016, EXPERT REV NEUROTHER, V16, P803, DOI 10.1080/14737175.2016.1181542
   Peeken JC, 2018, STRAHLENTHER ONKOL, V194, P580, DOI 10.1007/s00066-018-1276-4
   Perry JR, 2012, NEURO-ONCOLOGY, V14, P73, DOI 10.1093/neuonc/nos197
   Prandoni P, 2005, LANCET ONCOL, V6, P401, DOI 10.1016/S1470-2045(05)70207-2
   Prandoni P, 1999, HAEMATOLOGICA, V84, P437
   QUEVEDO JF, 1994, MAYO CLIN PROC, V69, P329, DOI 10.1016/S0025-6196(12)62216-2
   Rao A, 2016, J NEUROSURG, V124, P1008, DOI 10.3171/2015.4.JNS142732
   Raper DMS, 2017, WORLD NEUROSURG, V98, P555, DOI 10.1016/j.wneu.2016.11.084
   Rong Y, 2005, CANCER RES, V65, P1406, DOI 10.1158/0008-5472.CAN-04-3376
   RUFF RL, 1983, ANN NEUROL, V13, P334, DOI 10.1002/ana.410130320
   Saadatnia M, 2009, INT J STROKE, V4, P111, DOI 10.1111/j.1747-4949.2009.00260.x
   Saposnik G, 2011, STROKE, V42, P1158, DOI 10.1161/STR.0b013e31820a8364
   Sari S, 2015, CLIN NEUROL NEUROSUR, V134, P44, DOI 10.1016/j.clineuro.2015.04.013
   Semrad TJ, 2007, J NEUROSURG, V106, P601, DOI 10.3171/jns.2007.106.4.601
   Silvani A, 2011, NEUROL SCI, V32, pS229, DOI 10.1007/s10072-011-0793-z
   Simanek R, 2007, NEURO-ONCOLOGY, V9, P89, DOI 10.1215/15228517-2006-035
   Stam J, 2005, NEW ENGL J MED, V352, P1791, DOI 10.1056/NEJMra042354
   Streiff MB, 2015, J NEURO-ONCOL, V124, P299, DOI 10.1007/s11060-015-1840-z
   Stricker H, 2014, VASA, V43, P239, DOI 10.1024/0301-1526/a000358
   Vargo JA, 2011, J NEURO-ONCOL, V104, P595, DOI 10.1007/s11060-010-0519-8
   WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X
   Wen PY, 2006, J NEURO-ONCOL, V80, P313, DOI 10.1007/s11060-006-9193-2
   White RH, 2003, THROMB HAEMOSTASIS, V90, P446, DOI 10.1160/TH03-03-0152
   Wun T, 2009, BEST PRACT RES CL HA, V22, P9, DOI 10.1016/j.beha.2008.12.001
   Yuh WTC, 2000, J MAGN RESON IMAGING, V12, P808, DOI 10.1002/1522-2586(200012)12:6<808::AID-JMRI3>3.0.CO;2-N
   Yust-Katz S, 2015, J NEURO-ONCOL, V124, P87, DOI 10.1007/s11060-015-1805-2
   Zagardo MT, 1996, AM J NEURORADIOL, V17, P1953
   Zuurbier SM, 2017, ADV EXP MED BIOL, V906, P183, DOI 10.1007/5584_2016_115
NR 45
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E189
EP E197
DI 10.1016/j.wneu.2019.01.039
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700025
PM 30684707
DA 2020-05-12
ER

PT J
AU Henker, C
   Kriesen, T
   Schneider, B
   Glass, A
   Scherer, M
   Langner, S
   Erbersdobler, A
   Piek, J
AF Henker, Christian
   Kriesen, Thomas
   Schneider, Bjoern
   Glass, Aenne
   Scherer, Moritz
   Langner, Soenke
   Erbersdobler, Andreas
   Piek, Juergen
TI Correlation of Ki-67 Index with Volumetric Segmentation and its Value as
   a Prognostic Marker in Glioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioblastoma; Ki-67; Magnetic resonance imaging; Neuroimaging;
   Prognosis; Prognostic marker; Segmentation
ID LABELING INDEX; PRIMARY BRAIN; MULTIFORME; TEMOZOLOMIDE; CONCOMITANT;
   EXPRESSION; GROWTH; IMPACT
AB OBJECTIVE: Previous research has shown a strong correlation between the Ki-67 proliferation index and grade of malignancy in astrocytoma. Ki-67 has also shown encouraging results as a prognostic marker for patients' overall survival (OS). We focus on whether the index is linked to the appearance of glioblastoma on pretreatment magnetic resonance imaging (MRI) or to OS.
   METHODS: In our retrospective study, only isocitrate dehydrogenase IDH wild-type glioblastoma was included (n = 152). Ki-67 index was quantified via immunohistochemistry. On all pretreatment MRI, tumor compartments (tumor, necrosis, and edema) were volumetrically assessed. An OS subpopulation was filtered from the total cohort (residual tumor volume <= 2 cm(3)). In addition, a propensity score matching was executed.
   RESULTS: All volumetric assessed tumor volumes correlated with each other (P <= 0.011), although the Ki-67 index showed no correlation with any of the measured volumes. Concerning the OS, a cutoff value of 20% for the Ki-67 index showed a significant influence on patients' OS in multivariate analysis (P = 0.043).
   CONCLUSIONS: The unique appearance of every glioblastoma on MRI seems to be independent of the Ki-67 index. Furthermore, the Ki-67 index did show a distinct prognostic value for OS within our cohort at a cutoff value of 20% for Ki-67.
C1 [Henker, Christian; Kriesen, Thomas; Piek, Juergen] Univ Med Rostock, Dept Neurosurg, Rostock, Germany.
   [Schneider, Bjoern; Erbersdobler, Andreas] Univ Med Rostock, Inst Pathol, Rostock, Germany.
   [Glass, Aenne] Univ Med Rostock, Inst Biostat & Informat Med, Rostock, Germany.
   [Langner, Soenke] Univ Med Rostock, Inst Diagnost & Intervent Radiol, Rostock, Germany.
   [Scherer, Moritz] Univ Med Rostock, Dept Neurosurg, Rostock, Germany.
RP Henker, C (reprint author), Univ Med Rostock, Dept Neurosurg, Rostock, Germany.
EM christian.henker@med.uni-rostock.de
OI Henker, Christian/0000-0002-7591-3192
CR Bauchet L, 2010, NEURO-ONCOLOGY, V12, P725, DOI 10.1093/neuonc/noq030
   Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073
   CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5
   Chen Wen-Jie, 2015, Asian Pac J Cancer Prev, V16, P411
   Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005
   Criniere E, 2007, J NEURO-ONCOL, V83, P173, DOI 10.1007/s11060-006-9320-0
   DALRYMPLE SJ, 1994, NEUROSURGERY, V35, P1036, DOI 10.1227/00006123-199412000-00004
   Donato V, 2007, TUMORI, V93, P248
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Eidel O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169292
   GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Henker C, 2017, J NEURO-ONCOL, V135, P391, DOI 10.1007/s11060-017-2587-5
   Hui XH, 2013, ONCOL LETT, V6, P130, DOI 10.3892/ol.2013.1317
   Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8
   Jakovlevs A, 2014, ACTA CHIRURG LATVIEN, V14, P11, DOI DOI 10.2478/CHILAT-2014-0102
   Johannessen AL, 2006, PATHOL ONCOL RES, V12, P143, DOI 10.1007/BF02893360
   KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158
   Reavey-Cantwell JF, 2001, J NEURO-ONCOL, V55, P195, DOI 10.1023/A:1013845004294
   Robbins SL, 2018, ROBBINS BASIC PATHOL
   Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   Shimizu H, 2000, AM J NEURORADIOL, V21, P659
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Yoshida Y, 2010, J NEURO-ONCOL, V98, P41, DOI 10.1007/s11060-009-0064-5
   Yue Q, 2014, J NEURO-ONCOL, V116, P251, DOI 10.1007/s11060-013-1314-0
   2014, NEURO-ONCOLOGY, V16, P1478, DOI DOI 10.1093/NEUONC/NOU097
   1994, NEUROSURGERY, V35, P1036
NR 30
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1093
EP E1103
DI 10.1016/j.wneu.2019.02.006
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700137
PM 30790732
DA 2020-05-12
ER

PT J
AU Hohne, J
   Schebesch, KM
   de Laurentis, C
   Akcakaya, MO
   Pedersen, CB
   Brawanski, A
   Poulsen, FR
   Kiris, T
   Cavallo, C
   Broggi, M
   Ferroli, P
   Acerbi, F
AF Hoehne, Julius
   Schebesch, Karl-Michael
   de Laurentis, Camilla
   Akcakaya, Mehmet Osman
   Pedersen, Christian Bonde
   Brawanski, Alexander
   Poulsen, Frantz Rom
   Kiris, Talat
   Cavallo, Claudio
   Broggi, Morgan
   Ferroli, Paolo
   Acerbi, Francesco
TI Fluorescein Sodium in the Surgical Treatment of Recurrent Glioblastoma
   Multiforme
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fluorescein sodium; Fluorescence-guided surgery; High-grade glioma;
   Neurosurgery; PENTERO 900; Recurrent glioblastoma; Surgical microscope;
   YELLOW 560 nm filter
ID HIGH-GRADE GLIOMAS; GUIDED SURGERY; INTRAOPERATIVE FLUORESCENCE;
   MICROSCOPE FILTER; TUMOR VOLUME; RESECTION; SURVIVAL; EXTENT; BRAIN;
   ASSOCIATION
AB BACKGROUND: Glioblastoma multiforme (GBM) is the most common primary brain tumor and has a high recurrence rate. Maximizing the extent of resection (EOR) in recurrent GBM has proved to be the cornerstone of neurosurgical retreatment. The development of surgical microscopes fitted with fluorescein-specific filters has facilitated fluorescein-guided microsurgery and the identification of tumor tissue. Use of fluorescein sodium (FL) in primary high-grade glioma resection has shown promising results. Here, we present our experience with FL and the dedicated surgical microscope filter YELLOW 560 nm in 106 patients with recurrent GBM.
   METHODS: A total of 106 patients with recurrent GBM were included (53 women, 53 men; mean age, 53 years). A total of 5 mg/kg bodyweight of FL was intravenously injected approximately 45 minutes before craniotomy. A YELLOW 560 nm filter (PENTERO 900 [Carl Zeiss Meditec, Oberkochen Germany]) was used for microsurgical tumor resection and resection control. Surgical reports were reviewed regarding the degree of fluorescent staining. Postoperative magnetic resonance images were examined within 48 hours after surgery regarding the EOR and postoperative course regarding neurologic outcome, complications, and any adverse events.
   RESULTS: Bright fluorescent staining was present in all patients, which markedly enhanced tumor visibility and was deemed helpful for tumor resection. Seventeen patients (16%) showed residual tumor tissue on postoperative magnetic resonance imaging (MRI). Therefore, gross total resection was achieved in 89 patients (84%). No adverse events were registered postoperatively.
   CONCLUSIONS: FL and YELLOW 560 nm are readily available methods for fluorescence-guided tumor resection, similar to contrast enhancement in T1-weighted MRI. FL may improve resection in recurrent GBM with minimal risk, and tumor margins are clearly visualized. FL and the YELLOW 560 nm filter are safe and feasible tools for safe maximal resection of recurrent glioblastoma.
C1 [Hoehne, Julius; Schebesch, Karl-Michael; Brawanski, Alexander] Univ Med Ctr Regensburg, Dept Neurosurg, Regensburg, Germany.
   [de Laurentis, Camilla; Cavallo, Claudio; Broggi, Morgan; Ferroli, Paolo; Acerbi, Francesco] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Milan, Italy.
   [Akcakaya, Mehmet Osman; Kiris, Talat] Liv Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Pedersen, Christian Bonde; Poulsen, Frantz Rom] Odense Univ Hosp, Dept Neurosurg, Odense, Denmark.
RP Hohne, J (reprint author), Univ Med Ctr Regensburg, Dept Neurosurg, Regensburg, Germany.
EM julius.hoehne@ukr.de
OI Poulsen, Frantz Rom/0000-0001-5715-6901; de Laurentis,
   Camilla/0000-0003-1867-7899
CR Acerbi F, 2018, CLIN CANCER RES, V24, P52, DOI 10.1158/1078-0432.CCR-17-1184
   Acerbi F, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13487
   Acerbi F, 2013, ACTA NEUROCHIR, V155, P1277, DOI 10.1007/s00701-013-1734-9
   Bloch O, 2012, J NEUROSURG, V117, P1032, DOI 10.3171/2012.9.JNS12504
   Brown TJ, 2016, JAMA ONCOL, V2, P1460, DOI 10.1001/jamaoncol.2016.1373
   Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137
   Chen B, 2012, INT J MED SCI, V9, P708, DOI 10.7150/ijms.4843
   Diaz RJ, 2015, J NEUROSURG, V122, P1360, DOI 10.3171/2015.2.JNS132507
   Dilek O, 2011, J CLIN NEUROSCI, V18, P430, DOI 10.1016/j.jocn.2010.06.012
   Ening G, 2015, CLIN NEUROL NEUROSUR, V136, P89, DOI 10.1016/j.clineuro.2015.05.024
   Filippini G, 2008, NEURO-ONCOLOGY, V10, P79, DOI 10.1215/15228517-2007-038
   Gessler F, 2015, NEUROSURGERY, V77, P16, DOI 10.1227/NEU.0000000000000729
   Grabowski MM, 2014, J NEUROSURG, V121, P1115, DOI 10.3171/2014.7.JNS132449
   Hamamcioglu MK, 2016, CLIN NEUROL NEUROSUR, V143, P39, DOI 10.1016/j.clineuro.2016.02.006
   Hervey-Jumper SL, 2014, NEUROSURGERY, V75, P491, DOI 10.1227/NEU.0000000000000486
   Hohne J, 2017, CLIN NEUROL NEUROSUR, V155, P36, DOI 10.1016/j.clineuro.2017.02.014
   Hohne J, 2017, ACTA NEUROCHIR, V159, P363, DOI 10.1007/s00701-016-3054-3
   Keles GE, 1999, SURG NEUROL, V52, P371, DOI 10.1016/S0090-3019(99)00103-2
   Kern K, 2012, J CLIN NEUROSCI, V19, P99, DOI 10.1016/j.jocn.2011.07.021
   Koc K, 2008, BRIT J NEUROSURG, V22, P99, DOI 10.1080/02688690701765524
   Kubben PL, 2011, LANCET ONCOL, V12, P1062, DOI 10.1016/S1470-2045(11)70130-9
   Kuroiwa T, 1998, SURG NEUROL, V50, P41, DOI 10.1016/S0090-3019(98)00055-X
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Lee J, 2011, METHODS MOL BIOL, V763, P417, DOI 10.1007/978-1-61779-191-8_28
   Leon SP, 1996, CANCER-AM CANCER SOC, V77, P362, DOI 10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z
   Marko NF, 2014, J CLIN ONCOL, V32, P774, DOI 10.1200/JCO.2013.51.8886
   McGirt MJ, 2009, J NEUROSURG, V110, P156, DOI 10.3171/2008.4.17536
   Nduom EK, 2013, J NEUROSURG, V119, P427, DOI 10.3171/2013.3.JNS122226
   Neira JA, 2017, J NEUROSURG, V127, P111, DOI 10.3171/2016.7.JNS16232
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Okuda T, 2012, J CLIN NEUROSCI, V19, P1719, DOI 10.1016/j.jocn.2011.12.034
   Oppenlander ME, 2014, J NEUROSURG, V120, P846, DOI 10.3171/2013.12.JNS13184
   Prada F, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15573
   Quick-Weller J, 2016, BRIT J NEUROSURG, V30, P313, DOI 10.3109/02688697.2015.1119242
   Rey-Dios R, 2014, ACTA NEUROCHIR, V156, P1071, DOI 10.1007/s00701-014-2097-6
   Ringel F, 2016, NEURO-ONCOLOGY, V18, P96, DOI 10.1093/neuonc/nov145
   Russell SM, 2009, SURG NEUROL, V72, P242, DOI 10.1016/j.surneu.2008.11.012
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Schebesch KM, 2015, CLIN NEUROL NEUROSUR, V139, P125, DOI 10.1016/j.clineuro.2015.09.015
   Schebesch KM, 2013, ACTA NEUROCHIR, V155, P693, DOI 10.1007/s00701-013-1643-y
   Senft C, 2011, LANCET ONCOL, V12, P997, DOI 10.1016/S1470-2045(11)70196-6
   Seystahl K, 2016, CRIT REV ONCOL HEMAT, V99, P389, DOI 10.1016/j.critrevonc.2016.01.018
   Shinoda J, 2003, J NEUROSURG, V99, P597, DOI 10.3171/jns.2003.99.3.0597
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Suchorska B, 2016, NEURO-ONCOLOGY, V18, P549, DOI 10.1093/neuonc/nov326
   Tanahashi S, 2006, ANESTH ANALG, V103, P503, DOI 10.1213/01.ANE.0000227205.37935.10
   Tully PA, 2016, NEUROSURGERY, V79, P678, DOI 10.1227/NEU.0000000000001338
   Watkins S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5196
   Weller M, 2015, CLIN CANCER RES, V21, P2057, DOI 10.1158/1078-0432.CCR-14-2737
   Weller M, 2014, LANCET ONCOL, V15, pE395, DOI 10.1016/S1470-2045(14)70011-7
   Wirtz CR, 2000, NEUROL RES, V22, P354
   1998, SURG NEUROL, V50, P41
   2014, NEUROSURGERY, V75, P491, DOI DOI 10.1227/NEU.0000000000000486
   2009, SURG NEUROL, V72, P242, DOI DOI 10.1016/J.SURNEU.2008.11.012
NR 54
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E158
EP E164
DI 10.1016/j.wneu.2019.01.024
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700021
PM 30682505
DA 2020-05-12
ER

PT J
AU Hu, P
   Zhang, HQ
   Li, XY
   Tong, XZ
AF Hu, Peng
   Zhang, Hong-Qi
   Li, Xiao-Yu
   Tong, Xian-Zeng
TI Double-Barrel Superficial Temporal Artery to Proximal Middle Cerebral
   Artery Bypass to Treat Complex Intracranial Aneurysms: A Reliable High
   Blood Flow Bypass
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bypass; Complex; Intracranial aneurysm; STA
ID REVASCULARIZATION; OCCLUSION; SURGERY; COMPLICATIONS
AB BACKGROUND: The superficial temporal artery (STA) to proximal middle cerebral artery bypass has been reported before. However, the flow supply capacity of the double-barrel STA to proximal MCA bypass in treating complex intracranial aneurysms has not been well documented.
   METHODS: Consecutive cases using double-barrel STA to proximal MCA bypass to treat complex intracranial aneurysms during the past 5 years were collected. Somatosensory evoked potential monitoring and motor evoked potential monitoring were applied for each patient to identify any ischemic events during surgery. After bypass, the aneurysm was trapped, or the proximal parent artery was occluded. Digital subtraction angiography or computed tomography angiography was used to evaluate the patency of bypass postoperatively. Blood flow was measured by ultrasound before discharge.
   RESULTS: Among 1561 patients treated for intracranial aneurysms in our institute, 6 were included for the current report. There were 2 dominant M2 fusiform aneurysms, 2 M1 fusiform aneurysms, 1 supraclinoid internal carotid artery fusiform aneurysm, and 1 M1 bifurcation giant aneurysm. All 6 cases were successfully treated using this technique. One patient had temporary numbness in the contralateral extremities, which was caused by perforator complications. The blood flow carried by the STA was 108-232 mL/minute.
   CONCLUSIONS: When anastomosed to proximal branches, a double-barrel STA to MCA bypass can reliably provide a high blood flow of >100 mL/minute. Combined with aneurysm trapping or parent artery occlusion, this bypass algorithm could be an alternative treatment for complex intracranial aneurysms.
C1 [Hu, Peng; Zhang, Hong-Qi; Li, Xiao-Yu; Tong, Xian-Zeng] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Hu, P (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM doctor_hupeng@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81500988]; National Key R&D Program of China
   [2016YFC1300800]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81500988) and National Key R&D Program of China (Grant
   No. 2016YFC1300800).
CR Alaraj A, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E7
   Amin-Hanjani S, 2007, J NEUROSURG, V106, P291, DOI 10.3171/jns.2007.106.2.291
   Amin-Hanjani S, 2010, ACTA NEUROCHIR, V152, P1021, DOI 10.1007/s00701-010-0635-4
   Brockmann C, 2012, CLIN NEURORADIOL, V22, P39, DOI 10.1007/s00062-011-0116-z
   Cenzato M, 2016, J NEUROSURG SCI, V60, P70
   COLLICE M, 1986, NEUROSURGERY, V19, P992, DOI 10.1227/00006123-198612000-00015
   DIAZ FG, 1985, NEUROSURGERY, V17, P271, DOI 10.1227/00006123-198508000-00004
   DIAZ FG, 1985, J NEUROSURG, V63, P21, DOI 10.3171/jns.1985.63.1.0021
   DIAZ FG, 1982, NEUROSURGERY, V10, P563, DOI 10.1227/00006123-198205000-00003
   Esposito G, 2016, ACTA NEUROCHIR, V158, P1523, DOI 10.1007/s00701-016-2868-3
   FOX AJ, 1987, J NEUROSURG, V66, P40, DOI 10.3171/jns.1987.66.1.0040
   Grote E, 1982, Neurosurg Rev, V5, P83, DOI 10.1007/BF01743478
   HOPKINS LN, 1979, NEUROSURGERY, V5, P21, DOI 10.1227/00006123-197907010-00004
   Hu P, 2018, ACTA NEUROCHIR, V160, P1939, DOI 10.1007/s00701-018-3652-3
   Hu P, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.06.011
   Kodama N, 1982, Neurosurg Rev, V5, P87, DOI 10.1007/BF01743479
   Lawton MT, 1996, NEUROSURGERY, V38, P83, DOI 10.1097/00006123-199601000-00020
   Liu James K, 2003, Neurosurg Focus, V14, pe3
   NORNES H, 1977, J NEUROSURG, V47, P810, DOI 10.3171/jns.1977.47.6.0810
   Olteanu-Nerbe V, 1982, Neurosurg Rev, V5, P99, DOI 10.1007/BF01743482
   Peerless S J, 1982, Neurosurg Rev, V5, P77, DOI 10.1007/BF01743477
   Ramanathan D, 2012, NEUROSURGERY, V70, P1442, DOI 10.1227/NEU.0b013e31824c046f
   Rustemi O, 2016, NEUROSURGERY, V78, P332, DOI 10.1227/NEU.0000000000001074
   Sekhar LN, 2008, NEUROSURGERY, V62, P1373, DOI [10.1227/01.NEU.0000315873.41953.74, 10.1227/01.neu.0000333803.97703.c6]
   Sekhar LN, 2008, NEUROSURGERY, V62, P1440
   Sekhar LN, 2001, NEUROSURGERY, V49, P646, DOI 10.1097/00006123-200109000-00023
   SEKHAR LN, 1999, [No title captured], V2, P129
   SILVANI V, 1985, ACTA NEUROCHIR, V78, P142, DOI 10.1007/BF01808694
   SPETZLER RF, 1985, NEUROSURGERY, V16, P111, DOI 10.1227/00006123-198501000-00026
   SPETZLER RF, 1980, J NEUROSURG, V53, P22, DOI 10.3171/jns.1980.53.1.0022
   YASARGIL MG, 1970, SURGERY, V67, P221
   1996, NEUROSURGERY, V38, P83
   2016, NEUROSURGERY, V78, P332, DOI DOI 10.1227/NEU.0000000000001074
   2001, NEUROSURGERY, V49, P646
NR 34
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E884
EP E890
DI 10.1016/j.wneu.2019.01.203
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700109
PM 30743025
DA 2020-05-12
ER

PT J
AU Huang, YH
   Chow, KKH
   Aredo, JV
   Padda, SK
   Han, SS
   Kakusa, BW
   Gephart, MH
AF Huang, Yuhao
   Chow, Kevin K. H.
   Aredo, Jacqueline V.
   Padda, Sukhmani K.
   Han, Summer S.
   Kakusa, Bina W.
   Gephart, Melanie Hayden
TI Epidermal Growth Factor Receptor Mutation Status Confers Survival
   Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical
   Resection of Brain Metastases: A Retrospective Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adenocarcinoma; Brain metastases; Brain surgery; EGFR mutation; Lung
   cancer
ID OPEN-LABEL; 1ST-LINE TREATMENT; RADIATION-THERAPY; PHASE-III;
   CHEMOTHERAPY; ADENOCARCINOMA; OSIMERTINIB; CRIZOTINIB; ERLOTINIB;
   AFATINIB
AB BACKGROUND: Few prognostic markers are available for patients with non-small-cell lung cancer (NSCLC) undergoing neurosurgical resection of symptomatic brain metastases.
   OBJECTIVE: We investigated whether tumor mutation status (EGFR, KRAS, ALK, ROS1, and BRAF) and treatment history were associated with survival after neurosurgery.
   METHODS: We reviewed the electronic health records of 104 patients with NSCLC with genomic profiling who underwent neurosurgical resection for symptomatic brain metastases at an academic institution between January 2000 and January 2018. We used multivariate Cox proportional hazards regression models to evaluate the association between overall survival (OS) after neurosurgery and clinicopathologic factors, including mutation status.
   RESULTS: Mean age of patients in this study was 61 (+/- 12) years, and 44% were men. The median OS after neurosurgery was 24 months (95% confidence interval, 18-34 months). Our multivariate analysis showed that the presence of an EGFR mutation in the tumor was significantly associated with improved OS (hazard ratio [HR], 0.214; P = 0.029), independent of tyrosine kinase inhibitor use. Presence of KRAS, ALK, ROS1, and BRAF alterations was not associated with survival (all P > 0.05). Conversely, older age (HR, 1.039; P = 0.029), a history of multiple brain irradiation procedures ( HR, 9.197; P < 0.001), and presence of extracranial metastasis (HR, 2.556; P = 0.016) resulted in increased risk of mortality.
   CONCLUSIONS: Patients requiring surgical resection of an epidermal growth factor receptor-mutated NSCLC brain metastasis had an associated improved survival compared with patients without this mutation, independent of tyrosine kinase inhibitor use. Decreased survival was associated with older age, multiple previous brain radiation therapies, and extracranial metastasis.
C1 [Huang, Yuhao; Chow, Kevin K. H.; Aredo, Jacqueline V.; Han, Summer S.; Kakusa, Bina W.; Gephart, Melanie Hayden] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
   [Padda, Sukhmani K.] Stanford Univ, Dept Med, Sch Med, Div Oncol, Stanford, CA 94305 USA.
RP Gephart, MH (reprint author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
EM mghayden@stanford.edu
OI Kakusa, Bina/0000-0003-0907-2505
FU U.S. National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [K08 NS901527]
FX This study was supported by the U.S. National Institutes of Health
   (grant number K08 NS901527).
CR Andrews RJ, 1996, ACTA NEUROCHIR, V138, P382, DOI 10.1007/BF01420299
   Arrieta O, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-166
   Ballard P, 2016, CLIN CANCER RES, V22, P5130, DOI 10.1158/1078-0432.CCR-16-0399
   Billing PS, 2001, J THORAC CARDIOV SUR, V122, P548, DOI 10.1067/mtc.2001.116201
   Cai L, 2014, J NEURO-ONCOL, V120, P423, DOI 10.1007/s11060-014-1570-7
   Costa DB, 2015, J CLIN ONCOL, V33, P1881, DOI 10.1200/JCO.2014.59.0539
   Eichler AF, 2010, NEURO-ONCOLOGY, V12, P1193, DOI 10.1093/neuonc/noq076
   Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735
   Gaspar L, 1997, INT J RADIAT ONCOL, V37, P745, DOI 10.1016/S0360-3016(96)00619-0
   Getman V, 2004, EUR J CARDIO-THORAC, V25, P1107, DOI 10.1016/j.ejcts.2004.02.021
   Hoseok I, 2006, J KOREAN MED SCI, V21, P236
   Karlsson B, 2009, J NEUROSURG, V111, P449, DOI 10.3171/2008.10.JNS08214
   Lee DW, 2014, LUNG CANCER, V86, P363, DOI 10.1016/j.lungcan.2014.10.001
   Li ZY, 2015, ONCOTARGETS THER, V8, P855, DOI 10.2147/OTT.S80329
   Luo DD, 2014, TUMOR BIOL, V35, P2437, DOI 10.1007/s13277-013-1323-9
   Magnuson WJ, 2017, J CLIN ONCOL, V35, P1070, DOI 10.1200/JCO.2016.69.7144
   Magnuson WJ, 2016, INT J RADIAT ONCOL, V95, P673, DOI 10.1016/j.ijrobp.2016.01.037
   McPherson CM, 2010, NEURO-ONCOLOGY, V12, P711, DOI 10.1093/neuonc/noq005
   Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X
   Modi Amit, 2009, Interact Cardiovasc Thorac Surg, V8, P467, DOI 10.1510/icvts.2008.195776
   PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802
   Penel N, 2001, LUNG CANCER, V33, P143, DOI 10.1016/S0169-5002(01)00202-1
   Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795
   Postmus PE, 2007, J THORAC ONCOL, V2, P686, DOI 10.1097/JTO.0b013e31811f4703
   Rangachari D, 2015, LUNG CANCER, V88, P108, DOI 10.1016/j.lungcan.2015.01.020
   Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X
   Schuette W, 2004, LUNG CANCER, V45, pS253, DOI 10.1016/j.lungcan.2004.07.967
   Schuler M, 2016, J THORAC ONCOL, V11, P380, DOI 10.1016/j.jtho.2015.11.014
   Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]
   Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137
   Soria JC, 2017, LANCET, V389, P917, DOI 10.1016/S0140-6736(17)30123-X
   Sperduto PW, 2008, INT J RADIAT ONCOL, V70, P510, DOI 10.1016/j.ijrobp.2007.06.074
   Sperduto PW, 2017, JAMA ONCOL, V3, P827, DOI 10.1001/jamaoncol.2016.3834
   Sperduto PW, 2016, INT J RADIAT ONCOL, V96, P406, DOI 10.1016/j.ijrobp.2016.06.006
   Sperduto PW, 2010, INT J RADIAT ONCOL, V77, P655, DOI 10.1016/j.ijrobp.2009.08.025
   Togashi Y, 2012, CANCER CHEMOTH PHARM, V70, P399, DOI 10.1007/s00280-012-1929-4
   Tomasini P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122132
   Vansteenkiste J, 2017, ANN ONCOL, V28, P189, DOI 10.1093/annonc/mdx729.007
   Wang TJC, 2015, NEURO-ONCOLOGY, V17, P1022, DOI 10.1093/neuonc/nov043
   Wu YL, 2015, ANN ONCOL, V26, P1883, DOI 10.1093/annonc/mdv270
   Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1
   Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E487
EP E496
DI 10.1016/j.wneu.2019.01.112
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700065
PM 30710723
DA 2020-05-12
ER

PT J
AU Ironside, N
   Buell, TJ
   Chen, CJ
   Kumar, JS
   Paisan, GM
   Sokolowski, JD
   Liu, KC
   Ding, DL
AF Ironside, Natasha
   Buell, Thomas J.
   Chen, Ching-Jen
   Kumar, Jeyan S.
   Paisan, Gabriella M.
   Sokolowski, Jennifer D.
   Liu, Kenneth C.
   Ding, Dale
TI High-Grade Aneurysmal Subarachnoid Hemorrhage: Predictors of Functional
   Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Bleed; Morbidity; Mortality; Outcome; Severe; Subarachnoid
   hemorrhage
ID SHUNT-DEPENDENT HYDROCEPHALUS; ENDOVASCULAR TREATMENT; CEREBRAL
   INFARCTION; WORLD-FEDERATION; SINGLE-CENTER; RISK-FACTORS; MANAGEMENT;
   VASOSPASM; TIME; HYPERGLYCEMIA
AB BACKGROUND: Because the prognosis of high-grade aneurysmal subarachnoid hemorrhage (aSAH), classified as World Federation of Neurosurgical Societies (WFNS) grade IV-V, is generally poor, the functional outcomes of survivors have not been thoroughly explored. The aim of this retrospective cohort study is to determine predictors of functional independence in patients who survive a highgrade aSAH.
   METHODS: We retrospectively evaluated consecutive patients with aSAH admitted to a single institution from January 2000 to April 2015. Adult (age >= 18 years) patients with WFNS grade IV-V aSAH were included for analysis. Patients without sufficient baseline data, those who died before discharge, and those without follow-up data were excluded. Univariable and multivariable logistic regression analyses were used to identify factors associated with functional independence, defined as a modified Rankin Scale score of 0-2, at last follow-up.
   RESULTS: Of the 260 patients with a WFNS grade IV-V aSAH during the study period, 139 met the inclusion criteria. After a mean follow-up of 6.3 months, functional independence was achieved in 73% of high-grade aSAH survivors (101/139 patients) and in 39% of all high-grade aSAH cases (101/260 patients). Only a lack of cerebrospinal fluid shunt placement was found to be an independent predictor of functional independence in the multivariable analysis (odds ratio 0.28 [0.109-0.722]; P = 0.008).
   CONCLUSIONS: Because functional independence can be achieved in the majority of high-grade aSAH survivors, aggressive initial management of high-grade aSAH is warranted. Strategies that reduce the need for permanent cerebrospinal fluid diversion may improve functional outcomes in survivors of high-grade aSAH.
C1 [Ironside, Natasha] NewYork Presbyterian Columbia Univ, Med Ctr, Dept Neurosurg, New York, NY USA.
   [Buell, Thomas J.; Chen, Ching-Jen; Kumar, Jeyan S.; Sokolowski, Jennifer D.] Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA.
   [Paisan, Gabriella M.] Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.
   [Liu, Kenneth C.] Milton S Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA.
   [Ding, Dale] Univ Louisville, Dept Neurosurg, Louisville, KY 40292 USA.
RP Ding, DL (reprint author), Univ Louisville, Dept Neurosurg, Louisville, KY 40292 USA.
EM daleding1234@gmail.com
RI Ding, Dale/AAN-3583-2020
CR BAILES JE, 1990, J NEUROSURG, V72, P559, DOI 10.3171/jns.1990.72.4.0559
   Chua MH, 2016, STROKE, V47, P708, DOI 10.1161/STROKEAHA.115.011959
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   de Oliveira Manoel AL, 2016, NEUROCRIT CARE, V25, P338, DOI 10.1007/s12028-016-0305-3
   de Rooij NK, 2007, J NEUROL NEUROSUR PS, V78, P1365, DOI 10.1136/jnnp.2007.117655
   DRAKE CG, 1988, J NEUROSURG, V68, P985
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Goldberg J, 2018, STROKE, V49, P2883, DOI 10.1161/STROKEAHA.118.022869
   Han YY, 2018, WORLD NEUROSURG, V115, pE160, DOI 10.1016/j.wneu.2018.03.219
   Huang APH, 2010, NEUROSURGERY, V67, P964, DOI 10.1227/NEU.0b013e3181ee359c
   HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014
   Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P105
   Jaja BNR, 2013, NEUROCRIT CARE, V18, P143, DOI 10.1007/s12028-012-9792-z
   Juvela S, 2005, J NEUROSURG, V102, P998, DOI 10.3171/jns.2005.102.6.0998
   Juvela S, 2012, EUR J NEUROL, V19, P332, DOI 10.1111/j.1468-1331.2011.03523.x
   Kanat A, 2014, WORLD NEUROSURG, V82, pE386, DOI 10.1016/j.wneu.2013.08.007
   KASSELL NF, 1982, NEUROSURGERY, V11, P337, DOI 10.1227/00006123-198209000-00001
   KIBLER RF, 1961, BRAIN, V84, P45, DOI 10.1093/brain/84.1.45
   KOMOTAR RJ, 2009, NEUROSURGERY, V64
   Le Roux PD, 1999, ACT NEUR S, V72, P7
   LeRoux PD, 1996, J NEUROSURG, V85, P39, DOI 10.3171/jns.1996.85.1.0039
   Lovelock CE, 2010, NEUROLOGY, V74, P1494, DOI 10.1212/WNL.0b013e3181dd42b3
   McGirt MJ, 2007, J NEUROSURG, V107, P1080, DOI 10.3171/JNS-07/12/1080
   Nieuwkamp DJ, 2006, J NEUROL NEUROSUR PS, V77, P933, DOI 10.1136/jnnp.2005.084350
   Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7
   NOWAK G, 1994, ACTA NEUROCHIR, V126, P33, DOI 10.1007/BF01476491
   Okubo S, 2013, STROKE, V44, P547, DOI 10.1161/STROKEAHA.112.662312
   Paisan GM, 2018, NEUROSURGERY, V83, P393, DOI 10.1093/neuros/nyx393
   Rincon F, 2010, J NEUROSURG, V113, P774, DOI 10.3171/2010.2.JNS09376
   Rinkel GJE, 2011, LANCET NEUROL, V10, P349, DOI 10.1016/S1474-4422(11)70017-5
   Sandstrom N, 2013, J CLIN NEUROSCI, V20, P1213, DOI 10.1016/j.jocn.2012.11.012
   Schuss P, 2016, WORLD NEUROSURG, V85, P125, DOI 10.1016/j.wneu.2015.08.046
   Shirao S, 2010, CEREBROVASC DIS, V30, P105, DOI 10.1159/000314713
   Sokolowski JD, 2018, J NEUROINTERV SURG, V10, P367, DOI 10.1136/neurintsurg-2017-013363
   Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2
   Sugawara T, 2016, J NEUROSURG SCI, V60, P154
   Taylor CJ, 2011, NEUROCRIT CARE, V14, P341, DOI 10.1007/s12028-010-9377-7
   van den Berg R, 2011, CRIT CARE MED, V39, P2722, DOI 10.1097/CCM.0b013e3182282a70
   Wartenberg KE, 2011, CURR OPIN CRIT CARE, V17, P85, DOI 10.1097/MCC.0b013e328342f83d
   Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35
   Wilby MJ, 2003, STROKE, V34, P2508, DOI 10.1161/01.STR.0000089922.94684.13
   Wostrack M, 2013, ACTA NEUROCHIR, V155, P579, DOI 10.1007/s00701-013-1634-z
   Xie ZY, 2017, WORLD NEUROSURG, V106, P844, DOI 10.1016/j.wneu.2017.06.119
   Yu H, 2014, J CRANIOFAC SURG, V25, P902, DOI 10.1097/SCS.0000000000000561
   Zhao B, 2017, J NEUROSURG SCI, V61, P403, DOI 10.23736/S0390-5616.16.03457-3
   Zhao B, 2017, J NEUROSURG, V126, P1764, DOI 10.3171/2016.4.JNS152587
   Zhao B, 2016, NEUROSURGERY, V78, P224, DOI 10.1227/NEU.0000000000001038
   2009, NEUROSURGERY, V64, P397, DOI DOI 10.1227/01.NEU.0000338946.42939.C7
   2006, NEUROSURGERY, V59, P529, DOI DOI 10.1227/01.NEU.0000228680.22550.A2
   2008, NEUROSURGERY, V62, P618, DOI DOI 10.1227/01.NEU.0000297121.92817.B2
NR 50
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E723
EP E728
DI 10.1016/j.wneu.2019.01.162
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700090
PM 30735864
DA 2020-05-12
ER

PT J
AU Iwanaga, J
   Simonds, E
   Schumacher, M
   Yilmaz, E
   Altafulla, J
   Tubbs, RS
AF Iwanaga, Joe
   Simonds, Emily
   Schumacher, Maia
   Yilmaz, Emre
   Altafulla, Juan
   Tubbs, R. Shane
TI Anatomic Study of the Superior Cluneal Nerve and Its Related Groove on
   the Iliac Crest
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Low back pain; Lumbar vertebrae; Nerve compression syndrome;
   Pseudo sciatica
ID LOW-BACK-PAIN; ENTRAPMENT NEUROPATHY; SURGICAL-TREATMENT
AB OBJECTIVE: Superior cluneal nerve entrapment neuropathy is one cause of low back pain often referred to as "pseudo sciatica." Studies have found that the superior cluneal nerve can arise variably from T11 to L5. The osteofibrous tunnels formed by a groove on the iliac crest might compress the superior cluneal nerve. Therefore, the purpose of this study was to investigate the origin of the superior cluneal nerve and its course through such bony grooves.
   METHODS: Twenty sides from 10 fresh frozen Caucasian cadavers were used in this study. Once both the superior cluneal nerve and its groove were identified, the distance from the groove to the posterior superior iliac spine and midline was measured.
   RESULTS: A total of 12 grooves were identified in 11 of 20 sides (55%). On 10 sides, the nerve running on the groove was the medial branch of the superior cluneal nerve. The mean distance from the bony groove to the posterior superior iliac spine and midline was 45.2 +/- 11.2 mm and 65.3 +/- 8.2 mm, respectively.
   CONCLUSIONS: These results could help identify such bony grooves and better understand low back pain and its related anatomy.
C1 [Iwanaga, Joe; Simonds, Emily; Schumacher, Maia; Yilmaz, Emre; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Iwanaga, Joe] Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
   [Altafulla, Juan; Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.; Iwanaga, J (reprint author), Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
EM joei@seattlesciencefoundation.org
OI Altafulla, Juan/0000-0002-2110-8665
CR Hovelacque A, 1927, ANATOMIE NERFS CRANI
   Isu T, 2018, NEUROSPINE, V15, P25, DOI 10.14245/ns.1836024.012
   Iwanaga J, 2018, WORLD NEUROSURG, V116, pE766, DOI 10.1016/j.wneu.2018.05.087
   Kim K, 2018, MUSCLE NERVE, V57, P777, DOI 10.1002/mus.26007
   Kim Kyongsong, 2015, Surg Neurol Int, V6, pS619, DOI 10.4103/2152-7806.170455
   Kokubo R, 2017, WORLD NEUROSURG, V98, P132, DOI 10.1016/j.wneu.2016.10.096
   Konno T, 2017, J PAIN RES, V10, P2539, DOI 10.2147/JPR.S142115
   Kuniya H, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018-014-0139-7
   Kuniya H, 2013, J NEUROSURG-SPINE, V19, P76, DOI 10.3171/2013.4.SPINE12683
   Lu J, 1998, CLIN ORTHOP RELAT R, P224
   MAIGNE JY, 1991, ARCH PHYS MED REHAB, V72, P734
   Maigne JY, 1997, SPINE, V22, P1156, DOI 10.1097/00007632-199705150-00017
   MAIGNE JY, 1989, SURG RADIOL ANAT, V11, P289, DOI 10.1007/BF02098698
   Morimoto D, 2017, SPINE, V42, P783, DOI 10.1097/BRS.0000000000001913
   Morimoto D, 2013, J NEUROSURG-SPINE, V19, P71, DOI 10.3171/2013.3.SPINE12420
   Netter FH, 2018, ATLAS HUMAN ANATOMY
   Speed SSK, 2011, J MED CASES, V2, P101
   Standring S, 2015, GRAYS ANATOMY ANATOM
   Trescot Andrea M, 2003, Pain Physician, V6, P345
   Tubbs RS, 2010, J NEUROSURG-SPINE, V13, P356, DOI 10.3171/2010.3.SPINE09747
   Xu RM, 1996, SPINE, V21, P1017, DOI 10.1097/00007632-199605010-00004
NR 21
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E925
EP E928
DI 10.1016/j.wneu.2019.01.210
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700114
PM 30763748
DA 2020-05-12
ER

PT J
AU Jeffery, SMT
   Markia, B
   Pople, IK
   Aquilina, K
   Smith, J
   Mohamed, AZ
   Burchell, A
   Jenkins, L
   Walsh, P
   Clark, N
   Sacree, J
   Cramp, M
   Babiker, MOE
   Atherton, WG
   Clarke, A
   Edwards, RJ
AF Jeffery, Samuel M. T.
   Markia, Balazs
   Pople, Ian K.
   Aquilina, Kristian
   Smith, Jenny
   Mohamed, Amr Z.
   Burchell, Alison
   Jenkins, Lyn
   Walsh, Peter
   Clark, Natasha
   Sacree, Jenny
   Cramp, Mary
   Babiker, Mohamed O. E.
   Atherton, William Guy
   Clarke, Anna
   Edwards, Richard J.
TI Surgical Outcomes of Single-Level Bilateral Selective Dorsal Rhizotomy
   for Spastic Diplegia in 150 Consecutive Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral palsy; Complications; Operative outcomes; Selective dorsal
   rhizotomy; Spastic diplegia
ID CEREBRAL-PALSY; CHILDREN; COMPLICATIONS
AB OBJECTIVES: Selective dorsal rhizotomy (SDR) is used to improve spasticity, gait, and pain in children with spastic diplegia. There is growing evidence supporting its longterm benefits in terms of functional outcomes, independence, and quality of life. There is, however, little contemporary work describing the surgical morbidity of this irreversible procedure. The purpose of this study is to evaluate the surgical outcomes and complications of SDR at a single United Kingdom center.
   METHODS: Demographics, surgical, postoperative, and follow-up data for all patients undergoing SDR between 2011 and 2016 were collected from medical records.
   RESULTS: Preoperative Gross Motor Function Classification System levels in 150 consecutive patients were II (35%), III (65%), and IV (1%). Median age was 6 years and 58% were male patients. There were no deaths, cerebrospinal fluid leaks, returns to theater, or readmissions within 30 days. There were no new motor or sphincter deficits. Postoperative neuropathic pain was reported by 5.3% and sensory symptoms by 8.7%. Other complications included: postoperative nausea and vomiting (19.3%), superficial wound infection (3.3%), urinary retention (1.3%), headache (6.7%), and urine or chest infection (4.7%). Follow-up data were available for all patients (93% to 12 months, 72% to 24 months). Persistent neuropathic symptoms were reported in 6.5% at 24 months.
   CONCLUSIONS: SDR using a single-level approach is a safe procedure with low surgical morbidity. This study complements the growing evidence base in support of SDR for spastic diplegia and should help inform decisions when considering treatment options.
C1 [Jeffery, Samuel M. T.; Markia, Balazs; Pople, Ian K.; Mohamed, Amr Z.; Sacree, Jenny; Edwards, Richard J.] Univ Hosp Bristol NHS Fdn Trust, Bristol Royal Hosp Children, Dept Neurosurg, Bristol, Avon, England.
   [Smith, Jenny; Burchell, Alison; Jenkins, Lyn] Univ Hosp Bristol NHS Fdn Trust, Bristol Royal Hosp Children, Dept Paediat Physiotherapy, Bristol, Avon, England.
   [Clark, Natasha] Univ Hosp Bristol NHS Fdn Trust, Bristol Royal Hosp Children, Dept Paediat Anaesthesia, Bristol, Avon, England.
   [Babiker, Mohamed O. E.] Univ Hosp Bristol NHS Fdn Trust, Bristol Royal Hosp Children, Dept Paediat Neurol, Bristol, Avon, England.
   [Atherton, William Guy; Clarke, Anna] Univ Hosp Bristol NHS Fdn Trust, Bristol Royal Hosp Children, Dept Orthopaed Surg, Bristol, Avon, England.
   [Jeffery, Samuel M. T.; Pople, Ian K.; Aquilina, Kristian; Mohamed, Amr Z.; Sacree, Jenny; Edwards, Richard J.] North Bristol NHS Trust, Dept Neurosurg, Bristol, Avon, England.
   [Walsh, Peter] North Bristol NHS Trust, Dept Neurophysiol, Bristol, Avon, England.
   [Cramp, Mary] Univ West England, Ctr Hlth & Clin Res, Bristol, Avon, England.
   [Edwards, Richard J.] Univ Bristol, Sch Clin Sci, Bristol, Avon, England.
   [Jeffery, Samuel M. T.] Univ Hosp Plymouth NHS Trust, South West Neurosurg Ctr, Derriford Hosp, Plymouth, Devon, England.
   [Aquilina, Kristian] Great Ormond St Hosp Children NHS Fdn Trust, Dept Neurosurg, London, England.
   [Markia, Balazs] Natl Inst Clin Neurosci, Budapest, Hungary.
RP Edwards, RJ (reprint author), Univ Hosp Bristol NHS Fdn Trust, Bristol Royal Hosp Children, Dept Neurosurg, Bristol, Avon, England.; Edwards, RJ (reprint author), North Bristol NHS Trust, Dept Neurosurg, Bristol, Avon, England.; Edwards, RJ (reprint author), Univ Bristol, Sch Clin Sci, Bristol, Avon, England.
EM Richard.Edwards2@UHBristol.nhs.uk
RI Aquilina, Kristian/AAF-5334-2019
OI Jeffery, Samuel/0000-0002-2642-0906
CR ABBOTT R, 1993, NEUROSURGERY, V33, P851
   Aquilina K, 2015, ARCH DIS CHILD, V100, P798, DOI 10.1136/archdischild-2014-306874
   Buizer AI, 2017, EUR J PAEDIATR NEURO, V21, P350, DOI 10.1016/j.ejpn.2016.09.006
   Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x
   Cole GF, 2007, ARCH DIS CHILD, V92, P781, DOI 10.1136/adc.2006.111559
   Colver A, 2014, LANCET, V383, P1240, DOI 10.1016/S0140-6736(13)61835-8
   Dudley RWR, 2013, J NEUROSURG-PEDIATR, V12, P142, DOI 10.3171/2013.4.PEDS12539
   Eppinger Melissa Ann, 2015, Surg Neurol Int, V6, P111, DOI 10.4103/2152-7806.159382
   FASANO VA, 1978, CHILD BRAIN, V4, P289
   Graham David, 2016, J Spine Surg, V2, P195
   Grunt S, 2014, DEV MED CHILD NEUROL, V56, P302, DOI 10.1111/dmcn.12277
   Ingale H, 2016, CHILD NERV SYST, V32, P321, DOI 10.1007/s00381-015-2950-9
   Josenby AL, 2012, DEV MED CHILD NEUROL, V54, P429, DOI 10.1111/j.1469-8749.2012.04258.x
   Kai M, 2014, J CLIN NEUROSCI, V21, P116, DOI 10.1016/j.jocn.2013.04.020
   Martin S, 2016, GUIDELINES PREVENTIO, P7
   McLaughlin J, 2002, DEV MED CHILD NEUROL, V44, P17, DOI 10.1017/S0012162201001608
   Nordmark E, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-54
   Novak I, 2013, DEV MED CHILD NEUROL, V55, P885, DOI 10.1111/dmcn.12246
   Park TS, 2006, TECHNICAL NOTE NEURO, V21, pe7, DOI DOI 10.3171/F0C.2006.21.2.8
   Reynolds RM, 2014, J NEUROSURG-PEDIATR, V14, P266, DOI 10.3171/2014.5.PEDS13459
   RIEGLE EV, 1992, J NEUROSURG ANESTH, V4, P182, DOI 10.1097/00008506-199207000-00006
   Steinbok P, 1998, PEDIATR NEUROSURG, V28, P300, DOI 10.1159/000028668
   Trost JP, 2008, DEV MED CHILD NEUROL, V50, P765, DOI 10.1111/j.1469-8749.2008.03031.x
NR 23
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E60
EP E66
DI 10.1016/j.wneu.2018.12.187
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700010
PM 30659965
DA 2020-05-12
ER

PT J
AU Jiang, J
   Zhu, ZZ
   Qiu, Y
   Wang, B
   Yu, Y
AF Jiang, Jun
   Zhu, Ze-zhang
   Qiu, Yong
   Wang, Bin
   Yu, Yang
TI Postoperative Lumbar Curve Progression Deteriorates Shoulder Imbalance
   in Patients with Lenke Type 2B/C Adolescent Idiopathic Scoliosis Who
   Underwent Selective Thoracic Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Curve; Lumbar; Radiographic shoulder height; Scoliosis
ID DISTAL ADDING-ON; INSTRUMENTATION; BALANCE; SPINE; RISK; CLASSIFICATION;
   SURGERY; LEVEL
AB OBJECTIVE: To evaluate the association between postoperative lumbar curve progression and the shoulder height in patients with Lenke type 2B/C adolescent idiopathic scoliosis (AIS).
   METHODS: A total of 25 patients with Lenke type 2B/C AIS underwent posterior correction surgery in our institution from 2005-2014 were included. Standing x-ray films of the whole spine obtained before surgery, immediately after surgery, and at the last follow-up were analyzed with respect to the following parameters: proximal thoracic Cobb angle, main thoracic (MT) Cobb angle, lumbar Cobb angle, lumbar apical vertebral translation, distance between C7 plumb line and the central sacral vertical line, and radiographic shoulder height (RSH). Correlations between the change of RSH and the changes of other parameters were analyzed both immediately after surgery and at the last follow-up.
   RESULTS: The change of RSH was significantly negatively correlated with both the change of MT Cobb angle (P < 0.05) and that of lumbar Cobb angle (P < 0.05) immediately after surgery, whereas the interval-time change of RSH was significantly positively correlated with the interval-time change of lumbar Cobb angle (P < 0.05) and that of lumbar apical vertebral translation (P < 0.05) at the last follow-up. The change of MT Cobb angle was an independent predictor for the change of RSH immediately after surgery, whereas the interval-time change of lumbar Cobb angle was an independent predictor for the interval-time change of RSH at the last follow-up.
   CONCLUSIONS: Postoperative lumbar curve progression is a risk factor for deterioration of shoulder imbalance in patients with Lenke 2B/C AIS during the follow-up period.
C1 [Jiang, Jun; Zhu, Ze-zhang; Qiu, Yong; Wang, Bin; Yu, Yang] Nanjing Univ, Sch Med, Dept Spine Surg, Affiliated Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.
RP Zhu, ZZ (reprint author), Nanjing Univ, Sch Med, Dept Spine Surg, Affiliated Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.
EM zhuzezhang@126.com
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [81601867]; Natural Science Foundation of Jiangsu Province,
   ChinaNatural Science Foundation of Jiangsu Province [BK20160107]
FX This work was supported by the Natural Science Foundation of China
   (81601867) and the Natural Science Foundation of Jiangsu Province, China
   (BK20160107).
CR Akel I, 2008, EUR SPINE J, V17, P348, DOI 10.1007/s00586-007-0546-0
   Amir D, 2016, SPINE, V41, P1122, DOI 10.1097/BRS.0000000000001497
   Arlet V, 2000, EUR SPINE J, V9, P156, DOI 10.1007/s005860050227
   Bridwell KH, 2004, J NEUROSURG-SPINE, V1, P1, DOI 10.3171/spi.2004.1.1.0001
   Cao K, 2014, SPINE, V39, pE705, DOI 10.1097/BRS.0000000000000325
   Chang MS, 2010, SPINE, V35, P2128, DOI 10.1097/BRS.0b013e3181e5e36e
   Cho RH, 2012, SPINE, V37, P1384, DOI 10.1097/BRS.0b013e31824bac7a
   Dobbs MB, 2006, SPINE, V31, P2400, DOI 10.1097/01.brs.0000240212.31241.8e
   Edwards CC, 2004, SPINE, V29, P536, DOI 10.1097/01.BRS.0000109992.22248.77
   Fischer CR, 2011, EUR SPINE J, V20, P1048, DOI 10.1007/s00586-011-1730-9
   Heary RF, 2007, SPINAL DEFORMITIES E
   Ibrahim K, 1991, ORTHOP T, V15, P114
   Ilharreborde B, 2008, J PEDIATR ORTHOPED, V28, P733, DOI 10.1097/BPO.0b013e318185a36b
   KING HA, 1983, J BONE JOINT SURG AM, V65, P1302, DOI 10.2106/00004623-198365090-00012
   Kuklo TR, 2006, SPINE, V31, P1240, DOI 10.1097/01.brs.0000217774.13433.a7
   Kuklo TR, 2001, SPINE, V26, P1966, DOI 10.1097/00007632-200109150-00006
   Kuklo TR, 1976, SPINE, V27, P2013
   Lee CS, 2017, SPINE J, V17, P1033, DOI 10.1016/j.spinee.2017.03.020
   Lenke LG, 2003, SPINE, V28, pS199, DOI 10.1097/01.BRS.0000092216.16155.33
   Liljenqvist U, 2002, EUR SPINE J, V11, P336, DOI 10.1007/s00586-002-0415-9
   Luk KDK, 2008, SPINE, V33, P2192, DOI 10.1097/BRS.0b013e31817bd86a
   Matsumoto M, 2013, SPINE, V38, P737, DOI 10.1097/BRS.0b013e318279b666
   Namikawa T, 2015, SCOLIOSIS SPINAL DIS, V10, DOI 10.1186/1748-7161-10-S2-S18
   Ni HJ, 2011, J SPINAL DISORD TECH, V24, P437, DOI 10.1097/BSD.0b013e31820500c9
   Ritzman TF, 2008, SPINE, V33, P2643, DOI 10.1097/BRS.0b013e3181891806
   Rose PS, 2007, ORTHOP CLIN N AM, V38, P521, DOI 10.1016/j.ocl.2007.06.001
   Smyrnis PN, 2009, EUR SPINE J, V18, P522, DOI 10.1007/s00586-009-0902-3
   Studer D, 2015, J CHILD ORTHOP, V9, P153, DOI 10.1007/s11832-015-0653-0
   Suk SI, 2000, SPINE, V25, P2342, DOI 10.1097/00007632-200009150-00012
   Wang T, 2008, CHINESE MED J-PEKING, V121, P1456, DOI 10.1097/00029330-200808010-00022
   Wang Y, 2011, SPINE, V36, P1113, DOI 10.1097/BRS.0b013e3181f51e95
NR 31
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E175
EP E182
DI 10.1016/j.wneu.2019.01.032
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700023
PM 30684704
DA 2020-05-12
ER

PT J
AU Kilic, M
   Kilic, B
   Aydin, MD
   Kanat, A
   Yilmaz, I
   Eseoglu, M
   Gundogdu, B
AF Kilic, Mustafa
   Kilic, Betul
   Aydin, Mehmet Dumlu
   Kanat, Ayhan
   Yilmaz, Ilhan
   Eseoglu, Metehan
   Gundogdu, Betul
TI Paradoxic Relations between Basilar Artery Reconfiguration and Superior
   Cervical Ganglia Ischemia After Bilateral Common Carotid Artery Ligation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basilar artery vasodilatation; Common carotid artery ligation;
   Degenerated neuron density; Superior cervical ganglion
ID SPINAL SUBARACHNOID HEMORRHAGE; STELLATE GANGLION; CEREBRAL-ISCHEMIA;
   NODOSE GANGLION; NEURON DENSITY; VASOSPASM; SYMPATHECTOMY; DEGENERATION;
   VOLUME; MECHANISM
AB BACKGROUND: The relationship between superior cervical ganglia (SCG) ischemia due to bilateral common carotid artery ligation (BCCAL) and basilar artery (BA) reconfiguration was investigated.
   METHODS: Twenty-three rabbits were randomly divided into 3 groups: group III rabbits underwent BCCAL (n = 13), group II rabbits were sham-operated controls (n = 5), and group I rabbits did not undergo surgery (n = 5). Degenerated neuron densities (DND) within the SCG were correlated with the BA vasodilatation index (VDI).
   RESULTS: Mean live and DND in SCG of group I rabbits were 11.235 +/- 982/mu m(3) and 11 +/- 3/mu m(3), respectively, with a mean heart rate of 294 +/- 21 beats/min. Mean SCG DND and heart rates were 213 +/- 42/mu m(3) and 242 +/- 17 beats/min for the sham group (group II) rabbits and 1743 +/- 285/mu m(3) and 199 +/- 19 beats/min for the study group (group III) rabbits, respectively. The BA VDI values in the sham group (group II) (1.32 +/- 0.10) and the study group (group III) (0.976 +/- 0.112) significantly differed from those in the control group (group I) (1.65 +/- 0.12; P < 0.005) versus the sham group (group II) (P < 0.0001) versus the BCCAL applied group (group III) and between group II and group III (P < 0.005).
   CONCLUSIONS: A meaningful and paradoxic correlation was detected between the BA VDI values and degenerated neuron density of SCG after BCCAL. Although a low degenerated neuron density within SCG may provoke excessive sympathetic activity and prevent excessive BA dilatation with steno-occlusive carotid artery diseases, a high degenerated neuron density may cause dangerous vasodilatation of BA.
C1 [Kilic, Mustafa; Yilmaz, Ilhan] Sisli Hamidiye Etfal Educ & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Kilic, Betul] Kocaeli Derince Educ & Res Hosp, Dept Pediat Neurol, Kocaeli, Turkey.
   [Aydin, Mehmet Dumlu] Ataturk Univ, Med Fac, Dept Neurosurg, Erzurum, Turkey.
   [Kanat, Ayhan] Recep Tayyip Erdogan Univ, Med Fac, Dept Neurosurg, Rize, Turkey.
   [Eseoglu, Metehan] Medipol Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Gundogdu, Betul] Ataturk Univ, Med Fac, Dept Pathol, Erzurum, Turkey.
RP Aydin, MD (reprint author), Ataturk Univ, Med Fac, Dept Neurosurg, Erzurum, Turkey.
EM nmda11@hotmail.com
RI Kanat, Ayhan/N-2296-2015
OI Kanat, Ayhan/0000-0002-8189-2877
CR AMES A, 1968, AM J PATHOL, V52, P437
   Aydin MD, 2002, ACTA NEUROCHIR, V144, P369, DOI 10.1007/s007010200051
   Aydin MD, 2011, EXP NEUROL, V230, P90, DOI 10.1016/j.expneurol.2010.09.018
   Aydin MD, 2017, WORLD NEUROSURG, V106, P570, DOI 10.1016/j.wneu.2017.06.176
   Aydin MD, 2012, NEUROSURG QUART, V22, P1, DOI 10.1097/WNQ.0b013e3182011683
   Aygul R, 2013, ANAL QUANT CYTOL, V35, P217
   Bostan H, 2018, NORTH CLIN ISTANB, V5, P176, DOI [10.14744/nci.2017.28190, 10.14744/ncl.2017.28190]
   Bunc G, 2000, WIEN KLIN WOCHENSCHR, V112, P533
   Cheng LJ, 2016, CHINESE MED J-PEKING, V129, P549, DOI 10.4103/0366-6999.176991
   Eseoglu M, 2014, ACTA NEUROCHIR, V156, P963, DOI 10.1007/s00701-014-1994-z
   Falck B, 1968, SCAND J CLIN LAB I S, V102
   GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x
   HART MN, 1980, HYPERTENSION, V2, P419, DOI 10.1161/01.HYP.2.4.419
   Kacem K, 2006, AUTON NEUROSCI-BASIC, V124, P38, DOI 10.1016/j.autneu.2005.11.003
   Kanat A, 2003, NEUROSURGERY, V52, P1508, DOI 10.1227/01.NEU.0000068349.22859.C6
   Kanat A, 2011, NEUROL NEUROCHIR POL, V45, P63
   Kanat A, 2010, ACTA NEUROCHIR, V152, P2167, DOI 10.1007/s00701-010-0793-4
   Kaur G, 2007, BRAIN RES, V1139, P6, DOI 10.1016/j.brainres.2006.12.084
   Kayaci S, 2011, AUTON NEUROSCI-BASIC, V165, P163, DOI 10.1016/j.autneu.2011.06.008
   Kilic M, 2018, WORLD NEUROSURG, V119, pE1029, DOI 10.1016/j.wneu.2018.08.054
   Kovacic S, 2006, AUTON NEUROSCI-BASIC, V130, P28, DOI 10.1016/j.autneu.2006.05.002
   Metaxa E, 2010, STROKE, V41, P1774, DOI 10.1161/STROKEAHA.110.585992
   OLDENDORF WH, 1989, J NEUROPATH EXP NEUR, V48, P534, DOI 10.1097/00005072-198909000-00004
   Onen MR, 2016, WORLD NEUROSURG, V92, P463, DOI 10.1016/j.wneu.2016.04.067
   Ozdemir NG, 2017, TURK NEUROSURG, V27, P874, DOI 10.5137/1019-5149.JTN.17206-16.2
   Ozturk C, 2018, J NEUROL SURG PART A, V79, P302, DOI 10.1055/s-0037-1608841
   SADOSHIMA S, 1983, STROKE, V14, P575, DOI 10.1161/01.STR.14.4.575
   Faleiros ATD, 2006, ARQ NEURO-PSIQUIAT, V64, P572, DOI 10.1590/S0004-282X2006000400006
   Yilmaz I, 2017, WORLD NEUROSURG, V100, P138, DOI 10.1016/j.wneu.2016.12.034
   Yolas C, 2016, WORLD NEUROSURG, V89, P208, DOI 10.1016/j.wneu.2016.01.082
   Yolas C, 2016, WORLD NEUROSURG, V86, P79, DOI 10.1016/j.wneu.2015.09.004
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E658
EP E664
DI 10.1016/j.wneu.2019.01.144
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700082
PM 30716499
DA 2020-05-12
ER

PT J
AU Kim, M
   Lee, HS
   Lee, S
   Park, JC
   Ahn, JS
   Kwon, DH
   Kwun, BD
   Park, W
AF Kim, Moinay
   Lee, Heui Seung
   Lee, Seungjoo
   Park, Jung Cheol
   Ahn, Jae Sung
   Kwon, Do Hoon
   Kwun, Byung Duk
   Park, Wonhyoung
TI Pediatric Intracranial Aneurysms: Favorable Outcomes Despite Rareness
   and Complexity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent; Aneurysm; Child; Endovascular treatment; Intracranial
   aneurysm; Pediatric; Surgery
ID MIDDLE CEREBRAL-ARTERY; SUBARACHNOID HEMORRHAGE; NATURAL-HISTORY;
   ENDOVASCULAR TREATMENT; CLINICAL-FEATURES; COIL EMBOLIZATION; CASE
   SERIES; CHILDREN; MANAGEMENT; CHILDHOOD
AB OBJECTIVE: Pediatric intracranial aneurysms (IAs) are rare and differ from their adult counterparts in terms of their aneurysmal characteristics, presentation, treatment, and outcomes. Their treatment is often more difficult and complex compared with that of adults. However, studies outlining the clinical effect of pediatric IAs remain sparse.
   METHODS: We retrospectively reviewed the data from patients aged <= 18 years admitted to our hospital from 2000 to 2017 with a diagnosis of IAs.
   RESULTS: From the sample of 8207 patients with an IA diagnosis, 26 patients with 33 IAs were involved. Our cohort included 17 males and 9 females, with a mean age of 12.5 years. The mean follow-up duration was 4 years and 3 months. Seven patients (26.92%) were assumed to have a traumatic origin for their IAs. Ruptured aneurysms were more common than unruptured ones (61.53% vs. 38.46%). Complex features were observed in 14 aneurysms (42.42%). Initially, microsurgical and endovascular treatment were both performed in 10 patients (38.46%). A good recovery was obtained in 16 patients (61.54%) as determined by the Glasgow outcome scale scores at the 6-month follow-up visits. The complete obliteration of aneurysms was observed in 17 patients (65.38%). Endovascular treatment was the initial treatment in 3 patients with incomplete obliteration.
   CONCLUSIONS: The treatment of pediatric IAs is challenging and technically demanding owing to their discrete nature compared with adult IAs and the need for greater surgical skills. We found a male predominance, with internal carotid artery bifurcation as the most frequent location of the aneurysms. Despite the greater incidence of ruptured and complex aneurysm cases, many patients had experienced a good recovery at the 6-month follow-up examinations.
C1 [Kim, Moinay; Lee, Heui Seung; Lee, Seungjoo; Park, Jung Cheol; Ahn, Jae Sung; Kwon, Do Hoon; Park, Wonhyoung] Univ Ulsan, Coll Med, Dept Neurosurg, Asan Med Ctr, Seoul, South Korea.
   [Kwun, Byung Duk] Kyung Hee Univ, Sch Med, Dept Neurosurg, Seoul, South Korea.
RP Park, W (reprint author), Univ Ulsan, Coll Med, Dept Neurosurg, Asan Med Ctr, Seoul, South Korea.
EM elevenes@gmail.com
OI Park, Jung Cheol/0000-0001-6677-455X
CR Aeron G, 2012, RADIOGRAPHICS, V32, P667, DOI 10.1148/rg.323105224
   Agid R, 2005, CHILD NERV SYST, V21, P1030, DOI 10.1007/s00381-005-1152-2
   Agid R, 2007, NEUROIMAG CLIN N AM, V17, P153, DOI 10.1016/j.nic.2007.02.001
   Agid R, 2007, J NEUROSURG, V106, P328, DOI 10.3171/ped.2007.106.4.328
   Allison JW, 1998, PEDIATR RADIOL, V28, P223, DOI 10.1007/s002470050336
   Aryan HE, 2006, J CLIN NEUROSCI, V13, P188, DOI 10.1016/j.jocn.2005.07.006
   Barburoglu M, 2017, AM J NEURORADIOL, V38, P113, DOI 10.3174/ajnr.A4959
   Beez T, 2016, J CHILD NEUROL, V31, P773, DOI 10.1177/0883073815609153
   Biagi L, 2007, J MAGN RESON IMAGING, V25, P696, DOI 10.1002/jmri.20839
   Buis DR, 2006, CHILD NERV SYST, V22, P1395, DOI 10.1007/s00381-006-0142-3
   Burrows AM, 2013, J NEUROINTERV SURG, V5, pE47, DOI 10.1136/neurintsurg-2012-010478.rep
   Byoun HS, 2016, J KOREAN NEUROSURG S, V59, P11, DOI [10.3340/jkns.2016.59.1.11, 10.3340/jkns.2015.59.1.11]
   Cobb MIPH, 2017, CHILD NERV SYST, V33, P685, DOI 10.1007/s00381-016-3311-z
   Dashti R, 2007, SURG NEUROL, V67, P441, DOI 10.1016/j.surneu.2006.11.056
   deBray JM, 1997, J NEUROL NEUROSUR PS, V63, P46, DOI 10.1136/jnnp.63.1.46
   Delgado Almandoz JE, 2013, BMJ CASE REP, V2013
   Ducruet AF, 2010, NEUROSURG REV, V33, P37, DOI 10.1007/s10143-009-0233-1
   Etminan N, 2013, STROKE, V44, P799, DOI 10.1161/STROKEAHA.112.673806
   Ezerioha N, 2015, CASE REP NEUROL, V7, P152, DOI 10.1159/000437256
   Fulkerson DH, 2011, J NEUROSURG-PEDIATR, V8, P79, DOI 10.3171/2011.4.PEDS10583
   Garg K, 2014, CHILD NERV SYST, V30, P873, DOI 10.1007/s00381-013-2336-9
   Gemmete JJ, 2013, NEUROIMAG CLIN N AM, V23, P771, DOI 10.1016/j.nic.2013.03.018
   Ghali MGZ, 2018, WORLD NEUROSURG, V111, pE287, DOI [10.1016/J.WNEU.2017.12.057, 10.1016/j.wneu.2017.12.057]
   Handa J, 1976, Surg Neurol, V6, P25
   Hasegawa H, 2011, CHILD NERV SYST, V27, P1011, DOI 10.1007/s00381-010-1384-7
   Hayashi S, 2014, NEUROL MED-CHIR, V54, P150, DOI 10.2176/nmc.cr2012-0399
   HERMAN JM, 1992, PEDIATR NEUROSURG, V17, P66
   Hetts SW, 2011, AM J NEURORADIOL, V32, P2017, DOI 10.3174/ajnr.A2680
   Hetts SW, 2009, AM J NEURORADIOL, V30, P1315, DOI 10.3174/ajnr.A1587
   Honda M, 2008, PEDIATR NEUROSURG, V44, P426, DOI 10.1159/000149914
   Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660
   Huang J, 2005, SURG NEUROL, V63, P424, DOI 10.1016/j.surneu.2004.11.023
   Javalkar V, 2009, NEUROL INDIA, V57, P772, DOI 10.4103/0028-3886.59475
   JENNETT B, 1975, LANCET, V1, P480
   Jordan Lori C, 2008, Curr Treat Options Neurol, V10, P399, DOI 10.1007/s11940-008-0042-9
   Julien JS, 2008, NEUROSURGERY, V63, P204, DOI 10.1227/01.NEU.0000316857.80632.9A
   Kan P, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011718.rep
   KANAAN I, 1995, MINIM INVAS NEUROSUR, V38, P1, DOI 10.1055/s-2008-1053453
   Kannoth S, 2009, NEUROCRIT CARE, V11, P120, DOI 10.1007/s12028-009-9208-x
   Kasahara E, 1996, ACTA PAEDIATR JAPON, V38, P684
   Khurana VG, 2005, J NEUROSURG, V102, P526, DOI 10.3171/jns.2005.102.3.0526
   KITANAKA C, 1994, NEUROSURGERY, V34, P620, DOI 10.1227/00006123-199404000-00008
   Koroknay-Pal P, 2012, J NEUROSURG-PEDIATR, V9, P636, DOI 10.3171/2012.2.PEDS11491
   Krings T, 2005, NEURORADIOLOGY, V47, P931, DOI 10.1007/s00234-005-1438-9
   Krings T, 2008, INTERV NEURORADIOL, V14, P39, DOI 10.1177/15910199080140S107
   Krings T, 2010, CHILD NERV SYST, V26, P1309, DOI 10.1007/s00381-009-1054-9
   Krishna H, 2005, ACTA NEUROCHIR, V147, P469, DOI 10.1007/s00701-005-0481-y
   Larson P S, 2000, Neurosurg Focus, V8, pe4
   Lasjaunias P, 2005, CHILD NERV SYST, V21, P437, DOI 10.1007/s00381-004-1125-x
   Lasjaunias P L, 1997, Interv Neuroradiol, V3, P215
   Lasjaunias PL, 2000, INTERV NEURORADIOL, V6, P113, DOI 10.1177/159101990000600205
   Lee VH, 2007, ARCH NEUROL-CHICAGO, V64, P1115, DOI 10.1001/archneur.64.8.1115
   Liang JT, 2009, CHILD NERV SYST, V25, P317, DOI 10.1007/s00381-008-0725-2
   Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625
   Liu P, 2016, WORLD NEUROSURG, V94, P513, DOI 10.1016/j.wneu.2016.05.039
   LOCKSLEY HB, 1966, J NEUROSURG, V25, P321, DOI 10.3171/jns.1966.25.3.0321
   LOCKSLEY HB, 1966, J NEUROSURG, V25, P219, DOI 10.3171/jns.1966.25.2.0219
   Matheus MG, 2003, AM J NEURORADIOL, V24, P709
   Mehrotra A, 2012, J NEUROSURG-PEDIATR, V10, P340, DOI 10.3171/2012.7.PEDS11455
   Mehta RI, 2010, RADIOGRAPHICS, V30, P1133, DOI 10.1148/rg.304095199
   MEYER FB, 1989, J NEUROSURG, V70, P420, DOI 10.3171/jns.1989.70.3.0420
   Mizutani T, 2011, J NEUROSURG, V114, P1037, DOI 10.3171/2010.9.JNS10668
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Molyneux Andrew, 2002, J Stroke Cerebrovasc Dis, V11, P304, DOI 10.1053/jscd.2002.130390
   NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006
   Oh MC, 2012, J NEUROSURG, V116, P942, DOI 10.3171/2011.12.JNS11875
   OSTERGAARD JR, 1991, BRIT J NEUROSURG, V5, P575, DOI 10.3109/02688699109002879
   Park Hun-Soo, 2014, Surg Neurol Int, V5, pS143, DOI 10.4103/2152-7806.134807
   Park W, 2017, WORLD NEUROSURG, V97, P351, DOI 10.1016/j.wneu.2016.09.119
   PATEL AN, 1971, J NEUROSURG, V35, P571, DOI 10.3171/jns.1971.35.5.0571
   POPE FM, 1991, BRIT J NEUROSURG, V5, P551, DOI 10.3109/02688699109002878
   Proust F, 2001, J NEUROSURG, V94, P733, DOI 10.3171/jns.2001.94.5.0733
   Provenzale JM, 1996, J COMPUT ASSIST TOMO, V20, P185, DOI 10.1097/00004728-199603000-00004
   Rao VY, 2013, CHILD NERV SYST, V29, P685, DOI 10.1007/s00381-012-1924-4
   Rizzi M, 2012, PEDIATR NEUROSURG, V48, P313, DOI 10.1159/000351578
   Ronkainen A, 1998, STROKE, V29, P359, DOI 10.1161/01.STR.29.2.359
   Sanai N, 2006, J NEUROSURG, V104, P82, DOI 10.3171/ped.2006.104.2.82
   Sanai N, 2010, CHILD NERV SYST, V26, P1319, DOI 10.1007/s00381-010-1210-2
   Saraf R, 2012, J NEUROSURG-PEDIATR, V10, P230, DOI 10.3171/2012.5.PEDS1210
   Savastano LE, 2014, J NEUROSURG-PEDIATR, V14, P550, DOI 10.3171/2014.7.PEDS1449
   SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426
   Schievink WI, 2001, NEW ENGL J MED, V344, P898, DOI 10.1056/NEJM200103223441206
   SCHRAMM J, 1993, SURG NEUROL, V40, P26, DOI 10.1016/0090-3019(93)90165-W
   Sedat J, 1999, INTERV NEURORADIOL, V5, P151, DOI 10.1177/159101999900500207
   Sharma BS, 2007, CHILD NERV SYST, V23, P327, DOI 10.1007/s00381-006-0253-x
   Shin SH, 2013, INTERV NEURORADIOL, V19, P222, DOI 10.1177/159101991301900212
   St Julien J, 2008, NEUROSURGERY, V63, P201
   St Julien J, 2008, NEUROSURGERY, V63, P210
   STEHBENS WE, 1963, ARCH PATHOL, V75, P45
   STOANE L, 1966, RADIOLOGY, V87, P262, DOI 10.1148/87.2.262
   Sun Jian-jun, 2004, Beijing Da Xue Xue Bao Yi Xue Ban, V36, P272
   Sveinsson O, 2015, BMJ CASE REP, V2015
   TAIRA T, 1991, SURG NEUROL, V36, P303, DOI 10.1016/0090-3019(91)90093-O
   Tanaka S, 2007, CHILD NERV SYST, V23, P701, DOI 10.1007/s00381-006-0263-8
   Vachhani JA, 2016, WORLD NEUROSURG, V96, DOI 10.1016/j.wneu.2016.09.078
   van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6
   van Rooij WJ, 2009, AM J NEURORADIOL, V30, P12, DOI 10.3174/ajnr.A1267
   VENTUREYRA ECG, 1994, CHILD NERV SYST, V10, P361, DOI 10.1007/BF00335125
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Yamaura Akira, 1994, Contemporary Neurosurgery, V16, P1
   Yoshimoto Y, 1997, STROKE, V28, P370, DOI 10.1161/01.STR.28.2.370
   1994, NEUROSURGERY, V34, P620
   2017, J NEUROL SCI, V372, P250, DOI DOI 10.1016/J.JNS.2016.11.057
   2009, AM J NEURORADIOL, V30, P303, DOI DOI 10.3174/AJNR.A1353
   2018, NEUROSURGERY, V82, P815, DOI DOI 10.1093/NEUROS/NYX305
   2005, SURG NEUROL, V63, P424, DOI DOI 10.1016/J.SURNEU.2004.11.023
NR 107
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1203
EP E1216
DI 10.1016/j.wneu.2019.01.280
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700150
PM 30794975
DA 2020-05-12
ER

PT J
AU Kim, SU
   Sung, JH
   Lee, DH
   Yi, HJ
   Lee, HJ
   Yang, JH
   Lee, IW
AF Kim, Sang Uk
   Sung, Jae Hoon
   Lee, Dong Hoon
   Yi, Ho Jun
   Lee, Hyung-Jin
   Yang, Ji-Ho
   Lee, Il-Woo
TI Feasibility of Using Neck Extension to Overcome a Difficult Aortic Arch
   and Gain Access to the Carotid Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiography; Aortic arch; Catheter; Neck motion
ID CEREBRAL-ANGIOGRAPHY; ANATOMIC FACTORS; GUIDE CATHETER; ANGIOPLASTY;
   IMPACT; AGE
AB OBJECTIVE: The purpose of this study was to investigate neck movement and various conditions of the aortic arch that may hinder access to the carotid artery during neurointerventional procedures.
   METHODS: We reviewed 230 patients who underwent internal carotid artery angiography between February 2016 and October 2016. Use of a Davis catheter (DC) was first attempted and if not possible, movement (right, left, flexion, and extension) of the patient's head was tried before catheter exchange. We analyzed the success rate after neck motion in relation to various aortic arch factors.
   RESULTS: Only extension of the patient's neck was effective. Of the 209 patients with right side angiography, 23 had failed access with a DC, but neck extension was effective in 3 patients (13%). Failure to insert a DC was significantly correlated with age, male sex, acute angle, arch elongation, aortic calcification, and carotid artery angulation on the right side, whereas access was not gained in 24 out of 208 patients who underwent left side angiography, and neck extension was successful in 7 patients (29.2%). Also, significant factors determining the catheter exchangewere age, male sex, acute angle, arch elongation, and aortic calcification. In the DC access failure group, neck extension was significantly more effective for younger aged patients (P = 0.011).
   CONCLUSIONS: Factors such as older age, acute arch angle, higher elongation type, arch calcification, and carotid artery angulation were verified as factors affecting access by a simple catheter; however, neck extension was shown to facilitate access in about 10%-30% of patents.
C1 [Kim, Sang Uk; Lee, Hyung-Jin; Yang, Ji-Ho; Lee, Il-Woo] Catholic Univ Korea, Coll Med, Daejeon St Marys Hosp, Dept Neurosurg, Daejeon, South Korea.
   [Sung, Jae Hoon; Lee, Dong Hoon; Yi, Ho Jun] Catholic Univ Korea, Coll Med, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea.
RP Sung, JH (reprint author), Catholic Univ Korea, Coll Med, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea.
EM jaehoonsung@gmail.com
OI Lee, Dong Hoon/0000-0002-3796-8707; Sung, Jae Hoon/0000-0003-3738-6413
CR Adriaans BP, 2018, HEART, V104, P1772, DOI 10.1136/heartjnl-2017-312866
   Burzotta F, 2015, CATHETER CARDIO INTE, V86, P480, DOI 10.1002/ccd.25947
   Chang FC, 2009, J NEUROSURG, V110, P437, DOI 10.3171/2008.7.17627
   Choudhry FA, 2016, J NEUROINTERV SURG, V8, P536, DOI 10.1136/neurintsurg-2015-011671
   Daniel GK, 2006, CATHETER CARDIO INTE, V68, P803, DOI 10.1002/ccd.20888
   Eckard DA, 2003, AM J NEURORADIOL, V24, P275
   Fang HY, 2010, ANN VASC SURG, V24, P670, DOI 10.1016/j.avsg.2009.12.001
   Lam RC, 2007, J VASC SURG, V45, P875, DOI 10.1016/j.jvs.2006.12.059
   Lee TH, 2005, AM J NEURORADIOL, V26, P1375
   Lin SC, 2005, ANN VASC SURG, V19, P798, DOI 10.1007/s10016-005-8045-4
   Marinkovic S, 2017, FOLIA MORPHOL, V76, P100, DOI 10.5603/FM.a2016.0037
   Matsumoto Y, 2001, AM J NEURORADIOL, V22, P704
   Mokin M, 2015, J NEUROINTERV SURG, V7, P108, DOI 10.1136/neurintsurg-2013-011007
   Osborn AG, 1999, DIAGNOSTIC CEREBRAL
   Peeling L, 2014, J NEUROINTERV SURG, V6, P129, DOI 10.1136/neurintsurg-2013-010655
   Ruzsa Z, 2014, EUROINTERVENTION, V10, P381, DOI 10.4244/EIJV10I3A64
   Sekikawa A, 2012, ATHEROSCLEROSIS, V222, P473, DOI 10.1016/j.atherosclerosis.2012.03.027
   Setacci C, 2006, J ENDOVASC THER, V13, P302, DOI 10.1583/06-1836.1
   Sievert H, 1996, CATHETER CARDIO DIAG, V39, P421
   SIMMONS CR, 1973, AM J ROENTGENOL, V119, P605, DOI 10.2214/ajr.119.3.605
   Takata M, 2017, WORLD NEUROSURG, V105, P529, DOI 10.1016/j.wneu.2017.06.023
   WELLS TR, 1993, PEDIATR PATHOL, V13, P203, DOI 10.3109/15513819309048207
   White JB, 2008, NEURORADIOLOGY, V50, P185, DOI 10.1007/s00234-007-0313-2
   Wholey MH, 1998, CATHETER CARDIO DIAG, V44, P1
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E110
EP E116
DI 10.1016/j.wneu.2018.12.216
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700016
PM 30677582
DA 2020-05-12
ER

PT J
AU Kim, T
   Kwon, OK
   Ban, SP
   Kim, YD
   Won, YD
AF Kim, Tackeun
   Kwon, O-Ki
   Ban, Seung Pil
   Kim, Young Deok
   Won, Yu Deok
TI A Phantom Menace to Medical Personnel During Endovascular Treatment of
   Cerebral Aneurysms: Real-Time Measurement of Radiation Exposure During
   Procedures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Endovascular; Exposure; Medical staff; Radiation
ID PATIENT; INTERVENTIONS; REDUCTION; OPERATOR; STAFF; IR
AB BACKGROUND: The number of endovascular treatment procedures performed for cerebral aneurysms has markedly increased. However, little is known about the annual effective radiation dose to medical staff in neuro-intervention fields. We performed a retrospective observational study to investigate the real-time radiation dose to surgeons, nurses, anesthesiologists, and radiologic technologists during endovascular treatment of intracranial aneurysms.
   METHODS: We measured the real-time radiation doses for 2 weeks using standard and reinforced protection, during which 28 procedures were performed, including 23 coil embolizations for unruptured intracranial aneurysms. Four procedures were excluded because of an inadequately equipped sensor, which resulted in inappropriate data collection. The procedure time was defined from intubation to extubation. Five RaySafe i2 detectors were installed at the chest level of the operator, attending nurse, radiologic technologist, and anesthesiologist and just inside the front door of the hybrid operating room.
   RESULTS: The median doses per session with standard protection to the operator, attending nurse, anesthesiologist, and radiologic technologist were 11.16, 2.60, 4.76, and 1.93 mu Sv, respectively. The dose to the operator, attending nurse, and anesthesiologist had decreased to 6.63, 0.39, and 1.52 mu Sv under reinforced protection, respectively. However, the session dose for the radiologic technologist had increased to 3.12 mu Sv.
   CONCLUSIONS: We confirmed the differences in the amount of radiation exposure for different roles. An additional lead screen, which provided more effective protection on the operator side, was proved effective for attenuating radiation exposure during endovascular treatment. All personnel involved in the hybrid operating room were exposed to acceptable effective doses.
C1 [Kim, Tackeun; Kwon, O-Ki; Ban, Seung Pil; Kim, Young Deok; Won, Yu Deok] Seoul Natl Univ, Bundang Hosp, Dept Neurosurg, Seongnam, South Korea.
   [Kim, Tackeun; Kwon, O-Ki; Ban, Seung Pil; Kim, Young Deok; Won, Yu Deok] Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.
RP Kwon, OK (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Neurosurg, Seongnam, South Korea.; Kwon, OK (reprint author), Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.
EM kwonoki@snu.ac.kr
RI Kim, Tackeun/G-8079-2012
OI Kim, Tackeun/0000-0002-4375-8095; Won, Yu Deok/0000-0002-8822-6631
CR [Anonymous], 2007, Ann ICRP, V37, P1, DOI 10.1016/j.icrp.2008.08.001
   Bartal G, 2014, CARDIOVASC INTER RAD, V37, P289, DOI 10.1007/s00270-013-0685-0
   Chida K, 2013, AM J ROENTGENOL, V200, P138, DOI 10.2214/AJR.11.8455
   Guercio JR, 2015, INT ANESTHESIOL CLIN, V53, P87, DOI 10.1097/AIA.0000000000000044
   Heilmaier C, 2016, J VASC INTERV RADIOL, V27, P584, DOI 10.1016/j.jvir.2015.11.033
   Kim T, 2016, INT J STROKE, V11, P917, DOI 10.1177/1747493016660096
   Kim YD, 2018, J NEUROINTERV SURG, V10, P1218, DOI 10.1136/neurintsurg-2018-013757
   Komemushi A, 2014, J VASC INTERV RADIOL, V25, P1195, DOI 10.1016/j.jvir.2014.03.021
   Kuon E, 2002, AM J CARDIOL, V89, P44, DOI 10.1016/S0002-9149(01)02161-0
   Miller DL, 2003, J VASC INTERV RADIOL, V14, P711, DOI 10.1097/01.RVI.0000079980.80153.4B
   National Council on Radiation Protection and Measurements, 1995, 122 NCRP
   Sonig A, 2018, AM J NEURORADIOL, V39, P734, DOI 10.3174/ajnr.A5552
   Strauss KJ, 2006, RADIOLOGY, V240, P621, DOI 10.1148/radiol.2403060698
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E289
EP E296
DI 10.1016/j.wneu.2019.01.063
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700037
PM 30685367
DA 2020-05-12
ER

PT J
AU Konakondla, S
   Albers, JA
   Li, X
   Barber, SM
   Nakhla, J
   Houghton, CE
   Telfeian, AE
   Oyelese, AA
   Fridley, JS
   Gokaslan, ZL
AF Konakondla, Sanjay
   Albers, J. Andrew
   Li, Xun
   Barber, Sean M.
   Nakhla, Jonathan
   Houghton, Caitlin E.
   Telfeian, Albert E.
   Oyelese, Adetokunbo A.
   Fridley, Jared S.
   Gokaslan, Ziya L.
TI Maximizing Sacral Chordoma Resection by Precise 3-Dimensional Tumor
   Modeling in the Operating Room Using Intraoperative Computed Tomography
   Registration with Preoperative Magnetic Resonance Imaging Fusion and
   Intraoperative Neuronavigation: A Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraoperative neuronavigation; MRI-CT fusion; Sacral chordoma
ID MOBILE SPINE; CONDITIONAL SURVIVAL; FUNCTIONAL OUTCOMES;
   PROGNOSTIC-FACTORS; SURGICAL-TREATMENT; THERAPY
AB INTRODUCTION: The primary treatment for patients with sacral chordoma is en bloc surgical resection with negative margins, which has been shown to reduce local recurrence and tumor-related morbidity. Here we describe the use of intraoperative neuronavigation using preoperative spine magnetic resonance imaging fused to intraoperative computed tomography (CT) to create 3-dimensional tumor reconstructions in the operating room for intraoperative identification of bone and soft-tissue margins for maximal safe tumor resection.
   METHODS: A single-institution retrospective chart review was completed to encompass our experience of 6 consecutive patients who had sacral chordoma resections using our described navigation protocol. We collected data on patient demographics, previous surgeries, radiation therapy, preoperative examination, spinal levels involved, dural involvement, estimated blood loss, surgery time, tissue diagnosis, follow-up, postoperative examination, complications, and recurrence. Primary outcome was en bloc resection with negative margins as planned preoperatively.
   RESULTS: Negative surgical margins were achieved in 5 of 5 patients, who were preoperatively planned for en bloc resection with negative margins. The most common levels involved were S4-S5. All patients had a stable or improved neurologic examination after en bloc surgical resection. The average follow-up was 5.4 months +/- 84.6 days. No patient had residual or recurrent tumor at last follow-up.
   CONCLUSIONS: Magnetic resonance imaging-CT fusion and 3-dimensional reconstruction techniques using an intraoperative CT scanner with image-guided navigation to aid preoperative planning and surgical resection of sacral chordomas are not well represented in the literature. This technique can be used for planning en bloc surgical resections and for more precisely identifying tumor margins intraoperatively.
C1 [Konakondla, Sanjay; Li, Xun; Barber, Sean M.; Nakhla, Jonathan; Telfeian, Albert E.; Oyelese, Adetokunbo A.; Fridley, Jared S.; Gokaslan, Ziya L.] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Providence, RI 02903 USA.
   [Albers, J. Andrew] St Louis Univ, Sch Med, St Louis, MO USA.
   [Houghton, Caitlin E.] Brainlab Inc, Westchester, IL USA.
RP Gokaslan, ZL (reprint author), Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Providence, RI 02903 USA.
EM ziya_gokaslan@brown.edu
CR Bakker SH, 2018, EUR SPINE J, V27, P3043, DOI 10.1007/s00586-018-5764-0
   Bergh P, 2000, CANCER-AM CANCER SOC, V88, P2122, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2122::AID-CNCR19>3.0.CO;2-1
   Boriani S, 2006, SPINE, V31, P493, DOI 10.1097/01.brs.0000200038.30869.27
   Chen KW, 2010, SPINAL CORD, V48, P166, DOI 10.1038/sc.2009.95
   Fourney DR, 2005, J NEUROSURG-SPINE, V3, P111, DOI 10.3171/spi.2005.3.2.0111
   Gokaslan ZL, 2016, J NEUROSURG-SPINE, V24, P644, DOI 10.3171/2015.7.SPINE15201
   Hanna SA, 2008, CLIN ORTHOP RELAT R, V466, P2217, DOI 10.1007/s11999-008-0356-7
   Imai R, 2016, INT J RADIAT ONCOL, V95, P322, DOI 10.1016/j.ijrobp.2016.02.012
   Ji T, 2017, CLIN ORTHOP RELAT R, V475, P620, DOI 10.1007/s11999-016-4773-8
   McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735
   Mima M, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130512
   Moran D, 2015, SPINE J, V15, P222, DOI 10.1016/j.spinee.2014.08.445
   Mukherjee D, 2013, EUR SPINE J, V22, P1375, DOI 10.1007/s00586-012-2621-4
   Pillai S, 2018, J ORTHOP, V15, P679, DOI 10.1016/j.jor.2018.04.001
   Schwab JH, 2017, CLIN ORTHOP RELAT R, V475, P631, DOI 10.1007/s11999-016-4871-7
   Srivastava A, 2013, J RADIAT RES, V54, P43, DOI 10.1093/jrr/rrt057
   Yang YK, 2016, CHINESE MED J-PEKING, V129, P162, DOI 10.4103/0366-6999.173465
   2002, J NEUROSURG S, V97, P98
NR 18
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1125
EP E1131
DI 10.1016/j.wneu.2019.01.257
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700140
PM 30790740
DA 2020-05-12
ER

PT J
AU Kondo, H
   Kiura, Y
   Sakamoto, S
   Okazaki, T
   Yamasaki, F
   Iida, K
   Tominaga, A
   Kurisu, K
AF Kondo, Hiroshi
   Kiura, Yoshihiro
   Sakamoto, Shigeyuki
   Okazaki, Takahito
   Yamasaki, Fumiyuki
   Iida, Koji
   Tominaga, Atsushi
   Kurisu, Kaoru
TI Comparative Evaluation of Angioscopy and Intravascular Ultrasound for
   Assessing Plaque Protrusion During Carotid Artery Stenting Procedures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioscopy; Carotid artery stenting; Plaque protrusion
ID OPTICAL COHERENCE TOMOGRAPHY; HIGH-RISK; CORONARY ANGIOSCOPY;
   BRAIN-LESIONS; ENDARTERECTOMY; ANGIOPLASTY
AB BACKGROUND: Evaluation of plaque protrusion after carotid artery stenting (CAS) is important for predicting periprocedural ischemic complications. In contrast to intravascular ultrasound (IVUS), angioscopy allows direct visualization of the plaque. The aim of this study was to evaluate utility and safety of angioscopy during CAS and compare it with IVUS.
   METHODS: The study included 13 carotid artery stenosis lesions in 11 consecutive patients (mean age 70.5 years; 10 men) at a single center. During CAS procedure, poststenting plaque protrusion was evaluated with angioscopy and IVUS.
   RESULTS: Mean level of internal carotid artery stenosis was 79.2%. Eight lesions were symptomatic, and 5 lesions were predicted to have vulnerable plaque by preprocedural magnetic resonance imaging. A carotid WALLSTENT was placed in all cases. After stenting, angioscopy provided good visualization in all cases. Plaque protrusions were observed in 1 case by IVUS and in 8 cases by angioscopy. Diffusion-weighted imaging showed positive lesions in 3 cases (23%). For 2 of these lesions, plaque protrusions were observed by angioscopy but not by IVUS. All lesions associated with positive diffusion-weighted imaging findings were observed to have yellow plaque on angioscopy.
   CONCLUSIONS: Angioscopy provided direct visualization of stent lumens after CAS. Angioscopy detected more plaque protrusion than IVUS and allowed clearer observation of plaque characteristics. Angioscopy may be more useful than IVUS for examination of plaque protrusion and plaque evaluation after CAS, especially for plaque identified as potentially vulnerable by preprocedural examination.
C1 [Kondo, Hiroshi; Kiura, Yoshihiro; Tominaga, Atsushi] Hiroshima Prefectural Hosp, Dept Neurosurg & Neuroendovasc Therapy, Hiroshima, Japan.
   [Kondo, Hiroshi; Kiura, Yoshihiro; Sakamoto, Shigeyuki; Okazaki, Takahito; Yamasaki, Fumiyuki; Iida, Koji; Tominaga, Atsushi; Kurisu, Kaoru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
RP Kondo, H (reprint author), Hiroshima Prefectural Hosp, Dept Neurosurg & Neuroendovasc Therapy, Hiroshima, Japan.; Kondo, H (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
EM springhascome0224@gmail.com
OI Kondo, Hiroshi/0000-0003-3981-3052; Sakamoto,
   Shigeyuki/0000-0003-3683-4771
CR Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   de Donato G, 2013, EUR J VASC ENDOVASC, V45, P579, DOI 10.1016/j.ejvs.2013.03.005
   Hitchner E, 2014, J VASC SURG, V59, P774, DOI 10.1016/j.jvs.2013.09.028
   Kastrup A, 2006, STROKE, V37, P2312, DOI 10.1161/01.STR.0000236492.86303.85
   Kobayashi E, 2000, INTERV NEURORADIOL, V6, P165, DOI 10.1177/15910199000060S125
   Kondo H, 2017, J NEUROENDOVASCULAR, V11, P547
   Kotsugi M, 2017, JACC-CARDIOVASC INTE, V10, P824, DOI 10.1016/j.jcin.2017.01.029
   Koyanagi M, 2012, J NEUROENDOVASCULAR, V6, P240
   Kubo T, 2008, JACC-CARDIOVASC INTE, V1, P74, DOI 10.1016/j.jcin.2007.11.001
   Matsuo K, 2013, EUROINTERVENTION, V9, P235, DOI 10.4244/EIJV9I2A39
   McDonnell CO, 2006, EUR J VASC ENDOVASC, V32, P46, DOI 10.1016/j.ejvs.2005.12.026
   MIZUNO K, 1989, J AM COLL CARDIOL, V13, P363, DOI 10.1016/0735-1097(89)90513-5
   Pinero P, 2006, AM J NEURORADIOL, V27, P1338
   Sakamoto S, 2015, ACTA NEUROCHIR, V157, P371, DOI 10.1007/s00701-014-2311-6
   Satouh K, 2015, SURG CEREB STROKE JP, V43, P347
   Schnaudigel S, 2008, STROKE, V39, P1911, DOI 10.1161/STROKEAHA.107.500603
   Shinozaki N, 2014, J STROKE CEREBROVASC, V23, P2622, DOI 10.1016/j.jstrokecerebrovasdis.2014.06.007
   SIEGEL RJ, 1991, CIRCULATION, V84, P109, DOI 10.1161/01.CIR.84.1.109
   SPEARS JR, 1983, J AM COLL CARDIOL, V1, P1311, DOI 10.1016/S0735-1097(83)80145-4
   Tanemura H, 2005, AM J NEURORADIOL, V26, P1943
   Tanemura H, 2013, STROKE, V44, P105, DOI 10.1161/STROKEAHA.112.663138
   UCHIDA Y, 1987, AM HEART J, V114, P1216, DOI 10.1016/0002-8703(87)90199-2
   Uchida Y, 2011, J CARDIOL, V57, P18, DOI 10.1016/j.jjcc.2010.11.001
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
   Yamada K, 2011, ATHEROSCLEROSIS, V215, P399, DOI 10.1016/j.atherosclerosis.2011.01.002
   Yoshimura S, 2013, OPTICAL COHERENCE TO
   Yoshimura S, 2011, STROKE, V42, P3132, DOI 10.1161/STROKEAHA.111.615708
   Yoshimura S, 2011, JACC-CARDIOVASC IMAG, V4, P432, DOI 10.1016/j.jcmg.2011.01.013
NR 28
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E448
EP E455
DI 10.1016/j.wneu.2019.01.102
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700060
PM 30708079
OA Bronze, Green Published
DA 2020-05-12
ER

PT J
AU Kronenburg, A
   Bulder, MMM
   Bokkers, RPH
   Hartkamp, NS
   Hendrikse, J
   Vonken, EJ
   Kappelle, LJ
   van der Zwan, A
   Klijn, CJM
   Braun, KPJ
AF Kronenburg, Annick
   Bulder, Marcel M. M.
   Bokkers, Reinoud P. H.
   Hartkamp, Nolan S.
   Hendrikse, Jeroen
   Vonken, Evert-jan
   Kappelle, L. Jaap
   van der Zwan, Albert
   Klijn, Catharina J. M.
   Braun, Kees P. J.
TI Cerebrovascular Reactivity Measured with ASL Perfusion MRI, Ivy Sign,
   and Regional Tissue Vascularization in Moyamoya
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain ischemia; Collateral circulation; Moyamoya; Perfusion imaging
ID CEREBRAL-BLOOD-FLOW; SPIN-LABELING MRI; DISEASE; REVASCULARIZATION;
   CHILDREN; STRESS; IMAGES; SPECT; CT
AB BACKGROUND: Arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) may be used to determine brain regions at risk for ischemia in patients with moyamoya vasculopathy and to identify patients who may benefit from surgical revascularization. We aimed to investigate whether 1) the severity of moyamoya is related to the presence of leptomeningeal collaterals and cerebrovascular reactivity (CVR), 2) the presence of collaterals and ivy sign reflects disturbed CVR, and 3) arterial transit artefacts (ATAs) and ivy sign reflect the presence of collaterals.
   METHODS: We determined severity of moyamoya on digital subtraction angiography (DSA) according to the modified Suzuki classification in 20 brain regions and scored regional tissue revascularization using a 4-point scale. Regional CVR and ATAs were assessed on ASL perfusion MRI, ivy sign on fluid attenuation inversion recovery MRI.
   RESULTS: In 11 patients (median age 36 years; 91% female), we studied 203 regions. ATAs were associated with the presence of collaterals on DSA (P < 0.01). Of all regions with clearly visible collateral vessels on DSA, however, only 24% had ATAs. Ivy sign was not related to the presence or absence of collaterals nor to CVR. In 10% of regions with good vascularization on DSA, CVR was poor showed steal.
   CONCLUSIONS: ATAs were associated with the presence of collaterals on DSA. Although DSA vascularization scores correlated with CVR, 10% of regions with good vascularization on DSA had absent CVR or steal on ASL-MRI. DSA and ivy sign did not provide adequate information on the hemodynamic status of brain tissue in patients with moyamoya vasculopathy.
C1 [Kronenburg, Annick; Bulder, Marcel M. M.; Kappelle, L. Jaap; van der Zwan, Albert; Klijn, Catharina J. M.; Braun, Kees P. J.] Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands.
   [Bokkers, Reinoud P. H.; Hartkamp, Nolan S.; Hendrikse, Jeroen; Vonken, Evert-jan] UMC Utrecht, Dept Radiol, Utrecht, Netherlands.
   [Bulder, Marcel M. M.] Bravis Hosp, Dept Neurol, Bergen Op Zoom, Norway.
   [Bokkers, Reinoud P. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, Med Imaging Ctr, Groningen, Netherlands.
   [Klijn, Catharina J. M.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Neurol, Ctr Neurosci,Med Ctr, Nijmegen, Netherlands.
RP Kronenburg, A (reprint author), Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands.
EM A.Kronenburg@umcutrecht.nl
RI Klijn, C.J.M./E-1700-2016
OI Klijn, C.J.M./0000-0002-8495-4578
FU Dutch Brain Foundation (Christine Bader Fund Irene Children's Hospital)
   [2012(1)-179]; Tutein Nolthenius Oldenhof Fund; Johanna Children Fund;
   Friends of the Wilhelmina Children's Hospital; Dutch Heart
   FoundationNetherlands Heart Foundation [2012T077, 2013T047];
   ZonMwNetherlands Organization for Health Research and Development
   [015008048]
FX This work was supported by the Dutch Brain Foundation ([2012(1)-179];
   the Christine Bader Fund Irene Children's Hospital), the Tutein
   Nolthenius Oldenhof Fund, the Johanna Children Fund, and Friends of the
   Wilhelmina Children's Hospital. C. J. M. Klijn is supported by a
   Clinical Established Investigator grant from the Dutch Heart Foundation
   (grant number 2012T077) and an Aspasia grant from ZonMw (grant number
   015008048). R. P. H. Bokkers is supported by a Physician in Training
   grant from the Dutch Heart Foundation (grant number 2013T047).
CR Andaluz N, 2010, NEUROSURG REV, V33, P225, DOI 10.1007/s10143-010-0237-x
   Bokkers RPH, 2010, RADIOLOGY, V256, P201, DOI 10.1148/radiol.10091262
   Bulder MMM, 2014, CEREBROVASC DIS, V37, P14, DOI 10.1159/000355889
   Calamante F, 2001, STROKE, V32, P2810, DOI 10.1161/hs1201.099893
   Deibler AR, 2008, AM J NEURORADIOL, V29, P1228, DOI 10.3174/ajnr.A1030
   Derdeyn CP, 1999, STROKE, V30, P1019, DOI 10.1161/01.STR.30.5.1019
   Detre JA, 1999, JMRI-J MAGN RESON IM, V10, P870, DOI 10.1002/(SICI)1522-2586(199911)10:5<870::AID-JMRI36>3.0.CO;2-D
   Goetti R, 2013, NEURORADIOLOGY, V55, P639, DOI 10.1007/s00234-013-1155-8
   Heyn C, 2010, AM J NEURORADIOL, V31, P862, DOI 10.3174/ajnr.A1922
   Horie N, 2014, STROKE, V45, P1488, DOI 10.1161/STROKEAHA.114.004755
   Ideguchi R, 2011, ACTA RADIOL, V52, P291, DOI 10.1258/ar.2011.100367
   Kaku Y, 2013, CEREBROVASC DIS, V36, P19, DOI 10.1159/000351143
   Kang KH, 2008, AM J NEURORADIOL, V29, P1487, DOI 10.3174/ajnr.A1129
   Kawashima M, 2009, AM J NEURORADIOL, V30, P1709, DOI 10.3174/ajnr.A1679
   Kim JJ, 2004, STROKE, V35, P1340, DOI 10.1161/01.STR.0000126043.83777.3a
   Kronenburg A, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-013-0423-7
   Kuwabara Y, 1997, CLIN NEUROL NEUROSUR, V99, pS74, DOI 10.1016/S0303-8467(97)00061-9
   Lee M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.1.FOCUS08300
   Nariai T, 2005, J NEUROL NEUROSUR PS, V76, P663, DOI 10.1136/jnnp.2003.025049
   Noguchi T, 2011, EUR J RADIOL, V80, pE557, DOI 10.1016/j.ejrad.2011.01.016
   OGAWA A, 1990, ACTA NEUROCHIR, V105, P30, DOI 10.1007/BF01664854
   Petersen ET, 2006, BRIT J RADIOL, V79, P688, DOI 10.1259/bjr/67705974
   Petersen ET, 2006, MAGN RESON MED, V55, P219, DOI 10.1002/mrm.20784
   Phi JH, 2015, J KOREAN NEUROSURG S, V57, P408, DOI 10.3340/jkns.2015.57.6.408
   Schubert GA, 2009, NEUROSURG REV, V32, P29, DOI 10.1007/s10143-008-0159-z
   Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622
   So Y, 2005, STROKE, V36, P1485, DOI 10.1161/01.STR.0000170709.95185.b1
   Sugino T, 2013, J STROKE CEREBROVASC, V22, P811, DOI 10.1016/j.jstrokecerebrovasdis.2012.05.010
   Vuignier S, 2013, ACTA NEUROCHIR, V155, P2097, DOI 10.1007/s00701-013-1860-4
   Zaharchuk G, 2011, STROKE, V42, P2485, DOI 10.1161/STROKEAHA.111.616466
   2008, AM J NEURORADIOL, V29, P1487, DOI DOI 10.3174/AJNR.A1129
   2009, NEUROSURG REV, V32, P29, DOI DOI 10.1007/S10143-008-0159-Z
   2010, NEUROSURG REV, V33, P225, DOI DOI 10.1007/S10143-010-0237-X
NR 33
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E639
EP E650
DI 10.1016/j.wneu.2019.01.140
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700080
PM 30716498
DA 2020-05-12
ER

PT J
AU Kurucz, P
   Ganslandt, O
   Buchfelder, M
   Barany, L
AF Kurucz, Peter
   Ganslandt, Oliver
   Buchfelder, Michael
   Barany, Laszlo
TI Arachnoid Membranes Around the Cisternal Segment of the Trigeminal
   Nerve: A Cadaveric Anatomic Study and Intraoperative Observations During
   Minimally Invasive Microvascular Decompression Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid membranes; Endoscopic anatomy; Microvascular decompression;
   Posterior fossa; Retrosigmoid keyhole approach; Trigeminal nerve;
   Trigeminal neuralgia
ID ENDOSCOPIC VASCULAR DECOMPRESSION; ASSISTED BRAIN SURGERY; MICROSURGICAL
   ANATOMY; LILIEQUISTS MEMBRANE; POSTERIOR-FOSSA; INTERPEDUNCULAR CISTERN;
   CEREBELLOPONTINE ANGLE; RETROSIGMOID APPROACH; CRANIAL NERVES; PETROSAL
   VEIN
AB OBJECTIVE: The minimally invasive microvascular decompression (MVD) for trigeminal neuralgia is technically a more challenging operation compared with the standard retrosigmoidal approach. Endoscopic assistance could help to widen the field of view of the microscope during MVD. An extended view around the cisternal segment of the trigeminal nerve can be achieved only with the targeted dissection of the arachnoid membranes. The goal of our study was to analyze the three-dimensional organization of these membranes around the trigeminal nerve.
   METHODS: Microsurgical, endoscopic, and macroscopic anatomic examinations were performed on 50 fresh human cadaveric specimens. Retrospective analysis of the video documentations of 50 MVDs was performed to describe the surgical relevance of the examined membranes.
   RESULTS: The trigeminal nerve is surrounded circumferentially by 4 inner arachnoid membranes: laterally and caudally by the trigeminal membrane (TM), cranially by the superior cerebellar membrane (SCM), and medially by the junction between the cranial edge of the anterior pontine membrane and the lateral edge mesencephalic leaf of the Liliequist membrane complex. The superior cerebellar artery was located in every case cranial from the SCM. This membrane served as a safety plane to dissect the vessel from the nerve. The SCM was laterally adherent to the TM, which made the arachnoid dissection challenging. The superior petrosal vein was located cranially and laterally from the described inner arachnoid membranes, but the transverse pontine vein was embedded into the membrane complex.
   CONCLUSIONS: Knowledge of the described anatomy of the arachnoid membranes around the trigeminal nerve is essential to safely perform an MVD.
C1 [Kurucz, Peter; Ganslandt, Oliver] Klinikum Stuttgart, Dept Neurosurg, Katharinenhosp, Stuttgart, Germany.
   [Kurucz, Peter; Buchfelder, Michael] Friedrich Alexander Univ Erlangen Nuremberg, Dept Neurosurg, Erlangen, Germany.
   [Barany, Laszlo] Semmelweis Univ, Lab Appl & Clin Anat, Dept Anat Histol & Embryol, Budapest, Hungary.
RP Kurucz, P (reprint author), Klinikum Stuttgart, Dept Neurosurg, Katharinenhosp, Stuttgart, Germany.; Kurucz, P (reprint author), Friedrich Alexander Univ Erlangen Nuremberg, Dept Neurosurg, Erlangen, Germany.
EM kuruczp@gmail.com
CR Algin O, 2016, NEURORADIOLOGY, V58, P637, DOI 10.1007/s00234-016-1669-y
   Anik I, 2011, ACTA NEUROCHIR, V153, P1701, DOI 10.1007/s00701-011-0978-5
   Belykh E, 2018, WORLD NEUROSURG, V119, pE1, DOI 10.1016/j.wneu.2018.04.218
   Bohman LE, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14318
   Broggi M, 2013, ACTA NEUROCHIR, V155, P1709, DOI 10.1007/s00701-013-1824-8
   Charalampaki P, 2008, SKULL BASE-INTERD AP, V18, P117, DOI 10.1055/s-2007-1003927
   Choudhari KA, 2007, BRIT J NEUROSURG, V21, P288, DOI 10.1080/02688690701397773
   Cohen-Gadol AA, 2011, CLIN NEUROL NEUROSUR, V113, P844, DOI 10.1016/j.clineuro.2011.06.003
   Dubey A, 2018, WORLD NEUROSURG, V113, pE612, DOI 10.1016/j.wneu.2018.02.108
   Ebner FH, 2009, EJSO-EUR J SURG ONC, V35, P552, DOI 10.1016/j.ejso.2008.06.011
   Fries G, 1998, NEUROSURGERY, V42, P226, DOI 10.1097/00006123-199802000-00008
   Froelich SC, 2008, NEUROSURGERY, V63, P1, DOI 10.1227/01.neu.0000335004.22628.ee
   Fushimi Y, 2003, RADIOLOGY, V229, P360, DOI 10.1148/radiol.2292021507
   Halpern CH, 2013, MINIM INVASIVE SURG, V2013, DOI 10.1155/2013/739432
   Gonzalez-Quarante LH, 2017, WORLD NEUROSURG, V106, P775, DOI 10.1016/j.wneu.2017.07.110
   Inoue K, 2009, NEUROSURGERY, V65, P644, DOI 10.1227/01.NEU.0000351774.81674.32
   JANNETTA PJ, 1985, ARCH NEUROL-CHICAGO, V42, P800, DOI 10.1001/archneur.1985.04210090068018
   Jannetta PJ, 2005, NEUROSURG FOCUS, V18, P1
   Jarrahy R, 2000, OTOLARYNG HEAD NECK, V123, P218, DOI 10.1067/mhn.2000.107451
   Jarrahy R, 2002, MINIM INVAS NEUROSUR, V45, P32, DOI 10.1055/s-2002-23586
   Jiao YB, 2018, WORLD NEUROSURG, V110, pE1, DOI 10.1016/j.wneu.2017.09.138
   Key Axel RG., 1875, STUDIEN ANATOMIE NER
   Komatsu F, 2017, J NEUROL SURG PART A, V78, P291, DOI 10.1055/s-0036-1592077
   Kurucz P, 2013, INNOV NEUROSUR, V1, P55
   Kurucz P, 2013, INNOV NEUROSUR, V1, P91, DOI DOI 10.1515/INS-2013-0008
   Kurucz P, 2018, WORLD NEUROSURG, V120, pE877, DOI 10.1016/j.wneu.2018.08.180
   Kurucz P, 2017, NEUROSURG REV, V40, P427, DOI 10.1007/s10143-016-0800-1
   Lang SS, 2012, ORL J OTO-RHINO-LARY, V74, P293, DOI 10.1159/000342795
   Lee JYK, 2017, J NEUROSURG, V126, P1676, DOI 10.3171/2016.5.JNS1621
   LILIEQUIST B, 1956, ACTA RADIOL, V46, P61, DOI 10.3109/00016925609170813
   Lu J, 2005, J NEUROSURG, V103, P337, DOI 10.3171/jns.2005.103.2.0337
   Lu J, 2003, MINIM INVAS NEUROSUR, V46, P149
   Lu J, 2007, CLIN ANAT, V20, P502, DOI 10.1002/ca.20448
   Lu J, 2015, SURG RADIOL ANAT, V37, P127, DOI 10.1007/s00276-014-1361-z
   Masuoka J, 2011, NEUROSURG REV, V34, P373, DOI 10.1007/s10143-011-0310-0
   MATSUNO H, 1988, NEUROSURGERY, V23, P58, DOI 10.1227/00006123-198807000-00012
   MATSUSHIMA T, 1983, J NEUROSURG, V59, P63, DOI 10.3171/jns.1983.59.1.0063
   Matsushima T, 2000, ACTA NEUROCHIR, V142, P557, DOI 10.1007/s007010050469
   McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001
   Melvill RL, 1996, J NEUROSURG, V84, P127, DOI 10.3171/jns.1996.84.1.0127
   Mitsos AP, 2008, NEUROSURG REV, V31, P327, DOI 10.1007/s10143-008-0144-6
   Miyazaki H, 2005, LARYNGOSCOPE, V115, P1612, DOI 10.1097/01.mlg.0000172038.22929.63
   Oiwa Y, 2004, NEUROL MED-CHIR, V44, P94, DOI 10.2176/nmc.44.94
   Otani N, 2018, J NEUROSURG, V128, P1522, DOI 10.3171/2017.1.JNS161243
   Perneczky A, 1998, NEUROSURGERY, V42, P219, DOI 10.1097/00006123-199802000-00001
   Perneczky A, 2008, KEYHOLE APPROACHES N
   Rak R, 2004, NEUROSURGERY, V54, P876, DOI 10.1227/01.NEU.0000115151.52925.37
   Setty P, 2014, WORLD NEUROSURG, V81, P603, DOI 10.1016/j.wneu.2013.10.036
   Shigeno T, 2002, NEUROL MED-CHIR, V42, P184, DOI 10.2176/nmc.42.184
   Skrap M, 2010, NEUROSURGERY, V66, P88, DOI 10.1227/01.NEU.0000367556.35258.FA
   Spetzler RF, 2012, J NEUROSURG, V116, P291, DOI 10.3171/2011.8.JNS101896
   Steinberg JA, 2019, J NEUROSURG, V130, P1315, DOI 10.3171/2017.10.JNS17971
   Sufianov AA, 2009, CHILD NERV SYST, V25, P301, DOI 10.1007/s00381-008-0746-x
   Teo C, 2015, PRINCIPLES PRACTICE
   Teo C, 2006, NEUROSURGERY S2, V59, DOI DOI 10.1227/01.NEU.0000232768.47615.82DISCUSSI0N
   Vaz-Guimaraes F, 2015, ACTA NEUROCHIR, V157, P611, DOI 10.1007/s00701-014-2332-1
   Vinas FC, 1996, NEUROL RES, V18, P305
   Vinas FC, 2001, MINIM INVAS NEUROSUR, V44, P104, DOI 10.1055/s-2001-15999
   Wang H, 2018, J NEUROSURG, V129, P324, DOI 10.3171/2017.5.JNS17515
   Wang SS, 2011, ACTA NEUROCHIR, V153, P191, DOI 10.1007/s00701-010-0823-2
   YASARGIL MG, 1976, J NEUROSURG, V44, P298
   Zhang XA, 2012, CHILD NERV SYST, V28, P65, DOI 10.1007/s00381-011-1599-2
   Zhong J, 2014, NEUROL RES, V36, P882, DOI 10.1179/1743132814Y.0000000344
   2011, NEUROSURG REV, V34, P373, DOI DOI 10.1007/S10143-011-0310-0
NR 64
TC 1
Z9 1
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E262
EP E272
DI 10.1016/j.wneu.2019.01.060
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700034
PM 30684703
DA 2020-05-12
ER

PT J
AU Kwon, SM
   Kim, JH
   Kim, YH
   Hong, SH
   Kim, CJ
AF Kwon, Sae Min
   Kim, Jeong Hoon
   Kim, Young-Hoon
   Hong, Seok Ho
   Kim, Chang Jin
TI Treatment and Survival Outcomes of Primary Intracranial Squamous Cell
   Carcinoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epidermoid cyst; Intracranial; Malignant transformation; Outcome;
   Squamous cell carcinoma; Treatment
ID EPIDERMOID CYST; MALIGNANT-TRANSFORMATION; CEREBELLOPONTINE ANGLE;
   LEPTOMENINGEAL CARCINOMATOSIS; SURGICAL-TREATMENT; DERMOID CYST;
   BRAIN-STEM; REMOVAL; TUMORS; CT
AB BACKGROUND: Primary intracranial squamous cell carcinoma (SCC) is a rare neoplasm associated with malignant transformation of benign epidermoid or dermoid cysts. The optimal treatment and prognosis of this rare disease are unclear.
   METHODS: A comprehensive literature review identified all reports relevant to clinical presentation, treatment, and outcome of primary intracranial SCC. All available data were extracted from the included literature. Two patients diagnosed with malignant transformation of an epidermoid cyst in our institutewere also included in the study. Survival analysiswas conducted to determine the factors affecting patient outcomes.
   RESULTS: A total of 62 cases were identified and selected for the present study. The median survival regardless of treatment was 12.8 months. Median survival for patients treated with surgery alone and surgery with radiotherapy was 5 months and 35 months, respectively (P = 0.037). Patients who underwent gross total resection showed relatively increased survival compared with those who underwent subtotal resection (median, 48 months vs. 25 months; P = 0.067). Patients with leptomeningeal carcinomatosis had a significantly decreased median survival of 10 months, as opposed to 41 months (P = 0.005).
   CONCLUSIONS: Primary intracranial SCC shows poor prognosis, with controversial management. The results of this study indicate that complete resection of tumor when possible, followed by radiotherapy, is the optimal treatment for improving patient outcome.
C1 [Kwon, Sae Min; Kim, Jeong Hoon; Kim, Young-Hoon; Hong, Seok Ho; Kim, Chang Jin] Univ Ulsan, Dept Neurol Surg, Asan Med Ctr, Coll Med, Seoul, South Korea.
RP Kim, JH (reprint author), Univ Ulsan, Dept Neurol Surg, Asan Med Ctr, Coll Med, Seoul, South Korea.
EM jhkim1@amc.seoul.kr
OI Kim, Young-Hoon/0000-0002-8852-6503; Kwon, Sae Min/0000-0001-9720-6037
CR ABRAMSON RC, 1989, NEUROSURGERY, V24, P574, DOI 10.1227/00006123-198904000-00014
   ACCIARRI N, 1993, BRIT J NEUROSURG, V7, P565, DOI 10.3109/02688699308995081
   Agarwal S, 2007, CLIN NEUROL NEUROSUR, V109, P888, DOI 10.1016/j.clineuro.2007.07.026
   Akar Z, 2003, NEUROL MED-CHIR, V43, P275, DOI 10.2176/nmc.43.275
   Asahi T, 2001, J CLIN NEUROSCI, V8, P572, DOI 10.1054/jocn.2000.0856
   Badat N, 2018, J NEURORADIOLOGY, V45, P337, DOI 10.1016/j.neurad.2018.07.002
   Bayindir C, 1996, ACTA NEUROCHIR, V138, P1008, DOI 10.1007/BF01411292
   BONDESON L, 1984, ACTA CYTOL, V28, P487
   Chon KH, 2012, J KOREAN NEUROSURG S, V52, P148, DOI 10.3340/jkns.2012.52.2.148
   DAVIDSON SI, 1960, J NEUROL NEUROSUR PS, V23, P176, DOI 10.1136/jnnp.23.2.176
   Ding SH, 2016, ONCOL LETT, V11, P3097, DOI 10.3892/ol.2016.4368
   DUBOIS PJ, 1981, J COMPUT ASSIST TOMO, V5, P433, DOI 10.1097/00004728-198106000-00025
   Ernst P., 1912, VERH DTSCH PATHOL GE, V15, P226
   FEIN JM, 1981, NEUROSURGERY, V9, P179, DOI 10.1227/00006123-198108000-00014
   Feng R, 2014, INT J CLIN EXP MED, V7, P312
   FOX H, 1965, J NEUROL NEUROSUR PS, V28, P276, DOI 10.1136/jnnp.28.3.276
   GAO PY, 1992, AM J NEURORADIOL, V13, P863
   GARCIA CA, 1981, J NEUROSURG, V54, P824, DOI 10.3171/jns.1981.54.6.0824
   Ge PF, 2009, NEUROL MED-CHIR, V49, P442, DOI 10.2176/nmc.49.442
   GIANGASPERO F, 1984, VIRCHOWS ARCH A, V402, P459, DOI 10.1007/BF00734642
   GOLDMAN SA, 1987, J NEUROSURG, V66, P618, DOI 10.3171/jns.1987.66.4.0618
   Guan LM, 2004, CHINESE MED J-PEKING, V117, P1880
   GUIDETTI B, 1977, J NEUROSURG, V47, P12, DOI 10.3171/jns.1977.47.1.0012
   Hamlat A, 2005, J NEURO-ONCOL, V74, P187, DOI 10.1007/s11060-004-5175-4
   Hamlat A, 2003, ACTA NEUROL BELG, V103, P221
   Hao SY, 2010, J FORMOS MED ASSOC, V109, P390, DOI 10.1016/S0929-6646(10)60068-X
   Kano T, 2010, NEUROL MED-CHIR, V50, P349, DOI 10.2176/nmc.50.349
   Khan RB, 2001, NEUROLOGY, V56, P1419, DOI 10.1212/WNL.56.10.1419
   Kim MS, 2008, J KOREAN NEUROSURG S, V44, P401, DOI 10.3340/jkns.2008.44.6.401
   KNORR JR, 1991, AM J NEURORADIOL, V12, P1182
   KOBAYASHI T, 1993, NEUROCHIRURGIA, V36, P26
   Kodama H, 2007, J NEURO-ONCOL, V82, P171, DOI 10.1007/s11060-006-9255-5
   Lakhdar F, 2011, CASE REP NEUROL MED, DOI 10.1155/2011/525289
   LANDERS JW, 1960, ARCH PATHOL, V70, P419
   LATACK JT, 1985, RADIOLOGY, V157, P361, DOI 10.1148/radiology.157.2.3876574
   LEWIS AJ, 1983, J NEUROSURG, V59, P538, DOI 10.3171/jns.1983.59.3.0538
   Link MJ, 2002, J NEUROSURG, V97, P1237, DOI 10.3171/jns.2002.97.5.1237
   Mascarenhas Annika, 2017, Surg Neurol Int, V8, P186, DOI 10.4103/sni.sni_99_17
   Michael LM, 2005, BRIT J NEUROSURG, V19, P505, DOI 10.1080/02688690500495356
   Monaco R, 2003, NEUROPATHOLOGY, V23, P219, DOI 10.1046/j.1440-1789.2003.00497.x
   Murase S, 1999, NEUROL MED-CHIR, V39, P49, DOI 10.2176/nmc.39.49
   Nagasawa D, 2012, J CLIN NEUROSCI, V19, P21, DOI 10.1016/j.jocn.2011.06.002
   Nagasawa DT, 2013, CLIN NEUROL NEUROSUR, V115, P1071, DOI 10.1016/j.clineuro.2012.10.026
   Nakao Y, 2010, NEUROL MED-CHIR, V50, P236, DOI 10.2176/nmc.50.236
   Nawashiro H, 2001, NEURORADIOLOGY, V43, P891, DOI 10.1007/s002340100612
   NISHIO S, 1995, NEUROSURGERY, V37, P329, DOI 10.1227/00006123-199508000-00021
   Nishiura I, 1989, Neurol Med Chir (Tokyo), V29, P600, DOI 10.2176/nmc.29.600
   Oertel J, 2002, J NEUROSURG, V97, P1244, DOI 10.3171/jns.2002.97.5.1244
   Ogata N, 1996, SURG NEUROL, V46, P477, DOI 10.1016/S0090-3019(96)00222-4
   Ozutemiz C, 2017, TURK NEUROSURG, V27, P312, DOI 10.5137/1019-5149.JTN.12722-14.0
   Pagni F, 2007, NEUROPATHOLOGY, V27, P566, DOI 10.1111/j.1440-1789.2007.00820.x
   Park Jin Woo, 2003, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V34, P159
   Pikis S, 2016, J CLIN NEUROSCI, V33, P59, DOI 10.1016/j.jocn.2016.04.008
   Raheja A, 2016, WORLD NEUROSURG, V88, DOI 10.1016/j.wneu.2015.11.039
   Roh TH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009423
   SALAZAR J, 1987, ACTA NEUROCHIR, V85, P34, DOI 10.1007/BF01402367
   SALYER D, 1973, CANCER, V31, P713, DOI 10.1002/1097-0142(197303)31:3<713::AID-CNCR2820310334>3.0.CO;2-S
   Shirabe T, 2003, NEUROPATHOLOGY, V23, P225, DOI 10.1046/j.1440-1789.2003.00499.x
   Vellutini EAS, 2014, BRIT J NEUROSURG, V28, P507, DOI 10.3109/02688697.2013.869552
   Solanki SP, 2017, BRIT J NEUROSURG, V31, P497, DOI 10.3109/02688697.2015.1125445
   Sun T, 2016, INT J CLIN EXP MED, V9, P4783
   Tamura K, 2006, J NEURO-ONCOL, V79, P67, DOI 10.1007/s11060-005-9117-6
   TOGLIA JU, 1965, J NEUROSURG, V23, P384, DOI 10.3171/jns.1965.23.4.0384
   TOGNETTI F, 1991, British Journal of Neurosurgery, V5, P303, DOI 10.3109/02688699109005191
   Tsugu H, 2001, NEUROL MED-CHIR, V41, P213, DOI 10.2176/nmc.41.213
   UCHINO A, 1995, NEURORADIOLOGY, V37, P155
   YAMAKAWA K, 1989, NEUROSURGERY, V24, P568, DOI 10.1227/00006123-198904000-00013
   YAMANAKA A, 1955, Gan, V46, P274
   1997, NEUROSURGERY, V40, P24
NR 69
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1
EP E9
DI 10.1016/j.wneu.2018.11.252
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700002
PM 30576830
DA 2020-05-12
ER

PT J
AU Lang, CD
   Wang, RJ
   Chen, ZM
   He, SF
   Zou, QH
   Wu, JN
   Zhu, XJ
AF Lang, Chuandong
   Wang, Ruijun
   Chen, Ziming
   He, Shaofu
   Zou, Qihua
   Wu, Jinna
   Zhu, Xiaojun
TI Incidence and Risk Factors of Cardiac Abnormalities in Patients with
   Idiopathic Scoliosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atrial septal defect; Cardiac abnormalities; Congenital heart disease;
   Echocardiogram; Idiopathic scoliosis; Risk factors; Spinal deformity
ID MITRAL-VALVE-PROLAPSE; CONGENITAL HEART-DISEASE; ASSOCIATION;
   PREVALENCE; ETIOLOGY
AB OBJECTIVE: We sought to investigate the incidence of cardiac abnormalities in patients with idiopathic scoliosis and identify risk factors related to cardiac abnormalities.
   METHODS: A cohort of 531 patients with idiopathic scoliosis requiring surgical treatment in our hospital from March 2009 to August 2017 were recorded. Clinical data including medical records, radiograph, and echocardiogram were collected. All patients were divided into groups: control, congenital heart disease (CHD), and other cardiac abnormalities (OCAs). The incidence and related factors for cardiac abnormalities were analyzed.
   RESULTS: The age of the study cohort was 17.8 +/- 7.3 years. The average Cobb angle was 57.7 +/- 16.5 degrees. Cardiac abnormalities were found in 149 (28.06%) patients, including 22 (4.14%) with CHD and 127 (23.92%) with OCAs. Atrial septal defect was the most common CHD with an incidence of 1.13% (6 of 531). Mitral valve prolapse was detected in 62 (11.68%) patients, which was the most prevalent OCA. Patients with CHD or OCAs weighed less as compared with patients without cardiac abnormalities. Low height was associated with CHD in patients with idiopathic scoliosis. Six patients with severe cardiac abnormalities must undergo cardiac intervention before scoliosis surgery.
   CONCLUSIONS: The overall incidence of cardiac abnormalities was 28.81% in patients with idiopathic scoliosis. An echocardiogram may be helpful as a preoperative examination for patients with idiopathic scoliosis before scoliosis surgery.
C1 [Lang, Chuandong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Guangzhou, Guangdong, Peoples R China.
   [Zhu, Xiaojun] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Musculoskeletal Oncol, Guangzhou, Guangdong, Peoples R China.
   [Zou, Qihua] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China.
   [Wu, Jinna] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Oncol, Zhuhai, Guangdong, Peoples R China.
   [Chen, Ziming] Shantou Univ, Coll Med, Shantou, Guangdong, Peoples R China.
   [Wang, Ruijun] Beijing Changping Hosp, Dept Surg, Beijing, Peoples R China.
   [He, Shaofu] Sun Yat Sen Univ, Affiliated Hosp 1, Radiat Dept, Guangzhou, Guangdong, Peoples R China.
RP Zhu, XJ (reprint author), Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Musculoskeletal Oncol, Guangzhou, Guangdong, Peoples R China.
EM zhuxj0929@163.com
CR Basu PS, 2002, SPINE, V27, P2255, DOI 10.1097/01.BRS.0000029425.58936.BA
   BONTEMPO CP, 1975, AM J CARDIOL, V36, P27
   Bozcali E, 2016, ASIAN SPINE J, V10, P226, DOI [10.4184/ASJ.2016.10.2.226, 10.4184/asj.2016.10.2.226]
   BYRD JA, 1988, CLIN ORTHOP RELAT R, P114
   Colomina MJ, 2002, PEDIATR CARDIOL, V23, P426, DOI 10.1007/s00246-002-1443-2
   DEVEREUX RB, 1989, ANN INTERN MED, V111, P305, DOI 10.7326/0003-4819-111-4-305
   DEVEREUX RB, 1982, LANCET, V2, P792
   Dhuper S, 1997, PEDIATR CARDIOL, V18, P425, DOI 10.1007/s002469900220
   Ede MMPN, 2016, INT ORTHOP, V40, P2075, DOI 10.1007/s00264-016-3132-4
   Heemskerk JL, 2018, SPINE J, V18, P1261, DOI 10.1016/j.spinee.2018.02.013
   Hiratzka LF, 2010, J AM COLL CARDIOL, V55, pE27, DOI 10.1016/j.jacc.2010.02.015
   HIRSCHFELD SS, 1982, PEDIATRICS, V70, P451
   Hoffman JIE, 2002, J AM COLL CARDIOL, V39, P1890, DOI 10.1016/S0735-1097(02)01886-7
   Ipp L, 2011, J PEDIATR ORTHOPED, V31, P764, DOI 10.1097/BPO.0b013e31822f14d6
   JERESATY RM, 1986, J AM COLL CARDIOL, V7, P231, DOI 10.1016/S0735-1097(86)80286-8
   KAWAKAMI N, 1995, SPINE, V20, P1252, DOI 10.1097/00007632-199506000-00008
   Liang JQ, 2013, J NEUROSURG-PEDIATR, V12, P505, DOI 10.3171/2013.8.PEDS13117
   Liu LM, 2010, ORTHOPEDICS, V33, DOI 10.3928/01477447-20101021-08
   Liu YT, 2011, EUR SPINE J, V20, P2111, DOI 10.1007/s00586-011-1818-2
   LUKE MJ, 1968, J PEDIATR-US, V73, P725, DOI 10.1016/S0022-3476(68)80178-7
   RECKLES LN, 1975, J BONE JOINT SURG AM, VA 57, P449, DOI 10.2106/00004623-197557040-00002
   ROTH A, 1973, CLIN ORTHOP RELAT R, P95
   Shen JX, 2013, SPINE, V38, P814, DOI 10.1097/BRS.0b013e31827ed125
   Stanger P, 1999, AM J CARDIOL, V83, P908, DOI 10.1016/S0002-9149(98)01063-7
   van der Linde D, 2011, J AM COLL CARDIOL, V58, P2241, DOI 10.1016/j.jacc.2011.08.025
   WRIGHT WD, 1956, J BONE JOINT SURG AM, V38, P1131, DOI 10.2106/00004623-195638050-00016
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E824
EP E828
DI 10.1016/j.wneu.2019.01.177
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700102
PM 30738943
DA 2020-05-12
ER

PT J
AU Lee, CC
   Yang, HC
   Lin, CJ
   Chen, CJ
   Wu, HM
   Shiau, CY
   Guo, WY
   Pan, DHC
   Liu, KD
   Chung, WY
   Peng, SJ
AF Lee, Cheng-Chia
   Yang, Huai-Che
   Lin, Chung-Jung
   Chen, Ching-Jen
   Wu, Hsiu-Mei
   Shiau, Cheng-Ying
   Guo, Wan-Yuo
   Pan, David Hung-Chi
   Liu, Kang-Du
   Chung, Wen-Yuh
   Peng, Syu-Jyun
TI Intervening Nidal Brain Parenchyma and Risk of Radiation-Induced Changes
   After Radiosurgery for Brain Arteriovenous Malformation: A Study Using
   an Unsupervised Machine Learning Algorithm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adverse radiation effects; Arteriovenous malformation; Fuzzy c-means;
   Gamma knife radiosurgery; Image analysis; Radiation-induced changes;
   Stereotactic radiosurgery
ID GAMMA-KNIFE SURGERY; STEREOTACTIC RADIOSURGERY; IMAGING CHANGES;
   OUTCOMES; OBLITERATION; MULTICENTER; MANAGEMENT; INJURY
AB OBJECTIVE: To assess the sensitivity and specificity of arteriovenous malformation (AVM) nidal component identification and quantification using an unsupervised machine learning algorithm and to evaluate the association between intervening nidal brain parenchyma and radiationinduced changes (RICs) after stereotactic radiosurgery.
   METHODS: Fully automated segmentation via unsupervised classification with fuzzy c-means clustering was used to analyze the AVM nidus on T2-weighted magnetic resonance imaging studies. The proportions of vasculature, brain parenchyma, and cerebrospinal fluid were quantified. These were compared with the results from manual segmentation. The association between the brain parenchyma component and RIC development was assessed.
   RESULTS: The proposed algorithm was applied to 39 unruptured AVMs in 39 patients (17 female and 22 male patients), with a median age of 27 years. The median proportion of the constituents was as follows: vasculature, 31.3%; brain parenchyma, 48.4%; and cerebrospinal fluid, 16.8%. RICs were identified in 17 of the 39 patients (43.6%). Compared with manual segmentation, the automated algorithm was able to achieve a Dice similarity index of 79.5% (sensitivity, 73.5%; specificity, 85.5%). RICs were associated with a greater proportion of intervening nidal brain parenchyma (52.0% vs. 45.3%; P = 0.015). Obliteration was not associated with greater proportions of nidal vasculature (36.0% vs. 31.2%; P = 0.152).
   CONCLUSIONS: The automated segmentation algorithm was able to achieve classification of the AVM nidus components with relative accuracy. Greater proportions of intervening nidal brain parenchyma were associated with RICs.
C1 [Lee, Cheng-Chia; Yang, Huai-Che; Pan, David Hung-Chi; Liu, Kang-Du; Chung, Wen-Yuh] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan.
   [Lin, Chung-Jung; Wu, Hsiu-Mei; Shiau, Cheng-Ying; Guo, Wan-Yuo] Taipei Vet Gen Hosp, Dept Radiol, Taipei, Taiwan.
   [Shiau, Cheng-Ying] Taipei Vet Gen Hosp, Ctr Canc, Taipei, Taiwan.
   [Lee, Cheng-Chia; Yang, Huai-Che; Lin, Chung-Jung; Wu, Hsiu-Mei; Guo, Wan-Yuo; Pan, David Hung-Chi; Liu, Kang-Du; Chung, Wen-Yuh] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Lee, Cheng-Chia] Natl Yang Ming Univ, Brain Res Ctr, Taipei, Taiwan.
   [Chen, Ching-Jen] Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA USA.
   [Peng, Syu-Jyun] Natl Chiao Tung Univ, Biomed Elect Translat Res Ctr, Hsinchu, Taiwan.
   [Peng, Syu-Jyun] Natl Chiao Tung Univ, Inst Elect, Hsinchu, Taiwan.
   [Pan, David Hung-Chi] Taipei Med Univ, Shuang Ho Hosp, Dept Neurosurg, Taipei, Taiwan.
RP Peng, SJ (reprint author), Natl Chiao Tung Univ, Biomed Elect Translat Res Ctr, Hsinchu, Taiwan.; Peng, SJ (reprint author), Natl Chiao Tung Univ, Inst Elect, Hsinchu, Taiwan.
EM blue.year@msa.hinet.net
OI Lin, Chung Jung/0000-0003-2370-6316
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [105-2314-B-075-021, 107-2221-E-009-103]; Center for
   Neuromodulation Medical Electronics Systems from the Featured Areas
   Research Center Program within the Ministry of Education in Taiwan
FX This work was partly supported by the Ministry of Science and
   Technology, Taiwan (project no. 105-2314-B-075-021, 107-2221-E-009-103)
   and partly supported by the Center for Neuromodulation Medical
   Electronics Systems from the Featured Areas Research Center Program
   within the framework of the Higher Education Sprout Project by the
   Ministry of Education in Taiwan.
CR Aoyama H, 2001, RADIOTHER ONCOL, V59, P323, DOI 10.1016/S0167-8140(01)00303-6
   BEZDEK JC, 1984, COMPUT GEOSCI, V10, P191, DOI 10.1016/0098-3004(84)90020-7
   Blamek S, 2010, ACTA NEUROCHIR SUPPL, V106, P187, DOI 10.1007/978-3-211-98811-4_34
   Bose R, 2015, NEUROSURGERY, V76, P623, DOI 10.1227/NEU.0000000000000660
   Buis DR, 2010, RADIOTHER ONCOL, V95, P250, DOI 10.1016/j.radonc.2010.03.003
   Ding DL, 2017, J NEUROSURG, V126, P859, DOI 10.3171/2016.1.JNS152564
   Ding D, 2014, J NEUROSURG, V121, P457, DOI 10.3171/2014.1.JNS131713
   Ding D, 2014, J NEUROSURG, V121, P470, DOI 10.3171/2014.2.JNS131605
   Ding D, 2013, NEUROSURGERY, V73, P816, DOI 10.1227/NEU.0000000000000106
   Ding D, 2013, J NEUROSURG, V118, P958, DOI 10.3171/2013.2.JNS121239
   Flickinger JC, 2000, INT J RADIAT ONCOL, V46, P1143, DOI 10.1016/S0360-3016(99)00513-1
   FLICKINGER JC, 1992, INT J RADIAT ONCOL, V23, P19, DOI 10.1016/0360-3016(92)90539-T
   Guo WY, 2006, STEREOT FUNCT NEUROS, V84, P162, DOI 10.1159/000094955
   Han JH, 2008, J NEUROSURG, V109, P191, DOI 10.3171/JNS/2008/109/8/0191
   Hayhurst C, 2012, INT J RADIAT ONCOL, V82, P803, DOI 10.1016/j.ijrobp.2010.12.014
   Huang PP, 2012, NEUROSURGERY, V71, P632, DOI 10.1227/NEU.0b013e31825fd247
   Ilyas A, 2018, J NEUROSURG, V128, P1354, DOI 10.3171/2016.12.JNS162478
   Ilyas A, 2018, J NEUROSURG, V128, P154, DOI 10.3171/2016.9.JNS161571
   Ilyas A, 2018, NEUROSURGERY, V83, P365, DOI 10.1093/neuros/nyx502
   Ji ZX, 2011, COMPUT MED IMAG GRAP, V35, P383, DOI 10.1016/j.compmedimag.2010.12.001
   Kano H, 2017, STROKE, V48, P84, DOI 10.1161/STROKEAHA.116.014825
   Kiran NAS, 2009, ACTA NEUROCHIR, V151, P1575, DOI 10.1007/s00701-009-0335-0
   Lee CC, 2015, J NEUROSURG, V123, P136, DOI 10.3171/2014.10.JNS141565
   Lee CC, 2011, CLIN NEUROL NEUROSUR, V113, P668, DOI 10.1016/j.clineuro.2011.03.010
   Lin CJ, 2018, J NEUROINTERV SURG, V10, P580, DOI 10.1136/neurintsurg-2017-013387
   Miyawaki L, 1999, INT J RADIAT ONCOL, V44, P1089, DOI 10.1016/S0360-3016(99)00102-9
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   Moosa S, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.5.FOCUS14205
   Morikawa M, 1996, INT J RADIAT ONCOL, V34, P663, DOI 10.1016/0360-3016(95)02160-4
   Parkhutik V, 2013, NEURORADIOLOGY, V55, P405, DOI 10.1007/s00234-012-1115-8
   Rahmathulla G, 2013, J CLIN NEUROSCI, V20, P485, DOI 10.1016/j.jocn.2012.09.011
   Schneider BF, 1997, J NEUROSURG, V87, P352, DOI 10.3171/jns.1997.87.3.0352
   Shuto T, 2015, ACTA NEUROCHIR, V157, P293, DOI 10.1007/s00701-014-2298-z
   Starke RM, 2017, J NEUROSURG-PEDIATR, V19, P136, DOI 10.3171/2016.9.PEDS16284
   Steinberg GK, 1996, J NEUROSURG, V84, P920, DOI 10.3171/jns.1996.84.6.0920
   Szeifert GT, 1997, NEUROSURGERY, V40, P61, DOI 10.1097/00006123-199701000-00013
   Yen CP, 2013, J NEUROSURG, V118, P63, DOI 10.3171/2012.10.JNS12402
   1997, NEUROSURGERY, V40, P61
   2005, J NEUROSURG S, V102, P4
   2015, NEUROSURGERY, V76, P623, DOI DOI 10.1227/NEU.0000000000000660
   2006, NEUROSURGERY, V59, P553, DOI DOI 10.1227/01.NEU.0000227476.95859.F1
   2012, NEUROSURGERY, V71, P632, DOI DOI 10.1227/NEU.0B013E31825FD247
NR 42
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E132
EP E138
DI 10.1016/j.wneu.2018.12.220
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700018
PM 30677586
DA 2020-05-12
ER

PT J
AU Lee, HJ
   Park, J
   Lee, IW
   Yi, JS
   Kim, T
AF Lee, Hong-Jae
   Park, Jinah
   Lee, Il-Woo
   Yi, Jin-Seok
   Kim, Taeho
TI Clinical, Radiographic, and Morphometric Risk Factors for Adjacent and
   Remote Vertebral Compression Fractures Over a Minimum Follow-up of 4
   Years After Percutaneous Vertebroplasty for Osteoporotic Vertebral
   Compression Fractures: Novel Three-dimensional Voxel-Based Morphometric
   Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone mineral density; Osteoporosis; Percutaneous vertebroplasty; Risk
   factor; Vertebral compression fracture; Voxel
ID CEMENT AUGMENTATION; RANDOMIZED-TRIAL; BONE-CEMENT; EXTRAVASATION;
   KYPHOPLASTY; STIFFNESS; STRENGTH; EFFICACY; DENSITY; LEAKAGE
AB OBJECTIVE: This study aimed to analyze the risk factors for secondary new vertebral compression fractures (SNVCFs) after percutaneous vertebroplasty (PVP) for osteoporotic vertebral compression fractures.
   METHODS: We evaluated the association of SNVCFs (adjacent vertebral compression fractures [AVCFs] and remote vertebral compression fractures) with clinical, radiographic, and PVP procedure-related morphologic parameters based on the data collected from 402 patients over a minimum follow-up of 4 years after PVP. Procedure-related morphologic parameters were assessed using a three-dimensional voxel-based analysis. Univariate and multivariate regression analyses were conducted.
   RESULTS: On univariate analysis, bone mineral density (BMD), preoperative compression ratio, preoperative sagittal index (SI), and intradiscal bone cement leakage were significantly associated with SNVCF and AVCF (P < 0.05), whereas only BMD and preoperative SI were significantly associated with remote vertebral compression fracture (P < 0.05). A large ratio of bone cement volume to vertebral body volume and skewed bone cement distribution along the inferior-to-superior axis were especially significant risk factors for AVCF (P = 0.027 and P = 0.029, respectively). On multivariate analysis, BMD was significantly associated with SNVCF (P = 0.041), whereas upper adjacent intradiscal bone cement leakage was significantly associated with AVCF (P = 0.003).
   CONCLUSIONS: Low BMD, high preoperative compression ratio, and high preoperative SI may be predictive factors for SNVCFs. In particular, to prevent AVCF, the injected bone cement should be distributed both evenly and symmetrically along the inferior-to-superior axis and the relative bone cement volume should not be excessive. Bone cement should be injected carefully to avoid upper adjacent intradiscal leakage. Prompt BMD correction is important to prevent SNVCF.
C1 [Lee, Hong-Jae; Lee, Il-Woo; Yi, Jin-Seok] Catholic Univ Korea, Coll Med, Daejeon St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
   [Park, Jinah; Kim, Taeho] Korea Adv Inst Sci & Technol, Sch Comp, Daejeon, South Korea.
RP Lee, HJ (reprint author), Catholic Univ Korea, Coll Med, Daejeon St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
EM kosailee73@gmail.com
FU Hanmi Pharmaceutical Co. Ltd. [HM-IIT-ESO-039]
FX This study was supported by research grants from Hanmi Pharmaceutical
   Co. Ltd. (HM-IIT-ESO-039).
CR Aquarius R, 2013, SPINE, V38, P2092, DOI 10.1097/01.brs.0000435029.88434.97
   Bae JS, 2017, WORLD NEUROSURG, V99, P387, DOI 10.1016/j.wneu.2016.12.038
   Baroud G, 2003, RADIOLOGY, V229, P606, DOI 10.1148/radiol.2292030378
   Baroud G, 2003, EUR SPINE J, V12, P421, DOI 10.1007/s00586-002-0512-9
   Baroud Gamal, 2006, J Long Term Eff Med Implants, V16, P265
   Belkoff SM, 2001, SPINE, V26, P1537, DOI 10.1097/00007632-200107150-00007
   Belkoff SM, 2000, SPINE, V25, P1061, DOI 10.1097/00007632-200005010-00004
   Buchbinder R, 2009, NEW ENGL J MED, V361, P557, DOI 10.1056/NEJMoa0900429
   Chen XB, 2016, CLIN SPINE SURG, V29, pE365, DOI 10.1097/BSD.0b013e3182aa28d6
   Clark W, 2016, LANCET, V388, P1408, DOI 10.1016/S0140-6736(16)31341-1
   Eichler MC, 2016, J NEUROSURG-SPINE, V25, P528, DOI 10.3171/2016.2.SPINE15907
   Enkhbaatar NE, 2018, RADIOLOGY, V288, P129, DOI 10.1148/radiol.2018171804
   FARCY JPC, 1990, SPINE, V15, P958, DOI 10.1097/00007632-199009000-00022
   Grados F, 2000, RHEUMATOLOGY, V39, P1410, DOI 10.1093/rheumatology/39.12.1410
   Graham J, 2007, SPINE, V32, pE505, DOI 10.1097/BRS.0b013e318133fc73
   JANG JS, 2002, SPINE, V27, P416, DOI DOI 10.1097/00007632-200210010-00021
   Jesse MK, 2015, PAIN PHYSICIAN, V18, pE805
   Kallmes DF, 2009, NEW ENGL J MED, V361, P569, DOI 10.1056/NEJMoa0900563
   Kang SK, 2011, ANN REHABIL MED-ARM, V35, P844, DOI 10.5535/arm.2011.35.6.844
   Kayanja Mark M, 2004, Spine J, V4, P76, DOI 10.1016/j.spinee.2003.07.003
   Kolb JP, 2013, EUR SPINE J, V22, P1650, DOI 10.1007/s00586-013-2809-2
   Lee DG, 2015, J SPINAL DISORD TECH, V28, pE578, DOI 10.1097/BSD.0000000000000043
   Lee SW, 2007, J CLIN NEUROSCI, V14, P961, DOI 10.1016/j.jocn.2006.08.005
   LEMIEUX L, 1994, MED PHYS, V21, P1749, DOI 10.1118/1.597276
   Li YA, 2012, SPINE, V37, P179, DOI 10.1097/BRS.0b013e3181f72b05
   Liang D, 2015, J SURG RES, V195, P246, DOI 10.1016/j.jss.2014.12.053
   Lin CC, 2007, AM J NEURORADIOL, V28, P1042, DOI 10.3174/ajnr.A0520
   Lin EP, 2004, AM J NEURORADIOL, V25, P175
   Lu JY, 2015, CLIN NEUROL NEUROSUR, V139, P272, DOI 10.1016/j.clineuro.2015.10.026
   Luo J, 2017, SPINE J, V17, P863, DOI 10.1016/j.spinee.2017.01.013
   Moreland D B, 2001, Spine J, V1, P66, DOI 10.1016/S1529-9430(01)00013-4
   Ringer AJ, 2013, WORLD NEUROSURG, V80, P428, DOI 10.1016/j.wneu.2012.09.005
   Rousing R, 2010, SPINE, V35, P478, DOI 10.1097/BRS.0b013e3181b71bd1
   Singh Roop, 2015, Asian J Neurosurg, V10, P181, DOI 10.4103/1793-5482.161166
   Syed MI, 2005, AM J NEURORADIOL, V26, P2397
   Tanigawa N, 2005, AM J ROENTGENOL, V184, P567, DOI 10.2214/ajr.184.2.01840567
   Tanigawa N, 2007, AM J ROENTGENOL, V189, pW348, DOI 10.2214/AJR.07.2186
   Trout AT, 2006, AM J NEURORADIOL, V27, P217
   Tseng YY, 2009, SPINE, V34, P1917, DOI 10.1097/BRS.0b013e3181ac8f07
   Uppin AA, 2003, RADIOLOGY, V226, P119, DOI 10.1148/radiol.2261011911
   Voormolen MHJ, 2006, J VASC INTERV RADIOL, V17, P71, DOI 10.1097/01.RVI.0000190910.43602.3C
   Weng DHH, 2015, SPINE, V40, P1903, DOI 10.1097/BRS.0000000000001066
   Woermann FG, 1999, BRAIN, V122, P2101, DOI 10.1093/brain/122.11.2101
   Xin L, 2016, SPINE J, V16, P1468, DOI 10.1016/j.spinee.2016.07.529
   Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100
   Yang EZ, 2016, SPINE, V41, P653, DOI 10.1097/BRS.0000000000001298
   Yokoyama K, 2013, NEUROL RES, V35, P608, DOI 10.1179/1743132813Y.0000000173
   Zhang ZT, 2013, J SPINAL DISORD TECH, V26, pE150, DOI 10.1097/BSD.0b013e31827412a5
   2015, INT ORTHOP, V39, P727, DOI DOI 10.1007/S00264-014-2620-7
NR 49
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E146
EP E157
DI 10.1016/j.wneu.2019.01.020
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700020
PM 30682507
DA 2020-05-12
ER

PT J
AU Lee, JA
   Kim, KH
   Kong, DS
   Lee, S
   Park, SK
   Park, K
AF Lee, Jeong-A.
   Kim, Kyung-Hee
   Kong, Doo-Sik
   Lee, Seunghoon
   Park, Sang-Ku
   Park, Kwan
TI Algorithm to Predict the Outcome of Microvascular Decompression for
   Hemifacial Spasm: A Data-Mining Analysis Using a Decision Tree
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decision tree; Hemifacial spasm; Microvascular decompression; Outcome;
   Prediction model
ID DELAYED FACIAL PALSY; PROGNOSTIC-FACTORS; FOLLOW-UP; DISAPPEARANCE;
   EXPERIENCE; EMPHASIS; PATTERNS
AB OBJECTIVE: Although microvascular decompression (MVD) is the primary treatment for hemifacial spasm (HFS), the postoperative course is variable. This study aimed to develop a prediction model of the outcome of MVD in patients with HFS by investigating influential factors.
   METHODS: Electronic medical records of 1624 patients with HFS who underwent MVD from July 2004 to January 2015 were reviewed. The relationships between patient-related, disease-related, and surgery-related factors and postoperative outcome were analyzed using multinomial logistic regression. A predictive model for MVD outcome was developed using decision tree analysis.
   RESULTS: The mean follow-up duration after surgery was 30.2 months (median, 23.5 months; range, 6.0-133.3 months). For the 1624 patients, the overall improvement rate was 90.5%. Overall, 984 patients (60.6%) showed improvement of spasm immediately after surgery, 486 (29.9%) experienced delayed improvement, and 154 (9.5%) showed persistence of spasm. Outcome of patients with HFS after MVD was predicted by 4 items: postoperative delayed facial palsy, degree of preoperative spasm, intraoperative indentation on the facial nerve, and sex. The patients were classified into 6 categories and improvement of spasm immediately after surgery showed 35%-91%, delayed improvement 6%-46%, and persistence of spasm 0%-59%. The accuracy of the developed prediction model was 0.608.
   CONCLUSIONS: Male sex, mild degree of preoperative spasm, intraoperative indentation on the facial nerve, and postoperative delayed facial palsy were better favorable prognostic factors of MVD in patients with HFS. This novel algorithm may be useful to predict the outcome of MVD in these patients.
C1 [Lee, Jeong-A.; Kong, Doo-Sik; Lee, Seunghoon; Park, Kwan] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Neurosurg, Seoul, South Korea.
   [Park, Sang-Ku] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Neurol, Seoul, South Korea.
   [Kim, Kyung-Hee] Chung Ang Univ, Dept Nursing, Seoul, South Korea.
RP Park, K (reprint author), Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Neurosurg, Seoul, South Korea.
EM kwanpark@skku.edu
OI Park, Sang-Ku/0000-0002-0546-9014
CR Chang WS, 2012, ACTA NEUROCHIR, V154, P1613, DOI 10.1007/s00701-012-1424-z
   Cheng J, 2015, WORLD NEUROSURG, V84, P920, DOI 10.1016/j.wneu.2015.04.040
   Chung SS, 2001, STEREOT FUNCT NEUROS, V77, P190, DOI 10.1159/000064620
   Hatayama T, 2015, NEUROL MED-CHIR, V55, P663, DOI 10.2176/nmc.ra.2014-0386
   Hothorn T, 2006, J COMPUT GRAPH STAT, V15, P651, DOI 10.1198/106186006X133933
   Hothorn T, 2006, AM STAT, V60, P257, DOI 10.1198/000313006X118430
   Hua Z, 2016, J CRANIOFAC SURG, V27, P781, DOI 10.1097/SCS.0000000000002521
   Ishikawa M, 2001, NEUROSURGERY, V49, P847, DOI 10.1097/00006123-200110000-00013
   Jin YC, 2015, NEUROSURG REV, V38, P567, DOI 10.1007/s10143-015-0622-6
   Jo KW, 2013, NEUROSURG REV, V36, P297, DOI 10.1007/s10143-012-0420-3
   Kim HR, 2009, J KOREAN NEUROSURG S, V45, P336, DOI 10.3340/jkns.2009.45.6.336
   Kong DS, 2006, J KOREAN SKULL BASE, V1, P84
   Lee JA, 2012, STEREOT FUNCT NEUROS, V90, P16, DOI 10.1159/000330396
   Lee MH, 2016, NEUROSURG REV, V39, P151, DOI 10.1007/s10143-015-0666-7
   Li CS, 2005, ACTA NEUROCHIR, V147, P617, DOI 10.1007/s00701-005-0492-8
   Li ST, 2016, WORLD NEUROSURG, V92, P218, DOI 10.1016/j.wneu.2016.05.012
   Li ST, 2010, ACTA NEUROCHIR, V152, P2113, DOI 10.1007/s00701-010-0837-9
   Liu LX, 2016, ACTA NEUROCHIR, V158, P379, DOI 10.1007/s00701-015-2652-9
   Lv MY, 2017, BRIT J NEUROSURG, V31, P322, DOI 10.1080/02688697.2017.1297368
   Miller LE, 2012, BRIT J NEUROSURG, V26, P438, DOI 10.3109/02688697.2011.641613
   Oh ET, 2008, J KOREAN NEUROSURG S, V44, P245, DOI 10.3340/jkns.2008.44.4.245
   Park JS, 2008, ACTA NEUROCHIR, V150, P235, DOI 10.1007/s00701-007-1457-x
   Shah A, 2017, BRIT J NEUROSURG, V31, P327, DOI 10.1080/02688697.2016.1257110
   Soriano-Baron Hector, 2015, Surg Neurol Int, V6, P83, DOI 10.4103/2152-7806.157443
   Strobl C, 2009, PSYCHOL METHODS, V14, P323, DOI 10.1037/a0016973
   Terasaka S, 2016, NEUROSURG REV, V39, P607, DOI 10.1007/s10143-016-0729-4
   Wang XH, 2013, NEUROSURG REV, V36, P637, DOI 10.1007/s10143-013-0480-z
   Weber C., 1999, MATH METHODS STAT, V8, P220
   Xia L, 2015, J CRANIOFAC SURG, V26, P408, DOI 10.1097/SCS.0000000000001406
   2013, NEUROSURG REV, V36, P637, DOI DOI 10.1007/S10143-013-0480-Z
   2001, NEUROSURGERY, V49, P847
   2006, NEUROSURGERY, V58, P1162, DOI DOI 10.1227/01.NEU.0000215954.97948.B3
   2013, NEUROSURG REV, V36, P297, DOI DOI 10.1007/S10143-012-0420-3
NR 33
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E797
EP E806
DI 10.1016/j.wneu.2019.01.172
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700098
PM 30738936
DA 2020-05-12
ER

PT J
AU Lee, MH
   Kim, J
   Kim, ST
   Shin, HM
   You, HJ
   Choi, JW
   Seol, HJ
   Nam, DH
   Lee, JI
   Kong, DS
AF Lee, Min Ho
   Kim, Junhyung
   Kim, Sung-Tae
   Shin, Hye-Mi
   You, Hye-Jin
   Choi, Jung Won
   Seol, Ho Jun
   Nam, Do-Hyun
   Lee, Jung-Il
   Kong, Doo-Sik
TI Prediction of IDH1 Mutation Status in Glioblastoma Using Machine
   Learning Technique Based on Quantitative Radiomic Data
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioblastoma; Isocitrate dehydrogenase; Machine learning; Magnetic
   resonance imaging; Mutation
ID ADC HISTOGRAM ANALYSIS; MAGNETIC-RESONANCE-SPECTROSCOPY;
   GENE-EXPRESSION; RADIOGENOMIC ANALYSIS; VOLUMETRIC-ANALYSIS; IMAGING
   BIOMARKER; MOLECULAR SUBTYPE; SURVIVAL; MULTIFORME; GLIOMAS
AB OBJECTIVE: Isocitrate dehydrogenase 1 (IDH1) mutation status is an independent favorable prognostic factor for glioblastoma (GBM) and is usually determined by sequencing or immunohistochemistry. An accurate prediction of IDH1 mutation status via noninvasive methods helps establish the appropriate treatment strategy. We aimed to predict IDH1 mutation status using quantitative radiomic data in patients with GBM.
   METHODS: Between May 2010 and June 2015, we retrospectively identified 88 patients with newly diagnosed GBM. After semiautomatic segmentation of the lesions, we extracted 31 features from preoperative multiparametric magnetic resonance images. We also determined IDH1 mutation status using targeted sequencing and immunohistochemistry. A training cohort (n = 88) was used to train machine learning-based classifiers, with internal validation. The machine-learning technique was then validated in an external dataset of 35 patients with GBM.
   RESULTS: We detected the IDH1 mutation in 12 out of 88 GBMs. Multiparametric radiomic profiles revealed that the IDH1 mutation was associated with a smaller enhancing area volume and a larger necrotic area volume. Using the machine learning-based classification algorithms, we identified 70.3%-87.3% of prediction rate of IDH1 mutation status and found 66.3%-83.4% accuracy in the external validation set.
   CONCLUSIONS: We demonstrate that machine learning algorithms can predict IDH1 mutation status in GBM using preoperative multiparametric magnetic resonance images.
C1 [Lee, Min Ho; Choi, Jung Won; Seol, Ho Jun; Nam, Do-Hyun; Lee, Jung-Il; Kong, Doo-Sik] Sungkyunkwan Univ, Sch Med, Brain Tumor Ctr, Dept Neurosurg, Seoul, South Korea.
   [Kim, Sung-Tae] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiol, Seoul, South Korea.
   [Kim, Junhyung] Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea.
   [Shin, Hye-Mi; You, Hye-Jin; Nam, Do-Hyun] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea.
RP Kong, DS (reprint author), Sungkyunkwan Univ, Sch Med, Brain Tumor Ctr, Dept Neurosurg, Seoul, South Korea.
EM neurokong@gmail.com
OI Lee, Min Ho/0000-0001-6174-7579
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI14C3418, NRF-2015M3A9A7029740]; National Research Foundation
   - Ministry of Science, ICT, and Future Planning (MSIP) of Korea
FX This research was supported by a grant from the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   (HI14C3418), and by a grant (NRF-2015M3A9A7029740) from the National
   Research Foundation, funded by the Ministry of Science, ICT, and Future
   Planning (MSIP) of Korea. There are no known conflicts of interest
   associated with this publication.
CR Baldock AL, 2014, NEURO-ONCOLOGY, V16, P779, DOI 10.1093/neuonc/nou027
   Carlson MRJ, 2007, CLIN CANCER RES, V13, P2592, DOI 10.1158/1078-0432.CCR-06-2772
   Colen RR, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-30
   de la Fuente MI, 2016, NEURO-ONCOLOGY, V18, P283, DOI 10.1093/neuonc/nov307
   Diehn M, 2008, P NATL ACAD SCI USA, V105, P5213, DOI 10.1073/pnas.0801279105
   Ellingson BM, 2014, AM J NEURORADIOL, V35, P673, DOI 10.3174/ajnr.A3748
   Ellingson BM, 2013, AM J NEURORADIOL, V34, P533, DOI 10.3174/ajnr.A3253
   Ellingson BM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-014-0506-0
   Ellingson BM, 2011, J NEURO-ONCOL, V102, P95, DOI 10.1007/s11060-010-0293-7
   Emblem KE, 2015, RADIOLOGY, V275, P228, DOI 10.1148/radiol.14140770
   Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490
   Gevaert O, 2014, RADIOLOGY, V273, P168, DOI 10.1148/radiol.14131731
   Gutman DA, 2013, RADIOLOGY, V267, P560, DOI 10.1148/radiol.13120118
   Hartmann C, 2010, ACTA NEUROPATHOL, V120, P707, DOI 10.1007/s00401-010-0781-z
   Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9
   Houillier C, 2010, NEUROLOGY, V75, P1560, DOI 10.1212/WNL.0b013e3181f96282
   Hu LS, 2017, NEURO-ONCOLOGY, V19, P128, DOI 10.1093/neuonc/now135
   Ichimura K, 2009, NEURO-ONCOLOGY, V11, P341, DOI 10.1215/15228517-2009-025
   Kong DS, 2016, ONCOTARGET, V7, P11526, DOI 10.18632/oncotarget.7115
   Laing C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071947
   Lambin P, 2013, NAT REV CLIN ONCOL, V10, P27, DOI 10.1038/nrclinonc.2012.196
   Lambin P, 2012, EUR J CANCER, V48, P441, DOI 10.1016/j.ejca.2011.11.036
   Lee JK, 2017, NAT GENET, V49, P594, DOI 10.1038/ng.3806
   Leu K, 2017, J NEURO-ONCOL, V134, P177, DOI 10.1007/s11060-017-2506-9
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Macyszyn L, 2016, NEURO-ONCOLOGY, V18, P417, DOI 10.1093/neuonc/nov127
   Mohri M, 2012, FDN MACHINE LEARNING, P480
   Naeini KM, 2013, NEURO-ONCOLOGY, V15, P626, DOI 10.1093/neuonc/not008
   Nagashima H, 2016, NEURO-ONCOLOGY, V18, P1559, DOI 10.1093/neuonc/now090
   Natsumeda M, 2018, NEUROSURG REV, V41, P641, DOI 10.1007/s10143-017-0908-y
   Nobusawa S, 2009, CLIN CANCER RES, V15, P6002, DOI 10.1158/1078-0432.CCR-09-0715
   Ohgaki H, 2014, CLIN CANCER RES, V20, P2013, DOI 10.1158/1078-0432.CCR-14-0238
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159
   Pope WB, 2012, AM J NEURORADIOL, V33, P1059, DOI 10.3174/ajnr.A2917
   Pope WB, 2011, AM J NEURORADIOL, V32, P882, DOI 10.3174/ajnr.A2385
   Pope WB, 2008, RADIOLOGY, V249, P268, DOI 10.1148/radiol.2491072000
   Pope WB, 2015, NEUROIMAG CLIN N AM, V25, P105, DOI 10.1016/j.nic.2014.09.006
   Pope WB, 2009, RADIOLOGY, V252, P182, DOI 10.1148/radiol.2521081534
   Qi ST, 2014, ONCOL LETT, V7, P1895, DOI 10.3892/ol.2014.2013
   Sanson M, 2009, J CLIN ONCOL, V27, P4150, DOI 10.1200/JCO.2009.21.9832
   Sonoda Y, 2015, BRAIN TUMOR PATHOL, V32, P99, DOI 10.1007/s10014-014-0211-3
   Tietze A, 2018, J NEUROSURG, V128, P391, DOI 10.3171/2016.10.JNS161793
   Yamashita K, 2016, AM J NEURORADIOL, V37, P58, DOI 10.3174/ajnr.A4491
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
   Zacharaki EI, 2012, AM J NEURORADIOL, V33, P1065, DOI 10.3174/ajnr.A2939
   Zhang BQ, 2017, NEURO-ONCOLOGY, V19, P109, DOI 10.1093/neuonc/now121
   Zinn PO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025451
NR 48
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E688
EP E696
DI 10.1016/j.wneu.2019.01.157
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700086
PM 30735871
DA 2020-05-12
ER

PT J
AU Li, GZ
   Wang, Q
   Liu, H
   Yang, Y
AF Li, Guangzhou
   Wang, Qing
   Liu, Hao
   Yang, Yi
TI Postoperative Heterotopic Ossification After Cervical Disc Replacement
   Is Likely a Reflection of the Degeneration Process
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent segment degeneration; Cervical disc replacement; Degeneration;
   Heterotopic ossification; Spondylosis
ID FOLLOW-UP; ARTHROPLASTY; ADJACENT; FUSION; CLASSIFICATION; OUTCOMES;
   DISEASE
AB BACKGROUND: The cause of postoperative heterotopic ossification (HO) after cervical disc replacement (CDR) is unclear. The aim of the present study was to investigate the incidence of HO, its clinical significance, and whether the degree of preoperative degeneration was associated with its occurrence.
   METHODS: Patients who had undergone CDR using the Prestige-LP disc with a minimum of 48 months of follow-up were included. The patients were divided into 2 groups stratified by the presence of HO. The clinical outcomes (visual analog scale for neck and arm pain, neck disability index, and Japanese Orthopaedic Association scores) and radiographic parameters were collected and analyzed pre- and postoperatively and compared between the 2 groups. The preoperative degeneration at the operated levels was evaluated using the Kellgren-Lawrence scale and Miyazaki magnetic resonance imaging grading system.
   RESULTS: A total of 69 patients (89 levels) were identified, and the average age at surgery was 45.8 years. The overall incidence of HO at the final follow-up visit was 37.7% (26 of 69 of patients), and an increasing incidence and severity of HO was observed during the follow-up period. Significant and maintained improvements for all clinical outcome measures were observed, and the presence of HO did not influence these improvements. Segments with greater severe preoperative degeneration had a greater incidence of HO (P < 0.01). However, no statistical significant correlation between the degree of preoperative degeneration and the grade of HO was observed.
   CONCLUSION: The presence of HO after CDR was a relatively frequent finding at the final follow-up visit but did not influence patients' improvements. Segments with higher grades of preoperative degeneration had a greater incidence of HO; thus, HO is likely a reflection of the degeneration process.
C1 [Li, Guangzhou; Liu, Hao; Yang, Yi] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Sichuan, Peoples R China.
   [Li, Guangzhou; Wang, Qing] Southwest Med Univ, Dept Spine Surg, Affiliated Hosp, Luzhou, Peoples R China.
RP Liu, H (reprint author), Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Sichuan, Peoples R China.
EM pro_liuhao@163.com
CR Chang HK, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.10.FOCUS16411
   Chung SB, 2012, ACTA NEUROCHIR, V154, P1017, DOI 10.1007/s00701-012-1309-1
   Ding C, 2013, ACTA ORTHOP BELG, V79, P338
   Eck JC, 2002, SPINE, V27, P2431, DOI 10.1097/00007632-200211150-00003
   Gornet MF, 2016, INT J SPINE SURG, V10, DOI 10.14444/3024
   Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009
   Hisey MS, 2015, J SPINAL DISORD TECH, V28, pE237, DOI 10.1097/BSD.0000000000000185
   Kang J, 2015, EUR SPINE J, V24, P2023, DOI 10.1007/s00586-015-4096-6
   Kaye ID, 2017, CURR REV MUSCULOSKE, V10, P147, DOI 10.1007/s12178-017-9396-5
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Kim KS, 2016, CLIN SPINE SURG, V29, pE309, DOI 10.1097/BSD.0000000000000054
   Lanman TH, 2017, J NEUROSURG-SPINE, V27, P7, DOI 10.3171/2016.11.SPINE16746
   Lee JH, 2010, SPINE J, V10, P676, DOI 10.1016/j.spinee.2010.04.017
   McAfee PC, 2003, J SPINAL DISORD TECH, V16, P384, DOI 10.1097/00024720-200308000-00010
   McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256-005-0958-z
   Mehren C, 2017, EUR SPINE J, V26, P2441, DOI 10.1007/s00586-017-5204-6
   MENKES CJ, 1991, J RHEUMATOL, V18, P13
   Miyazaki M, 2008, J SPINAL DISORD TECH, V21, P288, DOI 10.1097/BSD.0b013e31813c0e59
   Robertson JT, 2005, J NEUROSURG-SPINE, V3, P417, DOI 10.3171/spi.2005.3.6.0417
   Tu TH, 2011, J NEUROSURG-SPINE, V14, P457, DOI 10.3171/2010.11.SPINE10444
   Wu JC, 2012, J NEUROSURG-SPINE, V16, P163, DOI 10.3171/2011.10.SPINE11497
   Yi S, 2010, SPINE, V35, P1556, DOI 10.1097/BRS.0b013e3181c6526b
   Zhou FF, 2018, SPINE, V43, pE163, DOI 10.1097/BRS.0000000000002264
   Zhou HH, 2015, SPINE, V40, pE332, DOI 10.1097/BRS.0000000000000776
   2005, NEUROSURGERY, V57, P759, DOI DOI 10.1227/01.NEU.0000175856.31210.58
NR 25
TC 4
Z9 4
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1063
EP E1068
DI 10.1016/j.wneu.2019.01.244
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700132
PM 30780040
DA 2020-05-12
ER

PT J
AU Li, H
   Zhang, B
   Wang, W
   Wei, MH
   Liu, BY
   Wu, Z
AF Li, Huan
   Zhang, Bin
   Wang, Wei
   Wei, Ming-Hao
   Liu, Bai-Yun
   Wu, Zhen
TI Clinical Features, Intradural Transcavernous Surgical Management, and
   Outcomes of Giant Cavernous Sinus Hemangiomas: A Single-Institution
   Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus; Hemangioma; Intradural approach; Transcavernous
ID GAMMA-KNIFE RADIOSURGERY; STEREOTACTIC RADIOSURGERY; CRANIAL NERVES;
   SURGERY; MENINGIOMAS; DIAGNOSIS; TOLERANCE
AB BACKGROUND: Cavernous sinus hemangiomas (CSHs) are rare vascular tumors. Stereotactic radiosurgery is an effective treatment for small CSHs. The optimal treatment for giant CSHs is controversial. This study reports advantages of a complete intradural transcavernous approach in total resection of CSHs.
   METHODS: Between January 2012 and January 2017, 15 patients with giant CSHs were treated surgically. All cases were evaluated with a contrast-enhanced magnetic resonance imaging scan and confirmed histopathologically. A complete intradural approach was used for all patients. Clinical manifestations, radiographic characteristics, operative techniques, and outcomes of patients were analyzed.
   RESULTS: Headache was the most common initial symptom, followed by decreased visual acuity and diplopia. Postoperative magnetic resonance imaging showed that gross total resection was achieved in 13 patients. Two patients had experienced total ipsilateral visual loss for several years before surgery; vision improved in all remaining patients with preoperative visual diminution. The most common early neurologic deficit was cranial nerve VI dysfunction, which was observed in 9 patients (60%; 5 new deficits). Only 2 patients (13.3%) experienced permanent morbidity on long-term follow-up. The early postoperative morbidity rate for cranial nerve III dysfunction was 33.3% (5 patients), and only 1 patient (6.7%) experienced permanent morbidity. Four patients (26.7%) had slight postoperative facial numbness.
   CONCLUSIONS: Surgical total resection is the primary and reasonable choice for giant CSHs. Microsurgical resection of giant CSHs through a completely intradural transcavernous approach is an alternative treatment option for giant CSHs.
C1 [Li, Huan; Zhang, Bin; Wang, Wei; Wei, Ming-Hao; Liu, Bai-Yun; Wu, Zhen] Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Liu, Bai-Yun] Capital Med Univ, Beijing Neurosurg Inst, Neurotrauma Lab, Beijing, Peoples R China.
   [Liu, Bai-Yun] Beijing Inst Brain Disorders, Nerve Injury & Repair Ctr, Beijing, Peoples R China.
   [Liu, Bai-Yun] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Liu, Bai-Yun] Beijing Key Lab Cent Nervous Syst Injury, Beijing, Peoples R China.
   [Wang, Wei] Tianjin Fifth Ctr Hosp, Dept Neurosurg, Tianjin, Peoples R China.
RP Liu, BY (reprint author), Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM liubaiyun1212@163.com
CR Bansal S, 2014, J CLIN NEUROSCI, V21, P968, DOI 10.1016/j.jocn.2013.09.008
   BRADAC GB, 1987, NEURORADIOLOGY, V29, P578, DOI 10.1007/BF00350447
   Chou CW, 2010, NEUROSURGERY, V67, P611, DOI 10.1227/01.NEU.0000378026.23116.E6
   Goel A, 2003, NEUROL MED-CHIR, V43, P112, DOI 10.2176/nmc.43.112
   Gonzalez L Fernando, 2006, Neurosurg Focus, V21, pe6
   Ivanov P, 2008, MINIM INVAS NEUROSUR, V51, P140, DOI 10.1055/s-2008-1065346
   Iwai Y, 1999, NEUROL MED-CHIR, V39, P288, DOI 10.2176/nmc.39.288
   Khan AA, 2009, NEUROSURGERY, V65, P914, DOI 10.1227/01.NEU.0000356987.98197.71
   Leavitt JA, 2013, INT J RADIAT ONCOL, V87, P524, DOI 10.1016/j.ijrobp.2013.06.2047
   Leber KA, 1998, J NEUROSURG, V88, P43, DOI 10.3171/jns.1998.88.1.0043
   Lee CC, 2017, J NEUROSURG, V126, P1498, DOI 10.3171/2016.4.JNS152097
   Li MH, 2015, CLIN NEUROL NEUROSUR, V136, P110, DOI 10.1016/j.clineuro.2015.06.004
   Li P, 2012, J NEUROSURG, V117, P89, DOI 10.3171/2012.7.GKS12992
   LINSKEY ME, 1992, NEUROSURGERY, V30, P101, DOI 10.1227/00006123-199201000-00018
   Mahajan A, 2017, WORLD J RADIOL, V9, P330, DOI 10.4329/wjr.v9.i8.330
   Mirzayan MJ, 2007, NEUROSURGERY, V60, P952, DOI 10.1227/01.NEU.0000255428.16550.72
   Natarajan SK, 2007, NEUROSURGERY, V60, P965, DOI 10.1227/01.NEU.0000255472.52882.D6
   Park CK, 2016, ACTA NEUROCHIR, V158, P313, DOI 10.1007/s00701-015-2657-4
   Peker S, 2004, ACTA NEUROCHIR, V146, P337, DOI 10.1007/s00701-004-0231-6
   Seo Y, 2000, NEUROL MED-CHIR, V40, P575, DOI 10.2176/nmc.40.575
   Shi JX, 1999, NEUROSURGERY, V45, P1308, DOI 10.1097/00006123-199912000-00006
   Sohn CH, 2003, AM J NEURORADIOL, V24, P1148
   Song SW, 2014, J NEURO-ONCOL, V118, P163, DOI 10.1007/s11060-014-1414-5
   Suri A, 2007, NEUROSURGERY, V60, P483, DOI 10.1227/01.NEU.0000255333.95532.13
   Thompson TP, 2000, NEUROSURGERY, V47, P778, DOI 10.1097/00006123-200009000-00052
   TISHLER RB, 1993, INT J RADIAT ONCOL, V27, P215, DOI 10.1016/0360-3016(93)90230-S
   Wang X, 2018, J NEUROSURG, V128, P60, DOI 10.3171/2016.10.JNS16693
   Wang Y, 2016, WORLD NEUROSURG, V94, P18, DOI 10.1016/j.wneu.2016.06.094
   Yamamoto M, 2010, J NEUROSURG, V112, P772, DOI 10.3171/2009.6.JNS08271
   Yin YH, 2013, J CLIN NEUROSCI, V20, P128, DOI 10.1016/j.jocn.2012.01.050
   Zhou LF, 2003, SURG NEUROL, V60, P31, DOI 10.1016/S0090-3019(03)00190-3
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E754
EP E763
DI 10.1016/j.wneu.2019.01.165
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700093
PM 30735865
DA 2020-05-12
ER

PT J
AU Li, YZ
   Zhang, XY
   Dai, J
   Wang, JS
   Wu, H
   Liu, JH
   Chen, J
   Zhu, YX
   Zhao, FD
AF Li, Yongzhong
   Zhang, Xuyang
   Dai, Jie
   Wang, Jiasheng
   Wu, Hao
   Liu, Junhui
   Chen, Jian
   Zhu, Yixiao
   Zhao, Fengdong
TI Changes in the Flexion-Relaxation Response After Percutaneous Endoscopic
   Lumbar Discectomy in Patients with Disc Herniation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Flexion-relaxation; Lumbar disc herniation; Percutaneous endoscopic
   lumbar discectomy; Surface electromyography
ID LOW-BACK-PAIN; ERECTORES SPINAE; MUSCLE FUNCTION; DYNAMIC EMG; BEHAVIOR;
   RESPONSIVENESS; PERFORMANCE; PATTERNS; MODEL; FEAR
AB BACKGROUND: Previous studies of percutaneous endoscopic lumbar discectomy (PELD) to treat lumbar disc herniation (LDH) have shown good clinical results. However, limited information has been reported regarding postoperative improvement in back muscle function. We aimed to determine whether changes in neuromuscular patterns, assessed using the flexion-relaxation phenomenon (FRP), could be observed after PELD.
   METHODS: A total of 30 patients participated in the present study. The patients' muscle functions were evaluated before and after PELD using surface electromyography and self-report measures. The evaluated action included 3 repetitions of a trunk flexion and extension movement. The association between the FRP measures and patient-reported outcomes was evaluated.
   RESULTS: At 4 weeks after PELD, the patients had significantly lower visual analog scale and Quebec Back Pain Disability Scale (QBPDS) scores and significantly increased gross range of motion. Also, we observed a reduction in erector spinae muscle activation at L3 in the maximum voluntary flexion phase. Normalized electromyographic root-mean-square values were significantly reduced in the maximum voluntary flexion phase and significantly increased in the extension phase. Postoperatively, 60% of the patients successfully achieved flexion-relaxation compared with 7% of the patients preoperatively. A significant correlation was found between the FRP measures and patient-reported outcomes, except for the Fear-Avoidance Beliefs Questionnaire scale.
   CONCLUSION: PELD for individuals with LDH appears to normalize paraspinal muscle activation during lumbar flexion-extension movement. The gross range of motion and disability-related limitations of physical activity also improved.
C1 [Li, Yongzhong; Zhang, Xuyang; Wang, Jiasheng; Wu, Hao; Liu, Junhui; Chen, Jian; Zhao, Fengdong] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
   [Dai, Jie] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Rehabil Med, Hangzhou, Zhejiang, Peoples R China.
   [Zhu, Yixiao] Xiaohehushu St Community Hlth Serv Ctr, Dept Rehabil Med, Hangzhou, Zhejiang, Peoples R China.
RP Zhao, FD (reprint author), Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
EM zhaofengdong@zju.edu.cn
OI Zhao, Fengdong/0000-0002-2945-8707
CR Agha RA, 2017, INT J SURG, V46, P198, DOI 10.1016/j.ijsu.2017.08.586
   AHERN DK, 1990, SPINE, V15, P92, DOI 10.1097/00007632-199002000-00008
   Colloca CJ, 2005, J MANIP PHYSIOL THER, V28, P623, DOI 10.1016/j.jmpt.2005.08.005
   Descarreaux M, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-10
   Durmus D, 2010, RHEUMATOL INT, V30, P901, DOI 10.1007/s00296-009-1072-7
   FLOYD WF, 1955, J PHYSIOL-LONDON, V129, P184, DOI 10.1113/jphysiol.1955.sp005347
   Gadjradj PS, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.10.FOCUS15484
   Geisser ME, 2005, J PAIN, V6, P711, DOI 10.1016/j.jpain.2005.06.008
   Geisser ME, 2004, CLIN J PAIN, V20, P61, DOI 10.1097/00002508-200403000-00001
   Gejo R, 1999, SPINE, V24, P1023, DOI 10.1097/00007632-199905150-00017
   GRONBLAD M, 1991, ACTA ORTHOP SCAND, V62, P614
   HAIG AJ, 1993, SPINE, V18, P926, DOI 10.1097/00007632-199306000-00020
   Hides JA, 1996, SPINE, V21, P2763, DOI 10.1097/00007632-199612010-00011
   Kaigle AM, 1998, J SPINAL DISORD, V11, P163
   Kang QJ, 2017, EXP THER MED, V13, P2927, DOI 10.3892/etm.2017.4293
   KEELEY J, 1986, SPINE, V11, P31, DOI 10.1097/00007632-198601000-00009
   KIPPERS V, 1984, SPINE, V9, P740, DOI 10.1097/00007632-198410000-00015
   Konstantinou K, 2008, SPINE, V33, P2464, DOI 10.1097/BRS.0b013e318183a4a2
   Lalanne K, 2009, J MANIP PHYSIOL THER, V32, P203, DOI 10.1016/j.jmpt.2009.02.010
   Leinonen V, 2003, SPINE, V28, P842, DOI 10.1097/00007632-200304150-00019
   LETHEM J, 1983, BEHAV RES THER, V21, P401, DOI 10.1016/0005-7967(83)90009-8
   Liang C, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1164-y
   Marshall LW, 2010, CLIN BIOMECH, V25, P6, DOI 10.1016/j.clinbiomech.2009.09.003
   Marshall P, 2006, SPINE, V31, pE877, DOI 10.1097/01.brs.0000244557.56735.05
   Mayer TG, 2009, SPINE, V34, P2458, DOI 10.1097/BRS.0b013e3181b20070
   Merletti R, 1999, IEEE T BIO-MED ENG, V46, P810, DOI 10.1109/10.771190
   Neblett R, 2003, SPINE, V28, P1435, DOI 10.1097/00007632-200307010-00015
   Neblett R, 2014, SPINE J, V14, P892, DOI 10.1016/j.spinee.2013.07.442
   Neblett R, 2010, CLIN J PAIN, V26, P403, DOI 10.1097/AJP.0b013e3181d2bd8c
   NOUWEN A, 1987, SPINE, V12, P777, DOI 10.1097/00007632-198710000-00012
   O'Shaughnessy J, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-72
   Roberts S, 1995, SPINE, V20, P2645, DOI 10.1097/00007632-199512150-00005
   Sanchez-Zuriaga D, 2015, J MANIP PHYSIOL THER, V38, P130, DOI 10.1016/j.jmpt.2014.11.002
   Sinkemani A, 2015, ASIAN SPINE J, V9, P833, DOI 10.4184/asj.2015.9.6.833
   Stubbs M, 1998, J ELECTROMYOGR KINES, V8, P197, DOI 10.1016/S1050-6411(97)00012-6
   Ramos LAV, 2016, EUR SPINE J, V25, P1435, DOI 10.1007/s00586-015-4375-2
   Wallbom AS, 2009, AM J PHYS MED REHAB, V88, P302, DOI 10.1097/PHM.0b013e318198b6ed
   Zhao K, 2005, J BIOMECH, V38, P1943, DOI 10.1016/j.jbiomech.2004.07.029
   1987, SPINE PHILA PA 1976, V12, P561
NR 39
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1042
EP E1049
DI 10.1016/j.wneu.2019.01.238
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700129
PM 30776518
DA 2020-05-12
ER

PT J
AU Liang, F
   Zhang, YP
   Yan, P
   Ma, C
   Liang, SK
   Jiang, P
   Jiang, CH
AF Liang, Fei
   Zhang, Yupeng
   Yan, Peng
   Ma, Chao
   Liang, Shikai
   Jiang, Peng
   Jiang, Chuhan
TI Predictors of Periprocedural Complications and Angiographic Outcomes of
   Endovascular Therapy for Large and Giant Intracranial Posterior
   Circulation Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular therapy; Large and giant aneurysms; Periprocedural
   complications; Pipeline embolization device; Posterior circulation
ID NATURAL-HISTORY; MANAGEMENT; PIPELINE; COILING
AB OBJECTIVE: To explore the predictors of periprocedural complications and angiographic outcomes in large and giant intracranial posterior circulation aneurysms after endovascular treatment.
   METHODS: Data from 99 patients with 103 large (>= 10 mm; n = 94) and giant (>25 mm; n = 9) posterior circulation aneurysms treated with endovascular therapy at a single center were retrospectively analyzed. The treatment procedures included endovascular trapping (n = 15), coiling (n = 6), stent only (n = 10), stent-assisted coiling (n = 48), and pipeline embolization device (PED; n = 24). The outcome endpoints were the number of periprocedural complications and number of complete occlusions without any complication.
   RESULTS: Multivariate analysis revealed that intradural vertebral aneurysms (P = 0.041) and aneurysms <= 25 mm (P = 0.042) were associated with low periprocedural complication rates after endovascular therapy. Aneurysms not involving side branches (P = 0.024) and intradural vertebral aneurysms (P = 0.032) were predictors of complete aneurysm obliteration. No statistically significant differences were found in aneurysmal complete obliteration (P = 0.119) or periprocedural complications (P = 0.248) between a PED and traditional stent and coiling. Additionally, aneurysms not involving side branches (P = 0.030), intradural vertebral artery aneurysms (P = 0.003), and aneurysms treated with a PED (P = 0.020) were more likely to achieve complete occlusion over time.
   CONCLUSIONS: Aneurysm location, aneurysm size, and side branch involvement were predictors of periprocedural complications and angiographic outcomes of endovascular therapy for large and giant intracranial posterior circulation aneurysms. PED use provided no advantages compared with traditional stent and coiling in aneurysmal occlusion rates and periprocedural complications. Large case-control and long-term follow-up studies are needed to further explore the predictors of complications and angiographic outcomes and optimal treatment options for these aneurysms.
C1 [Liang, Fei; Zhang, Yupeng; Yan, Peng; Ma, Chao; Jiang, Peng; Jiang, Chuhan] Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.
   [Liang, Fei; Zhang, Yupeng; Yan, Peng; Ma, Chao; Jiang, Peng; Jiang, Chuhan] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Liang, Shikai] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Neurosurg, Beijing, Peoples R China.
RP Jiang, CH (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.; Jiang, CH (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
EM jiangchuhan126@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81371314]; High-level Personnel Training Program of
   Beijing Health System [2013-2-016]
FX This work was supported by the National Natural Science Foundation of
   China (grant 81371314) and the High-level Personnel Training Program of
   Beijing Health System (grant 2013-2-016).
CR Becske T, 2017, J NEUROSURG, V127, P81, DOI 10.3171/2015.6.JNS15311
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Cagnazzo F, 2018, AM J NEURORADIOL, V39, P852, DOI 10.3174/ajnr.A5591
   Chalouhi N, 2014, AM J NEURORADIOL, V35, P546, DOI 10.3174/ajnr.A3696
   Choi IS, 2003, EUR J RADIOL, V46, P178, DOI 10.1016/S0720-048X(03)00090-1
   Coert BA, 2007, J NEUROSURG, V106, P855, DOI 10.3171/jns.2007.106.5.855
   Darsaut TE, 2011, NEUROSURGERY, V68, P903, DOI 10.1227/NEU.0b013e3182098ad0
   DRAKE CG, 1981, STROKE, V12, P273, DOI 10.1161/01.STR.12.3.273
   Gao X, 2012, J CLIN NEUROSCI, V19, P364, DOI 10.1016/j.jocn.2011.03.038
   Gonzalez NR, 2008, NEUROSURGERY, V62, P1324, DOI [10.1227/01.NEU.0000237559.93852.F1, 10.1227/01.neu.0000333797.59585.c0]
   Huh CW, 2018, J KOREAN NEUROSURG S, V61, P450, DOI 10.3340/jkns.2017.0606.004
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Liang F, 2018, WORLD NEUROSURG, V112, pE683, DOI 10.1016/j.wneu.2018.01.129
   Limaye US, 2012, NEUROL INDIA, V60, P597, DOI 10.4103/0028-3886.105193
   LOCKSLEY HB, 1966, J NEUROSURG, V25, P321, DOI 10.3171/jns.1966.25.3.0321
   Parkinson RJ, 2008, NEUROSURGERY, V62, P1336, DOI [10.1227/01.NEU.0000237410.32115.C9, 10.1227/01.neu.0000333798.67209.1f]
   Raymond J, 2014, AM J NEURORADIOL, V35, P1667, DOI 10.3174/ajnr.A4035
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Siddiqui AH, 2012, J NEUROSURG, V116, P1258, DOI 10.3171/2012.2.JNS111942
   van Rooij WJ, 2009, AM J NEURORADIOL, V30, P12, DOI 10.3174/ajnr.A1267
   Wang CB, 2016, NEURORADIOLOGY, V58, P391, DOI 10.1007/s00234-016-1649-2
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E378
EP E384
DI 10.1016/j.wneu.2019.01.080
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700049
PM 30703589
DA 2020-05-12
ER

PT J
AU Liu, LH
   Wang, HM
   Wang, Q
   Wang, JG
   Liang, Y
   Li, Y
   Liang, Q
   Jin, WD
   Zhou, Q
   Wang, ZL
AF Liu, Liehua
   Wang, Haoming
   Wang, Qian
   Wang, Jiangang
   Liang, Yong
   Li, Ying
   Liang, Qiang
   Jin, Weidong
   Zhou, Qiang
   Wang, Zili
TI A Study of the Sagittal Angle of Lumbar Bicortical Pedicle Screws from
   the Anatomic Perspective of the Lumbar Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Bicortical pedicle screw; Cephalic angle; Lumbar artery;
   Sagittal section angle
ID PLACEMENT
AB OBJECTIVE: To observe anatomic relationships between lumbar bicortical pedicle screws (BPSs) at 2 sagittal section angles (SSAs) and lumbar artery (LA).
   METHODS: We observed 2 SSAs, vertical angle and cephalic angle, of the BPS. The positions at which the BPS breaks through the anterior vertebral cortex were defined as point A and point B. Distances from point A and point B to LAs were measured. The percentage of risk of injury to LAs was calculated according to these distances.
   RESULTS: At the same transverse section angle on the left and right side in L1 and L2, distance from point A to LA was significantly greater than distance from point B to LA (P < 0.001) except at a transverse section angle of 0 degrees on the right side in L2 (P > 0.05). At the same transverse section angle on the left in L3 and L4, distance from point B to LA was significantly greater than distance from point A to LA (P < 0.001). The percentages of high risk of injury to the LA resulting from BPSs at the vertical angle in L1 and L2were 0% -6.2%. The percentages of high risk of injury to the LA resulting from BPSs at the cephalic angle on the left side in L3 and L4 were 0% -18.5%.
   CONCLUSIONS: Lumbar BPSs present a risk of injury to the LA. The vertical angle is the recommended SSA for BPSs in L1 and L2, and the cephalic angle is the recommended SSA in L3 and L4.
C1 [Liu, Liehua; Liang, Qiang; Jin, Weidong; Wang, Zili] Ningxia Med Univ, Gen Hosp, Dept Spinal Surg, Yinchuan, Peoples R China.
   [Liu, Liehua; Zhou, Qiang] Chongqing Med Univ, Gen Hosp, Affiliated Hosp 3, Dept Spine Surg, Chongqing, Peoples R China.
   [Wang, Haoming] Three Gorges Cent Hosp, Dept Orthoped, Chongqing, Peoples R China.
   [Wang, Jiangang] 13 Peoples Hosp Chongqing, Dept Orthoped, Chongqing, Peoples R China.
   [Liang, Yong; Li, Ying] Army Third Mil Med Univ, Southwest Hosp, Dept Radiol, Chongqing, Peoples R China.
RP Wang, ZL (reprint author), Ningxia Med Univ, Gen Hosp, Dept Spinal Surg, Yinchuan, Peoples R China.
EM wangzlnx@126.com
FU Chongqing Municipal Health and the Family Planning Commission
   [2015MSXM083, 2016MSXM084]
FX This work was supported by Chongqing Municipal Health and the Family
   Planning Commission (Grant Nos. 2015MSXM083 and 2016MSXM084).
CR Alvarez Postigo M, 2017, Rev Esp Cir Ortop Traumatol, V61, P436, DOI 10.1016/j.recot.2017.06.003
   Bezer M, 2012, J SPINAL DISORD TECH, V25, pE178, DOI 10.1097/BSD.0b013e31825dd542
   Iwamoto S, 2016, J MED INVESTIG, V63, P45, DOI 10.2152/jmi.63.45
   Karami KJ, 2015, J SPINAL DISORD TECH, V28, pE133, DOI 10.1097/BSD.0000000000000178
   Kato M, 2015, J SPINAL DISORD TECH, V28, pE336, DOI 10.1097/BSD.0b013e31828ffc70
   Kim YY, 2015, EUR SPINE J, V24, P2525, DOI 10.1007/s00586-015-4159-8
   Le Cann S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127463
   Liu LH, 2015, BIOMED RES INT, DOI 10.1155/2015/357206
   MIRKOVIC S, 1991, SPINE PHILA PA 197 S, V16, pS28
   Nishihara M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185923
   Pillai ST, 2014, J CARDIAC SURG, V29, P377, DOI 10.1111/jocs.12327
   Ponnusamy KE, 2011, SPINE J, V11, P54, DOI 10.1016/j.spinee.2010.09.024
   Sugimoto Y, 2013, ACTA MED OKAYAMA, V67, P113
   Tulamo R, 2018, J NEUROINTERV SURG, V10, pI58, DOI 10.1136/jnis.2009.002055.rep
   Zerati AE, 2017, ANN VASC SURG, V39, DOI 10.1016/j.avsg.2016.06.020
   2001, J NEUROSURG S, V95, P253
NR 16
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E435
EP E441
DI 10.1016/j.wneu.2019.01.100
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700058
PM 30708080
DA 2020-05-12
ER

PT J
AU Longo, M
   Ramos, RD
   Gelfand, Y
   Echt, M
   Kinon, MD
   Yassari, R
AF Longo, Michael
   Ramos, Rafael De la Garza
   Gelfand, Yaroslav
   Echt, Murray
   Kinon, Merritt D.
   Yassari, Reza
TI Incidence and Predictors of Hardware Failure After Instrumentation for
   Spine Metastasis: A Single-Institutional Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hardware failure; Instrumentation failure; Multiple myeloma; Spine
   metastasis
ID BONE-RESORPTION; MULTIPLE-MYELOMA; RIB CAGE; RECONSTRUCTION;
   INSTABILITY; RESECTION; SURVIVAL; OUTCOMES; MARKERS; LESIONS
AB OBJECTIVE: We report a retrospective analysis of hardware failure in patients requiring instrumentation for spinal metastasis.
   METHODS: In a retrospective study at a single institution, we identified 58 patients who underwent spinal instrumentation for metastasis from 2012 to 2018. Hardware failure was defined as screw pullout/loosening, cage migration, progressive kyphosis, or an otherwise-noticeable instrumentation deficit detectable on imaging. Risk factors for hardware failure with a P < 0.05 in in univariate were included in multivariate logistic regression models controlled for age, sex, and previously identified risk factors for hardware failure.
   RESULTS: In total, 58 patients required instrumentation for metastatic spine disease. Median age was 60.2 years (interquartile range 49.0-66.3), 38 patients (65.5%) were male, and median follow-up was 8.1 months (interquartile range 3.1-20.7). Eight patients (13.8%) developed signs of hardware failure during follow-up, of whom 2 patients (3.4%) underwent operative revision. In univariate analysis, Eastern Cooperative Oncology Group performance status >2 (P = 0.049) and multiple myeloma lesions (P = 0.010) were significant predictors of failure. Both factors maintained significance in a multivariate logistic regression model controlled for age, sex, history of spine radiation, and number of fused levels with P = 0.047; odds ratio 12.7 (95% confidence interval 1.03-156.4) for Eastern Cooperative Oncology Group performance status over 2 and P = 0.012; odds ratio 31.5 (95% confidence interval 2.2-460.0) for multiple myeloma lesions.
   CONCLUSIONS: The rate of hardware failure in this cohort was 13.8%, although operative revision rate was 3.4%. Spinal instrumentation in patients with poor preoperative functional status or multiple myeloma may be more likely to develop instrumentation failure.
C1 [Longo, Michael; Ramos, Rafael De la Garza; Gelfand, Yaroslav; Echt, Murray; Kinon, Merritt D.; Yassari, Reza] Montefiore Med Ctr, Albert Einstein Coll Med, Spine Res Grp, Bronx, NY 10467 USA.
   [Ramos, Rafael De la Garza; Gelfand, Yaroslav; Echt, Murray; Kinon, Merritt D.; Yassari, Reza] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol Surg, Bronx, NY 10467 USA.
RP Yassari, R (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Spine Res Grp, Bronx, NY 10467 USA.; Yassari, R (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol Surg, Bronx, NY 10467 USA.
EM ryassari@montefiore.org
OI Echt, Murray/0000-0002-4504-4918; Longo, Michael/0000-0002-2462-6118
CR Akeyson EW, 1996, J NEUROSURG, V85, P211, DOI 10.3171/jns.1996.85.2.0211
   Amankulor NM, 2014, SPINE J, V14, P1850, DOI 10.1016/j.spinee.2013.10.028
   Amelot A, 2017, SPINE, V42, P400, DOI 10.1097/BRS.0000000000001766
   de Ruiter GCW, 2014, SPINE J, V14, P2085, DOI 10.1016/j.spinee.2013.12.029
   Douglas S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-261
   Durr HR, 2002, SPINE, V27, P320
   Epstein Nancy E, 2014, Surg Neurol Int, V5, pS66, DOI 10.4103/2152-7806.130674
   Falahati-Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Fisher CG, 2010, SPINE, V35, pE1221, DOI 10.1097/BRS.0b013e3181e16ae2
   Folsch C, 2012, BIOMED ENG-BIOMED TE, V57, P473, DOI 10.1515/bmt-2012-0012
   Frankel BA, 2007, NEUROSURGERY, V61, P531, DOI 10.1227/01.NEU.0000290899.15567.68
   Gao X, 2018, J NEURO-ONCOL, V137, P387, DOI 10.1007/s11060-017-2728-x
   Garnero P, 1996, J BONE MINER RES, V11, P1531
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Heidecke V, 2003, ACTA NEUROCHIR, V145, P873, DOI 10.1007/s00701-003-0107-1
   Jandial R, 2013, J NEUROSURG-SPINE, V19, P27, DOI 10.3171/2013.4.SPINE12344
   Johnson RD, 2014, LANDMARK PAPERS NEUR
   KURIHARA N, 1990, J IMMUNOL, V144, P4226
   Ling DC, 2018, INT J RADIAT ONCOL, V101, P602, DOI 10.1016/j.ijrobp.2018.02.035
   LIPS P, 1990, BONE MINER, V9, P49, DOI 10.1016/0169-6009(90)90099-2
   Luksanapruksa P, 2017, SPINE J, V17, P689, DOI 10.1016/j.spinee.2016.12.003
   Mannen EM, 2015, SPINE, V40, pE760, DOI 10.1097/BRS.0000000000000879
   Moon KY, 2011, J KOREAN NEUROSURG S, V50, P216, DOI 10.3340/jkns.2011.50.3.216
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Pedreira R, 2017, J CLIN NEUROSCI, V45, P166, DOI 10.1016/j.jocn.2017.05.038
   Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Uneda S, 2003, BRIT J HAEMATOL, V120, P53, DOI 10.1046/j.1365-2141.2003.04040.x
   Vrionis FD, 2004, NEUROSURG FOCUS, V15, pE12
   Wang JC, 2004, J NEUROSURG-SPINE, V1, P287, DOI 10.3171/spi.2004.1.3.0287
   Watkins R, 2005, SPINE, V30, P1283, DOI 10.1097/01.brs.0000164257.69354.bb
   Yoo Wonsuk, 2014, Int J Appl Sci Technol, V4, P9
   Zadnik PL, 2015, J NEUROSURG-SPINE, V22, P301, DOI 10.3171/2014.9.SPINE14554
   2003, ACTA NEUROCHIR WIEN, V145, P873, DOI DOI 10.1007/S00701-003-0107-1
NR 34
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1170
EP E1175
DI 10.1016/j.wneu.2019.01.272
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700145
PM 30794977
DA 2020-05-12
ER

PT J
AU Lvov, I
   Grin, A
   Talypov, A
   Kordonskiy, A
   Sytnik, A
   Khushnazarov, U
   Smirnov, V
   Krylov, V
AF Lvov, Ivan
   Grin, Andrey
   Talypov, Aleksandr
   Kordonskiy, Anton
   Sytnik, Aleksey
   Khushnazarov, Ulugbek
   Smirnov, Vladimir
   Krylov, Vladimir
TI A Comparison of the Long-Term Results of Posterior Transarticular
   Stand-Alone Screw Instrumentation and Magerl Technique in Patients with
   Traumatic Atlantoaxial Instability: Mean 5-Year Follow-Up Study with
   Radiological and Patient-Rated Outcomes Assessments
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial joint degeneration; Atlanto-odontoid joint degeneration;
   C1-C2 fusion; Magerl technique; Stand-alone screw instrumentation;
   Transarticular fixation
ID RHEUMATOID-ARTHRITIS; ODONTOID FRACTURES; FIXATION; FUSION
AB OBJECTIVE: To perform a radiological analysis of the degeneration of C1-C2 joints after C1-C2 transarticular fixation (TAF) and compare the long-term results of a routine Magerl technique (RMT) to a posterior transarticular C1-C2 stand-alone screw instrumentation (SAS) application.
   METHODS: A total of 40 patients (26 men and 14 women) were included in the present retrospective observational cohort study. The mean follow-up period was 61.7 months (range, 11-118). The mean patient age at the baseline examination was 48.4 years (range, 22-82). Of the 40 patients, 11 were included in the RMT group and 29 in the SAS group.
   RESULTS: The structure of 80 atlantoaxial joints was analyzed, with grade 4 degenerative changes observed in 57 joints (71.3%). Of the 40 analyzed atlanto-odontoid joints, grade 4 degenerative changes were revealed in 18 joints (45%). C1-C2 bone fusion was observed in 38 patients (95%) and stable fibrous fusion in 2 patients (5%). No cases of C1-C2 nonunion were revealed. No statistically significant differences in the frequency of C1-C2 fracture consolidation or C1-C2 fusion were revealed between the RMT and SAS groups.
   CONCLUSIONS: The application of cortical lag screws in TAF might result in stable atlantoaxial joint fusion formation without joint curettage. Atlanto-odontoid joint fusion was also observed after C1-C2 TAF. The application of cortical lag screws for bilateral fixation using the SAS technique resulted in C1-C2 fusion in 93.1% of cases, comparable to the results with the Magerl technique.
C1 [Lvov, Ivan; Grin, Andrey; Talypov, Aleksandr; Kordonskiy, Anton; Khushnazarov, Ulugbek; Smirnov, Vladimir; Krylov, Vladimir] Sklifosovsky Res Inst Emergency Care, Moscow, Russia.
   [Grin, Andrey; Krylov, Vladimir] AI Evdokimov Moscow Med Univ, Moscow, Russia.
   [Sytnik, Aleksey] Moscow City Hosp 13, Moscow, Russia.
RP Lvov, I (reprint author), Sklifosovsky Res Inst Emergency Care, Moscow, Russia.
EM dr.speleolog@gmail.com
OI Lvov, Ivan/0000-0003-1718-0792
CR Bapat MR, 2007, EUR SPINE J, V16, P187, DOI 10.1007/s00586-006-0071-6
   Bisson EF, 2015, J NEUROL SURG PART A, V76, P274, DOI 10.1055/s-0034-1376192
   Chun HJ, 2009, SPINE, V34, P2384, DOI 10.1097/BRS.0b013e3181b04f1d
   Elliott RE, 2014, J SPINAL DISORD TECH, V27, P11, DOI 10.1097/BSD.0b013e318277da19
   Elliott RE, 2013, WORLD NEUROSURG, V80, P627, DOI 10.1016/j.wneu.2012.03.012
   Finn MA, 2010, NEUROSURGERY, V66, pA184, DOI 10.1227/01.NEU.0000365798.53288.A3
   Ito H, 2008, SPINE, V33, P1655, DOI 10.1097/BRS.0b013e31817b5c07
   Lakshmanan P, 2005, EUR SPINE J, V14, P78, DOI 10.1007/s00586-004-0743-z
   Madawi AA, 1997, J NEUROSURG, V86, P961, DOI 10.3171/jns.1997.86.6.0961
   Magerl F, 1986, CERVICAL SPINE, P322
   Nagaria J, 2009, SPINE, V34, P2880, DOI 10.1097/BRS.0b013e3181b4e218
   Sorimachi Y, 2011, EUR SPINE J, V20, P798, DOI 10.1007/s00586-010-1611-7
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Wu AM, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018-017-0640-x
NR 14
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1138
EP E1150
DI 10.1016/j.wneu.2019.01.263
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700142
PM 30780035
DA 2020-05-12
ER

PT J
AU Ma, JP
   Li, D
   Chen, YJ
   Zhang, Y
   Song, LR
   Tian, KB
   Yang, Y
   Chen, LP
   Weng, JC
   Cao, XY
   Hao, SY
   Wang, L
   Wu, Z
   Zhang, JT
AF Ma, Junpeng
   Li, Da
   Chen, Yujia
   Zhang, Yuan
   Song, Lairong
   Tian, Kaibing
   Yang, Yang
   Chen, Liangpeng
   Weng, Jiancong
   Cao, Xiaoyu
   Hao, Shuyu
   Wang, Liang
   Wu, Zhen
   Zhang, Junting
TI Low Transforming Growth Factor-beta 3 Expression Predicts Tumor
   Malignancy in Meningiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Meningiomas; Mortality; Prognosis; Recurrence; TGF-beta 3
ID BETA-RECEPTOR EXPRESSION; BENIGN MENINGIOMAS; PROGNOSTIC-FACTORS;
   CLINICAL-FEATURES; GRADE; SURGERY; RECURRENCE; MANAGEMENT; RISK
AB OBJECTIVE: We sought to clarify the expression characteristics and prognostic significance of transforming growth factor (TGF)-beta 3 in cranial meningiomas.
   METHODS: We analyzed the expression of TGF-beta 3 at the mRNA level in 38 frozen meningioma samples. Clinical data collection, follow-up, correlations, and survival analyses were performed.
   RESULTS: World Health Organization (WHO) grade I meningiomas showed an average expression level of 2.55, which was higher than that of WHO grade II (average of 1.50) and WHO grade III (average of 0.21) (Kruskal-Wallis test, P = 0.008). For meningiomas with a history of surgery, the mean TGF-beta 3 expression level was 0.71, much lower than that of primary meningiomas with a mean value of 2.55 (Mann-Whitney U-test, P = 0.008). According to the Kaplan-Meier analysis and univariate Cox analysis, WHO grade (P = 0.001), history of surgery (P < 0.001), tumor volume (P = 0.045), preoperative Karnofsky Performance Status (P = 0.001), peritumoral brain edema (P = 0.039), postoperative radiotherapy (P = 0.001), degree of resection (P = 0.039), and TGF-beta 3 expression (P = 0.038) were prognostic factors for tumor recurrence. In addition, WHO grade (P < 0.001), history of surgery (P < 0.001), preoperative Karnofsky Performance Status (P = 0.002), peritumoral brain edema (P = 0.006), postoperative radiotherapy (P = 0.007), bone invasion (P = 0.03), and TGF-beta 3 expression (P = 0.041) were prognostic factors for mortality.
   CONCLUSIONS: TGF-beta 3 expression levels gradually declined with the increase of WHO grade and were lower in recurrent meningiomas than in primary meningiomas. Besides, low TGF-beta 3 expression was found to predict tumor recurrence and mortality in meningiomas based on univariate analysis.
C1 [Ma, Junpeng; Li, Da; Chen, Yujia; Zhang, Yuan; Song, Lairong; Tian, Kaibing; Yang, Yang; Chen, Liangpeng; Weng, Jiancong; Cao, Xiaoyu; Hao, Shuyu; Wang, Liang; Wu, Zhen; Zhang, Junting] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Ma, Junpeng; Li, Da; Chen, Yujia; Zhang, Yuan; Song, Lairong; Tian, Kaibing; Yang, Yang; Chen, Liangpeng; Weng, Jiancong; Cao, Xiaoyu; Hao, Shuyu; Wang, Liang; Wu, Zhen; Zhang, Junting] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
RP Zhang, JT (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Zhang, JT (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
EM zhangjunting2003@aliyun.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81672506, 81872052, 81472370]; Outstanding Talent
   Training Projects Foundation of Beijing [2017000021469G261,
   2017000021469G259]
FX This work was supported by the National Natural Science Foundation of
   China (81672506, Dr. Zhen Wu; 81872052, Dr. Shuyu Hao; and 81472370, Dr.
   Junting Zhang) and the Outstanding Talent Training Projects Foundation
   of Beijing (2017000021469G261, Dr. Da Li; 2017000021469G259, Dr. Yang
   Yang).
CR Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63
   Akhurst RJ, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022301
   Al-Mowallad A, 2006, ANTICANCER RES, V26, P543
   Cao XY, 2015, WORLD NEUROSURG, V84, P1014, DOI 10.1016/j.wneu.2015.05.032
   Champeaux C, 2016, J NEURO-ONCOL, V129, P337, DOI 10.1007/s11060-016-2181-2
   Condra KS, 1997, INT J RADIAT ONCOL, V39, P427, DOI 10.1016/S0360-3016(97)00317-9
   Espinosa AB, 2006, CLIN CANCER RES, V12, P772, DOI 10.1158/1078-0432.CCR-05-1480
   Figueroa JD, 2010, BREAST CANCER RES TR, V121, P727, DOI 10.1007/s10549-009-0590-z
   Gousias K, 2016, J NEUROSURG, V125, P551, DOI 10.3171/2015.9.JNS15754
   Domingues PH, 2014, NEURO-ONCOLOGY, V16, P735, DOI 10.1093/neuonc/not325
   Hug EB, 2000, J NEURO-ONCOL, V48, P151, DOI 10.1023/A:1006434124794
   Hwang WL, 2016, NEURO-ONCOLOGY, V18, P863, DOI 10.1093/neuonc/nov285
   JELLINGER K, 1975, J NEUROL, V208, P279, DOI 10.1007/BF00312803
   Johnson MD, 2017, WORLD NEUROSURG, V104, P113, DOI 10.1016/j.wneu.2017.03.058
   Johnson MD, 2011, J NEURO-ONCOL, V103, P277, DOI 10.1007/s11060-010-0399-y
   JOHNSON MD, 1992, LAB INVEST, V67, P360
   JOHNSON MD, 1992, AM J PATHOL, V141, P633
   Kim JH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006594
   Kolakshyapati M, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17730
   Kruchko C, 2018, NEURO-ONCOLOGY, V20, P295, DOI 10.1093/neuonc/noy006
   Li CG, 1998, INT J CANCER, V79, P455, DOI 10.1002/(SICI)1097-0215(19981023)79:5<455::AID-IJC2>3.3.CO;2-K
   Marciscano AE, 2016, J NEUROSURG, V124, P106, DOI 10.3171/2015.1.JNS142228
   Masalha W, 2018, J NEURO-ONCOL, V136, P147, DOI 10.1007/s11060-017-2634-2
   Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2
   Moon Kyung-Sub, 2017, Brain Tumor Research and Treatment, V5, P54
   Nanda A, 2017, J NEUROSURG, V126, P201, DOI 10.3171/2016.1.JNS151842
   Proctor DT, 2018, WORLD NEUROSURG, V119, P366, DOI 10.1016/j.wneu.2018.08.019
   Rahimi RA, 2007, J CELL BIOCHEM, V102, P593, DOI 10.1002/jcb.21501
   Soyuer S, 2004, RADIOTHER ONCOL, V71, P85, DOI 10.1016/j.radonc.2004.01.006
   Sugitani I, 1998, WORLD J SURG, V22, P731, DOI 10.1007/s002689900461
   Tao XG, 2018, J NEURO-ONCOL, V136, P515, DOI 10.1007/s11060-017-2671-x
   Zhang GJ, 2018, WORLD NEUROSURG, V117, pE57, DOI 10.1016/j.wneu.2018.04.226
   Zhang H, 2017, WORLD NEUROSURG, V97, P693, DOI 10.1016/j.wneu.2016.10.010
   Zhang Y.E., 2017, COLD SPRING HARBOR P, V9
   Zhu HD, 2015, J CLIN NEUROSCI, V22, P690, DOI 10.1016/j.jocn.2014.10.023
NR 35
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E353
EP E360
DI 10.1016/j.wneu.2019.01.077
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700046
PM 30703597
DA 2020-05-12
ER

PT J
AU Maejima, R
   Takeuchi, M
   Wakao, N
   Kamiya, M
   Aoyama, M
   Joko, M
   Osuka, K
   Takayasu, M
AF Maejima, Ryuya
   Takeuchi, Mikinobu
   Wakao, Norimitsu
   Kamiya, Mitsuhiro
   Aoyama, Masahiro
   Joko, Masahiro
   Osuka, Koji
   Takayasu, Masakazu
TI Reliability of an Intraoperative Radiographic Anteroposterior View of
   the Spinal Midline for Detection of Pedicle Screws Breaching the Medial
   Pedicle Wall in the Thoracic, Lumbar, and Sacral Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fusion; Malposition; M line; Pedicle screw; Radiography; Simple; Spinal
   midline
ID INTERBODY FUSION; ACCURACY; PLACEMENT; FIXATION; COMPLICATIONS
AB OBJECTIVE: The purpose of this study was to determine the sensitivity and specificity of using the spinal midline (M line) on a radiographic anteroposterior (AP) view for detecting pedicle screws (PSs) breaching the medial pedicle wall.
   METHODS: We retrospectively reviewed 145 patients who underwent fusion surgery using PSs between January 2006 and May 2017. We defined the M line as a line that connected the upper and lower spinous processes through the fixed vertebrae. The M line was positive if the tip of the PS crossed the M line. The reference standard was a computed tomography scan. The reliability of the M line was examined.
   RESULTS: The subjects included 145 patients (70 men and 75 women; mean age, 63.4 years). A total of 599 PSs were examined. Most cases were because of spondylolisthesis (66.9%). Most screws were inserted at a lower lumber level (77.6%). Analysis of the diagnostic accuracy of the M line yielded a sensitivity of 74.1% and a specificity of 95.3%. In addition, the positive predictive value of the M line was 42.6%, and the negative predictive value of the M line was 98.7%.
   CONCLUSIONS: Assessment of the M line via an intra-operative radiographic AP view is a simple, readily available, complementary method for detecting PSs that have breached the medial pedicle wall in the thoracic, lumbar, and sacral spine. In particular, the M line has a strong negative predictive value, which is much more meaningful.
C1 [Maejima, Ryuya; Takeuchi, Mikinobu; Aoyama, Masahiro; Joko, Masahiro; Osuka, Koji; Takayasu, Masakazu] Aichi Med Univ, Dept Neurol Sci, Nagakute, Aichi, Japan.
   [Wakao, Norimitsu; Kamiya, Mitsuhiro] Aichi Med Univ, Dept Orthoped Surg, Nagakute, Aichi, Japan.
   [Takeuchi, Mikinobu] Aichi Spine Inst, Dept Spine Surg, Inuyama, Aichi, Japan.
RP Takeuchi, M (reprint author), Aichi Med Univ, Dept Neurol Sci, Nagakute, Aichi, Japan.; Takeuchi, M (reprint author), Aichi Spine Inst, Dept Spine Surg, Inuyama, Aichi, Japan.
EM neuromicky@hotmail.com
CR Attar A, 2001, EUR SPINE J, V10, P10, DOI 10.1007/s005860000198
   Bydon M, 2014, J NEUROSURG-SPINE, V21, P320, DOI 10.3171/2014.5.SPINE13567
   Castro WHM, 1996, SPINE, V21, P1320, DOI 10.1097/00007632-199606010-00008
   DAVNE SH, 1992, SPINE, V17, pS184, DOI 10.1097/00007632-199206001-00021
   Ebraheim NA, 1997, SPINE, V22, P2338, DOI 10.1097/00007632-199710150-00003
   ESSES SI, 1993, SPINE, V18, P2231, DOI 10.1097/00007632-199311000-00015
   Fan SW, 2010, SPINE, V35, P1615, DOI 10.1097/BRS.0b013e3181c70fe3
   FARBER GL, 1995, SPINE, V20, P1494, DOI 10.1097/00007632-199507000-00010
   GERTZBEIN SD, 1990, SPINE, V15, P11, DOI 10.1097/00007632-199001000-00004
   Ikeuchi H, 2016, ARCH ORTHOP TRAUM SU, V136, P1195, DOI 10.1007/s00402-016-2502-0
   Karikari IO, 2010, SPINE, V35, pS294, DOI 10.1097/BRS.0b013e3182022ddc
   Kotani Y, 2003, J NEUROSURG, V99, P257, DOI 10.3171/spi.2003.99.3.0257
   Mason A, 2014, J NEUROSURG-SPINE, V20, P196, DOI 10.3171/2013.11.SPINE13413
   Miller CA, 2016, INT J SPINE SURG, V10, DOI 10.14444/3038
   Nadeau M, 2015, GLOB SPINE J, V05, pA105, DOI [10.1055/s-0035-1554209, DOI 10.1055/S-0035-1554209]
   Oh HS, 2013, SPINE J, V13, P1751, DOI 10.1016/j.spinee.2013.03.042
   ROYCAMILLE R, 1970, PRESSE MED, V78, P1447
   Sugawara T, 2013, SPINAL SURG, V27, P277
   Takeuchi M, 2015, NEUROSURG REV, V38, P573, DOI 10.1007/s10143-015-0610-x
   van Dijk JD, 2015, SPINE, V40, pE986, DOI 10.1097/BRS.0000000000000960
   WEINSTEIN JN, 1988, SPINE, V13, P1012, DOI 10.1097/00007632-198809000-00008
   WEST JL, 1991, SPINE, V16, P576, DOI 10.1097/00007632-199105000-00016
   WEST JL, 1991, J BONE JOINT SURG AM, V73A, P1179, DOI 10.2106/00004623-199173080-00006
   YUAN HA, 1994, SPINE, V19, pS2279
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E257
EP E261
DI 10.1016/j.wneu.2019.01.058
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700033
PM 30684715
DA 2020-05-12
ER

PT J
AU Maldonado-Naranjo, AL
   Golubovsky, JL
   Frizon, LA
   Hogue, O
   Lobel, DA
   Machado, AG
   Steinmetz, MP
   Nagel, SJ
AF Maldonado-Naranjo, Andres L.
   Golubovsky, Joshua L.
   Frizon, Leonardo A.
   Hogue, Olivia
   Lobel, Darlene A.
   Machado, Andre G.
   Steinmetz, Michael P.
   Nagel, Sean J.
TI The Role of Additional Spine Surgery in the Management of Failed Back
   Surgery Syndrome, Complex Regional Pain Syndrome, and Intractable Pain
   in the Setting of Previous or Concurrent Spinal Cord Stimulation:
   Indications and Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complex regional pain syndrome; Failed back surgery syndrome;
   Intractable pain; Repeat spine surgery; Spinal cord stimulation
ID DEGENERATIVE SPONDYLOLISTHESIS; COMPLICATIONS; MULTICENTER
AB OBJECTIVE: Spinal cord stimulation (SCS) is both relatively safe and reversible. Although SCS is generally regarded as a last resort, some of these patients will undergo additional spinal surgery after the device has been implanted or after its removal. We present a descriptive study of subsequent spinal surgery after SCS implantation.
   METHODS: A retrospective review of patients who had undergone percutaneous or paddle SCS lead placement at our institution from 2009 to 2016 was performed. Patients who had only undergone trials or who had not undergone spine surgery after SCS implantation were excluded.
   RESULTS: We identified 22 patients (5.7%) who had undergone spine surgery during the course of SCS treatment or after SCS removal, or both, of a total 383 patients who had undergone paddle and/or percutaneous SCS implantation. The most common additional spine interventions included lumbosacral decompression and fusion (n = 15; 42%). Of 36 surgeries, the most frequent indications for subsequent intervention were stenosis or restenosis (n = 16; 73%) and spine deformity (n = 6; 27%). The median EuroQol-5D index was 0.397 preoperatively and 0.678 postoperatively.
   CONCLUSIONS: To the best of our knowledge, the present study is the first to describe spine surgery in the setting of SCS implantation. Our results have indicated that spine surgery subsequent to, or concurrent with, SCS implantation appears to occur in few patients. Our study results suggest a modest improvement in quality of life outcomes. Therefore, clinicians should remember that patients might require further spine surgery despite the use of SCS implantation and, thus, might require reevaluation by the spine team.
C1 [Maldonado-Naranjo, Andres L.; Frizon, Leonardo A.; Lobel, Darlene A.; Machado, Andre G.; Steinmetz, Michael P.; Nagel, Sean J.] Cleveland Clin Fdn, Dept Neurol Surg, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Lobel, Darlene A.; Machado, Andre G.; Nagel, Sean J.] Cleveland Clin Fdn, Ctr Neurol Restorat, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Steinmetz, Michael P.] Cleveland Clin Fdn, Neurol Inst, Ctr Spine Hlth, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Hogue, Olivia] Cleveland Clin Fdn, Lerner Res Inst, Dept Quantitat Hlth Sci, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Golubovsky, Joshua L.] Case Western Reserve Univ, Lerner Coll Med, Cleveland, OH 44106 USA.
RP Golubovsky, JL (reprint author), Case Western Reserve Univ, Lerner Coll Med, Cleveland, OH 44106 USA.
EM goluboj@ccf.org
CR Aiudi CM, 2017, PAIN PHYSICIAN, V20, pE1073
   Akmal S, 2008, NEUROMODULATION, V11, P282, DOI 10.1111/j.1525-1403.2008.00177.x
   Birklein F, 2018, NAT REV NEUROL, V14, P272, DOI 10.1038/nrneurol.2018.20
   Colloca L, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.2
   Deer TR, 2017, NEUROMODULATION, V20, P15, DOI 10.1111/ner.12564
   Deer TR, 2014, NEUROMODULATION, V17, P571, DOI 10.1111/ner.12206
   Gerling MC, 2017, SPINE, V42, P1559, DOI 10.1097/BRS.0000000000002196
   Kapural L, 2016, NEUROSURGERY, V79, P667, DOI 10.1227/NEU.0000000000001418
   Katzan Irene, 2011, AMIA Annu Symp Proc, V2011, P683
   Krishnaney AA, 2007, NEUROL CLIN, V25, P507, DOI 10.1016/j.ncl.2007.01.005
   Kumar K, 2007, PAIN, V132, P179, DOI 10.1016/j.pain.2007.07.028
   Maldonado-Naranjo AL, 2018, NEUROMODULATION, V21, P513, DOI 10.1111/ner.12643
   Matsunaga S, 2000, J NEUROSURG, V93, P194, DOI 10.3171/spi.2000.93.2.0194
   North RB, 2005, NEUROSURGERY, V56, P98, DOI 10.1227/01NEU.0000144839.65524.E0
   Park P, 2004, SPINE, V29, P1938, DOI 10.1097/01.brs.0000137069.88904.03
   Sears NC, 2011, NEUROMODULATION, V14, P312, DOI 10.1111/j.1525-1403.2011.00372.x
   Stidd DA, 2014, J PAIN RES, V7, P465, DOI 10.2147/JPR.S66414
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E416
EP E423
DI 10.1016/j.wneu.2019.01.091
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700055
PM 30703586
DA 2020-05-12
ER

PT J
AU Matsukawa, H
   Miyazaki, T
   Kiko, K
   Kamiyama, H
   Ota, N
   Noda, K
   Takahashi, O
   Shonai, T
   Fujisawa, T
   Tokuda, S
   Tanikawa, R
AF Matsukawa, Hidetoshi
   Miyazaki, Takanori
   Kiko, Katsunari
   Kamiyama, Hiroyasu
   Ota, Nakao
   Noda, Kosumo
   Takahashi, Osamu
   Shonai, Takaharu
   Fujisawa, Takashi
   Tokuda, Sadahisa
   Tanikawa, Rokuya
TI Thick Clot in the Inferior Limiting Sulcus on Computed Tomography Image
   as an Indicator of Sylvian Subpial Hematoma in Patients with Aneurysmal
   Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal subarachnoid hemorrhage; Clot thickness in the inferior
   limiting sulcus outcome; Risk factor; Subpial hematoma
ID CEREBRAL-ARTERY ANEURYSM; DECOMPRESSIVE CRANIECTOMY; INTRASYLVIAN
   HEMATOMAS; VASOSPASM; REMOVAL; RUPTURE; REPAIR
AB OBJECTIVE: Sylvian subpial hematoma (SSH) is occasionally observed in aneurysm subarachnoid hemorrhage (aSAH) when accompanied with the thick clot in the inferior limiting sulcus (ILS). We aimed to determine whether the thickness of the clot in the ILS (TCILS) was an indicator of SSH.
   METHODS: Data from 150 consecutive patients with aSAH were retrospectively analyzed. The relationship between TCILS on axial computed tomography (CT) image and intraoperatively confirmed SSH was reviewed. In patients without SSH, the average of the clot thickness in the bilateral ILS was used. The primary outcome was SSH.
   RESULTS: The median TCILS of the SSH group (n = 18, 12%) was larger than that of the non-SSH group (n = 132, 88%) (21 vs. 2.1 mm, respectively; P < 0.001). The intraclass correlation coefficients for clot thickness in the right and left ILS between 2 observers were 0.97 (P < 0.001) and 0.85 (P < 0.001). The TCILS threshold of >= 6.0 mm was associated with SSH, with a sensitivity of 89% and specificity of 99%. The unadjusted and adjusted odds ratios of the SSH of clot thickness in the affected ILS >= 6 mm relative to clot thickness in the affected ILS <6 mm were 263 (95% confidence interval [CI], 46-5063) and 137 (95% CI, 19-3029), respectively.
   CONCLUSIONS: The clot thickness in the ILS on CT image was easily measured and could be a marker of SSH. SSH assessment could be useful in helping us predict the clinical course in patients with aSAH.
C1 [Matsukawa, Hidetoshi; Miyazaki, Takanori; Kiko, Katsunari; Kamiyama, Hiroyasu; Ota, Nakao; Noda, Kosumo; Tokuda, Sadahisa; Tanikawa, Rokuya] Teishinkai Hosp, Dept Neurosurg, Stroke Ctr, Sapporo, Hokkaido, Japan.
   [Shonai, Takaharu] Teishinkai Hosp, Dept Radiol, Sapporo, Hokkaido, Japan.
   [Fujisawa, Takashi] Teishinkai Hosp, Dept Pathol, Sapporo, Hokkaido, Japan.
   [Takahashi, Osamu] St Lukes Int Univ, Grad Sch Publ Hlth, St Lukes Int Hosp, Internal Med, Tokyo, Japan.
RP Tanikawa, R (reprint author), Teishinkai Hosp, Dept Neurosurg, Stroke Ctr, Sapporo, Hokkaido, Japan.
EM taniroku@gmail.com
OI Ota, Nakao/0000-0002-7074-1125; Matsukawa, Hidetoshi/0000-0001-8229-4935
CR Anderson C, 2000, STROKE, V31, P1843
   Baskaya MK, 2001, CLIN NEUROL NEUROSUR, V103, P23, DOI 10.1016/S0303-8467(01)00104-4
   Budohoski KP, 2014, J NEUROL NEUROSUR PS, V85, P1343, DOI 10.1136/jnnp-2014-307711
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0
   Fukuda H, 2015, J NEUROSURG, V123, P686, DOI 10.3171/2014.10.JNS141658
   Hansen-Schwartz J, 2008, FRONT BIOSCI-LANDMRK, V13, P2160, DOI 10.2741/2831
   Hilditch CA, 2016, BMJ CASE REP, V2016
   Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660
   HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014
   Hussein HM, 2014, J STROKE CEREBROVASC, V23, P2687, DOI 10.1016/j.jstrokecerebrovasdis.2014.06.013
   Ishikawa T, 2007, CURRENTLY PRACTICAL, V17, P1027
   Kazumata K, 2010, NEUROL MED-CHIR, V50, P884, DOI 10.2176/nmc.50.884
   Keyrouz SG, 2007, CRIT CARE, V11, DOI 10.1186/cc5958
   Kortman HGJ, 2015, AM J NEURORADIOL, V36, P1026, DOI 10.3174/ajnr.A4162
   Li MH, 2017, RADIOLOGY, V284, P191, DOI 10.1148/radiol.2017161469
   Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625
   Matsukawa H, 2015, WORLD NEUROSURG, V84, P1798, DOI 10.1016/j.wneu.2015.07.069
   Minami N, 2014, NEUROL MED-CHIR, V54, P227, DOI 10.2176/nmc.cr2013-0025
   Ota N, 2017, WORLD NEUROSURG, V107, P630, DOI 10.1016/j.wneu.2017.08.088
   Pegoli M, 2015, J NEUROSURG, V122, P414, DOI 10.3171/2014.10.JNS14290
   Roth P, 2008, J NEUROL, V255, P1018, DOI 10.1007/s00415-008-0824-8
   Saito A, 2010, NEUROL MED-CHIR, V50, P281, DOI 10.2176/nmc.50.281
   Shimoda M, 1997, J NEUROSURG, V87, P170, DOI 10.3171/jns.1997.87.2.0170
   Shimoda M, 1999, J NEUROSURG, V91, P408, DOI 10.3171/jns.1999.91.3.0408
   Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018
   Suzuki K, 2015, NEURORADIOL J, V28, P337, DOI 10.1177/1971400915576664
   Tanikawa R, 1996, SURG CEREBRAL STROKE, V24, P129
   Tanikawa Rokuya, 2007, No Shinkei Geka, V35, P17
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Weller R. O., 2005, Morphologie, V89, P22, DOI 10.1016/S1286-0115(05)83235-7
   Yoshimoto Y, 1999, BRIT J NEUROSURG, V13, P18, DOI 10.1080/02688699944131
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E612
EP E619
DI 10.1016/j.wneu.2019.01.138
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700078
PM 30716497
DA 2020-05-12
ER

PT J
AU Matsushima, K
   Kohno, M
   Nakajima, N
   Izawa, H
   Ichimasu, N
   Tanaka, Y
   Sora, S
AF Matsushima, Ken
   Kohno, Michihiro
   Nakajima, Nobuyuki
   Izawa, Hitoshi
   Ichimasu, Norio
   Tanaka, Yujiro
   Sora, Shigeo
TI Retrosigmoid Intradural Suprajugular Approach to Jugular Foramen Tumors
   with Intraforaminal Extension: Surgical Series of 19 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebellopontine angle tumor; Hearing; Infralabyrinthine; Jugular
   foramen neuroma; Meningioma; Schwannoma; Skull base surgery
ID MICROSURGICAL MANAGEMENT; TEMPORAL BONE; REMOVAL; FOSSA; SCHWANNOMAS;
   POSTERIOR; ANATOMY; BASE
AB OBJECTIVE: The intraforaminal component of jugular foramen tumors is difficult to access surgically, as it requires complex approaches for radical removal and leads to a high recurrence due to residual tumor. The retrosigmoid suprajugular approach, intradural drilling of the roof of the jugular foramen, has been recently proposed for removal of such intraforaminal component without sacrificing the sigmoid-jugular venous system or requiring additional approaches. This study presents our experience with this approach and introduces the use of intraoperative continuous vagus nerve monitoring.
   METHODS: Nineteen patients (14 with neuromas and 5 with meningiomas) were operated using this approach over a 12.5-year period. In the more recent 14 cases, continuous vagus nerve monitoring was performed with a ball-type electrode placed on the proximal vagus nerve.
   RESULTS: More than 95% of the tumor removal was achieved in all but the first neuroma case. Extubation immediately after surgery and oral feeding within a week postoperatively was achieved in all patients. Seven of 9 patients with preoperative hearing disturbance symptomatically improved after surgery. All but the first case had no signs of recurrence during the follow-up period (average of 58 months).
   CONCLUSIONS: The retrosigmoid suprajugular approach is safe and effective for removal of tumors extending into the jugular foramen, maintaining a chance of hearing improvement. Intraoperative continuous vagus nerve monitoring is useful to avoid postoperative complications in such surgeries.
C1 [Matsushima, Ken; Kohno, Michihiro; Nakajima, Nobuyuki; Izawa, Hitoshi; Ichimasu, Norio; Tanaka, Yujiro] Tokyo Med Univ, Dept Neurosurg, Shinjuku Ku, Tokyo, Japan.
   [Kohno, Michihiro; Sora, Shigeo] Tokyo Metropolitan Police Hosp, Dept Neurosurg, Nakano Ku, Tokyo, Japan.
RP Kohno, M (reprint author), Tokyo Med Univ, Dept Neurosurg, Shinjuku Ku, Tokyo, Japan.; Kohno, M (reprint author), Tokyo Metropolitan Police Hosp, Dept Neurosurg, Nakano Ku, Tokyo, Japan.
EM mkouno-nsu@umin.ac.jp
OI Matsushia, Ken/0000-0002-6492-3694
CR Amano M, 2011, ACTA NEUROCHIR, V153, P1059, DOI 10.1007/s00701-010-0937-6
   Arnautovic KI, 2002, J NEUROSURG, V97, P12, DOI 10.3171/jns.2002.97.1.0012
   Bakar B, 2010, NEUROL MED-CHIR, V50, P89, DOI 10.2176/nmc.50.89
   Bulsara KR, 2008, J NEUROSURG, V109, P794, DOI 10.3171/JNS/2008/109/11/0794
   CHEUNG SW, 1995, AM J OTOL, V16, P200
   FISCH U, 1979, ARCH OTOLARYNGOL, V105, P99
   Friedman AH, 2011, NEUROSURGERY, V69, P240
   GARDNER G, 1977, LARYNGOSCOPE, V87, P665, DOI 10.1002/lary.5540870503
   George B, 1995, SURG NEUROL, V44, P279, DOI 10.1016/0090-3019(95)00174-3
   HAKUBA A, 1979, SURG NEUROL, V11, P83
   Kadri Paulo A S, 2004, Neurosurg Focus, V17, pE9
   KAYE AH, 1984, J NEUROSURG, V60, P1045, DOI 10.3171/jns.1984.60.5.1045
   Komune N, 2016, HEAD NECK-J SCI SPEC, V38, pE1041, DOI 10.1002/hed.24156
   Liu JK, 2006, NEUROSURGERY S1, V59
   MANN WJ, 1991, SKULL BASE SURG, V1, P137, DOI 10.1055/s-2008-1056995
   Matsushima K, 2016, CURR PRACT NEUROSURG, V26, P1041
   Matsushima Ken, 2017, Neurosurg Focus, V43, pV3, DOI 10.3171/2017.10.FocusVid.17290
   Matsushima K, 2017, WORLD NEUROSURG, V103, P620, DOI 10.1016/j.wneu.2017.04.079
   Matsushima K, 2014, J NEUROSURG, V121, P397, DOI 10.3171/2014.3.JNS132419
   MAZZONI A, 1995, SKULL BASE SURG, V5, P157, DOI 10.1055/s-2008-1058930
   Oghalai JS, 2004, OTOL NEUROTOL, V25, P570, DOI 10.1097/00129492-200407000-00026
   Ramina R, 2007, NEUROSURG FOCUS, V17, pE5
   RAND RW, 1965, J NEUROL NEUROSUR PS, V28, P311, DOI 10.1136/jnnp.28.4.311
   Salas E, 1999, J NEUROSURG, V90, P206, DOI 10.3171/spi.1999.90.2.0206
   SAMII M, 1995, J NEUROSURG, V82, P711, DOI 10.3171/jns.1995.82.5.0711
   Samii M, 2000, J NEUROSURG, V92, P235, DOI 10.3171/jns.2000.92.2.0235
   Samii M, 2016, J NEUROSURG, V124, P1061, DOI 10.3171/2015.3.JNS142904
   Samii M, 2015, NEUROSURGERY, V77, P424, DOI 10.1227/NEU.0000000000000831
   SASAKI T, 1991, SKULL BASE SURG, V1, P152
   Sedney CL, 2013, NEUROSURGERY, V72, P42, DOI 10.1227/NEU.0b013e3182770e74
   Seoane E, 1999, NEUROSURGERY, V44, P553, DOI 10.1097/00006123-199903000-00065
   Yamakami I, 1999, SURG NEUROL, V51, P60, DOI 10.1016/S0090-3019(97)00452-7
   1997, NEUROSURGERY, V41, P149
NR 33
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E984
EP E991
DI 10.1016/j.wneu.2019.01.223
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700122
PM 30763751
DA 2020-05-12
ER

PT J
AU Meling, TR
   Da Broi, M
   Scheie, D
   Helseth, E
   Smoll, NR
AF Meling, Torstein R.
   Da Broi, Michele
   Scheie, David
   Helseth, Eirik
   Smoll, Nicolas R.
TI Meningioma Surgery-Are We Making Progress?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Craniotomy; Improvement; Intracranial tumor; Meningioma;
   Overall survival; Retreatment-free survival
ID GAMMA-KNIFE RADIOSURGERY; INTRACRANIAL MENINGIOMAS; SIMPSON GRADE;
   FOLLOW-UP; RECURRENCE; EXPERIENCE; MANAGEMENT; MORBIDITY; RESECTION; AGE
AB BACKGROUND: To study improvements in outcomes after surgery for intracranial meningiomas.
   METHODS: We performed a longitudinal observational study comparing 1469 patients operated on for intracranial meningioma in 4 consecutive time frames (1990-1994, 1995-1999, 2000-2004, and 2005-2010).
   RESULTS: Median age at surgery was 58.3 years. Median follow-up was 7 years. Patients in later periods were older than in the earlier ones (odds ratio [OR], 1.19 [1.09-1.32]; P < 0.0005), indicating a trend toward operating on more elderly patients. Before 2000, 42%, 32%, 6%, 19%, and 0.3% achieved Simpson grade (SG) I, II, III, IV, and V, respectively, whereas the SG rates were 35%, 37%, 4%, 23%, and 0.9% after 2000 (OR, 1.18 [1.06-1.30]; P < 0.005). The perioperative mortality (OR, 0.65 [0.46-0.91]; P < 0.05) and worsened neurologic outcome rate (OR, 0.70 [0.60-0.83]; P < 0.0001) were significantly lower in later decades, but the 4 surgical periods were similar regarding postoperative infections and hematomas. Retreatment-free survival (RFS) and overall survival (OS) increased significantly over the 4 time frames (P < 0.05 and P < 0.0001, respectively). Multivariate analysis confirmed the improvement of surgical radicality, neurologic outcome, perioperative mortality, OS, and RFS.
   CONCLUSIONS: Meningioma surgery as well as patient population changed over the 2 decades considered in this study. We observed higher rates of gross total resection in the later period and the perioperative outcomes improved or were unchanged, which signifies better long-term outcomes, RFS, and OS.
C1 [Meling, Torstein R.; Da Broi, Michele; Helseth, Eirik] Univ Oslo, Fac Med, Oslo, Norway.
   [Meling, Torstein R.; Helseth, Eirik] Oslo Univ Hosp, Dept Neurosurg, Oslo, Norway.
   [Meling, Torstein R.] Univ Geneva, Med Ctr, Dept Neurosurg, Geneva, Switzerland.
   [Meling, Torstein R.] Univ Geneva, Fac Med, Geneva, Switzerland.
   [Scheie, David] Rigshosp, Sect Neuropathol, Copenhagen, Denmark.
   [Smoll, Nicolas R.] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, Australia.
RP Meling, TR (reprint author), Univ Oslo, Fac Med, Oslo, Norway.; Meling, TR (reprint author), Univ Geneva, Med Ctr, Dept Neurosurg, Geneva, Switzerland.; Meling, TR (reprint author), Univ Geneva, Fac Med, Geneva, Switzerland.
EM torsteinrmeling@gmail.com
RI Helseth, Eirik/AAH-2466-2020; Smoll, Nicolas/D-3322-2013
OI Da Broi, Michele/0000-0003-1527-1594; Smoll, Nicolas/0000-0002-6923-9701
CR Asthagiri AR, 2007, NEUROL CLIN, V25, P1209, DOI 10.1016/j.ncl.2007.07.009
   Bartek J, 2015, WORLD NEUROSURG, V83, P673, DOI 10.1016/j.wneu.2015.01.022
   Bir SC, 2016, WORLD NEUROSURG, V90, P546, DOI 10.1016/j.wneu.2015.12.101
   Black P, 1998, ACTA NEUROCHIR, V140, P1013, DOI 10.1007/s007010050209
   Boviatsis EJ, 2007, SURG NEUROL, V68, P407, DOI 10.1016/j.surneu.2006.11.071
   Chaichana KL, 2013, WORLD NEUROSURG, V79, P515, DOI 10.1016/j.wneu.2012.02.051
   Cohen-Inbar O, 2010, ACTA NEUROCHIR, V152, P87, DOI 10.1007/s00701-009-0552-6
   CORNU P, 1990, ACTA NEUROCHIR, V102, P98, DOI 10.1007/BF01405421
   Couldwell WT, 1996, J NEUROSURG, V84, P20, DOI 10.3171/jns.1996.84.1.0020
   DeJesus O, 1996, NEUROSURGERY, V39, P915, DOI 10.1097/00006123-199611000-00005
   DeMonte F, 2011, AL MEFTYS MENINGIOMA
   DOYLE FH, 1981, LANCET, V2, P53
   Gousias K, 2016, J NEUROSURG, V125, P551, DOI 10.3171/2015.9.JNS15754
   Heald JB, 2014, ACTA NEUROCHIR, V156, P383, DOI 10.1007/s00701-013-1923-6
   KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
   Kondziolka D, 2008, NEUROSURGERY, V62, P53, DOI 10.1227/01.NEU.0000311061.72626.0D
   Konglund A, 2013, ACTA NEUROL SCAND, V127, P161, DOI 10.1111/j.1600-0404.2012.01692.x
   Lassen B, 2011, NEUROSURGERY, V68, P1259, DOI 10.1227/NEU.0b013e31820c0441
   Linsler S, 2016, CLIN NEUROL NEUROSUR, V149, P98, DOI 10.1016/j.clineuro.2016.08.007
   Mathiesen T, 1996, NEUROSURGERY, V39, P2, DOI 10.1097/00006123-199607000-00002
   MAURICEWILLIAMS RS, 1992, BRIT J NEUROSURG, V6, P131, DOI 10.3109/02688699209002915
   Meling TR, 2019, NEUROSURG REV, V42, P163, DOI 10.1007/s10143-018-0976-7
   Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207
   Otero-Rodriguez A, 2016, WORLD NEUROSURG, V96, P483, DOI 10.1016/j.wneu.2016.09.007
   Portela MC, 2015, BMJ QUAL SAF, V24, P325, DOI 10.1136/bmjqs-2014-003620
   Sheehan JP, 2015, J NEUROSURG, V122, P1479, DOI 10.3171/2014.10.JNS14139
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Sindou MP, 2006, J NEUROSURG, V105, P514, DOI 10.3171/jns.2006.105.4.514
   Statistisk Sentralbyra, 2018, POP POP CHANG STAT S
   World Bank Group, 2016, WORLD BANK DAT NORW
   Wu A, 2018, WORLD NEUROSURG, V111, pE142, DOI 10.1016/j.wneu.2017.12.012
   Zachenhofer I, 2006, NEUROSURGERY, V58, P28, DOI 10.1227/01.NEU.0000190654.82265.A3
   2008, NEUROSURGERY, V62, P53, DOI DOI 10.1227/01.NEU.0000296986.77158.4C
   1998, MAYO CLIN P, V73, P936
   1996, NEUROSURGERY, V39, P2
   1998, ACTA NEUROCHIR WIEN, V140, P1013
   2011, NEUROSURGERY, V68, P1259, DOI DOI 10.1227/NEU.0B013E31820C0441
NR 37
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E205
EP E213
DI 10.1016/j.wneu.2019.01.042
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700027
PM 30684722
DA 2020-05-12
ER

PT J
AU Metwali, H
   Raemaekers, M
   Kniese, K
   Samii, A
AF Metwali, Hussam
   Raemaekers, Mathijs
   Kniese, Katja
   Samii, Amir
TI Resting-State Functional Connectivity in Neurosurgical Patients Under
   Propofol Anesthesia: Detectability and Variability Between Patients and
   Between Sessions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Functional connectivity; Intraoperative magnetic resonance imaging;
   Resting-state fMRI
ID DEFAULT MODE; BRAIN; NETWORK; CORTEX; MRI
AB BACKGROUND: Intraoperative assessment of functional connectivity (FC) provides a new possibility for mapping the eloquent brain region before, during, and after tumor resection. The aim of this study was to perform a systematic analysis of detectability of FC and its variation between subjects and sessions.
   METHODS: FC was analyzed in 10 patients with pituitary adenoma under propofol anesthesia before and after tumor resection. FC of each session (20 sessions total) was correlated to a reference matrix of a group of healthy subjects to evaluate variations of overall, interhemispheric, and intrahemispheric FC between sessions.
   RESULTS: Resting-state patterns could be detected during anesthesia (F-1,F-9 = 112.14, P < 0.001). There was a significant effect of session (F-1,F-9 = 19.401, P = 0.002), which included a reduction in resting state from the first to second session. There was no effect of connection type (F-2,F-8 = 1.498, P = 0.280), and there was no interaction between connection type and session (F-2,F-8 = 0.187, P = 0.833). The correlation between the observed reduction in resting-state activity between the sessions and the time span between sessions was not significant (r = 0.25, P = 0.29). FC of the first session showed a significant correlation to the initial dose of anesthesia (r = 0.7, P = 0.007). However, there was no significant correlation between the total dose of propofol and FC of the second session (r = 1.7, P = 0.6).
   CONCLUSIONS: Significant FC could be detected under anesthesia but showed a significant decrease in the second session. To implement FC intraoperative brain mapping, further studies are required to optimize the depth sedation to obtain stable FC between sessions.
C1 [Metwali, Hussam; Kniese, Katja; Samii, Amir] Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
   [Metwali, Hussam; Samii, Amir] Leibniz Inst Neurobiol, Magdeburg, Germany.
   [Metwali, Hussam; Raemaekers, Mathijs] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.
RP Metwali, H (reprint author), Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.; Metwali, H (reprint author), Leibniz Inst Neurobiol, Magdeburg, Germany.; Metwali, H (reprint author), Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.
EM drhussamm@yahoo.com
CR Agarwal S, 2016, BRAIN CONNECT, V6, P267, DOI 10.1089/brain.2015.0402
   Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002
   Beckmann CF, 2005, PHILOS T ROY SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634
   Bisdas S, 2016, ACAD RADIOL, V23, P192, DOI 10.1016/j.acra.2015.10.013
   BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409
   Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107
   Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5
   Calhoun VD, 2008, HUM BRAIN MAPP, V29, P1265, DOI 10.1002/hbm.20463
   Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581
   Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021
   Duff EP, 2007, NEUROINFORMATICS, V5, P223, DOI 10.1007/s12021-007-9001-y
   Duffau H, 2014, WORLD NEUROSURG, V82, P601, DOI 10.1016/j.wneu.2014.03.024
   Esposito R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040231
   Fahlbusch R, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.12.FOCUS15631
   Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1
   Gerganov VM, 2011, J CLIN NEUROSCI, V18, P669, DOI 10.1016/j.jocn.2010.08.017
   Guldenmund P, 2012, ARCH ITAL BIOL, V150, P107, DOI 10.4449/aib.v150i2.1373
   Guldenmund P, 2016, BRAIN CONNECT, V6, P225, DOI 10.1089/brain.2015.0369
   Guldenmund P, 2013, BRAIN CONNECT, V3, P273, DOI 10.1089/brain.2012.0117
   Harris RJ, 2014, J NEURO-ONCOL, V116, P373, DOI 10.1007/s11060-013-1304-2
   Ibrahim AE, 2001, ANESTHESIOLOGY, V95, P1151, DOI 10.1097/00000542-200111000-00019
   Krainik A, 2004, NEUROLOGY, V62, P1323, DOI 10.1212/01.WNL.0000120547.83482.B1
   Lehericy S, 2000, J NEUROSURG, V92, P589, DOI 10.3171/jns.2000.92.4.0589
   Martino J, 2011, ANN NEUROL, V69, P521, DOI 10.1002/ana.22167
   Park JE, 2016, NEURORADIOLOGY, V58, P311, DOI 10.1007/s00234-015-1621-6
   Raemaekers M, 2018, BRAIN STRUCT FUNCT, V223, P1909, DOI 10.1007/s00429-017-1604-y
   Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676
   Roder C, 2016, J NEUROSURG, V125, P401, DOI 10.3171/2015.7.JNS15617
   Schmitz G, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-32
   Shimony JS, 2009, ACAD RADIOL, V16, P578, DOI 10.1016/j.acra.2009.02.001
   Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009
   Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141
   Zhang JS, 2015, NEUROSURG REV, V38, P319, DOI 10.1007/s10143-014-0585-z
   2017, WORLD NEUROSURG, V103, P538, DOI DOI 10.1016/J.WNEU.2017.04.041
   1999, ANESTH ANALG, V89, P1311
   2009, NEUROSURGERY S, V65, P226, DOI DOI 10.1227/01.NEU.0000350868.95634.CA
NR 36
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1160
EP E1169
DI 10.1016/j.wneu.2019.01.266
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700144
PM 30780041
DA 2020-05-12
ER

PT J
AU Mo, XY
   Shen, JL
   Jiang, W
   Zhang, XJ
   Zhou, N
   Wang, YY
   Hu, ZM
   Hao, J
AF Mo, Xiaoyi
   Shen, Jieliang
   Jiang, Wei
   Zhang, Xiaojun
   Zhou, Nian
   Wang, Yiyang
   Hu, Zhenming
   Hao, Jie
TI Percutaneous Endoscopic Lumbar Diskectomy for Axillar Herniation at
   L5-S1 via the Transforaminal Approach Versus the Interlaminar Approach:
   A Prospective Clinical Trial
SO WORLD NEUROSURGERY
LA English
DT Article
DE Axillar; Interlaminar diskectomy; Lumbar disk herniation; Minimally
   invasive; Transforaminal diskectomy
ID DISC HERNIATIONS; MICRODISCECTOMY; METAANALYSIS; OUTCOMES; SPINE
AB OBJECTIVE: To evaluate the results of percutaneous endoscopic transforaminal diskectomy (PETD) in comparison with percutaneous endoscopic interlaminar diskectomy (PEID) for axillar herniation at L5-S1.
   METHODS: From January 2017 to March 2018, 80 patients admitted with axillar herniation at L5-S1 were randomly recruited into 2 groups: 40 cases in the PETD group and 40 in the PEID group. Each group separately underwent PETD or PEID. Patient sex, age, body mass index, axillar herniation size, number of C-arm fluoroscopies, operation time, postoperative bed time, complications, and clinical effect were compared. Both groups were followed-up using the Oswestry Disability Index (ODI), visual analog scale (VAS), and Macnab criteria.
   RESULTS: Except for 1 case in the PETD group that switched to the PEID group, the patients completed the study as expected. All patients were followed-up. Preoperative demographics were not significantly different (P > 0.05) between the 2 groups. The mean number of C-arm fluoroscopies (12.44 +/- 3.21) and the operation time (66.49 +/- 16.29 minutes) of the PETD group were significantly improved compared with the PEID group (number of fluoroscopies: 3.41 +/- 0.81, P < 0.001; operation time: 53.56 +/- 10.82 minutes, P < 0.001), but the postoperative bed rest time and complication rate were not (P > 0.05). The postoperative ODI and VAS scores were obviously improved in both groups when compared with preoperation (P < 0.001). There were no significant differences between the 2 groups in the Macnab criteria or VAS and ODI scores at the same time point (P > 0.05).
   CONCLUSIONS: For axillar herniation at L5-S1, PEID can ignore the anatomic obstruction with advantages including a shorter operation time and less intraoperative radiation exposure. PETD has a clinical effect similar to that of PEID, but the process of it is more dangerous and harder than PEID.
C1 [Mo, Xiaoyi; Shen, Jieliang; Jiang, Wei; Zhang, Xiaojun; Zhou, Nian; Wang, Yiyang; Hu, Zhenming; Hao, Jie] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing, Peoples R China.
RP Hao, J (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing, Peoples R China.
EM hjie2005@aliyun.com
CR Ahn SS, 2016, WORLD NEUROSURG, V86, P250, DOI [10.1016/J.WNEU.2015.09.047, 10.1016/j.wneu.2015.09.047]
   Ahn Y, 2013, SPINE, V38, P617, DOI 10.1097/BRS.0b013e318275ca58
   Choi G, 2008, SPINE, V33, pE508, DOI 10.1097/BRS.0b013e31817bfa1a
   Choi G, 2009, SPINE, V34, pE443, DOI 10.1097/BRS.0b013e31817c4f39
   Choi KC, 2017, WORLD NEUROSURG, V106, P484, DOI 10.1016/j.wneu.2017.07.035
   Choi KC, 2016, PAIN PHYSICIAN, V19, pE291
   Choi KC, 2013, PAIN PHYSICIAN, V16, P547
   Ding WL, 2018, ORTHOPADE, V47, P574, DOI 10.1007/s00132-018-3528-5
   Fan Zhao, 2015, Zhonghua Yi Xue Za Zhi, V95, P973
   Hasegawa T, 1996, SPINE, V21, P1005, DOI 10.1097/00007632-199605010-00001
   HIJIKATA S, 1989, CLIN ORTHOP RELAT R, P9
   Hsu HT, 2013, EUR SPINE J, V22, P727, DOI 10.1007/s00586-012-2540-4
   KAMBIN P, 1983, CLIN ORTHOP RELAT R, P127
   Kim CH, 2018, SPINE, V43, P585, DOI 10.1097/BRS.0000000000002473
   Kolcun JPG, 2017, ASIAN SPINE J, V11, P832, DOI 10.4184/asj.2017.11.5.832
   Lee Low Yong, 2017, Asian J Neurosurg, V12, P620, DOI 10.4103/ajns.AJNS_331_16
   Li Jie, 2015, Zhonghua Yi Xue Za Zhi, V95, P3852
   Li XC, 2016, PAIN PHYSICIAN, V19, P103
   Milette PC, 2000, RADIOL CLIN N AM, V38, P1267, DOI 10.1016/S0033-8389(08)70006-X
   Ruetten S, 2007, J NEUROSURG-SPINE, V6, P521, DOI 10.3171/spi.2007.6.6.521
   Ruetten S, 2008, SPINE, V33, P931, DOI 10.1097/BRS.0b013e31816c8af7
   Satoh I, 2006, J SPINAL DISORD TECH, V19, P104, DOI 10.1097/01.bsd.0000180991.98751.95
   Schoenfeld AJ, 2011, SPINE, V36, pE1477, DOI 10.1097/BRS.0b013e3181f2d52c
   Takeshima T, 2000, SPINE, V25, P450, DOI 10.1097/00007632-200002150-00010
   2017, NEUROCIRUGIA, V28, P235, DOI DOI 10.1016/J.NEUCIR.2017.03.003
NR 25
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E508
EP E514
DI 10.1016/j.wneu.2019.01.114
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700067
PM 30710722
DA 2020-05-12
ER

PT J
AU Mohammed, N
   Hung, YC
   Xu, ZY
   Starke, RM
   Kano, H
   Lee, J
   Mathieu, D
   Kaufmann, AM
   Grills, IS
   Cifarelli, CP
   Vargo, JA
   Chytka, T
   Janouskova, L
   Feliciano, CE
   Mercado, RR
   Lunsford, LD
   Sheehan, JP
AF Mohammed, Nasser
   Hung, Yi-Chieh
   Xu, Zhiyuan
   Starke, Robert M.
   Kano, Hideyuki
   Lee, John
   Mathieu, David
   Kaufmann, Anthony M.
   Grills, Inga S.
   Cifarelli, Christopher P.
   Vargo, John A.
   Chytka, Tomas
   Janouskova, Ladislava
   Feliciano, Caleb E.
   Mercado, Rafael Rodriguez
   Lunsford, L. Dade
   Sheehan, Jason P.
TI A Propensity Score-Matched Cohort Analysis of Outcomes After
   Stereotactic Radiosurgery in Older versus Younger Patients with Dural
   Arteriovenous Fistula: An International Multicenter Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous; Dural; Fistula; Gamma Knife; Older; Radiosurgery;
   Stereotactic radiosurgery
ID TRANSARTERIAL EMBOLIZATION; MALFORMATIONS; TRANSVERSE
AB OBJECTIVE: This study aims to evaluate the outcomes of Gamma Knife stereotactic radiosurgery (SRS) for dural arteriovenous fistulas (dAVFs) in older patients (>= 65 years) compared with younger patients (age <65 years).
   METHODS: Two groups with a total of 96 patients were selected from a database of 133 patients with dAVF from 9 international medical centers with a minimum 6 months follow-up. A 1:2 propensity matching was performed by nearest-neighbor matching criteria based on sex, Borden grade, maximum radiation dose given, and location. The older cohort consisted of 32 patients and the younger cohort consisted of 64 patients. The mean overall follow-up in the combined cohort was 42.4 months (range, 6-210 months).
   RESULTS: In the older cohort, a transverse sinus location was found to significantly predict dAVF obliteration (P = 0.01). The post-SRS actuarial 3-year and 5-year obliteration rates were 47.7% and 78%, respectively. There were no cases of post-SRS hemorrhage. In the younger cohort, the cavernous sinus location was found to significantly predict obliteration (P = 0.005). The 3-year and 5-year actuarial obliteration rates were 56% and 70%, respectively. Five patients (7.8%) hemorrhaged after SRS. Margin dose >= 25 Gy was predictive of unfavorable outcome. The obliteration rate (P = 0.3), post-SRS hemorrhage rate (P = 0.16), and persistent symptoms after SRS (P = 0.83) were not statistically different between the 2 groups.
   CONCLUSIONS: SRS achieves obliteration in most older patients with dAVF, with an acceptable rate of complication. There was no increased risk of postradiosurgery complications in the older cohort compared with the younger patients.
C1 [Starke, Robert M.] Univ Miami, Dept Neurol Surg, Coral Gables, FL 33124 USA.
   [Mohammed, Nasser; Hung, Yi-Chieh; Xu, Zhiyuan; Sheehan, Jason P.] Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22903 USA.
   [Kano, Hideyuki; Lunsford, L. Dade] Univ Pittsburgh, Dept Neurol Surg, Pittsburg, KS USA.
   [Lee, John] Univ Penn, Dept Neurol Surg, Philadelphia, PA 19104 USA.
   [Mathieu, David] Univ Sherbrooke, Dept Neurol Surg, Ctr Rech CHUS, Sherbrooke, PQ, Canada.
   [Kaufmann, Anthony M.] Univ Manitoba, Dept Neurol Surg, Winnipeg, MB, Canada.
   [Grills, Inga S.] Beaumont Hlth Syst, Dept Radiat Oncol, Dearborn, MI USA.
   [Cifarelli, Christopher P.; Vargo, John A.] West Virginia Univ, Dept Neurol Surg, Morgantown, WV 26506 USA.
   [Chytka, Tomas; Janouskova, Ladislava] Na Homolce Hosp, Dept Neurol Surg, Prague, Czech Republic.
   [Feliciano, Caleb E.; Mercado, Rafael Rodriguez] Univ Puerto Rico, Dept Neurol Surg, San Juan, PR 00936 USA.
RP Sheehan, JP (reprint author), Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22903 USA.
EM jsheehan@virginia.edu
RI mohammed, nasser/AAG-1525-2019
OI mohammed, nasser/0000-0002-3811-3559; Mathieu, David/0000-0003-2029-6315
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [U54 GM104942]
CR AWAD IA, 1990, J NEUROSURG, V72, P839, DOI 10.3171/jns.1990.72.6.0839
   Cifarelli CP, 2010, NEUROSURGERY, V67, P1230, DOI 10.1227/NEU.0b013e3181eff6f7
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Duffau H, 1999, J NEUROSURG, V90, P78, DOI 10.3171/jns.1999.90.1.0078
   Falero R A P, 2012, AJNR Am J Neuroradiol, V33, pE130, DOI 10.3174/ajnr.A3360
   Friedman JA, 2001, J NEUROSURG, V94, P886, DOI 10.3171/jns.2001.94.6.0886
   Guo WY, 1998, AM J NEURORADIOL, V19, P1081
   HOUSER OW, 1979, MAYO CLIN PROC, V54, P651
   Hurst RW, 1998, AM J NEURORADIOL, V19, P1267
   KERBER CW, 1973, NEURORADIOLOGY, V6, P175, DOI 10.1007/BF00335317
   LASJAUNIAS P, 1986, J NEUROSURG, V64, P724, DOI 10.3171/jns.1986.64.5.0724
   LEWIS AI, 1994, J NEUROSURG, V81, P851, DOI 10.3171/jns.1994.81.6.0851
   Link MJ, 1996, J NEUROSURG, V84, P804, DOI 10.3171/jns.1996.84.5.0804
   Lucas CP, 1997, NEUROSURGERY, V40, P1119, DOI 10.1097/00006123-199706000-00002
   Natarajan SK, 2010, WORLD NEUROSURG, V73, P365, DOI 10.1016/j.wneu.2010.01.009
   Pan DHC, 2002, J NEUROSURG, V96, P823, DOI 10.3171/jns.2002.96.5.0823
   Soderman M, 2008, STROKE, V39, P1735, DOI 10.1161/STROKEAHA.107.506485
   Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313
   Sturiale CL, 2013, STROKE, V44, P1897, DOI 10.1161/STROKEAHA.113.001524
   Tonetti DA, 2019, J NEUROSURG, V130, P972, DOI 10.3171/2017.10.JNS171802
   van Dijk JMC, 2002, STROKE, V33, P1233, DOI 10.1161/01.STR.0000014772.02908.44
   Vespa J., OLDER PEOPLE PROJECT
   Zipfel GJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0928
   1997, NEUROSURGERY, V40, P1119
   2009, NEUROSURGERY, V64, P241, DOI DOI 10.1227/01.NEU.0000338066.30665.B2
   2006, J NEUROSURG S, V105, P43
   2005, SURG NEUROL, V64, P392, DOI DOI 10.1016/J.SURNEU.2004.12.026
   2012, NEUROSURGERY, V71, P594, DOI DOI 10.1227/NEU.0B013E31825EABDB
   1997, NEUROSURGERY, V40, P452
NR 29
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1114
EP E1124
DI 10.1016/j.wneu.2019.01.253
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700139
PM 30790731
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Montano, N
   Gaudino, S
   Giordano, C
   Pignotti, F
   Ioannoni, E
   Rapisarda, A
   Olivi, A
AF Montano, Nicola
   Gaudino, Simona
   Giordano, Carolina
   Pignotti, Fabrizio
   Ioannoni, Eleonora
   Rapisarda, Alessandro
   Olivi, Alessandro
TI Possible Prognostic Role of Magnetic Resonance Imaging Findings in
   Patients with Trigeminal Neuralgia and Multiple Sclerosis Who Underwent
   Percutaneous Balloon Compression: Report of Our Series and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Magnetic resonance imaging; Multiple sclerosis; Percutaneous balloon
   compression; Prognosis; Trigeminal neuralgia
ID MICROVASCULAR DECOMPRESSION; INVOLVEMENT; PREVALENCE; PAIN
AB OBJECTIVE: We studied the correlation of magnetic resonance imaging (MRI) findings with the prognosis of patients with multiple sclerosis (MS)-related trigeminal neuralgia (TN) who had undergone percutaneous balloon compression (PBC). To the best of our knowledge, no studies have previously reported on this topic. We also performed a review of pertinent studies.
   METHODS: From a surgical series of 82 patients with TN who had undergone PBC from January 2013 to June 2017, we identified 16 patients with MS (mean age, 54.81 +/- 8.51 years; mean follow-up, 38.12 +/- 19.86 months). Using brain MRI, we evaluated the presence of a lesion in the trigeminal nerve root entry zone and trigeminal nuclei. With other clinical and procedure-related factors, we studied its effect on acute pain relief (pain free at hospital discharge) and pain-free survival (PFS).
   RESULTS: Of the 16 patients, 15 (93.75%) reported acute pain relief; 8 patients (50.00%) experienced a recurrence of pain. At the latest follow-up visit, an excellent outcome (Barrow Neurological Institute grade 1-2) was obtained for 75% of patients and a good outcome (Barrow Neurological Institute grade 3) for 25%. No patient experienced uncontrolled pain. The presence of a pear-like balloon shape during surgery (P = 0.0053) and a MRI detectable lesion in the trigeminal pathway (P = 0.049) were associated with greater PFS.
   CONCLUSIONS: PBC can be efficient in treating MS-related TN. Some factors, such as a pear-like balloon shape during surgery and evidence of a MRI-detectable lesion in the trigeminal pathway were associated with longer PFS.
C1 [Montano, Nicola; Pignotti, Fabrizio; Rapisarda, Alessandro; Olivi, Alessandro] Catholic Univ, Fdn Policlin Univ A Gemelli IRCCS, Inst Neurosurg, Rome, Italy.
   [Gaudino, Simona; Giordano, Carolina] Catholic Univ, Fdn Policlin Univ A Gemelli IRCCS, Inst Radiol, Rome, Italy.
   [Ioannoni, Eleonora] Catholic Univ, Fdn Policlin Univ A Gemelli IRCCS, Neurosurg Intens Care Unit, Rome, Italy.
RP Montano, N (reprint author), Catholic Univ, Fdn Policlin Univ A Gemelli IRCCS, Inst Neurosurg, Rome, Italy.
EM nicolamontanomd@yahoo.it
RI Rapisarda, Alessandro/AAF-3354-2019; Montano, Nicola/M-4565-2016
OI Montano, Nicola/0000-0002-4965-1950
CR Athanasiou TC, 2005, BRIT J NEUROSURG, V19, P463, DOI 10.1080/02688690500495067
   Bergenheim AT, 2013, WORLD NEUROSURG, V79, P359, DOI 10.1016/j.wneu.2012.03.014
   Broggi G, 2004, NEUROSURGERY, V55, P830, DOI 10.1227/01.NEU.0000137656.59536.0E
   Chen DQ, 2016, MULT SCLER J, V22, P51, DOI 10.1177/1352458515579440
   Cruccu G, 2009, PAIN, V143, P186, DOI 10.1016/j.pain.2008.12.026
   da Silva CJ, 2005, MULT SCLER J, V11, P282, DOI 10.1191/1352458505ms1186oa
   de Sousa DA, 2013, J NEUROL, V260, P2179, DOI 10.1007/s00415-013-7015-y
   Gass A, 1997, NEUROLOGY, V49, P1142, DOI 10.1212/WNL.49.4.1142
   HOOGE JP, 1995, NEUROLOGY, V45, P1294, DOI 10.1212/WNL.45.7.1294
   Kouzounias K, 2010, NEUROSURGERY, V67, P925, DOI 10.1227/NEU.0b013e3181eb5230
   LAZAR ML, 1979, NEUROSURGERY, V5, P711, DOI 10.1227/00006123-197912000-00013
   Liu Y, 2013, EUR J RADIOL, V82, P783, DOI 10.1016/j.ejrad.2012.11.027
   Lummel N, 2015, NEURORADIOLOGY, V57, P259, DOI 10.1007/s00234-014-1463-7
   Martin S, 2015, J NEUROSURG, V123, P1507, DOI 10.3171/2014.11.JNS14736
   MEANEY JFM, 1995, J NEUROL NEUROSUR PS, V59, P253, DOI 10.1136/jnnp.59.3.253
   MEGLIO M, 1989, PAIN, V38, P9, DOI 10.1016/0304-3959(89)90066-3
   MEGLIO M, 1990, STEREOT FUNCT NEUROS, V54-5, P76, DOI 10.1159/000100194
   Mills RJ, 2010, BRIT J RADIOL, V83, P493, DOI 10.1259/bjr/65228893
   Montano N, 2015, THER CLIN RISK MANAG, V11, P289, DOI 10.2147/TCRM.S37592
   Montano N, 2014, ACTA NEUROL BELG, V114, P59, DOI 10.1007/s13760-013-0263-x
   Montano N, 2013, CLIN NEUROL NEUROSUR, V115, P567, DOI 10.1016/j.clineuro.2012.07.011
   Montano N, 2012, ACTA NEUROCHIR, V154, P779, DOI 10.1007/s00701-012-1301-9
   Nakashima I, 2001, ARCH NEUROL-CHICAGO, V58, P101, DOI 10.1001/archneur.58.1.101
   Obermann Mark, 2010, Ther Adv Neurol Disord, V3, P107, DOI 10.1177/1756285609359317
   Osterberg A, 2005, EUR J PAIN, V9, P531, DOI 10.1016/j.ejpain.2004.11.005
   RUGE D, 1958, J NEUROSURG, V15, P528, DOI 10.3171/jns.1958.15.5.0528
   Solaro C, 2004, NEUROLOGY, V63, P919, DOI 10.1212/01.WNL.0000137047.85868.D6
   Solaro C, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-012-0320-5
   TEKKOK IH, 1992, NEUROSURG REV, V15, P117, DOI 10.1007/BF00313506
NR 29
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E575
EP E581
DI 10.1016/j.wneu.2019.01.134
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700074
PM 30716488
DA 2020-05-12
ER

PT J
AU Moser, M
   Schmassmann, P
   Noger, M
   Baur, M
   Nevzati, E
AF Moser, Manuel
   Schmassmann, Philip
   Noger, Markus
   Baur, Martin
   Nevzati, Edin
TI Usefulness of Fat Suppression Magnetic Resonance Imaging of Osteoporotic
   Vertebral Fractures in Preventing Subsequent Fractures After Kyphoplasty
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone marrow edema; Cement augmentation; Fat suppression; Kyphoplasty;
   Magnetic resonance imaging; Osteoporosis; Vertebral fracture
ID COMPRESSION FRACTURES; RANDOMIZED-TRIAL; PERCUTANEOUS VERTEBROPLASTY;
   CEMENT AUGMENTATION; BALLOON KYPHOPLASTY; MRI; PREVALENCE; LEVEL
AB BACKGROUND: Preoperative magnetic resonance imaging with fat suppression (FS-MRI) is useful to detect bone marrow edema in osteoporotic vertebral fractures (OVFs) and thus can improve diagnostic accuracy and influence surgical strategy for percutaneous augmentation. The role of preoperative FS-MRI in preventing subsequent fractures after balloon kyphoplasty has not been investigated in initially subclinical fractures or fractures without obvious morphologic changes.
   METHODS: From January 2010 to December 2017, 214 consecutive patients underwent balloon kyphoplasty for painful OVFs. We defined 2 groups based on preoperative imaging (100 patients had preoperative FS-MRI and 114 patients had no MRI) and then compared baseline and surgical characteristics. The primary end point was incidence of subsequent fractures within 12 months after treatment.
   RESULTS: The 214 patients underwent kyphoplasty of 414 vertebrae. Comparing FS-MRI with no-MRI groups, spontaneous fractures occurred significantly more (58% vs. 26.3%; P < 0.001) and fractures were more often multilevel (>= 4 levels) (15% vs. 2.6%; P = 0.001), respectively. Overall incidence of subsequent vertebral fractures was 25.7% (32% in FS-MRI, 20.2% in no-MRI groups; P = 0.048). Average time to diagnosis of subsequent fractures did not differ between the 2 groups (9.3 FS-MRI vs. 11.5 weeks no-MRI; P = 0.411). Age >= 80 years at the time of balloon kyphoplasty was associated with a higher odds ratio (2.3) for subsequent fractures within 12 months (P = 0.039).
   CONCLUSIONS: Surgical treatment according to preoperative FS-MRI did not reduce occurrence of subsequent OVFs and did not prolong fracture-free intervals within 12 months after kyphoplasty.
C1 [Moser, Manuel; Noger, Markus; Baur, Martin] Cantonal Hosp Lucerne, Dept Spine Surg, Luzern, Switzerland.
   [Moser, Manuel; Schmassmann, Philip; Nevzati, Edin] Cantonal Hosp Lucerne, Dept Neurosurg, Luzern, Switzerland.
   [Schmassmann, Philip] Univ Basel, Fac Med, Basel, Switzerland.
   [Nevzati, Edin] Univ Colorado, Sch Med, Dept Neurosurg, Aurora, CO USA.
RP Moser, M (reprint author), Cantonal Hosp Lucerne, Dept Spine Surg, Luzern, Switzerland.; Moser, M (reprint author), Cantonal Hosp Lucerne, Dept Neurosurg, Luzern, Switzerland.
EM manuel.moser@luks.ch
OI Moser, Manuel/0000-0003-4517-359X
CR Ballane G, 2017, OSTEOPOROSIS INT, V28, P1531, DOI 10.1007/s00198-017-3909-3
   Beall DP, 2019, NEUROSURGERY, V84, P169, DOI 10.1093/neuros/nyy017
   Berlemann U, 2002, J BONE JOINT SURG BR, V84B, P748, DOI 10.1302/0301-620X.84B5.11841
   Bliuc D, 2010, JAMA-J AM MED ASSOC, V301, P513, DOI DOI 10.1001/jama.2009.50
   Boonen S, 2011, J BONE MINER RES, V26, P1627, DOI 10.1002/jbmr.364
   Briggs AM, 2006, EUR SPINE J, V15, P1785, DOI 10.1007/s00586-006-0158-0
   Buchbinder R, 2009, NEW ENGL J MED, V361, P557, DOI 10.1056/NEJMoa0900429
   Deibert CP, 2016, PAIN PHYSICIAN, V19, pE1167
   Del Grande F, 2014, RADIOGRAPHICS, V34, P217, DOI 10.1148/rg.341135130
   DIXON WT, 1984, RADIOLOGY, V153, P189, DOI 10.1148/radiology.153.1.6089263
   Do H M, 2000, Top Magn Reson Imaging, V11, P235
   Firanescu CE, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1551
   Fribourg D, 2004, SPINE, V29, P2270, DOI 10.1097/01.brs.0000142469.41565.2a
   Grafe IA, 2011, EUR J TRAUMA EMERG S, V37, P379, DOI 10.1007/s00068-010-0050-9
   Green RAR, 2004, SKELETAL RADIOL, V33, P129, DOI 10.1007/s00256-003-0725-y
   Harrop JS, 2004, SPINE, V29, P2120, DOI 10.1097/01.brs.0000141176.63158.8e
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657-013-0136-1
   Hubschle L, 2014, SPINE J, V14, P2063, DOI 10.1016/j.spinee.2013.12.019
   Jacobson RE, 2017, CUREUS, V9, DOI 10.7759/cureus.1776
   Kallmes DF, 2009, NEW ENGL J MED, V361, P569, DOI 10.1056/NEJMoa0900563
   Kanchiku T, 2003, SPINE, V28, P2522, DOI 10.1097/01.BRS.0000092384.29767.85
   Kanchiku Tsukasa, 2003, J Orthop Sci, V8, P463, DOI 10.1007/s00776-003-0665-3
   Lau E, 2008, J BONE JOINT SURG AM, V90A, P1479, DOI 10.2106/JBJS.G.00675
   Lieberman IH, 2001, SPINE, V26, P1631, DOI 10.1097/00007632-200107150-00026
   Nieuwenhuijse MJ, 2012, SPINE, V37, P974, DOI 10.1097/BRS.0b013e318238bf22
   Omi H, 2014, EUR SPINE J, V23, P2705, DOI 10.1007/s00586-014-3490-9
   Park SY, 2013, J SPINAL DISORD TECH, V26, pE80, DOI 10.1097/BSD.0b013e318261f438
   Polikeit A, 2003, SPINE, V28, P991, DOI 10.1097/00007632-200305150-00006
   Spiegl UJA, 2009, EUR SPINE J, V18, P1287, DOI 10.1007/s00586-009-1045-2
   Tatsumi RL, 2010, SPINE J, V10, P979, DOI 10.1016/j.spinee.2010.08.027
   Tsujio T, 2011, SPINE, V36, P1229, DOI 10.1097/BRS.0b013e3181f29e8d
   Van Meirhaeghe J, 2013, SPINE, V38, P971, DOI 10.1097/BRS.0b013e31828e8e22
   Wardlaw D, 2009, LANCET, V373, P1016, DOI 10.1016/S0140-6736(09)60010-6
   Watts NB, 2001, OSTEOPOROSIS INT, V12, P429, DOI 10.1007/s001980170086
   2009, SPINE, V34, P609, DOI DOI 10.1097/BRS.0B013E31819740BB
NR 35
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E764
EP E773
DI 10.1016/j.wneu.2019.01.167
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700094
PM 30735867
DA 2020-05-12
ER

PT J
AU Muskens, IS
   Gupta, S
   Robertson, FC
   Moojen, WA
   Kolias, AG
   Peul, WC
   Broekman, MLD
AF Muskens, Ivo S.
   Gupta, Saksham
   Robertson, Faith C.
   Moojen, Wouter A.
   Kolias, Angelos G.
   Peul, Wilco C.
   Broekman, Marike L. D.
TI When Time Is Critical, Is Informed Consent Less So? A Discussion of
   Patient Autonomy in Emergency Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Emergency; Ethics; Neurosurgery
ID HEMICRANIECTOMY; STROKE
AB Neurosurgical interventions frequently occur in an emergency setting. In this setting, patients often have impaired consciousness and are unable to directly express their values and wishes regarding their treatment. The limited time available for clinical decision making has great ethical implications, as the informed consent procedure may become compromised. The ethical situation may be further challenged by different views between the patient, family members, and the neurosurgeon; the presence of advance directives; the use of an innovative procedure; or if the procedure is part of a research project. This moral opinion piece presents the implications of time constraints and a lack of patient capacity for autonomous decision making in emergency neurosurgical situations. Potential solutions to these challenges are presented that may help to improve ethical patient management in emergency settings. Emergency neurosurgery challenges the respect of autonomy of the patient. The outcome in most scenarios will rely on the neurosurgeon acting in a professional way to manage each unique situation in an ethically sound manner.
C1 [Muskens, Ivo S.] Univ Southern Calif, Keck Sch Med, Dept Preventat Med, Los Angeles, CA 90033 USA.
   [Muskens, Ivo S.; Moojen, Wouter A.; Peul, Wilco C.; Broekman, Marike L. D.] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands.
   [Muskens, Ivo S.; Gupta, Saksham; Robertson, Faith C.; Broekman, Marike L. D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
   [Moojen, Wouter A.; Peul, Wilco C.] Haga Teaching Hosp, Dept Neurosurg, The Hague, Netherlands.
   [Moojen, Wouter A.; Peul, Wilco C.; Broekman, Marike L. D.] Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands.
   [Kolias, Angelos G.] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge, England.
RP Broekman, MLD (reprint author), Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands.; Broekman, MLD (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.; Broekman, MLD (reprint author), Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands.
EM m.broekman@haaglandenmc.nl
OI Muskens, Ivo/0000-0001-6183-8083
CR Akkad A, 2004, BJOG-INT J OBSTET GY, V111, P1133, DOI 10.1111/j.1471-0528.2004.00240.x
   Appelbaum PS, 2007, NEW ENGL J MED, V357, P1834, DOI 10.1056/NEJMcp074045
   Beauchamp TL, 2013, PRINCIPLES BIOMEDICA
   Broekman ML, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003790
   Caplan AL, 2014, J MED ETHICS, V40, P301, DOI 10.1136/medethics-2012-100492
   Clark DJ, 2013, ACTA NEUROCHIR, V155, P1329, DOI 10.1007/s00701-013-1748-3
   Dasenbrock HH, 2017, STROKE, V48, P704, DOI 10.1161/STROKEAHA.116.014727
   Geurts M, 2013, STROKE, V44, P2506, DOI 10.1161/STROKEAHA.113.002014
   Green MJ, 2018, AM J HOSP PALLIAT ME, V35, P866, DOI 10.1177/1049909117744554
   Havens JM, 2015, J TRAUMA ACUTE CARE, V78, P306, DOI 10.1097/TA.0000000000000517
   Hofmeijer J, 2013, J NEUROL, V260, P1396, DOI 10.1007/s00415-012-6810-1
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Joseph B, 2016, J TRAUMA ACUTE CARE, V81, P723, DOI 10.1097/TA.0000000000001162
   Kolias AG, 2013, BRIT J NEUROSURG, V27, P330, DOI 10.3109/02688697.2013.779365
   Morrison CA, 2009, J SURG RES, V157, P115, DOI 10.1016/j.jss.2009.03.051
   Pretz JL, 2009, J TRAUMA, V67, P1443, DOI 10.1097/TA.0b013e3181bba255
   Ragoschke-Schumm A, 2015, CEREBROVASC DIS, V40, P286, DOI 10.1159/000441194
   Redmann AJ, 2012, ANN SURG, V255, P418, DOI 10.1097/SLA.0b013e31823b6782
   Sjostrand M, 2013, J MED PHILOS, V38, P710, DOI 10.1093/jmp/jht049
   Zaki MM, 2018, WORLD NEUROSURG, V114, pE1038, DOI 10.1016/j.wneu.2018.03.142
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E336
EP E340
DI 10.1016/j.wneu.2019.01.074
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700043
PM 30690144
DA 2020-05-12
ER

PT J
AU Nair, BR
   Rajshekhar, V
AF Nair, Bijesh Ravindran
   Rajshekhar, Vedantam
TI Factors Predicting the Need for Prolonged (> 24 Months) Antituberculous
   Treatment in Patients with Brain Tuberculomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antituberculous treatment; Brain tuberculoma
ID NERVOUS-SYSTEM TUBERCULOSIS; SHORT-COURSE CHEMOTHERAPY; INTRACRANIAL
   TUBERCULOMAS; SURGERY; CT; PATHOGENESIS; MANAGEMENT; DIAGNOSIS
AB BACKGROUND: Patients with brain tuberculomas are generally managed with 12-18 months of antituberculous treatment (ATT) with or without surgery. However, a subset of these patients may require ATT for longer periods. We studied the factors that were associated with the need for prolonged ATT (>24 months) in patients with brain tuberculomas.
   METHODS: This retrospective study included patients with intracranial tuberculomas managed from January 2000 to December 2015 if they were followed up until completion of therapy and resolution of the tuberculoma/s. The predictive factors analyzed were the number of lesions (solitary vs. multiple), location (infratentorial vs. supratentorial and infratentorial), previous ATT treatment (yes vs. no), surgery (yes vs. no), and size of the lesion (<= 2.5 cm vs. >2.5 cm).
   RESULTS: Of the 86 patients, 19 (22%) received ATT for >2 years. On multivariate analysis, multiple lesions were significantly associated with the need for prolonged ATT (P = 0.02). Size of the tuberculoma showed a trend toward significance (P = 0.06), with tuberculomas >2.5cm having a 3.68 times increased risk of requiring prolonged ATT.
   CONCLUSIONS: Although 78% of brain tuberculomas resolve with 12-24 months of ATT, 22% required >24 months of ATT. Multiple tuberculomas had significant association with prolonged ATT, with a median duration of resolution of 36 months. Because tuberculomas >2.5 cm were likely to need longer duration of ATT, brain tuberculomas that require surgery should be excised totally or reduced in size to <2.5 cm to enable early resolution.
C1 [Nair, Bijesh Ravindran; Rajshekhar, Vedantam] Christian Med Coll & Hosp, Dept Neurol Sci, Vellore, Tamil Nadu, India.
RP Nair, BR (reprint author), Christian Med Coll & Hosp, Dept Neurol Sci, Vellore, Tamil Nadu, India.
EM drbijeshr@cmcvellore.ac.in
CR American Thoracic Society, 2003, MMWR Recomm Rep, V52, P1
   [Anonymous], 2011, TUB CLIN DIAGN MAN T
   Awada A, 1998, J NEUROL SCI, V156, P47, DOI 10.1016/S0022-510X(98)00024-0
   Cardona PJ, 2009, INFECTION, V37, P80, DOI 10.1007/s15010-008-8087-y
   DeLance AR, 2013, J CLIN NEUROSCI, V20, P1333, DOI 10.1016/j.jocn.2013.01.008
   Ersahin M, 2010, TURK NEUROSURG, V20, P295, DOI 10.5137/1019-5149.JTN.3071-10.1
   Goyal V, 2019, ANN INDIAN ACAD NEUR, V22, P37, DOI 10.4103/aian.AIAN_70_18
   Gupta RK, 1996, MAGN RESON MED, V36, P829, DOI 10.1002/mrm.1910360605
   HARDER E, 1983, AM J MED, V74, P570, DOI 10.1016/0002-9343(83)91011-2
   Kumar R, 2002, CHILD NERV SYST, V18, P118, DOI 10.1007/s00381-002-0575-2
   Li H, 2012, J CLIN NEUROSCI, V19, P691, DOI 10.1016/j.jocn.2011.05.045
   Morales H, 2015, NEURORADIOL J, V28, P294, DOI 10.1177/1971400915592077
   Poonnoose SI, 2003, NEUROSURGERY, V53, P873, DOI 10.1227/01.NEU.0000083553.25421.6F
   RAJESWARI R, 1995, TUBERCLE LUNG DIS, V76, P311, DOI 10.1016/S0962-8479(05)80029-2
   Rajshekhar V, 1997, ACTA NEUROL SCAND, V96, P76
   RAJSHEKHAR V, 1993, BRIT J NEUROSURG, V7, P665, DOI 10.3109/02688699308995096
   RAJSHEKHAR V, 1993, J NEUROSURG, V78, P402, DOI 10.3171/jns.1993.78.3.0402
   Rajshekhar V, 1996, TUBERCLE LUNG DIS, V77, P295, DOI 10.1016/S0962-8479(96)90091-X
   Rajshekhar V, 2015, ACTA NEUROCHIR, V157, P1665, DOI 10.1007/s00701-015-2501-x
   Ramachandran R, 2017, J NEUROL SCI, V381, P256, DOI 10.1016/j.jns.2017.08.3258
   Rich AR, 1933, B JOHNS HOPKINS HOSP, V52, P5
   Rock RB, 2008, CLIN MICROBIOL REV, V21, P243, DOI 10.1128/CMR.00042-07
   SELVAPANDIAN S, 1994, NEUROSURGERY, V35, P845, DOI 10.1227/00006123-199411000-00007
   Sharma SK, 2017, INDIAN J MED RES, V145, P448, DOI 10.4103/ijmr.IJMR_1950_16
   Thwaites G, 2009, J INFECTION, V59, P167, DOI 10.1016/j.jinf.2009.06.011
   Trivedi R, 2009, INDIAN J RADIOL IMAG, V19
   Wang S, 1996, Zhonghua Jie He He Hu Xi Za Zhi, V19, P107
   Wasay M, 2003, J NEUROIMAGING, V13, P240, DOI 10.1177/1051228403013003007
   WHO, 2017, GLOB TUB REP
   2003, AM J RESP CRIT CARE, V167, P603
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E236
EP E247
DI 10.1016/j.wneu.2019.01.053
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700031
PM 30684718
DA 2020-05-12
ER

PT J
AU Newman, WC
   Engh, JA
AF Newman, W. Christopher
   Engh, Johnathan A.
TI Stereotactic-Guided Dilatable Endoscopic Port Surgery for Deep-Seated
   Brain Tumors: Technical Report with Comparative Case Series Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Colloid cyst; Endoscopic port; Iatrogenic brain injury;
   Stereotactic
ID FIBER TRACKING; MINIMAL ACCESS; RESECTION; LESIONS; RETRACTION;
   DILATATION; REMOVAL
AB OBJECTIVE: Deep-seated brain tumors are often best treated by primary surgical excision. Traditional microsurgical techniques can cause retraction injury and require extensive brain dissection. To mitigate this risk, stereotactic-guided tubular retractors were developed; however, the risk of shear injury remains. We created a stereotactic-guided dilatable port system to create a corridor for deep brain tumor surgery along the trajectory of a brain needle to minimize iatrogenic brain injury.
   METHODS: Of the 8 included patients (6 colloid cysts, 1 metastasis, 1 intraventricular meningioma), 5 had undergone frameless and 3 frame-based stereotactic targeting. We used a tans-sulcal trajectory and a 2.6-mm stereotactic needle. At the target depth, the cannula was removed and the balloon inflated to 14 mm. The balloon was deflated and removed before placing the port. Pre- and 3-month post-operative magnetic resonance imaging scans were used to measure the T2-weighted signal change and residual cannulation defect. These patients were compared with a case-matched standard endoscopic port surgery cohort.
   RESULTS: All patients had undergone total lesional resection without new neurologic deficits. Patients undergoing dilatable endoscopic port surgery (DEPS) had significantly smaller residual cannulation defects (P < 0.05) but no significant differences in postoperative T2-weighted signal changes or diffusion restriction volumes at 3 months postoperatively (P > 0.05).
   CONCLUSIONS: DEPS might be a safe alternative to standard endoscopic port surgery or microsurgery for deep-seated brain tumors. The degree of iatrogenic injury using DEPS, as determined by magnetic resonance imaging analysis, might be equivalent to or less than that with standard port surgery techniques, although larger sample sizes are needed for validation.
C1 [Newman, W. Christopher] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA.
   [Engh, Johnathan A.] Lexington Med Ctr, Lexington Brain & Spine Inst, Columbia, SC 29212 USA.
RP Engh, JA (reprint author), Lexington Med Ctr, Lexington Brain & Spine Inst, Columbia, SC 29212 USA.
EM jaengh@lexhealth.org
CR Abraham RG, 2003, MINIM INVAS NEUROSUR, V46, P138
   Akai T, 2008, MINIM INVAS NEUROSUR, V51, P83, DOI 10.1055/s-2007-1004562
   ALBIN MS, 1997, ACTA NEUROLOG SC S64, V56, pS522
   Almenawer SA, 2013, NEUROSURG REV, V36, P321, DOI 10.1007/s10143-012-0442-x
   ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052
   Bander ED, 2016, J NEUROSURG, V124, P1053, DOI 10.3171/2015.4.JNS142576
   BENNETT MH, 1977, STROKE, V8, P487, DOI 10.1161/01.STR.8.4.487
   DONAGHY RMP, 1972, AM J SURG, V123, P429, DOI 10.1016/0002-9610(72)90195-X
   Dujovny M, 2010, NEUROL RES, V32, P675, DOI 10.1179/016164110X12644252260439
   Fahim DK, 2009, J NEUROSURG-PEDIATR, V3, P101, DOI 10.3171/2008.11.PEDS08280
   Fernandez-Miranda JC, 2010, J NEUROSURG, V113, P990, DOI 10.3171/2009.10.JNS09933
   Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510
   HIRSCH JF, 1991, J NEUROSURG, V74, P1014, DOI 10.3171/jns.1991.74.6.1014
   Hong CS, 2016, J NEUROSURG, V124, P799, DOI 10.3171/2015.1.JNS141113
   Jho HD, 2002, MINIM INVAS NEUROSUR, V45, P114, DOI 10.1055/s-2002-32487
   Jo KW, 2011, NEUROSURG REV, V34, P457, DOI 10.1007/s10143-011-0319-4
   KELLY PJ, 1992, STEREOT FUNCT NEUROS, V59, P84, DOI 10.1159/000098922
   KELLY PJ, 1988, J NEUROSURG, V69, P301, DOI 10.3171/jns.1988.69.2.0301
   Levine NB, 2006, MINIM INVAS NEUROSUR, V49, P317, DOI 10.1055/s-2006-950391
   Little AS, 2010, NEUROSURGERY S, V67
   MADRAZO I, 1990, SURG NEUROL, V33, P226, DOI 10.1016/0090-3019(90)90190-Z
   Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781
   MORITA A, 1993, NEUROSURGERY, V32, P920, DOI 10.1227/00006123-199306000-00006
   SHAHBABIAN S, 1983, SURG NEUROL, V20, P310, DOI 10.1016/0090-3019(83)90086-1
   Sivakanthan S, 2018, J NEUROL SURG PART A, V79, P191, DOI 10.1055/s-0037-1606543
   Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036
   Zhong J, 2003, NEUROL RES, V25, P831, DOI 10.1179/016164103771953925
   2010, NEUROSURGERY SUPPL O, V67, P198, DOI DOI 10.1227/01.NEU.0000382974.81828.F9
   2010, NEUROSURGERY SUPPL O, V67, P277
NR 29
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E812
EP E819
DI 10.1016/j.wneu.2019.01.175
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700100
PM 30738944
DA 2020-05-12
ER

PT J
AU Ni, B
   Hu, YS
   Tao, W
   Shu, W
   Zhu, HW
AF Ni Bing
   Hu Yonsheng
   Tao Wei
   Shu Wei
   Zhu Hongwei
TI Dorsal Root Entry Zone Lesion for Neuropathic Pain Due to Thoracolumbar
   Spine Fracture: Long-Term Result
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dorsal root entry zone; Neuropathic pain; Spinal cord injuries
ID MICROSURGICAL DREZOTOMY; CORD-INJURY; DREZ; EFFICACY
AB OBJECTIVE: To retrospectively evaluate long-term efficacy and safety of dorsal root entry zone (DREZ) lesion for treatment of neuropathic pain within the lower extremities and perineal region after thoracolumbar spine fracture.
   METHODS: Forty-two patients were treated with posterior laminectomy under general anesthesia. The DREZ regions of the spinal cord segments were ablated under a microscope. Data regarding pain relief, pain variation over time, and postoperative complications were collected. The relationship between injured spinal column segment, spinal cord, nerve root, and pain territory were analyzed retrospectively.
   RESULTS: Spinal column injury segments were located between T12 and L4. Pain territories were distributed between the T11 and S5 dermatomes with varying ranges, at an average of 2-6 segments higher than the spinal cord injury segments. Pain relief rate was 100% in 21 patients (50.0%) and was over 50% in 14 patients (33.3%). Eighteen patients (42.9%) developed temporary tingling in the upper edge of the spinal cord lesion segment after surgery. Of the 4 patients with unilateral lower extremity pain, 2 developed postoperative persistent pain in the contralateral lower extremity.
   CONCLUSIONS: For patients with neuropathic pain of the lower extremities and/or the perineal region after thoracolumbar spine fracture, pain within the lower extremities was mostly because of nerve root injury. Pain in the perineal region caused by L1 fracture was attributed to spinal cord injury segmental pain. Nerve root injury pain had a good prognosis after DREZ lesion; the effect of DREZ lesion for spinal cord injury segmental pain may be uncertain.
C1 [Ni Bing; Hu Yonsheng; Shu Wei; Zhu Hongwei] Capital Med Univ, Xuanwu Hosp, Being Inst Funct Neurosurg, Beijing, Peoples R China.
   [Tao Wei] Shenzhen Univ, Gen Hosp, Dept Neurosurg, Shenzhen, Peoples R China.
RP Ni, B (reprint author), Capital Med Univ, Xuanwu Hosp, Being Inst Funct Neurosurg, Beijing, Peoples R China.
EM 13810621038@163.com
CR Awad Ahmed J, 2013, Surg Neurol Int, V4, P64, DOI 10.4103/2152-7806.112182
   Chivukula S, 2015, WORLD NEUROSURG, V84, P494, DOI 10.1016/j.wneu.2015.04.025
   Chun HJ, 2011, WORLD NEUROSURG, V75, P551, DOI 10.1016/j.wneu.2010.12.005
   Haninec P, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0225-9
   Kirazli O, 2014, ACTA NEUROCHIR, V156, P2351, DOI 10.1007/s00701-014-2252-0
   Ko AL, 2016, J NEUROSURG, V124, P1470, DOI 10.3171/2015.2.JNS142572
   Konrad P, 2014, NEUROSURG CLIN N AM, V25, P699, DOI 10.1016/j.nec.2014.07.010
   Lagauche D., 2009, Annals of Physical and Rehabilitation Medicine, V52, P180, DOI 10.1016/j.rehab.2008.12.010
   Mann R, 2013, SPINAL CORD, V51, P564, DOI 10.1038/sc.2013.34
   Mehta Swati, 2013, Top Spinal Cord Inj Rehabil, V19, P78, DOI 10.1310/sci1901-78
   Moreno-Duarte I, 2014, NEUROIMAGE, V85, P1003, DOI 10.1016/j.neuroimage.2013.05.097
   NASHOLD BS, 1981, J NEUROSURG, V55, P414, DOI 10.3171/jns.1981.55.3.0414
   Piyawattanametha N, 2017, ACTA NEUROCHIR, V159, P2431, DOI 10.1007/s00701-017-3345-3
   Ruiz-Juretschke F, 2011, NEUROLOGIA, V26, P26, DOI 10.1016/j.nrl.2010.10.003
   Sindou M, 2001, PAIN, V92, P159, DOI 10.1016/S0304-3959(00)00487-5
   Sindou M, 2011, WORLD NEUROSURG, V75, P447, DOI 10.1016/j.wneu.2011.01.034
   Sindou MP, 2004, SEMINARS NEUROSURGER, V15, P221
   Takai K, 2017, J NEUROSURG-SPINE, V27, P178, DOI 10.3171/2017.1.SPINE16234
   Wilcox SL, 2015, J NEUROSCI, V35, P2508, DOI 10.1523/JNEUROSCI.3756-14.2015
NR 19
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1050
EP E1056
DI 10.1016/j.wneu.2019.01.242
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700130
PM 30776514
DA 2020-05-12
ER

PT J
AU Oh, TK
   Jeon, YT
   Sohn, H
   Chung, SH
   Do, SH
AF Oh, Tak Kyu
   Jeon, Young-Tae
   Sohn, Hyemin
   Chung, Seung Hyun
   Do, Sang-Hwan
TI Association of Perioperative Hyperchloremia and Hyperchloremic Metabolic
   Acidosis with Acute Kidney Injury After Craniotomy for Intracranial
   Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acidosis; Acute kidney injury; Anesthesia; Neurosurgery
ID MORTALITY; INFUSION; MANNITOL; DISEASE; SURGERY; RISK
AB BACKGROUND: The present study evaluated the relationships among perioperative hyperchloremic metabolic acidosis (HCA), hyperchloremia, and postoperative acute kidney injury (AKI) in patients who had undergone craniotomy for intracranial hemorrhage (ICH).
   METHODS: The present retrospective cohort study included adult patients who had undergone craniotomy for traumatic or spontaneous ICH from January 2005 to December 2017. The association of perioperative hyperchloremia (serum chloride [Cl-] >110 mmol/L during postoperative days 0-3), an increase in Cl- levels (maximum Cl- level in postoperative days 0-3 minus the baseline Cl- level before surgery), and perioperative HCA (Cl- >110 mmol/L; pH <7.35, with a bicarbonate level <24 mmol/L) with the incidence of AKI was analyzed using multivariable logistic regression analysis.
   RESULTS: A total of 968 patients were included. Of these patients, 117 (12.1%) had postoperative AKI. The multivariable logistic regression analysis showed that the development of HCA was associated with a 1.850-fold increase in the incidence of postoperative AKI (odds ratio [OR], 1.850; 95% confidence interval [CI], 1.102-3.106; P = 0.020). However, hyperchloremia was not significantly related to the incidence of postoperative AKI (P = 0.207). Additionally, the presence of hyperchloremia and an increase in Cl- levels were both associated with an increased incidence of HCA (hyperchloremia group: OR, 2.162; 95% CI, 1.490-3.138; P < 0.001; 1-mmol/L increase in Cl- level: OR, 1.035; 95% CI, 1.008-1.062; P = 0.011).
   CONCLUSIONS: Perioperative HCA was independently related to an increased incidence of AKI after craniotomy for ICH. An increase in Cl- levels and perioperative hyperchloremia were associated with increased development of HCA but were not significantly related to the development of postoperative AKI.
C1 [Oh, Tak Kyu; Jeon, Young-Tae; Sohn, Hyemin; Chung, Seung Hyun; Do, Sang-Hwan] Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Seongnam, South Korea.
   [Jeon, Young-Tae; Do, Sang-Hwan] Seoul Natl Univ, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea.
RP Do, SH (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Seongnam, South Korea.; Do, SH (reprint author), Seoul Natl Univ, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea.
EM shdo@snu.ac.kr
CR Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3
   Bellomo R, 2012, LANCET, V380, P756, DOI 10.1016/S0140-6736(11)61454-2
   Brienza N, 2010, CURR OPIN CRIT CARE, V16, P353, DOI 10.1097/MCC.0b013e32833a9ef5
   Chawla LS, 2014, NEW ENGL J MED, V371, P58, DOI 10.1056/NEJMra1214243
   Magalhaes PADF, 2016, LIFE SCI, V146, P58, DOI 10.1016/j.lfs.2016.01.007
   de Vasconcellos K, 2018, J CRIT CARE, V45, P45, DOI 10.1016/j.jcrc.2018.01.019
   Deng YJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04627-3
   Fang L, 2010, RENAL FAILURE, V32, P673, DOI 10.3109/0886022X.2010.486492
   Goren O, 2015, BRIT J ANAESTH, V115, P3, DOI 10.1093/bja/aev380
   Hallan S, 2004, AM J KIDNEY DIS, V44, P84, DOI 10.1053/j.ajkd.2004.03.027
   Hobson C, 2015, ANN SURG, V261, P1207, DOI 10.1097/SLA.0000000000000732
   Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454
   Kim DG, 2011, WORLD NEUROSURG, V75, P397, DOI 10.1016/j.wneu.2011.03.031
   Kim MY, 2014, J NEUROSURG, V120, P1340, DOI 10.3171/2013.12.JNS13888
   Lewington AJP, 2013, KIDNEY INT, V84, P457, DOI 10.1038/ki.2013.153
   Lin SY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002032
   McCluskey SA, 2013, ANESTH ANALG, V117, P412, DOI 10.1213/ANE.0b013e318293d81e
   Mendelow AD, 2005, LANCET, V365, P387
   Monteiro J., 2017, FLUIDS ELECTROLYTE M, P815
   Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766
   Neto AS, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.07.38
   Oh TK, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2216-5
   Oh TK, 2019, J NEUROSURG ANESTH, V31, P311, DOI 10.1097/ANA.0000000000000512
   Palant CE, 2017, CURR OPIN ANESTHESIO, V30, P100, DOI 10.1097/ACO.0000000000000428
   Patel Nachiket, 2016, Proc (Bayl Univ Med Cent), V29, P7
   Siqueira EMP, 2017, ACTA PAUL ENFERM, V30, P101, DOI 10.1590/1982-0194201700015
   Poca MA, 1998, ACT NEUR S, V71, P27
   Prough DS, 1999, ANESTHESIOLOGY, V90, P1247, DOI 10.1097/00000542-199905000-00003
   Sadan O, 2017, CRIT CARE MED, V45, P1382, DOI 10.1097/CCM.0000000000002497
   Scheingraber S, 1999, ANESTHESIOLOGY, V90, P1265, DOI 10.1097/00000542-199905000-00007
   SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091
   Silva Junior João Manoel, 2009, Rev. Bras. Anestesiol., V59, P304, DOI 10.1590/S0034-70942009000300005
   Sneyd JR, 2005, BRIT J ANAESTH, V94, P778, DOI 10.1093/bja/aei141
   Suetrong B, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1499-7
   Toyonaga Y, 2017, NEPHROLOGY, V22, P720, DOI 10.1111/nep.12840
   WAKABAYASHI Y, 1986, TOHOKU J EXP MED, V149, P145, DOI 10.1620/tjem.149.145
   Yessayan L, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0750-z
   2014, J NEUROSURG, V120, P736, DOI DOI 10.3171/2013.10.JNS122419
NR 38
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1226
EP E1240
DI 10.1016/j.wneu.2019.02.015
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700152
PM 30797920
DA 2020-05-12
ER

PT J
AU Ordonez-Rubiano, EG
   Valderrama-Arias, FA
   Forbes, JA
   Johnson, JM
   Younus, I
   Marin-Munoz, JH
   Sanchez-Montano, M
   Angulo, DA
   Cifuentes-Lobelo, HA
   Cortes-Lozano, W
   Pedraza-Ciro, MC
   Bello-Davila, ML
   Patino-Gomez, JG
   Ordonez-Mora, EG
AF Ordonez-Rubiano, Edgar G.
   Valderrama-Arias, Francisco A.
   Forbes, Jonathan A.
   Johnson, Jason M.
   Younus, Iyan
   Marin-Munoz, Jorge H.
   Sanchez-Montano, Mariana
   Angulo, Diego A.
   Cifuentes-Lobelo, Hernando A.
   Cortes-Lozano, William
   Pedraza-Ciro, Maria C.
   Leonardo Bello-Davila, May
   Patino-Gomez, Javier G.
   Ordonez-Mora, Edgar G.
TI Identification of Preoperative Language Tracts for Intrinsic
   Frontotemporal Diseases: A Pilot Reconstruction Algorithm in a
   Middle-Income Country
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diffusion tensor imaging; Language; Temporal lobe; Tractography; White
   matter
ID CORTICOSPINAL TRACT; BRAIN-TUMORS; SURGICAL OUTCOMES; AWAKE CRANIOTOMY;
   PREDICTIVE-VALUE; MR TRACTOGRAPHY; FIBER TRACKING; DIFFUSION; SURGERY;
   CONNECTIVITY
AB OBJECTIVE: Diffusion tensor imaging (DTI) tractography provides useful information that can be used to optimize surgical planning and help avoid injury during subcortical dissection of eloquent tracts. The objective is to provide a safe, timely, and affordable algorithm for preoperative DTI language reconstruction for intrinsic frontotemporal diseases.
   METHODS: We reviewed a prospectively acquired database of preoperative DTI reconstruction for resection of left frontotemporal lesions over 3 years at Hospital de San Jose and Hospital Infantil Universitario San Jose, Fundacion Universitaria de Ciencias de la Salud, Bogota, Colombia. Preoperative and postoperative clinical and radiographic features were determined from retrospective chart review. A comprehensive review of the structural and functional anatomy of the language tracts was performed. Separate reconstruction of both ventral (semantic) and dorsal (phonologic) stream pathways is described: arcuate fasciculus, superior longitudinal fasciculus, inferior fronto-occipital fasciculus, uncinate fasciculus, and inferior longitudinal fasciculus.
   RESULTS: Between January 2015 and January 2018, 44 tumor cases were found to be resected with preoperative fiber tracking planning and neuronavigation-guided surgery. Ten patients (7 women, 3 men) aged 28-65 years underwent resection of an intrinsic frontotemporal lesion with preoperative DTI tractography reconstruction of language tracts. Eight cases (80%) were high-grade gliomas and 2 (20%) were cavernous malformations. In 5 cases (50%), the lesion was in the frontal lobe and in 5 (50%), it was in the temporal lobe. The extent of resection was classified as gross total resection (100%), subtotal resection (>90%), or partial resection (<90%). Gross total resection was achieved in 5 cases (50%), subtotal resection was achieved in 4 cases (40%), and partial resection in the remaining case (10%). Compromised tracts included superior longitudinal fasciculus in 7 (70%), inferior longitudinal fasciculus in 4 (40%), the arcuate fasciculus in 3 (30%), and uncinate fasciculus in 1 (10%). Language function was unchanged or improved in 90% of patients. New-onset postoperative language decline occurred in 1 patient, who recovered transient phonemic paraphasias 1 month after resection. The mean follow-up time was 7 months (range, 4-12 months). Residual tumors were treated with radiation and/or with chemotherapy as indicated in an outpatient setting.
   CONCLUSIONS: We present a safe and efficacious preoperative DTI language reconstruction algorithm that could be used as a feasible treatment strategy in a challenging subset of tumors in low-to middle-income countries.
C1 [Ordonez-Rubiano, Edgar G.; Valderrama-Arias, Francisco A.; Cifuentes-Lobelo, Hernando A.; Cortes-Lozano, William; Patino-Gomez, Javier G.; Ordonez-Mora, Edgar G.] Hosp Infantil Univ San Jose, Fdn Univ Ciencias Salud, Dept Neurol Surg, Bogota, Colombia.
   [Forbes, Jonathan A.] Univ Cincinnati, Coll Med, Dept Neurol Surg, Cincinnati, OH USA.
   [Johnson, Jason M.] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Neuroradiol, Houston, TX 77030 USA.
   [Younus, Iyan] Weill Cornell Med Coll, New York, NY USA.
   [Marin-Munoz, Jorge H.] Hosp Infantil Univ San Jose, Fdn Univ Ciencias Salud, Dept Diagnost Radiol, Diagnost Imaging, Bogota, Colombia.
   [Sanchez-Montano, Mariana] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Diagnost Radiol, Neuroradiol, Mexico City, DF, Mexico.
   [Angulo, Diego A.] Univ Los Andes, Syst & Comp Engn, IMAGINE, Bogota, Colombia.
   [Angulo, Diego A.] Imex Res, ImExHS, Bogota, Colombia.
   [Pedraza-Ciro, Maria C.] Clin Los Nogales, Dept Neurol Surg, Bogota, Colombia.
   [Leonardo Bello-Davila, May] Hosp Infantil Univ San Jose, Fdn Univ Ciencias Salud, Dept Neurol, Bogota, Colombia.
RP Ordonez-Rubiano, EG (reprint author), Hosp Infantil Univ San Jose, Fdn Univ Ciencias Salud, Dept Neurol Surg, Bogota, Colombia.
EM egordonez@fucsalud.edu.co
RI Ordonez-Rubiano, Edgar G/Z-4435-2019
OI Pedraza Ciro, Mauricio/0000-0001-8726-5578; Ordonez-Rubiano, Edgar
   Gerardo/0000-0003-1179-5825
CR Alexander DC, 2005, NEUROIMAGE, V27, P357, DOI 10.1016/j.neuroimage.2005.04.008
   Angulo DA, 2016, FRONT NEUROINFORM, V10, DOI 10.3389/fninf.2016.00036
   Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582
   Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018
   Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007
   Ashburner J, 2009, MAGN RESON IMAGING, V27, P1163, DOI 10.1016/j.mri.2009.01.006
   Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022
   Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8
   Bermnan JI, 2008, NEUROIMAGE, V39, P215, DOI 10.1016/j.neuroimage.2007.08.021
   Bernal B, 2010, MAGN RESON IMAGING, V28, P217, DOI 10.1016/j.mri.2009.07.008
   Bucci M, 2013, NEUROIMAGE-CLIN, V3, P361, DOI 10.1016/j.nicl.2013.08.008
   Catani M, 2008, CORTEX, V44, P953, DOI 10.1016/j.cortex.2008.04.002
   Catani M, 2008, CORTEX, V44, P911, DOI 10.1016/j.cortex.2008.05.001
   Caverzasi E, 2016, J NEUROSURG, V125, P33, DOI 10.3171/2015.6.JNS142203
   Caverzasi E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100274
   Chang EF, 2015, J NEUROSURG, V122, P250, DOI 10.3171/2014.10.JNS132647
   Charpak N, 1997, PEDIATRICS, V100, P682, DOI 10.1542/peds.100.4.682
   Cho Z. H., 2015, 7 0 TESLA MRI BRAIN
   Cotton F, 2005, SURG RADIOL ANAT, V27, P64, DOI 10.1007/s00276-004-0283-6
   Duffau H, 2005, BRAIN, V128, P797, DOI 10.1093/brain/awh423
   Fernandez-Miranda JC, 2008, NEUROSURGERY, V62, P989, DOI [10.1227/01.NEU.0000297076.98175.67, 10.1227/01.neu.0000333767.05328.49]
   Fernandez-Miranda JC, 2010, J NEUROSURG, V113, P156, DOI 10.3171/2009.10.JNS091460
   Fujii M, 2015, J NEUROSURG, V122, P1390, DOI 10.3171/2014.10.JNS14945
   Garrett MC, 2012, NEUROSURG CLIN N AM, V23, P497, DOI 10.1016/j.nec.2012.05.003
   Henry RG, 2004, NEUROIMAGE, V21, P616, DOI 10.1016/j.neuroimage.2003.09.047
   Hervey-Jumper SL, 2015, J NEUROSURG, V123, P325, DOI 10.3171/2014.10.JNS141520
   Jiao YM, 2017, WORLD NEUROSURG, V105, P478, DOI 10.1016/j.wneu.2017.05.159
   Kamali A, 2014, BRAIN STRUCT FUNCT, V219, P269, DOI 10.1007/s00429-012-0498-y
   Kikuta K, 2008, ACTA NEUROCHIR SUPPL, V103, P11
   Kiuchi K, 2011, J PSYCHIATR RES, V45, P1095, DOI 10.1016/j.jpsychires.2011.01.011
   Lin FX, 2016, WORLD NEUROSURG, V88, P538, DOI 10.1016/j.wneu.2015.10.074
   Lin YX, 2018, J NEUROSURG, V128, P541, DOI 10.3171/2016.10.JNS161179
   Mandelli ML, 2014, J NEUROSURG, V121, P349, DOI 10.3171/2014.4.JNS131160
   Monteiro Gina Torres Rego, 2003, Cad. Saúde Pública, V19, P1139, DOI 10.1590/S0102-311X2003000400035
   Moritz-Gasser S, 2012, J NEURO-ONCOL, V107, P633, DOI 10.1007/s11060-011-0789-9
   Philippi CL, 2009, J NEUROSCI, V29, P15089, DOI 10.1523/JNEUROSCI.0796-09.2009
   Pineros M, 2016, CANCER EPIDEMIOL, V44, pS141, DOI 10.1016/j.canep.2016.04.007
   Pineros M, 2013, CANCER EPIDEMIOL, V37, P233, DOI 10.1016/j.canep.2013.02.003
   Quinones-Hinojosa A, 2003, J NEUROSURG, V99, P311, DOI 10.3171/jns.2003.99.2.0311
   Ribas GC, 2006, NEUROSURGERY, V59, P177, DOI 10.1227/01.NEU.0000240682.28616.b2
   Servadei F, 2018, WORLD NEUROSURG, V112, P315, DOI 10.1016/j.wneu.2018.01.047
   Sollmann N, 2016, J NEUROSCI METH, V267, P45, DOI 10.1016/j.jneumeth.2016.04.002
   Southwell DG, 2016, J NEUROSURG, V124, P1460, DOI 10.3171/2015.5.JNS142833
   Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042
   Szelenyi A, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09237
   Teixidor P, 2007, J NEURO-ONCOL, V81, P305, DOI 10.1007/s11060-006-9233-y
   Ulmer JL, 2014, NEUROIMAG CLIN N AM, V24, P599, DOI 10.1016/j.nic.2014.08.002
   Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642
   Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165
   2006, NEUROSURGERY S2, V59, P177
NR 50
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E729
EP E742
DI 10.1016/j.wneu.2019.01.163
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700091
PM 30735870
DA 2020-05-12
ER

PT J
AU Ota, N
   Noda, K
   Hatano, Y
   Hashimoto, A
   Miyazaki, T
   Kondo, T
   Kinoshita, Y
   Kamiyama, H
   Tokuda, S
   Kamada, K
   Tanikawa, R
AF Ota, Nakao
   Noda, Kosumo
   Hatano, Yuto
   Hashimoto, Atsumu
   Miyazaki, Takanori
   Kondo, Tomomasa
   Kinoshita, Yu
   Kamiyama, Hiroyasu
   Tokuda, Sadahisa
   Kamada, Kyousuke
   Tanikawa, Rokuya
TI Preoperative Predictors and Prognosticators After Microsurgical Clipping
   of Poor-Grade Subarachnoid Hemorrhage: A Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clipping; Frailty; Poor grade; Prognostic factors; Subarachnoid
   hemorrhage
ID RUPTURED CEREBRAL ANEURYSMS; CLOT REMOVAL; VASOSPASM; ASSOCIATION; AGE
AB BACKGROUND: Contrary to expectations, some patients with poor-grade subarachnoid hemorrhage (SAH) show favorable outcomes. However, the factors predictive of good prognosis are unclear. The purposes of this study were to identify factors related to poor-grade SAH and to analyze preoperative prognostic factors.
   METHODS: We included 186 patients with SAH who underwent surgical clipping or conservative treatment immediately after SAH diagnosis. Physiologic, radiographic, and blood examination data were collected retrospectively. Factors related to poor World Federation of Neurological Societies (WFNS) grade (WFNS IV and V) and poor outcome (modified Rankin Scale scores 3-6) were analyzed.
   RESULTS: The patients (mean age, 61.6 years) included 134 women (72%). Seventy patients (38.2%) had poor WFNS scores. On multivariate analysis, age >= 70 years (adjusted odds ratio [OR], 3.73), midline shift (OR, 4.89), and the absence of cerebrospinal fluid in the high-convexity cortical sulci (OR, 5.47) and ambient cistern (OR, 4.83) were predictive of poor WFNS scores. Age >= 70 years (OR, 8.36), WFNS grade 5 (OR, 15.35), intracerebral hematoma (OR, 3.32), and Evans index (EI) >= 0.3 (OR, 4.40) were predictive of poor outcome. Body mass index (OR, 0.87), intraventricular hemorrhage (OR, 3.86), glycated hemoglobin level (OR, 2.78), and age >= 70 years (OR, 4.12) were predictive of EI >= 0.3.
   CONCLUSIONS: Poor outcomes correlated with older age, brain-destructive hemorrhage, and EI >= 0.3. The EI reflects both hydrocephalus and the patient's frailty. Radiographic signs of poor-grade SAH were not correlated with poor outcome, suggesting that early decompressive surgery may improve outcome.
C1 [Ota, Nakao; Noda, Kosumo; Hatano, Yuto; Hashimoto, Atsumu; Miyazaki, Takanori; Kondo, Tomomasa; Kinoshita, Yu; Kamiyama, Hiroyasu; Tokuda, Sadahisa; Tanikawa, Rokuya] Sapporo Teishinkai Hosp, Dept Neurosurg, Stroke Ctr, Higashi Ku, Sapporo, Hokkaido, Japan.
   [Kamada, Kyousuke] Asahikawa Med Univ, Dept Neurosurg, Asahikawa, Hokkaido, Japan.
RP Tanikawa, R (reprint author), Sapporo Teishinkai Hosp, Dept Neurosurg, Stroke Ctr, Higashi Ku, Sapporo, Hokkaido, Japan.
EM taniroku@gmail.com
OI Ota, Nakao/0000-0002-7074-1125
CR BAILES JE, 1990, J NEUROSURG, V72, P559, DOI 10.3171/jns.1990.72.4.0559
   Bekelis K, 2017, WORLD NEUROSURG, V99, P320, DOI 10.1016/j.wneu.2016.12.023
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Furtner J, 2017, EUR RADIOL, V27, P3167, DOI 10.1007/s00330-016-4707-6
   Gallucci M, 2018, J ALZHEIMERS DIS, V62, P1623, DOI 10.3233/JAD-170938
   Guresir E, 2008, NEUROSURGERY, V63, P1088, DOI 10.1227/01.NEU.0000335170.76722.B9
   Hirabayashi N, 2016, DIABETES CARE, V39, P1543, DOI 10.2337/dc15-2800
   Hsieh PC, 2018, J NEUROSURG, V129, P876, DOI 10.3171/2017.5.JNS17794
   Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P105
   Junius-Walker U, 2018, EUR J INTERN MED, V56, P3, DOI 10.1016/j.ejim.2018.04.023
   Lanzino G, 1996, J NEUROSURG, V85, P410, DOI 10.3171/jns.1996.85.3.0410
   Matsukawa H, 2015, WORLD NEUROSURG, V84, P1798, DOI 10.1016/j.wneu.2015.07.069
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2015, LANCET, V385, P691, DOI 10.1016/S0140-6736(14)60975-2
   Ota N, 2017, WORLD NEUROSURG, V107, P630, DOI 10.1016/j.wneu.2017.08.088
   Park J, 2014, ACTA NEUROCHIR, V156, P1655, DOI 10.1007/s00701-014-2133-6
   Proust F, 2010, J NEUROSURG, V112, P1200, DOI 10.3171/2009.10.JNS08754
   Ranganathan K, 2014, J SURG RES, V186, P246, DOI 10.1016/j.jss.2013.07.059
   Schuss P, 2016, WORLD NEUROSURG, V85, P125, DOI 10.1016/j.wneu.2015.08.046
   Schuss P, 2013, J NEUROSURG, V118, P984, DOI 10.3171/2012.11.JNS121435
   SHERMAN JL, 1987, AM J ROENTGENOL, V148, P193, DOI 10.2214/ajr.148.1.193
   SHIBUYA M, 1992, J NEUROSURG, V76, P571, DOI 10.3171/jns.1992.76.4.0571
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Teo M, 2017, WORLD NEUROSURG, V105, P270, DOI 10.1016/j.wneu.2017.05.005
   van den Berg R, 2011, CRIT CARE MED, V39, P2722, DOI 10.1097/CCM.0b013e3182282a70
   Westermaier T, 2007, NEUROSURGERY, V61, P482, DOI 10.1227/01.NEU.0000290893.85072.F9
   Wostrack M, 2013, ACTA NEUROCHIR, V155, P579, DOI 10.1007/s00701-013-1634-z
   2008, NEUROSURGERY, V63, P1088, DOI DOI 10.1227/01.NEU.0000335170.76722.B9
   2007, NEUROSURGERY, V61, P482, DOI DOI 10.1227/01.NEU.0000280034.30501.DO
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E582
EP E592
DI 10.1016/j.wneu.2019.01.135
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700075
PM 30716502
DA 2020-05-12
ER

PT J
AU Ou, YW
   Dong, JQ
   Wu, L
   Xu, L
   Wang, L
   Liu, BY
   Li, JS
   Liu, WM
AF Ou, Yunwei
   Dong, Jinqian
   Wu, Liang
   Xu, Long
   Wang, Lei
   Liu, Baiyun
   Li, Jingsheng
   Liu, Weiming
TI The Clinical Characteristics, Treatment, and Outcomes of Chronic
   Subdural Hematoma in Young Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid cyst; Chronic subdural hematoma; Clinical characteristics;
   Outcome; Ventriculoperitoneal shunt; Young patients
ID ARACHNOID CYSTS; SURGICAL-TREATMENT; MIDDLE FOSSA; MANAGEMENT;
   EVACUATION; HEMORRHAGE
AB OBJECTIVE: To investigate the clinical characteristics, treatment, and outcomes of chronic subdural hematomas (CSDH) in young patients.
   METHODS: We retrospectively reviewed young patients under 40 years of age who received diagnoses of and were surgically treated for CSDH between August 2011 and May 2017. Clinical data, computed tomographic findings, surgical outcomes, and recurrencewere collected for further analysis.
   RESULTS: A total of 101 patients (92 male; 91.1%) were analyzed. Ages ranged from 1 to 40 years (27.3 +/- 10.5), and 59 (58.4%) patients had a history of recent head trauma. The most frequent symptoms were headache (86.1%) and dizziness (26.7%). A total of 60 (59.4%) patients had arachnoid cyst (AC), and 8 (7.9%) patients had ventriculoperitoneal (V-P) shunt. After burr hole drainage craniotomy, all patients experienced good outcomes, and 1 patient experienced recurrence requiring reoperation. Sixty-eight patients with AC/V-P shunts had a higher incidence of head trauma (P = 0.014), younger age at onset P < 0.001), and lower incidence of dizziness (P = 0.013) than did those without AC/V-P shunts. Surgical recurrence rates and outcomes did not differ significantly between patients with and without AC/V-P shunts.
   CONCLUSIONS: Headache is the most common symptom, and AC/V-P shunts are risk factors of CSDH in young patients. AC/V-P shunt-associated CSDH is associated with younger morbidity. Head trauma is a risk factor for AC/V-P shunt-associated CSDH, but is not significance in patients without AC/V-P shunts. Catheter drainage through a burr hole may be the first-choice surgical procedure in treatment of CSDH in young patients, including AC/V-P shunt-associated CSDH.
C1 [Ou, Yunwei; Dong, Jinqian; Wu, Liang; Xu, Long; Wang, Lei; Liu, Baiyun; Li, Jingsheng; Liu, Weiming] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Ou, Yunwei; Dong, Jinqian; Liu, Baiyun] Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China.
   [Ou, Yunwei; Xu, Long; Liu, Weiming] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Liu, Weiming] Ningxia Peoples Hosp, Neurol Ctr, Yinchuan, Ningxia, Peoples R China.
RP Liu, WM (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Liu, WM (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Liu, WM (reprint author), Ningxia Peoples Hosp, Neurol Ctr, Yinchuan, Ningxia, Peoples R China.
EM liuweimingnsok@sina.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81502150]; Beijing Outstanding Talent Training
   Project [2015000021469G222]; National Key Technology Research and
   Development Program of the Ministry of Science and Technology of
   ChinaNational Key Technology R&D Program [2014BAI04B01, 2015BAI12B04,
   2013BAI09B03]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AR064874, AR068950]
FX This work was supported by the National Natural Science Foundation of
   China (81502150), the Beijing Outstanding Talent Training Project
   (2015000021469G222), and National Key Technology Research and
   Development Program of the Ministry of Science and Technology of China
   (2014BAI04B01, 2015BAI12B04 and 2013BAI09B03). C.W. was supported by NIH
   grants (AR064874 and AR068950).
CR Adin Mehmet Emin, 2018, Radiol Case Rep, V13, P516, DOI 10.1016/j.radcr.2017.12.006
   Al-Holou WN, 2013, J NEUROSURG, V118, P222, DOI 10.3171/2012.10.JNS12548
   Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255
   Asghar M, 2002, J ROY SOC MED, V95, P290, DOI 10.1258/jrsm.95.6.290
   Banks JL, 2007, STROKE, V38, P1091, DOI 10.1161/01.STR.0000258355.23810.c6
   Beck J, 2014, J NEUROSURG, V121, P1380, DOI 10.3171/2014.6.JNS14550
   Bosma JJD, 2000, ACTA NEUROCHIR, V142, P1307, DOI 10.1007/s007010070030
   Brennan PM, 2017, J NEUROSURG, V127, P732, DOI 10.3171/2016.8.JNS16134
   Domenicucci M, 2009, J NEUROSURG, V110, P1250, DOI 10.3171/2008.4.17509
   Jiang RC, 2018, JAMA NEUROL, V75, P1338, DOI 10.1001/jamaneurol.2018.2030
   Kode S, 2018, CUREUS, V10, DOI 10.7759/cureus.2550
   KUDO H, 1992, Neurologia Medico-Chirurgica, V32, P207, DOI 10.2176/nmc.32.207
   Kwak YS, 2013, CHILD NERV SYST, V29, P77, DOI 10.1007/s00381-012-1896-4
   Liu ZY, 2014, PEDIATR EMERG CARE, V30, P345, DOI 10.1097/PEC.0000000000000128
   MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637
   Missori P, 2002, BRIT J NEUROSURG, V16, P63, DOI 10.1080/026886902753512637
   Mori K, 2003, ACTA NEUROCHIR, V145, P533, DOI 10.1007/s00701-003-0026-1
   Mori K, 2002, J NEUROTRAUM, V19, P1017, DOI 10.1089/089771502760341938
   Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371
   Musluman AM, 2018, TURK NEUROSURG, V28, P776, DOI 10.5137/1019-5149.JTN.21513-17.3
   PAGE A, 1987, J NEUROL NEUROSUR PS, V50, P1001, DOI 10.1136/jnnp.50.8.1001
   Parsch CS, 1997, NEUROSURGERY, V40, P483, DOI 10.1097/00006123-199703000-00010
   ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263
   Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6
   Shrestha Rajendra, 2014, Asian J Neurosurg, V9, P168, DOI 10.4103/1793-5482.142739
   Takizawa K, 2015, NEUROL MED-CHIR, V55, P727, DOI 10.2176/nmc.oa.2015-0016
   Toi H, 2018, J NEUROSURG, V128, P222, DOI 10.3171/2016.9.JNS16623
   Wester K, 2008, J NEUROL NEUROSUR PS, V79, P72, DOI 10.1136/jnnp.2007.117358
   Wu XX, 2018, WORLD NEUROSURG, V109, pE118, DOI 10.1016/j.wneu.2017.09.115
   2003, ACTA NEUROCHIR WIEN, V145, P533, DOI DOI 10.1007/S00701-003-0026-1
NR 30
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1241
EP E1246
DI 10.1016/j.wneu.2019.02.017
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700153
PM 30797913
DA 2020-05-12
ER

PT J
AU Strapasson, ACP
   Antunes, ACM
   Oppitz, PP
   Dalsin, M
   Rieder, CRD
AF Paim Strapasson, Atahualpa Caue
   Martins Antunes, Apio Claudio
   Oppitz, Paulo Petry
   Dalsin, Marcos
   de Mello Rieder, Carlos Roberto
TI Postoperative Confusion in Patients with Parkinson Disease Undergoing
   Deep Brain Stimulation of the Subthalamic Nucleus
SO WORLD NEUROSURGERY
LA English
DT Article
DE Confusion; Deep brain stimulation; Parkinson's disease; Postoperative;
   Subthalamic nucleus
ID METAANALYSIS
AB BACKGROUND: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for patients with Parkinson disease. One adverse event is the development of postoperative confusion. The aim of this study was to report the incidence and associated factors of postoperative confusion after STN DBS surgery.
   METHODS: This was a retrospective cohort study by chart review of patients with Parkinson disease who underwent STN DBS in a Brazilian public academic hospital from January 2013 to October 2017. The primary outcome was the incidence of postoperative confusion. The association of the outcome and imaging and clinical variables was evaluated.
   RESULTS: Among 49 patients who underwent STN DBS for Parkinson disease, the incidence of postoperative confusion was 26.5% (95% confidence interval 15%-41.1%). Univariate analysis identified the following variables associated with development of confusion: age (63.2 +/- 7.8 years vs. 55.4 +/- 9.1 years, P = 0.009), disease duration (16.5 +/- 5.1 years vs. 13.2 +/- 4.2 years, P = 0.027), Charlson comorbidity index (2 [interquartile range 1-3] vs. 1 [0-1 interquartile range], P = 0.002), width of the third ventricle (5.4 +/- 2.1 mm vs. 4 +/- 1.6 mm, P = 0.018), and cella media index (5 +/- 1 vs. 5.6 +/- 0.8, P = 0.018). After adjustment, Charlson comorbidity index remained significant (adjusted relative risk 1.64, 95% confidence interval 1.17-2.3, P = 0.004).
   CONCLUSIONS: The incidence of postoperative confusion in this cohort was 26.5%. After analysis of confounding factors, the Charlson comorbidity index was significantly associated with postoperative confusion.
C1 [Paim Strapasson, Atahualpa Caue] Univ Fed Rio Grande do Sul, HCPA, Dept Neurosurg, Porto Alegre, RS, Brazil.
   [Martins Antunes, Apio Claudio] Univ Fed Rio Grande do Sul, HCPA, Dept Neurosurg, Porto Alegre, RS, Brazil.
   [Oppitz, Paulo Petry; Dalsin, Marcos] HCPA, Dept Neurosurg, Porto Alegre, RS, Brazil.
   [de Mello Rieder, Carlos Roberto] UFCSPA, HCPA, Dept Neurol, Porto Alegre, RS, Brazil.
RP Strapasson, ACP (reprint author), Univ Fed Rio Grande do Sul, HCPA, Dept Neurosurg, Porto Alegre, RS, Brazil.
EM drstrapasson@gmail.com
RI Rieder, Carlos Roberto M/O-6600-2018
OI Rieder, Carlos Roberto M/0000-0003-2950-7211
CR Andrade-Souza YM, 2005, NEUROSURGERY, V56, P56, DOI 10.1227/01.NEU.0000145797.35968.ED
   [Anonymous], 2015, J AM COLL SURGEONS, V220, P136, DOI 10.1016/j.jamcollsurg.2014.10.019
   Benabid AL, 2009, LANCET NEUROL, V8, P67, DOI 10.1016/S1474-4422(08)70291-6
   Bourne SK, 2012, STEREOT FUNCT NEUROS, V90, P167, DOI 10.1159/000338094
   Camicioli R, 2011, MOVEMENT DISORD, V26, P1443, DOI 10.1002/mds.23700
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Dalaker TO, 2011, MOVEMENT DISORD, V26, P297, DOI 10.1002/mds.23443
   de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Gologorsky Y, 2011, NEUROSURGERY, V69, P294, DOI 10.1227/NEU.0b013e318214abda
   Ho AL, 2018, J NEUROL NEUROSUR PS, V89, P687, DOI 10.1136/jnnp-2016-314500
   Kalakoti P, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.3.FOCUS1547
   Kenney C, 2007, J NEUROSURG, V106, P621, DOI 10.3171/jns.2007.106.4.621
   Kleiner-Fisman G, 2006, MOVEMENT DISORD, V21, pS290, DOI 10.1002/mds.20962
   Kramer DR, 2012, STEREOT FUNCT NEUROS, V90, P20, DOI 10.1159/000332056
   Litvan I, 2003, MOVEMENT DISORD, V18, P467, DOI 10.1002/mds.10459
   Pilitsis JG, 2005, STEREOT FUNCT NEUROS, V83, P67, DOI 10.1159/000086676
   Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571
   Sheshadri V, 2017, CAN J NEUROL SCI, V44, P697, DOI 10.1017/cjn.2017.224
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Weaver F, 2005, J NEUROSURG, V103, P956, DOI 10.3171/jns.2005.103.6.0956
   Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929
   2006, J NEUROL NEUROSUR PS, V77, P12, DOI DOI 10.1136/JNNP.2005.069161
   2010, STEREOT FUNCT NEUROS, V88, P296, DOI DOI 10.1159/000316762
   2014, J CLIN NEUROSCI, V21, P1192, DOI DOI 10.1016/J.JOCN.2013.12.007
NR 25
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E966
EP E971
DI 10.1016/j.wneu.2019.01.216
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700119
PM 30763744
DA 2020-05-12
ER

PT J
AU Passias, PG
   Poorman, GW
   Horn, SR
   Jalai, CM
   Bortz, C
   Segreto, F
   Diebo, BM
   Daniels, A
   Hamilton, DK
   Sciubba, D
   Smith, J
   Neuman, B
   Shaffrey, CI
   LaFage, V
   LaFage, R
   Schwab, F
   Bess, S
   Ames, C
   Hart, R
   Soroceanu, A
   Mundis, G
   Eastlack, R
AF Passias, Peter G.
   Poorman, Gregory W.
   Horn, Samantha R.
   Jalai, Cyrus M.
   Bortz, Cole
   Segreto, Frank
   Diebo, Bassel M.
   Daniels, Alan
   Hamilton, D. Kojo
   Sciubba, Daniel
   Smith, Justin
   Neuman, Brian
   Shaffrey, Christopher I.
   LaFage, Virginie
   LaFage, Renaud
   Schwab, Frank
   Bess, Shay
   Ames, Christopher
   Hart, Robert
   Soroceanu, Alexandra
   Mundis, Gregory
   Eastlack, Robert
CA Int Spine Study Grp
TI Effect of Obesity on Radiographic Alignment and Short-Term Complications
   After Surgical Treatment of Adult Cervical Deformity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alignment; Cervical deformity; Complications; Obese; Obesity; Surgery
ID BODY-MASS INDEX; SPINAL DEFORMITY; RISK-FACTORS; OUTCOMES; SURGERY;
   FUSION; IMPACT; BIOMECHANICS; ASSOCIATION; PARAMETERS
AB OBJECTIVE: We investigated the 30-day complication incidence and 1-year radiographic correction in obese patients undergoing surgical treatment of cervical deformity.
   METHODS: The patients were stratified according to World Health Organization's definition for obesity: obese, patients with a body mass index of >= 30 kg/m(2); and nonobese, patients with a body mass index of <30 kg/m(2). The patients had undergone surgery for the treatment of cervical deformity. The patient baseline demographic, comorbidity, and radiographic data were compared between the 2 groups at baseline and 1 year postoperatively. The 30-day complication incidence was stratified according to complication severity (any, major, or minor), and type (cardiopulmonary, dysphagia, infection, neurological, and operative). Binary logistic regression models were used to assess the effect of obesity on developing those complications, with adjustment for patient age and levels fused.
   RESULTS: A total of 124 patients were included, 53 obese and 71 nonobese patients. The 2 groups had a similar T1 slope minus cervical lordosis (obese, 37.2 degrees vs. nonobese, 36.9 degrees; P = 0.932) and a similar C2-C7 (-5.9 degrees vs. -7.3 degrees; P = 0.718) and C2-C7 (50.1 mm vs. 44.1 mm; P = 0.184) sagittal vertical axis. At the 1-year follow-up examination, the T1 pelvic angle (1.0 degrees vs. -3.1 degrees; P = 0.021) and C2-S1 sagittal vertical axis (-5.9 mm vs. -35.0 mm; P = 0.036) were different, and the T1 spinopelvic inclination (-1.0 degrees vs. -2.9 degrees; P = 0.123) was similar. The obese patients had a greater risk of overall short-term complications (odds ratio, 2.5; 95% confidence interval, 1.1-6.1) and infectious complications (odds ratio, 5.0; 95% confidence interval, 1.0-25.6).
   CONCLUSIONS: Obese patients had a 5 times greater odds of developing infections after surgery for adult cervical deformity. Obese patients also showed significantly greater pelvic anteversion after cervical correction.
C1 [Passias, Peter G.; Poorman, Gregory W.; Horn, Samantha R.; Jalai, Cyrus M.; Bortz, Cole; Segreto, Frank] NYU Langone Orthoped Hosp, Dept Orthoped, New York, NY 10003 USA.
   [Diebo, Bassel M.] SUNY Downstate Med Sch, Dept Orthoped Surg, Brooklyn, NY USA.
   [Daniels, Alan] Brown Univ, Dept Orthoped Surg, Warren Alpert Sch Med, Providence, RI 02912 USA.
   [Hamilton, D. Kojo] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA.
   [Sciubba, Daniel] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Neuman, Brian] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD USA.
   [Smith, Justin; Shaffrey, Christopher I.] Univ Virginia, Med Ctr, Dept Neurosurg, Charlottesville, VA USA.
   [LaFage, Virginie; LaFage, Renaud; Schwab, Frank] Hosp Special Surg, Dept Orthoped, 535 E 70th St, New York, NY 10021 USA.
   [Bess, Shay] Rocky Mt Scoliosis & Spine, Denver, CO USA.
   [Ames, Christopher] Univ Calif San Francisco, Sch Med, Dept Neurol Surg, San Francisco, CA USA.
   [Hart, Robert] Swedish Neurosci Inst, Dept Orthopaed Surg, Seattle, WA USA.
   [Soroceanu, Alexandra] Univ Calgary, Dept Orthopaed Surg, Calgary, AB, Canada.
   [Mundis, Gregory] San Diego Ctr Spinal Disorders, La Jolla, CA USA.
   [Eastlack, Robert] Scripps Clin, Div Orthopaed Surg, La Jolla, CA 92037 USA.
   [Int Spine Study Grp] Int Spine Study Grp, Denver, CO USA.
RP Passias, PG (reprint author), NYU Langone Orthoped Hosp, Dept Orthoped, New York, NY 10003 USA.
EM Peter.Passias@nyumc.org
RI /AAA-4616-2020; Lafage, Virginie/E-7747-2010
OI bess, shay/0000-0002-9697-8999; Lafage, Virginie/0000-0002-0119-7111
FU DePuy Synthes
FX The International Spine Study Group is funded through research grants
   from DePuy Synthes and individual donations. Dr. Passias reports a
   consultancy with Medicrea and Spinewave, speaking or teaching
   arrangements with Zimmer Biomet, a grant from CSRS, and scientific
   advisory board membership at Allosource. Dr. Daniels reports a
   consultancy with Stryker, DePuy Synthes, Globus, and Stryker and
   research/fellowship support from Orthofix. Dr. Sciubba reports
   consultancy with DePuy Synthes, Medtronic, Stryker, NuVasive, and K2M.
   Dr. Smith reports grants from DePuy Synthes, consultancy with
   Zimmer-Biomet, NuVasive, and Cerapedics, royalties from Zimmer-Biomet,
   speaking or teaching arrangements from Zimmer-Biomet and Nuvasive. Dr.
   Shaffrey reports grants from DePuy Synthes, National Institutes of
   Health, Department of Defense, and AOSpine; a consultancy with
   Medtronic, Nuvasive, Zimmer Biomet, K2M, Stryker, and In Vivo;
   royalties/patents from Medtronic, Nuvasive, and Zimmer Biomet; and
   stockholder earnings from Nuvasive. Dr. Lafage reports grants from SRS,
   DePuy, K2M, Stryker, and NuVasive; speaking or teaching arrangements
   from DePuy, MSD, and AOSpine; consultancy from NuVasive; and
   shareholder/board of directors for Nemaris Inc. Dr. Schwab reports
   royalties from Zimmer Biomet, MSD, and K2M; stock ownership in Nemaris
   Inc.; consulting for NuVasive, Zimmer Biomet, and Medtronic; speaking
   and teaching for MSD, NuVasive, and Zimmer Biomet; membership on the
   board of directors for Nemaris Inc.; and grants from DePuy Spine,
   NuVasive, Stryker, and K2M. Dr. Bess reports consultancy for K2M and
   Allosource and support of nonestudy-related clinical or research efforts
   from DePuy Synthes, Medtronic, NuVasive, K2M, and Orthofix. Dr. Ames
   reports grants from DePuy; consultancy from DePuy, Medtronic, Stryker;
   and royalties from Stryker and Zimmer Biomet. Dr. Hart reports grant
   from Medtronic; speaking fees from Globus, Seaspine, and DePuy; and
   other disclosures from CSRS, ISSG, and ISSLS. Dr. Mundis reports a
   consultancy from K2M and DePuy Synthes; royalties from K2M; and
   nonfinancial support from Nuvasive.
CR Browning RC, 2007, MED SCI SPORT EXER, V39, P1632, DOI 10.1249/mss.0b013e318076b54b
   Buerba RA, 2014, SPINE J, V14, P1643, DOI 10.1016/j.spinee.2013.09.054
   Diebo BG, 2015, SPINE, V40, P642, DOI 10.1097/BRS.0000000000000844
   Djurasovic M, 2008, SPINE, V33, P1789, DOI 10.1097/BRS.0b013e31817b8f6f
   Fanuele JC, 2002, SPINE, V27, P306, DOI 10.1097/00007632-200202010-00021
   Farcy JPC, 1997, SPINE, V22, P2452, DOI 10.1097/00007632-199710150-00025
   Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39
   GELB DE, 1995, SPINE, V20, P1351, DOI 10.1097/00007632-199506000-00005
   Jalai CM, 2017, SPINE J, V17, P681, DOI 10.1016/j.spinee.2016.11.016
   Lafage V, 2009, SPINE, V34, pE599, DOI 10.1097/BRS.0b013e3181aad219
   Legaye Jean, 2005, Acta Orthop Belg, V71, P213
   Park P, 2016, WORLD NEUROSURG, V87, P55, DOI 10.1016/j.wneu.2015.12.024
   Puvanesarajah V, 2016, J NEUROSURG-SPINE, V25, P486, DOI 10.3171/2016.2.SPINE151345
   Rodriguez-Martinez NG, 2016, J NEUROSURG-SPINE, V24, P615, DOI 10.3171/2015.7.SPINE141306
   Runhaar J, 2011, OBES REV, V12, P1071, DOI 10.1111/j.1467-789X.2011.00916.x
   Schwab F, 2006, SPINE, V31, pE959, DOI 10.1097/01.brs.0000248126.96737.0f
   Sebastian A, 2016, SPINE J, V16, P504, DOI 10.1016/j.spinee.2015.12.009
   Smith JS, 2016, NEUROSURGERY, V79, P378, DOI 10.1227/NEU.0000000000001129
   Soroceanu A, 2015, J NEUROSURG-SPINE, V23, P656, DOI 10.3171/2015.3.SPINE14743
   Srinivasan D, 2014, J CLIN NEUROSCI, V21, P1159, DOI 10.1016/j.jocn.2013.11.017
   Tang JA, 2012, NEUROSURGERY, V71, P662, DOI 10.1227/NEU.0b013e31826100c9
   Tetreault L, 2017, EUR SPINE J, V26, P78, DOI 10.1007/s00586-016-4660-8
   Vismara L, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-3
   2010, EUR SPINE J, V19, P982, DOI DOI 10.1007/S00586-009-1269-1
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1082
EP E1088
DI 10.1016/j.wneu.2019.01.248
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700135
PM 30790725
DA 2020-05-12
ER

PT J
AU Patil, H
   Gupta, R
AF Patil, Harshad
   Gupta, Rakesh
TI A Comparative Study of Bolus Dose of Hypertonic Saline, Mannitol, and
   Mannitol Plus Glycerol Combination in Patients with Severe Traumatic
   Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hypertonic saline; Mannitol; Mannitol plus glycerol combination; Raised
   intracranial pressure; Severe traumatic brain injury
ID RAISED INTRACRANIAL-PRESSURE; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY;
   HEMORRHAGIC-SHOCK; RESUSCITATION; MANAGEMENT; DEXTRAN; HYPERVENTILATION;
   HYPERTENSION; TRIAL
AB BACKGROUND: This prospective randomized controlled study compared the efficacy of an equiosmolar and isovolumetric dose of 3% hypertonic saline, 20% mannitol, and 10% mannitol plus 10% glycerol combination in reducing the raised intracranial pressure (ICP) in patients with severe traumatic brain injury (TBI).
   METHODS: A total of 120 patients of severe TBI with increased ICP were randomized to receive an equiosmolar and isovolumetric dose of 3% hypertonic saline, 20% mannitol, and 10% mannitol plus 10% glycerol combination at a defined infusion rate, which was stopped when ICP was <15 mm Hg.
   RESULTS: A total of 120 patients with severe TBI (aged >18 years, Glasgow Coma Scale <= 8, and had sustained elevated ICP of >20 mm Hg for more than 5 minutes) were randomized during the study. All data were presented as mean (minimum-maximum). A one-way analysis of variance test was used to analyze the effect across the treatment group, and Tukey's method was used for multiple comparisons. A paired t-test was employed to analyze the effect of the medication within each group. All 3 drugs decreased ICP below 15 mm Hg (P < 0.0001). The maximum change in ICP occurred after a bolus dose of 3% hypertonic saline followed by 10% mannitol plus 10% glycerol combination and then 20% mannitol (60% vs. 57% vs. 55%, respectively). Mean arterial pressure and cerebral perfusion pressure were increased after the bolus dose of study medications. Maximum changes occurred after infusion of 3% hypertonic saline followed by 10% mannitol plus 10% glycerol combination and 20% mannitol (P < 0.0349 and < 0.0013, respectively). There was no statistically significant change in the hematocrit value noted after the bolus dose of any of the study medications. Serum sodium and osmolarity were raised significantly after the bolus dose of study medications. Maximum changes in serum sodium and osmolarity occurred after the bolus dose of 3% hypertonic saline. The mean dose required to reduce ICP below 15 mm Hg for 3% hypertonic saline: 1.4 mL/kg, for 10% mannitol plus 10% glycerine: 1.7 mL/kg, and for 20% mannitol: 2.0 mL/kg. The mean time required to reduce ICP below 15 mm Hg for 3% hypertonic saline: 16 minutes, for 10% mannitol plus 10% glycerine: 19 minutes, and for 20% mannitol: 23 minutes. The maximum change in the Glasgow Coma Scale occurred after the bolus dose of 3% hypertonic saline, followed by 10% mannitol plus 10% glycerol combination and then 20% mannitol.
   CONCLUSIONS: All 3 osmotic compounds exhibit comparable effectiveness in reducing ICP when a similar osmotic load is administrated, but 3% hypertonic saline appeared to be more effective followed by 10% mannitol plus 10% glycerol combination and 20% mannitol. A dose of 1.4 mL/kg can be recommended as an initial bolus dose for 3% hypertonic saline. Hypertonic saline can be recommended to treat patients with pretreatment hypovolemia, hyponatremia, or renal failure. There is no clear benefit compared with 20% mannitol in regard to neurologic outcome, even though there is a minor positive trend for 3% hypertonic saline and 10% mannitol plus 10% glycerol combination.
C1 [Patil, Harshad] Bansal Hosp, Dept Neurosurg, Bhopal, India.
   [Gupta, Rakesh] Aurobindo Hosp, Dept Neurosurg, Indore, Madhya Pradesh, India.
RP Patil, H (reprint author), Bansal Hosp, Dept Neurosurg, Bhopal, India.
EM dr.harshadpatil@gmail.com
CR Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6
   BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015
   Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994
   Bratton SL, 2008, J NEUROTRAUM, V25, P276
   Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7
   Chesnut R M, 1995, New Horiz, V3, P581
   Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929
   FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002
   Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41
   Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767
   Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019
   Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5
   KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584
   Kempski O, 1996, ACT NEUR S, V66, P114
   MOON PF, 1995, CRIT CARE MED, V23, P323, DOI 10.1097/00003246-199502000-00019
   Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142
   MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731
   Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596
   Otsubo K, 1993, Nihon Ika Daigaku Zasshi, V60, P231
   Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0
   Procaccio F, 2000, J Neurosurg Sci, V44, P11
   Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003
   Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685
   Schwab S, 1997, NEUROLOGY, V48, P1608, DOI 10.1212/WNL.48.6.1608
   Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877
   Sheikh AA, 1996, CRIT CARE MED, V24, P1226, DOI 10.1097/00003246-199607000-00027
   Soni A., 2009, Trends in Medical Research, V4, P42, DOI 10.3923/tmr.2009.42.48
   Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7
   Tamta Anupama, 2009, Int J Biomed Sci, V5, P428
   Treib J, 1997, THROMB HAEMOSTASIS, V78, P974
   Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF
   Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419
   Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4
NR 33
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E221
EP E228
DI 10.1016/j.wneu.2019.01.051
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700029
PM 30684710
DA 2020-05-12
ER

PT J
AU Perez, JL
   Ozpinar, A
   Kano, H
   Phan, B
   Niranjan, A
   Lunsford, LD
AF Perez, Jennifer L.
   Ozpinar, Alp
   Kano, Hideyuki
   Phan, BaDoi
   Niranjan, Ajay
   Lunsford, L. Dade
TI Salvage Stereotactic Radiosurgery in Breast Cancer Patients with
   Multiple Brain Metastases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Breast cancer; Brain metastases; Radiosurgery; Recurrence; Salvage
   therapy
ID GAMMA-KNIFE RADIOSURGERY; CEREBRAL METASTASES; THERAPY; MANAGEMENT;
   COURSES
AB BACKGROUND: The overall survival rates for breast cancer are increasing due to controlled brain disease and improved systemic treatments. This study examined neurologic outcomes, tumor control, and survival data in breast cancer patients with multiple brain metastases and who required salvage stereotactic radiosurgery (SRS) for recurrent breast cancer brain metastases.
   METHODS: The study included 231 patients with a primary diagnosis of breast cancer who underwent SRS for more than 1 brain metastases from May 1993 and July 2007. Survival analyses via univariate and multivariate Cox regression demonstrated interactions between survival and predictor values including Karnofsky Performance Scale, Recursive Partitioning Analysis Class, number of brain metastases, whole-brain radiotherapy (WBRT), immunotherapy, and chemotherapy.
   RESULTS: Of the 231 patients, the survival rate was 53% at 1 year and 26% at 5 years from initial SRS. Controlled systemic disease, adjuvant chemotherapy, and Recursive Partitioning Analysis class II were significant predictors of increased survival, while WBRT was a significant predictor of decreased survival. The median survival in patients who received WBRT after SRS was 11 months versus 23 months in those who did not. The local tumor control rate at initial follow-up was 95%. Of these, 40% of patients underwent additional brain SRS. Following salvage SRS, 8% of patients developed symptomatic adverse radiation events; however, the development of symptomatic adverse radiation events had no effect on patient survival.
   CONCLUSIONS: This report indicated that both initial and salvage SRS procedures in breast cancer patients with multiple brain metastases are effective for local control of intracranial disease while minimizing adverse radiation effects.
C1 [Perez, Jennifer L.; Phan, BaDoi] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
   [Ozpinar, Alp; Kano, Hideyuki; Niranjan, Ajay; Lunsford, L. Dade] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA.
RP Perez, JL (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
EM jlp232@pitt.edu
OI Perez, Jennifer/0000-0001-6512-0327; Phan, BaDoi/0000-0001-6331-5980
CR Bowden G, 2015, J NEUROSURG, V122, P766, DOI 10.3171/2014.12.JNS141111
   Bowden G, 2014, J NEURO-ONCOL, V118, P141, DOI 10.1007/s11060-014-1408-3
   Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3
   Deng Z, 2018, NIGER J CLIN PRACT, V21, P401, DOI 10.4103/njcp.njcp_315_16
   Koffer P, 2017, WORLD NEUROSURG, V104, P589, DOI 10.1016/j.wneu.2017.04.103
   Koiso T, 2016, J NEUROSURG, V125, P2, DOI 10.3171/2016.6.GKS161404
   Kotecha R, 2017, NEUROSURGERY, V80, P871, DOI 10.1093/neuros/nyw147
   Kwon KY, 2007, CLIN NEUROL NEUROSUR, V109, P132, DOI 10.1016/j.clineuro.2006.06.007
   Lucas JT, 2015, INT J RADIAT ONCOL, V92, P1008, DOI 10.1016/j.ijrobp.2015.04.032
   Mckay WH, 2017, J NEUROSURG, V127, P148, DOI 10.3171/2016.5.JNS153051
   Miller JA, 2017, NEUROSURGERY, V81, P147, DOI 10.1093/neuros/nyw166
   Monaco EA, 2013, CANCER-AM CANCER SOC, V119, P226, DOI 10.1002/cncr.27504
   Rae Ali, 2016, Adv Radiat Oncol, V1, P294, DOI 10.1016/j.adro.2016.08.007
   Shultz DB, 2015, INT J RADIAT ONCOL, V92, P993, DOI 10.1016/j.ijrobp.2015.04.036
   Silva D, 2017, NEUROSURG CLIN N AM, V28, P525, DOI 10.1016/j.nec.2017.05.015
   Sperduto PW, 2008, INT J RADIAT ONCOL, V70, P510, DOI 10.1016/j.ijrobp.2007.06.074
   Stokes TB, 2015, J NEURO-ONCOL, V121, P583, DOI 10.1007/s11060-014-1670-4
   Viani GA, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-53
   Yamamoto M, 2012, INT J RADIAT ONCOL, V83, P1399, DOI 10.1016/j.ijrobp.2011.10.018
   2011, J CLIN ONCOL, V29, P134, DOI DOI 10.1200/JCO.2010.30.1655
   2014, J NEUROSURG S, V121, P16, DOI DOI 10.3171/2014.8.GKS141421
NR 21
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E479
EP E486
DI 10.1016/j.wneu.2019.01.108
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700064
PM 30710716
DA 2020-05-12
ER

PT J
AU Pieters, TA
   Li, YI
   Towner, JE
   Schmidt, T
   Vates, GE
   Pilcher, W
   Li, YM
AF Pieters, Thomas A.
   Li, Yan Icy
   Towner, James E.
   Schmidt, Tyler
   Vates, G. Edward
   Pilcher, Webster
   Li, Yan Michael
TI Comparative Analysis of Decompression Versus Decompression and Fusion
   for Surgical Management of Lumbar Spondylolisthesis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fusion; Lumbar decompression; NSQIP; Spondylolisthesis
ID SPINAL STENOSIS; CLINICAL GUIDELINE; LAMINECTOMY; DIAGNOSIS
AB OBJECTIVE: When lumbar stenosis involves spondylolisthesis, many surgeons include fixation. Two recent trials have shown no consensus to definitive treatment. We aimed to add to the discourse of fusion versus decompression in patients with lumbar spondylolisthesis by providing a large-scale generalizable study.
   METHODS: We used multicenter, prospectively collected data from the American College of Surgeons National Surgical Quality Improvement Program database to compare 30-day outcomes for decompression alone versus combination decompression and fusion in the treatment of lumbar spondylolisthesis. Logistic regression models were used to analyze the effect of surgical type on multiple characteristics. Univariate 2-tailed chi(2) analyses were used to identify further outcome differences.
   RESULTS: In total, 9606 patients with treated lumbar spondylolisthesis were identified (907 decompression only, 8699 decompression and fusion). The fusion group tended to be younger (P < 0.001) and was more likely to be smokers (P = 0.01). Unplanned return to surgery was 3.02% in the fusion group, compared with 1.02% (P = 0.011). Minor adverse events occurred in 12.8% of the fusion group versus 4.9% (P < 0.001). Major adverse events occurred in 4.5% of the fusion group versus 3.1% (P = 0.0498). There was no significant difference in 30-day mortality, prolonged admission, or 30-day readmission.
   CONCLUSIONS: Unplanned return to the operating room and major and minor adverse events were greater for patients undergoing fusion. This could influence future decision-making in lumbar spondylolisthesis. This study indicates that further investigation is warranted but that decompression may be associated with less morbidity in the properly selected patient.
C1 [Pieters, Thomas A.; Li, Yan Icy; Towner, James E.; Schmidt, Tyler; Vates, G. Edward; Pilcher, Webster; Li, Yan Michael] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA.
   [Li, Yan Icy] Nanjing Med Univ, Dept Bioinformat, Nanjing, Jiangsu, Peoples R China.
RP Li, YM (reprint author), Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA.
EM Yanm_Li@urmc.rochester.edu
CR Alimi M, 2015, J NEUROSURG-SPINE, V22, P339, DOI 10.3171/2014.11.SPINE13597
   Atlas SJ, 1996, SPINE, V21, P1794
   Birkmeyer JD, 2001, ARCH SURG-CHICAGO, V136, P405, DOI 10.1001/archsurg.136.4.405
   Childers CP, 2018, JAMA SURG, V153, DOI 10.1001/jamasurg.2017.6233
   Fischgrund JS, 1997, SPINE, V22, P2807, DOI 10.1097/00007632-199712150-00003
   Forsth P, 2016, NEW ENGL J MED, V374, P1413, DOI 10.1056/NEJMoa1513721
   Ghogawala Z, 2016, NEW ENGL J MED, V374, P1424, DOI 10.1056/NEJMoa1508788
   Glassman SD, 2000, SPINE, V25, P2608, DOI 10.1097/00007632-200010150-00011
   Kalichman L, 2009, SPINE J, V9, P545, DOI 10.1016/j.spinee.2009.03.005
   Kreiner DS, 2013, SPINE J, V13, P734, DOI 10.1016/j.spinee.2012.11.059
   Machado GC, 2016, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858
   Malmivaara A, 2007, SPINE, V32, P1, DOI 10.1097/01.brs.0000251014.81875.6d
   Matz PG, 2016, SPINE J, V16, P439, DOI 10.1016/j.spinee.2015.11.055
   Overdevest GM, 2015, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD010036.PUB2
   Pereira EAC, 2017, J CLIN NEUROSCI, V35, P56, DOI 10.1016/j.jocn.2016.09.010
   Weinstein JN, 2007, NEW ENGL J MED, V356, P2257, DOI 10.1056/NEJMoa070302
   2017, WORLD NEUROSURG, V103, P859, DOI DOI 10.1016/J.WNEU.2017.04.109
   1996, SPINE PHILA PA 1976, V21, P1787
NR 18
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1183
EP E1188
DI 10.1016/j.wneu.2019.01.275
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700147
PM 30794979
DA 2020-05-12
ER

PT J
AU Prajakta, G
   Horisawa, S
   Kawamata, T
   Taira, T
AF Prajakta, Ghate
   Horisawa, Shiro
   Kawamata, Takakazu
   Taira, Takaomi
TI Feasibility of Staged Bilateral Radiofrequency Ventral Intermediate
   Nucleus Thalamotomy for Bilateral Essential Tremor
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bilateral tremor; Bilateral Vim thalamotomy; Radiofrequency lesioning
ID QUALITY STANDARDS SUBCOMMITTEE; PARKINSONS-DISEASE; STEREOTAXIC
   THALAMOTOMY; AMERICAN-ACADEMY; SURGERY
AB BACKGROUND: Patients with bilateral and/or midline/axial tremor have significant diminution in quality of life (QOL). Various studies report high complication rates with bilateral thalamotomy. However, use of primitive methods in these studies confers questionable validity. We conducted a retrospective observational cohort study in patients with medication-refractory bilateral essential tremor treated with staged bilateral radiofrequency ventral intermediate nucleus thalamotomy to subjectively examine the impact of any adverse effects on QOL and patient satisfaction.
   METHODS: Eight patients who had undergone staged bilateral radiofrequency ventral intermediate nucleus thalamotomy were included and completed a customized questionnaire. Patients returned the completed questionnaire by mail for statistical analysis.
   RESULTS: All 8 patients had improved QOL. Seven patients were satisfied with the received treatment, although residual neck and hand tremor remained in 5 and 4 patients, respectively. None of the patients reported worsening of symptoms or severe disability in any area. Adverse effects included speech difficulty, difficulty in concentration, memory loss, and calculation difficulty. All 8 patients were self-reliant in doing everyday tasks that were not possible before the treatment suggesting the nondisabling nature of the adverse effects that occurred.
   CONCLUSIONS: Adverse effects that are nondisabling and hence acceptable to the patient can be considered acceptable adverse effects. Staged bilateral radiofrequency ventral intermediate nucleus thalamotomy definitely improves QOL in patients with medication-refractory bilateral essential tremor despite occurrence of acceptable adverse effects.
C1 [Prajakta, Ghate; Horisawa, Shiro; Kawamata, Takakazu; Taira, Takaomi] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
   [Prajakta, Ghate] Reliance Hosp, Navi Mumbai, India.
RP Taira, T (reprint author), Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
EM ttaira@twmu.ac.jp
CR Akbostanci MC, 1999, STEREOT FUNCT NEUROS, V72, P174, DOI 10.1159/000029722
   Alshaikh J, 2017, CLIN NEUROL NEUROSUR, V158, P103, DOI 10.1016/j.clineuro.2017.04.025
   BRAVO G, 1967, CONFIN NEUROL, V29, P133
   Duma CM, 1998, J NEUROSURG, V88, P1044, DOI 10.3171/jns.1998.88.6.1044
   GILLINGHAM FJ, 1964, BMJ-BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5410.656
   GOLDMAN MS, 1992, J NEUROSURG, V76, P924, DOI 10.3171/jns.1992.76.6.0924
   GOLDMAN MS, 1992, STEREOT FUNCT NEUROS, V58, P22, DOI 10.1159/000098966
   Guiot G, 1982, CORRELATIVE NEUROSUR, P481
   HIRAI T, 1983, BRAIN, V106, P1001, DOI 10.1093/brain/106.4.1001
   Jenkins A C, 1968, Med J Aust, V1, P585
   KELLY PJ, 1980, J NEUROSURG, V53, P332, DOI 10.3171/jns.1980.53.3.0332
   KRAYENBUHL H, 1961, J NEUROSURG, V18, P429, DOI 10.3171/jns.1961.18.4.0429
   MATSUMOTO K, 1984, J NEUROSURG, V60, P1033, DOI 10.3171/jns.1984.60.5.1033
   NAGASEKI Y, 1986, J NEUROSURG, V65, P296, DOI 10.3171/jns.1986.65.3.0296
   SELBY G, 1967, J NEUROL SCI, V5, P315, DOI 10.1016/0022-510X(67)90139-6
   SPEAKMAN TJ, 1963, CAN MED ASSOC J, V89, P652
   Zesiewicz TA, 2011, NEUROLOGY, V77, P1752, DOI 10.1212/WNL.0b013e318236f0fd
   Zesiewicz TA, 2005, NEUROLOGY, V64, P2008, DOI 10.1212/01.WNL.0000163769.28552.CD
   Zirh A, 1999, J NEUROL NEUROSUR PS, V66, P772, DOI 10.1136/jnnp.66.6.772
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E992
EP E997
DI 10.1016/j.wneu.2019.01.224
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700123
PM 30771542
DA 2020-05-12
ER

PT J
AU Puffer, RC
   Yue, JK
   Mesley, M
   Billigen, JB
   Sharpless, J
   Fetzick, AL
   Puccio, AM
   Diaz-Arrastia, R
   Okonkwo, DO
AF Puffer, Ross C.
   Yue, John K.
   Mesley, Matthew
   Billigen, Julia B.
   Sharpless, Jane
   Fetzick, Anita L.
   Puccio, Ava M.
   Diaz-Arrastia, Ramon
   Okonkwo, David O.
TI Recovery Trajectories and Long-Term Outcomes in Traumatic Brain Injury:
   A Secondary Analysis of the Phase 3 Citicoline Brain Injury Treatment
   Clinical Trial
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clinical; Outcomes; Recovery; TBI; Trajectory; Trial
ID TEMPORAL PROFILE; MORTALITY; SCALE
AB BACKGROUND: Prospects for recovery after traumatic brain injury (TBI) are often underestimated, potentially leading to withdrawal of care in the comatose TBI patient who may ultimately have a favorable outcome with aggressive care. Outcomes and trajectories of recovery in a large series of patients with TBI were evaluated at 30, 90, and 180 days postinjury.
   METHODS: A secondary analysis of the phase 3 Citicoline Brain Injury Treatment (COBRIT) trial was performed analyzing recovery trajectories and long-term outcomes at 30, 90, and 180 days postinjury. A Glasgow Outcome Scale-Extended (GOS-E) score of 5 or higher was considered favorable. Pearson chi(2) analysis was used, and a P value of 0.05 was considered significant. A locally weighted, polynomial regression model was used to model recovery trajectories in a nonlinear fashion.
   RESULTS: Subjects with TBI in the COBRIT trial had high rates of favorable outcome (57% of severe TBI, 86% of moderate TBI, and 93% of complicated mild TBI) at 6-month follow-up. These favorable outcomes often converted from high rates of unfavorable outcome at initial 1-month follow-up (85% of severe TBI, 57% of moderate TBI, and 21% of complicated mild TBI). Recovery trajectories had not plateaued at 6 months, suggesting that further improvement occurs beyond 6 months postinjury.
   CONCLUSIONS: In this secondary analysis of the COBRIT trial, most patients had favorable outcomes by the GOS-E at 6 months postinjury in all complicated mild and moderate TBI groups, with over half of patients with severe TBI achieving a favorable outcome as well. Of subjects in a vegetative state (GOS-E score 2) at 1 month postinjury, 18% improved to a favorable outcome by 6 months postinjury. There was substantial improvement in all groups from 1 to 6 months, and this improvement may continue beyond 6 months. Clinical trials in TBI should consider recovery curves with repeated measures to assess outcomes because arbitrary single-moment outcome determination likely underestimates treatment effect in TBI care.
C1 [Puffer, Ross C.] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Yue, John K.; Mesley, Matthew; Billigen, Julia B.; Sharpless, Jane; Fetzick, Anita L.; Puccio, Ava M.; Okonkwo, David O.] UPMC, Dept Neurosurg, Pittsburgh, PA 15213 USA.
   [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
RP Okonkwo, DO (reprint author), UPMC, Dept Neurosurg, Pittsburgh, PA 15213 USA.
EM okonkwodo@upmc.edu
RI Yue, John K/P-1348-2015
OI Yue, John K/0000-0001-9694-7722
CR CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169
   Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460
   Dean D, 2015, ACAD EMERG MED, V22, P54, DOI 10.1111/acem.12555
   Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819
   Lilley EJ, 2016, J TRAUMA ACUTE CARE, V80, P998, DOI 10.1097/TA.0000000000001028
   Plaisier BR, 2002, AM SURGEON, V68, P159
   Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587
   Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786
   Vedantam A, 2018, J NEUROSURG, V129, P234, DOI 10.3171/2017.3.JNS162720
   Whitmore RG, 2012, J NEUROSURG, V116, P1106, DOI 10.3171/2012.1.JNS11962
   Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573
   Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015
   Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256
NR 13
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E909
EP E915
DI 10.1016/j.wneu.2019.01.207
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700112
PM 30763755
DA 2020-05-12
ER

PT J
AU Qin, XD
   He, Z
   Qiu, Y
   Zhu, ZZ
AF Qin, Xiaodong
   He, Zhong
   Qiu, Yong
   Zhu, Zezhang
TI Anterior Spinal Overgrowth of the Thoracic Spine May Not Be Involved in
   the Initiation of Adolescent Idiopathic Scoliosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; Anterior overgrowth; Chiari I
   malformation; Etiopathogenesis
ID CHIARI-I MALFORMATION; SYRINGOMYELIA; MANAGEMENT; CHILDREN
AB OBJECTIVE: To compare vertebral morphology among patients with adolescent idiopathic scoliosis (AIS), patients with Chiari I malformation (CMS)-associated scoliosis, and normal control subjects, with the goal of determining the role of anterior column overgrowth in the development of AIS.
   METHODS: One hundred and forty adolescent girls were enrolled (50 with AIS, 40 with CMS, and 50 control subjects). Thoracic computed tomography images were obtained for all subjects. Anterior height of the vertebral body (VBHa), posterior height of the vertebral body (VBHp), and height of the pedicle (PH) were measured for each level. Finally, the ratios of VBHa and VBHp to PH were calculated and compared among the 3 groups.
   RESULTS: Compared with the control group, both the AIS and CMS groups exhibited consistently longer VBHa and VBHp for most thoracic vertebral bodies, whereas the PH of most vertebral bodies was shorter in both AIS and CMS groups. Moreover, the ratios for differential growth between the anterior and posterior elements of each thoracic vertebra in both the AIS and CMS groups were significantly larger than the ratios in the control group. However, for all mentioned parameters, there were no significant differences between the AIS and CMS groups.
   CONCLUSIONS: Faster growth of the anterior spinal column was confirmed by longer vertebral bodies and shorter pedicles in both patient groups. Relative anterior spinal overgrowth of the thoracic spine is not involved in the initiation of AIS, and the abnormal growth pattern of the vertebral body in AIS might be a secondary change to the spinal curve.
C1 [Qin, Xiaodong; He, Zhong; Qiu, Yong; Zhu, Zezhang] Nanjing Univ, Med Sch, Drum Tower Hosp, Spine Surg, Nanjing, Jiangsu, Peoples R China.
RP Zhu, ZZ (reprint author), Nanjing Univ, Med Sch, Drum Tower Hosp, Spine Surg, Nanjing, Jiangsu, Peoples R China.
EM zhuzezhang@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81171672]
FX This work was supported by the National Natural Science Foundation of
   China (81171672).
CR ARAI S, 1993, SPINE, V18, P1591, DOI 10.1097/00007632-199309000-00004
   CHARRY O, 1994, J PEDIATR ORTHOPED, V14, P309, DOI 10.1097/01241398-199405000-00007
   DICKSON RA, 1984, J BONE JOINT SURG BR, V66, P8
   Eule JM, 2002, SPINE, V27, P1451, DOI 10.1097/00007632-200207010-00015
   Ghanem IB, 1997, SPINE, V22, P1313, DOI 10.1097/00007632-199706150-00006
   Guo X, 2003, J BONE JOINT SURG BR, V85B, P1026, DOI 10.1302/0301-620X.85B7.14046
   HARRINGTON PR, 1977, CLIN ORTHOP RELAT R, P17
   ISU T, 1990, NEUROSURGERY, V26, P591, DOI 10.1227/00006123-199004000-00006
   Liljenqvist UR, 2002, J BONE JOINT SURG AM, V84A, P359, DOI 10.2106/00004623-200203000-00005
   Liljenqvist UR, 2000, SPINE, V25, P1247, DOI 10.1097/00007632-200005150-00008
   LONSTEIN JE, 1994, LANCET, V344, P1407
   Magge SN, 2011, J NEUROSURG-PEDIATR, V7, P30, DOI 10.3171/2010.10.PEDS1057
   Maiocco B, 1997, SPINE, V22, P2537, DOI 10.1097/00007632-199711010-00014
   McCarthy RE, 1999, ORTHOP CLIN N AM, V30, P435, DOI 10.1016/S0030-5898(05)70096-1
   Milhorat TH, 1999, NEUROSURGERY, V44, P1005, DOI 10.1097/00006123-199905000-00042
   Millner P A, 1996, Eur Spine J, V5, P362, DOI 10.1007/BF00301963
   Nash John, 2002, WMJ, V101, P35
   Ono Atsushi, 2002, Spine (Phila Pa 1976), V27, pE23, DOI 10.1097/00007632-200201150-00011
   Ozerdemoglu RA, 2003, SPINE, V28, P1410, DOI 10.1097/00007632-200307010-00011
   ROAF ROBERT, 1966, J BONE JOINT SURG B BRIT, V48, P786
   Schijman E, 2004, CHILD NERV SYST, V20, P341, DOI 10.1007/s00381-003-0882-2
   Schlosser TPC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160267
   Schlosser TPC, 2014, SPINE, V39, pE1159, DOI 10.1097/BRS.0000000000000467
   Tokunaga M, 2001, J BONE JOINT SURG BR, V83B, P371, DOI 10.1302/0301-620X.83B3.11021
   Wu T, 2012, EUR SPINE J, V21, P1143, DOI 10.1007/s00586-011-2064-3
   Xiong B, 1995, Eur Spine J, V4, P11, DOI 10.1007/BF00298411
   Zhu Zezhang, 2013, Spine Deform, V1, P25, DOI 10.1016/j.jspd.2012.07.005
   1952, J BONE JOINT SURG B, V34, P421
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E319
EP E325
DI 10.1016/j.wneu.2019.01.071
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700041
PM 30685373
DA 2020-05-12
ER

PT J
AU ReFaey, K
   Tripathi, S
   Bohnen, AM
   Waddle, MR
   Peterson, J
   Vazquez-Ramos, C
   Bondoc, CM
   Quinones-Hinojosa, A
   Trifiletti, DM
AF ReFaey, Karim
   Tripathi, Shashwat
   Bohnen, Angela M.
   Waddle, Mark R.
   Peterson, Jennifer
   Vazquez-Ramos, Carla
   Bondoc, Celine M.
   Quinones-Hinojosa, Alfredo
   Trifiletti, Daniel M.
TI The Reliability of YouTube Videos Describing Stereotactic Radiosurgery:
   A Call for Action
SO WORLD NEUROSURGERY
LA English
DT Article
DE CyberKnife; Gamma Knife; Patient education; Stereotactic radiosurgery;
   YouTube
ID INFORMATION; QUALITY
AB BACKGROUND: Gamma Knife radiosurgery was introduced in the 1960s and is currently used worldwide. The internet has become a foremost source of information used by patients and their families. In this study, we aim to evaluate the accuracy and reliability of the Gamma Knife radiosurgeryerelated YouTube videos.
   METHODS: We searched YouTube and the first 3 pages sorted according to "Relevance-Based Ranking" were included for analysis. Four independent health care workers from different disciplines evaluated the videos using the validated DISCERN tool.
   RESULTS: Our search resulted in 65,774 videos, and 14 videos met inclusion criteria. Our study found that 50% (7 of 14) of the videos were uploaded by university-affiliated hospitals; 14% of videos scored 3. The search term "Radiosurgery for intraaxial brain lesions" had the highest percentage of moderate videos (DISCERN = 3) (50%).
   CONCLUSIONS: Patients and caregivers turn to online sources to gather information about the disease. However, the available YouTube published videos are published without proper academic monitoring, as in such a free platform, published videos tend to catch a general audience for different purposes, which leads to diminishing quality control. Academic medical institutions should consider a proper monitoring process for videos to improve the accuracy of the published information for the patients.
C1 [ReFaey, Karim; Bohnen, Angela M.; Peterson, Jennifer; Vazquez-Ramos, Carla; Quinones-Hinojosa, Alfredo; Trifiletti, Daniel M.] Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
   [Tripathi, Shashwat] Univ Texas Austin, Coll Nat Sci, Austin, TX 78712 USA.
   [Waddle, Mark R.; Peterson, Jennifer; Trifiletti, Daniel M.] Mayo Clin, Dept Radiat Oncol, Jacksonville, FL 32224 USA.
   [Bondoc, Celine M.] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Ctr Innovat, Jacksonville, FL 32224 USA.
RP Quinones-Hinojosa, A (reprint author), Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
EM quinones@mayo.edu
OI Tripathi, Shashwat/0000-0001-8172-7532; ReFaey,
   Karim/0000-0001-7227-1529
CR Berkowitz O, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2012.11.FOCUS12295
   Charnock D, 1999, J EPIDEMIOL COMMUN H, V53, P105, DOI 10.1136/jech.53.2.105
   FIELD KM, 2010, J CLIN ONCOL S, V28
   Hamilton T, 2016, J NEUROSURG, V125, P160, DOI 10.3171/2016.7.GKS161425
   Heo J, 2016, J CANCER EDUC, V33, P769
   LEKSELL L, 1951, ACTA CHIR SCAND, V102, P316
   MacLeod MG, 2015, ARTHROSCOPY, V31, P136, DOI 10.1016/j.arthro.2014.06.009
   ReFaey K, 2018, J CLIN NEUROSCI, V55, P1, DOI 10.1016/j.jocn.2018.07.001
   Rittberg R, 2016, CLIN RHEUMATOL, V35, P1329, DOI 10.1007/s10067-015-2910-5
   Rossler B, 2012, CLIN NEUROL NEUROSUR, V114, P655, DOI 10.1016/j.clineuro.2011.12.048
   Samuel N, 2017, WORLD NEUROSURG, V105, P394, DOI 10.1016/j.wneu.2017.05.111
   Stamelou M, 2011, NEW ENGL J MED, V365, P1160, DOI 10.1056/NEJMc1107673
   Sunshine J, 2012, J NEUROINTERV SURG, V1, pA17
   Tenyi D, 2016, EPILEPSIA, V57, P1310, DOI 10.1111/epi.13432
   Underhill Cathy, 2008, Health Rep, V19, P65
NR 15
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E398
EP E402
DI 10.1016/j.wneu.2019.01.086
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700052
PM 30703604
DA 2020-05-12
ER

PT J
AU Rieger, B
   Sitoci-Ficici, KH
   Reinshagen, C
   Brautferger, U
   Schackert, G
   Hudak, R
   Zivcak, J
   Molcanyi, M
   Pinzer, T
AF Rieger, Bernhard
   Sitoci-Ficici, Kerim Hakan
   Reinshagen, Clemens
   Brautferger, Uta
   Schackert, Gabriele
   Hudak, Radovan
   Zivcak, Jozef
   Molcanyi, Marek
   Pinzer, Thomas
TI Endoscopic and Microscopic Segmental Decompression via Translaminar
   Crossover Spinal Approach in Elderly Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biokinemetrie; Endoscopy; Lumbar decompression; Spinal navigation;
   Translaminar crossover approach
ID INTERLAMINAR APPROACH; LUMBAR; STENOSIS; SURGERY; FUTURE
AB OBJECTIVE: For effective minimally invasive lumbar decompression, we changed the routine of segmental decompression. Using a high-speed drill or an ultrasound knife, we created a working channel, starting at the base of the spinous process of the upper vertebra slightly above the disc level, to target and decompress the contralateral recess, and termed it the translaminar crossover decompression (TCD). We evaluated the feasibility and compared the outcomes of a navigation-guided endoscopic translaminar crossover approach for segmental decompression (eTCD) in elderly patients with microscopic decompression using the same approach (mTCD).
   METHODS: A total of 740 elderly patients were enrolled in a prospective cohort study. Of the 740 patients, 297, who had undergone mTCD, and 253, who had undergone eTCD, completed a 1-year follow-up visit. In addition to the surgical data, numerical rating scales (NRSs) for back and leg pain, the Core Outcome Measures Index and Oswestry Disability Index were recorded preoperatively and 3, 6, and 12 months after surgery. The MacNab criteria were supplemented by qualitative assessment of the patients' postoperative pain-free walking distance.
   RESULTS: A comparison of the preoperative and postoperative clinical scores showed significant improvement after TCD in both cohorts (P < 0.01): Oswestry Disability Index, from 50.3% +/- 12.6% to 15.5% +/- 7.43%; NRS (back), from 6.9 +/- 1.9 to 2.5 +/- 1.3; NRS (leg), from 8.0 +/- 0.85 to 1.6 +/- 0.33; Core Outcome Measures Index (back), from 7.8 +/- 2.0 to 2.7 +/- 1.5. No statistically significant differences were found in the outcomes between the 2 cohorts.
   CONCLUSIONS: TCD inherently eliminated central stenosis and facilitated decompression of both recesses via mutual undercutting, with preservation of facet joint integrity.
C1 [Rieger, Bernhard] Short Care Clin, Greifswald, Germany.
   [Rieger, Bernhard; Sitoci-Ficici, Kerim Hakan; Schackert, Gabriele; Pinzer, Thomas] Dresden Univ Hosp, Dept Neurosurg, Dresden, Germany.
   [Rieger, Bernhard; Sitoci-Ficici, Kerim Hakan; Schackert, Gabriele; Pinzer, Thomas] Dresden Univ Hosp, Univ Comprehens Spine Ctr, Dresden, Germany.
   [Reinshagen, Clemens] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
   [Brautferger, Uta] Task Force Prospect Spine, Cologne, Germany.
   [Hudak, Radovan; Zivcak, Jozef] Tech Univ Kosice, Dept Biomed Engn, Kosice, Slovakia.
   [Molcanyi, Marek] Med Univ Graz, Dept Neurosurg, Graz, Austria.
   [Molcanyi, Marek] Univ Cologne, Fac Med, Inst Neurophysiol, Cologne, Germany.
   [Molcanyi, Marek] Univ Cologne, Univ Hosp Cologne, Cologne, Germany.
RP Rieger, B (reprint author), Short Care Clin, Greifswald, Germany.; Rieger, B (reprint author), Dresden Univ Hosp, Dept Neurosurg, Dresden, Germany.; Rieger, B (reprint author), Dresden Univ Hosp, Univ Comprehens Spine Ctr, Dresden, Germany.
EM biokinemetrie@gmail.com
RI Zivcak, Jozef/AAD-6090-2019; Hudak, Radovan/AAD-5403-2019
CR Ahn Y, 2014, EXPERT REV MED DEVIC, V11, P605, DOI 10.1586/17434440.2014.940314
   Biondi-Zoccai GGL, 2006, EUR HEART J, V27, P2667, DOI 10.1093/eurheartj/ehl334
   Bourgeois AC, 2015, J SPINAL DISORD TECH, V28, P324, DOI 10.1097/BSD.0000000000000152
   Dea N, 2016, SPINE J, V16, P23, DOI 10.1016/j.spinee.2015.09.062
   Deyo RA, 2010, JAMA-J AM MED ASSOC, V303, P1259, DOI 10.1001/jama.2010.338
   Guha D, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15259
   Haddadi K, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00019
   Kambin P, 1996, J NEUROSURG, V84, P462, DOI 10.3171/jns.1996.84.3.0462
   Kim HS, 2017, WORLD NEUROSURG, V103, P201, DOI 10.1016/j.wneu.2017.03.130
   Krzok Guntram, 2017, J Spine Surg, V3, P260, DOI 10.21037/jss.2017.06.11
   Lurie J, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.h6234
   Overdevest G, 2015, EUR SPINE J, V24, P2244, DOI 10.1007/s00586-015-4098-4
   Patel J, 2017, CURR OPIN ANESTHESIO, V30, P598, DOI 10.1097/ACO.0000000000000495
   Ramhmdani S, 2018, WORLD NEUROSURG, V113, pE383, DOI 10.1016/j.wneu.2018.02.039
   Reinshagen C, 2015, EBIOMEDICINE, V2, P1005, DOI 10.1016/j.ebiom.2015.09.010
   Reinshagen C, 2015, J CLIN NEUROSCI, V22, P1030, DOI 10.1016/j.jocn.2015.01.013
   Rieger B, 2016, [Deutsches Patent-und Markenamt, German Patent and Trademark Office], Patent No. [DE102017216864.1, 1020172168641]
   Rieger B, 2017, WORLD NEUROSURG, V106, P578, DOI 10.1016/j.wneu.2017.06.184
   Rieger B, 2017, EUR SPINE J, V26, P3147, DOI 10.1007/s00586-016-4928-z
   Roder C, 2005, EUR SPINE J, V14, P920, DOI 10.1007/s00586-005-1023-2
   Ruetten S, 2013, OPER ORTHOP TRAUMATO, V25, P31, DOI 10.1007/s00064-012-0195-2
   Ruetten S, 2009, J NEUROSURG-SPINE, V10, P476, DOI 10.3171/2008.7.17634
   Spetzger U, 2013, MINIM INVASIV THER, V22, P227, DOI 10.3109/13645706.2013.821414
   Torudom Y, 2016, ASIAN SPINE J, V10, P335, DOI 10.4184/asj.2016.10.2.335
   Waldrop R, 2015, NEUROSURGERY, V77, pS46, DOI 10.1227/NEU.0000000000000950
   Wang B, 2011, SPINE J, V11, P122, DOI 10.1016/j.spinee.2010.12.006
   Weinstein JN, 2008, NEW ENGL J MED, V358, P794, DOI 10.1056/NEJMoa0707136
   Yabe Y, 2015, SPINE, V40, P429, DOI 10.1097/BRS.0000000000000795
NR 28
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E361
EP E371
DI 10.1016/j.wneu.2019.01.078
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700047
PM 30703594
DA 2020-05-12
ER

PT J
AU Roach, J
   Gaastra, B
   Bulters, D
   Shtaya, A
AF Roach, Joy
   Gaastra, Benjamin
   Bulters, Diederik
   Shtaya, Anan
TI Safety, Accuracy, and Cost Effectiveness of Bedside Bolt External
   Ventricular Drains (EVDs) in Comparison with Tunneled EVDs Inserted in
   Theaters
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bolt; Cerebrospinal fluid (CSF); External ventricular drain (EVD);
   Hydrocephalus; Tunneled
ID OUTCOME ANALYSIS; COMPLICATIONS; PLACEMENT
AB OBJECTIVES: External ventricular drain (EVD) placement is required frequently in neurosurgical patients to divert cerebrospinal fluid and monitor intracranial pressure. The usual practice is the tunneled EVD technique performed in operating theaters. EVD insertion through a bolt in intensive care also is described. We employ both practices in our institute. Herein, we compare the indications, accuracy, safety, and costs of the 2 techniques.
   METHODS: This was a retrospective cohort study of a prospectively maintained EVD database of all patients undergoing first frontal EVD placement between January 2010 and December 2015. Those patients with preceding cerebrospinal fluid infection were excluded. We compared bolt EVD with tunneled EVD techniques in terms of accuracy of EVD tip location by analyzing computed tomography scans to grade catheter tip location as optimal (ipsilateral frontal horn) or otherwise suboptimal, and complications that include infection and revision rates.
   RESULTS: In total, 579 eligible patients aged 3 months to 84 years were identified; 430 had tunneled EVDs and 149 bolt EVDs. The most frequent diagnosis was intracranial hemorrhage (73% bolt vs. 50.4% tunneled group; P < 0.001). Other diagnoses included tumor (4.7% bolt vs. 19.1% tunneled; P < 0.001) and traumatic brain injury (17.5% bolt vs. 17.4% tunneled). In the bolt EVD group 66.4% of EVD tips were optimal, compared with 61.0% in the tunneled group (P = 0.33). Infection was confirmed in 15 (10.0%) bolt EVDs compared with 61 (14.2%) tunneled EVDs (P = 0.2). Each bolt EVD kit costs 260 pound, whereas placing a tunneled one in the theater costs 1316 pound.
   CONCLUSIONS: Bedside bolt EVD placement is safe, accurate, and cost effective in selective patients with hemorrhage-related hydrocephalus.
C1 [Roach, Joy; Gaastra, Benjamin; Bulters, Diederik; Shtaya, Anan] Univ Hosp Southampton, Wessex Neurol Ctr, Southampton, Hants, England.
   [Shtaya, Anan] St Georges Univ London, Mol & Clin Sci Res Inst, Neurosci Res Ctr, London, England.
   [Shtaya, Anan] St Georges Univ Hosp NHS Trust, London, England.
RP Shtaya, A (reprint author), Univ Hosp Southampton, Wessex Neurol Ctr, Southampton, Hants, England.; Shtaya, A (reprint author), St Georges Univ London, Mol & Clin Sci Res Inst, Neurosci Res Ctr, London, England.; Shtaya, A (reprint author), St Georges Univ Hosp NHS Trust, London, England.
EM ashtaya@sgul.ac.uk
OI Shtaya, Anan/0000-0001-7459-8437; Gaastra, Ben/0000-0002-7517-6882
CR Asaad SK, 2019, ACTA NEUROCHIR, V161, P33, DOI 10.1007/s00701-018-3737-z
   Bergdal O, 2013, CLIN NEUROL NEUROSUR, V115, P1972, DOI 10.1016/j.clineuro.2013.05.026
   Cinibulak Z, 2016, ACTA NEUROCHIR, V158, P847, DOI 10.1007/s00701-016-2747-y
   Fichtner J, 2014, CLIN NEUROL NEUROSUR, V122, P70, DOI 10.1016/j.clineuro.2014.04.018
   Foreman PM, 2015, CLIN NEUROL NEUROSUR, V128, P94, DOI 10.1016/j.clineuro.2014.09.026
   James M, 2015, Open Orthop J, V9, P495, DOI 10.2174/1874325001509010495
   Jamjoom AAB, 2018, J NEUROL NEUROSUR PS, V89, P120, DOI 10.1136/jnnp-2017-316415
   Jensen TS, 2016, ACTA NEUROCHIR, V158, P1491, DOI 10.1007/s00701-016-2863-8
   Keong NCH, 2012, NEUROSURGERY, V71, P394, DOI 10.1227/NEU.0b013e318257bebb
   Nowacki A, 2018, WORLD NEUROSURG, V114, pE1290, DOI 10.1016/j.wneu.2018.03.199
   Roitberg BZ, 2001, BRIT J NEUROSURG, V15, P324
   Schodel P, 2012, BRIT J NEUROSURG, V26, P227, DOI 10.3109/02688697.2011.603853
   Schodel P, 2012, J CLIN NEUROSCI, V19, P267, DOI 10.1016/j.jocn.2011.04.026
   Shtaya A, 2019, J NEUROSURG, V130, P1268, DOI 10.3171/2017.11.JNS171892
   Toma AK, 2009, NEUROSURGERY, V65, P1197, DOI 10.1227/01.NEU.0000356973.39913.0B
   2009, NEUROSURGERY, V65, P1197, DOI DOI 10.1227/01.NEU.0000356973.39913.0B
   2012, NEUROSURGERY, V71, P394, DOI DOI 10.1227/NEU.0B013E318257BEBB
NR 17
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E473
EP E478
DI 10.1016/j.wneu.2019.01.106
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700063
PM 30735879
DA 2020-05-12
ER

PT J
AU Ros-Sanjuan, A
   Iglesias-Morono, S
   Carrasco-Brenes, A
   Bautista-Ojeda, D
   Arraez-Sanchez, MA
AF Ros-Sanjuan, Angela
   Iglesias-Morono, Sara
   Carrasco-Brenes, Antonio
   Bautista-Ojeda, Dolores
   Angel Arraez-Sanchez, Miguel
TI Atypical Meningiomas: Histologic and Clinical Factors Associated With
   Recurrence
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atypical meningioma; Predictive factor; Prognosis; Tumor recurrence
ID ORGANIZATION GRADE I; MODERN NEUROSURGICAL TREATMENT; SIMPSON GRADE;
   PROGNOSTIC-FACTORS; ADJUVANT RADIOTHERAPY; CRANIAL MENINGIOMAS; FREE
   SURVIVAL; PROGRESSION; PREDICTORS; MANAGEMENT
AB BACKGROUND: Atypical meningioma is a heterogeneous group of tumors with an unpredictable behavior. Our objectives were to study patients with atypical meningioma, monitor their follow-up, identify the histologic characteristics, and analyze factors associated with severe outcomes.
   METHODS: This retrospective study involved 28 patients with atypical meningioma from 1994 to 2014. The histologic samples were reviewed under current criteria. The association with recurrence and survival was analyzed statistically for clinical, therapeutic, histologic, and molecular factors.
   RESULTS: The average age at the time of diagnosis was 55.5 years (range, 18-83 years) and 57% were female. Total resection (Simpson grade I) was performed in 10 cases (38%). Adjuvant radiotherapy was given to 13 patients. During the 77-month follow-up, 64% had a recurrence or progression. The average time to first recurrence and overall survival were 43.83 months and 149 months, respectively. Recurrence was found in 85% of the patients whose samples presented necrosis. Of the tumors, 84% showed a high mitotic index (4-20 mitoses/10 high-power field). Of the 4 patients with a low mitotic index (<4 mitoses/10 high-power field), the degree of resection was subtotal and 3 experienced disease progression. Of patients with Ki67 >9.9%, 67% had recurrence. The degree of resection was the only variable significantly associated with tumor recurrence.
   CONCLUSIONS: The high rate of recurrence observed and the short disease-free survival exemplify the unpredictable behavior of atypical meningiomas. Total resection was the only significant factor associated with recurrence. However, the presence of atypical features, such as necrosis or high Ki67, is frequent in patients with disease progression.
C1 [Ros-Sanjuan, Angela; Iglesias-Morono, Sara; Carrasco-Brenes, Antonio; Angel Arraez-Sanchez, Miguel] Hosp Reg Univ, Dept Neurosurg, Malaga, Spain.
   [Bautista-Ojeda, Dolores] Hosp Costa Sol, Dept Pathol, Malaga, Spain.
RP Ros-Sanjuan, A (reprint author), Hosp Reg Univ, Dept Neurosurg, Malaga, Spain.
EM siglesias95@yahoo.es
CR Andric M, 2012, CLIN NEUROL NEUROSUR, V114, P699, DOI 10.1016/j.clineuro.2011.11.023
   Barrett Olivia Claire, 2019, Int J Radiat Oncol Biol Phys, V103, P453, DOI 10.1016/j.ijrobp.2018.09.019
   Bruna J, 2007, NEUROPATHOLOGY, V27, P114, DOI 10.1111/j.1440-1789.2007.00750.x
   Budohoski KP, 2018, ACTA NEUROCHIR, V160, P1813, DOI 10.1007/s00701-018-3593-x
   Cao XY, 2015, WORLD NEUROSURG, V84, P1014, DOI 10.1016/j.wneu.2015.05.032
   Coppola Federico, 2017, Surg Neurol Int, V8, pS37, DOI 10.4103/sni.sni_286_17
   Ehresman JS, 2018, WORLD NEUROSURG, V109, pE588, DOI 10.1016/j.wneu.2017.10.028
   Fernandez Christian, 2016, Adv Radiat Oncol, V1, P89, DOI 10.1016/j.adro.2016.03.001
   Gennatas ED, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204161
   Goyal LK, 2000, INT J RADIAT ONCOL, V46, P57, DOI 10.1016/S0360-3016(99)00349-1
   Hale AT, 2018, J CLIN NEUROSCI, V48, P71, DOI 10.1016/j.jocn.2017.11.013
   Hammouche S, 2014, ACTA NEUROCHIR, V156, P1475, DOI 10.1007/s00701-014-2156-z
   Hasan S, 2015, WORLD NEUROSURG, V83, P808, DOI 10.1016/j.wneu.2014.12.037
   Heros RC, 2010, J NEUROSURG, V113, P1026, DOI 10.3171/2010.2.JNS10280
   Jansen M, 2012, NEUROPATH APPL NEURO, V38, P213, DOI 10.1111/j.1365-2990.2011.01222.x
   Jo K, 2010, J CLIN NEUROSCI, V17, P1362, DOI 10.1016/j.jocn.2010.03.036
   Kane AJ, 2011, CANCER-AM CANCER SOC, V117, P1272, DOI 10.1002/cncr.25591
   Klinger DR, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.033
   Komotar RJ, 2012, J NEUROSURG, V117, P679, DOI 10.3171/2012.7.JNS112113
   Las Heras F, 2017, REV MED CLIN CONDES, V28, P352
   Lee JH, 2017, J KOREAN NEUROSURG S, V60, P661, DOI 10.3340/jkns.2017.0303.008
   Lin CK, 2012, HISTOPATHOLOGY, V60, P320, DOI 10.1111/j.1365-2559.2011.04085.x
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Lu YP, 2019, EUR RADIOL, V29, P1318, DOI 10.1007/s00330-018-5632-7
   Mair R, 2011, J NEUROSURG, V115, P811, DOI 10.3171/2011.5.JNS11112
   Olar A, 2015, BRAIN PATHOL, V25, P266, DOI 10.1111/bpa.12174
   Otero-Rodriguez A, 2016, WORLD NEUROSURG, V96, P483, DOI 10.1016/j.wneu.2016.09.007
   Park H, 2009, INT J RADIAT ONCOL, V75, pS238, DOI 10.1016/j.ijrobp.2009.07.548
   Park HJ, 2013, J NEURO-ONCOL, V115, P241, DOI 10.1007/s11060-013-1219-y
   Rogers L, 2010, J NEURO-ONCOL, V99, P393, DOI 10.1007/s11060-010-0343-1
   Shakir SI, 2018, J NEUROSURG, V19, P1
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Sughrue ME, 2010, J NEUROSURG, V113, P1029, DOI 10.3171/2010.3.JNS091971
   Sun SQ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14757
   Sun SQ, 2014, NEUROSURGERY, V75, P356, DOI 10.1227/NEU.0000000000000462
   Sun SQ, 2014, NEUROSURGERY, V75, P347, DOI 10.1227/NEU.0000000000000461
   Wang CY, 2017, NEURO-ONCOLOGY, V19, P1263, DOI 10.1093/neuonc/nox007
   Wang YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep35743
   Wilbers E, 2014, ACTA NEUROCHIR, V156, P1853, DOI 10.1007/s00701-014-2148-z
   Zaher A, 2013, WORLD NEUROSURG, V80, P549, DOI 10.1016/j.wneu.2013.07.001
NR 40
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E248
EP E256
DI 10.1016/j.wneu.2019.01.056
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700032
PM 30684705
DA 2020-05-12
ER

PT J
AU Roth, J
   Sela, G
   Andelman, F
   Nossek, E
   Elran, H
   Ram, Z
AF Roth, Jonathan
   Sela, Gal
   Andelman, Fani
   Nossek, Erez
   Elran, Hanoch
   Ram, Zvi
TI The Impact of Colloid Cyst Treatment on Neurocognition
SO WORLD NEUROSURGERY
LA English
DT Article
DE Colloid cyst; Fornix; Hydrocephalus; Memory; Neurocognitive function;
   Resection
ID NORMATIVE DATA; FORNIX; 3RD-VENTRICLE; ANTEROGRADE; RESECTION; AMNESIA;
   SCORES
AB BACKGROUND: Colloid cysts (CC) have been associated with neurocognitive function (NCF) decline, both preoperatively and after resection. Factors such as local pressure on the fornix and hydrocephalus are thought to contribute to preoperative NCF decline. The potential cause of postoperative decline is thought to be forniceal injury during surgery. In the current series, we describe NCF outcomes amongst patients with CC, both nonoperated and operated.
   METHODS: A total of 36 patients (23 operated, 13 nonoperated) were included in this retrospective study. All patients underwent at least 1 NCF evaluation battery. Of the 13 nonoperated cases, 5 had follow-up tests too. Of the 23 operated, 14 had both pre- and postoperative tests, and 8 had early and late postoperative tests.
   RESULTS: There was no significant difference in baseline NCF between nonoperated and operated cases (as evaluated preoperatively). Nonoperated patients had a stable NCF test over time. Patients who were operated showed a significant improvement after surgery in several NCF variables. There was no significant change in NCF between early and late postoperative evaluation. None of the operated patients had a postoperative NCF decline.
   CONCLUSIONS: Patients with CC should undergo routine NCF testing with a standardized protocol, whether they are operated or followed. Surgery has a positive impact on NCF; however, it remains to be determined if the improvement is solely secondary to treatment of hydrocephalus, or to a reduction of local pressure on the fornices. It remains to be determined whether the surgical technique, that is, endoscopic, interhemispheric, or transcortical, has an impact on NCF outcome.
C1 [Roth, Jonathan; Sela, Gal; Andelman, Fani; Nossek, Erez; Elran, Hanoch; Ram, Zvi] Tel Aviv Univ, Tel Aviv Med Ctr, Dept Neurosurg, Tel Aviv, Israel.
RP Roth, J (reprint author), Tel Aviv Univ, Tel Aviv Med Ctr, Dept Neurosurg, Tel Aviv, Israel.
EM jonaroth@gmail.com
OI Roth, Jonathan/0000-0002-4267-8835
CR Aggleton JP, 2008, Q J EXP PSYCHOL, V61, P1441, DOI 10.1080/17470210802215335
   Ausman JI, 2002, SURG NEUROL, V57, P305, DOI 10.1016/S0090-3019(02)00732-2
   Beaumont TL, 2016, J NEUROSURG, V125, P1420, DOI 10.3171/2015.11.JNS151396
   Crosson B., 1990, CLIN NEUROPSYCHOL, V4, P253, DOI 10.1080/13854049008401908
   Denby CE, 2009, AM J NEURORADIOL, V30, P736, DOI 10.3174/ajnr.A1424
   Desai KI, 2002, SURG NEUROL, V57, P295, DOI 10.1016/S0090-3019(02)00701-2
   GARCIABENGOCHEA F, 1987, SURG NEUROL, V27, P361, DOI 10.1016/0090-3019(87)90012-7
   Greenlee JDW, 2008, NEUROSURGERY, V63, P51, DOI [10.1227/01.NEU.0000297004.20222.ED, 10.1227/01.neu.0000317373.00018.6f]
   Hamer PCD, 2002, J NEUROSURG, V96, P1041, DOI 10.3171/jns.2002.96.6.1041
   Hellwig D, 2003, NEUROSURGERY, V52, P525, DOI 10.1227/01.NEU.0000047671.27057.55
   HODGES JR, 1991, J NEUROL NEUROSUR PS, V54, P633, DOI 10.1136/jnnp.54.7.633
   Horn EM, 2007, NEUROSURGERY, V60, P613, DOI 10.1227/01.NEU.0000255409.61398.EA
   INGRAHAM LJ, 1988, PERCEPT MOTOR SKILL, V67, P187, DOI 10.2466/pms.1988.67.1.187
   Kave G, 2005, J CLIN EXP NEUROPSYC, V27, P690, DOI 10.1080/13803390490918499
   Kave G, 2005, BRAIN LANG, V92, P204, DOI 10.1016/j.bandl.2004.06.004
   Levine NB, 2007, MINIM INVAS NEUROSUR, V50, P313, DOI 10.1055/s-2007-993215
   MCMACKIN D, 1995, ACTA NEUROCHIR, V135, P12, DOI 10.1007/BF02307408
   MEYERS JE, 1996, REY COMPLEX FIGURE T
   Moorthy RK, 2006, STEREOT FUNCT NEUROS, V84, P205, DOI 10.1159/000095166
   Peterson KA, 2016, J NEUROL, V263, P1669, DOI 10.1007/s00415-016-8097-0
   Poreh A, 2006, NEUROPSYCHOLOGIA, V44, P2241, DOI 10.1016/j.neuropsychologia.2006.05.020
   Rangel-Castilla L, 2014, J NEUROSURG, V121, P790, DOI 10.3171/2014.5.JNS132031
   Sampath R, 2010, NEUROSURGERY, V66, P368, DOI 10.1227/01.NEU.0000363858.17782.82
   Shapiro S, 2009, J NEUROSURG, V110, P112, DOI 10.3171/2008.4.17495
   Tsivilis D, 2008, NAT NEUROSCI, V11, P834, DOI 10.1038/nn.2149
   Vakil E, 2010, CLIN NEUROPSYCHOL, V24, P662, DOI 10.1080/13854040903493522
   Wechsler D., 1997, WECHSLER MEMORY SCAL
   Wechsler D., 1997, WECHSLER ADULT INTEL
NR 28
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E372
EP E377
DI 10.1016/j.wneu.2019.01.079
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700048
PM 30703590
DA 2020-05-12
ER

PT J
AU Rubiano, AM
   Maldonado, M
   Montenegro, J
   Restrepo, CM
   Khan, AA
   Monteiro, R
   Faleiro, RM
   Carreno, JN
   Amorim, R
   Paiva, W
   Munoz, E
   Paranhos, J
   Soto, A
   Armonda, R
   Rosenfeld, JV
AF Rubiano, Andres M.
   Maldonado, Miguel
   Montenegro, Jorge
   Restrepo, Claudia M.
   Khan, Ahsan Ali
   Monteiro, Ruy
   Faleiro, Rodrigo M.
   Carreno, Jose N.
   Amorim, Robson
   Paiva, Wellingson
   Munoz, Erick
   Paranhos, Jorge
   Soto, Alvaro
   Armonda, Rocco
   Rosenfeld, Jeffrey V.
TI The Evolving Concept of Damage Control in Neurotrauma: Application of
   Military Protocols in Civilian Settings with Limited Resources
SO WORLD NEUROSURGERY
LA English
DT Article
DE Damage control; Global surgery; Low resources; Military neurotrauma;
   Neurotrauma; Severe TBI
ID TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; MANAGEMENT;
   MORTALITY; OUTCOMES; SURGERY; ETHICS
AB OBJECTIVE: The aim of the present review was to describe the evolution of the damage control concept in neurotrauma, including the surgical technique and medical postoperative care, from the lessons learned from civilian and military neurosurgeons who have applied the concept regularly in practice at military hospitals and civilian institutions in areas with limited resources.
   METHODS: The present narrative review was based on the experience of a group of neurosurgeons who participated in the development of the concept from their practice working in military theaters and low-resources settings with an important burden of blunt and penetrating cranial neurotrauma.
   RESULTS: Damage control surgery in neurotrauma has been described as a sequential therapeutic strategy that supports physiological restoration before anatomical repair in patients with critical injuries. The application of the concept has evolved since the early definitions in 1998. Current strategies have been supported by military neurosurgery experience, and the concept has been applied in civilian settings with limited resources.
   CONCLUSION: Damage control in neurotrauma is a therapeutic option for severe traumatic brain injury management in austere environments. To apply the concept while using an appropriate approach, lessons must be learned from experienced neurosurgeons who use this technique regularly.
C1 [Rubiano, Andres M.] El Bosque Univ, Inst Neurosci & Neurosurg, Bogota, Colombia.
   [Rubiano, Andres M.; Montenegro, Jorge; Restrepo, Claudia M.; Khan, Ahsan Ali] Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England.
   [Rubiano, Andres M.] MEDITECH Fdn, INUB MEDITECH Res Grp, Cali, Colombia.
   [Rubiano, Andres M.] MEDITECH Fdn, Cali Valle, Colombia.
   [Maldonado, Miguel] Nueva Granada Mil Univ, Sch Med, Cent Mil Hosp, Bogota, Colombia.
   [Montenegro, Jorge; Restrepo, Claudia M.; Khan, Ahsan Ali] MEDITECH Fdn, Dept Res, INUB MEDITECH Res Grp, Cali, Colombia.
   [Montenegro, Jorge] Puerto Asis Hosp, Puerto Asis, Colombia.
   [Restrepo, Claudia M.] Nueva Granada Mil Univ, Cent Mil Hosp, Bogota, Colombia.
   [Khan, Ahsan Ali] Univ Cambridge, Dept Neurosurg Neurotrauma & Global Sury, MEDITECH Fdn, Barrow Neurol Inst, Cambridge, England.
   [Monteiro, Ruy] Hosp Municipal Miguel Couto, Neurol Surg Serv, Rio De Janeiro, Brazil.
   [Faleiro, Rodrigo M.] Hosp Sao Joao XXIII, Dept Neurosurg, Belo Horizonte, MG, Brazil.
   [Carreno, Jose N.] Santa Fe Fdn Univ Hosp, Neurointens Care Unit, Bogota, Colombia.
   [Carreno, Jose N.] Nueva Granada Mil Univ, Cent Mil Hosp, Bogota, Colombia.
   [Amorim, Robson] Univ Sao Paulo, Emergency Neurosurg Serv, Hosp Clin, Sch Med, Manaus, Amazonas, Brazil.
   [Paiva, Wellingson] Univ Sao Paulo, Neurosurg Intens Care Unit, Dept Neurol, Sao Paulo, Brazil.
   [Munoz, Erick] Nueva Granada Mil Univ, Neurol Surg Serv, Cent Mil Hosp, Bogota, Colombia.
   [Paranhos, Jorge] Santa Casa de Misericordia Hosp, Intens Care Unite, Sao Joao Del Rei, MG, Brazil.
   [Paranhos, Jorge] Santa Casa de Misericordia Hosp, Neuroemergency Serv, Sao Joao Del Rei, MG, Brazil.
   [Soto, Alvaro] San Antonio Hosp, Neurosurg Serv, Pitalito, Huila, Colombia.
   [Armonda, Rocco] Med Star Georgetown Univ Hosp, Dept Neuroendovasc Surg, Med Star Washington Hosp Ctr, Washington, DC USA.
   [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia.
   [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic, Australia.
   [Rosenfeld, Jeffrey V.] Uniformed Serv Univ Hlth Sci, Dept Surg, F Edward Hebert Sch Med, Bethesda, MD USA.
RP Rubiano, AM (reprint author), El Bosque Univ, Inst Neurosci & Neurosurg, Bogota, Colombia.; Rubiano, AM (reprint author), Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England.; Rubiano, AM (reprint author), MEDITECH Fdn, INUB MEDITECH Res Grp, Cali, Colombia.; Rubiano, AM (reprint author), MEDITECH Fdn, Cali Valle, Colombia.
EM andresrubiano@aol.com
RI RUBIANO, ANDRES M/K-6704-2012
OI RUBIANO, ANDRES M/0000-0001-8931-3254; Maldonado Moran, Miguel
   Angel/0000-0001-8315-4109
FU National Institute for Health Research (NIHR) Global Health Research
   Group on Neurotrauma; NIHRNational Institute for Health Research (NIHR)
   [16/137/105]
FX Dr. Rubiano and Dr. Khan are supported by the National Institute for
   Health Research (NIHR) Global Health Research Group on Neurotrauma. The
   Group was commissioned by the NIHR using Official Development Assistance
   funding (project 16/137/105). The views expressed in this manuscript are
   those of the authors and are not necessarily those of the UK National
   Health Service, NIHR, or the UK Department of Health.
CR Alvis-Miranda Hernando Raphael, 2014, Bull Emerg Trauma, V2, P3
   Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Charry JD, 2016, BRIT J NEUROSURG, V30, P235, DOI 10.3109/02688697.2015.1096905
   Charry JD, 2016, J NEUROSCI RURAL PRA, V7, P7, DOI 10.4103/0976-3147.172151
   Chesnut RM, 2018, J NEUROTRAUM, V35, P54, DOI 10.1089/neu.2016.4472
   Chowdhury T, 2014, SAUDI J ANAESTH, V8, P114, DOI 10.4103/1658-354X.125971
   Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500
   Dulou R, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1016
   Dunn LT, 2002, J NEUROL NEUROSUR PS, V73, pI23
   Fuller G, 2014, PREHOSP EMERG CARE, V18, P60, DOI 10.3109/10903127.2013.831507
   Galvagno SM, 2017, J TRAUMA ACUTE CARE, V83, P668, DOI 10.1097/TA.0000000000001584
   Georgoff P, 2010, WORLD NEUROSURG, V74, P331, DOI 10.1016/j.wneu.2010.03.025
   Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424
   GILLON R, 1994, BRIT MED J, V309, P184, DOI 10.1136/bmj.309.6948.184
   Godat L, 2013, WORLD J EMERG SURG, V8, DOI 10.1186/1749-7922-8-53
   Griswold D, 2016, WORLD NEUROSURG, V93, P474, DOI 10.1016/j.wneu.2016.06.044
   Hendrickson P, 2018, WORLD NEUROSURG, V110, pE952, DOI 10.1016/j.wneu.2017.11.142
   Holcomb JB, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002339
   Honeybul S, 2012, MED J AUSTRALIA, V196, P531, DOI 10.5694/mja11.11485
   Kesinger MR, 2014, INJURY, V45, P1350, DOI 10.1016/j.injury.2014.04.037
   Kotwal RS, 2018, MIL MED, V183, P134, DOI 10.1093/milmed/usx211
   Lamb CM, 2014, BRIT J ANAESTH, V113, P242, DOI 10.1093/bja/aeu233
   Larsen Morten Schultz, 2011, Ugeskr Laeger, V173, P1273
   Limpastan Kriengsak, 2013, Journal of the Medical Association of Thailand, V96, P678
   Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033
   MacGoey P, 2016, TRAUMA, V18, P165, DOI 10.1177/1460408616629507
   Maciunas Robert J, 2006, Clin Neurosurg, V53, P267
   MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28
   Marshall SA, 2015, ENCY TRAUMA CARE
   Moore JM, 2016, CLIN NEUROL NEUROSUR, V148, P13, DOI 10.1016/j.clineuro.2016.06.012
   Mwita CC, 2016, J NEUROSCI RURAL PRA, V7, P97, DOI 10.4103/0976-3147.165390
   Ojo O A, 2015, Niger Postgrad Med J, V22, P45
   Pitts LH, 1998, J TRAUMA, V44, P989
   Punchak M, 2018, WORLD NEUROSURG, V112, pE240, DOI 10.1016/j.wneu.2018.01.029
   Ragel BT, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.3.FOCUS1028
   Rosenfeld JV, 2015, ANZ J SURG, V85, P600, DOI 10.1111/ans.13207
   Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2
   Rosenfeld JV, 2004, INJURY, V35, P655, DOI 10.1016/j.injury.2004.03.006
   ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008
   Rotondo MF, 1997, SURG CLIN N AM, V77, P761, DOI 10.1016/S0039-6109(05)70582-X
   Rubiano AM, 2004, NEUROLOGICAL SURG PR, P1
   Rubiano AM, 2007, NEUROTRAUMA NEURO IN, P211
   Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035
   Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28
   Sedney CL, 2014, J NEUROSCI RURAL PRA, V5, P212, DOI 10.4103/0976-3147.133555
   Servadei F, 2018, WORLD NEUROSURG, V112, P315, DOI 10.1016/j.wneu.2018.01.047
   Shackelford SA, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.9.FOCUS18404
   Shchedrenok V V, 2013, Vestn Khir Im I I Grek, V172, P11
   Shenai MB, 2014, J NEUROSURG, V121, P277, DOI 10.3171/2014.4.JNS131805
   Sinha Virendra Deo, 2012, Asian J Neurosurg, V7, P75, DOI 10.4103/1793-5482.98648
   Sitsapesan HA, 2013, WORLD NEUROSURG, V79, P568, DOI 10.1016/j.wneu.2012.09.018
   Teff RJ, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1017
   Vieira E, 2018, J NEUROSURG, V129, P1017, DOI 10.3171/2017.4.JNS152954
   World Federation of Neurosurgical Societies, BOG DECL
   Zador Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158762
   Ziaeirad Marzieh, 2018, Iran J Nurs Midwifery Res, V23, P211, DOI 10.4103/ijnmr.IJNMR_65_17
   1998, J TRAUMA, V44, P984
   2017, CURR OPIN CRIT CARE, V23, P498, DOI DOI 10.1097/MCC.0000000000000455
   2018, ANAESTH CRIT CARE PA, V37, P171, DOI DOI 10.1016/J.ACCPM.2017.12.001
NR 60
TC 1
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E82
EP E93
DI 10.1016/j.wneu.2019.01.005
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700013
PM 30659971
DA 2020-05-12
ER

PT J
AU Salami, AA
   Okunlola, AI
   Ajani, MA
   Adekanmbi, AA
   Balogun, JA
AF Salami, Ayodeji A.
   Okunlola, Abiodun I.
   Ajani, Mustapha A.
   Adekanmbi, Adefisayo A.
   Balogun, James A.
TI Pediatric Meningiomas in Southwestern Nigeria: A Single-Institutional
   Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal; Grade; Histology; Intracranial; Meningioma
ID INTRACRANIAL MENINGIOMAS; SKULL BASE; CHILDHOOD
AB BACKGROUND: Meningiomas are the second commonest intracranial tumors in many places worldwide. They are rare in the pediatric age group, however, and most studies have been able to document only a few patients. Meningiomas in pediatric patients have also been shown to behave differently from those in the adult population. This study was done to examine histologic types of meningiomas seen in pediatric patients from a predominantly African population using the 2016 World Health Organization (WHO) grading system for intracranial tumors.
   METHODS: Data from the operating logs of patients and histology reports of the samples sent to the pathology department during the study period were extracted. The data obtained were the age, sex, location of the intracranial tumor, histologic diagnosis, WHO grade, and tumor recurrence.
   RESULTS: Nine pediatric age patients were found among the 166 surgically excised meningiomas received at the pathology department in our institution over a 19-year period. The age range was from 8 months to 17 years. There was a male-to-female ratio of 1:2 with a female predominance. Six tumors were basally located. All tumors were WHO grade I with transitional meningiomas being the commonest followed by meningothelial. There was no history of recurrence in any of the tumors after complete surgical excisions.
   CONCLUSIONS: Our study showed the rarity of meningiomas in the study population, and there was a predominance of basally located tumors.
C1 [Salami, Ayodeji A.] Univ Ibadan, Dept Pathol, Coll Med, Ibadan, Nigeria.
   [Okunlola, Abiodun I.; Adekanmbi, Adefisayo A.] Univ Coll Hosp, Div Neurosurg, Dept Surg, Ibadan, Nigeria.
   [Ajani, Mustapha A.] Babcock Univ, Dept Histopathol, Ilishan Remo, Ogun State, Nigeria.
   [Balogun, James A.] Univ Ibadan, Div Neurosurg, Dept Surg, Coll Med, Ibadan, Nigeria.
RP Salami, AA (reprint author), Univ Ibadan, Dept Pathol, Coll Med, Ibadan, Nigeria.
EM ayodejisalami@gmail.com
OI Salami, Ayodeji/0000-0002-6218-8315
CR Amirjamshidi A, 2000, CHILD NERV SYST, V16, P406, DOI 10.1007/s003819900205
   Bondy M, 1996, J NEURO-ONCOL, V29, P197, DOI 10.1007/BF00165649
   Cornelius JF, 2013, ACTA NEUROCHIR, V155, P407, DOI 10.1007/s00701-012-1611-y
   Dudley RWR, 2018, J NEUROONCOL, P1
   Greene S, 2008, PEDIATR NEUROSURG, V44, P9, DOI 10.1159/000110656
   Gump WC, 2015, J NEUROL SURG PART B, V76, P66, DOI 10.1055/s-0034-1390012
   Hatef J, 2014, WORLD NEUROSURG, V82, P258, DOI 10.1016/j.wneu.2014.06.040
   Idowu O, 2007, J NEUROL SCI-TURK, V24, P212
   Kane AJ, 2011, CANCER-AM CANCER SOC, V117, P1272, DOI 10.1002/cncr.25591
   Korhonen K, 2006, J NEURO-ONCOL, V80, P1, DOI 10.1007/s11060-006-9146-9
   Kotecha RS, 2011, LANCET ONCOL, V12, P1229, DOI 10.1016/S1470-2045(11)70275-3
   Kotecha RS, 2011, J NEURO-ONCOL, V104, P1, DOI 10.1007/s11060-010-0503-3
   Lakshmi S, 2015, INT J MED RES HEALTH, V4, P827, DOI 10.5958/2319-5886.2015.00164.2
   Menon G, 2009, ACTA NEUROCHIR, V151, P239, DOI 10.1007/s00701-009-0206-8
   Mezue WC, 2012, SURG NEUROL INT, V3, P1
   Mezue WC, 2012, J NEUROSCI RURAL PRA, V3, P320, DOI 10.4103/0976-3147.102613
   Odebode TO, 2006, J CLIN NEUROSCI, V13, P649, DOI 10.1016/j.jocn.2005.07.023
   Ogun GO, 2016, PAN AFR MED J, V8688, P1
   Perry A., 2009, RUSSELL RUBINSTEINS, P427
   Perry A, 2016, WHO CLASSIFICATION T, P232
   Tufan K, 2005, PEDIATR NEUROSURG, V41, P1, DOI 10.1159/000084858
   Uche EO, 2013, CHILD NERV SYST, V29, P1131, DOI 10.1007/s00381-013-2105-9
   William O, 1975, CANCER, V36, P36370
   2010, NEUROCHIRURGIE, V56, P309, DOI DOI 10.1016/J.NEUCHI.2010.05.008
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E94
EP E97
DI 10.1016/j.wneu.2018.12.200
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700014
PM 30660895
DA 2020-05-12
ER

PT J
AU Schneider, M
   Schuss, P
   Guresir, A
   Wach, J
   Hamed, M
   Vatter, H
   Guresir, E
AF Schneider, Matthias
   Schuss, Patrick
   Gueresir, Agi
   Wach, Johannes
   Hamed, Motaz
   Vatter, Hartmut
   Gueresir, Erdem
TI Cranial Nerve Outcomes After Surgery for Frontal Skull Base Meningiomas:
   The Eternal Quest of the Maximum-Safe Resection with the Lowest
   Morbidity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extent of resection; Frontal skull base meningiomas; Patient quality of
   life; Postoperative cranial nerve morbidity
ID GAMMA-KNIFE SURGERY; LONG-TERM OUTCOMES; STEREOTACTIC RADIOSURGERY;
   GRADE I; RECURRENCE; RADIOTHERAPY; EXTENT
AB OBJECTIVE: Maximal aggressive meningioma resection has been suggested to provide the best tumor control rates. However, radical surgery of meningiomas located at the frontal skull base can be accompanied by impairment of adjacent cranial nerve function that negatively affects patients' quality of life. We, therefore, analyzed our institutional database for cases of new cranial nerve deficits and postoperative cerebrospinal fluid (CSF) leakage stratified by the extent of tumor resection.
   METHODS: From February 2009 to April 2017, 195 patients underwent resection of frontal skull base meningioma at our institution. Postoperative new deficits of cranial nerve function and CSF leakage were stratified by the resection into Simpson grade I resection with excision of the dural tail as an aggressive surgical approach and Simpson grade II-V resection.
   RESULTS: Simpson grade I resection was associated with a significantly greater percentage of new cranial nerve deficits immediately after surgery (30%) compared with Simpson grade II (13%; P = 0.007) and Simpson grade II-V (17%; P = 0.035). The differences were greater at the 12-month follow-up point (29% Simpson grade I, 6% Simpson grade II [P < 0.001]; 10% Simpson grade II-V [P = 0.001]). Postoperative CSF leakage occurred in 10.1% of Simpson grade I versus 2.3% of Simpson grade II resections (P = 0.048). The retreatment rates did not differ between these 2 groups (2.5% vs. 3.4%; P = 1.000).
   CONCLUSIONS: We found high levels of new cranial nerve morbidity and CSF leakage after radical removal of frontal skull base meningiomas that included the adjacent dura. Thus, less aggressive surgery for frontobasal meningioma should be preferred.
C1 [Schneider, Matthias; Schuss, Patrick; Gueresir, Agi; Wach, Johannes; Hamed, Motaz; Vatter, Hartmut; Gueresir, Erdem] Rheinische Friedrich Wilhelms Univ, Dept Neurosurg, Bonn, Germany.
RP Schneider, M (reprint author), Rheinische Friedrich Wilhelms Univ, Dept Neurosurg, Bonn, Germany.
EM matthias.schneider@ukb.uni-bonn.de
RI guresir, erdem/AAL-4484-2020
OI guresir, erdem/0000-0002-6624-6885
CR Bassiouni H, 2009, J NEUROSURG, V111, P1078, DOI 10.3171/2009.3.17685
   Chen CM, 2011, NEUROSURG REV, V34, P281, DOI 10.1007/s10143-011-0321-x
   Chuang CC, 2004, J NEURO-ONCOL, V66, P241, DOI 10.1023/B:NEON.0000013500.11150.36
   Combs SE, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-226
   Couldwell WT, 2011, NEUROSURG FOCUS, V30
   Faramand A, 2018, J NEURO-ONCOL, V139, P341, DOI 10.1007/s11060-018-2866-9
   Flannery TJ, 2017, J NEUROSURG, V127, P67, DOI 10.3171/2009.8.JNS09695
   Gousias K, 2016, J NEUROSURG, V125, P551, DOI 10.3171/2015.9.JNS15754
   Hasegawa T, 2007, J NEUROSURG, V107, P745, DOI 10.3171/JNS-07/10/0745
   Hye RJ, 2015, J VASC SURG, V61, P1208, DOI 10.1016/j.jvs.2014.12.039
   Ichinose T, 2010, J NEUROSURG, V113, P1072, DOI 10.3171/2010.2.JNS091118
   Iwai Y, 2008, J NEUROSURG, V109, P804, DOI 10.3171/JNS/2008/109/11/0804
   JAASKELAINEN J, 1986, SURG NEUROL, V26, P461, DOI 10.1016/0090-3019(86)90259-4
   Komotar RJ, 2012, WORLD NEUROSURG, V77, P713, DOI 10.1016/j.wneu.2011.08.025
   Kondziolka D, 1998, NEUROSURGERY, V43, P405, DOI 10.1097/00006123-199809000-00001
   Kondziolka D, 1999, J NEUROSURG, V91, P44, DOI 10.3171/jns.1999.91.1.0044
   Levine ZT, 1999, NEUROSURGERY, V45, P221, DOI 10.1097/00006123-199908000-00003
   Mariniello G, 2008, ZBL NEUROCHIR, V69, P175, DOI 10.1055/s-2008-1077077
   McGovern SL, 2010, J NEUROSURG, V112, P925, DOI 10.3171/2009.9.JNS09617
   Mendenhall WM, 2003, CANCER, V98, P1473, DOI 10.1002/cncr.11645
   Nakamura M, 2006, NEUROSURGERY, V58, P626, DOI 10.1227/01.NEU.0000197104.78684.5D
   Neil-Dwyer G, 2000, ACTA NEUROCHIR, V142, P367, DOI 10.1007/s007010050444
   Pechlivanis I, 2011, J NEUROSURG SCI, V55, P319
   Przybylowski CJ, 2015, J CLIN NEUROSCI, V22, P161, DOI 10.1016/j.jocn.2014.07.028
   Seifert V, 2010, ACTA NEUROCHIR, V152, P1099, DOI 10.1007/s00701-010-0633-6
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Starke R, 2014, J NEURO-ONCOL, V119, P169, DOI 10.1007/s11060-014-1470-x
   Starke RM, 2012, J NEUROSURG, V116, P588, DOI 10.3171/2011.11.JNS11530
   Sughrue ME, 2010, J NEUROSURG, V113, P1029, DOI 10.3171/2010.3.JNS091971
   Topsakal C, 2008, NEUROSURG REV, V31, P45, DOI 10.1007/s10143-007-0105-5
   Turgut M, 1996, AUST NZ J SURG, V66, P144, DOI 10.1111/j.1445-2197.1996.tb01143.x
   Williams BJ, 2017, J NEUROSURG, V127, P92, DOI 10.3171/2011.1.JNS091939
   Winther TL, 2017, WORLD NEUROSURG, V99, P104, DOI 10.1016/j.wneu.2016.11.034
   2008, NEUROSURGERY, V62, P556, DOI DOI 10.1227/01.NEU.0000297113.72625.D1
NR 34
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E790
EP E796
DI 10.1016/j.wneu.2019.01.171
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700097
PM 30738945
DA 2020-05-12
ER

PT J
AU Shah, A
   Goel, A
   Jhawar, SS
   Patil, A
   Rangnekar, R
   Goel, A
AF Shah, Abhidha
   Goel, Aimee
   Jhawar, Sukhdeep Singh
   Patil, Abhinandan
   Rangnekar, Ranjit
   Goel, Atul
TI Neural Circuitry: Architecture and Function-A Fiber Dissection Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fiber dissection; Function; Klingler's technique; White fibers
ID HUMAN BRAIN; LONGITUDINAL FASCICULUS; IN-VIVO; ANATOMY; TRACTOGRAPHY;
   HUMANS
AB OBJECTIVE: White fiber dissection using a gyrus-based approach was performed to study the various associations, commissural, and projection fiber bundles of the brain.
   METHODS: Ten previously frozen and formalin-fixed cadaveric human brains were included. The fiber dissection techniques described by Klingler were used. The primary dissection tools were thin handmade wooden spatulas and curved metallic spatulas with tips of various sizes. The fibers were studied by the naked eye and with the use of magnification. The various fiber bundles were studied using a gyrus-based approach. The dissection was performed through each named gyrus, and the fiber tracts encountered during dissection were identified, and their relationship to other adjacent fiber bundles was studied.
   RESULTS: From our dissections, the white fibers of the brain were divided architecturally into 5 groups-4 horizontal groups and 1 vertical group. The 4 horizontal groups were the superficial, middle, deep, and central groups. The association fibers constituted the superficial, middle, and deep groups. The commissural fibers formed the central group, and the projection fibers formed the vertical group. The course of the fiber bundles and their functional co-relationship were determined.
   CONCLUSIONS: When planning the surgical trajectory, knowledge of the location of white matter tracts is essential to help minimize the occurrence of postoperative deficits. Fiber dissection using the Klingler technique is useful in gaining an understanding of the complex 3-dimensional nature of these white matter tracts and can provide a valuable resource in neurosurgical training.
C1 [Shah, Abhidha; Jhawar, Sukhdeep Singh; Patil, Abhinandan; Rangnekar, Ranjit; Goel, Atul] King Edward Mem Hosp, Dept Neurosurg, Bombay, Maharashtra, India.
   [Shah, Abhidha; Jhawar, Sukhdeep Singh; Patil, Abhinandan; Rangnekar, Ranjit; Goel, Atul] Seth GS Med Coll, Mumbai, Maharashtra, India.
   [Goel, Aimee] Charing Cross Hosp, London, England.
RP Shah, A (reprint author), King Edward Mem Hosp, Dept Neurosurg, Bombay, Maharashtra, India.; Shah, A (reprint author), Seth GS Med Coll, Mumbai, Maharashtra, India.
EM abhidha@gmail.com
CR Almairac F, 2015, BRAIN STRUCT FUNCT, V220, P1983, DOI 10.1007/s00429-014-0773-1
   Bruni J.E., 2009, HUMAN NEUROANATOMY T
   Fernandez-Miranda JC, 2008, NEUROSURGERY, V62, P989, DOI [10.1227/01.NEU.0000297076.98175.67, 10.1227/01.neu.0000333767.05328.49]
   Fernandez-Miranda JC, 2012, NEUROSURGERY, V71, P430, DOI 10.1227/NEU.0b013e3182592faa
   Geschwind N, 2010, NEUROPSYCHOL REV, V20, P128, DOI 10.1007/s11065-010-9131-0
   Goel A, 2014, ACTA NEUROCHIR, V156, P825, DOI 10.1007/s00701-013-1990-8
   Gungor A, 2017, J NEUROSURG, V126, P945, DOI 10.3171/2016.1.JNS152082
   Hickok G, 2000, TRENDS COGN SCI, V4, P131, DOI 10.1016/S1364-6613(00)01463-7
   Jones DK, 2005, AM J GERIAT PSYCHIAT, V13, P1092, DOI 10.1176/appi.ajgp.13.12.1092
   Kamali A, 2014, BRAIN STRUCT FUNCT, V219, P269, DOI 10.1007/s00429-012-0498-y
   Kier EL, 2004, AM J NEURORADIOL, V25, P677
   Klingler J, 1935, SCHWEIZ ARCH NEUROL, V36, P247
   Makris N, 2005, CEREB CORTEX, V15, P854, DOI 10.1093/cercor/bhh186
   Makris N, 2007, NEUROIMAGE, V37, P1100, DOI 10.1016/j.neuroimage.2007.05.042
   Maldonado IL, 2013, J ANAT, V223, P38, DOI 10.1111/joa.12055
   NAUTA WJH, 1958, BRAIN, V81, P319, DOI 10.1093/brain/81.3.319
   Peltier J, 2010, J NEUROSURG, V112, P1033, DOI 10.3171/2009.6.JNS08132
   Ribas GC, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.11.FOCUS09245
   Schmahmann JD, 2007, J HIST NEUROSCI, V16, P362, DOI 10.1080/09647040600620468
   Shah Abhidha, 2016, Asian J Neurosurg, V11, P276, DOI 10.4103/1793-5482.175626
   Shah A, 2015, J NEUROSURG, V123, P824, DOI 10.3171/2015.3.JNS15539
   Shah A, 2012, J CLIN NEUROSCI, V19, P289, DOI 10.1016/j.jocn.2011.04.039
   Tubbs RS, 2015, OPER NEUROSURG, V11, P322, DOI 10.1227/NEU.0000000000000747
   Wen HT, 1999, NEUROSURGERY, V45, P549, DOI 10.1097/00006123-199909000-00028
   Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201
   Yagmurlu K, 2015, OPER NEUROSURG, V11, P274, DOI 10.1227/NEU.0000000000000704
NR 26
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E620
EP E638
DI 10.1016/j.wneu.2019.01.139
PG 19
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700079
PM 30716486
DA 2020-05-12
ER

PT J
AU Shirakawa, M
   Yoshimura, S
   Uchida, K
   Yamada, K
   Sakamoto, D
   Iida, T
   Takada, Y
   Ishikura, R
AF Shirakawa, Manabu
   Yoshimura, Shinichi
   Uchida, Kazutaka
   Yamada, Kiyofumi
   Sakamoto, Daisuke
   Iida, Tomoko
   Takada, Yoshihiro
   Ishikura, Reiichi
TI Coil Embolization for Cerebral Aneurysms Using a Semi-Jailing Technique
   and Open-Cell Stent
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coil embolization; Open-cell stent; Semijailing technique
ID NECKED INTRACRANIAL ANEURYSMS; ASSISTED COILING; ENDOVASCULAR TREATMENT;
   APPOSITION; DEPLOYMENT
AB BACKGROUND: Numerous reports have described the semi-jailing technique (SJT) using a closed-cell stent for stent-assisted coil embolization, revealing issues including poor expansion and thrombotic complications in curved vessels. This paper reports preliminary experience with SJT using an open-cell stent, a novel type of stent allowing stent placement from a microcatheter.
   METHODS: First, this research investigated differences between open-and closed-cell types in SJT using silicone vessel models. Next, 43 patients who underwent SJT for the internal carotid artery were divided into 2 groups to investigate treatment outcomes: 24 patients with placement of an open-cell stent (open-cell group) and 19 patients with closed-cell stents (closed-cell group).
   RESULTS: In the silicone vessel model, coils could be placed with the open-cell stent deployed with a shorter length than the closed-cell stent. No significant differences were found between groups in terms of maximum diameter of the aneurysm or dome-neck ratio. The open-cell group showed a trend toward higher complete embolization immediately after surgery (54.2% vs. 26.3%, P = 0.06), with few cases of stent malapposition (0% vs. 31.6%, P < 0.01). However, 1 case of ischemic complication in the closedcell group and 1 case of hemorrhagic complication in open-cell group occurred. All cases of modified Rankin Scale scores at discharge were 0-1.
   CONCLUSIONS: Although the open-cell stent carries the disadvantage of an unresheathable design, coil placement with a shorter stent deployment length may be advantageous during SJT for internal carotid artery aneurysm embolization with favorable consequences for excellent vessel wall apposition.
C1 [Shirakawa, Manabu; Yoshimura, Shinichi; Uchida, Kazutaka; Yamada, Kiyofumi; Sakamoto, Daisuke; Iida, Tomoko] Hyogo Coll Med, Dept Neurosurg, Nishinomiya, Hyogo, Japan.
   [Takada, Yoshihiro] Meiwa Hosp, Dept Radiol, Nishinomiya, Hyogo, Japan.
   [Ishikura, Reiichi] Hyogo Coll Med, Dept Radiol, Nishinomiya, Hyogo, Japan.
RP Yoshimura, S (reprint author), Hyogo Coll Med, Dept Neurosurg, Nishinomiya, Hyogo, Japan.
EM hyogoneuro@yahoo.co.jp
CR Adeeb N, 2017, STROKE, V48, P1322, DOI 10.1161/STROKEAHA.116.015308
   Akpek S, 2005, AM J NEURORADIOL, V26, P1223
   Biondi A, 2007, NEUROSURGERY, V61, P460, DOI 10.1227/01.NEU.0000290890.62201.A9
   Byun JS, 2013, J KOREAN NEUROSURG S, V53, P241, DOI 10.3340/jkns.2013.53.4.241
   Gao X, 2010, INTERV NEURORADIOL, V16, P385, DOI 10.1177/159101991001600404
   Heller RS, 2011, AM J NEURORADIOL, V32, P1714, DOI 10.3174/ajnr.A2584
   Heller RS, 2011, J NEUROINTERV SURG, V3, P340, DOI 10.1136/jnis.2010.004499
   Hong B, 2009, NEUROSURGERY, V65, P1131, DOI 10.1227/01.NEU.0000356983.23189.16
   Kim SY, 2017, J KOREAN NEUROSURG S, V60, P644, DOI 10.3340/jkns.2017.0193
   Ko JK, 2017, J KOREAN NEUROSURG S, V60, P146, DOI 10.3340/jkns.2016.0607.002
   Rong-Bo Q, 2013, TURK NEUROSURG, V23, P179, DOI 10.5137/1019-5149.JTN.6274-12.1
   Roy D, 2001, STROKE, V32, P1998, DOI 10.1161/hs0901.095600
   Wang J, 2018, J NEUROINTERV SURG, V10, P687, DOI 10.1136/neurintsurg-2017-013272
   Yoo Minwook, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P363, DOI 10.7461/jcen.2016.18.4.363
   Zheng YT, 2017, ACTA NEUROCHIR, V159, P93, DOI 10.1007/s00701-016-3022-y
   2012, DRUGS RD, V12, P1
NR 16
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E16
EP E21
DI 10.1016/j.wneu.2018.12.065
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700004
PM 30593963
DA 2020-05-12
ER

PT J
AU Shrivastava, A
   Mohammed, N
   Xu, ZY
   Liscak, R
   Kosak, M
   Krsek, M
   Karim, KA
   Lee, CC
   Martinez-Moreno, N
   Vance, ML
   Lunsford, LD
   Sheehan, JP
AF Shrivastava, Adesh
   Mohammed, Nasser
   Xu, Zhiyuan
   Liscak, Roman
   Kosak, Mikulas
   Krsek, Michal
   Karim, Khaled Abdel
   Lee, Cheng-Chia
   Martinez-Moreno, Nuria
   Vance, Mary Lee
   Lunsford, L. Dade
   Sheehan, Jason P.
TI Outcomes After Gamma Knife Stereotactic Radiosurgery in Pediatric
   Patients with Cushing Disease or Acromegaly: A Multi-Institutional Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acromegaly; Cushing disease; Gamma Knife radiosurgery; Stereotactic
   radiosurgery
ID SINGLE CENTERS EXPERIENCE; RADIATION-THERAPY; PITUITARY-ADENOMAS;
   ENDOCRINE; SURGERY; TUMORS; RADIOTHERAPY; CHILDREN
AB OBJECTIVE: Pituitary adenomas comprise about 3% of all intracranial tumors in pediatric patients. This study examines the role of stereotactic radiosurgery in the management of pediatric acromegaly or patients with Cushing disease (CD).
   METHODS: From an international consortium, we retrospectively collected treatment and outcome data on pediatric adrenocorticotrophic hormone and growth hormonee secreting pituitary adenomas treated with Gamma Knife radiosurgery (GKRS). There were a total of 36 patients including 24 with CD and 12 with acromegaly. The data were analyzed to assess outcomes including tumor control, endocrine remission, and adverse effects. Statistical analysis was performed to determine correlation between clinical/treatment parameters and outcomes.
   RESULTS: At the last follow-up after GKRS, endocrine remission rates for CD and acromegaly were 80% and 42%, respectively. Tumor control was achieved in 87.5% of patients with CD and in 42% of patients with acromegaly. New pituitary hormone deficiency occurred in 7 of the 36 patients at a median time of 18 months after GKRS (range, 12-81 months). The predictive factors for endocrine remission were age <15 years (P = 0.015) and margin dose (P = 0.042). The median endocrine follow-up was 63.7 months (range, 7-246 months).
   CONCLUSIONS: GKRS affords reasonable rates of endocrine remission and tumor control in most pediatric patients with functioning adenomas. The most common post-GKRS complication was hypopituitarism, although this occurred in only a few patients. Given the larger at-risk period for pediatric patients, further study is required to evaluate for delayed recurrences and hypopituitarism.
C1 [Shrivastava, Adesh; Mohammed, Nasser; Xu, Zhiyuan; Sheehan, Jason P.] Univ Virginia, Dept Neurosurg, Charlottesville, VA 22904 USA.
   [Liscak, Roman; Kosak, Mikulas; Krsek, Michal] Na Homolce Hosp, Dept Stereotact & Radiat Neurosurg, Prague, Czech Republic.
   [Karim, Khaled Abdel] Ain Shams Univ, Dept Clin Oncol, Cairo, Egypt.
   [Lee, Cheng-Chia] Taipei Vet Gen Hosp, Dept Neurosurg, Taipei, Taiwan.
   [Martinez-Moreno, Nuria] Ruber Int Hosp, Dept Neurol Surg & Gamma Knife Radiosurg, Madrid, Spain.
   [Vance, Mary Lee] Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA USA.
   [Lunsford, L. Dade] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA.
   [Shrivastava, Adesh] All India Inst Med Sci, Dept Neurosurg, Bhopal, MP, India.
RP Sheehan, JP (reprint author), Univ Virginia, Dept Neurosurg, Charlottesville, VA 22904 USA.
EM jps2f@virginia.edu
RI Karim, Khaled Abdel/C-8895-2015; Kosak, Mikulas/AAJ-5546-2020; mohammed,
   nasser/AAG-1525-2019
OI mohammed, nasser/0000-0002-3811-3559
FU International Gamma Knife Research Foundation
FX The study is supported by the International Gamma Knife Research
   Foundation, which manages the international multicenter coordination.
   R.L. is a consultant for Elekta. L.D.L. is a consultant and stockholder
   in Elekta AB.
CR Abunimer AM, 2019, WORLD NEUROSURG, V123, pE186, DOI 10.1016/j.wneu.2018.11.117
   [Anonymous], 1988, PEDIATRICS, V81, P736
   Ding D, 2019, NEUROSURGERY, V84, P717, DOI 10.1093/neuros/nyy178
   Ding D, 2014, J NEURO-ONCOL, V117, P445, DOI 10.1007/s11060-013-1262-8
   Duffner PK, 2004, NEUROLOGIST, V10, P293, DOI 10.1097/01.nrl.0000144287.35993.96
   Estrada J, 1997, NEW ENGL J MED, V336, P172, DOI 10.1056/NEJM199701163360303
   Franzin A, 2012, INT J ENDOCRINOL, DOI 10.1155/2012/342034
   Guaraldi F, 2014, HORM RES PAEDIAT, V81, P145, DOI 10.1159/000357673
   Katznelson L, 2014, J CLIN ENDOCR METAB, V99, P3933, DOI 10.1210/jc.2014-2700
   Keil Margaret F, 2008, Expert Rev Neurother, V8, P563, DOI 10.1586/14737175.8.4.563
   Lafferty AR, 1999, J CLIN ENDOCR METAB, V84, P4317, DOI 10.1210/jc.84.12.4317
   Lee CC, 2014, J CLIN ENDOCR METAB, V99, P1273, DOI 10.1210/jc.2013-3743
   Loeffler JS, 2011, J CLIN ENDOCR METAB, V96, P1992, DOI 10.1210/jc.2011-0251
   Mehta GU, 2017, J CLIN ENDOCR METAB, V102, P4284, DOI 10.1210/jc.2017-01385
   Merchant TE, 2009, J CLIN ONCOL, V27, P3691, DOI 10.1200/JCO.2008.21.2738
   Minniti G, 2007, J NEURO-ONCOL, V84, P79, DOI 10.1007/s11060-007-9344-0
   Nieman LK, 2008, J CLIN ENDOCR METAB, V93, P1526, DOI 10.1210/jc.2008-0125
   Perry A, 2018, J NEUROL SURG PART B, V79, DOI 10.1055/s-0038-1625984
   Rohrer TR, 2009, J ENDOCRINOL INVEST, V32, P294, DOI 10.1007/BF03345714
   Savage Martin O, 2012, Indian J Endocrinol Metab, V16, pS171, DOI 10.4103/2230-8210.104032
   Sheehan JP, 2013, J NEUROSURG, V119, P1486, DOI 10.3171/2013.7.JNS13217
   Sheehan JP, 2011, J NEUROSURG, V114, P303, DOI 10.3171/2010.5.JNS091635
   Trifiletti DM, 2018, INT J RADIAT ONCOL, V101, P610, DOI 10.1016/j.ijrobp.2018.02.023
   Wein L, 2012, INTERN MED J, V42, P1153, DOI 10.1111/j.1445-5994.2012.02903.x
   Wilson PJ, 2014, J CLIN NEUROSCI, V21, P100, DOI 10.1016/j.jocn.2013.04.007
   Wilson PJ, 2013, J CLIN NEUROSCI, V20, P1506, DOI 10.1016/j.jocn.2012.11.026
   Xu ZY, 2013, NEUROSURGERY, V72, P630, DOI 10.1227/NEU.0b013e3182846e44
NR 27
TC 2
Z9 2
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1104
EP E1113
DI 10.1016/j.wneu.2019.01.252
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700138
PM 30790739
DA 2020-05-12
ER

PT J
AU Singh, S
   Marutirao, R
   Deora, H
   Das, KK
   Bhaisora, KS
   Sardhara, J
   Parab, A
   Mehrotra, A
   Srivastava, AK
   Jaiswal, S
   Behari, S
   Jaiswal, AK
AF Singh, Suyash
   Marutirao, Raghvendra
   Deora, Harsh
   Das, Kuntal K.
   Bhaisora, Kamlesh S.
   Sardhara, Jayesh
   Parab, Abhijit
   Mehrotra, Anant
   Srivastava, Arun K.
   Jaiswal, Sushila
   Behari, Sanjay
   Jaiswal, Awadhesh K.
TI Endoscopic Route for Excision of Intraventricular Neurocysticercosis:
   Light at the End of the Tunnel
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopy; Intraventricular cyst; Neurocysticercosis
ID CYSTICERCAL CYSTS; 4TH-VENTRICLE; HYDROCEPHALUS; PREVALENCE; MANAGEMENT;
   DIAGNOSIS; REMOVAL
AB BACKGROUND: Poor sanitation, poor hygiene, and archaic cooking practices have led to neurocysticercosis (NCC) being endemic in India. Apart from a cortical location that leads to seizures, intraventricular NCC can present with hydrocephalus and sudden deterioration in sensorium. Consequently, endoscopic excision plays an important role in its treatment because a dilated ventricle offers a minimally invasive and less traumatic route to the pathology.
   METHODS: All endoscopically excised intraventricular NCC cases operated were retrospectively analyzed from 2014 to 2017, discussing surgical nuances and postoperative outcome.
   RESULTS: Twelve such cases were found (mean age, 21.9 +/- 8.36 years; 9 men and 3 women). The mean follow-up period was 21.17 +/- 13.96 months (range, 2-40 months). The most common site was the aqueduct and fourth ventricle.
   CONCLUSIONS: An endoscopic approach is a feasible and safe tool for treating this disease. Technical nuances such as entry point and trajectory of endoscope need to be kept in mind while operating.
C1 [Singh, Suyash; Marutirao, Raghvendra; Deora, Harsh; Das, Kuntal K.; Bhaisora, Kamlesh S.; Sardhara, Jayesh; Parab, Abhijit; Mehrotra, Anant; Srivastava, Arun K.; Jaiswal, Sushila; Behari, Sanjay; Jaiswal, Awadhesh K.] SGPGI, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
RP Jaiswal, AK (reprint author), SGPGI, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
EM jaiswal_dr_2002@yahoo.co.in
RI DEORA, HARSH/A-5817-2019
OI DEORA, HARSH/0000-0003-3247-1117
CR Aggarwal OP, 2005, INDIAN J COMMUNITY M, V0, P10
   Anandh B, 2001, MINIM INVAS NEUROSUR, V44, P194, DOI 10.1055/s-2001-19928
   Baird RA, 2013, NEUROLOGY, V80, P1424, DOI 10.1212/WNL.0b013e31828c2f3e
   Bergsneider M, 1999, J NEUROSURG, V91, P340, DOI 10.3171/jns.1999.91.2.0340
   Ceja-Espinosa A, 2017, Surg Neurol Int, V8, P232, DOI 10.4103/sni.sni_251_17
   CHANG KH, 1991, AM J NEURORADIOL, V12, P509
   Chowdhary A, 2010, CASE REP MED, DOI 10.1155/2010/245259
   COLLI BO, 1986, J NEUROSURG, V65, P309, DOI 10.3171/jns.1986.65.3.0309
   CRUZ I, 1995, J NEUROL SCI, V133, P152, DOI 10.1016/0022-510X(95)00181-Z
   Cudlip SA, 1998, BRIT J NEUROSURG, V12, P452, DOI 10.1080/02688699844691
   Cuetter AC, 1997, CLIN INFECT DIS, V24, P157, DOI 10.1093/clinids/24.2.157
   Del Brutto OH, 2001, NEUROLOGY, V57, P177, DOI 10.1212/WNL.57.2.177
   ESTANOL B, 1983, NEUROSURGERY, V13, P119, DOI 10.1227/00006123-198308000-00002
   Garcia HH, 2002, CLIN MICROBIOL REV, V15, P747, DOI 10.1128/CMR.15.4.747-756.2002
   Goel D, 2011, NEUROL INDIA, V59, P37, DOI 10.4103/0028-3886.76855
   Goel RK, 2008, J CLIN NEUROSCI, V15, P1096, DOI 10.1016/j.jocn.2007.10.004
   Gravori Tooraj, 2002, Neurosurg Focus, V12, pe7
   Husain M, 2007, ACTA NEUROCHIR, V149, P341, DOI 10.1007/s00701-006-1059-z
   Jensen TO, 2016, ASIAN PAC J TROP MED, V9, P815, DOI 10.1016/j.apjtm.2016.06.016
   Kaif M, 2019, TURK NEUROSURG, V29, P59, DOI 10.5137/1019-5149.JTN.21389-17.3
   Prasad KN, 2007, T ROY SOC TROP MED H, V101, P1241, DOI 10.1016/j.trstmh.2007.04.019
   Psarros TG, 2004, MINIM INVAS NEUROSUR, V47, P346, DOI 10.1055/s-2004-830134
   Rajshekhar V, 2010, INT J SURG, V8, P100, DOI 10.1016/j.ijsu.2009.12.006
   Rangel-Castilla L, 2014, J NEUROSURG, V121, P790, DOI 10.3171/2014.5.JNS132031
   Schroeder HWS, 2004, CHILD NERV SYST, V20, P878, DOI 10.1007/s00381-004-0946-y
   Sinha S, 2012, BRIT J NEUROSURG, V26, P305, DOI 10.3109/02688697.2011.635820
   TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50
   ZEE CS, 1984, AM J NEURORADIOL, V5, P727
   Zymberg ST, 2003, ARQ NEURO-PSIQUIAT, V61, P204, DOI 10.1590/S0004-282X2003000200009
NR 29
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E74
EP E81
DI 10.1016/j.wneu.2018.12.191
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700012
PM 30684716
DA 2020-05-12
ER

PT J
AU Snyder, DJ
   Neifert, SN
   Gal, JS
   Deutsch, BC
   Caridi, JM
AF Snyder, Daniel J.
   Neifert, Sean N.
   Gal, Jonathan S.
   Deutsch, Brian C.
   Caridi, John M.
TI Posterior Cervical Decompression and Fusion: Assessing Risk Factors for
   Nonhome Discharge and the Impact of Disposition on Postdischarge
   Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bundled payments; Episode-based outcomes; Nonhome discharge; Outcomes;
   SNF; Unplanned readmission
ID TOTAL JOINT ARTHROPLASTY; DESTINATION; PREDICTORS; SURGERY; COSTS
AB BACKGROUND: The purpose of this study was to identify predictors for postacute care facility discharge for patients undergoing posterior cervical decompression and fusion (PCDF) and to determine if discharge placement impacts postdischarge outcomes.
   METHODS: Patients undergoing PCDF from 2012 to 2015 were queried from the NSQIP database (n = 8743) and separated by discharge placement. Outcomes included nonhome discharge, unplanned 30-day readmission, and adverse events (AEs), both before and after discharge. Demographics and comorbidities were analyzed using bivariate analysis. Multivariate logistic regression was used to identify predictors for nonhome discharge, readmission, and severe AE after discharge.
   RESULTS: Patients with nonhome discharges were significantly older (67.4 vs. 58.6 years; P < 0.001), sicker (82% vs. 54% American Society of Anesthesiologists >2; P < 0.001), and more functionally dependent (16% vs. 3.4%; P < 0.001), with a greater comorbidity burden. Patients with PCDF had an increased likelihood of nonhome discharge if they had a dependent functional status (odds ratio [OR], 2.99; 95% confidence interval [CI], 2.33-3.82; P < 0.001), diabetes (OR, 1.32; 95% CI, 1.13-1.55; P = 0.0007), and an American Society of Anesthesiologists >2 (OR, 1.75; 95% CI, 1.5-2.05; P < 0.001), as well as if they were older (OR, 1.06; 95% CI, 1.05-1.06; P < 0.001) and female (OR, 1.31; 95% CI, 1.14-1.5; P = 0.0002). Patients with PCDF with nonhome discharges had an increased likelihood of having a severe postdischarge AE (OR, 1.71; 95% CI, 1.26-2.33; P = 0.0006) and an unplanned readmission (OR, 1.45; 95% CI, 1.15-1.82; P = 0.002).
   CONCLUSIONS: Results of this cross-sectional study suggest that patients with PCDF discharged to a postacute care facility have a higher likelihood of having a severe AE after discharge as well as a higher likelihood of being readmitted.
C1 [Snyder, Daniel J.; Neifert, Sean N.; Deutsch, Brian C.] Icahn Sch Med Mt Sinai, Dept Med Educ, New York, NY 10029 USA.
   [Gal, Jonathan S.] Mt Sinai Hosp, Dept Anesthesiol Perioperat & Pain Med, New York, NY 10029 USA.
   [Caridi, John M.] Mt Sinai Hosp, Dept Neurosurg, New York, NY 10029 USA.
   [Caridi, John M.] Mt Sinai Hosp, Dept Orthoped, New York, NY 10029 USA.
RP Snyder, DJ (reprint author), Icahn Sch Med Mt Sinai, Dept Med Educ, New York, NY 10029 USA.
EM Daniel.Snyder@Icahn.Mssm.Edu
OI Caridi, John/0000-0003-2841-585X; Deutsch, Brian/0000-0002-8622-9951
CR Aldebeyan S, 2016, SPINE, V41, P1535, DOI 10.1097/BRS.0000000000001575
   American College of Surgeons National Surgical Quality Improvement Program, 2016, PART 2016
   [Anonymous], 2014, ADVERSE EVENTS SKILL
   Barsoum WK, 2010, J ARTHROPLASTY, V25, P885, DOI 10.1016/j.arth.2009.06.022
   Bini SA, 2010, J ARTHROPLASTY, V25, P114, DOI 10.1016/j.arth.2008.11.007
   Bozic KJ, 2014, CLIN ORTHOP RELAT R, V472, P188, DOI 10.1007/s11999-013-3034-3
   Brasel KJ, 2002, J SURG RES, V107, P223, DOI 10.1006/jsre.2002.6512
   Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575
   Bundled Payments for Care Improvement (BPCI), BUNDLED PAYMENTS CAR
   Burke RE, 2016, J AM MED DIR ASSOC, V17, P249, DOI 10.1016/j.jamda.2015.11.005
   Choy W, 2018, SPINE, V43, P356, DOI 10.1097/BRS.0000000000001450
   Cramer JA, 2008, INT J CLIN PRACT, V62, P76, DOI 10.1111/j.1742-1241.2007.01630.x
   Di Capua J, 2017, SPINE, V42, P1538, DOI 10.1097/BRS.0000000000002140
   Gruskay JA, 2015, SPINE J, V15, P1188, DOI 10.1016/j.spinee.2013.10.022
   Keswani A, 2016, J ARTHROPLASTY, V31, P1155, DOI 10.1016/j.arth.2015.11.044
   Kuhns CA, 2005, SPINE, V30, P2424, DOI 10.1097/01.brs.0000184314.26543.7d
   Marquez-Lara A, 2014, SPINE, V39, P476, DOI 10.1097/BRS.0000000000000165
   Medicare, FIND COMP NURS HOM N
   Medvedev G, 2016, SPINE, V41, P1477, DOI 10.1097/BRS.0000000000001564
   Mok JM, 2016, INT J SPINE SURG, V10, DOI 10.14444/3019
   Oldmeadow LB, 2003, J ARTHROPLASTY, V18, P775, DOI 10.1016/S0883-5403(03)00151-7
   Raphael DR, 2014, PERIOPER MED, V3, DOI 10.1186/2047-0525-3-6
   Schoenfeld AJ, 2013, SPINE J, V13, P1171, DOI 10.1016/j.spinee.2013.02.071
   Shepperd S, 2009, COCHRANE DB SYST REV, V1
   Shepperd S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub4
   Sibia US, 2017, J ARTHROPLASTY, V32, P381, DOI 10.1016/j.arth.2016.08.003
   Ugiliweneza B, 2014, SPINE, V39, P1235, DOI 10.1097/BRS.0000000000000378
   Ye I, 2018, WORLD NEUROSURG, V119, pE574, DOI 10.1016/j.wneu.2018.07.213
   Yi F, 2014, CLIN COLON RECT SURG, V27, P32, DOI 10.1055/s-0034-1366917
   2006, J ARTHROPLASTY S, V21, P151, DOI DOI 10.1016/J.ARTH.2006.04.015
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E958
EP E965
DI 10.1016/j.wneu.2019.01.214
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700118
PM 30763752
DA 2020-05-12
ER

PT J
AU Summaka, M
   Zein, H
   Abou Abbas, L
   Elias, C
   Elias, E
   Fares, Y
   Naim, I
   Nasser, Z
AF Summaka, Marwa
   Zein, Hiba
   Abou Abbas, Linda
   Elias, Charbel
   Elias, Elias
   Fares, Youssef
   Naim, Ibrahim
   Nasser, Zeina
TI Validity and Reliability of the Arabic Patient Health Questionnaire-9 in
   Patients with Spinal Cord Injury in Lebanon
SO WORLD NEUROSURGERY
LA English
DT Article
DE Depression; Lebanon; Patient health Questionnaire-9; Psychometrics;
   Spinal cord injury
ID QUALITY-OF-LIFE; RATING-SCALE; DEPRESSION; PAIN; INDIVIDUALS;
   PREVALENCE; PHQ-9
AB BACKGROUND: Depression is a prevalent and disabling condition associated with spinal cord injury (SCI). Such associated negative factor warrants the use of valid and reliable psychological assessment tools among this group. One of the available assessment means is the Patient Health Questionnaire-9 (PHQ-9), a short screening measure that evaluates depression status. Our aim is to test the psychometric properties of the Arabic version of the PHQ-9 including validity and reliability among Lebanese individuals with SCI.
   METHODS: This is a cross-sectional study conducted between January and June 2018, including 51 participants with SCI. Questionnaire and assessment measures were administered to the subjects. The internal consistency, test-retest reliability, and the factor structure of the PHQ-9 were evaluated in addition to the convergent validity, which was established by comparing the scale's total score with the scores of the Hamilton Depression Rating Scale.
   RESULTS: Exploratory factor analysis revealed 3 factors accounting for 66.2% of the total variance. The scale demonstrated good internal consistency (Cronbach's alpha = 0.71) and test-retest reliability (Intraclass correlation coefficient = 0.88). Significant correlation was found between the PHQ-9 and the Hamilton Depression Rating Scale (r = 0.71) suggesting good convergent validity.
   CONCLUSIONS: Our findings suggest that the PHQ-9 has good psychometric properties and is a valid and reliable measure of depression among the Lebanese individuals with SCI.
C1 [Summaka, Marwa; Zein, Hiba; Abou Abbas, Linda; Fares, Youssef; Nasser, Zeina] Lebanese Univ, Neurosci Res Ctr, Fac Med Sci, Dept Neurosurg, Hadath, Lebanon.
   [Elias, Charbel; Elias, Elias] Amer Univ Beirut, Fac Med, Neurosurg Div, Beirut, Lebanon.
   [Naim, Ibrahim] Hlth Rehabil Integrat & Res Ctr, Beirut, Lebanon.
RP Nasser, Z (reprint author), Lebanese Univ, Neurosci Res Ctr, Fac Med Sci, Dept Neurosurg, Hadath, Lebanon.
EM znasser6@gmail.com
RI Abou Abbas, Linda/U-6802-2017
OI Abou Abbas, Linda/0000-0001-9185-3831
CR Ataoglu E, 2013, SPINAL CORD, V51, P23, DOI 10.1038/sc.2012.51
   Bagby RM, 2004, AM J PSYCHIAT, V161, P2163, DOI 10.1176/appi.ajp.161.12.2163
   Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348
   Bombardier CH, 2012, ARCH PHYS MED REHAB, V93, P1838, DOI 10.1016/j.apmr.2012.04.019
   Ebrahimzadeh MH, 2014, ARCH TRAUMA RES, V3, DOI 10.5812/atr.17917
   Fabrigar LR, 1999, PSYCHOL METHODS, V4, P272, DOI 10.1037/1082-989X.4.3.272
   Fares J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017214
   Fares Y, 2013, J INFECT PUBLIC HEAL, V6, P482, DOI 10.1016/j.jiph.2013.05.006
   Ghazwin MY, 2015, ARCH NEUROSCI, V2, DOI 10.5812/archneurosci.21529
   Guzelkucuk U, 2015, SPINAL CORD, V53, P441, DOI 10.1038/sc.2014.211
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Jazayeri SB, 2015, NEUROEPIDEMIOLOGY, V45, P28, DOI 10.1159/000435785
   Khazaeipour Z, 2017, SPINAL CORD, V55, P1039, DOI 10.1038/sc.2017.80
   Khazaeipour Z, 2014, J SPINAL CORD MED, V37, P338, DOI 10.1179/2045772313Y.0000000174
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Merghati-Khoei E, 2017, SPINAL CORD, V55, P269, DOI 10.1038/sc.2016.106
   Moghimian M, 2015, ARCH TRAUMA RES, V4, DOI 10.5812/atr.19280
   Mousavi V., 2017, IRAN J NEUROSURG, V2, P9
   Obeid S, 2018, ENCEPHALE, V44, P397, DOI 10.1016/j.encep.2017.10.010
   Richardson EJ, 2016, J SPINAL CORD MED, V39, P535, DOI 10.1080/10790268.2016.1151145
   Salamati Payman, 2015, Med J Islam Repub Iran, V29, P198
   Sawaya H, 2016, PSYCHIAT RES, V239, P245, DOI 10.1016/j.psychres.2016.03.030
   Tabachnick B.G., 2007, USING MULTIVARIATE S
   Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd
   van Leeuwen CM, 2012, ARCH PHYS MED REHAB, V93, P2170, DOI 10.1016/j.apmr.2012.07.006
   WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742
   Williams R, 2015, ARCH PHYS MED REHAB, V96, P133, DOI 10.1016/j.apmr.2014.08.016
   Wollaars MM, 2007, CLIN J PAIN, V23, P383, DOI 10.1097/AJP.0b013e31804463e5
   Worthington RL, 2006, COUNS PSYCHOL, V34, P806, DOI 10.1177/0011000006288127
   2018, J SPINAL CORD MED, V41, P645, DOI DOI 10.1080/10790268.2016.1275447
NR 31
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1016
EP E1022
DI 10.1016/j.wneu.2019.01.234
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700126
PM 30771543
DA 2020-05-12
ER

PT J
AU Sun, H
   Deng, LY
   Deng, J
   Wang, J
   Zhang, H
   Chen, KH
   Li, HF
   Ning, X
   Yang, H
AF Sun, Hong
   Deng, Luoyi
   Deng, Jin
   Wang, Jian
   Zhang, Hao
   Chen, Kunhao
   Li, Hongfei
   Ning, Xu
   Yang, Hua
TI The Efficacy and Safety of Prophylactic Intravenous Tranexamic Acid on
   Perioperative Blood Loss in Patients Treated with Posterior Lumbar
   Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood loss; Posterior lumbar interbody fusion; Retrospective
   case-control study; Tranexamic acid
ID SPINE SURGERY; TRANSFUSION; REDUCTION
AB OBJECTIVE: To investigate the efficacy and safety of a prophylactic intravenous administration of tranexamic acid (TXA) 30 minutes before skin incision on perioperative blood loss in patients treated with posterior lumbar interbody fusion (PLIF).
   METHODS: A total of 63 patients who underwent PLIF were recruited and divided into a TXA group (n = 26) and a control group (n = 37). Intraoperative blood loss, postoperative blood loss, duration of tube drainage, hospitalization time, blood transfusion rate, and incidence of complications were compared between the 2 groups.
   RESULTS: There were no significant differences in the demographic characteristics and laboratory results between the 2 groups. The intraoperative blood loss, 24-hour postoperative drainage volume, 24-hour postoperative hidden blood loss, perioperative overt blood loss, hospitalization time, and postoperative duration of tube drainage were significantly reduced in the TXA group compared with the control group. In addition, the perioperative blood transfusion rate was lower in the TXA group (7.7%) than in the control group (16.22%), but the difference was not statistically significant. During a 3-month follow-up period, no pulmonary embolism, liver failure, or renal dysfunction was observed in the 2 groups. Likewise, the incidence of deep venous thrombosis was not found in the TXA group compared with 1 case in the control group, hence the difference was not statistically significant.
   CONCLUSIONS: A prophylactic intravenous administration of TXA 30 minutes before skin incision effectively reduces the perioperative blood loss, duration of tube drainage, and hospitalization time, and it does not increase the risk of complications. However, TXA may not be able to decrease the rate of blood transfusion.
C1 [Sun, Hong; Deng, Luoyi; Wang, Jian; Zhang, Hao; Ning, Xu; Yang, Hua] Guizhou Med Univ, Affiliated Hosp, Dept Orthopaed, Guiyang, Guizhou, Peoples R China.
   [Deng, Jin] Guizhou Med Univ, Affiliated Hosp, Dept Emergency Med, Guiyang, Guizhou, Peoples R China.
   [Chen, Kunhao; Li, Hongfei] Guizhou Med Univ, Dept Clin Med Coll, Guiyang, Guizhou, Peoples R China.
RP Ning, X (reprint author), Guizhou Med Univ, Affiliated Hosp, Dept Orthopaed, Guiyang, Guizhou, Peoples R China.
EM 179451982@qq.com
OI Sun, Hong/0000-0002-4195-501X
FU Guizhou Provincial Science and Technology Project [QianKeHeLH
   [2016]7253]
FX This study was funded by the Guizhou Provincial Science and Technology
   Project (Grant NO. QianKeHeLH [2016]7253).
CR ANDERSSON L, 1965, SCAND J HAEMATOL, V2, P230
   ASTEDT B, 1987, SCAND J GASTROENTERO, V22, P22, DOI 10.3109/00365528709089756
   Bagoly Z, 2017, BIOMED RES INT, DOI 10.1155/2017/4645137
   Bagsby DT, 2015, J ARTHROPLASTY, V30, P2106, DOI 10.1016/j.arth.2015.06.040
   Cheriyan T, 2015, SPINE J, V15, P752, DOI 10.1016/j.spinee.2015.01.013
   Cho SK, 2012, J BONE JOINT SURG AM, V94A, P1952, DOI 10.2106/JBJS.K.00632
   Colomina MJ, 2017, BRIT J ANAESTH, V118, P380, DOI 10.1093/bja/aew434
   Coric D, 1997, Neurosurg Focus, V3, pe5
   Endres S, 2011, BMC SURG, V11, DOI 10.1186/1471-2482-11-29
   Farrokhi MR, 2011, J NEUROSURG ANESTH, V23, P290, DOI 10.1097/ANA.0b013e31822914a1
   GROSS JB, 1983, ANESTHESIOLOGY, V58, P277, DOI 10.1097/00000542-198303000-00016
   Hui SY, 2018, SPINE J, V18, P1325, DOI 10.1016/j.spinee.2017.11.017
   Kim KT, 2017, EUR SPINE J, V26, P2851, DOI 10.1007/s00586-017-5230-4
   Kolev K, 2016, BRIT J HAEMATOL, V175, P12, DOI 10.1111/bjh.14255
   Kushioka J, 2017, J NEUROSURG-SPINE, V26, P363, DOI 10.3171/2016.8.SPINE16528
   Liang JQ, 2016, CLIN NEUROL NEUROSUR, V147, P110, DOI 10.1016/j.clineuro.2016.06.001
   Lin ZLX, 2016, ORTHOPEDICS, V39, P119, DOI 10.3928/01477447-20160301-05
   NADLER SB, 1962, SURGERY, V51, P224
   Nagabhushan RM, 2018, SPINE, V43, pE267, DOI 10.1097/BRS.0000000000002315
   Naik BI, 2015, J NEUROSURG-SPINE, V23, P239, DOI 10.3171/2014.12.SPINE14620
   Neilipovitz DT, 2004, EUR SPINE J, V13, pS62, DOI 10.1007/s00586-004-0716-2
   Peters A, 2015, SPINE, V40, pE443, DOI 10.1097/BRS.0000000000000799
   PILBRANT A, 1981, EUR J CLIN PHARMACOL, V20, P65, DOI 10.1007/BF00554669
   Raksakietisak M, 2015, SPINE, V40, pE1257, DOI 10.1097/BRS.0000000000001063
   Satoh I, 2006, J SPINAL DISORD TECH, V19, P104, DOI 10.1097/01.bsd.0000180991.98751.95
   Shakeri M, 2018, ASIAN SPINE J, V12, P484, DOI 10.4184/asj.2018.12.3.484
   Shi HY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005718
   Sperzel M, 2007, J THROMB HAEMOST, V5, P2113, DOI 10.1111/j.1538-7836.2007.02717.x
   Sui WY, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1006-y
   Tanaka N, 2001, J BONE JOINT SURG BR, V83B, P702, DOI 10.1302/0301-620X.83B5.11745
   Tsutsumimoto T, 2011, SPINE, V36, P1913, DOI 10.1097/BRS.0b013e3181fb3a42
   Wang Q, 2013, EUR SPINE J, V22, P2035, DOI 10.1007/s00586-013-2836-z
   Waskowski J, 2019, MED KLIN-INTENSIVMED, V114, P642, DOI 10.1007/s00063-018-0402-5
   Willner D, 2016, ANESTH ANALG, V123, P1307, DOI 10.1213/ANE.0000000000001485
   Wong J, 2008, ANESTH ANALG, V107, P1479, DOI 10.1213/ane.0b013e3181831e44
   Xie JM, 2015, SPINE J, V15, P647, DOI 10.1016/j.spinee.2014.11.023
   Yuan QM, 2017, EUR SPINE J, V26, P131, DOI 10.1007/s00586-016-4899-0
   Zou HB, 2015, BMC SURG, V15, DOI 10.1186/s12893-015-0062-9
NR 38
TC 0
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E198
EP E204
DI 10.1016/j.wneu.2019.01.040
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700026
PM 30684701
DA 2020-05-12
ER

PT J
AU Sun, JC
   Sun, KQ
   Wang, SM
   Yang, HS
   Wang, Y
   Xu, XM
   Shi, JG
AF Sun, Jingchuan
   Sun, Kaiqiang
   Wang, Shunmin
   Yang, Haisong
   Wang, Yuan
   Xu, Ximing
   Shi, Jiangang
TI "Shelter Technique" in the Treatment of Ossification of the Posterior
   Longitudinal Ligament Involving the C2 Segment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior controllable antedisplacement and fusion; Cervical myelopathy;
   Ossification of the posterior longitudinal ligament; Shelter technique;
   Surgical technique
ID CERVICAL SPONDYLOTIC MYELOPATHY; OCCUPYING RATIO; FUSION; SURGERY;
   EFFICACY; DECOMPRESSION; LAMINOPLASTY; DISKECTOMY; CORPECTOMY; CURVATURE
AB BACKGROUND: Anterior or posterior decompression has been widely used to treat patients with ossification of the posterior longitudinal ligament (OPLL). However, when OPLL extends to the C2 level, the complex anatomic structures around the C2 vertebral body and postoperative destabilization or kyphosis would make it difficult to perform anterior or posterior surgery. This study proposed a novel technique named "shelter technique" to deal with C2 OPLL.
   METHODS: Sixteen patients with cervical OPLL involving the C2 segment were included. The OPLL below C2 was dealt with anterior controllable antedisplacement and fusion, including diskectomy of involved levels, resection of the anterior vertebral bodies, installation of the intervertebral cages and anterior cervical plate, isolation of the vertebrae-OPLL complex (VOC), and the final hoisting of the VOC. When dealing with C2 OPLL, the posterior portion of the C2 vertebral body was resected to create the shelter based on the thickness of the C2 OPLL, which could provide space for further antedisplacement of the ossified mass behind the C2 vertebra. Finally, OPLL behind C2 was moved forward together with the antedisplacement of VOC below C2.
   RESULTS: Postoperative magnetic resonance imaging and computed tomography scan showed sufficient decompression of the spinal cord, including the C2 segment, and the shelter provided enough space for the antedisplacement of the ossified mass behind the C2 segment. At the final follow-up of 1 year, neurologic function of all patients recovered significantly.
   CONCLUSIONS: The shelter technique can be relatively effective and safe for patients with OPLL involving the C2 segment. However, further studies with more cases and longer follow-up will be required to reveal the surgical value of the technique.
C1 [Sun, Jingchuan; Sun, Kaiqiang; Wang, Shunmin; Yang, Haisong; Wang, Yuan; Xu, Ximing; Shi, Jiangang] Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
RP Shi, JG (reprint author), Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
EM shijiangangspine@163.com
FU Shanghai Science and Technology Commission Technology Support Project
   [18441905800]; National Nature and Science Foundation of ChinaNational
   Natural Science Foundation of China [81802218]
FX This study is supported by the Shanghai Science and Technology
   Commission Technology Support Project (18441905800) and National Nature
   and Science Foundation of China (81802218).
CR An HS, 1991, SPINE, V16, P548
   Chen Y, 2009, EUR SPINE J, V18, P1541, DOI 10.1007/s00586-009-1029-2
   Chin KR, 2007, SPINE, V32, P2585, DOI 10.1097/BRS.0b013e318158dec8
   Fujimori T, 2014, SPINE, V39, P58, DOI 10.1097/BRS.0000000000000054
   Fujimura Y, 1996, ARCH ORTHOP TRAUM SU, V115, P203, DOI 10.1007/BF00434554
   Haller JM, 2011, SPINE, V36, P2116, DOI 10.1097/BRS.0b013e31820408af
   Iwasaki M, 2007, SPINE, V32, P647, DOI 10.1097/01.brs.0000257560.91147.86
   Kawaguchi Y, 2014, SPINE J, V14, P955, DOI 10.1016/j.spinee.2013.07.457
   Kim P, 2007, J NEUROSURG-SPINE, V7, P293, DOI 10.3171/SPI-07/09/293
   Kimura H, 2014, EUR SPINE J, V23, P1491, DOI 10.1007/s00586-014-3253-7
   Lee MJ, 2007, SPINE J, V7, P141, DOI 10.1016/j.spinee.2006.02.024
   Lee SE, 2016, WORLD NEUROSURG, V90, P51, DOI 10.1016/j.wneu.2015.11.074
   Li H, 2017, J CLIN NEUROSCI, V45, P270, DOI 10.1016/j.jocn.2017.08.003
   Liu HC, 2013, EUR SPINE J, V22, P1480, DOI 10.1007/s00586-013-2707-7
   Matsunaga S, 2012, SPINE, V37, pE309, DOI 10.1097/BRS.0b013e318241ad33
   Mazur M, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.12.FOCUS10255
   Odate S, 2017, J NEUROSURG-SPINE, V26, P466, DOI 10.3171/2016.9.SPINE16430
   Riew K Daniel, 2013, Evid Based Spine Care J, V4, P42, DOI 10.1055/s-0033-1341606
   Rihn JA, 2011, CLIN ORTHOP RELAT R, V469, P658, DOI 10.1007/s11999-010-1731-8
   Secer HI, 2018, TURK NEUROSURG, V28, P257, DOI 10.5137/1019-5149.JTN.20007-17.1
   Segebarth Brad, 2010, SAS J, V4, P3, DOI 10.1016/j.esas.2009.12.001
   Song KJ, 2012, EUR SPINE J, V21, P1551, DOI 10.1007/s00586-012-2296-x
   Sun JC, 2018, EUR SPINE J, V27, P1469, DOI 10.1007/s00586-017-5437-4
   Uei H, 2018, J NEUROSURG-SPINE, V29, P150, DOI 10.3171/2017.12.SPINE17549
   Wang L, 2019, SPINE, V44, pE150, DOI 10.1097/BRS.0000000000002807
   Wu JC, 2018, NEUROSPINE, V15, P33, DOI 10.14245/ns.1836084.042
   Yang H, 2018, WORLD NEUROSURG, V38, P205
   Yew AY, 2019, SPINE, V44, pE82, DOI 10.1097/BRS.0000000000002770
   Yue WM, 2005, EUR SPINE J, V14, P677, DOI 10.1007/s00586-004-0849-3
   2002, J NEUROSURG S, V96, P180
NR 30
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E456
EP E464
DI 10.1016/j.wneu.2019.01.104
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700061
PM 30710725
DA 2020-05-12
ER

PT J
AU Sun, JL
   Zhou, WW
   Mao, KC
   He, YF
   Yao, JZ
   Tang, ZY
   Song, MR
   Liu, QQ
   Zhu, H
   Ju, SQ
   Shi, JL
   Shi, W
AF Sun, Junlong
   Zhou, Wenwu
   Mao, Kangcheng
   He, Yunfeng
   Yao, Junzhong
   Tang, Zhongyu
   Song, Mengruo
   Liu, Qianqian
   Zhu, Hui
   Ju, Shaoqing
   Shi, Jinlong
   Shi, Wei
TI Examination of Plasma Cell-Free DNA of Glioma Patients by Whole Exome
   Sequencing
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cell-free DNA; Glioma; Liquid biopsy; Whole exome sequencing
AB OBJECTIVES: To analyze the plasma cell-free DNA (CfDNA) in glioma patients with high throughout sequencing for a novel non-invasive method for the early diagnosis and management of glioma.
   METHODS: Six patients with glioma were recruited from the Affiliated Hospital of Nantong University from June 2015 to September 2016. Their plasma samples were tested for Cf-DNA by whole exon sequencing and mutations were analyzed by bioinformatics.
   RESULTS: After filtering the raw sequencing data of CfDNA, 33,173 mutations were obtained from 12,462 genes of which 442 genes and 655 mutation sites were identical to that in the Catalogue of Somatic Mutations in Cancer database. However, when we compared the Cf-DNA data with the glioma mutated loci in the Cancer Genome Alta database, only 4 mutations matched with the glioma sequences in the Cancer Genome Alta and did not correspond to that of the paired-tumor tissues.
   CONCLUSIONS: There were some cancer-related somatic mutations in the Cf-DNA of glioma patients, but no identical mutations were found in the paired solid tumors. Therefore, plasma Cf-DNA mutations may not be a suitable marker for the detection of glioma.
C1 [Zhou, Wenwu; Mao, Kangcheng; He, Yunfeng; Tang, Zhongyu; Song, Mengruo; Liu, Qianqian; Shi, Jinlong; Shi, Wei] Nantong Univ, Affiliated Hosp, Jiangsu Clin Med Ctr Tissue Engn & Nerve Injury R, Nantong, Jiangsu, Peoples R China.
   [Zhou, Wenwu; Mao, Kangcheng; He, Yunfeng; Tang, Zhongyu; Song, Mengruo; Liu, Qianqian; Shi, Jinlong; Shi, Wei] Nantong Univ, Affiliated Hosp, Dept Neurosurg, Nantong, Jiangsu, Peoples R China.
   [Sun, Junlong; Zhou, Wenwu; Yao, Junzhong; Zhu, Hui; Ju, Shaoqing; Shi, Jinlong; Shi, Wei] Nantong Univ, Affiliated Hosp, Dept Clin Res Ctr, Nantong, Jiangsu, Peoples R China.
RP Shi, W (reprint author), Nantong Univ, Affiliated Hosp, Jiangsu Clin Med Ctr Tissue Engn & Nerve Injury R, Nantong, Jiangsu, Peoples R China.; Shi, W (reprint author), Nantong Univ, Affiliated Hosp, Dept Neurosurg, Nantong, Jiangsu, Peoples R China.; Shi, W (reprint author), Nantong Univ, Affiliated Hosp, Dept Clin Res Ctr, Nantong, Jiangsu, Peoples R China.
EM ntshiwei123@163.com
FU Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2015M581845]; Postdoctoral Research Funding Plan in Jiangsu Province
   [1601039A]; Nantong Science and Technology Plan [MS32016016,
   MS32015023]; Young Medical Talent Project in Jiangsu Province
   [QNRC2016691]
FX This work was supported by the Postdoctoral Science Foundation (Grant
   Number: 2015M581845); the Postdoctoral Research Funding Plan in Jiangsu
   Province (Grant Number: 1601039A); the Nantong Science and Technology
   Plan (Grant Number: MS32016016, MS32015023), and the Young Medical
   Talent Project in Jiangsu Province (Grant Number: QNRC2016691).
CR Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Chen J, 2013, J MOL NEUROSCI, V50, P368, DOI 10.1007/s12031-013-0014-8
   De Mattos-Arruda L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9839
   Fontanilles M, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0820-z
   Georgakis MK, 2017, EUR J CANCER, V86, P46, DOI 10.1016/j.ejca.2017.08.030
   Gudbjartsson DF, 2015, SCI DATA, V2, DOI 10.1038/sdata.2015.11
   Lu T, 2017, AM J CANCER RES, V7, P2318
   Maltoni R, 2017, ONCOTARGET, V8, P16642, DOI 10.18632/oncotarget.15120
   Mehra N, 2018, EUR UROL, V74, P283, DOI 10.1016/j.eururo.2018.02.013
   Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065
   Nizamutdinov D, 2018, WORLD NEUROSURG, V109, pE67, DOI 10.1016/j.wneu.2017.09.104
   Piil K, 2018, EUR J CANCER CARE, V27, DOI 10.1111/ecc.12806
   Pu WY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2977-7
   Shi W, 2012, J MOL NEUROSCI, V46, P470, DOI 10.1007/s12031-011-9617-0
   Song H, 2014, ATHEROSCLEROSIS, V233, P307, DOI 10.1016/j.atherosclerosis.2013.11.081
   Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273
   Van Roy N, 2017, CLIN CANCER RES, V23, P6305, DOI 10.1158/1078-0432.CCR-17-0675
NR 17
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E424
EP E428
DI 10.1016/j.wneu.2019.01.092
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700056
PM 30703591
DA 2020-05-12
ER

PT J
AU Talari, HR
   Hamidian, Y
   Moussavi, N
   Fakharian, E
   Abedzadeh-kalahroudi, M
   Akbari, H
   Taher, EB
AF Talari, Hamid Reza
   Hamidian, Yaser
   Moussavi, Nooshin
   Fakharian, Esmail
   Abedzadeh-kalahroudi, Masoumeh
   Akbari, Hossein
   Taher, Elaheh Baban
TI The Prognostic Value of Rotterdam Computed Tomography Score in
   Predicting Early Outcomes Among Children with Traumatic Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Children; Computed tomography; Head injury; Rotterdam scoring system
ID GLASGOW COMA SCALE; HEAD-INJURY; CT FINDINGS; CLASSIFICATION; MODEL
AB BACKGROUND: Prediction of traumatic brain injury (TBI) among children is of great importance for accurate clinical decision making.
   OBJECTIVES: This study aimed to determine the prognostic value of the Rotterdam scoring system in predicting early outcome among children with TBI.
   METHODS: This study was conducted in 2017 on 506 children with brain injury in Kashan, Iran. A checklist was used to collect demographic and clinical characteristics of patients such as age, sex, mechanism of trauma, Glasgow Coma Scale (GCS) score, need for surgery, and brain injury outcome. Moreover, each participant's computed tomography scan was evaluated and scored using the Rotterdam system. Sensitivity, specificity, positive and negative predictive values, and the best cut-off score were calculated for the Rotterdam system. The relationships of the Rotterdam score with participants' characteristics were examined using the chi(2) test, whereas the predictors of brain injury outcome were identified using the logistic regression analysis.
   RESULTS: Pediatric death rate was 4.3%. Most deaths were among children who were male, aged < 4, had developed brain injury owing to traffic accidents, had a GCS score of 3-8, suffered from compressed skull fracture and frontal lobe injury, had cerebral edema, and had a Rotterdam score of 5. The sensitivity and specificity of a Rotterdam score 3 were 86.4% and 97.9%, respectively. The logistic regression analysis indicated that only GCS and Rotterdam scores were significant predictors of brain injury outcome.
   CONCLUSIONS: At a cut-off score of 3, the Rotterdam system can be used to predict TBI outcome among children with acceptable sensitivity and specificity.
C1 [Talari, Hamid Reza; Hamidian, Yaser; Moussavi, Nooshin; Fakharian, Esmail; Abedzadeh-kalahroudi, Masoumeh; Akbari, Hossein; Taher, Elaheh Baban] Kashan Univ Med Sci, Trauma Res Ctr, Kashan, Iran.
RP Abedzadeh-kalahroudi, M (reprint author), Kashan Univ Med Sci, Trauma Res Ctr, Kashan, Iran.
EM Abedzadeh@kaums.ac.ir
RI Abedzadeh-Kalahroudi, Masoumeh/G-4114-2017
OI Abedzadeh-Kalahroudi, Masoumeh/0000-0002-7318-6294; Moosavi Buki,
   Nooshin/0000-0003-0888-0068
FU Deputy of Research, Kashan University of Medical Sciences [96173]
FX This study was supported by the Deputy of Research, Kashan University of
   Medical Sciences (Grant no: 96173).
CR Adelson P David, 2003, Pediatr Crit Care Med, V4, pS9
   Araki T, 2017, NEUROL MED-CHIR, V57, P82, DOI 10.2176/nmc.ra.2016-0191
   Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052
   Centers for Disease Control and Prevention, 1999, WIS QARS LEAD CAUS D
   Corral L, 2009, BRAIN INJURY, V23, P403, DOI 10.1080/02699050902788477
   FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809
   Fujimoto K, 2016, J NEUROSURG, V124, P1640, DOI 10.3171/2015.4.JNS142760
   Haque Anwarul, 2018, J Ayub Med Coll Abbottabad, V30, P140
   Hirsch W, 2002, PAEDIATR ANAESTH, V12, P337, DOI 10.1046/j.1460-9592.2002.00837.x
   Huang YH, 2012, NEUROSURGERY, V71, P80, DOI 10.1227/NEU.0b013e3182517aa1
   Imran A, 2016, ANN KING EDWARD MED, V22, P232
   Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c
   Leitgeb J, 2013, ARCH ORTHOP TRAUM SU, V133, P199, DOI 10.1007/s00402-012-1652-y
   Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448
   Liesemer K, 2014, PEDIATR CRIT CARE ME, V15, P554, DOI 10.1097/PCC.0000000000000150
   Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668
   MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14
   Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017
   Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035
   Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057
   Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421
   Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25
   Pillai SV, 2003, NEUROL INDIA, V51, P345
   Sarkar K, 2014, J NEUROSURG-PEDIATR, V13, P307, DOI 10.3171/2013.12.PEDS13223
   Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20
   Talari HR, 2016, WORLD NEUROSURG, V87, P195, DOI 10.1016/j.wneu.2015.11.055
   Tasaki O, 2009, J TRAUMA, V66, P304, DOI 10.1097/TA.0b013e31815d9d3f
   Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092
   2007, J PEDIATR SURG, V42, P1903, DOI DOI 10.1016/J.JPEDSURG.2007.07.020
   1992, NEUROSURGERY, V31, P435
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E139
EP E145
DI 10.1016/j.wneu.2018.12.221
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700019
PM 30677579
DA 2020-05-12
ER

PT J
AU Tang, N
   Zhao, H
   Shen, JX
   Zhang, JG
   Li, SG
AF Tang, Ning
   Zhao, Hong
   Shen, Jian-Xiong
   Zhang, Jian-Guo
   Li, Shu-Gang
TI Magnetically Controlled Growing Rod for Early-Onset Scoliosis:
   Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Early-onset scoliosis; Magnetically controlled growing rod;
   Meta-analysis
ID COMPLICATIONS; CHILDREN; SURGERY
AB BACKGROUND: The goal of the current systematic review and meta-analysis was to explore the utilization of a magnetically controlled growing rod (MCGR) for the treatment of early-onset scoliosis based on eligible studies demonstrating efficacy.
   METHODS: Online electronic databases were searched to identify the eligible studies updated to April 2018 according to index words. Several studies in the literature that were relevant to the present analysis were also included. Mean difference or relative risk along with 95% confidence interval was used to analyze the main outcomes.
   RESULTS: Eleven studies were included in the meta-analysis with 186 patients in the MCGR group and 64 patients in the conventionally growing rod (CGR) group; 3 studies were case control studies, and 8 studies were self-control studies. The results indicated that MCGR had significantly decreased the Cobb angle and thoracic kyphosis and increased T1-T12 and T1-S1 distances. In addition, the incidence of complications after MCGR therapy was 0.37%. However, there was no significant difference in the change of Cobb angle and incidence of complications between the MCGR and CGR groups.
   CONCLUSIONS: We demonstrated that MCGR significantly reduced the Cobb angle and thoracic kyphosis while markedly increasing T1-T12 and T1-S1 distances. However, a close comparison of MCGR with CGR reveals more high-quality randomized control trials with a larger sample size and long-term follow-ups are necessary to gather more robust evidence on the efficacy of MCGR for early-onset scoliosis.
C1 [Tang, Ning; Zhao, Hong; Shen, Jian-Xiong; Zhang, Jian-Guo; Li, Shu-Gang] Chinese Acad Med Sci, Dept Orthoped, Peking Union Med Coll Hosp, Beijing, Peoples R China.
RP Zhao, H (reprint author), Chinese Acad Med Sci, Dept Orthoped, Peking Union Med Coll Hosp, Beijing, Peoples R China.
EM pumchhongzhao@163.com
RI Shen, Jianxiong/AAH-6200-2019
CR Akbarnia Behrooz A, 2014, Spine Deform, V2, P493, DOI 10.1016/j.jspd.2014.09.050
   Akbarnia BA, 2013, SPINE, V38, P665, DOI 10.1097/BRS.0b013e3182773560
   Akbarnia BA, 2012, SPINE, V37, P1109, DOI 10.1097/BRS.0b013e318240ff67
   Akbarnia BA, 2010, SPINE, V35, P2193, DOI 10.1097/BRS.0b013e3181f070b5
   Bess S, 2010, J BONE JOINT SURG AM, V92A, P2533, DOI 10.2106/JBJS.I.01471
   Cheung KMC, 2012, LANCET, V379, P1967, DOI 10.1016/S0140-6736(12)60112-3
   Cunin V, 2015, ORTHOP TRAUMATOL-SUR, V101, pS109, DOI 10.1016/j.otsr.2014.06.032
   Dannawi Z, 2013, BONE JOINT J, V95B, P75, DOI 10.1302/0301-620X.95B1.29565
   Doany ME, 2018, SPINE, V43, P148, DOI 10.1097/BRS.0000000000002274
   Figueiredo N, 2016, NEUROSCIENCES, V21, P17, DOI 10.17712/nsj.2016.1.20150266
   Hickey B A, 2014, Eur Spine J, V23 Suppl 1, pS61, DOI 10.1007/s00586-013-3163-0
   Kotwicki T, 2013, ADOLESC HEALTH MED T, V4, P59, DOI 10.2147/AHMT.S32088
   Kwan KYH, 2017, SPINE, V42, pE1410, DOI 10.1097/BRS.0000000000002297
   Larson N, 2011, J AM ACAD NURSE PRAC, V23, P392, DOI 10.1111/j.1745-7599.2011.00634.x
   Lebon J, 2017, EUR SPINE J, V26, P1567, DOI 10.1007/s00586-016-4929-y
   Phillips JH, 2013, SPINE, V38, P324, DOI 10.1097/BRS.0b013e31826c6743
   Sankar WN, 2010, SPINE, V35, P2091, DOI 10.1097/BRS.0b013e3181c6edd7
   Skaggs DL, 2014, J PEDIATR ORTHOPED, V34, P260, DOI 10.1097/BPO.0000000000000073
   Teoh KH, 2016, SPINE J, V16, pS40, DOI 10.1016/j.spinee.2015.12.099
   Teoh KH, 2016, SPINE J, V16, pS34, DOI 10.1016/j.spinee.2015.12.098
   Thompson W, 2016, BONE JOINT J, V98B, P1240, DOI [10.1302/0301-620X.9859.37545, 10.1302/0301-620X.98B9.37545]
   Xu GJ, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0413-y
NR 22
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E593
EP E601
DI 10.1016/j.wneu.2019.01.136
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700076
PM 30716487
DA 2020-05-12
ER

PT J
AU Taweesomboonyat, C
   Tunthanathip, T
   Kaewborisutsakul, A
   Saeheng, S
   Oearsakul, T
   Riabroi, K
   Khumtong, R
AF Taweesomboonyat, Chin
   Tunthanathip, Thara
   Kaewborisutsakul, Anukoon
   Saeheng, Sakchai
   Oearsakul, Thakul
   Riabroi, Kittipong
   Khumtong, Rujimas
TI Outcome of Ruptured Posterior Communicating Artery Aneurysm Treatment
   Comparing Between Clipping and Coiling Techniques
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clipping; Coiling; Outcome; Ruptured posterior communicating artery
   aneurysm; Treatment
ID ENDOVASCULAR-COILING; INTRACRANIAL ANEURYSMS; TRIAL; OCCLUSION
AB BACKGROUND: Very few data stratify the functional outcome of ruptured posterior communicating artery (PCoA) aneurysm treatment based on each treatment strategy. Therefore, the authors aimed to evaluate the outcome of PCoA aneurysm treatment to compare the clipping and coiling techniques and find the factors that determined the treatment outcomes.
   METHODS: Patients with ruptured PCoA aneurysm at Songklanagarind Hospital between November 2002 and March 2018 were retrospectively reviewed and classified into the clipping group or the coiling group. The primary outcome was the modified Rankin Scale (mRS) at 6 months after treatment, and the patients were stratified into "good outcome" (mRS 0-2) and "poor outcome" (mRS 3-6). Using logistic regression analysis, various factors were analyzed for association with the treatment outcome.
   RESULTS: This study included 189 patients: 104 and 85 patients in the clipping and coiling groups, respectively. Patients in the coiling group were significantly older, with more underlying diseases. However, the treatment outcomes at 6 months were not significantly different between the 2 groups. The percentages of poor outcomes in the clipping and coiling groups were 28% and 31%, respectively (P = 0.734). Older age, seizure, higher Hunt and Hess grade, deterioration before aneurysm obliteration, an aneurysm on the left side, and a medially projected PCoA aneurysm were statistically significantly correlated with poor outcomes.
   CONCLUSIONS: Neurosurgical clipping and endovascular coiling are effective treatments for aneurysm obliteration in ruptured PCoA aneurysm. An aneurysm on the left side and a medially projected PCoA aneurysm were the factors correlated with poor outcome.
C1 [Taweesomboonyat, Chin; Tunthanathip, Thara; Kaewborisutsakul, Anukoon; Saeheng, Sakchai; Oearsakul, Thakul] Prince Songkla Univ, Fac Med, Songklanagarind Hosp, Div Neurosurg,Dept Surg, Hat Yai, Thailand.
   [Riabroi, Kittipong; Khumtong, Rujimas] Prince Songkla Univ, Fac Med, Songklanagarind Hosp, Div Diagnost Radiol,Dept Radiol, Hat Yai, Thailand.
RP Taweesomboonyat, C (reprint author), Prince Songkla Univ, Fac Med, Songklanagarind Hosp, Div Neurosurg,Dept Surg, Hat Yai, Thailand.
EM chin.3ch@hotmail.com
OI Tunthanathip, Thara/0000-0002-6303-836X
CR de Oliveira JG, 2007, NEUROSURGERY, V61, P924, DOI 10.1227/01.neu.0000303188.72425.24
   Dorai Z, 2003, NEUROSURGERY, V52, P763, DOI 10.1227/01.NEU.0000053222.74852.2D
   Golshani Kiarash, 2010, Surg Neurol Int, V1, P88, DOI 10.4103/2152-7806.74147
   Hart Y, 2011, J NEUROSURG, V115, P1159, DOI 10.3171/2011.6.JNS101836
   Liao CC, 2013, INT J SURG, V11, P998, DOI 10.1016/j.ijsu.2013.05.038
   Lusseveld E, 2002, J NEUROL NEUROSUR PS, V73, P591, DOI 10.1136/jnnp.73.5.591
   McDougall CG, 2012, J NEUROSURG, V116, P135, DOI 10.3171/2011.8.JNS101767
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux Andrew, 2002, J Stroke Cerebrovasc Dis, V11, P304, DOI 10.1053/jscd.2002.130390
   Ojemann RG, 1988, SURG MANAGEMENT CERE, P179
   Ryttlefors M, 2008, STROKE, V39, P2720, DOI 10.1161/STROKEAHA.107.506030
   Smith TR, 2015, WORLD NEUROSURG, V84, P942, DOI 10.1016/j.wneu.2015.05.073
   Spetzler RF, 2013, J NEUROSURG, V119, P12
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Taki W, 2011, WORLD NEUROSURG, V76, P437, DOI 10.1016/j.wneu.2011.04.026
   WOLLSCHL.G, 1967, AMER J ROENTGENOL RA, V101, P68, DOI 10.2214/ajr.101.1.68
   2007, NEUROSURGERY, V61, P924, DOI DOI 10.1227/01.NEU.0000280090.83866.26
   2003, NEUROSURGERY, V52, P763
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E183
EP E188
DI 10.1016/j.wneu.2019.01.037
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700024
PM 30684714
DA 2020-05-12
ER

PT J
AU Thorsteinsdottir, J
   Siller, S
   Dorn, F
   Briegel, J
   Tonn, JC
   Schichor, C
AF Thorsteinsdottir, Jun
   Siller, Sebastian
   Dorn, Franziska
   Briegel, Josef
   Tonn, Joerg-Christian
   Schichor, Christian
TI Use of a New Indocyanine Green Pooling Technique for Improved
   Visualization of Spinal Dural AV Fistula: A Single-Center Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural AV fistula; Indocyanine green; Video angiography; Visualization
ID ARTERIOVENOUS-FISTULAS; CLINICAL-FEATURES; SURGICAL-TREATMENT;
   VIDEOANGIOGRAPHY; MANAGEMENT; ANGIOGRAPHY; EXPERIENCE
AB BACKGROUND: Intraoperative indocyanine green video angiography (ICG-VAG) is a useful tool in cerebral vascular surgery. In spinal procedures such as dural arteriovenous (AV) fistula, use of ICG-VAG is limited due to lower perfusion pressure. Therefore, we developed a new pooling technique with adapted workflow to improve intraoperative visualization.
   METHODS: Patients operated on spinal dural AV fistulas using ICG-VAG were prospectively included. A new workflow for ICG-VAG was applied: 1) temporary clip placement at the suspected fistula point, 2) ICG administration during 100% oxygenation, 3) ICG pooling proximal of temporary clip, 4) clip removal/observation of vascular filling. Case records, clinical data, magnetic resonance imaging, digital subtraction angiography (DSA), and clinical outcome were analyzed retrospectively.
   RESULTS: A total of 11 patients (median age 68 years, average course of disease 15 months) were included. Optimized, inverted workflow resulted in considerable pooling of ICG in the supplying feeder of the AV fistula in all cases. Complete obliteration was confirmed in 10 of 11 patients by postoperative DSA. However, 1 patient had an additional, preoperative radiologically undetected small feeder that enlarged until postoperative DSA and made successful reoperation necessary. After the median follow-up of 33.2 months, the Aminoff-Logue scale was decreased in all patients, and the McCormick score (modified Rankin score) was improved in 9 (8) patients and remained stable in 2 (3) patients.
   CONCLUSIONS: Procedure modification in terms of ICG pooling enabled us to detect more easily the pathologic vascular architecture. ICG-VAG is a useful adjunct in the surgical treatment of spinal dural AV fistula because it is a real-time, noninvasive, and radiation-free technique with adequate image resolution.
C1 [Thorsteinsdottir, Jun; Siller, Sebastian; Tonn, Joerg-Christian; Schichor, Christian] Ludwig Maximilians Univ Munchen, Dept Neurosurg, Munich, Germany.
   [Dorn, Franziska] Ludwig Maximilians Univ Munchen, Dept Neuroradiol, Munich, Germany.
   [Briegel, Josef] Ludwig Maximilians Univ Munchen, Dept Anesthesiol, Munich, Germany.
RP Schichor, C (reprint author), Ludwig Maximilians Univ Munchen, Dept Neurosurg, Munich, Germany.
EM christian.schichor@med.uni-muenchen.de
RI Briegel, Josef/AAG-3774-2019; Dorn, Franziska/AAA-7754-2020
OI Dorn, Franziska/0000-0001-9093-8307
CR AMINOFF MJ, 1974, BRAIN, V97, P197, DOI 10.1093/brain/97.1.197
   Behrens S, 1999, J NEUROL, V246, P181, DOI 10.1007/s004150050331
   Chibbaro S, 2015, J CLIN NEUROSCI, V22, P180, DOI 10.1016/j.jocn.2014.07.024
   Eskandar EN, 2002, J NEUROSURG, V96, P162, DOI 10.3171/spi.2002.96.2.0162
   Hacein-Bey L, 2014, CLIN NEUROL NEUROSUR, V121, P64, DOI 10.1016/j.clineuro.2014.01.018
   Haga S, 2011, ACTA NEUROCHIR, V153, P1641, DOI 10.1007/s00701-011-1018-1
   Holling M, 2013, NEUROSURGERY, V73, P93, DOI 10.1227/NEU.0b013e31828772a4
   Horie N, 2012, SPINE, V37, pE264, DOI 10.1097/BRS.0b013e31822ba834
   Jellema K, 2003, J NEUROL NEUROSUR PS, V74, P1438, DOI 10.1136/jnnp.74.10.1438
   Kim EH, 2011, ACTA NEUROCHIR WIEN, V153, P94
   Li ZF, 2015, CLIN NEUROL NEUROSUR, V128, P56, DOI 10.1016/j.clineuro.2014.11.002
   Misra BK, 2012, J CLIN NEUROSCI, V19, P892, DOI 10.1016/j.jocn.2011.09.020
   Narvid J, 2008, NEUROSURGERY, V62, P159, DOI 10.1227/01.NEU.0000311073.71733.C4
   Ng YP, 2013, J CLIN NEUROSCI, V20, P224, DOI 10.1016/j.jocn.2011.12.038
   Oh JK, 2011, SPINE, V36, pE1578, DOI 10.1097/BRS.0b013e318213c41e
   Raabe A, 2005, J NEUROSURG, V103, P982, DOI 10.3171/jns.2005.103.6.0982
   Raabe A, 2005, ZENTRALBL NEUROCHIR, V66, P7
   Rashad S, 2014, CLIN NEUROL NEUROSUR, V125, P81, DOI 10.1016/j.clineuro.2014.07.028
   Julian JAS, 2013, EUR SPINE J, V22, pS471, DOI 10.1007/s00586-012-2646-8
   Steinmetz MP, 2004, NEUROSURGERY, V55, P77, DOI 10.1227/01.NEU.0000126878.95006.0F
   Tacconi L, 1997, BRIT J NEUROSURG, V11, P298
   Takai K, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.12.FOCUS15574
   Wang GH, 2013, J CLIN NEUROSCI, V20, P831, DOI 10.1016/j.jocn.2012.06.014
   Westphal M, 1999, NEUROSURGERY, V45, P1314
   Westphal R, 1999, NEUROSURGERY, V45, P451
   2005, ZENTRALBL NEUROCHIR, V66, P1, DOI DOI 10.1055/S-2004-836223
   2011, ACTA NEUROCHIR WEIN, V153, P1487, DOI DOI 10.1007/S00701-011-1046-X
   2004, NEUROSURGERY, V55, P77, DOI DOI 10.1227/01.NEU.0000126878.95006.0F
NR 28
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E67
EP E73
DI 10.1016/j.wneu.2018.12.190
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700011
PM 30659976
DA 2020-05-12
ER

PT J
AU Timmer, M
   Seibl-Leven, M
   Wittenstein, K
   Grau, S
   Stavrinou, P
   Rohm, G
   Krischek, B
   Goldbrunner, R
AF Timmer, Marco
   Seibl-Leven, Matthias
   Wittenstein, Klaus
   Grau, Stefan
   Stavrinou, Pantelis
   Roehm, Gabriele
   Krischek, Boris
   Goldbrunner, Roland
TI Long-Term Outcome and Health-Related Quality of Life of Elderly Patients
   After Meningioma Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Age; Elderly; HRQOL; Meningioma; Outcome; Quality of life; SF-36;
   Surgery
ID INTRACRANIAL MENINGIOMAS; RESECTION
AB OBJECTIVE: The incidence of meningiomas increases with increasing age. Because the median age for the diagnosis is 65 years, the patients' general health condition, comorbidities, and procedural risks will influence the postoperative functional outcomes. The aim of our study was to assess the long-term impairments of health-related quality of life (HRQOL) after meningioma resection in different age groups of elderly patients.
   METHODS: We analyzed the HRQOL of 133 patients aged >54 years at surgery who had undergone surgical meningioma resection from 2004 to 2010. The median age was 67.3 +/- 7.4 years. The average interval between surgery and questionnaire completion was 3.8 +/- 2.5 years. Six different 5-year age groups were established. The patients completed the Medical Outcomes Study short-form 36-item questionnaire, and the results were compared with general population values. The Kruskal-Wallis test and Mann-Whitney U test were used for statistical analysis.
   RESULTS: We found significantly lower levels of physical function, vitality, social role functioning, mental health, and general health perception and significantly greater levels of pain between the older age groups (in particular, 75-79 years) and younger patients aged 55-59 years. The physical component summary showed a steadily and stepwise decline from younger to older patients. However, the most significant differences in HRQOL were not related to age but to comorbidities.
   CONCLUSION: Our findings suggest that Karnofsky performance scale and American Society of Anesthesiologists scores have a strong effect on long-term HRQOL, especially for older patients after meningioma resection. These data should be a substantial consideration in the preoperative decision-making process.
C1 [Timmer, Marco; Seibl-Leven, Matthias; Wittenstein, Klaus; Grau, Stefan; Stavrinou, Pantelis; Roehm, Gabriele; Krischek, Boris; Goldbrunner, Roland] Univ Hosp Cologne, Ctr Neurosurg, Dept Gen Neurosurg, Cologne, Germany.
RP Timmer, M (reprint author), Univ Hosp Cologne, Ctr Neurosurg, Dept Gen Neurosurg, Cologne, Germany.
EM marco.timmer@uk-koeln.de
OI Grau, Stefan/0000-0002-9742-527X
CR Abel TJ, 2017, J NEUROSURG, V127, P1467, DOI 10.3171/2017.4.JNS17740
   ARIENTA C, 1990, ACTA NEUROCHIR, V107, P47, DOI 10.1007/BF01402612
   Arienta C, 1992, Aging (Milano), V4, P29
   BARBARO NM, 1987, NEUROSURGERY, V20, P525, DOI 10.1227/00006123-198704000-00003
   Benz LS, 2018, CANCER-AM CANCER SOC, V124, P161, DOI 10.1002/cncr.30975
   Black P, 1998, ACTA NEUROCHIR, V140, P1013, DOI 10.1007/s007010050209
   Cohen-Inbar O, 2011, ACTA NEUROCHIR, V153, P1501, DOI 10.1007/s00701-011-1034-1
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   GOLDSMITH BJ, 1994, J NEUROSURG, V80, P195, DOI 10.3171/jns.1994.80.2.0195
   Grossman R, 2011, WORLD NEUROSURG, V75, P279, DOI 10.1016/j.wneu.2010.09.003
   Ikawa F, 2017, NEUROL MED-CHIR, V57, P521, DOI 10.2176/nmc.ra.2017-0011
   Kim SR, 2017, WORLD NEUROSURG, V98, P50, DOI 10.1016/j.wneu.2016.10.085
   Konglund A, 2013, ACTA NEUROL SCAND, V127, P161, DOI 10.1111/j.1600-0404.2012.01692.x
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   Louis D.N., 2000, PATHOLOGY GENETICS T, P176
   MASTRONARDI L, 1995, NEUROSURGERY, V36, P270, DOI 10.1227/00006123-199502000-00005
   MCGRAIL KM, 1994, SURG NEUROL, V42, P2, DOI 10.1016/0090-3019(94)90241-0
   Miao YF, 2010, J CLIN NEUROSCI, V17, P446, DOI 10.1016/j.jocn.2009.07.111
   Mohsenipour I, 2001, ACTA NEUROCHIR, V143, P547, DOI 10.1007/s007010170059
   Patil CG, 2010, J NEUROL NEUROSUR PS, V81, P502, DOI 10.1136/jnnp.2009.185074
   Pintea B, 2018, CLIN NEUROL NEUROSUR, V166, P36, DOI 10.1016/j.clineuro.2018.01.016
   Pompili A, 1997, Minerva Med, V88, P229
   Poon MTC, 2014, BRIT J NEUROSURG, V28, P303, DOI 10.3109/02688697.2013.841857
   Proust F, 1997, NEUROCHIRURGIE, V43, P15
   Saraf S, 2011, ONCOLOGIST, V16, P1604, DOI 10.1634/theoncologist.2011-0193
   Schul DB, 2012, NEUROSURGERY, V70, P555, DOI 10.1227/NEU.0b013e318233a99a
   Tanti MJ, 2017, ACTA NEUROL SCAND, V136, P246, DOI 10.1111/ane.12711
   van Nieuwenhuizen D, 2007, J NEURO-ONCOL, V84, P271, DOI 10.1007/s11060-007-9366-7
   Vogelbaum MA, 2010, J NEURO-ONCOL, V99, P417, DOI 10.1007/s11060-010-0375-6
   Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3
   Wu A, 2018, WORLD NEUROSURG, V111, pE142, DOI 10.1016/j.wneu.2017.12.012
   Zhao XC, 2018, J CLIN NEUROSCI, V56, P143, DOI 10.1016/j.jocn.2018.06.011
   2017, ACTA NEUROCHIR WIEN, V159, P2149, DOI DOI 10.1007/S00701-017-3332-8
   2017, NEURO-ONCOLOGY, V19, P897, DOI DOI 10.1093/NEUONC/NOW250
   1998, ACTA NEUROCHIR WIEN, V140, P1013
   2005, NEUROSURGERY, V57, P866, DOI DOI 10.1227/01.NEU.0000179923.66729.87
NR 36
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E697
EP E710
DI 10.1016/j.wneu.2019.01.158
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700087
PM 30735873
DA 2020-05-12
ER

PT J
AU Velayutham, P
   Murthy, M
   Babu, KS
AF Velayutham, Parthiban
   Murthy, Muthukumar
   Babu, Krothapalli Srinivasa
TI Time-Dependent Bidirectional Neuroprotection by Adenosine 2A Receptor in
   Experimental Traumatic Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adenosine 2A receptor; cAMP; Glutamate; IL-1 beta; Traumatic brain
   injury
ID A(2A) RECEPTOR; PHOSPHODIESTERASE INHIBITOR; INDUCED EXCITOTOXICITY;
   ACTIVATION; NEUROINFLAMMATION; GLUTAMATE; PROTEIN; DAMAGE; ACCUMULATION;
   INFLAMMATION
AB BACKGROUND: Traumatic brain injury (TBI) results in both focal and diffuse brain pathological features that become severely exacerbated after the initial injury. Owing to this disease complexity, no effective therapeutic measure has yet been devised aimed directly at these pathological processes. We developed a clinically relevant model of TBI and tested the bidirectional neuroprotective role of adenosine 2A receptors (A2ARs) at different times.
   METHODS: Wistar rats were divided into 4 treatment groups (sham, TBI, A2AR agonist [CGS-21680], and A2AR antagonist [SCH-58261]) and 4 post-TBI intervals (15 minutes and 1, 12, and 24 hours). A2AR agonist and antagonist effects were tested by the neurological functional score (NFS) and levels of cyclic adenosine monophosphate, interleukin-1 beta, oxidative stress antioxidant markers, and caspase-3.
   RESULTS: The A2AR agonist-treated group showed significant NFS improvement at 15 minutes and 1 hour after TBI compared with the TBI group. However, no improvement was observed at 12 and 24 hours. The A2AR antagonists resulted in no NFS improvement at 15 minutes and 1 hour, and significant improvement observed at 12 and 24 hours. Significant neuroprotective effect with an A2AR agonist were observed with cyclic adenosine monophosphate, interleukin-1 beta, oxidative stress markers, catalase, and caspase-3 levels at 15 minutes and 1 hour after TBI. The A2AR antagonist showed no effect at these intervals but showed a protective effect at 12 and 24 hours after TBI.
   CONCLUSIONS: The A2AR agonist showed a beneficial neuroprotective effect at the early stages after TBI, and the A2AR antagonist showed a benefit at the later stages after TBI. These findings suggest that A2AR agonists and antagonists should be used in accordance with the point at which the TBI occurred.
C1 [Velayutham, Parthiban; Murthy, Muthukumar; Babu, Krothapalli Srinivasa] Christian Med Coll & Hosp, Dept Neurol Sci, Neurophysiol Unit, Vellore, Tamil Nadu, India.
RP Velayutham, P (reprint author), Christian Med Coll & Hosp, Dept Neurol Sci, Neurophysiol Unit, Vellore, Tamil Nadu, India.
EM parthibanus@gmail.com
OI Krothapalli, Srinivasa Babu/0000-0001-8575-3965
FU Science and Engineering Research Board, New Delhi, India
   [SERC/LS-315/2011]
FX The present study was supported by the Young Scientist Scheme (grant
   SERC/LS-315/2011) from the Science and Engineering Research Board, New
   Delhi, India.
CR Ahmad AS, 2005, PHARMACOL BIOCHEM BE, V81, P805, DOI 10.1016/j.pbb.2005.06.007
   Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011
   Block F, 2001, NEUROSCI LETT, V298, P103, DOI 10.1016/S0304-3940(00)01729-8
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999
   Chen JF, 2008, CURR PHARM DESIGN, V14, P1490, DOI 10.2174/138161208784480126
   CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006
   Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096
   Concannon CG, 2001, GENE EXPRESSION, V9, P195, DOI 10.3727/000000001783992605
   Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1
   Dai SS, 2011, REV NEUROSCIENCE, V22, P231, DOI 10.1515/RNS.2011.020
   Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010
   Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31
   Fredholm BB, 2001, PHARMACOL REV, V53, P527
   Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259
   Fredholm BB, 2005, ANNU REV PHARMACOL, V45, P385, DOI 10.1146/annurev.pharmtox.45.120403.095731
   Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241
   Hu S, 1997, NEUROCHEM INT, V30, P427, DOI 10.1016/S0197-0186(96)00078-2
   Jenner P, 2009, PARKINSONISM RELAT D, V15, P406, DOI [10.1016/j.parkreldis.2008.12.006, 10.1016/S1353-8020(09)70829-6]
   Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1
   Kabadi SV, 2015, J CEREBR BLOOD F MET, V35, P2010, DOI 10.1038/jcbfm.2015.165
   Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112
   KATO H, 1995, EUR J PHARMACOL, V272, P107, DOI 10.1016/0014-2999(94)00694-3
   Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1
   Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020
   Li Y, 2006, NEUROSCIENCE, V141, P2029, DOI 10.1016/j.neuroscience.2006.05.014
   Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014
   Manjunath S, 2009, INDIAN J PHARMACOL, V41, P97, DOI 10.4103/0253-7613.55202
   Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x
   Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101
   Nolan Y, 2003, EXP NEUROL, V184, P794, DOI 10.1016/S0014-4886(03)00301-7
   Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056
   Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002
   Popoli P, 2007, PROG NEUROBIOL, V81, P331, DOI 10.1016/j.pneurobio.2006.12.005
   Rock KL, 2008, ANNU REV PATHOL-MECH, V3, P99, DOI 10.1146/annurev.pathmechdis.3.121806.151456
   Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060
   SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255
   TANAKA M, 1994, J NEUROCHEM, V63, P266
   Tramontina F, 2002, CELL MOL NEUROBIOL, V22, P373, DOI 10.1023/A:1020732304591
   Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200
   Xu K, 2010, NEUROSCIENCE, V167, P475, DOI 10.1016/j.neuroscience.2010.02.020
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E743
EP E753
DI 10.1016/j.wneu.2019.01.164
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700092
PM 30735877
DA 2020-05-12
ER

PT J
AU Volovici, V
   Ercole, A
   Citerio, G
   Stocchetti, N
   Haitsma, IK
   Huijben, JA
   Dirven, CMF
   van der Jagt, M
   Steyerberg, EW
   Nelson, D
   Cnossen, MC
   Maas, AIR
   Polinder, S
   Menon, DK
   Lingsma, HF
AF Volovici, Victor
   Ercole, Ari
   Citerio, Giuseppe
   Stocchetti, Nino
   Haitsma, Iain K.
   Huijben, Jilske A.
   Dirven, Clemens M. F.
   van der Jagt, Mathieu
   Steyerberg, Ewout W.
   Nelson, David
   Cnossen, Maryse C.
   Maas, Andrew I. R.
   Polinder, Suzanne
   Menon, David K.
   Lingsma, Hester F.
CA CENTER-TBI Collaborators
TI Variation in Guideline Implementation and Adherence Regarding Severe
   Traumatic Brain Injury Treatment: A CENTER-TBI Survey Study in Europe
SO WORLD NEUROSURGERY
LA English
DT Article
DE CENTER-TBI; European; Guidelines; Guideline adherence; Implementation;
   Implementation barriers; Severe TBI
ID MANAGEMENT
AB OBJECTIVE: Guidelines may reduce practice variation and optimize patient care. We aimed to study differences in guideline use in the management of traumatic brain injury (TBI) patients and analyze reasons for guideline nonadherence.
   METHODS: As part of a prospective, observational, multicenter European cohort study, participants from 68 centers in 20 countries were asked to complete 72-item questionnaires regarding their management of severe TBI. Six questions with multiple sub-questions focused on guideline use and implementation.
   RESULTS: Questionnaires were completed by 65 centers. Of these, 49 (75%) reported use of the Brain Trauma Foundation guidelines for the medical management of TBI or related institutional protocols, 11 (17%) used no guidelines, and 5 used other guidelines (8%). Of 54 centers reporting use of any guidelines, 41 (75%) relied on written guidelines. Four centers of the 54 (7%) reported no formal implementation efforts. Structural attention to the guidelines during daily clinical rounds was reported by 21 centers (38%). The most often reported reasons for nonadherence were "every patient is unique" and the presence of extracranial injuries, both for centers that did and did not report the use of guidelines.
   CONCLUSIONS: There is substantial variability in the use and implementation of guidelines in neurotrauma centers in Europe. Further research is needed to strengthen the evidence underlying guidelines and to overcome implementation barriers.
C1 [Volovici, Victor; Haitsma, Iain K.; Dirven, Clemens M. F.] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands.
   [Volovici, Victor; Huijben, Jilske A.; Steyerberg, Ewout W.; Cnossen, Maryse C.; Polinder, Suzanne; Lingsma, Hester F.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands.
   [van der Jagt, Mathieu] Erasmus MC, Dept Intens Care Adults, Rotterdam, Netherlands.
   [Ercole, Ari; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge, England.
   [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy.
   [Citerio, Giuseppe] San Gerardo Hosp, ASST Monza, Neurointens Care Unit, Monza, Italy.
   [Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplants, Milan, Italy.
   [Stocchetti, Nino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Anesthesia & Crit Care, Neurosci Intens Care Unit, Milan, Italy.
   [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands.
   [Nelson, David] Karolinska Inst, Sect Perioperat Med & Intens Care, Dept Physiol & Pharmacol, Stockholm, Sweden.
   [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium.
   [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium.
RP Volovici, V (reprint author), Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands.; Volovici, V (reprint author), Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands.
EM v.volovici@erasmusmc.nl
RI Maas, Andrew/C-5584-2013; Ercole, Ari/B-6288-2009; Citerio,
   Giuseppe/B-1839-2015
OI Maas, Andrew/0000-0003-1612-1264; Ercole, Ari/0000-0001-8350-8093;
   Citerio, Giuseppe/0000-0002-5374-3161; Rossi,
   Sandra/0000-0002-9963-8121; Huijben, Jilske
   (Antonia)/0000-0002-2892-5406
FU European Commission, Seventh Framework ProgrammeEuropean Union (EU)
   [602150]
FX All authors report funding from the European Commission, Seventh
   Framework Programme, grant number 602150.
CR Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998
   Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Cnossen M.C., 2016, J NEUROTRAUMA, pprint
   Cnossen MC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1816-9
   Cnossen MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161367
   Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060
   Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21
   Huijben JA, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2000-6
   Lyseng-Williamson KA, 2011, DRUGS, V71, P489, DOI 10.2165/11204490-000000000-00000
   Shafi S, 2014, J NEUROSURG, V120, P773, DOI 10.3171/2013.12.JNS132151
   Thomas L., 1999, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000349, DOI 10.1002/14651858.CD000349]
   Torbic H, 2013, AM J HEALTH-SYST PH, V70, P759, DOI 10.2146/ajhp120203
   Volovici V, 2017, NEUROSURGERY, V81, pE21, DOI 10.1093/neuros/nyx183
   2007, J TRAUMA, V63, P841, DOI DOI 10.1097/TA.0B013E318123FC21
NR 15
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E515
EP E520
DI 10.1016/j.wneu.2019.01.116
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700068
PM 30710717
DA 2020-05-12
ER

PT J
AU Wang, JF
   Che, FY
   Zhang, JL
   Zhang, M
   Xiao, S
   Liu, Y
   Zhou, LJ
   Su, QP
   You, CP
   Lu, YC
   Heng, XY
AF Wang, Jinfeng
   Che, Fengyuan
   Zhang, Jinling
   Zhang, Ming
   Xiao, Shuai
   Liu, Yan
   Zhou, Liangjian
   Su, Quanping
   You, Cuiping
   Lu, Yucheng
   Heng, Xueyuan
TI Diagnostic and Prognostic Potential of Serum Cell-Free microRNA-214 in
   Glioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cell-free miR-214; Circulating miRNAs; Glioma; Noninvasive diagnosis;
   Prognostic factor
ID CENTRAL-NERVOUS-SYSTEM; DOWN-REGULATION; BIOMARKER; CANCER;
   GLIOBLASTOMA; TUMORS
AB OBJECTIVE: We aimed to expound feasibility of serum cell-free microRNA-214 (miR-214) as a noninvasive biomarker for glioma in this study.
   PATIENTS AND METHODS: We detected expression of miR-214 in medium from 2 glioma cell lines to confirm whether it is secretory in screening phase. Then, we verified cell-free miR-214 expression in serum samples from an independent set of 100 preoperative patients with glioma, 30 matching postoperative patients, and 100 healthy controls.
   RESULTS: MiR-214 was secreted from glioma cell lines. Extracellular miR-214 levels were significantly overexpressed in preoperative serum from glioma patients with glioma, whereas its expression significantly decreased in matched postoperative serum. Upregulated cell-free miR-214 in serum was significantly associated with higher tumor grade, absence of isocitrate dehydrogenase, and unmethylated methylguanine methyltransferase promoter. Extracellular miR-214 in serum could effectively distinguish patients with glioma from healthy control (area under the curve = 0.885; 95% confidence interval, 0.833-0.926). Moreover, serum cell-free miR-214 was an independent prognostic indicator of overall survival for patients with glioma.
   CONCLUSIONS: Serum cell-free miR-214 could serve as a promising noninvasive biomarker of glioma in tumor stratification, early diagnosis, and prognostic evaluation.
C1 [Wang, Jinfeng] Shandong Univ, Linyi Peoples Hosp, Dept Clin Lab, Linyi, Shandong, Peoples R China.
   [Che, Fengyuan; Zhang, Ming] Shandong Univ, Linyi Peoples Hosp, Dept Neurol, Linyi, Shandong, Peoples R China.
   [Heng, Xueyuan] Shandong Univ, Linyi Peoples Hosp, Dept Neurosurg, Linyi, Shandong, Peoples R China.
   [Wang, Jinfeng; Che, Fengyuan; Su, Quanping; You, Cuiping; Lu, Yucheng] Shandong Univ, Linyi Peoples Hosp, Cent Lab, Linyi, Shandong, Peoples R China.
   [Zhang, Jinling; Xiao, Shuai; Liu, Yan; Zhou, Liangjian] Shandong Univ, Linyi Peoples Hosp, Canc Ctr & Steering Comm, Linyi, Shandong, Peoples R China.
   [Zhang, Ming] Shandong Med Coll, Affiliated Hosp, Dept Neurol, Linyi, Shandong, Peoples R China.
RP Che, FY (reprint author), Shandong Univ, Linyi Peoples Hosp, Dept Neurol, Linyi, Shandong, Peoples R China.; Che, FY (reprint author), Shandong Univ, Linyi Peoples Hosp, Cent Lab, Linyi, Shandong, Peoples R China.
EM che1971@126.com
OI Wang, Jinfeng/0000-0002-4454-8997
FU Key Research and Development Program of Linyi City, Shandong Province,
   China [2016ZK001]; Medicine and Health Science Technology Development
   Plan of Shandong Province, China [2017WS323]
FX This work was supported by the Key Research and Development Program of
   Linyi City, Shandong Province, China (grant number 2016ZK001) and the
   Medicine and Health Science Technology Development Plan of Shandong
   Province, China (grant number 2017WS323).
CR Chen TS, 2010, NUCLEIC ACIDS RES, V38, P215, DOI 10.1093/nar/gkp857
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Chen X, 2011, MICRORNAS IN CANCER TRANSLATIONAL RESEARCH, P499, DOI 10.1007/978-94-007-0298-1_21
   Chi KR, 2016, NATURE, V532, P269, DOI 10.1038/532269a
   Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76
   Cuddapah VA, 2014, NAT REV NEUROSCI, V15, P455, DOI 10.1038/nrn3765
   Hu J, 2014, INT J CANCER, V135, P1187, DOI 10.1002/ijc.28757
   Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165
   Im H, 2014, NAT BIOTECHNOL, V32, P490, DOI 10.1038/nbt.2886
   Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6
   Lai NS, 2015, BRIT J CANCER, V112, P1241, DOI 10.1038/bjc.2015.91
   Lan FM, 2018, CELL ONCOL, V41, P25, DOI 10.1007/s13402-017-0355-3
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Ruopp MD, 2008, BIOMETRICAL J, V50, P419, DOI 10.1002/bimj.200710415
   Schwarzenbach H, 2012, BREAST CANCER RES TR, V134, P933, DOI 10.1007/s10549-012-1988-6
   Seliger C, 2019, INT J CANCER, V144, P273, DOI 10.1002/ijc.31783
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Turner KL, 2014, GLIA, V62, P971, DOI 10.1002/glia.22655
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Wang JF, 2015, J SURG ONCOL, V111, P992, DOI 10.1002/jso.23937
   Wang JF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118086
   Wei XT, 2016, MOL NEUROBIOL, V53, P163, DOI 10.1007/s12035-014-8993-1
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Westphal M, 2015, NAT REV NEUROL, V11, P556, DOI 10.1038/nrneurol.2015.171
   Yue X, 2016, J NEUROSURG, V124, P122, DOI 10.3171/2015.1.JNS141577
   Zhao ZQ, 2012, BMB REP, V45, P641, DOI 10.5483/BMBRep.2012.45.11.097
   Zhi F, 2015, NEURO-ONCOLOGY, V17, P383, DOI 10.1093/neuonc/nou169
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1217
EP E1225
DI 10.1016/j.wneu.2019.02.009
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700151
PM 30794970
DA 2020-05-12
ER

PT J
AU Wang, K
   Ma, XJ
   Hao, SY
   Du, J
   Zhang, LW
   Zhang, JT
   Wu, Z
AF Wang, Ke
   Ma, Xiu-Jian
   Hao, Shu-Yu
   Du, Jiang
   Zhang, Li-Wei
   Zhang, Jun-Ting
   Wu, Zhen
TI Skull Base Juvenile Psammomatoid Ossifying Fibroma: Clinical
   Characteristics, Treatment, and Prognosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clinical; JPOF; Juvenile psammomatoid ossifying fibroma; Skull base
ID ENDOSCOPIC RESECTION
AB OBJECTIVE: The diagnosis and management for juvenile psammomatoid ossifying fibroma (JPOF) of the skull base are challenging, and clinical data are limited.
   METHODS: A retrospective review of JPOF was performed, and the clinical characteristics, treatment strategy, and prognosis were analyzed.
   RESULTS: There were 23 patients pathologically confirmed with JPOF, most with JPOF located in the skull base area (19/23, 82.6%). Of those tumors, 43.5% presented with dura matter breakthrough. Most of the chief complaints were headache (n = 8, 34.8%) and visual impairment (n = 5, 21.7%). Most of the tumors were solid tumors with spherical appearance, frequently accompanied by cysts of various size (n = 14, 60.9%). Craniotomy, mostly via the frontal approach, was the most common approach in the present series, comprising 73.6% (17/23) of all cases. The endoscopic endonasal approach was performed in 6 cases (26.1%). In total, 62.5% of patients (15/23) underwent gross total resection, 8.7% of patients (2/23) underwent subtotal resection, and 26.1% of patients (6/23) underwent partial resection. After a mean follow up of 66.1 +/- 36.1 months (range, 3-124), 3 patients (13.6%) suffered from tumor recurrence with a mean recurrence time of 13 months.
   CONCLUSIONS: The present series of skull base JPOFs showed that radical surgery combined with skull base reconstruction contributed to overall good prognosis. Further studies are needed to evaluate the long-term outcomes and to characterize its pathologic characteristics.
C1 [Wang, Ke; Ma, Xiu-Jian; Hao, Shu-Yu; Zhang, Li-Wei; Zhang, Jun-Ting; Wu, Zhen] Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Wang, Ke; Ma, Xiu-Jian; Hao, Shu-Yu; Zhang, Li-Wei; Zhang, Jun-Ting; Wu, Zhen] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Du, Jiang] Beijing Neurosurg Inst, Dept Neuropathol, Beijing, Peoples R China.
RP Wu, Z (reprint author), Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Wu, Z (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
EM wuzhen1966@aliyun.com
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [814742370, 81672506]; Special Fund for The Talents of Beijing
   [2016000021469G212]
FX This work was supported in part by the Natural Science Foundation of
   China (814742370 to Dr. J-T. Zhang and 81672506 to Dr. Wu) and the
   Special Fund for The Talents of Beijing (2016000021469G212 to Dr. Wang).
CR Apiani MC, 2015, ACTA OTORHINOLARYNGO, V35, P355, DOI 10.14639/0392-100X-533
   Ariyasathitman S, 2012, AURIS NASUS LARYNX, V39, P314, DOI 10.1016/j.anl.2011.07.019
   Chang CC, 2008, J FORMOS MED ASSOC, V107, P288, DOI 10.1016/S0929-6646(08)60089-3
   El-Mofty S, 2002, ORAL SURG ORAL MED O, V93, P296, DOI 10.1067/moe.2002.121545
   Foss RD, 2007, HEAD NECK PATHOL, V1, P33, DOI 10.1007/s12105-007-0001-x
   Hanna E, 2009, ARCH OTOLARYNGOL, V135, P1219, DOI 10.1001/archoto.2009.173
   Kawaguchi M, 2018, DENTOMAXILLOFAC RAD, V47, DOI 10.1259/dmfr.20180085
   Manes RP, 2013, INT FORUM ALLERGY RH, V3, P161, DOI 10.1002/alr.21067
   Owosho AA, 2014, OR SURG OR MED OR PA, V118, P734, DOI 10.1016/j.oooo.2014.09.010
   Rowland NC, 2013, J NEUROSURG-PEDIATR, V11, P687, DOI 10.3171/2013.2.PEDS12253
   Salina Andrea Carolina Inacio, 2017, Radiol Case Rep, V12, P313, DOI 10.1016/j.radcr.2017.03.019
   Sarode SC, 2011, ORAL ONCOL, V47, P1110, DOI 10.1016/j.oraloncology.2011.06.513
   Urs AB, 2013, ANN DIAGN PATHOL, V17, P198, DOI 10.1016/j.anndiagpath.2012.06.003
   Wang H, 2014, EUR ARCH OTO-RHINO-L, V271, P2975, DOI 10.1007/s00405-014-2972-z
   Wang K, 2015, CLIN NEUROL NEUROSUR, V130, P20, DOI 10.1016/j.clineuro.2014.12.016
   Zhou QY, 2017, WORLD NEUROSURG, V101, P390, DOI 10.1016/j.wneu.2017.01.119
   2016, J NEUROSURG PEDIAT, V17, P318, DOI DOI 10.3171/2015.7.PEDS1521
NR 17
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E843
EP E848
DI 10.1016/j.wneu.2019.01.197
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700104
PM 30743026
DA 2020-05-12
ER

PT J
AU Wang, K
   Zhang, ZJ
   Chen, JX
   Wu, AM
   Wang, XY
   Sheng, SR
AF Wang, Ke
   Zhang, Zeng-Jie
   Chen, Jiao-Xiang
   Wu, Ai-Min
   Wang, Xiang-Yang
   Sheng, Sun-Ren
TI Design and Application of Individualized, 3-Dimensional-Printed
   Navigation Template for Placing Cortical Bone Trajectory Screws in
   Middle-Upper Thoracic Spine: Cadaver Research Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cadaver research; Cortical bone trajectory screw; Individualized 3D
   navigation template; Middle-upper thoracic spine
ID PEDICLE SCREW; ENTRY POINT; PLACEMENT; FIXATION; INSTRUMENTATION;
   SCOLIOSIS; PATIENT; RECONSTRUCTION; COMPLICATIONS; FUSION
AB OBJECTIVE: To evaluate the safety and accuracy of use of a 3-dimensional printed navigation template in the placement of a cortical bone trajectory (CBT) screw in the middle-upper thoracic spine.
   METHODS: Ten human cadavers were included in the study. Sixty CBT screws were placed on 1 side, using the free-hand technique, and 60 CBT screws were placed on the other side, using the navigation template that was designed and printed using data from 10 cadavers. The safety and accuracy of use of the CBT screws were directly evaluated by radiography and computed tomography.
   RESULTS: Computed tomography revealed that 2 and 3 of 60 screws, placed using the navigation template, were broken in the medial or lateral areas and in the superior or inferior pedicle wall, respectively. Furthermore, 8 screws were broken in the medial or lateral areas and 11 screws were broken in the superior or inferior pedicle wall when the free-hand technique was used. Radiography revealed that 3 screws in zone I, 55 screws in zone II, and 2 screws in zone III were placed using the navigation template. Furthermore, 7 screws in zone I, 45 screws in zone II, and 8 screws in zone III were placed using the free-hand technique.
   CONCLUSIONS: In this cadaver study, insertion of the CBT screws in the middle-upper thoracic spine with the assistance of the navigation template was safe and convenient.
C1 [Sheng, Sun-Ren] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.
   Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
RP Sheng, SR (reprint author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.
EM shengsunren82330@126.com
CR Chung KJ, 2008, INT ORTHOP, V32, P657, DOI 10.1007/s00264-007-0363-4
   Di Silvestre M, 2007, SPINE, V32, P1655, DOI 10.1097/BRS.0b013e318074d604
   ESSES SI, 1993, SPINE, V18, P2231, DOI 10.1097/00007632-199311000-00015
   Garg B, 2019, SPINE J, V19, P56, DOI 10.1016/j.spinee.2018.05.001
   Hardin Carolyn A, 2013, Asian J Neurosurg, V8, P153, DOI 10.4103/1793-5482.121687
   Hyun SJ, 2015, J KOREAN NEUROSURG S, V58, P9, DOI 10.3340/jkns.2015.58.1.9
   Jeong HS, 2014, ARCH ORTHOP TRAUM SU, V134, P1551, DOI 10.1007/s00402-014-2075-8
   Kim YJ, 2004, SPINE, V29, P333, DOI 10.1097/01.BRS.0000109983.12113.9B
   Li JM, 2014, J BIOMED RES, V28, P64, DOI [10.7555/JBR.27.20130051, 10.7555/JBR.29.20140054, 10.3969/j.issn.1671-7449.2014.01.012]
   Liang H, 2017, BONE JOINT J, V99B, P267, DOI [10.1302/0301-620X.99B2.BJJ-2016-0654.R2, 10.1302/0301-620X.99B2.BJJ-2016-0654.R1]
   Lim CGT, 2014, CRANIOMAX TRAUM REC, V7, P143, DOI 10.1055/s-0034-1371080
   Lu S, 2009, SPINE, V34, pE959, DOI 10.1097/BRS.0b013e3181c09985
   Lu S, 2009, INT J MED ROBOT COMP, V5, P184, DOI 10.1002/rcs.249
   Matsukawa K, 2017, CLIN SPINE SURG, V30, pE497, DOI 10.1097/BSD.0000000000000130
   Matsukawa K, 2014, J NEUROSURG-SPINE, V21, P203, DOI 10.3171/2014.3.SPINE13665
   Matsukawa K, 2014, SPINE, V39, pE240, DOI 10.1097/BRS.0000000000000116
   Matsukawa K, 2013, J SPINAL DISORD TECH, V26, pE248, DOI 10.1097/BSD.0b013e318288ac39
   Mizuno M, 2014, NEUROL MED-CHIR, V54, P716, DOI 10.2176/nmc.st.2013-0395
   Mizutani J, 2008, EUR SPINE J, V17, P644, DOI 10.1007/s00586-008-0611-3
   Mobbs RJ, 2013, ORTHOP SURG, V5, P56, DOI 10.1111/os.12027
   Perez-Orribo L, 2013, SPINE, V38, P635, DOI 10.1097/BRS.0b013e318279a95e
   Ponnusamy KE, 2011, SPINE J, V11, P54, DOI 10.1016/j.spinee.2010.09.024
   Qi DB, 2014, SPINE, V39, pE980, DOI 10.1097/BRS.0000000000000398
   Rajasekaran S, 2007, SPINE, V32, pE56, DOI 10.1097/01.brs.0000252094.64857.ab
   Rodriguez A, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13521
   ROYCAMILLE R, 1986, ORTHOP CLIN N AM, V17, P147
   Sheng SR, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004676
   SKINNER R, 1990, SPINE, V15, P195, DOI 10.1097/00007632-199003000-00007
   Sugawara T, 2013, J NEUROSURG-SPINE, V19, P185, DOI 10.3171/2013.4.SPINE121059
   Ueno M, 2013, J NEUROSURG-SPINE, V19, P600, DOI 10.3171/2013.7.SPINE13191
   Viau M, 2002, J SPINAL DISORD TECH, V15, P450, DOI 10.1097/00024720-200212000-00002
   Villard J, 2014, SPINE, V39, P1004, DOI 10.1097/BRS.0000000000000351
   Wang X, 2017, INDIAN J ORTHOP, V51, P468, DOI 10.4103/0019-5413.209955
   Watanabe K, 2010, J NEUROSURG-SPINE, V13, P246, DOI 10.3171/2010.3.SPINE09497
   Xu RM, 1998, SPINE, V23, P1065, DOI 10.1097/00007632-199805010-00021
NR 35
TC 2
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E348
EP E352
DI 10.1016/j.wneu.2019.01.076
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700045
PM 30703596
OA Bronze
DA 2020-05-12
ER

PT J
AU Wong, H
   Banfield, J
   Hughes, N
   Shankar, JJS
AF Wong, Helen
   Banfield, Jillian
   Hughes, Nicole
   Shankar, Jai Jai Shiva
TI Are Anterior Communicating Aneurysms Truly Anterior Communicating
   Aneurysms? An Observational Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior communicating aneurysm; Subarachnoid hemorrhages
ID ARTERY ANEURYSMS; ENDOVASCULAR TREATMENT; RUPTURE; RISK
AB OBJECTIVE: The term anterior communicating (ACom) aneurysm is often broadly used to classify any aneurysm formed on the A1-A2 junction, A1, A2, or ACom arteries. Aneurysm location has been associated with rupture risk, so whether an aneurysm is truly formed on the ACom artery can critically affect treatment decisions. The aim of this study was to reclassify broadly termed ACom aneurysms into 4 subgroups (A1, A2, true ACom, and A1-A2 junction) based on their location.
   METHODS: A retrospective, pilot study was conducted to identify all consecutive patients with ACom aneurysm managed over the past 4 years in a single center. Using computed tomography angiography, aneurysms were classified into 1 of the 4 subgroups. Additional information was collected on patient demographics, subarachnoid hemorrhages, projections of aneurysm dome, and aneurysm diameter.
   RESULTS: A total of 48 aneurysms with available computed tomography angiography imaging were included in the final analysis. The reclassification of ACom aneurysms into subgroups resulted in 40 A1-A2 junction, 6 true ACom, 2 A2, and zero A1 aneurysms. A total of 100% versus 80% of true ACom and A1-A2 junction aneurysms ruptured, respectively. All elective coiling procedures were performed on unruptured A1-A2 junction aneurysms.
   CONCLUSIONS: We found only 13% of the aneurysms initially referred to as ACom to be true ACom aneurysms. A more nuanced approach to ACom aneurysm classification may better guide management strategies.
C1 [Wong, Helen; Banfield, Jillian; Hughes, Nicole; Shankar, Jai Jai Shiva] Dalhousie Univ, Dept Diagnost Radiol, Halifax, NS, Canada.
   [Shankar, Jai Jai Shiva] Univ Manitoba, Dept Radiol, Winnipeg, MB, Canada.
RP Shankar, JJS (reprint author), Dalhousie Univ, Dept Diagnost Radiol, Halifax, NS, Canada.; Shankar, JJS (reprint author), Univ Manitoba, Dept Radiol, Winnipeg, MB, Canada.
EM shivajai1@gmail.com
OI Shankar, Jai/0000-0002-3707-9723
CR Agrawal A, 2008, MINIM INVAS NEUROSUR, V51, P131, DOI 10.1055/s-2008-1073169
   Ahmed O, 2015, NEURORADIOL J, V28, P389, DOI 10.1177/1971400915594503
   Asif KS, 2016, INTERV NEUROL, V5, P57, DOI 10.1159/000444662
   Baharoglu MI, 2012, J NEUROSURG, V116, P871, DOI 10.3171/2011.11.JNS11311
   Bijlenga P, 2013, STROKE, V44, P3018, DOI 10.1161/STROKEAHA.113.001667
   Cai W, 2018, WORLD NEUROSURG, V109, P119, DOI 10.1016/j.wneu.2017.09.118
   Foutrakis GN, 1999, AM J NEURORADIOL, V20, P1309
   Lauric A, 2014, J NEUROINTERV SURG, V6, P733, DOI 10.1136/neurintsurg-2013-010987
   Matsukawa H, 2013, J NEUROSURG, V118, P978, DOI 10.3171/2012.11.JNS121210
   Mitsos AP, 2013, NEURORADIOL J, V26, P71, DOI 10.1177/197140091302600112
   Moon K, 2015, NEUROSURGERY, V77, P566, DOI 10.1227/NEU.0000000000000878
   Proust F, 2003, J NEUROSURG, V99, P3, DOI 10.3171/jns.2003.99.1.0003
   Rinaldo L, 2017, WORLD NEUROSURG, V108, P662, DOI 10.1016/j.wneu.2017.09.092
   Shao XT, 2016, CLIN NEUROL NEUROSUR, V143, P99, DOI 10.1016/j.clineuro.2016.02.023
   UJIIE H, 1993, STROKE, V24, P1850, DOI 10.1161/01.STR.24.12.1850
   VANDERARK GD, 1970, J NEUROSURG, V32, P300, DOI 10.3171/jns.1970.32.3.0300
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   YASARGIL MG, 1975, ADV TECHNICAL STANDA, V2, P113
NR 18
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1089
EP E1092
DI 10.1016/j.wneu.2019.01.249
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700136
PM 30790745
DA 2020-05-12
ER

PT J
AU Wright, JM
   Raghavan, A
   Wright, CH
   Alonso, A
   Momotaz, H
   Sweet, J
   Sajatovic, M
   Selman, W
AF Wright, James M.
   Raghavan, Alankrita
   Wright, Christina Huang
   Alonso, Andrea
   Momotaz, Hasina
   Sweet, Jennifer
   Sajatovic, Martha
   Selman, Warren
TI Impact of Dual-Layer Duraplasty During Hemicraniectomy on Morbidity and
   Operative Metrics of Cranioplasty: A Retrospective Case-Control Study
   Comparing a Single-Layer with a Dual-Layer Technique
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood loss; Cranioplasty; Duraplasty; Hemicraniectomy; Operative time;
   Reoperation
ID ADHESION PREVENTIVE MATERIAL; DECOMPRESSIVE CRANIECTOMY; DURAL
   SUBSTITUTE; COLLAGEN MATRIX; POLYTETRAFLUOROETHYLENE; COMPLICATIONS;
   SAFETY
AB BACKGROUND: Dural substitutes used during hemicraniectomy provide a barrier and dissection plane during subsequent cranioplasty. A recent review by our group showed that use of dural substitutes in hemicraniectomy is associated with reduction in estimated blood loss (EBL) and operative time (OT). In our experience, the use of a dual-layer technique facilitates a dissection plane with minimal adhesions. We hypothesized that use of this dual-layer technique would show decreased OT and EBL in patients undergoing cranioplasty.
   METHODS: We conducted a retrospective case-control study comparing use of single-layer versus dual-layer duraplasty on cranioplasty operative outcomes. Data on dual-layer cases were collected from patients who underwent cranioplasty from 2013 to 2017. These data were matched to controls from 2008 to 2012. Patients were identified by query of a neurosurgical database of all procedures performed at our institution. Patients were included if they had complete surgical records for cranioplasty. Cases and controls were compared with a Student t test, chi(2) test, or Fisher exact test.
   RESULTS: A total of 78 controls and 45 cases met inclusion criteria. All baseline characteristics between cohorts were similar except for surgical indication. Mean OT (102.97 minutes vs. 102.18 minutes) and mean EBL were not significantly different (204.66 mL vs. 190 mL) between cohorts.
   CONCLUSIONS: In this study, we did not detect any significant difference between EBL and OT with use of single-layer versus dual-layer duraplasty. Mean EBL was slightly higher in the controls compared with cases but this difference was not statistically or clinically significant. This concept would benefit from a prospective randomized study.
C1 [Wright, James M.; Wright, Christina Huang; Sweet, Jennifer; Selman, Warren] Univ Hosp Cleveland, Med Ctr, Dept Neurol Surg, Cleveland, OH 44106 USA.
   [Momotaz, Hasina; Sajatovic, Martha] Univ Hosp Cleveland, Med Ctr, Neurol & Behav Outcomes Ctr, Cleveland, OH 44106 USA.
   [Sajatovic, Martha] Univ Hosp Cleveland, Med Ctr, Dept Neurol & Psychiat, Cleveland, OH 44106 USA.
   [Wright, James M.; Raghavan, Alankrita; Wright, Christina Huang; Alonso, Andrea; Momotaz, Hasina; Sweet, Jennifer; Sajatovic, Martha; Selman, Warren] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA.
RP Wright, JM (reprint author), Univ Hosp Cleveland, Med Ctr, Dept Neurol Surg, Cleveland, OH 44106 USA.; Wright, JM (reprint author), Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA.
EM James.Wright@UHHospitals.org
OI Wright, James/0000-0002-4482-7582; Wright, Christina/0000-0002-7817-0451
CR Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2
   Bender A, 2013, BRAIN INJURY, V27, P1073, DOI 10.3109/02699052.2013.794972
   Brazoloto TM, 2017, ACTA NEUROCHIR, V159, P799, DOI 10.1007/s00701-017-3137-9
   Bulters D, 2010, BRIT J NEUROSURG, V24, P75, DOI 10.3109/02688690903506135
   CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5
   Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962
   Griessenauer CJ, 2015, WORLD NEUROSURG, V84, P2059, DOI 10.1016/j.wneu.2015.08.009
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Huang YH, 2011, J TRAUMA, V71, P533, DOI 10.1097/TA.0b013e318203208a
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Kamalabai RP, 2018, WORLD NEUROSURG, V111, pE105, DOI 10.1016/j.wneu.2017.12.005
   Kawaguchi T, 2003, NEUROL MED-CHIR, V43, P320, DOI 10.2176/nmc.43.320
   Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106
   Lee CH, 2007, CLIN NEUROL NEUROSUR, V109, P667, DOI 10.1016/j.clineuro.2007.05.015
   Liang ES, 2016, BRIT J NEUROSURG, V30, P122, DOI 10.3109/02688697.2015.1080216
   Missori P, 2008, SURG NEUROL, V70, P437, DOI 10.1016/j.surneu.2007.03.029
   Mumert ML, 2012, J CLIN NEUROSCI, V19, P455, DOI 10.1016/j.jocn.2011.09.004
   Oladunjoye AO, 2013, J NEUROSURG, V118, P776, DOI 10.3171/2013.1.JNS121475
   Pierson M, 2016, WORLD NEUROSURG, V86, P153, DOI 10.1016/j.wneu.2015.09.078
   Raghavan A, 2018, WORLD NEUROSURG, V119, P282, DOI 10.1016/j.wneu.2018.08.024
   Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176
   Stendel R, 2008, J NEUROSURG, V109, P215, DOI 10.3171/JNS/2008/109/8/0215
   Vakis A, 2006, CLIN NEUROL NEUROSUR, V108, P798, DOI 10.1016/j.clineuro.2005.11.026
   Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002
   Zanaty M, 2015, J NEUROSURG, V123, P182, DOI 10.3171/2014.9.JNS14405
   Zanaty Mario, 2014, ScientificWorldJournal, V2014, P356042, DOI 10.1155/2014/356042
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1189
EP E1195
DI 10.1016/j.wneu.2019.01.276
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700148
PM 30794972
DA 2020-05-12
ER

PT J
AU Wu, DF
   He, W
   Lin, S
   Han, B
   Zee, CS
AF Wu, Dong-fang
   He, Wen
   Lin, Song
   Han, Bo
   Zee, Chi-Shing
TI Using Real-Time Fusion Imaging Constructed from Contrast-Enhanced
   Ultrasonography and Magnetic Resonance Imaging for High-Grade Glioma in
   Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Contrast-enhanced ultrasonography; Enhanced T1-weighted MRI; Fusion
   imaging; High-grade glioma; Volume navigation
ID INTRAOPERATIVE ULTRASOUND; SURVIVAL; RESECTION; ANGIOGENESIS;
   GLIOBLASTOMA; SURGERY; MRI; CLASSIFICATION; PERFLUBUTANE; PATIENT
AB OBJECTIVE: To compare the observation of high-grade glioma (HGG) based on intraoperative multiplane ultrasonography (US) images and preoperative reconstructive coplanar T1-weighted enhanced magnetic resonance imaging (MRI) using volume navigation (V Nav) fusion image technology.
   METHODS: We retrospectively evaluated intraoperative data obtained from 16 patients diagnosed with HGG (grade III and IV). Overall, 18 nodules observed in 15 patients were examined. HGG images from US and contrast-enhanced US (CEUS) were compared with those from preoperative reconstructive coplanar enhanced T1-weighted MRI using automatic V Nav fusion image technology.
   RESULTS: All HGG tumors were detected. Images of 13 of 18 tumors (72.2%) with obscure margins using B-mode US were improved with clear tumor boundaries using CEUS imaging. The relative difference in tumor area between CEUS and enhanced MRI modalities in 14 mainly solid component lesions was considered statistically significant (P value < 0.05). There was a perfect correlation of the enhanced area between coplanar CEUS and enhanced MRI.
   CONCLUSIONS: The V Nav fusion image system combining intraoperative real-time US imaging with reconstructive preoperative coplanar MRI is valuable for imageguided HGG resection. It is suitable for neurosurgeons who lack the expertise in US technology to discern the brain structure and allows better recognition of tumor and edema tissues comparedwith reconstructive preoperative coplanar-enhanced MRI in real time and in multiplane from different angles. In addition, CEUS combined with B-mode US could improve tumor detection and resection control in neurosurgery, even in single US-guided operations.
C1 [Wu, Dong-fang; He, Wen] Capital Med Univ, Beijing Tiantan Hosp, Dept Ultrasound, Beijing, Peoples R China.
   [Lin, Song; Han, Bo] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Zee, Chi-Shing] Univ Southern Calif, Dept Radiol, Keck Sch Med, Los Angeles, CA USA.
RP He, W (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Ultrasound, Beijing, Peoples R China.
EM hewen168@sohu.com
CR Aizer AA, 2015, CANCER-AM CANCER SOC, V121, P4376, DOI 10.1002/cncr.29639
   Arlt F, 2016, ACTA NEUROCHIR, V158, P685, DOI 10.1007/s00701-016-2738-z
   Artzi M, 2015, J NEURO-ONCOL, V121, P349, DOI 10.1007/s11060-014-1639-3
   Beyer LP, 2017, ULTRASCHALL MED, V38, P619, DOI 10.1055/s-0043-105264
   Bonekamp D, 2015, J MAGN RESON IMAGING, V42, P87, DOI 10.1002/jmri.24756
   Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137
   Cheng LG, 2016, BIOMED RES INT, DOI 10.1155/2016/2643862
   DEAN BL, 1990, RADIOLOGY, V174, P411, DOI 10.1148/radiology.174.2.2153310
   Dohrmann GJ, 2001, NEUROSURG CLIN N AM, V12, P155, DOI 10.1016/S1042-3680(18)30074-3
   Eyupoglu IY, 2016, ONCOTARGET, V7, P25755, DOI 10.18632/oncotarget.8367
   Grabowski MM, 2014, J NEUROSURG, V121, P1115, DOI 10.3171/2014.7.JNS132449
   Guo J, 2012, ACTA NEUROCHIR, V154, P1361, DOI 10.1007/s00701-012-1418-x
   HAUGHTON VM, 1988, RADIOLOGY, V166, P829, DOI 10.1148/radiology.166.3.3340779
   Huang YH, 2013, CANCER RES, V73, P2943, DOI 10.1158/0008-5472.CAN-12-4354
   Kazmierski B, 2018, ABDOM RADIOL, V43, P880, DOI 10.1007/s00261-017-1307-0
   Lekht I, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15570
   Miyamoto Y, 2014, AM J ROENTGENOL, V202, pW400, DOI 10.2214/AJR.12.10518
   Moiyadi AV, 2016, WORLD NEUROSURG, V93, P81, DOI 10.1016/j.wneu.2016.05.083
   Moiyadi AV, 2015, ACTA NEUROCHIR, V157, P957, DOI 10.1007/s00701-015-2386-8
   Munkvold BKR, 2018, NEUROSURGERY, V83, P288, DOI 10.1093/neuros/nyx392
   Nandhu MS, 2014, CANCER RES, V74, P5435, DOI 10.1158/0008-5472.CAN-14-0685
   Numata K, 2012, EUR J RADIOL, V81, P2746, DOI 10.1016/j.ejrad.2011.11.052
   Pan IW, 2015, J CLIN NEUROSCI, V22, P1575, DOI 10.1016/j.jocn.2015.03.032
   Prada F, 2017, RADIOLOGY, V285, P242, DOI 10.1148/radiol.2017161206
   Prada F, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15573
   Prada F, 2015, WORLD NEUROSURG, V84, P1699, DOI 10.1016/j.wneu.2015.07.025
   Prada F, 2014, J ULTRASOUND, V17, P243, DOI 10.1007/s40477-014-0111-8
   Prada F, 2014, BIOMED RES INT, DOI 10.1155/2014/484261
   Ramjiawan RR, 2017, ANGIOGENESIS, V20, P185, DOI 10.1007/s10456-017-9552-y
   Ritschel K, 2015, INT J COMPUT ASS RAD, V10, P531, DOI 10.1007/s11548-014-1089-6
   ROSTOMILY RC, 1994, NEUROSURGERY, V35, P378, DOI 10.1227/00006123-199409000-00004
   Selbekk T, 2013, ACTA NEUROCHIR, V155, P973, DOI 10.1007/s00701-013-1647-7
   Steno A, 2015, CLIN NEUROL NEUROSUR, V135, P96, DOI 10.1016/j.clineuro.2015.05.012
   Stieglitz LH, 2013, NEUROSURGERY, V72, P796, DOI 10.1227/NEU.0b013e318287072d
   Van Dreden Patrick, 2017, Critical Reviews in Oncogenesis, V22, P219, DOI 10.1615/CritRevOncog.2018024859
   Zhang J, 2016, J NEUROSURG, V124, P1585, DOI 10.3171/2015.6.JNS142651
NR 36
TC 3
Z9 3
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E98
EP E109
DI 10.1016/j.wneu.2018.12.215
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700015
PM 30677585
DA 2020-05-12
ER

PT J
AU Xiong, Y
   Xu, L
   Bi, LY
   Yang, JZ
   Wang, FX
   Qu, Y
   Zhao, ZY
   Yang, YD
   Zhao, DY
   Li, CH
   Yu, X
AF Xiong, Yang
   Xu, Lin
   Bi, Lian-Yong
   Yang, Ji-Zhou
   Wang, Feng-Xian
   Qu, Yi
   Zhao, Zi-Yi
   Yang, Yong-Dong
   Zhao, Ding-Yan
   Li, Chuan-Hong
   Yu, Xing
TI Dynamic Fusion Process in the Anterior Cervical Discectomy and Fusion
   with Self-Locking Stand-Alone Cages
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACDF; Cervical spine; Classification; Fusion; Non-fusion; Self-locking
   stand-alone cage; Spine
ID PROFILE ANCHORED SPACER; INTERBODY FUSION; PEEK CAGE; PLATE; OUTCOMES;
   SPINE; DECOMPRESSION; KYPHOSIS; BONE
AB BACKGROUND: Self-locking stand-alone cages can achieve satisfactory clinical results and fusion rate. However, there have been no reports on the causes and relationship of different fusion state. This study is to classify the different fusion states of the index level and to explore the potential contributing factors and links of them.
   METHODS: From June 2008 to October 2011, 42 patients underwent anterior cervical discectomy and fusion with MC+ cages. More than 5 years' follow-up was reviewed. The fusion state and the relevant clinical and radiologic records were reviewed retrospectively.
   RESULTS: At the last follow-up, the fusion proportion of type I, II, III, and IV was 11.7%, 16.9%, 26.9%, and 42.9%, respectively. The overall fusion rate was 97.4%. For all the fused types, significant improvement for the visual analog scale, Japanese Orthopaedic Association, and Neck Disability Index scores was found at the last follow-up (P < 0.05). However, there were no significant differences between the 4 types (P > 0.05). For sagittal vertical axis, type IV was significantly larger than that of type I, II, and III (P < 0.05), and for range of motion, type III was significantly larger than that of type II and IV (P < 0.05).
   CONCLUSIONS: For anterior cervical discectomy and fusion with self-locking stand-alone cages, the fusion of the index level seems to be a progressive dynamic process during the mid-term follow-up, which may be influenced by the location of the cage, the aagittal vertical axis of the index level, and the global range of motion of the cervical spine. Satisfactory clinical results could be achieved by all the fused types.
C1 [Xiong, Yang; Xu, Lin; Bi, Lian-Yong; Yang, Ji-Zhou; Wang, Feng-Xian; Qu, Yi; Zhao, Zi-Yi; Yang, Yong-Dong; Zhao, Ding-Yan; Li, Chuan-Hong; Yu, Xing] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Orthoped, Beijing, Peoples R China.
RP Yu, X (reprint author), Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Orthoped, Beijing, Peoples R China.
EM yuxing34163@163.com
CR Abumi K, 1999, SPINE, V24, P2389, DOI 10.1097/00007632-199911150-00017
   Anderst W, 2013, SPINE, V38, pE594, DOI 10.1097/BRS.0b013e31828ca5c7
   Bai JY, 2015, INT J CLIN EXP MED, V8, P19746
   Bucci MN, 2017, MED DEVICES-EVID RES, V10, P61, DOI 10.2147/MDER.S127133
   Buttermann GR, 2018, SPINE, V43, P207, DOI 10.1097/BRS.0000000000002273
   CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36
   Chang-Jung C, 2008, SPINE, V33, P2524, DOI 10.1097/BRS.0b013e318185289c
   Chen YQ, 2016, EUR SPINE J, V25, P2255, DOI 10.1007/s00586-016-4391-x
   Choi MK, 2016, ACTA NEUROCHIR, V158, P481, DOI 10.1007/s00701-015-2692-1
   El-Tantawy Ahmad, 2015, Eur J Orthop Surg Traumatol, V25 Suppl 1, pS135, DOI 10.1007/s00590-015-1611-8
   Goffin J, 2004, J SPINAL DISORD TECH, V17, P79, DOI 10.1097/00024720-200404000-00001
   Kapetanakis Stylianos, 2017, J Spine Surg, V3, P312, DOI 10.21037/jss.2017.06.21
   Kim CH, 2015, J SPINAL DISORD TECH, V28, pE17, DOI 10.1097/BSD.0000000000000137
   Kim YS, 2018, J CLIN NEUROSCI, V47, P341, DOI 10.1016/j.jocn.2017.10.022
   Mattei TA, 2016, EUR SPINE J, DOI [10.1007/s00586-015-4358-3, DOI 10.1007/S00586-015-4358-3]
   Nambiar M, 2017, EUR SPINE J, V26, P2258, DOI 10.1007/s00586-017-5015-9
   Oh JK, 2013, J SPINAL DISORD TECH, V26, P415, DOI 10.1097/BSD.0b013e31824c7d22
   Park JY, 2016, J CLIN NEUROSCI, V33, P83, DOI 10.1016/j.jocn.2016.01.042
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Topuz K, 2009, EUR SPINE J, V18, P238, DOI 10.1007/s00586-008-0869-5
   Vavruch L, 2002, SPINE, V27, P1694, DOI 10.1097/00007632-200208150-00003
   Wang B, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2136-1
   Wang ZW, 2015, EUR SPINE J, V24, P148, DOI 10.1007/s00586-014-3628-9
   Xie YZ, 2015, INT ORTHOP, V39, P1129, DOI 10.1007/s00264-014-2610-9
   Zajonz D, 2014, PATIENT SAF SURG, V8, DOI 10.1186/s13037-014-0043-4
   Zhou J, 2017, J CLIN NEUROSCI, V43, P196, DOI 10.1016/j.jocn.2017.04.022
   Zhou JA, 2011, ACTA NEUROCHIR, V153, P115, DOI 10.1007/s00701-010-0821-4
NR 27
TC 0
Z9 0
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E678
EP E687
DI 10.1016/j.wneu.2019.01.152
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700085
PM 30735878
DA 2020-05-12
ER

PT J
AU Xu, HM
   Hu, F
   Wang, XY
   Tong, SL
AF Xu, Hong-Ming
   Hu, Fei
   Wang, Xiang-Yang
   Tong, Song-Lin
TI Relationship Between Apoptosis of Endplate Microvasculature and
   Degeneration of the Intervertebral Disk
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoptosis; Blood vessel; Endplate; Intervertebral disk degeneration;
   TUNEL
ID LOW-BACK-PAIN; CELLS; DIFFUSION
AB OBJECTIVE: To explore the relationship between intervertebral disk degeneration and endplate microvasculature, and to determine the role of apoptosis in the pathophysiology underlying end plate microvasculature.
   METHODS: Twelve 6-month-old rabbits were randomly divided into group A (control group where animals underwent a sham operation, in which the loading device was implanted but without loading) and group B (degeneration group, where a calibrated spring within the loading device would immediately create static shear force of 50 N to the disk of L4-5). Paraffin-embedded midsagittal sections of the L4-5 disk were obtained 4 weeks after surgery in the both groups. Sections were stained with cluster of differentiation (CD) 31 immunohistochemistry to measure the blood vessel density in the endplate, with CD31 immunofluorescence and terminal dUTP nick-end labeling (TUNEL) to detect the apoptosis of vascular endothelial cells in the endplate.
   RESULTS: After 4 weeks, the microvasculature density was 91 +/- 8 vessels/mm(2) in group A and 47 +/- 2 vessels/mm(2) (P < 0.001) in group B, demonstrating that vessels were reduced in the endplate of intervertebral disk degeneration. CD31 immunofluorescence and TUNEL showed that apoptosis of vascular endothelial cells exists in the endplate of intervertebral disk degeneration.
   CONCLUSIONS: The results of this study suggest that apoptosis of vascular endothelial cells results in a decrease in endplate microvasculature density, further affecting the pathologic process of intervertebral disk degeneration.
C1 [Xu, Hong-Ming; Tong, Song-Lin] Wenzhou Med Univ, Affiliated Cixi Hosp, Dept Orthopaed Surg, Ningbo, Zhejiang, Peoples R China.
   [Hu, Fei] Ningbo Univ, Sch Med, Diabet Res Ctr, Ningbo, Zhejiang, Peoples R China.
   [Wang, Xiang-Yang] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.
RP Wang, XY (reprint author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.
EM xiangyangwang@126.com
FU Medical and Health Science and Technology Program of Zhejiang Province
   [2018KY740]; Major Scientific and Technological Project of Medical and
   Health of Zhejiang Province [WKJ-ZJ-1527]; Zhejiang Public Service
   Technology Research Program/Social Development [LGF18H060008]
FX This work was supported by the Medical and Health Science and Technology
   Program of Zhejiang Province (2018KY740), Major Scientific and
   Technological Project of Medical and Health of Zhejiang Province
   (WKJ-ZJ-1527), and Zhejiang Public Service Technology Research
   Program/Social Development (LGF18H060008).
CR Adams MA, 2012, J ANAT, V221, P497, DOI 10.1111/j.1469-7580.2012.01551.x
   AOKI J, 1987, RADIOLOGY, V164, P411, DOI 10.1148/radiology.164.2.3602378
   Ariga K, 2001, SPINE, V26, P2414, DOI 10.1097/00007632-200111150-00004
   CROCK HV, 1984, SPINE, V9, P702, DOI 10.1097/00007632-198410000-00009
   ECKERT C, 1947, J BONE JOINT SURG, V29, P447
   Freburger JK, 2009, ARCH INTERN MED, V169, P251, DOI 10.1001/archinternmed.2008.543
   Gen H, 1990, Nihon Seikeigeka Gakkai Zasshi, V64, P572
   Gen H, 1990, Nihon Seikeigeka Gakkai Zasshi, V64, P560
   Gruber HE, 1998, SPINE, V23, P751, DOI 10.1097/00007632-199804010-00001
   Gruber HE, 2000, SPINE, V25, P2153, DOI 10.1097/00007632-200009010-00002
   Holm S, 2004, J SPINAL DISORD TECH, V17, P64, DOI 10.1097/00024720-200402000-00012
   Horner HA, 2001, SPINE, V26, P2543, DOI 10.1097/00007632-200112010-00006
   Lotz JC, 2013, GLOB SPINE J, V3, P153, DOI 10.1055/s-0033-1347298
   Lotz JC, 2000, SPINE, V25, P1477, DOI 10.1097/00007632-200006150-00005
   Luoma K, 2000, SPINE, V25, P487, DOI 10.1097/00007632-200002150-00016
   Marras WS, 2001, SPINE, V26, P2566, DOI 10.1097/00007632-200112010-00009
   MCFADDEN KD, 1989, SPINE, V14, P867, DOI 10.1097/00007632-198908000-00017
   NACHEMSON A, 1970, ACTA ORTHOP SCAND, V41, P589, DOI 10.3109/17453677008991550
   Nagatsuka H, 2005, J ORAL PATHOL MED, V34, P70, DOI 10.1111/j.1600-0714.2004.00227.x
   OSTI OL, 1990, SPINE, V15, P762, DOI 10.1097/00007632-199008000-00005
   Ribatti D, 2007, LEUKEMIA RES, V31, P439, DOI 10.1016/j.leukres.2006.10.014
   Rodriguez AG, 2012, J ORTHOP RES, V30, P280, DOI 10.1002/jor.21513
   Urban JPG, 2004, SPINE, V29, P2700, DOI 10.1097/01.brs.0000146499.97948.52
   URBAN JPG, 1978, BIORHEOLOGY, V15, P203
   Xia DD, 2015, EUR SPINE J, V24, P1711, DOI 10.1007/s00586-015-3816-2
   Zhao CQ, 2010, AGE, V32, P161, DOI 10.1007/s11357-009-9121-4
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E392
EP E397
DI 10.1016/j.wneu.2019.01.085
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700051
PM 30703600
DA 2020-05-12
ER

PT J
AU Xu, M
   Xu, J
   Huang, X
   Chen, DQ
   Chen, MY
   Zhong, P
AF Xu, Ming
   Xu, Jian
   Huang, Xiang
   Chen, Danqi
   Chen, Mingyu
   Zhong, Ping
TI Small Extended Bifrontal Approach for Midline Anterior Skull Base
   Meningiomas: Our Experience with 54 Consecutive Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior skull base; Olfactory groove meningioma; Planum sphenoidale
   meningioma; Surgical approach; Tuberculum sellae meningioma
ID TUBERCULUM SELLAE MENINGIOMAS; OLFACTORY GROOVE MENINGIOMAS; SUBFRONTAL
   APPROACH; INTERHEMISPHERIC APPROACH; SUBCRANIAL APPROACH; LESIONS;
   TUMORS; CLASSIFICATION; PRESERVATION; CRANIOTOMY
AB OBJECTIVE: To describe the technique of a small extended bifrontal approach and review the clinical outcome of patients with midline anterior skull base (MASB) meningiomas treated using this technique.
   METHODS: The small extended bifrontal craniotomy extends inferiorly to the nasofrontal suture without entering the orbit, superiorly 3 cm above the supraorbital rim, and laterally 3 cm to the midline on both sides. A review of a prospectively acquired database was performed of 54 consecutive patients with MASB meningiomas who underwent this craniotomy.
   RESULTS: Twenty-nine patients with olfactory groove meningiomas, 2 with planum sphenoidale meningiomas (PSMs), and 23 with tuberculum sellae meningiomas (TSMs) were treated using this technique. Gross total resection was achieved in all patients. Of 29 patients with olfactory groove meningiomas, 12 (41.4%) had normal olfaction at presentation and 8 had preservation of olfaction postoperatively. Of 25 patients with TSMs/PSMs, 23 (92.0%) had preoperative visual impairment, with 13 showing improved vision (56.5%), 8 unchanging (34.8%), and 2 deteriorating (8.7%) after surgery. The most common complications were anosmia and hyposmia, which occurred in 5 patients (20.0%) and 3 patients (12.0%) with TSMs/PSMs, respectively. No mortality was reported. There was no recurrence in all patients after a mean follow-up of 39.5 months (range, 16-64 months).
   CONCLUSIONS: The small extended bifrontal approach is a safe and effective technique for resection of MASB meningiomas, which provides adequate surgical exposure with less approach-related morbidity. It is an excellent alternative for surgeons who favor the bifrontal approach and its extended variations.
C1 [Xu, Ming; Xu, Jian; Huang, Xiang; Chen, Danqi; Chen, Mingyu; Zhong, Ping] Fudan Univ, Dept Neurosurg, Huashan Hosp, Shanghai, Peoples R China.
RP Zhong, P (reprint author), Fudan Univ, Dept Neurosurg, Huashan Hosp, Shanghai, Peoples R China.
EM zhp228899@163.com
FU Natural Science Foundation of ShanghaiNatural Science Foundation of
   Shanghai [17ZR1403800]
FX This work was sponsored by the Natural Science Foundation of Shanghai
   (grant number 17ZR1403800).
CR Arai H, 2000, ACTA NEUROCHIR, V142, P751, DOI 10.1007/s007010070089
   Barzaghi LR, 2017, WORLD NEUROSURG, V101, P315, DOI 10.1016/j.wneu.2017.02.039
   Chi JH, 2006, NEUROSURGERY, V59, P426, DOI 10.1227/01.NEU.0000223508.60923.91
   Chi John H, 2003, Neurosurg Focus, V14, pe6
   Chokyu I, 2011, J NEUROSURG, V115, P802, DOI 10.3171/2011.5.JNS101812
   DEROME P, 1972, NEUROCHIRURGIE, V18, P1
   Feiz-Erfan I, 2008, SKULL BASE-INTERD AP, V18, P29, DOI 10.1055/s-2007-994292
   Ganna A, 2009, BRIT J NEUROSURG, V23, P422, DOI 10.1080/02688690902968836
   Hallacq P, 2001, SKULL BASE-INTERD AP, V11, P35, DOI 10.1055/s-2001-12786
   Hentschel SJ, 2011, ALMEFTYS MENINGIOMAS, P196
   Hentschel Stephen J, 2003, Neurosurg Focus, V14, pe4
   Jho HD, 1997, MINIM INVAS NEUROSUR, V40, P62, DOI 10.1055/s-2008-1053418
   Kleiber JC, 2014, ACTA NEUROCHIR, V156, P2283, DOI 10.1007/s00701-014-2223-5
   Kurtsoy A, 2004, NEUROSURG REV, V27, P267, DOI 10.1007/s10143-004-0322-0
   Li MS, 2014, J NEUROSURG, V120, P315, DOI 10.3171/2013.11.JNS13552
   Liu JK, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17722
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Matano F, 2016, NEUROSURG REV, V39, P63, DOI 10.1007/s10143-015-0647-x
   Morales-Valero SF, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13569
   Nakamura M, 2008, NEUROSURGERY, V62, P1224, DOI [10.1227/01.NEU.0000255453.20602.80, 10.1227/01.neu.0000333788.83349.1e]
   Nakamura M, 2006, NEUROSURGERY, V59, P1019, DOI 10.1227/01.NEU.0000245600.92322.06
   Pallini R, 2015, WORLD NEUROSURG, V83, P219, DOI 10.1016/j.wneu.2014.11.001
   Patel K, 2016, BRIT J NEUROSURG, V30, P104, DOI 10.3109/02688697.2015.1071329
   Rachinger W, 2010, ACTA NEUROCHIR, V152, P931, DOI 10.1007/s00701-010-0646-1
   RAVEH J, 1995, J NEUROSURG, V82, P1002, DOI 10.3171/jns.1995.82.6.1002
   Reisch R, 2005, NEUROSURGERY, V57, P242, DOI 10.1227/01.NEU.0000178353.42777.2C
   Romani R, 2012, NEUROSURGERY, V70, P1504, DOI 10.1227/NEU.0b013e31824a36e8
   Romani R, 2009, NEUROSURGERY, V65, P39, DOI 10.1227/01.NEU.0000346266.69493.88
   Safaee MM, 2018, OPER NEUROSURG, V14, P386, DOI 10.1093/ons/opx134
   Sepehrnia A, 1999, NEUROSURGERY, V44, P113, DOI 10.1097/00006123-199901000-00068
   Spektor S, 2005, NEUROSURGERY, V57, P268, DOI 10.1227/01.NEU.0000176409.70668.EB
   Sughrue ME, 2011, AL MEFTYS MENINGIOMA, P206
   TERASAKA S, 2011, NEUROSURGERY S1, V68, pNIL86, DOI DOI 10.1227/NEU.0b013e31820781e1
   Wanibuchi M, 2009, PHOTOATLAS SKULL BAS, P50
   ZHOU LF, 1995, CHINESE MED J-PEKING, V108, P407
NR 35
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E35
EP E43
DI 10.1016/j.wneu.2018.12.172
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700007
PM 30639482
DA 2020-05-12
ER

PT J
AU Yan, P
   Zhang, YP
   Liang, F
   Ma, C
   Liang, SK
   Guo, F
   Jiang, CH
AF Yan, Peng
   Zhang, Yupeng
   Liang, Fei
   Ma, Chao
   Liang, Shikai
   Guo, Feng
   Jiang, Chuhan
TI Comparison of Safety and Effectiveness of Endovascular Treatments for
   Unruptured Intracranial Large or Giant Aneurysms in Internal Carotid
   Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial aneurysm; Parent artery occlusion; Pipeline embolization
   device; Stent-assisted coiling
ID PIPELINE EMBOLIZATION DEVICE; PARENT VESSEL; PARACLINOID ANEURYSMS;
   CEREBRAL ANEURYSMS; CAVERNOUS SINUS; NATURAL-HISTORY; FLOW DIVERSION;
   OCCLUSION; EXPERIENCE; PREDICTORS
AB PURPOSE: To analyze and compare safety and efficacy of different endovascular treatment modalities for unruptured intracranial large or giant aneurysms.
   METHODS: We retrospectively reviewed 126 consecutive patients with 128 large (15-24 mm) or giant (>= 25 mm) aneurysms that were treated with different endovascular procedures between January 2014 and February 2017. We compared clinical and angiographic outcomes and occurrence of technical events among 3 treatment modalities.
   RESULTS: Complete occlusion at last follow-up was achieved in 65.6%, 90.5%, and 72.0% of aneurysms in stent-assisted coiling, parent artery occlusion, and Pipeline embolization device (PED) groups (P = 0.119). Complete occlusion rate at 6-month follow-up (odds ratio = 1.81, P = 0.396) and at last angiographic follow-up (odds ratio = 3.64, P = 0.123), was not superior with parent artery occlusion compared with PED. Retreatment rate was significantly different among all groups (P < 0.001); the rate was highest in the stent-assisted coiling group (21.9%). Rates of hemorrhagic events and ischemic events were not significantly different among groups (P = 0.581). Mass effect exacerbation was more frequently seen in the stent-assisted coiling group (24.4% vs. 7.7% and 3.3%, P = 0.004). Major complication rate was higher in the parent artery occlusion group compared with the PED group, but the difference was not statistically significant (19.2% vs. 16.4%, odds ratio = 1.21, P = 0.763). Rate of technical events was significantly different in the 3 groups (P = 0.0437), and technical events occurred more often in the PED group (18.0%).
   CONCLUSIONS: For large and giant aneurysms located in the internal carotid artery, outcome for endovascular treatment remains poor, even with the introduction of PED.
C1 [Yan, Peng; Zhang, Yupeng; Liang, Fei; Ma, Chao; Guo, Feng; Jiang, Chuhan] Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.
   [Yan, Peng; Zhang, Yupeng; Liang, Fei; Ma, Chao; Guo, Feng; Jiang, Chuhan] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Liang, Shikai] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Neurosurg, Beijing, Peoples R China.
RP Jiang, CH (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.; Jiang, CH (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
EM jiangchuhan126@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81371314]; High-level Personnel Training Program of
   Beijing Health System [2013-2-016]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81371314) and High-level Personnel Training Program of
   Beijing Health System (Grant No. 2013-2-016).
CR Adeeb N, 2017, AM J NEURORADIOL, V38, P2295, DOI 10.3174/ajnr.A5375
   Bechan RS, 2016, AM J NEURORADIOL, V37, P125, DOI 10.3174/ajnr.A4487
   Becske T, 2017, J NEUROSURG, V127, P81, DOI 10.3171/2015.6.JNS15311
   Becske T, 2017, NEUROSURGERY, V80, P40, DOI 10.1093/neuros/nyw014
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Bender MT, 2019, J NEUROSURG, V130, P259, DOI 10.3171/2017.11.JNS171738
   Cagnazzo F, 2018, AM J NEURORADIOL, V39, P852, DOI 10.3174/ajnr.A5591
   Clarencon F, 2011, NEURORADIOLOGY, V53, P973, DOI 10.1007/s00234-010-0800-8
   Colby GP, 2018, J NEUROSURG, V129, P1475, DOI 10.3171/2017.7.JNS171289
   D'Urso PI, 2012, AM J NEURORADIOL, V33, P1470, DOI 10.3174/ajnr.A3009
   Fargen KM, 2018, J NEUROINTERV SURG, V10, P44, DOI 10.1136/neurintsurg-2016-012808
   Jabbour P, 2013, NEUROSURGERY, V73, P113, DOI 10.1227/01.neu.0000429844.06955.39
   Kumar NG, 2017, J NEUROL SCI, V372, P250, DOI 10.1016/j.jns.2016.11.057
   Labeyrie MA, 2015, AM J NEURORADIOL, V36, P140, DOI 10.3174/ajnr.A4064
   Lanzino G, 2012, AM J NEURORADIOL, V33, P2158, DOI 10.3174/ajnr.A3207
   Liang F, 2018, WORLD NEUROSURG, V112, pE683, DOI 10.1016/j.wneu.2018.01.129
   Lin LM, 2015, J NEUROINTERV SURG, V7, P628, DOI 10.1136/neurintsurg-2014-011298
   Lubicz B, 2003, NEURORADIOLOGY, V45, P650, DOI 10.1007/s00234-003-1047-4
   Nelson PK, 2011, AM J NEURORADIOL, V32, P34, DOI 10.3174/ajnr.A2421
   Sahlein DH, 2015, J NEUROSURG, V123, P897, DOI 10.3171/2014.12.JNS141777
   Sluzewski M, 2003, AM J NEURORADIOL, V24, P257
   Szikora I, 2010, AM J NEURORADIOL, V31, P1139, DOI 10.3174/ajnr.A2023
   van der Schaaf IC, 2002, STROKE, V33, P313, DOI 10.1161/hs0102.101479
   van Rooij WJ, 2012, AM J NEURORADIOL, V33, P323, DOI 10.3174/ajnr.A2759
   Vincent F, 2005, AM J NEURORADIOL, V26, P1372
   Wang B, 2015, ACTA RADIOL, V56, P105, DOI 10.1177/0284185113520312
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Wiebers DO, 2006, NEUROIMAG CLIN N AM, V16, P383, DOI 10.1016/j.nic.2006.04.005
   Zanaty M, 2014, STROKE, V45, P2656, DOI 10.1161/STROKEAHA.114.006247
   2017, NEURORADIOLOGY, V59, P1291, DOI DOI 10.1007/S00234-017-1930-Z
   2009, NEUROSURGERY, V64, P632, DOI DOI 10.1227/01.NEU.0000339109.98070.65
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E385
EP E391
DI 10.1016/j.wneu.2019.01.082
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700050
PM 30703601
DA 2020-05-12
ER

PT J
AU Yan, ZY
   Zheng, K
   Xiong, Y
   Lan, FJ
   Wang, YH
   Tan, XX
   Zhong, M
   Li, ZQ
AF Yan, Zhiyuan
   Zheng, Kuang
   Xiong, Ye
   Lan, Fujun
   Wang, Yunhui
   Tan, Xianxi
   Zhong, Ming
   Li, Zequn
TI Intracranial Complex Ruptured Aneurysms Coiled with Overlapping
   Low-Profile Visualized Intraluminal Support Stents: Another Available
   Option for Complex Ruptured Intracranial Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complex; Intracranial aneurysms; LVIS stents; Overlapping; Ruptured
ID ASSISTED COILING; ENDOVASCULAR TREATMENT; CAVERNOUS ANEURYSMS; PARENT
   ARTERY; SAFETY; COMPLICATIONS; EMBOLIZATION; EFFICACY; LVIS
AB BACKGROUND: Overlapping stents represent a new paradigm in endovascular interventions, especially for complex and wide-necked aneurysms. The low-profile visualized intraluminal support (LVIS) device is a new generation of self-expanding braided stents recently introduced in China for stent-assisted coiling of intracranial aneurysms. We report several cases of intracranial aneurysms coiled using overlapping LVIS stents to evaluate its efficacy and safety.
   METHODS: Patients with ruptured intracranial aneurysms treated with double LVIS stents at our center between November 2014 and May 2016 were reviewed. The clinical data and technical results are presented.
   RESULTS: Ten patients with 15 aneurysms were treated with double LVIS stents, with a 100% technical success rate. No mortality was observed. Immediate angiographic outcome evaluation showed complete occlusion in 13 aneurysms (86.7%) and neck remnants in 2 aneurysms (13.3%).
   CONCLUSIONS: Double LVIS stents are safe and effective in the treatment of intracranial aneurysms, especially complex aneurysms.
C1 [Yan, Zhiyuan; Zheng, Kuang; Xiong, Ye; Lan, Fujun; Wang, Yunhui; Tan, Xianxi; Zhong, Ming; Li, Zequn] Wenzhou Med Univ, Dept Neurosurg, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China.
RP Li, ZQ (reprint author), Wenzhou Med Univ, Dept Neurosurg, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China.
EM Yzy89668@sina.com
CR Brinjikji W, 2013, STROKE, V44, P442, DOI 10.1161/STROKEAHA.112.678151
   Chalouhi N, 2014, AM J NEURORADIOL, V35, P546, DOI 10.3174/ajnr.A3696
   Chalouhi N, 2013, AM J NEURORADIOL, V34, P1987, DOI 10.3174/ajnr.A3538
   Fang YB, 2014, CLIN NEUROL NEUROSUR, V123, P34, DOI 10.1016/j.clineuro.2014.04.023
   Feng X, 2018, WORLD NEUROSURG, V109, pE99, DOI 10.1016/j.wneu.2017.09.112
   Feng ZZ, 2016, J NEUROINTERV SURG, V8, P1192, DOI 10.1136/neurintsurg-2015-012090
   Hong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082311
   Iosif C, 2018, J NEUROINTERV SURG, V10, P675, DOI 10.1136/neurintsurg-2017-013375
   Kim SY, 2017, J KOREAN NEUROSURG S, V60, P644, DOI 10.3340/jkns.2017.0193
   Kiyofuji S, 2018, J NEUROINTERV SURG, V10, P500, DOI 10.1136/neurintsurg-2017-013312
   Li H, 2016, INT J NEUROSCI, V126, P46, DOI 10.3109/00207454.2014.992427
   Liu L, 2010, NEURORADIOL J, V23, P737, DOI 10.1177/197140091002300616
   Mattei TA, 2013, NEUROSURG REV, V36, P505, DOI 10.1007/s10143-013-0459-9
   Miyachi S, 2017, J STROKE CEREBROVASC, V26, P1071, DOI 10.1016/j.jstrokecerebrovasdis.2016.12.023
   Mu S, 2016, CLIN NEURORADIOL, V26, P291, DOI 10.1007/s00062-014-0369-4
   Nishido H, 2014, AM J NEURORADIOL, V35, P339, DOI 10.3174/ajnr.A3658
   Piotin M, 2010, STROKE, V41, P110, DOI 10.1161/STROKEAHA.109.558114
   Qi Peng, 2016, Zhonghua Wai Ke Za Zhi, V54, P363, DOI 10.3760/cma.j.issn.0529-5815.2016.05.009
   Wagner A, 2012, NEURORADIOLOGY, V54, P709, DOI 10.1007/s00234-011-0949-9
   Walsh KM, 2014, J NEUROINTERV SURG, V6, P184, DOI 10.1136/neurintsurg-2013-010648
   Wang B, 2015, ACTA RADIOL, V56, P105, DOI 10.1177/0284185113520312
   Wang C, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0959-9
   Wang J, 2018, J NEUROINTERV SURG, V10, P687, DOI 10.1136/neurintsurg-2017-013272
   Wang Jun, 2016, Zhonghua Wai Ke Za Zhi, V54, P358, DOI 10.3760/cma.j.issn.0529-5815.2016.05.008
   Zhang XX, 2016, INTERV NEURORADIOL, V22, P659, DOI 10.1177/1591019916656584
   2013, NEUROSURG REV, V36, P505, DOI DOI 10.1007/S10143-013-0459-9
NR 26
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E22
EP E28
DI 10.1016/j.wneu.2018.12.142
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700005
PM 30630046
DA 2020-05-12
ER

PT J
AU Yang, D
   Geng, Y
   Zhang, M
   Lin, M
   Shi, ZH
   Zi, WJ
   Hao, YG
   Wang, HM
   Liu, WH
   Wang, W
   Xu, GL
   Xiong, YY
   Liu, XF
AF Yang, Dong
   Geng, Yu
   Zhang, Meng
   Lin, Min
   Shi, Zhonghua
   Zi, Wenjie
   Hao, Yonggang
   Wang, Huaiming
   Liu, Wenhua
   Wang, Wei
   Xu, Gelin
   Xiong, Yunyun
   Liu, Xinfeng
CA ACTUAL Investigators
TI Complete Recanalization May Exert the Most Important Effect on Outcomes
   of Endovascular Treatment in Acute Ischemic Stroke with Small Infarct
   Core Beyond 6 Hours
SO WORLD NEUROSURGERY
LA English
DT Article
DE Infarct; Recanalization; Stroke; Time window
ID INTERVENTIONAL MANAGEMENT; ANGIOGRAPHIC REPERFUSION; SYMPTOM ONSET;
   TIME; THROMBECTOMY; THERAPY; VOLUME; TRIAL
AB OBJECTIVE: To explore the differences among grades of recanalization on outcomes of endovascular treatment for acute anterior large vessel occlusion with small infarct core beyond the 6-hour time window.
   METHODS: Patients beyond the 6-hour time window with Alberta Stroke Program Early Computed Tomography Score >7 were retrospectively enrolled from the endovascular treatment for acute anterior circulation ischemic stroke (ACTUAL) registry. They were divided into 3 groups according to the degree of recanalization: modified treatment in cerebral infarction (mTICI) 0-2a, 2b, and 3. We compared the differences of outcomes among groups on modified Rankin Scale score at 90 days, symptomatic intracerebral hemorrhage within 72 hours, and mortality.
   RESULTS: A total of 101 patients were enrolled. Median time from onset to groin puncture was 415 minutes (interquartile range: 387-497 minutes). Favorable functional outcomes were significantly better in patients with successful recanalization than in patients with failed recanalization (mTICI 0-2a, 22.7% [5/22]; mTICI 2b, 48.0% [12/25]; and mTICI 3, 61.1% [33/54]; trend P = 0.01). Complete recanalization (mTICI 3) (odds ratio, 5.34; 95% confidence interval, 1.71-16.66; P = 0.004) was associated with good functional outcome. Mortality was different among groups at 90 days (mTICI 0-2a, 36.4% [8/22]; mTICI 2b, 0, [0/25]; P = 0.001; mTICI 0-2a, 36.4% [8/22]; mTICI 3, 9.3% [5/54]; P = 0.008; and mTICI 2b, 0, [0/25]; mTICI 3, 9.3% [5/54]; P = 0.173). There were no significant differences of symptomatic intracranial hemorrhage among groups (mTICI 0-2a, 22.7% [5/22]; mTICI 2b, 12.0% [3/25]; and mTICI 3, 9.3% [5/54]; P = 0.28).
   CONCLUSIONS: For acute anterior circulation stroke patients, who were beyond the 6-hour time window, yet with small ischemic core, complete recanalization following endovascular treatment may play the most important role on clinical outcome.
C1 [Yang, Dong; Zi, Wenjie; Hao, Yonggang; Wang, Huaiming; Xu, Gelin; Xiong, Yunyun; Liu, Xinfeng] Nanjing Univ, Jinling Hosp, Dept Neurol, Med Sch, Nanjing, Jiangsu, Peoples R China.
   [Geng, Yu] Zhejiang Prov Peoples Hosp, Dept Neurol, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Meng] Third Mil Med Univ, Res Inst Surg, Daping Hosp, Dept Neurol, Chongqing, Peoples R China.
   [Lin, Min] Fuzhou Gen Hosp Nanjing Mil Reg, Dept Neurol, Fuzhou, Fujian, Peoples R China.
   [Shi, Zhonghua] Peoples Liberat Army, Dept Neurosurg, Hosp 101, Wuxi, Jiangsu, Peoples R China.
   [Hao, Yonggang] Soochow Univ, Dept Emergency Med, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.
   [Wang, Huaiming] Peoples Liberat Army, Dept Neurol, Hosp 89, Weifang, Shandong, Peoples R China.
   [Liu, Wenhua] Wuhan 1 Hosp, Dept Neurol, Wuhan, Hubei, Peoples R China.
   [Wang, Wei] Yangzhou Univ, Peoples Hosp Yangzhou 1, Dept Radiol, Yangzhou, Jiangsu, Peoples R China.
RP Liu, XF (reprint author), Nanjing Univ, Jinling Hosp, Dept Neurol, Med Sch, Nanjing, Jiangsu, Peoples R China.
EM xfliu2@vip.163.com
OI Wang, Huaiming/0000-0002-3409-0927; yang, dong/0000-0002-2695-0499
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81530038, 81220108008, 81671172]; Jiangsu
   Provincial Special Program of Medical Science [BL2013025]
FX This project is supported by National Natural Science Foundation of
   China (No. 81530038, No. 81220108008, and No. 81671172), Jiangsu
   Provincial Special Program of Medical Science (No. BL2013025).
CR Abou-Chebl A, 2010, STROKE, V41, P1996, DOI 10.1161/STROKEAHA.110.578997
   Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Almekhlafi MA, 2014, INTERV NEURORADIOL, V20, P21, DOI 10.15274/INR-2014-10004
   Bang OY, 2008, J NEUROL NEUROSUR PS, V79, P625, DOI 10.1136/jnnp.2007.132100
   Bang OY, 2011, STROKE, V42, P693, DOI 10.1161/STROKEAHA.110.595256
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Cheng-Ching E, 2015, AM J NEURORADIOL, V36, P1272, DOI 10.3174/ajnr.A4274
   Demeestere J, 2017, NEUROLOGY, V88, P2248, DOI 10.1212/WNL.0000000000004028
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Hakimelahi R, 2014, STROKE, V45, P2936, DOI 10.1161/STROKEAHA.114.005644
   Hao YG, 2017, STROKE, V48, P1203, DOI 10.1161/STROKEAHA.116.016368
   Higashida RT, 2003, STROKE, V34, pE109, DOI 10.1161/01.STR.0000082721.62796.09
   Jayaraman MV, 2013, AM J NEURORADIOL, V34, P135, DOI 10.3174/ajnr.A3278
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Jovin TG, 2011, STROKE, V42, P2206, DOI 10.1161/STROKEAHA.110.604223
   Khatri P, 2014, LANCET NEUROL, V13, P567, DOI 10.1016/S1474-4422(14)70066-3
   Kleine JF, 2017, J NEUROINTERV SURG, V9, P117, DOI 10.1136/neurintsurg-2015-012218
   Lansberg MG, 2015, NEUROLOGY, V85, P708, DOI 10.1212/WNL.0000000000001853
   Lansberg MG, 2012, LANCET NEUROL, V11, P860, DOI 10.1016/S1474-4422(12)70203-X
   Martini SR, 2007, J CEREBR BLOOD F MET, V27, P435, DOI 10.1038/sj.jcbfm.9600355
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Nogueira RG, 2011, STROKE, V42, P3144, DOI 10.1161/STROKEAHA.111.624163
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Ryu Chang-Woo, 2017, Neurointervention, V12, P20, DOI 10.5469/neuroint.2017.12.1.20
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Tomsick T, 2008, AM J NEURORADIOL, V29, P582, DOI 10.3174/ajnr.A0843
   von Kummer R, 2015, STROKE, V46, P2981, DOI 10.1161/STROKEAHA.115.010049
   Wouters A, 2016, INT J STROKE, V11, P127, DOI 10.1177/1747493015607503
   Zi WJ, 2017, CEREBROVASC DIS, V44, P248, DOI 10.1159/000478667
   2013, EUR J NEUROL, V20, P865, DOI DOI 10.1111/ENE.12069
NR 31
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E544
EP E551
DI 10.1016/j.wneu.2019.01.131
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700071
PM 30716496
DA 2020-05-12
ER

PT J
AU Yang, JR
   Kuo, CF
   Chung, TT
   Liao, HT
AF Yang, Jia-Ruei
   Kuo, Chang-Fu
   Chung, Ting-Ting
   Liao, Han-Tsung
TI Increased Risk of Dementia in Patients with Craniofacial Trauma: A
   Nationwide Population-Based Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Facial bone fracture; Mild traumatic brain injury; Neurodegenerative
   disease; Postinjury comorbidities; Posttraumatic epilepsy; Traumatic
   brain injury
ID CLOSED-HEAD INJURIES; BRAIN-INJURY; ALZHEIMERS-DISEASE; FACIAL
   FRACTURES; MAXILLOFACIAL FRACTURES; EPILEPSY; EPIDEMIOLOGY; IMPACT;
   DIAGNOSIS; ACCURACY
AB OBJECTIVE: The role of maxillofacial trauma in dementia risk is not well established. The aim of this study was to evaluate the association between craniofacial trauma, including facial bone fracture and traumatic brain injury (TBI), and dementia.
   METHODS: Using Taiwan's National Health Insurance Research Database, we identified 501,889 adults who had had >= 1 medical record of craniofacial trauma between 2000 and 2010 and did not have a dementia diagnosis at baseline. Diagnoses of craniofacial trauma, including facial bone fracture and TBI, and dementia were made using International Classification of Diseases, Ninth Revision codes. The standardized incidence ratio was used to determine whether craniofacial trauma was associated with a greater risk of incident dementia compared with the general population. The Cox proportional hazards model was used to predict the risk of dementia among the trauma cohort by comparing the patients with and without comorbidities.
   RESULTS: A total of 501,889 patients with craniofacial trauma were included, of which 1.5% (n = 7804) developed dementia. Facial bone fracture (standardized incidence ratio, 1.58; 95% confidence interval, 1.25-2.00) was shown to be associated with an increased dementia risk compared with the general population. In addition, craniofacial trauma accompanied with postinjury comorbidities was associated with an increased risk of dementia during follow-up periods compared with the group without comorbidities.
   CONCLUSIONS: Craniofacial traumas, especially facial bone fracture, were associated with an increased risk of subsequent dementia. Maintaining a high index of suspicion for associated TBIs in all patients with facial trauma is crucial, even if no obvious initial signs and symptoms of brain injury are observed.
C1 [Yang, Jia-Ruei] Chang Gung Mem Hosp, Dept Surg, Taoyuan, Taiwan.
   [Kuo, Chang-Fu] Chang Gung Mem Hosp, Div Rheumatol, Dept Allergy & Immunol, Taoyuan, Taiwan.
   [Chung, Ting-Ting] Chang Gung Mem Hosp, Off Big Data Res, Taoyuan, Taiwan.
   [Kuo, Chang-Fu] Univ Nottingham, Sch Med, Div Rheumatol, Dept Orthopaed & Dermatol, Nottingham, England.
   [Liao, Han-Tsung] Chang Gung Univ, Chang Gung Mem Hosp, Div Trauma Plast Surg,Coll Med, Dept Plast & Reconstruct Surg,Craniofacial Res Ct, Taoyuan, Taiwan.
   [Liao, Han-Tsung] Xiamen Chang Gung Mem Hosp, Dept Plast Surg, Xiamen, Peoples R China.
RP Liao, HT (reprint author), Chang Gung Univ, Chang Gung Mem Hosp, Div Trauma Plast Surg,Coll Med, Dept Plast & Reconstruct Surg,Craniofacial Res Ct, Taoyuan, Taiwan.; Liao, HT (reprint author), Xiamen Chang Gung Mem Hosp, Dept Plast Surg, Xiamen, Peoples R China.
EM lia01211@gmail.com
OI LIAO, HAN-TSUNG/0000-0001-9259-9839
FU Center for Big Data Analytics and Statistics [CLRPG3D0044]
FX The authors would like to thank Chang Gung Memorial Hospital for
   statistical assistance and support from the maintenance project of the
   Center for Big Data Analytics and Statistics (grant CLRPG3D0044). This
   manuscript was edited by Wallace Academic Editing.
CR Ankarath S, 2002, INJURY, V33, P473, DOI 10.1016/S0020-1383(02)00048-7
   Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104
   Bangen KJ, 2010, CLIN NEUROPSYCHOL, V24, P1193, DOI 10.1080/13854041003736778
   Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600
   Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038
   Breteler MMB, 1995, AM J EPIDEMIOL, V142, P1300, DOI 10.1093/oxfordjournals.aje.a117597
   CHANG CJ, 1994, J TRAUMA, V37, P807, DOI 10.1097/00005373-199411000-00017
   Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2
   DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X
   Down KE, 1995, INT J ORAL MAX SURG, V24, P409, DOI 10.1016/S0901-5027(05)80469-2
   Eggers C, 2017, J NEUROL, V264, P1715, DOI 10.1007/s00415-017-8503-2
   Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857
   Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x
   Gao HB, 2017, BRAIN RES, V1657, P1, DOI 10.1016/j.brainres.2016.11.028
   Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001
   Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668
   Gardner RC, 2014, ANN NEUROL, V75, P339, DOI 10.1002/ana.24121
   Gottesman RF, 2010, LANCET NEUROL, V9, P895, DOI 10.1016/S1474-4422(10)70164-2
   Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549
   HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q
   Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21
   Hesdorffer DC, 1996, NEUROLOGY, V46, P727, DOI 10.1212/WNL.46.3.727
   Hobbs JG, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15617
   Hohlrieder M, 2004, INT J ORAL MAX SURG, V33, P389, DOI 10.1016/j.ijom.2003.10.011
   Hyder AA, 2007, NEUROREHABILITATION, V22, P341
   Institute of Medicine, 2009, GULF WAR HLTH, V7
   JOHNSON RM, 1995, J TRAUMA, V38, P876, DOI 10.1097/00005373-199506000-00008
   Kamei Satoshi, 2016, Brain Nerve, V68, P317, DOI 10.11477/mf.1416200400
   Kato Hiroko, 2016, Brain Nerve, V68, P309, DOI 10.11477/mf.1416200399
   Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14
   Knopman DS, 2007, BRIT J RADIOL, V80, pS121, DOI 10.1259/bjr/75681080
   Kraus JF, 2003, ANN EMERG MED, V41, P18, DOI 10.1067/mem.2003.1
   Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026
   Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001
   LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542
   Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422
   Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50
   Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2
   Levine DA, 2015, JAMA-J AM MED ASSOC, V314, P41, DOI 10.1001/jama.2015.6968
   Li YJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169650
   LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D
   Lin MR, 2009, ACCIDENT ANAL PREV, V41, P710, DOI 10.1016/j.aap.2009.03.010
   Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002
   Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x
   Martin RCG, 2002, AM SURGEON, V68, P477
   Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005
   National Center for Injury Prevention, 2003, C MILD TRAUM BRAIN I, P18
   Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028
   Pandey S, 2015, J MAXILLOFAC ORAL SU, V14, P32, DOI 10.1007/s12663-013-0578-4
   Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4
   Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503
   Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38
   Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158
   Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035
   Puljula J, 2012, INJURY, V43, P2100, DOI 10.1016/j.injury.2012.04.010
   RONTAL E, 1979, ANN OTO RHINOL LARYN, V88, P382, DOI 10.1177/000348947908800315
   SAHAI H, 1993, BIOMETRICAL J, V35, P857, DOI 10.1002/bimj.4710350716
   Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119
   Selassie AW, 2014, EPILEPSY RES, V108, P305, DOI 10.1016/j.eplepsyres.2013.12.002
   Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747
   Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013
   Snyder HM, 2015, ALZHEIMERS DEMENT, V11, P710, DOI 10.1016/j.jalz.2014.10.008
   St Germaine-Smith C, 2012, NEUROLOGY, V79, P1049, DOI 10.1212/WNL.0b013e3182684707
   Takada LT, 2013, SEMIN NEUROL, V33, P348, DOI 10.1055/s-0033-1359314
   Tung YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129043
   Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015
   Zandi M, 2013, ORAL MAXILLOFAC SURG, V17, P201, DOI 10.1007/s10006-012-0368-z
   Ziebell JM, 2017, BRAIN BEHAV IMMUN, V59, P1, DOI 10.1016/j.bbi.2016.03.008
   Zohar O, 2011, NEUROBIOL DIS, V41, P329, DOI 10.1016/j.nbd.2010.10.001
   1990, AM J EPIDEMIOL, V131, P491
NR 70
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E563
EP E574
DI 10.1016/j.wneu.2019.01.133
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700073
PM 30716485
DA 2020-05-12
ER

PT J
AU Yang, JS
   Chen, H
   Chu, L
   Liu, P
   Yan, L
   Liu, TJ
   Tian, F
   Zhang, JN
   Hao, DJ
AF Yang, Jun-Song
   Chen, Hao
   Chu, Lei
   Liu, Peng
   Yan, Liang
   Liu, Tuan-Jiang
   Tian, Fang
   Zhang, Jia-Nan
   Hao, Ding-Jun
TI Does Additional Bone Grafting of Atlantoaxial Joint Increase Bone Fusion
   Rate of Iliac Crest Autograft in Posterior Occipitocervical Fusion?
   Retrospective, Controlled Study with 2-Year Follow-up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial arthrodesis; Atlantoaxial joints; Basilar invagination;
   Bone graft; Occipitocervical fusion; Posterior approach
ID CERVICAL-SPINE; SCREW; PSEUDOARTHROSIS; SUBSTITUTES; ALLOGRAFT; FIXATION
AB OBJECTIVE: We sought to explore whether additional bone grafting of the atlantoaxial joint increases the bone fusion rate of iliac crest autograft in posterior occipitocervical fusion surgery.
   METHODS: From January 2012 to January 2016, a total of 78 patients who had basilar invagination with occipitalization of the atlas came to our tertiary spine center. Except for those lost to follow-up (10 cases) or who had a followup time < 2 years (20 cases), there were 48 patients retrospectively included in this study. In the control group, a piece of autogenous iliac corticocancellous bone was placed between the occipital and C2 vertebral lamina for fusion. In the hybrid fusion group, besides posterior occipitocervical autograft, some granular bone harvested from the iliac crest was packed into the bilateral atlantoaxial joint. X-ray imaging and cervical computed tomography (CT) were performed during follow-up.
   RESULTS: The operations were completed successfully in all patients without intraoperative complications. Only 21 (87.5%) patients in the control group had confirmed posterior bony fusion on CT, while 24 (100%) patients in the hybrid fusion group had confirmed posterior bony fusion. There were postoperative implant-related complications in 2 patients. Both cases belonged to the control group (8.3%). Three patients (12.5%) complained of transient numbness in the posterior occipital region: 2 patients in the hybrid group and 1 patient in the control group. The mean duration to posterior occipitocervical fusion was 5.5 months in the hybrid fusion group versus 6.1 months in the control group (P = 0.757). Of note, in the hybrid fusion group, the process of atlantoaxial joint fusion was faster than that of posterior occipitocervical fusion (5.1 months vs. 5.5 months, P = 0.823).
   CONCLUSIONS: Additional bone grafting of the atlantoaxial joint could increase the bone fusion rate of iliac crest autograft in posterior occipitocervical fusion.
C1 [Yang, Jun-Song; Chen, Hao; Liu, Peng; Yan, Liang; Liu, Tuan-Jiang; Tian, Fang; Zhang, Jia-Nan; Hao, Ding-Jun] Xi An Jiao Tong Univ, Dept Spine Surg, Honghui Hosp, Hlth Sci Ctr, Xian, Shaanxi, Peoples R China.
   [Chen, Hao] Xian Med Univ, Grad Sch, Xian, Shaanxi, Peoples R China.
   [Chu, Lei] Chongqing Med Univ, Orthopaed, Affiliated Hosp 2, Chongqing, Peoples R China.
RP Hao, DJ (reprint author), Xi An Jiao Tong Univ, Dept Spine Surg, Honghui Hosp, Hlth Sci Ctr, Xian, Shaanxi, Peoples R China.
EM dingjun.hao@qq.com
OI liu, peng/0000-0003-3453-2278; chen, hao/0000-0002-7122-9027
FU Chinese National Natural Science FoundationNational Natural Science
   Foundation of China [81772357]
FX The Chinese National Natural Science Foundation (81772357 for Ding-Jun
   Hao) provided a grant. All authors declare that they have no conflicts
   of interest.
CR ABUMI K, 1994, J SPINAL DISORD, V7, P19, DOI 10.1097/00002517-199407010-00003
   Cone W, 1937, J BONE JOINT SURG, V19, P584
   Eck KR, 2000, J SPINAL DISORD, V13, P501, DOI 10.1097/00002517-200012000-00006
   Elliott RE, 2014, WORLD NEUROSURG, V81, P411, DOI 10.1016/j.wneu.2012.03.013
   Fillingham Y, 2016, BONE JOINT J, V98B, P6, DOI [10.1302/0301-620X.98B.36350, 10.1302/0301-620X.98B1.36350]
   FROST HM, 1994, ANGLE ORTHOD, V64, P175
   GOLDBERG VM, 1987, CLIN ORTHOP RELAT R, P7
   Grabowski G, 2013, J AM ACAD ORTHOP SUR, V21, P51, DOI 10.5435/JAAOS-21-01-51
   Guerado E, 2011, INJURY, V42, pS64, DOI 10.1016/j.injury.2011.06.200
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   He X, 2017, WORLD NEUROSURG, V100, P230, DOI 10.1016/j.wneu.2016.12.131
   Huang DG, 2017, CLIN NEUROL NEUROSUR, V162, P95, DOI 10.1016/j.clineuro.2017.10.002
   Lall R, 2010, NEUROSURGERY, V67, P1396, DOI 10.1227/NEU.0b013e3181f1ec73
   Leven D, 2016, ASIAN SPINE J, V10, P776, DOI 10.4184/asj.2016.10.4.776
   Lubelski D, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.02.077
   Niu CC, 2009, SPINE, V34, P2715, DOI 10.1097/BRS.0b013e3181b47232
   Raizman NM, 2009, J AM ACAD ORTHOP SUR, V17, P494, DOI 10.5435/00124635-200908000-00003
   TSUANG Y-H, 1989, Taiwan yixuehui zazhi, V88, P989
   Yu WD, 2011, AM J ORTHOPED, V40, P205
   Zimmermann G, 2011, INJURY, V42, pS16, DOI 10.1016/j.injury.2011.06.199
NR 20
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E29
EP E34
DI 10.1016/j.wneu.2018.12.153
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700006
PM 30711657
DA 2020-05-12
ER

PT J
AU Yang, NN
   Luo, M
   Yu, Y
   Wang, J
   Xia, L
   Wang, WG
AF Yang, Ningning
   Luo, Ming
   Yu, Yi
   Wang, Jie
   Xia, Lei
   Wang, Wengang
TI Is It Better to Resect a Bony Spur Before Corrective Surgery for
   Congenital Scoliosis with Type I Split Cord Malformation?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bony spur; Congenital scoliosis; Type I split cord malformation
ID SPINAL DEFORMITY; DIASTEMATOMYELIA; ABNORMALITIES; EMBRYOGENESIS;
   ANOMALIES; EFFICACY; SAFETY
AB OBJECTIVE: To compare bony spur resection (BR) with bony spur nonresection (BN) treatment in patients with congenital scoliosis and type I split cord malformation.
   METHODS: Patients with congenital scoliosis and type I split cord malformation who underwent corrective surgery in a single institution from 2008 to 2015 were retrospectively evaluated. Patients were divided into 2 groups according to whether BR was performed or not: the BR group included 12 patients, and the BN group included 20 patients. Complications and perioperative and radiographic data were recorded and compared.
   RESULTS: The study included 32 patients. Mean age at surgery was 14.3 years, and average follow-up period was 2.8 years. There were no statistically significant differences in correction rate of the major curve or other radiographic parameters at final follow-up. Preoperative concerns (6.8 vs. 5.8, P = 0.006), operative times (508.5 minutes vs. 311.3 minutes, P = 0.009), blood loss (1433.3 mL vs. 1015.8 mL, P = 0.064), and hospital charges ($22,387.80 vs. $15,706.8, P = 0.032) were lower in the BN group than in the BR group. Total and major complication rates were higher in the BR group than in the BN group, even though there were no statistically significant differences (58.3% vs. 30.0% and 8.3% vs. 5.0%, respectively).
   CONCLUSIONS: In patients with congenital scoliosis and type I split cord malformation, not resecting the bony spur can achieve satisfactory radiographic and clinical outcomes with potentially fewer complications.
C1 [Yang, Ningning; Luo, Ming; Wang, Jie; Xia, Lei; Wang, Wengang] Zhengzhou Univ, Inst Spinal Deform, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
   [Yu, Yi] Xinxiang Med Univ, Dept Gastroenterol & Hepatol, Affiliated Hosp 1, Weihui, Henan, Peoples R China.
RP Xia, L (reprint author), Zhengzhou Univ, Inst Spinal Deform, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
EM ynnynzzu@126.com
FU Department of Education of Henan Province Scientific and Technological
   Breakthrough Project [172102310090]; Henan Natural Science Foundation
   Research Project [142300410379]
FX Funds were received in support of this work from the Department of
   Education of Henan Province Scientific and Technological Breakthrough
   Project (172102310090) and Henan Natural Science Foundation Research
   Project (142300410379).
CR Ayvaz M, 2007, J PEDIATR ORTHOPED, V27, P380, DOI 10.1097/01.bpb.0000271334.73643.81
   Ayvaz Mehmet, 2009, Spine (Phila Pa 1976), V34, P2413, DOI 10.1097/BRS.0b013e3181b9c61b
   Basu PS, 2002, SPINE, V27, P2255, DOI 10.1097/01.BRS.0000029425.58936.BA
   BRADFORD DS, 1991, J PEDIATR ORTHOPED, V11, P36, DOI 10.1097/01241398-199101000-00009
   Chen B, 2015, SPINE, V40, pE1005, DOI 10.1097/BRS.0000000000001039
   Feng F, 2016, J BONE JOINT SURG AM, V98, P2096, DOI 10.2106/JBJS.16.00414
   Feng F, 2016, SPINE, V41, P1310, DOI 10.1097/BRS.0000000000001530
   HOOD RW, 1980, J BONE JOINT SURG AM, V62, P520, DOI 10.2106/00004623-198062040-00005
   Hui H, 2012, SPINE, V37, P2104, DOI 10.1097/BRS.0b013e3182608988
   KEIM HA, 1973, J BONE JOINT SURG AM, VA 55, P1425, DOI 10.2106/00004623-197355070-00009
   LINDER M, 1982, NEUROSURGERY, V11, P622, DOI 10.1227/00006123-198211000-00006
   Mahapatra AK, 2005, J NEUROSURG, V103, P531, DOI 10.3171/ped.2005.103.6.0531
   MCMASTER MJ, 1984, J BONE JOINT SURG AM, V66A, P588, DOI 10.2106/00004623-198466040-00015
   MILLER A, 1993, J BONE JOINT SURG AM, V75A, P1308, DOI 10.2106/00004623-199309000-00006
   PANG DL, 1992, NEUROSURGERY, V31, P481, DOI 10.1227/00006123-199209000-00011
   PANG DL, 1992, NEUROSURGERY, V31, P451, DOI 10.1227/00006123-199209000-00010
   Shen JX, 2016, J BONE JOINT SURG AM, V98, P926, DOI 10.2106/JBJS.15.00882
   Shen JX, 2013, SPINE, V38, P814, DOI 10.1097/BRS.0b013e31827ed125
   Sinha S, 2006, CHILD NERV SYST, V22, P3, DOI 10.1007/s00381-005-1145-1
   TSOU PM, 1980, CLIN ORTHOP RELAT R, P211
   WINTER RB, 1974, J BONE JOINT SURG AM, VA 56, P27, DOI 10.2106/00004623-197456010-00003
NR 21
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1151
EP E1159
DI 10.1016/j.wneu.2019.01.265
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700143
PM 30790730
DA 2020-05-12
ER

PT J
AU Ye, IB
   Girdler, SJ
   Cheung, ZB
   White, SJ
   Ranson, WA
   Cho, SKW
AF Ye, Ivan B.
   Girdler, Steven J.
   Cheung, Zoe B.
   White, Samuel J.
   Ranson, William A.
   Cho, Samuel Kang-Wook
TI Risk Factors Associated with 30-Day Mortality After Open Reduction and
   Internal Fixation of Vertebral Fractures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Fixation; Mortality; NSQIP; Open reduction internal
   fixation; ORIF; Spinal fracture; Vertebral fracture
ID COMPLICATIONS; EPIDEMIOLOGY; DEFORMITY; OUTCOMES; PROGRAM; INJURY;
   TRENDS
AB OBJECTIVE: Few studies have examined the outcomes of open reduction and internal fixation of vertebral fractures. The purpose of this study was to determine patient-related and surgery-related risk factors associated with 30-day postoperative mortality after open reduction and internal fixation (ORIF) of cervical, thoracic, and lumbar vertebral fractures.
   METHODS: This was a retrospective cohort study of data from the 2010-2014 ACS-NSQIP database. Adult patients who underwent ORIF of vertebral fractures in the cervical, thoracic, or lumbar spine were included. Patients were divided into 2 groups on the basis of the occurrence of 30-day postoperative mortality. A univariate analysis was performed to compare baseline patient characteristics, comorbidities, operative variables, and 30-day postoperative complications between the mortality and non-mortality groups. A subsequent multivariate regression analysis adjusting for patient and operative factors was then performed to identify independent risk factors for 30-day mortality.
   RESULTS: A total of 900 patients who underwent vertebral ORIF were included. The overall 30-day postoperative mortality rate was 1.56%. The mortality group had a higher incidence of pneumonia, pulmonary complications, cardiac complications, blood transfusion, sepsis, and prolonged hospitalization. Multivariate regression analysis identified pulmonary comorbidity and diabetes as independent predictors of 30-day mortality following ORIF of vertebral fractures.
   CONCLUSIONS: Pulmonary comorbidity and diabetes were found to be independent risk factors for 30-day mortality after ORIF of vertebral fractures. Recognizing these risk factors is important in preoperative risk stratification, perioperative care, and patient counseling.
C1 [Ye, Ivan B.; Girdler, Steven J.; Cheung, Zoe B.; White, Samuel J.; Ranson, William A.; Cho, Samuel Kang-Wook] Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
RP Cho, SKW (reprint author), Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
EM samuel.cho@mountsinai.org
RI Cheung, Zoe/AAG-4511-2020
OI Cheung, Zoe/0000-0002-0189-5390
CR Amin S, 2014, J BONE MINER RES, V29, P581, DOI 10.1002/jbmr.2072
   Belmont PJ, 2015, J ORTHOP TRAUMA, V29, pE476, DOI 10.1097/BOT.0000000000000328
   Butt MF, 2007, INT ORTHOP, V31, P259, DOI 10.1007/s00264-006-0161-4
   Cheng LM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009073.pub2
   Crist BD, 2018, SURG INFECT, V19, P535, DOI 10.1089/sur.2018.018
   Edmond SL, 2005, OSTEOPOROSIS INT, V16, P1086, DOI 10.1007/s00198-004-1815-y
   Graumam RQ, 2018, OSTEOPOROSIS INT, V29, P1457, DOI 10.1007/s00198-018-4483-z
   Guo JB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127145
   Gupta H, 2013, CHEST, V143, P1599, DOI 10.1378/chest.12-1499
   Kayal R, 2009, BONE, V44, P357, DOI 10.1016/j.bone.2008.10.042
   Melton LJ, 2003, J BONE MINER RES, V18, P1139, DOI 10.1359/jbmr.2003.18.6.1139
   Molina CS, 2015, CLIN ORTHOP RELAT R, V473, P1574, DOI 10.1007/s11999-014-3597-7
   Costa TMDL, 2018, OSTEOPOROSIS INT, V29, P2537, DOI 10.1007/s00198-018-4643-1
   Nagao M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13417-w
   Norris R, 2011, INJURY, V42, P1313, DOI 10.1016/j.injury.2011.03.021
   Pneumaticos SG, 2013, INJURY, V44, P703, DOI 10.1016/j.injury.2012.12.005
   Ramos RD, 2017, CLIN SPINE SURG, V30, pE896, DOI 10.1097/BSD.0000000000000404
   Robertson A, 2002, SPINE, V27, P2825, DOI 10.1097/00007632-200212150-00019
   Schousboe JT, 2016, J CLIN DENSITOM, V19, P8, DOI 10.1016/j.jocd.2015.08.004
   Shao JS, 2018, INT J SURG, V56, P124, DOI 10.1016/j.ijsu.2018.06.018
   Singh R, 2014, ASIAN SPINE J, V8, P298, DOI 10.4184/asj.2014.8.3.298
   Smetana GW, 2006, ANN INTERN MED, V144, P581, DOI 10.7326/0003-4819-144-8-200604180-00009
   WONG DH, 1995, ANESTH ANALG, V80, P276, DOI 10.1097/00000539-199502000-00013
   Wood K, 2003, J BONE JOINT SURG AM, V85A, P773, DOI 10.2106/00004623-200305000-00001
   Wren SM, 2010, J AM COLL SURGEONS, V210, P491, DOI 10.1016/j.jamcollsurg.2010.01.009
   Wyndaele M, 2006, SPINAL CORD, V44, P523, DOI 10.1038/sj.sc.3101893
   Zuckerman Scott L, 2018, J Spine Surg, V4, P333, DOI 10.21037/jss.2018.05.28
NR 27
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1069
EP E1073
DI 10.1016/j.wneu.2019.01.247
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700133
PM 30790742
DA 2020-05-12
ER

PT J
AU Yi, JL
   Glover, M
   Charitable, J
   Ramcharran, H
   Kurra, S
   Tallarico, RA
   Sun, MH
   Lavelle, WF
AF Yi, Juneyoung L.
   Glover, Michael
   Charitable, John
   Ramcharran, Harry
   Kurra, Swamy
   Tallarico, Richard A.
   Sun, Mike H.
   Lavelle, William F.
TI Perioperative Intravenous Corticosteroids and Radiographic Prevertebral
   Soft Tissue Swelling in Anterior Cervical Fusion for Degenerative
   Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical fusion; Prevertebral soft tissue swelling (PSTS); PSTS
   index; PSTS ratio; Steroid
ID DISKECTOMY; EFFICACY; SURGERY
AB OBJECTIVE: Prevertebral soft tissue swelling (PSTS) is a known complication of anterior cervical fusion (ACF). Prior studies have shown that perioperative steroids may reduce PSTS after ACF. We retrospectively evaluated the role of perioperative intravenous (IV) corticosteroid administration in minimizing radiographic PSTS measurements in patients undergoing ACF for degenerative disease.
   METHODS: Records of 100 consecutive patients undergoing ACF for degenerative disease (Current Procedural Terminology code 63075) from January 2010 through December 2012 by 2 orthopedic spine fellowship-trained surgeons at a single institution were retrospectively reviewed. Patients were included on the basis of specific criteria. They were then separated into comparison and IV steroid groups. Demographic and surgical data were collected. Last, measurements of PSTS, which included PSTS ratio and PSTS index (PSTSI), were obtained from plain radiographs preoperatively and at 3 postoperative time points.
   RESULTS: Eighty patients were included; 26 received IV steroids at the surgeon's discretion (12 intraoperatively, 11 postoperatively and 3 at both time periods). With the exception of a history of prior anterior cervical spine surgery (3.70% comparison vs. 23.08% IV steroid, P = 0.01), there was no statistically significant demographic characteristic. Furthermore, there was no statistically significant surgical characteristic. Last, there was no statistically significant difference between groups at any time point for either PSTS ratio at any level or PSTSI.
   CONCLUSIONS: There does not appear to be a role for perioperative IV steroid administration in minimizing radiographic PSTS in patients undergoing ACF for degenerative disease. The relationship between perioperative IV steroid administration and PSTS requires further investigation.
C1 [Yi, Juneyoung L.] SUNY Upstate Med Univ, Dept Neurosurg, Syracuse, NY 13210 USA.
   [Glover, Michael; Kurra, Swamy; Tallarico, Richard A.; Sun, Mike H.; Lavelle, William F.] SUNY Upstate Med Univ, Dept Orthoped Surg, Syracuse, NY 13210 USA.
   [Charitable, John; Ramcharran, Harry] SUNY Upstate Med Univ, Coll Med, Syracuse, NY 13210 USA.
RP Lavelle, WF (reprint author), SUNY Upstate Med Univ, Dept Orthoped Surg, Syracuse, NY 13210 USA.
EM lavellew@upstate.edu
CR Angevine PD, 2003, SPINE, V28, P931, DOI 10.1097/00007632-200305010-00016
   Buchholz DW, 1997, DYSPHAGIA, V12, P9
   Emery SE, 2009, SPINE, V34, P229, DOI 10.1097/BRS.0b013e318193a287
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   Jeyamohan SB, 2015, J NEUROSURG-SPINE, V23, P137, DOI 10.3171/2014.12.SPINE14477
   Lee SH, 2011, SPINE, V36, P2286, DOI 10.1097/BRS.0b013e318237e5d0
   Martin RE, 1997, DYSPHAGIA, V12, P2, DOI 10.1007/PL00009513
   Pedram M, 2003, EUR SPINE J, V12, P84, DOI 10.1007/s00586-002-0495-6
   Sagi HC, 2002, SPINE, V27, P949, DOI 10.1097/00007632-200205010-00013
   Siasios I, 2018, NEUROSURG REV, V41, P47, DOI 10.1007/s10143-016-0741-8
   Song KJ, 2014, SPINE J, V14, P2954, DOI 10.1016/j.spinee.2014.06.005
   Song KJ, 2012, CLIN ORTHOP SURG, V4, P77, DOI 10.4055/cios.2012.4.1.77
   2003, SPINE, V28, P931
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E784
EP E789
DI 10.1016/j.wneu.2019.01.169
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700096
PM 30738939
DA 2020-05-12
ER

PT J
AU Yi, XH
   Ding, CY
   Xu, H
   Huang, TF
   Kang, DZ
   Wang, DS
AF Yi, Xuehan
   Ding, Chenyu
   Xu, Hao
   Huang, Tingfeng
   Kang, Dezhi
   Wang, Desheng
TI Three-Dimensional Printed Models in Anatomy Education of the Ventricular
   System: A Randomized Controlled Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3-Dimensional printing; Anatomy education; Randomized controlled trial;
   Ventricular system
ID MEDICAL-EDUCATION; LIVER; SKULL
AB BACKGROUND: The ventricular system is a set of brain cavities without solid tissues and the basis of surgical brain anatomy. To the best of our knowledge, the effect of using 3-dimensional (3D) printed models (3DPMs) on anatomy education of the ventricular system has not been reported.
   METHODS: We established 3DPMs for the ventricular system and performed a randomized controlled study to evaluate the educational effect of 3DPMs, 3D images (3DIs), and 2-dimensional images (2DIs). We randomly divided 60 second-year medical students into 3 groups, with 3DPMs, 3DIs, and 2DIs used as teaching aids, 1 for each group. Before and after the anatomy class on the features of ventricular system, all students completed the same test.
   RESULTS: No statistical significant differences were detected between the mean values of the pretest scores of the 3 groups (P > 0.05). For the post-test scores, the students in the 3DPM and 3DI groups performed significantly better than those in the 2DI group in terms of the practice test score (3DPM group vs. 2DI group, P < 0.001; 3DPM group vs. 2DI group, P = 0.009) and total score (3DPM group vs. 2DI group, P = 0.001; 3DI group vs. 2DI group, P = 0.025). From the students' evaluation results, the 3DPM group performed better than the 3DI group for "enjoyment" and "attitude" (P = 0.039 and P = 0.025, respectively).
   CONCLUSIONS: Compared with 2DIs, use of 3DPMs and 3DIs could improve the effectiveness of teaching the anatomy of the complex ventricular system. In addition, 3DPMs could markedly increase the interest and enthusiasm of students.
C1 [Yi, Xuehan; Xu, Hao; Wang, Desheng] Fujian Med Univ, Union Hosp, Dept Otolaryngol Head & Neck Surg, Fuzhou, Fujian, Peoples R China.
   [Ding, Chenyu; Kang, Dezhi] Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
   [Huang, Tingfeng] Fujian Med Univ, Sch Basic Med Sci, Fuzhou, Fujian, Peoples R China.
RP Wang, DS (reprint author), Fujian Med Univ, Union Hosp, Dept Otolaryngol Head & Neck Surg, Fuzhou, Fujian, Peoples R China.
EM 531154173@qq.com
CR Adams CM, 2011, ANAT SCI EDUC, V4, P340, DOI 10.1002/ase.256
   Bizzotto N, 2015, SURG INNOV, V22, P548, DOI 10.1177/1553350614547773
   Chapman SJ, 2013, ANN ANAT, V195, P409, DOI 10.1016/j.aanat.2013.03.005
   Chen G, 2010, CHINESE MED J-PEKING, V123, P146, DOI 10.3760/cma.j.issn.0366-6999.2010.02.004
   Chen S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00647-1
   Cook DA, 2010, ADV HEALTH SCI EDUC, V15, P455, DOI 10.1007/s10459-008-9117-3
   Dietrich CA, 2017, ANGLE ORTHOD, V87, P782, DOI 10.2319/01091-727.1
   Fu F, 2017, NEURAL REGEN RES, V12, P614, DOI 10.4103/1673-5374.205101
   Igami T, 2014, WORLD J SURG, V38, P3163, DOI 10.1007/s00268-014-2740-7
   Javan R, 2017, J DIGIT IMAGING, V30, P576, DOI 10.1007/s10278-017-9951-z
   Knoedler M, 2015, UROLOGY, V85, P1257, DOI 10.1016/j.urology.2015.02.053
   Kong XX, 2016, J SURG EDUC, V73, P264, DOI 10.1016/j.jsurg.2015.10.002
   Li ZZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11570
   Lim KHA, 2016, ANAT SCI EDUC, V9, P213, DOI 10.1002/ase.1573
   Mashiko T, 2015, WORLD NEUROSURG, V83, P351, DOI 10.1016/j.wneu.2013.10.032
   McMenamin PG, 2014, ANAT SCI EDUC, V7, P479, DOI 10.1002/ase.1475
   Mogali SR, 2018, ANAT SCI EDUC, V11, P54, DOI 10.1002/ase.1703
   Narayanan V, 2015, EUR ARCH OTO-RHINO-L, V272, P753, DOI 10.1007/s00405-014-3300-3
   Ploch CC, 2016, WORLD NEUROSURG, V90, P668, DOI 10.1016/j.wneu.2016.02.081
   Powers MK, 2016, CURR OPIN UROL, V26, P283, DOI 10.1097/MOU.0000000000000274
   Preece D, 2013, ANAT SCI EDUC, V6, P216, DOI 10.1002/ase.1345
   Pujol S, 2016, ACAD RADIOL, V23, P507, DOI 10.1016/j.acra.2015.12.012
   Ryan JR, 2015, WORLD NEUROSURG, V84, P1333, DOI 10.1016/j.wneu.2015.06.016
   Scawn RL, 2015, ORBIT, V34, P216, DOI 10.3109/01676830.2015.1049367
   Thawani JP, 2017, NEUROSURGERY, V80, P635, DOI 10.1093/neuros/nyx009
   Witowski JS, 2017, TELEMED E-HEALTH, V23, P943, DOI 10.1089/tmj.2017.0049
   2015, ARCH PATHOL LAB MED, V139, P1048, DOI DOI 10.5858/ARPA.2014-0408-OA
NR 27
TC 3
Z9 3
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E891
EP E901
DI 10.1016/j.wneu.2019.01.204
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700110
PM 30743037
DA 2020-05-12
ER

PT J
AU Yu, ZD
   Zhang, N
   Hameed, NUF
   Qiu, TM
   Zhuang, DX
   Lu, JF
   Wu, JS
AF Yu, Zhengda
   Zhang, Nan
   Hameed, N. U. Farrukh
   Qiu, Tianming
   Zhuang, Dongxiao
   Lu, Junfeng
   Wu, Jinsong
TI The Analysis of Risk Factors and Survival Outcome for Chinese Patients
   with Epilepsy with High-Grade Glioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epilepsy; Function; Glioma; Survival
ID PRIMARY BRAIN-TUMORS; SEIZURES; INHIBITION; RESECTION; FEATURES
AB OBJECTIVE: To evaluate the risk factors of tumor-related epilepsy (TRE) and the relationship between TRE and functional/survival outcomes in patients with high-grade glioma (HGG).
   METHODS: The clinical data of 587 patients with HGG were retrospectively analyzed. A chi(2) test and logistic multiple-regression analysis were used to analyze factors associated with TRE. Logistic and Cox regression were used to analyze factors that may influence functional and survival outcomes.
   RESULTS: Glioma location in temporal (odds ratio [OR], 0.439; P = 0.04) and parietal lobes (OR, 0.092; P = 0.02) were independent protective factors of preoperative epilepsy, compared with gliomas of frontal lobe. Preoperative epilepsy (OR, 9.290; P < 0.001) and dominant hemispheric location (OR, 2.616; P = 0.04) were independent risk factors of postoperative epilepsy. On univariate analysis, patients with preoperative epilepsy had longer progression-free survival (PFS) (P = 0.001) and overall survival (OS) (P < 0.001). Multivariate analysis further confirmed that preoperative epilepsy was an independent protective factor of OS (hazard ratio, 0.587; P = 0.008).
   CONCLUSIONS: In patients with HGG, preoperative epilepsy is significantly associated with tumor involvement of the frontal lobe, whereas postoperative epilepsy is associated with preoperative epilepsy and dominant hemispheric location. Also, patients with HGG with preoperative epilepsy have better PFS and OS.
C1 [Yu, Zhengda; Zhang, Nan; Hameed, N. U. Farrukh; Qiu, Tianming; Zhuang, Dongxiao; Lu, Junfeng; Wu, Jinsong] Fudan Univ, Huashan Hosp, Dept Neurol Surg, Glioma Surg Div, Shanghai, Peoples R China.
RP Wu, JS (reprint author), Fudan Univ, Huashan Hosp, Dept Neurol Surg, Glioma Surg Div, Shanghai, Peoples R China.
EM wjsongc@126.com
RI Qiu, Tianming/AAF-7597-2020
OI Zhuang, Dong xiao/0000-0002-4964-6529
CR Aibaidula A, 2015, CELL TISSUE BANK, V16, P271, DOI 10.1007/s10561-014-9459-4
   Al-Hajri A, 2017, J NEUROPATH EXP NEUR, V76, P1023, DOI 10.1093/jnen/nlx090
   Berendsen S, 2016, NEURO-ONCOLOGY, V18, P700, DOI 10.1093/neuonc/nov238
   Bobustuc GC, 2010, NEURO-ONCOLOGY, V12, P917, DOI 10.1093/neuonc/noq044
   Buckingham SC, 2011, NAT MED, V17, P1269, DOI 10.1038/nm.2453
   Chang EF, 2011, J NEUROSURG, V114, P566, DOI 10.3171/2010.6.JNS091246
   Dabscheck G, 2015, EPILEPSIA, V56, pE139, DOI 10.1111/epi.13080
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   de Groot M, 2012, BRAIN, V135, P1002, DOI 10.1093/brain/awr310
   Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x
   Ghinda D, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.12.FOCUS15572
   Huberfeld G, 2016, NAT REV NEUROL, V12, P204, DOI 10.1038/nrneurol.2016.26
   Iuchi T, 2015, J CLIN NEUROSCI, V22, P87, DOI 10.1016/j.jocn.2014.05.036
   Jacoby A, 2008, EPILEPSY BEHAV, V12, P286, DOI 10.1016/j.yebeh.2007.10.006
   Kolker S, 2002, EUR J NEUROSCI, V16, P21, DOI 10.1046/j.1460-9568.2002.02055.x
   Lieu AS, 2000, EPILEPSY RES, V38, P45
   Lin NU, 2015, LANCET ONCOL, V16, pE270, DOI 10.1016/S1470-2045(15)70057-4
   Lynam LM, 2007, CLIN NEUROL NEUROSUR, V109, P634, DOI 10.1016/j.clineuro.2007.05.017
   Neal A, 2018, EPILEPSY BEHAV, V78, P30, DOI 10.1016/j.yebeh.2017.10.027
   Norden AD, 2002, EPILEPSY BEHAV, V3, P219, DOI 10.1016/S1525-5050(02)00029-X
   Pallud J, 2014, BRAIN, V137, P449, DOI 10.1093/brain/awt345
   Rahman Z, 2015, EPILEPSY BEHAV, V48, P88, DOI 10.1016/j.yebeh.2015.03.016
   Ruda R, 2012, NEURO-ONCOLOGY, V14, P55, DOI 10.1093/neuonc/nos199
   Shi ZF, 2015, BIOPRESERV BIOBANK, V13, P31, DOI 10.1089/bio.2014.0089
   Sizoo EM, 2010, NEURO-ONCOLOGY, V12, P1162, DOI 10.1093/neuonc/nop045
   Toledo M, 2017, EPILEPSY RES, V130, P1, DOI 10.1016/j.eplepsyres.2016.12.013
   van Breemen MSM, 2007, LANCET NEUROL, V6, P421, DOI 10.1016/S1474-4422(07)70103-5
   Vornetti G, 2017, J CLIN NEUROSCI, V44, P158, DOI 10.1016/j.jocn.2017.06.022
   Weller M, 2011, NEUROLOGY, V77, P1156, DOI 10.1212/WNL.0b013e31822f02e1
   You G, 2012, NEURO-ONCOLOGY, V14, P230, DOI 10.1093/neuonc/nor205
   Zhong Z, 2015, EPILEPSY RES, V109, P100, DOI 10.1016/j.eplepsyres.2014.09.012
   Zhou XW, 2016, CLIN NEUROL NEUROSUR, V151, P113, DOI 10.1016/j.clineuro.2016.10.001
   2008, J NEUROSURG, V108, P227, DOI DOI 10.3171/JNS/2008/108/2/0227
NR 33
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E947
EP E957
DI 10.1016/j.wneu.2019.01.213
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700117
PM 30763739
DA 2020-05-12
ER

PT J
AU Yu, ZY
   Guo, R
   Zheng, J
   Li, M
   Wen, DK
   Li, H
   You, C
   Ma, L
AF Yu, Zhiyuan
   Guo, Rui
   Zheng, Jun
   Li, Mou
   Wen, Dingke
   Li, Hao
   You, Chao
   Ma, Lu
TI Comparison of Acute Moyamoya Disease-Related and Idiopathic Primary
   Intraventricular Hemorrhage in Adult Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Characteristics; Moyamoya disease; Outcome; Primary intraventricular
   hemorrhage
ID INTRACEREBRAL HEMORRHAGE; CLINICAL CHARACTERISTICS; PROGNOSTIC-FACTORS;
   FEATURES; OUTCOMES; DRAINAGE
AB OBJECTIVE: Primary intraventricular hemorrhage (PIVH) is a rare condition in adult patients. PIVH occurs frequently in adult hemorrhagic Moyamoya disease (MMD). Idiopathic PIVH is defined as PIVH without cerebrovascular abnormalities. This study is aimed to compare the baseline characteristics and outcomes of acute MMD-related and idiopathic PIVH.
   METHODS: Adult patients with acute MMD-related or idiopathic PIVH were retrospectively included. Baseline characteristics and outcomes at discharge were obtained and compared. Chi-square test, Student's t-test, or rank-sum test were used in statistical analyses.
   RESULTS: This study finally included 32 patients with acute MMD-related PIVH and 112 with acute idiopathic PIVH. Patients with acute MMD-related PIVH were significantly younger (53.3 +/- 15.8 vs. 42.8 +/- 12.2 years, P < 0.001). The admission systolic blood pressure in patients with acute idiopathic PIVH was significantly higher (161.7 +/- 30.9 vs. 134.6 +/- 24.6 mm Hg, P < 0.001). Patients with acute idiopathic PIVH had significantly higher admission serum urea (5.68 +/- 2.66 vs. 4.34 +/- 1.62 mmol/L, P = 0.008), cystatin C (0.97 +/- 0.72 vs. 0.68 +/- 0.16 mg/L, P = 0.023), and uric acid (309.01 +/- 105.97 vs. 242.24 +/- 77.65 mu mol/L, P = 0.001). In patients with acute MMD-related PIVH, only one (3.1%) patient was dead at discharge. In contrast, a total of 22 (19.6%) patients with acute idiopathic patients died at discharge (P = 0.027).
   CONCLUSIONS: Compared with patients with acute idiopathic PIVH, patients with acute MMD-related PIVH have younger age, lower blood pressure, and better renal function. Moreover, patients with acute MMD-related PIVH have lower short-term mortality.
C1 [Yu, Zhiyuan; Guo, Rui; Zheng, Jun; Wen, Dingke; Li, Hao; You, Chao; Ma, Lu] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Li, Mou] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Sichuan, Peoples R China.
RP Ma, L (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM alex80350305@126.com
CR Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609
   Angelopoulos M, 1995, SURG NEUROL, V44, P433, DOI 10.1016/0090-3019(95)00261-8
   Baker AD, 2018, INT J STROKE, V13, P11, DOI 10.1177/1747493017730745
   Butcher KS, 2013, STROKE, V44, P620, DOI 10.1161/STROKEAHA.111.000188
   Flint AC, 2008, NEUROCRIT CARE, V8, P330, DOI 10.1007/s12028-008-9070-2
   Fujimura M, 2016, FRONT NEUROL NEUROSC, V40, P204, DOI 10.1159/000448314
   Garton T, 2017, EXPERT OPIN THER TAR, V21, P1111, DOI 10.1080/14728222.2017.1397628
   Ge PC, 2017, WORLD NEUROSURG, V106, P224, DOI [10.1016/J.WNEU.2017.06.145, 10.1016/j.wneu.2017.06.145]
   Giray S, 2009, TURK NEUROSURG, V19, P338
   Guo R, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005089
   Hanley DF, 2017, LANCET, V389, P603, DOI 10.1016/S0140-6736(16)32410-2
   Jang DK, 2014, AM J NEURORADIOL, V35, P1124, DOI 10.3174/ajnr.A3819
   Jiang HQ, 2018, WORLD NEUROSURG, V116, pE1032, DOI 10.1016/j.wneu.2018.05.153
   Jiang HQ, 2014, J NEUROSURG, V121, P1048, DOI 10.3171/2014.7.JNS132434
   Jo KI, 2016, J KOREAN NEUROSURG S, V59, P117, DOI 10.3340/jkns.2016.59.2.117
   Kim JK, 2013, J KOREAN NEUROSURG S, V54, P296, DOI 10.3340/jkns.2013.54.4.296
   Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0
   Lee SH, 2017, MED SCI MONITOR, V23, P1401, DOI 10.12659/MSM.899309
   Li QL, 2018, BIOMED REP, V8, P191, DOI 10.3892/br.2017.1030
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Nah HW, 2012, STROKE, V43, P1947, DOI 10.1161/STROKEAHA.112.654004
   Passero S, 2002, ACTA NEUROL SCAND, V105, P115, DOI 10.1034/j.1600-0404.2002.1o118.x
   Qureshi AI, 2016, NEW ENGL J MED, V375, P1033, DOI 10.1056/NEJMoa1603460
   Song P, 2018, CURR MED SCI, V38, P880, DOI 10.1007/s11596-018-1957-3
   Staykov D, 2017, ANN NEUROL, V81, P93, DOI 10.1002/ana.24834
   Wan M, 2015, BRIT J NEUROSURG, V29, P189, DOI 10.3109/02688697.2014.976177
   Weinstein R, 2017, J STROKE CEREBROVASC, V26, P995, DOI 10.1016/j.jstrokecerebrovasdis.2016.11.114
   Yeo SS, 2011, EUR NEUROL, V66, P235, DOI 10.1159/000330942
   You SJ, 2016, CEREBROVASC DIS, V42, P455, DOI 10.1159/000448340
   Zhang S, 2017, J NEUROL, V264, P382, DOI 10.1007/s00415-016-8367-x
NR 30
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E313
EP E318
DI 10.1016/j.wneu.2019.01.070
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700040
PM 30685378
DA 2020-05-12
ER

PT J
AU Yuce, I
   Kahyaoglu, O
   Cavusoglu, HA
   Cavusoglu, H
   Aydin, Y
AF Yuce, Ismail
   Kahyaoglu, Okan
   Cavusoglu, Halit Arda
   Cavusoglu, Halit
   Aydin, Yunus
TI Long-Term Clinical Outcome and Reoperation Rate for Microsurgical
   Bilateral Decompression via Unilateral Approach of Lumbar Spinal
   Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bilateral decompression; Lumbar spinal stenosis; Microdiscectomy;
   Reoperation rate; Unilateral approach
ID NONOPERATIVE TREATMENT; SURGICAL-TREATMENT; CANAL STENOSIS; LAMINECTOMY;
   LAMINOTOMY; OPERATIONS
AB OBJECTIVE: To evaluate long-term outcome and reoperation rate for microsurgical bilateral decompression via unilateral approach of lumbar spinal stenosis, a common degenerative spinal disease of the lumbar spine.
   METHODS: In this observational prospective study, 918 patients were treated for single-level or multilevel lumbar spinal stenosis by bilateral decompression via unilateral approach between January 2002 and January 2016. Of 918 patients, 180 underwent microdiscectomy with decompression. Follow-up consisted of radiologic investigations, Oswestry Disability Index questionnaire, and 36-Item Short-Form Health Survey at 6 and 12 months postoperatively.
   RESULTS: There were 492 female patients (53.6%) and 426 male patients (46.4%) with a mean age of 63.83 +/- 10.16 years (range, 43-79 years). Symptom duration was 4-49 months. Average follow-up time was 98 months (range, 25-168 months), and reoperation rate was 2.5%. Oswestry Disability Index scores decreased significantly (from 30.65 +/- 7.82 to 11.32 +/- 2.50 at 6 months and 11.30 +/- 2.49 at 12 months), and 36-Item Short-Form Health Survey parameter scores demonstrated a significant improvement in the early and late follow-up results.
   CONCLUSIONS: Bilateral decompression via unilateral approach for lumbar spinal stenosis allowed a sufficient and safe decompression of the neural structures, resulting in a highly significant reduction of symptoms and disability, acceptable reoperation rate, and improved health-related quality of life.
C1 [Yuce, Ismail; Cavusoglu, Halit] Acibadem Mehmet Ali Aydinlar Univ, Vocat Sch Hlth Serv, Istanbul, Turkey.
   [Kahyaoglu, Okan; Aydin, Yunus] Fulya Hosp, Acibadem Healthcare Grp, Istanbul, Turkey.
   [Cavusoglu, Halit Arda] Bahcesehir Univ, Med Fac, Istanbul, Turkey.
RP Yuce, I (reprint author), Acibadem Mehmet Ali Aydinlar Univ, Vocat Sch Hlth Serv, Istanbul, Turkey.
EM dr.ismailyuce@gmail.com
OI Yuce, Ismail/0000-0002-7385-9137
CR Blumenthal C, 2013, J NEUROSURG-SPINE, V18, P340, DOI 10.3171/2013.1.SPINE12537
   Deyo RA, 2011, J BONE JOINT SURG AM, V93A, P1979, DOI 10.2106/JBJS.J.01292
   GETTY CJM, 1981, J BONE JOINT SURG BR, V63, P330
   Ghiselli G, 2004, J BONE JOINT SURG AM, V86A, P1497, DOI 10.2106/00004623-200407000-00020
   Hong SW, 2011, SPINE, V36, pE172, DOI 10.1097/BRS.0b013e3181db998c
   Jansson KA, 2005, EUR SPINE J, V14, P659, DOI 10.1007/s00586-004-0851-9
   Mackay DC, 1998, BRIT J NEUROSURG, V12, P556, DOI 10.1080/02688699844420
   Malmivaara A, 2007, SPINE, V32, P1, DOI 10.1097/01.brs.0000251014.81875.6d
   Mariconda M, 2002, J SPINAL DISORD TECH, V15, P39, DOI 10.1097/00024720-200202000-00006
   Mayer HM, 2003, ORTHOPADE, V32, P889, DOI 10.1007/s00132-003-0536-9
   McCulloch JA, 1991, ADULT SPINE PRINCIPL
   Nystrom B, 2001, UPSALA J MED SCI, V106, P123, DOI 10.3109/2000-1967-165
   POSTACCHINI F, 1993, J BONE JOINT SURG BR, V75, P386
   Thome C, 2005, J NEUROSURG-SPINE, V3, P129, DOI 10.3171/spi.2005.3.2.0129
   Tsai RYC, 1998, J SPINAL DISORD, V11, P389
   Wang JC, 1998, J BONE JOINT SURG AM, V80A, P1728, DOI 10.2106/00004623-199812000-00002
   Weiner BK, 1999, SPINE, V24, P2268, DOI 10.1097/00007632-199911010-00016
   Weinstein JN, 2008, NEW ENGL J MED, V358, P794, DOI 10.1056/NEJMoa0707136
   Weinstein JN, 2009, J BONE JOINT SURG AM, V91A, P1295, DOI 10.2106/JBJS.H.00913
   WHITE AA, 1990, CLIN BIOMECHANICS SP
   Wilby MJ, 2006, BRIT J NEUROSURG, V20, P391, DOI 10.1080/02688690601048195
   Yamashita K, 2006, SPINE, V31, P1484, DOI 10.1097/01.brs.0000219940.26390.26
   YOUNG S, 1988, NEUROSURGERY, V23, P628, DOI 10.1227/00006123-198811000-00014
   2007, EUR SPINE J, V16, P2133, DOI DOI 10.1007/S00586-007-0471-2
   2007, J NEUROSURG-SPINE, V7, P579, DOI DOI 10.3171/SPI-07/12/579
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E465
EP E472
DI 10.1016/j.wneu.2019.01.105
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700062
PM 30710724
DA 2020-05-12
ER

PT J
AU Zeeshan, Q
   Patel, A
   Cheng, CY
   Zhao, NH
   Barber, J
   Ghodke, BV
   Sekhar, LN
AF Zeeshan, Qazi
   Patel, Anoop
   Cheng, Chun-Yu
   Zhao, Ning-Hui
   Barber, Jason
   Ghodke, Basavaraj V.
   Sekhar, Laligam N.
TI Resection of Meningiomas Involving Major Dural Venous Sinuses:
   Classification, Technique, and Long-Term Results
SO WORLD NEUROSURGERY
LA English
DT Article
DE Collateralization; Dural venous sinus; Kaplan-Meier; Karnofsky
   Performance Status (KPS); Meningioma; Sinus pericranii; Sinus
   reconstruction
ID SUPERIOR SAGITTAL SINUS; GROSS TOTAL RESECTION; PARASAGITTAL
   MENINGIOMAS; ADJUVANT RADIOTHERAPY; EXPERIENCE; MANAGEMENT; SURVIVAL;
   REMOVAL; SURGERY; SYSTEM
AB OBJECTIVE: Management of meningiomas with major dural venous sinus involvement is challenging. We present our case series and perspective on reconstruction of the sinuses.
   METHODS: Fifty-five patients underwent operations between 2005 and 2016 and the retrospective data were collected and analyzed.
   RESULTS: The cohort was younger with a mean of 51.3 years (range, 19-72 years) predominantly involving the superior sagittal sinus (44 patients). Sinus involvement was classified into group 1 (<50% of sinus, n = 28), group 2 (50%-99%, n = 8), and group 3 (total occlusion, n = 19). Venous collateralization was present in 100% of group 2 and 3 and in 36% of group 1 occlusions. Sinus pericranii was seen in 22 patients. Gross total resection was achieved in 87.2%, and sinus reconstruction followed in 38 patients (24 by direct suture and 14 by a patch graft). Pathology showed 36 (65%) World Health Organization grade I, 18 (33%) grade II, and 1 (2%) grade III tumors. During the mean follow-up of 60 months (range, 1-132 months), sinus was patent (74%) or narrowed but patent (24%) in 98%; 2 recurrences (3.6%) were observed (at 24 and 120 months). The mean preoperative/postoperative Karnofsky Performance Status and Kaplan-Meier cumulative overall/recurrence-free survival were 84.2%/88.1% and 90.9%/80.1%, respectively.
   CONCLUSIONS: These meningiomas present in a younger population, are more likely to be World Health Organization grade II or III, necessitating a more aggressive tumor resection strategy. Aggressive resection coupled with sinus reconstruction results in good long-term surgical outcome and low recurrence rates.
C1 [Zeeshan, Qazi; Patel, Anoop; Cheng, Chun-Yu; Zhao, Ning-Hui; Barber, Jason; Ghodke, Basavaraj V.; Sekhar, Laligam N.] Univ Washington, Harborview Med Ctr, Dept Neurosurg, 325 9Th Ave, Seattle, WA 98104 USA.
   [Cheng, Chun-Yu] Chang Gung Mem Hosp, Dept Neurosurg, Chiayi, Taiwan.
   [Cheng, Chun-Yu] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Zhao, Ning-Hui] Kunming Med Univ, Affiliated Hosp 2, Dept Neurosurg, Kunming, Yunnan, Peoples R China.
RP Sekhar, LN (reprint author), Univ Washington, Harborview Med Ctr, Dept Neurosurg, 325 9Th Ave, Seattle, WA 98104 USA.
EM lsekhar@uw.edu
OI Cheng, Chun-Yu/0000-0003-2233-2666
CR Adachi K, 2017, NEUROL MED-CHIR, V57, P505, DOI 10.2176/nmc.ra.2016-0336
   Aghi Manish, 2006, Prog Neurol Surg, V19, P80, DOI 10.1159/000095184
   Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63
   Aizer AA, 2015, CANCER-AM CANCER SOC, V121, P4376, DOI 10.1002/cncr.29639
   ALRODHAN NRF, 1990, NEUROSURGERY, V26, P832, DOI 10.1227/00006123-199005000-00016
   Amuluru K, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.129
   Anthofer J, 2017, WORLD NEUROSURG, V104, P560, DOI 10.1016/j.wneu.2017.05.025
   Caroli E, 2006, NEUROSURG REV, V29, P236, DOI 10.1007/s10143-006-0020-1
   Cheung VLS, 2018, J NEURO-ONCOL, V136, P351, DOI 10.1007/s11060-017-2659-6
   Coppola Federico, 2017, Surg Neurol Int, V8, pS37, DOI 10.4103/sni.sni_286_17
   DiMeco F, 2004, NEUROSURGERY, V55, P1263, DOI 10.1227/01.NEU.0000143373.74160.F2
   DiMeco F, 2008, NEUROSURGERY, V62, P1124, DOI [10.1227/01.NEU.0000143373.74160.F2, 10.1227/01.neu.0000333779.73940.c4]
   Georgoulis G, 2017, OPER NEUROSURG, V13, P283, DOI 10.1093/ons/opw021
   Guclu B, 2010, ACTA NEUROCHIR, V152, P941, DOI 10.1007/s00701-009-0572-2
   Han MS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004705
   Hasseleid BF, 2012, J NEUROSURG, V117, P999, DOI 10.3171/2012.9.JNS12294
   Hwang SK, 2004, SKULL BASE-INTERD AP, V14, P21, DOI 10.1055/s-2004-821356
   Hwang WL, 2016, NEURO-ONCOLOGY, V18, P863, DOI 10.1093/neuonc/nov285
   Ko KW, 2007, J CLIN NEUROSCI, V14, P747, DOI 10.1016/j.jocn.2006.05.005
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Ma Jingjian, 2002, Neurosurg Focus, V12, pecp1
   Mantovani A, 2014, WORLD NEUROSURG, V82, P455, DOI 10.1016/j.wneu.2013.06.024
   Mathiesen T, 2014, WORLD NEUROSURG, V81, P116, DOI 10.1016/j.wneu.2013.01.095
   Mazur MD, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.8.FOCUS13340
   Murrone D, 2017, J CLIN NEUROSCI, V37, P25, DOI 10.1016/j.jocn.2016.11.002
   Nanda A, 2016, J CLIN NEUROSCI, V31, P112, DOI 10.1016/j.jocn.2016.02.021
   OKA K, 1994, J NEUROSURG, V81, P520, DOI 10.3171/jns.1994.81.4.0520
   Park HJ, 2013, J NEURO-ONCOL, V115, P241, DOI 10.1007/s11060-013-1219-y
   Perry A, 1997, AM J SURG PATHOL, V21, P1455, DOI 10.1097/00000478-199712000-00008
   Raza SM, 2010, NEUROSURGERY, V67, P885, DOI 10.1227/NEU.0b013e3181ef2a18
   Ricci Alessandro, 2017, Surg Neurol Int, V8, P1, DOI 10.4103/2152-7806.198728
   Rogers L, 2010, J NEURO-ONCOL, V99, P393, DOI 10.1007/s11060-010-0343-1
   Rydzewski NR, 2018, CANCER-AM CANCER SOC, V124, P734, DOI 10.1002/cncr.31088
   Samadi N, 2007, MALAYS J MED SCI, V14, P46
   Saraf S, 2011, ONCOLOGIST, V16, P1604, DOI 10.1634/theoncologist.2011-0193
   SchmidElsaesser R, 1997, NEUROSURGERY, V41, P1005, DOI 10.1097/00006123-199711000-00001
   Sindou M, 2005, ACT NEUR S, V94, P167
   Sindou M, 2001, J CLIN NEUROSCI, V8, P8, DOI 10.1054/jocn.2001.0868
   Sindou M, 2000, ADV TECH STAND NEUR, V26, P131
   Sindou M, 2014, WORLD NEUROSURG, V81, P46, DOI 10.1016/j.wneu.2013.07.119
   Sindou MP, 2006, J NEUROSURG, V105, P514, DOI 10.3171/jns.2006.105.4.514
   Sughrue ME, 2011, J CLIN NEUROSCI, V18, P628, DOI 10.1016/j.jocn.2010.10.001
   Tomasello F, 2013, J NEUROSURG, V119, P74, DOI 10.3171/2012.11.JNS112011
   2004, NEUROSURGERY, V55, P1263
   1990, NEUROSURGERY, V26, P832
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E521
EP E536
DI 10.1016/j.wneu.2019.01.128
PG 16
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700069
PM 30716491
DA 2020-05-12
ER

PT J
AU Zhang, DD
   Lin, H
   Liu, JL
   Liu, ZS
   Yan, J
   Cai, XD
AF Zhang, Doudou
   Lin, Hai
   Liu, Jiali
   Liu, Zesi
   Yan, Jie
   Cai, Xiaodong
TI Electrode Reconstruction Assists Postoperative Contact Selection in Deep
   Brain Stimulation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Contact selection; Deep brain stimulation; Electrode reconstruction;
   Subthalamic nucleus; Volume of tissue activated
ID SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE; ACTIVATION
AB BACKGROUND: Postoperative contact selection of deep brain stimulation (DBS), testing one contact at a time, is a clinically time-consuming procedure being challenged by incoming applications of more complex DBS leads. The objective of this study is to guide clinicians to select the optimal contact by neuroanatomic information derived from electrode reconstruction.
   METHODS: We reviewed 33 patients with Parkinson disease who underwent bilateral subthalamic nucleus (STN) DBS with preoperative magnetic resonance imaging and postoperative computed tomography scan. All electrodes were reconstructed in standardized Montreal Neurological Institute and Hospital space, and the volume of tissue activated (VTA) was estimated for each contact. According to the DISTAL atlas, we calculated 6 neuroanatomic parameters: the distances of each contact to the STN and the motor part of the STN (M-STN), the volumes of the overlapping areas of the VTA and STN/M-STN, and the number and ratio of fiber tracts through both the VTA and motor areas (primary motor cortex and supplementary motor area).
   RESULTS: All 6 parameters showed significant group differences between clinical optimal and nonoptimal contacts by permutation test. Moreover, the possibility of being the optimal contact was estimated for all contacts under the combination of these 6 parameters using a generalized linear model, which resulted in accuracy of 72.7% for prediction of contact selection.
   CONCLUSIONS: Electrode reconstruction could assist in selecting the clinical optimal contact and improving its efficiency.
C1 [Zhang, Doudou; Lin, Hai; Liu, Jiali; Liu, Zesi; Yan, Jie; Cai, Xiaodong] Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Dept Funct Neuro, Shenzhen, Peoples R China.
   [Zhang, Doudou; Lin, Hai; Liu, Jiali; Yan, Jie; Cai, Xiaodong] Shenzhen Univ, Sch Med, Shenzhen, Peoples R China.
   [Lin, Hai] Shenzhen Key Lab Neurosurg, Shenzhen, Peoples R China.
   [Liu, Zesi] Shantou Univ, Med Coll, Shantou, Guangdong, Peoples R China.
RP Cai, XD (reprint author), Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Dept Funct Neuro, Shenzhen, Peoples R China.; Cai, XD (reprint author), Shenzhen Univ, Sch Med, Shenzhen, Peoples R China.
EM 13632660199@139.com
CR Abosch A, 2010, NEUROSURGERY, V67, P1745, DOI 10.1227/NEU.0b013e3181f74105
   Accolla EA, 2014, HUM BRAIN MAPP, V35, P5083, DOI 10.1002/hbm.22533
   Astrom M, 2015, IEEE T BIO-MED ENG, V62, P664, DOI 10.1109/TBME.2014.2363494
   Benabid AL, 2009, LANCET NEUROL, V8, P67, DOI 10.1016/S1474-4422(08)70291-6
   Chen YK, 2018, WORLD NEUROSURG, V114, pE1079, DOI 10.1016/j.wneu.2018.03.149
   Ewert S, 2018, NEUROIMAGE, V170, P271, DOI 10.1016/j.neuroimage.2017.05.015
   Horn A, 2015, NEUROIMAGE, V107, P127, DOI 10.1016/j.neuroimage.2014.12.002
   Husch A, 2018, BRAIN STIMUL, V11, P863, DOI 10.1016/j.brs.2018.01.031
   Kuhn AA, 2017, MOVEMENT DISORD, V32, P11, DOI 10.1002/mds.26703
   McIntyre CC, 2004, J NEUROPHYSIOL, V91, P1457, DOI 10.1152/jn.00989.2003
   Miocinovic S, 2013, JAMA NEUROL, V70, P163, DOI 10.1001/2013.jamaneurol.45
   Odekerken VJJ, 2013, LANCET NEUROL, V12, P37, DOI 10.1016/S1474-4422(12)70264-8
   Patrick N, 2016, MED CLIN N AM, V100, P173, DOI 10.1016/j.mcna.2015.08.015
   Petersen MV, 2018, ANN CLIN TRANSL NEUR, V5, P888, DOI 10.1002/acn3.589
   Plantinga BR, 2018, NEUROIMAGE, V168, P403, DOI 10.1016/j.neuroimage.2016.09.023
   Pollo C, 2014, BRAIN, V137, P2015, DOI 10.1093/brain/awu102
   Toda H, 2009, J NEUROSURG, V111, P737, DOI 10.3171/2008.12.JNS0861
   Volkmann J, 2002, MOVEMENT DISORD, V17, pS181, DOI 10.1002/mds.10162
   Yao C, 2019, PARKINSONISM RELAT D, V58, P40, DOI 10.1016/j.parkreldis.2018.05.014
   2017, ANN NEUROL, V82, P67, DOI DOI 10.1002/ANA.24974
NR 20
TC 1
Z9 2
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E442
EP E447
DI 10.1016/j.wneu.2019.01.101
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700059
PM 30708078
DA 2020-05-12
ER

PT J
AU Zhang, D
   Liu, BG
   Zhu, JC
   Li, CX
   Wei, FN
   Yuan, Y
   Zhu, D
AF Zhang, Duo
   Liu, Baoge
   Zhu, Jichao
   Li, Chenxi
   Wei, Fengning
   Yuan, Yuan
   Zhu, Di
TI Comparison of Clinical and Radiologic Outcomes Between Self-Locking
   Stand-Alone Cage and Cage with Anterior Plate for Multilevel Anterior
   Cervical Discectomy and Fusion: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACDF; Anterior cervical decompression and fusion; Anterior plate;
   Meta-analysis; Multilevel cervical spondylosis; Self-locking stand-alone
   cage
ID PROFILE ANCHORED SPACER; POLYETHERETHERKETONE PEEK CAGES; SAGITTAL
   ALIGNMENT PARAMETERS; ADJACENT-LEVEL OSSIFICATION; ZERO-P SPACER;
   SPONDYLOTIC MYELOPATHY; INTERBODY FUSION; INTEGRATED PLATE; DISC
   DISEASE; RISK-FACTORS
AB OBJECTIVE: This meta-analysis was conducted to evaluate the therapeutic effects in clinical and radiologic outcomes of a self-locking stand-alone cage (SSC) and cage-with-plate (CP) for multilevel anterior cervical discectomy and fusion (ACDF).
   METHODS: A systematic search was performed for all comparative studies reported up to August 2018. Operative time, hospital stay, intraoperative blood loss, Japanese Orthopedic Association score, Neck Disability Index (NDI), cervical and segmental Cobb angle, intervertebral height, fusion rate, incidence of subsidence, dysphagia, and adjacent segment degeneration were analyzed with the RevMan 5.3.3 software.
   RESULTS: A total of 15 studies were included. There was no difference regarding preoperative or postoperative Japanese Orthopedic Association score, Neck Disability Index, segmental Cobb angle and intervertebral height, preoperative cervical Cobb angle, fusion rate, incidence of subsidence, and adjacent segment degeneration between the SSC and CP group (P > 0.05). However, the SSC group had shorter operative time (mean difference [MD], -11.35; 95% confidence interval [CI], -16.24 to -3.66) and hospital stay (MD, -0.64; 95% CI, -1.21 to -0.06), less intraoperative blood loss (MD, -13.22; 95% CI, -19.03 to -7.41) and postoperative cervical Cobb angle (MD, -0.70; 95% CI, -1.35 to -0.06), and lower incidence of dysphagia significantly (odds ratio, -0.57; 95% CI, 0.40-0.82) (P < 0.05).
   CONCLUSIONS: ACDF with SSC and CP in multilevel cervical spondylosis achieved similar clinical relief. Although CP maintained better cervical lordosis, SSC contributed to less surgical pain and fewer complications. ACDF with SSC is safe and efficient in treating multilevel cervical spondylosis.
C1 [Zhang, Duo; Liu, Baoge; Zhu, Jichao; Li, Chenxi; Zhu, Di] Capital Med Univ, Beijing Tiantan Hosp, Dept Orthopaed, Beijing, Peoples R China.
   [Wei, Fengning] China Japan Friendship Hosp, Dept Emergency, Beijing, Peoples R China.
   [Yuan, Yuan] China Rehabil Res Ctr, Dept Spinal Cord Injury Rehabil, Beijing, Peoples R China.
RP Zhu, D (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Orthopaed, Beijing, Peoples R China.
EM zhudi214@126.com
OI Zhang, Duo/0000-0001-9011-4316
FU Beijing Municipal Administration of Hospitals Incubating Program
   [PX2018072]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [81472137, 81772370]; Youth Science
   Foundation of Beijing Tian Tan Hospital [2016-YQN-12]; Beijing Municipal
   Administration of Hospitals Clinical Medicine Development of Special
   Support [XMLX201803]
FX This work was supported by Beijing Municipal Administration of Hospitals
   Incubating Program, code PX2018072, the National Natural Science
   Foundation of China (number 81472137, 81772370), Youth Science
   Foundation of Beijing Tian Tan Hospital (number 2016-YQN-12) and Beijing
   Municipal Administration of Hospitals Clinical Medicine Development of
   Special Support, code XMLX201803.
CR Bartels RHMA, 2006, NEUROSURGERY, V58, P502, DOI 10.1227/01.NEU.0000197258.30821.50
   Bydon Mohamad, 2014, Surg Neurol Int, V5, pS74, DOI 10.4103/2152-7806.130676
   Carreon LY, 2016, SCOLIOSIS SPINAL DIS, V11, DOI 10.1186/s13013-016-0072-0
   Chen Y, 2016, CLIN NEUROL NEUROSUR, V144, P72, DOI 10.1016/j.clineuro.2016.03.010
   Chen YY, 2017, CLIN SPINE SURG, V30, pE1111, DOI 10.1097/BSD.0000000000000440
   Chen YY, 2015, EUR SPINE J, V24, P1666, DOI 10.1007/s00586-015-3919-9
   Chen YQ, 2016, EUR SPINE J, V25, P2255, DOI 10.1007/s00586-016-4391-x
   Chou YC, 2008, J CLIN NEUROSCI, V15, P1240, DOI 10.1016/j.jocn.2007.05.016
   Chung C, 2012, SPINE J, V12, p100S, DOI DOI 10.1016/J.SPINEE.2012.08.277
   De la Garza-Ramos R, 2016, J NEUROSURG-SPINE, V24, P885, DOI 10.3171/2015.10.SPINE15795
   Demircan MN, 2007, J CLIN NEUROSCI, V14, P723, DOI 10.1016/j.jocn.2006.02.026
   Duan YC, 2016, J CLIN NEUROSCI, V33, P11, DOI 10.1016/j.jocn.2016.01.046
   Dufour T, 2010, BRIT J NEUROSURG, V24, P633, DOI 10.3109/02688691003793029
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   Fraser JF, 2007, J NEUROSURG-SPINE, V6, P298, DOI 10.3171/spi.2007.6.4.298
   Frempong-Boadu A, 2002, J SPINAL DISORD TECH, V15, P362, DOI 10.1097/00024720-200210000-00004
   Grasso G, 2014, EUR SPINE J, V23, pS650, DOI 10.1007/s00586-014-3553-y
   He SH, 2018, SPINE, V43, pE259, DOI 10.1097/BRS.0000000000002323
   Iyer S, 2016, SPINE, V41, P371, DOI 10.1097/BRS.0000000000001221
   Kast E, 2009, NEUROSURG REV, V32, P207, DOI 10.1007/s10143-008-0168-y
   Klineberg E, 2010, ORTHOP CLIN N AM, V41, P193, DOI 10.1016/j.ocl.2009.12.010
   Klingler JH, 2014, SCI WORLD J, DOI 10.1155/2014/398396
   Koller H, 2007, EUR SPINE J, V16, P2055, DOI 10.1007/s00586-007-0398-7
   Konya D, 2009, J CLIN NEUROSCI, V16, P404, DOI 10.1016/j.jocn.2008.07.070
   Lee MJ, 2005, J SPINAL DISORD TECH, V18, P406, DOI 10.1097/01.bsd.0000177211.44960.71
   Lee YS, 2015, SPINE, V40, pE563, DOI 10.1097/BRS.0000000000000864
   Liu WJ, 2015, THER CLIN RISK MANAG, V11, DOI 10.2147/TCRM.S92511
   Liu YJ, 2016, EUR SPINE J, V25, P1881, DOI 10.1007/s00586-016-4500-x
   Malloy KM, 2002, CLIN ORTHOP RELAT R, P27
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Nagoshi N, 2017, J BONE JOINT SURG AM, V99, P1069, DOI 10.2106/JBJS.16.00325
   Njoku I, 2014, J NEUROSURG-SPINE, V21, P529, DOI 10.3171/2014.6.SPINE12951
   Park JY, 2016, J CLIN NEUROSCI, V33, P83, DOI 10.1016/j.jocn.2016.01.042
   Park JB, 2005, J BONE JOINT SURG AM, V87A, P558, DOI 10.2106/JBJS.C.01555
   Pitzen TR, 2009, SPINE, V34, P641, DOI 10.1097/BRS.0b013e318198ce10
   Qi M, 2013, BONE JOINT J, V95B, P543, DOI 10.1302/0301-620X.95B4.30992
   Qian L, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018-014-0063-x
   Scholz M, 2015, SPINE, V40, pE375, DOI 10.1097/BRS.0000000000000768
   Shi S, 2015, SPINE J, V15, P1973, DOI 10.1016/j.spinee.2015.04.024
   Smith-Hammond CA, 2004, SPINE, V29, P1441, DOI 10.1097/01.BRS.0000129100.59913.EA
   Song KJ, 2010, EUR SPINE J, V19, P1677, DOI 10.1007/s00586-010-1283-3
   Song KJ, 2009, SPINE, V34, P2886, DOI 10.1097/BRS.0b013e3181b64f2c
   Tome-Bermejo F, 2017, CLIN SPINE SURG, V30, pE648, DOI 10.1097/BSD.0000000000000293
   Wang ZW, 2015, EUR SPINE J, V24, P148, DOI 10.1007/s00586-014-3628-9
   Wells G, 2011, NEWCASTLE OTTAWA SCA
   Wu JC, 2012, NEUROSURGERY, V70, P594, DOI 10.1227/NEU.0b013e318232d4f2
   Wu WJ, 2012, EUR SPINE J, V21, P1374, DOI 10.1007/s00586-011-2131-9
   Xingping W, 2016, J CERVICODYNIA LUMBO, V37, P542
   Yalamanchili PK, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/783762
   Yang HS, 2015, ARCH ORTHOP TRAUM SU, V135, P781, DOI 10.1007/s00402-015-2212-z
   Yang LL, 2012, ORTHOPEDICS, V35, pE1503, DOI 10.3928/01477447-20120919-20
   Yang Y, 2016, INT J CLIN EXP MED, V9, P21772
   Yun DJ, 2017, WORLD NEUROSURG, V97, P189, DOI 10.1016/j.wneu.2016.09.065
   Zheng BL, 2017, BMC SURG, V17, DOI 10.1186/s12893-017-0316-9
   Zhou J, 2018, CLIN NEUROL NEUROSUR, V170, P73, DOI 10.1016/j.clineuro.2018.04.033
   Zhou J, 2011, J CLIN NEUROSCI, V18, P1505, DOI 10.1016/j.jocn.2011.02.045
   Zhu B, 2013, EUR SPINE J, V22, P1583, DOI 10.1007/s00586-013-2817-2
   Zhu Jia, 2017, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V34, P150
NR 58
TC 0
Z9 0
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E117
EP E131
DI 10.1016/j.wneu.2018.12.218
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700017
PM 30677575
DA 2020-05-12
ER

PT J
AU Zhang, F
   Ren, YM
   Fu, W
   Yang, ZJ
   Wen, DK
   Hu, X
   Tao, CY
   Li, X
   You, C
   Xin, T
   Yang, M
AF Zhang, Fan
   Ren, Yanming
   Fu, Wei
   Yang, Zijia
   Wen, Dingke
   Hu, Xin
   Tao, Chuanyuan
   Li, Xi
   You, Chao
   Xin, Tao
   Yang, Mu
TI Predictive Accuracy of Neutrophil-to-Lymphocyte Ratio on Long-Term
   Outcome in Patients with Spontaneous Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neutrophil-to-lymphocyte ratio; Spontaneous intracerebral hemorrhage
ID MORTALITY; COUNT; BRAIN
AB BACKGROUND: It is well established that inflammation plays a critical role in the progression of intracerebral hemorrhage (ICH). Recently the neutrophil-to-lymphocyte ratio (NLR) was identified as a predictor for the short-term outcome in ICH patients. However, the association of NLR with the long-term outcome in patients with ICH remains unknown. Here, we aimed to assess the relationship between NLR and the long-term prognosis in ICH patients.
   METHODS: All patients with spontaneous ICH who were hospitalized at West China Hospital of Sichuan University from October 2013 to May 2017 were retrospectively enrolled. White blood count, absolute count of neutrophils, and lymphocytes were extracted from electronic medical records, and NLR was calculated according to admission neutrophil count (ANC) and lymphocyte count (ALC). The associations between long-term outcomes and laboratory biomarkers were estimated by multivariable logistic regression analysis. Receiver operating characteristic (ROC) curves were also determined to compare the predictive powers between each inflammatory factor.
   RESULTS: A total of 481 ICH patients were included in the study. Of those, 204 presented with unfavorable outcomes, and 142 were dead within 6 months. Age, Glasgow Coma Scale (GCS) scores, WBC, ANC, NLR, hematoma size, and hydrocephalus were independently associated with poor prognosis of ICH. Multiple linear analysis showed GCS, hematoma volume, WBC, ANC, and ALC to be correlated with NLR. Moreover, in comparison with other single laboratory determinations, NLR also showed better predictive capacity for long-term mortality and morbidity, for which the best predictive cutoff values were 9.07 and 8.69, respectively.
   CONCLUSIONS: NLR independently predicts 180-day morbidity and 180-day mortality in patients with spontaneous ICH.
C1 [Zhang, Fan; Ren, Yanming; Fu, Wei; Wen, Dingke; Hu, Xin; Tao, Chuanyuan; Li, Xi; You, Chao; Yang, Mu] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Zhang, Fan] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
   [Yang, Zijia; Yang, Mu] Chengdu First Peoples Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Xin, Tao] Shandong Univ, Shandong Prov Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China.
   [Yang, Mu] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada.
   [Yang, Mu] McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada.
RP Yang, M (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.; Yang, M (reprint author), Chengdu First Peoples Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.; Yang, M (reprint author), McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada.; Yang, M (reprint author), McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada.
EM muyangdoc@163.com
FU Sichuan University postdoctoral grant [2017SCU12048]; West China
   Hospital postdoctoral grant [2018HXBH031]; China postdoctoral science
   foundationChina Postdoctoral Science Foundation [2018M633373]; Sichuan
   Health commission grant [18PJ425]; Sichuan province science and
   technology grant [2015SZ0051]; West China hospital academic excellence
   grant [2016102]
FX F. Zhang is supported by Sichuan University postdoctoral grant
   (2017SCU12048), West China Hospital postdoctoral grant (2018HXBH031),
   China postdoctoral science foundation grant (2018M633373), and Sichuan
   Health commission grant (18PJ425). M. Yang is a Catherine Bushnell
   fellow (2015). This study was also supported by Sichuan province science
   and technology grant (2015SZ0051) and West China hospital academic
   excellence grant (2016102).
CR Adeoye O, 2014, J STROKE CEREBROVASC, V23, pE107, DOI 10.1016/j.jstrokecerebrovasdis.2013.09.006
   Babadjouni RM, 2017, J NEUROINTERV SURG, V9, P1202, DOI 10.1136/neurintsurg-2017-013197
   Boehme AK, 2016, NEUROCRIT CARE, V25, P133, DOI 10.1007/s12028-016-0255-9
   Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc
   Giede-Jeppe A, 2017, CEREBROVASC DIS, V44, P26, DOI 10.1159/000468996
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   Lattanzi S, 2016, STROKE, V47, P1654, DOI 10.1161/STROKEAHA.116.013627
   Liesz A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074839
   Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765
   Morotti A, 2016, STROKE, V47, P1473, DOI 10.1161/STROKEAHA.116.013176
   Moxon-Emre I, 2011, J NEUROPATH EXP NEUR, V70, P218, DOI 10.1097/NEN.0b013e31820d94a5
   Mracsko E, 2014, STROKE, V45, P2107, DOI 10.1161/STROKEAHA.114.005801
   Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907
   Sun YM, 2017, AM J EMERG MED, V35, P429, DOI 10.1016/j.ajem.2016.11.037
   Tao CY, 2017, NEUROCRIT CARE, V26, P393, DOI 10.1007/s12028-016-0332-0
   Tao CY, 2017, BIOMARK MED, V11, P33, DOI 10.2217/bmm-2016-0187
   Tokgoz S, 2014, J STROKE CEREBROVASC, V23, P2163, DOI 10.1016/j.jstrokecerebrovasdis.2014.04.007
   Tokgoz S, 2013, J STROKE CEREBROVASC, V22, P1169, DOI 10.1016/j.jstrokecerebrovasdis.2013.01.011
   Wang F, 2016, J STROKE CEREBROVASC, V25, P182, DOI 10.1016/j.jstrokecerebrovasdis.2015.09.013
   Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403
   Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5
   2014, J NEUROINTERV SURG, V6, P578, DOI DOI 10.1136/NEURINTSURG-2013-010780
NR 24
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E651
EP E657
DI 10.1016/j.wneu.2019.01.143
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700081
PM 30716500
DA 2020-05-12
ER

PT J
AU Zhang, L
   Wang, HD
   Pan, YX
   Mao, L
AF Zhang, Li
   Wang, Handong
   Pan, Yunxi
   Mao, Lei
TI Effect Analysis of Microsurgical Clipping and Endovascular Embolization
   for the Treatment of Middle Cerebral Artery Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular embolization; Microsurgical clipping; Middle cerebral
   artery aneurysms; Outcome
ID INTRACRANIAL ANEURYSMS; SUBARACHNOID HEMORRHAGE; SURGICAL-TREATMENT;
   ANGIOGRAPHY; COILING; SAFETY; MANAGEMENT; HEMATOMA; IMPACT; RISK
AB OBJECTIVE: To evaluate the safety and effectiveness of microsurgical clipping and endovascular embolization for the treatment of middle cerebral artery aneurysm (MCAA).
   MATERIAL AND METHODS: The clinical data of 482 patients with MCAA treated with microsurgical clipping or endovascular embolization were analyzed retrospectively. According to whether the aneurysms were ruptured, patients were divided into a ruptured group and an unruptured group. Demographics, clinical manifestation, and postoperative complications were recorded.
   RESULTS: In the microsurgical clipping group (257 patients), there were 114 male and 143 female patients. The mean age was (55 +/- 10) years and the mean course of disease was 3 (1, 36) days. The total numbers of MCAA were 274, including 179 ruptured aneurysms and 95 unruptured aneurysms. In the endovascular embolization group (225 patients), there were 98 male and 127 female patients. The mean age was (54 +/- 11) years and the mean course of disease was 10 (1, 55) days. The total numbers of MCAA were 234, including 126 ruptured aneurysms and 108 unruptured aneurysms. There was no difference between the incidence of complications in the ruptured and unruptured groups. The outcome of the endovascular embolization group was better than the microsurgical clipping group in ruptured aneurysms (P = 0.000). The recurrence rate of the endovascular embolization group was greater than the microsurgical clipping group in ruptured aneurysms (P = 0.023).
   CONCLUSIONS: Both microsurgical clipping and endovascular embolization were safe and effective methods for the treatment of MCAA, but patients with ruptured MCAAs treated with endovascular embolization were more likely to experience recurrence.
C1 [Zhang, Li; Wang, Handong; Pan, Yunxi; Mao, Lei] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
RP Wang, HD (reprint author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
EM njhdwang@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81672503, 81702484]
FX This study was supported by National Natural Science Foundation of China
   (No. 81672503 and No. 81702484).
CR Acik V, 2017, WORLD NEUROSURG, V108, P774, DOI 10.1016/j.wneu.2017.09.078
   Bond KM, 2017, AM J NEURORADIOL, V38, P766, DOI 10.3174/ajnr.A5095
   Brown RD, 2014, LANCET NEUROL, V13, P393, DOI 10.1016/S1474-4422(14)70015-8
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Dellaretti M, 2018, WORLD NEUROSURG, V117, pE580, DOI 10.1016/j.wneu.2018.06.091
   Diaz OM, 2014, WORLD NEUROSURG, V81, P322, DOI 10.1016/j.wneu.2012.12.011
   Durst CR, 2016, WORLD NEUROSURG, V86, DOI 10.1016/j.wneu.2015.10.016
   Feng ZZ, 2015, J STROKE CEREBROVASC, V24, P1357, DOI 10.1016/j.jstrokecerebrovasdis.2015.02.016
   Germans MR, 2015, WORLD NEUROSURG, V84, P222, DOI 10.1016/j.wneu.2015.04.003
   Hosogai M, 2018, WORLD NEUROSURG, V119, pE728, DOI 10.1016/j.wneu.2018.07.254
   Karamanakos PN, 2010, ACTA NEUROCHIR, V152, P1493, DOI 10.1007/s00701-010-0714-6
   Kikuchi T, 2017, WORLD NEUROSURG, V107, P226, DOI [10.1016/J.WNEU.2017.07.161, 10.1016/j.wneu.2017.07.161]
   Kim J, 2018, WORLD NEUROSURG, V118, pE745, DOI 10.1016/j.wneu.2018.07.031
   Kim KH, 2013, J CLIN NEUROSCI, V20, P520, DOI 10.1016/j.jocn.2012.02.054
   Lee KM, 2016, J KOREAN NEUROSURG S, V59, P6, DOI 10.3340/jkns.2016.59.1.6
   Lee S, 2018, CLCWEB-COMP LIT CULT, V20, DOI 10.7771/1481-4374.3284
   Li MG, 2018, NEUROSURG REV, V41, P675, DOI 10.1007/s10143-017-0913-1
   Liu XJ, 2018, CLIN NEUROL NEUROSUR, V170, P93, DOI 10.1016/j.clineuro.2018.04.034
   Matsukawa H, 2018, J NEUROSURG, V129, P490, DOI 10.3171/2017.3.JNS162984
   Matsukawa H, 2018, WORLD NEUROSURG, V117, pE563, DOI 10.1016/j.wneu.2018.06.077
   Mooney MA, 2018, J NEUROSURG, P1
   Quintana EM, 2019, RADIOLOGIA-MADRID, V61, P42, DOI 10.1016/j.rx.2018.09.003
   Nanda Anil, 2014, J La State Med Soc, V166, P160
   Navratil O, 2017, ACTA NEUROCHIR, V159, P543, DOI 10.1007/s00701-016-3070-3
   Novakovic N, 2016, ACTA CLIN CROAT, V55, P659, DOI 10.20471/acc.2016.55.04.19
   O'Neill AH, 2017, J NEUROINTERV SURG, V9, P761, DOI 10.1136/neurintsurg-2016-012629
   Sanelli PC, 2014, AM J NEURORADIOL, V35, P1714, DOI 10.3174/ajnr.A3947
   Smith TR, 2015, WORLD NEUROSURG, V84, P942, DOI 10.1016/j.wneu.2015.05.073
   Stapleton CJ, 2016, INTERV NEURORADIOL, V22, P654, DOI 10.1177/1591019916663479
   Texakalidis P, 2017, CLIN NEUROL NEUROSUR, V161, P78, DOI 10.1016/j.clineuro.2017.08.003
   Wan SS, 2019, SOL RRL, V3, DOI 10.1002/solr.201800250
   Yang H, 2019, CELL TRANSPLANT, V28, P767, DOI 10.1177/0963689718823517
   Yu LB, 2019, WORLD NEUROSURG, V122, pE838, DOI 10.1016/j.wneu.2018.10.160
   Yu L, 2018, J DRUG TARGET, V26, P905, DOI 10.1080/1061186X.2018.1450413
   Zaidat OO, 2014, NEUROSURG CLIN N AM, V25, P455, DOI 10.1016/j.nec.2014.04.005
   2007, AM J NEURORADIOL, V28, P1567, DOI DOI 10.3174/AJNR.A0595
NR 36
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1074
EP E1081
DI 10.1016/j.wneu.2019.02.004
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700134
PM 30790728
DA 2020-05-12
ER

PT J
AU Zhang, Q
   Han, XG
   Xu, YF
   Liu, YJ
   Liu, B
   He, D
   Sun, YQ
   Tian, W
AF Zhang, Qi
   Han, Xiao-Guang
   Xu, Yun-Feng
   Liu, Ya-Jun
   Liu, Bo
   He, Da
   Sun, Yu-Qing
   Tian, Wei
TI Robot-Assisted Versus Fluoroscopy-Guided Pedicle Screw Placement in
   Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cohort study; Fluoroscopy-guided; Pedicle screw placement; Robot;
   Transforaminal lumbar interbody fusion
ID FACET JOINT VIOLATIONS; INTERNAL-FIXATION; SPINE; COMPLICATIONS;
   ACCURACY
AB OBJECTIVE: To compare the clinical accuracy and perioperative outcomes for pedicle screw placement in transforaminal lumbar interbody fusion (TLIF) between the robot-assisted (RA) technique and fluoroscopy-guided (FG) technique.
   METHODS: Seventy-seven patients scheduled to undergo RA (n = 43) and FG (n = 44) TLIF surgery were included. Patient demographics, radiographic accuracy, and perioperative outcomes were recorded and compared. The accuracy of pedicle screw placement was according to the Gertzbein and Robbins scale and facet joint violation. Perioperative outcomes mainly included operative time, radiation exposure, and revisions.
   RESULTS: Of the 176 screws in the RA group, 164 screws were grade A, and 9, 2, and 1 screws were grades B, C, and D, respectively. Of the 204 screws in the FG group, 175 screws were grade A, with 16 screws scored as grade B, 8 screws scored as grade C, 3 screws scored as grade D, and 2 screws scored as grade E. The rate of perfect screw position (grade A) was higher in the RA group than in the FG group (93.2% vs. 85.8%, respectively; P = 0.020). In the FG group, 191 screws (93.6%) were clinically acceptable (groups A and B), whereas more acceptable screw positions were achieved in the RA group (98.3%; P = 0.024). Fewer screws in the RA group violated the proximal facet joint (5 vs. 24 screws, respectively; P = 0.001). The radiation dose was lower in the RA group (25.9 +/- 14.2 vs. 70.5 +/- 27.3 mSv, respectively; P < 0.001). Two screws in the FG group required a revision, but no revision was required in the RA group.
   CONCLUSIONS: RA pedicle screw placement is an accurate and safe procedure in TLIF for lumbar degenerative disease.
C1 [Tian, Wei] Peking Univ, Sch Clin Med 4, Dept Spine Surg, Beijing, Peoples R China.
   Beijing Jishuitan Hosp, Beijing, Peoples R China.
RP Tian, W (reprint author), Peking Univ, Sch Clin Med 4, Dept Spine Surg, Beijing, Peoples R China.
EM tianwei_spine@sina.com
RI Tian, Wei/AAJ-7853-2020
OI Tian, Wei/0000-0002-1067-600X; Zhang, Qi/0000-0002-1953-3427
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1713221]; Beijing Natural Science
   FoundationBeijing Natural Science Foundation [Z170001]
FX This study was funded by the National Natural Science Foundation of
   China (U1713221) and Beijing Natural Science Foundation (Z170001).
CR Alaid A, 2018, NEUROSURG REV, V41, P489, DOI 10.1007/s10143-017-0877-1
   Babu R, 2012, NEUROSURGERY, V71, P962, DOI 10.1227/NEU.0b013e31826a88c8
   Coe JD, 2006, SPINE, V31, P345, DOI 10.1097/01.brs.0000197188.76369.13
   Gaines RW, 2000, J BONE JOINT SURG AM, V82A, P1458, DOI 10.2106/00004623-200010000-00013
   GERTZBEIN SD, 1990, SPINE, V15, P11, DOI 10.1097/00007632-199001000-00004
   Hyun SJ, 2017, SPINE, V42, P353, DOI 10.1097/BRS.0000000000001778
   Jutte PC, 2002, EUR SPINE J, V11, P594, DOI 10.1007/s00586-002-0469-8
   Kantelhardt S, 2011, EUR SPINE J, V20, P860, DOI 10.1007/s00586-011-1729-2
   Kim HJ, 2017, INT J MED ROBOT COMP, V13, DOI 10.1002/rcs.1779
   Kim HJ, 2015, SPINE, V40, P87, DOI 10.1097/BRS.0000000000000680
   Laudato PA, 2018, SPINE, V43, pE373, DOI 10.1097/BRS.0000000000002449
   Le XF, 2018, WORLD NEUROSURG, V120, pE745, DOI 10.1016/j.wneu.2018.08.157
   Lonjon N, 2016, EUR SPINE J, V25, P947, DOI 10.1007/s00586-015-3758-8
   Park SM, 2018, YONSEI MED J, V59, P438, DOI 10.3349/ymj.2018.59.3.438
   Pihlajamaki H, 1997, J BONE JOINT SURG BR, V79B, P183, DOI 10.1302/0301-620X.79B2.7224
   Ringel F, 2012, SPINE, V37, pE496, DOI 10.1097/BRS.0b013e31824b7767
   Roser F, 2013, NEUROSURGERY, V72, pA12, DOI 10.1227/NEU.0b013e318270d02c
   ROYCAMILLE R, 1986, CLIN ORTHOP RELAT R, P7
   Staartjes VE, 2018, WORLD NEUROSURG, V116, P433, DOI 10.1016/j.wneu.2018.05.159
   Tian W, 2017, CHINESE MED J-PEKING, V130, P1617, DOI 10.4103/0366-6999.208251
   Tian W, 2016, SPINE, V41, pB2, DOI 10.1097/BRS.0000000000001674
   Tian W, 2016, ORTHOP SURG, V8, P400, DOI 10.1111/os.12266
   Tian W, 2014, CHINESE MED J-PEKING, V127, P3852, DOI 10.3760/cma.j.issn.0366-6999.20141860
   van Dijk JD, 2015, SPINE, V40, pE986, DOI 10.1097/BRS.0000000000000960
   Wang JQ, 2017, CHINESE MED J-PEKING, V130, P2527, DOI 10.4103/0366-6999.217080
NR 25
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E429
EP E434
DI 10.1016/j.wneu.2019.01.097
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700057
PM 30708077
DA 2020-05-12
ER

PT J
AU Zhang, X
   Wang, XH
   Zhao, H
   Tang, YD
   Zhou, P
   Yuan, Y
   Zhu, J
   Li, ST
AF Zhang, Xin
   Wang, Xu-Hui
   Zhao, Hua
   Tang, Yin-Da
   Zhou, Ping
   Yuan, Yan
   Zhu, Jin
   Li, Shi-Ting
TI Surgical Treatment of Secondary Hemifacial Spasm: Long-Term Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE AMR; Hemifacial spasm; HFS; MVD
ID CEREBELLOPONTINE ANGLE; MICROVASCULAR DECOMPRESSION; CYST
AB BACKGROUND: Hemifacial spasm (HFS) is generally caused by the root exit zone of the facial nerve compressed by an overlying arterial loop. HFS can also be caused by various types of tumor, aneurysm, or arteriovenous malformation. We retrospectively analyzed patients to evaluate possible differences in the demographic and clinical features between primary and secondary HFS.
   METHODS: A retrospective study of 3140 cases of HFS treated in our department between January 2009 and June 2016. Among the 3140 total cases, 26 patients had secondary HFS.
   RESULTS: The 26 tumors of secondary HFS included 11 meningiomas, 8 epidermoid cysts, and 7 vestibular schwannomas. Compared to those with idiopathic HFS, those patients with tumor-induced HFS were significantly younger (P < 0.05). Secondary HFS tended to have responsible vessels, and were observed in 20 (76.92%) of these 26 patients. The long-term effective rate of operation was 84% in the secondary HFS group and was 96.45% in the primary HFS group (P < 0.05); the incidence rate of complication was 12% in the secondary HFS group and was 3.06% in the primary HFS group (P < 0.05).
   CONCLUSIONS: In cases of secondary HFS, facial nerves of most patients were compressed by blood vessels, so microvascular decompression after tumor resection plays an important role. We should examine the entire nerve root for possible vascular compression.
C1 [Li, Shi-Ting] Shanghai Jiao Tong Univ, Dept Neurosurg, Xinhua Hosp, Sch Med, Shanghai, Peoples R China.
   Shanghai Jiao Tong Univ, Ctr Diag & Treatment Cranial Nerve Dis, Shanghai, Peoples R China.
RP Li, ST (reprint author), Shanghai Jiao Tong Univ, Dept Neurosurg, Xinhua Hosp, Sch Med, Shanghai, Peoples R China.
EM lishiting@xinhuamed.com.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81671205, 81401033]; Shanghai Science Committee
   [14DZ1930303, 16DZ2341800]; Shanghai Municipal Health Bureau
   [2013SY019]; Shanghai Xinhua Hospital fund [15LC21, 15YJ05]
FX This study was funded by the National Natural Science Foundation of
   China (No. 81671205, No. 81401033), the Shanghai Science Committee (No.
   14DZ1930303, No. 16DZ2341800), the Shanghai Municipal Health Bureau (No.
   2013SY019), and the Shanghai Xinhua Hospital fund (No. 15LC21, No.
   15YJ05).
CR Harada A, 2002, J NEUROSURG, V97, P482, DOI 10.3171/jns.2002.97.2.0482
   Hasegawa M, 2016, NEUROSURG REV, V39, P259, DOI 10.1007/s10143-015-0684-5
   HIGASHI S, 1992, SURG NEUROL, V37, P289, DOI 10.1016/0090-3019(92)90155-G
   INOUE T, 1995, NEUROSURGERY, V36, P846, DOI 10.1227/00006123-199504000-00029
   Iwai Y, 2001, NEUROL MED-CHIR, V41, P87, DOI 10.2176/nmc.41.87
   Jannetta P J, 1997, Clin Neurosurg, V44, P331
   JANNETTA PJ, 1984, NEUROSURGERY, V14, P89, DOI 10.1227/00006123-198401000-00021
   Kobata H, 2002, NEUROSURGERY, V50, P276, DOI 10.1097/00006123-200202000-00008
   Kondo A, 2012, ACTA NEUROCHIR, V154, P773, DOI 10.1007/s00701-012-1277-5
   Lee SH, 2010, ACTA NEUROCHIR, V152, P1901, DOI 10.1007/s00701-010-0796-1
   MOLLER AR, 1985, NEUROSURGERY, V16, P612, DOI 10.1227/00006123-198505000-00005
   NAGATA S, 1992, SURG NEUROL, V38, P204, DOI 10.1016/0090-3019(92)90170-R
   Ying TT, 2011, INT J SURG, V9, P347, DOI 10.1016/j.ijsu.2011.02.010
   Zhao H, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.127
NR 14
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E10
EP E15
DI 10.1016/j.wneu.2018.12.035
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700003
PM 30579009
DA 2020-05-12
ER

PT J
AU Zhang, YP
   Yan, P
   Liang, F
   Ma, C
   Liang, SK
   Jiang, CH
AF Zhang, Yupeng
   Yan, Peng
   Liang, Fei
   Ma, Chao
   Liang, Shikai
   Jiang, Chuhan
TI Predictors of Epilepsy Presentation in Unruptured Brain Arteriovenous
   Malformations: A Quantitative Evaluation of Location and Radiomics
   Features on T2-Weighted Imaging
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Classification; Epilepsy; Machine learning;
   Radiomics
ID LOW-GRADE GLIOMAS; CEREBROVASCULAR RESERVE; SEIZURE; MANAGEMENT
AB OBJECTIVE: To explore predictors of epilepsy presentation in unruptured brain arteriovenous malformations (bAVMs) with quantitative evaluation of location and radiomics features on T2-weighted imaging.
   METHODS: This retrospective study identified 117 patients with unruptured bAVMs. Cases were randomly split into training dataset (n = 90) and test dataset (n = 27). On the training dataset, we applied atlas-based analysis to identify epilepsy-susceptible brain regions of bAVMs, and then applied the radiomics technique to explore shape, intensity, and textural features that were correlated with epilepsy presentation. Informative radiomics predictors were selected by least absolute shrinkage and selection operator with 3-fold cross-validation. A linear classification score was then constructed, and we tested if we could precisely identify epilepsy-susceptible bAVMs with the location and radiomics predictors.
   RESULTS: Two brain regions and 4 radiomics features were screened out as predictors for epilepsy. The percent of damage of the right precentral gyrus and the right superior longitudinal fasciculus was associated with epilepsy presentation. The 4 radiomics features were Original_firstorder_Median, Wavelet-LHL_firstorder_InterquartileRange, Wavelet-HHL_firstorder_InterquartileRange, and Wavelet-HHH_glrlm_RunVariance. Epileptogenic bAVMs had larger variance of run lengths, larger median value, and interquartile range of voxel intensities. On the training dataset, these 6 predictors were able to classify epilepsy-susceptible bAVMs with accuracy at 0.822, and the area under the curve was 0.866 (95% confidence interval, 0.791-0.940). On the test dataset, sensitivity, specificity, and accuracy of classification reached 0.786, 0.769, and 0.778, respectively.
   CONCLUSIONS: Epilepsy-susceptible bAVMs had distinct locations and radiomics features on T2-weighted imaging.
C1 [Zhang, Yupeng; Yan, Peng; Liang, Fei; Ma, Chao; Jiang, Chuhan] Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.
   [Zhang, Yupeng; Yan, Peng; Liang, Fei; Ma, Chao; Jiang, Chuhan] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Liang, Shikai] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Neurosurg, Beijing, Peoples R China.
RP Jiang, CH (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.; Jiang, CH (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
EM jiangchuhan126@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81371314, 81771233, 81441038]; High Level Personnel
   Training Program of Beijing Health System [2013-2-016]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81371314, 81771233, and 81441038) and the High Level
   Personnel Training Program of Beijing Health System (Grant No.
   2013-2-016). The authors declared no other conflicts of interests.
CR Aerts HJWL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5006
   Faria AV, 2012, NEUROIMAGE, V61, P613, DOI 10.1016/j.neuroimage.2012.03.078
   Ferlisi M, 2016, Acta Neurochir Suppl, V123, P147, DOI 10.1007/978-3-319-29887-0_21
   Fierstra J, 2011, BRAIN, V134, P100, DOI 10.1093/brain/awq286
   Jain R, 2018, RADIOLOGY, V289, P807, DOI 10.1148/radiol.2018182033
   Josephson CB, 2016, NEUROLOGY, V86, P64, DOI 10.1212/WNL.0000000000002240
   Karnath HO, 2018, NEUROIMAGE, V165, P180, DOI 10.1016/j.neuroimage.2017.10.028
   Kenzie JM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00505
   Lawton MT, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.8
   Liu ZY, 2018, NEUROIMAGE-CLIN, V19, P271, DOI 10.1016/j.nicl.2018.04.024
   Lv X, 2010, INTERV NEURORADIOL, V16, P39, DOI 10.1177/159101991001600105
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   Nathan SK, 2018, WORLD NEUROSURG, V115, pE523, DOI 10.1016/j.wneu.2018.04.086
   Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458
   Pallud J, 2014, BRAIN, V137, P449, DOI 10.1093/brain/awt345
   Sun Y, 2016, TURK NEUROSURG, V26, P341, DOI 10.5137/1019-5149.JTN.9190-13.1
   Tomari S, 2017, SEIZURE-EUR J EPILEP, V52, P22, DOI 10.1016/j.seizure.2017.09.007
   Tong XZ, 2016, WORLD NEUROSURG, V87, P598, DOI 10.1016/j.wneu.2015.10.060
   van Griethuysen JJM, 2017, CANCER RES, V77, pE104, DOI 10.1158/0008-5472.CAN-17-0339
   Van Roost D, 2001, NEUROSURGERY, V48, P709, DOI 10.1097/00006123-200104000-00001
   von der Brelie C, 2015, NEUROSURGERY, V77, P762, DOI 10.1227/NEU.0000000000000919
   Wang YY, 2015, NEURO-ONCOLOGY, V17, P282, DOI 10.1093/neuonc/nou130
   Yang HB, 2017, WORLD NEUROSURG, V105, P37, DOI 10.1016/j.wneu.2017.05.031
   Yang PF, 2018, WORLD NEUROSURG, V110, pE659, DOI 10.1016/j.wneu.2017.11.067
   Zhang BJ, 2018, ANGIOLOGY, V69, P380, DOI 10.1177/0003319717715579
   2001, NEUROSURGERY, V48, P709
NR 26
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E1008
EP E1015
DI 10.1016/j.wneu.2019.01.229
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700125
PM 30771548
DA 2020-05-12
ER

PT J
AU Zhao, BQ
   Zhang, C
   Zhao, XH
   Yao, JJ
   Li, J
   Ma, YQ
   Shi, W
   Zheng, ZZ
AF Zhao, Benqi
   Zhang, Chen
   Zhao, Xihai
   Yao, Jingjing
   Li, Jie
   Ma, Yongqiang
   Shi, Wei
   Zheng, Zhuozhao
TI Stratification of Grade of Spinal Cord Non-Ependymal Gliomas by Magnetic
   Resonance Imaging
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gliomas; Grade; Magnetic resonance imaging; Spinal cord
ID MR; CLASSIFICATION; ASTROCYTOMA; NEOPLASMS; VOLUME; TUMORS
AB OBJECTIVE: The purpose of this study was to demonstrate the usefulness of conventional magnetic resonance imaging (MRI) in stratification of spinal cord non-ependymal gliomas.
   METHODS: Forty-one patients (mean age, 29.9 +/- 16.8 years; 27 men) with first-diagnosed spinal cord non-ependymal gliomas underwent conventional MRI including T1-weighted, T2-weighted (T2W) and contrast-enhanced T1-weighted imaging sequences. The tumors were removed by surgery and processed by histology 1 week after MRI. Patients were divided into low-grade and high-grade groups according to histological findings. The MRI features of gliomas including signal-to-noise-ratio (SNR), margins, heterogeneity, edema, enhancement, tumor size, longitudinal location, and presence of syrinx were measured and compared between low-grade and high-grade groups using the chi(2) test and the Mann-Whitney U test.
   RESULTS: The SNR of low-grade gliomas on T2W images was significantly higher than that of high-grade gliomas (165.0 +/- 108.7 vs. 98.6 +/- 44.4; P = 0.016 by the Mann-Whitney U test). The margins of low-grade gliomas were found to be clearer compared to that of high-grade gliomas (54.5% vs. 5.3%; P = 0.001). Receiver-operating-characteristic analysis revealed that the area under the curve of 1/SNR, margin and the combination of 1/SNR and margin was 0.722 (95% confidence interval [CI], 0.564-0.880), 0.736 (95% CI, 0.578-0.894), and 0.845 (95% CI, 0.717-0.973), respectively. No significant differences were found in the heterogeneity, edema, enhancement level, enhancement SNR, size, longitudinal location, cyst, hemorrhage, and intramedullary location between low-grade and high-grade non-ependymal gliomas (all P > 0.05).
   CONCLUSIONS: The characteristics of signal intensity and margin on T2W imaging are valuable in stratification of spinal cord non-ependymal gliomas.
C1 [Zhao, Benqi; Zhang, Chen; Zhao, Xihai; Li, Jie; Ma, Yongqiang; Zheng, Zhuozhao] Tsinghua Univ, Sch Clin Med, Beijing Tsinghua Changgung Hosp, Dept Radiol, Beijing, Peoples R China.
   [Yao, Jingjing] Tsinghua Univ, Sch Clin Med, Beijing Tsinghua Changgung Hosp, Dept Pathol, Beijing, Peoples R China.
   [Shi, Wei] Tsinghua Univ, Sch Clin Med, Beijing Tsinghua Changgung Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Zhao, Xihai] Tsinghua Univ, Sch Med, Ctr Biomed Imaging Res, Dept Biomed Engn, Beijing, Peoples R China.
RP Zheng, ZZ (reprint author), Tsinghua Univ, Sch Clin Med, Beijing Tsinghua Changgung Hosp, Dept Radiol, Beijing, Peoples R China.
EM zzhuozhao@aliyun.com
RI Zhao, Xihai/AAD-7181-2020
FU Beijing Tsinghua Changgung Hospital Fund [12017C1022]
FX This study is supported by Beijing Tsinghua Changgung Hospital Fund
   (Grant No. 12017C1022).
CR ARONEN HJ, 1994, RADIOLOGY, V191, P41, DOI 10.1148/radiology.191.1.8134596
   DEAN BL, 1990, RADIOLOGY, V174, P411, DOI 10.1148/radiology.174.2.2153310
   Eroes CA, 2010, ACTA NEUROCHIR, V152, P611, DOI 10.1007/s00701-009-0577-x
   Ginsberg LE, 1998, SURG NEUROL, V49, P436, DOI 10.1016/S0090-3019(97)00360-1
   Guzman-De-Villoria JA, 2014, CANC IMAGING, V12, P14
   HELSETH A, 1989, J NEUROSURG, V71, P842, DOI 10.3171/jns.1989.71.6.0842
   Horger M, 2011, EUR J RADIOL, V79, P389, DOI 10.1016/j.ejrad.2010.04.024
   Knopp EA, 1999, RADIOLOGY, V211, P791, DOI 10.1148/radiology.211.3.r99jn46791
   Law M, 2002, RADIOLOGY, V222, P715, DOI 10.1148/radiol.2223010558
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Lowe GM, 2000, J NEURO-ONCOL, V47, P195, DOI 10.1023/A:1006462321234
   Moharamzad Y, 2018, NEURORADIOL J, V31, DOI 10.1177/1971400917743099
   Newman S, 1993, EUR RADIOL, V3, P49
   Raco A, 2010, J NEUROSURG-SPINE, V12, P144, DOI 10.3171/2009.6.SPINE08910
   Seo HS, 2010, AM J NEURORADIOL, V31, P498, DOI 10.3174/ajnr.A1864
   Shin JH, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.3.1790783
   WATANABE M, 1992, NEURORADIOLOGY, V34, P463, DOI 10.1007/BF00598951
   2003, AJNR AM J NEURORADIO, V24, P1989
NR 18
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E902
EP E908
DI 10.1016/j.wneu.2019.01.205
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700111
PM 30743029
DA 2020-05-12
ER

PT J
AU Zheng, JF
   Guo, ZD
   Xu, R
   He, ZH
   Sun, XC
AF Zheng, Jianfeng
   Guo, Zongduo
   Xu, Rui
   He, Zhaohui
   Sun, Xiaochuan
TI Microsurgical Treatment for Patients with Fenestrated Anterior
   Communicating Artery Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior communicating artery; Clipping; Fenestration; Intracranial
   aneurysm; Outcome
ID INTRACRANIAL SACCULAR ANEURYSMS; CEREBRAL-ARTERY; CT ANGIOGRAPHY;
   RISK-FACTORS; RUPTURE; ANATOMY; FREQUENCY; OUTCOMES
AB OBJECTIVE: The purpose of this study was to investigate the imaging characteristics of fenestrated anterior communicating artery (AcomA) aneurysm and clinical outcome of patients with fenestrated AcomA aneurysm.
   METHODS: We performed a retrospective study of consecutive patients with AcomA aneurysms between January 2013 and December 2017. According to the vascular variations of the AcomA, the patients were divided into 2 groups: fenestrated AcomA aneurysms and non-fenestrated AcomA aneurysms. Baseline characteristics, clinical complications, and outcomes of patients were analyzed.
   RESULTS: A total of 217 patients with AcomA aneurysms were included in this study. Compared to non-fenestrated AcomA aneurysms, the size of fenestrated AcomA aneurysms was significantly smaller (P < 0.001). Moreover, the patients with fenestrated AcomA aneurysms had a higher rate of rebleeding (P = 0.036), hydrocephalus (P = 0.017), delayed cerebral ischemia (P = 0.021), and pulmonary infection (P = 0.017) than those with non-fenestrated AcomA aneurysms. According to the Glasgow Outcome Scale (GOS) at follow-up, the patients with fenestrated AcomA aneurysms had a higher rate of disability (P = 0.035) (GOS 2-3) and mortality (P = 0.013) (GOS 1).
   CONCLUSIONS: Fenestrated AcomA aneurysms are associated with higher clinical complications, and identification of AcomA fenestration contributes to successful clipping of AcomA aneurysms.
C1 [Zheng, Jianfeng; Guo, Zongduo; Xu, Rui; He, Zhaohui; Sun, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing, Peoples R China.
RP Guo, ZD (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing, Peoples R China.
EM stonegzd@163.com
OI sun, xiao chuan/0000-0001-6992-332X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571159, 81671160]; 13th Five-Year National Key
   Research Project of China [2016YFC1300800]
FX The authors thank the following funding agencies for their support:
   National Natural Science Foundation of China (No. 81671160), National
   Natural Science Foundation of China (No. 81571159), and 13th Five-Year
   National Key Research Project of China (2016YFC1300800). We acknowledge
   the service provided by the First Affiliated Hospital of Chongqing
   Medical University.
CR Andaluz N, 2003, NEUROSURGERY, V52, P1140, DOI 10.1227/01.NEU.0000057834.83222.9F
   Aoki Yasuko, 2013, No Shinkei Geka, V41, P1075
   Bayrak AH, 2011, EUR J RADIOL, V77, P392, DOI 10.1016/j.ejrad.2009.09.015
   Bharatha A, 2008, SURG RADIOL ANAT, V30, P397, DOI 10.1007/s00276-008-0340-7
   Bijlenga P, 2013, STROKE, V44, P3018, DOI 10.1161/STROKEAHA.113.001667
   Cai W, 2018, WORLD NEUROSURG, V109, P119, DOI 10.1016/j.wneu.2017.09.118
   Castro MA, 2009, AM J NEURORADIOL, V30, P297, DOI 10.3174/ajnr.A1323
   Chalouhi N, 2013, NEUROSURGERY, V72, P437, DOI 10.1227/NEU.0b013e3182804e9c
   Choi JH, 2016, NEURORADIOLOGY, V58, P155, DOI 10.1007/s00234-015-1610-9
   de Gast AN, 2008, AM J NEURORADIOL, V29, P296, DOI 10.3174/ajnr.A0807
   Dehdashti AR, 2016, WORLD NEUROSURG, V91, P34, DOI 10.1016/j.wneu.2016.03.051
   Dimmick SJ, 2008, INTERV NEURORADIOL, V14, P441, DOI 10.1177/159101990801400410
   FINLAY HM, 1994, STROKE, V25, P1799, DOI 10.1161/01.STR.25.9.1799
   Friedlander RM, 1996, J NEUROSURG, V84, P681, DOI 10.3171/jns.1996.84.4.0681
   Froelich S, 2011, NEUROSURGERY, V68, P310, DOI 10.1227/NEU.0b013e3182117063
   Heit JJ, 2017, AM J NEURORADIOL, V38, P2119, DOI 10.3174/ajnr.A5355
   Hernesniemi J, 2008, SURG NEUROL, V70, P8, DOI 10.1016/j.surneu.2008.01.056
   Inagawa T, 2010, WORLD NEUROSURG, V73, P155, DOI 10.1016/j.surneu.2009.03.007
   Inagawa T, 2010, CEREBROVASC DIS, V30, P72, DOI 10.1159/000314623
   Lai LT, 2013, J CLIN NEUROSCI, V20, P1688, DOI 10.1016/j.jocn.2013.02.015
   Li Q, 2014, ACTA RADIOL, V55, P840, DOI 10.1177/0284185113506138
   Lin N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079635
   Lv FJ, 2011, ACTA NEUROCHIR SUPPL, V110, P239, DOI 10.1007/978-3-7091-0356-2_43
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Mortimer AM, 2016, J NEUROINTERV SURG, V8, P256, DOI 10.1136/neurintsurg-2014-011620
   Nossek E, 2016, NEUROSURG REV, V39, P225, DOI 10.1007/s10143-015-0677-4
   Park JS, 2018, WORLD NEUROSURG, V111, pE379, DOI 10.1016/j.wneu.2017.12.071
   PERLMUTTER D, 1976, J NEUROSURG, V45, P259, DOI 10.3171/jns.1976.45.3.0259
   SANDERS WP, 1993, AM J NEURORADIOL, V14, P675
   Serizawa T, 1997, NEUROSURGERY, V40, P1211, DOI 10.1097/00006123-199706000-00019
   Sgreccia A, 2018, ACTA NEUROCHIR, V160, P1143, DOI 10.1007/s00701-018-3551-7
   Sturiale CL, 2019, J NEUROSURG SCI, V63, P588, DOI 10.23736/S0390-5616.18.04225-X
   van Rooij SBT, 2015, AM J NEURORADIOL, V36, P1167, DOI 10.3174/ajnr.A4236
   Wang H, 2015, INT J CLIN EXP MED, V8, P21114
   Wermer MJH, 2007, STROKE, V38, P1404, DOI 10.1161/01.STR.0000260955.51401.cd
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E807
EP E811
DI 10.1016/j.wneu.2019.01.173
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700099
PM 30738937
DA 2020-05-12
ER

PT J
AU Zhong, JL
   Cao, K
   Wang, B
   Li, HZ
   Zhou, XM
   Xu, XH
   Lin, N
   Liu, QF
   Lu, HD
AF Zhong, Junlong
   Cao, Kai
   Wang, Bin
   Li, Huizi
   Zhou, Xuemei
   Xu, Xianghe
   Lin, Nan
   Liu, Quanfei
   Lu, Huading
TI Incidence and Risk Factors for Proximal Junctional Kyphosis in
   Adolescent Idiopathic Scoliosis After Correction Surgery: A
   Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; Incidence; Meta-analysis; Proximal
   junctional kyphosis; Risk factors
ID SPINAL INSTRUMENTATION
AB OBJECTIVE: To evaluate the incidence and risk factors associated with proximal junctional kyphosis (PJK) in patients with adolescent idiopathic scoliosis (AIS) after correction surgery.
   METHODS: PubMed, Embase, and Cochrane Library were searched from inception until August 2018 to obtain relevant studies. After study selection and data extraction, statistical analysis was performed with RevMan 5.3. The odds ratios (ORs) and weight mean differences (WMDs) with 95% confidence intervals (CIs) for all available factors were analyzed using fixed or random effects models.
   RESULTS: A total of 7 studies were included in this meta-analysis. The overall incidence of PJK in AIS was 14% (95% CI, 8%-20%). Among the potential risk factors, proximal implants with screws (OR, 1.64; 95% CI, 1.13-2.39; P = 0.010), instrumentation types with all screws (OR, 1.78; 95% CI, 1.19-2.67; P = 0.005), larger preoperative thoracic kyphosis (TK) (WMD, 7.50; 95% CI, 5.75-9.26; P < 0.001), larger preoperative lumbar lordosis (LL) (WMD, 4.85; 95% CI, 2.79-6.92; P < 0.001), larger postoperative LL (WMD, 2.00; 95% CI, 0.09-3.91; P = 0.040), greater change in TK (WMD, -6.75; 95% CI, -9.72 to -3.78; P < 0.001), and greater change in LL (WMD, -3.26; 95% CI, -5.40 to -1.12; P = 0.003) were identified as risk factors for PJK.
   CONCLUSIONS: The incidence of PJK in patients with AIS was 14%. Proximal implants with screws and instrumentation types with all screws were significantly associated with increased occurrence of PJK. Larger preoperative TK, larger preoperative LL, larger postoperative LL, greater TK change, and greater LL change were also identified as risk factors for PJK in AIS after correction surgery.
C1 [Zhong, Junlong; Wang, Bin; Li, Huizi; Xu, Xianghe; Lin, Nan; Lu, Huading] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Orthopaed, Zhuhai, Peoples R China.
   [Cao, Kai] Nanchang Univ, Affiliated Hosp 2, Dept Orthopaed, Nanchang, Jiangxi, Peoples R China.
   [Zhou, Xuemei] Gannan Med Univ, Affiliated Hosp 2, Dept Neurol, Ganzhou, Peoples R China.
   [Liu, Quanfei] Nanchang Univ, Affiliated Hosp 1, Dept Orthopaed, Nanchang, Jiangxi, Peoples R China.
RP Lu, HD (reprint author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Orthopaed, Zhuhai, Peoples R China.
EM johnnielu@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81572174, 81772384]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81572174 and 81772384).
CR Cho SK, 2015, J AM ACAD ORTHOP SUR, V23, P408, DOI 10.5435/JAAOS-D-14-00143
   Ferrero E, 2018, EUR SPINE J, V27, P2241, DOI 10.1007/s00586-018-5640-y
   Ghailane S, 2017, ARCH ORTHOP TRAUM SU, V137, P631, DOI 10.1007/s00402-017-2684-0
   Hassanzadeh Hamid, 2013, Spine Deform, V1, P299, DOI 10.1016/j.jspd.2013.05.008
   Helgeson MD, 2010, SPINE, V35, P177, DOI 10.1097/BRS.0b013e3181c77f8c
   Kim YJ, 2005, SPINE, V30, P2045, DOI 10.1097/01.brs.0000179084.45839.ad
   Kim YJ, 2007, SPINE, V32, P2731, DOI 10.1097/BRS.0b013e31815a7ead
   Lafage V, 2011, SPINE, V36, P1037, DOI 10.1097/BRS.0b013e3181eb9469
   Lee J, 2016, ASIAN SPINE J, V10, P593, DOI 10.4184/asj.2016.10.3.593
   Liu FY, 2016, EUR SPINE J, V25, P2376, DOI 10.1007/s00586-016-4534-0
   Lonner BS, 2017, SPINE DEFORM, V5, P181, DOI DOI 10.1016/J.JSPD.2016.10.003
   Pahys JM, 2018, SPINE, V43, pE1322, DOI 10.1097/BRS.0000000000002700
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tambe AD, 2018, BONE JOINT J, V100B, P415, DOI 10.1302/0301-620X.100B4.BJJ-2017-0846.R2
   Thawrani DP, 2014, SPINE, V39, pE826, DOI 10.1097/BRS.0000000000000367
   Zhao J, 2018, J ORTHOP SCI, V23, P744, DOI 10.1016/j.jos.2018.05.010
   Zhu ZZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9355
   Zou LX, 2019, NEUROSURG REV, V42, P671, DOI 10.1007/s10143-018-1004-7
   2013, EUR SPINE J, V22, P2414, DOI DOI 10.1007/S00586-013-2852-Z
NR 19
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E326
EP E335
DI 10.1016/j.wneu.2019.01.072
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700042
PM 30690145
DA 2020-05-12
ER

PT J
AU Zucchelli, M
   Nicolini, F
   Toni, F
   Maffei, M
   Palandri, G
   Galassi, E
AF Zucchelli, Mino
   Nicolini, Francesca
   Toni, Francesco
   Maffei, Monica
   Palandri, Giorgio
   Galassi, Ercole
TI Shunted Hydrocephalus: Who Has More Chances to Get Rid of the Shunt?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Secondary endoscopic third ventriculostomy; Shunt
   malfunction
ID ENDOSCOPIC 3RD VENTRICULOSTOMY; OBSTRUCTIVE HYDROCEPHALUS; OUTCOME
   ANALYSIS; 3RD-VENTRICULOSTOMY; COMPLICATIONS; REMOVAL; FAILURE; INFANTS;
   SUCCESS; AGE
AB OBJECTIVE/BACKGROUND: The natural history and the outlook of patients with hydrocephalus are dramatically affected using cerebrospinal fluid shunts. The several issues related with a long-standing shunt should suffice to justify all the possible attempts to free the patient from it. This study focused on the role of secondary endoscopic third ventriculostomy (ETV) in the achievement of shunt removal in cases of shunt malfunction, and to identify patients who could benefit most from the procedure.
   METHODS: In the period of 2006-2015, ETV was attempted in 47 patients >6 months old with ventriculoperitoneal shunt malfunction who presented with increased ventricle size compared with the previous neuroradiological examinations; simultaneously the shunt was removed or ligated.
   RESULTS: The overall success rate of secondary ETV was 74% (shunt-free patients with normalized intracranial pressure and absence of symptoms attributable to hydrocephalus) in patients with a long shunt duration (up to 30 years). The number of previous shunt revision procedures (P = 0.026) and lower age (P = 0.017) correlate with the likelihood of secondary ETV failure, a score of 80 as ETV success score (calculated for both pediatric and adult patients, even if the score was meant for the pediatric population) correlates with secondary ETV success (P = 0.014).
   CONCLUSIONS: Many patients with shunt malfunction can benefit from secondary ETV even after decades of shunting. Age at secondary ETV, the number of previous shunt revisions, and the ETV success score can help to better identify the best candidates for the procedure.
C1 [Zucchelli, Mino; Nicolini, Francesca; Galassi, Ercole] IRCCS Ist Sci Neurol Bologna, Pediat Neurosurg, Bologna, Italy.
   [Palandri, Giorgio] IRCCS Ist Sci Neurol Bologna, Neurosurg, Bologna, Italy.
   [Toni, Francesco; Maffei, Monica] IRCCS Ist Sci Neurol Bologna, Pediat Neuroradiol, Bologna, Italy.
RP Zucchelli, M (reprint author), IRCCS Ist Sci Neurol Bologna, Pediat Neurosurg, Bologna, Italy.
EM minoz@inwind.it
OI zucchelli, mino/0000-0002-7494-355X; Palandri,
   Giorgio/0000-0002-9306-0242; Toni, Francesco/0000-0002-1916-0077
CR Baldauf J, 2007, CHILD NERV SYST, V23, P623, DOI 10.1007/s00381-007-0335-4
   Baskin JJ, 1998, J NEUROSURG, V88, P478, DOI 10.3171/jns.1998.88.3.0478
   Beems T, 2002, CHILD NERV SYST, V18, P605, DOI 10.1007/s00381-002-0652-6
   BIERBRAUER KS, 1991, PEDIATR NEUROSURG, V16, P287, DOI 10.1159/000120544
   Bilginer B, 2009, CHILD NERV SYST, V25, P683, DOI 10.1007/s00381-008-0779-1
   Boschert J, 2003, J NEUROSURG, V98, P1032, DOI 10.3171/jns.2003.98.5.1032
   Drake JM, 1998, NEUROSURGERY, V43, P294, DOI 10.1097/00006123-199808000-00068
   Drake JM, 1995, THE SHUNT BOOK, P121
   Hader WJ, 2008, NEUROSURGERY, V63, P168, DOI 10.1227/01.NEU.0000310762.26035.B0
   HEMMER R, 1976, DEV MED CHILD NEUROL, V18, P69
   Koch D, 2004, CHILD NERV SYST, V20, P405, DOI 10.1007/s00381-004-0958-7
   Kulkarni AV, 2009, J PEDIATR-US, V155, P254, DOI 10.1016/j.jpeds.2009.02.048
   Labidi M, 2015, J NEUROSURG, V123, P1447, DOI 10.3171/2014.12.JNS141240
   Maldonado IL, 2010, ACTA NEUROCHIR, V152, P1449, DOI 10.1007/s00701-009-0587-8
   O'Brien DF, 2005, J NEUROSURG, V103, P393, DOI 10.3171/ped.2005.103.5.0393
   Pindrik J, 2013, J NEUROSURG-PEDIATR, V11, P722, DOI 10.3171/2013.3.PEDS12489
   Rekate HL, 2008, J NEUROSURG-PEDIATR, V2, P1, DOI 10.3171/PED/2008/2/7/001
   Rekate HL, 2004, NEUROSURG CLIN N AM, V15, P39, DOI 10.1016/S1042-3680(03)00074-3
   SAINTEROSE C, 1992, PEDIATR NEUROSURG, V17, P2, DOI 10.1159/000120557
   Sankey EW, 2016, J NEUROSURG, V124, P1413, DOI 10.3171/2015.4.JNS15129
   Siomin V, 2002, J NEUROSURG, V97, P519, DOI 10.3171/jns.2002.97.3.0519
   Spennato P, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.005
   Sufianov A, 2008, MINIM INVAS NEUROSUR, V51, P158, DOI 10.1055/s-2008-1046760
   WHITFIELD PC, 1995, J NEUROSURG, V83, P1101, DOI 10.3171/jns.1995.83.6.1101
   Woodworth G, 2007, NEUROL RES, V29, P27, DOI 10.1179/016164106X119914
   Zucchelli M, 2018, PEDIATR NEUROSURG, V53, P163, DOI 10.1159/000487090
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP E229
EP E235
DI 10.1016/j.wneu.2019.01.052
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700030
PM 30684709
DA 2020-05-12
ER

PT J
AU Oksanen, A
   Interisano, M
   Isomursu, M
   Heikkinen, P
   Tonanzi, D
   Oivanen, L
   Pozio, E
AF Oksanen, Antti
   Interisano, Maria
   Isomursu, Marja
   Heikkinen, Petra
   Tonanzi, Daniele
   Oivanen, Leena
   Pozio, Edoardo
TI Trichinella spiralis prevalence among wildlife of a boreal region
   rapidly reduced in the absence of spillover from the domestic cycle (vol
   262C, pg 1, 2018)
SO VETERINARY PARASITOLOGY
LA English
DT Correction
C1 [Oksanen, Antti; Isomursu, Marja; Heikkinen, Petra] Finnish Food Safety Author Evira FINPAR, Elekt Katie 3, Oulu 90590, Finland.
   [Interisano, Maria; Tonanzi, Daniele; Pozio, Edoardo] Ist Super Sanita, European Union Reference Lab Parasites, Rome, Italy.
   [Oivanen, Leena] Finnish Food Safety Author Evira, Mustialankatu 3, Helsinki 00790, Finland.
RP Pozio, E (reprint author), Ist Super Sanita, European Union Reference Lab Parasites, Rome, Italy.
EM edoardo.pozio@iss.it
CR Antti O, 2018, VET PARASITOL, V262, P1, DOI 10.1016/j.vetpar.2018.09.002
NR 1
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 1
EP 1
DI 10.1016/j.vetpar.2019.02.005
PG 1
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200001
PM 31079820
OA Bronze
DA 2020-05-12
ER

PT J
AU Barry, R
   Nissly, RH
   Feria, W
   Thirumalapura, N
   Tewari, D
   Jayarao, BM
   Kuchipudi, SV
AF Barry, Rhiannon
   Nissly, Ruth H.
   Feria, Willard
   Thirumalapura, Nagaraja
   Tewari, Deepanker
   Jayarao, Bhushan M.
   Kuchipudi, Suresh, V
TI A probe-based real-time PCR assay for the detection of Neospora caninum
   in clinical samples from cattle
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Neospora caninum; Neosporosis; Diagnostic; Probe-based real-time PCR;
   TaqMan
ID DNA; DIAGNOSIS
AB Neospora caninum is an apicomplexan protozoan parasite that is a leading cause of abortion in cattle. Detection of parasite-specific DNA by PCR is a highly sensitive method for identifying the presence of N. caninum in a variety of tissues. We developed and validated a probe-based real-time PCR assay targeting the conserved Nc5 gene of N. caninum. Using N. caninum strain Nc-1 genomic DNA and a synthetic gene fragment as amplification standards, we determined the PCR amplification efficiency and the limit of detection to be 95.60% and 3 copies, respectively. Five pathogens frequently associated with bovine abortions, namely bovine viral diarrhea virus types I and II, bovine alphaherpesvirus-1, Chlamydia, and Leptospira, were tested to ensure analytical exclusivity. A total of 103 clinical samples from aborted fetuses were tested concurrently with a standard conventional PCR and the new probe-based real-time PCR assay. All tested samples showed 100% agreement between these two assays. In conclusion, the probe-based real-time PCR assay facilitates accurate and rapid detection of N. caninum from abortions in cattle.
C1 [Barry, Rhiannon; Nissly, Ruth H.; Jayarao, Bhushan M.; Kuchipudi, Suresh, V] Penn State Univ, Dept Vet & Biomed Sci, Penn State Anim Diagnost Lab, Wiley Lane, University Pk, PA 16802 USA.
   [Feria, Willard; Thirumalapura, Nagaraja; Tewari, Deepanker] Bur Anim Hlth & Diagnost Serv, Penn Dept Agr, Penn Vet Lab, 2305 N Cameron St, Harrisburg, PA 17110 USA.
RP Kuchipudi, SV (reprint author), Penn State Univ, Dept Vet & Biomed Sci, Anim Diagnost Lab, Wiley Lane, University Pk, PA 16802 USA.
EM skuchipudi@psu.edu
FU Animal Health and Diagnostic Commission of the Pennsylvania Department
   of Agriculture
FX This work was supported by the funds provided to the Pennsylvania Animal
   Diagnostic Laboratory System by the Animal Health and Diagnostic
   Commission of the Pennsylvania Department of Agriculture.
CR Almeria S, 2016, EXP PARASITOL, V168, P62, DOI 10.1016/j.exppara.2016.06.009
   Baszler TV, 1999, J CLIN MICROBIOL, V37, P4059, DOI 10.1128/JCM.37.12.4059-4064.1999
   Collantes-Fernandez E, 2002, J CLIN MICROBIOL, V40, P1194, DOI 10.1128/JCM.40.4.1194-1198.2002
   Constantin EM, 2011, BERL MUNCH TIERARZTL, V124, P148, DOI 10.2376/0005-9366-124-148
   Ramos AE, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2549-y
   Ghalmi F, 2008, VET PARASITOL, V155, P161, DOI 10.1016/j.vetpar.2008.04.007
   Kaufmann H, 1996, MOL CELL PROBE, V10, P289, DOI 10.1006/mcpr.1996.0038
   Klein C, 2019, J WILDLIFE DIS, V55, P196, DOI 10.7589/2018-02-027
   Mahittikorn A, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2330-2
   McAllister MM, 2016, VET CLIN N AM-FOOD A, V32, P443, DOI 10.1016/j.cvfa.2016.01.012
   Muller N, 2002, J CLIN MICROBIOL, V40, P252, DOI 10.1128/JCM.40.1.252-255.2002
   Okeoma CM, 2005, EXP PARASITOL, V110, P48, DOI 10.1016/j.exppara.2005.01.008
   Pereira GR, 2014, VET PARASITOL, V199, P129, DOI 10.1016/j.vetpar.2013.10.018
   Reichel MP, 2013, INT J PARASITOL, V43, P133, DOI 10.1016/j.ijpara.2012.10.022
   Reid AJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002567
   Reisberg K, 2013, J VET DIAGN INVEST, V25, P614, DOI 10.1177/1040638713497483
   Sinnott FA, 2017, VET PARASITOL, V239, P19, DOI 10.1016/j.vetpar.2017.04.008
   Thilsted J P, 1989, J Vet Diagn Invest, V1, P205
   Tian AL, 2018, VET PARASITOL, V258, P24, DOI 10.1016/j.vetpar.2018.06.004
   Yamage M, 1996, J PARASITOL, V82, P272, DOI 10.2307/3284160
NR 20
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 2
EP 6
DI 10.1016/j.vetpar.2019.04.002
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200002
PM 31079823
DA 2020-05-12
ER

PT J
AU Nielsen, MK
   Sauermann, CW
   Leathwick, DM
AF Nielsen, Martin K.
   Sauermann, Christian W.
   Leathwick, Dave M.
TI The effect of climate, season, and treatment intensity on anthelmintic
   resistance in cyathostomins: A modelling exercise
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cyathostomin; Simulation; Anthelmintic resistance; Refugia; Climate;
   Selective therapy
ID PARASITE CONTROL PRACTICES; SMALL STRONGYLES; REDUCED ACTIVITY; CRITICAL
   TESTS; FIELD-TESTS; IVERMECTIN; HORSES; MOXIDECTIN; EFFICACY;
   QUESTIONNAIRE
AB Anthelmintic resistance is widespread in equine cyathostomin populations across the world, and with no new anthelmintic drug classes in the pharmaceutical pipeline, the equine industry is forced to abandon traditional parasite control regimens. Current recommendations aim at reducing treatment intensity and identifying high strongylid egg shedders in a targeted treatment approach. But, virtually nothing is known about the effectiveness of these recommendations, nor their applicability to different climatic regions, making it challenging to tailor sustainable recommendations for equine parasite control. This study made use of a computer model of the entire cyathostomin life-cycle to evaluate the influence of climate and seasonality on the development of anthelmintic resistance in cyathostomin parasites. Furthermore, the study evaluated the impact of recommended programs involving selective anthelmintic therapy on delaying anthelmintic resistance development. All simulations evaluated the use of a single anthelmintic (L.e., ivermectin) over the course of 40 model years. The study made use of weather station data representing four different climatic zones: a cold humid continental climate, a temperate oceanic climate, a cold semi-arid climate, and a humid subtropical climate. Initially, the impact of time of the year was evaluated when a single anthelmintic treatment was administered once a year in any of the twelve months. The next simulations evaluated the impact of treatment intensities varying between 2 and 6 treatments per year. And finally, we evaluated treatment schedules consisting of a combination of strategic treatments administered to all horses and additional treatments administered to horses exceeding a predetermined fecal egg count threshold. Month of treatment had a large effect on resistance development in colder climates, but little or no impact in subtropical and tropical climates. Resistance development was affected by treatment intensity, but was also strongly affected by climate. Selective therapy delayed resistance development in all modelled scenarios, but, again, this effect was climate dependent with the largest delays observed in the colder climates. This study is the first to demonstrate the value of cyathostomin parasite refugia in managing anthelmintic resistance, and also that climate and seasonality are important. This modelling exercise has allowed an illustration of concepts believed to play important roles in anthelmintic resistance in equine cyathostomins, but has also identified knowledge gaps and new questions to address in future studies.
C1 [Nielsen, Martin K.] Univ Kentucky, Dept Vet Sci, MH Gluck Equine Res Ctr, Lexington, KY 40506 USA.
   [Sauermann, Christian W.; Leathwick, Dave M.] AgRes Grasslands, Private Bag 11008, Palmerston North 4442, New Zealand.
RP Nielsen, MK (reprint author), Univ Kentucky, Dept Vet Sci, MH Gluck Equine Res Ctr, Lexington, KY 40506 USA.
EM martin.nielsen@uky.edu
OI Nielsen, Martin/0000-0002-8942-6803
FU Zoetis; AgResearch SSIF; University of Kentucky, Department of
   Veterinary Science Clay Fellowship Fund
FX The authors wish to thank Dr. Jay Donecker for initiating this project
   and Dr. Thomas Geurden for his encouragement and support. This work was
   principally funded by a grant from Zoetis with additional funding from
   AgResearch SSIF. The University of Kentucky, Department of Veterinary
   Science Clay Fellowship Fund supported Dr. Nielsen's sabbatical at
   AgResearch in 2018.
CR Becher AM, 2018, VET PARASITOL, V259, P6, DOI 10.1016/j.vetpar.2018.07.001
   DUNCAN JL, 1991, EQUINE VET J, V23, P226, DOI 10.1111/j.2042-3306.1991.tb02762.x
   Geurden T, 2014, VET PARASITOL, V204, P291, DOI 10.1016/j.vetpar.2014.04.013
   GOMEZ HH, 1991, EQUINE VET J, V23, P198, DOI 10.1111/j.2042-3306.1991.tb02754.x
   HERD RP, 1990, COMP CONT EDUC PRACT, V12, P732
   Kaplan RM, 2010, EQUINE VET EDUC, V22, P306, DOI 10.1111/j.2042-3292.2010.00084.x
   Klei TR, 2001, VET PARASITOL, V98, P315, DOI 10.1016/S0304-4017(01)00436-8
   KLEI TR, 1980, AM J VET RES, V41, P1747
   Leathwick DM, 2019, VET PARASITOL, V268, P53, DOI 10.1016/j.vetpar.2019.03.004
   Leathwick DM, 2015, VET PARASITOL, V209, P210, DOI 10.1016/j.vetpar.2015.02.031
   Love S, 1999, VET PARASITOL, V85, P113, DOI 10.1016/S0304-4017(99)00092-8
   Lyons ET, 2008, PARASITOL RES, V103, P209, DOI 10.1007/s00436-008-0959-7
   Lyons ET, 2009, PARASITOL RES, V104, P569, DOI 10.1007/s00436-008-1231-x
   LYONS ET, 1980, AM J VET RES, V41, P2069
   Lyons ET, 2011, PARASITOL RES, V108, P355, DOI 10.1007/s00436-010-2068-7
   Lyons ET, 2010, PARASITOL RES, V107, P1495, DOI 10.1007/s00436-010-2025-5
   Menne M. J., 2015, US HIST CLIMATOLOGY
   Nielsen M., 2016, AAEP PARASITE CONTRO
   Nielsen MK, 2018, VET PARASITOL, V250, P45, DOI 10.1016/j.vetpar.2017.12.012
   Peregrine AS, 2014, VET PARASITOL, V201, P1, DOI 10.1016/j.vetpar.2014.01.004
   Relf VE, 2012, EQUINE VET J, V44, P466, DOI 10.1111/j.2042-3306.2011.00493.x
   Robert M, 2015, EQUINE VET J, V47, P694, DOI 10.1111/evj.12344
   Rosanowski SM, 2016, EQUINE VET J, V48, P387, DOI 10.1111/evj.12558
   Salle G, 2015, VET REC OPEN, V2
   Sangster NC, 1999, VET PARASITOL, V85, P189, DOI 10.1016/S0304-4017(99)00099-0
   Tzelos T, 2017, VET PARASITOL, V237, P70, DOI 10.1016/j.vetpar.2017.02.018
NR 26
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 7
EP 12
DI 10.1016/j.vetpar.2019.04.003
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200003
PM 31079830
DA 2020-05-12
ER

PT J
AU Rani, S
   Cerqueira-Cezar, CK
   Murata, FHA
   Sadler, M
   Kwok, OCH
   Pradhan, AK
   Hill, DE
   Urban, JF
   Dubey, JP
AF Rani, S.
   Cerqueira-Cezar, Camila K.
   Murata, Fernando H. A.
   Sadler, M.
   Kwok, O. C. H.
   Pradhan, A. K.
   Hill, D. E.
   Urban, J. F., Jr.
   Dubey, J. P.
TI Toxoplasma gondii tissue cyst formation and density of tissue cysts in
   shoulders of pigs 7 and 14 days after feeding infected mice tissues
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Toxoplasma gondii; Pigs; Tissue cysts; Bioassay; Density of tissue cysts
ID RESPONSES; OOCYSTS; RISK; PORK
AB Among the meat sources of Toxoplasma gondii, pork is considered important in the epidemiology of toxoplasmosis in the USA. How soon after infection T. gondii forms tissue cysts in pork is unknown. In the present study, eight serologically negative -3 months old pigs were fed mouse tissues infected with VEG (Type III) strain of T. gondii and euthanized 7 (4 pigs) and 14 days (4 pigs) post-inoculation (p.i.). Meat from the right shoulder of each pig was bioassayed in mice for T. gondii tissue cysts by peptic digestion. From each pig, the shoulder muscle was cut at random spots into 5 g, 10 g and 50 g portions. Extreme care was taken to use different scalpels and forceps to minimize cross contamination among 17 samples (6 replicates of each 5 g and 10 g portions and 5 replicates of 50 g). From the four pigs euthanized at 7 days p.i., a composite of -200 g of leftover meat from each shoulder was bioassayed in cats and their feces were tested for oocyst excretion. All eight pigs developed T. gondii antibodies (modified agglutination test, MAT, 1: 80 or higher) and viable T. gondii was isolated from shoulder meat of each pig. All four cats fed pork from excreted T. gondii oocysts. The density of T. gondii, based on mouse infectivity, varied within 5-50 g samples each pig, and between pigs within the same group, day 7 versus day 14 p.i. There were no significant differences in mouse bioassay results obtained with day 7 versus day 14 infected pigs. Overall, the rate of isolation of T. gondii increased with sample size of meat bioassayed. Results demonstrate that tissue cysts are formed early in infection and they are unevenly distributed.
C1 [Rani, S.; Pradhan, A. K.] Univ Maryland, Dept Nutr & Food Sci, College Pk, MD 20742 USA.
   [Cerqueira-Cezar, Camila K.; Murata, Fernando H. A.; Sadler, M.; Kwok, O. C. H.; Hill, D. E.; Urban, J. F., Jr.; Dubey, J. P.] ARS, USDA, BARC, Anim Parasit Dis Lab, Beltsville, MD 20705 USA.
   [Pradhan, A. K.] Univ Maryland, Ctr Food Safety & Secur Syst, College Pk, MD 20742 USA.
   [Urban, J. F., Jr.] ARS, USDA, Beltsville Human Nutr Res Ctr, Diet Genom & Immunol Lab, Beltsville, MD 20705 USA.
   [Urban, J. F., Jr.] ARS, USDA, Beltsville Human Nutr Res Ctr, Anim Parasit Dis Lab, Beltsville, MD 20705 USA.
RP Dubey, JP (reprint author), USDA ARS, Beltsville Agr Res Ctr, Anim Parasit Dis Lab, Bldg 1001, Beltsville, MD 20705 USA.
EM jitender.dubey@ars.usda.gov
RI Murata, Fernando Henrique Antunes/AAD-5840-2020
OI Murata, Fernando Henrique Antunes/0000-0002-4642-9553; Urban,
   Joseph/0000-0002-1590-8869
FU DOEUnited States Department of Energy (DOE) [DE-SC0014664]
FX This research was supported in part by an appointment to the
   Agricultural Research Service (ARS) Research Participation Program
   administered by the Oak Ridge Institute for Science and Education
   (ORISE) through an interagency agreement between the U.S. Department of
   Energy (DOE) and the United States Department of Agriculture (USDA).
   ORISE is managed by Oak Ridge Associated Universities (ORAU) under DOE
   contract number DE-SC0014664. All opinions expressed in this paper are
   the author's and do not necessarily reflect the policies and views of
   USDA, ARS, DOE, or ORAU/ORISE.
CR Boch J., 1964, Berliner und Muenchner Tieraerztliche Wochenschrift, V77, P244
   Boch J., 1964, Berl. Munch. Tierarztl. Wschr., V77, P161
   DEMEUTER P, 1978, ANN SOC BELG MED TR, V58, P95
   Dubey JP, 2008, INT J PARASITOL, V38, P1257, DOI 10.1016/j.ijpara.2008.03.007
   Dubey J.P., 2010, TOXOPLASMOSIS ANIMAL, P1
   DUBEY JP, 1995, J PARASITOL, V81, P410, DOI 10.2307/3283823
   Dubey JP, 1996, AM J VET RES, V57, P1733
   DUBEY JP, 1986, J AM VET MED ASSOC, V188, P1035
   DUBEY JP, 1988, AM J VET RES, V49, P910
   Dubey JP, 2005, J PARASITOL, V91, P1082, DOI 10.1645/GE-683.1
   Dubey JP, 2001, J PARASITOL, V87, P215, DOI 10.1645/0022-3395(2001)087[0215:OSBCFI]2.0.CO;2
   DUBEY JP, 1987, EQUINE VET J, V19, P337, DOI 10.1111/j.2042-3306.1987.tb01426.x
   Guo M, 2017, FOOD CONTROL, V73, P1210, DOI 10.1016/j.foodcont.2016.10.038
   JANITSCH.K, 1970, ZENTBL BAKTERIOLOG P, V215, P123
   Wingstrand A, 1997, VET PARASITOL, V72, P129, DOI 10.1016/S0304-4017(97)00034-4
   WORK K, 1970, ACTA PATHOLOG MICROB, VB 78, P129
NR 16
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 13
EP 15
DI 10.1016/j.vetpar.2019.04.004
PG 3
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200004
PM 31079821
DA 2020-05-12
ER

PT J
AU Fairlie-Clarke, K
   Kaseja, K
   Sotomaior, C
   Brady, N
   Moore, K
   Stear, M
AF Fairlie-Clarke, Karen
   Kaseja, Karolina
   Sotomaior, Cristina
   Brady, Nicola
   Moore, Kirsty
   Stear, Michael
TI Salivary IgA: A biomarker for resistance to Teladorsagia circumcincta
   and a new estimated breeding value
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE IgA; Nematode resistance; Saliva test; Teladorsagia circumcincta;
   Selective breeding
ID LAMBS; SHEEP; INFECTION; FECUNDITY; IMMUNITY; MUCOSAL
AB Teladorsagia circumcincta is the dominant nematode of sheep in cool, temperate climates. Faecal nematode egg counts (FEC) are widely used to identify the intensity of infection and as a measure of host resistance to nematodes. However due to density-dependent effects on worm fecundity the relationship between FEC and worm burden is not linear. In addition collecting FEC data is challenging on a practical level and there is a need for more reliable markers of resistance. There are two major known mechanisms of immunity to T. circumcincta: IgE against third stage larvae (L3) and IgA against fourth stage larvae (L4), which inhibits parasite growth. In this study salivary IgA responses were measured in over 5000 animals against L3 antigen by Enzyme Linked Immunosorbent Assay (ELISA). Antigen-specific IgA levels were negatively correlated with FEC (r = -0.26, SE = 0.02) and were heritable (h(2) = 0.16, SE = 0.04) indicating that they can be used to identify resistant animals suitable for inclusion in selective breeding programs. Antigen-specific IgA responses were not negatively correlated with muscle depth. Our analyses indicate that selection for T. circumcincta L3 antigen-specific IgA is possible without impacting on the production traits for the Lleyn breed.
C1 [Fairlie-Clarke, Karen; Brady, Nicola] Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Garscube Campus,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.
   [Sotomaior, Cristina] Pontificia Univ Catolica Parana PUCPR, Sch Life Sci, Grad Program Anim Sci, BR-80215901 Curitiba, Parana, Brazil.
   [Kaseja, Karolina; Moore, Kirsty] Scotlands Rural Coll SRUC, Anim & Vet Sci, Peter Wilson Bldg,Kings Bldg,West Mains Rd, Edinburgh EH9 3JG, Midlothian, Scotland.
   [Stear, Michael] La Trobe Univ, Agribio, Dept Anim Plant & Soil Sci, Bundoora, Vic 3086, Australia.
RP Fairlie-Clarke, K (reprint author), Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland.
EM karen.fairlie-clarke@moredun.ac.uk
RI Stear, Michael/AAG-6329-2020; Sotomaior, Cristina/C-3422-2013
OI Stear, Michael/0000-0001-5054-1348; Sotomaior,
   Cristina/0000-0001-9281-3743
FU BBSRC Animal Health Research Grant [BB/L004070/1]; University of Glasgow
FX This work was supported by BBSRC Animal Health Research Grant
   BB/L004070/1 and the University of Glasgow.
CR Bishop SC, 2000, PARASITOLOGY, V121, P435, DOI 10.1017/S0031182099006526
   Bishop SC, 1996, ANIM SCI, V63, P423, DOI 10.1017/S1357729800015319
   Brandtzaeg P, 2007, VACCINE, V25, P5467, DOI 10.1016/j.vaccine.2006.12.001
   Brandtzaeg P, 2007, ANN NY ACAD SCI, V1098, P288, DOI 10.1196/annals.1384.012
   Ceyhan A, 2015, SMALL RUMINANT RES, V131, P29, DOI 10.1016/j.smallrumres.2015.07.024
   de Cisneros JPJ, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0416
   De Cisneros JPJ, 2014, PARASITOLOGY, V141, P875, DOI 10.1017/S0031182013002321
   Denwood MJ, 2008, PARASITOLOGY, V135, P1225, DOI 10.1017/S0031182008004708
   Ellis S, 2014, INT J PARASITOL, V44, P743, DOI 10.1016/j.ijpara.2014.05.007
   Gilmour AR, 2009, ASREML USER GUIDE RE
   Jackson F, 2009, SMALL RUMINANT RES, V86, P40, DOI 10.1016/j.smallrumres.2009.09.015
   Klasing Kirk C., 2004, Acta Zoologica Sinica, V50, P961
   Lee C Y, 2011, J Parasitol Res, V2011, P101848, DOI 10.1155/2011/101848
   Lidauer M.H., 2011, TECHNICAL REFERENCE
   Martinez-Valladares M, 2005, PARASITE IMMUNOL, V27, P213, DOI 10.1111/j.1365-3024.2005.00769.x
   Mcrae KM, 2014, VET PARASITOL, V206, P200, DOI 10.1016/j.vetpar.2014.10.023
   Murphy L, 2010, PARASITOLOGY, V137, P1249, DOI 10.1017/S0031182010000028
   Romeo C, 2014, PARASITOL RES, V113, P3403, DOI 10.1007/s00436-014-4005-7
   Shaw RJ, 2012, VET PARASITOL, V186, P109, DOI 10.1016/j.vetpar.2011.11.051
   Signet Breeding Services, 2014, SIGN GUID BREED WORM
   SMITH G, 1987, PARASITOLOGY, V95, P373, DOI 10.1017/S0031182000057814
   Stear M. J., 2003, Animal Health Research Reviews, V4, P45, DOI 10.1079/AHRR200351
   Stear MJ, 1995, PARASITE IMMUNOL, V17, P643, DOI 10.1111/j.1365-3024.1995.tb01010.x
   Strain SAJ, 2002, PARASITOLOGY, V124, P545, DOI 10.1017/S0031182002001531
   Traversa D, 2016, SMALL RUMINANT RES, V135, P75, DOI 10.1016/j.smallrumres.2015.12.014
NR 25
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 16
EP 20
DI 10.1016/j.vetpar.2019.04.005
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200005
PM 31079822
DA 2020-05-12
ER

PT J
AU Sitt, T
   Henson, S
   Morrison, WI
   Toye, P
AF Sitt, Tatjana
   Henson, Sonal
   Morrison, W. Ivan
   Toye, Philip
TI Similar levels of diversity in the gene encoding the p67 sporozoite
   surface protein of Theileria parva are observed in blood samples from
   buffalo and cattle naturally infected from buffalo
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Theileria parva; Buffalo; Cattle; p67; Diversity; East Coast fever;
   Corridor disease
ID VACCINE ANTIGEN; BOVINE; POPULATION; LAWRENCEI; SEQUENCE; EPITOPES
AB Theileria parva is a tick-transmitted, apicomplexan protozoan found in buffalo (Syncerus caffer) and cattle in eastern, central and southern Africa. The parasite causes a fatal, lymphoproliferative disease in susceptible cattle. Previous studies have shown that the parasites in buffalo comprise a more heterogeneous population than those in cattle, which has led to the concept that the population of parasites circulating in cattle represents a restricted subpopulation of those in buffalo. The present study was undertaken to identify if and where this restriction may occur in cattle naturally infected with parasites from buffalo, by sequencing the T. parva p67 antigen gene from eight buffalo and 12 acutely infected cattle from the same endemic site in Kenya. From 103 sequences, we detected 44 different alleles. Nine alleles were found in both cattle and buffalo, and 17 and 18 found only in the cattle and buffalo populations respectively. Nucleotide and amino acid sequence analyses revealed a similar level of diversity of parasites in both hosts. Principal coordinates and phylogenetic tree analyses did not reveal any clustering associated with the host animals, and the number and degree of mixed T. parva infections was similar in the respective populations. The results suggest that any restriction in the ability of T. parva from buffalo to survive and be transmitted from cattle occurs after entry into and initial transformation of bovine lymphocytes.
C1 [Sitt, Tatjana; Henson, Sonal; Toye, Philip] ILRI, POB 30709, Nairobi 00100, Kenya.
   [Morrison, W. Ivan] Univ Edinburgh, Roslin Inst, Roslin EH25 9RG, Midlothian, Scotland.
   [Sitt, Tatjana] Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Manhattan, KS 66506 USA.
RP Toye, P (reprint author), ILRI, POB 30709, Nairobi 00100, Kenya.
EM p.toye@cgiar.org
RI Sitt, Tatjana/L-7968-2015
OI Henson, Sonal/0000-0002-2002-5462
FU Department for International Development (UK Government); Biotechnology
   and Biological Sciences Research Council (BBSRC) UK of the Combating
   Infectious Diseases of Livestock for International Development (CIDLID)
   program [BB/H009515/1]
FX This work was partially supported by a grant awarded jointly by the
   Department for International Development (UK Government) and the
   Biotechnology and Biological Sciences Research Council (BBSRC) UK grant
   number BB/H009515/1 of the Combating Infectious Diseases of Livestock
   for International Development (CIDLID) program. The study was conducted
   as part of the CGIAR Research Program on Livestock and Fish, led by
   ILRI, and is supported by contributors to the CGIAR Trust Fund.
CR BARNETT SF, 1966, BRIT VET J, V122, P396, DOI 10.1016/S0007-1935(17)40406-4
   Freeman AR, 2006, GENETICS, V173, P1503, DOI 10.1534/genetics.105.053280
   Gardner MJ, 2005, SCIENCE, V309, P134, DOI 10.1126/science.1110439
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hemmink JD, 2018, INT J PARASITOL, V48, P287, DOI 10.1016/j.ijpara.2017.10.006
   HULLIGER L, 1964, NATURE, V203, P728, DOI 10.1038/203728a0
   IRVIN AD, 1983, VET REC, V113, P192, DOI 10.1136/vr.113.9.192
   JURA WGZ, 1980, VET PARASITOL, V7, P275, DOI 10.1016/0304-4017(80)90047-3
   MORRISON WI, 1981, EXP PARASITOL, V52, P248, DOI 10.1016/0014-4894(81)90080-1
   MUKHEBI AW, 1992, PREV VET MED, V12, P73, DOI 10.1016/0167-5877(92)90070-V
   MUSOKE AJ, 1984, IMMUNOLOGY, V52, P231
   NEITZ W. O., 1955, Journal of the South African Veterinary Medical Association, V26, P79
   Nene V, 1999, INFECT IMMUN, V67, P1261, DOI 10.1128/IAI.67.3.1261-1266.1999
   Nene V, 1996, INFECT IMMUN, V64, P2056, DOI 10.1128/IAI.64.6.2056-2061.1996
   NENE V, 1992, MOL BIOCHEM PARASIT, V51, P17, DOI 10.1016/0166-6851(92)90196-Q
   Norval RAI, 1992, EPIDEMIOLOGY THEILER
   Obara I, 2015, PARASITOL RES, V114, P1729, DOI 10.1007/s00436-015-4358-6
   Oura CAL, 2011, VET PARASITOL, V175, P212, DOI 10.1016/j.vetpar.2010.10.032
   Oura CAL, 2005, MOL BIOCHEM PARASIT, V140, P229, DOI 10.1016/j.molbiopara.2004.12.015
   Pelle R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019015
   Sibeko KP, 2010, VET PARASITOL, V167, P244, DOI 10.1016/j.vetpar.2009.09.026
   Sitt T, 2015, INT J PARASITOL-PAR, V4, P244, DOI 10.1016/j.ijppaw.2015.04.006
NR 22
TC 1
Z9 1
U1 3
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 21
EP 27
DI 10.1016/j.vetpar.2019.04.006
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200006
PM 31079824
DA 2020-05-12
ER

PT J
AU Sauermann, CW
   Nielsen, MK
   Luo, DW
   Leathwick, DM
AF Sauermann, Christian W.
   Nielsen, Martin K.
   Luo, Dongwen
   Leathwick, Dave M.
TI Modelling the development of anthelmintic resistance in cyathostomin
   parasites: The importance of genetic and fitness parameters
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Anthelmintic resistance; Model; Genetics; Cyathostomins; Horse;
   nematodes
ID TRICHOSTRONGYLUS-COLUBRIFORMIS; HAEMONCHUS-CONTORTUS; GASTROINTESTINAL
   PARASITES; BENZIMIDAZOLE RESISTANCE; SMALL STRONGYLES; PARASCARIS SPP.;
   CRITICAL TESTS; TARGET WORMS; IVERMECTIN; EFFICACY
AB Previously described models for the free-living and parasitic phases of the cyathostomin life-cycle were combined into a single model for the complete life-cycle. The model simulates a single free-living population on pasture utilising parasite egg output from the horses and localised temperature and rainfall data to estimate infective larval density on herbage. Multiple horses of different ages are possible, each with an individualised anthelmintic treatment programme. Genotypes for anthelmintic resistance are included allowing for up to three resistance genes with 2 alleles each. Because little is known of the genetics of resistance to anthelmintics in cyathostomins, the first use of this model was to compare the effect of different assumptions regarding the inheritance of resistance on model outputs. Comparisons were made between single and two-gene inheritance, where the heterozygote survival was dominant, intermediate or recessive under treatment, and with or without a fitness disadvantage associated with the resistance mechanism. Resistance developed fastest when the heterozygotes survived anthelmintic treatment (i.e., were dominant) and slowest when they did not (Le., were recessive). Resistance was slower to develop when inheritance was poly-genic compared to a single gene, and when there was a fitness cost associated with the resistance mechanism, although the latter variable was the least influential. Importantly, while these genetic factors sometimes had a large influence on the rate at which resistant genotypes built up in the model populations, their order of ranking was always the same, when different anthelmintic use strategies were compared. Therefore, the described model is a useful tool for evaluating different treatment and management strategies on their potential to select for resistance.
C1 [Sauermann, Christian W.; Luo, Dongwen; Leathwick, Dave M.] AgRes Grasslands, Private Bag 11008, Palmerston North 4442, New Zealand.
   [Nielsen, Martin K.] Univ Kentucky, Dept Vet Sci, MH Gluck Equine Res Ctr, Lexington, KY USA.
RP Sauermann, CW (reprint author), AgRes Grasslands, Private Bag 11008, Palmerston North 4442, New Zealand.
EM christian.sauermann@agresearch.co.nz
OI Nielsen, Martin/0000-0002-8942-6803
FU Zoetis; AgResearch SSIF; Clay Fellowship at the M.H. Gluck Equine
   Research Center
FX Y We thank Drs. Jay M. Donecker and T. Geurden for their support and
   encouragement of this project. This work was instigated and initially
   funded by Zoetis. It continues with funding from AgResearch SSIF. The
   Clay Fellowship at the M.H. Gluck Equine Research Center funded Dr.
   Nielsen's sabbatical leave at AgResearch in 2018 to complete this
   project.
CR BARNES EH, 1995, PARASITOL TODAY, V11, P56, DOI 10.1016/0169-4758(95)80117-0
   BARNES EH, 1990, INT J PARASITOL, V20, P823, DOI 10.1016/0020-7519(90)90019-J
   Beech RN, 2011, PARASITOLOGY, V138, P160, DOI 10.1017/S0031182010001198
   Bellaw JL, 2018, INT J PARASITOL, V48, P97, DOI 10.1016/j.ijpara.2017.08.009
   Blackhall WJ, 2011, PARASITOL RES, V109, P1199, DOI 10.1007/s00436-011-2426-0
   BOGAN JA, 1988, J VET PHARMACOL THER, V11, P260, DOI 10.1111/j.1365-2885.1988.tb00151.x
   BUCKNELL DG, 1995, INT J PARASITOL, V25, P711, DOI 10.1016/0020-7519(94)00214-9
   DONALD AD, 1980, INT J PARASITOL, V10, P381, DOI 10.1016/0020-7519(80)90039-9
   Doyle SR, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5592-6
   Drogemuller M, 2004, J PARASITOL, V90, P868, DOI 10.1645/GE3305RN
   GETTINBY G, 1989, VET PARASITOL, V32, P57, DOI 10.1016/0304-4017(89)90155-6
   Gibson T. E., 1953, Journal of Helminthology, V27, P29, DOI 10.1017/S0022149X00023488
   Gokbulut C, 2010, VET PARASITOL, V170, P120, DOI 10.1016/j.vetpar.2010.01.041
   Gopal RM, 2001, NEW ZEAL VET J, V49, P133, DOI 10.1080/00480169.2001.36220
   Kaschny M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004781
   Klei TR, 2001, VET PARASITOL, V98, P315, DOI 10.1016/S0304-4017(01)00436-8
   Klei TR, 1999, VET PARASITOL, V85, P123, DOI 10.1016/S0304-4017(99)00093-X
   KLEI TR, 1980, AM J VET RES, V41, P1747
   Leathwick DM, 2013, VET PARASITOL, V191, P293, DOI 10.1016/j.vetpar.2012.09.020
   Leathwick DM, 2012, VET PARASITOL, V186, P93, DOI 10.1016/j.vetpar.2011.11.050
   Leathwick DM, 2019, VET PARASITOL, V268, P53, DOI 10.1016/j.vetpar.2019.03.004
   Leathwick DM, 2017, VET PARASITOL, V243, P29, DOI 10.1016/j.vetpar.2017.05.032
   Leathwick DM, 2017, VET PARASITOL, V240, P75, DOI 10.1016/j.vetpar.2017.03.026
   Leathwick DM, 2016, VET PARASITOL, V228, P108, DOI 10.1016/j.vetpar.2016.08.019
   Leathwick DM, 2015, INT J PARASITOL-DRUG, V5, P9, DOI 10.1016/j.ijpddr.2015.01.001
   Leathwick DM, 2015, VET PARASITOL, V209, P210, DOI 10.1016/j.vetpar.2015.02.031
   Leathwick DM, 2013, VET PARASITOL, V198, P145, DOI 10.1016/j.vetpar.2013.08.022
   Leathwick DM, 1995, INT J PARASITOL, V25, P1479, DOI 10.1016/0020-7519(95)00059-3
   Lichtenfels JR, 2008, VET PARASITOL, V156, P4, DOI 10.1016/j.vetpar.2008.04.026
   Lloberas M, 2012, EXP PARASITOL, V131, P304, DOI 10.1016/j.exppara.2012.04.014
   Love S, 1999, VET PARASITOL, V85, P113, DOI 10.1016/S0304-4017(99)00092-8
   Lyons ET, 2009, PARASITOL RES, V104, P569, DOI 10.1007/s00436-008-1231-x
   LYONS ET, 1980, AM J VET RES, V41, P2069
   Lyons ET, 2010, PARASITOL RES, V107, P1495, DOI 10.1007/s00436-010-2025-5
   MAINGI N, 1990, PARASITOLOGY, V100, P327, DOI 10.1017/S0031182000061345
   MARTIN PJ, 1990, INT J PARASITOL, V20, P867, DOI 10.1016/0020-7519(90)90024-H
   MARTIN PJ, 1988, INT J PARASITOL, V18, P333, DOI 10.1016/0020-7519(88)90142-7
   Nielsen MK, 2014, VET PARASITOL, V204, P55, DOI 10.1016/j.vetpar.2013.11.030
   Nielsen MK, 2010, VET PARASITOL, V174, P77, DOI 10.1016/j.vetpar.2010.08.007
   Nielsen M. K., 2013, NEMATODES EQUINE INF
   Peregrine AS, 2014, VET PARASITOL, V201, P1, DOI 10.1016/j.vetpar.2014.01.004
   PRICHARD RK, 1990, INT J PARASITOL, V20, P515, DOI 10.1016/0020-7519(90)90199-W
   R Core Team, 2012, R LANG ENV STAT COMP
   REID SWJ, 1995, EQUINE VET J, V27, P127, DOI 10.1111/j.2042-3306.1995.tb03048.x
   Relf VE, 2012, EQUINE VET J, V44, P466, DOI 10.1111/j.2042-3306.2011.00493.x
   Robert M, 2015, EQUINE VET J, V47, P694, DOI 10.1111/evj.12344
   Rosanowski SM, 2016, EQUINE VET J, V48, P387, DOI 10.1111/evj.12558
   Salle G, 2015, VET REC OPEN, V2
   Sangster NC, 1998, INT J PARASITOL, V28, P503, DOI 10.1016/S0020-7519(97)00194-X
   Saumell C, 2017, VET PARASITOL, V236, P62, DOI 10.1016/j.vetpar.2017.01.025
   SMITH G, 1990, INT J PARASITOL, V20, P913, DOI 10.1016/0020-7519(90)90030-Q
   Sutherland IA, 2002, VET PARASITOL, V109, P91, DOI 10.1016/S0304-4017(02)00247-9
   WALLER PJ, 1989, INT J PARASITOL, V19, P99, DOI 10.1016/0020-7519(89)90027-1
NR 53
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 28
EP 33
DI 10.1016/j.vetpar.2019.04.007
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200007
PM 31079825
DA 2020-05-12
ER

PT J
AU Soutter, F
   Solano-Gallego, L
   Attipa, C
   Gradoni, L
   Fiorentino, E
   Manzillo, VF
   Oliva, G
   Tasker, S
   Helps, C
   Catchpole, B
AF Soutter, Francesca
   Solano-Gallego, Laia
   Attipa, Charalampos
   Gradoni, Luigi
   Fiorentino, Eleonora
   Manzillo, Valentina Foglia
   Oliva, Gaetano
   Tasker, Severine
   Helps, Chris
   Catchpole, Brian
TI An investigation of polymorphisms in innate and adaptive immune response
   genes in canine leishmaniosis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Leishmania; Genetics; Dogs; Innate; Adaptive
ID CLASS-II TRANSACTIVATOR; VISCERAL LEISHMANIASIS; DIAGNOSIS; INFANTUM;
   PCR; SUSCEPTIBILITY; INFECTION; DOGS; ASSOCIATION; EXPRESSION
AB The outcome of infection with Leishmania infantum in dogs is variable, which is thought to be due to the nature of the immune response mounted by the host. As a consequence, the clinical signs and severity of canine leishmaniosis vary between individual dogs. Host immunogenetic factors might play an important role in determining the outcome of infection. The aim of this study was to examine polymorphisms in innate and adaptive immune response genes, to determine whether any of these were associated with susceptibility or resistance to L. infantum infection. Genomic DNA was obtained from two groups: pet dogs in endemic regions of Europe and a group of Beagles exposed to sand fly infection as part of a vaccine study. Genotyping was performed using a SNP (single nucleotide polymorphism) array for selected immune response genes. The first part of the study compared 62 clinical cases with 101 clinically unaffected dogs that were seronegative for Leishmania antibodies. One SNP in the CIITA gene demonstrated a significantly higher minor allele frequency in the case group, compared with the control group at the individual SNP level after permutation, but was not significant after correction for multiple testing. The second part of the study examined 48 Beagle dogs exposed to L. infantum over two transmission seasons. Twenty-seven dogs with a resistant phenotype (no evidence of clinical disease, seronegative at the end of the study period, negative on lymph node culture and only transiently PCR positive in bone marrow) were compared with 21 dogs demonstrating a susceptible phenotype (clinical disease, seropositive, positive lymph node culture and consistently PCR positive in bone marrow). Three SNPs in TLR3, two SNPs in PTPN22 and one SNP in TLR4 and ILIA were associated with the susceptible phenotype in the Beagle group at the individual SNP level after permutation analysis, but were not significant after correction for multiple testing. Further validation of these SNPs is required in a larger cohort of dogs, ideally with extreme phenotypes to confirm an association with the outcome of L. infantum infection.
C1 [Soutter, Francesca; Attipa, Charalampos; Catchpole, Brian] Royal Vet Coll, Dept Pathobiol & Populat Sci, N Mymms AL9 7TA, Herts, England.
   [Solano-Gallego, Laia] Univ Autonoma Barcelona, Fac Vet, Dept Med & Cirurgia Anim, Barcelona, Spain.
   [Attipa, Charalampos] Cyvets Vet Ctr, Paphos, Cyprus.
   [Gradoni, Luigi; Fiorentino, Eleonora] Ist Super Sanita, Dept Infect Dis, Unit Vector Borne Dis, Rome, Italy.
   [Manzillo, Valentina Foglia; Oliva, Gaetano] Univ Naples Federico II, Dipartimento Med Vet & Prod Anim, Naples, Italy.
   [Tasker, Severine; Helps, Chris] Univ Bristol, Diagnost Labs, Mol Diagnost Unit, Bristol BS40 5DU, Avon, England.
RP Soutter, F (reprint author), Royal Vet Coll, Dept Pathobiol & Populat Sci, N Mymms AL9 7TA, Herts, England.
EM fsoutter@rvc.ac.uk
RI Gradoni, Luigi/C-4962-2016; Solano-Gallego, Laia/H-6470-2015
OI Solano-Gallego, Laia/0000-0001-8479-4896; Attipa,
   Charalampos/0000-0001-6039-6586; Helps, Chris/0000-0003-3405-4843
FU Biotechnology and Biological Sciences Research Council
   (BBSRC)Collaborative Awards in Science and Engineering (CASE)
   studentship [BB/I015655/1]; Zoetis
FX This study was supported by a Biotechnology and Biological Sciences
   Research Council (BBSRC)Collaborative Awards in Science and Engineering
   (CASE) studentship (BB/I015655/1) in partnership with Zoetis.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543
   Cortes S, 2004, T ROY SOC TROP MED H, V98, P12, DOI 10.1016/S0035-9203(03)00002-6
   Cortes S, 2012, PARASITOLOGY, V139, P191, DOI 10.1017/S0031182011001909
   Criswell LA, 2005, AM J HUM GENET, V76, P561, DOI 10.1086/429096
   Davison LJ, 2012, HUM MOL GENET, V21, P322, DOI 10.1093/hmg/ddr468
   Flandin JF, 2006, EUR J IMMUNOL, V36, P411, DOI 10.1002/eji.200535079
   Francino O, 2006, VET PARASITOL, V137, P214, DOI 10.1016/j.vetpar.2006.01.011
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gramiccia M, 2005, INT J PARASITOL, V35, P1169, DOI 10.1016/j.ijpara.2005.07.001
   Hosein S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140325
   Hostomska J, 2008, VECTOR-BORNE ZOONOT, V8, P443, DOI 10.1089/vbz.2007.0214
   Itoh-Lindstrom Y, 1999, J IMMUNOL, V163, P2425
   Karmakar S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002646
   Koutinas AF, 1999, J AM ANIM HOSP ASSOC, V35, P376, DOI 10.5326/15473317-35-5-376
   Kropf P, 2004, INFECT IMMUN, V72, P1920, DOI 10.1128/IAI.72.4.1920-1928.2004
   Kropf P, 2004, J LEUKOCYTE BIOL, V76, P48, DOI 10.1189/jlb.1003484
   Liu H, 2015, NAT GENET, V47, P267, DOI 10.1038/ng.3212
   Maia C, 2008, VET PARASITOL, V158, P274, DOI 10.1016/j.vetpar.2008.07.028
   Maia C, 2015, VET PARASITOL, V213, P2, DOI 10.1016/j.vetpar.2015.05.003
   Oliva G, 2006, J CLIN MICROBIOL, V44, P1318, DOI 10.1128/JCM.44.4.1318-1322.2006
   Oliva G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003213
   Palatnik-de-Sousa CB, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-197
   Paltrinieri S, 2010, JAVMA-J AM VET MED A, V236, P1184, DOI 10.2460/javma.236.11.1184
   PINELLI E, 1994, INFECT IMMUN, V62, P229, DOI 10.1128/IAI.62.1.229-235.1994
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Quilez J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035349
   Quinnell RJ, 2003, IMMUNOGENETICS, V55, P23, DOI 10.1007/s00251-003-0545-1
   Quinnell RJ, 2001, PARASITOLOGY, V122, P253, DOI 10.1017/S0031182001007363
   Shaw SE, 2009, VET PARASITOL, V163, P281, DOI 10.1016/j.vetpar.2009.03.025
   Short AD, 2007, J HERED, V98, P518, DOI 10.1093/jhered/esm048
   Short AD, 2013, J HERED, V104, P807, DOI 10.1093/jhered/est051
   Solano-Gallego L, 2009, VET PARASITOL, V165, P1, DOI 10.1016/j.vetpar.2009.05.022
   Solano-Gallego L, 2001, VET PARASITOL, V96, P265, DOI 10.1016/S0304-4017(00)00446-5
   Solano-Gallego L, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-111
   Stanford SM, 2014, NAT REV RHEUMATOL, V10, P602, DOI 10.1038/nrrheum.2014.109
   Utsunomiya YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136749
   Vlkova M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001344
   Zhang XQ, 2007, J CLIN VIROL, V40, P197, DOI 10.1016/j.jcv.2007.08.016
NR 39
TC 1
Z9 1
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 34
EP 41
DI 10.1016/j.vetpar.2019.04.011
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200008
PM 31079826
DA 2020-05-12
ER

PT J
AU Foroutan, M
   Fakhri, Y
   Riahi, SM
   Ebrahimpour, S
   Namroodi, S
   Taghipour, A
   Spotin, A
   Gamble, HR
   Rostami, A
AF Foroutan, Masoud
   Fakhri, Yadolah
   Riahi, Seyed Mohammad
   Ebrahimpour, Soheil
   Namroodi, Somayeh
   Taghipour, Ali
   Spotin, Adel
   Gamble, H. Ray
   Rostami, Ali
TI The global seroprevalence of Toxoplasma gondii in pigs: A systematic
   review and meta-analysis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Toxoplasmosis; Serology; Pig; Zoonosis; Meta-analysis
ID MODIFIED AGGLUTINATION-TEST; RISK-FACTORS; DOMESTIC PIGS; SLAUGHTERED
   PIGS; FATTENING PIGS; MOLECULAR CHARACTERIZATION; TRICHINELLA-SPIRALIS;
   SEROLOGICAL SURVEY; COMMERCIAL ELISA; NEOSPORA-CANINUM
AB Toxoplasmosis, caused by the protozoan parasite Toxoplasma gondii, is an important disease with worldwide distribution. Infection can occur from ingesting raw or undercooked infected meat, and among food animal species, pork is known to be one of the main sources of meat-borne infection. Here, we present results of the first systematic review and meta-analysis on the global T. gondii seroprevalence in pigs. PubMed/MEDLINE, Scopus, and EMBASE databases were comprehensively searched for relevant studies published between January 1, 1990 and October 25, 2018. We used a random effects model to calculate pooled seroprevalence estimates with 95% confidence intervals (CI) and analyzed data from five continents. We also conducted subgroup and meta-regression analyses to evaluate the effects of geographical and climate variables on pooled seroprevalence rates. Among 1542 publications identified, 148 studies containing 150 datasets were included in the meta-analysis, and comprised 148,092 pigs from 47 countries. The pooled global T. gondii seroprevalence in pigs was estimated to be 19% (95 %CI, 17-22%; 23,696/148,092), with the lowest seroprevalence in Europe (13%; 10-15%) and highest seroprevalence in Africa (25%; 17-34%) and North America (25%; 19-33%). The seropositivity rates in Asia and South America regions were (21%, 16-26%) and (23%; 17-30%), respectively. A significantly higher T. gondii seroprevalence was associated with higher mean annual temperature and lower geographical latitude. The presence of cats on farms was identified as a potential risk factor for T. gondii seropositivity (OR, 1.41; 95%CI, 1.00-2.02). Our findings highlight the importance of pigs as a possible source of human T. gondii infections.
C1 [Foroutan, Masoud] Abadan Sch Med Sci, Abadan, Iran.
   [Foroutan, Masoud; Taghipour, Ali] Tarbiat Modares Univ, Fac Med Sci, Dept Parasitol, Tehran, Iran.
   [Fakhri, Yadolah] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Dept Environm Hlth Engn, Tehran, Iran.
   [Riahi, Seyed Mohammad] Birjand Univ Med Sci, Fac Hlth, Dept Epidemiol & Biostat, Social Determinants Hlth Res Ctr, Birjand, Iran.
   [Ebrahimpour, Soheil; Rostami, Ali] Babol Univ Med Sci, Hlth Res Inst, Infect Dis & Trop Med Res Ctr, Babol Sar, Iran.
   [Namroodi, Somayeh] Gorgan Univ Agr Sci & Nat Resources, Fac Fisheries & Environm Sci, Dept Environm Sci, Gorgan, Golestan, Iran.
   [Spotin, Adel] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran.
   [Spotin, Adel] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Gamble, H. Ray] Natl Acad Sci, 2101 Constitut Ave Nw, Washington, DC 20418 USA.
   [Rostami, Ali] Babol Univ Med Sci, Hlth Res Inst, Mmunoregulat Res Ctr, Babol Sar, Iran.
RP Rostami, A (reprint author), Babol Univ Med Sci, Hlth Res Inst, Infect Dis & Trop Med Res Ctr, Babol Sar, Iran.
EM a.rostami@mubabol.ac.ir
RI Spotin, Adel/C-2275-2015; Foroutan, Masoud/AAD-6837-2020; rostami,
   ali/R-3347-2017
OI Spotin, Adel/0000-0002-3009-9537; Foroutan, Masoud/0000-0002-8661-7217;
   taghipour, ali/0000-0002-6876-5902; rostami, ali/0000-0002-1358-1321;
   Fakhri, Yadolah/0000-0002-3579-7641
CR Abdel-Hafeez Ekhlas Hamed, 2015, J Egypt Soc Parasitol, V45, P671
   Alvarado-Esquivel C, 2012, J PARASITOL, V98, P1248, DOI 10.1645/GE-3184.1
   Alvarado-Esquivel C, 2011, J PARASITOL, V97, P616, DOI 10.1645/GE-2755.1
   Alvarado-Esquivel C, 2015, EUR J MICROBIOL IMMU, V5, P112, DOI [10.1556/EUJMI-D-15-00004, 10.1556/EuJMI-D-15-00004]
   Alvarado-Esquivel C, 2014, TROP ANIM HEALTH PRO, V46, P705, DOI 10.1007/s11250-014-0551-3
   ARIAS ML, 1994, REV BIOL TROP, V42, P15
   Arko-Mensah J, 2000, ACTA TROP, V76, P27, DOI 10.1016/S0001-706X(00)00085-1
   ASSADIRAD AM, 1995, VET PARASITOL, V57, P289, DOI 10.1016/0304-4017(94)00677-5
   Bacci C, 2015, INT J FOOD MICROBIOL, V202, P54, DOI 10.1016/j.ijfoodmicro.2015.03.002
   Balea Anamaria, 2012, Scientia Parasitologica, V13, P163
   Bamba S., 2017, J PARASITOL VECTOR B, V9, P106
   Bamba S, 2016, INT J FOOD MICROBIOL, V230, P10, DOI 10.1016/j.ijfoodmicro.2016.04.016
   Bartova E, 2011, PARASITOLOGY, V138, P1369, DOI 10.1017/S0031182011001041
   Basso W, 2013, INT J PARASITOL, V43, P565, DOI 10.1016/j.ijpara.2013.02.003
   Hernandez-Cortazar IB, 2016, FOODBORNE PATHOG DIS, V13, P695, DOI 10.1089/fpd.2016.2165
   Belluco S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153856
   Berger-Schoch AE, 2011, ZOONOSES PUBLIC HLTH, V58, P472, DOI 10.1111/j.1863-2378.2011.01395.x
   Bezerra RA, 2009, REV BRAS PARASITOL V, V18, P78, DOI 10.4322/rbpv.01803015
   Cademartori BG, 2014, VET PARASITOL, V203, P207, DOI 10.1016/j.vetpar.2014.02.009
   Caporali E. H. G., 2005, Arquivos de Ciencias Veterinarias e Zoologia da UNIPAR, V8, P19
   Carletti R. T., 2005, Semina: Ciencias Agrarias (Londrina), V26, P563
   Casartelli-Alves L, 2014, VET PARASITOL, V204, P346, DOI 10.1016/j.vetpar.2014.05.039
   Cavalcante GT, 2006, J PARASITOL, V92, P863, DOI 10.1645/GE-830R.1
   Chandrawathani P, 2008, TROP BIOMED, V25, P257
   Chang G N, 1991, Southeast Asian J Trop Med Public Health, V22 Suppl, P111
   Chang QC, 2013, J PARASITOL, V99, P544, DOI 10.1645/12-102.1
   Chikweto A, 2011, J PARASITOL, V97, P950, DOI 10.1645/GE-2811.1
   Andrade MMC, 2013, RES VET SCI, V94, P587, DOI 10.1016/j.rvsc.2013.01.006
   Correa R, 2008, VET PARASITOL, V153, P9, DOI 10.1016/j.vetpar.2008.01.017
   Damriyasa IM, 2005, DEUT TIERARZTL WOCH, V112, P223
   Davies PR, 1998, PREV VET MED, V36, P67, DOI 10.1016/S0167-5877(98)00072-5
   de Azevedo SS, 2010, REV BRAS PARASITOL V, V19, P80, DOI 10.1590/S1984-29612010000200002
   De Berardinis A, 2017, FOODBORNE PATHOG DIS, V14, P637, DOI 10.1089/fpd.2017.2305
   De Moura AB, 2007, REV BRAS PARASITOL V, V16, P54
   de Sousa RA, 2014, REV BRAS PARASITOL V, V23, P98, DOI 10.1590/S1984-29612014015
   de Sousa S, 2006, VET PARASITOL, V135, P133, DOI 10.1016/j.vetpar.2005.08.012
   Deksne G, 2013, J PARASITOL, V99, P44, DOI 10.1645/GE-3187.1
   Devleesschauwer B, 2013, VECTOR-BORNE ZOONOT, V13, P872, DOI 10.1089/vbz.2013.1313
   Djokic V, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1753-5
   dos Santos CBD, 2005, VET PARASITOL, V131, P207, DOI 10.1016/j.vetpar.2005.04.039
   Du F, 2012, VET PARASITOL, V187, P53, DOI 10.1016/j.vetpar.2011.12.036
   Dubey JP, 2007, VET PARASITOL, V148, P207, DOI 10.1016/j.vetpar.2007.06.033
   Dubey JP, 2012, VET PARASITOL, V188, P14, DOI 10.1016/j.vetpar.2012.03.008
   Dubey JP, 2010, ZOONOSES PUBLIC HLTH, V57, P60, DOI 10.1111/j.1863-2378.2009.01274.x
   Dubey JP, 2009, VET PARASITOL, V164, P89, DOI 10.1016/j.vetpar.2009.05.018
   Dubey JP, 2008, J EUKARYOT MICROBIOL, V55, P467, DOI 10.1111/j.1550-7408.2008.00345.x
   DUBEY JP, 1995, J PARASITOL, V81, P410, DOI 10.2307/3283823
   DUBEY JP, 1992, VET PARASITOL, V43, P57, DOI 10.1016/0304-4017(92)90048-E
   DUBEY JP, 1991, J PARASITOL, V77, P517, DOI 10.2307/3283154
   DUBEY JP, 1995, J PARASITOL, V81, P723, DOI 10.2307/3283961
   Dubey JP, 2002, J PARASITOL, V88, P1234, DOI 10.1645/0022-3395(2002)088[1234:HPOVTG]2.0.CO;2
   Dubey JP, 1998, J PARASITOL, V84, P862, DOI 10.2307/3284606
   Dubey JP, 2001, J PARASITOL, V87, P215, DOI 10.1645/0022-3395(2001)087[0215:OSBCFI]2.0.CO;2
   DUBEY JP, 1995, J PARASITOL, V81, P48, DOI 10.2307/3284004
   DUBEY JP, 1995, AM J VET RES, V56, P1030
   Dzib-Paredes GF, 2016, VET PARASITOL, V229, P45, DOI 10.1016/j.vetpar.2016.09.016
   EDELHOFER R, 1994, PARASITOL RES, V80, P642, DOI 10.1007/BF00932946
   Esteves F, 2014, VET PARASITOL, V200, P8, DOI 10.1016/j.vetpar.2013.12.017
   Fakhri Y, 2018, ENVIRON POLLUT, V242, P1467, DOI 10.1016/j.envpol.2018.07.087
   Fallahi S, 2018, J GYNECOL OBSTET HUM, V47, P133, DOI 10.1016/j.jogoh.2017.12.003
   Fan CK, 2004, J PARASITOL, V90, P653, DOI 10.1645/GE-177R
   Feitosa TF, 2017, VET PARASITOL, V244, P76, DOI 10.1016/j.vetpar.2017.07.017
   Feitosa TF, 2014, VET PARASITOL, V202, P305, DOI 10.1016/j.vetpar.2014.03.015
   Felin E, 2015, ZOONOSES PUBLIC HLTH, V62, P456, DOI 10.1111/zph.12174
   Foroutan M., 2018, INT J INFECT, V5, DOI DOI 10.5812/IJI
   Foroutan-Rad M, 2016, TRANSFUS MED REV, V30, P116, DOI 10.1016/j.tmrv.2016.03.002
   Frazao-Teixeira E, 2011, J PARASITOL, V97, P44, DOI 10.1645/GE-2457.1
   Freitas JA, 2009, ARQ BRAS MED VET ZOO, V61, P1230, DOI 10.1590/S0102-09352009000500030
   Gajadhar AA, 1998, J PARASITOL, V84, P759, DOI 10.2307/3284584
   Gamble HR, 1999, VET PARASITOL, V82, P129, DOI 10.1016/S0304-4017(99)00004-7
   Gamble HR, 2005, VET PARASITOL, V128, P177, DOI 10.1016/j.vetpar.2004.11.019
   Garcia JL, 2006, EXP PARASITOL, V113, P100, DOI 10.1016/j.exppara.2005.12.011
   Garcia-Bocanegra I, 2010, RES VET SCI, V89, P85, DOI 10.1016/j.rvsc.2010.01.017
   Garcia-Bocanegra I, 2010, PARASITOL INT, V59, P421, DOI 10.1016/j.parint.2010.06.001
   GARCIAVAZQUEZ Z, 1993, PREV VET MED, V17, P127, DOI 10.1016/0167-5877(93)90061-W
   Gardner IA, 2010, ZOONOSES PUBLIC HLTH, V57, P82, DOI 10.1111/j.1863-2378.2009.01281.x
   Gazzonis AL, 2018, PARASITOL RES, V117, P539, DOI 10.1007/s00436-017-5736-z
   Gebremedhin EZ, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0384-y
   Gebreyes WA, 2008, FOODBORNE PATHOG DIS, V5, P199, DOI 10.1089/fpd.2007.0071
   Grace D, 2015, INT J ENV RES PUB HE, V12, P10490, DOI 10.3390/ijerph120910490
   Guo M, 2015, J FOOD PROTECT, V78, P457, DOI 10.4315/0362-028X.JFP-14-328
   Haghighi A, 2018, EPIDEMIOL INFECT, V146, P1880, DOI 10.1017/S0950268818001863
   Halova D, 2013, ZOONOSES PUBLIC HLTH, V60, P168, DOI 10.1111/j.1863-2378.2012.01514.x
   Hamilton CM, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0776-7
   HEJLICEK K, 1993, ACTA VET BRNO, V62, P159, DOI 10.2754/avb199362030159
   Hernandez M, 2014, TRANSBOUND EMERG DIS, V61, P477, DOI 10.1111/tbed.12049
   Herrero L, 2016, VET PARASITOL, V224, P52, DOI 10.1016/j.vetpar.2016.05.010
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hill DE, 2010, ZOONOSES PUBLIC HLTH, V57, P53, DOI 10.1111/j.1863-2378.2009.01275.x
   HIRVELAKOSKI V, 1992, ACTA VET SCAND, V33, P21
   Holec-Gasior L, 2010, POL J VET SCI, V13, P457
   Hove T, 2005, ONDERSTEPOORT J VET, V72, P231
   Hove T, 1999, J PARASITOL, V85, P372, DOI 10.2307/3285650
   Huang CQ, 2010, TROP ANIM HEALTH PRO, V42, P115, DOI 10.1007/s11250-009-9393-9
   Huong LTT, 2007, J PARASITOL, V93, P951, DOI 10.1645/GE-1163R.1
   Ichikawa-Seki M, 2015, PARASITOL INT, V64, P484, DOI 10.1016/j.parint.2015.07.004
   Inoue Isamu, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P38
   Jiang HH, 2014, FOODBORNE PATHOG DIS, V11, P362, DOI 10.1089/fpd.2013.1686
   Jittapalapong S, 2005, VET PARASITOL, V127, P17, DOI 10.1016/j.vetpar.2004.08.019
   Jones JL, 2001, AM J EPIDEMIOL, V154, P357, DOI 10.1093/aje/154.4.357
   Khademvatan S, 2013, BRIT POULTRY SCI, V54, P76, DOI 10.1080/00071668.2013.763899
   Kijlstra A, 2004, INVEST OPHTH VIS SCI, V45, P3165, DOI 10.1167/iovs.04-0326
   Kijlstra A, 2009, TRENDS PARASITOL, V25, P18, DOI 10.1016/j.pt.2008.09.008
   Klun I, 2006, VET PARASITOL, V135, P121, DOI 10.1016/j.vetpar.2005.08.010
   Klun I, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-17
   Kofoed Kristina Gronbech, 2017, Vet Parasitol Reg Stud Reports, V10, P136, DOI 10.1016/j.vprsr.2017.10.004
   Kuruca LJ, 2016, CONT AGR, V65, P1
   Kuruca L, 2017, PARASITOL RES, V116, P3117, DOI 10.1007/s00436-017-5623-7
   Limon G, 2017, FOODBORNE PATHOG DIS, V14, P269, DOI 10.1089/fpd.2016.2197
   Lindsay DS, 2003, J EUKARYOT MICROBIOL, V50, P687, DOI 10.1111/j.1550-7408.2003.tb00688.x
   Liu XJ, 2012, J PARASITOL, V98, P440, DOI 10.1645/GE-2989.1
   Lopes AP, 2013, VET PARASITOL, V193, P266, DOI 10.1016/j.vetpar.2012.12.001
   Luciano DM, 2011, REV BRAS PARASITOL V, V20, P351, DOI 10.1590/S1984-29612011000400018
   Lunden A, 2002, SCAND J INFECT DIS, V34, P362, DOI 10.1080/00365540110080205
   Macaulay Gavin, 2018, ICES COOPERATIVE RESEARCH REPORT-RAPPORT DES RECHERCHES COLLECTIVES, P1
   Magalhaes FJR, 2017, PARASITOL INT, V66, P43, DOI 10.1016/j.parint.2016.11.014
   Marca MC, 1996, VET PARASITOL, V67, P99, DOI 10.1016/S0304-4017(96)01031-X
   Marques-Santos F, 2017, PESQUI VET BRASIL, V37, P570, DOI [10.1590/S0100-736X2017000600006, 10.1590/s0100-736x2017000600006]
   Matsuo K, 2014, PARASITOL INT, V63, P638, DOI 10.1016/j.parint.2014.04.003
   Meerburg BG, 2006, VECTOR-BORNE ZOONOT, V6, P266, DOI 10.1089/vbz.2006.6.266
   Millar PR, 2008, PESQUI VET BRASIL, V28, P15, DOI 10.1590/S0100-736X2008000100002
   Moher D, 2015, SYST REV-LONDON, V4, DOI 10.1186/2046-4053-4-1
   Munoz-Zanzi C, 2012, ZOONOSES PUBLIC HLTH, V59, P389, DOI 10.1111/j.1863-2378.2012.01471.x
   Muraro LS, 2010, REV BRAS PARASITOL V, V19, P254, DOI 10.1590/S1984-29612010000400012
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Onyiche ThankGod Emmanuel, 2015, J Parasit Dis, V39, P309, DOI 10.1007/s12639-013-0350-1
   Ortega-Pacheco A, 2011, VET PARASITOL, V175, P367, DOI 10.1016/j.vetpar.2010.10.018
   Pablos-Tanarro A, 2018, PARASITOL RES, V117, P1419, DOI 10.1007/s00436-018-5837-3
   PANDEY VS, 1992, ANN TROP MED PARASIT, V86, P313, DOI 10.1080/00034983.1992.11812671
   Papatsiros VG, 2016, VECTOR-BORNE ZOONOT, V16, P48, DOI 10.1089/vbz.2015.1845
   Papini R, 2017, J FOOD PROTECT, V80, P515, DOI 10.4315/0362-028X.JFP-16-314
   Pardini L, 2012, VET PARASITOL, V189, P204, DOI 10.1016/j.vetpar.2012.04.014
   Pastiu AI, 2013, PARASITOL RES, V112, P2403, DOI 10.1007/s00436-013-3353-z
   dos Santos HLEPL, 2015, SEMIN-CIENC AGRAR, V36, P1999, DOI 10.5433/1679-0359.2015v36n3Supl1p1999
   Pezerico G. B., 2007, Arquivos do Instituto Biologico Sao Paulo, V74, P267
   Piassa FR, 2010, REV BRAS PARASITOL V, V19, P152, DOI 10.1590/S1984-29612010000300005
   Pipia AP, 2018, PARASITOL RES, V117, P1637, DOI 10.1007/s00436-018-5823-9
   Poljak Z, 2008, CAN J VET RES, V72, P303
   Powell LF, 2016, EPIDEMIOL INFECT, V144, P1538, DOI 10.1017/S0950268815002794
   RAJAMANICKAM C, 1990, TROP ANIM HEALTH PRO, V22, P61, DOI 10.1007/BF02243502
   Roqueplo C, 2011, PARASITE, V18, P345, DOI 10.1051/parasite/2011184345
   Rostami A, 2018, FOOD CONTROL, V91, P404, DOI 10.1016/j.foodcont.2018.04.028
   Rostami A, 2017, VET PARASITOL, V244, P12, DOI 10.1016/j.vetpar.2017.07.013
   Rostami A, 2016, REV INST MED TROP SP, V58, DOI [10.1590/S1678-9946201658070, 10.1590/s1678-9946201658070]
   Saavedra GM, 2004, J PARASITOL, V90, P902, DOI 10.1645/GE-258R
   Sabbagh P., 2018, AM J INFECT CONTROL
   Fernandes EFTS, 2012, J PARASITOL, V98, P690, DOI 10.1645/GE-3032.1
   Santoro A, 2017, ACTA VET SCAND, V59, DOI 10.1186/s13028-017-0349-1
   Santoro A, 2017, RES VET SCI, V115, P353, DOI 10.1016/j.rvsc.2017.06.025
   Scallan E, 2011, EMERG INFECT DIS, V17, P16, DOI [10.3201/eid1701.P21101, 10.3201/eid1701.091101p2]
   Seefeldt S L, 1989, J Vet Diagn Invest, V1, P124
   Shaapan RM, 2008, VET PARASITOL, V153, P359, DOI 10.1016/j.vetpar.2008.02.016
   Sharma R. N., 2015, Open Journal of Veterinary Medicine, V5, P138, DOI 10.4236/ojvm.2015.56019
   Shu FF, 2011, J ANIM VET ADV, V10, P1638
   Slany M, 2016, INT J FOOD MICROBIOL, V238, P252, DOI 10.1016/j.ijfoodmicro.2016.09.020
   SMITH HJ, 1991, CAN J VET RES, V55, P380
   SMITH KE, 1992, VET PARASITOL, V42, P199, DOI 10.1016/0304-4017(92)90062-E
   Sroka J, 2008, B VET I PULAWY, V52, P545
   Sroka J, 2007, B VET I PULAWY, V51, P535
   Sroka J, 2011, ANN AGR ENV MED, V18, P335
   Steinparzer R, 2015, ZOONOSES PUBLIC HLTH, V62, P119, DOI 10.1111/zph.12122
   Suarez-Aranda F, 2000, VET PARASITOL, V91, P23, DOI 10.1016/S0304-4017(00)00249-1
   Tao Q, 2011, J PARASITOL, V97, P262, DOI 10.1645/GE-2646.1
   Thiptara A, 2006, ANN NY ACAD SCI, V1081, P336, DOI 10.1196/annals.1373.047
   Samico-Fernandes EFT, 2017, ACTA PARASITOL, V62, P466, DOI 10.1515/ap-2017-0054
   Samico-Fernandes EFT, 2015, PARASITOL RES, V114, P3927, DOI 10.1007/s00436-015-4664-z
   Trevisani N., 2013, Archives of Veterinary Science, V18, P14
   Tuda J, 2017, PARASITOL INT, V66, P615, DOI 10.1016/j.parint.2017.04.011
   Turcekova L, 2013, ACTA PARASITOL, V58, P361, DOI 10.2478/s11686-013-0154-6
   van der Giessen J, 2007, VET PARASITOL, V148, P371, DOI 10.1016/j.vetpar.2007.06.009
   VANKNAPEN F, 1995, VET QUART, V17, P87, DOI 10.1080/01652176.1995.9694539
   Venturini MC, 2004, VET PARASITOL, V124, P161, DOI 10.1016/j.vetpar.2004.07.003
   Veronesi F, 2011, ZOONOSES PUBLIC HLTH, V58, P178, DOI 10.1111/j.1863-2378.2010.01336.x
   Villari S, 2009, VET PARASITOL, V161, P1, DOI 10.1016/j.vetpar.2009.01.019
   Vostalova E, 2000, ACTA VET BRNO, V69, P209, DOI 10.2754/avb200069030209
   Wallander C, 2016, VET PARASITOL, V224, P27, DOI 10.1016/j.vetpar.2016.05.005
   Wang DW, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1525-2
   Wang ZD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00389
   WEIGEL RM, 1995, J PARASITOL, V81, P736, DOI 10.2307/3283964
   Wilking H, 2016, SCI REP-UK, V6, DOI 10.1038/srep22551
   Wu DY, 2012, TROP ANIM HEALTH PRO, V44, P685, DOI 10.1007/s11250-011-9965-3
   Wu F, 2017, VECTOR-BORNE ZOONOT, V17, P517, DOI 10.1089/vbz.2016.2103
   Wu SM, 2012, VECTOR-BORNE ZOONOT, V12, P654, DOI 10.1089/vbz.2012.0968
   Xu P, 2015, TROP BIOMED, V32, P116
   Xu Y., 2014, CHINA SCI WORLD J, V2014
   Yan C, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1432-6
   Yu HJ, 2011, J PARASITOL, V97, P748, DOI 10.1645/GE-2713.1
   Zhou DH, 2010, J PARASITOL, V96, P673, DOI 10.1645/GE-2416.1
   Zhu CH, 2012, IRAN J PARASITOL, V7, P89
   Zou FC, 2009, PARASITOL INT, V58, P306, DOI 10.1016/j.parint.2009.06.002
NR 190
TC 8
Z9 8
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 42
EP 52
DI 10.1016/j.vetpar.2019.04.012
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200009
PM 31079827
DA 2020-05-12
ER

PT J
AU Marques, CB
   Ramos, F
   Fernandes, F
   Sangioni, LA
   Kommers, G
   Unterleider, CE
   Vogel, FSF
AF Marques, Camila Balconi
   Ramos, Fernanda
   Fernandes, Fagner
   Sangioni, Luis Antonio
   Kommers, Glaucia
   Unterleider, Carlos Eduardo
   Flores Vogel, Fernanda Silveira
TI In vitro and in vivo acaricidal activity evaluation of organo-modified
   siloxanes in populations of Rhipicephalus microplus
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Acaricide; Resistance; Cattle; Tick; Pyperonyl butoxide; Organo-modified
   siloxane
ID BOOPHILUS-MICROPLUS; RESISTANCE; IXODIDAE; TESTS
AB Infestations of Rhipicephalus microplus cause significant damage to cattle breeding and their control is primarily based on chemical products. There are extensive reports of efficacy losses of acaricid products over time, as well as resistance of the parasites to them, thereby making it necessary to search for new alternatives. The present work aimed to determine the in vitro and in vivo acaricidal activity of organo-modified siloxanes with and without piperonyl butoxide (PBO) in southern Brazil. For the in vitro test, engorged females of R. microplus were collected and submitted to the immersion test. The formulation containing organo-modified siloxanes was tested at 4 different concentrations: 0.6, 1.0, 2.5, and 5.0%. The lowest dilutions (0.6, 1.0, and 2.5%) were also tested with the inclusion of 10% PBO. The in vivo test was performed by applying 2.5% organo-modified siloxanes, and the addition of 10% PBO was applied by spraying. The results showed high acaricidal activity (100%) in vitro in the concentration of 5% on non-associated forms, and in combinations of concentrations of 0.6, 1.0, 2.5% with PBO. The in vivo results also increased the efficacy with the association of PBO. In view of the current multi-resistance scenario of the R. microplus tick to the different commercially available acaricidal products, this study investigated the use of this product in association with PBO as an alternative to R. microplus control and found positive results. To the authors' knowledge, this is the first study to use organo-modified siloxanes against ticks.
C1 [Marques, Camila Balconi; Ramos, Fernanda; Fernandes, Fagner; Sangioni, Luis Antonio; Flores Vogel, Fernanda Silveira] Univ Fed Santa Maria, Dept Med Vet Prevent, Lab Doencas Parasitarias Ladopar, Av Roraima 1000,Predio 44,Sala 5139, BR-97105900 Santa Maria, RS, Brazil.
   [Kommers, Glaucia] Univ Fed Santa Maria, Lab Patol Vet, Av Roraima 1000,Predio 44,Sala 5139, BR-97105900 Santa Maria, RS, Brazil.
   [Unterleider, Carlos Eduardo] Pirisa Piretro Ind Ltda, Av Oscar Martins Rangel 5700, BR-95600000 Taquara, RS, Brazil.
RP Marques, CB (reprint author), Univ Fed Santa Maria, Dept Med Vet Prevent, Lab Doencas Parasitarias Ladopar, Av Roraima 1000,Predio 44,Sala 5139, BR-97105900 Santa Maria, RS, Brazil.
EM balconi.camila@gmail.com
RI Marques, Camila Balconi/V-7797-2019; Fernandes, Fagner/AAH-3611-2020
OI Marques, Camila Balconi/0000-0001-9535-6496; Sangioni, Luis
   Antonio/0000-0002-2364-1084
CR ARANTES G.J., 1995, REV BRAS PARASITOL V, V4, P89
   Brazil MAPA, 1997, REG TECN LIC REN LIC
   Brazil MAPA, 1989, NORM PROD CONTR UT P
   Castro-Janer E, 2010, VET PARASITOL, V173, P300, DOI 10.1016/j.vetpar.2010.06.036
   Chiminazzo C., 2004, VET FOCO, V2, P57
   DRUMMOND RO, 1973, J ECON ENTOMOL, V66, P130, DOI 10.1093/jee/66.1.130
   Grisi L, 2014, REV BRAS PARASITOL V, V23, P150, DOI 10.1590/S1984-29612014042
   Holdsworth PA, 2006, VET PARASITOL, V136, P29, DOI 10.1016/j.vetpar.2005.11.011
   Kessler R. H., 1998, CARRAPATO TRISTEZA P, p[9, 74]
   Kidd H., 1994, AGROCHEMICALS HDB
   Klafke GM, 2006, VET PARASITOL, V142, P386, DOI 10.1016/j.vetpar.2006.07.001
   Liszka D., 2014, INT PEST CONTROL, V56
   Martins JR, 2001, VET REC, V149, P64
   Mathias M. I. C., 2013, GUIA BASICO MORFOLOG
   Reck J, 2014, VET PARASITOL, V201, P128, DOI 10.1016/j.vetpar.2014.01.012
   ROULSTON W. J., 1967, AUST VET J, V43, P129, DOI 10.1111/j.1751-0813.1967.tb08916.x
   Tozzi A., 1999, PIPERONYL BUTOXIDE, P1, DOI DOI 10.1016/B978-012286975-4/50003-6
   United States Environmental Protection Agency, 2002, USEPA OPP CHEM INGR
NR 18
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 53
EP 56
DI 10.1016/j.vetpar.2019.04.013
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200010
PM 31079828
DA 2020-05-12
ER

PT J
AU Velez, J
   Lange, MK
   Zieger, P
   Yoon, I
   Failing, K
   Bauer, C
AF Velez, Juan
   Lange, Malin K.
   Zieger, Peter
   Yoon, Ilkyu
   Failing, Klaus
   Bauer, Christian
TI Long-term use of yeast fermentation products in comparison to
   halofuginone for the control of cryptosporidiosis in neonatal calves
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cryptosporidium parvum; Calf; Neonatal diarrhea; Saccharomyces
   cerevisiae; Fermented product; Halofuginone
ID NATURAL CRYPTOSPORIDIOSIS; MOLECULAR-IDENTIFICATION; DAIRY CALVES;
   RISK-FACTORS; PREVALENCE; PARVUM; PREVENTION; PAROMOMYCIN; DIARRHEA;
   LACTATE
AB The objective of this study was to compare the effect of non-GMO Saccharomyces cerevisiae fermentation products (SCFP) with that of a halofuginone treatment against Cryptosporidium parvum infection in pre-weaned calves on a commercial dairy farm. A total of 123 neonatal female calves, housed in individual hutches, were enrolled sequentially based on date of birth in 41 blocks of 3 animals each. Calves within each block were allocated to one of 3 treatments: remaining untreated, fed with SCFP (Diamond V SmartCare (R) at 1 g/d in milk and NutriTek (R) at 5 g/d in starter grain) for the first 63 days of life, or treated with halofuginone (0.1 mg/kg/d) for the first 7 days of life. Fecal samples collected on days 4-21 post-partum were examined for both Cryptosporidium oocysts and coproantigen. The presence and intensity of diarrhea were monitored by scoring daily for the first 4 weeks of life. Calves were weighed at 0, 21, 42 and 63 days of age. Almost all calves were Cryptosporidium-positive at least once during the study. Halofuginone significantly reduced the number of Cryptosporidium-positive fecal samples as compared to the two other groups. Based on the coproantigen scores, both halofuginone and SCFP feeding significantly reduced the intensity of Cryptosporidium infection as compared to the untreated group. Diarrhea was recorded in almost all calves at least once. Neither the proportion of diarrheic calves nor the intensity and duration of diarrhea differed among the 3 treatment groups significantly. The mean daily weight gain during the first 3 weeks of life was significantly lower in halofuginone treated calves than in both other groups; however, at the end of the study period the total weight gain did not significantly differ among the 3 treatment groups. In conclusion, the clinical results and weight gains of pre-weaning supplementation with the SCFP were neither better nor worse than the 7-day halofuginone treatment suggesting that the SCFP feeding may be from the clinical point of view a natural alternative measure, instead of halofuginone treatment, in bovine cryptosporidiosis.
C1 [Velez, Juan; Lange, Malin K.; Bauer, Christian] Justus Liebig Univ Giessen, Inst Parasitol, Schubertstr 81, D-35392 Giessen, Germany.
   [Zieger, Peter; Yoon, Ilkyu] Diamond V, Cedar Rapids, IA 52404 USA.
   [Failing, Klaus] Justus Liebig Univ, Fac Vet Med, Unit Biomath & Data Proc, Giessen, Germany.
RP Bauer, C (reprint author), Justus Liebig Univ Giessen, Inst Parasitol, Schubertstr 81, D-35392 Giessen, Germany.
EM christian.bauer@vetmed.uni-giessen.de
OI Velez, Juan/0000-0002-8635-7267
FU Diamond V, Cedar Rapids, Iowa, USA
FX This study was funded through a grant by Diamond V, Cedar Rapids, Iowa,
   USA. PZ and IY are current employees of Diamond V.
CR Ackermann H., 2010, BIAS WINDOWS VERSION
   Al Mawly J, 2015, NEW ZEAL VET J, V63, P147, DOI 10.1080/00480169.2014.966168
   Almawly J, 2013, VET PARASITOL, V197, P59, DOI 10.1016/j.vetpar.2013.04.029
   [Anonymous], 2000, EMEAMRL74100FINAL
   [Anonymous], 2017, VET REC, V180, P490
   Bangoura B, 2012, PARASITOL RES, V110, P875, DOI 10.1007/s00436-011-2569-z
   Broglia A, 2008, VET PARASITOL, V154, P8, DOI 10.1016/j.vetpar.2008.02.029
   Castro-Hermida JA, 2002, VET PARASITOL, V106, P11, DOI 10.1016/S0304-4017(02)00038-9
   Cavalier-Smith T, 2014, EUR J PROTISTOL, V50, P472, DOI 10.1016/j.ejop.2014.07.002
   Chartier C, 2013, VET J, V198, P148, DOI 10.1016/j.tvjl.2013.06.011
   Chou WK, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00037
   De Waele V, 2010, PREV VET MED, V96, P143, DOI 10.1016/j.prevetmed.2010.06.017
   Delafosse A, 2015, PREV VET MED, V118, P406, DOI 10.1016/j.prevetmed.2015.01.005
   Deplazes P., 2016, PARASITOLOGY VET MED, P122
   Dixon WJ, 1993, BMDP STAT SOFTWARE
   Faber JE, 2002, VET PARASITOL, V104, P1, DOI 10.1016/S0304-4017(01)00610-0
   FAYER R, 1993, J PARASITOL, V79, P771, DOI 10.2307/3283619
   Fayer Ronald, 2007, P1, DOI 10.1201/9781420052275.ch1
   Feng YY, 2018, TRENDS PARASITOL, V34, P997, DOI 10.1016/j.pt.2018.07.009
   Geurden T, 2012, VET PARASITOL, V190, P383, DOI 10.1016/j.vetpar.2012.06.039
   Geurden T, 2010, EXP PARASITOL, V124, P98, DOI 10.1016/j.exppara.2009.03.001
   Gillhuber Julia, 2014, BMC Res Notes, V7, P112, DOI 10.1186/1756-0500-7-112
   Grinberg A, 2002, VET REC, V151, P606, DOI 10.1136/vr.151.20.606
   HEINE J, 1982, ZBL VET MED B, V29, P324
   Holzhausen I., 2019, GERMANY PARASITOL RE, DOI [10.1007/s00436-019-06266-1, DOI 10.1007/S00436-019-06266-1]
   Joachim A, 2003, VET PARASITOL, V112, P277, DOI 10.1016/S0304-4017(03)00006-2
   Matsubayashi M, 2018, PARASITOL RES, V117, P339, DOI 10.1007/s00436-017-5689-2
   Meganck V, 2015, PREV VET MED, V118, P64, DOI 10.1016/j.prevetmed.2014.11.007
   Niine T, 2018, RES VET SCI, V117, P200, DOI 10.1016/j.rvsc.2017.12.015
   Park J., 2014, TELEMEDICINE E HLTH, P1
   Potters Idzi, 2010, Open Parasitology Journal, V4, P1
   Shahiduzzaman M, 2012, VET PARASITOL, V188, P203, DOI 10.1016/j.vetpar.2012.03.052
   Silverlas C, 2009, PREV VET MED, V91, P73, DOI 10.1016/j.prevetmed.2009.05.003
   Stockdale H.D., 2008, CRYPTOSPORIDIUM CRYP, P255
   Sulaiman IM, 2005, J CLIN MICROBIOL, V43, P2805, DOI 10.1128/JCM.43.6.2805-2809.2005
   Thompson R. C. A., 2016, FOOD WATERBORNE PARA, V4, P54, DOI [10.1016/j.fawpar.2016.08.004, DOI 10.1016/J.FAWPAR.2016.08.004]
   Thomson S, 2017, VET RES, V48, DOI 10.1186/s13567-017-0447-0
   Trotz-Williams LA, 2011, VET REC, V168, DOI 10.1136/vr.d1492
   Trotz-Williams LA, 2007, PREV VET MED, V82, P12, DOI 10.1016/j.prevetmed.2007.05.003
   Urie NJ, 2018, J DAIRY SCI, V101, P9229, DOI 10.3168/jds.2017-14019
   Urie NJ, 2018, J DAIRY SCI, V101, P9168, DOI 10.3168/jds.2017-14010
   Urie NJ, 2018, J DAIRY SCI, V101, P9199, DOI 10.3168/jds.2017-14060
   Vazquez Flores S., 2016, J ANIM SCI S5, V94, P714
   Weaver DM, 2000, J VET INTERN MED, V14, P569, DOI 10.1892/0891-6640(2000)014&lt;0569:PTOCII&gt;2.3.CO;2
   Xiao JX, 2016, J DAIRY SCI, V99, P5401, DOI 10.3168/jds.2015-10563
   Xiao LH, 1999, APPL ENVIRON MICROB, V65, P3386
   YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979
   Zambriski JA, 2013, PARASITOL RES, V112, P1247, DOI 10.1007/s00436-012-3258-2
NR 48
TC 0
Z9 0
U1 3
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY
PY 2019
VL 269
BP 57
EP 64
DI 10.1016/j.vetpar.2019.04.008
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IB1TG
UT WOS:000470047200011
PM 31079829
OA Green Published
DA 2020-05-12
ER

PT J
AU Meulen, AST
   Munoz, FM
   Kaslow, DC
   Klugman, KP
   Omer, SB
   Vora, P
   Stergachis, A
AF Meulen, Ajoke Sobanjo-ter
   Munoz, Flor M.
   Kaslow, David C.
   Klugman, Keith P.
   Omer, Saad B.
   Vora, Prachi
   Stergachis, Andy
TI Maternal interventions vigilance harmonization in low- and middle-income
   countries: Stakeholder meeting report; Amsterdam, May 1-2, 2018
SO VACCINE
LA English
DT Article
DE Pregnancy; Maternal immunization; Pharmacovigilance; Newborn; Vaccine;
   Safety surveillance
ID INACTIVATED INFLUENZA VACCINE; RISKS; IMMUNIZATION
AB Although major reductions in maternal and child mortality were achieved in the Millennium Development Goals era, progress must be accelerated to meet Sustainable Development Goals health targets by 2030. An estimated 2.7 million neonatal deaths and 2.6 million stillbirths still occur annually. Over the past several years there has been renewed global interest in innovative approaches to maternal immunization to potentially decrease mortality and severe morbidity in neonates, and in the pregnant woman and her fetus. Several new vaccines are in clinical development for indications in pregnant women, e.g., vaccines against respiratory syncytial virus, and group B streptococcus. Achieving near-concurrent introduction of new maternal vaccines in high-, middle-, and low-income countries requires that mechanisms are in place for appropriate safety monitoring worldwide.
   The Bill & Melinda Gates Foundation convened a global expert meeting in Amsterdam on May 1-2, 2018, to discuss a framework for appropriate pharmacovigilance for vaccines used during pregnancy based on integrated maternal interventions vigilance (MIV) systems and collection of appropriate data to inform timely decision-making by and for pregnant women. Planning for MIV requires a multidisciplinary, collaborative approach that fully leverages and builds upon existing resources, and builds new capabilities and capacity where needed. Meeting participants identified priority actions including (1) establishing background rates to better evaluate emerging safety signals and vaccine effectiveness, (2) identifying potential sentinel vaccine surveillance sites, (3) developing data sharing capabilities, (4) creating guidance documents and protocols, and (5) the advanced preparation of culturally-appropriate communication plans and risk management plans.
   Integrating MIV across the routine obstetric and neonatal health care delivery continuum and all relevant programs and data systems could result in fundamental improvements in maternal, neonatal and child health. Improved pregnancy pharmacovigilance platforms may strengthen other vaccine and drug product safety systems and improve maternal and child research capabilities in LMICs.
C1 [Meulen, Ajoke Sobanjo-ter; Klugman, Keith P.; Vora, Prachi] Bill & Melinda Gates Fdn, 500 5th Ave N, Seattle, WA 98109 USA.
   [Munoz, Flor M.] Baylor Coll Med, Dept Pediat, Sect Infect Dis, Houston, TX 77030 USA.
   [Munoz, Flor M.] Texas Childrens Hosp, Houston, TX 77030 USA.
   [Kaslow, David C.] PATH, 2201 Westlake Ave, Seattle, WA USA.
   [Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
   [Stergachis, Andy] Univ Washington, Sch Pharm, Global Med Program, BOX 357631, Seattle, WA 98195 USA.
   [Stergachis, Andy] Univ Washington, Sch Publ Hlth, Global Med Program, BOX 357631, Seattle, WA 98195 USA.
RP Meulen, AST (reprint author), Bill & Melinda Gates Fdn, 500 5th Ave N, Seattle, WA 98109 USA.
EM Ajoke.Sobanjo-TerMeulen@gatesfoundation.org; florm@bcm.edu;
   dkaslow@path.org; Keith.Klugman@gatesfoundation.org; somer@emory.edu;
   Prachi.Vora@gatesfoundation.org; stergach@uw.edu
OI Munoz, Flor/0000-0002-0457-7689
FU Bill and Melinda Gates FoundationGates Foundation
FX This forum was supported by The Bill and Melinda Gates Foundation.
CR Ahonkhai V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166515
   [Anonymous], 2014, PRACT APPR RISK MIN
   Bergin N, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050847
   Committee for Medicinal Products for Human Use, 2005, GUID EXP MED PROD PR
   Donahue JG, 2017, VACCINE, V35, P5314, DOI 10.1016/j.vaccine.2017.06.069
   Inter-agency Group for Child Mortality Estimation, 2015, LEV TRENDS CHILD MOR
   Irving SA, 2013, OBSTET GYNECOL, V121, P159, DOI [10.1097/AOG.0b013e318279f56f, http://10.1097/AOG.0b013e318279f56f]
   Kharbanda EO, 2017, J PEDIATR-US, V187, P234, DOI 10.1016/j.jpeds.2017.04.039
   Kharbanda EO, 2013, OBSTET GYNECOL, V122, P659, DOI 10.1097/AOG.0b013e3182a1118a
   Kochhar S, 2017, VACCINE, V35, P6469, DOI 10.1016/j.vaccine.2017.09.033
   Lackritz E, 2017, MATERNAL IMMUNIZATIO
   LaFond A, 2015, HEALTH POLICY PLANN, V30, P298, DOI 10.1093/heapol/czu011
   Lambach P., 2017, 4 INT NEON MAT IMM S
   Lawn JE, 2017, CLIN INFECT DIS, V65, pS89, DOI 10.1093/cid/cix653
   Lawn JE, 2016, LANCET, V387, P587, DOI 10.1016/S0140-6736(15)00837-5
   Moro PL, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.050
   Nordin JD, 2014, J PEDIATR-US, V164, P1051, DOI 10.1016/j.jpeds.2014.01.037
   Omer SB, 2018, PEDIATR INFECT DIS J, V37, P436, DOI [10.1097/INF.0000000000001914, 10.1097/inf.0000000000001914]
   Omer SB, 2017, NEW ENGL J MED, V376, P1256, DOI 10.1056/NEJMra1509044
   Seale AC, 2017, CLIN INFECT DIS, V65, pS125, DOI 10.1093/cid/cix585
   Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]
   Tinto H, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0101-0
   Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1
   UN Sustainable Development Knowledge Platform, 2017, PROGR SUST DEV GOAL
   United Nations Secretary General, 2017, REP SECR GEN PROGR S
   US Food and Drug Administration, 2002, GUID IND EST PREGN E
   World Health Organization, 2018, GLOBAL VACCINE SAFET
NR 27
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2643
EP 2650
DI 10.1016/j.vaccine.2019.03.060
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200001
PM 30955981
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Pacheco, FC
   Franca, GVA
   Elidio, GA
   Domingues, CMAS
   de Oliveira, C
   Guilhem, DB
AF Pacheco, Flavia C.
   Franca, Giovanny V. A.
   Elidio, Guilherme A.
   Domingues, Carla Magda Allan S.
   de Oliveira, Cesar
   Guilhem, Dirce B.
TI Trends and spatial distribution of MMR vaccine coverage in Brazil during
   2007-2017
SO VACCINE
LA English
DT Article
DE Measles; Vaccination coverage; Measles-mumps-rubella vaccine; Spatial
   analysis; Time series studies
ID PROGRESS
AB We analyzed the time trends and spatial distribution of MMR vaccine coverage in Brazil during 2007-2017. In early 2018, a measles outbreak started in the North region of Brazil, reaching 11 of the 27 federal units by January 24, 2019. In this period, 10,302 cases were confirmed. Although the reintroduction of measles in Brazil is likely due to migration from Venezuela, the spread of the virus was made possible by the low levels of MMR coverage, as a result of significant decreases during the study period. Areas with high concentration of municipalities with low coverage are more susceptible to the spread of the virus, especially in the North and Northeast regions. Increasing vaccination coverage is essential to block the ongoing outbreak in Brazil. Vaccination strategies might target priority areas, especially those with a marked decrease in coverage. Moreover, it is essential to extend actions to travelers, migrants and refugees. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Pacheco, Flavia C.; Franca, Giovanny V. A.; Guilhem, Dirce B.] Univ Brasilia, Postgrad Program Hlth Sci, Brasilia, DF, Brazil.
   [Pacheco, Flavia C.; Franca, Giovanny V. A.; Elidio, Guilherme A.; Domingues, Carla Magda Allan S.] Minist Hlth, Secretariat Hlth Surveillance, Brasilia, DF, Brazil.
   [de Oliveira, Cesar] UCL, Dept Epidemiol & Publ Hlth, London, England.
RP Pacheco, FC (reprint author), QRSW Quadra 6 Bloco B07 Apto 204, BR-70675627 Brasilia, DF, Brazil.
EM flavia.pacheco@saude.gov.br
RI Araujo de Franca, Giovanny Vinicius/L-7385-2018
OI Araujo de Franca, Giovanny Vinicius/0000-0002-7530-2017
FU National Council for Scientific and Technological Development -
   CNPqNational Council for Scientific and Technological Development
   (CNPq); Research Productivity Grant 1-D (2016-2020)
FX DBG receives funding from the National Council for Scientific and
   Technological Development - CNPq and Research Productivity Grant 1-D
   (2016-2020).
CR BITHELL JF, 1990, STAT MED, V9, P691, DOI 10.1002/sim.4780090616
   Dabbagh A, 2017, MMWR-MORBID MORTAL W, V66, P1148, DOI 10.15585/mmwr.mm6642a6
   Succi RCD, 2018, J PEDIAT-BRAZIL, V94, P574, DOI 10.1016/j.jped.2018.01.008
   Domingues CMAS, 2013, EPIDEMIOL SERV SAUDE, V22, P9, DOI 10.5123/S1679-49742013000100002
   Elidio GA, 2019, EURO SURVEILL, P24
   Gastanaduy PA, 2018, HUM VACC IMMUNOTHER, V22, P1
   Ministry of Health. Brazil, 2018, 342018 MIN HLTH
   Ministry of Health. Brazil, 2019, 362019 MIN HLTH
   MORAN PAP, 1950, BIOMETRIKA, V37, P17, DOI 10.2307/2332142
   Moss WJ, 2017, LANCET, V390, P2490, DOI 10.1016/S0140-6736(17)31463-0
   Moura ADA, 2015, EPIDEMIOL SERV SAUDE, V2018
   Pan American Health Organization/World Health Organization, 2019, EP UPD MEASL 18 JAN
   Pan American Health Organization/World Health Organization, 2018, EP UPD MEASL 20 JUL
   Pan American Health Organization/World Health Organization. 55th Directing Council, 2016, 68 SESS REG COMM WHO, P6
   Prais S.J., 1954, TREND ESTIMATORS SER
   Sato APS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052001199, 10.11606/s1518-8787.2018052001199]
   Victora CG, 2017, LANCET GLOB HEALTH, V5, pE402, DOI [10.1016/S2214-109X(17)30077-3, 10.1016/s2214-109x(17)30077-3]
   World Health Organization WHO, 2018, WORLD HLTH STAT 2018
NR 18
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2651
EP 2655
DI 10.1016/j.vaccine.2019.04.019
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200002
PM 30987853
DA 2020-05-12
ER

PT J
AU Ries, C
   Beer, M
   Hoffmann, B
AF Ries, Christina
   Beer, Martin
   Hoffmann, Bernd
TI BTV antibody longevity in cattle five to eight years post BTV-8
   vaccination
SO VACCINE
LA English
DT Article
DE BTV 8; Serology; Antibody longevity; Vaccination; Booster effect
ID VIRUS SEROTYPE 8; BLUETONGUE; RESPONSES; VACCINES; DISEASE; SHEEP
AB The Bluetongue virus serotype -8 (BTV-8) epizootic in Germany (2006-2008) was successfully eradicated, essentially by the massive application of commercially available inactivated BTV-8 vaccines. While a six-year antibody longevity of BTV antibodies post BTV-8 vaccination in cattle has been described previously, our study investigated the BTV-8-vaccine antibodies in cattle for up to eight years. In total, 157 bovine serum samples were analysed for the presence of group-specific BTV antibodies in both a commercial cELISA, and a BTV-8- specific serum neutralization test. A robust number of cattle were seropositive for group- and serotype-specific neutralising antibodies for five or more years. In selected animals, born and vaccinated in 2009 or later, the presence of BTV antibodies for up to eight years post BTV-8 vaccination could be confirmed. Our data also show, that booster vaccination prolonged the antibody longevity of vaccine-induced antibodies and the number of serologically positive cattle. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ries, Christina; Beer, Martin; Hoffmann, Bernd] Friedrich Loeffler Inst, Inst Diagnost Virol, Sudufer 10, D-17943 Greifswald, Germany.
RP Hoffmann, B (reprint author), Friedrich Loeffler Inst, Inst Diagnost Virol, Sudufer 10, D-17943 Greifswald, Germany.
EM bernd.hoffmann@fli.de
FU EU Horizon 2020 project PALE-Blue [727393]
FX This work was supported of the EU Horizon 2020 project PALE-Blue (Grant
   number: 727393).
CR Ayrle H, 2018, VACCINE, V36, P5807, DOI 10.1016/j.vaccine.2018.08.015
   Baetza HJ, 2014, VET IMMUNOL IMMUNOP, V158, P116, DOI 10.1016/j.vetimm.2013.09.001
   Bartram DJ, 2011, VET J, V188, P193, DOI 10.1016/j.tvjl.2010.04.001
   Batten CA, 2013, VACCINE, V31, P3783, DOI 10.1016/j.vaccine.2013.06.033
   Conraths FJ, 2009, EMERG INFECT DIS, V15, P433, DOI 10.3201/eid1503.081210
   Courtejoie N, 2018, TRANSBOUND EMERG DIS, V65, pe173, DOI 10.1111/tbed.12718
   Eschbaumer M, 2012, VACCINE, V30, P7142, DOI 10.1016/j.vaccine.2012.08.030
   Eschbaumer M, 2009, VACCINE, V27, P4169, DOI 10.1016/j.vaccine.2009.04.056
   Gethmann J, 2015, VACCINE, V33, P214, DOI 10.1016/j.vaccine.2014.10.025
   Gethmann J, 2009, VACCINE, V27, P4118, DOI 10.1016/j.vaccine.2009.04.072
   Glass EJ, 2012, VET IMMUNOL IMMUNOP, V148, P90, DOI 10.1016/j.vetimm.2011.05.009
   Hamblin C, 2004, Vet Ital, V40, P538
   Hund A, 2012, VET MICROBIOL, V154, P247, DOI 10.1016/j.vetmic.2011.07.019
   MAYR A, 1974, VIROLOGISCHE ARBEITS, V1, P35
   Oura CAL, 2012, VACCINE, V30, P112, DOI 10.1016/j.vaccine.2011.10.100
   Oura CAL, 2009, VACCINE, V27, P7326, DOI 10.1016/j.vaccine.2009.09.070
   OUTTERIDGE PM, 1993, IMMUNOL CELL BIOL, V71, P355, DOI 10.1038/icb.1993.42
   Vitale N, 2016, TRANSBOUND EMERG DIS, V63, P175, DOI 10.1111/tbed.12241
   Zanolari P, 2010, J VET INTERN MED, V24, P956, DOI 10.1111/j.1939-1676.2010.0538.x
   Zientara S, 2013, VET MICROBIOL, V165, P33, DOI 10.1016/j.vetmic.2013.01.010
NR 20
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2656
EP 2660
DI 10.1016/j.vaccine.2019.03.082
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200003
PM 30979569
DA 2020-05-12
ER

PT J
AU Charania, NA
   Gaze, N
   Kung, JY
   Brooks, S
AF Charania, Nadia A.
   Gaze, Nina
   Kung, Janice Y.
   Brooks, Stephanie
TI Vaccine-preventable diseases and immunisation coverage among migrants
   and non-migrants worldwide: A scoping review of published literature,
   2006 to 2016
SO VACCINE
LA English
DT Review
DE Scoping review; Migrants; Refugees; Immunisation; Vaccination; Coverage;
   Vaccine-preventable disease
ID IMMIGRANT PREGNANT-WOMEN; HEALTH-CARE SERVICES; FOREIGN-BORN ARAB;
   INFLUENZA VACCINATION; HEPATITIS-B; UNITED-STATES; INFECTIOUS-DISEASES;
   ENDEMIC COUNTRY; US-BORN; CHILDREN
AB Background: Studies of vaccine-preventable disease (VPD) burden and immunisation coverage among migrants compared to locally-born populations present a mixed picture on whether migrants experience disproportionate VPD rates and immunisation inequities, and what the associated factors are. We conducted a scoping review to explore differences in VPD burden and immunisation coverage between migrants and non-migrants worldwide.
   Methods: We followed Arksey and O'Malley's five stage scoping review method. We searched for empirical, peer-reviewed literature published in English that compared VPD burden and/or immunisation coverage between migrant and non-migrant groups published between 2006 and 2016 using MEDLINE, EMBASE, CINAHL, Sociological Abstracts, and Web of Science databases. Relevant information from the studies were charted in Microsoft Excel and results were summarised using a descriptive analytical method.
   Results: Forty-five studies met the inclusion criteria (n =13 reporting on VPD burden; n = 27 reporting on immunisation rates; n = 5 reporting on both). Studies that met the criteria only reported findings from high income countries or high-middle income countries. Accounting for results that were presented according to separate ethnic migrant sub-groups, almost all of the studies comparing VPD burden (n = 17, 89%) reported higher burden among migrants compared to non-migrants, while most studies measuring immunisation rates (n = 26, 70%) noted lower rates among migrants. Numerous factors contributed to these findings, including the influence of migrants' nativity, socio-economic status, migration background, generation status, residential duration, cultural/personal beliefs, language proficiency and healthcare utilisation.
   Conclusions: Considerable variability of study foci and methodologies limited our ability to make definitive conclusions and comparisons, but the literature suggests that migrant populations generally experience higher VPD burden and lower immunisation rates. The findings highlight a number of important considerations for future research and immunisation programme planning. Future research should explore factors that influence VPD burden and immunisation rates, and strategies to overcome barriers to vaccine uptake among migrants. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Charania, Nadia A.; Gaze, Nina] Auckland Univ Technol, Dept Publ Hlth, 640 Great South Rd, Auckland 2025, New Zealand.
   [Kung, Janice Y.] Univ Alberta, Walter C Mackenzie Hlth Sci Ctr 2K3 28, John W Scott Hlth Sci Lib, Edmonton, AB T6G 2E1, Canada.
   [Brooks, Stephanie] Univ Alberta, Dept Pediat, 116 St & 85 Ave, Edmonton, AB T6G 2R3, Canada.
RP Charania, NA (reprint author), Auckland Univ Technol, Dept Publ Hlth, 640 Great South Rd, Auckland 2025, New Zealand.
EM nadia.charania@aut.ac.nz
OI Kung, Janice/0000-0001-8676-8675; Charania, Nadia
   A./0000-0002-8265-5742; Brooks, Stephanie/0000-0002-9648-0090
FU Auckland University of Technology
FX This work was supported by a grant from the Auckland University of
   Technology. The funding source had no involvement in designing the
   study; collecting, analyzing, or interpreting the data; writing the
   manuscript; or deciding to submit it for publication.
CR Tomas BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082440
   Abraham BK, 2013, J IMMIGR MINOR HEALT, V15, P381, DOI 10.1007/s10903-012-9624-4
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI DOI 10.1080/1364557032000119616
   Astray-Mochales J, 2016, VACCINE, V34, P4898, DOI 10.1016/j.vaccine.2016.08.065
   Ben Morrison T, 2012, J IMMIGR MINOR HEALT, V14, P968, DOI 10.1007/s10903-012-9632-4
   Budhwani H, 2016, PUBLIC HEALTH, V138, P146, DOI 10.1016/j.puhe.2016.04.003
   Buelow VH, 2008, J IMMIGR MINOR HEALT, V10, P37, DOI 10.1007/s10903-007-9048-8
   Cai W, 2011, PEDIATR INFECT DIS J, V30, P19, DOI 10.1097/INF.0b013e3181ef22d5
   Carnicer-Pont D, 2008, EUR J PUBLIC HEALTH, V18, P688, DOI 10.1093/eurpub/ckn098
   Chu JJ, 2013, EUR J PUBLIC HEALTH, V23, P642, DOI 10.1093/eurpub/cks067
   Chung HJ, 2016, BMC INT HEALTH HUM R, V16, DOI 10.1186/s12914-016-0085-z
   Dallo FJ, 2015, AM J MENS HEALTH, V9, P124, DOI 10.1177/1557988314532285
   Dallo FJ, 2015, WOMEN HEALTH ISS, V25, P56, DOI 10.1016/j.whi.2014.10.002
   de Casadevante VF, 2016, PAPILLOMAVIRUS RES, V2, P78, DOI 10.1016/j.pvr.2016.03.003
   Dominguez A, 2007, EUR J PUBLIC HEALTH, V17, P560, DOI 10.1093/eurpub/ckm034
   Erkens CGM, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-295
   Fabiani M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166517
   Fargues P, 2012, 201214 MPC RR R SCHU
   Gelman A, 2013, J ADOLESCENT HEALTH, V53, P756, DOI 10.1016/j.jadohealth.2013.07.002
   Graetz V, 2017, BRIT MED BULL, V121, P5, DOI 10.1093/bmb/ldw057
   Gushulak BD, 2004, CLIN INFECT DIS, V38, P1742, DOI 10.1086/421268
   Guthmann JP, 2013, VACCINE, V31, P5666, DOI 10.1016/j.vaccine.2013.09.059
   Guttmann A, 2008, AMBUL PEDIATR, V8, P205, DOI 10.1016/j.ambp.2008.01.010
   Heywood AE, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay010
   IOM, 2017, WORLD MIGR REP 2018
   Islam MM, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.020309
   Jimenez-Garcia R, 2008, J INFECTION, V57, P472, DOI 10.1016/j.jinf.2008.10.005
   Jimenez-Garcia R, 2008, VACCINE, V26, P4218, DOI 10.1016/j.vaccine.2008.05.053
   Joseph NP, 2012, WOMEN HEALTH ISS, V22, pE571, DOI 10.1016/j.whi.2012.09.003
   Karki S, 2016, VACCINE, V34, P6388, DOI 10.1016/j.vaccine.2016.10.012
   Kyrka A, 2009, J MED VIROL, V81, P582, DOI 10.1002/jmv.21434
   Lam E, 2016, CONFL HEALTH, V10, DOI 10.1186/s13031-016-0094-5
   Lawrence J, 2005, HEALTH SOC CARE COMM, V13, P451, DOI 10.1111/j.1365-2524.2005.00572.x
   Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69
   Levy V, 2010, J IMMIGR MINOR HEALT, V12, P828, DOI 10.1007/s10903-009-9239-6
   Limina RM, 2015, J IMMIGR MINOR HEALT, V17, P66, DOI 10.1007/s10903-013-9888-3
   Lin CC, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-49
   Liu CY, 2007, VACCINE, V25, P7706, DOI 10.1016/j.vaccine.2007.07.056
   Lu PJ, 2014, AM J PREV MED, V47, P722, DOI 10.1016/j.amepre.2014.08.009
   McKeary M, 2010, J REFUG STUD, V23, P523, DOI 10.1093/jrs/feq038
   Mendiola Jennifer, 2016, Prev Med Rep, V3, P25, DOI 10.1016/j.pmedr.2015.11.006
   Meynard A, 2016, J IMMIGR MINOR HEALT, V18, P353, DOI 10.1007/s10903-015-0185-1
   Mikolajczyk RT, 2008, INT J PUBLIC HEALTH, V53, P180, DOI 10.1007/s00038-008-8002-4
   Mipatrini D, 2017, PATHOG GLOB HEALTH, V111, P59, DOI 10.1080/20477724.2017.1281374
   Moller SP, 2018, EUR J CANCER PREV, V27, P42, DOI 10.1097/CEJ.0000000000000274
   Moller SP, 2016, EUR J PEDIATR, V175, P539, DOI 10.1007/s00431-015-2663-9
   Morris MD, 2009, J COMMUN HEALTH, V34, P529, DOI 10.1007/s10900-009-9175-3
   Ng E, 2016, VACCINE, V34, P4437, DOI 10.1016/j.vaccine.2016.06.079
   Perruchoud R., 2011, GLOSSARY MIGRATION
   Poethko-Muller C, 2009, VACCINE, V27, P2563, DOI 10.1016/j.vaccine.2009.02.009
   Quang YN, 2010, J AM COLL HEALTH, V59, P37, DOI 10.1080/07448481.2010.486811
   Ricco M, 2016, IND HEALTH, V54, P554, DOI 10.2486/indhealth.2015-0249
   Riggs E, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-117
   Riise OR, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0487-4
   Romanus V, 2006, Euro Surveill, V11, P14
   Ruesen C, 2014, EUROSURVEILLANCE, V19, P14, DOI 10.2807/1560-7917.ES2014.19.11.20738
   Sandgren A, 2014, EUR RESPIR J, V43, P1159, DOI 10.1183/09031936.00117213
   Talukder YS, 2007, EPIDEMIOL INFECT, V135, P1344, DOI 10.1017/S0950268807008497
   UNHCR, 2016, GLOB TRENDS FORC DIS
   United Nations, 2017, INT MIGR REP
   Varan AK, 2017, J IMMIGR MINOR HEALT, V19, P779, DOI 10.1007/s10903-016-0465-4
   Vilajeliu A, 2015, VACCINE, V33, P1767, DOI 10.1016/j.vaccine.2015.02.043
   Whelan J, 2012, VACCINE, V30, P5651, DOI 10.1016/j.vaccine.2012.06.080
   Williams GA, 2016, SCAND J PUBLIC HEALT, V44, P6, DOI 10.1177/1403494815610182
   Wilson L, 2018, VACCINE, V36, P1055, DOI 10.1016/j.vaccine.2018.01.025
   Wolf E, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4544
   World Health Organization, 2018, VACC DIS
   Zahraei SM, 2014, ARCH IRAN MED, V17, P698, DOI 0141710/AIM.0011
NR 68
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2661
EP 2669
DI 10.1016/j.vaccine.2019.04.001
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200004
PM 30967311
DA 2020-05-12
ER

PT J
AU Gentile, A
   Paget, J
   Bellei, N
   Torres, JP
   Vazquez, C
   Laguna-Torres, VA
   Plotkin, S
AF Gentile, Angela
   Paget, John
   Bellei, Nancy
   Torres, Juan Pablo
   Vazquez, Cynthia
   Laguna-Torres, V. Alberto
   Plotkin, Stanley
CA GII
TI Influenza in Latin America: A report from the Global Influenza
   Initiative (GII)
SO VACCINE
LA English
DT Review
DE Influenza; Latin America; Epidemiology; Surveillance; Vaccination;
   Global Influenza Initiative
ID SEASONAL INFLUENZA; BURDEN; MORTALITY; DEATHS; HOSPITALIZATIONS;
   VACCINATION; BENEFITS; VACCINES; ILLNESS; IMPACT
AB The Global Influenza Initiative (GII) is a global expert group that aims to raise acceptance and uptake of influenza vaccines globally and provides recommendations and strategies to address challenges at local, national, regional, and global levels. This article provides a consolidated estimation of disease burden in Latin America, currently lacking in published literature, and delivers the Gil recommendations specific to Latin America that provide guidance to combat existing vaccination challenges.
   While many countries worldwide, especially in the tropics and subtropics, do not have a seasonal influenza policy, 90% of Latin American countries have a seasonal influenza policy in place. Local governments in the Latin American countries and The Pan American Health Organization's Technical Advisory Group on Vaccine-preventable Diseases play a major role in improving the vaccination coverage and reducing the overall disease burden. Influenza seasonality poses the biggest challenge in deciding on optimal timing for vaccination in Latin America, as in temperate climates seasonal influenza activity peaks during the winter months (November-February and May-October) in the northern and southern hemispheres, respectively, while in the tropics and subtropical regions it usually occurs throughout the year, but especially during the rainy season. Besides this, vaccine mismatch with circulating strains, misconception concerning influenza vaccine effectiveness, and poor disease and vaccine awareness among the public are also key challenges that need to be overcome. Standardization of clinical case definitions is important across all Latin American countries. Surveillance (mostly passive) has improved substantially in the Latin American countries over the past decade, but more is still required to better understand the disease burden and help inform policies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gentile, Angela] Ricardo Gutierrez Childrens Hosp, Beauchef 214 6 Piso 1424 Capital Fed 1405, RA-1405 Buenos Aires, DF, Argentina.
   [Paget, John] Netherlands Inst Hlth Serv Res NIVEL, NL-3513 CR Utrecht, Netherlands.
   [Bellei, Nancy] Univ Fed Sao Paulo, Dept Med, BR-04024002 Sao Paulo, Brazil.
   [Torres, Juan Pablo] Univ Chile, Fac Med, Div Pediat Infect Dis, Dept Pediat, Santiago 1058, Chile.
   [Vazquez, Cynthia] Cent Lab Publ Hlth, Dept Virol, Asuncion 1429, Paraguay.
   [Laguna-Torres, V. Alberto] San Marcos Univ, Virol Sect, Trop Med Inst Daniel A Carrion, Lima 15081, Peru.
   [Plotkin, Stanley] Univ Penn, Doylestown, PA 18907 USA.
RP Gentile, A (reprint author), Ricardo Gutierrez Childrens Hosp, Beauchef 214 6 Piso 1424 Capital Fed 1405, RA-1405 Buenos Aires, DF, Argentina.
EM angelagentile21@gmail.com; J.Paget@nivel.nl; nbellei@uol.com.br;
   jptorres@uchile.cl; stanley.plotkin@vaxconsult.com
RI ; Bellei, Nancy/D-8641-2016
OI LAGUNA-TORRES, VICTOR ALBERTO/0000-0002-9507-6301; Bellei,
   Nancy/0000-0001-6080-5693
FU Sanofi Pasteur
FX The GII is funded by an educational grant from Sanofi Pasteur. Medical
   writing support, funded by Sanofi Pasteur, was provided by Debaditya
   Das, PhD, of PAREXEL International.
CR Laguna-Torres VA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006118
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   Argentinean and Brazilian Influenza Vaccine Working Group, 2017, Rev Panam Salud Publica, V41, pe76
   Azziz-Baumgartner E, 2015, EMERG INFECT DIS, V21, P1209, DOI 10.3201/eid2107.140788
   Caini S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174592
   Camilloni B, 2009, VACCINE, V27, P4099, DOI 10.1016/j.vaccine.2009.04.078
   Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases (NCIRD), TYP INFL VIR
   Cheng PY, 2015, INFLUENZA OTHER RESP, V9, P13, DOI 10.1111/irv.12317
   Coleman BL, 2018, INFLUENZA OTHER RESP, V12, P22, DOI 10.1111/irv.12504
   Davila-Torres J, 2015, ARCH MED RES, V46, P63, DOI 10.1016/j.arcmed.2014.11.005
   Dawood FS, 2012, LANCET INFECT DIS, V12, P687, DOI 10.1016/S1473-3099(12)70121-4
   de Francisco N, 2015, VACCINE, V33, P6537, DOI 10.1016/j.vaccine.2015.10.066
   Descalzo MA, 2016, INFLUENZA OTHER RESP, V10, P340, DOI 10.1111/irv.12385
   Douce RW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022206
   El Omeiri N, 2018, VACCINE, V36, P3555, DOI 10.1016/j.vaccine.2017.06.036
   Arango AE, 2015, INFLUENZA OTHER RESP, V9, P1, DOI 10.1111/irv.12271
   Arlant LHF, 2016, J PEDIAT INF DIS SOC, V5, P1, DOI 10.1093/jpids/piv107
   Arlant LHF, 2015, REV CHIL INFECTOL, V32, P198
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137
   Hendriks J, 2018, VACCINE, V36, P3993, DOI 10.1016/j.vaccine.2018.05.099
   Hirve S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153003
   Independent Accountability Panel, 2018, REP PRIV SECT WHO IS
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Jamotte A, 2017, HUM VACC IMMUNOTHER, V13, P877, DOI 10.1080/21645515.2016.1256928
   Keshavarz M, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2014
   Kraay ANM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3425-x
   Laguna-Torres VA, 2011, INFLUENZA OTHER RESP, V5, P123, DOI 10.1111/j.1750-2659.2010.00182.x
   Lewnard JA, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020028
   de Souz MDM, 2013, B WORLD HEALTH ORGAN, V91, P525, DOI 10.2471/BLT.12.116871
   McQuestion M, 2017, J PUBLIC HEALTH POL, V38, P3, DOI 10.1057/s41271-016-0052-x
   Ministry of Health-Argentina, 2018, INFL VACC
   Ministry of Health -Argentina, 2018, B INT VIG
   Ministry of Health-Chile, SIT INFL VIR RESP IN
   Ministry of Health-Chile, 2018, CAMP VAC INFL 2018
   Ministry of Health-Paraguay, OP GUID ILI SENT SUR
   Ministry of Health-Paraguay, 2017, EP B
   Ministry of Health-Paraguay, EP UPD 2018
   Miyaki C, 2011, VACCINE S1, V29
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   Netherlands Institute for Health Services Research, EP SIGN SEAS INFL RE
   Newman LP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193263
   Pan American Health Organization, INFL ORV COUNTR CUM
   Pan American Health Organization, PAHO INFL OTH RESP V
   Pan American Health Organization, 40 EW PAHO
   Perosa AH, 2015, MEM I OSWALDO CRUZ, V110, P606, DOI 10.1590/0074-02760150044
   Ropero-Alvarez AM, 2016, HUM VACC IMMUNOTHER, V12, P2206, DOI 10.1080/21645515.2016.1157240
   Ropero-Alvarez AM, 2012, VACCINE, V30, P916, DOI 10.1016/j.vaccine.2011.11.092
   Ropero-Alvarez AM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-361
   Savy V, 2013, INFLUENZA OTHER RESP, V7, P1017, DOI 10.1111/irv.12036
   Sotomayor V, 2018, INFLUENZA OTHER RESP, V12, P138, DOI 10.1111/irv.12502
   Technical Advisory Group on Vaccine -preventable Diseases (TAG), 2015, 23 M CUB
   World Health Organization, MAN EST DIS BURD ASS
   World Health Organization, WHO GLOB EP SURV STA
   World Health Organization, INFL SEAS TIM FORM V
   World Health Organization, WHO SEAS INFL VACC U
   World Health Organization (WHO), WHO PREF PROD CHAR N
   World Health Organization (WHO), 2018, WHO INFL SEAS FACT S
NR 58
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2670
EP 2678
DI 10.1016/j.vaccine.2019.03.081
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200005
PM 30975568
DA 2020-05-12
ER

PT J
AU Lecouturier, V
   Bernard, MC
   Berry, C
   Carayol, S
   Richier, E
   Boudet, F
   Heinrichs, J
AF Lecouturier, Valerie
   Bernard, Marie-Clotilde
   Berry, Catherine
   Carayol, Sebastien
   Richier, Eric
   Boudet, Florence
   Heinrichs, Jon
TI Immunogenicity and protection conferred by an optimized purified
   inactivated Zika vaccine in mice
SO VACCINE
LA English
DT Article
DE Zika; Vaccine; Immunogenicity; Protection; Mouse
ID MONOCLONAL-ANTIBODIES; VIRUS; IMMUNIZATION; TRANSMISSION; CHALLENGE;
   IMMUNITY; MODEL
AB After decades of inconsequential infections, and sporadic outbreaks in the Asia-Pacific region between 2007 and 2013, Zika virus caused a widespread epidemic in South America in 2015 that was complicated by severe congenital infections. After the WHO declared a Public Health Emergency of International Concern in February 2016, vaccine development efforts based on different platforms were initiated. Several candidates have since been evaluated in clinical phase I studies. Of these, a Zika purified inactivated vaccine (ZPIV), adjuvanted with aluminum hydroxide, developed by the Walter Reed Army Institute of Research (WRAIR), yielded high seroconversion rates. Sanofi Pasteur further optimized the vaccine in terms of production scale, purification conditions and regulatory compliance, using its experience in flavivirus vaccine development. Here we report that the resulting optimized vaccine (ZPIV-SP) elicited robust seroneutralizing antibody responses and provided complete protection from homologous Zika virus strain challenge in immunocompetent BALB/c mice. ZPIV-SP also showed improved immunogenicity compared with the first-generation vaccine, and improved efficacy in the more permissive interferon receptor-deficient A129 mice. Finally, analysis of the IgG response directed towards nonstructural protein 1 (NS1) suggests that viral NS1 was efficiently removed during the optimized purification process of ZPIV-SP. Together, these results suggest that the optimized vaccine is well suited for further evaluation in larger animal models and late-stage clinical studies. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Lecouturier, Valerie; Bernard, Marie-Clotilde; Berry, Catherine; Boudet, Florence] Sanofi Pasteur, Res & Dev, Marcy Letoile, France.
   [Carayol, Sebastien] Sanofi Pasteur, Bioproc R&D, Marcy Letoile, France.
   [Richier, Eric] Sanofi Pasteur, Analyt R&D, Marcy Letoile, France.
   [Heinrichs, Jon] Sanofi Pasteur, Discovery Dr, Swiftwater, PA USA.
RP Lecouturier, V (reprint author), 1541,Ave Marcel Merieux, F-69280 Marcy Letoile, France.
EM Valerie.lecouturier@sanofi.com
FU Sanofi Pasteur SA; Department of Health and Human Services; Office of
   the Assistant Secretary for Preparedness and Response; Biomedical
   Advanced Research and Development Authority, United States
   [HHS01002016000039C]
FX This study has been funded by Sanofi Pasteur SA and with Federal Funds
   from the Department of Health and Human Services; Office of the
   Assistant Secretary for Preparedness and Response; Biomedical Advanced
   Research and Development Authority, United States, under Contract No.
   HHS01002016000039C.
CR Abbink P, 2018, NAT REV MICROBIOL, V16, P594, DOI 10.1038/s41579-018-0039-7
   Abbink P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4163
   Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Alaniz AJ, 2017, INT J EPIDEMIOL, V46, P966, DOI 10.1093/ije/dyw366
   Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034
   Barouch DH, 2017, IMMUNITY, V46, P176, DOI 10.1016/j.immuni.2017.02.005
   Brault AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15039-8
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dirikov E, 2016, MMWR-MORBID MORTAL W, V65, P910, DOI [10.15585/mmwr.mm6534e1, DOI 10.15585/MMWR.MM6534E1]
   Dowall SD, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005704
   Dowall SD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004658
   Durbin A, 2017, EXPERT REV VACCINES, V16, P781, DOI 10.1080/14760584.2017.1345309
   Epelboin Y, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005933
   Giel-Moloney M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31375-9
   Grischott F, 2016, TRAVEL MED INFECT DI, V14, P313, DOI 10.1016/j.tmaid.2016.07.002
   Guy B, 2009, AM J TROP MED HYG, V80, P302, DOI 10.4269/ajtmh.2009.80.302
   HENCHAL EA, 1988, J GEN VIROL, V69, P2101, DOI 10.1099/0022-1317-69-8-2101
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Kam YW, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92428
   Krauer F, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002203
   Lanciotti RS, 2016, EMERG INFECT DIS, V22, P933, DOI 10.3201/eid2205.160065
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   Modjarrad K, 2018, LANCET, V391, P563, DOI 10.1016/S0140-6736(17)33106-9
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   SCHLESINGER JJ, 1985, J IMMUNOL, V135, P2805
   Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322
   Sumathy K, 2017, SCI REP-UK, V7, DOI 10.1038/srep46375
   Tebas Pablo, 2017, N Engl J Med, DOI 10.1056/NEJMoa1708120
   WHO, 2015, VACCINE, V33, P76, DOI 10.1016/j.vaccine.2014.05.040
NR 33
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2679
EP 2686
DI 10.1016/j.vaccine.2019.04.013
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200006
PM 30967310
OA Other Gold
DA 2020-05-12
ER

PT J
AU Sando, E
   Suzuki, M
   Furumoto, A
   Asoh, N
   Yaegashi, M
   Aoshima, M
   Ishida, M
   Hamaguchi, S
   Otsuka, Y
   Morimoto, K
AF Sando, Eiichiro
   Suzuki, Motoi
   Furumoto, Akitsugu
   Asoh, Norichika
   Yaegashi, Makito
   Aoshima, Masahiro
   Ishida, Masayuki
   Hamaguchi, Sugihiro
   Otsuka, Yoshihito
   Morimoto, Konosuke
TI Impact of the pediatric 13-valent pneumococcal conjugate vaccine on
   serotype distribution and clinical characteristics of pneumococcal
   pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study
   (J-PAVE)
SO VACCINE
LA English
DT Article
DE Pneumococcal pneumonia; PCV13 serotypes; PPV23; Vaccine; Streptococcus
   pneumoniae
ID CARE-ASSOCIATED PNEUMONIA; DISEASE; REPLACEMENT; MULTICENTER;
   POPULATION; CHILDREN; ENGLAND; WALES; OLDER
AB Background: The pediatric 13-valent pneumococcal conjugate vaccine (PCV13) was included in the pediatric immunization programme in Japan in late 2013. The impact of vaccination on the serotype distribution and clinical characteristics of pneumococcal pneumonia has not been described.
   Methods: The first phase of this multicentre prospective study was conducted at community-based hospitals in Japan from 2011 to 2014. The second phase was conducted from 2016 to 2017. Pneumococcal isolates and clinical data were collected from patients with community-acquired pneumonia who were >= 15 years of age. Patients were classified by pneumococcal serotype to PCV13 serotype, 23-valent pneumococcal polysaccharide vaccine (PPV23) non-PCV13 serotype, and non-vaccine serotype.
   Results: A total of 484 patients were enrolled, 241 in the first phase and 243 in the second. The proportion of PCV13 serotypes decreased from 53% to 33% (p < 0.001), whereas PPV23 non-PCV13 serotypes did not change (p = 0.754). PCV13 serotypes were associated with increased risk of elevated blood urea nitrogen (adjusted odds ratio 2.49; 95% confidence interval: 1.49-4.16) and hospitalization (adjusted odds ratio 1.74; 95% confidence interval: 1.02-2.95). These associations were not observed in patients with PPV23 non-PCV13 serotypes.
   Conclusions: The occurrence of pneumococcal pneumonia caused by vaccine-covered serotypes dramatically decreased following the introduction of pediatric PCV13. The PCV13 serotypes were associated with pneumonia severity. (C) 2019 Published by Elsevier Ltd.
C1 [Sando, Eiichiro; Suzuki, Motoi; Morimoto, Konosuke] Nagasaki Univ, Inst Trop Med, Dept Clin Med, Sakamoto 1-12-4, Nagasaki 8528523, Japan.
   [Sando, Eiichiro; Morimoto, Konosuke] Nagasaki Univ, Grad Sch Biomed Sci, Dept Clin Trop Med, Nagasaki, Japan.
   [Sando, Eiichiro; Yaegashi, Makito] Kameda Med Ctr, Dept Gen Internal Med, Chiba, Japan.
   [Furumoto, Akitsugu] Nagasaki Rosai Hosp, Dept Infect Dis, Nagasaki, Japan.
   [Asoh, Norichika] Juzenkai Hosp, Dept Internal Med, Nagasaki, Japan.
   [Aoshima, Masahiro] Kameda Med Ctr, Dept Pulmonol, Chiba, Japan.
   [Ishida, Masayuki] Chikamori Hosp, Dept Resp Med, Kochi, Japan.
   [Hamaguchi, Sugihiro] Fukushima Med Univ, Dept Gen Internal Med, Fukushima, Japan.
   [Otsuka, Yoshihito] Kameda Med Ctr, Dept Lab Med, Chiba, Japan.
RP Morimoto, K (reprint author), Nagasaki Univ, Inst Trop Med, Dept Clin Med, Sakamoto 1-12-4, Nagasaki 8528523, Japan.
EM komorimo@nagasaki-u.ac.jp
OI Suzuki, Motoi/0000-0002-8340-0880
FU PfizerPfizer; Nagasaki University; AMED (Japan Agency for Medical
   Research and Development)Japan Agency for Medical Research and
   Development (AMED) [17fk0108302h1603]
FX The APSG-J study was supported by Pfizer and Nagasaki University. The
   J-PAVE study was supported by AMED (Japan Agency for Medical Research
   and Development, grant number 17fk0108302h1603).
CR Akata K, 2017, J INFECT CHEMOTHER O
   [Anonymous], 2015, INT JCV1 STAT AD PNE
   Benfield T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072743
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Browall S, 2014, EUR RESPIR J, V44, P1646, DOI 10.1183/09031936.00080814
   Chiba N, 2014, EMERG INFECT DIS, V20, P1132, DOI 10.3201/eid2007.131485
   Daniel P, 2018, VACCINE, V36, P1614, DOI 10.1016/j.vaccine.2018.02.005
   Falkenhorst G, 2016, BUNDESGESUNDHEITSBLA, V59, P1623, DOI 10.1007/s00103-016-2466-9
   Ikuse T, 2018, EPIDEMIOL INFECT, V146, DOI 10.1017/S0950268818002133
   Katoh S, 2017, JPN J INFECT DIS, V70, P495, DOI 10.7883/yoken.JJID.2016.311
   Maruyama T, 2013, CLIN INFECT DIS, V57, P1373, DOI 10.1093/cid/cit571
   Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1
   Miyazaki H, 2017, J INFECT CHEMOTHER O
   Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3
   Morimoto K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122247
   Murakami Y, 2018, JAP J PUBLIC HLTH, V65, P20
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Rodrigo C, 2015, EUR RESPIR J, V45, P1632, DOI 10.1183/09031936.00183614
   Sakiyama H, 2017, J AMBULATORY GENER P, V20, P272
   Schillberg E, 2014, CLIN INFECT DIS, V59, P651, DOI 10.1093/cid/ciu366
   Shindo Y, 2009, CHEST, V135, P633, DOI 10.1378/chest.08-1357
   Suzuki M, 2017, LANCET INFECT DIS, V17, P313, DOI [10.1016/S1473-3099(17)30049-X, 10.1016/s1473-3099(17)30049-x]
   Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
NR 24
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2687
EP 2693
DI 10.1016/j.vaccine.2019.04.009
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200007
PM 30975569
DA 2020-05-12
ER

PT J
AU Leroux-Roels, G
   De Boever, F
   Maes, C
   Nguyen, TLA
   Baker, S
   Lopez, AG
AF Leroux-Roels, Geert
   De Boever, Fien
   Maes, Cathy
   Thi Lien-Anh Nguyen
   Baker, Sherryl
   Lopez, Antonio Gonzalez
TI Safety and immunogenicity of a respiratory syncytial virus fusion
   glycoprotein F subunit vaccine in healthy adults: Results of a phase 1,
   randomized, observer-blind, controlled, dosage-escalation study
SO VACCINE
LA English
DT Article
DE Respiratory syncytial virus; Glycoprotein; Subunit vaccine; Adjuvant;
   Immunogenicity; Safety
ID MATERNAL ANTIBODY; YOUNG-CHILDREN; POSTFUSION F; INFECTION; INFANTS;
   BURDEN; RISK
AB Introduction: Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in infants. An investigational vaccine using an engineered recombinant RSV fusion glycoprotein in its post-fusion conformation (RSV F subunit vaccine) has been developed to protect young infants via maternal immunization. This first-in-human, phase I, observer-blind study (NCT02298179) evaluated the safety and immunogenicity of different dosages and formulations of RSV F subunit vaccine in healthy non-pregnant women and men aged 18-45 years.
   Methods: Participants were enrolled (1:1:1) in a stepwise dosage-escalation manner into three cohorts to receive RSV F subunit vaccine containing 45 mu g, 90 mu g and 135 mu g of RSV F glycoprotein. Within each cohort, participants were randomized (1:1:1:1) to receive two doses of RSV F subunit vaccine with (aluminum hydroxide or MF59) or without adjuvant, or placebo, >= 28 days apart. Safety (until day 365 post-dose 2), anti-RSV neutralizing antibodies (NAbs) and serum total binding antibodies to RSV F protein (until day 181 post-dose 1) were evaluated.
   Results: All formulations were well-tolerated. No vaccine-related serious adverse events were reported. All participants were seropositive for anti-RSV NAbs at baseline, with geometric mean titers (GMTs) ranging from 184 (95% confidence interval [CI]: 127-266) to 380 (95% CI: 272-531). At 28 days post-dose 1, anti-RSV NAb GMTs in vaccine recipients ranged from 893 (95% CI: 702-1,136) to 1,602 (95% CI: 1,243-2,064). No booster effect was observed, but immune responses were maintained above pre-vaccination levels for six months post-dose 1. Ratios of RSV F total binding antibodies fold changes to NAb fold changes ranged from 2.79 to 4.12 at 28 days post-dose 1. The impact of the adjuvant was limited.
   Conclusions: A single dose of each formulation of RSV subunit F vaccine was well-tolerated and enhanced preexisting NAb titers through six months of follow-up. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Leroux-Roels, Geert; De Boever, Fien; Maes, Cathy] Ghent Univ Hosp, Ctr Vaccinol, C Heymanslaan 10, B-9000 Ghent, Belgium.
   [Thi Lien-Anh Nguyen] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
   [Baker, Sherryl; Lopez, Antonio Gonzalez] GSK, 14200 Shady Grove Rd, Rockville, MD 20850 USA.
   [Baker, Sherryl] RSC Stat Consulting LLC, POB 1066, Sparta, NJ 07871 USA.
RP Lopez, AG (reprint author), GSK, 14200 Shady Grove Rd, Rockville, MD 20850 USA.
EM Geert.LerouxRoels@UGent.be; Fien.DeBoever@uzgent.be;
   Cathy.Maes@uzgent.be; antonio.y.gonzalez@gsk.com
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX GlaxoSmithKline Biologicals SA.
CR Amirthalingam G, 2016, CLIN INFECT DIS, V63, pS236, DOI 10.1093/cid/ciw559
   Beran J, 2018, J INFECT DIS, V217, P1616, DOI 10.1093/infdis/jiy065
   Capella C, 2017, J INFECT DIS, V216, P1398, DOI 10.1093/infdis/jix489
   Demicheli V, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000003.pub2
   Falloon J, 2017, J INFECT DIS, V216, P1362, DOI 10.1093/infdis/jix503
   Glenn GM, 2016, J INFECT DIS, V213, P411, DOI 10.1093/infdis/jiv406
   Glenn GM, 2013, VACCINE, V31, P524, DOI 10.1016/j.vaccine.2012.11.009
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026
   GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3
   Gonzalez PA, 2012, REV MED VIROL, V22, P230, DOI 10.1002/rmv.1704
   Graham BS, 2011, IMMUNOL REV, V239, P149, DOI 10.1111/j.1600-065X.2010.00972.x
   Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877
   Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507
   Hogan AB, 2016, THEOR POPUL BIOL, V110, P78, DOI 10.1016/j.tpb.2016.04.003
   Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758
   Jorquera PA, 2017, EXPERT REV RESP MED, V11, P609, DOI 10.1080/17476348.2017.1338567
   Lambach P, 2015, VACCINE, V33, P6376, DOI 10.1016/j.vaccine.2015.08.036
   Langley JM, 2017, J INFECT DIS, V215, P24, DOI 10.1093/infdis/jiw453
   Littel-van den Hurk SV, 2012, CURR OPIN VIROL, V2, P300, DOI 10.1016/j.coviro.2012.01.008
   Mazur NI, 2019, J INFECT DIS, V219, P59, DOI 10.1093/infdis/jiy477
   McLellan JS, 2013, CURR TOP MICROBIOL, V372, P83, DOI 10.1007/978-3-642-38919-1_4
   Modjarrad K, 2016, VACCINE, V34, P190, DOI 10.1016/j.vaccine.2015.05.093
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Ngwuta JO, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4241
   Ochola R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008088
   OGILVIE MM, 1981, J MED VIROL, V7, P263, DOI 10.1002/jmv.1890070403
   Olafsdottir TA, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01872
   Pellegrini M, 2009, VACCINE, V27, P6959, DOI 10.1016/j.vaccine.2009.08.101
   Phung E, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010023
   Piedra PA, 2003, VACCINE, V21, P3479, DOI 10.1016/S0264-410X(03)00355-4
   Prescott WA, 2010, PHARMACOECONOMICS, V28, P279, DOI 10.2165/11531860-000000000-00000
   Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]
   Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3
   Swanson KA, 2011, P NATL ACAD SCI USA, V108, P9619, DOI 10.1073/pnas.1106536108
   Widjaja I, 2016, J VIROL, V90, P5965, DOI 10.1128/JVI.00235-16
   Zhang Y, 2013, J EXP MED, V210, P457, DOI 10.1084/jem.20120150
NR 36
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2694
EP 2703
DI 10.1016/j.vaccine.2019.04.011
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200008
PM 30987852
OA Other Gold
DA 2020-05-12
ER

PT J
AU Azzari, C
   Serranti, D
   Nieddu, F
   Moriondo, M
   Casini, A
   Lodi, L
   de Benedictis, FM
   De Vitis, E
   Cavone, F
   Cortimiglia, M
   Indolfi, G
   Lombardi, E
   Carloni, I
   Cutrera, R
   Lucenteforte, E
   Resti, M
   Ricci, S
AF Azzari, Chiara
   Serranti, Daniele
   Nieddu, Francesco
   Moriondo, Maria
   Casini, Arianna
   Lodi, Lorenzo
   de Benedictis, Fernando M.
   De Vitis, Elisa
   Cavone, Federica
   Cortimiglia, Martina
   Indolfi, Giuseppe
   Lombardi, Enrico
   Carloni, Ines
   Cutrera, Renato
   Lucenteforte, Ersilia
   Resti, Massimo
   Ricci, Silvia
TI Significant impact of pneumococcal conjugate vaccination on pediatric
   parapneumonic effusion: Italy 2006-2018
SO VACCINE
LA English
DT Article
DE Parapneumonic effusion; Streptococcus pneumoniae; Molecular
   surveillance; Realtime PCR; Vaccination impact; Child
ID POLYMERASE-CHAIN-REACTION; US CHILDREN; SEROTYPE DISTRIBUTION; HERD
   PROTECTION; EMPYEMA; DISEASE; ADULTS; PNEUMONIA; ADOLESCENTS; INFECTION
AB Etiology and serotyping of parapneumonic effusion (PPE) and the impact of vaccination was evaluated over a 12-year period, before and after the PCV13 introduction (2011) for Italian children From 0 to 16 years of age.
   Five hundred and two children were evaluated; 226 blood and 356 pleural fluid samples were obtained and tested using Realtime-PCR and culture. In the pre-PCV13 era S. pneumoniae was the most frequent pathogen identified (64/90; 71.1%) with a large predominance of serotypes 1 (42.4%), 3 (23.7%), 7F (5.1%) and 19A (11.9%).
   The impact of vaccination, calculated on children 0-8 years of age, demonstrated a significant reduction of PPE: with an incidence rate of 2.82 (95%CL 2.32-3.41) in the pre-PCV13 era and an age-standardized rate (ASR) of 0.66 (95% CL 0.37-1.99) in the post-PCV13 era, p < 0.0001. No increase in non-PCV13 serotypes was recorded. S. pneumoniae remained the most frequent pathogen identified in the post-PCV13 era in unvaccinated children with an unchanged serotype distribution: respectively 26/66 (39.4%), 25/66 (37.9%), 5/66 (7.6%), and 4/66 (6.1%) for 1, 3, 7F and 19A. On the other hand 7F and 19A disappeared in vaccinated children and serotype 1 and 3 decreased by 91.8% and 31.5%, respectively. Realtime PCR was significantly more sensitive than culture both in pleural fluid (79.7% vs 12.5%) and in blood (17.8% vs 7.4%).
   In conclusion, our findings indicate that routine immunization with PCV13 has significantly reduced the burden of childhood PPE in vaccinated children, without increasing PPE due to other bacteria and without serotype shift. Moreover, the impact of PCV13 may be underestimated due to the increase in pneumococcal surveillance in Italy. Data has also shown that Real-time PCR is an essential tool to better define the etiology of PPE and to monitor vaccination plans. Longer studies will be necessary to evaluate the role of herd protection in PPE prevention. (C) 2019 Published by Elsevier Ltd.
C1 [Azzari, Chiara; Nieddu, Francesco; Moriondo, Maria; Casini, Arianna; Lodi, Lorenzo; De Vitis, Elisa; Cortimiglia, Martina; Ricci, Silvia] Univ Florence, Dept Hlth Sci, Viale Pieraccini 24, I-50139 Florence, Italy.
   [Azzari, Chiara; Nieddu, Francesco; Moriondo, Maria; Casini, Arianna; Lodi, Lorenzo; De Vitis, Elisa; Cortimiglia, Martina; Ricci, Silvia] Meyer Childrens Univ Hosp, Viale Pieraccini 24, I-50139 Florence, Italy.
   [Serranti, Daniele; Cavone, Federica; Indolfi, Giuseppe; Lombardi, Enrico; Resti, Massimo] Meyer Childrens Univ Hosp, Dept Pediat, Viale Pieraccini 24, I-50139 Florence, Italy.
   [de Benedictis, Fernando M.] Salesi Childrens Hosp Fdn, Via Filippo Corridoni 10, I-60123 Ancona, Italy.
   [Carloni, Ines] Salesi Childrens Hosp, Dept Mother & Child Hlth, Pediat Unit, Via Filippo Corridoni 10, I-60123 Ancona, Italy.
   [Cutrera, Renato] Bambino Gesu Pediat Hosp, Pediat Resp Unit, Piazza St Onofrio 4, I-00165 Rome, Italy.
   [Lucenteforte, Ersilia] Univ Pisa, Dept Clin & Expt Med, Med Stat, Pisa, Italy.
RP Nieddu, F (reprint author), Meyer Childrenss Univ Hosp, Pediat Immunol Lab, Viale Pieraccini 24, I-50139 Florence, Italy.
EM chiara.azzari@unifi.it; daniele.serranti@meyer.it;
   francesco.nieddu@meyer.it; maria.moriondo@meyer.it;
   arianna.casini@unifi.it; lorenzo.lodi@unifi.it;
   pediatria@fmdebenedictis.it; elisa.devitis@meyer.it;
   martina.cortimiglia@meyer.it; giuseppe.indolfi@meyer.it;
   enrico.lombardi@meyer.it; ines.nisi@libero.it;
   ersilia.lucenteforte@unipi.it; massimo.resti@meyer.it;
   silvia.ricci@meyer.it
RI Indolfi, Giuseppe/AAK-5548-2020; Lucenteforte, Ersilia/AAB-9055-2019;
   ricci, silvia/AAA-5030-2019; CASINI, ARIANNA/AAB-8551-2019; Cortimiglia,
   Martina/AAA-2753-2019; Azzari, Chiara/AAB-8584-2019; Moriondo,
   Maria/AAB-7883-2019; Resti, Massimo/AAB-8756-2019; /K-2737-2018
OI Indolfi, Giuseppe/0000-0003-3830-9823; Lucenteforte,
   Ersilia/0000-0001-5608-5902; Azzari, Chiara/0000-0001-7236-1655;
   Moriondo, Maria/0000-0001-9653-8371; Resti, Massimo/0000-0001-6350-1361;
   Serranti, Daniele/0000-0001-7240-1127; Cortimiglia,
   Martina/0000-0002-3175-947X; Nieddu, Francesco/0000-0003-4460-3631;
   /0000-0001-7140-1694; Lodi, Lorenzo/0000-0001-6902-544X
FU Italian Center for Disease Control and Prevention [CCM-4393 117-2006];
   University of Florence
FX This work was supported partly by the Italian Center for Disease Control
   and Prevention [CCM-4393 117-2006] and partly by the University of
   Florence.
CR Amodio E., 2014, EUROMEDITERANEAN BIO, V9, P19, DOI [10.3269/1970-5492.2014.9.3, DOI 10.3269/1970-5492.2014.9.3]
   Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9
   Azzari C, 2016, EMERG INFECT DIS, V22, P469, DOI 10.3201/eid2203.150928
   Azzari C, 2016, HUM VACC IMMUNOTHER, V12, P344, DOI 10.1080/21645515.2015.1102811
   Azzari C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009282
   Balfour-Lynn IM, 2005, THORAX, V60, P1, DOI 10.1136/thx.2004.030676
   Ben-Shimol S, 2018, VACCINE, V36, P5477, DOI 10.1016/j.vaccine.2017.05.059
   Biradar S, 2015, PROCEEDINGS OF THE 2015 INTERNATIONAL CONFERENCE ON POWER AND ADVANCED CONTROL ENGINEERING (ICPACE), P423, DOI 10.1109/ICPACE.2015.7274985
   Byington CL, 2002, CLIN INFECT DIS, V34, P434, DOI 10.1086/338460
   Corcoran M, 2017, EPIDEMIOL INFECT, V145, P2390, DOI 10.1017/S0950268817001194
   de Benedictis FM, ERS HDB PAEDIAT RESP, P258, DOI [10.1183/9781849840392.029612, DOI 10.1183/9781849840392.029612]
   Fitzwater SP, 2012, PEDIATR INFECT DIS J, V31, P501, DOI 10.1097/INF.0b013e31824de9f6
   Grijalva CG, 2010, CLIN INFECT DIS, V50, P805, DOI 10.1086/650573
   Krenke K, 2016, RESP MED, V116, P28, DOI 10.1016/j.rmed.2016.05.009
   Lewnard JA, 2019, LANCET INFECT DIS, V19, pE213, DOI 10.1016/S1473-3099(18)30660-1
   Li STT, 2010, PEDIATRICS, V125, P26, DOI 10.1542/peds.2009-0184
   Marimon JM, 2015, FUTURE MICROBIOL, V10, P909, DOI [10.2217/FMB.14.143, 10.2217/fmb.14.143]
   Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1
   Moore MR, 2016, LANCET RESP MED, V4, P399, DOI 10.1016/S2213-2600(16)00052-7
   Nath S, 2015, ARCH DIS CHILD, V100, P255, DOI 10.1136/archdischild-2014-306525
   Nieddu F, 2017, VACCINE, V35, P1544, DOI 10.1016/j.vaccine.2017.01.064
   Olarte L, 2017, CLIN INFECT DIS, V64, P1699, DOI 10.1093/cid/cix115
   Pasinato A, 2014, VACCINE, V32, P1375, DOI 10.1016/j.vaccine.2014.01.023
   Pernica JM, 2014, CAN J INFECT DIS MED, V25, P151, DOI 10.1155/2014/757963
   Regev-Yochay G, 2017, VACCINE, V35, P2449, DOI 10.1016/j.vaccine.2017.03.031
   Resti M, 2010, CLIN INFECT DIS, V51, P1042, DOI 10.1086/656579
   Resti M, 2009, CLIN THER, V31, P1266, DOI 10.1016/j.clinthera.2009.06.010
   Shigayeva A, 2016, VACCINE, V34, P846, DOI 10.1016/j.vaccine.2015.11.021
   Simonsen L, 2014, LANCET RESP MED, V2, P387, DOI 10.1016/S2213-2600(14)70032-3
   Strachan RE, 2011, EMERG INFECT DIS, V17, P1839, DOI 10.3201/eid1710.101825
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
   Wiese AD, 2016, VACCINE, V34, P6243, DOI 10.1016/j.vaccine.2016.10.062
NR 32
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2704
EP 2711
DI 10.1016/j.vaccine.2019.04.012
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200009
PM 30981627
OA Other Gold
DA 2020-05-12
ER

PT J
AU Clarke, RM
   Paterson, P
   Sirota, M
AF Clarke, Richard M.
   Paterson, Pauline
   Sirota, Miroslav
TI Determinants of satisfaction with information and additional
   information-seeking behaviour for the pertussis vaccination given during
   pregnancy
SO VACCINE
LA English
DT Article
DE Information-seeking behaviour; Decision making; Vaccine hesitancy;
   Trust; Coping strategies; Psychosocial
ID DECISION-MAKING; INTERNET; WOMEN; PERCEPTION; ATTITUDES; NEEDS
AB Objectives: Information search and processing is critical to the vaccine decision-making process. However, the role of drivers of information satisfaction and search is not fully understood. Here, we investigated the predictive potential of psychosocial characteristics related to satisfaction with information and additional information-seeking about the pertussis vaccine currently recommended during pregnancy.
   Design: Cross-sectional online questionnaire study.
   Methods: A UK based sample of 314 women who had given birth during the previous six months was recruited to participate. The questionnaire included measures of the psycho-social predictors: trust, coping strategies, attitude towards vaccine information-seeking behaviour and risk perception of vaccination during pregnancy, and measures of two outcome variables: satisfaction with information received from a health care professional and whether participants engaged in vaccine information-seeking behaviour.
   Results: Trust in health care professionals, a perceived behavioural control of own vaccine information-seeking behaviour, and an engaged problem-focused strategy for coping with stress were significant predictors of satisfaction with official information given by a health care professional. 40% of women sought out additional information about vaccination however, none of the psychosocial factors measured significantly predicted the behaviour.
   Conclusions: We found that high trust in health care professionals, a perceived ability to seek out accurate information about vaccines and actively focusing on problems as a means of coping with stress, drives satisfaction in official vaccine information. We also developed measures of these variables that could be used in further research. (C) 2019 Published by Elsevier Ltd.
C1 [Clarke, Richard M.; Paterson, Pauline] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
   [Sirota, Miroslav] Univ Essex, Dept Psychol, Colchester CO4 3SQ, Essex, England.
RP Clarke, RM (reprint author), London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM richard.clarke@lshtm.ac.uk
RI Sirota, Miroslav/A-2419-2017
OI Sirota, Miroslav/0000-0003-2117-9532
FU Economic and Social Research CouncilEconomic & Social Research Council
   (ESRC)
FX This study was supported by the Economic and Social Research Council.
CR AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Allam A, 2014, J MED INTERNET RES, V16, P237, DOI 10.2196/jmir.2642
   Baker LM, 2007, COMPR CHILD ADOLES N, V30, P39, DOI 10.1080/01460860701366666
   Bath Guillaum, 2004, HEAL, V10, P5
   Betsch C, 2013, MED DECIS MAKING, V33, P14, DOI 10.1177/0272989X12452342
   Betsch C, 2012, VACCINE, V30, P1143, DOI 10.1016/j.vaccine.2011.12.021
   Betsch C, 2011, MED DECIS MAKING, V31, P742, DOI 10.1177/0272989X11400419
   Bianco A, 2013, J MED INTERNET RES, V15, P268, DOI 10.2196/jmir.2752
   Bodeker B, 2014, VACCINE, V32, P4131, DOI 10.1016/j.vaccine.2014.06.007
   Buchanan R, 2014, HEALTH INFO LIBR J, V31, P227, DOI 10.1111/hir.12073
   Bults M, 2011, VACCINE, V29, P6226, DOI 10.1016/j.vaccine.2011.06.075
   Campbell H, 2015, BR J MIDWIFERY, V23, P566, DOI DOI 10.12968/BJ0M.2015.23.8.566
   Cook J, 2016, NEUTRALISING MISINFO, P1
   Donaldson B, 2015, VACCINE, V33, P5822, DOI 10.1016/j.vaccine.2015.08.093
   Ellingson M, 2018, HUM VACC IMMUNOTHER, V14, P767, DOI 10.1080/21645515.2018.1425114
   Flory D, 2012, LONDON DEP HLTH, P1
   Gao LL, 2013, MIDWIFERY, V29, P730, DOI 10.1016/j.midw.2012.07.003
   Gauld NJ, 2016, J PRIM HEALTH CARE, V8, P344, DOI 10.1071/HC15049
   GRIFFIN RJ, 1999, ENVIRON RES, V80, pS23
   Grimes HA, 2014, MIDWIFERY, V30, pE26, DOI 10.1016/j.midw.2013.10.007
   Guidry JPD, 2015, VACCINE, V33, P5051, DOI 10.1016/j.vaccine.2015.08.064
   Hameen-Anttila K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002594
   Hall MA, 2002, MED CARE RES REV, V59, P293, DOI 10.1177/1077558702059003004
   Harmsen IA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1219
   Hendry M, 2013, VACCINE, V31, P5152, DOI 10.1016/j.vaccine.2013.08.091
   Henninger M, 2013, OBSTET GYNECOL, V121, P741, DOI 10.1097/AOG.0b013e3182878a5a
   Jackson C, 2008, HEALTH EXPECT, V11, P232, DOI 10.1111/j.1369-7625.2008.00496.x
   Jones Abbey M, 2012, Adv Prev Med, V2012, P932741, DOI 10.1155/2012/932741
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   King CL, 2018, INFLUENZA OTHER RESP, V12, P514, DOI 10.1111/irv.12547
   Kowal SP, 2015, CAN J PUBLIC HEALTH, V106, pE230, DOI 10.17269/cjph.106.4803
   Lagan BM, 2011, BIRTH-ISS PERINAT C, V38, P336, DOI 10.1111/j.1523-536X.2011.00488.x
   Lalor JG, 2008, J ADV NURS, V64, P185, DOI 10.1111/j.1365-2648.2008.04778.x
   Lambert SD, 2007, QUAL HEALTH RES, V17, P1006, DOI 10.1177/1049732307305199
   Larsson M, 2009, MIDWIFERY, V25, P14, DOI 10.1016/j.midw.2007.01.010
   Lowe P, 2009, QUAL HEALTH RES, V19, P1476, DOI 10.1177/1049732309348368
   Manika D, 2014, J HEALTH COMMUN, V19, P1232, DOI 10.1080/10810730.2013.872727
   Nan XL, 2012, HEALTH COMMUN, V27, P829, DOI 10.1080/10410236.2012.661348
   Public Health England, 2018, HLTH PROT REP, V12, P1
   Ruijs WLM, 2011, EUR J PUBLIC HEALTH, V21, P344, DOI 10.1093/eurpub/ckq172
   Shea JA, 2008, J GEN INTERN MED, V23, P727, DOI 10.1007/s11606-008-0575-3
   Tobin D. L., 1984, COPING STRATEGIES IN
   Wallace C, 2006, BMJ-BRIT MED J, V332, P146, DOI 10.1136/bmj.38678.681840.68
   Walter D, 2012, EUROSURVEILLANCE, V17, P9
   Ward JK, 2017, HEALTH RISK SOC, V19, P38, DOI 10.1080/13698575.2017.1299856
   Weiner JL, 2015, AM J PREV MED, V49, pS426, DOI 10.1016/j.amepre.2015.07.002
   Wheeler M, 2013, HUM VACC IMMUNOTHER, V9, P1782, DOI 10.4161/hv.25959
   WILSON TD, 1981, J DOC, V37, P3, DOI 10.1108/eb026702
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
   Yom-Tov Elad, 2014, AMIA Annu Symp Proc, V2014, P1238
NR 50
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2712
EP 2720
DI 10.1016/j.vaccine.2019.04.008
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200010
PM 30975566
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Darling, RJ
   Senapati, S
   Kelly, SM
   Kohut, ML
   Narasimhan, B
   Wannemuehler, MJ
AF Darling, Ross J.
   Senapati, Sujata
   Kelly, Sean M.
   Kohut, Marian L.
   Narasimhan, Balaji
   Wannemuehler, Michael J.
TI STING pathway stimulation results in a differentially activated innate
   immune phenotype associated with low nitric oxide and enhanced antibody
   titers in young and aged mice
SO VACCINE
LA English
DT Article
DE Metabolism; Nitric oxide; Vaccine; BAFF; Adjuvant; STING; Cyclic
   dinucleotide; TLR agonist
ID DENDRITIC CELL; B-CELL; BAFF; ANTIGEN; IMMUNOMETABOLISM; METABOLISM;
   SURVIVAL; SUPPORTS; TNF
AB Background: One of the most concerning public health issues, related to vaccination and disease prevention, is the inability to induce durable immune responses following a single-dose immunization. In this regard, the nature of the inflammatory environment induced by vaccine adjuvants can negatively impact the resulting immune response. To address these concerns, new strategies to vaccine design are needed in order to improve the outcomes of immune responses, particularly in immunologically disadvantaged populations.
   Methods: Comparisons of the scope of innate immune activation induced by TLR agonists versus cyclic dinucleotides (CDNs) was performed. Their effects on the activation characteristics (e.g., metabolism, cytokine secretion) of bone marrow derived dendritic cells (BMDCs) were studied. In addition, the differential effects on in vivo induction of antibody responses were measured.
   Results: As compared to TLR ligands, the stimulation of BMDCs with CDNs induced distinctly different metabolic outcomes. Marked differences were observed in the production of nitric oxide (NO) and the cytokine BAFF. These distinct differences were correlated with improved (i.e., more rapid and persistent) vaccine antibody responses in both aged and young mice.
   Conclusions: Our results illustrate that the innate immune pathway targeted by adjuvants can critically impact the outcome of the immune response post-vaccination. Specifically, CDN stimulation of APCs induced an activation phenotype that was characterized by decreased innate effector molecule production (e.g., NO) and increased BAFF. This was attributed to the induction of an innate inflammatory environment that enabled the host to make the most of the existing B lymphocyte potential. The use of adjuvants that differentially engage mechanisms of innate immune activation would be particularly advantageous for the generation of robust, single dose vaccines. The results of this study demonstrated that CDNs induced differential innate activation and enhanced vaccine induced antibody responses in both young and aged mice. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Darling, Ross J.; Wannemuehler, Michael J.] Iowa State Univ, Dept Vet Microbiol & Preventat Med, 1800 Christensen Dr, Ames, IA 50011 USA.
   [Senapati, Sujata; Kelly, Sean M.; Narasimhan, Balaji] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA USA.
   [Kohut, Marian L.] Iowa State Univ, Dept Kinesiol, Ames, IA USA.
   [Kohut, Marian L.; Narasimhan, Balaji; Wannemuehler, Michael J.] Iowa State Univ, Nanovaccine Inst, Ames, IA USA.
RP Wannemuehler, MJ (reprint author), Iowa State Univ, Dept Vet Microbiol & Preventat Med, 1800 Christensen Dr, Ames, IA 50011 USA.
EM mjwannem@iastate.edu
OI Senapati, Sujata/0000-0001-5579-3544
FU NIH-NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI111466]; Iowa State University
   Nanovaccine Institute; Vlasta Klima Balloun Faculty Chair
FX Funding was provided by support from NIH-NIAID [R01 AI111466]; the Iowa
   State University Nanovaccine Institute; B.N. acknowledges the support of
   the Vlasta Klima Balloun Faculty Chair.
CR Abdul-Cader MS, 2016, ARCH VIROL, V161, P2075, DOI 10.1007/s00705-016-2904-x
   Araki K, 2010, IMMUNOL REV, V235, P234, DOI 10.1111/j.0105-2896.2010.00898.x
   Banete A, 2018, J LEUKOCYTE BIOL, V103, P1189, DOI 10.1002/JLB.2MIR0917-383R
   Bingisser RM, 1998, J IMMUNOL, V160, P5729
   Blaser H, 2016, TRENDS CELL BIOL, V26, P249, DOI 10.1016/j.tcb.2015.12.002
   Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002
   Cai X, 2014, MOL CELL, V54, P289, DOI 10.1016/j.molcel.2014.03.040
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Danilchanka O, 2013, CELL, V154, P962, DOI 10.1016/j.cell.2013.08.014
   DEGUCHI M, 1995, IMMUNOL LETT, V45, P157, DOI 10.1016/0165-2478(94)00246-N
   Diavatopoulos DA, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a029553
   Ebensen T, 2007, VACCINE, V25, P1464, DOI 10.1016/j.vaccine.2006.10.033
   Everts B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00203
   Everts B, 2014, NAT IMMUNOL, V15, P323, DOI 10.1038/ni.2833
   Everts B, 2012, BLOOD, V120, P1422, DOI 10.1182/blood-2012-03-419747
   Garcia-Ortiz A, 2018, TRENDS MOL MED, V24, P412, DOI 10.1016/j.molmed.2018.02.002
   Giordano D, 2014, J IMMUNOL, V193, P1110, DOI 10.4049/jimmunol.1303158
   Hailemichael Y, 2013, NAT MED, V19, P465, DOI 10.1038/nm.3105
   Igarashi K, 2017, NAT REV IMMUNOL, V17, P437, DOI 10.1038/nri.2017.26
   Jang KJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7750
   Jenal U, 2017, NAT REV MICROBIOL, V15, P271, DOI 10.1038/nrmicro.2016.190
   Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540
   Lee M, 2017, RESULTS PROBL CELL D, V62, P181, DOI 10.1007/978-3-319-54090-0_8
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883
   Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064
   Min HY, 2005, IMMUNOL REV, V205, P7, DOI 10.1111/j.0105-2896.2005.00263.x
   Mitchell TC, 2017, CURR OPIN IMMUNOL, V47, P17, DOI 10.1016/j.coi.2017.06.009
   O'Hagan DT, 2015, VACCINE, V33, pB14, DOI 10.1016/j.vaccine.2015.01.088
   O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570
   Okin D, 2012, CURR BIOL, V22, pR733, DOI 10.1016/j.cub.2012.07.029
   Olekhnovitch R, 2014, J CLIN INVEST, V124, P1711, DOI 10.1172/JCI72058
   Qiao JT, 2018, METABOLISM, V81, P13, DOI 10.1016/j.metabol.2017.09.010
   Sammicheli S, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah6789
   Schmid-Schonbein GW, 2012, P NATL ACAD SCI USA, V109, P3, DOI 10.1073/pnas.1117710109
   Schneider P, 2003, IMMUNOL LETT, V88, P57, DOI 10.1016/S0165-2478(03)00050-6
   Schweighoffer E, 2013, IMMUNITY, V38, P475, DOI 10.1016/j.immuni.2012.11.015
   Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7
   Shah HB, 2013, J IMMUNOL, V191, P1154, DOI 10.4049/jimmunol.1300263
   Si CP, 2016, ONCOTARGET, V7, P74834, DOI 10.18632/oncotarget.11361
   Simioni PU, 2017, INT J IMMUNOPATH PH, V30, P44, DOI 10.1177/0394632016678873
   Simon AK, 2015, P BIOL SCI, P282, DOI 10.1098/rsnb.2014.308q
   Tabibian-Keissar H, 2016, EUR J IMMUNOL, V46, P480, DOI 10.1002/eji.201545586
   Thwe PM, 2018, CANCER LETT, V412, P236, DOI 10.1016/j.canlet.2017.10.032
   Van den Bossche J, 2017, TRENDS IMMUNOL, V38, P395, DOI 10.1016/j.it.2017.03.001
   Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520
   Vora KA, 2003, J IMMUNOL, V171, P547, DOI 10.4049/jimmunol.171.2.547
   Wagner-Muniz DA, SINGLE DOSE CO UNPUB
   Yamamoto K, 1998, CLIN EXP IMMUNOL, V114, P94
   Zhang LJ, 2018, TRENDS MOL MED, V24, P30, DOI 10.1016/j.molmed.2017.11.005
NR 50
TC 1
Z9 1
U1 4
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2721
EP 2730
DI 10.1016/j.vaccine.2019.04.004
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200011
PM 30987850
DA 2020-05-12
ER

PT J
AU Haveri, A
   Ikonen, N
   Kantele, A
   Anttila, VJ
   Ruotsalainen, E
   Savolainen-Kopra, C
   Julkunen, I
AF Haveri, Anu
   Ikonen, Niina
   Kantele, Anu
   Anttila, Veli-Jukka
   Ruotsalainen, Eeva
   Savolainen-Kopra, Carita
   Julkunen, Ilkka
TI Seasonal influenza vaccines induced high levels of neutralizing
   cross-reactive antibody responses against different genetic group
   influenza A(H1N1)pdm09 viruses
SO VACCINE
LA English
DT Article
DE Antibodies; Microneutralization test; Humoral immunity; Influenza A;
   Pandemic; Vaccine
ID HEMAGGLUTINATION INHIBITION; H1N1 2009; ANTIGENIC STRUCTURE; PHASE-III;
   IMMUNOGENICITY; SAFETY; VACCINATION; CANDIDATE; CHILDREN; A(H3N2)
AB Influenza A(H1N1)pdm09 viruses have been circulating throughout the world since the 2009 pandemic. A/California/07/2009 (H1N1) virus was included in seasonal influenza vaccines for seven years altogether, providing a great opportunity to analyse vaccine-induced immunity in relation to the postpandemic evolution of the A(H1N1)pdm09 virus. Serum antibodies against various epidemic strains of influenza A (H1N1)pdm09 viruses were measured among health care workers (HCWs) by haemagglutination inhibition and microneutralization tests before and after 2010 and 2012 seasonal influenza vaccinations. We detected high responses of vaccine-induced neutralizing antibodies to six distinct genetic groups. Our results indicate antigenic similarity between vaccine and circulating A(H1N1)pdm09 strains, and substantial vaccine-induced immunity against circulating epidemic viruses. (C) 2019 Published by Elsevier Ltd.
C1 [Haveri, Anu; Ikonen, Niina; Savolainen-Kopra, Carita; Julkunen, Ilkka] Natl Inst Hlth & Welf THL, Dept Hlth Secur, Expert Microbiol Unit, POB 30, Helsinki 00271, Finland.
   [Kantele, Anu; Anttila, Veli-Jukka; Ruotsalainen, Eeva] Univ Helsinki, Inflammat Ctr, Div Infect Dis, POB 348, Hus Helsinki 00029, Finland.
   [Kantele, Anu; Anttila, Veli-Jukka; Ruotsalainen, Eeva] Helsinki Univ Hosp, POB 348, Hus Helsinki 00029, Finland.
   [Julkunen, Ilkka] Univ Turku, Inst Biomed, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.
   [Julkunen, Ilkka] Turku Univ Hosp, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.
RP Haveri, A (reprint author), Natl Inst Hlth & Welf THL, Dept Hlth Secur, Expert Microbiol Unit, POB 30, Helsinki 00271, Finland.
EM anu.haveri@thl.fi
FU National Institute for Health and Welfare (THL); Ministry of Social
   Affairs and Health
FX The study was supported by funds from the National Institute for Health
   and Welfare (THL) and the Ministry of Social Affairs and Health. The
   funding organization had no role in the study design, data collection
   and analysis, decision to publish or preparation of the manuscript.
CR Bae EY, 2013, CLIN VACCINE IMMUNOL, V20, P811, DOI 10.1128/CVI.00008-13
   Barr IG, 2014, VACCINE, V32, P4713, DOI 10.1016/j.vaccine.2014.02.014
   CATON AJ, 1982, CELL, V31, P417, DOI 10.1016/0092-8674(82)90135-0
   Cheng LW, 2012, J VIROL METHODS, V182, P43, DOI 10.1016/j.jviromet.2012.03.004
   de Jong J C, 2003, Dev Biol (Basel), V115, P63
   Domachowske JB, 2013, J INFECT DIS, V207, P1878, DOI 10.1093/infdis/jit091
   Eidem S, 2015, VACCINE, V33, P4146, DOI 10.1016/j.vaccine.2015.05.081
   Gaglani M, 2014, J INFECT DIS, V209, P1705, DOI 10.1093/infdis/jit825
   GERHARD W, 1981, NATURE, V290, P713, DOI 10.1038/290713a0
   Grund S, 2011, J VIROL METHODS, V171, P369, DOI 10.1016/j.jviromet.2010.11.024
   Hammond A., 2018, Weekly Epidemiological Record, V93, P429
   Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453
   Haveri A, 2015, Euro Surveill, V20, P21028, DOI 10.2807/1560-7917.ES2015.20.5.21028
   HILLIS DM, 1993, METHOD ENZYMOL, V224, P456, DOI 10.1016/0076-6879(93)24035-S
   Hsu JP, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-414
   Huijskens E, 2011, CLIN VACCINE IMMUNOL, V18, P1401, DOI 10.1128/CVI.05046-11
   Ikonen N, 2013, INFLUENSSAKAUSI SUOM
   Ikonen N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013329
   Jain VK, 2013, NEW ENGL J MED, V369, P2481, DOI 10.1056/NEJMoa1215817
   Kieninger D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-343
   Koel BF, 2015, J VIROL, V89, P3763, DOI 10.1128/JVI.02962-14
   Kong WL, 2015, MICROB PATHOGENESIS, V89, P62, DOI 10.1016/j.micpath.2015.09.002
   Langley JM, 2013, J INFECT DIS, V208, P544, DOI 10.1093/infdis/jit263
   Langley JM, 2012, VACCINE, V30, P3389, DOI 10.1016/j.vaccine.2012.03.046
   Laurie KL, 2015, CLIN VACCINE IMMUNOL, V22, P957, DOI 10.1128/CVI.00278-15
   Lin SY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0062983e62983, DOI 10.1371/JOURNAL.PONE.0062983E62983]
   Lin YP, 2015, INFLUENZA OTHER RESP, V9, P331, DOI 10.1111/irv.12333
   lkonen N, 2014, INFLUENSSAKAUSI SUOM
   lkonen N, 2016, INFLUENSSAKAUSI SUOM
   Lyytikainen O, 2011, EURO SURVEILL, V16
   Matsumoto H, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-44
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5
   Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182
   Stephenson I, 2009, EMERG INFECT DIS, V15, P1250, DOI 10.3201/eid1508.081754
   Strengell M, 2013, INFLUENZA OTHER RESP, V7, P431, DOI 10.1111/j.1750-2659.2012.00415.x
   Strengell M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025848
   Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Tavakoli A, 2017, IRAN J PUBLIC HEALTH, V46, P1690
   The Francis Crick Institute, 2018, REP PREP WHO ANN CON
   Tinoco JC, 2014, VACCINE, V32, P1480, DOI 10.1016/j.vaccine.2014.01.022
   Truelove S, 2016, INFLUENZA OTHER RESP, V10, P518, DOI 10.1111/irv.12408
   Verschoor CP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131531
   Wedde M, 2015, INT J MED MICROBIOL, V305, P762, DOI 10.1016/j.ijmm.2015.08.030
   World Health Organization, 2019, REC COMP INFL VIR VA
   World Health Organization Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU
   World Health Organization (WHO), 2016, REC COMP INFL VIR VA
NR 48
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2731
EP 2740
DI 10.1016/j.vaccine.2019.03.078
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200012
PM 30954308
DA 2020-05-12
ER

PT J
AU Gorman, DR
   Bielecki, K
   Willocks, LJ
   Pollock, KG
AF Gorman, D. R.
   Bielecki, K.
   Willocks, L. J.
   Pollock, K. G.
TI A qualitative study of vaccination behaviour amongst female Polish
   migrants in Edinburgh, Scotland
SO VACCINE
LA English
DT Article
DE Hesitancy; Vaccine; Immunisation; Polish; Scotland; UK
ID HPV VACCINATION; KNOWLEDGE; HESITANCY; CHILDREN; MEASLES; MUMPS; WOMEN
AB Vaccine hesitancy is increasing and failure to vaccinate is well-recognised in Europe as a contributing factor to outbreaks of infectious diseases. In Lothian and Scotland, low vaccine uptake has been seen in migrants - notably in the Polish group who have arrived since 2004. The recent Vaccine Confidence in European Union report highlights a concerning recent decline in vaccine confidence in Poland.
   We held three focus groups containing 13 Polish women about the childhood vaccination programme in Lothian, with specific focus on influenza and Human Papillomavirus vaccinations. Key emergent themes were: trust in the national vaccination policy, trust in the vaccination providers (health professionals), trust in the individual vaccines, balancing the risk of disease, and language and communication.
   Polish norms, beliefs and behaviours shape how Polish migrants navigate the UK health system and its vaccination programme. While not confident in the Scottish primary care model and its generalist practitioners, the participants liked the ethos of informed consent in Scotland and compared this favourably with the compulsory vaccination policy in Poland. There was a belief that vaccines in Scotland were of higher quality than Poland and with fewer adverse effects.
   Respondents reported returning to Poland for specialist clinical appointments and diagnostic testing. They regularly access Polish clinical expertise and their opinions about health are influenced by Polish friends and family. They say they have difficulty finding official UK Government and health authority vaccination material and often access Polish media, online resources and information. They are familiar with anti-vaccination activities in Poland.
   Consequently, there are important unmet information needs for this group of parents who may not be making truly informed choices about vaccination. This requires further investigation especially as migration continues and declining immunisation uptake is reported in many countries across Europe. (C) 2019 Published by Elsevier Ltd.
C1 [Gorman, D. R.; Bielecki, K.; Willocks, L. J.] NHS Lothian, Directorate Publ Hlth & Hlth Policy, Edinburgh, Midlothian, Scotland.
   [Pollock, K. G.] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland.
RP Gorman, DR (reprint author), Publ Hlth, 2-4 Waterloo Pl, Edinburgh EH1 3EG, Midlothian, Scotland.
EM Dermot.Gorman@nhslothian.scot.nhs.uk
OI Bielecki, Klaudia/0000-0002-0178-9758
CR [Anonymous], 2018, LIV BIRTHS COUNTR BI
   Bielecki K, 2019, VACCINE, V37, P693, DOI 10.1016/j.vaccine.2018.11.029
   Braczkowska B, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040756
   Braczkowska Bogumila, 2017, Przegl Epidemiol, V71, P227
   Brydak LB, 2012, MED SCI MONITOR, V18, pRA166, DOI 10.12659/MSM.883534
   Corcoran B, 2018, LANCET, V391, P2103, DOI 10.1016/S0140-6736(18)30854-7
   Czarkowski M. P, 2014, PRZEGL EPIDEMIOL, V68, P559
   Czarkowski Miroslaw P, 2014, Przegl Epidemiol, V68, P455
   Donaldson B, 2015, VACCINE, V33, P5822, DOI 10.1016/j.vaccine.2015.08.093
   Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039
   European Centre for Disease Prevention and Control, 2017, POL REC VACC
   European Centre for Disease Prevention and Control, 2019, MONTHL MEASL RUB MON
   Forster A. S., 2016, EPIDEMIOLOGY COMMUNI, V71, P544
   Fournet N, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5103-8
   Ganczak M, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010095
   Ganczak M, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14060665
   Ganczak M, 2013, VACCINE, V31, P5687, DOI 10.1016/j.vaccine.2013.09.056
   Gorman DR, 2018, PUBLIC HEALTH, V158, P86, DOI 10.1016/j.puhe.2017.11.026
   Jaroszewicz M, 2018, MIGRATION UKRAINE PO
   Jaroszewska K., 2014, Postepy Nauk Medycznych, V27, P617
   Jayaweera H., 2014, HLTH MIGRANTS UK WHA
   Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019
   Kanitz EE, 2012, VACCINE, V30, P5222, DOI 10.1016/j.vaccine.2012.06.012
   Korczynska M. R., 2017, Przeglad Epidemiologiczny, V71, P319
   Larson H, 2018, STATE VACCINE CONFID
   Larson HJ, 2018, LANCET, V392, P2244, DOI 10.1016/S0140-6736(18)32608-4
   Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   McCann A., 2016, IMPROVING HLTH MIGRA
   Mixer RE, 2007, J EPIDEMIOL COMMUN H, V61, P797, DOI 10.1136/jech.2005.045633
   Mrozek-Budzyn Dorota, 2012, Przegl Epidemiol, V66, P107
   Mrozek-Budzyn D, 2013, VACCINE, V31, P2551, DOI 10.1016/j.vaccine.2013.03.057
   Mrozek-Budzyn Dorota, 2011, Przegl Epidemiol, V65, P491
   Napolitano F, 2018, VACCINE, V36, P7536, DOI 10.1016/j.vaccine.2018.10.050
   National Records of Scotland, 2018, POP COUNTR BIRTH NAT
   Owsianka B., 2015, PRZEGL EPIDEMIOL, V69, P151
   Owsianka Barbara, 2015, Przegl Epidemiol, V69, P53
   Pollock KG, 2019, VACCINE, V37, P690, DOI 10.1016/j.vaccine.2018.10.097
   Public Health England, 2015, PREN PERT IMM PROGR
   Sawada M, 2018, INT J CLIN ONCOL, V23, P121, DOI 10.1007/s10147-017-1188-9
   Sim JA, 2011, PUBLIC HEALTH, V125, P505, DOI 10.1016/j.puhe.2011.05.005
   Sime D, 2014, HEALTH PLACE, V30, P86, DOI 10.1016/j.healthplace.2014.08.006
   Zarobkiewicz MK, 2017, HUM VACC IMMUNOTHER, V13, P2654, DOI 10.1080/21645515.2017.1365994
   Zuk P, 2019, VACCINE, V37, P1491, DOI 10.1016/j.vaccine.2019.01.073
NR 45
TC 2
Z9 2
U1 6
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2741
EP 2747
DI 10.1016/j.vaccine.2019.03.073
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200013
PM 30979570
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Gagneur, A
   Bergeron, J
   Gosselin, V
   Farrands, A
   Baron, G
AF Gagneur, Arnaud
   Bergeron, Julie
   Gosselin, Virginie
   Farrands, Anne
   Baron, Genevieve
TI A complementary approach to the vaccination promotion continuum: An
   immunization-specific motivational-interview training for nurses
SO VACCINE
LA English
DT Article
DE Motivational interview; Training; Skills; Vaccination promotion; Nurse
ID HELPFUL RESPONSES QUESTIONNAIRE; HESITANCY; SKILLS; ADDICTION
AB Aim: To develop and validate immunization-specific motivational-interview (MI) training for immunization nurses.
   Background: We previously demonstrated that a MI-based intervention on immunisation, performed during postpartum by MI-trained healthcare workers at the hospital maternity ward, reduced parental vaccine hesitancy (VH) and increased vaccine coverage of their children. In this study, we propose immunization-specific MI training for immunization nurses. Together, MI-based training and interventions provide complementary approaches to existing strategies along the vaccination promotion continuum.
   Design: Multiple pretest/posttest design with questionnaires self-administered before and after each training days (4 time points).
   Methods: We developed an in-person immunization-specific MI-training workshop for immunization nurses, held on two days three months apart, with 7 h of MI-training dispensed on day 1, and 4 h on day 2. The self-administered Motivational Interviewing Skills in Immunization (MISI) questionnaire was used at four time points (before and after each of the 2 training days) to evaluate three core aspects of participant MI training: (1) MI-knowledge acquisition; (2) MI-skills application and (3) self-rated self-confidence in applying MI knowledge and skills in vaccination clinical practice. Between November 2016 to December 2017, 34 immunization nurses enrolled in our MI-training workshops.
   Results: The immunization-specific MI-training improved the three core areas evaluated in participants i.e. MI-knowledge acquisition, MI-skills application, and self-rated self-confidence in applying these in vaccination clinical practice.
   Conclusions: Our immunization-specific MI-training enabled immunization nurses to significantly improve MI knowledge, skills and self-confidence in applying MI in the clinic. These results, taken together with those on the MI-based intervention for parents that we previously reported, support the notion of proposing validated immunization-specific MI training for immunization nurses in order to curb parental VH.
   Impact: Immunization-specific MI-training would be easily amenable for the training of other health professionals in the field of immunization to help promote vaccination and curb parental VH. (C) 2019 Published by Elsevier Ltd.
C1 [Gagneur, Arnaud] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pediat, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
   [Gagneur, Arnaud; Bergeron, Julie; Gosselin, Virginie; Farrands, Anne; Baron, Genevieve] Ctr Hosp Univ Sherbrooke, Ctr Rech, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
   [Bergeron, Julie; Baron, Genevieve] Univ Sherbrooke, Dept Res Hlth Sci, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
   [Baron, Genevieve] Eastern Townships Publ Hlth Dept, 300 King Est,Bur 300, Sherbrooke, PQ J1G 1B1, Canada.
RP Gagneur, A (reprint author), Ctr Hosp Univ Sherbrooke, Neonatol Unit, Pediat Dept, 3001,12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
EM Arnaud.Gagneur@USherbrooke.ca
FU Eastern Townships' Public Health Department
FX This study was funded by the Eastern Townships' Public Health
   Department. The authors have no financial relationships relevant to this
   article to disclose.
CR Baer JS, 2004, DRUG ALCOHOL DEPEN, V73, P99, DOI 10.1016/j.drugalcdep.2003.10.001
   Broers S, 2005, PATIENT EDUC COUNS, V58, P279, DOI 10.1016/j.pec.2005.06.001
   Brug J, 2007, J NUTR EDUC BEHAV, V39, P8, DOI 10.1016/j.jneb.2006.08.010
   Cucciare MA, 2012, J GEN INTERN MED, V27, P953, DOI 10.1007/s11606-012-2016-6
   Dempsey A.F., 2016, PED AC SOC M 2016 BA
   Dempsey AF, 2018, JAMA PEDIAT, V172, DOI [10.1001/jamapediatrics.2018.0016e180016, DOI 10.1001/JAMAPEDIATRICS.2018.0016E180016]
   Dempsey AF, 2018, ACAD PEDIATR, V18, pS23, DOI 10.1016/j.acap.2017.09.001
   Dube E, 2016, QUAL HEALTH RES, V26, P411, DOI 10.1177/1049732315573207
   Gagneur A, 2018, J INFECT DIS THER, V6, P5, DOI [10.4172/2332-0877.1000379, DOI 10.4172/2332-0877.1000379]
   Gagneur A, 2013, U SHERBROOKE CTR HOS
   Gagneur A, 2019, HUM VACC IMMUNOTHER, V15, P2446, DOI 10.1080/21645515.2019.1586030
   Gagneur A, 2018, VACCINE, V36, P6553, DOI 10.1016/j.vaccine.2017.10.049
   Gagneur A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5724-y
   Hartzler B, 2015, J SUBST ABUSE TREAT, V55, P52, DOI 10.1016/j.jsat.2015.02.006
   Kirkpatrick DL, 2006, EVALUATING TRAINING
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lemaitre T, 2019, HUM VACC IMMUNOTHER, V15, P732, DOI 10.1080/21645515.2018.1549451
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Madson MB, 2009, J SUBST ABUSE TREAT, V36, P101, DOI 10.1016/j.jsat.2008.05.005
   MILLER WR, 1991, J CLIN PSYCHOL, V47, P444, DOI 10.1002/1097-4679(199105)47:3<444::AID-JCLP2270470320>3.0.CO;2-U
   Moyers TB, 2016, J SUBST ABUSE TREAT, V65, P36, DOI 10.1016/j.jsat.2016.01.001
   Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943
   Shafer MS, 2004, J SUBST ABUSE TREAT, V26, P141, DOI 10.1016/S0740-5472(03)00167-3
   Soderlund LL, 2011, PATIENT EDUC COUNS, V84, P16, DOI 10.1016/j.pec.2010.06.025
   Walters ST, 2005, J SUBST ABUSE TREAT, V29, P283, DOI 10.1016/j.jsat.2005.08.006
   Wheeler M, 2013, HUM VACC IMMUNOTHER, V9, P1782, DOI 10.4161/hv.25959
   WHO, 2019, 10 THREATS GLOB HLTH
NR 28
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 6
PY 2019
VL 37
IS 20
BP 2748
EP 2756
DI 10.1016/j.vaccine.2019.03.076
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2ZV
UT WOS:000468718200014
PM 30954309
DA 2020-05-12
ER

PT J
AU Laconi, A
   Catelli, E
   Cecchinato, M
   Naylor, CJ
AF Laconi, Andrea
   Catelli, Elena
   Cecchinato, Mattia
   Naylor, Clive J.
TI Two similar commercial live attenuated AMPV vaccines prepared by random
   passage of the identical field isolate, have unrelated sequences
SO VACCINE
LA English
DT Article
DE Vaccine; Avian metapneumovirus; Attenuation; Farm vaccine detection
ID TURKEY RHINOTRACHEITIS; VIRUS; VIRULENCE
AB Since late '80 s Avian metapneumovirus subtype A causes sufficient disease in Europe for commercial companies to have started developing live attenuated vaccines. Here, two of those vaccines were fully consensus sequenced alongside their progenitor field strain (#8544). Sequences comparison shows that the attenuation of field strain #8544 was associated with no common substitutions between the two derived vaccines. This finding suggests that the attenuation of field viruses via serial passage on cell cultures or tissues is the result of a random process, rather than a mechanism aiming to achieve a specific sequence. Furthermore, field vaccination strategies would greatly benefit by the unambiguous vaccine markers identified in this study, enabling a prompt and confident vaccines detection. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Laconi, Andrea; Naylor, Clive J.] Univ Liverpool, Dept Infect Biol, Leahurst Campus, Neston CH64 7TE, Cheshire, England.
   [Catelli, Elena] Univ Bologna, Dept Vet Med Sci, Via Tolara di Sopra 50, I-40064 Ozzano Dellemilia, BO, Italy.
   [Cecchinato, Mattia] Univ Padua, Dept Anim Med Prod & Hlth, Viale Univ 16, I-35020 Legnaro, PD, Italy.
RP Laconi, A (reprint author), Ist Zooprofilatt Sperimentale Venezie, Padua, Italy.
EM alaconi@izsvenezie.it
OI CATELLI, ELENA/0000-0002-6232-0857; Laconi, Andrea/0000-0003-0102-7021
CR Brown PA, 2011, J GEN VIROL, V92, P346, DOI 10.1099/vir.0.026740-0
   Catelli E, 2006, VACCINE, V24, P6476, DOI 10.1016/j.vaccine.2006.06.076
   Catelli E, 2010, VACCINE, V28, P916, DOI 10.1016/j.vaccine.2009.10.149
   Cecchinato M, 2014, VACCINE, V32, P4660, DOI 10.1016/j.vaccine.2014.06.030
   COOK JKA, 1989, AVIAN PATHOL, V18, P511, DOI 10.1080/03079458908418623
   JONES RC, 1986, VET REC, V119, P599
   Listorti V, 2017, VACCINE, V35, P5531, DOI 10.1016/j.vaccine.2017.06.021
   Lupini C, 2011, AVIAN PATHOL, V40, P525, DOI 10.1080/03079457.2011.607428
   Mas V, 2011, J VIROL, V85, P12650, DOI 10.1128/JVI.05485-11
   NAYLOR CJ, 1994, VACCINE, V12, P1225, DOI 10.1016/0264-410X(94)90248-8
   Naylor CJ, 2007, J GEN VIROL, V88, P1767, DOI 10.1099/vir.0.82755-0
   WILDING GP, 1986, VET REC, V118, P735, DOI 10.1136/vr.118.26.735-b
   WILLIAMS RA, 1991, AVIAN PATHOL, V20, P45, DOI 10.1080/03079459108418740
   Yun BL, 2015, SCI REP-UK, V5, DOI 10.1038/srep15584
NR 14
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2765
EP 2767
DI 10.1016/j.vaccine.2019.04.036
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400001
PM 31003913
DA 2020-05-12
ER

PT J
AU Wang, B
   Santoreneos, R
   Giles, L
   Afzali, HHA
   Marshall, H
AF Wang, Bing
   Santoreneos, Renee
   Giles, Lynne
   Afzali, Hossein Haji Ali
   Marshall, Helen
TI Case fatality rates of invasive meningococcal disease by serogroup and
   age: A systematic review and meta-analysis
SO VACCINE
LA English
DT Review
DE Meningococcal; Systematic review; Case fatality rates; Age; Serogroup
ID CHANGING EPIDEMIOLOGY; SEQUENCE TYPE; ENGLAND; WALES; BURDEN; AUSTRALIA;
   SUSCEPTIBILITY; NETHERLANDS; POPULATION; HAJJ
AB Introduction: Invasive meningococcal disease (IMD) is uncommon but still causes considerable public health burden due to its high mortality and morbidity. This review aims to quantitatively synthesise all published evidence pertinent to mortality caused by IMD and assess the effect of age and serogroup on case fatality rates (CFRs).
   Methods: The PubMed and Embase databases, and the Cochrane Library were searched. Articles reporting national CFRs and published in English between January 2000 and May 2018 were eligible. The studies reporting mortality resulting from a specific symptom of IMD (e.g. meningococcal meningitis) were excluded. Mixed-effects logistic regression with a restricted cubic spline was used to analyse CFRs as a function of age. Random-effects meta-analyses were performed to estimate an overall CFR and CFRs by serogroup.
   Results: Among 48 eligible studies reporting national CFRs, 40 studies were included in meta-analyses representing 163,758 IMD patients. CFRs ranged from 4.1% to 20.0% with the pooled overall CFR of 8.3% (95% confidence interval (CI): 7.5-9.1%). Serogroup B was associated with a lower pooled CFR (6.9% (95%Cl: 6.0-7.8%)) than other serogroups (W: 12.8% (95%Cl: 10.7-15.0%); C: 12.0% (95%Cl: 10.5-13.5%); Y: 10.8% (95%Cl: 8.2-13.4%)). The meta-analysis was not performed for serogroup A (MenA) cases due to a small number of MenA patients who were enrolled in eligible studies. For laboratory confirmed IMD cases, the predicted CFR was 9.0% in infants, gradually decreased to 7.0% in 7-year olds, subsequently increased to 15.0% in young adults aged 28 years, stabilised between 15 and 20% in mid-aged adults and reached a high in elderly people.
   Conclusions: Our findings can provide useful information for better understanding the mortality risks, and quantifying the burden associated with IMD mortality. (C) 2019 Published by Elsevier Ltd.
C1 [Wang, Bing; Marshall, Helen] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.
   [Wang, Bing; Marshall, Helen] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia.
   [Wang, Bing; Giles, Lynne; Afzali, Hossein Haji Ali; Marshall, Helen] Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia.
   [Wang, Bing; Marshall, Helen] Womens & Childrens Hosp, VIRTU, Adelaide, SA, Australia.
   [Santoreneos, Renee] Womens & Childrens Hosp, Adelaide, SA, Australia.
RP Marshall, H (reprint author), Womens & Childrens Hosp, VIRTU, Adelaide, SA, Australia.
EM bing.wang@adelaide.edu.au; renee.santoreneos@gmail.com;
   lynne.giles@adelaide.edu.au; hossein.hajialiafzali@adelaide.edu.au;
   helen.marshall@adelaide.edu.au
OI Giles, Lynne/0000-0001-9054-9088
FU National Health and Medical Research Council (NHMRC, Australia) Career
   Development FellowshipNational Health and Medical Research Council of
   Australia [1084951]
FX HM is supported by the National Health and Medical Research Council
   (NHMRC, Australia) Career Development Fellowship (1084951). Authors are
   grateful for the generous support provided by Mr Mark McMillan, Dr
   Stuart Howell, and Dr Hannah Christensen. Authors would also like to
   thank Prof Anna Skoczyliska, Ms Eisin McDonald, Dr Germaine Hanquet, and
   Dr Shamez Ladhani for kindly providing additional information.
CR Archer BN, 2017, MED J AUSTRALIA, V207, P382, DOI 10.5694/mja16.01340
   Baccarini C, 2013, HUM VACC IMMUNOTHER, V9, P162, DOI 10.4161/hv.22302
   Baker M G, 2001, J Paediatr Child Health, V37, pS13, DOI 10.1046/j.1440-1754.2001.00722.x
   Balding J, 2003, GENES IMMUN, V4, P533, DOI 10.1038/sj.gene.6364020
   Ben-Shimol S, 2013, INFECTION, V41, P791, DOI 10.1007/s15010-013-0439-6
   Bradburn MJ, 1999, STATA TECHN B, V8
   Bramham K, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2301
   Brotherton J, 2004, COMMUN DIS INTELL S2, V28, pS41
   Brotherton J, 2007, COMMUN DIS INTELL, V31, pS1
   Chiu Clayton, 2010, Commun Dis Intell Q Rep, V34 Supp, pS1
   Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6
   Cizman M, 2001, INT J ANTIMICROB AG, V17, P27, DOI 10.1016/S0924-8579(00)00309-5
   Cohn AC, 2010, CLIN INFECT DIS, V50, P184, DOI 10.1086/649209
   Dale AP, 2013, EXPERT REV ANTI-INFE, V11, P187, DOI [10.1586/ERI.12.161, 10.1586/eri.12.161]
   Darton T, 2009, CLIN INFECT DIS, V48, P587, DOI 10.1086/596707
   Daures M, 2015, J CLIN IMMUNOL, V35, P47, DOI 10.1007/s10875-014-0104-6
   Davison K L, 2002, Commun Dis Public Health, V5, P213
   de Greeff SC, 2008, EUR J CLIN MICROBIOL, V27, P985, DOI 10.1007/s10096-008-0535-1
   Dey A, 2016, COMMUN DIS INTELL, V40, pS1
   du Chatelet IP, 2017, J INFECTION, V74, P564, DOI 10.1016/j.jinf.2017.02.011
   Edge C, 2016, J INFECTION, V73, P427, DOI 10.1016/j.jinf.2016.07.016
   European Centre for Disease Prevention and Control, ANN EP REP 2016 INV
   Gil-Prieto R, 2011, VACCINE, V29, P5765, DOI 10.1016/j.vaccine.2011.05.089
   Goldacre MJ, 2013, J PUBLIC HEALTH-UK, V35, P413, DOI 10.1093/pubmed/fdt004
   Goldacre MJ, 2003, BRIT MED J, V327, P596, DOI 10.1136/bmj.327.7415.596
   Gottfredsson M, 2006, EMERG INFECT DIS, V12, P1066
   Gottfredsson M, 2011, CLIN INFECT DIS, V53, pE117, DOI 10.1093/cid/cir500
   Gray SJ, 2006, J MED MICROBIOL, V55, P887, DOI 10.1099/jmm.0.46288-0
   Gunaratnam P, 2013, WEST PAC SURVEILL RE, V4, P4, DOI [10.5365/WPSAR.2013.4.4.001, 10.5365/wpsar.2013.4.4.001]
   Hahne SJM, 2002, LANCET, V359, P582, DOI 10.1016/S0140-6736(02)07716-4
   Hanquet GC, 2014, KCE REPORTS, V231
   Harrell Jr FE, 2015, SPRINGER SER STAT, DOI DOI 10.1007/978-3-319-19425-7
   Harrison LH, 2006, CLIN MICROBIOL REV, V19, P142, DOI 10.1128/CMR.19.1.142-164.2006
   Hart CA, 2006, BMJ-BRIT MED J, V333, P685, DOI 10.1136/bmj.38968.683958.AE
   Howitz M, 2009, EPIDEMIOL INFECT, V137, P1631, DOI 10.1017/S0950268809002428
   Husain EH, 2015, J INFECT PUBLIC HEAL, V8, P441, DOI 10.1016/j.jiph.2015.01.009
   Institute TJB, 2016, JOANN BRIGGS I REV M
   Knol MJ, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.16.18-00158
   Knol MJ, 2017, LANCET PUBLIC HEALTH, V2, pE473, DOI 10.1016/S2468-2667(17)30157-3
   Ladhani SN, 2015, CLIN INFECT DIS, V60, P578, DOI 10.1093/cid/ciu881
   Ladhani SN, 2012, VACCINE, V30, P3710, DOI 10.1016/j.vaccine.2012.03.011
   Ladhani SN, 2012, EMERG INFECT DIS, V18, P63, DOI 10.3201/eid1801.110901
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   MacNeil JR, 2018, CLIN INFECT DIS, V66, P1276, DOI 10.1093/cid/cix993
   Martin NV, 2016, COMMUN DIS INTELL, V40, pE454
   Martinon-Torres F, 2016, J ADOLESCENT HEALTH, V59, pS12, DOI 10.1016/j.jadohealth.2016.03.041
   Mayer LW, 2002, J INFECT DIS, V185, P1596, DOI 10.1086/340414
   McDonald EJF, 2014, EPIDEMIOLOGY INVASIV
   McIntyre P, 2002, COMMUN DIS INTELL S, V2002, P32
   Memish Z, 2013, EUROSURVEILLANCE, V18, P11
   Muscat M, 2009, J MED MICROBIOL, V58, P1492, DOI 10.1099/jmm.0.011312-0
   Parikh SR, 2018, VACCINE, V36, P3876, DOI 10.1016/j.vaccine.2018.02.038
   Perrocheau A, 2005, Euro Surveill, V10, P238
   Piscopo T, 2000, EUR J EPIDEMIOL, V16, P1051, DOI 10.1023/A:1010865315425
   Roed C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009662
   Montero JMSR, 2009, J INFECTION, V58, P15, DOI 10.1016/j.jinf.2008.10.009
   Ruedin HJ, 2004, EUR J CLIN MICROBIOL, V23, P517, DOI 10.1007/s10096-004-1159-8
   Sadarangani M, 2015, CLIN INFECT DIS, V60, pE27, DOI 10.1093/cid/civ028
   Schrauder A, 2007, EPIDEMIOL INFECT, V135, P657, DOI 10.1017/S0950268806007151
   Shigematsu M, 2002, EPIDEMIOL INFECT, V129, P459, DOI 10.1017/S0950268802007549
   Skoczynska A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071943
   Squires S G, 2004, Can Commun Dis Rep, V30, P17
   Squires S G, 2000, Can Commun Dis Rep, V26, P177
   Sridhar S, 2015, LANCET INFECT DIS, V15, P1334, DOI 10.1016/S1473-3099(15)00217-0
   Steindl G, 2011, WIEN KLIN WOCHENSCHR, V123, P10, DOI 10.1007/s00508-011-0058-0
   Stoof SP, 2015, CLIN INFECT DIS, V61, P1281, DOI 10.1093/cid/civ506
   Strifler L, 2016, J PEDIAT INF DIS SOC, V5, P417, DOI 10.1093/jpids/piv065
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Trotter CL, 2002, J MED MICROBIOL, V51, P855, DOI 10.1099/0022-1317-51-10-855
   Vyse A, 2013, EXPERT REV ANTI-INFE, V11, P597, DOI [10.1586/ERI.13.42, 10.1586/eri.13.42]
   Wang B, 2018, PHARMACOECONOMICS, V36, P1201, DOI 10.1007/s40273-018-0679-5
   WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390
   Whittaker R, 2017, VACCINE, V35, P2034, DOI 10.1016/j.vaccine.2017.03.007
   Yezli S, 2016, INT J INFECT DIS, V47, P60, DOI 10.1016/j.ijid.2016.04.007
NR 74
TC 6
Z9 5
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2768
EP 2782
DI 10.1016/j.vaccine.2019.04.020
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400002
PM 30987851
DA 2020-05-12
ER

PT J
AU Abdellrazeq, GS
   Elnaggar, MM
   Bannantine, JP
   Schneider, DA
   Souza, CD
   Hwang, J
   Mahmoud, AHA
   Hulubei, V
   Fry, LM
   Park, KT
   Davis, WC
AF Abdellrazeq, Gaber S.
   Elnaggar, Mahmoud M.
   Bannantine, John P.
   Schneider, David A.
   Souza, Cleverson D.
   Hwang, Julianne
   Mahmoud, Asmaa H. A.
   Hulubei, Victoria
   Fry, Lindsay M.
   Park, Kun-Taek
   Davis, William C.
TI A peptide-based vaccine for Mycobacterium avium subspecies
   paratuberculosis
SO VACCINE
LA English
DT Article
DE Zoonotic pathogen; Mycobacterium avium subspecies; paratuberculosis;
   Propidium monoazide; Flow cytometry; Intracellular killing; Monocyte
   derived dendritic cells; Cytotoxic T cells; Bovine
ID MONOPHOSPHORYL-LIPID-A; MUTANTS; DISEASE; PROTEIN; CATTLE; TUBERCULOSIS;
   CANDIDATES; EXPRESSION; CHALLENGE; STIMULATE
AB Recent efforts to develop a live attenuated vaccine against Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of Johne's disease (JD), revealed relA is important in Map virulence. Deletion of the relA gene impairs the ability of Map to establish a persistent infection. Analysis of the basis for this observation revealed infection with a relA deletion mutant (Delta relA) elicits development of cytotoxic CD8 T cells (CTL) with the ability to kill intracellular bacteria. Further analysis of the recall response elicited by Delta relA vaccination showed a 35 kDa membrane peptide (MMP) is one of the targets of the immune response, suggesting it might be possible to develop a peptide-based vaccine based on MMP. To explore this possibility, ex vivo vaccination studies were conducted with MMP alone and incorporated into a nanoparticle (NP) vector comprised of poly (D, L-lactide-co-glycolide) and monophosphoryl lipid A (PLGA/MPLA). As reported, ex vivo vaccination studies showed CD8 CTL were elicited with classic and monocyte derived dendritic cells (cDC and MoDC) pulsed with MMP alone and incorporated into a PGLA/MPLA vector. Incorporation of MMP into a NP vector enhanced the ability of CD8 CTL to kill intracellular bacteria. The findings indicate incorporation of MMP into a PGLAIMPLA nanoparticle vector is one of the possible ways to develop a MMP based vaccine for Johne's disease. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Abdellrazeq, Gaber S.; Elnaggar, Mahmoud M.; Schneider, David A.; Mahmoud, Asmaa H. A.; Hulubei, Victoria; Fry, Lindsay M.; Davis, William C.] Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA.
   [Abdellrazeq, Gaber S.; Elnaggar, Mahmoud M.] Alexandria Univ, Fac Vet Med, Dept Microbiol, Alexandria, Egypt.
   [Bannantine, John P.] ARS, USDA, Natl Anim Dis Ctr, Ames, IA USA.
   [Schneider, David A.; Fry, Lindsay M.] ARS, USDA, Anim Dis Res Unit, Pullman, WA USA.
   [Souza, Cleverson D.; Hwang, Julianne] Washington State Univ, Dept Vet Clin Sci, Pullman, WA 99164 USA.
   [Mahmoud, Asmaa H. A.] Vet Quarantine Alexandria, Minist Agr, Gen Org Vet Serv, Alexandria, Egypt.
   [Park, Kun-Taek] Inje Univ, Dept Biotechnol, Injero 197, Kimhae Si, Gyeongsangnam D, South Korea.
RP Davis, WC (reprint author), Washington State Univ, Dept Vet Microbiol Pathol, PO 647040, Pullman, WA 99164 USA.
EM davisw@wsu.edu
RI Abdellrazeq, Gaber/C-7667-2015; Schneider, David/A-2833-2010
OI Abdellrazeq, Gaber/0000-0002-8677-911X; Fry,
   Lindsay/0000-0003-0938-9254; Park, Kun Taek/0000-0001-6177-0373;
   Elnaggar, Mahmoud/0000-0003-4501-7722; Schneider,
   David/0000-0001-9659-6731; Hwang, Julianne/0000-0002-9222-1729
FU State Univ.
FX Support was provided by the Wash. State Univ. Monoclonal Antibody
   Center.
CR Abdellrazeq GS, 2018, VET RES, V49, DOI 10.1186/s13567-018-0549-3
   Alonso-Hearn M, 2012, J DAIRY SCI, V95, P618, DOI 10.3168/jds.2009-2860
   Bannantine JP, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00126
   Bannantine JP, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00088
   Bannantine JP, 2012, CLIN VACCINE IMMUNOL, V19, P1083, DOI 10.1128/CVI.00195-12
   Bannantine JP, 2010, PROTEIN EXPRES PURIF, V72, P223, DOI 10.1016/j.pep.2010.03.019
   Bannantine JP, 2003, MICROBIOL-SGM, V149, P2061, DOI 10.1099/mic.0.26323-0
   Bannantine JP, 2014, GENOME ANNOUNC, V2
   Chen JW, 2012, VACCINE, V30, P3015, DOI 10.1016/j.vaccine.2011.11.029
   Corripio-Miyar Y, 2015, VET RES, V46, DOI 10.1186/s13567-015-0246-4
   Dahl JL, 2003, P NATL ACAD SCI USA, V100, P10026, DOI 10.1073/pnas.1631248100
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Dowling JK, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.22
   Elnaggar MM, 2016, VET IMMUNOL IMMUNOP, V178, P57, DOI 10.1016/j.vetimm.2016.06.010
   Faisal SM, 2013, CLIN VACCINE IMMUNOL, V20, P572, DOI 10.1128/CVI.00653-12
   Fichter M, 2015, VACCINE, V33, P838, DOI 10.1016/j.vaccine.2014.12.072
   Harris NB, 2001, CLIN MICROBIOL REV, V14, P489, DOI 10.1128/CMR.14.3.489-512.2001
   Hauryliuk V, 2015, NAT REV MICROBIOL, V13, P298, DOI 10.1038/nrmicro3448
   Hruska K, 2014, VET MED-CZECH, V59, P583, DOI 10.17221/7822-VETMED
   Juste Ramon A, 2009, BMC Res Notes, V2, P233, DOI 10.1186/1756-0500-2-233
   Kralik P, 2010, INT J FOOD MICROBIOL, V141, pS80, DOI 10.1016/j.ijfoodmicro.2010.03.018
   Leite FL, 2015, VET MICROBIOL, V175, P275, DOI 10.1016/j.vetmic.2014.11.009
   Li LL, 2007, CLIN VACCINE IMMUNOL, V14, P102, DOI 10.1128/CVI.00138-06
   Park KT, 2008, APPL ENVIRON MICROB, V74, P1687, DOI 10.1128/AEM.01208-07
   Park KT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165247
   Park KT, 2015, VET IMMUNOL IMMUNOP, V168, P118, DOI 10.1016/j.vetimm.2015.09.002
   Park KT, 2015, VET IMMUNOL IMMUNOP, V163, P216, DOI 10.1016/j.vetimm.2014.12.008
   Park KT, 2014, J MICROBIOL METH, V99, P58, DOI 10.1016/j.mimet.2014.02.003
   Park KT, 2011, VACCINE, V29, P4709, DOI 10.1016/j.vaccine.2011.04.090
   Planesse C, 2015, CYTOKINE, V73, P190, DOI 10.1016/j.cyto.2015.01.028
   Schonenbrucher H, 2008, APPL ENVIRON MICROB, V74, P2751, DOI 10.1128/AEM.02534-07
   Settles EW, 2014, VACCINE, V32, P2062, DOI 10.1016/j.vaccine.2014.02.010
   Singh K, 2013, VET RES COMMUN, V37, P109, DOI 10.1007/s11259-013-9551-4
   Singh S. V., 2014, Journal of Public Health and Epidemiology, V6, P20
   Singh SV, 2016, FRONT MED-LAUSANNE, V3, DOI 10.3389/fmed.2016.00049
   Souza CD, 2017, J APPL MICROBIOL, V123, P54, DOI 10.1111/jam.13491
   Souza C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075924
   Sweeney RW, 2009, AM J VET RES, V70, P493, DOI 10.2460/ajvr.70.4.493
   Wang DB, 2013, EXPERT OPIN BIOL TH, V13, P1639, DOI 10.1517/14712598.2013.838556
   Weiss LA, 2013, J BACTERIOL, V195, P5629, DOI 10.1128/JB.00759-13
   Zhang YJ, 2016, EXP PARASITOL, V170, P73, DOI 10.1016/j.exppara.2016.09.003
NR 41
TC 3
Z9 3
U1 3
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2783
EP 2790
DI 10.1016/j.vaccine.2019.04.040
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400003
PM 31003915
DA 2020-05-12
ER

PT J
AU Bercovich, S
   Anis, E
   Kassem, E
   Rubinstein, U
   Ephros, M
   Cohen, D
   Muhsen, K
AF Bercovich, Shayel
   Anis, Emilia
   Kassem, Eias
   Rubinstein, Uri
   Ephros, Moshe
   Cohen, Dani
   Muhsen, Khitam
TI Validation of parental reports of rotavirus vaccination of their
   children compared to the national immunization registry
SO VACCINE
LA English
DT Article
DE Validity; Parental report; Registry; Rotavirus immunization;
   Effectiveness
ID UNIVERSAL IMMUNIZATION; MOTHERS REPORTS; ISRAEL; HOSPITALIZATIONS;
   ACCURACY; VACCINES; AGE
AB Background: The introduction of rotavirus vaccines into national immunization programs necessitates vaccine effectiveness evaluations. Parental report of vaccination status is a simple and accessible source of information; however, its validity is unclear.
   Aims: To validate parental reports of rotavirus immunization compared to documentation of vaccination in national immunization registry, and to assess vaccine effectiveness by each method.
   Methods: Parents of 1272 children aged 2-59 months from northern Israel hospitalized for gastroenteritis in 2011-2015 were interviewed on the sociodemographics and rotavirus vaccination status of their child. Rotavirus immunization status based on parental report was compared to that documented in the national immunization registry, which was considered the gold standard. Stool samples collected from patients were tested for rotavirus antigen by immunochromotgraphy. In a rotavirus test-negative case-control study, vaccination history was compared between children found positive for rotavirus and those who tested negative. Vaccine effectiveness for >= 1 dose vs. zero doses was calculated as: (1-adjusted odds ratio)* 100.
   Results: The sensitivity and specificity of parental report of their child's immunization with a rotavirus vaccine were 97% (95% CI 96-98), and 75% (95% CI 65-82), respectively. Kappa coefficient was 0.69 (p < 0.001) for the agreement between the two methods. Rotavirus vaccine effectiveness was 72% (95% CI 54-84) when using parental report of rotavirus immunization and 79% (95% CI 62-88) when using the registry.
   Conclusion: Parental report of their child's immunization with a rotavirus vaccine demonstrated high sensitivity, although the specificity was relatively low. Vaccine effectiveness was similar regardless of method used to determine rotavirus immunization status. Parental report of vaccination status can be useful in vaccine effectiveness assessment. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bercovich, Shayel; Cohen, Dani; Muhsen, Khitam] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, IL-69978 Tel Aviv, Israel.
   [Anis, Emilia] Minist Hlth, Div Epidemiol, Jerusalem, Israel.
   [Kassem, Eias] Hillel Yaffe Med Ctr, Dept Pediat, Hadera, Israel.
   [Rubinstein, Uri] Laniado Med Ctr, Dept Pediat, Netanya, Israel.
   [Ephros, Moshe] Carmel Hosp, Dept Pediat, Haifa, Israel.
   [Ephros, Moshe] Technion Israel Inst Technol, Fac Med, Haifa, Israel.
RP Muhsen, K (reprint author), Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, IL-69978 Tel Aviv, Israel.
EM kmuhsen@post.tau.ac.il
OI Cohen, Daniel/0000-0003-2664-2303
FU Department of Immunization, Vaccination and Biologicals [V27-181-190];
   Israel National Institute for Health Policy and Research
   [2011/154(DC-PI)]
FX This work was supported by the, Department of Immunization, Vaccination
   and Biologicals (V27-181-190) in the first year and by the Israel
   National Institute for Health Policy and Research (grant
   (2011/154(DC-PI). The funding agencies had no role in the study design;
   collection, analysis and interpretation of data; writing or submitting
   the article to publication.
CR Anis E, 2013, EUROSURVEILLANCE, V18, P2, DOI 10.2807/1560-7917.ES2013.18.38.20586
   Araujo CLP, 2007, CAD SAUDE PUBLICA, V23, P2421, DOI 10.1590/S0102-311X2007001000017
   Bat-Erdene U, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-S1-S3
   Binyaruka P, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3270-z
   Blanc AK, 2016, J GLOB HLTH, V6
   Cohen D, 2006, VACCINE, V24, P5604, DOI 10.1016/j.vaccine.2006.04.024
   GAREABALLAH ET, 1989, B WORLD HEALTH ORGAN, V67, P669
   George K, 1990, Indian J Pediatr, V57, P588, DOI 10.1007/BF02726779
   Immunization VaB Wold Health Organization., 2005, GUID EST EC BURD DIA
   Israel Central Bureau of Statistics, 2013, CHAR CLASS LOC GEOGR
   Langsten R, 1998, SOC SCI MED, V46, P1205, DOI 10.1016/S0277-9536(97)10049-1
   Liu L., 2013, PLOS ONE, V8
   Muhsen K, 2018, CLIN MICROBIOL INFEC, V24, P53, DOI 10.1016/j.cmi.2017.04.018
   Muhsen K, 2017, HUM VACC IMMUNOTHER, V13, P1722, DOI 10.1080/21645515.2017.1297908
   Muhsen K, 2016, VACCINE, V34, P5916, DOI 10.1016/j.vaccine.2016.10.021
   Muhsen K, 2015, HUM VACC IMMUNOTHER, V11, P2475, DOI 10.1080/21645515.2015.1056951
   Muhsen K, 2011, VACCINE, V29, P3878, DOI 10.1016/j.vaccine.2011.03.047
   Muhsen K, 2010, HUM VACCINES, V6, P450, DOI 10.4161/hv.6.6.11759
   Muhsen K, 2009, J INFECT DIS, V200, pS254, DOI 10.1086/605425
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Stein-Zamir C, 2011, PROCEDIA VACCINOL, V4, DOI 10.1016/j.provac.2011.07.002
   Stein-Zamir C, 2010, ISR MED ASSOC J, V12, P296
   Suarez L, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e3
   Tasher D, 2016, VACCINE, V34, P299, DOI 10.1016/j.vaccine.2015.11.066
   Travassos MA, 2015, AM J TROP MED HYG, V93, P416, DOI 10.4269/ajtmh.15-0198
   VALADEZ JJ, 1992, AM J PUBLIC HEALTH, V82, P120, DOI 10.2105/AJPH.82.1.120
   Weinberg GA, 2010, J INFECT DIS, V201, P1607, DOI 10.1086/652404
   Wold Health Organization. Immunization coverage, IMM VACC BIOL
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2791
EP 2796
DI 10.1016/j.vaccine.2019.04.037
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400004
PM 31003916
DA 2020-05-12
ER

PT J
AU Kim, JH
   Chun, BC
   Song, JY
   Kim, HY
   Bae, IG
   Kim, DM
   Choi, YH
   Jun, YH
   Choi, WS
   Kang, SH
   Kwon, HH
   Jeong, HW
   Kee, SY
   Hur, J
   Chung, JW
   Yoon, YK
   Sohn, JW
   Yang, KS
   Kim, MJ
AF Kim, Jong Hun
   Chun, Byung Chul
   Song, Joon Young
   Kim, Hyo Youl
   Bae, In-Gyu
   Kim, Dong-Min
   Choi, Young Hwa
   Jun, Yoon Hee
   Choi, Won Suk
   Kang, Seong Hee
   Kwon, Hyun Hee
   Jeong, Hye Won
   Kee, Sae Yoon
   Hur, Jian
   Chung, Jin Won
   Yoon, Young Kyung
   Sohn, Jang Wook
   Yang, Kyung Sook
   Kim, Min Ja
TI Direct effectiveness of pneumococcal polysaccharide vaccine against
   invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia
   in elderly population in the era of pneumococcal conjugate vaccine: A
   case-control study
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; 23-valent pneumococcal vaccine; Effectiveness;
   Case-control study; Pneumococcal infections
ID COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE;
   ANTIBIOTIC-RESISTANCE; SEROTYPE DISTRIBUTION; GENERAL-POPULATION;
   OPTIONAL USE; ADULTS; IMMUNIZATION; ENGLAND; KOREA
AB Background: While herd effects and serotype replacement by childhood pneumococcal protein conjugated vaccines (PCVs) continues to accumulate worldwide, direct effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal diseases in the elderly has been challenged. We estimated the direct effectiveness of PPV23 in the elderly population.
   Methods: For a hospital-based case-control study, cases of invasive pneumococcal disease (IPD) and non-bacteremic pneumococcal pneumonia (NBPP) (adults >= 65 years) were identified in 14 hospitals participated in the pneumococcal surveillance program from March 2013 to October 2015, following implementation of PPV23 national immunization program (NIP) for the elderly in the Republic of Korea. Controls matched by age, sex, and hospital were selected at ratios of 1:2 (IPD) or 1:1 (NBPP). Clinical data and vaccination records were collected. Vaccine effectiveness was calculated as (1-adjusted odds ratio) x 100.
   Results: We enrolled 148 IPD and 557 NBPP cases, and 295 IPD and 557 NBPP controls for analyses. Overall effectiveness of PPV23 against IPD was 28.5% [95% confidence interval (CI) -5.8%-51.6%] and against NBPP was 10.2% (-15.1-30.6) in all patients >= 65 years. However, in subgroup analysis of patients aged 65-74 years, PPV23 was protective against IPD [effectiveness 57.4% (19.4-77.5)] and against NBPP [effectiveness 35.0% (2.3-56.7)]. Furthermore, serotype-specific effectiveness of PPV23 against IPD was 90.6% (27.6-98.8) for PPV23-unique serotypes and 81.3% (38.6-94.3) for PPV23 serotypes excluding serotype 3.
   Conclusions: This study indicates that PPV23 with broad serotype coverage might be beneficial in preventing IPD and NBPP due to non-PCV13 serotypes in the young-elderly, with potentially increasing effectiveness in the setting of childhood PCV NIP. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kim, Jong Hun; Yoon, Young Kyung; Sohn, Jang Wook; Kim, Min Ja] Korea Univ, Dept Internal Med, Div Infect Dis, Anam Hosp,Coll Med, Inchon Ro 73, Seoul 02841, South Korea.
   [Chun, Byung Chul] Korea Univ, Dept Prevent Med, Coll Med, Seoul, South Korea.
   [Song, Joon Young] Korea Univ, Guro Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Seoul, South Korea.
   [Kim, Hyo Youl] Yonsei Univ, Wonju Coll Med, Dept Internal Med, Wonju, South Korea.
   [Bae, In-Gyu] Gyeongsang Natl Univ, Sch Med, Gyeongsang Natl Univ Hosp, Dept Internal Med, Jinju, South Korea.
   [Kim, Dong-Min] Chosun Univ, Coll Med, Dept Internal Med, Gwangju, South Korea.
   [Choi, Young Hwa] Ajou Univ Hosp, Internal Med, Dept Infect Dis, Suwon, South Korea.
   [Jun, Yoon Hee] Cheju Halla Gen Hosp, Dept Internal Med, Jeju Si, South Korea.
   [Choi, Won Suk] Korea Univ, Dept Internal Med, Div Infect Dis, Ansan Hosp,Coll Med, Ansan, South Korea.
   [Kang, Seong Hee] Konyang Univ, Coll Med, Dept Internal Med, Daejeon, South Korea.
   [Kwon, Hyun Hee] Daegu Catholic Univ, Dept Internal Med, Daegu, South Korea.
   [Jeong, Hye Won] Chungbuk Natl Univ, Coll Med, Dept Internal Med, Div Infect Dis, Cheongju, South Korea.
   [Kee, Sae Yoon] Sahmyook Med Ctr, Dept Internal Med, Div Infect Dis, Seoul, South Korea.
   [Hur, Jian] Yeungnam Univ, Med Ctr, Dept Internal Med, Daegu, South Korea.
   [Chung, Jin Won] Chung Ang Univ Hosp, Dept Internal Med, Div Infect Dis, Seoul, South Korea.
   [Yang, Kyung Sook] Korea Univ, Dept Biostat, Coll Med, Seoul, South Korea.
   [Kim, Min Ja] Korea Univ, Res Inst Emerging Infect Dis, Seoul, South Korea.
RP Kim, MJ (reprint author), Korea Univ, Dept Internal Med, Div Infect Dis, Anam Hosp,Coll Med, Inchon Ro 73, Seoul 02841, South Korea.
EM macropha@korea.ac.kr
OI Chun, Byung Chul/0000-0001-6576-8916
FU Korea Centers for Disease Control and Prevention [2015-E32008-00]
FX This research was supported by funding (No. 2015-E32008-00) from the
   Korea Centers for Disease Control and Prevention.
CR Andrews NJ, 2012, VACCINE, V30, P6802, DOI 10.1016/j.vaccine.2012.09.019
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Cho EY, 2014, DIAGN MICR INFEC DIS, V78, P481, DOI 10.1016/j.diagmicrobio.2013.12.016
   Cho EY, 2012, J KOREAN MED SCI, V27, P716, DOI 10.3346/jkms.2012.27.7.716
   Choi MJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008429
   Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010
   Curcio D, 2015, INT J INFECT DIS, V37, P30, DOI 10.1016/j.ijid.2015.05.003
   Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368
   Rodriguez MAG, 2014, EUROSURVEILLANCE, V19, P35, DOI 10.2807/1560-7917.ES2014.19.40.20922
   Harboe ZB, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000081
   Htar MTT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177985
   Kim JH, 2018, INT J INFECT DIS, V74, P136, DOI 10.1016/j.ijid.2018.07.018
   Korea Centers for Disease Control and Prevention, 2014, PHWR, V7, P449
   Kraicer-Melamed H, 2016, VACCINE, V34, P4083, DOI 10.1016/j.vaccine.2016.06.045
   Kraicer-Melamed H, 2016, VACCINE, V34, P1540, DOI 10.1016/j.vaccine.2016.02.024
   Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5
   Moberley S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub3
   Ochoa-Gondar O, 2014, CLIN INFECT DIS, V58, P909, DOI 10.1093/cid/ciu002
   Poolman J, 2009, VACCINE, V27, P3213, DOI 10.1016/j.vaccine.2009.03.017
   Romero-Steiner S, 1999, CLIN INFECT DIS, V29, P281, DOI 10.1086/520200
   Rozenbaum MH, 2013, EUR J CLIN MICROBIOL, V32, P305, DOI 10.1007/s10096-012-1778-4
   SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101
   Statistics Korea, EXPL KOR STAT 2018
   Suzuki M, 2017, LANCET INFECT DIS, V17, P313, DOI [10.1016/S1473-3099(17)30049-X, 10.1016/s1473-3099(17)30049-x]
   Tsaban G, 2017, VACCINE, V35, P2882, DOI 10.1016/j.vaccine.2017.04.032
   Tsai YH, 2015, VACCINE, V33, P2897, DOI 10.1016/j.vaccine.2015.04.068
   Yang TU, 2016, VACCINE, V34, P1623, DOI 10.1016/j.vaccine.2016.01.043
   Yu JG, 2011, CLIN VACCINE IMMUNOL, V18, P1900, DOI 10.1128/CVI.05312-11
NR 28
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2797
EP 2804
DI 10.1016/j.vaccine.2019.04.017
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400005
PM 31005428
DA 2020-05-12
ER

PT J
AU Narean, JS
   Glanville, N
   Nunn, CM
   Niespodziana, K
   Valenta, R
   Johnston, SL
   McLean, GR
AF Narean, Janakan Sam
   Glanville, Nicholas
   Nunn, Christine M.
   Niespodziana, Katarzyna
   Valenta, Rudolf
   Johnston, Sebastian L.
   McLean, Gary R.
TI Epitope mapping of antibodies induced with a conserved rhinovirus
   protein generating protective anti-rhinovirus immunity
SO VACCINE
LA English
DT Article
DE Rhinovirus; Subunit vaccine; Antibodies; Epitope; Neutralisation
ID NEUTRALIZING ANTIBODY; MONOCLONAL-ANTIBODIES; NUMBERING SYSTEM; CAPSID
   PROTEIN; VACCINE; INFECTION; CELLS; RECEPTOR; PEPTIDE; VIRUS
AB Human rhinovirus (RV) infections are the principle cause of common colds and precipitate asthma and chronic obstructive pulmonary disease (COPD) exacerbations. Currently there is no vaccine for RV which is largely due to the existence of similar to 160 serotypes/strains. We demonstrated previously that immunising mice with highly conserved VP4 and VP2 regions of the RV polyprotein (RV-A16 VP0) generated cross-reactive immunity to RV in vivo. The current study investigated and mapped the epitopes of RV-A16 VP0 that are targets for antibodies in serum samples from VP0 immunisation and RV challenge studies in mice. Recombinant capsid proteins, peptide pools and individual peptides spanning the immunogen sequence (RV-Al 6 VP0) were assessed for IgG binding sites to identify epitopes. We found that peptide pools covering the C-terminus of VP4, the N-terminus of VP2 and the neutralising Nlm-II site within VP2 were bound by serum IgG from immunised mice. The Nlm-II site peptide pool blocked IgG binding to the immunogen RV-A16 VP0 and individual peptides within the pool binding IgG were further mapped. Thus, we have identified immunodominant epitopes of RV vaccine candidate RV-A16 VP0, noting that strong IgG binding antibodies were observed that target a key neutralising epitope that is highly variable amongst RV serotypes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Narean, Janakan Sam; Nunn, Christine M.; McLean, Gary R.] London Metropolitan Univ, Sch Human Sci, Cellular & Mol Immunol Res Ctr, London, England.
   [Narean, Janakan Sam; Glanville, Nicholas; Johnston, Sebastian L.; McLean, Gary R.] Imperial Coll London, Natl Heart & Lung Inst, Airway Dis Sect, London, England.
   [Niespodziana, Katarzyna; Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.
   [Valenta, Rudolf] FMBA Russia, NRC Inst Immunol, Moscow, Russia.
   [Valenta, Rudolf] Sechenov First Moscow State Med Univ, Immunopathol Lab, Dept Clin Immunol & Allergy, Moscow, Russia.
   [Glanville, Nicholas] VirTus Resp Res, London, England.
RP McLean, GR (reprint author), London Metropolitan Univ, Sch Human Sci, Cellular & Mol Immunol Res Ctr, London, England.
EM g.mclean@londonmet.ac.uk
RI Johnston, Sebastian Lennox/I-2423-2012
OI Johnston, Sebastian Lennox/0000-0003-3009-9200; Glanville,
   Nicholas/0000-0003-0946-5050
FU Sanofi Pasteur; MRC Centre Grant [G1000758]; ERCEuropean Research
   Council (ERC) [233015]; European UnionEuropean Union (EU) [260895];
   Austrian Science FundAustrian Science Fund (FWF) [P29398]; Rosetrees
   TrustRosetrees Trust [A684]; Dunhill Medical Trust serendipity award
   [SA29/0513]
FX All authors approve this submission. The authors acknowledge this work
   was supported in part by grants from Sanofi Pasteur (to SLJ), MRC Centre
   Grant G1000758 (to SLJ), ERC Advanced Grant 233015 (to SLJ) the European
   Union FP7 collaborative project grant 260895 (to SLJ and RV), grant
   P29398 of the Austrian Science Fund (to KN), Rosetrees Trust grant A684
   (to NG) and Dunhill Medical Trust serendipity award SA29/0513 (to GRM).
   The funders had no input into study design. Authors NG, SLJ and GRM are
   co inventors of a US patent regarding the rhinovirus vaccine. Authors RV
   and KN are co-inventors of a patent application regarding rhinovirus
   diagnostics by antibodies. JSN, NG and GRM designed and performed
   experiments. CMN created structural images. KN and RV provided reagents.
   JSN, GRM, SLJ and RV analysed data and wrote the paper.
CR Alper CM, 1996, LARYNGOSCOPE, V106, P1298, DOI 10.1097/00005537-199610000-00025
   APPLEYARD G, 1990, J GEN VIROL, V71, P1275, DOI 10.1099/0022-1317-71-6-1275
   BARCLAY WS, 1989, EPIDEMIOL INFECT, V103, P659, DOI 10.1017/S095026880003106X
   Blanco Jorge C G, 2014, Trials Vaccinol, V3, P52
   Bochkov YA, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0608-7
   Bottermann M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37457
   BUSCHO RF, 1972, J IMMUNOL, V108, P169
   CAREY BS, 1992, J MED VIROL, V36, P251, DOI 10.1002/jmv.1890360404
   COLONNO RJ, 1989, J VIROL, V63, P36, DOI 10.1128/JVI.63.1.36-42.1989
   CONANT RM, 1968, J IMMUNOL, V100, P107
   CONANT RM, 1968, J IMMUNOL, V100, P114
   DOGGETT JE, 1963, BMJ-BRIT MED J, P34
   Dong YC, 2017, P NATL ACAD SCI USA, V114, P8017, DOI 10.1073/pnas.1707369114
   DOUGLAS RG, 1972, P SOC EXP BIOL MED, V139, P899
   Edlmayr J, 2011, EUR RESPIR J, V37, P44, DOI 10.1183/09031936.00149109
   Foss S, 2015, IMMUNOL REV, V268, P328, DOI 10.1111/imr.12363
   FOX JP, 1976, AM J EPIDEMIOL, V103, P345, DOI 10.1093/oxfordjournals.aje.a112233
   FRANCIS MJ, 1987, J GEN VIROL, V68, P2687, DOI 10.1099/0022-1317-68-10-2687
   Gaido CM, 2016, J VIROL, V90, P10459, DOI 10.1128/JVI.01701-16
   Gern JE, 1997, J INFECT DIS, V175, P1108, DOI 10.1086/516449
   Glanville N, 2015, CURR OPIN VIROL, V11, P83, DOI 10.1016/j.coviro.2015.03.004
   Glanville N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003669
   Gould VMW, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00900
   Hadfield AT, 1997, STRUCTURE, V5, P427, DOI 10.1016/S0969-2126(97)00199-8
   HAMORY BH, 1975, J INFECT DIS, V132, P623, DOI 10.1093/infdis/132.6.623
   Katpally U, 2009, J VIROL, V83, P7040, DOI 10.1128/JVI.00557-09
   Lee S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12838
   MCCRAY J, 1987, NATURE, V329, P736, DOI 10.1038/329736a0
   McLean GR, 2012, ANTIVIR RES, V95, P193, DOI 10.1016/j.antiviral.2012.06.006
   MITCHISON D A, 1965, Br Med J, V1, P1344
   Muehling LM, 2016, J IMMUNOL, V197, P3214, DOI 10.4049/jimmunol.1600663
   Niespodziana K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04591-0
   Papadopoulos NG, 2017, J ALLERGY CLIN IMMUN, V140, P921, DOI 10.1016/j.jaci.2017.07.001
   Patel MC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01646
   PERKINS JC, 1969, AM J EPIDEMIOL, V90, P319, DOI 10.1093/oxfordjournals.aje.a121076
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0
   SHERRY B, 1986, J VIROL, V57, P246, DOI 10.1128/JVI.57.1.246-257.1986
   SKERN T, 1987, J GEN VIROL, V68, P315, DOI 10.1099/0022-1317-68-2-315
   SMITH TJ, 1993, P NATL ACAD SCI USA, V90, P7015, DOI 10.1073/pnas.90.15.7015
   Smith TJ, 1996, NATURE, V383, P350, DOI 10.1038/383350a0
   Stobart CC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02412
   To KKW, 2017, J FORMOS MED ASSOC, V116, P496, DOI 10.1016/j.jfma.2017.04.009
   TORMO J, 1994, EMBO J, V13, P2247, DOI 10.1002/j.1460-2075.1994.tb06506.x
   TORMO J, 1992, PROTEIN SCI, V1, P1154, DOI 10.1002/pro.5560010909
   Watkinson RE, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005253
   Wimalasundera SS, 1997, J INFECT DIS, V176, P755, DOI 10.1086/514101
NR 47
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2805
EP 2813
DI 10.1016/j.vaccine.2019.04.018
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400006
PM 31003914
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Van Buynder, PG
   Van Buynder, JL
   Menton, L
   Thompson, G
   Sun, J
AF Van Buynder, P. G.
   Van Buynder, J. L.
   Menton, L.
   Thompson, G.
   Sun, J.
TI Antigen specific vaccine hesitancy in pregnancy
SO VACCINE
LA English
DT Article
DE Maternal immunisation; Influenza vaccine; Pertussis vaccine; Vaccine
   hesitancy
ID PERTUSSIS VACCINATION; INFLUENZA VACCINE; WOMEN; IMMUNIZATION;
   ASSOCIATION; SAFETY
AB Background: Vaccinations in pregnancy are recommended for the potential benefits of preventing severe pertussis disease in newborns and for preventing the impact of influenza on the pregnant woman, her foetus in utero and, the newborn in the first six months of life. Published data in Australia suggested that coverage rates were sub-optimal so the reasons for this were reviewed.
   Methods: A cross-sectional survey of 1014 postnatal women, aged 18 years and older, who had given birth in the previous six months was undertaken on the Gold Coast in Queensland, Australia. Participants completed a brief questionnaire on provided smart tablets at public vaccination clinics or with a researcher by phone or via an on-line link.
   Results: Just over 85% of survey respondents received a pertussis booster with many of those not receiving vaccine having had it in a recent pregnancy. Only 36.7% of respondents had an influenza vaccine in pregnancy with key barriers being belief in influenza vaccine, seasonality of parturition and a lack of recommendation from the attending obstetric carers.
   Discussion: While maternal pertussis vaccine programs are a success, work needs to be done to improve the public perception of the risk benefit equation surrounding influenza vaccine in general, and particularly its use in pregnancy. Research is required into approaches to altering practitioner attitudes as well as how to alter public perceptions. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Van Buynder, P. G.; Sun, J.] Griffith Univ, Sch Med, Southport, Qld, Australia.
   [Van Buynder, P. G.; Van Buynder, J. L.; Menton, L.; Thompson, G.] Gold Coast Hlth Serv, Southport, Qld, Australia.
RP Van Buynder, PG (reprint author), 305-230 Marine Parade, Southport, Qld 4215, Australia.
EM pjvb@iinet.net.au; janvb@iinet.net.au; linda.menton@health.qld.gov.au;
   Gina.thompson@health.qld.gov.au; jsun@griffith.edu.au
OI Sun, Jing/0000-0002-0097-2438
CR [Anonymous], IMM COV RAT ALL CHIL
   Blain AE, 2016, CLIN INFECT DIS, V63, pS221, DOI 10.1093/cid/ciw528
   Donahue JG, 2017, VACCINE, V35, P5314, DOI 10.1016/j.vaccine.2017.06.069
   Donegan K, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4219
   Eberhardt CS, 2016, CLIN INFECT DIS, V62, P829, DOI 10.1093/cid/ciw027
   IBM Corporation, 2016, REL IBM SPSS STAT WI
   Kharbanda EO, 2014, JAMA-J AM MED ASSOC, V312, P1897, DOI 10.1001/jama.2014.14825
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   Overton K, 2016, N TERRIT DIS CONTROL, V23, P1
   Pillsbury A, 2014, COMMUN DIS INTELL, V38, pE179
   Puig-Barbera J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154970
   Quinn HE, 2007, COMMUN DIS INTELL, V31, P205
   Taksdal SE, 2013, AUST FAM PHYSICIAN, V42, P582
   Wiley KE, 2013, MED J AUSTRALIA, V198, P373, DOI 10.5694/mja12.11849
NR 15
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2814
EP 2820
DI 10.1016/j.vaccine.2019.04.021
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400007
PM 30992221
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ward, K
   Stewart, S
   Wardle, M
   Sodha, SV
   Tanifum, P
   Ayebazibwe, N
   Mayanja, R
   Luzze, H
   Ehlman, DC
   Conklin, L
   Abbruzzese, M
   Sandhu, HS
AF Ward, Kirsten
   Stewart, Steven
   Wardle, Melissa
   Sodha, Samir V.
   Tanifum, Patricia
   Ayebazibwe, Nicholas
   Mayanja, Robert
   Luzze, Henry
   Ehlman, Daniel C.
   Conklin, Laura
   Abbruzzese, Molly
   Sandhu, Hardeep S.
TI Building health workforce capacity for planning and monitoring through
   the Strengthening Technical Assistance for routine immunization training
   (START) approach in Uganda
SO VACCINE
LA English
DT Article
DE Vaccination; Immunization programs; Health workforce capacity building;
   In-service training; Mentoring; Program evaluation
ID MIDDLE-INCOME COUNTRIES; CARE SERVICES; SUPERVISION; CHILDREN
AB Introduction: The Global Vaccine Action Plan identifies workforce capacity building as a key strategy to achieve strong immunization programs. The Strengthening Technical Assistance for Routine Immunization Training (START) approach aimed to utilize practical training methods to build capacity of district and health center staff to implement routine immunization (RI) planning and monitoring activities, as well as build supportive supervision skills of district staff.
   Methods: First implemented in Uganda, the START approach was executed by trained external consultants who used existing tools, resources, and experiences to mentor district-level counterparts and, with them, conducted on-the-job training and mentorship of health center staff over several site visits. Implementation was routinely monitored using daily activity reports, pre and post surveys of resources and systems at districts and health centers and interviews with START consultants.
   Results: From July 2013 through December 2014 three START teams of four consultants per team, worked 6 months each across 50 districts in Uganda including the five divisions of Kampala district (45% of all districts). They conducted on-the-job training in 444 selected under-performing health centers, with a median of two visits to each (range 1-7, IQR: 1-3). More than half of these visits were conducted in collaboration with the district immunization officer, providing the opportunity for mentorship of district immunization officers. Changes in staff motivation and awareness of challenges; availability and completion of RI planning and monitoring tools and systems were observed. However, the START consultants felt that potential durability of these changes may be limited by contextual factors, including external accountability, availability of resources, and individual staff attitude.
   Conclusions: Mentoring and on-the-job training offer promising alternatives to traditional classroom training and audit-focused supervision for building health workforce capacity. Further evidence regarding comparative effectiveness of these strategies and durability of observed positive change is needed. Published by Elsevier Ltd.
C1 [Ward, Kirsten; Stewart, Steven; Wardle, Melissa; Sodha, Samir V.; Tanifum, Patricia; Ehlman, Daniel C.; Conklin, Laura; Sandhu, Hardeep S.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA.
   [Ayebazibwe, Nicholas] African Field Epidemiol Network AFENET Secretaria, Wings B&C,Ground Floor,Lugogo House, Kampala, Uganda.
   [Mayanja, Robert; Luzze, Henry] Minist Hlth, Uganda Natl Expanded Program Immunizat, Kampala, Uganda.
   [Abbruzzese, Molly] Bill & Melinda Gates Fdn, 500 Fifth Ave North, Seattle, WA 98109 USA.
RP Ward, K (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA.
EM wvk8@cdc.gov; znc4@cdc.gov; xxg1@cdc.gov; zty6@cdc.gov; wqj4@cdc.gov;
   nayebazibwe@afenet.net; mayanjarobati@gmail.com; euh3@cdc.gov;
   dvj3@cdc.gov; Molly.Abbruzzese@gatesfoundation.org; hjs3@cdc.gov
OI Ehlman, Daniel/0000-0001-6817-2739
FU CDC through Bill and Melinda Gates Foundation (BMGF); UNEPI; African
   Field Epidemiology Network (AFENET); Bill and Melinda Gates Foundation
   (BMGF)Gates Foundation
FX The START approach in Uganda was funded by CDC through a grant from the
   Bill and Melinda Gates Foundation (BMGF). The named author from the Bill
   and Melinda Gates Foundation provided initial input into the design of
   the START approach. The authors gratefully acknowledge the support and
   contributions of: Uganda START consultants Abhay Bohara, Josephine
   Mburah, George Momanyi, Beatrice Muraguri, Olana Tsegaye Sonto, Shafia
   Tayyab, and Misrak Tezera; UNEPI, Bill and Melinda Gates Foundation
   (BMGF), African Field Epidemiology Network (AFENET), Nicole Keusch, Jeff
   Higgins from the Geospatial Research, Analysis and Services Program
   (GRASP) at CDC and all District and health facility staff who worked
   with the START consultants. The views in this manuscript are solely the
   responsibility of the authors and do not necessarily represent the
   official views of CDC or other institutions/agencies.
CR [Anonymous], WHO UNICEF COV EST 2
   Bailey C, 2016, INT J GYNECOL OBSTET, V132, P117, DOI 10.1016/j.ijgo.2015.10.004
   Bamberger M, 2014, REAL WORLD EVALUATIO
   Bluestone J, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-51
   Bosch-Capblanch X, 2012, TROP MED INT HEALTH, V17, P697, DOI 10.1111/j.1365-3156.2012.02989.x
   Bosch-Capblanch X, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006413.pub2
   Bryan RL, 2009, HEALTH PROMOT PRACT, V10, P557, DOI 10.1177/1524839907308117
   Centers for Disease Control and Prevention (CDC), 2013, MMWR Morb Mortal Wkly Rep, V62, P858
   Christie CA, IMPROVEMENT SCI EVAL, P11
   Ciccio L, 2010, RURAL REMOTE HEALTH, V10
   Creswell J. W., 2013, RES DESIGN QUALITATI
   Djibuti M, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S11
   Forss K., 2002, EVALUATION, V8, P29, DOI DOI 10.1177/1358902002008001515
   Golden SD, 2012, HEALTH EDUC BEHAV, V39, P364, DOI 10.1177/1090198111418634
   Guthrie T, 2014, ADDRESSING SUBNATION
   La Fond A, 2003, GUIDE MONITORING EVA
   Leslie HH, 2016, HEALTH AFFAIR, V35, P1716, DOI 10.1377/hlthaff.2016.0261
   Machingaidze S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001405
   Madede T, 2017, HUM RESOUR HEALTH, V15, DOI 10.1186/s12960-017-0213-4
   Management Sciences for Health (MSH), 2011, LEAD WAY PRES TRAIN
   Matovu JKB, 2013, BMC INT HEALTH HUM R, V13, DOI 10.1186/1472-698X-13-8
   Mertens DM, 2013, NEW DIRECTIONS EVALU, V2013, P5, DOI DOI 10.1002/EV.20053
   Mutabaruka E, 2010, East Afr J Public Health, V7, P37
   O'Malley G, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-50
   Omaswa F, 1997, B WORLD HEALTH ORGAN, V75, P155
   Ozawa S, 2017, B WORLD HEALTH ORGAN, V95, P629, DOI 10.2471/BLT.16.178475
   Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086
   Patton M. Q., 2012, ESSENTIALS UTILIZATI
   Patton M.Q, 2014, QUALITATIVE RES EVAL
   Peters DH, 2009, DIR DEV, P1, DOI 10.1596/978-0-8213-7888-5
   Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6
   Rowe AK, 2018, LANCET GLOB HEALTH, V6, pE1163, DOI 10.1016/S2214-109X(18)30398-X
   Ryman T, 2010, J PUBLIC HEALTH-UK, V32, P18, DOI 10.1093/pubmed/fdp048
   SAS Institute, 2011, SAS VERS 9 31M1
   Shimp Lora, 2017, Pan Afr Med J, V27, P21, DOI 10.11604/pamj.supp.2017.27.3.11516
   Simister N, 2010, 23 INT TRAIN NGO RES
   Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001
   Stewart S, 2016, PARIS REV, P120
   Trochim W. M., 2016, RES METHODS ESSENTIA
   Uganda Government Ministry of Health, 2016, UG HLTH FAC MAST LIS
   VANDELAER J, 2008, B WHO, V86
   Vasan A, 2016, HLTH POLICY PLAN, P1
   WHO, 2012, GLOB VACC ACT PLAN 2
   World Health Organization, GLOB ROUT IMM STRAT
   World Health Organization, 2012, GLOB VACC ACT PLAN A
   World Health Organization Regional Office for Africa, EXP PROGR IMM PROT C
   World Health Organization & UNICEF, 2009, MICR IMM SERV DEL US
   Wynn B. O., 2005, CHALLENGES PROGRAM E
   Yamnill S., 2001, HUMAN RESOURCE DEV Q, V12, P195, DOI DOI 10.1002/HRDQ.7
NR 49
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2821
EP 2830
DI 10.1016/j.vaccine.2019.04.015
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400008
PM 31000410
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU O'Mahony, JF
   Paulden, M
AF O'Mahony, James F.
   Paulden, Mike
TI Appraising the cost-effectiveness of vaccines in the UK: Insights from
   the Department of Health Consultation on the revision of methods
   guidelines
SO VACCINE
LA English
DT Article
DE Cost-effectiveness; Economic appraisal; Methods guidelines
ID ECONOMIC-EVALUATION; DECISION-MAKING; RECOMMENDATIONS; UNCERTAINTY
AB The UK Department of Health and Social Care recently held a consultation on proposals to revise the methods for the appraisal of cost-effectiveness of vaccines as applied by the Joint Committee on Vaccination and Immunisation (JCVI). This presents a useful opportunity to review the current methods applied by the JCVI and examine the proposals for their improvement. Reviewing such methods is timely as there is mounting evidence that key elements of the health economic appraisal of all healthcare interventions in the UK need to be revised, In particular, there is a need to reassess both the cost-effectiveness threshold used to judge if an intervention is cost-effective and the discount rates used to assess the present value of health gains that occur in the future. Accordingly, we critically appraise the methods and their proposed changes. Overall, the 27 recommendations made within the recent consultation on proposed changes indicate a sensible and carefully considered approach to methods reform. We identify 11 recommendations that deserve further comment or reconsideration. In particular, there are reasons to question the basis for the proposed reduction of the discount rate from 3.5% to 1.5%. We also find that aspects of the current methods for considering uncertainty in the cost-effectiveness of vaccines require revision. Both the discounting and uncertainty analyses recommendations do not appear to be well grounded in economic theory, empirically justified or consistent with the methods set out by the National Institute for Health and Care Excellence. (C) 2019 Published by Elsevier Ltd.
C1 [O'Mahony, James F.] Trinity Coll Dublin, Ctr Hlth Policy & Management, Sch Med, Dublin, Ireland.
   [Paulden, Mike] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.
   [O'Mahony, James F.] Trinity Coll Dublin, Room 2-12,2-4 Foster Pl, Dublin, Ireland.
RP O'Mahony, JF (reprint author), Trinity Coll Dublin, Ctr Hlth Policy & Management, Sch Med, Dublin, Ireland.; O'Mahony, JF (reprint author), Trinity Coll Dublin, Room 2-12,2-4 Foster Pl, Dublin, Ireland.
EM jfomahon@tcd.ie
CR Attema AE, 2018, PHARMACOECONOMICS, V36, P745, DOI 10.1007/s40273-018-0672-z
   Barton P, 2011, HEALTH ECON, V20, P853, DOI 10.1002/hec.1651
   Brouwer WBF, 2000, J HEALTH ECON, V19, P439, DOI 10.1016/S0167-6296(99)00038-7
   CADTH, 2017, GUID EC EV HLTH TECH
   CEMIPP Working Group, REV COST EFF METH IM
   Chakraborty S, DISCOUNTING EVALUATI
   Christensen H, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5725
   Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3
   Claxton K, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19140
   Claxton K, 2011, HEALTH ECON, V20, P2, DOI 10.1002/hec.1612
   Culyer Anthony, 2007, J Health Serv Res Policy, V12, P56, DOI 10.1258/135581907779497567
   DHSC, 2018, COST EFF METH VACC P
   Drummond MF, 2015, PRINCIPLES EC EVALUA
   Drummond Michael F., 2015, METHODS EC EVALUATIO
   Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635
   HM Treasury, 2018, GREEN BOOK CENTR GOV
   House of Commons Health Committee, 2007, 1 HOUS COMM HLTH COM
   Hoyle M, 2011, PHARMACOECONOMICS, V29, P1, DOI 10.2165/11584230-000000000-00000
   JCVI, 2013, COD OF PRACT
   JCVI, 2018, STAT HPV VACC JOINT
   Koerkamp BG, 2007, MED DECIS MAKING, V27, P101, DOI 10.1177/0272989X06297394
   Lipscomb J, 1996, COST EFFECTIVENESS H, P214
   McCabe C, 2008, PHARMACOECONOMICS, V26, P733, DOI 10.2165/00019053-200826090-00004
   Neumann PJ, 2016, COST EFFECTIVENESS H
   NICE, 2013, GUID METH TECHN APPR
   O'Mahony J, 2011, VALUE HEALTH, V14, P1174, DOI 10.1016/j.jval.2011.09.001
   O'Mahony JF, 2015, PHARMACOECONOMICS, V33, P1255, DOI 10.1007/s40273-015-0309-4
   O'Mahony JF, 2014, VALUE HEALTH, V17, P493, DOI 10.1016/j.jval.2013.02.014
   Paulden M, 2017, EXPERT REV PHARM OUT, V17, P239, DOI 10.1080/14737167.2017.1330152
   Paulden M, 2017, PHARMACOECONOMICS, V35, P5, DOI 10.1007/s40273-016-0482-0
   Paulden M, 2014, PHARMACOECONOMICS, V32, P1043, DOI 10.1007/s40273-014-0204-4
   Quiggin J, 2008, CLIMATIC CHANGE, V89, P195, DOI 10.1007/s10584-008-9434-9
   Thokala P, 2018, PHARMACOECONOMICS, V36, P509, DOI 10.1007/s40273-017-0606-1
   Torrance GW, 1996, COST EFFECTIVENESS H, P54
   VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505
NR 35
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2831
EP 2837
DI 10.1016/j.vaccine.2019.03.072
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400009
PM 31000411
DA 2020-05-12
ER

PT J
AU Mihigo, R
   Okeibunor, J
   Cernuschi, T
   Petu, A
   Satoulou, A
   Zawaira, F
AF Mihigo, Richard
   Okeibunor, Joseph
   Cernuschi, Tania
   Petu, Amos
   Satoulou, Alexis
   Zawaira, Felicitas
TI Improving access to affordable vaccines for middle-income countries in
   the african region
SO VACCINE
LA English
DT Article
DE African Region; Immunization; Middle income countries; Vaccine access;
   Affordability
AB Despite the remarkable power of immunization reducing morbidity and mortality due to vaccine preventable diseases, one in five African children still does not receive all the basic, necessary vaccines. This is particularly true of the 10 middle-income countries (MICs) in the WHO African Region, where data demonstrates that immunization coverage is decreasing. These countries are not eligible for Gavi support in accessing new vaccines because of their relatively high per capita income level and will gradually increase with the transitioning of countries out of Gavi support. Thus, WHO was requested to facilitate access to affordable vaccines in relation to middle-income countries and those transitioning out of Gavi support in the near future. With commitment to address the issue, WHO Regional Office for Africa convened a consultative meeting from 09 to 11 April 2018 in Brazzaville, Congo to explore ways of improving access to affordable vaccines for MICs in the Region. The meeting brought together 17 low, middle and upper middle income countries in the African Region. Immunization partners and other WHO Regions also participated in the consultation to share experiences and explore ways of increasing access to affordable vaccines in MICs in the African Region. At the end of the meeting a number of solutions and action points were proposed for implementation in the Region. (C) 2019 Published by Elsevier Ltd.
C1 [Mihigo, Richard; Okeibunor, Joseph; Zawaira, Felicitas] WHO Reg Off Africa, Brazzaville, Rep Congo.
   [Cernuschi, Tania] WHO Headquarters, Geneva, Switzerland.
   [Petu, Amos] WHO Intercountry Support Team East & Southern Afr, Harare, Zimbabwe.
   [Satoulou, Alexis] WHO Intercountiy Support Team West Africa, Ouagadougou, Burkina Faso.
RP Okeibunor, J (reprint author), WHO AFRO, Brazzaville, Rep Congo.
EM mihigor@who.int; okeibunorj@who.int; cernuschit@who.int; petua@who.int;
   satouloua@who.int; zawairaf@who.int
FU World Health OrganizationWorld Health Organization [001]
CR Adebayo B., 2016, PUNCH
   [Anonymous], 2017, WORLD POP PROSP 2017
   Balding B., 2006, MANDATORY VACCINATIO
   Chan Margaret, 2014, Public Health Rep, V129 Suppl 3, P7
   Gavi, GVAP PROGR ADDR GROU
   JHSPH, BEN CHILDH IMM 16 44
   Killeen RM, 2007, CPJ RPC S2, V140, pS2
   Mihigo RM, 2016, VACCINE, V34, P5827, DOI 10.1016/j.vaccine.2016.06.036
   Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086
   UNICEF, IMM MAN MOR LIV SAV
   WHO, 2016, FULF PROM ENS IMM AL
   WHO/AFRO and WHO/EMRO, BUS CAS IMM AFR CONT
   WHO/UNICEF, 2017, EST NAT IMM COV 2017
   World Health Organization, 2015, MIDDL INC COUNTR STR
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2838
EP 2842
DI 10.1016/j.vaccine.2019.03.077
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400010
PM 30979568
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Attwell, K
   Drislane, S
   Leask, J
AF Attwell, Katie
   Drislane, Shevaun
   Leask, Julie
TI Mandatory vaccination and no fault vaccine injury compensation schemes:
   An identification of country-level policies
SO VACCINE
LA English
DT Article
DE Immunization; Vaccination; Mandatory; Compensation; Policy; Adverse
   events; Social contract
ID PROGRAM
AB Background: To prevent the spread of infectious diseases, governments have implemented a number of policies, including a range of mandatory vaccination policies. In addition, some governments have implemented no fault vaccine injury compensation schemes as a legal mechanism of recourse for individuals experiencing adverse events following vaccination. We aimed to identify countries with mandatory vaccination policies that also have no fault compensation schemes.
   Methods: To identify countries with mandatory childhood vaccination policies, we utilized existing publications, lists and databases, also conducting multiple country searches and policy detail verification. We then investigated compensation schemes for each country with childhood vaccination mandates, using an existing study and database/internet searches.
   Results: Of the 62 countries we identified with mandatory childhood vaccination policies, we found evidence that only 7 (11%) had also implemented no fault compensation schemes.
   Conclusions: No-fault compensation schemes are one government approach to address unintended consequences of vaccination. Few countries have implemented these schemes, including those with mandatory vaccination policies. Mandatory vaccination invokes a strong need to protect those who fall victim to extremely rare cases of provable no-fault vaccine injury. Countries that mandate childhood vaccination without providing no fault compensation schemes could be seen as abrogating the social contract. This is particularly important when public policies limit parental choice regarding whether to vaccinate. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Attwell, Katie; Drislane, Shevaun] Univ Western Australia, Polit Sci & Int Relat, 35 Stirling Highway, Crawley, WA 6009, Australia.
   [Attwell, Katie] Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, Nedlands, WA, Australia.
   [Leask, Julie] Univ Sydney, Fac Med & Hlth, Susan Wakil Sch Nursing & Midwifery, MPH, Sydney, NSW, Australia.
RP Attwell, K (reprint author), Univ Western Australia, Polit Sci & Int Relat, 35 Stirling Highway, Crawley, WA 6009, Australia.
EM katie.attwell@uwa.edu.au
RI attwell, Katie/D-4346-2018
OI attwell, Katie/0000-0002-0366-2160; Leask, Julie/0000-0001-5095-1443
CR Al-Enezi M, 2015, KUWAIT TIMES
   Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   [Anonymous], 2007, LAW PREV FIGHT INF D
   [Anonymous], 2015, SLOVAK SPECTATOR
   Aquino F, 2017, VACCINE, V35, P4494, DOI 10.1016/j.vaccine.2017.07.029
   Asian Development Bank, 2001, MONG NAT IMM PROGR F
   Attwell K, 2018, VACCINE, V36, P7377, DOI 10.1016/j.vaccine.2018.10.019
   British Medical Association, 2003, CHILDH IMM GUID HEAL
   Bureau of Democracy Human Rights and Labor, 2016, INT REL FREED REP AN
   Bureau of Democracy Human Rights and Labor, 2016, INT REL FREED REP US
   Caribbean EPI Managers Meeting, 2016, CAR EPI MAN M 32 M C
   Centers for Disease Control and Prevention, 2017, STAT SCH IMM REQ VAC
   Centers for Disease Control and Prevention, STAT VACC REQ
   Cetani T., 2002, HLTH CARE SYSTEMS TR
   Chisinau NG, 2013, RESISTANCE MOLDOVA H
   Evans G, 1999, VACCINE, V17, pS25, DOI 10.1016/S0264-410X(99)00291-1
   Giri Bhakta R, 2011, Indian J Community Med, V36, P109, DOI 10.4103/0970-0218.84128
   Halabi SF, 2017, JAMA-J AM MED ASSOC, V317, P471, DOI 10.1001/jama.2016.19492
   Hales CM, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw064
   HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243
   Haverkate M, 2012, EURO SURVEILL, V1
   Isaacs D, 2004, J PAEDIATR CHILD H, V40, P247, DOI 10.1111/j.1440-1754.2004.00357.x
   Kaic B, 2007, COLLEGIUM ANTROPOL, V31, P117
   Keelan J, 2011, DESIGNING NO FAULT V
   Keelan J, 2011, AM J PUBLIC HEALTH, V101, P2016, DOI 10.2105/AJPH.2011.300198
   Kelly HA, 2011, MED J AUSTRALIA, V195, P4, DOI 10.5694/j.1326-5377.2011.tb03176.x
   Kluger J., 2015, TIME
   Leask J, 2017, J PAEDIATR CHILD H, V53, P439, DOI 10.1111/jpc.13472
   Lee S -G, 2012, KOREAN NATL IMMUNIZA
   Looker C, 2011, B WORLD HEALTH ORGAN, V89, P371, DOI 10.2471/BLT.10.081901
   MacDonald NE, 2018, VACCINE, V36, P5811, DOI 10.1016/j.vaccine.2018.08.042
   Mello MM, 2008, BIOETHICS, V22, P32, DOI 10.1111/j.1467-8519.2007.00590.x
   Menning L., 2018, WHO JOINT REPORTING
   Ministry of Health and Social Security, 2016, STRAT PLAN HLTH 2016
   National Bioethics Committee of Republic San Marino, 2016, BIOETH VAL VACC IND
   National Centre for Immunisation Research and Surveillance, 2017, NO JAB NO PLAY NO JA
   Offit PA, 2008, NEW ENGL J MED, V358, P2089, DOI 10.1056/NEJMp0802904
   Pan American Health Organization, 2002, PAHO SCI TECHN PUBL
   Pejin LS, 2016, 2016 EUROPEAN SOCIAL
   Rosenberg-Carlson M., 2017, VACCINES ARE HUMAN R
   Saad A, 2009, OPEN VACCINE J, V2, P77
   Sabin Vaccine Institute, 2018, LEG APPR IMM EUR REG
   Santisteban M. J., 2011, PREVENTATIVE HLTH CA
   Seither R, 2013, MMWR-MORBID MORTAL W, V62, P607
   Tang CW, 2011, PEDIATR NEONATOL, V52, P98, DOI 10.1016/j.pedneo.2011.02.009
   Tripathi S., 2017, DECCAN CHRONICLE
   Valente M., 2013, DOCTORS ARGENTINA SO
   Verweij M, 2004, VACCINE, V22, P3122, DOI 10.1016/j.vaccine.2004.01.062
   Vicari A., 2013, GLOBAL IMMUNIZ NEWS
   Walkinshaw E, 2011, CAN MED ASSOC J, V183, pE1167, DOI 10.1503/cmaj.109-3993
   Walkinshaw E, 2011, CAN MED ASSOC J, V183, pE1165, DOI 10.1503/cmaj.109-3992
   Ward JK, 2018, VACCINE, V36, P1801, DOI 10.1016/j.vaccine.2018.02.095
   WHO, 2018, WHO VACC REACT RAT I
   Wilson K, 2012, CAN J PUBLIC HEALTH, V103, P122, DOI 10.1007/BF03404215
   World Health Organisation, 2018, USER MANUAL
   World Health Organization, 2014, GLOB MAN SURV ADV EV
   Zanonia G, 2009, VACCINE, V27, P3376, DOI 10.1016/j.vaccine.2009.01.059
NR 57
TC 4
Z9 4
U1 1
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2843
EP 2848
DI 10.1016/j.vaccine.2019.03.065
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400011
PM 31000414
DA 2020-05-12
ER

PT J
AU Alberts, CJ
   Boyd, A
   Bruisten, SM
   Heijman, T
   Hogewoning, A
   van Rooijen, M
   Siedenburg, E
   Sonder, GJB
AF Alberts, Catharina J.
   Boyd, Anders
   Bruisten, Sylvia M.
   Heijman, Titia
   Hogewoning, Arjan
   van Rooijen, Martijn
   Siedenburg, Evelien
   Sonder, Gerard J. B.
TI Hepatitis A incidence, seroprevalence, and vaccination decision among
   MSM in Amsterdam, the Netherlands
SO VACCINE
LA English
DT Article
DE Hepatitis A virus; the Netherlands; Men who have sex with men; Sexual
   transmission; Epidemiology; HAV IgG seroprevalence
ID RISK GROUPS; MEN MSM; SEX; VIRUS; OUTBREAK; IMMUNITY; INFECTION; PROGRAM
AB Background: Several outbreaks of Hepatitis A virus (HAV) were recently documented among men who have sex with men (MSM) in Europe. We investigated the HAV incidence among MSM in Amsterdam, the Netherlands; and HAV seroprevalence and HAV vaccination decision among MSM visiting the Sexually Transmitted Infection (STI) clinic in Amsterdam.
   Methods: Using surveillance data from 1992 to 2017 of MSM with acute HAV in Amsterdam, we estimated the incidence by calendar year and age. We explored HAV seroprevalence by calendar year and age, determinants for HAV seropositivity, and opting-in/out for HAV vaccination using data collected among MSM that visited the STI clinic between 2006 and 2017 and were included in a nationwide Hepatitis B virus (HBV) vaccination programme. Offering HAV vaccination at the STI clinic differed over three consecutive periods: not offered, offered for free, or offered for 75 euros. Logistic regression analyses were used to explore determinants.
   Results: HAV incidence increased in 2016/17 after 4 years of absence and peaked in MSM around 35 years of age. Among MSM visiting the STI clinic, HAV seroprevalence was 37% (95%CI = 35-40%), which was constant over the period 2006-2017, and increased with age (p < 0.001). Determinants for HAV seropositivity in multivariable analysis were: older age (p < 0.001), originating from an HAV endemic country (p < 0.001), and being HBV seropositive (p = 0.001). MSM opted-in more frequently when HAV vaccination was offered for free versus paid (89% versus 11%, respectively; p < 0.001). Younger MSM were less inclined to vaccinate when payment was required (p = 0.010). Post-hoc analyses showed that 98% versus 46% of MSM visiting the Amsterdam STI clinic would be protected against HAV infection if HAV vaccination was offered for free or for 75 euros, respectively.
   Conclusions: The MSM population of Amsterdam is vulnerable to a new HAV outbreak. We strongly recommend that MSM have access to free hepatitis A vaccination. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Alberts, Catharina J.; Boyd, Anders; Bruisten, Sylvia M.; Heijman, Titia; Hogewoning, Arjan; van Rooijen, Martijn; Siedenburg, Evelien; Sonder, Gerard J. B.] Publ Hlth Serv Amsterdam GGD, Dept Infect Dis, Amsterdam, Netherlands.
   [Boyd, Anders] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, INSERM, Paris, France.
   [Bruisten, Sylvia M.; Hogewoning, Arjan; Sonder, Gerard J. B.] Amsterdam Univ Med Ctr UMC, AI&II, Amsterdam, Netherlands.
RP Sonder, GJB (reprint author), Publ Hlth Serv Amsterdam GGD, Dept Infect Dis, Natl Coordinat Ctr Travelers Hlth Advise, Amsterdam, Netherlands.; Sonder, GJB (reprint author), Nieuwe Achtergracht 100, NL-1018 WT Amsterdam, Netherlands.
EM aboyd@ggd.amsterdam.nl; SBruisten@ggd.amsterdam.nl;
   theijman@ggd.amsterdam.nl; ahogewoning@ggd.amsterdam.nl;
   mvrooijen@ggd.amsterclam.nl; esiedenburg@ggd.amsterdam.nl;
   gerardsonder@gmail.com
FU GGD Amsterdam [75722495]
FX Funding was kindly provided by a Research and Development grant from GGD
   Amsterdam (number 75722495).
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87
   Beebeejaun K, 2017, EUROSURVEILLANCE, V22, P7, DOI 10.2807/1560-7917.ES.2017.22.5.30454
   Bruisten SM, 2001, J MED VIROL, V63, P88, DOI 10.1002/1096-9071(20000201)63:2&lt;88::AID-JMV1001&gt;3.0.CO;2-G
   Centraal Bureau voor de Statistiek (CBS) (Statistics Netherlands), BEV 1 JAN GEM GESL L
   Charre C, 2017, EUROSURVEILLANCE, V22, P11, DOI 10.2807/1560-7917.ES.2017.22.48.17-00742
   Chen GJ, 2017, J INFECT DIS, V215, P1339, DOI 10.1093/infdis/jix123
   Curran D, 2016, HUM VACC IMMUNOTHER, V12, P2765, DOI 10.1080/21645515.2016.1203495
   den Daas C, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2445-3
   European Centre for Disease Prevention and Control, 2013, OUTBR HEP A VIR INF
   European Commission Directorate-General for Maritime Affairs and Fisheries (EU), 2016, HOR 2020 EUR UN FUND, P1
   Freidl GS, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.8.30468
   Friesema IHM, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.23.1800265
   Gallot C, 2011, EMERG INFECT DIS, V17, P566, DOI 10.3201/eid1703.101479
   Gossner CM, 2015, EUROSURVEILLANCE, V20, P16
   Gozlan Y, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.29.30575
   Heywood AE, 2012, VACCINE, V30, P6020, DOI 10.1016/j.vaccine.2012.07.058
   Jacobsen KH, 2010, VACCINE, V28, P6653, DOI 10.1016/j.vaccine.2010.08.037
   KANE M, 1995, B WORLD HEALTH ORGAN, V73, P15
   Lanini S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185428
   Marra E, 2016, PAPILLOMAVIRUS RES, V2, P178, DOI 10.1016/j.pvr.2016.11.001
   Martin A, 2006, HEPATOLOGY, V43, pS164, DOI 10.1002/hep.21052
   Ndumbi P, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.33.1700641
   Organization WH, 2016, GLOB HLTH SECT STRAT
   Perevoscikovs J, 2008, EUROSURVEILLANCE, V13, P1
   Petrignani M, 2010, EUROSURVEILLANCE, V15, P9
   PRADIER M, 2018, SEX TRANSM INFECT, V18, DOI DOI 10.1136/SEXTRANS-2017-053395
   Regan DG, 2016, EPIDEMIOL INFECT, V144, P1528, DOI 10.1017/S0950268815002605
   Rivas V, 2018, EUROSURVEILLANCE, V23, P14, DOI 10.2807/1560-7917.ES.2018.23.9.18-00060
   Rodriguez-Tajes S, 2018, LIVER INT, V38, P588, DOI 10.1111/liv.13606
   Severi E, 2015, EUROSURVEILLANCE, V20, P29
   Shouval D, 2011, IMMUNOLOGICAL BASIS
   Tjon G, 2007, J MED VIROL, V79, P488, DOI 10.1002/jmv.20821
   van Rijckevorsel G, 2013, J HEPATOL, V59, P1177, DOI 10.1016/j.jhep.2013.08.002
   van Rooijen MS, 2018, SEX TRANSM DIS, V45, P534, DOI 10.1097/OLQ.0000000000000794
   van Steenbergen JE, 2004, J INFECT DIS, V189, P471, DOI 10.1086/381152
   van Steenbergen JE, 2002, J HEPATOL, V37, P507, DOI 10.1016/S0168-8278(02)00213-1
   Weerakoon AP, 2012, VACCINE, V30, P3430, DOI 10.1016/j.vaccine.2012.03.024
   Werber D, 2017, EUROSURVEILLANCE, V22, P5
NR 38
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2849
EP 2856
DI 10.1016/j.vaccine.2019.03.048
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400012
PM 30992222
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Manokaran, G
   Sujatmoko
   McPherson, KG
   Simmons, CP
AF Manokaran, Gayathri
   Sujatmoko
   McPherson, Kirsty Grace
   Simmons, Cameron Paul
TI Attenuation of a dengue virus replicon by codon deoptimization of
   nonstructural genes
SO VACCINE
LA English
DT Article
DE Dengue; Codon deoptimization; Replicon; Vaccine; Attenuation
ID ADAPTATION INDEX; STRAIN 16681; PAIR BIAS; VACCINE; GENOME; EFFICACY;
   USAGE
AB The overwhelming increase of dengue virus (DENV) infections in recent years shows that current strategies to combat dengue do not work. The lack of a highly effective dengue vaccine and the limited effectivity of vector controls exacerbate this situation. To point the way to a novel method of creating DENV vaccine candidates, here we disrupted the codon usage in a DENV-2 reporter replicon to generate variants with different replication characteristics. Six different mutated constructs containing stretches of altered codon usage in the non-structural genes were generated. The mutated sequences were deoptimized to the least favorable codons for human cells. We studied the replication efficiency of these constructs by measuring luciferase reporter activity, relative RNA fold change, and NS1 secretion. Our findings showed that the level of virus attenuation is closely associated with the amount of codon deoptimization. Indeed, replication was completely abolished in extensively-deoptimized constructs D2Rep-6 and D2Rep-5, intermediate with constructs D2Rep-4 (771 bp silent mutations) and D2Rep-3 (756 bp silent mutations) and restored almost to wildtype levels with constructs D2Rep-2 (394 silent mutations) and D2Rep-1 (48 silent mutations). We also determined that the position of codon deoptimization within the genome is crucial to the degree of attenuation observed. Based on our analysis, we propose that the design for an ideal DENV vaccine candidate could include 700-1500 silent mutations within the NS2A and NS3 genes. Our results suggest that codon deoptimization is an ideal strategy that can readily be used to develop a DENV vaccine candidate with "fine-tuned" attenuation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Manokaran, Gayathri; Sujatmoko; McPherson, Kirsty Grace; Simmons, Cameron Paul] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic, Australia.
   [Manokaran, Gayathri; Simmons, Cameron Paul] Monash Univ, Inst Vector Borne Dis, Clayton, Vic, Australia.
   [Simmons, Cameron Paul] Wellcome Trust Major Overseas Programme, Oxford Univ Clin Res Unit, Dist 5, Ho Chi Minh City, Vietnam.
RP Simmons, CP (reprint author), Monash Univ, Inst Vector Borne Dis, Clayton, Vic, Australia.
EM cameron.simmons@worldmosquito.org
RI McPherson, Kirsty G/E-6331-2017
OI McPherson, Kirsty G/0000-0003-3083-6303
FU Wellcome Trust (UK)Wellcome Trust; National Health and Medical Research
   Council (Australia)National Health and Medical Research Council of
   Australia; Duke-NUS Medical School, Singapore
FX This work was supported by the Wellcome Trust (UK) and the National
   Health and Medical Research Council (Australia). The authors wish to
   thank Professor Ooi Eng Eong, Duke-NUS Medical School, Singapore for
   providing the dengue 2 replicon used in this study.
CR Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Broadbent AJ, 2016, VACCINE, V34, P563, DOI 10.1016/j.vaccine.2015.11.054
   Butrapet S, 2000, J VIROL, V74, P3011, DOI 10.1128/JVI.74.7.3011-3019.2000
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Carbone A, 2003, BIOINFORMATICS, V19, P2005, DOI 10.1093/bioinformatics/btg272
   Cheng BYH, 2017, VIROLOGY, V501, P35, DOI 10.1016/j.virol.2016.11.001
   Cheng BYH, 2015, J VIROL, V89, P3523, DOI 10.1128/JVI.03401-14
   Coleman JR, 2008, SCIENCE, V320, P1784, DOI 10.1126/science.1155761
   GRANTHAM R, 1980, NUCLEIC ACIDS RES, V8, pR49, DOI 10.1093/nar/8.1.197-c
   Gustafsson C, 2004, TRENDS BIOTECHNOL, V22, P346, DOI 10.1016/j.tibtech.2004.04.006
   GUTMAN GA, 1989, P NATL ACAD SCI USA, V86, P3699, DOI 10.1073/pnas.86.10.3699
   Holden KL, 2006, VIROLOGY, V344, P439, DOI 10.1016/j.virol.2005.08.034
   Jenkins GM, 2002, J MOL EVOL, V54, P156, DOI 10.1007/s00239-001-0064-3
   Kinney RM, 1997, VIROLOGY, V230, P300, DOI 10.1006/viro.1997.8500
   Kunec D, 2016, CELL REP, V14, P55, DOI 10.1016/j.celrep.2015.12.011
   Le Nouen C, 2014, P NATL ACAD SCI USA, V111, P13169, DOI 10.1073/pnas.1411290111
   Li P, 2018, J VIROL, V92, DOI 10.1128/JVI.00209-18
   Mueller S, 2006, J VIROL, V80, P9687, DOI 10.1128/JVI.00738-06
   SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281
   Shen SH, 2015, P NATL ACAD SCI USA, V112, P4749, DOI 10.1073/pnas.1502864112
   Stauft CB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198303
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Woelk CH, 2002, MOL BIOL EVOL, V19, P2333, DOI 10.1093/oxfordjournals.molbev.a004059
NR 23
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2857
EP 2863
DI 10.1016/j.vaccine.2019.03.062
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400013
PM 31000413
DA 2020-05-12
ER

PT J
AU Parker, KH
   Kemp, TJ
   Isaacs-Soriano, K
   Abrahamsen, M
   Pan, YJ
   Lazcano-Ponce, E
   Salmeron, J
   Pinto, LA
   Giuliano, AR
AF Parker, Katherine H.
   Kemp, Troy J.
   Isaacs-Soriano, Kimberly
   Abrahamsen, Martha
   Pan, Yuanji
   Lazcano-Ponce, Eduardo
   Salmeron, Jorge
   Pinto, Ligia A.
   Giuliano, Anna R.
TI HPV-specific antibodies at the oral cavity up to 30 months after the
   start of vaccination with the quadrivalent HPV vaccine among mid-adult
   aged men
SO VACCINE
LA English
DT Article
DE HPV vaccine; Mouthwash; Saliva; Human papillomavirus
ID AS04-ADJUVANTED VACCINE; PAPILLOMAVIRUS; INFECTION; EFFICACY;
   IMMUNOGENICITY; INFLUENZA; CANCER; ELISA
AB Background: HPV-16 and HPV-18 cause most oropharyngeal cancers, which are increasing in incidence among males. Although HPV vaccines are highly effective against a number of HPV-associated cancers, efficacy for oropharyngeal cancers has not yet been demonstrated. In addition, the level of antibodies required for protection against oral HPV infection is unknown.
   Methods: 150 men ages 27-45 years from Tampa, FL, USA, and Cuernavaca, Mexico, received Gardasil at Day 1, Months 2, and 6. Then, sera and oral gargles were collected one month, 12 months, and 24 months after completion of the three doses (Month 7, 18 and 30 of the study) and tested for anti-HPV-16 and HPV-18 IgG antibody levels by a L1 VLP ELISA.
   Results: All participants developed detectable serum anti-HPV-16 and anti-HPV-18 antibodies and most had detectable antibodies in oral gargles at Month 7 (HPV-16: 93.2%; HPV-18: 72.1%). By months 18 and 30, oral antibodies were detectable in a lower number of participants (HPV-16, 39.8% and 29.6%; HPV-18, 10.7% and 4.6% of individuals, respectively). Overall, oral HPV-16- and 18-specific antibody levels, normalized to total IgG at months 7, 18, and 30, correlated with serum levels (HPV-16, R-2= 0.93; HPV-18, R-2= 0.91).
   Conclusions: Reduced detectability of oral and serum HPV-16 and HPV-18 antibodies was observed at months 18 and 30 after initiation of the quadrivalent vaccination. However, when detectable, serum and oral HPV-16 and HPV-18 antibody levels were strongly correlated. (C) 2019 Published by Elsevier Ltd.
C1 [Parker, Katherine H.; Kemp, Troy J.; Pan, Yuanji; Pinto, Ligia A.] Frederick Natl Lab Canc Res, HPV Immunol Lab, Frederick, MD USA.
   [Isaacs-Soriano, Kimberly; Abrahamsen, Martha; Giuliano, Anna R.] H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res Canc, Tampa, FL USA.
   [Lazcano-Ponce, Eduardo; Salmeron, Jorge] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico.
RP Pinto, LA (reprint author), Frederick Natl Lab Canc Res, Vaccine Immun & Canc Program, Frederick, MD 21702 USA.
EM pintol@mail.nih.gov
OI Giuliano, Anna R/0000-0002-5440-8859
FU Merck Sharp Dohme CorpMerck & Company; Miles for Moffitt program at the
   Moffitt Cancer Center in Tampa, Florida; National Cancer Institute,
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [HHSN261200800001E]; Moffitt Cancer Center
FX This work was supported by a research grant from the
   Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp [to
   A.R.G.]; Miles for Moffitt program at the Moffitt Cancer Center in
   Tampa, Florida; and this project has been funded in whole or in part
   with Federal funds from the National Cancer Institute, National
   Institutes of Health under Contract No. HHSN261200800001E and support
   from the Moffitt Cancer Center. The content of this publication does not
   necessarily reflect the views or policies of the Department of Health
   and Human Services, nor does mention of trade names, commercial
   products, or organizations imply endorsement by the U.S. Government. The
   opinions expressed in this paper are those of the authors and do not
   necessarily represent those of the funders. The funders of the study had
   no role in the design and conduct of the study; collection, management,
   analysis, and interpretation of the data; and preparation, review, or
   approval of the manuscript.
CR Anayannis NVJ, 2015, ARCH PATHOL LAB MED, V139, P1373, DOI 10.5858/arpa.2014-0554-RA
   Bergot Anne-Sophie, 2011, Cancers (Basel), V3, P3461, DOI 10.3390/cancers3033461
   Brandtzaeg P, 2013, J ORAL MICROBIOL, V5, DOI 10.3402/jom.v5i0.20401
   BROKSTAD KA, 1995, J INFECT DIS, V171, P198, DOI 10.1093/infdis/171.1.198
   Brokstad KA, 2002, J INFECT DIS, V185, P878, DOI 10.1086/339710
   Campbell CMP, 2013, J IMMUNOL METHODS, V400, P117, DOI 10.1016/j.jim.2013.10.005
   Dauner JG, 2012, MOL CELL PROBE, V26, P73, DOI 10.1016/j.mcp.2012.01.002
   Dauner JG, 2010, VACCINE, V28, P5407, DOI 10.1016/j.vaccine.2010.06.018
   Dessy FJ, 2008, HUM VACCINES, V4, P425, DOI 10.4161/hv.4.6.6912
   Giuliano AR, 2015, VACCINE, V33, P5640, DOI 10.1016/j.vaccine.2015.08.072
   Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537
   Granade TC, 2002, CLIN DIAGN LAB IMMUN, V9, P194, DOI 10.1128/CDLI.9.1.194-197.2002
   Herrero R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068329
   Jemal A, 2013, JNCI-J NATL CANCER I, V105, P175, DOI 10.1093/jnci/djs491
   Kemp TJ, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00061
   Kjaer SK, 2018, CLIN INFECT DIS, V66, P339, DOI 10.1093/cid/cix797
   Kreimer AR, 2013, LANCET, V382, P877, DOI 10.1016/S0140-6736(13)60809-0
   Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7
   Olsson SE, 2007, VACCINE, V25, P4931, DOI 10.1016/j.vaccine.2007.03.049
   Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4
   Pinto LA, 2016, J INFECT DIS, V214, P1276, DOI 10.1093/infdis/jiw359
   Romanowski B, 2016, HUM VACC IMMUNOTHER, V12, P20, DOI 10.1080/21645515.2015.1065363
   Villa LL, 2006, BRIT J CANCER, V95, P1459, DOI 10.1038/sj.bjc.6603469
NR 23
TC 3
Z9 3
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 9
PY 2019
VL 37
IS 21
BP 2864
EP 2869
DI 10.1016/j.vaccine.2019.03.064
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ2WV
UT WOS:000468710400014
PM 31005426
DA 2020-05-12
ER

PT J
AU Duclos, P
   Martinez, L
   MacDonald, N
   Asturias, E
   Nohynek, H
   Lambert, PH
   Afaayo, R
   Andersson, L
   Angele, S
   Arora, N
   Ashfield, R
   Asturias, E
   Beal, AS
   Bose, A
   Comiadiere, B
   Costa Clemens, SA
   Cutland, C
   Dochez, C
   Duclos, P
   Finan, A
   Finn, A
   Gambillara Fonck, V
   Kagina, B
   Kane, NCT
   Koeck, JL
   Kraehenbuhl, JP
   Lambert, PH
   Lindstrand, A
   Lynch, JA
   Macdonald, N
   Malande, OO
   Martinez, L
   Meric, C
   Mosina, L
   Muloiwa, R
   Nohynek, H
   Pansier, B
   Pattyn, J
   Paul, S
   Phalipon, A
   Podda, A
   Rodewald, L
   Scott, A
   Talbot, K
   Tikoo, S
   Tipping, J
   Van Damme, P
   Wang, LK
   Wouters, I
AF Duclos, Philippe
   Martinez, Lindsay
   MacDonald, Noni
   Asturias, Edwin
   Nohynek, Hanna
   Lambert, Paul-Henri
   Afaayo, Rachel
   Andersson, Lizzelott
   Angele, Sandra
   Arora, Narendra
   Ashfield, Rebecca
   Asturias, Edwin
   Beal, Amanda Shortell
   Bose, Anuradha
   Comiadiere, Behazine
   Costa Clemens, Sue Ann
   Cutland, Clare
   Dochez, Carine
   Duclos, Philippe
   Finan, Amy
   Finn, Adam
   Gambillara Fonck, Veronica
   Kagina, Benjamin
   Kane, Ndeye Coumba Toure
   Koeck, Jean-Louis
   Kraehenbuhl, Jean-Pierre
   Lambert, Paul-Henri
   Lindstrand, Ann
   Lynch, Julia Anne
   Macdonald, Noni
   Malande, Oliver Ombeva
   Martinez, Lindsay
   Meric, Claude
   Mosina, Liudmila
   Muloiwa, Rudzani
   Nohynek, Hanna
   Pansier, Benedicte
   Pattyn, Jade
   Paul, Stephane
   Phalipon, Armelle
   Podda, Audino
   Rodewald, Lance
   Scott, Anthony
   Talbot, Keipp
   Tikoo, Suresh
   Tipping, Jane
   Van Damme, Pierre
   Wang, Likui
   Wouters, Ine
CA Global Vaccinology Training Works
TI Global vaccinology training: Report from an ADVAC workshop
SO VACCINE
LA English
DT Article
DE Vaccinology; Vaccines; Vaccinology training; Advanced vaccinology
   training; Global; Workshop
ID OUTCOMES
AB At a workshop on 7-8 November 2018 the leaders of 26 advanced vaccinology courses met to carry out an extensive review of the existing courses worldwide, in order to identify education gaps and future needs and discuss potential collaboration. The main conclusions of the workshop concerned: opportunities for strengthening and expanding the global coverage of vaccinology training; evaluation of vaccinology courses; updating knowledge after the course; how to facilitate post-course 'cascade' training; developing and sharing best practices; the application of online and innovative approaches in adult education; and how to reduce costs and facilitate wider access to vaccinology training. The importance of collaboration and information exchange through networks of alumni and between courses was stressed. A web platform to provide information about existing courses for potential applicants is needed. Lack of sustainable funding is a constraint for vaccinology training and needs to be addressed. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Duclos, Philippe; Lambert, Paul-Henri] Univ Geneva, Ctr Vaccinol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.
   [Martinez, Lindsay] 13 Chemin Maurice Ravel, CH-1290 Versoix, Switzerland.
   [MacDonald, Noni] Dalhousie Univ, Div Pediat Infect, IWK Hlth Ctr, 5850-5980 Univ Ave,POB 9700, Halifax, NS B3H 4R2, Canada.
   [Asturias, Edwin] Univ Colorado, Sch Med, 13199 E Montview Blvd,Suite 310, Aurora, CO 80045 USA.
   [Nohynek, Hanna] Natl Inst Hlth & Welf, Dept Vaccines & Immune Protect, 166 Mannerheimintie,POB 30, FI-00271 Helsinki, Finland.
   [Martinez, Lindsay] Univ Nacl Autonoma Mexico, Carlos Slim Fdn, Mexico City, DF, Mexico.
   [Angele, Sandra; Pansier, Benedicte] Fdn Merieux, Veyrier Du Lac, France.
   [Arora, Narendra] INCLEN, Child Fdn, New Delhi, India.
   [Ashfield, Rebecca] Univ Oxford, Jenner Inst, Oxford, England.
   [Asturias, Edwin] Univ Colorado, Boulder, CO 80309 USA.
   [Beal, Amanda Shortell] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Bose, Anuradha] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
   [Comiadiere, Behazine] INSERM, Paris, France.
   [Costa Clemens, Sue Ann] Univ Siena, Inst Global Hlth, Siena, Italy.
   [Cutland, Clare] Univ Witwatersrand, Johannesburg, South Africa.
   [Dochez, Carine; Pattyn, Jade; Wouters, Ine] Univ Antwerp, Antwerp, Belgium.
   [Duclos, Philippe; Lambert, Paul-Henri] Univ Geneva, Geneva, Switzerland.
   [Finan, Amy] Sabin Vaccine Inst, Washington, DC USA.
   [Finn, Adam] Univ Bristol, Bristol, Avon, England.
   [Gambillara Fonck, Veronica] Limmatech Biol, Schlieren, Switzerland.
   [Kagina, Benjamin; Muloiwa, Rudzani] Univ Cape Town, Rondebosch, South Africa.
   [Kane, Ndeye Coumba Toure] Univ Dakar, Dakar, Senegal.
   [Koeck, Jean-Louis] Direct Cent Serv Sante Armees, Lyon, France.
   [Kraehenbuhl, Jean-Pierre] Hlth Sci E Training Fdn, Lausanne, Switzerland.
   [Lindstrand, Ann] WHO, Geneva, Switzerland.
   [Lynch, Julia Anne] Int Vaccine Inst, Seoul, South Korea.
   [Macdonald, Noni] Dalhousie Univ, Halifax, NS, Canada.
   [Malande, Oliver Ombeva] Africa Ctr Vaccines & Immunizat, Nairobi, Kenya.
   [Mosina, Liudmila] WHO Reg Off Europe, Copenhagen, Denmark.
   [Nohynek, Hanna] Natl Inst Hlth & Welf Finland, Helsinki, Finland.
   [Paul, Stephane] Univ Jean Monet, St Etienne, France.
   [Phalipon, Armelle] Inst Pasteur, Paris, France.
   [Podda, Audino] GSK Vaccines Inst Global Hlth, Siena, Italy.
   [Rodewald, Lance] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China.
   [Scott, Anthony] London Sch Hyg & Trop Med, London, England.
   [Talbot, Keipp] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Tikoo, Suresh] Univ Saskatchewan, Saskatoon, SK, Canada.
   [Tipping, Jane] Univ Toronto, Fac Med, Toronto, ON, Canada.
   [Van Damme, Pierre] Univ Antwerp, Vaccine & Infect Dis Inst, Antwerp, Belgium.
   [Wang, Likui] Univ Chinese Acad Sci, Beijing, Peoples R China.
RP Duclos, P (reprint author), Univ Geneva, Ctr Vaccinol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.
EM Philippe.Duclos@unige.ch; lindsay-martinez@bluewin.ch;
   noni.macdonald@dal.ca; Edwin.asturias@childrenscolorado.org;
   hanna.nohynek@thl.fi; Paul.Lambert@unige.ch
RI Asturias, Edwin/D-9842-2016
OI Asturias, Edwin/0000-0002-1275-0787
FU Bill & Melinda Gates Foundation, Seattle, WA, USAGates Foundation
   [OPP48961]
FX This Global Vaccinology Training Workshop was supported by the Bill &
   Melinda Gates Foundation, Seattle, WA, USA (Grant OPP48961)
CR Caffarella R., 2013, PLANNING PROGRAMS AD
   Cervero RM, 2015, J CONTIN EDUC HEALTH, V35, P131, DOI 10.1002/chp.21290
   Davis D, 2010, CAN MED ASSOC J, V182, pE89, DOI 10.1503/cmaj.081241
   Dean P. J., 2001, Q REV DISTANCE ED, V2, P247
   Knowles M, 1990, ADULT LEARNER NEGLEC
   Lambert PH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01134
   Mann Karen V, 2002, J Contin Educ Health Prof, V22, P69, DOI 10.1002/chp.1340220202
   Marinopoulos Spyridon S, 2007, Evid Rep Technol Assess (Full Rep), P1
   Moore DE, 2009, J CONTIN EDUC HEALTH, V29, P1, DOI 10.1002/chp.20001
   Rath B, 2015, CURR DRUG SAF, V10, P23, DOI 10.2174/157488631001150407104537
   Taylor DCM, 2013, MED TEACH, V35, pE1561, DOI 10.3109/0142159X.2013.828153
   Vorsters A, 2010, VACCINE, V28, P2053, DOI 10.1016/j.vaccine.2009.12.033
NR 12
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2871
EP 2881
DI 10.1016/j.vaccine.2019.02.062
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500001
PM 30898392
OA Other Gold
DA 2020-05-12
ER

PT J
AU Shen, EX
   Lambert, SB
   Malo, JA
   Bennett, S
   Sheridan, SL
   Vasant, BR
   Ware, RS
AF Shen, Eddie X.
   Lambert, Stephen B.
   Malo, Jonathan A.
   Bennett, Sonya
   Sheridan, Sarah L.
   Vasant, Bhakti R.
   Ware, Robert S.
TI Perinatal immunoprophylaxis in babies born to hepatitis B virus-positive
   mothers in Queensland Australia: A data linkage study
SO VACCINE
LA English
DT Article
DE Hepatitis B; Immunoprophylaxis; Perinatal; Vaccine; Maternal health
ID SURFACE-ANTIGEN; IMMUNIZATION; TRANSMISSION; VACCINATION; INFECTION;
   SEROCLEARANCE; PREVENTION; INFANTS; BURDEN; BIRTH
AB Vertical transmission from mother-to-child is an important mode of hepatitis B virus (HBV) infection, accounting for up to half of all incident cases globally. We evaluated the uptake of HBV neonatal vaccination and immunoglobulin delivery in Queensland, Australia, between 2001 and 2013. We identified HBV-positive mothers using linked notifiable conditions, hospitalisation, and perinatal administrative data. Perinatal receipt of monovalent HBV vaccine and hepatitis B immunoglobulin were examined. Of 710,859 live births, with 5753 infants (0.81%) born to identified HBV-positive mothers; 91.7% received HBV neonatal vaccine. Immunoglobulin uptake was 20.0% in 2012 and 36.6% in 2013. Uptake was higher when the mother's HBV-positive status was recorded in perinatal records (69.6% if maternal HBV status recorded on perinatal data collection vs 9.5% otherwise). Delivery of neonatal HBV vaccination in Queensland was high. Improved identification and documentation of HBV-positive mothers' status during the antenatal period was associated with increased immunoglobulin administration. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shen, Eddie X.] Univ Queensland, Fac Med, Herston, Qld 4006, Australia.
   [Shen, Eddie X.] Univ Queensland, Queensland Ctr Intellectual & Dev Disabil, MRI UQ, Mater Hosp, Raymond Terrace, South Brisbane, Qld 4101, Australia.
   [Lambert, Stephen B.] Univ Queensland, Child Hlth Res Ctr, South Brisbane, Qld 4101, Australia.
   [Malo, Jonathan A.; Bennett, Sonya; Vasant, Bhakti R.] Metro South Publ Hlth Unit, Level 1,39 Kessels Rd, Coopers Plains, Qld 4108, Australia.
   [Sheridan, Sarah L.] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance, Sydney, NSW 2145, Australia.
   [Ware, Robert S.] Griffith Univ, Menzies Hlth Inst Queensland, 170 Kessels Rd, Nathan, Qld 4111, Australia.
RP Shen, EX (reprint author), Univ Queensland, Queensland Ctr Intellectual & Dev Disabil, MRI UQ, Mater Hosp, Raymond Terrace, South Brisbane, Qld 4101, Australia.
EM eddie.shen@uq.net.au
RI Lambert, Stephen/B-8348-2008; Ware, Robert/B-2024-2014
OI Lambert, Stephen/0000-0002-2709-193X; Ware, Robert/0000-0002-6129-6736
CR Australian Bureau of Statistics (ABS), 2014, AUSTR STAT GEOGR STA
   Borgia G, 2012, WORLD J GASTROENTERO, V18, P4677, DOI 10.3748/wjg.v18.i34.4677
   Centers for Disease Control and Prevention, PER HEP B PREV PROGR
   Chang MH, 2007, SEMIN FETAL NEONAT M, V12, P160, DOI 10.1016/j.siny.2007.01.013
   Chen SCC, 2013, PEDIATRICS, V131, pE1135, DOI 10.1542/peds.2012-1262
   Chu CM, 2007, HEPATOLOGY, V45, P1187, DOI 10.1002/hep.21612
   Chu CM, 2010, ANTIVIR THER, V15, P133, DOI 10.3851/IMP1497
   Deng L, 2017, PUBLIC HEALTH RES PR, V27, DOI 10.17061/phrp2751745
   Deng L, 2017, MED J AUSTRALIA, V206, P301, DOI 10.5694/mja16.00823
   Department of Immigration and Citizenship, 2013, AUSTR MIGR TRENDS 20, P179
   Hendry A, 2017, COMMUN DIS INTELL, V41, pE106
   Keeble S, 2015, HUM VACC IMMUNOTHER, V11, P1153, DOI 10.1080/21645515.2015.1019977
   Ko SC, 2014, VACCINE, V32, P2127, DOI 10.1016/j.vaccine.2014.01.099
   Lee CF, 2006, BMJ-BRIT MED J, V332, P328, DOI 10.1136/bmj.38719.435833.7C
   Liu B, 2012, VACCINE, V30, P7309, DOI 10.1016/j.vaccine.2012.09.033
   Lu Y, 2017, VACCINE, V35, P40, DOI 10.1016/j.vaccine.2016.11.061
   MacLachlan JH, 2013, AUST NZ J PUBL HEAL, V37, P416, DOI 10.1111/1753-6405.12049
   McGregor S, 2018, HIV VIRAL HEPATITIS
   National Centre for Immunisation Research and Surveillance, 2015, SIGN EV HEP B VACC P
   National Health and Medical Research Centre, 2017, AUSTR IMM HDB
   Pink B., 2006, 2039 0 INFORM PAPER
   Schillie S, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6701a1
   Stanaway JD, 2016, LANCET, V388, P1081, DOI 10.1016/S0140-6736(16)30579-7
   STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503
   Van Schalkwyk J, 2014, CAN J GASTROENTEROL, V28, P525, DOI 10.1155/2014/549764
   Woodring Joseph, 2019, MMWR Morb Mortal Wkly Rep, V68, P195, DOI 10.15585/mmwr.mm6808a2
   World Health Organisation Regional Office for the Western Pacific, 2018, REG FRAM TRIPL EL MO
   Zhao Z, 2011, VACCINE, V30, P14, DOI 10.1016/j.vaccine.2011.10.076
NR 28
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2884
EP 2888
DI 10.1016/j.vaccine.2019.04.052
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500003
PM 31023554
DA 2020-05-12
ER

PT J
AU Yagi, A
   Ueda, Y
   Ikeda, S
   Sekine, M
   Nakayama, T
   Miyagi, E
   Enomoto, T
AF Yagi, Asami
   Ueda, Yutaka
   Ikeda, Sayaka
   Sekine, Masayuki
   Nakayama, Tomio
   Miyagi, Etsuko
   Enomoto, Takayuki
TI Evaluation of future cervical cancer risk in Japan, based on birth year
SO VACCINE
LA English
DT Article
DE Cervical cancer; CIN3; HPV vaccine; Birth year; Japan
ID VACCINATION
AB In 2013, following the Ministry of Health, Labor and Welfare (MHLW)'s announced suspension of its vaccine recommendation due to media reports of "adverse events", HPV vaccination dropped to almost 0%. Here, we analyzed, by birth year, the cumulative vaccinations for girls up to age 16 (maximum age for public subsidies) and the results of cervical cancer screening in Matsuyama City. The incidence of CIN3 or worse was 0.09% (7/7872) for these unvaccinated generation born between 1991 and 1993, and 0.00% (0/7389) for the vaccination generation born between 1994 and 1996. This study is the first to show the significant reduction in incidence of CIN3+depending on birth year in Japan. We must keep in mind that the unacceptable high risk for cervical cancer has already begun for an entire new generation of unvaccinated girls born in or after 2000. This data encourages a resumption of MHLWs recommendation for HPV vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yagi, Asami; Ueda, Yutaka] Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Ikeda, Sayaka] Tokyo Metropolitan Hlth & Med Treatment Corp, Dept Gynecol, Tama Hokubu Med Ctr, 1-7-1 Aoba Cho, Tokyo 1898511, Japan.
   [Sekine, Masayuki; Enomoto, Takayuki] Niigata Univ, Grad Sch Med & Dent Sci, Dept Obstet & Gynecol, Chuo Ku, 1-757 Asahimachi Dori, Niigata 9518510, Japan.
   [Nakayama, Tomio] Natl Canc Ctr, Ctr Publ Hlth Sci, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
   [Miyagi, Etsuko] Yokohama City Univ, Grad Sch Med, Dept Obstet & Gynecol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
RP Ueda, Y (reprint author), Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM ZVF03563@nifty.ne.jp
FU Health and Labor Sciences Research GrantMinistry of Health, Labour and
   Welfare, Japan [H29-024]
FX This study was supported by a Health and Labor Sciences Research Grant
   (H29-024).
CR Kudo R, 2016, INT J PATHOL CLIN RE, V2
   Luostarinen T, 2018, INT J CANCER, V142, P2186, DOI 10.1002/ijc.31231
   Ozawa N, 2017, TOHOKU J EXP MED, V243, P329, DOI 10.1620/tjem.243.329
   Tanaka Y, 2016, LANCET ONCOL, V17, P868, DOI 10.1016/S1470-2045(16)00147-9
   Ueda Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23947-6
   Yagi A, 2019, CANCER RES, V79, P1252, DOI 10.1158/0008-5472.CAN-18-3109
   Yagi A, 2018, HUM VACC IMMUNOTHER, V14, P2497, DOI 10.1080/21645515.2018.1480240
   Yagi A, 2017, HUM VACC IMMUNOTHER, V13, P1700, DOI 10.1080/21645515.2017.1292190
NR 8
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2889
EP 2891
DI 10.1016/j.vaccine.2019.04.044
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500004
PM 31027925
DA 2020-05-12
ER

PT J
AU Layton, JB
   Butler, AM
   Brookhart, MA
   Panozzo, CA
AF Layton, J. Bradley
   Butler, Anne M.
   Brookhart, M. Alan
   Panozzo, Catherine A.
TI Variation in rotavirus vaccination coding in state US Medicaid data
SO VACCINE
LA English
DT Article
DE Claims data; Immunization; Observational research; Medicaid; Rotavirus;
   Real-world data
ID COMPLETION
AB Differences in state Medicaid policies and practices may result in variation in the recording of individual level vaccination claims, which may present challenges for vaccination research using state Medicaid data. We describe differences in procedure coding for rotavirus vaccination in four states' Medicaid programs by identifying rotavirus vaccine-specific codes and oral vaccine administration codes. The proportion of vaccinated children with vaccine-specific and oral vaccine administration codes differed substantially across states: two states used vaccine-specific codes almost exclusively (95.9% and 99.0%); one had exclusively oral vaccine administration codes (>99.9%); another had a mixture (32.1% vaccine-specific codes, 40.0% oral vaccine administration codes, and 27.9% both). Depending on the research question, studies using Medicaid data in states without (or with incomplete) vaccine-specific coding may be infeasible. Prior to initiating research, investigators should carefully evaluate state Medicaid policies and patterns of vaccination uptake, as vaccine reimbursement policies and availability of vaccine claims may vary. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Layton, J. Bradley] RTI Hlth Solut, Res Triangle Pk, NC USA.
   [Layton, J. Bradley; Brookhart, M. Alan] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Butler, Anne M.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Butler, Anne M.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
   [Panozzo, Catherine A.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA.
   [Panozzo, Catherine A.] Harvard Med Sch, Boston, MA 02115 USA.
RP Layton, JB (reprint author), 200 Pk Off Dr,POB 12194, Res Triangle Pk, NC 27709 USA.
EM jblayton@rti.org; anne.butler@wustl.edu; abrookhart@unc.edu;
   Catherine_Panozzo@harvardpilgrim.org
RI Layton, Bradley/B-4950-2018
OI Layton, Bradley/0000-0003-0994-5820
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [5R21HD080214];
   CER Strategic Initiative of UNC's Clinical & Translational Science Award
   [UL1TR001111]; UNC School of Medicine
FX This work was funded by the US National Institutes of Health (grant
   number 5R21HD080214). The database infrastructure used for this project
   was funded by the CER Strategic Initiative of UNC's Clinical &
   Translational Science Award (UL1TR001111) and the UNC School of
   Medicine.
CR Anonymous, 2007, Morbidity and Mortality Weekly Report, V55, pQ1
   Byrd VLH, 2015, MATH POLICY RES
   Calnan M, 2016, HUM VACC IMMUNOTHER, V12, P1235, DOI 10.1080/21645515.2015.1136041
   Centers for Medicare & Medicaid Services, 2018, UND NUMB CHILDR EV E
   Centers for Medicare & Medicaid Services, 2018, MED MAN CAR ENR PROG, P2016
   Garfield R, 2018, MEDICAID MANAGED CAR
   Hill HA, 2017, MMWR-MORBID MORTAL W, V66, P1171, DOI 10.15585/mmwr.mm6643a3
   Kaiser Family Foundation, 2018, MED ENR AG
   Kaiser Family Foundation, 2018, MED INC EL LIM INF A
   Krishnarajah G, 2015, VACCINE, V33, P479, DOI 10.1016/j.vaccine.2014.06.059
   Panozzo CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073825
NR 11
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2892
EP 2895
DI 10.1016/j.vaccine.2019.02.074
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500005
PM 30876721
DA 2020-05-12
ER

PT J
AU McGirr, A
   Widenmaier, R
   Curran, D
   Espie, E
   Mrkvan, T
   Oostvogels, L
   Simone, B
   McElhaney, JE
   Burnett, H
   Haeussler, K
   Thano, A
   Wang, X
   Newson, RS
AF McGirr, Ashleigh
   Widenmaier, Robyn
   Curran, Desmond
   Espie, Emmanuelle
   Mrkvan, Tomas
   Oostvogels, Lidia
   Simone, Benedetto
   McElhaney, Janet E.
   Burnett, Heather
   Haeussler, Katrin
   Thano, Adriana
   Wang, Xuan
   Newson, Rachel S.
TI The comparative efficacy and safety of herpes zoster vaccines: A network
   meta-analysis
SO VACCINE
LA English
DT Review
DE Comparative efficacy; Herpes zoster; Post-herpetic neuralgia;
   Reactogenicity; Safety; Vaccine
ID ADULTS GREATER-THAN-OR-EQUAL-TO-60 YEARS; POSTHERPETIC NEURALGIA;
   SHINGLES PREVENTION; SUBUNIT VACCINE; DOUBLE-BLIND; IMMUNOGENICITY;
   TOLERABILITY; IMPACT
AB Background: We estimated the relative efficacy and safety of vaccines for prevention of herpes zoster (HZ) using network meta-analysis (NMA) based on evidence from randomized controlled trials.
   Methods: A systematic literature review evaluated two different HZ vaccines: adjuvanted recombinant zoster vaccine (RZV) and zoster vaccine live (ZVL), with different formulations assessed. Detailed feasibility assessment indicated that a NMA was feasible for efficacy (incidence of HZ and postherpetic neuralgia [PHN]) and safety (serious adverse events [SAE] and reactogenicity [injection-site reactions, systemic reaction]) outcomes. Primary analyses included frequentist NMAs with fixed effects for efficacy outcomes, due to limited data availability, and both fixed and random effects for safety and reactogenicity outcomes. As age is a known effect modifier of vaccine efficacy (VE), VE analyses were stratified by age.
   Results: RZV demonstrated significantly higher HZ efficacy than ZVL in adults >= 60 years of age (YOA) (VERZV = 0.92 (95% confidence interval [95%Cl]: 0.88, 0.94), VEZVL = 0.51 (95%Cl: 0.44, 0.57)) and adults >= 70 YOA (VERZV = 0.91 (95%Cl: 0.87, 0.94), VEZVL = 0.37 (95%Cl: 0.25, 0.48)). Similarly, RZV demonstrated significantly higher PHN efficacy than ZVL in adults >= 60 YOA (VERZV = 0.89 (95%Cl: 0.70, 0.96), VEZVL = 0.66 (95%Cl: 0.48, 0.78)) and adults >= 70 YOA (VERZV = 0.89 (95%Cl: 0.69, 0.96), VEZVL = 0.67 (95%Cl: 0.44, 0.80)). RZV was associated with significantly more injection-site and systemic reactions compared to most formulations of ZVL and placebo, however definitions and data collection procedures differed across the included studies. There were no statistically significant differences found between RZV and any formulation of ZVL or placebo for SAES.
   Conclusion: RZV is significantly more effective in reducing HZ and PHN incidence in adults >= 60 YOA, compared with ZVL. As anticipated with an adjuvanted vaccine, RZV results in more reactogenicity following immunization. No differences in SAES were found between RZV and ZVL. (C) 2019 GlaxoSmithKline SA. Published by Elsevier Ltd.
C1 [McGirr, Ashleigh; Widenmaier, Robyn] GSK Canada, 7333 Mississauga Rd N, Mississauga, ON L5N 6L4, Canada.
   [Curran, Desmond; Espie, Emmanuelle; Mrkvan, Tomas; Oostvogels, Lidia] GSK, 20 Ave Fleming, B-1300 Wavre, Belgium.
   [Simone, Benedetto] GSK, Stockley Pk West,1-3 Ironbridge Rd, Uxbridge UB11 1BT, Middx, England.
   [McElhaney, Janet E.] Hlth Sci North Res Inst, 41 Ramsey Lake Rd, Sudbury, ON P3E 5J1, Canada.
   [Burnett, Heather] Evidera, 7575 Trans Canada Hwy,Suite 404, St Laurent, PQ H4T 1V6, Canada.
   [Haeussler, Katrin] ICON Plc, Konrad Zuse Pl 11, D-81829 Munich, Germany.
   [Thano, Adriana; Newson, Rachel S.] ICON Plc, De Molen 84, NL-3995 AX Houten, Netherlands.
   [Wang, Xuan] ICON Plc, Klarabergsviadukten 90 Hus D, S-11164 Stockholm, Sweden.
   [Oostvogels, Lidia] CureVac AG, Tubingen, Germany.
RP McGirr, A (reprint author), GSK Canada, 7333 Mississauga Rd N, Mississauga, ON L5N 6L4, Canada.
EM ashleigh.a.mcgirr@gsk.com
OI Curran, Desmond/0000-0002-7423-0111
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline [207814, HO-17-18078]
FX GlaxoSmithKline Biologicals SA was the funding source and was involved
   in all stages of the study conduct and analysis (GSK study identifier:
   207814 and HO-17-18078). GlaxoSmithKline Biologicals SA also funded all
   costs associated with the development and the publishing of the present
   manuscript. All authors had full access to the data and agreed with the
   submission of the publication.
CR Advisory Committee on Immunization Practices, 2017, SUMM REP OCT 25 26 2
   [Anonymous], 2017, EPIDEMIOLOGISCHES B, V34, P333, DOI DOI 10.17886/EPIBULL-2017-044.1
   Beals CR, 2016, LANCET INFECT DIS, V16, P915, DOI 10.1016/S1473-3099(16)00133-X
   Berger R, 1998, J INFECT DIS, V178, pS99, DOI 10.1086/514265
   Boivin G, 2010, CAN J INFECT DIS MED, V21, P45, DOI 10.1155/2010/178036
   Bresnitz E, 2018, 16 NAT IMM C 05 07 J
   Chlibek R, 2013, J INFECT DIS, V208, P1953, DOI 10.1093/infdis/jit365
   Comite sur l'immunisation du Quebec, 2018, AV PERT AJ VACC ZON
   Cope S, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-93
   Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   Curran D, 2016, OPEN FORUM INFECT S1, V3, P912, DOI [10.1093/ofid/ofw194.77, DOI 10.1093/OFID/OFW194.77]
   Diez-Domingo J, 2015, VACCINE, V33, P789, DOI 10.1016/j.vaccine.2014.12.024
   Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5
   Food and Drug Administration, 2017, BLA APPR
   Gagliardi AMZ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008858.pub3
   Gilderman LI, 2008, CLIN VACCINE IMMUNOL, V15, P314, DOI 10.1128/CVI.00310-07
   Hata A, 2016, DIABETIC MED, V33, P1094, DOI 10.1111/dme.13038
   Health Canada, 2017, SHINGR PROD MON
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Jansen JP, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-159
   Johnson RW, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-37
   Kerzner B, 2007, J AM GERIATR SOC, V55, P1499, DOI 10.1111/j.1532-5415.2007.01397.x
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   Leroux-Roels G, 2016, CLIN IMMUNOL, V169, P16, DOI 10.1016/j.clim.2016.05.007
   MacIntyre CR, 2010, HUM VACCINES, V6, P894, DOI 10.4161/hv.6.11.12852
   McElhaney JE, 2016, OPEN FORUM INFECT S1, V3, P127, DOI [10.1093/ofid/ofw194.40, DOI 10.1093/OFID/OFW194.40]
   Mueller NH, 2008, NEUROL CLIN, V26, P675, DOI 10.1016/j.ncl.2008.03.011
   Murray AV, 2011, HUM VACCINES, V7, P1130, DOI 10.4161/hv.7.11.17982
   Oxman MN, 2008, J INFECT DIS, V197, pS228, DOI 10.1086/522159
   Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
   Poder A, 2016, OPEN FORUM INFECT S1, V3, P753, DOI [10.1093/ofid/ofw172.616, DOI 10.1093/OFID/OFW172.616]
   Robert Koch Institut, 2018, EPID B, V50, P541
   Rucker G, 2012, RES SYNTH METHODS, V3, P312, DOI 10.1002/jrsm.1058
   Russell AF, 2015, VACCINE, V33, P3129, DOI 10.1016/j.vaccine.2015.04.090
   Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037
   Schmader KE, 2012, CLIN INFECT DIS, V55, P1320, DOI 10.1093/cid/cis638
   Schmader KE, 2018, OPEN FORUM INFECT S1, V5, pS746, DOI [10.1093/ofid/ofy210.2141, DOI 10.1093/OFID/OFY210.2141]
   Schmader KE, 2012, CLIN INFECT DIS, V54, P922, DOI 10.1093/cid/cir970
   Schwarz TF, 2016, OPEN FORUM INFECT S1, V3, P751, DOI [10.1093/ofid/ofw172.614, DOI 10.1093/OFID/OFW172.614]
   Simberkoff MS, 2010, ANN INTERN MED, V152, P545, DOI 10.7326/0003-4819-152-9-201005040-00004
   The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 2019, ICH GUID WORK PROD
   Tricco AC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4029
   Tyring SK, 2007, VACCINE, V25, P1877, DOI 10.1016/j.vaccine.2006.10.027
   Vermeulen JN, 2012, VACCINE, V30, P904, DOI 10.1016/j.vaccine.2011.11.096
   Vesikari T, 2013, HUM VACC IMMUNOTHER, V9, P858, DOI 10.4161/hv.23412
   Vink P, 2017, HUM VACC IMMUNOTHER, V13, P574, DOI 10.1080/21645515.2016.1232787
   Weinberg A, 2017, J IMMUNOL S1, V198, P225
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2896
EP 2909
DI 10.1016/j.vaccine.2019.04.014
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500006
PM 30982636
OA Other Gold
DA 2020-05-12
ER

PT J
AU Nguyen, A
   Schwalbe, N
AF Nguyen, Aurelia
   Schwalbe, Nina
TI Apples and oranges? Can second generation vaccines become as low cost as
   generic medicines?
SO VACCINE
LA English
DT Review
DE Second generation vaccines; Generic medicines; Vaccines; Vaccine cost
ID CHALLENGES; STANDARDS
AB The recent approval of multiple new vaccines and their introduction in many Gavi countries have been the impetus for efforts to reduce the costs of these vaccines. In this paper, we provide an overview of the main cost drivers for bringing second generation vaccines and compares these, where relevant, to the cost of bringing generic medicines to market. We argue that the main cost drivers for vaccine development are fixed, implying that second-generation vaccines do not lead to the same price reduction as normally seen with generic drugs. Lastly, we provide recommendations of the areas within vaccine development that could support further cost reductions. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Nguyen, Aurelia] Gavi, Vaccine Alliance, Chemin Pommier 40, CH-1218 Geneva, Switzerland.
   [Schwalbe, Nina] Columbia Univ, Heilbrunn Dept Populat & Family Hlth, Mailman Sch Publ Hlth, 60 Haven B-2, New York, NY 10032 USA.
RP Schwalbe, N (reprint author), Columbia Univ, Heilbrunn Dept Populat & Family Hlth, Mailman Sch Publ Hlth, 60 Haven B-2, New York, NY 10032 USA.
EM anguyen@gavi.org; Nrs2@cumc.columbia.edu
CR Banker RD, 2014, ACCOUNT REV, V89, P839, DOI 10.2308/accr-50661
   Chandrasekharan S, 2015, VACCINE, V33, P6366, DOI 10.1016/j.vaccine.2015.08.063
   Elmgren L, 2013, VACCINE, V31, pB163, DOI 10.1016/j.vaccine.2012.10.117
   Gerdts V, 2015, ILAR J, V56, P53, DOI 10.1093/ilar/ilv009
   Hume HKC, 2017, VACCINE, V35, P4480, DOI 10.1016/j.vaccine.2017.02.069
   Institute of Medicine (U.S.) Committee on the Evaluation of Vaccine Purchase Financing in the United States, 2004, FIN VACC 21 CENT ASS
   Mercer Management Consulting, 2005, PNEUM CONJ PRO UNPUB
   Milstien J, 1997, VACCINE, V15, P1358, DOI 10.1016/S0264-410X(97)00053-4
   Milstien J, 2009, EXPERT REV VACCINES, V8, P559, DOI [10.1586/erv.09.23, 10.1586/ERV.09.23]
   Moon S, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-39
   Page M, 2017, FUTURE VIROL, V12, P431, DOI 10.2217/fvl-2017-0003
   Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003
   Robinson JM, 2016, VACCINE BOOK, 2ND EDITION, P77, DOI 10.1016/B978-0-12-802174-3.00005-9
   Serdobova I, 2006, AM J PUBLIC HEALTH, V96, P1554, DOI 10.2105/AJPH.2005.074583
   Sheridan C, 2005, NAT BIOTECHNOL, V23, P1359, DOI 10.1038/nbt1105-1359
   Ulmer JB, 2006, NAT BIOTECHNOL, V24, P1377, DOI 10.1038/nbt1261
   United Nations, 2016, SUST DEV GOALS REP 2
   Weinberg SH, 2012, HUM VACC IMMUNOTHER, V8, P1066, DOI 10.4161/hv.20506
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2910
EP 2914
DI 10.1016/j.vaccine.2019.04.016
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500007
PM 31010712
OA Other Gold
DA 2020-05-12
ER

PT J
AU Da Silva, DM
   Skeate, JG
   Chavez-Juan, E
   Luhen, KP
   Wu, JM
   Wu, CM
   Kast, WM
   Hwang, K
AF Da Silva, Diane M.
   Skeate, Joseph G.
   Chavez-Juan, Elena
   Luhen, Kim P.
   Wu, Jiun-Ming
   Wu, Chia-Mao
   Kast, W. Martin
   Hwang, KinKai
TI Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial
   exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical
   mouse model for HPV-associated disease
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Therapeutic vaccine; CpG adjuvant; GPI-0100
   adjuvant; HPV16-induced tumors
ID RECEPTOR 9 AGONIST; SUBUNIT VACCINE; IMMUNOLOGICAL CHARACTERIZATION;
   PHASE-I; RESPONSES; DNA; ANTIGEN; IMMUNOTHERAPY; CANCER; TRIAL
AB Persistent human papillomavirus (HPV) infection is causally linked to the development of several human cancers, including cervical, vulvar, vaginal, anal, penile, and oropharyngeal cancers. To address the need for a therapeutic vaccine against HPV-associated diseases, here we test and compare the immunogenicity and therapeutic efficacy of a bacterial exotoxin fusion protein covalently linked to the HPV16 E7 oncoprotein adjuvanted with CpG or GPI-0100 in the C3.43 preclinical HPV16-transformed tumor model. We show that TVGV-1 protein vaccine adjuvanted with either CpG or GPI-0100 adjuvant induces a high frequency of E7-specific CD8(+) T cells, and both adjuvants are able to assist the immune response in inducing polyfunctional cytokine-secreting lytic T cells that show therapeutic efficacy against well-established C3.43 tumors. CpG-adjuvanted TVGV-1 resulted in higher frequencies of IFN gamma secreting and degranulating E7-specific T cells compared to GPI-0100-adjuvanted TVGV-1, resulting in marginally increased in vivo efficacy. Despite minor differences in immune response outcomes, we consider both CpG ODN and GPI-0100 to be promising vaccine adjuvants to increase the immunogenicity and therapeutic efficacy of the TVGV-1 protein for HPV16-driven cancers. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Da Silva, Diane M.; Kast, W. Martin] Univ Southern Calif, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA.
   [Da Silva, Diane M.; Chavez-Juan, Elena; Luhen, Kim P.; Kast, W. Martin] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
   [Skeate, Joseph G.; Kast, W. Martin] Univ Southern Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
   [Wu, Jiun-Ming; Wu, Chia-Mao] TheVax Genet Vaccine Co Ltd, Zhubei City 302, Hsinchu County, Taiwan.
   [Hwang, KinKai] TheVax Genet Vaccine Co Ltd, Irvine, CA 92618 USA.
RP Da Silva, DM (reprint author), Univ Southern Calif, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA.; Da Silva, DM (reprint author), Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
EM Diane.DaSilva@med.usc.edu
OI Kast, W Martin/0000-0003-2321-3159
FU TheVax Genetics Vaccine Co., Ltd.; National Institutes of Health
   (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 CA074397]; NIH Cancer Center
   Support GrantUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P30CA014089]
FX This study was funded by TheVax Genetics Vaccine Co., Ltd. The C3.43
   tumor model was developed with support from National Institutes of
   Health (NIH) grant R01 CA074397 (to W.M.K). W.M. K. holds the Walter A.
   Richter Cancer Chair. We thank the Norris Comprehensive Cancer Center
   Beckman Center for Immune Monitoring (supported in part by the NIH
   Cancer Center Support Grant P30CA014089) for technical assistance. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Cancer
   Institute or the National Institutes of Health.
CR Amato RJ, 2014, J IMMUNOTHER, V37, P237, DOI 10.1097/CJI.0000000000000029
   Amato RJ, 2013, J IMMUNOTHER, V36, P268, DOI 10.1097/CJI.0b013e3182917f59
   Barrios K, 2012, CANCER IMMUNOL IMMUN, V61, P1307, DOI 10.1007/s00262-012-1259-8
   Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498
   Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]
   Chabeda A, 2018, PAPILLOMAVIRUS RES, V5, P46, DOI 10.1016/j.pvr.2017.12.006
   CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308
   Chen SC, 2014, ACTA BIOCH BIOPH SIN, V46, P6, DOI 10.1093/abbs/gmt121
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083
   Dreno B, 2018, LANCET ONCOL, V19, P916, DOI 10.1016/S1470-2045(18)30254-7
   Dubensky TW, 2010, SEMIN IMMUNOL, V22, P155, DOI 10.1016/j.smim.2010.04.007
   Evans TG, 2001, VACCINE, V19, P2080, DOI 10.1016/S0264-410X(00)00415-1
   FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929
   Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
   Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635
   Goletz TJ, 1997, HUM IMMUNOL, V54, P129, DOI 10.1016/S0198-8859(97)00081-5
   Hirsh V, 2011, J CLIN ONCOL, V29, P2667, DOI 10.1200/JCO.2010.32.8971
   Huang CY, 2007, GYNECOL ONCOL, V107, P404, DOI 10.1016/j.ygyno.2007.06.031
   Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038
   JINNO Y, 1989, J BIOL CHEM, V264, P15953
   Kanodia S, 2007, CURR CANCER DRUG TAR, V7, P79, DOI 10.2174/156800907780006869
   Kensil C R, 1995, Pharm Biotechnol, V6, P525
   Kim SK, 2000, VACCINE, V19, P530, DOI 10.1016/S0264-410X(00)00195-X
   Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0
   Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U
   Kruit WHJ, 2013, J CLIN ONCOL, V31, P2413, DOI 10.1200/JCO.2012.43.7111
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Liao CW, 2005, CANCER RES, V65, P9089, DOI 10.1158/0008-5472.CAN-05-0958
   Marciani DJ, 2000, VACCINE, V18, P3141, DOI 10.1016/S0264-410X(00)00118-3
   Marciani DJ, 2003, VACCINE, V21, P3961, DOI 10.1016/S0264-410X(03)00298-6
   MARCIANI DJ, 1991, VACCINE, V9, P89, DOI 10.1016/0264-410X(91)90262-5
   Newman MJ, 1997, VACCINE, V15, P1001, DOI 10.1016/S0264-410X(96)00293-9
   Peng S, 2006, GENE THER, V13, P257, DOI 10.1038/sj.gt.3302646
   Preville X, 2005, CANCER RES, V65, P641
   Ragupathi G, 2002, P NATL ACAD SCI USA, V99, P13699, DOI 10.1073/pnas.202427599
   Santos FN, 2007, VACCINE, V25, P6176, DOI 10.1016/j.vaccine.2007.06.005
   Serrano B, 2015, EUR J CANCER, V51, P1732, DOI 10.1016/j.ejca.2015.06.001
   Skeate JG, 2016, HUM VACC IMMUNOTHER, V12, P1418, DOI 10.1080/21645515.2015.1136039
   Slingluff CL, 2016, CANCER IMMUNOL IMMUN, V65, P25, DOI 10.1007/s00262-015-1770-9
   Slovin SF, 2005, VACCINE, V23, P3114, DOI 10.1016/j.vaccine.2005.01.072
   Smith KA, 2009, CLIN CANCER RES, V15, P6167, DOI 10.1158/1078-0432.CCR-09-0645
   Steinbach A, 2018, INT J CANCER, V142, P224, DOI 10.1002/ijc.31027
   Sun HX, 2009, VACCINE, V27, P1787, DOI 10.1016/j.vaccine.2009.01.091
   Vandepapeliere P, 2008, VACCINE, V26, P1375, DOI 10.1016/j.vaccine.2007.12.038
   Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008
   Wechsler EI, 2012, J VIROL, V86, P6358, DOI 10.1128/JVI.07069-11
   WU JY, 1992, J IMMUNOL, V148, P1519
   Zent CS, 2012, LEUKEMIA LYMPHOMA, V53, P211, DOI 10.3109/10428194.2011.608451
   Zhang P, 2003, VACCINE, V21, P4459, DOI 10.1016/S0264-410X(03)00438-9
NR 52
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2915
EP 2924
DI 10.1016/j.vaccine.2019.04.043
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500008
PM 31010714
OA Other Gold
DA 2020-05-12
ER

PT J
AU Huertas-Diaz, MC
   Phan, S
   Elson, A
   Nunez, I
   Wei, HL
   Sakamoto, K
   He, B
AF Huertas-Diaz, Maria Cristina
   Shannon Phan
   Elson, Andrew
   Nunez, Ivette
   Wei, Huiling
   Sakamoto, Kaori
   He, Biao
TI Parainfluenza virus 5 (PIV5) amplifying virus-like particles expressing
   respiratory syncytial virus (RSV) antigens protect mice against RSV
   infection
SO VACCINE
LA English
DT Article
DE Respiratory syncytial virus; Parainfluenza virus 5; Amplifying
   virus-like particles; Vaccine
ID VACCINE; GLYCOPROTEIN; IMMUNIZATION; RESISTANCE; FUSION; 22K
AB Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in children under one year of age. In addition to causing severe respiratory diseases in children, it is also a major cause of morbidity and mortality among the elderly and immunocompromised individuals. RSV is the most common cause of lower respiratory tract infections, yet there are currently no licensed vaccines. A parainfluenza virus 5 (PIV5)-based amplifying virus-like particle (AVLP), which enables the use of PIV5 RNA transcription/replication machinery to express gene of interest, has recently been developed. We evaluated the PIV5-based AVLP system as a vaccine platform for RSV by incorporating the fusion protein (F) gene and the transcription factor protein (M2-1) gene of RSV into the PIV5-AVLP backbone (AVLP-F and AVLP-M2-1, respectively). Mice immunized with a single dose of the AVLP-F or AVLP-M2-1 developed RSV-F or RSV-M2-1-specific immune responses, respectively. Both vaccine candidates elicited antigen-specific cell-mediated responses at levels comparable to or higher than an RSV infection. Most importantly, each vaccine was able to induce protection against RSV A2 challenge in the mouse model. These results indicate the potential of the PIV5-based AVLP system as a platform for vaccines against RSV infection. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Huertas-Diaz, Maria Cristina; Shannon Phan; Elson, Andrew; Nunez, Ivette; Wei, Huiling; He, Biao] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.
   [Sakamoto, Kaori] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA.
   [Elson, Andrew] Univ Alabama Birmingham, Birmingham, AL USA.
RP He, B (reprint author), Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.
EM bhe@uga.edu
FU endowment Fred C. Davison Distinguished University Chair in Veterinary
   Medicine
FX The authors thank all of the members of Biao He's laboratory for their
   helpful discussion and technical assistance. This work was supported by
   the endowment Fred C. Davison Distinguished University Chair in
   Veterinary Medicine to B.H.
CR Blodorn K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100392
   CHERRIE AH, 1992, J VIROL, V66, P2102, DOI 10.1128/JVI.66.4.2102-2110.1992
   Cimica V, 2016, CLIN VACCINE IMMUNOL, V23, P451, DOI 10.1128/CVI.00720-15
   Collins PL, 2013, FIELDS VIROLOGY, P1086
   CONNORS M, 1991, J VIROL, V65, P1634, DOI 10.1128/JVI.65.3.1634-1637.1991
   Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
   Green CA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008748
   Griffiths C, 2017, CLIN MICROBIOL REV, V30, P277, DOI 10.1128/CMR.00010-16
   Gu HJ, 2015, HUM VACC IMMUNOTHER, V11, P1057, DOI 10.1080/21645515.2015.1011993
   Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877
   Hwang HS, 2014, ANTIVIR RES, V110, P115, DOI 10.1016/j.antiviral.2014.07.016
   Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870
   Jiao YY, 2017, ANTIVIR RES, V144, P57, DOI 10.1016/j.antiviral.2017.05.005
   Johnson TR, 1998, J VIROL, V72, P2871, DOI 10.1128/JVI.72.4.2871-2880.1998
   KIM HW, 1971, PEDIATRICS, V48, P745
   KULKARNI AB, 1995, J VIROL, V69, P1261, DOI 10.1128/JVI.69.2.1261-1264.1995
   Lee JS, 2014, VACCINE, V32, P5866, DOI 10.1016/j.vaccine.2014.08.045
   Neuzil KM, 2016, CLIN VACCINE IMMUNOL, V23, P186, DOI 10.1128/CVI.00037-16
   OLMSTED RA, 1986, P NATL ACAD SCI USA, V83, P7462, DOI 10.1073/pnas.83.19.7462
   Phan SI, 2014, VACCINE, V32, P3050, DOI 10.1016/j.vaccine.2014.03.049
   Pierantoni A, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2015.18
   Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI 10.1586/ERV.10.115
   Schmitt AP, 1999, J VIROL, V73, P8703, DOI 10.1128/JVI.73.10.8703-8712.1999
   Schmitt AP, 2002, J VIROL, V76, P3952, DOI 10.1128/JVI.76.8.3952-3964.2002
   Schmitt PT, 2010, J VIROL, V84, P12810, DOI 10.1128/JVI.01885-10
   Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6
   Taylor G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5757
   Tripp RA, 2001, NAT IMMUNOL, V2, P732, DOI 10.1038/90675
   Waning DL, 2002, J VIROL, V76, P9284, DOI 10.1128/JVI.76.18.9284-9297.2002
   WEI HL, 2017, VACCINES, V2, DOI DOI 10.1038/S41541-017-0031-7
   Wheeler CM, 2008, VACCINE, V26, P686, DOI 10.1016/j.vaccine.2007.11.043
NR 31
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2925
EP 2934
DI 10.1016/j.vaccine.2019.04.042
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500009
PM 31010715
OA Other Gold
DA 2020-05-12
ER

PT J
AU Karppinen, S
   Toivonen, L
   Schuez-Havupalo, L
   Teros-Jaakkola, T
   Waris, M
   Auranen, K
   Palmu, AA
   Peltola, V
AF Karppinen, Sinikka
   Toivonen, Laura
   Schuez-Havupalo, Linnea
   Teros-Jaakkola, Tamara
   Waris, Matti
   Auranen, Kari
   Palmu, Arto A.
   Peltola, Ville
TI Effectiveness of the ten-valent pneumococcal Haemophilus influenzae
   protein D conjugate vaccine (PHiD-CV10) against all respiratory tract
   infections in children under two years of age
SO VACCINE
LA English
DT Article
DE Acute otitis media; Children; Pneumococcal conjugate vaccine;
   Respiratory tract infection; Streptococcus pneumoniae
ID STREPTOCOCCUS-PNEUMONIAE; RHINOVIRUS INFECTION; NASOPHARYNGEAL CARRIAGE;
   VIRAL COINFECTION; OTITIS-MEDIA; VIRUS; TRANSMISSION; COMMUNITY;
   FAMILIES; DISEASE
AB Background: Pneumococcal conjugate vaccines reduce the incidence of invasive pneumococcal diseases, pneumonia, acute otitis media (AOM), and antimicrobial prescriptions in children. We investigated the effectiveness of at least one dose of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GSK) against respiratory tract infections (RTIs) in children under two years of age.
   Methods: 424 children enrolled in a cluster-randomized, double-blind Finnish Invasive Pneumococcal disease (FinIP) vaccine trial during the years 2009-2010 were actively followed in a prospective cohort study (STEPS study) for RTIs from birth to two years of age. Children received the PHiD-CV10 vaccine, or a control vaccine (hepatitis A or B vaccine) according to an age-specific schedule. Data on RTIs were collected by symptom diaries, clinic visits, an electronic registry on hospitalizations, and by nasal swab samples analyzed for respiratory viruses. We estimated the vaccine effectiveness against all RTI episodes and RTI episodes with or without AOM by comparing the corresponding incidence rates between PHiD-CV10-vaccinated and control children, adjusted for presence of siblings and cluster as a random effect.
   Results: A total of 3193 RTI episodes were documented after the first vaccination in 368 children with all data available. The majority of the illnesses were upper RTIs caused by rhinovirus. The PHiD-CV10-vaccinated children had lower mean annual rates of all RTI episodes (6.4; 95% confidence interval [CI], 6.0-6.8) and RTI episodes with AOM (1.0; 95% CI, 0.9-1.2) as compared to the control children (7.4; 95% CI, 6.8-8.0 and 1.3; 95% CI, 1.1-1.6, respectively). The vaccine effectiveness was 12% (95% CI, 2-22%) against all
   Conclusions: Vaccination with PHiD-CV10 resulted in lower rates of RTIs in children under two years of age compared to children vaccinated with control vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Karppinen, Sinikka; Toivonen, Laura; Schuez-Havupalo, Linnea; Teros-Jaakkola, Tamara; Peltola, Ville] Turku Univ Hosp, Dept Paediat & Adolescent Med, Turku 20521, Finland.
   [Karppinen, Sinikka; Toivonen, Laura; Schuez-Havupalo, Linnea; Teros-Jaakkola, Tamara; Peltola, Ville] Univ Turku, Turku, Finland.
   [Waris, Matti] Univ Turku, Dept Virol & Clin Virol, Turku, Finland.
   [Waris, Matti] Turku Univ Hosp, Turku, Finland.
   [Auranen, Kari] Univ Turku, Dept Math & Stat, Turku, Finland.
   [Auranen, Kari] Univ Turku, Dept Clin Med, Turku, Finland.
   [Palmu, Arto A.] Natl Inst Hlth & Welf, Dept Publ Hlth Solut, Tampere, Finland.
RP Karppinen, S (reprint author), Turku Univ Hosp, Dept Paediat & Adolescent Med, Turku 20521, Finland.
EM simahe@utu.fi
FU University of Turku; Abo Akademi University; Turku University Hospital;
   Academy of FinlandAcademy of Finland [123571, 140251, 277535];
   Foundation for Pediatric Research; Specified Government Transfers,
   Hospital District of Southwest Finland; Finnish Medical Foundation;
   GlaxoSmithKline Biologicals SAGlaxoSmithKline; National Institute for
   Health and Welfare, Finland
FX The STEPS study was supported by the University of Turku; Abo Akademi
   University; Turku University Hospital; Academy of Finland grants 123571,
   140251, and 277535; the Foundation for Pediatric Research; and research
   funds from the Specified Government Transfers, Hospital District of
   Southwest Finland. Dr. Karppinen was supported by the Finnish Medical
   Foundation and the Foundation for Pediatric Research. The FinIP trial
   was funded by GlaxoSmithKline Biologicals SA, and the National Institute
   for Health and Welfare, Finland.
CR Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Bosch AATM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003057
   Cebey-Lopez M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152481
   Chonmaitree T, 2008, CLIN INFECT DIS, V46, P815, DOI 10.1086/528685
   Dagan R, 2001, PEDIATR INFECT DIS J, V20, P951, DOI 10.1097/00006454-200110000-00008
   Diavatopoulos DA, 2010, FASEB J, V24, P1789, DOI 10.1096/fj.09-146779
   Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602
   Fan RR, 2016, EMERG INFECT DIS, V22, P1996, DOI 10.3201/eid2211.160902
   Feikin DR, 2014, LANCET, V383, P1762, DOI 10.1016/S0140-6736(13)61682-7
   Glennie S, 2016, MUCOSAL IMMUNOL, V9, P56, DOI 10.1038/mi.2015.35
   Goulding J, 2011, J INFECT DIS, V204, P1086, DOI 10.1093/infdis/jir467
   Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165
   Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9
   GWALTNEY JM, 1975, J INFECT DIS, V132, P62, DOI 10.1093/infdis/132.1.62
   Heikkinen T, 2004, J INFECT DIS, V190, P1369, DOI 10.1086/424527
   Honkinen M, 2012, CLIN MICROBIOL INFEC, V18, P300, DOI 10.1111/j.1469-0691.2011.03603.x
   Ishizuka S, 2003, J INFECT DIS, V188, P1928, DOI 10.1086/379833
   Jartti T, 2011, EUR J CLIN MICROBIOL, V30, P233, DOI 10.1007/s10096-010-1075-z
   Jokela P, 2015, J CLIN VIROL, V70, P72, DOI 10.1016/j.jcv.2015.07.294
   Karppinen S, 2017, AM J RESP CRIT CARE, V196, P1172, DOI 10.1164/rccm.201702-0357OC
   Karppinen S, 2013, J PEDIATR INFECT DIS, V2, P240, DOI 10.1093/jpids/pit025
   Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030
   Lee GM, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0001
   Littorin N, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1750-5
   Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077
   Mallia P, 2012, AM J RESP CRIT CARE, V186, P1117, DOI 10.1164/rccm.201205-0806OC
   McCullers JA, 2002, J INFECT DIS, V186, P341, DOI 10.1086/341462
   McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05
   McCullers JA, 2011, ANTIVIR THER, V16, P123, DOI 10.3851/IMP1730
   Nguyen DT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001049
   Oliver BGG, 2008, THORAX, V63, P519, DOI 10.1136/thx.2007.081752
   Osterback R, 2013, J CLIN MICROBIOL, V51, P3960, DOI 10.1128/JCM.01646-13
   Palmu AA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172690
   Palmu AA, 2014, LANCET INFECT DIS, V14, P205, DOI [10.1016, 10.1016/S1473-3099(13)70338-4]
   Palmu AA, 2013, LANCET, V381, P214, DOI 10.1016/S0140-6736(12)61854-6
   Peltola V, 2008, J INFECT DIS, V197, P382, DOI 10.1086/525542
   Peltola V, 2011, PEDIATR INFECT DIS J, V30, P456, DOI 10.1097/INF.0b013e318208ee82
   Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869
   Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632, DOI 10.1086/381547
   Saez-Llorens X, 2017, HUM VACC IMMUNOTHER, V13, P1213, DOI 10.1080/21645515.2017.1287640
   Sharma-Chawla N, 2016, INFECT IMMUN, V84, P3445, DOI 10.1128/IAI.00422-16
   Short KR, 2012, MBIO, V3, DOI 10.1128/mBio.00255-12
   Sigurdsson S, 2015, PEDIATR INFECT DIS J, V34, P1385, DOI 10.1097/INF.0000000000000899
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Skevaki CL, 2015, PEDIATR INFECT DIS J, V34, P1296, DOI 10.1097/INF.0000000000000872
   Smith CM, 2014, AM J RESP CRIT CARE, V190, P196, DOI 10.1164/rccm.201311-2110OC
   Syrjanen RK, 2001, J INFECT DIS, V184, P451, DOI 10.1086/322048
   Toivonen L, 2016, PEDIATR INFECT DIS J, V35, pE362, DOI 10.1097/INF.0000000000001304
   Toivonen L, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1309
   Toivonen L, 2015, J CLIN VIROL, V62, P8, DOI 10.1016/j.jcv.2014.11.018
   Verkaik NJ, 2011, CLIN MICROBIOL INFEC, V17, P1840, DOI 10.1111/j.1469-0691.2011.03480.x
   Vesikari T, 2016, J PEDIAT INF DIS SOC, V5, P237, DOI 10.1093/jpids/piw010
   Waris M, 2013, J CLIN VIROL, V58, P200, DOI 10.1016/j.jcv.2013.06.002
   WEBSTER L. T., 1932, JOUR EXP MED, V55, P445, DOI 10.1084/jem.55.3.445
   Wolter N, 2014, J INFECT DIS, V210, P1649, DOI 10.1093/infdis/jiu326
NR 55
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2935
EP 2941
DI 10.1016/j.vaccine.2019.04.026
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500010
PM 31027929
DA 2020-05-12
ER

PT J
AU Bettampadi, D
   Boulton, ML
   Power, LE
   Hutton, DW
AF Bettampadi, Deepti
   Boulton, Matthew L.
   Power, Laura E.
   Hutton, David W.
TI Are community health workers cost-effective for childhood vaccination in
   India?
SO VACCINE
LA English
DT Article
DE Accredited social health activists; ASHA; India; Measles; Vaccine; Cost
   effectiveness; Community health workers; Sustainable development goals
ID CARE
AB Introduction: Accredited Social Health Activists (ASHAs) are female community health workers whose primary role is to promote utilization of primary healthcare services and improve sanitation in rural areas and are financially incentivized for services provided. Prior studies evaluating ASHAs have been largely qualitative, and assess their knowledge, skills, and practice. Globally, there have been very few studies that have quantitatively assessed community health workers. We analyzed the cost effectiveness of ASHAs in facilitating measles vaccination among children under 5 years during 2012-2013.
   Methods: We utilized Markov modeling simulating a cohort of children in villages with and without ASHAs. We extrapolated the health states to a lifetime of 68 years to estimate the effects of ASHA intervention. Measles vaccination rates were obtained from 2013 District Level Household and Facilities Survey 4. Other parameter estimates were obtained from a review of relevant literature.
   Results: ASHA intervention was highly cost effective at $162 per DALY averted compared to no ASHA and remained cost effective with the ASHA incentive increased from $2 to $15, across the range of probabilities and cost parameters. Analyses were sensitive to probability of death due to childhood pneumonia, susceptibility to measles after one dose measles vaccine, and probability of pneumonia after measles infection.
   Conclusion: ASHAs were cost-effective under a wide range of scenarios even when a single health outcome such as measles vaccination was considered. The Government of India and individual state governments of India should consider increasing the incentives provided to ASHAs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bettampadi, Deepti; Boulton, Matthew L.; Power, Laura E.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
   [Boulton, Matthew L.; Power, Laura E.] Michigan Med, Dept Internal Med, Div Infect Dis, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
   [Hutton, David W.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
RP Bettampadi, D (reprint author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM bdeepti@umich.edu
RI Bettampadi, Deepti/W-5804-2019
OI Bettampadi, Deepti/0000-0002-4331-1568
CR Akela B, 2017, ACCREDITED SOCIAL HL
   [Anonymous], 2018, TIMES INDIA
   ASHA, 2011, WHICH WAY FORW EV AS
   Bettampadi D, 2018, CHILDHOOD VACC UNPUB
   Bhatia K., 2014, ECON POLIT WEEKLY, V49, P145
   Bhatt H., 2012, RAPID APPRAISAL FUNC
   CDC, 2015, MORBIDITY MORTALITY
   Dabral M, 2009, INDIAN PEDIATR, V46, P957
   Farooqui H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129191
   Fisher DL, 2015, QJM-INT J MED, V108, P177, DOI 10.1093/qjmed/hcu113
   Gopalakrishnan S, 2007, INT J HEAL, V6
   Jit M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0446-9
   Kapil Umesh, 2002, Indian Journal of Pediatrics, V69, P597, DOI 10.1007/BF02722688
   Mavalankar D, 2008, CHANGING ROLE AUXILI, DOI [10.13140/RG.2.1.3731.5044, DOI 10.13140/RG.2.1.3731.5044]
   National Rural Health Mission, 2011, ASHA WHICH WAY FORW
   National Sample Survey of India, 2014, KEY IND SOC CONS IND
   Perry HB, 2014, ANNU REV PUBL HEALTH, V35, P399, DOI 10.1146/annurev-publhealth-032013-182354
   Prinja S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091781
   Puri A, 2002, INDIAN PEDIATR, V5, P5
   Rice AL, 2000, B WORLD HEALTH ORGAN, V78, P1207
   Ruth MG, 2018, PUBLIC HEAL RES, V8, P1, DOI [10.5923/i.phr20180801.01, DOI 10.5923/J.PHR.20180801.01]
   Saprii L, 2015, HUM RESOUR HEALTH, V13, DOI 10.1186/s12960-015-0094-3
   Scott K, 2010, AIDS CARE, V22, P1606, DOI 10.1080/09540121.2010.507751
   Sharma Munesh K, 2004, Indian J Med Sci, V58, P47
   Shrivastava SR, 2012, RURAL REMOTE HEALTH, V12
   SOMMER A, 1990, INT OPHTHALMOL, V14, P195, DOI 10.1007/BF00158318
   Sundararaman T, 2012, BMC P S5, V6, pO30, DOI [10.1186/1753-6561-6-s5-o30, DOI 10.1186/1753-6561-6-S5-O30]
   Thakur J. S., 2002, Indian Journal of Pediatrics, V69, P33, DOI 10.1007/BF02723774
   The Central Intelligence Agency, 2017, WORLD FACTBOOK
   Uzicanin A, 2011, J INFECT DIS, V204, pS133, DOI 10.1093/infdis/jir102
   Vaughan K, 2015, HUM RESOUR HEALTH, V13, DOI 10.1186/s12960-015-0070-y
   Vellakkal S, 2017, SOC SCI MED, V178, P55, DOI 10.1016/j.socscimed.2017.01.059
   Wagner AL, 2018, J PUBLIC HEALTH-UK, V40, pE164, DOI 10.1093/pubmed/fdx087
   WANGOMBE JK, 1984, SOC SCI MED, V18, P375, DOI 10.1016/0277-9536(84)90055-8
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   World Health Organization, 2004, GLOB BURD DIS, V2004, P1
NR 36
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2942
EP 2951
DI 10.1016/j.vaccine.2019.04.038
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500011
PM 31010713
DA 2020-05-12
ER

PT J
AU Boilesen, DR
   Ragonnaud, E
   Laursen, H
   Andersson, AMC
   Tolver, A
   Spiess, K
   Holst, PJ
AF Boilesen, Ditte R.
   Ragonnaud, Emeline
   Laursen, Henriette
   Andersson, Anne-Marie C.
   Tolver, Anders
   Spiess, Katja
   Holst, Peter J.
TI CD8+T cells induced by adenovirus-vectored vaccine are capable of
   preventing establishment of latent murine gamma-herpesvirus 68 infection
SO VACCINE
LA English
DT Article
DE Adenoviral vectored vaccine; CD8 T cells; Murine gammaherpesvirus 68;
   Invariant chain
ID IMMUNITY; PROTECTION; QUALITY; ANTIGEN; VIREMIA; FUSION; MEMORY
AB CD8+ T cells are known to control infections, but their role in preventing latent infection from establishing has not been thoroughly investigated.
   We hypothesized that a potent CD8+ T cell response patrolling the mucosal viral entry points could kill the first infected cells and thereby abrogate the infection before latency is established.
   To investigate this, replication deficient adenovirus serotype 5 vectors encoding murine gamma-herpesvirus-68 CD8+ T cell epitopes linked to the T cell adjuvant Invariant chain, were developed. We show that intranasal vaccination of mice reduces the risk of establishment of latent infection from multiple intranasal ID50 challenges with murine gamma-herpesvirus-68 by 81% per exposure at 14 days post vaccination. Protection waned over time, but immune responses were extended by heterologous prime-boost vaccination applied simultaneously intramuscularly and intranasally, and animals vaccinated 66 days prior to challenge showed a strong trend of long-term protection.
   Our data provides evidence that CD8+ T cells are able to protect against establishment of latent infection. Although the protective efficacy is difficult to maintain over time, this proof-of-concept study suggests a role for a CD8+ T cell arm in future vaccine strategies against latent human viral infections caused by pathogens such as HIV and multiple herpes virus. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Boilesen, Ditte R.; Ragonnaud, Emeline; Laursen, Henriette; Andersson, Anne-Marie C.; Holst, Peter J.] Univ Copenhagen, Ctr Med Parasitol, Dept Immunol & Microbiol, Copenhagen, Denmark.
   [Tolver, Anders] Univ Copenhagen, Dept Math Sci, Copenhagen, Denmark.
   [Spiess, Katja] Univ Copenhagen, Dept Neurosci & Pharmacol, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Ragonnaud, Emeline] NIA, NIH, Baltimore, MD 21224 USA.
   [Boilesen, Ditte R.; Andersson, Anne-Marie C.; Holst, Peter J.] InProTher ApS, DK-2200 Copenhagen, Denmark.
RP Boilesen, DR (reprint author), Panum Inst, Ctr Med Parasitol, ISIM, 7-13-16 Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark.
EM drb@sund.ku.dk
OI Holst, Peter Johannes/0000-0002-1279-304X; ragonnaud,
   emeline/0000-0001-5460-7789
FU Hede Nielsen Family foundation; Novo Nordisk FoundationNovo Nordisk
   Foundation
FX The authors wish to acknowledge GlaxoSmithKline Biologicals SA for
   providing access to chimpanzee 63 vectors, and Kristine Niss Arfeldt and
   Christopher Collins for kindly providing the murine gamma-herpesvirus
   strains. In particular, we wish to thank Birita Frittleifsdottir
   Kjaerbaek for experimental assistance during animal immunizations and
   challenges. The authors wish to thank the Hede Nielsen Family foundation
   and the Novo Nordisk Foundation for financial support during these
   studies. The authors declare no competing financial interests.
CR Amanna IJ, 2011, VIROLOGY, V411, P206, DOI 10.1016/j.virol.2010.12.016
   Barton E, 2011, ANNU REV IMMUNOL, V29, P351, DOI 10.1146/annurev-immunol-072710-081639
   Belyakov IM, 2008, VIROLOGY, V381, P106, DOI 10.1016/j.virol.2008.08.019
   Capone S, 2014, MOL THER, V22, P1039, DOI 10.1038/mt.2014.15
   Collins CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033230
   Colloca S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002925
   Croyle MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003548
   Flano E, 2005, J IMMUNOL, V174, P4972, DOI 10.4049/jimmunol.174.8.4972
   Freeman ML, 2010, J VIROL, V84, P2881, DOI 10.1128/JVI.02229-09
   Gredmark-Russ S, 2008, J VIROL, V82, P12205, DOI 10.1128/JVI.01463-08
   Grujic M, 2009, J GEN VIROL, V90, P414, DOI 10.1099/vir.0.002105-0
   Hansen SG, 2013, SCIENCE, V340, P940, DOI 10.1126/science.1237874
   Hoegh-Petersen M, 2009, VACCINE, V27, P6723, DOI 10.1016/j.vaccine.2009.08.104
   Holst PJ, 2007, J GEN VIROL, V88, P1708, DOI 10.1099/vir.0.82727-0
   Holst PJ, 2008, J IMMUNOL, V180, P3339, DOI 10.4049/jimmunol.180.5.3339
   Hudgens MG, 2009, BIOMETRICS, V65, P1223, DOI 10.1111/j.1541-0420.2009.01189.x
   Kim JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018556
   Kulkarni V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060245
   Le Gall S, 2007, J CLIN INVEST, V117, P3563, DOI 10.1172/JCI32047
   Marques S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000177
   Masopust D, 2009, J INTERN MED, V265, P125, DOI 10.1111/j.1365-2796.2008.02054.x
   Masopust D, 2006, J IMMUNOL, V177, P831, DOI 10.4049/jimmunol.177.2.831
   Mikkelsen M, 2011, J IMMUNOL, V186, P2355, DOI 10.4049/jimmunol.1001877
   Ndhlovu ZM, 2015, IMMUNITY, V43, P591, DOI 10.1016/j.immuni.2015.08.012
   Nolen TL, 2015, STAT MED, V34, P1981, DOI 10.1002/sim.6462
   Ragonnaud E, 2017, J IMMUNOTHER, V40, P51, DOI 10.1097/CJI.0000000000000153
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Sehrawat S, 2012, CELL REPORTS, V1, P461, DOI 10.1016/j.celrep.2012.03.009
   Selinger C, 2014, CLIN VACCINE IMMUNOL, V21, P1650, DOI 10.1128/CVI.00455-14
   Sorensen MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087831
   Spencer AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100538
   Steffensen MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034884
   Uddback IEM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20137
   Whitney JB, 2014, NATURE, V512, P74, DOI 10.1038/nature13594
   Xu H, 2017, EBIOMEDICINE
NR 36
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2952
EP 2959
DI 10.1016/j.vaccine.2019.04.034
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500012
PM 31006497
DA 2020-05-12
ER

PT J
AU Ming, M
   Bernardo, L
   Williams, K
   Kolattukudy, P
   Kapoor, N
   Chan, LG
   Pagnon, A
   Piras, F
   Su, J
   Gajewska, B
   Salha, D
   Gisonni-Lex, L
AF Ming, Marin
   Bernardo, Lidice
   Williams, Kimberley
   Kolattukudy, Pappachan
   Kapoor, Nidhi
   Chan, Leslie G.
   Pagnon, Anke
   Piras, Fabienne
   Su, Jin
   Gajewska, Beata
   Salha, Danielle
   Gisonni-Lex, Lucy
TI An in vitro functional assay to measure the biological activity of TB
   vaccine candidate H4-IC31
SO VACCINE
LA English
DT Article
DE Cellular immune response; In vitro potency; Tuberculosis vaccine;
   Vaccine evaluation; Mycobacterium tuberculosis; Cell based potency
ID TUBERCULOSIS VACCINE; H4IC31; REPERTOIRE; PROTECTION; ADULTS
AB Potency assays for vaccine products are an important regulatory requirement, and are used to assess product quality and consistency prior to lot release for clinical testing. Ideally they measure an established correlate of efficacy or protection. In cases where there is no known correlate of protection, however, a functional assay that measures a biological response to a vaccine can be applied as a potency assay. Here we describe an in vitro assay which quantitatively measures human T cell activation as a biological response to the TB vaccine candidate H4-IC31. The Cytokine Secretion Assay (CSA) is based on the ability of peripheral blood mononuclear cells (PBMCs) from a Bacillus Calmette-Guerin (BCG)-vaccinated human donor to process and respond to H4-IC31. The ability of H4-IC31 to stimulate a cellular immune response is measured through the quantification of secreted IFN'y and is reported as relative stimulatory activity (RSA) compared to an in-house reference standard. The CSA is specific to the H4-IC31 vaccine, determines the RSA of H4-IC31 in the range of 50% to 150% of the reference standard, and is stability indicating as it detects differences in RSA between intact and heat treated H4-IC31. Although the CSA does not provide a link to clinical efficacy, it fulfills the critical requirements for a biological potency test to assess TB vaccine candidates and can be used along with biochemical and immunochemical assays to define a product profile during clinical development, while eliminating the use of animals for product testing. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Ming, Marin; Bernardo, Lidice; Williams, Kimberley; Chan, Leslie G.; Su, Jin; Gajewska, Beata; Salha, Danielle; Gisonni-Lex, Lucy] Sanofi Pasteur, Analyt Sci, 1755 Steeles Ave West, Toronto, ON, Canada.
   [Kolattukudy, Pappachan; Kapoor, Nidhi] Univ Cent Florida, Burnett Sch Biomed Sci, 6900 Lake Nona Blvd, Orlando, FL 32816 USA.
   [Pagnon, Anke; Piras, Fabienne] Sanofi Pasteur, Res Dept, 1541 Ave Marcel Merieux, Marcy Letoile, France.
   [Kapoor, Nidhi] Sanford Burnham Prebys Med Discovery Inst, Orlando, FL USA.
   [Chan, Leslie G.] Univ British Columbia, Vancouver, BC, Canada.
   [Salha, Danielle] Altasciences, Bioanalyt Serv, Laval, PQ, Canada.
RP Ming, M (reprint author), Sanofi Pasteur, Analyt Sci, 1755 Steeles Ave West, Toronto, ON, Canada.
EM Marin.Ming@sanofi.com
FU Sanofi Pasteur
FX The laboratory of Pappachan Kolattukudy and Nidhi Kapoor at the
   University of Central Florida, Burnett School of Biomedical Science
   received funding from Sanofi Pasteur to conduct the M.tb infection and
   granuloma research described in this manuscript.
CR Arlehamn CSL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005760
   Behar SM, 2007, EXPERT REV VACCINES, V6, P441, DOI 10.1586/14760584.6.3.441
   Billeskov R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039909
   Ellis A, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.01009-16
   Gaseitsiwe S, 2010, CLIN VACCINE IMMUNOL, V17, P168, DOI 10.1128/CVI.00208-09
   Geldenhuys H, 2015, VACCINE, V33, P3592, DOI 10.1016/j.vaccine.2015.05.036
   Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976
   ICH, 1999, SPEC TEST PROC ACC C
   Jeyanathan M, 2016, J INFECT DIS, V214, P1996, DOI 10.1093/infdis/jiw467
   Kapoor N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053657
   Kritsch CE, 2005, J CHROMATOGR B, V822, P263, DOI 10.1016/j.jchromb.2005.06.013
   Little SF, 2004, VACCINE, V22, P2843, DOI 10.1016/j.vaccine.2003.12.027
   McFarland R, 2011, PROCEDIA VACCINOL, V5, P16, DOI 10.1016/j.provac.2011.10.002
   Mothe BR, 2015, TUBERCULOSIS, V95, P722, DOI 10.1016/j.tube.2015.07.005
   Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]
   Norrby M, 2017, VACCINE, V35, P1652, DOI 10.1016/j.vaccine.2017.01.055
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Seder RA, 2000, NATURE, V406, P793, DOI 10.1038/35021239
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   SILVER RF, 1995, J IMMUNOL, V154, P4665
   Triccas JA, 2016, PNEUMONIA, V8, DOI 10.1186/s41479-016-0020-z
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2960
EP 2966
DI 10.1016/j.vaccine.2019.04.035
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500013
PM 31010716
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kochhar, S
   Clarke, E
   Izu, A
   Kekane-Mochwari, KE
   Cutland, CL
AF Kochhar, Sonali
   Clarke, Ed
   Izu, Alane
   Kekane-Mochwari, Kebonethebe Emmanuel
   Cutland, Clare L.
TI Immunization in pregnancy safety surveillance in low and middle-income
   countries- field performance and validation of novel case definitions
SO VACCINE
LA English
DT Article
DE Immunisation; Vaccines; Safety; Pregnant women; Maternal immunisation;
   Adverse events following immunisation; AEFI; IMPRINT; Brighton
   Collaboration; GAIA; Case definitions, evaluation; Pregnancy outcomes;
   LMIC; Clinical trials; Preterm birth; Stillbirth; Hypertension;
   Gestational age; Ultrasound; Diagnostic certainty; Low resource setting
ID DATA-COLLECTION; BRIGHTON COLLABORATION; GUIDELINES; VACCINATION; WOMEN
AB Background: A globally standardized approach in high and low and middle-income countries (LMIC) to actively monitor the safety of vaccines for pregnant women during development and implementation phases is critical. Brighton Collaboration's (BC) Global Alignment of Immunization Safety Assessment in Pregnancy (GALA) project has developed globally standardized case definitions (CDs) of key obstetric and neonatal terms for the assessment of safety of vaccines in pregnancy. CDs are categorized into levels of diagnostic certainty, facilitating their use in varied settings. This study evaluates the field performance of CDs in LMIC.
   Methods: Data from pregnant participants of RCTs for trivalent inactivated influenza vaccine conducted at Chris Hani Baragwanath Academic Hospital, South Africa (SA) between 2011 and 2013 were reviewed retrospectively for preterm birth, stillbirth and hypertension CDs and the Gestational age assessment (GA) algorithm. Data from an ongoing pneumococcal vaccine trial (conducted at MRC Unit, The Gambia) were collected prospectively for GA.
   Results: For GA, 600 mother-infant dyads from Gambia and 155 mother-infant dyads from SA were reviewed. Level 2B (unsure LMP and US in 2nd trimester) was the most common level seen in Gambia (63%) and level 3B1 (unsure LMP with physical examination) in SA (43%). Preterm deliveries had similar results in SA. The pregnancy-induced hypertension definition performed well, with 96% (54/56) of cases fulfilling 'level 1' for 'preeclampsia with severe features'. 24 stillbirths were identified and 21 records were reviewed; 73.3% (11/15) of the stillbirths classified as antepartum by attending physicians and 83.3% (5/6) of the intrapartum stillbirths did not fulfil the criteria for any level of certainty.
   Conclusion: BC CDs for neonatal and maternal outcomes (preterm and hypertension) and GA were sensitive, reliable and feasible to use in RCTs in SA and Gambia. Modifications to the stillbirth CD are required to improve its usefulness in varied settings. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Kochhar, Sonali] Global Healthcare Consulting, New Delhi, India.
   [Kochhar, Sonali] Erasmus MC, Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.
   [Kochhar, Sonali] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Clarke, Ed] London Sch Hyg & Trop Med, Vaccines & Immun Theme, MRC Unit Gambia, Banjul, Gambia.
   [Izu, Alane; Kekane-Mochwari, Kebonethebe Emmanuel; Cutland, Clare L.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, Natl Res Fdn Vaccine Preventable Dis, Fac Hlth Sci,MRC,Dept Sci & Technol, Johannesburg, South Africa.
   [Cutland, Clare L.] Univ Witwatersrand, African Leadership Vaccinol Expertise ALIVE, Fac Hlth Sci, Johannesburg, South Africa.
RP Kochhar, S (reprint author), Erasmus MC, Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.
EM sonalikochhar@yaahoo.co.in
FU Global Challenges Research Fund (GCRF) Networks in Vaccines Research and
   Development - Medical Research Council (MRC), UK; BBSRCBiotechnology and
   Biological Sciences Research Council (BBSRC)
FX This work was supported by the Global Challenges Research Fund (GCRF)
   Networks in Vaccines Research and Development which was co-funded by the
   Medical Research Council (MRC), UK Medical Research Council (MRC), UK
   and BBSRC.
CR [Anonymous], 2018, DEL CAR
   BATES DW, 1994, CLIN INFECT DIS, V18, pS11, DOI 10.1093/clinids/18.Supplement_1.S11
   Bonhoeffer J, 2016, VACCINE, V34, P5993, DOI 10.1016/j.vaccine.2016.07.006
   Da Silva FT, 2016, VACCINE, V34, P6057, DOI 10.1016/j.vaccine.2016.03.044
   Divala TH, 2015, VACCINE, V33, P6401, DOI 10.1016/j.vaccine.2015.08.042
   Giles Michelle L, 2018, F1000Res, V7, DOI 10.12688/f1000research.15475.1
   Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152
   Kochhar S, 2018, VACCINE
   Kochhar S, 2017, VACCINE, V35, P6575, DOI 10.1016/j.vaccine.2017.03.103
   Kohl KS, 2007, VACCINE, V25, P5858, DOI 10.1016/j.vaccine.2007.04.056
   Kohl KS, 2003, PHARMACOEPIDEM DR S, V12, P335, DOI 10.1002/pds.851
   Kohl KS, 2005, ADV PATIENT SAFETY R, V2
   Komaroff AL, 1996, AM J MED, V100, P56, DOI 10.1016/S0002-9343(96)90012-1
   Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480
   Moro PL, 2016, VACCINE, V34, P5991, DOI 10.1016/j.vaccine.2016.08.026
   Padhi BK, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001851
   Quinn JA, 2016, VACCINE, V34, P6047, DOI 10.1016/j.vaccine.2016.03.045
   Rath B, 2010, VACCINE, V28, P3488, DOI 10.1016/j.vaccine.2010.02.053
   Regan AK, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0495-2
   Rouse CE, 2016, VACCINE, V34, P6069, DOI 10.1016/j.vaccine.2016.03.038
   Stark JH, 2019, INT HEALTH, V11, P128, DOI 10.1093/inthealth/ihy066
   Swamy GK, 2015, OBSTET GYNECOL, V125, P212, DOI 10.1097/AOG.0000000000000581
   Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046
NR 23
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2019
VL 37
IS 22
BP 2967
EP 2974
DI 10.1016/j.vaccine.2019.03.074
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9BT
UT WOS:000469151500014
PM 31014963
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Najminoori, M
   Mohebbi, A
   Afrooz, K
   Arabi, BG
AF Najminoori, Mahjabin
   Mohebbi, Ali
   Afrooz, Kambiz
   Arabi, Babak Ghadami
TI The effect of magnetic field and operating parameters on cathodic copper
   winning in electrowinning process
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Magnetic field; Operating parameter; Copper; Electrowinning; Cathodic
   copper morphology
ID SURFACE-MORPHOLOGY; ELECTRODEPOSITION; ORIENTATION; DEPOSITS
AB Current efficiency and quality of deposited copper are important parameters in copper electrowinning industries. The effects of imposing an external magnetic field, Fe3+ and Cu2+ mass concentrations and electrical current density on the current efficiency, the thickness of the cathodic copper sheet and its morphology in copper electrowinning process were studied at different experimental operating conditions in a cuboid cell. A full factorial design of experiment is applied here to relate current efficiency and the standard deviation (STDEV) of the thickness with and without magnetic field, Fe3+ concentration (2.5 and 3.5 g/L), Cu2+ concentration (35 and 40 g/L) and electrical current density (150 and 220 A/m(2)) with constant acid concentration of 175 g/L at temperature of 40 degrees C for a synthetic electrolyte. Scanning electron microscope (SEM) is applied in studying the surface morphology of the deposited cathodic copper in all tests. The obtained results indicated that the presence of the magnetic field and increasing Fe3+ concentration could decrease the current efficiency up to 17 and 7%, respectively. While increasing Cu2+ concentration and electrical current density increased the current efficiency. Presence of magnetic field, increasing Fe3+ concentration and electrical current density increased the thickness uniformity of copper sheets. Investigation of SEM surface images revealed variations in these main parameters had different effects on deposited cathodic copper morphology. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Najminoori, Mahjabin; Mohebbi, Ali] Shahid Bahonar Univ Kerman, Fac Engn, Dept Chem Engn, Kerman, Iran.
   [Afrooz, Kambiz] Shahid Bahonar Univ Kerman, Fac Engn, Dept Elect Engn, Kerman, Iran.
   [Arabi, Babak Ghadami] Sarcheshmeh Copper Complex, Kerman, Iran.
RP Mohebbi, A (reprint author), Shahid Bahonar Univ Kerman, Fac Engn, Dept Chem Engn, Kerman, Iran.
EM amohebbi@uk.ac.ir
RI Mohebbi, Ali/F-6012-2017
OI Mohebbi, Ali/0000-0002-2303-7231
FU Sarcheshmeh Copper Complex, Iran
FX The authors acknowledge the efforts of Sarcheshmeh Copper Complex, Iran
   in financial support of this work.
CR Alfantazi AM, 2003, J APPL ELECTROCHEM, V33, P217, DOI 10.1023/A:1024014727082
   Bao S, 2018, EFFECTS CURRENT DENS, P611
   Barnes S.C., 1960, ELECTROCHIM ACTA, V2, P195
   Bund A, 2003, ELECTROCHIM ACTA, V49, P147, DOI 10.1016/j.electacta.2003.04.009
   Coey JMD, 2007, J SOLID STATE ELECTR, V11, P711, DOI 10.1007/s10008-006-0254-4
   Das SC, 1996, INT J MINER PROCESS, V46, P91, DOI 10.1016/0301-7516(95)00056-9
   Doesburg J, 2000, MAT SCI ENG B-SOLID, V78, P44, DOI 10.1016/S0921-5107(00)00515-8
   FAHIDY TZ, 1983, J APPL ELECTROCHEM, V13, P553, DOI 10.1007/BF00617811
   Fischer H, 1954, ELEKTROLYTISCHE ABSC, V12
   Hinds G, 2001, ELECTROCHEM COMMUN, V3, P215, DOI 10.1016/S1388-2481(01)00136-9
   Ispas A, 2005, 15 RIG 6 PAMIR C FUN
   Joy S., 2010, COPPER 2010, P1379
   Krause A, 2007, ELECTROCHIM ACTA, V52, P6338, DOI 10.1016/j.electacta.2007.04.054
   Krause A, 2005, 15 RIG 6 PAMIR C FUN
   Loong Hey Y, 2007, ELECTROKINETIC APPL
   Matsushima H, 2007, ELECTROCHIM ACTA, V53, P161, DOI 10.1016/j.electacta.2007.01.043
   MOHANTA S, 1972, CAN J CHEM ENG, V50, P248, DOI 10.1002/cjce.5450500219
   Msindo Z. S, 2010, THESIS
   Muhlenhoff S, 2013, ELECTROCHEM COMMUN, V36, P80, DOI 10.1016/j.elecom.2013.09.025
   Najminoori M, 2015, HYDROMETALLURGY, V153, P88, DOI 10.1016/j.hydromet.2015.02.005
   Pick H., 1960, ELECTROCHIM ACTA, V2, P165, DOI [DOI 10.1016/0013-4686(60)87014-4, 10.1016/0013-4686(60)87014-4]
   RAO GM, 1986, J APPL ELECTROCHEM, V16, P775, DOI 10.1007/BF01006932
   Shannon JC, 1997, J ELECTROCHEM SOC, V144, pL314, DOI 10.1149/1.1838144
   TACKEN RA, 1995, J APPL ELECTROCHEM, V25, P1
   Tunnicliffe M, 2011, THESIS
   WINAND R, 1994, ELECTROCHIM ACTA, V39, P1091, DOI 10.1016/0013-4686(94)E0023-S
   Yue GK, 2009, CHEM ENG J, V147, P79, DOI 10.1016/j.cej.2008.11.044
NR 27
TC 1
Z9 1
U1 8
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 1
EP 19
DI 10.1016/j.ces.2018.12.061
PG 19
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700001
DA 2020-05-12
ER

PT J
AU Tzirakis, F
   Tsivintzelis, I
   Papadopoulos, AI
   Seferlis, P
AF Tzirakis, Fragkiskos
   Tsivintzelis, Ioannis
   Papadopoulos, Athanasios, I
   Seferlis, Panos
TI Experimental measurement and assessment of equilibrium behaviour for
   phase change solvents used in CO2 capture
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CO2 capture; Phase equilibria; Phase change solvents; DMCA; MCA; AMP;
   MAPA
ID AQUEOUS-SOLUTIONS; ABSORPTION; SOLUBILITY; MONOETHANOLAMINE; MIXTURES;
   BINARY; DEEA
AB Phase change solvents are receiving increased attention in the effort to significantly reduce regeneration energy requirements in post combustion CO2 capture processes with chemical absorption. In this study, the phase behavior of various phase change, aqueous amine solutions, was experimentally investigated. A new experimental apparatus was developed and evaluated by determining the CO2 solubility in aqueous monoethanolamine (MEA) solutions at 40, 60 and 80 degrees C. Subsequently, new experimental data were obtained for aqueous solutions containing N,N-dimethylcyclohexylamine (DMCA), methylcyclohexylamine (MCA) and 2-amino-2-methyl-1 -propanol (AMP) at 40, 60 and 90 degrees C that exhibit phase change behavior. It was observed that the investigated solutions present vapor - liquid equilibrium (VLE) at 40 degrees C and vapor-liquid-liquid equilibrium (VLLE) at 60 and 90 degrees C for CO2 partial pressures up to approximately 70 kPa. In addition, screening experiments were performed using sulfolane, which has been previously used for gas sweeting applications, instead of AMP in the DMCA-MCA mixture. However, such system presents relatively low CO2 solubility, compared to the aforementioned (DMCA-MCA-AMP) system and aqueous MEA solutions. Finally, additional screening experiments were performed for two aqueous DMCA - 3-methylaminopropylamine (MAPA) amine solutions at different concentrations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tzirakis, Fragkiskos; Tsivintzelis, Ioannis; Papadopoulos, Athanasios, I; Seferlis, Panos] Ctr Res & Technol Hellas, Chem Proc & Energy Resources Inst, Thessaloniki 57001, Greece.
   [Tsivintzelis, Ioannis] Aristotle Univ Thessaloniki, Dept Chem Engn, Thessaloniki 54124, Greece.
   [Seferlis, Panos] Aristotle Univ Thessaloniki, Dept Mech Engn, Thessaloniki 54124, Greece.
RP Tzirakis, F (reprint author), Ctr Res & Technol Hellas, Chem Proc & Energy Resources Inst, Thessaloniki 57001, Greece.
EM tzirakis@cperi.certh.gr
RI Tsivintzelis, Ioannis/AAJ-8425-2020
OI Tsivintzelis, Ioannis/0000-0002-4907-4794; Papadopoulos,
   Athanasios/0000-0001-6584-5811; Tzirakis,
   Fragkiskos/0000-0001-9062-3321; Seferlis, Panos/0000-0002-4077-4284
FU European Union's Horizon 2020 research and innovation program [727503 -
   ROLINCAP - H2020-LCE-2016-2017/H2020-L CE-2016-RES-CCS-RIA]
FX This work has received funding from the European Union's Horizon 2020
   research and innovation program under the grant agreement 727503 -
   ROLINCAP - H2020-LCE-2016-2017/H2020-L CE-2016-RES-CCS-RIA.
CR Aaron D, 2005, SEP SCI TECHNOL, V40, P321, DOI 10.1081/SS-200042244
   Aronu UE, 2011, CHEM ENG SCI, V66, P6393, DOI 10.1016/j.ces.2011.08.042
   Arshad MW, 2016, INT J GREENH GAS CON, V53, P401, DOI 10.1016/j.ijggc.2016.08.014
   Arshad MW, 2014, J CHEM ENG DATA, V59, P764, DOI 10.1021/je400886w
   Arshad MW, 2013, ENRGY PROCED, V37, P1532, DOI 10.1016/j.egypro.2013.06.029
   Bui M, 2018, ENERG ENVIRON SCI, V11, P1062, DOI [10.1039/c7ee02342a, 10.1039/C7EE02342A]
   Ciftja AF, 2013, CHEM ENG SCI, V102, P378, DOI 10.1016/j.ces.2013.08.036
   Goral M., 2012, J PHYS CHEM REF DATA, V41
   Hartono A, 2013, CHEM ENG SCI, V101, P401, DOI 10.1016/j.ces.2013.06.052
   Jeffery G.H., 1989, VOGELS TXB QUANTITAT
   Jeon SB, 2014, J TAIWAN INST CHEM E, V45, P2673, DOI 10.1016/j.jtice.2014.08.008
   JOU FY, 1995, CAN J CHEM ENG, V73, P140, DOI 10.1002/cjce.5450730116
   Kim H, 2017, CHEM ENG SCI, V166, P181, DOI 10.1016/j.ces.2017.03.045
   Kim I, 2011, INT J GREENH GAS CON, V5, P390, DOI 10.1016/j.ijggc.2010.05.003
   Mangalapally HP, 2011, CHEM ENG SCI, V66, P5512, DOI 10.1016/j.ces.2011.06.054
   Papadopoulos A. I., 2017, PROCESS SYSTEMS MAT
   Papadopoulos AI, 2016, MOL SYST DES ENG, V1, P313, DOI 10.1039/c6me00049e
   Pinto DDD, 2014, INT J GREENH GAS CON, V28, P318, DOI 10.1016/j.ijggc.2014.07.002
   Sarker Nilay Kumar, 2016, Egyptian Journal of Petroleum, V25, P343, DOI 10.1016/j.ejpe.2015.08.004
   Sartori S, 1980, Process and Amine-Solvent Absorbent for Removing Acidic Gases from Gaseous Mixtures, Patent No. [US4240923A, 4240923A]
   SHEN KP, 1992, J CHEM ENG DATA, V37, P96, DOI 10.1021/je00005a025
   Tan Y.K., 2010, THESIS
   TONTIWACHWUTHIKUL P, 1991, J CHEM ENG DATA, V36, P130, DOI 10.1021/je00001a038
   Xu ZC, 2013, IND ENG CHEM RES, V52, P9790, DOI 10.1021/ie4012936
   Xu ZC, 2013, INT J GREENH GAS CON, V16, P107, DOI 10.1016/j.ijggc.2013.03.013
   Zhang J., 2013, THESIS
   Zhang JF, 2013, ENRGY PROCED, V37, P1254, DOI 10.1016/j.egypro.2013.05.224
   Zhang JF, 2012, CHEM ENG RES DES, V90, P743, DOI 10.1016/j.cherd.2012.03.016
   Zhang JF, 2011, CHEM ENG TECHNOL, V34, P1481, DOI 10.1002/ceat.201100099
NR 29
TC 5
Z9 5
U1 6
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 20
EP 27
DI 10.1016/j.ces.2018.12.045
PG 8
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700002
DA 2020-05-12
ER

PT J
AU Qin, Y
   Zhao, CH
   Huang, B
AF Qin, Yan
   Zhao, Chunhui
   Huang, Biao
TI A new soft-sensor algorithm with concurrent consideration of slowness
   and quality interpretation for dynamic chemical process
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Soft sensor; Quality-relevant slow feature regression; Slowness; Quality
   interpretation; Dynamic process
ID PREDICTION; PHASE; IDENTIFICATION; SELECTION
AB Slowly varying process variations represented by slow features, which reflect the inherent dynamics of chemical processes, are revealed to be advantageous for quality prediction. However, if slow features are extracted from process variables as predictors without the supervision of quality indices, some obvious disadvantages are observed: (1) low quality interpretation and redundant slow features since quality information is not considered for feature extraction; (2) a lack of analysis to investigate the relationship between slow features and quality interpretation, especially for different types of quality indices. To solve the above-mentioned problems, a new soft-sensor algorithm, quality-relevant slow feature regression (QSFR), is proposed in the present work. It defines a new objective function by concurrent consideration of slowness and quality interpretation, yielding more meaningful features as predictors to interpret quality index. On the basis of this, a critical feature selection strategy is proposed based on quality interpretation to determine the retained features for regression. Moreover, an in-depth analysis of the properties of retained features is provided to reveal the hidden mechanism and how the slow time-varying process variations influence the quality interpretation. This algorithm can extract more powerful features as predictors and enhance understanding of inherent nature of slow features. Finally, the feasibility and performance of the proposed method are well illustrated for a well-known benchmark process and a real chemical process. The developed QSFR algorithm performs better than traditional slow feature regression method, in which the values of RMSE of three specific quality indices have been reduced by 8.87%, 16.60%, and 3.40%, respectively. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Qin, Yan; Zhao, Chunhui] Zhejiang Univ, Coll Control Sci & Engn, State Key Lab Ind Control Technol, Hangzhou 310027, Zhejiang, Peoples R China.
   [Huang, Biao] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB T6G 2V4, Canada.
RP Zhao, CH (reprint author), Zhejiang Univ, Coll Control Sci & Engn, State Key Lab Ind Control Technol, Hangzhou 310027, Zhejiang, Peoples R China.
EM chhzhao@zju.edu.cn
RI Huang, Biao/F-2736-2010
OI Huang, Biao/0000-0001-9082-2216
FU NSFC-Zhejiang Joint Fund for the Integration of Industrialization and
   Informatization [U1709211]; Zhejiang Key Research and Development
   Project [2019C03100, 2019C01048]
FX This work is supported by NSFC-Zhejiang Joint Fund for the Integration
   of Industrialization and Informatization (No. U1709211 and Zhejiang Key
   Research and Development Project (2019C03100 and 2019C01048).
CR Chiu CC, 2013, CHEMOMETR INTELL LAB, V125, P153, DOI 10.1016/j.chemolab.2013.04.006
   Corbett B, 2016, AICHE J, V62, P1581, DOI 10.1002/aic.15155
   Dayal BS, 1997, J CHEMOMETR, V11, P73, DOI 10.1002/(SICI)1099-128X(199701)11:1<73::AID-CEM435>3.0.CO;2-#
   Dong J, 2015, NEUROCOMPUTING, V154, P77, DOI 10.1016/j.neucom.2014.12.017
   DOWNS JJ, 1993, COMPUT CHEM ENG, V17, P245, DOI 10.1016/0098-1354(93)80018-I
   Grbic R, 2013, COMPUT CHEM ENG, V58, P84, DOI 10.1016/j.compchemeng.2013.06.014
   He QP, 2005, AICHE J, V51, P555, DOI 10.1002/aic.10325
   JOLLIFFE IT, 1982, APPL STAT-J ROY ST C, V31, P300, DOI 10.2307/2348005
   KASPAR MH, 1993, CHEM ENG SCI, V48, P3447, DOI 10.1016/0009-2509(93)85001-6
   Khatibisepehr S, 2013, J PROCESS CONTR, V23, P1575, DOI 10.1016/j.jprocont.2013.05.007
   Li WQ, 2018, IEEE T IND ELECTRON, V65, P2683, DOI 10.1109/TIE.2017.2745452
   Lu NY, 2004, CHEM ENG SCI, V59, P855, DOI 10.1016/j.ces.2003.12.003
   Luo LJ, 2018, CHEM ENG SCI, V189, P221, DOI 10.1016/j.ces.2018.05.055
   Ma YJ, 2017, IEEE T IND ELECTRON, V64, P7171, DOI 10.1109/TIE.2017.2688970
   Nomikos P, 1995, CHEMOMETR INTELL LAB, V30, P97, DOI 10.1016/0169-7439(95)00043-7
   Qin Y, 2017, CHEM ENG SCI, V166, P130, DOI 10.1016/j.ces.2017.03.033
   Reis MS, 2016, CHEM ENG PROG, V112, P46
   Russell EL, 2000, CHEMOMETR INTELL LAB, V51, P81, DOI 10.1016/S0169-7439(00)00058-7
   Shang C, 2015, P AMER CONTR CONF, P912, DOI 10.1109/ACC.2015.7170850
   Shang C, 2015, AICHE J, V61, P4126, DOI 10.1002/aic.14937
   Strang G., 2003, INTRO LINEAR ALGEBRA, P343
   Vanhatalo E, 2017, CHEMOMETR INTELL LAB, V167, P1, DOI 10.1016/j.chemolab.2017.05.016
   Wiskott L, 2002, NEURAL COMPUT, V14, P715, DOI 10.1162/089976602317318938
   WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9
   Wooldridge J. M., 2013, INTRO ECONOMETRICS M, P35
   Yao Y, 2009, J PROCESS CONTR, V19, P816, DOI 10.1016/j.jprocont.2008.11.001
   Yu HL, 2004, CHEMOMETR INTELL LAB, V73, P199, DOI 10.1016/j.chemolab.2004.04.006
   Yu WK, 2018, IEEE T IND ELECTRON, V65, P5931, DOI 10.1109/TIE.2017.2782232
   Zhang SM, 2018, CHEM ENG SCI, V178, P104, DOI 10.1016/j.ces.2017.12.025
   Zhao CH, 2018, AICHE J, V64, P1662, DOI 10.1002/aic.16048
   Zhao CH, 2017, IEEE T CONTR SYST T, V25, P842, DOI 10.1109/TCST.2016.2576018
   Zhao CH, 2016, J PROCESS CONTR, V38, P31, DOI 10.1016/j.jprocont.2015.12.002
   Zhao CH, 2015, CHEMOMETR INTELL LAB, V146, P396, DOI 10.1016/j.chemolab.2015.06.008
NR 33
TC 6
Z9 6
U1 8
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 28
EP 39
DI 10.1016/j.ces.2019.01.011
PG 12
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700003
DA 2020-05-12
ER

PT J
AU Ding, ML
   Yue, SH
   Li, J
   Wang, YR
   Wang, HX
AF Ding, Mingliang
   Yue, Shihong
   Li, Jia
   Wang, Yaru
   Wang, Huaxiang
TI Second-order sensitivity coefficient based electrical tomography imaging
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Electrical tomography; Second-order sensitivity; Image reconstruction;
   Quadratic programming
ID RESISTANCE TOMOGRAPHY; CAPACITANCE TOMOGRAPHY; IMPEDANCE TOMOGRAPHY;
   ALGORITHM; RECONSTRUCTION; TANKS
AB In this paper, efforts are made to improve the spatial resolution of electrical tomography imaging (ETI), which has succeeded in many fields in the past decades as an advanced process tomography technique. However, its spatial resolution is usually too low to be efficiently used in applications due to the inaccurate sensitivity coefficient. Most of the existing ETI algorithms use the linear components of sensitivity coefficient owing to easy implementation and comprehensive operation. However, the neglected nonlinear parts may contain more useful information. In this paper, we characterized the nonlinear second-order sensitivity coefficient, analyzed its major characteristics, and finally proposed a novel ETI model, which was helpful for improving the spatial resolution of the ETI process. Experimental results showed that this model had higher spatial resolutions than the traditional models that only used linear sensitivity coefficients. The research in this paper can provide reference for the ETI-related applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ding, Mingliang; Yue, Shihong; Li, Jia; Wang, Yaru; Wang, Huaxiang] Tianjin Univ, Sch Elect & Informat Engn, Tianjin 300072, Peoples R China.
   [Ding, Mingliang] Qufu Normal Univ, Sch Engn, Rizhao 276826, Peoples R China.
RP Yue, SH (reprint author), Tianjin Univ, Sch Elect & Informat Engn, Tianjin 300072, Peoples R China.
EM shyue1999@tju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [61573251]
FX This work was supported by the National Natural Science Foundation of
   China (No. 61573251).
CR Carletti C, 2016, CHEM ENG SCI, V152, P478, DOI 10.1016/j.ces.2016.06.044
   Chandrasekera TC, 2015, CHEM ENG SCI, V126, P679, DOI 10.1016/j.ces.2015.01.011
   Cilliers JJ, 2001, MEAS SCI TECHNOL, V12, P997, DOI 10.1088/0957-0233/12/8/302
   Lima CR, 2007, MEAS SCI TECHNOL, V18, P2847, DOI 10.1088/0957-0233/18/9/014
   Ding ML, 2018, FLOW MEAS INSTRUM, V59, P72, DOI 10.1016/j.flowmeasinst.2017.11.012
   Dong F, 2003, FLOW MEAS INSTRUM, V14, P183, DOI 10.1016/S0955-5986(03)00024-4
   Hao JN, 2013, FLOW MEAS INSTRUM, V29, P39, DOI 10.1016/j.flowmeasinst.2012.10.007
   Hosseini S, 2010, CHEM ENG SCI, V65, P1374, DOI 10.1016/j.ces.2009.10.007
   Ma YX, 1997, CHEM ENG SCI, V52, P2197, DOI 10.1016/S0009-2509(97)00045-6
   Marashdeh Q, 2008, IND ENG CHEM RES, V47, P3708, DOI 10.1021/ie0713590
   Polydorides N, 2002, MEAS SCI TECHNOL, V13, P1862, DOI 10.1088/0957-0233/13/12/309
   SANTOSA F, 1990, SIAM J APPL MATH, V50, P216, DOI 10.1137/0150014
   Sapkota A, 2015, FLOW MEAS INSTRUM, V46, P334, DOI 10.1016/j.flowmeasinst.2015.06.023
   Sharifi M, 2013, CHEM ENG RES DES, V91, P1625, DOI 10.1016/j.cherd.2013.05.026
   Soleimani M, 2007, MEAS SCI TECHNOL, V18, P3287, DOI 10.1088/0957-0233/18/11/004
   Sun BY, 2015, MEAS SCI TECHNOL, V26, DOI 10.1088/0957-0233/26/12/125402
   Tan WH, 2017, IEEE SENS J, V17, P8234, DOI 10.1109/JSEN.2017.2705108
   Vauhkonen M, 1998, IEEE T MED IMAGING, V17, P285, DOI 10.1109/42.700740
   Wang JR, 2014, J MED BIOL ENG, V34, P598, DOI 10.5405/jmbe.1774
   Wang Q, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.4760253
   Wang SS, 2017, J PETROL SCI ENG, V157, P833, DOI 10.1016/j.petrol.2017.07.075
   Warsito, 1999, CHEM ENG SCI, V54, P4711, DOI 10.1016/S0009-2509(99)00175-X
   Yang WQ, 1999, MEAS SCI TECHNOL, V10, P1065, DOI 10.1088/0957-0233/10/11/315
   Yang YJ, 2017, IEEE SENS J, V17, P5589, DOI 10.1109/JSEN.2017.2728179
   Yao JF, 2017, IEEE SENS J, V17, P8196, DOI 10.1109/JSEN.2017.2682929
NR 25
TC 1
Z9 2
U1 3
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 40
EP 49
DI 10.1016/j.ces.2019.01.020
PG 10
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700004
DA 2020-05-12
ER

PT J
AU Yu, XB
   Shen, YS
AF Yu, Xiaobing
   Shen, Yansong
TI Model analysis of gas residence time in an ironmaking blast furnace
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD; Blast furnace; RTD; Flow patterns; Transient behavior; Model
ID MATHEMATICAL-MODEL; MULTI-FLUID; FLOW; DISTRIBUTIONS; PREDICTION; BED;
   PERFORMANCE; PARTICLES; SOLIDS; MOTION
AB Gas residence time distribution (RTD) is an effective and convenient indicator for evaluating the performance of complex multiphase chemical reactors including ironmaking blast furnaces (BFs). However, in the open literature, there lacks the systematic RTD research for BFs. In this study, an integrated mathematical model is developed for describing the gas RTD of a BF. The model combines a steady multi-fluid model for describing the in-furnace state of flow and thermo-chemical behavior of gas-solid-liquid phases and a transient model for describing the dynamic behavior of tracer materials. The results show that the gas flow field inside the BF is quite complex, resulting from many factors such as furnace geometry and coupled thermo-chemical behaviors of other phases. The tail of gas RTD curve resulted from the lagging phenomenon of tracer flow inside BFs, is captured. The gas RTD is discussed by using mean residence time, dispersion of molecules distribution, cumulative distribution function and residence time intensity function. Under the given BF conditions, mean residence time and space time of gas fluids are predicted as 13.5 s and 16.3 s, respectively. The existence of stagnant flow in the BF can be both derived and directly identified. Moreover, it is indicated the gas flow patterns in the BF are composed of piston-type flow, stagnant flow and limited mixing flow. This study provides a cost-effective tool for better understanding BF gas flow dynamics and optimizing BF operations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yu, Xiaobing; Shen, Yansong] Univ New South Wales, Sch Chem Engn, Sydney, NSW 2052, Australia.
RP Shen, YS (reprint author), Univ New South Wales, Sch Chem Engn, Sydney, NSW 2052, Australia.
EM ys.shen@unsw.edu.au
RI Shen, Yansong/A-9037-2010
OI Shen, Yansong/0000-0001-8472-8805
FU Australian Research CouncilAustralian Research Council [LP160101100,
   DP180101232]; Baosteel; China Scholarship CouncilChina Scholarship
   Council
FX This work is financially supported by Australian Research Council
   (LP160101100, DP180101232) and Baosteel. The first author wishes to
   acknowledge the financial support from China Scholarship Council.
CR Austin P. R, 1997, MODELLING BLAST FURN
   Austin PR, 1998, ISIJ INT, V38, P239, DOI 10.2355/isijinternational.38.239
   Austin PR, 1997, ISIJ INT, V37, P748, DOI 10.2355/isijinternational.37.748
   Austin PR, 1997, ISIJ INT, V37, P458, DOI 10.2355/isijinternational.37.458
   BILOUS O, 1955, AICHE J, V1, P513, DOI 10.1002/aic.690010422
   BUFFHAM BA, 1993, CHEM ENG SCI, V48, P3879, DOI 10.1016/0009-2509(93)80366-X
   Chen JH, 2009, IND ENG CHEM RES, V48, P8172, DOI 10.1021/ie801644d
   Cholette A., 1960, CAN J CHEM ENG, V38, P1
   DANCKWERTS PV, 1954, CHEM ENG SCI, V3, P26, DOI 10.1016/0009-2509(54)80004-2
   DANCKWERTS PV, 1958, CHEM ENG SCI, V8, P93, DOI 10.1016/0009-2509(58)80040-8
   DANCKWERTS PV, 1953, CHEM ENG SCI, V2, P1, DOI 10.1016/0009-2509(53)80001-1
   de Castro JA, 2000, ISIJ INT, V40, P637, DOI 10.2355/isijinternational.40.637
   de Castro JA, 2017, J MATER RES TECHNOL, V6, P258, DOI 10.1016/j.jmrt.2017.05.007
   Dong XF, 2010, METALL MATER TRANS B, V41, P330, DOI 10.1007/s11663-009-9327-y
   Fogler H. S., 2016, ELEMENTS CHEM REACTI
   Fu D, 2014, J THERM SCI ENG APPL, V6, DOI 10.1115/1.4025946
   FULLER EN, 1966, IND ENG CHEM, V58, P19, DOI 10.1021/ie50677a007
   Geerdes M, 2015, MODERN BLAST FURNACE
   Geng SJ, 2017, POWDER TECHNOL, V320, P555, DOI 10.1016/j.powtec.2017.07.085
   GILLILAND ER, 1952, IND ENG CHEM, V44, P218, DOI 10.1021/ie50505a060
   Han QQ, 2015, PARTICUOLOGY, V21, P187, DOI 10.1016/j.partic.2014.10.011
   Hua LN, 2018, CHEM ENG SCI, V186, P168, DOI 10.1016/j.ces.2018.04.027
   Kuang SB, 2014, MINER ENG, V63, P45, DOI 10.1016/j.mineng.2013.11.002
   Levenspiel O., 1964, ADV CHEM ENG, V4, P95, DOI 10.1016/S0065-2377(08)60240-9
   Li Z, 2018, METALL MAT T B
   Liu G.Q., 2009, FRONTIERS ENERGY POW, V4, P280
   NAOR P, 1963, IND ENG CHEM FUND, V2, P278, DOI 10.1021/i160008a007
   Nauman EB, 2008, IND ENG CHEM RES, V47, P3752, DOI 10.1021/ie071635a
   NAUMAN EB, 1981, CHEM ENG COMMUN, V8, P53, DOI 10.1080/00986448108912576
   Nauman EB, 2002, CHEM ENG RES DES, V80, P681, DOI 10.1205/026387602760312890
   NAUMAN EB, 1991, CHEM ENG J BIOCH ENG, V47, P141, DOI 10.1016/0300-9467(91)85019-R
   Nogami H, 2005, COMPUT CHEM ENG, V29, P2438, DOI 10.1016/j.compchemeng.2005.05.024
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   Plasari E, 1999, NUKLEONIKA, V44, P39
   Rangarajan D, 2014, IND ENG CHEM RES, V53, P4983, DOI 10.1021/ie301936r
   Ring T, 2004, PREDICTING RESIDENCE, P31
   Shen Y. S, 2014, METALL MATER TRANS B, V46, P432
   Shen YS, 2016, METALL MATER TRANS B, V47, P1052, DOI 10.1007/s11663-015-0557-x
   Shen YS, 2011, STEEL RES INT, V82, P532, DOI 10.1002/srin.201100045
   Sun XS, 2016, PHYS REV E, V94, DOI 10.1103/PhysRevE.94.063301
   VRBATA O, 1979, POWDER TECHNOL, V22, P179, DOI 10.1016/0032-5910(79)80024-8
   WILKE CR, 1950, CHEM ENG PROG, V46, P95
   WOLF D, 1963, IND ENG CHEM FUND, V2, P287, DOI 10.1021/i160008a008
   YAGI J, 1993, ISIJ INT, V33, P619, DOI 10.2355/isijinternational.33.619
   Yaji J, 1980, TETSU TO HAGANE, V66, P1888
   Yang K, 2010, ISIJ INT, V50, P972, DOI 10.2355/isijinternational.50.972
   Yang SL, 2013, IND ENG CHEM RES, V52, P13222, DOI 10.1021/ie401811y
   Yu XB, 2018, METALL MATER TRANS B, V49, P2370, DOI 10.1007/s11663-018-1332-6
   Zhang ZL, 2016, METALL MATER TRANS B, V47, P467, DOI 10.1007/s11663-015-0483-y
   Zou Z, 2017, PARTICUOLOGY, V32, P30, DOI 10.1016/j.partic.2016.09.005
   ZWIETERING TN, 1959, CHEM ENG SCI, V11, P1, DOI 10.1016/0009-2509(59)80068-3
NR 51
TC 4
Z9 4
U1 3
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 50
EP 63
DI 10.1016/j.ces.2018.12.062
PG 14
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700005
DA 2020-05-12
ER

PT J
AU Zhang, RG
   Peng, M
   Ling, LX
   Wang, BJ
AF Zhang, Riguang
   Peng, Mao
   Ling, Lixia
   Wang, Baojun
TI PdIn intermetallic material with isolated single-atom Pd sites - A
   promising catalyst for direct formic acid fuel cell
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Intermetallic structures; HCOOH oxidation; Single-atom Pd site; Pd
   trimer; Catalytic performance
ID TOTAL-ENERGY CALCULATIONS; FINDING SADDLE-POINTS; ELECTROCATALYTIC
   PERFORMANCE; HCOOH DECOMPOSITION; HYDROGEN-PRODUCTION; EFFICIENT
   CATALYST; SURFACE HYDROXYLS; CO2 HYDROGENATION; OXIDATION; NANOPARTICLES
AB Isolated single-atom Pd sites in intermetallic structures have the higher stability and unique catalytic properties. This study was designed to investigate the properties of isolated single-atom Pd sites in PdIn intermetallic toward formic acid oxidation compared to Pd3In and the pure Pd using density functional theory calculation. Unexpectedly, CO adsorption over PdIn catalyst is significantly lower than those over Pd3In and the pure Pd catalysts, an indication that CO poisoning is remarkably reduced on PdIn catalysts compared to the Pd3In and pure Pd catalysts. More importantly, PdIn catalyst with isolated single-atom Pd sites exhibits higher selectivity for formic acid oxidation to CO2 and inhibits CO formation, whereas Pd3In catalyst with Pd trimer presents better selectivity for formic acid oxidation to CO, which poisons Pd-based catalyst. Moreover, compared to the pure Pd catalyst, PdIn catalyst with isolated single-atom Pd sites not only has the higher activity and stability but also maximize atomic efficiency for noble metal Pd to reduce the catalyst cost. It is expected that the method applied in this research is beneficial to for the design and evaluation of intermetallic catalysts in clean energy technology development. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Riguang; Peng, Mao; Ling, Lixia; Wang, Baojun] Taiyuan Univ Technol, Key Lab Coal Sci & Technol Minist Educ & Shanxi P, Taiyuan 030024, Shanxi, Peoples R China.
RP Wang, BJ (reprint author), Taiyuan Univ Technol, Key Lab Coal Sci & Technol Minist Educ & Shanxi P, Taiyuan 030024, Shanxi, Peoples R China.
EM wangbaojun@tyut.edu.cn
FU Key projects of National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [21736007]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [21776193, 21476155]; China Scholarship CouncilChina Scholarship Council
   [201606935026]; Top Young Innovative Talents of Shanxi
FX This work is financially supported by the Key projects of National
   Natural Science Foundation of China (No. 21736007), the National Natural
   Science Foundation of China (Nos. 21776193, 21476155), the China
   Scholarship Council (201606935026), the Top Young Innovative Talents of
   Shanxi, and U.S. NSF-sponsored NCAR-Wyoming Supercomputing Center
   (NWSC).
CR BLOCHL PE, 1994, PHYS REV B, V50, P17953, DOI 10.1103/PhysRevB.50.17953
   Cao XM, 2011, CATAL TODAY, V165, P71, DOI 10.1016/j.cattod.2010.12.056
   Chen YX, 2006, ANGEW CHEM INT EDIT, V45, P981, DOI 10.1002/anie.200502172
   Cho J, 2017, ACS CATAL, V7, P2553, DOI 10.1021/acscatal.6b02825
   Cho J, 2014, J PHYS CHEM C, V118, P22553, DOI 10.1021/jp5050817
   Choi Y, 2009, J AM CHEM SOC, V131, P13054, DOI 10.1021/ja903013x
   Clay JP, 2014, J CATAL, V320, P106, DOI 10.1016/j.jcat.2014.09.026
   Corma A, 2013, NAT CHEM, V5, P775, DOI [10.1038/NCHEM.1721, 10.1038/nchem.1721]
   Cui ZM, 2013, J MATER CHEM A, V1, P1179, DOI 10.1039/c2ta00435f
   Dai L, 2011, J POWER SOURCES, V196, P9369, DOI 10.1016/j.jpowsour.2011.08.004
   Dong QZ, 2017, INT J ELECTROCHEM SC, V12, P1389, DOI 10.20964/2017.02.02
   Duan T, 2016, J PHYS CHEM C, V120, P2234, DOI 10.1021/acs.jpcc.5b10831
   Fan Y, 2016, RSC ADV, V6, P43980, DOI 10.1039/c6ra07560f
   Feng QC, 2017, J AM CHEM SOC, V139, P7294, DOI 10.1021/jacs.7b01471
   Flytzani-Stephanopoulos M, 2012, ANNU REV CHEM BIOMOL, V3, P545, DOI 10.1146/annurev-chembioeng-062011-080939
   Gu XJ, 2011, J AM CHEM SOC, V133, P11822, DOI 10.1021/ja200122f
   Guo XG, 2014, SCIENCE, V344, P616, DOI 10.1126/science.1253150
   Ha S, 2006, J POWER SOURCES, V158, P129, DOI 10.1016/j.jpowsour.2005.09.048
   Ha S, 2005, J POWER SOURCES, V144, P28, DOI 10.1016/j.jpowsour.2004.12.031
   Haan JL, 2010, J PHYS CHEM C, V114, P11665, DOI 10.1021/jp102990t
   Haan JL, 2010, ELECTROCHIM ACTA, V55, P2477, DOI 10.1016/j.electacta.2009.12.004
   HARRIS IR, 1968, J LESS-COMMON MET, V16, P427, DOI 10.1016/0022-5088(68)90141-0
   He F, 2016, J POWER SOURCES, V316, P8, DOI 10.1016/j.jpowsour.2016.03.062
   Henkelman G, 1999, J CHEM PHYS, V111, P7010, DOI 10.1063/1.480097
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   Hu CQ, 2014, INT J HYDROGEN ENERG, V39, P381, DOI 10.1016/j.ijhydene.2013.10.067
   Hu CQ, 2012, INT J HYDROGEN ENERG, V37, P15956, DOI 10.1016/j.ijhydene.2012.08.035
   Hu SZ, 2014, ELECTROCHEM COMMUN, V38, P107, DOI 10.1016/j.elecom.2013.11.010
   Hu SZ, 2012, ELECTROCHIM ACTA, V83, P354, DOI 10.1016/j.electacta.2012.06.111
   Huang W., 2016, ANGEW CHEM, V128, P13639, DOI DOI 10.1002/ange.201604708
   Jiang J, 2002, J ELECTROANAL CHEM, V520, P64, DOI 10.1016/S0022-0728(01)00739-2
   KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133
   Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169
   Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0
   Kyriakou G, 2012, SCIENCE, V335, P1209, DOI 10.1126/science.1215864
   Lee JK, 2008, ELECTROCHIM ACTA, V53, P3474, DOI 10.1016/j.electacta.2007.12.031
   Lee JH, 2016, J MATER CHEM A, V4, P14141, DOI 10.1039/c6ta03654f
   Lee SY, 2014, ACS CATAL, V4, P2402, DOI 10.1021/cs500227j
   Lee S, 2016, ACS CATAL, V6, P134, DOI 10.1021/acscatal.5b01691
   Li JD, 2012, J MOL CATAL A-CHEM, V365, P103, DOI 10.1016/j.molcata.2012.08.016
   Li RS, 2011, ELECTROCHIM ACTA, V56, P6860, DOI 10.1016/j.electacta.2011.05.097
   Li XG, 2016, ADV MATER, V28, P2427, DOI 10.1002/adma.201505281
   Lin J, 2013, J AM CHEM SOC, V135, P15314, DOI 10.1021/ja408574m
   Liu P, 2007, J CHEM PHYS, V126
   Liu YX, 2016, ADV MATER, V28, P4747, DOI 10.1002/adma.201600603
   Liu ZL, 2009, ELECTROCHEM COMMUN, V11, P1667, DOI 10.1016/j.elecom.2009.06.023
   Lovic JD, 2005, J ELECTROANAL CHEM, V581, P294, DOI 10.1016/j.jelechem.2005.05.002
   Lu L, 2012, ELECTROCHIM ACTA, V85, P187, DOI 10.1016/j.electacta.2012.08.113
   Miao KH, 2017, ELECTROCHIM ACTA, V251, P588, DOI 10.1016/j.electacta.2017.08.167
   Miyake H, 2008, PHYS CHEM CHEM PHYS, V10, P3662, DOI 10.1039/b805955a
   Momma K, 2011, J APPL CRYSTALLOGR, V44, P1272, DOI 10.1107/S0021889811038970
   Mori K, 2013, ACS CATAL, V3, P1114, DOI 10.1021/cs400148n
   Moses-DeBusk M, 2013, J AM CHEM SOC, V135, P12634, DOI 10.1021/ja401847c
   Olsen RA, 2004, J CHEM PHYS, V121, P9776, DOI 10.1063/1.1809574
   Pan YX, 2010, J CATAL, V272, P227, DOI 10.1016/j.jcat.2010.04.003
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Peterson EJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5885
   Qi YY, 2015, RSC ADV, V5, P21170, DOI 10.1039/c5ra01925g
   Qiao BT, 2011, NAT CHEM, V3, P634, DOI [10.1038/NCHEM.1095, 10.1038/nchem.1095]
   Ren MJ, 2014, J PHYS CHEM C, V118, P12669, DOI 10.1021/jp5033417
   Sheppard D., 2012, J CHEM PHYS, V136
   Sheppard D, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2841941
   Singh S, 2014, AICHE J, V60, P1303, DOI 10.1002/aic.14401
   Tedsree K, 2011, NAT NANOTECHNOL, V6, P302, DOI [10.1038/nnano.2011.42, 10.1038/NNANO.2011.42]
   Tierney HL, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.246102
   Uhm S, 2009, PHYS CHEM CHEM PHYS, V11, P9326, DOI 10.1039/b909525j
   Upham DC, 2017, SCIENCE, V358, P917, DOI 10.1126/science.aao5023
   Wang GC, 2006, J PHYS CHEM B, V110, P9, DOI 10.1021/jp055689e
   Wang JJ, 2009, INT J HYDROGEN ENERG, V34, P8270, DOI 10.1016/j.ijhydene.2009.07.082
   Wang P, 2017, ACS CATAL, V7, P1955, DOI 10.1021/acscatal.6b03544
   Wang RF, 2008, J POWER SOURCES, V180, P205, DOI 10.1016/j.jpowsour.2008.02.027
   Wang XM, 2008, ELECTROCHEM COMMUN, V10, P1644, DOI 10.1016/j.elecom.2008.08.043
   Wang YY, 2016, INT J HYDROGEN ENERG, V41, P7342, DOI 10.1016/j.ijhydene.2016.03.116
   Wang YY, 2014, COMPUT THEOR CHEM, V1049, P51, DOI 10.1016/j.comptc.2014.09.020
   Wang YY, 2014, J PHYS CHEM C, V118, P2067, DOI 10.1021/jp410742p
   Wei HS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6634
   Westerstrom R, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.115440
   Wunder S, 2011, ACS CATAL, V1, P908, DOI 10.1021/cs200208a
   Xu CX, 2012, J POWER SOURCES, V199, P124, DOI 10.1016/j.jpowsour.2011.10.075
   Yan H, 2015, J AM CHEM SOC, V137, P10484, DOI 10.1021/jacs.5b06485
   Yang XF, 2013, ACCOUNTS CHEM RES, V46, P1740, DOI 10.1021/ar300361m
   Zhang HJ, 2012, NAT MATER, V11, P49, DOI [10.1038/NMAT3143, 10.1038/nmat3143]
   Zhang L, 2014, ACS CATAL, V4, P1546, DOI 10.1021/cs500071c
   Zhang RG, 2012, J PHYS CHEM C, V116, P22266, DOI 10.1021/jp211900z
   Zhang RG, 2012, APPL CATAL B-ENVIRON, V126, P108, DOI 10.1016/j.apcatb.2012.07.009
   Zhang ZH, 2009, FUEL CELLS, V9, P114, DOI 10.1002/fuce.200800074
   Zhao XJ, 2014, RSC ADV, V4, P58631, DOI 10.1039/c4ra05591h
   Zhong WH, 2015, J POWER SOURCES, V278, P203, DOI 10.1016/j.jpowsour.2014.12.071
   Zhou SD, 2011, CATAL LETT, V141, P726, DOI 10.1007/s10562-011-0553-y
   Zou LL, 2015, NANO RES, V8, P2777, DOI 10.1007/s12274-015-0784-0
NR 90
TC 3
Z9 3
U1 32
U2 159
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 64
EP 78
DI 10.1016/j.ces.2019.01.018
PG 15
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700006
DA 2020-05-12
ER

PT J
AU Salmi, T
   Russo, V
AF Salmi, Tapio
   Russo, Vincenzo
TI Reaction engineering approach to the synthesis of sodium borohydride
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sodium borohydride; Trimethyl borate; Synthesis; Kinetics; Slurry
   reactor; Mathematical model
AB A mathematical model for the synthesis of sodium borohydride (NaBH4) from finely dispersed solid sodium hydride (NaH) and dissolved trimethyl borate (B(OH)(3)) in inert mineral oil was developed. The model is based on a plausible reaction mechanism of dissolved and adsorbed trimethyl borate on the surface of sodium hydride, where the reaction is presumed to take place. The surface reaction between sodium hydride and trimethyl borate leads to the formation of main (NaBH4) and side products (methoxy borohydrides), which was verified by chemical analysis of sodium borohydride and methanol in the water extract of the oil phase. Extensive kinetic experiments in a laboratory-scale isothermal and isobaric slurry reactor enabled a detailed kinetic analysis of the data, including the derivation of a mathematical model for the formation of sodium borohydride in a semibatch slurry reactor. The kinetic model was verified with experimental information and can be used as an element for process design. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Salmi, Tapio] Abo Akad Univ, PCC Chem Engn, Lab Ind Chem & React Engn, FI-20500 Turku, Finland.
   Univ Napoli Federico II, Chem Sci Dept, IT-80126 Naples, Italy.
RP Salmi, T (reprint author), Abo Akad Univ, PCC Chem Engn, Lab Ind Chem & React Engn, FI-20500 Turku, Finland.
EM tapio.salmi@abo.fi
RI Russo, Vincenzo/L-9658-2019; Salmi, Tapio/U-5462-2019
OI Russo, Vincenzo/0000-0002-1867-739X; 
FU Abo Akademi University; Academy of FinlandAcademy of Finland [319002]
FX This work is a part of activities at the Johan Gadolin Process Chemistry
   Centre (PCC), a centre of excellence in scientific research financed by
   Abo Akademi University. Financial support from Academy of Finland,
   Academy Professor grant (319002) to T. Salmi is gratefully acknowledged.
   The authors are grateful to Professor Dr. L.-E. Lindfors, Professor Dr
   E. Y. O. Paatero and Mr B. Sjoberg for inspiring discussions and
   constructive proposals during the experimental work. The article is
   dedicated to the memory of Professor, PhD (MIT) Leif Hummelstedt.
CR [Anonymous], 2003, ULLMANNS ENCY IND CH, V16, P721
   [Anonymous], 1995, KIRK OTHMER ENCY CHE, V13, P606
   BROWN HC, 1953, J AM CHEM SOC, V75, P192, DOI 10.1021/ja01097a051
   Kreevoy MM, 1979, VENTRON ALEMBIC, V15, P2
   Li ZP, 2003, J ALLOY COMPD, V349, P232, DOI 10.1016/S0925-8388(02)00872-1
   Pecak V, 1967, MASCHINE WERKZEUG, V68, P36
   Salmi T., 2011, CHEM REACTION ENG RE, P311
   Salmi T, 2011, CHEM ENG PROCESS, V50, P1076, DOI 10.1016/j.cep.2011.05.015
   Schlesinger H. J., 2004, J AM CHEM SOC, V75, P186
   SCHLESINGER HI, 1953, J AM CHEM SOC, V75, P205, DOI 10.1021/ja01097a054
   SCHUBERT F, 1960, ANGEW CHEM INT EDIT, V72, P994, DOI 10.1002/ange.19600722413
   Wu Y, 2004, REV CHEM PROCESSES S
NR 12
TC 2
Z9 2
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 79
EP 87
DI 10.1016/j.ces.2019.01.007
PG 9
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700007
DA 2020-05-12
ER

PT J
AU Pal, S
   Kulkarni, AA
AF Pal, Sayan
   Kulkarni, Amol A.
TI Quantitative comparison of strategies to delay clogging in straight
   capillaries
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Micro-capillary; Clogging time; Segmented flow; wettability;
   Multipoint-injection
ID FLOW; MICROREACTOR; PARTICLES; INTENSIFICATION; PRECIPITATION;
   MICROCHANNELS; SOLIDS
AB It is challenging to achieve non-stop flow of a liquid-solid suspension through small channels as it eventually leads to clogging. This paper presents a quantitative comparison of four different techniques for enhancement of solid handling processes in microchannels of two different diameters. These techniques include dosing of the inert gas phase, dosing of the inert and immiscible liquid phase, and changing the wall wettability and multi-point injection, which, in principle, individually follow different mechanisms to delay clogging. An antisolvent based method for precipitation of salt was used to generate solid particles during flow. Clogging time at various flow rates from all the methods was measured and analysed. Irrespective of the method of delaying clogging, the scaling law of clogging time as a function of residence time was seen to remain unchanged. Among these methods, dosing of an inert, immiscible liquid has been identified as the most effective and robust method to delay clogging while enhancing transport of particles in segmented flow. (C) 2019 Elsevier Ltd. All rights reserved.
C1 Acad Sci & Innovat Res AcSIR, CSIR NCL Campus, Pune, Maharashtra, India.
   [Kulkarni, Amol A.] CSIR, Natl Chem Lab, Chem Eng & Proc Dev Div, Pune 411008, Maharashtra, India.
RP Kulkarni, AA (reprint author), CSIR, Natl Chem Lab, Chem Eng & Proc Dev Div, Pune 411008, Maharashtra, India.
EM aa.kulkarni@ncl.res.in
OI Pal, Sayan/0000-0001-7828-5526
FU Council of Scientific and Industrial Research (CSIR)Council of
   Scientific & Industrial Research (CSIR) - India
   [JRF/31/GATE/11(33)/2013-EMR-I]; Dept. of Science Tech
   [DST/SJF/ETA03/2014-15]
FX SP acknowledges the Council of Scientific and Industrial Research (CSIR)
   for JRF/31/GATE/11(33)/2013-EMR-I Dated 07.05.2014. Authors thank the
   Dept. of Science & Tech. (GoI) for the funding through Swarnajayanti
   Fellowship DST/SJF/ETA03/2014-15.
CR Aoki N, 2011, IND ENG CHEM RES, V50, P4672, DOI 10.1021/ie1024326
   Asmatulu R, 2005, J MAGN MAGN MATER, V292, P108, DOI 10.1016/j.jmmm.2004.10.103
   Assmann N, 2011, CHEM ENG PROCESS, V50, P822, DOI 10.1016/j.cep.2011.05.009
   BERLAN J, 1992, ULTRASONICS, V30, P203, DOI 10.1016/0041-624X(92)90078-Z
   Castro F, 2013, CHEM ENG J, V215, P979, DOI 10.1016/j.cej.2012.11.014
   Dersoir B, 2015, MICROFLUID NANOFLUID, V19, P953, DOI 10.1007/s10404-015-1624-y
   Dressaire E, 2017, SOFT MATTER, V13, P37, DOI 10.1039/c6sm01879c
   Eain MM, 2013, INT J HEAT FLUID FL, V44, P515, DOI 10.1016/j.ijheatfluidflow.2013.08.009
   Flowers B. S., 2012, CHALLENGES, V3, P194, DOI DOI 10.3390/CHALLE3020194
   Freitas S, 2006, ULTRASON SONOCHEM, V13, P76, DOI 10.1016/j.ultsonch.2004.10.004
   Gau H, 1999, SCIENCE, V283, P46, DOI 10.1126/science.283.5398.46
   Haber J, 2014, CHEM ENG PROCESS, V84, P14, DOI 10.1016/j.cep.2014.02.007
   Hartman RL, 2012, ORG PROCESS RES DEV, V16, P870, DOI 10.1021/op200348t
   Hartman RL, 2010, ORG PROCESS RES DEV, V14, P1347, DOI 10.1021/op100154d
   Horie T, 2010, ORG PROCESS RES DEV, V14, P405, DOI 10.1021/op900306z
   Kim Y, 2017, J MEMBRANE SCI, V534, P25, DOI 10.1016/j.memsci.2017.04.010
   Klaseboer E., 2014, PHYS FLUIDS, V26
   Koos P, 2012, GREEN PROCESS SYNTH, V1, P11, DOI 10.1515/greenps-2011-0501
   Kuhn S, 2011, LAB CHIP, V11, P2488, DOI 10.1039/c1lc20337a
   Kuhn S, 2011, LANGMUIR, V27, P6519, DOI 10.1021/la2004744
   Kulkarni AA, 2013, ORG PROCESS RES DEV, V17, P1293, DOI 10.1021/op400138v
   McQuade DT, 2013, J ORG CHEM, V78, P6384, DOI 10.1021/jo400583m
   Nalajala VS, 2011, ULTRASON SONOCHEM, V18, P345, DOI 10.1016/j.ultsonch.2010.06.016
   Nilsson A, 2004, LAB CHIP, V4, P131, DOI 10.1039/b313493h
   Noel T, 2011, CHEM SCI, V2, P287, DOI 10.1039/c0sc00524j
   Pal S, 2016, CHEM ENG SCI, V153, P344, DOI 10.1016/j.ces.2016.07.012
   Perry JL, 2008, MICROFLUID NANOFLUID, V5, P357, DOI 10.1007/s10404-007-0254-4
   Poe SL, 2006, ANGEW CHEM INT EDIT, V45, P1544, DOI 10.1002/anie.200503925
   Porta R, 2016, ORG PROCESS RES DEV, V20, P2, DOI 10.1021/acs.oprd.5b00325
   Sander JRG, 2014, ULTRASON SONOCHEM, V21, P1908, DOI 10.1016/j.ultsonch.2014.02.005
   Santos RM, 2012, CHEM ENG COMMUN, V199, P1626, DOI 10.1080/00986445.2012.660712
   Sedelmeier J, 2010, ORG LETT, V12, P3618, DOI 10.1021/ol101345z
   Sendekie ZB, 2016, LANGMUIR, V32, P1478, DOI 10.1021/acs.langmuir.5b04218
   Sharp KV, 2005, MICROFLUID NANOFLUID, V1, P376, DOI 10.1007/s10404-005-0043-x
   Sicignano L, 2018, CHEM ENG J, V341, P639, DOI 10.1016/j.cej.2018.02.037
   Su YH, 2009, AICHE J, V55, P1948, DOI 10.1002/aic.11787
   Wang K, 2015, AICHE J, V61, P1722, DOI 10.1002/aic.14758
   Wu KJ, 2014, CHIM OGGI, V32, P62
   Wyss HM, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.061402
   Yahya N., 2010, IJBAS IJENS, V10, P95
   Zhao B, 2001, SCIENCE, V291, P1023, DOI 10.1126/science.291.5506.1023
   Zhao CX, 2011, CHEM ENG SCI, V66, P1394, DOI 10.1016/j.ces.2010.08.038
NR 42
TC 2
Z9 2
U1 4
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 88
EP 99
DI 10.1016/j.ces.2019.01.015
PG 12
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700008
DA 2020-05-12
ER

PT J
AU Zhao, HQ
   Xu, ZW
   Zhao, HB
AF Zhao, Hanqing
   Xu, Zuwei
   Zhao, Haibo
TI Population balance Monte Carlo simulation of self-assembly of core
   (micro-Al2O3)-shell (nano-TiO2) structure in aqueous suspensions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Population balance modeling; Hetero-aggregation; Extended-DLVO theory;
   Core-shell structure; Chemical looping; Oxygen carrier
ID HETEROAGGREGATION; COAGULATION; MODEL; NANOPARTICLES; AGGREGATION;
   PARTICLES; DYNAMICS; COLLOIDS
AB This study aimed to employ population balance Monte Carlo (PBMC) method to guide the tailor-making of core-shell microarchitecture of particles in aqueous suspensions. Larger micro-Al2O3 (mu m-Al2O3) particles were coated with smaller nano-TiO2 (nm-TiO2) particles by self-assembly technique, under the consideration of complex colloidal particle dynamics. For a desired core-shell structure, hetero-aggregation (TiO2-Al2O3) with a higher priority than homo-aggregation (Al2O3-Al2O3, TiO2-TiO2) can be achieved by adjusting Derjaguin-Landau-Verwey-Overbeek (DLVO) forces through the process parameters pH and ionic strength (IS). To simulate such multicomponent aggregation, PBMC was adopted to directly track the competition of various aggregations and the change of particle variables, based on Brownian motion and extended-DLVO theory. For better understanding the competition kinetics, attachment efficiency was calculated to reveal quantitatively the combined effect of van der Waals attraction, electric double layer repulsion/attraction, and hydration repulsion. A charge balance model was developed to view the change of particle surface electrostatic potential issued from the aggregation of various charged particles. A dynamic light scattering measurement was conducted to validate the PBMC simulation. This PBM method was implemented to explore the effects of pH and IS, then to obtain the optimized coverage efficiency of the final core-shell composite particles. These findings look promising for understanding inherent particle dynamics and rationalizing self-assembly process of core-shell microarchitectures. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhao, Hanqing; Xu, Zuwei; Zhao, Haibo] Huazhong Univ Sci & Technol, Sch Energy & Power Engn, State Key Lab Coal Combust, Wuhan, Hubei, Peoples R China.
RP Zhao, HB (reprint author), Huazhong Univ Sci & Technol, Sch Energy & Power Engn, State Key Lab Coal Combust, Wuhan, Hubei, Peoples R China.
EM hzhao@mail.hust.edu.cn
RI Zhao, Haibo/G-5575-2010
OI Zhao, Haibo/0000-0002-2693-4499; Xu, Zuwei/0000-0001-8375-5051
FU National Key R&D Program of China [2016YFB0600801]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [51606079]
FX This work was funded by National Key R&D Program of China
   (2016YFB0600801), National Natural Science Foundation of China (Grant
   Nos. 51606079).
CR Atmuri AK, 2013, COLLOID SURFACE A, V436, P325, DOI 10.1016/j.colsurfa.2013.07.002
   Cao TC, 2017, PHYS CHEM CHEM PHYS, V19, P15160, DOI 10.1039/c7cp01955f
   Cerbelaud M, 2008, LANGMUIR, V24, P3001, DOI 10.1021/la702104u
   Cerbelaud M, 2017, ADV PHYS-X, V2, P35, DOI 10.1080/23746149.2016.1254064
   Cerbelaud M, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3328876
   Cerbelaud M, 2009, J COLLOID INTERF SCI, V332, P360, DOI 10.1016/j.jcis.2008.11.063
   Chaturbedi A, 2016, CHEM ENG RES DES, V113, P96, DOI 10.1016/j.cherd.2016.07.004
   Chen JC, 2004, ADV COLLOID INTERFAC, V112, P159, DOI 10.1016/j.cis.2004.10.001
   Hao XM, 2013, AEROSOL SCI TECH, V47, P1125, DOI 10.1080/02786826.2013.823642
   HOGG R, 1966, T FARADAY SOC, V62, P1638, DOI 10.1039/tf9666201638
   Hunter R. J., 1987, FDN COLLOID SCI
   Kim T, 2005, LANGMUIR, V21, P9524, DOI 10.1021/la0504560
   Kim T, 2008, J COLLOID INTERF SCI, V318, P238, DOI 10.1016/j.jcis.2007.10.029
   Kobayashi M, 2005, LANGMUIR, V21, P5761, DOI 10.1021/la046829z
   Li KG, 2011, J NANOPART RES, V13, P6483, DOI 10.1007/s11051-011-0548-z
   LIN MY, 1990, J PHYS-CONDENS MAT, V2, P3093, DOI 10.1088/0953-8984/2/13/019
   Liu HH, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/4/045708
   Liu HH, 2011, ENVIRON SCI TECHNOL, V45, P9284, DOI 10.1021/es202134p
   Lyklema J, 1995, FUNDAMENTALS INTERFA, V2
   Peng WW, 2016, FUEL, V170, P226, DOI 10.1016/j.fuel.2015.12.004
   Peng WW, 2015, ENVIRON SCI TECHNOL, V49, P8237, DOI 10.1021/acs.est.5b01415
   Praetorius A, 2014, ENVIRON SCI TECHNOL, V48, P10690, DOI 10.1021/es501655v
   Rollie S, 2009, J COLLOID INTERF SCI, V336, P551, DOI 10.1016/j.jcis.2009.04.031
   Tourbin M, 2008, CHEM ENG SCI, V63, P5239, DOI 10.1016/j.ces.2008.06.028
   Wang HT, 2015, ADV COLLOID INTERFAC, V226, P24, DOI 10.1016/j.cis.2015.07.002
   Xu ZW, 2015, COMBUST FLAME, V162, P3030, DOI 10.1016/j.combustflame.2015.05.006
   Xu ZW, 2015, J COMPUT PHYS, V281, P844, DOI 10.1016/j.jcp.2014.10.055
   Xu ZW, 2014, J AEROSOL SCI, V74, P11, DOI 10.1016/j.jaerosci.2014.03.006
   Zhao HB, 2014, IND ENG CHEM RES, V53, P6047, DOI 10.1021/ie500316g
   Zhao HB, 2011, PARTICUOLOGY, V9, P414, DOI 10.1016/j.partic.2011.04.003
   Zhao HB, 2010, J COMPUT PHYS, V229, P6931, DOI 10.1016/j.jcp.2010.05.031
NR 31
TC 3
Z9 3
U1 2
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 100
EP 112
DI 10.1016/j.ces.2018.12.059
PG 13
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700009
DA 2020-05-12
ER

PT J
AU Zhao, X
   Qiu, ZS
   Zhao, C
   Xu, JG
   Zhang, YB
AF Zhao, Xin
   Qiu, Zhengsong
   Zhao, Chao
   Xu, Jiangen
   Zhang, Yubin
TI Inhibitory effect of water-based drilling fluid on methane hydrate
   dissociation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrate dissociation inhibitor; Methane hydrate; Drilling fluid;
   Inhibitory effect; Lecithin
ID EQUILIBRIUM CONDITIONS; MECHANICAL-PROPERTIES; WELLBORE STABILITY;
   DOMINATED SYSTEMS; GAS; DECOMPOSITION; MODEL; TEMPERATURE; PREDICTION;
   DEPOSITION
AB Hydrate dissociation poses a significant problem during drilling operations in hydrate-bearing sediments. The drilling fluid is in direct contact with hydrates, and understanding its inhibitory effect on hydrate dissociation is important for stabilizing hydrates during drilling operations. In this work, an apparatus was designed for investigating hydrate dissociation in drilling fluids, and the effects of thermodynamic hydrate inhibitors (THIs), polyvinyl pyrrolidone (PVP), and soybean lecithin on hydrate dissociation were studied. The inhibitory effect of a water-based drilling fluid in the presence of the potential hydrate dissociation inhibitors was also studied. An unexpected inhibitory effect occurred with ethylene glycol (EG) at concentrations below 10 wt%, resulting from a range of factors including the dissociation driving force, and mass and heat transfers in the EG solution. PVP and lecithin reduced the hydrate dissociation rate and increased the time required for complete dissociation of hydrates. These can, therefore, be used in waterbased drilling fluids to inhibit hydrate dissociation. A combination of 0.1 wt% PVP and 0.5 wt% lecithin was selected as an optimal hydrate dissociation inhibitor, considering its inhibitory effect and compatibility with the drilling fluid. Using EG at a concentration below 10 wt% as a THI instead of NaCl can also help inhibit hydrate dissociation. The findings of this work provide a basis for the development and design of drilling fluids for drilling in hydrate-bearing sediments. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhao, Xin; Qiu, Zhengsong; Zhao, Chao; Xu, Jiangen; Zhang, Yubin] China Univ Petr East China, Sch Petr Engn, Qingdao 266580, Peoples R China.
   [Zhao, Xin; Qiu, Zhengsong] China Univ Petr East China, Minist Educ, Key Lab Unconvent Oil & Gas Dev, Qingdao 266580, Peoples R China.
   [Zhao, Xin; Qiu, Zhengsong] China Univ Petr East China, Shandong Key Lab Oilfield Chem, Qingdao 266580, Peoples R China.
RP Zhao, X; Qiu, ZS (reprint author), 66 Changjiang West Rd, Qingdao 266580, Shandong, Peoples R China.
EM zhaoxin@upc.edu.cn; qiuzs63@sina.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51804331]; National Basic Research Program of
   ChinaNational Basic Research Program of China [2015CB251205]; Shandong
   Provincial Natural Science FoundationNatural Science Foundation of
   Shandong Province [ZR2017BEE036]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [18CX02032A]
FX This work was supported by the National Natural Science Foundation of
   China (No. 51804331), the National Basic Research Program of China (No.
   2015CB251205), the Shandong Provincial Natural Science Foundation (No.
   ZR2017BEE036), and the Fundamental Research Funds for the Central
   Universities (No. 18CX02032A).
CR Aminnaji M, 2017, J NAT GAS SCI ENG, V45, P840, DOI 10.1016/j.jngse.2017.06.030
   [Anonymous], 2005, HDB FUND A
   Bruusgaard H, 2009, CRYST GROWTH DES, V9, P3014, DOI 10.1021/cg070568k
   Chong ZR, 2016, APPL ENERG, V162, P1633, DOI 10.1016/j.apenergy.2014.12.061
   Daraboina N, 2011, ENERG FUEL, V25, P4384, DOI 10.1021/ef200813v
   Daraboina N, 2011, ENERG FUEL, V25, P4398, DOI 10.1021/ef200814z
   Del Villano L, 2011, CHEM ENG SCI, V66, P1973, DOI 10.1016/j.ces.2011.01.057
   DHOLABHAI PD, 1991, CAN J CHEM ENG, V69, P800, DOI 10.1002/cjce.5450690324
   Dragomir N, 2011, ENERG FUEL, V25, P4392
   ENGLEZOS P, 1988, AICHE J, V34, P1718, DOI 10.1002/aic.690341017
   English N. J, 2009, J CHEM PHYS, V131, P53
   Fereidounpour A, 2015, J NAT GAS SCI ENG, V26, P921, DOI 10.1016/j.jngse.2015.06.038
   Fereidounpour A, 2014, J NAT GAS SCI ENG, V20, P422, DOI 10.1016/j.jngse.2014.07.006
   Freij-Ayoub R, 2007, J PETROL SCI ENG, V57, P209, DOI 10.1016/j.petrol.2005.10.011
   Gao YH, 2017, SPE J, V22, P756, DOI 10.2118/184398-PA
   Goel N, 2001, J PETROL SCI ENG, V29, P115, DOI 10.1016/S0920-4105(01)00094-8
   Gulbrandsen AC, 2017, ENERG FUEL, V31, P9863, DOI 10.1021/acs.energyfuels.6b03478
   Gulbrandsen AC, 2017, ENERG FUEL, V31, P8505, DOI 10.1021/acs.energyfuels.6b03487
   Han H, 2016, FUEL, V182, P446, DOI 10.1016/j.fuel.2016.05.112
   Hardwick JS, 2018, CHEM ENG SCI, V175, P98, DOI 10.1016/j.ces.2017.09.003
   Hong DN, 2006, CHEM ENG SCI, V61, P1846, DOI 10.1016/j.ces.2005.10.037
   Kang SP, 2013, RSC ADV, V3, P19920, DOI 10.1039/c3ra43891k
   Karig SP, 2014, CHEM ENG SCI, V116, P817, DOI 10.1016/j.ces.2014.04.035
   Kawamura T, 2003, ENERG FUEL, V17, P614, DOI 10.1021/ef020174x
   Kelland MA, 2006, ENERG FUEL, V20, P825, DOI 10.1021/ef050427x
   Khabibullin T, 2011, SPE DRILL COMPLETION, V26, P287, DOI 10.2118/131332-PA
   Li G, 2007, ENERG FUEL, V21, P3388, DOI 10.1021/ef060644d
   Li SX, 2015, FUEL, V160, P117, DOI 10.1016/j.fuel.2015.07.085
   Liu KQ, 2017, FUEL, V209, P567, DOI 10.1016/j.fuel.2017.08.034
   Liu TQ, 2010, ACTA PHYS-CHIM SIN, V26, P311, DOI 10.3866/PKU.WHXB20100145
   Makogon YF, 2010, J NAT GAS SCI ENG, V2, P49, DOI 10.1016/j.jngse.2009.12.004
   Meng M, 2018, FUEL, V219, P223, DOI 10.1016/j.fuel.2018.01.115
   Ning FL, 2013, GEOPHYS J INT, V193, P1370, DOI 10.1093/gji/ggt015
   Panter JL, 2011, ENERG FUEL, V25, P2572, DOI 10.1021/ef200196z
   [陈卫东 CHEN Weidong], 2007, [化工学报, Journal of Chemical Industry and Engineering (China)], V58, P2895
   PENG D, 1976, IND ENG CHEM FUND, V15, P59, DOI 10.1021/i160057a011
   Schofield T, 1997, SPE ANN TECHN C EXH
   Semenov AP, 2015, CHEM ENG SCI, V137, P161, DOI 10.1016/j.ces.2015.06.031
   Shi BH, 2018, FUEL, V233, P743, DOI 10.1016/j.fuel.2018.06.054
   Sohn YH, 2017, CHEM ENG SCI, V168, P444, DOI 10.1016/j.ces.2017.05.010
   Song GC, 2018, CHEM ENG SCI, V192, P477, DOI 10.1016/j.ces.2018.07.055
   Song GC, 2017, J NAT GAS SCI ENG, V45, P26, DOI 10.1016/j.jngse.2017.04.032
   STRYJEK R, 1986, CAN J CHEM ENG, V64, P323, DOI 10.1002/cjce.5450640224
   Sultan N, 2004, MAR GEOL, V213, P379, DOI 10.1016/j.margeo.2004.10.015
   Sun YF, 2018, ENERG FUEL, V32, P7585, DOI 10.1021/acs.energyfuels.8b01682
   Tang CP, 2018, FUEL, V214, P505, DOI 10.1016/j.fuel.2017.11.063
   Torsaeter M, 2015, OTC ARCT TECHN C OFF
   [王乐 Wang Le], 2017, [中国海上油气, China Offshore Oil and Gas], V29, P107
   Wang ZY, 2019, FUEL, V236, P870, DOI 10.1016/j.fuel.2018.09.066
   Yagasaki T, 2015, PHYS CHEM CHEM PHYS, V17, P32347, DOI 10.1039/c5cp03008k
   Yuan Q, 2013, FUEL, V106, P417, DOI 10.1016/j.fuel.2012.12.044
   Zhao X, 2019, J PETROL SCI ENG, V173, P112, DOI 10.1016/j.petrol.2018.09.098
   Zhao X, 2017, J PETROL SCI ENG, V154, P405, DOI 10.1016/j.petrol.2017.04.036
NR 53
TC 16
Z9 17
U1 16
U2 51
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 113
EP 122
DI 10.1016/j.ces.2018.12.057
PG 10
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700010
HC Y
HP N
DA 2020-05-12
ER

PT J
AU El Hage, R
   Chauvet, F
   Biscans, B
   Cassayre, L
   Maurice, L
   Tzedakis, T
AF El Hage, R.
   Chauvet, F.
   Biscans, B.
   Cassayre, L.
   Maurice, L.
   Tzedakis, T.
TI Kinetic study of the dissolution of vanadyl sulfate and vanadium
   pentoxide in sulfuric acid aqueous solution
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Vanadyl sulfate; Vanadium pentoxide; Dissolution kinetics; Vanadium
   redox battery; Solubility
ID REDOX-FLOW BATTERY; POSITIVE HALF-CELL; CHEMISTRY; PROGRESS; SYSTEM
AB The study deals with the 'vanadium (IV) sulfate' and 'vanadium (V) pentoxide' dissolution processes in 3 M H2SO4 aqueous media. Several measurements of the concentration of dissolved VO(2)(+)and VO2+ were achieved in the range of 0-40 degrees C, and allowed to understand the limitations of the dissolution process ('endothermic' - mass transport for VOSO4 and 'exothermic' - reaction with the proton for V2O5). In addition, simple models were proposed (diffusion/accumulation for VOSO4 and kinetic rate for V2O5) and their resolution leads to theoretical kinetic equations describing the temporal evolution of these concentrations with satisfactory agreement with the experimental curves. Solubility's data and their temperature dependence were determined for both vanadium compounds involved. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [El Hage, R.; Chauvet, F.; Tzedakis, T.] CAMPUS Univ Toulouse III Paul Sabatier, UMR CNRS 5503, Lab Genie Chim, FSI, 118 Route Narbonne, F-31062 Toulouse, France.
   [Biscans, B.; Cassayre, L.] CAMPUS INP ENSIACET, UMR CNRS 5503, Lab Genie Chim, 4 Allee Emile Monso, F-31432 Toulouse, France.
   [Maurice, L.] Univ Toulouse III Paul Sabatier, 118 Route Narbonne, F-31062 Toulouse, France.
RP Tzedakis, T (reprint author), Univ Toulouse III Paul Sabatier, UMR CNRS 5503, Chem Engn Lab, FSI, 118 Route Narbonne, F-31062 Toulouse, France.
EM tzedakis@chimie.ups-tlse.fr
RI chauvet, fabien/B-4137-2014
OI chauvet, fabien/0000-0002-3102-0368; Cassayre,
   Laurent/0000-0001-6876-6086
FU Agence Nationale de la Recherche, FranceFrench National Research Agency
   (ANR)
FX This study was supported by the Agence Nationale de la Recherche,
   France. The authors would like to acknowledge Brigitte Dustou, Laure
   Latapie and Sandrine Desclaux for the technical support they provided
   for the accomplishment of this work.
CR Amirante R, 2017, ENERG CONVERS MANAGE, V132, P372, DOI 10.1016/j.enconman.2016.11.046
   Ashby M. F., MAT ENERGY STORAGE S
   BAES CF, 1976, HYDROLYSIS CATIONS
   Brooker RP, 2015, J ELECTROCHEM SOC, V162, pA608, DOI 10.1149/2.0371504jes
   Chen HS, 2009, PROG NAT SCI-MATER, V19, P291, DOI 10.1016/j.pnsc.2008.07.014
   Cheng M., 1991, THESIS
   Choi C, 2017, RENEW SUST ENERG REV, V69, P263, DOI 10.1016/j.rser.2016.11.188
   Choi NH, 2013, J ELECTROCHEM SOC, V160, pA973, DOI 10.1149/2.145306jes
   Crans DC, 2004, CHEM REV, V104, P849, DOI 10.1021/cr020607t
   Cunha A, 2015, INT J ENERG RES, V39, P889, DOI 10.1002/er.3260
   Cussler E.L., 1984, DIFFUSION MASS TRANS
   Elvingson K, 1998, INORG CHEM, V37, P6153, DOI 10.1021/ic9712333
   Fassulo O. T., 1965, SULFURIC ACID USE HA
   Fu Q, 2001, APPL OPTICS, V40, P1354, DOI 10.1364/AO.40.001354
   Guzman J, 2002, LANGMUIR, V18, P1567, DOI 10.1021/la010802n
   Ivakin A. A, 1973, RUSS J INORG CHEM, V18, P956
   Jiang Z, 2016, J CHEM PHYS, V145, DOI 10.1063/1.4962748
   Kausar N, 2002, THESIS
   Kim KJ, 2015, J MATER CHEM A, V3, P16913, DOI 10.1039/c5ta02613j
   LeFlem G, 1964, LE SYSTEME V2O5 THO2
   Leung P, 2012, RSC ADV, V2, P10125, DOI 10.1039/c2ra21342g
   Li LY, 2011, ADV ENERGY MATER, V1, P394, DOI 10.1002/aenm.201100008
   Parasuraman A, 2013, ELECTROCHIM ACTA, V101, P27, DOI 10.1016/j.electacta.2012.09.067
   POST K, 1976, ELECTROCHIM ACTA, V21, P401, DOI 10.1016/0013-4686(76)85115-8
   Rahman F, 1998, J POWER SOURCES, V72, P105, DOI 10.1016/S0378-7753(97)02692-X
   Rahman F., 1998, THESIS
   Rahman F, 2009, J POWER SOURCES, V189, P1212, DOI 10.1016/j.jpowsour.2008.12.113
   RYCHCIK M, 1988, J POWER SOURCES, V22, P59, DOI 10.1016/0378-7753(88)80005-3
   SELBIN J, 1965, CHEM REV, V65, P153, DOI 10.1021/cr60234a001
   Skyllas-Kazacos M., 1988, All-vanadium redox battery, Patent No. [US4786567, 4786567US]
   Skyllas-Kazacos M., 2007, MATER FORUM, P72
   Skyllas-Kazacos M, 2016, CHEMSUSCHEM, V9, P1521, DOI 10.1002/cssc.201600102
   SUM E, 1985, J POWER SOURCES, V15, P179, DOI 10.1016/0378-7753(85)80071-9
   SUM E, 1985, J POWER SOURCES, V16, P85, DOI 10.1016/0378-7753(85)80082-3
   Thaller L. H., 1977, 79067 NASA
   Thaller L. H., 1974, INT EN CONV ENG C 9, P924
   Vijayakumar M, 2013, J POWER SOURCES, V241, P173, DOI 10.1016/j.jpowsour.2013.04.072
   Vijayakumar M, 2011, J POWER SOURCES, V196, P3669, DOI 10.1016/j.jpowsour.2010.11.126
   WALLACE RM, 1966, J PHYS CHEM-US, V70, P3922, DOI 10.1021/j100884a029
   Wang W, 2013, ADV FUNCT MATER, V23, P970, DOI 10.1002/adfm.201200694
NR 40
TC 1
Z9 1
U1 4
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 123
EP 136
DI 10.1016/j.ces.2019.01.024
PG 14
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700011
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Yan, P
   Jin, HB
   He, GX
   Guo, XY
   Ma, L
   Yang, SH
   Zhang, RY
AF Yan, Peng
   Jin, Haibo
   He, Guangxiang
   Guo, Xiaoyan
   Ma, Lei
   Yang, Suohe
   Zhang, Rongyue
TI CFD simulation of hydrodynamics in a high-pressure bubble column using
   three optimized drag models of bubble swarm
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pressurized bubble column; Simulation; CFD; ERT
ID GAS-LIQUID FLOW; MASS-TRANSFER; NUMERICAL-SIMULATION; LIFT FORCE;
   HOLD-UP; REACTORS; BEHAVIOR; FLUID; DISTRIBUTIONS; COALESCENCE
AB The gas-liquid flow characteristics in an air-water system were studied using electrical resistance tomography (ERT) in a pressurized gas-liquid bubble column with an inner diameter of 0.30 m and a height of 6.60 m. The effects of the superficial gas velocity and system pressure on the radial gas holdup were investigated under superficial gas velocities (0.120-0.312 m/s) and system pressures (0.5-2.0 MPa). Two-fluid computational fluid dynamics (CFD) was used to simulate the hydrodynamics of the bubble column in two- and three-dimensions, and the drag force, transverse lift force, turbulent dispersion force, and wall lubrication force were introduced for model correction. Based on the determination of the transverse lift force, turbulent diffusion force, and wall lubrication force in previous works of our group, three different of drag model schemes were proposed in this study. In the Model A, based on Roghair's drag model, a density correction and the gas holdup of large and small bubbles were introduced to correct the model; in the Model B, while the gas holdup of large bubbles was greater than 0.08, the influence of small bubbles was ignored. The small bubbles and liquid were integrated into a single phase (the dense phase), while the large bubbles were the dilute phase; in the Model C, an energy minimization multi-scale (EMMS) concept based on the double bubble size model was used, and relationship between the drag coefficient and the bubble diameter were introduced to modify the models. Moreover, through optimizing adjustment of the model parameter, the simulation results with the three models were found to be consistent with the experimental results obtained from ERT technique. These results may facilitate improvements in the design and scale-up of bubble columns with high-pressure and high superficial gas velocities, as well as the significance of further research. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yan, Peng; Jin, Haibo; He, Guangxiang; Guo, Xiaoyan; Ma, Lei; Yang, Suohe; Zhang, Rongyue] Beijing Inst Petrochem Technol, Sch Chem Engn, Beijing Key Lab Fuel Cleanliness & Efficient Cata, Beijing 102617, Peoples R China.
RP Jin, HB; He, GX (reprint author), Beijing Inst Petrochem Technol, Sch Chem Engn, Beijing Key Lab Fuel Cleanliness & Efficient Cata, Beijing 102617, Peoples R China.
EM jinhaibo@bipt.edu.cn; hgx@bipt.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91634101]; Project of Construction of Innovative
   Teams and Teacher Career Development for Universities and Colleges under
   Beijing Municipality [IDHT20180508]
FX Finalcial supported by the National Natural Science Foundation of China
   (91634101) and The Project of Construction of Innovative Teams and
   Teacher Career Development for Universities and Colleges under Beijing
   Municipality (IDHT20180508).
CR Al Mesfer MK, 2016, CHEM ENG J, V300, P317, DOI 10.1016/j.cej.2016.04.075
   AUTON TR, 1987, J FLUID MECH, V183, P199, DOI 10.1017/S002211208700260X
   Bennett MA, 2002, MINER ENG, V15, P225
   Besagni G, 2017, INT J MULTIPHAS FLOW, V94, P53, DOI 10.1016/j.ijmultiphaseflow.2017.04.015
   Besagni G, 2017, CHEM ENG SCI, V160, P144, DOI 10.1016/j.ces.2016.11.031
   Bouaifi M, 2001, CHEM ENG PROCESS, V40, P97, DOI 10.1016/S0255-2701(00)00129-X
   Buffo A, 2016, CHEM ENG RES DES, V113, P284, DOI 10.1016/j.cherd.2016.08.004
   Chen P, 2005, CHEM ENG SCI, V60, P1085, DOI 10.1016/j.ces.2004.09.070
   Chen P, 2004, MODELING FLUID DYNAM
   CHEN RC, 1994, AICHE J, V40, P1093, DOI 10.1002/aic.690400702
   Daily W., 2004, LEADING EDGE, V23, P438, DOI DOI 10.1190/1.1729225
   Degaleesan S, 2001, AICHE J, V47, P1913, DOI 10.1002/aic.690470904
   Gandhi B, 1999, POWDER TECHNOL, V103, P80, DOI 10.1016/S0032-5910(98)00182-X
   Ge W, 2002, CHEM ENG SCI, V57, P3993, DOI 10.1016/S0009-2509(02)00234-8
   Guedon GR, 2017, CHEM ENG SCI, V161, P138, DOI 10.1016/j.ces.2016.12.015
   Herrmann U, 1998, IND ENG CHEM RES, V37, P759, DOI 10.1021/ie970275w
   Ishii M, 2006, THERMO FLUID DYN 2 P, DOI [10.1007/978-0-387-29187-1, DOI 10.1007/978-0-387-29187-1]
   Jin H, 2007, CHEM ENG J, V130, P179, DOI 10.1016/j.cej.2006.08.032
   Jin HB, 2013, CHEM ENG TECHNOL, V36, P1721, DOI 10.1002/ceat.201200551
   Jin HB, 2013, PARTICUOLOGY, V11, P225, DOI 10.1016/j.partic.2012.05.005
   Jin HB, 2010, FLOW MEAS INSTRUM, V21, P228, DOI 10.1016/j.flowmeasinst.2010.02.005
   Jin HB, 2006, CHINESE J CHEM ENG, V14, P127, DOI 10.1016/S1004-9541(06)60049-9
   Jin HB, 2005, CHEM ENG SCI, V60, P5955, DOI 10.1016/j.ces.2005.02.064
   Jin HB, 2005, CHEM ENG J, V115, P45, DOI 10.1016/j.cej.2005.09.003
   Kantarci N, 2005, PROCESS BIOCHEM, V40, P2263, DOI 10.1016/j.procbio.2004.10.004
   Kulkami AA, 2008, CHEM ENG SCI, V63, P1710, DOI 10.1016/j.ces.2007.10.029
   LAHEY RT, 1993, NUCL ENG DES, V141, P177, DOI 10.1016/0029-5493(93)90101-E
   Lau YM, 2011, CHEM ENG SCI, V66, P3309, DOI 10.1016/j.ces.2011.01.053
   Lehr F, 2002, AICHE J, V48, P2426, DOI 10.1002/aic.690481103
   Leonard C, 2015, CHEM ENG RES DES, V100, P391, DOI 10.1016/j.cherd.2015.05.013
   Letzel HM, 1999, CHEM ENG SCI, V54, P2237, DOI 10.1016/S0009-2509(98)00418-7
   Li JH, 1999, CHEM ENG SCI, V54, P5409, DOI 10.1016/S0009-2509(99)00274-2
   Lin TJ, 2005, INT J MULTIPHAS FLOW, V31, P239, DOI 10.1016/j.ijmultiphaseflow.2004.11.004
   Liu X, 2017, CIESC J, V68
   Olmos E, 2001, CHEM ENG SCI, V56, P6359, DOI 10.1016/S0009-2509(01)00204-4
   Roghair I, 2013, AICHE J, V59, P1791, DOI 10.1002/aic.13949
   Rollbusch P, 2015, CHEM ENG SCI, V126, P660, DOI 10.1016/j.ces.2014.11.061
   Sasaki S, 2017, EXP THERM FLUID SCI, V82, P359, DOI 10.1016/j.expthermflusci.2016.11.032
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   Tabib MV, 2008, CHEM ENG J, V139, P589, DOI 10.1016/j.cej.2007.09.015
   Thomas N. H., 1983, INT C PHYS MOD MULT
   Tomiyama A, 1998, MULTIPHASE SCIENCE AND TECHNOLOGY, VOL 10 ISSUE 4 1998, P369
   Wang TF, 2006, AICHE J, V52, P125, DOI 10.1002/aic.10611
   Wang TF, 2007, CHEM ENG SCI, V62, P7107, DOI 10.1016/j.ces.2007.08.033
   Wilcox DC, 1993, TURBULENCE MODELING
   WILKINSON PM, 1990, CHEM ENG SCI, V45, P2309, DOI 10.1016/0009-2509(90)80110-Z
   WILKINSON PM, 1992, AICHE J, V38, P544, DOI 10.1002/aic.690380408
   Wongwailikhit K, 2018, CHEM ENG TECHNOL, V41, P461, DOI 10.1002/ceat.201700293
   Xiao Q, 2017, CHEM ENG J, V329, P88, DOI 10.1016/j.cej.2017.06.008
   Xiao Q, 2013, CHEM ENG SCI, V100, P279, DOI 10.1016/j.ces.2013.02.027
   Yang GY, 2017, CHEM ENG SCI, V170, P251, DOI 10.1016/j.ces.2017.01.013
   Yang N, 2007, CHEM ENG SCI, V62, P6978, DOI 10.1016/j.ces.2007.08.034
   Yang N, 2011, CHEM ENG SCI, V66, P3212, DOI 10.1016/j.ces.2011.02.029
   Yang S, 2004, HYDRODYNAMIC CHARACT
   Zhang B, 2018, CHINESE J CHEM ENG, V26, P1350, DOI 10.1016/j.cjche.2018.01.003
   Zhang Y, 2011, HYDRODYNAMICS TURBUL
   Zhou RT, 2017, POWDER TECHNOL, V314, P466, DOI 10.1016/j.powtec.2016.09.083
NR 57
TC 2
Z9 2
U1 11
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 137
EP 155
DI 10.1016/j.ces.2019.01.019
PG 19
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700012
DA 2020-05-12
ER

PT J
AU Bazaikin, YV
   Derevschikov, VS
   Malkovich, EG
   Lysikov, AI
   Okunev, AG
AF Bazaikin, Ya, V
   Derevschikov, V. S.
   Malkovich, E. G.
   Lysikov, A., I
   Okunev, A. G.
TI Evolution of sorptive and textural properties of CaO-based sorbents
   during repetitive sorption/regeneration cycles: Part II. Modeling of
   sorbent sintering during initial cycles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
ID CO2 CAPTURE; CAPACITY; SERIES
AB A new model describing the evolution of sorptive and textural properties of a CaO-based sorbent during repetitive sorption/regeneration cycles has been developed. The proposed model considers the morphology of nascent monodisperse CaO and the sintering of sorbent grains upon the assumption of the surface mass-transfer mechanism. In addition, the obtained model allows predicting the change in the textural properties of the sorbent (e.g. the values of specific surface area and mean pore size) during the sorption/regeneration cycles. The obtained results show that the model of surface sintering is well applicable to the description of the decay of the sorbent sorption capacity in initial several cycles, while the previously developed model of the volume sintering provides good prediction of this decay only after several cycles. It can be assumed that during the cycling, the sintering of the sorbent switches from the surface to the volume regime. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bazaikin, Ya, V; Malkovich, E. G.] Sobolev Inst Math, Pr Koptyuga 4, Novosibirsk 630090, Russia.
   [Derevschikov, V. S.; Lysikov, A., I; Okunev, A. G.] Boreskov Inst Catalysis, Pr Lavrentieva 5, Novosibirsk 630090, Russia.
   [Derevschikov, V. S.; Malkovich, E. G.; Lysikov, A., I; Okunev, A. G.] Novosibirsk State Univ, Str Pirogova 2, Novosibirsk 630090, Russia.
   [Bazaikin, Ya, V] Univ Hradec Kralove, Fac Sci, Rokitanskeho 62, Hradec Kralove 50003, Czech Republic.
RP Derevschikov, VS (reprint author), Boreskov Inst Catalysis, Pr Lavrentieva 5, Novosibirsk 630090, Russia.; Derevschikov, VS (reprint author), Novosibirsk State Univ, Str Pirogova 2, Novosibirsk 630090, Russia.
EM derevshchikov@mail.ru
RI Bazaikin, Yaroslav V./D-6144-2018
OI Bazaikin, Yaroslav V./0000-0003-3043-4224
FU Government of the Novosibirsk Region (Russian Federation)
   [17-43-543303]; Russian Foundation of Basic Research (Russian
   Federation) [18-01-00579, 18-05-00031];  [AAAA-A17-117041710077-4]; 
   [0303-2016-0010]
FX This work was performed within the framework of budget project
   AAAA-A17-117041710077-4 (No. 0303-2016-0010) for Boreskov Institute of
   Catalysis (Russian Federation). Evgeniy Malkovich thanks the Government
   of the Novosibirsk Region (Russian Federation) for financial support
   (research project No. 17-43-543303). Yaroslav Bazaikin acknowledges
   institutional support of the University Hradec Kralove (Czech Republic)
   and thanks Russian Foundation of Basic Research (Russian Federation) for
   financial support (grants 18-01-00579 and 18-05-00031).
CR Abanades JC, 2003, ENERG FUEL, V17, P308, DOI 10.1021/ef020152a
   Abanades JC, 2002, CHEM ENG J, V90, P303, DOI 10.1016/S1385-8947(02)00126-2
   Bazaikin YV, 2016, CHEM ENG SCI, V152, P709, DOI 10.1016/j.ces.2016.06.064
   BERNAL JD, 1960, NATURE, V188, P910, DOI 10.1038/188910a0
   BORGWARDT RH, 1989, IND ENG CHEM RES, V28, P493, DOI 10.1021/ie00088a019
   BORGWARDT RH, 1989, CHEM ENG SCI, V44, P53
   Derevschikov V, 2017, MICROPOR MESOPOR MAT, V238, P56, DOI 10.1016/j.micromeso.2016.02.032
   do Carmo M. P., 1976, DIFFERENTIAL GEOMETR
   DULLIEN F.A.L., 1992, FLUID TRANSPORT PORE
   Geguzin Ya. E., 1984, PHYS OF SINTERING
   German RM, 2014, SINTERING: FROM EMPIRICAL OBSERVATIONS TO SCIENTIFIC PRINCIPLES, P1
   Grasa GS, 2006, IND ENG CHEM RES, V45, P8846, DOI 10.1021/ie0606946
   Kang SJL, 2005, SINTERING DENSIFICAT, DOI [10.1016/B978-075066385-4/50009-1, DOI 10.1016/B978-075066385-4/50009-1]
   Kenarsari SD, 2015, J CO2 UTIL, V9, P1, DOI 10.1016/j.jcou.2014.11.001
   Khawam A, 2006, J PHYS CHEM B, V110, P17315, DOI 10.1021/jp062746a
   Kierzkowska AM, 2013, CHEMSUSCHEM, V6, P1130, DOI 10.1002/cssc.201300178
   Liu JX, 1997, POWDER METALL, V40, P48, DOI 10.1179/pom.1997.40.1.48
   Lysikov AI, 2007, IND ENG CHEM RES, V46, P4633, DOI 10.1021/ie0702328
   Mohamed M, 2016, PROCEDIA ENGINEER, V148, P78, DOI 10.1016/j.proeng.2016.06.438
   MULLINS WW, 1957, J APPL PHYS, V28, P333, DOI 10.1063/1.1722742
   NICHOLS FA, 1965, J APPL PHYS, V36, P1826, DOI 10.1063/1.1714360
   Shi JW, 2017, APPL ENERG, V203, P412, DOI [10.1016/j.apenergy.2017.06.050, 10.1016/J.apenergy.2017.06.050]
   Torquato S, 1993, CHORD LENGTH DISTRIB, P98, DOI [10.1063/1.464812, DOI 10.1063/1.464812]
   Wang WJ, 2014, APPL ENERG, V125, P246, DOI 10.1016/j.apenergy.2014.03.066
NR 24
TC 0
Z9 0
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 156
EP 163
DI 10.1016/j.ces.2018.12.065
PG 8
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700013
DA 2020-05-12
ER

PT J
AU Hultgren, M
   Ikonen, E
   Kovacs, J
AF Hultgren, Matias
   Ikonen, Enso
   Kovacs, Jeno
TI Integrated control and process design for improved load changes in
   fluidized bed boiler steam path
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Integrated control and process design; Power plant control; Process
   optimization; Performance relative gain array; Closed-loop disturbance
   gain; Plant-wide control
ID MODEL-PREDICTIVE CONTROL; THERMAL POWER-PLANT; COORDINATED CONTROL;
   COMBINED HEAT; TURBINE UNIT; OPTIMIZATION; STATE; CONSTRAINTS;
   ALGORITHM; SYSTEMS
AB Integrated control and process design is considered for a power plant to obtain improved load changes in output electrical power (MWe). Fast load transitions are increasingly needed in conventional power plants, which calls for a deeper integration between the boiler and its control system. An integrated design methodology is applied to an industrial boiler steam path in this paper; no past reports of such an application exist in the literature. The methodology utilizes dynamic optimization together with performance relative gain array and closed-loop disturbance gain controllability analysis. The aim is to optimize the boiler steam storage distribution, the turbine valve operation, and the electrical power and main steam pressure controllers during different MWe ramp reference trajectories. The methodology was successful in defining closed-loop designs with excellent MWe setpoint tracking, small steam pressure disturbances and minimal steam throttling. The results also highlighted the challenges related to integrated design in power plants. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hultgren, Matias; Ikonen, Enso; Kovacs, Jeno] Univ Oulu, Syst Engn, POB 4300, FI-90014 Linnanmaa, Oulun Yliopisto, Finland.
RP Hultgren, M (reprint author), Outotec, Kuparitie 10,POB 69, FI-28101 Pori, Finland.
EM hultgrenmatias@gmail.com; Enso.Ikonen@oulu.fi; Jeno.Kovacs@oulu.fi
FU Graduate School in Chemical Engineering (GSCE) doctoral program (Academy
   of Finland, Finnish Ministry of Education)
FX The authors would like to acknowledge the industrial-academic
   cooperation between the University of Oulu and Sumitomo SHI FW Energia
   Oy (Varkaus, Finland). The work was partly funded by the Graduate School
   in Chemical Engineering (GSCE) doctoral program (Academy of Finland,
   Finnish Ministry of Education)
CR Alobaid F, 2017, PROG ENERG COMBUST, V59, P79, DOI 10.1016/j.pecs.2016.11.001
   Astrom KJ, 2006, ADV PID CONTROL ISA
   Aurora C, 2004, INT J ROBUST NONLIN, V14, P415, DOI 10.1002/rnc.890
   BRISTOL EH, 1966, IEEE T AUTOMAT CONTR, VAC11, P133, DOI 10.1109/TAC.1966.1098266
   Capra F, 2015, ENERGY, V90, P329, DOI 10.1016/j.energy.2015.06.113
   Chan KH, 2014, COMPUT CHEM ENG, V70, P91, DOI 10.1016/j.compchemeng.2014.03.011
   Chen C, 2017, P FOCAPO CPC 2017 C
   CONN AR, 1991, SIAM J NUMER ANAL, V28, P545, DOI 10.1137/0728030
   Conn AR, 1997, MATH COMPUT, V66, P261, DOI 10.1090/S0025-5718-97-00777-1
   Diangelakis N. A, 2016, ADV ENERGY SYSTEMS E, P475
   Diangelakis N. A, 2017, P FOCAPO CPC 2017 C
   Diangelakis NA, 2017, COMPUT CHEM ENG, V102, P128, DOI 10.1016/j.compchemeng.2016.10.015
   Dolezal R, 1970, PROCESS DYNAMICS AUT
   Franzosi R, 2006, P AMER CONTR CONF, V1-12, P3451, DOI 10.1109/ACC.2006.1657252
   Garduno-Rdmirez R, 2005, CONTROL ENG PRACT, V13, P1475, DOI 10.1016/j.conengprac.2005.03.006
   Garrido Juan, 2009, 2009 European Control Conference (ECC), P4007
   Goldberg D. E., 1989, GENETIC ALGORITHMS S
   Hultgren M, 2015, P 22 INT C FLUID BED, P1195
   Hultgren M, 2017, IFAC PAPERSONLINE, V50, P1997, DOI 10.1016/j.ifacol.2017.08.180
   Hultgren M, 2017, IND ENG CHEM RES, V56, P14290, DOI 10.1021/acs.iecr.7b03259
   IEA, 2011, HARN VAR REN GUID BA
   Jin B, 2015, ENERG CONVERS MANAGE, V106, P782, DOI 10.1016/j.enconman.2015.09.077
   Joronen T, 2007, VOIMALAITOSAUTOMAATI
   Klauco M, 2017, APPL THERM ENG, V110, P1437, DOI 10.1016/j.applthermaleng.2016.09.041
   Klefenz G, 1986, AUTOMATIC CONTROL ST
   Kong XB, 2015, ENERGY, V93, P309, DOI 10.1016/j.energy.2015.09.030
   Kookos IK, 2004, COMP AID CH, V17, P216
   Kovacs J., 2012, MODELLING CONTROL DE, V45, P196
   Kundur PS, 2012, ELECTR POWER ENGN SE
   Lagarias JC, 1998, SIAM J OPTIMIZ, V9, P112, DOI 10.1137/S1052623496303470
   LAUB AJ, 1981, IEEE T AUTOMAT CONTR, V26, P407, DOI 10.1109/TAC.1981.1102602
   Lawrynczuk M, 2017, ISA T, V67, P476, DOI 10.1016/j.isatra.2017.01.016
   Liu XJ, 2010, IEEE T CONTR SYST T, V18, P1116, DOI 10.1109/TCST.2009.2034640
   Long DT, 2017, ENERGY, V133, P941, DOI 10.1016/j.energy.2017.05.179
   Ma LY, 2016, CONTROL ENG PRACT, V53, P194, DOI 10.1016/j.conengprac.2015.09.002
   MCAVOY TJ, 1983, IND ENG CHEM PROC DD, V22, P42, DOI 10.1021/i200020a008
   Niva L, 2017, IFAC PAPERSONLINE, V50, P2023, DOI 10.1016/j.ifacol.2017.08.199
   Niva L, 2015, INT J GREENH GAS CON, V43, P93, DOI 10.1016/j.ijggc.2015.10.012
   Ogunnaike B. A., 1994, PROCESS DYNAMICS MOD
   Prasad G, 2000, IEE P-CONTR THEOR AP, V147, P523, DOI 10.1049/ip-cta:20000634
   Prasad G, 2002, T I MEAS CONTROL, V24, P107, DOI 10.1191/0142331202tm053oa
   ROVNAK JA, 1991, IEEE T ENERGY CONVER, V6, P320, DOI 10.1109/60.79639
   Sakizlis V, 2004, COMPUT CHEM ENG, V28, P2069, DOI 10.1016/j.compchemeng.2004.03.018
   Sarkar D. K., 2015, THERMAL POWER PLANT
   Sharifzadeh M, 2013, CHEM ENG RES DES, V91, P2515, DOI 10.1016/j.cherd.2013.05.007
   Skogestad S., 2005, MULTIVARIABLE FEEDBA
   Vega P, 2014, COMPUT CHEM ENG, V71, P602, DOI 10.1016/j.compchemeng.2014.05.010
   Wang W, 2017, J PROCESS CONTR, V50, P11, DOI 10.1016/j.jprocont.2016.12.002
   Wang W, 2015, ENERGY, V88, P927, DOI 10.1016/j.energy.2015.07.061
   Wang W, 2014, ENERGY, V64, P533, DOI 10.1016/j.energy.2013.11.001
   WITCHER MF, 1977, ISA T, V16, P35
   Yuan ZH, 2012, AICHE J, V58, P1640, DOI 10.1002/aic.13786
   Zhang F, 2017, APPL THERM ENG, V118, P90, DOI 10.1016/j.applthermaleng.2017.01.111
   Zhang S, 2012, ISA T, V51, P609, DOI 10.1016/j.isatra.2012.04.003
   Zhou YL, 2017, APPL THERM ENG, V125, P1047, DOI 10.1016/j.applthermaleng.2017.07.077
NR 55
TC 1
Z9 1
U1 5
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 164
EP 178
DI 10.1016/j.ces.2019.01.025
PG 15
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700014
DA 2020-05-12
ER

PT J
AU Lewandowski, B
   Fertig, M
   Ulbricht, M
   Krekel, G
AF Lewandowski, Bjoern
   Fertig, Micha
   Ulbricht, Mathias
   Krekel, Georg
TI Relationship between bubble characteristics and hydrodynamic parameters
   for single bubbles in presence of surface active agents
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Single bubbles; Particle image velocimetry; Shadowgraphy; Turbulent
   kinetic energy; Proper orthogonal decomposition
ID CRITICAL COALESCENCE CONCENTRATION; COHERENT STRUCTURES; GAS-BUBBLES;
   AQUEOUS-SOLUTIONS; LIQUID FLOWS; SIZE; FROTHERS; VELOCITY; ADSORPTION;
   DYNAMICS
AB Rising single air bubbles were investigated in aqueous solutions of hexadecylamine (HDA) and methyl isobutyl carbinol (MIBC) as surface active agents at varying concentrations at a constant gas flow rate. Shadowgraphy was applied to determine main bubble characteristics, such as equivalent diameter, morphology, and rising velocity. From these characteristics, critical parameters like the concentration at the minimum bubble velocity were derived. Simultaneous application of Particle Image Velocimetry (PIV) provided information about hydrodynamic parameters, e.g. the induced liquid velocities and vortex shedding.
   From surface tension measurements, the concentration of adsorbed species on the interface and packing densities of HDA and MIBC on the bubble surface could be calculated. HDA exhibited a better adsorption and a higher packing density on the bubble surface compared to MIBC due to the ionic character and the straight hydrocarbon chain. The bubble characteristics were therefore more strongly affected by HDA than by MIBC.
   Combining the Shadowgraphy and PIV results it was found that the mean liquid velocity as well as the amount of induced turbulent kinetic energy increased with increasing concentration of surfactants in the solutions, while the investigated bubble characteristics such as equivalent diameter and rising velocity decreased. The increase in mean liquid velocity and induced turbulent kinetic energy could be correlated with the oscillating frequency of the bubble trajectory, which also increased with increasing surfactant concentration. The vortex shedding process could be visualised using Proper Orthogonal Decomposition (POD) revealing the micro-process of energy cascading. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lewandowski, Bjoern; Fertig, Micha; Krekel, Georg] Niederrhein Univ Appl Sci, Fac Chem, Adlerstr 32, D-47798 Krefeld, Germany.
   [Lewandowski, Bjoern; Ulbricht, Mathias] Univ Duisburg Essen, Lehrstuhl Tech Chem 2, Univ Str 7, D-45141 Essen, Germany.
RP Lewandowski, B (reprint author), Niederrhein Univ Appl Sci, Fac Chem, Adlerstr 32, D-47798 Krefeld, Germany.; Lewandowski, B (reprint author), Univ Duisburg Essen, Lehrstuhl Tech Chem 2, Univ Str 7, D-45141 Essen, Germany.
EM Bjoern.Lewandowski@hs-niederrhein.de
RI Ulbricht, Mathias/L-5844-2015
OI Ulbricht, Mathias/0000-0002-2094-0708; Lewandowski,
   Bjorn/0000-0003-2481-7309
CR Al Ba'ba'a HB, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4033749
   Aldrich C, 2000, MINER ENG, V13, P1049, DOI 10.1016/S0892-6875(00)00089-3
   Aliyu AM, 2018, EXP THERM FLUID SCI, V97, P21, DOI 10.1016/j.expthermflusci.2018.04.003
   Alke A., 2009, FDMP, V1, P1
   Ata S, 2005, INT J MINER PROCESS, V76, P123, DOI 10.1016/j.minpro.2004.12.007
   Burdukova E, 2009, CAN J CHEM ENG, V87, P441, DOI 10.1002/cjce.20177
   Butt HJ, 2003, PHYS CHEM INTERFACES
   CHANG CH, 1995, COLLOID SURFACE A, V100, P1, DOI 10.1016/0927-7757(94)03061-4
   Cho YS, 2002, CAN J CHEM ENG, V80, P299, DOI 10.1002/cjce.5450800216
   Cho YS, 2002, INT J MINER PROCESS, V64, P69, DOI 10.1016/S0301-7516(01)00064-3
   Cierpka C., 2008, THESIS
   Clift R., 1978, BUBBLES DROPS PARTIC
   Comley BA, 2002, INT J MINER PROCESS, V64, P81, DOI 10.1016/S0301-7516(01)00065-5
   Cosadia I., 2006, 13 INT S APPL LAS TE
   Dantec Dynamics A/S, 2015, DYNAMICSTUDIO US GUI
   DAVIES JT, 1963, INTERFACIAL PHENOMEN
   Delafosse A, 2011, CHEM ENG SCI, V66, P1728, DOI 10.1016/j.ces.2011.01.011
   Di Marco P, 2003, INT J THERM SCI, V42, P435, DOI 10.1016/S1290-0729(02)00044-3
   Drzymala J., 2007, MINERAL PROCESSING F
   Drzymala J, 2018, MINERALS-BASEL, V8, DOI 10.3390/min8020053
   Dukhin S.S., 1995, DYNAMICS ADSORPTION
   Dukhin SS, 1998, STUD INTERF SCI, V6, P367, DOI 10.1016/S1383-7303(98)80025-2
   Evans R, 2018, ANAL CHEM, V90, P3987, DOI 10.1021/acs.analchem.7b05032
   Farn R.J., 2006, CHEM TECHNOLOGY SURF
   Feng LH, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3540679
   Finch JA, 2008, MINER ENG, V21, P949, DOI 10.1016/j.mineng.2008.04.006
   Fleckenstein S, 2013, CHEM ENG SCI, V102, P514, DOI 10.1016/j.ces.2013.08.033
   Fong C, 2015, J COLLOID INTERF SCI, V449, P364, DOI 10.1016/j.jcis.2015.01.045
   Frumkin A, 1925, Z PHYS CHEM-STOCH VE, V116, P466
   Fukunaga K., 1990, INTRO STAT PATTERN R
   Gelinas S, 2005, J COLLOID INTERF SCI, V291, P187, DOI 10.1016/j.jcis.2005.04.094
   GRACE JR, 1976, T I CHEM ENG-LOND, V54, P167
   Grau RA, 2002, MINER ENG, V15, P507, DOI 10.1016/S0892-6875(02)00074-2
   Grau RA, 2006, CAN J CHEM ENG, V84, P170
   GRIFFIN WC, 1949, J SOC COSMET CHEM, V1, P311
   Gupta A., 2006, P INT SEM MIN PROC T, P279
   Han K. N., 2009, PRINCIPLES MINERAL P
   Harkins WD, 1930, J AM CHEM SOC, V52, P1751, DOI 10.1021/ja01368a004
   HE Z, 1991, J COLLOID INTERF SCI, V146, P442, DOI 10.1016/0021-9797(91)90209-Q
   Hemandez-Aguilar JR, 2006, INT J MINER PROCESS, V79, P89, DOI 10.1016/j.minpro.2005.12.003
   Huang J, 2017, CHEM ENG SCI, V157, P182, DOI 10.1016/j.ces.2016.05.013
   Jensch M., 2008, 14 INT S APPL LAS TE
   Jia WH, 2013, INT J ELECTROCHEM SC, V8, P5828
   KARAMANEV DG, 1994, AICHE J, V40, P1418, DOI 10.1002/aic.690400814
   Karamanev DG, 1996, CHEM ENG COMMUN, V147, P75, DOI 10.1080/00986449608936496
   Kim HD, 2010, J MECH SCI TECHNOL, V24, P977, DOI 10.1007/s12206-010-0210-1
   Kim SM, 2010, J VISUAL-JAPAN, V13, P213, DOI 10.1007/s12650-010-0029-y
   KLIMPEL RR, 1991, INT J MINER PROCESS, V33, P369, DOI 10.1016/0301-7516(91)90064-P
   Kowalczuk PB, 2017, MINERALS-BASEL, V7, DOI 10.3390/min7070118
   Kowalczuk PB, 2013, IND ENG CHEM RES, V52, P11752, DOI 10.1021/ie401263k
   Kraume M, 2012, TRANSPORTVORGANGE VE
   Laskowski J.S., 2004, PHYSICOCHEM PROBL MI, V38, P13
   Laskowski JS, 2013, MINER ENG, V45, P170, DOI 10.1016/j.mineng.2013.02.010
   Laskowski JS, 2003, CAN J CHEM ENG, V81, P63
   Lewandowski B, 2018, EXP THERM FLUID SCI, V98, P158, DOI 10.1016/j.expthermflusci.2018.05.016
   Lewandowski B., 2019, CHEM INGENIEUR TECHN
   Lewandowski B., 2018, 7 EUR YOUNG ENG C MO, P367
   Lewandowski B., 2019, MEAS SCI TECHNOL
   Li YP, 2012, WATER SCI TECHNOL, V65, P1060, DOI 10.2166/wst.2012.933
   Lumley JL, 1970, STOCHASTIC TOOLS TUR
   Machon V, 1997, CHEM ENG RES DES, V75, P339, DOI 10.1205/026387697523651
   MALYSA E, 1987, COLLOID SURFACE, V23, P29, DOI 10.1016/0166-6622(87)80247-0
   Malysa K, 2005, ADV COLLOID INTERFAC, V114, P205, DOI 10.1016/j.cis.2004.08.004
   Marangoni C., 1871, ANN PHYS, V219, P337
   Meyer KE, 2007, 7 INT S PART IM VEL
   Mobius D., 1998, DROPS BUBBLES INTERF
   Nassif M, 2013, MINER ENG, V50-51, P64, DOI 10.1016/j.mineng.2013.06.011
   OKAZAKI S, 1964, B CHEM SOC JPN, V37, P144, DOI 10.1246/bcsj.37.144
   Paria S, 2005, IND ENG CHEM RES, V44, P3091, DOI 10.1021/ie049471a
   Pesci C, 2018, J FLUID MECH, V856, P709, DOI 10.1017/jfm.2018.723
   Pope S. B., 2000, TURBULENT FLOWS
   Rafiei AA, 2011, INT J MINER PROCESS, V98, P89, DOI 10.1016/j.minpro.2010.10.011
   Rao S. R., 2004, SURFACE CHEM FROTH F, V1
   RATULOWSKI J, 1990, J FLUID MECH, V210, P303, DOI 10.1017/S0022112090001306
   Richardson L. F., 2007, WEATHER PREDICTION N
   Rosen MJ, 2012, SURFACTANTS AND INTERFACIAL PHENOMENA, 4TH EDITION, P1, DOI 10.1002/9781118228920
   Saarenrinne P, 2000, EXP FLUIDS, V29, pS300, DOI 10.1007/s003480070032
   Saito T, 2010, CHEM ENG J, V158, P39, DOI 10.1016/j.cej.2008.07.021
   Sam A, 1996, INT J MINER PROCESS, V47, P177, DOI 10.1016/0301-7516(95)00088-7
   Shen L., 2016, PHYSICOCHEM PROB MIN
   SIROVICH L, 1987, Q APPL MATH, V45, P573, DOI 10.1090/qam/910463
   SIROVICH L, 1987, Q APPL MATH, V45, P561, DOI 10.1090/qam/910462
   SIROVICH L, 1987, Q APPL MATH, V45, P583, DOI 10.1090/qam/910464
   Tadros T. F., 2008, APPL SURFACTANTS PRI
   Tagawa Y, 2014, J FLUID MECH, V738, P124, DOI 10.1017/jfm.2013.571
   Tan YH, 2013, INT J MINER PROCESS, V119, P1, DOI 10.1016/j.minpro.2012.12.003
   Tan YH, 2016, MINER ENG, V95, P14, DOI 10.1016/j.mineng.2016.05.012
   Tan YH, 2016, MINER ENG, V92, P1, DOI 10.1016/j.mineng.2016.02.003
   Von karman T, 2004, AERODYNAMICS SELECTE
   Wang GC, 2016, POWDER TECHNOL, V302, P196, DOI 10.1016/j.powtec.2016.07.025
   Wills B.A., 2016, WILLS MINERAL PROCES
   Xu D, 2013, EXP THERM FLUID SCI, V44, P662, DOI 10.1016/j.expthermflusci.2012.09.006
   Xuming W, 2018, PHYSICOCHEM PROB MIN
   Yan C, 2013, FARADAY DISCUSS, V160, P45, DOI 10.1039/c2fd20118f
   Yang C, 2001, J COLLOID INTERF SCI, V243, P128, DOI 10.1006/jcis.2001.7842
   Yi SJ, 2010, J MECH SCI TECHNOL, V24, P1819, DOI 10.1007/s12206-010-0628-5
   Tan YH, 2018, PHYSICOCHEM PROBL MI, V54, P40, DOI 10.5277/ppmp1814
   Zhang W., 2016, J MINER MAT CHARACT, V4, P251
   Zhang W, 2014, J CENT SOUTH UNIV, V21, P720, DOI 10.1007/s11771-014-1994-4
   Zhang W, 2012, MINERALS-BASEL, V2, P208, DOI 10.3390/min2030208
   Zhang Y, 2003, COLLOID SURFACE A, V223, P45, DOI 10.1016/S0927-7757(03)00189-4
   Zhu HZ, 2018, CHEM ENG RES DES, V137, P461, DOI 10.1016/j.cherd.2018.08.005
NR 102
TC 2
Z9 2
U1 6
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 179
EP 198
DI 10.1016/j.ces.2019.01.026
PG 20
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700015
DA 2020-05-12
ER

PT J
AU Sun, Z
   Shi, JT
   Wu, KL
   Zhang, T
   Feng, D
   Huang, L
   Shi, YB
   Ramachandran, H
   Li, XF
AF Sun, Zheng
   Shi, Juntai
   Wu, Keliu
   Zhang, Tao
   Feng, Dong
   Huang, Liang
   Shi, Yongbo
   Ramachandran, Hariharan
   Li, Xiangfang
TI An analytical model for gas transport through elliptical nanopores
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Elliptical nanopores; Shale gas reservoirs; Knudsen diffusion; Continuum
   flow
ID FRACTURED VERTICAL WELL; NEWTONIAN FLUID-FLOWS; MICRO-GASEOUS FLOW;
   SHALE GAS; APPARENT PERMEABILITY; SHEAR DISPERSION; SEMIANALYTICAL
   MODEL; DISCRETE FRACTURE; DIFFUSIVE LEAKAGE; WATER SATURATION
AB Effect of pore geometry on nanoconfined gas transport capacity has not been clearly revealed. Elliptical cross-section can vary from circular to slit-like shape by adjusting the aspect ratio (AR), which covers a wide range of pore shapes and shares more research value over that of regular cross-section. In this paper, a novel analytical model for gas transport in elliptical nanopores is established based on weighted superposition of continuum flow and Knudsen diffusion, which possesses more solidified theoretical background than existed models for elliptical nanopores. Results show that contribution of Knudsen diffusion will increase with the increase of AR at a certain pore scale. For a certain pressure point, the contribution of continuum flow mechanism within large pore scale will be greater than that within small pore scale. The discrepancy of simplifying elliptical cross-section as circle is about 90% in continuum flow, 50% in slip flow and 10% in transition flow as well as Knudsen diffusion. The proposed model can advance current understanding of gas transport characteristics through realistic shale matrix. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sun, Zheng; Shi, Juntai; Wu, Keliu; Zhang, Tao; Feng, Dong; Li, Xiangfang] China Univ Petr, State Key Lab Petr Resources & Engn, Beijing 102249, Peoples R China.
   [Sun, Zheng] Texas A&M Univ, Dept Petr Engn, College Stn, TX 77843 USA.
   [Huang, Liang] Univ Calif Berkeley, Dept Chem & Biomol Engn, Berkeley, CA 94720 USA.
   [Shi, Yongbo] Yangtze Univ, Petr Engn Coll, Wuhan 430100, Hubei, Peoples R China.
   [Ramachandran, Hariharan] Univ Texas Austin, Dept Petr & Geosyst Engn, Austin, TX 78712 USA.
RP Sun, Z; Shi, JT; Wu, KL (reprint author), Texas A&M Univ, Dept Petr Engn, College Stn, TX 77843 USA.
EM sunzheng1993@tamu.edu; szcupbSPE@163.com; wukeliu19850109@163.com
RI Wu, Keliu/F-8287-2016; Sun, Zheng/H-1503-2019; SHI, JUNTAI/AAG-4395-2020
OI Wu, Keliu/0000-0002-0021-5007; Sun, Zheng/0000-0002-3844-3953;
   Ramachandran, Hariharan/0000-0001-5979-0930
FU National Science and Technology Major Projects of China [2016ZX05042,
   2016ZX05039]; National Natural Science Foundation Projects of
   ChinaNational Natural Science Foundation of China [51504269, 51490654];
   Science Foundation of China University of Petroleum, Beijing
   [2462018YJRC033, C201605]; China Scholarship CouncilChina Scholarship
   Council [2018060440071]
FX The research was supported by National Science and Technology Major
   Projects of China (No. 2016ZX05042 and No. 2016ZX05039) and the National
   Natural Science Foundation Projects of China (No. 51504269 and No.
   51490654). The first author also acknowledges Science Foundation of
   China University of Petroleum, Beijing (No. 2462018YJRC033 and No.
   C201605) to support part of this work and China Scholarship Council for
   financial support (No. 2018060440071).
CR Afsharpoor A, 2016, FUEL, V180, P580, DOI 10.1016/j.fuel.2016.04.078
   Akkutlu IY, 2016, COMPUTAT GEOSCI, V20, P953, DOI 10.1007/s10596-016-9571-6
   Akkutlu IY, 2017, J NAT GAS SCI ENG, V48, P65, DOI 10.1016/j.jngse.2017.02.040
   Bahrami M, 2009, J FLUID ENG-T ASME, V131, DOI 10.1115/1.3059699
   Beskok A, 1999, MICROSCALE THERM ENG, V3, P43
   Cao P, 2016, FUEL, V178, P103, DOI 10.1016/j.fuel.2016.03.055
   Civan F, 2010, TRANSPORT POROUS MED, V82, P375, DOI 10.1007/s11242-009-9432-z
   Darabi H, 2012, J FLUID MECH, V710, P641, DOI 10.1017/jfm.2012.424
   Dejam M, 2017, WATER RESOUR RES, V53, P8187, DOI 10.1002/2017WR021257
   Dejam M, 2018, J POROUS MEDIA, V21, P1121, DOI 10.1615/JPorMedia.2018028668
   Dejam M, 2019, INT J HEAT MASS TRAN, V128, P1307, DOI 10.1016/j.ijheatmasstransfer.2018.09.061
   Dejam M, 2018, INT J GREENH GAS CON, V78, P177, DOI 10.1016/j.ijggc.2018.08.007
   Dejam M, 2018, J HYDROL, V565, P289, DOI 10.1016/j.jhydrol.2018.08.020
   Dejam M, 2018, SPE J, V23, P1669, DOI 10.2118/189994-PA
   Dejam M, 2018, CHEM ENG SCI, V189, P296, DOI 10.1016/j.ces.2018.05.058
   Dejam M, 2018, ADV WATER RESOUR, V111, P36, DOI 10.1016/j.advwatres.2017.10.029
   Dejam M, 2016, J CONTAM HYDROL, V185, P87, DOI 10.1016/j.jconhyd.2016.01.007
   Dejam M, 2015, CHEM ENG SCI, V137, P205, DOI 10.1016/j.ces.2015.06.028
   Dejam M, 2014, J HYDROL, V519, P3520, DOI 10.1016/j.jhydrol.2014.10.050
   Dejam M, 2014, ADV WATER RESOUR, V74, P14, DOI 10.1016/j.advwatres.2014.08.005
   Dejam M, 2013, TRANSPORT POROUS MED, V100, P159, DOI 10.1007/s11242-013-0210-6
   Duan ZP, 2007, INT J THERM SCI, V46, P1104, DOI 10.1016/j.ijthermalsci.2007.01.026
   ELDRIDGE BD, 1976, AICHE J, V22, P942, DOI 10.1002/aic.690220526
   Ertekin T., 1986, SPE FORMATION EVAL, V1, P43, DOI DOI 10.2118/12045-PA
   Feng D, 2018, CHEM ENG SCI, V186, P228, DOI 10.1016/j.ces.2018.04.055
   Feng D, 2018, INT J HEAT MASS TRAN, V118, P900, DOI 10.1016/j.ijheatmasstransfer.2017.11.049
   Geng LD, 2018, J NAT GAS SCI ENG, V55, P354, DOI 10.1016/j.jngse.2018.04.025
   Guo CH, 2015, FUEL, V143, P107, DOI 10.1016/j.fuel.2014.11.032
   Gupta N, 2018, FUEL, V220, P120, DOI 10.1016/j.fuel.2018.01.120
   Huang L, 2018, APPL ENERG, V210, P28, DOI 10.1016/j.apenergy.2017.10.122
   Huang L, 2018, FUEL, V211, P159, DOI 10.1016/j.fuel.2017.09.060
   Javadpour F, 2007, J CAN PETROL TECHNOL, V46, P55, DOI 10.2118/07-10-06
   Javadpour F, 2009, J CAN PETROL TECHNOL, V48, P16, DOI 10.2118/09-08-16-DA
   Li HT, 2016, J NAT GAS SCI ENG, V35, P567, DOI 10.1016/j.jngse.2016.09.003
   Li J, 2018, AICHE J, V64, P3529, DOI 10.1002/aic.16196
   Li J, 2018, FUEL, V225, P519, DOI 10.1016/j.fuel.2018.03.186
   Li J, 2017, INT J COAL GEOL, V179, P253, DOI 10.1016/j.coal.2017.06.008
   Li J, 2016, INT J COAL GEOL, V159, P135, DOI 10.1016/j.coal.2016.03.012
   Liu JC, 2014, CHEM ENG SCI, V111, P1, DOI 10.1016/j.ces.2014.01.014
   Liu WY, 2018, J NAT GAS SCI ENG, V59, P168, DOI 10.1016/j.jngse.2018.08.027
   Ma JS, 2014, FUEL, V116, P498, DOI 10.1016/j.fuel.2013.08.041
   Qiu XD, 2019, PHYS CHEM CHEM PHYS, V21, P224, DOI 10.1039/c8cp06691d
   Rahmanian MR, 2013, SPE J, V18, P38, DOI 10.2118/149223-PA
   Rahmanifard H, 2018, J NAT GAS SCI ENG, V52, P367, DOI 10.1016/j.jngse.2018.01.047
   Ren WX, 2016, AICHE J, V62, P2893, DOI 10.1002/aic.15254
   Rubin C, 2019, FUEL, V241, P12, DOI 10.1016/j.fuel.2018.12.015
   Sheikholeslami M, 2019, INT J HEAT MASS TRAN, V130, P1322, DOI 10.1016/j.ijheatmasstransfer.2018.11.020
   Sheikholeslami M, 2019, COMPUT METHOD APPL M, V344, P1, DOI 10.1016/j.cma.2018.09.025
   Sheikholeslami M, 2019, COMPUT METHOD APPL M, V344, P306, DOI 10.1016/j.cma.2018.09.042
   Sheikholeslami M, 2019, COMPUT METHOD APPL M, V344, P319, DOI 10.1016/j.cma.2018.09.044
   Shi J, 2013, SPE UNC RES C CAN
   Singh H, 2014, SPE RESERV EVAL ENG, V17, P414, DOI 10.2118/170243-PA
   Sone Y., 1987, Journal of the Vacuum Society of Japan, V30, P425
   Sun H, 2017, INT J HEAT MASS TRAN, V104, P227, DOI 10.1016/j.ijheatmasstransfer.2016.07.083
   Sun H, 2015, INT J HEAT MASS TRAN, V83, P192, DOI 10.1016/j.ijheatmasstransfer.2014.11.075
   Sun Z, 2018, SPE J, DOI [10.2118/194021-PA, DOI 10.2118/194021-PA]
   Sun Z, 2019, J PETROL SCI ENG, V175, P286, DOI 10.1016/j.petrol.2018.12.047
   Sun Z, 2018, INT J HEAT MASS TRAN, V126, P1007, DOI 10.1016/j.ijheatmasstransfer.2018.05.078
   Sun Z, 2018, J PETROL SCI ENG, V166, P611, DOI 10.1016/j.petrol.2018.03.084
   Sun Z, 2018, IND ENG CHEM RES, V57, P3430, DOI 10.1021/acs.iecr.8b00271
   Sun Z, 2018, J NAT GAS SCI ENG, V49, P365, DOI 10.1016/j.jngse.2017.11.022
   Sun Z, 2017, INT J HEAT MASS TRAN, V115, P1008, DOI 10.1016/j.ijheatmasstransfer.2017.07.123
   Sun Z, 2017, FUEL, V204, P214, DOI 10.1016/j.fuel.2017.05.047
   THOMSON SL, 1975, VACUUM, V25, P151, DOI 10.1016/0042-207X(75)91404-9
   Wang JJ, 2017, INT J COAL GEOL, V169, P62, DOI 10.1016/j.coal.2016.11.013
   Wang JJ, 2016, FUEL, V181, P478, DOI 10.1016/j.fuel.2016.05.032
   Wang JJ, 2016, INT J HEAT MASS TRAN, V95, P94, DOI 10.1016/j.ijheatmasstransfer.2015.12.009
   Wang K, 2017, APPL ENERG, V206, P1416, DOI 10.1016/j.apenergy.2017.09.119
   Wang M, 2007, COMPUT FLUIDS, V36, P1291, DOI 10.1016/j.compfluid.2006.12.006
   Wu KL, 2016, INT J HEAT MASS TRAN, V93, P408, DOI 10.1016/j.ijheatmasstransfer.2015.10.003
   Wu KL, 2015, CHEM ENG J, V281, P813, DOI 10.1016/j.cej.2015.07.012
   Wu KL, 2015, AICHE J, V61, P2079, DOI 10.1002/aic.14791
   Wu YS, 2014, SPE J, V19, P845, DOI 10.2118/163609-PA
   Xu JZ, 2018, FUEL, V219, P353, DOI 10.1016/j.fuel.2018.01.114
   Xu JZ, 2017, AICHE J, V63, P3224, DOI 10.1002/aic.15678
   Yin Y, 2017, FUEL, V210, P569, DOI 10.1016/j.fuel.2017.09.018
   Yu W, 2018, AICHE J, V64, P2251, DOI 10.1002/aic.16060
   Yu W, 2017, SPE RESERV EVAL ENG, V20, P547, DOI 10.2118/178747-PA
   Yu WC, 2018, ENERGY, V162, P853, DOI 10.1016/j.energy.2018.08.039
   Yu WC, 2018, RELIAB ENG SYST SAFE, V175, P128, DOI 10.1016/j.ress.2018.03.007
   Zhang LH, 2018, J PETROL SCI ENG, V166, P104, DOI 10.1016/j.petrol.2018.03.038
   Zhang T, 2018, CHEM ENG SCI, V187, P280, DOI 10.1016/j.ces.2018.05.016
   Zhang T, 2017, CHEM ENG SCI, V174, P1, DOI 10.1016/j.ces.2017.08.023
   Zhou DW, 2018, INT J ROCK MECH MIN, V110, P111, DOI 10.1016/j.ijrmms.2018.07.010
NR 84
TC 12
Z9 12
U1 14
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 199
EP 209
DI 10.1016/j.ces.2019.01.013
PG 11
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700016
DA 2020-05-12
ER

PT J
AU Yang, W
   Li, F
   Li, QM
AF Yang, Wei
   Li, Fang
   Li, Qiming
TI Preparation of sandwich-structured
   Ce0.8Sm0.2O1.9-Sm(0.6)Sr(0.4)FeO(3-delta )ceramic membranes and its
   oxygen permeability
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ceramic membrane; Sandwich-structure; Chemical etching; Porous support;
   Oxygen permeation
ID HOLLOW-FIBER MEMBRANE; PERMEATION PROPERTIES; PARTIAL OXIDATION; CERAMIC
   MEMBRANES; TRANSPORT; METHANE; STABILITY; REACTOR; FLUX; GAS
AB Ce0.8SM0.2O1.9-SM0.6Sr0.4FeO3-delta (SDC-SSF) dual-phase ceramic membranes with sandwich-structure were fabricated by chemical etching method. By this method, SSF perovskite particles was etched from both sides of SDC-SSF dual phase membrane, and a SDC/SDC-SSF/SDC three-layer membrane with sandwich structure could be obtained. Crystal phase, microstructure and elemental distribution of SDC-SSF sandwich-structured membranes were investigated. XRD and SEM-EDS results demonstrate that SDC fluorite particles can be well reserved to form porous supports after leaching out SSF perovskite particles and a SDC-SSF dense functional layer was firmly sandwiched between two SDC porous supports, in which common shrinkage mismatch between thin film and porous support can be readily avoided. Thickness of SDC-SSF dense layer can be precisely controlled by changing the etching time. Oxygen permeation tests reveal that our SDC-SSF membranes exhibit an obviously improved oxygen permeation flux. Especially while cobalt-based catalysts were introduced into SDC porous supports, its oxygen flux could be further increase up to 0.95 ml.min(-1).cm(-2). (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Wei; Li, Fang; Li, Qiming] Liaoning Shihua Univ, Coll Chem Chem Engn & Environm Engn, Fushun 113001, Peoples R China.
RP Li, QM (reprint author), Liaoning Shihua Univ, Coll Chem Chem Engn & Environm Engn, Fushun 113001, Peoples R China.
EM lqm_dicp@163.com
FU National Natural Science FoundationNational Natural Science Foundation
   of China [21703091, 21201096]; Education Department of Liaoning
   Province, China [LZ2015050]
FX This work was supported by National Natural Science Foundation
   (21703091, 21201096) and the Education Department of Liaoning Province,
   China (LZ2015050).
CR Bi XX, 2017, J MEMBRANE SCI, V522, P91, DOI 10.1016/j.memsci.2016.09.008
   Cao ZW, 2015, MATER LETT, V147, P88, DOI 10.1016/j.matlet.2015.02.033
   Deng ZQ, 2004, SOLID STATE IONICS, V170, P187, DOI 10.1016/j.ssi.2004.04.006
   Escribano JA, 2017, J EUR CERAM SOC, V37, P5223, DOI 10.1016/j.jeurceramsoc.2017.05.032
   Geffroy PM, 2017, CHEM ENG SCI, V162, P245, DOI 10.1016/j.ces.2017.01.006
   Gil AG, 2015, CHEM ENG SCI, V137, P364, DOI 10.1016/j.ces.2015.06.051
   He W, 2014, J MEMBRANE SCI, V452, P294, DOI 10.1016/j.memsci.2013.09.063
   Kaiser A, 2016, J MEMBRANE SCI, V513, P85, DOI 10.1016/j.memsci.2016.04.016
   Kharton VV, 2003, SOLID STATE IONICS, V160, P247, DOI 10.1016/S0167-2738(03)00183-8
   Lee S, 2006, DESALINATION, V193, P236, DOI 10.1016/j.desal.2005.06.061
   Li QM, 2013, MATER RES BULL, V48, P1160, DOI 10.1016/j.materresbull.2012.12.014
   Li QM, 2010, SEP PURIF TECHNOL, V73, P38, DOI 10.1016/j.seppur.2009.09.005
   Li QM, 2008, J MEMBRANE SCI, V325, P11, DOI 10.1016/j.memsci.2008.08.002
   Liu T, 2016, J MEMBRANE SCI, V520, P354, DOI 10.1016/j.memsci.2016.07.046
   Magnone E, 2018, CERAM INT, V44, P12948, DOI 10.1016/j.ceramint.2018.04.110
   Ovtar S, 2017, J MEMBRANE SCI, V523, P576, DOI 10.1016/j.memsci.2016.09.060
   Pirou S, 2016, FUEL PROCESS TECHNOL, V152, P192, DOI 10.1016/j.fuproc.2016.06.019
   Qiu ZH, 2018, CHEM ENG SCI, V177, P18, DOI 10.1016/j.ces.2017.11.006
   Reichmann M, 2016, J POWER SOURCES, V324, P774, DOI 10.1016/j.jpowsour.2016.06.009
   Ruiz-Trejo E, 2015, CHEM ENG SCI, V127, P269, DOI 10.1016/j.ces.2015.01.047
   Shao X, 2018, CHEM ENG SCI, V192, P541, DOI 10.1016/j.ces.2018.07.058
   Unger LS, 2018, J EUR CERAM SOC, V38, P2388, DOI 10.1016/j.jeurceramsoc.2017.12.042
   Unije U, 2017, J MEMBRANE SCI, V524, P334, DOI 10.1016/j.memsci.2016.10.037
   Wang Y, 2017, APPL SURF SCI, V416, P574, DOI 10.1016/j.apsusc.2017.04.201
   Xue J, 2017, CHEM ENG J, V327, P202, DOI 10.1016/j.cej.2017.06.104
   Zhang WW, 2016, SOLID STATE IONICS, V292, P88, DOI 10.1016/j.ssi.2016.05.011
   Zhang YW, 2013, INT J HYDROGEN ENERG, V38, P8783, DOI 10.1016/j.ijhydene.2013.05.019
   Zhu XF, 2008, J MEMBRANE SCI, V309, P120, DOI 10.1016/j.memsci.2007.10.011
   Zhu XF, 2011, SOLID STATE IONICS, V185, P27, DOI 10.1016/j.ssi.2011.01.005
   Zou Y, 2018, CERAM INT, V44, P2822, DOI 10.1016/j.ceramint.2017.11.026
NR 30
TC 3
Z9 3
U1 2
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 210
EP 219
DI 10.1016/j.ces.2019.01.023
PG 10
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700017
DA 2020-05-12
ER

PT J
AU Bian, YY
   Li, H
   Shen, SF
AF Bian, Yangyang
   Li, Hui
   Shen, Shufeng
TI Reaction kinetics of carbon dioxide with potassium prolinate in
   water-lean solvents
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Kinetics; Potassium prolinate; CO2; Ethanol; Water lean solvent
ID POSTCOMBUSTION CO2 CAPTURE; AMINO-ACID SALTS; ABSORPTION PERFORMANCE;
   DIETHYLENETRIAMINE; SARCOSINE
AB Water-lean absorbents have potential applications for energy-efficient CO2 capture. In this work, the chemical kinetics of the reaction between carbon dioxide (CO2 ) and potassium prolinate (ProK) in ethanol, ethylene glycol and water solvents was measured in a stirred cell reactor with a stable gas-liquid interface at temperatures from 275.2 to 285.2 K and ProK molar concentrations up to 2.0 M. The experiments were performed under the pseudo-first-order regime to determine the overall kinetic rate constant (k(ov)) using two-film theory. The results showed that the reaction rates in each polar solvent increase considerably as the increasing ProK concentrations and temperatures. The reaction order was found to be in the range of 1.4-2.0 with respect to ProK concentration, depending on the solvents used. The kinetic results for the reaction in ethanol were also interpreted based on zwitterion mechanism and termolecular mechanism. The calculated from the two proposed models match well with the experimental data. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bian, Yangyang; Li, Hui; Shen, Shufeng] Hebei Univ Sci & Technol, Sch Chem & Pharmaceut Engn, Shijiazhuang 050018, Hebei, Peoples R China.
RP Shen, SF (reprint author), Hebei Univ Sci & Technol, Sch Chem & Pharmaceut Engn, Shijiazhuang 050018, Hebei, Peoples R China.
EM sfshen@hebust.edu.cn
FU Key Program of Hebei Provincial Natural Science Foundation
   [B2018208154]; Training Program for Talent Engineers of Hebei Province
   [A2017002022]
FX We thank Dr. George Chen from the University of Melbourne for improving
   the use of English in this manuscript. The authors would also like to
   acknowledge Key Program of Hebei Provincial Natural Science Foundation
   (Grant No. B2018208154) and Training Program for Talent Engineers of
   Hebei Province (Grant No. A2017002022) for financial support.
CR Aronu UE, 2011, IND ENG CHEM RES, V50, P10465, DOI 10.1021/ie200596y
   Bian YY, 2018, CHINESE J CHEM ENG, V26, P2318, DOI 10.1016/j.cjche.2018.02.022
   Bian YY, 2017, J CHEM ENG DATA, V62, P3169, DOI 10.1021/acs.jced.7b00267
   Bian YY, 2016, J CHEM ENG DATA, V61, P2391, DOI 10.1021/acs.jced.6b00013
   DECOURSEY WJ, 1974, CHEM ENG SCI, V29, P1867, DOI 10.1016/0009-2509(74)85003-7
   Derks PWJ, 2006, CHEM ENG SCI, V61, P6837, DOI 10.1016/j.ces.2006.07.009
   Guo H, 2018, ENERG FUEL, V32, P6943, DOI 10.1021/acs.energyfuels.8b01012
   Hartono A, 2009, CHEM ENG SCI, V64, P3205, DOI 10.1016/j.ces.2009.04.018
   Heldebrant DJ, 2017, CHEM REV, V117, P9594, DOI 10.1021/acs.chemrev.6b00768
   Kang MK, 2017, INT J GREENH GAS CON, V63, P281, DOI 10.1016/j.ijggc.2017.05.020
   Kang MK, 2017, ENERG FUEL, V31, P8383, DOI 10.1021/acs.energyfuels.7b00768
   Kierzkowska-Pawlak H, 2017, INT J GREENH GAS CON, V57, P134, DOI 10.1016/j.ijggc.2016.12.019
   Kierzkowska-Pawlak H, 2015, INT J GREENH GAS CON, V37, P76, DOI 10.1016/j.ijggc.2015.03.002
   Kumar PS, 2003, AICHE J, V49, P203, DOI 10.1002/aic.690490118
   Li H, 2018, J CHEM THERMODYN, V126, P82, DOI 10.1016/j.jct.2018.06.021
   Li JW, 1997, ANAL CHEM, V69, P2530, DOI 10.1021/ac961005a
   Lin PH, 2014, INT J GREENH GAS CON, V26, P69, DOI 10.1016/j.ijggc.2014.04.020
   MacDowell N, 2010, ENERG ENVIRON SCI, V3, P1645, DOI 10.1039/c004106h
   Machida H, 2017, J CHEM THERMODYN, V113, P64, DOI 10.1016/j.jct.2017.05.043
   Majchrowicz ME, 2014, IND ENG CHEM RES, V53, P11460, DOI 10.1021/ie501083v
   Park SW, 2005, SEPAR SCI TECHNOL, V40, P1885, DOI 10.1081/SS-200064536
   Paul S, 2012, INT J GREENH GAS CON, V8, P169, DOI 10.1016/j.ijggc.2012.02.013
   Portugal AF, 2007, CHEM ENG SCI, V62, P6534, DOI 10.1016/j.ces.2007.07.068
   Rochelle GT, 2009, SCIENCE, V325, P1652, DOI 10.1126/science.1176731
   SADA E, 1986, CHEM ENG J BIOCH ENG, V33, P87, DOI 10.1016/0300-9467(86)80038-7
   SADA E, 1985, AICHE J, V31, P1297, DOI 10.1002/aic.690310808
   Shen SF, 2017, INT J GREENH GAS CON, V56, P1, DOI 10.1016/j.ijggc.2016.11.011
   Shen SF, 2016, ENERG FUEL, V30, P6585, DOI 10.1021/acs.energyfuels.6b01092
   Shen SF, 2016, CHEM ENG SCI, V146, P76, DOI 10.1016/j.ces.2016.02.026
   Shen SF, 2016, ENVIRON SCI TECHNOL, V50, P2054, DOI 10.1021/acs.est.5b04515
   Shen SF, 2013, CHEM ENG J, V222, P478, DOI 10.1016/j.cej.2013.02.093
   Simons K, 2010, IND ENG CHEM RES, V49, P9693, DOI 10.1021/ie100241y
   SNIJDER ED, 1993, J CHEM ENG DATA, V38, P475, DOI 10.1021/je00011a037
   Thee H, 2014, INT J GREENH GAS CON, V20, P212, DOI 10.1016/j.ijggc.2013.10.027
   van Hoist J, 2009, CHEM ENG SCI, V64, P59, DOI 10.1016/j.ces.2008.09.015
   Vitillo JG, 2017, CHEM REV, V117, P9521, DOI 10.1021/acs.chemrev.7b00403
   Wang M, 2015, APPL ENERG, V158, P275, DOI 10.1016/j.apenergy.2015.08.083
   Zhao Y, 2017, ENERG FUEL, V31, P14033, DOI 10.1021/acs.energyfuels.7b02800
   Zhong N, 2016, IND ENG CHEM RES, V55, P7307, DOI 10.1021/acs.iecr.6b00981
NR 39
TC 0
Z9 0
U1 2
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 220
EP 230
DI 10.1016/j.ces.2019.01.027
PG 11
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700018
DA 2020-05-12
ER

PT J
AU Kurose, Y
   Ishizawa, K
   Soriano, MR
   Harada, S
AF Kurose, Yudai
   Ishizawa, Kanami
   Soriano, Ma Rebecca
   Harada, Shusaku
TI Scale-independent model of gravitational settling of particulate
   suspension in a fractal channel
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Particulate suspension; Gravitational settling; Dispersion; Complex
   channel; Fractal characteristics
ID PARTICLES; SEDIMENTATION
AB Gravitational settling of solid particles into a fractal-shaped channel was investigated experimentally and theoretically. Previous studies have reported that the settling behavior of particles in liquid-filled channels depends strongly on particle properties and suspension conditions. At small particle size and high concentration, particles settle collectively like an immiscible fluid with respect to the surrounding one. In this study, we examined the gravitational dispersion behavior of solid particles in a three-dimensional fractal-shaped channel under various collective conditions. The experimental results showed that the settling behavior varies with the collectivity of suspended particles. In the case of high collectivity conditions, settling velocity is enhanced by a density-driven instability, which depends not only on the physical properties of the particles and fluid but also on channel geometry. We developed a model of temporal change in the volumetric occupancy ratio of the suspended particles region. This model describes the invasion of particles into a fractal channel. Our model comprises only the fractal characteristics of the channel, such as a homothetic ratio and a bifurcation number. Consequently, This model could provide a rough prediction of the gravity-induced invasion behavior of particles into any fractal-shaped channel. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kurose, Yudai; Ishizawa, Kanami; Soriano, Ma Rebecca; Harada, Shusaku] Hokkaido Univ, Fac Engn, Div Sustainable Resources Engn, N13W8, Sapporo, Hokkaido 0608628, Japan.
RP Harada, S (reprint author), Hokkaido Univ, Fac Engn, Div Sustainable Resources Engn, N13W8, Sapporo, Hokkaido 0608628, Japan.
EM harada@eng.hokudai.ac.jp
RI Harada, Shusaku/A-5216-2012
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26420095]
FX This study was supported by JSPS KAKENHI Grants No. 26420095.
CR ADACHI K, 1978, CHEM ENG SCI, V33, P115, DOI 10.1016/0009-2509(78)85077-5
   Blanchette F, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1947987
   DAVIS RH, 1985, ANNU REV FLUID MECH, V17, P91, DOI 10.1146/annurev.fl.17.010185.000515
   Fitts C.R., 2012, GROUNDWATER SCI
   Guazzelli E, 2011, ANNU REV FLUID MECH, V43, P97, DOI 10.1146/annurev-fluid-122109-160736
   Guha S, 2017, PHYS FLUIDS, V29
   Guyon E., 2001, PHYS HYDRODYNAMICS
   Harada S, 2012, EUR PHYS J E, V35, DOI 10.1140/epje/i2012-12001-6
   Harada S, 2013, CHEM ENG SCI, V93, P307, DOI 10.1016/j.ces.2013.01.054
   Jury W.A., 2004, SOIL PHYS
   Kretzschmar R., 1998, PHYS CHEM EARTH, V23, P133
   Metzger B, 2007, J FLUID MECH, V580, P283, DOI 10.1017/S0022112007005381
   Nitsche JM, 1997, J FLUID MECH, V340, P161, DOI 10.1017/S0022112097005223
   SHARP DH, 1984, PHYSICA D, V12, P3, DOI 10.1016/0167-2789(84)90510-4
   Voltz C, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.021408
   Voltz C, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.011404
   Voltz C, 2000, PHYS REP, V337, P117, DOI 10.1016/S0370-1573(00)00058-2
   XUE JZ, 1992, PHYS REV LETT, V69, P1715, DOI 10.1103/PhysRevLett.69.1715
   Yamamoto Y, 2015, INT J MULTIPHAS FLOW, V73, P71, DOI 10.1016/j.ijmultiphaseflow.2015.03.007
NR 19
TC 0
Z9 0
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 231
EP 239
DI 10.1016/j.ces.2018.12.049
PG 9
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700019
DA 2020-05-12
ER

PT J
AU Shi, PG
   Zhang, L
   Tian, W
   Li, HL
   Wang, QY
   Yi, HG
   Yin, Y
   Wang, AQ
   Ning, P
   Dong, FL
   Wang, JN
AF Shi, Pange
   Zhang, Ling
   Tian, Wei
   Li, Helei
   Wang, Qiongyu
   Yi, Honggen
   Yin, Yin
   Wang, Aiqing
   Ning, Ping
   Dong, Fenglin
   Wang, Jiannan
TI Preparation and anticoagulant activity of functionalised silk fibroin
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Silk fibroin; Cationisation; Hirudin; Electrostatic binding;
   Anticoagulant activity
ID VITRO BLOOD COMPATIBILITY; RECOMBINANT HIRUDIN; THROMBIN;
   IMMOBILIZATION; HEMOCOMPATIBILITY; CYTOCOMPATIBILITY; DIAMETER; COMPLEX;
   DOMAIN; FILMS
AB Firstly, negatively charged silk fibroin (SF) was cationically modified by covalent linkage with polyethylene glycol diamine (NH2-PEG-NH2). The surface charge of cationic SF film changed from negative to positive when SF:NH 2 -PEG-NH2 = 100:0.5, and enhanced with increasing NH2-PEG-NH2. Zeta potential was maximal and stable when SF:NH2-PEG-NH2 = 100:5. NH2-PEG-NH2 induced SF films to adopt a stable crystalline structure. After cationisation, SF films were loaded with hirudin (SF-PEG-HIR film) by non covalent linkage. The effective load capacity of hirudin on the surface of cationic SF films was highest (>40 U/cm(2)) when SF: NH2-PEG-NH2 = 100:10. The ability of SF-PEG-HIR films to inhibit thrombin activity improved with increasing hirudin content while thrombin activity was reduced significantly (A(405) decreased from 0.563 to 0.03) when the hirudin loading was 40 U/cm(2). Likewise, thrombin activity in fresh plasma was reduced significantly (A(405) decreased from 0.102 to 0.067). Release dynamics showed that thrombin activity decreased linearly within 2 h, then more slowly thereafter. SF-PEG-HIR films markedly prolonged the activated partial thrombin time and significantly inhibited adhesion of platelets. Thus hirudin can be stably loaded on cationic SF films via electrostatic interaction, maintaining high thrombin inhibition activity, and significantly improving the anticoagulant properties of SF films. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shi, Pange; Zhang, Ling; Tian, Wei; Li, Helei; Wang, Qiongyu; Yi, Honggen; Wang, Jiannan] Soochow Univ, Coll Text & Clothing Engn, Natl Engn Lab Modern Silk, 199 Ren Ai Rd,Suzhou Ind Pk, Suzhou 215123, Jiangsu, Peoples R China.
   [Yin, Yin] Soochow Univ, Lab Anim Res Ctr, Suzhou 215123, Jiangsu, Peoples R China.
   [Wang, Aiqing; Ning, Ping] Soochow Univ, Dept Med, Suzhou 215123, Jiangsu, Peoples R China.
   [Dong, Fenglin] Soochow Univ, Affiliated Hosp 1, Dept Ultrasonog, Suzhou 215006, Jiangsu, Peoples R China.
RP Wang, JN (reprint author), Soochow Univ, Coll Text & Clothing Engn, Natl Engn Lab Modern Silk, 199 Ren Ai Rd,Suzhou Ind Pk, Suzhou 215123, Jiangsu, Peoples R China.
EM wangjn@suda.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51873141, 51473108]; Natural Science Foundation of
   Jiangsu Province of ChinaNatural Science Foundation of Jiangsu Province
   [BK20181192]; College Natural Science Research Project of Jiangsu
   Province of China [18KJA540001]
FX This work was supported by National Natural Science Foundation of China
   (Nos 51873141, 51473108), Natural Science Foundation of Jiangsu Province
   of China (No BK20181192), College Natural Science Research Project of
   Jiangsu Province of China (No 18KJA540001).
CR Alt E, 2000, CIRCULATION, V101, P1453, DOI 10.1161/01.CIR.101.12.1453
   Aper T, 2016, ACTA BIOMATER, V29, P21, DOI 10.1016/j.actbio.2015.10.012
   Aytemiz D, 2013, ADV HEALTHC MATER, V2, P361, DOI 10.1002/adhm.201200227
   Bagdy D., 1976, HIRUDIN METHODS ENZY, V45, P669, DOI 10.1016/S0076-6879(76)45057-7
   Bouchnita A, 2016, APPL MATH LETT, V51, P74, DOI 10.1016/j.aml.2015.07.010
   Cestari M, 2014, BIOMACROMOLECULES, V15, P1762, DOI 10.1021/bm500132g
   CHANG JY, 1983, FEBS LETT, V164, P307, DOI 10.1016/0014-5793(83)80307-X
   Choi WS, 2016, ACS APPL MATER INTER, V8, P4336, DOI 10.1021/acsami.5b12052
   Cipolatti EP, 2016, RSC ADV, V6, P104675, DOI 10.1039/c6ra22047a
   GOOSEN MFA, 1980, THROMB RES, V20, P543, DOI 10.1016/0049-3848(80)90142-5
   Gouzy MF, 2004, BIOMATERIALS, V25, P3493, DOI 10.1016/j.biomaterials.2003.10.091
   Hao Y, 2015, MATER TECHNOL, V30, P327, DOI 10.1179/1753555715Y.0000000003
   Hashi CK, 2010, ARTERIOSCL THROM VAS, V30, P1621, DOI 10.1161/ATVBAHA.110.208348
   Kang TY, 2013, ACTA BIOMATER, V9, P4716, DOI 10.1016/j.actbio.2012.08.042
   Lahann J, 2001, BIOMATERIALS, V22, P817, DOI 10.1016/S0142-9612(00)00244-1
   Lee SJ, 2007, J BIOMED MATER RES A, V83A, P999, DOI 10.1002/jbm.a.31287
   Ma XL, 2006, J BIOMED MATER RES B, V78B, P89, DOI 10.1002/jbm.b.30466
   Madden PW, 2011, BIOMATERIALS, V32, P4076, DOI 10.1016/j.biomaterials.2010.12.034
   MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027
   MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692
   MARKWARDT F, 1992, THROMB RES, V68, P475, DOI 10.1016/0049-3848(92)90060-N
   MARKWARDT F, 1994, THROMB RES, V74, P1, DOI 10.1016/0049-3848(94)90032-9
   Martin K, 2009, CIRC RES, V105, P214, DOI 10.1161/CIRCRESAHA.109.199984
   Meng M, 2008, J CONTROL RELEASE, V128, P113, DOI 10.1016/j.jconrel.2008.03.001
   Monti P, 1998, J RAMAN SPECTROSC, V29, P297, DOI 10.1002/(SICI)1097-4555(199804)29:4<297::AID-JRS240>3.0.CO;2-G
   Mottaghitalab F, 2015, J CONTROL RELEASE, V206, P161, DOI 10.1016/j.jconrel.2015.03.020
   Nalvuran H, 2018, INT J BIOL MACROMOL, V114, P77, DOI 10.1016/j.ijbiomac.2018.03.072
   Nowak G, 1996, SEMIN THROMB HEMOST, V22, P197, DOI 10.1055/s-2007-999008
   Park SH, 2010, BIOMATERIALS, V31, P6162, DOI 10.1016/j.biomaterials.2010.04.028
   Qin HN, 2007, CHINESE J CHEM ENG, V15, P586, DOI 10.1016/S1004-9541(07)60128-1
   RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926
   Sanchez-Lopez JC, 2012, J PHYS D APPL PHYS, V45, DOI 10.1088/0022-3727/45/37/375401
   She ZD, 2010, POLYM INT, V59, P55, DOI 10.1002/pi.2688
   Shi PJ, 2013, BIOMACROMOLECULES, V14, P4465, DOI 10.1021/bm401381s
   Sun D, 2015, J BIOMED MATER RES B, V103, P556, DOI 10.1002/jbm.b.33241
   Sun D, 2013, ADV MATER RES-SWITZ, V796, P136, DOI 10.4028/www.scientific.net/AMR.796.136
   Takahara J, 2010, ACTA BIOMATER, V6, P3138, DOI 10.1016/j.actbio.2010.02.052
   Tamada Y, 2004, BIOMATERIALS, V25, P377, DOI 10.1016/S0142-9612(03)00533-7
   Tu F. F, 2018, POLYMERS, V10, P1
   Wang JN, 2014, MAT SCI ENG C-MATER, V34, P429, DOI 10.1016/j.msec.2013.09.039
   Wang L, 2014, RSC ADV, V4, P40312, DOI 10.1039/c4ra04529g
   Wang QY, 2017, MAT SCI ENG C-MATER, V75, P237, DOI 10.1016/j.msec.2017.02.035
   Wei YL, 2014, TEXT RES J, V84, P959, DOI 10.1177/0040517513512401
   Zamanzadeh M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15784-w
   Zhao CS, 2001, ARTIF ORGANS, V25, P60
   Zheng ZW, 2015, J BIOMED MATER RES A, V103, P878, DOI 10.1002/jbm.a.35226
NR 46
TC 1
Z9 1
U1 9
U2 49
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 240
EP 248
DI 10.1016/j.ces.2019.01.022
PG 9
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700020
DA 2020-05-12
ER

PT J
AU Kellogg, KM
   Liu, PY
   Hrenya, CM
AF Kellogg, Kevin M.
   Liu, Peiyuan
   Hrenya, Christine M.
TI Continuum prediction of entrainment rates and agglomeration of
   gas-fluidized, lightly-cohesive particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Cohesive particles; Agglomeration; Entrainment; Agglomerate breakage;
   Population balance
ID NUMERICAL-SIMULATION; BEHAVIOR; FORCES; TRANSPORT; DYNAMICS; BEDS
AB In this work, a continuum theory for cohesive particles developed recently (Kellogg et al., 2017) is applied to lightly-cohesive particles in an unbounded, gas-solid riser. The novelty of this recent theory is its fundamental incorporation of the effects of the granular temperature (i.e., continuum measure of impact velocity) and the material and cohesion properties on the rates of aggregation and breakage of agglomerates. Here, we extend this theory to multiphase systems and place particular emphasis on its ability to predict entrainment rate, as past empirical correlations vary by orders of magnitude when applied to the same system (Chew et al., 2015). Specifically, continuum predictions of entrainment rates and agglomer- ate fraction are compared with Discrete Element Method (DEM) simulations of lightly-cohesive particles in a gas-solid flow. The agreement obtained for these quantities provides preliminary validation for the use of the continuum theory for cohesive particles in gas-solid flows. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kellogg, Kevin M.; Liu, Peiyuan; Hrenya, Christine M.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA.
RP Hrenya, CM (reprint author), Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA.
EM hrenya@colorado.edu
RI Liu, Peiyuan/W-2754-2017
OI Liu, Peiyuan/0000-0002-9679-5797; Kellogg, Kevin/0000-0002-0074-0821
FU Dow Corning Corporation; National Science FoundationNational Science
   Foundation (NSF) [ACI-1532235, ACI-1532236, CBET-1707046]; University of
   Colorado Boulder; Colorado State University
FX The authors are grateful for the financial support provided by the Dow
   Corning Corporation, a wholly owned subsidiary of the Dow Chemical
   Company, and the National Science Foundation (CBET-1707046). The authors
   thank Casey LaMarche for stimulating discussions. This work utilized the
   RMACC Summit supercomputer, which is supported by the National Science
   Foundation (Awards ACI-1532235 and ACI-1532236), the University of
   Colorado Boulder, and Colorado State University. The Summit
   supercomputer is a joint effort of the University of Colorado Boulder
   and Colorado State University.
CR Anand A, 2009, CHEM ENG SCI, V64, P5268, DOI 10.1016/j.ces.2009.09.001
   Benyahia S, 2006, POWDER TECHNOL, V162, P166, DOI 10.1016/j.powtec.2005.12.014
   Cahyadi A, 2015, POWDER TECHNOL, V275, P220, DOI 10.1016/j.powtec.2015.02.010
   Castellanos A, 2005, ADV PHYS, V54, P263, DOI 10.1080/17461390500402657
   Chaudhuri B, 2006, POWDER TECHNOL, V165, P105, DOI 10.1016/j.powtec.2006.04.001
   Chew JW, 2015, CHEM ENG J, V260, P152, DOI 10.1016/j.cej.2014.08.086
   Figueroa I, 2009, POWDER TECHNOL, V195, P203, DOI 10.1016/j.powtec.2009.06.002
   Galvin JE, 2014, AICHE J, V60, P473, DOI 10.1002/aic.14307
   Garzo V, 1999, PHYS REV E, V59, P5895, DOI 10.1103/PhysRevE.59.5895
   GELDART D, 1984, POWDER TECHNOL, V37, P25, DOI 10.1016/0032-5910(84)80003-0
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Hill R. J., 2001, J FLUID MECH, V448
   Hou QF, 2012, CHEM ENG SCI, V84, P449, DOI 10.1016/j.ces.2012.08.051
   Iddir H, 2005, AICHE J, V51, P1620, DOI 10.1002/aic.10429
   Kellogg KM, 2017, J FLUID MECH, V832, P345, DOI 10.1017/jfm.2017.642
   Liu DY, 2016, AICHE J, V62, P2259, DOI 10.1002/aic.15219
   Liu PY, 2017, CHEM ENG J, V324, P380, DOI 10.1016/j.cej.2017.04.118
   Liu PY, 2016, AICHE J, V62, P3529, DOI 10.1002/aic.15383
   Liu PY, 2016, CHEM ENG SCI, V145, P266, DOI 10.1016/j.ces.2016.02.024
   MANSOORI GA, 1971, J CHEM PHYS, V54, P1523, DOI 10.1063/1.1675048
   Mikami T, 1998, CHEM ENG SCI, V53, P1927, DOI 10.1016/S0009-2509(97)00325-4
   Motlagh AHA, 2014, CHEM ENG SCI, V120, P22, DOI 10.1016/j.ces.2014.08.042
   Rabinovich YI, 2000, J COLLOID INTERF SCI, V232, P10, DOI 10.1006/jcis.2000.7167
   Ringl C, 2012, ASTROPHYS J, V752, DOI 10.1088/0004-637X/752/2/151
   Syamlal M., 1993, MFIX DOCUMENTATION T
   van der Hoef MA, 2008, ANNU REV FLUID MECH, V40, P47, DOI 10.1146/annurev.fluid.40.111406.102130
NR 26
TC 1
Z9 1
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 249
EP 257
DI 10.1016/j.ces.2019.01.012
PG 9
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700021
DA 2020-05-12
ER

PT J
AU Hoang, NH
   Dochain, D
AF Ha Hoang, N.
   Dochain, Denis
TI A comment on thermodynamically consistent feasibility condition of
   asymptotic observers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Asymptotic observers; Reaction invariants; State estimation; Estimation
   selection; Thermodynamics; CSTR
ID CHEMICAL-REACTION SYSTEMS; STIRRED-TANK REACTORS; HAMILTONIAN-SYSTEMS;
   REACTION INVARIANTS; INCREMENTAL IDENTIFICATION; NONLINEAR OBSERVERS;
   NETWORK DYNAMICS; BATCH REACTORS; STATE; STABILIZATION
AB In this note, an extension of the design of asymptotic observers is proposed for the thermodynamically consistent non-isothermal continuous stirred tank reactor (involving n(c) active chemical species with n(r) independent reactions) that has incomplete state information. The two well-known constraints for the implementations of the asymptotic observer are the process operating conditions and the availability of temperature measurement together with (n(r) - 1) concentration measurements. However, even though the process operating conditions are justified, the requirement of having good estimation performances and high accuracy of (n(c) - n(r) + 1) state estimates may only be guaranteed if a so-called feasibility condition of the observer is fulfilled. This feasibility condition is formulated via the full rank constraint of a structural matrix, which is related to the stoichiometric coefficient matrix. A sufficient condition for the fulfilment of the full rank constraint shows that the process estimation selection is not made arbitrarily. Interestingly, as the designed observer is based on thermodynamic information only and does not require knowledge of reaction kinetics, the solution proposed to the feasibility condition has a clear physical meaning. Numerical simulations considered for Van de Vusse reaction system illustrate the application of the theoretical results. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ha Hoang, N.] Duy Tan Univ, Inst Res & Dev, Da Nang, Vietnam.
   [Dochain, Denis] Catholic Univ Louvain, ICTEAM, 4-6 Ave G Lemaitre, B-1348 Louvain La Neuve, Belgium.
RP Hoang, NH (reprint author), Duy Tan Univ, Inst Res & Dev, Da Nang, Vietnam.
EM hoangngocha2@duytan.edu.vn; denis.dochain@uclouvain.be
CR Aggarwal M, 2011, J PROCESS CONTR, V21, P1390, DOI 10.1016/j.jprocont.2011.07.008
   Alamir M, 1999, INT J CONTROL, V72, P1204, DOI 10.1080/002071799220353
   Ali JM, 2015, COMPUT CHEM ENG, V76, P27, DOI 10.1016/j.compchemeng.2015.01.019
   Alvarez-Ramirez J, 2000, CHEM ENG SCI, V55, P5497, DOI 10.1016/S0009-2509(00)00173-1
   ALVAREZRAMIREZ J, 1995, CHEM ENG SCI, V50, P1393, DOI 10.1016/0009-2509(94)00506-M
   Amrhein M, 1999, CHEM ENG SCI, V54, P579, DOI 10.1016/S0009-2509(98)00270-X
   Andrieu V, 2009, AUTOMATICA, V45, P422, DOI 10.1016/j.automatica.2008.07.015
   Antonelli R, 2003, AUTOMATICA, V39, P1817, DOI 10.1016/S0005-1098(03)00177-8
   ARIS R, 2000, ELEMENTARY CHEM REAC
   ASBJORNS.OA, 1970, CHEM ENG SCI, V25, P1627, DOI 10.1016/0009-2509(70)80054-9
   ASBJORNSEN OA, 1972, CHEM ENG SCI, V27, P709, DOI 10.1016/0009-2509(72)85007-3
   Bastin G., 1990, ON LINE ESTIMATION A
   Besancon G, 2007, LECT NOTES CONTR INF, V363, P1
   Bhatt N, 2012, CHEM ENG SCI, V83, P24, DOI 10.1016/j.ces.2012.05.040
   Billeter J, 2018, COMPUT CHEM ENG, V114, P296, DOI 10.1016/j.compchemeng.2017.09.021
   Bonvin D, 1998, J PROCESS CONTR, V8, P355, DOI 10.1016/S0959-1524(98)00010-9
   Caccavale F, 2011, ADV IND CONTROL, P1, DOI 10.1007/978-0-85729-195-0
   CALLEN HB, 1985, THERMODYNAMICS INTRO
   de Groot SR, 1962, NONEQUILIBRIUM THERM
   DEVALLIERE P, 1989, COMPUT CHEM ENG, V13, P11, DOI 10.1016/0098-1354(89)89003-9
   Dochain D, 2003, J PROCESS CONTR, V13, P801, DOI 10.1016/S0959-1524(03)00026-X
   Dochain D, 2009, INT J CONTROL, V82, P1389, DOI 10.1080/00207170802236085
   DOCHAIN D, 1992, CHEM ENG SCI, V47, P4167, DOI 10.1016/0009-2509(92)85166-9
   Eberard D, 2007, REP MATH PHYS, V60, P175, DOI 10.1016/S0034-4877(07)00024-9
   Ederer M, 2011, AUTOMATICA, V47, P1097, DOI 10.1016/j.automatica.2011.01.072
   Farina L., 2000, PUR AP M-WI
   Favache A, 2011, SYST CONTROL LETT, V60, P618, DOI 10.1016/j.sysconle.2011.04.021
   Favache A, 2010, CHEM ENG SCI, V65, P5204, DOI 10.1016/j.ces.2010.06.019
   FJELD M, 1974, CHEM ENG SCI, V29, P1917, DOI 10.1016/0009-2509(74)85009-8
   Garcia-Sandoval JP, 2017, J PROCESS CONTR, V51, P18, DOI 10.1016/j.jprocont.2016.09.011
   GAUTHIER JP, 1992, IEEE T AUTOMAT CONTR, V37, P875, DOI 10.1109/9.256352
   GEORGAKIS C, 1986, CHEM ENG SCI, V41, P1471, DOI 10.1016/0009-2509(86)85232-0
   GIBONFARGEOT AM, 1994, CHEM ENG SCI, V49, P2287, DOI 10.1016/S0009-2509(94)85061-5
   GLANSDORFF P, 1964, PHYSICA, V30, P351, DOI 10.1016/0031-8914(64)90009-6
   Glansdorff P., 1971, THERMODYNAMIC THEORY
   Green D.W., 2008, PERRYS CHEM ENG HDB
   Grmela M, 2015, ENTROPY-SWITZ, V17, P5938, DOI 10.3390/e17095938
   Guay M, 2016, IEEE T AUTOMAT CONTR, V61, P1075, DOI 10.1109/TAC.2015.2455671
   Hoang NH, 2013, ANNU REV CONTROL, V37, P278, DOI 10.1016/j.arcontrol.2013.09.007
   Hidayat Z., 2011, 2011 IEEE International Symposium on Robotic and Sensors Environments (ROSE 2011), P166, DOI 10.1109/ROSE.2011.6058523
   Hoang H, 2011, J PROCESS CONTR, V21, P1449, DOI 10.1016/j.jprocont.2011.06.014
   Hoang H, 2014, P 19 IFAC WORLD C CA, V47, P9123
   Hoang NH, 2013, COMPUT CHEM ENG, V58, P156, DOI 10.1016/j.compchemeng.2013.06.016
   Hoang NH, 2017, MATH COMP MODEL DYN, V23, P135, DOI 10.1080/13873954.2016.1237973
   Hoang NH, 2013, SYST CONTROL LETT, V62, P170, DOI 10.1016/j.sysconle.2012.11.013
   Karlin I., 2005, LECT NOTES PHYS INVA
   Khalil H. K., 2002, NONLINEAR SYSTEMS
   Kjelstrup S., 2017, NONEQUILIBRIUM THERM
   Kravaris C, 2013, COMPUT CHEM ENG, V51, P111, DOI 10.1016/j.compchemeng.2012.06.001
   Ling C, 2017, AICHE J, V63, P3384, DOI 10.1002/aic.15707
   Luyben W. L., 1990, PROCESS MODELING SIM
   Maschke B, 2000, IEEE T AUTOMAT CONTR, V45, P1498, DOI 10.1109/9.871758
   MASCHKE BM, 1992, J FRANKLIN I, V329, P923, DOI 10.1016/S0016-0032(92)90049-M
   Moreno JA, 2008, INT J CONTROL, V81, P1062, DOI 10.1080/00207170701636534
   Ortega R, 2002, AUTOMATICA, V38, P585, DOI 10.1016/S0005-1098(01)00278-3
   Otero-Muras I, 2008, MATH COMPUT SIMULAT, V79, P999, DOI 10.1016/j.matcom.2008.02.019
   Prigogine I., 1961, INTRO THERMODYNAMICS
   Ramirez H, 2017, IEEE T AUTOMAT CONTR, V62, P1431, DOI 10.1109/TAC.2016.2572403
   Ramirez H, 2013, CHEM ENG SCI, V89, P223, DOI 10.1016/j.ces.2012.12.002
   Rodrigues D, 2015, COMPUT CHEM ENG, V73, P23, DOI 10.1016/j.compchemeng.2014.10.009
   SANDLER SL, 1999, CHEM ENG THERMODYNAM
   Soroush M, 1997, CHEM ENG SCI, V52, P387, DOI 10.1016/S0009-2509(96)00391-0
   Srinivasan B, 1998, AICHE J, V44, P1858, DOI 10.1002/aic.690440815
   Srinivasan S, 2017, THESIS
   Srinivasan S., 2013, IFAC P, V46, P102
   Srinivasan S, 2012, CHEM ENG J, V207, P785, DOI 10.1016/j.cej.2012.07.063
   Van Der Lee A. M., 2000, Conference Digest. 2000 International Quantum Electronics Conference (Cat. No.00TH8504), DOI 10.1109/IQEC.2000.907797
   van der Schaft AJ, 2016, INT J CONTROL, V89, P731, DOI 10.1080/00207179.2015.1095353
   VANDEVUSSE JG, 1964, CHEM ENG SCI, V19, P994, DOI 10.1016/0009-2509(64)85109-5
   Viel F, 1997, AUTOMATICA, V33, P1437, DOI 10.1016/S0005-1098(97)00071-X
   WALLER KV, 1981, IND ENG CHEM PROC DD, V20, P1, DOI 10.1021/i200012a001
   Wang L, 2018, J MATH CHEM, V56, P1707, DOI 10.1007/s10910-018-0882-9
   Ydstie BE, 2016, IFAC PAPERSONLINE, V49, P943, DOI 10.1016/j.ifacol.2016.07.321
   Zhao ZX, 2016, IFAC PAPERSONLINE, V49, P1091, DOI 10.1016/j.ifacol.2016.07.348
   ZIMMER G, 1994, INT J CONTROL, V60, P595, DOI 10.1080/00207179408921482
NR 75
TC 2
Z9 2
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 258
EP 274
DI 10.1016/j.ces.2019.01.010
PG 17
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700022
DA 2020-05-12
ER

PT J
AU Qu, Z
   Wu, H
   Zhou, Y
   Yang, LX
   Wu, XY
   Wu, YZ
   Ren, YX
   Zhang, N
   Liu, YT
   Jiang, ZY
AF Qu, Zihan
   Wu, Hong
   Zhou, Yue
   Yang, Leixin
   Wu, Xingyu
   Wu, Yingzhen
   Ren, Yanxiong
   Zhang, Ning
   Liu, Yutao
   Jiang, Zhongyi
TI Constructing interconnected ionic cluster network in polyelectrolyte
   membranes for enhanced CO2 permeation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ionic cluster network; Spatial distribution; CO2-philic domain;
   Polyelectrolyte membranes; CO2 separation
ID ANION-EXCHANGE MEMBRANES; POLYMER ELECTROLYTE MEMBRANES; GAS SEPARATION
   PERFORMANCE; FACILITATED TRANSPORT; COPOLYMER MEMBRANE; PERMEABILITY;
   MORPHOLOGY; SWOLLEN; STRATEGY
AB Membranes with fast CO2 transport pathways have attracted intense attention due to their outstanding CO2 permeability, showing potential for industrial application. Regulating the spatial distribution of CO2 philic groups in polymer-based membranes is expected to be a promising strategy to achieve the fast CO2 transport pathways. In membrane matrix, the interconnected network of concentrated domains of CO2 facilitated transport groups provides membranes with specific CO2 transport pathways and finally leads to their high separation performance. In this study, a novel kind of polyelectrolyte membrane, quaternary ammonium polysulfone with interconnected ionic clusters, is prepared to enhance the CO2 permeability. The hydrophilic quaternary ammonium groups tend to aggregate spontaneously to create ionic clusters. Furthermore, under humidified conditions, these ionic clusters are connected by water to form an ionic cluster network in the membrane matrix. The ionic cluster network plays the crucial role in accelerating the selective transport for CO2 molecules over CH4 by the reversible interaction between CO2 and ion pairs. By tuning the quaternization degree of polysulfone, a series of polyelectrolyte membranes with different size of ionic clusters were developed. Membranes with hydrated ionic clusters (5-9 nm) show dramatic enhancement in CO2 separation performance, especially in CO2 permeability. The as-prepared quaternary ammonium polysulfone membrane with 8.98 nm ionic clusters exhibited the high CO2 permeability of 1109.44 Barrer and a high CO2/CH4 selectivity of 29.70, which exceeds 2008 Robeson upper bound limit. The optimized separation performance of QA-PSf membranes is attractive for potential application such as CO2 capture from flue gas and natural gas. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Qu, Zihan; Wu, Hong; Zhou, Yue; Yang, Leixin; Wu, Xingyu; Wu, Yingzhen; Ren, Yanxiong; Zhang, Ning; Liu, Yutao; Jiang, Zhongyi] Tianjin Univ, Sch Chem Engn & Technol, Key Lab Green Chem Technol, Minist Educ, 135 Yaguan Rd, Tianjin 300072, Peoples R China.
   [Qu, Zihan; Wu, Hong; Zhou, Yue; Yang, Leixin; Wu, Xingyu; Wu, Yingzhen; Ren, Yanxiong; Zhang, Ning; Liu, Yutao; Jiang, Zhongyi] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
   [Wu, Hong] Tianjin Univ, Tianjin Key Lab Membrane Sci & Desalinat Technol, Tianjin 300072, Peoples R China.
RP Wu, H (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Key Lab Green Chem Technol, Minist Educ, 135 Yaguan Rd, Tianjin 300072, Peoples R China.
EM wuhong@tju.edu.cn
RI ; Ren, Yanxiong/S-6389-2017
OI Wu, Yingzhen/0000-0003-0165-3970; Ren, Yanxiong/0000-0002-5356-8236
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21878215, 21576189, 21490583, 21621004]; National
   Key R&D Program of China [2017YFB0603400]; State Key Laboratory of
   Separation Membranes and Membrane Processes [M1-201501]; Tianjin
   Polytechnic University [M1-201501]; National Science Fund for
   Distinguished Young ScholarsNational Natural Science Foundation of
   ChinaNational Science Fund for Distinguished Young Scholars [21125627];
   Program of Introducing Talents of Discipline to UniversitiesMinistry of
   Education, China - 111 Project [B06006]; State Key Laboratory of
   Organic-Inorganic Composites [oic-201701004]; Nation Key Laboratory of
   United Laboratory for Chemical Engineering [SKL-ChE-17B01]
FX The authors gratefully acknowledge the financial support from the
   National Natural Science Foundation of China (Nos. 21878215, 21576189,
   21490583 and 21621004), the National Key R&D Program of China
   (2017YFB0603400), State Key Laboratory of Separation Membranes and
   Membrane Processes and Tianjin Polytechnic University (No. M1-201501),
   the National Science Fund for Distinguished Young Scholars (No.
   21125627), Program of Introducing Talents of Discipline to Universities
   (B06006), State Key Laboratory of Organic-Inorganic Composites
   (oic-201701004) and Nation Key Laboratory of United Laboratory for
   Chemical Engineering (SKL-ChE-17B01).
CR Ahn SH, 2014, MACROMOL RES, V22, P160, DOI 10.1007/s13233-014-2014-0
   Cao L, 2017, CHEM SOC REV, V46, P6725, DOI 10.1039/c5cs00906e
   Carlisle TK, 2013, IND ENG CHEM RES, V52, P1023, DOI 10.1021/ie202305m
   Carlisle TK, 2012, J MEMBRANE SCI, V397, P24, DOI 10.1016/j.memsci.2012.01.006
   Chen DY, 2013, MACROMOLECULES, V46, P9270, DOI 10.1021/ma401620m
   Chen GQ, 2015, J MEMBRANE SCI, V487, P249, DOI 10.1016/j.memsci.2015.03.074
   Chi WS, 2013, J MEMBRANE SCI, V443, P54, DOI 10.1016/j.memsci.2013.04.049
   Cui ST, 2007, J PHYS CHEM B, V111, P2208, DOI 10.1021/jp066388n
   Deng LY, 2010, INT J GREENH GAS CON, V4, P638, DOI 10.1016/j.ijggc.2009.12.013
   Dong LL, 2016, NEW J CHEM, V40, P9148, DOI 10.1039/c6nj02013e
   Du NY, 2012, ENERG ENVIRON SCI, V5, P7306, DOI [10.1039/C1EE02668B, 10.1039/c1ee02668b]
   Elliott JA, 2000, MACROMOLECULES, V33, P4161, DOI 10.1021/ma991113+
   Gebel G, 2000, POLYMER, V41, P5829, DOI 10.1016/S0032-3861(99)00770-3
   He XY, 2017, ACS APPL MATER INTER, V9, P27676, DOI 10.1021/acsami.7b06424
   He YB, 2016, J MEMBRANE SCI, V515, P189, DOI 10.1016/j.memsci.2016.05.058
   Izgorodina EI, 2015, J PHYS CHEM B, V119, P11748, DOI 10.1021/acs.jpcb.5b05115
   Khan AL, 2011, J MEMBRANE SCI, V372, P87, DOI 10.1016/j.memsci.2011.01.056
   Kusoglu A, 2017, CHEM REV, V117, P987, DOI 10.1021/acs.chemrev.6b00159
   Li PY, 2015, J MEMBRANE SCI, V476, P243, DOI 10.1016/j.memsci.2014.11.050
   Li XQ, 2015, J MEMBRANE SCI, V474, P156, DOI 10.1016/j.memsci.2014.10.003
   Li YF, 2015, CHEM SOC REV, V44, P103, DOI 10.1039/c4cs00215f
   Li YF, 2014, ENERG ENVIRON SCI, V7, P1489, DOI 10.1039/c3ee43163k
   Lin XC, 2013, J POWER SOURCES, V233, P259, DOI 10.1016/j.jpowsour.2013.01.059
   Liu L, 2008, J MEMBRANE SCI, V310, P66, DOI 10.1016/j.memsci.2007.10.032
   Liu Y, 2014, J MEMBRANE SCI, V469, P198, DOI 10.1016/j.memsci.2014.06.050
   Liu Y, 2014, ACS APPL MATER INTER, V6, P13051, DOI 10.1021/am502936x
   Ma BR, 2018, ACS NANO, V12, P2311, DOI 10.1021/acsnano.7b07432
   Mauritz KA, 2004, CHEM REV, V104, P4535, DOI 10.1021/cr0207123
   Olivieri L, 2018, J MEMBRANE SCI, V566, P96, DOI 10.1016/j.memsci.2018.08.048
   Park CH, 2015, J MEMBRANE SCI, V492, P452, DOI 10.1016/j.memsci.2015.06.023
   Peckham TJ, 2010, ADV MATER, V22, P4667, DOI 10.1002/adma.201001164
   Peng DD, 2017, J MEMBRANE SCI, V522, P351, DOI 10.1016/j.memsci.2016.09.040
   Shi WY, 2016, BIORESOURCE TECHNOL, V210, P43, DOI 10.1016/j.biortech.2015.12.086
   Shin DW, 2017, CHEM REV, V117, P4759, DOI 10.1021/acs.chemrev.6b00586
   Shishatskiy S, 2010, J MEMBRANE SCI, V359, P44, DOI 10.1016/j.memsci.2009.09.006
   Sholl DS, 2016, NATURE, V532, P435, DOI 10.1038/532435a
   Si JJ, 2017, J MATER CHEM A, V5, P4003, DOI 10.1039/c6ta09277b
   Taniguchi I, 2017, J MEMBRANE SCI, V535, P239, DOI 10.1016/j.memsci.2017.04.046
   Wang SF, 2017, ANGEW CHEM INT EDIT, V56, P14246, DOI 10.1002/anie.201708048
   Wu J, 2012, LANGMUIR, V28, P7436, DOI 10.1021/la300394c
   Xin QP, 2015, J MEMBRANE SCI, V488, P13, DOI 10.1016/j.memsci.2015.02.047
   Xin QP, 2015, ACS APPL MATER INTER, V7, P1065, DOI 10.1021/am504742q
   Xue BL, 2013, J MATER CHEM A, V1, P8097, DOI 10.1039/c3ta11572k
   Yoo S, 2010, J MEMBRANE SCI, V363, P72, DOI 10.1016/j.memsci.2010.07.013
   Yue X, 2017, J APPL POLYM SCI, V134, DOI 10.1002/app.45333
   Yun S, 2014, J MATER CHEM A, V2, P6605, DOI 10.1039/c4ta00166d
   Zhang M, 2015, J MATER CHEM A, V3, P12284, DOI 10.1039/c5ta01420d
NR 47
TC 7
Z9 7
U1 20
U2 92
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 275
EP 284
DI 10.1016/j.ces.2018.12.050
PG 10
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700023
DA 2020-05-12
ER

PT J
AU Tang, TT
   Yu, P
   Shan, XW
   Che, HS
   Su, J
AF Tang, Tingting
   Yu, Peng
   Shan, Xiaowen
   Che, Huisu
   Su, Jian
TI Investigation of drag properties for flow through and around square
   arrays of cylinders at low Reynolds numbers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Permeable body; Drag; Cylinder array; Low-Reynolds number flow; Fluid
   mechanics; Computational fluid dynamics
ID STEADY FLOW; CIRCULAR-CYLINDER; HEAT-TRANSFER; VISCOUS-FLOW;
   NUMERICAL-SOLUTIONS; CREEPING FLOW; FLUID MOTION; SLOW FLOW; MECHANICS;
   MODEL
AB The drag properties of flow through and around square arrays of 10 x 10 evenly spaced circular cylinders with a wide range of solid fraction phi from 9.69 x 10(-11) to 0.785 and Reynold number of the array Re from 1 to 50 are investigated numerically. The purpose of the present study is to better understand the phenomena of flow through and around permeable bodies that appear in bioreactors and fluid-solid reactors, for example. Instead of using the semi-empirical porous medium model, the direct numerical simulation is employed in order to investigate the flow mechanism from a microscopic point of view. A peak in drag coefficient is observed for the range of phi investigated, which appears at a smaller phi as Re increases. Three flow regimes are identified based on the shape effects quantified via the averaged velocity within the array, and the drag property in each regime is analyzed. A novel drag formula is also found by investigating the dependence of drag on phi and R (Reynolds number based on the mean velocity within the array). Finally, the dimensionless macroscopic permeability Da is estimated via the Darcy's law. The drag ratio computed is in a good agreement with the previous results from porous media models. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tang, Tingting; Yu, Peng; Shan, Xiaowen; Su, Jian] Southern Univ Sci & Technol, Dept Mech & Aerosp Engn, Shenzhen 518055, Peoples R China.
   [Che, Huisu] Southeast Univ, Sch Mat Sci & Engn, Jiangsu Key Lab Construct Mat, Nanjing 210018, Jiangsu, Peoples R China.
RP Yu, P (reprint author), Southern Univ Sci & Technol, Dept Mech & Aerosp Engn, Shenzhen 518055, Peoples R China.
EM yup6@sustc.edu.cn
RI Yu, Peng/B-7942-2009; Chen, Huisu/G-5494-2010; Shan, Xiaowen/H-2836-2013
OI Yu, Peng/0000-0003-2073-7512; Chen, Huisu/0000-0003-1997-5476; Shan,
   Xiaowen/0000-0002-6350-9248
FU NSFCNational Natural Science Foundation of China [11672124]; Shenzhen
   Peacock Plan [KQTD2016022620054656]; Special Program for Applied
   Research on Super Computation of the NSFC-Guangdong Joint Fund (second
   phase) [U1501501]
FX The author P Yu would like to thank the financial support from NSFC
   (Grant No. 11672124), the Shenzhen Peacock Plan (KQTD2016022620054656),
   and the computational resource from the Special Program for Applied
   Research on Super Computation of the NSFC-Guangdong Joint Fund (second
   phase) under Grant No. U1501501. The authors would like to thank Dr. Y.
   Zeng from NMC, ASTAR for her valuable discussion.
CR Barta E, 2006, J FLUID MECH, V551, P1, DOI 10.1017/S0022112005008268
   Bhattacharyya S, 2006, CHEM ENG SCI, V61, P4451, DOI 10.1016/j.ces.2006.02.012
   Chang K, 2015, J FLUID MECH, V776, P161, DOI 10.1017/jfm.2015.321
   Cummins C, 2018, NATURE, V562, P414, DOI 10.1038/s41586-018-0604-2
   Cummins C, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.5001342
   DENNIS SCR, 1970, J FLUID MECH, V42, P471, DOI 10.1017/S0022112070001428
   Dhiman AK, 2006, NUMER HEAT TR A-APPL, V49, P717, DOI 10.1080/10407780500283325
   DRUMMOND JE, 1984, INT J MULTIPHAS FLOW, V10, P515, DOI 10.1016/0301-9322(84)90079-X
   Eames I, 2004, J FLUID MECH, V515, P371, DOI 10.1017/S0022112004000503
   ELLINGTON CP, 1980, J EXP BIOL, V85, P129
   Green H.L., 1957, PARTICULATE CLOUDS D
   HANRATTY TJ, 1957, AICHE J, V3, P293, DOI 10.1002/aic.690030230
   HAPPEL J, 1959, AICHE J, V5, P174, DOI 10.1002/aic.690050211
   Happel J., 2012, LOW REYNOLDS NUMBER, V1
   HASIMOTO H, 1959, J FLUID MECH, V5, P317, DOI 10.1017/S0022112059000222
   Hsu C T, 1990, J HEAT MASS TRANSFER, V8, P1587
   ISHII H, 1989, J CHEM ENG JPN, V22, P484, DOI 10.1252/jcej.22.484
   KANEDA Y, 1986, J FLUID MECH, V167, P455, DOI 10.1017/S0022112086002914
   Kiorboe T, 2001, MAR ECOL PROG SER, V211, P15, DOI 10.3354/meps211015
   Koch DL, 1997, J FLUID MECH, V349, P31, DOI 10.1017/S002211209700671X
   Kundu P. K., 2008, FLUID MECH
   LINTS MC, 1993, AICHE SYM S, V89, P35
   Liu ML, 2018, THESIS
   MASLIYAH JH, 1980, CAN J CHEM ENG, V58, P299, DOI 10.1002/cjce.5450580303
   NANDAKUMAR K, 1982, CAN J CHEM ENG, V60, P202, DOI 10.1002/cjce.5450600202
   NEALE G, 1973, CHEM ENG SCI, V28, P1865, DOI 10.1016/0009-2509(73)85070-5
   Nicolle A, 2011, J FLUID MECH, V679, P1, DOI 10.1017/jfm.2011.77
   Noymer PD, 1998, CHEM ENG SCI, V53, P2859, DOI 10.1016/S0009-2509(98)00117-1
   Noymer PD, 1998, INT J HEAT MASS TRAN, V41, P147, DOI 10.1016/S0017-9310(97)00065-3
   Paliwal B, 2003, CHEM ENG SCI, V58, P5315, DOI 10.1016/j.ces.2003.09.010
   Park J, 1998, KSME INT J, V12, P1200, DOI 10.1007/BF02942594
   Patankar S., 1983, NUMERICAL PREDICTION, P54, DOI DOI 10.1016/B978-0-08-030937-8.50013-1
   SANGANI AS, 1982, INT J MULTIPHAS FLOW, V8, P343, DOI 10.1016/0301-9322(82)90047-7
   SANGANI AS, 1982, INT J MULTIPHAS FLOW, V8, P193, DOI 10.1016/0301-9322(82)90029-5
   Sbutega K, 2015, THESIS
   Scheidegger A., 1958, PHYS FLOW POROUS MED
   Sen S, 2011, INT J NUMER METH FL, V67, P1160, DOI 10.1002/fld.2416
   Sharma A, 2004, NUMER HEAT TR A-APPL, V45, P247, DOI 10.1080/10407780490278562
   Shimizu Y., 1978, T JAPAN SOC MECH E B, V44, P2699
   SOMASUNDARAN P, 1975, J FLUID ENG-T ASME, V97, P379, DOI 10.1115/1.3447321
   Taddei S, 2016, J FLUID MECH, V798, P27, DOI 10.1017/jfm.2016.312
   Takami H., 1969, PHYS FLUIDS       S2, V12, pII
   Tamada K., 1957, Q J MECH APPL MATH, V10, P425, DOI [DOI 10.1093/QJMAM/10.4.425, 10.1093/qjmam/10.4.425]
   Tang TT, 2016, INT J HEAT MASS TRAN, V103, P984, DOI 10.1016/j.ijheatmasstransfer.2016.07.095
   TRITTON DJ, 1959, J FLUID MECH, V6, P547, DOI 10.1017/S0022112059000829
   Vainshtein P, 2004, J AEROSOL SCI, V35, P383, DOI 10.1016/j.jaerosci.2003.09.004
   Valdes-Parada FJ, 2009, PHYSICA A, V388, P789, DOI 10.1016/j.physa.2008.11.024
   Weller HG, 1998, COMPUT PHYS, V12, P620, DOI 10.1063/1.168744
   Wieselsberger C, 1921, PHYS Z, V22, P321
   Yu P, 2010, INT J HEAT FLUID FL, V31, P141, DOI 10.1016/j.ijheatfluidflow.2009.12.009
   Yu P, 2012, INT J HEAT FLUID FL, V36, P142, DOI 10.1016/j.ijheatfluidflow.2012.03.002
   Yu P, 2011, COMPUT FLUIDS, V42, P1, DOI 10.1016/j.compfluid.2010.09.040
   Yu P, 2009, INT J HEAT MASS TRAN, V52, P316, DOI 10.1016/j.ijheatmasstransfer.2008.06.021
   Zdravkovich M., 1997, FLOW CIRCULAR CYLIND, V1
NR 54
TC 3
Z9 3
U1 3
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 285
EP 301
DI 10.1016/j.ces.2019.01.017
PG 17
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700024
DA 2020-05-12
ER

PT J
AU Lu, X
   Xie, P
   Ingham, DB
   Ma, L
   Pourkashanian, M
AF Lu, X.
   Xie, P.
   Ingham, D. B.
   Ma, L.
   Pourkashanian, M.
TI Modelling of CO2 absorption in a rotating packed bed using an Eulerian
   porous media approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rotating packed bed; CFD simulation; CO2 absorption; Liquid amine;
   Porous media model
ID REACTIVE MASS-TRANSFER; FLUID-DYNAMICS CFD; GAS-LIQUID; CARBON-DIOXIDE;
   STRUCTURED-PACKING; CHEMICAL ABSORPTION; PROCESS INTENSIFICATION;
   AQUEOUS-SOLUTIONS; AMINE SOLUTIONS; 2-PHASE FLOW
AB The rotating packed bed (RPB) is a promising reactor for CO2 capture with liquid amine because of its high mass transfer rate and energy and space savings. The CFD simulations of RPBs generally use the volume of fluid (VOF) method, but this method is prohibitively expensive for 3D simulations, in particular for large-scale reactors. The Eulerian method is a promising and effective method; however, there are still several difficulties, such as the settings for the porous media models in the gas-liquid counter-current flow and the interfacial area between the gas and liquid. To overcome these difficulties in the Eulerian method, this paper uses a new porous media model, a novel liquid generation-elimination model for numerically investigating the gas-liquid counter-current flow in RPBs and a new interfacial area model derived from the VOF simulation. These new models, incorporating the two-film reaction-enhancement mass transfer model, have successfully simulated the CO2 capture process with monoethanolamine (MEA) solutions in a RPB under both low (30 wt%) and high (90 wt%) concentration conditions. The results show that the overall gas phase mass transfer coefficient (K(G)a) increases with increasing the rotation speeds and the liquid to gas mass flow rate (L/G ratio). The simulations were validated by the experimental data and the results were analysed and discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lu, X.; Xie, P.; Ingham, D. B.; Ma, L.; Pourkashanian, M.] Univ Sheffield, Fac Engn, Dept Mech Engn, Energy 2050, Sheffield S10 2TN, S Yorkshire, England.
RP Ma, L (reprint author), Univ Sheffield, Fac Engn, Dept Mech Engn, Energy 2050, Sheffield S10 2TN, S Yorkshire, England.
EM lin.ma@sheffield.ac.uk
OI Ma, Lin/0000-0002-3731-8464; xie, peng/0000-0001-7156-7061
FU Engineering and Physical Science Research Council (EPSRC)Engineering &
   Physical Sciences Research Council (EPSRC) [EP/M001458/2]; China
   Scholarship CouncilChina Scholarship Council; University of Sheffield
FX The authors would like to acknowledge the financial support provided by
   the Engineering and Physical Science Research Council (EPSRC) under
   grant EP/M001458/2. In addition, P. Xie would like to acknowledge the
   China Scholarship Council and the University of Sheffield for funding
   his research studies.
CR Aboudheir A, 2003, CHEM ENG SCI, V58, P5195, DOI 10.1016/j.ces.2003.08.014
   Amundsen TG, 2009, J CHEM ENG DATA, V54, P3096, DOI 10.1021/je900188m
   [Anonymous], 2017, EL INF OV
   Ansys Inc, 2013, ANSYS FLUENT THEOR G
   Asendrych D, 2013, CHEM PROCESS ENG-INZ, V34, P269, DOI 10.2478/cpe-2013-0022
   Attou A, 1999, CHEM ENG SCI, V54, P785, DOI 10.1016/S0009-2509(98)00285-1
   Burns JR, 2000, CHEM ENG SCI, V55, P2401, DOI 10.1016/S0009-2509(99)00520-5
   Chen YS, 2005, IND ENG CHEM RES, V44, P1043, DOI 10.1021/ie0499409
   Chen YS, 2005, IND ENG CHEM RES, V44, P7868, DOI 10.1021/ie048962s
   Chen YS, 2006, IND ENG CHEM RES, V45, P6846, DOI 10.1021/ie060399l
   Fitzgerald FD, 2014, ENRGY PROCED, V63, P6239, DOI 10.1016/j.egypro.2014.11.655
   Guo F, 1997, CHEM ENG SCI, V52, P3853, DOI 10.1016/S0009-2509(97)00229-7
   Guo TY, 2017, IND ENG CHEM RES, V56, P8169, DOI 10.1021/acs.iecr.7b01759
   Guo TY, 2016, IND ENG CHEM RES, V55, P4856, DOI 10.1021/acs.iecr.6b00213
   HALMANN M, 1999, GREENHOUSE GAS CARBO
   Hassan-Beck H. M, 1997, THESIS
   HIKITA H, 1977, CHEM ENG J BIOCH ENG, V13, P7, DOI 10.1016/0300-9467(77)80002-6
   Hlushkou D, 2006, J CHROMATOGR A, V1126, P70, DOI 10.1016/j.chroma.2006.06.011
   Horng SY, 2002, IND ENG CHEM RES, V41, P257, DOI 10.1021/ie010671l
   Hosseini SM, 2014, HEAT MASS TRANSFER, V50, P1393, DOI 10.1007/s00231-014-1343-z
   HUGHMARK GA, 1967, AICHE J, V13, P1219, DOI 10.1002/aic.690130638
   Iliuta I, 2004, CHEM ENG SCI, V59, P879, DOI 10.1016/j.ces.2003.11.020
   Iso Y, 2013, ENRGY PROCED, V37, P860, DOI 10.1016/j.egypro.2013.05.178
   Jassim MS, 2007, IND ENG CHEM RES, V46, P2823, DOI 10.1021/ie051104r
   Jeannot MA, 1997, ANAL CHEM, V69, P235, DOI 10.1021/ac960814r
   Joel AS, 2017, APPL ENERG, V203, P11, DOI 10.1016/j.apenergy.2017.05.157
   Kang JL, 2016, INT J GREENH GAS CON, V46, P228, DOI 10.1016/j.ijggc.2016.01.017
   Kang JL, 2014, INT J GREENH GAS CON, V25, P141, DOI 10.1016/j.ijggc.2014.04.011
   Kim J, 2016, COMPUT CHEM ENG, V88, P39, DOI 10.1016/j.compchemeng.2016.02.006
   Kolodziej A, 2009, CHEM ENG PROCESS, V48, P816, DOI 10.1016/j.cep.2008.10.009
   Lappalainen K, 2008, IND ENG CHEM RES, V47, P8436, DOI 10.1021/ie8003754
   Lee J, 2017, ENRGY PROCED, V114, P1834, DOI 10.1016/j.egypro.2017.03.1312
   LEVICH VG, 1962, PHYSICOCHEMICAL HYDR
   Liu GB, 2006, CHEM ENG SCI, V61, P6511, DOI 10.1016/j.ces.2006.05.035
   Liu GB, 2006, IND ENG CHEM RES, V45, P3220, DOI 10.1021/ie051184z
   Liu HS, 1996, IND ENG CHEM RES, V35, P3590, DOI 10.1021/ie960183r
   Lu X, 2018, CHEM ENG SCI, V189, P123, DOI 10.1016/j.ces.2018.04.074
   Lu X, 2016, POWDER TECHNOL, V304, P41, DOI 10.1016/j.powtec.2016.07.063
   Luo Y, 2012, IND ENG CHEM RES, V51, P16320, DOI 10.1021/ie302531j
   Ma CR, 2015, J CHEM THEORY COMPUT, V11, P3189, DOI 10.1021/acs.jctc.5b00379
   Mah R. S. H., 1983, CHEM ENG COMMUM, V39, P147
   Mansourizadeh A, 2009, J HAZARD MATER, V171, P38, DOI 10.1016/j.jhazmat.2009.06.026
   Martinez EL, 2012, COMPUT-AIDED CHEM EN, V30, P1158
   Mishra D.P., 2014, THESIS
   MOONEY KG, 1981, J PHARM SCI, V70, P13, DOI 10.1002/jps.2600700103
   MUNJAL S, 1989, CHEM ENG SCI, V44, P2245, DOI 10.1016/0009-2509(89)85159-0
   MUNJAL S, 1989, CHEM ENG SCI, V44, P2257, DOI 10.1016/0009-2509(89)85160-7
   Niegodajew P, 2016, APPL MATH MODEL, V40, P10222, DOI 10.1016/j.apm.2016.07.003
   Oi LE, 2010, MATH COMP MODEL DYN, V16, P511, DOI 10.1080/13873954.2010.491676
   Oko Eni, 2017, Int J Coal Sci Technol, V4, P5, DOI 10.1007/s40789-017-0159-0
   Onda K., 1968, J CHEM ENG JPN, V1, P56, DOI DOI 10.1252/JCEJ.1.56
   Penttila A, 2011, FLUID PHASE EQUILIBR, V311, P59, DOI 10.1016/j.fluid.2011.08.019
   Pham DA, 2015, CHEM ENG SCI, V132, P259, DOI 10.1016/j.ces.2015.04.009
   Rajan S, 2011, IND ENG CHEM RES, V50, P986, DOI 10.1021/ie100899r
   Raynal L, 2007, CHEM ENG SCI, V62, P7196, DOI 10.1016/j.ces.2007.08.010
   Raynal L, 2009, ENRGY PROCED, V1, P917, DOI 10.1016/j.egypro.2009.01.122
   Sebastia-Saez D, 2014, ENRGY PROCED, V63, P1229, DOI 10.1016/j.egypro.2014.11.133
   Sebastia-Saez D, 2018, CHEM ENG SCI, V176, P356, DOI 10.1016/j.ces.2017.09.046
   Sebastia-Saez D, 2015, INT J GREENH GAS CON, V33, P40, DOI 10.1016/j.ijggc.2014.11.019
   Shearer C, 2017, EARTHS FUTURE, V5, P408, DOI 10.1002/2017EF000542
   Shi X, 2013, CHEM ENG J, V228, P1040, DOI 10.1016/j.cej.2013.05.081
   SNIJDER ED, 1993, J CHEM ENG DATA, V38, P475, DOI 10.1021/je00011a037
   Tan CS, 2006, SEP PURIF TECHNOL, V49, P174, DOI 10.1016/j.seppur.2005.10.001
   U. S. Energy Information Administration, 2017, EL POW MONTHL DAT SE, P20585
   Versteeg GF, 1996, CHEM ENG COMMUN, V144, P113, DOI 10.1080/00986449608936450
   Wang M, 2015, APPL ENERG, V158, P275, DOI 10.1016/j.apenergy.2015.08.083
   Wang Z, 2013, ENERG FUEL, V27, P6887, DOI 10.1021/ef401488c
   Wegner K., 2017, THEORIES MASS TRANSF
   WELLEK RM, 1978, CAN J CHEM ENG, V56, P181, DOI 10.1002/cjce.5450560205
   Xie P., 2019, CHEM ENG SCI
   Xie P, 2017, CHEM ENG SCI, V172, P216, DOI 10.1016/j.ces.2017.06.040
   Yang WJ, 2010, CHEM ENG J, V156, P582, DOI 10.1016/j.cej.2009.04.013
   Yang YC, 2016, CHEM ENG J, V294, P111, DOI 10.1016/j.cej.2016.02.054
   Yang YC, 2015, CHEM ENG SCI, V138, P244, DOI 10.1016/j.ces.2015.07.044
   Zhao BT, 2016, RENEW SUST ENERG REV, V65, P44, DOI 10.1016/j.rser.2016.06.059
   Zhao BT, 2014, APPL ENERG, V136, P132, DOI 10.1016/j.apenergy.2014.08.108
NR 76
TC 2
Z9 2
U1 4
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 302
EP 318
DI 10.1016/j.ces.2019.01.029
PG 17
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700025
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Lu, JH
   Lei, HY
   Dai, CS
AF Lu, J. H.
   Lei, H. Y.
   Dai, C. S.
TI Analysis of Henry's law and a unified lattice Boltzmann equation for
   conjugate mass transfer problem
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Conjugate mass transfer; Henry's law; Lattice Boltzmann method;
   Asymptotic analysis
ID NUMERICAL-SIMULATION; DROPLET FLOW; MODEL; HEAT; GAS; BIOREACTOR;
   INTERFACES; BUBBLES; SURFACE; VOLUME
AB The most challenging problem for simulating conjugate mass transfer problem is the variable concentration jump described by the double film theory at the phase interface. In the present paper, the physical mechanism of Henry's law is analyzed, and it is found that Henry's law can be expressed as a relation between two constant weight coefficients in lattice Boltzmann method (LBM). As a consequence, a unified multi-relaxation-time (MRT) lattice Boltzmann equation (LBE) for conjugate mass transfer is proposed. The asymptotic analysis proves that the interface conditions, including the concentration jump determined by the double film theory and mass flux continuity, can be ensured with second-order accuracy. Five test cases containing both transient and steady conjugate mass transfer problems with straight or curved interfaces are calculated to validate the present method. The results show that the proposed MRT LBE has both simplicity and good accuracy. It is capable of simulating conjugate mass transfer at both steady and transient periods, with a stationary or moving interface. Especially, it has a good numerical stability at large distribution coefficient and diffusivity coefficient ratio. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lu, J. H.; Lei, H. Y.; Dai, C. S.] Tianjin Univ, Sch Mech Engn, Key Lab Efficient Utilizat Low & Medium Grade Ene, MOE, 135 Yaguan Rd, Tianjin 300050, Peoples R China.
RP Dai, CS (reprint author), Tianjin Univ, Sch Mech Engn, Key Lab Efficient Utilizat Low & Medium Grade Ene, MOE, 135 Yaguan Rd, Tianjin 300050, Peoples R China.
EM csdai@tju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [41574176, 41672234]
FX This work is financially supported by the National Natural Science
   Foundation of China (Grant No. 41574176 and No. 41672234).
CR Amaral PFF, 2008, BIOTECHNOL BIOENG, V99, P588, DOI 10.1002/bit.21640
   BEENACKERS AACM, 1993, CHEM ENG SCI, V48, P3109, DOI 10.1016/0009-2509(93)80199-Z
   Bothe D., 2003, ASME JSME 2003 4 JOI, V2, P423
   Chen S, 2016, INT J HEAT MASS TRAN, V102, P637, DOI 10.1016/j.ijheatmasstransfer.2016.06.082
   Davidson MR, 2002, NUMER HEAT TR B-FUND, V41, P291, DOI 10.1080/104077902753541023
   Deshpande KB, 2006, CHEM ENG SCI, V61, P6486, DOI 10.1016/j.ces.2006.06.012
   Dumont E, 2006, BIOCHEM ENG J, V30, P245, DOI 10.1016/j.bej.2006.05.003
   Fathi H, 2017, J ELECTROCHEM SOC, V164, pF298, DOI 10.1149/2.0871704jes
   Ginzburg I, 2010, J STAT PHYS, V139, P1090, DOI 10.1007/s10955-010-9969-9
   GUNSTENSEN AK, 1991, PHYS REV A, V43, P4320, DOI 10.1103/PhysRevA.43.4320
   Guo KK, 2015, INT J HEAT MASS TRAN, V88, P306, DOI 10.1016/j.ijheatmasstransfer.2015.04.064
   Haroun Y, 2012, CHEM ENG SCI, V75, P342, DOI 10.1016/j.ces.2012.03.011
   Haroun Y, 2010, CHEM ENG SCI, V65, P2896, DOI 10.1016/j.ces.2010.01.012
   Huang RZ, 2015, J COMPUT PHYS, V294, P346, DOI 10.1016/j.jcp.2015.03.064
   Hussein MA, 2008, INT J COMPUT FLUID D, V22, P341, DOI 10.1080/10618560802077806
   Jung RT, 2001, CHEM ENG TECHNOL, V24, P1071, DOI 10.1002/1521-4125(200110)24:10<1071::AID-CEAT1071>3.0.CO;2-A
   Koynov A, 2005, AICHE J, V51, P2786, DOI 10.1002/aic.10529
   Li D, 2017, INT J HEAT MASS TRAN, V115, P1334, DOI 10.1016/j.ijheatmasstransfer.2017.07.048
   Li LK, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.043308
   Marschall H, 2012, CHEM ENG SCI, V78, P111, DOI 10.1016/j.ces.2012.02.034
   Molaeimanesh GR, 2015, INT J HYDROGEN ENERG, V40, P5169, DOI 10.1016/j.ijhydene.2015.02.097
   Nieves-Remacha MJ, 2015, IND ENG CHEM RES, V54, P6649, DOI 10.1021/acs.iecr.5b00480
   Niu ZQ, 2018, J ELECTROCHEM SOC, V165, pF986, DOI 10.1149/2.1191811jes
   Onea A, 2009, CHEM ENG SCI, V64, P1416, DOI 10.1016/j.ces.2008.11.008
   Ponoth SS, 2000, CHEM ENG SCI, V55, P1237, DOI 10.1016/S0009-2509(99)00412-1
   Radl S, 2008, CHEM ENG SCI, V63, P3279, DOI 10.1016/j.ces.2008.03.025
   Radl S, 2007, AICHE J, V53, P1861, DOI 10.1002/aic.11211
   Sato T, 2000, J FLUID ENG-T ASME, V122, P510, DOI 10.1115/1.1287504
   SHAN XW, 1993, PHYS REV E, V47, P1815, DOI 10.1103/PhysRevE.47.1815
   Swift MR, 1996, PHYS REV E, V54, P5041, DOI 10.1103/PhysRevE.54.5041
   Wagner AJ, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.045702
   Yan YY, 2007, J COMPUT PHYS, V227, P763, DOI 10.1016/j.jcp.2007.08.010
   Yang C, 2005, CHEM ENG SCI, V60, P2643, DOI 10.1016/j.ces.2004.11.054
   Yoshida H, 2014, PHYS REV E, V90, DOI 10.1103/PhysRevE.90.013303
   Yoshida H, 2010, J COMPUT PHYS, V229, P7774, DOI 10.1016/j.jcp.2010.06.037
NR 35
TC 2
Z9 2
U1 4
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 319
EP 331
DI 10.1016/j.ces.2019.01.021
PG 13
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700026
DA 2020-05-12
ER

PT J
AU Saha, B
   Kumar, S
   Sengupta, S
AF Saha, Biswajit
   Kumar, Suman
   Sengupta, Sonali
TI Green synthesis of nano silver on TiO2 catalyst for application in
   oxidation of thiophene
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Silver nanoparticles; Tulsi leaf extract; Titanium dioxide; Thiophene;
   Catalytic oxidation; Kinetic model
ID DESULFURIZATION; NANOPARTICLES; DIBENZOTHIOPHENE; DISPERSION; EXTRACT;
   DEACTIVATION; DEPOSITION; REDUCTION; ALUMINA; FUELS
AB The present research work describes the preparation of silver nanoparticles from silver nitrate, and Tulsi (Ocimum tenuiflorum) leaf extract, impregnation on titanium dioxide (TiO2) and evaluation of the catalytic activity of this nano silver impregnated TiO2 in the oxidation reaction of thiophene. Tertiarybutyl hydroperoxide was used as an oxidant in the reaction. The catalyst was characterized by BET, SEM, XRF, TEM, UV-Vis spectroscopy, XPS and TPR. The effect of process parameters such as speed of agitation, catalyst weight, oxidant to sulfur mole ratio, silver loading in the catalyst and temperature on the oxidation reaction was studied. Both pseudo-homogeneous and heterogeneous kinetic models were considered and applied for the result. The pseudo-homogeneous form of rate equation shows the reaction follows second order kinetics and is endothermic. Langmuir-Hinshelwood kinetic model is proposed, considering the reaction as a heterogeneous one with solid catalyst and found that surface reaction is the rate controlling step. This model is well fitted with experimental data. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Saha, Biswajit; Kumar, Suman; Sengupta, Sonali] IIT Kharagpur, Chem Engn Dept, Kharagpur, W Bengal, India.
RP Sengupta, S (reprint author), IIT Kharagpur, Chem Engn Dept, Kharagpur, W Bengal, India.
EM sonalis@che.iitkgp.ac.in
CR Abboud Y, 2014, APPL NANOSCI, V4, P571, DOI 10.1007/s13204-013-0233-x
   Agnihotri S, 2014, RSC ADV, V4, P3974, DOI 10.1039/c3ra44507k
   Akhtar MS, 2013, ACS SUSTAIN CHEM ENG, V1, P591, DOI 10.1021/sc300118u
   Alvarez-Amparan MA, 2017, CATAL TODAY, V282, P133, DOI 10.1016/j.cattod.2016.07.002
   Banerjee P., 2014, BIORESOURCES BIOPROC, V1, P3, DOI [10.1186/s40643-014-0003-y, DOI 10.1186/S40643-014-0003-Y]
   Bhasarkar JB, 2015, BIORESOURCE TECHNOL, V187, P369, DOI 10.1016/j.biortech.2015.03.102
   Edison TJI, 2012, PROCESS BIOCHEM, V47, P1351, DOI 10.1016/j.procbio.2012.04.025
   Fan XQ, 2015, RSC ADV, V5, P28305, DOI 10.1039/c5ra01480h
   Hassani SS, 2009, CRYST RES TECHNOL, V44, P948, DOI 10.1002/crat.200900126
   Jain Siddhant, 2017, Sci Rep, V7, P15867, DOI 10.1038/s41598-017-15724-8
   Khan MS, 2014, AIP CONF PROC, V1621, P10, DOI 10.1063/1.4898438
   Kholodovich AN, 2005, REACT KINET CATAL L, V86, P381, DOI 10.1007/s11144-005-0334-y
   Kohantorabi M, 2017, APPL ORGANOMET CHEM, V31, DOI 10.1002/aoc.3806
   Lee DS, 2014, J TAIWAN INST CHEM E, V45, P705, DOI 10.1016/j.jtice.2013.07.007
   Li HM, 2009, REACT KINET CATAL L, V96, P165, DOI 10.1007/s11144-009-5426-7
   Li LT, 2016, FUEL, V167, P9, DOI 10.1016/j.fuel.2015.11.047
   Loo YY, 2012, INT J NANOMED, V7, P4263, DOI 10.2147/IJN.S33344
   Maity U, 2012, J NANOENG NANO MANUF, V2, P241
   Maity U, 2016, J ENERGY INST, V89, P648, DOI 10.1016/j.joei.2015.06.001
   Mogal SI, 2014, IND ENG CHEM RES, V53, P5749, DOI 10.1021/ie404230q
   Mokhtar WNAW, 2015, CLEAN TECHNOL ENVIR, V17, P1487, DOI 10.1007/s10098-014-0873-x
   Pacioni N.L., 2015, SILVER NANOPARTICLE, P13, DOI DOI 10.1007/978-3-319-11262-6_2
   Peng JX, 2007, APPL CATAL B-ENVIRON, V73, P282, DOI 10.1016/j.apcatb.2006.12.012
   Melian EP, 2012, APPL CATAL B-ENVIRON, V127, P112, DOI 10.1016/j.apcatb.2012.08.007
   Rao KG, 2015, INT J ADV RES PHYS S, V2, P1
   Regali F, 2014, CATAL TODAY, V223, P87, DOI 10.1016/j.cattod.2013.08.028
   Rossetti I, 2005, APPL CATAL A-GEN, V282, P315, DOI 10.1016/j.apcata.2004.12.024
   Saha S, 2010, LANGMUIR, V26, P2885, DOI 10.1021/la902950x
   Sandee A.J., 2013, ORGANOMETAL CHEM BIO, V31
   Schill L, 2012, APPL CATAL B-ENVIRON, V127, P323, DOI 10.1016/j.apcatb.2012.08.035
   Schwengber CA, 2016, J ENVIRON CHEM ENG, V4, P3688, DOI 10.1016/j.jece.2016.07.001
   Sengupta A, 2012, IND ENG CHEM RES, V51, P147, DOI 10.1021/ie2024068
   Sharma D, 2019, ARAB J CHEM, V12, P3576, DOI 10.1016/j.arabjc.2015.11.002
   Tang Q, 2013, ULTRASON SONOCHEM, V20, P1168, DOI 10.1016/j.ultsonch.2013.02.002
   VISHWANATHAN V, 1990, J CHEM SOC CHEM COMM, P78, DOI 10.1039/c39900000078
   Xie D, 2015, CHINESE J CATAL, V36, P1205, DOI 10.1016/S1872-2067(15)60897-X
   Zaid H.F.M., 2015, APPL MECH MAT, V699, P210
   Zhu WS, 2014, KOREAN J CHEM ENG, V31, P211, DOI 10.1007/s11814-013-0224-3
NR 38
TC 4
Z9 4
U1 10
U2 59
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 332
EP 341
DI 10.1016/j.ces.2018.12.063
PG 10
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700027
DA 2020-05-12
ER

PT J
AU Ding, ZJ
   Liu, Z
   Liu, R
   Yang, C
AF Ding, Zijing
   Liu, Zhou
   Liu, Rong
   Yang, Chun
TI Breakup of ultra-thin liquid films on vertical fiber enhanced by
   Marangoni effect
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE van der Waals attractions; Marangoni effect; Thin films
ID DROP FORMATION; VISCOUS BEADS; FLOWS; INSTABILITIES; ABSOLUTE; DYNAMICS
AB An ultra-thin liquid film flowing down a vertical uniformly heated cylinder under the influence of gravity is investigated. A thin liquid film model is derived, assuming that the film thickness h is much smaller than the fiber radius a. To predict the breakup of film, the van der Waals attraction, proportional to h(-3), is taken into account. Linear stability analysis shows that the Rayleigh-Plateau instability is enhanced by the long-range attractions and Marangoni effect. The spatial-temporal stability analysis shows that the instability is absolute when A + M > 0.17 (A is a composite Hamaker number accounting for the strength of van der Waals attractions and M is the Marangoni number). A self-similarity analysis shows that the film thins as h similar to(t(r) - t)(1/5) (t(r) is the breakup time), which is supported by the numerical simulations of the thin film model. Although the scaling is independent on the Marangoni effect, nonlinear simulations demonstrate that the breakup time t(r) decreases as the Marangoni effect becomes stronger, demonstrating that the breakup process is accelerated by the Marangoni effect. Nonlinear simulation also shows that the thin heated or non-heated film mainly breaks up in the absolutely unstable regime. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ding, Zijing] Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge, England.
   [Liu, Zhou] Shenzhen Univ, Coll Chem & Environm Engn, Shenzhen, Peoples R China.
   [Liu, Rong] Guilin Univ Elect Technol, Sch Mech & Elect Engn, Guilin, Peoples R China.
   [Yang, Chun] Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore, Singapore.
RP Liu, Z (reprint author), Shenzhen Univ, Coll Chem & Environm Engn, Shenzhen, Peoples R China.
EM z.ding@damtp.cam.ac.uk; zhouliu@szu.edu.cn; rongliu@guet.edu.cn;
   mcyang@ntu.edu.sg
RI Ding, Zijing/F-3773-2019
OI Ding, Zijing/0000-0001-6756-0182
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21706161]
FX The authors appreciate the three anonymous referees for their many
   helpful comments. Z.L acknowledges support from the National Natural
   Science Foundation of China (21706161).
CR Burelbach J., 1988, J FLUID MECH, V380, P233
   Chang HC, 1999, J FLUID MECH, V380, P233, DOI 10.1017/S0022112098003632
   Chao YC, 2018, CHEM ENG SCI, V175, P354, DOI 10.1016/j.ces.2017.10.013
   Chen JL, 1996, J COLLOID INTERF SCI, V182, P564, DOI 10.1006/jcis.1996.0501
   Craster RV, 2006, J FLUID MECH, V553, P85, DOI 10.1017/S0022112006008706
   Davalos-Orozco LA, 2000, PHYS FLUIDS, V12, P2198, DOI 10.1063/1.1286594
   Ding Z., 2017, PHYS FLUIDS, V29, P1
   Ding ZJ, 2018, CHEM ENG SCI, V177, P261, DOI 10.1016/j.ces.2017.11.039
   Duprat C, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.234501
   FRENKEL AL, 1992, EUROPHYS LETT, V18, P583, DOI 10.1209/0295-5075/18/7/003
   HUERRE P, 1990, ANNU REV FLUID MECH, V22, P473, DOI 10.1146/annurev.fl.22.010190.002353
   JOHNSON RE, 1987, J FLUID MECH, V184, P245, DOI 10.1017/S0022112087002878
   KALLIADASIS S, 1994, J FLUID MECH, V261, P135, DOI 10.1017/S0022112094000297
   Kliakhandler IL, 2001, J FLUID MECH, V429, P381, DOI 10.1017/S0022112000003268
   Lister JR, 2006, J FLUID MECH, V552, P311, DOI 10.1017/S0022112006008822
   Liu R, 2017, INT J HEAT MASS TRAN, V112, P918, DOI 10.1016/j.ijheatmasstransfer.2017.05.030
   Liu R, 2014, PHYS REV E, V90, DOI 10.1103/PhysRevE.90.033005
   Mayo LC, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.053018
   Novbari E, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3154586
   RUCKENSTEIN E, 1974, J CHEM SOC FARAD T 2, V70, P132, DOI 10.1039/f29747000132
   Ruyer-Quil C, 2008, J FLUID MECH, V603, P431, DOI 10.1017/S0022112008001225
   Ruyer-Quil C, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.046302
   Sheludko A., 1967, ADV COLLOID INTERFAC, V1, P391, DOI [DOI 10.1016/0001-8686(67)85001-2, 10.1016/0001-8686(67)85001-2.]
   Shkadov VY, 2008, MOSC UNIV MECH BULL, V63, P122, DOI 10.3103/S0027133008050038
   Sisoev GM, 2006, CHEM ENG SCI, V61, P7279, DOI 10.1016/j.ces.2006.08.033
   Sweetland M, 2000, INT J HEAT MASS TRAN, V43, P777, DOI 10.1016/S0017-9310(99)00180-5
   WILLIAMS MB, 1982, J COLLOID INTERF SCI, V90, P220, DOI 10.1016/0021-9797(82)90415-5
NR 27
TC 6
Z9 6
U1 4
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 342
EP 348
DI 10.1016/j.ces.2018.12.058
PG 7
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700028
DA 2020-05-12
ER

PT J
AU Lu, XW
   Yang, JN
   Li, XY
   Sun, FY
   Wang, F
   Chao, YQ
AF Lu, Xingwen
   Yang, Jiani
   Li, Xiaoyan
   Sun, Feiyun
   Wang, Fei
   Chao, Yuanqing
TI Effects of phase transformation on properties of alumina ceramic
   membrane: A new assessment based on quantitative X-ray diffraction
   (QXRD)
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ceramic membrane; Alumina; Physical properties; Membrane flux
ID THERMAL-DECOMPOSITION; CRYSTAL-STRUCTURE; MICROFILTRATION; BOEHMITE;
   NANOPARTICLES; TEMPERATURE; FABRICATION; POZZOLAN; SUPPORTS; BAYERITE
AB Alumina ceramic membranes were synthesized by pressing boehmite into disc form and sintering at different temperatures. Quantitative X-ray diffraction (QXRD) analysis was firstly used for determining the compositions of different types of alumina in membrane products. The result quantitative determined that alumina membranes experienced a series of phase transition from boehmite gamma-alumina -> delta-alumina -> theta-alumina -> alpha-alumina from 450 to 1300 degrees C. Below 850 degrees C, no significant alumina transformation (i.e. gamma-alumina was the dominate phase) was detected in fabricated membranes, which corresponded to stable membrane properties (i.e. porosity, BET surface area, pore size and chemical stability). At 950-1300 degrees C, substantial phase transformation was detected as follows, theta-alumina significantly increased from 1.21 to 61.6% (950-1125 degrees C), and alpha-alumina increased gradually from 3.98 to 100% (1100-1300 degrees C). Accordingly, the substantial phase transformation lead to the significant change in membrane properties at 950-1300 degrees C. Lower temperature (1150 degrees C) membrane containing 8.2% theta-alumina and 91.8% alpha-alumina showed comparable properties with 1300 degrees C consist of 100% alpha-alumina sintered products due to the similar alumina composition in the products. The overall results indicated that the properties of membrane were accordingly determined by the structure and content of alumina phases in membrane products. This strategy proposed a valuable method for production of lower temperature alumina-based ceramic membrane. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lu, Xingwen; Yang, Jiani] Guangdong Univ Technol, Sch Environm Sci & Engn, Guangzhou 510006, Guangdong, Peoples R China.
   [Lu, Xingwen; Yang, Jiani] Guangdong Univ Technol, Inst Environm Hlth & Pollut Control, Guangzhou 510006, Guangdong, Peoples R China.
   [Lu, Xingwen; Li, Xiaoyan; Wang, Fei] Univ Hong Kong, Dept Civil Engn, Pokfulam Rd, Hong Kong, Peoples R China.
   [Sun, Feiyun] Harbin Inst Technol, Shenzhen Grad Sch, Shenzhen Key Lab Water Resource Utilizat & Enviro, Shenzhen 518055, Peoples R China.
   [Wang, Fei] Jinan Univ, Guangzhou Key Lab Environm Exposure & Hlth, Sch Environm, Guangzhou 510632, Guangdong, Peoples R China.
   [Wang, Fei] Jinan Univ, Guangdong Key Lab Environm Pollut & Hlth, Guangzhou 510632, Guangdong, Peoples R China.
   [Lu, Xingwen; Chao, Yuanqing] Sun Yat Sen Univ, Guangdong Prov Key Lab Environm Pollut Control &, Guangzhou 510275, Guangdong, Peoples R China.
   [Chao, Yuanqing] Sun Yat Sen Univ, Sch Environm Sci & Engn, Guangzhou 510275, Guangdong, Peoples R China.
RP Wang, F (reprint author), Univ Hong Kong, Dept Civil Engn, Pokfulam Rd, Hong Kong, Peoples R China.; Wang, F (reprint author), Jinan Univ, Guangzhou Key Lab Environm Exposure & Hlth, Sch Environm, Guangzhou 510632, Guangdong, Peoples R China.; Wang, F (reprint author), Jinan Univ, Guangdong Key Lab Environm Pollut & Hlth, Guangzhou 510632, Guangdong, Peoples R China.
EM feiwang1984@gmail.com
RI Li, Xiao-yan/C-1808-2009
FU Science and Technology Program of Guangzhou, China [201804010103];
   Special Fund for Soil Pollution and Control of Shaoguan, China
   [2017sgtyfz302]; Research Fund Program of Guangdong Provincial Key
   Laboratory of Environmental Pollution Control and Remediation Technology
   [2018K18]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
FX This research was supported by Science and Technology Program of
   Guangzhou, China (201804010103), Special Fund for Soil Pollution and
   Control of Shaoguan, China (2017sgtyfz302), the Research Fund Program of
   Guangdong Provincial Key Laboratory of Environmental Pollution Control
   and Remediation Technology (2018K18), and the Fundamental Research Funds
   for the Central Universities.
CR Abdullah N, 2018, J MEMB SCI
   Achiou B, 2018, J ENVIRON CHEM ENG, V6, P4429, DOI 10.1016/j.jece.2018.06.049
   Achiou B, 2017, DESALINATION, V419, P181, DOI 10.1016/j.desal.2017.06.014
   Antsiferov VN, 2001, REFRACT IND CERAM+, V42, P57, DOI 10.1023/A:1011301320402
   Bahaabad M. S, 2014, J ADV MAT PROCESS, V2, P15
   Barma S, 2014, CERAM INT, V40, P11299, DOI 10.1016/j.ceramint.2014.03.134
   Boudaira B, 2016, DESALIN WATER TREAT, V57, P5258, DOI 10.1080/19443994.2015.1021998
   Boumaza A, 2009, J SOLID STATE CHEM, V182, P1171, DOI 10.1016/j.jssc.2009.02.006
   Busca G, 2014, ADV CATAL, V57, P319, DOI 10.1016/B978-0-12-800127-1.00003-5
   Cai SH, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.224104
   Chagas LH, 2014, MATER RES BULL, V49, P216, DOI 10.1016/j.materresbull.2013.08.072
   Chang YF, 2017, CERAM INT, V43, P12684, DOI 10.1016/j.ceramint.2017.06.150
   Chen RY, 2017, J ALLOY COMPD, V699, P170, DOI 10.1016/j.jallcom.2016.12.390
   Cowan MG, 2016, ACCOUNTS CHEM RES, V49, P724, DOI 10.1021/acs.accounts.5b00547
   De La Torre AG, 2001, J APPL CRYSTALLOGR, V34, P196, DOI 10.1107/S0021889801002485
   Del Colle R, 2011, CERAM INT, V37, P1161, DOI 10.1016/j.ceramint.2010.11.039
   Dong ZJ, 2017, CERAM INT, V43, P11006, DOI 10.1016/j.ceramint.2017.05.142
   Du XL, 2009, MATER RES BULL, V44, P660, DOI 10.1016/j.materresbull.2008.06.031
   Fu LP, 2015, J AM CERAM SOC, V98, P1658, DOI 10.1111/jace.13487
   George J, 2005, INT J BIOL MACROMOL, V37, P189, DOI 10.1016/j.ijbiomac.2005.10.007
   Ha JH, 2018, ADV APPL CERAM, V117, P1, DOI 10.1080/17436753.2017.1369658
   Hao ZJ, 2018, CERAM INT, V44, P7963, DOI 10.1016/j.ceramint.2018.01.235
   Hashimoto H, 2018, J EUR CERAM SOC, V38, P1836, DOI 10.1016/j.jeurceramsoc.2017.11.032
   Hemmer E, 2012, MICROPOR MESOPOR MAT, V163, P229, DOI 10.1016/j.micromeso.2012.06.057
   Hossain FM, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.235101
   Huang SC, 1999, J POROUS MAT, V6, P153, DOI 10.1023/A:1009687523387
   Hubadillah SK, 2018, CERAM INT, V44, P4538, DOI 10.1016/j.ceramint.2017.12.215
   Isobe T, 2006, J EUR CERAM SOC, V26, P2213, DOI 10.1016/j.jeurceramsoc.2005.04.014
   Issaoui M, 2018, COMPTES RENDUS CHIMI
   Iwase K, 2011, INORG CHEM, V50, P4548, DOI 10.1021/ic200253w
   Iyengar SS, 2001, POWDER DIFFR, V16, P20, DOI 10.1154/1.1332076
   Jedidi I, 2009, J HAZARD MATER, V172, P152, DOI 10.1016/j.jhazmat.2009.06.151
   Jedidi I, 2009, CERAM INT, V35, P2747, DOI 10.1016/j.ceramint.2009.03.021
   Kim J, 2010, ENVIRON POLLUT, V158, P2335, DOI 10.1016/j.envpol.2010.03.024
   Kujawa J, 2014, ACS APPL MATER INTER, V6, P14223, DOI 10.1021/am5035297
   Kukukova A, 2009, CHEM ENG RES DES, V87, P633, DOI 10.1016/j.cherd.2009.01.001
   Lee A, 2016, ENVIRON SCI-WAT RES, V2, P17, DOI [10.1039/c5ew00159e, 10.1039/C5EW00159E]
   Lee SK, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.095501
   Lee WE, 2001, J EUR CERAM SOC, V21, P2583, DOI 10.1016/S0955-2219(01)00274-6
   Lee W, 2014, CHEM REV, V114, P7487, DOI 10.1021/cr500002z
   Lee YP, 1999, PHYS CHEM CHEM PHYS, V1, P4681, DOI 10.1039/a905178c
   Levin I, 1998, J AM CERAM SOC, V81, P1995
   Lima MMRA, 2012, J ALLOY COMPD, V538, P66, DOI 10.1016/j.jallcom.2012.05.024
   Magallanes-Perdomo M, 2009, KEY ENG MATER, V396-398, P127, DOI 10.4028/www.scientific.net/KEM.396-398.127
   MCHARDY WJ, 1971, MINERAL MAG, V38, P358, DOI 10.1180/minmag.1971.038.295.11
   Mouiya M, 2018, DESALINATION, V427, P42, DOI 10.1016/j.desal.2017.11.005
   Nel R. J. J., 2009, IND ENG CHEM RES, V48, P5230, DOI DOI 10.1021/IE801930R
   Nishihora RK, 2018, J EUR CERAM SOC, V38, P988, DOI 10.1016/j.jeurceramsoc.2017.11.047
   Padaki M, 2015, DESALINATION, V357, P197, DOI 10.1016/j.desal.2014.11.023
   Pardo P, 2018, CERAM INT, V44, P11486, DOI 10.1016/j.ceramint.2018.03.210
   Raman L. P, 2011, CHEM ENG PROGR, V211, P83
   Rendtorff NM, 2010, HYPERFINE INTERACT, V198, P211, DOI 10.1007/s10751-010-0177-4
   Sahu N, 2011, B MATER SCI, V34, P1495, DOI 10.1007/s12034-011-0349-0
   Shih K, 2007, J EUR CERAM SOC, V27, P91, DOI 10.1016/j.jeurceramsoc.2006.04.176
   Tantau U, 2014, RADIAT PHYS CHEM, V95, P73, DOI 10.1016/j.radphyschem.2013.01.040
   Tellez-Vazquez JO, 2016, MATER CHARACT, V112, P155, DOI 10.1016/j.matchar.2015.12.023
   Van Gestel T, 2003, J MEMBRANE SCI, V214, P21, DOI 10.1016/S0376-7388(02)00517-3
   Vega V, 2017, J IND ENG CHEM, V52, P66, DOI 10.1016/j.jiec.2017.03.025
   Wang YH, 2009, J ALLOY COMPD, V467, P405, DOI 10.1016/j.jallcom.2007.12.007
   Weber R, 2003, DESALINATION, V157, P113, DOI 10.1016/S0011-9164(03)00390-4
   Wei ZL, 2016, J ALLOY COMPD, V683, P474, DOI 10.1016/j.jallcom.2016.05.088
   Workneh S, 2008, J MEMBRANE SCI, V309, P189, DOI 10.1016/j.memsci.2007.10.033
   Xia CR, 2001, J AM CERAM SOC, V84, P1903
   Yang HM, 2010, APPL CLAY SCI, V47, P438, DOI 10.1016/j.clay.2009.12.021
   Zawrah MF, 2017, CERAM INT, V43, P17104, DOI 10.1016/j.ceramint.2017.09.127
   Zhang XX, 2008, J CRYST GROWTH, V310, P3674, DOI 10.1016/j.jcrysgro.2008.05.016
NR 66
TC 1
Z9 1
U1 3
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 349
EP 358
DI 10.1016/j.ces.2018.12.054
PG 10
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700029
DA 2020-05-12
ER

PT J
AU Huang, JK
   Lu, YJ
   Wang, H
AF Huang, Jikai
   Lu, Youjun
   Wang, Hao
TI Minimum bubbling fluidization velocity in a supercritical water
   fluidized bed acquired by the dual-capacitance probe method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Supercritical water fluidized bed; Minimum bubbling fluidization
   velocity; Dual-capacitance probe method
ID BIOMASS GASIFICATION; FINE POWDERS; PARTICLE FLUIDIZATION; VOLUME
   CONCENTRATION; HYDROGEN-PRODUCTION; CARBON-DIOXIDE; SOLIDS; PARTICULATE;
   DYNAMICS
AB Supercritical water fluidized bed (SCWFB) is a newly developed reactor for coal and biomass gasification without releasing pollutants. The knowledge of two-phase flow properties in SCWFB is still lacked so far in literatures due to the extreme operating condition of high-pressure and high-temperature supercritical water. In this paper, a special dual-capacitance probe measurement system is developed for the extreme flow environment in SCWFB. It is found that the linear relationship is more precise in converting the capacitance of the probe sensor into local volume fraction of solids in SCWFB than Bottcher relationship. With the help of the newly-developed dual-capacitance probe measurement system, an experimental study on the bubbling fluidization in a SCWFB is carried out when the system pressure is in the range of 20-27 MPa and the system temperature is in the range of 410-570 degrees C. Four groups of quartz sands with different mean diameters which belong to Geldart type B classification are fluidized. It is found that the bed expansion method which was used in literatures to identify the onset of bubbling fluidization in supercritical carbon dioxide fluidized bed doesn't have enough precision in a SCWFB. To solve this problem, a new method of identifying the onset of bubbling fluidization in SCWFB is proposed. The minimum bubbling Reynolds number increases with the Archimedes number in a logarithmic relationship in SCWFB. At last, a new predicting correlation of the minimum bubbling fluidization velocity in SCWFB is proposed: Re-mb = 26.7091n(Ar + 10253.88) - 247.339, 1900 < Ar < 180000
   The relative error of the new predicting correlation is within +/- 20% and the averaged relative error is 7.5%. The research work in this paper provides useful guidance for the optimization and operation of SCWFB reactor. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Huang, Jikai; Lu, Youjun; Wang, Hao] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
   [Huang, Jikai] Qilu Univ Technol, Shandong Acad Sci, Energy Res Inst, Jinan 250014, Shandong, Peoples R China.
RP Lu, YJ (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
EM yjlu@mail.xjtu.edu.cn
RI Lu, Youjun/O-4256-2014
FU Nation Key Research and Development Program of China [2016YFB0600102];
   National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [91634109, 51676158]
FX This work was financially supported by the Nation Key Research and
   Development Program of China (2016YFB0600102) and National Nature
   Science Foundation of China through contract No. 91634109 and No.
   51676158.
CR ABRAHAMSEN AR, 1980, POWDER TECHNOL, V26, P35, DOI 10.1016/0032-5910(80)85005-4
   Cao JT, 2008, POWDER TECHNOL, V183, P127, DOI 10.1016/j.powtec.2007.11.033
   GELDART D, 1978, POWDER TECHNOL, V19, P133, DOI 10.1016/0032-5910(78)80084-9
   Guo LJ, 2013, INT J HYDROGEN ENERG, V38, P12953, DOI 10.1016/j.ijhydene.2013.04.089
   Hage B, 1996, J CHEM ENG JPN, V29, P594, DOI 10.1252/jcej.29.594
   Hage B, 1997, POWDER TECHNOL, V93, P235, DOI 10.1016/S0032-5910(97)03276-2
   Hulme I, 2005, IND ENG CHEM RES, V44, P4254, DOI 10.1021/ie049837j
   Jin H, 2010, INT J HYDROGEN ENERG, V35, P7151, DOI 10.1016/j.ijhydene.2010.01.099
   Koda S, 2006, J SUPERCRIT FLUID, V38, P427, DOI 10.1016/j.supflu.2005.11.018
   Liu DJ, 1996, CHEM ENG SCI, V51, P4045, DOI 10.1016/0009-2509(96)00247-3
   Lu YJ, 2008, INT J HYDROGEN ENERG, V33, P6066, DOI 10.1016/j.ijhydene.2008.07.082
   Lu YJ, 2015, INT J MULTIPHAS FLOW, V73, P130, DOI 10.1016/j.ijmultiphaseflow.2015.03.011
   Lu YJ, 2014, CHEM ENG SCI, V117, P283, DOI 10.1016/j.ces.2014.06.032
   Lu YJ, 2013, INT J MULTIPHAS FLOW, V49, P78, DOI 10.1016/j.ijmultiphaseflow.2012.10.005
   Martin V, 2017, POWDER TECHNOL, V318, P242, DOI 10.1016/j.powtec.2017.06.009
   Marzocchella A, 2000, AICHE J, V46, P901, DOI 10.1002/aic.690460505
   Matsumura Y, 2005, BIOMASS BIOENERG, V29, P269, DOI 10.1016/j.biombioe.2005.04.006
   Matsumura Y, 2004, INT J HYDROGEN ENERG, V29, P701, DOI 10.1016/j.ijhydene.2003.09.005
   Niu FH, 2007, IND ENG CHEM RES, V46, P3153, DOI 10.1021/ie0606789
   Olaofe OO, 2011, CHEM ENG SCI, V66, P2764, DOI 10.1016/j.ces.2011.03.030
   Patil DJ, 2005, CHEM ENG SCI, V60, P57, DOI 10.1016/j.ces.2004.07.059
   Potic B, 2005, CHEM ENG SCI, V60, P5982, DOI 10.1016/j.ces.2005.04.047
   Richardson J., 1954, T I CHEM ENG-LOND, V32, P38
   SIMONE S, 1980, POWDER TECHNOL, V26, P161, DOI 10.1016/0032-5910(80)85059-5
   Tanneur V, 2008, POWDER TECHNOL, V187, P190, DOI 10.1016/j.powtec.2008.02.011
   Vogt C, 2005, POWDER TECHNOL, V158, P102, DOI 10.1016/j.powtec.2005.04.022
   VonHippel A. R., 1954, DIELECTRIC MAT APPL
   Wei LP, 2016, POWDER TECHNOL, V304, P89, DOI 10.1016/j.powtec.2016.08.025
   Wei LP, 2016, CHEM ENG RES DES, V109, P657, DOI 10.1016/j.cherd.2016.03.012
   Wei LP, 2013, INT J HYDROGEN ENERG, V38, P13117, DOI 10.1016/j.ijhydene.2013.01.148
   Wiesendorf V, 2000, POWDER TECHNOL, V110, P143, DOI 10.1016/S0032-5910(99)00276-4
NR 31
TC 2
Z9 2
U1 7
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 359
EP 370
DI 10.1016/j.ces.2018.12.056
PG 12
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700030
DA 2020-05-12
ER

PT J
AU Gkinis, PA
   Koronaki, ED
   Skouteris, A
   Aviziotis, IG
   Boudouvis, AG
AF Gkinis, P. A.
   Koronaki, E. D.
   Skouteris, A.
   Aviziotis, I. G.
   Boudouvis, A. G.
TI Building a data-driven reduced order model of a chemical vapor
   deposition process from low-fidelity CFD simulations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reduced order model; CVD; POD; Artificial neural networks; Data-driven
   models; Deposition model
ID CVD REACTOR; FLOW; AL; STABILITY; DYNAMICS; ALUMINUM; GEOMETRY
AB A computational methodology is introduced for the development of a Reduced Order Model (ROM) using data from low-fidelity, in terms of the spatial discretization, Computational Fluid Dynamics (CFD) simulations. The methodology is applied in the context of investigating efficiently, new chemistry pathways in Chemical Vapor Deposition (CVD) processes by comparing experimental findings with simulation results. The proposed approach involves building a very coarse, yet three-dimensional CFD model of the process that does not include chemical reactions, which provides "snapshots", i.e. time instances, of the dynamic behavior of the system. This bundle of low-fidelity data is used for generating a reduced order model by implementing Proper Orthogonal Decomposition (POD), for the time-invariant subspace approximation of the data and Artificial Neural Networks (ANN) for the time-dependent coefficients. This last step circumvents the need for Galerkin projection of the equations on the subspace, rendering therefore the approach equation-free and purely data-driven. The ultimate goal addressed in this work is to produce fast approximations of the temperature, pressure and flow field in a CVD reactor, which will then be used as starting points of high-fidelity, in terms of the computational mesh, CFD simulations, that include multiple surface and gas phase reactions. Given the quality of approximations, the model corrects for the species distributions after only a few time-steps, providing thus quick and accurate deposition-rate and uniformity results. This allows for efficient and easy fine-tuning adjustments of the chemistry model diminishing the need to solve the high-fidelity model many times. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gkinis, P. A.; Koronaki, E. D.; Skouteris, A.; Aviziotis, I. G.; Boudouvis, A. G.] Natl Tech Univ Athens, Sch Chem Engn, Zographos Campus, Athens 15780, Greece.
   [Aviziotis, I. G.] Tech Univ Chemnitz, Mat Innovat Energy Concepts, Inst Chem, Fac Nat Sci, D-09107 Chemnitz, Germany.
RP Koronaki, ED (reprint author), Natl Tech Univ Athens, Sch Chem Engn, Zographos Campus, Athens 15780, Greece.
EM ekor@mail.ntua.gr
RI Boudouvis, Andreas/B-2307-2010
OI Boudouvis, Andreas/0000-0001-6651-7318
CR Aviziotis IG, 2016, CHEM ENG SCI, V155, P449, DOI 10.1016/j.ces.2016.08.039
   Aviziotis IG, 2015, PHYS STATUS SOLIDI C, V12, P923, DOI 10.1002/pssc.201510023
   Aviziotis IG, 2013, SURF COAT TECH, V230, P273, DOI 10.1016/j.surfcoat.2013.06.014
   BERKOOZ G, 1993, ANNU REV FLUID MECH, V25, P539, DOI 10.1146/annurev.fl.25.010193.002543
   Bright I, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4836815
   Chaudhuri S, 2008, J AM CHEM SOC, V130, P10576, DOI 10.1021/ja800136k
   Cheimarios N, 2012, CHEM ENG J, V181, P516, DOI 10.1016/j.cej.2011.11.008
   Cheimarios N, 2011, COMPUT CHEM ENG, V35, P2632, DOI 10.1016/j.compchemeng.2011.03.008
   DEANE AE, 1991, PHYS FLUIDS A-FLUID, V3, P2337, DOI 10.1063/1.857881
   FOTIADIS DI, 1990, J CRYST GROWTH, V102, P441, DOI 10.1016/0022-0248(90)90403-8
   Gkinis PA, 2017, J CRYST GROWTH, V458, P140, DOI 10.1016/j.jcrysgro.2016.10.065
   Hinze M., 2005, DIMENSION REDUCTION, P261, DOI DOI 10.1007/3-540-27909-1_10
   JENSEN KF, 1991, ANNU REV FLUID MECH, V23, P197, DOI 10.1146/annurev.fl.23.010191.001213
   Kawamura H., 2003, PHYS REV, V67, P1
   Kiran B, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4754506
   Koronaki ED, 2016, CHEM ENG SCI, V150, P26, DOI 10.1016/j.ces.2016.04.043
   Koronaki ED, 2014, ECS SOLID STATE LETT, V3, pP37, DOI 10.1149/2.002404ssl
   Lu X, 2018, CHEM ENG SCI, V189, P123, DOI 10.1016/j.ces.2018.04.074
   Mitrovic B, 2007, J CRYST GROWTH, V303, P323, DOI 10.1016/j.jcrysgro.2006.11.247
   Nakajima T, 2003, MOL PHYS, V101, P267, DOI 10.1080/00268970210162817
   Pawlowski RP, 2001, J PHYS IV, V11, P197, DOI 10.1051/jp4:2001325
   Psarellis GM, 2018, CHEM ENG SCI, V177, P464, DOI 10.1016/j.ces.2017.12.006
   SIROVICH L, 1987, Q APPL MATH, V45, P561, DOI 10.1090/qam/910462
   Suryawanshi PL, 2018, CHEM ENG SCI, V189, P431, DOI 10.1016/j.ces.2018.03.026
   Theodoropoulos C, 1997, J CRYST GROWTH, V170, P72, DOI 10.1016/S0022-0248(96)00637-9
   Theodoropoulos C, 2000, J CRYST GROWTH, V217, P65, DOI 10.1016/S0022-0248(00)00402-4
   van Santen H, 2001, INT J HEAT MASS TRAN, V44, P659, DOI 10.1016/S0017-9310(00)00121-6
   Xenidou TC, 2007, SURF COAT TECH, V201, P8868, DOI 10.1016/j.surfcoat.2007.04.080
   Xie H., 2009, P 8 INT C MACH LEARN
   Xie WG, 2015, J PROCESS CONTR, V35, P50, DOI 10.1016/j.jprocont.2015.07.009
   Xie WG, 2012, COMPUT-AIDED CHEM EN, V30, P1212
   Yun JH, 1998, J VAC SCI TECHNOL A, V16, P419, DOI 10.1116/1.581040
   Zhang JY, 2018, CHEM ENG SCI, V189, P212, DOI 10.1016/j.ces.2018.05.056
NR 33
TC 0
Z9 0
U1 7
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 371
EP 380
DI 10.1016/j.ces.2019.01.009
PG 10
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700031
DA 2020-05-12
ER

PT J
AU Tarumi, M
   Matsuzaki, Y
   Suzuki, K
AF Tarumi, Moto
   Matsuzaki, Yoichi
   Suzuki, Kimihito
TI Theoretical study on the redox reaction mechanism of quinone compounds
   in industrial processes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Density functional calculations; Naphthoquinone; Proton-coupled electron
   transfer (PCET); Redox chemistry; Takahax process
ID COUPLED ELECTRON-TRANSFER; REDUCTION POTENTIALS; DENSITY;
   PHENOXYL/PHENOL; BENZYL/TOLUENE; DERIVATIVES; ABSORPTION; KINETICS;
   ENERGY; MODEL
AB Density functional theory calculations have been performed to understand the reaction mechanisms of the industrial desulfurization process, also called the Takahax process, which is used in Japanese steelworks to remove hydrogen sulfide (H2S) from coke oven gas. In this process, H2S is oxidized by 1,4-naphthoquinone-2-sulfonic acid (NQS), which is itself reduced to 1,4-dihydroxynaphthalene-2-sulfonic acid (NQSH(2)). NQS can be regarded as a catalyst. On the basis of our calculations, we have revealed that the rate-determining steps in the catalytic reactions can be characterized as proton-coupled electron transfer (PCET) that is governed by the frontier molecular orbitals of catalysts. Furthermore, energetic considerations show that the sequential electron and proton transfer mechanism may comparably contribute to the concerted mechanism depending on the magnitude of the electrostatic interaction between the electron donor and acceptor that stabilizes the TS of the concerted PCET. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tarumi, Moto; Matsuzaki, Yoichi; Suzuki, Kimihito] Nippon Steel & Sumitomo Met Corp, Adv Technol Res Labs, 20-1 Shintomi, Futtsu, Chiba 2938511, Japan.
RP Tarumi, M (reprint author), Nippon Steel & Sumitomo Met Corp, Adv Technol Res Labs, 20-1 Shintomi, Futtsu, Chiba 2938511, Japan.
EM tarumi.7h8.moto@jp.nssmc.com
OI Tarumi, Moto/0000-0002-5205-1454
CR Bachman JE, 2014, J PHYS CHEM A, V118, P8852, DOI 10.1021/jp5060777
   BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311
   Cramer CJ, 1999, CHEM REV, V99, P2161, DOI 10.1021/cr960149m
   Frisch MJ, 2009, GAUSSIAN 09 REVISION
   Hamamura K, 1977, P S TREATM COK OV GA, V10, P1
   Huynh MT, 2016, J AM CHEM SOC, V138, P15903, DOI 10.1021/jacs.6b05797
   Inami H, 1967, AROMATICS, V19, P53
   Kelly CP, 2006, J PHYS CHEM A, V110, P2493, DOI 10.1021/jp055336f
   Kohl A.L, 1979, GAS PURIFICATION
   KURRECK H, 1995, ANGEW CHEM INT EDIT, V34, P849, DOI 10.1002/anie.199508491
   Maezawa M, 1958, JP Patent, Patent No. [33-007084B, 33007084]
   MARCUS RA, 1952, J CHEM PHYS, V20, P359, DOI 10.1063/1.1700424
   Marenich AV, 2009, J PHYS CHEM B, V113, P6378, DOI 10.1021/jp810292n
   Matsuzaki Y, 2013, J PHYS CHEM A, V117, P9274, DOI 10.1021/jp406636a
   Mayer JM, 2002, J AM CHEM SOC, V124, P11142, DOI 10.1021/ja012732c
   Mayer JM, 2004, ANNU REV PHYS CHEM, V55, P363, DOI 10.1146/annurev.physchem.55.091602.094446
   Namazian M, 2007, J PHYS CHEM A, V111, P7227, DOI 10.1021/jp0725883
   Onoda M, 2016, J SUSTAIN METALL, V2, P209, DOI 10.1007/s40831-016-0067-3
   Petr J, 2004, CHEM ENG PROCESS, V43, P887, DOI 10.1016/S0255-2701(03)00111-9
   Pliego JR, 2001, J PHYS CHEM A, V105, P7241, DOI 10.1021/jp004192w
   Roginsky VA, 1999, J CHEM SOC PERK T 2, P871, DOI 10.1039/a807650b
   Santacesaria E, 1999, CHEM ENG SCI, V54, P2799, DOI 10.1016/S0009-2509(98)00377-7
   Skone JH, 2006, J AM CHEM SOC, V128, P16655, DOI 10.1021/ja0656548
   Song YZ, 2006, SPECTROCHIM ACTA A, V65, P333, DOI 10.1016/j.saa.2005.11.003
   Sowa F, 2011, AISTECH C P, V2011, P179
   Takashima R, 1964, JP Patent, Patent No. [39-001015B, 39001015]
   TAKEUCHI H, 1980, CHEM ENG COMMUN, V4, P181, DOI 10.1080/00986448008935902
   Uchimiya M, 2006, ENVIRON SCI TECHNOL, V40, P3515, DOI 10.1021/es052578k
   WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6
   WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843
   Yamada H, 2011, J PHYS CHEM A, V115, P3079, DOI 10.1021/jp109851k
   Yamada H, 2010, IND ENG CHEM RES, V49, P2449, DOI 10.1021/ie901185v
   Zwicky J. F, 1980, IRON STEEL ENG, V57, P37
NR 33
TC 0
Z9 0
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 381
EP 387
DI 10.1016/j.ces.2019.01.006
PG 7
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700032
DA 2020-05-12
ER

PT J
AU Siegler, TD
   Shimpi, TM
   Sampath, WS
   Korgel, BA
AF Siegler, Timothy D.
   Shimpi, Tushar M.
   Sampath, Walajabad S.
   Korgel, Brian A.
TI Development of wide bandgap perovskites for next-generation low-cost
   CdTe tandem solar cells
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Perovskites; Cadmium telluride; Tandem solar cell; Optical haze;
   Photovoltaics
ID POWER CONVERSION EFFICIENCY; LEAD IODIDE PEROVSKITE; LOW-TEMPERATURE;
   SILICON; CH3NH3PBBR3; MODULES; LAYER; BACK; CRYSTALLIZATION; DEGRADATION
AB To continue towards long-term reduction in the price of energy generated by photovoltaic (PV) solar cells, technological innovations are needed to achieve significant increases in device efficiency without increasing manufacturing costs. One approach is to utilize the existing capability to manufacture thin film CdTe PVs at very low cost and add another inexpensive thin film absorber to create a tandem solar cell to improve device efficiency. For this, a semiconductor with an optimal bandgap must be identified, along with a suitable device architecture. The wide bandgap perovskite methylammonium lead bromide (CH3NH3PbBr3, MAPBr) has a well-matched band gap of 2.3 eV for a CdTe tandem device. It can be processed at relatively low temperature, and is also suitable for CIGS and all-perovskite tandems. We fabricated MAPBr PVs and found that optical scattering, or haze, was significant in these perovskite layers. This limits the transmitted light reaching the bottom cell. The performance of a four-terminal (4T) perovskite-CdTe tandem cell was modeled using the 1D Solar Cell Capacitance Simulator (SCAPS) software package to determine how much haze could be tolerated and still achieve an efficiency boost compared to the CdTe cell. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Siegler, Timothy D.; Korgel, Brian A.] Univ Texas Austin, McKetta Dept Chem Engn, Austin, DC 78712 USA.
   [Siegler, Timothy D.; Korgel, Brian A.] Univ Texas Austin, Texas Mat Inst, Austin, DC 78712 USA.
   [Shimpi, Tushar M.; Sampath, Walajabad S.] Colorado State Univ, Dept Mech Engn, Next Generat PV Ctr, Ft Collins, CO 80523 USA.
RP Korgel, BA (reprint author), Univ Texas Austin, McKetta Dept Chem Engn, Austin, DC 78712 USA.; Korgel, BA (reprint author), Univ Texas Austin, Texas Mat Inst, Austin, DC 78712 USA.
EM tsiegler@utexas.edu; sampath@engr.colostate.edu; korgel@che.utexas.edu
OI Sampath, Walajabad/0000-0002-7855-640X; Shimpi,
   Tushar/0000-0001-5986-9462; Siegler, Timothy/0000-0001-6033-2232
FU Robert A. Welch FoundationThe Welch Foundation [F-1464]; NSF
   Industry/University Cooperative Research Center on Next Generation
   Photo-voltaics [IIP-1540028, IIP-1822206, IIP-1540007, IIP-1821526];
   United States Government under DoD, Air Force Office of Scientific
   Research, National Defense Science and Engineering Graduate (NDSEG)
   Fellowship [32 CFR 168a]
FX The authors acknowledge financial support of this work from the Robert
   A. Welch Foundation (F-1464) and the NSF Industry/University Cooperative
   Research Center on Next Generation Photo-voltaics (IIP-1540028,
   IIP-1822206, IIP-1540007, IIP-1821526). TDS acknowledges support by the
   United States Government under DoD, Air Force Office of Scientific
   Research, National Defense Science and Engineering Graduate (NDSEG)
   Fellowship, 32 CFR 168a. We would like to acknowledge Anna Webb for
   providing technical support for the DIC optical microscope.
CR Adhyaksa GWP, 2017, NANO LETT, V17, P5206, DOI 10.1021/acs.nanolett.7b01092
   Alberti A, 2017, J PHYS CHEM C, V121, P13577, DOI 10.1021/acs.jpcc.7b04196
   Albrecht S, 2016, J OPTICS-UK, V18, DOI 10.1088/2040-8978/18/6/064012
   Albrecht S, 2016, ENERG ENVIRON SCI, V9, P81, DOI 10.1039/c5ee02965a
   Alsema E. A., 2006, 21 EUR P
   ASTM International, 2015, STAND TEST METH REFL
   Ba LX, 2018, PROG PHOTOVOLTAICS, V26, P924, DOI 10.1002/pip.3037
   Bailie CD, 2015, ENERG ENVIRON SCI, V8, P956, DOI 10.1039/c4ee03322a
   Bercegol A, 2018, J PHYS CHEM C, V122, P23345, DOI 10.1021/acs.jpcc.8b07436
   Bett AJ, 2017, ENRGY PROCED, V124, P567, DOI 10.1016/j.egypro.2017.09.293
   Braunger S, 2018, J PHYS CHEM C, V122, P17123, DOI 10.1021/acs.jpcc.8b06459
   Brown GF, 2009, LASER PHOTONICS REV, V3, P394, DOI 10.1002/lpor.200810039
   Burgelman M, 2000, THIN SOLID FILMS, V361, P527, DOI 10.1016/S0040-6090(99)00825-1
   Bush KA, 2018, ACS ENERGY LETT, V3, P1225, DOI 10.1021/acsenergylett.8b00544
   Bush KA, 2017, NAT ENERGY, V2, DOI 10.1038/nenergy.2017.9
   Bush KA, 2016, ADV MATER, V28, P3937, DOI 10.1002/adma.201505279
   Chelvanathan P, 2010, CURR APPL PHYS, V10, pS387, DOI 10.1016/j.cap.2010.02.018
   Chen B, 2016, ADV ENERGY MATER, V6, DOI 10.1002/aenm.201601128
   Chen CC, 2015, MATER HORIZ, V2, P203, DOI 10.1039/c4mh00237g
   Chen WJ, 2018, ADV MATER, V30, DOI 10.1002/adma.201800855
   Christians JA, 2015, J AM CHEM SOC, V137, P1530, DOI 10.1021/ja511132a
   Compaan AD, 2004, SOL ENERGY, V77, P815, DOI 10.1016/j.solener.2004.06.013
   Cuming V., 2015, NEW ENERGY OUTLOOK 2
   Degans Hanne, 2017, IMEC REPORTS RECORD
   DEVOS A, 1980, J PHYS D APPL PHYS, V13, P839, DOI 10.1088/0022-3727/13/5/018
   Dimroth F, 2006, PHYS STATUS SOLIDI C, V3, P373, DOI 10.1002/pssc.200564172
   Domanski K, 2016, ACS NANO, V10, P6306, DOI 10.1021/acsnano.6b02613
   Duong T, 2016, IEEE J PHOTOVOLT, V6, P679, DOI 10.1109/JPHOTOV.2016.2521479
   Durose K, 1999, J CRYST GROWTH, V197, P733, DOI 10.1016/S0022-0248(98)00962-2
   Eperon GE, 2016, SCIENCE, V354, P861, DOI 10.1126/science.aaf9717
   Eperon GE, 2015, J MATER CHEM A, V3, P19688, DOI 10.1039/c5ta06398a
   Fan RD, 2017, SOL RRL, V1
   Forgacs D, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201602121
   Fu F, 2017, NAT ENERGY, V2, DOI 10.1038/nenergy.2016.190
   Fu F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9932
   Green MA, 2018, PROG PHOTOVOLTAICS, V26, P427, DOI 10.1002/pip.3040
   Green MA, 2014, NAT PHOTONICS, V8, P506, DOI [10.1038/NPHOTON.2014.134, 10.1038/nphoton.2014.134]
   Guchhait A, 2017, ACS ENERGY LETT, V2, P807, DOI 10.1021/acsenergylett.7b00187
   Han QF, 2018, SCIENCE, V361, P904, DOI 10.1126/science.aat5055
   Hao F, 2014, J AM CHEM SOC, V136, P8094, DOI 10.1021/ja5033259
   Hao F, 2014, NAT PHOTONICS, V8, P489, DOI 10.1038/nphoton.2014.82
   Heo JH, 2016, ADV MATER, V28, P5121, DOI 10.1002/adma.201501629
   Heo JH, 2014, ADV MATER, V26, P8179, DOI 10.1002/adma.201403140
   Hoffmann JB, 2017, CHEM MATER, V29, P9767, DOI 10.1021/acs.chemmater.7b03751
   Hoke ET, 2015, CHEM SCI, V6, P613, DOI 10.1039/c4sc03141e
   Holmberg VC, 2012, J PHYS CHEM C, V116, P22486, DOI 10.1021/jp308231W
   IEA, 2017, TRACK CLEAN EN PROGR
   Jacobsson TJ, 2016, ENERG ENVIRON SCI, V9, P1706, DOI 10.1039/c6ee00030d
   Jang YH, 2017, J MATER CHEM A, V5, P19439, DOI 10.1039/c7ta06163c
   Jaysankar M, 2018, ENERG ENVIRON SCI, V11, P1489, DOI 10.1039/c8ee00237a
   Jaysankar M, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201602807
   Jiang FY, 2016, J MATER CHEM A, V4, P1208, DOI 10.1039/c5ta08744a
   Jost M, 2016, ENRGY PROCED, V102, P43, DOI 10.1016/j.egypro.2016.11.316
   Kapil G, 2018, NANO LETT, V18, P3600, DOI 10.1021/acs.nanolett.8b00701
   Karani A, 2018, ACS ENERGY LETT, V3, P869, DOI 10.1021/acsenergylett.8b00207
   Kephart JM, 2016, SOL ENERG MAT SOL C, V157, P266, DOI 10.1016/j.solmat.2016.05.050
   Kephart JM, 2015, PROG PHOTOVOLTAICS, V23, P1484, DOI 10.1002/pip.2578
   Kim J, 2018, ADV MATER, V30, DOI 10.1002/adma.201803830
   Kim J, 2018, ADV MATER, V30, DOI 10.1002/adma.201706275
   Kinoshita T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9834
   Kranz L, 2015, J PHYS CHEM LETT, V6, P2676, DOI 10.1021/acs.jpclett.5b01108
   Kranz L, 2013, IEEE PHOT SPEC CONF, P1644, DOI 10.1109/PVSC.2013.6744460
   Kulbak M, 2016, J PHYS CHEM LETT, V7, P167, DOI 10.1021/acs.jpclett.5b02597
   Lal NN, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201602761
   Lazard Inc, 2018, LAZ LEV COST EN VERS
   Lee C., 2009, IEEE PHOT SPEC C PVS, P1118, DOI [10.1109/PVSC.2009.5411215, DOI 10.1109/PVSC.2009.5411215]
   Lee JW, 2014, ADV MATER, V26, P4991, DOI 10.1002/adma.201401137
   Leijtens T, 2018, SUSTAIN ENERG FUELS, V2, P2450, DOI 10.1039/c8se00314a
   Li Y, 2017, J MATER CHEM C, V5, P134, DOI 10.1039/c6tc04510c
   Liu MZ, 2013, NATURE, V501, P395, DOI 10.1038/nature12509
   Liu Y, 2016, ACS APPL MATER INTER, V8, P7070, DOI 10.1021/acsami.5b12740
   Loper P, 2015, PHYS CHEM CHEM PHYS, V17, P1619, DOI 10.1039/c4cp03788j
   Long MZ, 2018, ADV MATER, V30, DOI 10.1002/adma.201801562
   MACKINTOSH FC, 1989, PHYS REV B, V40, P9342, DOI 10.1103/PhysRevB.40.9342
   Mailoa JP, 2016, ENERG ENVIRON SCI, V9, P2644, DOI 10.1039/c6ee01778a
   Mailoa JP, 2015, APPL PHYS LETT, V106, DOI 10.1063/1.4914179
   Mayer J. N., 2015, CURRENT FUTURE COST
   McMeekin DP, 2016, SCIENCE, V351, P151, DOI 10.1126/science.aad5845
   Munshi A, 2016, J ELECTRON MATER, V45, P4612, DOI 10.1007/s11664-016-4484-7
   Munshi AH, 2018, IEEE J PHOTOVOLT, V8, P310, DOI 10.1109/JPHOTOV.2017.2775139
   Nelson J., 2003, PHYS SOLAR CELLS
   Noh JH, 2013, NANO LETT, V13, P1764, DOI 10.1021/nl400349b
   Paetzold UW, 2017, J MATER CHEM A, V5, P9897, DOI 10.1039/c7ta01651d
   Parrott ES, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201802803
   Peng J, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201601768
   Pisoni S, 2017, J MATER CHEM A, V5, P13639, DOI 10.1039/c7ta04225f
   Quiroz COR, 2018, J MATER CHEM A, V6, P3583, DOI 10.1039/c7ta10945h
   Rajagopal A, 2017, ADV MATER, V29, DOI 10.1002/adma.201702140
   Raugei M, 2007, ENERGY, V32, P1310, DOI 10.1016/j.energy.2006.10.003
   Rehman W, 2015, ADV MATER, V27, P7938, DOI 10.1002/adma.201502969
   Ruhle S, 2017, PHYS STATUS SOLIDI A, V214, DOI 10.1002/pssa.201600955
   Ruhle S, 2016, SOL ENERGY, V130, P139, DOI 10.1016/j.solener.2016.02.015
   Sahli F, 2018, NAT MATER, V17, P820, DOI 10.1038/s41563-018-0115-4
   Sahli F, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201701609
   Schneider BW, 2014, OPT EXPRESS, V22, pA1422, DOI 10.1364/OE.22.0A1422
   SEIA, 2017, SOL MARK INS REP 201
   Shah A, 1999, SCIENCE, V285, P692, DOI 10.1126/science.285.5428.692
   Shen HP, 2018, ENERG ENVIRON SCI, V11, P394, DOI 10.1039/c7ee02627g
   Sheng R, 2017, J PHYS CHEM C, V121, P27256, DOI 10.1021/acs.jpcc.7b05517
   Sheng R, 2015, J PHYS CHEM LETT, V6, P3931, DOI 10.1021/acs.jpclett.5b01608
   Shi D, 2015, SCI REP-UK, V5, DOI 10.1038/srep16504
   Sigman M. B, 2005, CHEM SOC, V127, P10089, DOI [10.1021/ja051956i, DOI 10.1021/JA051956I]
   Slavney AH, 2018, ANGEW CHEM INT EDIT, V57, P12765, DOI 10.1002/anie.201807421
   Sofia SE, 2018, NAT ENERGY, V3, P387, DOI 10.1038/s41560-018-0126-z
   Song ZN, 2017, ENERG ENVIRON SCI, V10, P1297, DOI 10.1039/c7ee00757d
   Song ZN, 2016, J PHYS CHEM LETT, V7, P5114, DOI 10.1021/acs.jpclett.6b02415
   Sutton RJ, 2016, ADV ENERGY MATER, V6, DOI 10.1002/aenm.201502458
   Swanson DE, 2018, J APPL PHYS, V123, DOI 10.1063/1.5023811
   Duong T, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201700228
   Todorov T. K., 2018, HALIDE PEROVSKITES P
   Todorov T, 2015, ADV ENERGY MATER, V5, DOI 10.1002/aenm.201500799
   Todorov T, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4899275
   Uhl AR, 2017, J MATER CHEM A, V5, P3214, DOI 10.1039/c7ta00562h
   Uzu H, 2015, APPL PHYS LETT, V106, DOI 10.1063/1.4905177
   Voggu VR, 2017, ACS ENERGY LETT, V2, P574, DOI 10.1021/acsenergylett.7b00001
   Wang YQ, 2018, J MATER CHEM A, V6, P13090, DOI 10.1039/c8ta03054e
   Werner J, 2018, ACS ENERGY LETT, V3, P2052, DOI 10.1021/acsenergylett.8b01165
   Werner J, 2018, ADV MATER INTERFACES, V5, DOI 10.1002/admi.201700731
   Werner J, 2016, APPL PHYS LETT, V109, DOI 10.1063/1.4971361
   Werner J, 2016, ACS ENERGY LETT, V1, P474, DOI 10.1021/acsenergylett.6b00254
   Werner J, 2016, J PHYS CHEM LETT, V7, P161, DOI 10.1021/acs.jpclett.5b02686
   Werner J, 2015, SOL ENERG MAT SOL C, V141, P407, DOI 10.1016/j.solmat.2015.06.024
   Wu YL, 2017, ENERG ENVIRON SCI, V10, P2472, DOI 10.1039/c7ee02288c
   Yang Y, 2015, ACS NANO, V9, P7714, DOI 10.1021/acsnano.5b03189
   Yang ZB, 2016, ADV MATER, V28, P8990, DOI 10.1002/adma.201602696
   Zhang YK, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201701569
   Zhang YF, 2018, ACS ENERGY LETT, V3, P1808, DOI 10.1021/acsenergylett.8b00540
   Zhao DW, 2018, ACS ENERGY LETT, V3, P305, DOI 10.1021/acsenergylett.7b01287
   Zhao DW, 2017, NAT ENERGY, V2, DOI 10.1038/nenergy.2017.18
   Zheng JH, 2018, ENERG ENVIRON SCI, V11, P2432, DOI 10.1039/c8ee00689j
   Zheng XJ, 2015, NANO ENERGY, V17, P269, DOI 10.1016/j.nanoen.2015.08.023
NR 131
TC 5
Z9 5
U1 16
U2 94
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 388
EP 397
DI 10.1016/j.ces.2019.01.003
PG 10
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700033
DA 2020-05-12
ER

PT J
AU Dai, X
   Zhou, WY
   Yang, S
   Sun, FA
   Qian, JF
   He, MY
   Chen, Q
AF Dai, Xuan
   Zhou, Weiyou
   Yang, Song
   Sun, Fu'an
   Qian, Junfeng
   He, Mingyang
   Chen, Qun
TI Microchannel process for phenol production via the cleavage of cumene
   hydroperoxide
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Phenol; Microchannel reactor; Cumene hydroperoxide; Decomposition
ID MICROSTRUCTURED REACTORS; CATALYTIC DECOMPOSITION; HYDROXYLATION;
   OXIDATION; ACID; ACETONE
AB Phenol is commercially produced through cumene hydroperoxide (CHP) cleavage in kettle reactor, having the disadvantages of hazard potential, low selectivity, low efficiency and complicated process. In the study, microchannel reactor has been introduced into the decomposition using sulfuric acid as the catalyst. The influences of various reaction conditions, including temperature, the ratio of sulfuric acid/CHP and residence time, on the reaction have been studied. Compared with kettle reactor, the present process can afford almost quantitative yield of phenol with reduced acid amount and shortened reaction time under higher reaction temperature. The microchannel process can also provide higher security of CHP cleavage. The microtechnology probably gives an alternative protocol for the production of phenol through CHP decomposition. In addition, the possible main reaction pathways for the CHP cleavage in microchannel reactor have been discussed according to the obtained results. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dai, Xuan; Zhou, Weiyou; Yang, Song; Sun, Fu'an; Qian, Junfeng; He, Mingyang; Chen, Qun] Changzhou Univ, Jiangsu Key Lab Adv Catalyt Mat & Technol, Changzhou 213164, Peoples R China.
RP Zhou, WY; Chen, Q (reprint author), Changzhou Univ, Jiangsu Key Lab Adv Catalyt Mat & Technol, Changzhou 213164, Peoples R China.
EM zhouwy426@126.com; chenq_cczu@126.com
OI zhou, weiyou/0000-0003-0149-0921
FU Advanced Catalysis and Green Manufacturing Collaborative Innovation
   Center of Changzhou University; Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD); Jiangsu Key Laboratory of
   Advanced Catalytic Materials and Technology [BM2012110]; Natural Science
   Foundation of Jiangsu Province of ChinaNatural Science Foundation of
   Jiangsu Province [BK20181461]; National Science Foundation of
   ChinaNational Natural Science Foundation of China [21403018, 21676030]
FX This work was supported by Advanced Catalysis and Green Manufacturing
   Collaborative Innovation Center of Changzhou University, A Project
   Funded by the Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD), Jiangsu Key Laboratory of Advanced
   Catalytic Materials and Technology (BM2012110), Natural Science
   Foundation of Jiangsu Province of China (BK20181461) and National
   Science Foundation of China (21403018, 21676030).
CR Boswell MC, 1918, J AM CHEM SOC, V40, P1786, DOI 10.1021/ja02245a005
   Conley ML, 2016, IND ENG CHEM RES, V55, P5865, DOI 10.1021/acs.iecr.6b00975
   Di Somma I, 2008, AICHE J, V54, P1579, DOI 10.1002/aic.11487
   Duma V, 2004, CHEM ENG J, V99, P227, DOI 10.1016/j.cej.2003.11.012
   Haber J, 2012, IND ENG CHEM RES, V51, P1474, DOI 10.1021/ie201158a
   Han L, 2014, CHINESE J CHEM ENG, V22, P854, DOI 10.1016/j.cjche.2014.06.006
   Hofmann LE, 2018, J ORG CHEM, V83, P431, DOI 10.1021/acs.joc.7b02333
   Hou HY, 2006, J THERM ANAL CALORIM, V85, P145, DOI 10.1007/s10973-005-7364-6
   Huang DG, 2002, CHEM ENG J, V88, P215, DOI 10.1016/S1385-8947(02)00003-7
   Jahnisch K, 2004, ANGEW CHEM INT EDIT, V43, P406, DOI 10.1002/anie.200300577
   KAEDING WW, 1961, J ORG CHEM, V26, P3144, DOI 10.1021/jo01067a026
   Kiwi-Minsker L, 2005, CATAL TODAY, V110, P2, DOI 10.1016/j.cattod.2005.09.011
   Knifton JF, 1997, APPL CATAL A-GEN, V161, P199, DOI 10.1016/S0926-860X(97)00070-7
   Kobayashi J, 2006, CHEM-ASIAN J, V1, P22, DOI 10.1002/asia.200600058
   Koltunov KY, 2008, APPL CATAL A-GEN, V336, P29, DOI 10.1016/j.apcata.2007.08.019
   Lavery CB, 2013, ADV SYNTH CATAL, V355, P981, DOI 10.1002/adsc.201300088
   Pennemann H, 2016, CATAL TODAY, V278, P3, DOI 10.1016/j.cattod.2016.04.032
   Rueping M, 2010, ADV SYNTH CATAL, V352, P2961, DOI 10.1002/adsc.201000538
   Schmidt RJ, 2005, APPL CATAL A-GEN, V280, P89, DOI 10.1016/j.apcata.2004.08.030
   Selvin R, 2001, APPL CATAL A-GEN, V219, P125, DOI 10.1016/S0926-860X(01)00674-3
   Selvin R, 2010, REACT KINET MECH CAT, V100, P197, DOI 10.1007/s11144-010-0165-3
   SUPPES GJ, 1989, IND ENG CHEM RES, V28, P1146, DOI 10.1021/ie00092a005
   TOLAND WG, 1961, J AM CHEM SOC, V83, P2507, DOI 10.1021/ja01472a021
   VODNAR J, 1979, REACT KINET CATAL L, V10, P237, DOI 10.1007/BF02068990
   Wang HF, 2018, CHEM ENG SCI, V177, P399, DOI 10.1016/j.ces.2017.11.023
   Wang K, 2010, Patent No. [WO 2010098916 A2, 2010098916]
   Wang YW, 2001, IND ENG CHEM RES, V40, P1125, DOI 10.1021/ie990900s
   Wong WK, 2003, EUR J INORG CHEM, P3539, DOI 10.1002/ejic.200300238
   Xu J, 2018, APPL CATAL A-GEN, V549, P31, DOI 10.1016/j.apcata.2017.09.015
   Yadav GD, 2003, APPL CATAL A-GEN, V244, P341, DOI 10.1016/S0926-860X(02)00605-1
   Ye JC, 2014, IND ENG CHEM RES, V53, P12614, DOI 10.1021/ie500165m
   Zakoshansky VM, 2007, PETROL CHEM+, V47, P273, DOI 10.1134/S096554410704007X
   Zhu QC, 2010, J HAZARD MATER, V175, P646, DOI 10.1016/j.jhazmat.2009.10.057
NR 33
TC 0
Z9 0
U1 7
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 398
EP 404
DI 10.1016/j.ces.2019.01.031
PG 7
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700034
DA 2020-05-12
ER

PT J
AU Liu, L
   Bai, BF
AF Liu, Li
   Bai, Bofeng
TI A mechanistic model for the prediction of swirling annular flow pattern
   transition
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas-liquid flow; Swirling annular flow; Flow pattern transition;
   Mechanistic model
ID GAS-LIQUID FLOW; VERTICAL 2-PHASE FLOW; CHURN TRANSITION; WHOLE RANGE;
   HUGE WAVE; SLUG; VISCOSITY; BUBBLE; PHASE
AB The accurate prediction of flow patterns and their transition is extremely important for proper design, operation and optimization of two-phase flow systems, since the parameters such as pressure loss and heat and mass transfer are strongly dependent on the flow pattern. So far, the non-swirling gas-liquid flow in straight pipes have been widely studied and various mechanisms that lead to flow pattern transition have been clarified and modeled. However, the dynamics of gas-liquid flow under swirling condition are not well understood, and no detailed models are available for the prediction of swirling flow pattern transition. To address this, in our previous work (Liu and Bai, 2018), a visualization experiment aimed at classifying flow regimes in swirling gas-liquid flow was presented and three typical swirling flow regimes, i.e., swirling gas column flow, swirling intermittent flow and swirling annular flow were classified and defined, respectively. As the swirling annular flow can be regarded as a special case of conventional annular flow (i.e., when tangential velocity does not equal zero), in present paper, a mechanistic model for the prediction of the swirling annular flow pattern transition was developed considering its physical interest and great practical significance. Two physical mechanisms that lead to the transition from swirling annular flow to other flow patterns were revealed and modeled, respectively. The model was evaluated against a wide range of swirling and non-swirling experimental data and based on this model, the effects of different parameters (e.g., hydraulic diameter, working pressure and swirl angle) on the boundary of flow pattern transition were presented. Results revealed that the range of swirling annular flow enlarges with the increase of the working pressure and swirl angle but narrows with the hydraulic diameter. Taking these influencing factors into account, a generalized formula for the prediction of the swirling annular flow pattern transition was proposed. Compared with existing empirical correlations for annular flow, the newly developed correlation provided more accurate and reasonable prediction of flow pattern transition for both swirling annular flow and annular flow. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Li] Shanghai Jiao Tong Univ, Sch Nucl Sci & Engn, Shanghai 200240, Peoples R China.
   [Liu, Li; Bai, Bofeng] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
RP Bai, BF (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
EM bfbai@mail.xjtu.edu.cn
RI bai, bofeng/C-7663-2011
FU China National Funds for Distinguished Young ScientistsNational Natural
   Science Foundation of China [51425603]
FX The financial support from China National Funds for Distinguished Young
   Scientists under the contract No. 51425603 is appreciated.
CR Abdelsalam A, 2016, INT J MULTIPHAS FLOW, V81, P15, DOI 10.1016/j.ijmultiphaseflow.2015.12.008
   Alves MVC, 2017, INT J MULTIPHAS FLOW, V89, P399, DOI 10.1016/j.ijmultiphaseflow.2016.12.001
   Baker O., 1954, OIL GAS J, V53, P185, DOI DOI 10.2118/323-G
   BARNEA D, 1985, INT COMMUN HEAT MASS, V12, P611, DOI 10.1016/0735-1933(85)90084-3
   BARNEA D, 1983, CAN J CHEM ENG, V61, P617, DOI 10.1002/cjce.5450610501
   BARNEA D, 1987, INT J MULTIPHAS FLOW, V13, P1, DOI 10.1016/0301-9322(87)90002-4
   BARNEA D, 1986, INT J MULTIPHAS FLOW, V12, P733, DOI 10.1016/0301-9322(86)90048-0
   BARNEA D, 1985, CHEM ENG SCI, V40, P131, DOI 10.1016/0009-2509(85)85053-3
   BARNEA D, 1980, INT J MULTIPHAS FLOW, V6, P217, DOI 10.1016/0301-9322(80)90012-9
   BARNEA D, 1985, INT J MULTIPHAS FLOW, V11, P43, DOI 10.1016/0301-9322(85)90004-7
   BRAUNER N, 1986, CHEM ENG SCI, V41, P159, DOI 10.1016/0009-2509(86)85209-5
   Chang SW, 2009, EXP THERM FLUID SCI, V33, P1087, DOI 10.1016/j.expthermflusci.2009.06.005
   Chen XT, 1997, CHEM ENG SCI, V52, P4269, DOI 10.1016/S0009-2509(97)00178-4
   Cheng LX, 2008, APPL MECH REV, V61, DOI 10.1115/1.2955990
   Da Hlaing N, 2007, EXP THERM FLUID SCI, V31, P567, DOI 10.1016/j.expthermflusci.2006.03.030
   Dukler A.E., 1986, MULTIPHASE SCI TECHN, V2, P1, DOI DOI 10.1007/978-3-662-01657-2_
   Funahashi H, 2016, NUCL ENG DES, V308, P205, DOI 10.1016/j.nucengdes.2016.08.030
   Furukawa T, 2001, INT J MULTIPHAS FLOW, V27, P1109, DOI 10.1016/S0301-9322(00)00066-5
   Gomez L, 2004, J FLUID ENG-T ASME, V126, P943, DOI 10.1115/1.1849254
   GOVAN AH, 1991, INT J MULTIPHAS FLOW, V17, P27, DOI 10.1016/0301-9322(91)90068-E
   Griffith P, 1964, 500329 MIT
   Gupta A., 1984, SWIRL FLOWS
   Haberstroh R. D, 1964, 500328 MIT
   Hewitt G, 1970, ANNULAR 2 PHASE FLOW
   Hewitt G. F, 1969, M2159 UKAEA
   HEWITT GF, 1985, PHYSICOCHEM HYDRODYN, V6, P69
   JAYANTI S, 1992, INT J MULTIPHAS FLOW, V18, P847, DOI 10.1016/0301-9322(92)90063-M
   Jayanti S, 1996, INT J MULTIPHAS FLOW, V22, P307, DOI 10.1016/0301-9322(95)00069-0
   JAYANTI S, 1993, INT J MULTIPHAS FLOW, V19, P531, DOI 10.1016/0301-9322(93)90066-4
   Jeon J, 2011, J FLUID ENG-T ASME, V133, DOI 10.1115/1.4005344
   Jones O. C, 1978, INTER SEMINAR MOMENT
   Julia JE, 2008, NUCL ENG DES, V238, P156, DOI 10.1016/j.nucengdes.2007.05.005
   KATAOKA H, 2008, J POWER ENERGY SYST, V2, P1120
   Liu L, 2018, CHEM ENG SCI
   Liu L, 2017, INTERFACIAL PHENOM H, V5, P9, DOI 10.1615/InterfacPhenomHeatTransfer.2018021108
   Liu L, 2016, NUCL ENG DES, V298, P229, DOI 10.1016/j.nucengdes.2016.01.001
   Liu W, 2015, EXP THERM FLUID SCI, V68, P187, DOI 10.1016/j.expthermflusci.2015.04.018
   Lucas D, 2005, INT J MULTIPHAS FLOW, V31, P1304, DOI 10.1016/j.ijmultiphaseflow.2005.07.004
   Mandhane J. M., 1974, International Journal of Multiphase Flow, V1, P537, DOI 10.1016/0301-9322(74)90006-8
   Manglik R.M., 2003, ADV HEAT TRANSFER, V36, P183
   Matas JP, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4871395
   Matsubayashi T, 2012, NUCL ENG DES, V249, P63, DOI 10.1016/j.nucengdes.2011.05.036
   MCQUILLAN KW, 1985, INT J MULTIPHAS FLOW, V11, P741, DOI 10.1016/0301-9322(85)90022-9
   MISHIMA K, 1984, INT J HEAT MASS TRAN, V27, P723
   Molina R., 2008, J ENERGY RES TECHNOL, V130, P1
   Murai Y, 2006, NUCL ENG DES, V236, P94, DOI 10.1016/j.nucengdes.2005.04.011
   NAMIE S, 1993, INT J MULTIPHAS FLOW, V19, P91, DOI 10.1016/0301-9322(93)90025-P
   REZKALLAH KS, 1995, ADV SPACE RES, V16, P133, DOI 10.1016/0273-1177(95)00147-7
   ROUHANI SZ, 1983, PROG NUCL ENERG, V11, P219, DOI 10.1016/0149-1970(83)90012-4
   Sarica C, 2000, SPE ANN TECHN C EXH
   Schmidt J, 2008, INT J MULTIPHAS FLOW, V34, P363, DOI 10.1016/j.ijmultiphaseflow.2007.10.013
   Seim J, 2011, 15 INT C MULT PROD T
   Shakutsui H, 2010, JPN J MULTIPHASE FLO, V24, P305
   Shoham O., 1982, FLOW PATTERN TRANSIT
   Spedding PL, 1998, CHEM ENG RES DES, V76, P612, DOI 10.1205/026387698525298
   Szalinski L, 2010, CHEM ENG SCI, V65, P3836, DOI 10.1016/j.ces.2010.03.024
   TAITEL Y, 1980, AICHE J, V26, P345, DOI 10.1002/aic.690260304
   TURNER RG, 1969, J PETROL TECHNOL, V21, P1475, DOI 10.2118/2198-PA
   van Nimwegen AT, 2018, INT J MULTIPHAS FLOW, V105, P1, DOI 10.1016/j.ijmultiphaseflow.2017.09.012
   WALLIS GB, 1969, ONE DIMENSIONAL 2 PH
   Waltrich PJ, 2015, EXP THERM FLUID SCI, V68, P652, DOI 10.1016/j.expthermflusci.2015.07.004
   Wang K, 2014, APPL THERM ENG, V64, P422, DOI 10.1016/j.applthermaleng.2013.12.064
   Wang K, 2013, CHEM ENG SCI, V104, P638, DOI 10.1016/j.ces.2013.09.022
   Wang K, 2012, CHEM ENG SCI, V79, P19, DOI 10.1016/j.ces.2012.05.011
   WHALLEY PB, 1980, INT J MULTIPHAS FLOW, V6, P345, DOI 10.1016/0301-9322(80)90026-9
   Wu Z, 2018, HEAT MASS TRANSFER, V54, P81, DOI 10.1007/s00231-017-2099-z
NR 66
TC 6
Z9 6
U1 6
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 405
EP 416
DI 10.1016/j.ces.2019.01.039
PG 12
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700035
DA 2020-05-12
ER

PT J
AU Liu, ZY
   Li, YH
   Yu, FH
   Zhu, J
   Xu, L
AF Liu, Zhiyuan
   Li, Yonghong
   Yu, Fuhang
   Zhu, Jiang
   Xu, Lei
TI Co-pyrolysis of oil sand bitumen with lignocellulosic biomass under
   hydrothermal conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Oil sand bitumen; Corncob; Co-pyrolysis; Supercritical water
ID SUPERCRITICAL WATER; HEAVY OIL; DENSITY POLYETHYLENE; ACTIVATED CARBON;
   ACID
AB Co-pyrolysis of oil sand bitumen and lignocellulosic biomass (corncob) under hydrothermal conditions was carried out to study the synergistic effects of oil sand bitumen and corncob under supercritical water conditions. Results have shown that the conversion of corncob to bio-oil is 75.8% and the dynamic viscosity of oil sand bitumen can be reduced from 6200 to 43 cP, simultaneously, within 40 min at 673 K and feedstock ratio of corncob: oil sand bitumen: water of 2:8:10 (mass), the coke generation from the bitumen by the co-pyrolysis is reduced significantly, compared with upgrading of oil sand bitumen individually in supercritical water; Besides, the unsaturated bond content of products was 1.36 mmol/g, reduced by 57.8%. Co-pyrolysis had eliminated the problem of high oxygen content in bio-oil, the oxygen content of the co-pyrolysis products reduced to 4.58% from 35.15% of bio-oil. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Yonghong] Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Key Lab Green Chem Technol, Tianjin 300072, Peoples R China.
   Natl Engn Res Ctr Distillat Technol, Tianjin 300072, Peoples R China.
   Collaborat Innovat Ctr Chem Sci & Engn, Tianjin 300072, Peoples R China.
RP Li, YH (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Key Lab Green Chem Technol, Tianjin 300072, Peoples R China.
EM yhli@tju.edu.cn
CR Amani MJ, 2014, FUEL, V134, P644, DOI 10.1016/j.fuel.2014.05.063
   Amin S, 2009, ENERG CONVERS MANAGE, V50, P1834, DOI 10.1016/j.enconman.2009.03.001
   Arita T, 2003, TETRAHEDRON LETT, V44, P1083, DOI 10.1016/S0040-4039(02)02704-1
   Bai F, 2013, FUEL PROCESS TECHNOL, V106, P267, DOI 10.1016/j.fuproc.2012.07.031
   Blasi C. D, 2016, ENERGY TECHNOL-GER, V4, P1
   Bohli T, 2016, ENVIRON SCI POLLUT R, V23, P15852, DOI 10.1007/s11356-015-4330-0
   BP, 2017, BP STAT REV WORLD EN
   Bridgwater A, 2009, Patent No. [CA, EP 2074192, A2, 2074192]
   Chen Y, 2016, IND ENG CHEM RES, V55, P9578, DOI 10.1021/acs.iecr.6b02323
   Cheng ZM, 2009, ENERG FUEL, V23, P3178, DOI 10.1021/ef900132z
   Choi K. H., 2014, US. Patent, Patent No. 8864978
   Demirbas A, 2002, ENERG SOURCE, V24, P471, DOI 10.1080/00908310252889979
   Di Blasi C, 1999, IND ENG CHEM RES, V38, P2216, DOI 10.1021/ie980711u
   Faillace JG, 2017, J ANAL APPL PYROL, V126, P70, DOI 10.1016/j.jaap.2017.06.023
   Fedyaeva ON, 2017, J SUPERCRIT FLUID, V126, P55, DOI 10.1016/j.supflu.2017.02.016
   Fekhar B, 2018, EARTH ENV SCI, V154, P1
   Furimsky E, 2013, IND ENG CHEM RES, V52, P17695, DOI 10.1021/ie4034768
   Furimsky E, 2009, IND ENG CHEM RES, V48, P2752, DOI 10.1021/ie800865k
   Gudiyella S, 2018, AICHE J, V64, P1732, DOI 10.1002/aic.16131
   He F, 2017, IND ENG CHEM RES, V56, P1782, DOI 10.1021/acs.iecr.7b00307
   Ikura M, 2003, BIOMASS BIOENERG, V24, P221, DOI 10.1016/S0961-9534(02)00131-9
   Joppert N, 2015, WASTE MANAGE, V36, P166, DOI 10.1016/j.wasman.2014.11.023
   Kida Y, 2014, PHYS CHEM CHEM PHYS, V16, P9220, DOI 10.1039/c4cp00711e
   Kim DW, 2018, ENERG CONVERS MANAGE, V161, P234, DOI 10.1016/j.enconman.2018.02.005
   Komioh H, 2016, ENERG FUEL, V30, P10358, DOI 10.1021/acs.energyfuels.6b02428
   Kozhevnikov IV, 2010, J SUPERCRIT FLUID, V55, P217, DOI 10.1016/j.supflu.2010.08.009
   Li N, 2015, ENERGIES, V8, P8962, DOI 10.3390/en8088962
   [刘贺 Liu He], 2018, [燃料化学学报, Journal of Fuel Chemistry and Technology], V46, P45
   Morimoto M, 2010, J SUPERCRIT FLUID, V55, P223, DOI 10.1016/j.supflu.2010.08.002
   Qiao PQ, 2017, ENERG FUEL, V31, P9179, DOI 10.1021/acs.energyfuels.7b01387
   Qureshi KM, 2018, J ANAL APPL PYROL, V131, P52, DOI 10.1016/j.jaap.2018.02.010
   Radfarnia HR, 2015, FUEL, V159, P653, DOI 10.1016/j.fuel.2015.06.094
   Ramage J, 1996, RENEWABLE ENERGY POW, V8, P444
   Ranganathan P, 2018, FUEL PROCESS TECHNOL, V171, P162, DOI 10.1016/j.fuproc.2017.11.008
   Rocha JA, 2018, ENERG FUEL, V32, P1440, DOI 10.1021/acs.energyfuels.7b03532
   Sato T, 2015, J SUPERCRIT FLUID, V104, P171, DOI 10.1016/j.supflu.2015.06.004
   Tan XC, 2014, FUEL PROCESS TECHNOL, V118, P49, DOI 10.1016/j.fuproc.2013.08.007
   Timko MT, 2015, J SUPERCRIT FLUID, V96, P114, DOI 10.1016/j.supflu.2014.09.015
   Vadillo V, 2013, IND ENG CHEM RES, V52, P7617, DOI 10.1021/ie400156c
   Varadaraj R, 2007, ENERG FUEL, V21, P199, DOI 10.1021/ef060425s
   Vilcaez J, 2012, FUEL, V102, P379, DOI 10.1016/j.fuel.2012.07.024
   Wahyudiono, 2011, J SUPERCRIT FLUID, V60, P127, DOI 10.1016/j.supflu.2011.08.015
   Wang JX, 2016, RSC ADV, V6, P93260, DOI 10.1039/c6ra20955f
   Yang HP, 2006, ENERG FUEL, V20, P388, DOI 10.1021/ef0580117
   Yeh TM, 2013, J CHEM TECHNOL BIOT, V88, P13, DOI 10.1002/jctb.3933
   Zhang Q, 2007, ENERG CONVERS MANAGE, V48, P87, DOI 10.1016/j.enconman.2006.05.010
   Zhao LQ, 2006, ENERG FUEL, V20, P2067, DOI 10.1021/ef060110c
   Zhu CC, 2013, FUEL PROCESS TECHNOL, V111, P111, DOI 10.1016/j.fuproc.2013.02.003
NR 48
TC 2
Z9 2
U1 7
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 417
EP 425
DI 10.1016/j.ces.2018.12.052
PG 9
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700036
DA 2020-05-12
ER

PT J
AU Aguilera, AF
   Tolvanen, P
   Eranen, K
   Warna, J
   Leveneur, S
   Marchant, T
   Salmi, T
AF Aguilera, Adriana Freites
   Tolvanen, Pasi
   Eranen, Kari
   Warna, Johan
   Leveneur, Sebastien
   Marchant, Timothy
   Salmi, Tapio
TI Kinetic modelling of Prileschajew epoxidation of oleic acid under
   conventional heating and microwave irradiation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Epoxidation; Fatty acid; Kinetics; Modelling; Microwaves; Process
   intensification
ID EPOXIDIZED VEGETABLE-OILS; IN-SITU EPOXIDATION; OXIRANE RING; SOYBEAN
   OIL; THERMAL RISK; COTTONSEED OIL; ACETIC-ACID; DEGRADATION; PARAMETERS;
   H2O2
AB Epoxidation of oleic acid by peracetic acid (PAA) was studied in a recycled reactor system under conventional heating and microwave irradiation. This reaction system consists of several steps. Thus, a kinetic modelling strategy to diminish the number of parameters to be estimated was developed by investigating each reaction step: PAA synthesis and decomposition, epoxidation and ring-opening. The energy balance for microwave heating was correlated with the concentration of the microwave-absorbent species and the total input power of the microwaves. The epoxidation reaction was conducted in the vigorously stirred tank reactor under isothermal conditions within a temperature range of 50-70 degrees C. The organic phase content was 32-45% v/v. The interfacial mass transfer was supposed to be faster than the intrinsic reaction kinetics suppressing the use of mass transfer correlations. Nonlinear regression was used to estimate the kinetic parameters. Two models were developed for microwave and conventional heating respectively. The perhydrolysis showed to be the slowest reaction, followed by the epoxidation and the ring-opening. The use of microwave irradiation resulted in considerable process intensification for the epoxidation process. By employing microwave heating, the perhydrolysis step in the aqueous phase was enhanced, and the reaction time was reduced by 50% in best cases, which implies that the reactor size can be diminished by microwave technology. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Aguilera, Adriana Freites; Tolvanen, Pasi; Eranen, Kari; Warna, Johan; Leveneur, Sebastien; Salmi, Tapio] Abo Akad Univ, Johan Gadolin Proc Chem Ctr PCC, Dept Chem Engn, Lab Ind Chem & React Engn, FI-20500 Turku, Finland.
   [Leveneur, Sebastien] Inst Natl Sci Appl Rouen, Lab Securite Proc Chim, FR-76800 St Etienne Du Rouvray, France.
   [Marchant, Timothy] Univ Wollongong, Sch Math & Appl Stat, Wollongong, NSW 2522, Australia.
RP Salmi, T (reprint author), Abo Akad Univ, Johan Gadolin Proc Chem Ctr PCC, Dept Chem Engn, Lab Ind Chem & React Engn, FI-20500 Turku, Finland.
RI leveneur, sebastien/F-2833-2018; Salmi, Tapio/U-5462-2019
OI leveneur, sebastien/0000-0001-9528-6440; 
FU Academy of FinlandAcademy of Finland [319002, 320115]; Fortum
   Foundation; Abo Akademi Forskningsinstitut
FX This work is part of the activities financed by Academy of Finland, the
   Academy Professor grants 319002 (T. Salmi) and 320115 (A. Freites
   Aguilera). Financial support from Fortum Foundation and Abo Akademi
   Forskningsinstitut is gratefully acknowledged. The University of
   Wollongong (UPW) and Institut National des Sciences Appliquees de Rouen
   (INSA) are gratefully acknowledged for fruitful scientific
   collaboration.
CR Aguilera AF, 2018, IND ENG CHEM RES, V57, P3876, DOI 10.1021/acs.iecr.7b05293
   Aguilera AF, 2016, CHEM ENG PROCESS, V102, P70, DOI 10.1016/j.cep.2016.01.011
   Osuna AAB, 2010, ING INVEST, V30, P188
   Brooks S, 2011, CH CRC HANDB MOD STA, pXIX
   CADDICK S, 1995, TETRAHEDRON, V51, P10403, DOI 10.1016/0040-4020(95)00662-R
   Cai XS, 2018, INT J CHEM KINET, V50, P726, DOI 10.1002/kin.21208
   Campanella A, 2005, CATAL TODAY, V107-08, P208, DOI 10.1016/j.cattod.2005.07.092
   Campanella A, 2004, EUR J LIPID SCI TECH, V106, P524, DOI 10.1002/ejlt.200400965
   Campanella A, 2008, CHEM ENG J, V144, P466, DOI 10.1016/j.cej.2008.07.016
   Campanella A, 2007, CHEM ENG PROCESS, V46, P210, DOI 10.1016/j.cep.2006.06.001
   Campanella A, 2006, CHEM ENG J, V118, P141, DOI 10.1016/j.cej.2006.01.010
   Casson Moreno V, 2017, PROCESS SAF ENVIRON, V109, P529, DOI 10.1016/j.psep.2017.05.001
   CHOU TC, 1986, CHEM ENG COMMUN, V41, P253, DOI 10.1080/00986448608911722
   Corporation TL, 2006, STAND TEST PROC DET
   de la Hoz A, 2005, CHEM SOC REV, V34, P164, DOI 10.1039/b411438h
   Dinda S, 2008, BIORESOURCE TECHNOL, V99, P3737, DOI 10.1016/j.biortech.2007.07.015
   Frank P., 1954, INVENTOR PROCESS EPO
   Gamage P. K., 2009, J NATL SCI FDN SRI L, V37
   Goud VV, 2007, CHEM ENG SCI, V62, P4065, DOI 10.1016/j.ces.2007.04.038
   Goud VV, 2006, J AM OIL CHEM SOC, V83, P635, DOI 10.1007/s11746-006-1250-7
   Goud VV, 2006, BIORESOURCE TECHNOL, V97, P1365, DOI 10.1016/j.biortech.2005.07.004
   GREENSPAN FP, 1948, ANAL CHEM, V20, P1061, DOI 10.1021/ac60023a020
   Haario H., 2001, MODEST USERS GUIDE
   Hill JM, 1996, APPL MATH MODEL, V20, P3, DOI 10.1016/0307-904X(95)00107-U
   Jankovic M., 2004, HEM IND, V58, P569, DOI DOI 10.2298/HEMIND0412569J
   JAY RR, 1964, ANAL CHEM, V36, P667, DOI 10.1021/ac60209a037
   Kostik V., 2013, Journal of Hygienic Engineering and Design, V4, P112
   Lee MZC, 2002, J ENG MATH, V44, P125, DOI 10.1023/A:1020820213620
   LEIS JR, 1988, ACM T MATH SOFTWARE, V14, P61, DOI 10.1145/42288.214371
   Leveneur S., 2009, THESIS
   Leveneur S, 2008, IND ENG CHEM RES, V47, P656, DOI 10.1021/ie070670e
   Leveneur S, 2018, THERMOCHIM ACTA, V666, P10, DOI 10.1016/j.tca.2018.05.024
   Leveneur S, 2017, ORG PROCESS RES DEV, V21, P543, DOI 10.1021/acs.oprd.6b00405
   Leveneur S, 2015, J THERM ANAL CALORIM, V122, P795, DOI 10.1007/s10973-015-4793-8
   Leveneur S, 2014, J TAIWAN INST CHEM E, V45, P1449, DOI 10.1016/j.jtice.2014.01.015
   Leveneur S, 2010, RES CHEM INTERMEDIAT, V36, P389, DOI 10.1007/s11164-010-0149-y
   Leveneur S, 2009, CHEM ENG SCI, V64, P4101, DOI 10.1016/j.ces.2009.05.055
   MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030
   Petrovic ZS, 2002, EUR J LIPID SCI TECH, V104, P293, DOI 10.1002/1438-9312(200205)104:5<293::AID-EJLT293>3.0.CO;2-W
   RANGARAJAN B, 1995, J AM OIL CHEM SOC, V72, P1161, DOI 10.1007/BF02540983
   Santacesaria E, 2012, IND ENG CHEM RES, V51, P8760, DOI 10.1021/ie2016174
   Santacesaria E, 2011, CHEM ENG J, V173, P198, DOI 10.1016/j.cej.2011.05.018
   Sinadinovic-Fiser S, 2001, J AM OIL CHEM SOC, V78, P725, DOI 10.1007/s11746-001-0333-9
   Sinadinovic-Fiser S, 2012, CHEM ENG PROCESS, V62, P106, DOI 10.1016/j.cep.2012.08.005
   Tan SG, 2010, POLYM-PLAST TECHNOL, V49, P1581, DOI 10.1080/03602559.2010.512338
   Wu ZY, 2018, IND CROP PROD, V122, P266, DOI 10.1016/j.indcrop.2018.06.007
   Wu ZY, 2016, CAN J CHEM ENG, V94, P1576, DOI 10.1002/cjce.22526
   Zheng JL, 2016, AICHE J, V62, P726, DOI 10.1002/aic.15037
NR 48
TC 6
Z9 6
U1 3
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 426
EP 438
DI 10.1016/j.ces.2019.01.035
PG 13
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700037
DA 2020-05-12
ER

PT J
AU Song, YX
   Xin, F
   Gezi, GY
   Lou, S
   Cao, C
   Wang, JZ
AF Song, Yuexiao
   Xin, Feng
   Gezi Guangyong
   Lou, Shuo
   Cao, Chen
   Wang, Junzheng
TI Uniform generation of water slugs in air flowing through
   superhydrophobic microchannels with T-junction
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Superhydrophobic microchannel; T-junction; Water slug; Contact angle
   hysteresis; Uniformity
ID RECTANGULAR MICROCHANNELS; NUMERICAL-SIMULATION; SURFACE WETTABILITY;
   DRAG REDUCTION; SEGMENTED FLOW; DROP FORMATION; PRESSURE-DROP;
   CONTACT-ANGLE; 2-PHASE FLOW; TAYLOR FLOW
AB This article describes an approach to render all walls of a rectangular microchannel superhydrophobic by coating them with hydrophobically modified silica nanoparticles. Differences between the coated nanoparticles in terms of feature size and structure resulted in different contact angle hysteresis (CAH) on the channel walls. The generation of water slugs in a continuous air flow was experimentally studied in the superhydrophobic microchannels with T-junction. The breakup mechanism of water slugs was proved to accord with the squeezing regime by analyzing the data collected from pressure sensor and high-speed camera at the T-junction. A home-made optical measurement system was employed to investigate the uniformity of the water slugs, which was characterized by the standard deviation and coefficient of variation of slug length. The results showed that superhydrophobic microchannels with CAH lower than 15 degrees could produce uniform water slugs in a slug flow pattern, whereas those with CAH of nearly 30 degrees led to unstable flow. Lower CAH and higher gas flow rate were preferred to reduce slug length and improve slug uniformity. An empirical scaling law was established to predict the slug length and was based on the finding that the total length and number of water slugs in the microchannel were controlled by the volumetric flow ratio of water to air and water flow rate, respectively. This work provides a novel microfluidic platform to generate uniform liquid-in-gas slugs under moderate ranges of air flow rate from 5 mL min(-1) to 30 mL min(-1)(6 < Re-G < 40) and volumetric flow ratio of water to air from 1/300 to 1/2, and this performance benefits from superhydrophobic coatings with low CAH. (C) 2019 Tianjin University. Published by Elsevier Ltd.
C1 [Song, Yuexiao; Xin, Feng; Gezi Guangyong; Lou, Shuo; Cao, Chen; Wang, Junzheng] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
RP Xin, F (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
EM xinf@tju.edu.cn
RI Song, Yuexiao/G-2834-2018; Wang, Junzheng/G-3853-2010
OI Song, Yuexiao/0000-0003-1640-554X; Wang, Junzheng/0000-0002-0060-4248;
   Xin, Feng/0000-0003-0877-8434
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21776206, 21276180]
FX This work was supported by the National Natural Science Foundation of
   China (grant numbers 21776206, 21276180).
CR Abate AR, 2012, LAB CHIP, V12, P1516, DOI 10.1039/c2lc21263c
   Ahn CH, 2004, P IEEE, V92, P154, DOI 10.1109/JPROC.2003.820548
   Amstad E, 2015, SCIENCE, V349, P956, DOI 10.1126/science.aac9582
   Bandara T, 2015, CHEM ENG SCI, V126, P283, DOI 10.1016/j.ces.2014.12.007
   BARAJAS AM, 1993, INT J MULTIPHAS FLOW, V19, P337, DOI 10.1016/0301-9322(93)90007-H
   Barthlott W, 1997, PLANTA, V202, P1, DOI 10.1007/s004250050096
   Carcouet CCMC, 2014, ADV FUNCT MATER, V24, P5745, DOI 10.1002/adfm.201400111
   Carroll B, 2013, J FLUID ENG-T ASME, V135, DOI 10.1115/1.4024057
   Carroll B, 2012, EXP FLUIDS, V53, P1301, DOI 10.1007/s00348-012-1361-x
   Carroll B, 2013, HEAT TRANSFER ENG, V34, P120, DOI 10.1080/01457632.2013.703087
   Solvas XCI, 2011, CHEM COMMUN, V47, P1936, DOI 10.1039/c0cc02474k
   CHAUDHURY MK, 1992, SCIENCE, V256, P1539, DOI 10.1126/science.256.5063.1539
   Cheah MJ, 2013, LANGMUIR, V29, P9918, DOI 10.1021/la4011967
   Choi C, 2011, EXP THERM FLUID SCI, V35, P1086, DOI 10.1016/j.expthermflusci.2011.03.003
   Cubaud T, 2006, FLUID DYN RES, V38, P772, DOI 10.1016/j.fluiddyn.2005.12.004
   Das A, 2018, J MICROMECH MICROENG, V28, DOI 10.1088/1361-6439/aaab36
   Dilip D, 2018, INT J HEAT MASS TRAN, V119, P551, DOI 10.1016/j.ijheatmasstransfer.2017.11.093
   Dolovich MB, 2011, LANCET, V377, P1032, DOI 10.1016/S0140-6736(10)60926-9
   Duncanson WJ, 2012, LAB CHIP, V12, P2135, DOI 10.1039/c2lc21164e
   Fang C, 2008, INT J MULTIPHAS FLOW, V34, P690, DOI 10.1016/j.ijmultiphaseflow.2007.08.008
   Feng L, 2002, ADV MATER, V14, P1857, DOI 10.1002/adma.200290020
   Fu TT, 2010, CHEM ENG SCI, V65, P3739, DOI 10.1016/j.ces.2010.03.012
   Fuerstman MJ, 2007, LAB CHIP, V7, P1479, DOI 10.1039/b706549c
   Garstecki P, 2006, LAB CHIP, V6, P693
   Gemoets HPL, 2016, CHEM SOC REV, V45, P83, DOI 10.1039/c5cs00447k
   Gogolides E, 2015, MICROELECTRON ENG, V132, P135, DOI 10.1016/j.mee.2014.10.002
   Gong XQ, 2012, CHEM-EUR J, V18, P2768, DOI 10.1002/chem.201104059
   Guo F, 2009, MICROGRAVITY SCI TEC, V21, P51, DOI 10.1007/s12217-009-9146-4
   Gupta R, 2009, CHEM ENG SCI, V64, P2941, DOI 10.1016/j.ces.2009.03.018
   Han WB, 2018, AUST J CHEM, V71, P957, DOI 10.1071/CH18320
   Han WB, 2018, J MICRO-NANOLITH MEM, V17, DOI 10.1117/1.JMM.17.2.025502
   Jiang KQ, 2015, J COLLOID INTERF SCI, V448, P275, DOI 10.1016/j.jcis.2015.02.023
   Kittiampon N, 2017, INT J GREENH GAS CON, V63, P431, DOI 10.1016/j.ijggc.2017.06.014
   Lee SW, 2000, J AM CHEM SOC, V122, P5395, DOI 10.1021/ja994076a
   Li D, 2018, SENSOR ACTUAT B-CHEM, V255, P1048, DOI 10.1016/j.snb.2017.08.152
   Lou S, 2018, LANGMUIR, V34, P7738, DOI 10.1021/acs.langmuir.8b00166
   Mastiani M, 2017, RSC ADV, V7, P48512, DOI 10.1039/c7ra09710g
   Ou J, 2004, PHYS FLUIDS, V16, P4635, DOI 10.1063/1.1812011
   Peng DY, 2017, AICHE J, V63, P2378, DOI 10.1002/aic.15584
   Peng DY, 2015, CHEM ENG SCI, V128, P11, DOI 10.1016/j.ces.2015.01.064
   Qu WX, 2018, J COLLOID INTERF SCI, V524, P289, DOI 10.1016/j.jcis.2018.03.101
   Rotem A, 2012, LAB CHIP, V12, P4263, DOI 10.1039/c2lc40546f
   Shah R. K., 1978, ADV HEAT TRANSFER
   Shahriari A, 2016, MICROFLUID NANOFLUID, V20, DOI 10.1007/s10404-015-1671-4
   Song D, 2014, EXP FLUIDS, V55, DOI 10.1007/s00348-014-1783-8
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Tirandazi P, 2018, SENSOR ACTUAT B-CHEM, V267, P279, DOI 10.1016/j.snb.2018.03.057
   Tirandazi P, 2017, J MICROMECH MICROENG, V27, DOI 10.1088/1361-6439/aa7595
   van Steijn V, 2007, CHEM ENG SCI, V62, P7505, DOI 10.1016/j.ces.2007.08.068
   van Steijn V, 2010, LAB CHIP, V10, P2513, DOI 10.1039/c002625e
   Wang JZ, 2015, LANGMUIR, V31, P1610, DOI 10.1021/la504955b
   Wang S, 2007, ADV MATER, V19, P3423, DOI 10.1002/adma.200700934
   Warnier MJF, 2008, CHEM ENG J, V135, pS153, DOI 10.1016/j.cej.2007.07.008
   Zhang LX, 2015, AICHE J, V61, P4028, DOI 10.1002/aic.14938
   Zhang LX, 2015, CHEM ENG J, V263, P452, DOI 10.1016/j.cej.2014.11.004
NR 55
TC 1
Z9 1
U1 5
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 439
EP 450
DI 10.1016/j.ces.2019.01.041
PG 12
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700038
OA Other Gold
DA 2020-05-12
ER

PT J
AU Afshari, S
   Hejazi, SH
   Kantzas, A
AF Afshari, Saied
   Hejazi, Seyed Hossein
   Kantzas, Apostolos
TI Pore-level modeling of effective longitudinal thermal dispersion in
   non-isothermal flows through granular porous media
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Thermal dispersion; Non-isothermal flow; Heat transport; Porous media;
   Pore-scale simulation; Viscous fingering
ID NEWTONIAN FLUID-FLOWS; HEAT-TRANSFER; PACKED-BEDS; CONDUCTIVITY;
   TRANSPORT; BOUNDARY; UNSTEADY
AB In non-isothermal flows through porous media, the rate of heat transport across the domain and the distribution of temperature profile are strongly affected by the thermal properties of the fluid and solid phases, flow conditions, and the topological geometry of the pore structure. The combined effect of these parameters on the dynamics of heat transfer is generally characterized by the thermal dispersion coefficient. In this study, we model thermal dispersion in granular porous media using pore-scale numerical simulations. The flow and heat transport equation are solved in a porous domain at the pore-level to obtain the distribution of temperature inside the fluid phase and solid grains. The effluent temperature profile at the outlet is then fitted to the analytical solution of the macroscale heat advection-dispersion equation to determine the longitudinal component of the effective thermal dispersion tensor. Several simulation runs are carried out to investigate the effect of Peclet number, fluid to solid thermal conductivity and heat capacity ratios, and the temperature-dependent viscosity on the variation of the longitudinal thermal dispersion coefficient. The results indicate the existence of different thermal dispersion regimes separated by a threshold Peclet number. Below the threshold, thermal dispersion is dominated by conduction and longitudinal dispersion coefficient is equal to the effective thermal conductivity of the porous medium. Above the threshold, there is a transition region in which both conduction and advection are responsible for the heat ttansport. At higher Peclet numbers, dispersion regime is advection-dominated and normalized dispersion coefficient increases with the Peclet number and thermal conductivity ratio whereas it decreases with the heat capacity ratio. In this regime, the relationship between dispersion coefficient and Peclet number follows a power-law functionality with the exponent decreasing with the heat capacity ratio. To summarize the results, a characterization diagram is constructed for thermal dispersion regime based on the values of Peclet number and thermal conductivity ratio. Finally, the presence of viscous fingering due to the monotonically increasing viscosity along the flow is observed to further increase the longitudinal thermal dispersion. The outcomes of this study are of great importance in the design, implementation, and performance optimization of thermal processes in granular porous media. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Afshari, Saied; Hejazi, Seyed Hossein; Kantzas, Apostolos] Univ Calgary, Dept Chem & Petr Engn, Calgary, AB T2N 1N4, Canada.
RP Afshari, S (reprint author), ES902,2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.
EM saied.afshari@ucalgary.ca
FU FUR program from NSERC; AITF/i-CORE; Athabasca Oil Corporation; Laricina
   Energy Ltd.; Devon Canada; Energie; Husky Energy; Petro China Canada;
   Canadian Natural Resources Limited; Suncor Energy; Schulich School of
   Engineering, University of Calgary; Imperial Oil University Research
   Award; Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada
FX The authors acknowledge the financial support of the FUR program from
   NSERC, AITF/i-CORE, and the sponsoring companies: Athabasca Oil
   Corporation, Laricina Energy Ltd., Devon Canada, Energie, Husky Energy,
   Petro China Canada, Canadian Natural Resources Limited, Suncor Energy,
   and Schulich School of Engineering, University of Calgary. This work
   also was supported in part by the Imperial Oil University Research Award
   and the Natural Sciences and Engineering Research Council of Canada
   (NSERC) discovery grant.
CR Afshari S, 2018, ADV WATER RESOUR, V119, P125, DOI 10.1016/j.advwatres.2018.06.005
   Afshari S, 2018, PHYS REV FLUIDS, V3, DOI 10.1103/PhysRevFluids.3.054501
   Alshare AA, 2010, INT J HEAT MASS TRAN, V53, P2294, DOI 10.1016/j.ijheatmasstransfer.2009.11.001
   AMIRI A, 1994, INT J HEAT MASS TRAN, V37, P939, DOI 10.1016/0017-9310(94)90219-4
   Askari R, 2017, GEOPHYS RES LETT, V44, P8285, DOI 10.1002/2017GL074651
   Bear J, 1972, DYNAMICS FLUIDS PORO
   Buckinx G, 2016, J FLUID MECH, V804, P298, DOI 10.1017/jfm.2016.543
   CHENG P, 1987, INT J HEAT MASS TRAN, V30, P2373, DOI 10.1016/0017-9310(87)90228-6
   CHENG P, 1988, CHEM ENG SCI, V43, P2523, DOI 10.1016/0009-2509(88)85186-8
   CLEMENT K, 1983, CHEM ENG SCI, V38, P835, DOI 10.1016/0009-2509(83)80003-7
   Dejam M, 2019, INT J HEAT MASS TRAN, V128, P1307, DOI 10.1016/j.ijheatmasstransfer.2018.09.061
   Dejam M, 2018, CHEM ENG SCI, V189, P296, DOI 10.1016/j.ces.2018.05.058
   DUBNER H, 1968, J ACM, V15, P115, DOI 10.1145/321439.321446
   Guardo A, 2006, CHEM ENG SCI, V61, P4341, DOI 10.1016/j.ces.2006.02.011
   GUNN DJ, 1974, CHEM ENG SCI, V29, P1363, DOI 10.1016/0009-2509(74)80160-0
   GUNN DJ, 1975, CHEM ENG SCI, V30, P261, DOI 10.1016/0009-2509(75)80014-5
   HSU CT, 1990, INT J HEAT MASS TRAN, V33, P1587, DOI 10.1016/0017-9310(90)90015-M
   Jeong N, 2011, INT J HEAT MASS TRAN, V54, P4389, DOI 10.1016/j.ijheatmasstransfer.2011.05.003
   Kovscek AR, 2012, J PETROL SCI ENG, V98-99, P130, DOI 10.1016/j.petrol.2012.08.004
   Kuwahara F, 1996, J HEAT TRANS-T ASME, V118, P756, DOI 10.1115/1.2822696
   Kuwahara F, 1999, J HEAT TRANS-T ASME, V121, P160, DOI 10.1115/1.2825930
   LEVEC J, 1985, AICHE J, V31, P591, DOI 10.1002/aic.690310409
   LEVEC J, 1985, AICHE J, V31, P581, DOI 10.1002/aic.690310408
   Mahjoob S, 2008, INT J HEAT MASS TRAN, V51, P3701, DOI 10.1016/j.ijheatmasstransfer.2007.12.012
   Molina-Giraldo N, 2011, INT J THERM SCI, V50, P1223, DOI 10.1016/j.ijthermalsci.2011.02.004
   Moyne C, 1997, ADV WATER RESOUR, V20, P63, DOI 10.1016/S0309-1708(96)00023-1
   Nian YL, 2017, J PETROL SCI ENG, V151, P507, DOI 10.1016/j.petrol.2017.01.026
   OchoaTapia JA, 1997, INT J HEAT MASS TRAN, V40, P2691, DOI 10.1016/S0017-9310(96)00250-5
   Ozgumus T, 2016, INT J THERM SCI, V104, P135, DOI 10.1016/j.ijthermalsci.2016.01.003
   Ozgumus T, 2013, APPL MECH REV, V65, DOI 10.1115/1.4024351
   Pedras MHJ, 2008, INT J HEAT MASS TRAN, V51, P5359, DOI 10.1016/j.ijheatmasstransfer.2008.04.030
   Pritchard D, 2004, J FLUID MECH, V508, P133, DOI 10.1017/S0022112004009000
   Saada MA, 2006, HEAT MASS TRANSFER, V42, P995, DOI [10.1007/s00231-005-0061-y, 10.1007/s0023I-005-0061-y]
   SAHRAOUI M, 1994, INT J HEAT MASS TRAN, V37, P1029, DOI 10.1016/0017-9310(94)90227-5
   WHITAKER S, 1999, THEORY APPL TRANSPOR
   Xu JY, 2010, INT J HEAT FLUID FL, V31, P57, DOI 10.1016/j.ijheatfluidflow.2009.10.003
   YAGI S, 1960, AICHE J, V6, P543, DOI 10.1002/aic.690060407
   Yang C, 2010, INT J HEAT MASS TRAN, V53, P3222, DOI 10.1016/j.ijheatmasstransfer.2010.03.004
   Zheng L., 2018, HYDROLOGICAL PROCESS, P1
NR 39
TC 2
Z9 2
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 451
EP 462
DI 10.1016/j.ces.2019.01.028
PG 12
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700039
DA 2020-05-12
ER

PT J
AU Qaderi, A
   Jamaati, J
   Bahiraei, M
AF Qaderi, Alireza
   Jamaati, Jafar
   Bahiraei, Mehdi
TI CFD simulation of combined electroosmotic-pressure driven micro-mixing
   in a microchannel equipped with triangular hurdle and zeta-potential
   heterogeneity
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Micro-mixing; Combined electroosmot c-pressure driven; flow; Hurdle;
   Heterogeneous zeta-potential; Microchannel
ID SURFACE-CHARGE; MASS-TRANSPORT; FLOW; FLUIDS
AB The numerical simulation for micro-mixing of the combined electroosmotic-pressure driven flow inside the microchannels with the triangular obstacles (hurdles) and heterogeneous zeta-potential is carried out. The simulation is conducted by solving the steady state equations of momentum, electric fields and concentration field, while the Nernst-Planck equation is used for identifying the ions distribution inside the channel. It is supposed that a fluid having different concentrations enters the 2D rectangular microchannel. The results show that for the straight homogeneous microchannels, greater adverse pressure gradients cause better mixing. Moreover, the microchannels having the hurdles or heterogeneous zeta-potential produce the superior mixing performance such that the mixing efficiency increases up to 15.4% and 48.1% for the microchannels with the hurdles and heterogeneous zeta-potential, respectively. This improvement reaches 87% for the microchannels with both hurdles and zeta-potential heterogeneity. It is found that the location of the hurdles does not affect the mixing performance while the height of the hurdles has intense effect on the mixing quality. Thereby, changing the height of the hurdles from 0.05H to 0.2H, improves the mixing efficiency about 11.4% and 15.6% for the homogeneous and heterogeneous zeta-potential cases, respectively. The length of the hurdles has different effects based on the zeta-potential situation so that in the case of heterogeneous zeta-potential, length of the hurdles has intense effect on the mixing, while for the homogeneous channels, this effect dramatically decreases. It is also found that increasing the zeta-potential on the hurdles leads to better mixing performance while increment of the zeta-potential on the straight parts of the walls weakens the mixing performance. Investigating the effect of the charge arrangement shows that the NP-PN arrangement makes the mixing quality better. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Qaderi, Alireza; Jamaati, Jafar] Razi Univ, Dept Mech Engn, Kermanshah, Iran.
   [Bahiraei, Mehdi] Kermanshah Univ Technol, Dept Mech Engn, Kermanshah, Iran.
RP Qaderi, A (reprint author), Razi Univ, Dept Mech Engn, Kermanshah, Iran.
EM qaderi.alireza@razi.ac.ir
OI Bahiraei, Mehdi/0000-0003-1103-3118
CR Afonso AM, 2014, MICROFLUID NANOFLUID, V16, P1131, DOI 10.1007/s10404-013-1279-5
   Azari M, 2019, INT J HEAT MASS TRAN, V128, P150, DOI 10.1016/j.ijheatmasstransfer.2018.08.106
   Bag N, 2018, J NONNEWTON FLUID ME
   Bera S, 2013, INT J ENG SCI, V62, P165, DOI 10.1016/j.ijengsci.2012.09.006
   Bhagat AAS, 2007, J MICROMECH MICROENG, V17, P1017, DOI 10.1088/0960-1317/17/5/023
   Bhattacharyya S, 2015, APPL MATH MODEL, V39, P4337, DOI 10.1016/j.apm.2014.12.050
   Bhattacharyya S, 2013, J FLUID ENG-T ASME, V135, DOI 10.1115/1.4023446
   Bhattacharyya S, 2010, J FLUID ENG-T ASME, V132, DOI 10.1115/1.4001308
   Biddiss E, 2004, ANAL CHEM, V76, P3208, DOI 10.1021/ac035451r
   Bockelmann H, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.4722000
   Cheng YL, 2018, CHEM ENG PROCESS, V127, P93, DOI 10.1016/j.cep.2018.03.017
   CUSSLER EL, 1997, DIFFUSION
   Ebrahimi S, 2014, INT J HEAT MASS TRAN, V75, P565, DOI 10.1016/j.ijheatmasstransfer.2014.04.004
   Erickson D, 2008, ENCY MICROFLUIDICS N, P560, DOI [10.1007/978-0-387-48998-8_446, DOI 10.1007/978-0-387-48998-8_446]
   Gaikwad HS, 2019, P I MECH ENG E-J PRO, V233, P871, DOI 10.1177/0954408918809612
   Hadigol M, 2011, J NON-NEWTON FLUID, V166, P965, DOI 10.1016/j.jnnfm.2011.05.001
   Hadigol M, 2011, COLLOID SURFACE A, V374, P142, DOI 10.1016/j.colsurfa.2010.10.045
   Haque A, 2017, ASME 2017 FLUIDS ENG
   Hemadri V, 2018, MICROFLUID NANOFLUID, V22, DOI 10.1007/s10404-018-2034-8
   Herr AE, 2000, ANAL CHEM, V72, P1053, DOI 10.1021/ac990489i
   Hu YD, 2004, J COLLOID INTERF SCI, V280, P527, DOI 10.1016/j.jcis.2004.08.011
   Jain M, 2013, COMPUT CHEM ENG, V49, P18, DOI 10.1016/j.compchemeng.2012.09.004
   Kazemi Z, 2017, CHEM ENG PROCESS, V121, P188, DOI 10.1016/j.cep.2017.08.015
   Kim HJ, 2009, J HEAT TRANS-T ASME, V131, DOI 10.1115/1.3139109
   Lee JSH, 2005, ANAL CHIM ACTA, V530, P273, DOI 10.1016/j.aca.2004.09.026
   Medina I, 2018, CHEM ENG SCI, V184, P259, DOI 10.1016/j.ces.2018.03.051
   Mirbozorgi SA, 2006, J FLUID ENG-T ASME, V128, P1133, DOI 10.1115/1.2353261
   Ramirez JC, 2006, BIOMED MICRODEVICES, V8, P325, DOI 10.1007/s10544-006-9819-3
   Sadeghi A, 2017, INT J THERM SCI, V122, P162, DOI 10.1016/j.ijthermalsci.2017.08.019
   Sheu TWH, 2016, COMMUN COMPUT PHYS, V19, P496, DOI 10.4208/cicp.230914.040615a
   Somasundaran P, 2004, ENCY SURFACE COLLOID
   Sun CL, 2012, MICROSYST TECHNOL, V18, P1237, DOI 10.1007/s00542-012-1475-3
   Wang W., 2007, BIOMEMS TECHNOLOGIES
   Wautelet M, 2001, EUR J PHYS, V22, P601, DOI 10.1088/0143-0807/22/6/305
   Wong SH, 2003, SENSOR ACTUAT B-CHEM, V95, P414, DOI 10.1016/S0925-4005(03)00447-7
   Wu ZM, 2008, ELECTROCHIM ACTA, V53, P5827, DOI 10.1016/j.electacta.2008.03.039
   Yang JT, 2008, CHEM ENG SCI, V63, P1871, DOI 10.1016/j.ces.2007.12.027
NR 37
TC 5
Z9 5
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 463
EP 477
DI 10.1016/j.ces.2019.01.034
PG 15
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700040
DA 2020-05-12
ER

PT J
AU Yin, X
   Zeng, Y
   Yao, J
   Du, ZP
   Zhang, H
   Sun, T
   Wang, GY
AF Yin, Xia
   Zeng, Yi
   Yao, Jie
   Du, Zhiping
   Zhang, Hua
   Sun, Teng
   Wang, Gongying
TI Intrinsic reaction kinetics and mechanism for the reverse
   disproportionation reaction to methyl phenyl carbonate
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Methyl phenyl carbonate; Diphenyl carbonate; Intrinsic kinetics;
   Catalysis mechanism
ID DIMETHYL CARBONATE; DIPHENYL CARBONATE; TRANSESTERIFICATION;
   DISTILLATION; ESTERIFICATION; METHANOLYSIS; CATALYST; PHOSGENE; ETHANOL
AB The extensive researches about the thermodynamic and intrinsic kinetic of disproportionation reaction of methyl phenyl carbonate to diphenyl carbonate were investigated independently with dibutyltin oxide as a catalyst, at a temperature range of 433.15-473.15 K and different catalyst concentrations in a stirred batch reactor, for a deeper knowledge of reaction essence. This reaction was found endothermic and showed hardly any reaction in the absence of catalyst which indicate an inferior kinetic characteristics. The reaction rate increases with an increasing catalyst concentration until the concentration went to 8.08 x 10(4) mol mol( 1). A possible mechanism involving an in-situ Sn-based species was proposed and finally verified by a good agreement between experimental and simulated data. The available Sn-based species was then demonstrated to play a real catalytic role by extra experiments. All results can also be further utilized to explore the essence of transesterification reaction network. (C) 2018 Published by Elsevier Ltd.
C1 [Yin, Xia; Du, Zhiping] Wuhan Inst Technol, Sch Chem Engn & Pharm, Key Lab Novel Reactor & Green Chem Technol Hubei, Key Lab Green Chem Proc,Minist Educ, 693 Xiong Chu Rd, Wuhan 430205, Hubei, Peoples R China.
   [Zeng, Yi; Yao, Jie; Zhang, Hua; Sun, Teng; Wang, Gongying] Chinese Acad Sci, Chengdu Inst Organ Chem, 9 Four Sect People South Rd, Chengdu 610041, Sichuan, Peoples R China.
RP Wang, GY (reprint author), Chinese Acad Sci, Chengdu Inst Organ Chem, 9 Four Sect People South Rd, Chengdu 610041, Sichuan, Peoples R China.
EM gywang@cioc.ac.cn
RI ; , Yin/J-9649-2014
OI Zhang, Hua/0000-0001-5936-7876; , Yin/0000-0002-6344-7091; Wang,
   Gongying/0000-0002-7839-6186
FU Demonstration Project of Transfer and Transformation of Scientific and
   Technological Achievements in Sichuan Province [18CGSF0036]; Youths
   Science Foundation of Wuhan Institute of Technology
FX This work has been supported by the Demonstration Project of Transfer
   and Transformation of Scientific and Technological Achievements in
   Sichuan Province [grant number 18CGSF0036, grant name Development and
   industrial application of large-scale transesterification reactor]; and
   the Youths Science Foundation of Wuhan Institute of Technology.
   Gratitude will be expressed to the Editor and the anonymous reviewers
   who made very useful comments and remarks.
CR Chipperfield A. J., 1994, P AD COMP ENG DES CO
   Du Z, 2008, CATAL COMMUN, V9, P239, DOI 10.1016/j.catcom.2007.05.044
   Du ZP, 2006, J MOL CATAL A-CHEM, V246, P200, DOI 10.1016/j.molcata.2005.10.030
   Fu X.C., 2005, PHYS CHEM
   Gong JL, 2007, APPL CATAL A-GEN, V316, P1, DOI 10.1016/j.apcata.2006.09.006
   Hatanaka I, 2003, J ORGANOMET CHEM, V674, P96, DOI 10.1016/S0022-328X(03)00203-1
   Haubrock J, 2008, IND ENG CHEM RES, V47, P9862, DOI 10.1021/ie071176d
   Haubrock J, 2008, IND ENG CHEM RES, V47, P9854, DOI 10.1021/ie0711170
   Jin F, 2018, CATALYSIS TODAY
   Keller T, 2012, CHEM ENG J, V180, P309, DOI 10.1016/j.cej.2011.11.072
   Keller T, 2011, IND ENG CHEM RES, V50, P11073, DOI 10.1021/ie2014982
   Kim WB, 2004, IND ENG CHEM RES, V43, P1897, DOI 10.1021/ie034004z
   Long Q, 2014, J IND MANAG OPTIM, V10, P1279, DOI 10.3934/jimo.2014.10.1279
   Mei FM, 2004, ORG PROCESS RES DEV, V8, P372, DOI 10.1021/op0302098
   Niu HY, 2006, J MOL CATAL A-CHEM, V259, P292, DOI 10.1016/j.molcata.2006.06.040
   Niu HY, 2005, J MOL CATAL A-CHEM, V235, P240, DOI 10.1016/j.molcata.2005.03.023
   Oemar U, 2014, AICHE J, V60, P4190, DOI 10.1002/aic.14573
   OKI M, 1971, B CHEM SOC JPN, V44, P3419, DOI 10.1246/bcsj.44.3419
   Ono Y, 1997, APPL CATAL A-GEN, V155, P133, DOI 10.1016/S0926-860X(96)00402-4
   Patidar P, 2012, CHEM ENG J, V207, P377, DOI 10.1016/j.cej.2012.06.139
   Schon N., 1993, Process for the Preparation of Diaryl Carbonates., Patent No. [US patent 5344954, 5344954]
   Steyer F, 2007, IND ENG CHEM RES, V46, P1099, DOI 10.1021/ie060781y
   STRATTON J, 1992, J ORG CHEM, V57, P3237, DOI 10.1021/jo00037a050
   Sun W. Z., 2016, CAN J CHEM ENG, V9999, P1
   Tang RZ, 2014, CHINESE J CATAL, V35, P457, DOI 10.1016/S1872-2067(14)60059-0
   Tao S. C., 2003, J ANHUI U SCI TECHNO, V23, P3
   Tong DS, 2007, J MOL CATAL A-CHEM, V268, P120, DOI 10.1016/j.molcata.2006.12.013
   Wang F, 2007, IND ENG CHEM RES, V46, P8972, DOI 10.1021/ie061480r
   Wang SL, 2015, J MOL CATAL A-CHEM, V398, P248, DOI 10.1016/j.molcata.2014.11.014
   Wang SL, 2014, CHEM J CHINESE U, V35, P2177, DOI 10.7503/cjcu20140334
   Wang Y, 2005, ACTA CHIM SINICA, V63, P603
   Yin X., 2018, 31 ANN C CHIN CHEM S
   Yin X, 2014, IND ENG CHEM RES, V53, P19087, DOI 10.1021/ie502989y
   [殷霞 Yin Xia], 2013, [化学工程, Chemical Engineering (China)], V41, P1
   Zhang JY, 2014, AICHE J, V60, P3804, DOI 10.1002/aic.14554
NR 35
TC 1
Z9 1
U1 3
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 478
EP 485
DI 10.1016/j.ces.2018.11.037
PG 8
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700041
DA 2020-05-12
ER

PT J
AU Wang, C
   Yang, QQ
   Wang, JY
   Zhao, J
   Wan, XY
   Guo, Z
   Yang, YH
AF Wang, Chuan
   Yang, Qingqing
   Wang, Jieyu
   Zhao, Jun
   Wan, Xiaoyue
   Guo, Zhen
   Yang, Yanhui
TI Application of support vector machine on controlling the silanol groups
   of silica xerogel with the aid of segmented continuous flow reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Support vector machine; Design of experiments; Continuous flow reactor;
   Silanol group; Silica
ID SURFACE; NANOPARTICLES; OPTIMIZATION; CATALYSTS; DESIGN; HYDROGENATION;
   SPECTROSCOPY; MODEL; WATER; OIL
AB In recent years, machine learning (ML) has been extensively attempted on all sections in development of functional materials such as material discovery, determination of experimental factors for the discovered materials, and tuning experimental factors to produce the selected materials. Design of experiment (DoE) and response surface methodology (RSM) are efficient strategies to screen experimental factors and study the correlation between material property and experimental factors. Usually, second order quadratic model is applied to construct the response surface. ML-based models, such as Gaussian process and neural networks, have also be implemented into the RSM. In this work, a ML model based on support vector machine (SVM) was built to analyze the high-throughput experimental data from DoE. Silica xerogel was chosen as a model material, the goal was to control the diversity of the silanol groups on the surfaces of silica. Silica samples were prepared following the central composite design (CCD) in a segmented continuous flow reactor. Sodium silicate and CO2 were used as the raw materials. Both quadratic model and SVM model were studied on the analysis of experimental data. SVM model showed better performance in fitting and predicting, which was attributed to the advantage of handling complex nonlinear correlations. Based on the response surface generated by the SVM model, correlations between experimental factors and diversity of silanol groups were identified. With the guidance of the SVM model, two samples with desired silica surface properties were prepared and attempted as supporting materials for heterogeneous catalysis. The impact of surface silanol groups on the catalytic performance was discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Chuan; Yang, Qingqing; Wang, Jieyu; Zhao, Jun; Wan, Xiaoyue; Guo, Zhen; Yang, Yanhui] Nanjing Tech Univ, Jiangsu Natl Synerget Innovat Ctr Adv Mat, Inst Adv Synth, Sch Chem & Mol Engn, Nanjing 211816, Jiangsu, Peoples R China.
RP Guo, Z; Yang, YH (reprint author), Nanjing Tech Univ, Jiangsu Natl Synerget Innovat Ctr Adv Mat, Inst Adv Synth, Sch Chem & Mol Engn, Nanjing 211816, Jiangsu, Peoples R China.
EM ias_zguo@njtech.edu.cn; yhyang@njtech.edu.cn
RI Yang, Yanhui/C-7162-2008
FU Nanjing Tech University; SICAM Fellowship from Jiangsu National
   Synergetic Innovation Center for Advanced Materials
FX We gratefully acknowledge the financial support from Nanjing Tech
   University and SICAM Fellowship from Jiangsu National Synergetic
   Innovation Center for Advanced Materials.
CR Anbari E, 2015, CHEM ENG J, V276, P213, DOI 10.1016/j.cej.2015.04.019
   Azqhandi MHA, 2017, J COLLOID INTERF SCI, V505, P278, DOI 10.1016/j.jcis.2017.05.098
   Birch DJS, 2000, PHYS REV E, V62, P2977, DOI 10.1103/PhysRevE.62.2977
   BOGUSH GH, 1991, J COLLOID INTERF SCI, V142, P1, DOI 10.1016/0021-9797(91)90029-8
   BRINKER CJ, 1989, SOL GEL SCI PHYS CHE
   Cai X, 2009, CHEM ENG J, V151, P380, DOI 10.1016/j.cej.2009.03.060
   Carrete J, 2014, ADV FUNCT MATER, V24, P7427, DOI 10.1002/adfm.201401201
   Chamkalani A, 2012, CHEM ENG SCI, V81, P202, DOI 10.1016/j.ces.2012.06.060
   Chattopadhyay P, 2003, IND ENG CHEM RES, V42, P465, DOI 10.1021/ie020261c
   Chen JJF, 2017, CHEM ENG SCI, V159, P31, DOI 10.1016/j.ces.2016.02.037
   Chi GY, 2012, CHEM ENG RES DES, V90, P1235, DOI 10.1016/j.cherd.2011.12.012
   Curtarolo S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.135503
   Dashtian K, 2017, J COLLOID INTERF SCI, V494, P114, DOI 10.1016/j.jcis.2017.01.072
   Dijkstra TW, 2002, J AM CHEM SOC, V124, P9856, DOI 10.1021/ja0122243
   Douglas M. C, 2009, DESIGN ANAL EXPT
   Gallas JP, 2009, LANGMUIR, V25, P5825, DOI 10.1021/la802688w
   Gromping U, 2014, J STAT SOFTW, V56, P1
   Hasegawa K, 2010, CURR COMPUT-AID DRUG, V6, P24, DOI 10.2174/157340910790980124
   Hessel V, 2013, CHEMSUSCHEM, V6, P746, DOI 10.1002/cssc.201200766
   HOFFMANN P, 1987, SURF SCI, V188, P181, DOI 10.1016/S0039-6028(87)80150-4
   Khan SA, 2004, LANGMUIR, V20, P8604, DOI 10.1021/la0499012
   Kim E, 2017, CHEM MATER, V29, P9436, DOI 10.1021/acs.chemmater.7b03500
   Knossalla J, 2016, NEW J CHEM, V40, P4361, DOI 10.1039/c5nj03033a
   Li Z, 2017, J MATER CHEM A, V5, P24131, DOI 10.1039/c7ta01812f
   Liou TH, 2011, MATER SCI ENG B-ADV, V176, P521, DOI 10.1016/j.mseb.2011.01.007
   Mebane WR, 2011, J STAT SOFTW, V42, P1
   MORROW BA, 1992, J PHYS CHEM-US, V96, P1395, DOI 10.1021/j100182a068
   Nosengo N, 2016, NATURE, V533, P22, DOI 10.1038/533022a
   Pyzer-Knapp EO, 2016, MATER HORIZ, V3, P226, DOI 10.1039/c5mh00282f
   Robertson K, 2017, CHEM CENT J, V11, DOI 10.1186/s13065-016-0229-1
   Sekhon J, 1998, POLIT ANAL, V7, P187, DOI DOI 10.HTTP://DX.D0I.0RG/10.1093/PAN/7.1.187
   Shekarriz M, 2014, CAN J CHEM ENG, V92, P828, DOI 10.1002/cjce.21921
   Smola AJ, 2004, STAT COMPUT, V14, P199, DOI 10.1023/B:STCO.0000035301.49549.88
   Tang QH, 2010, CHEM ENG J, V156, P423, DOI 10.1016/j.cej.2009.11.002
   Tang QH, 2009, CATAL LETT, V128, P210, DOI 10.1007/s10562-008-9740-x
   Tsai MS, 2006, J NANOPART RES, V8, P943, DOI 10.1007/s11051-005-9047-4
   Ulissi ZW, 2017, ACS CATAL, V7, P6600, DOI 10.1021/acscatal.7b01648
   Yan WJ, 2012, CHEM ENG SCI, V76, P26, DOI 10.1016/j.ces.2012.03.049
   Yang YH, 2005, MICROPOR MESOPOR MAT, V86, P303, DOI 10.1016/j.micromeso.2005.07.045
   Yang YH, 2004, MICROPOR MESOPOR MAT, V74, P133, DOI 10.1016/j.micromeso.2004.06.012
NR 40
TC 2
Z9 2
U1 11
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 486
EP 495
DI 10.1016/j.ces.2019.01.032
PG 10
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700042
DA 2020-05-12
ER

PT J
AU Sulaiman, M
   Climent, E
   Hammouti, A
   Wachs, A
AF Sulaiman, Mostafa
   Climent, Eric
   Hammouti, Abdelkader
   Wachs, Anthony
TI Mass transfer towards a reactive particle in a fluid flow: Numerical
   simulations and modeling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Catalyst particle; Mass transfer; Sherwood number; Chemical reaction;
   Thiele modulus
ID BIOMASS GASIFICATION; CHEMICAL-REACTION; HEAT-TRANSFER; HENRY NUMBER;
   PACKED-BEDS; SPHERE; INTERFACE; TRANSPORT; BUBBLES
AB We study mass transfer towards a solid spherical catalyst particle experiencing a first order irreversible reaction coupled to an external laminar flow. Internal chemical reaction and convective-diffusive mass transfer in the surrounding fluid flow are coupled by concentration and flux boundary conditions at the particle surface. Through this coupling, the mean particle surface and volume concentrations are predicted and the internal/external Sherwood numbers are obtained. We investigate the interplay between convection, diffusion, and reaction by computational fluid dynamics and establish a model for the mass transfer coefficient accounting for diffusion and internal first-order chemical reaction. We obtain a prediction of the mass transfer coefficient through mass balance or using the classical additivity rule. The model is numerically validated by fully resolved numerical simulations over a wide range of Reynolds number, Schmidt number and Thiele modulus which shows that assuming decoupled treatment of external and internal mass transfer gives very accurate predictions. Finally, we test the unsteady response of the model. The model predicts the evolution of the mean volume concentration for a particle placed in a steady convective-diffusive stream. Predictions of the unsteady model are in very good agreement with computed results. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sulaiman, Mostafa; Hammouti, Abdelkader] IFP Energies Nouvelles, Rond Point Echangeur Solaize, Fluid Mech Dept, BP 3, F-69360 Solaize, France.
   [Climent, Eric] Univ Toulouse, IMFT, Toulouse, France.
   [Wachs, Anthony] Univ British Columbia, Dept Math, 1984 Math Rd, Vancouver, BC V6T 1Z2, Canada.
   [Wachs, Anthony] Univ British Columbia, Dept Chem & Biol Engn, 2360 East Mall, Vancouver, BC V6T 1Z3, Canada.
RP Climent, E (reprint author), Univ Toulouse, IMFT, Toulouse, France.
EM ecliment@imft.fr
OI wachs, anthony/0000-0002-8545-7688
CR Baruah D, 2017, BIOMASS BIOENERG, V98, P264, DOI 10.1016/j.biombioe.2017.01.029
   Bird R. B, 2015, TRANSPORT PHENOMENA
   Bohn CD, 2012, J COMPUT PHYS, V231, P5334, DOI 10.1016/j.jcp.2012.04.021
   Calmet I, 1997, PHYS FLUIDS, V9, P438, DOI 10.1063/1.869138
   Clift R., 2005, BUBBLES DROPS PARTIC
   Dierich F, 2018, CHEM ENG SCI, V175, P296, DOI 10.1016/j.ces.2017.09.055
   Dixon AG, 2010, IND ENG CHEM RES, V49, P9012, DOI 10.1021/ie100298q
   Feng ZG, 2000, INT J HEAT MASS TRAN, V43, P219, DOI 10.1016/S0017-9310(99)00133-7
   GUNN DJ, 1978, INT J HEAT MASS TRAN, V21, P467, DOI 10.1016/0017-9310(78)90080-7
   Ismail TM, 2018, WASTE MANAGE, V73, P476, DOI 10.1016/j.wasman.2017.06.018
   Jarullah AT, 2017, FUEL, V206, P657, DOI 10.1016/j.fuel.2017.05.092
   Juncu G, 2002, HEAT MASS TRANSFER, V38, P523, DOI [10.1007/s002310100256, 10.1007/S002310100256]
   Juncu G, 2001, HEAT MASS TRANSFER, V37, P519, DOI 10.1007/s002310100211
   KLEINMAN LS, 1995, IND ENG CHEM RES, V34, P3621, DOI 10.1021/ie00037a051
   Losey MW, 2001, IND ENG CHEM RES, V40, P2555, DOI 10.1021/ie000523f
   Lu JT, 2018, CHEM ENG SCI, V176, P1, DOI 10.1016/j.ces.2017.10.018
   MAGNAUDET J, 1995, J FLUID MECH, V284, P97, DOI 10.1017/S0022112095000280
   Mikulandric R, 2016, ENERG CONVERS MANAGE, V125, P264, DOI 10.1016/j.enconman.2016.04.067
   Neves D, 2017, J ANAL APPL PYROL, V127, P57, DOI 10.1016/j.jaap.2017.09.002
   Partopour Behnam, 2018, ChemEngineering, V2, DOI 10.3390/chemengineering2010002
   Partopour B, 2017, POWDER TECHNOL, V322, P258, DOI 10.1016/j.powtec.2017.09.009
   Piche S, 2001, ENVIRON SCI TECHNOL, V35, P4817, DOI 10.1021/es011099s
   Pigeonneau F, 2014, AICHE J, V60, P3376, DOI 10.1002/aic.14520
   RANZ WE, 1952, CHEM ENG PROG, V48, P141
   Rossetti I, 2017, CATAL TODAY
   RUCKENSTEIN E, 1971, CHEM ENG SCI, V26, P647, DOI 10.1016/0009-2509(71)86008-6
   Shao XM, 2012, INT J HEAT MASS TRAN, V55, P6775, DOI 10.1016/j.ijheatmasstransfer.2012.06.085
   SHERWOOD TK, 1957, IND ENG CHEM, V49, P1030, DOI 10.1021/ie50570a038
   WAKAO N, 1978, CHEM ENG SCI, V33, P1375, DOI 10.1016/0009-2509(78)85120-3
   Wehinger GD, 2017, COMPUT CHEM ENG, V101, P11, DOI 10.1016/j.compchemeng.2017.02.029
   WHITAKER S, 1972, AICHE J, V18, P361, DOI 10.1002/aic.690180219
NR 31
TC 1
Z9 1
U1 3
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 496
EP 507
DI 10.1016/j.ces.2018.12.051
PG 12
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700043
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Fechtner, M
   Kienle, A
AF Fechtner, M.
   Kienle, A.
TI Equilibrium theory of ion exchange chromatography with variable solution
   normality and steric hindrance
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ion exchange; Chromatography; Solution normality; Steric hindrance;
   Equilibrium theory; Selectivity reversal
ID EFFICIENT SIMULATION; PH; PROTEINS; SEPARATION; GRADIENTS; BEHAVIOR
AB The paper extends equilibrium theory of ion exchange chromatography to account for variable solution normality and steric hindrance. Both effects are crucial for many separations including the separation of proteins. Analytical solutions are given for a full chromatographic cycle consisting of the loading of an empty bed equilibrated at different salt concentrations followed by a regeneration step. Special emphasis is on selectivity reversals. It is shown that additional reversals may occur due to a change in solution normality. Results are illustrated step by step and relation to ion exchange chromatography with constant solution normality and/or mass action equilibrium without steric hindrance is discussed. Theoretical findings are validated by comparison with numerical simulation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fechtner, M.; Kienle, A.] Otto von Guericke Univ, Univ Pl 2, D-39106 Magdeburg, Germany.
   [Kienle, A.] Max Planck Inst Dynami Komplexer Tech Syst, D-39106 Magdeburg, Germany.
RP Kienle, A (reprint author), Otto von Guericke Univ, Univ Pl 2, D-39106 Magdeburg, Germany.
EM kienle@mpi-magdeburg.mpg.de
OI Kienle, Achim/0000-0002-9011-0451
FU International Max Planck Research School for Advanced Methods in Process
   and Systems Engineering - IMPRS ProEng; center of dynamic systems (CDS)
   - EU-programme ERDF (European Regional Development Fund)
FX The financial support of the International Max Planck Research School
   for Advanced Methods in Process and Systems Engineering - IMPRS ProEng
   is greatly acknowledged. The research was also supported by the center
   of dynamic systems (CDS), funded by the EU-programme ERDF (European
   Regional Development Fund).
CR BROOKS CA, 1992, AICHE J, V38, P1969, DOI 10.1002/aic.690381212
   Carta G., 2010, PROTEIN CHROMATOGRAP
   Fechtner M, 2017, CHEM ENG SCI, V171, P471, DOI 10.1016/j.ces.2017.06.004
   Fechtner M, 2018, COMPUT-AIDED CHEM EN, V43, P295, DOI 10.1016/B978-0-444-64235-6.50055-3
   Findenegg GH, 2007, J CHROMATOGR A, V1150, P236, DOI 10.1016/j.chroma.2007.01.073
   Frey DD, 1996, BIOTECHNOL PROGR, V12, P65, DOI 10.1021/bp950061e
   Gallant S, 1996, AICHE J, V42
   Gallant SR, 1996, J CHROMATOGR A, V725, P295, DOI 10.1016/0021-9673(95)00909-4
   GALLANT SR, 1995, J CHROMATOGR A, V702, P125, DOI 10.1016/0021-9673(94)00992-I
   HELFFERICH FG, 1970, MULTICOMPONENT CHROM
   Janson J, 2011, PROTEIN PURIFICATION, V1
   Karkov HS, 2013, J CHROMATOGR A, V1318, P149, DOI 10.1016/j.chroma.2013.10.004
   Lax P, 1973, CBMS NSF REGIONAL C, V1
   MATLAB, 2014, VERS 8 4 0
   Mazzotti M, 2013, ANNU REV CHEM BIOMOL, V4, P119, DOI 10.1146/annurev-chembioeng-061312-103318
   Nagai H, 2004, SEP SCI TECHNOL, V39
   Natarajan V, 2002, BIOTECHNOL BIOE, V78
   Pabst TM, 2008, BIOTECHNOL PROGR, V24, P1096, DOI 10.1002/btpr.53
   Pabst TM, 2007, J CHROMATOGR A, V1142, P19, DOI 10.1016/j.chroma.2006.08.066
   Perez JS, 2005, BIOTECHNOL PROGR, V21, P902, DOI 10.1021/bp040025s
   Rhee H.-K., 1989, 1 ORDER PARTIAL DIFF, VII
   Schiesser W.E., 1991, NUMERICAL METHOD LIN
   Smoller J., 1994, SHOCK WAVES REACTION
   Steinebach F, 2017, IND ENG CHEM RES, V56, P13483, DOI 10.1021/acs.iecr.7b00569
   Tondeur D, 1970, CHEM ENG J, V1, P337
   Tondeur D, 1969, THESIS
   UNGER J, 1995, COMPUT CHEM ENG, V19, P867, DOI 10.1016/0098-1354(94)00094-5
   VELAYUDHAN A, 1988, J CHROMATOGR, V443, P13, DOI 10.1016/S0021-9673(00)94779-4
NR 28
TC 1
Z9 1
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 508
EP 527
DI 10.1016/j.ces.2019.01.040
PG 20
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700044
DA 2020-05-12
ER

PT J
AU Xie, P
   Lu, XS
   Ding, HB
   Yang, X
   Ingham, D
   Ma, L
   Pourkashanian, M
AF Xie, Peng
   Lu, Xuesong
   Ding, Hongbing
   Yang, Xin
   Ingham, Derek
   Ma, Lin
   Pourkashanian, Mohamed
TI A mesoscale 3D CFD analysis of the liquid flow in a rotating packed bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rotating packed bed; CFD; Liquid holdup; Interfacial area; Flow pattern;
   VOF model
ID POSTCOMBUSTION CO2 CAPTURE; INTERFACIAL MASS-TRANSFER; CARBON-DIOXIDE
   ABSORPTION; DRY PRESSURE-DROP; GAS-LIQUID; PROCESS INTENSIFICATION;
   NUMERICAL-SIMULATION; 3-DIMENSIONAL SIMULATION; CHEMICAL ABSORPTION;
   MULTIPHASE FLOW
AB Rotating packed beds (RPBs), as a type of process intensification technology, are promising to be employed as high-efficiency CO2 absorbers. However, the detailed understanding of the liquid flow in the RPB is still very limited. The complex and dense packing of the bed and the multiscale of the RPB make it very difficult to perform numerical simulations in detail, in particular for full 3D simulations. In this paper, a mesoscale 3D CFD modelling approach is proposed which can be used to investigate the liquid flow in both laboratory- and large-scale RPBs in detail and accuracy. A 3D representative elementary unit of the RPB has been built and validated with experimental observations, and then it is employed to investigate the gas-liquid flows at different locations, across a typical RPB, so that the overall characteristics of the liquid flow in the RPB can be assembled. The proposed approach enables the detailed prediction of the liquid holdup, droplets formation, effective interfacial area, wetted packing area and specific surface area of the liquid within real 3D packing structures throughout the bed. New correlations to predict the liquid holdup, effective interfacial area, and specific surface area of the liquid are proposed, and the sensitivities of these quantities to the rotational speed, liquid flow rate, viscosity and contact angle have been investigated. The results have been compared with experimental data, previous correlations and theoretical values and it shows that the new correlations have a good accuracy in predicting these critical quantities. Further, recommendations for scale-up and operation of an RPB for CO2 capture are provided. This proposed model leads to a much better understanding of the liquid flow behaviours and can assist in the RPB optimisation design and scaling up. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xie, Peng; Lu, Xuesong; Ding, Hongbing; Yang, Xin; Ingham, Derek; Ma, Lin; Pourkashanian, Mohamed] Univ Sheffield, Fac Engn, Dept Mech Engn, Energy 2050, Sheffield S10 2TN, S Yorkshire, England.
   [Ding, Hongbing] Tianjin Univ, Sch Elect & Informat Engn, Tianjin Key Lab Proc Measurement & Control, Tianjin 300072, Peoples R China.
RP Ma, L (reprint author), Univ Sheffield, Fac Engn, Dept Mech Engn, Energy 2050, Sheffield S10 2TN, S Yorkshire, England.
EM lin.ma@sheffield.ac.uk
RI Ding, Hongbing/AAC-6298-2019
OI Ding, Hongbing/0000-0002-0316-134X; xie, peng/0000-0001-7156-7061; Ma,
   Lin/0000-0002-3731-8464
FU EPSRCEngineering & Physical Sciences Research Council (EPSRC)
   [EP/M001458/2]; China Scholarship CouncilChina Scholarship Council;
   University of Sheffield
FX The authors acknowledge the financial support from the EPSRC grants
   (EP/M001458/2, Process Intensification for Post-combustion Carbon
   Capture using Rotating Packed Bed through Systems Engineering
   Techniques) and The Expanded Metal Company for providing the packing
   samples. P. Xie would like to acknowledge the China Scholarship Council
   and the University of Sheffield for funding his research studies.
CR Albert C, 2014, INT J HEAT MASS TRAN, V69, P343, DOI 10.1016/j.ijheatmasstransfer.2013.10.025
   Amundsen TG, 2009, J CHEM ENG DATA, V54, P3096, DOI 10.1021/je900188m
   ANSYS Inc, 2016, THEOR GUID ANSYS FLU
   BASIC A, 1995, AICHE J, V41, P301, DOI 10.1002/aic.690410212
   Biliyok C, 2012, INT J GREENH GAS CON, V9, P428, DOI 10.1016/j.ijggc.2012.05.001
   Bothe D, 2013, CHEM ENG SCI, V101, P283, DOI 10.1016/j.ces.2013.05.029
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Burns JR, 1996, CHEM ENG SCI, V51, P1347, DOI 10.1016/0009-2509(95)00367-3
   Burns JR, 2000, CHEM ENG SCI, V55, P2401, DOI 10.1016/S0009-2509(99)00520-5
   Chen JF, 2000, IND ENG CHEM RES, V39, P948, DOI 10.1021/ie990549a
   Chen JF, 2010, AICHE J, V56, P1053, DOI 10.1002/aic.11911
   Chen YH, 2004, IND ENG CHEM RES, V43, P228, DOI 10.1021/ie030545c
   Chen YS, 2005, IND ENG CHEM RES, V44, P1043, DOI 10.1021/ie0499409
   Chen YS, 2002, IND ENG CHEM RES, V41, P1583, DOI 10.1021/ie010752h
   Chen YS, 2006, IND ENG CHEM RES, V45, P6846, DOI 10.1021/ie060399l
   Chu GW, 2014, IND ENG CHEM RES, V53, P15731, DOI 10.1021/ie502519v
   Ding HB, 2018, INT J HEAT MASS TRAN, V124, P929, DOI 10.1016/j.ijheatmasstransfer.2018.03.111
   Guo K, 2000, CHEM ENG SCI, V55, P1699, DOI 10.1016/S0009-2509(99)00369-3
   Guo K, 2014, ENVIRON SCI TECHNOL, V48, P6844, DOI 10.1021/es404913e
   Guo TY, 2017, IND ENG CHEM RES, V56, P8169, DOI 10.1021/acs.iecr.7b01759
   Guo TY, 2016, IND ENG CHEM RES, V55, P4856, DOI 10.1021/acs.iecr.6b00213
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Hu JG, 2014, CHEM ENG SCI, V116, P243, DOI 10.1016/j.ces.2014.05.002
   Jassim M.S., 2002, THESIS
   Jassim MS, 2007, IND ENG CHEM RES, V46, P2823, DOI 10.1021/ie051104r
   Joel AS, 2017, APPL ENERG, V203, P11, DOI 10.1016/j.apenergy.2017.05.157
   Joel AS, 2015, APPL THERM ENG, V74, P47, DOI 10.1016/j.applthermaleng.2014.02.064
   Joel AS, 2014, INT J GREENH GAS CON, V21, P91, DOI 10.1016/j.ijggc.2013.12.005
   Kang JL, 2014, INT J GREENH GAS CON, V25, P141, DOI 10.1016/j.ijggc.2014.04.011
   Li QS, 2016, CHEM ENG SCI, V143, P23, DOI 10.1016/j.ces.2015.12.014
   Lin CC, 2000, CHEM ENG RES DES, V78, P397, DOI 10.1205/026387600527293
   Liu BT, 2016, IND ENG CHEM RES, V55, P7810, DOI 10.1021/acs.iecr.5b05003
   Liu Y, 2017, CHEM ENG SCI, V170, P365, DOI 10.1016/j.ces.2017.01.033
   Llerena-Chavez H, 2009, CHEM ENG SCI, V64, P2113, DOI 10.1016/j.ces.2009.01.019
   Lopes RJG, 2009, AICHE J, V55, P2920, DOI 10.1002/aic.11862
   Lu X, 2018, CHEM ENG SCI, V189, P123, DOI 10.1016/j.ces.2018.04.074
   Luo Y, 2017, CHEM ENG SCI, V170, P347, DOI 10.1016/j.ces.2016.10.023
   Luo Y, 2012, IND ENG CHEM RES, V51, P16320, DOI 10.1021/ie302531j
   MENTER FR, 1994, AIAA J, V32, P1598, DOI 10.2514/3.12149
   Nijemeisland M, 2001, CHEM ENG J, V82, P231, DOI 10.1016/S1385-8947(00)00360-0
   Ozkan F, 2016, ENG APPL COMP FLUID, V10, P100, DOI 10.1080/19942060.2015.1061555
   Ouyang Y, 2018, CHEM ENG PROCESS, V123, P185, DOI 10.1016/j.cep.2017.09.005
   Qi WZ, 2017, CHEM ENG PROCESS, V118, P62, DOI 10.1016/j.cep.2017.04.020
   Rajan S, 2011, IND ENG CHEM RES, V50, P986, DOI 10.1021/ie100899r
   Ramshaw C, 1981, US Patent, Patent No. [4283255, 4,283,255]
   Raynal L, 2007, CHEM ENG SCI, V62, P7196, DOI 10.1016/j.ces.2007.08.010
   Sang L, 2017, CHEM ENG SCI, V158, P429, DOI 10.1016/j.ces.2016.10.044
   Sebastia-Saez D, 2018, CHEM ENG SCI, V176, P356, DOI 10.1016/j.ces.2017.09.046
   Sebastia-Saez D, 2015, INT J GREENH GAS CON, V42, P388, DOI 10.1016/j.ijggc.2015.08.016
   Sebastia-Saez D, 2015, INT J GREENH GAS CON, V33, P40, DOI 10.1016/j.ijggc.2014.11.019
   Shi X, 2013, CHEM ENG J, V228, P1040, DOI 10.1016/j.cej.2013.05.081
   Singh RK, 2018, CHEM ENG J, V353, P949, DOI 10.1016/j.cej.2018.07.067
   Singh RK, 2017, INT J GREENH GAS CON, V64, P87, DOI 10.1016/j.ijggc.2017.07.005
   Singh RK, 2016, CHEM ENG SCI, V142, P244, DOI 10.1016/j.ces.2015.11.029
   Smith Dimas, 2009, Recent Patents on Materials Science, V2, P209
   Sun B, 2013, AICHE J, V59, P3119, DOI 10.1002/aic.14082
   Thiels M, 2016, IFAC PAPERSONLINE, V49, P895, DOI 10.1016/j.ifacol.2016.07.303
   Uchiyama K, 2003, INT J HEAT MASS TRAN, V46, P457, DOI 10.1016/S0017-9310(02)00301-0
   Wang H. W., 1999, PARTIAL LEAST SQUARE
   Wang M, 2015, APPL ENERG, V158, P275, DOI 10.1016/j.apenergy.2015.08.083
   Wu W, 2018, IND ENG CHEM RES, V57, P2031, DOI 10.1021/acs.iecr.7b04901
   Xie P, 2017, ENRGY PROCED, V142, P3407, DOI 10.1016/j.egypro.2017.12.478
   Xie P, 2017, CHEM ENG SCI, V172, P216, DOI 10.1016/j.ces.2017.06.040
   Xing T, 2011, J FLUID ENG-T ASME, V133, DOI 10.1115/1.4005030
   Xing T, 2010, J FLUID ENG-T ASME, V132, DOI 10.1115/1.4001771
   Xu YY, 2009, CHEM ENG TECHNOL, V32, P1227, DOI 10.1002/ceat.200900099
   Xu YY, 2014, IND ENG CHEM RES, V53, P7797, DOI 10.1021/ie500047a
   Xu Z, 2014, J THERM SCI, V23, P338, DOI 10.1007/s11630-014-0715-5
   Yan ZY, 2014, AICHE J, V60, P2705, DOI 10.1002/aic.14449
   Yan ZY, 2012, IND ENG CHEM RES, V51, P10472, DOI 10.1021/ie202257t
   [杨旷 Yang Kuang], 2011, [北京化工大学学报. 自然科学版, Journal of Beijing University of Chemical Technology. Natural Science Edition], V38, P7
   Yang X, 2017, P COMBUST INST, V36, P3341, DOI 10.1016/j.proci.2016.06.060
   Yang YC, 2019, J CHEM TECHNOL BIOT, V94, P1017, DOI 10.1002/jctb.5880
   Yang YC, 2016, CHEM ENG J, V294, P111, DOI 10.1016/j.cej.2016.02.054
   Yang YC, 2015, CHEM ENG SCI, V138, P244, DOI 10.1016/j.ces.2015.07.044
   Yang YC, 2015, CAN J CHEM ENG, V93, P1138, DOI 10.1002/cjce.22183
   Youngs D. L., 1982, TIME DEPENDENT MULTI
   Yu CH, 2016, APPL ENERG, V175, P269, DOI 10.1016/j.apenergy.2016.05.044
   Zhang J, 2000, J CHEM ENG CHIN U, V14, P378
   Zhang JP, 2017, CHEM ENG SCI, V170, P204, DOI 10.1016/j.ces.2017.03.058
   Zhao BT, 2014, APPL ENERG, V136, P132, DOI 10.1016/j.apenergy.2014.08.108
   Zheng XH, 2016, CHEM ENG J, V285, P236, DOI 10.1016/j.cej.2015.09.083
   Zou HK, 2017, FUEL, V204, P47, DOI 10.1016/j.fuel.2017.05.017
NR 83
TC 3
Z9 4
U1 4
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 528
EP 545
DI 10.1016/j.ces.2019.01.038
PG 18
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700045
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Carr, EJ
AF Carr, Elliot J.
TI Rear-surface integral method for calculating thermal diffusivity from
   laser flash experiments
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Laser flash method; Thermal diffusivity; Parameter estimation; Heat
   transfer
ID FINITE PULSE-TIME; TEMPERATURE
AB The laser flash method for measuring thermal diffusivity of solids involves subjecting the front face of a small sample to a heat pulse of radiant energy and recording the resulting temperature rise on the opposite (rear) surface. For the adiabatic case, the widely-used standard approach estimates the thermal diffusivity from the rear-surface temperature rise history by calculating the half rise time: the time required for the temperature rise to reach one half of its maximum value. In this article, we develop a novel alternative approach by expressing the thermal diffusivity exactly in terms of the area enclosed by the rear-surface temperature rise curve and the steady-state temperature over time. Approximating this integral numerically leads to a simple formula for the thermal diffusivity involving the rear-surface temperature rise history. Using synthetic experimental data we demonstrate that the new formula produces estimates of the thermal diffusivity - for a typical test case - that are more accurate and less variable than the standard approach. The article concludes by briefly commenting on extension of the new method to account for heat losses from the sample. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Carr, Elliot J.] Queensland Univ Technol, Sch Math Sci, Brisbane, Qld, Australia.
RP Carr, EJ (reprint author), Queensland Univ Technol, Sch Math Sci, Brisbane, Qld, Australia.
EM elliot.carr@qut.edu.au
OI Carr, Elliot/0000-0001-9972-927X
FU Australian Research CouncilAustralian Research Council [DE150101137]
FX This research was funded by the Australian Research Council
   (DE150101137). Insightful comments from two anonymous referees greatly
   improved the quality of this paper.
CR [Anonymous], 2013, E146113 ASTM
   AZUMI T, 1981, REV SCI INSTRUM, V52, P1411, DOI 10.1063/1.1136793
   Blumm J, 2002, HIGH TEMP-HIGH PRESS, V34, P515, DOI 10.1068/htjr061
   CAPE JA, 1963, J APPL PHYS, V34, P1909, DOI 10.1063/1.1729711
   Carr EJ, 2018, PHYS REV E, V97, DOI 10.1103/PhysRevE.97.042115
   Carr EJ, 2017, PHYS REV E, V96, DOI 10.1103/PhysRevE.96.012116
   Chen LG, 2010, COMP MATER SCI, V50, P77, DOI 10.1016/j.commatsci.2010.07.009
   COWAN RD, 1963, J APPL PHYS, V34, P926, DOI 10.1063/1.1729564
   Czel B, 2013, INT J THERMOPHYS, V34, P1993, DOI 10.1007/s10765-013-1496-x
   D'Alessandro G, 2018, COMPUT THERM SCI, V10, P251, DOI 10.1615/ComputThermalScien.2017021201
   Ellery AJ, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.041135
   GEMBAROVIC J, 1994, REV SCI INSTRUM, V65, P3535, DOI 10.1063/1.1144534
   HECKMAN RC, 1973, J APPL PHYS, V44, P1455, DOI 10.1063/1.1662393
   JAMES HM, 1980, J APPL PHYS, V51, P4666, DOI 10.1063/1.328337
   JOSELL D, 1995, J APPL PHYS, V78, P6867, DOI 10.1063/1.360452
   Parker W. J., 1962, ADV ENERG CONVERS, V2, P87
   PARKER WJ, 1961, J APPL PHYS, V32, P1679, DOI 10.1063/1.1728417
   Simpson MJ, 2013, J HYDROL, V501, P241, DOI 10.1016/j.jhydrol.2013.08.005
   Tao Y, 2015, REV SCI INSTRUM, V86, DOI 10.1063/1.4936590
   TAYLOR RE, 1964, APPL PHYS LETT, V5, P212, DOI 10.1063/1.1723593
   Vozar L, 2003, HIGH TEMP-HIGH PRESS, V35-6, P253, DOI 10.1068/htjr119
   Zhao YH, 2016, INT J HEAT MASS TRAN, V101, P470, DOI 10.1016/j.ijheatmasstransfer.2016.05.068
NR 22
TC 2
Z9 2
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 546
EP 551
DI 10.1016/j.ces.2019.01.014
PG 6
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700046
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Sutherland, K
   Pakzad, L
   Fatehi, P
AF Sutherland, Kayte
   Pakzad, Leila
   Fatehi, Pedram
TI CFD population balance modeling and dimensionless group analysis of a
   multiphase oscillatory baffled column (OBC) using moving overset meshes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Population balance; OBC; Overset mesh; CFD; Dimensionless groups
ID SUSPENSION POLYMERIZATION; SIZE DISTRIBUTIONS; AXIAL-DISPERSION;
   RESIDENCE TIME; FLOW PATTERNS; PARTICLE-SIZE; SCALE-UP; BATCH;
   STABILIZER; BREAKUP
AB This paper presents a CFD model and hydrodynamic study of a moving-baffle oscillatory baffled column (moving-baffle OBC). This work marks the first instance that moving overset meshing was used to simulate agitator motion in a fluid system. Population balance results are validated with experimental data for the inverse-suspension of non-reactive aqueous acrylamide in Isopar oil. A comparison of the droplet size distributions produced via various multiphase simulation methods was performed, resulting in a better overall agreement with the experimental literature for simulations applying the volume of fluid (VOF) multiphase method. Hydrodynamic studies reveal patterns of local flow circulations and center-most axial currents in relation to agitator position. Examination of the dimensionless groups traditionally used to describe flow conditions for moving-baffle OBCs reveal a considerable discrepancy between the previously-defined oscillatory Reynolds number and oscillatory Strouhal number with numbers derived from fluid flow within the column. A numerical correction has been presented to illustrate the nonlinear effect of oscillation amplitude on fluid flow through the system and to provide a more realistic estimation of the Reynolds number and Strouhal number for the modeled moving-baffle OBC. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sutherland, Kayte; Pakzad, Leila; Fatehi, Pedram] Lakehead Univ, Dept Chem Engn, Thunder Bay, ON P7B 5E1, Canada.
RP Pakzad, L (reprint author), Lakehead Univ, Dept Chem Engn, Thunder Bay, ON P7B 5E1, Canada.
EM lpakzad@lakeheadu.ca
OI fatehi, pedram/0000-0002-3874-5089
FU Natural Sciences and Engineering Council of Canada (NSERC)Natural
   Sciences and Engineering Research Council of Canada
FX We gratefully acknowledged the financial support of the Natural Sciences
   and Engineering Council of Canada (NSERC). We would also like to
   acknowledge the support of Compute Canada for providing the solving
   platform and technical support.
CR Abbott MSR, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2012.0036
   Bortolin S, 2014, HEAT TRANSFER ENG, V35, P193, DOI 10.1080/01457632.2013.812493
   Briggs NEB, 2015, ORG PROCESS RES DEV, V19, P1903, DOI 10.1021/acs.oprd.5b00206
   BRUNOLD CR, 1989, CHEM ENG SCI, V44, P1227, DOI 10.1016/0009-2509(89)87022-8
   CHATZI EG, 1991, IND ENG CHEM RES, V30, P1307, DOI 10.1021/ie00054a035
   Duineveld P. C., 1994, THESIS
   Ekambara K, 2007, CHEM ENG SCI, V62, P7205, DOI 10.1016/j.ces.2007.08.048
   Fitch AW, 2005, CHEM ENG J, V112, P197, DOI 10.1016/j.cej.2005.07.013
   Gaidhani HK, 2005, CHEM ENG RES DES, V83, P640, DOI 10.1205/cherd.04355
   Hagesaether L, 2002, CHEM ENG SCI, V57, P3251, DOI 10.1016/S0009-2509(02)00197-5
   HARRISON STL, 1992, CHEM ENG SCI, V47, P490, DOI 10.1016/0009-2509(92)80039-F
   Harvey AP, 2001, IND ENG CHEM RES, V40, P5371, DOI 10.1021/ie0011223
   HOUNSLOW MJ, 1988, AICHE J, V34, P1821, DOI 10.1002/aic.690341108
   Jian H, 2005, CHEM ENG RES DES, V83, P1163, DOI 10.1205/cherd.03312
   Kacker R, 2017, CHEM ENG J, V317, P413, DOI 10.1016/j.cej.2017.02.007
   KONNO M, 1982, J CHEM ENG JPN, V15, P131, DOI 10.1252/jcej.15.131
   Lawton S, 2009, ORG PROCESS RES DEV, V13, P1357, DOI 10.1021/op900237x
   Lehr F, 2001, CHEM ENG SCI, V56, P1159, DOI 10.1016/S0009-2509(00)00335-3
   Liao YX, 2009, CHEM ENG SCI, V64, P3389, DOI 10.1016/j.ces.2009.04.026
   LITSTER JD, 1995, AICHE J, V41, P591
   Lobry E, 2015, CHEM ENG J, V259, P505, DOI 10.1016/j.cej.2014.08.014
   Luo H., 1993, THESIS
   Manninen M, 2013, J CHEM TECHNOL BIOT, V88, P553, DOI 10.1002/jctb.3979
   Ni X, 1998, CHEM ENG RES DES, V76, P635, DOI 10.1205/026387698525162
   Ni X, 2002, CHEM ENG SCI, V57, P2849, DOI 10.1016/S0009-2509(02)00081-7
   Ni X, 1999, CHEM ENG SCI, V54, P841, DOI 10.1016/S0009-2509(98)00279-6
   Ni X, 1997, CHEM ENG SCI, V52, P3209, DOI 10.1016/S0009-2509(97)00104-8
   Ni X, 2001, AICHE J, V47, P1746, DOI 10.1002/aic.690470807
   Ni X, 2001, CHEM ENG RES DES, V79, P33, DOI 10.1205/026387601528507
   Ni XW, 2008, CRYST GROWTH DES, V8, P2875, DOI 10.1021/cg7012039
   Ni XW, 2010, CHEM ENG J, V156, P226, DOI 10.1016/j.cej.2009.10.045
   Ni XW, 2002, POWDER TECHNOL, V124, P281, DOI 10.1016/S0032-5910(02)00022-0
   Ni XW, 1996, J CHEM TECHNOL BIOT, V65, P65, DOI 10.1002/(SICI)1097-4660(199601)65:1<65::AID-JCTB352>3.0.CO;2-1
   Ni XW, 2001, CAN J CHEM ENG, V79, P444, DOI 10.1002/cjce.5450790318
   Oliveira MSN, 2003, J CHEM TECHNOL BIOT, V78, P220, DOI 10.1002/jctb.755
   Pacek AW, 1998, CHEM ENG SCI, V53, P2005, DOI 10.1016/S0009-2509(98)00068-2
   Pakzad L, 2008, CHEM ENG PROCESS, V47, P2218, DOI 10.1016/j.cep.2007.12.003
   Ranade V.V., 2002, COMPUTATIONAL FLOW M
   RANDOLPH AD, 1971, THEORY PARTICULATE P
   Rao NVR, 2000, CAN J CHEM ENG, V78, P261, DOI 10.1002/cjce.5450780133
   Reis N, 2004, CHEM ENG SCI, V59, P4967, DOI 10.1016/j.ces.2004.09.013
   Roudsari S. F, 2015, THESIS
   Roudsari SF, 2012, COMPUT CHEM ENG, V45, P124, DOI 10.1016/j.compchemeng.2012.06.013
   Schiller L., 1935, Z VER DTSCH ING, V77, P318
   Schutz S, 2009, CHEM ENG SCI, V64, P3935, DOI 10.1016/j.ces.2009.04.046
   Siddique H, 2015, ORG PROCESS RES DEV, V19, P1871, DOI 10.1021/acs.oprd.5b00127
   SOBEY IJ, 1985, J FLUID MECH, V151, P395, DOI 10.1017/S0022112085001021
   Spicer PT, 1996, AICHE J, V42, P1612, DOI 10.1002/aic.690420612
   Taivassalo V, 1996, USITC PUBL, V288
   Versteeg H. K., 2007, INTRO COMPUTATIONAL
NR 50
TC 3
Z9 3
U1 5
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 552
EP 570
DI 10.1016/j.ces.2019.01.005
PG 19
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700047
DA 2020-05-12
ER

PT J
AU Boettcher, R
   Eichmann, S
   Mueller, P
AF Boettcher, Ronny
   Eichmann, Sascha
   Mueller, Peter
TI Influence of viscous damping and elastic waves on energy dissipation
   during impacts
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Elastic waves; Viscoelasticity; Impact; Coefficient of restitution;
   Energy dissipation; Contact model
ID COEFFICIENT; RESTITUTION; SPHERES; MODEL
AB For impacts on plane surfaces (plates), the coefficient of restitution or more precisely, the energy dissipation due to elastic waves (Rayleigh, longitudinal, transverse and flexural waves) on the one hand and due to viscoelastic properties on the other hand is calculated, analysed and experimentally investigated. Models concerning elastic waves (Zener, Hunter) and their modifications introduced by us within our latest publications (Boettcher et al., 2016, 2017a, 2017b), which (like the majority of the models in literature) are related to spheres and parabolically impinging bodies, are briefly summarized and extended for the impact of cones to achieve a more realistic description of impact processes and a better understanding of the physical relations.
   The bending model of Zener is described on the basis of rheological models (contact model) and a simple, general viscoelastic model for a sphere is introduced. Furthermore, two different variants of a combined model are derived with which the coefficient of restitution based on flexural waves (inelasticity parameter lambda) and viscoelastic properties (viscoelastic inelasticity parameter xi) can be calculated. Likewise, analytically approximate solutions are derived. In chemical and process engineering, the proposed approach enables for instance a better description of the impact process between (elastic-plastic) granules or particles with viscous properties (e.g., gamma-Al2O3 or synthetic granules) and thin apparatus walls at which flexural waves as well as viscous damping can depict a (decisive) role (fluidized bed, pneumatic conveying).
   First experimental evaluations show the extent to which viscoelasticity depends on the individual materials and the influence of viscoelasticity within the range of the (developing) flexural wave. The combined model shows a qualitative good agreement to the experimental measurements, but also an increasing deviation from the experimental values with increasing viscous damping. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Boettcher, Ronny; Mueller, Peter] Otto von Guericke Univ, Mech Proc Engn, Univ Pl 2, D-39106 Magdeburg, Germany.
   [Eichmann, Sascha] Eberhard Karls Univ Tuebingen, Math Sci Fac, Morgenstelle 10, D-72076 Tubingen, Germany.
RP Mueller, P (reprint author), Otto von Guericke Univ, Mech Proc Engn, Univ Pl 2, D-39106 Magdeburg, Germany.
EM ronny.boettcher@ovgu.de; sascha.eichmann@math.uni-tuebingen.de;
   peter.mueller@ovgu.de
FU German Research Foundation (DFG)German Research Foundation (DFG) [TO
   156/40-1]
FX The authors thank their co-worker Farhad Jebelisinaki and their students
   (Steffi Wuensche and Raphael Busse) who have participated in the
   development of this work. The authors also thank the German Research
   Foundation (DFG) for the financial support of this study within the
   framework of the Research Grant: TO 156/40-1 "Statische und dynamische
   Beanspruchung elastischer, plastischer und viskoser Granulate".
CR Aman S, 2016, ADV POWDER TECHNOL, V27, P1244, DOI 10.1016/j.apt.2016.04.012
   Boettcher R, 2017, INT J IMPACT ENG, V104, P45, DOI 10.1016/j.ijimpeng.2017.02.012
   Boettcher R, 2017, INT J SOLIDS STRUCT, V106, P229, DOI 10.1016/j.ijsolstr.2016.11.016
   Bottcher R, 2016, CHEM-ING-TECH, V88, P1002, DOI 10.1002/cite.201500155
   Brilliantov NV, 1996, PHYS REV E, V53, P5382, DOI 10.1103/PhysRevE.53.5382
   Cremer L, 2010, KORPERSCHALL PHYSIKA
   Foelsing A, 1997, HEINRICH HERTZ BIOGR
   Giesekus H., 1994, PHANOMENOLOGISCHE RH
   Hertz H., 1881, J REINE ANGEW MATH, V92, P156, DOI DOI 10.1515/CRIL.1882.92.156>
   HUNTER SC, 1957, J MECH PHYS SOLIDS, V5, P162, DOI 10.1016/0022-5096(57)90002-9
   HUTCHINGS IM, 1979, J PHYS D APPL PHYS, V12, P1819, DOI 10.1088/0022-3727/12/11/010
   Koller M. G, 1983, 7299 ETH
   KOLLER MG, 1987, INT J SOLIDS STRUCT, V23, P1387, DOI 10.1016/0020-7683(87)90004-7
   KUWABARA G, 1987, JPN J APPL PHYS 1, V26, P1230, DOI 10.1143/JJAP.26.1230
   Lamb H, 1917, P R SOC LOND A-CONTA, V93, P114, DOI 10.1098/rspa.1917.0008
   Meinhard H, 1999, THESIS
   Mueller P, 2011, THESIS
   Muller P, 2015, POWDER TECHNOL, V278, P138, DOI 10.1016/j.powtec.2015.03.023
   Pahl M., 1995, PRAKTISCHE RHEOLOGIE
   Popov VL, 2010, KONTAKTMECHANIK REIB
   Raman CV, 1920, PHYS REV, V15, P277, DOI 10.1103/PhysRev.15.277
   Ramirez R, 1999, PHYS REV E, V60, P4465, DOI 10.1103/PhysRevE.60.4465
   Rayleigh L., 1885, P LOND MATH SOC, V1, P4, DOI DOI 10.1112/PLMS/S1-17.1.4
   REED J, 1985, J PHYS D APPL PHYS, V18, P2329, DOI 10.1088/0022-3727/18/12/004
   Schafer J, 1996, J PHYS I, V6, P5, DOI 10.1051/jp1:1996129
   Schwager T, 2007, GRANUL MATTER, V9, P465, DOI 10.1007/s10035-007-0065-z
   Sibanc R, 2013, CHEM ENG SCI, V86, P50, DOI 10.1016/j.ces.2012.04.037
   True M, 2018, MEAS SCI TECHNOL, V29, DOI 10.1088/1361-6501/aadb67
   Weir G, 2005, CHEM ENG SCI, V60, P3637, DOI 10.1016/j.ces.2005.01.040
   Wu C., 2001, THESIS
   Wu CY, 2005, INT J IMPACT ENG, V32, P593, DOI 10.1016/j.ijimpeng.2005.08.007
   Zener C, 1941, PHYS REV, V59, P669, DOI 10.1103/PhysRev.59.669
NR 32
TC 1
Z9 1
U1 8
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 571
EP 587
DI 10.1016/j.ces.2019.01.036
PG 17
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700048
DA 2020-05-12
ER

PT J
AU Liu, L
   Bai, BF
AF Liu, Li
   Bai, Bofeng
TI Flow regime identification of swirling gas-liquid flow with image
   processing technique and neural networks
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Swirling gas-liquid flow; Flow regime map; Liquid holdup; Image
   processing; Neutral network
ID VERTICAL 2-PHASE FLOW; SEPARATION PERFORMANCE; PRESSURE-DROP;
   HEAT-TRANSFER; PATTERN; CLASSIFICATION; ENHANCEMENT; TRANSITIONS;
   FRACTION; SIGNALS
AB Swirling flow is one of the commonly-recognized techniques to control working processes in various engineering fields. A fundamental understanding of the swirling flow pattern is significantly important for proper design, operation and optimization of swirling flow systems. Although a large amount of work has been done on conventional non-swirling two-phase flow, investigations on swirling flow regime classification are still scarce. In this paper, a visualization experiment was carried out to study the gas-liquid flow in a vertical pipe containing a swirler with four helical vanes. The typical flow regimes in swirling gas-liquid flow were first classified and defined by visual observation. Subsequently, the liquid holdup was measured with the proposed image processing technique and statistically analyzed through PDF and CPDF. Owing to its integral and stable feature, CPDF was then utilized along with a self-organizing neural network (SONN) to identify the swirling flow regimes objectively. Finally, a swirling flow regime map was proposed and compared with the previous non-swirling and swirling maps available in the publications. Based on this study, the influence of the centrifugal force on phase distribution of gas-liquid flow was clarified and the general relationship between swirling gas-liquid flow and non-swirling gasliquid flow was concluded. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Li] Shanghai Jiao Tong Univ, Sch Nucl Sci & Engn, Shanghai 200240, Peoples R China.
   [Liu, Li; Bai, Bofeng] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
RP Bai, BF (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
EM bfbai@mail.xjtu.edu.cn
RI bai, bofeng/C-7663-2011
FU China National Funds for Distinguished Young ScientistsNational Natural
   Science Foundation of China [51425603]
FX The China National Funds for Distinguished Young Scientists under Grant
   No. 51425603 is acknowledged for supporting this study.
CR Baker O., 1954, OIL GAS J, V53, P185, DOI DOI 10.2118/323-G
   Chang SW, 2009, EXP THERM FLUID SCI, V33, P1087, DOI 10.1016/j.expthermflusci.2009.06.005
   Chen SW, 2012, PROCEEDINGS OF THE 20TH INTERNATIONAL CONFERENCE ON NUCLEAR ENGINEERING AND THE ASME 2012 POWER CONFERENCE - 2012, VOL 3, P467
   Julia JE, 2011, INT J HEAT FLUID FL, V32, P164, DOI 10.1016/j.ijheatfluidflow.2010.09.003
   Figueiredo MMF, 2016, EXP THERM FLUID SCI, V70, P29, DOI 10.1016/j.expthermflusci.2015.08.010
   FRYER PJ, 1982, INT J MULTIPHAS FLOW, V8, P285, DOI 10.1016/0301-9322(82)90037-4
   Funahashi H, 2016, NUCL ENG DES, V308, P205, DOI 10.1016/j.nucengdes.2016.08.030
   Ghosh S, 2012, CHEM ENG SCI, V84, P417, DOI 10.1016/j.ces.2012.08.042
   Goda H., 2002, P 10 INT C NUCL ENG
   Gomez L, 2004, J FLUID ENG-T ASME, V126, P943, DOI 10.1115/1.1849254
   Hamdani A, 2016, J MECH SCI TECHNOL, V30, P3897, DOI 10.1007/s12206-016-0801-6
   Hernandez L, 2006, MEAS SCI TECHNOL, V17, P1511, DOI 10.1088/0957-0233/17/6/032
   Hewitt G, 1970, ANNULAR 2 PHASE FLOW
   Hewitt G.F., 1969, M2159 UKAEA AERE
   Hreiz R, 2014, INT J MULTIPHAS FLOW, V58, P15, DOI 10.1016/j.ijmultiphaseflow.2013.08.006
   Imao S, 1996, INT J HEAT FLUID FL, V17, P444, DOI 10.1016/0142-727X(96)00057-4
   Jafari M, 2017, APPL THERM ENG, V124, P883, DOI 10.1016/j.applthermaleng.2017.06.095
   Jones O. C.  Jr., 1975, International Journal of Multiphase Flow, V2, P273, DOI 10.1016/0301-9322(75)90015-4
   Julia JE, 2008, NUCL ENG DES, V238, P156, DOI 10.1016/j.nucengdes.2007.05.005
   Kanizawa FT, 2012, INT J MULTIPHAS FLOW, V47, P50, DOI 10.1016/j.ijmultiphaseflow.2012.07.003
   KATAOKA H, 2008, J POWER ENERGY SYST, V2, P1120
   Kawahara A, 2002, INT J MULTIPHAS FLOW, V28, P1411, DOI 10.1016/S0301-9322(02)00037-X
   KELESSIDIS VC, 1989, INT J MULTIPHAS FLOW, V15, P173, DOI 10.1016/0301-9322(89)90069-4
   Lee JY, 2008, INT J HEAT MASS TRAN, V51, P3442, DOI 10.1016/j.ijheatmasstransfer.2007.10.037
   Li ZX, 2018, INT J HEAT MASS TRAN, V118, P812, DOI 10.1016/j.ijheatmasstransfer.2017.11.037
   Liang FC, 2017, AICHE J, V63, P2348, DOI 10.1002/aic.15570
   Liang F, 2014, EXP THERM FLUID SCI, V59, P43, DOI 10.1016/j.expthermflusci.2014.07.013
   Ling XX, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.10.108001
   Liu L, 2017, INTERFACIAL PHENOM H, V5, P9, DOI 10.1615/InterfacPhenomHeatTransfer.2018021108
   Liu L, 2016, NUCL ENG DES, V298, P229, DOI 10.1016/j.nucengdes.2016.01.001
   Liu W., 2014, P ASME FEDSM 2014
   Liu W, 2015, EXP THERM FLUID SCI, V68, P187, DOI 10.1016/j.expthermflusci.2015.04.018
   Magaud F, 2003, J FLUID ENG-T ASME, V125, P239, DOI 10.1115/1.1539870
   Mandhane J. M., 1974, International Journal of Multiphase Flow, V1, P537, DOI 10.1016/0301-9322(74)90006-8
   Matsubayashi T, 2012, NUCL ENG DES, V249, P63, DOI 10.1016/j.nucengdes.2011.05.036
   Mi Y, 2001, NUCL ENG DES, V204, P87, DOI 10.1016/S0029-5493(00)00325-3
   MISHIMA K, 1984, INT J HEAT MASS TRAN, V27, P723
   Mohanraj M, 2015, INT J THERM SCI, V90, P150, DOI 10.1016/j.ijthermalsci.2014.11.030
   Murai Y, 2006, NUCL ENG DES, V236, P94, DOI 10.1016/j.nucengdes.2005.04.011
   NAMIE S, 1993, INT J MULTIPHAS FLOW, V19, P91, DOI 10.1016/0301-9322(93)90025-P
   Omebere-Iyar NK, 2007, CHEM ENG RES DES, V85, P180, DOI 10.1205/cherd05059
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pan LM, 2015, INT J HEAT MASS TRAN, V89, P165, DOI 10.1016/j.ijheatmasstransfer.2015.05.073
   Paranjape S, 2011, J FLUID ENG-T ASME, V133, DOI 10.1115/1.4004836
   Raeiszadeh F, 2018, CHEM ENG RES DES, V137, P10, DOI 10.1016/j.cherd.2018.07.002
   Raeiszadeh F, 2016, INT J MULTIPHAS FLOW, V81, P1, DOI 10.1016/j.ijmultiphaseflow.2016.01.002
   Rocha AD, 2015, INT J HEAT FLUID FL, V53, P81, DOI 10.1016/j.ijheatfluidflow.2015.02.003
   Roman AJ, 2016, INT COMMUN HEAT MASS, V71, P254, DOI 10.1016/j.icheatmasstransfer.2015.12.033
   Rosa ES, 2010, INT J MULTIPHAS FLOW, V36, P738, DOI 10.1016/j.ijmultiphaseflow.2010.05.001
   SANTOSO B, 2012, MOD APPL SCI, V6, P56
   Schlegel JP, 2009, NUCL ENG DES, V239, P2864, DOI 10.1016/j.nucengdes.2009.08.004
   Schubring D, 2010, INT J MULTIPHAS FLOW, V36, P815, DOI 10.1016/j.ijmultiphaseflow.2010.05.007
   Shaban H, 2014, INT J MULTIPHAS FLOW, V67, P106, DOI 10.1016/j.ijmultiphaseflow.2014.08.012
   Shakutsui H., 2000, P 4 JSME KSME THERM, P69
   Shakutsui H, 2010, JPN J MULTIPHASE FLO, V24, P305
   Sheikholeslami M, 2015, RENEW SUST ENERG REV, V49, P444, DOI 10.1016/j.rser.2015.04.113
   Xie T, 2004, CHEM ENG SCI, V59, P2241, DOI 10.1016/j.ces.2004.02.017
   Xiong ZQ, 2014, ANN NUCL ENERGY, V63, P138, DOI 10.1016/j.anucene.2013.07.026
   Yin JL, 2016, ANN NUCL ENERGY, V97, P1, DOI 10.1016/j.anucene.2016.06.018
   Zhang Z., 2018, ADV MECH ENG, V10, P1, DOI DOI 10.1109/TGRS.2018.2830100
NR 60
TC 8
Z9 8
U1 16
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 588
EP 601
DI 10.1016/j.ces.2019.01.037
PG 14
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700049
DA 2020-05-12
ER

PT J
AU Kharaghani, A
   Le, KH
   Tran, TTH
   Tsotsas, E
AF Kharaghani, Abdolreza
   Kieu Hiep Le
   Thi Thu Hang Tran
   Tsotsas, Evangelos
TI Reaction engineering approach for modeling single wood particle drying
   at elevated air temperature
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reaction engineering approach; Continuum model; Drying kinetics; Single
   wood particle; Elevated temperature
ID POROUS-MEDIA; MASS; CFD; KINETICS; HEAT
AB In this paper, a semi-empirical drying model for convective drying of a single wood particle at elevated temperature is developed based on the reaction engineering approach (REA). The parameter of this model is determined and verified against both experimental and numerical data. The method proposed to identify the REA model parameter operates as follows: the evolution of the moisture content of a single wood particle over time is measured accurately by using a magnetic suspension balance. A continuum-scale model that takes into account major transport mechanisms relevant to wood particle drying is developed within the frame of volume averaging approach. Continuum model predictions are successfully assessed against the measurements conducted at four different inlet gas temperatures. A set of numerical simulation results obtained at 120 degrees C is used to deduce the REA model parameter. The fact that the REA model can fairly well reflect the experimental data at higher drying temperatures, i.e. 140 degrees C, 160 degrees C and 180 degrees C, is used to evaluate the accuracy of the REA model parameter. The REA model is also assessed using the continuum model simulations which are obtained for particles of different dimeters (2-20 mm) in a wide range of drying conditions (initial moisture content varies between 0.3 kg water/kg dry solid and 0.6 kg water/kg dry solid and air velocity between 0.005 m/s and 5 m/s). The results indicate that the REA model parameter is insensitive to variations of the drying conditions with an exception of inlet air velocity. The developed REA model can thus be considered as a simple predictive tool for drying of wood particles in a wide range of process conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kharaghani, Abdolreza; Tsotsas, Evangelos] Otto von Guericke Univ, Thermal Proc Engn, Magdeburg, Germany.
   [Kieu Hiep Le; Thi Thu Hang Tran] Hanoi Univ Sci & Technol, Sch Heat Engn & Refrigerat, Heat Engn Dept, 01 Dai Co Viet St, Hanoi, Vietnam.
RP Le, KH (reprint author), Hanoi Univ Sci & Technol, Sch Heat Engn & Refrigerat, Heat Engn Dept, 01 Dai Co Viet St, Hanoi, Vietnam.
EM hiep.lekieu@hust.edu.vn
RI Tsotsas, Evangelos/E-6610-2013; Kharaghani, Abdolreza/AAM-7292-2020
OI Tsotsas, Evangelos/0000-0001-9575-1138; Le, Kieu
   Hiep/0000-0003-0620-7021
FU Forschungs-Gesellschaft Verfahrens-Technik [18971 BR/1]
FX The experimental part of this study has been conducted in the frame of
   Forschungs-Gesellschaft Verfahrens-Technik funded project (IGF-No. 18971
   BR/1) with the help of Dr.-Ing. Nelli Hampel.
CR Burgschweiger J, 1999, CAN J CHEM ENG, V77, P333, DOI 10.1002/cjce.5450770220
   Burgschweiger J, 2002, CHEM ENG SCI, V57, P5021, DOI 10.1016/S0009-2509(02)00424-4
   Chen HY, 2016, CONSTR BUILD MATER, V126, P130, DOI 10.1016/j.conbuildmat.2016.09.027
   Chen XD, 2015, DRY TECHNOL, V33, P1899, DOI 10.1080/07373937.2015.1069326
   Ertekin C, 2017, CRIT REV FOOD SCI, V57, P701, DOI 10.1080/10408398.2014.910493
   Fyhr C, 1998, DRY TECHNOL, V16, P1339, DOI 10.1080/07373939808917465
   Groenewold C, 2002, CHEM ENG J, V86, P217, DOI 10.1016/S1385-8947(01)00292-3
   Groenewold H, 2007, CHEM ENG SCI, V62, P481, DOI 10.1016/j.ces.2006.09.017
   Vu HT, 2018, INT J CHEM ENG, DOI 10.1155/2018/9456418
   Kemp IC, 2019, DRY TECHNOL, V37, P475, DOI 10.1080/07373937.2018.1463244
   Kucuk H, 2014, DRY TECHNOL, V32, P757, DOI 10.1080/07373937.2013.873047
   Langrish TAG, 2009, J FOOD ENG, V93, P218, DOI 10.1016/j.jfoodeng.2009.01.019
   Le KH, 2018, DRY TECHNOL, V36, P1866, DOI 10.1080/07373937.2018.1444633
   Le KH, 2018, INT J HEAT MASS TRAN, V124, P1033, DOI 10.1016/j.ijheatmasstransfer.2018.04.032
   Le KH, 2017, DRY TECHNOL, V35, P1584, DOI 10.1080/07373937.2016.1264414
   Moghaddam AA, 2017, WATER RESOUR RES, V53, P10433, DOI 10.1002/2017WR021162
   Mujumdar A. S., 2014, HDB IND DRYING
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   Pel L, 1996, INT J HEAT MASS TRAN, V39, P1273, DOI 10.1016/0017-9310(95)00201-4
   Perre P, 1999, INT J HEAT MASS TRAN, V42, P4501, DOI 10.1016/S0017-9310(99)00098-8
   Perre P, 2015, DRY TECHNOL, V33, P1949, DOI 10.1080/07373937.2015.1076836
   Putranto A, 2016, INT J FOOD PROP, V19, P1726, DOI 10.1080/10942912.2014.999863
   Putranto A, 2014, PROCEDIA CHEM, V9, P77, DOI 10.1016/j.proche.2014.05.010
   Putranto A, 2011, CHEM ENG SCI, V66, P2149, DOI 10.1016/j.ces.2011.02.025
   Redman AL, 2017, WOOD SCI TECHNOL, V51, P701, DOI 10.1007/s00226-017-0908-7
   Sepehri A, 2018, CHEM ENG PROCESS, V128, P10, DOI 10.1016/j.cep.2018.04.006
   Tran TTH, 2017, DRY TECHNOL, V35, P1571, DOI 10.1080/07373937.2016.1263204
   Tsotsas E, 2015, DRY TECHNOL, V33, P1859, DOI 10.1080/07373937.2015.1047954
   Tsotsas E, 2009, MODERN DRYING TECHNOLOGY, VOL 2: EXPERIMENTAL TECHNIQUES, P1
   VDI-Gesellschaft Energietechnik, 2010, HEAT ATLAS
   Vu H. T., 2006, THESIS
   WHITAKER S, 1977, ADV HEAT TRANSFER, V13, P119
   Woo MW, 2008, CHEM ENG RES DES, V86, P1038, DOI 10.1016/j.cherd.2008.04.003
   Woo MW, 2008, DRY TECHNOL, V26, P1180, DOI 10.1080/07373930802306953
NR 34
TC 2
Z9 2
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 602
EP 612
DI 10.1016/j.ces.2019.01.042
PG 11
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700050
DA 2020-05-12
ER

PT J
AU Su, JW
   Chai, GL
   Wang, L
   Cao, WD
   Gu, ZL
   Chen, CG
   Xu, XY
AF Su, Junwei
   Chai, Guoliang
   Wang, Le
   Cao, Weidong
   Gu, Zhaolin
   Chen, Chungang
   Xu, Xiao Yun
TI Pore-scale direct numerical simulation of particle transport in porous
   media
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluid-particle flow; Pore scale; Fictitious domain method; Discrete
   element method
ID IMMERSED-BOUNDARY METHOD; DISCRETE ELEMENT SIMULATION; FICTITIOUS DOMAIN
   APPROACH; FLOWS; BED; CFD; DEM; DEPOSITION; DISPERSION; ALGORITHM
AB A computational platform for direct numerical simulation of fluid-particle two-phase flow in porous media is presented in this study. In the proposed platform, the Navier-Stokes equations are used to describe the motion of the continuous phase, while the discrete element method (DEM) is employed to evaluate particle-particle and particle-wall interactions, with a fictitious domain method being adopted to evaluate particle-fluid interactions. Particle-wall contact states are detected by the ERIGID scheme. Moreover, a new scheme, namely, base point-increment method is developed to improve the accuracy of particle tracking in porous media. In order to improve computationally efficiency, a time splitting strategy is applied to couple the fluid and DEM solvers, allowing different time steps to be used which are adaptively determined according to the stability conditions of each solver. The proposed platform is applied to particle transport in a porous medium with its pore structure being reconstructed from micro-CT scans from a real rock. By incorporating the effect of pore structure which has a comparable size to the particles, numerical results reveal a number of distinct microscopic flow mechanisms and the corresponding macroscopic characteristics. The time evolution of the inlet to outlet pressure-difference consists of large-scale spikes and small-scale fluctuations. Apart from the influence through direct contacts between particles, the motion of a particle can also be affected by particles without contact through blocking a nearby passage for fluid flow. Particle size has a profound influence on the macroscopic motion behavior of particles. Small particles are easier to move along the main stream and less dispersive in the direction perpendicular to the flow than large particles. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Su, Junwei; Chai, Guoliang; Gu, Zhaolin] Xi An Jiao Tong Univ, Sch Human Settlement & Civil Engn, Xian 710049, Shaanxi, Peoples R China.
   [Wang, Le] Xian Shiyou Univ, Mech Engn Coll, Xian 710049, Shaanxi, Peoples R China.
   [Cao, Weidong] Sinopec Grp, Shengli Oilfield Co, Res Inst Explorat & Dev, Dongying 257015, Peoples R China.
   [Chen, Chungang] Xi An Jiao Tong Univ, Sch Aerosp, Xian 710049, Shaanxi, Peoples R China.
   [Chen, Chungang] Xi An Jiao Tong Univ, State Key Lab Strength & Vibrat Mech Struct, Xian 710049, Shaanxi, Peoples R China.
   [Xu, Xiao Yun] Imperial Coll London, Dept Chem Engn, London SW7 2AZ, England.
RP Chen, CG (reprint author), Xi An Jiao Tong Univ, Sch Aerosp, Xian 710049, Shaanxi, Peoples R China.; Chen, CG (reprint author), Xi An Jiao Tong Univ, State Key Lab Strength & Vibrat Mech Struct, Xian 710049, Shaanxi, Peoples R China.
EM cgchen@mail.xjtu.edu.cn
OI Su, Junwei/0000-0001-5185-3976
FU National Science and Technology Major Project [2016ZX05011003]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [21306145]
FX This work is supported by National Science and Technology Major Project
   (No. 2016ZX05011003) and National Natural Science Foundation of China
   (No. 21306145).
CR Boccardo G, 2014, J COLLOID INTERF SCI, V417, P227, DOI 10.1016/j.jcis.2013.11.007
   Chen H, 2015, INT J NUMER METH ENG, V103, P598, DOI 10.1002/nme.4913
   CRANK J, 1947, P CAMB PHILOS SOC, V43, P50, DOI 10.1017/S0305004100023197
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Deen NG, 2013, IND ENG CHEM RES, V52, P11266, DOI 10.1021/ie303411k
   Deng J, 2006, INT J NUMER METH FL, V52, P1195, DOI 10.1002/fld.1237
   Fallah H., 2012, GEOMATERIALS, V2, P57, DOI DOI 10.4236/gm.2012.23009
   Gallier S, 2014, J COMPUT PHYS, V256, P367, DOI 10.1016/j.jcp.2013.09.015
   Ge W, 2017, REV CHEM ENG, V33, P551, DOI 10.1515/revce-2015-0079
   Gitis V, 2010, CHEM ENG J, V163, P78, DOI 10.1016/j.cej.2010.07.044
   Glowinski R, 2001, J COMPUT PHYS, V169, P363, DOI 10.1006/jcph.2000.6542
   Glowinski R., 2015, COMPUT METHODS APPL, V30, P1043
   ISSA RI, 1986, J COMPUT PHYS, V62, P40, DOI 10.1016/0021-9991(86)90099-9
   Jasak H, 1999, INT J NUMER METH FL, V31, P431, DOI 10.1002/(SICI)1097-0363(19990930)31:2<431::AID-FLD884>3.0.CO;2-T
   Jung J, 2018, MICROSYST TECHNOL, V24, P1071, DOI 10.1007/s00542-017-3462-1
   Kang S. -W., 2010, THESIS
   Kempe T, 2012, J COMPUT PHYS, V231, P3663, DOI 10.1016/j.jcp.2012.01.021
   Kleinstreuer Clement, 2014, World J Clin Cases, V2, P742, DOI 10.12998/wjcc.v2.i12.742
   Kuang SB, 2008, INT J MULTIPHAS FLOW, V34, P1023, DOI 10.1016/j.ijmultiphaseflow.2008.06.007
   Lima E Silva ALF, 2003, J COMPUT PHYS, V189, P351, DOI 10.1016/S0021-9991(03)00214-6
   Lu J., 2018, CHEM ENG SCI, V81, P329
   Macpherson GB, 2009, COMMUN NUMER METH EN, V25, P263, DOI 10.1002/cnm.1128
   Maniyeri R, 2014, INT J ENG RES, V3, P213
   McBride D, 2018, MINERALS-BASEL, V8, DOI 10.3390/min8010009
   Munjiza A, 1998, INT J NUMER METH ENG, V43, P131, DOI 10.1002/(SICI)1097-0207(19980915)43:1<131::AID-NME447>3.0.CO;2-S
   Nie BS, 2018, FUEL, V214, P272, DOI 10.1016/j.fuel.2017.10.084
   Papamichos E, 2001, INT J NUMER ANAL MET, V25, P789, DOI 10.1002/nag.154
   Qiu Y., 2014, SPE IMPR OIL REC S
   RHIE CM, 1983, AIAA J, V21, P1525, DOI 10.2514/3.8284
   Rougier E, 2004, INT J NUMER METH ENG, V61, P856, DOI 10.1002/nme.1092
   Shapiro AA, 2010, PHYSICA A, V389, P2473, DOI 10.1016/j.physa.2010.02.049
   Shigeto Y, 2013, CHEM ENG J, V231, P464, DOI 10.1016/j.cej.2013.07.073
   Su J., 2016, INT J POLYM SCI, V1, P1
   Su JW, 2015, INT J NUMER METH ENG, V103, P759, DOI 10.1002/nme.4911
   Su JW, 2014, POWDER TECHNOL, V253, P393, DOI 10.1016/j.powtec.2013.12.009
   Su JW, 2011, CHEM ENG SCI, V66, P6069, DOI 10.1016/j.ces.2011.08.025
   Su SW, 2007, COMPUT FLUIDS, V36, P313, DOI 10.1016/j.compfluid.2005.09.004
   Sun R, 2015, INT J MULTIPHAS FLOW, V77, P142, DOI 10.1016/j.ijmultiphaseflow.2015.08.014
   TSUJI Y, 1992, POWDER TECHNOL, V71, P239, DOI 10.1016/0032-5910(92)88030-L
   Uhlmann M, 2005, J COMPUT PHYS, V209, P448, DOI 10.1016/j.jcp.2005.03.017
   Wan DC, 2007, J COMPUT APPL MATH, V203, P561, DOI 10.1016/j.cam.2006.04.021
   Wang ZL, 2008, INT J MULTIPHAS FLOW, V34, P283, DOI 10.1016/j.ijmultiphaseflow.2007.10.004
   Xu L, 2018, CHEM ENG SCI, V183, P60, DOI 10.1016/j.ces.2018.02.050
   Yang SL, 2014, AICHE J, V60, P2788, DOI 10.1002/aic.14494
   Yang SL, 2014, CHEM ENG J, V236, P158, DOI 10.1016/j.cej.2013.09.082
   Zamani A, 2009, J PETROL SCI ENG, V69, P71, DOI 10.1016/j.petrol.2009.06.016
   Zhang H, 2018, POWDER TECHNOL, V332, P79, DOI 10.1016/j.powtec.2018.03.055
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
NR 48
TC 9
Z9 10
U1 10
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 613
EP 627
DI 10.1016/j.ces.2019.01.033
PG 15
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700051
DA 2020-05-12
ER

PT J
AU Pease, LF
   Daniel, RC
   Burns, CA
AF Pease, Leonard F.
   Daniel, Richard C.
   Burns, Carolyn A.
TI Slurry rheology of Hanford sludge
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Radioactive waste; High ionic strength slurries; Yield stress;
   Polydispersed slurries; Environmental sustainability
ID RICE STARCH MIXTURES; YIELD-STRESS; GUAR GALACTOMANNAN; BULK STRESS;
   SUSPENSIONS; YODEL; MODEL
AB This article evaluates the slurry viscosity of radioactive waste. Hanford waste is a motley mixture of particle sizes and densities composed of metal and oxide particles with constituents spanning much of the periodic table stored at high ionic strength and high pH. Hanford wastes have traditionally been represented as simply an ideal Bingham plastic, but this rheological approximation often provides a poor fit from 0 to 200 1/s, precisely the range of interest for engineering design of waste transport and mixing systems. A modified Cross formulation inclusive of a yield stress is used to fit stress-strain rate data for reconstituted Hanford REDOX sludge waste, measured by increasing shear-rate (up-ramp) and decreasing shear-rate (down-ramp) sweeps. This continuous single equation formulation quantitatively matches experimental data better than other rheological models including the Bingham plastic and Herschel-Bulkley approximations. The increase of viscosity and yield stress from up ramp to down ramp suggests the formation of particle microstructure during shear due to attractive forces. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Pease, Leonard F.; Daniel, Richard C.; Burns, Carolyn A.] Pacific Northwest Natl Lab, 902 Battelle Blvd,POB 999,MSIN K9-89, Richland, WA 99352 USA.
RP Pease, LF (reprint author), Pacific Northwest Natl Lab, 902 Battelle Blvd,POB 999,MSIN K9-89, Richland, WA 99352 USA.
EM fluids@pnnl.gov
FU Laboratory Directed Research and Development Program at PNNL, a
   multiprogram national laboratory [DE-AC05-76RLO 1830]
FX We gratefully acknowledge the generous provision of electronic data from
   Fiskum et al., (2008), Lumetta et al., (2009) and Shimskey et al.,
   (2009) and insightful conservations with Lenna Mahoney, Matt Fountain,
   Jacob Reynolds, and Judith Bamberger. A portion of this research was
   supported by the Laboratory Directed Research and Development Program at
   PNNL, a multiprogram national laboratory operated for the U.S.
   Department of Energy by Battelle Memorial Institute under Contract
   DE-AC05-76RLO 1830.
CR Auroux PA, 2002, ANAL CHEM, V74, P2637, DOI 10.1021/ac020239t
   Baharanchi AA, 2018, NUCL ENG DES, V332, P307, DOI 10.1016/j.nucengdes.2018.03.011
   BARNES HA, 1985, RHEOL ACTA, V24, P323, DOI 10.1007/BF01333960
   BATCHELOR GK, 1972, J FLUID MECH, V56, P401, DOI 10.1017/S0022112072002435
   BATCHELOR GK, 1977, J FLUID MECH, V83, P97, DOI 10.1017/S0022112077001062
   BUSCALL R, 1991, J CHEM SOC FARADAY T, V87, P1365, DOI 10.1039/ft9918701365
   CROSS MM, 1965, J COLL SCI IMP U TOK, V20, P417, DOI 10.1016/0095-8522(65)90022-X
   Devyatkov SY, 2016, IND ENG CHEM RES, V55, P6595, DOI 10.1021/acs.iecr.6b00820
   ELLWOOD KRJ, 1990, J RHEOL, V34, P787, DOI 10.1122/1.550144
   EVANS ID, 1992, J RHEOL, V36, P1313, DOI 10.1122/1.550262
   Fiskum S, 2008, PNNL17368
   Flatt RJ, 2006, J AM CERAM SOC, V89, P1244, DOI 10.1111/j.1551-2916.2005.00888.x
   Flatt RJ, 2007, J AM CERAM SOC, V90, P1038, DOI 10.1111/j.1551-2916.2007.01595.x
   Garg A, 2016, LANGMUIR, V32, P11837, DOI 10.1021/acs.langmuir.6b02824
   GAY EC, 1969, AICHE J, V15, P815, DOI 10.1002/aic.690150606
   HUSBAND DM, 1993, J RHEOL, V37, P215, DOI 10.1122/1.550442
   Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1
   KALYON DM, 1993, J RHEOL, V37, P35, DOI 10.1122/1.550435
   Krieger I. M., 1972, Advances in Colloid and Interface Science, V3, P111, DOI 10.1016/0001-8686(72)80001-0
   Larson RG, 1999, STRUCTURE RHEOLOGY C
   Lumetta G. J, 2009, PNNL17992
   Macosko CW, 1994, RHEOLOGY PRINCIPLES
   Mahoney L. A, 1995, PNL10695
   Nguyen V. C, 2016, RPPRPT59600 LLC
   Peterson RA, 2018, ENVIRON SCI TECHNOL, V52, P381, DOI 10.1021/acs.est.7b04077
   Rayment P, 1998, CARBOHYD POLYM, V35, P55, DOI 10.1016/S0144-8617(97)00231-2
   Rayment P, 1995, CARBOHYD POLYM, V28, P121, DOI 10.1016/0144-8617(95)00110-7
   Ren Y, 2003, CARBOHYD POLYM, V53, P401, DOI 10.1016/S0144-8617(03)00117-6
   Scales PJ, 1998, AICHE J, V44, P538, DOI 10.1002/aic.690440305
   Shimskey R. W, 2009, PNNL17965
   Stuer M, 2014, ADV ENG MATER, V16, P774, DOI 10.1002/adem.201400099
   Wells B. E, 2011, PNNL19250
   Wells BE, 2011, PNNL20646
   Wilson KC, 2010, CAN J CHEM ENG, V88, P179, DOI 10.1002/cjce.20267
   Zhou ZW, 2001, CHEM ENG SCI, V56, P2901, DOI 10.1016/S0009-2509(00)00473-5
NR 35
TC 2
Z9 2
U1 2
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 628
EP 634
DI 10.1016/j.ces.2018.12.044
PG 7
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700052
DA 2020-05-12
ER

PT J
AU Vandewalle, LA
   Lengyel, I
   West, DH
   Van Geem, KM
   Marin, GB
AF Vandewalle, Laurien A.
   Lengyel, Istvan
   West, David H.
   Van Geem, Kevin M.
   Marin, Guy B.
TI Catalyst ignition and extinction: A microkinetics-based bifurcation
   study of adiabatic reactors for oxidative coupling of methane
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Oxidative coupling of methane; Bifurcation analysis; Ignition;
   Extinction; Autothermal operation
ID STATISTICAL-ANALYSIS; OXIDE CATALYSTS; PERFORMANCE; CONVERSION;
   KINETICS; FUELS
AB Understanding ignition and extinction behavior is of crucial importance for oxidative coupling of methane (OCM). Therefore, for the first time the bifurcation behavior of OCM has been investigated while considering both homogeneous gas phase reactions and heterogeneous reactions using a detailed microkinetic model. Three different adiabatic reactor models are considered: a plug flow reactor (PFR), a continuously stirred tank reactor (CSTR) and a lumped thermal reactor (LTR) model. The latter represents the limiting case with zero backmixing (cf. PFR behavior) for species and perfect thermal backmixing (cf. CSTR behavior). For homogeneous processes this reactor type could for example be realized by adding a high thermal conductivity inert to the reactor tubes, for catalytic processes a high thermal conductivity catalyst could be used.
   The bifurcation behavior in these reactor types is compared with a focus on methane conversion, C-2 yields and their dependence on operating conditions such as inlet composition, inlet temperature and space time. Steady state multiplicity is observed for adiabatic CSTR and LTR models. This multiplicity of steady states is not observed for isothermal reactor models, indicating that it is caused solely by thermal backmixing and is not related to chemical feedback features such as autocatalysis. The start-up procedures or initial conditions determine the actual steady state that is obtained. Among the three investigated reactor types, a LTR shows the highest product yields and the lowest extinction temperatures, which allows autothermal operation at a much lower inlet temperature compared to a PFR and CSTR. For OCM without catalyst, autothermal operation on the ignited branch at ambient inlet temperatures and reasonable space times is only possible by using methane-to-oxygen ratios below 3 leading to low selectivities. For catalytic OCM compared to OCM without catalyst, the range for autothermal operation is much broader and it is much easier to find feasible operating conditions allowing autothermal operation at ambient inlet temperatures.
   By operating a LTR on the ignited branch at ambient inlet temperature of 300 K, methane-to-oxygen ratio CH4:O-2 = 6, space time V/F-CH4,F-0= 0.02 s, bulk density of Sn-Li/MgO = 1000 kg(cat)/m(3) and pressure P =1 bar, overall C-2 selectivities (i.e. sum of ethane, ethylene and acetylene selectivity) of 80% can be obtained at methane conversions as high as 30%. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Vandewalle, Laurien A.; Van Geem, Kevin M.; Marin, Guy B.] Univ Ghent, Lab Chem Technol, Technol Pk 914, B-9052 Ghent, Belgium.
   [Lengyel, Istvan; West, David H.] SABIC Technol & Innovat, Sugar Land, TX 77478 USA.
RP Van Geem, KM (reprint author), Univ Ghent, Lab Chem Technol, Technol Pk 914, B-9052 Ghent, Belgium.
EM Kevin.VanGeem@UGent.be
FU Fund for Scientific Research Flanders (FWO)FWO
FX LAV gratefully acknowledges financial support from a doctoral fellowship
   from the Fund for Scientific Research Flanders (FWO).
CR Alexiadis VI, 2014, APPL CATAL B-ENVIRON, V150, P496, DOI 10.1016/j.apcatb.2013.12.043
   Amghizar I, 2017, ENGINEERING-PRC, V3, P171, DOI 10.1016/J.ENG.2017.02.006
   ANNAPRAGADA AV, 1990, J CATAL, V123, P130, DOI 10.1016/0021-9517(90)90162-D
   Aseem A, 2018, CHEM ENG J, V331, P132, DOI 10.1016/j.cej.2017.08.093
   Balakotaiah V., 1996, CHEM ENG ED      FAL, V30, P234
   Balakotaiah V, 2014, CURR OPIN CHEM ENG, V5, P68, DOI 10.1016/j.coche.2014.05.002
   Berezowski M, 2000, CHEM ENG SCI, V55, P4291, DOI 10.1016/S0009-2509(00)00058-0
   CHEN Q, 1994, AICHE J, V40, P521, DOI 10.1002/aic.690400313
   CHEN Q, 1994, CATAL TODAY, V21, P309, DOI 10.1016/0920-5861(94)80152-5
   Couwenberg PM, 1996, IND ENG CHEM RES, V35, P3999, DOI 10.1021/ie9504617
   Couwenberg PM, 1996, IND ENG CHEM RES, V35, P415, DOI 10.1021/ie9502852
   Doedel E. J., 2007, AUTO 07P CONTINUATIO
   Froment G. F., 2011, CHEM REACTOR ANAL DE
   GRAY P, 1984, CHEM ENG SCI, V39, P1087, DOI 10.1016/0009-2509(84)87017-7
   HINSON PG, 1991, J CHEM SOC CHEM COMM, P1430, DOI 10.1039/c39910001430
   Jaso S, 2010, CHEM ENG SCI, V65, P6341, DOI 10.1016/j.ces.2010.08.019
   Jelemensky L, 1996, CHEM ENG SCI, V51, P1767, DOI 10.1016/0009-2509(96)00035-8
   Karakaya C, 2016, PROG ENERG COMBUST, V55, P60, DOI 10.1016/j.pecs.2016.04.003
   Kechagiopoulos PN, 2014, IND ENG CHEM RES, V53, P1825, DOI 10.1021/ie403160s
   KELLER GE, 1982, J CATAL, V73, P9, DOI 10.1016/0021-9517(82)90075-6
   Kondratenko E. V., 2008, HDB HETEROGENEOUS CA, DOI [10.1002/9783527610044.hetcat0152, DOI 10.1002/9783527610044.HETCAT0152]
   Kondratenko EV, 2017, CATAL SCI TECHNOL, V7, P366, DOI 10.1039/c6cy01879c
   Kondratenko EV, 2015, CATAL SCI TECHNOL, V5, P1668, DOI 10.1039/c4cy01443j
   Lee JY, 2013, FUEL, V106, P851, DOI 10.1016/j.fuel.2013.01.026
   LEE JS, 1989, KOREAN J CHEM ENG, V6, P54, DOI 10.1007/BF02698112
   Lengyel I, 2018, CURR OPIN CHEM ENG, V21, P41, DOI 10.1016/j.coche.2018.02.013
   Lunsford J.H., 1990, CATAL TODAY, V6, P235
   Lunsford JH, 2000, CATAL TODAY, V63, P165, DOI 10.1016/S0920-5861(00)00456-9
   Metcalfe WK, 2013, INT J CHEM KINET, V45, P638, DOI 10.1002/kin.20802
   National Academies of Sciences Medicine and Engineering, 2016, CHANG LANDSC HYDR FE, DOI [10.17226/23555, DOI 10.17226/23555]
   Noon D, 2013, CHEMCATCHEM, V5, P146, DOI 10.1002/cctc.201200408
   Obradovic A, 2016, CHEM ENG TECHNOL, V39, P1996, DOI 10.1002/ceat.201600216
   Olivos-Suarez AI, 2016, ACS CATAL, V6, P2965, DOI 10.1021/acscatal.6b00428
   Sarsani S, 2017, CHEM ENG J, V328, P484, DOI 10.1016/j.cej.2017.07.002
   Sun Z, 2018, CHEM ENG J, V343, P770, DOI 10.1016/j.cej.2018.02.004
   VOSKRESENSKAYA EN, 1995, CATAL REV, V37, P101, DOI 10.1080/01614949508007092
   Wang K, 2009, CATAL COMMUN, V10, P807, DOI 10.1016/j.catcom.2008.12.001
   West D. H, 2018, KEYNOTE ISCRE 25
   Wolf E. E, 1992, METHANE CONVERSION O, DOI [10.1007/978-94-015-7449-5, DOI 10.1007/978-94-015-7449-5]
   ZANTHOFF H, 1990, IND ENG CHEM RES, V29, P2, DOI 10.1021/ie00097a001
   Zavyalova U, 2011, CHEMCATCHEM, V3, P1935, DOI 10.1002/cctc.201100186
NR 41
TC 9
Z9 9
U1 5
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 635
EP 651
DI 10.1016/j.ces.2018.08.053
PG 17
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700053
DA 2020-05-12
ER

PT J
AU Frumkin, JA
   Doherty, MF
AF Frumkin, Jeffrey A.
   Doherty, Michael F.
TI Ultimate bounds on reaction selectivity for batch reactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Attainable regions; Reactor design; Reactor optimization; Reaction
   selectivity; Batch reactors
ID ATTAINABLE REGION; GEOMETRIC VIEWPOINT; KINETIC BOUNDS; OPTIMIZATION;
   DESIGN
AB Targets and benchmarks are useful in chemical process design as they provide an objective, quantitative assessment of a proposed process flowsheet. In addition, with target bounds on reaction selectivity one can also explore the sustainability limits for a chemistry of interest. Unfortunately, targets for reaction selectivity are difficult to obtain using conventional design methods. In 2001, Feinberg and Ellison developed the Continuous Flow Stirred Tank Reactor (CFSTR) Equivalence Principle, providing a methodology to obtain ultimate bounds on steady-state productivity for a chemistry of interest entirely independent of process design. In previous articles, we showed how the CFSTR Equivalence Principle can be used to obtain bounds on reaction selectivity independent of process design for steady-state processes. In this article we prove that the CFSTR Equivalence Principle is also applicable to batch and semi-batch processes, thus providing a unifying framework to obtain an ultimate target for reaction selectivity applicable to all candidate processes for a chemistry of interest. This limit also applies to systems with periodic and chaotic operations. We demonstrate the method with an example for the production of lactic acid through the alkaline conversion of fructose. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Frumkin, Jeffrey A.; Doherty, Michael F.] Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA.
RP Doherty, MF (reprint author), Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA.
EM mfd@ucsb.edu
FU Chemical Life Cycle Collaborative at UCSB; US EPAUnited States
   Environmental Protection Agency [RD835579]
FX This work was supported by the Chemical Life Cycle Collaborative at UCSB
   and the US EPA, Grant #RD835579.
CR Abraham TK, 2004, IND ENG CHEM RES, V43, P449, DOI 10.1021/ie030497w
   Abts G, 2000, POLYCARBONATES, DOI [10.1002/14356007.a21_207.pub2, DOI 10.1002/14356007.A21_207.PUB2]
   ACHENIE LKE, 1990, COMPUT CHEM ENG, V14, P23, DOI 10.1016/0098-1354(90)87003-8
   Albrecht K, 2000, POLYMETHACRYLATES, DOI [10.1002/14356007.a21_473.pub2, DOI 10.1002/14356007.A21_473.PUB2]
   Biegler LT, 2004, COMPUT CHEM ENG, V28, P1169, DOI 10.1016/j.compchemeng.2003.11.003
   Cabassud M, 2005, CHEM ENG COMMUN, V192, P758, DOI 10.1080/009864490519852
   Dowling AW, 2015, COMPUT CHEM ENG, V72, P3, DOI 10.1016/j.compchemeng.2014.05.013
   DURAN MA, 1986, AICHE J, V32, P123, DOI 10.1002/aic.690320114
   Feinberg M, 2002, IND ENG CHEM RES, V41, P3751, DOI 10.1021/ie010807f
   Feinberg M, 2001, IND ENG CHEM RES, V40, P3181, DOI 10.1021/ie000697x
   Feinberg M, 2000, CHEM ENG SCI, V55, P3553, DOI 10.1016/S0009-2509(00)00007-5
   Feinberg M, 2000, CHEM ENG SCI, V55, P2455, DOI 10.1016/S0009-2509(99)00511-4
   Feinberg M, 1997, CHEM ENG SCI, V52, P1637, DOI 10.1016/S0009-2509(96)00471-X
   Fischer I, 2000, POLY VINYL CHLORIDE, DOI [10.1002/14356007.a21_717.pub2, DOI 10.1002/14356007.A21_717.PUB2]
   Frumkin JA, 2019, IND ENG CHEM RES, V58, P6042, DOI 10.1021/acs.iecr.8b04143
   GLASSER D, 1987, IND ENG CHEM RES, V26, P1803, DOI 10.1021/ie00069a014
   HILDEBRANDT D, 1990, CHEM ENG SCI, V45, P2161, DOI 10.1016/0009-2509(90)80091-R
   HILDEBRANDT D, 1990, IND ENG CHEM RES, V29, P49, DOI 10.1021/ie00097a009
   Horn F. J. M, 1964, CHEM REACTION ENG
   KOKOSSIS AC, 1991, CHEM ENG SCI, V46, P1361, DOI 10.1016/0009-2509(91)85063-4
   KOKOSSIS AC, 1994, CHEM ENG SCI, V49, P1037, DOI 10.1016/0009-2509(94)80010-3
   Krahe M, 2000, BIOCH ENG ULLMANNS E, DOI [10.1002/14356007.b04_381S, DOI 10.1002/14356007.B04_381, 10.1002/14356007.b04_381]
   Lakshmanan A, 1996, IND ENG CHEM RES, V35, P1344, DOI 10.1021/ie950344b
   Maul J, 2000, POLYSTYRENE STYRENE, DOI [10.1002/14356007.a21_615.pub2, DOI 10.1002/14356007.A21_615.PUB2]
   Ming D, 2013, CHEM ENG SCI, V99, P203, DOI 10.1016/j.ces.2013.06.001
   Ming D, 2010, IND ENG CHEM RES, V49, P10549, DOI 10.1021/ie1004493
   Moran S, 2000, REACTOR TYPES THEIR, DOI [10.1002/14356007.b04_087.pub2, DOI 10.1002/14356007.B04_087.PUB2]
   Ouhadi T, 2000, THERMOPLASTIC ELASTO, DOI [10.1002/14356007.a26_633.pub4, DOI 10.1002/14356007.A26_633.PUB4]
   Pollak P, 2000, FINE CHEM, DOI [10.1002/14356007.q11_q01, DOI 10.1002/14356007.Q11_Q01]
   PURI PS, 1980, J AM OIL CHEM SOC, V57, pA850, DOI 10.1007/BF02687676
   Rinno H, 2000, POLY VINYL ESTERS, DOI [10.1002/14356007.a22_001, DOI 10.1002/14356007.A22_001]
   Tang YZ, 2007, IND ENG CHEM RES, V46, P5624, DOI 10.1021/ie061489t
   TANG Yunli, 2005, THESIS
   Tobita H, 2000, POLYM PROCESSES 2 MO, DOI [10.1002/14356007.o21_o01.pub2, DOI 10.1002/14356007.O21_O01.PUB2]
   Turkay M, 1996, COMPUT CHEM ENG, V20, P959, DOI 10.1016/0098-1354(95)00219-7
NR 35
TC 2
Z9 2
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2019
VL 199
BP 652
EP 660
DI 10.1016/j.ces.2018.11.030
PG 9
WC Engineering, Chemical
SC Engineering
GA HN4LZ
UT WOS:000460156700054
DA 2020-05-12
ER

PT J
AU Mwenda, JM
   Mandomando, I
   Jere, KC
   Cunliffe, NA
   Steele, AD
AF Mwenda, Jason M.
   Mandomando, Inacio
   Jere, Khuzwayo C.
   Cunliffe, Nigel A.
   Steele, A. Duncan
TI Evidence of reduction of rotavirus diarrheal disease after rotavirus
   vaccine introduction in national immunization programs in the African
   countries: Report of the 11th African rotavirus symposium held in
   Lilongwe, Malawi
SO VACCINE
LA English
DT Article
DE Rotavirus; Diarrhea; Vaccine; African rotavirus symposium
ID IMPACT; HOSPITALIZATIONS; SURVEILLANCE; EFFICACY; INTUSSUSCEPTION;
   IMPLEMENTATION; MORTALITY; ETIOLOGY; INFANTS; DEATHS
AB The 11th African Rotavirus Symposium was held in Lilongwe, Malawi from May 28th to 30th 2017. Over 270 delegates (73% from Africa) from 40 countries of which 30 (75%) were from African countries attended the symposium. Participants in this symposium included research scientists, clinicians, immunization managers, public health officials, policymakers and vaccine manufacturers. At the time of the symposium, 38 of the 54 (70%) countries in Africa had introduced rotavirus vaccines into their national immunization schedules. Delegates shared progress from rotavirus surveillance and vaccine impact monitoring, demonstrating the impact of the vaccine against rotavirus diarrheal hospitalizations. Data supported the beneficial effect and safety of WHO pre-qualified available vaccines up to 2017 (RotaTeq, Rotarix). This symposium highlighted the dramatic impact of the rotavirus vaccination, called for urgent adoption of these vaccines in remaining countries, particularly those with high disease burden and large birth cohorts (e.g. Nigeria, Democratic Republic of Congo) to attain the full public health benefits of rota virus vaccination in Africa.
C1 [Mwenda, Jason M.] WHO, Reg Off Africa, Brazzaville, Rep Congo.
   [Mandomando, Inacio] CISM, Maputo, Mozambique.
   [Mandomando, Inacio] Minist Saude, INS, Maputo, Mozambique.
   [Jere, Khuzwayo C.] Univ Malawi, Coll Med, Dept Med Lab Sci, Malawi Liverpool Wellcome Clin Res Programme, Blantyre, Malawi.
   [Jere, Khuzwayo C.; Cunliffe, Nigel A.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Steele, A. Duncan] Bill & Melinda Gates Fdn, Global Hlth, Enter & Diarrheal Dis, Seattle, WA USA.
RP Mwenda, JM (reprint author), WHO, Family & Reprod Hlth Cluster, VPD Sentinel Site Surveillance & New Vaccines Imp, Reg Off Africa, Box 06, Brazzaville, Rep Congo.
EM mwendaj@who.int
OI Mandomando, Inacio/0000-0002-1078-2187; Jere,
   Khuzwayo/0000-0003-3376-8529
FU Bill & Melinda Gates Foundation, Seattle, WA, USAGates Foundation; World
   Health Organization, Regional Office for Africa (WHO/AFRO), Brazzaville,
   Congo; Centers for Disease Control and Prevention (CDC), Atlanta, GA,
   USAUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA
FX Thanks to all the 11th African Rotavirus Symposium delegates and the
   presenters. Thanks to the Malawi-Liverpool Wellcome Clinical Research
   Programme, College of Medicine, University of Malawi, University of
   Liverpool, the International Steering Committee and the Local Organizing
   Committee. This symposium was supported by the following organizations:
   Bill & Melinda Gates Foundation, Seattle, WA, USA; the World Health
   Organization, Regional Office for Africa (WHO/AFRO), Brazzaville, Congo;
   the Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA;
   and we also acknowledge various colleagues for their contributions to
   writing and reviewing this manuscript.
CR Bar-Zeev N, 2016, CLIN INFECT DIS, V62, pS220, DOI 10.1093/cid/civ1025
   BHAN MK, 1993, J INFECT DIS, V168, P282, DOI 10.1093/infdis/168.2.282
   Bhandari N, 2014, LANCET, V383, P2136, DOI 10.1016/S0140-6736(13)62630-6
   Bines JE, 2018, NEW ENGL J MED, V378, P719, DOI 10.1056/NEJMoa1706804
   Bucardo F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19718-y
   Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186
   Ella R, 2018, HUM VACC IMMUNOTHER, V14, P1791, DOI 10.1080/21645515.2018.1450709
   Enane LA, 2016, CLIN INFECT DIS, V62, pS168, DOI 10.1093/cid/civ1210
   Isanaka S, 2017, NEW ENGL J MED, V376, P1121, DOI [10.1056/nejmoa1609462, 10.1056/NEJMoa1609462]
   Kallenberg J, 2016, HEALTH AFFAIR, V35, P250, DOI 10.1377/hlthaff.2015.1079
   Kulkarni PS, 2017, VACCINE, V35, P6228, DOI 10.1016/j.vaccine.2017.09.014
   Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8
   Mandomando I, 2017, VACCINE, V35, P1663, DOI 10.1016/j.vaccine.2017.01.072
   Marlow R, 2015, EUROSURVEILLANCE, V20, P21, DOI 10.2807/1560-7917.ES.2015.20.48.30077
   Mwape I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187761
   Mwenda JM, 2017, MMWR-MORBID MORTAL W, V66, P1192, DOI 10.15585/mmwr.mm6643a7
   Mwila-Kazimbaya K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189351
   Naik SP, 2017, VACCINE, V35, P2962, DOI 10.1016/j.vaccine.2017.04.025
   Nonvignon J, 2017, VACCINE, pS0264
   Operario DJ, 2017, J INFECT DIS, V216, P220, DOI 10.1093/infdis/jix294
   Platts-Mills JA, 2017, CLIN INFECT DIS, V65, P1144, DOI 10.1093/cid/cix494
   Sanchez-Uribe E, 2016, CLIN INFECT DIS, V62, pS133, DOI 10.1093/cid/civ1205
   Shah MP, 2017, EXPERT REV VACCINES, V16, P987, DOI 10.1080/14760584.2017.1371595
   Sindhu KNC, 2017, CURR OPIN INFECT DIS, V30, P473, DOI 10.1097/QCO.0000000000000397
   Sow SO, 2017, VACCINE, V35, P5511, DOI 10.1016/j.vaccine.2017.08.084
   Tate JE, 2018, NEW ENGL J MED, V378, P1521, DOI [10.1056/NEJMoa1713909, 10.1056/nejmoa1713909]
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Zade JK, 2014, VACCINE, V32, pA124, DOI 10.1016/j.vaccine.2014.03.003
NR 28
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 2975
EP 2981
DI 10.1016/j.vaccine.2019.03.047
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300001
PM 31029514
DA 2020-05-12
ER

PT J
AU Dellepiane, N
   Pagliusi, S
   Akut, P
   De Clercq, N
   Desai, S
   Dias, J
   McGoldrick, M
   Nurnaeni, I
   Scheppler, L
   Stavale, M
   Almutairi, A
   Barbosa, P
   Chokshi, NA
   Comellas, S
   Ghadge, S
   Jeong, SG
   Susanti, L
   Kannappa, SV
   Utom, M
   Xiong, QR
AF Dellepiane, Nora
   Pagliusi, Sonia
   Akut, Prashant
   De Clercq, Norbert
   Desai, Samir
   Dias, Jacqueline
   McGoldrick, Mic
   Nurnaeni, Ida
   Scheppler, Lorenz
   Stavale, Monique
   Almutairi, Abdulaziz
   Barbosa, Paula
   Chokshi, Nirav Amitkumar
   Comellas, Sebastian
   Ghadge, Shubhangi
   Jeong, Seon Gyeong
   Susanti, Lin
   Kannappa, Srinivas Vellimedu
   Utom, Mira
   Xiong, Qiaoruo
CA Regulatory Experts Working Grp
TI Opportunities for improving access to vaccines in emerging countries
   through efficient and aligned registration procedures: An industry
   perspective
SO VACCINE
LA English
DT Article
DE Registration; Reliance; cTD; Procurement; Testing; Inspection
AB Vaccines play an essential role in preventing infectious diseases. Their registration in importing countries is often cumbersome and unpredictably lengthy, leading to delays in vaccine access for populations that need them most. This report builds on a previous publication identifying challenges for registration of vaccines in emerging countries. As a matter of social responsibility, it was judged necessary to address the challenges and offer a set of solutions for open dialogue. Based on regular exchange of information and experiences, a group of regulatory experts from the vaccine industry developed three sets of proposals for consideration by vaccine stakeholders, with a view to improving the situation, by fostering regulatory convergence, with viable options for streamlining registration procedures through reliance on other experienced regulators or international agencies. Further, it offers options for alignment of structure and contents of Common Technical Document modules and presents a harmonized template application form that could potentially be used by all countries.
C1 [Dellepiane, Nora] Consultants Sarl, Trelex, Switzerland.
   [Pagliusi, Sonia] DCVMN Int, Nyon, Switzerland.
   [Akut, Prashant; Ghadge, Shubhangi] Serum Inst India Pvt Ltd, Pune, Maharashtra, India.
   [De Clercq, Norbert] GSK Vaccines, Wavre, Belgium.
   [Desai, Samir] Zydus Healthcare, Ahmadabad, Gujarat, India.
   [Dias, Jacqueline] Pfizer, Brussels, Belgium.
   [McGoldrick, Mic] Merck & Co Inc, West Point, PA USA.
   [Nurnaeni, Ida] PT Biofarma, Bandung, Indonesia.
   [Scheppler, Lorenz] Janssen Vaccines, Bern, Switzerland.
   [Stavale, Monique] BioManguinhos Fiocruz, Rio De Janeiro, Brazil.
   [Barbosa, Paula] IFPMA, Geneva, Switzerland.
   [Chokshi, Nirav Amitkumar] Zydus Cadila, Ahmadabad, Gujarat, India.
   [Comellas, Sebastian] Sinergium Biotech, Garin, Buenos Aires, Argentina.
   [Jeong, Seon Gyeong] LG Chem, Seoul, South Korea.
   [Susanti, Lin; Utom, Mira] Biofarma, Bandung, Indonesia.
   [Kannappa, Srinivas Vellimedu] Bharat Biotechnol Int, Hyderabad, Telangana, India.
   [Xiong, Qiaoruo] China Natl Biotech Grp, Beijing, Peoples R China.
RP Pagliusi, S (reprint author), DCVMN Int, Nyon, Switzerland.
EM s.pagliusi@dcvmn.net
FU Bill & Melinda Gates Foundation, Seattle, WAGates Foundation [OPP
   1113279]
FX This work was partially supported by the Bill & Melinda Gates
   Foundation, Seattle, WA [grant number OPP 1113279, awarded to DCVMN
   International]. The funder had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Ahonkhai V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166515
   [Anonymous], 2016, ORG COMM TECHN DOC R
   [Anonymous], 2018, MEMB OBS
   ANVISA toma GMP de INVIMA, 2018, PHARMABIZ SUD AM
   CDSCO, 2015, NOT PRES M REG PATHW
   Dellepiane N, 2018, VACCINE, V36, P3389, DOI 10.1016/j.vaccine.2018.03.049
   EMA, 2018, EMA8212782015
   European Commission (EC), 2006, COMM TECHN DOC CTD
   European Medicines Agency (EMA), 2018, EMA2216962018
   European Medicines Agency (EMA), 2017, EMACHMPICH4532762016
   Ndomondo-Sigonda M, 2017, PHARM MED, V31, P383, DOI 10.1007/s40290-017-0210-x
   Pharmaceutical inspection co-operation scheme (PIC/S), 2018, GUID GMP INSP REL
   Regnstrom J, 2010, EUR J CLIN PHARMACOL, V66, P39, DOI 10.1007/s00228-009-0756-y
   The international council for harmonisation of technical requirements for pharmaceuticals for human use (ICH), 1998, ETHN FACT ACC FOR CL
   The United Nations Children's Fund (UNICEF), SUPPL LOG IMM
   Therapeutic Goods Administration (TGA), 2018, PRES M TGA VERS 2 1
   U.S. Food and Drug Administration (FDA), 2017, 81011 FDA SOPP
   WHO, 2016, WHO TECH REP SER, V996, P1
   World Health Organization, 2018, VACC QUAL CONTR LAB
   World Health Organization, 2018, MOD CERT PHARM PROD
   World Health Organization, 2018, WHO PUBL INSP REP WH
   World Health Organization, 2018, QAS18774 WHO
   World Health Organization, 2017, 14 M WHO ADV COMM SA
   World Health Organization, 2016, QAS16686 WHO
   2013, WHO TECHN REP SER, V978, P1
NR 25
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 2982
EP 2989
DI 10.1016/j.vaccine.2019.03.025
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300002
PM 31027928
OA Other Gold
DA 2020-05-12
ER

PT J
AU Featherstone, JD
   Bell, RA
   Ruiz, JB
AF Featherstone, Jieyu D.
   Bell, Robert A.
   Ruiz, Jeanette B.
TI Relationship of people's sources of health information and political
   ideology with acceptance of conspiratorial beliefs about vaccines
SO VACCINE
LA English
DT Article
DE Social media; Conspiracy beliefs; Vaccines; Political ideology
ID ONLINE; SEARCH
AB Background: Conspiracies about vaccination are prevalent. We assessed how the health information sources people rely upon and their political ideologies are associated with acceptance of vaccine conspiracies.
   Methods: Online survey (N = 599) on Amazon's Mechanical Turk crowdsource platform. Hypotheses were tested via structural equation modeling.
   Results: Acceptance of vaccine conspiracy beliefs was associated positively with greater reliance on social media for health information (coef. = 0.42, p < .001), inversely related to use of medical websites (coef. = -0.21, p < .001), and not significantly related to use of providers for health information (coef. = -0.13, p = .061). In addition, liberal political orientation was negatively associated with acceptance of vaccine conspiracies (coef. = -0.29, p < .001).
   Conclusions: An understanding of vaccine conspiracy acceptance requires a consideration of people's health information sources. The greater susceptibility of political conservatives to conspiracy beliefs extends to the topic of vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Featherstone, Jieyu D.; Bell, Robert A.; Ruiz, Jeanette B.] Univ Calif Davis, Dept Commun, One Shields Ave, Davis, CA 95616 USA.
RP Featherstone, JD (reprint author), Univ Calif Davis, Dept Commun, One Shields Ave, Davis, CA 95616 USA.
EM jding@ucdavis.edu; rabell@ucdavis.edu; jbruiz@ucdavis.edu
CR Bialik K, 2018, 14 AM HAVE CHANGED T
   Cotten SR, 2004, SOC SCI MED, V59, P1795, DOI 10.1016/j.socscimed.2004.02.020
   Diaz JA, 2002, J GEN INTERN MED, V17, P180, DOI 10.1046/j.1525-1497.2002.10603.x
   Dobransky K, 2012, HEALTH COMMUN, V27, P331, DOI 10.1080/10410236.2011.585451
   Fox S, 2006, ONLINE HLTH SEARCH 2
   Freeman D, 2017, SOC PSYCH PSYCH EPID, V52, P595, DOI 10.1007/s00127-017-1354-4
   Funk C, 2017, VAST MAJORITY AM SAY
   Guidry JPD, 2015, VACCINE, V33, P5051, DOI 10.1016/j.vaccine.2015.08.064
   Hamilton LC, 2015, SAGE OPEN, V5, DOI 10.1177/2158244015602752
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Kline RB, 2005, PRINCIPLES PRACTICE
   Madden K, 2012, VACCINE, V30, P3741, DOI 10.1016/j.vaccine.2011.10.025
   Motta M, 2018, AM POLIT RES, V46, P465, DOI 10.1177/1532673X17719507
   Oliver JE, 2014, JAMA INTERN MED, V174, P817, DOI 10.1001/jamainternmed.2014.190
   Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043
   Song H, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4193
   Temoka E., 2013, S D MED
   Xiao N, 2014, DECIS SUPPORT SYST, V57, P417, DOI 10.1016/j.dss.2012.10.047
NR 20
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 2993
EP 2997
DI 10.1016/j.vaccine.2019.04.063
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300005
PM 31031028
DA 2020-05-12
ER

PT J
AU Rodriguez, SA
   Savas, LS
   Loomba, P
   Vernon, SW
   Fernandez, ME
AF Rodriguez, Serena A.
   Savas, Lara S.
   Loomba, Preena
   Vernon, Sally W.
   Fernandez, Maria E.
TI Low-income Hispanic parent recall of daughters' HPV vaccination status:
   Correlates of accurate reporting of daughters' HPV-vaccine naive status
   compared with electronic health records
SO VACCINE
LA English
DT Article
DE HPV vaccination; Adolescents; Parental recall; Immunization registries;
   Hispanic
ID IMMUNIZATION INFORMATION-SYSTEMS; HUMAN-PAPILLOMAVIRUS VACCINATION
AB Purpose: This study aimed to (1) assess the accuracy of parental recall of adolescent (11-17 years) daughters' HPV vaccine initiation in a low-income, urban Hispanic population, and (2) describe the correlates of accurate recall.
   Methods: We compared parental recall of HPV vaccine naivety to daughter's electronic medical records to calculate the proportion of parents accurately reporting HPV naive status. We used mixed effects logistic regression to identify correlates of accurate recall.
   Results: We verified vaccination status for 1103 daughters of participants who reported their daughters were HPV vaccine-naive; 69.3% of parents accurately reported their daughters as HPV vaccine-naive. Parents of older daughters (13-17 years) compared to younger daughters (11-12 years) had significantly lower odds of accurately reporting daughters as unvaccinated (AOR = 0.60; 95% CI 0.42-0.83).
   Discussion: Underreporting of vaccination status among our study population corresponds with national data that suggest lower income and minority populations underreport HPV vaccination initiation and completion. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rodriguez, Serena A.] Univ Texas Southwestern Med Ctr Dallas, Dept Populat & Data Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
   [Savas, Lara S.; Loomba, Preena; Vernon, Sally W.; Fernandez, Maria E.] Univ Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, 7000 Fannin,25th Floor, Houston, TX 77030 USA.
RP Rodriguez, SA (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Populat & Data Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Serena.Rodriguez@UTSouthwestern.edu; Lara.Staub@uth.tmc.edu;
   Preena.Loomba@uth.tmc.edu; Sally.W.Vernon@uth.tmc.edu;
   Maria.E.Fernandez@uth.tmc.edu
OI Savas, Lara/0000-0003-0799-4012; Rodriguez, Serena/0000-0002-4466-6002
FU Cancer Prevention and Research Institute of Texas (CPRIT) [RP130459,
   RP100865]; University of Texas School of Public Health Cancer Education
   and Career Development Program - National Cancer Institute/National
   Institutes of Health [R25 CA57712]; University of Texas Health Science
   Center at Houston, School of Public Health Department of Health
   Promotion and Behavioral Sciences
FX This work was supported by the Cancer Prevention and Research Institute
   of Texas (CPRIT) grant RP130459 and RP100865. SAR was supported by a
   predoctoral fellowship from the University of Texas School of Public
   Health Cancer Education and Career Development Program - National Cancer
   Institute/National Institutes of Health Grant R25 CA57712. SAR received
   partial support from the University of Texas Health Science Center at
   Houston, School of Public Health Department of Health Promotion and
   Behavioral Sciences. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of CPRIT,
   the National Cancer Institute, or the National Institutes of Health. The
   authors thank Natalie Fernandez-Espada, Diana Lopez, Angelia Roncancio,
   Sharon Coan, Milet Serna, and Jennifer Villamar for their support in
   data collection, database maintenance, and project coordination.
CR Apte G, 2015, CLIN PEDIATR, V54, P987, DOI 10.1177/0009922815590115
   Attanasio L, 2014, PUBLIC HEALTH REP, V129, P237, DOI 10.1177/003335491412900305
   Boakye EA, 2017, AM J PREV MED, V52, P742, DOI 10.1016/j.amepre.2016.10.016
   Boom JA, 2010, J PUBLIC HEALTH MAN, V16, pE18, DOI 10.1097/PHH.0b013e3181cbc4ec
   Centers for Disease Control and Prevention, 2016, VACC CHILDR VFC 2016
   Collins Brian K, 2006, J Health Soc Policy, V22, P77, DOI 10.1300/J045v22n01_06
   Dorell CG, 2011, PUBLIC HEALTH REP, V126, P60, DOI 10.1177/00333549111260S208
   Foutz J, 2017, UNINSURED PRIMER KEY
   Groom H, 2015, J PUBLIC HEALTH MAN, V21, P227, DOI 10.1097/PHH.0000000000000069
   Hopkins DP, 2015, J PUBLIC HEALTH MAN, V21, P249, DOI 10.1097/PHH.0000000000000092
   Lu PJ, 2012, VACCINE, V30, P3278, DOI 10.1016/j.vaccine.2012.03.015
   Markowitz LE, 2014, MMWR RECOMM REP, V63, P1
   Rodriguez SA, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00164
   Statacorp, 2017, STAT STAT SOFTW REL
   Stupiansky NW, 2012, J ADOLESCENT HEALTH, V50, P103, DOI 10.1016/j.jadohealth.2011.04.010
   Suarez L, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e3
   U.S. Department of Health and Human Services Assistant Secretary for Planning and Evaluation, US FED POV GUID US D
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 2998
EP 3001
DI 10.1016/j.vaccine.2019.04.064
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300006
PM 31036458
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Xeuatvongsa, A
   Mott, JA
   Khanthamaly, V
   Patthammavong, C
   Phounphenghak, K
   McKinlay, M
   Mirza, S
   Lafond, KE
   McCarron, M
   Corwin, A
   Moen, A
   Olsen, SJ
   Bresee, JS
AF Xeuatvongsa, A.
   Mott, J. A.
   Khanthamaly, V.
   Patthammavong, C.
   Phounphenghak, K.
   McKinlay, M.
   Mirza, S.
   Lafond, K. E.
   McCarron, M.
   Corwin, A.
   Moen, A.
   Olsen, S. J.
   Bresee, J. S.
TI Progress toward sustainable influenza vaccination in the Lao Peoples'
   Democratic Republic, 2012-2018
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine; Policy; Laos; Vaccination program
ID PANDEMIC INFLUENZA; BIRTH OUTCOMES; PDR; IMMUNIZATION
AB Despite global recommendations for influenza vaccination of high-risk, target populations, few low and middle-income countries have national influenza vaccination programs. Between 2012 and 2017, Lao PDR planned and conducted a series of activities to develop its national influenza vaccine program as a part of its overall national immunization program. In this paper, we review the underlying strategic planning for this process, and outline the sequence of activities, research studies, partnerships, and policy decisions that were required to build Laos' influenza vaccine program. The successful development and sustainability of the program in Laos offers lessons for other low and middle-income countries interested in initiating or expanding influenza immunization. Published by Elsevier Ltd.
C1 [Xeuatvongsa, A.; Patthammavong, C.; Phounphenghak, K.] Minist Hlth, Viangchan, Laos.
   [Mott, J. A.] Ctr Dis Control & Prevent, Bangkok, Thailand.
   [Khanthamaly, V.] Ctr Dis Control & Prevent, Viangchan, Laos.
   [McKinlay, M.] Task Force Global Hlth, Atlanta, GA USA.
   [Mirza, S.; Lafond, K. E.; McCarron, M.; Moen, A.; Olsen, S. J.; Bresee, J. S.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Corwin, A.] Thammasat Univ, Fac Publ Hlth, Bangkok, Thailand.
RP Bresee, JS (reprint author), 1600 Clifton Rd NE, Atlanta, GA 30033 USA.
EM jsb6@cdc.gov
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   Hirve S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153003
   Howard N, 2018, HUM VACC IMMUNOTHER, V14, P1539, DOI 10.1080/21645515.2018.1444321
   Khamphaphongphane B, 2013, INFLUENZA OTHER RESP, V7, P304, DOI 10.1111/j.1750-2659.2012.00394.x
   Olsen SJ, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1168-5
   Olsen SJ, 2016, CLIN INFECT DIS, V63, P487, DOI 10.1093/cid/ciw290
   Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045
   Phengxay M, 2015, INFLUENZA OTHER RESP, V9, P94, DOI 10.1111/irv.12299
   Phommasack B, 2012, AM J TROP MED HYG, V87, P965, DOI 10.4269/ajtmh.2012.12-0074
   Vongphrachanh P, 2010, INFLUENZA OTHER RESP, V4, P47, DOI 10.1111/j.1750-2659.2009.00120.x
   Xeuatvongsa A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121717
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3002
EP 3005
DI 10.1016/j.vaccine.2019.04.047
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300007
PM 31027926
DA 2020-05-12
ER

PT J
AU Cohet, C
   van der Most, R
   Bauchau, V
   Bekkat-Berkani, R
   Doherty, TM
   Schuind, A
   Da Silva, FT
   Rappuoli, R
   Garcon, N
   Innis, BL
AF Cohet, Catherine
   van der Most, Robbert
   Bauchau, Vincent
   Bekkat-Berkani, Rafik
   Doherty, T. Mark
   Schuind, Anne
   Da Silva, Fernanda Tavares
   Rappuoli, Rino
   Garcon, Nathalie
   Innis, Bruce L.
TI Safety of AS03-adjuvanted influenza vaccines: A review of the evidence
SO VACCINE
LA English
DT Review
DE Adjuvant system; Vaccine; Influenza; Reactogenicity; Safety;
   Pharmacovigilance
ID GUILLAIN-BARRE-SYNDROME; A/H1N1 2009 INFLUENZA; A H1N1 VACCINE;
   OBSERVER-BLIND; SEASONAL INFLUENZA; IMMUNE-RESPONSE; PANDEMIC H1N1;
   PHASE-III; A(H1N1)PDM09 VACCINE; PROSPECTIVE COHORT
AB Clinical and post-licensure data have demonstrated that AS03-adjuvanted inactivated split virion vaccines, many with reduced antigen content, are effective against influenza infection. The objective of this review is to provide a comprehensive assessment of the safety of trivalent seasonal, monovalent pre-pandemic and pandemic AS03-adjuvanted influenza vaccines, based on non-clinical, clinical and post-licensure data in various populations. Non-clinical studies on local tolerance, toxicology and safety pharmacology did not raise any safety concerns with AS03 administered alone or combined with various influenza antigens. Data from clinical trials with over 55,000 vaccinated subjects showed that AS03-adjuvanted influenza vaccines were generally well tolerated and displayed an acceptable safety profile, although the power to detect rare events was limited. Approximately 90 million doses of A/H1N1pdm09 pandemic influenza vaccines (Pandemrix and Arepanrix H1N1) were administered worldwide, which contributed post-licensure data to the collective safety data for AS03-adjuvanted influenza vaccines. An association between Pandemrix and narcolepsy was observed during the A/H1N1pdm09 pandemic, for which a role of a CD4 T cell mimicry sequence in the haemagglutinin protein of A/H1N1pdm09 cannot be excluded. Provided that future AS03-adjuvanted influenza vaccines do not contain this putative mimicry sequence, this extensive safety experience supports the further development and use of AS03-adjuvanted inactivated split virion candidate vaccines against seasonal and pandemic influenza infections. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Cohet, Catherine] GSK, Clin R&D, Av Fleming 20, B-1300 Wavre, Belgium.
   [van der Most, Robbert] GSK, Translat Sci, Wavre, Belgium.
   [Bauchau, Vincent] GSK, Signal & Benefit Risk Sci, Wavre, Belgium.
   [Bekkat-Berkani, Rafik] GSK, Global Med Affairs, Philadelphia, PA USA.
   [Doherty, T. Mark] GSK, Global Med Affairs, Wavre, Belgium.
   [Schuind, Anne] GSK, Clin R&D, Rockville, MD USA.
   [Da Silva, Fernanda Tavares] GSK, Vaccine Safety Evaluat & Risk Management, Wavre, Belgium.
   [Rappuoli, Rino] GSK, Res & Dev Ctr, Siena, Italy.
   [Garcon, Nathalie] Bioaster Technol Res Inst, Lyon, France.
   [Innis, Bruce L.] GSK, Vaccine Discovery & Dev, King Of Prussia, PA USA.
   [Innis, Bruce L.] PATH, Ctr Vaccine Innovat & Access, Washington, DC USA.
RP Cohet, C (reprint author), GSK, Clin R&D, Av Fleming 20, B-1300 Wavre, Belgium.
EM catherine.x.cohet@gsk.com
OI Cohet, Catherine/0000-0002-0022-7251
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals SA.
CR Ahmed SS, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2354
   Andrews N, 2011, VACCINE, V29, P7878, DOI 10.1016/j.vaccine.2011.08.069
   Andrews N, 2011, J INFECT DIS, V203, P32, DOI 10.1093/infdis/jiq014
   Arnheim-Dahlstrom L, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7594
   Ashton MP, 2016, SCI REP-UK, V6, DOI 10.1038/srep32899
   Avery RK, 2012, CURR OPIN INFECT DIS, V25, P464, DOI 10.1097/QCO.0b013e328355a79b
   Bakken IJ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1263-7
   Baz M, 2013, VIRUS RES, V178, P78, DOI 10.1016/j.virusres.2013.05.006
   Beck CR, 2012, J INFECT DIS, V206, P1250, DOI 10.1093/infdis/jis487
   Bernard-Valnet R, 2016, P NATL ACAD SCI USA, V113, P10956, DOI 10.1073/pnas.1603325113
   Black S, 2015, EXPERT REV VACCINES, V14, P1543, DOI 10.1586/14760584.2015.1091733
   Bollaerts K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149289
   Brakemeier S, 2012, NEPHROL DIAL TRANSPL, V27, P423, DOI 10.1093/ndt/gfr278
   Carmona A, 2010, VACCINE, V28, P5837, DOI 10.1016/j.vaccine.2010.06.065
   Martinez AC, 2014, HUM VACC IMMUNOTHER, V10, P1959, DOI 10.4161/hv.28743
   Cherif H, 2013, EUR J HAEMATOL, V90, P413, DOI 10.1111/ejh.12094
   Chu DWS, 2009, VACCINE, V27, P7428, DOI 10.1016/j.vaccine.2009.07.102
   Cleary BJ, 2014, EUR J OBSTET GYN R B, V178, P163, DOI 10.1016/j.ejogrb.2014.04.015
   Cohet C, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009264
   Cohet C, 2015, PHARMACOEPIDEM DR S, V24, P406
   Cordero E, 2012, CURR OPIN ORGAN TRAN, V17, P601, DOI 10.1097/MOT.0b013e3283592622
   Couch RB, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-425
   Da Silva FT, 2015, HUM VACC IMMUNOTHER, V11, P1814, DOI 10.1080/21645515.2015.1043501
   De Serres G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038563
   de Vries L, 2014, BIRTH DEFECTS RES A, V100, P731, DOI 10.1002/bdra.23243
   De Wals P, 2012, JAMA-J AM MED ASSOC, V308, P175, DOI 10.1001/jama.2012.7342
   Destexhe E, 2013, J PHARMACOL TOX MET, V68, P367, DOI 10.1016/j.vascn.2013.04.003
   Dieleman J, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3908
   Diez-Domingo J, 2015, INFLUENZA OTHER RESP, V9, P68, DOI 10.1111/irv.12295
   Diez-Domingo J, 2010, PEDIATR INFECT DIS J, V29, pE35, DOI 10.1097/INF.0b013e3181daf921
   Dodd CN, 2013, VACCINE, V31, P4448, DOI 10.1016/j.vaccine.2013.06.032
   Dye TJ, 2018, PAEDIATR RESPIR REV, V25, P14, DOI 10.1016/j.prrv.2016.12.005
   European Medicines Agency, 2009, EMEA3593812009
   European Medicines Agency, 2016, EMACHMP5663592015
   European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, 2017, EU PAS REG STUD NUMB
   Fell Deshayne B, 2012, Am J Public Health, V102, pe33, DOI 10.2105/AJPH.2011.300606
   Ferguson M, 2012, J INFECT DIS, V205, P733, DOI 10.1093/infdis/jir641
   Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635
   Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/ERV.11.192, 10.1586/erv.11.192]
   Giannoccaro MP, 2017, SLEEP, V40, DOI 10.1093/sleep/zsw056
   Grimaldi-Bensouda L, 2011, AM J EPIDEMIOL, V174, P326, DOI 10.1093/aje/kwr072
   GSK, 2018, INFL A H5N1 VIR MON
   Haberg SE, 2013, NEW ENGL J MED, V368, P333, DOI 10.1056/NEJMoa1207210
   Han F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003880
   Han F, 2013, ANN NEUROL, V73, P560, DOI 10.1002/ana.23799
   Han F, 2011, ANN NEUROL, V70, P410, DOI 10.1002/ana.22587
   Harris T, 2014, EURO SURVEILL, V19
   Heijmans S, 2011, J INFECT DIS, V203, P1054, DOI 10.1093/infdis/jiq174
   Huang WT, 2016, PHARMACOEPIDEM DR S, V25, P524
   Isai A, 2012, VACCINE, V30, P7123, DOI 10.1016/j.vaccine.2012.09.032
   Jackson AC, 2016, CAN J NEUROL SCI, V43, P819, DOI 10.1017/cjn.2016.291
   Jackson LA, 2015, JAMA-J AM MED ASSOC, V314, P237, DOI 10.1001/jama.2015.7916
   Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019
   Kallen B, 2012, BJOG-INT J OBSTET GY, V119, P1583, DOI 10.1111/j.1471-0528.2012.03470.x
   Katerinis I, 2011, AM J TRANSPLANT, V11, P1727, DOI 10.1111/j.1600-6143.2011.03604.x
   Kosalaraksa P, 2015, J INFECT DIS, V211, P801, DOI 10.1093/infdis/jiu548
   Langley JM, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-279
   Langley JM, 2011, J INFECT DIS, V203, P1729, DOI 10.1093/infdis/jir172
   Langley JM, 2010, J INFECT DIS, V201, P1644, DOI 10.1086/652701
   Lansbury LE, 2017, VACCINE, V35, P1996, DOI 10.1016/j.vaccine.2017.02.059
   Latorre D, 2018, NATURE, V562, P63, DOI 10.1038/s41586-018-0540-1
   Leahy TR, 2014, INFLUENZA OTHER RESP, V8, P360, DOI 10.1111/irv.12243
   Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5
   Ludvigsson JF, 2016, ANN INTERN MED, V165, P848, DOI 10.7326/M16-0139
   Ludvigsson JF, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5585
   Luo G, 2018, P NATL ACAD SCI USA, V115, pE12323, DOI 10.1073/pnas.1818150116
   Madan A, 2017, VACCINE, V35, P4621, DOI 10.1016/j.vaccine.2017.07.013
   Madan A, 2017, VACCINE, V35, P1865, DOI 10.1016/j.vaccine.2017.02.057
   Madan A, 2017, VACCINE, V35, P1431, DOI 10.1016/j.vaccine.2017.01.054
   Mahmud SM, 2018, EMERG INFECT DIS, V24, P1267, DOI 10.3201/eid2407.161783
   McElhaney JE, 2013, LANCET INFECT DIS, V13, P485, DOI 10.1016/S1473-3099(13)70046-X
   Mignot E, 1997, SLEEP, V20, P1012
   Montplaisir J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108489
   Morel S, 2011, VACCINE, V29, P2461, DOI 10.1016/j.vaccine.2011.01.011
   Moris P, 2011, J CLIN IMMUNOL, V31, P443, DOI 10.1007/s10875-010-9490-6
   Nazareth I, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001912
   Nolan T, 2014, J INFECT DIS, V210, P545, DOI 10.1093/infdis/jiu173
   Oberle D, 2015, SLEEP, V38, P1619, DOI 10.5665/sleep.5060
   Oppermann M, 2012, VACCINE, V30, P4445, DOI 10.1016/j.vaccine.2012.04.081
   Pasternak B, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2794
   Persson I, 2014, J INTERN MED, V275, P172, DOI 10.1111/joim.12150
   Planty C, 2017, HUM VACC IMMUNOTHER, V13, P90, DOI 10.1080/21645515.2016.1227518
   Poder A, 2014, VACCINE, V32, P1121, DOI 10.1016/j.vaccine.2013.11.031
   Prestel J, 2014, PHARMACOEPIDEM DR S, V23, P1192, DOI 10.1002/pds.3638
   Roman F, 2010, VACCINE, V28, P1740, DOI 10.1016/j.vaccine.2009.12.014
   Romio S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082222
   Rouleau I, 2013, VACCINE, V31, P5989, DOI 10.1016/j.vaccine.2013.10.033
   Rousseau B, 2012, ANN ONCOL, V23, P450, DOI 10.1093/annonc/mdr141
   Rumke HC, 2008, VACCINE, V26, P2378, DOI 10.1016/j.vaccine.2008.02.068
   Rumke HC, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-348
   Sarkanen TO, 2018, SLEEP MED REV, V38, P177, DOI 10.1016/j.smrv.2017.06.006
   Schaffer SA, 2011, AM J TRANSPLANT, V11, P2751, DOI 10.1111/j.1600-6143.2011.03743.x
   Segal L, 2015, J APPL TOXICOL, V35, P1564, DOI 10.1002/jat.3130
   Segal L, 2015, REGUL TOXICOL PHARM, V73, P116, DOI 10.1016/j.yrtph.2015.06.003
   Siegrist CA, 2012, ANTIVIR THER, V17, P893, DOI 10.3851/IMP2103
   Steffens B, 2011, EUR J MED RES, V16, P289, DOI 10.1186/2047-783X-16-7-289
   Stowe J, 2011, VACCINE, V29, P9467, DOI 10.1016/j.vaccine.2011.10.029
   Sturkenboom MCJM, 2015, VACCINE, V33, pB6, DOI 10.1016/j.vaccine.2015.03.026
   Tavares F, 2011, VACCINE, V29, P6358, DOI 10.1016/j.vaccine.2011.04.114
   Tavares F, 2011, VACCINE, V29, P6402, DOI 10.1016/j.vaccine.2011.04.026
   Toyoda H, 2015, BRAIN BEHAV IMMUN, V49, P148, DOI 10.1016/j.bbi.2015.05.003
   van der Most RG, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008409
   Van Effelterre T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151575
   Vassalli A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad2353
   Vaughn DW, 2014, HUM VACC IMMUNOTHER, V10, P2942, DOI 10.4161/21645515.2014.972149
   Vellozzi C, 2014, CLIN INFECT DIS, V58, P1149, DOI 10.1093/cid/ciu005
   Verity C, 2014, ARCH DIS CHILD, V99, P532, DOI 10.1136/archdischild-2013-304475
   Verstraeten T, 2016, HUM VACC IMMUNOTHER, V12, P187, DOI 10.1080/21645515.2015.1068486
   Waddington CS, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2649
   Weibel D, 2018, VACCINE, V36, P6202, DOI 10.1016/j.vaccine.2018.08.008
   Wijnans L, 2016, EXPERT REV VACCINES, V15, P573, DOI 10.1586/14760584.2016.1164045
   Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760
   Yang WH, 2013, VACCINE, V31, P4389, DOI 10.1016/j.vaccine.2013.07.007
NR 113
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3006
EP 3021
DI 10.1016/j.vaccine.2019.04.048
PG 16
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300008
PM 31031030
OA Other Gold
DA 2020-05-12
ER

PT J
AU Joosten, SA
   Ottenhoff, THM
   Lewinsohn, DM
   Hoft, DF
   Moody, DB
   Seshadri, C
   Altman, JD
   Behar, SM
   Chien, YH
   Hanekom, WA
   Kronenberg, M
   Picker, LJ
   Sacha, JB
   Scriba, TJ
   Sharpe, S
   Treiner, E
   Van Rhijn, I
   Williams, A
AF Joosten, Simone A.
   Ottenhoff, Tom H. M.
   Lewinsohn, David M.
   Hoft, Daniel F.
   Moody, D. Branch
   Seshadri, Chetan
   Altman, John D.
   Behar, Samuel M.
   Chien, Yueh-hsiu
   Hanekom, Willem A.
   Kronenberg, Mitchell
   Picker, Louis J.
   Sacha, Jonah B.
   Scriba, Thomas J.
   Sharpe, Sally
   Treiner, Emmanuel
   Van Rhijn, Ildiko
   Williams, Ann
CA Collaboration TB Vaccine Discover
   Bill Melinda Gates Fdn
TI Harnessing donor unrestricted T-cells for new vaccines against
   tuberculosis
SO VACCINE
LA English
DT Review
DE Vaccine; Tuberculosis; Donor-unrestricted T-cells; Tetramers
ID CALMETTE-GUERIN VACCINATION; MYCOBACTERIUM-TUBERCULOSIS; MAIT CELLS;
   HLA-E; BUTYROPHILIN 3A1; LIPID ANTIGEN; DIACYLATED SULFOGLYCOLIPIDS;
   IMMUNE-RESPONSES; RHESUS MACAQUES; BCG VACCINATION
AB Mycobacterium bovis bacille Calmette-Guerin (BCG) prevents extrapulmonary tuberculosis (TB) and death among infants but fails to consistently and sufficiently prevent pulmonary TB in adults. Thus, TB remains the leading infectious cause of death worldwide, and new vaccine approaches are urgently needed. T-cells are important for protective immunity to Mycobacterium tuberculosis (Mtb), but the optimal T-cell antigens to be included in new vaccines are not established. T-cells are often thought of as responding mainly to peptide antigens presented by polymorphic major histocompatibility complex (MHC) I and II molecules. Over the past two decades, the number of non-peptidic Mtb derived antigens for alpha beta and gamma delta T-cells has expanded rapidly, creating broader perspectives about the types of molecules that could be targeted by T-cell-based vaccines against TB. Many of these non-peptide responsive T-cell subsets in humans are activated in a manner that is unrestricted by classical MHC-dependent antigen-presenting systems, but instead require essentially nonpolymorphic presentation systems. These systems are Cluster of differentiation 1 (CD1), MHC related protein 1 (MR1), butyrophilin 3A1, as well as the nonclassical MHC class Ib family member HLA-E. Thus, the resulting T-cell responses can be shared among a genetically diverse population, creating the concept of donor-unrestricted T-cells (DURTs). Here, we review evidence that DURTs are an abundant component of the human immune system and recognize many antigens expressed by Mtb, including antigens that are expressed in BCG and other candidate whole cell vaccines. Further, DURTs exhibit functional diversity and demonstrate the ability to control microbial infection in small animal models. Finally, we outline specific knowledge gaps and research priorities that must be addressed to realize the full potential of DURTs as part of new TB vaccines approaches. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Joosten, Simone A.; Ottenhoff, Tom H. M.] Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands.
   [Lewinsohn, David M.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Dept Med, Portland, OR USA.
   [Hoft, Daniel F.] St Louis Univ, Doisy Res Ctr, Dept Internal Med, 8th Floor,1100 S Grand Blvd, St Louis, MO 63104 USA.
   [Moody, D. Branch] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Dept Med, Boston, MA 02115 USA.
   [Seshadri, Chetan] Univ Washington, Dept Med, Div Infect Dis, Seattle, WA USA.
   [Seshadri, Chetan] Univ Washington, TB Res & Training Ctr, Seattle, WA 98195 USA.
RP Seshadri, C (reprint author), Univ Washington, Med Ctr, 750 Republican St,Room E663, Seattle, WA 98109 USA.
EM seshadri@u.washington.edu
RI Joosten, Simone A/F-1357-2011; Scriba, Thomas/AAH-9413-2020
OI Joosten, Simone A/0000-0002-9878-0863; Scriba,
   Thomas/0000-0002-0641-1359; Ottenhoff, T.H.M./0000-0003-3706-3403;
   Seshadri, Chetan/0000-0003-2783-7540
FU  [OPP1190451]
FX The authors would like to acknowledge all the members of the CTVD DURT
   Working Group for helpful discussions and critical review of the
   manuscript. Listed in alphabetical order, these are John D. Altman,
   Samuel M. Behar, Yueh-hsiu Chien, Willem A. Hanekom, Mitchell
   Kronenberg, Louis J. Picker, Jonah B. Sacha, Thomas J. Scriba, Sally
   Sharpe, Emmanuel Treiner, Ildiko Van Rhijn, and Ann Williams. The
   authors also acknowledge the efforts of Adriaan Minnaard, Martine
   Gilleron, and Jacques Prandi for synthesizing mycobacterial lipid
   antigens that are available through the Bill and Melinda Gates
   Foundation Lipid Bank (OPP1190451 to C.S.).
CR Abate G, 2016, INFECT IMMUN, V84, P580, DOI 10.1128/IAI.01262-15
   Afrache H, 2017, IMMUNOGENETICS, V69, P379, DOI 10.1007/s00251-017-0980-z
   Arbues A, 2013, VACCINE, V31, P4867, DOI 10.1016/j.vaccine.2013.07.051
   Bai L, 2012, EUR J IMMUNOL, V42, P2505, DOI 10.1002/eji.201242531
   BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0
   Behar SM, 1999, J EXP MED, V189, P1973, DOI 10.1084/jem.189.12.1973
   Bian Y, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006384
   Blazevic A, 2017, TUBERCULOSIS, V105, P108, DOI 10.1016/j.tube.2017.05.001
   Boer MC, 2015, CLIN VACCINE IMMUNOL, V22, P778, DOI 10.1128/CVI.00162-15
   Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869
   Caccamo N, 2015, EUR J IMMUNOL, V45, P1069, DOI 10.1002/eji.201445193
   Cendron D, 2007, EUR J IMMUNOL, V37, P549, DOI 10.1002/eji.200636343
   Chancellor A, 2017, P NATL ACAD SCI USA, V114
   Chen Z, 2017, MUCOSAL IMMUNOL, V10, P58, DOI 10.1038/mi.2016.39
   Cheng CF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22061-x
   Chua WJ, 2012, INFECT IMMUN, V80, P3256, DOI 10.1128/IAI.00279-12
   Corbett AJ, 2014, NATURE, V509, P361, DOI 10.1038/nature13160
   Cowley SC, 2005, J EXP MED, V202, P309, DOI 10.1084/jem.20050569
   Dascher CC, 2003, INT IMMUNOL, V15, P915, DOI 10.1093/intimm/dxg091
   de Jong A, 2007, CHEM BIOL, V14, P1232, DOI 10.1016/j.chembiol.2007.09.010
   de Jong A, 2010, NAT IMMUNOL, V11, P1102, DOI 10.1038/ni.1956
   de la Salle H, 2005, SCIENCE, V310, P1321, DOI 10.1126/science.1115301
   DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429
   DeWitt WS, 2018, J IMMUNOL, V201, P888, DOI 10.4049/jimmunol.1800186
   Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632
   Ding Y, 2015, CLIN VACCINE IMMUNOL, V22, P761, DOI 10.1128/CVI.00612-14
   Dusseaux M, 2011, BLOOD, V117, P1250, DOI 10.1182/blood-2010-08-303339
   Felio K, 2009, J EXP MED, V206, P2497, DOI 10.1084/jem.20090898
   Fletcher HA, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0617-3
   Fletcher HA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11290
   Flynn JL, 2015, IMMUNOL REV, V264, P60, DOI 10.1111/imr.12258
   Georgel P, 2011, MOL IMMUNOL, V48, P769, DOI 10.1016/j.molimm.2010.12.002
   Gherardin NA, 2016, IMMUNITY, V44, P32, DOI 10.1016/j.immuni.2015.12.005
   Gilleron M, 2004, J EXP MED, V199, P649, DOI 10.1084/jem.20031097
   Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298
   Gold MC, 2013, MUCOSAL IMMUNOL, V6, P35, DOI 10.1038/mi.2012.45
   Gold MC, 2014, J EXP MED, V211, P1601, DOI 10.1084/jem.20140507
   Gold MC, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000407
   Gold MC, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040039
   Gras S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13257
   Greene JM, 2017, MUCOSAL IMMUNOL, V10, P802, DOI 10.1038/mi.2016.91
   Grimsley C, 1997, HUM IMMUNOL, V52, P33, DOI 10.1016/S0198-8859(96)00241-8
   Grode L, 2013, VACCINE, V31, P1340, DOI 10.1016/j.vaccine.2012.12.053
   Gu SY, 2017, P NATL ACAD SCI USA, V114, pE7311, DOI 10.1073/pnas.1707547114
   Guiard J, 2009, J IMMUNOL, V182, P7030, DOI 10.4049/jimmunol.0804044
   Hansen SG, 2018, NAT MED, V24, P130, DOI 10.1038/nm.4473
   Hansen SG, 2016, SCIENCE, V351, P714, DOI 10.1126/science.aac9475
   Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519
   Hansen SG, 2013, SCIENCE, V340, P940, DOI 10.1126/science.1237874
   Harriff MJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao2556
   Harriff MJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04894-0
   Hatherill M, 2018, NEW ENGL J MED
   Hawkridge T, 2008, J INFECT DIS, V198, P544, DOI 10.1086/590185
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Heinzel AS, 2002, J EXP MED, V196, P1473, DOI 10.1084/jem.20020609
   Hoare HL, 2006, NAT IMMUNOL, V7, P256, DOI 10.1038/ni1312
   Hoft DF, 1998, J IMMUNOL, V161, P1045
   Howson LJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02540-x
   Ishizuka AS, 2016, NAT MED, V22, P614, DOI 10.1038/nm.4110
   James CA, 2018, CELL CHEM BIOL, V25, P392, DOI 10.1016/j.chembiol.2018.01.006
   Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036
   Joosten SA, 2016, J IMMUNOL RES, DOI 10.1155/2016/2695396
   Joosten SA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000782
   Kallert S, 2015, TUBERCULOSIS, V95, P452, DOI 10.1016/j.tube.2015.04.001
   Kasmar AG, 2013, J IMMUNOL, V191, P4499, DOI 10.4049/jimmunol.1301660
   Kasmar AG, 2011, J EXP MED, V208, P1741, DOI 10.1084/jem.20110665
   Keller AN, 2017, NAT IMMUNOL, V18, P402, DOI 10.1038/ni.3679
   Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605
   Koay HF, 2016, NAT IMMUNOL, V17, P1300, DOI 10.1038/ni.3565
   Kurioka A, 2015, MUCOSAL IMMUNOL, V8, P429, DOI 10.1038/mi.2014.81
   Laddy DJ, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00776-17
   Lai X, 2003, CLIN EXP IMMUNOL, V133, P182, DOI 10.1046/j.1365-2249.2003.02209.x
   Layre E, 2009, CHEM BIOL, V16, P82, DOI 10.1016/j.chembiol.2008.11.008
   Layton ED, 2018, J IMMUNOL METHODS, V458, P44, DOI 10.1016/j.jim.2018.04.004
   Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890
   Lepore M, 2017, ELIFE, V6, DOI 10.7554/eLife.24476
   Lin PL, 2012, AIDS RES HUM RETROV, V28, P1693, DOI [10.1089/aid.2012.0028, 10.1089/AID.2012.0028]
   Ly D, 2013, J EXP MED, V210, P729, DOI 10.1084/jem.20120624
   Lyke KE, 2017, P NATL ACAD SCI USA, V114, P2711, DOI 10.1073/pnas.1615324114
   Mangan BA, 2013, J IMMUNOL, V191, P30, DOI 10.4049/jimmunol.1300121
   Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790
   McGill JL, 2014, VET IMMUNOL IMMUNOP, V159, P133, DOI 10.1016/j.vetimm.2014.02.010
   McMurtrey C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188288
   Meierovics A, 2013, P NATL ACAD SCI USA, V110, pE3119, DOI 10.1073/pnas.1302799110
   Meierovics AI, 2016, J EXP MED, V213, P2793, DOI 10.1084/jem.20160637
   Minhinnick A, 2016, J INFECT DIS, V213, P824, DOI 10.1093/infdis/jiv482
   Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271
   Montamat-Sicotte DJ, 2011, J CLIN INVEST, V121, P2493, DOI 10.1172/JCI46216
   Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119
   Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283
   Morita D, 2013, INFECT IMMUN, V81, P311, DOI 10.1128/IAI.00871-12
   Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]
   Peng MY, 2008, CELL MOL IMMUNOL, V5, P203, DOI 10.1038/cmi.2008.25
   PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1
   PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0
   Prezzemolo T, 2017, EUR J IMMUNOL
   Qaqish A, 2017, J IMMUNOL, V198, P4753, DOI 10.4049/jimmunol.1602019
   Reinink P, 2016, IMMUNOGENETICS, V68, P515, DOI 10.1007/s00251-016-0926-x
   Riegert P, 1998, J IMMUNOL, V161, P4066
   Rodgers JR, 2005, NAT REV IMMUNOL, V5, P459, DOI 10.1038/nri1635
   Rosat JP, 1999, J IMMUNOL, V162, P366
   Rowland R, 2011, EXPERT REV VACCINES, V10, P645, DOI [10.1586/ERV.11.28, 10.1586/erv.11.28]
   Roy A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4643
   Roy S, 2016, J IMMUNOL, V196, P1933, DOI 10.4049/jimmunol.1502202
   Roy S, 2014, P NATL ACAD SCI USA, V111, pE4648, DOI 10.1073/pnas.1408549111
   Rusk RA, 2017, VET IMMUNOL IMMUNOP, V193, P38, DOI 10.1016/j.vetimm.2017.10.004
   Sakala IG, 2015, J IMMUNOL, V195, P587, DOI 10.4049/jimmunol.1402545
   Sandstrom A, 2014, IMMUNITY, V40, P490, DOI 10.1016/j.immuni.2014.03.003
   Scriba TJ, 2010, EUR J IMMUNOL, V40, P279, DOI 10.1002/eji.200939754
   Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800
   Seshadri C, 2017, GENES IMMUN, V18, P8, DOI 10.1038/gene.2016.41
   Seshadri C, 2014, GENES IMMUN, V15, P195, DOI 10.1038/gene.2014.5
   Seshadri C, 2015, J IMMUNOL, V195, P4595, DOI 10.4049/jimmunol.1501285
   Seshadri C, 2013, J IMMUNOL, V191, P1586, DOI 10.4049/jimmunol.1300575
   Shang SB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02709
   Shen Y, 2002, SCIENCE, V295, P2255, DOI 10.1126/science.1068819
   Sherwood AM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002536
   Spencer CT, 2008, J IMMUNOL, V181, P4471, DOI 10.4049/jimmunol.181.7.4471
   Spencer CT, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003119
   Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121
   Strong RK, 2003, J BIOL CHEM, V278, P5082, DOI 10.1074/jbc.M208268200
   Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4
   Toulon A, 2009, J EXP MED, V206, P743, DOI 10.1084/jem.20081787
   Ulrichs T, 2003, INFECT IMMUN, V71, P3076, DOI 10.1128/IAI.71.6.3076-3087.2003
   Ussher JE, 2016, EUR J IMMUNOL, V46, P1600, DOI 10.1002/eji.201545969
   Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509
   van Meijgaarden KE, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004671
   Van Rhijn I, 2017, EUR J IMMUNOL, V47, P1525, DOI 10.1002/eji.201747062
   Van Rhijn I, 2015, NAT REV IMMUNOL, V15, P643, DOI 10.1038/nri3889
   Van Rhijn I, 2015, J IMMUNOL, V195, P1927, DOI 10.4049/jimmunol.1500943
   Van Rhijn I, 2013, NAT IMMUNOL, V14, P706, DOI 10.1038/ni.2630
   Van Rhijn I, 2013, ADV EXP MED BIOL, V783, P181, DOI 10.1007/978-1-4614-6111-1_10
   Vavassori S, 2013, NAT IMMUNOL, V14, P908, DOI 10.1038/ni.2665
   Verreck FAW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005264
   von Reyn CF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175215
   von Reyn CF, 2010, AIDS, V24, P675, DOI 10.1097/QAD.0b013e3283350f1b
   Walters LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05459-z
   Wang H, 2015, J IMMUNOL, V195, P4583, DOI 10.4049/jimmunol.1500314
   Wang HM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05202-8
   Werninghaus K, 2009, J EXP MED, V206, P89, DOI 10.1084/jem.20081445
   World Health Organization, 2017, WHO REPORT
   Wu HL, 2018, J IMMUNOL, V200, P49, DOI 10.4049/jimmunol.1700841
   Xi XY, 2013, CLIN VACCINE IMMUNOL, V20, P530, DOI 10.1128/CVI.00584-12
   Xia M, 2016, INFECT IMMUN, V84, P2449, DOI 10.1128/IAI.01322-15
   Zhao J, 2015, ELIFE, V4
   Zumla A, 2013, NEW ENGL J MED, V368, P745, DOI 10.1056/NEJMra1200894
NR 146
TC 9
Z9 11
U1 3
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3022
EP 3030
DI 10.1016/j.vaccine.2019.04.050
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300009
PM 31040086
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Jiang, HY
   Shi, YD
   Zhang, X
   Pan, LY
   Xie, YR
   Jiang, CM
   Deng, M
   Ruan, B
AF Jiang, Hai-yin
   Shi, Yu-dan
   Zhang, Xue
   Pan, Li-ya
   Xie, Yi-rui
   Jiang, Chun-ming
   Deng, Min
   Ruan, Bing
TI Human papillomavirus vaccination and the risk of autoimmune disorders: A
   systematic review and meta-analysis
SO VACCINE
LA English
DT Review
DE HPV; Vaccine; Autoimmune disorders; Immune; Meta-analysis
ID GUILLAIN-BARRE-SYNDROME; ADVERSE EVENTS; AS04-ADJUVANTED VACCINE;
   MULTIPLE-SCLEROSIS; HPV VACCINATION; OPTIC NEURITIS; VIRUS VACCINE;
   SAFETY; WOMEN; INFECTION
AB Introduction: Human papillomavirus (HPV) vaccination has been proven to effectively protect against HPV infection and infection-associated cancer. However, there are concerns about the relationship between HPV vaccination and the risk of autoimmune disorders (ADs). Therefore, we performed a systematic review and meta-analysis to comprehensively evaluate the relationship between HPV vaccination and ADs risk.
   Methods: To identify relevant studies, we conducted a systematic search in EMBASE and PubMed databases of scientific articles published through June 2018. Fixed or random effects models were adopted to estimate overall relative risk.
   Results: In total, 20 studies (12 cohort studies, 6 case-control studies, and 2 randomized controlled trials) involving more than 169,000 AD events were included in our meta-analysis. Our results show that HPV vaccination was not associated with an increased risk of subsequent ADs (odds ratio [OR] = 1.003, 95% confidence interval (CI): 0.95-1.06), particularly among those with a prior ADs (OR = 0.82, 95% CI: 0.7-0.96). Most of the subgroup analysis results based on the location or type of ADs were consistent with the overall results
   Conclusion: No evidence of an association between HPV vaccination and ADs was found. Given the low number of estimates for individual AD, additional and larger observational studies are needed to verify our findings. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jiang, Hai-yin; Zhang, Xue; Pan, Li-ya; Xie, Yi-rui; Deng, Min; Ruan, Bing] Zhejiang Univ, Affiliated Hosp 1, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Shi, Yu-dan] Taizhou First Peoples Hosp, Dept Chinese Internal Med, Taizhou 318020, Zhejiang, Peoples R China.
   [Jiang, Chun-ming] Zhejiang Univ, Sch Med, Affiliated Hangzhou Peoples Hosp 1, Dept Pediat, Hangzhou, Zhejiang, Peoples R China.
RP Ruan, B (reprint author), Zhejiang Univ, Affiliated Hosp 1, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China.
EM ruanbing@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81601186]; Medical et Health Technology Program of
   Zhejiang Province [2016KYA072]
FX This study was supported by the National Natural Science Foundation of
   China (Grant No.81601186) and the Medical et Health Technology Program
   of Zhejiang Province (Grant No. 2016KYA072)
CR Andrews N, 2017, VACCINE, V35, P1729, DOI 10.1016/j.vaccine.2017.01.076
   Angelo MG, 2014, PHARMACOEPIDEM DR S, V23, P466, DOI 10.1002/pds.3554
   Arnheim-Dahlstom L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5906
   Baker B, 2015, EXPERT OPIN DRUG SAF, V14, P1387, DOI 10.1517/14740338.2015.1073710
   Balamoutsos G, 2010, MULT SCLER, V16, pS93
   Baxter R, 2016, CLIN INFECT DIS, V63, P79, DOI 10.1093/cid/ciw224
   Ben-Horin S, 2014, AUTOIMMUN REV, V13, P24, DOI 10.1016/j.autrev.2013.06.002
   Bizjak M, 2016, SEMIN HEMATOL, V53, pS48, DOI 10.1053/j.seminhematol.2016.04.014
   Caorsi R, 2012, AUTOIMMUN REV, V12, P81, DOI 10.1016/j.autrev.2012.07.027
   Chao C, 2012, J INTERN MED, V271, P193, DOI 10.1111/j.1365-2796.2011.02467.x
   Clifford GM, 2017, CLIN INFECT DIS, V64, P1228, DOI 10.1093/cid/cix135
   Das A, 2008, MED J AUSTRALIA, V189, P178, DOI 10.5694/j.1326-5377.2008.tb01960.x
   Deceuninck G, 2018, EXPERT REV VACCINES, V17, P99, DOI 10.1080/14760584.2018.1388168
   Della Corte C, 2011, VACCINE, V29, P4654, DOI 10.1016/j.vaccine.2011.05.002
   Esposito S, 2014, EXPERT REV VACCINES, V13, P1387, DOI 10.1586/14760584.2014.943195
   Ford AC, 2013, AM J GASTROENTEROL, V108, P1268, DOI 10.1038/ajg.2013.138
   Frisch M, 2018, INT J EPIDEMIOL, V47, P634, DOI 10.1093/ije/dyx273
   Geier DA, 2017, IMMUNOL RES, V65, P46, DOI 10.1007/s12026-016-8815-9
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   Grimaldi-Bensouda L, 2014, J INTERN MED, V275, P398, DOI 10.1111/joim.12155
   Grimaldi-Bensouda L, 2017, J AUTOIMMUN, V79, P84, DOI 10.1016/j.jaut.2017.01.005
   Gronlund O, 2016, J Intern Med, V280, P618, DOI 10.1111/joim.12535
   Hanley SJB, 2015, LANCET, V385, P2571, DOI 10.1016/S0140-6736(15)61152-7
   Hansen BT, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019005
   Heijstek MW, 2014, ANN RHEUM DIS, V73, P1500, DOI 10.1136/annrheumdis-2013-203429
   Higgins, 2014, COCHRANE HDB SYSTEMA
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hviid A, 2018, J INTERN MED, V283, P154, DOI 10.1111/joim.12694
   Ito Haruyasu, 2016, Nihon Rinsho Meneki Gakkai Kaishi, V39, P145, DOI 10.2177/jsci.39.145
   Langer-Gould A, 2014, JAMA NEUROL, V71, P1506, DOI 10.1001/jamaneurol.2014.2633
   Lehtinen M, 2016, HUM VACC IMMUNOTHER, V12, P3177, DOI 10.1080/21645515.2016.1183847
   Lin CQ, 2018, LANCET INFECT DIS, V18, P198, DOI [10.1016/S1473-3099(17)30653-9, 10.1016/s1473-3099(17)30653-9]
   Liu EY, 2018, CAN MED ASSOC J, V190, pE648, DOI 10.1503/cmaj.170871
   Lyrio LDC, 2013, RHEUMATOL INT, V33, P335, DOI 10.1007/s00296-012-2426-0
   Menge T, 2012, NEUROLOGY, V79, P285, DOI 10.1212/WNL.0b013e31825fdead
   Miranda S, 2017, VACCINE, V35, P4761, DOI 10.1016/j.vaccine.2017.06.030
   Mouchet J, 2018, PHARMACOL RES, V132, P108, DOI 10.1016/j.phrs.2018.04.007
   Paul K., 1982, SOC SCI MED, V2016, P193
   Pellegrino P, 2014, AUTOIMMUN REV, V13, P736, DOI 10.1016/j.autrev.2014.01.054
   Radetti G, 2014, ENDOCR DEV, V26, P158, DOI 10.1159/000363162
   Scheller NM, 2015, JAMA-J AM MED ASSOC, V313, P54, DOI 10.1001/jama.2014.16946
   Soybilgic A, 2010, LUPUS, V19, P177
   Sridhar G, 2017, HUM VACC IMMUNOTHER, V13, P1705, DOI 10.1080/21645515.2017.1310788
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Verstraeten T, 2008, VACCINE, V26, P6630, DOI 10.1016/j.vaccine.2008.09.049
   Wang MH, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1250-0
   Wildemann B, 2009, NEUROLOGY, V72, P2132, DOI 10.1212/WNL.0b013e3181aa53bb
   Willame C, 2016, HUM VACC IMMUNOTHER, V12, P2862, DOI 10.1080/21645515.2016.1199308
   Zard E, 2014, AUTOIMMUN REV, V13, P730, DOI 10.1016/j.autrev.2014.03.001
NR 50
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3031
EP 3039
DI 10.1016/j.vaccine.2019.04.049
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300010
PM 31036452
DA 2020-05-12
ER

PT J
AU Jiang, BM
   Patel, M
   Glass, RI
AF Jiang, Baoming
   Patel, Manish
   Glass, Roger I.
TI Polio endgame: Lessons for the global rotavirus vaccination program
SO VACCINE
LA English
DT Review
DE Poliovirus; Rotavirus; Rotavirus vaccine; Oral polio vaccine;
   Inactivated polio vaccine
ID INTUSSUSCEPTION RISK; PARALYTIC POLIOMYELITIS; UNITED-STATES; SILENT
   REINTRODUCTION; INTESTINAL IMMUNITY; CHILDHOOD DIARRHEA;
   ENHANCED-POTENCY; CUTTER INCIDENT; HEALTH-BENEFITS; DOUBLE-BLIND
AB Poliovirus and rotavirus share notable similarities. Although rotavirus is not amenable to eradication because of animal reservoirs, live, attenuated oral vaccines have been the bedrock of both prevention and control programs, providing intestinal and humoral immunity. Both programs have also encountered safety concerns and suboptimal immune responses to oral vaccines in low-income settings that have been challenges, prompting the search for alternative solutions. In this paper, we review the progress made by polio prevention and eradication efforts over the past six decades. Specifically, we discuss the roles of the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV) in achieving polio eradication, and explore potential application of these lessons to rotavirus. Recent scientific evidence has confirmed that a combined schedule of IPV and OPV adds synergistic value that may give the polio eradication effort the tools to end all poliovirus circulation worldwide. For rotavirus, oral vaccine is the only currently licensed and recommended vaccine for use in all children worldwide, providing heterologous protection against a broad range of strains. However, parenteral rotavirus vaccines are in the pre-clinical and clinical trial stage and insight from polio provides strong justification for accelerating the development of these vaccines. While challenges for parenteral rotavirus vaccines will need to be addressed, such as achieving protection against a broad range of strains, the principle of combined use of oral and parenteral rotavirus vaccines may provide the necessary humoral and intestinal immunity necessary to close the efficacy gaps between developing and developed countries, therefore controlling rotavirus worldwide. This strategy may also potentially reduce risk of intussusception. Published by Elsevier Ltd.
C1 [Jiang, Baoming] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Patel, Manish] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA.
   [Glass, Roger I.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
RP Patel, M (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS A-04, Atlanta, GA 30329 USA.
EM aul3@cdc.gov
CR Aliabadi N, 2016, CLIN MICROBIOL INFEC, V22, pS128, DOI 10.1016/j.cmi.2016.03.007
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P301
   [Anonymous], 1994, Wkly Epidemiol Rec, V69, P293
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P201
   Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Aylward B, 2011, VACCINE, V29, pD80, DOI 10.1016/j.vaccine.2011.10.005
   Aylward RB, 2006, BIOLOGICALS, V34, P133, DOI 10.1016/j.biologicals.2006.02.012
   Bar-Zen N, 2015, LANCET INFECT DIS, V15, P422, DOI 10.1016/S1473-3099(14)71060-6
   Beale A. J., 1993, Public Health Reviews, V21, P129
   BEALE AJ, 1990, LANCET, V335, P839, DOI 10.1016/0140-6736(90)90945-2
   Berkovich S, 1959, NEW ENGL J MED, V264, P1325
   Bhandari N, 2014, LANCET, V383, P2136, DOI 10.1016/S0140-6736(13)62630-6
   BISHOP RF, 1973, NEW ENGL J MED, V289, P1096
   Bonkoungou Isidore Juste O, 2018, Vaccine, V36, P7170, DOI 10.1016/j.vaccine.2017.12.056
   Bowen MD, 2012, EXPERT REV VACCINES, V11, P1311, DOI [10.1586/ERV.12.114, 10.1586/erv.12.114]
   Bresee JS, 2005, PEDIATR INFECT DIS J, V24, P947, DOI 10.1097/01.inf.0000186295.18969.e6
   Burnett E, 2018, PEDIATR DRUGS, V20, P223, DOI 10.1007/s40272-018-0283-3
   Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186
   Carlin JB, 2013, CLIN INFECT DIS, V57, P1427, DOI 10.1093/cid/cit520
   Clark AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188267
   Desai R, 2012, CLIN INFECT DIS, V54, P1397, DOI 10.1093/cid/cis191
   Dolan S, 2017, J INFECT DIS
   Enane LA, 2016, CLIN INFECT DIS, V62, pS168, DOI 10.1093/cid/civ1210
   ENDERS JF, 1949, SCIENCE, V109, P85, DOI 10.1126/science.109.2822.85
   Esona MD, 2010, HUM VACCIN, V6
   Estivariz CF, 2013, CURR OPIN VIROL, V3, P309, DOI 10.1016/j.coviro.2013.05.007
   Estivariz CF, 2012, LANCET INFECT DIS, V12, P128, DOI 10.1016/S1473-3099(11)70190-6
   Franco MA, 2006, VACCINE, V24, P2718, DOI 10.1016/j.vaccine.2005.12.048
   Galindo M, 2007, NEW ENGL J MED, V356, P1536
   Garon J, 2016, EXPERT REV VACCINES, P1
   Gastanaduy PA, 2016, CLIN INFECT DIS, V62, pS161, DOI 10.1093/cid/civ1207
   Gentsch JR, 2005, J INFECT DIS, V192, pS146, DOI 10.1086/431499
   GHENDON Y, 1994, B WORLD HEALTH ORGAN, V72, P973
   Glass RI, 2006, LANCET, V368, P323, DOI 10.1016/S0140-6736(06)68815-6
   Glass RI, 2018, VACCINE, V36, P2233, DOI 10.1016/j.vaccine.2018.03.008
   Grassly NC, 2006, SCIENCE, V314, P1150, DOI 10.1126/science.1130388
   Grassly NC, 2012, J INFECT DIS, V205, P1554, DOI 10.1093/infdis/jis241
   Groome MJ, 2017, LANCET INFECT DIS, V17, P843, DOI [10.1016/S1473-3099(17)30242-6, 10.1016/s1473-3099(17)30242-6]
   Henderson DA, 1997, REV MED VIROL, V7, P83, DOI 10.1002/(SICI)1099-1654(199707)7:2&lt;83::AID-RMV193&gt;3.0.CO;2-Q
   Herremans MMPT, 1997, CLIN DIAGN LAB IMMUN, V4, P499, DOI 10.1128/CDLI.4.5.499-503.1997
   Hird TR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002599
   Hull HF, 1997, SCIENCE, V277, P780, DOI 10.1126/science.277.5327.780
   HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4
   do Carmo GMI, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001024
   Isanaka S, 2017, NEW ENGL J MED, V376, P1121, DOI [10.1056/nejmoa1609462, 10.1056/NEJMoa1609462]
   Jafari H, 2014, SCIENCE, V345, P922, DOI 10.1126/science.1255006
   Jiang BM, 2013, HUM VACC IMMUNOTHER, V9, P1634, DOI 10.4161/hv.24958
   Jiang BM, 2008, VACCINE, V26, P6754, DOI 10.1016/j.vaccine.2008.10.008
   Jiang BM, 2002, CLIN INFECT DIS, V34, P1351, DOI 10.1086/340103
   JIANG V, 2010, HUM VACCIN, V6
   John J, 2014, LANCET, V384, P1505, DOI 10.1016/S0140-6736(14)60934-X
   John T J, 1972, Indian Pediatr, V9, P252
   JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457
   JOHN TJ, 1975, AM J EPIDEMIOL, V102, P414, DOI 10.1093/oxfordjournals.aje.a112180
   JOHN TJ, 1975, AM J EPIDEMIOL, V102, P422, DOI 10.1093/oxfordjournals.aje.a112181
   John TJ, 2004, B WORLD HEALTH ORGAN, V82, P53
   JOHN TJ, 1976, B WORLD HEALTH ORGAN, V54, P115
   Kapusinszky B, 2010, FEMS IMMUNOL MED MIC, V58, P211, DOI 10.1111/j.1574-695X.2009.00621.x
   Kew O, 2002, SCIENCE, V296, P356, DOI 10.1126/science.1068284
   Kew OM, 2005, ANNU REV MICROBIOL, V59, P587, DOI 10.1146/annurev.micro.58.030603.123625
   Kuehn BM, 2010, JAMA-J AM MED ASSOC, V304, P30, DOI 10.1001/jama.2010.863
   Leshem E, 2014, LANCET INFECT DIS, V14, P847, DOI 10.1016/S1473-3099(14)70832-1
   Lopman BA, 2011, J INFECT DIS, V204, P980, DOI 10.1093/infdis/jir492
   Ma HL, 2011, VACCINE, V29, P8429, DOI 10.1016/j.vaccine.2011.07.123
   Montagnon B J, 1989, Dev Biol Stand, V70, P27
   Moran-Gilad J, 2016, CLIN MICROBIOL INFEC, V22, pS140, DOI 10.1016/j.cmi.2016.06.018
   Moran-Gilad J, 2015, J CLIN VIROL, V66, P51, DOI 10.1016/j.jcv.2015.03.005
   MORINIERE BJ, 1993, LANCET, V341, P1545, DOI 10.1016/0140-6736(93)90693-B
   Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804
   MURRAY R, 1961, JAMA-J AM MED ASSOC, V175, P843, DOI 10.1001/jama.1961.03040100007003
   NATHANSON N, 1963, AM J HYG, V78, P16, DOI 10.1093/oxfordjournals.aje.a120327
   NATHANSON N, 1963, AM J HYG, V78, P29, DOI 10.1093/oxfordjournals.aje.a120328
   Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320
   ONORATO IM, 1991, J INFECT DIS, V163, P1, DOI 10.1093/infdis/163.1.1
   Parker EPK, 2014, J INFECT DIS, V210, P853, DOI 10.1093/infdis/jiu182
   Patel M, 2017, J INFECT DIS, V216, pS1, DOI 10.1093/infdis/jix117
   Patel M, 2016, NEW ENGL J MED, V374, P501, DOI 10.1056/NEJMp1514467
   Patel M, 2015, EXPERT REV VACCINES, V14, P749, DOI 10.1586/14760584.2015.1001750
   Patel M, 2009, J INFECT DIS, V200, pS39, DOI 10.1086/605035
   Patel M, 2009, JAMA-J AM MED ASSOC, V301, P2243, DOI 10.1001/jama.2009.756
   Patel MM, 2013, PEDIATR INFECT DIS J, V32, pE134, DOI 10.1097/INF.0b013e31827d3b68
   Patel MM, 2012, LANCET INFECT DIS, V12, P561, DOI 10.1016/S1473-3099(12)70029-4
   Patel MM, 2011, NEW ENGL J MED, V364, P2283, DOI 10.1056/NEJMoa1012952
   Patel MM, 2011, PEDIATR INFECT DIS J, V30, pS1, DOI 10.1097/INF.0b013e3181fefa1f
   Patel MM, 2009, EXPERT REV VACCINES, V8, P1555, DOI [10.1586/erv.09.106, 10.1586/ERV.09.106]
   PATRIARCA PA, 1991, REV INFECT DIS, V13, P926
   Pitzer VE, 2011, J R SOC INTERFACE
   Platt LR, 2014, J INFECT DIS, V210, pS380, DOI 10.1093/infdis/jiu184
   Resch TK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18973-9
   Rha B, 2014, EXPERT REV VACCINES, V13, P1339, DOI 10.1586/14760584.2014.942223
   Richardson V, 2011, NEW ENGL J MED, V365, P772, DOI 10.1056/NEJMc1100062
   Richardson V, 2010, NEW ENGL J MED, V362, P299, DOI 10.1056/NEJMoa0905211
   Roberts SJ, 2001, INDEPENDENT COMPONENT ANALYSIS: PRINCIPLES AND PRACTICE, P1
   ROBERTSON SE, 1988, LANCET, V1, P897
   Rose TL, 2013, EMERG INFECT DIS, V19, P1843, DOI 10.3201/eid1911.121407
   Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434
   SABIN AB, 1959, BRIT MED J, V1, P663, DOI 10.1136/bmj.1.5123.663
   SALK JE, 1954, AM J PUBLIC HEALTH, V44, P563, DOI 10.2105/AJPH.44.5.563
   Steele AD, 2019, HUM VACC IMMUNOTHER, V15, P1215, DOI 10.1080/21645515.2018.1553593
   STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568
   Sutter RW, 2013, VACCINES, P598
   Tasher D, 2016, VACCINE, V34, P299, DOI 10.1016/j.vaccine.2015.11.066
   Tate JE, 2018, NEW ENGL J MED, V378, P1521, DOI [10.1056/NEJMoa1713909, 10.1056/nejmoa1713909]
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Tate JE, 2018, EXPERT OPIN DRUG SAF
   Tsolenyanu Enyonam, 2018, Vaccine, V36, P7185, DOI 10.1016/j.vaccine.2018.01.058
   TULCHINSKY T, 1994, ISRAEL J MED SCI, V30, P489
   Velasquez DE, 2018, EXPERT REV VACCINES, V17, P145, DOI 10.1080/14760584.2018.1418665
   Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664
   Vidor E, 2013, VACCINES, P573
   Wang YH, 2019, VACCINE, V37, P698, DOI 10.1016/j.vaccine.2018.12.043
   Wang YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166038
   Wang YH, 2010, VACCINE, V28, P5432, DOI 10.1016/j.vaccine.2010.06.006
   WARD NA, 1995, LANCET, V345, P318, DOI 10.1016/S0140-6736(95)90305-4
   Weintraub ES, 2014, NEW ENGL J MED, V370, P513, DOI 10.1056/NEJMoa1311738
   World Health Organization, 2012, SCI EV SUPP 5 M SAGE
   Yih WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMoa1303164
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
NR 118
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3040
EP 3049
DI 10.1016/j.vaccine.2019.04.023
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300011
PM 31027927
DA 2020-05-12
ER

PT J
AU Atkinson, KM
   Wilson, K
   Murphy, MSQ
   El-Halabi, S
   Kahale, LA
   Laflamme, LL
   El-Khatib, Z
AF Atkinson, Katherine M.
   Wilson, Kumanan
   Murphy, Malia S. Q.
   El-Halabi, Soha
   Kahale, Lara A.
   Laflamme, Lucie L.
   El-Khatib, Ziad
TI Effectiveness of digital technologies at improving vaccine uptake and
   series completion - A systematic review and meta-analysis of randomized
   controlled trials
SO VACCINE
LA English
DT Review
DE Immunization; Technology; Vaccination Coverage; Health Education; Mobile
   Applications
ID TEXT MESSAGE REMINDERS; INFLUENZA VACCINATION; IMMUNIZATION RATES;
   MEASLES; IMPACT; INTERVENTION; COVERAGE; URBAN
AB Background: Recent outbreaks and renewed concerns about immunization coverage call for new and effective interventions to improve vaccine uptake. Digital technologies have the potential to help address both suboptimal vaccine uptake and series completion. However, the effectiveness of pushing information and reminders to patients through digital technologies to address vaccination is not known.
   Objective(s): The aim of this study is to determine if digital push interventions are effective in increasing vaccine uptake and series completion compared to non-digital interventions.
   Methods: We searched for RCTs where adults or parents of children were eligible for vaccination, the intervention was digital-push and the comparison group was non-digital. We included outcomes of vaccine uptake or series completion. We estimated summary effect sizes, heterogeneity using the chi(2) test and quantified using the 12 statistic. Where heterogeneity remained significant, we conducted subgroup analyses. We assessed risk of bias, certainty of evidence and publication bias.
   Results: The search identified 159 peer-reviewed scientific publications. After review, a total of 12 manuscripts representing 13 empirical studies published between 2012 and 2016 were included. When comparing digital push interventions to non-digital ones, patients had 1.18[1.11,1.25] the odds of receiving vaccination or series completion compared to controls. In parents of children aged 18 and younger, those receiving digital push had a 1.22[1.15,1.30] increased odds compared to controls. Both analyses had high statistical heterogeneity, with 12 values of 86% and 79% respectively. The risk of bias was low with 10 of 13 studies considered low risk in five or more domains. The certainty of evidence for series completion was very low and for vaccine uptake was assessed to be moderate.
   Conclusion: This study provides evidence that digital push technologies have a modest, positive impact on vaccine uptake and series completion compared to non-digital interventions. (C) 2019 Published by Elsevier Ltd.
C1 [Atkinson, Katherine M.; Laflamme, Lucie L.; El-Khatib, Ziad] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.
   [Atkinson, Katherine M.; Wilson, Kumanan; Murphy, Malia S. Q.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
   [Wilson, Kumanan] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
   [El-Halabi, Soha] Skoun Lebanese Addict Ctr, Beirut, Lebanon.
   [El-Halabi, Soha] Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, Sweden.
   [Kahale, Lara A.] Amer Univ Beirut, AUB GRADE Ctr, Beirut, Lebanon.
   [El-Khatib, Ziad] UQAT, World Hlth Programme, Quebec City, PQ, Canada.
RP Wilson, K (reprint author), Ottawa Hosp Res Inst, 1053 Carling Ave,Box 684, Ottawa, ON K1Y 4E9, Canada.
EM katkinson@ohri.ca; kwilson@ohri.ca
FU Canadian Institute for Health Research (CIHR) Doctoral Research
   AwardCanadian Institutes of Health Research (CIHR)
   [CIHR-IRSC:0092002293]; Grand Challenges Canada-Stars in Global Health
   [R-ST-POC-1807-12490]
FX This research did not receive any specific grant from funding agencies
   in the public, commercial or not-for-profit sectors. KA is supported
   through a Canadian Institute for Health Research (CIHR) Doctoral
   Research Award (CIHR-IRSC:0092002293). ZEK is supported by a Grand
   Challenges Canada-Stars in Global Health (Grant ID
   #R-ST-POC-1807-12490).
CR Abramson ZH, 2010, ANN FAM MED, V8, P293, DOI 10.1370/afm.1132
   Ahlers-Schmidt CR, 2012, HEALTH EDUC BEHAV, V39, P538, DOI 10.1177/1090198111420866
   Ahlers-Schmidt CR, 2012, VACCINE, V30, P5305, DOI 10.1016/j.vaccine.2012.06.058
   Ahlers-schmidt CR, 2011, MED 2 0 C
   [Anonymous], 2018, ANTIVAXXERS MEASLES
   Bangure D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1470-6
   Blumberg S. J., 2018, WIRELESS SUBSTITUTIO
   Calvert N, 2013, LANCET, V381, P1625, DOI 10.1016/S0140-6736(13)60953-8
   Clark SJ, 2011, PEDIATRICS
   Darville GC, 2018, J ADOLESC FAM HLTH, V9, P9
   Davis FD, 1985, THEORY RES
   Dawson B, 2015, AUST NZ J PUBL HEAL, V39, P104, DOI 10.1111/1753-6405.12328
   Domek GJ, 2016, VACCINE, V34, P2437, DOI 10.1016/j.vaccine.2016.03.065
   European Centre for Disease Control and Prevention, 2018, MEASL OUTBR STILL ON
   Ghadieh AS, 2015, VACCINE, V33, P5868, DOI 10.1016/j.vaccine.2015.07.050
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Herrett E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016604
   Hofstetter AM, 2015, VACCINE, V33, P5741, DOI 10.1016/j.vaccine.2015.09.042
   Hutchins SS, 2004, J INFECT DIS, V189, pS146, DOI 10.1086/379651
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   Jpt H, 2011, HDB SYST REV INT VER
   Kempe A, 2015, JAMA PEDIATR, V169, P365, DOI 10.1001/jamapediatrics.2014.3670
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Majumder MS, 2015, JAMA PEDIATR, V169, P494, DOI 10.1001/jamapediatrics.2015.0384
   Nagykaldi Z, 2012, J AM BOARD FAM MED, V25, P158, DOI 10.3122/jabfm.2012.02.110130
   O'Leary ST, 2015, PEDIATRICS
   Ozawa S, 2013, HUM VACC IMMUNOTHER, V9, P1774, DOI 10.4161/hv.24961
   Parasuraman A, 2015, J SERV RES-US, V18, P59, DOI 10.1177/1094670514539730
   Patel A, 2014, VACCINE, V32, P2428, DOI 10.1016/j.vaccine.2014.02.095
   Pich J, 2019, INT J NURS STUD, V91, P144, DOI 10.1016/j.ijnurstu.2018.05.015
   Richman AR, 2016, J AM COLL HEALTH, V64, P269, DOI 10.1080/07448481.2015.1117466
   Ruffin MT, 2015, J AM BOARD FAM MED, V28, P324, DOI 10.3122/jabfm.2015.03.140082
   Stack ML, 2011, HEALTH AFFAIR, V30, P1021, DOI 10.1377/hlthaff.2011.0382
   Stockwell MS, 2014, AM J PUBLIC HEALTH, V104, pE7, DOI 10.2105/AJPH.2013.301620
   Stockwell MS, 2012, JAMA-J AM MED ASSOC, V307, P1702, DOI 10.1001/jama.2012.502
   Stockwell MS, 2012, AM J PUBLIC HEALTH, V102, pE15, DOI 10.2105/AJPH.2011.300331
   Stockwell MS, 2014, PEDIATRICS
   Szilagyi PG, 2000, JAMA-J AM MED ASSOC, V284, P1820, DOI 10.1001/jama.284.14.1820
   Tozzi AE, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00036
   Vann JCJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003941.pub3
   Wilson K, 2015, HUM VACC IMMUNOTHER, V11, P2395, DOI 10.1080/21645515.2015.1057362
   World Health Organization, 2014, NEV MISS AN JAB
   World Health Organization, 2018, MEASL CAS HIT REC HI
   Zhao Y, 2003, MODEL COMPUTATION PU
NR 44
TC 2
Z9 2
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3050
EP 3060
DI 10.1016/j.vaccine.2019.03.063
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300012
PM 31036457
DA 2020-05-12
ER

PT J
AU Moller, J
   Kraner, M
   Sonnewald, U
   Sangal, V
   Tittlbach, H
   Winkler, J
   Winkler, TH
   Melnikov, V
   Lang, R
   Sing, A
   Mattos-Guaraldi, AL
   Burkovski, A
AF Moeller, Jens
   Kraner, Max
   Sonnewald, Uwe
   Sangal, Vartul
   Tittlbach, Hannes
   Winkler, Julia
   Winkler, Thomas H.
   Melnikov, Vyacheslav
   Lang, Roland
   Sing, Andreas
   Mattos-Guaraldi, Ana Luiza
   Burkovski, Andreas
TI Proteomics of diphtheria toxoid vaccines reveals multiple proteins that
   are immunogenic and may contribute to protection of humans against
   Corynebacterium diphtheriae
SO VACCINE
LA English
DT Article
DE Coryriebacteria; Corynebacterium ulcerans; Exoproteome; Mass
   spectrometry; Proteomics; Secretome; Vaccination
ID BORDETELLA-PERTUSSIS; LIQUID-CHROMATOGRAPHY; PROVIDES INSIGHTS;
   VACCINATION; TETANUS; QUANTITATION; RESURGENCE; MIXTURES; ULCERANS;
   STATES
AB Introduced for mass immunization in the 1920s, vaccines against diphtheria are among the oldest and safest vaccines known. The basic principle of their production is the inactivation of purified diphtheria toxin by formaldehyde cross-linking, which converts the potentially fatal toxin in a completely harmless protein aggregate, which is still immunogenic. Since in addition to diphtheria toxin also other proteins may be secreted by Corynebacterium diphtheriae during cultivation, we assumed that diphtheria toxoid might not be the only component present in the vaccine. To address this question, we established a protocol to reverse formaldehyde cross-linking and carried out mass spectrometric analyses. Different secreted, membrane-associated and cytoplasmic proteins of C. diphtheriae were detected in several vaccine preparations from across the world. Based on these results, bioinformatics and Western blot analyses were applied to characterize if these proteins are immunogenic and may therefore support protection against C diphtheriae. In frame of this study, we could show that the C diphtheriae toxoid vaccines induce antibodies against different C. diphtheriae proteins and against diphtheria toxin secreted by Corynebacterium ulcerans, an emerging pathogen which is outnumbering C diphtheriae as cause of diphtheria-like illness in Western Europe. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Moeller, Jens; Burkovski, Andreas] Friedrich Alexander Univ Erlangen Nurnberg, Staudtstr 5, D-91058 Erlangen, Germany.
   [Kraner, Max; Sonnewald, Uwe] Friedrich Alexander Univ Erlangen Nurnberg, Lehrstuhl Biochem, Erlangen, Germany.
   [Sangal, Vartul] Northumbria Univ, Fac Hlth & Life Sci, Newcastle Upon Tyne, Tyne & Wear, England.
   [Tittlbach, Hannes; Winkler, Thomas H.] Friedrich Alexander Univ Erlangen Nurnberg, Lehrstuhl Genet, Erlangen, Germany.
   [Winkler, Julia] Friedrich Alexander Univ Erlangen Nurnberg, Med Klin 5, Univ Klinikum Erlangen, Erlangen, Germany.
   [Melnikov, Vyacheslav] Gabrichevsky Res Inst Epidemiol & Microbiol, Moscow, Russia.
   [Lang, Roland] Friedrich Alexander Univ Erlangen Nurnberg, Inst Clin Microbiol Immunol & Hyg, Univ Klinikum Erlangen, Erlangen, Germany.
   [Sing, Andreas] Bayer Landesamt Gesundheit & Lebensmittelsicherhe, German Natl Consiliary Lab Diphtheria, Oberschleissheim, Germany.
   [Mattos-Guaraldi, Ana Luiza] Univ Estado Rio de Janeiro, Fac Ciencias Med, Rio De Janeiro, Brazil.
RP Burkovski, A (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Staudtstr 5, D-91058 Erlangen, Germany.
EM andreas.burkovski@fau.de
RI Sangal, Vartul/AAB-5426-2020; Melnikov, Vyacheslav G/L-2795-2014;
   Sonnewald, Uwe/J-7875-2012
OI Sangal, Vartul/0000-0002-7405-8446; Melnikov, Vyacheslav
   G/0000-0002-0825-7930; Sonnewald, Uwe/0000-0003-1835-5339
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG)
   [SFB796]; German Academic Exchange Service (DAAD fellowship)
FX The study was supported by the Deutsche Forschungsgemeinschaft in frame
   of SFB796 (project B6 and Z1) and the German Academic Exchange Service
   (DAAD fellowship to V.M.).
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P417
   [Anonymous], 1991, MMWR Recomm Rep, V40, P1
   Antunes CA, 2018, GENOME ANNOUNC, P1
   BARKSDALE L, 1970, Bacteriological Reviews, V34, P378
   Berger A, 2018, CORYNEBACTERIUM ULCE
   Bittel M, 2018, PROTEOMES, V6, DOI 10.3390/proteomes6020018
   Blom J, 2016, NUCLEIC ACIDS RES, V44, pW22, DOI 10.1093/nar/gkw255
   BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203
   Bondarenko PV, 2002, ANAL CHEM, V74, P4741, DOI 10.1021/ac0256991
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Burkovski A, PROKARYOTES PROKARYO, P1
   Burkovski A, 2016, HUMAN EMERGING AND RE-EMERGING INFECTIONS: VIRAL AND PARASITIC INFECTIONS, VOL 1, P699
   Burkovski A, 2015, CORYNEBACTERIUM GLUTAMICUM: FROM SYSTEMS BIOLOGY TO BIOTECHNOLOGICAL APPLICATIONS, P1
   Cerdeno-Tarraga AM, 2003, NUCLEIC ACIDS RES, V31, P6516, DOI 10.1093/nar/gkg874
   Chelius D, 2002, J PROTEOME RES, V1, P317, DOI 10.1021/pr025517j
   Clarke KEN, 2017, WHO SAGE M 2017
   Deshpande A, 2015, EUROSURVEILLANCE, V20, P7, DOI 10.2807/1560-7917.ES.2015.20.49.30088
   Dias AASO, 2010, VECTOR-BORNE ZOONOT, V10, P743, DOI 10.1089/vbz.2009.0132
   Dittmann S, 2000, J INFECT DIS, V181, pS10, DOI 10.1086/315534
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Eskola J, 1998, BRIT MED BULL, V54, P635
   European Centre for Disease Prevention and Control, 2018, ANN EP REP 2016
   GALAZKA AM, 1995, EUR J EPIDEMIOL, V11, P107, DOI 10.1007/BF01719955
   GALAZKA AM, 1995, EUR J EPIDEMIOL, V11, P95, DOI 10.1007/BF01719954
   Ganeshalingham A, 2012, ARCH DIS CHILD, V97, P748, DOI 10.1136/archdischild-2011-300272
   Grosse-Kock S, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4276-3
   Guilhen FB, 2014, BIOLOGICALS, V42, P91, DOI 10.1016/j.biologicals.2013.11.010
   Hallander HO, 2005, J CLIN MICROBIOL, V43, P2856, DOI 10.1128/JCM.43.6.2856-2865.2005
   Hansmeier N, 2006, PROTEOMICS, V6, P2465, DOI 10.1002/pmic.200500360
   Hardy IRB, 1996, LANCET, V347, P1739, DOI 10.1016/S0140-6736(96)90811-9
   Hassan SS, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00044
   Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3
   Herzberg C, 2007, PROTEOMICS, V7, P4032, DOI 10.1002/pmic.200700491
   Hessling M, 2017, BIOSCI BIOTECHNO RES, V10, P1
   Hirata R, 2008, BRAZ J MED BIOL RES, V41, P986, DOI 10.1590/S0100-879X2008001100007
   HOLMES RK, 1969, J VIROL, V3, P586, DOI 10.1128/JVI.3.6.586-598.1969
   Hoskisson PA, 2018, MICROBIOL-SGM, V164, P865, DOI 10.1099/mic.0.000627
   Jamal SB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186401
   Kallonen T, 2009, EXPERT REV VACCINES, V8, P863, DOI [10.1586/erv.09.46, 10.1586/ERV.09.46]
   Keller JE, 2011, PROCEDIA VACCINOL, V5, P192, DOI 10.1016/j.provac.2011.10.019
   Kraner ME, 2017, PLANT J, V92, P696, DOI 10.1111/tpj.13702
   Kruger M, 2013, ANAEROBE, V23, P97, DOI 10.1016/j.anaerobe.2013.06.011
   Linggood FV, 1962, BR J EXP PATHOL, V44, P178
   Link AJ, 2009, PROTEOMICS COLD SPRI
   Loeffler F., 1884, MITTEILUNGEN KAISERL, P421
   Markina SS, 2000, J INFECT DIS, V181, pS27, DOI 10.1086/315535
   Milstien JB, 1996, VACCINE, V14, P313, DOI 10.1016/0264-410X(95)00181-Y
   Mooi FR, 2001, EMERG INFECT DIS, V7, P526, DOI 10.3201/eid0707.017708
   Moreira LD, 2003, APPL ENVIRON MICROB, V69, P5907, DOI 10.1128/AEM.69.10.5907-5913.2003
   Murphy JR., 1996, MED MICROBIOL, P200
   Okamoto K, 2018, J INFECT CHEMOTHER
   Old WM, 2005, MOL CELL PROTEOMICS, V4, P1487, DOI 10.1074/mcp.M500084-MCP200
   Popovic T, 2000, J INFECT DIS, V181, pS168, DOI 10.1086/315556
   Rappuoli R., 2014, CORYNEBACTERIUM DIPH, P225
   Rappuoli R, 1990, NEW GENERATION VACCI, P417
   Roux E., 1888, ANN I PASTEUR, V2, P629
   Sane J, 2016, EUROSURVEILLANCE, V21, P14, DOI 10.2807/1560-7917.ES.2016.21.2.30105
   Sangal V, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1980-8
   Sangal V, 2014, INFECT GENET EVOL, V21, P54, DOI 10.1016/j.meegid.2013.10.019
   Schafer W, 2016, CELL MICROBIOL, V19, P43
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   Sutherland BW, 2008, J MASS SPECTROM, V43, P699, DOI 10.1002/jms.1415
   Suwanpatcharakul M, 2016, BIOLOGICALS, V44, P534, DOI 10.1016/j.biologicals.2016.08.002
   Thaysen-Andersen M, 2007, VACCINE, V25, P2213, DOI 10.1016/j.vaccine.2006.12.033
   Tiwari TSP, 2012, PLOTKINS VACCINES
   Trost E, 2012, J BACTERIOL, V194, P3199, DOI 10.1128/JB.00183-12
   Vitek CR, 1998, EMERG INFECT DIS, V4, P539, DOI 10.3201/eid0404.980404
   Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145
   Wagner KS, 2011, CLIN MICROBIOL INFEC, V17, P519, DOI 10.1111/j.1469-0691.2010.03269.x
   Wagner KS, 2010, EPIDEMIOL INFECT, V138, P1519, DOI 10.1017/S0950268810001895
   Wang WX, 2003, ANAL CHEM, V75, P4818, DOI 10.1021/ac026468x
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   World Health Organization, 2018, DIPHTHERIA
   World Health Organization, 2018, IMM COV 2018
   World Health Organization, 2018, DIPTH REP CAS
   Xu YL, 2015, SCI REP-UK, V5, DOI 10.1038/srep13536
   Zasada AA, 2014, CORYNEBACTERIUM DIPH, P239
   Zhang L, 2010, EMERG INFECT DIS, V16, P1695, DOI 10.3201/eid1611.100401
NR 78
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3061
EP 3070
DI 10.1016/j.vaccine.2019.04.059
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300013
PM 31036455
DA 2020-05-12
ER

PT J
AU Zeng, YB
   Luo, ML
   Chen, JZ
   He, HQ
   Deng, X
   Xie, SY
   Fang, Y
AF Zeng, Yanbing
   Luo, Mingliang
   Chen, Junze
   He, Hanqing
   Deng, Xuan
   Xie, Shuyun
   Fang, Ya
TI An economic evaluation of the current measles vaccination program: A
   case study in Zhejiang Province, east China
SO VACCINE
LA English
DT Article
DE Measles vaccine; Economic evaluation; ICER
ID COST-EFFECTIVENESS; IMMUNIZATION; ELIMINATION; MUMPS; BENEFITS; COVERAGE
AB Objective: To evaluate the economic impact of the current measles vaccination program in Zhejiang Province, east China.
   Methods: A decision tree-Markov model with parameters from published literatures, government documents and surveys was developed and used to simulate over 40 years of a birth cohort in Zhejiang Province during the year 2014. The expected cost and effectiveness of the current measles vaccination program was compared against no vaccination. Costs were assessed from the payer's perspective. Benefits were defined as savings on the direct cost of measles treatment, and the effectiveness was measured according to the number of measles cases and deaths averted. The net present value (NPV), benefit-cost ratio (BCR) and incremental cost-effectiveness ratio (ICER) were also calculated. A threshold for cost-effectiveness of less than 3 times the Gross Domestic Product (GDP) per capita was used. One-way sensitivity analysis was performed to assess parameter uncertainties.
   Results: The total vaccination cost was estimated to be $2.52 million. The BCR of the current measles program was found to be 6.06 with a NPV of $7338 million. It was also calculated that a total of 195,165 measles cases and 191 measles-related deaths would be prevented by vaccination. The ICER was approximately $12.91 per case averted and $13,213.43 per death averted, respectively, which was cost-effective. The models were proven to be robust.
   Conclusions: The current measles vaccination program appeared to be cost-effective and to offer substantial benefits. The results of this analysis sought to contribute to the justification of future investments to achieve the goal of measles elimination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zeng, Yanbing; Luo, Mingliang; Chen, Junze; Fang, Ya] Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Sch Publ Hlth, Xiamen 361102, Fujian, Peoples R China.
   [Zeng, Yanbing; Luo, Mingliang; Chen, Junze; Fang, Ya] Xiamen Univ, Key Lab Hlth Technol Assessment Fujian Prov, Sch Publ Hlth, Xiamen 361102, Fujian, Peoples R China.
   [He, Hanqing; Deng, Xuan; Xie, Shuyun] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou 310051, Zhejiang, Peoples R China.
RP Fang, Y (reprint author), Xiamen Univ, Sch Publ Hlth, Xiangan Nan Rd, Xiamen 361102, Fujian, Peoples R China.
EM fangya@xmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71874147, 81573257]; Natural Science Fund of Fujian
   ProvinceNatural Science Foundation of Fujian Province [2017J01133]
FX This work was supported by National Natural Science Foundation of China
   [grant numbers 71874147, 81573257] and the project of Natural Science
   Fund of Fujian Province [grant numbers 2017J01133].
CR Acharya A, 2002, VACCINE, V20, P3332, DOI 10.1016/S0264-410X(02)00296-7
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205
   AXNICK NW, 1969, PUBLIC HEALTH REP, V84, P673, DOI 10.2307/4593651
   Babigumira JB, 2011, J INFECT DIS, V204, pS116, DOI 10.1093/infdis/jir132
   Bae GR, 2013, VACCINE, V31, P2661, DOI 10.1016/j.vaccine.2013.04.014
   Bester JC, 2016, JAMA PEDIATR, V170, P1209, DOI 10.1001/jamapediatrics.2016.1787
   Beutels P, 2003, EPIDEMIOL INFECT, V130, P273, DOI 10.1017/S0950268802008142
   Beutels P, 2002, VACCINE, V20, P3551, DOI 10.1016/S0264-410X(02)00335-3
   CDC, 1991, MMWR-MORBID MORTAL W, V17, P186
   CDC, COMPL MEASL
   CDC, 2009, EPIDEMIOLOGY PREVENT
   Dabbagh A, 2017, MMWR-MORBID MORTAL W, V66, P1148, DOI 10.15585/mmwr.mm6642a6
   David B, 2014, J VACCINES VACCIN, V5, P1
   Dayan GH, 2004, VACCINE, V22, P475, DOI 10.1016/j.vaccine.2003.07.007
   Demicheli V, 2013, EVID BASED CHILD HLT, V8, P2076, DOI DOI 10.1002/EBCH.1948
   Filia A, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-169
   Hoshi SL, 2014, VACCINE, V32, P4189, DOI 10.1016/j.vaccine.2014.05.020
   Jian F, 2011, CHINESE J VACCINES I, P333
   Jinfeng Z, 2006, STRAIT J PREV MED, P8
   Kim SY, 2008, PHARMACOECONOMICS, V26, P191, DOI 10.2165/00019053-200826030-00004
   Li Q, 2014, INT J ENV RES PUB HE, V11, P2713, DOI 10.3390/ijerph110302713
   Ma C, 2014, B WORLD HEALTH ORGAN, V92, P340, DOI 10.2471/BLT.13.130195
   Ma C, 2011, J INFECT DIS, V204, pS447, DOI 10.1093/infdis/jir103
   Madsen LB, 2014, TROP MED INT HEALTH, V19, P177, DOI 10.1111/tmi.12233
   Montgomery JP, 2015, PEDIATR INFECT DIS J, V34, P289, DOI 10.1097/INF.0000000000000562
   Moss WJ, 2012, LANCET, V379, P153, DOI 10.1016/S0140-6736(10)62352-5
   Progress WHO, 2013, MMWR-MORBID MORTAL W, V23, P233
   Shayo GA, 2017, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-4597-9
   Shichang X., 2015, ANN REPORT DIS CONTR
   Statistics Bureau of Zhejiang Province Zhejiang survey team of the National Bureau of Statistics, 2015, ZHEJ STAT YB
   Takahashi K, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-254
   Thompson KM, 2016, RISK ANAL, V36, P1297, DOI 10.1111/risa.12331
   Walker DG, 2010, VACCINE, V28, P2356, DOI 10.1016/j.vaccine.2009.06.035
   Wang L, 2017, ADV INTEL SYS RES, V145, P20
   WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739
   WHO, REPR OFF CHIN MEASL
   World Health Organization, MEASL FACT SHEET
   Yiyu L, 2016, MEASLES
   Yongqiu L, 2017, MODERN PREVENT MED, P106
   Zhou FJ, 2004, J INFECT DIS, V189, pS131, DOI 10.1086/378987
NR 40
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3071
EP 3077
DI 10.1016/j.vaccine.2019.04.057
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300014
PM 31040084
DA 2020-05-12
ER

PT J
AU Francis, MR
   Nuorti, JP
   Kompithra, RZ
   Larson, H
   Balraj, V
   Kang, G
   Mohan, VR
AF Francis, Mark Rohit
   Nuorti, J. Pekka
   Kompithra, Rajeev Zachariah
   Larson, Heidi
   Balraj, Vinohar
   Kang, Gagandeep
   Mohan, Venkata Raghava
TI Vaccination coverage and factors associated with routine childhood
   vaccination uptake in rural Vellore, southern India, 2017
SO VACCINE
LA English
DT Article
DE Universal immunization program; Mission Indradhanush; EPI cluster
   survey; Routine immunization coverage; Rural Vellore
ID IMMUNIZATION COVERAGE; CHILDREN; DELAY; DETERMINANTS; TIMELINESS;
   DISTRICT
AB Background: Vellore district in southern India was selected for intensified immunization efforts through India's Mission Indradhanush campaign based on 74% coverage in the National Family Health Survey in 2015. As rural households rely almost entirely on the Universal Immunization Program (UIP), we assessed routine immunization coverage and factors associated with vaccination status of children in rural Vellore.
   Methods: We conducted a cross-sectional household survey among parents or primary caretakers of children aged 12-23 months during August-September 2017 using two-stage, EPI cluster sampling. We verified vaccination histories from vaccination cards and collected data on sociodemographic and non-socio-demographic characteristics by using mobile data capture. Associations with vaccination status were examined with univariate and multivariate logistic regression models.
   Results: A total of 643 children were included. Coverage of BCG, third dose pentavalent/DPT, measles/MR vaccines and full vaccination (BCG, three doses of polio and pentavalent/DPT and measles/MR vaccines) among children with vaccination cards (n = 606) was 94%, 96%, 93% and 84%, respectively. Of children with vaccination cards, 70.8% had received all recommended doses according to the UIP schedule. No socio-demographic differences were identified, but parents' familiarity with the schedule (Adjusted Prevalence Odds Ratio (aPOR): 2.06, 95%Cl = 1.26-3.38) and receiving information on recommended vaccinations during antenatal visits (aPOR: 2.16, 95% CI = 1.13-4.12) were significantly associated with full vaccination status of the children.
   Conclusions: We found higher UIP antigen coverage and proportion of fully vaccinated children than previously reported from rural Vellore. However, adherence to the recommended schedule was still not optimal. Our study highlights the potential of improving parental awareness of vaccination schedule and targeting health education interventions at pregnant women during antenatal visits to sustain and improve routine immunization coverage. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Francis, Mark Rohit; Nuorti, J. Pekka] Tampere Univ, Hlth Sci Unit, Fac Social Sci, Tampere, Finland.
   [Nuorti, J. Pekka] Natl Inst Hlth & Welf, Infect Dis & Vaccines, Dept Hlth Protect, Helsinki, Finland.
   [Kompithra, Rajeev Zachariah] Christian Med Coll & Hosp, Well Baby Immunizat Clin, Dept Pediat Unit 1, Vellore, Tamil Nadu, India.
   [Larson, Heidi] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Balraj, Vinohar] Soc Appl Studies, Vellore, Tamil Nadu, India.
   [Kang, Gagandeep] Christian Med Coll & Hosp, Div Gastrointestinal Sci, Vellore, Tamil Nadu, India.
   [Mohan, Venkata Raghava] Christian Med Coll & Hosp, Dept Community Hlth, Vellore, Tamil Nadu, India.
RP Mohan, VR (reprint author), Christian Med Coll & Hosp, Dept Community Hlth, Vellore, Tamil Nadu, India.
EM venkat@cmcvellore.ac.in
RI KOMPITHRA, RAJEEV ZACHARIAH/AAF-1601-2020
OI Kang, Gagandeep/0000-0002-3656-564X
FU Christian Medical College, Vellore, Tamil Nadu, India; Health Sciences
   Unit, Faculty of Social Sciences, Tampere University, Finland
FX This fieldwork was supported by the Christian Medical College, Vellore,
   Tamil Nadu, India. MRF was supported by the Health Sciences Unit,
   Faculty of Social Sciences, Tampere University, Finland.
CR Awofeso N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-358
   Balasubramanian P, 2012, EC POLIT WKLY, VXLVII, P19
   Binyaruka P, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3270-z
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Clark A, 2009, LANCET, V373, P1543, DOI 10.1016/S0140-6736(09)60317-2
   Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053
   Dasgupta R, 2014, INDIAN J PEDIATR, V81, P847, DOI 10.1007/s12098-014-1426-3
   Devasenapathy N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013015
   Dixit P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066175
   Dombkowski KJ, 2002, AM J PREV MED, V23, P36, DOI 10.1016/S0749-3797(02)00442-7
   Fadnes LT, 2011, VACCINE, V29, P3564, DOI 10.1016/j.vaccine.2011.02.093
   Francis MR, 2018, VACCINE, V36, P6559, DOI 10.1016/j.vaccine.2017.08.026
   George K, 1990, Indian J Pediatr, V57, P588, DOI 10.1007/BF02726779
   Gibson DG, 2017, LANCET GLOB HEALTH, V5, pE428, DOI [10.1016/S2214-109X(17)30072-4, 10.1016/s2214-109x(17)30072-4]
   Gibson DG, 2015, VACCINE, V33, P6778, DOI 10.1016/j.vaccine.2015.10.021
   Government of India, 2015, MON ON LARG FULL IMM
   Government of India, 2015, MISS INDR PUT VACC E
   Hoest C, 2017, VACCINE, V35, P443, DOI 10.1016/j.vaccine.2016.11.075
   Hughes MM, 2016, VACCINE, V34, P933, DOI 10.1016/j.vaccine.2015.12.061
   International Institute for Population Sciences (IIPS), 2016, NAT FAM HLTH SURV NF
   International Institute for Population Sciences (IIPS) and ICF, 2017, NAT FAM HLTH SURV 4
   KEJA K, 1988, World Health Statistics Quarterly, V41, P59
   Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3
   Kumar A, 2011, J POPUL RES, V28, P301, DOI 10.1007/s12546-011-9069-y
   Masthi NRR, 2017, ANN TROP MED PUBLIC, V10, P76, DOI 10.4103/1755-6783.205544
   Medhanyie AA, 2015, J CLIN EPIDEMIOL, V68, P80, DOI 10.1016/j.jclinepi.2014.09.006
   Ministry of Health and Family Welfare GOI, 2015, COND HLTH CAMP 2015
   Ministry of Health and Family Welfare GOI, 2017, IMP MISS INDR 2017
   Ministry of Health and Family Welfare Government of India, 2017, NAT IMM SCHED INF CH
   Morris SS, 2000, J EPIDEMIOL COMMUN H, V54, P381, DOI 10.1136/jech.54.5.381
   Murhekar MV, 2017, INDIAN J MED RES, V145, P377, DOI 10.4103/ijmr.IJMR_1666_15
   Oyo-Ita A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub2
   Paul Sourabh, 2015, J Family Med Prim Care, V4, P9, DOI 10.4103/2249-4863.152238
   Rammohan A, 2015, SOC SCI MED, V145, P163, DOI 10.1016/j.socscimed.2015.05.004
   Shrivastwa N, 2016, PEDIATR INFECT DIS J, V35, P955, DOI 10.1097/INF.0000000000001223
   Shrivastwa N, 2015, AM J PREV MED, V49, pS435, DOI 10.1016/j.amepre.2015.05.008
   Srinivasan R, 2017, INDIAN PEDIATR, V54, P777
   Sun MP, 2010, VACCINE, V28, P1264, DOI 10.1016/j.vaccine.2009.11.015
   Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065
   Tomlinson M, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-51
   Travasso C, 2015, BMJ-BRIT MED J, V350, DOI [10.1136/bmj.h1688h1688, DOI 10.1136/BMJ.H1688H1688]
   Varma GR, 2008, J PUBLIC HEALTH-HEID, V16, P389, DOI 10.1007/s10389-008-0186-9
   Vashishtha VM, 2013, INDIAN PEDIATR, V50, P111, DOI 10.1007/s13312-013-0025-0
   Vashishtha VM, 2014, INDIAN PEDIATR, V51, P785, DOI 10.1007/s13312-014-0504-y
   World Health Organization, 2008, TRAIN MIDL MAN MOD E
   World Health Organization, WHO S E AS REG CERT
   Yadav K, 2012, J TROP PEDIATRICS, V58, P133, DOI 10.1093/tropej/fmr059
NR 47
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3078
EP 3087
DI 10.1016/j.vaccine.2019.04.058
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300015
PM 31040085
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Sowe, A
   Johansson, K
AF Sowe, Alieu
   Johansson, Klara
TI Disentangling the rural-urban immunization coverage disparity in The
   Gambia: A Fairlie decomposition
SO VACCINE
LA English
DT Article
DE Immunization inequalities; Immunization coverage; Fairlie decomposition;
   Full immunization; Healthcare disparities
ID MIDDLE-INCOME COUNTRIES; SOCIOECONOMIC INEQUALITIES; ROUTINE
   IMMUNIZATION; VACCINATION COVERAGE; CHILDREN; VACCINES; EQUITY
AB Introduction: Exploring factors underlying disparities in immunization uptake is highly relevant and can contribute to improved immunization interventions globally. The Gambia is an interesting case, since higher immunization coverage in rural areas has been shown for many years, yet the factors explaining this unexpected rural-urban disparity have not been studied. The aim of our study was to quantify the rural-urban disparity in immunization coverage and identify factors that contribute to explaining it.
   Methods: Data from the nationally representative Demographic and Health Survey 2013 was used to select children aged 12-23 months (Weighted n = 1644) for the study. The outcome measure was full immunization status, the grouping variable was area of residence. Descriptive statistics were used to analyze the proportions of full immunization and rural-urban residence across the exposure variables. The Fairlie decomposition technique was used to decompose factors contributing to explaining the coverage disparity.
   Results: The findings show that there is a disparity of 16.06 percentage points to the advantage of the rural areas and the exposure variables explained 76.49% of the disparity. Material factors explained 92.03% of the explained disparity with maternal occupation and household wealth quintile being the only significant individual material variable contributors to the explained disparity. Lower household wealth quintile and working especially in agriculture were associated with higher immunization coverage and they were more common in rural areas. Religion and mother's age group e each contributed somewhat to the explained inequality.
   Conclusions: There was a large immunization coverage disparity between rural and urban areas in The Gambia. This disparity was mainly explained by mothers working in agriculture and living in the poorest households, being more likely to immunize their children - unexpected findings. Our study showed that the drivers of healthcare disparities differ by setting and deserve more research. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sowe, Alieu] Minist Hlth & Social Welf, Banjul, Gambia.
   [Johansson, Klara] Umea Univ, Dept Epidemiol & Global Hlth, Umea, Sweden.
RP Sowe, A (reprint author), Minist Hlth & Social Welf, Banjul, Gambia.
EM sowea1@yahoo.com; klara.johansson@umu.se
OI Johansson, Klara/0000-0002-3749-998X; Sowe, Alieu/0000-0003-3786-3021
FU Swedish Institute Scholarship
FX We wish to thank the Epidemiology and Global Health Unit of Umea
   University, Sweden, for providing the master training which gave rise to
   this work. The master training was made possible thanks to a Swedish
   Institute Scholarship. We thank the DHS Program and survey participants.
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Adokiya MN, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0196-6
   Arsenault C, 2017, VACCINE, V35, P951, DOI 10.1016/j.vaccine.2016.12.041
   Ataguba JE, 2016, HEALTH POLICY PLANN, V31, P1212, DOI 10.1093/heapol/czw053
   Awoh AB, 2016, J EPIDEMIOL COMMUN H, V70, P305, DOI 10.1136/jech-2015-205652
   Barata RB, 2012, J EPIDEMIOL COMMUN H, V66, P934, DOI 10.1136/jech-2011-200341
   Barros AJD, 2012, LANCET, V379, P1225, DOI 10.1016/S0140-6736(12)60113-5
   Cassell JA, 2006, HEALTH POLICY PLANN, V21, P373, DOI 10.1093/heapol/czl020
   Central Statistics Department, 1998, GAMB MULT CLUST SURV
   Central Statistics Department, 2002, GAMB MULT IND CLUST
   Chao FQ, 2018, LANCET GLOB HEALTH, V6, pE535
   Crocker-Buque T, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4473-7
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Fairlie RW, 2006, EXTENSION BLINDER OA
   Fatiregun AA, 2012, VACCINE, V30, P730, DOI 10.1016/j.vaccine.2011.11.082
   Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004
   Forshaw J, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2890-y
   Gambia Bureau of Statistics, 2013, GAMB 2013 POP HOUS C
   GBoS, 2011, INT HOUS SURV INC EX
   GBoS, 2007, GAMB MULT IND CLUST
   Gidado Saheed, 2014, Pan Afr Med J, V18 Suppl 1, P9, DOI 10.11694/pamj.supp.2014.18.1.4149
   Hancioglu A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001391
   Hosseinpoor AR, 2016, LANCET GLOB HEALTH, V4, pE617, DOI 10.1016/S2214-109X(16)30141-3
   Howie SRC, 2013, CLIN INFECT DIS, V57, P1527, DOI 10.1093/cid/cit598
   Jann B, 2008, STATA J, V8, P453, DOI 10.1177/1536867X0800800401
   Kassahun Melkamu Beyene, 2015, BMC Res Notes, V8, P239, DOI 10.1186/s13104-015-1192-y
   Kazungu Jacob S, 2017, Wellcome Open Res, V2, P12, DOI 10.12688/wellcomeopenres.10690.1
   Kim SY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-260
   Lakew Y, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2078-6
   Mackenzie GA, 2017, LANCET INFECT DIS, V17, P965, DOI 10.1016/S1473-3099(17)30321-3
   Miyahara R, 2016, VACCINE, V34, P3335, DOI 10.1016/j.vaccine.2016.05.017
   Nelson KN, 2016, VACCINE, V34, P5495, DOI 10.1016/j.vaccine.2016.09.038
   Payne S, 2014, HEALTH POLICY PLANN, V29, P193, DOI 10.1093/heapol/czt004
   Prusty RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104598
   Restrepo-Mendez MC, 2016, B WORLD HEALTH ORGAN, V94, P794, DOI 10.2471/BLT.15.162172
   Scott S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107280
   Singh PK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073102
   StataCorp, 2013, STAT STAT SOFTW REL
   The Gambia Bureau of Statistics (GBOS), 2011, GAMB MULT IND CLUST
   The Gambia Bureau of Statistics ICF International, 2014, GAMB DEM HLTH SURV 2
   WHO UNICEF., 2017, WHO UNICEF EST TIM S
   Word Health Organization, 2015, VACC COV CLUST SURV
NR 42
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3088
EP 3096
DI 10.1016/j.vaccine.2019.04.062
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300016
PM 31036454
DA 2020-05-12
ER

PT J
AU Yagnik, B
   Sharma, D
   Padh, H
   Desai, P
AF Yagnik, Bhrugu
   Sharma, Drashya
   Padh, Harish
   Desai, Priti
TI Oral immunization with LacVax (R) OmpA induces protective immune
   response against Shigella flexneri 2a ATCC 12022 in a murine model
SO VACCINE
LA English
DT Article
DE Lactococcus lactis; Mucosal immunity; Outer membrane protein (OmpA);
   Oral vaccine; Shigella
ID MEMBRANE PROTEIN-A; LACTOCOCCUS-LACTIS; DYSENTERIAE TYPE-1;
   ESCHERICHIA-COLI; IFN-GAMMA; EXPRESSION; CELLS; INFECTION; VACCINES;
   PATHOGENESIS
AB Shigellosis is an acute invasive disease of the lower intestine, which afflicts millions of people worldwide with an estimated one million fatalities per annum. Despite of extensive research during the last two decades, a vaccine against multi-drug resistant Shigella is not yet available in the market. To provide a safe, effective and broad-spectrum vaccine against Shigella, we explored food grade bacteria Lactococcus lactis (L. lactis) for the delivery of conserved antigenic protein; Outer membrane protein A (OmpA) to the mucosal sites for effective elicitation of systemic and mucosal immunity. We have previously confirmed the immunogenic potential of recombinant L. lactis expressing OmpA (LacVax (R) OmpA) in BALB/c mice. In the present study, we have characterized the humoral and cellular immune profile of LacVax (R) OmpA and assessed its protective efficacy using a newly developed human like murine shigellosis model. The significant increase in OmpA specific serum IgG, fecal sIgA and a Th1 dominant immune response (indicated by high INF-gamma/IL-4 ratio) in LacVax (R) OmpA immunized mice revealed successful activation of humoral and cellular immunity. The LacVax (R) OmpA immunized animals were also protected from human-like shigellosis when challenged with S. flexneri 2a ATCC 12022. The antigen specific serum IgG, fecal sIgA, INF-gamma and IL-10 levels were found to be the significant correlates of protection. Collectively these results suggest that the LacVax (R) OmpA is a promising prophylactic candidate against shigellosis. However, the protective efficacy of LacVax (R) OmpA in the higher animals would further strengthen its future application in humans. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yagnik, Bhrugu; Sharma, Drashya; Desai, Priti] BV Patel Pharmaceut Educ & Res Dev PERD Ctr, Dept Cell & Mol Biol, Ahmadabad, Gujarat, India.
   [Yagnik, Bhrugu; Sharma, Drashya] Sardar Patel Univ, BRD Sch Biosci, Vallabh Vidhyanagar, Gujarat, India.
   [Padh, Harish] Sardar Patel Univ, Vallabh Vidhyanagar, Gujarat, India.
   [Desai, Priti] IAR, Dept Biol Sci & Biotechnol, Gandhinagar, Gujarat, India.
   [Yagnik, Bhrugu] Emory Univ, Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.
   [Yagnik, Bhrugu] Emory Univ, Dept Microbiol & Immunol, Emory Sch Med, Atlanta, GA 30329 USA.
RP Desai, P (reprint author), IAR, Dept Biol Sci & Biotechnol, Gandhinagar, Gujarat, India.
EM preetindesai79@gmail.com
RI Yagnik, Bhrugu/S-3301-2019
OI Yagnik, Bhrugu/0000-0002-5819-7892
FU Lady Tata Memorial Trust's Ph.D. Fellowship ORS 2014-16; Lady Tata
   Memorial Trust's Ph.D. Fellowship SRS 2016-17
FX Bhrugu Yagnik is a recipient of Lady Tata Memorial Trust's Ph.D.
   Fellowship ORS 2014-16 & SRS 2016-17).
CR Ahmed B, 2014, VACCINE, V32, P3909, DOI 10.1016/j.vaccine.2014.05.054
   Audouy SAL, 2006, VACCINE, V24, P5434, DOI 10.1016/j.vaccine.2006.03.054
   Bahey-El-Din M, 2008, VACCINE, V26, P5304, DOI 10.1016/j.vaccine.2008.07.047
   Bahey-El-Din M, 2012, VACCINE, V30, P685, DOI 10.1016/j.vaccine.2011.11.098
   Bermudez-Humaran LG, 2002, APPL ENVIRON MICROB, V68, P917, DOI 10.1128/AEM.68.2.917-922.2002
   Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8
   Chamekh M, 2008, J IMMUNOL, V180, P4292, DOI 10.4049/jimmunol.180.6.4292
   DeRoeck D, 2005, VACCINE, V23, P2762, DOI 10.1016/j.vaccine.2004.11.044
   Drouault S, 1999, APPL ENVIRON MICROB, V65, P4881
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927
   Heine SJ, 2015, IMMUNOL CELL BIOL, V93, P641, DOI 10.1038/icb.2015.24
   Jehl SP, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002809
   Jennison AV, 2004, FEMS MICROBIOL REV, V28, P43, DOI 10.1016/j.femsre.2003.07.002
   Kim SJ, 2006, APPL MICROBIOL BIOT, V72, P462, DOI 10.1007/s00253-005-0285-2
   Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6
   Mani S, 2016, VACCINE, V34, P2887, DOI 10.1016/j.vaccine.2016.02.075
   Mantis NJ, 2011, MUCOSAL IMMUNOL, V4, P603, DOI 10.1038/mi.2011.41
   Masood MI, 2011, CRIT REV MICROBIOL, V37, P91, DOI 10.3109/1040841X.2010.536522
   McArthur MA, 2017, VACCINE, V35, P6803, DOI 10.1016/j.vaccine.2017.05.034
   Medina M, 2008, INFECT IMMUN, V76, P2696, DOI 10.1128/IAI.00119-08
   Mitragotri S, 2005, NAT REV IMMUNOL, V5, P905, DOI 10.1038/nri1728
   Morello E, 2008, J MOL MICROB BIOTECH, V14, P48, DOI 10.1159/000106082
   Mosser DM, 2008, IMMUNOL REV, V226, P205, DOI 10.1111/j.1600-065X.2008.00706.x
   Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057
   Niyogi SK, 2003, JPN J INFECT DIS, V56, P33
   Noreen N, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-28
   Pei HD, 2005, APPL MICROBIOL BIOT, V68, P220, DOI 10.1007/s00253-004-1869-y
   Perez CA, 2005, J APPL MICROBIOL, V99, P1158, DOI 10.1111/j.1365-2672.2005.02709.x
   Phalipon A, 2008, MICROBES INFECT, V10, P1057, DOI 10.1016/j.micinf.2008.07.016
   Pore D, 2011, PLOS ONE, V6, P11
   Samandari T, 2000, J IMMUNOL, V164, P2221, DOI 10.4049/jimmunol.164.4.2221
   Sansonetti P, 1996, RES IMMUNOL, V147, P595, DOI 10.1016/S0923-2494(97)85227-3
   Sharma D, 2017, MICROBES INFECT, V19, P47, DOI 10.1016/j.micinf.2016.09.002
   Shimanovich AA, 2017, CLIN VACCINE IMMUNOL, V24, P1, DOI 10.1128/CVI.00412-16
   Simon JK, 2011, CLIN IMMUNOL, V139, P185, DOI 10.1016/j.clim.2011.02.003
   Stoof SP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138665
   Taneja N, 2007, J CLIN MICROBIOL, V45, P678, DOI 10.1128/JCM.02247-06
   von Seidlein L, 2006, PLOS MED, V3, P1556, DOI 10.1371/journal.pmed.0030353
   Wahid R, 2013, CLIN IMMUNOL, V148, P35, DOI 10.1016/j.clim.2013.03.009
   WELLS JM, 1993, MOL MICROBIOL, V8, P1155, DOI 10.1111/j.1365-2958.1993.tb01660.x
   World Health Organization, 2015, WAT SAN HLTH WAT REL
   World Health Organization, 2017, DIARRH DIS
   Yagnik B, 2017, J APPL MICROBIOL, V122, P493, DOI 10.1111/jam.13353
   Yagnik B, 2018, GENE THER, V25, P485, DOI 10.1038/s41434-018-0033-8
   Yagnik B, 2017, MICROBIOL IMMUNOL, V61, P123, DOI 10.1111/1348-0421.12473
   Yagnik B, 2016, MICROBES INFECT, V18, P237, DOI 10.1016/j.micinf.2015.11.006
   Yagnik B, 2016, INDIAN J MICROBIOL, V56, P80, DOI 10.1007/s12088-015-0556-2
   Yam KK, 2008, VACCINE, V26, P2689, DOI 10.1016/j.vaccine.2008.03.024
   Zhang JW, 2007, J CLIN INVEST, V117, P871, DOI 10.1172/JCI31860
NR 49
TC 1
Z9 2
U1 4
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3097
EP 3105
DI 10.1016/j.vaccine.2019.04.053
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300017
PM 31047673
OA Green Published
DA 2020-05-12
ER

PT J
AU Aiba, Y
   Umeda, K
   Rahman, S
   Nguyen, SV
   Komatsu, Y
AF Aiba, Yuji
   Umeda, Koji
   Rahman, Shofiqur
   Nguyen, Sa V.
   Komatsu, Yasuhiko
TI Synergistic effect of anti-Helicobacter pylori urease immunoglobulin Y
   from egg yolk of immunized hens and Lactobacillus johnsonii No.1088 to
   inhibit the growth of Helicobacter pylon in vitro and in vivo
SO VACCINE
LA English
DT Article
DE Helicobacter pylori; Immunoglobulin Y; Urease; Lactic acid bacteria;
   Lactobacillus johnsonii
ID INFECTION; CLARITHROMYCIN; COLONIZATION; ANTIBODIES; GASTRITIS; STOMACH;
   STRAIN; IGY
AB Helicobacter pylori is a pathogenic bacterium that infects the stomach, causing chronic gastritis; and it is also considered to be related to the occurrence of gastric cancers. Although some eradication regimens including multiple antibiotics have been developed, the emergence of resistance to antibiotics becomes problematic. Therefore, other approaches to compensate or augment the effects of standard regimens are needed. In this study, we examined the possible synergistic effects of anti-H. pylori urease IgY and Lactobacillus johnsonii No.1088 (LJ88) both in vitro and in vivo. Anti-H. pylori urease IgY was purified from egg yolks laid by the hens immunized with urease purified from H. pylori. LJ88 is a unique strain of lactic acid bacterium isolated from human gastric juice, and it has been reported to inhibit H. pylori both in vitro and in vivo. The in vitro mixed culture study showed that anti-H. pylori urease IgY augmented the anti-H. pylori activity of LJ88 against both clarithromycin-sensitive and-resistant H. pylori strains. In a germ-free mice infection model, combined administration of daily anti-H. pylori urease IgY and weekly living LJ88 significantly reduced H. pylori infections, whereas either monotherapy did not. In an in vivo human gut microbiota-associated mice model, not only daily administration of living LJ88 but also heat-killed one significantly reduced an H. pylori infection in the stomach when combined with anti-H. pylori urease IgY. The extent of reduction of the stomach H. pylori by such a combination therapy was larger than that reported for LJ88 monotherapy. These results taken together revealed a synergistic effect of anti-H. pylori urease IgY and living or heat-killed LJ88, thus suggesting that such a combination might be a promising therapy to possibly compensate and/or augment standard anti-H. pylori regimens. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Aiba, Yuji; Komatsu, Yasuhiko] Snowden Co Ltd, Res Dev Dept, Chiyoda Ku, 3-7-16 Iwamoto Cho, Tokyo 1010032, Japan.
   [Aiba, Yuji] Tokai Univ, Dept Psychiat, Sch Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.
   [Umeda, Koji; Rahman, Shofiqur; Nguyen, Sa V.] EW Nutr Japan KK, 839-7 Sano, Gifu, Gifu 5011101, Japan.
RP Komatsu, Y (reprint author), Snowden Co Ltd, Res Dev Dept, Chiyoda Ku, 3-7-16 Iwamoto Cho, Tokyo 1010032, Japan.
EM y_komatsu@snowden.co.jp
FU EW Nutrition Japan K.K; Snowden Co., Ltd.
FX This study was funded by EW Nutrition Japan K.K and Snowden Co., Ltd.
CR Aiba Y, 2017, FEMS MICROBIOL LETT, V364, DOI 10.1093/femsle/fnx102
   Aiba Y, 2015, MICROBIOLOGYOPEN, V4, P465, DOI 10.1002/mbo3.252
   Borhani K, 2015, CLIN EXP VACCINE RES, V4, P177, DOI 10.7774/cevr.2015.4.2.177
   Clyne M, 2007, FEMS MICROBIOL LETT, V268, P135, DOI 10.1111/j.1574-6968.2007.00648.x
   Croxen MA, 2006, J BACTERIOL, V188, P2656, DOI 10.1128/JB.188.7.2656-2665.2006
   Dang YA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095548
   Hong KS, 2018, VACCINE, V36, P371, DOI 10.1016/j.vaccine.2017.11.082
   Horie K, 2004, J DAIRY SCI, V87, P4073, DOI 10.3168/jds.S0022-0302(04)73549-3
   Hu Y, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00168
   Icatlo FC, 1998, J BIOL CHEM, V273, P18130, DOI 10.1074/jbc.273.29.18130
   Kabir AMA, 1997, GUT, V41, P49, DOI 10.1136/gut.41.1.49
   Kibe R, 2005, APPL ENVIRON MICROB, V71, P3171, DOI 10.1128/AEM.71.6.3171-3178.2005
   Kobayashi I, 2007, J CLIN MICROBIOL, V45, P4006, DOI 10.1128/JCM.00740-07
   Komatsu Y, 2016, PREBIOTICS PROBIOTIC, P363
   Malekshahi ZV, 2011, MICROB PATHOGENESIS, V51, P366, DOI 10.1016/j.micpath.2011.06.002
   Malfertheiner P, 2007, GUT, V56, P772, DOI 10.1136/gut.2006.101634
   MARSHALL BJ, 1984, LANCET, V1, P1311
   MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x
   MORRIS A, 1987, AM J GASTROENTEROL, V82, P192
   Muller S, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0067-3
   NAGATA K, 1992, INFECT IMMUN, V60, P4826, DOI 10.1128/IAI.60.11.4826-4831.1992
   Nishizawa T, 2015, J CLIN GASTROENTEROL, V49, P468, DOI 10.1097/MCG.0000000000000165
   Pant N, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-86
   Peek RM, 2002, J GASTROENTEROL, V37, P10, DOI 10.1007/BF02990093
   R Core Team, 2016, R LANG ENV STAT COMP
   Shin JH, 2004, J MED MICROBIOL, V53, P31, DOI 10.1099/jmm.0.05327-0
   Shin JH, 2003, J MED MICROBIOL, V52, P217, DOI 10.1099/jmm.0.04978-0
   Shin JH, 2002, CLIN DIAGN LAB IMMUN, V9, P1061, DOI 10.1128/CDLI.9.5.1061-1066.2002
   Suzuki H, 2004, ALIMENT PHARM THER, V20, P185, DOI 10.1111/j.1365-2036.2004.02027.x
   Suzuki S, 2016, AM J GASTROENTEROL, V111, P949, DOI 10.1038/ajg.2016.182
   Vilaichone Ratha Korn, 2018, Asian Pac J Cancer Prev, V19, P1411
   Wang BN, 2014, INT J CLIN EXP PATHO, V7, P6430
   Yang Yun-Hui, 2012, Lab Anim Res, V28, P55, DOI 10.5625/lar.2012.28.1.55
NR 33
TC 0
Z9 0
U1 2
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3106
EP 3112
DI 10.1016/j.vaccine.2019.04.045
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300018
PM 31031029
DA 2020-05-12
ER

PT J
AU Van Damme, P
   Leroux-Roels, G
   Vandermeulen, C
   De Ryck, I
   Tasciotti, A
   Dozot, M
   Moraschini, L
   Testa, M
   Arora, AK
AF Van Damme, Pierre
   Leroux-Roels, Geert
   Vandermeulen, Corinne
   De Ryck, Iris
   Tasciotti, Annaelisa
   Dozot, Marie
   Moraschini, Luca
   Testa, Marco
   Arora, Ashwani Kumar
TI Safety and immunogenicity of non-typeable Haemophilus
   influenzae-Moraxella catarrhalis vaccine
SO VACCINE
LA English
DT Article
DE Acute exacerbation; COPD; Clinical trial; Haemophilus influenzae;
   Moraxella catarrhalis
ID T-CELL RESPONSES; STREPTOCOCCUS-PNEUMONIAE; USPA2 PROTEIN;
   EPITHELIAL-CELLS; COPD; EXACERBATIONS; VITRONECTIN; ANTIGEN; BINDING;
   MICROBIOME
AB Non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) are frequent pathogens in acute exacerbations of COPD. We assessed the safety, reactogenicity and immunogenicity of different investigational vaccine formulations containing surface proteins of NTHi (PD andPE-PilA) and Mcat (UspA2) in adults with smoking history >= 10 pack-years, to immunologically represent the COPD population.
   Participants received two doses 60 days apart in a randomised, observer-blind, placebo-controlled study (NCT02547974). In step 1, 30 healthy adults aged 18-40 years were randomised (1:1) to receive a non-adjuvanted formulation (10-10-PLAIN) or placebo. In step 2, 90 smokers/ex-smokers aged 5070 years randomly (1:1:1) received an AS01-adjuvanted formulation containing either 10 mu g of each antigen (10-10-AS01) or 10 mu g of each NTHi antigen and 3.3 mu g of Mcat antigen (10-3-AS01), or placebo.
   Incidences of solicited local adverse events (AEs) tended to be highest in the AS01-adjuvanted vaccine groups. Most solicited AEs had mild/moderate intensity. No vaccine-related serious AEs were reported. The 10-3-AS01 formulation induced the best humoral immune response against the NTHi antigens. Responses against the Mcat antigen were similar across groups, with waning immunogenicity after 30 days post-dose 2.
   The investigational NTHi-Mcat vaccine had an acceptable safety and reactogenicity profile and good immunogenicity in older adults with a smoking history. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Van Damme, Pierre] Univ Antwerp, Ctr Evaluat Vaccinat, Antwerp, Belgium.
   [Leroux-Roels, Geert] Univ Ghent, Ctr Vaccinol, Ghent, Belgium.
   [Leroux-Roels, Geert] Ghent Univ Hosp, Ghent, Belgium.
   [Vandermeulen, Corinne] Katholieke Univ Leuven, Leuven Univ Vaccinol Ctr, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium.
   [De Ryck, Iris; Tasciotti, Annaelisa; Moraschini, Luca; Testa, Marco; Arora, Ashwani Kumar] GSK Vaccines, Siena, Italy.
   [Dozot, Marie] GSK, Rixensart, Belgium.
RP Testa, M (reprint author), GSK, Clin Res & Dev, Via Fiorentina 1, I-53100 Siena, Italy.
EM marco.x.testa@gsk.com
RI Vandermeulen, Corinne/AAK-8690-2020
OI Vandermeulen, Corinne/0000-0002-1954-7554
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX The study funder, GlaxoSmithKline Biologicals SA, designed the study in
   collaboration with the investigators, and coordinated collection,
   analysis and interpretation of data. The investigators obtained data and
   cared for the study participants. The authors had full access to all
   data in the study, contributed to the writing of the report and had
   final responsibility for the decision to submit for publication.
CR Adeloye D, 2015, J GLOB HEALTH, V5, P186, DOI [10.7189/jogh.05.020415, 10.7189/jogh.05-020415]
   Armbruster CE, 2010, MBIO, V1, DOI 10.1128/mBio.00102-10
   Attia AS, 2006, INFECT IMMUN, V74, P1597, DOI 10.1128/IAI.74.3.1597-1611.2006
   Attia AS, 2005, INFECT IMMUN, V73, P2400, DOI 10.1128/IAI.73.4.2400-2410.2005
   Barcelo B, 2008, EUR RESPIR J, V31, P555, DOI 10.1183/09031936.00010407
   Berglund J, 2014, CLIN VACCINE IMMUNOL, V21, P56, DOI 10.1128/CVI.00430-13
   Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4
   Cazzola M, 2008, EUR RESPIR J, V31, P416, DOI 10.1183/09031936.00099306
   Chen DX, 1996, INFECT IMMUN, V64, P1900, DOI 10.1128/IAI.64.6.1900-1905.1996
   Chen DX, 1999, INFECT IMMUN, V67, P1310, DOI 10.1128/IAI.67.3.1310-1316.1999
   Da Silva FT, 2013, VACCINE, V31, P1870, DOI 10.1016/j.vaccine.2013.01.042
   Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632
   Droemann D, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-68
   *FOOD DRUG ADM, GUID IND TOX GRAD SC
   Forsgren A, 2008, CLIN INFECT DIS, V46, P726, DOI 10.1086/527396
   Froes F, 2017, INT J CHRONIC OBSTR, V12, P3457, DOI 10.2147/COPD.S140378
   GOLD Board and Science Committee, GLOB STRAT DIAGN MAN
   Hallstrom T, 2009, J IMMUNOL, V183, P2593, DOI 10.4049/jimmunol.0803226
   Huang YJ, 2017, TRANSL RES, V179, P71, DOI 10.1016/j.trsl.2016.06.007
   Jurcisek JA, 2007, MOL MICROBIOL, V65, P1288, DOI 10.1111/j.1365-2958.2007.05864.x
   Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120
   Lafontaine ER, 2000, J BACTERIOL, V182, P1364, DOI 10.1128/JB.182.5.1364-1373.2000
   Leroux-Roels G, 2016, CLIN IMMUNOL, V169, P16, DOI 10.1016/j.clim.2016.05.007
   Leroux-Roels G, 2016, VACCINE, V34, P3156, DOI 10.1016/j.vaccine.2016.04.051
   Leroux-Roels I, 2015, VACCINE, V33, P577, DOI 10.1016/j.vaccine.2013.10.052
   Mackay AJ, 2013, IMMUNOL ALLERGY CLIN, V33, P95, DOI 10.1016/j.iac.2012.10.006
   Mayhew D, 2018, THORAX, V73, P422, DOI 10.1136/thoraxjnl-2017-210408
   Moris P, 2011, J CLIN IMMUNOL, V31, P443, DOI 10.1007/s10875-010-9490-6
   Pauksens K, 2014, CLIN VACCINE IMMUNOL, V21, P651, DOI 10.1128/CVI.00807-13
   Pera A, 2015, MATURITAS, V82, P50, DOI 10.1016/j.maturitas.2015.05.004
   Perez Antonia C, 2017, VACCINE, DOI [10.1016/i.vaccine2016.12.066, DOI 10.1016/I.VACCINE.2016.12.066]
   Samukawa T, 2000, INFECT IMMUN, V68, P1569, DOI 10.1128/IAI.68.3.1569-1573.2000
   Schaar V, 2011, ANTIMICROB AGENTS CH, V55, P3845, DOI 10.1128/AAC.01772-10
   Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561
   Singh B, 2013, INFECT IMMUN, V81, P801, DOI 10.1128/IAI.01111-12
   Singh B, 2011, MOL MICROBIOL, V81, P80, DOI 10.1111/j.1365-2958.2011.07678.x
   Takanashi S, 1999, EUR RESPIR J, V14, P309, DOI 10.1034/j.1399-3003.1999.14b12.x
   Tan TT, 2007, J INFECT DIS, V195, P1661, DOI 10.1086/517611
   Tan TT, 2006, INFECT IMMUN, V74, P6377, DOI 10.1128/IAI.00702-06
   Van Braeckel E, 2011, CLIN INFECT DIS, V52, P522, DOI 10.1093/cid/ciq160
   Vandepapeliere P, 2008, VACCINE, V26, P1375, DOI 10.1016/j.vaccine.2007.12.038
   Wilkinson TMA, 2017, THORAX, V72, P919, DOI 10.1136/thoraxjnl-2016-209023
NR 42
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3113
EP 3122
DI 10.1016/j.vaccine.2019.04.041
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300019
PM 31029515
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wilson, SE
   Murray, J
   Bunko, A
   Johnson, S
   Buchan, SA
   Crowcroft, NS
   Dubey, V
   Loh, LC
   MacLeod, M
   Taylor, C
   Deeks, SL
AF Wilson, Sarah E.
   Murray, Jillian
   Bunko, Andrean
   Johnson, Steven
   Buchan, Sarah A.
   Crowcroft, Natasha S.
   Dubey, Vinita
   Loh, Lawrence C.
   MacLeod, Melissa
   Taylor, Christina
   Deeks, Shelley L.
TI Characteristics of immunized and un-immunized students, including
   non-medical exemptions, in Ontario, Canada: 2016-2017 school year
SO VACCINE
LA English
DT Article
DE Immunization; Non-medical exemptions; Medical-exemptions; Vaccine
   hesitancy; Vaccine acceptance; Immunization policy
ID VACCINE EXEMPTIONS; CALIFORNIA; REQUIREMENTS; PERTUSSIS; TRENDS; RATES;
   CHILDREN
AB Background: Our objectives were: (1) to quantify and describe un-immunized students in Ontario, Canada and assess the extent to which these students have exemptions; and (2) to quantify and describe students with non-medical exemptions (NMEs), including what proportion have up-to-date immunizations.
   Methods: We examined Ontario students 7 to 17 years-of-age in the 2016-2017 school year using information within a centralized immunization repository. We identified and described students with different immunization/exemption classifications by age, sex, school type, geography and area-level material deprivation using descriptive and multivariable logistic regression analyses. Finally, we assessed the immunization status of students with NMEs, by antigen.
   Results: We found that students could be recorded as un-immunized with or without an NME, or be immunized with an NME. From a cohort of 1.65 million students, 2.9% of students had zero vaccine doses recorded, and of these 68% had no exemption of any kind. A total of 2.4% of students had an NME. Of these, 39% were un-immunized and 61% had received >= 1 vaccine. Among all students with NMEs, 19-48% had up-to-date immunizations, varying by antigen. Factors associated with increased odds of having a NME and being un-immunized included: attendance at private and 'other' schools, rural residence, and geography. Older age and greater area-level deprivation were associated with a reduced odds.
   Conclusions: Our assessment revealed that Ontario students with NMEs cannot be assumed to be un-immunized and at risk for all vaccine-preventable diseases. Conversely, not all un-immunized students had NMEs suggesting that future studies of un-immunized children in Ontario must consider additional factors beyond NME status alone. Other jurisdictions that use NME data to inform research and surveillance of vaccine hesitancy and risks for VPD outbreaks may wish to undertake a similar assessment to determine how well student NMEs correlate with student immunization status. Crown Copyright (C) 2019 Published by Elsevier Ltd.
C1 [Wilson, Sarah E.; Murray, Jillian; Bunko, Andrean; Johnson, Steven; Buchan, Sarah A.; Crowcroft, Natasha S.; Deeks, Shelley L.] Publ Hlth Ontario, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada.
   [Wilson, Sarah E.; Buchan, Sarah A.; Crowcroft, Natasha S.; Dubey, Vinita; Loh, Lawrence C.; Deeks, Shelley L.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Wilson, Sarah E.; Buchan, Sarah A.; Crowcroft, Natasha S.] ICES, Toronto, ON, Canada.
   [Crowcroft, Natasha S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Dubey, Vinita] Toronto Publ Hlth, Toronto, ON, Canada.
   [Loh, Lawrence C.] Peel Publ Hlth, Mississauga, ON, Canada.
   [MacLeod, Melissa] Southwestern Publ Hlth, Woodstock, ON, Canada.
   [Taylor, Christina] Huron Cty Hlth Unit, Clinton, ON, Canada.
RP Wilson, SE (reprint author), Publ Hlth Ontario, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada.
EM sarah.wilson@oahpp.ca
OI Crowcroft, Natasha/0000-0002-6761-8783
FU Public Health Ontario
FX This project was funded by Public Health Ontario.
CR Aloe C, 2017, P NATL ACAD SCI USA, V114, P7101, DOI 10.1073/pnas.1700240114
   Atwell JE, 2013, PEDIATRICS, V132, P624, DOI 10.1542/peds.2013-0878
   Beard Frank H, 2016, Med J Aust, V204, P275
   Birnbaum MS, 2013, VACCINE, V31, P750, DOI 10.1016/j.vaccine.2012.11.092
   Brennan JM, 2017, AM J PUBLIC HEALTH, V107, P108, DOI 10.2105/AJPH.2016.303498
   Buttenheim AM, 2015, VACCINE, V33, P6250, DOI 10.1016/j.vaccine.2015.09.075
   Carrel M, 2015, PEDIATRICS, V136, P80, DOI 10.1542/peds.2015-0831
   Deeks S L, 2014, Can Commun Dis Rep, V40, P42
   Delamater PL, 2017, JAMA-J AM MED ASSOC, V318, P863, DOI 10.1001/jama.2017.9242
   Feikin DR, 2000, JAMA-J AM MED ASSOC, V284, P3145, DOI 10.1001/jama.284.24.3145
   Hahne S, 2009, PEDIATR INFECT DIS J, V28, P795, DOI 10.1097/INF.0b013e3181a3e2d5
   Institut National de Sante de Publique du Quebec, 2013, ENQ COUV VACC ENF 1
   Jones M, 2014, AM J PUBLIC HEALTH, V104, pE3, DOI 10.2105/AJPH.2014.302065
   Lieu TA, 2015, PEDIATRICS, V135, P280, DOI 10.1542/peds.2014-2715
   Matheson FI, 2011, 2011 ONTARIO MARGINA
   Michigan Department of Health and Human Services, 2017, IMM STAT SCH CHILDR
   Navin MC, 2018, VACCINE, V36, P1751, DOI 10.1016/j.vaccine.2018.02.046
   Olive JK, 2018, PLOS MED, V15, DOI [10.1371/journal.pmed1002576, DOI 10.1371/JOURNAL.PMED1002576]
   Omer SB, 2012, NEW ENGL J MED, V367, P1170, DOI 10.1056/NEJMc1209037
   Omer SB, 2008, AM J EPIDEMIOL, V168, P1389, DOI 10.1093/aje/kwn263
   Ontario Agency for Health Protection and Promotion (Public Health Ontario), 2017, TECHN ANN IMM COV RE
   Ontario. Ministry of Health and Long-Term Care, 2017, PAN DAT STAND BEST P
   Public Health Agency of Canada, 2017, VACC COV CAN CHILDR
   Richards JL, 2013, VACCINE, V31, P3009, DOI 10.1016/j.vaccine.2013.04.053
   Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470
   Salmon Daniel A, 2009, WMJ, V108, P17
   Shaw J, 2018, IMMUNIZATION MANDATE, V5, DOI [10.1093/ofid/ofy130, DOI 10.1093/OFID/OFY130]
   Smith PJ, 2017, VACCINE, V35, P5346, DOI 10.1016/j.vaccine.2017.08.036
   Wang E, 2014, AM J PUBLIC HEALTH, V104, pE62, DOI 10.2105/AJPH.2014.302190
   Wilson Sarah E, 2015, CMAJ Open, V3, pE317, DOI 10.9778/cmajo.20140088
NR 30
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3123
EP 3132
DI 10.1016/j.vaccine.2019.04.033
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300020
PM 31029513
OA Other Gold
DA 2020-05-12
ER

PT J
AU Jonker, EFF
   Uijlings, MAC
   Visser, LG
   Soonawala, D
AF Jonker, Emile F. F.
   Uijlings, Marjolein A. C.
   Visser, Leonardus G.
   Soonawala, Darius
TI Comparison of the immunogenicity of Dukoral (R) oral cholera vaccine
   between renal transplant recipients on either a calcineurin inhibitor or
   mycophenolate - A controlled trial
SO VACCINE
LA English
DT Article
DE Oral cholera vaccine; Renal transplant recipient; Calcineurin inhibitor;
   Mycophenolate; Cholera toxin; Vibriocidal antibody response; IgA;
   Anti-toxin antibody
ID ENTEROTOXIGENIC ESCHERICHIA-COLI; IMMUNOSUPPRESSIVE THERAPY; PROTECTION;
   SAFETY; IMMUNIZATION; INFECTION; EFFICACY; LIVE
AB Background: The evidence for recommendations regarding vaccination in solid organ transplant recipients is sparse. There is little data comparing vaccine responses between groups on different immunosuppressive drugs. This study was conducted to evaluate the antibody response to Dukoral (R) oral cholera vaccine in renal transplant recipients (RTR).
   Methods: In a single-center non-randomized controlled clinical trial, healthy volunteers (n = 21) and renal transplant recipients (n = 30) were vaccinated with the oral whole cell/recombinant B subunit cholera vaccine Dukoral (R) (Valneva Inc., Vienna, Austria). The RTR were stratified according to their maintenance immunosuppressive therapy: either prednisone and a calcineurin inhibitor (cyclosporine A or tacrolimus; P/CNI group; n = 15) or prednisone and mycophenolate (P/MMF group; n = 15). All volunteers ingested Dukoral (R) at baseline and at day 14. Serum samples were drawn at day 0 and day 21. The primary outcome was seroconversion, defined as either a 3-fold IgA serum titer increase in anti-cholera toxin B antibodies and/or a 4-fold rise in the serum vibriocidal titer.
   Results: Follow-up was complete. Seroconversion after vaccination was 57% (standard error, SE 9%) in RTR and 81% (SE 9%) in healthy controls (Relative Risk, RR 0.70; 95% CI 0.48-1.02). When stratified according to maintenance immunosuppression, the seroconversion rate was 67% (SE 12%) in the P/CNI group (RR compared with controls 0.82; 95% CI 0.55-1.25) and 47% (SE 13%) in the P/MMF group (RR compared with controls 0.58; 95% CI 0.32-1.03).
   Conclusion: Adverse events were mild to moderate and transient. The response to Dukoral was weaker and the seroconversion rate was lower in renal transplant recipients than in healthy controls. In particular, those using mycophenolate had a poor response. Nevertheless, more than half of the transplant recipients seroconverted. Therefore oral vaccines should not be discarded as a potential tool for protection of solid organ transplant recipients. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jonker, Emile F. F.; Uijlings, Marjolein A. C.; Visser, Leonardus G.] Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands.
   [Soonawala, Darius] Leiden Univ, Med Ctr, Dept Nephrol, C7,POB 9600, NL-2300 RC Leiden, Netherlands.
   [Soonawala, Darius] Haga Teaching Hosp, Dept Internal Med, The Hague, Netherlands.
RP Soonawala, D (reprint author), Leiden Univ, Med Ctr, Dept Nephrol, C7,POB 9600, NL-2300 RC Leiden, Netherlands.
EM d.soonawala@lumc.nl
OI Visser, Leo/0000-0002-3600-9782
CR Agency EM, 2004, EU103263001003 AG EM
   Agency EM, 2009, EMA6436442014
   Ahmed T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009029.pub2
   Azevedo LS, 2013, TRANSPL INFECT DIS, V15, P612, DOI 10.1111/tid.12140
   Bi QF, 2017, LANCET INFECT DIS, V17, P1080, DOI [10.1016/s1473-3099(17)30359-6, 10.1016/S1473-3099(17)30359-6]
   Bishop AL, 2011, EXPERT REV VACCINES, V10, P79, DOI 10.1586/ERV.10.150
   Chen WH, 2015, CLIN VACCINE IMMUNOL, V22, P129, DOI 10.1128/CVI.00560-14
   Croce E, 2017, VACCINE, V35, P1216, DOI 10.1016/j.vaccine.2017.01.048
   Eckardt KU, 2009, AM J TRANSPLANT, V9, pS1, DOI 10.1111/j.1600-6143.2009.02834.x
   Eckerle I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056974
   Haney DJ, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00098-17, 10.1128/cvi.00098-17]
   Hayney Mary S, 2004, Prog Transplant, V14, P346
   Ivers LC, 2015, J INFECT DIS, V212, P779, DOI 10.1093/infdis/jiv108
   Jeon HJ, 2014, TRANSPL INFECT DIS, V16, P511, DOI 10.1111/tid.12217
   Kabir S, 2014, CLIN VACCINE IMMUNOL, V21, P1195, DOI 10.1128/CVI.00378-14
   Lopez AL, 2018, CLIN INFECT DIS, V66, P1960, DOI 10.1093/cid/cix1039
   McKenzie R, 2007, VACCINE, V25, P3684, DOI 10.1016/j.vaccine.2007.01.043
   Moal V, 2015, J CLIN VIROL, V68, P32, DOI 10.1016/j.jcv.2015.04.011
   Mulley WR, 2012, KIDNEY INT, V82, P212, DOI 10.1038/ki.2012.106
   Pittet LF, 2013, CURR OPIN ORGAN TRAN, V18, P543, DOI 10.1097/MOT.0b013e3283636c88
   Saha D, 2004, J INFECT DIS, V189, P2318, DOI 10.1086/421275
   SANCHEZ JL, 1995, T ROY SOC TROP MED H, V89, P542, DOI 10.1016/0035-9203(95)90103-5
   Struijk GH, 2015, TRANSPL INFECT DIS, V17, P192, DOI 10.1111/tid.12368
   Struijk GH, 2010, KIDNEY INT, V78, P934, DOI 10.1038/ki.2010.269
   Visser LG, 2012, INFECT DIS CLIN N AM, V26, P609, DOI 10.1016/j.idc.2012.06.003
   Weinke T, 2008, Travel Med Infect Dis, V6, P362, DOI 10.1016/j.tmaid.2006.05.003
   Willcocks LC, 2007, AM J TRANSPLANT, V7, P2006, DOI 10.1111/j.1600-6143.2007.01869.x
NR 27
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2019
VL 37
IS 23
BP 3133
EP 3139
DI 10.1016/j.vaccine.2019.04.010
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HZ9FD
UT WOS:000469160300021
PM 31029516
DA 2020-05-12
ER

PT J
AU Yang, GC
   Schneck, NA
   Barefoot, N
   Yang, YH
   Gollapudi, D
   Arnold, FJ
   Cooper, JW
   Lei, QP
AF Yang, Gengcheng
   Schneck, Nicole A.
   Barefoot, Nathan
   Yang, Yanhong
   Gollapudi, Deepika
   Arnold, Frank J.
   Cooper, Jonathan W.
   Lei, Q. Paula
TI Titer measurement of HIV-1 envelope trimeric glycoprotein in cell
   culture media by a new tandem ion exchange and size exclusion
   chromatography (IEC-SEC) method
SO VACCINE
LA English
DT Article
DE HIV-1; Vaccine; Cell culture; Titer; Quantification; HPLC; Tandem
   chromatography
AB An efficient and specific liquid chromatography (LC)-based assay was developed to monitor the production of recombinant HIV-1 trimeric envelope glycoprotein (HIV Env trimer), a candidate vaccine for HIV-1 infection, in cell culture media to support scale-up process development. In this method, titer measurement was achieved by coupling a weak anion exchange chromatography (IEC) column with a size exclusion chromatography (SEC) column. This assay was specific, accurate, precise, and has been qualified for its intended purpose, with a limit of quantification (LOQ) of 10 mu g/mL. This tandem separation strategy offered a reliable and timely analytical support to directly monitor the titer of HIV Env trimer during cell growth, without any extra sample purification steps. Published by Elsevier Ltd.
C1 [Yang, Gengcheng; Schneck, Nicole A.; Barefoot, Nathan; Yang, Yanhong; Gollapudi, Deepika; Arnold, Frank J.; Cooper, Jonathan W.; Lei, Q. Paula] NIAID, Vaccine Prod Program, Vaccine Res Ctr, NIH, Gaithersburg, MD USA.
RP Lei, QP (reprint author), 9 West Watkins Mill Rd, Gaithersburg, MD 20878 USA.
EM paula.lei@nih.gov
FU Intramural Research Program of the Vaccine Research Center (VRC),
   National Institute of Allergy and Infectious Diseases (NIAID), National
   Institutes of Health (NIH)
FX This work was supported by the Intramural Research Program of the
   Vaccine Research Center (VRC), National Institute of Allergy and
   Infectious Diseases (NIAID), National Institutes of Health (NIH). This
   research did not receive any specific grant from funding agencies in the
   public, commercial, or not-for-profit sectors.
CR Chuang GY, 2017, J VIROL, V91, DOI 10.1128/JVI.02268-16
   Depetris RS, 2012, J BIOL CHEM, V287, P24239, DOI 10.1074/jbc.M112.371898
   ICH, 2005, VAL AN PROC TEST MET
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Marchese RD, 2009, CLIN VACCINE IMMUNOL, V16, P387, DOI 10.1128/CVI.00415-08
   Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808
   Stephenson KE, 2016, CURR OPIN IMMUNOL, V41, P39, DOI 10.1016/j.coi.2016.05.011
   Wang FQ, 2015, BIOPHARM INT, V28, P32
NR 8
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3142
EP 3145
DI 10.1016/j.vaccine.2019.04.089
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700002
PM 31060952
DA 2020-05-12
ER

PT J
AU Dora, EG
   Rossi, SL
   Weaver, SC
   Tucker, SN
   Mateo, R
AF Dora, Emery G.
   Rossi, Shannan L.
   Weaver, Scott C.
   Tucker, Sean N.
   Mateo, Roberto
TI An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies
   and protects mice against chikungunya virus-induced footpad swelling
SO VACCINE
LA English
DT Article
DE Chikungunya; Oral; Vaccine; Tablet; Adenovirus
ID AVIAN INFLUENZA; RESPONSES; DELIVERY
AB Over the past decade, chikungunya virus (CHIKV) has emerged as a major cause of mosquito-borne disease with transmission reported in over 100 countries worldwide. Although several strategies have been pursued for the development of a CHIKV vaccine, none has been approved yet. In this study, we describe the development of several vaccine vectors that express the structural proteins of the La Reunion CHIKV strain LR2006-OPY1. Protection from virus-induced pathologic changes was observed in vaccinated C57BL/6 mice, an important model for CHIKV vaccine development because of their ability to recapitulate several signs shown in infected humans. This study uniquely demonstrates the capacity of a mucosally-administered adenovirus vaccine to induce serum antibody responses and confer protective efficacy in a pre-clinical model. Our data provide further evidence in support of the clinical development of this oral Ad-CHIKV vaccine strategy in populations at high risk of contracting the disease. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dora, Emery G.; Tucker, Sean N.; Mateo, Roberto] Vaxart Inc, 395 Oyster Point, San Francisco, CA 94080 USA.
   [Rossi, Shannan L.; Weaver, Scott C.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
   [Rossi, Shannan L.; Weaver, Scott C.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
RP Mateo, R (reprint author), Vaxart Inc, 395 Oyster Point, San Francisco, CA 94080 USA.
EM rmateo@vaxart.com
FU Vaxart, Inc.; WRCEVA through NIH [R24AI120942]
FX Vaxart, Inc. funded this study, and virus reagents were supported by the
   WRCEVA through NIH grant R24AI120942.
CR Brandler S, 2013, VACCINE, V31, P3718, DOI 10.1016/j.vaccine.2013.05.086
   Broeckel R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005637
   Chan Yi-Hao, 2015, Med Sci (Basel), V3, P64, DOI 10.3390/medsci3030064
   Erasmus JH, 2017, NAT MED, V23, P192, DOI 10.1038/nm.4253
   Kim L, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121077
   Kim L, 2016, SCI REP-UK, V6, DOI 10.1038/srep37295
   Langsjoen RM, 2018, MBIO, V9, DOI 10.1128/mBio.02449-17
   LEVITT NH, 1986, VACCINE, V4, P157, DOI 10.1016/0264-410X(86)90003-4
   Liebowitz D, 2015, LANCET INFECT DIS, V15, P1041, DOI 10.1016/S1473-3099(15)00266-2
   Miner JJ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3438
   NIAID, 2013, CHIK VIR VACC TRIAL
   Pan American Health Organization, 2018, FACTSH CHIK
   Peters W, 2013, VACCINE, V31, P1752, DOI 10.1016/j.vaccine.2013.01.023
   Reisinger EC, 2018, LANCET, V392, P2718, DOI 10.1016/S0140-6736(18)32488-7
   Rossi SL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003797
   Scallan CD, 2013, CLIN VACCINE IMMUNOL, V20, P85, DOI 10.1128/CVI.00552-12
   Schwartz O, 2010, NAT REV MICROBIOL, V8, P491, DOI 10.1038/nrmicro2368
   Smalley C, 2016, VACCINE, V34, P2976, DOI 10.1016/j.vaccine.2016.03.076
   Tapia F, 2016, APPL MICROBIOL BIOT, V100, P2121, DOI 10.1007/s00253-015-7267-9
   Tharmarajah Kothila, 2017, F1000Res, V6, P2114, DOI 10.12688/f1000research.12461.1
   Tsetsarkin K, 2006, VECTOR-BORNE ZOONOT, V6, P325, DOI 10.1089/vbz.2006.6.325
   Tucker SN, 2003, MOL THER, V8, P392, DOI 10.1016/S1525-0016(03)00180-1
   World Health Organization, 2018, CHIK MOMB
NR 23
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3146
EP 3150
DI 10.1016/j.vaccine.2019.04.069
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700003
PM 31047675
DA 2020-05-12
ER

PT J
AU Farcet, MR
   Karbiener, M
   Rabel, PO
   Schirmer, A
   Ilk, R
   Kreil, TR
AF Farcet, Maria R.
   Karbiener, Michael
   Rabel, Philip O.
   Schirmer, Andreas
   Ilk, Reinhard
   Kreil, Thomas R.
TI Measles virus neutralizing antibodies in immunoglobulin lots produced
   from plasma collected in Europe or the United States
SO VACCINE
LA English
DT Article
DE IGIV; lmmunoglobulin, intravenous; lmmunoglobulin, subcutaneous;
   Neutralization assays; Measles vaccination; Post-exposure prophylaxis
AB Vaccination against measles has reduced disease, although measles virus antibody (MVAb) levels are lower after vaccination than natural infection. lmmunoglobulin (IG) preparations thus contain decreasing MVAb titers. US IG lot release requires a minimum titer of MVAb, yet equivalent information is not available for other geographies. Using a measles virus neutralization assay, IG fractionated from US or EU plasma is shown to contain similar levels of MVAb always above US regulatory requirements, supportive of equivalent protection against MV infection. Thus, the dosage for post-exposure prophylaxis in the EU could be aligned with the US FDA's treatment recommendations. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Farcet, Maria R.; Karbiener, Michael; Rabel, Philip O.; Schirmer, Andreas; Kreil, Thomas R.] Baxter AG, Global Pathogen Safety, A-1221 Vienna, Austria.
   [Ilk, Reinhard] Baxter AG, Mfg Sci, A-1221 Vienna, Austria.
   [Farcet, Maria R.; Karbiener, Michael; Rabel, Philip O.; Schirmer, Andreas; Ilk, Reinhard; Kreil, Thomas R.] Takeda Grp Co, Vienna, Austria.
RP Kreil, TR (reprint author), Takeda, Benatzkygasse 2-6, A-1221 Vienna, Austria.
EM maria.farcet@takeda.com; michael.karbiener@takeda.com;
   philip.rabel@takeda.com; schirmer@takeda.com; reinhard.ilk@takeda.com;
   thomas.kreil@takeda.com
FU TakedaTakeda Pharmaceutical Company Ltd
FX This study was funded by Baxter AG, Vienna, Austria, now part of the
   Takeda group of companies.
CR Agence nationale de securite du medicament et des produits de sante (ANSM), 2018, HIER IND IMM HUM POL
   Audet S, 2006, J INFECT DIS, V194, P781, DOI 10.1086/506363
   CHRISTENSON B, 1994, VACCINE, V12, P129, DOI 10.1016/0264-410X(94)90049-3
   Dabbagh A, 2018, MMWR-MORBID MORTAL W, V67, P1323, DOI 10.15585/mmwr.mm6747a6
   European Centre for Disease Prevention and Control, MONTHL MEASL RUB MON
   Farrugia A, 2019, VACCINE, V37, P3942, DOI 10.1016/j.vaccine.2018.11.059
   Galel SA, 2018, TRANSFUSION, V58, P649, DOI [10.1111/trf.14457, 10.1111/trf.15014]
   Matysiak-Klose D, 2018, VACCINE, V36, P7916, DOI 10.1016/j.vaccine.2018.10.070
   Modrof J, 2017, J INFECT DIS, V216, P977, DOI 10.1093/infdis/jix428
   Poelsler G, 2008, VOX SANG, V94, P184, DOI 10.1111/j.1423-0410.2007.01016.x
   Public Health England, 2017, GUID POST PROPH MEAS
   Ritter S, 2012, BUNDESGESUNDHEITSBLA, V55, P914, DOI 10.1007/s00103-012-1515-2
   Schreiber GB, 2017, SOURCE PLASMA DONORS
   Vandeberg P, 2018, TRANSFUSION, V58, P3072, DOI 10.1111/trf.15024
   Wadman M, 2019, SCIENCE, V363, P677, DOI 10.1126/science.363.6428.677
   WHO, 2011, AG DISTR BLOOD DON C
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3151
EP 3153
DI 10.1016/j.vaccine.2019.04.022
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700004
PM 31060953
OA Other Gold
DA 2020-05-12
ER

PT J
AU Bonomo, ME
   Kim, RY
   Deem, MW
AF Bonomo, Melia E.
   Kim, Rachel Y.
   Deem, Michael W.
TI Modular epitope binding predicts influenza quasispecies dominance and
   vaccine effectiveness: Application to 2018/19 season
SO VACCINE
LA English
DT Article
DE Seasonal influenza; Immunity; Antigenic distance; Mathematical models;
   Vaccine effectiveness; Vaccination planning
ID UNITED-STATES; VIRUS; PROTECTION; EVOLUTION
AB The modular binding sites on the influenza A(H3N2) hemagglutinin protein are under significant pressure to acquire mutations in order to evade human antibody recognition. Analysis of these hemagglutinin epitopes in the strains circulating during 2017/18 and early 2018/19 identified the emergence of a new antigenic cluster that has grown from 4% of circulating strains to 11%. We regressed our module-based antigenic distance, p(epitope), with A(H3N2) vaccine effectiveness from recent studies conducted by the US Centers for Disease Control and Prevention (r(2) = 0.92), and we used this to estimate that the 2018/19 vaccines will protect against most circulating A(H3N2) strains. The pEpitope model is useful for A(H3N2) influenza vaccine virus selection and development, and it has the potential to aid national or regional regulatory authorities in making geographically localized decisions. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Bonomo, Melia E.; Deem, Michael W.] Rice Univ, Dept Phys & Astron, 6100 Main St, Houston, TX 77005 USA.
   [Bonomo, Melia E.; Deem, Michael W.] Rice Univ, Ctr Theoret Biol Phys, 6100 Main St, Houston, TX 77005 USA.
   [Kim, Rachel Y.] Rice Univ, Weiss Sch Nat Sci, 6100 Main St, Houston, TX 77005 USA.
   [Deem, Michael W.] Rice Univ, Dept Bioengn, 6100 Main St, Houston, TX 77005 USA.
RP Deem, MW (reprint author), Rice Univ, 6500 Main St STE 1030, Houston, TX 77030 USA.
EM meb16@rice.edu; ryk4@rice.edu; mwdeem@rice.edu
RI ; Deem, Michael/P-3595-2014
OI Bonomo, Melia/0000-0002-1551-5731; Deem, Michael/0000-0002-4298-3450
FU Center for Theoretical Biological Physics at Rice University, Houston TX
   [National Science Foundation] [PHY 1427654]; Welch FoundationThe Welch
   Foundation [C-1917-20170325]
FX This work was supported by the Center for Theoretical Biological Physics
   at Rice University, Houston TX [National Science Foundation, PHY
   1427654] and the Welch Foundation [C-1917-20170325].
CR Alan H, 2017, VACCINE, V35, P1104, DOI 10.1016/j.vaccine.2017.01.018
   Bonomo ME, 2018, CLIN INFECT DIS, V67, P1129, DOI 10.1093/cid/ciy323
   Doyle JD, 2019, MMWR-MORBID MORTAL W, V68, P135, DOI 10.15585/mmwr.mm6806a2
   He JK, 2010, PROTEIN ENG DES SEL, V23, P935, DOI 10.1093/protein/gzq078
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jackson ML, 2017, NEW ENGL J MED, V377, P534, DOI [10.1056/NEJMoa1700153, 10.1056/nejmoa1700153]
   Kobayashi Y, 2012, J VIROL
   McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647
   Munoz ET, 2005, VACCINE, V23, P1144, DOI 10.1016/j.vaccine.2004.08.028
   Ohmit SE, 2014, CLIN INFECT DIS, V58, P319, DOI 10.1093/cid/cit736
   Pan K, 2011, PROTEIN ENG DES SEL, V24, P291, DOI 10.1093/protein/gzq105
   Pan YD, 2016, VACCINE, V34, P4610, DOI 10.1016/j.vaccine.2016.07.015
   Petrova VN, 2018, NAT REV MICROBIOL, V16, P47, DOI 10.1038/nrmicro.2017.118
   Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211
   Sun J, 2006, MOD PHYS LETT B, V20, P63, DOI 10.1142/S0217984906010494
   Treanor JJ, 2012, CLIN INFECT DIS, V55, P951, DOI 10.1093/cid/cis574
   Weinberg GA, 2010, J INFECT DIS, V201, P1607, DOI 10.1086/652404
   Xie H, 2017, CLIN INFECT DIS, V65, P259, DOI 10.1093/cid/cix269
   ZHAO SY, 2017, EUROSURVEILLANCE, V22, DOI DOI 10.3390/MOLECULES22101721
   Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
NR 21
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3154
EP 3158
DI 10.1016/j.vaccine.2019.03.068
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700005
PM 31060950
OA Other Gold
DA 2020-05-12
ER

PT J
AU Hocknell, RE
   Cleary, DW
   Srifeungfung, S
   Clarke, SC
AF Hocknell, Rebecca E.
   Cleary, David W.
   Srifeungfung, Somporn
   Clarke, Stuart C.
TI Serotype distribution of disease-causing Streptococcus pneumoniae in
   Thailand: A systematic review
SO VACCINE
LA English
DT Review
DE Invasive pneumococcal disease; IPD; non-IPD; Pneumococcus; Thailand;
   Pneumococcal conjugate vaccine
ID INVASIVE PNEUMOCOCCAL DISEASE; ANTIMICROBIAL RESISTANCE; CONJUGATE
   VACCINE; CHILDREN YOUNGER; PREVALENCE; SUSCEPTIBILITY; CARRIAGE;
   COLONIZATION; EPIDEMIOLOGY; SURVEILLANCE
AB Background: Streptococcus pneumoniae infection is associated with a high morbidity and mortality worldwide. There are currently >98 known serotypes; the most burdensome are covered by current pneumococcal conjugate vaccines (PCVs) such as PCV10 (Synflorix (R)) and (Prevnar 13 (R)) PCV13. However, at present no PCV is available on the National Expanded Programme of Immunization (EPI) in Thailand.
   Methods: Here we report a systematic review of studies regarding pneumococci associated with invasive pneumococcal disease (IPD) and non-IPD in Thailand. The NCBI PubMed database and Google Scholar were used to identify relevant papers published from 1st January 1990 to 21st August 2017. The quantitative analysis was reported as the distribution of serotypes across two age groups, <= 5 and >5years old, as these were the most commonly reported. Where age was not stated, or data was combined, data were categorised as all ages.
   Results: The search returned 15 relevant articles. From these the five most common disease-causing serotypes, in rank order, were 6B, 23F, 14, 19A and 19F. Vaccine coverage would be 55.3% for PCV10 and 69.7% for PCV13. There was insufficient data to draw conclusions regarding non-invasive disease-causing pneumococcal serotypes.
   Conclusion: This review demonstrates that the serotypes which were most responsible for disease in Thailand are included in PCV10 and PCV13. Better surveillance data of IPD and non-IPD are required for monitoring vaccine effectiveness if PCV is implemented nationally. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hocknell, Rebecca E.; Cleary, David W.; Clarke, Stuart C.] Univ Southampton, Fac Med, Southampton, Hants, England.
   [Hocknell, Rebecca E.; Cleary, David W.; Clarke, Stuart C.] Univ Southampton, Inst Life Sci, Southampton, Hants, England.
   [Cleary, David W.; Clarke, Stuart C.] Univ Hosp Southampton Fdn NHS Trust, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England.
   [Srifeungfung, Somporn] Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok, Thailand.
   [Srifeungfung, Somporn] Siam Univ, Fac Med, Bangkok, Thailand.
   [Clarke, Stuart C.] Univ Southampton, Global Hlth Res Inst, Southampton, Hants, England.
RP Clarke, SC (reprint author), Univ Southampton, Infect Dis Epidemiol Grp, Acad Unit Clin & Expt Sci, Univ Hosp Southampton Fdn NHS Trust, Mail Point 814,Level C Fac Med, Southampton SO16 6YD, Hants, England.
EM S.C.Clarke@southampton.ac.uk
OI Clarke, Stuart/0000-0002-7009-1548; Hocknell,
   Rebecca/0000-0002-7207-352X; Cleary, David/0000-0003-4533-0700
FU PfizerPfizer; GSKGlaxoSmithKline
FX SCC acts as principal investigator on studies conducted on behalf of
   University Hospital Southampton NHS Foundation Trust/University of
   Southampton that are sponsored by vaccine manufacturers but receives no
   personal payments from them. SCC has participated in advisory boards for
   vaccine manufacturers but receives no personal payments for this work.
   SCC has received financial assistance from vaccine manufacturers to
   attend conferences. DWC was a post-doctoral researcher on projects
   funded by Pfizer and GSK between April 2014 and October 2017. All grants
   and honoraria are paid into accounts within the respective NHS Trusts or
   Universities, or to independent charities. All other authors have no
   conflicts of interest.
CR Alexandre C, 2010, ACTA PAEDIATR, V99, P1686, DOI 10.1111/j.1651-2227.2010.01914.x
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   [Anonymous], 2007, Wkly Epidemiol Rec, V82, P93
   [Anonymous], 2008, Wkly Epidemiol Rec, V83, P373
   Arushothy R, 2018, INT J INFECT DIS, DOI [10.1016/Apd.2018.17.009, DOI 10.1016/APD.2018.17.009]
   Baggett HC, 2009, CLIN INFECT DIS, V48, pS65, DOI 10.1086/596484
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Bravo LC, 2009, VACCINE, V27, P7282, DOI 10.1016/j.vaccine.2009.04.046
   Bruce MG, 2015, VACCINE, V33, P4813, DOI 10.1016/j.vaccine.2015.07.080
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   Cardozo DM, 2008, J MED MICROBIOL, V57, P185, DOI 10.1099/jmm.0.47470-0
   Chewapreecha C, 2014, NAT GENET, V46, P305, DOI 10.1038/ng.2895
   Choi EH, 2008, EMERG INFECT DIS, V14, P275, DOI 10.3201/eid1402.070807
   Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368
   Feikin DR, 2005, CLIN INFECT DIS, V41, P481, DOI 10.1086/432015
   Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15
   Hanage WP, 2010, EPIDEMICS-NETH, V2, P80, DOI 10.1016/j.epidem.2010.03.005
   Harboe ZB, 2010, VACCINE, V28, P2642, DOI 10.1016/j.vaccine.2010.01.017
   Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83, DOI 10.1016/S1473-3099(05)01280-6
   Houseman C, 2017, EMERG INFECT DIS, V23, P122, DOI 10.3201/eid2301.160897
   Hung IFN, 2013, INT J INFECT DIS, V17, pE364, DOI 10.1016/j.ijid.2013.01.004
   Imohl M, 2010, J CLIN MICROBIOL, V48, P1291, DOI 10.1128/JCM.01937-09
   Jauneikaite E, 2012, VACCINE, V30, P3503, DOI 10.1016/j.vaccine.2012.03.066
   Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348
   Klugman K, 2001, AS PAC ADV BOARD M 1
   Kulpeng W, 2013, VACCINE, V31, P2839, DOI 10.1016/j.vaccine.2013.03.047
   Le C, 2011, J VACCINES VACCIN S, VS2
   Levine S, 2006, PEDIATR INFECT DIS J, V25, P176, DOI 10.1097/01.inf.0000199303.43096.3c
   Limwattananon S, 2007, B WORLD HEALTH ORGAN, V85, P600, DOI 10.2471/BLT.06.033720
   Luby SP, 2009, CLIN INFECT DIS, V48, pS97, DOI 10.1086/596487
   MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491
   Martens P, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-21
   McIntosh EDG, 2011, EXPERT REV VACCINES, V10, P109, DOI [10.1586/erv.10.145, 10.1586/ERV.10.145]
   McNeil H C, 2016, Med J Malaysia, V71, P134
   National Economic and Social Development Board of Thailand, POP PROJ CLASS SEX P
   Ndlangisa K, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01149-17
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Phongsamart W, 2007, VACCINE, V25, P1275, DOI 10.1016/j.vaccine.2006.10.001
   Phongsamart W, 2014, HUM VACC IMMUNOTHER, V10, P1866, DOI 10.4161/hv.28675
   Rhodes J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066038
   Romney MG, 2008, CLIN INFECT DIS, V47, P768, DOI 10.1086/591128
   Shainheit MG, 2014, INFECT IMMUN, V82, P694, DOI 10.1128/IAI.01289-13
   Simonsen L, 2011, MBIO, V2, DOI 10.1128/mBio.00309-10
   Song JH, 1999, CLIN INFECT DIS, V28, P1206, DOI 10.1086/514783
   Song JH, 2004, ANTIMICROB AGENTS CH, V48, P2101, DOI 10.1128/AAC.48.6.2101-2107.2004
   Srifeungfung S, 2014, HUM VACC IMMUNOTHER, V10, P40, DOI 10.4161/hv.26418
   Srifeungfung S, 2010, VACCINE, V28, P3440, DOI 10.1016/j.vaccine.2010.02.071
   Srifeungfung Somporn, 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P469
   Tai SS, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4010004
   Towse A, 2004, BRIT MED J, V328, P103, DOI 10.1136/bmj.328.7431.103
   Tricarico S, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0030-5
   Turner P, 2012, CLIN MICROBIOL INFEC, V18, P970, DOI 10.1111/j.1469-0691.2011.03711.x
   Turner P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067933
   Turner P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038271
   Turner P, 2011, J CLIN MICROBIOL, V49, P1784, DOI 10.1128/JCM.00157-11
   Wahl B, 2016, 10 INT S PNEUM PNEUM
   Westerink MAJ, 2012, AGING DIS, V3, P51
   WHO, 2017, GLOB ANT RES SURV SY
   WHO, COUNTR PNEUM CONJ VA
   WHO, 2018 GLOB SUMM WHO U
   Yao KH, 2011, VACCINE, V29, P2296, DOI 10.1016/j.vaccine.2011.01.027
NR 61
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3159
EP 3166
DI 10.1016/j.vaccine.2019.04.085
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700006
PM 31060951
DA 2020-05-12
ER

PT J
AU Shi, ST
   Zhu, HR
   Xia, XY
   Liang, ZH
   Ma, XH
   Sun, BB
AF Shi, Shuting
   Zhu, Haoru
   Xia, Xinyu
   Liang, Zhihui
   Ma, Xuehu
   Sun, Bingbing
TI Vaccine adjuvants: Understanding the structure and mechanism of
   adjuvanticity
SO VACCINE
LA English
DT Review
DE Adjuvant; Aluminum salt; Structure-activity relationship; Immunogenicity
ID ALUMINUM-CONTAINING ADJUVANTS; MONOPHOSPHORYL-LIPID-A; T-CELL RESPONSES;
   IMMUNE-RESPONSES; CALCIUM-PHOSPHATE; DENDRITIC CELLS; ANTIGEN UPTAKE;
   CPG-DNA; GLA-SE; IMMUNOGENICITY
AB In conjugate, inactivated, recombinant, and toxoid vaccines, adjuvants are extensively and essentially used for enhanced and long-lasting protective immune responses. Depending on the type of diseases and immune responses required, adjuvants with different design strategies are developed. With aluminum salt-based adjuvants as the most used ones in commercial vaccines, other limited adjuvants, e.g., AS01, AS03, AS04, CpG ODN, and MF59, are used in FDA-approved vaccines for human use. In this paper, we review the uses of different adjuvants in vaccines including the ones used in FDA-approved vaccines and vaccines under clinical investigations. We discuss how adjuvants with different formulations could affect the magnitude and quality of adaptive immune response for optimized protection against specific pathogens. We emphasize the molecular mechanisms of various adjuvants, with the aim to establish structure-activity relationships (SARs) for designing more effective and safer adjuvants for both preventative and therapeutic vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shi, Shuting; Zhu, Haoru; Xia, Xinyu; Liang, Zhihui; Ma, Xuehu; Sun, Bingbing] Dalian Univ Technol, State Key Lab Fine Chem, 2 Linggong Rd, Dalian 116024, Peoples R China.
   [Shi, Shuting; Zhu, Haoru; Xia, Xinyu; Liang, Zhihui; Ma, Xuehu; Sun, Bingbing] Dalian Univ Technol, Sch Chem Engn, 2 Linggong Rd, Dalian 116024, Peoples R China.
RP Sun, BB (reprint author), Dalian Univ Technol, 2 Linggong Rd, Dalian 116024, Liaoning, Peoples R China.
EM bingbingsun@dlut.edu.cn
RI Sun, Bingbing/I-8197-2012
OI Sun, Bingbing/0000-0002-5444-5078
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31870919]; Natural Science Foundation of Liaoning
   ProvinceNatural Science Foundation of Liaoning Province [20180550597];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [DUT17RC(3)021]; Recruitment
   Program of Global Youth Experts
FX This work was supported by the National Natural Science Foundation of
   China (No. 31870919), Natural Science Foundation of Liaoning Province
   (No. 20180550597), and Fundamental Research Funds for the Central
   Universities (No. DUT17RC(3)021). Bingbing Sun also thank the
   Recruitment Program of Global Youth Experts for supports.
CR Aimanianda V, 2009, TRENDS PHARMACOL SCI, V30, P287, DOI 10.1016/j.tips.2009.03.005
   Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005
   ALLISON AC, 1974, NATURE, V252, P252, DOI 10.1038/252252a0
   ALSHAKHSHIR R, 1994, VACCINE, V12, P472, DOI 10.1016/0264-410X(94)90127-9
   Aravantinou M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161730
   Ascarateil S, 2015, J IMMUNOTHER CANC S2, V3, P428
   Aucouturier Jerome, 2002, Expert Rev Vaccines, V1, P111, DOI 10.1586/14760584.1.1.111
   Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114
   Baca-Estrada ME, 1999, J INTERF CYTOK RES, V19, P455, DOI 10.1089/107999099313893
   Baden LR, 2011, J INFECT DIS, V204, P1541, DOI 10.1093/infdis/jir615
   BANGHAM AD, 1965, NATURE, V208, P1295, DOI 10.1038/2081295a0
   Bennett JW, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004423
   Berger Anderson R., 2018, INCORPORATION CPG OL
   Billiau A, 2001, J LEUKOCYTE BIOL, V70, P849
   Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]
   Burrell LS, 2000, VACCINE, V18, P2188, DOI 10.1016/S0264-410X(00)00031-1
   Campbell JD, 2017, METHODS MOL BIOL, V1494, P15, DOI 10.1007/978-1-4939-6445-1_2
   Caulfield MJ, 2014, HUMAN VACC, V3, P139
   Cech PG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022273
   Cioncada R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185843
   Clegg CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088979
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Cooper CL, 2005, CPG 7909 ADJUVANT IM
   Di Sabatino A, 2011, CYTOKINE GROWTH F R, V22, P19, DOI 10.1016/j.cytogfr.2010.09.003
   Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   Disis ML, 1996, BLOOD, V88, P202
   Doring G, 2007, P NATL ACAD SCI USA, V104, P11020, DOI 10.1073/pnas.0702403104
   EGWANG TG, 1984, IMMUNOLOGY, V51, P207
   Eisenbarth S, 2008, CRUCIAL ROLE NALP3 I
   el Kassas H, ADJUVANT APPL INTERF
   Ellis RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046094
   Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306
   Franchi L, 2008, NIRP3 INFLAMMASOME I
   Francica JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7565
   Frosner G, 2009, J TRAVEL MED, V16, P413, DOI 10.1111/j.1708-8305.2009.00351.x
   Galli G, 2009, P NATL ACAD SCI USA, V106, P3877, DOI 10.1073/pnas.0813390106
   Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6.5.723
   Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/ERV.11.192, 10.1586/erv.11.192]
   Ghimire TR, 2012, IMMUNOL LETT, V147, P55, DOI 10.1016/j.imlet.2012.06.002
   Giannini SL, 2006, VACCINE, V24, P5937, DOI 10.1016/j.vaccine.2006.06.005
   GlaxoSmithKline, 2018, CERVARIX HUM PAP BIV
   GlaxoSmithKline, 2018, INFL H5N1 VIR MON VA
   Glenny AT, 1930, BMJ-BRIT MED J, V1930, P244, DOI 10.1136/bmj.2.3632.244
   Gordon DL, 2016, VACCINE, V34, P3780, DOI 10.1016/j.vaccine.2016.05.071
   GUPTA RK, 1995, VACCINE, V13, P1263, DOI 10.1016/0264-410X(95)00011-O
   Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8
   Gupta RK, 1996, VACCINE, V14, P1412, DOI 10.1016/S0264-410X(96)00073-4
   He Q, 2000, CLIN DIAGN LAB IMMUN, V7, P899, DOI 10.1128/CDLI.7.6.899-903.2000
   Hem SL, 2007, EXPERT REV VACCINES, V6, P685, DOI 10.1586/14760584.6.5.685
   HERBERT WJ, 1966, NATURE, V210, P747, DOI 10.1038/210747a0
   Vo HTM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00641
   Hogenesch H., 2002, MECH STIMULATION IMM
   HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x
   HogenEsch H, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00406
   Huleatt JW, 2007, VACCINE, V25, P763, DOI 10.1016/j.vaccine.2006.08.013
   Hutchison S, 2012, FASEB J, V26, P1272, DOI 10.1096/fj.11-184556
   Jacobson JM, 1999, J ACQ IMMUN DEF SYND, V2016, P163
   Jalah R, 2012, HUM VACC IMMUNOTHER, V8, P1620, DOI 10.4161/hv.21407
   Jin B, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/690438
   Johnson DA, 1999, J MED CHEM, V42, P4640, DOI 10.1021/jm990222b
   Joseph A, 2006, VACCINE, V24, P3990, DOI 10.1016/j.vaccine.2005.12.017
   Joseph S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00149
   Kalams SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029231
   Kalimuddin S, 2017, VACCINE, V35, P7127, DOI 10.1016/j.vaccine.2017.10.097
   Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9
   Kammer AR, 2007, VACCINE, V25, P7065, DOI 10.1016/j.vaccine.2007.07.052
   Kester KE, 2014, VACCINE, V32, P6683, DOI 10.1016/j.vaccine.2014.06.033
   Klinman DM, 2007, MICROBES INFECT, V9, P1478, DOI 10.1016/j.micinf.2007.08.002
   Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329
   Kommareddy S, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P249, DOI 10.1016/B978-0-12-804019-5.00013-X
   Krieg A, 1995, CPG MOTIFS BACTERIAL
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Kumar H, 2009, BIOCHEM J, V420, P1, DOI 10.1042/BJ20090272
   Lee P, 2001, J CLIN ONCOL, V19, P3836, DOI 10.1200/JCO.2001.19.18.3836
   Li P, 2015, POLYSACCHARIDES CAND
   Li X, 2018, CHEM SOC REV, V47, P4954, DOI 10.1039/c8cs00028j
   Liang F, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2094
   Liebowitz D, 2015, LANCET INFECT DIS, V15, P1041, DOI 10.1016/S1473-3099(15)00266-2
   Lipford GB, 2000, J IMMUNOL, V165, P1228, DOI 10.4049/jimmunol.165.3.1228
   MANNHALTER JW, 1985, CLIN EXP IMMUNOL, V61, P143
   MASIHI KN, 1986, INT J IMMUNOPHARMACO, V8, P339
   Masson J-D, 2016, CALCIUM PHOSPHATE SU
   Masson JD, 2017, EXPERT REV VACCINES, V16, P289, DOI 10.1080/14760584.2017.1244484
   Mayer KH, 2001, CLIN INFECT DIS, V32, P476, DOI 10.1086/318496
   Medicine USNLo, STUD ASS SAF IMM MAL
   Medicine USNLo, TREATM HBIG GM CSF H
   Morel S, 2011, VACCINE, V29, P2461, DOI 10.1016/j.vaccine.2011.01.011
   Moris P, 2011, J CLIN IMMUNOL, V31, P443, DOI 10.1007/s10875-010-9490-6
   Moser Christian, 2003, Expert Rev Vaccines, V2, P189, DOI 10.1586/14760584.2.2.189
   Moser C, 2011, EXPERT REV VACCINES, V10, P437, DOI [10.1586/ERV.11.15, 10.1586/erv.11.15]
   O'Hagan D, 2013, HIST MF59 R ADJUVANT
   O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061
   OTT G, METH MOLEC MED, V42, P211
   Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830
   Persing DH, 2002, TRENDS MICROBIOL, V10, pS32, DOI 10.1016/S0966-842X(02)02426-5
   Pichyangkul S, 2008, INFECT IMMUN, V76, P229, DOI 10.1128/IAI.00977-07
   Pillet S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0043-3
   Podolak I, 2010, PHYTOCHEM REV, V9, P425, DOI 10.1007/s11101-010-9183-z
   Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414
   Ramanathan V, 1979, COMPLEMENT ACTIVATIO
   Rappuoli R, 2018, SEMIN IMMUNOL
   Reimer JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041451
   Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065
   Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402
   Seya T, 2009, IMMUNOL REV, V227, P44, DOI 10.1111/j.1600-065X.2008.00723.x
   Sirima SB, 2017, VACCINE, V35, P6218, DOI 10.1016/j.vaccine.2017.09.027
   Sokolovska A, 2007, VACCINE, V25, P4575, DOI 10.1016/j.vaccine.2007.03.045
   Sparwasser T, 2000, BACTERIAL CPG DNA AC
   Sun BN, 2018, VACCINE, V36, P5226, DOI 10.1016/j.vaccine.2018.07.040
   Sun BB, 2017, ACS APPL MATER INTER, V9, P21697, DOI 10.1021/acsami.7b05817
   Sun BB, 2016, J MATER CHEM B, V4, P5496, DOI [10.1039/C6TB01131D, 10.1039/c6tb01131d]
   Sun BB, 2013, ACS NANO, V7, P10834, DOI 10.1021/nn404211j
   Sun BB, 2013, SMALL, V9, P1595, DOI 10.1002/smll.201201962
   Sun HX, 2009, VACCINE, V27, P1787, DOI 10.1016/j.vaccine.2009.01.091
   Technology DD, 2017, PAND ADJ H1N1 INFL V
   Terhune TD, 2014, VACCINE, V32, P5149, DOI 10.1016/j.vaccine.2014.07.052
   van Doorn E, 2016, HUM VACC IMMUNOTHER, V12, P159, DOI 10.1080/21645515.2015.1071455
   Vandepapeliere P, 2008, VACCINE, V26, P1375, DOI 10.1016/j.vaccine.2007.12.038
   Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008
   WALLS RS, 1977, P SOC EXP BIOL MED, V156, P431
   Wu YM, 2015, VACCINE, V33, P7518, DOI 10.1016/j.vaccine.2015.09.097
   Wu YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002636
   Yam KK, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00207
   Yamshchikov GV, 2001, INT J CANCER, V92, P703, DOI 10.1002/1097-0215(20010601)92:5<703::AID-IJC1250>3.0.CO;2-5
   Zhang C.J., 2011, DYE FINISH, V8, P1, DOI DOI 10.1371/J0URNAL.P0NE.0023849
   Zhu D, 2016, NAT PROD CHEM RES, V3, pe113, DOI DOI 10.4172/2329-6836.1000E113
NR 127
TC 9
Z9 9
U1 26
U2 43
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3167
EP 3178
DI 10.1016/j.vaccine.2019.04.055
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700007
PM 31047671
DA 2020-05-12
ER

PT J
AU Doyon-Plourde, P
   Fakih, I
   Tadount, F
   Fortin, E
   Quach, C
AF Doyon-Plourde, Pamela
   Fakih, Iman
   Tadount, Fazia
   Fortin, Elise
   Quach, Caroline
TI Impact of influenza vaccination on healthcare utilization - A systematic
   review
SO VACCINE
LA English
DT Review
DE Influenza; Vaccines; Vaccine effectiveness; Healthcare; Aged
ID AGED 65 YEARS; PREVENTING HOSPITALIZATION; CARDIOPULMONARY DISEASE;
   REDUCES HOSPITALIZATION; PNEUMOCOCCAL VACCINES; ELDERLY-PATIENTS; OLDER;
   POPULATION; ASSOCIATION; INFECTION
AB Introduction: Although a vaccine-preventable disease, influenza causes approximately 3-5 million cases of severe illness and about 290,000-650,000 deaths worldwide, which occur primarily among people 65 years and older. Nonetheless, prevention of influenza and its complications rely mainly on vaccination. We aimed to systematically evaluate influenza vaccine effectiveness at reducing healthcare utilization in older adults, defined as the reduction of outpatient visits, ILI and influenza hospitalizations, utilization of antibiotics and cardiovascular events by vaccination status during the influenza season.
   Methods: We searched MEDLINE, EMBASE, CINAHL, Cochrane Library and considered any seasonal influenza vaccine, excluding the pandemic (2009-10 season) vaccine. Reviewers independently assessed data extraction and quality assessment.
   Results: Of the 8308 citations retrieved, 22 studies were included in the systematic review. Overall, two studies (9%) were deemed at moderate risk of bias, thirteen (59%) at serious risk of bias and seven (32%) at critical risk of bias. For outpatient visits, we found modest evidence of protection by the influenza vaccine. For all-cause hospitalization outcomes, we found a wide range of results, mostly deemed at serious risk of bias. The included studies suggested that the vaccine may protect older adults against influenza hospitalizations and cardiovascular events. No article meeting our inclusion criteria explored the use of antibiotics and ILI hospitalizations. The high heterogeneity between studies hindered the aggregation of data into a meta-analysis.
   Conclusion: The variability between studies prevented us from drawing a clear conclusion on the effectiveness of the influenza vaccine on healthcare utilization in older adults. Overall, the data suggests that the vaccine may result in a reduction of healthcare utilization in the older population. Further studies of higher quality are necessary. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Doyon-Plourde, Pamela; Tadount, Fazia; Fortin, Elise; Quach, Caroline] Univ Montreal, Fac Med, Dept Microbiol Infect Dis & Immunol, Montreal, PQ, Canada.
   [Doyon-Plourde, Pamela; Fakih, Iman; Tadount, Fazia; Quach, Caroline] CHU St Justine, Res Inst, Montreal, PQ, Canada.
   [Fakih, Iman] McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
   [Fortin, Elise] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada.
   [Quach, Caroline] CHU St Justine, Dept Pediat Lab Med, Montreal, PQ, Canada.
   [Quach, Caroline] CHU St Justine, Infect Prevent & Control, Montreal, PQ, Canada.
RP Quach, C (reprint author), Ctr Hosp Univ St Justine, 3175 Ch Cote St Catherine,B17-102, Montreal, PQ H3T 1C5, Canada.
EM c.quach@umontreal.ca
OI Quach, Caroline/0000-0002-1170-9475
FU Chercheur boursier de merite career award from the Fonds de recherche du
   Quebec - Sante
FX This research did not receive any specific grant from funding agencies
   in the public, commercial, or not-for-profit sectors. CQ is supported by
   a Chercheur boursier de merite career award from the Fonds de recherche
   du Quebec - Sante.
CR Barnes M, 2015, HEART, V101, P1738, DOI 10.1136/heartjnl-2015-307691
   Chan TC, 2014, J AM MED DIR ASSOC, V15, DOI 10.1016/j.jamda.2013.10.008
   Christenson B, 2001, LANCET, V357, P1008, DOI 10.1016/S0140-6736(00)04237-9
   Christenson B, 2004, EUR RESPIR J, V23, P363, DOI 10.1183/09031936.04.00063504
   Crocetti E, 2001, EUR J EPIDEMIOL, V17, P163, DOI 10.1023/A:1017978420601
   Deguchi Y, 2001, J GERONTOL A-BIOL, V56, pM391, DOI 10.1093/gerona/56.6.M391
   Eick-Cost Angelia A, 2015, MSMR, V22, P2
   Falchi A, 2013, HUM VACC IMMUNOTHER, V9, P2453, DOI 10.4161/hv.25513
   Fang YA, 2016, ACTA CARDIOL SIN, V32, P290, DOI 10.6515/ACS20150424L
   Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003
   Gasparini R, 2013, HUM VACC IMMUNOTHER, V9, P144, DOI 10.4161/hv.22231
   GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661
   Government of Canada PHAoC, 2016, CAN IMM GUID CHAPT I
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Hak E, 2002, J EPIDEMIOL COMMUN H, V56, P951, DOI 10.1136/jech.56.12.951
   Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008
   Havers F, 2016, CLIN INFECT DIS, V63, P1304, DOI 10.1093/cid/ciw512
   Hergens M, 2017, EUROSURVEILLANCE, V22, P32, DOI 10.2807/1560-7917.ES.2017.22.8.30469
   Hottes TS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022618
   Jackson LA, 2006, INT J EPIDEMIOL, V35, P345, DOI 10.1093/ije/dyi275
   Jefferson T, 2005, LANCET, V366, P1165, DOI 10.1016/S0140-6736(05)67339-4
   Jefferson T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004876.pub3
   Kafatos G, 2013, INFLUENZA OTHER RESP, V7, P1175, DOI 10.1111/irv.12163
   Kissling E, 2009, EURO SURVEILL, V14
   Lavallee P, 2002, STROKE, V33, P513, DOI 10.1161/hs0202.102328
   Leval A, 2016, EUROSURVEILLANCE, V21, DOI [10.2807/1560-7917ES.2016.21.43.30381, DOI 10.2807/1560-7917ES.2016.21.43.30381]
   Lin HC, 2014, INT J ENV RES PUB HE, V11, P3639, DOI 10.3390/ijerph110403639
   McElhaney JE, 2017, VACCINE, V35, P6269, DOI 10.1016/j.vaccine.2017.09.084
   Ozasa K, 2006, VACCINE, V24, P2537, DOI 10.1016/j.vaccine.2005.12.022
   Pera A, 2015, MATURITAS, V82, P50, DOI 10.1016/j.maturitas.2015.05.004
   Seo YB, 2014, HUM VACC IMMUNOTHER, V10, P423, DOI 10.4161/hv.26858
   Seo YB, 2013, VACCINE, V31, P1426, DOI 10.1016/j.vaccine.2012.10.024
   Simonsen L, 2007, INT J EPIDEMIOL, V36, P631, DOI 10.1093/ije/dym084
   Simpson CR, 2013, NIHR J LIB SOUTHAMPT
   Souty C, 2015, HUM VACC IMMUNOTHER, V11, P1621, DOI 10.1080/21645515.2015.1046661
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Sung LC, 2014, VACCINE, V32, P3843, DOI 10.1016/j.vaccine.2014.04.064
   Takahashi H, 2001, JPN J INFECT DIS, V54, P184
   Vu T, 2002, VACCINE, V20, P1831, DOI 10.1016/S0264-410X(02)00041-5
   World Health Organization, 2013, GLOB EP SURV STAND I
NR 40
TC 3
Z9 3
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3179
EP 3189
DI 10.1016/j.vaccine.2019.04.051
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700008
PM 31047677
OA Other Gold
DA 2020-05-12
ER

PT J
AU Vekemans, J
   Crofts, J
   Baker, CJ
   Goldblatt, D
   Heath, PT
   Madhi, SA
   Le Doare, K
   Andrews, N
   Pollard, AJ
   Saha, SK
   Schrag, SJ
   Smith, PG
   Kaslow, DC
AF Vekemans, Johan
   Crofts, Jonathan
   Baker, Carol J.
   Goldblatt, David
   Heath, Paul T.
   Madhi, Shabir A.
   Le Doare, Kirsty
   Andrews, Nick
   Pollard, Andrew J.
   Saha, Samir K.
   Schrag, Stephanie J.
   Smith, Peter G.
   Kaslow, David C.
TI The role of immune correlates of protection on the pathway to licensure,
   policy decision and use of group B Streptococcus vaccines for maternal
   immunization: considerations from World Health Organization
   consultations
SO VACCINE
LA English
DT Review
DE Group B Streptococcus; Vaccines; Correlates of protection; Maternal
   immunization; Neonatal sepsis
ID CAPSULAR POLYSACCHARIDE; MENINGOCOCCAL VACCINES; III POLYSACCHARIDE;
   CONJUGATE VACCINE; PREGNANT-WOMEN; ANTIBODY; DISEASE; PROTEIN;
   SEROGROUP; LEVEL
AB The development of a group B Streptococcus (GBS) vaccine for maternal immunization constitutes a global public health priority, to prevent GBS-associated early life invasive disease, stillbirth, premature birth, maternal sepsis, adverse neurodevelopmental consequences, and to reduce perinatal antibiotic use. Sample size requirements for the conduct of a randomized placebo-controlled trial to assess vaccine efficacy against the most relevant clinical endpoints, under conditions of appropriate ethical standards of care, constitute a significant obstacle on the pathway to vaccine availability. Alternatively, indirect evidence of protection based on immunologic data from vaccine and sero-epidemiological studies, complemented by data from opsonophagocytic in vitro assays and animal models, could be considered as pivotal data for licensure, with subsequent confirmation of effectiveness against disease outcomes in post-licensure evaluations. Based on discussions initiated by the World Health Organization we present key considerations about the potential role of correlates of protection towards an accelerated pathway for GBS vaccine licensure and wide scale use. Priority activities to support progress to regulatory and policy decision are outlined. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Vekemans, Johan] WHO, Initiat Vaccine Res, 20 Av Appia, CH-1202 Geneva, Switzerland.
   [Crofts, Jonathan] Publ Hlth England, B Joint Comm Vaccinat & Immunisat, Wellington House,133-155 Waterloo Rd, London SE1 8UG, England.
   [Baker, Carol J.] Univ Texas McGovern Med Sch, Div Pediat Infect Dis, 6431 Fannin St,MSB 3-126, Houston, TX 77030 USA.
   [Goldblatt, David] UCL, Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.
   [Heath, Paul T.; Le Doare, Kirsty] St Georges Univ London, Inst Infect & Immun, Cranmer Terrace, London SW17 0RE, England.
   [Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, MRC, Resp & Meningeal Pathogens Res Unit, York Rd, ZA-2193 Johannesburg, South Africa.
   [Andrews, Nick] Publ Hlth England, Stat Unit, 61 Colindale Av, London NW9 5EQ, England.
   [Pollard, Andrew J.] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford OX3 9DU, England.
   [Pollard, Andrew J.] NIHR Oxford Biomed Res Ctr, Oxford OX3 9DU, England.
   [Saha, Samir K.] Dhaka Shishu Hosp, Child Hlth Res Fdn, Bangladesh Inst Child Hlth, Dhaka 1207, Bangladesh.
   [Schrag, Stephanie J.] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [Smith, Peter G.] London Sch Hyg & Trop Med, Trop Epidemiol Grp, London WC1E 7HT, England.
   [Kaslow, David C.] PATH, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA.
RP Vekemans, J (reprint author), WHO, Initiat Vaccine Res, 20 Av Appia, CH-1202 Geneva, Switzerland.
EM vekemansj@who.int; jonathan.crofts@phe.gov.uk; d.goldblatt@ucl.ac.uk;
   pheath@sgul.ac.uk; madhis@rmpru.co.za; kiledoar@sgul.ac.uk;
   andrews@phe.gov.uk; andrew.pollard@paediatrics.ox.ac.uk; zha6@cdc.gov;
   p.smith@lshtm.ac.uk; dkaslow@path.org
RI Goldblatt, David/C-5972-2008
OI Goldblatt, David/0000-0002-0769-5242
FU Bill & Melinda Gates Foundation, Seattle, WAGates Foundation
   [OPP1134011]
FX This work was supported by the Bill & Melinda Gates Foundation, Seattle,
   WA [OPP1134011]. The funder had no role in preparation of the manuscript
   or decision to publish.
CR Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9
   Baker CJ, 2014, J INFECT DIS, V209, P781, DOI 10.1093/infdis/jit549
   BAKER CJ, 1981, PEDIATRICS, V68, P544
   BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404
   BALTIMORE RS, 1981, INFECT IMMUN, V32, P56, DOI 10.1128/IAI.32.1.56-61.1981
   Chen X, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-29
   Dangor Z, 2016, CURR OPIN INFECT DIS, V29, P262, DOI 10.1097/QCO.0000000000000266
   Dangor Z, 2015, VACCINE, V33, P6793, DOI 10.1016/j.vaccine.2015.10.019
   Dangor Z, 2015, EXPERT REV VACCINES, V14, P1651, DOI 10.1586/14760584.2015.1085307
   Daugla DM, 2014, LANCET, V383, P40, DOI 10.1016/S0140-6736(13)61612-8
   Davies JK, 1999, AM J OBSTET GYNECOL, V181, P803, DOI 10.1016/S0002-9378(99)70305-4
   Fabbrini M, 2018, J INFECTION, V76, P449, DOI 10.1016/j.jinf.2018.01.006
   Fabbrini M, 2016, CLIN INFECT DIS, V63, P746, DOI 10.1093/cid/ciw377
   FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208
   Feikin DR, 2014, LANCET, V383, P1762, DOI 10.1016/S0140-6736(13)61682-7
   Fernandez J, 2000, J INFECT DIS, V182, P1553, DOI 10.1086/315870
   Fothergill LD, 1933, J IMMUNOL, V24, P273
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307
   HEMMING VG, 1987, J INFECT DIS, V156, P655, DOI 10.1093/infdis/156.4.655
   Heyderman RS, 2016, LANCET INFECT DIS, V16, P546, DOI 10.1016/S1473-3099(15)00484-3
   Jokinen JT, 2004, J INFECT DIS, V190, P545, DOI 10.1086/422531
   KAYHTY H, 1983, J INFECT DIS, V147, P1100
   KAYHTY H, 1994, BIOLOGICALS, V22, P397, DOI 10.1006/biol.1994.1062
   Kobayashi Miwako, 2016, F1000Res, V5, P2355
   Larsson C, 2006, ARCH DIS CHILD-FETAL, V91, pF403, DOI 10.1136/adc.2005.090472
   Le Doare K, 2019, LANCET INFECT DIS, V19, pE162, DOI 10.1016/S1473-3099(18)30659-5
   Lin FYC, 2004, J INFECT DIS, V190, P928, DOI 10.1086/422756
   Lin FYC, 2001, J INFECT DIS, V184, P1022, DOI 10.1086/323350
   MacNeil JR, 2015, MMWR-MORBID MORTAL W, V64, P1171, DOI 10.15585/mmwr.mm6441a3
   Madhi SA, 2017, CLIN INFECT DIS, V65, P1897, DOI 10.1093/cid/cix666
   Madhi SA, 2016, LANCET INFECT DIS, V16, P923, DOI 10.1016/S1473-3099(16)00152-3
   MADOFF LC, 1994, J CLIN INVEST, V94, P286, DOI 10.1172/JCI117319
   Madrid L, 2017, CLIN INFECT DIS, V65, pS160, DOI 10.1093/cid/cix656
   Miller E, 2001, VACCINE, V20, pS58, DOI 10.1016/S0264-410X(01)00299-7
   O'Brien KL, 2016, LANCET, V387, P1887, DOI 10.1016/S0140-6736(16)30394-4
   Ojal J, 2018, CLIN INFECT DIS, V66, P121, DOI 10.1093/cid/cix742
   Paoletti LC, 2000, J INFECT DIS, V181, P653, DOI 10.1086/315285
   Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3
   Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407
   Russell NJ, 2017, CLIN INFECT DIS, V65, pS100, DOI 10.1093/cid/cix658
   Seale AC, 2017, CLIN INFECT DIS, V65, pS200, DOI 10.1093/cid/cix664
   Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119
   Tappero JW, 1999, JAMA-J AM MED ASSOC, V281, P1520, DOI 10.1001/jama.281.16.1520
   Vekemans J, 2019, VACCINE, V37, P7391, DOI 10.1016/j.vaccine.2017.09.087
   World Health Organization, 2013, WHOIVB1301
NR 47
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3190
EP 3198
DI 10.1016/j.vaccine.2019.04.039
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700009
PM 31031031
OA Green Published, Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Tung, WC
   Lu, MG
   Qiu, XW
   Ervin, S
AF Tung, Wei-Chen
   Lu, Minggen
   Qiu, Xiangwen
   Ervin, Susan
TI Human papillomavirus knowledge, attitudes, and vaccination among Chinese
   college students in the United States
SO VACCINE
LA English
DT Article
DE Chinese college students; HPV attitudes; HPV knowledge; HPV vaccination
ID HPV VACCINATION; PREDICTORS; COVERAGE; BELIEFS; WOMEN
AB Human papilloma virus (HPV) is the most common sexually transmitted infection in the USA with some strains increasing the risk of certain cancers. The HPV vaccine, introduced in 2006, has reduced the infection rate, although racial/ethnic disparities in vaccination exist. Asian college students are among those with the lowest vaccination rates, however there has been little exploration as to why. The purposes of this study were to assess (a) knowledge and attitudes regarding HPV and its vaccine, (b) HPV vaccination practices, and (c) factors associated with HPV-related knowledge and attitudes, and vaccination among Chinese college students in the USA. This cross-sectional quantitative survey collected data face-to-face and online from 449 participants. The mean scores for HPV knowledge and attitudes were 40.87 and 2.36 indicating a low-to-moderate level of knowledge but a moderately positive attitude regrading HPV transmission and vaccination. Only half (50.8%) knew that the vaccination could be received after the age of 18 years. Only 38.3% reported having receiving at least one dose of the vaccine, with 92.4% receiving their first HPV vaccines in the USA. Multiple logistic regression showed that men and non-health sciences majors had lower knowledge about HPV. Older students, those without a primary care provider, and those who completed the survey in English had more negative attitudes about the HPV and vaccine. Participants who were younger, female, had a higher level of knowledge, had more positive attitudes, and completed the survey online were associated with better vaccination status. Findings from this study provide insight into Chinese college students' knowledge and attitudes about HPV and HPV vaccination and may be used to develop culturally sensitive programs that address the risk of HPV and the benefits of HPV vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tung, Wei-Chen; Ervin, Susan] Univ Nevada, Orvis Sch Nursing, Reno, NV 89557 USA.
   [Lu, Minggen] Univ Nevada, Sch Community Hlth Sci, Reno, NV 89557 USA.
   [Qiu, Xiangwen] Univ Calif Davis, Davis, CA 95616 USA.
RP Tung, WC (reprint author), Univ Nevada, Orvis Sch Nursing, Reno, NV 89557 USA.
EM wctung@unr.edu
FU Smernoff Research Award
FX This study was funded by the Smernoff Research Award.
CR Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3
   Barnard M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182266
   Centers for Disease Control and Prevention, GEN HPV INF FACT SHE
   Cheung T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198615
   Choi EPH, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061099
   Dany M, 2015, VACCINE, V33, P1001, DOI 10.1016/j.vaccine.2015.01.009
   Gao HJ, 2016, J IMMIGR MINOR HEALT, V18, P1085, DOI 10.1007/s10903-016-0349-7
   Huang LY, 2017, TAIWAN J PUBLIC HLTH, V36, P77
   Institute of International Education, LEAD PLAC OR FACT SH
   Kamimura A, 2018, J INFECT PUBLIC HEAL, V11, P120, DOI 10.1016/j.jiph.2017.06.006
   Lee HY, 2015, J AM COLL HEALTH, V63, P316, DOI 10.1080/07448481.2015.1031237
   Li WB, 2018, J HEALTH COMMUN, V23, P581, DOI 10.1080/10810730.2018.1493060
   Liu A, 2018, J PAEDIATR CHILD H, V54, P302, DOI 10.1111/jpc.13693
   Marchand E, 2012, J COMMUN HEALTH, V37, P1136, DOI 10.1007/s10900-012-9572-x
   McQuillan G., 2017, PREVALENCE HPV ADULT
   Pan XF, 2016, LANCET INFECT DIS, V16, P1322, DOI 10.1016/S1473-3099(16)30450-9
   Rosenthal SL, 2011, VACCINE, V29, P890, DOI 10.1016/j.vaccine.2009.12.063
   Simon S., 2016, HPV TEEN GIRLS 64 VA
   Thompson EL, 2016, PREV MED, V86, P92, DOI 10.1016/j.ypmed.2016.02.003
   Thompson VLS, 2017, HEALTH SOC WORK, V42, pE1, DOI 10.1093/hsw/hlw050
   U. S. Department of Health and Human Services, 2008, HPV VACC AD
   Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P874, DOI 10.15585/mmwr.mm6633a2
   World Health Organization, HUM PAP HPV CERV CAN
   World Health Organization, GUID INTR HPV VACC N
NR 24
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3199
EP 3204
DI 10.1016/j.vaccine.2019.04.084
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700010
PM 31047678
DA 2020-05-12
ER

PT J
AU Cheng, HW
   Chen, J
   Cai, ZZ
   Du, LP
   Hou, JB
   Qiao, XW
   Zheng, QS
AF Cheng, Haiwei
   Chen, Jin
   Cai, Zizheng
   Du, Luping
   Hou, Jibo
   Qiao, Xuwen
   Zheng, Qisheng
TI Development of GEM-PA-nanotrap for purification of foot-and-mouth
   disease virus
SO VACCINE
LA English
DT Article
DE FMDV; Affinity purification; Gram-positive enhancer matrix particles;
   Nanobody; Nanotrap
ID DOMAIN ANTIBODY FRAGMENTS; SEROTYPE-O; PARTICLES; ANTIGENS; 146S;
   QUANTIFICATION; CELLS; IMMUNOGENICITY; RECOGNITION; DISPLAY
AB Vaccination is the primary preventative measure against outbreaks of foot-and-mouth disease (FMD). The efficacy of inactivated FMD vaccines is mainly determined by the integrity of foot-and-mouth disease virus (FMDV) particles (referred to as 146S particles), and impurities in the inactivated vaccines could result in side effects. In this study, we developed an effective affinity purification method for the purification of FMDV from cellular lysates, referred to as GEM-PA-nanotrap. To develop the GEM-PA-nanotrap, a nanobody (Nb205) against FMDV vaccine strain O/MYA98/BY/2010 146S particles was selected from a non-immunized library and fused to a peptidoglycan-binding protein anchor (PA). The PA-Nb205 fusion protein was non-covalently coupled to the surface of Gram-positive enhancer matrix (GEM) particles, which were prepared from the non-living, non-genetically modified, Gram-positive, food-grade Lactococcus lactis bacteria. The GEM-PA-nanotrap was used to purify FMDV from cellular lysates through a simple incubation and centrifugation step. The FMDV recovery rate was more than 99%, the efficiency of nonviral protein removal was about 98.3%, and the purification process had almost no effect on the integrity and immunogenicity of 146S particles. Therefore, the GEM-PA-nanotrap has potential as an effective method for the recovery and purification of FMDV during the vaccine manufacturing process. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cheng, Haiwei; Chen, Jin; Du, Luping; Hou, Jibo; Qiao, Xuwen; Zheng, Qisheng] Jiangsu Acad Agr Sci, Inst Vet Immunol & Engn, Nanjing 210014, Jiangsu, Peoples R China.
   [Cheng, Haiwei; Chen, Jin; Du, Luping; Hou, Jibo; Qiao, Xuwen; Zheng, Qisheng] Jiangsu Acad Agr Sci, Key Lab Vet Biol Engn & Technol, Minist Agr, Natl Res Ctr Engn & Technol Vet Biol, Nanjing 210014, Jiangsu, Peoples R China.
   [Cheng, Haiwei; Chen, Jin; Du, Luping; Hou, Jibo; Qiao, Xuwen; Zheng, Qisheng] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.
   [Cai, Zizheng] Nanjing Agr Univ, Nanjing 210095, Jiangsu, Peoples R China.
RP Qiao, XW; Zheng, QS (reprint author), Jiangsu Acad Agr Sci, Inst Vet Immunol & Engn, Nanjing 210014, Jiangsu, Peoples R China.
EM qxwshyi2011@hotmail.com; immun_tech@163.com
FU National Natural Science FoundationNational Natural Science Foundation
   of China [31802220]
FX This work was supported by the National Natural Science Foundation
   (31802220). We wish to thank Dr. YK Wan (Chinese Academy of Sciences,
   Shanghai) for providing the vector, helper phage and Escherichia coli
   strains. We thank Liwen Bianji, Edanz Editing China
   (www.liwenbianji.cn/ac), for editing the English text of a draft of this
   manuscript.
CR ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0
   Audouy SAL, 2006, VACCINE, V24, P5434, DOI 10.1016/j.vaccine.2006.03.054
   BACHRACH HL, 1964, AM J VET RES, V25, P333
   BARTELING SJ, 1974, ARCH GES VIRUSFORSCH, V45, P362, DOI 10.1007/BF01242879
   Bolden JS, 2016, BIOLOGICALS, V44, P434, DOI 10.1016/j.biologicals.2016.04.009
   Bosma T, 2006, APPL ENVIRON MICROB, V72, P880, DOI 10.1128/AEM.72.1.880-889.2006
   BROWN F, 1961, NATURE, V192, P1163, DOI 10.1038/1921163a0
   CARTWRIGHT B, 1980, J GEN VIROL, V50, P369, DOI 10.1099/0022-1317-50-2-369
   Correa W, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122737
   De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103
   Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803
   DOEL TR, 1982, ARCH VIROL, V73, P185, DOI 10.1007/BF01314726
   Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7
   Du P, 2017, J CHROMATOGR B, V1049, P16, DOI 10.1016/j.jchromb.2016.12.033
   Feng X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149569
   Fridy PC, 2014, NAT METHODS, V11, P1253, DOI [10.1038/NMETH.3170, 10.1038/nmeth.3170]
   Fry EE, 2005, CURR TOP MICROBIOL, V288, P71
   Goldman ER, 2008, ANAL CHEM, V80, P8583, DOI 10.1021/ac8014774
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Harmsen MM, 2007, VET MICROBIOL, V120, P193, DOI 10.1016/j.vetmic.2006.10.029
   Harmsen MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00960
   Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142
   Kabat EA, 1991, NIH PUBLICATION, V91, P324
   Kirchhofer A, 2010, NAT STRUCT MOL BIOL, V17, P133, DOI 10.1038/nsmb.1727
   Li H, 2015, PROTEIN EXPRES PURIF, V113, P23, DOI 10.1016/j.pep.2015.04.011
   Li L, 2018, J IND MICROBIOL BIOT, V45, P889, DOI 10.1007/s10295-018-2061-1
   Li PC, 2016, VACCINE, V34, P696, DOI 10.1016/j.vaccine.2015.09.007
   Liang SQ, 2017, BIOCHEM ENG J, V124, P99, DOI 10.1016/j.bej.2017.05.004
   Liang T, 2014, ARCH VIROL, V159, P657, DOI 10.1007/s00705-013-1872-7
   Monegal A, 2009, PROTEIN ENG DES SEL, V22, P273, DOI 10.1093/protein/gzp002
   Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X
   PAY TWF, 1987, VACCINE, V5, P60, DOI 10.1016/0264-410X(87)90011-9
   RAO MG, 1994, VET MICROBIOL, V39, P135, DOI 10.1016/0378-1135(94)90094-9
   Rasmussen SGF, 2011, NATURE, V469, P175, DOI 10.1038/nature09648
   Rodriguez LL, 2009, VACCINE, V27, pD90, DOI 10.1016/j.vaccine.2009.08.039
   Rothbauer U, 2008, MOL CELL PROTEOMICS, V7, P282, DOI 10.1074/mcp.M700342-MCP200
   Rothbauer U, 2006, NAT METHODS, V3, P887, DOI 10.1038/NMETH953
   SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470
   Thanongsaksrikul J, 2010, J BIOL CHEM, V285, P9657, DOI 10.1074/jbc.M109.073163
   van Roosmalen ML, 2006, METHODS, V38, P144, DOI 10.1016/j.ymeth.2005.09.015
   VANMAANEN C, 1990, BIOLOGICALS, V18, P315, DOI 10.1016/1045-1056(90)90036-Y
   Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6
   Wang D, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0437-2
   Wild T F, 1967, J Gen Virol, V1, P247, DOI 10.1099/0022-1317-1-2-247
   Yang M, 2008, VACCINE, V26, P3377, DOI 10.1016/j.vaccine.2008.04.062
   Yang PC, 1999, VET REC, V145, P731
   Yang YL, 2015, VACCINE, V33, P1143, DOI 10.1016/j.vaccine.2015.01.031
   Yin SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063500
   ZHANG J, 2013, BIOTECHNOLOGY, V12, P135, DOI DOI 10.3923/biotech.2013.135.139
   Zhang YP, 2018, PROTEIN EXPRES PURIF, V141, P19, DOI 10.1016/j.pep.2017.08.010
NR 50
TC 3
Z9 3
U1 3
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3205
EP 3213
DI 10.1016/j.vaccine.2019.04.078
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700011
PM 31036456
DA 2020-05-12
ER

PT J
AU Pato, TP
   Souza, MCO
   Mattos, DA
   Caride, E
   Ferreira, DF
   Gaspar, LP
   Freire, MS
   Castilho, LR
AF Pato, Tania P.
   Souza, Marta C. O.
   Mattos, Diogo A.
   Caride, Elena
   Ferreira, Davis F.
   Gaspar, Luciane P.
   Freire, Marcos S.
   Castilho, Leda R.
TI Purification of yellow fever virus produced in Vero cells for
   inactivated vaccine manufacture
SO VACCINE
LA English
DT Article
DE Yellow fever virus (YFV); Downstream processing; Virus purification;
   Inactivated vaccine; Chromatographic techniques
ID INFLUENZA-A; IMMUNOGENICITY; CHROMATOGRAPHY; PROTEINS; VECTORS; CAPTURE
AB Yellow fever (YF) is a high-lethality viral disease, endemic in tropical regions of South America and Africa, with a population of over 900 million people under risk. A highly effective attenuated vaccine, produced in embryonated eggs, has been used for about 80 years. However, egg-based production limits manufacturing capacity, and vaccine shortage led to the emergency use of a fractional dose (1/5) by the WHO in an outbreak in Africa in 2016 and by Brazilian authorities during an outbreak in 2018. In addition, rare but fatal adverse events of this vaccine have been reported since 2001. These two aspects make clear the need for the development of a new vaccine. In an effort to develop an inactivated YF vaccine, Bio-Manguinhos/FIOCRUZ started developing a new vaccine based on the production of the attenuated 17DD virus in serum-free conditions in Vero cells propagated in bioreactors, followed by chromatography-based purification and beta-propiolactone inactivation.
   Virus purification was studied in this work. Capture was performed using an anion-exchange membrane adsorber (Sartobind (R) Q), resulting in a virus recovery of 80.2 +/- 4.8% and a residual DNA level of 1.3 +/- 1.6 ng/dose, thus in accordance with the recommendations of the WHO (<10 ng/dose). However, the level of host cell proteins (HCP) was still high for a human vaccine, so a second chromatography step was developed based on a multimodal resin (Capto (TM) Core 700). This step resulted in a virus recovery of 65.7 +/- 4.8% and decreased HCP levels to 345 +/- 25 ppm. The overall virus recovery in these chromatography steps was 52.7%. SDS-PAGE of the purified sample showed a band with molecular mass of 56 kDa, thus consistent with the virus envelope protein (E) and corresponding to 96.7% of identified proteins. A Western blot stained with an antibody against the E protein showed a single band, confirming the identity of the sample. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Pato, Tania P.; Souza, Marta C. O.; Mattos, Diogo A.; Caride, Elena; Gaspar, Luciane P.; Freire, Marcos S.] Biomanguinhos, Oswaldo Cruz Fdn FIOCRUZ, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Pato, Tania P.; Castilho, Leda R.] Fed Univ Rio de Janeiro UFRJ, Inst Chem, Biochem Program, Av Athos Silveira Ramos 149,Bl A, BR-21941909 Rio De Janeiro, RJ, Brazil.
   [Ferreira, Davis F.] Fed Univ Rio de Janeiro UFRJ, Inst Microbiol, Virol Dept, Av Carlos Chagas 373,Bl 1, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Castilho, Leda R.] Fed Univ Rio de Janeiro UFRJ, COPPE, Cell Culture Engn Lab, Cx Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
RP Pato, TP (reprint author), Biomanguinhos, Oswaldo Cruz Fdn FIOCRUZ, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM tania@bio.fiocruz.br
FU FaperjCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq); CapesCAPES
FX The authors wish to thank the Brazilian research funding agencies
   Faperj, CNPq and Capes for financial support.
CR Blom H, 2014, VACCINE, V32, P3721, DOI 10.1016/j.vaccine.2014.04.033
   BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203
   Bonaldo MC, 2017, MEM I OSWALDO CRUZ, V112, P447, DOI 10.1590/0074-02760170134
   Caufour PS, 2001, VIRUS RES, V79, P1, DOI 10.1016/S0168-1702(01)00273-8
   CDC, 2018, YELL FEV MAPS
   Chagas MP, 2013, THESIS
   FDA, 2010, CHAR QUAL CELL SUBST
   Garske T, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001638
   GE HEALTHCARE, 2012, 28998307 AA GE HEALT
   Hayes EB, 2010, VACCINE, V28, P8073, DOI 10.1016/j.vaccine.2010.10.015
   Kalbfuss B, 2007, J MEMBRANE SCI, V299, P251, DOI 10.1016/j.memsci.2007.04.048
   Mattos DA, 2015, VACCINE, V33, P4288, DOI 10.1016/j.vaccine.2015.04.050
   Monath TP, 2012, EXPERT REV VACCINES, V11, P427, DOI [10.1586/ERV.12.6, 10.1586/erv.12.6]
   Monath TP, 2010, VACCINE, V28, P3827, DOI 10.1016/j.vaccine.2010.03.023
   Morenweiser R, 2005, GENE THER, V12, pS103, DOI 10.1038/sj.gt.3302624
   Nestola P, 2015, BIOTECHNOL BIOENG, V112, P843, DOI 10.1002/bit.25545
   Ohtake S, 2015, WILEY SER BIOTECHNOL, P287
   PAHO, 2018, BRAZ LAUNCH WORLDS L
   PATH Vaccine and Pharmaceutical Technologies Group, 2012, SUMM STAB DAT INV FO
   Pato TP, 2014, VACCINE, V32, P2789, DOI 10.1016/j.vaccine.2014.02.036
   Pato TP, 2014, THESIS
   Paules CI, 2017, NEW ENGL J MED, V376, P1397, DOI 10.1056/NEJMp1702172
   Peixoto C, 2008, BIOTECHNOL PROGR, V24, P1290, DOI 10.1002/btpr.25
   Pereira RC, 2015, VACCINE, V33, P4261, DOI 10.1016/j.vaccine.2015.03.077
   Souza MCO, 2009, VACCINE, V27, P6420, DOI 10.1016/j.vaccine.2009.06.023
   Vicente T, 2009, GENE THER, V16, P766, DOI 10.1038/gt.2009.33
   Vicente T, 2008, J MEMBRANE SCI, V311, P270, DOI 10.1016/j.memsci.2007.12.021
   Wang X, 2009, BIOTECHNOL BIOENG, V103, P446, DOI 10.1002/bit.22304
   Weigel T, 2014, J VIROL METHODS, V207, P45, DOI 10.1016/j.jviromet.2014.06.019
   WHO, 2019, YELL FEV BRAZ
   WHO, 2007, STUD GROUP CELL SUBS
   WHO, 2013, YELL FEV VACC BOOST
   WHO, 2018, EL YELL FEV EP EYE S
   World Health Organization, 2016, 14 WHO
   World Health Organization, 2017, 32 WHO
NR 35
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3214
EP 3220
DI 10.1016/j.vaccine.2019.04.077
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700012
PM 31047674
DA 2020-05-12
ER

PT J
AU Elikaee, S
   Mohebali, M
   Rezaei, S
   Eslami, H
   Khamesipour, A
   Keshavarz, H
   Eshraghian, MR
AF Elikaee, Samira
   Mohebali, Mehdi
   Rezaei, Sassan
   Eslami, Hamid
   Khamesipour, Ali
   Keshavarz, Hossein
   Eshraghian, Mohammad Reza
TI Leishmania major p27 gene knockout as a novel live attenuated vaccine
   candidate: Protective immunity and efficacy evaluation against cutaneous
   and visceral leishmaniasis in BALB/c mice
SO VACCINE
LA English
DT Article
DE Leishmania; Gene knockout; Vaccine; Immunity; Cross protection; BALB/c
   mice
ID CENTRIN DELETED PARASITES; CROSS-PROTECTION; DONOVANI; IL-4;
   SUSCEPTIBILITY; CHALLENGE; MUTANT; IRAN
AB Leishmaniasis is a growing health problem in many parts of the world and efforts to find vaccine against the disease are a public health priority. Live attenuated vaccines are the gold standard for protection against intracellular pathogens such as Leishmania spp. Defined genetic alteration of the Leishmania genome can be achieved using a gene-targeted disruption strategy that allows for the selection of parasites lacking genes essential for long-term survival and virulence. Previously, we demonstrated that genetically modified live attenuated Leishmania major, lacking the p27gene (Lmp27(-/-)) is safe and induces cellular immunity in BALB/c mice. p27 is a component of the COX complex that is responsible for ATP synthesis. In the current study, the Lmp27(-/-) strain was assessed as a live attenuated vaccine. Overall protective immunity and efficacy were evaluated at various time periods following Leishmania major (L, major) and Leishmania infantum (L infantum) challenges separately in BALB/c mice. Cytokine and anti-Leishmania antibody levels, splenocyte proliferation, delayed type hypersensitivity (DTH), skin lesion development, and parasite burden in the liver and spleen were the measured variables. The results demonstrated that immunized mice had a significant T-helper type 1 (Th1) response, smaller skin lesions and lower parasite burdens in their liver and spleens following a L major challenge. Furthermore, the Lmp27(-/-) mutant also granted cross-protection against L. infantum infection.
   These results suggest that immunization with Lmp27(-/-) parasites provide significant protective immunity and efficacy against infection with homologous as well as heterologous species of Leishmania parasites. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Elikaee, Samira; Mohebali, Mehdi; Rezaei, Sassan; Keshavarz, Hossein] Univ Tehran Med Sci, Sch Publ Hlth, Dept Med Parasitol & Mycol, Tehran, Iran.
   [Mohebali, Mehdi; Keshavarz, Hossein] Univ Tehran Med Sci, Res Ctr Endem Parasites Iran, Tehran, Iran.
   [Eslami, Hamid] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Tehran, Iran.
   [Khamesipour, Ali] Univ Tehran Med Sci, Ctr Res & Training Skin Dis & Leprosy, Tehran, Iran.
   [Eshraghian, Mohammad Reza] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran.
RP Mohebali, M (reprint author), Univ Tehran Med Sci, Sch Publ Hlth, Dept Med Parasitol & Mycol, Tehran, Iran.
EM mehdimohebali.tums@gmail.com
FU Tehran University of Medical SciencesTehran University of Medical
   Sciences [92-01-160-21598, 97-03-160-39686]
FX This study was financially supported by Tehran University of Medical
   Sciences (Projects No 92-01-160-21598 and 97-03-160-39686).
CR Alvar J, 2006, ADV PARASIT, V61, P223, DOI 10.1016/S0065-308X(05)61006-8
   Alves-Silva MV, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00100
   Anand S, 2015, SCI REP-UK, V5, DOI 10.1038/srep10706
   Badiee A, 2007, EXP PARASITOL, V115, P127, DOI 10.1016/j.exppara.2006.07.002
   Bhattacharya P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004963
   Birnbaum R, 2011, DERMATOL CLIN, V29, P89, DOI 10.1016/j.det.2010.08.014
   Carrion J, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-150
   De Luca PM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00151
   Dey R, 2014, J IMMUNOL, V193, P3513, DOI 10.4049/jimmunol.1303145
   Dey R, 2013, J IMMUNOL, V190, P2138, DOI 10.4049/jimmunol.1202801
   Elikaee S, 2018, CELL IMMUNOL, V332, P24, DOI 10.1016/j.cellimm.2018.07.002
   Evans KJ, 2012, J TROP MED, DOI 10.1155/2012/892817
   Fiuza JA, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004322
   Fiuza JA, 2015, VACCINE, V33, P280, DOI 10.1016/j.vaccine.2014.11.039
   Fiuza JA, 2013, VACCINE, V31, P1785, DOI 10.1016/j.vaccine.2013.01.048
   Gicheru MM, 1997, EXP PARASITOL, V85, P109, DOI 10.1006/expr.1996.4117
   Holakouie-Naieni K, 2017, ACTA TROP, V166, P67, DOI 10.1016/j.actatropica.2016.11.004
   Kima PE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00156
   Launois P, 1997, IMMUNITY, V6, P541, DOI 10.1016/S1074-7613(00)80342-8
   McCall LI, 2013, VACCINE, V31, P1420, DOI 10.1016/j.vaccine.2012.11.065
   McMahon-Pratt D, 2004, IMMUNOL REV, V201, P206, DOI 10.1111/j.0105-2896.2004.00190.x
   Mohebali M, 2013, IRAN J PARASITOL, V8, P348
   Santi AMM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30076-7
   Nation CS, 2012, PARASITOL RES, V111, P1407, DOI 10.1007/s00436-012-2899-5
   Noben-Trauth N, 1999, J IMMUNOL, V162, P6132
   Okwor I, 2009, P NATL ACAD SCI USA, V106, P13951, DOI 10.1073/pnas.0905184106
   Papadopoulou B, 2002, INFECT IMMUN, V70, P62, DOI 10.1128/IAI.70.1.62-68.2002
   Peacock CS, 2007, NAT GENET, V39, P839, DOI 10.1038/ng2053
   Rochette Annie, 2008, BMC Genomics, V9, P255, DOI 10.1186/1471-2164-9-255
   Selvapandiyan A, 2006, INDIAN J MED RES, V123, P455
   Selvapandiyan A, 2014, VACCINE, V32, P3895, DOI 10.1016/j.vaccine.2014.05.009
   Selvapandiyan A, 2012, J TROP MED, DOI 10.1155/2012/631460
   Selvapandiyan A, 2009, J IMMUNOL, V183, P1813, DOI 10.4049/jimmunol.0900276
   Silvestre R, 2008, ARCH IMMUNOL THER EX, V56, P123, DOI 10.1007/s00005-008-0010-9
   Singh RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01176
   Stager S, 2003, INFECT IMMUN, V71, P4804, DOI 10.1128/IAI.71.8.4804-4807.2003
   TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Tonui WK, 2007, AM J TROP MED HYG, V76, P579, DOI 10.4269/ajtmh.2007.76.579
   Uzonna JE, 2004, J IMMUNOL, V172, P3793, DOI 10.4049/jimmunol.172.6.3793
   Veras PST, 1999, MEM I OSWALDO CRUZ, V94, P491, DOI 10.1590/S0074-02761999000400011
   World Health Organization, 2014, MAN CAS MAN CUT LEIS
NR 42
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3221
EP 3228
DI 10.1016/j.vaccine.2019.04.068
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700013
PM 31047672
DA 2020-05-12
ER

PT J
AU Haber, M
   Lopman, BA
   Tate, JE
   Shi, M
   Parashar, UD
AF Haber, Michael
   Lopman, Benjamin A.
   Tate, Jacqueline E.
   Shi, Meng
   Parashar, Umesh D.
TI Effect of propensity of seeking medical care on the bias of the
   estimated effectiveness of rotavirus vaccines from studies using a
   test-negative case-control design
SO VACCINE
LA English
DT Article
DE Rotavirus vaccines; Test-negative design; Vaccine effectiveness;
   Confounding bias; Selection bias; Probability models
AB Background: Rotavirus is the leading cause of severe diarrhea among children worldwide, and vaccines can reduce morbidity and mortality by 50-98%. The test-negative control (TNC) study design is increasingly used for evaluating the effectiveness of vaccines against rotavirus and other vaccine-preventable diseases. In this study design, symptomatic patients who seek medical care are tested for the pathogen of interest. Those who test positive (negative) are classified as cases (controls).
   Methods: We use a probability model to evaluate the bias of estimates of rotavirus vaccine effectiveness (VE) against rotavirus diarrhea resulting in hospitalization in the presence of possible confounding and selection biases due to differences in the propensity of seeking medical care (PSMC) between vaccinated and unvaccinated children.
   Results: The TNC-based VE estimate corrects for confounding bias when the confounder's effects on the probabilities of rotavirus and non-rotavirus related hospitalizations are equal. If this condition is not met, then the estimated VE may be substantially biased. The bias is more severe in low-income countries, where VE is known to be lower. Under our model, differences in PSMC between vaccinated and unvaccinated children do not result in selection bias when the TNC study design is used.
   Conclusions: In practice, one can expect the association of PSMC (or other potential confounders) with the probabilities of rotavirus and non-rotavirus related hospitalization to be similar, in which case the confounding effects will only result in small bias in the VE estimate from TNC studies. The results of this work, along with those of our previous paper, confirm the TNC design can be expected to provide reliable estimates of rotavirus VE in both high- and low-income countries. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Haber, Michael; Shi, Meng] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA.
   [Lopman, Benjamin A.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Lopman, Benjamin A.; Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Haber, M (reprint author), Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA.
EM mhaber@emory.edu
FU Centers for Disease Controls and Prevention (CDC) via an IPA
   [18IPA1812107]
FX This work was supported by the Centers for Disease Controls and
   Prevention (CDC) via an IPA [18IPA1812107]. The findings and conclusions
   in this report are those of the author(s) and do not necessarily
   represent the official position of the Centers for Disease Control and
   Prevention.
CR Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Haber M, 2018, VACCINE, V36, P5071, DOI 10.1016/j.vaccine.2018.06.072
   Jackson ML, 2018, VACCINE, V36, P751, DOI 10.1016/j.vaccine.2017.12.022
   Mwenda JM, 2017, MMWR-MORBID MORTAL W, V66, P1192, DOI 10.15585/mmwr.mm6643a7
   Schwartz LM, 2017, VACCINE, V35, P184, DOI 10.1016/j.vaccine.2016.10.077
   Shi M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2838-2
   Skowronski DM, 2007, VACCINE, V25, P2842, DOI 10.1016/j.vaccine.2006.10.002
   Sullivan SG, 2014, EXPERT REV VACCINES, V13, P1571, DOI 10.1586/14760584.2014.966695
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Tate JE, 2016, CLIN INFECT DIS, V62, pS106, DOI 10.1093/cid/civ1014
NR 10
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3229
EP 3233
DI 10.1016/j.vaccine.2019.04.065
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700014
PM 31036459
DA 2020-05-12
ER

PT J
AU Ortega-Vargas, S
   Espitia, C
   Sahagun-Ruiz, A
   Parada, C
   Balderas-Loaeza, A
   Villa-Mancera, A
   Quiroz-Romero, H
AF Ortega-Vargas, S.
   Espitia, C.
   Sahagun-Ruiz, A.
   Parada, C.
   Balderas-Loaeza, A.
   Villa-Mancera, A.
   Quiroz-Romero, H.
TI Moderate protection is induced by a chimeric protein composed of leucine
   aminopeptidase and cathepsin L1 against Fasciola hepatica challenge in
   sheep
SO VACCINE
LA English
DT Article
DE Fasciola hepatica; Chimeric protein; Immunization; Sheep
ID GLUTATHIONE-S-TRANSFERASE; IMMUNE-RESPONSE; SM14 ANTIGEN; INFECTION;
   VACCINE; CATTLE; ADJUVANT; ANTIBODY; LIVER; TRICLABENDAZOLE
AB Leucine aminopeptidase (FhLAP) and cathepsin L1 (FhCL1) of Fasciola hepatica play a critical role in parasite feeding, migration through host tissue, and immune evasion. These antigens have been tested for immune protection as single components with variable degrees of success. The chimeric-protein approach could improve protection levels against fasciolosis. Previously, we reported the design and construction of a chimeric protein composed of antigenic sequences of FhLAP and FhCL1 of F. hepatica. The goal of the present study was to express and evaluate the immune-protective capacity of this chimeric protein (rFhLAP-CL1) in sheep. Animals were randomly allocated into five groups with five animals in each group. Groups 1, 2 and 3 were immunized twice with 100 mu g, 200 mu g and 400 mu g of rFhLAP-CL1 emulsified with Quil A adjuvant, whereas groups 4 and 5 were the adjuvant control and infection control groups, respectively. The animals were then challenged with 200 metacercariae two weeks after the rFhLAP-CL1 booster. The fluke burden was reduced by 25.5%, 30.7% (p < 0.05) and 46.5% (p < 0.01) in sheep immunized with 100 mu g, 200 mu g and 400 mu g of chimeric protein, respectively, in comparison to the infection control group. There was a reduction of 22.7% (p < 0.05) and 24.4% (p < 0.01) in fecal egg count in groups 2 and 3, respectively, compared to the infection control group. Sheep immunized with chimeric protein produced F. hepatica excretion-secretion product-specific total IgG antibody, which were increased after challenge. Moreover, the levels of rFhLAP-CL1-specific IgG1 and IgG2 isotypes in immunized sheep increased rapidly two weeks after the first immunization and were significantly more elevated than those of the control groups, indicating a mixed Thl/Th2 response. This is a preliminary evaluation of the chimeric protein rFhLAP-CL1 as a possible immunogen against F. hepatica infection in sheep. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ortega-Vargas, S.; Balderas-Loaeza, A.; Quiroz-Romero, H.] Univ Nacl Autonoma Mexico, Fac Med Vet & Zootecnia, Dept Parasitol, Av Univ 3000, Ciudad De Mexico 04510, Mexico.
   [Espitia, C.; Parada, C.] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Inmunol, Mexico City 04510, DF, Mexico.
   [Sahagun-Ruiz, A.] Univ Nacl Autonoma Mexico, Fac Med Vet & Zootecnia, Dept Microbiol & Inmunol, Av Univ 3000, Mexico City 04510, DF, Mexico.
   [Villa-Mancera, A.] Benemerita Univ Autonoma Puebla, Fac Med Vet & Zootecnia, 4 Sur 304 Col Ctr, Puebla 75482, Mexico.
RP Ortega-Vargas, S (reprint author), Univ Nacl Autonoma Mexico, Fac Med Vet & Zootecnia, Dept Parasitol, Av Univ 3000, Ciudad De Mexico 04510, Mexico.
EM fmvz.samy@comunidad.unam.mx
RI Sahagun-Ruiz, Alfredo/AAE-2549-2020; Villa-Mancera, Abel/K-2265-2016
OI Villa-Mancera, Abel/0000-0002-5997-5641; Sahagun-Ruiz,
   Alfredo/0000-0002-9737-1945
FU DGAPA-UNAMUniversidad Nacional Autonoma de Mexico [PAPIIT-IN 214,915];
   National Council of Science and Technology (CONACYT), MexicoConsejo
   Nacional de Ciencia y Tecnologia (CONACyT) [401,769]
FX This study was supported by the project PAPIIT-IN 214,915 DGAPA-UNAM as
   well the scholarship 401,769 granted by the National Council of Science
   and Technology (CONACYT), Mexico.
CR Acosta D, 2008, MOL BIOCHEM PARASIT, V158, P52, DOI 10.1016/j.molbiopara.2007.11.011
   Anugraha G, 2015, SCAND J IMMUNOL, V82, P380, DOI 10.1111/sji.12340
   Arguedas M, 2009, 2009 8TH IEEE INTERNATIONAL SYMPOSIUM ON NETWORK COMPUTING AND APPLICATIONS, P118, DOI 10.1109/NCA.2009.54
   Buffoni L, 2012, VET PARASITOL, V185, P315, DOI 10.1016/j.vetpar.2011.09.027
   Buffoni L, 2010, PARASITOL INT, V59, P147, DOI 10.1016/j.parint.2009.12.005
   Collins PR, 2004, J BIOL CHEM, V279, P17038, DOI 10.1074/jbc.M308831200
   De Bont J, 2003, VET PARASITOL, V113, P135, DOI 10.1016/S0304-4017(02)00450-8
   Dias DS, 2018, TRANSL RES, V200, P18, DOI 10.1016/j.trsl.2018.05.001
   Gonzalez-Sanchez ME, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193118
   Garza-Cuartero L, 2018, VACCINE, V36, P958, DOI 10.1016/j.vaccine.2018.01.020
   Gauci C, 2008, INT J PARASITOL, V38, P1041, DOI 10.1016/j.ijpara.2007.11.006
   Golden O, 2010, VACCINE, V28, P5551, DOI 10.1016/j.vaccine.2010.06.039
   Hacariz O, 2009, VACCINE, V27, P45, DOI 10.1016/j.vaccine.2008.10.035
   Hernandez-Guzman K, 2016, J HELMINTHOL, V90, P7, DOI 10.1017/S0022149X14000686
   Ortiz JMJ, 2016, VACCINE, V34, P3913, DOI 10.1016/j.vaccine.2016.05.053
   Kaba SA, 2008, CLIN VACCINE IMMUNOL, V15, P1674, DOI 10.1128/CVI.00164-08
   Maggioli G, 2016, VET PARASITOL, V224, P13, DOI 10.1016/j.vetpar.2016.05.007
   Maggioli G, 2011, VACCINE, V29, P9057, DOI 10.1016/j.vaccine.2011.09.020
   Marcilla A, 2008, CLIN VACCINE IMMUNOL, V15, P95, DOI 10.1128/CVI.00338-07
   Mas-Coma S, 2005, J HELMINTHOL, V79, P207, DOI 10.1079/JOH2005296
   Molina-Hernandez V, 2015, VET PARASITOL, V208, P101, DOI 10.1016/j.vetpar.2015.01.004
   Morrison CA, 1996, VACCINE, V14, P1603, DOI 10.1016/S0264-410X(96)00147-8
   Mulcahy G, 1998, VACCINE, V16, P932, DOI 10.1016/S0264-410X(97)00289-2
   Novobilsky A, 2015, INT J PARASITOL-DRUG, V5, P172, DOI 10.1016/j.ijpddr.2015.07.003
   O'Neill SM, 1998, AM J TROP MED HYG, V58, P417, DOI 10.4269/ajtmh.1998.58.417
   Ortiz P, 2013, VET PARASITOL, V195, P118, DOI 10.1016/j.vetpar.2013.01.001
   Pacheco IL, 2017, VET PARASITOL, V238, P61, DOI 10.1016/j.vetpar.2017.03.022
   Piacenza L, 1999, INFECT IMMUN, V67, P1954
   Pinheiro CS, 2014, PARASITE IMMUNOL, V36, P303, DOI 10.1111/pim.12118
   Raina OK, 2011, ACTA TROP, V118, P217, DOI 10.1016/j.actatropica.2011.02.008
   Rivera F, 2016, EXP PARASITOL, V160, P31, DOI 10.1016/j.exppara.2015.11.002
   Rojas-Caraballo J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105323
   SEXTON JL, 1990, J IMMUNOL, V145, P3905
   Shabani SH, 2017, MOL IMMUNOL, V90, P158, DOI 10.1016/j.molimm.2017.06.033
   SMEAL MG, 1983, AUST VET J, V60, P329, DOI 10.1111/j.1751-0813.1983.tb02833.x
   Spithill TW, 1999, FASCIOLOSIS, P377
   Sun HX, 2009, VACCINE, V27, P1787, DOI 10.1016/j.vaccine.2009.01.091
   Villa-Mancera A, 2008, PARASITOLOGY, V135, P1437, DOI 10.1017/S003118200800471X
   Villa-Mancera A, 2014, PARASITOL RES, V113, P243, DOI 10.1007/s00436-013-3650-6
   Yang W, 2000, VACCINE, V19, P103, DOI 10.1016/S0264-410X(00)00165-1
   Zafra R, 2008, J COMP PATHOL, V139, P169, DOI 10.1016/j.jcpa.2008.06.004
NR 41
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3234
EP 3240
DI 10.1016/j.vaccine.2019.04.067
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700015
PM 31036453
DA 2020-05-12
ER

PT J
AU Poellabauer, E
   Angermayr, R
   Behre, U
   Zhang, P
   Harper, L
   Schmitt, HJ
   Erber, W
AF Poellabauer, E.
   Angermayr, R.
   Behre, U.
   Zhang, P.
   Harper, L.
   Schmitt, H. J.
   Erber, W.
TI Seropersistence and booster response following vaccination with
   FSME-IMMUN in children, adolescents, and young adults
SO VACCINE
LA English
DT Article
DE TBE; Tick-borne encephalitis; Tick; Encephalitis
ID TICK-BORNE ENCEPHALITIS; 0.5 ML; ANTIBODIES; PERSISTENCE; VACCINES;
   SAFETY
AB Background: Tick-borne encephalitis (TBE) is a viral disease that can have a severe clinical course and considerable long-term morbidity. As no curative treatment exists, vaccination is the primary means of prevention. Long-term antibody seropersistence 2-5 years after the 3-dose primary immunization and 3-10 years after first booster was evaluated, as well as booster responses in children, adolescents and young adults.
   Methods: Subjects who participated in these phase 4 prospective, open-label follow-up studies received all vaccinations with FSME-IMMUN. After 3-dose primary immunization, subjects were followed for 25 years. Overall, 205 out of 358 subjects (57%) received the first booster and 179 of these subjects (87%) enrolled in a further 10-year follow-up. Antibody seropersistence was assessed annually. Subjects with a TBE antibody titer below a pre-specified cut-off at the yearly blood draw received a booster. Seropositivity rates and geometric mean fold rises (GMERs) were assessed.
   Results: In children who received their 3-dose primary immunization between 1 and 15 years of age, the seropositivity rate 5 years after the 3rd dose was 84.9% by NT and 72.0% by ELISA. One month post-first booster, all subjects were seropositive by NT and 98.5% by ELISA. Response to first booster by GMFR ranged from 3.7 to 11.4. At 5 years post-first booster, seropositivity was 99.4% by NT and 97.5% by ELISA, and at 10 years, was 90.3% by NT and 87.7% by ELISA. Although seropositivity rates differed between age groups, all subjects (100%) who received a second booster responded with a robust increase of TBEV antibodies.
   Discussion: Long-lasting seropersistence of TBEV antibodies after the 3-dose primary immunization and first booster was demonstrated as well as a competent immune memory response in those who received a first or second booster at any time during the 15-year follow-up. Therefore, an extension of FSME-IMMUN booster interval up to 10 years after the 3-dose primary immunization seems warranted. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Poellabauer, E.] Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, Vienna, Austria.
   [Zhang, P.; Harper, L.] Pfizer Inc, Collegeville, PA USA.
   [Schmitt, H. J.] Pfizer Inc, Paris, France.
   [Erber, W.] Pfizer Inc, Vienna, Austria.
RP Erber, W (reprint author), Pfizer Inc, Vienna, Austria.
EM wilhelm.erber@pfizer.com
FU Pfizer, Inc.Pfizer
FX This study was sponsored by Pfizer, Inc. P. Zhang, L. Harper, H.J.
   Schmitt and W. Erber are employees of Pfizer and may hold stock/stock
   options in the company.
CR Adner N, 2001, SCAND J INFECT DIS, V33, P843, DOI 10.1080/00365540110027358
   Andersson CR, 2010, VACCINE, V28, P2827, DOI 10.1016/j.vaccine.2010.02.001
   Beran J, 2018, VACCINE
   Brokera M, 2008, VACCINE, V26, P863, DOI 10.1016/j.vaccine.2007.11.046
   Heinz FX, 2013, EMERG INFECT DIS, V19, P69, DOI 10.3201/eid1901.120458
   Kaiser R, 1999, BRAIN, V122, P2067, DOI 10.1093/brain/122.11.2067
   Kaiser R, 2008, INFECT DIS CLIN N AM, V22, P561, DOI 10.1016/j.idc.2008.03.013
   Kollaritsch H, 2012, EXPERT REV VACCINES, V11, P1103, DOI [10.1586/erv.12.86, 10.1586/ERV.12.86]
   Konior R, 2017, VACCINE, V35, P3607, DOI 10.1016/j.vaccine.2017.03.059
   Lindquist L, 2008, LANCET, V371, P1861, DOI 10.1016/S0140-6736(08)60800-4
   Loew-Baselli A, 2011, VACCINE, V29, P7307, DOI 10.1016/j.vaccine.2011.07.089
   Loew-Baselli A, 2009, HUM VACCINES, V5, P551, DOI 10.4161/hv.5.8.8571
   Paulke-Korinek M, 2009, VACCINE, V27, P7027, DOI 10.1016/j.vaccine.2009.09.068
   Pavlova BG, 2003, VACCINE, V21, P742, DOI 10.1016/S0264-410X(02)00593-5
   Plentz A, 2009, VACCINE, V27, P853, DOI 10.1016/j.vaccine.2008.11.082
   Rendi-Wagner P, 2004, VACCINE, V23, P427, DOI 10.1016/j.vaccine.2004.07.002
   Rendi-Wagner P, 2007, VACCINE, V25, P5097, DOI 10.1016/j.vaccine.2007.01.116
   Rendi-Wagner P, 2006, INT J MED MICROBIOL, V296, P202, DOI 10.1016/j.ijmm.2006.01.030
   Schosser R, 2014, VACCINE, V32, P2375, DOI 10.1016/j.vaccine.2014.01.072
   Schuler M, 2014, EUROSURVEILLANCE, V19, P39, DOI 10.2807/1560-7917.ES2014.19.13.20756
   Steffen R, 2018, NO EUR C TRAV MED NE
   Stiasny K, 2009, VACCINE, V27, P7021, DOI 10.1016/j.vaccine.2009.09.069
   Zavadska D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204844
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3241
EP 3250
DI 10.1016/j.vaccine.2019.03.032
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700016
PM 30928173
DA 2020-05-12
ER

PT J
AU Masters, NB
   Wagner, AL
   Ding, YX
   Zhang, Y
   Boulton, ML
AF Masters, Nina B.
   Wagner, Abram L.
   Ding, Yaxing
   Zhang, Ying
   Boulton, Matthew L.
TI Assessing measles vaccine failure in Tianjin, China
SO VACCINE
LA English
DT Article
DE Measles; China; Tianjin; Vaccine failure; Vaccine effectiveness;
   Measles-containing vaccine
ID RISK-FACTORS
AB Despite increasing global measles vaccination coverage, progress toward measles elimination has slowed in recent years. In China, children receive a measles-containing vaccine (MCV) at 8 months, 18-24 months, and some urban areas offer a third dose at age 4-6 years. However, substantial measles cases in Tianjin, China, occur among individuals who have received multiple MCV doses. This study describes the vaccination history of measles cases 8 months - 19 years old. Data came from measles cases in Tianjin's reportable disease surveillance system (2009-2013), and from a case control study (2011-2015). Twenty-nine percent of those in the surveillance dataset and 54.4% of those in the case series received at least one dose of MCV. The minimum and median time-to-diagnosis since vaccination revealed an increase in time since vaccination for incremental doses. Considerable measles cases in Tianjin occur in vaccinated children, and further research is needed to understand the reasons for vaccine failure. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Masters, Nina B.; Wagner, Abram L.; Boulton, Matthew L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Ding, Yaxing; Zhang, Ying] Tianjin Ctr Dis Control & Prevent, Div Expanded Programs Immunizat, Tianjin 300011, Peoples R China.
RP Masters, NB (reprint author), 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM masterSn@umich.edu
OI Masters, Nina/0000-0002-3155-6058; Wagner, Abram/0000-0003-4691-7802
FU National Institutes of Health, National Institute of Allergy and
   Infectious Disease, Division of Microbial and Infectious Diseases
   [U01-AI-088671]; PhRMA Foundation (Health Outcomes Post Doctoral
   Fellowship)
FX This work was supported by the National Institutes of Health, National
   Institute of Allergy and Infectious Disease, Division of Microbial and
   Infectious Diseases [U01-AI-088671].; ALW was supported by the PhRMA
   Foundation (Health Outcomes Post Doctoral Fellowship). The PhRMA
   Foundation did not have any role in the study design; the collection,
   analysis, and interpretation of data; the writing of the report; or the
   decision to submit the paper for publication. We report no other
   external funding for this manuscript.
CR Brinkman ID, 2019, J INFECT DIS, V220, P594, DOI 10.1093/infdis/jiz159
   CUTTS FT, 1995, BIOLOGICALS, V23, P95
   Durrheim DN, 2014, VACCINE, V32, P6880, DOI 10.1016/j.vaccine.2014.10.061
   Fu J, 2013, CHIN J VAC IMMUN, V19, P222
   Hales CM, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw064
   Hamborsky J, 2015, EPIDEMIOLOGY PREVENT, P209
   He HG, 2014, VACCINE, V32, P4001, DOI 10.1016/j.vaccine.2014.04.044
   Liu Q, 2017, MOB INF SYST, V2017, DOI 10.1155/2017/2358618
   Moss WJ, 2006, NAT REV MICROBIOL, V4, P900, DOI 10.1038/nrmicro1550
   Nsubuga F, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-017-2941-4
   Perry RT, 2015, MMWR-MORBID MORTAL W, V64, P1246, DOI [10.15585/mmwr.6444a4, 10.15585/mmwr.mm6444a4]
   Pillsbury A, 2015, WEST PAC SURVEILL RE, V6, P43, DOI [10.5365/WPSAR.2015.6.2.007, 10.5365/wpsar.2015.6.2.007]
   Uzicanin A, 2011, J INFECT DIS, V204, pS133, DOI 10.1093/infdis/jir102
   World Health Organization (WHO), 2009, MEASL IMM BAS IMM
   World Health Organization (WHO), 2009, MEASL POS PAP
   World Health Organization (WHO), 2012, GLOB MEASL RUB STRAT
   XIANG JZ, 1983, REV INFECT DIS, V5, P506
   Zahidie A, 2014, JCPSP-J COLL PHYSICI, V24, P882, DOI 12.2014/JCPSP.882888
   Zhang Y, 2017, PUBLIC HEALTH, V151, P114, DOI 10.1016/j.puhe.2017.07.001
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3251
EP 3254
DI 10.1016/j.vaccine.2019.05.005
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400001
PM 31078327
DA 2020-05-12
ER

PT J
AU Vedhara, K
   Ayling, K
   Sunger, K
   Caldwell, DM
   Halliday, V
   Fairclough, L
   Avery, A
   Robles, L
   Garibaldi, J
   Welton, NJ
   Royal, S
AF Vedhara, Kavita
   Ayling, Kieran
   Sunger, Kanchan
   Caldwell, Deborah M.
   Halliday, Vanessa
   Fairclough, Lucy
   Avery, Anthony
   Robles, Luke
   Garibaldi, Jonathan
   Welton, Nicky J.
   Royal, Simon
TI Psychological interventions as vaccine adjuvants: A systematic review
SO VACCINE
LA English
DT Review
DE Vaccinations; Antibodies; Psychological interventions
ID HEPATITIS-B VACCINATION; ANTIBODY-RESPONSE; INFLUENZA VACCINATION;
   IMMUNE-RESPONSE; EFFICACY; STRESS; BOOSTER; ADULTS; IMMUNOGENICITY;
   DISCLOSURE
AB Objectives: The effectiveness of vaccines is known to be altered by a range of psychological factors. We conducted a systematic review to evaluate the effects of psychological interventions on the ability of vaccines to protect against disease, as measured by antibody responses.
   Methods: Electronic databases (EMBASE, Medline, PsychINFO, CINAHL) were searched from their inception to 6th February 2018.
   Results: The search yielded 9 eligible trials conducted with 1603 participants and four broad categories of intervention: meditation/mindfulness (n = 3), massage (n = 3), expressive writing (n = 2) and cognitive behavioural stress management (n = 1). Some evidence of benefit on the antibody response to vaccination was observed in 6/9 of all trials and in 4/7 of randomised controlled trials. However, effects on antibody levels were often mixed, with only 3 of 6 trials showing benefit demonstrating an improvement in all antibody outcomes and at all time points assessed. Trials demonstrating benefit also provided direct or indirect evidence of adequate adherence with the intervention; and in 50% of these trials, there was also evidence that the intervention was effective in changing the mediating psychological constructs targeted by the intervention.
   Conclusions: This literature is characterised by considerable heterogeneity in terms of intervention type, vaccine type, age of participants and the temporal relationship between vaccination and intervention. We conclude that there is early evidence to suggest that psychological interventions may enhance the antibody response to vaccination. However, the effects are inconsistent, with the greatest likelihood of benefit seen in trials evidencing adequate adherence with the intervention. Future work would benefit from rigorous intervention development that focuses on achieving adequate adherence and large well-controlled randomised trials with a focus on an agreed set of outcomes. (C) 2019 Published by Elsevier Ltd.
C1 [Vedhara, Kavita; Ayling, Kieran; Sunger, Kanchan; Avery, Anthony] Univ Nottingham, Sch Med, Div Primary Care, Nottingham NG7 2RD, England.
   [Caldwell, Deborah M.; Welton, Nicky J.] Univ Bristol, Sch Social & Community Med, Bristol BS8 2PS, Avon, England.
   [Halliday, Vanessa] Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.
   [Fairclough, Lucy] Univ Nottingham, Sch Life Sci, Nottingham NG7 2UH, England.
   [Robles, Luke] Univ Bristol, Sch Social & Community Med, Bristol BS8 2BN, Avon, England.
   [Garibaldi, Jonathan] Univ Nottingham, Sch Comp Sci, Nottingham, England.
   [Royal, Simon] Univ Nottingham, Cripps Hlth Ctr, Univ Nottingham Hlth Serv, Nottingham NG7 2QW, England.
RP Vedhara, K (reprint author), Univ Nottingham, Sch Med, Div Primary Care, Nottingham NG7 2RD, England.
EM kavita.vedhara@nottingham.ac.uk
RI Fairclough, Lucy/Q-8685-2018
OI Fairclough, Lucy/0000-0003-4581-9741; Vedhara,
   Kavita/0000-0002-9940-7534; Ayling, Kieran/0000-0003-1766-8800
FU Nottingham City Clinical Commissioning Group through a Research
   Capability Funding award; National Institute for Health Research School
   for Primary Care Research (NIHR SPCR)
FX The contribution of Dr Simon Royal was supported by the Nottingham City
   Clinical Commissioning Group through a Research Capability Funding
   award. Dr Kieran Ayling was supported by funding from the National
   Institute for Health Research School for Primary Care Research (NIHR
   SPCR). The views expressed are those of the author(s) and not
   necessarily those of the NIHR, the NHS or the Department of Health.
   Contributions of the other authors were not funded by any specific
   grants from funding agencies in the public, commercial, or
   not-for-profit sectors.
CR Bonaventura P, 2015, AUTOIMMUN REV, V14, P277, DOI 10.1016/j.autrev.2014.11.008
   BRIEM H, 1994, J MED VIROL, V44, P443, DOI 10.1002/jmv.1890440424
   CDC, 1999, JAMA-J AM MED ASSOC, V281, P1481, DOI [10.1001/jama.281.16.1481, DOI 10.1001/JAMA.281.16.1481]
   Cohen J., 1992, CURRENT DIRECTIONS P, V1, P98, DOI [10.1111/1467-8721.ep10768783, DOI 10.1111/1467-8721.EP10768783]
   Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3
   De Winter JCF, 2013, WHY SELECTIVE PUBLIC
   DiazGranados CA, 2012, VACCINE, V31, P49, DOI 10.1016/j.vaccine.2012.10.084
   ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460
   Gallagher S, 2008, BRAIN BEHAV IMMUN, V22, P456, DOI 10.1016/j.bbi.2007.10.018
   Hayney MS, 2014, HUM VACC IMMUNOTHER, V10, P83, DOI 10.4161/hv.26661
   HERBERT TB, 1993, PSYCHOSOM MED, V55, P364, DOI 10.1097/00006842-199307000-00004
   Higgins J, 2011, COCHRANE COLLAB, V5, P1, DOI DOI 10.1002/9780470712184
   Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473
   HOROWITZ MM, 1988, ANN INTERN MED, V108, P185, DOI 10.7326/0003-4819-108-2-185
   HSU CY, 1995, PEDIATR INFECT DIS J, V14, P567, DOI 10.1097/00006454-199507000-00003
   Huang Fu-Yuan, 1999, Acta Paediatrica Sinica, V40, P166
   Jefferson T, 2005, LANCET, V366, P1165, DOI 10.1016/S0140-6736(05)67339-4
   Loft P, 2012, PSYCHOSOM MED, V74, P982, DOI 10.1097/PSY.0b013e31826fb7d2
   McLaren N, 1998, AUST NZ J PSYCHIAT, V32, P86, DOI 10.3109/00048679809062712
   MILNE A, 1992, J INFECT DIS, V166, P942, DOI 10.1093/infdis/166.4.942
   Nauta JJP, 2009, BIOLOGICALS, V37, P216, DOI 10.1016/j.biologicals.2009.02.002
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3
   Pascoe AR, 2014, BRAIN BEHAV IMMUN, V39, P33, DOI 10.1016/j.bbi.2013.10.003
   Pedersen AF, 2009, BRAIN BEHAV IMMUN, V23, P427, DOI 10.1016/j.bbi.2009.01.004
   PETRIE KJ, 1995, J CONSULT CLIN PSYCH, V63, P787, DOI 10.1037/0022-006X.63.5.787
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Provinciali M, 2009, CANCER IMMUNOL IMMUN, V58, P1959, DOI 10.1007/s00262-009-0665-z
   Richens JL, 2010, J BIOMOL SCREEN, V15, P562, DOI 10.1177/1087057110362099
   Roberts J, 1999, HEALTH ECON, V8, P459, DOI 10.1002/(SICI)1099-1050(199908)8:5<459::AID-HEC454>3.3.CO;2-L
   Siegrist CA, 2013, VACCINES, P14, DOI DOI 10.1016/B978-1-4557-0090-5.00004-5
   Simmons JP, 2011, PSYCHOL SCI, V22, P1359, DOI 10.1177/0956797611417632
   SMART RG, 1965, CAN PSYCHOLOGIST, V5, P225
   Stetler C, 2006, INT J BEHAV MED, V13, P60, DOI 10.1207/s15327558ijbm1301_8
   Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4
   VANDAMME P, 1994, J MED VIROL, V44, P435, DOI 10.1002/jmv.1890440422
   Vanherwegen AS, 2017, ENDOCRIN METAB CLIN, V46, P1061, DOI 10.1016/j.ecl.2017.07.010
   Vedhara K, 2003, PSYCHOTHER PSYCHOSOM, V72, P245, DOI 10.1159/000071895
   Vedhara K, 1999, LANCET, V353, P627, DOI 10.1016/S0140-6736(98)06098-X
   Yang Yang, 2008, V52, P64, DOI 10.1159/000134285
NR 40
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3255
EP 3266
DI 10.1016/j.vaccine.2019.04.091
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400002
PM 31068258
DA 2020-05-12
ER

PT J
AU Kochhar, S
   Edwards, KM
   Alvarez, AMR
   Moro, PL
   Ortiz, JR
AF Kochhar, Sonali
   Edwards, Kathryn M.
   Alvarez, Alba Maria Ropero
   Moro, Pedro L.
   Ortiz, Justin R.
TI Introduction of new vaccines for immunization in pregnancy -
   Programmatic, regulatory, safety and ethical considerations
SO VACCINE
LA English
DT Review
DE Vaccines; Immunisation; Pregnancy; Maternal Immunization; Introduction;
   Program; Regulatory; Safety; Vaccination coverage; Health policies;
   Antenatal care; Global policies; Country-level policy making;
   Pharmacovigilance; Healthcare providers; Antenatal care; Vaccine
   hesitancy
ID INFLUENZA IMMUNIZATION; MATERNAL IMMUNIZATION; ADVERSE EVENTS;
   UNITED-STATES; VACCINATION; WOMEN; COUNTRIES; PERTUSSIS; CARE;
   CHALLENGES
AB Immunizing pregnant women is a promising strategy to reduce infectious disease-related morbidity and mortality in pregnant women and their infants. Important pre-requisites for the successful introduction of new vaccines for immunization in pregnancy include political commitment and adequate financial resources: trained, committed and sufficient numbers of healthcare workers to deliver the vaccines; close integration of immunization programs with antenatal care and Maternal and Child Health services; adequate access to antenatal care by pregnant women in the country (especially in low and middle-income countries (LMIC)); and a high proportion of births occurring in health facilities (to ensure maternal and neonatal follow-up can be done). The framework needed to advance a vaccine program from product licensure to successful country-level implementation includes establishing and organizing evidence for anticipated vaccine program impact, developing supportive policies, and translating policies into local action. International and national coordination efforts, proactive planning from conception to implementation of the programs (including country-level policy making, planning, and implementation, regulatory guidance, pharmacovigilance) and country-specific and cultural factors must be taken into account during the vaccines introduction. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Kochhar, Sonali] Global Healthcare Consulting, New Delhi, India.
   [Kochhar, Sonali] Erasmus MC, Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.
   [Kochhar, Sonali; Ortiz, Justin R.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Infect Dis, Nashville, TN 37232 USA.
   [Alvarez, Alba Maria Ropero] WHO, PAHO, Dept Family Hlth Promot & Life Course FPL, Comprehens Family Immunizat Unit, Washington, DC USA.
   [Moro, Pedro L.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA USA.
   [Ortiz, Justin R.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
RP Kochhar, S (reprint author), Erasmus MC, Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.
EM sonalikochhar@yahoo.co.in
OI Ortiz, Justin/0000-0002-3138-5965
FU Intramural CDC HHS [CC999999]
CR Abu Raya B, 2017, LANCET INFECT DIS, V17, pE209, DOI 10.1016/S1473-3099(17)30190-1
   Abu Raya B, 2014, VACCINE, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038
   Alvarez AMR, 2017, REV PANAM SALUD PUBL, V41, DOI 10.26633/RPSP.2017.159
   American College of Obstetricians and Gynecologists, 2016, MAT INFL REV PROGR T
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P53
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P433
   [Anonymous], 2013, Wkly Epidemiol Rec, V88, P269
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   [Anonymous], 2016, LAB INF IN INFL VACC
   Arriola CS, 2016, VACCINE, V34, P1086, DOI 10.1016/j.vaccine.2015.12.065
   Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091
   Bill and Melinda Gates Foundation & Global Alliance to Prevent Prematurity and Stillbirth, 2016, MAT IMM SAF MON LOW
   Cassidy C, 2016, HUM VACC IMMUNOTHER, V12, P2010, DOI 10.1080/21645515.2016.1175697
   Chamberlain AT, 2017, SCIENCE, V358, P452, DOI 10.1126/science.aao4219
   Chamberlain AT, 2015, PLOS CURR, V7, DOI [10.1371/currentsoutbreaksd37b61bceebae5a7a06d40a301cfa819, DOI 10.1371/CURRENTSOUTBREAKSD37B61BCEEBAE5A7A06D40A301CFA819]
   Chandler RE, 2017, DRUG SAFETY, V40, P1167, DOI 10.1007/s40264-017-0593-3
   Council for International Organisations of Medical Sciences (CIOMS), 2016, INT ETH GUID HLTH RE
   DEABAJO FJ, 2005, PHARM MED, V19, P209
   Duclos P, 2010, VACCINE, V28, pA18, DOI 10.1016/j.vaccine.2010.02.027
   Fell DB, 2017, VACCINE, V35, P5738, DOI 10.1016/j.vaccine.2017.08.037
   Fulton TR, 2015, VACCINE, V33, P6453, DOI 10.1016/j.vaccine.2015.08.043
   Gomes MF, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0430-2
   Gruber Marion, 2014, REGULATORY ISSUES MA
   Gruber MF, 2015, VACCINE, V33, P6499, DOI 10.1016/j.vaccine.2015.05.107
   Halsey NA, 2017, VACCINE, V35, P6154, DOI 10.1016/j.vaccine.2017.09.049
   Heath PT, 2017, LANCET INFECT DIS, V17, pE223, DOI 10.1016/S1473-3099(17)30232-3
   Hodgins S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160562
   Hodgins S, 2014, GLOB HEALTH-SCI PRAC, V2, P173, DOI 10.9745/GHSP-D-13-00176
   Huang WT, 2014, VACCINE, V32, P6463, DOI 10.1016/j.vaccine.2014.09.054
   Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052
   Kochhar S, 2018, VACCINE
   Kochhar S, 2017, VACCINE, V35, P6469, DOI 10.1016/j.vaccine.2017.09.033
   Kochhar S, 2017, VACCINE, V35, P6575, DOI 10.1016/j.vaccine.2017.03.103
   Kochhar S, 2013, EXPERT REV VACCINES, V12, P1465, DOI 10.1586/14760584.2013.855612
   Lambach P, 2015, VACCINE, V33, P6493, DOI 10.1016/j.vaccine.2015.08.037
   Lambach P, 2015, VACCINE, V33, P6376, DOI 10.1016/j.vaccine.2015.08.036
   Levine OS, 2010, HUM VACCINES, V6, P1021, DOI 10.4161/hv.6.12.13076
   MacDougall DM, 2016, HUM VACC IMMUNOTHER, V12, P857, DOI 10.1080/21645515.2015.1101524
   Manning Susan E., 2008, Morbidity and Mortality Weekly Report, V57, P1
   Marchant A, 2017, LANCET INFECT DIS, V17, pE197, DOI 10.1016/S1473-3099(17)30229-3
   Marshall H, 2016, HUM VACC IMMUNOTHER, V12, P848, DOI 10.1080/21645515.2015.1127485
   Moniz MH, 2014, HUM VACC IMMUNOTHER, V10, P2562, DOI 10.4161/21645515.2014.970901
   Moro PL, 2015, HUM VACC IMMUNOTHER, V11, P2872, DOI 10.1080/21645515.2015.1072664
   Moro PL, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.047
   Naleway AL, 2013, VACCINE, V31, P2898, DOI 10.1016/j.vaccine.2013.03.069
   Neels P, 2017, VACCINE, V35, P2329, DOI 10.1016/j.vaccine.2017.02.056
   Orenstein LAV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046638
   Ortiz JR, 2017, CURR OPIN INFECT DIS, V30, P455, DOI 10.1097/QCO.0000000000000392
   Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045
   [Pan American Health Organization Pan American Health Organization], 2017, MAT NEON IMM FIELD G
   Roberts JN, 2015, VACCINE, V33, P966, DOI 10.1016/j.vaccine.2014.12.068
   Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]
   Sakala IG, 2016, HUM VACC IMMUNOTHER, V12, P3065, DOI 10.1080/21645515.2016.1215392
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Sato APS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052000295, 10.11606/s1518-8787.2018052000295]
   Schrag SJ, 2013, VACCINE, V31, pD20, DOI 10.1016/j.vaccine.2012.11.056
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   Skoff TH, 2017, CLIN INFECT DIS, V65, P1977, DOI 10.1093/cid/cix724
   Sobanjo-ter Meulen A, 2015, VACCINE, V33, P6388, DOI 10.1016/j.vaccine.2015.08.047
   Swamy GK, 2015, OBSTET GYNECOL, V125, P212, DOI 10.1097/AOG.0000000000000581
   Tam J, 2018, CASE REP INFECT DIS, DOI 10.1155/2018/7567914
   Thigpen MC, 2011, NEW ENGL J MED, V364, P2016, DOI 10.1056/NEJMoa1005384
   Top KA, 2016, LANCET GLOB HEALTH, V4, pE690, DOI 10.1016/S2214-109X(16)30182-6
   Trifiro G, 2014, J INTERN MED, V275, P551, DOI 10.1111/joim.12159
   UNICEF, ONL HALF WOM WORLDW
   Vekemans J, 2019, VACCINE, V37, P7394, DOI 10.1016/j.vaccine.2017.09.092
   Vekemans J, 2019, VACCINE, V37, P7391, DOI 10.1016/j.vaccine.2017.09.087
   Verweij M, 2016, LANCET INFECT DIS, V16, P1324, DOI 10.1016/S1473-3099(16)30349-8
   Vizzotti C, 2015, VACCINE, V33, P6413, DOI 10.1016/j.vaccine.2015.07.109
   WHO, 2014, SAF IMM PREGN REV EV
   WHO World Health Organization, WHO GLOB HLTH OBS GH
   Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046
   World Health Organization, 2016, WHO REC ANT CAR POS
   [World Health Organization World Health Organization], 2017, GLOB VACC ACT PLAN S
   World Health Organization, 2005, VACC INTR GUID ADD V
   World Health Organization, WHO REC ANT CAR POS
   [World Health Organization World Health Organization], 2018, ASS PROGR SUIT VACC
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   [World Health Organization Organization WH], 2016, IMPL INFL VACC PREGN
   World Health Organization, 2017, METH ASS MISS OPP VA
   World Hlth Org, 2018, VACCINE, V36, P3421, DOI 10.1016/j.vaccine.2017.07.063
   Xu S, 2014, BIOMETRICAL J, V56, P513, DOI 10.1002/bimj.201300012
NR 82
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3267
EP 3277
DI 10.1016/j.vaccine.2019.04.075
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400003
PM 31072733
OA Green Accepted, Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Torcel-Pagnon, L
   Bauchau, V
   Mahy, P
   Htar, MTT
   van der Sande, M
   Mahe, C
   Krause, TG
   Charrat, A
   Simondon, F
   Kurz, X
AF Torcel-Pagnon, Laurence
   Bauchau, Vincent
   Mahy, Patrick
   Htar, Myint Tin Tin
   van der Sande, Marianne
   Mahe, Cedric
   Krause, Tyra Grove
   Charrat, Anne
   Simondon, Francois
   Kurz, Xavier
CA ADVANCE Consortium
   P95
   UNIBAS
   EMA
   ECDC
   SURREY
   EMC
   SYNAPSE
   OU
   LSHTM
   PEDIANET
   KI
   ASLCR
   AEMPS
   AUH
   UTA
   SCIENSANO
   MHRA
   SSI
   RCGP
   RIVM
   GSK
   SP
   NOVARTIS
   MSD
   JANSSEN
   PFIZER
   TAKEDA
   ARS Toscana
   IDIAP JORDI GOL
   ADVANCE
   ESDY
   HCDCP
   IMB
   AIFA
   ANSM
   VVKT
   WUM
   PHE
   BCF
   ICL
   UOA
   NCE
   FISABIO
   EOF
   THL
   UNIME
   IRD
   VGRID
   UMCU
TI Guidance for the governance of public-private collaborations in vaccine
   post-marketing settings in Europe
SO VACCINE
LA English
DT Article; Proceedings Paper
CT European Scientific Conference on Applied Infectious Disease
   Epidemiology (ESCAIDE) - Guidance for the Governance of Public-Private
   Collaborations in Vaccine Post-Marketing Settings in Europe
CY NOV 21-23, 2018
CL MALTA
DE Public-private partnership; Vaccine benefit-risk; Post-marketing
   studies; Governance model; Multi-stakeholders collaboration
ID ADVANCE CODE; CONDUCT
AB Introduction: The 2009 influenza pandemic highlighted challenges for vaccine post-marketing monitoring in Europe, particularly the need to have appropriate infrastructures to strengthen public-private collaborations (PPCs) with suitable processes to improve stakeholder interactions and collection and analysis of safety and effectiveness data. The ADVANCE consortium comprises public and private stakeholders who have worked together to build and test new system components for vaccine post-marketing projects, one component being a governance framework for efficient, transparent and trustworthy PPCs.
   Methods: Based on the results of a landscape analysis and screening of formalised existing governance structures, we identified the elements of a governance framework and developed recommendations to support stakeholders willing and able to implement collaborative projects. These proposals and their implementation were discussed by 70 experts during a workshop to gain from their experience.
   Results: We identified core governance principles and defined five fundamental functions (decision-making, scientific advice, quality control and audit, implementation and management, and financial administration) that can be attributed to individual partner organisations or to a committee with representatives from more than one partner organisation. We propose a generic governance model with options for its adaptation to specific contexts and projects. The advantages and disadvantages of PPCs were also examined. Stakeholders' concerns (e.g. scientific integrity and public trust) were addressed through recommendations about transparent decision-making rules and conflict of interest management.
   Conclusions: No one-size-fits-all solution for PPC governance exists but our recommendations could be used to set-up a tailored-made and fully transparent governance structure supporting collaborative projects in the European vaccine post-marketing environment. To allow the rapid establishment of robust projects, the next steps will involve this guidance being used by real-world collaborations to assess what works and what does not work and what added-value can be obtained from these collaborations. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Torcel-Pagnon, Laurence; Mahe, Cedric; Charrat, Anne] Sanofi Pasteur, VEM, Campus Sanofi Lyon,14 Espace Henry Vallee, F-69007 Lyon, France.
   [Bauchau, Vincent] GSK, Vaccine Clin Safety & Pharmacovigilance, Wavre, Belgium.
   [Mahy, Patrick] Sciensano, Expertise, Serv Provis & Customer Relat, Brussels, Belgium.
   [Htar, Myint Tin Tin] Pfizer Inc, Clin Epidemiol, Paris, France.
   [van der Sande, Marianne] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Bilthoven, Netherlands.
   [van der Sande, Marianne] Inst Trop Med, Dept Publ Hlth, Antwerp, Belgium.
   [van der Sande, Marianne] Univ Utrecht, Julius Ctr Hlth Sci & Primary Care, Univ Med Ctr Utrecht, Utrecht, Netherlands.
   [Krause, Tyra Grove] Statens Serum Inst, Dept Infect Dis Epidemiol & Prevent, Copenhagen, Denmark.
   [Simondon, Francois] IRD, MERIT Res Unit, Paris, France.
   [Simondon, Francois] Paris Descartes Univ, Paris, France.
   [Kurz, Xavier] European Med Agcy, Pharmacovigilance & Epidemiol Dept, London, England.
RP Torcel-Pagnon, L (reprint author), Sanofi Pasteur, VEM, Campus Sanofi Lyon,14 Espace Henry Vallee, F-69007 Lyon, France.
EM laurence.pagnon@sanofi.com; vincent.g.bauchau@gsk.com;
   Patrick.Mahy@sciensano.be; Myint.TinTinHtar@pfizer.com;
   mvandersande@itg.be; cedric.mahe@sanofi.com; TGV@ssi.dk;
   anne.charrat@sanofi.com; francois.simondon@ird.fr;
   xavier.kurz@ema.europa.eu
OI van der Sande, Marianne AB/0000-0002-4778-6739
FU Innovative Medicines Initiative Joint Undertaking [115557]; European
   UnionEuropean Union (EU)
FX The ADVANCE project has received support from the Innovative Medicines
   Initiative Joint Undertaking (www.imi.europa.eu) under Grant Agreement
   no. 115557, resources of which are composed of financial contribution
   from the European Union's Seventh Framework Programme (FP7/2007-2013)
   and in-kind contributions from member companies of the European
   Federation of Pharmaceutical Industries and Associations (EFPIA).
CR [Anonymous], WORKSH REP
   Denoel P, 2018, NAT REV DRUG DISCOV
   European Medicines Agency, HANDL COMP INT
   European Medicines Agency, EMA22101712011
   European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), ENCEPP GUID METH STA
   Goldman M, 2015, NAT REV DRUG DISCOV, V14, P1, DOI 10.1038/nrd4520
   Innovative Medicines Initiative, ADV ACC DEV VACC BEN
   Kurz X, 2017, VACCINE, V35, P1844, DOI 10.1016/j.vaccine.2017.02.039
   Kurz X, 2011, VACCINE, V29, P4378, DOI 10.1016/j.vaccine.2011.04.005
   Organisation for Economic Co-operation and Development, MAN CONFL INT PUBL S
   Sturkenboom M, 2018, VACCINE
   Sturkenboom M, 2018, VACCINE, V36, P194, DOI 10.1016/j.vaccine.2017.08.043
   The Gavi Alliance, GOV LEG STRUCT
   Wittelsberger A., 2014, JHPOR, V2, P12
   World Health Organisation, GUID DECL INT WHO EX
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3278
EP 3289
DI 10.1016/j.vaccine.2019.04.073
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400004
PM 31072735
OA Other Gold
DA 2020-05-12
ER

PT J
AU Sambala, EZ
   Wiyeh, AB
   Ngcobo, N
   Machingaidze, S
   Wiysonge, CS
AF Sambala, Evanson Z.
   Wiyeh, Alison B.
   Ngcobo, Ntombenhle
   Machingaidze, Shingai
   Wiysonge, Charles S.
TI New vaccine introductions in Africa before and during the decade of
   vaccines - Are we making progress?
SO VACCINE
LA English
DT Article
DE Africa; New and underutilized vaccines; Gavi support; Decade of vaccines
ID IMMUNIZATION
AB Vaccines are excellent investments with far-reaching rewards beyond individual and population health, but their introduction into national programs has been historically slow in Africa. We provide an overview of the introduction of new and underutilized vaccines in countries of the WHO African Region by 2017, using data from the WHO-UNICEF Joint Reporting Form. By 2017, all 47 countries had introduced vaccines containing hepatitis B (compared to 11% in 2000 and 98% in 2010) and Haemophilus influenzae type b (Hib) (compared to 4% in 2000 and 91% in 2010). The proportion of countries that had introduced other vaccines by 2017 was 83% for pneumococcal conjugate vaccine (PCV) from 7% in 2010, 72% for rotavirus vaccine from 2% in 2010, 55% for the second dose of a measles-containing vaccine (MCV2) (compared to 11% in 2000 and 17% in 2010), and 45% for rubella-containing vaccines (RCV) (compared to 4% in 2000 and 7% in 2010). From 2000 to 2010, there was no significant difference between countries eligible (N = 36) and those not eligible (N = 10) for Gavi support in the introduction of hepatitis B and PCV. However, Gavi eligible countries were more likely to introduce Hib and non-Gavi eligible countries were more likely to introduce MCV2 and RCV. From 2010 to 2017, the only significant differences that remained between the two groups of countries were with mumps, inactivated polio and seasonal influenza vaccines; which non-Gavi eligible countries were more likely to have introduced. There has been significant progress in the introduction of new childhood vaccines in Africa, mostly driven by Gavi support. As many countries are expected to transition out of Gavi support soon, there is need for countries in the region to identify predictable, reliable and sustainable immunization funding mechanisms. This requires commitments and actions that go beyond the purchase of vaccines. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Sambala, Evanson Z.; Wiyeh, Alison B.; Ngcobo, Ntombenhle; Wiysonge, Charles S.] South African Med Res Council, Cochrane South Africa, Cape Town, South Africa.
   [Machingaidze, Shingai] European & Developing Countries Clin Trials Partn, Cape Town, South Africa.
   [Wiysonge, Charles S.] Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Cape Town, South Africa.
   [Wiysonge, Charles S.] Stellenbosch Univ, Fac Med & Hlth Sci, Ctr Evidence Based Hlth Care, Div Epidemiol & Biostat,Dept Global Hlth, Cape Town, South Africa.
RP Sambala, EZ (reprint author), South African Med Res Council, Cochrane South Africa, POB 19070, ZA-7505 Tygerberg, South Africa.
EM Evanson.Sambala@mrc.ac.za
RI Wiysonge, Charles/AAF-2845-2019
OI Wiysonge, Charles/0000-0002-1273-4779
CR Andrus JK, 2017, REV PANAM SALUD PUBL, V41, DOI 10.26633/RPSP.2017.121
   [Anonymous], 2013, GLOBAL VACCINE ACTIO
   Gavi Alliance, 2012, GHAN ROLLS OUT VACC
   Gavi Alliance Secretariat, 2015, REP NEW PROP IND REV
   Haidari LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064303
   Hammitt LL, 2016, LANCET GLOB HEALTH, V4, pE185, DOI 10.1016/S2214-109X(15)00316-2
   Hyde TB, 2012, VACCINE, V30, P6347, DOI 10.1016/j.vaccine.2012.08.029
   Lahariya Chandrakant, 2015, J Family Med Prim Care, V4, P487, DOI 10.4103/2249-4863.174263
   Loharikar A, 2016, MMWR-MORBID MORTAL W, V65, P1136, DOI 10.15585/mmwr.mm6541a3
   Lupande D, 2017, PAN AFR MED J, V27, DOI 10.11604/pamj.2017.27.260.12575
   Machingaidze S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001405
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   Mihigo R, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0989-7
   Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086
   Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003
   WHO, 2014, PRINC CONS ADD VACC
   WHO UNICEF World Bank, 2009, STATE WORLD VACCINES
   World Health Organization, 2018, MEASL
   Zaffran M, 2013, VACCINE, V31, pB73, DOI 10.1016/j.vaccine.2012.11.036
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3290
EP 3295
DI 10.1016/j.vaccine.2019.05.002
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400005
PM 31076160
OA Other Gold
DA 2020-05-12
ER

PT J
AU Hechter, RC
   Qian, L
   Tartof, SY
   Sy, LS
   Klein, NP
   Weintraub, E
   Mercado, C
   Naleway, A
   McLean, HO
   Jacobsen, SJ
AF Hechter, Rulin C.
   Qian, Lei
   Tartof, Sara Y.
   Sy, Lina S.
   Klein, Nicola P.
   Weintraub, Eric
   Mercado, Cheryl
   Naleway, Allison
   McLean, Huong O.
   Jacobsen, Steven J.
TI Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink
   Project
SO VACCINE
LA English
DT Article
DE Vaccine safety; HIV; Vaccine Safety Datalink
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCOCCAL POLYSACCHARIDE VACCINE;
   INFLUENZA VACCINATION; BORDETELLA-PERTUSSIS; UNITED-STATES; HEPATITIS-A;
   IMMUNOGENICITY; DISEASE; PREDICTORS; CONJUGATE
AB Objectives: We evaluate safety of routine vaccination among adults infected with human immunodeficiency virus (HIV) in five healthcare organizations in the United States.
   Methods: We conducted a retrospective cohort study of HIV-infected adults who received inactivated influenza vaccines, hepatitis B vaccines, pneumococcal vaccines, or tetanus, diphtheria, and acellular pertussis vaccines between 2002 and 2013. We conducted self-controlled case series analysis to estimate the relative risk (RR) for 11 pre-specified adverse events (AEs) requiring medical attention.
   Results: Among 20,417 HIV-infected adults (90.2% male), a total of 137,674 vaccine doses were administered. Based on ICD-9 codes, we detected an increased risk of cellulitis and infection (RR: 1.18, 95% CI: 1.03-1.35) among all patients, and an increased risk of stroke/cerebrovascular diseases among patients with an HIV viral load >10,000 copies/ml (adjusted RR: 3.94, 95% CI: 1.32-11.72). Further analyses on chart confirmed cases of stroke/cerebrovascular diseases indicated no statistically significant increased risk (adjusted RR: 1.72, 95% CI: 0.41-7.24). There was no evidence of increased risk for other AEs following routine vaccination in HIV-infected adults.
   Conclusions: Routinely administered vaccines are generally safe for HIV-infected adults. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hechter, Rulin C.; Qian, Lei; Tartof, Sara Y.; Sy, Lina S.; Mercado, Cheryl; Jacobsen, Steven J.] Kaiser Permanente Southern Calif, Pasadena, CA 91101 USA.
   [Klein, Nicola P.] Kaiser Permanente Northern Calif, Walnut Creek, CA USA.
   [Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA.
   [Naleway, Allison] Kaiser Permanente Northwest, Washington, DC USA.
   [McLean, Huong O.] Marshfield Clin Res Inst, Marshfield, WI USA.
RP Hechter, RC (reprint author), Kaiser Permanante Southern Calif, Dept Res & Evaluat, 100 S Los Robles,2nd Floor, Pasadena, CA 91101 USA.
EM Rulin.C.Hechter@kp.org; Lei.X.Qian@kp.org; Sara.Y.Tartof@kp.org;
   Lina.S.Sy@kp.org; Klein@kp.org; eiw8@cdc.gov; Cheryl.M.Carlson@kp.org;
   Allison.Naleway@kpchr.org; mclean.huong@marshfieldresearch.org;
   Steven.J.Jacobsen@kp.org
OI Jacobsen, Steven/0000-0002-8174-8533; Hechter, Rulin/0000-0001-8684-6506
FU Vaccine Safety Datalink [200-2012-53580]; Centers for Disease Control
   and Prevention (CDC)United States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA
FX This study was funded through the Vaccine Safety Datalink under contract
   200-2012-53580 from the Centers for Disease Control and Prevention
   (CDC). The sponsor reviewed and approved the manuscript and approved
   submission of the manuscript for publication.
CR Abzug MJ, 2006, PEDIATR INFECT DIS J, V25, P920, DOI 10.1097/01.inf.0000237830.33228.c3
   Bailey CL, 2008, INT J INFECT DIS, V12, pE77, DOI 10.1016/j.ijid.2008.05.1226
   Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816
   Beyer WEP, 2011, VACCINE, V29, P5785, DOI 10.1016/j.vaccine.2011.05.040
   CDC, 2014, REC AD IMM SCHED US
   COLEBUNDERS R, 1994, EUR J CLIN MICROBIOL, V13, P313, DOI 10.1007/BF01974608
   DOEBBELING BN, 1990, J INFECT DIS, V161, P1296, DOI 10.1093/infdis/161.6.1296
   Durham MD, 2011, PREV MED, V53, P89, DOI 10.1016/j.ypmed.2011.04.015
   Fine AD, 2001, CLIN INFECT DIS, V32, P1784, DOI 10.1086/320747
   Flynn PM, 2012, J INFECT DIS, V206, P421, DOI 10.1093/infdis/jis360
   Gallagher KM, 2007, J INFECT DIS, V196, P339, DOI 10.1086/519165
   Hakim H, 2012, VACCINE, V30, P879, DOI 10.1016/j.vaccine.2011.11.105
   Harrison N, 2017, HIV MED, V18, P500, DOI 10.1111/hiv.12483
   Higgs R, 2012, MUCOSAL IMMUNOL, V5, P485, DOI 10.1038/mi.2012.54
   Ho A, 2017, CLIN INFECT DIS
   Ho YL, 2013, VACCINE, V31, P4047, DOI 10.1016/j.vaccine.2013.04.065
   Horster S, 2010, J INFECTION, V61, P484, DOI 10.1016/j.jinf.2010.09.030
   KAPLAN JE, 2009, MMWR RECOMM REP, V58, pCE201
   Kaplan Jonathan E., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Koskan AM, 2018, LGBT HEALTH, V5, P145, DOI 10.1089/lgbt.2017.0109
   Marcus JL, 2016, AIDS PATIENT CARE ST, V30, P463, DOI 10.1089/apc.2016.0165
   Meiring S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149104
   Radwan HM, 2000, CLIN INFECT DIS, V31, P604, DOI 10.1086/313985
   Sukumaran L, 2015, VACCINE, V33, P4446, DOI 10.1016/j.vaccine.2015.07.037
   Sullivan PS, 2000, AIDS, V14, P2781, DOI 10.1097/00002030-200012010-00018
   Tedaldi EM, 2004, CLIN INFECT DIS, V38, P1483
   Tempia S, 2017, INFLUENZA OTHER RESP
   Thio CL, 2002, LANCET, V360, P1921, DOI 10.1016/S0140-6736(02)11913-1
   Troy SB, 2016, JAIDS-J ACQ IMM DEF, V73, P282, DOI 10.1097/QAI.0000000000001037
   Tseng HF, 2013, CLIN INFECT DIS, V56, P315, DOI 10.1093/cid/cis871
   Valour F, 2014, VACCINE, V32, P4558, DOI 10.1016/j.vaccine.2014.06.015
   Vielemeyer O, 2004, J CLIN MICROBIOL, V42, P847, DOI 10.1128/JCM.42.2.847-849.2004
   von Elten KA, 2014, HUM VACC IMMUNOTHER, V10, P1767, DOI 10.4161/hv.28559
   Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302
   Yin Z, 2012, AIDS, V26, P87, DOI 10.1097/QAD.0b013e32834dcf27
NR 35
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3296
EP 3302
DI 10.1016/j.vaccine.2019.04.080
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400006
PM 31064675
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Awad, S
   Abdo, N
   Yusef, D
   Jawarneh, A
   Babaa, A
   Alwady, D
   Al-Bawayeh, H
   Kasrawi, I
   Amaireh, M
   Obeidat, M
   Amer, NB
   Alonze, S
AF Awad, Samah
   Abdo, Nour
   Yusef, Dawood
   Jawarneh, Afnan
   Babaa, Ahmad
   Alwady, Deya
   Al-Bawayeh, Haitham
   Kasrawi, Ismail
   Amaireh, Mohamad
   Obeidat, Motaz
   Amer, Nama Bany
   Alonze, Saad
TI Knowledge, attitudes and practices related to influenza illness and
   vaccination in children: Role of awareness campaigns in changing
   parents' attitudes toward influenza vaccination in Jordan
SO VACCINE
LA English
DT Article
DE Influenza; Influenza vaccine; Children; Jordan; Knowledge; Awareness
   campaign
ID SEASONAL INFLUENZA; EPIDEMIOLOGY; COVERAGE; US
AB Background: Influenza infection is associated with a significant health burden in children, especially in developing countries. The influenza vaccine is an important preventive strategy for flu illness. Aim of this study to assess knowledge, attitudes and practices (KAP) related to influenza illness and vaccination in children in the Jordanian population and to study the effect of awareness campaigns on changing the attitudes of parents toward vaccinating their children against influenza.
   Methods: A cross-sectional study was conducted among families visiting shopping malls and parks in November 2016. A questionnaire was administered via in-person interviews. Answers to KAP questions regarding influenza illness and vaccination were summed, with a total KAP score of 30. Facts about influenza illness and vaccination were explained to parents and provided in printed pamphlets.
   Results: There were 1241 respondents. 10.9% of participants had vaccinated their children during the last season 2015/2016. The mean KAP score (standard deviation) was 16.21 (4.61). People living in urban areas, with high monthly income >600 JD and healthcare workers had higher KAP scores than their counterparts. Compared to other sources of information about the influenza vaccine, health resources correlated most with vaccinating children. Awareness and educational pamphlets changed attitudes positively in 29% of parents who refused the influenza vaccine for their children.
   Conclusions: Awareness about influenza illness and vaccination is insufficient, and the coverage rate of influenza vaccination in children is low in the Jordanian population. Implementing public health policies is necessary to spread knowledge about influenza illness and vaccination and to promote the practice of receiving the influenza vaccine in children. Educational campaigns are helpful in changing the attitudes of parents toward vaccinating their children against the flu. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Awad, Samah; Yusef, Dawood] Jordan Univ Sci & Technol, Fac Med, Dept Pediat & Neonatol, POB 3030, Irbid 22110, Jordan.
   [Abdo, Nour] Jordan Univ Sci & Technol, Fac Med, Dept Publ Hlth & Community Med, POB 3030, Irbid 22110, Jordan.
   [Jawarneh, Afnan; Babaa, Ahmad; Alwady, Deya; Al-Bawayeh, Haitham; Kasrawi, Ismail; Amaireh, Mohamad; Obeidat, Motaz; Alonze, Saad] Jordan Univ Sci & Technol, Fac Med, Irbid, Jordan.
RP Awad, S (reprint author), Jordan Univ Sci & Technol, Fac Med, Dept Pediat & Neonatol, POB 3030, Irbid 22110, Jordan.
EM smawad@just.edu.jo
CR Abu-rish EY, 2016, FAM PRACT, V33, P690, DOI 10.1093/fampra/cmw086
   Al-Abdallat M, 2016, INFLUENZA OTHER RESP, V10, P91, DOI 10.1111/irv.12354
   Alhammadi A, 2015, VACCINE, V33, P3821, DOI 10.1016/j.vaccine.2015.06.082
   Assaf AM, 2016, VIRAL IMMUNOL, V29, P516, DOI 10.1089/vim.2015.0135
   Caini S, 2018, INFLUENZA OTHER RESP, V12, P344, DOI 10.1111/irv.12544
   Daley MF, 2005, ARCH PEDIAT ADOL MED, V159, P986, DOI 10.1001/archpedi.159.10.986
   Endrich MM, 2009, VACCINE, V27, P4018, DOI 10.1016/j.vaccine.2009.04.029
   Ferdinands JM, 2014, J INFECT DIS, V210, P674, DOI 10.1093/infdis/jiu185
   Gargano LM, 2015, HUM VACC IMMUNOTHER, V11, P1641, DOI 10.1080/21645515.2015.1038445
   Grohskopf LA, 2017, AM J TRANSPLANT, V17, P2970, DOI 10.1111/ajt.14511
   Imburgia TM, 2017, VACCINE, V35, P2338, DOI 10.1016/j.vaccine.2017.03.060
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   Jefferson T, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004879.pub5
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   Lee SI, 2012, INFLUENZA RES TREAT, V2012, DOI [10.1155/2012/753164753164, DOI 10.1155/2012/753164753164]
   Masadeh MM, 2014, HUM VACC IMMUNOTHER, V10, P1762, DOI 10.4161/hv.28608
   Meharry PM, 2014, MATERN CHILD HLTH J, V18, P1205, DOI 10.1007/s10995-013-1352-4
   Neuzil KM, 2002, ARCH PEDIAT ADOL MED, V156, P986, DOI 10.1001/archpedi.156.10.986
   Newcombe J, 2014, VACCINE, V32, P6364, DOI 10.1016/j.vaccine.2014.06.044
   Newcombe JP, 2017, J PAEDIATR CHILD H, V53, P711, DOI 10.1111/jpc.13406
   Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Shono A, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0821-3
   WHO, 2015, GLOB ACT PLAN INFL V
   Wong VWY, 2016, VACCINE, V34, P20, DOI 10.1016/j.vaccine.2015.11.020
   Zhe W, 2010, IEEE IMAGE PROC, P2005, DOI 10.1109/ICIP.2010.5649090
NR 27
TC 1
Z9 1
U1 4
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3303
EP 3309
DI 10.1016/j.vaccine.2019.04.083
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400007
PM 31072734
DA 2020-05-12
ER

PT J
AU Mascaro, V
   Pileggi, C
   Curra, A
   Bianco, A
   Pavia, M
AF Mascaro, Valentina
   Pileggi, Claudia
   Curra, Angela
   Bianco, Aida
   Pavia, Maria
TI HPV vaccination coverage and willingness to be vaccinated among 18-30
   year-old students in Italy
SO VACCINE
LA English
DT Article
DE Papillomavirus; Vaccination; Attitudes; Prevention
ID HUMAN-PAPILLOMAVIRUS VACCINATION; ADVISORY-COMMITTEE; SEXUAL-BEHAVIOR;
   YOUNG-WOMEN; KNOWLEDGE; ATTITUDES; ACCEPTABILITY; PERCEPTIONS; PARENTS;
   CANCER
AB Objectives: In Italy, free HPV vaccination has been offered to 12 years-old girls since 2007, while for males only since 2015. The aims of our study were: to measure HPV vaccination coverage among young women; to assess willingness to receive HPV vaccination among unvaccinated males and females; to evaluate the association of coverage and attitudes with knowledge regarding HPV and with sexual behavior.
   Methods: A cross-sectional survey was conducted in an Italian region among 18-30 year-old students attending medical and healthcare professions schools. Participants completed a self-administered questionnaire exploring knowledge, attitudes and behaviors related to HPV infections, sexually transmitted diseases and their prevention. Information on vaccination status was also verified for each student through the immunization records provided by the participants during the occupational medical visit.
   Results: 517 students were enrolled, with a 97% response rate. Of female participants, 40.5% had received at least one dose of HPV vaccine, while among unvaccinated participants, 60.5% stated their willingness to be vaccinated. A negative attitude towards HPV vaccination was associated with an older age, whereas a correct knowledge that both sexes are at risk of HPV infection, and the knowledge that vaccine protects against cervical cancer were confirmed to be associated to a willingness to receive HPV vaccination.
   Conclusions: Our results showed low HPV vaccination coverage among young women and high reported willingness to receive vaccination among both sexes. More active education on the link between HPV and all related cancers could be beneficial to help prevent significant burden of the HPV-related diseases. (C) 2019 Published by Elsevier Ltd.
C1 [Mascaro, Valentina; Pileggi, Claudia; Curra, Angela; Bianco, Aida; Pavia, Maria] Univ Catanzaro Magna Graecia, Med Sch, Dept Hlth Sci, Via T Campanella 115, Catanzaro, Italy.
RP Pavia, M (reprint author), Univ Catanzaro Magna Graecia, Med Sch, Dept Hlth Sci, Via T Campanella 115, Catanzaro, Italy.
EM valentina.mascaro@unicz.it; claudiapileggi@unicz.it;
   angelacurra@libero.it; a.bianco@unicz.it; pavia@unicz.it
CR Aujo JC, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-155
   Barnard M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182266
   Bianco A, 2014, HUM VACC IMMUNOTHER, V10, P2536, DOI 10.4161/21645515.2014.969614
   Black LL, 2009, VACCINE, V27, P1668, DOI 10.1016/j.vaccine.2009.01.035
   Blodt S, 2012, EUR J PUBLIC HEALTH, V22, P808, DOI 10.1093/eurpub/ckr188
   Center for Disease Control and Prevention, TYP FUNG DIS VAG CAN
   Centers for Disease Control and Prevention, 2008, MMWR, V57
   Centers for Disease Control and Prevention, MAN CANC AR LINK HPV
   Centers for Disease Control and Prevention (CDC), GEN HPV FACT SHEET
   Dahlstrom LA, 2010, INT J CANCER, V126, P500, DOI 10.1002/ijc.24712
   Davlin SL, 2015, J PEDIATR ADOL GYNEC, V28, P19, DOI 10.1016/j.jpag.2014.01.109
   De Groot AS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171631
   Di Giuseppe G, 2008, BRIT J CANCER, V99, P225, DOI 10.1038/sj.bjc.6604454
   Donadiki EM, 2014, PUBLIC HEALTH, V128, P268, DOI 10.1016/j.puhe.2013.12.004
   Dunne EF, 2014, MMWR-MORBID MORTAL W, V63, P69
   Einstein MH, 2009, HUM VACCINES, V5, P705, DOI 10.4161/hv.5.10.9518
   Fontenot HB, 2014, J AM COLL HEALTH, V62, P186, DOI 10.1080/07448481.2013.872649
   Forster AS, 2012, VACCINE, V30, P4939, DOI 10.1016/j.vaccine.2012.05.053
   HOSMER DW, 2000, WILEY PS TX, P1
   Italian Ministry of Health, 2014, AGG SCHED VACC ANT V
   Italian Ministry of Health, NAT IMM PROGR 2017 2, P55
   Italian Ministry of Health, COP VACC 31 12 2017
   LaJoie AS, 2018, PAPILLOMAVIRUS RES, V5, P114, DOI 10.1016/j.pvr.2018.03.007
   Lenselink CH, 2008, PUBLIC HEALTH, V122, P1295, DOI 10.1016/j.puhe.2008.02.010
   Lewandowski B, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012846
   Liddon N, 2010, J ADOLESCENT HEALTH, V46, P113, DOI 10.1016/j.jadohealth.2009.11.199
   Markowitz LE, 2014, MMWR RECOMM REP, V63, P1
   Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5
   Mullins TLK, 2016, VACCINE, V34, P4040, DOI 10.1016/j.vaccine.2016.06.026
   Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7
   Nadarzynski T, 2014, SEX TRANSM INFECT, V90, P515, DOI 10.1136/sextrans-2013-051357
   Napolitano F, 2016, HUM VACC IMMUNOTHER, V12, P1504, DOI 10.1080/21645515.2016.1156271
   Niccolai LM, 2013, CANCER EPIDEM BIOMAR, V22, P1446, DOI 10.1158/1055-9965.EPI-13-0272
   Nickel Brooke, 2017, Prev Med Rep, V8, P169, DOI 10.1016/j.pmedr.2017.10.005
   Rysavy MB, 2014, J PEDIATR ADOL GYNEC, V27, P67, DOI 10.1016/j.jpag.2013.08.009
   Saslow D, 2016, CA-CANCER J CLIN, V66, P375, DOI 10.3322/caac.21355
   Schiller JT, 2016, EBIOMEDICINE, V10, P5, DOI 10.1016/j.ebiom.2016.08.005
   Stephens Dionne P, 2016, Hisp Health Care Int, V14, P184
   Suryadevara M, 2016, HUM VACC IMMUNOTHER, V12, P1491, DOI 10.1080/21645515.2015.1123359
   Thompson EL, 2016, J HEALTH PSYCHOL, DOI [10.1177/1359105316672924.1359105316672924, DOI 10.1177/1359105316672924.1359105316672924]
   Thompson EL, 2017, J ADOLESCENT HEALTH, V61, P288, DOI 10.1016/j.jadohealth.2017.05.015
   Wisk LE, 2014, SEX TRANSM DIS, V41, P117, DOI 10.1097/OLQ.0000000000000086
   Wright TC, 2008, GYNECOL ONCOL, V109, pS40, DOI 10.1016/j.ygyno.2008.02.002
NR 43
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3310
EP 3316
DI 10.1016/j.vaccine.2019.04.081
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400008
PM 31064676
DA 2020-05-12
ER

PT J
AU Tretyakova, I
   Tibbens, A
   Jokinen, JD
   Johnson, DM
   Lukashevich, IS
   Pushko, P
AF Tretyakova, Irina
   Tibbens, Alexander
   Jokinen, Jenny D.
   Johnson, Dylan M.
   Lukashevich, Igor S.
   Pushko, Peter
TI Novel DNA-launched Venezuelan equine encephalitis virus vaccine with
   rearranged genome
SO VACCINE
LA English
DT Article
DE DNA vaccine; Live-attenuated vaccine; iDNA infectious clone; Venezuelan
   equine encephalitis virus; VEEV; VEE; TC83; TC-83
ID LIVE-ATTENUATED VACCINES; NEUTRALIZING ANTIBODIES; IN-VITRO; INITIATES
   REPLICATION; AEROSOL CHALLENGE; IMMUNE-RESPONSE; ENCEPHALOMYELITIS;
   IMMUNOGENICITY; EFFICACY; IMMUNIZATION
AB Novel live-attenuated V4020 vaccine was prepared for Venezuelan equine encephalitis virus (VEEV), an alphavirus from the Togaviridae family. The genome of V4020 virus was rearranged, with the capsid gene expressed using a duplicate subgenomic promoter downstream from the glycoprotein genes. V4020 also included both attenuating mutations from the TC83 VEEV vaccine secured by mutagenesis to prevent reversion mutations. The full-length infectious RNA of V4020 vaccine virus was expressed from pMG4020 plasmid downstream from the CMV promoter and launched replication of live-attenuated V4020 in vitro or in vivo. BALB/c mice vaccinated with a single dose of V4020 virus or with pMG4020 plasmid had no adverse reactions to vaccinations and developed high titers of neutralizing antibodies. After challenge with the wild type VEEV, vaccinated mice survived with no morbidity, while all unvaccinated controls succumbed to lethal infection. Intracranial injections in mice showed attenuated replication of V4020 vaccine virus as compared to the TC83. We conclude that V4020 vaccine has safety advantage over TC83, while provides equivalent protection in a mouse VEEV challenge model. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tretyakova, Irina; Tibbens, Alexander; Pushko, Peter] Medigen Inc, 8420 Gas House Pike,Suite S, Frederick, MD 21701 USA.
   [Jokinen, Jenny D.; Johnson, Dylan M.; Lukashevich, Igor S.] Univ Louisville, 505 S Hancock St, Louisville, KY 40202 USA.
RP Pushko, P (reprint author), Medigen Inc, 8420 Gas House Pike,Suite S, Frederick, MD 21701 USA.
EM ppushko@medigen-usa.com
RI Johnson, Dylan MacGregor/AAI-9809-2020
OI Johnson, Dylan MacGregor/0000-0002-3630-0588
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI094863]
FX We sincerely thank Tek Lamichhane, Rachel Gannon, Elena Klyushnenkova,
   and Noble Life Sciences staff for contributions to this study. The
   authors declare that they have no conflicts of interest. IT, AT and PP
   are the full-time Medigen employees and PP serves as director at
   Medigen. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the funding agency.
   Research reported in this publication was supported by the National
   Institute of Allergy and Infectious Diseases of the National Institutes
   of Health under Award Number AI094863.
CR BERGE TO, 1961, J IMMUNOL, V87, P509
   BERGE TO, 1961, AM J HYG, V73, P209, DOI 10.1093/oxfordjournals.aje.a120178
   Brault AC, 2004, P NATL ACAD SCI USA, V101, P11344, DOI 10.1073/pnas.0402905101
   Coffey LL, 2011, P NATL ACAD SCI USA, V108, P16038, DOI 10.1073/pnas.1111650108
   DAVIS NL, 1995, VIROLOGY, V212, P102, DOI 10.1006/viro.1995.1458
   DAVIS NL, 1989, VIROLOGY, V171, P189, DOI 10.1016/0042-6822(89)90526-6
   Dupuy LC, 2011, CLIN VACCINE IMMUNOL, V18, P707, DOI 10.1128/CVI.00030-11
   Dupuy LC, 2010, VACCINE, V28, P7345, DOI 10.1016/j.vaccine.2010.09.005
   Erasmus JH, 2018, J VIROL, V92, DOI 10.1128/JVI.01274-17
   Erwin-Cohen RA, 2012, HUM VACC IMMUNOTHER, V8, P1053, DOI 10.4161/hv.20300
   Fine DL, 2007, VACCINE, V25, P1868, DOI 10.1016/j.vaccine.2006.10.030
   Fine DL, 2010, J VIROL METHODS, V163, P424, DOI 10.1016/j.jviromet.2009.11.006
   Flanagan EB, 2003, J VIROL, V77, P5740, DOI 10.1128/JVI.77.10.5740-5748.2003
   Go YY, 2014, CLIN EXP VACCINE RES, V3, P58, DOI 10.7774/cevr.2014.3.1.58
   Grabenstein JD, 2006, EPIDEMIOL REV, V28, P3, DOI 10.1093/epirev/mxj003
   Hall RA, 2003, P NATL ACAD SCI USA, V100, P10460, DOI 10.1073/pnas.1834270100
   Hodgson LA, 1999, VACCINE, V17, P1151, DOI 10.1016/S0264-410X(98)00335-1
   Hoke Charles H Jr, 2005, Mil Med, V170, P92
   Kendra JA, 2017, J VIROL, V91, DOI 10.1128/JVI.01766-16
   Kenney JL, 2011, VACCINE, V29, P2230, DOI 10.1016/j.vaccine.2011.01.055
   KINNEY RM, 1993, J VIROL, V67, P1269, DOI 10.1128/JVI.67.3.1269-1277.1993
   Kitchen LW, 2007, VACCINE, V25, P7017, DOI 10.1016/j.vaccine.2007.07.030
   Martin SS, 2010, VACCINE, V28, P3143, DOI 10.1016/j.vaccine.2010.02.056
   Martin SS, 2010, VACCINE, V28, P1031, DOI 10.1016/j.vaccine.2009.10.126
   Nickols B, 2017, VIROLOGY, V512, P66, DOI 10.1016/j.virol.2017.09.005
   Paessler S, 2006, J VIROL, V80, P2784, DOI 10.1128/JVI.80.6.2784-2796.2006
   Paessler S, 2003, J VIROL, V77, P9278, DOI 10.1128/JVI.77.17.9278-9286.2003
   Paessler S, 2009, VACCINE, V27, pD80, DOI 10.1016/j.vaccine.2009.07.095
   Phillpotts RJ, 1999, VACCINE, V17, P982, DOI 10.1016/S0264-410X(98)00315-6
   Pittman PR, 1996, VACCINE, V14, P337, DOI 10.1016/0264-410X(95)00168-Z
   Pratt WD, 2003, VACCINE, V21, P3854, DOI 10.1016/S0264-410X(03)00328-1
   Pushko P, 2001, J VIROL, V75, P11677, DOI 10.1128/JVI.75.23.11677-11685.2001
   Pushko P, 2001, U.S. Patent, Patent No. 6296854
   Pushko P, 2016, EXPERT REV VACCINES, V15, P1223, DOI 10.1080/14760584.2016.1175943
   RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391
   Rossi SL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003797
   Rouxel RN, 2016, J VIROL, V90, P10857, DOI 10.1128/JVI.01024-16
   SCHERER WF, 1987, AM J TROP MED HYG, V36, P194, DOI 10.4269/ajtmh.1987.36.194
   Sharma A, 2011, VACCINE, V29, P953, DOI 10.1016/j.vaccine.2010.11.033
   SMART D L, 1975, Journal of Wildlife Diseases, V11, P195
   Steel JJ, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-356
   Steele KE, 1998, VET PATHOL, V35, P386, DOI 10.1177/030098589803500508
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   Surman SR, 2007, J VIROL METHODS, V141, P30, DOI 10.1016/j.jviromet.2006.11.024
   Tretyakova I, 2014, VIROLOGY, V468, P28, DOI 10.1016/j.virol.2014.07.050
   Tretyakova I, 2014, J INFECT DIS, V209, P1882, DOI 10.1093/infdis/jiu114
   Tretyakova I, 2013, VACCINE, V31, P1019, DOI 10.1016/j.vaccine.2012.12.050
   Vaughn JA, 2011, AM FAM PHYSICIAN, V84, P1015
   Weaver SC, 2004, ANNU REV ENTOMOL, V49, P141, DOI 10.1146/annurev.ento.49.061802.123422
   Weaver SC, 1999, AM J TROP MED HYG, V60, P441, DOI 10.4269/ajtmh.1999.60.441
   WEAVER SC, 1993, VIROLOGY, V195, P700, DOI 10.1006/viro.1993.1421
NR 51
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3317
EP 3325
DI 10.1016/j.vaccine.2019.04.072
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400009
PM 31072736
DA 2020-05-12
ER

PT J
AU Feldman, RA
   Fuhr, R
   Smolenov, I
   Ribeiro, A
   Panther, L
   Watson, M
   Senn, JJ
   Smith, M
   Almarsson, O
   Pujar, HS
   Laska, ME
   Thompson, J
   Zaks, T
   Ciaramella, G
AF A Feldman, Robert
   Fuhr, Rainard
   Smolenov, Igor
   Ribeiro, Amilcar (Mick)
   Panther, Lori
   Watson, Mike
   Senn, Joseph J.
   Smith, Mike
   Almarsson, Orn
   Pujar, Hari S.
   Laska, Michael E.
   Thompson, James
   Zaks, Tal
   Ciaramella, Giuseppe
TI mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic
   potential are immunogenic and well tolerated in healthy adults in phase
   1 randomized clinical trials
SO VACCINE
LA English
DT Article
DE mRNA; Vaccines; Pandemic influenza; Safety; lmmunogenicity
ID HUMAN INFECTION; H1N1 INFLUENZA; A(H7N9) VIRUS; OPEN-LABEL; SAFETY;
   PREPAREDNESS
AB Background: We evaluated safety and immunogenicity of the first mRNA vaccines against potentially pandemic avian H1ON8 and H7N9 influenza viruses.
   Methods: Two randomized, placebo-controlled, double-blind, phase 1 clinical trials enrolled participants between December 2015 and August 2017 at single centers in Germany (H1ON8) and USA (H7N9). Healthy adults (ages 18-64 years for H1ON8 study; 18-49 years for H7N9 study) participated. Participants received vaccine or placebo in a 2-dose vaccination series 3 weeks apart. H1ON8 intramuscular (IM) dose levels of 25, 50, 75, 100, and 400 a and intradermal dose levels of 25 and 50 mu g were evaluated. H7N9 IM 10-, 25-, and 50-pg dose levels were evaluated; 2-dose series 6 months apart was also evaluated. Primary endpoints were safety (adverse events) and tolerability. Secondary immunogenicity outcomes included humoral (hemagglutination inhibition [HAI], microneutralization [MN] assays) and cell-mediated responses (ELISPOT assay).
   Results: H10N8 and H7N9 mRNA IM vaccines demonstrated favorable safety and reactogenicity profiles. No vaccine-related serious adverse event was reported. For H1ON8 (N = 201), 100-mu g IM dose induced HAI titers >= 1:40 in 100% and MN titers >= 1:20 in 87.0% of participants. The 25-mu g intradermal dose induced HAI titers >= 1:40 in 64.7% of participants compared to 34.5% of participants receiving the IM dose. For H7N9 (N = 156), IM doses of 10, 25, and 50 mu g achieved HAI titers >= 1:40 in 36.0%, 96.3%, and 89.7% of participants, respectively. MN titers >= 1:20 were achieved by 100% in the 10- and 25-mu g groups and 96.6% in the 50-mu g group. Seroconversion rates were 78.3% (HAI) and 87.0% (MN) for H1ON8 (100 mu g IM) and 96.3% (HAI) and 100% (MN) in H7N9 (50 mu g). Significant cell-mediated responses were not detected in either study.
   Conclusions: The first mRNA vaccines against H1ON8 and H7N9 influenza viruses were well tolerated and elicited robust humoral immune responses. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [A Feldman, Robert] Miami Res Associates, 6280 Sunset Dr,Suite 600, So Miami, FL 33143 USA.
   [Fuhr, Rainard] PAREXEL Int GmbH Klinikum Westend, House 18,Spandauer Damm 130, D-14050 Berlin, Germany.
   [Smolenov, Igor; Ribeiro, Amilcar (Mick); Panther, Lori; Watson, Mike; Senn, Joseph J.; Smith, Mike; Almarsson, Orn; Pujar, Hari S.; Laska, Michael E.; Thompson, James; Zaks, Tal; Ciaramella, Giuseppe] Moderna, 500 Technol Sq, Cambridge, MA 02139 USA.
RP Watson, M (reprint author), Moderna, 500 Technol Sq, Cambridge, MA 02139 USA.
EM Rainard.Fuhr@parexel.com; Lori.Panther@modernatx.com;
   mike.watson@modernatx.com; Joe.senn@modernatx.com;
   Mike.smith@modernatx.com; Orn.almarsson@modernatx.com;
   Hari.pujar@modernatx.com; James.thompson@modematx.com;
   Tal.zaks@modernatx.com
RI Smolenov, Igor/N-8950-2015
OI Smolenov, Igor/0000-0002-7075-9827; Watson, Michael/0000-0002-5316-5373
FU Moderna
FX Formulation support was provided by Luis Brito and Kimberly Hassett.
   Statistical support was provided by Strategistat, SPRL, Belgium. Medical
   writing support was provided by Stephanie Eide of BioBridges, Wellesley
   Hills, MA and Julia R. Gage of Gage Medical Writing, LLC, Moorpark, CA
   and was funded by Moderna.
CR Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P460
   [Anonymous], 2014, Wkly Epidemiol Rec, V89, P105
   Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035
   Borse RH, 2013, EMERG INFECT DIS, V19, P439, DOI 10.3201/eid1903.120394
   Cohen J, 2017, SCIENCE, V357, P1222, DOI 10.1126/science.357.6357.1222
   Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18
   Cox RJ, 2013, HUM VACC IMMUNOTHER, V9, P405, DOI 10.4161/hv.22908
   De Groot AS, 2013, HUM VACC IMMUNOTHER, V9, P950, DOI 10.4161/hv.24939
   Della Cioppa G, 2014, HUM VACC IMMUNOTHER, V10, P1701, DOI 10.4161/hv.28618
   *EUR AG EV MED PRO, NOT GUID HARM REQ IN
   Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802
   Gao RB, 2013, NEW ENGL J MED, V368, P1888, DOI 10.1056/NEJMoa1304459
   Greenberg ME, 2009, NEW ENGL J MED, V361, P2405, DOI 10.1056/NEJMoa0907413
   Guo L, 2014, EMERG INFECT DIS, V20, P192, DOI 10.3201/eid2002.131094
   Hannoun C, 2004, VIRUS RES, V103, P133, DOI 10.1016/j.virusres.2004.02.025
   HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610
   Hu ZL, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01898
   Jackson LA, 2015, JAMA-J AM MED ASSOC, V314, P237, DOI 10.1001/jama.2015.7916
   Kallen KJ, 2013, HUM VACC IMMUNOTHER, V9, P2263, DOI 10.4161/hv.25181
   Kamal RP, 2017, J VIROL, V91, DOI 10.1128/JVI.01202-17
   Ke CW, 2017, EMERG INFECT DIS, V23, P1332, DOI 10.3201/eid2308.170600
   Larson RC, 2012, VALUE HEALTH, V15, P158, DOI 10.1016/j.jval.2011.07.014
   Ledgerwood JE, 2011, LANCET INFECT DIS, V11, P916, DOI 10.1016/S1473-3099(11)70240-7
   Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006
   Lindgren G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01539
   Moa AM, 2016, VACCINE, V34, P4092, DOI 10.1016/j.vaccine.2016.06.064
   Pascua PNQ, 2014, CLIN EXP VACCINE RES, V3, P140, DOI 10.7774/cevr.2014.3.2.140
   Reisinger KS, 2009, CLIN VACCINE IMMUNOL, V16, P1810, DOI 10.1128/CVI.00207-09
   Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017
   Roman F, 2010, CLIN INFECT DIS, V51, P668, DOI 10.1086/655830
   *US FDA, GUID IND CLIN DAT NE
   US Food and Drug Administration, GUID IND TOX GRAD SC
   US Food and Drug Administration Center for Biologics Evaluation and Research., GUID IND EST MAX SAF
   Vachieri SG, 2014, NATURE, V511, P475, DOI 10.1038/nature13443
   WEBSTER R, WHO MANUAL ANIMAL IN
   Weir JP, 2016, INFLUENZA OTHER RESP, V10, P354, DOI 10.1111/irv.12383
   Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682
   Yen C, 2015, LANCET INFECT DIS, V15, P340, DOI 10.1016/S1473-3099(14)70999-5
NR 39
TC 11
Z9 11
U1 3
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3326
EP 3334
DI 10.1016/j.vaccine.2019.04.074
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400010
PM 31079849
OA Other Gold
DA 2020-05-12
ER

PT J
AU Xie, LL
   Zai, JJ
   Yi, K
   Li, YM
AF Xie, Lilan
   Zai, Junjie
   Yi, Kai
   Li, Yaoming
TI Intranasal immunization with recombinant Vaccinia virus Tiantan
   harboring Zaire Ebola virus gp elicited systemic and mucosal
   neutralizing antibody in mice
SO VACCINE
LA English
DT Article
DE Vaccinia virus vector; Ebola virus; GP; Mucosal slgA; Neutralization
ID PROTECTIVE IMMUNITY; RHESUS-MONKEYS; ADENOVIRUS; INFECTIONS; PROTEIN;
   ROUTE; HIV-1
AB Accumulating literature revealed that human mucosa was likely one of the important routes for EBOV attachment and further infection. Therefore inducing effective mucosal immune responses play key role in preventing the virus infection. Vaccinia virus Tiantan strain (VV) was a remarkably attenuated poxvirus, which has been broadly exploited as a multifunctional vector during the development of genetically recombinant vaccine and cancer therapeutic agent. In this study, we generated a recombinant VV harboring EBOV gp (VV-(Egp)) that was used to immunize mice, followed by assessing immune responses, particularly the mucosal immune responses to EBOV GP. A stable and further attenuated VV-(Egp) in which the VV ha gene was replaced with the EBOV gp, was generated. In BALB/c mouse model, intranasal immunization with VV-(Egp) elicited robust humoral and cellular immune responses, including high level of neutralizing serum IgG and IgA against EBOV, and a large amount of GP-specific IFN-gamma secreting lymphocytes. More importantly, EBOV GP-specific neutralizing secreted IgA (sIgA) in nasal wash and both sIgA and IgG in vaginal wash were induced. In summary, immunization with a safe and stable recombinant W carrying a single EBOV gp conferred robust systemic immune response and mucosal neutralizing antibodies, indicating that the recombinant virus could be utilized as a viral vector for plug-and-play universal platform in mucosal vaccine development. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xie, Lilan; Zai, Junjie; Yi, Kai; Li, Yaoming] Wuhan Univ Bioengn, Hubei Engn Res Ctr Viral Vector, Appl Biotechnol Res Ctr, Wuhan 430400, Hubei, Peoples R China.
RP Li, YM (reprint author), Wuhan Univ Bioengn, Coll Life Sci & Technol, Wuhan 430400, Hubei, Peoples R China.
EM limeming@webmail.hzau.edu.cn
FU Hubei Provincial Natural Science Foundation of ChinaNational Natural
   Science Foundation of China [2018CFB449]; High-level Scientific Research
   Foundation for the introduction of talent of Wuhan University of
   Bioengineering [2017KQ01]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [81202381]
FX We sincerely thank Dr. Cao at the Huazhong Agricultural University for
   editorial assistance. This work was supported by grants from Hubei
   Provincial Natural Science Foundation of China 2018CFB449, High-level
   Scientific Research Foundation for the introduction of talent of Wuhan
   University of Bioengineering (2017KQ01), and National Natural Science
   Foundation of China (81202381).
CR Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015
   Domi A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19041-y
   Ewer K, 2016, NEW ENGL J MED, V374, P1635, DOI 10.1056/NEJMoa1411627
   Fan XT, 2018, VACCINE, V36, P4354, DOI 10.1016/j.vaccine.2018.05.075
   Feldmann H, 2018, ANNU REV MICROBIOL, V72, P423, DOI 10.1146/annurev-micro-090817-062414
   Garcia-Arriaza J, 2017, J VIROL, V91, DOI 10.1128/JVI.02182-16
   Huttner A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj1701
   Jaax NK, 1996, ARCH PATHOL LAB MED, V120, P140
   JOHNSON E, 1995, INT J EXP PATHOL, V76, P227
   Khan IU, 2018, ANTIVIR RES, V159, P95, DOI 10.1016/j.antiviral.2018.10.001
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Li YM, 2009, J GENE MED, V11, P57, DOI 10.1002/jgm.1271
   Li ZL, 2011, P NATL ACAD SCI USA, V108, P4388, DOI 10.1073/pnas.1012861108
   Liu Q, 2015, AIDS, V29, P649, DOI 10.1097/QAD.0000000000000595
   Merens A, 2018, MED MALADIES INFECT, V48, P83, DOI 10.1016/j.medmal.2017.11.002
   Mittal SK, 2000, VACCINE, V19, P253, DOI 10.1016/S0264-410X(00)00170-5
   Patel A, 2007, J INFECT DIS, V196, pS413, DOI 10.1086/520603
   Pollara J, 2015, J VIROL, V89, P9952, DOI 10.1128/JVI.01560-15
   Qiu XG, 2011, CLIN IMMUNOL, V141, P218, DOI 10.1016/j.clim.2011.08.008
   Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216
   Sheng MM, 2014, SCI CHINA LIFE SCI, V57, P959, DOI 10.1007/s11427-014-4742-y
   Su QD, 2018, VACCINE, V36, P6053, DOI 10.1016/j.vaccine.2018.09.003
   Takada A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00034
   Xiao HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083274
   Yu J, 2018, ANTIVIR RES, V153, P49, DOI 10.1016/j.antiviral.2018.03.004
   Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024296
   Zurawski G, 2017, J VIROL, V91, DOI 10.1128/JVI.01596-16
NR 27
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3335
EP 3342
DI 10.1016/j.vaccine.2019.04.070
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400011
PM 31076161
DA 2020-05-12
ER

PT J
AU Kumar, A
   Gupta, VK
   Mandil, R
   Rahal, A
   Verma, AK
   Yadav, SK
AF Kumar, Amit
   Gupta, V. K.
   Mandil, Rajesh
   Rahal, Anu
   Verma, A. K.
   Yadav, S. K.
TI Interplay of oxidative stress and antioxidant bio markers in oil
   adjuvant Brucella melitensis vaccinated and challenged mice
SO VACCINE
LA English
DT Article
DE Oxidative stress; Immune response; Oil adjuvant; Brucella melitensis
ID DENDRITIC CELLS; ABORTUS; RECOGNITION; BIOMARKERS; INDUCTION; PROTEINS;
   CATALASE; TISSUE; DAMAGE; BLOOD
AB The intracellular nature of Brucella leads to rise in oxidative stress due to bacterial invasion, particularly at the site of predilection spleen and lymph nodes. The present study aimed to evaluate the erythrocytic and tissue specific oxidative stress responses induced during oil adjuvant killed Brucella melitensis vaccination. The results of the study clearly implicated a significant increase in level of catalase, and superoxide dismutase (SOD) activity and lipid peroxidation (LPG), and total protein content in erythrocytes after vaccination. The activity of glutathione-S-transferase (GST) was unaltered during the period of experiment. The catalase activity and GSH content was significantly increased in lung and spleen tissues. The tissues GST levels increased significantly in all tissues, while tissue SOD level increased significantly only in lung tissues. Thus, it can be inferred that oil adjuvant based Brucella vaccine induces negligible signs of inflammatory pathophysiology and supports the development of significant level of protection against virulent Brucella challenge. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kumar, Amit] Sardar Vallabhbhai Patel Univ Agr & Technol, Coll Biotechnol, Dept Immunol & Def Mech, Meerut 250110, Uttar Pradesh, India.
   [Gupta, V. K.] Indian Vet Res Inst, CADRAD, Izatnagar 243122, Uttar Pradesh, India.
   [Mandil, Rajesh] Sardar Vallabhbhai Patel Univ Agr & Technol, Coll Vet & Anim Sci, Dept Vet Pharmacol, Meerut 250110, Uttar Pradesh, India.
   [Rahal, Anu] Cent Inst Res Goats, Div Goat Hlth, Farha 281122, Mathura, India.
   [Verma, A. K.] Sardar Vallabhbhai Patel Univ Agr & Technol, Coll Vet & Anim Sci, Dept Vet Med, Meerut 250110, Uttar Pradesh, India.
   [Yadav, S. K.] DUVASU, Coll Vet & Anim Sci, Dept Vet Microbiol, Mathura 281001, India.
RP Kumar, A (reprint author), Sardar Vallabhbhai Patel Univ Agr & Technol, Coll Biotechnol, Dept Immunol & Def Mech, Meerut 250110, Uttar Pradesh, India.
EM balyan74@gmail.com
RI ; kumar, amit/B-6708-2014
OI Verma, Amit/0000-0002-8438-5002; kumar, amit/0000-0003-3767-4343
FU DUVASU, Mathura
FX The authors are thankful to Dean, College of Veterinary Sciences and
   Hon'ble Vice Chancellor, DUVASU, Mathura for providing financial support
   and facilities to conduct study. The adjuvant was a generous gift by
   Seppic, France.
CR Al-Khafaji W. S., 2012, Iraqi Journal of Veterinary Sciences, V26, P15
   ALLISON AC, 1991, MOL IMMUNOL, V28, P279, DOI 10.1016/0161-5890(91)90074-T
   Amit Kumar, 2013, Trends in Medical Research, V8, P32
   Angelini G, 2002, P NATL ACAD SCI USA, V99, P1491, DOI 10.1073/pnas.022630299
   Arenas GN, 2000, INFECT IMMUN, V68, P4255, DOI 10.1128/IAI.68.7.4255-4263.2000
   Baldi Pablo C, 2013, Recent Pat Antiinfect Drug Discov, V8, P18
   Bennett SJ, 2013, STUDIES ARTHRITIS JO, P33
   Bergmeyer H. U., 1983, METHOD ENZYMAT AN, Vthird, P273
   Blasco JM, 1997, PREV VET MED, V31, P275, DOI 10.1016/S0167-5877(96)01110-5
   BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672
   Celli J, 2003, J EXP MED, V198, P545, DOI 10.1084/jem.20030088
   Cheeseman KH, 1992, FREE RADICALS MED, P481
   Cochran W. G., 1989, STAT METHODS
   DESCOTES J, 1988, PHARMACOLOGY, V36, P134, DOI 10.1159/000138370
   Dorval J, 2003, TOXICOL APPL PHARM, V192, P191, DOI 10.1016/S0041-008X(03)00281-3
   Enright F. M., 1990, Animal brucellosis., P301
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   Jain R, 2011, VACCINE, V29, P8118, DOI 10.1016/j.vaccine.2011.08.029
   KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J
   Kaufmann SHE, 1991, SEMIN IMMUNOL, V3, P1
   King MR, 2006, J IMMUNOL, V176, P2765, DOI 10.4049/jimmunol.176.5.2765
   Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312
   Lawrence DA, 1996, J LEUKOCYTE BIOL, V60, P611
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Madesh M, 1998, INDIAN J BIOCHEM BIO, V35, P184
   Minas A, 2006, SMALL RUMINANT RES, V62, P101, DOI 10.1016/j.smallrumres.2005.07.031
   Mitra E, 2012, FOOD CHEM TOXICOL, V50, P1340, DOI 10.1016/j.fct.2012.01.048
   Moghaddam AE, 2011, J IMMUNOL, V187, P1626, DOI 10.4049/jimmunol.1003906
   MURRAY PJ, 1992, J BACTERIOL, V174, P4193, DOI 10.1128/JB.174.13.4193-4196.1992
   Nagy A., 2006, CSH PROTOC, V2006
   Naroeni A, 2001, INFECT IMMUN, V69, P486, DOI 10.1128/IAI.69.1.486-493.2001
   Office International des Epizooties (OIE), 2010, MAN STAND DIAGN TEST, P251
   Pappas G, 2006, LANCET INFECT DIS, V6, P91, DOI 10.1016/S1473-3099(06)70382-6
   Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P2387
   PRINS HK, 1969, BIOCH METHODS RED CE, P127
   Rahal Anu, 2014, Vet Med Int, V2014, P853627, DOI 10.1155/2014/853627
   Rahal A, 2014, BIOMED RES INT, DOI 10.1155/2014/761264
   RILEY LK, 1984, INFECT IMMUN, V46, P224, DOI 10.1128/IAI.46.1.224-230.1984
   Roop RM, 2004, MOL MICROBIOL, V52, P621, DOI 10.1111/j.1365-2958.2004.04017.x
   SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4
   SHAFIQURREHMAN, 1984, TOXICOL LETT, V21, P333, DOI 10.1016/0378-4274(84)90093-6
   Skugor S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-503
   SORG DA, 1964, P SOC EXP BIOL MED, V115, P1131, DOI 10.3181/00379727-115-29134
   Tkachenko H, 2014, FISH PHYSIOL BIOCHEM, V40, P1289, DOI 10.1007/s10695-014-9924-9
   Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744
   Ural MS, 2013, CHEMOSPHERE, V90, P2059, DOI 10.1016/j.chemosphere.2012.12.006
   Velisek J, 2011, AQUACULTURE, V310, P369, DOI 10.1016/j.aquaculture.2010.11.010
   WATERS RV, 1986, INFECT IMMUN, V51, P816, DOI 10.1128/IAI.51.3.816-825.1986
   YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5
   Yan H, 1997, BIOCHEM J, V328, P599, DOI 10.1042/bj3280599
   Yan ZH, 2010, J BIOL CHEM, V285, P41525, DOI 10.1074/jbc.M110.189944
   Young DB, 1990, STRESS PROTEINS BIOL, P131
   Zhang YT, 2004, BASIC CLIN PHARMACOL, V95, P53, DOI 10.1111/j.1742-7843.2004.950202.x
NR 53
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3343
EP 3351
DI 10.1016/j.vaccine.2019.04.060
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400012
PM 31064674
DA 2020-05-12
ER

PT J
AU Isturiz, RE
   Ramirez, J
   Self, WH
   Grijalva, CG
   Counselman, FL
   Volturo, G
   Ostrosky-Zeichner, L
   Peyrani, P
   Wunderink, RG
   Sherwin, R
   Overcashi, JS
   Oliva, SP
   File, T
   Wiemken, TL
   McLaughlin, JM
   Pride, MW
   Gray, S
   Alexander, R
   Ford, KD
   Jiang, Q
   Jodar, L
AF Isturiz, Raul E.
   Ramirez, Julio
   Self, Wesley H.
   Grijalva, Carlos G.
   Counselman, Francis L.
   Volturo, Gregory
   Ostrosky-Zeichner, Luis
   Peyrani, Paula
   Wunderink, Richard G.
   Sherwin, Robert
   Overcashi, J. Scott
   Oliva, Senen Pena
   File, Thomas
   Wiemken, Timothy L.
   McLaughlin, John M.
   Pride, Michael W.
   Gray, Sharon
   Alexander, Ronika
   Ford, Kimbal D.
   Jiang, Qin
   Jodar, Luis
TI Pneumococcal epidemiology among us adults hospitalized for
   community-acquired pneumonia
SO VACCINE
LA English
DT Article
DE Pneumonia; Streptococcus; Pneumococcus; Community
ID CONJUGATE VACCINE; UNITED-STATES; PCV7/PCV13 INTRODUCTION;
   POLYSACCHARIDE VACCINE; ADVISORY-COMMITTEE; YOUNG-CHILDREN; DISEASE;
   IMPACT; MENINGITIS; BURDEN
AB Background: Few studies have measured the burden of adult pneumococcal disease after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into the US infant vaccination schedule. Further, most data regarding pneumococcal serotypes are derived from invasive pneumococcal disease (IPD), which represents only a fraction of all adult pneumococcal disease burden. Understanding which pneumococcal serotypes cause pneumonia in adults is critical for informing current immunization policy. The objective of this study was to measure the proportion of radiographically-confirmed (CXR+) community-acquired pneumonia (CAP) caused by PCV13 serotypes in hospitalized US adults.
   Methods: This observational, prospective surveillance study recruited hospitalized adults aged >= 18 years from 21 acute care hospitals across 10 geographically-dispersed cities in the United States between October 2013 and September 2016. Clinical and demographic data were collected during hospitalization. Vital status was ascertained 30 days after enrollment. Pneumococcal serotypes were detected via culture from the respiratory tract and normally-sterile sites (including blood and pleural fluid). Additionally, a novel, Luminex-based serotype-specific urinary antigen detection (UAD) assay was used to detect serotypes included in PCV13.
   Results: Of 15,572 enrolled participants, 12,055 eligible patients with CXR+CAP were included in the final analysis population. Mean age was 64.1 years and 52.7% were aged >= 65 years. Common comorbidities included chronic obstructive pulmonary disease (43.0%) and diabetes mellitus (28.6%). PCV13 serotypes were detected in 552/12,055 (4.6%) of all patients and 265/6347 (4.2%) of those aged >65 years. Among patients aged 18-64 years PCV13 serotypes were detected in 3.8-5.3% of patients depending on their risk status.
   Conclusions: After implementation of a pneumococcal conjugate vaccination program in US children, and despite the herd protection observed in US adults, a persistent burden of PCV13-type CAP remains in this population. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Isturiz, Raul E.; Peyrani, Paula; McLaughlin, John M.; Gray, Sharon; Alexander, Ronika; Ford, Kimbal D.; Jiang, Qin; Jodar, Luis] Pfizer Inc, Collegeville, PA 19426 USA.
   [Ramirez, Julio; Oliva, Senen Pena; Wiemken, Timothy L.] St Louis Univ, Ctr Hlth Outcomes Res, St Louis, MO 63103 USA.
   [Self, Wesley H.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN USA.
   [Grijalva, Carlos G.] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN USA.
   [Counselman, Francis L.] Eastern Virginia Med Sch, Dept Emergency Med, Norfolk, VA 23501 USA.
   [Volturo, Gregory] Univ Massachusetts, Sch Med, Dept Emergency Med, Worcester, MA USA.
   [Ostrosky-Zeichner, Luis] McGovern Med Sch, Houston, TX USA.
   [Ostrosky-Zeichner, Luis] Mem Hermann Med Ctr, Houston, TX USA.
   [Wunderink, Richard G.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Sherwin, Robert] Wayne State Univ, Dept Emergency Med, Detroit, MI USA.
   [Overcashi, J. Scott] eStudysite Clin Res, Chula Vista, CA USA.
   [File, Thomas] Northeast Ohio Med Univ, Summa Hlth, Akron, OH USA.
   [Pride, Michael W.] Pfizer Inc, Pearl River, NY USA.
RP Isturiz, RE (reprint author), Pfizer Inc, Collegeville, PA 19426 USA.
OI Ramirez, Julio/0000-0001-7801-5374
FU Pfizer, Inc.Pfizer
FX This study was sponsored by Pfizer, Inc.
CR Alexander RM, 2017, JRI, V1, P35, DOI [10.18297/JRI/, DOI 10.18297/JRI/]
   Angoulvant F, 2014, CLIN INFECT DIS, V58, P918, DOI 10.1093/cid/ciu006
   [Anonymous], 1997, MMWR Recomm Rep, V46, P1
   [Anonymous], 2012, BINAXNOWA
   Bello S, 2014, CHEST, V146, P1029, DOI 10.1378/chest.13-2853
   Ben-Shimol S, 2016, VACCINE, V34, P4543, DOI 10.1016/j.vaccine.2016.07.038
   Bishop PA, 2018, HANDB RESOUR MIDDLE, P175
   Black CL, 2017, MMWR-MORBID MORTAL W, V66, P728, DOI 10.15585/mmwr.mm6627a4
   Curcio D, 2015, INT J INFECT DIS, V37, P30, DOI 10.1016/j.ijid.2015.05.003
   Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005
   El Bcheraoui C, 2018, JAMA-J AM MED ASSOC, V319, P1248, DOI 10.1001/jama.2018.2089
   File TM, 2010, POSTGRAD MED, V122, P130, DOI 10.3810/pgm.2010.03.2130
   File TM, 2004, AM J MED, V117, P39, DOI 10.1016/j.amjmed.2004.07.007
   Greenberg D, 2015, VACCINE, V33, P4623, DOI 10.1016/j.vaccine.2015.06.062
   Grijalva CG, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv135
   Harboe ZB, 2014, CLIN INFECT DIS, V59, P1066, DOI 10.1093/cid/ciu524
   Huang SS, 2011, VACCINE, V29, P3398, DOI 10.1016/j.vaccine.2011.02.088
   Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245
   Kyaw MH, 2005, J INFECT DIS, V192, P377, DOI 10.1086/431521
   Lee GM, 2014, J PEDIATR INFECT DIS, V3, P23, DOI 10.1093/jpids/pit057
   McLaughlin J, 2017, OPEN FORUM INFECT DI, V4, pS468, DOI [10.1093/ofid/ofx163.1197, DOI 10.1093/OFID/OFX163.1197]
   McLaughlin JM, 2019, HUM VACC IMMUNOTHER, V15, P584, DOI 10.1080/21645515.2018.1538611
   Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1
   Musher DM, 2014, NEW ENGL J MED, V371, P1619, DOI 10.1056/NEJMra1312885
   Musher DM, 2013, J INFECTION, V67, P11, DOI 10.1016/j.jinf.2013.03.003
   Pilishvili T, 2016, DIRECT INDIRECT IMPA
   Pride MW, 2012, CLIN VACCINE IMMUNOL, V19, P1131, DOI 10.1128/CVI.00064-12
   Pride MW, 2012, CLIN VACCINE IMMUNOL, DOI [10.1128/CV1.00064-12, DOI 10.1128/CV1.00064-12]
   Ramirez JA, 2017, CLIN INFECT DIS, V65, P1806, DOI 10.1093/cid/cix647
   Restrepo MI, 2008, CHEST, V133, P610, DOI 10.1378/chest.07-1456
   Roos KLTK, 2015, MENINGITIS ENCEPHALI
   Said MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060273
   Shea KM, 2014, INFECT DIS, V1, DOI [10.1093/ofid/ofu024, DOI 10.1093/OFID/OFU024]
   Sherwin RL GS, 2012, IN IDWEEK JOINT M ID
   Sherwin RL, 2013, J INFECT DIS, V208, P1813, DOI 10.1093/infdis/jit506
   Stockmann C, 2013, PEDIATRICS, V132, P421, DOI 10.1542/peds.2013-0621
   Thigpen MC, 2011, NEW ENGL J MED, V364, P2016, DOI 10.1056/NEJMoa1005384
   Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822
   University of York, 2009, SYSTEMATIC REV CRDS
   Wardlaw T, 2006, LANCET, V368, P1048, DOI 10.1016/S0140-6736(06)69334-3
   Weycker D, 2010, VACCINE, V28, P4955, DOI 10.1016/j.vaccine.2010.05.030
   Williams WW, 2013, MMWR-MORBID MORTAL W, V62, P66
   Wunderink RG, 2018, CLIN INFECT DIS, V66, P1504, DOI 10.1093/cid/cix1066
   Wyrwich KW, 2015, PATIENT-RELAT OUTCOM, V6, P215, DOI 10.2147/PROM.S85779
   Yildirim I, 2015, INFECT DIS CLIN N AM, V29, P679, DOI 10.1016/j.idc.2015.07.009
NR 45
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3352
EP 3361
DI 10.1016/j.vaccine.2019.04.087
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400013
PM 31072732
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Salas, A
   Pardo-Seco, J
   Cebey-Lopez, M
   Martinon-Martinez, JM
   Gomez-Rial, J
   Curras-Tuala, MJ
   Pischedda, S
   Barral-Arca, R
   Justicia-Grande, A
   Rivero-Calle, I
   Vilar, J
   Martinon-Torres, F
AF Salas, A.
   Pardo-Seco, J.
   Cebey-Lopez, M.
   Martinon-Martinez, J. M.
   Gomez-Rial, J.
   Curras-Tuala, M. J.
   Pischedda, S.
   Barral-Arca, R.
   Justicia-Grande, A.
   Rivero-Calle, I
   Vilar, J.
   Martinon-Torres, F.
TI Impact of rotavirus vaccination on childhood hospitalizations for
   seizures: Heterologous or unforeseen direct vaccine effects?
SO VACCINE
LA English
DT Article
DE Rotavirus vaccine; Rotavirus infection; Rotavirus prevention; Febrile
   seizure
ID CEREBROSPINAL-FLUID; SEVERE DIARRHEA; GASTROENTERITIS; CHILDREN;
   MONOVALENT; INFECTION; DISEASE; DEATHS
AB There is a growing interest in the possible relationship between rotavirus (RV) vaccine and hospitalizations due to childhood seizures. We explored variation in hospitalization rates after 9 years of vaccination against pre-vaccination period for children <5 years of age from Galicia (Northwest Spain) before and after the introduction of the RV vaccines. Hospitalization rates for childhood seizures in Galician children were compared before and after RV vaccine introduction (in 2007) using different statistical approaches, including time series analyses. Our study cohort totaled 7,712 children <5 years of age admitted to hospital between 2002 and 2015 for "all kind of childhood seizures". Hospitalization rates decreases steadily with reductions ranging from 22.3% (95% CI: 15.0-29.1) in 2008, to 50.9% (95% CI: 45.5-55.7) in 2014, and significant results were also observed for <1, 1, and 2-year-old children in comparison with pre-vaccination period hospitalization rate. Regression models indicate a negative association between RV vaccination and hospitalizations for all kind of seizures. In addition, time series analyses are consistent with this finding and predict that vaccination coverage will affect hospitalization rates for "all kind of seizures" after 9 months. The results strongly support that RV vaccination has significantly reduced hospitalization rates due to childhood seizures. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Salas, A.; Pardo-Seco, J.; Cebey-Lopez, M.; Martinon-Martinez, J. M.; Gomez-Rial, J.; Curras-Tuala, M. J.; Pischedda, S.; Barral-Arca, R.; Justicia-Grande, A.; Rivero-Calle, I; Martinon-Torres, F.] Hosp Clin Univ, Grp Invest Genet Vacunas Infecc & Pediat GENVIP, Galicia, Spain.
   [Salas, A.; Pardo-Seco, J.; Cebey-Lopez, M.; Martinon-Martinez, J. M.; Gomez-Rial, J.; Curras-Tuala, M. J.; Pischedda, S.; Barral-Arca, R.; Justicia-Grande, A.; Rivero-Calle, I; Martinon-Torres, F.] Univ Santiago de Compostela SERGAS, Galicia, Spain.
   [Salas, A.; Pardo-Seco, J.; Pischedda, S.; Barral-Arca, R.] Univ Santiago de Compostela, Fac Med, Inst Ciencias Forenses, Unidade Xenet, Galicia, Spain.
   [Salas, A.; Pardo-Seco, J.; Pischedda, S.; Barral-Arca, R.] Hosp Clin Univ Santiago SERGAS, Inst Invest Sanitarias IDIS, GenPoB Res Grp, Galicia, Spain.
   [Vilar, J.] Univ A Coruna, Dept Math, Campus Elvina SN, La Coruna 15071, Spain.
RP Martinon-Torres, F (reprint author), Hosp Clin Univ, Grp Invest Genet Vacunas Infecc & Pediat GENVIP, Galicia, Spain.; Martinon-Torres, F (reprint author), Univ Santiago de Compostela SERGAS, Galicia, Spain.
EM federico.martinon.torres@sergas.es
RI Tuala, Maria Jose Curras/AAD-7498-2020; Martinon-Torres,
   Federico/E-4982-2016; Salas, Antonio/U-2029-2019; Pardo-Seco, Jacobo
   J/G-3752-2016; Cebey, Miriam/K-9347-2014
OI Tuala, Maria Jose Curras/0000-0002-6390-8505; Martinon-Torres,
   Federico/0000-0002-9023-581X; Salas, Antonio/0000-0002-2336-702X;
   Pardo-Seco, Jacobo J/0000-0002-8059-8908; Cebey,
   Miriam/0000-0003-0599-7519; Pischedda, Sara/0000-0001-6731-2349; Barral
   Arca, Ruth/0000-0003-2900-1288; Justicia Grande,
   Antonio/0000-0002-0410-3328; Rivero Calle, Irene/0000-0002-3678-9264;
   Gomez Rial, Jose/0000-0002-3173-8484
FU Instituto de Salud Carlos III (Proyecto de Investigacion en Salud,
   Accion Estrategica en Salud: Cofinanciado FEDER [GePEM
   ISCIII/PI16/01478]; project ReSVinext/Cofinanciado FEDER
   [ISCIII/PI16/01569]; Conselleria de Sanidade, Xunta de GaliciaXunta de
   Galicia [RHI07/2, PS09749, 10PXIB918184PR]; Instituto de Salud Carlos
   III (Intensificacion de la actividad investigadora 2007-2012)
   [PI16/01569]; Fondo de InvestigaciOn Sanitaria (FIS) del Plan Nacional
   de I+D+I [PI070069/PI1000540]; Tondos FEDER'; Grupo Gallego de Genetica
   Vacunas Infecciones y Pediatria [2016-PG071, REDES 2016GI-1344 G3VIP,
   ED341D R2016/021]
FX This study received support from the Instituto de Salud Carlos III
   (Proyecto de Investigacion en Salud, Accion Estrategica en Salud):
   project GePEM ISCIII/PI16/01478/Cofinanciado FEDER) (A.S.) and project
   ReSVinext ISCIII/PI16/01569/Cofinanciado FEDER (F.M.-T.); Conselleria de
   Sanidade, Xunta de Galicia (RHI07/2-inten sificaci6n actividad
   investigadora, PS09749 and 10PXIB918184PR), Instituto de Salud Carlos
   III (Intensificacion de la actividad investigadora 2007-2012,
   PI16/01569), Fondo de InvestigaciOn Sanitaria (FIS; PI070069/PI1000540)
   del Plan Nacional de I+D+I and Tondos FEDER' (F.M.-T.), and 2016-PG071
   Consolidacion e Estructuracion REDES 2016GI-1344 G3VIP (Grupo Gallego de
   Genetica Vacunas Infecciones y Pediatria, ED341D R2016/021) (A.S. and
   F.M.T).
CR Biggart R, 2018, VACCINE, V36, P4589, DOI 10.1016/j.vaccine.2018.06.029
   Boom JA, 2010, PEDIATR INFECT DIS J, V29, P1133, DOI 10.1097/INF.0b013e3181ed18ab
   Boom JA, 2010, PEDIATRICS, V125, pE199, DOI 10.1542/peds.2009-1021
   Box G., 1970, TIME SERIES ANAL FOR
   Burke RM, 2018, CLIN INFECT DIS
   Candy DCA, 2007, PLOS MED, V4, P614, DOI 10.1371/journal.pmed.0040117
   Correia JB, 2010, J INFECT DIS, V201, P363, DOI 10.1086/649843
   Cortese MM, 2013, PEDIATRICS, V132, pE25, DOI 10.1542/peds.2012-3804
   Cryer JD, 2008, SPRINGER TEXTS STAT, P1
   DiFazio MP, 2007, J CHILD NEUROL, V22, P1367, DOI 10.1177/0883073807307083
   Enane LA, 2016, CLIN INFECT DIS, V62, pS168, DOI 10.1093/cid/civ1210
   Goldwater PN, 2001, J PAEDIATR CHILD H, V37, P206, DOI 10.1046/j.1440-1754.2001.00596.x
   Gomez-Rial J, 2019, INFECT DRUG RESIST, V12, P989, DOI 10.2147/IDR.S208756
   Gomez-Rial J, 2019, INFECT DRUG RESIST, V12, P55, DOI 10.2147/IDR.S186404
   Lloyd MB, 2010, PEDIATR NEUROL, V42, P404, DOI 10.1016/j.pediatrneurol.2010.03.002
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   Martinon-Torres F, 2012, HUM VACC IMMUNOTHER, V8, P946, DOI 10.4161/hv.20178
   NISHIMURA S, 1993, BRAIN DEV-JPN, V15, P457, DOI 10.1016/0387-7604(93)90088-P
   Orrico-Sanchez A, 2018, HUM VACC IMMUNOTHER, V2, P1
   Orrico-Sanchez A, 2019, INFECT DRUG RESIST, V12, P707, DOI 10.2147/IDR.S202716
   Pang XL, 1996, PEDIATR INFECT DIS J, V15, P543, DOI 10.1097/00006454-199606000-00015
   Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562
   Pardo-Seco J, 2015, PEDIATR INFECT DIS J, V34, P769, DOI 10.1097/INF.0000000000000723
   Payne DC, 2014, CLIN INFECT DIS, V58, P173, DOI 10.1093/cid/cit671
   Perrett KP, 2019, JAMA PEDIAT
   Pringle KD, 2018, J INFECT DIS, V217, P581, DOI 10.1093/infdis/jix589
   R core development team, 2011, R LANG ENV STAT COMP
   Rivero-Calle I, 2016, J INFECTION, V72, pS98, DOI 10.1016/j.jinf.2016.04.029
   Sheridan SL, 2016, J PEDIAT INF DIS SOC, V5, P206, DOI 10.1093/jpids/piu097
   Shui IM, 2009, VACCINE, V27, P5307, DOI 10.1016/j.vaccine.2009.06.092
   Staat MA, 2011, PEDIATRICS, V128, pE267, DOI 10.1542/peds.2010-3722
   Takeuchi M, 2014, HUM VACC IMMUNOTHER, V10, P1421, DOI 10.4161/hv.28284
   Vaarala O, 2017, PEDIATR INFECT DIS J, V36, P674, DOI 10.1097/INF.0000000000001600
   Yeom JS, 2014, J CHILD NEUROL, V29, P331, DOI 10.1177/0883073812469052
NR 34
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3362
EP 3368
DI 10.1016/j.vaccine.2019.04.086
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400014
PM 31064673
DA 2020-05-12
ER

PT J
AU Wang, L
   Zhang, X
   Zhang, Q
   Zhan, S
AF Wang, Li
   Zhang, Xuan
   Zhang, Qian
   Zhan, Sheng
TI Understanding medical students' practices and perceptions towards
   vaccination in China: A qualitative study in a medical university
SO VACCINE
LA English
DT Article
DE Vaccination; Medical students; Qualitative study; Focus group interview;
   In-depth interview
ID HEALTH-CARE WORKERS; SEASONAL INFLUENZA VACCINATION; HEPATITIS-B;
   KNOWLEDGE; ATTITUDES; IMMUNIZATION; COVERAGE; POLICY
AB The qualitative study aims to understand and conceptualize Chinese medical students' practices and perceptions towards vaccination. Focus groups (n = 5) were conducted through convenience sampling in a medical university in October 2016 in Anhui, China. Two years later, 6 participants among them were follow-up interviewed. All the interviews were audio-recorded, then transcribed verbatim, and analyzed using constant comparative method. Opinions of 22 participants (13 females, 9 males) were collected. Results revealed that hepatitis B vaccination was discussed the most frequently, and most of participants were vaccinated against (or had documented immunity to) hepatitis B before or during their clinical internship. None of the participants reported other vaccines uptake. Three dimensions of themes were identified: (i) at individual level, the factor "feeling less infection risk" might strengthen their perceived barriers. The factors "laziness" and "fluke mind" would be used to rationalize their inactive practices about vaccination; (ii) at social level, themes involved "inactive organizational behaviors", "suggestions from people around", and "social norms". Decision-making of medical students' vaccination was more relying on themselves and influenced more by their classmates before or during their internship, rather than being influenced more by their families/universities as before. (iii) at professional level, there are two contradictions about the participants' behaviors and attitudes. One is that they may have inappropriate behaviors because of their lack of knowledge, but sometimes they seem too satisfied about their medical knowledge to vaccination. The other is that there are both vigilance response and desensitization to occupational infection risk. It is suggested that efforts should be strengthened to spread scientific knowledge of infectious diseases and immunization as long as medical students enter the university. Publicity and organizational activities should be strengthened, and related researches should be carried out by the government or scholars. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Li] Anhui Med Univ, Sch Hlth Serv Management, Dept Hlth Serv Management, Hefei, Anhui, Peoples R China.
   [Wang, Li] Beijing Normal Univ, Sch Social Dev & Publ Policy, Beijing, Peoples R China.
   [Zhang, Xuan] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China.
   [Zhang, Qian] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Med & Hlth Management, Wuhan, Hubei, Peoples R China.
   [Zhan, Sheng] Anhui Med Univ, Clin Med Sch 1, Hefei, Anhui, Peoples R China.
RP Wang, L (reprint author), Anhui Med Univ, Sch Hlth Serv Management, Dept Hlth Serv Management, Hefei, Anhui, Peoples R China.
EM wangli@mail.bnu.edu.cn; zhangxuan@chinacdc.cn
OI Wang, Li/0000-0001-9464-9908
FU Anhui Medical University [XJ201814]; China National Undergraduate
   Training Programs for Innovation and Entrepreneurship [201610366002]
FX This study was supported by Grants for Scientific Research of BSKY
   (XJ201814) from Anhui Medical University and the China National
   Undergraduate Training Programs for Innovation and Entrepreneurship
   (201610366002). The authors thank all those participants in the study.
   The authors are grateful to Qiujie Zhang from Beijing Academy of Science
   and Technology, and in particular the two anonymous reviewers and their
   constructive comments which significantly improved the paper.
CR Afonso NM, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3969-x
   Al-Hazmi AH, 2015, ANN MED HEALTH SCI R, V5, P13, DOI 10.4103/2141-9248.149765
   [Anonymous], 2010, LANCET, V376, P565, DOI 10.1016/S0140-6736(10)61277-9
   [Anonymous], 2009, NATURE, V461, P698, DOI 10.1038/461698a
   Betsch C, 2012, VACCINE, V30, P1143, DOI 10.1016/j.vaccine.2011.12.021
   Beyea S C, 2000, AORN J, V71, P1281, DOI 10.1016/S0001-2092(06)61446-4
   Cao L, 2009, ZHONG HUA YI YUAN GA, V19, P1680
   Carman WF, 2000, LANCET, V355, P93, DOI 10.1016/S0140-6736(99)05190-9
   Charmaz K., 2014, CONSTRUCTING GROUNDE
   Cui FQ, 2017, EMERG INFECT DIS, V23, P765, DOI 10.3201/eid2305.161477
   de Paula SI, 2016, REV INST MED TROP SP, V58, DOI [10.1590/S1678-9946201658082, 10.1590/s1678-9946201658082]
   Edge R, 2017, QUAL HEALTH RES, V27, P1982, DOI 10.1177/1049732317720664
   Edge R, 2016, LANCET, V388, P46
   Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Gao L, 2015, JIE FANG JUN HU LI Z, V32, P48
   Gao Y, 2016, YING YONG YU FANG YI, V22, P486
   Guest G, 2017, FIELD METHOD, V29, P3, DOI 10.1177/1525822X16639015
   Hao H, 2017, ZHONG GUO YI MIAO HE, V2, P113
   Hernandez-Garcia I, 2012, VACCINE, V31, P1, DOI 10.1016/j.vaccine.2012.10.104
   Jaiyeoba O, 2014, AM J INFECT CONTROL, V42, P69, DOI 10.1016/j.ajic.2013.06.020
   Lehmann BA, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0929-5
   Liu Y, 2016, YI XUE YU SHE HUI, V29, P70
   Loulergue P, 2014, VACCINE, V32, P4855, DOI 10.1016/j.vaccine.2014.01.014
   Loulergue P, 2013, VACCINE, V31, P2835, DOI 10.1016/j.vaccine.2013.04.004
   Lv W, 2017, ZHONG GUO BING DU BI, V7, P478
   Ma B, 2014, WEI SHENG ZHI YE JIA, V32, P126
   Ma C, 2016, ZHONG GUO YI MIAO HE, P481
   Machowicz R, 2010, EUR J MED RES, V15, P235
   Maltezou HC, 2011, VACCINE, V29, P9557, DOI 10.1016/j.vaccine.2011.09.076
   Mei L, 2015, ZHONG GUO XIAO YI, V29, P768
   Mena G, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-99
   Milunic SL, 2010, INFECT CONT HOSP EP, V31, P85, DOI 10.1086/649219
   Nordehn Glenn, 2004, Minn Med, V87, P48
   Okamoto S, 2008, PEDIATR INT, V50, P300, DOI 10.1111/j.1442-200X.2008.02576.x
   Papagiannis D, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13030323
   Salgado CD, 2004, INFECT CONT HOSP EP, V25, P923, DOI 10.1086/502321
   Dinelli MIS, 2009, AM J INFECT CONTROL, V37, P858, DOI 10.1016/j.ajic.2009.04.283
   Saxen H, 1999, PEDIATR INFECT DIS J, V18, P779, DOI 10.1097/00006454-199909000-00007
   Song X, 2016, ZHONG GUO YI MIAO HE, V22, P94
   Statistics Bureau of Anhui Province, 2017, STAT B EC SOC DEV AN
   Walker L, 2016, VACCINE, V34, P6193, DOI 10.1016/j.vaccine.2016.10.074
   WHO, 2018, 3 WHO
   Wicker S, 2013, VACCINE, V31, P5111, DOI 10.1016/j.vaccine.2013.08.070
   Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908
   [武晓丽 Wu Xiaoli], 2018, [中国公共卫生, China Journal of Public Health], V34, P1282
   Yan X, 2015, ZHONG GUO SHI YONG Y, V10, P240
   Yang J, 2016, VACCINE, V34, P5724, DOI 10.1016/j.vaccine.2016.10.013
   Yuan Q, 2018, HEPATITIS B VIRUS ST
   Zhang H, 2016, ZHONG GUO XUE XIAO W, V37, P87
   Zhang X, 2014, ZHONG GUO NONG CUN W, V2, P167
   Zheng YB, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1278-0
   ZHU X, 2008, CHIN J VACC IMMUN, V14, P398
NR 52
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2019
VL 37
IS 25
BP 3369
EP 3378
DI 10.1016/j.vaccine.2019.03.053
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ID0FZ
UT WOS:000471360400015
PM 31076158
DA 2020-05-12
ER

PT J
AU Sellitto, MA
   Hermann, FF
   Blers, AE
   Barbosa-Povoa, AP
AF Sellitto, Miguel Afonso
   Hermann, Felipe F.
   Blers, Attila E., Jr.
   Barbosa-Povoa, Ana P.
TI Describing and organizing green practices in the context of Green Supply
   Chain Management: Case studies
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Green Supply Chain Management; Green manufacturing; Eco-design;
   Eco-efficiency; Solid waste
ID CRITICAL SUCCESS FACTORS; ENVIRONMENTAL-MANAGEMENT;
   CONCEPTUAL-FRAMEWORK; DECISION FRAMEWORK; PERFORMANCE; INITIATIVES;
   DRIVERS; SUSTAINABILITY; IMPLEMENTATION; PRESSURES
AB The purpose of this article is to present a qualitative model that allows researchers and practitioners to analyze activities that can contribute to eco-efficiency in the context of Green Supply Chain Management. A literature review identified 21 green practices, organized in four groups using duster analysis: collaboration, innovation, operation, and mitigation. Practices and aspects of these were embedded into a model, which was tested in four companies in the footwear industry. Each practice was analyzed and appraised regarding how the activity contributes to the overall eco-efficiency in the supply chain. The most contributory practice is the existence of a specific strategy to deal with environmental impact. The most contributory aspect is mitigation. The companies in the sample predominantly demonstrate a reactive attitude in facing the challenges posed by eco-efficiency, which can help managers to formulate a new strategic approach to improve eco-efficiency. The main scientific value added by the article is a structured reference model to help practitioners and scholars analyze how green practices can improve eco-efficiency in the supply chain.
C1 [Sellitto, Miguel Afonso; Hermann, Felipe F.; Blers, Attila E., Jr.; Barbosa-Povoa, Ana P.] Univ Vale Rio dos Sinos, Ave Unisinos 950, BR-93022000 Sao Leopoldo, Brazil.
RP Sellitto, MA (reprint author), Univ Vale Rio dos Sinos, Ave Unisinos 950, BR-93022000 Sao Leopoldo, Brazil.
EM sellitto@unisinos.br
RI Sellitto, Miguel/F-6639-2017; Barbosa-Povoa, Ana/A-8578-2012
OI Sellitto, Miguel/0000-0002-8561-9085; Barbosa-Povoa,
   Ana/0000-0001-6594-9653
FU CNPq, the Brazilian Agency for Research; Tordesillas Doctoral Consortium
   - Society of Jesus
FX We recognized the importance of the practitioners and companies that
   received the researchers. The research was partially funded by CNPq, the
   Brazilian Agency for Research, and by the Tordesillas Doctoral
   Consortium, sponsored by Society of Jesus.
CR Ageron B, 2012, INT J PROD ECON, V140, P168, DOI 10.1016/j.ijpe.2011.04.007
   Agi MAN, 2017, J ENVIRON MANAGE, V188, P351, DOI 10.1016/j.jenvman.2016.11.081
   Ahi P, 2013, J CLEAN PROD, V52, P329, DOI 10.1016/j.jclepro.2013.02.018
   Ahmed W, 2018, MANAG ENVIRON QUAL, V29, P740, DOI 10.1108/MEQ-11-2017-0140
   Ajamieh A, 2016, J BUS RES, V69, P4667, DOI 10.1016/j.jbusres.2016.03.056
   Amit R., 2012, INT J ENG MANAGEMENT, V3, P339
   Azevedo SG, 2011, TRANSPORT RES E-LOG, V47, P850, DOI 10.1016/j.tre.2011.05.017
   Bose I, 2012, DECIS SUPPORT SYST, V52, P624, DOI 10.1016/j.dss.2011.10.020
   Carvalho H, 2017, RESOUR CONSERV RECY, V120, P75, DOI 10.1016/j.resconrec.2016.09.025
   Chan RYK, 2012, IND MARKET MANAG, V41, P621, DOI 10.1016/j.indmarman.2012.04.009
   Chatterjee K, 2018, J CLEAN PROD, V184, P101, DOI 10.1016/j.jclepro.2018.02.186
   Cheng Ling Tan, 2016, International Journal of Business Innovation and Research, V11, P539
   Chien MK, 2007, INT J ENVIRON SCI TE, V4, P383
   Choi D, 2015, OPER MANAGE RES, V8, P69, DOI 10.1007/s12063-015-0100-x
   Chuang Y., 2018, INT J INF TECH DECIS, V17, P1
   Darnall N., 2008, BUS STRATEG ENVIRON, V17, P30, DOI DOI 10.1002/BSE.557
   Diabat A, 2011, RESOUR CONSERV RECY, V55, P659, DOI 10.1016/j.resconrec.2010.12.002
   Eltayeb TK, 2011, RESOUR CONSERV RECY, V55, P495, DOI 10.1016/j.resconrec.2010.09.003
   Eltayeb TK, 2009, OPER SUPPLY CHAIN MA, V2, P93
   Fahimnia B, 2015, INT J PROD ECON, V162, P101, DOI 10.1016/j.ijpe.2015.01.003
   Felix T.S., 2007, SOCIAL BEHAV SCI J, V35, P417, DOI DOI 10.1016/J.SBSPR0.2012.02.049
   Garg C., 2017, UNCERTAIN SUPPLY CHA, V5, P59, DOI DOI 10.5267/J.USCM.2016.7.002
   Genovese A, 2017, OMEGA-INT J MANAGE S, V66, P344, DOI 10.1016/j.omega.2015.05.015
   Ghadimi P, 2019, RESOUR CONSERV RECY, V140, P72, DOI 10.1016/j.resconrec.2018.09.005
   Govindan K, 2016, RESOUR CONSERV RECY, V107, P185, DOI 10.1016/j.resconrec.2015.05.022
   Govindan K, 2015, EXPERT SYST APPL, V42, P7207, DOI 10.1016/j.eswa.2015.04.030
   Govindan K, 2014, J CLEAN PROD, V85, P212, DOI 10.1016/j.jclepro.2014.05.068
   Govindan K, 2014, EUR J OPER RES, V233, P293, DOI 10.1016/j.ejor.2013.10.058
   Green K.W, 2013, SUPPLY CHAIN MANAG I, V17, P20
   Green KW, 2012, IND MARKET MANAG, V41, P1008, DOI 10.1016/j.indmarman.2012.02.003
   Gunasekaran A, 2015, TRANSPORT RES E-LOG, V74, P1, DOI 10.1016/j.tre.2015.01.002
   Gupta S, 2011, IIMB MANAG REV, V23, P234, DOI 10.1016/j.iimb.2011.09.002
   Hair J.F., 2010, MULTIVARIATE DATA AN
   Handfield R, 2005, BUSINESS STRATEGY EN, V14, P1, DOI DOI 10.1002/BSE.422
   Hassini E, 2012, INT J PROD ECON, V140, P69, DOI 10.1016/j.ijpe.2012.01.042
   Hsu CC, 2013, INT J OPER PROD MAN, V33, P656, DOI 10.1108/IJOPM-10-2011-0401
   Igarashi M, 2013, J PURCH SUPPLY MANAG, V19, P247, DOI 10.1016/j.pursup.2013.06.001
   Jabbour AB, 2014, RESOUR CONSERV RECY, V92, P255, DOI 10.1016/j.resconrec.2014.02.004
   Jiang W, 2018, INT J COMPUT COMMUN, V13, P337, DOI 10.15837/ijccc.2018.3.3283
   Jun Sun, 2018, IEEE Engineering Management Review, V46, P117, DOI 10.1109/EMR.2018.2809907
   Kirchoff JF, 2016, INT J PHYS DISTR LOG, V46, P269, DOI 10.1108/IJPDLM-03-2015-0055
   Klassen RD, 2004, UNDERSTANDING SUPPLY, P229
   Kushwaha GS, 2016, J CLEAN PROD, V121, P116, DOI 10.1016/j.jclepro.2015.07.072
   Laari S, 2017, J CLEAN PROD, V141, P1303, DOI 10.1016/j.jclepro.2016.09.114
   Large RO, 2011, J PURCH SUPPLY MANAG, V17, P176, DOI 10.1016/j.pursup.2011.04.006
   Lee SM, 2013, MANAGE DECIS, V51, P1753, DOI 10.1108/MD-12-2012-0841
   Lee VH, 2014, EXPERT SYST APPL, V41, P6983, DOI 10.1016/j.eswa.2014.05.022
   Leung Lawrence, 2015, J Family Med Prim Care, V4, P324, DOI 10.4103/2249-4863.161306
   Li Y, 2011, J SUSTAINABLE DEV, V4, P101, DOI DOI 10.5539/JSD.V4N3P101
   Lo SM, 2014, INT J OPER PROD MAN, V34, P93, DOI 10.1108/IJOPM-04-2012-0133
   Jabbour ABLD, 2015, TRANSPORT RES E-LOG, V74, P139, DOI 10.1016/j.tre.2014.12.011
   Luthra S, 2014, J ADV MANAG RES, V11, P20, DOI 10.1108/JAMR-07-2012-0027
   Luthra S, 2016, J CLEAN PROD, V121, P142, DOI 10.1016/j.jclepro.2016.01.095
   Luthra S, 2015, RESOUR POLICY, V46, P37, DOI 10.1016/j.resourpol.2014.12.006
   Maditati DR, 2018, RESOUR CONSERV RECY, V139, P150, DOI 10.1016/j.resconrec.2018.08.004
   Malviya RK, 2018, BUS STRATEG ENVIRON, V27, P475, DOI 10.1002/bse.2016
   Mangla S, 2014, GLOBAL J FLEX SYST M, V15, P203, DOI DOI 10.1007/S40171-014-0067-8
   Mauricio André Luiz, 2017, Gest. Prod., V24, P78, DOI 10.1590/0104-530x2267-16
   Nunes B, 2010, BENCHMARKING, V17, P396, DOI 10.1108/14635771011049362
   Perotti S, 2012, INT J PHYS DISTR LOG, V42, P640, DOI 10.1108/09600031211258138
   Rao P, 2005, INT J OPER PROD MAN, V25, P898, DOI 10.1108/01443570510613956
   Rehman M., 2015, INT J PROCESS MANAGE, V5, P229, DOI DOI 10.1504/IJPMB.2015.068670
   Rha J., 2010, IMPACT GREEN SUPPLY
   Rostamzadeh R, 2015, ECOL INDIC, V49, P188, DOI 10.1016/j.ecolind.2014.09.045
   Sari K, 2017, COMPUT IND ENG, V105, P338, DOI 10.1016/j.cie.2017.01.016
   Sarkis J, 2003, J CLEAN PROD, V11, P397, DOI 10.1016/S0959-6526(02)00062-8
   Savaskan RC, 2004, MANAGE SCI, V50, P239, DOI 10.1287/mnsc.1030.0186
   Sellitto M., 2019, ENG MANAG J
   Sellitto M., 2018, CHEM ENG T, V70, P211
   Sellitto Miguel Afonso, 2013, Ambient. soc., V16, P141, DOI 10.1590/S1414-753X2013000100009
   Sellitto MA, 2012, THEOR FOUND CHEM EN+, V46, P691, DOI 10.1134/S0040579512060206
   Sellitto MA, 2015, CHEM ENGINEER TRANS, V43, P1315, DOI 10.3303/CET1543220
   Sellitto MA, 2018, J IND COMPET TRADE, V18, P513, DOI 10.1007/s10842-018-0272-9
   Sellitto MA, 2018, BUS PROCESS MANAG J, V24, P23, DOI 10.1108/BPMJ-03-2016-0067
   Sellitto Miguel Afonso, 2017, Journal of Environmental Assessment Policy and Management, V19, P1750001, DOI [10.1142/S1464333217500016, 10.1142/s1464333217500016]
   Sellitto Miguel Afonso, 2016, Gest. Prod., V23, P871, DOI 10.1590/0104-530x2516-15
   Seuring S, 2008, J CLEAN PROD, V16, P1699, DOI 10.1016/j.jclepro.2008.04.020
   Seuring S, 2013, DECIS SUPPORT SYST, V54, P1513, DOI 10.1016/j.dss.2012.05.053
   Shang KC, 2010, J ENVIRON MANAGE, V91, P1218, DOI 10.1016/j.jenvman.2010.01.016
   Sharma VK, 2017, J CLEAN PROD, V141, P1194, DOI 10.1016/j.jclepro.2016.09.103
   Shi VG, 2012, SUPPLY CHAIN MANAG, V17, P54, DOI 10.1108/13598541211212203
   Srivastava SK, 2007, INT J MANAG REV, V9, P53, DOI 10.1111/j.1468-2370.2007.00202.x
   Tachizawa EM, 2015, INT J OPER PROD MAN, V35, P1546, DOI 10.1108/IJOPM-01-2015-0023
   Tan C. K., 2013, IND MANAG DATA SYST, V113, P696, DOI [DOI 10.1108/02635570710734262, 10.1108/02635570710734262]
   Testa F, 2010, J CLEAN PROD, V18, P953, DOI 10.1016/j.jclepro.2010.03.005
   Toke L.K., 2012, INT J APPL SCI ENG R, V1, P372, DOI DOI 10.6088/IJASER.0020101038
   Tseng ML, 2013, J CLEAN PROD, V40, P22, DOI 10.1016/j.jclepro.2010.08.007
   Wang XJ, 2015, TECHNOL FORECAST SOC, V95, P191, DOI 10.1016/j.techfore.2015.02.004
   Wu GC, 2012, INT J PROD ECON, V135, P618, DOI 10.1016/j.ijpe.2011.05.023
   Yin RK, 2013, EVALUATION-US, V19, P321, DOI 10.1177/1356389013497081
   Zhu Q., 2012, INT J OPER PROD MAN, V25, P449
   Zhu QH, 2006, J CLEAN PROD, V14, P472, DOI 10.1016/j.jclepro.2005.01.003
   Zhu QH, 2004, J OPER MANAG, V22, P265, DOI 10.1016/j.jom.2004.01.005
   Zhu QH, 2008, INT J PROD ECON, V111, P261, DOI 10.1016/j.ijpe.2006.11.029
   Zhu QH, 2008, TRANSPORT RES E-LOG, V44, P1, DOI 10.1016/j.tre.2006.06.003
   Zhu QH, 2007, J CLEAN PROD, V15, P1041, DOI 10.1016/j.jclepro.2006.05.021
   Zhu QH, 2013, J PURCH SUPPLY MANAG, V19, P106, DOI 10.1016/j.pursup.2012.12.001
   Zhu QH, 2010, MANAG RES REV, V33, P380, DOI 10.1108/01409171011030471
NR 98
TC 7
Z9 7
U1 2
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 1
EP 10
DI 10.1016/j.resconrec.2019.02.013
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200001
DA 2020-05-12
ER

PT J
AU Mintz, KK
   Henn, L
   Park, J
   Kurman, J
AF Mintz, Keren Kaplan
   Henn, Laura
   Park, Joonha
   Kurman, Jenny
TI What predicts household waste management behaviors? Culture and type of
   behavior as moderators
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Recycling; Minimization; Social norms; Environmental orientation;
   Cross-cultural differences; Waste management
ID PRO-ENVIRONMENTAL BEHAVIOR; PROENVIRONMENTAL BEHAVIOR; ECOLOGICAL
   PARADIGM; REDUCTION; NORMS; DETERMINANTS; COLLECTION; STRATEGIES;
   BELIEFS; LESSONS
AB This study seeks to examine the factors predicting waste management behaviors- recycling (difficult and easy) and waste minimization-based on social norms and environmental orientation in a cross-cultural context. A survey conducted among 401 university students from Japan, Germany and Israel included measures of social norms for recycling and minimization, biospheric value orientation, environmental concern (NEP), and waste management behaviors. Results showed that difficult recycling was lower than the other two behaviors, and that household waste management behaviors were higher among Germans than among the other two groups. The relative contribution of environmental orientation to waste management behavior was generally weaker in Japan than in Germany and Israel. Social norms significantly predicted easy recycling and minimization in all three groups, and difficult recycling only in Germany and Israel. Social norms were a stronger predictor of easy recycling among Israelis than among Japanese. The research results imply that both structural contexts and cultural factors influence the extent to which people engage in recycling and waste minimization. The results highlight the importance of integrating cultural considerations into waste management strategies.
C1 [Mintz, Keren Kaplan] Univ Haifa, Shamir Res Inst, Dept Educ & Social Sci, Kazerin, Israel.
   [Mintz, Keren Kaplan; Kurman, Jenny] Univ Haifa, Dept Psychol, Haifa, Israel.
   [Henn, Laura] Otto von Guericke Univ, Inst Psychol, Magdeburg, Germany.
   [Park, Joonha] NUCB Business Sch, Grad Sch Management, Nagoya, Aichi, Japan.
RP Mintz, KK (reprint author), Shamir Res Inst, Dept Educ & Social Sci, IL-1290000 Kazerin, Israel.
EM KerenKM@gri.org.il
OI Park, Joonha/0000-0002-0764-5173
FU University of Haifa; Israel Institute, Washington D.C. [20005]
FX The work of Dr. Keren Kaplan Mintz was supported by a post-doctoral
   scholarship given by the University of Haifa.; The work of the Israeli
   team was supported by Israel Institute, Washington D.C., grant No.
   20005.
CR ANDERSON L, 1991, ADV CONSUM RES, V18, P129
   Ayalon O., 2013, OECD GREENING HOUSEH, P219
   Bamberg S, 2003, J ENVIRON PSYCHOL, V23, P21, DOI 10.1016/S0272-4944(02)00078-6
   Barr S, 2007, ENVIRON BEHAV, V39, P435, DOI 10.1177/0013916505283421
   Bechtel RB, 2006, INT J PSYCHOL, V41, P145, DOI 10.1080/00207590500345401
   Bertoldo R., 2018, CULT PSYCHOL
   Bertoldo R, 2016, RESOUR CONSERV RECY, V112, P45, DOI 10.1016/j.resconrec.2016.03.020
   Bratt C, 2015, ENVIRON BEHAV, V47, P436, DOI 10.1177/0013916514525038
   Chan R. Y. K., 2002, J INT CONSUMER MARKE, V14, P9, DOI DOI 10.1300/J046V14N02_02
   Cialdini R. B., 1998, HDB SOCIAL PSYCHOL, V4, P151, DOI DOI 10.2307/2654253
   CIALDINI RB, 1991, ADV EXP SOC PSYCHOL, V24, P201
   de Groot JIM, 2008, ENVIRON BEHAV, V40, P330, DOI 10.1177/0013916506297831
   de Groot JIM, 2013, SUSTAINABILITY-BASEL, V5, P1829, DOI 10.3390/su5051829
   Dunlap RE, 2000, J SOC ISSUES, V56, P425, DOI 10.1111/0022-4537.00176
   Earth911, 2017, GERM REC PROGR ACT W
   Ebreo A, 2001, ENVIRON BEHAV, V33, P424, DOI 10.1177/00139160121973061
   Eisler AD, 2003, J ENVIRON PSYCHOL, V23, P89, DOI 10.1016/S0272-4944(02)00083-X
   Eom K, 2016, PSYCHOL SCI, V27, P1331, DOI 10.1177/0956797616660078
   Eom K, 2015, J CROSS CULT PSYCHOL, V46, P1313, DOI 10.1177/0022022115600262
   Gutberlet J, 2015, WASTE MANAGE, V45, P22, DOI 10.1016/j.wasman.2015.06.023
   Hendry J., 1993, WRAPPING CULTURE POL
   Hofstede G, 2010, CULTURES ORG SOFTWAR
   Hotta Y, 2014, WASTE MANAGE RES, V32, P857, DOI 10.1177/0734242X14539721
   How to Germany, 2018, ALL REC GERM
   Japanese Ministry of the Environment, 2014, HIST CURR STAT WAST
   Kaiser FG, 2000, J APPL SOC PSYCHOL, V30, P952, DOI 10.1111/j.1559-1816.2000.tb02505.x
   Kaiser FG, 2010, PERS SOC PSYCHOL REV, V14, P351, DOI 10.1177/1088868310366452
   Kaiser FG, 2009, J APPL SOC PSYCHOL, V39, P186, DOI 10.1111/j.1559-1816.2008.00435.x
   Kim H, 1999, J PERS SOC PSYCHOL, V77, P785, DOI 10.1037/0022-3514.77.4.785
   Kim HS, 2007, J PERS SOC PSYCHOL, V92, P1, DOI 10.1037/0022-3514.92.1.1
   Kollmuss A., 2002, ENVIRON EDUC RES, V8, P239, DOI DOI 10.1080/13504620220145401
   Kormos C, 2014, J ENVIRON PSYCHOL, V40, P359, DOI 10.1016/j.jenvp.2014.09.003
   Kurman J, 2003, J CROSS CULT PSYCHOL, V34, P496, DOI 10.1177/0022022103256474
   Markus HR, 2016, CURR OPIN PSYCHOL, V8, P161, DOI 10.1016/j.copsyc.2015.10.028
   Matsuda T, 2018, WASTE MANAGE, V71, P2, DOI 10.1016/j.wasman.2017.10.014
   Mayer FS, 2004, J ENVIRON PSYCHOL, V24, P503, DOI 10.1016/j.jenvp.2004.10.001
   McCurry J., 2011, JAPAN STREETS AHEAD
   Milfont TL, 2006, ENVIRON BEHAV, V38, P745, DOI 10.1177/0013916505285933
   Milfont TL, 2016, CURR OPIN PSYCHOL, V8, P194, DOI 10.1016/j.copsyc.2015.09.009
   Miliute-Plepiene J, 2016, RESOUR CONSERV RECY, V113, P40, DOI 10.1016/j.resconrec.2016.05.008
   MoEP, 2018, SOL WAST POL PLANN
   Nelles M, 2016, PROCEDIA ENVIRON SCI, V35, P6, DOI 10.1016/j.proenv.2016.07.001
   OECD, 2000, STRAT WAST PREV
   Otto S, 2018, J CLEAN PROD, V204, P33, DOI 10.1016/j.jclepro.2018.08.293
   Schultz PW, 2014, EUR PSYCHOL, V19, P107, DOI 10.1027/1016-9040/a000163
   Schultz PW, 1996, SOC PSYCHOL QUART, V59, P375, DOI 10.2307/2787078
   Steg L., 2012, OXFORD HDB ENV CONSE, P81, DOI DOI 10.1093/OXFORDHB/9780199733026.013.0005
   Steg L, 2014, J ENVIRON PSYCHOL, V38, P104, DOI 10.1016/j.jenvp.2014.01.002
   Steg L, 2009, J ENVIRON PSYCHOL, V29, P309, DOI 10.1016/j.jenvp.2008.10.004
   STERN PC, 1995, ENVIRON BEHAV, V27, P723, DOI 10.1177/0013916595276001
   Swami V, 2011, J ENVIRON PSYCHOL, V31, P21, DOI 10.1016/j.jenvp.2010.08.001
   Tam KP, 2017, J ENVIRON PSYCHOL, V53, P213, DOI 10.1016/j.jenvp.2017.09.001
   Tankard ME, 2017, PSYCHOL SCI, V28, P1334, DOI 10.1177/0956797617709594
   TASC, 2016, ZER WAST POL ISR IS
   Tonglet M, 2004, RESOUR CONSERV RECY, V42, P27, DOI 10.1016/j.resconrec.2004.02.001
   UNEP, 2015, GLOB WAST MAN OUTL
   Varotto A, 2017, J ENVIRON PSYCHOL, V51, P168, DOI 10.1016/j.jenvp.2017.03.011
   Wan C, 2015, ENVIRON SCI POLICY, V54, P409, DOI 10.1016/j.envsci.2015.06.023
   Zou X, 2009, J PERS SOC PSYCHOL, V97, P579, DOI 10.1037/a0016399
   1999, J AESTHET ART CRITIC, V57, P257
   1999, BASIC APPL SOC PSYCH, V21, P25
NR 61
TC 3
Z9 3
U1 8
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 11
EP 18
DI 10.1016/j.resconrec.2019.01.045
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200002
DA 2020-05-12
ER

PT J
AU Chen, S
   Song, Y
   Ding, YT
   Qian, XY
   Zhang, M
AF Chen, Sai
   Song, Yan
   Ding, Yueting
   Qian, Xiangyan
   Zhang, Ming
TI Research on the strategic interaction and convergence of China's
   environmental public expenditure from the perspective of inequality
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Environmental public expenditure; Strategic interaction; Perspective of
   inequality; China
ID REGULATORY COMPETITION; GOVERNMENT EXPENDITURE; SPILLOVER; QUALITY;
   DETERMINANTS; POLICY; TRADE; GREEN; MODEL; RACE
AB Environmental public expenditure (EPE), which is critical to ecological protection and environmental governance, has not played its due role. From the perspective of inequality, this paper utilizes the single-regime and two-regime spatial panel models to explore the strategic interaction pattern of EPE and analyze the convergence of per capita environmental investment based on the data from 30 provinces in China from 2000-2015. The main results are as the following. A significant imitative strategic interaction in inter-provincial EPE is observed, that is, one region would reduce its EPE accordingly if EPE in its competitive area was reduced first. Underdeveloped regions are more sensitive to regional strategy changes. Furthermore, the low-pollution areas are more sensitive to the decisions on EPE in the neighboring regions. The convergence of inter-provincial EPE indicates that the gap between provinces further leads to the imitation pattern of expenditure, which better explains the steadily low EPE among different regions in the long term. Based on the conclusions of this study, we recommended policies, such as narrow regional differences, weaken the unequal aversion of local governments, and improve interactive strategies.
C1 [Chen, Sai; Song, Yan; Ding, Yueting; Qian, Xiangyan; Zhang, Ming] China Univ Min & Technol, Sch Management, Xuzhou 221116, Jiangsu, Peoples R China.
   [Chen, Sai; Song, Yan; Zhang, Ming] China Univ Min & Technol, Jiangsu Energy Econ & Management Res Base, Xuzhou 221116, Jiangsu, Peoples R China.
RP Song, Y; Zhang, M (reprint author), China Univ Min & Technol, Sch Management, Xuzhou 221116, Jiangsu, Peoples R China.
EM syan118@163.com; zhangmingdlut@163.com
RI Ding, Yueting/AAG-7465-2020; Zhang, Ming/V-5262-2019
OI Ding, Yueting/0000-0003-4418-2355; Zhang, Ming/0000-0003-3023-1419
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71874189, 71774158]; China's Post-doctoral Science
   FundChina Postdoctoral Science Foundation [2015M580484, 2016T90517];
   Jiangsu Social Science Fund [18JD013, 16JD008]; High-level Talents
   Project of "Six Talents Peaks" in Jiangsu Province [JY-077]; Qinlan
   project of Jiangsu
FX The authors gratefully acknowledge the financial support from the
   National Natural Science Foundation of China (71874189, 71774158),
   China's Post-doctoral Science Fund (2015M580484, 2016T90517), Jiangsu
   Social Science Fund (18JD013, 16JD008), High-level Talents Project of
   "Six Talents Peaks" in Jiangsu Province (JY-077) and Qinlan project of
   Jiangsu.
CR Allen R. G., 1998, FAO Irrigation and Drainage Paper
   Bai J., 2016, COMP ENV FINANCE EXP, P1
   Baicker K, 2005, J PUBLIC ECON, V89, P529, DOI 10.1016/j.jpubeco.2003.11.003
   BARRO RJ, 1983, J MONETARY ECON, V12, P101, DOI 10.1016/0304-3932(83)90051-X
   Brueckner JK, 2003, INT REGIONAL SCI REV, V26, P175, DOI 10.1177/0160017602250974
   CASE AC, 1993, J PUBLIC ECON, V52, P285, DOI 10.1016/0047-2727(93)90036-S
   Chen J., 2016, EC Q, V15, P693
   Chen S, 2014, J MACROMOL SCI A, V51, P173, DOI 10.1080/10601325.2014.864932
   CHEN SQ, 2014, FINANCE TRADE RES, V7, P85, DOI DOI 10.1007/S12274-013-0374-Y
   Chen WY, 2017, CITIES, V71, P1, DOI 10.1016/j.cities.2017.07.003
   Chen XY, 2017, J CLEAN PROD, V142, P915, DOI 10.1016/j.jclepro.2016.02.119
   Costa H, 2015, REG STUD, V49, P1441, DOI 10.1080/00343404.2013.835798
   Deng HH, 2012, CHINA WORLD ECON, V20, P103, DOI 10.1111/j.1749-124X.2012.01304.x
   Elhorst JP, 2009, J REGIONAL SCI, V49, P931, DOI 10.1111/j.1467-9787.2009.00613.x
   Ermini B, 2010, LOCAL GOV STUD, V36, P655, DOI 10.1080/03003930.2010.506979
   Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151
   Fredriksson PG, 2002, J URBAN ECON, V51, P101, DOI 10.1006/juec.2001.2239
   Fu Y., 2007, MANAGEMENT WORLD, V3, P4
   Galinato GI, 2018, RESOUR ENERGY ECON, V53, P114, DOI 10.1016/j.reseneeco.2018.04.001
   Galinato GI, 2016, ECOL ECON, V122, P43, DOI 10.1016/j.ecolecon.2015.10.025
   GORDON RH, 1983, Q J ECON, V98, P567, DOI 10.2307/1881778
   Halkos GE, 2013, ECOL ECON, V91, P48, DOI 10.1016/j.ecolecon.2013.04.002
   Konisky DM, 2007, AM J POLIT SCI, V51, P853, DOI 10.1111/j.1540-5907.2007.00285.x
   Lenka gfastna, 2009, AUCO CZECH EC REV, V3, P7
   Levinson A, 2003, NATL TAX J, V56, P91, DOI 10.17310/ntj.2003.1.06
   Li B, 2017, J CLEAN PROD, V153, P342, DOI 10.1016/j.jclepro.2016.10.042
   Li HB, 2005, J PUBLIC ECON, V89, P1743, DOI 10.1016/j.jpubeco.2004.06.009
   Li W, 2017, RESOUR CONSERV RECY, V126, P162, DOI 10.1016/j.resconrec.2017.07.043
   Li YM, 2018, RESOUR CONSERV RECY, V139, P104, DOI 10.1016/j.resconrec.2018.07.021
   Lopez R, 2011, J ENVIRON ECON MANAG, V62, P180, DOI 10.1016/j.jeem.2011.03.001
   Lu H, 2017, RESOUR CONSERV RECY, V120, P166, DOI 10.1016/j.resconrec.2016.12.008
   Lundberg J, 2006, REG STUD, V40, P631, DOI 10.1080/00343400600868788
   Ning YD, 2019, RESOUR CONSERV RECY, V141, P211, DOI 10.1016/j.resconrec.2018.10.022
   Ren SG, 2018, J CLEAN PROD, V173, P245, DOI 10.1016/j.jclepro.2016.08.113
   Renard M., 2012, STRATEGIC INTERACTIO
   SalaiMartin XX, 1996, ECON J, V106, P1019, DOI 10.2307/2235375
   Sarr M, 2010, ECON GOV, V11, P183, DOI 10.1007/s10101-010-0075-x
   Shi D., 2017, CONT FINANCE EC, V4, P3
   Siano R. D., 2017, REG STUD J REG STUD, V51, P1
   Wang WP, 2013, CHINA POPUL RESOUR E, V3, P123
   Weibust I., 2016, GREEN LEVIATHAN CASE
   Woods ND, 2006, SOC SCI QUART, V87, P174, DOI 10.1111/j.0038-4941.2006.00375.x
   Wu J., 2013, INCENTIVES OUTCOMES
   Yin H., 2011, EC RES J, V7, P55
   Yu YH, 2013, ANN REGIONAL SCI, V50, P203, DOI 10.1007/s00168-011-0488-7
   Yu YH, 2011, SOC SCI J, V48, P458, DOI 10.1016/j.soscij.2011.05.006
   Zeng BH, 2019, RESOUR CONSERV RECY, V142, P204, DOI 10.1016/j.resconrec.2018.12.002
   Zhang QX, 2017, J CLEAN PROD, V161, P143, DOI 10.1016/j.jclepro.2017.05.096
   Zhang Z., 2010, EC RES, V5, P82
   Zheng HM, 2018, RESOUR CONSERV RECY, V132, P339, DOI 10.1016/j.resconrec.2017.05.010
   Zhu PF, 2011, EC RES J, V6, P133
   Zuo C, 2015, CHINA QUART, V224, P955, DOI 10.1017/S0305741015001289
   2017, CHEMOSPHERE, V183, P429, DOI DOI 10.1016/J.CHEMOSPHERE.2017.05.133
   2016, J CLEAN PROD, V112, P1443, DOI DOI 10.1016/J.JCLEPRO.2015.05.005
   2017, J CLEAN PROD, V142, P1800, DOI DOI 10.1016/J.JCLEPRO.2016.11.104
NR 55
TC 2
Z9 2
U1 5
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 19
EP 30
DI 10.1016/j.resconrec.2019.02.017
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200003
DA 2020-05-12
ER

PT J
AU Kuo, TC
   Lin, SH
   Tseng, ML
   Chiu, ASF
   Hsu, CW
AF Kuo, Tsai Chi
   Lin, Syu-Hong
   Tseng, Ming-Lang
   Chiu, Anthony S. F.
   Hsu, Chia-Wei
TI Biofuels for vehicles in Taiwan: Using system dynamics modeling to
   evaluate government subsidy policies
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Biofuels; Ethanol; System dynamic modeling; Subsidy policy
ID ETHANOL SUPPLY CHAIN; RENEWABLE ENERGY; FOSSIL-FUELS; FEASIBILITY;
   IMPACTS; BRAZIL; YIELD; OIL; TAX
AB This study proposes a biofuel model in Taiwan that considers the government subsidy policy, market demand, biofuel production cost, and social cost attributes. Biofuel is a prospective alternative and renewable solution to energy and environmental challenges in the transportation sector. However, the development of biofuels is constrained by several factors including the amount of land available (the primary constraint), marketing of residual resources, and technological improvements. Economic feasibility and competition analysis and use of residual resources limited the actual amount of residual resources utilized to produce biofuel. Prior studies have examined the potential to commercialize biofuels where resources are limited. Despite insufficient land availability, biofuel commercialization has the potential to be mutually beneficial and risk-sharing in the supply chain. The contribution of this study is to develop a dynamic system model to explore the potential for biofuel commercialization in Taiwan despite its limited Biofuel resources. Through this model, this study considered E3 vehicles that use a fuel blend of 3% ethanol and 97% gasoline. Data were collected from institutional statistical reports. The results showed there is a large commercial opportunity; however, biofuel resources are insufficient. To deal with this resource insufficient, the Taiwanese government could use this model to develop an appropriate subsidy policy that adjusts prices based on market demand and technological improvements.
C1 [Kuo, Tsai Chi] Chung Yuan Christian Univ, Dept Ind & Syst Engn, Taoyuan, Taiwan.
   [Kuo, Tsai Chi] Chung Yuan Christian Univ, R&D Ctr Membrane Technol, Taoyuan, Taiwan.
   [Lin, Syu-Hong] Chung Yuan Christian Univ, Dept Ind & Syst Engn, Taoyuan, Taiwan.
   [Tseng, Ming-Lang] Asia Univ, Inst Innovat & Circular Econ, Taichung, Taiwan.
   [Chiu, Anthony S. F.] De La Salle Univ, Manila, Philippines.
   [Hsu, Chia-Wei] Tungnan Univ, Dept Travel, New Taipei, Taiwan.
   [Tseng, Ming-Lang] China Med Univ, Dept Med Res, Taichung, Taiwan.
RP Tseng, ML (reprint author), Asia Univ, Inst Innovat & Circular Econ, Taichung, Taiwan.; Tseng, ML (reprint author), China Med Univ, Dept Med Res, Taichung, Taiwan.
EM tckuo@cycu.edu.tw; tsengminglang@gmail.com; anthony.chiu@dlsu.edu.ph;
   jcwhsu@gmail.com
RI Kuo, Tsai Chi/U-5547-2019; Tseng, Ming Lang/M-9051-2014
OI Kuo, Tsai Chi/0000-0002-4661-5276; Tseng, Ming Lang/0000-0002-2702-3590;
   Chiu, Anthony Shun Fung/0000-0003-2411-7302
CR Andree BPJ, 2017, RENEW SUST ENERG REV, V67, P848, DOI 10.1016/j.rser.2016.09.048
   Azad AK, 2015, RENEW SUST ENERG REV, V43, P331, DOI 10.1016/j.rser.2014.11.047
   BOE, 2016, WHIT PAP EN IND TECH
   Castellacci F, 2018, ECON MODEL, V70, P272, DOI 10.1016/j.econmod.2017.11.010
   Chang CC, 2012, AGR ECON-BLACKWELL, V43, P205, DOI 10.1111/j.1574-0862.2011.00577.x
   Chen HH, 2014, RENEW SUST ENERG REV, V37, P215, DOI 10.1016/j.rser.2014.04.055
   Chen TsuiMiao, 2013, Modern Applied Science, V7, P19
   de Jong S, 2017, APPL ENERG, V195, P1055, DOI 10.1016/j.apenergy.2017.03.109
   Demczuk A, 2017, BIOMASS BIOENERG, V97, P186, DOI 10.1016/j.biombioe.2016.12.021
   Doumax-Tagliavini V, 2018, RENEW SUST ENERG REV, V94, P430, DOI 10.1016/j.rser.2018.06.020
   Ekener-Petersen E, 2014, ENERG POLICY, V73, P416, DOI 10.1016/j.enpol.2014.05.034
   Eurostat, 2014, GREENH GAS EM IPCC S
   Hao H, 2018, RENEW SUST ENERG REV, V82, P645, DOI 10.1016/j.rser.2017.09.045
   Huang C-H., 2011, INVESTIGATION ETHANO
   Humbird D, 2011, PROCESS DESIGN EC BI
   Kung CC, 2019, ENERGY, V167, P1051, DOI 10.1016/j.energy.2018.11.064
   Kung CC, 2017, J CLEAN PROD, V142, P965, DOI 10.1016/j.jclepro.2016.05.034
   Lapan H, 2012, J ENVIRON ECON MANAG, V63, P224, DOI 10.1016/j.jeem.2011.10.001
   Le LT, 2013, BIOMASS BIOENERG, V54, P227, DOI 10.1016/j.biombioe.2013.04.004
   Leong WH, 2018, RENEW SUST ENERG REV, V91, P950, DOI 10.1016/j.rser.2018.04.066
   Lu C, 2018, J CLEAN PROD, V181, P365, DOI 10.1016/j.jclepro.2018.01.227
   Lu L, 2014, ENRGY PROCED, V61, P2105, DOI 10.1016/j.egypro.2014.12.086
   Mai T, 2018, TOURISM MANAGE, V68, P336, DOI 10.1016/j.tourman.2018.04.005
   Mazumder DB, 2014, ENERG ECON, V44, P361, DOI 10.1016/j.eneco.2014.04.023
   Millinger M, 2017, ENERG POLICY, V107, P394, DOI 10.1016/j.enpol.2017.05.013
   Moncada JA, 2017, APPL ENERG, V185, P895, DOI 10.1016/j.apenergy.2016.10.070
   Moraes MAFD, 2014, RENEW SUST ENERG REV, V40, P716, DOI 10.1016/j.rser.2014.07.210
   Chavez MMM, 2018, TRANSPORT RES E-LOG, V116, P136, DOI 10.1016/j.tre.2018.06.001
   Moser D, 2013, BIOMASS BIOENERG, V50, P35, DOI 10.1016/j.biombioe.2012.10.004
   Moula Md Munjur E., 2017, International Journal of Sustainable Built Environment, V6, P434, DOI 10.1016/j.ijsbe.2017.07.008
   Ng Rex T. L., 2016, APPL ENERG, V216, P116
   Oladosu G, 2013, ENERG POLICY, V61, P1127, DOI 10.1016/j.enpol.2013.06.124
   Quddus MA, 2018, INT J PROD ECON, V195, P27, DOI 10.1016/j.ijpe.2017.09.019
   Ren JZ, 2015, RENEW SUST ENERG REV, V52, P382, DOI 10.1016/j.rser.2015.07.115
   Rendon-Sagardi MA, 2014, APPL ENERG, V123, P358, DOI 10.1016/j.apenergy.2014.01.023
   Rodionova MV, 2017, INT J HYDROGEN ENERG, V42, P8450, DOI 10.1016/j.ijhydene.2016.11.125
   Rodolfi L, 2009, BIOTECHNOL BIOENG, V102, P100, DOI 10.1002/bit.22033
   Saravanan AP, 2018, J CLEAN PROD, V193, P734, DOI 10.1016/j.jclepro.2018.05.033
   Su CL, 2009, ENERG POLICY, V37, P754, DOI 10.1016/j.enpol.2008.09.076
   Tan RR, 2017, RESOUR CONSERV RECY, V127, P244, DOI 10.1016/j.resconrec.2017.09.010
   TEIC, 2018, BIOR
   Tseng L. F., 2017, BIOFUEL REFINERY CHI
   Voloshin RA, 2016, INT J HYDROGEN ENERG, V41, P17257, DOI 10.1016/j.ijhydene.2016.07.084
   Wen PL, 2015, ENERGY, V89, P294, DOI 10.1016/j.energy.2015.05.131
   Xie F., TRANSPORTATION RES E, V111, P130
   Xu J, 2018, ENERGY, V160, P452, DOI 10.1016/j.energy.2018.06.126
   Zhang HM, 2014, ENERG POLICY, V65, P270, DOI 10.1016/j.enpol.2013.10.009
NR 47
TC 3
Z9 3
U1 3
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 31
EP 39
DI 10.1016/j.resconrec.2019.02.005
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200004
DA 2020-05-12
ER

PT J
AU Alvarenga, RAF
   Dewulf, J
   Guinee, J
   Schulze, R
   Weihed, P
   Bark, G
   Drielsma, J
AF Alvarenga, Rodrigo A. F.
   Dewulf, Jo
   Guinee, Jeroen
   Schulze, Rita
   Weihed, Par
   Bark, Glenn
   Drielsma, Johannes
TI Towards product-oriented sustainability in the (primary) metal supply
   sector
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Review
DE Raw materials; Mining; Metal; Life cycle; Sustainability
ID LIFE-CYCLE ASSESSMENT; LCA; HARMONIZATION; BENEFITS; IMPACTS; CRADLE
AB Consideration of sustainable supply of (primary) metals is increasingly influencing the policy agenda of western societies. Environmental sustainability can be managed from different perspectives, including a site-oriented one (strongly used by the mining sector) and a product-oriented one (as with life cycle assessment). The objectives of this article are to analyse and discuss the differences in these perspectives; to discuss potential benefits to the metal/mining sector of also considering the product-oriented perspective; and to propose ways for a smooth implementation. We made use of literature and expert knowledge, on top of interviews with different stakeholders, to identify why and how these perspectives are (not) used in the metal/mining sector. Moreover, we identified three key concerns related to the implementation of a product-oriented perspective in the sector (e.g., use of unrepresentative life cycle inventory (LCI) datasets for metal-based products) and proposed three corrective actions for all of them (e.g., increase the quantity and quality of LCI). Finally, we discuss how the corrective actions could be implemented in the sector in a smooth way and some potential benefits from its implementation.
C1 [Alvarenga, Rodrigo A. F.; Dewulf, Jo] Univ Ghent, Ghent, Belgium.
   [Guinee, Jeroen; Schulze, Rita] Leiden Univ, Leiden, Netherlands.
   [Weihed, Par; Bark, Glenn] Lulea Univ Technol, Lulea, Sweden.
   [Drielsma, Johannes] Euromines, Brussels, Belgium.
RP Alvarenga, RAF (reprint author), Univ Ghent, Sustainable Syst Engn Grp STEN, Dept Green Chem & Technol, Fac Biosci Engn, Coupure Links 653 Blok B, B-9000 Ghent, Belgium.
EM rodrigo.alvarenga@ugent.be; jo.dewulf@ugent.be
RI Guinee, Jeroen/K-7931-2013
OI Guinee, Jeroen/0000-0003-2558-6493; Alvarenga,
   Rodrigo/0000-0002-6597-6421
FU KIC EIT Raw Materials [16121]
FX We would like to thank for the financial support of KIC EIT Raw
   Materials for funding the project SUPRIM (project number 16121).
   Moreover, we would like to thank Prof. Dr. Johan Verrue (Verrue
   Consulting) and several external stakeholders (that we want to keep them
   anonymous) for their support on understanding and identifying different
   perceptions among different communities (LCA community, Mining Sector
   and Geologists).
CR Agrifootprint, 2018, AGR FOOTPR DAT
   Alvarenga R. A. F., 2017, EIT RAW MAT
   Awuah-Offei K, 2011, INT J LIFE CYCLE ASS, V16, P82, DOI 10.1007/s11367-010-0246-6
   Bullock R. L., 2011, SME MINING ENG HDB
   Davidson AJ, 2016, INT J LIFE CYCLE ASS, V21, P1624, DOI 10.1007/s11367-015-1021-5
   De Camillis C, 2013, INT J LIFE CYCLE ASS, V18, P263, DOI 10.1007/s11367-012-0460-5
   Debaveye S, 2016, ENVIRON RES, V144, P19, DOI 10.1016/j.envres.2015.10.027
   Del Borghi A, 2013, INT J LIFE CYCLE ASS, V18, P293, DOI 10.1007/s11367-012-0513-9
   Drielsma J., 2017, COMMUNICATION
   Elshkaki A, 2018, ENVIRON SCI TECHNOL, V52, P2491, DOI 10.1021/acs.est.7b05154
   Europe Plastics, 2018, PLAST EUR EC
   European Commission, 2016, RAW MAT SCOR
   Finnveden G, 2009, J ENVIRON MANAGE, V91, P1, DOI 10.1016/j.jenvman.2009.06.018
   Gilbertson LM, 2014, ENVIRON SCI TECHNOL, V48, P11360, DOI 10.1021/es5006576
   Greig AL, 2016, INT J LIFE CYCLE ASS, V21, P1554, DOI 10.1007/s11367-015-0990-8
   GRI, 2011, SUST REP GUID
   GRI, 2010, SUST REP GUID MIN ME
   Hardwick AP, 2016, INT J LIFE CYCLE ASS, V21, P1616, DOI 10.1007/s11367-015-0967-7
   Hodge R. A., 2011, SME MINING ENG HDB
   ICMM, 2017, OUR HIST
   IFC, 2017, ENV SOC PERF STAND I
   International Institute for Environment and Development (IIED), 2002, BREAK NEW GROUND REP
   ISO, 2015, ENV MAN SYST REQ GUI
   ISO, 2006, ENV MAN LIF CYCL ASS
   Laget S., 2017, COMMUNICATION
   LCM, 2018, LIF CYCL MAN LCM C S
   Life Cycle Initiative, 2018, GLOSS LIF CYCL TERMS
   MAC, 2017, 101 MAC TSM
   Millstein D, 2017, NAT ENERGY, V2, DOI 10.1038/nenergy.2017.134
   Mistry M., 2018, COMMUNICATION
   Mistry M, 2016, INT J LIFE CYCLE ASS, V21, P1637, DOI 10.1007/s11367-016-1080-2
   Mistry M, 2016, INT J LIFE CYCLE ASS, V21, P1559, DOI 10.1007/s11367-016-1085-x
   Natural Resources Canada, 1994, WHIT MIN IN
   Nelson M. G., 2011, SME MINING ENG HDB
   Northey S, 2013, J CLEAN PROD, V40, P118, DOI 10.1016/j.jclepro.2012.09.027
   Nunez P, 2016, INT J LIFE CYCLE ASS, V21, P1594, DOI 10.1007/s11367-015-1003-7
   Ohno T., 1988, TOYOTA PRODUCTION SY
   Pajula T, 2017, DYNAMICS LONG LIFE A
   Pedro A, 2017, MINER ECON, V30, P153, DOI 10.1007/s13563-017-0108-9
   PRE, 2018, WHY FOOD SUST LCAS M
   Santero N, 2016, INT J LIFE CYCLE ASS, V21, P1543, DOI 10.1007/s11367-015-1022-4
   Stewart M, 2006, J CLEAN PROD, V14, P1042, DOI 10.1016/j.jclepro.2004.08.008
   Stylianou KS, 2016, INT J LIFE CYCLE ASS, V21, P734, DOI 10.1007/s11367-015-0961-0
   Swart P, 2013, ENVIRON SCI TECHNOL, V47, P13917, DOI 10.1021/es4030518
   Tilton J.E., 2016, MINERAL EC POLICY
   Westfall LA, 2016, INT J LIFE CYCLE ASS, V21, P1573, DOI 10.1007/s11367-015-0995-3
   2011, ENVIRON SCI TECHNOL, V45, P90, DOI DOI 10.1021/ES101316V
   2016, INT J LIFE CYCLE ASS, V21, P1580, DOI DOI 10.1007/S11367-016-1131-8
   2015, INT J LIFE CYCLE ASS, V20, P1199, DOI DOI 10.1007/S11367-015-0926-3
NR 49
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 40
EP 48
DI 10.1016/j.resconrec.2019.02.018
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200005
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Horton, PM
   Allwood, JM
   Cleaver, C
AF Horton, Philippa Maia
   Allwood, Julian M.
   Cleaver, Christopher
TI Implementing material efficiency in practice: A case study to improve
   the material utilisation of automotive sheet metal components
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Material utilisation; Material efficiency; Stamping; Blanking; Forming;
   Design-for-manufacture
ID BLANK HOLDER FORCE; SUSTAINABILITY; OPTIMIZATION; BARRIERS; DESIGN;
   PERFORMANCE; REDUCTION; INDUSTRY; ENERGY; STEEL
AB There is an opportunity to reduce the amount of sheet metal currently used to manufacture automotive components, despite the available cost and CO2 savings, the automotive industry has not realised the full potential of these saving opportunities. To understand why, a practical case study was set up with an automotive manufacturer. A cross-functional team was established with the scope to make changes to five components using a structured design process to improve material efficiency. The trial identified realistic opportunities to improve material utilisation by 20%pts, and save 9million pound and 5 kilotonnes of CO2 annually. The greatest saving opportunities were found early in the product development cycle, before the production method is determined by component geometry. Of these, 3%pts were actually implemented on the production vehicle, saving 1.8million pound and 1.5 kilotonnes of CO2 annually. The case study identified significant barriers to implementing material efficiency strategies in an industrial setting. To overcome these barriers material utilisation should be considered early in the product design process and high in the vehicle platform hierarchy. As a result of this investigation, new business processes are being generated to support design for material utilisation at the automotive manufacturer. This case study approach should be considered to increase implementation for other aspects of material demand reduction.
C1 [Horton, Philippa Maia; Allwood, Julian M.; Cleaver, Christopher] Univ Cambridge, Cambridge CB2 1PZ, England.
RP Allwood, JM (reprint author), Univ Cambridge, Cambridge CB2 1PZ, England.
EM Allwood-office@eng.cam.ac.uk
RI Allwood, Julian/K-5115-2013
OI Allwood, Julian/0000-0003-0931-3831
FU Jaguar Land Rover; EPSRCEngineering & Physical Sciences Research Council
   (EPSRC) [EP/N02351X/1]
FX This research is sponsored and supported by Jaguar Land Rover and EPSRC
   Grant No. EP/N02351X/1 authors would like to thank all the engineers who
   participated in the case study, especially Maninder Arora, Paul Cassell,
   Alan Hunt, James Icke, Stephen Manley, Anthony Riley, Farhad Riyahi, Ian
   Slee, Niall Shimmin and Alexander Watson. The authors would also like to
   thank Jim Harper, Mark Clifton & Gethin Davies from Jaguar Land Rover;
   Dan Marinac from Forming Technologies Inc; and Trevor Dutton and Paul
   Richardson from Dutton Simulations for their ongoing project support.
CR Atherton J, 2007, INT J LIFE CYCLE ASS, V12, P59, DOI 10.1065/lca2006.11.283
   Azevedo S., 2013, BALT J MANAG     APR, P208
   Behrens BA, 2008, PROD ENG-RES DEV, V2, P73, DOI 10.1007/s11740-007-0076-y
   Belecheanu R, 2006, R&D MANAGE, V36, P517, DOI 10.1111/j.1467-9310.2006.00451.x
   Carruth MA, 2013, CIRP ANN-MANUF TECHN, V62, P267, DOI 10.1016/j.cirp.2013.03.052
   Cullen JM, 2012, ENVIRON SCI TECHNOL, V46, P13048, DOI 10.1021/es302433p
   Edwards KL, 2003, MATER DESIGN, V24, P355, DOI 10.1016/S0261-3069(03)00041-4
   Engert S, 2016, J CLEAN PROD, V113, P822, DOI 10.1016/j.jclepro.2015.11.094
   Ettlie JE, 2007, J PROD INNOVAT MANAG, V24, P20, DOI 10.1111/j.1540-5885.2006.00230.x
   Horton P, 2018, MRS ADV, V3, P1393, DOI 10.1557/adv.2018.280
   Horton PM, 2017, J MATER PROCESS TECH, V249, P78, DOI 10.1016/j.jmatprotec.2017.05.037
   Ingarao G, 2011, J CLEAN PROD, V19, P337, DOI 10.1016/j.jclepro.2010.10.005
   JLR, 2016, NOV U CAMBR I SUST L
   Kallstrom H., 2015, RAW MAT BIGGEST COST
   Kitayama S, 2015, STRUCT MULTIDISCIP O, V52, P1001, DOI 10.1007/s00158-015-1293-1
   Kumar S, 2016, PROD PLAN CONTROL, V27, P604, DOI 10.1080/09537287.2016.1165307
   LEWIS H, 2001, DESIGN ENV GLOBAL GU
   Lin ZQ, 2007, J MATER PROCESS TECH, V183, P339, DOI 10.1016/j.jmatprotec.2006.10.027
   Linton JD, 2007, J OPER MANAG, V25, P1075, DOI 10.1016/j.jom.2007.01.012
   Luthra S, 2016, J CLEAN PROD, V121, P142, DOI 10.1016/j.jclepro.2016.01.095
   Milford RL, 2011, RESOUR CONSERV RECY, V55, P1185, DOI 10.1016/j.resconrec.2011.05.021
   Naceur H, 2004, J MATER PROCESS TECH, V151, P183, DOI 10.1016/j.jmatprotec.2004.04.036
   Penna CCR, 2012, TECHNOL FORECAST SOC, V79, P999, DOI 10.1016/j.techfore.2011.09.006
   Sattari H, 2007, J MATER PROCESS TECH, V184, P84, DOI 10.1016/j.jmatprotec.2006.11.008
   Schoggl JP, 2017, J CLEAN PROD, V140, P1602, DOI 10.1016/j.jclepro.2016.09.195
   Shahbazi S, 2016, J CLEAN PROD, V127, P438, DOI 10.1016/j.jclepro.2016.03.143
   Shim HB, 2004, P I MECH ENG B-J ENG, V218, P1099, DOI 10.1243/0954405041897040
   Shim HB, 2015, P I MECH ENG B-J ENG, V229, P990, DOI 10.1177/0954405414535582
   Shim HB, 2013, P I MECH ENG B-J ENG, V227, P1514, DOI 10.1177/0954405413480141
   Stewart R, 2016, PROC CIRP, V48, P22, DOI 10.1016/j.procir.2016.04.063
   Trianni A, 2012, ENERGY, V37, P494, DOI 10.1016/j.energy.2011.11.005
   Verhoef PC, 2012, J PROD INNOVAT MANAG, V29, P559, DOI 10.1111/j.1540-5885.2012.00925.x
   Veshagh A., 2015, 310 P LCE 2006, P305
   Zaki M., 2014, JURNAL TEKNOLOGI SCI, V70, P117
   Zhang SH, 2004, J MATER PROCESS TECH, V151, P39, DOI 10.1016/j.jmatprotec.2004.04.098
   2010, ENVIRON SCI TECHNOL, V44, P1888, DOI DOI 10.1021/ES902909K
   2013, INT J PROD ECON, V145, P463, DOI DOI 10.1016/J.IJPE.2013.04.007
NR 37
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 49
EP 66
DI 10.1016/j.resconrec.2019.02.012
PG 18
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200006
DA 2020-05-12
ER

PT J
AU Khoo, HH
AF Khoo, Hsien H.
TI LCA of plastic waste recovery into recycled materials, energy and fuels
   in Singapore
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE LCA; Plastic wastes; Plant capacities; Mechanical recycling; Pyrolysis;
   Gasification
ID LIFE-CYCLE ASSESSMENT; MANAGEMENT-SYSTEMS; INCINERATION; VALUATION;
   PYROLYSIS
AB In Singapore, 822,200 tonnes of plastic waste was generated in 2016, with only 7% recycled. Due to the complex nature of plastic waste mixtures, mechanical recycling is often inefficient, leading to a majority of waste being incinerated. In this article, alternative solutions are introduced to address the waste problem, such as recovering valuable fuels from plastics via thermochemical methods. Life cycle assessment (LCA) was adopted to investigate 8 scenarios of plastic waste management options. In a nation with land scarcity, the scales and sizes of each plastic waste recycling/recovery method is also taken into consideration. The results demonstrated how different combinations of four plastics valorization technologies, and associated capacities, affected the potential environmental benefits and drawbacks of plastic waste treatment systems. In order to enable selecting the best option among the 8 scenarios, normalization and weighting was carried out.
C1 [Khoo, Hsien H.] Inst Chem & Engn Sci, 1 Pesek Rd, Jurong Isl 627833, Singapore.
RP Khoo, HH (reprint author), Inst Chem & Engn Sci, 1 Pesek Rd, Jurong Isl 627833, Singapore.
EM khoohsien_hui@ices.a-star.edu.sg
FU ExxonMobil Chemical Company
FX With special to appreciation ExxonMobil Chemical Company for funding
   this research work. Their feedback and guidance received during the
   course of this LCA project were highly valuable. And also, additional
   appreciation to colleagues Naraharisetti Pavan Kumar, for help in
   evaluating the sizes of the pyrolysis/gasification facilities, and Zhou
   Ying, for data collection and compilation.
CR Ahlroth S, 2014, RESOUR CONSERV RECY, V85, P34, DOI 10.1016/j.resconrec.2013.11.012
   Ahlroth S, 2011, J CLEAN PROD, V19, P145, DOI 10.1016/j.jclepro.2010.04.016
   Al-Salem SM, 2017, J ENVIRON MANAGE, V197, P177, DOI 10.1016/j.jenvman.2017.03.084
   Ang BW, 2015, APPL ENERG, V148, P314, DOI 10.1016/j.apenergy.2015.03.088
   [Anonymous], 2017, WAST STAT OV REC
   [Anonymous], 2006, 14040 ISO
   [Anonymous], 2016, WAST EN WORLD EN RES
   [Anonymous], 2006, 14044 ISO
   Astrup T, 2009, WASTE MANAGE RES, V27, P789, DOI 10.1177/0734242X09343774
   Bassi SA, 2017, WASTE MANAGE, V69, P545, DOI 10.1016/j.wasman.2017.07.042
   Beston Machinery, 2016, WAST PLAST PYR PLANT
   Blengini GA, 2012, WASTE MANAGE, V32, P1712, DOI 10.1016/j.wasman.2012.04.010
   Brems A., 2013, NAT SCI, V5, P695, DOI DOI 10.4236/NS.2013.56086
   Bundesamt Umwelt, 2017, PLAST WAST GERM
   Butler E, 2011, WASTE BIOMASS VALORI, V2, P227, DOI 10.1007/s12649-011-9067-5
   Chen XD, 2011, WASTE MANAGE, V31, P168, DOI 10.1016/j.wasman.2010.08.010
   Clavreul J, 2012, WASTE MANAGE, V32, P2482, DOI 10.1016/j.wasman.2012.07.008
   Cleary J, 2010, INT J LIFE CYCLE ASS, V15, P579, DOI 10.1007/s11367-010-0186-1
   Cossu R, 2017, WASTE MANAGE, V69, P567, DOI 10.1016/j.wasman.2017.08.007
   Das P, 2018, RESOUR CONSERV RECY, V128, P69, DOI 10.1016/j.resconrec.2017.09.025
   Ecolnvent, 2018, TRANSP FREIGHT BARG
   EPD, 2015, WAST STAT HONG KONG
   Fabry F, 2013, WASTE BIOMASS VALORI, V4, P421, DOI 10.1007/s12649-013-9201-7
   Fukushima M, 2009, J MATER CYCLES WASTE, V11, P11, DOI 10.1007/s10163-008-0212-6
   Gear M, 2018, J CLEAN PROD, V180, P735, DOI 10.1016/j.jclepro.2018.01.015
   Gershman Brickner Bratton Inc., 2013, GBB1203801 AM CHEM C
   Gradus R., 2016, 2016039VI TI VU U AM
   Heijungs R, 2007, INT J LIFE CYCLE ASS, V12, P211, DOI 10.1065/lca2006.07.260
   Hennlock M., 2014, EC POLICY INSTRUMENT
   Ho J. C., 2015, SINGAPORESINGAPORES
   Huijbregts MAJ, 2017, INT J LIFE CYCLE ASS, V22, P138, DOI 10.1007/s11367-016-1246-y
   Johnke B., 2001, EMISSIONS WASTE INCI
   Karidis A., 2017, WASTE TO ENERGY ALTE
   Khoo HH, 2010, SCI TOTAL ENVIRON, V408, P1367, DOI 10.1016/j.scitotenv.2009.10.072
   Kungkajit C, 2015, ENRGY PROCED, V79, P528, DOI 10.1016/j.egypro.2015.11.529
   Kunwar B, 2016, RENEW SUST ENERG REV, V54, P421, DOI 10.1016/j.rser.2015.10.015
   Kuo JH, 2011, INT J GREENH GAS CON, V5, P889, DOI 10.1016/j.ijggc.2011.03.001
   Laner D, 2015, WASTE MANAGE, V46, P653, DOI 10.1016/j.wasman.2015.09.006
   Laurent A, 2014, WASTE MANAGE, V34, P573, DOI 10.1016/j.wasman.2013.10.045
   Laurent A, 2014, WASTE MANAGE, V34, P589, DOI 10.1016/j.wasman.2013.12.004
   Low M., 2018, POLICY BRIEF 2018 SI
   Manfredi S, 2011, INT J LIFE CYCLE ASS, V16, P937, DOI 10.1007/s11367-011-0315-5
   McDougall F.R., 2003, INTEGRATED SOLID WAS
   Morandin M., 2016, P ECOS JUN 19 23
   Nagy DI, 2017, THESIS
   National Environment Agency, 2016, TUAS S INC PLANT
   National Environmental Agency, 2017, AIR QUAL SING
   Neidel T.L., 2013, REPORT INITIAL ASSES
   Ocean Recovery Alliance, 2015, 2015 PLAST TO FUEL P
   PE International, 2015, LCA MAN OPT POL WAST
   Perugini F, 2005, ENVIRON PROG, V24, P137, DOI 10.1002/ep.10078
   Plastics2Oil, 2018, P20 TECHN
   Prado V, 2017, INT J LIFE CYCLE ASS, V22, P2018, DOI 10.1007/s11367-017-1281-3
   Recycling International, 2010, PLANS UKS 1 PLAST TO
   Rigamonti L, 2014, RESOUR CONSERV RECY, V85, P42, DOI 10.1016/j.resconrec.2013.12.012
   RTI International, 2012, 0212876000 RTI
   Sala S, 2015, INT J LIFE CYCLE ASS, V20, P1568, DOI 10.1007/s11367-015-0958-8
   Sandoval D., 2018, BRIGHTMARK ENERGY TA
   Sharuddin SDA, 2016, ENERG CONVERS MANAGE, V115, P308, DOI 10.1016/j.enconman.2016.02.037
   Skone T., 2010, DOENEIL403110509
   Slagstad H, 2013, WASTE MANAGE, V33, P212, DOI 10.1016/j.wasman.2012.09.020
   Tan RBH, 2010, ENERGY, V35, P4910, DOI 10.1016/j.energy.2010.08.036
   Thinkstep, 2018, GABI PROD SUST PERF
   TNO, 2001, EC REC SCEN PLAST PA
   Toft R., 2016, WASTE STAT 2014
   Tsiamis D., 2013, THESIS
   Tunesi S, 2011, WASTE MANAGE, V31, P561, DOI 10.1016/j.wasman.2010.08.023
   Vadxx, 2018, PLAST TO EC
   Vink T., 2014, PLASTIC RECYCLING KO
   Whiting K., 2013, WASTE TECHNOLOGIES W
   Wilson B, 2013, COMP ASSESSMENT COMM
   Wong SL, 2015, RENEW SUST ENERG REV, V50, P1167, DOI 10.1016/j.rser.2015.04.063
   WRAP, 2016, PLAST MARK SIT REP
   WRAP, 2008, LCA MAN OPT MIX WAST
   Yolin C., 2015, WASTE MANAGEMENT REC
   Zhong ZW, 2011, RENEW ENERG, V36, P2227, DOI 10.1016/j.renene.2011.01.021
   Zia KM, 2007, REACT FUNCT POLYM, V67, P675, DOI 10.1016/j.reactfunctpolym.2007.05.004
   2015, WASTE MANAGE, V38, P486, DOI DOI 10.1016/J.WASMAN.2014.12.005
NR 78
TC 7
Z9 7
U1 17
U2 35
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 67
EP 77
DI 10.1016/j.resconrec.2019.02.010
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200007
DA 2020-05-12
ER

PT J
AU Wang, Q
   Wu, J
   Zhao, NG
   Zhu, QY
AF Wang, Qiang
   Wu, Jie
   Zhao, Nenggui
   Zhu, Qingyuan
TI Inventory control and supply chain management: A green growth
   perspective
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Green growth; Recycling; Government subsidy; Inventory; Green supply
   chain
ID MODEL; COMPETITION; EFFICIENCY; REDUCTION; DESIGN; POLICIES; IMPACT;
   CHINA; PRICE
AB Green growth is becoming an important mode for the sustainable operation of economy and society in the world. All countries are developing innovative methodologies to achieve green growth. Particularly, inventory and pricing are important technologies for companies' leadership to make decisions. The increasingly polluted environment has made sustainable utilization of resources and environmental protection more urgent, however, there is very little literature studying inventory and pricing from a green growth perspective. To fill this gap, we consider both inventory and pricing decisions for companies under different green growth mechanisms. We first consider the single period inventory model with a remanufactured supplier and the government subsidy for single and dual sourcing system, respectively, further derive the optimal order decisions for the retailer. Then, we assume the customers are environmentally sensitive and there is a green supplier in the market, examine the optimal pricing decisions for the retailer using the two-stage optimization method. We explore the value of the recycling supplier and government subsidy in the numerical study; furthermore, we examine the influences of the green degree of product on the optimal price decisions for different products. One interesting finding is that the retailer should order more green products no matter how expensive it is, as long as the customers in the market are environmentally sensitive.
C1 [Wang, Qiang; Wu, Jie; Zhao, Nenggui] Univ Sci & Technol China, Sch Management, Hefei 230026, Anhui, Peoples R China.
   [Zhu, Qingyuan] Nanjing Univ Aeronaut & Astronaut, Coll Econ & Management, Nanjing 210000, Jiangsu, Peoples R China.
   [Zhu, Qingyuan] Nanjing Univ Aeronaut & Astronaut, Res Ctr Soft Energy Sci, 29 Jiangiun Ave, Nanjing 211106, Jiangsu, Peoples R China.
RP Wu, J (reprint author), Univ Sci & Technol China, Sch Management, Hefei 230026, Anhui, Peoples R China.
EM qiangwan@mail.ustc.edu.cn; jacky012@mail.ustc.edu.cn;
   zhaoneng@mail.ustc.edu.cn; zqynuaa@nuaa.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71571173]
FX This work was supported by the National Natural Science Foundation of
   China under grant 71571173.
CR Absi N, 2013, EUR J OPER RES, V227, P55, DOI 10.1016/j.ejor.2012.11.044
   Arikan E, 2014, INT J PROD ECON, V157, P15, DOI 10.1016/j.ijpe.2014.04.029
   Bouchery Y, 2012, EUR J OPER RES, V222, P229, DOI 10.1016/j.ejor.2012.05.004
   Carvalho H, 2017, RESOUR CONSERV RECY, V120, P75, DOI 10.1016/j.resconrec.2016.09.025
   Castillo VE, 2018, J BUS LOGIST, V39, P38, DOI 10.1111/jbl.12176
   Chen X, 2013, OPER RES LETT, V41, P172, DOI 10.1016/j.orl.2012.12.003
   Choi SC, 1996, J RETAILING, V72, P117, DOI 10.1016/S0022-4359(96)90010-X
   Coskun S, 2016, J CLEAN PROD, V110, P149, DOI 10.1016/j.jclepro.2015.02.063
   Ding HP, 2016, EUR J OPER RES, V255, P463, DOI 10.1016/j.ejor.2016.05.003
   El Saadany AMA, 2010, COMPUT IND ENG, V58, P352, DOI 10.1016/j.cie.2009.01.017
   Fahimnia B, 2015, EUR J OPER RES, V247, P1, DOI 10.1016/j.ejor.2015.04.034
   Ghadimi P, 2019, RESOUR CONSERV RECY, V140, P72, DOI 10.1016/j.resconrec.2018.09.005
   Govindan K, 2014, INT J PROD ECON, V147, P555, DOI 10.1016/j.ijpe.2013.08.018
   Guide VDR, 2003, J OPER MANAG, V21, P259, DOI 10.1016/S0272-6963(02)00110-9
   Guide VDR, 2000, INTERFACES, V30, P125, DOI 10.1287/inte.30.3.125.11656
   Gunasekaran A., 2015, GREEN SUPPLY CHAIN C
   Hua GW, 2011, INT J PROD ECON, V132, P178, DOI 10.1016/j.ijpe.2011.03.024
   Jaber MY, 2013, INT J PROD RES, V51, P69, DOI 10.1080/00207543.2011.651656
   Khouja M, 1996, J OPER RES SOC, V47, P1530, DOI 10.2307/3010611
   Klosterhalfen S, 2011, INT J PROD ECON, V133, P302, DOI 10.1016/j.ijpe.2010.02.004
   Kurata H, 2007, EUR J OPER RES, V180, P262, DOI 10.1016/j.ejor.2006.04.002
   Li B, 2016, J CLEAN PROD, V112, P2029, DOI 10.1016/j.jclepro.2015.05.017
   Ma WM, 2013, EUR J OPER RES, V226, P221, DOI 10.1016/j.ejor.2012.10.033
   Mahadevan B, 2003, EUR J OPER RES, V151, P536, DOI 10.1016/S0377-2217(02)00627-6
   Mallidis I, 2012, J TRANSP GEOGR, V22, P118, DOI 10.1016/j.jtrangeo.2011.12.007
   McGuire TW, 2008, MARKET SCI, V27, P115, DOI 10.1287/mksc.1070.0335
   Nagurney A, 2007, INT J SUSTAIN TRANSP, V1, P29, DOI 10.1080/15568310601060077
   Roy A, 2009, COMPUT IND ENG, V56, P87, DOI 10.1016/j.cie.2008.04.004
   Savaskan RC, 2004, MANAGE SCI, V50, P239, DOI 10.1287/mnsc.1030.0186
   Sheu JB, 2012, INT J PROD ECON, V138, P201, DOI 10.1016/j.ijpe.2012.03.024
   Song J., 2012, HDB NEWSVENDOR PROBL, V176, P297, DOI [DOI 10.1007/978-1-4614-3600-3_13, DOI 10.1007/978-1-4614-3600-3]
   Song ML, 2018, RESOUR CONSERV RECY, V128, P197, DOI 10.1016/j.resconrec.2016.08.015
   Tseng ML, 2019, RESOUR CONSERV RECY, V141, P145, DOI 10.1016/j.resconrec.2018.10.009
   Tseng ML, 2018, RESOUR CONSERV RECY, V128, P122, DOI 10.1016/j.resconrec.2017.01.007
   van der Laan E, 1999, MANAGE SCI, V45, P733, DOI 10.1287/mnsc.45.5.733
   Van Der Laan E., 1997, EFFECTS REMANUFACTUR
   Winslow KM, 2018, RESOUR CONSERV RECY, V129, P263, DOI 10.1016/j.resconrec.2017.11.001
   Xu L, 2018, RESOUR CONSERV RECY, V131, P297, DOI 10.1016/j.resconrec.2017.10.012
   Yang L, 2018, J CLEAN PROD, V194, P300, DOI 10.1016/j.jclepro.2018.05.129
   Yang L, 2017, J CLEAN PROD, V142, P993, DOI 10.1016/j.jclepro.2016.08.018
   Zhao SL, 2018, RESOUR CONSERV RECY, V128, P176, DOI 10.1016/j.resconrec.2016.07.005
   Zhu WG, 2017, EUR J OPER RES, V258, P165, DOI 10.1016/j.ejor.2016.08.053
   2013, INT J PROD ECON, V143, P109, DOI DOI 10.1016/J.IJPE.2012.12.007
NR 43
TC 3
Z9 3
U1 10
U2 32
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 78
EP 85
DI 10.1016/j.resconrec.2019.02.024
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200008
DA 2020-05-12
ER

PT J
AU Li, XL
   Yang, XJ
   Wei, Q
   Zhang, B
AF Li, Xiaoliang
   Yang, Xiaojin
   Wei, Qi
   Zhang, Bing
TI Authoritarian environmentalism and environmental policy implementation
   in China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Policy implementation; Authoritarian environmentalism; Expected utility;
   Incentive mechanism
ID ENFORCEMENT; POLITICIANS; BUREAUCRATS; GOVERNANCE; GAP
AB Policy implementation is essential to the effectiveness of environmental governance. Focusing on two types of policies in China, law derived environmental policies and plan derived environmental policies; this research analyzed the impact of the central government's rules, regulations, and mechanism for rewards/penalties on local governments' policy implementation. The results indicate that local governments selectively implement environmental policies. This selective implementation effort is primarily determined by the authoritarian environmentalism and the target responsibility system imposed by the central government. Local governments focus their attention on the attitude of the central government toward that policy because the scope of its reward/penalty system provides a signaling effect for different policies. The central government's regulatory oversight of policy implementation has also increased the binding power of the incentive mechanism. China's environmental law or policy implementation should make the government work paramountly.
C1 [Li, Xiaoliang; Yang, Xiaojin] Beijing Univ Chem Technol, Dept Environm Sci & Engn, Beijing 100029, Peoples R China.
   [Li, Xiaoliang] Chinese Acad Environm Planning, Beijing 100012, Peoples R China.
   [Wei, Qi; Zhang, Bing] Nanjing Univ, State Key Lab Pollut Control & Resource Reuse, Sch Environm, Nanjing 210023, Jiangsu, Peoples R China.
RP Yang, XJ (reprint author), Beijing Univ Chem Technol, Dept Environm Sci & Engn, Beijing 100029, Peoples R China.
EM yangxj@mail.buct.edu.cn
CR Ahlers AL, 2018, CHINA QUART, V234, P299, DOI 10.1017/S0305741017001370
   Akella A., 2004, STRENGTHENING WEAKES
   Alesina A, 2007, AM ECON REV, V97, P169, DOI 10.1257/aer.97.1.169
   Ambec S, 2013, REV ENV ECON POLICY, V7, P2, DOI 10.1093/reep/res016
   Becker G. S., 1974, CRIME PUNISHMENT EC, P1
   BESLEY T, 1995, AM ECON REV, V85, P25
   Brewer GA, 2005, J PUBL ADM RES THEOR, V15, P505, DOI 10.1093/jopart/mui031
   Burgess R, 2012, Q J ECON, V127, P1707, DOI 10.1093/qje/qjs034
   Cannon J, 2011, REGUL GOV, V5, P262, DOI 10.1111/j.1748-5991.2011.01102.x
   Carter Neil T., 2007, ENV GOVERNANCE CHINA
   Clement F, 2009, LAND USE POLICY, V26, P458, DOI 10.1016/j.landusepol.2008.06.003
   COHEN M, 1998, MONITORING ENFORCEME
   Dewatripont M, 1999, REV ECON STUD, V66, P199, DOI 10.1111/1467-937X.00085
   Dongol Y, 2012, ENVIRON MANAGE, V50, P181, DOI 10.1007/s00267-012-9896-4
   Doyle T, 2006, ENVIRON POLIT, V15, P750, DOI 10.1080/09644010600937199
   Eaton S., 2013, CHINA Q
   Gilley B, 2012, ENVIRON POLIT, V21, P287, DOI 10.1080/09644016.2012.651904
   Han HJ, 2015, ENVIRON POLIT, V24, P810, DOI 10.1080/09644016.2015.1051324
   Heberer T., 2011, J CURR CHIN AFFAIRS, V40
   Heyes A, 2000, J REGUL ECON, V17, P107, DOI 10.1023/A:1008157410380
   Hill CJ, 2006, J PUBL ADM RES THEOR, V16, P263, DOI 10.1093/jopart/mui043
   Holmstrom B, 1999, REV ECON STUD, V66, P169, DOI 10.1111/1467-937X.00083
   Jia R., 2018, WORKING PAPER
   Kostka G., 2013, WORKING PAPER SERIES
   Kostka G, 2012, CHINA QUART, P765, DOI 10.1017/S0305741012000860
   Li HB, 2005, J PUBLIC ECON, V89, P1743, DOI 10.1016/j.jpubeco.2004.06.009
   Lieberthal Kenneth, 1997, CHINA ENV SERIES, V1, P3
   List JA, 2006, Q J ECON, V121, P1249, DOI 10.1162/qjec.121.4.1249
   Liu LX, 2012, ENVIRON SCI POLICY, V21, P106, DOI 10.1016/j.envsci.2012.05.001
   Liu NN, 2015, PUBLIC ADMIN REV, V75, P85, DOI 10.1111/puar.12285
   Lo K, 2015, ENVIRON SCI POLICY, V54, P152, DOI 10.1016/j.envsci.2015.06.001
   May PJ, 2009, J PUBL ADM RES THEOR, V19, P453, DOI 10.1093/jopart/mum030
   Morriss Andrew P., 2008, REGULATION LITIGATIO
   Oosterwaal A, 2012, J PUBL ADM RES THEOR, V22, P195, DOI 10.1093/jopart/mur037
   Palmer M, 1998, CHINA QUART, P788
   Qian YY, 1997, J ECON PERSPECT, V11, P83, DOI 10.1257/jep.11.4.83
   Ran R, 2013, J ENVIRON POL PLAN, V15, P17, DOI 10.1080/1523908X.2012.752186
   Riccucci Norma M., 2005, MANAGEMENT MATTERS S
   de Abreu MCS, 2018, RESOUR CONSERV RECY, V138, P99, DOI 10.1016/j.resconrec.2018.07.001
   Sowers J., 2007, Journal of Environment & Development, V16, P375, DOI 10.1177/1070496507309112
   Swanson KE, 2001, ENVIRON MANAGE, V27, P481, DOI 10.1007/s002670010164
   Tong J., 2011, CONT FINAN EC, V6
   Tosun J, 2012, ENVIRON POLICY GOV, V22, P437, DOI 10.1002/eet.1582
   van Rooij B, 2006, DEV CHANGE, V37, P57, DOI 10.1111/j.0012-155X.2006.00469.x
   VANMETER DS, 1975, ADMIN SOC, V6, P445, DOI 10.1177/009539977500600404
   Wang CM, 2010, PROCEDIA ENVIRON SCI, V2, P1701, DOI 10.1016/j.proenv.2010.10.181
   Wang M. Y., 2008, VILL ENV LAW J, V19, P95
   Wu J., 2012, INCENTIVES OUT UNPUB
   Wu J., 2013, INCENTIVES OUTCOMES
   Xu YA, 2011, ENVIRON SCI TECHNOL, V45, P380, DOI 10.1021/es1025678
   Yano Y, 2009, J AGR ECON, V60, P530, DOI 10.1111/j.1477-9552.2009.00208.x
   Young O. R., 2015, GLOBAL ENV CHANGE
   Yu XY, 2013, RESOUR CONSERV RECY, V80, P64, DOI 10.1016/j.resconrec.2013.09.001
   Zhan X., 2013, J PUBLIC ADM RES THE
   Zhang KunMin, 2007, China Population, Resources and Environment, V17, P1, DOI 10.1016/S1872-583X(07)60006-0
   Zhang XB, 2006, J COMP ECON, V34, P713, DOI 10.1016/j.jce.2006.08.006
   Zhang XH, 2010, CHINA QUART, P307, DOI 10.1017/S0305741010000251
   Zhou L.A., 2007, EC RES J, P36
   Zhu JM, 2019, REGUL GOV, V13, P384, DOI 10.1111/rego.12172
   2012, ENERG POLICY, V48, P779, DOI DOI 10.1016/J.ENPOL.2012.06.015
NR 60
TC 12
Z9 12
U1 10
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 86
EP 93
DI 10.1016/j.resconrec.2019.02.011
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200009
DA 2020-05-12
ER

PT J
AU Diaz-Elsayed, N
   Rezaei, N
   Guo, TJ
   Mohebbi, S
   Zhang, Q
AF Diaz-Elsayed, Nancy
   Rezaei, Nader
   Guo, Tianjiao
   Mohebbi, Shima
   Zhang, Qiong
TI Wastewater-based resource recovery technologies across scale: A review
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Review
DE Water reuse; Energy recovery; Nutrient recovery; Wastewater treatment;
   System scale
ID LIFE-CYCLE ASSESSMENT; URINE SOURCE SEPARATION; PERSONAL CARE PRODUCTS;
   TREATMENT PLANTS; POTABLE WATER; PHOSPHORUS RECOVERY;
   ENERGY-CONSUMPTION; GREYWATER REUSE; URBAN WATER; MANAGEMENT
AB Over the past few decades, wastewater has been evolving from a waste to a valuable resource. Wastewater can not only dampen the effects of water shortages by means of water reclamation, but it also provides the medium for energy and nutrient recovery to further offset the extraction of precious resources. Since identifying viable resource recovery technologies can be challenging, this article offers a review of technologies for water, energy, and nutrient recovery from domestic and municipal wastewater through the lens of the scale of implementation. The system scales were classified as follows: small scale (design flows of 17 m(3)/day or less), medium scale (8 to 20,000 m(3)/day), and large scale (3800 m(3)/day or more). The widespread implementation of non-potable reuse (NPR) projects across all scales highlighted the ease of implementation associated with lower water quality requirements and treatment schemes that resembled conventional wastewater treatment. Although energy recovery was mostly achieved in large-scale plants from biosolids management or hydraulic head loss, the highest potential for concentrated nutrient recovery occurred in small-scale systems using urine source separating technologies. Small-scale systems offered benefits such as the ability for onsite resource recovery and reuse that lowered distribution and transportation costs and energy consumption, while larger scales benefited from lower per unit costs and energy consumption for treatment. The removal of pharmaceuticals and personal care products remained a challenge across scales, but unit processes such as reverse osmosis, nanofiltration, activated carbon, and advanced oxidation processes exhibited high removal efficiency for select contaminants.
C1 [Diaz-Elsayed, Nancy; Rezaei, Nader; Guo, Tianjiao; Mohebbi, Shima; Zhang, Qiong] Univ S Florida, Dept Civil & Environm Engn, 4202 E Fowler Ave, Tampa, FL 33620 USA.
   [Guo, Tianjiao] Zhejiang Univ, Inst Ind Ecol & Environm, Yuquan Campus,38 Zheda Rd, Hangzhou 310027, Zhejiang, Peoples R China.
   [Mohebbi, Shima] Univ Oklahoma, Sch Ind & Syst Engn, 202 W Boyd St, Norman, OK 73019 USA.
RP Zhang, Q (reprint author), Univ S Florida, 4202 E Fowler Ave,ENG 030, Tampa, FL 33620 USA.
EM giongzhang@usf.edu
RI Guo, Tianjiao/K-6152-2015; Diaz-Elsayed, Nancy/B-8932-2017
OI Guo, Tianjiao/0000-0001-9604-905X; 
FU National Science Foundation Faculty Early Career Development (CAREER)
   grant of the United States [1454559]
FX This material is based upon work supported by the National Science
   Foundation Faculty Early Career Development (CAREER) grant of the United
   States (No. 1454559). Any opinions, findings, and conclusions or
   recommendations expressed in this material are those of the authors and
   do not necessarily reflect the views of the National Science Foundation.
CR Amann A, 2018, RESOUR CONSERV RECY, V130, P127, DOI 10.1016/j.resconrec.2017.11.002
   Anand CK, 2014, WASTE MANAGE, V34, P329, DOI 10.1016/j.wasman.2013.10.006
   [Anonymous], 2014, WASTEWATER TREATMENT
   [Anonymous], 2017, WASTEWATER TREATMENT
   [Anonymous], 2017, ENERGY EFFICIENCY PR
   [Anonymous], 2013, CITY MANAGERS REPORT
   [Anonymous], 2018, DELHI CHARTER TOWNSH
   [Anonymous], 2018, RECYCLED WATER DAILY
   [Anonymous], 2016, FRESNO BEE
   [Anonymous], 2018, POINT LOMA WASTEWATE
   [Anonymous], 2017, POINT LOMA WASTEWATE
   Asano T., 2007, WATER REUSE ISSUES T
   Bachmann N., 2015, IEA BIOENERGY
   Bakir HA, 2001, J ENVIRON MANAGE, V61, P319, DOI 10.1006/jema.2000.0414
   Biohabitats, 2019, COLD CLIM CONSTR WET
   BioMicrobics, 2017, BIOMICROBIES SUST
   Bloetscher F, 2005, WATER ENVIRON RES, V77, P480, DOI 10.2175/106143005X67395
   Bravo L, 2011, WATER SCI TECHNOL, V64, P440, DOI 10.2166/wst.2011.522
   Brehm JM, 2013, ENVIRON MANAGE, V52, P113, DOI 10.1007/s00267-013-0056-2
   British Columbia EOCPO, 2015, FAC CLASS
   Brown and Caldwell, 2012, PAC NW CLEAN WAT ASS
   Brown V, 2010, WATER SCI TECHNOL, V62, P510, DOI 10.2166/wst.2010.296
   Brueck T., 2012, WATER SECTOR WORKFOR
   Bruursema T., 2011, NEW NSF 350 350 1
   Bullitt Foundation, 2013, BULL CTR BUILD FEAT
   Byrne DM, 2017, ENVIRON SCI-WAT RES, V3, P1002, DOI 10.1039/c7ew00175d
   Cartmell E, 2006, ENVIRON SCI TECHNOL, V40, P649, DOI 10.1021/es052181g
   CDPH, 2014, REG REL REC WAT
   CH2M HILL, 2010, UDWQ POTW NUTR REM C
   Chae KJ, 2013, ENERG CONVERS MANAGE, V75, P664, DOI 10.1016/j.enconman.2013.08.028
   Chen Z, 2017, RESOUR CONSERV RECY, V117, P125, DOI 10.1016/j.resconrec.2016.11.008
   Chow CWK, 2018, CHEMOMETR INTELL LAB, V177, P140, DOI 10.1016/j.chemolab.2018.03.006
   Chung G, 2008, ENVIRON MODELL SOFTW, V23, P893, DOI 10.1016/j.envsoft.2007.10.002
   Church J, 2015, SCI TOTAL ENVIRON, V529, P275, DOI 10.1016/j.scitotenv.2015.05.007
   Cloete NA, 2016, IEEE ACCESS, V4, P3975, DOI 10.1109/ACCESS.2016.2592958
   Cornejo PK, 2016, ENVIRON SCI TECHNOL, V50, P6680, DOI 10.1021/acs.est.5b05055
   Cornel P, 2011, TREATISE ON WATER SCIENCE, VOL 4: WATER-QUALITY ENGINEERING, P337
   Cornel P, 2009, WATER SCI TECHNOL, V59, P1069, DOI 10.2166/wst.2009.045
   Cossio C, 2018, ENVIRON TECHNOL, V39, P1393, DOI 10.1080/09593330.2017.1330364
   Crook J., 2007, INNOVATIVE APPL WATE, V2
   Daigger GT, 2009, WATER ENVIRON RES, V81, P809, DOI 10.2175/106143009X425898
   Danfoss, 2014, CAS STOR GEN SURPL P
   Denver Water, 2016, ADD REC WAT TEST
   Denver Water, 2016, REC WAT QUAL STAND
   du Pisani PL, 2006, DESALINATION, V188, P79, DOI 10.1016/j.desal.2005.04.104
   EcoDrain, 2019, A1000 GREYW HEAT EXC
   ECOfluid, 2017, CAS STUD
   ECOfluid, 2017, CAS STUD UNIVERCITY
   Eggimann S, 2015, WATER RES, V84, P218, DOI 10.1016/j.watres.2015.07.004
   Egle L, 2015, RESOUR CONSERV RECY, V105, P325, DOI 10.1016/j.resconrec.2015.09.016
   EPRI & WRF, 2013, EL US MAN MUN WAT SU
   Etter B, 2011, WATER RES, V45, P852, DOI 10.1016/j.watres.2010.10.007
   Florida DEP, 2013, RUL 62 699 TREATM PL
   Gander M, 2000, SEP PURIF TECHNOL, V18, P119, DOI 10.1016/S1383-5866(99)00056-8
   Gassie LW, 2017, WATER RES, V125, P384, DOI 10.1016/j.watres.2017.08.062
   Geoenvironment Technologies, 2018, MUN BIOS MAN
   Gerrity D, 2013, J WATER SUPPLY RES T, V62, P321, DOI 10.2166/aqua.2013.041
   Gikas P., 2014, 2 INT C SUST SOL WAS
   Gikas P, 2009, J ENVIRON MANAGE, V90, P144, DOI 10.1016/j.jenvman.2007.08.016
   Gleeson T, 2012, NATURE, V488, P197, DOI 10.1038/nature11295
   Gu YF, 2017, APPL ENERG, V204, P1463, DOI 10.1016/j.apenergy.2017.02.069
   Guest JS, 2009, ENVIRON SCI TECHNOL, V43, P6126, DOI 10.1021/es9010515
   Gunady M, 2015, J ENVIRON PUBLIC HEA, DOI 10.1155/2015/716957
   Guo TJ, 2015, WATER RES, V75, P146, DOI 10.1016/j.watres.2015.02.033
   Guo TJ, 2014, WATER SCI TECHNOL, V69, P223, DOI 10.2166/wst.2013.734
   Han HG, 2018, CHINESE J CHEM ENG, V26, P2093, DOI 10.1016/j.cjche.2018.03.027
   Hao XD, 2015, WATER RES, V87, P424, DOI 10.1016/j.watres.2015.05.050
   Hasik V, 2017, ENVIRON SCI TECHNOL, V51, P1110, DOI 10.1021/acs.est.6b03879
   Hawthorne M., 2016, CHICAGO TRIB
   HUBER SE, 2017, 3 HUBER PROJ WAST HE
   IAPMO, 2015, 2015 UN PLUMB COD 15
   ICC, 2015, 2015 INT PLUMB COD S
   Idaho DEQ, 2015, WAST SYST CLASS
   ILFI, 2017, LIV BUILD CHALL
   INTEWA, 2016, NSF CERT
   Iorhemen OT, 2016, MEMBRANES, V6, DOI 10.3390/membranes6020033
   Ishii SKL, 2015, WATER RES, V79, P88, DOI 10.1016/j.watres.2015.04.010
   Jia F, 2018, PROG NUCL ENERG, V103, P20, DOI 10.1016/j.pnucene.2017.11.008
   Karath K., 2016, NEW SCI
   Kavvada O, 2016, ENVIRON SCI TECHNOL, V50, P13184, DOI 10.1021/acs.est.6b02386
   Khan S. J., 2018, CURR OPIN ENV SCI HL, V2, P55, DOI [10.1016/j.coesh.2018.02.002, DOI 10.1016/J.COESH.2018.02.002]
   Krzeminski P, 2017, J MEMBRANE SCI, V527, P207, DOI 10.1016/j.memsci.2016.12.010
   Lahnsteiner J, 2007, WATER SCI TECHNOL, V55, P441, DOI 10.2166/wst.2007.022
   Lambrou TP, 2014, IEEE SENS J, V14, DOI 10.1109/JSEN.2014.2316414
   Landry KA, 2016, WATER RES, V105, P487, DOI 10.1016/j.watres.2016.09.024
   Larsen TA, 2009, ENVIRON SCI TECHNOL, V43, P6121, DOI 10.1021/es803001r
   Lehtoranta S, 2014, J CLEAN PROD, V65, P439, DOI 10.1016/j.jclepro.2013.08.024
   Libralato G, 2012, J ENVIRON MANAGE, V94, P61, DOI 10.1016/j.jenvman.2011.07.010
   Lim JY, 2018, J IND ENG CHEM, V66, P29, DOI 10.1016/j.jiec.2018.05.028
   Linares RV, 2016, WATER RES, V88, P225, DOI 10.1016/j.watres.2015.10.017
   Lockwood B., 2018, COMMUNICATION
   Lundie S, 2004, ENVIRON SCI TECHNOL, V38, P3465, DOI 10.1021/es034206m
   Lyu SD, 2016, J ENVIRON SCI, V39, P86, DOI 10.1016/j.jes.2015.11.012
   Madramootoo CA, 2013, IRRIG DRAIN, V62, P255, DOI 10.1002/ird.1704
   Makropoulos C, 2018, J ENVIRON MANAGE, V216, P285, DOI 10.1016/j.jenvman.2017.07.026
   Maricopa County Environmental Services, 2007, MAR COUNT ENV HLTH C
   Market Wired, 2011, REV WAST TREATM REN
   Martin L, 2014, TEXAS LEADS WAY 1 DI
   Maryam B., 2017, J WATER PROCESS ENG
   Maryland Department of the Environment, 2013, DES GUID WAST FAC
   Massoud MA, 2009, J ENVIRON MANAGE, V90, P652, DOI 10.1016/j.jenvman.2008.07.001
   Matos C, 2014, SCI TOTAL ENVIRON, V493, P463, DOI 10.1016/j.scitotenv.2014.05.129
   Maurer M, 2005, WA SCI TECHNOL, V5, P145
   Maurer M, 2013, SOURCE SEPARATION AND DECENTRALIZATION FOR WASTEWATER MANAGEMENT, P85
   McCarty PL, 2011, ENVIRON SCI TECHNOL, V45, P7100, DOI 10.1021/es2014264
   Means E. G., 2006, STRATEGIC ASSESSMENT
   Mehta CM, 2015, CRIT REV ENV SCI TEC, V45, P385, DOI 10.1080/10643389.2013.866621
   Melin T, 2006, DESALINATION, V187, P271, DOI 10.1016/j.desal.2005.04.086
   Menge J., 2007, TREATMENT WASTEWATER
   Mikkonen L., 2019, HEAT RECOVERY WASTEW, P161
   Milian M., 2015, MODEL COMMUNICATION
   Mitchell C., 2013, TRANSITIONING SUSTAI
   Mo WW, 2013, J ENVIRON MANAGE, V127, P255, DOI 10.1016/j.jenvman.2013.05.007
   Monteith H., 2008, STATE SCI REPORT ENE
   Muller E.A., 2010, ABFALL, V57, P437
   Mutamim NSA, 2012, DESALINATION, V305, P1, DOI 10.1016/j.desal.2012.07.033
   MWRA, 2009, DEER ISL SEW TREATM
   MWRA, 2013, REN SUST EN IN DEER
   Namibia DWA, 1988, 824NA8811364 NAM DWA
   New Jersey DEP, 2008, RUL REG GOV LIC WAT
   Newfoundland and Labrador DEC, 2014, OP CERT WAT WAST SYS
   Nexus, 2015, NEX EWATER
   Nexus, 2017, NEX EWATER WAT HEAT
   Noe-Hays A., 2015, P WATER ENV FED, V2015, P3993, DOI 10.2175/193864715819538921
   Nowak O, 2003, WATER SCI TECHNOL, V48, P33
   NRC, 2012, WAT REUS POT EXP NAT
   NSF, 2019, NSF ANSI STAND 350 W
   NSF, 2017, NSF ANSI 350 ONS RES
   NYS DEC, 2014, NEW YORK STAT DES ST
   OCWD, 2019, GREEN ACR PROJ
   OCWD, 2019, GROUNDW REPL SYST
   Ostara, 2017, OST NUTR MAN SOL
   Patneaude K., 2010, MWRAS RENEWABLE SUST
   Pinellas County, 2013, POT WAT SUPPL WAST R
   Pinellas County, 2015, RECL WAT CONS CONF R
   Pinellas County, 2017, S CROSS BAYOU WAT RE
   Pinellas County, 2019, WE DUNN WAT RECL FAC
   Plappally AK, 2012, RENEW SUST ENERG REV, V16, P4818, DOI 10.1016/j.rser.2012.05.022
   POSD, 2007, GREEN INV FUND GRANT
   Power C, 2014, SUSTAIN ENERGY TECHN, V7, P166, DOI 10.1016/j.seta.2014.06.001
   Prince Edward Island DCLE, 2016, WAT WAST FAC CLASS
   Rahman MM, 2014, ARAB J CHEM, V7, P139, DOI 10.1016/j.arabjc.2013.10.007
   Raucher RS, 2014, OPPORTUNITIES EC DIR
   Rezaei N, 2019, ENVIRON SCI-WAT RES, V5, P102, DOI 10.1039/c8ew00336j
   Rowland I, 2000, WATER SCI TECHNOL, V41, P33
   Roy MM, 2011, WASTE MANAGE, V31, P2228, DOI 10.1016/j.wasman.2011.06.008
   San Bruno G, 2010, ENERGY RECOVERY EXIS
   Schaider LA, 2017, ENVIRON SCI TECHNOL, V51, P7304, DOI 10.1021/acs.est.6b04778
   Schoen ME, 2017, MICROB RISK ANAL, V5, P25, DOI 10.1016/j.mran.2015.10.001
   Schuetze T, 2010, CITIES FUTURE SERIES, P213
   SD Public Utilities, 2015, R920090001 SD PUBL U
   Selby H. W., 1979, United States Patent, Patent No. [US 4145279, 4145279]
   Severn R, 2003, FILTR SEPARAT, V40, P28
   Shaffer DL, 2012, J MEMBRANE SCI, V415, P1, DOI 10.1016/j.memsci.2012.05.016
   Shehabi A, 2012, ENVIRON RES LETT, V7, DOI 10.1088/1748-9326/7/2/024007
   Shin C, 2018, BIORESOURCE TECHNOL, V247, P1038, DOI 10.1016/j.biortech.2017.09.002
   Showley R., 2016, SAN DIEGO UNION TRIB
   Sievers D. M., 1993, DESIGN SUBMERGED FLO
   Simmit L, 2016, WASTEWATER TREATMENT
   Soda S, 2010, WATER SCI TECHNOL, V61, P365, DOI 10.2166/wst.2010.827
   Stefanakis A.I., 2014, VERTICAL FLOW CONSTR
   Steinle-Darling E., 2016, DIRECT POTABLE REUSE, V2
   Stillwell Ashlynn S, 2010, Sustainability, V2, P945, DOI 10.3390/su2040945
   Sutherland J., 2015, WATEREUSE TEX ANN C
   SWRCB (State Water Resources Control Board), 2016, INV FEAS DEV UN WAT
   Tchobanoglous G., 2011, DIRECT POTABLE REUSE
   Tchobanoglous G, 2013, SOURCE SEPARATION AND DECENTRALIZATION FOR WASTEWATER MANAGEMENT, P101
   Tennessee DEC, 2007, RUL TENN DEP ENV CON
   Tervahauta T, 2013, WATER-SUI, V5, P1006, DOI 10.3390/w5031006
   Town and Country Engineering Inc, 2015, FENN FAC PLANN DOC
   Trussell R. R., 2015, EQUIVALENCY ADV TREA
   Ueno Y, 2001, ENVIRON TECHNOL, V22, P1373, DOI 10.1080/09593332208618196
   Ursin E., 2013, P NAT ONS WAST REC A, P17
   US Census Bureau, 2012, 2010 CENS POP HOUS S
   US EIA, 2017, WHAT IS EFF DIFF TYP
   US Environmental Protection Agency, 2012, PUBL DRINK WAT SYST
   US Environmental Protection Agency, 2012, EPA600R12618
   US EPA, 2000, EPA832F00064
   *US EPA, 2000, EPA832F00024
   *US EPA, 1993, EPA832R93005
   *US EPA, 2008, [No title captured]
   Vand Aarhus, 2019, MARS DENM WAST PLANT
   Vaughn Concrete Products Inc, 2015, PREC CONCR SEPT TANK
   Viswanathan S., 2010, WATER WASTES DIGEST, P20
   Vorosmarty CJ, 2000, SCIENCE, V289, P284, DOI 10.1126/science.289.5477.284
   Wang HL, 2008, ENVIRON SCI POLLUT R, V15, P308, DOI 10.1007/s11356-008-0012-5
   Warsinger DM, 2018, PROG POLYM SCI, V81, P209, DOI 10.1016/j.progpolymsci.2018.01.004
   Washington State Legislature, 2000, WASH ADM COD 173 230
   Waste Technologies of Australia, 2006, FLEM RAC MULT WAT RE
   Water Environment Association of Texas, 2010, PEN WAT RECL PLANT U
   Water Issues Committee, 2016, GREEN ACR PROJ FUT D
   WateReuse, 2018, STAT POL REG
   Whitelaw C., 2017, COMMUNICATION
   Wilderer PA, 2000, WATER SCI TECHNOL, V41, P1
   Wilsenach JA, 2003, WATER SCI TECHNOL, V48, P1
   Winans K., 2012, SMALL SCALE NATURAL, P1
   Wu XQ, 2015, SCI TOTAL ENVIRON, V536, P655, DOI 10.1016/j.scitotenv.2015.07.129
   Xu P, 2010, J MEMBRANE SCI, V353, P111, DOI 10.1016/j.memsci.2010.02.037
   Yang QF, 2016, WATER SCI TECHNOL, V74, P672, DOI 10.2166/wst.2016.251
   Yang Y, 2017, SCI TOTAL ENVIRON, V596, P303, DOI 10.1016/j.scitotenv.2017.04.102
   Zhao PS, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00067
   Zimmerman JB, 2008, ENVIRON SCI TECHNOL, V42, P4247, DOI 10.1021/es0871457
   2017, WATER RES, V115, P149, DOI DOI 10.1016/J.WATRES.2017.02.047
NR 203
TC 12
Z9 12
U1 53
U2 104
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 94
EP 112
DI 10.1016/j.resconrec.2018.12.035
PG 19
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200010
DA 2020-05-12
ER

PT J
AU Halkos, G
   Tsilika, K
AF Halkos, George
   Tsilika, Kyriaki
TI Understanding transboundary air pollution network: Emissions,
   depositions and spatio-temporal distribution of pollution in European
   region
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Source-receptor air pollution; Weighted network; Heatmaps;
   Programming-based tools
ID EMEP MSC-W; ABATEMENT POLICY; TRANSPORT; SULFUR; CHINA; MODEL;
   PERFORMANCE; MULTIMODEL; REDUCTION; NITROGEN
AB The primary objective of this paper is the structural analysis of source-receptor air pollution problems in the EU region. Two views are provided for the analysis: an emission-driven view and a deposition-driven view. Different visualization modules are used to reproduce the global pollution network and identify the biggest sources and sinks of pollution. Visual modelling helps to understand the linkages and interconnections in the transboundary pollution network. Our interactive outputs give the options to bring out the crucial actions of the global sourcereceptor air pollution scheme and highlight the top emitters or receptors of pollution. Ranking of countries in decreasing order of pollution responsibility and/or vulnerability using graph metrics is a main result. Data sources are emissions-depositions (or source-receptor) tables of air pollutants, available online from the data repository of the European Monitoring and Evaluation Program (EMEP) of the Long-Range Transmission of Air Pollutants in Europe. In our computer-based visual analysis, we design custom visualizations by writing code.
C1 [Halkos, George; Tsilika, Kyriaki] Univ Thessaly, Dept Econ, Lab Operat Res, Volos, Greece.
RP Tsilika, K (reprint author), Univ Thessaly, Dept Econ, Lab Operat Res, Volos, Greece.
EM halkos@uth.gr; ktsilika@uth.gr
RI Halkos, George/AAE-4772-2020; Tsilika, Kyriaki/E-2117-2018
OI Tsilika, Kyriaki/0000-0002-9213-3120
CR AAS W, 2005, 62005 EMEPCCC NILU
   Andersson-Skold Y, 1999, ATMOS ENVIRON, V33, P1111, DOI 10.1016/S1352-2310(98)00296-9
   [Anonymous], 2015, 1 EMEP MET I NORW ME
   [Anonymous], 2018, MATH VERS 11 3
   Barrat A, 2004, P NATL ACAD SCI USA, V101, P3747, DOI 10.1073/pnas.0400087101
   Berge E, 1998, TELLUS B, V50, P205, DOI 10.1034/j.1600-0889.1998.t01-2-00001.x
   Bergstrom R., 2012, ATMOS CHEM PHYS DISC, V12
   Cai BF, 2018, RESOUR CONSERV RECY, V129, P232, DOI 10.1016/j.resconrec.2017.10.036
   Carslaw DC, 2012, ENVIRON MODELL SOFTW, V27-28, P52, DOI 10.1016/j.envsoft.2011.09.008
   Fagerli H., 2008, TRANSBOUNDARY ACIDIF, P89
   Fagerli H, 2008, ENVIRON POLLUT, V154, P448, DOI 10.1016/j.envpol.2008.01.024
   Feng C, 2017, J CLEAN PROD, V144, P323, DOI 10.1016/j.jclepro.2017.01.005
   Fiore A, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003855
   Fujii H, 2016, ENVIRON SCI POLLUT R, V23, P2802, DOI 10.1007/s11356-015-5523-2
   Galili T, 2018, BIOINFORMATICS, V34, P1600, DOI 10.1093/bioinformatics/btx657
   Halkos G., 1994, ENVIRON RESOUR ECON, V4, P127, DOI [DOI 10.1007/BF00692200, 10.1007/BF00692200]
   Halkos G., 1992, THESIS
   HALKOS GE, 1993, ENERG POLICY, V21, P1035, DOI 10.1016/S0301-4215(06)80006-6
   Halkos G, 2018, ENVIRON ECON POLICY, V20, P619, DOI 10.1007/s10018-017-0208-3
   Halkos GE, 2017, BUS STRATEG ENVIRON, V26, P1162, DOI 10.1002/bse.1976
   Halkos GE, 2017, ENVIRON RESOUR ECON, V68, P753, DOI 10.1007/s10640-016-0046-y
   Halkos GE, 2017, ECON ANAL POLICY, V53, P140, DOI 10.1016/j.eap.2017.01.005
   Halkos GE, 2014, APPL MATH COMPUT, V246, P586, DOI 10.1016/j.amc.2014.08.044
   HUTTON JP, 1995, ENERG ECON, V17, P259, DOI 10.1016/0140-9883(95)00023-N
   Jeske D., 2018, WILEY STATSREF STAT, P1, DOI [10.1002/9781118445112.stat08055, DOI 10.1002/9781118445112.STAT08055]
   Jiang MH, 2019, J CLEAN PROD, V208, P426, DOI 10.1016/j.jclepro.2018.10.127
   Kanemoto K, 2014, GLOBAL ENVIRON CHANG, V24, P52, DOI 10.1016/j.gloenvcha.2013.09.008
   Keating T., 2007, AIR POLLUTION STUDIE, V16, P145
   Minitab 17 Statistical Software, 2010, COMPUTER SOFTWARE
   Munir M., 2014, IMPLEMENTATION POLLU, DOI [10.2139/ssm.2378796, DOI 10.2139/SSM.2378796]
   Newman MEJ, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.026118
   Opsahl T, 2010, SOC NETWORKS, V32, P245, DOI 10.1016/j.socnet.2010.03.006
   Orudjev Nazim Y., 2016, P 2016 7 INT C INF I, P1, DOI DOI 10.1109/IISA.2016.7785416
   Qu H, 2007, IEEE T VIS COMPUT GR, V13, P1408, DOI 10.1109/TVCG.2007.70523
   R Development Core Team, 2011, R LANG ENV STAT COMP
   Reidmiller DR, 2009, ATMOS CHEM PHYS, V9, P5027, DOI 10.5194/acp-9-5027-2009
   Sanderson MG, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035389
   Schaap M., 2012, PERFORMANCE EUROPEAN
   Shindell DT, 2008, ATMOS CHEM PHYS, V8, P5353, DOI 10.5194/acp-8-5353-2008
   Simpson D, 2012, ATMOS CHEM PHYS, V12, P7825, DOI 10.5194/acp-12-7825-2012
   Simpson D., 2003, 12003 EMEP MSCW NOR
   STAM A, 1992, EUR J OPER RES, V56, P263, DOI 10.1016/0377-2217(92)90227-Z
   Su B, 2016, ECOL INDIC, V67, P78, DOI 10.1016/j.ecolind.2016.02.020
   Sun D, 2018, RESOUR CONSERV RECY, V129, P416, DOI 10.1016/j.resconrec.2016.09.021
   Tableau, 2014, VIS AN BEST PRACT, P41
   Tan J., 2018, ATMOS CHEM PHYS DISC, V2018, P1, DOI [10.5194/acp-2017-1121, DOI 10.5194/ACP-2017-1121]
   Tan JN, 2018, ATMOS CHEM PHYS, V18, P12223, DOI 10.5194/acp-18-12223-2018
   VANLOON M, 2004, R2004282 TNO
   Vestreng V, 2007, ATMOS CHEM PHYS, V7, P3663, DOI 10.5194/acp-7-3663-2007
   Wang Y, 2017, ECOL INDIC, V77, P250, DOI 10.1016/j.ecolind.2017.02.016
   2017, J ENVIRON MANAGE 1, V202, P232, DOI DOI 10.1016/J.JENVMAN.2017.07.038
   2019, RESOUR CONSERV RECY, V142, P59, DOI DOI 10.1016/J.RESCONREC.2018.11.015
   2016, ENERG ECON, V60, P112, DOI DOI 10.1016/J.ENECO.2016.08.024
NR 53
TC 3
Z9 3
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 113
EP 123
DI 10.1016/j.resconrec.2019.02.014
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200011
DA 2020-05-12
ER

PT J
AU Tam, E
   Soulliere, K
   Sawyer-Beaulieu, S
AF Tam, Edwin
   Soulliere, Katie
   Sawyer-Beaulieu, Susan
TI Managing complex products to support the circular economy
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Recycling; Reuse; Recovery; Simple consumer good;
   Complex consumer good; End-of-life; Design
AB The circular economy champions recovering materials and returning them to productivity, and advocates designing out pollution, retaining materials for re-use, and being regenerative, instead of conventional disposal in our current linear economy. However, for the circular economy to succeed, waste materials need to be efficiently returned for production and the time-tested processes of reuse, recovery, and recycling will be essential. This paper provides an enhanced perspective on critical issues that need to be addressed to enable the circular economy. Much of the popular efforts presently target recovering simple consumer products (e.g., beverage containers). However, there are greater challenges when considering multiple materials from complex consumer products, such as electronics or automobiles, that have reached their end-of-life. These challenges include how to address: material identification and separation; ensuring purity; distribution and transportation; and establishing a viable market for recovered goods/materials. The circular economy further emphasizes the design of products and services to facilitate restorative mechanisms. However, product design varies significantly across different consumer items, and the trade-offs engineers and designers make for enabling circularity from complex goods will vary significantly compared to simple goods. Finally, while it is essential to embrace a new design ethic for future products or services, significantly more attention is needed towards enhancing the reuse and recovery potential from "current" end-of-life complex products because they were designed one or two generations ago: they are unlikely to have circularity designed into their makeup. Innovation in improving the recovery of EoL complex consumer products will be vital to supporting a robust circular economy.
C1 [Tam, Edwin; Soulliere, Katie; Sawyer-Beaulieu, Susan] Univ Windsor, Civil & Environm Engn, Windsor, ON, Canada.
RP Tam, E (reprint author), Univ Windsor, Civil & Environm Engn, Windsor, ON, Canada.
EM edwintam@uwindsor.ca
CR Buekens A, 2014, J MATER CYCLES WASTE, V16, P398, DOI 10.1007/s10163-014-0244-z
   CBC (The Conference Board of Canada), 2018, C BOARD CAN CAN PERF
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Rose CM, 1998, IEEE INT SYMP ELECTR, P322, DOI 10.1109/ISEE.1998.675079
   Sawyer-Beaulieu S, 2015, SAE INT J MATER MANU, V8, P118, DOI 10.4271/2014-01-9101
NR 5
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 124
EP 125
DI 10.1016/j.resconrec.2018.12.030
PG 2
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200012
DA 2020-05-12
ER

PT J
AU Islam, M
   Managi, S
AF Islam, Moinul
   Managi, Shunsuke
TI Green growth and pro-environmental behavior: Sustainable resource
   management using natural capital accounting in India
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Green growth; Natural capital; SDGs; Environmental knowledge;
   Pro-environmental behavior
ID ECOSYSTEM SERVICES; CONSUMERS; CHINA; CONSERVATION; ATTITUDES; GENDER
AB The natural capital (NC) of India and its management system are essential conditions of the welfare path to the sustainable development of the country. We conduct an accounting process for India's NC to measure sustainability to ensure that future generations will have the equal total wealth per capita accessible to them as that available to the present generation. We then describe the combination of the renewable and non-renewable NC that is relevant within the concepts of welfare and sustainability. First, we note that India has successful forestation, which has enhanced welfare for its residents. However, the other renewables (e.g., cropland, fishery) and non-renewables (e.g., fossil fuels, minerals) are continuously degraded as a result of economic development and population growth. Second, we discuss the correlation between sustainable resource management and pro-environmental behavior (PEB) and explain the importance of considering these factors to achieve green growth. Third, to provide practitioners with useful information on how to promote PEB and to discover the determinants of PEB, we analyze the survey data of 5,200 respondents from all Indian states. We identify that environmental knowledge is an important determinant of individuals' PEB in India. In the policy analysis, we evaluate the challenges to achieving sustainable development goals (SDGs) using NC accounting in India. We recommend several policy implications to maintain NC at a sustainable level and to achieve SDGs.
C1 [Managi, Shunsuke] Kyushu Univ, Sch Engn, Urban Inst, 744 Motooka, Fukuoka, Fukuoka 8190395, Japan.
   Kyushu Univ, Sch Engn, Dept Urban & Environm Engn, 744 Motooka, Fukuoka, Fukuoka 8190395, Japan.
RP Managi, S (reprint author), Kyushu Univ, Sch Engn, Urban Inst, 744 Motooka, Fukuoka, Fukuoka 8190395, Japan.
EM managi.s@gmail.com
RI Islam, Moinul/M-9369-2019; Managi, Shunsuke/G-1740-2013
OI Islam, Moinul/0000-0002-0309-3156; Managi, Shunsuke/0000-0001-7883-1427
FU Ministry of Education, Culture, Sports, Science and Technology in Japan
   (MEXT)Ministry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [2600000]
FX This work was supported by the following Grant in Aid from the Ministry
   of Education, Culture, Sports, Science and Technology in Japan (MEXT):
   Grant in Aid for Specially Promoted Research 2600000. Any opinions,
   findings, and conclusions expressed in this material are those of the
   authors and do not necessarily reflect the views of the MEXT.
CR Adomssent M., 2007, INT J SUSTAINABILITY, V8, P385, DOI DOI 10.1108/14676370710823564
   Arrow KJ, 2012, ENVIRON DEV ECON, V17, P317, DOI 10.1017/S1355770X12000137
   Australian Bureau of Statistics, 2001, AUSTR SYST NAT ACC C
   Azqueta D, 2007, ECOL ECON, V63, P22, DOI 10.1016/j.ecolecon.2007.02.029
   Barber N., 2009, ENV KNOWLEDGE ATTITU
   Barbier EB, 2007, ECON POLICY, P178
   Bartiaux F, 2008, J CLEAN PROD, V16, P1170, DOI 10.1016/j.jclepro.2007.08.013
   Bolt K., 2002, MANUAL CALCULATING A, P1
   Bradley J. C., 1999, J ENVIRON EDUC, V30, P17, DOI DOI 10.1080/00958969909601873
   Bronfman NC, 2015, SUSTAINABILITY-BASEL, V7, P14133, DOI 10.3390/su71014133
   BROOKER G, 1976, J CONSUM RES, V3, P107, DOI 10.1086/208658
   Chen JD, 2018, PROBL EKOROZW, V13, P91
   CHEN Y, 2012, GLOB, P8, DOI DOI 10.1109/AINA.2012.62
   Clark CF, 2003, J ENVIRON PSYCHOL, V23, P237, DOI 10.1016/S0272-4944(02)00105-6
   Clayton S., 2015, CONSERVATION PSYCHOL
   Cowling R. M., 2008, P NATL ACAD SCI US
   Daly H, 1989, COMMON GOOD
   Davidson DJ, 1996, ENVIRON BEHAV, V28, P302, DOI 10.1177/0013916596283003
   Diamantopoulos A, 2003, J BUS RES, V56, P465, DOI 10.1016/S0148-2963(01)00241-7
   FOLKE C, 1994, INVESTING IN NATURAL CAPITAL, P1
   GARDNER GT, 1996, ENV PROBLEMS HUMAN B
   Gifford R., 2007, ENV PSYCHOL PRINCIPL
   Gifford R, 2014, INT J PSYCHOL, V49, P141, DOI 10.1002/ijop.12034
   Griggs D, 2013, NATURE, V495, P305, DOI 10.1038/495305a
   Grunert S. C., 1993, ACR EUR ADV
   Guerry AD, 2015, P NATL ACAD SCI USA, V112, P7348, DOI 10.1073/pnas.1503751112
   Guo LL, 2018, RESOUR CONSERV RECY, V128, P143, DOI 10.1016/j.resconrec.2016.09.035
   Huntley B., 2005, MAINSTREAMING BIODIV
   Islam M., 2018, SUSTAIN SCI
   Jaccard J., 1983, STAT BEHAV SCI
   Kaiser FG, 2003, APPL PSYCHOL-INT REV, V52, P598, DOI 10.1111/1464-0597.00153
   Knight AT, 2006, CONSERV BIOL, V20, P408, DOI 10.1111/j.1523-1739.2006.00305.x
   Laroche M, 2001, J CONSUM MARK, V18, P503, DOI 10.1108/EUM0000000006155
   Lozano R, 2006, J CLEAN PROD, V14, P787, DOI 10.1016/j.jclepro.2005.12.010
   Lu H, 2017, RESOUR CONSERV RECY, V120, P166, DOI 10.1016/j.resconrec.2016.12.008
   MALONEY MP, 1973, AM PSYCHOL, V28, P583, DOI 10.1037/h0034936
   Managi S, 2018, INCLUSIVE WEALTH REP
   Merino-Saum A, 2018, RESOUR CONSERV RECY, V139, P90, DOI 10.1016/j.resconrec.2018.07.007
   Miao Z, 2018, APPL GEOGR, V98, P184, DOI 10.1016/j.apgeog.2018.07.020
   Nickerson R., 2002, PSYCHOL ENV CHANGE
   Oguz D, 2010, AFR J AGR RES, V5, P2629
   Olsson P, 2006, ECOL SOC, V11
   Pearce D, 1998, ENVIRONMENT, V40, P23, DOI DOI 10.1080/00139159809605092
   PICKETT GM, 1993, J PUBLIC POLICY MARK, V12, P234, DOI 10.1177/074391569101200208
   Ryan L., 2003, LOND GROUP M ROM 5 7
   Saphores JDM, 2012, RESOUR CONSERV RECY, V60, P49, DOI 10.1016/j.resconrec.2011.12.003
   Schlegelmilch B.B., 1996, EUR J MARKETING, V30, P35, DOI DOI 10.1108/03090569610118740
   SHRUM LJ, 1995, J ADVERTISING, V24, P71, DOI 10.1080/00913367.1995.10673477
   Smith R., 2001, STAT CAN NAT C SUST
   Ulgiati S, 1998, ECOL MODEL, V108, P23, DOI 10.1016/S0304-3800(98)00016-7
   UN, 2015, UN GEN ASS 69 SESS
   UNU IHDP, 2012, INCL WEALTH REP 2012
   UNU-IHDP UNEP, 2014, INCL WEALTH REP 2014
   Van der Ploeg S., 2010, TEEB VALUATION DATAB
   Wackernagel M, 1999, ECOL ECON, V29, P375, DOI 10.1016/S0921-8009(98)90063-5
   Wang F, 2019, RESOUR CONSERV RECY, V141, P431, DOI 10.1016/j.resconrec.2018.10.024
   Widegren O, 1998, ENVIRON BEHAV, V30, P75, DOI 10.1177/0013916598301004
   World Bank, 2011, ENVIRON DEV, P1, DOI 10.1596/978-0-8213-8488-6
   Zelezny LC, 2000, J SOC ISSUES, V56, P443, DOI 10.1111/0022-4537.00177
   Zilahy G, 2009, J CLEAN PROD, V17, P1057, DOI 10.1016/j.jclepro.2009.03.018
   2001, ENV BEHAV, V33, P181
   2013, J CLEAN PROD, V48, P126, DOI DOI 10.1016/J.JCLEPRO.2012.11.030
NR 62
TC 4
Z9 4
U1 11
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 126
EP 138
DI 10.1016/j.resconrec.2019.02.027
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200013
DA 2020-05-12
ER

PT J
AU Huang, ZH
   Du, XJ
   Castillo, CSZ
AF Huang, Zhonghua
   Du, Xuejun
   Castillo, Carlos Salvador Zepeda
TI How does urbanization affect farmland protection? Evidence from China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Urbanization; Farmland protection; Farmland change; Land financing;
   Urban sprawl; China
ID URBAN LAND EXPANSION; RAPID URBANIZATION; CONVERSION; FINANCE;
   INDUSTRIALIZATION; DYNAMICS; PATTERNS; BEHAVIOR; SPRAWL; POLICY
AB China's urbanization and farmland protection problem has attracted attention from around the world. However, the relationship and mechanism between urbanization and farmland protection have not been yet fully understood. We address this gap by examining the impacts of urbanization on farmland area, based on Chinese prefecture-level cities' panel data over 1990-2013. We employ the instrumental variable method and satellite nightlight data for robust analysis. Our findings reveal that urbanization has significant negative effects on farmland area. Urbanization causes much higher rates of farmland loss in medium-sized cities and in the more developed eastern area of China. China's farmland dynamic balance policy has a significant positive effect on farmland area. We further test the impact channels and find that land financing and urban sprawl reinforce the negative impact of urbanization on farmland area. The problem of farmland quality loss is needed to study in future research.
C1 [Huang, Zhonghua] Zhejiang Univ Technol, Sch Management, Hangzhou 310023, Zhejiang, Peoples R China.
   [Du, Xuejun] Zhejiang Univ Sci & Technol, Sch Econ & Management, Hangzhou 310023, Zhejiang, Peoples R China.
   [Castillo, Carlos Salvador Zepeda] Univ Portsmouth, Econ & Finance, Portsmouth, Hants, England.
RP Du, XJ (reprint author), Zhejiang Univ Sci & Technol, Sch Econ & Management, Hangzhou 310023, Zhejiang, Peoples R China.
EM duxuejun@aliyun.com
FU National Social Science Foundation of China [17BGL130]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [71774143, 71373243]; Key Project of Philosophy and Social Science of
   Zhejiang Province [18NDJC030Z]; Zhejiang Provincial Natural Science
   FoundationNatural Science Foundation of Zhejiang Province [LY17G030016];
   Project of Philosophy and Social Science of Zhejiang Province
   [15NDJC185YB]; Major Project of Philosophy and Social Science of the
   Chinese Ministry of Education [18JZD033]; Advance Project of Humanities
   and Social Sciences of Zhejiang University of Technology; Research
   Center of Technology Innovation and Enterprises Internationalization,
   Key Research Base of Philosophy and Social Science of Zhejiang Province
FX This research was supported by National Social Science Foundation of
   China (No. 17BGL130), National Natural Science Foundation of China (No.
   71774143; No. 71373243), the Key Project of Philosophy and Social
   Science of Zhejiang Province (18NDJC030Z), Zhejiang Provincial Natural
   Science Foundation (LY17G030016), Project of Philosophy and Social
   Science of Zhejiang Province (15NDJC185YB), Major Project of Philosophy
   and Social Science of the Chinese Ministry of Education (18JZD033), the
   Advance Project of Humanities and Social Sciences of Zhejiang University
   of Technology, and the Research Center of Technology Innovation and
   Enterprises Internationalization, Key Research Base of Philosophy and
   Social Science of Zhejiang Province.
CR Alonso W, 1964, LOCATION LAND USE
   Angrist J., 2008, MOSTLY HARMLESS ECON, P169
   Bai XM, 2012, ENVIRON SCI TECHNOL, V46, P132, DOI 10.1021/es202329f
   BRUECKNER JK, 1983, REV ECON STAT, V65, P479, DOI 10.2307/1924193
   Cao GZ, 2008, CHINA WORLD ECON, V16, P19, DOI 10.1111/j.1749-124X.2008.00104.x
   Chamberlin J, 2014, FOOD POLICY, V48, P51, DOI 10.1016/j.foodpol.2014.05.002
   Chen T, 2016, J DEV ECON, V123, P86, DOI 10.1016/j.jdeveco.2016.08.005
   Cheng L, 2015, LAND USE POLICY, V48, P552, DOI 10.1016/j.landusepol.2015.06.014
   Dang G. Y., 2010, RURAL BUS MANAG, V3, P32
   Deng JS, 2009, LANDSCAPE URBAN PLAN, V92, P187, DOI 10.1016/j.landurbplan.2009.05.001
   Deng XZ, 2008, J URBAN ECON, V63, P96, DOI 10.1016/j.jue.2006.12.006
   Deng XZ, 2015, LAND USE POLICY, V45, P1, DOI 10.1016/j.landusepol.2015.01.007
   Du XJ, 2017, ECOL INDIC, V81, P243, DOI 10.1016/j.ecolind.2017.05.040
   Feng J, 2015, CHINA ECON REV, V36, P184, DOI 10.1016/j.chieco.2015.09.004
   Glaeser Edward, 2012, TRIUMPH CITY OUR GRE
   Huang J., 2005, P SOC PHOTO-OPT INS, V5884
   Huang ZH, 2018, J URBAN PLAN DEV, V144, DOI 10.1061/(ASCE)UP.1943-5444.0000476
   Huang ZH, 2018, CHINA AGR ECON REV, V10, P425, DOI [10.1108/caer-10-2015-0130, 10.1108/CAER-10-2015-0130]
   Huang ZH, 2018, CHINA ECON REV, V50, P85, DOI 10.1016/j.chieco.2018.04.004
   Huang ZH, 2017, URBAN STUD, V54, P1328, DOI 10.1177/0042098016664691
   Huang ZH, 2017, CITIES, V60, P323, DOI 10.1016/j.cities.2016.10.006
   Islam M.R., 2013, INT J SCI ENG RES, V4, P391
   Jiang L, 2012, LANDSCAPE URBAN PLAN, V108, P131, DOI 10.1016/j.landurbplan.2012.08.008
   Li YF, 2018, RESOUR CONSERV RECY, V132, P291, DOI 10.1016/j.resconrec.2017.03.009
   Lichtenberg E, 2008, LAND USE POLICY, V25, P59, DOI 10.1016/j.landusepol.2006.01.005
   Liu YS, 2014, LAND USE POLICY, V40, P6, DOI 10.1016/j.landusepol.2013.03.013
   Liu ZF, 2012, LANDSCAPE URBAN PLAN, V106, P62, DOI 10.1016/j.landurbplan.2012.02.013
   Long HL, 2009, LAND USE POLICY, V26, P322, DOI 10.1016/j.landusepol.2008.04.001
   Saiz A, 2010, Q J ECON, V125, P1253, DOI 10.1162/qjec.2010.125.3.1253
   Seto KC, 2003, LAND ECON, V79, P106, DOI 10.2307/3147108
   Small C, 2005, REMOTE SENS ENVIRON, V96, P277, DOI 10.1016/j.rse.2005.02.002
   Small C, 2011, REMOTE SENS ENVIRON, V115, P269, DOI 10.1016/j.rse.2010.08.021
   Tan MH, 2005, LAND USE POLICY, V22, P187, DOI 10.1016/j.landusepol.2004.03.003
   Tan MH, 2011, J GEOGR SCI, V21, P49, DOI 10.1007/s11442-011-0828-7
   Tao R, 2010, URBAN STUD, V47, P2217, DOI 10.1177/0042098009357961
   Tian L, 2015, LAND USE POLICY, V45, P117, DOI 10.1016/j.landusepol.2015.01.006
   UN-Habitat, 2010, WORLD URB PROSP 2009
   Wang H, 2012, HABITAT INT, V36, P201, DOI 10.1016/j.habitatint.2011.06.004
   Wang H, 2010, HABITAT INT, V34, P454, DOI 10.1016/j.habitatint.2009.12.004
   Wang YM, 2008, URBAN GEOGR, V29, P327, DOI 10.2747/0272-3638.29.4.327
   Wang YT, 2018, RESOUR CONSERV RECY, V133, P21, DOI 10.1016/j.resconrec.2018.01.038
   WHITE MJ, 1988, J URBAN ECON, V24, P129, DOI 10.1016/0094-1190(88)90035-6
   Xi FM, 2012, LANDSCAPE URBAN PLAN, V104, P34, DOI 10.1016/j.landurbplan.2011.09.003
   Xu CG, 2011, J ECON LIT, V49, P1076, DOI 10.1257/jel.49.4.1076
   Ye L, 2014, J URBAN AFF, V36, P354, DOI 10.1111/juaf.12105
   Zhang WW, 2014, LAND USE POLICY, V38, P467, DOI 10.1016/j.landusepol.2013.12.008
   Zhu JM, 2005, URBAN STUD, V42, P1369, DOI 10.1080/00420980500150714
   2014, FOOD POLICY, V49, P50, DOI DOI 10.1016/J.FOODPOL.2014.06.008
   2007, P NATL ACAD SCI USA, V104, P7301, DOI DOI 10.1073/PNAS.0610172104
   2015, FOOD POLICY, V56, P100, DOI DOI 10.1016/J.FOODPOL.2015.08.002
   2014, NATURE, V509, P158
NR 51
TC 6
Z9 6
U1 12
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 139
EP 147
DI 10.1016/j.resconrec.2018.12.023
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200014
DA 2020-05-12
ER

PT J
AU Gomes, SD
   Zhou, JL
   Li, WG
   Long, GC
AF Gomes, Samuel de Carvalho
   Zhou, John L.
   Li, Wengui
   Long, Guangcheng
TI Progress in manufacture and properties of construction materials
   incorporating water treatment sludge: A review
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Review
DE Water treatment sludge; Construction materials; Mechanical properties;
   Durability; Solid waste recycling
ID TREATMENT PLANT SLUDGE; RICE HUSK ASH; TREATMENT RESIDUALS; WASTE
   MATERIALS; HEAVY-METALS; SOLID-WASTE; CONCRETE; CEMENT; GEOPOLYMER;
   INDUSTRIAL
AB Water treatment sludge (WTS) management is a growing global problem for water treatment plants (WTPs) and governments. Considering the scarcity of raw materials in many parts of the planet and unique properties of WTS, extensive research has been conducted on the application of WFS in the production of construction materials such as roof tiles, bricks, lightweight aggregates, cement, concrete and geopolymers. This paper critically reviews the progress in the application of WTS in construction materials, by synthesizing results from recent studies. Research findings have revealed that incorporation of 10% alum-based sludge in ceramic bricks is satisfactory with a small reduction of mechanical performance. Using the iron-based sludge, the bricks presented better mechanical strength than the reference clay-bricks. Concerning WTS application in concrete, 5% replacement of cement or sand by WTS was considered as the ideal value for the application in a variety of structural and non-structural concrete without adverse effect on concrete mechanical performance. Furthermore, this paper discusses sludge-amended concrete in terms of durability, potential leaching of toxic elements and cost, and suggests topics for future research on the sustainable management of WTS.
C1 [Gomes, Samuel de Carvalho; Zhou, John L.; Li, Wengui] Univ Technol Sydney, Sch Civil & Environm Engn, Sydney, NSW 2007, Australia.
   [Zhou, John L.; Long, Guangcheng] Cent S Univ, Sch Civil Engn, 68 South Shaoshan Rd, Changsha 410075, Hunan, Peoples R China.
RP Zhou, JL (reprint author), Univ Technol Sydney, Sch Civil & Environm Engn, Sydney, NSW 2007, Australia.
EM junliang.zhou@uts.edu.au
RI Zhou, John/E-7610-2011
OI Zhou, John/0000-0003-1393-1608; Li, Wengui/0000-0002-4651-1215
FU Endeavour Postgraduate Scholarship, Australia; Australian Research
   Council (ARC)Australian Research Council
FX The authors would like to acknowledge the financial support from the
   Endeavour Postgraduate Scholarship, Australia, in the form of a Masters
   by research grant (Samuel De Carvalho Gomes). The funding supports from
   the Australian Research Council (ARC) are also greatly appreciated.
CR ABNT, 2004, 100042004 ABNT NBR
   ABNT, 2015, 50172015 ABNT NBR IS
   ACI, 2014, 213R14 ACI, P38
   Ahmad T, 2016, J CLEAN PROD, V124, P1, DOI 10.1016/j.jclepro.2016.02.073
   Ahmad T., 2017, ENVIRON MONIT ASSESS, V189, P1
   Ahmad T, 2018, CONSTR BUILD MATER, V175, P664, DOI 10.1016/j.conbuildmat.2018.04.227
   Al-tersawy Sherif H, 2016, INT J ENG SCI RES TE, V5, P138
   Alqam M, 2011, JORDAN J CIV ENG, V5, P268
   Anderson M., 2003, RECYCLING REUSE WAST, P417
   [Anonymous], 2015, C87615 ASTM
   [Anonymous], 2017, C330C330M17A ASTM
   [Anonymous], 2005, 012004 CCES
   Associacao Brasileira de Normas Tecnicas (ABNT)-Brazilian Standard, 2014, 61182014 ABNT NBR
   ASTM, 2017, C61817A ASTM
   ASTM, 2015, D559D559M ASTM
   ASTM, 2018, C37318 ASTM
   Babatunde AO, 2007, CRIT REV ENV SCI TEC, V37, P129, DOI 10.1080/10643380600776239
   Baker R. J., 2005, TR535 IHRB IOW STAT
   Basheer L, 2001, CONSTR BUILD MATER, V15, P93, DOI 10.1016/S0950-0618(00)00058-1
   Benlalla A, 2015, APPL CLAY SCI, V118, P171, DOI 10.1016/j.clay.2015.09.012
   Bignozzi MC, 2011, PROCEDIA ENGINEER, V21, P915, DOI 10.1016/j.proeng.2011.11.2094
   Bijen J., 2003, DURABILITY ENG STRUC, P261
   BIS (Bureau of Indian Standards), 2015, 148912015 BIS IS
   BIS (Bureau of Indian Standards), 1992, 1077 BIS
   Chen HX, 2010, CEMENT CONCRETE COMP, V32, P436, DOI 10.1016/j.cemconcomp.2010.02.009
   Chen YL, 2011, CONSTR BUILD MATER, V25, P2107, DOI 10.1016/j.conbuildmat.2010.11.025
   Chiang KY, 2010, ENVIRON ENG SCI, V27, P137, DOI 10.1089/ees.2009.0036
   Chiang KY, 2009, J HAZARD MATER, V171, P76, DOI 10.1016/j.jhazmat.2009.05.144
   Cremades LV, 2018, J CLEAN PROD, V201, P1071, DOI 10.1016/j.jclepro.2018.08.094
   da Silva EM, 2015, WATER SCI TECHNOL, V71, P1638, DOI 10.2166/wst.2015.132
   Dahhou M, 2016, WASTE BIOMASS VALORI, V7, P1177, DOI 10.1007/s12649-016-9513-5
   Dahhou M, 2018, J MATER CYCLES WASTE, V20, P891, DOI 10.1007/s10163-017-0650-0
   Dassanayake KB, 2015, WASTE MANAGE, V38, P321, DOI 10.1016/j.wasman.2014.11.025
   DAVIDOVITS J, 1991, J THERM ANAL, V37, P1633, DOI 10.1007/BF01912193
   Dondi M, 2016, CONSTR BUILD MATER, V127, P394, DOI 10.1016/j.conbuildmat.2016.09.111
   Duxson P, 2005, COLLOID SURFACE A, V269, P47, DOI 10.1016/j.colsurfa.2005.06.060
   Ei-Eswed BI, 2017, APPL CLAY SCI, V140, P148, DOI 10.1016/j.clay.2017.02.003
   El-Didamony H., 2014, HBRC J, V10, P73, DOI DOI 10.1016/j.hbrcj.2013.09.004
   Evuti A. M., 2011, Advances in Applied Science Research, V2, P410
   Ewais EMM, 2017, REFRACT IND CERAM+, V58, P136, DOI 10.1007/s11148-017-0071-6
   Fernandes F. M., 2010, MAT TECHNOLOGIES PRA, P29, DOI DOI 10.1007/978-90-481-2684-2_3
   Fernandez LP, 2018, MATERIA-BRAZIL, V23, DOI [10.1590/s1517-707620180003.0490, 10.1590/S1517-707620180003.0490]
   Finlay N., 2015, THESIS
   Fujiwara M., 2011, 1 JAP SING WORKSH S
   Gastaldini ALG, 2015, CONSTR BUILD MATER, V94, P513, DOI 10.1016/j.conbuildmat.2015.07.038
   Geraldo RH, 2017, J CLEAN PROD, V149, P146, DOI 10.1016/j.jclepro.2017.02.076
   Corrochano BG, 2011, INT J ENVIRON SCI TE, V8, P667, DOI 10.1007/BF03326251
   Gonzalez-Corrochano B., 2017, ENVIRON TECHNOL, V39, P2511
   Hagemann SE, 2019, J CLEAN PROD, V214, P916, DOI 10.1016/j.jclepro.2018.12.324
   Hassan KM, 2014, WASTE MANAGE, V34, P1072, DOI 10.1016/j.wasman.2013.09.022
   Hegazy B.E.-D.E., 2012, AUSTR J BASIC APPL S, V6, P453
   Henderson J. L., 2009, 4225 WAT RES FDN
   Hidalgo AM, 2017, J ENVIRON ENG, V143, DOI 10.1061/(ASCE)EE.1943-7870.0001176
   Hoppen C., 2005, Cerâmica, V51, P85, DOI 10.1590/S0366-69132005000200003
   Horpibulsuk S, 2016, J MATER CIVIL ENG, V28, DOI 10.1061/(ASCE)MT.1943-5533.0001351
   Huang C, 2001, WATER SCI TECHNOL, V44, P273
   Huang CH, 2013, CONSTR BUILD MATER, V43, P174, DOI 10.1016/j.conbuildmat.2013.02.016
   Huang CP, 2005, J ENVIRON ENG, V131, P272, DOI 10.1061/(ASCE)0733-9372(2005)131:2(272)
   Huang SC, 2007, J HAZARD MATER, V144, P52, DOI 10.1016/j.jhazmat.2006.09.094
   Rodriguez NH, 2010, CEMENT CONCRETE RES, V40, P778, DOI 10.1016/j.cemconres.2009.11.012
   Ippolito JA, 1999, J ENVIRON QUAL, V28, P1644, DOI 10.2134/jeq1999.00472425002800050031x
   Jia HF, 2014, ECOL ENG, V71, P48, DOI 10.1016/j.ecoleng.2014.07.013
   Jonker A, 2005, J EUR CERAM SOC, V25, P3145, DOI 10.1016/j.jeurceramsoc.2004.07.024
   Kashyap S, 2017, MATER TODAY-PROC, V4, P2946, DOI 10.1016/j.matpr.2017.02.176
   Keeley J, 2014, CRIT REV ENV SCI TEC, V44, P2675, DOI 10.1080/10643389.2013.829766
   Komljenovic M, 2010, J HAZARD MATER, V181, P35, DOI 10.1016/j.jhazmat.2010.04.064
   Komlos J, 2013, J ENVIRON ENG, V139, P1237, DOI 10.1061/(ASCE)EE.1943-7870.0000737
   Krol A., 2011, ARCHITECT CIVIL ENG, V4, P71
   Lee YE, 2018, ENERGIES, V11, DOI 10.3390/en11123292
   Lee YC, 2012, ENVIRON ENG SCI, V29, P284, DOI 10.1089/ees.2010.0479
   Li ZF, 2013, ECOL ENG, V53, P165, DOI 10.1016/j.ecoleng.2012.12.038
   Lima DD, 2016, PROCEDIA ENGINEER, V145, P1201, DOI 10.1016/j.proeng.2016.04.155
   Lin KL, 2005, CEMENT CONCRETE RES, V35, P1999, DOI 10.1016/j.cemconres.2005.06.008
   Maiden P., 2015, ACTEW WATER SEAWATER
   Ministry of Health, 2017, WELL NZ GUID DRINK W
   Mitchell J.K., 2005, FUNDAMENTALS SOIL BE, V3
   Monteiro SN, 2014, CONSTR BUILD MATER, V68, P599, DOI 10.1016/j.conbuildmat.2014.07.006
   NEN, 2004, 73752004 NEN
   Nimwinya E, 2016, J CLEAN PROD, V119, P128, DOI 10.1016/j.jclepro.2016.01.060
   Nowasell QC, 2015, ACI MATER J, V112, P69
   O'Kelly BC, 2009, PROC INST CIV ENG-WA, V162, P85, DOI 10.1680/warm.2009.162.2.85
   O'Kelly BC, 2008, CAN GEOTECH J, V45, P715, DOI 10.1139/T07-109
   Ooi TY, 2018, J ENVIRON MANAGE, V228, P13, DOI 10.1016/j.jenvman.2018.09.008
   Pan JR, 2004, WATER SCI TECHNOL, V50, P183
   Phair JW, 2002, INT J MINER PROCESS, V66, P121, DOI 10.1016/S0301-7516(02)00013-3
   Pizzi N.G., 2010, WATER TREATMENT
   Ramer D., 2000, GEOTECHNICS HIGH WAT
   Ramirez KG, 2017, MANAG ENVIRON QUAL, V28, P821, DOI 10.1108/MEQ-09-2015-0178
   Raut SP, 2011, CONSTR BUILD MATER, V25, P4037, DOI 10.1016/j.conbuildmat.2011.04.038
   Renault F, 2009, EUR POLYM J, V45, P1337, DOI 10.1016/j.eurpolymj.2008.12.027
   Sales A, 2011, CONSTR BUILD MATER, V25, P2793, DOI 10.1016/j.conbuildmat.2010.12.057
   Sales A, 2010, CONSTR BUILD MATER, V24, P2446, DOI 10.1016/j.conbuildmat.2010.06.012
   Salwa M.S., 2013, AUST J BASIC APPL SC, V7, P246
   Shih KM, 2011, J ENVIRON MONITOR, V13, P829, DOI 10.1039/c0em00596g
   Singh B, 2015, CONSTR BUILD MATER, V85, P78, DOI 10.1016/j.conbuildmat.2015.03.036
   Snellings R, 2012, REV MINERAL GEOCHEM, V74, P211, DOI 10.2138/rmg.2012.74.6
   Soltan AMM, 2016, J CLEAN PROD, V117, P139, DOI 10.1016/j.jclepro.2016.01.017
   Sudagar A, 2018, APPL CLAY SCI, V152, P196, DOI 10.1016/j.clay.2017.11.013
   Suksiripattanapong C, 2015, CONSTR BUILD MATER, V94, P807, DOI 10.1016/j.conbuildmat.2015.07.091
   Suksiripattanapong C, 2015, CONSTR BUILD MATER, V82, P20, DOI 10.1016/j.conbuildmat.2015.02.040
   Tafarel NF, 2016, MATERIA-BRAZIL, V21, P974, DOI [10.1590/S1517-707620160004.0090, 10.1590/s1517-707620160004.0090]
   Tang Z, 2019, J CLEAN PROD, V218, P810, DOI 10.1016/j.jclepro.2019.01.337
   Tang Z, 2019, CONSTR BUILD MATER, V200, P474, DOI 10.1016/j.conbuildmat.2018.12.157
   TAY JH, 1991, J ENVIRON ENG-ASCE, V117, P236, DOI 10.1061/(ASCE)0733-9372(1991)117:2(236)
   Teixeira SR, 2011, APPL CLAY SCI, V53, P561, DOI 10.1016/j.clay.2011.05.004
   Thaniya K., 2010, ENERGY RES J, V1, P131, DOI DOI 10.3844/EDSP.2010.131.134
   The Central Intelligence Agency, 2017, WORLD FACTBOOK
   Townsend JP, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-41
   Toya T, 2007, CERAM INT, V33, P573, DOI 10.1016/j.ceramint.2005.11.009
   USEPA, 1992, 1311 USEPA
   Waijarean N, 2017, J MATER SCI, V52, P7345, DOI 10.1007/s10853-017-0970-4
   Waijarean N, 2014, CONSTR BUILD MATER, V50, P486, DOI 10.1016/j.conbuildmat.2013.08.047
   WANG MC, 1992, J ENVIRON ENG-ASCE, V118, P848, DOI 10.1061/(ASCE)0733-9372(1992)118:6(848)
   Wang XR, 2008, J HAZARD MATER, V160, P489, DOI 10.1016/j.jhazmat.2008.03.054
   Watanabe Y., 2011, GEOTECHNICAL SPECIAL, P1075
   Wei N, 2015, INT J ENV RES PUB HE, V12, P4992, DOI 10.3390/ijerph120504992
   Wolff E, 2015, J CLEAN PROD, V96, P282, DOI 10.1016/j.jclepro.2014.06.018
   Xu GR, 2008, J HAZARD MATER, V153, P1031, DOI 10.1016/j.jhazmat.2007.09.056
   Xu GR, 2008, J HAZARD MATER, V150, P394, DOI 10.1016/j.jhazmat.2007.04.121
   Xu GR, 2010, WATER RES, V44, P2930, DOI 10.1016/j.watres.2010.02.014
   Zamora RMR, 2008, J ENVIRON SCI HEAL A, V43, P1562, DOI 10.1080/10934520802293750
   2009, J HAZARD MATER, V165, P995, DOI DOI 10.1016/J.JHAZMAT.2008.10.113
   2008, ENVIRON SCI TECHNOL, V42, P7417, DOI DOI 10.1021/ES801446H
   2013, CONSTR BUILD MATER, V41, P464, DOI DOI 10.1016/J.CONBUILDMAT.2012.12.041
NR 124
TC 7
Z9 7
U1 20
U2 47
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 148
EP 159
DI 10.1016/j.resconrec.2019.02.032
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200015
DA 2020-05-12
ER

PT J
AU Hossain, MU
   Sohail, A
   Ng, ST
AF Hossain, Md. Uzzal
   Sohail, Ammar
   Ng, S. Thomas
TI Developing a GHG-based methodological approach to support the sourcing
   of sustainable construction materials and products
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Construction materials; Greenhouse gases; Sourcing approach;
   Sustainability sourcing; Construction industry
ID LIFE-CYCLE ASSESSMENT; SUPPLY CHAINS; ENVIRONMENTAL EVALUATION; MATERIAL
   SELECTION; PORTLAND-CEMENT; WASTE MATERIALS; CONCRETE; LCA; PERFORMANCE;
   IMPACT
AB While the assessment of environmental impacts of different construction materials is widely studied globally, the development of robust mechanisms for material sourcing as an integral step to transit into a sustainable supply chain is still sparse. Integrating environmental performance into an industry level supply chain is indeed a challenging task due to the absence of standardized methodology. This paper presents a methodological approach for sustainable construction material sourcing by highlighting the greenhouse gas (GHG) emissions. The proposed approach is then adopted to 12 case construction materials and products which are commonly used in to Hong Kong, and the hotspots for existing sourcing of the selected materials and products are identified while the GHG emissions are assessed based on their sourcing locations. Alternative scenarios for sourcing are identified based on a decision matrix developed according to this methodological approach. The results demonstrate that sustainable sourcing of the 12 selected materials and products by adopting the alternative scenarios can reduce 28% of the total GHG emissions compared to the base scenarios. As the scope of emission reduction for resource-scarce high-density city like Hong Kong is limited, sustainable sourcing of materials may significantly influence the emission reduction target of the construction industry. The proposed approach can help underpin sustainable sourcing of materials which can be effectively adopted in other regions to enhance the sustainability performance of the industry.
C1 [Hossain, Md. Uzzal; Sohail, Ammar; Ng, S. Thomas] Univ Hong Kong, Dept Civil Engn, Pokfulam, Hong Kong, Peoples R China.
RP Ng, ST (reprint author), Univ Hong Kong, Dept Civil Engn, Pokfulam, Hong Kong, Peoples R China.
EM tstng@hku.hk
CR Acquaye A, 2018, EUR J OPER RES, V269, P188, DOI 10.1016/j.ejor.2017.10.057
   Bazan E., 2017, BOOK OPER SERV MANAG, V2017, P52, DOI [10.4018/978-1-5225-0635-5.CH003, DOI 10.4018/978-1-5225-0635-5.CH003]
   Braga AM, 2017, J CLEAN PROD, V162, P529, DOI 10.1016/j.jclepro.2017.06.057
   Cheng KL, 2018, RESOUR CONSERV RECY, V133, P10, DOI 10.1016/j.resconrec.2018.02.003
   CLCD, 2010, CHIN LIF CYCL DAT VE
   Craig AJ, 2013, TRANSPORT RES D-TR E, V22, P49, DOI 10.1016/j.trd.2013.02.016
   Bojarski AD, 2009, COMPUT CHEM ENG, V33, P1747, DOI 10.1016/j.compchemeng.2009.04.009
   De Luca P, 2017, J GREEN BUILD, V12, P141, DOI 10.3992/1943-4618.12.4.141
   Di Filippo J, 2019, CEMENT CONCRETE COMP, V101, P67, DOI 10.1016/j.cemconcomp.2018.08.003
   Di Maria A, 2018, INT J LIFE CYCLE ASS, V23, P2091, DOI 10.1007/s11367-018-1440-1
   Ding T, 2016, WASTE MANAGE, V56, P367, DOI 10.1016/j.wasman.2016.05.031
   Ecoinvent 3.0, 2013, TRANSP FREIGHT SEA T
   Farkavcova VG, 2018, TRANSPORT RES D-TR E, V61, P68, DOI 10.1016/j.trd.2017.04.025
   Goswein V, 2018, RESOUR CONSERV RECY, V137, P1, DOI 10.1016/j.resconrec.2018.05.021
   Govindan K, 2016, RENEW SUST ENERG REV, V55, P1274, DOI 10.1016/j.rser.2015.07.100
   HKMTS, 2018, HONG KONG MERCH TRAD
   Hossain MU, 2018, RENEW SUST ENERG REV, V82, P597, DOI 10.1016/j.rser.2017.09.048
   Hossain MU, 2017, RESOUR CONSERV RECY, V120, P199, DOI 10.1016/j.resconrec.2016.12.012
   Hossain MU, 2016, RESOUR CONSERV RECY, V109, P67, DOI 10.1016/j.resconrec.2016.02.009
   Hossain MU, 2016, INT J LIFE CYCLE ASS, V21, P70, DOI 10.1007/s11367-015-0988-2
   Iffa E, 2017, J GREEN BUILD, V12, P35, DOI 10.3992/1943-4618.12.4.35
   IO, 2018, IND OV IO OV CONSTR
   Ioannidou D, 2017, RESOUR CONSERV RECY, V126, P25, DOI 10.1016/j.resconrec.2017.07.016
   Kirschstein T, 2015, TRANSPORT RES B-METH, V73, P13, DOI 10.1016/j.trb.2014.12.004
   Kono J, 2018, J CLEAN PROD, V196, P1356, DOI 10.1016/j.jclepro.2018.06.057
   Kurda R, 2018, J CLEAN PROD, V194, P735, DOI 10.1016/j.jclepro.2018.05.177
   Li Y, 2016, J CLEAN PROD, V120, P221, DOI 10.1016/j.jclepro.2015.12.071
   Mahmoudkelaye S., 2018, CASE STUDIES CONSTRU, V9, DOI [10.1016/J.CSCM.2018.E00200, DOI 10.1016/J.CSCM.2018.E00200]
   Mathiyazhagan K., 2018, J ADV MANAGE RES, DOI [10.1108/JAMR-09-2018, DOI 10.1108/JAMR-09-2018]
   Meisterling K, 2009, J CLEAN PROD, V17, P222, DOI 10.1016/j.jclepro.2008.04.009
   Mousavi-Nasab SH, 2018, J CLEAN PROD, V182, P466, DOI 10.1016/j.jclepro.2018.02.062
   Munier N, 2011, ECOL INDIC, V11, P1020, DOI 10.1016/j.ecolind.2011.01.006
   Nealer R, 2012, TRANSPORT RES A-POL, V46, P588, DOI 10.1016/j.tra.2011.11.010
   Prosman EJ, 2018, J CLEAN PROD, V172, P2782, DOI 10.1016/j.jclepro.2017.11.134
   Ramful R., 2018, J GREEN BUILD, V13, P1
   Russell E, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10030629
   Shemfe MB, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10093193
   Tasca AL, 2017, J CLEAN PROD, V140, P725, DOI 10.1016/j.jclepro.2016.06.170
   Turk J, 2015, WASTE MANAGE, V45, P194, DOI 10.1016/j.wasman.2015.06.035
   Uctug FG, 2017, J GREEN BUILD, V12, P79, DOI 10.3992/1943-4618.12.2.79
   Wang J, 2018, J GREEN BUILD, V13, P103, DOI 10.3992/1943-4618.13.4.103
   Xing K, 2016, J CLEAN PROD, V139, P191, DOI 10.1016/j.jclepro.2016.08.042
   Yang Y, 2019, INT J LIFE CYCLE ASS, V24, P211, DOI 10.1007/s11367-018-1532-y
   Yazdanbakhsh A, 2018, INT J LIFE CYCLE ASS, V23, P1163, DOI 10.1007/s11367-017-1360-5
   Zhang JL, 2014, INT J LIFE CYCLE ASS, V19, P745, DOI 10.1007/s11367-013-0689-7
   Zuo J, 2017, RENEW SUST ENERG REV, V70, P358, DOI 10.1016/j.rser.2016.11.251
NR 46
TC 4
Z9 4
U1 3
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 160
EP 169
DI 10.1016/j.resconrec.2019.02.030
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200016
DA 2020-05-12
ER

PT J
AU Obata, SH
   Agostinho, F
   Almeida, CMVB
   Giannetti, BF
AF Obata, Sasquia H.
   Agostinho, Feni
   Almeida, Cecilia M. V. B.
   Giannetti, Biagio F.
TI LEED certification as booster for sustainable buildings: Insights for a
   Brazilian context
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Brazil; Green building rating systems; LEED; Sustainable buildings
ID GREEN; INFORMATION; SYSTEMS; ENERGY; COST; LCA
AB Green labels have strong potential in identifying buildings with lower load on the natural environment, among which the leadership in energy and environmental design (LEED) is the most used certification worldwide. LEED's potential in truly reflecting a building's sustainability degree has been receiving criticisms in the scientific literature. The more recent LEED versions represent, in theory, improvements over the previous ones in an attempt to overcome such criticism. This work assesses the way in which LEED certification is pushing buildings towards higher sustainability degrees. Primary data are based on the Brazilian certified buildings up to 2016, totalizing 276 projects evaluated under statistical approaches, including the Kruskall Wallis analysis, credit achievement degree, and skewness indices. Results show that energy & atmosphere and material & resource categories received lower scores among all other categories for the 2009 LEED version than for the 2.0/2.2 version. The 2009 LEED framework allowed the certified Brazilian buildings to pursue those easier-to-obtain scores, which raises doubts about whether the LEED label push to strong sustainability since its core concept is based on energy and material consumption. Notwithstanding, the evaluated projects in Brazil pursue lower degrees of sustainability because they apply efforts in obtaining the minimum scores required by a specific label. Although demanding improvements, LEED certification should be promoted as an important tool towards sustainable development due to its innumerous advantages.
C1 [Obata, Sasquia H.; Agostinho, Feni; Almeida, Cecilia M. V. B.; Giannetti, Biagio F.] Paulista Univ UNIP, Postgrad Program Prod Engn, Sao Paulo, Brazil.
   [Obata, Sasquia H.] Mackenzie Presbiterian Univ, Sao Paulo, Brazil.
   [Obata, Sasquia H.] Armando Alvarez Penteado Fdn FAAP, Sao Paulo, Brazil.
RP Agostinho, F (reprint author), Univ Paulista UNIP, Programa Posgrad Engn Prod, Lab Prod & Meio Ambiente, Rua Dr Bacelar 1212, BR-04026002 Sao Paulo, Brazil.
EM feni@unip.br
RI Almeida, Cecilia M V B/G-7865-2012; Giannetti, Biagio F./AAC-8306-2019;
   Obata, Sasquia/W-2859-2019; Agostinho, Feni Dalano Roosevelt/C-9351-2018
OI Obata, Sasquia/0000-0002-0639-8465; Agostinho, Feni Dalano
   Roosevelt/0000-0002-6445-2175; Almeida, Cecilia M V
   B/0000-0002-0473-906X; Giannetti, Biagio Fernando/0000-0002-2337-4457
FU Paulista University (UNIP); CNPq BrazilNational Council for Scientific
   and Technological Development (CNPq) [307422/2015-1]
FX Authors are grateful for the financial support from Paulista University
   (UNIP). Thanks also to Westermann M. for his collaboration in the data
   mining process, Marcelo Succi for his collaboration on statistical
   analysis, and Jose Hugo de Oliveira for the English language review. FA
   is grateful to CNPq Brazil (307422/2015-1).
CR Alyami SH, 2012, SUSTAIN CITIES SOC, V5, P52, DOI 10.1016/j.scs.2012.05.004
   Berardi U, 2017, RESOUR CONSERV RECY, V123, P230, DOI 10.1016/j.resconrec.2016.03.014
   Champagne CL, 2016, PROCEDIA ENGINEER, V145, P380, DOI 10.1016/j.proeng.2016.04.095
   Cidell J, 2009, LANDSCAPE URBAN PLAN, V91, P142, DOI 10.1016/j.landurbplan.2008.12.001
   Doan DT, 2017, BUILD ENVIRON, V123, P243, DOI 10.1016/j.buildenv.2017.07.007
   Dekkiche H, 2016, PROCEDIA ENGINEER, V145, P844, DOI 10.1016/j.proeng.2016.04.110
   Donghwan G., 2015, ENERGY BUILD, V86, P697
   Dwaikat LN, 2016, ENERG BUILDINGS, V110, P396, DOI 10.1016/j.enbuild.2015.11.021
   Gelowitz MDC, 2018, RESOUR CONSERV RECY, V136, P436, DOI 10.1016/j.resconrec.2018.05.008
   Gurgun AP, 2016, PROCEDIA ENGINEER, V164, P432, DOI 10.1016/j.proeng.2016.11.641
   Nguyen HT, 2017, RESOUR CONSERV RECY, V127, P8, DOI 10.1016/j.resconrec.2017.08.012
   Humbert S, 2007, INT J LIFE CYCLE ASS, V12, P46, DOI 10.1065/lca2006.12.291
   Jalaei F, 2015, SUSTAIN CITIES SOC, V18, P95, DOI 10.1016/j.scs.2015.06.007
   Jun MA, 2017, ADV ENG INFORM, V32, P224, DOI 10.1016/j.aei.2017.03.004
   Kubba S., 2016, LEED V4 PRACTICES CE
   Ma J, 2016, BUILD ENVIRON, V98, P121, DOI 10.1016/j.buildenv.2016.01.005
   Mattoni B, 2018, RENEW SUST ENERG REV, V82, P950, DOI 10.1016/j.rser.2017.09.105
   Meadows Dennis L., 1972, LIMITS GROWTH
   Michael M, 2017, ENERG BUILDINGS, V139, P22, DOI 10.1016/j.enbuild.2017.01.006
   Mousa RA, 2017, PROCEDIA ENVIRON SCI, V37, P572, DOI 10.1016/j.proenv.2017.03.044
   Neumayer E., 2003, WEAK VERSUS STRONG S, DOI DOI 10.4337/9781849805438
   Newsham GR, 2009, ENERG BUILDINGS, V41, P897, DOI 10.1016/j.enbuild.2009.03.014
   Odum H. T., 2001, PROSPEROUS WAY DOWN, P326
   Rakha T, 2018, SUSTAIN CITIES SOC, V39, P568, DOI 10.1016/j.scs.2018.02.040
   Rockstrom J, 2009, NATURE, V461, P472, DOI 10.1038/461472a
   Scofield JH, 2009, ENERG BUILDINGS, V41, P1386, DOI 10.1016/j.enbuild.2009.08.006
   Shad R, 2017, RENEW SUST ENERG REV, V67, P324, DOI 10.1016/j.rser.2016.09.004
   Shan M, 2018, SUSTAIN CITIES SOC, V39, P172, DOI 10.1016/j.scs.2018.02.034
   Suzer O, 2015, J ENVIRON MANAGE, V154, P266, DOI 10.1016/j.jenvman.2015.02.029
   UNEP, 2018, UN ENV PROGR SUST BU
   USEPA, 2000, QAG9QA00 USEPA
   USEPA, 2013, EPA600R07041
   Vyas GS, 2018, SUSTAIN CITIES SOC, V36, P107, DOI 10.1016/j.scs.2017.09.023
   Wackernagel M, 1996, OUR ECOLOGICAL FOOTP
   Wangel J, 2016, ENVIRON IMPACT ASSES, V56, P200, DOI 10.1016/j.eiar.2015.10.003
   Wu P., 2018, SUSTAINABILITY, V20, P1
   Wu P, 2017, RENEW SUST ENERG REV, V68, P370, DOI 10.1016/j.rser.2016.10.007
   Wu P, 2016, BUILD ENVIRON, V102, P167, DOI 10.1016/j.buildenv.2016.03.026
   Zhao J, 2012, SUSTAIN CITIES SOC, V5, P37, DOI 10.1016/j.scs.2012.05.009
   2017, J CLEAN PROD, V164, P209, DOI DOI 10.1016/J.JCLEPRO.2017.06.206
NR 40
TC 2
Z9 2
U1 3
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 170
EP 178
DI 10.1016/j.resconrec.2019.02.037
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200017
DA 2020-05-12
ER

PT J
AU Casey, K
   Lichrou, M
   Fitzpatrick, C
AF Casey, Katherine
   Lichrou, Maria
   Fitzpatrick, Colin
TI Treasured trash? A consumer perspective on small Waste Electrical and
   Electronic Equipment (WEEE) divestment in Ireland
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Small WEEE; Consumer research; Consumer experiences and interpretations;
   Perceived value of WEEE; Household WEEE divestment process
ID WILLINGNESS-TO-PAY; RECYCLING BEHAVIORS; ATTITUDES; MANAGEMENT;
   RESIDENTS; AWARENESS; PERCEPTIONS; CONSUMPTION; KNOWLEDGE; DISPOSAL
AB Small Waste Electrical and Electronic Equipment (sWEEE) is a particularly problematic category of electronic waste. A growing body of research indicates that sWEEE tends to be either stockpiled or disposed of improperly (references). However, despite this, little attention has been given to the meanings people ascribe to their electronic and electrical possessions; meanings which continue to apply even when they are disused or broken. The purpose of this study was to generate insight into this area and to identify opportunities for intervention to increase sWEEE recycling. A quasi-ethnographic approach was used to investigate sWEEE disposal behaviour from the perspective of Irish consumers. The rationale for this approach was the need to reconcile the policy perspective on sWEEE with the subjective experiences and interpretations that drive people's behaviour. The findings reveal that from the time electronic and electrical devices enter consumers' lives until their disposal, they exist in fluid in-between states of meaning and have perceived value. Before divestment, sWEEE typically undergoes a four-stage journey: a) once electrical and electronic equipment (EEE) is no longer used, it tends to be either consciously stored or abandoned in the home (inactive EEE); b) a trigger prompts consumers to divest of the inactive EEE (critical moment); c) provoked to take action, consumers must decide precisely what to discard and how (transition from EEE to WEEE); d) consumers decide to recycle or not (divestment). The paper concludes by discussing the implications of these findings in terms of encouraging increased sWEEE recycling.
C1 [Casey, Katherine; Lichrou, Maria] Univ Limerick, Dept Management & Mkt, Kemeny Business Sch, Limerick, Ireland.
   [Fitzpatrick, Colin] Univ Limerick, Fac Sci & Engn, Dept Elect & Comp Engn, Limerick, Ireland.
RP Lichrou, M (reprint author), Univ Limerick, Dept Management & Mkt, Kemeny Business Sch, Limerick, Ireland.
EM catherine.casey@ul.ie; maria.lichrou@ul.ie; colin.Fitzpatrick@ul.ie
RI Lichrou, Maria/AAL-6778-2020
OI Fitzpatrick, Colin/0000-0002-3542-6437; Lichrou,
   Maria/0000-0003-4532-1433
FU Environmental Protection Agency (EPA) Research Programme2014-2020;
   EPAUnited States Environmental Protection Agency; WEEE Ireland; European
   Recycling Platform; Producer Register Limited; Department of
   Communications, Climate Action and Environment
FX This research is part of a project funded by the Environmental
   Protection Agency (EPA) Research Programme2014-2020. The project was
   co-funded by the EPA, WEEE Ireland, the European Recycling Platform and
   the Producer Register Limited. The EPA Research Programme is a
   Government of Ireland initiative funded by the Department of
   Communications, Climate Action and Environment.
CR Abeliotis K, 2006, WIT TRANS ECOL ENVIR, V92, P405, DOI 10.2495/WM060431
   Afroz R, 2013, J CLEAN PROD, V52, P185, DOI 10.1016/j.jclepro.2013.02.004
   Albinsson P. A., 2009, J CONSUM BEHAV, V8, P340, DOI DOI 10.1002/CB.301
   Arnould E.J., 1998, REPRESENTING CONSUME, P85
   ARNOULD EJ, 1994, J MARKETING RES, V31, P484, DOI 10.2307/3151878
   Atkinson P., 2014, FOR ETHNOGRAPHY, V4, P550, DOI [10.1007/s13398-014-0173-7.2, DOI 10.1007/S13398-014-0173-7.2]
   Barr S, 2006, GEOFORUM, V37, P906, DOI 10.1016/j.geoforum.2006.05.002
   Belk RW, 2013, J CONSUM RES, V40, P477, DOI 10.1086/671052
   BELK RW, 1988, J CONSUM RES, V14, P449, DOI 10.1086/209128
   BELK RW, 1989, J CONSUM RES, V16, P1, DOI 10.1086/209191
   BELK RW, 1988, J CONSUM RES, V15, P139, DOI 10.1086/209154
   Benton D., 2015, CIRCULAR EC SMART DE
   Bouvier R, 2011, RESOUR CONSERV RECY, V55, P1051, DOI 10.1016/j.resconrec.2011.05.019
   Byrne S, 2014, RESOUR CONSERV RECY, V87, P89, DOI 10.1016/j.resconrec.2014.03.001
   Chi XW, 2014, J CLEAN PROD, V80, P87, DOI 10.1016/j.jclepro.2014.05.056
   Dai YC, 2015, RESOUR CONSERV RECY, V102, P9, DOI 10.1016/j.resconrec.2015.06.004
   Dalrymple I, 2007, CIRCUIT WORLD, V33, P52, DOI 10.1108/03056120710750256
   Darby L, 2005, RESOUR CONSERV RECY, V44, P17, DOI 10.1016/j.resconrec.2004.09.002
   Davies A. R., 2005, ENV ATTITUDES BEHAV
   DiGiacomo A, 2018, J ENVIRON PLANN MAN, V61, P309, DOI 10.1080/09640568.2017.1305332
   Dimitrakakis E, 2009, J HAZARD MATER, V161, P913, DOI 10.1016/j.jhazmat.2008.04.054
   Dindarian A, 2012, J CLEAN PROD, V32, P22, DOI 10.1016/j.jclepro.2012.03.015
   Dwivedy M, 2013, ENVIRON DEV, V6, P48, DOI 10.1016/j.envdev.2013.03.001
   Elliott R., 2003, QUALITATIVE MARKET R, V6, P215, DOI DOI 10.1108/13522750310495300
   Eurostat, 2017, WAST DAT
   Eutostat, 2014, ENV EN
   Fraige FY, 2012, J ENVIRON PLANN MAN, V55, P161, DOI 10.1080/09640568.2011.586492
   Friege H, 2015, WASTE MANAGE RES, V33, P223, DOI 10.1177/0734242X14567500
   Gaskell G, 2000, QUALITATIVE RES TEXT, P38, DOI DOI 10.4135/9781849209731
   Gurauskiene Inga, 2008, Environmental Research, Engineering and Management, V46, P56
   Gutierrez Ester, 2011, International Journal of Society Systems Science, V3, P385, DOI 10.1504/IJSSS.2011.043214
   Gutierrez E, 2011, WASTE MANAGE RES, V29, P622, DOI 10.1177/0734242X10377914
   Halpem D., 2004, PERSONAL RESPONSIBIL
   Hertz C., 2011, MUSEUM ANTHR REV
   Islam MT, 2016, J CLEAN PROD, V137, P728, DOI 10.1016/j.jclepro.2016.07.111
   Johnson M., 2016, DEV MODEL ASCERTAIN
   Kleine S.S., 2004, ACAD MARKETING SCI R, V1, P1
   La Barbera F., 2014, QUALITY ACCESS SUCCE, V15, P213
   Ladner Sam, 2014, PRACTICAL ETHNOGRAPH
   Lastovicka J. L., 2005, 3 PATHS DISPOSITION, P31
   Li B, 2012, PROCEDIA ENVIRON SCI, V16, P469, DOI 10.1016/j.proenv.2012.10.064
   Li JH, 2012, WASTE MANAGE RES, V30, P1187, DOI 10.1177/0734242X12456728
   Makov T., 2018, FRONT ENERGY RES, V6, P39, DOI [10.3389/fenrg.2018.00039, DOI 10.3389/FENRG.2018.00039]
   Martin M, 2006, RESOUR CONSERV RECY, V48, P357, DOI 10.1016/j.resconrec.2005.09.005
   Martinho G, 2017, J CLEAN PROD, V156, P147, DOI 10.1016/j.jclepro.2017.04.039
   McCoole F., 2014, NATL WASTE REPORT 20
   MCCRACKEN G, 1986, J CONSUM RES, V13, P71, DOI 10.1086/209048
   Nixon H, 2007, J ENVIRON MANAGE, V84, P547, DOI 10.1016/j.jenvman.2006.07.003
   Nnorom IC, 2009, J CLEAN PROD, V17, P1629, DOI 10.1016/j.jclepro.2009.08.009
   Ongondo FO, 2011, WASTE MANAGE, V31, P1307, DOI 10.1016/j.wasman.2011.01.032
   Ongondo FO, 2011, WASTE MANAGE, V31, P1617, DOI 10.1016/j.wasman.2011.01.031
   Perez-Belis V, 2017, J CLEAN PROD, V158, P261, DOI 10.1016/j.jclepro.2017.04.143
   Price LL, 2000, J CONSUM RES, V27, P179, DOI 10.1086/314319
   ROOK DW, 1985, J CONSUM RES, V12, P251, DOI 10.1086/208514
   Roster CA, 2001, ADV CONSUM RES, V28, P425
   Saphores JDM, 2006, ENVIRON BEHAV, V38, P183, DOI 10.1177/0013916505279045
   Saphores JDM, 2007, J ENVIRON PLANN MAN, V50, P113, DOI 10.1080/09640560601048549
   Saritha V, 2015, POLLUTION, V1, P31, DOI 10.7508/pj.2015.01.004
   Sivanthanu B., 2016, INT J APPL ENV SCI, V11, P413
   Song QB, 2016, PROCEDIA ENVIRON SCI, V31, P635, DOI 10.1016/j.proenv.2016.02.116
   Speake J., 2015, HUM GEOGR J STUD RES, V9, P241, DOI DOI 10.5719/HGE0.2015.92.8
   Spradley J, 1979, ETHNOGRAPHIC INTERVI
   Valentine G, 1999, AREA, V31, P67, DOI 10.1111/j.1475-4762.1999.tb00172.x
   Wang ZH, 2011, J CLEAN PROD, V19, P977, DOI 10.1016/j.jclepro.2010.09.016
   WEEE Ireland, 2017, WEEE IR ANN ENV REP
   WEEE Ireland, 2016, WEEE IR ANN REP 2015
   Welfens MJ, 2016, J CLEAN PROD, V132, P108, DOI 10.1016/j.jclepro.2015.11.082
   Wilkinson S., 2003, ENV PROT
   Wilson GT, 2017, WASTE MANAGE, V60, P521, DOI 10.1016/j.wasman.2016.12.023
   Xevgenos D, 2015, WASTE BIOMASS VALORI, V6, P657, DOI 10.1007/s12649-015-9389-9
   YLA-MELLA J., 2014, J WASTE MANAGEMENT, V2014
   Yla-Mella J, 2015, WASTE MANAGE, V45, P374, DOI 10.1016/j.wasman.2015.02.031
   2014, QUAL RES, V14, P3, DOI DOI 10.1177/1468794112459671
   2013, RESOUR CONSERV RECY, V73, P94, DOI DOI 10.1016/J.RESCONREC.2012.12.012
NR 74
TC 5
Z9 5
U1 5
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 179
EP 189
DI 10.1016/j.resconrec.2019.02.015
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200018
OA Green Accepted
DA 2020-05-12
ER

PT J
AU He, K
   Hertwich, EG
AF He, Kehan
   Hertwich, Edgar G.
TI The flow of embodied carbon through the economies of China, the European
   Union, and the United States
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Embodied CO2 emission; Input-Output Model; Consumption-based account;
   Scope 3 Greenhouse Gas Protocol
ID GREENHOUSE-GAS EMISSIONS; LIFE-CYCLE ASSESSMENT; CO2 EMISSIONS; TRADE;
   FOOTPRINT; LEVEL; MODEL
AB Indirect CO2 emissions are gaining increasing interests in addition to direct CO2 emissions, as policy makers become more aware of the possibilities for structural and technical change, sometimes resulting from policies, to move CO2 emissions along supply chains. An analysis of the composition of emissions and carbon efficiency of production and their development over time may inform the formulation of demand-side and supply-side solutions for emission reduction over the entire life-cycle. In addition, understanding of emissions embodied in trade (EET) at intermediate and final stages is crucial for allocation of emission responsibilities in a fair manner. Hence, we account for global direct and indirect intermediate and final CO2 emissions using the global, multiregional input-output model EXIOBASE 3.3. We present results for the flow of embodied carbon through the economies of 49 countries and regions using an interactive visualization and provide a comparative analysis of China, the US, and the EU. It shows that China has undergone rapid, continuous increase in both intermediate and final indirect CO2 emissions compared to the other two economies from 1995 to 2015, to 26.1 Pg and 11.0 Pg respectively. Emission intensities in China are on average 3.7 times of the US and 2.4 times of the EU in the year 2015, implying the possibility of further reducing emission by efficiency improvement and fuel switching. CO2 EETs of intermediate production by sectors in the three economies are also reported.
C1 [He, Kehan; Hertwich, Edgar G.] Yale Univ, Sch Forestry & Environm Studies, Ctr Ind Ecol, New Haven, CT 06511 USA.
RP Hertwich, EG (reprint author), Yale Univ, Sch Forestry & Environm Studies, Ctr Ind Ecol, New Haven, CT 06511 USA.
EM edgar.hertwich@yale.edu
RI Hertwich, Edgar/Y-9537-2019
OI Hertwich, Edgar/0000-0002-4934-3421
CR Abdi A, 2018, INT J PROJ MANAG, V36, P397, DOI 10.1016/j.ijproman.2017.12.003
   Allwood J. M., 2012, SUSTAINABLE MAT BOTH, P231
   Asif M, 2007, RENEW SUST ENERG REV, V11, P1388, DOI 10.1016/j.rser.2005.12.004
   Baiocchi G, 2010, ENVIRON SCI TECHNOL, V44, P1177, DOI 10.1021/es902662h
   Blanco G, 2014, DRIVERS TRENDS MITIG
   Bocken NMP, 2017, J IND ECOL, V21, P476, DOI 10.1111/jiec.12606
   Central Gov. PRC, 2008, CIRC EC PROM LAW PEO
   Chen ZM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05905-y
   EPA, 2017, OV GREENH GAS
   European Commission, 2017, EDG
   European Commission, 2018, IMPL CIRC EC ACT PLA
   Feng KS, 2014, ECOL INDIC, V47, P26, DOI 10.1016/j.ecolind.2014.04.045
   Fischedick M., 2014, IND CLIMATE CHANGE 2
   Gallego B., 2005, ECON SYST RES, V17, P365, DOI DOI 10.1080/09535310500283492
   Hertwich EG, 2018, ENVIRON RES LETT, V13, DOI 10.1088/1748-9326/aae19a
   Hertwich EG, 2009, ENVIRON SCI TECHNOL, V43, P6414, DOI 10.1021/es803496a
   Huang RZ, 2016, J CLEAN PROD, V135, P1559, DOI 10.1016/j.jclepro.2015.04.109
   Jiang XM, 2017, ENERG POLICY, V109, P734, DOI 10.1016/j.enpol.2017.07.058
   Jiang XM, 2017, ECOL ECON, V139, P102, DOI 10.1016/j.ecolecon.2017.04.027
   Jiang XM, 2016, APPL ENERG, V184, P1132, DOI 10.1016/j.apenergy.2016.06.142
   Johnson RC, 2017, REV ECON STAT, V99, P896, DOI 10.1162/REST_a_00665
   Lenzen M., 2004, J APPL INPUT OUTPUT, V10, P1
   Liang S, 2017, J IND ECOL, V21, P953, DOI 10.1111/jiec.12477
   Mi ZF, 2016, APPL ENERG, V184, P1073, DOI 10.1016/j.apenergy.2016.06.094
   MOHURD, 2017, 2016 CONSTR SECT DEV
   Nassen J, 2007, ENERGY, V32, P1593, DOI 10.1016/j.energy.2007.01.002
   Owen A, 2016, ECON SYST RES, V28, P243, DOI 10.1080/09535314.2015.1135309
   Paciornik N., 2006, GEN GUIDANCE REPORTI, V1
   Pan C, 2017, EARTHS FUTURE, V5, P934, DOI 10.1002/2017EF000625
   Peters G. P., 2004, PRODUCTION FACTORS P
   Peters GP, 2008, ECOL ECON, V65, P13, DOI 10.1016/j.ecolecon.2007.10.014
   PULLES T, 2007, [No title captured]
   Raupach MR, 2007, P NATL ACAD SCI USA, V104, P10288, DOI 10.1073/pnas.0700609104
   Roberts KG, 2010, ENVIRON SCI TECHNOL, V44, P827, DOI 10.1021/es902266r
   Sato M, 2014, ECOL ECON, V105, P106, DOI 10.1016/j.ecolecon.2014.05.006
   Sodersten CJH, 2018, ENVIRON SCI TECHNOL, V52, P13250, DOI 10.1021/acs.est.8b02791
   Sommer M, 2017, ECOL ECON, V136, P62, DOI 10.1016/j.ecolecon.2016.12.008
   Stadler K., 2018, J IND ECOL, V22, P1
   Su B, 2014, APPL ENERG, V114, P377, DOI 10.1016/j.apenergy.2013.09.036
   UN, 2008, SYST NAT ACC
   Weber CL, 2010, ENVIRON SCI TECHNOL, V44, P1895, DOI 10.1021/es9017909
   Wiedmann T, 2018, NAT GEOSCI, V11, P314, DOI 10.1038/s41561-018-0113-9
   Wiedmann T, 2009, ECON SYST RES, V21, P175, DOI 10.1080/09535310903541256
   World Economic Forum, 2016, ENV SUST PRINC REAL
NR 44
TC 3
Z9 3
U1 9
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 190
EP 198
DI 10.1016/j.resconrec.2019.02.016
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200019
DA 2020-05-12
ER

PT J
AU Tazi, N
   Kim, J
   Bouzidi, Y
   Chatelet, E
   Liu, G
AF Tazi, Nacef
   Kim, Junbeum
   Bouzidi, Youcef
   Chatelet, Eric
   Liu, Gang
TI Waste and material flow analysis in the end-of-life wind energy system
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Wind energy; Material flow analysis; End of life; Wind turbine wastes;
   Maintenance; Recycling
ID MANAGEMENT; CONSUMPTION; PATHWAYS; DENMARK; POWER; TOOL
AB In the specific case of French onshore wind farms, waste management of these systems has become an important factor of the wind energy industry's sustainability. The aim of this paper is to quantify wind turbine (WT) material wastes and flows across the Champagne-Ardenne (CA) region from 2002 to 2020. To do so, a material flow analysis (MFA) model was used. It included three maintenance strategies used for onshore wind turbines. Results show that more than 1 million tons of material will ultimately be generated at the EoL of CA wind farms. The main EoL materials are ferrous and non-ferrous metals, polymers, glass and concrete. The main EoL materials are ferrous and non-ferrous metals, polymers, glass and concrete. In this total, blades and composite EoL materials that need to be managed, account for more than 27,000 tons; there are 523,227 tons of steel and iron materials that need to be handled; 6617 tons of copper, and 28,179 tons of aluminum flows. Landfill concrete accounts for 734,230 tons. When the concrete in foundation is not considered, 73% of an average wind turbine can be recycled. With the first generation of WT reaching their EoL phase and taking into account that no dismantling or recycling facilities of WT components have emerged in the French territory, the potential of WT wastes available for treatment (recycle, incinerate, landfill etc.) is still increasing.
C1 [Tazi, Nacef; Chatelet, Eric] Univ Technol Troyes, CNRS, LM2S STMR, Charles Delaunay Inst, Troyes, France.
   [Tazi, Nacef; Kim, Junbeum; Bouzidi, Youcef] Univ Technol Troyes, Dept Humanities Environm & Informat Technol HETIC, CREIDD Res Ctr Environm Studies & Sustainabil, Troyes, France.
   [Liu, Gang] Univ Southern Denmark, Dept Chem Engn Biotechnol & Environm Technol, SDU Life Cycle Engn, DK-5230 Odense, Denmark.
RP Kim, J (reprint author), Univ Technol Troyes, Dept Humanities Environm & Informat Technol HETIC, CREIDD Res Ctr Environm Studies & Sustainabil, Troyes, France.
EM junbeum.kim@utt.fr
OI Liu, Gang/0000-0002-7613-1985
FU French regional council of Grand-Est; European regional development fund
   (FEDER)European Union (EU)
FX The authors are grateful to the reviewers' comments that considerably
   enhance the quality of this work. This research project is supported by
   the French regional council of Grand-Est and the European regional
   development fund (FEDER).
CR Agamuthu P, 2015, RESOUR CONSERV RECY, V105, P177, DOI 10.1016/j.resconrec.2015.09.018
   Andersen P.D., 2014, DTU INT ENERGY REPOR, V2014, P91
   [Anonymous], 2017, WIND ENERGY MARKET I
   Arvesen A, 2012, RENEW SUST ENERG REV, V16, P5994, DOI 10.1016/j.rser.2012.06.023
   Baccini P., 1991, METABOLISM ANTHROPOS
   Barrett J., 2002, MAT FLOW ANAL ECOLOG
   Bertram M, 2017, RESOUR CONSERV RECY, V125, P48, DOI 10.1016/j.resconrec.2017.05.014
   Bringezu S., 1997, P 1 CONACCOUNT WORKS
   Brunner P. H., 2004, INT J LIFE CYCLE ASS, V9, P337, DOI DOI 10.1007/BF02979426
   Cencic O, 2008, J ENV ENG MANAG, V18, P3
   Ciacci L, 2017, RESOUR CONSERV RECY, V123, P108, DOI 10.1016/j.resconrec.2016.08.008
   Crawford RH, 2009, RENEW SUST ENERG REV, V13, P2653, DOI 10.1016/j.rser.2009.07.008
   Denny E, 2007, IEEE T POWER SYST, V22, P605, DOI 10.1109/TPWRS.2007.894864
   Elshkaki A, 2014, APPL ENERG, V136, P548, DOI 10.1016/j.apenergy.2014.09.064
   FEE, 2017, ONSH WIND EN EOL TER
   FOX T. R., 2016, RECYCLING WIND TURBI
   Fraile D., 2018, WIND POWER 2017 ANN
   Gusukuma M, 2018, RESOUR CONSERV RECY, V138, P142, DOI 10.1016/j.resconrec.2018.07.014
   GWEC, 2017, GLOB WIND REP 2017
   Tran HP, 2018, RESOUR CONSERV RECY, V139, P78, DOI 10.1016/j.resconrec.2018.07.031
   Haapala Karl R., 2014, International Journal of Sustainable Manufacturing, V3, P170, DOI 10.1504/IJSM.2014.062496
   Habib K, 2014, ENVIRON SCI TECHNOL, V48, P12229, DOI 10.1021/es501975y
   Kim J, 2017, ENVIRON SCI POLLUT R, V24, P25137, DOI 10.1007/s11356-017-0152-6
   Kim J, 2015, APPL ENERG, V139, P327, DOI 10.1016/j.apenergy.2014.11.003
   Kleijn R, 2000, ECOL ECON, V32, P241, DOI 10.1016/S0921-8009(99)00090-7
   Klinglmair M, 2016, RESOUR CONSERV RECY, V109, P166, DOI 10.1016/j.resconrec.2016.03.009
   Kytzia S, 2004, REAL AND VIRTUAL WORLDS OF SPATIAL PLANNING, P281
   Lantz E., 2013, P AWEA WIND POW C
   Liu G, 2013, NAT CLIM CHANGE, V3, P338, DOI [10.1038/nclimate1698, 10.1038/NCLIMATE1698]
   Liu P, 2017, WASTE MANAGE, V62, P229, DOI 10.1016/j.wasman.2017.02.007
   Ma Y., 2017, 11 ANN TECHCONNECT W
   Makarichi L, 2018, RESOUR CONSERV RECY, V139, P351, DOI 10.1016/j.resconrec.2018.07.024
   Martinez E, 2010, APPL ENERG, V87, P2293, DOI 10.1016/j.apenergy.2009.11.025
   Meylan G, 2017, RESOUR CONSERV RECY, V123, P1, DOI 10.1016/j.resconrec.2016.01.006
   Nakajima K, 2018, RESOUR CONSERV RECY, V133, P369, DOI 10.1016/j.resconrec.2017.08.029
   ObservER, 2016, J EOLIEN, V07-08, P38
   OSullivan C., 2017, THESIS
   Pivnenko K, 2016, ENVIRON SCI TECHNOL, V50, P12302, DOI 10.1021/acs.est.6b01791
   Ragheb A., 2010, NUCL REN EN C INREC
   Razdan P., 2015, LIFE CYCLE ASSESSMEN
   SER, 2014, FRENCH ONSH WIND EN
   Tazi N., 2017, ENVIRON SCI POLLUT R, P1
   Tazi N, 2017, ENERGIES, V10, DOI 10.3390/en10030276
   Vadoudi K, 2015, WASTE MANAGE RES, V33, P919, DOI 10.1177/0734242X15597775
   Varun, 2009, RENEW SUST ENERG REV, V13, P1067, DOI 10.1016/j.rser.2008.08.004
   Vestas, 2006, LIF CYCL ASS WIND TU
   Vestas, 2006, LIF CYCL ASS EL PROD
   Vestas, 2011, LIF CYCL ASS EL PROD
   Yokoyama K.M., 2009, J IND ECOL, V13, P687
   Zhang JX, 2016, J CLEAN PROD, V133, P451, DOI 10.1016/j.jclepro.2016.05.101
   Ziemann S, 2018, RESOUR CONSERV RECY, V133, P76, DOI 10.1016/j.resconrec.2018.01.031
   Zimmermann T, 2013, RESOURCES-BASEL, V2, P303, DOI 10.3390/resources2030303
   Zimmermann T, 2014, RESOURCES-BASEL, V3, P291, DOI 10.3390/resources3010291
   Zimmermann T, 2013, INT J LIFE CYCLE ASS, V18, P49, DOI 10.1007/s11367-012-0467-y
   2009, RENEW SUST ENERG REV, V13, P2104, DOI DOI 10.1016/J.RSER.2009.01.001
   2017, RESOUR CONSERV RECY, V122, P21, DOI DOI 10.1016/J.RESCONREC.2017.01.021
NR 56
TC 3
Z9 3
U1 7
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 199
EP 207
DI 10.1016/j.resconrec.2019.02.039
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200020
DA 2020-05-12
ER

PT J
AU Ai, N
   Zheng, JJ
   Chen, WQ
AF Ai, Ning
   Zheng, Junjun
   Chen, Wei-Qiang
TI US end-of-life electric vehicle batteries: Dynamic inventory modeling
   and spatial analysis for regional solutions
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Electric vehicles (EV); Batteries; End-of-life management; Material flow
   analysis; Product flow analysis; Waste management
ID FUTURE; STRATEGIES; MECHANISMS; DEMAND
AB While electric vehicles (EVs) have been promoted for green consumption, improper or inadequate management of end-of-life (EOL) EV batteries, as the current practice, compromises the benefits of EV adoption. This study aims to contribute to both theoretical research of material flow analysis and timely management of EOL EV batteries at various geographic scales (i.e., national, state, and county).
   Theoretically, this study tests two battery lifespan scenarios (i.e., constantly at 3-8 years and dynamically increasing over time), three discard probability functions (i.e., uniform, truncated normal, and Weibull), and three EV sale projections (i.e., low, moderate, and high). Results show that the short-term EOL volume (by 2025) can be particularly sensitive to the lifespan parameter. The long-term estimates involve most uncertainties related to the EV market penetration. Various discard probability functions generally derive similar results.
   In practical terms, the results suggest that necessary infrastructure for proper EOL EV battery management is needed sooner than the public may have perceived. This study urges for regional planning that incorporates both temporal and spatial considerations. To illustrate an example of regional solutions, this study adopts empirical data in California to simulate and spatially match EOL EV battery clusters and the renewable energy facilities that can potentially reuse EV batteries as energy storage. Meanwhile, the spatial mis-match between the supply and demand, as can be the case in other regions, calls for region-wide coordination in terms of both infrastructure development and transportation planning.
C1 [Ai, Ning; Zheng, Junjun] Univ Illinois, Dept Urban Planning & Policy, 412 S Peoria St, Chicago, IL 60607 USA.
   [Ai, Ning] Univ Illinois, Inst Environm Sci & Policy, 412 S Peoria St, Chicago, IL 60607 USA.
   [Chen, Wei-Qiang] Chinese Acad Sci, Key Lab Urban Environm & Hlth, Inst Urban Environm, Xiamen 361021, Peoples R China.
RP Ai, N (reprint author), Univ Illinois, Dept Urban Planning & Policy, 412 S Peoria St, Chicago, IL 60607 USA.; Ai, N (reprint author), Univ Illinois, Inst Environm Sci & Policy, 412 S Peoria St, Chicago, IL 60607 USA.
EM ain@uic.edu
RI CAS, KLUEH/T-5743-2019
OI Ai, Ning/0000-0003-3391-491X; Zheng, Junjun/0000-0003-0334-1890
FU US National Science Foundation (NSF)National Science Foundation (NSF);
   University of Illinois at Chicago Chancellor's Discovery Fund for
   Multidisciplinary Research; Chinese Academy of Sciences Pioneer Hundred
   Talents Program
FX The authors Ning Ai and Junjun Zheng appreciate the support they
   received from the US National Science Foundation (NSF) under Grant
   CyberSEES Type II: Data Integration for Urban Metabolism (No.
   CISE-1331800), and the support from the University of Illinois at
   Chicago Chancellor's Discovery Fund for Multidisciplinary Research. The
   author Wei-Qiang Chen appreciate the support from the Chinese Academy of
   Sciences Pioneer Hundred Talents Program. Any opinions, findings, and
   conclusions or recommendations expressed in this material are those of
   the author(s) and do not necessarily reflect the views of the sponsors.
CR Ahmadi L, 2017, INT J LIFE CYCLE ASS, V22, P111, DOI 10.1007/s11367-015-0959-7
   Al-karakchi A. A. A., 2015, P 20185 50 INT U C U, p1~3, DOI DOI 10.1109/UPEC.2015.7339846
   American Manganese Inc, 2018, CO BUS PLAN
   ARB, 2010, CAL LOW EM VEH REG A
   ARB, 2017, CAL ADV CLEAN CARS M
   Babaee S, 2014, ENVIRON SCI TECHNOL, V48, P1382, DOI 10.1021/es4045677
   Barre A, 2013, J POWER SOURCES, V241, P680, DOI 10.1016/j.jpowsour.2013.05.040
   Becker T. A., 2009, ELECT VEHICLES US NE, P24
   Block D, 2015, ELECT VEHICLE SALES
   BNEF, 2017, EL VEH OUTL 2017
   BNEF, 2016, EL VEH OUTL 2016
   Brunner P. H., 2004, INT J LIFE CYCLE ASS, V9, P337, DOI DOI 10.1007/BF02979426
   Cano ZP, 2018, NAT ENERGY, V3, P279, DOI 10.1038/s41560-018-0108-1
   Cao L., 2016, 229 ECS M MAY 29 JUN
   Catenacci M, 2013, ENERG POLICY, V61, P403, DOI 10.1016/j.enpol.2013.06.078
   CEC, 2015, ENV SOUND MAN END OF
   Chen WJ, 2009, ANAL BIOCHEM, V394, P62, DOI 10.1016/j.ab.2009.07.020
   CNCDA, 2017, CAL AUT 2016 Q4 COMP
   CSIRO, 2016, EL NETW TRANSF ROADM
   CVRP, 2017, CAL CLEAN VEH REB PR
   EIA (U.S. Energy Information Administration), 2017, ANN EN OUTL 2017
   EVI, 2018, GLOB EV OUTL 2018 CR
   EVI, 2011, TECHN ROADM EL PLUG
   Friends of the Earth Europe, 2013, LESS IS MOR RES EFF
   Fulton L, 2015, EV MARKET DEV CURREN
   Georgi-Maschler T, 2012, J POWER SOURCES, V207, P173, DOI 10.1016/j.jpowsour.2012.01.152
   Hendrickson T. P., 2015, PLUG IN ELECT VEHICL
   Hendrickson TP, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/1/014011
   Hoyer C, 2015, J BUS EC, V85, P505, DOI [10.1007/s11573014-07442, DOI 10.1007/S11573-014-0744-2]
   Idjis H., 2017, AUTOMOBILE REVOLUTIO, P117
   InsideEVs, 2018, MONTHL PLUG IN SAL S
   Kampker A., 2017, EL VEH INT C 2017, P1
   Kinnaman TC, 2014, J ENVIRON ECON MANAG, V68, P54, DOI 10.1016/j.jeem.2014.01.004
   Lache R, 2009, ELECT CARS PLUGGED 2
   Li-Cycle Corp, 2018, FUT LITH ION BATT RE
   Lutsey N., 2015, TRANSITION GLOBAL ZE
   Matsuno Y, 2012, RESOUR CONSERV RECY, V61, P83, DOI 10.1016/j.resconrec.2012.01.002
   McManus W., 2009, MARKET MODELS PREDIC
   NERC (North East Recycling Council, 2017, DISP BANS MAND REC U
   Neubauer J, 2015, IDENTIFYING OVERCOMI
   Oguchi M., 2006, J JPN SOC WASTE MANA, V17, P50
   Plug-In America, 2012, PLUG IN AM BATT SURV
   Ramage M., 2010, TRANSITIONS ALTERNAT
   Ramoni MO, 2013, CLEAN TECHNOL ENVIR, V15, P881, DOI 10.1007/s10098-013-0588-4
   Richa K, 2017, J IND ECOL, V21, P715, DOI 10.1111/jiec.12607
   Richa K, 2017, INT J LIFE CYCLE ASS, V22, P66, DOI 10.1007/s11367-015-0942-3
   Richa K, 2014, RESOUR CONSERV RECY, V83, P63, DOI 10.1016/j.resconrec.2013.11.008
   Simic V, 2012, RESOUR CONSERV RECY, V60, P78, DOI 10.1016/j.resconrec.2011.11.012
   Standridge C. R., 2014, REMANUFACTURING REPU
   Standridge CR, 2015, J IND ENG MANAG-JIEM, V8, P823, DOI 10.3926/jiem.1418
   Suresh Kumar E, 2012, INT J ENG SCI ADV TE, V2, P1210
   Tang YY, 2018, J CLEAN PROD, V186, P388, DOI 10.1016/j.jclepro.2018.03.043
   Terazono A., 2006, J MATER CYCLES WASTE, V8, P1, DOI DOI 10.1007/S10163-005-0147-0
   US EIA, 2017, US EN MAPP SYST
   Wang F, 2013, WASTE MANAGE, V33, P2397, DOI 10.1016/j.wasman.2013.07.005
   Wang X, 2014, J ENVIRON MANAGE, V135, P126, DOI 10.1016/j.jenvman.2014.01.021
   Wang X, 2014, RESOUR CONSERV RECY, V83, P53, DOI 10.1016/j.resconrec.2013.11.009
   Wanxia Shen, 2015, Materials Science Forum, V814, P447, DOI 10.4028/www.scientific.net/MSF.814.447
   Wernick IK, 2005, MAT FLOWS ACCOUNTS T
   Winslow KM, 2018, RESOUR CONSERV RECY, V129, P263, DOI 10.1016/j.resconrec.2017.11.001
   Wu D, 2013, ENERG POLICY, V63, P419, DOI 10.1016/j.enpol.2013.07.132
   Yeh S, 2008, ENVIRON SCI TECHNOL, V42, P8202, DOI 10.1021/es8005805
   Yun L, 2018, RESOUR CONSERV RECY, V136, P198, DOI 10.1016/j.resconrec.2018.04.025
   Ziemann S, 2018, RESOUR CONSERV RECY, V133, P76, DOI 10.1016/j.resconrec.2018.01.031
   Zou HY, 2013, GREEN CHEM, V15, P1183, DOI 10.1039/c3gc40182k
   2006, ECOL ECON, V59, P142, DOI DOI 10.1016/J.ECOLECON.2005.09.025
   2015, SAE INT J MAT MANUF, V8, P544, DOI DOI 10.4271/2015-01-1306
   2017, RESOUR CONSERV RECY, V127, P233, DOI DOI 10.1016/J.RESCONREC.2017.08.019
NR 68
TC 3
Z9 3
U1 3
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 208
EP 219
DI 10.1016/j.resconrec.2019.01.021
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200021
DA 2020-05-12
ER

PT J
AU Song, Y
   Zhao, CN
   Zhang, M
AF Song, Yan
   Zhao, Chunan
   Zhang, Ming
TI Does haze pollution promote the consumption of energy-saving appliances
   in China? An empirical study based on norm activation model
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Haze pollution; Energy-saving appliances; Extended norm activation model
ID CITIZENS ENVIRONMENTAL COMPLAINT; PERCEIVED CONSUMER EFFECTIVENESS;
   EFFICIENT HOUSEHOLD APPLIANCES; PLANNED BEHAVIOR; PURCHASING INTENTIONS;
   FOOD-CONSUMPTION; RENEWABLE ENERGY; ANTECEDENTS; ATTITUDE; IMPACT
AB Under the dual pressure of energy shortage and air pollution, the widespread use of energy-saving appliances has become an important means of energy conservation and emission reduction in China. However, it is limited to explore the impact of altruism on energy-saving appliances use from the perspective of pro-environmental behavior. To remedy the problem, according to the particular situation of China, we propose an extended norm activation theory model. The 435 valid questionnaires have been analyzed using the structural equation model and the hierarchical regression model. The results prove that, haze pollution has promoted the consumption of energy-saving appliances for urban residents in China; personal norm, environmental concern, and perceived consumer effectiveness all have a significant positive impact on purchasing behavior of energy-saving appliance; personal norm is influenced by four cognitive factors of awareness of consequences, ascription of responsibility, environmental concern and perceived consumer effectiveness; personal norm mediates the relationship between environmental concern, perceived consumer effectiveness and purchasing behavior, respectively; herd mentality negatively moderates the relationship between environmental concern and purchasing behavior, and positively moderates the relationship between personal norm and purchasing behavior. Instead, policy and propaganda only positively moderate the relationship between personal norm and purchasing behavior. Moreover, the results also confirmed the appropriateness of the extended norm activation theory for exploring urban residents' purchasing behavior of energy-saving appliances. The findings could be helpful for a better understanding of urban residents' purchasing behavior of energy-saving appliances, which in turn promotes the development of energy-saving appliances.
C1 [Song, Yan; Zhao, Chunan; Zhang, Ming] China Univ Min & Technol, Sch Management, Xuzhou 221116, Jiangsu, Peoples R China.
   [Song, Yan; Zhang, Ming] China Univ Min & Technol, Jiangsu Energy Econ & Management Res Base, Xuzhou 221116, Jiangsu, Peoples R China.
RP Zhang, M (reprint author), China Univ Min & Technol, Sch Management, Xuzhou 221116, Jiangsu, Peoples R China.
EM zhangmingdlut@163.com
RI Zhang, Ming/V-5262-2019
OI Zhang, Ming/0000-0003-3023-1419
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71804182, 71403266, 71573029]; China's
   Post-doctoral Science FundChina Postdoctoral Science Foundation
   [2015M580484, 2016T90517]; Jiangsu Social Science Fund [18JD013];
   High-level Talents Project of "Six Talents Peaks" in Jiangsu Province
   [JY-077]; Qinlan project of Jiangsu
FX The authors gratefully acknowledge the financial support from the
   National Natural Science Foundation of China (71804182, 71403266,
   71573029), China's Post-doctoral Science Fund (2015M580484, 2016T90517),
   Jiangsu Social Science Fund (18JD013), High-level Talents Project of
   "Six Talents Peaks" in Jiangsu Province (JY-077) and Qinlan project of
   Jiangsu.
CR Abrahamse W, 2007, J ENVIRON PSYCHOL, V27, P265, DOI 10.1016/j.jenvp.2007.08.002
   Aiken L. S., 1991, EVALUATION PRACTICE, V14, P167
   Baldini M, 2018, ENERG POLICY, V120, P503, DOI 10.1016/j.enpol.2018.05.048
   Bang HK, 2000, PSYCHOL MARKET, V17, P449, DOI 10.1002/(SICI)1520-6793(200006)17:6<449::AID-MAR2>3.0.CO;2-8
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   BECK L, 1991, J RES PERS, V25, P285, DOI 10.1016/0092-6566(91)90021-H
   Chen MF, 2014, INT J HOSP MANAG, V36, P221, DOI 10.1016/j.ijhm.2013.09.006
   Cheng HH, 2013, INT J INFORM MANAGE, V33, P185, DOI 10.1016/j.ijinfomgt.2012.09.003
   Cheng Z. N., 2017, TIANJIN SCI TECHNOL, V12, P103
   Christian A. K., 2009, J APPL SOC PSYCHOL, V39, P1807
   de Groot J, 2007, J APPL SOC PSYCHOL, V37, P1817, DOI 10.1111/j.1559-1816.2007.00239.x
   De Groot JIM, 2009, J SOC PSYCHOL, V149, P425, DOI 10.3200/SOCP.149.4.425-449
   du Can SD, 2014, ENERG POLICY, V72, P56, DOI 10.1016/j.enpol.2014.04.035
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Fujii S, 2006, J ENVIRON PSYCHOL, V26, P262, DOI 10.1016/j.jenvp.2006.09.003
   Galarraga I, 2016, ENERG POLICY, V90, P24, DOI 10.1016/j.enpol.2015.12.010
   Gao X. F., 2011, STUDY ONLINE GROUP B, V58
   Gaspar R, 2011, ENERG POLICY, V39, P7335, DOI 10.1016/j.enpol.2011.08.057
   Graafland J, 2017, J CLEAN PROD, V141, P967, DOI 10.1016/j.jclepro.2016.09.171
   Guo L. J., 2014, ISSUES AGR EC, V35, P78
   He XH, 2018, J CLEAN PROD, V172, P3546, DOI 10.1016/j.jclepro.2017.05.088
   HOPPER JR, 1991, ENVIRON BEHAV, V23, P195, DOI 10.1177/0013916591232004
   Kang JY, 2013, INT J CONSUM STUD, V37, P442, DOI 10.1111/ijcs.12013
   Kelly G, 2012, RENEW SUST ENERG REV, V16, P6851, DOI 10.1016/j.rser.2012.08.003
   Kim Y, 2005, ADV CONSUM RES, V32, P592
   KINNEAR TC, 1974, J MARKETING, V38, P20, DOI 10.2307/1250192
   Lan Y. B., 2017, J GUIYANG U NAT SCI, V12, P45
   Lascu D., 1999, J MARKETING THEORY P, V7, P1, DOI DOI 10.1080/10696679.1999.11501836
   Lewandowski C. M., 2015, CHINAS ENV CRISIS EF
   Li G.Z., 2016, J ZHENGZHOU I AERONA, V6, P79
   Lippa R. A., 1990, INTRO SOCIAL PSYCHOL
   Liu T., 2017, ENV EC POLICY STUDIE, V20, P1
   Liu Y. C., 2013, EMPIRICAL RES MODEL
   Lv R.S., 2016, RESOUR ENV ARID AREA, V09, P14
   Ma G., 2012, J CHONGQING U SOC SC, V18, P36
   Ma G, 2013, ENERG POLICY, V56, P591, DOI 10.1016/j.enpol.2013.01.024
   [芈凌云 Mi Lingyun], 2016, [资源科学, Resources Science], V38, P609
   Mizobuchi K, 2016, ENERG POLICY, V93, P137, DOI 10.1016/j.enpol.2016.03.001
   Moller M, 2018, TRAVEL BEHAV SOC, V11, P69, DOI 10.1016/j.tbs.2017.12.005
   Mostafa M. M., 2010, PSYCHOL MARK, V24, P445
   Pan Y., 2014, MANAGE WORLD, V4, P90, DOI DOI 10.19744/J.CNKI.11-1235/F.2014.04.010
   Park J, 2014, FAM CONSUM SCI RES J, V42, P278, DOI 10.1111/fcsr.12061
   Peters A, 2011, TRANSPORT RES F-TRAF, V14, P229, DOI 10.1016/j.trf.2011.01.003
   Qi H. F., 2011, RES EC MANAGE, V1, P24
   Radpour S, 2017, ENERGY, V134, P951, DOI 10.1016/j.energy.2017.06.039
   Roberts JA, 1996, J BUS RES, V36, P217, DOI 10.1016/0148-2963(95)00150-6
   Schultz PW, 2005, J CROSS CULT PSYCHOL, V36, P457, DOI 10.1177/0022022105275962
   SCHWARTZ SH, 1973, J EXP SOC PSYCHOL, V9, P349, DOI 10.1016/0022-1031(73)90071-1
   Schwartz SH, 1977, ADV EXPT SOCIAL PSYC, V10, P221, DOI DOI 10.1016/S0065-2601(08)60358-5
   Sheng G. H., 2018, STAT INF FORUM, V5, P114
   Smith JR, 2007, J COMMUNITY APPL SOC, V17, P363, DOI 10.1002/casp.906
   Straughan RD, 1999, J CONSUM MARK, V16, P558, DOI 10.1108/07363769910297506
   Tan CS, 2017, ENERG POLICY, V107, P459, DOI 10.1016/j.enpol.2017.05.027
   Nguyen TN, 2017, INT J CONSUM STUD, V41, P167, DOI 10.1111/ijcs.12323
   Tobler C, 2011, APPETITE, V57, P674, DOI 10.1016/j.appet.2011.08.010
   Trotta G, 2018, ENERG POLICY, V114, P529, DOI 10.1016/j.enpol.2017.12.042
   van der Werff E, 2015, ENERGY RES SOC SCI, V6, P8, DOI 10.1016/j.erss.2014.11.002
   Vermeir I, 2008, ECOL ECON, V64, P542, DOI 10.1016/j.ecolecon.2007.03.007
   Wang J. M., 2016, EXPT STUDY IMPACT CO
   Wang JM, 2016, J CLEAN PROD, V126, P325, DOI 10.1016/j.jclepro.2016.03.119
   Wang Y.N., 2018, CHINA MARK, V10, P119
   Wang ZH, 2018, RESOUR CONSERV RECY, V133, P1, DOI 10.1016/j.resconrec.2018.01.014
   Wang ZH, 2017, J CLEAN PROD, V161, P1000, DOI 10.1016/j.jclepro.2017.05.154
   Wang ZH, 2017, ENERG POLICY, V102, P430, DOI 10.1016/j.enpol.2016.12.049
   Wesley SC, 2012, J GLOB MARK, V25, P29
   Wierzbowski M, 2017, RENEW SUST ENERG REV, V74, P51, DOI 10.1016/j.rser.2017.02.046
   Wittenberg I, 2018, J ENVIRON PSYCHOL, V55, P110, DOI 10.1016/j.jenvp.2018.01.002
   Wu XH, 2018, J CLEAN PROD, V170, P399, DOI 10.1016/j.jclepro.2017.09.154
   Xiong M., 2014, CHINA POPUL RESOUR E, V163, P248
   Xu L., 2010, IND TRACK, V9, P54
   Yang S, 2015, J CLEAN PROD, V108, P841, DOI 10.1016/j.jclepro.2015.07.022
   Zhang XJ, 2018, RESOUR CONSERV RECY, V134, P121, DOI 10.1016/j.resconrec.2018.03.003
   Zhang XJ, 2017, J CLEAN PROD, V166, P148, DOI 10.1016/j.jclepro.2017.08.020
   Zhang YX, 2013, ENERG POLICY, V62, P1120, DOI 10.1016/j.enpol.2013.07.036
   2019, RESOUR CONSERV RECY, V141, P99, DOI DOI 10.1016/J.RESCONREC.2018.10.019
   2017, J CLEAN PROD, V145, P64, DOI DOI 10.1016/J.JCLEPRO.2016.12.169
NR 76
TC 6
Z9 6
U1 17
U2 44
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 220
EP 229
DI 10.1016/j.resconrec.2019.02.041
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200022
DA 2020-05-12
ER

PT J
AU Sigvardsen, NM
   Kirkelund, GM
   Jensen, PE
   Geiker, MR
   Ottosen, LM
AF Sigvardsen, Nina M.
   Kirkelund, Gunvor M.
   Jensen, Pernille E.
   Geiker, Mette R.
   Ottosen, Lisbeth M.
TI Impact of production parameters on physiochemical characteristics of
   wood ash for possible utilisation in cement-based materials
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Wood ash; Supplementary cementitious material; Multivariate modelling
ID FLY ASHES; WASTE ASH; CHEMICAL-COMPOSITION; MINERAL ADMIXTURES; BIOMASS
   COMBUSTION; REPLACEMENT; CONCRETE; HYDRATION; BEHAVIOR; MORTARS
AB Energy production is reorganised to mitigate the pressure on the global environment. This reorganisation leads to an increase in the production of wood ash (WA). Multivariate modelling was used to identify the link between production parameters and the physiochemical characteristics of different WAs and to determine which production parameters result in the WAs most suitable for utilisation in cement-based materials. Based on the multivariate model partial least square, WA originating from circulating fluidised bed combustion of wood chips made from whole trees is the optimal type of WA when utilised as a supplementary cementing material with pozzolanic activity. WA originating from the combustion of wood chips made from whole trees is the optimal type of WA when utilised as a supplementary cementing material with hydraulic activity. Furthermore, the combustion method and type of ash were seen to have the largest influence on the physiochemical characteristics of WAs compared to the other production parameters included in this study.
C1 [Sigvardsen, Nina M.; Kirkelund, Gunvor M.; Jensen, Pernille E.; Ottosen, Lisbeth M.] Tech Univ Denmark, Dept Civil Engn, Lyngby, Denmark.
   [Geiker, Mette R.] Norwegian Univ Sci & Technol, Dept Struct Engn, Trondheim, Norway.
RP Sigvardsen, NM (reprint author), Tech Univ Denmark, Dept Civil Engn, Lyngby, Denmark.
EM nimasi@byg.dtu.dk
RI Jensen, Pernille Erland E/A-1560-2011; Kirkelund, Gunvor
   Marie/I-9232-2012
OI Jensen, Pernille Erland E/0000-0003-4718-1630; Kirkelund, Gunvor
   Marie/0000-0002-5834-7029; Ottosen, Lisbeth M./0000-0001-7756-382X;
   Sigvardsen, Nina Marie/0000-0001-9526-3644
FU Department of Civil Engineering at the Technical University of Denmark;
   Emineral A/S; P.A.Fiskers Foundation; Toubro Foundation; Danielsen's
   Foundation; Spirekassen; EKOKEM; Martha and Paul Kerrn-Jespersens
   Foundation
FX The reported work was financially supported partially by the Department
   of Civil Engineering at the Technical University of Denmark and Emineral
   A/S and partially by scholarships granted by P.A.Fiskers Foundation, The
   Toubro Foundation, Danielsen's Foundation, Spirekassen, EKOKEM and
   Martha and Paul Kerrn-Jespersens Foundation. Halsnws Supply A/S, Koge
   Power Plant, Svebolle Viskinge District Heating Company, HOFOR
   Amagervaerket, Vartaverket Combined Heat and Power Plant and Herning
   Power station are acknowledged for supplying the investigated wood
   ashes. Kristine Bondo Pedersen is acknowledged for her great teachings
   regarding the multivariate data analysis.
CR [Anonymous], 2011, 1971 EN
   [Anonymous], 2005, 1962 EN
   [Anonymous], 2012, 450 EN
   [Anonymous], 2003, ANN BOOK ASTM STAND, P1, DOI DOI 10.1520/E0230
   Ban CC, 2011, RESOUR CONSERV RECY, V55, P669, DOI 10.1016/j.resconrec.2011.02.002
   Ban CheahChee, 2011, International Journal of Physical Sciences, V6, P6596
   Bellotto M., 1989, MRS ONLINE P LIB, V178, P45
   Berra M, 2015, CONSTR BUILD MATER, V76, P286, DOI 10.1016/j.conbuildmat.2014.11.052
   CEN, 2009, 14775 CEN
   Chowdhury S, 2015, J ADV RES, V6, P907, DOI 10.1016/j.jare.2014.08.006
   Christensen JH, 2005, J CHROMATOGR A, V1090, P133, DOI 10.1016/j.chroma.2005.07.025
   Danish Environmental Protection Agency, 2017, BEK ANV BIOASK JORDB, P1
   Deschner F, 2012, CEMENT CONCRETE RES, V42, P1389, DOI 10.1016/j.cemconres.2012.06.009
   Elinwa AU, 2002, CEMENT CONCRETE COMP, V24, P219, DOI 10.1016/S0958-9465(01)00039-7
   ETIEGNI L, 1991, BIORESOURCE TECHNOL, V37, P173, DOI 10.1016/0960-8524(91)90207-Z
   Hamid Y. S. A., 2009, DISSOLUTION KINETICS
   Herholdt A D., 1985, BETON BOGEN
   Illikainen M, 2014, FUEL, V135, P69, DOI 10.1016/j.fuel.2014.06.029
   Ingerslev M, 2011, BIOMASS BIOENERG, V35, P2697, DOI 10.1016/j.biombioe.2011.03.018
   International Energy Agency (IEA), 2007, TRACK IND EN EFF CO2
   Jackson J. E., 1991, USERS GUIDE PRINCIPA
   Kirkelund G. M., 2016, INT J SUSTAIN DEV PL, V11, P719
   Lanzerstorfer C, 2015, J ENVIRON SCI-CHINA, V30, P191, DOI 10.1016/j.jes.2014.08.021
   Lawrence P, 2005, CEMENT CONCRETE RES, V35, P1092, DOI 10.1016/j.cemconres.2004.07.004
   Lawrence P, 2003, CEMENT CONCRETE RES, V33, P1939, DOI 10.1016/s0008-8846(03)00183-2
   Lecuyer I., 1996, PHYS CHEM CHARACTERI, V1, P15
   Lothenbach B, 2011, CEMENT CONCRETE RES, V41, P1244, DOI 10.1016/j.cemconres.2010.12.001
   McKendry P, 2002, BIORESOURCE TECHNOL, V83, P37, DOI 10.1016/S0960-8524(01)00118-3
   Moosberg-Bustnes H, 2004, MATER STRUCT, V37, P74, DOI 10.1617/13694
   Neslen A., 2017, END COAL EU ENERGY C
   Neville A. M., 1996, PROPERTIES CONCRETE
   Pedersen KB, 2015, J HAZARD MATER, V283, P712, DOI 10.1016/j.jhazmat.2014.10.016
   Peyronnard O, 2011, RESOUR CONSERV RECY, V56, P22, DOI 10.1016/j.resconrec.2011.08.008
   Pitman RM, 2006, FORESTRY, V79, P563, DOI 10.1093/forestry/cpl041
   Rajamma R, 2009, J HAZARD MATER, V172, P1049, DOI 10.1016/j.jhazmat.2009.07.109
   Ramos T, 2013, CONSTR BUILD MATER, V49, P343, DOI 10.1016/j.conbuildmat.2013.08.026
   Schneider M, 2011, CEMENT CONCRETE RES, V41, P642, DOI 10.1016/j.cemconres.2011.03.019
   Shearer C. R., 2014, PRODUCTIVE REUSE COA
   Siddique R, 2008, WASTE MAT BY PRODUCT
   Siddique R, 2012, RESOUR CONSERV RECY, V67, P27, DOI 10.1016/j.resconrec.2012.07.004
   Snellings R, 2012, REV MINERAL GEOCHEM, V74, P211, DOI 10.2138/rmg.2012.74.6
   Teixeira ER, 2016, J CLEAN PROD, V112, P2221, DOI 10.1016/j.jclepro.2015.09.124
   Udoeyo FF, 2006, J MATER CIVIL ENG, V18, P605, DOI 10.1061/(ASCE)0899-1561(2006)18:4(605)
   van Loo S., 2010, HDB BIOMASS COMBUSTI
   VANROODE M, 1987, CEMENT CONCRETE RES, V17, P183, DOI 10.1016/0008-8846(87)90101-3
   Vassilev SV, 2014, FUEL, V117, P152, DOI 10.1016/j.fuel.2013.09.024
   Vassilev SV, 2010, FUEL, V89, P913, DOI 10.1016/j.fuel.2009.10.022
   Voshell S, 2018, RENEW SUST ENERG REV, V96, P479, DOI 10.1016/j.rser.2018.07.025
   Wang KS, 2001, HYDROMETALLURGY, V62, P73, DOI 10.1016/S0304-386X(01)00186-4
   Wig R. J., 1913, ACI J P, V9
   Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1
   Ye G, 2007, CEMENT CONCRETE COMP, V29, P94, DOI 10.1016/j.cemconcomp.2006.09.003
   Yeboah NNN, 2014, FUEL, V116, P438, DOI 10.1016/j.fuel.2013.08.030
   2009, FUEL PROCESS TECHNOL, V90, P871, DOI DOI 10.1016/J.FUPROC.2009.04.013
NR 54
TC 3
Z9 3
U1 3
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 230
EP 240
DI 10.1016/j.resconrec.2019.02.034
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200023
DA 2020-05-12
ER

PT J
AU Jiang, S
   Li, YP
   Suo, C
AF Jiang, S.
   Li, Y. P.
   Suo, C.
TI IFQP-EPS: Analyzing effects of queuing and storage issues on electric
   power systems under dual uncertainties
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Dual uncertainties; Electric power systems; Interval fuzzy; Planning;
   Queuing; Storage period
ID PROGRAMMING APPROACH; AIR-POLLUTION; MANAGEMENT; ENERGY; MODEL; WATER;
   OPTIMIZATION
AB In this study, an interval fuzzy queue-storage (IFQS) method is developed through integrating interval-parameter programming, fuzzy queue and storage theory into a general framework. IFQS is not only capable of reflecting the effects of queue and storage on electric power systems (EPS), but also helpful for dealing with dual uncertainties expressed as fuzzy sets and interval values. Then, an IFQS-EPS model is formulated for the City of Shijiazhuang (the capital of Hebei province), where M/M/1 (exponential interarrival time, exponential service time and one server) queue with fuzzy information and different storage periods are measured. Results reveal that (i) coal mines in Yulin, Datong and Jincheng would be the major coal suppliers for the study city (providing over 77% of coal); (ii) as waiting time adds 1 day, system cost would increase around $200 million and nitrogen dioxide (NOx) emission would grow approximately 91 ton; (iii) system cost and NOx emission would respectively decrease $370 x 10(6) and 90 x 10(3) ton when storage period varies from 10 day to 20 day; (iv) electricity generated by coal would reduce 5% due to the limitation of coal supply and the control of air pollution. Compared to interval-fuzzy queue (IFQ) approach, the developed IFQS method has advantages in balancing coal purchase batch and storage cost, such that an optimal system cost can be obtained. Results can not only facilitate to generate appropriate coal purchase and electricity generation plans, but also reveal effects of queuing and storage issues on EPS under complicated uncertainties.
C1 [Jiang, S.; Li, Y. P.] Beijing Normal Univ, Sch Environm, Beijing 100875, Peoples R China.
   [Jiang, S.; Suo, C.] North China Elect Power Univ, Sino Canada Resources & Environm Res Acad, Beijing 102206, Peoples R China.
   [Li, Y. P.] Univ Regina, Inst Energy Environm & Sustainable Communities, Regina, SK S4S 0A2, Canada.
RP Li, YP (reprint author), Beijing Normal Univ, Sch Environm, Beijing 100875, Peoples R China.
EM yongping.li@iseis.org
RI Li, Yongping/AAF-3298-2019
OI Li, Yongping/0000-0002-3253-4088
FU Beijing Natural Science FoundationBeijing Natural Science Foundation
   [L160011]; Innovative Engineering & Pre-research Project of Beijing
   Academy of Science and Technology [PXM2018_178215_000004]; 111
   ProjectMinistry of Education, China - 111 Project [B14008];
   Interdis-cipline Research Funds of Beijing Normal University
FX This research was supported by the Beijing Natural Science Foundation
   (L160011), the Innovative Engineering & Pre-research Project of Beijing
   Academy of Science and Technology (PXM2018_178215_000004), the 111
   Project (B14008), and the Interdis-cipline Research Funds of Beijing
   Normal University. The authors are grateful to the editors and the
   anonymous reviewers for their insightful comments and suggestions.
CR Ammenberg J, 2018, RESOUR CONSERV RECY, V129, P70, DOI 10.1016/j.resconrec.2017.10.010
   [Anonymous], 2017, SHIJ STAT YB
   Asl FB, 2018, ENVIRON RES, V161, P114, DOI 10.1016/j.envres.2017.10.050
   Babicheva TS, 2015, PROCEDIA COMPUT SCI, V55, P469, DOI 10.1016/j.procs.2015.07.016
   Chen B, 2017, J ENVIRON INFORM, V29, P88, DOI 10.3808/jei.201500293
   Chen XJ, 2014, STOCH ENV RES RISK A, V28, P1939, DOI 10.1007/s00477-014-0936-x
   Cheng GH, 2017, J ENVIRON INFORM, V30, P119, DOI 10.3808/jei.201500312
   Dalir F, 2018, J CLEAN PROD, V188, P362, DOI 10.1016/j.jclepro.2018.03.274
   Dong C, 2012, ENERGY, V37, P673, DOI 10.1016/j.energy.2011.10.030
   Haviv M, 2016, OPER RES LETT, V44, P196, DOI 10.1016/j.orl.2016.01.002
   HUANG GH, 1992, CIVIL ENG SYST, V9, P319, DOI 10.1080/02630259208970657
   Huang RY, 2017, RESOUR CONSERV RECY, V122, P185, DOI 10.1016/j.resconrec.2017.01.009
   Jafari M., 2018, IEEE J EMERG SEL TOP, DOI [10.1109/JESTPE.2018.2882509, DOI 10.1109/JESTPE.2018.2882509]
   Jin SW, 2018, J HAZARD MATER, V350, P27, DOI 10.1016/j.jhazmat.2018.02.007
   Khooban MH, 2018, IEEE T IND ELECTRON, V65, P7416, DOI 10.1109/TIE.2017.2784385
   Khooban MH, 2016, ISA T, V65, P220, DOI 10.1016/j.isatra.2016.07.002
   LI RJ, 1989, COMPUT MATH APPL, V17, P1143, DOI 10.1016/0898-1221(89)90044-8
   Li YP, 2017, J ENVIRON INFORM, V29, P1, DOI 10.3808/jei.201700359
   Liu D, 2018, TRANSPORT RES D-TR E, V61, P140, DOI 10.1016/j.trd.2017.06.006
   Liu F, 2018, RESOUR CONSERV RECY, V129, P345, DOI 10.1016/j.resconrec.2016.08.013
   Lott MC, 2017, ENERG POLICY, V101, P42, DOI 10.1016/j.enpol.2016.11.028
   Mardani MM, 2019, IEEE T IND ELECTRON, V66, P5676, DOI 10.1109/TIE.2018.2877191
   Mirakyan A, 2013, RENEW SUST ENERG REV, V22, P289, DOI 10.1016/j.rser.2013.01.033
   Pan QH, 2018, INT J PROD ECON, V204, P135, DOI 10.1016/j.ijpe.2018.08.002
   Qi MF, 2019, FUEL, V236, P1400, DOI 10.1016/j.fuel.2018.09.117
   Rodriguez Jauregui G. R., 2017, CONTAD ADMIN, V62, P733, DOI [DOI 10.1016/J.CYA.2017.05.001, 10.1016/j.cya.2017.05.001]
   Simic V, 2016, WASTE MANAGE, V52, P180, DOI 10.1016/j.wasman.2016.03.044
   Son H, 2017, RESOUR CONSERV RECY, V123, P200, DOI 10.1016/j.resconrec.2016.01.016
   Sun HG, 2011, ENG APPL ARTIF INTEL, V24, P840, DOI 10.1016/j.engappai.2011.03.010
   Sun Y, 2012, ENG OPTIMIZ, V44, P707, DOI 10.1080/0305215X.2011.604317
   Tang E, 2017, RESOUR POLICY, V51, P234, DOI 10.1016/j.resourpol.2017.01.007
   Tang X, 2018, RESOUR CONSERV RECY, V129, P307, DOI 10.1016/j.resconrec.2016.07.018
   Wang S, 2015, EUR J OPER RES, V240, P572, DOI 10.1016/j.ejor.2014.07.011
   Xu C, 2014, STOCH ENV RES RISK A, V28, P1613, DOI 10.1007/s00477-013-0815-x
   Xu Q, 2018, J ENVIRON INFORM, V31, P65, DOI 10.3808/jei.201700361
   Yu L, 2018, APPL ENERG, V212, P834, DOI 10.1016/j.apenergy.2017.12.089
   Zhang ZL, 2014, INT J ELEC POWER, V62, P429, DOI 10.1016/j.ijepes.2014.04.060
   Zhao F, 2013, INT J ELEC POWER, V47, P337, DOI 10.1016/j.ijepes.2012.11.006
   2017, IET SCI MEAS TECHNOL, V11, P991, DOI DOI 10.1049/IET-SMT.2017.0014
   2019, RESOUR CONSERV RECY, V142, P37, DOI DOI 10.1016/J.RESCONREC.2018.11.013
NR 40
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 241
EP 260
DI 10.1016/j.resconrec.2019.02.023
PG 20
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200024
DA 2020-05-12
ER

PT J
AU Yao, B
   Cai, BF
   Kou, F
   Yang, YM
   Chen, XP
   Wong, DS
   Liu, LS
   Fang, SX
   Liu, HL
   Wang, HY
   Zhang, LZ
   Li, JZ
   Kuang, GC
AF Yao, Bo
   Cai, Bofeng
   Kou, Fan
   Yang, Youming
   Chen, Xiping
   Wong, David S.
   Liu, Lisha
   Fang, Shuangxi
   Liu, Helin
   Wang, Hongyang
   Zhang, Lizhi
   Li, Jianzhong
   Kuang, Guochun
TI Estimating direct CO2 and CO emission factors for industrial rare earth
   metal electrolysis
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE CO2 (carbon dioxide); CO (carbon monoxide); Direct emission factor; Rare
   earth metal; Electrolysis
AB Rare earth (RE) metals are now being widely applied in new material industries with rapidly increasing production. However, there is limited research on greenhouse gas emission factors from RE metals production by electrolysis and currently no method exists to account for this industry's CO2 emissions in the '2006 IPCC Guidelines for National Greenhouse Gas Inventories'. This study employed two independent methods to determine direct carbon emission factors for industrial rare earth metals production by molten-salt electrolysis: continuous emissions monitoring by FTIR and time-integrated sampling with offline lab analysis, both measuring CO2 and CO concentrations in the exhaust gases from Pr-Nd, Dy-Fe and La potlines in three companies in China. The study confirmed that CO2 contributes > 97% of the total carbon emission factor. Direct carbon emissions per tonne RE metal electrolysis is equivalent to one tenth to a half of the emission factor for aluminum production (due to much lighter molar mass of Al) but is similar on a mole basis (carbon emissions per mole metal). Emission factors vary with the type of rare earth metal or alloy produced and from one facility to another, ranging from 165.0 to 672.4 kg/t-RE metal for CO2, 300 to 8.23 kg/t-RE metal for CO and 46.4 to 186.8 kg/t-RE metal for total carbon. Direct CO2 and CO emission factors from the two exhaust gas monitoring methods agreed well considering the uncertainties.
C1 [Yao, Bo; Liu, Lisha; Fang, Shuangxi; Wang, Hongyang] CMA, MOC, Beijing 100081, Peoples R China.
   [Cai, Bofeng] Chinese Acad Environm Planning, Ctr Climate Change & Environm Policy, Beijing 100012, Peoples R China.
   [Kou, Fan] Zhengzhou Nonferrous Met Res Inst Co Ltd, CHALCO, Zhengzhou, Henan, Peoples R China.
   [Yang, Youming] Jiangxi Univ Sci & Technol, 156 Kejia Ave, Ganzhou, Jiangxi, Peoples R China.
   [Chen, Xiping] Zhengzhou Univ, Collaborat Innovat Ctr Henan Resources & Mat Ind, Zhengzhou 450001, Henan, Peoples R China.
   [Wong, David S.] Univ Auckland, Light Met Res Ctr, Auckland Mail Ctr, Private Bag 92019, Auckland 1142, New Zealand.
   [Liu, Helin] Huazhong Univ Sci & Technol, Sch Architecture & Urban Planning, Wuhan, Hubei, Peoples R China.
   [Zhang, Lizhi] Qiandong Rare Earths Grp Co Ltd, Guangzhou, Jiangxi, Peoples R China.
   [Li, Jianzhong] Natl Engn Res Ctr Ion Rare Earth, Guangzhou, Jiangxi, Peoples R China.
   [Kuang, Guochun] Jiangxi South Rare Earth High Tech Co Ltd, Guangzhou, Jiangxi, Peoples R China.
RP Cai, BF (reprint author), Chinese Acad Environm Planning, Ctr Climate Change & Environm Policy, Beijing 100012, Peoples R China.; Chen, XP (reprint author), Zhengzhou Univ, Collaborat Innovat Ctr Henan Resources & Mat Ind, Zhengzhou 450001, Henan, Peoples R China.; Wong, DS (reprint author), Univ Auckland, Light Met Res Ctr, Auckland Mail Ctr, Private Bag 92019, Auckland 1142, New Zealand.; Liu, HL (reprint author), Huazhong Univ Sci & Technol, Sch Architecture & Urban Planning, Wuhan, Hubei, Peoples R China.
EM yaob@cma.gov.cn; caibf@caep.org.cn; nash603@163.com; yanguming@126.com;
   sici2001@163.com; david.wong@auckland.ac.nz; liulisha0126@163.com;
   fangsx@cma.gov.cn; hl362@hust.edu.cn; whyy-111@163.com;
   zhanglizhi@jxgqd.com; john-L@163.com; 361131668@qq.com
OI Wong, David/0000-0002-1852-537X
FU National Key R&D Program of China [2017YFB0504000]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [41575114, 41730103, 71673107]
FX The authors of this work acknowledge all parties involved in the
   measurement team and the three rare earth companies that participated in
   the study: Qiandong Rare Earths Group Co. Ltd, National Engineering
   Research Center for Ionic Rare Earth and Jiangxi South Rare Earth High
   Tech. Co. Ltd. Dr. Angelina Wenger from University of Bristol helps to
   develop the dilution system of integrated samples. This work was
   supported by the National Key R&D Program of China (2017YFB0504000) and
   National Natural Science Foundation of China (Grant No. 41575114, Grant
   No. 41730103 and Grant No. 71673107).
CR Ackerman KV, 2008, ENVIRON SCI TECHNOL, V42, P5688, DOI 10.1021/es800221q
   Cai BF, 2018, RESOUR CONSERV RECY, V136, P315, DOI 10.1016/j.resconrec.2018.04.018
   Chen X., 2018, COMMUNICATION
   [陈喜平 Chen Xiping], 2012, [轻金属, Light Metals], P33
   Eggleston H.S., 2006, 2006 IPCC GUIDELINES
   Evans S., 2009, CEM 2009 C
   Fraser P., 2013, MINERALS METALS MAT
   Jeon EC, 2010, APPL ENERG, V87, P205, DOI 10.1016/j.apenergy.2009.06.015
   Lee JCK, 2017, J IND ECOL, V21, P1277, DOI 10.1111/jiec.12491
   Liu K., 2001, CHIN J NONFERR MET, V11, P1118
   Liu W., 2008, METAL WORLD, V15, P38
   MITT (Ministry of Industry and Information Technology of the People's Republic of China), 2016, NOT DEV PLAN RAR EAR, P2016
   PENMAN J, 2000, GOOD PRACTICE GUIDAN
   Sprecher B, 2014, ENVIRON SCI TECHNOL, V48, P3951, DOI 10.1021/es404596q
   US EPA (the United States Environmental Protection Agency), 2009, TECHN SUPP DOC STAT
   Vogel H, 2017, J SUSTAIN METALL, V3, P99, DOI 10.1007/s40831-016-0086-0
   Wang Wei, 2012, Huanjing Kexue, V33, P8
   Zhang G, 2017, ATMOS ENVIRON, V160, P55, DOI 10.1016/j.atmosenv.2017.04.017
   Zhang LZ, 2018, ATMOS POLLUT RES, V9, P61, DOI 10.1016/j.apr.2017.06.006
   2015, ATMOS ENVIRON, V117, P220, DOI DOI 10.1016/J.ATMOSENV.2015.07.008
NR 20
TC 0
Z9 1
U1 8
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 261
EP 267
DI 10.1016/j.resconrec.2019.02.019
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200025
DA 2020-05-12
ER

PT J
AU Lopes, JRN
   Kalid, RD
   Rodriguez, JLM
   Avila, S
AF Nascimento Lopes, Jose Rafael
   Kalid, Ricardo de Araujo
   Moya Rodriguez, Jorge Laureano
   Avila Filho, Salvador
TI A new model for assessing industrial worker behavior regarding energy
   saving considering the theory of planned behavior, norm activation model
   and human reliability
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Behavior; Energy efficiency; Energy saving; Structural equation
   modeling; Theory of planned behavior
ID PRO-ENVIRONMENTAL BEHAVIOR; PARTIAL LEAST-SQUARES; CONSUMERS INTENTION;
   ELECTRIC VEHICLES; CAR USE; WORKPLACE; ORGANIZATIONS; DETERMINANTS;
   INDIVIDUALS; ANTECEDENTS
AB Application of energy efficiency measures is one of the most hopeful solutions to face global environmental challenges, to minimize natural resources consumption and the greenhouse effect. However, the level of implementation in the industrial sector is far below of what theoretically could be achieved due to several barriers, one of which is the behavior of industrial workers. The aim of this paper is to rank the critical factors of industrial worker behavior with relation to energy saving in an industrial organization. A case study was undertaken to analyze workers' intentions to adopt energy efficiency measures, using an extended model of the theory of planned behavior (TPB). A survey gathered the data to assess the model and a structural equation modeling (SEM) was fitted. The results indicate that two factors of the adjusted SEM model are not statistically significant, contrary to what was expected by the TPB and the human reliability; therefore, these two factors, subjective norms and performance shaping factors, should be the object of greater attention so as to influence the behavior of workers towards greater energy saving in industrial units.
C1 [Nascimento Lopes, Jose Rafael; Moya Rodriguez, Jorge Laureano; Avila Filho, Salvador] Univ Fed Bahia, Prof Aristides Novis St 2, Salvador, BA, Brazil.
   [Kalid, Ricardo de Araujo] Fed Univ South Bahia, Km 39 Access Highway Itabuna, Itabuna, Brazil.
RP Lopes, JRN (reprint author), Univ Fed Bahia, Prof Aristides Novis St 2, Salvador, BA, Brazil.
EM jrafael.lopes@gmail.com
RI de Araujo Kalid, Ricardo/P-8329-2019; Rodriguez, Jorge Laureano
   Moya/L-4928-2015
OI de Araujo Kalid, Ricardo/0000-0001-9265-5263; Rodriguez, Jorge Laureano
   Moya/0000-0003-0541-0191; Lopes, Jose Rafael/0000-0001-8627-7200
FU Coordenacdo de Aperfeicoamento de Pessoal de Nivel Superior -Brasil
   (CAPES) [001]; CNPqNational Council for Scientific and Technological
   Development (CNPq) [301105/2016-2]
FX This study was financed in part by the Coordenacdo de Aperfeicoamento de
   Pessoal de Nivel Superior -Brasil (CAPES) Finance Code 001. The authors
   also would like to thank to the CNPq Productivity of Research Funds
   Process 301105/2016-2 and the Chemical enterprise for providing
   personnel time and the required information for the research
CR Abdelaziz EA, 2011, RENEW SUST ENERG REV, V15, P150, DOI 10.1016/j.rser.2010.09.003
   ABESCO, 2017, DESP EN CUST MAIS R
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I, 1985, ACTION CONTROL COGNI, P11, DOI DOI 10.1007/978-3-642-69746-3_2
   Ajzen I, 2015, HEALTH PSYCHOL REV, V9, P131, DOI 10.1080/17437199.2014.883474
   Akyuz E, 2015, J LOSS PREVENT PROC, V34, P39, DOI 10.1016/j.jlp.2015.01.019
   Bagozzi R.P., 1988, J ACAD MARKET SCI, V16, P74, DOI [DOI 10.1007/BF02723327, 10.1007/BF02723327]
   Bamberg S, 2003, ENVIRON BEHAV, V35, P264, DOI 10.1177/0013916502250134
   Bamberg S, 2007, J ENVIRON PSYCHOL, V27, P190, DOI 10.1016/j.jenvp.2007.04.001
   BECK L, 1991, J RES PERS, V25, P285, DOI 10.1016/0092-6566(91)90021-H
   Bertoldo R, 2016, RESOUR CONSERV RECY, V112, P45, DOI 10.1016/j.resconrec.2016.03.020
   Blake J., 1999, LOCAL ENVIRON, V4, P257, DOI DOI 10.1080/13549839908725599
   BOLLEN KA, 1989, SOCIOL METHOD RES, V17, P303, DOI 10.1177/0049124189017003004
   Boomsma C, 2016, ENERGY RES SOC SCI, V15, P58, DOI 10.1016/j.erss.2016.02.004
   Boring RL, 2007, 2007 IEEE 8TH HUMAN FACTORS AND POWER PLANTS AND HPRCT 13TH ANNUAL MEETING, P177, DOI 10.1109/HFPP.2007.4413202
   Bortoleto AP, 2012, WASTE MANAGE, V32, P2195, DOI 10.1016/j.wasman.2012.05.037
   Chatterton T., 2011, INTRO THINKING ENERG
   Cohen J., 2013, STAT POWER ANAL BEHA, DOI [10.4324/9780203771587, DOI 10.4324/9780203771587]
   Davison A. C., 1997, INTRO BOOTSTRAP METH, P1, DOI [10.1017/CB09780511802843.002, DOI 10.1017/CB09780511802843.002]
   Dijkstra TK, 2015, MIS QUART, V39, P297, DOI 10.25300/MISQ/2015/39.2.02
   Dixon GN, 2015, ENERGY RES SOC SCI, V6, P121, DOI 10.1016/j.erss.2015.01.004
   Embrey D., 2004, GUIDELINES PREVENTIN, DOI [10.1002/9780470925096, DOI 10.1002/9780470925096]
   EPE, 2017, BRAZ EN BAL
   Ertz M, 2016, J BUS RES, V69, P3971, DOI 10.1016/j.jbusres.2016.06.010
   Fishbein M., 2011, PREDICTING CHANGING
   Fornara F, 2016, J ENVIRON PSYCHOL, V45, P1, DOI 10.1016/j.jenvp.2015.11.001
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Francis J.J., 2004, CONSTRUCTING QUESTIO
   Galyean W. J., 2011, SPAR H STEP BY STEP, DOI [10.2172/1027888, DOI 10.2172/1027888]
   Gao L, 2017, RESOUR CONSERV RECY, V127, P107, DOI 10.1016/j.resconrec.2017.08.030
   Gerarden T., 2015, J EC LIT CAMBRIDGE M, DOI [10.3386/w20904, DOI 10.3386/W20904]
   Greaves M, 2013, J ENVIRON PSYCHOL, V34, P109, DOI 10.1016/j.jenvp.2013.02.003
   Griffin R.W., 2011, ORG BEHAV
   Hair J., 2010, MULTIVAR DATA ANAL, P816, DOI DOI 10.1016/J.IJPHARM.2011.02.019
   Hair Jr JF, 2016, PRIMER PARTIAL LEAST
   He XH, 2018, J CLEAN PROD, V172, P3546, DOI 10.1016/j.jclepro.2017.05.088
   Hubert M, 2003, J CHEMOMETR, V17, P537, DOI 10.1002/cem.822
   IBGE, 2018, NAT ACC SYST
   IEA I. E. A., 2017, EN TECHN PERSP 2017, DOI [10.1787/energy-tech-2017-en, DOI 10.1787/ENERGY-TECH-2017-EN]
   Jackson T, 2005, SUSTAIN DEV RES NETW
   Joreskog KG, 1993, LISREL 8 STRUCTURAL
   Kaiser FG, 2003, PERS INDIV DIFFER, V35, P1033, DOI 10.1016/S0191-8869(02)00316-1
   Karatasou S, 2014, ADV BUILD ENERGY RES, V8, P137, DOI 10.1080/17512549.2013.809275
   Klockner CA, 2013, GLOBAL ENVIRON CHANG, V23, P1028, DOI 10.1016/j.gloenvcha.2013.05.014
   Klockner CA, 2009, J APPL SOC PSYCHOL, V39, P1807
   Kollmuss A., 2002, ENVIRON EDUC RES, V8, P239, DOI DOI 10.1080/13504620220145401
   Krajangsri T, 2017, J MANAGE ENG, V33, DOI 10.1061/(ASCE)ME.1943-5479.0000509
   Kuo TC, 2018, J CLEAN PROD, V192, P486, DOI 10.1016/j.jclepro.2018.04.250
   Kurisu K., 2016, PROENVIRONMENTAL BEH, DOI [10.1007/978-4-431-55834-7, DOI 10.1007/978-4-431-55834-7]
   Landry N, 2018, J ENVIRON PSYCHOL, V55, P18, DOI 10.1016/j.jenvp.2017.12.003
   Liobikiene G, 2016, ECOL ECON, V125, P38, DOI 10.1016/j.ecolecon.2016.02.008
   Lo SH, 2012, J APPL SOC PSYCHOL, V42, P2933, DOI 10.1111/j.1559-1816.2012.00969.x
   Lopes JR, 2018, ENERGIES, V11, DOI 10.3390/en11051271
   Lopes MAR, 2012, RENEW SUST ENERG REV, V16, P4095, DOI 10.1016/j.rser.2012.03.034
   Lorenzo D. K., 2001, API PUBLICATION
   Lynch D., 2010, EUR COUNC EN EFF EC
   Mayr S, 2007, TUTOR QUANT METHODS, V3, P51, DOI 10.20982/tqmp.03.2.p051
   McDonald FV, 2014, ADM SCI, V4, P276, DOI 10.3390/admsci4030276
   McLeod RW, 2017, PROCESS SAF ENVIRON, V110, P31, DOI 10.1016/j.psep.2017.01.012
   Murtagh N, 2013, ENERG POLICY, V62, P717, DOI 10.1016/j.enpol.2013.07.090
   Mykoniatis K., 2017, 2017 IEEE C COGN COM, P1, DOI 10.1109/COGSIMA.2017.7929604
   Onwezen MC, 2013, J ECON PSYCHOL, V39, P141, DOI 10.1016/j.joep.2013.07.005
   Peng DX, 2012, J OPER MANAG, V30, P467, DOI 10.1016/j.jom.2012.06.002
   Rasmussen M, 2015, SAFETY SCI, V76, P228, DOI 10.1016/j.ssci.2015.03.005
   Reason J., 1990, HUMAN ERROR, DOI [10.1017/CB09781139062367, DOI 10.1017/CB09781139062367]
   REN21, 2018, REN 2018 GLOB STAT R
   Ringle C. M., 2018, INT J HUM RESOUR MAN, DOI [10.1080/09585192.2017.1416655, DOI 10.1080/09585192.2017.1416655]
   Robbins S. P., 2013, ORG BEHAV
   Ruepert A, 2018, RESEARCH HANDBOOK ON EMPLOYEE PRO-ENVIRONMENTAL BEHAVIOUR, P106
   SCHWARTZ SH, 1980, SOC PSYCHOL QUART, V43, P441, DOI 10.2307/3033965
   SCHWARTZ SH, 1977, ADV EXPT SOCIAL PSYC, V10, P221, DOI DOI 10.1016/S0065-2601(08)60358-5
   Sniehotta FF, 2014, HEALTH PSYCHOL REV, V8, P1, DOI 10.1080/17437199.2013.869710
   Steg L, 2014, J ENVIRON PSYCHOL, V38, P104, DOI 10.1016/j.jenvp.2014.01.002
   Steg L, 2009, J ENVIRON PSYCHOL, V29, P309, DOI 10.1016/j.jenvp.2008.10.004
   Taufique KMR, 2018, J CLEAN PROD, V183, P46, DOI 10.1016/j.jclepro.2018.02.097
   Triandis H. C., 1977, INTERPERSONAL BEHAV
   Tudela A, 2013, TRANSPORT SURVEY METHODS: BEST PRACTICE FOR DECISION MAKING, P625
   van der Werff E, 2015, ENERGY RES SOC SCI, V6, P8, DOI 10.1016/j.erss.2014.11.002
   Wang B, 2018, ENERG POLICY, V116, P68, DOI 10.1016/j.enpol.2018.01.055
   Wang SY, 2018, ENERG POLICY, V115, P171, DOI 10.1016/j.enpol.2018.01.012
   Wang SY, 2016, TRANSPORTATION, V43, P123, DOI 10.1007/s11116-014-9567-9
   Wang ZH, 2014, J RENEW SUSTAIN ENER, V6, DOI 10.1063/1.4898363
   Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249
   Xu XJ, 2017, ENERGY RES SOC SCI, V32, P13, DOI 10.1016/j.erss.2017.02.011
   Yadav R, 2016, J CLEAN PROD, V135, P732, DOI 10.1016/j.jclepro.2016.06.120
   Zhang XJ, 2017, J CLEAN PROD, V166, P148, DOI 10.1016/j.jclepro.2017.08.020
   Zhang YX, 2013, ENERG POLICY, V62, P1120, DOI 10.1016/j.enpol.2013.07.036
   Zierler R, 2017, ENERG POLICY, V104, P38, DOI 10.1016/j.enpol.2017.01.033
   2008, J OPER MANAG, V26, P45, DOI DOI 10.1016/J.JOM.2007.04.001
   2016, J BUS ETHICS, V135, P605, DOI DOI 10.1007/S10551-015-2543-2.605-605
   2014, APPL ENERG, V134, P392, DOI DOI 10.1016/J.APENERGY.2014.08.048
   1995, ENVIRON BEHAV, V27, P699, DOI DOI 10.1177/0013916595275005
NR 92
TC 5
Z9 5
U1 14
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 268
EP 278
DI 10.1016/j.resconrec.2019.02.042
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200026
DA 2020-05-12
ER

PT J
AU Bobba, S
   Mathieux, F
   Blengini, GA
AF Bobba, Silvia
   Mathieux, Fabrice
   Blengini, Gian Andrea
TI How will second-use of batteries affect stocks and flows in the EU? A
   model for traction Li-ion batteries
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Second-use; Reuse; Europe; Material Flow Analysis (MFA);
   Materials/energy flows; Li-ion batteries
ID ELECTRIC VEHICLE-BATTERIES; LITHIUM-ION; 2ND USE; ENERGY; PRODUCTS;
   IMPACT; TRANSPORTATION; CONSTRAINT; EFFICIENCY; DEMAND
AB Although not yet developed in Europe, second-use of traction batteries enables an extension of their lifetime and potentially improves life cycle environmental performance. Li-ion batteries (LIBs) offer the most promising chemistry for traction batteries in electric vehicles (xEVs) and for second-use. Due to the novelty of the topic and the expected increase of e-mobility in the next decades, more efforts to understand the potential consequences of second-use of batteries from different perspectives are needed. This paper develops a dynamic, parameterised Material Flow Analysis (MFA) model to estimate stocks and flows of LIBs after their removal from xEVs along the specific processes of the european value-chain. Direct reuse, second-use and recycling are included in the model and parameters make it customisable and updatable.
   Focusing on full and plug-in electric vehicles, LIBs and energy storage capacity flows are estimated. Stocks and flows of two embedded materials relevant for Europe were also assessed (cobalt and lithium). Results showed that second-use corresponds to a better exploitation of LIBs' storage capacity. Meanwhile, Co and Li in-use stocks are locked in LIBs and their recovery is delayed by second-use; depending on the slower/faster development of second-use, the amount of Co available for recycling in 2030 ranges between 9% and 15% of Co demand and between 7 and 16% for Li. Uncertainty of inputs is addressed through sensitivity analysis.
   A variety of actors can use this MFA model to enhance knowledge of second-use of batteries in Europe and to support the effective management of LIBs along their value-chain.
C1 [Bobba, Silvia; Mathieux, Fabrice; Blengini, Gian Andrea] European Commiss, JRC, Ispra, Italy.
   [Bobba, Silvia; Blengini, Gian Andrea] Politecn Torino, Dept Environm Land & Infrastruct Engn, Corso Duca Abruzzi 24, I-10129 Turin, Italy.
   [Bobba, Silvia] SEIDOR SBS Serv, C Pujades 350, Barcelona 08019, Spain.
RP Mathieux, F (reprint author), European Commiss, JRC, Ispra, Italy.
EM fabrice.mathieux@ec.europa.eu
OI Mathieux, Fabrice/0000-0002-7746-9929; Blengini, Gian
   Andrea/0000-0002-7977-1363
CR ADEME, 2011, ET 2 VIE BATT VEH EL
   Ahmadi L, 2014, SUSTAIN ENERGY TECHN, V8, P9, DOI 10.1016/j.seta.2014.06.006
   Ahmadi L, 2014, SUSTAIN ENERGY TECHN, V6, P64, DOI 10.1016/j.seta.2014.01.006
   Ambrose H, 2014, ENVIRON RES LETT, V9, DOI 10.1088/1748-9326/9/9/094004
   APRA Europe, 2012, REM TERM
   Ardente F, 2014, J CLEAN PROD, V83, P126, DOI 10.1016/j.jclepro.2014.07.058
   Bank of America Merrill Lynch, 2016, TECHN GLOB EL VEH BA
   Berckmans G, 2017, ENERGIES, V10, DOI 10.3390/en10091314
   Blagoeva D. T., 2016, ASSESSMENT POTENTIAL, P2015, DOI [10.2790/08169, DOI 10.2790/08169]
   Bobba S., 2018, 29321 EUR EN, DOI [10.2760/53624, DOI 10.2760/53624, 10. 2760/53624]
   Bobba S, 2018, J ENERGY STORAGE, V19, P213, DOI 10.1016/j.est.2018.07.008
   Brunner PH, 2004, PRACTICAL HDB MAT FL
   Chmura A., 2016, PUTT SCI STAND PSIS
   Cobb J., 2014, LONG WILL ELECT CARS
   Cusenza MA, 2019, J CLEAN PROD, V215, P634, DOI 10.1016/j.jclepro.2019.01.056
   Daimler, 2015, DAIML SUST REP 2014
   EAFO, 2016, EL VEH EUR UN
   EC, 2018, LONG TERM VIS SUST F
   EC, 2017, BATTERIES MAJ OPP SU, DOI [10.2777/412120, DOI 10.2777/412120]
   EEA, 2016, EL VEH EUR, DOI [10.2800/100230, DOI 10.2800/100230]
   Elkind EN, 2014, REUSE REPOWER SAVE M
   EUROBAT, 2015, E MOB BATT R D ROADM
   EUROBAT, 2014, REV BATT TECHN AUT A
   European Commission, 2018, EUR BATT ALL
   Gruber PW, 2011, J IND ECOL, V15, P760, DOI 10.1111/j.1530-9290.2011.00359.x
   Habib H., 2017, CRM TRENDS SCENARIOS
   Heymans C, 2014, ENERG POLICY, V71, P22, DOI 10.1016/j.enpol.2014.04.016
   Huss A., 2013, TANK TO WHEELS REPOR, DOI [10.2788/40409, DOI 10.2788/40409]
   IEA, 2018, GLOB EV OUTL 2018 CR, DOI [10.1787/9789264302365-en, DOI 10.1787/9789264302365-EN]
   Igos E, 2019, INT J LIFE CYCLE ASS, V24, P794, DOI 10.1007/s11367-018-1477-1
   JRC, 2013, CRIT MET PATH DEC EU, DOI [10.2790/46338, DOI 10.2790/46338]
   Kampker A., 2017, INT J MECH AEROSPACE, V10, P6
   Kampman B., 2011, IMPACTS ELECT VEHICL, P165
   Kessels K., 2017, SUPPORT R D STRATEGY
   Kirmas A., 2017, SSRN ELECT J, DOI [10.2139/ssrn.2954629, DOI 10.2139/SSRN.2954629]
   Koch-Ciobotaru C, 2015, IEEE ENER CONV, P78, DOI 10.1109/ECCE.2015.7309672
   Langkau S, 2018, SUSTAIN MATER TECHNO, V16, P54, DOI 10.1016/j.susmat.2018.02.001
   Lebedeva N., 2016, 28534 EUR EN, DOI [10.2760/6060.JRC105010, DOI 10.2760/6060.JRC105010]
   Majeau-Bettez G, 2011, ENVIRON SCI TECHNOL, V45, P4548, DOI 10.1021/es103607c
   Mathieux F., 2017, 28832 EUR EN, DOI [10.2760/378123, DOI 10.2760/378123]
   McEachern A., 2012, ELECT VEH NEWS
   Melin H. E., 2018, LITHIUM ION BATTERY
   Mudgal S., 2014, EXPOST EVALUATION CE
   Muller E, 2014, ENVIRON SCI TECHNOL, V48, P2102, DOI 10.1021/es403506a
   Nakamura S, 2014, ENVIRON SCI TECHNOL, V48, P7207, DOI 10.1021/es500820h
   Natkunarajah N, 2015, PROC CIRP, V29, P740, DOI 10.1016/j.procir.2015.02.170
   Neubauer J, 2015, IDENTIFYING OVERCOMI
   Neubauer JS, 2015, SAE INT J MATER MANU, V8, P544, DOI 10.4271/2015-01-1306
   Olivetti EA, 2017, JOULE, V1, P229, DOI 10.1016/j.joule.2017.08.019
   Patry G, 2015, ENERGY SCI ENG, V3, P71, DOI 10.1002/ese3.47
   Pehlken A, 2017, INT J LIFE CYCLE ASS, V22, P40, DOI 10.1007/s11367-015-0925-4
   Perks C., 2016, ROLE COBALT BATTERY
   Petersen J., 2018, BATTERY CHEM ASSUMPT
   Pillot C., 2017, ADV AUT BATT C
   Pillot C., 2014, BATTERIES 2014
   Podias A., 2018, WORLD ELECT VEH J, V9, P24, DOI [10.3390/wevj9020024, DOI 10.3390/WEVJ9020024]
   Rehme M., 2016, 5 C FUT AUT TECHN CO, DOI [10.13140/RG.2.2.35238.93760, DOI 10.13140/RG.2.2.35238.93760]
   Reinhardt R, 2017, INT CONF EUR ENERG, DOI 10.1109/EEM.2017.7982031
   Reuter B., 2014, P C FUT AUT TECHN MU
   Richa K, 2014, RESOUR CONSERV RECY, V83, P63, DOI 10.1016/j.resconrec.2013.11.008
   Rohr S, 2017, PROCEDIA MANUF, V8, P603, DOI 10.1016/j.promfg.2017.02.077
   Rohr S., 2017, 2017 12 INT C EC VEH, P1, DOI [DOI 10.1109/EVER.2017.7935867, 10.1109/EVER.2017.7935867]
   Sathre R, 2015, J POWER SOURCES, V288, P82, DOI 10.1016/j.jpowsour.2015.04.097
   Schmidt T, 2016, RESOUR CONSERV RECY, V112, P107, DOI 10.1016/j.resconrec.2016.04.017
   Simon B, 2013, REV METALL-PARIS, V110, P65, DOI 10.1051/metal/2013056
   Simon B, 2015, RESOUR CONSERV RECY, V104, P300, DOI 10.1016/j.resconrec.2015.07.011
   Stahl H., 2018, STUDY SUPPORT EVALUA
   Standridge C. R., 2016, ADV REPURPOSING RECY
   Sun X, 2017, RESOUR CONSERV RECY, V124, P50, DOI 10.1016/j.resconrec.2017.04.012
   Sweeting WJ, 2012, ENERG POLICY, V51, P927, DOI 10.1016/j.enpol.2012.09.055
   Tamiang A., 2014, ELECTRODE CELLS MANU
   Tecchio P, 2017, J CLEAN PROD, V168, P1533, DOI 10.1016/j.jclepro.2017.05.198
   Thiel C, 2016, ENERG POLICY, V96, P153, DOI 10.1016/j.enpol.2016.05.043
   Timmers H., 2016, PUTT SCI STAND PSIS
   Tivander J., 2016, ENV METALS LI ION BA
   Viswanathan VV, 2011, IEEE T VEH TECHNOL, V60, P2963, DOI 10.1109/TVT.2011.2160378
   Wang X, 2014, RESOUR CONSERV RECY, V83, P53, DOI 10.1016/j.resconrec.2013.11.009
   Willson Q., 2018, WHY IT MAKES SENSE B
   Ziemann S, 2018, RESOUR CONSERV RECY, V133, P76, DOI 10.1016/j.resconrec.2018.01.031
   Zubi G, 2018, RENEW SUST ENERG REV, V89, P292, DOI 10.1016/j.rser.2018.03.002
   2014, ENVIRON SCI TECHNOL, V48, P1298, DOI DOI 10.1021/ES404877U
NR 81
TC 3
Z9 3
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 279
EP 291
DI 10.1016/j.resconrec.2019.02.022
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200027
PM 32255922
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Teixeira, ER
   Camoes, A
   Branco, FG
AF Teixeira, E. R.
   Camoes, A.
   Branco, F. G.
TI Valorisation of wood fly ash on concrete
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Review
DE Wood fly ash; Coal fly ash; Concrete; Cement replacement; Sustainability
ID SELF-COMPACTING CONCRETE; ALKALI-SILICA REACTION; RICE HUSK ASH;
   FLUIDIZED-BED COMBUSTION; LIFE-CYCLE ASSESSMENT; CANE BAGASSE ASH;
   BIOMASS COMBUSTION; RHEOLOGICAL BEHAVIOR; CEMENT REPLACEMENT;
   CHEMICAL-COMPOSITION
AB Wood fly ash (WFA) is a waste material produced in power plants as result of forest residues combustion to produce power and heat. In countries like Portugal, this waste is disposed of in landfills. Since this material shows pozzolanic characteristics, several studies have been done to evaluate its use as a construction material. This work shows an overview of some published results about the effect of the utilisation of WFA, as a supplementary cementitious material, on the durability and quality of concrete. The results showed that the increase on the wood fly ash content leads to a negative effect on the concrete properties when compared with a conventional concrete. However, the results showed that the behaviour of wood fly ash concrete is very similar to the coal fly ash concrete, which is the most pozzolanic material used in the world. In terms of durability, it was verified that WFA improved the most of the durability characteristics with the exception of carbonation resistance. However, more experimental analysis needs to be developed in terms of wood fly ash concrete durability. Results suggested that using wood fly ash to replace cement is a valuable sustainable option for concrete production. This manuscript discusses the key factors and attempts to provide new information about the application of the wood fly ash on concrete.
C1 [Teixeira, E. R.; Camoes, A.] Univ Minho, CTAC, Dept Civil Engn, Sch Engn, Campus Azurem, P-4800058 Guimaraes, Portugal.
   [Branco, F. G.] Univ Coimbra, INESC Coimbra, Dept Civil Engn, Rua Luis Reis Santos Polo II Univ, P-3030788 Coimbra, Portugal.
RP Teixeira, ER (reprint author), Univ Minho, CTAC, Dept Civil Engn, Sch Engn, Campus Azurem, P-4800058 Guimaraes, Portugal.
EM id5470@alunos.uminho.pt
RI Branco, Fernando G./F-8990-2010; Camoes, Aires/A-6535-2013
OI Branco, Fernando G./0000-0002-8648-678X; Camoes,
   Aires/0000-0002-9677-3627; Teixeira, Elisabete/0000-0003-1435-0733
FU Portuguese Foundation for Science and Technology (FCT)Portuguese
   Foundation for Science and Technology [PD/BD/52661/2014];
   Eco-Construction and Rehabilitation Doctoral Programme
   [PD/BD/52661/2014]; FEDER funds through the Competitivity Factors
   Operational Programme - COMPETE; FCT - Foundation for Science and
   TechnologyPortuguese Foundation for Science and Technology [POCI-01 -
   0145-FEDER - 007633]; Regional Operational Programme CENTRO2020
   [CENTRO-01 - 0145-FEDER - 000006]
FX The authors wish to thank the Portuguese Foundation for Science and
   Technology (FCT) and the Eco-Construction and Rehabilitation Doctoral
   Programme for supporting the PhD scholarship (reference
   PD/BD/52661/2014). This work was also financed by FEDER funds through
   the Competitivity Factors Operational Programme - COMPETE and by
   national funds through FCT -Foundation for Science and Technology within
   the scope of the project POCI-01 -0145-FEDER -007633 and through the
   Regional Operational Programme CENTRO2020 within the scope of the
   project CENTRO-01 - 0145-FEDER - 000006.
CR Abdullahi M, 2006, LEONARDO ELECT J PRA, V5, P9
   Ahmaruzzaman M, 2010, PROG ENERG COMBUST, V36, P327, DOI 10.1016/j.pecs.2009.11.003
   Aitcin P -C, 2008, MODERN CONCRETE TECH, DOI [10.1017/CB09781107415324.004, DOI 10.1017/CB09781107415324.004]
   AITCIN PC, 2011, MOD CONRETE TECHNOL, P1
   Al-mulali MZ, 2015, CEMENT CONCRETE COMP, V55, P129, DOI 10.1016/j.cemconcomp.2014.09.007
   Alhozaimy A, 1996, ACI MATER J, V93, P87
   Alonso C, 2000, CEMENT CONCRETE RES, V30, P1047, DOI 10.1016/S0008-8846(00)00265-9
   [Anonymous], 2012, 4501 EN I PORT QUAL
   Uson AA, 2013, RENEW SUST ENERG REV, V23, P242, DOI 10.1016/j.rser.2013.02.024
   Artelt C, 2008, CEMENT CONCRETE RES, V38, P633, DOI 10.1016/j.cemconres.2008.01.010
   ASTM, 2015, C61815 ASTM
   Aye T, 2011, CONSTR BUILD MATER, V25, P2988, DOI 10.1016/j.conbuildmat.2010.11.106
   Ban CC, 2011, RESOUR CONSERV RECY, V55, P669, DOI 10.1016/j.resconrec.2011.02.002
   Barathan S, 2013, INT J SCI ENG TECHNO, V2, P2009
   Barbosa R, 2013, CONSTR BUILD MATER, V48, P457, DOI 10.1016/j.conbuildmat.2013.07.031
   Barbosa R, 2013, FUEL PROCESS TECHNOL, V109, P124, DOI 10.1016/j.fuproc.2012.09.048
   Batt A. S., 2017, J CIVIL ENV ENG, V7, P1, DOI [10.4172/2165-784X.1000272, DOI 10.4172/2165-784X.1000272]
   Benhelal E, 2013, J CLEAN PROD, V51, P142, DOI 10.1016/j.jclepro.2012.10.049
   Berra M, 2015, CONSTR BUILD MATER, V76, P286, DOI 10.1016/j.conbuildmat.2014.11.052
   BERRY EE, 1980, J AM CONCRETE I, V77, P59
   Bijen J, 1996, CONSTR BUILD MATER, V10, P309, DOI 10.1016/0950-0618(95)00014-3
   CABRERA JG, 1988, MAG CONCRETE RES, V40, P177, DOI 10.1680/macr.1988.40.144.177
   Camoes A, 2005, INCOS 05 INT C CONCR
   Capablo J, 2009, ENERG FUEL, V23, P1965, DOI 10.1021/ef8008426
   Celik K, 2015, CEMENT CONCRETE COMP, V56, P59, DOI 10.1016/j.cemconcomp.2014.11.003
   Chalee W, 2013, CEMENT CONCRETE COMP, V37, P47, DOI 10.1016/j.cemconcomp.2012.12.007
   Chaunsali P, 2018, CEMENT CONCRETE COMP, V89, P41, DOI 10.1016/j.cemconcomp.2018.02.011
   Cheah CB, 2012, CONSTR BUILD MATER, V30, P320, DOI 10.1016/j.conbuildmat.2011.12.009
   Chindaprasirt P, 2007, CONSTR BUILD MATER, V21, P356, DOI 10.1016/j.conbuildmat.2005.08.010
   Chindaprasirt P, 2005, CEMENT CONCRETE COMP, V27, P425, DOI 10.1016/j.cemconcomp.2004.07.003
   Chowdhury S, 2015, J ADV RES, V6, P907, DOI 10.1016/j.jare.2014.08.006
   Chowdhury S, 2015, AIN SHAMS ENG J, V6, P429, DOI 10.1016/j.asej.2014.11.005
   Coelho A. M. S. L., 2010, THESIS
   Cordeiro GC, 2008, CEMENT CONCRETE COMP, V30, P410, DOI 10.1016/j.cemconcomp.2008.01.001
   Cordeiro GC, 2009, CEMENT CONCRETE RES, V39, P110, DOI 10.1016/j.cemconres.2008.11.005
   Cruz-Yusta M, 2011, ENVIRON SCI TECHNOL, V45, P6991, DOI 10.1021/es200968a
   Liao CP, 2007, FUEL PROCESS TECHNOL, V88, P149, DOI 10.1016/j.fuproc.2005.06.008
   da Silva PR, 2015, CONSTR BUILD MATER, V86, P101, DOI 10.1016/j.conbuildmat.2015.03.110
   Davidsson KO, 2007, ENERG FUEL, V21, P1959, DOI 10.1021/ef070055n
   Davraz M, 2008, CONSTR BUILD MATER, V22, P1093, DOI 10.1016/j.conbuildmat.2007.03.002
   Demirbas A, 2005, PROG ENERG COMBUST, V31, P171, DOI 10.1016/j.pecs.2005.02.002
   Eliche-Quesada D, 2017, CERAM INT, V43, P463, DOI 10.1016/j.ceramint.2016.09.181
   Emoto T, 2007, CEMENT CONCRETE RES, V37, P647, DOI 10.1016/j.cemconres.2007.01.009
   Esteves TC, 2012, CONSTR BUILD MATER, V26, P687, DOI 10.1016/j.conbuildmat.2011.06.075
   Esteves T. C. B., 2010, THESIS
   Fairbairn EMR, 2010, J ENVIRON MANAGE, V91, P1864, DOI 10.1016/j.jenvman.2010.04.008
   FAJUN W, 1985, CEMENT CONCRETE RES, V15, P174, DOI 10.1016/0008-8846(85)90024-9
   Fernandes I, 2004, MATER CHARACT, V53, P295, DOI 10.1016/j.matchar.2004.08.005
   Filho J. H., 2002, EFEITOS ADICAO CAL H
   Freeman E, 1997, FUEL, V76, P761, DOI 10.1016/S0016-2361(96)00193-7
   Fuller A, 2018, CONSTR BUILD MATER, V189, P825, DOI 10.1016/j.conbuildmat.2018.09.016
   Ganesan K, 2008, CONSTR BUILD MATER, V22, P1675, DOI 10.1016/j.conbuildmat.2007.06.011
   Garcia MD, 2013, CONSTR BUILD MATER, V41, P897, DOI 10.1016/j.conbuildmat.2012.11.081
   Garcia-Diaz E, 2006, CEMENT CONCRETE RES, V36, P395, DOI 10.1016/j.cemconres.2005.06.003
   Gonzalez-Kunz RN, 2017, SUSTAIN CITIES SOC, V31, P151, DOI 10.1016/j.scs.2017.03.001
   Hassan HS, 2019, J CLEAN PROD, V209, P1420, DOI 10.1016/j.jclepro.2018.11.137
   HE C, 2016, EFFECTS OF WOOD ASH, P101
   Helmuth R. A., 1987, FLY ASH CEMENT CONCR
   Hewlett P., 2004, LEAS CHEM CEMENT CON
   Horsakulthai V, 2011, CONSTR BUILD MATER, V25, P54, DOI 10.1016/j.conbuildmat.2010.06.057
   Hossain MM, 2016, CONSTR BUILD MATER, V116, P128, DOI 10.1016/j.conbuildmat.2016.04.147
   Hossain MU, 2017, RESOUR CONSERV RECY, V120, P199, DOI 10.1016/j.resconrec.2016.12.012
   Hou XQ, 2004, CEMENT CONCRETE RES, V34, P1683, DOI 10.1016/j.cemconres.2004.03.026
   Huang CH, 2013, CONSTR BUILD MATER, V46, P71, DOI 10.1016/j.conbuildmat.2013.04.016
   Huang Q, 2017, ADV CEM RES, V29, P45, DOI 10.1680/jadcr.16.00063
   Hussain S, 2017, J BUILD ENG, V10, P26, DOI 10.1016/j.jobe.2017.02.001
   Ichikawa T, 2009, CEMENT CONCRETE RES, V39, P716, DOI 10.1016/j.cemconres.2009.06.004
   Illikainen M, 2014, FUEL, V135, P69, DOI 10.1016/j.fuel.2014.06.029
   Jensen H., 1989, ADV CEM RES, V2, P121
   Kara P, 2012, CONSTR SCI, V13, P17, DOI DOI 10.2478/V10311-012-0003-0
   Khan AA, 2009, FUEL PROCESS TECHNOL, V90, P21, DOI 10.1016/j.fuproc.2008.07.012
   Khan MI, 2002, CEMENT CONCRETE RES, V32, P123, DOI 10.1016/S0008-8846(01)00641-X
   Koukouzas N, 2007, FUEL, V86, P2186, DOI 10.1016/j.fuel.2007.03.036
   Kovler K, 2011, CEMENT CONCRETE RES, V41, P775, DOI 10.1016/j.cemconres.2011.03.009
   Lagerblad B, 2005, CARBON DIOXIDE UPTAK
   Lane RO, 1982, CONCR INT, V4, P81
   Lessard JM, 2017, J MATER CIVIL ENG, V29, DOI 10.1061/(ASCE)MT.1943-5533.0001796
   Lisbeth M., 2016, WOOD ASH USED PARTLY, DOI [10.2495/SDP-V11-N5-781-791, DOI 10.2495/SDP-V11-N5-781-791]
   Loo S V, 2012, HDB BIOMASS COMBUSTI
   Mahmoudkhani M, 2007, ENVIRON SCI TECHNOL, V41, P4118, DOI 10.1021/es062079z
   Maresca A, 2019, WASTE MANAGE, V83, P113, DOI 10.1016/j.wasman.2018.11.003
   Maresca A, 2017, WASTE MANAGE, V70, P127, DOI 10.1016/j.wasman.2017.09.008
   Maschio S, 2011, CHEMOSPHERE, V85, P666, DOI 10.1016/j.chemosphere.2011.06.070
   Matjie RH, 2008, FUEL, V87, P857, DOI 10.1016/j.fuel.2007.05.050
   Miller B, 2006, ENERG FUEL, V20, P520, DOI 10.1021/ef058013r
   Miyandehi BM, 2016, CEMENT CONCRETE COMP, V74, P225, DOI 10.1016/j.cemconcomp.2016.10.006
   Modolo RCE, 2013, CONSTR BUILD MATER, V45, P275, DOI 10.1016/j.conbuildmat.2013.03.093
   Nagrockiene D, 2018, CONSTR BUILD MATER, V174, P369, DOI 10.1016/j.conbuildmat.2018.04.125
   Naik TR, 2005, CBU200515, P1
   Neville A, 2004, CEMENT CONCRETE RES, V34, P1275, DOI 10.1016/j.cemconres.2004.04.004
   Neville A.M., 1995, PROPERTIES CONCRETE
   Nochaiya T, 2010, FUEL, V89, P768, DOI 10.1016/j.fuel.2009.10.003
   Nurmesniemi H., 2012, J U CHEM TECHNOL MET, V47, P43
   Obernberger I., 2009, 17 EUR BIOM C EXH HA
   Omran A, 2018, CONSTR BUILD MATER, V186, P660, DOI 10.1016/j.conbuildmat.2018.07.084
   Ottosen LM, 2016, P 8 INT C WAST MAN E, V11, P781, DOI [10.2495/SDP-V11-N5-781-791, DOI 10.2495/SDP-V11-N5-781-791]
   Papadakis VG, 2000, CEMENT CONCRETE RES, V30, P1647, DOI 10.1016/S0008-8846(00)00388-4
   PARROTT LJ, 1995, MAG CONCRETE RES, V47, P103, DOI 10.1680/macr.1995.47.171.103
   Pavoine A, 2014, ACI MATER J, V111, P251
   Pettersson A, 2008, BIOMASS BIOENERG, V32, P236, DOI [10.1016/j.biombioe.2007.09.006, 10.1016/j.biombioe.2007.09.016]
   Pitman RM, 2006, FORESTRY, V79, P563, DOI 10.1093/forestry/cpl041
   Ponikiewski T, 2014, ARCH CIV MECH ENG, V14, P455, DOI 10.1016/j.acme.2013.10.014
   Rajamma R, 2015, COMPOS PART B-ENG, V77, P1, DOI 10.1016/j.compositesb.2015.03.019
   Rajamma R., 2011, THESIS
   Rajamma R, 2012, FUEL, V98, P265, DOI 10.1016/j.fuel.2012.04.006
   Rajamma R, 2009, J HAZARD MATER, V172, P1049, DOI 10.1016/j.jhazmat.2009.07.109
   Ramachandran VS, 1998, CEMENT CONCRETE COMP, V20, P149, DOI 10.1016/S0958-9465(97)00072-3
   RAMEZANIANPOUR AA, 1995, CEMENT CONCRETE COMP, V17, P125, DOI DOI 10.1016/0958-9465(95)00005-W
   Ramos T, 2013, CONSTR BUILD MATER, V49, P343, DOI 10.1016/j.conbuildmat.2013.08.026
   RAVINA D, 1986, CEMENT CONCRETE RES, V16, P227, DOI 10.1016/0008-8846(86)90139-0
   Reis MOB, 1996, BETA ESTRUTURAL 1996
   Reis Rui, 2015, Key Engineering Materials, V634, P288, DOI 10.4028/www.scientific.net/KEM.634.288
   Richardson M. G., 2003, FUNDAMENTALS DURABLE
   Rissanen J, 2018, CONSTR BUILD MATER, V180, P143, DOI 10.1016/j.conbuildmat.2018.05.014
   Rubio-Hernandez FJ, 2013, MATER STRUCT, V46, P587, DOI 10.1617/s11527-012-9915-1
   Ruiz B, 2017, PROCESS SAF ENVIRON, V105, P164, DOI 10.1016/j.psep.2016.11.005
   Sabet FA, 2013, CONSTR BUILD MATER, V44, P175, DOI 10.1016/j.conbuildmat.2013.02.069
   Sahoo S, 2017, J MATER CIVIL ENG, V29, DOI 10.1061/(ASCE)MT.1943-5533.0001759
   Sandberg P, 1999, CEMENT CONCRETE RES, V29, P473, DOI 10.1016/S0008-8846(98)00191-4
   Saraber A., 2012, RECYCLING BIOMASS AS, P2012
   Sate V., 2007, CONSTR BUILD MATER, V21, P1589, DOI [10.1016/j.conbuildmat.2005.09.011, DOI 10.1016/J.CONBUILDMAT.2005.09.011]
   Senff L, 2012, MAT SCI ENG A-STRUCT, V532, P354, DOI 10.1016/j.msea.2011.10.102
   Senff L, 2009, CONSTR BUILD MATER, V23, P2487, DOI 10.1016/j.conbuildmat.2009.02.005
   Sfikas IP, 2014, CONSTR BUILD MATER, V64, P121, DOI 10.1016/j.conbuildmat.2014.04.048
   Shearer C. R., 2011, EARLY AGE BEHAV BIOM
   Shi CJ, 2011, CEMENT CONCRETE RES, V41, P750, DOI 10.1016/j.cemconres.2011.03.016
   Siddique R, 2004, CEMENT CONCRETE RES, V34, P487, DOI 10.1016/j.cemconres.2003.09.002
   Siddique R, 2012, RESOUR CONSERV RECY, V67, P27, DOI 10.1016/j.resconrec.2012.07.004
   Singh S, 2011, INT J COAL GEOL, V87, P112, DOI 10.1016/j.coal.2011.05.006
   Skripkiunas G, 2017, PROCEDIA ENGINEER, V172, P1015, DOI 10.1016/j.proeng.2017.02.152
   Stark J, 2011, CEMENT CONCRETE RES, V41, P666, DOI 10.1016/j.cemconres.2011.03.028
   Steenari BM, 2010, FUEL, V89, P2026, DOI 10.1016/j.fuel.2010.02.006
   Steenari BM, 1999, FUEL, V78, P249, DOI 10.1016/S0016-2361(98)00137-9
   Steenari BM, 1999, BIOMASS BIOENERG, V16, P119, DOI 10.1016/S0961-9534(98)00070-1
   Steenari BM, 1997, BIOMASS BIOENERG, V13, P39, DOI 10.1016/S0961-9534(97)00024-X
   STRUBLE LJ, 1995, ADV CEM BASED MATER, V2, P224, DOI 10.1016/1065-7355(95)00017-L
   Tarelho LAC, 2015, ENERGY, V90, P387, DOI 10.1016/j.energy.2015.07.036
   Tarelho L A C, 2012, WORLD BIOEN 2012 C E
   Tarelho L. A. C., 2011, 19 EUR BIOM C EXH, P6
   Teixeira ER, 2019, CONSTR BUILD MATER, V197, P195, DOI 10.1016/j.conbuildmat.2018.11.173
   Teixeira E R, 2013, 21 EUR BIOM C EXH CO
   Teixeira ER, 2016, J CLEAN PROD, V112, P2221, DOI 10.1016/j.jclepro.2015.09.124
   TEIXEIRA ER, 2012, WORLD BIOENERGY 2012
   Thomas M, 1996, CEMENT CONCRETE RES, V26, P513, DOI 10.1016/0008-8846(96)00035-X
   Thomas MDA, 1999, CEMENT CONCRETE RES, V29, P1207, DOI 10.1016/S0008-8846(99)00096-4
   THOMAS MDA, 1992, MAG CONCRETE RES, V44, P217, DOI 10.1680/macr.1992.44.160.217
   Tkaczewska E, 2009, CONSTR BUILD MATER, V23, P2694, DOI 10.1016/j.conbuildmat.2008.12.018
   Torkaman J, 2014, CONSTR BUILD MATER, V50, P432, DOI 10.1016/j.conbuildmat.2013.09.044
   Tosti L, 2018, RESOUR CONSERV RECY, V134, P25, DOI 10.1016/j.resconrec.2018.03.004
   Udoeyo FF, 2006, J MATER CIVIL ENG, V18, P605, DOI 10.1061/(ASCE)0899-1561(2006)18:4(605)
   Ukrainczyk N, 2016, CHEM BIOCHEM ENG Q, V30, P137, DOI 10.15255/CABEQ.2015.2231
   Vamvuka D, 2008, BIORESOURCE TECHNOL, V99, P3534, DOI 10.1016/j.biortech.2007.07.049
   Vamvuka D, 2011, FUEL PROCESS TECHNOL, V92, P570, DOI 10.1016/j.fuproc.2010.11.013
   Vassilev SV, 2014, FUEL, V129, P292, DOI 10.1016/j.fuel.2014.04.001
   Vassilev SV, 2014, FUEL, V117, P152, DOI 10.1016/j.fuel.2013.09.024
   Vassilev SV, 2013, FUEL, V105, P40, DOI 10.1016/j.fuel.2012.09.041
   Vassilev SV, 2013, FUEL, V105, P19, DOI 10.1016/j.fuel.2012.10.001
   Vassilev SV, 2010, FUEL, V89, P913, DOI 10.1016/j.fuel.2009.10.022
   Velay-Lizancos M, 2017, CONSTR BUILD MATER, V157, P1126, DOI 10.1016/j.conbuildmat.2017.09.179
   Wang SZ, 2008, FUEL, V87, P359, DOI 10.1016/j.fuel.2007.05.027
   Wang SZ, 2008, FUEL, V87, P365, DOI 10.1016/j.fuel.2007.05.026
   Wang SZ, 2008, FUEL, V87, P372, DOI 10.1016/j.fuel.2007.05.024
   Wang SZ, 2007, FUEL PROCESS TECHNOL, V88, P1165, DOI 10.1016/j.fuproc.2007.06.016
   Wang SZ, 2015, CONSTR BUILD MATER, V82, P123, DOI 10.1016/j.conbuildmat.2015.02.021
   Wang Y, 2016, RESOUR CONSERV RECY, V109, P90, DOI 10.1016/j.resconrec.2016.02.010
   WBCSD I. E. A, 2009, CEM TECHN ROADM 2009, V36
   Wesche K., 2004, FLY ASH CONCRETE PRO
   WORTHINGTON JC, 1988, MATER SCI TECH SER, V4, P305, DOI 10.1179/mst.1988.4.4.305
   Xu G, 2018, RESOUR CONSERV RECY, V136, P95, DOI 10.1016/j.resconrec.2018.04.010
   Yammine J, 2008, CEMENT CONCRETE RES, V38, P890, DOI 10.1016/j.cemconres.2008.03.011
   Yang D, 2017, RESOUR CONSERV RECY, V119, P60, DOI 10.1016/j.resconrec.2016.06.017
   2009, FUEL PROCESS TECHNOL, V90, P871, DOI DOI 10.1016/J.FUPROC.2009.04.013
   2012, CONSTR BUILD MATER, V28, P633, DOI DOI 10.1016/J.CONBUILDMAT.2011.10.022
   2013, FUEL, V114, P71, DOI DOI 10.1016/J.FUEL.2012.04.042
   2014, CONSTR BUILD MATER, V68, P291, DOI DOI 10.1016/J.CONBUILDMAT.2014.06.071
   2010, FUEL PROCESS TECHNOL, V91, P1634, DOI DOI 10.1016/J.FUPROC.2010.06.012
NR 176
TC 2
Z9 2
U1 8
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 292
EP 310
DI 10.1016/j.resconrec.2019.02.028
PG 19
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200028
DA 2020-05-12
ER

PT J
AU Liu, DH
   Gao, XY
   An, HZ
   Qi, YB
   Sun, XQ
   Wang, Z
   Chen, ZH
   An, F
   Jia, NF
AF Liu, Donghui
   Gao, Xiangyun
   An, Haizhong
   Qi, Yabin
   Sun, Xiaoqi
   Wang, Ze
   Chen, Zhihua
   An, Feng
   Jia, Nanfei
TI Supply and demand response trends of lithium resources driven by the
   demand of emerging renewable energy technologies in China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Lithium resource; Supply and demand response; System dynamics; China;
   Renewable energy technologies
ID SYSTEM DYNAMICS MODEL; PRICE; MARKET; ENVIRONMENT; SIMULATION;
   MANAGEMENT; CAPACITY; IMPACT; GROWTH
AB The supply and demand response trends of lithium resources in China are investigated under the obvious changes caused by the rapid development of emerging renewable energy technologies (ERETs), such as electric energy storage (EES) and new energy vehicles (NEVs). A system dynamics model for renewable energy technology-lithium supply and demand is developed based on the industrial chain of lithium resources. Then, we analyze how the trends in the lithium market price, the supply and demand gap, the import volume, and the composition of lithium consumption will change with the rising demand of EES and NEVs. The model is simulated under three different demand level scenarios. The results show that the lithium market price will experience 2 processes in which the market price first gradually increases and is followed by a rapid decline, which is due to the incentive for upstream industries to increase production, resulting in oversupply. There are relatively large gaps between supply and demand, especially in later periods under a high NEV demand scenario. The import volume of lithium resources increases significantly after period 20 due to the rapid development of EES and NEVs. The import volume is much greater under the high scenario in later periods. The EES will play a significant role in the market, which tends to be ignored in the literature. Lithium recycling and extraction technologies, especially for brine, require a breakthrough to increase domestic production to cope with various challenges, including supply shortages and import risks.
C1 [Liu, Donghui; Gao, Xiangyun; An, Haizhong; Qi, Yabin; Sun, Xiaoqi; Wang, Ze; Chen, Zhihua; An, Feng; Jia, Nanfei] China Univ Geosci, Sch Econ & Management, Beijing 100083, Peoples R China.
   [Liu, Donghui; Gao, Xiangyun; An, Haizhong; Sun, Xiaoqi; Wang, Ze; Chen, Zhihua; An, Feng; Jia, Nanfei] Minist Nat Resources Peoples Republ China, Key Lab Carrying Capac Assessment Resource & Envi, Beijing 100083, Peoples R China.
   [Qi, Yabin] Natl Res Ctr Geoanal, Beijing, Peoples R China.
RP Gao, XY (reprint author), China Univ Geosci, Sch Econ & Management, Beijing 100083, Peoples R China.
EM gxy5669777@126.com
RI ; Gao, Xiangyun/R-6133-2016
OI An, Haizhong/0000-0002-6141-5619; Gao, Xiangyun/0000-0003-2101-1609
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [41871202, 71771022]; Humanities and Social Sciences
   planning funds project under the Ministry of Education of the PRC
   [17YJCZH047]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [265208247]; China Geological SurveyChina Geological Survey [DD20160227]
FX This research is supported by the National Natural Science Foundation of
   China (Grant No. 41871202, 71771022), the Humanities and Social Sciences
   planning funds project under the Ministry of Education of the PRC (Grant
   No. 17YJCZH047), the Fundamental Research Funds for the Central
   Universities (Grant No. 265208247), and the China Geological Survey
   (Grant No. DD20160227). The authors would also like to thank the
   anonymous reviewers for their comments and suggestions toward improving
   the manuscript.
CR Allena-Ozolina S, 2017, ENRGY PROCED, V128, P350, DOI 10.1016/j.egypro.2017.09.051
   Bertone E, 2018, APPL ENERG, V210, P409, DOI 10.1016/j.apenergy.2017.08.054
   Blumberga A., 2017, J CLEAN PROD
   Bradley D., 2014, LITHIUM HARNESSING R
   Ciez RE, 2016, J POWER SOURCES, V320, P310, DOI 10.1016/j.jpowsour.2016.04.073
   Dimitrovski A, 2007, INT J CRIT INFRASTRU, V3, P235, DOI 10.1504/IJCIS.2007.011553
   Elsawah S, 2017, ENVIRON MODELL SOFTW, V93, P127, DOI 10.1016/j.envsoft.2017.03.001
   Feng M., 2016, J HYDROL AMST, V543, P41
   Guney MS, 2017, RENEW SUST ENERG REV, V75, P1187, DOI 10.1016/j.rser.2016.11.102
   Guo LL, 2018, RESOUR CONSERV RECY, V128, P143, DOI 10.1016/j.resconrec.2016.09.035
   Hao H, 2017, RESOUR POLICY, V51, P100, DOI 10.1016/j.resourpol.2016.12.005
   He YX, 2017, ENERGY, V133, P9, DOI 10.1016/j.energy.2017.05.107
   Intelligence M., 2018, LITH MARK SEGM TYP A
   Jiao JL, 2014, APPL ENERG, V133, P363, DOI 10.1016/j.apenergy.2014.07.103
   Keilhacker ML, 2017, RESOUR CONSERV RECY, V125, P349, DOI 10.1016/j.resconrec.2017.05.004
   Kong R, 2017, RESOUR POLICY, V52, P19, DOI 10.1016/j.resourpol.2017.01.006
   lEA, 2018, OV REN WAST WORLD
   LEVENSPIEL O, 1980, CHEM ENG SCI, V35, P1821, DOI 10.1016/0009-2509(80)80132-1
   Liu XM, 2017, RENEW SUST ENERG REV, V73, P782, DOI 10.1016/j.rser.2017.02.019
   Luo ZB, 2017, RESOUR CONSERV RECY, V126, P186, DOI 10.1016/j.resconrec.2017.07.018
   Martin G, 2017, ENERGY STORAGE MATER, V6, P171, DOI 10.1016/j.ensm.2016.11.004
   Matinzadeh MM, 2017, ECOL MODEL, V347, P11, DOI 10.1016/j.ecolmodel.2016.12.014
   Morcillo JD, 2018, APPL ENERG, V216, P504, DOI 10.1016/j.apenergy.2018.02.104
   Simon B, 2014, METALL RES TECHNOL, V111, P191, DOI 10.1051/metal/2014010
   Song HS, 2017, TELECOMMUN POLICY, V41, P460, DOI 10.1016/j.telpol.2017.04.004
   Sterman J. D., 2002, SYSTEMS THINKING MOD
   Sterman JD, 2001, CALIF MANAGE REV, V43, P8, DOI 10.2307/41166098
   SVERDRUP H, 1983, CHEM SCRIPTA, V22, P12
   SVERDRUP H, 1988, WATER AIR SOIL POLL, V38, P387
   Sverdrup H., 1982, DISSOLUTION CALCITE
   Sverdrup HU, 2016, RESOUR CONSERV RECY, V114, P112, DOI 10.1016/j.resconrec.2016.07.002
   Timma L, 2017, ENERG POLICY, V109, P545, DOI 10.1016/j.enpol.2017.07.030
   USGS-United States Geological Survey, 2018, MINERAL COMMODITY SU
   Walters JP, 2016, ECOL MODEL, V333, P51, DOI 10.1016/j.ecolmodel.2016.04.015
   Wang D, 2018, RESOUR CONSERV RECY, V129, P432, DOI 10.1016/j.resconrec.2016.07.013
   Winslow KM, 2018, RESOUR CONSERV RECY, V129, P263, DOI 10.1016/j.resconrec.2017.11.001
   Xu Y, 2017, J CLEAN PROD, V165, P13, DOI 10.1016/j.jclepro.2017.07.093
   Zame KK, 2018, RENEW SUST ENERG REV, V82, P1646, DOI 10.1016/j.rser.2017.07.011
   Zeng XL, 2013, RESOUR CONSERV RECY, V80, P58, DOI 10.1016/j.resconrec.2013.08.003
   Zhao R, 2017, RESOUR CONSERV RECY, V124, P74, DOI 10.1016/j.resconrec.2017.04.010
   Ziemann S, 2018, RESOUR CONSERV RECY, V133, P76, DOI 10.1016/j.resconrec.2018.01.031
   2016, INT J HYDROGEN ENERG, V41, P2091, DOI DOI 10.1016/J.IJHYDENE.2016.06.243
   2017, ENERGY, V136, P1, DOI DOI 10.1016/J.ENERGY.2017.07.054
   2017, RESOUR CONSERV RECY, V124, P50, DOI DOI 10.1016/J.RESCONREC.2017.04.012
   2018, ENVIRON SCI TECHNOL, V52, P2827, DOI DOI 10.1021/ACS.EST.7B06092
   2017, JOULE, V1, P229, DOI DOI 10.1016/J.JOULE.2017.08.019
   2017, RESOUR CONSERV RECY, V119, P109, DOI DOI 10.1016/J.RESCONREC.2016.05.015
NR 47
TC 1
Z9 1
U1 18
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 311
EP 321
DI 10.1016/j.resconrec.2019.02.043
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200029
DA 2020-05-12
ER

PT J
AU Li, XY
   Ge, JP
   Chen, WQ
   Wang, P
AF Li, Xiang-Yang
   Ge, Jian-Ping
   Chen, Wei-Qiang
   Wang, Peng
TI Scenarios of rare earth elements demand driven by automotive
   electrification in China: 2018-2030
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Rare earth elements; Electric vehicles; Bass model; China
ID IN-USE STOCKS; MARKET PENETRATION; FLUORESCENT LAMPS; GAME ANALYSIS;
   MODEL; AUTOMOBILE; DIFFUSION; VEHICLES; CRITICALITY; METALS
AB China is accelerating automotive electrification to address the pressing oil shortage and environmental pollution issues. Automotive electrification can be achieved through four different major technology pathways: hybrid electric vehicles, plug-in hybrid electric vehicles, battery electric vehicles and fuel cell electric vehicles. These pathways all heavily rely on the use of critical mineral resources, such as rare earth elements (REEs). This study establishes different scenarios of the future technology mix and growth in automotive electrification in China by 2030 to predict the future demand of REEs associated with such scenarios. The widely applied Bass model is chosen to predict the future growth of these four technology pathways for electric vehicles under pessimistic, neutral and optimistic demand scenarios. Given the potential for technological advances, the effects of changes in the material intensity and component substitution are considered to effectively reflect future demand changes. Accordingly, the REE demand associated with the four technology pathways from 2018 to 2030 is estimated. The highest demand for REEs in automotive electrification will reach 315 thousand tons, accounting for 22% of global production during the prediction period. Specifically, the demands for Nd, Dy, Ce, Pr, and La will account for 51%, 20%, 12%, 9.5%, and 7.7% of the total demand, respectively. Moreover, the contrast between the supply and demand of Dy and Pr will be extremely large, and these elements will require more attention than others. For the successful development of automotive electrification in China, related policies and plans regarding the supplies of different types and quantities of REEs should be urgently established.
C1 [Li, Xiang-Yang; Ge, Jian-Ping] China Univ Geosci Beijing, Sch Econ & Management, Beijing 100083, Peoples R China.
   [Ge, Jian-Ping] Minist Nat Resources, Key Lab Carrying Capac Assessment Resources & Env, Beijing 100083, Peoples R China.
   [Chen, Wei-Qiang; Wang, Peng] Chinese Acad Sci, Key Lab Urban Environm & Hlth, Inst Urban Environm, Xiamen 361021, Fujian, Peoples R China.
RP Ge, JP (reprint author), China Univ Geosci Beijing, Sch Econ & Management, Beijing 100083, Peoples R China.; Chen, WQ (reprint author), Chinese Acad Sci, Key Lab Urban Environm & Hlth, Inst Urban Environm, Xiamen 361021, Fujian, Peoples R China.
EM gejianping@cugb.edu.cn; wqchen@iue.ac.cn
RI CAS, KLUEH/T-5743-2019; Wang, Peng/V-7927-2019
OI Wang, Peng/0000-0001-7170-1494
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71774149, 41671523]; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities [292018006, 292017023]; Beijing Social Science Foundation
   [16YJB031]; Key Laboratory of Carrying Capacity Assessment for Resources
   and the Environment, Ministry of Land and Resources [CCA2017.16]
FX This study is supported by grants from the National Natural Science
   Foundation of China (Grants nos. 71774149 and 41671523), the Fundamental
   Research Funds for the Central Universities (Grant nos. 292018006 and
   292017023), the Beijing Social Science Foundation (Grant no. 16YJB031)
   and the Key Laboratory of Carrying Capacity Assessment for Resources and
   the Environment, Ministry of Land and Resources (Grant no. CCA2017.16).
CR Alonso E, 2012, SAE INT J MATER MANU, V5, P473, DOI 10.4271/2012-01-1061
   Alonso E, 2012, ENVIRON SCI TECHNOL, V46, P3406, DOI 10.1021/es203518d
   Balakrishnan PV, 2014, PROD OPER MANAG, V23, P1183, DOI 10.1111/poms.12106
   BASS FM, 1969, MANAGE SCI, V15, P215, DOI 10.1287/mnsc.15.5.215
   Bicer Y, 2018, RESOUR CONSERV RECY, V132, P141, DOI 10.1016/j.resconrec.2018.01.036
   Binnemans K, 2013, J CLEAN PROD, V51, P1, DOI 10.1016/j.jclepro.2012.12.037
   Brusch M, 2015, STUD CLASS DATA ANAL, P229, DOI 10.1007/978-3-662-44983-7_20
   Chen WQ, 2015, P NATL ACAD SCI USA, V112, P6265, DOI 10.1073/pnas.1406866112
   Deetman S, 2018, ENVIRON SCI TECHNOL, V52, P4950, DOI 10.1021/acs.est.7b05549
   Du XY, 2011, J IND ECOL, V15, P836, DOI 10.1111/j.1530-9290.2011.00362.x
   Du XY, 2011, ENVIRON SCI TECHNOL, V45, P4096, DOI 10.1021/es102836s
   Eppstein MJ, 2011, ENERG POLICY, V39, P3789, DOI 10.1016/j.enpol.2011.04.007
   Field FR, 2017, ENVIRON SCI TECHNOL, V51, P14436, DOI 10.1021/acs.est.6b06063
   Ge JP, 2016, RESOUR POLICY, V50, P119, DOI 10.1016/j.resourpol.2016.09.002
   Ge Jianping, 2016, MINERALS, V6, P1
   Habib K, 2014, J CLEAN PROD, V84, P348, DOI 10.1016/j.jclepro.2014.04.035
   Han AP, 2016, RESOUR POLICY, V50, P149, DOI 10.1016/j.resourpol.2016.09.006
   Han AP, 2015, RESOUR POLICY, V46, P30, DOI 10.1016/j.resourpol.2015.07.007
   IEA (International Energy Agency), 2009, SOURCEOECD EN, V26, pi
   Ismai Z., 2016, AM I PHYS C SER, V1782, P149
   Jin HY, 2018, ENVIRON SCI TECHNOL, V52, P3796, DOI 10.1021/acs.est.7b05442
   Knobloch V, 2018, RESOUR CONSERV RECY, V138, P272, DOI 10.1016/j.resconrec.2018.05.027
   Kong D. Y., 2014, MATH PROBL ENG, V1, P1
   Li YS, 2017, INT CONF ENTERP SYST, P148, DOI 10.1109/ES.2017.31
   Liu Yingqi, 2016, EC MANAGEMENT STUDIE, V37, P86
   Liu ZW, 2018, ENERG POLICY, V115, P92, DOI 10.1016/j.enpol.2018.01.006
   Lucas A, 2012, ENERG POLICY, V41, P537, DOI 10.1016/j.enpol.2011.11.015
   Machacek E, 2015, RESOUR CONSERV RECY, V104, P76, DOI 10.1016/j.resconrec.2015.09.005
   Massiani J, 2015, RES TRANSP ECON, V50, P17, DOI 10.1016/j.retrec.2015.06.003
   McManus W., 2009, MARKET MODELS PREDIC
   Meshram P, 2017, J CLEAN PROD, V157, P322, DOI 10.1016/j.jclepro.2017.04.144
   MIIT, 2017, MED LONG TERM DEV PL
   MIIT (Ministry of Industry and Information Technology of the People's Republic of China), 2017, 2017 CHIN AUT IND YB
   MST (Ministry of Science and Technology of the People's Republic of China), 2018, EL VEH NEW EN VEH AC
   Ortego A, 2018, RESOUR CONSERV RECY, V136, P24, DOI 10.1016/j.resconrec.2018.04.006
   Park SY, 2011, ENERG POLICY, V39, P3307, DOI 10.1016/j.enpol.2011.03.021
   Pavel CC, 2017, SUSTAIN MATER TECHNO, V12, P62, DOI 10.1016/j.susmat.2017.01.003
   Rademaker JH, 2013, ENVIRON SCI TECHNOL, V47, P10129, DOI 10.1021/es305007w
   Ren B., 2013, SOFT SCI, V27, P17
   Restrepo E, 2017, ENVIRON SCI TECHNOL, V51, P1129, DOI 10.1021/acs.est.6b05743
   Riba JR, 2016, RENEW SUST ENERG REV, V57, P367, DOI 10.1016/j.rser.2015.12.121
   Rogers EM., 1962, DIFFISION INNOVATION
   Rollat A, 2016, WASTE MANAGE, V49, P427, DOI 10.1016/j.wasman.2016.01.011
   SAE-China, 2016, TECHN ROADM EN SAV N
   Schulze R, 2016, RESOUR CONSERV RECY, V113, P12, DOI 10.1016/j.resconrec.2016.05.004
   Shepherd S, 2012, TRANSPORT POLICY, V20, P62, DOI 10.1016/j.tranpol.2011.12.006
   Smith BJ, 2018, ENVIRON SCI TECHNOL, V52, P3803, DOI 10.1021/acs.est.7b05495
   State Council (State Council of the People's Republic of China), 2012, EN CONS NEW EN VEH I
   TAKADA H, 1991, J MARKETING, V55, P48, DOI 10.2307/1252237
   U. S. Department of Energy (DOE), 2010, CRITICAL MAT STRATEG
   USGS, 2018, MIN COMM SUMM 2018
   Wang QY, 2010, ENVIRON SCI TECHNOL, V44, P3870, DOI 10.1021/es903957e
   Wang XB, 2017, J CLEAN PROD, V154, P614, DOI 10.1016/j.jclepro.2017.03.200
   Wen B., 2017, CHINA MINING MAG, V26, P76
   Widmer JD, 2015, SUSTAIN MATER TECHNO, V3, P7, DOI 10.1016/j.susmat.2015.02.001
   Wu YF, 2014, RESOUR CONSERV RECY, V88, P21, DOI 10.1016/j.resconrec.2014.04.007
   Xu GC, 2016, J MATER CYCLES WASTE, V18, P469, DOI 10.1007/s10163-016-0487-y
   Yang XL, 2014, J HAZARD MATER, V279, P384, DOI 10.1016/j.jhazmat.2014.07.027
   2018, RESOUR CONSERV RECY, V139, P188, DOI DOI 10.1016/J.RESCONREC.2018.08.011
   2016, J MATER CYCLES WASTE, V18, P655, DOI DOI 10.1007/S10163-015-0360-4
NR 60
TC 2
Z9 2
U1 17
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 322
EP 331
DI 10.1016/j.resconrec.2019.02.003
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200030
DA 2020-05-12
ER

PT J
AU Aschemann-Witzel, J
   Gimenez, A
   Ares, G
AF Aschemann-Witzel, Jessica
   Gimenez, Ana
   Ares, Gaston
TI Household food waste in an emerging country and the reasons why:
   Consumer's own accounts and how it differs for target groups
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Consumer behaviour; Household; Qualitative; Target group;
   Emerging country
ID SUBOPTIMAL FOOD; PERCEPTION; BEHAVIOR; LOSSES; PREVENTION; PRODUCTS;
   ATTITUDE; DRIVERS; STORAGE; POINTS
AB A major share of food waste is caused in consumer households. Globally, this share is expected to increase with growing middle classes in emerging countries. Consumer behaviour factors causing food waste differ across the various food handling stages from purchase to use, as well as for the individual and the specific situation in question. In order to tackle food waste in the household, knowledge on the type of food wasted, the cause of waste, and the situation in which it occurs is needed for different target groups. Little research so far has studied household consumer related food waste in emerging countries. This study explored food waste in consumer's own accounts of a recent food waste incident in 540 Uruguayan households. It used a mixed-method approach composed of open-ended questions, which were analysed using content analysis. Differences in the frequency of mention of the identified categories between socioeconomic and sociodemographic groups were analysed. Results showed that leftovers and fresh vegetable and fruit were the categories most consumers recall wasting, and indicated that sub-optimality and prolonged storage were major reasons for discarding food. The higher the socioeconomic group, the greater the likelihood of wasting fresh produce, and the more often due to sub-optimality. Findings imply that avoidable food waste might increase with affluence levels. Public policies or collaborative public-private information or intervention campaigns directed at consumer households can more effectively contribute to decreasing food waste if targeted at the most relevant categories and causes of food waste.
C1 [Aschemann-Witzel, Jessica] Aarhus Univ, MAPP Ctr, Res Value Creat Food Sect, Fuglesangsalle 4, DK-8210 Aarhus V, Denmark.
   [Gimenez, Ana; Ares, Gaston] Univ Republ, Fac Quim, Inst Polo Tecnol Pando, Sensometr & Consumer Sci, By Pass Rutas 8 & 101 S-N, Pando 91000, Canelones, Uruguay.
RP Aschemann-Witzel, J (reprint author), Aarhus Univ, MAPP Ctr, Res Value Creat Food Sect, Fuglesangsalle 4, DK-8210 Aarhus V, Denmark.
EM jeaw@mgmt.au.dk; agimenez@fq.edu.uy; gares@fq.edu.uy
FU Danish Strategic Research CouncilDanske Strategiske Forskningsrad (DSF)
   [4144-00002A]; Comision Sectorial de Investigacion Cientifica and
   Espacio Interdisciplinario (Universidad de la Republica, Uruguay)
FX The study was conducted as part of the COSUS project funded by the
   Danish Strategic Research Council (Grant no. 4144-00002A. The Uruguayan
   team is indebted to Comision Sectorial de Investigacion Cientifica and
   Espacio Interdisciplinario (Universidad de la Republica, Uruguay) for
   financial support.
CR Aschemann-Witzel J, 2018, J MACROMARKETING, V38, P168, DOI 10.1177/0276146718763251
   Aschemann-Witzel J, 2018, FOOD QUAL PREFER, V68, P29, DOI 10.1016/j.foodqual.2018.01.020
   Aschemann-Witzel J, 2018, GLOBAL ENVIRON CHANG, V49, P85, DOI 10.1016/j.gloenvcha.2018.02.002
   Aschemann-Witzel J, 2018, FOOD QUAL PREFER, V63, P119, DOI 10.1016/j.foodqual.2017.08.007
   Aschemann-Witzel J, 2015, SUSTAINABILITY-BASEL, V7, P6457, DOI 10.3390/su7066457
   Bech-Larsen T, 2018, FOOD QUAL PREFER, V68, P191, DOI 10.1016/j.foodqual.2018.02.006
   Block LG, 2016, J PUBLIC POLICY MARK, V35, P292, DOI 10.1509/jppm.15.132
   Bove MI, 2008, ALIMENTOS BEBIDAS HO
   Chandon P, 2006, J MARKETING, V70, P118, DOI 10.1509/jmkg.70.4.118
   CINVE, 2016, IND NIV SOC PROP ACT
   de Hooge IE, 2017, FOOD QUAL PREFER, V56, P80, DOI 10.1016/j.foodqual.2016.09.012
   Edjabou ME, 2016, WASTE MANAGE, V52, P256, DOI 10.1016/j.wasman.2016.03.032
   Foley JA, 2011, NATURE, V478, P337, DOI 10.1038/nature10452
   Freyre G., 2002, CASA GRANDE SENZALA
   Gaiani S, 2018, WASTE MANAGE, V72, P17, DOI 10.1016/j.wasman.2017.11.012
   Ganglbauer E, 2013, ACM T COMPUT-HUM INT, V20, DOI 10.1145/2463579.2463582
   Hebrok M, 2017, J CLEAN PROD, V151, P380, DOI 10.1016/j.jclepro.2017.03.069
   Henz GP, 2017, HORTIC BRAS, V35, P472, DOI [10.1590/S0102-053620170402, 10.1590/s0102-053620170402]
   Hodges RJ, 2011, J AGR SCI, V149, P37, DOI 10.1017/S0021859610000936
   Jaeger SR, 2018, FOOD QUAL PREFER, V69, P10, DOI 10.1016/j.foodqual.2018.05.004
   Krippendorff K., 2004, CONTENT ANAL INTRO I
   Kulikovskaja V., 2017, J INT FOOD AGRIBUS M, V7, P1
   Kummu M, 2012, SCI TOTAL ENVIRON, V438, P477, DOI 10.1016/j.scitotenv.2012.08.092
   Langen N, 2015, PROC INST CIV ENG-WA, V168, P72, DOI 10.1680/warm.13.00036
   Morone P, 2018, J CLEAN PROD, V185, P749, DOI 10.1016/j.jclepro.2018.01.208
   Neff RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127881
   Parfitt J, 2010, PHILOS T R SOC B, V365, P3065, DOI 10.1098/rstb.2010.0126
   Parizeau K, 2015, WASTE MANAGE, V35, P207, DOI 10.1016/j.wasman.2014.09.019
   Porpino G, 2016, J ASS CONSUMER RES, V1, P41, DOI DOI 10.1086/684528
   Porpino G, 2015, INT J CONSUM STUD, V39, P619, DOI 10.1111/ijcs.12207
   Priefer C, 2016, RESOUR CONSERV RECY, V109, P155, DOI 10.1016/j.resconrec.2016.03.004
   Principato L., 2018, FOOD WASTE CONSUMER
   Quested TE, 2013, RESOUR CONSERV RECY, V79, P43, DOI 10.1016/j.resconrec.2013.04.011
   Romani S, 2018, APPETITE, V121, P215, DOI 10.1016/j.appet.2017.11.093
   Sautron V, 2015, APPETITE, V87, P90, DOI 10.1016/j.appet.2014.12.205
   Schanes K, 2018, J CLEAN PROD, V182, P978, DOI 10.1016/j.jclepro.2018.02.030
   Schmidt K, 2016, RESOUR CONSERV RECY, V111, P53, DOI 10.1016/j.resconrec.2016.04.006
   Silvennoinen K, 2014, BRIT FOOD J, V116, P1058, DOI 10.1108/BFJ-12-2012-0311
   Stancu V, 2016, APPETITE, V96, P7, DOI 10.1016/j.appet.2015.08.025
   Stefan V, 2013, FOOD QUAL PREFER, V28, P375, DOI 10.1016/j.foodqual.2012.11.001
   Steffen W, 2015, SCIENCE, V347, DOI 10.1126/science.1259855
   Terpstra MJ, 2005, BRIT FOOD J, V107, P526, DOI 10.1108/00070700510606918
   Thyberg KL, 2016, RESOUR CONSERV RECY, V106, P110, DOI 10.1016/j.resconrec.2015.11.016
   United Nations, 2015, SUST DEV GOALS GOAL
   Van Boxstael S, 2014, FOOD CONTROL, V37, P85, DOI 10.1016/j.foodcont.2013.08.043
   Van Herpen E., 2016, BEST PRACTICE ASSESS
   Visschers VHM, 2016, J ENVIRON PSYCHOL, V45, P66, DOI 10.1016/j.jenvp.2015.11.007
   Xue L, 2017, ENVIRON SCI TECHNOL, V51, P6618, DOI 10.1021/acs.est.7b00401
   2012, SOCIOL REV S2, V60, P121, DOI DOI 10.1111/1467-954X.12041
   2015, RESOUR CONSERV RECY, V101, P194, DOI DOI 10.1016/J.RESCONREC.2015.05.020
   2012, SOCIOL REV S2, V60, P102, DOI DOI 10.1111/1467-954X.12040
NR 51
TC 1
Z9 1
U1 11
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 332
EP 338
DI 10.1016/j.resconrec.2019.03.001
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200031
DA 2020-05-12
ER

PT J
AU Kiefer, CP
   Carrillo-Hermosilla, J
   Del Rio, P
AF Kiefer, Christoph P.
   Carrillo-Hermosilla, Javier
   Del Rio, Pablo
TI Building a taxonomy of eco-innovation types in firms. A quantitative
   perspective
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Eco-innovation; Cluster analyses; Spain; Small and medium-size
   enterprises; Circular economy
ID EMPIRICAL-EVIDENCE; ENVIRONMENTAL INNOVATION; CIRCULAR ECONOMY;
   TECHNOLOGY-PUSH; DRIVERS; PRODUCT; POLICY; DETERMINANTS; MANAGEMENT;
   GREEN
AB Eco-innovations, or innovations that reduce the environmental impacts of production and consumption activities, are considered crucial for sustainability transitions and a key element of a Circular Economy. Although previous contributions have acknowledged the existence of different types of eco-innovations (e.g., product vs. service or incremental vs. radical), a precise conceptualization of eco-innovation types, which takes into account its multifaceted character, is missing. Yet such a conceptualization is crucial in order to understand how eco-innovations contribute to a sustainable transition, how policy makers can promote different eco-innovation types, and how business practitioners can develop eco-innovations. This article covers this gap in the literature. Its aim is twofold: 1) to develop a quantitative method to categorise different eco-innovation types in a particular setting, taking into account their distinct features and dimensions; 2) to apply this method in a given sector and country, building a taxonomy of eco-innovation types. It draws on a survey of 197 Spanish industrial small and medium size enterprises (SMEs) which developed or adopted an eco-innovation between 2012 and 2013. The statistical analyses reveal the existence of a taxonomy of five eco-innovation types: systemic, externally driven, continuous improvement, radical (technology-push initiated) and eco-efficient. They differ in their techno-economic configurations, contribution to environmental sustainability and corporate goals and required changes in the firms. Specific policy and managerial implications are deducted.
C1 [Kiefer, Christoph P.; Del Rio, Pablo] CSIC, Inst Publ Policies & Goods IPP, Madrid, Spain.
   [Carrillo-Hermosilla, Javier] Univ Alcala UAH, Alcala De Henares, Spain.
RP Del Rio, P (reprint author), CSIC, Inst Publ Policies & Goods IPP, Madrid, Spain.
EM christoph.kiefer@csic.es; javier.carrillo@uah.es; pablo.delrio@csic.es
RI Carrillo-Hermosilla, Javier/K-2453-2012
OI Carrillo-Hermosilla, Javier/0000-0002-5566-8847; Kiefer, Christoph
   P./0000-0001-5414-9714
FU Spanish Ministry of Economy and Competitiveness [CSO2016-74888-C4-4-R];
   Chair of Corporate Social Responsibility at the University of Alcala
FX The research reported in this paper was partially funded by the Spanish
   Ministry of Economy and Competitiveness, research grant number
   CSO2016-74888-C4-4-R (AEI/FEDER, UE), and by the Chair of Corporate
   Social Responsibility at the University of Alcala.
CR Andersen M. M., 2008, DRUID C ENTR INN
   Ayyagari M, 2007, SMALL BUS ECON, V29, P415, DOI 10.1007/s11187-006-9002-5
   Belin J., 2011, DETERMINANTS SPECIFI
   Bocken NMP, 2014, J ENG TECHNOL MANAGE, V31, P43, DOI 10.1016/j.jengtecman.2013.10.004
   Brammer S, 2012, BUS STRATEG ENVIRON, V21, P423, DOI 10.1002/bse.717
   Braungart M, 2007, J CLEAN PROD, V15, P1337, DOI 10.1016/j.jclepro.2006.08.003
   CARRILLO-HERMOSILLA J., 2009, ECOINNOVATION SUSTAI
   Carrillo-Hermosilla J, 2010, J CLEAN PROD, V18, P1073, DOI 10.1016/j.jclepro.2010.02.014
   Castellacci F, 2017, J CLEAN PROD, V143, P1036, DOI 10.1016/j.jclepro.2016.12.016
   Coad A, 2016, RES POLICY, V45, P387, DOI 10.1016/j.respol.2015.10.015
   Csutora M., 2011, SOC EC, V33, P161, DOI DOI 10.1556/SOCEC.33.2011.1.12
   Cuerva MC, 2014, J CLEAN PROD, V68, P104, DOI 10.1016/j.jclepro.2013.10.049
   de Jesus A, 2018, ECOL ECON, V145, P75, DOI 10.1016/j.ecolecon.2017.08.001
   De Marchi V, 2012, RES POLICY, V41, P614, DOI 10.1016/j.respol.2011.10.002
   Del Rio G. P., 2005, BUSINESS STRATEGY EN, V14, P20, DOI DOI 10.1002/BSE.426
   del Rio P, 2015, BUS STRATEG ENVIRON, V24, P361, DOI 10.1002/bse.1822
   del Rio P, 2010, J IND ECOL, V14, P541, DOI 10.1111/j.1530-9290.2010.00259.x
   EU, 2012, SMALL CO BIG ID
   European Commission, 2017, WHAT IS SME
   Field A. P., 2013, DISCOVERING STAT USI, DOI [10.1024/1012-5302/a000397, DOI 10.1024/1012-5302/A000397]
   Forsman H, 2009, INT J INNOV MANAG, V13, P501, DOI 10.1142/S1363919609002492
   Franco MA, 2017, J CLEAN PROD, V168, P833, DOI 10.1016/j.jclepro.2017.09.056
   Frondel M, 2008, ECOL ECON, V66, P153, DOI 10.1016/j.ecolecon.2007.08.016
   Garcia-Granero EM, 2018, J CLEAN PROD, V191, P304, DOI 10.1016/j.jclepro.2018.04.215
   Hair J.F., 2010, MULTIVARIATE DATA AN
   Hair JF, 1998, MULTIVARIATE DATA AN
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   Horbach J, 2008, RES POLICY, V37, P163, DOI 10.1016/j.respol.2007.08.006
   Horbach J, 2018, BUS STRATEG ENVIRON, V27, P924, DOI 10.1002/bse.2042
   Horbach J, 2012, ECOL ECON, V78, P112, DOI 10.1016/j.ecolecon.2012.04.005
   Kammerer D, 2009, ECOL ECON, V68, P2285, DOI 10.1016/j.ecolecon.2009.02.016
   Kemp R., 2007, 04451324 EU
   Kesidou E, 2012, RES POLICY, V41, P862, DOI 10.1016/j.respol.2012.01.005
   Keskin D, 2013, J CLEAN PROD, V45, P50, DOI 10.1016/j.jclepro.2012.05.012
   Kiefer CP, 2017, J CLEAN PROD, V166, P1494, DOI 10.1016/j.jclepro.2017.07.241
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Klewitz J., 2012, J SMALL BUSINESS ENT, V25, P451, DOI DOI 10.1080/08276331.2012.10593584
   Klewitz J, 2014, J CLEAN PROD, V65, P57, DOI 10.1016/j.jclepro.2013.07.017
   Klewitz J, 2012, EUR J INNOV MANAG, V15, P442, DOI 10.1108/14601061211272376
   Likas A., 2011, ISA TECHNICAL REPORT
   Machiba T., 2010, INT EC EC POL, V7, P357, DOI DOI 10.1007/S10368-010-0171-Y
   Marin G., 2014, SEEDS WORKING PAPERS, DOI [10.1007/s00191-015-0407-7, DOI 10.1007/S00191-015-0407-7]
   Mazzanti M., 2005, EC POLIT, VXXII, P399
   McDonough W., 2010, CRADLE CRADLE REMAKI
   Nemet GF, 2009, RES POLICY, V38, P700, DOI 10.1016/j.respol.2009.01.004
   OECD, 2009, SUST MAN EC FRAM PRA
   Rave T., 2011, DETERMINANTS ENV INN
   Rehfeld KM, 2007, ECOL ECON, V61, P91, DOI 10.1016/j.ecolecon.2006.02.003
   Rennings K, 2006, ECOL ECON, V57, P45, DOI 10.1016/j.ecolecon.2005.03.013
   Saez-Martinez FJ, 2016, J CLEAN PROD, V138, P28, DOI 10.1016/j.jclepro.2016.04.108
   Triguero A, 2015, INNOV-MANAG POLICY P, V17, P24, DOI 10.1080/14479338.2015.1011059
   Triguero A, 2013, ECOL ECON, V92, P25, DOI 10.1016/j.ecolecon.2013.04.009
   Veugelers R, 2012, RES POLICY, V41, P1770, DOI 10.1016/j.respol.2012.06.012
   Wagner M., 2007, RES POLICY
   Wagner M, 2011, IND INNOV, V18, P747, DOI 10.1080/13662716.2011.621744
   Wagstaff K., 2001, P 18 INT C MACH LEAR, P577, DOI DOI 10.1109/TPAMI.2002.1017616
   Walz R., 2011, UN C PROM EC POL OPP
   Xavier AF, 2017, J CLEAN PROD, V149, P1278, DOI 10.1016/j.jclepro.2017.02.145
   2017, J CLEAN PROD, V142, P2277, DOI DOI 10.1016/J.JCLEPRO.2016.11.049
   2018, RESOUR CONSERV RECY, V129, P81, DOI DOI 10.1016/J.RESCONREC.2017.10.019
NR 60
TC 2
Z9 2
U1 11
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 339
EP 348
DI 10.1016/j.resconrec.2019.02.021
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200032
DA 2020-05-12
ER

PT J
AU Li, JL
   Lin, BQ
AF Li, Jianglong
   Lin, Boqiang
TI The sustainability of remarkable growth in emerging economies
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Remarkable growth; STFP; Driving forces; Emerging economies
ID ENERGY-CONSUMPTION; DECOMPOSITION ANALYSIS; INTERNATIONAL-TRADE; CO2
   EMISSIONS; TECHNOLOGICAL-PROGRESS; CHINA; PERFORMANCE; ENVIRONMENT;
   PRICE; PRODUCTIVITY
AB The remarkable GDP growth along with the dramatic increases in energy consumption and pollution emissions in emerging economies raise the concerns for the sustainability of their development pattern. However, the precise role of how energy and environment contribute to economic growth in emerging economies is still unknown. This paper explores the sustainability of remarkable GDP growth in emerging economies by using non-radial directional distance function (NDDF) to identify the sustainable total-factor productivity (STEP) growth in the emerging economies and comparing it with that in developed economies. Our research extends previous literature by highlighting the roles of energy and environment in economic growth. The results raise the concerns on the sustainability of the remarkable GDP growth (especially after 2000) in emerging economies due to their slow STFP growth after excluding the contributions from energy and environment. Furthermore, it is also found that compared with developed economies, the slower STFP growth in emerging economies is mainly caused by their disadvantages in innovation, although they are able to utilize existing technology by catch-up effect. Besides, analysis from the group heterogeneity among Asia, Eastern Europe and Latin America gives a better grasp of implications for stimulating the sustainable growth in emerging economies by promoting technology spillover from developed economies.
C1 [Li, Jianglong] Xi An Jiao Tong Univ, Sch Econ & Finance, Xian 710061, Shaanxi, Peoples R China.
   [Li, Jianglong] Harvard Univ, John A Paulson Sch Engn & Appl Sci, Harvard China Project, Cambridge, MA 02138 USA.
   [Lin, Boqiang] Xiamen Univ, Collaborat Innovat Ctr Energy Econ & Energy Polic, China Inst Studies Energy Policy, Sch Management, Xiamen 361005, Fujian, Peoples R China.
RP Lin, BQ (reprint author), Xiamen Univ, Collaborat Innovat Ctr Energy Econ & Energy Polic, China Inst Studies Energy Policy, Sch Management, Xiamen 361005, Fujian, Peoples R China.
EM bqlin@xmu.edu.cn
RI Lin, Boqiang/G-3960-2010
OI Lin, Boqiang/0000-0002-1308-400X
FU Xiamen University Flourish Plan Special Funding [1260-Y07200]; National
   Natural Foundation of ChinaNational Natural Science Foundation of China
   [71703120]; Social Science and Humanity Fund of the Ministry of
   Education [17YJC790068]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2016M602784, 2016M600772]; Special
   Foundation of China Postdoctoral Science [2018T111028, 2017T100729];
   Postdoctoral Science Foundation in Shaanxi Province [2017BSHTDZZ07];
   International Clean Energy Talents Program of China Scholarship Council
FX The paper is supported by Xiamen University Flourish Plan Special
   Funding (No: 1260-Y07200), National Natural Foundation of China (No:
   71703120), Social Science and Humanity Fund of the Ministry of Education
   (No: 17YJC790068), China Postdoctoral Science Foundation (Grant nos.
   2016M602784 and 2016M600772), Special Foundation of China Postdoctoral
   Science (Grant nos. 2018T111028 and 2017T100729), Postdoctoral Science
   Foundation in Shaanxi Province (No. 2017BSHTDZZ07), and the
   International Clean Energy Talents Program of China Scholarship Council
   (No. Liujinfa[2017]5047).
CR Ang BW, 2015, ENERG ECON, V51, P67, DOI 10.1016/j.eneco.2015.06.004
   Ang BW, 2004, ENERG POLICY, V32, P1131, DOI 10.1016/S0301-4215(03)00076-4
   Arrow KJ, 2012, ENVIRON DEV ECON, V17, P317, DOI 10.1017/S1355770X12000137
   Bas M, 2014, J COMP ECON, V42, P569, DOI 10.1016/j.jce.2013.06.005
   Cao BR, 2017, J CLEAN PROD, V142, P1002, DOI 10.1016/j.jclepro.2016.08.145
   Chen E.K., 1997, ASIAN-PAC ECON LIT, V11, P18, DOI DOI 10.1111/1467-8411.00002
   Chen SY, 2014, ENERG ECON, V44, P89, DOI 10.1016/j.eneco.2014.04.002
   Chen SY, 2009, FRONT ECON CHINA, V4, P548, DOI 10.1007/s11459-009-0029-9
   Chung YH, 1997, J ENVIRON MANAGE, V51, P229, DOI 10.1006/jema.1997.0146
   Considine TJ, 2006, J ENVIRON ECON MANAG, V52, P645, DOI 10.1016/j.jeem.2006.07.001
   Davis SJ, 2011, P NATL ACAD SCI USA, V108, P18554, DOI 10.1073/pnas.1107409108
   Du G, 2018, J CLEAN PROD, V184, P1102, DOI 10.1016/j.jclepro.2018.02.304
   Fare R, 2007, ENERGY, V32, P1055, DOI 10.1016/j.energy.2006.09.005
   Feng C, 2017, J CLEAN PROD, V144, P323, DOI 10.1016/j.jclepro.2017.01.005
   Fisher-Vanden K, 2004, RESOUR ENERGY ECON, V26, P77, DOI 10.1016/j.resenecco.2003.07.002
   Forslid R, 2018, J ENVIRON ECON MANAG, V91, P166, DOI 10.1016/j.jeem.2018.07.006
   HAMILTON JD, 1983, J POLIT ECON, V91, P228, DOI 10.1086/261140
   Hsieh CT, 2002, AM ECON REV, V92, P502, DOI 10.1257/00028280260136372
   International Monetary Fund (IMF), 2015, WORLD ECONOMIC OUTL
   Jagannathan R., 2017, BUR EC RES B AGING H
   Jorgenson D.W., 1987, PRODUCTIVITY US EC G
   Jorgenson DW, 2000, AM ECON REV, V90, P161, DOI 10.1257/aer.90.2.161
   Kilian L, 2009, AM ECON REV, V99, P1053, DOI 10.1257/aer.99.3.1053
   KRUGMAN P, 1994, FOREIGN AFF, V73, P62, DOI 10.2307/20046929
   Lee S, 2016, RESOUR CONSERV RECY, V107, P220, DOI 10.1016/j.resconrec.2016.01.003
   Li J., 2016, SUSTAINABILITY, V8, P1
   Li JL, 2017, RENEW SUST ENERG REV, V72, P83, DOI 10.1016/j.rser.2017.01.044
   Li JL, 2017, ENERG POLICY, V101, P366, DOI 10.1016/j.enpol.2016.10.036
   Lin BQ, 2014, ENERG POLICY, V74, P589, DOI 10.1016/j.enpol.2014.08.031
   LOPEZ R, 1994, J ENVIRON ECON MANAG, V27, P163, DOI 10.1006/jeem.1994.1032
   Meng X, 2018, RESOUR CONSERV RECY, V128, P508, DOI 10.1016/j.resconrec.2016.09.032
   Munir K, 2018, MANAG ENVIRON QUAL, V29, P1123, DOI 10.1108/MEQ-05-2018-0087
   Oh DH, 2010, ENERG ECON, V32, P146, DOI 10.1016/j.eneco.2009.07.006
   Ouyang XL, 2018, ENERG POLICY, V118, P573, DOI 10.1016/j.enpol.2018.04.022
   Ouyang XL, 2018, ENERGY, V145, P408, DOI 10.1016/j.energy.2018.01.009
   Peters GP, 2011, P NATL ACAD SCI USA, V108, P8903, DOI 10.1073/pnas.1006388108
   Sadorsky P, 2010, ENERG POLICY, V38, P2528, DOI 10.1016/j.enpol.2009.12.048
   Shen XB, 2017, RESOUR CONSERV RECY, V127, P21, DOI 10.1016/j.resconrec.2017.08.010
   Song ML, 2018, PROCESS SAF ENVIRON, V116, P745, DOI 10.1016/j.psep.2017.08.042
   Song ML, 2018, MANAGE DECIS, V56, P188, DOI 10.1108/MD-04-2017-0375
   Stern N, 2008, AM ECON REV, V98, P1, DOI 10.1257/aer.98.2.1
   Sun JW, 1998, ENERG ECON, V20, P85, DOI 10.1016/S0140-9883(97)00012-1
   Topalova P, 2011, REV ECON STAT, V93, P995, DOI 10.1162/REST_a_00095
   Wang SH, 2017, SCI TOTAL ENVIRON, V595, P201, DOI 10.1016/j.scitotenv.2017.03.243
   WECD, 1987, OUR COMMON FUTURE
   Yin Z, 2018, INT J PROD RES, V56, P4300, DOI 10.1080/00207543.2017.1410246
   YOUNG A, 1994, EUR ECON REV, V38, P964, DOI 10.1016/0014-2921(94)90132-5
   Zhang N, 2013, ENERG ECON, V40, P549, DOI 10.1016/j.eneco.2013.08.012
   Zhou P, 2012, EUR J OPER RES, V221, P625, DOI 10.1016/j.ejor.2012.04.022
   Zhou P, 2012, APPL ENERG, V90, P196, DOI 10.1016/j.apenergy.2011.02.025
   2017, EC MODEL, V64, P334, DOI DOI 10.1016/J.ECONMOD.2017.04.007
   2006, ENERG ECON, V28, P690, DOI DOI 10.1016/J.ENECO.2006.05.006
NR 52
TC 5
Z9 5
U1 6
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 349
EP 358
DI 10.1016/j.resconrec.2019.01.036
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200033
DA 2020-05-12
ER

PT J
AU Yousef, S
   Tatariants, M
   Tichonovas, M
   Sarwar, Z
   Jonuskiene, I
   Kliucininkas, L
AF Yousef, Samy
   Tatariants, Maksym
   Tichonovas, Martynas
   Sarwar, Zahid
   Jonuskiene, Ilona
   Kliucininkas, Linas
TI A new strategy for using textile waste as a sustainable source of
   recovered cotton
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Cotton; Textile waste; Recycling; Cotton fiber recovery; Polyester;
   Dimethyl sulfoxide
ID PRINTED-CIRCUIT BOARDS; OPTIMIZATION; CONSUMPTION; POLYESTER; ETHANOL;
   IMPACT; REUSE
AB Cotton is one of the primary resources in many modern industries and with increasing demand rates the current challenge is to find other sources of cotton production with lower prices and higher quality whereas cotton produced only by agriculture is not sufficient for these needs. This is focused on developing a new strategy to make the textile waste a new sustainable source of recovered cotton to face this shortage. This strategy is summarized as development of a chemical technology using sustainable and commercial chemicals to recover cotton from waste textile. The technology consists of three sequential processes: a) textile dye leaching using Nitric Acid as a pretreatment of the original waste, b) dissolution process using Dimethyl Sulfoxide (DMSO) as the main treatment to dissolve the organic materials from the treated fabric, including polyester and remaining organic part from textile dyes, and c) bleaching process using sodium hypochlorite and diluted hydrochloric acid for final recovered cotton purification. Preliminary experiments were performed at a laboratory scale to determine the optimum conditions on a few grams of two different types of denim fabric. To simulate the pilot scale, the main experimental work was conducted for full-size blue and black waste jeans trousers in a developed reactor with capacity 1 kg based on the preliminary experimental results. To close the lifecycle loop of the suggested strategy, rotary evaporator was used to extract the polymeric part and regenerate the spent DMSO, while the acid was regenerated by activated carbon. Additionally, suggestions on treatment of the water contaminated by acid and solvent (obtained after washing) were given. Morphology, thermal behavior, and chemical structure of the recovered cotton, regenerated acid, solvent, and recovered polyester were investigated. Based on the recycling rate (93%), profitability (1466 $/ tonne), greenhouse gas emissions (-1,534 CO(2-eq/)tonne), and sustainability assessment, the developed strategy can be seen as a high-potential approach for recovery of cotton.
C1 [Yousef, Samy] Kaunas Univ Technol, Fac Mech Engn & Design, Dept Prod Engn, LT-51424 Kaunas, Lithuania.
   [Tatariants, Maksym; Tichonovas, Martynas; Sarwar, Zahid; Kliucininkas, Linas] Kaunas Univ Technol, Fac Chem Technol, Dept Environm Technol, LT-50254 Kaunas, Lithuania.
   [Jonuskiene, Ilona] Kaunas Univ Technol, Fac Chem Technol, Dept Organ Chem, LT-50254 Kaunas, Lithuania.
   [Yousef, Samy] Akhbar Elyom Acad, Dept Prod Engn & Printing Technol, 6th Of October, Egypt.
RP Yousef, S (reprint author), Kaunas Univ Technol, Fac Mech Engn & Design, Dept Prod Engn, LT-51424 Kaunas, Lithuania.
EM ahmed.saed@ktu.lt
RI Tatariants, Maksym/O-4559-2019; Yousef, Samy/F-1042-2016
OI Tatariants, Maksym/0000-0002-5952-9801; Yousef, Samy/0000-0002-4846-3202
CR Agarwal B, 2013, CUTTING COTTON CARBO
   Bansal A, 2016, RENEW SUST ENERG REV, V58, P141, DOI 10.1016/j.rser.2015.12.122
   Byrne F. P., 2016, SUSTAINABLE CHEM PRO, V4, P7, DOI [10.1186/s40508-016-0051-z., DOI 10.1186/S40508-016-0051-Z]
   Chapagain AK, 2006, ECOL ECON, V60, P186, DOI 10.1016/j.ecolecon.2005.11.027
   Chen XJ, 2018, RESOUR CONSERV RECY, V137, P316, DOI 10.1016/j.resconrec.2018.06.011
   EEA, 2014, EEA GREENH GAS DAT V
   Esteve-Turrillas FA, 2017, RESOUR CONSERV RECY, V116, P107, DOI 10.1016/j.resconrec.2016.09.034
   Fortuna LM, 2017, WASTE MANAGE, V66, P178, DOI 10.1016/j.wasman.2017.04.032
   Garcia R, 2014, J CLEAN PROD, V66, P199, DOI 10.1016/j.jclepro.2013.11.073
   Gaspar D, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/9/094008
   Ge YT, 2018, APPL ENERG, V226, P935, DOI 10.1016/j.apenergy.2018.06.020
   Gert EV, 2000, CELLULOSE, V7, P57, DOI 10.1023/A:1009206113613
   Ghasemi M, 2017, BIORESOURCE TECHNOL, V228, P330, DOI 10.1016/j.biortech.2016.12.049
   Gholamzad E, 2014, CHEM ENG J, V253, P40, DOI 10.1016/j.cej.2014.04.109
   Hasanzadeh E, 2018, FUEL, V218, P41, DOI 10.1016/j.fuel.2018.01.035
   Hu YZ, 2018, RESOUR CONSERV RECY, V129, P27, DOI 10.1016/j.resconrec.2017.09.024
   Huang BJ, 2017, RESOUR CONSERV RECY, V119, P69, DOI 10.1016/j.resconrec.2016.06.013
   Karthik T, 2013, FIBER POLYM, V14, P465, DOI 10.1007/s12221-013-0465-0
   Khamparia S, 2017, FRONT ENV SCI ENG, V11, DOI [10.1007/s11783-017-0899-5, 10.1007/s11783-017-0899]
   Kobayashi S, 2005, J POLYM SCI POL CHEM, V43, P693, DOI 10.1002/pola.20662
   Kusuktham B, 2010, J MET MATER MINER, V20, P85
   Lee J, 2013, MATERIALS, V6, P2007, DOI 10.3390/ma6052007
   Li H, 2018, J CLEAN PROD, V195, P476, DOI 10.1016/j.jclepro.2018.05.259
   Li W., 2018, FUEL, DOI [10.1016/j.fue1.2018.06.041, DOI 10.1016/J.FUE1.2018.06.041]
   Liebert T., 2010, ACS SYM SER, V1033, P3, DOI DOI 10.1021/BK-2010-1033.CH001
   Luiken A., 2015, WOODHEAD PUBLISHING, DOI [10.1016/B978-0-85709-843-6.00018-47, DOI 10.1016/B978-0-85709-843-6.00018-47]
   Lv FJ, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.37
   Lynn CJ, 2018, RESOUR CONSERV RECY, V136, P306, DOI 10.1016/j.resconrec.2018.04.029
   Memon AA, 2017, SOL ENERGY, V150, P521, DOI 10.1016/j.solener.2017.04.052
   Norup N., 2018, WASTE MANAGE, DOI [10.1016/j.wasman.2018.07.0089.innovation/projects/en/projects/t4t8, DOI 10.1016/J.WASMAN.2018.07.0089.INNOVATION/PROJECTS/EN/PROJECTS/T4T8]
   Nunes LJR, 2018, J CLEAN PROD, V171, P1353, DOI 10.1016/j.jclepro.2017.10.154
   Oldenborg KA, 2019, SCI TOTAL ENVIRON, V650, P1969, DOI 10.1016/j.scitotenv.2018.09.298
   Otlowska O, 2018, MOLECULES, V23, DOI 10.3390/molecules23020339
   Ozturk B., 2018, SEP PURIF TECHNOL, DOI [10.1016/Lseppur.2018.05.052, DOI 10.1016/LSEPPUR.2018.05.052]
   Peng HF, 2017, J MOL LIQ, V241, P959, DOI 10.1016/j.molliq.2017.06.103
   Rahimi MH, 2011, J SURFACTANTS DETERG, V14, P595, DOI 10.1007/s11743-011-1255-6
   Rajkumar R, 2016, INT J POLYM ANAL CH, V21, P359, DOI 10.1080/1023666X.2016.1160509
   Sandin G., 2018, J CLEAN PROD, DOI [10.1016/jjclepro.2018.02.266, DOI 10.1016/JJCLEPRO.2018.02.266]
   Sandin G, 2018, J CLEAN PROD, V184, P353, DOI 10.1016/j.jclepro.2018.02.266
   Shu JH, 2017, RSC ADV, V7, P14395, DOI 10.1039/c7ra00287d
   Silva RV, 2019, RESOUR CONSERV RECY, V140, P23, DOI 10.1016/j.resconrec.2018.09.011
   Tatariants M, 2017, RSC ADV, V7, P37729, DOI 10.1039/c7ra07034a
   Turner DA, 2015, RESOUR CONSERV RECY, V105, P186, DOI 10.1016/j.resconrec.2015.10.026
   Wang HM, 2018, PROCESS SAF ENVIRON, V118, P143, DOI 10.1016/j.psep.2018.06.038
   Wang HH, 2017, MOLECULES, V22, DOI 10.3390/molecules22091419
   Yang CR, 2017, ACS SUSTAIN CHEM ENG, V5, P3524, DOI 10.1021/acssuschemeng.7b00245
   Zamani B, 2015, J IND ECOL, V19, P676, DOI 10.1111/jiec.12208
   Zhou X, 2016, ACS SUSTAIN CHEM ENG, V4, P5585, DOI 10.1021/acssuschemeng.6b01408
NR 48
TC 7
Z9 7
U1 30
U2 61
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 359
EP 369
DI 10.1016/j.resconrec.2019.02.031
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200034
DA 2020-05-12
ER

PT J
AU Huang, L
   Wang, DL
   He, C
   Pan, M
   Zhang, BJ
   Chen, QL
   Ren, JZ
AF Huang, Liu
   Wang, Dongliang
   He, Chang
   Pan, Ming
   Zhang, Bingjian
   Chen, Qinglin
   Ren, Jingzheng
TI Industrial wastewater desalination under uncertainty in coal-chemical
   eco-industrial parks
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Wastewater desalination; Uncertainty; Reverse osmosis; Data processing
   strategy; Robust design
ID GAS FLOWBACK WATER; OPTIMIZATION; ENERGY; TECHNOLOGIES; DESIGN; MODEL
AB This work proposes a stochastic multi-scenario model for the robust design of industrial wastewater desalination under uncertainty. For fully accommodating the diverse nature of wastewater variability, multiple uncertain design parameters consisting of salt concentration, flowrate, and inlet temperature of wastewater are taken into account for the realization of uncertainty. A three-step stochastic strategy for data processing including uncertainty characterization and quantification, data sampling, and data propagation is developed to generate a proper size of feeding scenarios. The detailed process model of the dual-stage reverse osmosis is incorporated in the optimization model for minimizing the expected specific production cost. Finally, we illustrate the applicability and effectiveness of the proposed stochastic multi-scenario model with an example from a coal-chemical eco-industrial park.
C1 [Huang, Liu] Guangdong Pharmaceut Univ, Sch Chem & Chem Engn, Zhongshan 528458, Peoples R China.
   [Wang, Dongliang] LanZhou Univ Technol, Sch Petrochem Engn, Lanzhou 730050, Gansu, Peoples R China.
   [He, Chang; Pan, Ming; Zhang, Bingjian; Chen, Qinglin] Sun Yet Sen Univ, Guangdong Engn Technol Res Ctr Petrochem Energy C, Sch Chem Engn & Technol, Guangzhou 510275, Guangdong, Peoples R China.
   [Ren, Jingzheng] Hong Kong Polytech Univ, Dept Ind & Syst Engn, Hong Kong, Peoples R China.
RP He, C (reprint author), Sun Yet Sen Univ, Guangdong Engn Technol Res Ctr Petrochem Energy C, Sch Chem Engn & Technol, Guangzhou 510275, Guangdong, Peoples R China.
EM hechang6@mail.sysu.edu.cn
OI Ren, Jingzheng/0000-0002-9690-5183
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21606261, 51776228]; Major Projects for Science and
   Technology of Gansu Province [18ZD2GD014]
FX Financial supports from the National Natural Science Foundation of China
   (No. 21606261, 51776228) and the Major Projects for Science and
   Technology of Gansu Province (No. 18ZD2GD014) are gratefully
   acknowledged.
CR Abass M, 2016, IND ENG CHEM RES, V55, P1995, DOI 10.1021/acs.iecr.5b03423
   An D, 2017, RESOUR CONSERV RECY, V119, P36, DOI 10.1016/j.resconrec.2016.08.002
   Andiappan V, 2016, J CLEAN PROD, V129, P496, DOI 10.1016/j.jclepro.2016.04.023
   Asatekin A, 2007, J MEMBRANE SCI, V298, P136, DOI 10.1016/j.memsci.2007.04.011
   ELHALWAGI MM, 1997, POLLUTION PREVENTION
   FILMTEC&TRADE; D., 2018, FLMTECTM REV OSM MEM
   Gencer E, 2018, RESOUR CONSERV RECY, V133, P331, DOI 10.1016/j.resconrec.2018.01.030
   Ghobeity A, 2010, DESALINATION, V263, P76, DOI 10.1016/j.desal.2010.06.041
   Gupta VK, 2012, RSC ADV, V2, P6380, DOI 10.1039/c2ra20340e
   Karuppiah R, 2012, AICHE J, V58, P2758, DOI 10.1002/aic.13880
   Khor CS, 2012, COMPUT CHEM ENG, V42, P48, DOI 10.1016/j.compchemeng.2012.02.020
   LAW A, 1991, SIMULATION MODELING
   Li MH, 2015, AICHE J, V61, P1233, DOI 10.1002/aic.14715
   Lu YY, 2007, J MEMBRANE SCI, V287, P219, DOI 10.1016/j.memsci.2006.10.037
   Malaeb L, 2011, DESALINATION, V267, P1, DOI 10.1016/j.desal.2010.09.001
   Misener R, 2014, J GLOBAL OPTIM, V59, P503, DOI 10.1007/s10898-014-0166-2
   Onishi VC, 2017, COMPUT-AIDED CHEM EN, V40A, P943, DOI 10.1016/B978-0-444-63965-3.50159-8
   Onishi VC, 2017, J CLEAN PROD, V164, P1219, DOI 10.1016/j.jclepro.2017.06.243
   Park C, 2010, J MEMBRANE SCI, V364, P52, DOI 10.1016/j.memsci.2010.07.055
   Shastri Y, 2011, IND ENG CHEM RES, V50, P4879, DOI 10.1021/ie101355x
   Subramanyan K, 2011, COMPUT CHEM ENG, V35, P2667, DOI 10.1016/j.compchemeng.2011.02.003
   Tiu BTC, 2017, RESOUR CONSERV RECY, V119, P89, DOI 10.1016/j.resconrec.2016.06.005
   Wang JW, 2014, J MEMBRANE SCI, V454, P516, DOI 10.1016/j.memsci.2013.12.034
   Wang SH, 2018, DESALINATION, V446, P83, DOI 10.1016/j.desal.2018.08.020
   Werber JR, 2017, DESALINATION, V402, P109, DOI 10.1016/j.desal.2016.09.028
   Williams CM, 2012, DESALINATION, V301, P42, DOI 10.1016/j.desal.2012.06.009
   Yang LL, 2014, IND ENG CHEM RES, V53, P17680, DOI 10.1021/ie500978h
   Zhu QP, 2017, ACS SUSTAIN CHEM ENG, V5, P10792, DOI 10.1021/acssuschemeng.7b02758
NR 28
TC 1
Z9 1
U1 6
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 370
EP 378
DI 10.1016/j.resconrec.2019.02.036
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200035
DA 2020-05-12
ER

PT J
AU Chen, JD
   Xu, C
   Managi, S
   Song, M
AF Chen, Jiandong
   Xu, Chong
   Managi, Shunsuke
   Song, Mahn
TI Energy-carbon performance and its changing trend: An example from
   China's construction industry
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Construction industry; Energy-carbon performance; Non-radical
   directional distance functions; Convergence analysis
ID LIFE-CYCLE ASSESSMENT; CO2 EMISSIONS; ENVIRONMENTAL IMPACTS; BUILDING
   CONSTRUCTION; CONVERGENCE ANALYSIS; DIOXIDE EMISSIONS; ECONOMIC-GROWTH;
   CONSUMPTION; EFFICIENCY; MODEL
AB Understanding energy-carbon performance (ECP) and its intrinsic characteristics is important for energy saving and emissions reduction in the construction industry. However, few studies have focused on energy or carbon performance simultaneously and their pattern over time. To address this gap, this study investigated the ECP in China's construction industry and its convergence characteristics across various provinces. We first constructed an ECP index (ECPI) using non-radical directional distance functions for the construction industry during 2003-2016. We then analyzed the convergence of ECPI using the convergence method proposed by Phillis and Sul (2007). The results showed that the overall ECPI was generally stable with some fluctuations over the sampling period, and there was no evidence to support the occurrence of convergence in the ECPI across the sample set. Furthermore, two club convergences of ECPI were recorded. Finally, we propose valuable suggestions for policymakers based on empirical results.
C1 [Chen, Jiandong] Southwestern Univ Finance & Econ, Sch Publ Adm, Chengdu, Sichuan, Peoples R China.
   [Xu, Chong] Southwestern Univ Finance & Econ, Sch Publ Finance & Taxat, Chengdu, Sichuan, Peoples R China.
   [Managi, Shunsuke] Kyushu Univ, Urban Inst, Nishi Ku, 744 Motooka, Fukuoka 8090375, Japan.
   [Song, Mahn] Anhui Univ Finance & Econ, Sch Stat & Appl Math, Bengbu, Peoples R China.
RP Song, M (reprint author), Anhui Univ Finance & Econ, Sch Stat & Appl Math, Bengbu, Peoples R China.
EM songmartin@163.com
RI Managi, Shunsuke/G-1740-2013; chen, jiandong/AAM-3236-2020
OI Managi, Shunsuke/0000-0001-7883-1427; Xu, Chong/0000-0003-1750-8284; ,
   Malin/0000-0001-6640-4225
FU Sichuan Province Social Science High Level Research Team Building
   Program; Program for Major Projects in Philosophy and Social Science
   Research under China's Ministry of Education [14JZD031]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [71473203, 71471001, 41771568, 71533004, 71503001, 71804001];
   National Key Research and Development Program of China [2016YFA0602500]
FX We appreciate the support received under Sichuan Province Social Science
   High Level Research Team Building Program, the Program for Major
   Projects in Philosophy and Social Science Research under China's
   Ministry of Education (grant number 14JZD031), the National Natural
   Science Foundation of China (grant numbers 71473203, 71471001, 41771568,
   71533004, 71503001 and 71804001), and the National Key Research and
   Development Program of China (grant number 2016YFA0602500).
CR Acquaye AA, 2010, BUILD ENVIRON, V45, P784, DOI 10.1016/j.buildenv.2009.08.022
   Ang BW, 1997, ENERGY J, V18, P59
   [Anonymous], CHIN EN STAT YB 2004
   BARRO RJ, 1992, J POLIT ECON, V100, P223, DOI 10.1086/261816
   BERNARD AB, 1995, J APPL ECONOM, V10, P97, DOI 10.1002/jae.3950100202
   CEIC, 2018, CHIN PREM DAT
   Chen JD, 2018, ECOL INDIC, V90, P554, DOI 10.1016/j.ecolind.2018.03.057
   Chen JD, 2018, TRANSFORM BUS ECON, V17, P112
   Choi Y, 2012, APPL ENERG, V98, P198, DOI 10.1016/j.apenergy.2012.03.024
   Chou JS, 2015, J CLEAN PROD, V101, P137, DOI 10.1016/j.jclepro.2015.04.001
   Cole RJ, 1996, BUILD ENVIRON, V31, P307, DOI 10.1016/0360-1323(96)00017-0
   de Wilde P, 2011, BUILD ENVIRON, V46, P1670, DOI 10.1016/j.buildenv.2011.02.006
   Dimoudi A, 2008, RESOUR CONSERV RECY, V53, P86, DOI 10.1016/j.resconrec.2008.09.008
   Dong YH, 2015, BUILD ENVIRON, V89, P183, DOI 10.1016/j.buildenv.2015.02.020
   El Hanandeh A, 2015, BUILD ENVIRON, V92, P192, DOI 10.1016/j.buildenv.2015.04.032
   Evans P, 1996, J MONETARY ECON, V37, P249, DOI 10.1016/S0304-3932(96)90036-7
   Evans P, 1996, J ECON DYN CONTROL, V20, P1027, DOI 10.1016/0165-1889(95)00888-8
   FARE R, 1989, REV ECON STAT, V71, P90
   Fare R., 1995, MULTIOUTPUT PRODUCTI, DOI [10.1007/978-94-011-0651-1, DOI 10.1007/978-94-011-0651-1]
   Fatorachian H, 2018, PROD PLAN CONTROL, V29, P633, DOI 10.1080/09537287.2018.1424960
   Gustavsson L, 2010, ENERG BUILDINGS, V42, P230, DOI 10.1016/j.enbuild.2009.08.018
   He XS, 2013, BUILD ENVIRON, V64, P130, DOI 10.1016/j.buildenv.2013.03.013
   Herrerias M, 2017, ENERG ECON, V62, P371, DOI 10.1016/j.eneco.2016.06.006
   Intergovernmental Panel on Climate Change (IPCC), 2006, INT PAN CLIM CHANG G, V2
   Karimpour M, 2014, BUILD ENVIRON, V73, P106, DOI 10.1016/j.buildenv.2013.11.019
   Kim YS, 2015, ENERG ECON, V49, P192, DOI 10.1016/j.eneco.2015.02.001
   Kneifel J, 2010, ENERG BUILDINGS, V42, P333, DOI 10.1016/j.enbuild.2009.09.011
   Lasi H, 2014, BUS INFORM SYST ENG+, V6, P239, DOI 10.1007/s12599-014-0334-4
   Li D., 2015, P 19 INT S ADV CONST, P193, DOI 10.1007/978-3-662-46994-1_17
   Li K, 2015, ENERG ECON, V48, P230, DOI 10.1016/j.eneco.2015.01.006
   Li W, 2017, RESOUR CONSERV RECY, V126, P162, DOI 10.1016/j.resconrec.2017.07.043
   Lin BQ, 2015, BUILD ENVIRON, V94, P239, DOI 10.1016/j.buildenv.2015.08.013
   Lin BQ, 2015, ENERG POLICY, V78, P113, DOI 10.1016/j.enpol.2014.12.025
   Lu YJ, 2016, BUILD ENVIRON, V95, P94, DOI 10.1016/j.buildenv.2015.09.011
   Ma L, 2018, RESOUR CONSERV RECY, V137, P101, DOI 10.1016/j.resconrec.2018.05.029
   Markandya A, 2006, ENERG ECON, V28, P121, DOI 10.1016/j.eneco.2005.10.005
   Monahan J, 2011, ENERG BUILDINGS, V43, P179, DOI 10.1016/j.enbuild.2010.09.005
   Oh DH, 2010, J PROD ANAL, V34, P183, DOI 10.1007/s11123-010-0178-y
   Ouyang XL, 2014, ENERG BUILDINGS, V84, P268, DOI 10.1016/j.enbuild.2014.08.027
   Phillips PCB, 2007, ECONOMETRICA, V75, P1771, DOI 10.1111/j.1468-0262.2007.00811.x
   Phillips PCB, 2009, J APPL ECONOMET, V24, P1153, DOI 10.1002/jae.1080
   Shibin KT, 2018, PROD PLAN CONTROL, V29, P908, DOI 10.1080/09537287.2018.1493139
   Silverman B. W., 1986, DENSITY ESTIMATION S
   Soytas U, 2009, ECOL ECON, V68, P1667, DOI 10.1016/j.ecolecon.2007.06.014
   Suzuki M, 1998, ENERG BUILDINGS, V28, P33, DOI 10.1016/S0378-7788(98)00010-3
   Oesterreich TD, 2016, COMPUT IND, V83, P121, DOI 10.1016/j.compind.2016.09.006
   Van Nguyen P, 2005, ENVIRON RESOUR ECON, V32, P495, DOI 10.1007/s10640-005-7687-6
   Wand M.P., 1994, KERNEL SMOOTHING
   Wang J, 2014, ENERGY, V65, P605, DOI 10.1016/j.energy.2013.11.015
   Wang K, 2013, APPL ENERG, V112, P1403, DOI 10.1016/j.apenergy.2013.04.021
   Wu P, 2014, BUILD ENVIRON, V77, P160, DOI 10.1016/j.buildenv.2014.03.023
   Yamaguchi Y, 2013, BUILD ENVIRON, V59, P187, DOI 10.1016/j.buildenv.2012.08.019
   Yan ZM, 2017, ENERG POLICY, V109, P499, DOI 10.1016/j.enpol.2017.07.024
   Bribian IZ, 2011, BUILD ENVIRON, V46, P1133, DOI 10.1016/j.buildenv.2010.12.002
   Zhang N, 2014, ENERG POLICY, V70, P193, DOI 10.1016/j.enpol.2014.03.031
   Zhang YJ, 2015, RENEW SUST ENERG REV, V41, P1255, DOI 10.1016/j.rser.2014.09.021
   Zhou P, 2012, EUR J OPER RES, V221, P625, DOI 10.1016/j.ejor.2012.04.022
   2017, MANAG ENV QUAL, V28, P315, DOI DOI 10.1108/MEQ-05-2015-0075
NR 58
TC 7
Z9 7
U1 3
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 379
EP 388
DI 10.1016/j.resconrec.2019.03.014
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200036
DA 2020-05-12
ER

PT J
AU van den Brink, S
   Kleijn, R
   Tukker, A
   Huisman, J
AF van den Brink, Susan
   Kleijn, Rene
   Tukker, Arnold
   Huisman, Jaco
TI Approaches to responsible sourcing in mineral supply chains
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Responsible sourcing; Minerals; Supply chains; Sustainability
ID AFRICA; TRADE
AB Over the last decade, 'responsible sourcing' has become a topic of broad interest. Policymakers, consumers and companies refer to 'responsible sourcing' as a way to address sustainability risks in globalized mineral supply chains, but the term is used to refer to a wide range of sustainability objectives pursued by a variety of approaches. To address the need for a definition and structuring of the topic, a review was performed of the existing literature and of company policies on 'responsible sourcing' of minerals. The study develops a framework for responsible sourcing, here defined as 'the management of social, environmental and/or economic sustainability in the supply chain through production data'. We propose that 'responsible sourcing' should be used as an umbrella term encompassing all sourcing designed to be 'socially responsible', 'green' or 'sustainable'. Two approaches to managing responsible sourcing of minerals were identified: supply chain due diligence and sourcing via sustainability schemes. This study maps the sustainability requirements of such schemes and uses these to categorize them as socially responsible sourcing, sustainable sourcing or green sourcing. It also identifies the extent in the supply chain to which the schemes provide assurance or certification and how far traceability extends. The study provides a framework for future research and a springboard for further development of approaches to responsible sourcing that can be used by both companies and academics.
C1 [van den Brink, Susan; Kleijn, Rene; Tukker, Arnold] Leiden Univ, Inst Environm Sci CML, Einsteinweg 2, NL-2333 CC Leiden, Netherlands.
   [Huisman, Jaco] European Commiss, JRC, Unit D3,Via E Fermi 2749, I-21027 Ispra, VA, Italy.
RP van den Brink, S (reprint author), Leiden Univ, Inst Environm Sci CML, Einsteinweg 2, NL-2333 CC Leiden, Netherlands.
EM s.van.den.brink@cml.leidenuniv.nl; Kleijn@cml.leidenuniv.nl;
   tukker@cml.leidenuniv.nl; jaco.huisman@ec.europa.eu
RI Tukker, Arnold/M-4596-2013
OI Tukker, Arnold/0000-0002-8229-2929; Huisman, Jaco/0000-0002-6283-7629
FU European Institute of Innovation and Technology (EIT), European Union,
   under the Horizon 2020 programme (EU Framework Programme for Research
   and Innovation)
FX The authors would like to thank the European Institute of Innovation and
   Technology (EIT), a body of the European Union, under the Horizon 2020
   programme (part of the EU Framework Programme for Research and
   Innovation), for supporting this research, which is a result of the CERA
   (certification of raw materials) project. We also thank Nigel Harle for
   his editing of our English.
CR ABC News, 2018, ABC NEWS
   Airbus, 2017, SUPPL COD COND
   Airike PE, 2016, J CLEAN PROD, V131, P639, DOI 10.1016/j.jclepro.2016.04.121
   Ali S. H., 2016, DESIGNING SUSTAINABI
   Aluminium Stewardship Initiative, 2014, PERF STAND
   [Anonymous], 2018, DEV DIAM STAND
   [Anonymous], 2017, FORTUNE
   Bettercoal, 2017, BETT COD VERS 1 1
   BGR, 2017, CERT TRAD CHAINS PRO
   Bleischwitz R, 2012, RESOUR POLICY, V37, P19, DOI 10.1016/j.resourpol.2011.12.008
   BRE Global, 2016, BRE ENV SUST STAND
   CCCMC, 2016, CHIN DUE DIL GUID RE
   Chapron G, 2017, NATURE, V545, P403, DOI 10.1038/545403a
   Danwatch, 2013, IT WORK STILL PAY PR
   Ecomatters, 2018, APPL BLOCKCH SUPPL C
   EDRM, 2017, CHAIN CUST
   Ernst and Young, 2012, CONFL MIN
   European Commission, 2018, MET IND
   European Commission, 2018, CONFL MIN REG EXPL
   Fair Stone, 2010, FAIR STON STAND
   FlatIcon, 2019, IC MIN SUPPL CHAINS
   Ghodeswar B., 2014, MARKET CONSUM BEHAV, V2, P991
   Glass J, 2011, INT J CONSTR MANAG, V11, P1, DOI 10.1080/15623599.2011.10773165
   Glass J., 2012, ENGAGING SMALL FIRMS
   Hilson G, 2014, DEV CHANGE, V45, P53, DOI 10.1111/dech.12069
   Hofmann H, 2018, J BUS ETHICS, V147, P115, DOI 10.1007/s10551-015-2963-z
   IBM, 2017, DIFF PUBL PRIV BLOCK
   ICC, 2008, ICC GUID RESP SOURC
   ICMM, 2015, DEM VAL GUID RESP SO
   International Conference of the Great Lakes Region, 2018, REG CERT MECH
   Investor Intel, 2017, COB SUPPL CHAIN TRAN
   IRMA, 2018, AB IRM
   ISEAL, 2016, CHAIN CUST MOD DEF
   Kashmanian Richard M., 2017, Environmental Quality Management, V26, P73, DOI 10.1002/tqem.21495
   Kickler K., 2017, SUSTAINABILITY SCHEM
   Kimberley Process, 2018, KIMB PROC CERT SCHEM
   Martin-Ortega O., 2013, NETHERLANDS Q HUM RI, V31, P44
   Nations United, 2011, GUID PRINC BUS HUM R
   OECD, 2018, 12 FOR RESP MIN SUPP
   OECD, 2016, OECD DUE DIL GUID RE
   Philips, 2019, WE AR WORK MAK OUR S
   RCS Global ICMM, 2017, BLOCKCH TRAC MIN MET
   Responsible Jewellerry Council, 2013, COD PRACT
   Responsible Minerals Assurance Programme, 2018, INTR INF SMELT REF
   Responsible Minerals Initiative, 2017, RESP MIN ASS PROC
   Responsible Mining Index, 2018, RESP MIN
   Sarfaty GA, 2015, HARVARD INT LAW J, V56, P419
   SEC, 2012, DISCL US CONFL MIN
   Seuring S, 2008, J CLEAN PROD, V16, P1699, DOI 10.1016/j.jclepro.2008.04.020
   SOMO, 2016, COB BLUES
   STRADE, 2018, SUCC IMPL CONFL MIN
   United Nations Global Compact, 2018, APPL SUST PRACT SUPP
   Upstill-Goddard J, 2015, P I CIVIL ENG-ENG SU, V168, P71, DOI 10.1680/ensu.14.00024
   Verney A. L., 2011, MANAGEMENT INNOVATIO
   Wall F., 2017, T I MIN METALL B, V1, DOI [10.1080/03717453.2017.1306305, DOI 10.1080/03717453.2017.1306305]
   XertifiX, 2018, XERT STAND
   Young J, 2013, P I CIVIL ENG-ENG SU, V166, P320, DOI 10.1680/ensu.12.00029
   Young SB, 2018, INT J LIFE CYCLE ASS, V23, P1429, DOI 10.1007/s11367-015-0932-5
   Zorzini M, 2015, INT J OPER PROD MAN, V35, P60, DOI 10.1108/IJOPM-07-2013-0355
   2015, HAGUE J RULE LAW, V7, P219, DOI DOI 10.1007/S40803-015-0014-6
NR 60
TC 5
Z9 5
U1 3
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 389
EP 398
DI 10.1016/j.resconrec.2019.02.040
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200037
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Li, YM
   Zhang, B
   Wang, B
   Wang, ZH
AF Li, Yiming
   Zhang, Bin
   Wang, Bo
   Wang, Zhaohua
TI Evolutionary trend of the coal industry chain in China: Evidence from
   the analysis of I-O and APL model
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Coal industry chain; Input-output model; Industrial linkage; APL model
ID SOCIAL LICENSE; MINING-INDUSTRY; LINKAGES; OPERATE; EXPLORATION
AB The coal industry is an important part of the national economy in China which provides the necessary energy and other resources to support economic development. To alleviate environmental pressures in China, there is an urgent need to change the national structure of the coal industry and to rationally analyze the coal industry chain (CIC). To achieve this purpose, a combined methodology of input-output analysis and an APL model, was used. Input-output tables from 2002 to 2015 were adopted, and the evolution of China's industrial chain was empirically analyzed at the macroscopic level. The results of the research show that coal production and the supply of electric power, steam and hot water constitute one of the four most important industrial chains in China. Industries that are firmly related to the coal industry are the chemical industry, smelting and pressing metals, general purpose electrical equipment manufacturing, power supply, and the construction industries. The number of intermediate links between the coal industry and various industries are increasing, and the economic distance has been extended. 2005 and 2007 were the most complex years for the CIC network, as these are most closely related to each other. Since 2010, the complexity of the CIC network has decreased, and the relationship between industries has begun to decline. It is of great importance for the government of China to determine the national economic strategy and formulate relevant policies by analyzing the industrial chain relationships and its trends of evolution.
C1 [Li, Yiming; Zhang, Bin; Wang, Bo; Wang, Zhaohua] Beijing Inst Technol, Sch Management & Econ, Beijing 100081, Peoples R China.
   [Li, Yiming; Zhang, Bin; Wang, Bo; Wang, Zhaohua] Beijing Inst Technol, Ctr Energy & Environm Policy Res, Beijing 100081, Peoples R China.
   [Wang, Zhaohua] Collaborat Innovat Ctr Elect Vehicles Beijing, Beijing 100081, Peoples R China.
   [Zhang, Bin; Wang, Zhaohua] Sustainable Dev Res Inst Econ & Soc Beijing, Beijing 100081, Peoples R China.
RP Wang, ZH (reprint author), Beijing Inst Technol, Sch Management & Econ, Beijing 100081, Peoples R China.; Wang, ZH (reprint author), Beijing Inst Technol, Ctr Energy & Environm Policy Res, Beijing 100081, Peoples R China.
EM wangzhaohua@bit.edu.cn
FU National Science Fund for Distinguished Young ScholarsNational Natural
   Science Foundation of ChinaNational Science Fund for Distinguished Young
   Scholars [71625003]; National Key Research and Development Program of
   China [2016YFA0602504]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [91746208, 71573016,
   71403021, 71521002, 71774014]; Humanities and Social Science Fund of
   Ministry of Education of ChinaMinistry of Education, China
   [17YJC630145]; China Postdoctoral Science FoundationChina Postdoctoral
   Science Foundation [2017M620648]; Joint Development Program of Beijing
   Municipal Commission of Education; International Graduate Exchange
   Program of Beijing Institute of Technology
FX The authors would like to thank anonymous reviewers for their critical
   comments but constructive suggestions. This study is supported by the
   National Science Fund for Distinguished Young Scholars (Reference No.
   71625003), Chang Jiang Distinguished Professor of MOE, National Key
   Research and Development Program of China (Reference No.
   2016YFA0602504), National Natural Science Foundation of China (Reference
   No. 91746208, 71573016, 71403021, 71521002, 71774014), Humanities and
   Social Science Fund of Ministry of Education of China (Reference
   No.17YJC630145), China Postdoctoral Science Foundation (Reference No.
   2017M620648) and Joint Development Program of Beijing Municipal
   Commission of Education. This study is also funded by International
   Graduate Exchange Program of Beijing Institute of Technology.
CR ANDERSON K, 1995, ENERG POLICY, V23, P485, DOI 10.1016/0301-4215(95)91229-6
   Bice S, 2014, RESOURCES-BASEL, V3, P62, DOI 10.3390/resources3010062
   Changli Y. U., 2007, MIN PROCESS EQUIP
   China K., 2010, KPMG INSIGHT
   Diana C, 2015, PROC ECON FINANC, V23, P428, DOI 10.1016/S2212-5671(15)00396-2
   Dietzenbacher E, 1997, J REGIONAL SCI, V37, P235, DOI 10.1111/0022-4146.00053
   Dietzenbacher E., 2003, USING AVERAGE PROPAG, P43
   Dietzenbacher E., 2015, INT REGIONAL SCI REV, V30, P362
   Figueiredo PN, 2016, RESOUR POLICY, V49, P405, DOI 10.1016/j.resourpol.2016.07.008
   Gang Dingo, 2005, J CHINA U MIN TECHNO, V14, P17
   Gorska R., 2015, APPL EC PAPERS
   Jonek-Kowalska I, 2015, EQUILIBRIUM, V10, P69, DOI 10.12775/EQUIL.2015.004
   lonela-Claudia D., 2010, ANALELE U CONSTANTIN, V1, P107
   Moffat K, 2014, RESOUR POLICY, V39, P61, DOI 10.1016/j.resourpol.2013.11.003
   Oosterhaven J, 2013, INT REGIONAL SCI REV, V36, P481, DOI 10.1177/0160017613486670
   Owen JR, 2013, RESOUR POLICY, V38, P29, DOI 10.1016/j.resourpol.2012.06.016
   Prno J, 2012, RESOUR POLICY, V37, P346, DOI 10.1016/j.resourpol.2012.04.002
   Render Y. Ixin, 2004, COAL SCI TECHNOL, P8
   Rosemberg CR, 2009, DISCOURSE PROCESS, V46, P572, DOI 10.1080/01638530902959588
   San Cristobal JR, 2006, RESOUR POLICY, V31, P1, DOI 10.1016/j.resourpol.2006.03.004
   Shi WX, 2017, RENEW SUST ENERG REV, V72, P1, DOI 10.1016/j.rser.2017.01.033
   Solomon F, 2008, RESOUR POLICY, V33, P142, DOI 10.1016/j.resourpol.2008.01.005
   Song Wei, 2009, CHINA MIN, V18, P29
   Ting L. I., 2016, EC SURVEY
   Wang Gang, 2011, CHINA MIN, V20, P29
   Wang Qianyuan, 2006, J CHINA U MIN TECHNO, V32, P28
   Wang Z., 2017, APPL ECON, V49, P1, DOI DOI 10.1080/00036846.2016.1189506
   Weng Yifei, 2008, J COAL SCI ENG, P94
   Yan Q, 2016, J ENVIRON ENG, V142, DOI 10.1061/(ASCE)EE.1943-7870.0001073
   Yang Q., 2018, ENERGY
   Yi D., 2017, J MINES METALS FUELS, V65, P479
   Yong-Gang L. I., 2014, COAL EC RES
   Yongda H. E., 2017, IND EC RES
   yuan Feng, 2010, J CHINA U MIN TECHNO, V19, P22
   Zhan Yanling, 2009, COAL IND CHAIN EVOLU
   Zhang YF, 2017, ENERG POLICY, V101, P162, DOI 10.1016/j.enpol.2016.11.036
   Zhao Shuying, 2009, CHINA MIN, V18, P52
NR 37
TC 0
Z9 0
U1 13
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 399
EP 410
DI 10.1016/j.resconrec.2019.02.026
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200038
DA 2020-05-12
ER

PT J
AU Wang, FT
   Yu, C
   Xiong, LC
   Chang, Y
AF Wang, Fengting
   Yu, Chang
   Xiong, Lichun
   Chang, Yuan
TI How can agricultural water use efficiency be promoted in China? A
   spatial-temporal analysis
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Agricultural water use efficiency; Stochastic frontier analysis;
   Spatiotemporal characteristics; Spatial autocorrelation model
ID CONSUMPTION; IRRIGATION; RESOURCES; PERSPECTIVE; IMPACT; INDIA
AB China's agricultural sector experienced rapid growth in the last two decades, with a tripled increase in sectorally total economic output from 2000 to 2017. However, expanding large-scale production also leads to substantial consumption of water resources. Using the panel data of China's 31 provinces from 2000 to 2015, this study adopts the stochastic frontiers analysis model to measure the country's agricultural water use efficiency (AWUE). We also develop a spatial econometric model to identify the main factors that influence AWUE. The results show that the AWUE of each province ascended during the observation period, presenting obvious spatial correlations and unbalanced development at the provincial level. The per capita disposable income of rural households and the proportion of high school or above education are key influencing factors of AWUE. Additionally, factors such as the total sown area of crops, the total storage capacity of reservoirs, and the number of water-saving machines, electric and diesel motors also exert certain influences. Therefore, improving the rural residents' income and the educational level of practitioners, promoting the scale of arable land, providing training for water-saving technology, and deploying water-efficient irrigation equipment can contribute to the sustainable agriculture of China.
C1 [Wang, Fengting] China Agr Univ, Coll Econ & Management, Beijing 100083, Peoples R China.
   [Yu, Chang; Xiong, Lichun] Beijing Forestry Univ, Sch Econ & Management, Beijing 100083, Peoples R China.
   [Chang, Yuan] Cent Univ Finance & Econ, Sch Management Sci & Engn, Beijing 102206, Peoples R China.
RP Yu, C (reprint author), 35 Qinghua East Rd, Beijing 100083, Peoples R China.; Chang, Y (reprint author), Shahe Higher Educ Pk, Beijing, Peoples R China.
EM wangft2016@cau.edu.cn; changyu@bjfu.edu.cn; lichunxiong@bjfu.edu.cn;
   yuan.chang@cufe.edu.cn
OI Yu, Chang/0000-0002-9795-3443; Chang, Yuan/0000-0002-9790-4529
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71804012]
FX This work was supported by "the National Natural Science Foundation of
   China (Grant No. 71804012)". We are indebted to the anonymous reviewers
   and the editor.
CR Aigner D., 1977, J ECONOMETRICS, V6, P21, DOI DOI 10.1016/0304-4076(77)90052-5
   Azad MAS, 2014, J ENVIRON MANAGE, V145, P314, DOI 10.1016/j.jenvman.2014.05.037
   Baguskas SA, 2018, AGR FOREST METEOROL, V252, P109, DOI 10.1016/j.agrformet.2018.01.015
   Battese G. E., 1992, J PROD ANAL, V3, P153, DOI DOI 10.1007/BF00158774
   BATTESE GE, 1977, AUST J AGR ECON, V21, P169, DOI 10.1111/j.1467-8489.1977.tb00204.x
   BERGEN WG, 1984, J ANIM SCI, V58, P1465
   Binet ME, 2014, ENVIRON RESOUR ECON, V59, P561, DOI 10.1007/s10640-013-9750-z
   Cao XC, 2018, ECOL INDIC, V86, P58, DOI 10.1016/j.ecolind.2017.12.016
   Chang Y, 2016, ENERGIES, V9, DOI 10.3390/en9020065
   Cliff AD, 1973, TRENDS ECOL EVOL, V14, P196
   Deng GY, 2016, ECOL INDIC, V69, P12, DOI 10.1016/j.ecolind.2016.03.052
   Dhehibi B, 2007, AFR J AGRIC RESOUR E, V1, P1
   Elhorst JP, 2012, J GEOGR SYST, V14, P5, DOI 10.1007/s10109-011-0158-4
   Fan LX, 2014, WATER RESOUR MANAG, V28, P853, DOI 10.1007/s11269-014-0520-7
   Fuentes E, 2018, RENEW SUST ENERG REV, V81, P1530, DOI 10.1016/j.rser.2017.05.229
   Gao HC, 2014, RESOUR CONSERV RECY, V93, P50, DOI 10.1016/j.resconrec.2014.09.009
   Geng QL, 2019, ECOL INDIC, V96, P329, DOI 10.1016/j.ecolind.2018.09.011
   Ghosh R, 2016, ENERG POLICY, V89, P11, DOI 10.1016/j.enpol.2015.11.011
   GRIFFITH DA, 1989, ECON GEOGR, V65, P160, DOI 10.2307/143780
   Hu ZN, 2016, RESOUR CONSERV RECY, V109, P102, DOI 10.1016/j.resconrec.2016.02.001
   Huang QQ, 2017, J ENVIRON ECON MANAG, V82, P1, DOI 10.1016/j.jeem.2016.10.003
   Jiang S, 2017, J CLEAN PROD, V149, P1210, DOI 10.1016/j.jclepro.2017.02.103
   Kaneko S., 2004, International Journal of Agricultural Resources, Governance and Ecology, V3, P231, DOI 10.1504/IJARGE.2004.006038
   Kang S. J., 2015, HUBEI AGR SCI, V54, P5162
   Karagiannis G., 2004, INDIAN ECON REV, V39, P149
   Kijne J., 2003, WATER PRODUCTIVITY A, P66
   Koenig WD, 1999, TRENDS ECOL EVOL, V14, P22, DOI 10.1016/S0169-5347(98)01533-X
   KOPP RJ, 1981, Q J ECON, V96, P477, DOI 10.2307/1882683
   Lesage J. P., 2009, INTRO SPATIAL ECONOM, P70
   Liu Lu, 2016, Chinese Journal of Biologicals, V29, P1200
   Ma SJ, 2015, J CLEAN PROD, V87, P839, DOI 10.1016/j.jclepro.2014.10.059
   Manjunatha AV, 2011, J ENVIRON MANAGE, V92, P2924, DOI 10.1016/j.jenvman.2011.07.001
   MEEUSEN W, 1977, INT ECON REV, V18, P435, DOI 10.2307/2525757
   Melton F. S., 2017, AGU FALL M
   Musaba E., 2014, J ECO SUSTAIN DEV, V5, P104
   Nair S, 2013, AGRON J, V105, P351, DOI 10.2134/agronj2012.0421
   National Bureau of Statistics, 2016, CHIN STAT YB
   Omezzine A, 1998, AGR WATER MANAGE, V37, P99, DOI 10.1016/S0378-3774(98)00045-6
   Onishi A., 2008, J GLOB ENV ENG, V13, P45
   Reinhard S, 2000, EUR J OPER RES, V121, P287, DOI 10.1016/S0377-2217(99)00218-0
   Ruiz-Canales A, 2015, AGR WATER MANAGE, V151, P1, DOI 10.1016/j.agwat.2014.12.001
   Shi QL, 2015, SUSTAINABILITY-BASEL, V7, P56, DOI 10.3390/su7010056
   Song ML, 2018, J CLEAN PROD, V184, P611, DOI 10.1016/j.jclepro.2018.02.259
   Sun SK, 2016, J CLEAN PROD, V112, P4569, DOI 10.1016/j.jclepro.2015.06.123
   Sun YH, 2017, J CLEAN PROD, V142, P613, DOI 10.1016/j.jclepro.2016.07.110
   Veettil P, 2013, WATER RESOUR MANAG, V27, P55, DOI 10.1007/s11269-012-0155-5
   Vicente J. R., 2004, REV EC E SOCIOL RURA, V42, P376
   Wallace JS, 2000, AGR ECOSYST ENVIRON, V82, P105, DOI 10.1016/S0167-8809(00)00220-6
   WALLACH B, 1984, PROF GEOGR, V36, P490, DOI 10.1111/j.0033-0124.1984.00490.x
   Wang YG, 2017, IEEE SENSOR, P418
   Win KT, 2015, PADDY WATER ENVIRON, V13, P51, DOI 10.1007/s10333-013-0406-y
   WWAP (United Nations World Water Assessment Progranune)/UN-Water, 2018, UN WORLD WAT DEV REP, P22
   Xiong LC, 2018, RESOUR CONSERV RECY, V130, P12, DOI 10.1016/j.resconrec.2017.11.009
   Xiong Y. J., 2016, CHINA ENV EARTH SCI, V75, P1
   Xue JY, 2017, AGR WATER MANAGE, V194, P78, DOI 10.1016/j.agwat.2017.09.003
   Yang Y., 2016, ECOLOGY, V32, P147
   2012, AGR WATER MANAGE, V108, P83, DOI DOI 10.1016/J.AGWAT.2012.01.005
   2019, SCI TOTAL ENVIRON, V650, P1101, DOI DOI 10.1016/J.SCITOTENV.2018.08.426
NR 58
TC 5
Z9 5
U1 12
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 411
EP 418
DI 10.1016/j.resconrec.2019.03.017
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200039
DA 2020-05-12
ER

PT J
AU Duchin, F
   Levine, SH
AF Duchin, Faye
   Levine, Stephen H.
TI The recovery of products and materials for reuse: The global context of
   resource management
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Global resource management; Economics-engineering collaboration;
   Recycling impacts on comparative advantage; World Trade Model (WTM);
   Rectangular Choice-of-Technology (RCOT) model
ID CIRCULAR ECONOMY; FLOW-ANALYSIS; WASTE; STEEL; LOSSES; WATER
AB We propose a framework for evaluating alternative approaches for recovering products and materials from capital goods that are no longer in use. It calls for deepening the existing collaborations between input-output economists and industrial ecologists to develop scenarios for the future and databases to support the analysis of global strategies for resource management. Our formulation offers the endogenous choice among technologies subject to resource constraints to minimize economy-wide use of factors of production in satisfying final demand. The determination is made on the basis of comparative advantage for a single economy and for the global setting. We develop an illustrative database for three regions characterized by different resource profiles for natural resource endowments and for the accumulation of built capital; they are roughly modeled on Japan, Guinea, and India. The material and economic consequences for each region, and for the world as a whole, are then calculated under alternative recovery scenarios. Sharp contrasts in region-specific outcomes are evident, and clear impacts of actions in one region on outcomes in other regions demonstrate the need for a global context. Next steps include making dynamics explicit by incorporating lifetimes of durable goods and infrastructure, varying production duration periods, and resource stock-flow relationships. The final section addresses the corresponding development challenges, in particular those surrounding jobs and livelihoods. These concerns need to inform design priorities for the scale and degree of decentralization of future technological systems, which are readily represented as technological alternatives.
C1 [Duchin, Faye] Rensselaer Polytech Inst, Dept Econ, Troy, NY 12180 USA.
   [Levine, Stephen H.] Tufts Univ, Dept Civil & Environm Engn, Medford, MA 02155 USA.
RP Duchin, F (reprint author), Rensselaer Polytech Inst, Dept Econ, Troy, NY 12180 USA.
EM duchif2@rpi.edu
OI Duchin, Faye/0000-0001-8134-438X
CR Allwood JM, 2011, RESOUR CONSERV RECY, V55, P362, DOI 10.1016/j.resconrec.2010.11.002
   Bartekova E., 2016, WORKING PAPERS, V2016-005
   Boulding K. E., 1966, ENV QUALITY ISSUES G
   Cazcarro I, 2016, ECON SYST RES, V28, P295, DOI 10.1080/09535314.2016.1161600
   Duchin F., 2005, ECON SYST RES, V17, P141, DOI DOI 10.1080/09535310500114903
   Duchin F., 2012, J EC STRUCT, V1, P11
   DUCHIN F, 1998, STRUCTURAL EC MEASUR
   Duchin F., 1985, METROECONOMICA, V37, P269, DOI DOI 10.1111/J.1467-999X.1985.TB00415.X
   Duchin F, 2016, J IND ECOL, V20, P783, DOI 10.1111/jiec.12302
   Duchin F, 2016, J IND ECOL, V20, P775, DOI 10.1111/jiec.12303
   Duchin F, 2012, ECON SYST RES, V24, P371, DOI 10.1080/09535314.2012.714746
   Duchin F, 2011, ECON SYST RES, V23, P281, DOI 10.1080/09535314.2011.571238
   Elshkaki A., 2018, RESOURCE DEMAND SCEN
   Exner A, 2015, ANTIPODE, V47, P342, DOI 10.1111/anti.12107
   Geissdoerfer M, 2017, J CLEAN PROD, V143, P757, DOI 10.1016/j.jclepro.2016.12.048
   Graedel T.E., 1995, IND ECOLOGY
   Japan Inc appears ill-prepared as labour shortages start to bite; INSIDE BUSINESS ASIA, 2018, FINANC TIMES, P12
   Kemp R, 2007, SUSTAIN INNOV, P87
   Kondo Y, 2005, ECON SYST RES, V17, P393, DOI DOI 10.1080/09535310500283526
   Korhonen J, 2018, J CLEAN PROD, V175, P544, DOI 10.1016/j.jclepro.2017.12.111
   Kovacs W. L., 1977, COLUM J ENVTL L, V3, P205
   Lee CM, 2017, INT J PR ENG MAN-GT, V4, P113, DOI 10.1007/s40684-017-0015-0
   LEONTIEF W, 1970, REV ECON STAT, V52, P262, DOI 10.2307/1926294
   Leontief W., 1986, FUTURE IMPACT AUTOMA
   LEVINE SH, 1989, IEEE T SYST MAN CYB, V19, P232, DOI 10.1109/21.31029
   Lopez-Morales CA, 2015, ECON SYST RES, V27, P154, DOI 10.1080/09535314.2014.980224
   McDowall W, 2017, J IND ECOL, V21, P651, DOI 10.1111/jiec.12597
   Nakamura S, 2007, J IND ECOL, V11, P50, DOI 10.1162/jiec.2007.1290
   Nakamura S, 2006, ECOL ECON, V57, P494, DOI 10.1016/j.ecolecon.2005.05.002
   Nakamura S, 2017, ENVIRON SCI TECHNOL, V51, P9469, DOI 10.1021/acs.est.7b01683
   Nakamura S, 2014, ENVIRON SCI TECHNOL, V48, P7207, DOI 10.1021/es500820h
   Nakamura S, 2009, ECO-EFFIC IND SCI, V26, P1
   Nakamura Shinichiro, 2002, Journal of Industrial Ecology, V6, P39, DOI 10.1162/108819802320971632
   Nakamura S, 2009, J IND ECOL, V13, P706, DOI 10.1111/j.1530-9290.2009.00153.x
   Ohno H, 2017, ENVIRON SCI TECHNOL, V51, P13086, DOI 10.1021/acs.est.7b04477
   Owen A., 2017, TECHNIQUES EVALUATIN
   Pauliuk S, 2017, RESOUR CONSERV RECY, V116, P84, DOI 10.1016/j.resconrec.2016.09.029
   PEARCE D, 1989, EC NATURAL RESOURCES
   Sella J., 1992, 1 YAL U SCH FOR ENV
   Springer NP, 2014, ENVIRON SCI TECHNOL, V48, P4444, DOI 10.1021/es4051988
   Stromman AH, 2009, J IND ECOL, V13, P38, DOI 10.1111/j.1530-9290.2008.00084.x
   Takase K, 2005, J IND ECOL, V9, P201, DOI 10.1162/1088198054084653
   Tisserant A, 2017, J IND ECOL, V21, P628, DOI 10.1111/jiec.12562
   2004, INT J LIFE CYCLE ASS, V9, P236, DOI DOI 10.1065/LCA2004.033.153
   2017, PROCEDIA CIRP, V61, P641, DOI DOI 10.1016/J.PROCIR.2016.11.251
   2011, ECON SYST RES, V23, P387, DOI DOI 10.1080/09535314.2011.635138
NR 46
TC 3
Z9 3
U1 1
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 422
EP 447
DI 10.1016/j.resconrec.2018.10.028
PG 26
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200041
DA 2020-05-12
ER

PT J
AU Nuss, P
   Ohno, H
   Chen, WQ
   Graedel, TE
AF Nuss, Philip
   Ohno, Hajime
   Chen, Wei-Qiang
   Graedel, T. E.
TI Comparative analysis of metals use in the United States economy
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Mixed-unit input-output tables; Network visualizations; Material flow
   analysis; Resource criticality analysis; Science-policy interface;
   Complexity science
ID MATERIAL FLOW-ANALYSIS; ALLOYING ELEMENTS; STEEL; CRITICALITY; CYCLES;
   END
AB Building a circular economy requires knowledge of physical material flows and stocks. One approach for obtaining data on the intersectoral exchanges of materials in an economy is with physical input-output tables (PIOTs). Using PIOTs of eleven alloying metals (aluminum, vanadium, chromium, manganese, iron, cobalt, nickel, copper, niobium, molybdenum, tungsten) for the entire United States economy in 2007, we apply network-based metrics and visualizations to identify key sectors and compare different PIOTs with each other. Some 40-45% of all intersectoral trade contains the major metals aluminum, copper, and iron, while this number ranges between only 11-15% for minor metals (e.g., cobalt, vanadium, niobium, molybdenum, tungsten). The majority of sectors rely on products containing the major metals, reflecting widespread use of those products in our modem economy. Network size provides an indication of supply chain steps required to move from metal production to finished product manufacturing. Supply chains for the minor metals require an average of 5-8 steps, while those of major metals involve 3 steps on average. Cobalt is used extensively to illustrate these results because its status as a "technology-critical material" demonstrates how these analytical approaches can reveal sector usage and dependency for a metal of potential supply concern. We conclude by presenting automobile supply chain networks and discuss the position of the automobile production sector in the US economy. The analytical and visualization approaches presented result in an improved understanding of metal flows and can help to better communicate underlying data, e.g., in a policy context.
C1 [Nuss, Philip] German Environm Agcy UBA, Unit 11 1, Fundamental Aspects Sustainabil Strategies & Scen, Woerlitzer Pl 1, Dessau Rosslau, Germany.
   [Ohno, Hajime] Tohoku Univ, Grad Sch Engn, Dept Chem Engn, Aoba Ku, 6-6-07 Aramaki Aza Aoba, Sendai, Miyagi 9808579, Japan.
   [Chen, Wei-Qiang] Chinese Acad Sci, Inst Urban Environm, Key Lab Urban Environm & Hlth, 1799 Jimei Rd, Xiamen 361021, Peoples R China.
   [Graedel, T. E.] Yale Sch Forestry & Environm Studies, Ctr Ind Ecol, 195 Prospect St, New Haven, CT 06511 USA.
RP Nuss, P (reprint author), German Environm Agcy UBA, Unit 11 1, Fundamental Aspects Sustainabil Strategies & Scen, Woerlitzer Pl 1, Dessau Rosslau, Germany.
EM philip@nuss.me
RI CAS, KLUEH/T-5743-2019
OI Ohno, Hajime/0000-0002-8826-3854; NUSS, Philip/0000-0001-9936-6886
FU U.S. National Science FoundationNational Science Foundation (NSF)
   [CBET-0932724]
FX Portions of this work were supported by the U.S. National Science
   Foundation under Grant CBET-0932724.
CR Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019
   Barabasi AL, 2003, SCI AM, V288, P60, DOI 10.1038/scientificamerican0503-60
   Barabasi AL, 2009, SCIENCE, V325, P412, DOI 10.1126/science.1173299
   Bastian M, 2009, INT AAAI C WEBL SOC
   BIO by Deloitte, 2015, STUD DAT RAW MAT SYS
   Blengini G., 2017, ASS METH EST EU LIST
   Blengini GA, 2017, RESOUR POLICY, V53, P12, DOI 10.1016/j.resourpol.2017.05.008
   BMUB, 2016, GERM RES EFF PROGR 2
   Brandes U., 2005, NETWORK ANAL METHODO
   Bringezu S., 2009, SUSTAINABLE RESOURCE
   Brunner P.H., 2016, HDB MAT FLOW ANAL EN
   Brunner PH, 2004, PRACTICAL HDB MAT FL
   Carroll A., 2014, OVERVIEW STRATEGIC M
   Chen WQ, 2016, ENVIRON SCI TECHNOL, V50, P3905, DOI 10.1021/acs.est.5b05095
   Chen WQ, 2012, ENVIRON SCI TECHNOL, V46, P8574, DOI 10.1021/es3010333
   Dewulf J, 2016, RESOUR POLICY, V50, P169, DOI 10.1016/j.resourpol.2016.09.008
   DG ENV, 2015, EU RES EFF SCOR 2015
   Du XY, 2015, J MATER CYCLES WASTE, V17, P218, DOI 10.1007/s10163-015-0353-3
   EC, 2010, COMM RES EV BAS POL
   EC, 2014, REP CRIT RAW MAT EU
   EC, 2011, COM
   EC (European Commission), 2018, SWD201817 EC
   European Commission (EC), 2017, REP CRIT RAW MAT EU
   EUROSTAT, 2013, EC WID MAT FLOW ACC
   Graedel TE, 2015, P NATL ACAD SCI USA, V112, P4257, DOI 10.1073/pnas.1500415112
   Grainger S, 2016, ENVIRON MODELL SOFTW, V85, P299, DOI 10.1016/j.envsoft.2016.09.004
   Greenfield A, 2013, RESOUR CONSERV RECY, V74, P1, DOI 10.1016/j.resconrec.2013.02.010
   Hagberg A. A., 2008, 7 PYTH SCI C SCIPY20, V2008, P11
   Hayes SM, 2018, RESOUR POLICY, V59, P192, DOI 10.1016/j.resourpol.2018.06.015
   Hearnshaw EJS, 2013, INT J OPER PROD MAN, V33, P442, DOI 10.1108/01443571311307343
   Hoekstra AY, 2014, SCIENCE, V344, P1114, DOI 10.1126/science.1248365
   Jackson Matthew O., 2010, SOCIAL EC NETWORKS
   Kito T., 2014, ID2412512 SSRN
   Klas C., 2011, USE POTENTIALLY CRIT
   Lenzen M, 2013, ECON SYST RES, V25, P20, DOI 10.1080/09535314.2013.769938
   Lenzen M, 2012, ENVIRON SCI TECHNOL, V46, P8374, DOI 10.1021/es300171x
   Manfredi S., 2017, 28526EN JRC EUR
   Mathieux F, 2017, CRITICAL RAW MAT CIR, DOI [10.2760/378123, DOI 10.2760/378123]
   Mayer A., 2018, J IND ECOL, DOI [10.1111/jiec.12809.0, DOI 10.1111/JIEC.12809.0]
   Miller R.E., 2009, INPUT OUTPUT ANAL FD
   Nakajima K, 2013, ENVIRON SCI TECHNOL, V47, P4653, DOI 10.1021/es3043559
   Nakamura S, 2005, MATER TRANS, V46, P2550, DOI 10.2320/matertrans.46.2550
   Nakamura S, 2007, J IND ECOL, V11, P50, DOI 10.1162/jiec.2007.1290
   Nakamura S, 2017, ENVIRON SCI TECHNOL, V51, P9469, DOI 10.1021/acs.est.7b01683
   Nakamura S, 2011, ENVIRON SCI TECHNOL, V45, P1114, DOI 10.1021/es1024299
   Nakamura S, 2009, J IND ECOL, V13, P706, DOI 10.1111/j.1530-9290.2009.00153.x
   Newman MEJ, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.066133
   Nuss P., 2018, 29219EN EUR, DOI [10.2760/751342, DOI 10.2760/751342]
   Nuss P, 2016, SUSTAIN MATER TECHNO, V10, P14, DOI 10.1016/j.susmat.2016.10.002
   Nuss P, 2016, ENVIRON SCI TECHNOL, V50, P4091, DOI 10.1021/acs.est.5b05094
   Nuss P, 2014, ENVIRON SCI TECHNOL, V48, P4171, DOI 10.1021/es405044w
   OECD, 2008, MEAS MAT FLOWS RES P, V1
   OECD, 2008, MEAS MAT FLOWS RES P
   Ohno H, 2017, ISIJ INT, V57, P193, DOI 10.2355/isijinternational.ISIJINT-2016-470
   Ohno H, 2016, ENVIRON SCI TECHNOL, V50, P4082, DOI 10.1021/acs.est.5b05093
   Ohno H, 2015, RESOUR CONSERV RECY, V100, P11, DOI 10.1016/j.resconrec.2015.04.001
   Ohno H, 2014, J IND ECOL, V18, P242, DOI 10.1111/jiec.12095
   Origin, 2015, ORIGINLAB
   Passarini L., 2018, EUR SCI TECHNICAL RE, DOI [10.2760/1079, DOI 10.2760/1079]
   Pauliuk S, 2015, J IND ECOL, V19, P104, DOI 10.1111/jiec.12149
   Ridoutt BG, 2010, GLOBAL ENVIRON CHANG, V20, P113, DOI 10.1016/j.gloenvcha.2009.08.003
   Soto-Viruet Y., 2013, 20131239 USGS
   Stocker TF, 2014, CLIMATE CHANGE 2013: THE PHYSICAL SCIENCE BASIS, P1, DOI 10.1017/cbo9781107415324
   Tukker A, 2013, ECON SYST RES, V25, P50, DOI 10.1080/09535314.2012.761952
   UNEP, 2016, GLOB MAT FLOWS RES P
   United Nations, 2011, WORLD POP PROSP 2010
   US FTC, 2017, BUYING NEW CAR CONS
   USBEA, 2014, BENCHM INP OUTP ACC
   Vidal-Legaz B., 2016, EU RAW MAT SCOREBOAR
   Wachs L., 2018, J EC STRUCT, V7, DOI [10.1186/s40008-018-0123-1, DOI 10.1186/S40008-018-0123-1]
   Wasserman S., 1994, SOCIAL NETWORK ANAL
   Weisz H, 2006, ECOL ECON, V57, P534, DOI 10.1016/j.ecolecon.2005.05.011
NR 72
TC 1
Z9 1
U1 6
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JUN
PY 2019
VL 145
BP 448
EP 456
DI 10.1016/j.resconrec.2019.02.025
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA HV8RO
UT WOS:000466251200042
DA 2020-05-12
ER

PT J
AU Bitencourt, MAO
   Torres-Rego, M
   Lima, MCJD
   Furtado, AA
   de Azevedo, EP
   do Egito, EST
   da Silva, AA
   Zucolotto, SM
   Fernandes-Pedrosa, MD
AF Oliveira Bitencourt, Mariana Angelica
   Torres-Rego, Manoela
   Jeronimo de Souza Lima, Maira Conceicao
   Furtado, Allanny Alves
   de Azevedo, Eduardo Pereira
   Tabosa do Egito, Eryvaldo Socrates
   da Silva-Junior, Arnobio Antnio
   Zucolotto, Silvana Maria
   Fernandes-Pedrosa, Matheus de Freitas
TI Protective effect of aqueous extract, fractions and phenolic compounds
   of Hancornia speciosa fruits on the inflammatory damage in the lungs of
   mice induced by Tityus serrulatus envenomation
SO TOXICON
LA English
DT Article
DE Anti-inflammatory activity; Chlorogenic acid; Hancornia speciosa; Rutin;
   Scorpion venom; Tityus serrulatus
ID SCORPION-VENOM; GOMES APOCYNACEAE; MEDICINAL-PLANTS; CHLOROGENIC ACID;
   LATEX; ACTIVATION; BAHIENSIS; INJURY
AB Scorpion envenomation has been considered a public health issue around the world. Tityus serrulatus represents a specie of major medical importance in Brazil due to mortality rates of approximately 1% among children and elderly populations. The aim of this work was to evaluate the in vivo anti-inflammatory potential of aqueous extract from Hancornia speciosa fruits, its fractions and its phenolic compounds against T. serrulatus envenomation. After receiving the T. serrulatus venom (TsV, 0.8 mg/kg) intraperitoneally, the animals were treated intravenously with the aqueous extract (20, 30 and 40 mg/kg), the arachnid antivenom (50 mu L/animal), the dichloromethane, ethyl acetate and n-butanol fractions (20 mg/kg) as well as rutin and chlorogenic acid (2, 2.5 and 5 mg/kg). The treatment with the aqueous extract, fractions and phenolic compounds decreased the migration of leukocytes to the peritoneal cavity and reduced the levels of IL-1 beta, IL-6 and IL-12. Moreover, the pulmonary histopathologic analysis showed a reduction in both interstitial and alveolar edema, as well as in the leukocytes infiltration and vascular ectasia in the mice's lungs, which evidences a protective effect attributed to H. speciosa. This is the first study that demonstrates the inhibitory potential of the aqueous extract from H. speciosa fruits against inflammation induced by TsV. These findings suggest that the bioactive compounds from the aqueous extract, especially chlorogenic acid and rutin, are responsible for the reported anti-inflammatory activity of H. speciosa.
C1 [Oliveira Bitencourt, Mariana Angelica; Torres-Rego, Manoela; Jeronimo de Souza Lima, Maira Conceicao; Furtado, Allanny Alves; da Silva-Junior, Arnobio Antnio; Fernandes-Pedrosa, Matheus de Freitas] Univ Fed Rio Grande do Norte, Dept Pharmaceut Sci, Lab Technol & Pharmaceut Biotechnol Tecbiofar, Coll Pharm, Rua Gen Gustavo Cordeiro de Farias S-N, BR-59012570 Natal, RN, Brazil.
   [Oliveira Bitencourt, Mariana Angelica; de Azevedo, Eduardo Pereira] Potiguar Univ UnP, Grad Program Biotechnol, Ave Senador Salgado Filho 1610, BR-59056000 Natal, RN, Brazil.
   [Jeronimo de Souza Lima, Maira Conceicao] Potiguar Univ UnP, Dept Vet Med, Ave Senador Salgado Filho 1610, BR-59056000 Natal, RN, Brazil.
   [Tabosa do Egito, Eryvaldo Socrates] Univ Fed Rio Grande do Norte, Coll Pharm, Dept Pharmaceut Sci, Lab Dispersed Syst LaSiD, Rua Gen Gustavo Cordeiro de Farias S-N, Natal, RN, Brazil.
   [Zucolotto, Silvana Maria] Univ Fed Rio Grande do Norte, Coll Pharm, Dept Pharmaceut Sci, Lab Pharmacognosy PNBio, Rua Gen Gustavo Cordeiro de Farias S-N, Natal, RN, Brazil.
RP Fernandes-Pedrosa, MD (reprint author), Univ Fed Rio Grande do Norte, Dept Pharmaceut Sci, Lab Technol & Pharmaceut Biotechnol Tecbiofar, Coll Pharm, Rua Gen Gustavo Cordeiro de Farias S-N, BR-59012570 Natal, RN, Brazil.
EM mariana.bitencourt@unp.br; manoelatorres@ufrn.edu.br; maira.lima@unp.br;
   allannyfurtado@ufrn.edu.br; azevedo@unp.br; socratesegito@gmail.com;
   arnobiosilva@gmail.com; silvanazucolotto@ufrnet.br; mffpedrosa@gmail.com
RI Torres-Rego, Manoela/E-8536-2019; de Freitas Fernandes-Pedrosa,
   Matheus/C-6398-2014
OI de Freitas Fernandes-Pedrosa, Matheus/0000-0003-4221-9580; Torres do
   Rego, Manoela/0000-0002-8535-1533; Zucolotto,
   Silvana/0000-0002-2768-0793
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERN [PRONEM/2011]; CAPESCAPES [Toxinology/2010]
FX This research was supported by grants from CNPq and financial support
   from FAPERN (PRONEM/2011) and CAPES (Toxinology/2010). Matheus de
   Freitas Fernandes-Pedrosa, Eryvaldo Socrates Tabosa do Egito and Arnobio
   Antonio da Silva-Junior CNPq fellowship-honored researchers. The authors
   give thanks Keyla Borges Ferreira Rocha by histopathological analysis.
CR Almeida LM, 2014, J MATER SCI-MATER M, V25, P2153, DOI 10.1007/s10856-014-5255-8
   Almeida S. P., 1998, CERRADO ESPECIES VEG, V38
   [Anonymous], 2018, AC AN PEC NOT REG SI
   Bahloul M, 2013, INT J CARDIOL, V162, P86, DOI 10.1016/j.ijcard.2011.10.013
   Barry CM, 2011, BRAIN RES, V1389, P143, DOI 10.1016/j.brainres.2011.02.082
   Bucaretchi F, 2014, TOXICON, V89, P17, DOI 10.1016/j.toxicon.2014.06.022
   Bucaretchi Fabio, 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P331, DOI 10.1590/S0036-46651995000400008
   Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021
   Choi S, 2013, BIOCHEM PHARMACOL, V86, P1468, DOI 10.1016/j.bcp.2013.08.066
   Chua LS, 2013, J ETHNOPHARMACOL, V150, P805, DOI 10.1016/j.jep.2013.10.036
   Correa M. P., 1974, DICIONARIO PLANTAS U, V1, P1
   Costa ES, 2008, PHYTOTHER RES, V22, P705, DOI 10.1002/ptr.2397
   da Silva TF, 2011, ANTON LEEUW INT J G, V99, P523, DOI 10.1007/s10482-010-9520-7
   de Lima JP, 2015, FOOD RES INT, V75, P216, DOI 10.1016/j.foodres.2015.05.045
   de Moura VM, 2017, J ETHNOPHARMACOL, V196, P168, DOI 10.1016/j.jep.2016.12.031
   de Silva HA, 2016, BRIT J CLIN PHARMACO, V81, P446, DOI 10.1111/bcp.12739
   DeMatos IM, 1997, COMP BIOCHEM PHYS C, V118, P143, DOI 10.1016/S0742-8413(97)00086-8
   Elgar D, 2006, AFR J BIOTECHNOL, V5, P2495
   Fialho EMS, 2011, TOXICON, V58, P480, DOI 10.1016/j.toxicon.2011.08.006
   FREIREMAIA L, 1993, TOXICON, V31, P1207, DOI 10.1016/0041-0101(93)90137-8
   Fukuhara YDM, 2003, TOXICON, V41, P49, DOI 10.1016/S0041-0101(02)00208-8
   Gomes E.D.B., 2013, METHODS AND INSTRUME, V3, P1
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   HIRSCHMANN GS, 1990, J ETHNOPHARMACOL, V29, P159, DOI 10.1016/0378-8741(90)90052-U
   Hwang SJ, 2014, INFLAMM RES, V63, P81, DOI 10.1007/s00011-013-0674-4
   Lima MCJD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112248
   Lima MCJDS, 2014, J ETHNOPHARMACOL, V153, P890, DOI 10.1016/j.jep.2014.03.060
   Koch I, 2015, APOCYNACEAE LISTA ES
   Macedo M., 2004, Rev. bras. farmacogn., V14, P45, DOI 10.1590/S0102-695X2004000300017
   Magalhaes A, 2011, J ETHNOPHARMACOL, V134, P82, DOI 10.1016/j.jep.2010.11.062
   Magalhaes MM, 1999, TOXICON, V37, P1155, DOI 10.1016/S0041-0101(98)00251-7
   Marinho DG, 2011, J ETHNOPHARMACOL, V135, P530, DOI 10.1016/j.jep.2011.03.059
   Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13
   Miyamoto JG, 2018, TOXICON, V141, P25, DOI 10.1016/j.toxicon.2017.11.005
   Moraes TDM, 2008, J ETHNOPHARMACOL, V120, P161, DOI 10.1016/j.jep.2008.08.001
   Neves JD, 2016, J ETHNOPHARMACOL, V183, P151, DOI 10.1016/j.jep.2016.02.041
   Ohkawara T, 2017, LIFE SCI, V190, P91, DOI 10.1016/j.lfs.2017.09.015
   Bitencourt MAO, 2014, BIOMED RES INT, DOI 10.1155/2014/378235
   Peres ACP, 2009, TOXICON, V53, P779, DOI 10.1016/j.toxicon.2009.02.002
   Pardal Pedro Pereira de Oliveira, 2003, Rev Soc Bras Med Trop, V36, P349
   PATHAK D, 1991, Fitoterapia, V62, P371
   Penido A. B., 2017, EVID-BASED COMPL ALT, V2017, P1
   Pereira AC, 2015, J ETHNOPHARMACOL, V161, P30, DOI 10.1016/j.jep.2014.11.050
   Pessini AC, 2003, INT IMMUNOPHARMACOL, V3, P765, DOI 10.1016/S1567-5769(03)00078-X
   Pessini AC, 2006, TOXICON, V48, P556, DOI 10.1016/j.toxicon.2006.07.006
   Petricevich VL, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/903295
   Pott A., 1994, PLANTAS PANTANAL, P320
   Pucca MB, 2015, TOXICON, V108, P272, DOI 10.1016/j.toxicon.2015.10.015
   Ramirez-Bello V, 2014, TOXICON, V82, P61, DOI 10.1016/j.toxicon.2014.02.011
   Sampaio T. S., 2008, THESIS
   Sampaio TS, 2006, FOOD CHEM, V95, P606, DOI 10.1016/j.foodchem.2005.01.038
   Santos U.P., 2016, PLOS ONE, V11, P1, DOI DOI 10.1371/J0URNAL.P0NE.0167531
   Shan JH, 2009, INT IMMUNOPHARMACOL, V9, P1042, DOI 10.1016/j.intimp.2009.04.011
   Silva GC, 2016, PHYTOMEDICINE, V23, P214, DOI 10.1016/j.phymed.2015.12.010
   Silva Junior J. F., 2004, REV BRAS FRUTIC, V26, P1, DOI DOI 10.1590/S0100-29452004000100001
   Rigoni VLS, 2016, TOXICON, V120, P22, DOI 10.1016/j.toxicon.2016.07.013
   Thwin MM, 2010, TOXICON, V56, P1275, DOI 10.1016/j.toxicon.2009.12.023
   Torres JB, 2002, REV SAUDE PUBL, V36, P631, DOI 10.1590/S0034-89102002000600014
   Torres-Rego M, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1259-x
   Venancio EJ, 2013, TOXICON, V69, P180, DOI 10.1016/j.toxicon.2013.02.012
   Yeh CH, 2014, FREE RADICAL BIO MED, V69, P249, DOI 10.1016/j.freeradbiomed.2014.01.028
   Zhang X, 2010, INJURY, V41, P746, DOI 10.1016/j.injury.2010.02.029
NR 62
TC 0
Z9 0
U1 2
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 1
EP 9
DI 10.1016/j.toxicon.2019.03.018
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000001
PM 30902683
DA 2020-05-12
ER

PT J
AU Zhou, YF
   Jin, YC
   Yu, H
   Shan, AS
   Shen, JL
   Zhou, CH
   Zhao, Y
   Fang, HT
   Wang, X
   Wang, JM
   Fu, YR
   Wang, R
   Li, RH
   Zhang, J
AF Zhou, Yongfeng
   Jin, Yongcheng
   Yu, Hao
   Shan, Anshan
   Shen, Jinglin
   Zhou, Changhai
   Zhao, Yun
   Fang, Hengtong
   Wang, Xin
   Wang, Junmei
   Fu, Yurong
   Wang, Rui
   Li, Ruihua
   Zhang, Jing
TI Resveratrol inhibits aflatoxin B1-induced oxidative stress and apoptosis
   in bovine mammary epithelial cells and is involved the Nrf2 signaling
   pathway
SO TOXICON
LA English
DT Article
DE Resveratrol; Aflatoxin B1; Oxidative stress; Nrf2; MAC-T cell
ID TRANSCRIPTION FACTOR NRF2; MITOCHONDRIAL; PROTECTS; DAMAGE; GENE; B-1
AB Aflatoxins are widely occurring food contaminants that are particularly harmful to dairy products and cows. The plant polyphenol resveratrol has been reported to have a good effect on increasing the resistance of cells toward toxins. Therefore, we measured the effects of aflatoxin B1 and resveratrol on the viability of the MAC-T cow mammary epithelial cell line. The appropriate treatment concentrations were assayed (12.81 mu M aflatoxin B1 and 43.81 mu M resveratrol) to verify the protective effect of resveratrol toward mammary epithelial cells. The results showed that resveratrol alleviates aflatoxin B1-induced cytotoxicity, including the increase in ROS and the decrease in mitochondrial membrane potential (MMP) and apoptosis in MAC-T cells. The expression of mRNA transcripts (including Nrf2, Keap1, NQO1, HO-1, SOD2 and HSP70) for components of the Nrf2 signaling pathway was evaluated by real-time fluorescent quantitative PCR, with resveratrol also exhibiting a good regulatory effect. Thus, resveratrol was shown to have an ameliorating effect on aflatoxin toxicity in MAC-T cells.
C1 [Zhou, Yongfeng; Jin, Yongcheng; Yu, Hao; Shen, Jinglin; Zhou, Changhai; Zhao, Yun; Fang, Hengtong; Wang, Xin; Wang, Junmei; Fu, Yurong; Wang, Rui; Li, Ruihua; Zhang, Jing] Jilin Univ, Coll Anim Sci, 5333 Xian Rd, Changchun, Jilin, Peoples R China.
   [Shan, Anshan] Northeast Agr Univ, Inst Anim Nutr, Harbin, Heilongjiang, Peoples R China.
RP Zhang, J (reprint author), Jilin Univ, Coll Anim Sci, 5333 Xian Rd, Changchun, Jilin, Peoples R China.
EM zhang_jing99@jlu.edu.cn
RI Shan, Anshan/U-9119-2019
OI zhou, yong feng/0000-0002-0506-4113; Jin, YongCheng/0000-0002-3462-3674
FU Jilin Science and Technology Development Project [20170307018NY];
   Special Project of the Province-University Co-constructing Program of
   Jilin Province [SXGJXX2017-4]; Open Projects of Northeast Agricultural
   University/Scientific Observing and Experimental Station of Animal
   Nutrition and Feed Science in Northeast, Ministry of Agriculture. China;
   Jilin Modern Agricultural Technology Demonstration and Extension Project
FX This research was financially supported by the Jilin Science and
   Technology Development Project (20170307018NY); the Special Project of
   the Province-University Co-constructing Program of Jilin Province
   (SXGJXX2017-4); the Open Projects of Northeast Agricultural
   University/Scientific Observing and Experimental Station of Animal
   Nutrition and Feed Science in Northeast, Ministry of Agriculture. China;
   and the Jilin Modern Agricultural Technology Demonstration and Extension
   Project. The funders had no role in the study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Agar G, 2011, TURK J MED SCI, V41, P1043, DOI 10.3906/sag-1011-1315
   [Anonymous], 1993, IARC MONOGRAPHS EVAL, V56
   Baldi A, 2003, ITAL J ANIM SCI, V2, P231, DOI 10.4081/ijas.2003.s1.231
   Beere HM, 2000, NAT CELL BIOL, V2, P469
   Bin W, 2015, J FOOD SCI, V79, pH1823
   Chen BL, 2016, ONCOTARGET, V7, P84989, DOI 10.18632/oncotarget.13356
   de Oliveira MR, 2016, BBA-GEN SUBJECTS, V1860, P727, DOI 10.1016/j.bbagen.2016.01.017
   Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005
   Han RW, 2013, FOOD CONTROL, V34, P35, DOI 10.1016/j.foodcont.2013.04.008
   Itoh K, 2015, J CLIN BIOCHEM NUTR, V56, P91, DOI 10.3164/jcbn.14-134
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5
   Kim J, 2017, J CELL BIOCH, V118
   Kumar P, 2016, FRONT MICROBIOL, V7
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Liu Y, 2016, ANIM SCI J, V87, P1490, DOI 10.1111/asj.12550
   Liu Y, 2014, TOXICOL REP, V1, P1076, DOI 10.1016/j.toxrep.2014.10.016
   Liu YJ, 2017, MOL MED REP, V15, P2457, DOI 10.3892/mmr.2017.6304
   Lizarraga-Paulin EG, 2011, AFLATOXINS - BIOCHEMISTRY AND MOLECULAR BIOLOGY, P255
   Mary VS, 2012, TOXICOLOGY, V302, P299, DOI 10.1016/j.tox.2012.08.012
   Peng X, 2016, ONCOTARGET, V7, P12222, DOI 10.18632/oncotarget.7731
   Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X
   Seo K, 2014, TOXICOL APPL PHARM, V280, P314, DOI 10.1016/j.taap.2014.08.011
   Shivender Singh Saini A. K, 2012, MINI REV GLOB ADV RE, V1, P8
   STUBBLEFIELD RD, 1983, AM J VET RES, V44, P1750
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x
   Yates MS, 2006, CANCER RES, V66, P2488, DOI 10.1158/0008-5472.CAN-05-3823
NR 28
TC 4
Z9 4
U1 10
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 10
EP 15
DI 10.1016/j.toxicon.2019.03.022
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000002
PM 30946912
DA 2020-05-12
ER

PT J
AU Aguirre, LS
   Sandoval, GV
   Medina, DM
   Martinez, OG
   Micheloud, JF
AF Aguirre, Laura S.
   Sandoval, Gabriela V.
   Medina, Diego M.
   Martinez, Olga G.
   Micheloud, Juan F.
TI Acute heart failure in rabbits by avocado leaf poisoning
SO TOXICON
LA English
DT Review
DE Persea americana; Poisoning; Rabbits; Cardiomyopathy
ID PERSEA-AMERICANA; AQUEOUS EXTRACT; LEAVES; BIM
AB The aim of this paper was to report an outbreak of avocado poisoning in rabbits in Salta, Argentina. Fourteen rabbits died of congestive heart failure within 30 h of ingesting fresh avocado leaves from pruned trees. They showed clinical signs of respiratory and cardiac distress. Full necropsies of four rabbits were performed and samples were collected for histopathology. The gross pathological observation included pleural and pericardial effusion, pulmonary oedema, slight ascites; the hearts appeared flabby and markedly pale. In addition, the stomach content consisted mostly of green feed with large amounts of avocado leaves. Epidermal fragments of Persea americana were identified by microhistological analysis of gastric content to get most efficiently to a correct diagnosis. Histopathological examination revealed degeneration and necrosis of myocytes and a mononuclear cellular infiltration mainly involving the myocardium and, to a lesser extent, the liver, lung and kidneys. Our observations indicate that avocado leaves should be avoided in the green diet of rabbits.
C1 [Aguirre, Laura S.; Sandoval, Gabriela V.; Medina, Diego M.; Micheloud, Juan F.] UCASAL, Fac Ciencias Agr & Vet, INTA EEA Salta, RN 68 Km 172, RA-4403 Cerrillos, Salta, Argentina.
   [Martinez, Olga G.] Univ Nacl Salta Salta, Catedra Diversidad Plantas, INTA EEA Salta, RN 68 Km 172, RA-4403 Cerrillos, Salta, Argentina.
   [Micheloud, Juan F.] INTA EEA Salta, Grp Trabajo Patol Epidemiol & Invest Diagnost, Area Sanidad Anim, IIACS Salta,INTA, RN 68 Km 172, RA-4403 Cerrillos, Salta, Argentina.
RP Aguirre, LS (reprint author), UCASAL, Fac Ciencias Agr & Vet, INTA EEA Salta, RN 68 Km 172, RA-4403 Cerrillos, Salta, Argentina.
EM sabrinaguirre22@gmail.com; micheloud.juan@inta.gob.ar
FU INTA (Instituto Nacional de Tecnologia Agropecuaria); Research council
   of Catholic University of Salta
FX Financial support was provided by INTA (Instituto Nacional de Tecnologia
   Agropecuaria), and Research council of Catholic University of Salta.
CR Appleman D., 1944, CALIFORNIA AVOCADO S, V37
   Barrientos-Priego A. F., 2003, Revista Fitotecnia Mexicana, V26, P285
   BUORO IBJ, 1994, ONDERSTEPOORT J VET, V61, P107
   BURGER WP, 1994, J S AFR VET ASSOC, V65, P113
   Butt AJ, 2006, MOL CANCER THER, V5, P2300, DOI 10.1158/1535-7163.MCT-06-0170
   Chanu V., 2010, INT J RES PHARM SCI, V1, P225
   Forero L., 2010, USITC PUBL, V8398, P1
   Fuller T., 1986, POISONOUS PLANTS CAL, P432
   GRANT R, 1991, J S AFR VET ASSOC, V62, P21
   HARGIS AM, 1989, J AM VET MED ASSOC, V194, P64
   Hurt L., 1943, ANN REP, P43
   Ip C, 2002, NUTR CANCER, V43, P52, DOI 10.1207/S15327914NC431_6
   Kendir G, 2018, J RES PHARM, V22, P347, DOI 10.12991/jrp.2018.74
   Kingsbury J., 1964, POISONOUS PLANTS US, P124
   Koller O., 1992, ABACATICULTURA, P138
   LESLIE DM, 1983, J RANGE MANAGE, V36, P730, DOI 10.2307/3898197
   Malo S., 1976, P W CAN NITR S CALG, P9
   MCKENZIE RA, 1991, AUST VET J, V68, P77, DOI 10.1111/j.1751-0813.1991.tb03147.x
   Mohammad Y., 2010, MILL PHARMACOGN REV, V4
   Oelrichs Peter B., 1995, Natural Toxins, V3, P344, DOI 10.1002/nt.2620030504
   Ojewole JAO, 2006, PHYTOTHER RES, V20, P696, DOI 10.1002/ptr.1940
   Owolabi MA, 2005, FITOTERAPIA, V76, P567, DOI 10.1016/j.fitote.2005.04.020
   Platt R., 1975, CALIFORNIA AVOCADO S, V58, P49
   Pliego-Alfaro F., 1992, V8, P323
   Roberts D, 2007, TLS-TIMES LIT SUPPL, P6
   STADLER P, 1991, J S AFR VET ASSOC, V62, P186
   Strasser A, 2000, ANN NY ACAD SCI, V917, P541
   Yagueddu C., 1996, J RANGE MANAGE, V50
   Yahia EM, 2011, WOODHEAD PUBL FOOD S, P125
NR 29
TC 0
Z9 0
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 16
EP 19
DI 10.1016/j.toxicon.2019.03.024
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000003
PM 30946913
DA 2020-05-12
ER

PT J
AU Isa, HI
   Ferreira, GCH
   Crafford, JE
   Botha, CJ
AF Isa, Hamza Ibrahim
   Ferreira, Gezina Catharina Helena
   Crafford, Jan Ernst
   Botha, Christoffel Jacobus
TI Evaluation of in vitro neutralization of epoxyscillirosidine by
   antibodies raised in sheep
SO TOXICON
LA English
DT Article
DE Antibodies; Epoxyscillirosidine; In vitro; Keyhole limpet haemocyanin;
   Moraea pallida; Neutralization
ID PLANT; VACCINATION; TOXICITY
AB Intoxication by Moraea pallida Bak. (yellow tulp) in livestock is of great importance in South Africa, ranking top among all plant-induced cardiac glycoside toxicosis. The toxic principle, a bufadienolide, is 1 alpha, 2 alpha-epoxyscillirosidine. Treatment of poisoning is challenging and affected livestock often succumbs due to the stress of handling. Manipulating animals to resist poisoning is a potential management strategy. The goal of this study was to explore the potential to develop a vaccine against epoxyscillirosidine by raising antibodies against epoxyscillirosidine in sheep and to assess the neutralization ability of the antibodies in vitro. Epoxyscillirosidine was successfully conjugated to keyhole limpet haemocyanin (KLH) and bovine serum albumin (BSA) rendering them immunogenic. The sheep, vaccinated with epoxyscillirosidine-KLH conjugate (n = 4) and KLH (n = 2) with Montanide, developed antibodies as determined with an indirect enzyme linked immunosorbent assay (ELISA). Total immunoglobulins from sera of vaccinated and control sheep that were purified and concentrated using ammonium sulphate precipitation were 11,940 and 7850 mu g, respectively. The in vitro neutralization assay using the methyl blue tetrazolium bromide (MTT) cell viability assay indicated no significant difference (p > 0.05) between anti-epoxyscillirosidine-KLH and KLH antibodies. Rather, the antibodies seemed to enhance the cytotoxicity of epoxyscillirosidine in H9c2 cells. Thus, it is necessary to develop improved vaccination methods to generate antibodies capable of neutralizing the functional group responsible for epoxyscillirosidine toxicity.
C1 [Isa, Hamza Ibrahim; Ferreira, Gezina Catharina Helena; Botha, Christoffel Jacobus] Univ Pretoria, Dept Paraclin Sci, ZA-0110 Onderstepoort, Gauteng, South Africa.
   [Crafford, Jan Ernst] Univ Pretoria, Dept Vet Trop Dis, ZA-0110 Onderstepoort, Gauteng, South Africa.
   [Isa, Hamza Ibrahim] Ahmadu Bello Univ, Dept Vet Pharmacol & Toxicol, Zaria, Nigeria.
RP Isa, HI (reprint author), Univ Pretoria, Dept Paraclin Sci, ZA-0110 Onderstepoort, Gauteng, South Africa.
EM hiisah@abu.edu.ng
OI Botha, Christo/0000-0003-1535-9270; Isa, Hamza/0000-0002-2928-0136;
   /0000-0001-7343-8327
FU Tshwane Animal Health Innovation Cluster [TAHC 12-00031]
FX This work was supported by the Tshwane Animal Health Innovation Cluster
   (Grant number TAHC 12-00031).
CR Abbas I. M, 2018, METH PROTOC, V1, P2
   Bergmann-Leitner ES, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-129
   Botha CJ, 2007, ONDERSTEPOORT J VET, V74, P307, DOI 10.4102/ojvr.v74i4.117
   Chakraborti AK, 2004, ORG BIOMOL CHEM, V2, P1277, DOI 10.1039/b400588k
   Clementi M E, 1991, Ann Ist Super Sanita, V27, P139
   Fonseca NBD, 2013, FOOD CHEM TOXICOL, V56, P149, DOI 10.1016/j.fct.2013.02.010
   Edgar J. A., 1998, P196
   ENSLIN PR, 1966, TETRAHEDRON, V22, P3213, DOI 10.1016/S0040-4020(01)82303-6
   Filipov NM, 1998, J ANIM SCI, V76, P2456
   GOODROW MH, 1990, J AGR FOOD CHEM, V38, P990, DOI 10.1021/jf00094a016
   Herrera C, 2015, J BIOL CHEM, V290, P27880, DOI 10.1074/jbc.M115.658070
   JOUBERT JPJ, 1982, J S AFR VET ASSOC, V53, P265
   Kamboj A.J., 2013, INT J PHARM PHARM SC, V5, P20
   Kellerman TS, 2009, ONDERSTEPOORT J VET, V76, P19
   Kellerman TS, 1996, ONDERSTEPOORT J VET, V63, P65
   KELLERMAN TS, 2005, PLANT POISONINGS MYC
   KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X
   Kuby J., 1994, IMMUNOLOGY
   Lee ST, 2003, J ANIM SCI, V81, P232
   Lemley P. V, 1994, HYBRIDOMA, V13
   MACDOUGALD OA, 1990, J ANIM SCI, V68, P3713
   Mariam SHS, 2015, SEP PURIF TECHNOL, V144, P133, DOI 10.1016/j.seppur.2015.02.012
   NAUDE T W, 1971, Onderstepoort Journal of Veterinary Research, V38, P255
   Singh KV, 2004, BIOCONJUGATE CHEM, V15, P168, DOI 10.1021/bc034158v
   Steyn PS, 1998, NAT PROD REP, V15, P397
   Surendranath K, 2008, CLIN VACCINE IMMUNOL, V15, P737, DOI 10.1128/CVI.00254-07
   Tijssen P, 1985, PRACTICE THEORY ENZY, P279
   Tong DW, 2008, ANIM FEED SCI TECH, V142, P74, DOI 10.1016/j.anifeedsci.2007.07.007
   Tong DW, 2007, COLLOID SURFACE B, V58, P61, DOI 10.1016/j.colsurfb.2006.10.014
   Torres OB, 2014, ANAL BIOANAL CHEM, V406, P5927, DOI 10.1007/s00216-014-8035-x
   Venkataramana M, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00511
   Wang Y, 2012, INT J MOL SCI, V13, P84, DOI 10.3390/ijms13010084
NR 32
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 20
EP 25
DI 10.1016/j.toxicon.2019.03.023
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000004
PM 30946914
DA 2020-05-12
ER

PT J
AU Valenzuela, C
   Torres, C
   Munoz, V
   Simbaina, JC
   Sanchez, A
   Bustamante, T
   Sepulveda, JM
   Piron, R
   Del Campo, M
   Lagos, N
AF Valenzuela, Carolina
   Torres, Cristian
   Munoz, Vanina
   Carlos Simbaina, Juan
   Sanchez, Andrella
   Bustamante, Tamara
   Sepulveda, Joaquin M.
   Piron, Robin
   Del Campo, Miguel
   Lagos, Nestor
TI Evaluation of Neosaxitoxin as a local anesthetic during piglet
   castration: A potential alternative for Lidocaine
SO TOXICON
LA English
DT Article
DE Piglet castration; Pain control; Long-acting pain blocker; Neosaxitoxin;
   Paralytic shellfish poison toxins; Lidocaine
ID RESPONSES
AB Objetive: To evaluate Neosaxitoxin (NeoSTX) as a local anesthetic drug, for pain control during and after piglet castration.
   Study design: Prospective, randomized and double-blind study.
   Animals: 24 commercial hybrids, males, 23-day-old piglets.
   Methods: The piglets were randomized into two groups: a Lidocaine group and a NeoSTX group. One minute before castration, they were injected intra-scrotally with a single dose of Lidocaine (20 mg, in 1 mL) and NeoSTX (0.1 mu g, in 1 mL), respectively.
   Results: NeoSTX does not generate vasoconstriction or scrotal contraction, unlike Lidocaine, where a decrease in temperature and scrotal size is observed within 5 min after the procedure. After 24 h, wound inflammation, as measured by scrotal size, was lower in the NeoSTX group. No significant difference could be shown between the vocalizations and facial expressions of pain of both groups during the castration procedure.
   Conclusions: A single dose of NeoSTX is safe and effective for pain management during and after piglet castration. NeoSTX treated piglets were less affected by castration than those in the Lidocaine group, thus reducing piglet stress and enhancing the quality of piglet convalescence.
C1 [Valenzuela, Carolina; Torres, Cristian; Munoz, Vanina; Carlos Simbaina, Juan; Sanchez, Andrella] Univ Chile, Fac Vet & Anim Sci, Santa Rosa 11735, Santiago 8820808, Chile.
   [Bustamante, Tamara; Sepulveda, Joaquin M.; Piron, Robin; Del Campo, Miguel; Lagos, Nestor] Univ Chile, Fac Med, Dept Physiol & Biophys, Membrane Biochem Lab, Independencia 1027, Santiago 8389100, Chile.
RP Lagos, N (reprint author), Univ Chile, Fac Med, Dept Physiol & Biophys, Membrane Biochem Lab, Independencia 1027, Santiago 8389100, Chile.
EM cvalenzuelav@u.uchile.cl; crtorres@uchile.cl; vanina.munoz@ug.uchile.cl;
   austrogenetica@gmail.com; andrella.sanchez.g@gmail.com;
   tamara.ibp@gmail.com; joasepulveda.bt@gmail.com; pironrsh@gmail.com;
   Miguel.delcampo@fucited.cl; nlagos@med.uchile.cl
OI Piron, Robin/0000-0003-2647-4995; Simbaina Solano, Juan
   Carlos/0000-0003-2420-2275
FU FONDECYTComision Nacional de Investigacion Cientifica y Tecnologica
   (CONICYT)CONICYT FONDECYT [1130037]
FX This study was supported by FONDECYT Grant # 1130037 Chile.
CR Alonso E, 2016, ARCH TOXICOL, V90, P479, DOI 10.1007/s00204-014-1444-y
   Black JA, 2013, NEURON, V80, P280, DOI 10.1016/j.neuron.2013.09.012
   BONNEAU M, 1982, LIVEST PROD SCI, V9, P687, DOI 10.1016/0301-6226(82)90017-3
   CASTRUM, 2017, PIG CASTR METH AN AN, DOI [10.2875/057159, DOI 10.2875/057159]
   De Briyne N, 2016, PORCINE HEALTH MANAG, V2, DOI 10.1186/s40813-016-0046-x
   Fredriksen B, 2009, ANIMAL, V3, P1480, DOI 10.1017/S1751731109004674
   Hancock T. M, 2018, VET ANAESTH ANALG, V31
   Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038
   Hug PJ, 2018, SCHWEIZ ARCH TIERH, V160, P461, DOI 10.17236/sat00169
   Lagos N, 2014, TOXINS AND BIOLOGICALLY ACTIVE COMPOUNDS FROM MICROALGAE VOL 2: BIOLOGICAL EFFECTS AND RISK MANAGEMENT, P309
   Llewellyn LE, 2006, NAT PROD REP, V23, P200, DOI 10.1039/b501296c
   Lobo K, 2015, ANESTHESIOLOGY, V123, P873, DOI 10.1097/ALN.0000000000000831
   Olson ME, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0735-3
   Caracas HCPM, 2009, J DENT, V37, P93, DOI 10.1016/j.jdent.2008.10.005
   Ranheim B, 2005, J VET PHARMACOL THER, V28, P481, DOI 10.1111/j.1365-2885.2005.00675.x
   Riquelme G, 2018, TOXICON, V141, P15, DOI 10.1016/j.toxicon.2017.11.004
   Rodriguez-Navarro AJ, 2007, ANESTHESIOLOGY, V106, P339, DOI 10.1097/00000542-200702000-00023
   Taylor AA, 2000, APPL ANIM BEHAV SCI, V70, P17, DOI 10.1016/S0168-1591(00)00143-X
   Taylor AA, 2001, APPL ANIM BEHAV SCI, V73, P35, DOI 10.1016/S0168-1591(01)00123-X
   Viscardi AV, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00051
NR 20
TC 0
Z9 0
U1 2
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 26
EP 30
DI 10.1016/j.toxicon.2019.03.021
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000005
PM 30951754
DA 2020-05-12
ER

PT J
AU Deka, A
   Abu Reza, M
   Hoque, KMF
   Deka, K
   Saha, S
   Doley, R
AF Deka, Archana
   Abu Reza, Md
   Hoque, Kazi Md Faisal
   Deka, Kamalakshi
   Saha, Sougata
   Doley, Robin
TI Comparative analysis of Naja kaouthia venom from North-East India and
   Bangladesh and its cross reactivity with Indian polyvalent antivenoms
SO TOXICON
LA English
DT Article
DE Naja kaouthia; Polyvalent antivenoms; Neutralization; Cross-reactivity;
   Immuno-depletion study
ID SNAKE-VENOMS; PHOSPHOLIPASE A(2); SPITTING COBRA; PROTEOMIC
   CHARACTERIZATION; ECHIS OCELLATUS; RUSSELII VENOM; THAI COBRA;
   SRI-LANKA; NEUTRALIZATION; PURIFICATION
AB Naja kaouthia is one of the most prevalent medically important snakes of North East India and Bangladesh responsible for most of the bite cases. In this study, an attempt was made to decipher venom variation of Naja kaouthia venom from North East India and Bangladesh. Using multidimensional methods including reverse phase HPLC, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (1D-PAGE) and two-dimensional gel electrophoresis (2D-PAGE), the quantitative differences in venom composition have been revealed. Moreover, tested in vitro biochemical and biological activities also exhibited differences which could be due to venom variability. Furthermore, neutralization efficacy of commercially available Indian polyvalent antivenoms (Vim, Bharat Serum, Haffkine) was evaluated and the results displayed significant differences in neutralizing efficacy between the antivenoms. Immunoblotting experiments showed antivenom molecules cross reacted with high molecular mass components while poorly reacted towards low molecular mass proteins. Immuno-depletion study demonstrated that Vins polyvalent antivenom was poor in immunocapturing the venom proteins of both North East Indian and Bangladesh origin Naja kaouthia at the ratio of 1:16 (venom: antivenom).
C1 [Deka, Archana; Doley, Robin] Tezpur Univ, Dept Mol Biol & Biotechnol, Mol Toxinol Lab, Tezpur 784028, Assam, India.
   [Abu Reza, Md; Hoque, Kazi Md Faisal] Univ Rajshahi, Dept Genet Engn & Biotechnol, Mol Biol & Prot Sci Lab, Rajshahi 6205, Bangladesh.
   [Deka, Kamalakshi] Tezpur Univ, Cell & Mol Biol Lab, Dept Mol Biol & Biotechnol, Tezpur 784028, Assam, India.
   [Saha, Sougata] Natl Inst Technol Durgapur, Dept Biotechnol, Durgapur 713209, W Bengal, India.
RP Doley, R (reprint author), Tezpur Univ, Dept Mol Biol & Biotechnol, Mol Toxinol Lab, Tezpur 784028, Assam, India.
EM doley@tezu.ernet.in
OI Reza, Dr. Abu/0000-0002-3146-2772
FU ICMR, Govt. of IndiaIndian Council of Medical Research (ICMR)
   [58/10/2015-TFV/BMS]; DBT, Govt. of IndiaDepartment of Biotechnology
   (DBT) India
FX RD acknowledges ICMR, Govt. of India for the grant (No.
   58/10/2015-TFV/BMS). AD acknowledges DBT, Govt. of India for Junior
   Research Fellowship.
CR Ali SA, 2013, J PROTEOMICS, V89, P15, DOI 10.1016/j.jprot.2013.05.015
   Alvarenga LM, 2014, TOXINS, V6, P2541, DOI 10.3390/toxins6082541
   Banerjee Y, 2005, J BIOL CHEM, V280, P42601, DOI 10.1074/jbc.M508987200
   BJARNASON JB, 1994, PHARMACOL THERAPEUT, V62, P325, DOI 10.1016/0163-7258(94)90049-3
   Bogarin G, 2000, TOXICON, V38, P1429, DOI 10.1016/S0041-0101(99)00236-6
   Brahma RK, 2017, THROMB RES, V152, P20, DOI 10.1016/j.thromres.2017.01.012
   Braud S, 2000, BIOCHIMIE, V82, P851, DOI 10.1016/S0300-9084(00)01178-0
   Calvete JJ, 2018, TOXICON, V148, P107, DOI 10.1016/j.toxicon.2018.04.015
   Calvete JJ, 2016, TOXICON, V119, P280, DOI 10.1016/j.toxicon.2016.06.022
   Calvete JJ, 2013, TOXICON, V75, P44, DOI 10.1016/j.toxicon.2013.03.020
   Calvete JJ, 2009, J PROTEOMICS, V72, P121, DOI 10.1016/j.jprot.2009.01.018
   Chippaux Jean-Philippe, 2010, Biologie Aujourd hui, V204, P87, DOI 10.1051/jbio/2009043
   CHIPPAUX JP, 1991, TOXICON, V29, P1279, DOI 10.1016/0041-0101(91)90116-9
   Daltry JC, 1996, NATURE, V379, P537, DOI 10.1038/379537a0
   Das D, 2016, J BIOCHEM MOL TOXIC, V30, P59, DOI 10.1002/jbt.21734
   Das Diganta, 2013, J Venom Res, V4, P31
   de la Rosa G, 2017, PEPTIDES, V88, P80, DOI 10.1016/j.peptides.2016.12.006
   Deka A, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21945
   Doley R, 2003, TOXICON, V41, P81, DOI 10.1016/S0041-0101(02)00213-1
   Doley Robin, 2010, P173
   Dubovskii PV, 2014, CURR MED CHEM, V21, P270
   Dutta S, 2017, J PROTEOMICS, V156, P29, DOI 10.1016/j.jprot.2016.12.018
   Dutta S, 2015, BIOCHIMIE, V110, P93, DOI 10.1016/j.biochi.2014.12.020
   Faisal T, 2018, J PROTEOMICS, V183, P1, DOI 10.1016/j.jprot.2018.05.003
   Faiz M. A., 2017, AM J TROP MED HYG
   Fry BG, 2001, TOXICOL APPL PHARM, V175, P140, DOI 10.1006/taap.2001.9233
   Fry BG, 2008, MOL CELL PROTEOMICS, V7, P215, DOI 10.1074/mcp.M700094-MCP200
   Fry BG, 2012, TOXICON, V60, P434, DOI 10.1016/j.toxicon.2012.02.013
   Furie B, 2008, NEW ENGL J MED, V359, P938, DOI 10.1056/NEJMra0801082
   Gasanov SE, 1997, J MEMBRANE BIOL, V155, P133, DOI 10.1007/s002329900165
   Gibbs H. L, 2009, TOXICON
   Gibbs HL, 2009, J MOL EVOL, V68, P113, DOI 10.1007/s00239-008-9186-1
   Girish V, 2012, EXACTIN SPECIFIC INH, P1
   Gowtham YJ, 2012, BIOCHEMISTRY-MOSCOW+, V77, P639, DOI 10.1134/S0006297912060119
   GUTIERREZ JM, 1990, TOXICON, V28, P1127, DOI 10.1016/0041-0101(90)90110-S
   Hung DZ, 2003, TOXICON, V41, P409, DOI 10.1016/S0041-0101(02)00336-7
   Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218
   Kerns RT, 1999, ARCH BIOCHEM BIOPHYS, V369, P107, DOI 10.1006/abbi.1999.1345
   Kini RM, 2006, BIOCHEM J, V397, P377, DOI 10.1042/BJ20060302
   Kini RM, 2003, TOXICON, V42, P827, DOI 10.1016/j.toxicon.2003.11.002
   Knudsen C, 2018, TRAV MED INFECT DIS, V3
   Kondo H., 1960, Japanese Journal of Medical Science and Biology, V18, P43
   Kulkeaw K, 2007, TOXICON, V49, P1026, DOI 10.1016/j.toxicon.2007.01.019
   Kumar KGS, 2018, INT J GEN MED, V11, P209, DOI 10.2147/IJGM.S136153
   Lauridsen LP, 2017, J PROTEOMICS, V150, P98, DOI 10.1016/j.jprot.2016.08.024
   Laustsen AH, 2015, TOXICON, V99, P23, DOI 10.1016/j.toxicon.2015.03.001
   Leon G, 2018, TOXICON, V151, P63, DOI 10.1016/j.toxicon.2018.06.084
   Lomonte B, 2008, J PROTEOME RES, V7, P2445, DOI 10.1021/pr8000139
   Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165
   Matsui T, 2000, BBA-PROTEIN STRUCT M, V1477, P146, DOI 10.1016/S0167-4838(99)00268-X
   MEIER J, 1986, TOXICON, V24, P395, DOI 10.1016/0041-0101(86)90199-6
   Mendez I, 2011, TOXICON, V58, P558, DOI 10.1016/j.toxicon.2011.08.018
   Modahl CM, 2016, TOXICON, V119, P8, DOI 10.1016/j.toxicon.2016.04.049
   Mukherjee AK, 2002, COMP BIOCHEM PHYS B, V131, P125, DOI 10.1016/S1096-4959(01)00473-0
   Mukherjee AK, 2007, BBA-GEN SUBJECTS, V1770, P187, DOI 10.1016/j.bbagen.2006.09.021
   Mukherjee AK, 2016, J PROTEOMICS, V144, P73, DOI 10.1016/j.jprot.2016.06.001
   Mukherjee AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101334
   Mukherjee AK, 2014, INT J BIOL MACROMOL, V67, P154, DOI 10.1016/j.ijbiomac.2014.02.058
   Mukherjee Ashis K, 2010, J Venom Res, V1, P37
   Oh AMF, 2019, J PROTEOMICS, V193, P243, DOI 10.1016/j.jprot.2018.10.016
   Oh AMF, 2017, J PROTEOMICS, V164, P1, DOI [10.1016/j.jrot.2017.04.018, 10.1016/j.jprot.2017.04.018]
   OUYANG C, 1976, BIOCHIM BIOPHYS ACTA, V420, P298, DOI 10.1016/0005-2795(76)90321-4
   Petras D, 2011, J PROTEOME RES, V10, P1266, DOI 10.1021/pr101040f
   Pla D, 2017, TOXINS, V9
   Pla D, 2012, TOXICON, V60, P688, DOI 10.1016/j.toxicon.2012.04.342
   PONGPRASIT P, 1988, Journal of the Medical Association of Thailand, V71, P475
   Rahman R, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000860
   Rivel M, 2016, TOXICON, V119, P171, DOI 10.1016/j.toxicon.2016.06.006
   Sanchez A, 2018, J PROTEOMICS, V181, P104, DOI 10.1016/j.jprot.2018.04.007
   Sanchez LV, 2015, TOXICON, V106, P97, DOI 10.1016/j.toxicon.2015.09.027
   Sanz L, 2006, J PROTEOME RES, V5, P2098, DOI 10.1021/pr0602500
   Saravu K, 2012, INDIAN J CRIT CARE M, V16, P187, DOI 10.4103/0972-5229.106499
   Shan LL, 2016, J PROTEOMICS, V138, P83, DOI 10.1016/j.jprot.2016.02.028
   Sharma M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153770
   Sharma M, 2015, TOXICON, V107, P266, DOI 10.1016/j.toxicon.2015.06.027
   Shashidharamurthy R, 2010, EXP TOXICOL PATHOL, V62, P587, DOI 10.1016/j.etp.2009.08.002
   Simpson ID, 2007, WILD ENVIRON MED, V18, P2, DOI 10.1580/06-WEME-CO-023R1.1
   Sintiprungrat K, 2016, J PROTEOMICS, V132, P131, DOI 10.1016/j.jprot.2015.10.007
   Squaiella-Baptistao CC, 2018, TOXICON, V150, P86, DOI 10.1016/j.toxicon.2018.05.008
   Stone SF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002326
   Tan KY, 2017, PEERJ, V5, DOI 10.7717/peerj.3142
   Tan KY, 2016, COMP BIOCHEM PHYS C, V185, P77, DOI 10.1016/j.cbpc.2016.03.005
   Tan KY, 2015, J PROTEOMICS, V120, P105, DOI 10.1016/j.jprot.2015.02.012
   TILBURY CR, 1982, S AFR MED J, V61, P308
   Vejayan J, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-6
   VISHWANATH BS, 1988, TOXICON, V26, P713, DOI 10.1016/0041-0101(88)90278-4
   Wang YL, 2010, J BIOL CHEM, V285, P37872, DOI 10.1074/jbc.M110.146290
   WARRELL DA, 1974, BMJ-BRIT MED J, V4, P437, DOI 10.1136/bmj.4.5942.437
   WARRELL DA, 1976, Q J MED, V45, P1
   Warrell DA, 2013, INDIAN J MED RES, V138, P37
   WHO F.A.O, 2006, NEGLECTED TROPICAL D
   Wong K. Y, 2016, AM J TROP MED HYG
   Wongtongkam N, 2005, MIL MED, V170, P336, DOI 10.7205/MILMED.170.4.336
   World Health Organization (WHO), 2017, 10 M WHO STRAT TECHN
   Xu N, 2017, J PROTEOMICS, V159, P19, DOI 10.1016/j.jprot.2017.02.018
NR 95
TC 1
Z9 1
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 31
EP 43
DI 10.1016/j.toxicon.2019.03.025
PG 13
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000006
PM 30953661
DA 2020-05-12
ER

PT J
AU Mazzola, EP
   Deeds, JR
   Stutts, WL
   Ridge, CD
   Dickey, RW
   White, KD
   Williamson, RT
   Martin, GE
AF Mazzola, Eugene P.
   Deeds, Jonathan R.
   Stutts, Whitney L.
   Ridge, Clark D.
   Dickey, Robert W.
   White, Kevin D.
   Williamson, R. Thomas
   Martin, Gary E.
TI Elucidation and partial NMR assignment of monosulfated maitotoxins from
   the Caribbean
SO TOXICON
LA English
DT Article
DE Dinoflagellate; Gambierdiscus; NMR spectroscopy; Liquid
   chromatography-mass spectrometry; High resolution mass spectrometry
ID POTENT ANTIFUNGAL SUBSTANCES; RELATIVE STEREOCHEMISTRY; POLYETHER
   COMPOUND; GAMBIERIC ACIDS; MARINE TOXIN; CIGUATOXIN; SPECTRA; HMQC
AB Compounds similar to maitotoxin (MTX) have been isolated from several laboratory strains of the dinoflagellate Gambierdiscus spp. from the Caribbean. Mass spectral results suggest that these compounds differ from MTX by the loss of one sulfate group and, in some cases, the loss of one methyl group with the addition of one degree of unsaturation. NMR experiments, using approximately 50 nmol of one of these compounds, have demonstrated that the 9-sulfo group of MTX is still present, suggesting that these compounds are 40-desulfo congeners of MTX.
C1 [Mazzola, Eugene P.] Univ Maryland, FDA Joint Inst, College Pk, MD 20742 USA.
   [Deeds, Jonathan R.; Stutts, Whitney L.; Ridge, Clark D.; White, Kevin D.] US FDA, Ctr Food Safety & Appl Nutr, Off Regulatory Sci, College Pk, MD 20740 USA.
   [Dickey, Robert W.] US FDA, Gulf Coast Seafood Lab, Off Food Safety, Dauphin Isl, AL 36528 USA.
   [Williamson, R. Thomas; Martin, Gary E.] Merck Res Labs, Proc & Analyt Chem, NMR Struct Elucidat Grp, Rahway, NJ 07065 USA.
   [Stutts, Whitney L.] North Carolina State Univ, Mol Educ Technol & Res Innovat Ctr, Raleigh, NC 27695 USA.
   [Dickey, Robert W.] Univ Texas Marine Sci Inst, Dept Marine Sci, Port Aransas, TX 78373 USA.
   [Williamson, R. Thomas] Univ North Carolina Wilmington, Dept Chem & Biochem, Wilmington, NC 28403 USA.
   [Martin, Gary E.] Seton Hall Univ, Dept Chem & Biochem, S Orange, NJ 07070 USA.
RP Ridge, CD (reprint author), US FDA, Ctr Food Safety & Appl Nutr, Off Regulatory Sci, College Pk, MD 20740 USA.
EM clark.ridge@fda.hhs.gov
OI Stutts, Whitney/0000-0002-9149-5031
CR ACD, 2014, C H NMR PRED VERS 14
   CROUCH RC, 1995, TETRAHEDRON, V51, P8409, DOI 10.1016/0040-4020(95)00360-K
   CROUCH RC, 1995, TETRAHEDRON LETT, V36, P6827, DOI 10.1016/00404-0399(50)1386V-
   Deeds Jonathan R., 2002, Harmful Algae, V1, P169, DOI 10.1016/S1568-9883(02)00027-6
   Deeds JR, 2010, TOXICON, V56, P150, DOI 10.1016/j.toxicon.2009.05.035
   Dickey RW, 2010, TOXICON, V56, P123, DOI 10.1016/j.toxicon.2009.09.008
   Holmes Michael J., 1994, Natural Toxins, V2, P64, DOI 10.1002/nt.2620020204
   HOLMES MJ, 1990, TOXICON, V28, P1159, DOI 10.1016/0041-0101(90)90116-O
   ISHIDA H, 1995, TETRAHEDRON LETT, V36, P725, DOI 10.1016/0040-4039(94)02326-7
   Kokinos John P., 1995, Palynology, V19, P143
   LEE MS, 1987, NEW J CHEM, V11, P753
   LEWIS RJ, 1991, TOXICON, V29, P1115, DOI 10.1016/0041-0101(91)90209-A
   LEWIS RJ, 1993, TOXICON, V31, P637, DOI 10.1016/0041-0101(93)90118-3
   Lewis RJ, 2001, TOXICON, V39, P97, DOI 10.1016/S0041-0101(00)00161-6
   Matsumori N, 1996, TETRAHEDRON LETT, V37, P1269, DOI 10.1016/0040-4039(95)02413-1
   Miller D. M., 1984, SEAFOOD TOXINS, P257
   MURATA M, 1994, J AM CHEM SOC, V116, P7098, DOI 10.1021/ja00095a013
   MURATA M, 1993, J AM CHEM SOC, V115, P2060, DOI 10.1021/ja00058a075
   MURATA M, 1992, J AM CHEM SOC, V114, P6594, DOI 10.1021/ja00042a070
   MURATA M, 1992, TETRAHEDRON LETT, V33, P525, DOI 10.1016/S0040-4039(00)93986-8
   MURATA M, 1989, J AM CHEM SOC, V111, P8929, DOI 10.1021/ja00206a032
   NAGAI H, 1992, J ORG CHEM, V57, P5448, DOI 10.1021/jo00046a029
   NAGAI H, 1992, J AM CHEM SOC, V114, P1102, DOI 10.1021/ja00029a057
   Nicolaou KC, 2008, ANGEW CHEM INT EDIT, V47, P7182, DOI 10.1002/anie.200801696
   Rodriguez I, 2015, ORG LETT, V17, P2392, DOI 10.1021/acs.orglett.5b00902
   SATAKE M, 1993, TETRAHEDRON LETT, V34, P1975, DOI 10.1016/S0040-4039(00)91978-6
   SATAKE M, 1993, J AM CHEM SOC, V115, P361, DOI 10.1021/ja00054a061
   SATAKE M, 1995, J AM CHEM SOC, V117, P7019, DOI 10.1021/ja00131a032
   Satoh H, 2005, TETRAHEDRON, V61, P7431, DOI 10.1016/j.tet.2005.05.074
   Selwood AI, 2008, CHEM RES TOXICOL, V21, P944, DOI 10.1021/tx700441w
   Smurnyy YD, 2005, TETRAHEDRON, V61, P9980, DOI 10.1016/j.tet.2005.08.022
   Watanabe R, 2013, TETRAHEDRON, V69, P10299, DOI 10.1016/j.tet.2013.10.022
   YOKOYAMA A, 1988, J BIOCHEM-TOKYO, V104, P184, DOI 10.1093/oxfordjournals.jbchem.a122438
   Zheng WJ, 1996, J AM CHEM SOC, V118, P7946, DOI 10.1021/ja961230+
NR 34
TC 0
Z9 0
U1 5
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 44
EP 50
DI 10.1016/j.toxicon.2019.03.026
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000007
PM 30954452
DA 2020-05-12
ER

PT J
AU Rex, CJ
   Mackessy, SP
AF Rex, Christopher J.
   Mackessy, Stephen P.
TI Venom composition of adult Western Diamondback Rattlesnakes (Crotalus
   atrox) maintained under controlled diet and environmental conditions
   shows only minor changes
SO TOXICON
LA English
DT Article
DE Diet; Enzyme toxins; Snake venom; Variation
ID ONTOGENIC VARIATION; SEASONAL-VARIATION; SNAKE VENOMICS; JUVENILE;
   STABILITY; EVOLUTION; HELLERI; WILD
AB Many species of snakes produce venom as a chemical means of procuring potentially fractious prey. Studies have increasingly focused on venom compositional variation between and within individual snakes of the same species/subspecies, with significant differences often being observed. This variation in composition has been attributed to differences in age, season, diet, and environment, suggesting that these factors could help explain the inter- and intra-specific variation found in some snake venoms, perhaps via some type of feedback mechanism(s). To address several of these possible sources of variation, this study utilized wild-caught Western Diamondback Rattlesnakes (Crotalus atrox) from Cochise Co., AZ. Sixteen adult C. atrox were maintained in the lab on a diet of NSA mice for eight months to determine whether venom composition changed in captivity under a static diet in a stable environment. Reducing 1-D SDS-PAGE, fibrinogen degradation assays, reversed-phase HPLC, and MALDI-TOF mass spectrometry revealed only minor differences over time within individuals. Venom L-amino acid oxidase (LAAO) and phosphodiesterase activities significantly increased over the course of captivity, with no changes occurring in azocasein metalloproteinase, kallikrein-like serine proteinase (KLSP), or thrombin-like serine proteinase (TLSP) activities. Snake total length was positively correlated with TLSP activity and negatively correlated with LAAO and KLSP activity. There was typically a much higher degree of variation between individuals than within individuals for all analyses performed and measurements collected. Because the overall "fingerprint" of each snakes venom remained more/less constant, it is concluded that biologically significant changes in venom composition did not occur within individual C. atrox as a function of captivity/diet. However, this study does indicate that differences in activity levels do occur in minor venom enzyme components, but the differences observed are likely to be of minimal significance to the production of antivenom or to subsequent treatment of human envenomations.
C1 [Rex, Christopher J.; Mackessy, Stephen P.] Univ Northern Colorado, Dept Biol Sci, 501 20th St, Greeley, CO 80639 USA.
   [Rex, Christopher J.] 3758 S 300 W, Albion, MI 37583 USA.
RP Mackessy, SP (reprint author), Univ Northern Colorado, Dept Biol Sci, 501 20th St, Greeley, CO 80639 USA.
EM stephen.mackessy@unco.edu
OI Mackessy, Stephen/0000-0003-4515-2545
FU University of Northern Colorado Graduate School and Graduate Student
   Association
FX We thank Drs. T. Schountz and M. P. Thomas for excellent suggestions on
   C. J. Rex's Master's thesis, from which this manuscript was prepared.
   This research was supported by grants awarded by the University of
   Northern Colorado Graduate School and Graduate Student Association to
   CJR.
CR Aird SD, 2008, COMP BIOCHEM PHYS B, V150, P222, DOI 10.1016/j.cbpb.2008.03.005
   Alape-Giron A, 2008, J PROTEOME RES, V7, P3556, DOI 10.1021/pr800332p
   Beaupre SJ, 1998, J COMP PHYSIOL B, V168, P497, DOI 10.1007/s003600050170
   BERTKE EM, 1966, TOXICON, V4, P73, DOI 10.1016/0041-0101(66)90070-5
   Biardi JE, 2011, TOXICON, V57, P323, DOI 10.1016/j.toxicon.2010.12.011
   BONILLA CA, 1969, TOXICON, V7, P327, DOI 10.1016/0041-0101(69)90034-8
   Boyer D. R., 1957, Herpetologica, V13, P213
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Calvete JJ, 2010, J PROTEOME RES, V9, P528, DOI 10.1021/pr9008749
   Calvete JJ, 2009, J PROTEOME RES, V8, P3055, DOI 10.1021/pr900249q
   Calvete JJ, 2009, FEBS LETT, V583, P1736, DOI 10.1016/j.febslet.2009.03.029
   Campbell J. A, 2004, VENOMOUS REPTILES W, P870
   Daltry JC, 1996, NATURE, V379, P537, DOI 10.1038/379537a0
   Daltry JC, 1996, TOXICON, V34, P67, DOI 10.1016/0041-0101(95)00122-0
   FIERO MK, 1972, TOXICON, V10, P81, DOI 10.1016/0041-0101(72)90095-5
   Freitas-de-Sousa LA, 2015, BIOCHIMIE, V118, P60, DOI 10.1016/j.biochi.2015.08.006
   Fry BG, 2008, MOL CELL PROTEOMICS, V7, P215, DOI 10.1074/mcp.M700094-MCP200
   Galizio ND, 2018, J PROTEOMICS, V186, P56, DOI 10.1016/j.jprot.2018.07.007
   Gibbs HL, 2011, J PROTEOMICS, V74, P2169, DOI 10.1016/j.jprot.2011.06.013
   GLENN JL, 1977, TOXICON, V16, P81
   Gold BS, 2004, EMERG MED CLIN N AM, V22, P423, DOI 10.1016/j.emc.2004.01.007
   GREGORYDWYER VM, 1986, TOXICON, V24, P995, DOI 10.1016/0041-0101(86)90005-X
   GUBENSEK F, 1974, TOXICON, V12, P167, DOI 10.1016/0041-0101(74)90241-4
   JIMENEZ-PORRAS JESUS M., 1964, TOXICON, V2, P187, DOI 10.1016/0041-0101(64)90021-2
   JIMENEZ-PORRAS JESUS M., 1964, TOXICON, V2, P155, DOI 10.1016/0041-0101(64)90017-0
   JIMENJM, 1961, J EXP ZOOL, V148, P251
   JOHNSON BD, 1968, TOXICON, V6, P5, DOI 10.1016/0041-0101(68)90061-5
   JOHNSON EK, 1987, NORTHWEST SCI, V61, P110
   JONES JM, 1976, COPEIA, P558, DOI 10.2307/1443375
   Junqueira-de-Azevedo ILM, 2016, TOXINS, V8, DOI 10.3390/toxins8080230
   Kalita B, 2018, EXPERT REV PROTEOMIC, V15, P837, DOI 10.1080/14789450.2018.1528150
   Kardong KV, 1997, NETH J ZOOL, V47, P411
   Lourenco A, 2013, TOXICON, V69, P75, DOI 10.1016/j.toxicon.2013.01.006
   Mackessy S. P., 2010, HDB VENOMS TOXINS RE
   Mackessy SP, 2006, TOXICON, V47, P537, DOI 10.1016/j.toxicon.2006.01.007
   MACKESSY SP, 1993, COMP BIOCHEM PHYS B, V106, P181, DOI 10.1016/0305-0491(93)90025-Z
   MacKessy SP, 2003, COPEIA, P769, DOI 10.1643/HA03-037.1
   Mackessy SP, 2002, J TOXICOL-TOXIN REV, V21, P43, DOI 10.1081/TXR-120004741
   MACKESSY SP, 1988, COPEIA, P92, DOI 10.2307/1445927
   MACKESSY SP, 2008, BIOL RATTLESNAKES, P495
   Mackessy SP, 2018, TOXINS, V10, DOI 10.3390/toxins10070271
   Mackessy SP, 2016, INTEGR COMP BIOL, V56, P1004, DOI 10.1093/icb/icw110
   Mackessy SP, 2010, TOXICON, V55, P1463, DOI 10.1016/j.toxicon.2010.02.028
   McCleary RJR, 2016, J PROTEOMICS, V144, P51, DOI 10.1016/j.jprot.2016.05.027
   MINTON SA, 1975, TOXICON, V13, P73, DOI 10.1016/0041-0101(75)90162-2
   MINTON SA, 1986, TOXICON, V24, P71, DOI 10.1016/0041-0101(86)90167-4
   MINTON SHERMAN A., 1957, COPEIA, V1957, P265, DOI 10.2307/1439150
   Munekiyo SM, 1998, COMP BIOCHEM PHYS B, V119, P119, DOI 10.1016/S0305-0491(97)00294-0
   OUYANG C, 1979, BIOCHIM BIOPHYS ACTA, V571, P270, DOI 10.1016/0005-2744(79)90097-4
   Pahari S, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-115
   REID HA, 1978, AM J TROP MED HYG, V27, P1053, DOI 10.4269/ajtmh.1978.27.1053
   Saviola AJ, 2014, TOXIN REV, V33, P185, DOI 10.3109/15569543.2014.942040
   SCHENBERG S., 1963, TOXICON, V1, P67, DOI 10.1016/0041-0101(63)90049-7
   Smith CF, 2016, TOXICON, V120, P110, DOI 10.1016/j.toxicon.2016.08.001
   STEBBINS R, 1985, FIELD GUIDE W REPTIL
   STRAIGHT R, 1976, NATURE, V261, P259, DOI 10.1038/261259a0
   Strickland JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35810-9
   Taylor EN, 2005, J EXP ZOOL PART A, V303A, P598, DOI 10.1002/jez.a.189
   TU AT, 1969, TOXICON, V6, P175, DOI 10.1016/0041-0101(69)90117-2
   Weldon CL, 2010, TOXICON, V55, P558, DOI 10.1016/j.toxicon.2009.10.010
   Zelanis A, 2010, J PROTEOME RES, V9, P2278, DOI 10.1021/pr901027r
NR 61
TC 3
Z9 3
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 51
EP 60
DI 10.1016/j.toxicon.2019.03.027
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000008
PM 30954451
DA 2020-05-12
ER

PT J
AU Del-Rei, THM
   Sousa, LF
   Rocha, MMT
   Freitas-de-Sousa, LA
   Travaglia-Cardoso, SR
   Grego, K
   Sant'Anna, SS
   Chalkidis, HM
   Moura-da-Silva, AM
AF Del-Rei, Tiago H. Moretto
   Sousa, Leijiane F.
   Rocha, Marisa M. T.
   Freitas-de-Sousa, Luciana A.
   Travaglia-Cardoso, Silvia R.
   Grego, Kathleen
   Sant'Anna, Savio S.
   Chalkidis, Hipocrates M.
   Moura-da-Silva, Ana M.
TI Functional variability of Bothrops atrox venoms from three distinct
   areas across the Brazilian Amazon and consequences for human envenomings
SO TOXICON
LA English
DT Article
DE Bothrops atrox; Snake; Venom; Antivenom; Snakebite; Amazon
ID SNAKE-VENOM; TRANSCRIPTOME ANALYSIS; NEUTRALIZING CAPACITY; ONTOGENIC
   VARIABILITY; METALLOPROTEINASE; JARARHAGIN; IDENTIFICATION; ANTIVENOMS;
   PLATELETS; PROTEINS
AB Variability in the composition of snake venoms occurs in different taxa and is usually correlated to snake fitness. Here, we compared B. atrox venoms from three different geographic regions across the Brazilian Amazon and found remarkable functional differences particularly between venoms from two populations separated by the Amazon River, in specimens born, raised and maintained under the same conditions at Institute Butantan serpentary. Venom from Presidente Figueiredo snakes induced stronger dermonecrosis, but was less procoagulant and lethal to mice; these activities were correlated to the presence of a PI-class SVMP and absence of a SVSP in the venom, respectively. Venom from Sao Bento snakes was more hemorrhagic, killed mice more efficiently, but induced lower signs of dermonecrosis, which was correlated to the higher proportion of SVMPs and the absence of a PI-class SVMP isoform. Belterra snakes, a reference of wild snakes, presented venoms with intermediate phenotypes. Commercial Bothrops antivenom was effective in neutralizing all biological activities evaluated in this study, including dermonecrosis and pro-coagulant, which are relevant for human snakebite accidents by B. atrox. Functional differences correlated to snake fitness may also imply in different symptomatology for B. atrox snakebite patients and deserve special attention from clinical toxicologists.
C1 [Del-Rei, Tiago H. Moretto; Sousa, Leijiane F.; Freitas-de-Sousa, Luciana A.; Moura-da-Silva, Ana M.] Insituto Butantan, Lab Imunopatol, BR-05503900 Sao Paulo, Brazil.
   [Rocha, Marisa M. T.; Grego, Kathleen; Sant'Anna, Savio S.] Insituto Butantan, Lab Herpetol, BR-05503900 Sao Paulo, Brazil.
   [Travaglia-Cardoso, Silvia R.] Insituto Butantan, Museu Biol, BR-05503900 Sao Paulo, Brazil.
   [Chalkidis, Hipocrates M.] Unama Ctr Univ Amazonia, Lab Pesquisas Zool, Santarem, PA, Brazil.
RP Moura-da-Silva, AM (reprint author), Insituto Butantan, Lab Imunopatol, BR-05503900 Sao Paulo, Brazil.
EM ana.moura@butantan.gov.br
RI Freitas-de-Sousa, Luciana A./U-1779-2017; Moura-da-Silva, Ana
   M/A-5247-2008; Grego, Kathleen F/A-6394-2014; Cardoso, Silvia R
   Travaglia/G-8956-2015; de Sousa, Leijiane F Figueira/F-8735-2017
OI Freitas-de-Sousa, Luciana A./0000-0002-4426-0731; Moura-da-Silva, Ana
   M/0000-0003-1787-6634; Grego, Kathleen F/0000-0003-4769-5818; de Sousa,
   Leijiane/0000-0001-6303-0897
FU CAPESCAPES [063/2010]; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2016/50,127-5, 2014/13,124-2]; CNPqNational Council
   for Scientific and Technological Development (CNPq) [304,025/2014-3]
FX CAPES-063/2010-Toxinology (Research funds and THMDR - MSc scholarship,
   LAFS - PhD scholarship); FAPESP (2016/50,127-5 - research funds, and
   2014/13,124-2 - LFS PhD scholarship); CNPq 304,025/2014-3 (AMMS
   fellowship).
CR Amazonas DR, 2018, J PROTEOMICS, V181, P60, DOI 10.1016/j.jprot.2018.03.032
   Amorim F. G, 2018, TOXINS, V10
   Andrade DV, 1999, HERPETOLOGICA, V55, P200
   Arlinghaus FT, 2012, TOXICON, V60, P512, DOI 10.1016/j.toxicon.2012.03.001
   Baldo C, 2008, TOXICON, V51, P54, DOI 10.1016/j.toxicon.2007.08.005
   Bernardoni JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109651
   BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345
   Calvete JJ, 2017, BIOCHEM J, V474, P611, DOI 10.1042/BCJ20160577
   Calvete JJ, 2011, J PROTEOMICS, V74, P510, DOI 10.1016/j.jprot.2011.01.003
   CAMPBELL JA, 2004, VENOMOUS REPTILES W
   Daltry JC, 1996, NATURE, V379, P537, DOI 10.1038/379537a0
   de Oliveira SS, 2017, TOXICON, V138, P102, DOI 10.1016/j.toxicon.2017.08.021
   de Queiroz MR, 2017, TOXICON, V133, P33, DOI 10.1016/j.toxicon.2017.04.013
   Durban J, 2017, J PROTEOME RES, V16, P3370, DOI 10.1021/acs.jproteome.7b00414
   Durban J, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-234
   Escalante T, 2011, J PROTEOMICS, V74, P1781, DOI 10.1016/j.jprot.2011.03.026
   Fernandez J, 2015, TOXICON, V107, P217, DOI 10.1016/j.toxicon.2015.08.016
   Franca F.O.S., 2009, ANIMAIS PECONHENTOS, P81
   Freitas-de-Sousa LA, 2015, BIOCHIMIE, V118, P60, DOI 10.1016/j.biochi.2015.08.006
   Freitas-de-Sousa LA, 2017, TOXINS, V9, DOI 10.3390/toxins9080239
   Furtado MFD, 2006, TOXICON, V48, P401, DOI 10.1016/j.toxicon.2006.06.005
   Furtado MDD, 2010, TOXICON, V55, P881, DOI 10.1016/j.toxicon.2009.12.014
   Gibbs HL, 2018, BIOL J LINN SOC, V123, P651, DOI 10.1093/biolinnean/blx158
   Gibbs HL, 2009, TOXICON, V53, P672, DOI 10.1016/j.toxicon.2009.01.034
   GREENE HW, 1997, SNAKES EVOLUTION MIS
   Guercio RAP, 2006, PROTEOME SCI, V4, DOI 10.1186/1477-5956-4-11
   GUTIERREZ JM, 1986, COMP BIOCHEM PHYS C, V84, P159, DOI 10.1016/0742-8413(86)90183-0
   Gutierrez JM, 2005, TOXICON, V45, P997, DOI 10.1016/j.toxicon.2005.02.029
   HOFMANN H, 1987, BIOCHEMISTRY-US, V26, P772, DOI 10.1021/bi00377a018
   Jimenez N, 2008, J INVEST DERMATOL, V128, P2421, DOI 10.1038/jid.2008.118
   Kamiguti AS, 1996, TOXICON, V34, P627, DOI 10.1016/0041-0101(96)00017-7
   Kamiguti AS, 1997, J BIOL CHEM, V272, P32599, DOI 10.1074/jbc.272.51.32599
   Kamiguti AS, 1996, BIOCHEM J, V320, P635, DOI 10.1042/bj3200635
   Kini RM, 2001, HAEMOSTASIS, V31, P218
   Knittel PS, 2016, TOXICON, V119, P1, DOI 10.1016/j.toxicon.2016.04.048
   Koutsouraki E, 2019, STEM CELL RES, V34, DOI 10.1016/j.scr.2018.11.019
   Laing GD, 2005, TOXICON, V45, P987, DOI 10.1016/j.toxicon.2005.02.013
   Barreto GNLS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005458
   Lopez-Lozano JL, 2002, TOXICON, V40, P997, DOI 10.1016/S0041-0101(02)00096-X
   Gutierrez JM, 2013, TOXICON, V62, P27, DOI 10.1016/j.toxicon.2012.09.006
   Moreno E, 2005, REV SOC BRAS MED TRO, V38, P15, DOI 10.1590/S0037-86822005000100004
   Moura-Da-Silva AM, 2007, CURR PHARM DESIGN, V13, P2893, DOI 10.2174/138161207782023711
   Neiva M, 2009, TOXICON, V53, P427, DOI 10.1016/j.toxicon.2009.01.006
   Nunez V, 2009, J PROTEOMICS, V73, P57, DOI 10.1016/j.jprot.2009.07.013
   Otero R, 1997, BRAZ J MED BIOL RES, V30, P375, DOI 10.1590/S0100-879X1997000300011
   Pardal PPD, 2004, T ROY SOC TROP MED H, V98, P28, DOI 10.1016/S0035-9203(03)00005-1
   Sajevic T, 2011, TOXICON, V57, P627, DOI 10.1016/j.toxicon.2011.01.006
   Salazar AM, 2007, THROMB RES, V120, P95, DOI 10.1016/j.thromres.2006.07.004
   Saldarriaga MM, 2003, TOXICON, V42, P405, DOI 10.1016/S0041-0101(03)00171-5
   Sanchez EF, 2010, ARCH BIOCHEM BIOPHYS, V496, P9, DOI 10.1016/j.abb.2010.01.010
   Saravia P, 2002, REV BIOL TROP, V50, P337
   Segura A, 2010, TOXICON, V56, P980, DOI 10.1016/j.toxicon.2010.07.001
   Serrano SMT, 2013, TOXICON, V62, P19, DOI 10.1016/j.toxicon.2012.09.003
   Silva MB, 2003, BIOCHEM J, V369, P129, DOI 10.1042/BJ20020449
   Sousa LF, 2018, TOXINS, V10, DOI 10.3390/toxins10100411
   Sousa LF, 2017, J PROTEOMICS, V159, P32, DOI 10.1016/j.jprot.2017.03.003
   Sousa LF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002442
   Stocker K., 1976, Methods Enzymol, V45, P214
   Wen FH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003701
   Zelanis A, 2016, J PROTEOMICS, V139, P26, DOI 10.1016/j.jprot.2016.02.030
   Zelanis A, 2011, PROTEOMICS, V11, P4218, DOI 10.1002/pmic.201100287
NR 61
TC 4
Z9 4
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 61
EP 70
DI 10.1016/j.toxicon.2019.04.001
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000009
PM 30991062
DA 2020-05-12
ER

PT J
AU Sanchez, MN
   Teibler, GP
   Sciani, JM
   Casafus, MG
   Marunak, SL
   Mackessy, SP
   Peichoto, ME
AF Sanchez, Matias N.
   Teibler, Gladys P.
   Sciani, Juliana M.
   Casafus, Milena G.
   Marunak, Silvana L.
   Mackessy, Stephen P.
   Peichoto, Maria E.
TI Unveiling toxicological aspects of venom from the Aesculapian False
   Coral Snake Erythrolamprus aesculapii
SO TOXICON
LA English
DT Article
DE Colubrid; Enzymes; Gland histology; Maxilla morphology; Rear-fanged
   snake; Toxins
ID DUVERNOYS GLAND SECRETION; BOIGA-IRREGULARIS; BROWN TREESNAKE;
   SERPENTES; PROTEINS; INGESTION; BITES; PREY; RNA
AB Most colubrid snake venoms have been poorly studied, despite the fact that they represent a great resource for biological, ecological, toxinological and pharmacological research. Herein, we explore the venom delivery system of the Aesculapian False Coral Snake Erythrolamprus aesculapii as well as some biochemical and toxicological properties of its venom. Its Duvernoy's venom gland is composed of serous secretory cells arranged in densely packed secretory tubules, and the most striking feature of its fang is their double-curved shape, exhibiting a beveled bladelike appearance near the tips. Although E. aesculapii resembles elapid snakes of the genus Micrurus in color pattern, this species produces a venom reminiscent of viperid venoms, containing mainly tissue damaging toxins such as proteinases. Prominent hemorrhage developed both locally and systemically in mice injected with the venom, and the minimum hemorrhagic dose was found to be 18.8 mu g/mouse; the lethal dose, determined in mice, was 9.5 +/- 3.7 mu g/g body weight. This work has toxicological implications that bites to humans by E. aesculapii could result in moderately severe local (and perhaps systemic) hemorrhage and gives insight into future directions for research on the venom of this species.
C1 [Sanchez, Matias N.; Casafus, Milena G.; Peichoto, Maria E.] Inst Nacl Med Trop INMeT, Consejo Nacl Invest Cient & Tecn CONICET, Neuquen & Jujuy S-N, RA-3370 Puerto Iguazu, Argentina.
   [Teibler, Gladys P.; Marunak, Silvana L.] Univ Nacl Nordeste UNNE, Fac Ciencias Vet FCV, Sargento Cabral 2139, RA-3400 Corrientes, Argentina.
   [Sciani, Juliana M.] Univ Sao Francisco, Lab Multidisciplinar Pesquisa, Ave Sao Francisco Assis 218, BR-12916900 Braganca Paulista, SP, Brazil.
   [Mackessy, Stephen P.] Univ Northern Colorado, Sch Biol Sci, 501 20th St,CB 92, Greeley, CO 80639 USA.
RP Peichoto, ME (reprint author), Inst Nacl Med Trop INMeT, Consejo Nacl Invest Cient & Tecn CONICET, Neuquen & Jujuy S-N, RA-3370 Puerto Iguazu, Argentina.
EM mepeichoto@yahoo.com.ar
RI Sciani, Juliana Mozer/B-6990-2012
OI Sciani, Juliana Mozer/0000-0001-7213-206X; Peichoto,
   Maria/0000-0001-7269-3086; Mackessy, Stephen/0000-0003-4515-2545
FU INMeT; CONICETConsejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET) [PIP 112-201301-00126-CO]; Agencia Nacional de Promocion
   Cientifica y Tecnologica from ArgentinaANPCyT [PICT-2013-1238]; RDFD
   travel/research grant from UNC
FX This work was supported by INMeT, CONICET (PIP 112-201301-00126-CO), and
   Agencia Nacional de Promocion Cientifica y Tecnologica (PICT-2013-1238)
   from Argentina, as well as an RDFD travel/research grant from UNC to
   SPM.
CR Quintana MA, 2017, COMP BIOCHEM PHYS C, V202, P55, DOI 10.1016/j.cbpc.2017.07.007
   Antunes TC, 2010, TOXICON, V56, P1443, DOI 10.1016/j.toxicon.2010.08.011
   Arzamendia V., 2012, CUAD HERPETOL, V26, P352
   BERNHEIMER AW, 1987, TOXICON, V25, P547, DOI 10.1016/0041-0101(87)90290-X
   BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203
   Braz HB, 2016, SALAMANDRA, V52, P211
   Dokmetjian JC, 2009, TOXICON, V53, P375, DOI 10.1016/j.toxicon.2008.12.015
   Coronado MA, 2018, TOXICON, V153, P106, DOI 10.1016/j.toxicon.2018.08.014
   de Lema T., 1978, Natureza em Revista, P38
   de Oliveira L, 2016, S AM J HERPETOL, V11, P54, DOI 10.2994/SAJH-D-16-00011.1
   ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9
   Giraudo A. R, 2014, PROBLEMATICA OFIDISM, P10
   Goncalves LRC, 2000, MEDIAT INFLAMM, V9, P101, DOI 10.1080/096293500411569
   GREENE HW, 1976, Z TIERPSYCHOL, V41, P113
   Junqueira-de-Azevedo ILM, 2016, TOXINS, V8, DOI 10.3390/toxins8080230
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lemoine K, 2004, WILD ENVIRON MED, V15, P82, DOI 10.1580/1080-6032(2004)015[0082:PHANAC]2.0.CO;2
   Lemoine K, 2003, REV CIENT-FAC CIEN V, V13, P371
   Mackessy S. P., 2010, HDB VENOMS TOXINS RE, P528
   Mackessy SP, 2006, TOXICON, V47, P537, DOI 10.1016/j.toxicon.2006.01.007
   McGivern JJ, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1061
   MINTON SA, 1990, J WILDERNESS MED, V1, P119, DOI 10.1580/0953-9859-1.2.119
   Modahl CM, 2018, J PROTEOMICS, V187, P223, DOI 10.1016/j.jprot.2018.08.004
   Modahl CM, 2018, P ROY SOC B-BIOL SCI, V285, DOI 10.1098/rspb.2018.1003
   *NAT RES COUNC, 1996, GUIDE CARE USE LAB A, P140
   Peichoto ME, 2006, TOXICON, V48, P520, DOI 10.1016/j.toxicon.2006.06.013
   Pla D, 2018, J PROTEOMICS, V174, P71, DOI 10.1016/j.jprot.2017.12.020
   Quelch J. J, 1893, ZOOL J LINN SOC-LOND, V17, P31
   Renner Marcia Ferret, 2000, Revista Brasileira de Zoologia, V17, P583
   Sanchez MN, 2014, HUM EXP TOXICOL, V33, P22, DOI 10.1177/0960327113493302
   Sanchez MN, 2018, TOXICON, V148, P202, DOI 10.1016/j.toxicon.2018.04.027
   Saviola AJ, 2014, TOXIN REV, V33, P185, DOI 10.3109/15569543.2014.942040
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   Serapicos Eliana de Oliveira, 2006, Pap. Avulsos Zool. (São Paulo), V46, P187, DOI 10.1590/S0031-10492006001500001
   Taub A. M., 1967, Bulletin of the American Museum of Natural History, V138, P1
   Torres-Bonilla KA, 2017, TOXICON, V131, P29, DOI 10.1016/j.toxicon.2017.02.030
   Weinstein SA, 2011, ELSEV INSIGHT, P33, DOI 10.1016/B978-0-12-387732-1.00004-X
   Weldon CL, 2010, TOXICON, V55, P558, DOI 10.1016/j.toxicon.2009.10.010
   ZALISKO EJ, 1992, COPEIA, P791
NR 39
TC 2
Z9 2
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 71
EP 81
DI 10.1016/j.toxicon.2019.04.007
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000010
PM 30998944
DA 2020-05-12
ER

PT J
AU Kheirandish, MH
   Jaliani, HZ
   Rahmani, B
   Nikukar, H
AF Kheirandish, Mohammad Hassan
   Jaliani, Hossein Zarei
   Rahmani, Behnaz
   Nikukar, Habib
TI Specific targeting of a pore-forming toxin (listeriolysin O) to
   LHRH-positive cancer cells using LHRH targeting peptide
SO TOXICON
LA English
DT Article
DE Drug delivery systems; Cell-targeting peptides; Pore-forming toxins;
   Listeriolysin O
ID DELIVERY; PURIFICATION; IMMUNOTOXIN; EXPRESSION; ANTIBODY;
   MONOCYTOGENES; PROTEINS
AB Conventional drug delivery systems have many limitations including cytotoxicity and affecting non-specific cells. Cell-targeting peptides (CTPs) as a potential class of targeting moiety have some advantages over previous targeting moieties such as monoclonal antibodies, offer additional benefits to design systems using CTPs. Here we have engineered listeriolysin O (LLO) pore-forming toxin by adding a luteinizing hormone-releasing hormone (LHRH) targeting peptide to its N-terminus. Two versions of the toxin, with and without targeting peptide, were sub-cloned into a bacterial expression plasmid. BL21 DE3 cells were used for induction of expression and recombinant proteins were purified using nickel-immobilized metal affinity chromatography column. In order to treat MDA-MB-231 and SKOV3 cell lines as LHRH receptor positive and negative cells, two mentioned LLO toxins were used to evaluate their cytotoxicity and specificity. Our results reveal that the IC50 of LLO toxin on MDA-MB-231 and SKOV3 cells was 0.32 and 0.41 mu g/ml respectively. Furthermore, IC50 of fusion LHRH-LLO toxin on the cells was 0.88 and 19.55 mu g/ml. Cytotoxicity of engineered LHRH-LLO toxin on negative cells was significantly 48-fold lower than wild-type LLO toxin. But this difference has been lowered to only 2.7-fold less cytotoxicity in positive cells. To the best of our knowledge, the current work as the first study regarding engineered toxin revealed that CDC family members could be used to target the specific cell-type.
C1 [Kheirandish, Mohammad Hassan; Jaliani, Hossein Zarei; Rahmani, Behnaz] Shahid Sadoughi Univ Med Sci, Sch Med, Dept Med Genet, Prot Engn Lab, Shohadaye Gomnam Blvd, Yazd, Iran.
   [Kheirandish, Mohammad Hassan; Jaliani, Hossein Zarei; Nikukar, Habib] Shahid Sadoughi Univ Med Sci, Dept Adv Med Sci & Technol, Fac Paramed, Yazd, Iran.
RP Jaliani, HZ (reprint author), Shahid Sadoughi Univ Med Sci, Sch Med, Dept Med Genet, Prot Engn Lab, Shohadaye Gomnam Blvd, Yazd, Iran.
EM hzarei@ssu.ac.ir
RI Jaliani, Hossein Zarei/R-5735-2019; Nikukar, Habib/AAJ-3000-2020
OI Jaliani, Hossein Zarei/0000-0002-6324-3785; 
FU Shahid Sadoughi University of Medical Sciences
FX This work was supported by a grant from the Deputy of Research and
   Technology, Shahid Sadoughi University of Medical Sciences and was
   written based on a data set of a Medical Biotechnology M.Sc. thesis
   registered in School of Medicine, Shahid Sadoughi University of Medical
   Sciences. Yazd, Iran.
CR Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137
   Ai SB, 2013, BRIT J PHARMACOL, V168, P1719, DOI 10.1111/bph.12055
   Bergelt S, 2009, PROTEIN SCI, V18, P1210, DOI 10.1002/pro.130
   Borghaei H, 2004, SEMIN NUCL MED, V34, P4, DOI 10.1053/j.semnuclmed.2003.11.002
   Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476-5381.2009.00190.x
   Cohen S, 2007, J BIOL CHEM, V282, P28301, DOI 10.1074/jbc.M703567200
   Dal Peraro M, 2016, NAT REV MICROBIOL, V14, P77, DOI 10.1038/nrmicro.2015.3
   Dharap SS, 2005, P NATL ACAD SCI USA, V102, P12962, DOI 10.1073/pnas.0504274102
   Giles RV, 1998, NUCLEIC ACIDS RES, V26, P1567, DOI 10.1093/nar/26.7.1567
   Gurkan C, 2003, PROTEIN EXPRES PURIF, V29, P103, DOI 10.1016/S1046-5928(03)00012-3
   Imani M, 2017, IRAN J BASIC MED SCI, V20, P380, DOI 10.22038/IJBMS.2017.8577
   Kayal S, 2006, FEMS MICROBIOL REV, V30, P514, DOI 10.1111/j.1574-6976.2006.00021.x
   Kheirandish MH, 2017, INT J MED LAB, V4, P189
   Kim NH, 2015, MOL PHARMACEUT, V12, P342, DOI 10.1021/mp5004543
   Krop I, 2014, CLIN CANCER RES, V20, P15, DOI 10.1158/1078-0432.CCR-13-0541
   Le Joncour V, 2018, BIOORGAN MED CHEM, V26, P2797, DOI 10.1016/j.bmc.2017.08.052
   Minko T, 2004, CURR DRUG TARGETS, V5, P389, DOI 10.2174/1389450043345443
   Orban E, 2011, BIOCONJUGATE CHEM, V22, P2154, DOI 10.1021/bc2004236
   Panchal R. G., 2002, Current Pharmaceutical Biotechnology, V3, P99, DOI 10.2174/1389201023378418
   Podobnik M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09623
   PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x
   Powell DJ, 2007, J IMMUNOL, V179, P4919, DOI 10.4049/jimmunol.179.7.4919
   Schnupf P, 2007, MICROBES INFECT, V9, P1176, DOI 10.1016/j.micinf.2007.05.005
   Stachowiak R, 2014, BMC BIOTECHNOL, V14, DOI 10.1186/1472-6750-14-77
   Torchilin Vladimir P, 2010, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-00477-3_1
   Tran SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022876
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Walev I, 2001, P NATL ACAD SCI USA, V98, P3185, DOI 10.1073/pnas.051429498
   Wan L, 2006, PROTEIN EXPRES PURIF, V48, P307, DOI 10.1016/j.pep.2006.02.005
NR 29
TC 0
Z9 0
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN
PY 2019
VL 164
BP 82
EP 86
DI 10.1016/j.toxicon.2019.04.005
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HZ9BY
UT WOS:000469152000011
PM 30991063
DA 2020-05-12
ER

PT J
AU Park, YS
   Sammartino, F
   Young, NA
   Corrigan, J
   Krishna, V
   Rezai, AR
AF Park, Yong-Sook
   Sammartino, Francesco
   Young, Nicole A.
   Corrigan, John
   Krishna, Vibhor
   Rezai, Ali R.
TI Anatomic Review of the Ventral Capsule/Ventral Striatum and the Nucleus
   Accumbens to Guide Target Selection for Deep Brain Stimulation for
   Obsessive-Compulsive Disorder
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anterior commissure; Deep brain stimulation; Internal capsule; Nucleus
   accumbens; Obsessive-compulsive disorder; Reward circuitry; Ventral
   striatum
ID MEDIAL FOREBRAIN-BUNDLE; ELECTRICAL-STIMULATION; EFFERENT PROJECTIONS;
   INTERNAL CAPSULE; BED NUCLEUS; COMPARTMENTAL ORGANIZATION;
   HIPPOCAMPAL-FORMATION; ANTERIOR COMMISSURE; RHESUS-MONKEY; RAT
AB BACKGROUND: Disturbances in the reward network of the brain underlie addiction, depression, and obsessive-compulsive disorder. The ventral capsule/ventral striatum and nucleus accumbens (NAc) region is a clinically approved target for deep brain stimulation for obsessive-compulsive disorder.
   METHODS: We performed a comprehensive literature review to define clinically relevant anatomy and connectivity of the ventral capsule/ventral striatum and NAc region to guide target selection for deep brain stimulation.
   RESULTS: Architecturally and functionally, the NAc is divided into the core and the shell, with each area having different connections. The shell primarily receives limbic information, and the core typically receives information from the motor system. In general, afferents from the prefrontal cortex, hippocampus, and amygdala are excitatory. The dopaminergic projections to the NAc from the ventral tegmental area modulate the balance of these excitatory inputs. Several important inputs to the NAc converge at the junction of the internal capsule (IC) and the anterior commissure (AC): the ventral amygdalofugal pathways that run parallel to and underneath the AC, the precommissural fornical fibers that run anterior to the AC, axons from the ventral prefrontal cortex and medial orbitofrontal cortex that occupy the most ventral part of the IC and embedding within the NAc and AC, and the superolateral branch of the medial forebrain bundle located parallel to the anterior thalamic radiation in the IC.
   CONCLUSIONS: The caudal part of the NAc passing through the IC-AC junction may be an effective target for deep brain stimulation to improve behavioral symptoms associated with obsessive-compulsive disorder.
C1 [Park, Yong-Sook] Chung Ang Univ Hosp, Dept Neurosurg, Seoul, South Korea.
   [Sammartino, Francesco; Young, Nicole A.; Corrigan, John; Krishna, Vibhor] Ohio State Univ, Dept Neurosurg, Columbus, OH 43210 USA.
   [Rezai, Ali R.] West Virginia Univ Hosp, Dept Neurosurg, Morgantown, WV USA.
RP Krishna, V (reprint author), Ohio State Univ, Dept Neurosurg, Columbus, OH 43210 USA.
EM vibhorkrishna@yahoo.com
RI Krishna, Vibhor/AAG-3809-2019
OI Krishna, Vibhor/0000-0002-4141-4192
CR Abelson JL, 2005, BIOL PSYCHIAT, V57, P510, DOI 10.1016/j.biopsych.2004.11.042
   Aggleton JP, 2008, Q J EXP PSYCHOL, V61, P1441, DOI 10.1080/17470210802215335
   Alonso P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133591
   Altman J, 1996, PSYCHOPHARMACOLOGY, V125, P285, DOI 10.1007/BF02246016
   Ambroggi F, 2008, NEURON, V59, P648, DOI 10.1016/j.neuron.2008.07.004
   Anderson D, 2003, J NEUROSURG, V98, P1104, DOI 10.3171/jns.2003.98.5.1104
   Aouizerate B, 2009, J NEUROSURG, V111, P775, DOI 10.3171/2009.2.JNS0881
   Axer H, 1999, PSYCHIAT RES-NEUROIM, V91, P141, DOI 10.1016/S0925-4927(99)00029-3
   AXER H, 1994, METHOD INFORM MED, V33, P488
   Baliki MN, 2013, J NEUROSCI, V33, P16383, DOI 10.1523/JNEUROSCI.1731-13.2013
   BERENDSE HW, 1993, NEUROSCI LETT, V150, P75, DOI 10.1016/0304-3940(93)90112-X
   Berridge CW, 1997, SYNAPSE, V27, P230, DOI 10.1002/(SICI)1098-2396(199711)27:3<230::AID-SYN8>3.0.CO;2-E
   Blomstedt P, 2013, WORLD NEUROSURG, V80, pE245, DOI 10.1016/j.wneu.2012.10.006
   Brauer K, 2000, BRAIN RES, V858, P151, DOI 10.1016/S0006-8993(00)01938-7
   Breiter HC, 1999, ANN NY ACAD SCI, V877, P523, DOI 10.1111/j.1749-6632.1999.tb09287.x
   BROG JS, 1993, J COMP NEUROL, V338, P255, DOI 10.1002/cne.903380209
   Chabardes S, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.03.010
   Cho Z. H., 2015, 7 0 TESLA MRI BRAIN
   Coenen VA, 2012, J NEUROPSYCH CLIN N, V24, P223, DOI 10.1176/appi.neuropsych.11080180
   Coenen VA, 2011, ACTA NEUROCHIR, V153, P1579, DOI 10.1007/s00701-011-1036-z
   Coenen VA, 2009, NEUROSURGERY, V64, P1106, DOI 10.1227/01.NEU.0000345631.54446.06
   Cote PY, 1996, HIPPOCAMPUS, V6, P483
   de Koning PP, 2011, CURR PSYCHIAT REP, V13, P274, DOI 10.1007/s11920-011-0200-8
   Denys D, 2006, PSYCHIAT CLIN N AM, V29, P553, DOI 10.1016/j.psc.2006.02.013
   Denys D, 2010, ARCH GEN PSYCHIAT, V67, P1061, DOI 10.1001/archgenpsychiatry.2010.122
   DEUTCH AY, 1992, NEUROSCIENCE, V46, P49, DOI 10.1016/0306-4522(92)90007-O
   Di Virgilio G, 1999, EXP BRAIN RES, V124, P1, DOI 10.1007/s002210050593
   Dong HW, 2009, P NATL ACAD SCI USA, V106, P11794, DOI 10.1073/pnas.0812608106
   Doshi PK, 2016, STEREOT FUNCT NEUROS, V94, P326, DOI 10.1159/000449066
   Engelhardt Eliasz, 2010, Dement. neuropsychol., V4, P293, DOI 10.1590/S1980-57642010DN40400007
   Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031
   Fayad SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167875
   Figee M, 2011, BIOL PSYCHIAT, V69, P867, DOI 10.1016/j.biopsych.2010.12.003
   Fontaine D, 2004, J NEUROSURG, V100, P1084, DOI 10.3171/jns.2004.100.6.1084
   Franzini A, 2010, NEUROL SCI, V31, P353, DOI 10.1007/s10072-009-0214-8
   Friedman DP, 2002, J COMP NEUROL, V450, P345, DOI 10.1002/cne.10336
   Fudge JL, 2002, J NEUROSCI, V22, P10078
   Fudge JL, 2002, NEUROSCIENCE, V110, P257, DOI 10.1016/S0306-4522(01)00546-2
   Galvez JF, 2015, PROG NEURO-PSYCHOPH, V58, P59, DOI 10.1016/j.pnpbp.2014.12.003
   GERFEN CR, 1987, J NEUROSCI, V7, P3935
   GERFEN CR, 1987, J NEUROSCI, V7, P3915
   GIMENEZAMAYA JM, 1995, J COMP NEUROL, V354, P127, DOI 10.1002/cne.903540109
   Goodman WK, 2010, BIOL PSYCHIAT, V67, P535, DOI 10.1016/j.biopsych.2009.11.028
   Greenberg BD, 2010, MOL PSYCHIATR, V15, P64, DOI 10.1038/mp.2008.55
   GROENEWEGEN HJ, 1984, J COMP NEUROL, V223, P347, DOI 10.1002/cne.902230303
   Groenewegen HJ, 1999, ANN NY ACAD SCI, V877, P49, DOI 10.1111/j.1749-6632.1999.tb09260.x
   GROENEWEGEN HJ, 1987, NEUROSCIENCE, V23, P103, DOI 10.1016/0306-4522(87)90275-2
   Gruber AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005062
   Guehl D, 2008, BIOL PSYCHIAT, V63, P557, DOI 10.1016/j.biopsych.2007.06.023
   Haber S. N., 2011, NEUROBIOLOGY SENSATI
   HABER SN, 1995, J NEUROSCI, V15, P4851
   HABER SN, 1990, J COMP NEUROL, V293, P282, DOI 10.1002/cne.902930210
   Hassler R, 1982, STEREOTAXY HUMAN BRA, P140
   HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y
   Heimer L, 1978, LIMBIC MECHANISMS CO, P95
   Huff W, 2010, CLIN NEUROL NEUROSUR, V112, P137, DOI 10.1016/j.clineuro.2009.11.006
   Hurwitz TA, 2006, STEREOT FUNCT NEUROS, V84, P228, DOI 10.1159/000096496
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   IKEMOTO K, 1995, EXP BRAIN RES, V104, P177
   Islam L, 2015, WORLD NEUROSURG, V83, P657, DOI 10.1016/j.wneu.2014.12.024
   Ito R, 2008, J NEUROSCI, V28, P6950, DOI 10.1523/JNEUROSCI.1615-08.2008
   Jimenez F, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.07.010
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515
   Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kamali A, 2016, BRAIN STRUCT FUNCT, V221, P3561, DOI 10.1007/s00429-015-1119-3
   Kamali A, 2015, NEUROSCI LETT, V608, P45, DOI 10.1016/j.neulet.2015.09.035
   KELLEY AE, 1982, NEUROSCIENCE, V7, P2321, DOI 10.1016/0306-4522(82)90198-1
   KLINGLER J, 1960, J COMP NEUROL, V115, P333, DOI 10.1002/cne.901150305
   KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J
   Kuhn J, 2008, NEUROMODULATION, V11, P128, DOI 10.1111/j.1525-1403.2008.00154.x
   Kuhn J, 2007, J NEUROL, V254, P963, DOI 10.1007/s00415-006-0404-8
   KUNISHIO K, 1994, J COMP NEUROL, V350, P337, DOI 10.1002/cne.903500302
   Lehman JF, 2011, J NEUROSCI, V31, P10392, DOI 10.1523/JNEUROSCI.0595-11.2011
   Lozano AM, 2008, BIOL PSYCHIAT, V64, P461, DOI 10.1016/j.biopsych.2008.05.034
   Lucas-Neto L, 2013, ACTA NEUROCHIR, V155, P2389, DOI 10.1007/s00701-013-1820-z
   Lucas-Neto L, 2015, NEUROMODULATION, V18, P341, DOI 10.1111/ner.12289
   Lucas-Neto L, 2014, STEREOT FUNCT NEUROS, V92, P291, DOI 10.1159/000365115
   Luyten L, 2016, MOL PSYCHIATR, V21, P1272, DOI 10.1038/mp.2015.124
   LYNDBALTA E, 1994, NEUROSCIENCE, V59, P609, DOI 10.1016/0306-4522(94)90181-3
   Mai JK, 2007, ATLAS HUMAN BRAIN ST
   Mallet L, 2002, LANCET, V360, P1302, DOI 10.1016/S0140-6736(02)11339-0
   Mavridis I, 2011, SURG RADIOL ANAT, V33, P583, DOI 10.1007/s00276-011-0804-z
   Mavridis IN, 2014, ACTA NEUROCHIR, V156, P589, DOI 10.1007/s00701-013-1883-x
   McKittrick CR, 2007, J NEUROCHEM, V100, P1247, DOI 10.1111/j.1471-4159.2006.04300.x
   Meidahl AC, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00117
   Meredith GE, 1996, J COMP NEUROL, V365, P628, DOI 10.1002/(SICI)1096-9861(19960219)365:4<628::AID-CNE9>3.0.CO;2-6
   MEREDITH GE, 1989, NEUROSCIENCE, V31, P327, DOI 10.1016/0306-4522(89)90377-1
   Moore H, 1999, BIOL PSYCHIAT, V46, P40, DOI 10.1016/S0006-3223(99)00078-5
   Morel A, 2002, J COMP NEUROL, V443, P86, DOI 10.1002/cne.10096
   Munte TF, 2008, FRONT HUM NEUROSCI, V1, DOI 10.3389/neuro.09.011.2007
   Mulders AEP, 2017, WORLD NEUROSURG, V104, DOI 10.1016/j.wneu.2017.05.067
   NAUTA WJH, 1978, NEUROSCIENCE, V3, P385, DOI 10.1016/0306-4522(78)90041-6
   Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0
   Neto LL, 2008, NEUROMODULATION, V11, P13, DOI 10.1111/j.1525-1403.2007.00138.x
   NIEUWENHUYS R, 1982, J COMP NEUROL, V206, P49, DOI 10.1002/cne.902060106
   Nuttin B, 1999, LANCET, V354, P1526, DOI 10.1016/S0140-6736(99)02376-4
   Nuttin BJ, 2003, NEUROSURGERY, V52, P1263, DOI 10.1227/01.NEU.0000064565.49299.9A
   O'Donnell P, 1999, ANN NY ACAD SCI, V877, P157, DOI 10.1111/j.1749-6632.1999.tb09267.x
   ODONNELL P, 1995, J NEUROSCI, V15, P3622
   PARENT A, 1984, BRAIN RES, V303, P385, DOI 10.1016/0006-8993(84)91224-1
   Peltier J, 2011, NEUROSURGERY, V69, P241, DOI 10.1227/NEU.0b013e31821bc822
   PICKEL VM, 1988, J COMP NEUROL, V272, P1, DOI 10.1002/cne.902720102
   Prensa L, 2003, J COMP NEUROL, V460, P345, DOI 10.1002/cne.10627
   Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8
   Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111
   Roh D, 2012, PSYCHIAT RES, V200, P1067, DOI 10.1016/j.psychres.2012.06.018
   Ruscio AM, 2010, MOL PSYCHIATR, V15, P53, DOI 10.1038/mp.2008.94
   Salamone JD, 2005, CURR OPIN PHARMACOL, V5, P34, DOI 10.1016/j.coph.2004.09.004
   Schlaepfer TE, 2013, BIOL PSYCHIAT, V73, P1204, DOI 10.1016/j.biopsych.2013.01.034
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   SCHULTZ W, 1992, J NEUROSCI, V12, P4595, DOI 10.1523/jneurosci.12-12-04595.1992
   SESACK SR, 1992, J COMP NEUROL, V320, P145, DOI 10.1002/cne.903200202
   Sesack SR, 2010, NEUROPSYCHOPHARMACOL, V35, P27, DOI 10.1038/npp.2009.93
   Shirayama Y, 2006, CURR NEUROPHARMACOL, V4, P277, DOI 10.2174/157015906778520773
   Strominger NL, 2012, RETICULAR FORMATION, P380
   Strominger NL, 2012, THALAMUS NOBACKS HUM, P397
   Sturm V, 2003, J CHEM NEUROANAT, V26, P293, DOI 10.1016/j.jchemneu.2003.09.003
   SWANSON LW, 1977, J COMP NEUROL, V172, P49, DOI 10.1002/cne.901720104
   TOTTERDELL S, 1989, J CHEM NEUROANAT, V2, P285
   Tsai HC, 2012, PSYCHIAT CLIN NEUROS, V66, P303, DOI 10.1111/j.1440-1819.2012.02352.x
   van den Munckhof Pepijn, 2013, Acta Neurochir Suppl, V117, P53, DOI 10.1007/978-3-7091-1482-7_9
   van Kuyck K, 2007, ACTA NEUROCHIR SUPPL, V97, P375
   Vanderah TW, 2016, DRIVES EMOTIONS NOLT, P579
   VOORN P, 1989, J COMP NEUROL, V289, P189, DOI 10.1002/cne.902890202
   VOORN P, 1994, EUR J NEUROSCI, V6, P1913, DOI 10.1111/j.1460-9568.1994.tb00582.x
   Winter L, 2018, WORLD NEUROSURG, V111, pE471, DOI 10.1016/j.wneu.2017.12.084
   Wolf Marina E, 2002, Mol Interv, V2, P146, DOI 10.1124/mi.2.3.146
   ZABORSZKY L, 1985, NEUROSCIENCE, V14, P427, DOI 10.1016/0306-4522(85)90302-1
   ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D
   ZAHM DS, 1993, J COMP NEUROL, V327, P220, DOI 10.1002/cne.903270205
NR 131
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 1
EP 10
DI 10.1016/j.wneu.2019.01.254
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400196
PM 30790738
DA 2020-05-12
ER

PT J
AU Jervaeus, A
   Fritzell, K
   Lundh-Hagelin, C
   von Vogelsang, AC
AF Jervaeus, Anna
   Fritzell, Kaisa
   Lundh-Hagelin, Carina
   von Vogelsang, Ann-Christin
TI Does the Time Trade-Off Method Reflect Health-Related Quality of Life? A
   Mixed-Methods Analysis of Preference Measures 10 Years After Aneurysmal
   Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Health-related quality of life; Intracranial aneurysm; Preference
   measures; Subarachnoid hemorrhage; Time trade-off
ID RESPONSE SHIFT; PERSONALITY; RUPTURE; VALUES
AB OBJECTIVE: To investigate if the time trade-off (TT0) method reflects health-related quality of life (HRQoL) 10 years after an aneurysmal subarachnoid hemorrhage (aSAH).
   METHODS: A cross-sectional study with a mixed-methods approach was used to follow up 208 patients treated for aSAH. Data were collected with intramethod mixing; the quantitative data consisted of the EQ-5D-3L instrument and a TT0 question, and the qualitative data comprised motivations to the TT0 answer. The quantitative data were analyzed statistically and comparisons were made between participants willing to trade off years and those not willing to trade off years. The qualitative data were merged in a matrix and analyzed with manifest content analysis.
   RESULTS: Participants willing to trade off years scored significantly lower HRQoL, and the correlation between EQ-5D(index) and EQ VAS to TT0 values were r(s) = 0.369 (P < 0.001) and r(s) = 0.345 (P < 0.001), respectively. In the content analysis, 4 categories emerged: perceived full health or satisfactory life; adaptability and managing strategies; the importance of hope and meaning in life; and unacceptable changes do not make life worth living. The results showed that several reasons other than health status were evident when expressing the willingness to trade off or not trade off life-years.
   CONCLUSIONS: Individuals willing to trade off years showed significantly poorer HRQoL; however the TT0 method did not seem to fully reflect HRQoL. Most participants did not want to trade off years, despite their living with severe disability, making it difficult to fully rely on the TT0 method in evaluation of medical outcome.
C1 [Jervaeus, Anna; Fritzell, Kaisa; Lundh-Hagelin, Carina] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden.
   [von Vogelsang, Ann-Christin] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
   [Lundh-Hagelin, Carina] Ersta Skondal Brack Univ Coll, Stockholm, Sweden.
   [von Vogelsang, Ann-Christin] Karolinska Univ Hosp, Theme Neuro, Stockholm, Sweden.
RP von Vogelsang, AC (reprint author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.; von Vogelsang, AC (reprint author), Karolinska Univ Hosp, Theme Neuro, Stockholm, Sweden.
EM ann-christin.von-vogelsang@ki.se
RI von Vogelsang, Ann-Christin/Y-2368-2019
OI von Vogelsang, Ann-Christin/0000-0002-3006-2443
CR Arnesen T M, 2003, Med Humanit, V29, P81, DOI 10.1136/mh.29.2.81
   Arnesen Trude, 2004, J Health Serv Res Policy, V9, P43, DOI 10.1258/135581904322716111
   Attema AE, 2013, EUR J HEALTH ECON, V14, pS53, DOI 10.1007/s10198-013-0508-x
   BENNETT KJ, 1996, QUALITY LIFE PHARMAC, P253
   Boye KS, 2014, EXPERT REV PHARM OUT, V14, P437, DOI 10.1586/14737167.2014.912562
   Burstrom K, 2006, HEALTH POLICY, V76, P359, DOI 10.1016/j.healthpol.2005.06.011
   Burstrom K, 2014, QUAL LIFE RES, V23, P431, DOI 10.1007/s11136-013-0496-4
   De Wit GA, 2000, HEALTH ECON, V9, P109, DOI 10.1002/(SICI)1099-1050(200003)9:2<109::AID-HEC503>3.0.CO;2-L
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
   Donohoe JE, 2011, QUAL LIFE RES, V20, P161, DOI 10.1007/s11136-010-9745-y
   Drummond M, 2005, METHODS EC EVALUATIO
   Feeny D, 1996, QUALITY LIFE PHARMAC, P85
   Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001
   Greebe P, 2010, J NEUROL, V257, P2059, DOI 10.1007/s00415-010-5660-y
   Janssen MF, 2013, QUAL LIFE RES, V22, P1717, DOI 10.1007/s11136-012-0322-4
   Johnson R. B., 2003, HDB MIXED METHODS SO, P297, DOI DOI 10.4135/9781506335193
   Katati MJ, 2007, CEREBROVASC DIS, V24, P66, DOI 10.1159/000103118
   King JT, 2005, STROKE, V36, P303, DOI 10.1161/01.STR.0000152950.46598.f1
   Meyer B, 2010, CEREBROVASC DIS, V30, P423, DOI 10.1159/000317078
   Ostlund U, 2011, INT J NURS STUD, V48, P369, DOI 10.1016/j.ijnurstu.2010.10.005
   Schwartz CE, 1999, SOC SCI MED, V48, P1531, DOI 10.1016/S0277-9536(99)00047-7
   van Nooten FE, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-015-0402-6
   van Nooten FE, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0276-7
   Visser-Meily JMA, 2009, STROKE, V40, P1526, DOI 10.1161/STROKEAHA.108.531277
   von Vogelsang AC, 2017, NEUROSURGERY, V81, P650, DOI 10.1093/neuros/nyx059
   von Vogelsang AC, 2015, WORLD NEUROSURG, V83, P1090, DOI 10.1016/j.wneu.2014.12.027
   von Vogelsang AC, 2013, WORLD NEUROSURG, V80, P328, DOI 10.1016/j.wneu.2012.06.041
   von Vogelsang AC, 2013, NEUROSURGERY, V72, P397, DOI 10.1227/NEU.0b013e3182804686
   von Vogelsang AC, 2013, WORLD NEUROSURG, V79, P130, DOI 10.1016/j.wneu.2012.03.032
   Wermer MJH, 2007, NEUROSURGERY, V60, P91, DOI 10.1227/01.NEU.0000249215.19591.86
   World Health Organization, INT CLASS DIS
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 11
EP 20
DI 10.1016/j.wneu.2019.02.036
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400197
PM 30797932
DA 2020-05-12
ER

PT J
AU O'Connor, KP
   Palejwala, AH
   Briggs, RG
   Massoth, L
   Argo, JL
   Glenn, CA
AF O'Connor, Kyle P.
   Palejwala, Ali H.
   Briggs, Robert G.
   Massoth, Landon
   Argo, Jimmy L.
   Glenn, Chad A.
TI Use of Pterional Craniotomy for Removal of Penetrating Object: Case
   Report and Surgical Video
SO WORLD NEUROSURGERY
LA English
DT Article
DE Penetrating injury; Pterional craniotomy; Tuberculum sellae
ID INJURY; MANAGEMENT
AB BACKGROUND: Penetrating injuries are dangerous because they can damage intracranial structures. Removal of the object carries this same risk of injury, so neurosurgeons often visualize the injury via craniotomy during removal.
   CASE DESCRIPTION: This report illustrates the case of a 41-year-old man who had a penetrating injury with a knife that started in the left nasal passage and extended to the parasellar region. Computed tomography angiography revealed an associated sphenoid fracture and showed the tip of the knife within the parasellar space with preservation of the internal carotid artery, ophthalmic artery, optic nerve, and pituitary gland. The patient was taken to the operating room for a right pterional craniotomy and the knife was removed in the operating room in a combined effort between neurosurgery and otorhinolaryngology.
   CONCLUSIONS: The patient progressed well without complications post-operatively and was discharged 5 days later. We provide a report with video showing our surgical approach for removal of a penetrating object through the tuberculum sellae.
C1 [O'Connor, Kyle P.; Palejwala, Ali H.; Briggs, Robert G.; Glenn, Chad A.] Univ Oklahoma, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK 73019 USA.
   [Massoth, Landon; Argo, Jimmy L.] Univ Oklahoma, Hlth Sci Ctr, Dept Otorhinolaryngol, Oklahoma City, OK USA.
RP Glenn, CA (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK 73019 USA.
EM chad-glenn@ouhsc.edu
OI Massoth, Landon/0000-0002-9735-2402
CR Bhatjiwale MG, 2001, BRIT J NEUROSURG, V15, P256, DOI 10.1080/02688690120057709
   Damm A, 2015, BMJ CASE REP, V2015
   de Holanda LF, 2016, WORLD NEUROSURG, V90, P420, DOI 10.1016/j.wneu.2016.03.015
   Ihama Y, 2012, FORENSIC SCI INT, V214, pE9, DOI 10.1016/j.forsciint.2011.07.004
   ILDAN F, 1994, J TRAUMA, V36, P116, DOI 10.1097/00005373-199401000-00020
   NATH FP, 1984, NEUROSURGERY, V14, P598, DOI 10.1227/00006123-198405000-00016
   Takanashi Y, 2002, J Neurosurg Sci, V46, P25
   Voisin MR, 2017, J CLIN NEUROSCI, V41, P88, DOI 10.1016/j.jocn.2017.03.008
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 21
EP 23
DI 10.1016/j.wneu.2019.02.080
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400198
PM 30825621
DA 2020-05-12
ER

PT J
AU Tanahashi, K
   Araki, Y
   Uda, K
   Muraoka, S
   Motomura, K
   Lushun, C
   Wakabayashi, T
   Natsume, A
AF Tanahashi, Kuniaki
   Araki, Yoshio
   Uda, Kenji
   Muraoka, Shinsuke
   Motomura, Kazuya
   Lushun, Chalise
   Wakabayashi, Toshihiko
   Natsume, Atsushi
TI Posterior Cerebral Artery Reconstruction by In-Situ Bypass with Superior
   Cerebellar Artery via Occipital Transtentorial Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE In-situ bypass; Occipital transtentorial approach; Posterior cerebral
   artery; Superior cerebellar artery; Thrombosed aneurysm; Trapping
ID SUPRACEREBELLAR TRANSTENTORIAL; SUBTEMPORAL APPROACH; ANEURYSMS;
   ANASTOMOSIS; SEGMENT
AB BACKGROUND: Posterior cerebral artery (PCA) aneurysms are relatively rare, and neck clipping is often difficult due to their fusiform shape. We report a case of a thrombosed aneurysm of the distal PCA for which curative trapping and parent artery reconstruction by in situ bypass were performed through an occipital transtentorial approach (OTA).
   CASE DESCRIPTION: A 67-year-old woman had been suffering from numbness in the right face and limbs for 4 months. Radiologic imaging demonstrated a thrombosed aneurysm on a distal portion of the left PCA. Curative trapping of the aneurysm and in-situ bypass between the distal PCA and superior cerebellar artery were performed through the OTA. Before surgery, we had evaluated access to the PCA and feasibility of the bypass in a cadaveric simulation. The PCA was well exposed in the posterior half of the ambient cistern, and the proximity of the distal PCA to the superior cerebellar artery through a tentorial incision was confirmed.
   CONCLUSIONS: This OTA could represent a useful option for definitive treatment of distal PCA aneurysms.
C1 [Tanahashi, Kuniaki; Araki, Yoshio; Uda, Kenji; Muraoka, Shinsuke; Motomura, Kazuya; Lushun, Chalise; Wakabayashi, Toshihiko; Natsume, Atsushi] Nagoya Univ, Dept Neurosurg, Grad Sch Med, Nagoya, Aichi, Japan.
RP Araki, Y (reprint author), Nagoya Univ, Dept Neurosurg, Grad Sch Med, Nagoya, Aichi, Japan.
EM y.araki@med.nagoya-u.ac.jp
OI Muraoka, Shinsuke/0000-0003-4225-110X
CR DRAKE CG, 1969, J NEUROSURG, V30, P468, DOI 10.3171/jns.1969.30.4.0468
   Goehre F, 2015, WORLD NEUROSURG, V83, P842, DOI 10.1016/j.wneu.2015.01.042
   Goehre F, 2014, NEUROSURGERY, V75, P134, DOI 10.1227/NEU.0000000000000363
   Honda M, 2004, NEUROL MED-CHIR, V44, P164, DOI 10.2176/nmc.44.164
   Inoue T, 2006, SURG NEUROL, V66, P638, DOI 10.1016/j.surneu.2006.03.035
   JAMIESON KG, 1971, J NEUROSURG, V35, P550, DOI 10.3171/jns.1971.35.5.0550
   Jittapiromsak P, 2009, NEUROSURGERY, V64, pS35, DOI [10.1227/01.NFU.0000334048.96722.A7, 10.1227/01.NEU.0000334048.96772.A7]
   Kawashima A, 2017, OPER NEUROSURG, V13, P309, DOI 10.1093/ons/opw033
   Keser N, 2018, WORLD NEUROSURG, V112, pE534, DOI 10.1016/j.wneu.2018.01.073
   Nakamura M, 2017, SURG CEREB STROKE, V45, P89
   Quinones-Hinojosa A, 2005, NEUROSURGERY, V57, P140, DOI 10.1227/01.NEU.0000163599.78896.F4
   Rodriguez-Hernandez A, 2013, J NEUROSURG, V118, P1053, DOI 10.3171/2013.2.JNS122250
   Saito H, 2006, SURG NEUROL, V65, P621, DOI 10.1016/j.surneu.2005.09.009
   SAKATA S, 1993, NEUROSURGERY, V32, P163, DOI 10.1227/00006123-199302000-00002
   SATO O, 1981, ACTA NEUROCHIR, V59, P195, DOI 10.1007/BF01406349
   Terasaka S, 2000, NEUROSURGERY, V47, P359, DOI 10.1097/00006123-200008000-00016
   Uygur E, 2007, J CLIN NEUROSCI, V14, P494, DOI 10.1016/j.jocn.2006.02.003
   Yamahata H, 2010, NEUROL MED-CHIR, V50, P1084, DOI 10.2176/nmc.50.1084
   Yasargil MG, 1984, MICRONEUROSURGERY, VII, P232
   Yonekawa Y, 2001, J NEUROSURG, V94, P339, DOI 10.3171/jns.2001.94.2.0339
   ZEAL AA, 1978, J NEUROSURG, V48, P534, DOI 10.3171/jns.1978.48.4.0534
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 24
EP 29
DI 10.1016/j.wneu.2019.02.127
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400199
PM 30844533
DA 2020-05-12
ER

PT J
AU Casabella, AM
   Kiyofuji, S
   Perry, A
   Graffeo, CS
   Eschbacher, KL
   Link, MJ
AF Casabella, Amanda M.
   Kiyofuji, Satoshi
   Perry, Avital
   Graffeo, Christopher S.
   Eschbacher, Kathryn L.
   Link, Michael J.
TI Renal Cell Carcinoma with Primary Presentation via Metastasis to the
   Trigeminal Ganglion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Case report; Cranial nerve; Metastasis; Renal cell cancer; Skull base;
   Trigeminal nerve
ID WHOLE-BRAIN RADIOTHERAPY; QUALITY-OF-LIFE; ANATOMIC FEASIBILITY; MECKELS
   CAVE; SURVIVAL; RADIOSURGERY
AB BACKGROUND: Renal cell carcinoma (RCC) accounts for similar to 8% of all brain metastatic disease; however, spread to the cranial nerves and their ganglia is uncommon. To the best of our knowledge, we report the first case of RCC metastatic to Meckel's cave, which was diagnosed secondary to new trigeminal sensory loss.
   METHODS: A 45-year-old man had presented with acute-onset right V3 numbness. Magnetic resonance imaging demonstrated contrast enhancement of the ipsilateral V3, extending from its root at the Gasserian ganglion to the foramen ovale.
   RESULTS: He elected for observation, and his symptoms resolved over several weeks. At the scheduled, routine 3-month follow-up examination, he reported symptomatic relapse with new concomitant hyperesthetic/neuropathic pain. Magnetic resonance imaging demonstrated interval enlargement of the enhancing lesion in an atypical pattern, potentially consistent with trigeminal schwannoma versus meningioma, and operative resection was recommended.
   CONCLUSION: We have reported a case of RCC presenting with numbness via metastatic spread to Meckel's cave. Although uncommon, metastasis is an important diagnostic consideration for enhancing cranial nerve lesions. Our case has demonstrated that, although a history of malignancy, multiple lesions, or systemic/constitutional symptoms are typical, rare cases can demonstrate isolated central nervous system findings. Thus, short-term radiographic surveillance is indicated if the diagnosis of an intracranial or cranial nerve mass lesion is equivocal.
C1 [Casabella, Amanda M.; Kiyofuji, Satoshi; Perry, Avital; Graffeo, Christopher S.; Link, Michael J.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Eschbacher, Kathryn L.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
   [Link, Michael J.] Mayo Clin, Dept Otolaryngol Head & Neck Surg, Rochester, MN 55905 USA.
   [Kiyofuji, Satoshi] Univ Tokyo, Dept Neurosurg, Tokyo, Japan.
RP Link, MJ (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.; Link, MJ (reprint author), Mayo Clin, Dept Otolaryngol Head & Neck Surg, Rochester, MN 55905 USA.
EM Link.Michael@Mayo.edu
CR Barnholtz-Sloan JS, 2004, J CLIN ONCOL, V22, P2865, DOI 10.1200/JCO.2004.12.149
   Bragstad S, 2018, J NEUROSURG, V129, P71, DOI 10.3171/2017.2.JNS161659
   Brown PD, 2017, LANCET ONCOL, V18, P1049, DOI 10.1016/S1470-2045(17)30441-2
   Cacho-Diaz B, 2019, CURR PROB CANCER, V43, P312, DOI 10.1016/j.currproblcancer.2018.06.002
   Chandrasekar T, 2017, UROL ONCOL-SEMIN ORI, V35, DOI 10.1016/j.urolonc.2017.06.060
   Dellaretti M, 2017, WORLD NEUROSURG, V108, P1, DOI 10.1016/j.wneu.2017.08.089
   Graffeo CS, 2017, WORLD NEUROSURG, V105, P1009, DOI 10.1016/j.wneu.2017.05.150
   Hoshi S, 2002, INT J UROL, V9, P618, DOI 10.1046/j.1442-2042.2002.00531.x
   Hughes JD, 2018, NEUROSURGERY, V83, P529, DOI 10.1093/neuros/nyx501
   Ippen FM, 2015, J ONCOL, DOI 10.1155/2015/636918
   Jindal V, 2018, MOL NEUROBIOL, V55, P7072, DOI 10.1007/s12035-018-0905-3
   Langley RE, 2013, CLIN ONCOL-UK, V25, pE23, DOI 10.1016/j.clon.2012.11.002
   Lee S, 2013, J KOREAN NEUROSURG S, V54, P384, DOI 10.3340/jkns.2013.54.5.384
   Lehrer EJ, 2019, RADIOTHER ONCOL, V130, P104, DOI 10.1016/j.radonc.2018.08.025
   Messerer M, 2012, J NEUROSURG, V116, P390, DOI 10.3171/2011.10.JNS11783
   Priddy BH, 2017, OPER NEUROSURG, V13, P614, DOI 10.1093/ons/opx042
   Razek AAKA, 2009, AM J NEURORADIOL, V30, P444, DOI 10.3174/ajnr.A1398
   Shuch B, 2008, CANCER-AM CANCER SOC, V113, P1641, DOI 10.1002/cncr.23769
   Sperduto PW, 2018, NEURO-ONCOLOGY, V20, P1652, DOI 10.1093/neuonc/noy099
   Sun M, 2019, EUR UROL FOCUS, V5, P474, DOI 10.1016/j.euf.2017.12.007
   Theuer SE, 2007, CLIN NEURORADIOL, V17, P41
   Trifiletti DM, 2018, CANCER-AM CANCER SOC, V124, P2072, DOI 10.1002/cncr.31352
   Tuleasca C, 2019, J NEUROSURG, V130, P733, DOI 10.3171/2017.9.JNS17545
   Wang A, 2015, J NEUROL SURG REP, V76, pE282, DOI 10.1055/s-0035-1566125
   Yagmurlu K, 2018, WORLD NEUROSURG, V114, P134, DOI 10.1016/j.wneu.2018.02.128
   Yildiz I, 2018, TUMORI J, V104, P444, DOI 10.5301/tj.5000635
   Zhang X, 2017, PHYSIOL MEAS, V38, P143, DOI 10.1088/1361-6579/aa7256
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 30
EP 36
DI 10.1016/j.wneu.2019.02.118
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400200
PM 30844522
DA 2020-05-12
ER

PT J
AU Yu, Q
   Fraser, JF
AF Yu, Qian
   Fraser, Justin F.
TI Use of Artemis Neuro Evacuation Device in Resection of Pituitary
   Adenoma: Initial Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral spinal fluid leak; Endonasal; Macroadenoma; Minimal invasive;
   Pituitary adenoma; Transsphenoidal
ID MANAGEMENT; SURGERY
AB BACKGROUND: Endoscopic transsphenoidal resection has become the primary approach for resection of pituitary macroadenomas. However, challenges such as narrow sinuses, dense tumor consistency, and invasion of surrounding structures exist.
   METHODS: We report a case in which the Artemis Neuro Evacuation device was used to endonasally remove a pituitary macroadenoma with suprasellar and parasellar extensions. The methodology and technical aspects of this device's novel use are illustrated.
   RESULTS: The long and narrow wand of the Artemis system allowed the operators to navigate through patient's narrow sinuses. Despite a dense tumor that did not come easily into a suction, the entire tumor debulking procedure lasted <10 minutes with the preservation of an intact arachnoid membrane using the Artemis. No perioperative complication was encountered, and the patient's neurologic deficits resolved.
   CONCLUSIONS: To the authors' knowledge, this represents the first reported case of the Artemis system's utility in the treatment of pituitary tumor beyond cranial hema-toma and hemorrhage.
C1 [Yu, Qian] Univ Kentucky, Coll Med, Lexington, KY USA.
   [Fraser, Justin F.] Univ Kentucky, Dept Neurol Surg, Lexington, KY 40506 USA.
   [Fraser, Justin F.] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA.
   [Fraser, Justin F.] Univ Kentucky, Dept Radiol, Lexington, KY 40506 USA.
   [Fraser, Justin F.] Univ Kentucky, Dept Neurosci, Lexington, KY 40506 USA.
RP Fraser, JF (reprint author), Univ Kentucky, Dept Neurol Surg, Lexington, KY 40506 USA.; Fraser, JF (reprint author), Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA.; Fraser, JF (reprint author), Univ Kentucky, Dept Radiol, Lexington, KY 40506 USA.; Fraser, JF (reprint author), Univ Kentucky, Dept Neurosci, Lexington, KY 40506 USA.
EM jfr235@uky.edu
OI Fraser, Justin/0000-0002-5980-3989
CR Cappabianca P, 2015, NEUROSURG CLIN N AM, V26, P323, DOI 10.1016/j.nec.2015.03.007
   Ciappetta P, 2017, WORLD NEUROSURG, V108, P479, DOI 10.1016/j.wneu.2017.07.138
   Dillen WL, 2018, J CLIN NEUROSCI, V55, P93, DOI 10.1016/j.jocn.2018.06.036
   Fiorella David, 2016, Neurosurgery, V63 Suppl 1, P187, DOI 10.1227/01.neu.0000489793.60158.20
   Jakimovski D, 2014, WORLD NEUROSURG, V82, pE513, DOI 10.1016/j.wneu.2013.06.005
   Jane Jr JA, 2000, ENDOTEXT
   McDowell BD, 2011, PITUITARY, V14, P23, DOI 10.1007/s11102-010-0253-4
   Miller BA, 2012, NEUROSURG CLIN N AM, V23, P587, DOI 10.1016/j.nec.2012.06.013
   Miller TR, 2015, STROKE, V46, P2017, DOI 10.1161/STROKEAHA.115.008228
   Nishioka H, 2017, NEUROL MED-CHIR, V57, P151, DOI 10.2176/nmc.ra.2016-0276
   Tan LA, 2016, J CLIN NEUROSCI, V27, P53, DOI 10.1016/j.jocn.2015.08.037
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 37
EP 40
DI 10.1016/j.wneu.2019.02.113
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400201
PM 30831281
DA 2020-05-12
ER

PT J
AU Dossani, RH
   Patra, DP
   Kosty, J
   Jumah, F
   Kuybu, O
   Mohammed, N
   Waqas, M
   Riaz, M
   Cuellar, H
AF Dossani, Rimal Hanif
   Patra, Devi P.
   Kosty, Jennifer
   Jumah, Fareed
   Kuybu, Okkes
   Mohammed, Nasser
   Waqas, Muhammad
   Riaz, Muhammad
   Cuellar, Hugo
TI Early Versus Delayed Flow Diversion for Ruptured Intracranial Aneurysms:
   A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Flow diversion; Ruptured aneurysm; Subarachnoid hemorrhage
ID PIPELINE EMBOLIZATION DEVICE; BLISTER-LIKE ANEURYSMS; ENDOVASCULAR
   TREATMENT; DIVERTOR TREATMENT; FOLLOW-UP; COILING; TRIAL
AB OBJECTIVE: The use and timing of flow diversion for aneurysmal subarachnoid hemorrhage is controversial. The objective of this study is to perform a meta-analysis and systematic review to compare overall complication rate between early versus delayed flow diversion for ruptured aneurysms.
   METHODS: A literature search for all eligible articles was performed using PubMed, Cochrane, and Web of Science databases. The primary outcome was the overall complication rate (any complication in the perioperative period), and secondary outcomes were 1) hemorrhage and 2) stroke/death (all hemorrhagic/ischemic strokes and/or death).
   RESULTS: Thirteen articles including 142 patients met inclusion criteria. Eighty-nine (62.7%) patients underwent early deployment of flow diverters (i.e., 2 days or less). The odds ratio for overall complication rate with early versus delayed flow diversion was 0.95 (95% confidence interval [CI] 0.36-2.49, P = 0.42). The odds ratio for the secondary outcome of hemorrhagic complication for early versus delayed flow diversion was 1.44 (95% CI 0.45-4.52, P = 0.87) and of stroke/death was 1.67 (95% CI 0.5-4.9, P = 0.69). The odds ratio of early versus delayed flow diversion for blister/dissecting/fusiform aneurysms was 0.82 (95% CI 0.29-2.30) and for saccular/giant aneurysms was 2.23 (95% CI 0.17-29.4). At last follow-up, 71.6% of patients had good performance status (modified Rankin Scale score 0-2), and the rate of angiographic aneurysm occlusion was 90.2%.
   CONCLUSIONS: This meta-analysis did not show a difference in overall complication rate between early versus delayed flow diversion for ruptured aneurysms. Early flow diversion for ruptured blister/fusiform/dissecting aneurysms carries a lower risk of aneurysm rerupture and overall complications as compared with that for ruptured saccular/giant aneurysms.
C1 [Dossani, Rimal Hanif; Patra, Devi P.; Kosty, Jennifer; Jumah, Fareed; Mohammed, Nasser; Cuellar, Hugo] Louisiana State Univ, Dept Neurosurg, Hlth Sci Ctr, Shreveport, LA 71105 USA.
   [Kuybu, Okkes] Louisiana State Univ, Dept Neurol, Hlth Sci Ctr, Shreveport, LA 71105 USA.
   [Waqas, Muhammad; Riaz, Muhammad] Aga Khan Univ Hosp, Sect Neurosurg, Karachi, Pakistan.
RP Dossani, RH (reprint author), Louisiana State Univ, Dept Neurosurg, Hlth Sci Ctr, Shreveport, LA 71105 USA.
EM rimalh@gmail.com
RI Jumah, Fareed.rizq@gmail.com/AAG-7529-2020; mohammed,
   nasser/AAG-1525-2019; Waqas, Muhammad/A-5673-2013
OI mohammed, nasser/0000-0002-3811-3559; Waqas,
   Muhammad/0000-0003-4500-7954; Jumah, Fareed/0000-0002-0743-4018;
   Cuellar, Hugo/0000-0002-8348-4535
CR Aguilar-Salinas P, 2016, EXPERT REV MED DEVIC, V13, P885, DOI 10.1080/17434440.2016.1231573
   Aydin K, 2017, AM J NEURORADIOL, V38, P2131, DOI 10.3174/ajnr.A5362
   Aydin K, 2015, J NEUROINTERV SURG, V7, P202, DOI 10.1136/neurintsurg-2013-011090
   Brinjikji W, 2015, J NEUROSURG, V122, P95, DOI 10.3171/2014.10.JNS141035
   Brisman JL, 2006, NEW ENGL J MED, V355, P928, DOI 10.1056/NEJMra052760
   Cerejo R, 2017, NEURORADIOLOGY, V59, P1285, DOI 10.1007/s00234-017-1936-6
   Cerejo R, 2017, J NEUROINTERV SURG, V9, P1064, DOI 10.1136/neurintsurg-2017-013020
   Chalouhi N, 2015, NEUROSURGERY, V76, P165, DOI 10.1227/NEU.0000000000000586
   Chalouhi N, 2014, NEUROSURGERY, V74, P527, DOI 10.1227/NEU.0000000000000309
   Chan RSK, 2014, INTERV NEURORADIOL, V20, P436, DOI 10.15274/NRJ-2014-10042
   Debray TPA, 2015, RES SYNTH METHODS, V6, P293, DOI 10.1002/jrsm.1160
   Duman E, 2017, TURK NEUROSURG, V27, P362, DOI 10.5137/1019-5149.JTN.16324-15.1
   Eller JL, 2014, EXPERT REV MED DEVIC, V11, P137, DOI 10.1586/17434440.2014.877188
   Guerrero WR, 2018, WORLD NEUROSURG, V109, pE164, DOI 10.1016/j.wneu.2017.09.125
   Heller RS, 2013, J NEUROSURG, V119, P1603, DOI 10.3171/2013.7.JNS122178
   Kalani MYS, 2013, NEUROSURGERY, V73, P1026, DOI 10.1227/NEU.0000000000000147
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Kallmes DF, 2017, J NEUROSURG, V127, P775, DOI 10.3171/2016.8.JNS16467
   Kamran M, 2011, NEURORADIOLOGY, V53, P501, DOI 10.1007/s00234-010-0767-5
   Lin N, 2015, J NEUROINTERV SURG, V7, P808, DOI 10.1136/neurintsurg-2014-011320
   Lozupone E, 2018, J NEUROSURG, V128, P1037, DOI 10.3171/2016.11.JNS161937
   Maus V, 2018, WORLD NEUROSURG, V111, pE424, DOI 10.1016/j.wneu.2017.12.095
   McAuliffe W, 2012, AM J NEURORADIOL, V33, P487, DOI 10.3174/ajnr.A2797
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2015, LANCET, V385, P691, DOI 10.1016/S0140-6736(14)60975-2
   Natarajan SK, 2017, NEUROSURG CLIN N AM, V28, P375, DOI 10.1016/j.nec.2017.02.011
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Rouchaud A, 2015, AM J NEURORADIOL, V36, P2331, DOI 10.3174/ajnr.A4438
   Ryan RW, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1757
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Walcott BP, 2017, NEUROCRIT CARE, V26, P465, DOI 10.1007/s12028-016-0318-y
   Walcott BP, 2016, JAMA NEUROL, V73, P1002, DOI 10.1001/jamaneurol.2016.0609
NR 33
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 41
EP 52
DI 10.1016/j.wneu.2019.02.044
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400202
PM 30822578
DA 2020-05-12
ER

PT J
AU Nagata, Y
   Takeuchi, K
   Yamamoto, T
   Ishikawa, T
   Kawabata, T
   Shimoyama, Y
   Wakabayashi, T
AF Nagata, Yuichi
   Takeuchi, Kazuhito
   Yamamoto, Taiki
   Ishikawa, Takayuki
   Kawabata, Teppei
   Shimoyama, Yoshie
   Wakabayashi, Toshihiko
TI Removal of the Medial Wall of the Cavernous Sinus for Functional
   Pituitary Adenomas: A Technical Report and Pathologic Significance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acromegaly; Cavernous sinus; Cushing disease; Medial wall; Medial
   wall-plasty; Medial wall removal; Pituitary adenoma
ID DURAL INVASION; CUSHINGS-DISEASE; RESECTION
AB BACKGROUND: Removal of the medial wall of the cavernous sinus (MW) is challenging for neurosurgeons. We describe a practical method of endoscopic MW removal via endonasal transsphenoidal approach to minimalize intraoperative blood loss and postoperative morbidities. We also present the pathologic significance of this technique for functional pituitary adenomas (FPAs).
   METHODS: We performed MW removal in patients with FPA with no well-defined pseudocapsule and a tumor in direct contact with the MW. The MW was judged to have tumor invasion based on the intraoperative appearance, and it was removed regardless of the appearance of MW involvement. Intraoperative findings and postoperative clinical, endocrinologic, and pathologic outcomes were retrospectively reviewed.
   RESULTS: Fourteen patients underwent MW removal for FPA, including 12 patients with acromegaly and 2 with Cushing disease. Mean intraoperative blood loss was 170 mL (range, 32-400 mL), and none of the patients required blood transfusion. Among the 7 patients without intraoperative apparent MW involvement, 4 (57.1%) had pathologically confirmed tumor invasion into the MW (occult invasion). Biochemical remission by surgery alone was achieved in 13 patients (92.9%). Transient oculomotor palsy occurred in 1 patient (7.1%).
   CONCLUSIONS: Occult tumor invasion into the MW was often detected in patients with FPA without a well-defined pseudocapsule but in direct contact with the MW. Our technique can enhance the effectiveness of surgery with minimal postoperative morbidities.
C1 [Nagata, Yuichi; Takeuchi, Kazuhito; Yamamoto, Taiki; Ishikawa, Takayuki; Kawabata, Teppei; Wakabayashi, Toshihiko] Nagoya Univ, Grad Sch Med, Dept Neurosurg, Nagoya, Aichi, Japan.
   [Shimoyama, Yoshie] Nagoya Univ Hosp, Dept Pathol & Clin Lab, Nagoya, Aichi, Japan.
RP Nagata, Y (reprint author), Nagoya Univ, Grad Sch Med, Dept Neurosurg, Nagoya, Aichi, Japan.
EM you1ngta@gmail.com
OI Nagata, Yuichi/0000-0003-4130-5380; Yamamoto, Taiki/0000-0001-9734-4931
CR Ayuk J, 2008, REV ENDOCR METAB DIS, V9, P33, DOI 10.1007/s11154-007-9067-8
   Cohen-Cohen S, 2019, J NEUROSURG, V131, P131, DOI 10.3171/2018.5.JNS18595
   Dickerman RD, 2002, J NEUROSURG, V97, P1343, DOI 10.3171/jns.2002.97.6.1343
   Kawamata T, 2005, NEUROSURG REV, V28, P201, DOI 10.1007/s10143-005-0384-7
   Kim EH, 2015, PITUITARY, V18, P397, DOI 10.1007/s11102-014-0587-4
   Lonser RR, 2012, J NEUROSURG, V116, P272, DOI 10.3171/2011.8.JNS11456
   Meij BP, 2002, J NEUROSURG, V96, P195, DOI 10.3171/jns.2002.96.2.0195
   Nagata Y, 2018, PITUITARY, V21, P1, DOI 10.1007/s11102-017-0836-4
   Newell-Price J, 2006, LANCET, V367, P1605, DOI 10.1016/S0140-6736(06)68699-6
   Nishioka Hiroshi, 2014, J Neurosurg, V121, P505, DOI 10.3171/2014.3.JNS132214
   Oldfield EH, 2017, NEUROSURGERY, V64, P27, DOI 10.1093/neuros/nyx378
   Park HH, 2018, WORLD NEUROSURG, V117, pE280, DOI 10.1016/j.wneu.2018.06.012
   Pivonello R, 2017, ENDOCRINE, V56, P10, DOI 10.1007/s12020-016-0984-8
   SELMAN WR, 1986, J NEUROSURG, V64, P402, DOI 10.3171/jns.1986.64.3.0402
   Steffensen C, 2010, NEUROENDOCRINOLOGY, V92, P1, DOI 10.1159/000314297
   Truong HQ, 2019, J NEUROSURG, V131, P122, DOI 10.3171/2018.3.JNS18596
NR 16
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 53
EP 58
DI 10.1016/j.wneu.2019.02.134
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400203
PM 30849552
DA 2020-05-12
ER

PT J
AU Akhaddar, A
AF Akhaddar, Ali
TI Contribution of Moroccan Neurosurgeons to the World Neurosurgical Data
   in PubMed: A Bibliometric Evaluation Over Time
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bibliometrics; Medical publication; Morocco; Neurosurgery; PubMed;
   Research; Scientific productivity
ID PRODUCTIVITY
AB BACKGROUND: Medical publications reflect the development of training, research, and health services. No objective data are available regarding neurosurgical publications from Morocco. Bibliometrics were used to evaluate the contribution of Moroccan neurosurgeons (MONSs) in neurosurgical journals worldwide and to discuss the strategies that can be applied to increase the quantity and quality of publications on this subject.
   METHODS: A literature search of reports by MONSs was performed using the PubMed database. The number and quality of the reports were evaluated with the impact factor of the neurosurgical journals and the h-index of each first author.
   RESULTS: The data from 174 identified studies reported from 1989 to 2018 were analyzed. MONSs have continued to report more studies every year worldwide. However, their contribution to neurosurgical journals has been gradually declining since 2012. Scientific publishing was limited to a few great neurosurgical departments and a few academic neurosurgeons in Morocco. Most of the reports were case reports, reported in the French language, included in non-neurosurgical journals, from single centers, and without international collaboration.
   CONCLUSIONS: Academic neurosurgeons in Morocco should prepare their residents and young researchers on research methodology and medical writing. Moroccan neurosurgical research should be more focused on modern neurosurgical topics by highlighting our particularities. More high level of evidence studies should be reported in English-language neurosurgical journals with a high impact factor and good scientific reputation. MONSs should continue to collaborate more often with each other and with foreign centers to further improve the quality and number of international publications, regardless of the difficulties they face.
C1 [Akhaddar, Ali] Mohammed V Univ, Avicenne Mil Hosp Marrakech, Dept Neurosurg, Rabat, Morocco.
   [Akhaddar, Ali] Mohammed V Univ, Fac Med & Pharm, Lab Biostat Clin Res & Epidemiol, Rabat, Morocco.
RP Akhaddar, A (reprint author), Mohammed V Univ, Avicenne Mil Hosp Marrakech, Dept Neurosurg, Rabat, Morocco.; Akhaddar, A (reprint author), Mohammed V Univ, Fac Med & Pharm, Lab Biostat Clin Res & Epidemiol, Rabat, Morocco.
EM akhaddar@hotmail.fr
OI Akhaddar, Ali/0000-0001-5743-2777
CR Akhaddar A, 2011, PUBLIER REV BIOMEDIC
   Akhaddar A, 2016, CRANIAL OSTEOMYELITI
   Akhaddar A, 2017, ATLAS INFECTIONS NEU
   Alimi Marjan, 2013, Surg Neurol Int, V4, P38, DOI 10.4103/2152-7806.109651
   Allen L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005910
   Altinors N, 2017, TURK NEUROSURG, V27, P1007, DOI 10.5137/1019-5149.JTN.17064-16.1
   El Khamlichi A, 2001, NEUROSURGERY, V48, P1344, DOI 10.1097/00006123-200106000-00034
   Gonzalez-Brambila CN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151328
   Hauptman JS, 2011, J NEUROSURG, V115, P1262, DOI 10.3171/2011.8.JNS11857
   Jamjoom AB, 2015, NEUROSCIENCES, V20, P392, DOI 10.17712/nsj.2015.4.20140735
   Jamjoom Bakur A, 2016, eNeurologicalSci, V4, P1, DOI 10.1016/j.ensci.2016.03.002
   Meo SA, 2014, EUR REV MED PHARMACO, V18, P1
   Prabhu VC, 2017, WORLD NEUROSURG, V105, P993, DOI 10.1016/j.wneu.2017.06.081
   Prato GP, 2013, J EVID-BASED DENT PR, V13, P130, DOI 10.1016/j.jebdp.2013.08.001
   Roldan-Valadez E, 2019, IRISH J MED SCI, V188, P939, DOI 10.1007/s11845-018-1936-5
   Sasaki T, 2011, NEUROL MED-CHIR, V51, P405, DOI 10.2176/nmc.51.405
   Shamim MS, 2011, CLIN NEUROL NEUROSUR, V113, P107, DOI 10.1016/j.clineuro.2010.09.013
   Slone RM, 1996, AM J ROENTGENOL, V167, P571, DOI 10.2214/ajr.167.3.8751654
   Waast R, 2009, EVALUATING NATL RES
   Wilkes FA, 2015, J NEUROSURG, V122, P948, DOI 10.3171/2014.11.JNS14856
   Yuen J, 2018, WORLD NEUROSURG, V119, pE328, DOI 10.1016/j.wneu.2018.07.144
NR 21
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 59
EP 65
DI 10.1016/j.wneu.2019.02.122
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400204
PM 30844530
DA 2020-05-12
ER

PT J
AU Castelnuovo, P
   Arosio, AD
   Volpi, L
   De Maria, F
   Ravasio, A
   Donati, S
   Azzolini, C
   Dallan, I
   Bignami, M
   Locatelli, D
AF Castelnuovo, Paolo
   Arosio, Alberto D.
   Volpi, Luca
   De Maria, Federico
   Ravasio, Arianna
   Donati, Simone
   Azzolini, Claudio
   Dallan, Iacopo
   Bignami, Maurizio
   Locatelli, Davide
TI Endoscopic Transnasal Cryo-Assisted Removal of Orbital Cavernous
   Hemangiomas: Case Report and Technical Hints
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cryo-assisted endoscopic surgery; Endoscopy; Orbital cavernous
   hemangiomas; Orbital surgery
ID MALFORMATIONS; ORBITOTOMY; MANAGEMENT; RESECTION; SURGERY; LESIONS;
   TUMORS
AB BACKGROUND: Cryoprobe devices are used by ophthalmic and orbital surgeons for extraction of fluid-filled intraorbital lesions. No series has described cryodissection via an exclusively transnasal approach. We describe 2 cases of purely endoscopic transnasal removal of intraconal orbital hemangiomas with the aid of a dedicated cryoprobe.
   METHODS: All transnasal endoscopic intraorbital procedures were collected and analyzed. In cases in which intraorbital dissection was performed with the use of an Optikon Cryo-line probe, clinical features, histology, size and location of the lesion, early and late complications, surgical procedure time, and hospital length of stay were analyzed. Patient follow-up included endoscopic endo-nasal evaluations performed at 2, 4, and 8 weeks after surgery and ophthalmologic and orthoptic evaluations performed 2 days and 2 months after surgery.
   RESULTS: Two transnasal intraorbital endoscopic procedures with the aid of the dedicated Cryo-line probe were collected. Lesions were located in the intraconal space, medial to the optic nerve. In both patients, the histologic evaluation was compatible with cavernous hemangioma, and complete resection was obtained. Mean hospital stay was 5.5 days. Postoperative ophthalmologic and orthoptic evaluations performed 2 months postoperatively revealed complete resolution of preoperative symptoms.
   CONCLUSIONS: Cryoprobes represent an adjunctive tool in the orbital surgeon's armamentarium useful in the extraction of fluid-filled intraorbital lesions. This preliminary experience suggests that their use can ease the removal of intraconal hemangiomas with an exclusively transnasal approach. The analysis of further cases is necessary to confirm safety and efficacy.
C1 [Castelnuovo, Paolo; Arosio, Alberto D.; Volpi, Luca; De Maria, Federico; Bignami, Maurizio] Univ Insubria, Osped Circolo & Fdn Macchi, Dept Biotechnol & Life Sci, Unit Otorhinolaryngol, Varese, Italy.
   [Castelnuovo, Paolo; Arosio, Alberto D.; Volpi, Luca; De Maria, Federico; Bignami, Maurizio; Locatelli, Davide] Univ Insubria, Dept Biotechnol & Life Sci, Head & Neck Surg & Forens Dissect Res Ctr HNS&FDR, Varese, Italy.
   [Ravasio, Arianna; Donati, Simone; Azzolini, Claudio] Univ Insubria, Osped Circolo & Fdn Macchi, Unit Opthamol, Varese, Italy.
   [Dallan, Iacopo] Univ Pisa, Azienda Osped Univ Pisana, Dept Surg Med Mol Pathol & Emergency Med, ENT Unit 1, Pisa, Italy.
   [Locatelli, Davide] Univ Insubria Varese, ASST Sette Laghi, Osped Circolo & Fdn Macchi, Div Neurol Surg,Dept Biotechnol & Life Sci, Varese, Italy.
RP Arosio, AD (reprint author), Univ Insubria, Osped Circolo & Fdn Macchi, Dept Biotechnol & Life Sci, Unit Otorhinolaryngol, Varese, Italy.; Arosio, AD (reprint author), Univ Insubria, Dept Biotechnol & Life Sci, Head & Neck Surg & Forens Dissect Res Ctr HNS&FDR, Varese, Italy.
EM albertodaniele.arosio@gmail.com
RI Bignami, Maurizio/AAA-1577-2020; Locatelli, Davide/AAH-5844-2020
OI Locatelli, Davide/0000-0003-1163-9611; Donati,
   Simone/0000-0002-6920-7021; Azzolini, Claudio/0000-0002-1334-0974
CR Arai H, 1996, NEUROSURGERY, V39, P1157, DOI 10.1097/00006123-199612000-00018
   Arai H, 1996, NEUROSURGERY, V39, P1162
   Bleier BS, 2016, INT FORUM ALLERGY RH, V6, P156, DOI 10.1002/alr.21645
   Calandriello L, 2017, SURV OPHTHALMOL, V62, P393, DOI 10.1016/j.survophthal.2017.01.004
   Campbell PG, 2011, MINIM INVAS NEUROSUR, V54, P41, DOI 10.1055/s-0030-1270465
   Carta F, 1998, J Neurosurg Sci, V42, P185
   Castelnuovo P, 2015, NEUROSURG CLIN N AM, V26, P463, DOI 10.1016/j.nec.2015.03.001
   Castelnuovo P, 2012, EUR ARCH OTO-RHINO-L, V269, P1929, DOI 10.1007/s00405-011-1917-z
   Cheng JW, 2008, CAN J OPHTHALMOL, V43, P234, DOI 10.3129/i08-005
   Cockerham K P, 2001, Neurosurg Focus, V10, pE3
   Dallan I, 2016, ENDOSCOPIC ORBITAL T
   Dallan I, 2015, EUR ARCH OTO-RHINO-L, V272, P3851, DOI 10.1007/s00405-015-3556-2
   Gdal-On M, 1998, OPHTHALMIC SURG LAS, V29, P969
   Henderson J W, 1976, Ophthalmic Surg, V7, P45
   Kiratli H, 2005, SURG NEUROL, V64, P71, DOI 10.1016/j.surneu.2004.09.046
   Kiratli H, 2009, ORBIT, V17, P119
   Kuppersmith RB, 1997, LARYNGOSCOPE, V107, P311, DOI 10.1097/00005537-199703000-00006
   LAZAR M, 1985, AUST NZ J OPHTHALMOL, V13, P417, DOI 10.1111/j.1442-9071.1985.tb00457.x
   LEATHERBARROW B, 1989, EYE, V3, P90, DOI 10.1038/eye.1989.13
   Lenzi R, 2016, EUR ARCH OTO-RHINO-L, V273, P2319, DOI 10.1007/s00405-015-3733-3
   LEONE CR, 1983, AM J OPHTHALMOL, V96, P1
   Locateli D, 2016, J NEUROSURG SCI, V60, P514
   LOEWENSTEIN A, 1993, EYE, V7, P597, DOI 10.1038/eye.1993.130
   Maroon Joseph C., 1992, Neurological Research, V14, P294
   Maus M, 1999, OPHTHALMIC PLAST REC, V15, P166, DOI 10.1097/00002341-199905000-00005
   McNab AA, 2014, ORBIT, V33, P359, DOI 10.3109/01676830.2014.915329
   Meyer D, 2006, ORBIT, V25, P45, DOI 10.1080/01676830500506101
   Murchison AP, 2011, LARYNGOSCOPE, V121, P463, DOI 10.1002/lary.21357
   NORRIS JL, 1981, ARCH OPHTHALMOL-CHIC, V99, P1400, DOI 10.1001/archopht.1981.03930020274014
   NORRIS JL, 1981, AM J OPHTHALMOL, V91, P249
   NORRIS JL, 1985, OPHTHALMOLOGY, V92, P34
   Paluzzi A, 2015, J NEUROL SURG PART B, V76, P12, DOI 10.1055/s-0033-1360580
   Pham Annette M, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P234, DOI 10.1097/01.moo.0000233593.84175.6e
   PUTTERMAN A, 1975, AM J OPHTHALMOL, V80, P88, DOI 10.1016/0002-9394(75)90875-2
   Rootman DB, 2014, BRIT J OPHTHALMOL, V98, P880, DOI 10.1136/bjophthalmol-2013-304460
   Rootman J, 2014, OPHTHAL PLAST RECONS, V30, P91, DOI 10.1097/IOP.0000000000000122
   Rosen N, 2010, ACTA OPHTHALMOL, V88, P675, DOI 10.1111/j.1755-3768.2009.01515.x
   Shields JA, 2004, OPHTHALMOLOGY, V111, P997, DOI 10.1016/j.ophtha.2003.01.002
   Signorelli F, 2015, WORLD J CLIN CASES, V3, P270, DOI 10.12998/wjcc.v3.i3.270
   Simmen D.J.N., 2013, MANUAL ENDOSCOPIC SI
   Tan SH, 2015, J LARYNGOL OTOL, V129, P928, DOI 10.1017/S0022215115001838
NR 41
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 66
EP 71
DI 10.1016/j.wneu.2019.01.235
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400205
PM 30771539
DA 2020-05-12
ER

PT J
AU Chen, XL
   Zhang, GP
AF Chen, Xiaoli
   Zhang, Guoping
TI Multiple Spinal Intramedullary Primitive Neuroectodermal Tumors
   Mimicking Acute Myelitis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Magnetic resonance imaging; Myelitis; Spinal cord tumor; Spinal
   primitive neuroectodermal tumors
AB BACKGROUND: Primitive neuroectodermal tumors (PNETs) are rare malignant neoplasms in the spinal cord that comprise undifferentiated or poorly differentiated neural crest cells. PNETs imaging findings lack specificity, making diagnosis difficult.
   CASE DESCRIPTION: A 16-year-old male patient presented with progressive weakness and numbness of the lower extremities for 1 month, which occurred after a cold. Significantly elevated protein levels were detected in his cerebrospinal fluid. Magnetic resonance imaging revealed multiple patchy or spindle-shaped hyperintensities on T2-weighted imaging, which is similar to acute myelitis imaging findings. However, the effect of hormone treatment was minimal. Enhanced magnetic resonance imaging with gadolinium-diethylenetriamine pentaacetic acid showed significant enhancement of intramedullary lesions and the meninges, which was diagnosed as tuberculosis and tuberculous meningitis. After therapy with quadruple antituberculosis treatment for 1 week, however, the T-spot was negative. Therefore, the antituberculosis regimen was ceased. Atypical cells were observed in cerebrospinal fluid from a third lumbar puncture. Next, most of the thoracic intramedullary lesions were resected. By histopathology, these lesions manifested as PNETs.
   CONCLUSIONS: This paper reports a very rare case of PNETs with multiple lesions in the spinal cord that mimicked acute myelitis and emphasizes that multiple PNETs lesions detected by magnetic resonance imaging could have an initial acute myelitis-like presentation, which should be considered a differential diagnosis.
C1 [Chen, Xiaoli] Shaanxi Prov Peoples Hosp, Dept Neurol, Xian, Shaanxi, Peoples R China.
   [Zhang, Guoping] Shaanxi Prov Peoples Hosp, Dept Radiol, Xian, Shaanxi, Peoples R China.
RP Zhang, GP (reprint author), Shaanxi Prov Peoples Hosp, Dept Radiol, Xian, Shaanxi, Peoples R China.
EM zhanggp_1314@163.com
CR Albrecht CF, 2003, J NEURO-ONCOL, V61, P113, DOI 10.1023/A:1022118317876
   Benesch M, 2011, J NEURO-ONCOL, V104, P279, DOI 10.1007/s11060-010-0485-1
   Kumar R, 2007, PEDIATR NEUROSURG, V43, P1, DOI 10.1159/000097517
   Shi QH, 2005, J CHONGQING MED U, V30, P630
   Wang GQ, 2017, MEDICINE, V96, P49
NR 5
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 72
EP 75
DI 10.1016/j.wneu.2019.02.108
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400206
PM 30831283
DA 2020-05-12
ER

PT J
AU Hirata, S
   Kobayashi, M
   Kamamoto, D
   Kosugi, K
   Yoshida, K
   Fujimaki, T
AF Hirata, Sachiko
   Kobayashi, Masahito
   Kamamoto, Dai
   Kosugi, Kenzo
   Yoshida, Kazunari
   Fujimaki, Takamitsu
TI Trigeminal Neuralgia Due to Petrosal Bone Deformity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior transpetrosal approach; Microvascular decompression;
   Neurovascular compression; Petrous bone; Trigeminal neuralgia
ID MICROVASCULAR DECOMPRESSION; POSTERIOR-FOSSA; NERVE; ANGLE; SECONDARY;
   PATHOGENESIS
AB BACKGROUND: There have been a few previous reports of trigeminal neuralgia caused by bony structures. We report a rare case of trigeminal neuralgia caused by petrous bone deformity.
   CASE DESCRIPTION: A-43-year-old man with facial pain in the left maxillary and mandibular divisions of the trigeminal nerve was referred to our hospital. Computed tomography showed bone hyperplasia protruding into the left cerebellopontine cistern, compressing the left trigeminal nerve. Administration of carbamazepine ameliorated facial pain, but the effect was unsatisfactory, and microvascular decompression was performed through the anterior transpetrosal approach. The protruding petrous bone was drilled out to release compression of the trigeminal nerve, thus straightening the deviated trajectory of the nerve. The superior cerebellar artery adjacent to the thickened petrosal bone seemed to have compressed the trigeminal nerve and was also transposed. The facial pain disappeared completely after microvascular decompression surgery.
   CONCLUSIONS: The anterior transpetrosal approach is an appropriate and essential strategy for trigeminal neuralgia caused by petrous bone deformity of the petrous apex.
C1 [Hirata, Sachiko; Kobayashi, Masahito; Fujimaki, Takamitsu] Saitama Med Univ Hosp, Dept Neurosurg, Saitama, Japan.
   [Kamamoto, Dai; Kosugi, Kenzo; Yoshida, Kazunari] Keio Univ, Sch Med, Dept Neurosurg, Tokyo, Japan.
RP Hirata, S (reprint author), Saitama Med Univ Hosp, Dept Neurosurg, Saitama, Japan.
EM hiratas@saitama-med.ac.jp
CR BABU R, 1991, NEUROSURGERY, V28, P886, DOI 10.1227/00006123-199106000-00018
   Barker FG, 1996, NEW ENGL J MED, V334, P1077, DOI 10.1056/NEJM199604253341701
   Brinzeu A, 2018, ACTA NEUROCHIR, V160, P971, DOI 10.1007/s00701-018-3468-1
   Cenzato M, 2010, WORLD NEUROSURG, V74, P544, DOI 10.1016/j.wneu.2010.03.035
   Holanda MMD, 2015, J CRANIOVERTEBRAL JU, V6, P76, DOI 10.4103/0974-8237.156062
   Fujimaki T, 2000, BRIT J NEUROSURG, V14, P531
   Garcia-Pastor C, 2006, SURG NEUROL, V66, P207, DOI 10.1016/j.surneu.2006.01.027
   GARDNER WJ, 1966, BRAIN, V89, P555, DOI 10.1093/brain/89.3.555
   Ha SM, 2012, ACTA NEUROCHIR, V154, P1627, DOI 10.1007/s00701-012-1327-z
   HADDAD FS, 1990, NEUROSURGERY, V26, P1033, DOI 10.1227/00006123-199006000-00019
   Horinek D, 2009, ACTA NEUROCHIR, V151, P669, DOI 10.1007/s00701-009-0283-8
   Inatomi Y, 1998, NEUROL SURG TOKYO, V26, P401
   KATO T, 1995, SURG NEUROL, V44, P33, DOI 10.1016/0090-3019(95)00056-9
   Kobata H, 2002, NEUROSURGERY, V50, P276, DOI 10.1097/00006123-200202000-00008
   Majoie CBLM, 1998, RADIOLOGY, V209, P557, DOI 10.1148/radiology.209.2.9807589
   Mata-Gomez J, 2017, NEUROCIRUGIA, V28, P247, DOI 10.1016/j.neucir.2017.01.004
   OGLEZNEV KY, 1991, ACTA NEUROCHIR, V110, P116, DOI 10.1007/BF01400677
   Parise M, 2013, ACTA NEUROCHIR, V155, P863, DOI 10.1007/s00701-012-1573-0
   Parise M, 2010, J NEUROSURG, V112, P900, DOI 10.3171/2009.10.JNS091517
   Shenouda EF, 2007, NEUROSURGERY, V60, P63, DOI 10.1227/01.NEU.0000249230.67118.3C
   TANCIONI F, 1995, SURG NEUROL, V44, P36, DOI 10.1016/0090-3019(95)00173-5
NR 21
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 79
EP 82
DI 10.1016/j.wneu.2019.02.114
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400208
PM 30831302
DA 2020-05-12
ER

PT J
AU Signorelli, F
   Stumpo, V
   Della Pepa, GM
   La Rocca, G
   Oliva, A
   Olivi, A
   Visocchi, M
AF Signorelli, Francesco
   Stumpo, Vittorio
   Della Pepa, Giuseppe Maria
   La Rocca, Giuseppe
   Oliva, Antonio
   Olivi, Alessandro
   Visocchi, Massimiliano
TI Step-up Establishment of Neurosurgical Laboratory Starting with Limited
   Resources-Tips and Tricks
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cadaver; Dissection; Laboratory; Neuroanatomy
ID CRANIOVERTEBRAL JUNCTION; BODY DONATION; MODEL; FEASIBILITY; POSTMORTEM
AB BACKGROUND: Neurosurgical diseases have a devastating impact on society. It is estimated that approximately 14 million essential neurosurgical cases develop worldwide annually, of which more than 80% arise in low- and middle-income countries. Neurosurgical cadaveric dissection remains largely unexploited as a learning tool for the training of surgeons in developing countries, often because of the assumed high costs.
   METHODS: The minimum requirements to establish a neurosurgical cadaver laboratory are the availability of minimally equipped environment to perform dissection, respecting safety requirements, fitting surgical instruments, anatomic samples, and materials to be used for preservation and preparation of anatomical specimens. Moving from these basic foundations, we established our Neurosurgical Dissection Laboratory at Fondazione Poli-clinico Universitario A. Gemelli IRCCS in Rome, Italy. The laboratory is located at the Institute of Public Health Section of Legal Medicine of University.
   RESULTS: After reviewing relevant literature and discussing our experience, we provide advice for setting up a neurosurgical dissection cadaver laboratory with specific focus on suitable location identification, surgical equipment procurement, fresh cadaver and frozen specimen acquisition, and preparation and description of a step-up strategy to progressively enrich the laboratory.
   CONCLUSIONS: Our study demonstrates the feasibility of establishing a neurosurgical cadaver dissection laboratory for training and research purposes even in presence of limited resources. The introduction of cost-effective guidelines and targeted funding could represent an added value to target the unmet neurosurgical disease need by promoting development of local neurosurgical expertise with the aim of providing health coverage for the treatment of common neurosurgical pathologies in developing countries.
C1 [Signorelli, Francesco; Stumpo, Vittorio; Della Pepa, Giuseppe Maria; La Rocca, Giuseppe; Oliva, Antonio; Olivi, Alessandro; Visocchi, Massimiliano] Fdn Policlin Univ A Gemelli, Inst Neurosurg, IRCCS, Rome, Italy.
RP Signorelli, F (reprint author), Fdn Policlin Univ A Gemelli, Inst Neurosurg, IRCCS, Rome, Italy.
EM francesco.signorelli1984@gmail.com
RI Signorelli, Francesco/Y-9746-2019; Pepa, Giuseppe Maria
   Della/AAC-1697-2019; Oliva, Antonio/K-1105-2018; visocchi,
   massimiliano/AAA-4267-2019; La Rocca, Giuseppe/AAG-3922-2019
OI Pepa, Giuseppe Maria Della/0000-0001-8698-3359; visocchi,
   massimiliano/0000-0002-5277-4468; La Rocca, Giuseppe/0000-0003-1830-4849
CR Aboud E, 2002, J NEUROSURG, V97, P1367, DOI 10.3171/jns.2002.97.6.1367
   [Anonymous], 2015, GLOB STAT REP ROAD S
   Ashour AM, 2016, WORLD NEUROSURG, V96, P261, DOI 10.1016/j.wneu.2016.04.048
   Bin P, 2016, OPEN MED-WARSAW, V11, P316, DOI 10.1515/med-2016-0060
   Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500
   Gasco J, 2013, NEUROSURGERY, V73, P39, DOI 10.1227/NEU.0000000000000102
   Gragnaniello C, 2014, J NEUROL SURG PART B, V75, P301, DOI 10.1055/s-0034-1368148
   Gragnaniello C, 2010, J NEUROSURG, V113, P1106, DOI 10.3171/2010.3.JNS09513
   Guan MW, 2013, CHINESE MED J-PEKING, V126, P1707, DOI 10.3760/cma.j.issn.0366-6999.20122844
   Hayashi N, 2008, CHILD NERV SYST, V24, P749, DOI 10.1007/s00381-007-0553-9
   Jones DG, 2012, CLIN ANAT, V25, P246, DOI 10.1002/ca.21223
   Jones DG, 2016, CLIN ANAT, V29, P55, DOI 10.1002/ca.22648
   Kshettry VR, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.06.036
   Liu JKC, 2015, J NEUROSURG, V123, P1331, DOI 10.3171/2014.11.JNS14902
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   Mock CN, 2015, LANCET, V385, P2209, DOI 10.1016/S0140-6736(15)60091-5
   Olabe J, 2009, SURG NEUROL, V72, P700, DOI 10.1016/j.surneu.2009.02.028
   Salma A, 2011, NEUROSURG REV, V34, P317, DOI 10.1007/s10143-011-0317-6
   Servadei F, 2018, WORLD NEUROSURG, V112, P315, DOI 10.1016/j.wneu.2018.01.047
   Shkarubo MA, 2018, WORLD NEUROSURG, V112, P110, DOI 10.1016/j.wneu.2018.01.102
   Smith Adam, 2015, J Spine Surg, V1, P57, DOI 10.3978/j.issn.2414-469X.2015.09.02
   Suri A, 2014, NEUROL INDIA, V62, P249, DOI 10.4103/0028-3886.136897
   Tschabitscher M, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2011.02.045
   Tubbs RS, 2009, J NEUROSURG, V111, P1165, DOI 10.3171/2009.3.JNS081653
   van Eijk RPA, 2015, AM J ROENTGENOL, V205, P1276, DOI 10.2214/AJR.15.14500
   Visocchi M, 2016, SPINE, V41, P669, DOI 10.1097/BRS.0000000000001288
   Visocchi M, 2018, WORLD NEUROSURG, V110, P544, DOI 10.1016/j.wneu.2017.06.125
   Visocchi M, 2017, ACTA NEUROCHIR SUPPL, V124, P117, DOI 10.1007/978-3-319-39546-3_18
   Wingfield HA, 2018, CLIN ANAT, V31, P86, DOI 10.1002/ca.23010
   Zada G, 2018, OPER NEUROSURG, V14, P72, DOI 10.1093/ons/opx074
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 83
EP 89
DI 10.1016/j.wneu.2019.02.034
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400209
PM 30797916
DA 2020-05-12
ER

PT J
AU Chung, KS
   Shin, DA
   Kim, KN
   Ha, Y
   Yoon, DH
   Yi, S
AF Chung, Kyu Seon
   Shin, Dong Ah
   Kim, Keung Nyun
   Ha, Yoon
   Yoon, Do Heum
   Yi, Seong
TI Vertebral Reconstruction with Customized 3-Dimensional-Printed Spine
   Implant Replacing Large Vertebral Defect with 3-Year Follow-up
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D-printed spine implant; Large vertebral defect; Vertebral body
   reconstruction
ID CERVICAL-SPINE; BODY
AB BACKGROUND: Destruction of the spine is a huge complication of infectious spondylitis and surgical intervention is required. However, vertebral defect is a major problem after surgical intervention and numerous methods have been researched to solve this problem. There are known methods that use variously designed, patient-customized 3-dimensional (3D)-printed implants in various medical fields. The use of 3D-printed implants has also been attempted in treating defects in the spine. We present a case of failure of expandable titanium cage fusion after infection, treated using a 3D-printed implant.
   CASE DESCRIPTION: The patient had undergone reconstruction surgery with expandable titanium cage due to infectious spondylitis and needed reoperation owing to recurrence of infections and failure of bone fusion. The problem we faced in this operation was a large vertebral defect, for which we used a 3D-printed implant. After 3 years of follow-up, the implant and bone fusion were intact and infection or mechanical complications were not seen.
   CONCLUSIONS: A 3D-printed implant could be an acceptable and alternative treatment option for replacing a large vertebral defect.
C1 [Chung, Kyu Seon; Shin, Dong Ah; Kim, Keung Nyun; Ha, Yoon; Yoon, Do Heum; Yi, Seong] Yonsei Univ, Severance Hosp, Coll Med, Dept Neurosurg,Spine & Spinal Cord Inst, Seoul, South Korea.
RP Yi, S (reprint author), Yonsei Univ, Severance Hosp, Coll Med, Dept Neurosurg,Spine & Spinal Cord Inst, Seoul, South Korea.
EM YISEONG@yuhs.ac
OI Kim, Keung Nyun/0000-0003-2248-9188
FU Yonsei University College of Medicine [6-2017-0067]; National Research
   Foundation of Korea (NRF) - Korea government [NRF-2014M3A7B4051596];
   Technology Innovation Program - Ministry of Trade, Industry Energy,
   Korea [10062712]
FX This study was supported by faculty research grant of Yonsei University
   College of Medicine for 2017 (6-2017-0067), the National Research
   Foundation of Korea NRF) grant funded by the Korea government
   (NRF-2014M3A7B4051596), and the Technology Innovation Program funded by
   the Ministry of Trade, Industry & Energy, Korea (10062712, Development
   of spinal fusion implant and its manufacturing system; the functionality
   optimized, patient-customized in terms of bioactive materials to meet
   the clinical needs).
CR Baek Kyeong Hee, 2016, Korean J Spine, V13, P120, DOI 10.14245/kjs.2016.13.3.120
   Choy WJ, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.05.133
   Feng DP, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-89
   Girolami M, 2018, EUR SPINE J
   Joubert C, 2015, WORLD NEUROSURG, V84, P1412, DOI 10.1016/j.wneu.2015.06.072
   Kim D, 2017, YONSEI MED J, V58, P453, DOI 10.3349/ymj.2017.58.2.453
   Langridge B, 2018, J SURG EDUC, V75, P209, DOI 10.1016/j.jsurg.2017.06.033
   Laufer I, 2012, CANCER CONTROL, V19, P122, DOI 10.1177/107327481201900206
   Lee GJ, 2014, J KOREAN NEUROSURG S, V55, P142, DOI 10.3340/jkns.2014.55.3.142
   Li XC, 2017, SPINE, V42, pE1326, DOI 10.1097/BRS.0000000000002229
   Liu XF, 2017, TISSUE ENG PT A, V23, P223, DOI [10.1089/ten.tea.2016.0246, 10.1089/ten.TEA.2016.0246]
   MacBarb Regina F, 2017, Int J Spine Surg, V11, P15, DOI 10.14444/4015
   Mobbs RJ, 2017, J NEUROSURG-SPINE, V26, P513, DOI 10.3171/2016.9.SPINE16371
   Nawaz F, 2007, AM J MED SCI, V334, P215, DOI 10.1097/MAJ.0b013e318141f723
   Olivares-Navarrete R, 2012, SPINE J, V12, P265, DOI 10.1016/j.spinee.2012.02.002
   Palmquist A, 2013, J BIOMATER APPL, V27, P1003, DOI 10.1177/0885328211431857
   Phan Kevin, 2016, J Spine Surg, V2, P314, DOI 10.21037/jss.2016.12.06
   Ventola C Lee, 2014, P T, V39, P704
   Xu NF, 2016, SPINE, V41, pE50, DOI 10.1097/BRS.0000000000001179
NR 19
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 90
EP 95
DI 10.1016/j.wneu.2019.02.020
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400210
PM 30797911
DA 2020-05-12
ER

PT J
AU Nakajima, M
   Hara, T
   Miyajima, M
   Akiba, C
   Kawamura, K
   Sugano, H
   Tange, Y
   Shimoji, K
   Karagiozov, K
   Arai, H
AF Nakajima, Madoka
   Hara, Takeshi
   Miyajima, Masakazu
   Akiba, Chihiro
   Kawamura, Kaito
   Sugano, Hidenori
   Tange, Yuichi
   Shimoji, Kazuaki
   Karagiozov, Kostadin
   Arai, Hajime
TI Shunt Malfunction and Calcification of Abdominal Fascia Tissue Resulting
   in Obstruction of Abdominal Catheter
SO WORLD NEUROSURGERY
LA English
DT Article
DE Calcified tissue; Lime stone; Shunt malfunction; Weight gain
ID VENTRICULOPERITONEAL; HYDROCEPHALUS
AB BACKGROUND: Experiencing a ventriculoperitoneal (VP) shunt complication is a major obstacle in the management of hydrocephalus. Degradation of a shunt catheter associated with surrounding tissue calcification could be 1 reason for a difference in facture rates. Furthermore, tissue reactions around cerebrospinal fluid shunts may be a sign of bacterial shunt infection, which is not uncommon.
   CASE DESCRIPTION: A 31-year-old man was living with a ventriculoperitoneal shunt since childhood. Consequently, his cerebrospinal fluid absorption was supposed to be modified by the shunt. Shunt malfunction later occurred concomitant with symptoms of headache and repeated vomiting. He had undergone shunt revision a year before presentation, but examination revealed that a new, extremely rare calcified lesion had formed in the aponeurosis of the abdomen, compressing the shunt tube. We removed it and replaced the shunt tube, thus relieving his symptoms.
   CONCLUSIONS: We treated a rare case of shunt dysfunction caused by calcification of the aponeurosis coinciding with significant weight gain over the course of a year. To the best of our knowledge, this is the first report to describe a case of shunt malfunction caused by calcification of the aponeurosis.
C1 [Nakajima, Madoka; Hara, Takeshi; Miyajima, Masakazu; Akiba, Chihiro; Kawamura, Kaito; Sugano, Hidenori; Tange, Yuichi; Shimoji, Kazuaki; Karagiozov, Kostadin; Arai, Hajime] Juntendo Univ, Fac Med, Dept Neurosurg, Tokyo, Japan.
RP Nakajima, M (reprint author), Juntendo Univ, Fac Med, Dept Neurosurg, Tokyo, Japan.
EM madoka66@juntendo.ac.jp
OI Nakajima, Madoka/0000-0002-8496-2973; Sugano,
   Hidenori/0000-0002-7836-6585
CR Boch AL, 1998, J NEUROSURG, V88, P975, DOI 10.3171/jns.1998.88.6.0975
   de Oliveira JG, 2007, NEUROSURGERY, V61, P924, DOI 10.1227/01.neu.0000303188.72425.24
   Hellwig D, 2005, NEUROSURG REV, V28, P1, DOI 10.1007/s10143-004-036-2
   James HE, 2008, J NEUROSURG-PEDIATR, V1, P223, DOI 10.3171/PED/2008/1/3/223
   Komotar RJ, 2002, NEUROSURGERY, V51, P1403, DOI 10.1097/00006123-200212000-00010
   Kural C, 2012, TURK NEUROSURG, V22, P779, DOI 10.5137/1019-5149.JTN.4139-11.1
   Murphy K, 2000, CHILD NERV SYST, V16, P4, DOI 10.1007/s003810050002
   Park MK, 2015, J KOREAN NEUROSURG S, V57, P359, DOI 10.3340/jkns.2015.57.5.359
   Salim Abubakr Darrag, 2015, Asian J Neurosurg, V10, P246, DOI 10.4103/1793-5482.161321
   STANNARD MW, 1995, AM J NEURORADIOL, V16, P1276
NR 10
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 96
EP 98
DI 10.1016/j.wneu.2019.01.285
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400211
PM 30831288
OA Other Gold
DA 2020-05-12
ER

PT J
AU Agrawal, M
   Gour, SSK
   Borkar, SA
AF Agrawal, Mohit
   Gour, Surya Sri Krishna
   Borkar, Sachin Anil
TI Unusual Calcification in Intramedullary Epidermoid Cyst
SO WORLD NEUROSURGERY
LA English
DT Article
DE Calcification; Epidermoid; Intramedullary; White epidermoid
AB BACKGROUND: Calcified intraspinal epidermoids are a rare entity. We discuss the various pathogenesis and the clinical implication of such a finding during surgery.
   CASE DESCRIPTION: A 32-year-old female presented with progressive spastic paraparesis with incontinence. Imaging showed an unusual intralesional calcification, which was removed. Postoperatively she had no fresh deficits.
   CONCLUSIONS: To our knowledge this is the first reported case of spinal intramedullary epidermoid with intralesional calcification.
C1 [Agrawal, Mohit; Gour, Surya Sri Krishna; Borkar, Sachin Anil] All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
RP Borkar, SA (reprint author), All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
EM sachin.aiims@gmail.com
CR HASEGAWA H, 1981, SURG NEUROL, V15, P372, DOI 10.1016/0090-3019(81)90174-9
   LUNARDI P, 1988, NEUROCHIRURGIA, V31, P219
   Osborn AG, 2006, RADIOLOGY, V239, P650, DOI 10.1148/radiol.2393050823
   Praveen KS, 2009, BRIT J NEUROSURG, V23, P90, DOI 10.1080/02688690802109812
   Ravindran K, 2017, J CLIN NEUROSCI, V42, P43, DOI 10.1016/j.jocn.2017.03.006
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 99
EP 100
DI 10.1016/j.wneu.2019.02.016
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400212
PM 30797922
DA 2020-05-12
ER

PT J
AU Rudrappa, S
   Govindasamy, R
   Sekar, A
   Tukkapuram, R
   Vikrama, A
AF Rudrappa, Satish
   Govindasamy, Ramachandran
   Sekar, Arunkumar
   Tukkapuram, Ramakrishna
   Vikrama, Amita
TI Hydrocephalic Attack-An Uncommon Complication of Spine Surgery: A Case
   Series and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hydrocephalic attack; Intracranial pressure; MRI CSF flow study;
   Pseudomeningocele
ID LUMBAR PSEUDOMENINGOCELE; SPONTANEOUS RESOLUTION
AB BACKGROUND: Spinal pseudomeningocele refers to an abnormal accumulation of cerebrospinal fluid (CSF) in a fibrous sac without arachnoid lining that occurs mostly as a result of an accidental dural opening. When accidental dural openings are found intraoperatively, they should be repaired to prevent further complications. Sometimes inadequately dealt dural openings, unnoticed, or postoperative dural openings may produce complications.
   CASE DESCRIPTION: Three patients had complications as a result of spine surgery and presented several days after the surgery with episodic symptoms of raised intracranial pressure, including headache, opisthotonos, altered breathing patterns, and altered sensorium. These symptoms increased whenever pressure was applied on the operated area suggesting hydrocephalic attacks. All 3 patients had a giant pseudomeningocele at the operated area, a complication that resulted from the spine surgery. Magnetic resonance imaging CSF flow study revealed hyperdynamic flow and increase in absolute stroke volume across the cerebral aqueduct when constant pressure was applied on the pseudomeningocele sac.
   CONCLUSIONS: Usually pseudomeningoceles are asymptomatic, and if symptomatic, the common presentations are local swelling, back pain, radiculopathy, and orthostatic headache. To our knowledge, this is the first article in the literature reporting the uncommon presentation of hydrocephalic attacks in 3 cases subsequent to CSF backflow from the sac, confirmed with MRI CSF flow study. This case series emphasizes rare presentations can result from transiently increased intracranial pressure related to postoperative pseudomeningocele in spine surgeries.
C1 [Rudrappa, Satish; Sekar, Arunkumar] Sakra World Hosp, Dept Neurosurg, Bangalore, Karnataka, India.
   [Govindasamy, Ramachandran; Tukkapuram, Ramakrishna] Sakra World Hosp, Dept Spine Surg, Bangalore, Karnataka, India.
   [Vikrama, Amita] Sakra World Hosp, Dept Radiol, Bangalore, Karnataka, India.
RP Govindasamy, R (reprint author), Sakra World Hosp, Dept Spine Surg, Bangalore, Karnataka, India.
EM mail2ram8544@gmail.com
OI Sekar, Arunkumar/0000-0001-9664-6620
CR Beier Alexandra D, 2009, Spine J, V9, pe9, DOI 10.1016/j.spinee.2009.06.012
   Bekavac I, 2003, AM J NEURORADIOL, V24, P838
   BLOCH R, 1976, J NEUROL SCI, V27, P485, DOI 10.1016/0022-510X(76)90215-X
   Couture Daniel, 2003, Neurosurg Focus, V15, pE6
   Drummond JC, 2014, CAN J ANESTH, V61, P656, DOI 10.1007/s12630-014-0164-3
   Endriga DT, 2016, EUR SPINE J, V25, pS157, DOI 10.1007/s00586-015-4308-0
   Enke Oliver, 2018, Spinal Cord Ser Cases, V4, P82, DOI 10.1038/s41394-018-0118-z
   Epstein Nancy E, 2013, Surg Neurol Int, V4, pS301, DOI 10.4103/2152-7806.111427
   Hamdan A, 2018, ACTA NEUROCHIR, V160, P479, DOI 10.1007/s00701-017-3446-z
   Hamilton RG, 2009, J SPINAL CORD MED, V32, P95, DOI 10.1080/10790268.2009.11760758
   Jones AA, 1998, SPINE, V14, P443
   Karaeminogullari O, 2005, NEUROSURGERY, V57, P215, DOI 10.1227/01.NEU.0000163688.17385.9B
   Khurana A, 2013, EUR SPINE J, V22, P2047, DOI 10.1007/s00586-013-2818-1
   Kohler E, 2010, INTERN MED J, V40, P228, DOI 10.1111/j.1445-5994.2009.02120.x
   Kumar AJS, 2003, SPINAL CORD, V41, P470, DOI 10.1038/sj.sc.3101462
   LEE KS, 1992, NEUROSURGERY, V30, P111, DOI 10.1227/00006123-199201000-00020
   Rege SV, 2016, ROM NEUROSURG, V30, P429
   Rudrappa S, 2018, INT J SURG CASE REP, V47, P41, DOI 10.1016/j.ijscr.2018.04.014
   Serino D, 2018, BRAIN DEV-JPN, V40, P77, DOI 10.1016/j.braindev.2017.06.011
   Solomon P, 2013, INDIAN J ORTHOP, V47, P417, DOI 10.4103/0019-5413.114937
   Thomas A, 2012, SPINE, V37, pE511, DOI 10.1097/BRS.0b013e3182373b95
   Weng YJ, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-53
   Wilson MH, 2016, J CEREBR BLOOD F MET, V36, P1338, DOI 10.1177/0271678X16648711
   Yildiz H, 2006, NEURORADIOLOGY, V48, P595, DOI 10.1007/s00234-006-0098-8
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 101
EP 106
DI 10.1016/j.wneu.2019.02.155
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400213
PM 30857997
DA 2020-05-12
ER

PT J
AU West, JL
   Frenkel, MB
   Renfrow, JJ
   Wilson, JA
AF West, James L.
   Frenkel, Mark B.
   Renfrow, Jaclyn J.
   Wilson, John A.
TI Craniocervical Osteoradionecrosis Treated with Neoadjuvant and Adjuvant
   Hyperbaric Oxygen in Combination with Posterior Spinal Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine; Craniocervical; Hyperbaric oxygen; Osteomyelitis;
   Osteoradionecrosis; Radiation therapy
ID CERVICAL-SPINE; RADIATION-THERAPY; HEAD
AB BACKGROUND: Radiation therapy for malignant head and neck cancers includes a risk for off-target effects to bony structures, posing a risk for osteoradionecrosis (ORN). Patients in whom ORN develops can also harbor concomitant osteomyelitis and reduced healing capacity, making for a particularly challenging entity to treat. Hyperbaric oxygen therapy (HBO) has been shown to be effective in the treatment of mandibular ORN in the otolaryngology literature; yet, few reports exist detailing its utility when treating ORN of the craniocervical junction. Herein, we report 2 cases of ORN of the craniocervical junction who received both neoadjuvant and adjuvant HBO in combination with posterior spinal fusion.
   CASE DESCRIPTION: Two patients with craniocervical junction ORN were treated with HBO delivered over 20 sessions before and after surgery in 90-minute treatments to 2.5 atmospheres of pressure. The patients underwent posterior occipital-cervical fusions with an average operative time of 301 (+/- 21.5) minutes with 250 (+/- 150) mL of blood loss. Both patients stayed in the hospital for 5 days, with no periprocedural complications. Outcomes included a 30% improvement of global assessment of function on follow-up EuroQol 5-Dimension Questionnaire. Postoperative imaging demonstrated solid bony fusion, and both patients returned to full work duty.
   CONCLUSIONS: ORN is a difficult-to-treat radiation complication in head and neck cancers. Few reports exist detailing treatment options for ORN of the craniocervical junction in conjunction with surgical stabilization. We report 2 successful cases of HBO-assisted treatment of ORN and highlight the important role HBO can play in promoting bony fusion in these at-risk patients.
C1 [West, James L.; Frenkel, Mark B.; Renfrow, Jaclyn J.; Wilson, John A.] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurosurg, Winston Salem, NC 27101 USA.
RP West, JL (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Neurosurg, Winston Salem, NC 27101 USA.
EM JWestNSU@gmail.com
OI West, James/0000-0002-9635-5628
CR Chen WJ, 2002, J TRAUMA, V52, P333, DOI 10.1097/00005373-200202000-00020
   Cheung JPY, 2013, EUR SPINE J, V22, P584, DOI 10.1007/s00586-012-2600-9
   Donovan DJ, 2005, J NEUROSURG-SPINE, V3, P159, DOI 10.3171/spi.2005.3.2.0159
   Khorsandi AS, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20140436
   King AD, 2010, EUR J RADIOL, V73, P629, DOI 10.1016/j.ejrad.2008.12.016
   Kouyoumdjian P, 2009, EUR SPINE J, V18, pS258, DOI 10.1007/s00586-009-0950-8
   Lee JS, 2010, J CLIN NEUROSCI, V17, P1064, DOI 10.1016/j.jocn.2009.10.037
   Lim AAT, 1999, AM J OTOLARYNG, V20, P408
   Ludwig SC, 2001, CURR OPIN ORTHOP, V12, P223
   MARX RE, 1987, ORAL SURG ORAL MED O, V64, P379, DOI 10.1016/0030-4220(87)90136-8
   MURRAY CG, 1980, INT J RADIAT ONCOL, V6, P543, DOI 10.1016/0360-3016(80)90380-6
   Owosho AA, 2017, ORAL ONCOL, V64, P44, DOI 10.1016/j.oraloncology.2016.11.015
   Pasquier D, 2004, RADIOTHER ONCOL, V72, P1, DOI 10.1016/j.radonc.2004.04.005
   Raggio BS, 2018, CURR OPIN OTOLARYNGO, V26, P254, DOI 10.1097/MOO.0000000000000459
   Raza A, 2013, BMJ CASE REP
   Rosko AJ, 2016, HEAD NECK-J SCI SPEC, V38, P1187, DOI 10.1002/hed.24348
   Tan SH, 2015, EUR SPINE J, V24, P2776, DOI 10.1007/s00586-015-4153-1
   van Wyk Frederik Carl, 2009, J Med Case Rep, V3, P7262, DOI 10.4076/1752-1947-3-7262
   Wu LA, 2012, RADIOLOGY, V264, P136, DOI 10.1148/radiol.12111714
   Yalcin N, 2011, J BONE JOINT SURG BR, V93B, P793, DOI 10.1302/0301-620X.93B6.24257
NR 20
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 107
EP 112
DI 10.1016/j.wneu.2019.02.177
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400214
PM 30858001
DA 2020-05-12
ER

PT J
AU Konstantinidis, A
   Cheesman, E
   O'Sullivan, J
   Pavaine, J
   Avula, S
   Pizer, B
   Kilday, JP
AF Konstantinidis, Athanasios
   Cheesman, Edmund
   O'Sullivan, James
   Pavaine, Juljia
   Avula, Shivaram
   Pizer, Barry
   Kilday, John-Paul
TI Intracranial Angiomatoid Fibrous Histiocytoma with EWSR1-CREB Family
   Fusions: A Report of 2 Pediatric Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiomatoid; Fibrous; Histiocytoma; Intracranial; Pediatric
ID VARIANT; TUMORS
AB BACKGROUND: Intracranial angiomatoid fibrous histiocytomas (AFHs) are very rare tumors. Histologically, classical cases have been reported exclusively in adults, with myxoid variants identified only in children. Here, we report the clinical presentation, treatment, biopsy, and molecular test results for 2 children with classical intracranial AFH and combine this with a literature review of published intracranial AFH and AFH-like cases.
   CASE DESCRIPTION: Two young girls presenting with abnormal neurologic signs, received diagnoses of intracranial AFHs from histopathologic analysis. No myxoid features were identified. Fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction testing demonstrated EWS1-ATF1 and EWS1-CREM gene fusions, respectively, verified by Sanger sequencing. Both patients underwent surgery only. The first child experienced local recurrence 5 years from initial surgery. Following a further complete resection, this patient has remained recurrence free over a subsequent 6-year follow-up period. The second patient has recently experienced local multinodular recurrence 28 months after initial surgery and is awaiting surgical re-excision. No additional chemotherapy/radiotherapy has been administered to either patient.
   CONCLUSIONS: This report describes the first 2 cases of nonmyxoid intracranial AFH in children; confirmed by molecular analysis. Our results suggest that a tumor spectrum incorporating classical and myxoid intracranial AFHs can occur in children and that gross total resection represents the treatment strategy of choice at diagnosis or following recurrence.
C1 [Konstantinidis, Athanasios; Kilday, John-Paul] Royal Manchester Childrens Hosp, Dept Haematol Oncol, Manchester, Lancs, England.
   [Cheesman, Edmund; Kilday, John-Paul] Royal Manchester Childrens Hosp, Childrens Brain Tumour Res Network, Manchester, Lancs, England.
   Royal Manchester Childrens Hosp, Dept Histopathol, Manchester, Lancs, England.
   [Cheesman, Edmund] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Div Canc Sci,Ctr Paediat Teenage & Young Adult Ca, Manchester, Lancs, England.
   [O'Sullivan, James] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Div Evol & Genom, Manchester, Lancs, England.
   [O'Sullivan, James] Manchester Univ Fdn NHS Trust, Manchester Ctr Genom Med, St Marys Hosp, Hlth Innovat Manchester, Manchester, Lancs, England.
   [Pavaine, Juljia] Manchester Univ Hosp NHS Fdn Trust, Acad Unit Paediat Radiol, Royal Manchester Childrens Hosp, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Pavaine, Juljia] Univ Manchester, Div Informat Imaging & Data Sci, Sch Hlth Sci, Fac Biol Med & Hlth,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Avula, Shivaram] Alder Hey Childrens Hosp, Dept Neuroradiol, Liverpool, Merseyside, England.
   [Pizer, Barry] Alder Hey Childrens Hosp, Dept Haematol Oncol, Liverpool, Merseyside, England.
RP Kilday, JP (reprint author), Royal Manchester Childrens Hosp, Dept Haematol Oncol, Manchester, Lancs, England.; Kilday, JP (reprint author), Royal Manchester Childrens Hosp, Childrens Brain Tumour Res Network, Manchester, Lancs, England.
EM John-Paul.Kilday@mft.nhs.uk
CR Ajlan AM, 2010, J COMPUT ASSIST TOMO, V34, P791, DOI 10.1097/RCT.0b013e3181e39755
   Alshareef MA, 2016, WORLD NEUROSURG, V96, P403, DOI 10.1016/j.wneu.2016.09.059
   Bale TA, 2018, BRAIN PATHOL, V28, P183, DOI 10.1111/bpa.12504
   Chen G, 2011, MODERN PATHOL, V24, P1560, DOI 10.1038/modpathol.2011.126
   Dunham C, 2008, AM J SURG PATHOL, V32, P478, DOI 10.1097/PAS.0b013e3181453451
   ENZINGER FM, 1979, CANCER, V44, P2147, DOI 10.1002/1097-0142(197912)44:6<2147::AID-CNCR2820440627>3.0.CO;2-8
   Gareton A, 2018, J NEUROPATH EXP NEUR, V77, P537, DOI 10.1093/jnen/nly039
   Hansen JM, 2015, CEPHALALGIA, V35, P1334, DOI 10.1177/0333102415583988
   Huerter ME, 2014, OCHSNER J, V14, P441
   Kao YC, 2017, AM J SURG PATHOL, V41, P482, DOI 10.1097/PAS.0000000000000788
   Li CS, 2004, SKELETAL RADIOL, V33, P604, DOI 10.1007/s00256-004-0769-7
   Marino-Enriquez Adrian, 2016, Surg Pathol Clin, V9, P457, DOI 10.1016/j.path.2016.04.009
   Ochalski PG, 2010, J NEUROSURG, V112, P978, DOI 10.3171/2009.8.JNS081518
   Parham DM, 2015, ANAL CHEM INSIGHTS, V10, P1, DOI [10.4137/ACICI.S32730, 10.4137/ACI.S32730]
   Paronetto M. P., 2013, INT J CELL BIOL, V2013
   Sciot R, 2018, HISTOPATHOLOGY, V72, P880, DOI 10.1111/his.13437
   Shi HJ, 2015, INT J CLIN EXP PATHO, V8, P772
   Spatz Moshe, 2018, Br J Neurosurg, P1, DOI 10.1080/02688697.2018.1451823
   Thway K, 2015, ARCH PATHOL LAB MED, V139, P674, DOI 10.5858/arpa.2014-0234-RA
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 113
EP 119
DI 10.1016/j.wneu.2019.02.107
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400215
PM 30831299
DA 2020-05-12
ER

PT J
AU Kanazawa, T
   Miwa, T
   Akiyama, T
   Ohara, K
   Kosugi, K
   Nishimoto, M
   Yoshida, K
AF Kanazawa, Tokunori
   Miwa, Tomoru
   Akiyama, Takenori
   Ohara, Kentaro
   Kosugi, Kenzo
   Nishimoto, Masaaki
   Yoshida, Kazunari
TI A Case of Aggressive Recurrent Intracranial Subdural Hematoma Associated
   with Angiosarcoma Originating from the Skull
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiosarcoma; Embolization; Middle meningeal artery; Skull; Subdural
   hematoma
ID METASTASIS; SCALP
AB BACKGROUND: Angiosarcoma often arises as a cutaneous disease in the scalp and the face; however, subdural hematoma (SDH) associated with angiosarcoma is extremely rare.
   CASE DESCRIPTION: A 72-year-old woman visited our hospital with gait disorder and progressive consciousness disturbance approximately 3 months after a minor head injury. Initially, on reviewing the results of imaging studies, she was diagnosed with traumatic chronic SDH. Despite repeated operations thereafter, including the embolization of the middle meningeal artery, her general condition progressively worsened, and computed tomography of head repeatedly showed the recurrence of SDH. Based on histopathologic and intraoperative findings, she was finally diagnosed with angiosarcoma originating from the skull. She died shortly thereafter because of aggressive recurrent intracranial SDH caused by leptomeningeal dissemination.
   CONCLUSIONS: In addition to cancers metastatic to the skull or dura mater, angiosarcoma should be included in the differential diagnosis for patients with repeated SDH and bone defect. An effective treatment for angiosarcoma with SDH that shows an unfavorable prognosis has not been established; however, an early diagnosis might be useful for a novel treatment.
C1 [Kanazawa, Tokunori; Miwa, Tomoru; Akiyama, Takenori; Kosugi, Kenzo; Nishimoto, Masaaki; Yoshida, Kazunari] Keio Univ, Sch Med, Dept Neurosurg, Tokyo, Japan.
   [Ohara, Kentaro] Keio Univ, Sch Med, Dept Pathol, Tokyo, Japan.
RP Miwa, T (reprint author), Keio Univ, Sch Med, Dept Neurosurg, Tokyo, Japan.
EM tenmiwa@gmail.com
RI Akiyama, Takenori/L-3453-2013
OI Akiyama, Takenori/0000-0003-2795-7411; Kanazawa,
   Tokunori/0000-0002-6191-1209
CR Abraham JA, 2007, ANN SURG ONCOL, V14, P1953, DOI 10.1245/s10434-006-9335-y
   Ashish K, 2014, TURK NEUROSURG, V24, P992, DOI [10.5137/1019-5149JTN.9708-13.0, 10.5137/1019-5149.JTN.9708-13.0]
   Chapas AM, 2005, J AM ACAD DERMATOL, V52, pS58, DOI 10.1016/j.jaad.2004.05.027
   CHOW RW, 1970, CANCER, V25, P902, DOI 10.1002/1097-0142(197004)25:4<902::AID-CNCR2820250424>3.0.CO;2-1
   Chugh Ashish P, 2014, Surg Neurol Int, V5, P92, DOI 10.4103/2152-7806.134365
   Coindre JM, 2001, CANCER-AM CANCER SOC, V91, P1914, DOI 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3
   George Kuriakose J, 2012, Surg Neurol Int, V3, P60, DOI 10.4103/2152-7806.97004
   Groves MD, 2011, NEUROSURG CLIN N AM, V22, P67, DOI 10.1016/j.nec.2010.08.006
   Ikeda H, 2018, WORLD NEUROSURG, V111, P201, DOI 10.1016/j.wneu.2017.12.116
   Kim E, 2017, WORLD NEUROSURG, V101, P520, DOI 10.1016/j.wneu.2017.02.070
   Lahat G, 2010, ANN SURG, V251, P1098, DOI 10.1097/SLA.0b013e3181dbb75a
   Lopes M, 1999, NEUROSURGERY, V44, P405, DOI 10.1097/00006123-199902000-00102
   Mark RJ, 1996, CANCER, V77, P2400, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.3.CO;2-K
   Matsumoto H, 2018, J CLIN NEUROSCI, V49, P40, DOI 10.1016/j.jocn.2017.11.009
   NAKA N, 1995, CANCER, V75, P989, DOI 10.1002/1097-0142(19950215)75:4<989::AID-CNCR2820750414>3.0.CO;2-K
   Natarajan M, 2012, NEUROL INDIA, V60, P148, DOI 10.4103/0028-3886.93624
   Pawlik TM, 2003, CANCER-AM CANCER SOC, V98, P1716, DOI 10.1002/cncr.11667
   Wang N, 2018, CANCER-AM CANCER SOC, V124, P21, DOI 10.1002/cncr.30911
   Yamada Y, 2013, HEAD NECK PATHOL, V7, P159, DOI 10.1007/s12105-012-0389-9
   Young RJ, 2010, LANCET ONCOL, V11, P983, DOI 10.1016/S1470-2045(10)70023-1
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 120
EP 123
DI 10.1016/j.wneu.2019.02.168
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400216
PM 30862578
DA 2020-05-12
ER

PT J
AU Sorenson, TJ
   Nicholson, PJ
   Hilditch, CA
   Murad, MH
   Brinjikji, W
AF Sorenson, Thomas J.
   Nicholson, Patrick J.
   Hilditch, Christopher A.
   Murad, Mohammad H.
   Brinjikji, Waleed
TI A Lesson from Cardiology: The Argument for Ultrasound-Guided Femoral
   Artery Access in Interventional Neuroradiology
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endovascular; Interventional neuroradiology; Neurointerventionalist;
   Transfemoral; Ultrasound
ID VASCULAR COMPLICATIONS; CLOSURE DEVICES; FLUOROSCOPY; GUIDANCE;
   PUNCTURE; TRIAL
AB PURPOSE: The transfemoral approach is widely used by neurointerventionalists for accessing the femoral artery in patients undergoing diagnostic and therapeutic endovascular procedures. In patients with more difficult anatomy, duplex ultrasonography (US) may be a valuable adjunct for femoral vascular access. We aimed to assess the evidence for the effectiveness of duplex US-guided femoral access within interventional neuroradiology.
   METHODS: We searched MEDLINE, Scopus, and EMBASE and included 5 randomized controlled trials. Odds ratios (ORs) and mean differences were pooled using the random-effects model.
   RESULTS: Meta-analysis of 5 RCTs that included 784 US-guided patients and 769 non-US-guided patients found that the US-guided approach was significantly favored in terms of time-to-access (weighted mean difference: 24.90 minutes, 95% confidence interval [CI] 12.41-37.38), first-pass success rate (OR 2.97; 95% CI 1.49-5.92), and total complication rate (OR 0.42, 95% CI 0.23-0.77). There were no statistically significant differences in technical success rate, number of attempts, or individual complications.
   CONCLUSIONS: US-guided femoral artery access for endovascular procedures is a safe and effective adjunct for visualizing the femoral artery during vascular access for endovascular procedures. Neurointerventionalists should consider a low threshold for its use, especially for patients with challenging anatomy or at high-risk of bleeding complications.
C1 [Sorenson, Thomas J.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
   [Sorenson, Thomas J.; Brinjikji, Waleed] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Murad, Mohammad H.] Mayo Clin, Ctr Sci Healthcare Delivery, Rochester, MN USA.
   [Brinjikji, Waleed] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA.
   [Nicholson, Patrick J.; Hilditch, Christopher A.] Toronto Western Hosp, Dept Med Imaging, Toronto, ON, Canada.
RP Brinjikji, W (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.; Brinjikji, W (reprint author), Mayo Clin, Dept Radiol, Rochester, MN 55905 USA.
EM brinjikji.waleed@mayo.edu
CR Abu-Fadel MS, 2009, CATHETER CARDIO INTE, V74, P533, DOI 10.1002/ccd.22174
   Castillo-Sang M, 2010, ANN VASC SURG, V24, P328, DOI 10.1016/j.avsg.2009.06.025
   Das N, 2011, CARDIOVASC INTER RAD, V34, P958, DOI 10.1007/s00270-011-0096-z
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dudeck O, 2004, INT J CARDIOVAS IMAG, V20, P363, DOI 10.1023/B:CAIM.0000041949.59255.3f
   Gedikoglu M, 2013, CATHETER CARDIO INTE, V82, P1187, DOI 10.1002/ccd.24955
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Huggins CE, 2009, J INVASIVE CARDIOL, V21, P105
   Marquis-Gravel G, 2018, J INTERV CARDIOL, V31, P496, DOI 10.1111/joic.12492
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Murad MH, 2017, MAYO CLIN PROC, V92, P423, DOI 10.1016/j.mayocp.2017.01.001
   Ortiz D, 2014, CIRC-CARDIOVASC INTE, V7, P821, DOI 10.1161/CIRCINTERVENTIONS.114.001306
   Romaguera R, 2012, AM J CARDIOL, V109, P75, DOI 10.1016/j.amjcard.2011.08.007
   Seto AH, 2010, JACC-CARDIOVASC INTE, V3, P751, DOI 10.1016/j.jcin.2010.04.015
   Slattery MM, 2015, CARDIOVASC INTER RAD, V38, P579, DOI 10.1007/s00270-014-0998-7
   Smilowitz NR, 2012, AM J CARDIOL, V110, P177, DOI 10.1016/j.amjcard.2012.02.065
   Vavalle John P, 2009, J Invasive Cardiol, V21, p21A
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 124
EP 128
DI 10.1016/j.wneu.2019.02.171
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400217
PM 30862603
DA 2020-05-12
ER

PT J
AU Han, QD
   Zhou, P
   Huang, YB
AF Han, Qingdong
   Zhou, Peng
   Huang, Yabo
TI Surgical Revascularization: Ligation of Extracranial Internal Carotid
   Artery and Superficial Temporal Artery-to-Middle Cerebral Artery Bypass
   in Patient with Extracranial Internal Carotid Aneurysm and Hemorrhagic
   Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extracranial internal carotid artery aneurysm; Moyamoya disease;
   Surgical revascularization
AB BACKGROUND: Extracranial internal carotid artery (EICA) aneurysm is regarded as a rare lesion. What is more, patients can suffer from EICA aneurysms and hemorrhagic moyamoya disease (MMD) simultaneously.
   CASE DESCRIPTION: A 38-year-old man was admitted to our hospital and underwent emergent tracheal intubation for hoarseness and breathing difficulty for 1 day. He had a pulsating mass of 2.5 cm in diameter in the left cervical area. Imaging examinations revealed the left EICA aneurysm and MMD. The patient underwent left superficial temporal artery-to-middle cerebral artery (STA-MCA) bypass and ligation of the left EICA simultaneously. Computed tomography revealed hemorrhagic stroke in the right basal ganglia region 20 days after the bypass. The hematoma disappeared 20 days after the stroke. Right bypass was performed 6 months after the left bypass. The patient was discharged with no neurologic abnormalities 10 days after the right bypass. He lived a normal life, and no neurologic abnormalities were found at the 6-month follow-up. Imaging examinations indicated the efficacy of the bilateral STA-MCA bypass and verified the disappearance of the left EICA aneurysm after the ligation.
   CONCLUSIONS: We present a case of EICA aneurysm and hemorrhagic MMD. Ligation of the left ECA eliminates the EICA aneurysm with no neurologic abnormalities. STA-MCA bypass can be regarded as an effective choice for hemorrhagic MMD. Further studies should be performed to confirm the effectiveness of combined surgical revascularization.
C1 [Han, Qingdong; Zhou, Peng; Huang, Yabo] Soochow Univ, Dept Neurosurg, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.
RP Huang, YB (reprint author), Soochow Univ, Dept Neurosurg, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.
EM 23273874@qq.com
OI Huang, Yabo/0000-0001-8372-1492
CR Ben Jmaa Hela, 2018, J Med Vasc, V43, P262, DOI 10.1016/j.jdmv.2018.04.003
   Claus Isabelle, 2020, Acta Chir Belg, V120, P42, DOI 10.1080/00015458.2018.1491515
   Domanin M, 2018, PEDIATR NEUROSURG, V53, P275, DOI 10.1159/000487089
   Ge PC, 2018, J STROKE CEREBROVASC, V27, P1517, DOI 10.1016/j.jstrokecerebrovasdis.2017.12.047
   Guzhin V E, 2016, Zh Vopr Neirokhir Im N N Burdenko, V80, P62, DOI 10.17116/neiro201680562-66
   Ishikawa T, 2018, WORLD NEUROSURG, V119, pE750, DOI 10.1016/j.wneu.2018.07.258
   Jang DK, 2017, J NEUROSURG, V127, P492, DOI 10.3171/2016.8.JNS152875
   Jiber H, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.170.5772
   Pourier VEC, 2018, EUR J NEUROL, V25, P1285, DOI 10.1111/ene.13720
   Qi M, 2018, TURK NEUROSURG, DOI [10.5137/1019-5149.JTN.21848-17.2, DOI 10.5137/1019-5149.JTN.21848-17.2]
   Rodriguez-Hernandez A, 2012, NEUROCIRUGIA, V23, P5, DOI 10.1016/j.neucir.2011.11.001
   SCHIEVINK WI, 1994, NEUROSURGERY, V35, P809, DOI 10.1227/00006123-199411000-00002
   van der Linde RA, 2018, EUR J VASC ENDOVASC, V55, P850, DOI 10.1016/j.ejvs.2018.02.033
NR 13
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 129
EP 133
DI 10.1016/j.wneu.2019.02.110
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400218
PM 30831284
DA 2020-05-12
ER

PT J
AU Hamilton, K
   Koueik, J
   Maganti, R
   Iskandar, B
AF Hamilton, Kimberly
   Koueik, Joyce
   Maganti, Rama
   Iskandar, Bermans
TI Slit Ventricle Syndrome Leads to 10-Year History of Repetitive Transient
   Central Herniation Masquerading as Seizures: Hydrocephalus Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brainstem herniation; Electroencephalogram; Shunt malfunction; Slit
   ventricle syndrome
AB BACKGROUND: Slit-ventricle syndrome (SVS) is a recognized complication of ventricular shunt malfunction, resulting in cyclical symptoms without ventricular dilatation. We present a case of SVS with transient, repetitive, and progressive signs of brainstem herniation evidenced by pupillary dilatation, posturing, and unresponsiveness, with diffuse voltage attenuation on electroencephalogram (EEG).
   CASE DESCRIPTION: A 32-year-old female presented with a history of hydrocephalus and ventriculoperitoneal shunt placement at 9 months of age. She began experiencing significant headaches in college, later accompanied by stereotypical 5- to 25-minute episodes of unresponsiveness, posturing and pupillary dilatation, and failing anticonvulsant therapy. No neurosurgical evaluation was sought because of small ventricles on brain imaging. Episodes became progressively more frequent over a 10-year period, eventually occurring daily. On presentation, 5 clinical events were captured on EEG over 12 hours of monitoring.
   With each episode, she became unresponsive and hypertensive, with fixed, dilated pupils and flexor posturing. Between events, she was awake and alert, without confusion or postictal state. She had papilledema and limited extraocular movements, with normal pupils and vital signs. Computed tomography scanning showed small ventricles. A shunt tap revealed no flow. With each episode onset, an EEG revealed an abrupt background rhythm slowing to 2-3 Hz delta range without epileptiform discharges. Between events, EEGs displayed normal waveform activity. Emergent ventriculoperitoneal shunt revision resulted in no further episodes in a 4-year follow-up period.
   CONCLUSIONS: SVS can lead to severe intermittent brainstem herniation syndrome in the setting of shunt malfunction. Seizure diagnosis should be reserved for cases with proven functional shunt and EEG confirmation of epileptiform activity.
C1 [Hamilton, Kimberly; Koueik, Joyce; Iskandar, Bermans] Univ Wisconsin Hosp & Clin, Dept Neurosurg, Madison, WI 53792 USA.
   [Maganti, Rama] Univ Wisconsin Hosp & Clin, Dept Neurol, Madison, WI 53792 USA.
RP Hamilton, K (reprint author), Univ Wisconsin Hosp & Clin, Dept Neurosurg, Madison, WI 53792 USA.
EM k.hamilton@neurosurgery.wisc.edu
CR EPSTEIN F, 1988, PEDIATR NEUROSCI, V14, P5, DOI 10.1159/000120354
   Kraemer MR, 2017, J NEUROSURG-PEDIATR, V20, P216, DOI 10.3171/2017.2.PEDS16265
   LUCAS S, 1994, J CHILD NEUROL, V9, P167, DOI 10.1177/088307389400900212
   MCLAURIN RL, 1987, PEDIATR NEUROSCI, V13, P118, DOI 10.1159/000120314
   OBANA WG, 1990, NEUROSURGERY, V27, P760, DOI 10.1227/00006123-199011000-00014
   OI S, 1987, CHILD NERV SYST, V3, P145, DOI 10.1007/BF00717890
   Rekate HL, 2004, PEDIATR NEUROSURG, V40, P259, DOI 10.1159/000083737
   Ros B, 2017, NEUROSURG REV, P1
NR 8
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 134
EP 138
DI 10.1016/j.wneu.2019.02.106
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400219
PM 30831286
DA 2020-05-12
ER

PT J
AU Vellutini, EDS
   Stamm, AEC
   Martins, HO
   de Oliveira, MF
   Coy, GPR
   Godoy, LF
   Gomes, MDT
AF Silva Vellutini, Eduardo de Arnaldo
   Cassol Stamm, Aldo Eden
   Martins, Henrique Oliveira
   de Oliveira, Matheus Fernandes
   Rodriguez Coy, Gustavo Pegos
   Godoy, Luiz Felipe
   Teles Gomes, Marcos de Queiroz
TI Role of Transnasal Endoscopic Surgery in the Treatment of Superficial
   Siderosis of Central Nervous System Secondary to Clivus Arachnoidocele:
   Report of Successful Case and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Central nervous system superficial siderosis; Clivus arachnoidocele;
   Endoscopic endonasal surgery; Treatment
AB BACKGROUND: Superficial siderosis (SS) of the central nervous system is a disease characterized by deposition of hemosiderin in the leptomeninges (arachnoid and pia mater) due to chronic intradural bleeding. One of the etiologic mechanisms proposed is a dural breach secondary to trauma with a consequent arachnoidocele in contact with an exuberant venous plexus. We describe a unique case of clival arachnoidocele treated by an endoscopic endonasal approach and closure of the defect with fat and nasoseptal flap.
   CASE DESCRIPTION: A 35-year-old man with a history of severe head trauma 20 years ago presented with hearing deficit and a mild motor ataxia impairing gait. Magnetic resonance imaging disclosed hemosiderin deposition throughout the brain cortical layer and in the cerebellum, affecting the dentate nucleus as well. A computed tomography revealed an osteolytic formation in the clivus, involving the inner bone table and bone marrow. The patient was then submitted to an endoscopic endonasal transclival approach to close the defect.
   CONCLUSIONS: SS may be a result of several etiologies generating repetitive meningeal bleeding. Our patient had the diagnosis of posttraumatic clival arachnoidocele and SS probably related to trauma with some dural injury. An endoscopic endonasal approach with tear reconstruction is feasible and successful to address clival arachnoidoceles and, in this case, to avoid progression of the SS.
C1 [Silva Vellutini, Eduardo de Arnaldo; Martins, Henrique Oliveira; de Oliveira, Matheus Fernandes; Teles Gomes, Marcos de Queiroz] DFV Neuro, Neurosurg Dept, Sao Paulo, Brazil.
   [Cassol Stamm, Aldo Eden; Rodriguez Coy, Gustavo Pegos] Ctr Otorhinolaryngol & Speech & Hearing Therapy S, Sao Paulo, Brazil.
   [Silva Vellutini, Eduardo de Arnaldo; Cassol Stamm, Aldo Eden; Martins, Henrique Oliveira; de Oliveira, Matheus Fernandes; Rodriguez Coy, Gustavo Pegos; Godoy, Luiz Felipe; Teles Gomes, Marcos de Queiroz] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Silva Vellutini, Eduardo de Arnaldo; Cassol Stamm, Aldo Eden; Martins, Henrique Oliveira; de Oliveira, Matheus Fernandes; Rodriguez Coy, Gustavo Pegos; Teles Gomes, Marcos de Queiroz] Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil.
RP de Oliveira, MF (reprint author), DFV Neuro, Neurosurg Dept, Sao Paulo, Brazil.; de Oliveira, MF (reprint author), Hosp Sirio Libanes, Sao Paulo, Brazil.; de Oliveira, MF (reprint author), Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil.
EM mafernoliv@yahoo.com.br
OI Oliveira, Matheus/0000-0003-1123-7583
CR Cheng CY, 2011, MED HYPOTHESES, V76, P823, DOI 10.1016/j.mehy.2011.02.028
   Egawa S, 2013, J NEUROSURG-SPINE, V18, P388, DOI 10.3171/2013.1.SPINE12649
   Fraser JF, 2010, NEUROSURGERY, V66
   Johans SJ, 2018, J NEUROSURG-PEDIATR, V21, P498, DOI 10.3171/2017.11.PEDS17302
   Kumar N, 2009, NEUROLOGY, V72, P671, DOI 10.1212/01.wnl.0000342457.22536.af
NR 5
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 142
EP 145
DI 10.1016/j.wneu.2019.02.186
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400221
PM 30862598
DA 2020-05-12
ER

PT J
AU Morinaga, Y
   Nii, K
   Sakamoto, K
   Inoue, R
   Mitsutake, T
   Hanada, H
AF Morinaga, Yusuke
   Nii, Kouhei
   Sakamoto, Kimiya
   Inoue, Ritsurou
   Mitsutake, Takafumi
   Hanada, Hayatsura
TI Recurrent Acute Ischemic Stroke Associated with Dolichoectatic Aneurysm
   of the Internal Carotid Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Best medical treatment; DOAC; Dolichoectatic
   aneurysm; ICA; Vertebrobasilar dolichoectasia
AB BACKGROUND: Cranial artery dolichoectasia is characterized by dilated, elongated, and tortuous cranial arteries. Dolichoectasia and dolichoectatic aneurysm-particularly of the internal carotid arteries (ICAs)-are rare but can lead to stroke. We report a case of suspected recurrent acute cerebral infarction and dolichoectatic aneurysm of the left ICA combined with right dolichoectatic aneurysm, vertebrobasilar dolichoectasia, and atrial fibrillation.
   CASE DESCRIPTION: An 80-year-old man experienced 3 days of recurrent aphasia episodes. He had a history of atrial fibrillation and hypertension. Neurologic findings indicated Wernicke aphasia. Magnetic resonance imaging showed acute cerebral infarction in the left temporal and parietal lobes. Magnetic resonance angiography and cerebral angiography showed dolichoectatic aneurysms in the C1-2 portion of the bilateral ICAs and vertebrobasilar dolichoectasia. Possible diagnoses included convulsion, cardioembolic infarction, atherothrombotic cerebral infarction, and acute ischemic stroke associated with the dolichoectatic aneurysm of the left ICA. Oral antiplatelet drugs, direct oral anticoagulants, and anticonvulsants were administered. Nine months after initial hospitalization, the patient had a recurrence of acute ischemic stroke and was rehospitalized. He was treated with a new direct oral anticoagulant, clopidogrel, statins, and ethyl icosapentate. At 2 years after initial hospitalization, he has had no recurrence of stroke, has a modified Rankin Scale score of 2, and is currently being followed as an outpatient.
   CONCLUSIONS: A direct oral anticoagulant (edoxaban) and clopidogrel were effective for suspected recurrent acute ischemic stroke associated with dolichoectatic aneurysm of the ICA combined with contralateral dolichoectatic aneurysm, vertebrobasilar dolichoectasia, and atrial fibrillation.
C1 [Morinaga, Yusuke; Nii, Kouhei; Sakamoto, Kimiya; Inoue, Ritsurou; Mitsutake, Takafumi; Hanada, Hayatsura] Fukuoka Univ, Dept Neurosurg, Chikushi Hosp, Chikushino, Japan.
RP Morinaga, Y (reprint author), Fukuoka Univ, Dept Neurosurg, Chikushi Hosp, Chikushino, Japan.
EM yu_the_morio@yahoo.co.jp
CR BLUMENKOPF B, 1985, NEUROSURGERY, V17, P797, DOI 10.1227/00006123-198511000-00012
   Boulloche N, 2007, J NEUROL, V254, P122, DOI 10.1007/s00415-006-0314-9
   Caplan LR, 2005, ANN NEUROL, V57, P469, DOI 10.1002/ana.20447
   COURVILLE C B, 1962, Bull Los Angel Neuro Soc, V27, P1
   De Georgia M, 1999, CEREBROVASC DIS, V9, P28, DOI 10.1159/000015892
   ECHIVERRI HC, 1989, STROKE, V20, P1741, DOI 10.1161/01.STR.20.12.1741
   FINNEY HL, 1976, J NEUROSURG, V45, P342, DOI 10.3171/jns.1976.45.3.0342
   HENNERICI M, 1987, SURG NEUROL, V27, P523, DOI 10.1016/0090-3019(87)90149-2
   Ling JC, 2007, CLIN IMMUNOL, V122, P255, DOI 10.1016/j.clim.2006.10.005
   NISHIZAKI T, 1986, STROKE, V17, P1277, DOI 10.1161/01.STR.17.6.1277
   Sadahiro H, 2014, J NEUROIMAGING, V24, P83, DOI 10.1111/j.1552-6569.2011.00656.x
   SCHOOLMAN A, 1967, J NEUROSURG, V26, P82, DOI 10.3171/jns.1967.26.1part1.0082
   Sidiropoulou MS, 2003, NEURORADIOLOGY, V45, P541, DOI 10.1007/s00234-003-1061-6
   Stephen E, 2008, EUR J VASC ENDOVASC, V35, P9, DOI 10.1016/j.ejvs.2007.08.003
   YU YL, 1982, J NEUROL NEUROSUR PS, V45, P29, DOI 10.1136/jnnp.45.1.29
NR 15
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 146
EP 150
DI 10.1016/j.wneu.2019.02.153
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400222
PM 30858000
DA 2020-05-12
ER

PT J
AU Sakakura, K
   Nakai, Y
   Ikeda, G
   Shiigai, M
   Watanabe, N
   Uemura, K
   Zaboronok, A
   Ishikawa, E
   Matsumura, A
AF Sakakura, Kazuki
   Nakai, Yasunobu
   Ikeda, Go
   Shiigai, Masanari
   Watanabe, Noriyuki
   Uemura, Kazuya
   Zaboronok, Alexander
   Ishikawa, Eiichi
   Matsumura, Akira
TI Transvenous Embolization of Dural Arteriovenous Fistula of the Anterior
   Condylar Confluence via the Intercavernous Sinus Assisted by Bone
   Subtraction Computed Tomography Angiography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior condylar confluence; Digital subtraction angiography; Dural
   arteriovenous fistula; Intercavernous sinus; Transvenous embolization
ID CT ANGIOGRAPHY; ENDOVASCULAR TREATMENT; ANEURYSMS
AB BACKGROUND: Dural arteriovenous fistulae (dAVFs) of the anatomically complex anterior condylar confluence (ACC) are often examined by computed tomography (CT) angiography and conventional angiography before treatment. Contrasted vessels often overlap with skull bones in enhanced CT scan and make it difficult to detect the shunt point of the dAVF. Bone subtraction CT angiography (BSCTA) can overcome this limitation and allow for superior imaging of dAVFs that may help to find an alternative access for catheterization.
   CASE DESCRIPTION: An 80-year-old woman suffered from right ear tinnitus, headache, and an audible bruit. Preoperative imaging showed a dAVF of the ACC. It was fed by the bilateral ascending pharyngeal artery, drained to the internal jugular vein (IJV) via the inferior petrosal sinus, and had an intraosseous shunt pouch. We therefore performed transvenous embolization (TVE) via the intercavernous sinus because the angle between the anterior condylar vein and the IJV was too sharp to catheterize vessels through the ipsilateral IJV.
   CONCLUSIONS: Understanding the inherently complex and individually unique venous anatomy of the ACC is crucial for treatment of dAVFs. BSCTA is an effective visualization technique for dAVFs of the ACC and allows for precise preoperative vascular structure evaluation. We suggest that in the case of the angle between the ACV and the IJV being too sharp to catheterize vessels through the ipsilateral IJV, TVE via the intercavernous sinus can be efficiently used.
C1 [Sakakura, Kazuki; Nakai, Yasunobu; Ikeda, Go; Watanabe, Noriyuki; Uemura, Kazuya] Tsukuba Med Ctr Hosp, Dept Neurosurg, Tsukuba, Ibaraki, Japan.
   [Shiigai, Masanari] Tsukuba Med Ctr Hosp, Dept Radiol, Tsukuba, Ibaraki, Japan.
   [Sakakura, Kazuki; Watanabe, Noriyuki; Zaboronok, Alexander; Ishikawa, Eiichi; Matsumura, Akira] Univ Tsukuba, Dept Neurosurg, Tsukuba, Ibaraki, Japan.
RP Zaboronok, A (reprint author), Univ Tsukuba, Dept Neurosurg, Tsukuba, Ibaraki, Japan.
EM a.zaboronok@md.tsukuba.ac.jp
RI Zaboronok, Alexander/W-4119-2019
OI Zaboronok, Alexander/0000-0002-6833-9866
CR Abiko M, 2008, INTERV NEURORADIOL, V14, P313, DOI 10.1177/159101990801400312
   Aulbach P, 2016, AM J NEURORADIOL, V37, P236, DOI 10.3174/ajnr.A4497
   Geibprasert S, 2008, STROKE, V39, P2783, DOI 10.1161/STROKEAHA.108.516757
   Hsu YH, 2014, INTERV NEURORADIOL, V20, P368, DOI 10.15274/NRJ-2014-10028
   Klisch J, 2003, NEUROSURGERY, V53, P836, DOI 10.1227/01.NEU.0000083551.26295.AB
   Koc O, 2013, TURK NEUROSURG, V23, P249, DOI 10.5137/1019-5149.JTN.4301-11.1
   Kondo Y, 2007, J NEUROENDOVASCULAR, V1, P31
   Miyachi S, 2008, INTERV NEURORADIOL, V14, P303, DOI 10.1177/159101990801400311
   Nishii T, 2015, AM J NEURORADIOL, V36, P2400, DOI 10.3174/ajnr.A4435
   Romijn M, 2008, AM J NEURORADIOL, V29, P134, DOI 10.3174/ajnr.A0741
   Ruiz DS, 2002, AM J NEURORADIOL, V23, P1500
   Sakamoto S, 2006, AM J NEURORADIOL, V27, P1332
   Sasaki T, 2008, J NEUROENDOVASC THER, V2, P212
   Shimizu N., 2015, JNET, V9, P179, DOI [10.5797/jnetoa.2015-0007, DOI 10.5797/JNET.OA.2015-0007]
   Spittau B, 2015, J NEUROSURG, V122, P883, DOI 10.3171/2014.10.JNS14377
   Wakabayashi K, 2012, J NEUROENDOVASC THER, V6, P196
   Zenteno Marco, 2015, Asian J Neurosurg, V10, P55, DOI 10.4103/1793-5482.151522
NR 17
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 151
EP 155
DI 10.1016/j.wneu.2019.02.175
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400223
PM 30857996
DA 2020-05-12
ER

PT J
AU Chan, AY
   Urgun, K
   Tran, DK
   Kyong, T
   Hsu, FPK
   Vadera, S
AF Chan, Alvin Y.
   Urgun, Kamran
   Diem Kieu Tran
   Kyong, Thomas
   Hsu, Frank P. K.
   Vadera, Sumeet
TI Cerebral Peduncle Volume and Motor Function Following Adult
   Hemispherectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomic; Corticospinal tract; Functional; Seizure
ID REFRACTORY EPILEPSY
AB BACKGROUND: Hemispherectomy is a successful and well-described treatment option for pediatric patients with hemispheric ictal onset, but adult outcomes have been far less studied. We describe the outcomes in adult patients with medically refractory epilepsy and hemispheric disease and the relationship to cerebral peduncle volume.
   CASE DESCRIPTIONS: We retrospectively reviewed adult hemispherectomy patients at our institution from 2015 to 2018. Patient data including demographic information, pathologic changes, seizure-free outcomes, and ipsilateral (i.e., surgical side) and contralateral (i.e., functional side) cerebral peduncle volume data were collected. We identified 4 adult patients who underwent hemispherectomy. The mean age at surgery was roughly 25 years. All patients were categorized as Engel I or II, and motor scores at last follow-up were unchanged. The mean volume for contralateral and ipsilateral cerebral peduncle means were 1.42 and 0.78 cm(3), respectively (P = 0.01).
   CONCLUSIONS: These findings suggest that smaller ipsilateral cerebral peduncle size could potentially be associated with unchanged postoperative hemiparesis. We hypothesize that smaller ipsilateral peduncle size could have represented corticospinal tract reorganization in childhood, implying that the removed brain matter was mostly noncontributory to contralateral motor function.
C1 [Chan, Alvin Y.; Urgun, Kamran; Diem Kieu Tran; Kyong, Thomas; Hsu, Frank P. K.; Vadera, Sumeet] Univ Calif Irvine, Comprehens Epilepsy Ctr, Orange, CA 92668 USA.
RP Chan, AY (reprint author), Univ Calif Irvine, Comprehens Epilepsy Ctr, Orange, CA 92668 USA.
EM alvin.chan@uci.edu
CR Cukiert A, 2009, EPILEPSIA, V50, P1381, DOI 10.1111/j.1528-1167.2008.01795.x
   Du XY, 2018, WORLD NEUROSURG, V116, pE634, DOI 10.1016/j.wneu.2018.05.057
   Gonzalez-Martinez JA, 2005, EPILEPSIA, V46, P1518, DOI 10.1111/j.1528-1167.2005.53704.x
   Griessenauer CJ, 2015, J NEUROSURG-PEDIATR, V15, P34, DOI 10.3171/2014.10.PEDS14155
   Jonas R, 2004, NEUROLOGY, V62, P1712, DOI 10.1212/01.WNL.0000127109.14569.C3
   Moosa ANV, 2013, EPILEPSIA, V54, P1771, DOI 10.1111/epi.12342
   Mullin JP, 2016, NEUROSURGERY, V79, P499, DOI 10.1227/NEU.0000000000001307
   Schusse CM, 2018, J NEUROSURG, V128, P853, DOI 10.3171/2016.9.JNS151778
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   Wang AC, 2018, J NEUROSURG-PEDIATR, V21, P81, DOI 10.3171/2017.7.PEDS17137
   WARABI T, 1987, NEURORADIOLOGY, V29, P409, DOI 10.1007/BF00341735
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 156
EP 159
DI 10.1016/j.wneu.2019.03.034
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400224
PM 30877000
DA 2020-05-12
ER

PT J
AU Park, SH
   Yoon, SY
   Park, KS
   Hwang, JH
   Hwang, SK
AF Park, Seong-Hyun
   Yoon, Sang-Youl
   Park, Ki-Su
   Hwang, Jeong-Hyun
   Hwang, Sung-Kyoo
TI Brain Metastasis from Nasopharyngeal Carcinoma Treated with Stereotactic
   Radiosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastasis; Nasopharyngeal carcinoma; Stereotactic radiosurgery
AB BACKGROUND: Nasopharyngeal carcinoma (NPC) is a common malignant tumor of the head and neck, and is associated with high recurrence and low survival rates; however, distant brain metastasis from NPC is rare.
   CASE DESCRIPTION: The authors report 3 cases of brain metastasis from NPC treated with stereotactic radiosurgery (SRS). A 49-year-old woman presented was diagnosed with brain metastasis from NPC, which occurred 53 months after the initial diagnosis of NPC. Brain magnetic resonance imaging (MRI) revealed a well-enhanced large tumor on the frontal lobe, which was treated with SRS. Six months later, brain MRI revealed progression of the tumor. A 44-year-old man had undergone craniotomy and removal of a cerebellar tumor pathologically confirmed as metastasis from NPC. The recurrent brain metastasis was diagnosed via routine MRI follow-up examination 23 months after surgery. Brain MRI revealed a heterogeneously enhanced cerebellar large tumor, which was treated using hypofractionated SRS. Three months later, brain MRI revealed a significant decrease in the tumor size. A 60-year-old man was diagnosed with distant brain metastasis from NPC via routine positron emission tomography follow-up examination 14 months after the initial diagnosis of NPC. Brain MRI confirmed a homogeneously enhanced tumor on the cavernous sinus, which was treated with SRS. Three months later, brain MRI revealed virtual disappearance of the tumor. All 3 patients had undergone concurrent chemoradiotherapy after the initial diagnosis of NPC and underwent salvage SRS for brain metastasis from NPC.
   CONCLUSIONS: Despite the poor prognosis, salvage SRS was performed for these rare brain metastases from NPC.
C1 [Park, Seong-Hyun; Yoon, Sang-Youl; Park, Ki-Su; Hwang, Jeong-Hyun; Hwang, Sung-Kyoo] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Neurosurg, Daegu, South Korea.
RP Park, SH (reprint author), Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Neurosurg, Daegu, South Korea.
EM nsdoctor@naver.com
OI Hwang, Jeong-Hyun/0000-0002-5306-6922; PARK,
   SEONG-HYUN/0000-0002-0982-5338
CR Chua DTT, 2006, INT J RADIAT ONCOL, V66, P1415, DOI 10.1016/j.ijrobp.2006.07.1364
   de Bree R, 2001, OTOLARYNG HEAD NECK, V124, P217, DOI 10.1067/mhn.2001.112478
   Elloumi F, 2013, CANCER RADIOTHER, V17, P768, DOI 10.1016/j.canrad.2013.09.004
   Enis O, 2004, ARCH ONCOLOGY, V12, P121
   Kaidar-Person O, 2012, CASE REP MED, DOI 10.1155/2012/405917
   KHOR TH, 1978, CLIN RADIOL, V29, P27, DOI 10.1016/S0009-9260(78)80160-3
   LIAW CC, 1994, J NEURO-ONCOL, V22, P227, DOI 10.1007/BF01052923
   Liu F, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-157
   Ngan RKC, 2002, CANCER, V94, P398, DOI 10.1002/cncr.10179
   Smee RI, 2010, AM J CLIN ONCOL-CANC, V33, P469, DOI 10.1097/COC.0b013e3181b4b037
NR 10
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 160
EP 163
DI 10.1016/j.wneu.2019.03.029
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400225
PM 30877007
DA 2020-05-12
ER

PT J
AU Ren, YM
   Liu, H
   Chen, TY
   You, C
   Li, J
AF Ren, Yanming
   Liu, Hao
   Chen, Teng-Yun
   You, Chao
   Li, Jin
TI Successful Management of Sacral Dural Arteriovenous Fistulas: A Case
   Series and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Lateral sacral artery; Sacral; Spinal dural arteriovenous fistula
ID SURGICAL-TREATMENT; BRANCHES; PATIENT
AB BACKGROUND: Spinal dural arteriovenous fistula (DAVF) occurs at any spinal level; however, a sacral location of fistula is extremely rare, and the clinical characteristics of sacral DAVF have not been well described. This study aimed to document the clinical features of sacral DAVF and review the existing literature.
   CASE DESCRIPTION: The first patient was a 55-year-old man who had progressive weakness and numbness in his lower extremities, along with mild urinary incontinence. The second case was a 32-year-old man who had a 1-year history of progressively worsening bilateral lower extremity weakness associated with diminished sensation. The third patient was a 43-year-old woman with 6-month history of progressive motor weakness of her lower limbs. On spinal angiography, a sacral DAVF with perimedullary vein drainage in all cases was observed. The sacral fistulas were completely obliterated with surgical intervention, and the symptoms of these patients have been gradually resolved. Follow-up magnetic resonance imaging showed complete or partial resolution of the edema within the spinal cord and disappearance of the abnormal vascular flow voids.
   CONCLUSIONS: Sacral DAVFs are extremely rare and are easily missed by spinal angiography. Clinicians should be aware of the possibility of the occurrence of sacral DAVFs, and spinal angiography for the complete assessment of spinal vasculature should be carried out.
C1 [Ren, Yanming; Chen, Teng-Yun; You, Chao; Li, Jin] Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Liu, Hao; Li, Jin] Sichuan Univ, Dept Neurosurg, West China Shangjin Nanfu Hosp, Chengdu, Sichuan, Peoples R China.
RP Li, J (reprint author), Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.; Li, J (reprint author), Sichuan Univ, Dept Neurosurg, West China Shangjin Nanfu Hosp, Chengdu, Sichuan, Peoples R China.
EM lijinwestchina@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571131]
FX This study was supported by National Natural Science Foundation of China
   (81571131).
CR Aadland TD, 2010, AM J NEURORADIOL, V31, P476, DOI 10.3174/ajnr.A1840
   Abe O, 1996, NEURORADIOLOGY, V38, P618, DOI 10.1007/s002340050320
   Abou Al-Shaar H, 2016, WORLD NEUROSURG, V90
   Alvarado AM, 2017, INTERV NEUROL, V6, P73, DOI 10.1159/000454929
   AMINOFF MJ, 1974, BRAIN, V97, P197, DOI 10.1093/brain/97.1.197
   Annaswamy TM, 2017, AM J PHYS MED REHAB, V96, pe147, DOI 10.1097/PHM.0000000000000645
   Borghei-Razavi H, 2014, CLIN NEUROL NEUROSUR, V124, P185, DOI 10.1016/j.clineuro.2014.06.040
   Brinjikji W, 2018, AM J NEURORADIOL, V39, P1953, DOI 10.3174/ajnr.A5784
   BURGUET JL, 1985, NEURORADIOLOGY, V27, P232, DOI 10.1007/BF00344494
   Chen CJ, 1998, NEURORADIOLOGY, V40, P393, DOI 10.1007/s002340050609
   DJINDJIAN M, 1989, J NEUROSURG, V71, P768, DOI 10.3171/jns.1989.71.5.0768
   Endo T, 2018, WORLD NEUROSURG, V110, pE383, DOI 10.1016/j.wneu.2017.11.002
   Gioppo A, 2018, J NEUROINTERV SURG, V10, P415, DOI 10.1136/neurintsurg-2017-013307
   Jin YJ, 2010, NEUROSURGERY, V66, P219, DOI 10.1227/01.NEU.0000359529.40577.A1
   Kaku Y, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.06.065
   KIM DI, 1991, J NEUROSURG, V75, P947, DOI 10.3171/jns.1991.75.6.0947
   Krisht KM, 2015, CASE REP NEUROL MED, DOI 10.1155/2015/526321
   LARSEN DW, 1995, SURG NEUROL, V43, P35, DOI 10.1016/0090-3019(95)80035-F
   Li JW, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.06.149
   Mhiri C, 2000, SPINAL CORD, V38, P711, DOI 10.1038/sj.sc.3101086
   MOURIER KL, 1989, ACTA NEUROCHIR, V100, P136, DOI 10.1007/BF01403601
   Nishio A, 2007, J CLIN NEUROSCI, V14, P65, DOI 10.1016/j.jocn.2005.10.020
   O'Brien WT, 2001, SURG NEUROL, V56, P175, DOI 10.1016/S0090-3019(01)00486-4
   Park KW, 2009, J KOREAN NEUROSURG S, V45, P115, DOI 10.3340/jkns.2009.45.2.115
   Przepiorka L, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00807
   Rosi A, 2018, J NEUROINTERV SURG, V10, P586, DOI 10.1136/neurintsurg-2017-013505
   Safaee MM, 2018, J NEUROSURG-SPINE, V29, P85, DOI 10.3171/2017.11.SPINE17988
   Saladino A, 2010, NEUROSURGERY, V67, P1350, DOI 10.1227/NEU.0b013e3181ef2821
   Sasamori Toru, 2011, No Shinkei Geka, V39, P505
   Schaat TJ, 2002, SPINE, V27, P893
   Schuss P, 2015, WORLD NEUROSURG, V83, P1002, DOI 10.1016/j.wneu.2015.02.026
   Steinmetz MP, 2004, NEUROSURGERY, V55, P77, DOI 10.1227/01.NEU.0000126878.95006.0F
   Suh DC, 2016, WORLD NEUROSURG, V96, P309, DOI 10.1016/j.wneu.2016.09.002
   Tan LA, 2014, J NEUROSURG-SPINE, V21, P279, DOI 10.3171/2014.3.SPINE13719
   Uetani H, 2018, MAGN RESON MED SCI, V17, P218, DOI 10.2463/mrms.mp.2016-0098
   Whitaker-Lea WA, 2018, WORLD NEUROSURG, V111, P73, DOI 10.1016/j.wneu.2017.12.065
NR 36
TC 1
Z9 1
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 164
EP 170
DI 10.1016/j.wneu.2019.02.129
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400226
PM 30844523
DA 2020-05-12
ER

PT J
AU Peto, I
   Abou-Al-Shaar, H
   Dehdashti, AR
AF Peto, Ivo
   Abou-Al-Shaar, Hussam
   Dehdashti, Amir R.
TI Multimodal Treatment of Occipital Tentorial Dural Arteriovenous Fistula
   Cognard III
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Cortical venous reflux; Dural arteriovenous
   fistula; Surgical disconnection
C1 [Peto, Ivo; Abou-Al-Shaar, Hussam; Dehdashti, Amir R.] North Shore Univ Hosp, Dept Neurosurg, Manhasset, NY 11030 USA.
RP Peto, I (reprint author), North Shore Univ Hosp, Dept Neurosurg, Manhasset, NY 11030 USA.
EM Ivo.peto@icloud.com
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 171
EP 171
DI 10.1016/j.wneu.2019.02.185
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400227
PM 30862601
DA 2020-05-12
ER

PT J
AU Hajdarpasic, E
   Dzurlic, A
   Mahmutbegovic, N
   Zahirovic, S
   Ahmetspahic, A
   Arnautovic, K
   Omerhodzic, I
AF Hajdarpasic, Edin
   Dzurlic, Almir
   Mahmutbegovic, Nevena
   Zahirovic, Salko
   Ahmetspahic, Adi
   Arnautovic, Kenan
   Omerhodzic, Ibrahim
TI Sepsis Caused by Bacterial Colonization of Migrated Distal
   Ventriculoperitoneal Shunt Catheter into the Pulmonary Artery: A First
   Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Sepsis; Shunt catheter migration; Ventriculoperitoneal shunt; VP shunt
   catheter pulmonary migration
ID INTRACARDIAC MIGRATION; CARDIAC MIGRATION; HEART; COMPLICATIONS;
   MANAGEMENT
AB BACKGROUND: Migration of distal ventriculoperitoneal (VP) shunt catheter into another body part has been described as a potentially serious surgical complication. We present the first case of sepsis caused by transcardial and pulmonary migration of a distal catheter into the heart and pulmonary artery, which was subsequently colonized by Klebsiella pneumoniae.
   CASE REPORT: A 56-year-old man underwent VP shunt insertion for hydrocephalus that developed after the surgery for intracranial meningioma. Three years later, he was admitted to department for infectious diseases because of persistent fever. Klebsiella pneumoniae was isolated from the blood cultures. Computed tomography (CT) of the thorax showed migration of the distal catheter into the heart and pulmonary artery. The migrated shunt catheter was retrieved without any complication with the assistance of a cardiovascular surgeon; microbiologic analysis confirmed that the catheter was colonized with K. pneumoniae. We decided to delay new VP shunt placement because of the positive blood cultures, and 3 weeks after the surgery, the patient was without signs of increased intracranial pressure and without any heart problems.
   CONCLUSION: Migration of a distal VP shunt catheter into the heart should be considered in patients with a previously placed VP shunt presenting with cardiopulmonary problems, arrhythmia, and/or fever. Neurosurgeons should be involved as soon as possible, and a multidisciplinary approach is warranted.
C1 [Hajdarpasic, Edin; Dzurlic, Almir; Zahirovic, Salko; Ahmetspahic, Adi; Omerhodzic, Ibrahim] Sarajevo Univ, Clin Ctr, Dept Neurosurg, Sarajevo, Bosnia & Herceg.
   [Mahmutbegovic, Nevena] Sarajevo Univ, Clin Ctr, Dept Neurol, Sarajevo, Bosnia & Herceg.
   [Arnautovic, Kenan] Univ Tennessee, Hlth Sci Ctr, Dept Neurosurg, Knoxville, TN 37996 USA.
   [Arnautovic, Kenan] Semmes Murphey Clin, Memphis, TN 38120 USA.
RP Arnautovic, K (reprint author), Univ Tennessee, Hlth Sci Ctr, Dept Neurosurg, Knoxville, TN 37996 USA.; Arnautovic, K (reprint author), Semmes Murphey Clin, Memphis, TN 38120 USA.
EM kenanarnaut@yahoo.com
RI Arnautovic, Kenan/AAI-6898-2020; Omerhodzic, Ibrahim/AAL-7976-2020
OI Arnautovic, Kenan/0000-0003-3745-288X; 
CR Aboukais R, 2015, NEUROCHIRURGIE, V61, P43, DOI 10.1016/j.neuchi.2014.10.109
   Chaudhry NS, 2015, J CLIN NEUROSCI, V22, P402, DOI 10.1016/j.jocn.2014.05.026
   Chong JY, 2008, J KOREAN NEUROSURG S, V44, P170, DOI 10.3340/jkns.2008.44.3.170
   CROFFORD MJ, 1983, AM J ROENTGENOL, V141, P369, DOI 10.2214/ajr.141.2.369
   Dossani RH, 2017, ANN VASC SURG, V45, P305, DOI 10.1016/j.avsg.2017.06.040
   Fewel ME, 2004, J NEUROSURG, V100, P206, DOI 10.3171/ped.2004.100.2.0206
   Frahm-Jensen G, 2015, J CLIN NEUROSCI, V22, P771, DOI 10.1016/j.jocn.2014.10.020
   Frazier JL, 2002, NEUROSURGERY, V51, P819, DOI 10.1097/00006123-200209000-00042
   GROSFELD JL, 1974, PEDIATRICS, V54, P791
   Hai Abdul, 2011, J Indian Assoc Pediatr Surg, V16, P31, DOI 10.4103/0971-9261.74521
   Hermann EJ, 2009, ACTA NEUROCHIR, V151, P647, DOI 10.1007/s00701-009-0282-9
   Imamura H, 2002, NEUROL MED-CHIR, V42, P181, DOI 10.2176/nmc.42.181
   Kang JK, 1996, CHILD NERV SYST, V12, P176, DOI 10.1007/BF00266827
   Kano T, 2010, NEUROL MED-CHIR, V50, P945, DOI 10.2176/nmc.50.945
   Kim MS, 2005, SURG NEUROL, V63, P185, DOI 10.1016/j.surneu.2004.04.022
   Kubo S, 2002, NEUROL MED-CHIR, V42, P572, DOI 10.2176/nmc.42.572
   Lyon K, 2016, WORLD NEUROSURG, V92, DOI 10.1016/j.wneu.2016.05.024
   Manix Marc, 2014, J La State Med Soc, V166, P21
   MORELL RC, 1994, J NEUROSURG ANESTH, V6, P132
   Nguyen HS, 2010, CHILD NERV SYST, V26, P1113, DOI 10.1007/s00381-010-1146-6
   Nordbeck P, 2010, CLIN RES CARDIOL, V99, P677, DOI 10.1007/s00392-010-0195-x
   PATEL CD, 1973, J NEUROSURG, V38, P761, DOI 10.3171/jns.1973.38.6.0761
   Ralston A, 2017, CHILD NERV SYST, V33, P703, DOI 10.1007/s00381-016-3324-7
   Reddy GK, 2011, NEUROSURGERY, V69, P774, DOI 10.1227/NEU.0b013e31821ffa9e
   Rizk E, 2009, J NEUROSURG-PEDIATR, V3, P525, DOI 10.3171/2009.2.PEDS08482
   Rodriguez-Sanchez JA, 2003, NEUROSURGERY, V52, P1510, DOI 10.1227/01.NEU.0000068351.22859.59
   Ruggiero C, 2010, CHILD NERV SYST, V26, P957, DOI 10.1007/s00381-009-1052-y
   Ryugo Masahiro, 2009, Ann Vasc Dis, V2, P51, DOI 10.3400/avd.AVDcr08038
   Sarangi GS, 2016, INT SURG J, V3, P390
   Wei QT, 2012, CHILD NERV SYST, V28, P1959, DOI 10.1007/s00381-012-1814-9
   Zairi F, 2012, BRIT J NEUROSURG, V26, P545, DOI 10.3109/02688697.2011.641612
NR 31
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 172
EP 180
DI 10.1016/j.wneu.2019.02.176
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400228
PM 30862581
DA 2020-05-12
ER

PT J
AU Fayed, I
   Conte, AG
   Voyadzis, JM
AF Fayed, Islam
   Conte, Anthony G.
   Voyadzis, Jean-Marc
TI Success and Failure of Percutaneous Minimally Invasive Direct Pars
   Repair: Analysis of Fracture Morphology
SO WORLD NEUROSURGERY
LA English
DT Article
DE Direct pars repair; Minimally invasive spine surgery; Pars
   interarticularis; Spondylolysis
ID LUMBAR SPONDYLOLYSIS; SCREW FIXATION; SURGICAL-TREATMENT;
   INTERNAL-FIXATION; INTERARTICULARIS; OUTCOMES; DEFECTS;
   SPONDYLOLISTHESIS; SURGERY; RETURN
AB BACKGROUND: Spondylolysis is a defect in the pars interarticularis that typically presents with axial back pain. Recently, minimally invasive spine techniques have increased in popularity and have been applied to the Buck technique of direct pars repair.
   CASE DESCRIPTION: In our series, 2 patients underwent minimally invasive direct pars repair by the percutaneous insertion of a cannulated lag screw across the pars defect with compression against the lamina. The defect was then decorticated and packed with bone grafting material through a tubular retractor. The clinical records, including preoperative imaging characteristics and intraoperative variables, were collected. The first patient was a 22-year-old woman with bilateral pars defects, and the second was a 21-year-old woman with a left-sided pars defect. They underwent minimally invasive direct pars repair without complications and were discharged home within 24-48 hours. In the first patient, the fusion was successful; however, the second experienced screw back out and required subsequent revision. The follow-up period was 25 months for patient 1 and 21 months for patient 2. The fracture morphology differed. The successfully repaired fractures were linear with smooth cortical edges and oriented perpendicular to the screw trajectory. The failed repair involved a unilateral, curved defect with comminuted cortical edges.
   CONCLUSION: Minimally invasive direct pars repair can be performed safely and effectively with shortened hospital stays and reduced morbidity. Fracture morphology and orientation could be important predictors of the success of surgery.
C1 [Fayed, Islam; Conte, Anthony G.; Voyadzis, Jean-Marc] MedStar Georgetown Univ Hosp, Dept Neurosurg, Washington, DC 20007 USA.
RP Fayed, I (reprint author), MedStar Georgetown Univ Hosp, Dept Neurosurg, Washington, DC 20007 USA.
EM islam.f.fayed@gmail.com
OI Fayed, Islam/0000-0002-4183-4744
CR Apfelbaum RI, 2000, J NEUROSURG, V93, P227, DOI 10.3171/spi.2000.93.2.0227
   BLANDA J, 1993, J SPINAL DISORD, V6, P406, DOI 10.1097/00002517-199306050-00007
   Brennan RP, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/8/E13
   Buck J E, 1970, J Bone Joint Surg Br, V52, P432
   Congeni J, 1997, AM J SPORT MED, V25, P248, DOI 10.1177/036354659702500220
   de Bodman C, 2014, J CHILD ORTHOP, V8, P97, DOI 10.1007/s11832-014-0560-9
   Debnath UK, 2007, SPINE, V32, P995, DOI 10.1097/01.brs.0000260978.10073.90
   Debnath UK, 2003, J BONE JOINT SURG BR, V85B, P244, DOI 10.1302/0301-620X.85B2.13074
   Debusscher F, 2007, EUR SPINE J, V16, P1650, DOI 10.1007/s00586-007-0392-0
   Drazin D, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11180
   Dunn Ian F, 2006, Neurosurg Focus, V21, pE4
   EISENSTEIN S, 1978, J BONE JOINT SURG BR, V60, P488
   Ghobrial GM, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17153
   Giudici F, 2011, EUR SPINE J, V20, P115, DOI 10.1007/s00586-011-1759-9
   Gutow AR, 2007, J AM ACAD ORTHOP SUR, V15, P474, DOI 10.5435/00124635-200708000-00004
   HADLEY MN, 1988, NEUROSURGERY, V22, P67, DOI 10.1227/00006123-198801000-00010
   Jia M, 2016, SPINE, V41, pB6, DOI 10.1097/BRS.0000000000001815
   Karatas AF, 2016, CLIN SPINE SURG, V29, P272, DOI 10.1097/BSD.0b013e318277cb7d
   KIMURA M, 1968, ORTHOP SURG, V19, P285
   Kolcun JPG, 2017, ASIAN SPINE J, V11, P832, DOI 10.4184/asj.2017.11.5.832
   Koval K J, 1992, J Orthop Trauma, V6, P340, DOI 10.1097/00005131-199209000-00012
   Lee GW, 2015, SPINE, V40, pE234, DOI 10.1097/BRS.0000000000000714
   Lu JK, 1997, CLIN ORTHOP RELAT R, P227
   Menga EN, 2014, SPINE, V39, P104, DOI 10.1097/BRS.0000000000000043
   MORSCHER E, 1984, ARCH ORTHOP TRAUM SU, V103, P175, DOI 10.1007/BF00435550
   NICOL RO, 1986, SPINE, V11, P1027, DOI 10.1097/00007632-198612000-00011
   Noggle JC, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/8/E15
   PEDERSEN AK, 1988, J BONE JOINT SURG AM, V70A, P15, DOI 10.2106/00004623-198870010-00004
   Rajasekaran S, 2011, INDIAN J ORTHOP, V45, P136, DOI 10.4103/0019-5413.77133
   Ranawat VS, 2003, INJURY, V34, P915, DOI 10.1016/S0020-1383(03)00034-2
   Reitman CA, 2002, SPINE, V27, pE174, DOI 10.1097/00007632-200203150-00022
   Rornmens PM, 2004, INJURY, V35, P1149, DOI 10.1016/j.injury.2003.12.002
   Saifuddin A, 1998, J BONE JOINT SURG BR, V80B, P208, DOI 10.1302/0301-620X.80B2.8219
   Snyder LA, 2014, J NEUROSURG-SPINE, V21, P329, DOI 10.3171/2014.5.SPINE13772
   Songer MN, 1998, SPINE, V23, P263, DOI 10.1097/00007632-199801150-00023
   Spoor AB, 2013, J NEUROSURG SCI, V57, P203
   Widi GA, 2013, CASE REP MED, DOI 10.1155/2013/659078
   WILTSE LL, 1976, CLIN ORTHOP RELAT R, P23
   Yeap EJ, 2016, FOOT ANKLE SURG, V22, P164, DOI 10.1016/j.fas.2015.06.008
NR 39
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 181
EP 188
DI 10.1016/j.wneu.2019.03.026
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400229
PM 30876997
DA 2020-05-12
ER

PT J
AU Wang, S
   Ahuja, CS
   Das, S
AF Wang, Shelly
   Ahuja, Christopher S.
   Das, Sunit
TI Arachnoiditis Ossificans: A Rare Etiology of Oil-Based Spinal
   Myelography and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arachnoiditis; Calcinosis; Contrast; Inflammation; Myelography;
   Ossification; Syringomyelia
AB BACKGROUND: Arachnoiditis ossificans (AO) is a rare entity characterized by the presence of calcified plaques formed by the metaplasia of arachnoid cells. Over 50 cases of AO have been reported, with predisposing factors including spinal trauma, hemorrhage, vascular abnormalities, and infection. The administration of oil-based contrast during myelography as an independent risk factor or in conjunction with other spinal pathology has been described in 9 cases.
   CASE DESCRIPTION: A 70-year-old woman presented for neurosurgical consultation in 2013 with a 2-year history of progressive midthoracic pain, right-sided chest wall allodynia, lower extremity weakness, and gait ataxia. Approximately 30 years ago, she received an oil-based contrast myelogram for investigation of spontaneous spinal hemorrhage. The procedure was well tolerated, and the patient experienced no allergic, hemorrhagic, traumatic, or infectious complications. No etiology was found for the spinal hemorrhage, and the patient recovered fully from that episode. Magnetic resonance imaging (MRI) of the thoracolumbar spine demonstrated multiple compressive intradural lesions in the upper thoracic spine and ventral tethering of the spinal cord at T7. MRI also demonstrated syringomyelia throughout the thoracic spine. Initially, the diagnosis of epidural mass or diastematomyelia was considered. To further characterize the epidural lesion, an unenhanced computed tomography (CT) scan was obtained, demonstrating a long segment of extensive calcification in the periphery of the thoracolumbar spine, with near-complete circumferential involvement from T5 to T11. The diagnosis of AO with extensive thoracic spine calcifications, syringomyelia, and spine cord tethering was made and confirmed at surgery.
   CONCLUSIONS: In addition to acute inflammation, oil-based contrast myelography also leads to arachnoiditis, calcification, and retained mass lesions because of its chronic inflammatory properties and slow resorptive rate. Three decades after its replacement with water-based contrast material, the chronic sequelae of oil-based contrast myelography may continue to manifest clinically and on CT imaging. Because of calcifications often encasing the spinal cord or nerve roots, management of AO is challenging, and neurologic deficits may persist even after surgery.T
C1 [Wang, Shelly] Univ Miami, Dept Surg, Div Neurosurg, Miami, FL USA.
   [Wang, Shelly; Ahuja, Christopher S.; Das, Sunit] Univ Toronto, Div Neurosurg, Dept Surg, Toronto, ON, Canada.
   [Ahuja, Christopher S.; Das, Sunit] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
   [Das, Sunit] St Michaels Hosp, Dept Neurosurg, Toronto, ON, Canada.
RP Das, S (reprint author), Univ Toronto, Div Neurosurg, Dept Surg, Toronto, ON, Canada.; Das, S (reprint author), Univ Toronto, Inst Med Sci, Toronto, ON, Canada.; Das, S (reprint author), St Michaels Hosp, Dept Neurosurg, Toronto, ON, Canada.
EM sunit.das@utoronto.ca
RI ; Das, Sunit/J-3903-2015
OI Wang, Shelly/0000-0002-9112-082X; Das, Sunit/0000-0002-2146-4168
CR DENNIS MD, 1983, SPINE, V8, P115, DOI 10.1097/00007632-198301000-00021
   Domenicucci M, 2004, NEUROSURGERY, V55, P985, DOI 10.1227/01.NEU.0000137281.65551.54
   Faure A, 2002, J NEUROSURG, V97, P239, DOI 10.3171/spi.2002.97.2.0239
   Frizzell B, 2001, AM J ROENTGENOL, V177, P461, DOI 10.2214/ajr.177.2.1770461
   Gopalakrishnan CV, 2010, BRIT J NEUROSURG, V24, P711, DOI 10.3109/02688697.2010.522746
   Herren RY, 1939, ARCH NEURO PSYCHIATR, V41, P1180
   Hwang SW, 2008, J NEUROSURG-SPINE, V8, P292, DOI 10.3171/SPI/2008/8/3/292
   Ibrahim George M, 2010, Evid Based Spine Care J, V1, P46, DOI 10.1055/s-0028-1100914
   JASPAN T, 1990, SPINE, V15, P148, DOI 10.1097/00007632-199002000-00022
   KAUFMAN AB, 1971, NEUROLOGY, V21, P1243, DOI 10.1212/WNL.21.12.1243
   KITAGAWA H, 1990, SPINE, V15, P1236, DOI 10.1097/00007632-199011010-00028
   Laitt R, 1996, BRIT J RADIOL, V69, P693, DOI 10.1259/0007-1285-69-824-693
   Lee SK, 2013, EUR SPINE J, V22, pS321, DOI 10.1007/s00586-012-2364-2
   Mello LR, 2001, J NEUROSURG, V94, P115, DOI 10.3171/spi.2001.94.1.0115
   Moens M, 2013, CLIN NEUROL NEUROSUR, V115, P1162, DOI 10.1016/j.clineuro.2012.09.017
   Navani A, 2006, REGION ANESTH PAIN M, V31, P82, DOI 10.1016/j.rapm.2005.07.193
   Shiraishi T, 1995, Eur Spine J, V4, P60, DOI 10.1007/BF00298421
   Slavin KV, 1999, J NEUROSURG, V91, P223, DOI 10.3171/spi.1999.91.2.0223
   Wang Liang, 2014, Chinese Medical Sciences Journal, V29, P125
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 189
EP 193
DI 10.1016/j.wneu.2019.02.178
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400230
PM 30862590
DA 2020-05-12
ER

PT J
AU Fiani, B
   Quadri, SA
   Cathel, A
   Farooqui, M
   Ramachandran, A
   Siddiqi, I
   Ghanchi, H
   Zafar, A
   Berman, BW
   Siddiqi, J
AF Fiani, Brian
   Quadri, Syed A.
   Cathel, Alessandra
   Farooqui, Mudassir
   Ramachandran, Anirudh
   Siddiqi, Imran
   Ghanchi, Hammad
   Zafar, Atif
   Berman, Blake W.
   Siddiqi, Javed
TI Esthesioneuroblastoma: A Comprehensive Review of Diagnosis, Management,
   and Current Treatment Options
SO WORLD NEUROSURGERY
LA English
DT Review
DE Esthesioneuroblastoma; Malignant neoplasm; Nasal cavity; Olfactory
   neuroblastoma; Olfactory neuroepithelium
ID ENDOSCOPIC ENDONASAL MANAGEMENT; ELECTIVE NODAL IRRADIATION; HIGH-DOSE
   CHEMOTHERAPY; PROTON-BEAM THERAPY; LONG-TERM OUTCOMES; SKULL BASE
   TUMORS; OLFACTORY NEUROBLASTOMA; RECURRENT ESTHESIONEUROBLASTOMA;
   RADIATION-THERAPY; CRANIOFACIAL RESECTION
AB INTRODUCTION: Many controversies exist in the diagnosis and management of this aggressively malignant condition, mainly because of limited literature and lack of randomized control trials, resulting in nonstandardized treatment methods. We performed a comprehensive review of the literature to identify management approach and treatment options for esthesioneuroblastoma.
   METHODS: An extensive review of the published literature was conducted in PubMed, OVID Medline, and EMBASE journals for studies of esthesioneuroblastoma. Terms for search included esthesioneuroblastoma (ENB) and olfactory neuroblastoma (ONB). No date restrictions were used.
   RESULTS: The search yielded 3876 related articles. Cross-checking of articles led to exclusion of duplicate articles. The remaining 1170 articles were screened for their full text and English language availability. Of 609 full-text articles available, animal studies, irrelevant articles, and studies with mixed/confusing data were excluded. We finalized 149 articles pertaining to the topic, including 119 original research articles, 3 book chapters, 11 reviews, 9 case reports, and 7 case series.
   CONCLUSIONS: Surgical resection followed by radiotherapy is the standard for treatment for higher-grade lesions. The endoscopic endonasal approach is gaining further recognition with more favorable outcomes and better survival than for open surgery. Postoperative radiotherapy is associated with the highest overall survival and shows benefit for patients with higher-stage disease and those who receive chemotherapy. Recurrence rates after treatment vary drastically in the literature and, therefore, prolonged follow-up with repeated imaging is recommended. Lifelong surveillance is recommended because of late recurrences associated with this tumor.
C1 [Fiani, Brian; Quadri, Syed A.; Cathel, Alessandra; Berman, Blake W.; Siddiqi, Javed] Desert Reg Med Ctr, Dept Neurosurg, Palm Springs, CA 92262 USA.
   [Quadri, Syed A.] Harvard Med Sch, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Farooqui, Mudassir; Zafar, Atif] Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA.
   [Ramachandran, Anirudh; Siddiqi, Imran] Western Univ Hlth Sci, Coll Osteopath Med Pacific, Pomona, CA USA.
   [Ghanchi, Hammad] Riverside Univ Hlth Syst, Dept Neurosurg, Moreno Valley, CA USA.
RP Fiani, B (reprint author), Desert Reg Med Ctr, Dept Neurosurg, Palm Springs, CA 92262 USA.
EM bfiani@outlook.com
OI Ghanchi, Hammad/0000-0002-1004-0837
CR Akimoto T, 2016, INT J RADIAT ONCOL, V96, pE337, DOI 10.1016/j.ijrobp.2016.06.1474
   Aldo C, 2011, TRANSNASAL ENDOSCOPI
   Argiris A, 2003, LARYNGOSCOPE, V113, P155, DOI 10.1097/00005537-200301000-00029
   Badie B, 2007, NEUROSURGICAL OPERAT, V1
   BAILEY BJ, 1975, ARCH OTOLARYNGOL, V101, P1
   Bak M, 2012, HEMATOL ONCOL CLIN N, V26, P1185, DOI 10.1016/j.hoc.2012.08.005
   BEITLER JJ, 1991, HEAD NECK-J SCI SPEC, V13, P321, DOI 10.1002/hed.2880130409
   Benfari G, 2008, ACTA OTORHINOLARYNGO, V28, P292
   Berger L, 1924, B ASS FRANC CANCER, V13, P410
   Bhattacharyya N, 1997, ARCH OTOLARYNGOL, V123, P34
   Bossi P, 2015, CANCER TREAT REV, V41, P836, DOI 10.1016/j.ctrv.2015.07.004
   Bradley Patrick J, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P112, DOI 10.1097/00020840-200304000-00009
   Broich G, 1997, ANTICANCER RES, V17, P2683
   CANTRELL RW, 1977, ANN OTO RHINOL LARYN, V86, P760, DOI 10.1177/000348947708600608
   CASTANEDA VL, 1991, AM J PEDIAT HEMATOL, V13, P62
   Cavallo LM, 2007, NEUROSURGERY, V61, P24, DOI 10.1227/01.NEU.0000280005.26449.2D
   Chakravarthi S, 2017, SEMIN PLAST SURG, V31, P203, DOI 10.1055/s-0037-1607274
   Chamberlain MC, 2002, CANCER, V95, P243, DOI 10.1002/cncr.10679
   Chang KC, 1997, HISTOPATHOLOGY, V30, P378, DOI 10.1046/j.1365-2559.1997.d01-615.x
   Chao KSC, 2001, HEAD NECK-J SCI SPEC, V23, P749, DOI 10.1002/hed.1107.abs
   Czapiewski P, 2018, HUM PATHOL, V79, P144, DOI 10.1016/j.humpath.2018.05.013
   Dagan R, 2016, INT J RADIAT ONCOL, V95, P377, DOI 10.1016/j.ijrobp.2016.02.019
   Dave SP, 2007, OTOLARYNG HEAD NECK, V136, P920, DOI 10.1016/j.otohns.2007.01.012
   Demiroz C, 2011, INT J RADIAT ONCOL, V81, pE255, DOI 10.1016/j.ijrobp.2011.03.036
   Dias FL, 1999, HEAD NECK-J SCI SPEC, V21, P12, DOI 10.1002/(SICI)1097-0347(199901)21:1<12::AID-HED2>3.3.CO;2-R
   Dias FL, 2003, ARCH OTOLARYNGOL, V129, P1186, DOI 10.1001/archotol.129.11.1186
   Dinca Eduard B, 2012, J Med Case Rep, V6, P240
   DJALILIAN M, 1977, SURG CLIN N AM, V57, P751
   DRAF W, 1991, OPERATIVE TECHNIQUES, V2, P234, DOI DOI 10.1016/S1043-1810(10)80087-9
   Dublin AB, 2016, J NEUROL SURG PART B, V77, P1, DOI 10.1055/s-0035-1564053
   DULGUEROV P, 1992, LARYNGOSCOPE, V102, P843, DOI 10.1288/00005537-199208000-00001
   Dulguerov P, 2001, LANCET ONCOL, V2, P683, DOI 10.1016/S1470-2045(01)00558-7
   Eich HT, 2005, STRAHLENTHER ONKOL, V181, P378, DOI 10.1007/s00066-005-1362-2
   Eich HT, 2003, STRAHLENTHER ONKOL, V179, P233, DOI 10.1007/s00066-003-1089-x
   Eich HT, 2001, INT J RADIAT ONCOL, V49, P155, DOI 10.1016/S0360-3016(00)00811-7
   ELKON D, 1979, CANCER, V44, P1087, DOI 10.1002/1097-0142(197909)44:3<1087::AID-CNCR2820440343>3.0.CO;2-A
   Faragalla H, 2009, ADV ANAT PATHOL, V16, P322, DOI 10.1097/PAP.0b013e3181b544cf
   Fitzek MM, 2002, CANCER-AM CANCER SOC, V94, P2623, DOI 10.1002/cncr.10537
   Folbe A, 2009, AM J RHINOL ALLERGY, V23, P91, DOI 10.2500/ajra.2009.23.3269
   FOOTE RL, 1993, INT J RADIAT ONCOL, V27, P835, DOI 10.1016/0360-3016(93)90457-7
   Gallia GL, 2012, J CLIN NEUROSCI, V19, P1478, DOI 10.1016/j.jocn.2012.03.011
   Gallia GL, 2011, NEUROSURG REV, V34, P465, DOI 10.1007/s10143-011-0329-2
   Gandhoke Charandeep S, 2017, Surg Neurol Int, V8, P83, DOI 10.4103/sni.sni_30_17
   Ganly I, 2005, HEAD NECK-J SCI SPEC, V27, P575, DOI 10.1002/hed.20165
   Gil Z, 2008, HEAD NECK-J SCI SPEC, V30, P567, DOI 10.1002/hed.20741
   Gil Z, 2012, CURR OPIN OTOLARYNGO, V20, P130, DOI 10.1097/MOO.0b013e3283506870
   Girod D, 2001, HEAD NECK-J SCI SPEC, V23, P500, DOI 10.1002/hed.1067
   GOLDSWEIG HG, 1990, AM J CLIN ONCOL-CANC, V13, P139, DOI 10.1097/00000421-199004000-00010
   Gruber GN, 2002, INT J RADIAT ONCOL, V54, P486, DOI 10.1016/S0360-3016(02)02941-3
   Halperin EC, 2018, PEREZ BRADYS PRINCIP
   Hanna E, 2009, ARCH OTOLARYNGOL, V135, P1219, DOI 10.1001/archoto.2009.173
   Haroon S, 2016, PAK J MED SCI, V32, P585, DOI 10.12669/pjms.323.9738
   Hwang CS, 2017, J CRANIO MAXILL SURG, V45, P120, DOI 10.1016/j.jcms.2016.10.004
   Irish J, 1997, J OTOLARYNGOL, V26, P1
   Ivan ME, 2015, J CLIN NEUROSCI, V22, P48, DOI 10.1016/j.jocn.2014.08.009
   Jethanamest D, 2007, ARCH OTOLARYNGOL, V133, P276, DOI 10.1001/archotol.133.3.276
   Jiang W, 2016, PRACT RADIAT ONCOL, V6, P241, DOI 10.1016/j.prro.2015.10.023
   Jiang W, 2016, J NEURO-ONCOL, V126, P201, DOI 10.1007/s11060-015-1935-6
   KADISH S, 1976, CANCER, V37, P1571, DOI 10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L
   Kairemo Kalevi J. A., 1998, Auris Nasus Larynx, V25, P173, DOI 10.1016/S0385-8146(98)00003-0
   Kamath VB, 2013, ORBIT, V32, P392, DOI 10.3109/01676830.2013.833252
   Kane AJ, 2010, J NEUROSURG, V113, P340, DOI 10.3171/2010.2.JNS091897
   Kased N, 2010, INT J RADIAT ONCOL, V78, pS447, DOI 10.1016/j.ijrobp.2010.07.1049
   Kim DW, 2004, CANCER-AM CANCER SOC, V101, P2257, DOI 10.1002/cncr.20648
   Kim YS, 2016, WORLD NEUROSURG, V96, DOI 10.1016/j.wneu.2016.08.126
   Koka VN, 1998, J LARYNGOL OTOL, V112, P628, DOI 10.1017/S0022215100141295
   Komotar RJ, 2013, WORLD NEUROSURG, V80, P148, DOI 10.1016/j.wneu.2012.12.003
   Konuthula N, 2016, INT J RADIAT ONCOL, V96, pE371, DOI 10.1016/j.ijrobp.2016.06.1564
   Kryzanski JT, 2008, SKULL BASE-INTERD AP, V18, P229, DOI 10.1055/s-2007-1003924
   Kumar M, 2002, J PEDIAT HEMATOL ONC, V24, P482, DOI 10.1097/00043426-200208000-00015
   Laigle-Donadey F, 2005, J NEURO-ONCOL, V75, P57, DOI 10.1007/s11060-004-8098-1
   Lapierre A, 2016, CANCER RADIOTHER, V20, P783, DOI 10.1016/j.canrad.2016.05.015
   Lepera D, 2018, HEAD NECK-J SCI SPEC, V40, P917, DOI 10.1002/hed.25045
   LEVINE PA, 1986, LARYNGOSCOPE, V96, P742
   Levine PA, 1999, LARYNGOSCOPE, V109, P1539, DOI 10.1097/00005537-199910000-00001
   Loy AH, 2006, ARCH OTOLARYNGOL, V132, P134, DOI 10.1001/archotol.132.2.134
   Lund V, 2011, RHINOLOGY, P1
   Mahooti S, 2006, CANCER CYTOPATHOL, V108, P86, DOI 10.1002/cncr.21718
   Malouf GG, 2013, EUR J CANCER, V49, P1324, DOI 10.1016/j.ejca.2012.12.008
   Manthuruthil C, 2016, WORLD NEUROSURG, V90, P1, DOI 10.1016/j.wneu.2016.02.035
   Marinelli JP, 2018, HEAD NECK-J SCI SPEC, V40, P2295, DOI 10.1002/hed.25209
   McElroy EA, 1998, NEUROSURGERY, V42, P1023, DOI 10.1097/00006123-199805000-00040
   McLean JN, 2007, OTOLARYNG HEAD NECK, V136, P998, DOI 10.1016/j.otohns.2006.11.051
   Mishima Y, 2004, CANCER-AM CANCER SOC, V101, P1437, DOI 10.1002/cncr.20471
   Monroe AT, 2003, HEAD NECK-J SCI SPEC, V25, P529, DOI 10.1002/hed.10247
   MORITA A, 1993, NEUROSURGERY, V32, P706, DOI 10.1227/00006123-199305000-00002
   Moussazadeh N, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16299
   Muskens IS, 2018, ACTA NEUROCHIR, V160, P59, DOI 10.1007/s00701-017-3390-y
   Nakagawa T, 2018, AURIS NASUS LARYNX, V45, P281, DOI 10.1016/j.anl.2017.05.001
   Nakamura N, 2017, RADIOTHER ONCOL, V122, P368, DOI 10.1016/j.radonc.2016.12.020
   Naples JG, 2016, LARYNGOSCOPE, V126, P1373, DOI 10.1002/lary.25803
   Nguyen QA, 1996, INT J PEDIATR OTORHI, V37, P45, DOI 10.1016/0165-5876(96)01365-1
   Nishimura H, 2007, INT J RADIAT ONCOL, V68, P758, DOI 10.1016/j.ijrobp.2006.12.071
   Noh OK, 2011, INT J RADIAT ONCOL, V79, P443, DOI 10.1016/j.ijrobp.2009.10.067
   OCONOR GT, 1985, CANCER, V55, P347, DOI 10.1002/1097-0142(19850115)55:2<347::AID-CNCR2820550207>3.0.CO;2-N
   Orton A, 2018, NEUROSURGERY, V83, P940, DOI 10.1093/neuros/nyx535
   Ow TJ, 2014, HEAD NECK-J SCI SPEC, V36, P524, DOI 10.1002/hed.23327
   Ozsahin M, 2010, INT J RADIAT ONCOL, V78, P992, DOI 10.1016/j.ijrobp.2009.09.019
   Palejwala SK, 2017, CUREUS, V9, DOI 10.7759/cureus.1245
   Palejwala SK, 2017, J NEUROL SURG REP, V78, pE86, DOI 10.1055/s-0037-1601877
   Papacharalampous GX, 2012, J CANC THER, V3, P1074
   Patel SG, 2003, CANCER, V98, P1179, DOI 10.1002/cncr.11630
   Peng XL, 2018, PATHOL RES PRACT, V214, P1123, DOI 10.1016/j.prp.2018.06.002
   PERRY C, 1988, ARCH OTOLARYNGOL, V114, P632
   Petruzzelli GJ, 2015, AM J OTOLARYNG, V36, P547, DOI 10.1016/j.amjoto.2015.02.008
   Pickuth D, 1999, BRIT J RADIOL, V72, P1052, DOI 10.1259/bjr.72.863.10700820
   Pickuth D, 1999, CLIN OTOLARYNGOL, V24, P457, DOI 10.1046/j.1365-2273.1999.00295.x
   Platek ME, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-41
   Polin RS, 1998, NEUROSURGERY, V42, P1029, DOI 10.1097/00006123-199805000-00045
   Porter AB, 2008, J NEURO-ONCOL, V90, P201, DOI 10.1007/s11060-008-9645-y
   Rawal RB, 2012, OTOLARYNG CLIN N AM, V45, P1127, DOI 10.1016/j.otc.2012.06.013
   Resto VA, 2000, HEAD NECK-J SCI SPEC, V22, P550, DOI 10.1002/1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0
   Rimmer J, 2014, LARYNGOSCOPE, V124, P1542, DOI 10.1002/lary.24562
   Rinaldo A, 2002, ACTA OTO-LARYNGOL, V122, P215, DOI 10.1080/00016480252814261
   Monteiro EMR, 2011, BRAZ J OTORHINOLAR, V77, P171, DOI 10.1590/S1808-86942011000200006
   Saito Atsushi, 2018, NMC Case Rep J, V5, P69, DOI 10.2176/nmccrj.cr.2017-0233
   Schmalbach CE, 2010, CURR OPIN OTOLARYNGO, V18, P238, DOI 10.1097/MOO.0b013e32833a4706
   Schmidt C, 2017, J LARYNGOL OTOL, V131, pS29, DOI 10.1017/S0022215116009592
   SCHRAMM VL, 1979, LARYNGOSCOPE, V89, P1077
   SGOUROS S, 1994, BRIT J NEUROSURG, V8, P617, DOI 10.3109/02688699409002958
   SHAH JP, 1987, AM J SURG, V154, P352, DOI 10.1016/0002-9610(89)90003-2
   Sheehan J, 2016, YOUMANS WINN NEUROLO, P1284
   Sivakumar Walavan, 2015, Surg Neurol Int, V6, pS628, DOI 10.4103/2152-7806.170464
   Slevin NJ, 1996, J LARYNGOL OTOL, V110, P1012, DOI 10.1017/S0022215100135649
   SMITH RR, 1954, CANCER, V7, P991, DOI 10.1002/1097-0142(195409)7:5<991::AID-CNCR2820070523>3.0.CO;2-P
   Sohrabi S, 2011, J CLIN ONCOL, V29, pE358, DOI 10.1200/JCO.2010.30.9278
   Soler ZM, 2012, LARYNGOSCOPE, V122, P244, DOI 10.1002/lary.22450
   STEWART FM, 1989, AM J CLIN ONCOL-CANC, V12, P217, DOI 10.1097/00000421-198906000-00008
   Suefuji H, 2018, ANTICANCER RES, V38, P1665, DOI 10.21873/anticanres.12399
   Tajudeen BA, 2015, J NEUROL SURG PART B, V76, P43, DOI 10.1055/s-0034-1390011
   Thomas Sarah Boby, 2016, Asian J Neurosurg, V11, P313, DOI 10.4103/1793-5482.145087
   Thompson LDR, 2009, HEAD NECK PATHOL, V3, P252, DOI 10.1007/s12105-009-0125-2
   Tseng Jeffrey, 2009, Ear Nose Throat J, V88, pE14
   Unger F, 2005, ACTA NEUROCHIR, V147, P595, DOI 10.1007/s00701-005-0521-7
   Van Gompel JJ, 2014, J NEUROL SURG PART B, V75, P409, DOI 10.1055/s-0034-1378151
   Van Gompel JJ, 2012, J NEUROL SURG PART B, V73, P331, DOI 10.1055/s-0032-1321512
   Van Gompel JJ, 2013, NEUROSURGERY, V72, P332, DOI 10.1227/NEU.0b013e31827fcdc2
   Vargo JA, 2012, HEAD NECK-J SCI SPEC, V34, P1153, DOI 10.1002/hed.21889
   Wadhwani M, 2018, OCUL ONCOL PATHOL, V4, P192, DOI 10.1159/000481507
   Walch C, 2000, LARYNGOSCOPE, V110, P635, DOI 10.1097/00005537-200004000-00018
   Ward PD, 2009, SKULL BASE-INTERD AP, V19, P133, DOI 10.1055/s-0028-1096195
   WATNE K, 1987, J NEURO-ONCOL, V5, P47, DOI 10.1007/BF00162764
   Woods RSR, 2018, J NEUROL SURG PART B, V79, P262, DOI 10.1055/s-0037-1607298
   Yin ZZ, 2015, RADIOTHER ONCOL, V117, P328, DOI 10.1016/j.radonc.2015.10.002
   Yin ZZ, 2016, ORAL ONCOL, V53, P48, DOI 10.1016/j.oraloncology.2015.11.021
   Yin ZZ, 2018, CANCER MANAG RES, V10, P1359, DOI 10.2147/CMAR.S151945
   Yousem DM, 2001, SEMIN ULTRASOUND CT, V22, P456, DOI 10.1016/S0887-2171(01)90001-0
   Yuan YJ, 2018, J CANCER, V9, P174, DOI 10.7150/jca.21605
   Zafereo ME, 2008, OTOLARYNG HEAD NECK, V138, P452, DOI 10.1016/j.otohns.2007.12.038
   ZAPPIA JJ, 1993, HEAD NECK-J SCI SPEC, V15, P190, DOI 10.1002/hed.2880150303
NR 150
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 194
EP 211
DI 10.1016/j.wneu.2019.03.014
PG 18
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400231
PM 30862589
DA 2020-05-12
ER

PT J
AU Wang, F
   Liu, YS
   Wang, MY
   Zhang, GD
AF Wang, Feng
   Liu, Yongsheng
   Wang, Mingyi
   Zhang, Guogdong
TI De Novo Aneurysm Formation After Wingspan Stenting of Intracranial
   Carotid Stenosis: Computational Hemodynamic Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computational fluid dynamics; De novo aneurysm; Stenting
ID FLUID-DYNAMICS; EMBOLIZATION; PLACEMENT
AB BACKGROUND: The pathophysiology of de novo aneurysm after stenting is poorly understood. Hemodynamic effects may play an important role. We report and discuss the hemodynamic analysis of de novo aneurysm after intracranial stenting.
   CASE DESCRIPTION: A 51-year-old female underwent angioplasty and coiling for stenosis associated with an aneurysm of the left intracranial carotid artery. Six years later, the follow-up digital subtraction angiography demonstrated a de novo aneurysm at the proximal tine of the Wingspan stent. Computational fluid dynamics simulations showed that stenting for intracranial stenosis resulted in higher oscillatory shear index and lower time-averaged wall shear stress in the neck region of de novo aneurysm.
   CONCLUSIONS: The hemodynamic change after stenting may lead to formation of a de novo aneurysm. After an initial injury that might result from the tine on the endothelial cells, stenting could produce high oscillatory shear index and low time-averaged wall shear stress near the tine, thus potentially inducing de novo aneurysm formation.
C1 [Wang, Feng; Liu, Yongsheng; Wang, Mingyi; Zhang, Guogdong] Dalian Med Univ, Affiliated Hosp 1, Dept Intervent Neuroradiol, Dalian, Peoples R China.
RP Liu, YS (reprint author), Dalian Med Univ, Affiliated Hosp 1, Dept Intervent Neuroradiol, Dalian, Peoples R China.
EM liuyongsheng_dl@163.com
CR Boussel L, 2008, STROKE, V39, P2997, DOI 10.1161/STROKEAHA.108.521617
   Cebral JR, 2011, AM J NEURORADIOL, V32, P145, DOI 10.3174/ajnr.A2419
   Cho WS, 2014, CLIN RADIOL, V69, pE63, DOI 10.1016/j.crad.2013.08.021
   Dabus G, 2013, J NEUROINTERV SURG, V5, P447, DOI 10.1136/neurintsurg-2012-010443
   Dalyai RT, 2011, ACTA NEUROCHIR, V153, P2147, DOI 10.1007/s00701-011-1112-4
   Gandini R, 2013, CLIN NEUROL NEUROSUR, V115, P741, DOI 10.1016/j.clineuro.2012.08.037
   Gao BL, 2013, NEUROSURGERY, V72, P739, DOI 10.1227/NEU.0b013e318286fab3
   Gao L, 2008, STROKE, V39, P2085, DOI 10.1161/STROKEAHA.107.509422
   Huang QH, 2011, AM J NEURORADIOL, V32, P1721, DOI 10.3174/ajnr.A2597
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Meng H, 2007, STROKE, V38, P1924, DOI 10.1161/STROKEAHA.106.481234
   Omodaka S, 2012, CEREBROVASC DIS, V34, P121, DOI 10.1159/000339678
   Stiefel MF, 2007, SURG NEUROL, V67, P99, DOI 10.1016/j.surneu.2006.02.046
   Tremmel M, 2010, WORLD NEUROSURG, V74, P306, DOI 10.1016/j.wneu.2010.05.008
   Turjman AS, 2014, CIRCULATION, V129, P373, DOI 10.1161/CIRCULATIONAHA.113.001444
NR 15
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 212
EP 215
DI 10.1016/j.wneu.2019.03.035
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400232
PM 30877006
DA 2020-05-12
ER

PT J
AU Cai, MQ
   He, HY
   Zhang, BY
   Luo, L
   Gong, J
   Li, WS
   Huang, TC
   Guo, Y
AF Cai, Meiqin
   He, Haiyong
   Zhang, Baoyu
   Luo, Lun
   Gong, Jin
   Li, Wensheng
   Huang, Tengchao
   Guo, Ying
TI An Ectopic Recurrent Craniopharyngioma of the Temporal Lobe: Case Report
   and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Craniopharyngioma; Ectopic recurrence; Ki-67
ID RESECTION; IMPLANTATION; SURGERY
AB BACKGROUND: Ectopic recurrent craniopharyngioma is rare. We present a case of a temporal ectopic recurrent tumor after a trans-eyebrow supraorbital keyhole approach and provide a review of the reported data with basic statistics.
   METHODS: We retrospectively reviewed 57 cases of craniopharyngiomas surgically treated at our institution. A temporal ectopic recurrent tumor with 10% high Ki-67 proliferation index expression was identified. The lesion underwent gross total resection without any complications. We also reviewed the related data and performed a basic statistical analysis.
   RESULTS: Our review found 64 cases of ectopic recurrent craniopharyngioma that had been reported (including the present case). The median interval until ectopic recurrence was 4.0 years (interquartile range, 2.0-10.0). Of the 64 lesions, 48 (75%) were adamantinous, 6 (9%) were papillary, and 10 (16%) were unknown. Also, 34 tumors (53%) were located in the previous surgical tract, and 30 (47%) had disseminated along the cerebrospinal fluid pathway. Of the 64 ectopic tumors, 50 (78%) could be resected in total without complications.
   CONCLUSIONS: Ectopic recurrent craniopharyngioma is a rare phenomenon. Meticulous protection of the entire surgical field and careful manipulation of the tumor during resection are required to prevent possible ectopic recurrence. Regular follow-up examinations are strongly recommended to detect any further recurrences. Gross total resection is the treatment of choice for ectopic recurrence.
C1 [Cai, Meiqin; He, Haiyong; Zhang, Baoyu; Luo, Lun; Gong, Jin; Li, Wensheng; Huang, Tengchao; Guo, Ying] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
RP Guo, Y (reprint author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
EM publicsjwk@163.com
CR Al Mahdi MM, 2018, TURK NEUROSURG, V28, P313, DOI 10.5137/1019-5149.JTN.17215-16.1
   Baba M, 1978, No Shinkei Geka, V6, P687
   BARLOON TJ, 1988, AM J NEURORADIOL, V9, P406
   Bianco AD, 2006, SURG NEUROL, V66, P437, DOI 10.1016/j.surneu.2005.12.027
   Bikmaz K, 2009, NEUROSURGERY, V64, P382, DOI [10.1227/01.NEU.0000337128.67045.70, 10.1227/01.NEU.0000337078.60998.98]
   Clark SW, 2015, NAGOYA J MED SCI, V77, P297
   de Blank PM, 2011, J PEDIAT HEMATOL ONC, V33, P392, DOI 10.1097/MPH.0b013e31820acfb2
   Dhellemmes P, 2006, J PEDIATR ENDOCR MET, V19, P329
   Du C, 2016, CHILD NERV SYST, V32, P1523, DOI 10.1007/s00381-016-3050-1
   Elfving M, 2011, CHILD NERV SYST, V27, P845, DOI 10.1007/s00381-010-1375-8
   Elliott RE, 2009, J NEUROSURG-PEDIATR, V4, P105, DOI 10.3171/2009.3.PEDS0948
   Elmaci L, 2002, NEURO-ONCOLOGY, V4, P123, DOI 10.1093/neuonc/4.2.123
   Frangou EM, 2009, CHILD NERV SYST, V25, P1143, DOI 10.1007/s00381-009-0917-4
   Freitag SK, 2001, BRIT J NEUROSURG, V15, P511, DOI 10.1080/02688690120097723
   Fuentes S, 2002, NEUROCHIRURGIE, V48, P345
   GOKALP HZ, 1991, NEUROSURGERY, V29, P446, DOI 10.1227/00006123-199109000-00020
   Goncalves CB, 2014, PITUITARY, V17, P214, DOI 10.1007/s11102-013-0490-4
   Gupta K, 1999, AM J NEURORADIOL, V20, P1059
   Ishii K, 2004, PEDIATR NEUROSURG, V40, P230, DOI 10.1159/000082297
   ISRAEL ZH, 1995, PEDIATR NEUROSURG, V22, P210, DOI 10.1159/000120903
   Ito M, 2001, NEUROSURGERY, V48, P933
   Jakobs M, 2012, J NEUROSURG, V117, P490, DOI 10.3171/2012.6.JNS111885
   Jeong IH, 2006, J NEURO-ONCOL, V79, P191, DOI 10.1007/s11060-006-9124-2
   Jian XD, 2017, TURK NEUROSURG, V27, P160, DOI 10.5137/1019-5149.JTN.12386-14.2
   Kawaguchi T, 2005, J CLIN NEUROSCI, V12, P307, DOI 10.1016/j.jocn.2004.01.009
   KEOHANE C, 1994, J NEUROL NEUROSUR PS, V57, P873, DOI 10.1136/jnnp.57.7.873
   Kim SK, 2001, CHILD NERV SYST, V17, P531, DOI 10.1007/s003810100458
   Lee DK, 2001, J NEUROSURG, V94, P617, DOI 10.3171/jns.2001.94.4.0617
   Lee JH, 1999, J NEUROSURG, V90, P796, DOI 10.3171/jns.1999.90.4.0796
   Lermen O, 2010, ACTA NEUROCHIR, V152, P309, DOI 10.1007/s00701-009-0537-5
   Liu JM, 2002, NEUROSURGERY, V50, P639, DOI 10.1097/00006123-200203000-00041
   Liubinas SV, 2011, J CLIN NEUROSCI, V18, P451, DOI 10.1016/j.jocn.2010.10.004
   MALIK JM, 1992, J NEUROSURG, V77, P804, DOI 10.3171/jns.1992.77.5.0804
   Nomura H, 2002, NEUROL MED-CHIR, V42, P268, DOI 10.2176/nmc.42.268
   Novak Z, 2008, MINIM INVAS NEUROSUR, V51, P165, DOI 10.1055/s-2008-1062743
   Novegno F, 2002, CHILD NERV SYST, V18, P468, DOI 10.1007/s00381-002-0641-9
   Park HR, 2017, WORLD NEUROSURG, V103, P465, DOI 10.1016/j.wneu.2017.04.047
   RAGOOWANSI AT, 1991, J NEUROSURG, V74, P653, DOI 10.3171/jns.1991.74.4.0653
   Renfrow JJ, 2018, J NEUROSURG PEDIAT, V29, P1
   Romani R, 2010, ACTA NEUROCHIR, V152, P297, DOI 10.1007/s00701-009-0415-1
   Salunke P, 2011, NEUROL INDIA, V59, P137, DOI 10.4103/0028-3886.76881
   Schmalisch K, 2010, ACTA NEUROCHIR, V152, P313, DOI 10.1007/s00701-009-0538-4
   TOMITA S, 1992, BRIT J NEUROSURG, V6, P587, DOI 10.3109/02688699209002377
   TOMITA T, 1993, PEDIATR NEUROSURG, V19, P6, DOI 10.1159/000120693
   Wang XY, 2010, J INT MED RES, V38, P1876, DOI 10.1177/147323001003800536
   Yamada Y, 2006, NEUROL MED-CHIR, V46, P598, DOI 10.2176/nmc.46.598
   Yang Y, 2015, BRIT J NEUROSURG, V29, P295, DOI 10.3109/02688697.2014.967751
NR 47
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 216
EP 222
DI 10.1016/j.wneu.2019.02.196
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400233
PM 30877004
DA 2020-05-12
ER

PT J
AU Upper, A
   Konar, SK
   Nandeesh, BN
   Shukla, D
AF Upper, Alok
   Konar, Subhas K.
   Nandeesh, B. N.
   Shukla, Dhaval
TI H3K27M-Positive Primary Spinal Glioblastoma Presenting with Hemorrhage-A
   Rare Clinical Entity
SO WORLD NEUROSURGERY
LA English
DT Article
DE H3K27M; Hemorrhage; Primary spinal glioblastoma; Surgery
ID LONG-TERM SURVIVAL; HIGH-GRADE GLIOMAS; CONUS MEDULLARIS; MULTIFORME;
   MUTATIONS; H3F3A; ASTROCYTOMA
AB BACKGROUND: Primary spinal glioblastoma multiforme is a rare and aggressive spinal tumor with dismal outcomes
   CASE DESCRIPTION: We have presented an unusual case-the first, to the best of our knowledge, to be reported-with intratumoral hemorrhage and sudden-onset quadriplegia in a patients with primary spinal glioblastoma multiforme. The patient underwent emergency surgical decompression. The patient died after a prolonged intensive care unit stay.
   CONCLUSION: The tumor was positive for histone molecular alteration, H3K27M.
C1 [Upper, Alok; Konar, Subhas K.; Shukla, Dhaval] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
   [Nandeesh, B. N.] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore, Karnataka, India.
RP Konar, SK (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
EM drsubhaskonar@gmail.com
OI Shukla, Dhaval/0000-0001-7613-1929
CR ASANO N, 1990, Neurologia Medico-Chirurgica, V30, P489, DOI 10.2176/nmc.30.489
   Aucourt J, 2012, J NEURORADIOLOGY, V39, P258, DOI 10.1016/j.neurad.2011.11.001
   Cacchione A, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0107-1
   Chan KM, 2013, GENE DEV, V27, P985, DOI 10.1101/gad.217778.113
   Choi WC, 2009, SURG NEUROL, V71, P234, DOI 10.1016/j.surneu.2007.07.059
   CIAPPETTA P, 1991, NEUROSURGERY, V28, P302, DOI 10.1227/00006123-199102000-00022
   COHEN AR, 1989, J NEUROSURG, V70, P50, DOI 10.3171/jns.1989.70.1.0050
   Gao Y, 2018, NEUROPATHOLOGY, V38, P165, DOI 10.1111/neup.12413
   Gessi M, 2015, ACTA NEUROPATHOL, V130, P435, DOI 10.1007/s00401-015-1463-7
   Gmeiner M, 2013, CLIN NEUROL NEUROSUR, V115, P501, DOI 10.1016/j.clineuro.2012.12.009
   GUIDETTI B, 1981, J NEUROSURG, V54, P323, DOI 10.3171/jns.1981.54.3.0323
   Harris OA, 2000, NEUROL RES, V22, P473
   Kim WH, 2011, J NEURO-ONCOL, V101, P247, DOI 10.1007/s11060-010-0249-y
   Konar SK, 2016, WORLD NEUROSURG, V86, P341, DOI 10.1016/j.wneu.2015.08.078
   Lee Sang-Hyo, 2016, Brain Tumor Res Treat, V4, P30, DOI 10.14791/btrt.2016.4.1.30
   Linsenmann T, 2015, J NEUROL SURG REP, V76, P128, DOI 10.1055/s-0035-1549227
   Marchan EM, 2007, J NEUROSURG-SPINE, V7, P656, DOI 10.3171/SPI-07/12/656
   Medhkour A, 2005, SURG NEUROL, V63, P576, DOI 10.1016/j.surneu.2004.08.044
   Mohammad F, 2017, NAT MED, V23, P483, DOI 10.1038/nm.4293
   Mori K, 2012, SPINE J, V12, pE1, DOI 10.1016/j.spinee.2011.12.005
   Nagaishi M, 2016, BRAIN TUMOR PATHOL, V33, P267, DOI 10.1007/s10014-016-0263-7
   Shankar GM, 2016, ACTA NEUROPATHOL, V131, P147, DOI 10.1007/s00401-015-1492-2
   Shen CX, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006634
   Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024
   Velz J, 2018, SN COMPHRENSIVE CLIN, V1, P15
   Viljoen Stephanus, 2014, Surg Neurol Int, V5, P101, DOI 10.4103/2152-7806.135305
   Wong AP, 2013, J NEURO-ONCOL, V115, P493, DOI [10.1007/s11060-013-1251-y, 10.1007/s11060-013-1296-y]
NR 27
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 223
EP 227
DI 10.1016/j.wneu.2019.03.025
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400234
PM 30876988
DA 2020-05-12
ER

PT J
AU Waqas, M
   Vakhari, K
   Weimer, PV
   Hashmi, E
   Davies, JM
   Siddiqui, AH
AF Waqas, Muhammad
   Vakhari, Kunal
   Weimer, Peter, V
   Hashmi, Eisa
   Davies, Jason M.
   Siddiqui, Adnan H.
TI Safety and Effectiveness of Embolization for Chronic Subdural Hematoma:
   Systematic Review and Case Series
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chronic subdural hematoma; Embolization; Endovascular treatment; Middle
   meningeal artery
ID MIDDLE MENINGEAL ARTERY; RECURRENCE; THERAPY
AB INTRODUCTION: Embolization of the middle meningeal artery (MMA) has emerged as a minimally invasive means of managing subdural hematoma. The purpose of this study was to systematically review the literature on the safety and effectiveness of this treatment and to share our clinical experience.
   METHODS: This review was registered with PROSPERO. PubMed, CINAHL, EMBASE, and the Cochrane Library were searched using MeSH (Medical Subject Headings) terms for MMA embolization and chronic subdural hematoma (CSDH) from January 2000 to November 2018. All articles in the English language literature describing MMA embolization for CSDH were included, irrespective of study design. Consecutive patients who underwent MMA embolization at our hospital between January 2017 and June 2018 comprised our clinical experience.
   RESULTS: Fifteen studies with 193 procedures were included in the review. Ninety-five cases (49.2%) involved primary MMA embolization; 88 embolizations (45.6%) for recurrent CSDH and 10 (5.2%) for prophylaxis after surgical evacuation were performed. Recurrence after MMA embolization requiring further treatment occurred in 7 cases (3.6%). All other patients had symptomatic relief with no further recurrence. No procedure-related complications were reported. Polyvinyl alcohol was the most commonly used material. Our series included 8 patients treated with Onyx. All had symptom relief and significant reduction in hematoma size; no recurrences or procedure-related complications were observed.
   CONCLUSIONS: MMA embolization of CSDH is safe and effective for CSDH treatment based on a documented recurrence rate of 3.6% and lack of reported complications.
C1 [Waqas, Muhammad; Vakhari, Kunal; Davies, Jason M.; Siddiqui, Adnan H.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA.
   [Davies, Jason M.; Siddiqui, Adnan H.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Bioinformat, Buffalo, NY 14260 USA.
   [Siddiqui, Adnan H.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Radiol, Buffalo, NY 14260 USA.
   [Davies, Jason M.; Siddiqui, Adnan H.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Canon Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.
   [Waqas, Muhammad; Vakhari, Kunal; Weimer, Peter, V; Hashmi, Eisa; Davies, Jason M.; Siddiqui, Adnan H.] Kaleida Hlth, Gates Vasc Inst, Dept Neurosurg, Buffalo, NY 14203 USA.
   [Davies, Jason M.; Siddiqui, Adnan H.] Jacobs Inst, Buffalo, NY 14203 USA.
RP Siddiqui, AH (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA.; Siddiqui, AH (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Bioinformat, Buffalo, NY 14260 USA.; Siddiqui, AH (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Radiol, Buffalo, NY 14260 USA.; Siddiqui, AH (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Canon Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.; Siddiqui, AH (reprint author), Kaleida Hlth, Gates Vasc Inst, Dept Neurosurg, Buffalo, NY 14203 USA.; Siddiqui, AH (reprint author), Jacobs Inst, Buffalo, NY 14203 USA.
EM asiddiqui@ubns.com
RI Siddiqui, Adnan H./AAG-9781-2019
FU National Center for Advancing Translational Sciences of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR001413]
FX M.W., K.V., P.V.W., E. H, none. J.M.D., research grant: National Center
   for Advancing Translational Sciences of the National Institutes of
   Health under award number KL2TR001413 to the University at Buffalo.
   speakers' bureau: Penumbra; Honoraria: Neurotrauma Science, LLC. A.H.S.,
   financial interest/investor/stock options/ownership: Amnis Therapeutics,
   Apama Medical, BlinkTBI, Inc, Buffalo Technology Partners, Inc.,
   Cardinal Health, CerebrotechMedical Systems, Inc, Claret Medical,
   Cognition Medical, Endostream Medical, Ltd, Imperative Care,
   International Medical Distribution Partners, Rebound Therapeutics Corp.,
   Silk Road Medical, StimMed, Synchron, Three Rivers Medical, Inc., Viseon
   Spine, Inc.; consultant/advisory board: Amnis Therapeutics, Boston
   Scientific, Canon Medical Systems USA, Inc., Cerebrotech Medical
   Systems, Inc., Cerenovus, Claret Medical, Corindus, Inc., Endostream
   Medical, Ltd, Guidepoint Global Consulting, Imperative Care, Integra,
   Medtronic, MicroVention, Northwest University; DSMB Chair for HEAT
   Trial, Penumbra, Rapid Medical, Rebound Therapeutics Corp., Silk Road
   Medical, StimMed, Stryker, Three Rivers Medical, Inc., VasSol, W. L.
   Gore & Associates; national principal investigator/steering committees:
   Cerenovus LARGE Trial and ARISE II Trial, Medtronic SWIFT PRIME and
   SWIFT DIRECT Trials, MicroVention FRED Trial & CONFIDENCE Study, MUSC
   POSITIVE Trial, Penumbra 3D Separator Trial, COMPASS Trial, INVEST
   Trial.
CR Ban SP, 2018, RADIOLOGY, V286, P909, DOI 10.1148/radiol.2017170053
   Chihara Hideo, 2014, NMC Case Rep J, V1, P1, DOI 10.2176/nmccrj.2013-0343
   D'Abbondanza JA, 2014, NEUROL RES, V36, P176, DOI 10.1179/1743132813Y.0000000279
   Edlmann E, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0881-y
   Hashimoto Takao, 2013, Surg Neurol Int, V4, P104, DOI 10.4103/2152-7806.116679
   Hirai S, 2004, INTERV NEURORADIOL, V10, P101, DOI 10.1177/15910199040100S218
   Ishihara H, 2007, Interv Neuroradiol, V13 Suppl 1, P141
   Kang Jiin, 2015, Korean J Neurotrauma, V11, P187, DOI 10.13004/kjnt.2015.11.2.187
   Kim E, 2017, WORLD NEUROSURG, V101, P520, DOI 10.1016/j.wneu.2017.02.070
   Link TW, 2019, NEUROSURGERY, V85, P801, DOI 10.1093/neuros/nyy521
   Link TW, 2018, WORLD NEUROSURG, V118, pE570, DOI 10.1016/j.wneu.2018.06.241
   Link TW, 2018, OPER NEUROSURG, V14, P556, DOI 10.1093/ons/opx154
   Mandai S, 2000, J NEUROSURG, V93, P686, DOI 10.3171/jns.2000.93.4.0686
   Mewada T, 2016, WORLD NEUROSURG, V92, DOI 10.1016/j.wneu.2016.05.042
   Mino Masaki, 2010, Surg Neurol Int, V1, P78, DOI 10.4103/2152-7806.73801
   Oh HJ, 2010, J KOREAN NEUROSURG S, V48, P518, DOI 10.3340/jkns.2010.48.6.518
   Srivatsan A, 2019, WORLD NEUROSURG, V122, P613, DOI 10.1016/j.wneu.2018.11.167
   STROOBANDT G, 1995, ACTA NEUROCHIR, V137, P6, DOI 10.1007/BF02188772
   Takahashi K, 2002, NEUROL SURG TOKYO, V30, P535
   Tempaku A, 2015, INTERV NEURORADIOL, V21, P366, DOI 10.1177/1591019915583224
   Tsukamoto Y, 2011, ACTA NEUROCHIR, V153, P1145, DOI 10.1007/s00701-010-0891-3
   Wada M, 2014, CLIN NEUROL NEUROSUR, V120, P49, DOI 10.1016/j.clineuro.2014.02.007
NR 22
TC 7
Z9 7
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 228
EP 236
DI 10.1016/j.wneu.2019.02.208
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400235
PM 30878752
DA 2020-05-12
ER

PT J
AU Jagetia, A
   Dutta, G
   Setia, V
   Singhal, GD
   Bodeliwala, S
   Srivastava, AK
AF Jagetia, Anita
   Dutta, Gautam
   Setia, Vikrant
   Singhal, Ghanshyam D.
   Bodeliwala, Shaam
   Srivastava, Arvind Kumar
TI Dissection of C2 Guiding to C1 Lateral Mass and Facilitation of Screw
   Placement: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial dislocation; Atlas; Craniovertebral junction; Lateral mass
   screw fixation
AB OBJECTIVE: Surgical intervention at the craniovertebral junction requires preoperative and intraoperative planning to get optimum postoperative results. Careful positioning minimizes the risk of iatrogenic injury and can also facilitate adequate surgical exposure. Tortuous venous channels that are usually encountered as the dissection proceeds may cause excessive bleeding before reaching the lateral mass (LM). However, both localization and placement may be made easier by altering the dissection technique and modifying the patient's position. Traditionally, the military tuck position is described for the dorsal approach to the craniovertebral junction. The objective of this study is to emphasize the role of arc or bow like position, a modification of prone position for adequate placement of C1 LM screw in these cases.
   METHODS: We operated on 68 patients with atlantoaxial dislocation in an arc or bow position from January 2013 to September 2018. In 58 patients, at least 1 C1 LM screw was placed.
   RESULTS: This position helped in easy and early recognition with easy trajectory for the C1 LM screw placement and less work force.
   CONCLUSIONS: Visual axis to the lateral mass of C1 in an arc/bow position with head elevation puts C1 LM more in the visual axis of the operator, which makes the trajectory straight without causing much angulation while inserting the screw. At the same time, the axis vertebra guides the surgeon to the C1 lateral mass with no handling of dura.
C1 [Jagetia, Anita; Dutta, Gautam; Setia, Vikrant; Singhal, Ghanshyam D.; Bodeliwala, Shaam; Srivastava, Arvind Kumar] Govind Ballabh Pant Inst Postgrad Med Educ & Res, Dept Neurosurg, New Delhi, India.
RP Jagetia, A (reprint author), Govind Ballabh Pant Inst Postgrad Med Educ & Res, Dept Neurosurg, New Delhi, India.
EM anitajagetia@gmail.com
CR GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   PENNING L, 1987, SPINE, V12, P732, DOI 10.1097/00007632-198710000-00003
   Rhoton AL, 2000, NEUROSURGERY, V47, pS155, DOI 10.1097/00006123-200009001-00017
   Thomas JA, 2010, J NEUROSURG-SPINE, V12, P337, DOI 10.3171/2009.10.SPINE08541
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 237
EP 240
DI 10.1016/j.wneu.2019.02.081
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400236
PM 30825619
DA 2020-05-12
ER

PT J
AU Taslimi, S
   Ku, JC
   Modabbernia, A
   Macdonald, RL
AF Taslimi, Shervin
   Ku, Jerry C.
   Modabbernia, Amirhossein
   Macdonald, R. Loch
TI Hemorrhage, Seizures, and Dynamic Changes of Familial versus Nonfamilial
   Cavernous Malformation: Systematic Review and Meta-analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cavernous malformation; Dynamic changes; Familial; Hemorrhage; Natural
   history; Seizure
ID NATURAL-HISTORY; MANAGEMENT; FEATURES; GENETICS; RISK; MRI
AB BACKGROUND: Cerebral cavernous malformations (CCMs) may be familial or nonfamilial. This systematic review compared the natural history of CCMs in familial compared with nonfamilial cases.
   METHODS: We searched MEDLINE, Web of Science, and EMBASE for natural history studies on CCMs up to September 2018. We included studies that followed at least 20 untreated patients. Primary outcomes were hemorrhage, seizures, and neuroimaging changes in familial and nonfamilial cases. Incidence rate per person-year (PY) or lesion-year (LY) of follow-up were used to pool the data using fixed-effects or random-effects models. We used the incidence rate ratio for comparison.
   RESULTS: We could not compare hemorrhage rates between familial and nonfamilial cases mainly owing to mixtures of subgroups of patients. The seizure rate was similar in familial and nonfamilial cases with pooled incidence rate of 1.5%/PY (95% confidence interval 1.1%-2.2%). The reseizure rate was higher than the seizure rate (P < 0.001). New lesion development was higher in familial cases (32.1%/PY vs. 0.7%/PY, P < 0.001). Signal change on neuroimaging ranged from 0.2%/LY to 2.4%/LY in familial cases. In familial cases, incidence rate of size change was 8%/PY (95% confidence interval 5.2%-12.2%) and 1.1%/LY (95% confidence interval 0.6%-1.6%).
   CONCLUSIONS: Familial CCMs show higher dynamic changes than nonfamilial cases. However, the presence of actual dynamic changes needs further assessment in nonfamilial cases. CCMs demonstrate a low incidence of seizure. First-time seizure increases the chance of recurrent seizure. Seizure rate based on the location and type of the lesion should be investigated further.
C1 [Taslimi, Shervin; Ku, Jerry C.; Macdonald, R. Loch] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.
   [Macdonald, R. Loch] St Michaels Hosp, Div Neurosurg, Labatt Family Ctr Excellence Brain Injury & Traum, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada.
   [Macdonald, R. Loch] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Modabbernia, Amirhossein] Mt Sinai Hosp, Icahn Sch Med, Dept Psychiat, New York, NY 10029 USA.
RP Macdonald, RL (reprint author), Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.; Macdonald, RL (reprint author), St Michaels Hosp, Div Neurosurg, Labatt Family Ctr Excellence Brain Injury & Traum, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada.; Macdonald, RL (reprint author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
EM macdonaldlo@smh.ca
CR Clatterbuck RE, 2000, J NEUROSURG, V93, P981, DOI 10.3171/jns.2000.93.6.0981
   DELCURLING O, 1991, J NEUROSURG, V75, P702, DOI 10.3171/jns.1991.75.5.0702
   Frischer JM, 2008, J NEUROL NEUROSUR PS, V79, P783, DOI 10.1136/jnnp.2007.132316
   Gross BA, 2016, J NEUROSURG-PEDIATR, V17, P123, DOI 10.3171/2015.2.PEDS14541
   Horne MA, 2016, LANCET NEUROL, V15, P166, DOI 10.1016/S1474-4422(15)00303-8
   Josephson CB, 2011, NEUROLOGY, V76, P1548, DOI 10.1212/WNL.0b013e3182190f37
   Kim DS, 1997, SURG NEUROL, V48, P9, DOI 10.1016/S0090-3019(96)00425-9
   KONDZIOLKA D, 1995, J NEUROSURG, V83, P820, DOI 10.3171/jns.1995.83.5.0820
   Kupersmith MJ, 2001, NEUROSURGERY, V48, P47, DOI 10.1097/00006123-200101000-00007
   Labauge P, 2001, NEUROLOGY, V57, P1825, DOI 10.1212/WNL.57.10.1825
   Labauge P, 2000, NEURORADIOLOGY, V42, P327, DOI 10.1007/s002340050893
   Labouge P, 2007, LANCET NEUROL, V6, P237, DOI 10.1016/S1474-4422(07)70053-4
   Li D, 2013, J NEUROSURG, V119, P996, DOI 10.3171/2013.7.JNS13462
   MARAIRE JN, 1995, NEUROSURGERY, V37, P591, DOI 10.1227/00006123-199510000-00001
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moriarity JL, 1999, NEUROSURGERY, V44, P1166, DOI 10.1097/00006123-199906000-00003
   Nikoubashman O, 2015, AM J NEURORADIOL, V36, P2177, DOI 10.3174/ajnr.A4427
   POZZATI E, 1989, NEUROSURGERY, V25, P92, DOI 10.1227/00006123-198907000-00017
   Raychaudhuri R, 2005, SURG NEUROL, V63, P319, DOI 10.1016/j.surneu.2004.05.032
   Riant F, 2010, FEBS J, V277, P1070, DOI 10.1111/j.1742-4658.2009.07535.x
   ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709
   Taslimi S, 2016, NEUROLOGY, V86, P1984, DOI 10.1212/WNL.0000000000002701
   TOMLINSON FH, 1994, NEUROSURGERY, V34, P792, DOI 10.1227/00006123-199405000-00002
   Washington CW, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.5.FOCUS10149
   Wilczynski NL, 2005, J AM MED INFORM ASSN, V12, P481, DOI 10.1197/jamia.M1752
   WILCZYNSKI NL, 2004, BMC MED, V2
   Willinsky R, 1996, Interv Neuroradiol, V2, P127
   ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 241
EP 246
DI 10.1016/j.wneu.2019.02.115
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400237
PM 30851471
DA 2020-05-12
ER

PT J
AU Yamada, H
   Saga, I
   Kojima, A
   Horiguchi, T
AF Yamada, Hiroki
   Saga, Isako
   Kojima, Atsuhiro
   Horiguchi, Takashi
TI Short-Term Spontaneous Resolution of Ruptured Peripheral Aneurysm in
   Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Moyamoya disease; Ruptured aneurysm; Spontaneous resolution; Thrombosis
ID CHOROIDAL ARTERY ANEURYSMS; SURGICAL REVASCULARIZATION; COLLATERAL
   VESSELS; PSEUDOANEURYSM; DISAPPEARANCE
AB BACKGROUND: Peripheral aneurysms are known to be a source of intracranial hemorrhage in patients with moyamoya disease. However, the natural history of ruptured peripheral aneurysms remains unclear. Some regress spontaneously, whereas others may rebleed. Direct treatments, such as surgical or intravascular treatment of the peripheral aneurysm, can have a risk of severe neurologic complications owing to the depth of the operative field and the fragility of the parent artery. A careful treatment policy is required.
   CASE DESCRIPTION: In a 29-year-old man with moyamoya disease with intraventricular hemorrhage, rupture of a right anterior choroidal artery aneurysm was diagnosed by cerebral angiography. The aneurysm was approximately 4 mm in size and existed in the plexal segment of the right anterior choroidal artery. Endovascular embolization of the aneurysm was planned. However, repeat angiography 3 weeks after aneurysm diagnosis demonstrated complete resolution of the aneurysm. Such short-term disappearance of an aneurysm is remarkably rare. We believe that the aneurysm was thrombosed for a brief period considering the slow blood flow detected inside the aneurysm during the initial angiography. The patient was discharged with no neurologic deficit and has remained recurrence-free for >1 year.
   CONCLUSIONS: Given that spontaneous resolution of an aneurysm may occur in a short period of time, we suggest that conservative treatment be considered as an option for ruptured peripheral aneurysms associated with moyamoya disease when direct treatment is risky.
C1 [Yamada, Hiroki; Saga, Isako; Kojima, Atsuhiro] Saitama City Hosp, Dept Neurosurg, Saitama, Japan.
   [Horiguchi, Takashi] Keio Univ, Dept Neurosurg, Sch Med, Tokyo, Japan.
RP Yamada, H (reprint author), Saitama City Hosp, Dept Neurosurg, Saitama, Japan.
EM yhiroki08@gmail.com
CR Arai Y, 2011, NEUROL MED-CHIR, V51, P774
   Borota Ljubisa, 1996, Neurologia Medico-Chirurgica, V36, P860, DOI 10.2176/nmc.36.860
   HAMADA J, 1994, J NEUROSURG, V80, P328, DOI 10.3171/jns.1994.80.2.0328
   Iwama T, 1997, CLIN NEUROL NEUROSUR, V99, pS187, DOI 10.1016/S0303-8467(97)00081-4
   Kanamori F, 2018, WORLD NEUROSURG, V109, P393, DOI 10.1016/j.wneu.2017.10.059
   Kawaguchi S, 1996, ACTA NEUROCHIR, V138, P1287, DOI 10.1007/BF01411057
   Kim SH, 2009, NEUROSURGERY, V65, P1000, DOI 10.1227/01.NEU.0000345648.46096.CE
   Kim YS, 2017, J CLIN NEUROSCI, V44, P236, DOI 10.1016/j.jocn.2017.06.055
   KODAMA N, 1978, J NEUROSURG, V48, P565, DOI 10.3171/jns.1978.48.4.0565
   Kodama N, 1996, SURG NEUROL, V46, P62, DOI 10.1016/0090-3019(96)00043-2
   KONISHI Y, 1985, NEUROSURGERY, V16, P484, DOI 10.1227/00006123-198504000-00009
   Kuroda S, 2001, NEUROSURGERY, V49, P463, DOI 10.1097/00006123-200108000-00039
   Lee JK, 2001, NEUROSURGERY, V48, P222, DOI 10.1097/00006123-200101000-00043
   Liu P, 2016, WORLD NEUROSURG, V94, P513, DOI 10.1016/j.wneu.2016.05.039
   Miyake H, 2000, NEUROL MED-CHIR, V40, P55, DOI 10.2176/nmc.40.55
   MURAKAMI H, 1984, Neurologia Medico-Chirurgica, V24, P794, DOI 10.2176/nmc.24.794
   Muroya T, 2013, J TRAUMA ACUTE CARE, V75, P417, DOI 10.1097/TA.0b013e31829fda77
   NAGAMINE Y, 1981, J NEUROSURG, V54, P673, DOI 10.3171/jns.1981.54.5.0673
   Ni W, 2018, J NEUROSURG, V128, P1813, DOI 10.3171/2017.3.JNS162290
   Ni W, 2012, J CLIN NEUROSCI, V19, P485, DOI 10.1016/j.jocn.2011.05.036
   Oka K, 1992, SURG CEREB STROKE JP, V20, P201
   OKUMA A, 1980, Neurological Surgery, V8, P181
   Peltier J, 2008, CHILD NERV SYST, V24, P1483, DOI 10.1007/s00381-008-0670-0
   Rhim JK, 2018, CLIN NEURORADIOL, V28, P191, DOI 10.1007/s00062-016-0554-8
   Takahashi H, 2016, J OBSTET GYNAECOL RE, V42, P730, DOI 10.1111/jog.12983
   Takahashi JC, 2010, NEUROL MED-CHIR, V50, P824, DOI 10.2176/nmc.50.824
   TANAKA Y, 1980, ACTA NEUROCHIR, V52, P35, DOI 10.1007/BF01400944
   Tani S, 1981, NO SOCCHU NO GEKA KE, V10, P99
   YABUMOTO M, 1983, SURG NEUROL, V20, P20, DOI 10.1016/0090-3019(83)90100-3
   Yang S, 2010, INTERV NEURORADIOL, V16, P433, DOI 10.1177/159101991001600410
   YOSHIHARA T, 1983, HIROSHIMA J MED SCI, V32, P25
   YUASA H, 1982, J NEUROSURG, V56, P131, DOI 10.3171/jns.1982.56.1.0131
   Zhang L, 2015, INT J MED SCI, V12, P234, DOI 10.7150/ijms.10837
NR 33
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 247
EP 251
DI 10.1016/j.wneu.2019.02.193
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400238
PM 30877003
DA 2020-05-12
ER

PT J
AU Johnson, R
   Karsonovich, T
   Farhat, H
   Nikas, D
AF Johnson, Ryan
   Karsonovich, Torin
   Farhat, Hamad
   Nikas, Dimitrios
TI De Novo Formation of Direct Arteriovenous Fistula Involving Anterior
   Communicating Artery Aneurysm in Remote Site from Prior Ruptured
   Arteriovenous Malformation in Pediatric Patient: Case Report and Review
   of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arteriovenous fistulas; Arteriovenous malformations; Cerebrovascular;
   Intracranial hemorrhage
AB BACKGROUND: De novo formation of arteriovenous malformations (AVMs) and arteriovenous fistulas (AVFs) is increasingly being reported in the neurosurgical literature, challenging the notion that AVMs are congenital in origin. Most of this literature centers around the pediatric population. After treatment of an AVM or AVF, recurrence, if any, appears to occur locally to the original insult. We present, to the best of our knowledge, the first case of a de novo direct AVF involving an anterior communicating artery aneurysm in a remote site from a prior ruptured AVM in a pediatric patient.
   CASE DESCRIPTION: We present a case of a 14-year-old female who presented 2 years prior with an intraparenchymal hemorrhage secondary to a left parietal arteriovenous malformation. That AVM was successfully micro-surgically resected and revealed complete angiographic obliteration on postoperative and surveillance angiograms. This patient now presents with a spontaneous intraventricular hemorrhage secondary to a ruptured anterior communicating artery complex aneurysm with a fistulous connection from this aneurysm to the inferior petrosal sinus. The aneurysm and direct AVF were not identified on prior surveillance imaging, indicating de novo formation in a remote site from her prior AVM.
   CONCLUSIONS: This case highlights the importance of long-term imaging surveillance in patients with AVMs. Further prospective studies are indicated to evaluate the long-term imaging surveillance necessary to detect early recurrence, thereby allowing doctors to institute earlier definitive treatment. The exact pathophysiology behind these lesions is not fully understood; however, this case lends support to an acquired etiology to vascular malformations.
C1 [Johnson, Ryan; Karsonovich, Torin] Advocate BroMenn Med Ctr, Grad Med Educ, Neurol Surg Residency, Bloomington, IL 61702 USA.
   [Farhat, Hamad; Nikas, Dimitrios] Advocate Christ Med Ctr, Dept Neurosurg, Oak Lawn, IL USA.
RP Johnson, R (reprint author), Advocate BroMenn Med Ctr, Grad Med Educ, Neurol Surg Residency, Bloomington, IL 61702 USA.
EM ryan.johnson2@advocatehealth.com
CR Flemming KD, 2016, YOUMAN WINN NEUROLOG, V4, P3446
   Gandhi D, 2012, AM J NEURORADIOL, V33, P1007, DOI 10.3174/ajnr.A2798
   Jeffree RL, 2009, PEDIATR NEUROSURG, V45, P296, DOI 10.1159/000235604
   Jimenez JE, 2017, J NEUROSURG-PEDIATR, V19, P149, DOI 10.3171/2016.9.PEDS16235
   Koch MJ, 2016, J CLIN NEUROSCI, V28, P162, DOI 10.1016/j.jocn.2015.11.021
   Lawton MT, 1996, NEUROSURGERY, V39, P639
   Miller TR, 2015, STROKE, V46, P2017, DOI 10.1161/STROKEAHA.115.008228
   Morgenstern PF, 2016, J NEUROSURG-PEDIATR, V17, P134, DOI 10.3171/2015.6.PEDS14708
   Pabaney AH, 2016, WORLD NEUROSURG, V96, DOI 10.1016/j.wneu.2016.09.062
   Shi S, 2018, J NEUROSURG, V128, P506, DOI 10.3171/2016.9.JNS161710
   Shidoh Satoka, 2017, NMC Case Rep J, V4, P89, DOI 10.2176/nmccrj.cr.2016-0272
   Yasargil MG, 1987, AVM BRAIN HIST EMBRY
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 252
EP 256
DI 10.1016/j.wneu.2019.02.209
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400239
PM 30878757
DA 2020-05-12
ER

PT J
AU Dogan, SN
   Bagcilar, O
   Mammadov, T
   Kizilkilic, O
   Islak, C
   Kocer, N
AF Dogan, Sebahat Nacar
   Bagcilar, Omer
   Mammadov, Togrul
   Kizilkilic, Osman
   Islak, Civan
   Kocer, Naci
TI De Novo Development of a Cerebral Arteriovenous Malformation: Case
   Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Acquired; Arteriovenous malformation; AVM; Cerebral; De novo
ID BRAIN; EXPRESSION; SYSTEM
AB BACKGROUND: Cerebral arteriovenous malformations (AVMs) have been commonly regarded as congenital. However, this suspected origin has been challenged by reports of de novo cerebral AVM.
   CASE DESCRIPTION: We have described a 25-year-old man without any known history of cerebrovascular disease, in whom cranial imaging demonstrated the de novo appearance of a pial AVM. Initial magnetic resonance imaging at 11 years of age had revealed the presence of a 2-cm parafalcine arachnoid cyst. Computed tomography and magnetic resonance imaging performed 14 years later showed a new cerebral AVM in the left frontal lobe, which was then confirmed angiographically.
   CONCLUSIONS: The findings from our case report and from 9 similar reports challenge the traditional theory that AVMs constitute congenital lesions.
C1 [Dogan, Sebahat Nacar] Istanbul Univ, Cerrahpasa Med Fac, Dept Radiol, SBU Gaziosmanpasa Taksim Training & Res Hosp, Istanbul, Turkey.
   [Bagcilar, Omer; Mammadov, Togrul; Kizilkilic, Osman; Islak, Civan; Kocer, Naci] Istanbul Univ, Cerrahpasa Med Fac, Dept Radiol, Div Neuroradiol, Istanbul, Turkey.
RP Kizilkilic, O (reprint author), Istanbul Univ, Cerrahpasa Med Fac, Dept Radiol, Div Neuroradiol, Istanbul, Turkey.
EM osmank@istanbul.edu.tr
RI islak, civan/AAH-3857-2019
OI Nacar Dogan, Sebahat/0000-0003-1512-5060
CR Al-Shahi R, 2002, J NEUROL NEUROSUR PS, V73, P547, DOI 10.1136/jnnp.73.5.547
   Bulsara KR, 2002, NEUROSURGERY, V50, P1137, DOI 10.1097/00006123-200205000-00036
   Cataltepe S, 2015, NEUROPATH APPL NEURO, V41, P646, DOI 10.1111/nan.12159
   Cenzato M, 2017, ACTA NEUROCHIR, V159, P1059, DOI 10.1007/s00701-017-3154-8
   Chen WQ, 2014, METHODS MOL BIOL, V1135, P309, DOI 10.1007/978-1-4939-0320-7_25
   Dalton A, 2018, BRIT J NEUROSURG, V32, P305, DOI 10.1080/02688697.2018.1478060
   Duong DH, 1999, NEW ENGL J MED, V340, P1812
   Farhat HI, 2011, DM-DIS MON, V57, P625, DOI 10.1016/j.disamonth.2011.08.021
   Hashimoto T, 2001, CIRC RES, V89, P111, DOI 10.1161/hh1401.094281
   Hill-Felberg S, 2015, J CELL MOL MED, V19, P1986, DOI 10.1111/jcmm.12580
   Lasjaunias P, 1997, Interv Neuroradiol, V3, P275
   Li LW, 2016, SCI REP-UK, V6, DOI 10.1038/srep37338
   Mahajan A, 2010, NEUROSURG REV, V33, P115, DOI 10.1007/s10143-009-0227-z
   Markham L, 2016, J NEUROL NEUROSCI, V6, P3
   McDonald J, 1993, HEREDITARY HEMORRHAG
   Mullan S, 1996, J NEUROSURG, V85, P9, DOI 10.3171/jns.1996.85.1.0009
   Mullan S, 1996, J NEUROSURG, V85, P1, DOI 10.3171/jns.1996.85.1.0001
   Murphy PA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002670
   Neil Jayson A, 2014, Surg Neurol Int, V5, P148, DOI 10.4103/2152-7806.142796
   Nilsson I, 2004, FASEB J, V18, P1507, DOI 10.1096/fj.03-1276com
   Ozsarac Murat, 2012, J Emerg Med, V43, pe17, DOI 10.1016/j.jemermed.2009.05.035
   Sandalcioglu IE, 2006, CEREBROVASC DIS, V21, P154, DOI 10.1159/000090526
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Stevens J, 2009, AM J NEURORADIOL, V30, P111, DOI 10.3174/ajnr.A1255
   VIDYASAGAR C, 1978, ACTA NEUROCHIR, V40, P103, DOI 10.1007/BF01773118
   Wu J, 2014, CHILD NERV SYST, V30, P1277, DOI 10.1007/s00381-014-2413-8
   Yasargil MG, 1987, MICROSURGERY AVM BRA, V1
   Yeo JJY, 2015, CHILD NERV SYST, V31, P609, DOI 10.1007/s00381-014-2609-y
NR 28
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 257
EP 260
DI 10.1016/j.wneu.2019.02.226
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400240
PM 30885864
DA 2020-05-12
ER

PT J
AU Eksi, MS
   Turgut, VU
   Ozcan-Eksi, EE
   Gungor, A
   Turgut, FNT
   Pamir, MN
AF Eksi, Murat Sakir
   Turgut, Veli Umut
   Ozcan-Eksi, Emel Ece
   Gungor, Abuzer
   Turgut, Fahriye Nur Tukel
   Pamir, M. Necmettin
TI Serotonin Syndrome Following Tramadol and Gabapentin Use After Spine
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delirium; Gabapentin; Serotonin syndrome; Tramadol
ID INDUCED DELIRIUM
AB BACKGROUND: Serotonin syndrome (SS) is a common disease entity and could result in death if missed. The incidence of SS is underestimated due to misdiagnosis of many cases, especially the ones with less severe presentation. Many medications have been depicted as the source of SS. We present a case of SS in a patient who received intravenous tramadol and oral gabapentin as pain management after spine surgery.
   CASE DESCRIPTION: A 66-year-old man was admitted to our outpatient clinic with walking difficulties for 2 months. He was neurologically intact. However, he had neurologic claudication. He was on insulin, telmisartanhydrochlorothiazide, amlodipine, and albuterol before the surgery, and these drugs were continued after the surgery. After he was diagnosed with lumbar spinal stenosis, he underwent total laminectomies of L3 and L4 and bilateral transpedicular screw placement from L1 to L5. He received tramadol 100 mg once daily intravenously and gabapentin 300 mg thrice daily orally after the spine surgery. He became confused, aggressive, and agitated during his stay in the hospital postoperatively. He became frustrated with even his children and wife. He started receiving haloperidol and quetiapine after psychiatry consultation. Because he worsened immediately after quetiapine and haloperidol, his medications were ceased in a step-by-step manner (first, tramadol and second, gabapentin). He became stable in a few hours, and his symptoms have improved since then.
   CONCLUSIONS: Physicians treating spine patients should be alert about SS in patients using both tramadol and gabapentin.
C1 [Eksi, Murat Sakir; Gungor, Abuzer; Pamir, M. Necmettin] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
   [Turgut, Veli Umut] Antalya Ataturk State Hosp, Dept Neurosurg, Antalya, Turkey.
   [Ozcan-Eksi, Emel Ece] Bahcesehir Univ, Sch Med, Dept Phys Med & Rehabil, Istanbul, Turkey.
   [Turgut, Fahriye Nur Tukel] Antalya Res & Educ Hosp, Dept Internal Med, Antalya, Turkey.
RP Eksi, MS (reprint author), Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
EM muratsakireksi@gmail.com
RI Eksi, Murat Sakir/I-3699-2012; Ozcan-Eksi, Emel Ece/F-3343-2014
OI Eksi, Murat Sakir/0000-0002-3036-0061; Ozcan-Eksi, Emel
   Ece/0000-0001-5704-7019; gungor, abuzer/0000-0002-2792-7610
CR Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867
   Bravo L, 2017, EXPERT OPIN DRUG DIS, V12, P1281, DOI 10.1080/17460441.2017.1377697
   Dayer P, 1997, DRUGS, V53, P18, DOI 10.2165/00003495-199700532-00006
   Doyle D., 2003, OXFORD TXB PALLIATIV
   Dunkley EJ, 2003, QJM, V96, P6325
   Frank Christopher, 2008, Can Fam Physician, V54, P988
   Ghosh S, 2013, CASE REP EMERG MED
   Gillman PK, 2004, PAIN MED, V5, P231, DOI 10.1111/j.1526-4637.2004.04033.x
   Goldstein DB, 2007, AM J MED, V120, P21, DOI 10.1016/j.amjmed.2007.02.004
   Kruszewse SP, 2009, J PSYCHIATR PRACT, V15, P314, DOI 10.1097/01.pra.0000358318.73684.df
   Kunig G, 2006, PHARMACOPSYCHIATRY, V39, P194, DOI 10.1055/s-2006-948331
   Mason PJ, 2000, MEDICINE, V79, P201, DOI 10.1097/00005792-200007000-00001
   Pelonero AL, 1998, PSYCHIATR SERV, V49, P1163, DOI 10.1176/ps.49.9.1163
   Takeshita Junji, 2009, Prim Care Companion J Clin Psychiatry, V11, P273, DOI 10.4088/PCC.08l00690
   Taylor CP, 1998, EPILEPSY RES, V29, P233, DOI 10.1016/s0920-1211(97)00084-3
   Watson WA, 2003, AM J EMERG MED, V21, P353, DOI 10.1016/S0735-6757(03)00088-3
   Wilson L, 2012, AM J OTOLARYNG, V33, P319, DOI 10.1016/j.amjoto.2011.10.002
   Young JWS, 2013, CAN MED ASSOC J, V185, pE352, DOI 10.1503/cmaj.121592
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 261
EP 263
DI 10.1016/j.wneu.2019.03.092
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400241
PM 30898741
DA 2020-05-12
ER

PT J
AU Hamamoto, PT
   Zanini, MA
   Fleury, A
AF Hamamoto Filho, Pedro Tadao
   Antonio Zanini, Marco
   Fleury, Agnes
TI Hydrocephalus in Neurocysticercosis: Challenges for Clinical Practice
   and Basic Research Perspectives
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebrospinal fluid; Hydrocephalus; Medical therapy; Neurocysticercosis;
   Ventriculoperitoneal shunts
ID CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; CELLULAR IMMUNE-RESPONSE;
   TAENIA-SOLIUM; CEREBRAL CYSTICERCOSIS; ENDOSCOPIC MANAGEMENT; MURINE
   CYSTICERCOSIS; SURGICAL-TREATMENT; UNITED-STATES; DIAGNOSIS
AB The objective of this paper is to discuss relevant data on the epidemiology of hydrocephalus in neurocysticercosis, the new knowledge coming from experimental studies, the pathophysiological mechanisms involved, and the controversies regarding clinical and surgical management, through a comprehensive review of the literature. Hydrocephalus is present at the onset of the disease in 16% to 51% of patients with neurocysticercosis and in 64% to 72% of patients with the extraparenchymal form of the disease. Animal models have successfully reproduced the disease and open new therapeutic approaches perspectives. Current guidelines suggest that, when hydrocephalus is due to viable cysts that can be excised surgically, cyst removal is recommended. On the other hand, degenerating cysts with protein discharge become fixed and evoke inflammation throughout the cerebrospinal fluid compartments. In these cases, surgical removal is risky, and ventriculoperitoneal shunts should be placed with close monitoring of infection and malfunction. Cysticidal treatment after shunt surgery is recommended in cases of cysts located in cerebral areas that prevent surgical management. In conclusion, mechanical obstruction and inflammation are the key pathophysiologic mechanisms in the development of neurocysticercosisinduced hydrocephalus. Anthelmintic drugs and surgical options should be used, but they have limitations. A better understanding of the disease can come from experimental models.
C1 [Hamamoto Filho, Pedro Tadao; Antonio Zanini, Marco] Univ Estadual Paulista, Botucatu Med Sch, Dept Neurol Psychol & Psychiat, UNESP, Botucatu, SP, Brazil.
   [Fleury, Agnes] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico.
   [Fleury, Agnes] Inst Nacl Neurol & Neurocirug, Ciudad De Mexico, Mexico.
RP Hamamoto, PT (reprint author), Univ Estadual Paulista, Botucatu Med Sch, Dept Neurol Psychol & Psychiat, UNESP, Botucatu, SP, Brazil.
EM phamamoto@fmb.unesp.br
RI Filho, Pedro Tadao Hamamoto/D-2800-2012; Zanini, Marco A/A-1413-2008;
   Zanini, Marco Antonio/M-4898-2019
OI Filho, Pedro Tadao Hamamoto/0000-0001-6436-9307; Zanini, Marco
   A/0000-0002-5712-9783; Fleury, Agnes/0000-0002-8930-2202
CR Agapejev S, 2007, ARQ NEURO-PSIQUIAT, V65, P674, DOI 10.1590/S0004-282X2007000400025
   Alroy KA, 2018, AM J TROP MED HYG, V99, P380, DOI 10.4269/ajtmh.17-0912
   Alvarez JI, 2006, J NEUROIMMUNOL, V173, P45, DOI 10.1016/j.jneuroim.2005.11.020
   Alvarez JI, 2007, BRAIN RES, V12, P1169
   Alvarez JI, 2007, J NEUROIMMUNOL, V187, P102, DOI 10.1016/j.jneuroim.2007.05.005
   Alvarez JI, 2010, PARASITOLOGY, V137, P359, DOI 10.1017/S0031182009991971
   Alvarez JI, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000218
   Amelot A, 2014, J CLIN NEUROL, V10, P363, DOI 10.3988/jcn.2014.10.4.363
   Arora N, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12439
   Bazan R, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005115
   Bazan R, 2015, ARQ NEURO-PSIQUIAT, V73, P852, DOI 10.1590/0004-282X20150120
   Bergsneider M, 2000, J NEUROSURG, V92, P14, DOI 10.3171/jns.2000.92.1.0014
   Bhattarai R, 2018, REV INST MED TROP SP, V60, DOI [10.1590/S1678-9946201860020, 10.1590/s1678-9946201860020]
   Bhattarai R, 2015, TROP MED INT HEALTH, V20, P1108, DOI 10.1111/tmi.12497
   Bueno EC, 2004, ACTA TROP, V91, P205, DOI 10.1016/j.actatropica.2004.05.010
   Paiva ALC, 2017, SAO PAULO MED J, V135, P146, DOI 10.1590/1516-3180.2016.0304171216
   Carabin H, 2006, TROP MED INT HEALTH, V11, P906, DOI 10.1111/j.1365-3156.2006.01627.x
   Carabin H, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001152
   Cardenas G, 2014, MED MICROBIOL IMMUN, V203, P373, DOI 10.1007/s00430-014-0345-2
   Cardona AE, 1999, J IMMUNOL, V162, P995
   Carpio A, 2008, J NEUROL NEUROSUR PS, V79, P1050, DOI 10.1136/jnnp.2008.144899
   CARPIO A, 1994, CAN J NEUROL SCI, V21, P43, DOI 10.1017/S0317167100048757
   Carpio A, 2018, EXPERT REV NEUROTHER, V18, P289, DOI 10.1080/14737175.2018.1451328
   Chavarria A, 2005, CLIN IMMUNOL, V116, P271, DOI 10.1016/j.clim.2005.04.008
   Citow Jonathan Stuart, 2002, Neurosurg Focus, V12, pe6
   Colli B O, 1994, Arq Neuropsiquiatr, V52, P166
   Colli BO, 2002, NEUROSURG FOCUS, V12, P3
   Coyle CM, 2014, CURR INFECT DIS REP, V16, DOI 10.1007/s11908-014-0437-6
   Coyle CM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001500
   Cuetter AC, 1997, CLIN INFECT DIS, V24, P157, DOI 10.1093/clinids/24.2.157
   Cuetter AC, 2002, NEUROSURG FOCUS, V12, P5
   DEGIORGIO CM, 2002, [No title captured], V12
   DELBIGIO MR, 1993, ACTA NEUROPATHOL, V85, P573, DOI 10.1007/BF00334666
   ESTANOL B, 1983, NEUROSURGERY, V13, P119, DOI 10.1227/00006123-198308000-00002
   ESTANOL B, 1986, J NEUROL NEUROSUR PS, V49, P1131, DOI 10.1136/jnnp.49.10.1131
   Fabiani S, 2013, ACTA TROP, V128, P18, DOI 10.1016/j.actatropica.2013.06.020
   Figueroa JJ, 2011, J NEUROIMAGING, V21, P38, DOI 10.1111/j.1552-6569.2009.00452.x
   Filippidis AS, 2012, ACTA NEUROCHIR SUPPL, V113, P55, DOI 10.1007/978-3-7091-0923-6_12
   Fleury A, 2015, ZOONOSES INFECT AFFE
   Fleury A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003980
   Fleury A, 2011, EXPERT REV ANTI-INFE, V9, P123, DOI [10.1586/eri.10.150, 10.1586/ERI.10.150]
   Flisser A, 2003, ACTA TROP, V87, P43, DOI 10.1016/S0001-706X(03)00054-8
   Fragoso G, 1998, INFECT IMMUN, V66, P760, DOI 10.1128/IAI.66.2.760-764.1998
   Garcia HH, 2014, LANCET NEUROL, V13, P1202, DOI 10.1016/S1474-4422(14)70094-8
   Garcia HH, 2004, NEW ENGL J MED, V350, P249, DOI 10.1056/NEJMoa031294
   Garcia HH, 2003, ACTA TROP, V87, P71, DOI 10.1016/S0001-706X(03)00057-3
   Garcia HH, 2002, AM J TROP MED HYG, V66, P427, DOI 10.4269/ajtmh.2002.66.427
   Garcia HH, 2002, CLIN MICROBIOL REV, V15, P747, DOI 10.1128/CMR.15.4.747-756.2002
   Goel RK, 2008, J CLIN NEUROSCI, V15, P1096, DOI 10.1016/j.jocn.2007.10.004
   Gongora-Rivera F, 2006, NEUROLOGY, V66, P436, DOI 10.1212/01.wnl.0000195887.63124.dc
   Gongora-Rivera F, 2008, NEUROLOGY, V71, P1119, DOI 10.1212/01.wnl.0000326961.34868.5b
   Gonzales I, 2016, PARASITE IMMUNOL, V38, P136, DOI 10.1111/pim.12307
   Guerra-Giraldez C, 2013, EXP PARASITOL, V134, P443, DOI 10.1016/j.exppara.2013.05.005
   Hamamoto PT, 2017, CHILD NERV SYST, V33, P119, DOI 10.1007/s00381-016-3239-3
   Hamamoto PT, 2015, ACTA CIR BRAS, V30, P819, DOI 10.1590/S0102-865020150120000005
   Tapia-Perez JH, 2013, WORLD NEUROSURG, V79, P340, DOI 10.1016/j.wneu.2012.10.003
   Husain M, 2007, ACTA NEUROCHIR, V149, P341, DOI 10.1007/s00701-006-1059-z
   Jimenez AJ, 2014, TISSUE BARRIERS, V2, DOI 10.4161/tisb.28426
   Kelley R, 2002, NEUROSURGERY, V50, P757, DOI 10.1097/00006123-200204000-00014
   Khade P, 2013, WORLD NEUROSURG, V79, P558, DOI 10.1016/j.wneu.2011.05.053
   Kiefer M, 1998, CHILD NERV SYST, V14, P263, DOI 10.1007/s003810050222
   Kimura-Hayama ET, 2010, RADIOGRAPHICS, V30, P1705, DOI 10.1148/rg.306105522
   Li ZY, 2017, WORLD NEUROSURG, V107, P853, DOI 10.1016/j.wneu.2017.08.059
   LOBATO RD, 1981, J NEUROSURG, V55, P786, DOI 10.3171/jns.1981.55.5.0786
   LOYO M, 1980, NEUROSURGERY, V7, P456, DOI 10.1227/00006123-198011000-00005
   Mahale RR, 2015, J CLIN NEUROL, V11, P203, DOI 10.3988/jcn.2015.11.3.203
   Marcin-Sierra M, 2017, PLOS NEGLECT TROP D, V11
   Martins-Melo FR, 2016, ACTA TROP, V153, P128, DOI 10.1016/j.actatropica.2015.10.011
   Matos-Silva H, 2012, ARQ NEURO-PSIQUIAT, V70, P287, DOI 10.1590/S0004-282X2012005000010
   Matushita H, 2011, CHILD NERV SYST, V27, P1709, DOI 10.1007/s00381-011-1500-3
   MCCORMICK GF, 1982, ARCH NEUROL-CHICAGO, V39, P534, DOI 10.1001/archneur.1982.00510210004002
   Milhomem AC, 2018, ARQ NEURO-PSIQUIAT, V76, P339, DOI [10.1590/0004-282x20180032, 10.1590/0004-282X20180032]
   Mishra PK, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-141
   Moura VBL, 2016, PARASITOLOGY, V143, P334, DOI 10.1017/S0031182015001572
   Nash TE, 2006, NEUROLOGY, V67, P1120, DOI 10.1212/01.wnl.0000238514.51747.3a
   O'Neal SE, 2015, EMERG INFECT DIS, V21, P969, DOI 10.3201/eid2106.141324
   Oka Yoshihisa, 1996, Neurologia Medico-Chirurgica, V36, P654, DOI 10.2176/nmc.36.654
   Owler Brian K, 2010, Cerebrospinal Fluid Res, V7, P15, DOI 10.1186/1743-8454-7-15
   Proano JV, 2009, CHILD NERV SYST, V25, P1467, DOI 10.1007/s00381-009-0933-4
   Proano JV, 2001, NEW ENGL J MED, V345, P879, DOI 10.1056/NEJMoa010212
   Psarros TG, 2003, MINIM INVAS NEUROSUR, V46, P331, DOI 10.1055/s-2003-812470
   Rajshekhar V, 2010, INT J SURG, V8, P100, DOI 10.1016/j.ijsu.2009.12.006
   Rangel-Castilla L, 2009, AM J TROP MED HYG, V80, P373, DOI 10.4269/ajtmh.2009.80.373
   Ranjan M, 2014, BRIT J NEUROSURG, V28, P626, DOI 10.3109/02688697.2013.872224
   Restrepo BI, 1998, J NEUROIMMUNOL, V89, P64, DOI 10.1016/S0165-5728(98)00112-X
   Rodriguez-Sosa M, 2004, INFECT IMMUN, V72, P4552, DOI 10.1128/IAI.72.8.4552-4560.2004
   Roman RAS, 1996, J NEUROSURG, V84, P629, DOI 10.3171/jns.1996.84.4.0629
   Sciutto E, 2013, MICROBES INFECT, V15, P524, DOI 10.1016/j.micinf.2013.03.007
   Shandera WX, 2006, CURR NEUROL NEUROSCI, V6, P453, DOI 10.1007/s11910-006-0046-3
   Sikasunge CS, 2009, VET PARASITOL, V160, P242, DOI 10.1016/j.vetpar.2008.11.015
   Silva HM, 2017, ARQ NEURO-PSIQUIAT, V75, P96, DOI [10.1590/0004-282X20160194, 10.1590/0004-282x20160194]
   Singh BB, 2017, ACTA TROP, V165, P161, DOI 10.1016/j.actatropica.2016.01.017
   Singh SK, 2015, VET PARASITOL, V214, P59, DOI 10.1016/j.vetpar.2015.09.017
   Sinha S, 2012, BRIT J NEUROSURG, V26, P305, DOI 10.3109/02688697.2011.635820
   Sinha S, 2009, J CLIN NEUROSCI, V16, P867, DOI 10.1016/j.jocn.2008.10.030
   SOTELO J, 1987, J NEUROSURG, V66, P686, DOI 10.3171/jns.1987.66.5.0686
   Sotelo J, 2011, CURR NEUROL NEUROSCI, V11, P529, DOI 10.1007/s11910-011-0226-7
   Suri A, 2008, J NEUROS-PEDIATR, V1, P35, DOI 10.3171/PED-08/01/035
   Takayanagui Osvaldo Massaiti, 2004, Expert Rev Neurother, V4, P129, DOI 10.1586/14737175.4.1.129
   Terrazas LI, 1998, J PARASITOL, V84, P74, DOI 10.2307/3284533
   Torres-Corzo JG, 2010, CLIN NEUROL NEUROSUR, V112, P11, DOI 10.1016/j.clineuro.2009.08.022
   Torres-Corzo JG, 2006, J NEUROSURG, V104, P746, DOI 10.3171/jns.2006.104.5.746
   Tourdias T, 2009, NEUROIMAGE, V47, P659, DOI 10.1016/j.neuroimage.2009.04.070
   Tuero I, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004143
   Verastegui MR, 2015, AM J PATHOL, V185, P2259, DOI 10.1016/j.ajpath.2015.04.015
   Villa OF, 1996, PARASITOLOGY, V112, P561, DOI 10.1017/S0031182000066142
   Wallin MT, 2004, NEUROLOGY, V63, P1559, DOI 10.1212/01.WNL.0000142979.98182.FF
   White AC, 2018, CURR OPIN INFECT DIS, V31, P377, DOI 10.1097/QCO.0000000000000480
   White AC, 2018, AM J TROP MED HYG, V98, P945, DOI 10.4269/ajtmh.18-88751
   Zymberg ST, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.019
NR 110
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 264
EP 271
DI 10.1016/j.wneu.2019.03.071
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400242
PM 30885859
DA 2020-05-12
ER

PT J
AU Almallouhi, E
   Anadani, M
   Al Kasab, S
   Lena, JR
   Spiotta, AM
AF Almallouhi, Eyad
   Anadani, Mohamad
   Al Kasab, Sami
   Lena, Jonathan R.
   Spiotta, Alejandro M.
TI Initial Experience in Direct Aspiration Thrombectomy Using a Novel
   0.071-Inch Aspiration Catheter
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aspiration catheter; Hemorrhage; Safety; Stroke; Thrombectomy
ID ACUTE ISCHEMIC-STROKE; 1ST PASS TECHNIQUE; ENDOVASCULAR TREATMENT;
   STENT-RETRIEVER; TECHNIQUE ADAPT; THERAPY; REVASCULARIZATION; TRIAL
AB INTRODUCTION: A Direct Aspiration First Pass Technique is one of the most widely used techniques in mechanical thrombectomy. Aspiration catheter size plays a major role in the success of this technique. The AXS Vecta (Stryker Neurovascular, Fremont, California, USA) aspiration catheter is the first approved 0.071-inch catheter for mechanical thrombectomy. Here, we report our initial experience with direct aspiration thrombectomy using the AXS Vecta aspiration catheter.
   METHODS: We reviewed the prospectively collected database of all consecutive patients with stroke who underwent thrombectomy using A Direct Aspiration First Pass Technique with the AXS Vecta aspiration catheter at our institution between September 26 and October 12, 2018.
   RESULTS: A total of 10 thrombectomy procedures were performed. Of those, 3 patients had M1 occlusion, 6 patients had M2 occlusion, and 1 patient had cervical carotid D M1 tandem occlusion. Modified Thrombolysis in Cerebral Ischemia grade 2b or greater revascularization was obtained in 9 of 10 patients. Median groin-to-reperfusion time was 29.5 (interquartile range 14.25-53.25) minutes. An intermediate catheter (3 Max) was used in all cases. No procedural complications or vascular injury were identified. The AXS Vecta catheter demonstrated excellent tractability and navigability in all cases except 1 case with severe narrowing of M1 segment secondary to atherosclerosis.
   CONCLUSIONS: In this early experience with the new AXS Vecta aspiration catheter, the catheter was safely navigated to the target vessel even at the level of M2 segment.
C1 [Almallouhi, Eyad; Anadani, Mohamad] Med Univ South Carolina, Dept Neurol, Charleston, SC 29425 USA.
   [Al Kasab, Sami; Lena, Jonathan R.; Spiotta, Alejandro M.] Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
RP Almallouhi, E (reprint author), Med Univ South Carolina, Dept Neurol, Charleston, SC 29425 USA.
EM Almallou@musc.odu
RI Anadani, Mohammad/J-6012-2019; Almallouhi, Eyad/V-1283-2019
OI Anadani, Mohammad/0000-0002-7813-2949; 
CR Alawieh Ali, 2020, Neurosurgery, V86, P61, DOI 10.1093/neuros/nyy444
   Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   [Anonymous], 2018, AXS VECT 71 ASP CATH
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9
   John Seby, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P350, DOI 10.7461/jcen.2014.16.4.350
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Lapergue B, 2016, AM J NEURORADIOL, V37, P1860, DOI 10.3174/ajnr.A4840
   Lapergue B, 2017, JAMA-J AM MED ASSOC, V318, P443, DOI 10.1001/jama.2017.9644
   Long TD, 2019, J NEUROINTERV SURG, V11, P190, DOI 10.1136/neurintsurg-2017-013702
   Mocco J, 2015, J NEUROINTERV SURG, V7, P79, DOI 10.1136/neurintsurg-2014-011591
   Mocco J, 2018, P INT STROK C LOS AN
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Spiotta AM, 2015, J NEUROINTERV SURG, V7, P2, DOI 10.1136/neurintsurg-2013-011022
   Turk AS, 2015, J NEUROINTERV SURG, V7, P666, DOI 10.1136/neurintsurg-2014-011282
   Turk AS, 2014, J NEUROINTERV SURG, V6, P260, DOI 10.1136/neurintsurg-2014-011125
   Vargas J, 2017, WORLD NEUROSURG, V99, P31, DOI 10.1016/j.wneu.2016.11.035
   Zaidat OO, 2013, STROKE, V44, P2650, DOI 10.1161/STROKEAHA.113.001972
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 272
EP 275
DI 10.1016/j.wneu.2019.03.055
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400243
PM 30880200
DA 2020-05-12
ER

PT J
AU Anglani, M
   Cecchin, D
   Cester, G
   Simonato, D
   Baracchine, C
   Della Puppa, A
   Causin, F
AF Anglani, Mariagiulia
   Cecchin, Diego
   Cester, Giacomo
   Simonato, Davide
   Baracchine, Claudio
   Della Puppa, Alessandro
   Causin, Francesco
TI F-18-Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance
   Monitoring of Brain Metabolic Changes in a Case of Arteriovenous
   Malformatione-Related Steal Phenomenon Symptoms
SO WORLD NEUROSURGERY
LA English
DT Article
DE F-18-FDG PET/MRI; AVM; Embolization; Steal phenomenon
ID PERFUSION
AB BACKGROUND: Unruptured brain arteriovenous malformations (AVMs) represent a complex disease in young healthy adults. Most often AVMs are clinically silent but also can display a neurologic syndrome due to hypoperfusion/hypometabolism in perilesional brain tissue called steal phenomenon.
   CASE DESCRIPTION: A 34-year-old woman was admitted to a secondary neurologic center complaining of a right hemiparesis and secondarily generalized seizures. Computed tomography scan and magnetic resonance imaging of the brain showed a left prerolandic AVMwithout signs of acute or previous bleedings. Digital subtraction angiography confirmed a left juxta-central AVM, with a diffuse pattern, fed by hypertrophic rolandic branches from the left middle cerebral artery. An F-18-fluorodeoxyglucose positron emission tomography-magnetic resonance imaging scan was performed 3 days after the critical episode. A significant hypometabolism in parenchymal regions ipsilaterally to the AVM was detected. Two embolization sessions were performed by means of N-butyl cyanoacrylate glue. At the end of the second procedure, a decrease of the shunt-flow and AVM size was observed. Six months later, F-18-fluorodeoxyglucose positron emission tomography-magnetic resonance imaging scan showed persistent hypometabolism located in the AVM area, with a significant improvement of the cortical hemispheric hypometabolism. The patient was asymptomatic and was sent to stereotactic radiosurgery to complete the treatment.
   CONCLUSIONS: In clinical practice, irritative symptoms in patients with unruptured AVMs could lead to erroneous evaluations. In case of fluctuating clinical syndromes, like our case, establishing that symptoms are related to a steal phenomenon is usually difficult.
C1 [Anglani, Mariagiulia; Cester, Giacomo; Causin, Francesco] Padova Univ Hosp, Dept Med DIMED, Neuroradiol Unit, Padua, Italy.
   [Cecchin, Diego] Padova Univ Hosp, Dept Med DIMED, Nucl Med Unit, Padua, Italy.
   [Baracchine, Claudio] Padova Univ Hosp, Dept Neurosci, Stroke Unit, Padua, Italy.
   [Della Puppa, Alessandro] Padova Univ Hosp, Dept Med DIMED, Neurosurg Unit, Padua, Italy.
   [Simonato, Davide] Padova Univ Hosp, Dept Med DIMED, Inst Radiol, Padua, Italy.
   [Cecchin, Diego] Univ Padua, PNC, Padua, Italy.
RP Anglani, M (reprint author), Padova Univ Hosp, Dept Med DIMED, Neuroradiol Unit, Padua, Italy.
EM mariagiulia.anglani@aopd.veneto.it
RI Simonato, Davide/AAM-2341-2020; Cecchin, Diego/V-5771-2019
OI Cecchin, Diego/0000-0001-7956-1924; Simonato,
   Davide/0000-0003-3601-9136; Anglani, Mariagiulia/0000-0002-3989-4553
CR Guo WY, 2004, AM J NEURORADIOL, V25, P1636
   Kaminaga T, 1999, J NEURORADIOLOGY, V26, P236
   Kim DJ, 2011, AM J NEURORADIOL, V32, P2061, DOI 10.3174/ajnr.A2659
   Kumar A, 2017, J NUCL MED TECHNOL, V45, P14, DOI 10.2967/jnumed.112.114397
   MANCHOLA IF, 1993, NEUROSURGERY, V33, P556, DOI 10.1227/00006123-199310000-00002
   OKABE T, 1983, J NEUROSURG, V59, P21, DOI 10.3171/jns.1983.59.1.0021
   Perez-Carrillo GJG, 2010, CURR PROBL DIAGN RAD, V39, P91, DOI 10.1067/j.cpradiol.2009.07.005
   Sarikaya I, 2015, AM J NUCL MED MOLEC, V5, P416
   Shimizu K, 2014, ACTA RADIOL OPEN, V3, DOI 10.1177/2047981613510160
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 276
EP 279
DI 10.1016/j.wneu.2019.02.167
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400244
PM 30862580
DA 2020-05-12
ER

PT J
AU Signorelli, F
   Messina, R
   Maduri, R
   Barbagallo, G
   Tacconi, L
AF Signorelli, Francesco
   Messina, Raffaella
   Maduri, Rodolfo
   Barbagallo, Giuseppe
   Tacconi, Leonello
TI Microsurgical Disconnection of Ruptured Intracranial Pial Arteriovenous
   Fistula Guided by Indocyanine Green Videoangiography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain vascular malformation; Indocyanine green; Pial arteriovenous
   fistula; Videoangiography
AB Intracranial arteriovenous fistulas, rare causes of spontaneous intracerebral bleeding, are direct communications between an arterial feeder and an arterialized vein that drains a normal brain. Arteriovenous disconnection is the only effective treatment for this type of vascular malformation, which is often reached microsurgically due to the difficult endovascular access. Intraoperative indocyanine green videoangiography (ICG-VA) is a valuable help in identifying the arterialized draining vein and its direct communication with the arterial feeder and in confirming real-time interruption of the fistula. We describe the case of a 46-year-old man presenting with sudden onset of headache and left arm motor and sensory deficits associated with a frontoparietal hematoma evacuated 1 week earlier in another institution. Digital subtraction angiography showed a direct communication between an anterior parietal branch of the right middle cerebral artery and a parietal vein. Given the difficulty to reach the point of the fistula endovascularly because of the small caliber and tortuosity of the arterial feeder, as well as the short and relatively rapid flow through the arteriovenous communication, we decided to proceed with microsurgical treatment. Under intraoperative neurophysiologic monitoring the fistula was located with the aid of ICG-VA and interrupted (Video 1). Both control ICG-VA and postoperative angiogram confirmed resolution of the fistula. At a 3-month follow-up the patient had a complete neurologic recovery.
C1 [Signorelli, Francesco; Messina, Raffaella] Univ Aldo Moro Bari, Dept Basic Med Sci Neurosci & Sense Organs, Div Neurosurg, Bari, Italy.
   [Maduri, Rodolfo] Univ Hosp Vaud, Div Neurosurg, Lausanne, Switzerland.
   [Barbagallo, Giuseppe] Policlin G Rodolico Univ Hosp, Div Neurosurg, Catania, Italy.
   [Tacconi, Leonello] Univ Hosp Trieste, Div Neurosurg, Trieste, Italy.
RP Signorelli, F (reprint author), Univ Aldo Moro Bari, Dept Basic Med Sci Neurosci & Sense Organs, Div Neurosurg, Bari, Italy.
EM francesco.signorelli@uniba.it
RI Rodolfo MADURI, FEBNS/A-7297-2019; Signorelli, Francesco/AAF-7550-2019
OI Rodolfo MADURI, FEBNS/0000-0001-6649-5585; Signorelli,
   Francesco/0000-0002-5040-1916; Messina, Raffaella/0000-0002-2819-3938;
   tacconi, leonello/0000-0003-3915-5635; BARBAGALLO, Giuseppe Maria
   Vincenzo/0000-0002-7760-6700
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 280
EP 280
DI 10.1016/j.wneu.2019.03.045
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400245
PM 30878746
DA 2020-05-12
ER

PT J
AU Koga, M
   Aoki, T
   Negoto, T
   Makizono, T
   Sugi, K
   Fujimori, K
   Kajiwara, S
   Komaki, S
   Yoshitomi, M
   Sugita, Y
   Morioka, M
AF Koga, Motohisa
   Aoki, Takachika
   Negoto, Tetsuya
   Makizono, Takehiro
   Sugi, Keisuke
   Fujimori, Kana
   Kajiwara, Sosho
   Komaki, Satoru
   Yoshitomi, Munetake
   Sugita, Yasuo
   Morioka, Motohiro
TI Leptomeningeal Carcinomatosis After Neoplastic Cerebral Aneurysm Rupture
SO WORLD NEUROSURGERY
LA English
DT Article
DE Breast cancer; Case report; Cerebrospinal fluid; Dissemination;
   Leptomeningeal carcinomatosis; Neoplastic cerebral aneurysm;
   Subarachnoid hemorrhage
ID BREAST-CANCER; VASOSPASM
AB BACKGROUND: Several possible mechanisms exist for the spread of a primary tumor to the leptomeninges in leptomeningeal carcinomatosis. This report describes a case caused by direct bleeding in the subarachnoid space from a neoplastic cerebral aneurysm rupture.
   CASE DESCRIPTION: A 48-year-old Japanese woman, who was diagnosed with breast carcinoma (pT3 pN2 M0) at the age of 45 years and underwent mastectomy and chemotherapy, was admitted in a coma following a suddenonset severe headache. Computed tomography revealed diffuse hemorrhage in the subarachnoid space, and angiography revealed an aneurysm at the distal middle cerebral artery. Superficial temporal artery - Lmiddle cerebral artery bypass, aneurysmal trapping, and aneurysm resection were performed within 24 hours of admission. Staining for AE1/AE3 revealed accumulation of atypical cells with a high nuclear-cytoplasmic ratio in the aneurysmal wall. After showing initial improvement, she developed disturbed consciousness due to complicated ventricular enlargement on day 45. Although the cerebrospinal fluid in the acute phase had no atypical cells, subsequent testing revealed atypical cells, which supported a diagnosis of leptomeningeal carcinomatosis due to breast cancer dissemination. The patient died on day 78 after receiving standard endocrine therapy and radiation therapy.
   CONCLUSIONS: Tumor cells reach the leptomeninges via hematogenous spread or direct extension from preexisting lesions and can undergo neuraxis dissemination via the cerebrospinal fluid. Subarachnoid hemorrhage and leptomeningeal carcinomatosis are both devastating conditions with extremely poor prognoses. This patient experienced delayed disturbed consciousness leptomeningeal carcinomatosis with decreased performance status, which made it difficult to justify aggressive treatment on the basis of her poor prognosis.
C1 [Koga, Motohisa; Aoki, Takachika; Negoto, Tetsuya; Makizono, Takehiro; Sugi, Keisuke; Fujimori, Kana; Kajiwara, Sosho; Komaki, Satoru; Yoshitomi, Munetake; Morioka, Motohiro] Kurume Univ, Sch Med, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
   [Sugita, Yasuo] Kurume Univ, Sch Med, Dept Pathol, Fukuoka, Fukuoka, Japan.
RP Negoto, T (reprint author), Kurume Univ, Sch Med, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
EM negoto_tetsuya@med.kurume-u.ac.jp
OI Negoto, Tetsuya/0000-0002-3443-7513
CR Boogerd W, 2004, EUR J CANCER, V40, P2726, DOI 10.1016/j.ejca.2004.08.012
   Dudani S, 2016, CLIN BREAST CANCER, V16, P456, DOI 10.1016/j.clbc.2016.07.014
   Eskridge JM, 1998, NEUROSURGERY, V42, P510, DOI 10.1097/00006123-199803000-00016
   Grossman SA, 1999, CANCER TREAT REV, V25, P103, DOI 10.1053/ctrv.1999.0119
   HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014
   Kesari S, 2003, NEUROL CLIN, V21, P25, DOI 10.1016/S0733-8619(02)00032-4
   Rao R, 2017, BREAST J, V23, P456, DOI 10.1111/tbj.12766
   Tanaka K, 2005, NEUROSURGERY, V56, P214, DOI 10.1227/01.neu.0000147975.24556.BC
   Tsutsumi K, 2017, J CLIN NEUROSCI, V40, P14, DOI 10.1016/j.jocn.2016.12.019
   Zheng J, 2015, CLIN NEUROL NEUROSUR, V128, P107, DOI 10.1016/j.clineuro.2014.11.010
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 281
EP 284
DI 10.1016/j.wneu.2019.02.058
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400246
PM 30822576
DA 2020-05-12
ER

PT J
AU Glauser, G
   Hudgins, E
   Choudhri, OA
AF Glauser, Gregory
   Hudgins, Eric
   Choudhri, Omar A.
TI Microsurgical Clip Reconstruction of Ruptured Dissecting PICA Aneurysm:
   2-Dimensional Operative Video
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm clipping; Cerebrovascular; Posterior inferior cerebellar artery
   aneurysm; Subarachnoid hemorrhage
AB This case is a presentation of technical tenets for the microsurgical clipping of a ruptured posterior inferior cerebellar artery (PICA) aneurysm (Video 1). The patient described in this case was a 19-year-old male with a history of poly-substance abuse who presented from an outside hospital after being found unresponsive and admitted for a subarachnoid hemorrhage 7 days earlier. Noninvasive vascular imaging completed at the outside hospital showed no clear intracranial aneurysm except some irregularity of left PICA proximally. The cerebral angiogram subsequently completed after transfer demonstrated a left dissecting PICA aneurysm from the anterior medullary segment of the PICA. Endovascular options were considered to be high risk for this patient due to the wide neck of the aneurysm. Stent coiling was not considered the best option given the concern about recent subarachnoid hemorrhage and the need for antiplatelets. This case is valuable to the literature as it illustrates technical steps required for reconstructing an aneurysm with a dissected wall with pseudoaneurysmal formation, the need for early proximal control, and the use of intraoperative adenosine for temporary cardiac standstill.
C1 [Glauser, Gregory; Hudgins, Eric; Choudhri, Omar A.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
RP Choudhri, OA (reprint author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
EM Omar.Choudhri@uphs.upenn.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 285
EP 285
DI 10.1016/j.wneu.2019.02.161
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400247
PM 30872198
DA 2020-05-12
ER

PT J
AU Das, KK
   Deora, H
   Srivastava, A
   Khatri, D
   Shankar, S
   Sardhara, J
   Behari, S
AF Das, Kuntal Kanti
   Deora, Harsh
   Srivastava, Arun
   Khatri, Deepak
   Shankar, Sanjog
   Sardhara, Jayesh
   Behari, Sanjay
TI Elongated Clivus with Deficient Anterior Atlantal Arch and Congenital
   Posterior Atlantooccipital Dislocation: Pathoembryology and Management
   Nuances of a Rare Form of Proatlas Segmentation Anomaly
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlanto-occipital dislocation; Bifid anterior arch; Myelopathy;
   Pediatric; Proatlas anomaly; Transoral surgery
ID ATLANTOAXIAL DISLOCATION
AB BACKGROUND: Proatlas segmentation anomalies represent a rare subset of congenital craniovertebral junction anomalies. In this condition, the structures originating from the proatlas, such as the clivus, occipital condyles, foramen magnum rim, and odontoid tip, may demonstrate congenital anomalies, usually without any spinal instability. Elongated clivus, as a result of nonsegmentation of the odontoid tip from the rest of the proatlas, has been reported before to cause ventral spinal cord compression. We report such a case with certain unreported other associations and explore the pathoembryology and management options of such complex anomalies.
   CASE DESCRIPTION: An 8-year old girl presented with a 2-year history of progressive spastic quadriparesis. On neuroimaging, the anterior arch of the atlas was deficient, the odontoid process was foreshortened, and the clivus was elongated, encroaching into the spinal canal leading to ventral spinal cord compression. Additionally, there was rotatory posterior dislocation of the occipital condyles onto the posterior atlantal arch and vertebral artery anomaly. This patient underwent transoral decompression followed by occipitocervical fusion using rods and screws with satisfactory results.
   CONCLUSIONS: Proatlas anomalies are rare, varied, and often subtle enough to go unrecognized. Knowledge of the embryology and its aberrations is necessary to understand these anomalies. Our case describes a rare form of bony anomalies pertaining to the fate of the proatlas with accompanying atlantooccipital dislocation.
C1 [Das, Kuntal Kanti; Deora, Harsh; Srivastava, Arun; Khatri, Deepak; Shankar, Sanjog; Sardhara, Jayesh; Behari, Sanjay] Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
RP Das, KK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
EM kkdas@sgpgi.ac.in
RI DEORA, HARSH/A-5817-2019; Khatri, Deepak/C-3554-2019
OI DEORA, HARSH/0000-0003-3247-1117; Khatri, Deepak/0000-0003-1902-9623
CR Bapat MR, 2018, SPINE, V42, P1426
   Behari S, 2004, NEUROL INDIA, V52, P489
   Goel A, 2015, NEUROSURGERY, V77, P296, DOI 10.1227/NEU.0000000000000761
   Jain VK, 2002, NEUROL INDIA, V50, P386
   Jain VK, 1999, NEUROL INDIA, V47, P188
   Lofrese G, 2015, SPINE, V40, pE992, DOI 10.1097/BRS.0000000000000946
   Menezes AH, 2008, CHILD NERV SYST, V24, P1101, DOI 10.1007/s00381-008-0605-9
   Muthukumar N, 2016, J PEDIATR NEUROSCI, V11, P14, DOI 10.4103/1817-1745.181246
   Pang D, 2011, CHILD NERV SYST, V27, P523, DOI 10.1007/s00381-010-1358-9
   Sardhara J, 2015, NEUROL INDIA, V63, P382, DOI 10.4103/0028-3886.158218
   Sindgikar P, 2016, NEUROL INDIA, V64, P1220, DOI 10.4103/0028-3886.193781
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 286
EP 290
DI 10.1016/j.wneu.2019.03.091
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400248
PM 30898752
DA 2020-05-12
ER

PT J
AU Fujimoto, A
   Masuda, Y
   Ichikawa, N
   Sato, K
   Baba, S
   Itamura, S
   Nishimura, M
   Enoki, H
   Okanishi, T
AF Fujimoto, Ayataka
   Masuda, Yosuke
   Ichikawa, Naoki
   Sato, Keishiro
   Baba, Shimpei
   Itamura, Shinji
   Nishimura, Mitsuyo
   Enoki, Hideo
   Okanishi, Tohru
TI Side Slit Guide Pipe for Precise Placement of Depth Electrodes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Accurate placement; Depth electrode; Neuronavigation; Side slit guide
   pipe; Stereoelectroencephalography
AB BACKGROUND: Using a stereotactic technique, surgeons can accurately place a depth electrode (DE), but sometimes the DE deviates from the intended target due to movement of the electrode or leakage of cerebrospinal fluid when placing the electrode. If DEs can be anchored before removing the catheter insertion guide pipe, more accurate placement may be possible.
   METHODS: We made a side slit guide pipe. When the DEs were anchored to the dura or the edge of the burr hole, the DE did not move when the guide pipe was removed. We measured the distance between the planned target and the tip of the electrode in 13 patients (3 female and 10 male patients; age range, 7-43 years; mean age 23.0 years; median age 27 years) withmedically intractable epilepsywho underwent DE placement with stereotactic neuronavigation guidance.
   RESULTS: There were 30 DEs implanted. The mean distance fromthe planned target to the tip of the DEwas 0.570 mm (range, 0.3-1.2 mm; median 0.5 mm; SD 0.212). The mean distance from the planned target to the tip of the DEwith dural anchoringwas 0.467 mm(range, 0.3-0.6 mm; median 0.45 mm; SD 0.121) and with burr hole edge anchoring was 0.596 mm (range, 0.3-1.2 mm; median 0.50 mm; SD 0.224; P = 0.205).
   CONCLUSIONS: DEs can be anchored using the side slit guide pipe for more precise placement.
C1 [Fujimoto, Ayataka; Masuda, Yosuke; Ichikawa, Naoki; Sato, Keishiro; Baba, Shimpei; Itamura, Shinji; Nishimura, Mitsuyo; Enoki, Hideo; Okanishi, Tohru] Seirei Hamamatsu Gen Hosp, Comprehens Epilepsy Ctr, Shizuoka, Japan.
RP Fujimoto, A (reprint author), Seirei Hamamatsu Gen Hosp, Comprehens Epilepsy Ctr, Shizuoka, Japan.
EM afujimotoscienceacademy@gmail.com
CR BACKLUND E-O, 1987, Neurological Research, V9, P147
   BACKLUND EO, 1993, ACTA NEUROCHIR, V121, P86, DOI 10.1007/BF01405189
   Dorfer C, 2014, NEUROSURGERY, V10, P590
   Dorfer C, 2017, J NEUROSURG, V126, P1622, DOI 10.3171/2016.5.JNS16388
   Dorfer C, 2014, OPER NEUROSURG, V10, P582, DOI 10.1227/NEU.0000000000000509
   Fujimoto A, 2017, NEUROL MED-CHIR, V57, P496, DOI 10.2176/nmc.tn.2017-0110
   Isnard J, 2018, NEUROPHYSIOL CLIN, V48, P5, DOI 10.1016/j.neucli.2017.11.005
   Ringel F, 2009, NEUROSURGERY, V64, P365, DOI 10.1227/01.NEU.0000341532.15867.1C
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 291
EP 295
DI 10.1016/j.wneu.2019.03.067
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400249
PM 30885874
DA 2020-05-12
ER

PT J
AU Yang, XL
   Wang, AOF
   Zhang, RJ
   Zhang, HB
AF Yang, Xiaoliang
   Wang, Xaiofeng
   Zhang, Rongjun
   Zhang, Hongbing
TI Bilateral Blindness After Incomplete Coiling of Small Anterior Cerebral
   Artery Aneurysm: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bilateral blindness; Clip; Coil; Endovascular; Small aneurysm
ID ENDOVASCULAR TREATMENT; UNRUPTURED ANEURYSMS; GIANT; OCCLUSION; DEFICITS
AB BACKGROUND: Complications after coiling of large, giant, and thrombosed aneurysms because of increased mass effect on surrounding structures have been widely reported. A case of bilateral blindness after incomplete coil embolization of a small anterior cerebral artery aneurysm is rare. We review the potential mechanisms, clinical progression, and proper treatment needs.
   CASE DESCRIPTION: A 50-year-old man was urgently admitted with subarachnoid hemorrhage. Digital subtraction angiography (DSA) showed a ruptured aneurysm of the A1 segment, anterior cerebral artery. An endovascular coil occlusion was performed without an additional device. The visual acuity of patient slowly decreased from the 13th day after endovascular intervention. His visual acuity improved after steroid therapy but then deteriorated again. DSA showed an enlarged aneurysm, and an urgent craniotomy was performed for optic nerve decompression. The patient finally became bilaterally blind, although hyperbaric oxygen, neurotrophy drugs, and other supporting treatment was given.
   CONCLUSIONS: Incomplete aneurysm coiling may result in bilateral blindness, even at a small anterior cerebral artery. Early DSA, steroid therapy, and secondary craniotomy for nerve decompression should be considered promptly for improving clinical outcome before nerve atrophy, although sometimes single steroid therapy is effective.
C1 [Yang, Xiaoliang; Wang, Xaiofeng; Zhang, Rongjun; Zhang, Hongbing] Third Hosp People Liberat Army, Dept Neurosurg, Baoji, Peoples R China.
RP Yang, XL (reprint author), Third Hosp People Liberat Army, Dept Neurosurg, Baoji, Peoples R China.
EM zhiyin100@163.com
OI Yang, Xiaoliang/0000-0003-0136-1935
CR Bhat DI, 2011, BRIT J NEUROSURG, V25, P644, DOI 10.3109/02688697.2010.544782
   Chmayssani M, 2011, NEUROSURGERY, V68, P1164, DOI 10.1227/NEU.0b013e31820edbd3
   Firat MM, 2000, NEURORADIOLOGY, V42, P142, DOI 10.1007/s002340050034
   HALBACH VV, 1994, J NEUROSURG, V80, P659, DOI 10.3171/jns.1994.80.4.0659
   Hara N, 2003, OPHTHALMOLOGICA, V217, P79, DOI 10.1159/000068247
   Hasan DM, 2012, STROKE, V43, P866, DOI 10.1161/STROKEAHA.111.637827
   Killer M, 2009, MINIM INVAS NEUROSUR, V52, P39, DOI 10.1055/s-0028-1104565
   KWAN ESK, 1991, J NEUROSURG, V75, P963, DOI 10.3171/jns.1991.75.6.0963
   LITOFSKY NS, 1994, NEUROSURGERY, V34, P548, DOI 10.1227/00006123-199403000-00027
   Lownie SP, 2000, J NEUROSURG, V92, P267, DOI 10.3171/jns.2000.92.2.0267
   Malisch TW, 1998, J NEUROSURG, V89, P956, DOI 10.3171/jns.1998.89.6.0956
   Meyers PM, 2004, NEUROSURGERY, V55, P1222, DOI 10.1227/01.NEU.0000140987.71791.DF
   Mitha AP, 2008, J NEUROSURG, V108, P1241, DOI 10.3171/JNS/2008/108/6/1241
   Nakatomi H, 2000, STROKE, V31, P896, DOI 10.1161/01.STR.31.4.896
   Oka Hidehiro, 1994, Neurological Surgery, V22, P677
   Russell SM, 2002, J NEUROSURG, V97, P705, DOI 10.3171/jns.2002.97.3.0705
   Tsuura M, 1998, NEURORADIOLOGY, V40, P184, DOI 10.1007/s002340050565
   Turner RD, 2008, NEUROSURGERY, V63, P469, DOI 10.1227/01.NEU.0000324730.37144.4B
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 296
EP 300
DI 10.1016/j.wneu.2019.03.076
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400250
PM 30898735
DA 2020-05-12
ER

PT J
AU Hou, K
   Li, GC
   Xu, BF
   Xu, K
   Yu, JL
AF Hou, Kun
   Li, Guichen
   Xu, Baofeng
   Xu, Kan
   Yu, Jinlu
TI Which Patients with Aneurysms Involving the a1-a2 Segment of the
   Anterior Inferior Cerebellar Artery Would Benefit from Parent Artery
   Occlusion?
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anterior inferior cerebellar artery; Dissecting aneurysm; Parent artery
   occlusion; Subarachnoid hemorrhage
ID ENDOVASCULAR TREATMENT; CLINICAL PRESENTATION; EMBOLIZATION;
   NOMENCLATURE
AB Anterior inferior cerebellar artery (AICA) trunk aneurysms are rare entities. Given the eloquence of the AICA in supplying the cerebellum and brainstem, in theory, sacrifice or occlusion of the a1-a2 segment in lesions involving the AICA may lead to various complications. However, some patients might experience no complication or favorable recovery. The subgroup of patients who would benefit from parent artery occlusion (PAO) among those with aneurysms involving the a1-a2 segment of the AICA remains to be explored. In this report, we present 2 cases of AICA dissecting aneurysms at the a1-a2 segment that were successfully occluded via coiling without postprocedural complications. A comprehensive literature review was also performed on patients with AICA aneurysms with occlusion at the a1-a2 segment. Sixteen patients were identified, and all of the cases had satisfactory outcomes. Of these patients, 11 of 16 (68.75%) had no neurologic deficits, and 5 of 16 (31.25%) had acceptable neurologic deficits. The prognosis was associated with collateral circulation of the AICA, and collateral circulation was discussed. In case of an a1-a2 aneurysm that is hard to occlude without sacrificing the parent artery, careful hemodynamic and morphologic evaluation for collateral flow is warranted. If collateral flow is demonstrated or the aneurysm is flow-related with cerebellar arteriovenous malformation, PAO of the a1-a2 segment can be an acceptable option.
C1 [Hou, Kun; Xu, Baofeng; Xu, Kan; Yu, Jinlu] Jilin Univ, Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
   [Li, Guichen] Jilin Univ, Hosp 1, Dept Neurol, Changchun, Jilin, Peoples R China.
RP Yu, JL (reprint author), Jilin Univ, Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
EM jlyu@jlu.edu.cn
RI Yu, Jinlu/G-7719-2019
OI Yu, Jinlu/0000-0003-2329-7946; Hou, Kun/0000-0001-7112-7883
CR Bambakidis NC, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.1.FOCUS0915
   Caplan JM, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FocusVid.14581
   Choi CH, 2006, ACTA NEUROCHIR, V148, P363, DOI 10.1007/s00701-005-0702-4
   CreveCoeur TS, 2019, CHILD NERV SYST, V35, P373, DOI 10.1007/s00381-018-3968-6
   Hou K, 2018, WORLD NEUROSURG, V115, P334, DOI 10.1016/j.wneu.2018.04.207
   Kocak A, 2008, J CLIN NEUROSCI, V15, P1420, DOI 10.1016/j.jocn.2006.06.023
   Lv XL, 2016, INTERV NEURORADIOL, V22, P643, DOI 10.1177/1591019916656474
   Lv XL, 2008, NEURORADIOL J, V21, P261, DOI 10.1177/197140090802100219
   Mahmoud M, 2012, INTERV NEURORADIOL, V18, P449, DOI 10.1177/159101991201800411
   Matsuyama T, 2002, NEUROL MED-CHIR, V42, P214, DOI 10.2176/nmc.42.214
   Nishi S, 1996, ACTA NEUROCHIR, V138, P294, DOI 10.1007/BF01411740
   Peluso JPP, 2007, AM J NEURORADIOL, V28, P1573, DOI 10.3174/ajnr.A0607
   Rodriguez-Hernandez A, 2013, WORLD NEUROSURG, V80, P103, DOI 10.1016/j.wneu.2012.09.010
   Rodriguez-Hernandez A, 2011, J NEUROSURG, V115, P387, DOI 10.3171/2011.3.JNS101413
   Santillan Alejandro, 2011, Surg Neurol Int, V2, P95, DOI 10.4103/2152-7806.82577
   Takemoto Y, 2015, ACTA NEUROCHIR, V157, P1045, DOI 10.1007/s00701-015-2397-5
   Tokimura H, 2012, NEUROSURG REV, V35, P497, DOI 10.1007/s10143-012-0390-5
   Vigo V, 2019, WORLD NEUROSURG, V123, pE536, DOI 10.1016/j.wneu.2018.11.207
NR 18
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 301
EP 309
DI 10.1016/j.wneu.2019.03.070
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400251
PM 30885868
DA 2020-05-12
ER

PT J
AU Onyia, CU
   Akinniranye, O
   Olaitan, A
   Agoha, C
AF Onyia, Chiazor U.
   Akinniranye, Olusegun
   Olaitan, Adebayo
   Agoha, Chimezie
TI Short Report on a Rare Presentation of Temporal Arachnoid Cyst and
   Lessons Learned
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid cyst; Neck stiffness; Nuchal rigidity; Uncal herniation
ID TONSILLAR HERNIATION; SYRINGOMYELIA
AB BACKGROUND: Stiff neck or nuchal rigidity is a significant clinical sign of neurologic disease. It is commonly associated with meningitis, subarachnoid hemorrhage, and posterior fossa tumors. It may also occur as a result of tonsillar impaction following pressure in the infratentorial compartment from an expanding posterior fossa mass. It is, however, not commonly known to be associated with uncal herniation.
   CASE DESCRIPTION: We report a recent experience on this association.
   CONCLUSIONS: In the presence of stiff neck or nuchal rigidity in a patient with clinical signs of uncal herniation from a temporal arachnoid cyst, this unusual association could possibly be owing to the effect of increased pressure in the posterior fossa from massive shift of brain tissue posteriorly following a rapid rise in middle cranial fossa pressure consequent on an acute enlargement of the cyst. A false impression of acute meningeal irritation in such a situation could be quite misleading, resulting in late diagnosis and subsequently a delay in timely intervention.
C1 [Onyia, Chiazor U.] Lagoon Hosp Grp, Dept Surg, Lagos, Nigeria.
   [Akinniranye, Olusegun; Olaitan, Adebayo] Lagoon Hosp Grp, Dept Anaesthesia, Lagos, Nigeria.
   [Agoha, Chimezie] Lagoon Hosp, Dept Surg, Lagos, Nigeria.
RP Onyia, CU (reprint author), Lagoon Hosp Grp, Dept Surg, Lagos, Nigeria.
EM shalomazor@yahoo.com
OI Onyia, Chiazor/0000-0002-4264-6876
CR Balani A, 2015, NEUROL INDIA, V63, P801, DOI 10.4103/0028-3886.166544
   Bauer Andrew M, 2005, Neurosurg Focus, V19, pE14
   Galarza M, 2010, NEUROSURG REV, V33, P305, DOI 10.1007/s10143-010-0262-9
   Hanrahan J, 2018, CHILD NERV SYST, V34, P2519, DOI 10.1007/s00381-018-3917-4
   Huang HY, 2011, INT J MED SCI, V8, P345, DOI 10.7150/ijms.8.345
   Huang JH, 2015, INT J CLIN EXP MED, V8, P18343
   Isler C, 2014, J SPINE NEUROSURG, V4, P2
   Joshi VP, 2013, J CRANIOVERTEBRAL JU, V4, P43, DOI 10.4103/0974-8237.121627
   Lee SH, 2014, KOREAN J ANESTHESIOL, V67, pS53, DOI 10.4097/kjae.2014.67.S.S53
   Martinez-Lage JF, 2007, NEUROCIRUGIA, V18, P227
   OLIVER L, 1959, Postgrad Med J, V35, P546
   Pillai LV, 2008, INDIAN J CRIT CARE M, V12, P42, DOI 10.4103/0972-5229.40951
   Rashid S, 2016, HEADACHE, V56, P1354, DOI 10.1111/head.12846
   Sharma Rajesh, 2016, Radiol Bras, V49, P337, DOI 10.1590/0100-3984.2013.0022
   Straussberg R, 2002, PEDIATR NEUROL, V26, P225, DOI 10.1016/S0887-8994(01)00364-2
   Tahir MZ, 2012, CNS NEUROL DISORD-DR, V11, P127
NR 16
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 310
EP 313
DI 10.1016/j.wneu.2019.02.230
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400252
PM 30885870
DA 2020-05-12
ER

PT J
AU Akhaddar, A
AF Akhaddar, Ali
TI African Contribution to the World Neurosurgical Literature During the
   Past Two Decades (1999-2018) Using PubMed Database
SO WORLD NEUROSURGERY
LA English
DT Review
DE Africa; Bibliometrics; Medical publication; Neurosurgery; PubMed;
   Research; Scientific productivity
ID TRENDS
AB BACKGROUND: To the best of our knowledge, no previous study has assessed the neurosurgical publications from Africa. A bibliometric analysis was performed in the present study to evaluate the contribution of African authors in neurosurgical journals worldwide and to discuss the approaches that could be used to enhance the quantity and quality of publications on this issue.
   METHODS: A literature search of neurosurgical publications by African investigators was performed using the PubMed database from 1999 to 2018. The total number of articles per country was tabulated and normalized by the number of neurosurgeons in each country.
   RESULTS: A total of 974 articles reported from 1999 to 2018 from 31 African countries were identified and analyzed. The number of African neurosurgical publications have increased remarkably during the past decade. However, a wide disparity exists in the productivity among the countries, especially when normalized by the number of neurosurgeons. Most of the research publications have been case series and case reports, with very few clinical trials, meta-analyses, or international collaborations. According to the neurosurgical research areas, the most representative subspecialties were the spine, intracranial tumor, hydrocephalus, and head injury.
   CONCLUSIONS: African neurosurgeons will be able to meet the challenges of the new century with the appropriate use of its resources and staff, regardless of the difficulties they face. However, African neurosurgical research could be improved by teaching research methods and medical writing and should focus more on modern neurosurgical topics by highlighting continental particularities. African neurosurgeons should collaborate with each other (locally, regionally, and abroad) and with foreign centers for better quality research and international visibility.
C1 [Akhaddar, Ali] Avicenne Mil Hosp Marrakech, Dept Neurosurg, Marrakech, Morocco.
   [Akhaddar, Ali] Mohammed V Univ, Lab Biostat Clin Res, Fac Med & Pharm, Rabat, Morocco.
   [Akhaddar, Ali] Mohammed V Univ, Epidemiol, Fac Med & Pharm, Rabat, Morocco.
RP Akhaddar, A (reprint author), Avicenne Mil Hosp Marrakech, Dept Neurosurg, Marrakech, Morocco.; Akhaddar, A (reprint author), Mohammed V Univ, Lab Biostat Clin Res, Fac Med & Pharm, Rabat, Morocco.; Akhaddar, A (reprint author), Mohammed V Univ, Epidemiol, Fac Med & Pharm, Rabat, Morocco.
EM akhaddar@hotmail.com
OI Akhaddar, Ali/0000-0001-5743-2777
CR Akhaddar A, 2017, ATLAS INFECT NEUROSU
   Akhaddar A, 2011, PUBLIER REV BIOMEDIC
   Akhaddar A, 2016, CRANIAL OSTEOMYELITI
   Akhaddar A, 2019, WORLD NEUROSURG, V126, P59, DOI 10.1016/j.wneu.2019.02.122
   Beer-Furlan A, 2019, WORLD NEUROSURG, V122, P29, DOI 10.1016/j.wneu.2018.10.081
   Bordons M, 2013, SCIENTOMETRICS, V96, P443, DOI 10.1007/s11192-012-0890-7
   Budohoski KP, 2018, WORLD NEUROSURG, V113, P436, DOI 10.1016/j.wneu.2018.01.085
   Burton A, 2017, LANCET NEUROL, V16, P499, DOI [10.1016/S1474-4422(17)30246-6, 10.1016/S1474-4422(17)30164-3, 10.1016/S1474-4422(17)30087-X]
   Cairo SB, 2018, PEDIATR SURG INT, V34, P467, DOI 10.1007/s00383-018-4238-0
   Davis MC, 2017, J NEUROSURG-PEDIATR, V20, P204, DOI 10.3171/2017.3.PEDS16433
   Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500
   Drubin DG, 2012, MOL BIOL CELL, V23, P1399, DOI 10.1091/mbc.E12-02-0108
   El Gindi S, 2002, NEUROSURGERY, V51, P789, DOI 10.1097/00006123-200209000-00032
   El Khamlichi A, 2001, NEUROSURGERY, V48, P1344, DOI 10.1097/00006123-200106000-00034
   El-Fiki M, 2014, WORLD NEUROSURG, V82, pE155, DOI 10.1016/j.wneu.2012.10.065
   El-Fiki M, 2011, WORLD NEUROSURG, V76, P28, DOI 10.1016/j.wneu.2011.05.012
   El-Fiki M, 2010, WORLD NEUROSURG, V73, P254, DOI 10.1016/j.wneu.2010.02.012
   Hauptman JS, 2011, J NEUROSURG, V115, P1262, DOI 10.3171/2011.8.JNS11857
   Jamjoom Bakur A, 2016, eNeurologicalSci, V4, P1, DOI 10.1016/j.ensci.2016.03.002
   Leidinger A, 2019, WORLD NEUROSURG, V121, pE493, DOI 10.1016/j.wneu.2018.09.145
   Leidinger A, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.7.FOCUS18287
   Liu WM, 2018, NEUROSURG REV, V41, P55, DOI 10.1007/s10143-016-0742-7
   Lund-Johansen M, 2017, WORLD NEUROSURG, V99, P403, DOI 10.1016/j.wneu.2016.12.051
   Mangat HS, 2018, WORLD NEUROSURG, V113, P411, DOI 10.1016/j.wneu.2018.01.086
   Mukhopadhyay S, 2019, J NEUROSURG, V130, P1142, DOI 10.3171/2018.10.JNS171723
   Orief Tamer, 2010, No Shinkei Geka, V38, P177
   Ormond DR, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.7.FOCUS18239
   Piquer J, 2010, WORLD NEUROSURG, V73, P280, DOI 10.1016/j.wneu.2010.02.015
   Russell VA, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00096
   Santos MM, 2018, WORLD NEUROSURG, V113, P425, DOI 10.1016/j.wneu.2018.01.084
   Tijssen RJW, 2007, SCIENTOMETRICS, V71, P303, DOI 10.1007/s11192-007-1658-3
   Turgut M, 2017, TUBERCULOSIS CENTRAL
   Turgut M, 2019, FUNGAL INFECTIONS CE
   Uthman OA, 2007, INT J HEALTH GEOGR, V6, DOI 10.1186/1476-072X-6-46
   Volmink J, 2005, BMJ-BRIT MED J, V331, P705, DOI 10.1136/bmj.331.7519.705
NR 35
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 314
EP 321
DI 10.1016/j.wneu.2019.03.095
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400253
PM 30898744
DA 2020-05-12
ER

PT J
AU Dasenbrock, HH
   See, AP
   Smalley, RJ
   Bi, WL
   Dolati, P
   Frerichs, KU
   Golby, AJ
   Chiocca, EA
   Aziz-Sultan, MA
AF Dasenbrock, Hormuzdiyar H.
   See, Alfred P.
   Smalley, Robert J.
   Bi, Wenya Linda
   Dolati, Parviz
   Frerichs, Kai U.
   Golby, Alexandra J.
   Chiocca, E. Antonio
   Aziz-Sultan, M. Ali
TI Frameless Stereotactic Navigation during Insular Glioma Resection using
   Fusion of Three-Dimensional Rotational Angiography and Magnetic
   Resonance Imaging
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiography; Frameless stereotaxy; Insular glioma; Neuronavigation
ID DIAGNOSTIC CEREBRAL-ANGIOGRAPHY; POSTOPERATIVE ISCHEMIC CHANGES; AWAKE
   CRANIOTOMY; SURGICAL-MANAGEMENT; LENTICULOSTRIATE ARTERIES; DOMINANT
   HEMISPHERE; CONSECUTIVE SERIES; GUIDED RESECTION; SURGERY; COMPLICATIONS
AB BACKGROUND: Perioperative cerebral infarction is a potential complication of glioma resection, of which insular tumors are at higher risk because of the proximity of middle cerebral artery branches, including the lateral lenticulostriates and long insular arteries. In this study, 3 patients received three-dimensional rotational angiography, which was fused with magnetic resonance imaging (MRI) for frameless stereotactic navigation during dominant-hemisphere insular glioma resection.
   METHODS: All patients obtained a preoperative catheter angiogram with a three-dimensional rotational acquisition of the ipsilateral internal carotid artery. The pixel-based axial three-dimensional angiography data, thin-cut structural MRI, tractography from diffusion tensor imaging, and expressive language activation from functional MRI were uploaded into the iPlan software (Brainlab, Heimstetten, Germany) and fused. The target tumor, regional blood vessels, adjacent functional areas, and their associated fiber tracts were segmented and overlaid on the appropriate MRI sequence. This image fusion was used preoperatively to visualize the relationship of the mass with the adjacent vasculature and intraoperatively for frameless stereotactic navigation to optimize preservation of arterial structures.
   RESULTS: Three patients aged 27-60 years with excellent baseline functional status presented with seizures and were found to have a large dominant-hemisphere T2 hyperintense nonenhancing insular mass. Surgical resection was performed using multimodality neuronavigation. None sustained a postoperative arterial infarction or a perioperative neurologic deficit.
   CONCLUSIONS: Neuronavigation using a fusion of three-dimensional rotational angiography with MRI is a technique that can be used for preoperative planning and during resection of insular gliomas to optimize preservation of adjacent arteries.
C1 [Dasenbrock, Hormuzdiyar H.; See, Alfred P.; Smalley, Robert J.; Bi, Wenya Linda; Dolati, Parviz; Frerichs, Kai U.; Golby, Alexandra J.; Chiocca, E. Antonio; Aziz-Sultan, M. Ali] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
   [Dasenbrock, Hormuzdiyar H.] Rush Univ, Dept Neurosurg, Chicago, IL 60612 USA.
   [Smalley, Robert J.] Naval Med Ctr, Dept Radiol, Portsmouth, VA USA.
   [Dolati, Parviz] Golshar Hosp, Dept Neurosurg, Rasht, Iran.
RP Dasenbrock, HH (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.; Dasenbrock, HH (reprint author), Rush Univ, Dept Neurosurg, Chicago, IL 60612 USA.
EM Hormuzdiyar_H_Dasenbrock@rush.edu
OI Dolati, Parviz/0000-0001-8230-9148
CR Abolfotoh M, 2015, OPER NEUROSURG, V11, P578, DOI 10.1227/NEU.0000000000000966
   Barbosa BJAP, 2016, CLIN NEUROL NEUROSUR, V149, P104, DOI 10.1016/j.clineuro.2016.08.001
   Alimohamadi M, 2016, WORLD NEUROSURG, V92, P151, DOI 10.1016/j.wneu.2016.04.079
   Ashour R, 2016, WORLD NEUROSURG, V91, P6, DOI 10.1016/j.wneu.2016.03.055
   Baran O, 2018, CLIN NEUROL NEUROSUR, V173, P52, DOI 10.1016/j.clineuro.2018.08.001
   Benet A, 2016, J NEUROSURG, V124, P469, DOI 10.3171/2014.12.JNS142182
   Carl B, 2018, WORLD NEUROSURG, V113, pE414, DOI 10.1016/j.wneu.2018.02.045
   Chaichana K, 2010, J NEUROSURG, V112, P997, DOI 10.3171/2009.9.JNS09805
   Chang SM, 2003, J NEUROSURG, V98, P1175, DOI 10.3171/jns.2003.98.6.1175
   Dawkins AA, 2007, NEURORADIOLOGY, V49, P753, DOI 10.1007/s00234-007-0252-y
   Dolati P, 2016, WORLD NEUROSURG, V95, P406, DOI 10.1016/j.wneu.2016.06.008
   Dolati Parviz, 2015, Surg Neurol Int, V6, P172, DOI 10.4103/2152-7806.170023
   Dolati P, 2015, CLIN NEUROL NEUROSUR, V139, P159, DOI 10.1016/j.clineuro.2015.10.006
   Dutzmann S, 2012, J NEURO-ONCOL, V107, P599, DOI 10.1007/s11060-011-0784-1
   Duffau H, 2004, CANCER-AM CANCER SOC, V100, P2622, DOI 10.1002/cncr.20297
   Duffau H, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.5.FOCUS0938
   Duffau H, 2009, J NEUROSURG, V110, P696, DOI 10.3171/2008.8.JNS08741
   Elhawary H, 2011, NEUROSURGERY, V68, P506, DOI 10.1227/NEU.0b013e3182036282
   Ferroli P, 2011, ACTA NEUROCHIR SUPPL, V109, P251, DOI 10.1007/978-3-211-99651-5_40
   Fifi JT, 2009, J VASC INTERV RADIOL, V20, P442, DOI 10.1016/j.jvir.2009.01.012
   Fredrickson VL, 2017, NEUROSURG CLIN N AM, V28, P603, DOI 10.1016/j.nec.2017.05.011
   Gempt J, 2013, J NEUROSURG, V119, P829, DOI 10.3171/2013.5.JNS121981
   Gempt J, 2013, J NEUROSURG, V118, P801, DOI 10.3171/2012.12.JNS12125
   Gonzalez LF, 2010, NEUROSURGERY, V67, P471, DOI 10.1227/01.NEU.0000372205.53792.E4
   Gravesteijn BY, 2018, NEUROL RES, V40, P87, DOI 10.1080/01616412.2017.1402147
   Hendrikse J, 2008, CEREBROVASC DIS, V26, P624, DOI 10.1159/000166838
   Hervey-Jumper SL, 2016, J NEUROSURG, V124, P482, DOI 10.3171/2015.4.JNS1521
   Ishikawa T, 2017, NEUROL MED-CHIR, V57, P28, DOI 10.2176/nmc.oa.2016-0042
   Ius T, 2014, J NEUROSURG, V120, P12, DOI 10.3171/2013.9.JNS13728
   Iwasaki M, 2014, NEUROL MED-CHIR, V54, P321, DOI 10.2176/nmc.cr2012-0361
   Kamiya-Matsuoka C, 2015, J NEURO-ONCOL, V125, P143, DOI 10.1007/s11060-015-1880-4
   Kasliwal MK, 2009, J NEUROSURG, V111, P1294, DOI 10.3171/2009.4.JNS09621
   Kaufmann TJ, 2007, RADIOLOGY, V243, P812, DOI 10.1148/radiol.2433060536
   Kawaguchi T, 2014, J NEUROSURG, V121, P1124, DOI 10.3171/2014.7.JNS13899
   Kim EH, 2011, ACTA NEUROCHIR, V153, P1487, DOI 10.1007/s00701-011-1046-x
   Kim YH, 2012, NEUROSURG CLIN N AM, V23, P199, DOI 10.1016/j.nec.2012.01.010
   Kumabe T, 2007, J NEUROSURG, V106, P263, DOI 10.3171/jns.2007.106.2.263
   Lenck S, 2017, INTERV NEURORADIOL, V23, P346, DOI 10.1177/1591019917702522
   Leng LZ, 2013, WORLD NEUROSURG, V79, P504, DOI 10.1016/j.wneu.2011.09.008
   Lim SP, 2011, J NEUROSURG, V114, P140, DOI 10.3171/2010.1.JNS09833
   Marinkovic S, 2001, CLIN ANAT, V14, P190, DOI 10.1002/ca.1032
   Martino J, 2015, J NEUROSURG, V123, P1081, DOI 10.3171/2014.11.JNS141992
   Michaud K, 2016, J NEURO-ONCOL, V130, P289, DOI 10.1007/s11060-016-2120-2
   Morshed RA, 2019, J NEUROSURG, V131, P467, DOI 10.3171/2018.4.JNS18375
   Moshel YA, 2008, J NEUROSURG, V109, P825, DOI 10.3171/JNS/2008/109/11/0825
   Motomura K, 2017, J NEUROSURG, V127, P790, DOI 10.3171/2016.9.JNS16152
   Neuloh G, 2007, NEUROPHYSIOL CLIN, V37, P383, DOI 10.1016/j.neucli.2007.09.002
   Neuloh G, 2007, J NEUROSURG, V106, P582, DOI 10.3171/jns.2007.106.4.582
   Ngwenya LB, 2013, J NEUROSURG, V118, P799, DOI 10.3171/2012.8.JNS121410
   Olubiyi OI, 2015, WORLD NEUROSURG, V84, P528, DOI 10.1016/j.wneu.2015.04.044
   Orringer DA, 2012, EXPERT REV MED DEVIC, V9, P491, DOI [10.1586/ERD.12.42, 10.1586/erd.12.42]
   Panigrahi M, 2017, WORLD NEUROSURG, V98, P587, DOI 10.1016/j.wneu.2016.11.001
   Rao AS, 2018, WORLD NEUROSURG, V109, pE426, DOI 10.1016/j.wneu.2017.09.199
   Rey-Dios R, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2012.12.FOCUS12342
   Risholm P, 2011, NEUROSURG CLIN N AM, V22, P197, DOI 10.1016/j.nec.2010.12.001
   Saito R, 2009, J NEUROSURG, V111, P278, DOI 10.3171/2008.11.JNS08858
   Scerrati A, 2014, CLIN NEUROL NEUROSUR, V124, P106, DOI 10.1016/j.clineuro.2014.06.032
   Signorelli F, 2010, ACTA NEUROCHIR, V152, P19, DOI 10.1007/s00701-009-0450-y
   Simon M, 2009, J NEUROSURG, V110, P685, DOI 10.3171/2008.7.JNS17639
   Skrap M, 2012, NEUROSURGERY, V70, P1081, DOI 10.1227/NEU.0b013e31823f5be5
   Srinivasan VM, 2016, J NEUROINTERV SURG, V8, P69, DOI 10.1136/neurintsurg-2014-011422
   Steno A, 2016, J NEUROSURG, V125, P1016, DOI 10.3171/2015.10.JNS151907
   Stidd DA, 2014, J NEUROSURG, V121, P745, DOI 10.3171/2014.6.JNS132386
   Tee J, 2012, ACTA NEUROCHIR, V154, P1159, DOI 10.1007/s00701-012-1363-8
   Thiex R, 2010, AM J NEURORADIOL, V31, P230, DOI 10.3174/ajnr.A1803
   Ture U, 2000, J NEUROSURG, V92, P676, DOI 10.3171/jns.2000.92.4.0676
   Ulmer S, 2006, NEUROLOGY, V67, P1668, DOI 10.1212/01.wnl.0000242894.21705.3c
   Wang DD, 2018, NEUROSURGERY, V83, P709, DOI 10.1093/neuros/nyx486
   Wang YH, 2017, J NEUROSURG, V126, P1788, DOI 10.3171/2016.5.JNS1685
   Wick W, 2006, NEUROLOGY, V67, P1540, DOI 10.1212/01.wnl.0000247252.82798.bf
   Willems PWA, 2007, J NEUROSURG, V106, P501, DOI 10.3171/jns.2007.106.3.501
   Wu AS, 2011, J NEUROSURG, V115, P1115, DOI 10.3171/2011.8.JNS11488
   YASARGIL MG, 1992, ACTA NEUROCHIR, V116, P147, DOI 10.1007/BF01540867
   Zhuang DX, 2016, WORLD NEUROSURG, V89, P84, DOI 10.1016/j.wneu.2016.01.067
NR 74
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 322
EP 330
DI 10.1016/j.wneu.2019.03.096
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400254
PM 30898738
DA 2020-05-12
ER

PT J
AU Gonzalez, A
   Saindane, AM
   Neill, SG
   Oyesiku, NM
   Ioachimescu, AG
AF Gonzalez, Adriana
   Saindane, Amit M.
   Neill, Stewart G.
   Oyesiku, Nelson M.
   Ioachimescu, Adriana G.
TI The Intriguing Case of a Double Pituitary Adenoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cushing disease; Double pituitary adenoma; Functional adenoma;
   Prolactinoma
AB BACKGROUND: When distinct pituitary hypersecretory manifestations coexist, the differential diagnosis includes plurihormonal or double pituitary adenomas. We describe a rare case of hypercortisolemia and hyperprolactinemia caused by 2 noncontiguous adenomas that required 2 surgeries.
   CASE DESCRIPTION: A 37-year-old woman presented with 6 months of weight gain, amenorrhea, joint pain, leg swelling, and skin changes. She received prednisone for possible systemic lupus erythematosus. Four months later, she presented with headaches and new-onset diabetes with glucose >1000 mg/dL. Work-up revealed a right-sided 1.1-cm pituitary adenoma and prolactin level of 152.9 ng/mL (normal: 3-27 ng/mL). She was advised to stop the prednisone, start bromocriptine, and see a pituitary specialist. Examination revealed centripetal obesity, supraclavicular and dorsocervical fat pads, violaceous wide striae, bilateral leg edema, and galactorrhea. Workup confirmed adrenocorticotrophic hormone-dependent Cushing syndrome, with a central-to-peripheral gradient on inferior petrosal sinus sampling bilaterally. Transsphenoidal adenenomectomy yielded an adenoma diffusely positive for prolactin. Postoperatively prolactin normalized, hypercortisolemia persisted, and magnetic resonance imaging findings raised suspicion for a 2-mm microadenoma. The patient underwent a second operation when an adrenocorticotrophic hormone-positive adenoma was identified. After 4 years, both hypersecretory syndromes remain in biochemical remission.
   CONCLUSIONS: A complete clinical and biochemical evaluation is necessary in patients with pituitary adenomas. Repeat surgery may be necessary for noncontiguous double adenomas.
C1 [Gonzalez, Adriana; Ioachimescu, Adriana G.] Emory Univ, Sch Med, Dept Med, Div Endocrinol, Atlanta, GA 30322 USA.
   [Saindane, Amit M.] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA USA.
   [Neill, Stewart G.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   [Oyesiku, Nelson M.; Ioachimescu, Adriana G.] Emory Univ, Sch Med, Dept Neurol Surg, Atlanta, GA 30322 USA.
RP Ioachimescu, AG (reprint author), Emory Univ, Sch Med, Dept Med, Div Endocrinol, Atlanta, GA 30322 USA.; Ioachimescu, AG (reprint author), Emory Univ, Sch Med, Dept Neurol Surg, Atlanta, GA 30322 USA.
EM aioachi@emory.edu
RI Ioachimescu, Adriana/V-8070-2019
CR Erfe JM, 2018, J NEUROSURG, V129, P629, DOI 10.3171/2017.3.JNS162245
   Iacovazzo D, 2013, ENDOCRINE, V43, P452, DOI 10.1007/s12020-013-9876-3
   KONTOGEORGOS G, 1992, NEUROSURGERY, V31, P840, DOI 10.1227/00006123-199211000-00003
   Magri F, 2010, J ENDOCRINOL INVEST, V33, P325, DOI [10.3275/6716, 10.1007/BF03346594]
   MAHLER C, 1991, PATHOL RES PRACT, V187, P598, DOI 10.1016/S0344-0338(11)80153-6
   Mete O, 2018, MODERN PATHOL, V31, P900, DOI 10.1038/s41379-018-0016-8
   Ogando-Rivas E, 2017, PITUITARY, V20, P702, DOI 10.1007/s11102-017-0826-6
   Ratliff JK, 2000, J NEUROSURG, V93, P753, DOI 10.3171/jns.2000.93.5.0753
   Roberts S, 2016, PITUITARY, V19, P472, DOI 10.1007/s11102-016-0727-0
   Saeger W, 2016, ENDOCR PATHOL, V27, P115, DOI 10.1007/s12022-016-9419-6
NR 10
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 331
EP 335
DI 10.1016/j.wneu.2019.02.242
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400255
PM 30898745
DA 2020-05-12
ER

PT J
AU Toh, K
   Suzuki, K
   Miyaoka, R
   Kitagawa, T
   Saito, T
   Nakano, Y
   Yamamoto, J
AF Toh, Keita
   Suzuki, Kohei
   Miyaoka, Ryo
   Kitagawa, Takehiro
   Saito, Takeshi
   Nakano, Yoshiteru
   Yamamoto, Junkoh
TI Giant Cerebral Aneurysm in a Patient with Cowden Syndrome Treated with
   Surgical Clipping
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cowden syndrome; Giant cerebral aneurysm; Multiple clipping; PTEN;
   Vascular anomaly
ID PTEN HAMARTOMA; ARTERIOVENOUS-MALFORMATION; DISEASE; FISTULA
AB BACKGROUND: Cowden syndrome is characterized by multiple hamartomas and accompanied by a germline mutation of the phosphatase and tensin homolog gene. Cowden syndrome has been described to be associated with vascular anomalies such as arteriovenous malformation and developmental venous anomalies with high frequency. However, the association of cerebral aneurysms with this syndrome has not been reported yet.
   CASE DESCRIPTION: A 39-year-old Japanese man presented with a subarachnoid hemorrhage due to a ruptured giant fusiform middle cerebral artery aneurysm. We diagnosed him with Cowden syndrome by clinical presentations as outlined in the National Comprehensive Cancer Network's criteria. As the ruptured fusiform aneurysm involved a middle cerebral artery bifurcation, we prepared for extracranial-intracranial bypass surgery. We successfully performed a surgical clipping using multiple tandem clipping techniques and suction decompression techniques. Bypass surgery was not performed as reconstruction of the M2 trunks was successfully completed.
   CONCLUSIONS: We present this rare case that potentially indicates an association between cerebral aneurysms and Cowden syndrome. Because vascular anomalies are not included in the diagnostic criteria for Cowden syndrome, intracranial vascular anomalies may be underestimated. We therefore recommended a careful search of vascular diseases, including cerebral aneurysms, in cases of Cowden syndrome.
C1 [Toh, Keita; Suzuki, Kohei; Miyaoka, Ryo; Kitagawa, Takehiro; Saito, Takeshi; Nakano, Yoshiteru; Yamamoto, Junkoh] Univ Occupat & Environm Hlth, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
RP Suzuki, K (reprint author), Univ Occupat & Environm Hlth, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
EM kohei@clinc.uoeh.ac.jp
OI Suzuki, Kohei/0000-0001-8343-4063; Toh, Keita/0000-0002-9618-9658
CR Akiyama Y, 2006, NEUROL MED-CHIR, V46, P446, DOI 10.2176/nmc.46.446
   Blumenthal GM, 2008, EUR J HUM GENET, V16, P1289, DOI 10.1038/ejhg.2008.162
   Busch RM, 2013, GENET MED, V15, P548, DOI 10.1038/gim.2013.1
   Deleris P, 2003, J BIOL CHEM, V278, P38884, DOI 10.1074/jbc.M300816200
   Guo D, 2018, INT J MOL MED, V42, P1637, DOI 10.3892/ijmm.2018.3706
   HANSSEN AMN, 1995, J MED GENET, V32, P117, DOI 10.1136/jmg.32.2.117
   Inukai K, 2018, BMC SURG, V18, DOI 10.1186/s12893-018-0355-x
   Jenny B, 2007, J NEUROSURG, V107, P307, DOI 10.3171/PED-07/10/307
   Kurek KC, 2012, AM J SURG PATHOL, V36, P671, DOI 10.1097/PAS.0b013e31824dd86c
   KYOSHIMA K, 1992, J NEUROSURG, V76, P880, DOI 10.3171/jns.1992.76.5.0880
   LLOYD KM, 1963, ANN INTERN MED, V58, P136, DOI 10.7326/0003-4819-58-1-136
   Lok C, 2005, MEDICINE, V84, P129, DOI 10.1097/01.md.0000158792.24888.d2
   Muthalagan E, 2014, INDIAN J PATHOL MICR, V57, P427, DOI 10.4103/0377-4929.138741
   Prats-Sanchez LA, 2016, J STROKE CEREBROVASC, V25, pE93, DOI 10.1016/j.jstrokecerebrovasdis.2016.03.048
   Sadahiro H, 2014, J STROKE CEREBROVASC, V23, P572, DOI 10.1016/j.jstrokecerebrovasdis.2013.04.021
   Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F
   Srinivasa RN, 2006, AM J NEURORADIOL, V27, P1927
   Tan WH, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.048934
   Torres AC, 2017, INTERDISCIP NEUROSUR, V10, P155, DOI 10.1016/j.inat.2017.09.007
   Turnbull MM, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.030569
   Xu F, 2018, WORLD NEUROSURG, V115, pE252, DOI 10.1016/j.wneu.2018.04.031
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 336
EP 340
DI 10.1016/j.wneu.2019.02.245
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400256
PM 30904793
DA 2020-05-12
ER

PT J
AU Romano, DG
   Frauenfelder, G
   Locatelli, G
   Panza, MP
   Siani, A
   Tartaglione, S
   Leonini, S
   Zobel, BB
   Saponiero, R
AF Romano, Daniele Giuseppe
   Frauenfelder, Giulia
   Locatelli, Gianpiero
   Panza, Maria Pia
   Siani, Alfredo
   Tartaglione, Salvatore
   Leonini, Sara
   Zobel, Bruno Beomonte
   Saponiero, Renato
TI Arterial Spin Labeling Magnetic Resonance Imaging to Diagnose
   Contrast-Induced Vasospasm After Intracranial Stent Embolization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arterial spin labeling (ASL); Cerebral blood flow (CBF);
   Contrast-induced encephalopathy (CIE); Cortical edema; Digital
   subtraction angiography (DSA); Intracranial vasospasm; Magnetic
   resonance imaging (MRI)
ID TRANSIENT CORTICAL BLINDNESS; BLOOD-BRAIN-BARRIER; COIL EMBOLIZATION;
   ENCEPHALOPATHY
AB BACKGROUND: Contrast-induced encephalopathy (CIE) is a rare and misdiagnosed complication of intravascular injection of contrast, responsible for arterial vasospasm and neurologic effects. Conventional radiologic findings are not in themselves specific for cerebral vasospasm diagnosis. We present a case in which arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) was useful in early diagnosis of CIE.
   CASE DESCRIPTION: A 56-year-old woman was admitted for elective flow-diverter embolization of a recanalized left supra-ophthalmic internal carotid artery aneurysm; at 4 hours postprocedure, she acutely developed sensitive aphasia and right arm paresis. Although no-contrast computed tomography and MRI with fluid-attenuated inversion recovery and diffusion-weighted imaging sequences did not demonstrate acute ischemic/hemorrhagic cerebral foci or cortical edema, ASL showed decreased cerebral blood flow (CBF) in the insular-temporal-parietal anterior lobe, suspected for hypoperfusion due to vasospasm, which was not confirmed by subsequent emergent digital subtraction angiography. At 16 hours, because of worsening symptoms, patient underwent an additional MRI, which showed slight insular cortical edema on fluid-attenuated inversion recovery and corresponding slight restricted diffusion-weighted imaging with a severe reduction in CBF value; at this time, emergent digital subtraction angiography demonstrated distal arterial vasospasm of left middle cerebral artery, and vasospasm therapy was started. Within 48 hours of symptom onset, the patient gradually improved to a complete neurologic recovery, with normalization of CBF values in the concerning cerebral region.
   CONCLUSIONS: CIE should always be considered in patients with focal neurologic deficits after iodinate contrast exposure. ASL perfusion MRI with CBF maps could be a promising tool for prompt, early confirmation of underlying vasospasm, as cortical edema and distal vasospasm could not be detected on conventional radiologic imaging.
C1 [Romano, Daniele Giuseppe; Locatelli, Gianpiero; Panza, Maria Pia; Siani, Alfredo; Tartaglione, Salvatore; Saponiero, Renato] AOU San Giovanni di Dio & Ruggi dAragona, Dept Neuroradiol, Salerno, Italy.
   [Frauenfelder, Giulia; Zobel, Bruno Beomonte] Policlin Univ Campus Biomed Roma, Dept Radiol, Rome, Italy.
   [Leonini, Sara] AOU Senese Policlin S Maria Scotte, Dept Neurol & Sensorineural Sci, Unit Neuroimaging & Neurointervent NINT, Siena, Italy.
RP Frauenfelder, G (reprint author), Policlin Univ Campus Biomed Roma, Dept Radiol, Rome, Italy.
EM g.frauenfelder@unicampus.it
RI Zobel, Bruno Beomonte/C-2676-2013
OI Zobel, Bruno Beomonte/0000-0001-9227-5535; Romano,
   Daniele/0000-0002-7357-7770
CR Alp BN, 2009, J INT MED RES, V37, P1246, DOI 10.1177/147323000903700433
   Cadiot D, 2018, CEPHALALGIA, V38, P949, DOI 10.1177/0333102417723570
   FISCHERWILLIAMS M, 1970, NEUROLOGY, V20, P353, DOI 10.1212/WNL.20.4.353
   Guimaraens L, 2010, CARDIOVASC INTER RAD, V33, P383, DOI 10.1007/s00270-009-9609-4
   HALEY EC, 1984, ANN NEUROL, V15, P100, DOI 10.1002/ana.410150118
   Haussen DC, 2013, J NEUROIMAGING, V23, P231, DOI 10.1111/j.1552-6569.2011.00655.x
   Kim DH, 2010, J KOREAN NEUROSURG S, V48, P524, DOI 10.3340/jkns.2010.48.6.524
   LANTOS G, 1989, NEUROLOGY, V39, P567, DOI 10.1212/WNL.39.4.567
   Lanzman Bryan, 2017, Top Magn Reson Imaging, V26, P83, DOI 10.1097/RMR.0000000000000120
   Leong S, 2012, INTERV NEURORADIOL, V18, P33, DOI 10.1177/159101991201800105
   Nagamine Y, 2014, INTERNAL MED, V53, P2133, DOI 10.2169/internalmedicine.53.2380
   Niimi Y, 2008, AM J NEURORADIOL, V29, P603, DOI 10.3174/ajnr.A0858
   Pagani-Estevez GL, 2017, NEUROCRIT CARE, V27, P261, DOI 10.1007/s12028-017-0394-7
   Torvik A, 1995, ACTA RADIOL, V36, P221, DOI 10.1177/0284185195036S39927
   Uchiyama Yusuke, 2006, Radiat Med, V24, P321, DOI 10.1007/s11604-006-0030-5
   Yu J, 2011, J ENDOVASC THER, V18, P545, DOI 10.1583/11-3476C.1
   Zwicker JC, 2002, CATHETER CARDIO INTE, V57, P47, DOI 10.1002/ccd.10246
NR 17
TC 0
Z9 0
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 341
EP 345
DI 10.1016/j.wneu.2019.03.069
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400257
PM 30885862
DA 2020-05-12
ER

PT J
AU Tyagi, G
   Prabhuraj, AR
   Bhat, DI
   Rao, MB
   Devi, BI
AF Tyagi, Gaurav
   Prabhuraj, A. R.
   Bhat, Dhananjaya, I
   Rao, Melia Bhaskara
   Devi, Bhagavatula Indira
TI Duplication of Ventral Dura as a Cause of Ventral Herniation of Spinal
   Cord-A Report of Two Cases and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brown-Sequard syndrome; Duplication of dura; Idiopathic spinal cord
   herniation; ISCH; Ventral dural defect; Ventral herniation of spinal
   cord
ID REPAIR
AB BACKGROUND: Idiopathic spinal cord herniation (ISCH) is a treatable spinal disease. It is rare and often misdiagnosed, causing a delay in management. The etiology is multifactorial, with one of the causes being duplication of the ventral dura. The spinal cord herniates within this defect and becomes strangulated, causing neurological deficits. We report the duplication of a ventral spinal cord as an important cause of ISCH in our review.
   CASE DESCRIPTION: We present 2 cases of ISCH with duplication of the dura, including their relevant clinical and imaging features. The patients underwent surgical reduction of the herniated spinal cord with enlargement of the defect and placement of a dural substitute ventral to the cord. We have also reported the outcomes of the 2 patients, with an emphasis on the factors predictive of poor outcomes (i.e., long-standing symptoms, a delay in intervention, poor neurological status at presentation, and a thinned out atrophic spinal cord found during surgery). We also reviewed the available data for duplication of the dura with ISCH.
   CONCLUSIONS: Very few asymptomatic patients can be treated conservatively. The surgical outcomes have been favorable for symptomatic patients. Proper exposure, gentle manipulation while reducing the herniated spinal cord, enlargement of the defect, and the use of intraoperative monitoring will help limit the postoperative deficits. Duplication of the ventral dura is an important cause of ISCH. It prevents the formation of an anterior pseudomeningocele after surgery. Owing to the rarity of the disease and the lack of follow-up data with recurrence rates, it has not been possible to form clear guidelines for management.
C1 [Tyagi, Gaurav; Prabhuraj, A. R.; Bhat, Dhananjaya, I; Rao, Melia Bhaskara; Devi, Bhagavatula Indira] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
RP Prabhuraj, AR (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
EM drprabhuraj@yahoo.co.in
CR Aizawa T, 2001, SPINE, V26, pE488
   Bartels RHMA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00476
   Baur A, 1997, EUR RADIOL, V7, P1259, DOI 10.1007/s003300050286
   BORGES LF, 1995, NEUROSURGERY, V36, P1028, DOI 10.1227/00006123-199505000-00023
   Brugieres P, 1999, AM J NEURORADIOL, V20, P935
   Delgado-Lopez PD, 2017, J NEUROSURG-SPINE, V26, P384, DOI 10.3171/2016.8.SPINE16318
   Dix JE, 1998, AM J NEURORADIOL, V19, P1345
   Gkekas N, 2017, BRIT J NEUROSURG, V31, P615, DOI 10.1080/02688697.2016.1199785
   Goetti R, 2013, JAMA NEUROL, V70, P125, DOI 10.1001/jamaneurol.2013.586
   Groen RJM, 2009, NEUROSURGERY, V64, pS145, DOI 10.1227/01.NEU.0000327686.99072.E7
   Herring EZ, 2018, OPER NEUROSURG HAGER, P1
   Hlubek RJ, 2019, OPER NEUROSURG, V16, P415, DOI 10.1093/ons/opy129
   Imagama S, 2009, J NEUROSURG-SPINE, V11, P310, DOI 10.3171/2009.4.SPINE08691
   Ishida M, 2008, J CLIN NEUROSCI, V15, P933, DOI 10.1016/j.jocn.2006.10.024
   Lui J, 2018, OPER NEUROSURG, V14, P252, DOI 10.1093/ons/opx108
   Maira G, 2006, J NEUROSURG-SPINE, V4, P10, DOI 10.3171/spi.2006.4.1.10
   Martinez Del Campo E, 2015, NEUROSURGERY, V77, pE492
   Matsumura T, 1996, Rinsho Shinkeigaku, V36, P566
   Miura Y, 1996, NEURORADIOLOGY, V38, P155
   Miyaguchi M, 2001, SPINE, V26, P1090, DOI 10.1097/00007632-200105010-00022
   Najjar MW, 2004, SURG NEUROL, V62, P161, DOI 10.1016/j.surneu.2003.10.030
   Nakagawa H, 2003, J SPINAL DISORD TECH, V16, P299, DOI 10.1097/00024720-200306000-00013
   Nakamura M, 2011, J ORTHOP SCI, V16, P347, DOI 10.1007/s00776-011-0065-z
   NAKAZAWA H, 1993, SPINE, V18, P2138, DOI 10.1097/00007632-199310001-00036
   Novak K, 2012, J NEUROSURG-SPINE, V16, P114, DOI 10.3171/2011.10.SPINE11109
   Oe T, 1990, Nihon Seikeigeka Gakkai Zasshi, V64, P43
   Prada F, 2012, ACTA NEUROCHIR, V154, P723, DOI 10.1007/s00701-011-1265-1
   Rajapakse D, 2016, BMJ CASE REP, V2016
   Reddy R, 2017, NEUROL INDIA, V65, P906, DOI 10.4103/neuroindia.NI_1064_16
   Saito T, 2004, J ORTHOP SCI, V9, P94, DOI 10.1007/s00776-003-0730-y
   Samuel N, 2015, J NEUROSURG-SPINE, V23, P306, DOI 10.3171/2014.12.SPINE14950
   Sasani M, 2009, J SPINAL CORD MED, V32, P86, DOI 10.1080/10790268.2009.11760757
   Shin JH, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.3.FOCUS1089
   Sugimoto T, 2005, J SPINAL DISORD TECH, V18, P106, DOI 10.1097/01.bsd.0000123427.12852.ae
   Szucs A, 2015, J NEUROL NEUROSCI, V6, P1, DOI [10.21767/2171-6625.S10012, DOI 10.21767/2171-6625.S10012]
   Tekkok IH, 2000, NEUROSURGERY, V46, P485, DOI 10.1097/00006123-200002000-00044
   TRONNIER VM, 1991, NEUROSURGERY, V29, P916, DOI 10.1227/00006123-199112000-00021
   Vallee B, 1999, ACTA NEUROCHIR, V141, P907, DOI 10.1007/s007010050396
   Verny C, 1999, NEUROCHIRURGIE, V45, P225
   Wada E, 2000, SPINE, V25, P1984, DOI 10.1097/00007632-200008010-00019
   Watanabe M, 2001, J NEUROSURG, V95, P169, DOI 10.3171/spi.2001.95.2.0169
   WORTZMAN G, 1974, J NEUROSURG, V41, P631, DOI 10.3171/jns.1974.41.5.0631
   Yamamoto N, 2014, INT J SPINE SURG, V8, DOI 10.14444/1029
NR 43
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 346
EP 353
DI 10.1016/j.wneu.2019.02.143
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400258
PM 30851464
DA 2020-05-12
ER

PT J
AU Karadag, A
   Senoglu, M
   Sayhan, S
   Okromelidze, L
   Middlebrooks, EH
AF Karadag, Ali
   Senoglu, Mehmet
   Sayhan, Sevil
   Okromelidze, Lela
   Middlebrooks, Erik H.
TI Klippel-Trenaunay-Weber Syndrome with Atypical Presentation of Cerebral
   Cavernous Angioma: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cavernous angioma; Genetics; Intracranial; Klippel-Trenaunay-Weber;
   RASA1
ID MALFORMATIONS; MANAGEMENT; CAPILLARY; RASA1
AB BACKGROUND: Klippel-Trenaunay-Weber syndrome (KTWS) is a rare syndrome characterized by the triad of cutaneous hemangiomas, venous varicosities, and osseous-soft tissue hypertrophy of the affected limb. Clinical manifestations, genetic testing, and radiologic imaging are the key steps in diagnosing this syndrome.
   CASE DESCRIPTION: An 18-month-old boy was brought for follow-up brain magnetic resonance imaging (MRI) with a history of right lower limb hypertrophy, cutaneous varicosities, and hemangiomas diagnosed at birth. A baseline MRI at 12 months revealed multiple hemorrhagic lesions within the cerebrum, the largest in the right temporal lobe, which was treated surgically at the age of 18 months because of its rapid growth. This is the youngest patient with KTWS treated surgically for intracranial hemangiomas.
   CONCLUSION: KTWS is a rare disease with a wide range of manifestations. Multisystemic evaluation of this group of patients should be performed to identify cavernous hemangiomas at the early stage of life and adequately treat them in the future. Treatment of KTWS patients with cavernous hemangiomas should not be different from the treatment of patients with any other hemangiomas, and surgical intervention should be considered on a case-to-case bases.
C1 [Karadag, Ali] Menemen State Hosp, Dept Neurosurg, Izmir, Turkey.
   [Senoglu, Mehmet] Hlth Sci Univ, Tepecik Res & Training Hosp, Dept Neurosurg, Izmir, Turkey.
   [Sayhan, Sevil] Hlth Sci Univ, Tepecik Res & Training Hosp, Dept Pathol, Izmir, Turkey.
   [Okromelidze, Lela; Middlebrooks, Erik H.] Mayo Clin, Dept Radiol, Jacksonville, FL 32224 USA.
   [Middlebrooks, Erik H.] Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
RP Senoglu, M (reprint author), Hlth Sci Univ, Tepecik Res & Training Hosp, Dept Neurosurg, Izmir, Turkey.
EM mehmetsenoglu@hotmail.com
OI Middlebrooks, Erik/0000-0002-4418-9605
CR AELVOET GE, 1992, BRIT J DERMATOL, V126, P603
   Alwalid O, 2018, CURR MED SCI, V38, P925, DOI 10.1007/s11596-018-1964-4
   BASKERVILLE PA, 1985, ANN SURG, V202, P624, DOI 10.1097/00000658-198511000-00015
   BASKERVILLE PA, 1985, BRIT J SURG, V72, P232, DOI 10.1002/bjs.1800720331
   Boon LM, 2005, CURR OPIN GENET DEV, V15, P265, DOI 10.1016/j.gde.2005.03.004
   Boutarbouch M, 2010, J CLIN NEUROSCI, V17, P1073, DOI 10.1016/j.jocn.2009.11.013
   Cakiroglu Y, 2013, CASE REP OBSTET GYNE, V2013, P595476
   CeballosQuintal JM, 1996, AM J MED GENET, V63, P426, DOI 10.1002/(SICI)1096-8628(19960614)63:3<426::AID-AJMG2>3.0.CO;2-P
   Gloviczki P, 2007, PHLEBOLOGY, V22, P291, DOI 10.1258/026835507782655209
   Goksu E, 2012, NEUROL NEUROCHIR POL, V46, P496, DOI 10.5114/ninp.2012.31362
   Gunel M, 2002, P NATL ACAD SCI USA, V99, P10677, DOI 10.1073/pnas.122354499
   Hershkovitz D, 2008, ARCH DERMATOL RES, V300, P385, DOI 10.1007/s00403-008-0842-5
   HOWLETT DC, 1994, EUR J RADIOL, V18, P224, DOI 10.1016/0720-048X(94)90340-9
   Jacob AG, 1998, MAYO CLIN PROC, V73, P28
   Kentab Amal Y, 2016, Sudan J Paediatr, V16, P86
   Luks VL, 2015, J PEDIATR-US, V166, P1048, DOI 10.1016/j.jpeds.2014.12.069
   Oda K, 2018, WORLD NEUROSURG, V109, P333, DOI 10.1016/j.wneu.2017.10.040
   Renard D, 2013, JAMA NEUROL, V70, P127, DOI 10.1001/jamaneurol.2013.587
   Ricks CB, 2014, BMJ CASE REP, V2014
   Sreekar H, 2013, J PLAST SURG HAND SU, V47, P303, DOI 10.3109/2000656X.2013.766201
   Sudmeyer M, 2011, J NEUROL, V258, P140, DOI 10.1007/s00415-010-5675-4
   Sung HM, 2015, ARCH PLAST SURG-APS, V42, P552, DOI 10.5999/aps.2015.42.5.552
   Torregrosa A, 2000, NEURORADIOLOGY, V42, P420, DOI 10.1007/s002340000310
   Wang SK, 2017, J VASC SURG-VENOUS L, V5, P587, DOI 10.1016/j.jvsv.2016.10.084
   Yoshinaga T, 2018, ACTA NEUROCHIR, V160, P287, DOI 10.1007/s00701-017-3408-5
   Zhai JL, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-018-2393-z
NR 26
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 354
EP 358
DI 10.1016/j.wneu.2019.03.132
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400259
PM 30905648
DA 2020-05-12
ER

PT J
AU Rubio, RR
   Shehata, J
   Kournoutas, I
   Chae, R
   Vigo, V
   Wang, MH
   El-Sayed, I
   Abla, AA
AF Rubio, Roberto Rodriguez
   Shehata, Joseph
   Kournoutas, Ioannis
   Chae, Ricky
   Vigo, Vera
   Wang, Minghao
   El-Sayed, Ivan
   Abla, Adib A.
TI Construction of Neuroanatomical Volumetric Models Using 3-Dimensional
   Scanning Techniques: Technical Note and Applications
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D animation; 3D scanning; Extended reality; Photogrammetry; Structured
   light scanning; Surgical neuroanatomy
ID COMPUTER-GRAPHICS; VIRTUAL-REALITY; LEARNING TOOL; ANATOMY; EDUCATION;
   VISUALIZATION; SIMULATION; IMAGES; BRAIN
AB BACKGROUND: Visuospatial features of neuroanatomy are likely the most difficult concepts to learn in anatomy. Three-dimensional (3D) modalities have gradually begun to supplement traditional 2-dimensionanl representations of dissections and illustrations. We have introduced and described the workflow of 2 innovative methods-photogrammetry (PGM) and structured light scanning (SLS)which have typically been used for reverse-engineering applications. In the present study, we have described a novel application of SLS and PGM that could enhance medical education and operative planning in neurosurgery.
   METHODS: We have described the workflow of SLS and PGM for creating volumetric models (VMs) of neuroanatomical dissections, including the requisite equipment and software. We have also provided step-by-step procedures on how users can postprocess and refine these images according to their specifications. Finally, we applied both methods to 3 dissected hemispheres to demonstrate the quality of the VMs and their applications.
   RESULTS: Both methods yielded VMs with suitable clarity and structural integrity for anatomical education, surgical illustration, and procedural simulation.
   CONCLUSIONS: The application of 3D computer graphics to neurosurgical applications has shown great promise. SLS and PGM can facilitate the construction of VMs with high accuracy and quality that can be used and shared in a variety of 3D platforms. Similarly, the technical demands are not high; thus, it is plausible that neurosurgeons could become quickly proficient and enlist their use in education and surgical planning. Although SLS is preferable in settings in which high accuracy is required, PGM is a viable alternative with a short learning curve.
C1 [Rubio, Roberto Rodriguez; Shehata, Joseph; Kournoutas, Ioannis; Chae, Ricky; Vigo, Vera; Wang, Minghao; Abla, Adib A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez; Shehata, Joseph; Kournoutas, Ioannis; Chae, Ricky; Vigo, Vera; Wang, Minghao; El-Sayed, Ivan; Abla, Adib A.] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez; El-Sayed, Ivan] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
   [Wang, Minghao] China Med Univ, Hosp 1, Dept Neurol Surg, Shenyang, Liaoning, Peoples R China.
RP Rubio, RR (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
EM luis.rodriguezrubio@ucsf.edu
OI Wang, Minghao/0000-0003-1705-0891; Chae, Ricky/0000-0001-5014-9303;
   Rodriguez-Rubio, Roberto/0000-0002-7206-309X
CR Adams JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139800
   Aso-Escario J, 2011, REV NEUROLOGIA, V53, P494, DOI 10.33588/rn.5308.2009075
   Barbero-Garcia I, 2017, WORLD NEUROSURG, V102, P545, DOI 10.1016/j.wneu.2017.03.015
   Bareither ML, 2013, ANAT SCI EDUC, V6, P170, DOI 10.1002/ase.1321
   Bell T, 2016, STRUCTURED LIGHT TEC, P1
   Berney S, 2015, ANAT SCI EDUC, V8, P452, DOI 10.1002/ase.1524
   Daneshmand M, 3D SCANNING COMPREHE
   Das AJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179264
   De Benedictis A, 2018, WORLD NEUROSURG, V115, pE279, DOI 10.1016/j.wneu.2018.04.036
   Donnelly L, 2009, MED TEACH, V31, P553, DOI 10.1080/01421590802512953
   Dorsey J., 1998, Computer Graphics, V32, P45
   El-Gamal FEA, 2016, EGYPT INFORM J, V17, P99, DOI 10.1016/j.eij.2015.09.002
   Estevez ME, 2010, ANAT SCI EDUC, V3, P309, DOI 10.1002/ase.186
   FRASER CS, 1993, ISPRS J PHOTOGRAMM, V48, P12, DOI 10.1016/0924-2716(93)90060-Z
   Hayes A, 2016, J BIOMECH, V49, P3753, DOI 10.1016/j.jbiomech.2016.09.042
   Hu A, 2010, J OTOLARYNGOL-HEAD N, V39, P315, DOI 10.2310/7070.2010.090074
   Javaid MA, 2018, ANAT SCI EDUC, V11, P81, DOI 10.1002/ase.1711
   Keedy AW, 2011, ANAT SCI EDUC, V4, P84, DOI 10.1002/ase.212
   Khot Z, 2013, ANAT SCI EDUC, V6, P211, DOI 10.1002/ase.1355
   Kirkman MA, 2014, J NEUROSURG, V121, P228, DOI 10.3171/2014.5.JNS131766
   Klingler J, 1935, SCHWEIZ ARCH NEUROL, V36, P247
   Kus A, 2009, SENSORS-BASEL, V9, P1967, DOI 10.3390/s90301967
   Levinson AJ, 2007, MED EDUC, V41, P495, DOI 10.1111/j.1365-2929.2006.02694.x
   Levoy M., 1987, DISPLAY SURFACES VOL
   Lisk K, 2015, ANAT SCI EDUC, V8, P140, DOI 10.1002/ase.1459
   Locketz GD, 2017, OTOLARYNG HEAD NECK, V156, P1142, DOI 10.1177/0194599817691474
   Machover C, 1998, IEEE COMPUT GRAPH, V18, P22, DOI 10.1109/MCG.1998.637265
   Maggio MP, 2012, J DENT EDUC, V76, P1497
   McIntire JP, 2014, DISPLAYS, V35, P18, DOI 10.1016/j.displa.2013.10.004
   Metzler R, 2012, TEACH LEARN MED, V24, P140, DOI 10.1080/10401334.2012.664963
   Nguyen N, 2014, ANAT SCI EDUC, V7, P280, DOI 10.1002/ase.1415
   Rios L, 2017, SPINE J, V17, P1523, DOI 10.1016/j.spinee.2017.05.012
   Rist F, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18030763
   Roach VA, 2012, ANAT SCI EDUC, V5, P138, DOI 10.1002/ase.1262
   Ruisoto P, 2012, ANAT SCI EDUC, V5, P132, DOI 10.1002/ase.1275
   Sturm P, 2010, FOUND TRENDS COMPUT, V6, P1, DOI 10.1561/0600000023
   Valenca J, 2012, EXP TECHNIQUES, V36, P71, DOI 10.1111/j.1747-1567.2011.00731.x
   Vidal FP, 2006, COMPUT GRAPH FORUM, V25, P113, DOI 10.1111/j.1467-8659.2006.00822.x
   Wu B, 2010, J EXP PSYCHOL-APPL, V16, P45, DOI 10.1037/a0018373
   Zhang Q, 2011, J DIGIT IMAGING, V24, P640, DOI 10.1007/s10278-010-9321-6
NR 40
TC 4
Z9 5
U1 4
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 359
EP 368
DI 10.1016/j.wneu.2019.03.099
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400260
PM 30898733
DA 2020-05-12
ER

PT J
AU Baran, O
   Kasimcan, O
   Sav, A
   Oruckaptan, H
AF Baran, Oguz
   Kasimcan, Omur
   Sav, Aydin
   Oruckaptan, Hakan
TI Holocord Pilocytic Astrocytoma in an Adult: A Rare Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Astrocytoma; Cord; Holocord; Pilocytic; Spinal
ID LOW-GRADE ASTROCYTOMA; SURGICAL-MANAGEMENT; CHILDREN; TUMORS
AB BACKGROUND: Intramedullary glial neoplasms affecting the entire spinal cord from the cervicomedullary junction to conus medullaris are termed holocord tumors. Pilocytic astrocytomas are relatively uncommon tumors forming holocord involvement. Hitherto 24 holocord astrocytoma cases were reported in the literature. Here, a case of an adult holocord pilocytic astrocytoma was presented.
   CASE DESCRIPTION: A 29-year-old female patient presented with a subtotal resection. Histopathologic examination revealed pilocytic astrocytoma, World Health Organization grade 1, presenting holocord involvement. Magnetic resonance imaging showed a mass containing necrotic and cystic foci leading to an expansion along the entire spinal cord extending from C4 to conus medullaris.
   CONCLUSIONS: Reported holocord pilocytic astrocytomas in the relevant literature cases were reviewed. When evaluating magnetic resonance imaging scans of adult patients with various neurologic symptoms, i.e., weakness and fecal and urinary incontinence, pilocytic astrocytoma should be considered among differential diagnoses of intramedullary mass lesions.
C1 [Baran, Oguz] Haseki Res & Training Hosp, Neurosurg Clin, Istanbul, Turkey.
   [Kasimcan, Omur] Istinye Univ, Neurosurg Clin, Istanbul, Turkey.
   [Sav, Aydin] Yeditepe Univ, Med Sch, Dept Pathol, Istanbul, Turkey.
   [Oruckaptan, Hakan] Mem Hosp, Neurosurg Clin, Ankara, Turkey.
RP Baran, O (reprint author), Haseki Res & Training Hosp, Neurosurg Clin, Istanbul, Turkey.
EM oguzbaran@gmail.com
RI BARAN, Oguz/AAG-3278-2019
OI sav, aydin/0000-0002-7326-7801
CR Bansal Sumit, 2017, Asian J Neurosurg, V12, P217, DOI 10.4103/1793-5482.144174
   BENZEL EC, 1987, SPINE, V12, P746, DOI 10.1097/00007632-198710000-00006
   Bond KM, 2018, WORLD NEUROSURG, V110, P276, DOI 10.1016/j.wneu.2017.11.102
   Chacko AG, 2000, CLIN NEUROL NEUROSUR, V102, P240, DOI 10.1016/S0303-8467(00)00100-1
   Collins VP, 2015, ACTA NEUROPATHOL, V129, P775, DOI 10.1007/s00401-015-1410-7
   Ebner FH, 2012, PEDIATR NEUROSURG, V48, P133, DOI 10.1159/000345593
   EPSTEIN F, 1981, J NEUROSURG, V54, P829, DOI 10.3171/jns.1981.54.6.0829
   Eroes CA, 2010, ACTA NEUROCHIR, V152, P611, DOI 10.1007/s00701-009-0577-x
   Goyal S, 2015, J EGYPT NATL CANCER, V27, P105, DOI 10.1016/j.jnci.2015.01.001
   IRIKURA T, 1990, Neurologia Medico-Chirurgica, V30, P966, DOI 10.2176/nmc.30.966
   Komotar RJ, 2005, NEUROSURGERY, V56, P206
   Lau B H, 1998, Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi, V39, P48
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   MINEHAN KJ, 1995, J NEUROSURG, V83, P590, DOI 10.3171/jns.1995.83.4.0590
   NIKAIDO Y, 1984, Neurological Surgery, V12, P523
   Samartzis D, 2015, GLOB SPINE J, V5, P425, DOI 10.1055/s-0035-1549029
   Sandalcioglu Ibrahim Erol, 2002, Eur J Paediatr Neurol, V6, P179, DOI 10.1053/ejpn.2002.0587
   Schittenhelm J, 2009, CLIN NEUROL NEUROSUR, V111, P203, DOI 10.1016/j.clineuro.2008.09.014
   SHAFRIR Y, 1992, J PEDIATR-US, V120, P266, DOI 10.1016/S0022-3476(05)80440-8
   She DJ, 2019, BMC MED IMAGING, V19, DOI 10.1186/s12880-018-0296-y
   TEDESCHI G, 1982, NEUROCHIRURGIA, V25, P27
   Tobias ME, 2008, CHILD NERV SYST, V24, P219, DOI 10.1007/s00381-007-0405-7
   VLES JSH, 1990, CLIN NEUROL NEUROSUR, V92, P361, DOI 10.1016/0303-8467(90)90066-E
   Zhao YD, 2015, EXP THER MED, V10, P2221, DOI 10.3892/etm.2015.2828
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 369
EP 375
DI 10.1016/j.wneu.2019.03.103
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400261
PM 30902768
DA 2020-05-12
ER

PT J
AU Martini, ML
   Mocco, J
   Panov, F
AF Martini, Michael L.
   Mocco, J.
   Panov, Fedor
TI Neurosurgical Approaches to Levodopa-Induced Dyskinesia
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adaptive deep brain stimulation; Cerebellar stimulation;
   Levodopa-induced dyskinesia; Motor cortex stimulation; Parkinson
   disease; Transcranial magnetic stimulation; Ultrasound ablation
ID DEEP-BRAIN-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; MOTOR CORTEX
   STIMULATION; ADVANCED PARKINSONS-DISEASE; SUBTHALAMIC NUCLEUS
   STIMULATION; GUIDED FOCUSED ULTRASOUND; THETA-BURST STIMULATION;
   POSTEROVENTRAL PALLIDOTOMY; PALLIDAL STIMULATION; CORTICAL STIMULATION
AB Levodopa has long been the standard of care for Parkinson disease (PD); however, the eventual onset of motor fluctuations and levodopa-induced dyskinesia (LID) complicates its utility in advanced PD. Current neurosurgical interventions remain some of the best options for LID. Deep brain stimulation (DBS) is currently the procedure of choice for patients with advanced PD, patients refractory to medical management, and patients with motor complications from levodopa therapy.
   Significant progress has been achieved in recent years, however, as newer techniques are making their way through preclinical and clinical studies. Use of interventional magnetic resonance imaging (iMRI) and a skull-mounted aiming device to guide electrode placement has improved accuracy in recent DBS studies. Adaptive "closed-loop" DBS represents another exciting advancement in the field, in which real-time feedback allows dynamic modulation of the stimulation delivered to the basal ganglia. Magnetic resonance-guided focused ultrasound (MRgFUS) is a novel approach to creating precise lesioning in the brain that has shown promising results in preliminary studies for various movement disorders, including dyskinesias, and may transform the neuroablation field. Transcranial magnetic stimulation, which can induce local and distant effects in cortical and subcortical areas, has shown efficacy in managing certain PD and LID symptoms in early studies. Finally, direct stimulation of the motor cortex and the cerebellum has shown therapeutic effects in PD and LID patients in certain studies. Taken together, many of these new techniques have shown great promise in early studies and may eventually be preferred treatment options for LID patients.
C1 [Martini, Michael L.; Mocco, J.; Panov, Fedor] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
RP Panov, F (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM fedor.panov@mountsinai.org
OI Martini, Michael/0000-0001-8169-7679
CR Ahlskog JE, 2001, MOVEMENT DISORD, V16, P448, DOI 10.1002/mds.1090
   Almeida L, 2017, SEMIN NEUROL, V37, P205, DOI 10.1055/s-0037-1601893
   Aviles-Olmos I, 2014, J NEUROL NEUROSUR PS, V85, P1419, DOI 10.1136/jnnp-2013-306907
   Azmi Hooman, 2016, Surg Neurol Int, V7, pS557, DOI 10.4103/2152-7806.187537
   BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344
   Benninger DH, 2012, NEUROREHAB NEURAL RE, V26, P1096, DOI 10.1177/1545968312445636
   Bezard E, 1999, NEUROSURGERY, V45, P346, DOI 10.1097/00006123-199908000-00030
   Bonenfant J, 2017, PARKINSONISM RELAT D, V34, P20, DOI 10.1016/j.parkreldis.2016.10.007
   Brusa L, 2012, PARKINSONISM RELAT D, V18, P59, DOI 10.1016/j.parkreldis.2011.08.019
   Burchiel KJ, 2013, J NEUROSURG, V119, P301, DOI 10.3171/2013.4.JNS122324
   Canavero S, 2002, J NEUROSURG, V97, P1208, DOI 10.3171/jns.2002.97.5.1208
   Canavero S, 2003, NEUROL RES, V25, P118, DOI 10.1179/016164103101201238
   CANAVERO S, MOV DISORD, V15, P169
   Castrioto A, 2011, ARCH NEUROL-CHICAGO, V68, P1550, DOI 10.1001/archneurol.2011.182
   Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398
   Chung CL, 2016, BRAIN STIMUL, V9, P475, DOI 10.1016/j.brs.2016.03.017
   Cilia R, 2007, MOVEMENT DISORD, V22, P111, DOI 10.1002/mds.21207
   Deeb W, 2016, FRONT INTEGR NEUROSC, V10, DOI 10.3389/fnint.2016.00038
   Delavallee M, 2008, NEUROSURGERY, V63, P101, DOI 10.1227/01.NEU.0000319636.21535.63
   deSouza RM, 2013, ANN NEUROL, V73, P565, DOI 10.1002/ana.23890
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Deuschl G, 2013, PARKINSONISM RELAT D, V19, P56, DOI 10.1016/j.parkreldis.2012.07.004
   Drouot' X, 2004, NEURON, V44, P769, DOI 10.1016/j.neuron.2004.11.023
   Elahi B, 2009, MOVEMENT DISORD, V24, P357, DOI 10.1002/mds.22364
   Elgebaly A, 2018, CNS SPECTRUMS, V23, P10, DOI 10.1017/S1092852917000062
   Esselink RAJ, 2004, NEUROLOGY, V62, P201, DOI 10.1212/01.WNL.0000103235.12621.C3
   Fasano A, 2012, LANCET NEUROL, V11, P429, DOI 10.1016/S1474-4422(12)70049-2
   Filipovic SR, 2009, MOVEMENT DISORD, V24, P246, DOI 10.1002/mds.22348
   FINE J, N ENGL J MED, V342, P1708
   Follett KA, 2010, NEW ENGL J MED, V362, P2077, DOI 10.1056/NEJMoa0907083
   Franca C, 2018, BRAIN STIMUL, V11, P249, DOI 10.1016/j.brs.2017.11.015
   Frizon LA, 2018, NEUROMODULATION, V21, P588, DOI 10.1111/ner.12744
   Gonzalez-Garcia N, 2011, J NEUROL, V258, P1268, DOI 10.1007/s00415-011-5923-2
   Hallett M, 1999, NEUROLOGY, V53, P1910, DOI 10.1212/WNL.53.9.1910
   Hariz MI, 2001, J NEUROSURG, V94, P552, DOI 10.3171/jns.2001.94.4.0552
   Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033
   Kim JY, 2008, MOVEMENT DISORD, V23, P207, DOI 10.1002/mds.21787
   Koch G, 2009, NEUROLOGY, V73, P113, DOI 10.1212/WNL.0b013e3181ad5387
   Kopell BH, 2006, MOVEMENT DISORD, V21, pS238, DOI 10.1002/mds.20958
   Krack P, 1999, BRAIN, V122, P1133, DOI 10.1093/brain/122.6.1133
   Krishnan S, 2016, NEUROL INDIA, V64, P81, DOI 10.4103/0028-3886.173663
   Lai EC, 2000, NEUROLOGY, V55, P1218, DOI 10.1212/WNL.55.8.1218
   LANG AE, ANN NEUROL, V47, pS19
   Lefaucheur JP, 2009, EXPERT REV NEUROTHER, V9, P1755, DOI [10.1586/ern.09.132, 10.1586/ERN.09.132]
   Magara A, 2014, J THER ULTRASOUND, V2, DOI 10.1186/2050-5736-2-11
   Manola L, 2005, MED BIOL ENG COMPUT, V43, P335, DOI 10.1007/BF02345810
   Manola L, 2007, CLIN NEUROPHYSIOL, V118, P464, DOI 10.1016/j.clinph.2006.09.012
   Matias CM, 2018, J NEUROSURG, V129, P1572, DOI 10.3171/2017.7.JNS171166
   Molina R, 2018, J NEUROSURG, V129, P308, DOI 10.3171/2017.6.JNS17626
   Moro E, 2010, MOVEMENT DISORD, V25, P578, DOI 10.1002/mds.22735
   Munhoz RP, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00065
   Na YC, 2015, NEUROLOGY, V85, P549, DOI 10.1212/WNL.0000000000001826
   Nakajima T, 2011, STEREOT FUNCT NEUROS, V89, P318, DOI 10.1159/000330379
   Nazzaro Jules M, 2013, Handb Clin Neurol, V116, P155, DOI 10.1016/B978-0-444-53497-2.00013-9
   Nimura T, 2004, J NEUROSURG, V100, P606, DOI 10.3171/jns.2004.100.4.0606
   Odekerken VJJ, 2016, NEUROLOGY, V86, P755, DOI 10.1212/WNL.0000000000002401
   Odekerken VJJ, 2013, LANCET NEUROL, V12, P37, DOI 10.1016/S1474-4422(12)70264-8
   Olanow CW, 2001, NEUROLOGY, V56, pS1, DOI 10.1212/WNL.56.suppl_5.S1
   Ostrem JL, 2016, J NEUROSURG, V124, P908, DOI 10.3171/2015.4.JNS15173
   Ostrem JL, 2013, CLIN NEUROL NEUROSUR, V115, P708, DOI 10.1016/j.clineuro.2012.08.019
   Oyama G, 2012, PARKINSONISM RELAT D, V18, P814, DOI 10.1016/j.parkreldis.2012.03.022
   Pagni CA, 2008, ACTA NEUROCHIR SUPPL, V101, P13
   Pagni CA, 2005, NEUROSURGERY, V57, DOI 10.1227/01.NEU.0000176857.66627.01
   PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847
   Rao Jayaraman, 2007, Curr Treat Options Neurol, V9, P205, DOI 10.1007/BF02938410
   Rascol O, 1998, BRAIN, V121, P527, DOI 10.1093/brain/121.3.527
   Saitoh Y, 2003, ACTA NEUROCHIR SUPPL, V87, P149
   Samuel M, 1998, BRAIN, V121, P59, DOI 10.1093/brain/121.1.59
   Schlesinger I, 2015, PARKINSONS DIS-US, V2015, DOI 10.1155/2015/219149
   Schuepbach WMM, 2013, NEW ENGL J MED, V368, P610, DOI 10.1056/NEJMoa1205158
   Shute J, 2016, NEUROLOGY, V86
   Starr PA, 2010, J NEUROSURG, V112, P479, DOI 10.3171/2009.6.JNS081161
   Strafella AP, 2006, NEUROIMAGE, V31, P1666, DOI 10.1016/j.neuroimage.2006.02.005
   Strafella AP, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-15-j0003.2001
   Swann NC, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aabc9b
   Swann NC, 2016, J NEUROSCI, V36, P6445, DOI 10.1523/JNEUROSCI.1128-16.2016
   Tan ZG, 2016, CLIN INTERV AGING, V11, P777, DOI 10.2147/CIA.S105505
   Tanner CM, 2013, NEW ENGL J MED, V368, P675, DOI 10.1056/NEJMe1214913
   Vitek JL, 2003, ANN NEUROL, V53, P558, DOI 10.1002/ana.10517
   Volkmann J, 2004, ANN NEUROL, V55, P871, DOI 10.1002/ana.20091
   Wagle-Shukla A, 2007, NEUROLOGY, V68, P704, DOI 10.1212/01.wnl.0000256036.20927.a5
   Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929
   Xie CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep25285
   Zaaroor M, 2018, J NEUROSURG, V128, P202, DOI 10.3171/2016.10.JNS16758
   Zibetti M, 2011, MOVEMENT DISORD, V26, P2327, DOI 10.1002/mds.23903
NR 85
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 376
EP 382
DI 10.1016/j.wneu.2019.03.056
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400262
PM 30880213
DA 2020-05-12
ER

PT J
AU Nozawa, S
   Nakano, A
   Fujiwara, K
   Nakaya, Y
   Fukumoto, S
   Fujishiro, T
   Kino, K
   Baba, I
   Akiyama, H
   Neo, M
AF Nozawa, Satoshi
   Nakano, Atsushi
   Fujiwara, Kenta
   Nakaya, Yoshiharu
   Fukumoto, Shingo
   Fujishiro, Takashi
   Kino, Keiichiro
   Baba, Ichiro
   Akiyama, Haruhiko
   Neo, Masashi
TI Interbody Bone Graft via Transdiskal Screw Holes as Treatment for
   High-Grade Spondylolisthesis
SO WORLD NEUROSURGERY
LA English
DT Article
DE High-grade spondylolisthesis; Transdiskal screw; Transpedicular bone
   graft
ID LUMBOSACRAL SPINE; FUSION
AB BACKGROUND: Controversy exists regarding surgical treatment of high-grade spondylolisthesis (HGS) in terms of decompression with surgical reduction or in situ fusion. In situ fusion has the advantage of being less technically demanding. However, the residual bone graft area is extremely limited, and posterolateral bone grafting is complex as the transverse process of the slipped vertebrae is located anterior to the sacral ala, which correlates with high rates of pseudoarthrosis.
   METHODS: Four cases of L5/S1 HGS complaining of low back pain were treated using our new bone graft technique with an exposed osseous end plate. Transdiskal screw holes were made from the S1 pedicle, and bone chips were packed into the L5/S disk space through the screw holes. The slipped L5 vertebra was fixed with a combination of L5/S1 transdiskal and L5 pedicle screws.
   RESULTS: All cases exhibited good bony fusion, and the low back pain disappeared in all patients up to the 12-month follow-up. This technique involved packing the bone into the closed space, relieving any concerns regarding bone graft migration.
   CONCLUSIONS: Transpedicular bone graft via transdiskal screw holes is an easy and practical technique for raising the fusion rate in surgical treatment of HGS.
C1 [Nozawa, Satoshi; Akiyama, Haruhiko] Gifu Univ, Dept Orthopaed Surg, Gifu, Japan.
   [Nakano, Atsushi; Fujiwara, Kenta; Nakaya, Yoshiharu; Fukumoto, Shingo; Fujishiro, Takashi; Kino, Keiichiro; Baba, Ichiro; Neo, Masashi] Osaka Med Coll, Dept Orthopaed Surg, Osaka, Japan.
RP Nozawa, S (reprint author), Gifu Univ, Dept Orthopaed Surg, Gifu, Japan.
EM noza618@yahoo.co.jp
OI Neo, Masashi/0000-0001-9208-6419; Nozawa, Satoshi/0000-0001-7293-023X
CR ABDU WA, 1994, SPINE, V19, P710, DOI 10.1097/00007632-199403001-00011
   BOHLMAN HH, 1982, J BONE JOINT SURG AM, V64, P415, DOI 10.2106/00004623-198264030-00012
   BOXALL D, 1979, J BONE JOINT SURG AM, V61, P479, DOI 10.2106/00004623-197961040-00001
   BRADFORD DS, 1987, J BONE JOINT SURG AM, V69A, P191, DOI 10.2106/00004623-198769020-00005
   Driscoll C, 2011, EUR SPINE J, V20, P1711, DOI [10.1007/s00586-011-1801-y, 10.1007/s00586-011-1932-1]
   Goel A, 2007, SURG NEUROL, V67, P135, DOI 10.1016/j.surneu.2006.05.059
   Grob D, 1996, Eur Spine J, V5, P281, DOI 10.1007/BF00301335
   Gum JL, 2018, SPINE DEFORM, V6, P84
   Hire JM, 2015, J NEUROSURG-SPINE, V22, P80, DOI 10.3171/2014.10.SPINE14138
   Hresko MT, 2007, SPINE, V32, P2208, DOI 10.1097/BRS.0b013e31814b2cee
   Minamide T, 2003, J SPINAL DISORD TECH, V16, P144, DOI 10.1097/00024720-200304000-00005
   Nakamae T, 2013, EUR J ORTHOP SURG TR, V23, P121
   PANJABI MM, 1994, J BONE JOINT SURG AM, V76A, P413, DOI 10.2106/00004623-199403000-00012
   Poussa M, 2006, SPINE, V31, P583, DOI 10.1097/01.brs.0000201401.17944.f7
   Suzuki H, 2018, SPINE SURG RELAT RES, V2, P290, DOI 10.22603/ssrr.2017-0074
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 383
EP 388
DI 10.1016/j.wneu.2019.02.201
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400263
PM 30876991
DA 2020-05-12
ER

PT J
AU Sherafatian, M
   Abdollahpour, HR
   Ghaffarpasand, F
   Yaghmaei, S
   Azadegan, M
   Heidari, M
AF Sherafatian, Masih
   Abdollahpour, Hamid Reza
   Ghaffarpasand, Fariborz
   Yaghmaei, Shekoofeh
   Azadegan, Maryam
   Heidari, Mojdeh
TI MicroRNA Expression Profiles, Target Genes, and Pathways in
   Intervertebral Disk Degeneration: A Meta-Analysis of 3 Microarray
   Studies
SO WORLD NEUROSURGERY
LA English
DT Review
DE Expression; Intervertebral disk degeneration; Meta-analysis; MicroRNA;
   Pathway; Target gene
ID LOW-BACK-PAIN; GLOBAL BURDEN; APOPTOSIS; PROLIFERATION; COLLAGEN;
   HOMOLOG; MIR-155; DISEASE; MATRIX; CELLS
AB BACKGROUND: Determining the expression profile and target genes of microRNA (miRNA) would assist in determining the pathophysiologic pathways in intervertebral disk degeneration (IDD). The aim of this study was to determine the expression profile of miRNA in degenerated intervertebral disks compared with normal healthy intervertebral disks.
   METHODS: We conducted a meta-analysis of 3 available miRNA expression datasets to identify a panel of co-deregulated miRNA genes and overlapping biological processes in IDD. Degenerated intervertebral disks were compared with normal healthy disks. We selected 35 miRNA features common to all 3 platforms. Then, we calculated differential expression P values from our unpaired data using metaMA package in R statistical software according to the moderated t test method (Limma). Based on the P values (where the threshold was <0.05), a list of differentially expressed miRNAs was identified.
   RESULTS: After normalization and selection of common miRNA features across all 3 platforms, we found a total of 5 differentially expressed miRNAs, among which miR-574-3p, miR-199a-5p, and miR-483-5p were not identified in any individual studies. Our results revealed that miR-199a-5p, miR-574-3p, miR-551a, and miR-640 are commonly upregulated in IDDs compared with control disks, whereas miR-483 is commonly downregulated. Pathway analysis of identified dysregulated miRNAs indicated the involvement of extracellular matrix-receptor interaction, adherens junction, and transforming growth factor-beta signaling pathway in the pathogenesis of IDDs. Moreover, the network of predicted targets for these miRNAs identified most affected target genes as ERBB4 and CLTC.
   CONCLUSIONS: We found that the identified miRNAs through meta-analysis are candidate predictive markers for IDDs through different pathways.
C1 [Sherafatian, Masih] Tarbiat Modares Univ, Fac Biol Sci, Dept Mol Genet, Tehran, Iran.
   [Abdollahpour, Hamid Reza] Shiraz Univ Med Sci, Dept Orthoped, Shiraz, Iran.
   [Ghaffarpasand, Fariborz] Shiraz Univ Med Sci, Res Ctr Neuromodulat & Pain, Shiraz, Iran.
   [Yaghmaei, Shekoofeh; Azadegan, Maryam] Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran.
   [Heidari, Mojdeh] Razi Univ, Fac Sci, Dept Biol, Kermanshah, Iran.
RP Ghaffarpasand, F (reprint author), Shiraz Univ Med Sci, Res Ctr Neuromodulat & Pain, Shiraz, Iran.
EM fariborz.ghaffarpasand@gmail.com
RI Ghaffarpasand, Fariborz/I-4204-2019; Sherafatian, Masih/J-2860-2019
OI Ghaffarpasand, Fariborz/0000-0002-1721-9987; Sherafatian,
   Masih/0000-0002-1101-1966
CR Akker G, 2018, CARTILAGE
   Ardestani A, 2018, TRENDS ENDOCRIN MET, V29, P492, DOI 10.1016/j.tem.2018.04.006
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Biyani A, 2004, J AM ACAD ORTHOP SUR, V12, P106, DOI 10.5435/00124635-200403000-00006
   Brown KR, 2009, BIOINFORMATICS, V25, P3327, DOI 10.1093/bioinformatics/btp595
   Burke JG, 2002, J BONE JOINT SURG BR, V84B, P196, DOI 10.1302/0301-620X.84B2.12511
   Cardenas CLL, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003291
   Clouet J, 2019, ADV DRUG DELIVER REV, V146, P306, DOI 10.1016/j.addr.2018.04.017
   Freemont AJ, 1997, LANCET, V350, P178, DOI 10.1016/S0140-6736(97)02135-1
   Gruber HE, 2007, SPINE J, V7, P444, DOI 10.1016/j.spinee.2006.08.015
   Hondke S, 2018, CARTILAGE
   Hoy D, 2012, ARTHRITIS RHEUM-US, V64, P2028, DOI 10.1002/art.34347
   Hoy D, 2014, ANN RHEUM DIS, V73, P968, DOI 10.1136/annrheumdis-2013-204428
   Hu P, 2015, MOL MED REP, V12, P4925, DOI 10.3892/mmr.2015.4022
   Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007
   Jing WL, 2015, CELL PROLIFERAT, V48, P284, DOI 10.1111/cpr.12176
   Lan PH, 2016, ONCOTARGET, V7, P63166, DOI 10.18632/oncotarget.11334
   Li HR, 2016, SPINE, V41, pE116, DOI 10.1097/BRS.0000000000001139
   Liu X, 2015, GENOM DATA, V5, P80, DOI 10.1016/j.gdata.2015.05.027
   Lv F, 2017, MED SCI MONITOR, V23, P659, DOI 10.12659/MSM.898660
   Lv Zheng-Tao, 2018, Oncotarget, V9, P15365, DOI 10.18632/oncotarget.23805
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805
   Nerlich AG, 2005, EUR SPINE J, V14, P17, DOI 10.1007/s00586-004-0745-x
   Park TSW, 2018, INFLAMMOPHARMACOLOGY, V26, P881, DOI 10.1007/s10787-018-0493-x
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Qian BP, 2016, SPINE, V41, P735, DOI 10.1097/BRS.0000000000001339
   Ramasamy A, 2008, PLOS MED, V5, P1320, DOI 10.1371/journal.pmed.0050184
   Rubin DI, 2007, NEUROL CLIN, V25, P353, DOI 10.1016/j.ncl.2007.01.004
   Sato T, 2018, J BIOCHEM, V164, P173, DOI 10.1093/jb/mvy040
   Schmoelz W, 2012, EUR SPINE J, V21, P939, DOI 10.1007/s00586-011-2121-y
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Shi CG, 2018, J CELL PHYSIOL, V233, P6589, DOI 10.1002/jcp.26280
   Specchia N, 2002, EUR SPINE J, V11, P145, DOI 10.1007/s00586-001-0361-y
   Tan HY, 2018, J CELL BIOCHEM, V119, P7218, DOI 10.1002/jcb.26888
   Tang Y, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-92
   Teixeira GQ, 2018, SPINE, V43, pE673, DOI 10.1097/BRS.0000000000002494
   Tokar T, 2018, NUCLEIC ACIDS RES, V46, pD360, DOI 10.1093/nar/gkx1144
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403
   Vo NV, 2013, SPINE J, V13, P331, DOI 10.1016/j.spinee.2012.02.027
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2
   Wang C, 2015, CLIN CHIM ACTA, V450, P333, DOI 10.1016/j.cca.2015.09.011
   Wang F, 2011, EUR J NUCL MED MOL I, V38, P1572, DOI 10.1007/s00259-011-1786-0
   Wang HQ, 2011, J PATHOL, V225, P232, DOI 10.1002/path.2931
   Wang Y., 2018, BIOL TRACE ELEM RES, V5, P1, DOI DOI 10.1002/jcb.28024
   Wang YH, 2017, CELL PHYSIOL BIOCHEM, V42, P2481, DOI 10.1159/000480211
   Wu M.H., 2018, INT J MOL SCI, V19
   Wuertz K, 2012, EUR CELLS MATER, V23, P103
   Yan MJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24932-9
   Ying SY, 2008, MOL BIOTECHNOL, V38, P257, DOI 10.1007/s12033-007-9013-8
   Ying Shao-Yao, 2013, Methods Mol Biol, V936, P1
   Zeng J, 2015, CELL PHYSIOL BIOCHEM, V37, P1289, DOI 10.1159/000430252
   Zhao B, 2014, INT J MOL MED, V33, P43, DOI 10.3892/ijmm.2013.1543
   Zhong BL, 2017, ONCOTARGET, V8, P75488, DOI 10.18632/oncotarget.20797
   Zhong JJ, 2017, ONCOTARGET, V8, P83523, DOI 10.18632/oncotarget.18315
NR 54
TC 4
Z9 4
U1 4
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 389
EP 397
DI 10.1016/j.wneu.2019.03.120
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400264
PM 30904808
DA 2020-05-12
ER

PT J
AU Glauser, G
   Choudhri, OA
AF Glauser, Gregory
   Choudhri, Omar A.
TI Microsurgical Clipping of Ophthalmic Aneurysms in an Endovascular Era:
   Sonopet-Assisted Intradural Clinoidectomy and Other Tenets
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm clipping; Cerebrovascular; Clinoidectomy; Multiple aneurysms;
   Ophthalmic artery aneurysm
AB These video cases present some unique technical tenets for microsurgical clipping of proximal internal carotid artery aneurysms (Video 1). The first patient is a 49-year-old woman with a history of a prior ruptured and treated right middle cerebral artery aneurysm who was found to have growth of known left middle cerebral artery and left internal carotid artery ophthalmic segment aneurysms on radiographic studies. An intradural clinoidectomy with Sonopet, with proximal control at cervical carotid and wide sylvian fissure exposure with ample sharp dissection of the aneurysm anatomy, allowed safe clipping of the ophthalmic aneurysm in this case. The second patient is a 39-year-old woman with a history of a prior left middle cerebral artery M2 occlusion with recent mechanical thrombectomy. The patient was found to have a 6-mm incidental, unruptured right internal cerebral artery paraophthalmic segment and 3-mm right posterior communicating artery aneurysm on radiographic studies. This patient underwent microsurgical clipping given unique patient factors. A similar controlled intradural clinoidectomy, with proximal cervical ICA control and aneurysmal segment trapping, allowed safe aneurysm exclusion. For patients with multiple aneurysms such as in these cases, the deeper proximal aneurysm should generally be treated first. The videos illustrate some key technical points in this regard.
C1 [Glauser, Gregory; Choudhri, Omar A.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
RP Choudhri, OA (reprint author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
EM Omar.Choudhri@uphs.upenn.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 398
EP 398
DI 10.1016/j.wneu.2019.03.097
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400265
PM 30898737
DA 2020-05-12
ER

PT J
AU Singh, S
   Kumar, A
   Mehrotra, A
   Rao, RN
   Behari, S
AF Singh, Suyash
   Kumar, Ashutosh
   Mehrotra, Anant
   Rao, Ram Naval
   Behari, Sanjay
TI Nonsecretory Paraganglioma in Cavernous Sinus Masquerading as Meningioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus; Neurocristopathies; Paraganglioma; Salt and pepper
   appearance
ID SKULL BASE; SUPRASELLAR
AB BACKGROUND: Paraganglioma in cavernous sinus is a rare entity often misdiagnosed as meningioma or schwannoma on radiology. The embryological origin, from cells of neural crest, does not explain the location per se. Because of its highly vascular nature and close proximity to the carotid artery, surgical excision is a challenge. We herein report the first case of cavernous sinus paraganglioma, without the characteristic "salt and pepper appearance," excised near completely by the subtemporal approach.
   CASE DESCRIPTION: A 30-year-old woman without a history of any comorbid conditions, particularly hypertension, presented with a 6-month history of progressive headache and double vision. She exhibited upward gaze palsy and hypoesthesia over the right half of her face. There was no papilledema and proptosis. Radiologic imaging revealed an extra-axial T1-weighted isointense, T2-weighted hyperintense lesion with homogenous intense contrast uptake in right parasellar region encasing cavernous internal carotid artery. Furthermore, the tumor was extending along the superior orbital fissure. Suspecting a cavernous sinus meningioma, we performed near-total excision via a subtemporal approach. Postoperative recovery was uneventful, and patient was discharged on fifth postoperative day. The histopathology and immunohistochemistry were consistent with paraganglioma. The patient underwent adjuvant radiotherapy and is under our outpatient follow-up.
   CONCLUSIONS: Paraganglioma must be considered in the differential diagnosis of parasellar tumors, even when secretory symptoms are absent. The radiologic findings are obscure, and it is difficult to differentiate it from more common tumors of this region such as meningioma, schwannoma, and pituitary adenoma. Surgical excision followed by radiotherapy is the mainstay of management.
C1 [Singh, Suyash; Kumar, Ashutosh; Mehrotra, Anant; Behari, Sanjay] Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
   [Rao, Ram Naval] Sanjay Gandhi Post Grad Inst Med Sci, Dept Pathol, Lucknow, Uttar Pradesh, India.
RP Mehrotra, A (reprint author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
EM dranantmehrotra@gmail.com
CR Arain A, 2012, JBR-BTR, V95, P124, DOI 10.5334/jbr-btr.281
   Chaudhry NS, 2013, J CLIN NEUROSCI, V20, P1615, DOI 10.1016/j.jocn.2013.02.004
   Hertel F, 2003, NEUROSURG REV, V26, P210, DOI 10.1007/s10143-003-0266-9
   Naggara O, 2005, NEURORADIOLOGY, V47, P753, DOI 10.1007/s00234-005-1422-4
   Noble ER, 1997, AM J NEURORADIOL, V18, P986
   Offergeld C, 2012, CLINICS, V67, P19, DOI 10.6061/clinics/2012(Sup01)05
   Peltier J, 2007, NEUROCHIRURGIE, V53, P391, DOI 10.1016/j.neuchi.2007.06.006
   PRABHAKAR S, 1984, SURG NEUROL, V22, P39, DOI 10.1016/0090-3019(84)90226-X
   Prajsnar Anna, 2011, Surg Neurol Int, V2, P45, DOI 10.4103/2152-7806.79763
   STEEL TR, 1993, NEUROSURGERY, V32, P844, DOI 10.1227/00006123-199305000-00021
   Tong Xian-zhou, 2008, Chinese Journal of Pathology, V37, P765
   Unal M, 2007, AURIS NASUS LARYNX, V34, P427, DOI 10.1016/j.anl.2006.12.003
NR 12
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 399
EP 404
DI 10.1016/j.wneu.2019.02.111
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400266
PM 30831293
DA 2020-05-12
ER

PT J
AU Li, YP
   Ahmed, R
   Rivera-Rivera, LA
   Stadler, JA
   Turski, P
   Aagaard-Kienitz, B
AF Li, Yiping
   Ahmed, Raheel
   Rivera-Rivera, Leonardo A.
   Stadler, James A., III
   Turski, Patrick
   Aagaard-Kienitz, Beverly
TI Serial Quantitative and Qualitative Measurements of Flow in Vein of
   Galen Malformations Using 4-Dimensional Flow Magnetic Resonance Imaging
   (Phase Contrast Vastly undersampled Isotropic PRojection)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral blood flow; Interventional; Novel imaging sequence; Phase
   contrast imaging; Vein of Galen malformation
AB BACKGROUND: Vein of Galen malformations (VoGMs) induce cerebrovascular dysfunction through arterial steal and venous hypertension resulting, if untreated, in severe neurologic morbidity and mortality. Noninvasive techniques for quantitative, serial evaluation of cerebrovascular hemodynamics in VoGMs are lacking. This proof of concept study using quantitative blood flow measurements from 4-dimensional flow magnetic resonance imaging may be useful as a noninvasive biomarker to guide timing of intervention and assess disease progression and treatment outcomes.
   CASE DESCRIPTION: Between July 2016 and July 2018, 4 patients harboring VoGMs underwent Phase Contrast Vastly undersampled Isotropic PRojection (PCVIPR) imaging at the University of Wisconsin Hospitals and Clinics. We applied PCVIPR imaging to assess its potential for obtaining anatomic and physiologic flow data before and after surgical embolization of VoGMs. Hemodynamic pressure parameters obtained from PCVIPR imaging were compared with stump pressures recorded in vivo. We found a decrease in mean arterial pressure from 97 mm Hg pretreatment to 65 mm Hg post treatment. These findings corroborate the decrement in venous pressure gradients documented on PCVIPR imaging. For all patients, pressure gradient changes on PCVIPR imaging correlated with in vivo arterial pressures and aided in clinical decision related to cerebrovascular evaluation, treatment planning, and clinical course.
   CONCLUSIONS: Four-dimensional flow magnetic resonance imaging/PCVIPR imaging has a potential role in determining endovascular embolization and therapeutic outcomes on the basis of objective and reproducible hemodynamic characteristics of the vascular lesion. It represents a novel, noninvasive approach that may guide the extent and timing of therapeutic intervention and treatment of cerebrovascular diseases in pediatric patients.
C1 [Li, Yiping; Ahmed, Raheel; Stadler, James A., III; Aagaard-Kienitz, Beverly] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53706 USA.
   [Turski, Patrick; Aagaard-Kienitz, Beverly] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI 53706 USA.
   [Rivera-Rivera, Leonardo A.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, 1530 Med Sci Ctr, Madison, WI 53706 USA.
RP Aagaard-Kienitz, B (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53706 USA.; Aagaard-Kienitz, B (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI 53706 USA.
EM baagaard-kienitz@uwhealth.org
OI Li, Yiping/0000-0002-2333-7736
FU NINDSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R01NS066982]; NIAUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Aging (NIA) [R01AG021155]; University of Wisconsin
   Department of Neurosurgery; University of Wisconsin Department of
   Radiology
FX The authors would like to thank the University of Wisconsin Departments
   of Neurosurgery and Radiology for their guidance and support. Grant
   support was provided by NINDS R01NS066982 and NIA R01AG021155.
CR FLEISCHER LH, 1993, STROKE, V24, P1897, DOI 10.1161/01.STR.24.12.1897
   Frawley GP, 2002, ARCH DIS CHILD-FETAL, V87, pF144, DOI 10.1136/fn.87.2.F144
   Geibprasert S, 2010, CHILD NERV SYST, V26, P35, DOI 10.1007/s00381-009-0959-7
   Gu TL, 2005, AM J NEURORADIOL, V26, P743
   Johnson KM, 2008, MAGN RESON MED, V60, P1329, DOI 10.1002/mrm.21763
   Khullar D, 2010, J NEUROSURG-PEDIATR, V6, P444, DOI 10.3171/2010.8.PEDS10231
   Lasjaunias PL, 2007, NEUROSURGERY, V60, P393
   Moftakhar R, 2007, AM J NEURORADIOL, V28, P1710, DOI 10.3174/ajnr.A0648
   Rivera-Rivera LA, 2018, AM J NEURORADIOL, V39, P485, DOI 10.3174/ajnr.A5494
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 405
EP 412
DI 10.1016/j.wneu.2019.02.131
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400267
PM 30849554
DA 2020-05-12
ER

PT J
AU Rubio, RR
   Chae, R
   Rutledge, WC
   De Vilalta, A
   Kournoutas, I
   Winkler, E
   Abla, AA
AF Rubio, Roberto Rodriguez
   Chae, Ricky
   Rutledge, W. Caleb
   De Vilalta, Alex
   Kournoutas, Ioannis
   Winkler, Ethan
   Abla, Adib A.
TI Clipping of High-Risk Dural Arteriovenous Fistula of the Posterior
   Fossa: 3-Dimensional Operative Video
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D video; Dural arteriovenous fistula; Myelopathy; Perimedullary veins;
   Posterior fossa; Posterior meningeal artery; Supracerebellar approach
AB Dural arteriovenous fistulas (DAVFs) represent 10%-15% of all intracranial arteriovenous malformations.(1) DAVFs located in the posterior cranial fossa are rare and often present with intracranial hemorrhage and myelopathy.(2) Arterial supply could be provided by the meningeal branches of the vertebral artery and external and internal carotid arteries.(3)
   A 68-year-old man presented with progressive lower-extremity weakness (Video 1). Magnetic resonance imaging revealed a patchy longitudinal cord signal abnormality extending from the cervicomedullary junction to C7. A tentorial DAVF supplied by the right posterior meningeal artery with drainage via dorsal and ventral perimedullary veins was identified on angiography. According to the Cognard classification, the patient's DAVF was determined to be high risk as a type V lesion with spinal venous drainage and progressive myelopathy.(4) The fistula was embolized with 50% ethanol resulting in near-complete occlusion. However, follow-up angiography revealed a persistent arteriovenous shunt and slightly worsening symptoms for the patient. He underwent a sitting supracerebellar approach with a torcular craniotomy for successful clip ligation of the dural arteriovenous fistula. The patient was discharged with improvements in lower-extremity strength and no residual arteriovenous shunting in postoperative imaging.
C1 [Rubio, Roberto Rodriguez; Chae, Ricky; De Vilalta, Alex; Kournoutas, Ioannis; Abla, Adib A.] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez; Chae, Ricky; Rutledge, W. Caleb; De Vilalta, Alex; Kournoutas, Ioannis; Winkler, Ethan; Abla, Adib A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
RP Abla, AA (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.; Abla, AA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
EM adib.abla@ucsf.edu
OI Rodriguez-Rubio, Roberto/0000-0002-7206-309X; Chae,
   Ricky/0000-0001-5014-9303
CR COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   NEWTON TH, 1969, RADIOLOGY, V93, P1071, DOI 10.1148/93.5.1071
   NEWTON TH, 1968, RADIOLOGY, V90, P27, DOI 10.1148/90.1.27
   PIEROT L, 1992, AM J NEURORADIOL, V13, P315
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 413
EP 413
DI 10.1016/j.wneu.2019.03.101
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400268
PM 30902767
DA 2020-05-12
ER

PT J
AU Hong, J
   Trus, TL
   Ball, PA
AF Hong, Jennifer
   Trus, Thadeus L.
   Ball, Perry A.
TI Laparoscopic-Assisted Intra-Abdominal Section of the Lateral Femoral
   Cutaneous Nerve for Meralgia Paresthetica Following Anterior Hip
   Arthroplasty
SO WORLD NEUROSURGERY
LA English
DT Article
DE Laparoscopic; Lateral femoral cutaneous nerve; Meralgia paresthetica;
   Pain; Peripheral nerve
ID DIAGNOSIS; INJURY
AB BACKGROUND: Meralgia paresthetica, a pain syndrome that is caused by injury to the lateral femoral cutaneous nerve, is a well-documented complication after anterior hip arthroplasty (THA). Traditional treatment of this peripheral nerve entrapment syndrome can be complicated in patients who have had THA via an anterior approach owing to the presence of scar in the postoperative bed.
   CASE DESCRIPTION: In a 70-year-old man, we performed a novel laparoscopic-assisted intra-abdominal approach to treat meralgia paresthetica in the setting of previous anterior THA.
   CONCLUSIONS: Minimally invasive intra-abdominal treatment of meralgia paresthetica following anterior THA results in durable pain relief. This approach is a helpful alternative to traditional techniques of decompression or section of the lateral femoral cutaneous nerve below the inguinal ligament.
C1 [Hong, Jennifer; Ball, Perry A.] Dartmouth Hitchcock Med Ctr, Div Neurosurg, Dept Surg, Lebanon, NH 03766 USA.
   [Trus, Thadeus L.] Dartmouth Hitchcock Med Ctr, Dept Surg, Div Minimally Invas & Bariatr Surg, Lebanon, NH 03766 USA.
RP Hong, J (reprint author), Dartmouth Hitchcock Med Ctr, Div Neurosurg, Dept Surg, Lebanon, NH 03766 USA.
EM Jennifer.Hong@hitchcock.org
CR Bhardwaj N, 2011, ANN ROY COLL SURG, V93, P491, DOI 10.1308/003588411X592130i
   Chopra PJ, 2014, J MINIM ACCESS SURG, V10, P159, DOI 10.4103/0972-9941.134883
   Eingartner Christoph, 2007, Ortop Traumatol Rehabil, V9, P8
   Harney D, 2007, PAIN MED, V8, P669, DOI 10.1111/j.1526-4637.2006.00227.x
   Homma Y, 2016, INT ORTHOP, V40, P1587, DOI 10.1007/s00264-015-2942-0
   KHALIL A, 2008, COCHRANE DB SYST REV, V3
   Lee Joong-Myung, 2016, Hip Pelvis, V28, P191, DOI 10.5371/hp.2016.28.4.191
   Macheras GA, 2016, HIP INT, V26, P338, DOI 10.5301/hipint.5000352
   Meermans G, 2017, BONE JOINT J, V99B, P732, DOI 10.1302/0301-620X.99B6.38053
   Nahabedian MY, 1995, ANN PLAS SURG, V35, P590, DOI 10.1097/00000637-199512000-00006
   Ozaki Y, 2016, ORTHOP TRAUMATOL-SUR, V102, P1043, DOI 10.1016/j.otsr.2016.08.019
   Payne R, 2017, ACTA NEUROCHIR, V159, P931, DOI 10.1007/s00701-017-3136-x
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 415
EP 417
DI 10.1016/j.wneu.2019.03.093
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400270
PM 30898736
DA 2020-05-12
ER

PT J
AU Kolcun, JPG
   Wang, MY
AF Kolcun, John Paul G.
   Wang, Michael Y.
TI Endoscopic Treatment of Thoracic Discitis with Robotic Access: A Case
   Report Merging Two Cutting-Edge Technologies
SO WORLD NEUROSURGERY
LA English
DT Article
DE Discitis; Endoscope; Hybrid surgery; Robotics; Technology; Thoracic
   spine
AB BACKGROUND: Emerging technologies in minimally invasive spinal surgery include surgical robots for navigation and spinal endoscopy. We applied these technologies in concert to treat a critically ill patient with thoracic discitis.
   CASE DESCRIPTION: The patient was an 83-year old woman with extensive medical comorbidities. In 2016, she was admitted from her skilled nursing facility with chest pain radiating to her left arm. Following a negative cardiac workup, computed tomography imaging revealed a right paramediastinal thoracic collection with endplate erosion at the T4 and T5 levels. Subsequent magnetic resonance imaging was consistent with spondylodiscitis. We developed a preoperative trajectory with targeting software to the target levels. Following positioning and calibration in the operating room, we used the robot to establish our planned trajectory along the T4-T5 transpedicular route on the left side. We established a working channel and docked the endoscope through the T4-T5 annulus. Frank pus extruded on entering the disc, which we immediately sampled and sent for culture. We next advanced the endoscope into the disc space, allowing us to clean the endplates with microcurettes and copious irrigation. The patient tolerated the procedure well and was sent to the intensive care unit in light of her general medical status. She recovered well and was discharged from our hospital on postoperative day 11 after a course of intravenous antibiotics.
   CONCLUSIONS: This case represents a novel endoscopic-robotic hybrid spine surgery that we believe will find further applications in spinal surgery.
C1 [Kolcun, John Paul G.; Wang, Michael Y.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
RP Wang, MY (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM Mwang2@med.miami.edu
CR Babic M, 2017, INFECT DIS CLIN N AM, V31, P279, DOI 10.1016/j.idc.2017.01.003
   Fiani B, 2020, NEUROSURG REV, V43, P17, DOI 10.1007/s10143-018-0971-z
   Joseph JR, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.2.FOCUS16544
   Madhavan K, 2017, WORLD NEUROSURG, V107, P511, DOI 10.1016/j.wneu.2017.07.069
   Overley SC, 2017, NEUROSURGERY, V80, pS86, DOI 10.1093/neuros/nyw077
   Sen RD, 2018, WORLD NEUROSURG, V120, pE1054, DOI 10.1016/j.wneu.2018.09.009
   Wagner R, 2016, WORLD NEUROSURG, V90, P194, DOI 10.1016/j.wneu.2016.02.086
NR 7
TC 0
Z9 0
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2019
VL 126
BP 418
EP 422
DI 10.1016/j.wneu.2019.03.036
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IA0BU
UT WOS:000469222400271
PM 30872196
DA 2020-05-12
ER

EF